<SEC-DOCUMENT>0001213900-25-052779.txt : 20250610
<SEC-HEADER>0001213900-25-052779.hdr.sgml : 20250610
<ACCEPTANCE-DATETIME>20250609200418
ACCESSION NUMBER:		0001213900-25-052779
CONFORMED SUBMISSION TYPE:	S-4/A
PUBLIC DOCUMENT COUNT:		143
FILED AS OF DATE:		20250610
DATE AS OF CHANGE:		20250609

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Avalon GloboCare Corp.
		CENTRAL INDEX KEY:			0001630212
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMPUTER PROGRAMMING SERVICES [7371]
		ORGANIZATION NAME:           	06 Technology
		EIN:				471685128
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-286738
		FILM NUMBER:		251035679

	BUSINESS ADDRESS:	
		STREET 1:		4400 ROUTE 9
		STREET 2:		SUITE 3100
		CITY:			FREEHOLD
		STATE:			NJ
		ZIP:			07728
		BUSINESS PHONE:		732-780-4400

	MAIL ADDRESS:	
		STREET 1:		4400 ROUTE 9
		STREET 2:		SUITE 3100
		CITY:			FREEHOLD
		STATE:			NJ
		ZIP:			07728

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avalon Globocare Corp.
		DATE OF NAME CHANGE:	20161018

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GLOBAL TECHNOLOGIES CORP
		DATE OF NAME CHANGE:	20150108
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4/A
<SEQUENCE>1
<FILENAME>ea0245032-s4a1_avalon.htm
<DESCRIPTION>AMENDMENT NO. 1 TO FORM S-4
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Jun 09 23:27:59 UTC 2025 -->
<html xmlns:avco="http://www.avalonglobocare.com/20250331" xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">As filed with the Securities and Exchange Commission
on June 10, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b style="-keep: true">Registration Statement No. 333-286738&#8239;</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true"><ix:nonNumeric contextRef="c0" name="dei:AmendmentDescription" id="ixv-88773">Amendment No. 1</ix:nonNumeric> </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">to</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Form <span style="-sec-ix-hidden: hidden-fact-0">S-4</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REGISTRATION STATEMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>UNDER</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>THE SECURITIES ACT OF 1933</i></b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-88774">AVALON GLOBOCARE CORP.</ix:nonNumeric> </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact Name of Registrant as Specified in Its
Charter)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center; width: 32%"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-96"><span style="font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center; width: 32%"><span style="font-size: 10pt"><b>2836</b></span></td> <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center; width: 32%"><span style="font-size: 10pt"><b>47-1685128</b></span></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>(Jurisdiction of<br/>
Incorporation or Organization)</b></span></td> <td>&#160;</td> <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>(Primary Standard Industrial<br/>
Classification Code Number)</b></span></td> <td>&#160;</td> <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>(I.R.S. Employer<br/>
Identification Number)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>4400 Route 9 South,&#160;Suite 3100</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Freehold,&#160;New Jersey&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(732)&#160;780-4400 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address, including zip code, and telephone
number, including area code, of Registrant&#8217;s principal executive offices)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Avalon GloboCare Corp. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Luisa Ingargiola</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Chief Financial Officer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>4400 Route 9 South, Suite 3100</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Freehold, New Jersey 07728</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Tel: (732) 780-4400</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Name, address, including zip code, and telephone
number, including area code, of agent for service) </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Copies to: </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Steven M. Skolnick, Esq.</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Stephen G. Zapf, Esq.</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Lowenstein Sandler LLP</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>1251 Avenue of the Americas</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>New York, New York 10020</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(212) 262-6700</b></p></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Joseph M. Lucosky, Esq.</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Scott E. Linsky, Esq.</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Lucosky Brookman LLP</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>101 Wood Avenue South, 5th Floor</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Iselin, New Jersey 08830</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(732) 395-4400</b></p></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>Approximate date of commencement
of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective and on completion of the business
combination described in the enclosed proxy statement/prospectus. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If the securities being registered on this Form
are to be offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the
following box.&#8194;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If this Form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering.&#8194;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If this Form is a post-effective amendment filed
pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering.&#8194;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; width: 20%"><span style="font-size: 10pt">Large accelerated filer</span></td> <td style="font-size: 10pt; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="font-size: 10pt; width: 25%"><span style="font-size: 10pt">Accelerated filer</span></td> <td style="font-size: 10pt; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-262"><span style="font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="font-size: 10pt"><span style="font-size: 10pt">Smaller reporting company</span></td> <td style="font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="ixv-269"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td style="font-size: 10pt"><span style="font-size: 10pt">Emerging growth company</span></td> <td style="font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-277"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided to Section 7(a)(2)(B) of the Securities Act.&#8194;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If applicable, place an X in the box to designate
the appropriate rule provision relied upon in conducting this transaction:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt; text-indent: 0.25in"><span style="font-size: 10pt">Exchange Act Rule 13e-4(i) (Cross-Border Issuer Tender Offer)</span></td>
    <td style="vertical-align: bottom; font-size: 10pt; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    </tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt; text-indent: 0.25in">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top; font-size: 10pt; text-indent: 0.25in"><span style="font-size: 10pt">Exchange Act Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)</span></td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    </tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>The Registrant hereby amends this Registration
Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which
specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission,
acting pursuant to said Section 8(a), may determine.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>






</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="color: Red"><b>The information in
this proxy statement/prospectus is not complete and may be changed. These securities described herein may not be sold until the registration
statement filed with the U.S. Securities and Exchange Commission is declared effective. This proxy statement/prospectus is not an offer
to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not
permitted. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="color: Red">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: Red"><b>PRELIMINARY PROXY
STATEMENT/PROSPECTUS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: Red"><b>SUBJECT TO COMPLETION,
DATED JUNE 10, 2025</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: center; padding: 2pt 5.4pt; width: 50%; font-size: 10pt"><img alt="" src="image_001.jpg"/></td>
    <td style="padding: 2pt 5.4pt; width: 50%; font-size: 10pt; text-align: center"><img alt="" src="image_002.jpg"/></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 0.25in Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AVALON GLOBOCARE CORP. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>4400 Route 9 South, Suite 3100</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Freehold, New Jersey 07728</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the Stockholders of Avalon
GloboCare Corp. and YOOV Group Holding Limited,</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On behalf of the Avalon GloboCare
Corp. (&#8220;Avalon&#8221;) board of directors, we are pleased to enclose the proxy statement/prospectus for the Merger (as defined below)
and the related facilitating transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As previously announced, Avalon,
Nexus MergerSub Limited, a business company incorporated in the British Virgin Islands and a wholly owned subsidiary of Avalon (&#8220;Merger
Sub&#8221;) and YOOV Group Holding Limited, a business company incorporated in the British Virgin Islands (&#8220;YOOV&#8221;), entered
into an Agreement and Plan of Merger, dated March 7, 2025 (the &#8220;Merger Agreement&#8221;), pursuant to which Merger Sub will merge
with and into YOOV, with YOOV surviving the merger (the &#8220;Surviving Corporation&#8221;) and becoming a wholly owned direct subsidiary
of Avalon (the &#8220;Merger&#8221;). The Merger will result in a publicly-traded company focused on empowering organizations of all sizes
to optimize operations, reduce costs, and enhance service delivery through Artificial Intelligence-as-a-Service (AIaaS) solutions, specializing
in intelligent business automation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the terms and conditions
of the Merger Agreement, immediately prior to the closing of the Merger, each then-outstanding YOOV preferred share, par value $0.10 per
share (the &#8220;YOOV Preferred Shares&#8221;), will either automatically be converted into YOOV Ordinary Shares or canceled and cease
to exist in accordance with their terms, and, at the closing of the Merger, each then-outstanding ordinary share, par value $0.10 per
share, of YOOV (the &#8220;YOOV Ordinary Shares&#8221;) (other than shares held in treasury and Dissenting Shares (as defined below))
will be converted into and become exchangeable for a number of shares of common stock, par value $0.0001 per share, of Avalon (the &#8220;Avalon
Common Stock&#8221;) equal to the Exchange Ratio (as defined below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the Merger,
existing equityholders of Avalon will own approximately 2.7% to 3.0% of the common stock of the Combined Company (as defined below) and
the existing equityholders of YOOV would own approximately 97.0% to 97.3% of the common stock of the Combined Company. See the section
entitled &#8220;<i>The Merger Agreement</i>&#8221; on page 3 of the attached proxy statement/prospectus for further information on the
consideration being paid to the equityholders of YOOV. The Avalon Common Stock is currently listed on The Nasdaq Capital Market, under
the symbol &#8220;ALBT.&#8221; After completion of the Merger, Avalon will be renamed &#8220;YOOV, Inc.&#8221; and it is expected that
the common stock of the Combined Company will trade on The Nasdaq Capital Market under the symbol &#8220;YOOV&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consummation of the Merger
is conditioned on, among other things, the listing approval for the Merger Shares (as defined below) on The Nasdaq Capital Market. Pursuant
to the Merger Agreement, Avalon agreed, subject to Avalon stockholder approval pursuant to the attached proxy statement/prospectus, to
effect the Reverse Stock Split (as defined below), if needed, to ensure the Avalon Common Stock will be able to meet the $4.00 minimum
bid price initial listing requirement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b style="-keep: true">Stockholders are cautioned
that YOOV, the wholly owned subsidiary of Avalon post-Merger, is a British Virgin Islands holding company with operations in Hong&#160;Kong
by its operating subsidiaries.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">We face potential risks
associated with YOOV. YOOV is a holding company incorporated in the British Virgin Islands with no material operations of its own. Headquartered
in Singapore, YOOV conducts its operations primarily in Hong&#160;Kong through its operating subsidiaries. After the Merger, stockholders
will not directly hold any equity interests in YOOV or its operating subsidiaries. This structure involves unique risks to investors.
As a holding company, we may rely on dividends from our subsidiaries for our cash requirements, including any payment of dividends to
our shareholders. The ability of our subsidiaries to pay dividends to us may be restricted by the debt they incur on their own behalf
or laws and regulations applicable to them. YOOV does not currently operate any of its business through variable interest entities, nor
does it operate any business in the People's Republic of China ("China" or the "PRC"). This position is not expected
to change upon completion of the Merger.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true"><span style="font-family: Times New Roman, Times, Serif">YOOV&#8217;s
operations are primarily located in Hong&#160;Kong, a Special Administrative Region of the PRC. YOOV does not derive any revenue or profits
from, nor does it have any customers in, the PRC. Its operations and customer base are concentrated in Hong Kong, where it conducts business
through its operating subsidiaries. YOOV and its subsidiaries face various legal and operational risks and uncertainties associated with
being based in or having the majority of the operations in Hong Kong. </span>As a special administrative region of the PRC, Hong Kong
enjoys separate governing and economic systems from that of mainland China under the principle of one country, two systems. The Basic
Law of the Hong Kong Special Administrative Region (the &#8220;Basic Law&#8221;) provides that PRC laws and regulations shall not be
applied in Hong Kong except for those listed in Annex III of the Basic Law, which is confined to laws relating to national defense, foreign
affairs, and other matters that are not within the scope of autonomy. YOOV therefore is not directly subject to PRC laws and regulations
regarding the general conduct of its business or regarding overseas listings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">While Hong Kong currently
maintains a separate legal and regulatory system from the PRC, any future changes to PRC laws or their interpretation&#8212;if extended
to Hong Kong&#8212;could introduce regulatory, liquidity, or enforcement risks that may materially affect YOOV&#8217;s operations. For
example, in future, YOOV may face risks and uncertainties regarding the enforcement of laws and the fact that rules and regulations in
the PRC can change quickly with little advance notice. In addition, in future, the Chinese government could intervene or influence our
operations at any time, or could exert more control over offerings conducted overseas or foreign investment in Hong Kong-based issuers,
which could result in a material change in our operations or the value of Avalon Common Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">For more information,
see &#8220;<i>Prospectus Summary&#160;&#8212;&#160;Potential Permission or Approvals Required from the PRC Authorities with respect to
the Operations of YOOV</i>.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Should the PRC government
in future choose to exercise significant oversight and discretion over the conduct of our business or could disallow this corporate structure,
they may intervene in or influence YOOV&#8217;s operations. Such governmental actions:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">&#8226;</span></td><td style="text-align: justify"><span style="-keep: true">could result
                                            in a material change in YOOV&#8217;s operations and/or the value of our securities;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">&#8226;</span></td><td style="text-align: justify"><span style="-keep: true">could significantly
                                            limit or completely hinder YOOV&#8217;s ability to continue its operations;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">&#8226;</span></td><td style="text-align: justify"><span style="-keep: true">could significantly
                                            limit or completely hinder the Combined Company&#8217;s ability to offer or continue to offer
                                            its securities to investors; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">&#8226;</span></td><td style="text-align: justify"><span style="-keep: true">may cause the
                                            value of our securities to significantly decline or be worthless.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, </span><span style="font-size: 10pt">See &#8220;<i>Risk Factors - Risks Related to YOOV&#8217;s Operations in
Hong Kong</i>.&#8221;</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On June 6, 2025, the last
trading day before the date of this proxy statement/prospectus, the closing sale price of Avalon Common Stock was $3.41 per share.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Avalon will seek the stockholder
approvals necessary to complete the Merger and other matters at its special meeting of stockholders (the &#8220;Special Meeting&#8221;).
The Special Meeting will be held via the internet at [&#8195;&#8195;] on [&#8195;&#8195;], 2025, at [ &#8195;&#8195;], Eastern time, unless
postponed or adjourned to a later date. At the Special Meeting, Avalon will ask its stockholders to, among other things, approve the issuance
of shares of Avalon Common Stock as consideration in the Merger, approve effecting the reverse stock split of Avalon Common Stock at a
ratio in the range from 1-for-2 to 1-for-20, with such specific ratio to be determined solely by the Avalon board of directors following
the Special Meeting, each as described in this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consummation of the Merger
is also conditioned on, among other things, the approval of the Merger by YOOV shareholders. As described in this proxy statement/prospectus,
the officers and directors of Avalon entered into voting agreements with YOOV and Avalon whereby such stockholders agreed to vote all
of their shares of Avalon Common Stock in favor of approving the proposals described in this proxy statement/prospectus. Additionally,
as further described in this proxy statement/prospectus, certain shareholders of YOOV entered into a voting agreement with YOOV and Avalon
whereby such stockholders agreed to vote all of their YOOV Ordinary Shares in favor of approving the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After careful consideration,
the Avalon and YOOV boards of directors have each unanimously approved the Merger Agreement and the related transactions and the Avalon
board of directors has approved the other proposals described in this proxy statement/prospectus, and determined that it is advisable
and in the best interests of its stockholders to consummate the Merger. The Avalon board of directors recommends that its stockholders
vote &#8220;FOR&#8221; the proposals described in this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">More information about Avalon,
YOOV and the Merger and related transactions is contained in this proxy statement/prospectus. We urge you to read the accompanying proxy
statement/prospectus, including the financial statements and annexes and other documents referred to herein, carefully and in their entirety.
IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER &#8220;<span style="text-decoration: none"><a href="#a_032">RISK FACTORS</a></span>&#8221;
BEGINNING ON PAGE <span style="background-color: white">17</span> OF THIS PROXY STATEMENT/PROSPECTUS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On behalf of the board of
directors, we thank you for your support and look forward to the successful completion of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: justify; width: 40%"><span style="font-size: 10pt">Sincerely,</span></td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: justify; width: 20%">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: justify; width: 40%">&#160;</td></tr>
  <tr>
    <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: top; font-size: 10pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; vertical-align: top; font-size: 10pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Wenzhao Lu</span></td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Wong Ling Yan Philip</p></td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><i>Chairman of the Board of Directors</i></span></td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><i>President &amp; Chief Executive Officer</i></span></td></tr>
  <tr>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><i>Avalon GloboCare Corp.</i></span></td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><i>YOOV Group Holding Limited</i></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying proxy statement/prospectus
is dated&#8195;&#8195; , 2025 and is first being mailed to the stockholders of Avalon on or about that date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THE U.S. SECURITIES AND EXCHANGE COMMISSION
NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED IN THIS PROXY STATEMENT/PROSPECTUS OR
ANY OF THE SECURITIES TO BE ISSUED IN THE MERGER, PASSED UPON THE MERITS OR FAIRNESS OF THE MERGER OR RELATED TRANSACTIONS OR PASSED UPON
THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS PROXY STATEMENT/PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL
OFFENSE.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 4 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AVALON GLOBOCARE CORP.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>4400 Route 9 South, Suite 3100<br/>
Freehold, NJ&#160;07728</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTICE OF SPECIAL MEETING OF STOCKHOLDERS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TO BE HELD ON [&#8195;&#8195;], 2025 </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the Stockholders of Avalon
GloboCare Corp.:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOTICE IS HEREBY GIVEN that
a special meeting of stockholders (the &#8220;Special Meeting&#8221;) of Avalon GloboCare Corp., a Delaware corporation (&#8220;Avalon,&#8221;
&#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;), will be held on [&#8195;], 2025, at [&#8195;], Eastern time. The Special Meeting
will be held via the Internet. Avalon stockholders will be able to listen to the meeting live, submit questions and vote online regardless
of location via the Internet at<i>&#160;</i>[&#8195;&#8195;]. You will be able to attend the Special Meeting by first registering at [&#8195;&#8195;]<i>.</i>
You will receive a meeting invitation by e-mail with your unique join link along with a password prior to the meeting date. <b>You will
not be able to attend the Special Meeting in person. </b>Only stockholders who hold shares of common stock, $0.0001 par value per share
of Avalon (&#8220;Avalon Common Stock&#8221;) at the close of business on [&#8195;], 2025, the record date for the Special Meeting, are
entitled to vote at the Special Meeting and any adjournments or postponements of the Special Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Special Meeting is being
held for the following purposes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; width: 0.5in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">1.</span></td>
    <td style="vertical-align: top; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The &#8220;Nasdaq Proposal&#8221;
    - to approve, pursuant to the rules of the Nasdaq Stock Market, the issuance of the Merger Shares (as defined below) pursuant to
    the terms of the Merger Agreement (as described in more detail herein); </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; width: 0.5in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">2.</span></td>
    <td style="vertical-align: top; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The &#8220;Reverse Stock Split
    Proposal&#8221; - to approve an amendment to Avalon&#8217;s Amended and Restated Certificate of Incorporation (as amended, the &#8220;Avalon
    Charter&#8221;) to effect a reverse stock split of only the outstanding shares of Avalon Common Stock and other outstanding securities
    of Avalon (with no change to the authorized capital stock of Avalon), at a ratio in the range from 1-for-2 to 1-for-20, with such
    ratio to be determined by the Avalon board of directors (the &#8220;Avalon Board&#8221;) and with such reverse stock split to be
    effected at such time and date as determined by the Avalon Board in its sole discretion, if necessary to be effectuated pursuant
    to the rules of The Nasdaq Capital Market to consummate the Merger (as defined below); </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; width: 0.5in; text-align: justify"><span style="font-size: 10pt">3.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The &#8220;Equity Plan Increase Proposal&#8221;
    - to approve an amendment to Avalon&#8217;s Amended and Restated 2020 Stock Incentive Plan (the &#8220;Amended and Restated 2020
    Plan&#8221;) to increase the number of shares available for issuance under the Amended and Restated 2020 Plan by 2,500,000 shares;</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">4. </span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The &#8220;Series C Preferred Stock Proposal&#8221;
    - to approve, pursuant to the rules of the Nasdaq Stock Market, the potential issuance of shares of Avalon Common Stock issuable
    upon conversion of Avalon&#8217;s Series C Convertible Preferred Stock (the &#8220;Avalon Series C Preferred Stock&#8221;);</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">5.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The &#8220;Series D Preferred Stock Proposal&#8221;
    - to approve, pursuant to the rules of the Nasdaq Stock Market, the potential issuance of shares of Avalon Common Stock issuable
    upon conversion of Avalon&#8217;s Series D Convertible Preferred Stock (the &#8220;Avalon Series D Preferred Stock&#8221;);</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">6. </span></td>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The &#8220;Increase
                                    in Authorized Shares Proposal&#8221; - to approve an amendment to the Avalon Charter to increase
                                    the number of shares of Avalon Common Stock authorized for issuance thereunder from 100,000,000 to
                                    200,000,000;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">7.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The &#8220;Golden Parachute Proposal&#8221; -
    to approve on an advisory (non-binding) basis, certain compensation payments that will be made by Avalon to its named executive officer
    in connection with the Merger; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 5 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; text-align: justify; width: 0.5in"><span style="font-size: 10pt">8.</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The &#8220;Adjournment Proposal&#8221; - to approve
    the adjournment of the Special Meeting in the event that the number of shares of Avalon Common Stock present or represented by proxy
    at the Special Meeting and voting &#8220;FOR&#8221; the adoption of Proposals No. 1 through 7 are insufficient to approve such proposals.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>After careful consideration,
the Avalon Board has unanimously determined that the form, terms and provisions of the Merger Agreement, including the Merger, are advisable
and in the best interests of Avalon and its stockholders, and unanimously recommends you vote &#8220;FOR&#8221; Proposals No. 1 through
8, as well as the Adjournment Proposal. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Avalon will transact no other
business at the Special Meeting, except such business as may properly be brought before the Special Meeting or any adjournment or postponement
thereof. Please refer to the proxy statement/prospectus of which this notice is a part for further information with respect to the business
to be transacted at the Special Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A quorum of Avalon&#8217;s
stockholders is necessary to hold a valid meeting. The holders of at least one-third (1/3) of the voting power of the shares of capital
stock outstanding and entitled to vote at the meeting, as of the record date, present in person, present by remote communication, if applicable,
or represented by proxy, will constitute a quorum for the transaction of business at the Special Meeting. Avalon will include proxies
marked as abstentions and broker non-votes to determine the number of shares present at the Special Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The approval of each of the
Nasdaq Proposal, the Reverse Stock Split Proposal, the Equity Plan Increase Proposal, the Series C Preferred Stock Proposal, Series D
Preferred Stock Proposal, the Increase in Authorized Shares Proposal, the Golden Parachute Proposal (on an advisory (non-binding) basis)
and the Adjournment Proposal requires the affirmative vote of a majority of the total votes properly cast by the Avalon Stockholders at
the Special Meeting. Accordingly, abstentions and broker non-votes, if any, will have no effect on the outcome of the Nasdaq Proposal,
the Reverse Stock Split Proposal, the Equity Plan Increase Proposal, the Series C Preferred Stock Proposal, Series D Preferred Stock Proposal,
the Increase in Authorized Shares Proposal, the Golden Parachute Proposal and the Adjournment Proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of the Record Date,
the Key Avalon Stockholders, including Avalon directors and officers, beneficially owned approximately [ &#160;&#160;]% of the outstanding shares
of Avalon Common Stock and, pursuant to the Voting Agreements, agreed to vote all of their shares of Avalon Common Stock in favor of
the approval of the Nasdaq Proposal, the Reverse Stock Split Proposal, the Equity Plan Increase Proposal, the Series C Preferred Stock
Proposal, Series D Preferred Stock Proposal, the Increase in Authorized Shares Proposal, the Golden Parachute Proposal (on an advisory
(non-binding) basis) and the Adjournment Proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Completion of the Merger is
conditioned upon, among other things, approval of the Nasdaq Proposal, the Reverse Stock Split Proposal, if necessary, and any other proposals
Avalon and YOOV mutually agree is necessary or desirable to consummate the transactions contemplated by the Merger Agreement. Further,
the consummation of the Merger is conditioned on, among other things, the adoption of the Merger Agreement by the YOOV shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Your attention is directed
to the proxy statement/prospectus accompanying this notice (including the financial statements and annexes attached thereto) for a more
complete description of the proposed Merger and related transactions and each of the proposals to be presented at the Special Meeting.
We encourage you to read this proxy statement/prospectus carefully in its entirety. <b>In particular, we urge you to read carefully the
section entitled &#8220;Risk Factors&#8221; beginning on page <span style="background-color: white">17</span> of the accompanying proxy
statement/prospectus. </b>If you have any questions or need assistance voting your shares, please contact Avalon at: Avalon GloboCare
Corp., 400 Route 9 South, Suite 3100, Freehold, NJ&#160;07728, Attn.: Secretary, or by phone at (732)&#160;780-4400.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Your vote is very important,
regardless of the number of shares of Avalon Common Stock.</b> Even if you plan to attend the Special Meeting, we request that you complete,
sign, date and return the enclosed proxy card in the envelope provided, or submit your proxy by telephone or the Internet prior to the
Special Meeting, and thus ensure that your shares will be represented and voted at the Special Meeting if you later become unable to attend.
If your shares are held in a stock brokerage account or by a bank or other nominee, please follow the instructions that you receive from
your broker, bank or other nominee to vote your shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: bottom; width: 60%">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: justify; width: 40%"><span style="font-size: 10pt">By Order of the Board of Directors,</span></td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: justify">&#160;</td></tr>
  <tr>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: justify">&#160;</td>
    <td style="border-top: Black 1pt solid; vertical-align: top; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Wenzhao Lu</span></td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><span style="text-decoration:underline">&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</span>, 2025</span></td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><i>Chairman of the Board of Directors</i></span></td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Freehold, NJ</span></td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: justify">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 6 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REFERENCES TO ADDITIONAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This proxy statement/prospectus
incorporates important business and financial information about Avalon GloboCare Corp. that is not included in or delivered with this
document. You may obtain this information without charge through the SEC website at www.sec.gov or upon your written or oral request by
contacting Avalon GloboCare Corp., 400 Route 9 South, Suite 3100, Freehold, NJ 07728, Attn.: Secretary, or by phone at (732) 780-4400.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>To ensure timely delivery
of these documents, any request for additional copies of materials should be made prior to the Special Meeting.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For additional details about
where you can find information about Avalon, see the section entitled &#8220;<i>Where You Can Find More Information</i>&#8221; of this
proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ABOUT THIS PROXY STATEMENT/PROSPECTUS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This document, which forms
part of a registration statement on Form S-4 filed with the SEC, by Avalon GloboCare Corp. (the &#8220;Registration Statement&#8221;),
constitutes a prospectus of Avalon under Section 5 of the Securities Act of 1933, as amended, with respect to the shares of Avalon Common
Stock to be issued if the Merger described below is consummated. This document also constitutes a notice of meeting and a proxy statement
under Section 14(a) of the Securities Exchange Act of 1934, as amended, with respect to the Special Meeting at which Avalon stockholders
will be asked to consider and vote upon the proposals contained in this proxy statement/prospectus and certain other related matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">You should rely only on the
information contained in this proxy statement/prospectus. Avalon has not authorized anyone to provide you with information that is different
from that contained in this proxy statement/prospectus. This proxy statement/prospectus is dated as of the date set forth above on the
cover page of this proxy statement/prospectus, and you should not assume that the information contained in this proxy statement/prospectus
is accurate as of any date other than such date. Neither the mailing of this proxy statement/prospectus to Avalon stockholders nor the
issuance by Avalon of shares of Avalon Common Stock as consideration pursuant to the Merger Agreement will create any implication to the
contrary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>This proxy statement/prospectus
does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, or the solicitation of a proxy, in any jurisdiction
in which or from any person to whom it is unlawful to make any such offer or solicitation in such jurisdiction. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The information concerning
Avalon contained in this proxy statement/prospectus has been provided by Avalon, and the information concerning YOOV contained in this
proxy statement/prospectus has been provided by YOOV.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>



</div><table cellpadding="0" style="width: 100%; border-spacing: 0px;">
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 1.5pt; padding-left: 0in">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; padding-top: 0in"><b>Page</b></td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="width: 90%; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_001">FREQUENTLY USED TERMS</a></td>
    <td style="width: 10%; text-align: center; padding-top: 0in; padding-bottom: 0in">iv</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_002">QUESTIONS AND ANSWERS ABOUT THE MERGER</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">vi</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_003">SUMMARY OF THE PROXY STATEMENT/PROSPECTUS</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">1</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_004">Parties to the Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">1</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_005">Avalon</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">1</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_006">YOOV</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">2</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_007">Merger Sub</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">2</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_008">The Merger Agreement</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">3</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_009">Merger Consideration</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">3</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_010">Conditions to the Closing</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">3</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_011">Non-Solicitation</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">3</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_012">Intervening Event</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">4</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_013">Superior Proposal</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">4</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_014">Termination of the Merger Agreement</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">4</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_015">Termination Fee</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">4</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_016">Certain Agreements Related to the Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">5</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_017">Voting Agreements</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">5</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_018">Lock-Up Agreements</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">5</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_019">Interests of Certain Persons in the Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">5</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_020">Avalon</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">5</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_021">YOOV</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">6</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_022">Reasons for the Approval of the Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">6</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_023">Opinion of Avalon&#8217;s Financial Advisor</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">6</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_024">Regulatory Approvals Required for the Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">7</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_025">Accounting Treatment of the Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">12</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_026">Material U.S. Federal Income Tax Consequences of the Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">12</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_027">Ownership Following the Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">13</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_028">Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">13</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_029">Comparison of Rights of Holders of Avalon Common Stock and YOOV Ordinary Shares</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">13</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_030">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">14</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_031">MARKET PRICE AND DIVIDEND INFORMATION</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">16</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_032">RISK FACTORS</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">17</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_033">Risks Related to the Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">17</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_034">Additional Risks Relating to the Combined Company after Completion of the Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">23</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_035">Risks Related to YOOV and its Operations</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">32</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_036">Risks Related to Avalon</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">48</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_037">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">73</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_038">THE SPECIAL MEETING OF AVALON STOCKHOLDERS</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">84</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_039">The Special Meeting</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">84</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_040">Date, Time and Place of the Special Meeting</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">84</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_041">Purpose of the Special Meeting</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">84</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_042">Recommendation of the Avalon Board of Directors</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">85</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_043">Record Date and Voting</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">85</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_044">Voting Your Shares</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">85</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_045">Who Can Answer Your Questions About Voting Your Shares</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">86</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_046">Quorum and Vote Required for the Proposals</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">86</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_047">Abstentions and Broker Non-Votes</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">86</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_048">Revocability of Proxies</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">87</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_049">Appraisal or Dissenters&#8217; Rights</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">87</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_050">Solicitation of Proxies</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">87</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_051">THE MERGER</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">88</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_052">The Background of the Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">88</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_053">Avalon&#8217;s Reasons for the Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">91</td></tr>
  </table><div>


</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 8; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; border-spacing: 0px;">
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in; width: 90%"><a href="#a_054">YOOV&#8217;s Reasons for the Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in; width: 10%">94</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_055">Interests of Avalon&#8217;s Directors and Officer in the Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">95</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_056">Continued Service</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">95</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_057">Stock Ownership and Voting Agreements</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">95</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_058">Indemnification and Insurance</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">95</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_059">Golden Parachute Compensation</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">95</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_060">Interests of YOOV&#8217;s Directors and Officers in the Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">97</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_061">Ownership Interests</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">97</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_062">Treatment of YOOV Preferred Shares</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">97</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_063">Management After the Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">97</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_064">Indemnification and Insurance</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">98</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_065">Regulatory Approvals Required for the Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">107</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_066">Accounting Treatment of the Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">107</td></tr>

<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in; width: 90%"><a href="#a_067">Appraisal Rights and Dissenters&#8217; Rights</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in; width: 10%">107</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_068">THE MERGER AGREEMENT</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">108</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_069">CERTAIN AGREEMENTS RELATED TO THE MERGER</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">125</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_070">Voting Agreements</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">125</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_071">Lock-Up Agreements</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">126</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_072">CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">127</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_073">PROPOSAL NO. 1&#8212;THE NASDAQ PROPOSAL</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">129</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_074">Merger Shares</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">129</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_075">Approval of the Issuance of the Merger Shares</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">129</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_076">Vote Required for Approval</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">129</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_077">PROPOSAL NO. 2&#8212;THE REVERSE STOCK SPLIT PROPOSAL</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">130</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_078">Approval of Reverse Stock Split of Avalon Common Stock</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">130</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_079">Reasons for Reverse Stock Split</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">130</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_080">Criteria to be Used for Determining Whether to Implement Reverse Stock Split</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">132</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_081">Certain Risks and Potential Disadvantages Associated with Reverse Stock Split</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">132</td></tr>

<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in; width: 90%"><a href="#a_082">Effective Reverse Stock Split Time</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in; width: 10%">133</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_083">Effects of Reverse Stock Split</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">133</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_084">Treatment of Fractional Shares</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">134</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_085">Record and Beneficial Stockholders</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">135</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_086">Accounting Consequences</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">135</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_087">No Dissenter&#8217;s or Appraisal Rights</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">135</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_088">Certain Material U.S. Federal Income Tax Consequences of the Reverse Stock Split</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">135</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_089">Tax Consequences of the Reverse Stock Split Generally</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">136</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_090">Vote Required for Approval</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">136</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_091">PROPOSAL NO. 3&#8212;THE EQUITY PLAN INCREASE PROPOSAL</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">137</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_092">Vote Required for Approval</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">144</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_093">PROPOSAL NO. 4&#8212;THE SERIES C PREFERRED STOCK PROPOSAL</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">145</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_094">Vote Required for Approval</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">146</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_095">PROPOSAL NO. 5&#8212;THE SERIES D PREFERRED STOCK PROPOSAL</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">147</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_096">Background and Overview</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">147</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_097">Vote Required for Approval</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">148</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_098">PROPOSAL NO. 6&#8212;THE INCREASE IN AUTHORIZED SHARES PROPOSAL</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">149</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_099">Vote Required for Approval</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">149</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_100">PROPOSAL NO. 7&#8212;THE GOLDEN PARACHUTE PROPOSAL</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">150</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_101">General</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">150</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_102">Vote Required for Approval</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">150</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_103">PROPOSAL NO. 8&#8212;THE ADJOURNMENT PROPOSAL</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">151</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_104">Vote Required for Approval</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">151</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_105">INFORMATION ABOUT YOOV</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">152</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_106">BUSINESS</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">152</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_107">YOOV EXECUTIVE COMPENSATION</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">165</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_108">YOOV MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">167</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_109">CERTAIN YOOV RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">182</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 9 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; border-spacing: 0px;">
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in; width: 90%"><a href="#a_110">INFORMATION ABOUT AVALON</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in; width: 10%">184</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#g_001">BUSINESS</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">184</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_111">AVALON EXECUTIVE COMPENSATION</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">194</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_112">AVALON MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">198</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_113">CERTAIN AVALON RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">210</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_114">MANAGEMENT AFTER THE MERGER</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">212</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_115">Executive Officers and Directors of the Combined Company Following the Merger</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">212</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_116">Executive Officers</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">212</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_117">Non-Employee Directors</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">215</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_118">Board Composition</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">216</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_119">Director Independence</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">216</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_120">Committees of the Board of Directors</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">217</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_121">Audit Committee</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">217</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_122">Compensation Committee</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">217</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 1in"><a href="#a_123">Nominating and Corporate Governance Committee</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">217</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_124">Compensation Committee Interlocks and Insider Participation</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">218</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_125">Director Compensation</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">218</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_126">Limitation on Liability and Indemnification of Directors and Officers</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">218</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_127">Code of Business Conduct and Ethics for Employees, Executive Officers, and Directors</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">219</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_128">DESCRIPTION OF AVALON&#8217;S SECURITIES</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">220</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_129">COMPARISON OF RIGHTS OF HOLDERS OF AVALON STOCK AND YOOV STOCK</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">224</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_130">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">229</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_131">YOOV</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">229</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_132">Shareholders Agreement</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">230</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_133">Avalon</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">230</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_134">LEGAL MATTERS</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">233</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_135">EXPERTS</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">233</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_136">ADDITIONAL INFORMATION</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">234</td></tr>

<tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in; width: 90%"><a href="#a_137">Annual Report</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in; width: 10%">234</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_138">Submitting Proxy Proposals and Director Nominations for the 2025 Annual Meeting</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">234</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_139">Householding&#8212;Delivery of Documents to Stockholders</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">234</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_140">WHERE YOU CAN FIND MORE INFORMATION</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">235</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_141">INDEX TO FINANCIAL STATEMENTS</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">F-1</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_142">YOOV FINANCIAL STATEMENTS</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">F-2</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_143">AVALON FINANCIAL STATEMENTS</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">F-52</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_144">ANNEX A: MERGER AGREEMENT</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">A-1</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_145">ANNEX B: OPINION OF ROTH</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">B-1</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_146">ANNEX C: REVERSE SPLIT CHARTER AMENDMENT</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">C-1</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_147">ANNEX D: EQUITY PLAN INCREASE</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">D-1</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_148">ANNEX E: INCREASE CHARTER AMENDMENT</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">E-1</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_149">PART II</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">II-1</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"> <a href="#a_150">INFORMATION NOT REQUIRED IN PROSPECTUS</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">II-1</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_151">Item&#8201;20. Indemnification of Directors and Officers</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">II-1</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_152">Item&#8201;21. Exhibits and Financial Statement Schedules</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">II-2</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0.5in"><a href="#a_153">Item&#8201;22. Undertakings</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">II-13</td></tr>
  <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#a_154">SIGNATURES</a></td>
    <td style="text-align: center; padding-top: 0in; padding-bottom: 0in">II-15</td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="clear: both; display: block;"><br/></span>
&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 10 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">FREQUENTLY USED TERMS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In this document:  </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="-keep: true">&#8220;AI&#8221; means
artificial intelligence which refers to the simulation of human intelligence processes by machines, enabling capabilities like learning,
reasoning, and problem-solving.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;AIaaS&#8221; means
AI as a service which is commonly referred to a cloud-based delivery model that allows businesses to access and integrate AI capabilities
into their business operations.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#8220;AI technologies&#8221;
means the tools, frameworks, and methodologies used to develop and deploy AI systems. This includes but not limited to Machine Learning,
Natural Language Processing, Computer vision, Large Language Models and Optical Character Recognition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#8220;Avalon&#8221; means, as the context requires
Avalon GloboCare Corp., a Delaware corporation.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#8220;Avalon Board&#8221; means the board of
directors of Avalon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Avalon Bylaws&#8221;
means the Amended and Restated Bylaws of Avalon, as amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Avalon Charter&#8221;
means the Amended and Restated Certificate of Incorporation of Avalon, as amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Avalon Common Stock&#8221;
means the common stock, par value $0.0001 per share, of Avalon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Avalon Preferred Stock&#8221;
means the Avalon Series C Preferred Stock and the Avalon Series D Preferred Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Avalon Series C Preferred
Stock&#8221; means the Series C Convertible Preferred Stock, par value $0.0001 per share, of Avalon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Avalon Series D Preferred
Stock&#8221; means the Series D Convertible Preferred Stock, par value $0.0001 per share, of Avalon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Avalon Stock Options&#8221;
means the options to purchase Avalon Common Stock outstanding immediately prior to the Effective Time, whether vested or unvested.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Avalon Transfer Agent&#8221;
means Vstock Transfer LLC,&#160;the transfer agent and registrar for Avalon Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Avalon Voting Agreement&#8221;
means the Voting Agreement, dated as of March 7, 2025, by and among Avalon, YOOV and the Key Avalon Stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Avalon Warrants&#8221;
means the warrants to purchase Avalon Common Stock outstanding immediately prior to the Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;BVI Companies Act&#8221;
means the BVI Business Companies Act, 2004 (as revised).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#8220;Closing&#8221;
means the consummation of the Merger at the Effective Time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Closing Date&#8221;
means the date on which the Closing occurs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Code&#8221; means
the Internal Revenue Code of 1986, as amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Combined Company&#8221;
means, as the context requires, Avalon and its subsidiaries following the Closing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;DGCL&#8221; means
the Delaware General Corporation Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Dissenting Shares&#8221;
means, collectively, any YOOV Ordinary Shares or YOOV Preferred Shares for which the holder thereof (i) has not voted in favor of the
Merger or consented in writing and (ii) has validly exercised the rights to dissent from the Merger in accordance with, and has complied
in all respects with, the BVI Companies Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Effective Time&#8221;
means the effective time of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 11 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Exchange Act&#8221;
means the U.S. Securities Exchange Act of 1934, as amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Exchange Ratio&#8221;
means the ratio (rounded to four decimal places), determined as follows: if the closing price of the Avalon Common Stock on Nasdaq on
the second (2<sup>nd</sup>) trading day immediately preceding the Effective Time is (x) less than or equal to $5.00, the Exchange Ratio
shall be 60,000,000 divided by the YOOV Outstanding Shares; or (y) greater than $5.00, the Exchange Ratio shall be 54,000,000 divided
by the YOOV Outstanding Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;GAAP&#8221; means
United States generally accepted accounting principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#8220;Key Avalon Stockholders&#8221;
means the officers and directors of Avalon who, in their capacity as stockholders of Avalon, executed the Avalon Voting Agreement and
Lock-Up Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#8220;Key YOOV Shareholders&#8221;
means the officers, directors and the following 5% or greater shareholders of YOOV, Facewell International Limited, Rich Joy International
Industrial Limited, Topsoil (HK) Limited and Pearl River Partners Limited, who, in their capacity as shareholders of YOOV, executed the
YOOV Voting Agreement. The Key YOOV Shareholders are the only YOOV shareholders necessary to approve the Merger.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Merger&#8221; means,
pursuant to the Merger Agreement, the merging of Merger Sub with and into YOOV, with YOOV surviving the Merger as a wholly owned subsidiary
of Avalon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Merger Agreement&#8221;
means the Agreement and Plan of Merger, dated as of March 7, 2025, as may be amended from time to time, by and among Avalon, YOOV and
Merger Sub.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Merger Shares&#8221;
means the number of shares of Avalon Common Stock equal to the Exchange Ratio for which such YOOV Ordinary Shares will be converted into
and exchanged for at the Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Merger Sub&#8221;
means Nexus MergerSub Limited, a business company incorporated in the British Virgin Islands and wholly owned subsidiary of Avalon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Nasdaq&#8221; means
The Nasdaq Stock Market LLC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;SEC&#8221; means the
U.S. Securities and Exchange Commission.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Securities Act&#8221;
means the U.S. Securities Act of 1933, as amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Special Meeting&#8221;
means the special meeting of Avalon stockholders to consider and vote upon the proposals set forth herein and any adjournment or postponement
thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#8220;YOOV&#8221; means
YOOV Group Holding Limited, a British Virgin Islands business company.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;YOOV Board&#8221;
means the board of directors of YOOV.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;YOOV Ordinary Shares&#8221;
means the common stock, par value $0.10 per share, of YOOV.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;YOOV Outstanding Shares&#8221;
means the total number of YOOV Ordinary Shares outstanding immediately prior to the Effective Time expressed on a fully diluted and as-converted
to YOOV Ordinary Share basis, assuming, without limitation or duplication, and calculated using the treasury stock method (i) the conversion
of each YOOV Preferred Share into YOOV Ordinary Shares immediately prior to the Effective Time and in accordance with YOOV&#8217;s memorandum
and articles of association; (ii) the conversion of any YOOV Ordinary Share purchase warrants or other securities convertible or exchangeable
into YOOV Ordinary Shares; and (iii) the issuance of YOOV Ordinary Shares in respect of all other rights to receive such shares that will
be outstanding immediately after the Effective Time, in each case pursuant to the instruments governing such securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;YOOV Preferred Shares&#8221;
means the preferred shares, par value $0.10 per share, of YOOV outstanding immediately prior to the Closing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;YOOV Voting Agreement&#8221;
means the Voting Agreement, dated as of March 7, 2025, by and among YOOV, Avalon and the Key YOOV Shareholders. &#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 12 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_002"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">QUESTIONS AND ANSWERS ABOUT
THE MERGER</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>The following questions
and answers briefly address some commonly asked questions regarding the proposed Merger and about the proposals to be presented at the
Special Meeting including with respect to the proposed Merger. The following questions and answers may not include all the information
that is important to Avalon stockholders. Stockholders are urged to read carefully this entire proxy statement/prospectus, including the
financial statements and annexes attached hereto and the other documents referred to herein. Except where indicated, the information in
this proxy statement/prospectus does not give effect to the proposed Reverse Stock Split of Avalon Common Stock, as described in this
proxy statement/prospectus. </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Why am I receiving this proxy statement/prospectus? </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2025, Avalon, YOOV and Merger Sub
    entered into the Merger Agreement pursuant to which Merger Sub will merge with and into YOOV, with YOOV surviving the Merger as a wholly
    owned subsidiary of Avalon. A copy of the Merger Agreement is attached to this proxy statement/prospectus as <span style="text-decoration:underline">Annex A</span>.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms and conditions of the
    Merger Agreement, immediately prior to the Effective Time, each then-outstanding YOOV Preferred Share will either automatically be
    converted into YOOV Ordinary Shares or canceled and cease to exist in accordance with their terms and, at the Effective Time, each
    then-outstanding YOOV Ordinary Share (other than shares held in treasury and Dissenting Shares) will be converted into and become
    exchangeable for a number of shares of Avalon Common Stock equal to the Exchange Ratio, as described in the section entitled &#8220;<i>The
    Merger Agreement-Merger Consideration.</i>&#8221;</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>What is the Exchange Ratio for the Merger Agreement? </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Exchange Ratio in the Merger Agreement
        sets forth the number of shares of Avalon Common Stock that will be issuable for each YOOV Ordinary Share outstanding in the
        Merger. The Exchange Ratio is subject to a collar mechanism and will be determined as follows: if the closing price of the Avalon
        Common Stock on Nasdaq on the second (2<sup>nd</sup>) trading day immediately preceding the Effective Time is (x) less than or
        equal to $5.00, the Exchange Ratio shall be 60,000,000 divided by the YOOV Outstanding Shares; or (y) greater than $5.00, the
        Exchange Ratio shall be 54,000,000 divided by the YOOV Outstanding Shares. Based on the closing price of Avalon Common Stock
        on Nasdaq of $3.41 on June 6, 2025, <span style="background-color: white">the latest practicable trading day prior to the date
        of this proxy statement/prospectus, and the number of YOOV Outstanding Shares on such date, it is estimated that the Exchange
        Ratio will be approximately 121.8. </span>Based on the estimated Exchange Ratio, Avalon is expected to issue 60,000,000 shares
        of Avalon Common Stock to the YOOV shareholders. <span style="background-color: white">Upon completion of the Merger, the current
        Avalon stockholders are expected to own approximately 2.7% to 3.0% of the common stock of the Combined Company and the YOOV shareholders
        are expected to own approximately 97.0% to 97.3% of the common stock of the Combined Company. The Exchange Ratio is an estimate
        only, and the actual Exchange Ratio and relative ownership interests of Avalon stockholders and YOOV shareholders in the Combined
        Company immediately following the Merger will depend on the market price of Avalon&#8217;s Common Stock two (2) trading days
        prior to the Merger and the number of YOOV Outstanding Shares on the Closing Date.</span></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Exchange Ratio will be adjusted equitably
    to reflect any change in the outstanding shares of capital stock of Avalon or YOOV which occurs as a result of any reclassification, recapitalization,
    reorganization, stock split (including the Reverse Stock Split, if approved and if necessary to be effectuated for the Combined Company
    to meet the $4.00 minimum bid price initial listing requirement following the Closing pursuant to the rules of The Nasdaq Capital Market)
    or combination, exchange or readjustment of shares, or any stock dividend or distribution is declared with a record date prior to the
    Effective Time.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a more detailed discussion of the Exchange
    Ratio, please see the section entitled &#8220;<i>The Merger Agreement-Exchange Ratio</i>.&#8221;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This proxy statement/prospectus and its annexes
    contain important information about the proposed Merger and the proposals to be acted upon at the Special Meeting. You should read this
    proxy statement/prospectus and its annexes carefully and in their entirety. This document also constitutes a prospectus of Avalon with
    respect to the Merger Shares issuable in connection with the Merger.</p></td></tr>
  </table><div>
</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 13 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>Q:</b></td><td style="text-align: justify"><b>What matters will stockholders consider at the Special Meeting?</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>A:</b></td><td style="text-align: justify">At the Special Meeting, Avalon will ask its stockholders to
vote in favor of the following proposals:</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">The &#8220;Nasdaq
                                            Proposal&#8221; - to approve, pursuant to the rules of the Nasdaq Stock Market, the issuance
                                            of the Merger Shares pursuant to the terms of the Merger Agreement;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">The &#8220;Reverse
                                            Stock Split Proposal&#8221; - to approve an amendment to the Avalon Charter to effect a reverse
                                            stock split of only the outstanding shares of Avalon Common Stock and other outstanding securities
                                            of Avalon (with no change to the authorized capital stock of Avalon), at a ratio in the range
                                            from 1-for-2 to 1-for-20, with such ratio to be determined by the Avalon Board and with such
                                            reverse stock split to be effected at such time and date as determined by the Avalon Board
                                            in its sole discretion, if necessary to be effectuated pursuant to the rules of The Nasdaq
                                            Capital Market to consummate the Merger;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">3.</td><td style="text-align: justify">The &#8220;Equity
                                            Plan Increase Proposal&#8221; - to approve an amendment to the Amended and Restated 2020
                                            Plan to increase the number of shares available for issuance under the Amended and Restated
                                            2020 Plan by 2,500,000 shares;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">4.</td><td style="text-align: justify">The &#8220;Series
                                            C Preferred Stock Proposal&#8221; - to approve, pursuant to the rules of the Nasdaq Stock
                                            Market, the potential issuance of shares of Avalon Common Stock issuable upon conversion
                                            of the Avalon Series C Preferred Stock;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">5.</td><td style="text-align: justify">The &#8220;Series
                                            D Preferred Stock Proposal&#8221; - to approve, pursuant to the rules of the Nasdaq Stock
                                            Market, the potential issuance of shares of Avalon Common Stock issuable upon conversion
                                            of the Avalon Series D Preferred Stock;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">6.</td><td style="text-align: justify">The &#8220;Increase
                                            in Authorized Shares Proposal&#8221; - to approve an amendment to the Avalon Charter to increase
                                            the number of shares of Avalon Common Stock authorized for issuance thereunder from 100,000,000
                                            to 200,000,000;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">7.</td><td style="text-align: justify">The &#8220;Golden
                                            Parachute Proposal&#8221;- to approve on an advisory (non-binding) basis, certain compensation
                                            payments that will be made by Avalon to its named executive officer in connection with the
                                            Merger; and</td>
</tr></table><div>



</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">8.</td><td style="text-align: justify">The &#8220;Adjournment
                                            Proposal&#8221; - to approve the adjournment of the Special Meeting in the event that the
                                            number of shares of Avalon Common Stock present or represented by proxy at the Special Meeting
                                            and voting &#8220;FOR&#8221; the adoption of Proposals No. 1 through 7 are insufficient to
                                            approve such proposals.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>What will happen upon the consummation of the Merger? </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">On the Closing Date, Merger Sub will merge with and into YOOV, with
    YOOV surviving the Merger as a wholly owned subsidiary of Avalon and Merger Sub will cease to exist. The Merger will have the effects
    specified under the BVI Companies Act. As consideration for the Merger, immediately prior to the Effective Time, each then-outstanding
    YOOV Preferred Share will either automatically be converted into YOOV Ordinary Shares or canceled and cease to exist in accordance
    with their terms, and, at the Effective Time, each then-outstanding YOOV Ordinary Share (other than shares held in treasury and Dissenting
    Shares) will be converted into and become exchangeable for a number of shares of Avalon Common Stock equal to the Exchange Ratio,
    as described in the sections entitled &#8220;<i>The Merger Agreement-Merger Consideration,</i>&#8221; and &#8220;<i>The Merger Agreement-Treatment
    of YOOV Preferred Shares.&#8221;</i>&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 14 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Why are the companies proposing to merge? </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt; text-underline-style: double">&#160;</span></td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Avalon and YOOV believe that combining the
two companies will create a company that will have cutting-edge AI technologies to deliver intelligent business automation solutions,
greater financial resources and an experienced senior management team. The Combined Company will focus on advancing YOOV&#8217;s AI-driven
workflow automation platform, which are described on page 152 under the section titled &#8220;<i>Information About YOOV</i>.&#8221;
If the Merger is not completed, Avalon will reconsider its strategic alternatives and may need to cease operations, dissolve or seek
protection of bankruptcy courts.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">In the event the Merger is consummated, the
    Combined Company intends to continue to develop and commercialize KetoAir.&#160; Avalon has been operating and developing the KetoAir
    business for almost two (2) years. Avalon has engaged its outside marketing team for the marketing and distribution of KetoAir
    through the remainder of 2025 and, following the completion of the Merger, the Combined Company intends to extend such engagement
    as long as the Combined Company determines that continuation of the marketing and sale of KetoAir is viable.&#160; In addition, Avalon
    is in negotiations for a long-term agreement for the development of a testing system using the same intellectual property and mechanism
    of KetoAir for the testing of THC.&#160; Avalon and YOOV also believe that there may be the opportunity to integrate the YOOV AI
    technologies into the KetoAir analytical data to further develop the product. Avalon and YOOV have not yet determined whether or
    not they will continue to own or will sell the real property currently owned by Avalon following the completion of the Merger.&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a more complete discussion of Avalon&#8217;s
    and YOOV&#8217;s reasons for the Merger, please see the sections entitled &#8220;<i>The Merger-Avalon&#8217;s Reasons for the Merger</i>&#8221;
    and &#8220;<i>The Merger-YOOV&#8217;s Reasons for the Merger</i>.&#8221;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Why is the Avalon Board recommending that stockholders approve the issuance of the Merger Shares, the Reverse Stock Split and the associated transactions?</b>&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In unanimously recommending that Avalon stockholders
    approve the issuance of the Merger Shares, the Reverse Stock Split and the related proposals, the Avalon Board considered various factors
    including the potential benefits and risks associated with these proposals and the Merger. In assessing the benefits of the Merger, the
    Avalon Board considered, among other things, the fact that the Combined Company will have cutting-edge AI technologies to deliver intelligent
    business automation solutions, greater financial resources and an experienced senior management team. The Avalon Board also considered
    the recommendation of the management of Avalon in favor of the Merger, alternatives reasonably available to Avalon, Avalon&#8217;s current
    financial situation measured against the financial resources available to the Combined Company and the alternatives reasonably available
    to Avalon. The Avalon Board weighed these benefits against potential risks associated with the transaction including the difficulties
    of combining the two companies based on differences in geographic location, the possibility that the Merger may not occur for various
    reasons and the possibility that anticipated benefits of the Merger may not be realized. After careful consideration of these benefits
    and risks, the Avalon Board unanimously recommends that Avalon stockholders approve the Merger.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a more complete discussion of the Avalon
    Board&#8217;s recommendation in favor of stockholders approving these proposals, please see the section entitled &#8220;<i>The&#160;Merger-Avalon&#8217;s&#160;Reasons&#160;for&#160;the
    Merger.</i>&#8221;</p></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>What equity stake will current Avalon stockholders and YOOV shareholders have in Avalon after the Closing? </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td style="text-align: justify"><span style="-keep: true">The number of shares of Avalon Common Stock that YOOV shareholders will
receive as consideration in the Merger is not fixed. Based on the closing price of Avalon Common Stock on Nasdaq of $3.41 on June 6, 2025,
the latest practicable trading day prior to the date of this proxy statement/prospectus, and the number of YOOV Outstanding Shares on
such date, it is estimated that the Exchange Ratio will be approximately <span style="background-color: white">121.8. </span>Based on
the estimated Exchange Ratio, Avalon is expected to issue 60,000,000 shares of Avalon Common Stock to the YOOV shareholders. <span style="background-color: white">Upon
completion of the Merger, the current Avalon stockholders are expected to own approximately 2.7% to 3.0% of the common stock of the Combined
Company and the YOOV shareholders are expected to own approximately 97.0% to 97.3% of the common stock of the Combined Company. The Exchange
Ratio is an estimate only, and the actual Exchange Ratio and relative ownership interests of Avalon stockholders and YOOV shareholders
in the Combined Company immediately following the Merger will depend on the market price of Avalon&#8217;s Common Stock two (2) trading
days prior to the Merger and the number of YOOV Outstanding Shares on the Closing Date.</span></span> </td></tr><tr style="vertical-align: top"><td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>If approved, how will the Reverse Stock Split impact the voting power of Avalon stockholders in the Combined Company?</b>&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Reverse Stock Split, if approved and if necessary
    to be effectuated for the Combined Company to meet the $4.00 minimum bid price initial listing requirement following the Closing pursuant
    to the rules of The Nasdaq Capital Market, will not impact the relative voting power of Avalon stockholders in the Combined Company because
    pursuant to the terms of the Merger Agreement, the Exchange Ratio will be proportionally adjusted based upon the actual reverse split
    ratio implemented in the Reverse Stock Split.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a more detailed discussion of the relative
    voting power of Avalon stockholders in the Combined Company, please see the section entitled &#8220;<i>The Merger&#160;Agreement-Exchange&#160;Ratio</i>.&#8221;</p></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 15 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->viii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Who will be the officers and directors of the Combined Company if the Merger is consummated? </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Merger Agreement provides that, immediately
    upon the Effective Time, the Combined Company Board will be comprised of seven (7) directors, five (5) of which will be designated
    by YOOV and two (2) of which will be designated by Avalon. The individuals currently identified to serve as directors of the Combined
    Company following the consummation of the Merger are Wenzhao Lu, the current Chairman of the Avalon Board, and Steven A. Sanders,
    a current director of Avalon, designated by Avalon and Wong Ling Yan Philip, Devere Andrew Bryan, Lam Heung Yeung Herman, Lourdes
    Felix and Kirsty Vanora Godfrey-Billy, designated by YOOV.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Immediately following the consummation of
the Merger, the following individuals will be the officers of the Combined Company: Wong Ling Yan Philip, the current President and Chief
Executive Officer of YOOV, as President and Chief Executive Officer, Luisa Ingargiola, the current Chief Financial Officer of Avalon,
as Chief Financial Officer and Wong Ho Chi Mark, the current Chief Technology Officer of YOOV, as Chief Technology Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please see the section entitled &#8220;<i>Management
    After the Merger</i>.&#8221;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>What conditions must be satisfied to complete the Merger? </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">There are a number of closing conditions in the Merger Agreement, including
    that Avalon&#8217;s stockholders approve the issuance of the Merger Shares. In addition, YOOV shareholders must adopt the Merger
    Agreement and approve the Merger and the transactions contemplated thereby. For a summary of the conditions that must be satisfied
    or waived prior to completion of the Merger, please see the section entitled &#8220;<i>The Merger Agreement-Conditions to the Completion
    of the Merger</i>.&#8221; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>What would be the consequence of a delisting of Avalon Common Stock from Nasdaq with respect to the Merger? </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt"><b>A:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The consummation of the Merger is conditioned on, among other things,
    the listing approval for the Combined Company&#8217;s securities on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;). An initial
    listing application has been filed with Nasdaq pursuant to which the Combined Company will need to meet the initial listing standards
    of Nasdaq. Avalon and YOOV expect the process with Nasdaq to be completed prior to the Closing Date. Since the Merger is conditioned
    upon approval of the listing by Nasdaq, the parties do not intend to complete the Merger without such approval The Merger Agreement
    also requires that Avalon shall use its commercially reasonable efforts to maintain its listing until the consummation of the Merger.
    On November 3, 2023, the Nasdaq staff notified Avalon that Avalon did not comply with the Minimum Bid Price Requirement for continued
    listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2) (the &#8220;Bid Price Notice&#8221;). Pursuant
    to the Bid Price Notice, Avalon had 180 calendar days from the date of the Bid Price Notice, or May 1, 2024, to regain compliance
    with the Minimum Bid Price Requirement. On May 2, 2024, Avalon received a letter from Nasdaq advising that Avalon had been granted
    a 180-day extension to October 28, 2024, to regain compliance with the Minimum Bid Price Requirement. In connection with regaining
    compliance with the Minimum Bid Price Requirement, Avalon implemented a reverse stock split on October 25, 2024. However, on October
    29, 2024, Avalon received notice from the Nasdaq staff that it failed to regain compliance with the Minimum Bid Price Requirement
    because the reverse stock split did not occur at least ten (10) business days prior to the deadline of on or before October 28, 2024,
    which served as basis for the delisting of Avalon&#8217;s securities from Nasdaq. Following the receipt of the Nasdaq notice, Avalon
    requested and received a hearing date to discuss the non-compliance notice with the Nasdaq staff. On November 19, 2024, prior to
    the date of the hearing, Avalon received a notice that it has regained compliance with Nasdaq&#8217;s Minimum Bid Price Requirement.
    On May 22, 2025, the Nasdaq Staff notified Avalon that Avalon did not comply with the minimum stockholders&#8217; equity requirement
    for continued listing on The Nasdaq Capital Market, under Listing Rule 5550(b)(1), because Avalon&#8217;s stockholders&#8217; equity
    of ($3,891,270), as reported in Avalon&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2025, was below the required
    minimum of $2.5 million, and because, as of May 22, 2025, Avalon did not meet the alternative compliance standards, relating to the
    market value of listed securities of $35 million or net income from continuing operations of $500,000 in the most recently completed
    fiscal year or in two of the last three most recently completed fiscal years (the &#8220;Stockholders&#8217; Equity Notice&#8221;).
    The Stockholders&#8217; Equity Notice has no immediate impact on the listing of the Avalon Common Stock. Avalon has forty-five (45)
    days from May 22, 2025, or through Monday, July 7, 2025, to submit to Nasdaq a plan to regain compliance with Listing Rule 5550(b)(1).
    If Nasdaq accepts Avalon&#8217;s plan, Nasdaq may grant an extension of up to 180 calendar days from May 22, 2025, or through Tuesday,
    November 18, 2025, to regain compliance. If Nasdaq does not accept Avalon&#8217;s plan, Avalon will have the right to appeal such
    decision to a Nasdaq hearings panel. Avalon intends to submit to Nasdaq, within the requisite time period, a plan to regain compliance
    with Listing Rule 5550(b)(1). In the event Avalon&#8217;s Common Stock is delisted from Nasdaq, the initial listing application is
    delated, or Nasdaq does not approve the Combined Company&#8217;s securities for listing on The Nasdaq Capital Market under the initial
    listing requirements, Avalon will not be able to satisfy such closing condition and the Merger may be delayed, or if not approved,
    may not be consummated. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>What vote is required to approve the proposals presented at the Special Meeting of stockholders? </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">The approval of each of the Nasdaq Proposal, the Reverse Stock Split Proposal, the Equity Plan Increase Proposal, the Series C Preferred Stock Proposal, Series D Preferred Stock Proposal, the Increase in Authorized Shares Proposal, the Golden Parachute Proposal (on an advisory (non-binding) basis) and the Adjournment Proposal requires the affirmative vote of a majority of the total votes properly cast by the Avalon Stockholders at the Special Meeting. Accordingly, abstentions and broker non-votes, if any, will have no effect on the outcome of the Nasdaq Proposal, the Reverse Stock Split Proposal, the Equity Plan Increase Proposal, the Series C Preferred Stock Proposal, Series D Preferred Stock Proposal, the Increase in Authorized Shares Proposal, the Golden Parachute Proposal and the Adjournment Proposal.</span></p>
                                    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                    <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">As of the Record Date,
                                    the Key Avalon Stockholders, including Avalon directors and officers, beneficially owned approximately
                                    [ &#160;&#160;]% of the outstanding shares of Avalon Common Stock and, pursuant to the Voting Agreements, agreed
                                    to vote all of their shares of Avalon Common Stock in favor of the approval of the Nasdaq Proposal,
                                    the Reverse Stock Split Proposal, the Equity Plan Increase Proposal, the Series C Preferred Stock
                                    Proposal, Series D Preferred Stock Proposal, the Increase in Authorized Shares Proposal, the Golden
                                    Parachute Proposal (on an advisory (non-binding) basis) and the Adjournment Proposal. </span></p></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 16 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ix<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Do YOOV&#8217;s shareholders need to approve the Merger? </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Yes. The adoption of the Merger Agreement and the approval of the Merger
    and related transactions by the YOOV shareholders requires the affirmative vote of the holders of at least a majority of the issued
    and outstanding equity interests of YOOV. Contemporaneously with the execution of the Merger Agreement, the Key YOOV Shareholders
    entered into the YOOV Voting Agreement pursuant to which, among other things and subject to the terms and conditions therein, the
    Key YOOV Shareholders agreed to vote all shares of YOOV capital stock beneficially owned by such stockholders at the time of the
    stockholder vote in favor of adoption and approval of the Merger Agreement and the approval of the transactions contemplated by the
    Merger Agreement, including the Merger, and any other matter necessary to consummate such transactions, and not to (a) transfer any
    of their YOOV Ordinary Shares (or enter into any arrangement with respect thereto) or (b) enter into any voting arrangement that
    is inconsistent with the YOOV Voting Agreement. Collectively, as of March 7, 2025, the Key YOOV Shareholders held approximately 53.5%
    of the outstanding shares of YOOV capital stock. For further information, please see the section entitled &#8220;<i>Certain Agreements
    Related to The Merger-Voting Agreements</i>.&#8221; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>How many votes do Avalon stockholders have at the Special Meeting?</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Each share of Avalon Common Stock is entitled to one vote at the Special Meeting for each share of Avalon Common Stock held of record as of the record date. As of the record date, there were [&#8195;] shares of Avalon Common Stock outstanding.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>What interests do Avalon&#8217;s current executive officer and directors have in the Merger? </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Avalon&#8217;s board of directors and executive
    officers may have interests in the Merger that are different from, in addition to or in conflict with, yours.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of March 7, 2025, the Key Avalon Stockholders,
    including Avalon directors and officers, beneficially owned approximately 26.1% of the outstanding shares of Avalon Common Stock.
    Luisa Ingargiola, currently Avalon&#8217;s Chief Financial Officer, will continue as the Chief Financial Officer of the Combined
    Company following the Closing. In addition, Ms. Ingargiola will receive certain &#8220;golden parachute&#8221; compensation in connection
    with the Merger, as described below. Wenzhao Lu, Lourdes Felix and Steven A. Sanders, currently directors on the Avalon Board, will
    also continue to serve as directors of the Combined Company following Closing. The Key Avalon Stockholders, including Avalon directors
    and officers, have also entered into the Avalon Voting Agreement in connection with the Merger.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For more information, please see the sections
    entitled &#8220;<i>The Merger-Interests of Avalon&#8217;s Directors and Officer in the Merger&#8221; and &#8220;Certain Agreements
    Related to the Merger-Voting Agreements</i>.&#8221;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>What interests do YOOV&#8217;s current officers and directors have in the Merger? </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The YOOV Board and executive officers may have
    interests in the Merger that are different from, in addition to or in conflict with, yours and the YOOV shareholders.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of March 7, 2025, the Key YOOV Shareholders,
    including YOOV&#8217;s directors and executive officers, beneficially owned approximately 53.5% of the outstanding YOOV Ordinary
    Shares. Wong Ling Yan Philip, currently YOOV&#8217;s President and Chief Executive Officer will continue as an executive officer
    and director of the Combined Company following the Closing. Wong Ho Chi Mark, the current Chief Technology Officer of YOOV, will
    continue as an executive officer of the Combined Company following Closing. Mr. Wong and Mr. Mark Wong and the Combined Company expect
    to enter into employment agreements, effective upon and subject to the Closing. The Key YOOV Shareholders, including YOOV&#8217;s
    directors and executive officers, have also entered into the YOOV Voting Agreement in connection with the Merger.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For more information, please see the sections
    titled &#8220;<i>The Merger-Interests of YOOV&#8217;s Directors and Officers in the Merger&#8221; and &#8220;Certain Agreements Related
    to the Merger-Voting Agreements</i>.&#8221;</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->x<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>What are the material U.S. federal income tax consequences of the Merger to Avalon&#8217;s United States stockholders? </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Avalon stockholders will not sell, exchange or dispose of any Avalon securities as a result of the Merger, so the Merger should not result in recognition of gain or loss by the Avalon stockholders for U.S. federal income tax purposes in respect of their Avalon securities. Please review the information in the section titled &#8220;<i>Certain Material U.S. Federal Income Tax Consequences of the Merger</i>&#8221; for a more complete description of certain material U.S. federal income tax consequences of the Merger to Avalon stockholders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>What are the material U.S. federal income tax consequences of the
    Reverse Stock Split to holders of Avalon Common Stock? </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">A holder of Avalon Common Stock should not recognize gain or loss for
    U.S. federal income tax purposes<b>&#160;</b>on the Reverse Stock Split (as such term is defined below under &#8220;<i>Proposal No.
    2 - The Reverse Stock Split Proposal</i>&#8221;), except to the extent such holder receives an additional fractional interest in
    a share as a result of the rounding up of fractional shares, and subject to the discussion under &#8220;<i>Proposal No. 2 - The Reverse
    Stock Split Proposal</i>.&#8221; Please review the information in the section titled &#8220;<i>Proposal No. 2 - The Reverse Stock
    Split Proposal</i> - <i>Certain Material U.S. Federal Income Tax Consequences of the Reverse Stock Split</i>&#8221; for a more complete
    description of certain material U.S. federal income tax consequences of the Reverse Stock Split to holders of Avalon Common Stock.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Do Avalon stockholders have appraisal rights in connection with
    the proposed Merger?</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No. There are no appraisal rights under the DGCL available to holders
    of shares of Avalon Common Stock and Avalon Preferred Stock in connection with the Merger.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>What will happen to Avalon if, for any reason, the Merger does not
    close?</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are certain circumstances under
        which the Merger Agreement may be terminated. Please see the section entitled &#8220;<i>The Merger Agreement-Termination of the
        Merger Agreement</i>&#8221; for information regarding the parties&#8217; specific termination rights.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If, as a result of the termination of the
    Merger Agreement or otherwise, Avalon is unable to complete the Merger by March 7, 2026 or obtain the approval to extend the deadline
    for Avalon to consummate the Merger, the Avalon Board may elect to, among other things, attempt to complete another strategic transaction
    like the Merger, attempt to purchase additional assets, enter into collaboration or joint venture agreements or attempt to sell or
    otherwise dispose of the various assets of Avalon. In addition, if the Merger is not completed, Avalon may not have sufficient capital
    to continue to operate its business in the short term and may become insolvent and be required to seek the protection of the bankruptcy
    courts or seek dissolution and, without additional funding or a strategic transaction, Avalon would likely be delisted from Nasdaq.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, under specified circumstances,
    Avalon may be required to pay YOOV a termination fee of $1.0 million.</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Do YOOV shareholders have appraisal rights if they object to the
    proposed Merger?</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any holder of the Dissenting Shares (other than those held in the treasury
    of YOOV, owned by YOOV or any of its direct or indirect wholly owned subsidiaries or by Avalon or any of its affiliates at the Effective
    Time) is entitled to payment of the fair value of his Dissenting Shares upon dissenting from the Merger in accordance with the BVI
    Companies Act. Please see the section entitled &#8220;<i>The Merger-Appraisal Rights and Dissenters&#8217; Rights.&#8221;</i>&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>When is the Merger expected to be completed?</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">It is currently anticipated that the Merger will be consummated promptly
    following the Special Meeting of stockholders, provided that all other conditions to the consummation of the Merger have been satisfied
    or waived. For a description of the conditions to the completion of the Merger, please see the section entitled &#8220;<i>The Merger
    Agreement-Conditions to the Completion of the Merger</i>.&#8221;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 18 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->xi<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>When and where will the Special Meeting be held? </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Special Meeting will be held in a virtual
    meeting format via live webcast only. The Special Meeting will be held on [&#8195;], 2025 at [&#8195;&#8195;], Eastern time. In order to
    participate in the Special Meeting live via the Internet, you must register at [&#8195;&#8195;] by 11:59 p.m. Eastern Time by [&#8195;],
    2025. On the day of the Special Meeting, if you have properly registered, you may enter the Special Meeting by logging in using the event
    password you received via email in your registration confirmation at [&#8195;&#8195;]. You will not be able to attend the Special Meeting
    in-person.&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you are a registered holder, you must register
    using the virtual control number included in your proxy materials or your proxy card. If you hold your shares beneficially through a bank
    or broker, you must provide a legal proxy from your bank or broker during registration and you will be assigned a virtual control number
    in order to vote your shares during the Special Meeting. If you are unable to obtain a legal proxy to vote your shares, you will still
    be able to attend the Special Meeting (but will not be able to vote your shares) so long as you demonstrate proof of stock ownership.
    Instructions on how to connect and participate via the Internet, including how to demonstrate proof of stock ownership, are posted at
    [&#8195;&#8195;].</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>What do I need to do now?</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">You are urged to carefully read and consider the information contained in this proxy statement/prospectus, including the financial statements and annexes attached hereto, and to consider how the Merger will affect you. You should then vote as soon as possible in accordance with the instructions provided in this proxy statement/prospectus on the enclosed proxy card or, if you hold your shares through a brokerage firm, bank or other nominee, on the voting instruction form provided by the broker, bank or nominee. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>How do I vote?</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">If you were a holder of Avalon Common Stock on [&#8195;], 2025, the record date for the Special Meeting, you may provide your proxy instructions in one of three different ways. First, you can mail your signed proxy card in the enclosed return envelope. Second, you may provide your proxy instructions via the Internet by following the instructions on your proxy card or voting instruction form. You may also vote your shares at the Special Meeting via live webcast. Please provide your proxy instructions only once, unless you are revoking a previously delivered proxy instruction, and as soon as possible so that your shares can be voted at the Special Meeting. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>What happens if I do not return a proxy card or otherwise provide proxy instructions, as applicable?</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Signed and dated proxies received by Avalon without an indication of how the stockholder intends to vote on a proposal will be voted &#8220;<b>FOR</b>&#8221; each of the proposals presented to Avalon&#8217;s stockholders in accordance with the recommendation of the Avalon Board. The proxyholders may use their discretion to vote on any other matters which properly come before the Special Meeting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 19 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->xii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>May I vote in person at the Special Meeting? </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Special Meeting will be held in a virtual
    meeting format via live webcast only. If your shares of Avalon Common Stock are registered directly in your name with the Avalon Transfer
    Agent, you are considered to be the stockholder of record with respect to those shares, and the proxy materials and proxy card are being
    sent directly to you by Avalon. If you are an Avalon stockholder of record, you must register using the virtual control number included
    in your proxy materials or your proxy card (if you received a printed copy of the proxy materials) in order to vote at the Special Meeting.
    If you hold your shares beneficially through a bank or broker, you are considered the beneficial owner of shares held in &#8220;street
    name&#8221; and you must provide a legal proxy from your bank or broker during registration and you will be assigned a virtual control
    number in order to vote your shares during the Special Meeting. If you are unable to obtain a legal proxy to vote your shares, you will
    still be able to attend the Special Meeting, so long as you demonstrate proof of stock ownership, but you will not be able to vote your
    shares. Even if you plan to attend the Special Meeting live via the internet, Avalon encourages you to vote in advance by internet or
    mail so that your vote will be counted if you later decide not to attend the Special Meeting live via the internet.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For more information, please see the section
    entitled &#8220;<i>The Special Meeting-Voting Your Shares</i>.&#8221;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>If my Avalon shares are held in &#8220;street name&#8221; by my broker, will my broker vote my shares for me? </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you are a beneficial owner of shares of Avalon
    Common Stock and do not instruct your broker, bank, or other agent how to vote your shares, the question of whether your broker or nominee
    will still be able to vote your shares depends on whether the New York Stock Exchange (the &#8220;NYSE&#8221;), deems the particular proposal
    to be a &#8220;routine&#8221; matter and how your broker or nominee exercises any discretion they may have in the voting of the shares
    that you beneficially own. Brokers and nominees can use their discretion to vote &#8220;uninstructed&#8221; shares with respect to matters
    that are considered to be &#8220;routine,&#8221; but not with respect to &#8220;non-routine&#8221; matters. Under the rules and interpretations
    of the NYSE, &#8220;non-routine&#8221; matters are matters that may substantially affect the rights or privileges of stockholder, such
    as mergers, stockholder proposals, elections of directors (even if not contested), executive compensation (including any advisory stockholder
    votes on executive compensation and on the frequency of stockholder votes on executive compensation), and certain corporate governance
    proposals, even if management-supported.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For any proposal that is considered a &#8220;routine&#8221;
    matter, your broker or nominee may vote your shares in its discretion either for or against the proposal even in the absence of your instruction.
    For any proposal that is considered a &#8220;non-routine&#8221; matter for which you do not give your broker instructions, the shares
    will be treated as broker non-votes. Broker non-votes occur when a beneficial owner of shares held in street name does not give instructions
    to the broker or nominee holding the shares as to how to vote on matters deemed &#8220;non-routine.&#8221; Broker non-votes will not be
    considered to be shares &#8220;entitled to vote&#8221; at the Special Meeting and will not be counted as having been voted on the applicable
    proposal. Avalon believes that the Nasdaq Proposal, the Equity Plan Increase Proposal, the Series C Preferred Stock Proposal, the Series
    D Preferred Stock Proposal and the Golden Parachute Proposal will be considered &#8220;non-routine&#8221; proposals and that the Reverse
    Stock Split Proposal, the Increase in Authorized Shares Proposal and Adjournment Proposal will be considered &#8220;routine&#8221; proposals.
    The determination of which proposals are deemed &#8220;routine&#8221; versus &#8220;non-routine&#8221; may not be made by the NYSE until
    after the date on which this proxy statement has been mailed to you. As such, it is important that you provide voting instructions to
    your bank, broker or other nominee, if you wish to determine the voting of your shares.</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>May I change my vote after I have submitted a proxy or provided proxy instructions? </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>A:</b></span></td><td style="text-align: justify">Yes. Avalon stockholders of record, other than the Key Avalon
Stockholders who are parties to the Avalon Voting Agreement, may change their vote at any time before their proxy is voted at the Special
Meeting, as applicable, in one of the following ways:</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">filing with the Secretary of Avalon, a letter revoking the
proxy;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">submitting another signed proxy with a later date; or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">attending the Special Meeting and voting online, provided
you file a written revocation with the Secretary of the Special Meeting prior to the voting of such proxy.</td>
</tr></table><div>



</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 20 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->xiii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>What is the quorum requirement for the Special Meeting? </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The holders of at least one-third (1/3) of the voting power of the shares of capital stock outstanding and entitled to vote at the meeting, as of the record date, present in person, present by remote communication, if applicable, or represented by proxy, will constitute a quorum for the transaction of business at the Special Meeting. Proxies marked as abstentions and broker non-votes, if any, will be included to determine the number of shares present at the Special Meeting. In the absence of a quorum, a majority of Avalon&#8217;s stockholders present in person or by proxy and entitled to vote at the Special Meeting will have the power to adjourn the Special Meeting. As of the record date there were [&#8195;] shares of Avalon Common Stock outstanding; [&#8195;] shares would be required to achieve a quorum. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>What risks should I consider in deciding whether to vote in favor of the proposals or to execute and return the written consent approving the Merger Agreement and the transactions contemplated thereby, as applicable?</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">You should carefully review this proxy statement/prospectus, including the section entitled &#8220;Risk Factors,&#8221; which sets forth certain risks and uncertainties related to the Merger, risks and uncertainties to which the Combined Company&#8217;s business will be subject, and risks and uncertainties to which each of Avalon and YOOV, as an independent company, is subject. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Who will solicit and pay the cost of soliciting proxies? </b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt"><b>A:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Avalon will bear all costs and expenses in connection with the solicitation of proxies, including the costs of preparing, printing and mailing this proxy statement/prospectus for the Special Meeting. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt"><b>Q:</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Who can help answer my questions?</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>A:</b></span></td><td style="text-align: justify">If you are an Avalon stockholder and would like additional copies,
without charge, of this proxy statement/prospectus or if you have questions about the Merger, including the procedures for voting your
shares, you should contact Avalon at:</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Avalon GloboCare Corp.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">400 Route 9 South, Suite 3100</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Freehold, NJ 07728</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Telephone: (732)&#160;780-4400</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Attention: Secretary</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 21 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->xiv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 5pt; border: Black 1.5pt solid">

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: center; text-indent: 0in">&#160;</p>

<a id="a_003"></a><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: center; text-indent: 0in">SUMMARY OF THE
PROXY STATEMENT/PROSPECTUS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><i>&#160;</i></p>

<p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>This summary highlights selected information
from this proxy statement/prospectus and does not contain all of the information that is important to you. To better understand the Merger
and the proposals to be considered at the Special Meeting, you should read this entire proxy statement/prospectus carefully, including
the annexes. Please see the section entitled &#8220;Where You Can Find More Information.&#8221; </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<a id="a_004"></a><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Parties to the Merger</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-indent: 0in">&#160;</p>

<a id="a_005"></a><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Avalon</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="-keep: true">Avalon
is a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products and expanding its intellectual
property portfolio in the area of cellular therapy. Avalon is currently marketing the KetoAir breathalyzer device and plans to develop
additional diagnostic uses of the breathalyzer technology. In addition, Avalon owns commercial real estate that houses its headquarters
in Freehold, New Jersey.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: 0.25in; background-color: white">Avalon
had the following areas of focus in 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Research and Development</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.25in; background-color: white">Avalon
is focused on bringing forward intellectual property through joint patent filings with various partners including the Massachusetts Institute
of Technology (&#8220;MIT&#8221;) and Arbele Biotherapeutics (&#8220;Arbele&#8221;).Avalon completed a sponsored research and co-development
project with MIT led by Professor Shuguang Zhang as Principal Investigator. Using the unique QTY code protein design platform, six water-soluble
variant cytokine receptors have been successfully designed and tested to show binding affinity to the respective cytokines. Avalon is
currently focused on bringing forward the intellectual property associated with this program through joint patent submissions. In addition,
Avalon partnered with Arbele to develop intellectual property related to cellular therapies as well as cellular immunotherapy. The Company
was recently granted a new patent in China jointly owned with Arbele related to CAR-T and CAR-NK cellular therapy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Product Commercialization</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.25in; background-color: white">Avalon
has begun the commercialization and development of a versatile breathalyzer system.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.25in; background-color: white">Avalon
was granted exclusive distributorship rights for the KetoAir from Qi Diagnostics for the following territories: North America, South America,
the European Union and the United Kingdom. For its commercialization strategy, Avalon intends to target the diabetes and obesity markets.
Avalon plans to sell the product through the KetoAir website and social media. Avalon believes the KetoAir device has some competitive
advantages to other methods for measuring ketosis and expect initial sales to occur in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.25in; background-color: white">Laboratory Acquisitions</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.25in; background-color: white">Avalon had embarked
on a laboratory rollup strategy focused on forming joint ventures and acquiring laboratories that were accretive to its commercial strategy.
As a first step, in February 2023, Avalon acquired a 40% membership interest in Lab Services MSO, LLC (&#8220;Lab Services MSO&#8221;).
Among other things, Lab Services MSO provides toxicology and wellness testing services, a broad portfolio of diagnostic tests, and a broad
array of test services. During 2025, to preserve cash, the Company entered into discussions with Lab Services MSO for the potential redemption
of our investment and on February 26, 2025, Avalon and Lab Services MSO entered into a Redemption and Abandonment Agreement, whereby Lab
Services MSO redeemed the 40% equity interest in Lab Services MSO held by Avalon. Accordingly, beginning in February 2025, Avalon no longer
offers laboratory services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.25in; background-color: white">The principal executive
offices of Avalon are located at 4400 Route 9 South, Suite 3100 Freehold, NJ 07728 and its telephone number is (732) 780-4400.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.25in">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 22; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<a id="a_006"></a><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">YOOV</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="-keep: true">YOOV
is a holding company incorporated in the British Virgin Islands with no material operations of its own. Headquartered in Singapore, YOOV
operates its sales and operations offices in Australia, Hong Kong, Malaysia, and Taiwan. YOOV derives the vast majority of its revenues
from operations in Hong Kong, which accounted for approximately 77.9% and 83.2% of total revenue for the year ended 2024 and nine months
ended December 31, 2024. A significant portion of its management, employees, and business operations are based in Hong Kong. As of April
30, 2025, YOOV employed 52 full time employees in Hong Kong, representing 94% of its total workforce, including functions of CEO and
management, investor relations, business development and marketing, research and development, etc. YOOV conducts its business through
its Hong Kong subsidiaries, including, but limited to, YOOV Internet Technology (Asia) Limited, YOOV Capital Limited and YOOV Insurance
Services Limited, which are integral to its core operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: 0.25in">YOOV is a prominent
provider of Artificial Intelligence-as-a-Service (AIaaS) solutions, specializing in intelligent business automation. AIaaS enables businesses
to incorporate AI tools and capabilities through a cloud platform without the need for significant infrastructure investment. This model
provides a more accessible and cost-effective way for businesses to bring AI into their applications and processes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.25in; background-color: white">YOOV&#8217;s mission is to
make advanced AI and automation technologies accessible to businesses without requiring technical expertise. By integrating AI with its
no-code workflow automation platform, YOOV enables businesses to automate complex workflows and tasks across diverse industries, empowering
businesses of all sizes to optimize operations, reduce costs, and enhance service delivery through its AIaaS solutions. To cope with the
global expansion plan, YOOV&#8217;s solutions are designed to address the challenges of modern businesses while fostering efficiency,
scalability, and growth. In addition, YOOV operates subsidiaries in financial and insurance services, including YOOV Capital Limited and
YOOV Insurance Services Limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_003.jpg"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">All of the dollar
amounts in this proxy statement/prospectus are expressed in U.S. dollars, except where otherwise indicated. References to &#8220;USD&#8221;
or &#8220;$&#8221; are to U.S. dollars, and any references to &#8220;HK$&#8221; are to Hong Kong dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 0.25in">YOOV&#8217;s functional
currency is HK$. Most of YOOV&#8217;s transactions are in HK$. Where applicable, YOOV has recorded its foreign currency transaction at
the spot rate at the day of the transaction and translated its balance sheet positions in another currency using the exchange rate in
effect at the balance sheet date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 0.25in">The average exchange
rates used for USD during the year ended March 31, 2023 and 2024, and the nine months ended December 31, 2023 and 2024 are based on the
noon-buying&#160;rate certified for custom purposes by the U.S. Federal Reserve Bank of New York set forth in the H.10 statistical release
of the Federal Reserve Board, were 0.1273, 0.1277, 0.1277, and 0.1282 per HK$, respectively.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">&#160;</p>

<a id="a_007"></a><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Merger Sub</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Nexus MergerSub Limited,
a wholly owned subsidiary of Avalon, was formed solely for the purpose of effectuating the Merger. Merger Sub was incorporated as a business
company in the British Virgin Islands on February 21, 2025. Merger Sub has no material assets and does not operate any business. To date,
Merger Sub has not conducted any activities other than those incidental to its formation and the execution of the Merger Agreement. After
the consummation of the Merger, it will cease to exist.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The principal executive offices
of Merger Sub are located at 4400 Route 9 South, Suite 3100 Freehold, NJ 07728.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 23 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<a id="a_008"></a><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">The Merger Agreement</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-indent: 0in">&#160;</p>

<a id="a_009"></a><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Merger Consideration</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">Immediately prior
to the Effective Time, each then-outstanding YOOV Preferred Share will either automatically be converted into YOOV Ordinary Shares or
canceled and cease to exist in accordance with their terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">At the Effective
Time, each then-outstanding YOOV Ordinary Share (other than shares held in treasury and Dissenting Shares) will be converted into and
become exchangeable for a number of shares of Avalon Common Stock equal to the Exchange Ratio.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3pt; text-align: justify; text-indent: 18.2pt"><span style="-keep: true">The number of shares
of Avalon Common Stock that YOOV shareholders will receive as consideration in the Merger is not fixed. The Exchange Ratio is subject
to a collar mechanism and will be determined as follows: if the closing price of the Avalon Common Stock on Nasdaq on the second (2<sup>nd</sup>)
trading day immediately preceding the Effective Time is (x) less than or equal to $5.00, the Exchange Ratio shall be 60,000,000 divided
by the YOOV Outstanding Shares; or (y) greater than $5.00, the Exchange Ratio shall be 54,000,000 divided by the YOOV Outstanding Shares.
Based on the closing price of Avalon Common Stock on Nasdaq of $3.41 on June 6, 2025, the latest practicable trading day prior to the
date of this proxy statement/prospectus, and the number of YOOV Outstanding Shares on such date, it is estimated that the Exchange Ratio
will be approximately 121.8. Based on the estimated Exchange Ratio, Avalon is expected to issue 60,000,000 shares of Avalon Common Stock
to the YOOV shareholders. Upon completion of the Merger, the current Avalon stockholders are expected to own approximately 2.7% to 3.0%
of the common stock of the Combined Company and the YOOV shareholders are expected to own approximately 97.0% to 97.3% of the common
stock of the Combined Company. The Exchange Ratio is an estimate only, and the actual Exchange Ratio and relative ownership interests
of Avalon stockholders and YOOV shareholders in the Combined Company immediately following the Merger will depend on the market price
of Avalon&#8217;s Common Stock two (2) trading days prior to the Merger and the number of YOOV Outstanding Shares on the Closing Date.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 18.2pt">The Exchange Ratio
will be adjusted equitably to reflect any change in the outstanding shares of capital stock of Avalon or YOOV which occurs as a result
of any reclassification, recapitalization, reorganization, stock split (including the Reverse Stock Split, if approved and if necessary
to be effectuated for the Combined Company to meet the $4.00 minimum bid price initial listing requirement following the Closing pursuant
to the rules of The Nasdaq Capital Market) or combination, exchange or readjustment of shares, or any stock dividend or distribution is
declared with a record date prior to the Effective Time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 0.25in">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 0.25in">The Exchange Ratio
is described in more detail in the section entitled &#8220;<i>The Merger Agreement-Exchange Ratio</i>.&#8221;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 18.2pt">The Merger Agreement
does not include a price-based termination right.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<a id="a_010"></a><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-indent: 0in">Conditions to the Closing</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 24.4pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.25in; background-color: white">Completion of the
Merger is conditioned upon, among other things, approval of the Nasdaq Proposal, the Reverse Stock Split Proposal, if necessary, and any
other proposals Avalon and YOOV mutually agree is necessary or desirable to consummate the transactions contemplated by the Merger Agreement.
Further, the consummation of the Merger is conditioned on, among other things, the adoption of the Merger Agreement by the YOOV shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The approval of the Nasdaq
Proposal and the Reverse Stock Split Proposal requires the affirmative vote of a majority of the total votes properly cast by the Avalon
Stockholders at the Special Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to obtaining
such stockholder approval, each of the other closing conditions set forth in the Merger Agreement must be satisfied or waived. For further
information, please see the section entitled &#8220;<i>The Merger Agreement-Conditions to the Completion of the Merger</i>.&#8221;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<a id="a_011"></a><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Non-Solicitation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each of Avalon and YOOV have
agreed that, subject to certain exceptions, neither they nor any of their respective subsidiaries will authorize any of their or their
subsidiaries&#8217; directors, officers, employees, financial advisors, attorneys, accountants, investment bankers, or other advisors,
agents or representatives retained by it or any of its subsidiaries to, directly or indirectly:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">solicit, initiate or propose the making, submission or announcement
of, or knowingly encourage, facilitate or assist, any proposal or offer that constitutes, or could reasonably be expected to lead to,
any Takeover Proposal (as defined below);</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 26.75pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">terminate, waive, amend or modify any provision of any existing
confidentiality, standstill or similar agreement with respect to a potential Takeover Proposal;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 26.75pt"></p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">enter into any letter of intent, memorandum of understanding,
agreement in principle, acquisition agreement, merger agreement or similar agreement providing for the consummation of a transaction
contemplated by any Takeover Proposal (other than a confidentiality agreement in connection with a Takeover Proposal from a Qualified
Person, as discussed below);</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">take any action that could reasonably be expected to lead
to a Takeover Proposal;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 26.75pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">other than informing Persons (as defined in the Merger Agreement)
of the existence of the provisions above, enter into, continue or otherwise participate in any discussions or negotiations regarding,
or furnish to any Person any non public information of such party for the purpose of encouraging, facilitating or responding to, any
Takeover Proposal or any proposal or inquiry that is reasonably expected to lead to a Takeover Proposal; and</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>






<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">publicly propose to do any of the above.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Notwithstanding
                                            the foregoing, before obtaining the applicable approvals of the Avalon stockholders or YOOV
                                            shareholders required to consummate the Merger, each party may furnish non-public information
                                            regarding such party and its subsidiaries to, and may enter into discussions or negotiations
                                            with, pursuant to a confidentiality agreement not materially less restrictive than the Confidentiality
                                            Agreement (as defined in the Merger Agreement), any third party in response to a bona fide
                                            written Takeover Proposal from a Qualified Person, subject to the satisfaction of certain
                                            conditions. For more information, please see the section entitled &#8220;<i>The Merger Agreement-Non-Solicitation</i>.&#8221;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<a id="a_012"></a><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Intervening
Event</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">Notwithstanding
                                            the foregoing, before obtaining the applicable approvals of the Avalon stockholders or YOOV
                                            shareholders required to consummate the Merger, the board of directors of either party may
                                            make an Adverse Recommendation Change (as defined below) in response to an Intervening Event
                                            (as defined below) if such Party&#8217;s board of directors determines in good faith, after
                                            consultation with its outside legal counsel, that the failure to do so would be a breach
                                            of such board of director&#8217;s fiduciary duties under applicable law, subject to the satisfaction
                                            of certain conditions. For more information, please see the section entitled &#8220;<i>The
                                            Merger Agreement-Intervening Event</i>.&#8221;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in"></p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-indent: 0in">&#160;</p>

<a id="a_013"></a><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Superior
Proposal</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.25in">However,
                                            before obtaining the applicable approvals from their respective stockholders required to
                                            consummate the Merger, each of Avalon and YOOV may make an Adverse Recommendation Change
                                            in response to a bona fide written Takeover Proposal, which the Avalon Board or the YOOV
                                            Board, respectively, determines in good faith, after consultation with their respective financial
                                            advisors and outside legal counsel, that such Takeover Proposal constitutes a Superior Proposal,
                                            as defined in the Merger Agreement, and that the failure to make an Adverse Recommendation
                                            Change, would be a breach of such party&#8217;s board of director&#8217;s fiduciary duties,
                                            in either such case, subject to the satisfaction of certain conditions. For more information,
                                            please see the section entitled &#8220;<i>The Merger Agreement-Superior Proposal</i>.&#8221;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<a id="a_014"></a><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Termination
of the Merger Agreement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Either
                                            Avalon or YOOV can terminate the Merger Agreement under certain circumstances, including
                                            by mutual written consent of Avalon and YOOV or if the Merger has not been consummated by
                                            March 7, 2026. For more information, please see the section entitled &#8220;<i>The Merger
                                            Agreement-Termination of the Merger Agreement</i>.&#8221;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<a id="a_015"></a><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Termination
Fee</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the Merger Agreement
is terminated under certain circumstances, Avalon will be required to pay the other party a termination fee of $1.0 million. Moreover,
if Avalon fails to pay such termination fee when due, then Avalon will be required to pay interest on, and reasonable fees and expenses
incurred in connection with, the collection of such overdue amount in addition to the $1.0 million termination fee. For more information,
please see the section entitled &#8220;<i>The Merger Agreement-Termination and Termination Fee</i>.&#8221;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 25 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>



<a id="a_016"></a><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Certain Agreements Related to the
Merger</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-indent: 0in">&#160;</p>

<a id="a_017"></a><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Voting Agreements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Concurrently with the execution
of the Merger Agreement, (i) the Key YOOV Shareholders entered into the YOOV Voting Agreement with Avalon and YOOV to vote all of their
shares of YOOV capital stock in favor of the approval and adoption of the Merger and the transactions contemplated thereby and against,
among other things, any Takeover Proposals and (ii) the Key Avalon Stockholders entered into the Avalon Voting Agreement with Avalon and
YOOV to vote all of their shares of capital stock of Avalon (a) in favor of, among other things, the approval of (1) the Nasdaq Proposal,
(2) the Reverse Stock Split Proposal and (3) any other proposals Avalon and YOOV mutually agree is necessary or desirable to consummate
the transactions contemplated by the Merger Agreement and (b) against, among other things, any Takeover Proposals.</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of March 7, 2025, (i)
the Key YOOV Shareholders, including YOOV&#8217;s directors and executive officers, beneficially owned approximately 53.5% of the outstanding
YOOV Ordinary Shares and (ii) the Key Avalon Stockholders, including Avalon directors and officers, beneficially owned approximately 26.1%
of the outstanding shares of Avalon Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For more information, please
see the section entitled &#8220;<i>Certain Agreements Related to the Merger</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<a id="a_018"></a><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Lock-Up Agreements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Concurrently
                                            with the execution of the Merger Agreement, certain Key YOOV Shareholders, including Wong
                                            Ho Chi Mark, Kwok Chi Yin, Facewell International Limited, Chan Ka Po, and Rich Joy International
                                            Industrial Limited, and the Key Avalon Stockholders, have entered into lock-up agreements
                                            (the &#8220;Lock-Up Agreements&#8221;), pursuant to which, subject to specified exceptions,
                                            they have agreed not to offer, pledge, sell, contract to sell, sell any option or contract
                                            to purchase, purchase any option or contract to sell, grant any option, right or warrant
                                            to purchase, or otherwise transfer or dispose of, directly or indirectly, any YOOV Ordinary
                                            Shares or Avalon Common Stock, as applicable, or any securities convertible into or exercisable
                                            or exchangeable for YOOV Ordinary Shares or Avalon Common Stock, as applicable, currently
                                            or thereafter owned until one hundred eighty (180) days after the Effective Time of the Merger.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of March 7, 2025, the
(i) certain Key YOOV Shareholders who executed Lock-Up Agreements beneficially owned approximately 47.7% of the outstanding YOOV Ordinary
Shares and (ii) Key Avalon Stockholders beneficially owned approximately 26.1% of the outstanding Avalon Common Stock. Accordingly, after
the Effective Time, approximately 47.0% of common stock of the Combined Company will be subject to the Lock-Up Agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For more information, please
see the section entitled &#8220;<i>Certain Agreements Related to the Merger</i>.&#8221;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">&#160;</p>

<a id="a_019"></a><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Interests of Certain Persons in the
Merger</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-indent: 0in">&#160;</p>

<a id="a_020"></a><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Avalon</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In considering the recommendation
of the Avalon Board to vote in favor of the proposals set forth in this proxy statement/prospectus, stockholders should be aware that,
aside from their interests as stockholders, certain Avalon directors and officer have interests in the Merger that are different from,
or in addition to, those of other stockholders generally. Avalon&#8217;s directors were aware of and considered these interests, among
other matters, in evaluating the Merger, and in recommending to stockholders that they approve the proposals set forth in this proxy statement/prospectus.
Avalon stockholders should take these interests into account in deciding whether to vote &#8220;<b>FOR</b>&#8221; the proposals set forth
in this proxy statement/prospectus. These interests include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Avalon directors and officers beneficially owning approximately 26.1% of the shares of Avalon Common Stock
as of March 7, 2025;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Luisa Ingargiola, currently Avalon&#8217;s Chief Financial Officer, continuing as Chief Financial Officer
of the Combined Company following the Closing and may be entitled to certain &#8220;golden parachute&#8221; compensation in connection
with the Merger, as described below;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">Wenzhao Lu, Lourdes Felix and
                                            Steven A. Sanders, currently directors on the Avalon Board, will continue to serve as directors
                                            of the Combined Company following Closing;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Wenzhao Lu holding shares of Avalon Series D Preferred Stock, which shall remain outstanding and survive
the Merger;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Each of Avalon&#8217;s directors and executive officers holding Avalon Stock Options, which shall remain
outstanding and survive the Merger;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The continued indemnification of current directors and officers of Avalon and the continuation of directors&#8217;
and officers&#8217; liability insurance after the Merger; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The Key Avalon Stockholders, including Avalon directors and officers, entering into the Avalon Voting
Agreement in connection with the Merger.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These interests may influence
the Avalon Board in making their recommendation that you vote in favor of the approval of the proposals set forth in this proxy statement/prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">For
                                            more information, please see the section entitled &#8220;<i>The Merger-Interests of Avalon&#8217;s
                                            Directors and Officer in the Merger</i>.&#8221;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<a id="a_021"></a><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">YOOV</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In considering the recommendation
of the YOOV Board with respect to approving the Merger Agreement and related transactions, YOOV shareholders should also be aware that
certain members of the YOOV Board and executive officers have interests in the Merger that may be different from, or in addition to, interests
they have as YOOV shareholders. These interests include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">YOOV directors and officers beneficially owning approximately
37.0% of the YOOV Ordinary Shares as of March 7, 2025;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Wong Ling Yan Philip, currently YOOV&#8217;s President and
Chief Executive Officer, continuing as an executive officer of the Combined Company following the Closing;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Wong
                                            Ho Chi Mark, the current Chief Technology Officer of YOOV, continuing as an executive officer
                                            of the Combined Company following the Closing;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Wong Ling Yan Philip continuing to serve as a director of
the Combined Company following Closing; and</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.6pt; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The Key YOOV Shareholders, including YOOV&#8217;s directors
and executive officers, entering into the YOOV Voting Agreement in connection with the Merger.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For
                                            more information, please see the section entitled &#8220;<i>The Merger-Interests of YOOV&#8217;s
                                            Directors and Officers in the Merger</i>.&#8221;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<a id="a_022"></a><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Reasons for the Approval of the Merger</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">After careful consideration,
the Avalon Board recommends that Avalon stockholders vote &#8220;<b>FOR</b>&#8221; each of the proposals being submitted to a vote of
the Avalon stockholders at the Special Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For a description of Avalon&#8217;s
reasons for the approval of the Merger and the recommendation of its board of directors, see the section entitled &#8220;<i>The Merger-Avalon&#8217;s
Reasons for the Merger</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For more information on
YOOV&#8217;s reasons for the Merger, see the section entitled &#8220;<i>The Merger-YOOV&#8217;s Reasons for the Merger</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<a id="a_023"></a><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Opinion of Avalon&#8217;s Financial
Advisor</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March 7, 2025, at a meeting
of the Avalon Board, Roth Capital Partners, LLC (&#8220;Roth&#8221;), Avalon&#8217;s advisor for purposes of rendering a fairness opinion
in connection with the Merger, rendered its oral opinion to the Avalon Board, subsequently confirmed by delivery of a written opinion,
dated March 7, 2025, to the Avalon Board, that the Exchange Ratio was fair, from a financial point of view, to Avalon as of the date of
such opinion and based on the various assumptions, qualifications and limitations set forth therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 27 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The full text of Roth&#8217;s
written opinion, dated March 7, 2025 (the &#8220;Opinion&#8221;), which describes the assumptions made, procedures followed, other matters
considered and limits of the review by Roth, is attached to this proxy statement/prospectus as <span style="text-decoration:underline">Annex B</span> and is incorporated into
this proxy statement/prospectus by reference. Avalon encourages its stockholders to read the Opinion in its entirety. The summary of the
Opinion set forth herein is qualified by reference to the full text of the Opinion. The Opinion is not a recommendation to the Avalon
Board or to any stockholder as to how to vote at the Special Meeting or to take any other action in connection with the Merger or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For
                                            additional information, see <span style="text-decoration:underline">Annex B</span> and the section entitled &#8220;<i>The Merger-Opinion
                                            of Avalon&#8217;s Financial Advisor</i>.&#8221;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<a id="a_024"></a><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Regulatory Approvals Required for
the Merger</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon must comply with applicable
federal and state securities laws and the rules and regulations of Nasdaq in connection with the issuance of shares of Avalon Common Stock
in connection with the Merger and the filing of this proxy statement/prospectus with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Potential Permission or Approvals Required from the PRC Authorities
with respect to the Operations of YOOV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">We face potential risks
associated with YOOV. YOOV is a holding company incorporated in the British Virgin Islands with no material operations of its own. Headquartered
in Singapore, YOOV conducts its operations primarily in Hong&#160;Kong through its operating subsidiaries. After the Merger, stockholders
will not directly hold any equity interests in YOOV or its operating subsidiaries. This structure involves unique risks to investors.
As a holding company, YOOV may rely on dividends from our subsidiaries for our cash requirements, including any payment of dividends
to our shareholders. The ability of its subsidiaries to pay dividends to YOOV may be restricted by the debt they incur on their own behalf
or laws and regulations applicable to them. YOOV does not operate any of its business through variable interest entities, nor does it
operate any business in the PRC. This position is not expected to change upon completion of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true"><span style="font-family: Times New Roman, Times, Serif">YOOV&#8217;s
operations are primarily located in Hong&#160;Kong, a Special Administrative Region of PRC. </span>As a special administrative region
of the PRC, Hong Kong enjoys separate governing and economic systems from that of mainland China under the principle of one country,
two systems. <span style="font-family: Times New Roman, Times, Serif">YOOV does not derive any revenue or profits from, nor does it have
any customers in, the PRC. Its operations and customer base are concentrated in Hong Kong, where it conducts business through its operating
subsidiaries. YOOV and its subsidiaries face various legal and operational risks and uncertainties associated with being based in or
having its operations in Hong Kong. </span>The Basic Law of the Hong Kong Special Administrative Region (the &#8220;Basic Law&#8221;)
provides that PRC laws and regulations shall not be applied in Hong Kong except for those listed in Annex III of the Basic Law, which
is confined to laws relating to national defense, foreign affairs, and other matters that are not within the scope of autonomy. YOOV
therefore is not directly subject to PRC laws and regulations regarding the general conduct of its business, including data protection,
cyber security and anti-monopoly laws, or regarding overseas listings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">While Hong Kong currently
maintains a separate legal and regulatory system from mainland China, However, there is no guarantee that if future PRC laws become applicable
to subsidiaries of YOOV. Any future changes to PRC laws or their interpretation&#8212;if extended to Hong Kong&#8212;could introduce
regulatory, liquidity, or enforcement risks that may materially affect YOOV&#8217;s operations. For example, in future, YOOV may face
risks and uncertainties regarding the enforcement of laws and the fact that rules and regulations in the PRC can change quickly with
little advance notice. In addition, in future, the Chinese government could intervene or influence our operations at any time, or could
exert more control over offerings conducted overseas or foreign investment in Hong Kong-based issuers, which could result in a material
change in our operations or the value of Avalon Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are aware that recently, the PRC government has initiated a series of regulatory actions and new policies to regulate business operations
in certain areas in China with little advance notice, including cracking down on illegal activities in the securities market, enhancing
supervision over China-based companies listed overseas using a variable interest entity structure, adopting new measures to extend the
scope of cybersecurity reviews, and expanding the efforts in anti-monopoly enforcement. It is also highly uncertain what the potential
impact such modified or new laws and regulations will have on YOOV&#8217;s operating subsidiaries&#8217; daily business operation, its
ability to accept foreign investments and the listing of our Ordinary Shares on U.S.&#160;or other foreign exchanges. The PRC government
may intervene or influence YOOV&#8217;s operations at any time and may exert more control over offerings conducted overseas and foreign
investment in Hong&#160;Kong-based issuers. The PRC government may also intervene or impose restrictions on YOOV&#8217;s ability to move
out of Hong&#160;Kong to distribute earnings and pay dividends or to reinvest in its business outside of Hong&#160;Kong. Furthermore,
PRC regulatory authorities may in the future promulgate laws, regulations or implementing rules that require our company or any of our
subsidiaries to obtain regulatory approval from PRC authorities before this offering. These actions could result in a material change
in our operations and could significantly limit or completely hinder our ability to complete this offering or cause the value of our
Ordinary Shares to significantly decline or become worthless. </span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">We believe that, a<span style="font-family: Times New Roman, Times, Serif">s
of the date of this prospectus, YOOV&#8217;s operations in Hong&#160;Kong are not subject to the regulatory actions or new policies mentioned
the above paragraph, nor are they subject to the review or prior approval of the Cyberspace Administration of China (the &#8220;CAC&#8221;)
or the China Securities Regulatory Commission (the &#8220;CSRC&#8221;). Uncertainties still exist, however, due to the possibility that
laws, regulations, or policies in the PRC could change rapidly in the future, which could significantly limit or completely hinder YOOV&#8217;s
operations in Hong&#160;Kong and could cause the value of our securities to significantly decline or be worthless and even delisting
of Avalon Common Stock. The delisting of Avalon Common Stock, or the threat of their being delisted, may materially and adversely affect
the value of the stockholders&#8217; investment in the future. </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p></div><div>

</div><!-- Field: Page; Sequence: 28 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="border: Black 1.5pt solid; padding: 5pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">YOOV is not subject to
any significant restrictions on buying or selling foreign exchange or on transferring cash between entities within our group, across
borders, or to U.S. investors. Nor are there any significant restrictions or limitations on YOOV&#8217;s ability to distribute earnings
(if any) from YOOV to the Combined Company and U.S. investors or our ability to settle amounts owed. However, there can be no assurance
that the PRC government will not intervene or impose restrictions on the ability of YOOV to buy or sell foreign exchange or transfer
or distribute cash within its organization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Should the PRC government,
in the future, choose to exercise significant oversight and discretion over the conduct of our business, they may intervene in or influence
YOOV&#8217;s operations. Such governmental actions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">could result
                                            in a material change in YOOV&#8217;s operations and/or the value of our securities;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">could significantly
                                            limit or completely hinder YOOV&#8217;s ability to continue its operations;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">could significantly
                                            limit or completely hinder the Combined Company&#8217;s ability to offer or continue to offer
                                            its securities to investors; and</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">may cause the
                                            value of our securities to significantly decline or be worthless.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, </span><span style="font-size: 10pt">See &#8220;<i>Risk Factors - Risks Related to YOOV&#8217;s Operations in
Hong Kong</i>.&#8221;</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Risk Factors&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0.25in; background-color: white"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Both Avalon and YOOV
are subject to various risks associated with their businesses and their industries. In addition, the Merger, including the possibility
that the Merger may not be completed, poses a number of risks to each company and its respective securityholders, including the following
risks:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Risks Related to the Merger</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The risk that the conditions to the closing of the transaction are not satisfied, including the failure
to obtain stockholder approval for the Merger.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The timing, receipt and terms and conditions of any required regulatory approvals of the Merger that could
cause the parties to abandon the Merger.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Avalon&#8217;s and YOOV&#8217;s ability to meet expectations regarding the timing and completion of the
Merger.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Uncertainties as to the timing of the consummation of the Merger and the ability of each of Avalon and
YOOV to consummate the Merger.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Risks related to Avalon&#8217;s continued listing on The Nasdaq Capital Market until the Closing.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Risks that Avalon&#8217;s stock price may decline significantly if the Merger is not completed.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The outcome of any legal proceedings that may be instituted against Avalon and others following the announcement
of the Merger Agreement.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Expectations regarding the strategies, prospects, plans, expectations and objectives of management of
Avalon or YOOV for future operations of the combined company following the Closing of the Merger.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The ability of the Combined Company to recognize the benefits that may be derived from the Merger, including
the commercial or market opportunity of the YOOV business.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Risks related to Avalon&#8217;s and YOOV&#8217;s ability to correctly estimate their respective operating
expenses and expenses associated with the Merger, uncertainties regarding the impact any delay in the Closing would have on the anticipated
cash resources of the Combined Company upon the Closing and other events and unanticipated spending and costs that could reduce the Combined
Company&#8217;s cash resources.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The occurrence of any event, change or other circumstance or condition that could give rise to the termination
of the Merger Agreement.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 29 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The fact that under the terms of the Merger Agreement, Avalon is restrained from soliciting other Takeover
Proposals during the pendency of the Merger, except in certain circumstances.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The effect of the announcement or pendency of the Merger on Avalon&#8217;s or YOOV&#8217;s business relationships,
operating results and business generally, including disruption of Avalon&#8217;s and YOOV&#8217;s management&#8217;s attention from ongoing
business operations due to the Merger and potential adverse reactions or changes to business relationships resulting from the announcement
or completion of the Merger.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The risk that the Merger Agreement may be terminated in circumstances that require Avalon to pay a termination
fee.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Risks Related to Avalon</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Avalon&#8217;s limited operating history makes it difficult for Avalon to evaluate its future business
prospects and make decisions based on those estimates of its future performance.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Avalon&#8217;s results of operations have not resulted in profitability and it may not be able to achieve
profitability going forward.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">There is substantial doubt about Avalon&#8217;s ability to continue as a going concern, which will affect
Avalon&#8217;s ability to obtain future financing and may require Avalon to curtail its operations.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.3pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Avalon&#8217;s cash will only fund its operations for a limited time and Avalon will need to raise additional
capital in order to support its business and business prospects.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.3pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.3pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">If the Merger is not completed, Avalon may not have sufficient capital to continue to operate its business
in the short term and may become insolvent and be required to seek the protection of the bankruptcy courts or seek dissolution and, without
additional funding or a strategic transaction, Avalon would likely be delisted from Nasdaq.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.3pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.3pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Joint ventures, joint ownership arrangements and other projects pose unique challenges and Avalon may
not be able to fully implement or realize synergies, expected returns or other anticipated benefits associated with such projects.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.3pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">In accordance with Avalon&#8217;s strategic development policy, Avalon may invest in companies for strategic
reasons and may not realize a return on its investments.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission,
fee payment and other requirements imposed by governmental patent agencies, and any patent protection Avalon may obtain in the future
could be reduced or eliminated for non-compliance with these requirements.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.3pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">It is difficult and costly to protect Avalon&#8217;s proprietary rights, and Avalon may not be able to
ensure their protection. If Avalon fails to protect or enforce its intellectual property rights adequately or secure rights to patents
of others, the value of its intellectual property rights would diminish.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.3pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.3pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Some of Avalon&#8217;s medical device products in the future may face significant government regulation,
and there is no guarantee that our medical devices will receive regulatory approval.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.3pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.3pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Even if Avalon&#8217;s medical devices receive regulatory approval, Avalon may still face future development
and regulatory difficulties.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.4pt; text-align: justify; background-color: white">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.4pt; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 30 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.4pt; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Any medical devices Avalon develops may become subject to unfavorable pricing regulations, third party
coverage and reimbursement practices or healthcare reform initiatives, thereby harming Avalon&#8217;s business.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.1pt; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The healthcare industry is heavily regulated in the U.S. at the federal, state, and local levels, and
Avalon&#8217;s failure to comply with applicable requirements may subject Avalon to penalties and negatively affect Avalon&#8217;s financial
condition.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.1pt; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Avalon&#8217;s officers, directors and principal stockholders own a significant percentage of Avalon Common
Stock and will be able to exert significant control over matters that are subject to stockholder approval, including the Merger.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">If Avalon is unable to maintain listing of Avalon Common Stock on The Nasdaq Capital Market or another
reputable stock exchange, it may be more difficult for Avalon&#8217;s stockholders to sell their securities.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.3pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The price of Avalon Common Stock may be volatile and fluctuate substantially, which could result in substantial
losses for Avalon&#8217;s stockholders.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.3pt; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Avalon stockholders may experience dilution of ownership interests because of the future issuance of additional
shares of Avalon Common Stock or Avalon Preferred Stock or other securities that are convertible into or exercisable for Avalon Common
Stock or Avalon Preferred Stock.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Risks Related to YOOV</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">YOOV faces risks related to system interruption, including failures caused or experienced by third-party service providers, and lack
of redundancy and timely upgrades.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 18.2pt"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Natural catastrophic events and man-made problems such as power disruptions, computer viruses, global
pandemics, a cyberattack or data security breaches and terrorism may disrupt YOOV&#8217;s business.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">A cyberattack, security breach or other unauthorized access or interruption to YOOV&#8217;s information
technology systems or those of its third-party service providers could delay or interrupt service to its customers and their customers,
harm its reputation or subject it to significant liability.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 18.2pt"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Global pandemics and health crises may significantly disrupt YOOV&#8217;s business activities, render staff unavailable, and cause
an integrity problem in the supply chain.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 18.2pt"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">YOOV&#8217;s business faces intense competition. Failures to differentiate itself in the market may negatively impact YOOV&#8217;s
business, financial condition, and results of operations.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 18.3pt"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">YOOV may not succeed in promoting and strengthening its YOOV brand, which may materially and adversely affect its business and results
of operations.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.3pt; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 18.3pt"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">YOOV&#8217;s expansion into new service offerings, technologies and geographic regions subjects it to additional business, legal,
financial and competitive risks.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.3pt; text-indent: -0.25in; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">YOOV conducts marketing activities to help attract potential customers for lead generation, and if it
is unable to attract these potential customers or convert them into customers in a cost-effective manner, YOOV&#8217;s business and results
of operations could be harmed.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 18.2pt"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">YOOV depends on third-party AI technologies and Application Programming Interfaces (APIs) to deliver functionality
on the AIaaS platform. Failures in these third-party technologies could negatively impact our business.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.1pt; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">If YOOV fails to adopt new technologies or adapt its platforms and systems to changing customer requirements
or emerging industry standards, its business may be materially and adversely affected.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 18.2pt"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">YOOV faces the risk that its substantial investments in research and development may not yield the anticipated
benefits.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Failures to retain and acquire customers may negatively impact YOOV&#8217;s recurring revenue and growth
prospects.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">If YOOV is unable to manage its growth or execute its strategies effectively, YOOV&#8217;s business and
prospects may be materially and adversely affected.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">YOOV may not be able to adequately protect its intellectual property rights.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Assertions, claims and allegations, even if not true, that YOOV has infringed or violated intellectual
property rights could harm YOOV&#8217;s business and reputation.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Some of YOOV&#8217;s software and systems contain open-source software, which may pose particular risks
to YOOV&#8217;s proprietary software and solutions.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Employment laws in some of the countries in which YOOV operates are relatively stringent.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">YOOV faces risks related to increased regulatory and social drive toward environmental sustainability,
which can establish new compliance burdens and operational limitations.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Additional costs related to compliance and reporting may be incurred as YOOV becomes a public company.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">YOOV&#8217;s financial and insurance services are subject to complex regulatory requirements.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Inconsistencies between the shareholders agreement and YOOV constitutional documents may adversely affect
shareholder rights and create legal uncertainty.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 18.2pt"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">The development and use of AI technologies is subject to an evolving and uncertain regulatory landscape
that may adversely impact YOOV&#8217;s business.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">Ethical concerns and public perception of AI could potentially limit market acceptance of YOOV&#8217;s
services and harm the reputation.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">YOOV&#8217;s business may be subject to seasonality, and variations in customer demand due to budgeting
cycles, industry dynamics, and economic trends could adversely affect its financial performance.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">The loss of key employees or the failure to attract qualified personnel could have a material adverse
effect on YOOV&#8217;s ability to run its business.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">If YOOV is unable to provide satisfactory customer experience, its reputation would be harmed and it could
lose customers.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">As a global business, YOOV is subject to risks associated with YOOV&#8217;s&#160;non-U.S.&#160;operations where such risks are not
present in the United States.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 32 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.25in"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">New tariffs and other trade measures could adversely affect YOOV&#8217;s business and financial results.</td></tr></table>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 18.2pt"/><td style="text-align: justify; width: 0.25in">&#9679;</td><td style="text-align: justify">YOOV is exposed to currency exchange rate fluctuations that may bring negative impacts on YOOV&#8217;s financial
condition and operational performance.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.1pt; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">YOOV&#8217;s
                                            operations are in Hong Kong, a special administrative region of the PRC. The PRC government
                                            may exercise significant oversight and discretion over the conduct of YOOV&#8217;s business
                                            and may intervene in or influence its operations at any time, which could result in a material
                                            change in its operations and/or the value of our securities.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">The Chinese
                                            government, in general, could exercise significant oversight and discretion over the conduct
                                            of YOOV&#8217;s business and has made statements indicating an intent to exert more oversight
                                            and control over offerings that are conducted overseas and over foreign investment in China-based
                                            issuers.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">Greater oversight
                                            by CAC over data security, particularly for companies seeking to list on a foreign exchange,
                                            could adversely impact our business and our offering.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">In the future,
                                            YOOV may be subject to PRC laws and regulations, including those regarding corporate structure,
                                            overseas listings, data- and cybersecurity, and anti-monopoly concerns, which could result
                                            in a material negative impact on its operations and the value of the securities we are registering
                                            for sale.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">After the Merger,
                                            we will be subject to risks relating to economic, political, legal, and social conditions
                                            in Hong Kong.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">The Law of
                                            the PRC on Safeguarding National Security in the Hong Kong Special Administrative Region
                                            (the &#8220;Hong Kong National Security Law&#8221;) could impact YOOV&#8217;s operations
                                            in Hong Kong.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">The Hong Kong
                                            legal system embodies uncertainties that could limit the availability of legal protections.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in; background-color: white">These
risks and other risks are discussed in greater detail under the section entitled &#8220;<i>Risk Factors</i>&#8221; in this proxy statement/prospectus.
Avalon and YOOV both encourage you to read and consider all of these risks carefully.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-indent: 0in">&#160;</p>

<a id="a_025"></a><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Accounting Treatment of the Merger</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 0.25in">Although Avalon
is the legal acquirer and will issue shares of Avalon Common Stock to effect the Merger with YOOV, the Merger will be accounted for as
a &#8220;reverse acquisition&#8221; under the acquisition method of accounting under the U.S. generally accepted accounting principles
(&#8220;GAAP&#8221;) with YOOV being considered the acquiror of Avalon for accounting purposes. Under the &#8220;acquisition&#8221; method
of accounting, the assets and liabilities of Avalon will be recorded, as of the completion of the Merger, at their respective fair values
in the financial statements of Avalon. The financial statements of Avalon issued after the completion of the Merger will reflect these
values but will not be restated retroactively to reflect the historical financial position or results of operations of Avalon.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 0.25in">For
                                            a more complete discussion of the accounting treatment of the Merger, see the section titled
                                            &#8220;THE MERGER - Accounting Treatment of the Merger.&#8221;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<a id="a_026"></a><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Material U.S. Federal Income Tax Consequences
of the Merger</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each of Avalon and YOOV intends
to take the position that the Merger is characterized as a reorganization within the meaning of Section 368(a) of the Code for U.S. federal
income tax purposes. Assuming the Merger is so characterized, in general and subject to the qualifications and limitations set forth in
the section entitled &#8220;<i>Certain Material U.S. Federal Income Tax Consequences of the Merger</i>,&#8221; the material tax consequences
to U.S. Holders (as defined herein) of YOOV Ordinary Shares would be as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">a U.S. Holder of YOOV Ordinary Shares should not recognize gain or loss upon the exchange of YOOV Ordinary
Shares for Avalon Common Stock pursuant to the Merger;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 26.75pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">a U.S. Holder of YOOV Ordinary Shares aggregate tax basis for the shares of Avalon Common Stock received
in the Merger should equal the stockholder&#8217;s aggregate tax basis in the YOOV Ordinary Shares surrendered upon the Closing; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 26.75pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the holding period of the shares of Avalon Common Stock received by a YOOV shareholder in the Merger should
include the holding period of the YOOV Ordinary Shares surrendered in exchange therefor provided the surrendered YOOV Ordinary Shares
is held as a capital asset (generally, property held for investment) at the time of the Merger.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify">&#160;</p>





</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 33 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon stockholders
will not sell, exchange or dispose of any shares of Avalon stock as a result of the Merger, so the Merger should not result in recognition
of gain or loss to the Avalon stockholders for U.S. federal income tax purposes in respect of their Avalon shares. Please review the information
in the section titled &#8220;<i>Certain Material U.S. Federal Income Tax Consequences of the Merger</i>&#8221; for a more complete description
of certain material U.S. federal income tax consequences of the Merger to Avalon stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The discussion of the material
U.S. federal income tax consequences contained in this proxy statement/prospectus is intended to provide only a general discussion and
is not a complete analysis or description of all potential U.S. federal income tax consequences of the Merger that may vary with, or are
dependent on, individual circumstances. In addition, the discussion does not address the effects of any foreign, state or local tax laws.
Accordingly, you should consult your tax advisor for a full understanding of the tax consequences of the Merger to you, including the
applicability and effect of federal, state, local and foreign income and other tax laws. For more information, please see the section
entitled &#8220;<i>Certain Material U.S. Federal Income Tax Consequences of the Merger</i>.&#8221;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">&#160;</p>

<a id="a_027"></a><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Ownership Following the Merger</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-indent: 0in">&#160;</p>

<a id="a_028"></a><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Merger</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Based
                                            on the closing price of Avalon Common Stock on Nasdaq of $3.41 on June 6, 2025, the latest
                                            practicable trading day prior to the date of this proxy statement/prospectus, and the number
                                            of YOOV Outstanding Shares on such date, <span style="background-color: white">it is anticipated
                                            that, </span>upon the completion of the Merger, the ownership of the Combined Company, on
                                            a pro forma basis, will be as follows:</span></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top"><td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Current Avalon equityholders will own approximately 2.7% to 3.0% of the common stock of the Combined Company;
and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.1pt; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 18.2pt"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Current YOOV equityholders will own approximately 97.0% to 97.3% of the common stock of the Combined Company.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.1pt; text-align: justify">&#160;</p>

<a id="a_029"></a><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-indent: 0in">Comparison of Rights of Holders of
Avalon Common Stock and YOOV Ordinary Shares</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a result of the Merger,
and the other proposed transactions contemplated thereby, the holders of YOOV Ordinary Shares and YOOV Preferred Shares will become holders
of Avalon Common Stock and their rights will be governed by Delaware law. Following the Merger, former YOOV securityholders may have different
rights as stockholders of the Combined Company than they had as YOOV shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Please see the section entitled
&#8220;<i>Comparison of Rights of Holders of Avalon Common Stock and YOOV Ordinary Shares</i>.<i>&#8221;</i>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</div><div>


</div><!-- Field: Page; Sequence: 34 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>



</div><div style="padding: 5pt; border: Black 1.5pt solid; width: 98%">

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>

<a id="a_030"></a><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTS</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This proxy statement/prospectus
contains or incorporates statements that constitute forward-looking statements within the meaning of the federal securities laws in relation
to Avalon, YOOV, the Merger and the other proposed transactions contemplated thereby. Any express or implied statements that do not relate
to historical or current facts or matters are forward-looking statements. In addition, any statements that refer to projections, forecasts
or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In
some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221;
&#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221;
&#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;seeks,&#8221; &#8220;target,&#8221; &#8220;endeavor,&#8221;
&#8220;potential,&#8221; &#8220;continue&#8221; or the negative of these terms or other comparable terminology, but the absence of these
words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs
concerning future developments and their potential effects. There can be no assurance that future developments affecting Avalon, YOOV
or the proposed transaction will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties
(some of which are beyond Avalon&#8217;s or YOOV&#8217;s control) or other assumptions that may cause actual results or performance to
be materially different from those expressed or implied by these forward-looking statements. In addition to other factors and matters
contained in or incorporated by reference in this document, Avalon and YOOV believe the following factors could cause actual results to
differ materially from those discussed in the forward-looking statements:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the risk that the conditions to the Closing are not satisfied, including the failure to obtain stockholder
approval for the Merger;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the timing, receipt and terms and conditions of any required governmental or regulatory approvals of the
Merger that could cause the parties to abandon the Merger;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Avalon&#8217;s and YOOV&#8217;s ability to meet expectations regarding the timing and completion of the
Merger;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">uncertainties as to the timing of the consummation of the Merger and the ability of each of Avalon and
YOOV to consummate the Merger;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">risks that Avalon&#8217;s stock price may decline significantly if the Merger is not completed;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">if the Merger is not completed, Avalon may not have sufficient capital to continue to operate its business
in the short term and may become insolvent and be required to seek the protection of the bankruptcy courts or seek dissolution and, without
additional funding or a strategic transaction, Avalon would likely be delisted from Nasdaq;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the outcome of any legal proceedings that may be instituted against Avalon and others following the announcement
of the Merger Agreement;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">expectations regarding the strategies, prospects, plans, expectations and objectives of management of
Avalon or YOOV for future operations of the Combined Company following the Closing;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the ability of the Combined Company to recognize the benefits that may be derived from the Merger, including
the commercial or market opportunity of the YOOV business;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

</div><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 35 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>



</div><div style="padding: 5pt; border: Black 1.5pt solid; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">risks related to Avalon&#8217;s and YOOV&#8217;s ability to correctly estimate their respective operating
expenses and expenses associated with the transaction, uncertainties regarding the impact any delay in the Closing would have on the anticipated
cash resources of the Combined Company upon Closing and other events and unanticipated spending and costs that could reduce the Combined
Company&#8217;s cash resources;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the occurrence of any event, change or other circumstance or condition that could give rise to the termination
of the Merger Agreement;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the fact that under the terms of the Merger Agreement, Avalon is restrained from soliciting other Takeover
Proposals during the pendency of the Merger, except in certain circumstances;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the effect of the announcement or pendency of the Merger on Avalon&#8217;s or YOOV&#8217;s business relationships,
operating results and business generally, including disruption of Avalon&#8217;s and YOOV&#8217;s management&#8217;s attention from ongoing
business operations due to the Merger and potential adverse reactions or changes to business relationships resulting from the announcement
or completion of the transaction;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the risk that the Merger Agreement may be terminated in circumstances that require Avalon to pay a termination
fee;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the outcome of any legal proceedings that may be instituted against Avalon, YOOV or any of their respective
directors or officers related to the Merger Agreement or the transactions contemplated thereby;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the ability of Avalon or YOOV to protect their respective intellectual property rights;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">competitive responses to the Merger;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">legislative, regulatory, political and economic developments beyond the parties&#8217; control;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">success in retaining, or changes required in, Avalon&#8217;s and YOOV&#8217;s officers, key employees
or directors;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Avalon&#8217;s public securities&#8217; potential liquidity and trading; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">developments and projections relating to YOOV&#8217;s competitors or its industry.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Should one or more of these
risks or uncertainties materialize, or should any of Avalon&#8217;s or YOOV&#8217;s assumptions prove incorrect, actual results may vary
in material respects from those projected in these forward-looking statements. There may be additional risks that Avalon considers immaterial
or which are unknown. You are urged to carefully review the disclosures Avalon and YOOV make concerning these risks and other factors
that may affect Avalon&#8217;s and YOOV&#8217;s business and operating results under the section titled &#8220;<i>Risk Factors</i>&#8221;
beginning on page <span style="background-color: white">17</span> of this proxy statement/prospectus. Additional factors that could cause
actual results to differ materially from those expressed in the forward-looking statements are discussed in reports filed with the SEC
by Avalon and incorporated by reference herein. Please see the section titled &#8220;<i>Where You Can Find More Information</i>&#8221;
beginning on page <span style="background-color: white">235</span> of this proxy statement/prospectus. There can be no assurance that
the Merger will be completed, or if it is completed, that it will be completed within the anticipated time period or that the expected
benefits of the Merger will be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any of these risks or
uncertainties materialize or any of these assumptions prove incorrect, the results of Avalon, YOOV or the Combined Company could differ
materially from the forward-looking statements. Any public statements or disclosures by Avalon and YOOV following this proxy statement/prospectus
that modify or impact any of the forward-looking statements contained in this proxy statement/prospectus will be deemed to modify or supersede
such statements in this proxy statement/prospectus. You are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date of this document. Avalon and YOOV do not intend, and undertake no obligation, to update any forward-looking
information to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events, unless
required by law to do so.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</div><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 36 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>



</div><div style="padding: 5pt; border: Black 1.5pt solid; width: 98%">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<a id="a_031"></a><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">MARKET PRICE AND DIVIDEND
INFORMATION</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Avalon Common Stock is
currently listed on The Nasdaq Capital Market under the symbol &#8220;ALBT.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">The closing price of the
Avalon Common Stock on March 7, 2025, the last day of trading prior to the announcement of the Merger, as reported on Nasdaq, was $7.23
per share. On June 6, 2025, the last trading day before the date of this proxy statement/prospectus, the closing sale price of Avalon
Common Stock was $3.41 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Because the market price
of the Avalon Common Stock is subject to fluctuation, the market value of the shares of the Avalon Common Stock that the YOOV shareholders
will be entitled to receive in the Merger may increase or decrease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV is a private company
and YOOV Ordinary Shares are not publicly traded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Assuming approval of Proposal
Nos. 1 through 7 and successful application for initial listing with The Nasdaq Capital Market, following the consummation of the Merger,
the Avalon Common Stock will trade on The Nasdaq Capital Market under the Combined Company&#8217;s new name, &#8220;YOOV, Inc.&#8221;
and new trading symbol &#8220;YOOV.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of [&#8195;], 2025, the
Record Date for the Special Meeting, there were approximately [&#8195;] registered holders of record of the Avalon Common Stock and [&#8195;]
holders of record of Avalon Preferred Stock. As of [&#8195;], 2025, the Record Date for the Special Meeting, YOOV had approximately [&#8195;]
holders of record of YOOV Ordinary Shares and [&#8195;] holders of record of YOOV Preferred Shares. For detailed information regarding
the beneficial ownership of certain Avalon and YOOV shareholders, see the sections of this proxy statement/prospectus titled &#8220;<i>Security
Ownership of Certain Beneficial Owners and Management-Avalon</i>&#8221; and &#8220;<i>Security Ownership of Certain Beneficial Owners
and Management-YOOV</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dividends</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon has not declared or
paid a cash dividend on its capital stock and does not intend to pay cash dividends for the foreseeable future. All dividends are subject
to the approval of the Avalon Board. Any future determinations to pay dividends on Avalon&#8217;s capital stock would depend on its results
of operations, its financial condition and liquidity requirements, restrictions that may be imposed by applicable laws or its contracts,
and any other factors that the Avalon Board in its sole discretion may consider relevant in declaring a dividend.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV has never paid or declared
any cash dividends on its capital stock. If the Merger does not occur, YOOV does not anticipate paying any cash dividends on its capital
stock in the foreseeable future, and YOOV intends to retain all available funds and any future earnings to fund the development and expansion
of its business. Any future determination to pay dividends will be at the discretion of the YOOV Board and will depend upon a number of
factors, including its results of operations, financial condition, future prospects, contractual restrictions, and restrictions imposed
by applicable laws and other factors the YOOV Board deems relevant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</div><div>




</div><!-- Field: Page; Sequence: 37 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_032"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">RISK FACTORS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>The Combined Company will face a market environment
that cannot be predicted and that involves significant risks, many of which will be beyond its control. In addition to the other information
contained in this proxy statement/prospectus, you should carefully consider the material risks described below before deciding how to
vote your shares of stock. In addition, you should consider the risks associated with the business of Avalon and YOOV because these risks
may also affect the Combined Company. You should also read and consider the other information in this proxy statement/prospectus. Please
see the section entitled &#8220;Where You Can Find More Information.&#8221;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_033"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to complete the Merger could negatively
impact the stock price and the future business and financial results of Avalon. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The parties&#8217; respective
obligations to complete the Merger are subject to the satisfaction or waiver of a number of conditions set forth in the Merger Agreement.
There can be no assurance that the conditions to completion of the Merger will be satisfied or waived or that the Merger will be completed.
If the Merger is not completed for any reason, the ongoing businesses of Avalon and YOOV may be materially and adversely affected and,
without realizing any of the benefits of having completed the Merger, Avalon and YOOV would be subject to a number of risks, including
the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Avalon may experience negative reactions from the financial markets, including negative impacts on the
trading price of Avalon Common Stock, which could affect Avalon&#8217;s ability to secure sufficient financing in the future on attractive
terms (or at all) as a standalone company, and, if Avalon is unable to obtain additional capital, it may need to cease operations, dissolve
or seek protection of bankruptcy courts;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.75pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Avalon may be required to pay YOOV a termination fee of $1,000,000 if Avalon fails to consummate the Merger
under specified circumstances;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.75pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Avalon and YOOV will be required to pay certain expenses incurred in connection with the Merger, whether
or not the Merger is completed;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.75pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the Merger Agreement places certain restrictions on the operation of each of Avalon&#8217;s and YOOV&#8217;s
respective businesses prior to the Closing, and such restrictions, the waiver of which is subject to the consent of the other parties,
may prevent Avalon or YOOV, as applicable, from making certain acquisitions, taking certain other specified actions or otherwise pursuing
business opportunities during the pendency of the Merger that Avalon or YOOV would have made, taken or pursued if these restrictions were
not in place; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">matters relating to the Merger (including integration planning) will require substantial commitments of
time and resources by Avalon and YOOV management and the expenditure of significant funds in the form of fees and expenses, which would
otherwise have been devoted to day-to-day operations and other opportunities that may have been beneficial to either Avalon or YOOV as
an independent company.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, each of Avalon
and YOOV could be subject to litigation related to any failure to complete the Merger or related to any proceeding to specifically enforce
Avalon&#8217;s and YOOV&#8217;s obligations under the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 38 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any of these risks materialize,
they may materially and adversely affect Avalon&#8217;s and YOOV&#8217;s business, financial condition, financial results and stock prices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For a description of the
circumstances under which a termination fee is payable, please see the section entitled &#8220;<i>The Merger Agreement-Termination and
Termination Fee</i>.&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Avalon and YOOV will be subject to business
uncertainties and contractual restrictions while the Merger is pending. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Uncertainty about the effect
of the Merger on employees, vendors and customers may have an adverse effect on Avalon or YOOV and consequently on the Combined Company
after the Closing. These uncertainties may impair Avalon&#8217;s and YOOV&#8217;s ability to retain and motivate key personnel and could
cause customers and others that deal with Avalon and YOOV, as applicable, to defer or decline entering into contracts with Avalon or
YOOV, as applicable, or making other decisions concerning Avalon or YOOV, as applicable, or seek to change existing business relationships
with Avalon or YOOV, as applicable. In addition, if key employees depart because of uncertainty about their future roles and the potential
complexities of the Merger, Avalon&#8217;s and YOOV&#8217;s businesses could be harmed. Furthermore, the Merger Agreement places certain
restrictions on the operation of Avalon&#8217;s and YOOV&#8217;s businesses prior to the Closing, which may delay or prevent Avalon and
YOOV from undertaking certain actions or business opportunities that may arise prior to the consummation of the Merger. Please see the
section entitled &#8220;<i>The Merger Agreement-Covenants; Conduct of Business Pending the Merger</i>&#8221; for a description of the
restrictive covenants applicable to Avalon and YOOV.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third parties may terminate or alter existing
contracts or relationships with Avalon or YOOV. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each of Avalon and YOOV has
contracts with customers, vendors and other business partners which may require Avalon or YOOV, as applicable, to obtain consents from
these other parties in connection with the Merger. If these consents cannot be obtained, the counterparties to these contracts and other
third parties with which Avalon and/or YOOV currently have relationships may have the ability to terminate, reduce the scope of or otherwise
materially adversely alter their relationships with either party in anticipation of the Merger, or with the Combined Company following
the Merger. The pursuit of such rights may result in Avalon and YOOV suffering a loss of potential future revenue, incurring liabilities
in connection with a breach of such agreements or losing rights that are material to their businesses. Any such disruptions could limit
the Combined Company&#8217;s ability to achieve the anticipated benefits of the Merger. The adverse effect of such disruptions could also
be exacerbated by a delay in the completion of the Merger or the termination of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Merger is subject to a number of closing
conditions and, if these conditions are not satisfied, the Merger Agreement may be terminated in accordance with its terms and the Merger
may not be completed. In addition, the parties have the right to terminate the Merger Agreement under other specified circumstances, in
which case the Merger would not be completed. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Merger is subject to
a number of closing conditions and, if these conditions are not satisfied or waived (to the extent permitted by law), the Merger will
not be completed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These conditions include,
among others: (i) the absence of certain legal impediments, (ii) effectiveness of this registration statement on Form S-4 relating to
the Merger, (iii) obtaining all governmental authorizations, (iv) obtaining the Avalon Stockholder Approval, (v) the approval of the Merger
Agreement and the Merger by YOOV shareholders and (vi) the approval of the Nasdaq listing application and the listing of the Merger Shares
on The Nasdaq Capital Market. In addition, each party&#8217;s obligation to complete the Merger is subject to the accuracy of the other
parties&#8217; representations and warranties in the Merger Agreement, the other parties&#8217; compliance, in all material respects,
with their respective covenants and agreements in the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 39 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The
                                            conditions to the Closing may not be fulfilled and, accordingly, the Merger may not be completed.
                                            In addition, if the Merger is not completed by March 7, 2026, any party may choose not to
                                            proceed with the Merger. Moreover, the parties can mutually decide to terminate the Merger
                                            Agreement at any time prior to the consummation of the Merger, before or after receipt of
                                            the Avalon Stockholder Approval and the approval of the Merger Agreement and the Merger by
                                            YOOV shareholders and each party may elect to terminate the Merger Agreement in certain other
                                            circumstances, as described in the section entitled &#8220;<i>The Merger Agreement-Termination
                                            of the Merger Agreement</i>.&#8221; If the Merger Agreement is terminated, Avalon or YOOV,
                                            as applicable, may incur substantial fees and expenses in connection with termination of
                                            such Agreement and neither of them will realize the anticipated benefits of the Merger. In
                                            addition, if the Merger is not completed, Avalon may not have sufficient capital to continue
                                            to operate its business in the long term and may become insolvent and be required to seek
                                            the protection of the bankruptcy courts and, without additional funding or a strategic transaction,
                                            we would likely be delisted from Nasdaq. For a description of the circumstances under which
                                            a termination fee is payable, please see the section entitled &#8220;<i>The Merger Agreement-Termination
                                            and Termination Fee</i>.&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Avalon or YOOV may waive one or more of
the closing conditions to the Merger without re-soliciting stockholder approval. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each of Avalon and YOOV has
the right to waive certain of the closing conditions to the Merger. Any such waiver may not require re-solicitation of stockholders, in
which case stockholders of Avalon and shareholders of YOOV will not have the chance to change their votes as a result of any such waiver
and Avalon and YOOV will have the ability to complete the Merger without seeking further stockholder approval. Any determination whether
to waive any condition to the Merger, whether stockholder approval would be re-solicited as a result of any such waiver or whether this
proxy statement/prospectus would be amended as a result of any waiver will be made Avalon or YOOV, as applicable, at the time of such
waiver based on the facts and circumstances as they exist at that time, and any such waiver could have an adverse effect on the Combined
Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Both Avalon&#8217;s stockholders and YOOV&#8217;s
shareholders will have a reduced ownership and voting interest after the Merger and will exercise less influence over management. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.2pt; text-align: justify; text-indent: 0.25in"><span style="-keep: true">The
                                            number of shares of Avalon Common Stock that YOOV shareholders will receive as consideration
                                            in the Merger is not fixed. Based on the closing price of Avalon Common Stock on Nasdaq of
                                            $3.41 on June 6, 2025, the latest practicable trading day prior to the date of this proxy
                                            statement/prospectus, and on the number of shares of YOOV Outstanding Shares on such date,
                                            the Exchange Ratio will be approximately <span style="background-color: white">121.8</span>.
                                            Based on the estimated Exchange Ratio, Avalon is expected to issue 60,000,000 shares of Avalon
                                            Common Stock to the YOOV shareholders. Upon completion of the Merger, the current Avalon
                                            stockholders are expected to own approximately 2.7% to 3.0% of the common stock of the Combined
                                            Company and the YOOV shareholders are expected to own approximately 97.0% to 97.3% of the
                                            common stock of the Combined Company. The Exchange Ratio is an estimate only, and the actual
                                            Exchange Ratio and relative ownership interests of Avalon stockholders and YOOV shareholders
                                            in the Combined Company immediately following the Merger will depend on the market price
                                            of Avalon&#8217;s Common Stock two (2) trading days prior to the Merger and the number of
                                            YOOV Outstanding Shares on the Closing Date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.2pt; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.3pt">Consequently, Avalon stockholders,
as a group, and YOOV shareholders, as a group, will each have reduced ownership and voting power in the Combined Company compared to their
current ownership and voting power in Avalon and YOOV, respectively. In particular, upon consummation of the Merger, Avalon stockholders,
as a group, will have less than a majority of the ownership and voting power of Avalon. In addition, YOOV shareholders, as a group, and
Avalon stockholders, as a group, will be able to exercise less collective influence over the management and policies of Avalon than they
currently exercise over the management and policies of their respective company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 40 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Merger Agreement limits Avalon&#8217;s
and YOOV&#8217;s ability to pursue alternatives to the Merger. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The
                                            Merger Agreement contains provisions that make it more difficult for Avalon and YOOV to enter
                                            into alternative transactions. The Merger Agreement contains certain provisions that restrict
                                            Avalon&#8217;s and YOOV&#8217;s ability to solicit or facilitate proposals from third parties
                                            with respect to transactions involving the financing or sale of Avalon or YOOV, as applicable,
                                            or provide non-public information to, or otherwise participate or engage in discussions or
                                            negotiations with, third parties or take certain other actions that would reasonably be expected
                                            to lead to a third-party acquisition proposal. Further, there are only limited exceptions
                                            to Avalon&#8217;s and YOOV&#8217;s agreement that its board of directors will not change
                                            its recommendation in favor of the adoption of the Merger Agreement. However, at any time
                                            prior to the receipt of the Avalon Stockholder Approval and the approval of the Merger Agreement
                                            and the Merger by YOOV shareholders, in response to an unsolicited superior proposal made
                                            by a third party, Avalon&#8217;s and YOOV&#8217;s board of directors, as applicable, may
                                            make an adverse recommendation change, and terminate the Merger Agreement to enter into an
                                            alternative acquisition agreement, if it concludes in good faith, after consultation with
                                            their respective outside financial advisors and outside legal counsel, that the failure to
                                            take such action would be inconsistent with the fiduciary duties of Avalon&#8217;s or YOOV&#8217;s
                                            board of directors under the circumstances and under applicable law. Please see the section
                                            entitled &#8220;<i>The Merger Agreement-Non-Solicitation.</i>&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As
                                            described above, Avalon may be required to pay a termination fee of $1,000,000 to YOOV if
                                            the Merger is not consummated under specified circumstances. Please see the section entitled
                                            &#8220;<i>The Merger Agreement-Termination and Termination Fee</i>&#8221;, including as described
                                            above, for a description of the circumstances under which such a termination fee is payable.
                                            Upon obtaining the Avalon Stockholder Approval, Avalon&#8217;s right to terminate the Merger
                                            Agreement in response to a superior proposal will cease.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, upon adoption
of the Merger Agreement by YOOV&#8217;s shareholders, YOOV&#8217;s right to terminate the Merger Agreement in response to a superior proposal
will cease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">While Avalon and YOOV believe
these provisions are reasonable, customary and not preclusive of other offers, the provisions might discourage a third party that has
an interest in acquiring all or a significant part of Avalon or YOOV from considering or proposing such an acquisition, even if such party
were prepared to pay consideration with a higher per-share value than the currently proposed merger consideration or if such party were
prepared to enter into an agreement that may be more favorable to Avalon or YOOV or their respective stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Projections considered by Avalon and
Roth may not be realized, which may adversely affect the market price of Avalon Common Stock following the completion of the Merger. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In
                                            performing its financial analyses and rendering its opinion related to the Merger, Roth relied
                                            on, among other things, certain information, including the Projections. Please see the sections
                                            entitled &#8220;<i>The Merger- YOOV Management Unaudited Prospective Financial Information</i>.&#8221;
                                            The Projections were prepared by, or at the direction of, the management of YOOV. None of
                                            these projections or forecasts were prepared with a view towards public disclosure or compliance
                                            with the published guidelines of the SEC, U.S. GAAP or the guidelines established by the
                                            American Institute of Certified Public Accountants for preparation and presentation of financial
                                            forecasts. These projections and forecasts are inherently based on various estimates and
                                            assumptions that are subject to the judgment of those preparing them. These projections and
                                            forecasts are also subject to significant economic, competitive, industry and other uncertainties
                                            and contingencies, all of which are difficult or impossible to predict and many of which
                                            are beyond the control of Avalon. There can be no assurance that YOOV&#8217;s financial condition,
                                            including its cash flows or results of operations will be consistent with those set forth
                                            in such projections and forecasts, which could have an adverse impact on the market price
                                            of Avalon Common Stock or the financial position of the Combined Company following the Closing.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Executive officers and directors of Avalon
and YOOV may have interests in the Merger that are different from, or in addition to, the rights of their respective stockholders. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Executive
                                            officers of Avalon and YOOV negotiated the terms of the Merger Agreement and the Avalon Board
                                            and the YOOV Board each approved the Merger Agreement and the Merger and recommend that each
                                            stockholder vote in favor of the proposals presented at the Special Meeting or in the written
                                            consent, as applicable. These executive officers and directors may have interests in the
                                            Merger that are different from, or in addition to, the Avalon or YOOV shareholders. These
                                            interests include the continued employment of certain executive officers of YOOV as executive
                                            officers of the Combined Company following the Merger, the continued service of certain directors
                                            Avalon and YOOV as directors of the Combined Company following the Merger, the indemnification
                                            of Avalon and YOOV executive officers and directors by Avalon. Stockholders should be aware
                                            of these interests when they consider their board of directors&#8217; recommendations that
                                            stockholders vote in favor of the Merger. For a description of the interests of Avalon&#8217;s
                                            executive officer and directors in the Merger, please see the section entitled &#8220;<i>The
                                            Merger-Interests of Avalon&#8217;s Directors and Officer in the Merger</i>.&#8221; For a
                                            description of the interests of YOOV&#8217;s executive officers and directors in the Merger,
                                            please see the section entitled &#8220;<i>The Merger-Interests of YOOV&#8217;s Directors
                                            and Officers in the Merger</i>.&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Avalon, YOOV and, subsequently, the Combined
Company may have difficulty attracting, motivating and retaining executives and other key employees in light of the proposed Merger. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Combined Company&#8217;s
success after the Merger will depend in part on each of Avalon&#8217;s and YOOV&#8217;s ability to retain key executives and other employees.
Uncertainty about the effect of the Merger on Avalon&#8217;s and YOOV&#8217;s employees may have an adverse effect on each company separately
and consequently, the Combined Company. This uncertainty may impair the Combined Company&#8217;s ability to attract, retain and motivate
key personnel. Employee retention may be particularly challenging during the pendency of the Merger, as Avalon&#8217;s and YOOV&#8217;s
employees may experience uncertainty about their future roles in the combined business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, YOOV&#8217;s
officers and employees hold YOOV Common Stock and, if the Merger is completed, these officers and employees will be entitled to the Avalon
Common Stock in respect of such shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Furthermore, if any of Avalon
or YOOV&#8217;s key employees depart or are at risk of departing, including because of issues relating to the uncertainty and difficulty
of integration, financial security or a desire not to become employees of the combined business, Avalon or YOOV, as applicable, may have
to incur significant costs in retaining such individuals or in identifying, hiring and retaining replacements for departing employees
and may lose significant expertise and talent, and the Combined Company&#8217;s ability to realize the anticipated benefits of the Merger
may be materially and adversely affected. No assurance can be given that the Combined Company will be able to attract or retain key employees
to the same extent that Avalon or YOOV has been able to attract or retain employees in the past.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 42 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Avalon and YOOV will incur significant transaction
and Merger-related transition costs in connection with the Merger. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon and YOOV expect that
they will incur significant, non-recurring costs in connection with consummating the Merger and integrating the operations of the two
companies post-Closing. Avalon and/or YOOV may incur additional costs to retain key employees. Avalon and/or YOOV will also incur significant
fees and expenses relating to financing arrangements and legal services (including any costs that would be incurred in defending against
any potential class action lawsuits and derivative lawsuits in connection with the Merger if any such proceedings are brought), accounting
and other fees and costs, associated with consummating the Merger. Some of these costs are payable regardless of whether the Merger is
completed. In addition, Avalon may be required to pay a termination fee of $1,000,000 if the Merger Agreement is terminated under specified
circumstances described in this proxy statement/prospectus. Though Avalon and YOOV continue to assess the magnitude of these costs, additional
unanticipated costs may be incurred in the Merger and the integration of the businesses of Avalon and YOOV.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The opinion of Avalon&#8217;s Financial
Advisor will not be updated to reflect changes in circumstances between the signing of the Merger Agreement on March 7, 2025 and the completion
of the Merger. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon
                                            has not obtained an updated Opinion from Roth as of the date of this proxy statement/prospectus,
                                            and Avalon does not anticipate asking Roth to update its the Opinion. Changes in the operations
                                            and prospects of Avalon and YOOV, general market and economic conditions and other factors
                                            that may be beyond the control of Avalon, and on which the Opinion was based in part, may
                                            significantly alter the prices of the shares of Avalon Common Stock by the Closing Date.
                                            The opinion does not speak as of the time the Merger will be completed or as of any date
                                            other than the date of the Opinion. Because Roth will not be updating the Opinion, which
                                            was issued in connection with the signing of the Merger Agreement on March 7, 2025, the Opinion
                                            will not address the fairness of the Exchange Ratio, from a financial point of view, to Avalon
                                            at the Closing Date. The Avalon Board&#8217;s recommendation that Avalon stockholders vote
                                            &#8220;<b>FOR</b>&#8221; the proposals included herein, however, is made as of the date of
                                            this proxy statement/prospectus. For a description of the Opinion that Avalon received from
                                            Roth, please see the section entitled &#8220;<i>The Merger-Opinion of Avalon&#8217;s Financial
                                            Advisor</i>.&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Avalon and YOOV may be the target of securities
class action and stockholder lawsuits which could result in substantial costs and may delay or prevent the Merger from being completed.
</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Securities class action lawsuits
and stockholder lawsuits are often brought against public companies that have entered into merger agreements. Even if the lawsuits are
without merit, defending against these claims can result in substantial costs and divert management time and resources. An adverse judgment
could result in monetary damages, which could have a negative impact on Avalon&#8217;s or YOOV&#8217;s liquidity and financial condition.
Additionally, if a plaintiff is successful in obtaining an injunction prohibiting completion of the Merger, then that injunction may delay
or prevent the Merger from being completed, which may adversely affect Avalon&#8217;s or YOOV&#8217;s or, if the Merger is completed but
delayed, the Combined Company&#8217;s business, financial position and results of operations. As of the date of this proxy statement/prospectus,
no such lawsuits have been filed in connection with the Merger and the parties cannot predict whether any will be filed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The lack of a public market for YOOV shares
makes it difficult to determine the fair market value of the YOOV shares, and YOOV shareholders may receive consideration in the Merger
that is less than the fair market value of the YOOV shares and/or Avalon may pay more than the fair market value of the YOOV shares. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV is privately held, and
its capital stock is not traded in any public market. The lack of a public market makes it extremely difficult to determine YOOV&#8217;s
fair market value. Because the percentage of Avalon&#8217;s equity to be issued to YOOV shareholders was determined based on negotiations
between the parties, it is possible that the value of the Avalon Common Stock to be received by YOOV shareholders will be less than the
fair market value of YOOV, or Avalon may pay more than the aggregate fair market value for YOOV.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_034"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Additional Risks Relating to the Combined Company
after Completion of the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Combined Company will be subject to
the risks that each of Avalon and YOOV faces. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following
                                            completion of the Merger, the Combined Company will be subject to numerous risks and uncertainties,
                                            including the risks faced by each of Avalon and YOOV, which are described in the documents
                                            that Avalon has filed with the SEC, including those set forth herein and those set forth
                                            in Avalon&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024,
                                            as updated by future filings after the date of this proxy statement/prospectus with the SEC
                                            by Avalon, and in the sections of this proxy statement/prospectus entitled &#8220;<i>Risk
                                            Factors-Risks Related to YOOV</i>&#8221; and entitled &#8220;<i>Risk Factors-Risks Related
                                            to Avalon.</i>&#8221; If any such risks actually occur, the business, financial condition,
                                            results of operations or cash flows of the Combined Company could be materially adversely
                                            affected.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market price for shares of Avalon Common
Stock may be affected by factors different from those affecting the market price for shares of YOOV Common Stock. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon completion of the Merger,
holders of YOOV Common Stock will become holders of Avalon Common Stock. Avalon&#8217;s and YOOV&#8217;s respective businesses differ,
and accordingly the results of operations of the Combined Company, and the market price of the common stock of the Combined Company,
will be affected by factors different from those currently affecting the results of operations of Avalon and YOOV independently. For
a discussion of the businesses of Avalon and YOOV and of certain factors to consider in connection with those businesses, please see
the sections entitled &#8220;<i>Information About YOOV</i>,&#8221; &#8220;<i>Information About Avalon,</i>&#8221;<i>&#8220;Risk Factors-Risks
Related to YOOV</i>&#8221; and <i>&#8220;Risk Factors-Risks Related to Avalon.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market price for shares of Avalon Common
Stock may decline as a result of the Merger, including as a result of some Avalon stockholders adjusting their portfolios. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The market value of Avalon
Common Stock at the time of consummation of the Merger may vary significantly from the price of Avalon Common Stock on the date the Merger
Agreement was executed, the date of this proxy statement/prospectus and the date of the Special Meeting. Following the consummation of
the Merger, the market price of Avalon Common Stock may decline if, among other things, the operational cost estimates in connection with
the operation of YOOV&#8217;s business or if the costs related to the Merger are greater than expected. The market price also may decline
if Avalon does not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial or industry analysts
or if the effect of the Merger on Avalon&#8217;s financial position, results of operations or cash flows is not consistent with the expectations
of financial or industry analysts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, sales of Avalon Common Stock by Avalon&#8217;s stockholders after the completion of the Merger may cause the market price of
Avalon Common Stock to decrease. Based on the number of shares of Avalon Common Stock outstanding as of <span style="background-color: white">June
6</span>, 2025, the latest practicable date before the date of this proxy statement/prospectus, approximately 62,132,236 shares of Avalon
Common Stock are expected to be issued and outstanding immediately after the Closing, without taking into effect the contemplated Reverse
Stock Split, if approved and if necessary to be effectuated for the Combined Company to meet the $4.00 minimum bid price initial listing
requirement following the Closing pursuant to the rules of The Nasdaq Capital Market, prior to the Effective Time. Although certain Avalon
stockholders and YOOV shareholders have entered into Lock-Up Agreements, Avalon stockholders and YOOV shareholders that are not party
to such Lock-Up Agreements or those who are party to such Lock-Up Agreements when such agreements expire, may decide not to hold the
shares of Avalon Common Stock that they receive in the Merger. Other Avalon stockholders, such as funds with limitations on their permitted
holdings of stock in individual issuers, may be required to sell the shares of Avalon Common Stock that they receive in the Merger. Such
sales of Avalon Common Stock could have the effect of depressing the market price for Avalon Common Stock and may take place promptly
following the Closing.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 44 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any of these events may make
it more difficult for Avalon to sell equity or equity-related securities, dilute your ownership interest in Avalon and have an adverse
impact on the price of Avalon Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Avalon does not expect to declare any cash
dividends in the foreseeable future. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">After the completion of the
Merger, Avalon does not anticipate declaring any cash dividends to holders of Avalon Common Stock in the foreseeable future. Consequently,
investors may need to rely on sales of their shares after price appreciation, which may never occur, as the only way to realize any future
gains on their investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Merger may not be accretive, and may
be dilutive, to the Combined Company&#8217;s earnings per share, which may negatively affect the market price of shares of Avalon Common
Stock. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon and YOOV currently
believe the Merger will result in a number of benefits, including stronger demand for the Combined Company&#8217;s products and services,
and that the Merger will be accretive to the Combined Company&#8217;s earnings. This belief is based, in part, on preliminary current
estimates that may materially change. In addition, future events and conditions, including adverse changes in market conditions, additional
transaction and integration-related costs and other factors such as the failure to realize some or all of the anticipated benefits of
the Merger, could decrease or delay the accretion that is currently anticipated or could result in dilution. Any dilution of, or decrease
in or delay of any accretion to, the Combined Company&#8217;s earnings per share could cause the price of shares of Avalon Common Stock
to decline or grow at a reduced rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Combined Company may incur losses for
the foreseeable future and may never achieve profitability. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Combined Company may
never become profitable, even if the Combined Company is able to achieve the prior operating results of YOOV. Even if the Combined Company
does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 45 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Following the Merger, the Combined Company
may be unable to integrate successfully the businesses of Avalon and YOOV and realize the anticipated benefits of the Merger. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Merger involves the combination
of two companies which currently operate as independent companies. Following the Merger, the Combined Company will be required to devote
significant management attention and resources to integrating its business practices and operations. The Combined Company may fail to
realize some or all of the anticipated benefits of the Merger if the integration process takes longer than expected or is more costly
than expected. Potential difficulties the Combined Company may encounter in the integration process include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the inability to successfully combine the businesses of Avalon and YOOV in a manner that permits the Combined
Company to achieve the anticipated benefits from the Merger, which would result in the anticipated benefits of the Merger not being realized
partly or wholly in the time frame currently anticipated or at all;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.75pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">creation of uniform standards, controls, procedures, policies, and information systems; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.75pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">potential unknown liabilities and unforeseen increased expenses, delays or regulatory conditions associated
with the Merger</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">In the event the Merger
is consummated, the Combined Company intends to continue to develop and commercialize KetoAir. Avalon has been operating and
developing the KetoAir business for almost two (2) years. Avalon has engaged its outside marketing team for the marketing and
distribution of KetoAir through the remainder of 2025 and, following the completion of the Merger, the Combined Company intends to
extend such engagement as long as the Combined Company determines that continuation of the marketing and sale of KetoAir is
viable.&#160; In addition, Avalon is in negotiations for a long term agreement for the development of a testing system using the
same intellectual property and mechanism of KetoAir for the testing of THC. Avalon and YOOV also believe that there may be the
opportunity to integrate the YOOV AI technologies into the KetoAir analytical data to further develop the product. Avalon and YOOV
have not yet determined whether or not they will continue to own or will sell the real property currently owned by Avalon following
the completion of the Merger.&#160;</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, Avalon and YOOV
have operated and, until the completion of the Merger, will continue to operate, independently. It is possible that the integration process
also could result in the diversion of each company&#8217;s management&#8217;s attention, the disruption or interruption of, or the loss
of momentum in, each company&#8217;s ongoing businesses or inconsistencies in standards, controls, procedures, and policies, any of which
could adversely affect the Combined Company&#8217;s ability to maintain its business relationships or the ability to achieve the anticipated
benefits of the Merger, or could otherwise adversely affect the business and financial results of the Combined Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the Combined Company fails to attract
and retain management and other key personnel, it may be unable to continue to successfully develop or commercialize its product candidates
or otherwise implement its business plan. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Combined Company&#8217;s
ability to compete in the highly competitive business automation industry depends on its ability to attract and retain highly qualified
managerial, legal, sales and marketing, and other personnel. The Combined Company will be highly dependent on the management and personnel
of YOOV. The loss of the services of any of these individuals could impede, delay, or prevent the successful development of its AIaaS
platforms and could negatively impact its ability to implement successfully its business plan. If the Combined Company loses the services
of any of these individuals, it might not be able to find suitable replacements on a timely basis or at all, and its business could be
harmed as a result. The Combined Company might not be able to attract or retain qualified management and other key personnel in the future
due to the intense competition for qualified personnel among other businesses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Combined Company will need to raise
additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">The
                                            Combined Company will require substantial additional funds to support business development
                                            and research and development activities. The Combined Company&#8217;s future capital requirements
                                            will depend upon a number of factors, such as the continued development and scaling of KetoAir,
                                            its AIaaS platform, expansion into new markets and industries, the growth of its global customer
                                            base, and the operational needs of its subsidiaries in financial and insurance services.
                                            Raising additional capital may be costly or difficult to obtain and could, for example, through
                                            the sale of common stock or securities convertible or exchangeable into common stock, significantly
                                            dilute stockholders&#8217; ownership interests in the Combined Company or inhibit the Combined
                                            Company&#8217;s ability to achieve its business objectives. If the Combined Company raises
                                            additional funds through public or private equity offerings, the terms of these securities
                                            may include liquidation or other preferences that adversely the rights of its common stockholders.
                                            In addition, any debt financing may subject the Combined Company to fixed payment obligations
                                            and covenants limiting or restricting its ability to take specific actions, such as incurring
                                            additional debt, making capital expenditures or declaring dividends. If the Combined Company
                                            raises additional capital through marketing and distribution arrangements or other collaborations,
                                            strategic alliances or licensing arrangements with third parties, the Combined Company may
                                            have to relinquish certain valuable rights under the agreements with such parties. Even if
                                            the Combined Company were to obtain sufficient funding, there can be no assurance that it
                                            will be available on terms acceptable to the Combined Company or its stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 46 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Combined Company will incur additional
costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Combined Company will
incur significant legal, accounting, and other expenses as a public company that YOOV did not incur as a private company, including costs
associated with public company reporting obligations under the Exchange Act. The Combined Company&#8217;s management team will consist
of the executive officers of YOOV prior to the Merger, some of whom have not previously managed and operated a public company. These executive
officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements
and compliance with applicable laws and regulations to ensure that the Combined Company complies with all these requirements. Any changes
the Combined Company makes to comply with these obligations may not be sufficient to allow it to satisfy its obligations as a public company
on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure
associated with being a public company, could also make it more difficult for the Combined Company to attract and retain qualified persons
to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance,
including directors&#8217; and officers&#8217; insurance, on acceptable terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>At the Effective Time of the Merger, failure
by the Combined Company to comply with the initial listing standards of Nasdaq will prevent its stock from being listed on Nasdaq. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At the Effective Time, Avalon,
under the new name &#8220;YOOV, Inc.,&#8221; will be required to meet the initial listing requirements to maintain the listing and continued
trading of its shares on the Nasdaq Capital Market. These initial listing requirements are more difficult to achieve than the continued
listing requirements. Pursuant to the Merger Agreement, Avalon agreed to use its commercially reasonable efforts to cause the shares of
Avalon Common Stock being issued in the Merger to be approved for listing on the Nasdaq Capital Market at or prior to the Effective Time
of the Merger. Based on information currently available to Avalon, Avalon anticipates that its stock may be unable to meet the $4.00 (or,
to the extent applicable, $3.00) minimum bid price initial listing requirement at the Closing unless it effects the Reverse Stock Split.
The Avalon Board intends to effect a reverse stock split of the shares of Avalon Common Stock at a ratio of between 1-for-2 to 1-for-20.
In addition, often times a reverse stock split will not result in a trading price for the affected common stock that is proportional to
the ratio of the split. Following the Merger, if the Combined Company is unable to satisfy Nasdaq continued listing requirements, Nasdaq
may notify the Combined Company that its shares of common stock will not continue to be listed on the Nasdaq Capital Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon a potential delisting
from Nasdaq, if the common stock of the Combined Company is not then eligible for quotation on another market or exchange, trading of
the shares could be conducted in the over-the-counter market or on an electronic bulletin board established for unlisted securities such
as the Pink Sheets or the OTC Bulletin Board. In such event, it is likely that there would be significantly less liquidity in the trading
of the common stock of the Combined Company; decreases in institutional and other investor demand for the shares, coverage by securities
analysts, market making activity and information available concerning trading prices and volume; and fewer broker dealers willing to execute
trades in the common stock of the Combined Company. Also, it may be difficult for the Combined Company to raise additional capital if
the Combined Company&#8217;s common stock is not listed on a major exchange. The occurrence of any of these events could result in a further
decline in the market price of the common stock of the Combined Company and could have a material adverse effect on the Combined Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the Combined Company is no longer a smaller
reporting company or otherwise no longer qualifies for applicable exemptions, the Combined Company will be subject to additional laws
and regulations affecting public companies that will increase the Combined Company&#8217;s costs and the demands on management and could
harm the Combined Company&#8217;s operating results and cash flows. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Combined Company will
be subject to the reporting requirements of the Exchange Act, which requires, among other things, that the Combined Company file with
the SEC, annual, quarterly, and current reports with respect to the Combined Company&#8217;s business and financial condition as well
as other disclosure and corporate governance requirements. Avalon and YOOV expect the Combined Company will qualify as a &#8220;smaller
reporting company,&#8221; as such term is defined in Rule 12b-2 under the Exchange Act, in at least the near term, which will allow the
Combined Company to take advantage of certain exemptions from disclosure requirements, including not being required to comply with the
auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation
in this proxy statement/prospectus and in the Combined Company&#8217;s periodic reports and proxy statements. If the Combined Company
is no longer a smaller reporting company or otherwise no longer qualifies for these exemptions, the Combined Company will be required
to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting
and other expenses to do so. If the Combined Company is not able to comply with the requirements in a timely manner or at all, the Combined
Company&#8217;s financial condition or the market price of the Combined Company&#8217;s common stock may be harmed. For example, if the
Combined Company or its independent auditor identifies deficiencies in the Combined Company&#8217;s internal control over financial reporting
that are deemed to be material weaknesses the Combined Company could face additional costs to remedy those deficiencies, the market price
of the Combined Company&#8217;s stock could decline or the Combined Company could be subject to sanctions or investigations by the SEC
or other regulatory authorities, which would require additional financial and management resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The unaudited pro forma financial information
included in this proxy statement/prospectus is preliminary and the Combined Company&#8217;s actual financial position or results of operations
after the Merger may differ materially. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The unaudited pro forma financial
information in this proxy statement/prospectus is presented for illustrative purposes only and is not necessarily indicative of what the
Combined Company&#8217;s actual financial position or results of operations would have been had the Merger been completed on the dates
indicated. The unaudited pro forma financial information reflects adjustments, which are based upon estimates, to allocate the purchase
price to tangible and identifiable intangible assets acquired and liabilities assumed, based on their estimated acquisition-date fair
values. The purchase price allocation reflected in this document is preliminary, and a final determination of the fair value of assets
acquired and liabilities assumed will be based on the actual net tangible and intangible assets and liabilities of YOOV that existed as
of the date of the completion of the Merger. Accordingly, the final purchase accounting adjustments may differ materially from the pro
forma information reflected in this proxy statement/prospectus. For more information, please see the section entitled &#8220;<i>Unaudited
Pro Forma Condensed Combined Financial Information</i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Provisions of the Combined Company Charter
and the Combined Company Bylaws, and provisions under Delaware law could make an acquisition of the Combined Company more difficult and
may prevent attempts by its stockholders to replace or remove its management. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the Merger Agreement,
immediately prior to the Effective Time, the Avalon Charter shall be amended to (i) change the name of Avalon to &#8220;YOOV, Inc.&#8221;,
(ii) effectuate the Reverse Stock Split, if approved and if necessary to be effectuated for the Combined Company to meet the $4.00 minimum
bid price initial listing requirement following the Closing pursuant to the rules of The Nasdaq Capital Market, (iii) increase the number
of authorized shares of common stock to 200,000,000 and (iv) make such other changes as shall be mutually agreed upon by Avalon and YOOV
prior to the filing of such amendment (the Avalon Charter, once amended as set forth herein, the &#8220;Combined Company Charter&#8221;).
Additionally, the Avalon Bylaws, immediately prior to the Effective Time, shall be amended to change the name of Avalon to &#8220;YOOV,
Inc.&#8221; (the Avalon Bylaws, once amended as set forth herein, the &#8220;Combined Company Bylaws&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 48 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Provisions that are included
in the Combined Company Charter and Combined Company Bylaws may discourage, delay or prevent a merger, acquisition or other change in
control of the Combined Company that stockholders may consider favorable, including transactions in which its common stockholders might
otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay
in the future for shares of the Combined Company&#8217;s common stock, thereby depressing the market price of its common stock. In addition,
because the Combined Company&#8217;s board of directors will be responsible for appointing the members of the Combined Company&#8217;s
management team, these provisions may frustrate or prevent any attempts by the Combined Company&#8217;s stockholders to replace or remove
its current management by making it more difficult for stockholders to replace members of the Combined Company&#8217;s board of directors.
Among other things, these provisions will include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the authorized number of the Combined Company&#8217;s directors may be changed only by resolution of its
board of directors and only its board of directors is authorized to fill vacant directorships and newly created directorships;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.75pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">advance notice requirements for nominations for election to the board of directors or for proposing matters
that can be acted on at stockholder meetings;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.75pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">stockholders are not entitled to the right to cumulate votes in the election of directors;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.75pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">limitations on who may call a special meeting of stockholders; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.75pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the board of directors is authorized to issue preferred stock without stockholder approval, which could
be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively
deterring acquisitions that have not been approved by the Combined Company&#8217;s board of directors.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Moreover,
                                            because the Combined Company will be incorporated in Delaware, it will be subject to the
                                            provisions of Section 203 of the DGCL, which generally prohibits a Delaware corporation from
                                            engaging in a business combination with an interested stockholder (which is generally defined
                                            to include any person that owns 15% or more of the corporation&#8217;s outstanding voting
                                            stock and their affiliates and associates) for three years following the time that the person
                                            becomes an &#8220;interested stockholder&#8221; unless, among other exclusions, (i) prior
                                            to the date the person becomes an interested stockholder, the board of directors approves
                                            either the business combination or the transaction which resulted in the stockholder becoming
                                            an interested stockholder, (ii) upon consummation of the transaction which resulted in the
                                            stockholder becoming an interested stockholder, the interested stockholder owned at least
                                            85% of the voting stock of the corporation outstanding at the time the transaction commenced
                                            (excluding certain shares), or (iii) the business combination is approved by the board of
                                            directors and by the affirmative vote of at least two-thirds of the outstanding voting stock
                                            that is not owned by the interested stockholder at a meeting and not by written consent.
                                            Although Avalon and YOOV believe these provisions collectively will provide for an opportunity
                                            to receive higher bids by requiring potential acquirors to negotiate with the Combined Company&#8217;s
                                            board of directors, they would apply even if the offer may be considered beneficial by some
                                            stockholders. In addition, these provisions may frustrate or prevent any attempts by the
                                            Combined Company&#8217;s stockholders to replace or remove then current management by making
                                            it more difficult for stockholders to replace members of the board of directors, which is
                                            responsible for appointing the members of management. For more information, please see the
                                            section entitled &#8220;<i>Description of Avalon&#8217;s Securities-Anti-Takeover Effects
                                            of Delaware Law and the Avalon Charter and the Avalon Bylaws</i>&#8221;</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 49 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Combined Company Bylaws will provide
that, unless the Combined Company consents in writing to the selection of an alternative forum, certain designated courts will be the
sole and exclusive forum for certain legal actions between the Combined Company and its stockholders, which could limit its stockholders&#8217;
ability to obtain a favorable judicial forum for disputes with the Combined Company or its directors, officers, employees or agents. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Combined Company Bylaws
will provide that, unless it consents in writing to an alternative forum, the Court of Chancery of the State of Delaware is the sole and
exclusive forum for (i) any derivative action or proceeding brought on its behalf, (ii) any action asserting a claim of or based on a
breach of fiduciary duty owed by any of its current or former directors, officers, stockholder or other employee&#160;of the Combined
Company to the Combined Company or its stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL,
the Combined Company Charter or the Combined Company Bylaws, or (iv) any action asserting a claim that is governed by the internal affairs
doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants
therein, which for purposes of this risk factor refers to herein as the &#8220;Delaware Forum Provision.&#8221; The Combined Company reserves
the right to assert that the Delaware Forum Provision applies to any derivative action or proceeding to procure a judgment in the Combined
Company&#8217;s favor, <i>provided that</i>, for the avoidance of doubt, the Delaware Forum Provision will not apply to claims arising
under the Securities Act, the Exchange Act or any other claim for which the federal district courts are, as a matter of the laws of the
United States, the sole and exclusive forum for determination of such a claim. It is, however, uncertain whether a court would enforce
the Delaware Forum Provision with respect to a derivative action or proceeding brought by a stockholder to enforce the Combined Company&#8217;s
rights under the Exchange Act. The Combined Company will not assert that the Delaware Forum Provision applies to any direct action brought
by a stockholder to enforce rights under the Exchange Act or Securities Act. The Delaware Certificate of Incorporation, which will be
the certificate of incorporation of Avalon-Delaware will further provide that, unless it consents in writing to an alternative forum,
federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising
under the Securities Act, which for purposes of this risk factor refers to herein as the &#8220;Federal Forum Provision.&#8221; It is,
however, uncertain whether a court would enforce the Federal Forum Provision with respect to a proceeding brought by a stockholder to
enforce its rights under the Securities Act. In addition, the Delaware Certificate of Incorporation will provide that any person or entity
purchasing or otherwise acquiring any interest in shares of its capital stock is deemed to have notice of and consented to the foregoing
Delaware Forum Provision and Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived
its compliance with the U.S. federal securities laws and the rules and regulations thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Delaware Forum Provision
and the Federal Forum Provision may impose additional litigation costs on stockholders of the Combined Company in pursuing any such claims,
particularly if the stockholders do not reside in or near the State of Delaware. Additionally, such provisions may limit its stockholders&#8217;
ability to bring a claim in a judicial forum that they find favorable for disputes with the Combined Company or its directors, officers,
employees or stockholders, which may discourage such lawsuits against the Combined Company and its directors, officers, employees and
stockholders even though an action, if successful, might benefit its stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 50 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Avalon and YOOV do not anticipate that the
Combined Company will pay any cash dividends in the foreseeable future. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The current expectation is
that the Combined Company will retain its future earnings, if any, to fund the growth of the Combined Company&#8217;s business as opposed
to paying dividends. As a result, capital appreciation, if any, of the common stock of the Combined Company will be your sole source of
gain, if any, for the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>An active trading market for the Combined
Company&#8217;s common stock may not develop and its stockholders may not be able to resell their shares of common stock for a profit,
if at all. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Prior to the Merger, there
had been no public market for shares of YOOV capital stock. An active trading market for the Combined Company&#8217;s shares of common
stock may never develop or be sustained. If an active market for the Combined Company&#8217;s common stock does not develop or is not
sustained, it may be difficult for its stockholders to sell their shares at an attractive price or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future sales of shares by existing stockholders
could cause the Combined Company&#8217;s stock price to decline. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">If existing securityholders
of Avalon and YOOV sell, or indicate an intention to sell, substantial amounts of the Combined Company&#8217;s common stock in the public
market after legal or contractual lock-up restrictions on resale discussed in this proxy statement/prospectus lapse, the trading price
of the common stock of the Combined Company could decline. Based on shares outstanding as of <span style="background-color: white">March
31</span>, 2025, after giving effect to the estimated Exchange Ratio and shares expected to be issued upon completion of the Merger,
approximately <span style="background-color: white">62,132,236</span> shares of Avalon Common Stock are expected to be issued and outstanding
immediately after the Closing, without taking into effect the contemplated Reverse Stock Split prior to the Effective Time. Of such outstanding
shares of common stock, approximately 33,138,914 shares will be freely tradeable upon completion of the Merger and approximately an additional
<span style="background-color: white">28,993,322</span> shares will become available for sale in the public market beginning one hundred
eighty (180) days after the Closing Date as a result of the expiration of the Lock-Up Agreements between Avalon and certain securityholders
of YOOV (and without giving effect to any restrictions on resale under securities laws), each without taking into effect the contemplated
Reverse Stock Split prior to the Effective Time. If these shares are sold, the trading price of the Combined Company&#8217;s common stock
could decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>After completion of the Merger, the Combined
Company&#8217;s executive officers, directors and principal stockholders may have the ability to control or significantly influence certain
matters submitted to the Combined Company&#8217;s stockholders for approval. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Upon
                                            the completion of the Merger, it is anticipated that the Combined Company&#8217;s executive
                                            officers, directors and principal stockholders will, in the aggregate, beneficially own approximately
                                            45.3% of the Combined Company&#8217;s outstanding shares of common stock. As a result, if
                                            these stockholders were to choose to act together, they may be able to control or significantly
                                            influence certain matters submitted to the Combined Company&#8217;s stockholders for approval,
                                            as well as the Combined Company&#8217;s management and affairs. For example, these stockholders,
                                            if they choose to act together, would control or significantly influence the election of
                                            directors and approval of any merger, consolidation or sale of all or substantially all of
                                            the Combined Company&#8217;s assets. This concentration of voting power could delay or prevent
                                            an acquisition of the Combined Company on terms that other stockholders may desire.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If equity research analysts do not publish
research or reports, or publish unfavorable research or reports, about the Combined Company, its business or its market, its stock price
and trading volume could decline. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The trading market for the
Combined Company&#8217;s common stock will be influenced by the research and reports that equity research analysts publish about it and
its business. Equity research analysts may elect to not provide research coverage of the Combined Company&#8217;s common stock after the
completion of the Merger, and such lack of research coverage may adversely affect the market price of its common stock. In the event it
does have equity research analyst coverage, the Combined Company will not have any control over the analysts or the content and opinions
included in their reports. The price of the Combined Company&#8217;s common stock could decline if one or more equity research analysts
downgrade its stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of the
Combined Company or fails to publish reports on it regularly, demand for its common stock could decrease, which in turn could cause its
stock price or trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 51 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Combined Company will have broad discretion
in the use of the cash and cash equivalents of the Combined Company and may invest or spend the proceeds in ways that may not increase
the value of your investment. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Combined Company will
have broad discretion over the use of the cash and cash equivalents of the Combined Company. You may not agree with the Combined Company&#8217;s
decisions, and its use of the proceeds may not yield any return on your investment. The Combined Company&#8217;s failure to apply these
resources effectively could compromise its ability to pursue its growth strategy and the Combined Company might not be able to yield a
significant return, if any, on its investment of these net proceeds. You will not have the opportunity to influence its decisions on how
to use the Combined Company&#8217;s cash resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Combined Company may be subject to adverse
legislative or regulatory tax changes that could negatively impact its financial condition. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The rules dealing with U.S.
federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal
Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely
affect the Combined Company or its stockholders. The Combined Company will assess the impact of various tax reform proposals and modifications
to existing tax treaties in all jurisdictions where the Combined Company has operations to determine the potential effect on its business
and any assumptions the Combined Company will make about its future taxable income. It cannot predict whether any specific proposals will
be enacted, the terms of any such proposals or what effect, if any, such proposals would have on its business if they were to be enacted.
For example, the United States enacted the Inflation Reduction Act of 2022, which implements, among other changes, a 1% excise tax on
certain stock buybacks. In addition, beginning in 2022, the Tax Cuts and Jobs Act, P.L. 115-97 eliminated the option to deduct research
and development expenditures and requires taxpayers to amortize them generally over five years. The U.S. Congress is considering legislation
that would restore the current deductibility of research and development expenditures, however, there is no assurance that the provision
will be repealed or otherwise modified. Such changes, among others, may adversely affect the Combined Company&#8217;s effective tax rate,
results of operation and general business condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Combined Company&#8217;s ability to
use net operating loss carryforwards and other tax attributes may be limited, including as a result of the Merger. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under current law, U.S. federal
net operating loss carryforwards generated in taxable periods beginning after December 31, 2017, may be carried forward indefinitely,
but the deductibility of such net operating loss carryforwards is limited to 80% of taxable income. It is uncertain if and to what extent
various states will conform to federal law. In addition, under Sections 382 and 383 of the Code, U.S. federal net operating loss carryforwards
and other tax attributes may become subject to an annual limitation in the event of certain cumulative changes in ownership. An &#8220;ownership
change&#8221; pursuant to Section 382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least
5% of a company&#8217;s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within
a rolling three-year period. The Combined Company&#8217;s ability to utilize its net operating loss carryforwards and other tax attributes
to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including in connection with the Merger
or other transactions. Similar rules may apply under state tax laws. If the Combined Company earns taxable income, such limitations could
result in increased future income tax liability to the Combined Company, and the Combined Company&#8217;s future cash flows could be adversely
affected. Avalon had a net operating loss carryforward as of December 31, 2024 of approximately $87.7 million, which is subject to limitations
and is expected to be subject to limitation under Section 382 of the Code following the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Unfavorable global economic conditions could
adversely affect the Combined Company&#8217;s business, financial condition, results of operations or cash flows. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Combined Company&#8217;s results of operations
could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic
downturn could result in a variety of risks to the Combined Company&#8217;s business, including the Combined Company&#8217;s ability to
raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain the Combined Company&#8217;s
suppliers, possibly resulting in supply disruption, or cause the Combined Company&#8217;s customers to delay making payments for its services.
Any of the foregoing could harm the Combined Company&#8217;s business and the Combined Company cannot anticipate all of the ways in which
the current economic climate and financial market conditions could adversely impact its business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>After the Merger, some of the directors
and officers of the Combined Company will live outside the United&#160;States; therefore, investors may not be able to enforce federal
securities laws or their other legal rights.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">After the Merger, some
of the directors and officers of the Combined Company will reside outside of the United&#160;States. As a result, it may be difficult,
or in some cases not possible, for investors in the United&#160;States to enforce their legal rights, to effect service of process upon
all of our directors or officers or to enforce judgments of United&#160;States courts predicated upon civil liabilities and criminal
penalties on our directors and officers under United&#160;States laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">In particular, investors
should be aware that there is uncertainty as to whether the courts of the&#160;<i>British Virgin Islands</i>, Hong Kong,&#160;or any
other applicable jurisdiction would recognize and enforce judgements of U.S.&#160;courts obtained against us or our directors or officers
predicted upon the civil liability provisions of the securities laws of the United&#160;States or any state in the United&#160;States
or entertain original actions brought in the&#160;<i>British Virgin Islands</i>, Hong Kong,&#160;or any other applicable jurisdiction&#8217;s
courts against us or our directors or officers predicated upon the securities laws of the United&#160;States or any state. For more information,
see &#8220;<i>Enforcement of Civil Liabilities</i>.&#8221;</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_035"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to YOOV and its Operations</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failures to retain and acquire customers
may negatively impact YOOV&#8217;s recurring revenue and growth prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV&#8217;s success is heavily
dependent on its ability to deliver value through its platform. Any failure to meet customer expectations, compounded by increased competition
in the market, could lead to higher customer churn rates. Such churn would directly threaten YOOV&#8217;s recurring revenue, which is
critical to its financial performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A substantial portion of YOOV&#8217;s
revenue is derived from subscription services and long-term customer contracts. Consequently, any reduction in customer retention or subscription
renewals could have a detrimental effect on YOOV&#8217;s overall revenue. Additionally, fluctuations in currency exchange rates or changes in
customer payment behavior may further exacerbate these risks, potentially leading to volatility in YOOV&#8217;s financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Given these factors, it is
imperative for YOOV to prioritize customer satisfaction and effective acquisition strategies to mitigate risks associated with customer
retention. Failure to do so or failure to acquire new customers could adversely affect its recurring revenue streams and hinder growth
prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>YOOV faces risks related to system interruption,
including failures caused or experienced by third-party service providers, and lack of redundancy and timely upgrades.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV&#8217;s success depends
on its ability to successfully develop and deliver its AIaaS solutions to customers and stably perform via its online platforms. If YOOV&#8217;s
online platforms are inaccessible due to system interruption, or if network infrastructure are not operational or performing to its customers&#8217;
satisfaction, YOOV could lose existing customers or fail to attract new customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 53 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any internet network interruptions,
latency, or problems with YOOV&#8217;s online platforms&#8217; availability could prevent customers from accessing and operating on YOOV&#8217;s
online platforms, and impact customers&#8217; business operations, which may cause customer dissatisfaction and damage its reputation
and brand. YOOV has experienced brief computer system interruptions in the past, and it believes that others can occur from time to time
in the future. YOOV&#8217;s systems and operations potentially are vulnerable to damage or interruption from a number of sources, including
the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Natural Disasters and Catastrophic Events: Including but not limited to typhoons, fires, power outages,
telecommunications failures, rainstorms, floods or terrorist attacks;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Cybersecurity Threats: Including computer malware, physical or electronic break-ins, security breaches,
hacking attacks and similar disruptions;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Third-party Vendor Failures: including data center and bandwidth providers, to ensure steady and high-speed
access to YOOV&#8217;s online platforms and systems. Any disruption in network access or co-location services, which house some of YOOV&#8217;s
servers and provide internet access, could significantly harm YOOV&#8217;s business. Additionally, any financial or operational difficulties
faced by these vendors, or their inability to handle increased volumes of use, could adversely affect YOOV&#8217;s operations. Incidents
of fraud also&#160;pose&#160;a&#160;risk.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV has not yet created
sufficient redundancy for its information technology systems and data, and it does not presently maintain backup copies of all its data.
YOOV has a limited disaster recovery plan in effect and may lack adequate insurance for losses resulting from natural disasters, catastrophic
events, or the resulting business interruption. Any substantial damage to, or disruption of, YOOV&#8217;s technology infrastructure could
cause interruptions, delays, data loss, or reduced system availability, which could have a material adverse effect on YOOV&#8217;s business,
financial condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV may be unable to accurately
project traffic flow rates or timing, including any traffic increases, or successfully and cost-effectively upgrade its systems and infrastructure
in a timely manner to accommodate higher traffic levels on its online platforms. If traffic volume or the number of users increases substantially,
YOOV may experience unanticipated system disruptions, slower response times, reduced customer service levels, and impaired quality and
delays in financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, YOOV must continually
upgrade and improve its technology and infrastructure to support business growth. Failure to do so could impede its growth. However, YOOV
cannot assure successful execution of its system upgrades and improvement strategies, which could require substantial investments. During
upgrades, systems may experience interruptions, and the new technologies or infrastructures may not be fully integrated with existing
systems on a timely basis, or at all. If existing or future technology and infrastructure do not function properly, it could cause system
disruptions and slow response times, affecting data transmission, which in turn could materially and adversely affect YOOV&#8217;s business,
financial condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Natural catastrophic events and man-made
problems such as power disruptions, computer viruses, global pandemics, a cyberattack or data security breaches and terrorism may disrupt
YOOV&#8217;s business. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">YOOV relies heavily on its network infrastructure
and IT systems for its business operations. An online attack, damage as a result of civil unrest, earthquake, fire, terrorist attack,
power loss, global pandemics (such as the COVID-19 pandemic), telecommunications failure, or other similar catastrophic event could cause
system interruptions, delays in accessing its service, reputational harm, and loss of critical data. Such events could prevent YOOV from
delivering its services to its customers. A catastrophic event that results in the destruction or disruption of YOOV&#8217;s data centers,
or its network infrastructure or IT systems, including any errors, defects, or failures in third-party hardware, could affect YOOV&#8217;s
ability to conduct normal business operations, and adversely affect its operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 54 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, as computer malware,
viruses, cyberattack, computer hacking, fraudulent use attempts, and phishing attacks have become more prevalent, YOOV faces increased
risk from these activities. These activities threaten the performance, reliability, security, and availability of its services. Any computer
malware, viruses, computer hacking, fraudulent use attempts, phishing attacks, or other data security breaches to YOOV&#8217;s systems
could, among other things, harm its reputation and ability to retain existing customers and attract new customers. It may also require
YOOV to expend significant capital and other resources to alleviate problems caused by any such cybersecurity attack or other security
breach or incident and implement additional security measures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV currently does not maintain
cybersecurity insurance, and in the event that it seeks to obtain such insurance coverage, it may not be available on acceptable terms
or may not be available in sufficient amounts to cover one or more large claims in connection with cybersecurity liabilities. Insurers
could also deny coverage as to any future claim.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A cyberattack, security breach or other
unauthorized access or interruption to YOOV&#8217;s information technology systems or those of its third-party service providers could
delay or interrupt service to its customers and their customers, harm its reputation or subject it to significant liability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Cybersecurity threats, privacy
breaches, insider threats or other incidents and malicious Internet-based activity continue to increase, evolve in nature, and become
more sophisticated. Information security risks for companies such as YOOV have significantly increased in recent years in part because
of the proliferation of new technologies, the use of Internet and telecommunications technologies to conduct financial transactions, and
the increased sophistication and activities of organized crime, hackers, terrorists, and other external parties, as well as nation-state
and nation-state-supported actors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Many companies that provide
services similar to YOOV&#8217;s have also reported a significant increase in cyberattack activity since the beginning of the COVID-19 pandemic.
In addition, because YOOV leverages service providers, including cloud, software, data center and other critical technology vendors to
deliver its solutions, it relies heavily on the data security practices and policies adopted by these third-party service providers. YOOV&#8217;s
ability to monitor its third-party service providers&#8217; data security is limited. A vulnerability in YOOV&#8217;s third-party service
providers&#8217; software or systems, a failure of its third-party service providers&#8217; safeguards, policies or procedures, or a breach
of a third-party service provider&#8217;s software or systems could result in the compromise of the confidentiality, integrity or availability
of YOOV&#8217;s systems or the data housed in its third-party solutions. In addition, in the event YOOV&#8217;s third-party service providers
and subprocesses are subject to security breaches, privacy breaches or other cybersecurity threats, its business may be impacted. YOOV
cannot guarantee that such incidents may not occur and could adversely affect its operations. YOOV and its third-party service providers
may be unable to anticipate or prevent techniques used in the future to obtain unauthorized access or to sabotage systems and cannot guarantee
that applicable recovery systems, security protocols, network protection mechanisms and other procedures are or will be adequate to prevent
network and service interruption, system failure or data loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Data security breaches could
also expose YOOV to liability under various laws and regulations across jurisdictions and increase the risk of litigation and governmental
or regulatory investigation. Due to concerns about data security and integrity, a growing number of legislative and regulatory bodies
have adopted breach notification and other requirements in the event that information subject to such laws is accessed by unauthorized
persons. YOOV may need to notify governmental authorities and affected individuals with respect to such incidents. For example, some jurisdictions,
including the EU, the United Kingdom, Brazil, and all 50 states in the United States, have enacted laws requiring companies to notify
individuals of data security breaches involving certain types of personal information, and YOOV&#8217;s agreements with certain customers
require it to notify them in the event of a security incident. Complying with such numerous and complex regulations in the event of a
data security breach would be expensive and difficult, and failure to comply with these regulations could subject YOOV to regulatory scrutiny
and additional liability. Such mandatory disclosures could lead to negative publicity and may cause YOOV&#8217;s customers to lose confidence
in the effectiveness of its data security measures and data handling. Moreover, if a high-profile security breach occurs with respect
to another business automation solution provider, customers may lose trust in the security of the business model generally, which could
adversely impact YOOV&#8217;s ability to retain existing customers or attract new ones. In addition, if YOOV&#8217;s security measures
fail to protect information adequately, it could be liable to its customers, their end-consumers, and consumers with whom YOOV has a direct
relationship. YOOV could be subject to fines and higher transaction fees, could face regulatory or other legal action, and its customers
could end their relationships with YOOV. The limitations of liability in YOOV&#8217;s contracts may not be enforceable or adequate or
would otherwise protect it from any such liabilities or damages with respect to any particular claim.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV is also subject to federal,
state, and foreign laws regarding cybersecurity and the protection of data. that may limit the use and adoption of its services, expose
it to liability, or otherwise adversely affect its business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Global pandemics and health crises may significantly
disrupt YOOV&#8217;s business activities, render staff unavailable, and cause an integrity problem in the supply chain.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The COVID-19 pandemic showed
how much harm a global health crisis can do to business in terms of operational disruption and big financial losses. If other pandemics
or health emergencies occur in the future, YOOV may be impeded in providing business continuity. High levels of sickness, isolation, or
movement restrictions may significantly diminish the availability of staff, causing workforce shortages that will impact operations and
productivity. This may be worsened if key staff or a large proportion of staff are affected in business-critical roles. Moreover, pandemics
may cause unpredictable fluctuations in customer demand. These health crises may trigger new government regulation or compliance in relation
to, say, health and safety measures, that may further add to operational burdens for YOOV. Non-compliance or failure to change in good
timing with the regulatory changes may result in legal liabilities and fines and may further disrupt YOOV&#8217;s operation. Due to both
these factors, significant operational and financial instability may arise, greatly affecting YOOV&#8217;s reputation and long-term viability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>YOOV&#8217;s business faces intense competition.
Failures to differentiate itself in the market may negatively impact on YOOV&#8217;s business, financial condition, and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The market for business automation
is intensely competitive. YOOV&#8217;s current and potential competitors include developers, resellers, and sales agents that offer a
wide range of similar service categories and related services. The competition in the market for business automation is expected to intensify
as companies develop new AI models and enhanced technologies, new competitors enter the market, competitors forge new business combinations
or alliances, and established companies in other market segments expand into business AI and become competitive with the business of YOOV.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 56 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Many of YOOV&#8217;s current
and potential competitors have larger customer and partner bases, better brand recognition, and greater financial, marketing, technical,
management, and other resources than YOOV. In addition, some of YOOV&#8217;s competitors have used and may continue to use aggressive
pricing or promotional strategies and may invest significantly more to their online platforms and system development than YOOV. Increased
competition may lead to reduced operating margins, profitability, market share, and brand recognition for YOOV.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV also faces competition
in international markets it currently competes in or may enter in the future. Competitors in these markets may be well-established global
and local operations with more experience and resources than YOOV, potentially impeding YOOV&#8217;s expansion and growth.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Moreover, YOOV could experience
significant competitive pressure if any of its partners, resellers, or sales agents were to initiate or expand their service offerings.
These entities have access to technical talents and may mimic YOOV&#8217;s business model, potentially connecting directly with YOOV&#8217;s
current and potential customers. This could lead to customers choosing to purchase from these new competitors instead of YOOV. Increased
competition from partners, resellers, and sales agents capable of maintaining high sales volumes could significantly reduce YOOV&#8217;s
market share and adversely affect YOOV&#8217;s operating results.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There is no assurance that
YOOV will be able to compete successfully against current and future competitors. Competitive pressures may have a material adverse effect
on YOOV&#8217;s business, financial condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>YOOV may not succeed in promoting and strengthening
its YOOV brand, which may materially and adversely affect its business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Brand recognition is a key
competitive factor in the market for business AI, automation and AIaaS, crucial for maintaining and expanding YOOV&#8217;s customer base,
market position, and bargaining power with vendors. Any loss of trust in the YOOV brand could harm its reputation and result in customers,
partners, vendors and other participants reducing their engagement with YOOV, which could materially reduce its profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If YOOV does not, or is unable
to continue to, promote and strengthen the YOOV brand, or if the brand fails to continue to be viewed favorably, YOOV may not be successful
in attracting new customers, which could have a material adverse effect on its financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Adverse publicity about YOOV
may arise from time to time. Negative comments about its online platforms, services offered, or management may appear in internet postings
and other media sources, and there is no assurance that other types of negative publicity of a more serious nature will not arise in the
future. For example, if YOOV&#8217;s customer service representatives fail to satisfy the individual needs of the customers, disgruntled
customers may disseminate negative comments about YOOV&#8217;s customer service. Any such negative publicity, regardless of veracity,
may have a material adverse effect on its business, reputation and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>YOOV&#8217;s expansion into new service
offerings, technologies and geographic regions subjects it to additional business, legal, financial and competitive risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An important element of YOOV&#8217;s
business strategy is to expand into new service offerings, technologies and regions, such as its expansion into Malaysia and other regions.
In pursuing these new areas, YOOV faces numerous risks and challenges, including new competitions, the increased need to develop new strategic
relationships, and strain on its management, personnel, operations, systems, technical performance, financial resources, and internal
financial control and reporting functions. There is no assurance that YOOV&#8217;s strategy will result in increased net sales or net
income. Furthermore, growth into new business areas may require changes to its existing business model and cost structure, modifications
to its infrastructure, and exposure to new regulatory and legal risks related to operating in new jurisdictions, any of which may require
expertise in areas in which it has little or no experience. These risks may pose a material adverse risk to YOOV&#8217;s business, financial
condition, and results of operations.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>YOOV conducts marketing activities to help
attract potential customers for lead generation, and if it is unable to attract these potential customers or convert them into customers
in a cost-effective manner, YOOV&#8217;s business and results of operations could be harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV&#8217;s success relies
on its ability to attract potential customers and convert them into customers in a cost-effective manner. YOOV uses search engines, social
media and affiliate networks to provide content, advertising banners, and other links that direct visitors to its websites, campaign sites,
and other sales channels. Approximately 60% of leads are generated from marketing activities, including paid and unpaid search engine
listings and affiliate networks. In particular, YOOV depends on search engines like Google, and Yahoo! as important marketing channels.
If these search engines change their search engine algorithms periodically, penalize YOOV for non-compliance with their guidelines, or
if competition increases for advertisements, YOOV may struggle to drive potential customers to its websites and campaign sites cost-effectively.
Additionally, YOOV sometimes pays third parties to achieve a higher ranking or to be featured in search results. If these third parties
modify or terminate their relationship with YOOV, increase their fees, if YOOV&#8217;s competitors offer them greater fees for traffic,
or if any free third-party platforms begin charging fees, YOOV&#8217;s expenses could rise, and traffic to its websites could decrease,
resulting in harm to its operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV&#8217;s success also
depends on its ability to convert the potential customers into paying customers. YOOV&#8217;s ability to convert potential customers into
paying customers depends on effectively identifying and purchasing relevant keyword search terms, providing relevant content on its online
platforms, and targeting other marketing programs such as internet portal referrals, email campaigns, and affiliate programs. If YOOV
cannot attract potential customers and convert them into paying customers cost-effectively, its business and financial results may be
harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 58 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>YOOV depends on third-party AI technologies
and Application Programming Interfaces (APIs) to deliver functionality on the AIaaS platform. Failures in these third-party technologies
could negatively impact our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV&#8217;s AIaaS platform
relies on third-party AI technologies, such as Machine Learning (ML), Natural Language Processing (NLP) and Computer Vision, as well as
APIs to deliver functionality to its customers. If any of these providers experience technical issues, service outages, or changes in
licensing terms, it could disrupt YOOV&#8217;s services and affect our ability to meet customer needs. Also, YOOV has no effective means
to ensure that these third parties will continue to perform these services to their satisfaction, in a manner satisfactory to its customers,
or on commercially reasonable terms. Reliance on third-party technologies and APIs may limit YOOV&#8217;s ability to fully control or
customize certain aspects of our platform, potentially affecting its competitive differentiation. If we are unable to maintain these relationships
we would need to find alternative providers and the YOOV business may be materially impacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If YOOV fails to adopt new technologies
or adapt its platforms and systems to changing customer requirements or emerging industry standards, its business may be materially and
adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To remain competitive, YOOV
must continually enhance and improve the responsiveness, functionality and features of its online platforms. The market for business automation
is characterized by rapid technological evolution, frequent introductions of new products and services embodying new technologies, the
emergence of new industry standards and practices, and changes in customer requirements and preferences, any of which could render YOOV&#8217;s
existing technologies and systems obsolete. YOOV may need to devote substantial resources, including financial resources, to developing
proprietary technologies or license technologies, enhancing its existing platforms and systems, and developing new services and technology
that address the increasingly sophisticated and varied needs of its current and prospective customers and adapting to technological advances
and emerging industry and regulatory standards and practices in a cost-effective and timely manner. The development of proprietary technology
entails significant technical and business risks. There is no assurance that YOOV&#8217;s efforts to develop proprietary technologies
will succeed or that any technology licenses will be available on commercially reasonable terms. Substantial investments will be required
to remain technologically competitive, and YOOV&#8217;s failure to do so may harm its business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>YOOV faces the risk that its substantial
investments in research and development may not yield the anticipated benefits.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV allocates significant
resources to enhance its online platform and to develop new features aimed at meeting the evolving needs of its customers. However, despite
these efforts, there is no assurance that the outcomes will align with expectations or deliver the desired value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The R&amp;D process inherently
involves uncertainty. Even with a well-defined strategy and a skilled team, projects can encounter unforeseen challenges that hinder progress
or lead to failures. For instance, a new feature might not resonate with users, or it could fail to integrate seamlessly with existing
systems, resulting in customer dissatisfaction. Such scenarios can lead to wasted investments of both time and money, diverting resources
from other potentially profitable initiatives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Moreover, if YOOV&#8217;s
R&amp;D efforts do not keep pace with market trends or technological advancements, it risks missing out on critical opportunities. Competitors
may capitalize on emerging technologies or customer preferences, potentially eroding YOOV&#8217;s market share. This situation could be exacerbated
in rapidly evolving sectors where agility and innovation are crucial for maintaining a competitive edge.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">While YOOV&#8217;s commitment to
R&amp;D is aimed at driving growth and enhancing its offerings, YOOV may spend significant capital on R&amp;D efforts that may be unsuccessful
and materially adverse to its operations, results and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 59 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If YOOV is unable to manage its growth or
execute its strategies effectively, YOOV&#8217;s business and prospects may be materially and adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV&#8217;s success depends
on its ability to manage the growth of its operations effectively. YOOV anticipates further expansion as it pursues its growth strategies.
YOOV&#8217;s expansion increases the complexity of its business and places a significant strain on its management, operations, technical
systems and financial resources. YOOV&#8217;s current and planned personnel, systems, procedures and controls may not be adequate to support
and effectively manage its future operations, especially as it employs personnel in several geographic locations. In addition, YOOV&#8217;s
growth will require improvements to its operational and financial systems, procedures, and controls, as well as the successful management
of international operations and the hiring of additional personnel. These efforts may not be successful, and YOOV may be unable to improve
its systems, procedures and controls in a timely manner. Delays or problems associated with any of these initiatives could harm its business
and operating results. These initiatives will also cause operating expenses to increase. If YOOV fails to accurately estimate and assess
its growth or fails to increase net sales to match its increased operating expenses, YOOV&#8217;s financial condition and results of operations
could suffer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>YOOV may not be able to adequately protect
its intellectual property rights.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV relies on trademark
and copyright law, trade secret protection, and confidentiality or licensing agreements with employees, sales agents, resellers, brand
partners and others to protect its proprietary rights. These measures may be inadequate, agreements may be violated or there may be inadequate
remedies for a violation of such agreements. YOOV&#8217;s competitors may independently develop equivalent proprietary information and
rights or may otherwise gain access to YOOV&#8217;s trade secrets or proprietary information, which could affect YOOV&#8217;s ability
to compete in the market. There is no assurance that the steps that YOOV has taken will adequately protect its proprietary rights.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, third parties
may infringe or misappropriate YOOV&#8217;s proprietary rights, and YOOV could be required to enforce its intellectual property rights,
which could require significant financial and managerial resources. YOOV has registered and common law trademark rights in certain jurisdictions.
Effective trademark, service mark, copyright, patent and trade secret protection may not be available in every region or jurisdiction
in which YOOV&#8217;s services may be made available online, which may cause YOOV&#8217;s business and operating results to suffer. In
addition, YOOV may be unable to acquire or protect relevant domain names in every region. If YOOV is not able to acquire or protect its
trademarks, domain names, or other intellectual property, it may experience difficulties in achieving and maintaining brand recognition
and customer loyalty, which could adversely impact its operations, results and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Assertions, claims and allegations, even
if not true, that YOOV has infringed or violated intellectual property rights could harm YOOV&#8217;s business and reputation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Third parties have asserted,
and may continue to assert, allegations and claims of intellectual property infringement against YOOV on the items or their descriptions
listed on YOOV&#8217;s websites and mobile apps. Any such claims, disputes or litigation, even if resolved in YOOV&#8217;s favor or not
true, could be time-consuming and costly to defend, and could divert its management&#8217;s efforts from growing its business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 60 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any third parties prevail
in their intellectual property rights claims against YOOV, YOOV may be required to pay significant licensing fees, damages and attorney&#8217;s
fees, and may even be liable for punitive damages if YOOV is found to have willfully infringed third parties&#8217; proprietary rights.
YOOV may have to stop using certain technology or solutions and need to develop or acquire alternative, non-infringing technology or solutions,
which could require significant time and resources and lead to interruption in its operations. YOOV could also be required to obtain a
license to use certain technologies, although such licenses may not be available on reasonable terms or at all, which may result in substantial
payments and royalties and significantly increase its operating expenses. If YOOV cannot develop non-infringing technology or license
the appropriate technology at commercially reasonable rates, a successfully asserted intellectual property claim could cause significant
business interruptions in YOOV&#8217;s operations, which could restrict YOOV&#8217;s ability to compete effectively and have a material
adverse effect on its financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Some of YOOV&#8217;s software and systems
contain open-source software, which may pose particular risks to YOOV&#8217;s proprietary software and solutions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV has incorporated open-source
software code into some of its internal software and systems and expects to continue to use this open-source software in the future. The
licenses applicable to open-source software typically require that the source code subject to the license be made available to the public
and that any modifications or derivative works to open-source software continue to be licensed under open-source licenses. From time to
time, YOOV may face intellectual property infringement claims from third parties, demands for the release or license of the open-source
software or derivative works that YOOV developed using such software, which could include YOOV&#8217;s proprietary source code, or claims
that otherwise seek to enforce the terms of the applicable open-source license. These claims could result in litigation and could require
YOOV to purchase a costly license, publicly release the affected portions of YOOV&#8217;s source code, be limited in the licensing of
YOOV&#8217;s technologies or cease offering the implicated solutions unless and until YOOV can re-engineer them to avoid infringement
or change the use of the implicated open-source software. In addition to risks related to license requirements, use of certain open-source
software can lead to greater risks than use of third-party commercial software, as open-source licensors generally do not provide warranties,
indemnities, or other contractual protections with respect to the software (e.g., non-infringement or functionality). YOOV&#8217;s use
of open-source software may also present additional security risks because the source code for open-source software is publicly available,
which may make it easier for hackers and other third parties to determine how to breach YOOV&#8217;s websites, mobile apps and systems
that rely on open-source software. Any of these risks could be difficult to eliminate or manage and, if not addressed, could have a material
adverse effect on YOOV&#8217;s business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our substantial liabilities and other financial
obligations could impair our financial condition, results of operations and cash flow, and our ability to fulfill our debt obligations,
as well as the Notes.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have significant liabilities,
including deferred revenue, and may incur substantial debt in the future, which could adversely affect our business, financial condition,
and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of March 31, 2024, we had
total liabilities of $28,788,193, which includes deferred revenue and other obligations. While not all of these liabilities represent
debt, we may incur significant debt obligations in the future. Any existing or future indebtedness could impose various restrictions and
covenants on us that may result in material adverse consequences, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We may have difficulties obtaining additional financing for working capital, capital expenditures, acquisitions,
or general business purposes on favorable terms, if at all, or our cost of borrowing may increase.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We may be at a competitive disadvantage compared to our competitors with proportionately less debt, or
we may be more vulnerable to, and have limited flexibility to respond to, competitive pressures or a downturn in our business or the economy
generally.</td></tr>
</table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 61 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">If our operating results are not sufficient to service our indebtedness, we may be required to reduce
distributions, delay or scale back business activities, investments, or capital expenditures, sell assets, or issue additional equity-all
of which could materially and adversely affect our financial condition, results of operations, and cash flows.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The operating and financial restrictions and covenants in any future financing agreements could restrict
our ability to finance our operations or growth initiatives, which may, in turn, limit our ability to make distributions to the shareholders.
Our ability to comply with these covenants may also be impaired if fluctuations in our working capital needs do not align with the timing
of our receipts from operations.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">If we fail to comply with our debt obligations and an event of default occurs, our lenders could declare
the outstanding principal and accrued interest immediately due and payable. This may trigger cross-defaults under other debt instruments
or contracts. In such an event, our assets may be insufficient to repay our debt in full.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Governmental, Regulatory and Legal Risks Related
to YOOV</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment laws in some of the countries
in which YOOV operates are relatively stringent.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In some of the countries where
YOOV operates, employment laws may grant significant job protection to employees, including rights on termination of employment and setting
maximum number of hours and days per week that a particular employee is permitted to work. In addition, in certain countries in which
it operates, YOOV is or may be required to consult and seek the advice of employee representatives and/or unions. These laws, coupled
with the requirement to consult with any relevant employee representatives and unions, could impact YOOV&#8217;s ability to react to market
changes and the needs of its business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>YOOV faces risks related to increased regulatory
and social drive toward environmental sustainability, which can establish new compliance burdens and operational limitations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As the global concern for
environmental sustainability grows, so are regulatory bodies across different countries imposing stricter standards and practices to reduce
their impact on the environment. YOOV might be driven to comply with a steadily expanding number of environmental regulations, probably
highly disruptive to business, such as introducing new technologies and processes for reducing carbon emissions, handling waste in a more
professional way, and using sustainable materials. If YOOV fails to comply with new and evolving standards, it could suffer severe consequences,
including heavy fines, legal liabilities, and reputational damage. If the perception is that YOOV is a company unconcerned with laws and
regulations or one that is harming the environment, this can result in the loss of public and consumer trust, which could negatively impact
brand value and weaken the competitiveness of YOOV. Also, investment expenses to be incurred in establishing and maintaining green practices
could substantially rise even though necessary for compliance. It might strain the financial resources of YOOV and hence affect its profitability.
Further, environmental regulations might constrain the operation of YOOV, either through input or output restrictions, and thus hamper
its production and growth potential.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Additional costs related to compliance and
reporting may be incurred as YOOV becomes a public company. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following YOOV&#8217;s listing
on Nasdaq, it will be required to adhere to a range of regulatory, reporting, and corporate governance obligations. These requirements
will likely lead to an increase in administrative, legal and accounting expenses, as the company will need to retain additional advisors
and employees and implement new systems and processes to ensure compliance. The transition to a public company status demands significant
focus and resources from YOOV&#8217;s management team. This shift may divert attention from core business operations and strategic initiatives,
potentially impacting overall performance and growth. As a publicly traded entity, YOOV will also face increased scrutiny from investors,
analysts, and regulatory bodies. This heightened visibility may lead to pressure to meet quarterly earnings expectations, which could
influence management decisions and prioritize short-term results over long-term strategic goals. Furthermore, the need to enhance internal
controls and compliance measures could impose additional financial burdens, straining YOOV&#8217;s budget and operational flexibility. Non-compliance
with regulatory requirements could result in penalties, fines, or reputational damage, further jeopardizing YOOV&#8217;s financial health and
market position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>YOOV&#8217;s financial and insurance services
are subject to complex regulatory requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV&#8217;s subsidiaries,
YOOV Capital and YOOV Insurance, operate in highly regulated industries that require compliance with a wide range of laws and regulations.
For example, YOOV Capital may fail to obtain and maintain licenses and permits necessary to conduct its operations in Hong Kong, and YOOV
Capital&#8217;s business may be materially and adversely affected as a result of any changes in the laws and regulations governing the
financial services industry in Hong Kong. Depending on the type of products and services being offered, financial service providers may
be subject to supervision and scrutiny by different authorities and may be required to obtain and hold different licenses or permits.
YOOV Capital is also subject to risks relating to litigation (including class actions), claims and potential liabilities under laws and
regulations applicable to financial services, including enforcement actions, investigations and examinations of regulatory authorities
in jurisdictions in which we are regulated or serve users or have users. In addition, engaging in insurance brokerage services through
YOOV Insurance entails navigating complex regulatory landscapes, including stringent compliance with anti-money laundering (AML) laws.
Failure to comply with AML laws, know-your-customer (KYC), consumer protection, or insurance brokerage regulations could result in fines,
legal action, or reputational damage. Regulatory changes could also increase compliance costs or limit our ability to offer certain services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Risks Related to YOOV&#8217;s Operations
in Hong Kong</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">YOOV is a holding company,
headquartered in Singapore, and conducts operations in Hong&#160;Kong through its operating subsidiaries. Hong&#160;Kong is a special
administrative region of the PRC, with China assumed sovereignty under the &#8220;one country, two systems&#8221; principle. The Hong&#160;Kong
Special Administrative Region&#8217;s constitutional document, the Basic Law, ensures that the current political situation will remain
in effect for 50&#160;years.&#160;As of the date of this filing, YOOV does not derive any revenue or profits from, nor does it have any
customers in, the PRC. Its operations and customer base are concentrated in Hong Kong, where it conducts business through its operating
subsidiaries. YOOV and its subsidiaries face various legal and operational risks and uncertainties associated with being based in or
having its operations in Hong Kong. <i>For additional information, see the section entitled "Potential Permission or Approvals Required
from the PRC Authorities with respect to the Operations of YOOV&#8221;.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">YOOV does not believe
there will be material adverse impact on the operations of YOOV or its operating subsidiaries resulting from the legal and operational
risks relating to the laws and regulations of PRC. <span style="font-family: Times New Roman, Times, Serif">Currently, YOOV is not materially
affected by recent statements by the PRC government indicating an intention to exert more oversight and control over offerings that are
conducted overseas and/or foreign investment in China-based issuers. However, due to certain long-arm provisions in the current PRC laws
and regulations, there remains regulatory uncertainty with respect to the implementation and interpretation of laws in China as they
may affect Hong&#160;Kong. The PRC government may choose to exercise additional oversight and discretion over Hong&#160;Kong, and the
policies, regulations, rules, and the enforcement of laws of the PRC government to which we are subject may change rapidly and with little
advance notice to us or our shareholders. As a result, the application, interpretation, and enforcement of new and existing laws and
regulations in the PRC and our assertions and beliefs of the risk imposed by the PRC legal and regulatory system are by their very nature
uncertain.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">YOOV does not operate
through a VIE structure, and upon completion of the Merger, we will have direct ownership of YOOV and do not have or intend to have any
contractual arrangement to establish a VIE structure with any entity in the PRC. We are aware that recently the PRC government initiated
a series of regulatory actions and statements to regulate business operations in certain areas in China, including enhanced oversight
of overseas listings, cybersecurity, and anti-monopoly enforcement, with little advance notice. While the full scope and impact of these
changes remain uncertain, we understand that these actions do not currently apply to YOOV and are not expected to affect its daily operations
or ability to accept foreign investment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">The PRC government may
intervene or influence our operations at any time and may exert more control over offerings conducted overseas and foreign investment
in Hong&#160;Kong-based issuers, which may result in a material change in YOOV&#8217;s operations and/or the value of our securities.
For example, there is currently no restriction or limitation under the laws of Hong&#160;Kong on the conversion of Hong&#160;Kong dollar
into foreign currencies and the transfer of currencies out of Hong&#160;Kong and the laws and regulations of the PRC on currency conversion
control do not currently have any material impact on the transfer of cash between the ultimate holding company and the operating subsidiaries
in Hong&#160;Kong. However, the PRC government may, in the future, impose restrictions or limitations on YOOV&#8217;s ability to move
money out of Hong&#160;Kong to distribute earnings and pay dividends to and from the other entities within its organization or to reinvest
in its business outside of Hong&#160;Kong. Such restrictions and limitations, if imposed in the future, may delay or hinder the expansion
of YOOV&#8217;s business to outside of Hong&#160;Kong and may affect our ability to receive funds from its operating subsidiaries in
Hong&#160;Kong. The promulgation of new laws or regulations, or the new interpretation of existing laws and regulations, in each case,
that restrict or otherwise unfavorably impact our ability to conduct our business could require us to change certain aspects of our business
to ensure compliance; decrease demand for our services; reduce revenues; increase costs; require us to obtain more licenses, permits,
approvals, or certificates; or subject us to additional liabilities. To the extent any new or more stringent measures are implemented,
our business, financial condition, and results of operations could be adversely affected and the value of our securities could decrease
or become worthless.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>The Hong&#160;Kong legal system embodies
uncertainties that could limit the availability of legal protections.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Hong&#160;Kong is a Special
Administrative Region of the PRC.&#160;Following British colonial rule from 1842 to 1997, China assumed sovereignty under the &#8220;one
country, two systems&#8221; principle. The Hong&#160;Kong Special Administrative Region&#8217;s constitutional document, the Basic Law,
ensures that the current political situation will remain in effect for 50&#160;years. The laws previously in force in Hong&#160;Kong,
that is, the common law, rules of equity, ordinances, subordinate legislation and customary law are maintained. Hong&#160;Kong has enjoyed
the freedom to function with a high degree of autonomy for its affairs, including currencies, immigration and customs operations, and
its independent judiciary system and parliamentary system. On July&#160;14, 2020, the United&#160;States signed an executive order to
end the special status enjoyed by Hong&#160;Kong post-1997. As the autonomy currently enjoyed may be compromised, it could potentially
impact Hong&#160;Kong&#8217;s common law legal system and may, in turn, bring about uncertainty in, for example, the enforcement of contractual
rights. This could, in turn, materially and adversely affect YOOV&#8217;s business and operations. Additionally, intellectual property
rights and confidentiality protections in Hong&#160;Kong may not be as effective as in the United&#160;States or other countries. Accordingly,
we cannot predict the effect of future developments in the Hong&#160;Kong legal system, including the promulgation of new laws, changes
to existing laws or the interpretation or enforcement thereof, or the pre-emption of local regulations by national laws. These uncertainties
could limit the legal protections available to us, including the ability to enforce YOOV&#8217;s agreements with its customers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 63 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b style="-keep: true"><i>Greater oversight
by CAC over data security, particularly for companies seeking to list on a foreign exchange, could adversely impact our business and
our offering.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Over the years, the PRC
has enacted a number of laws and regulations aimed at governing the collection and security of personal data. We do not believe YOOV
is subject to cybersecurity review by the Cyberspace Administration of China ("<b>CAC"</b>), or to any of the other personal
data-related laws and regulations described above, since YOOV is a BVI company without subsidiaries or operations in the PRC. In addition,
it does not currently have, and does not anticipate that it will be collecting, over one million users&#8217; personal information in
the foreseeable future, which might otherwise subject it to the Cybersecurity Review Measures. YOOV has not received any notice from
any authorities identifying it as a critical information infrastructure operator under the PRC law or otherwise requiring it to undergo
a cybersecurity review or network data security review by the CAC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">There remains uncertainty
as to whether PRC regulatory agencies, including the CAC, may in the future adopt new laws, regulations, or rules that could become applicable
to YOOV or its subsidiaries. There is no assurance that YOOV will be able to fully or timely comply with any of the personal data and
data security laws should they be deemed to be applicable to its operations. There is no certainty as to how any review or other actions
would impact YOOV&#8217;s operations, and we cannot guarantee that any clearance could be obtained or maintained if approved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>In the future, YOOV may be subject to
PRC laws and regulations, including those regarding corporate structure, overseas listings, data- and cybersecurity, and anti-monopoly
concerns, which could result in a material negative impact on its operations and the value of the securities we are registering for sale.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true"><span style="font-family: Times New Roman, Times, Serif">We
face risks associated with potentially YOOV. YOOV is a holding company </span>incorporated in the British Virgin Islands <span style="font-family: Times New Roman, Times, Serif">with
no material operations of its own. Headquartered in Singapore, YOOV conducts its operations primarily in Hong&#160;Kong through its operating
subsidiaries. After the Merger, stockholders will not directly hold any equity interests in YOOV or its operating subsidiaries. This
structure involves unique risks to investors. As a holding company, we may rely on dividends from our subsidiaries for our cash requirements,
including any payment of dividends to our shareholders. The ability of our subsidiaries to pay dividends to us may be restricted by the
debt they incur on their own behalf or laws and regulations applicable to them. YOOV does not currently operate any of its business through
variable interest entities, nor does it operate any business in the PRC. This position is not expected to change upon completion of the
Merger.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Although YOOV is not
currently subject to PRC laws and regulations, other than Annex III of the Basic Law, with its substantial operations in Hong Kong, there
remains uncertainty associated with the complex and evolving PRC laws and regulations, including whether and how PRC government statements
and regulatory developments, such as those relating to corporate structure, overseas listings, data- and cybersecurity, and anti-monopoly
concerns, would be applicable to Hong Kong companies such as YOOV, and whether and when the Chinese government might exercise significant
oversight over the conduct of business in Hong Kong. If YOOV were to become subject to PRC laws and regulations, it could incur material
costs to ensure compliance, and it might be subject to fines, no longer be permitted to conduct offerings to foreign investors, or no
longer be permitted to continue business operations as presently conducted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">The uncertainties regarding
the enforcement of laws and the fact that rules and regulations in China can change quickly with little advance notice, along with the
risk that the Chinese government may intervene in or influence YOOV&#8217;s operations, could result in a material change in its operations
and the value of the securities we are registering, including the possibility that the value of such securities could become worthless.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">As of the date of this
prospectus, these new laws and guidelines have not impacted YOOV&#8217;s ability to conduct its business. YOOV is headquartered in Singapore
and does not operate through a VIE structure. YOOV is not a cyberspace operator with personal information of more than 1 million users
or activities that affect or may affect the national security of China, and it does not possess documents and materials likely to affect
the national security or public interest of China. However, any change in foreign investment regulations or other policies in China,
or related enforcement actions by the PRC government, could result in a material change in YOOV&#8217;s operations and the value of Avalon
Common Stock and could significantly limit or completely hinder our ability to offer Avalon Common Stock to investors or cause the value
of Avalon Common Stock to significantly decline or be worthless.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>After the Merger, we will be subject
to risks relating to economic, political, legal, and social conditions in Hong Kong.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Even though much of YOOV&#8217;s
revenue is derived from licensees outside Hong Kong, any adverse changes in the economic, political, legal, and social conditions of
Hong Kong could lead to an adverse impact on the demand for YOOV&#8217;s services and result in deteriorating financial performance of
the Company. If Hong Kong experiences any other adverse economic, political or market conditions due to events beyond our control, such
as local economic downturn (including any actual or forecasted economic recession), protests, natural disasters, contagious disease outbreaks
or terrorist attacks, the business, financial condition or results of operations of YOOV may be materially and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">We cannot assure you
that there will not be any political movements or large-scale political unrest in Hong Kong that could adversely impact the market. If
such unrest or movement persists for a substantial period of time, it may lead to disruption of the general economic, political, and
social conditions in Hong Kong, and YOOV&#8217;s overall business, results of operations, and financial condition may be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>The Law of the PRC on Safeguarding National
Security in the Hong Kong Special Administrative Region (the &#8220;Hong Kong National Security Law&#8221;) could impact YOOV&#8217;s
operations in Hong Kong.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">On June 30, 2020, the
Standing Committee of the PRC National People&#8217;s Congress adopted the Hong Kong National Security Law. This law defines the duties
of the government bodies responsible for safeguarding national security and specifies four categories of offences - secession, subversion,
terrorist activities, and collusion with a foreign country or external elements to endanger national security - and their corresponding
penalties. On July 14, 2020, the U.S. President signed the Hong Kong Autonomy Act (the &#8220;HKAA&#8221;), into law, authorizing the
U.S. administration to impose blocking sanctions against individuals and entities who are determined to have materially contributed to
the erosion of Hong Kong&#8217;s autonomy. On August 7, 2020, the U.S. government imposed HKAA-authorized sanctions on eleven individuals,
including the then Hong Kong Chief Executive Carrie Lam and the current Hong Kong Chief Executive John Lee. On October 14, 2020, the
U.S. State Department submitted to relevant committees of Congress the report required under the HKAA, identifying persons materially
contributing to &#8220;the failure of the Government of China to meet its obligations under the Joint Declaration or the Basic Law.&#8221;
The HKAA further authorizes secondary sanctions, including the imposition of blocking sanctions, against foreign financial institutions
that knowingly conduct a significant transaction with a foreign person sanctioned under this authority. The imposition of sanctions may
directly affect foreign financial institutions as well as any third parties or customers dealing with any foreign financial institution
that is targeted. The ramifications of the Hong Kong National Security Law and the HKAA are still unfolding, and it is therefore difficult
to predict the full impact on Hong Kong and companies located in Hong Kong. If YOOV is accused of violating the Hong Kong National Security
Law or the HKAA by competent authorities, its business operations, financial position, and results of operations could be materially
and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160; </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>If we become subject to the recent scrutiny,
criticism, and negative publicity involving U.S.-listed China-based companies, we may have to expend significant resources to investigate
and/or defend the matter, which could harm YOOV&#8217;s business operations, this offering, and our reputation and could result in a
loss of the stockholders&#8217; investment in our securities, in particular if such matter cannot be addressed and resolved favorably.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">During the last several
years, U.S.-listed companies that have substantially all of their operations in China have been the subject of intense scrutiny by investors,
financial commentators, and regulatory agencies. Much of the scrutiny has centered on financial and accounting irregularities and mistakes,
lack of effective internal controls over financial reporting, and, in many cases, allegations of fraud. As a result of the scrutiny,
the publicly traded stock of many U.S.-listed Chinese companies that have been the subject of such scrutiny has sharply decreased in
value. Many of these companies are now subject to shareholder lawsuits and/or SEC enforcement actions that are conducting internal and/or
external investigations into the allegations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">If, after the Merger,
we become the subject of any such scrutiny, whether any allegations are true or not, we may have to expend significant resources to investigate
such allegations and/or defend the Company. Such investigations or allegations would be costly and time consuming and likely would distract
our management from our normal business and could result in our reputation being harmed. Our stock price could decline because of such
allegations, even if the allegations are false.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Changes in international trade policies,
trade disputes, barriers to trade, or the emergence of a trade war may dampen YOOV&#8217;s growth in Hong&#160;Kong.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Political events, international
trade disputes, and other business interruptions could harm or disrupt international commerce and the global economy, and they could
have a material adverse effect on YOOV and its customers, service providers, and other partners. International trade disputes could result
in tariffs and other protectionist measures that may materially and adversely affect YOOV&#8217;s business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Tariffs could increase
the cost of the services and products, which could affect customers&#8217; investment decisions. In addition, political uncertainty surrounding
international trade disputes and the potential of their escalation to trade war and global recession could have a negative effect on
customer confidence, which could materially and adversely affect YOOV&#8217;s business. YOOV also may have access to fewer business opportunities,
and its operations may be negatively impacted as a result. In addition, the current and future actions or escalations by either the United&#160;States
or China that affect trade relations may cause global economic turmoil and potentially have a negative impact on YOOV&#8217;s business
or its results of operations, as well as the financial condition of its clients, and we cannot provide any assurances as to whether such
actions will occur or the form that they may take.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Risks Related to YOOV&#8217;s Industry
and Business Environment</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The development and use of AI technologies
is subject to an evolving and uncertain regulatory landscape that may adversely impact YOOV&#8217;s business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The regulatory environment
surrounding AI is rapidly evolving, with governments and policymakers worldwide working to establish guidelines, standards, and legislation
to govern the development and deployment of AI technologies. This regulatory uncertainty may bring challenges to YOOV, as it must navigate
a constantly shifting landscape of rules, requirements, and compliance standards across different jurisdictions. This uncertainty may
complicate YOOV&#8217;s ability to plan long-term strategies, invest in R&amp;D, and ensure the compliance of its AI solutions. Failure to keep
up with regulatory changes can result in YOOV&#8217;s business AI solutions becoming non-compliant, potentially leading to the rejection or
removal of its products from the market, severe penalties, fines, and legal liabilities, or increased operational costs and disruptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Ethical concerns and public perception of
AI could potentially limit market acceptance of YOOV&#8217;s services and harm the reputation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are growing public concerns
about the ethical implications of AI, such as privacy, bias, and the potential displacement of human jobs. For example, providing business
AI automation solutions to customers may lead to displacement of human jobs, especially in areas with repetitive, low-skilled tasks. The
AI algorithms used in the business AI automation solutions may inherit biases from historical data or reflect the biases of the users,
leading to unfair or discriminatory outcomes in areas like employee performance evaluation or customer service; the integration of AI
technologies into sensitive business processes, such as financial or insurance applications may raise concerns around data privacy, security
and any unintended consequences. Negative public perception or controversies surrounding AI could limit market acceptance of YOOV&#8217;s
services and harm the reputation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 65 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>YOOV&#8217;s business may be subject to
seasonality, and variations in customer demand due to budgeting cycles, industry dynamics, and economic trends could adversely affect
its financial performance.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">While YOOV&#8217;s business
and the markets YOOV serves are generally not subject to significant seasonality, certain trends and external factors can influence the
timing of sales, implementation, and revenue recognition for business AI automation solutions. Demand for business AI automation solutions
is often impacted by the budgeting and procurement cycles of its customers, particularly large enterprise clients. Historically, YOOV
has observed increased activity during the fourth quarter of the calendar year as customers allocate unused budgets and finalize purchasing
decisions. Similarly, the first quarter tends to see a boost in demand as new budgets are approved and organizations prioritize investments
in automation technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, customer investment
timing can vary across industries due to specific regulatory deadlines and market pressures. For example, industries such as financial
services and healthcare often experience heightened demand at year-end as they address compliance requirements and pursue operational
efficiencies. Broader economic conditions and market trends may also influence customer priorities and the adoption of automation and
AI technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although the demand for business
AI automation solutions is generally consistent throughout the year, operational factors such as holiday schedules or fiscal year-end
priorities can affect the timing of solution implementation and deployment services. These timing considerations may result in minor fluctuations
in the recognition of revenue on a quarterly basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General Risk Factors Related to YOOV</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The loss of key employees or the failure
to attract qualified personnel could have a material adverse effect on YOOV&#8217;s ability to run its business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The loss of any of YOOV&#8217;s
current executives, key employees or key advisors, or the failure to attract, integrate, motivate and retain additional key employees,
could significantly impact YOOV&#8217;s business. Competition for well-qualified and skilled employees is intense globally, and YOOV&#8217;s
future success also depends on its continued ability to attract, develop, motivate and retain highly qualified and skilled employees,
particularly software engineers, data scientists and technology professionals. YOOV&#8217;s continued ability to compete effectively depends
on its ability to attract new employees and retain and motivate existing employees. All of its senior management and key personnel are
employees at will, and any of these employees could leave with little or no prior notice. If any member of its senior management team
or other key employees leaves YOOV, its ability to successfully operate its business and execute its business strategy could be adversely
affected. YOOV may also have to incur significant costs in identifying, hiring, training and retaining replacements of departing employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 66 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If YOOV is unable to provide satisfactory
customer experience, its reputation would be harmed and it could lose customers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The success of YOOV&#8217;s
business depends largely on its ability to provide superior customer experience to maintain and grow its customer base and keep its customers
highly engaged on its online platforms. This depends on various factors, including YOOV&#8217;s ability to continue to develop and deliver
practical business AI automation solutions and provide high-quality customer support and service. If YOOV&#8217;s customers are not satisfied
with its platforms or solutions, or if its online platforms are severely interrupted or otherwise fail to meet customers&#8217; requests,
YOOV&#8217;s reputation could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">It is crucial that YOOV continues
to improve its online platforms. If YOOV does not continue to invest in the development of its online platforms and customer service operations
or fails to provide a high-quality customer experience for any reason, YOOV may lose customers, which could adversely impact its operating
results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any material disruption or
slowdown in YOOV&#8217;s customer support services resulting from telephone or internet failures, power or service outages, natural disasters,
labor disputes, or other events could make it difficult or impossible for YOOV to provide adequate customer support. In addition, the
future volume of customer complaints and inquiries may exceed YOOV&#8217;s current system capacities. If this occurs, YOOV could experience
delays in responding to customer inquiries and addressing customer complaints and concerns. YOOV&#8217;s current level of customer support
may also fail to meet the customer expectations. Failure to provide satisfactory levels of customer service may harm YOOV&#8217;s reputation,
causing potential loss of existing customers and difficulty in acquiring new customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>As a global business, YOOV is subject to risks associated with
YOOV&#8217;s&#160;non-U.S.&#160;operations where such risks are not present in the United States.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV conducts its business
on a global basis, with sales outside the United States constituting approximately 100% of YOOV&#8217;s total revenue for the fiscal year
ended March 31, 2024, and a significant number of employees and contractors located in foreign countries. YOOV anticipates that international
sales will continue to represent a substantial portion of YOOV&#8217;s revenue and that YOOV&#8217;s strategy for continued growth and
profitability will entail further international expansion, particularly in emerging markets. Conducting business outside the United States
subjects YOOV to numerous risks, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">lost revenue as a result of
macroeconomic developments;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">decreased liquidity resulting
from longer accounts receivable collection cycles typical of foreign countries;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">lower productivity resulting
from difficulties YOOV encounters in staffing and managing sales, support and research and development operations across many countries;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">difficulties associated with
enforcing agreements and collecting receivables through foreign legal systems;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">disputes with third-party sales agents of YOOV&#8217;s products or
from third parties claiming distribution rights to YOOV&#8217;s products;</p></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">difficulties associated with
navigating foreign laws and legal systems;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">difficulties in identifying potential third-party sales agents or distribution
channels;</p></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 67 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the imposition by foreign governments
of trade barriers such as tariffs, quotas, preferential bidding and import restrictions;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">import or export licensing
requirements, both by the United States and foreign countries;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">acts of war, terrorism, theft
or other lawless conduct or other economic, social or political instability in or affecting foreign countries in which YOOV sells its
products or operates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">international sanctions regimes;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">adverse effects resulting from
changes in foreign regulations, rules, policies or other laws affecting sales of YOOV&#8217;s products or YOOV&#8217;s foreign operations;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">tax liability resulting from
international tax laws;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">increased financial accounting
and reporting burdens and complexities;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">increased costs to comply with
changes in legislative or regulatory requirements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">failure of laws to protect
YOOV&#8217;s intellectual property rights; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify">delays in obtaining import or export licenses, transportation
difficulties and delays resulting from inadequate local infrastructure.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The occurrence of any of these, or other factors
over which YOOV does not have control, could lead to reduced revenue and profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>New tariffs and other trade measures could adversely affect YOOV&#8217;s
business and financial results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Governments sometimes impose
additional duties, tariffs or taxes on certain imported products. The imposition of import tariffs or restrictions, or other changes in
U.S. trade policy, could trigger retaliatory actions by affected countries. Tariffs could increase the cost of the services and products,
which could affect customers&#8217; investment decisions. In addition, political uncertainty surrounding international trade disputes
and the potential of their escalation to trade war and global recession could have a negative effect on customer confidence, which could
materially and adversely affect our business. We also may have access to fewer business opportunities, and our operations may be negatively
impacted as a result.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>YOOV is exposed to currency exchange rate
fluctuations that may bring negative impacts on YOOV&#8217;s financial condition and operational performance</i></b><i>. </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A small movement in the exchange
rate could reduce the revenues and profitability of international operations. As an international business, YOOV generates transactions
in multiple currencies and remains exposed to any deterioration in the exchange rate between different countries it operates in. This
may yield substantial financial volatility for YOOV in terms of revenue, profitability, and net financial health. For instance, the money
generated in another country in a different currency may become less valuable if converted to YOOV&#8217;s base currency due to some adverse
change in exchange rates. This diminution reduces profit margins directly and may result in the showing of lower financial performance
than expected. On the expense side, costs incurred in stronger foreign currencies could escalate when converted to YOOV&#8217;s reporting currency,
thereby raising operational expenses and decreasing profitability. In addition, dealing with several currencies complicates financial
planning and forecasting. One misprediction of the exchange rate and YOOV is thrown off-balance in terms of finance. The fact that these
rates are naturally unpredictable further exaggerates the problems for long-term planning. Some countries have currency controls or foreign
exchange restrictions, which could make the repatriation of profits or efficient cash flow management a problem for YOOV. These limitations
may further reduce financial flexibility, making it hard to move money cross-border, settle with suppliers, or invest in growth opportunities.
Currency fluctuations also have tax implications that can increase the amount of taxes due in different jurisdictions or result in unbudgeted
tax liabilities. These include sophisticated financial strategies to reduce or eliminate these exposures with hedging instruments, but
it cannot guarantee effectiveness. Inadequate control of these currency risks could have severe impacts on YOOV&#8217;s financial condition
and operational performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 68 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_036"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Risks Related to Avalon</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An investment in Avalon Common
Stock involves a high degree of risk. In determining whether to purchase Avalon Common Stock, an investor should carefully consider all
of the material risks described below, together with the other information contained in this proxy statement/prospectus before making
a decision to purchase Avalon&#8217;s securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">All
references in this section to &#8220;Avalon,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;
mean Avalon and its subsidiaries unless we state otherwise, or the context otherwise indicates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General Operating and Business Risks</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our limited revenue makes it difficult for
us to evaluate our future business prospects and make decisions based on those estimates of our future performance</i></b>.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have limited operating
revenue. Because of the uncertainties related to our lack of significant revenue, we may be hindered in our ability to anticipate and
timely adapt to increases or decreases in revenues or expenses. If we make poor budgetary decisions as a result of unreliable historical
data, we could be less profitable or incur losses, which may result in a decline in our stock price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our results of operations have not resulted
in profitability and we may not be able to achieve profitability going forward.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We incurred net losses amounting
to approximately $7.9 million and $16.7 million for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024,
we had an accumulated deficit of approximately $87.7 million. If we incur additional significant losses, our stock price may decline,
perhaps significantly. Our management is developing plans to achieve profitability. Our business plan is speculative and unproven. There
is no assurance that we will be successful in executing our business plan or that even if we successfully implement our business plan,
that we will be able to curtail our losses now or in the future. Further, as we are a new enterprise, we expect that net losses will continue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There is substantial doubt about our ability
to continue as a going concern, which will affect our ability to obtain future financing and may require us to curtail our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our financial statements as
of December 31, 2024 were prepared under the assumption that we will continue as a going concern. The independent registered public accounting
firm that audited our 2024 financial statements, in their report, included an explanatory paragraph referring to our recurring losses
since inception and expressing management&#8217;s assessment and conclusion that there is substantial doubt in our ability to continue
as a going concern. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our
ability to continue as a going concern depends on our ability to obtain additional equity or debt financing, attain further operating
efficiencies, reduce expenditures, and, ultimately, to generate revenue. We cannot assure you, however, that we will be able to achieve
any of the foregoing. See Note 2 to our Consolidated Financial Statements for further details.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our cash will only fund our operations for
a limited time and we will need to raise additional capital in order to support our development.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are currently operating
at a loss and expect our operating costs will increase significantly as we continue to grow our operations. The independent registered
public accounting firm that audited our 2024 financial statements, in their report, included an explanatory paragraph referring to our
recurring losses since inception and expressing management&#8217;s assessment and conclusion that there is substantial doubt in our ability
to continue as a going concern. At December 31, 2024, we had cash of approximately $2.9 million. If the Merger is not consummated, we
will need to raise additional capital or generate substantial revenue in order to support our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 69 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If our available cash balances
are insufficient to satisfy our liquidity requirements, including due to risks described herein, we may seek to raise additional capital
through equity offerings, debt financings, collaborations or licensing arrangements. We will need to raise additional capital, and we
may also consider raising additional capital in the future to expand our business, to pursue strategic investments, to take advantage
of financing opportunities, or for other reasons, including to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">fund development and expansion of our operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">acquire or invest in complementary businesses or assets; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">finance capital expenditures and general and administrative expenses.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our present and future funding
requirements will depend on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our revenue growth rate and ability to generate cash flows from operating activities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our sales and marketing and research and development activities; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in regulatory oversight applicable to our products and services.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other than our debt facility
with our chairman, we have no arrangements or credit facilities in place as a source of funds, and there can be no assurance that we will
be able to raise sufficient additional capital on acceptable terms, or at all, and if we are not successful in raising additional capital,
we may not be able to continue as a going concern. We may seek additional capital through a combination of private and public equity offerings,
debt financings and strategic collaborations. Debt financing, if obtained, may involve agreements that include covenants limiting or restricting
our ability to take specific actions, such as incurring additional debt, that could increase our expenses and require that our assets
secure such debt. Equity financing, if obtained, could result in dilution to our then existing stockholders and/or require such stockholders
to waive certain rights and preferences. If such financing is not available on satisfactory terms, or is not available at all, we may
be required to delay, scale back or eliminate the development of business opportunities, seek dissolution or protection of the bankruptcy
courts and our operations and financial condition will be materially adversely affected. We can provide no assurances that any additional
sources of financing will be available to us on favorable terms, if at all. Future capital raises may dilute our existing stockholders&#8217;
ownership and/or have other adverse effects on our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we raise additional capital by issuing
equity securities, our existing stockholders&#8217; percentage ownership will be reduced and these stockholders may experience substantial
dilution. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we raise additional funds
by issuing debt securities, these debt securities would have rights senior to those of our common stock and the terms of the debt securities
issued could impose significant restrictions on our operations, including liens on our assets. If we raise additional funds through collaborations
and licensing arrangements, we may be required to relinquish some rights to our technologies or products, or to grant licenses on terms
that are not favorable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have significant outstanding
debt obligations and servicing these debt obligations will require a significant amount of capital, and our business may not be able to
pay our substantial debt.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024, we
had approximately $8.4 million of outstanding indebtedness. In order to service this indebtedness and any additional indebtedness we may
incur in the future, we will need to generate cash from our operating activities. Our ability to generate cash is subject, in part, to
our ability to successfully execute our business strategy, as well as general economic, financial, competitive, regulatory and other factors
beyond our control. If we are unable to generate sufficient cash to repay our debt obligations when they become due and payable, either
when they mature, or in the event of a default, we may not be able to obtain additional debt or equity financing on favorable terms, if
at all, which may negatively impact our business operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we breach any of the undertakings
or default on any of our obligations under our agreements with our lenders, our outstanding indebtedness could become immediately due
and payable, which would harm our business, financial condition and results of operations and could require us to reduce or cease operations.
If our indebtedness were to be accelerated, there can be no assurance that our assets would be sufficient to repay in full that indebtedness.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business and operations may be further
impacted by epidemics, outbreaks and other public health events.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Epidemics, outbreaks or other
public health events that are outside of our control could significantly disrupt our operations and adversely affect our financial condition.
The global or national outbreak of an illness or other communicable disease, or any other public health crisis, such as COVID-19, may
cause disruptions to our business and operations, which may include (i) shortages of employees, (ii) unavailability of contractors or
subcontractors, (iii) interruption of supplies from third parties upon which we rely, (iv) recommendations of, or restrictions imposed
by government and health authorities, including quarantines, to address an outbreak and (v) restrictions that we and our contractors,
subcontractors and our customers impose, including facility shutdowns, to ensure the safety of employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We depend upon key personnel and need additional
personnel.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our success depends on the
continuing services of Wenzhao Lu, our Chairman of the Board, and David Jin, Meng Li and Luisa Ingargiola, our executive officers. The
loss of Mr. Lu, Dr. Jin, Ms. Li or Ms. Ingargiola could have a material and adverse effect on our business operations. Additionally, the
success of our operations will largely depend upon our ability to successfully attract and maintain competent and qualified key management
personnel. As with any company with limited resources, there can be no guaranty that we will be able to attract such individuals or that
the presence of such individuals will necessarily translate into profitability for us. Our inability to attract and retain key personnel
may materially and adversely affect our business operations. The supply of qualified technical, professional, managerial and other personnel,
including lab medical directors and lab operations managers, is currently constrained; competition for qualified employees, even across
different industries, is intense, including as individuals leave the job market. We may lose, or fail to attract and retain, key management
personnel, or qualified skilled technical, professional or other employees. The same is true for patient-facing staff with specialized
training required to perform activities related to specimen collection. In the future, if competition for the services of these professionals
increases, we may not be able to continue to attract and retain individuals in its markets. Changes in key management, or the ability
to attract and retain qualified personnel, as a result of increased competition for talent, wage growth, or other market factors, could
lead to strategic and operational challenges and uncertainties, distractions of management from other key initiatives, and inefficiencies
and increased costs, any of which could adversely affect our business, financial condition, results of operations, and cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 71 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Joint ventures, joint ownership arrangements
and other projects pose unique challenges and we may not be able to fully implement or realize synergies, expected returns or other anticipated
benefits associated with such projects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are, and may be in the
future, involved in strategic joint ventures and other joint ownership arrangements. We may not always be in complete alignment with our
joint venture or joint owner counterparties; we may have differing strategic or commercial objectives and may be outvoted by our joint
venture partners or we may disagree on governance matters with respect to the joint venture entity or the jointly owned assets. As a result,
when we enter into joint ventures or joint ownership arrangements, we may be subject to a number of risks. In some joint ventures and
joint ownership arrangements we may not be responsible for the operation of projects and will rely on our joint venture or joint owner
counterparties for such services. Joint ventures and joint ownership arrangements may also require us to expend additional internal resources
that could otherwise be directed to other projects. If we are unable to successfully execute and manage our existing and any proposed
joint venture and joint owner arrangements, it could adversely impact our financial and operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may be undertaking, or
participating with various counterparties in, a number of projects that involve forming joint ventures and acquiring laboratories that
are accretive to our commercial strategy. Many of these projects could involve numerous regulatory, environmental, commercial, economic,
political and legal uncertainties that are beyond our control, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We may be unable to realize our forecasted commercial, operational or administrative synergies in connection with our joint venture and joint ownership arrangements; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Joint ventures and other joint ownership arrangements may demand substantial internal resources and may divert resources and attention from other areas of our business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a result of these uncertainties,
the anticipated benefits associated with our joint ventures and joint ownership arrangements may not be achieved or could be delayed.
In turn, this could negatively impact our cash flow and our ability to make or increase cash distributions to our partners.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We must effectively manage the growth of
our operations, or our company will suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To manage our growth, we believe
we must continue to implement and improve our services and products. We may not have adequately evaluated the costs and risks associated
with our planned expansion, and our systems, procedures, and controls may not be adequate to support our operations. In addition, our
management may not be able to achieve the rapid execution necessary to successfully offer our products and services and implement our
business plan on a profitable basis. The success of our future operating activities will also depend upon our ability to expand our support
system to meet the demands of our growing business. Any failure by our management to effectively anticipate, implement, and manage changes
required to sustain our growth would have a material adverse effect on our business, financial condition, and results of operations.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our revenue and results of operations may
suffer if we are unable to attract new tenants.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We presently derive our revenue
from rental revenue from our income-producing real estate property in New Jersey. Our growth therefore depends on our ability to attract
new tenants. This depends on our ability to understand and anticipate market and pricing trends and our tenants&#8217; needs. Our failure
to attract new tenants could materially and adversely affect our operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 72 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Potential liability claims may adversely
affect our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our services, which may include
recommendations and advice to organizations regarding complex business and operational processes and regulatory and compliance issues
may give rise to liability claims by our clients or by third parties who bring claims against our clients. Healthcare organizations often
are the subject of regulatory scrutiny and litigation, and we also may become the subject of such litigation based on our advice and services.
Any such litigation, whether or not resulting in a judgment against us, may adversely affect our reputation and could have a material
adverse effect on our financial condition and results of operations. We may not have adequate insurance coverage for claims against us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>In accordance with our strategic development
policy, we may invest in companies for strategic reasons and may not realize a return on our investments.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">From time to time, we may
make investments in companies. These investments may be for strategic objectives to support our key business initiatives but may also
be standalone investments or acquisitions. Such investments or acquisitions could include equity or debt instruments in private companies,
many of which may not be marketable at the time of our initial investment. These companies may range from early-stage companies that are
often still defining their strategic direction to more mature companies with established revenue streams and business models. The success
of these companies may depend on product development, market acceptance, operational efficiency, and other key business factors. The companies
in which we invest may fail because they may not be able to secure additional funding, obtain favorable investment terms for future financings,
or take advantage of liquidity events such as public offerings, mergers, and private sales. If any of these private companies fails, we
could lose all or part of our investment in that company. If we determine that impairment indicators exist and that there are other-than-temporary
declines in the fair value of the investments, we may be required to write down the investments to their fair value and recognize the
related write-down as an investment loss. For the year ended December 31, 2024, we had an impairment of goodwill acquired from Lab Services
MSO acquisition of approximately $0.3 million. In the future, we could have additional impairment charges related to investments that
we may make.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our strategic transactions involve risks,
and we may not realize the expected benefits because of numerous uncertainties and risks.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We regularly consider and
may enter into strategic transactions, including mergers, acquisitions, joint ventures, investments and other growth, market and geographic
expansion strategies, with the expectation that these transactions will result in increases in sales, cost savings, synergies, and other
various benefits. Our ability to deliver the expected benefits from any strategic transaction is subject to numerous uncertainties and
risks, including our ability to integrate personnel, labor models, financial, IT and other systems successfully; disruption of our ongoing
business and distraction of management; hiring additional management and other critical personnel; and increasing the scope, geographic
diversity, and complexity of our operations. Effective internal controls are necessary to provide reliable and accurate financial reports,
and the integration of businesses may create complexity in our financial systems and internal controls and make them more difficult to
manage. Integration of businesses into our internal control system could cause us to fail to meet our financial reporting obligations.
Additionally, we may recognize material impairments in the future, including in connection with assets we have acquired or divested in
a strategic transaction or charges to earnings associated with any strategic transaction, which may materially reduce our earnings. Our
shareholders may react unfavorably to our strategic transactions and strategic transactions may also be subject to regulatory uncertainty
due to the changing enforcement landscape. We may not realize the anticipated benefits from such transactions, we may be exposed to additional
liabilities of any acquired business or joint venture, and we may be exposed to litigation in connection with the strategic transaction.
Further, we may finance these strategic transactions by incurring additional debt, which could increase leverage or impact our ability
to access capital in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 73 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face intense competition which could
cause us to lose market share.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the healthcare markets
in which we operate, we will compete with large healthcare providers who have more significant financial resources, established market
positions, long-standing relationships, and who have more significant name recognition, technical, marketing, sales, distribution, financial
and other resources than we do. The resources available to our competitors to develop new services and products and introduce them into
the marketplace exceed the resources currently available to us. This intense competitive environment may require us to make changes in
our services, products, pricing, licensing, distribution, or marketing to develop a market position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with our obligations
in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business
relationships with our licensors, we could lose intellectual property rights that are important to our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are party to a research
agreement with the Massachusetts Institute of Technology (&#8220;MIT&#8221;) for development of chimeric antigen receptor (CAR) technology.
Although we have halted all research and development, MIT has granted us options to non-exclusively or exclusively license MIT inventions
arising under this research agreement and we continue to maintain our joint patent applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Moreover, Disputes may arise
regarding intellectual property subject to a licensing agreement, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the priority of invention of patented technology.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, the agreements
under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements
may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow
what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our
financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial
condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair
our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop
and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results
of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 74 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may face uncertainty and difficulty in
obtaining and enforcing our patents and other proprietary rights.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There can be no assurance
that any patent applications we file or license will be approved, or that challenges will not be instituted against the validity or enforceability
of any patent licensed-in or owned by us. Our pending and future patent applications may not result in patents being issued that protect
our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive product candidates.
Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent
competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our
patents by developing similar or alternative product candidates in a non-infringing manner. The cost of litigation to uphold the validity
and prevent infringement of a patent is substantial. Furthermore, there can be no assurance that others will not independently develop
substantially equivalent technologies not covered by patents to which we have rights or obtain access to our know-how. In addition, the
laws of certain countries may not adequately protect our intellectual property. Our competitors may possess or obtain patents on products
or processes that are necessary or useful to the development, use, or manufacture of our product candidates. There can also be no assurance
that our proposed technology will not infringe upon patents or proprietary rights owned by others, with the result that others may bring
infringement claims against us and require us to license such proprietary rights, which may not be available on commercially reasonable
terms, if at all. Any such litigation, if instituted, could have a material adverse effect, potentially including monetary penalties,
diversion of management resources, and injunction against continued manufacture, use, or sale of certain products or processes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We rely upon non-patented
proprietary know-how. There can be no assurance that we can adequately protect our rights in such non-patented proprietary know-how, or
that others will not independently develop substantially equivalent proprietary information or techniques or gain access to our proprietary
know-how. Any of the foregoing events could have a material adverse effect on us. In addition, if any of our trade secrets, know-how or
other proprietary information were to be disclosed, or misappropriated, the value of our trade secrets, know-how and other proprietary
rights would be significantly impaired and our business and competitive position would suffer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In September 2011, the Leahy-Smith
America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S.
patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation.
In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#8220;first to file&#8221; system in which
the first inventor to file a patent application will be entitled to the patent. Third parties are allowed to submit prior art before the
issuance of a patent by the U.S. Patent and Trademark Office, or USPTO, and may become involved in opposition, derivation, post-grant
and <i>inter partes </i>review, or interference proceedings challenging our patent rights. An adverse determination in any such submission,
proceeding or litigation could reduce the scope of, or invalidate, our patent rights, which could adversely affect our competitive position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The USPTO has developed new
and untested regulations and procedures to govern the full implementation of the Leahy-Smith Act, and many of the substantive changes
to patent law associated with the Leahy-Smith Act, and in particular, the &#8220;first-to-file&#8221; provisions, only became effective
in March 2013. The Leahy-Smith Act has also introduced procedures that may make it easier for third parties to challenge issued patents,
as well as to intervene in the prosecution of patent applications. Finally, the Leahy-Smith Act contains new statutory provisions that
still require the USPTO to issue new regulations for their implementation, and it may take the courts years to interpret the provisions
of the new statute. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business.
The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications
and the enforcement or defense of our issued patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 75 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to protect our intellectual
property rights throughout the world.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Filing, prosecuting and defending
patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property
rights in some countries outside the United States may be less extensive than those in the United States. In addition, the laws of some
foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently,
we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling
or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies
in jurisdictions where we do not obtain patent protection to develop their own products and may also export infringing products to territories
where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products
and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Many companies have encountered
significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection,
particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or
marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign
jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of
our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing
and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other
remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around
the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent terms may be inadequate to protect
our competitive position on our product candidates for an adequate amount of time.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Patents have a limited lifespan.
In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest
U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited.
Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive
products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new
product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result,
any patents we may obtain may not provide us with sufficient rights to exclude others from commercializing products similar or identical
to ours.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Obtaining and maintaining patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent
agencies, and any patent protection we may obtain in the future could be reduced or eliminated for non-compliance with these requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Periodic maintenance fees,
renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and
various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications.
The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and
other similar provisions during the patent application process. There are situations in which non-compliance can result in abandonment
or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In
such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>It is difficult and costly to protect our
proprietary rights, and we may not be able to ensure their protection. If we fail to protect or enforce our intellectual property rights
adequately or secure rights to patents of others, the value of our intellectual property rights would diminish.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our commercial viability will
depend in part on obtaining and maintaining patent protection and trade secret protection of our product candidates, and the methods used
to manufacture them, as well as successfully defending these patents against third-party challenges. Our ability to stop third parties
from making, using, selling, offering to sell, or importing our products is dependent upon the extent to which we obtain rights under
valid and enforceable patents or trade secrets that cover these activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The patent positions of pharmaceutical
and biopharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal principles
remain unresolved. No consistent policy regarding the breadth of claims allowed in biopharmaceutical patents has emerged to date in the
United States. The biopharmaceutical patent situation outside the United States is even more uncertain. Changes in either the patent laws
or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly,
we cannot predict the breadth of claims that may be allowed or enforced in the patents we own. Further, if any of our patents are deemed
invalid and unenforceable, it could impact our ability to commercialize or license our technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The degree of future protection
for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or
permit us to gain or keep our competitive advantage. For example:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">others may be able to make products that are similar to our product candidates but that are not covered by the claims of any patents;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we might not have been the first to make the inventions covered by any issued patents or patent applications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we might not have been the first to file patent applications for these inventions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">it is possible that any patent applications we own or license will not result in issued patents;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any issued patents may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges by third parties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may not develop additional proprietary technologies that are patentable or protectable under trade secrets law; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the patents of others may have an adverse effect on our business.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 77 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We also may rely on trade
secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets
are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside
scientific collaborators, and other advisors may unintentionally or willfully disclose our information to competitors. In addition, courts
outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent
knowledge, methods, and know-how.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims challenging
the inventorship of patents and other intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We or our licensors may be
subject to claims that former employees, collaborators or other third parties have an interest as an inventor or co-inventor in intellectual
property we own or license. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees,
consultants or others who are involved in developing our product candidates. We may be subject to claims by third parties asserting that
our licensors, employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual
property. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217;
ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending
any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership
of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against
such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing
could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If any of our trade secrets, know-how or
other proprietary information is disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly
impaired and our business and competitive position would suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our viability also depends
upon the skills, knowledge and experience of our scientific and technical personnel, and our consultants and advisors. To help protect
our proprietary know-how and our inventions for which patents may be unobtainable or difficult to obtain, we rely on trade secret protection
and confidentiality agreements. To this end, we require all of our employees, consultants, advisors and contractors to enter into agreements
which prohibit unauthorized disclosure and use of confidential information and, where applicable, require disclosure and assignment to
us of the ideas, developments, discoveries and inventions important to our business. These agreements are often limited in duration and
may not provide adequate protection for our trade secrets, know-how or other proprietary information in the event of any unauthorized
use or disclosure or the lawful development by others of such information. There is no assurance that such agreements will be honored
by such parties or enforced in whole or part by the courts. We cannot be certain that others will not gain access to these trade secrets
or that our patents will provide adequate protection. Others may independently develop substantially equivalent proprietary information
and techniques or otherwise gain access to our trade secrets. In addition, enforcing a claim that a third party illegally obtained and
is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. If any of our trade secrets, know-how
or other proprietary information is improperly disclosed, the value of our trade secrets, know-how and other proprietary rights would
be significantly impaired and our business and competitive position would suffer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 78 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may incur substantial costs as a result
of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to protect our rights
to, or use of, our technology.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we choose to go to court
to stop a third party from using the inventions claimed in our patents, that individual or company has the right to ask the court to rule
that such patents are invalid and/or should not be enforced against that third party. These lawsuits are expensive and would consume time
and other resources, even if we were successful in discontinuing the infringement of our patents. In addition, there is a risk that the
court will decide that these patents are not valid and that we do not have the right to stop the other party from using the inventions.
There is also the risk that, even if the validity of these patents is upheld, the court will refuse to stop the other party on the ground
that such other party&#8217;s activities do not infringe our rights to these patents. In addition, the U.S. Supreme Court has in the past
invalidated tests used by the USPTO in granting patents over the past 20 years. As a consequence, issued patents may be found to contain
invalid claims according to the newly revised standards. Some of our own patents may be subject to challenge and subsequent invalidation
in a variety of post-grant proceedings, particularly <i>inter partes</i> review, before the USPTO or during litigation under the revised
criteria, which make it more difficult to defend the validity of claims in already issued patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Furthermore, a third party
may claim that we or our manufacturing or commercialization partners are using inventions covered by the third party&#8217;s patent rights
and may go to court to stop us from engaging in our normal operations and activities, including making or selling our product candidates.
These lawsuits are costly and could affect our results of operations and divert the attention of managerial and technical personnel. There
is a risk that a court could decide that we or our commercialization partners are infringing the third party&#8217;s patents and order
us or our partners to stop the activities covered by the patents. In addition, there is a risk that a court could order us or our partners
to pay the other party damages for having violated the other party&#8217;s patents. The biotechnology industry has produced a proliferation
of patents, and it is not always clear to industry participants, including us, which patents cover various types of products, manufacturing
processes or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always
uniform. If we are sued for patent infringement, we would need to demonstrate that our products, manufacturing processes or methods of
use either do not infringe the patent claims of the relevant patent and/or that the patent claims are invalid, and we may not be able
to do this. Proving invalidity, in particular, is difficult since it requires a showing of clear and convincing evidence to overcome the
presumption of validity enjoyed by issued patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As some patent applications
in the United States may be maintained in secrecy until the patents are issued, because patent applications in the United States and many
foreign jurisdictions are typically not published until eighteen months after filing, and because publications in the scientific literature
often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our
issued patents or our pending applications, or that we were the first to invent the technology. Our competitors may have filed, and may
in the future file, patent applications covering technology similar to ours. Any such patent applications may have priority over our patent
applications or patents, which could further require us to obtain rights to issued patents covering such technologies. If another party
has filed a United States patent application on inventions similar to ours, we may have to participate in an interference proceeding declared
by the USPTO to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible
that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention
prior to our own invention, resulting in a loss of our U.S. patent position with respect to such inventions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Some of our competitors may
be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources.
In addition, any uncertainties resulting from the initiation and continuation of any litigation or <i>inter partes </i>review proceedings
could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 79 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Some jurisdictions in which
we operate have enacted legislation which allows members of the public to access information under statutes similar to the U.S. Freedom
of Information Act. Even though we believe our information would be excluded from the scope of such statutes, there are no assurances
that we can protect our confidential information from being disclosed under the provisions of such laws. If any confidential or proprietary
information is released to the public, such disclosures may negatively impact our ability to protect our intellectual property rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Breaches or compromises of our information
security systems or our information technology systems or infrastructure could result in exposure of private information, disruption of
our business and damage to our reputation, which could harm our business, results of operation and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We utilize information security
and information technology systems and websites that allow for the secure storage and transmission of proprietary or private information
regarding our clients, patients, employees, vendors and others, including individually identifiable health information. A security breach
of our network, hosted service providers, or vendor systems, may expose us to a risk of loss or misuse of this information, litigation
and potential liability. Hackers and data thieves are increasingly sophisticated and operate large-scale and complex automated attacks,
including on companies within the healthcare industry. Although we believe that we take appropriate measures to safeguard sensitive information
within our possession, we may not have the resources or technical sophistication to anticipate or prevent rapidly-evolving types of cyber-attacks
targeted at us, our clients, our patients, or others who have entrusted us with information. Actual or anticipated attacks may cause us
to incur costs, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts
and consultants. We invest in industry standard security technology to protect personal information. Advances in computer capabilities,
new technological discoveries, or other developments may result in the technology used by us to protect personal information or other
data being breached or compromised. To our knowledge, we have not experienced any material breach of our cybersecurity systems. If our
or our third-party service provider systems fail to operate effectively or are damaged, destroyed, or shut down, or there are problems
with transitioning to upgraded or replacement systems, or there are security breaches in these systems, any of the aforementioned could
occur as a result of natural disasters, software or equipment failures, telecommunications failures, loss or theft of equipment, acts
of terrorism, circumvention of security systems, or other cyber-attacks, we could experience delays or decreases in revenue, and reduced
efficiency of our operations. Additionally, any of these events could lead to violations of privacy laws, loss of customers, or loss,
misappropriation or corruption of confidential information, trade secrets or data, which could expose us to potential litigation, regulatory
actions, sanctions or other statutory penalties, any or all of which could adversely affect our business, and cause us to incur significant
losses and remediation costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be exposed to liabilities under the
Foreign Corrupt Practices Act, and any determination that we violated the Foreign Corrupt Practices Act or Chinese anti-corruption law
could have a material adverse effect on our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are subject to the Foreign Corrupt Practice Act, or FCPA, and other
laws that prohibit improper payments or offers of payments to foreign governments and their officials and political parties by U.S. persons
and issuers as defined by the statute, for the purpose of obtaining or retaining business. We have operations and agreements with third
parties where corruption may occur. It is our policy to implement safeguards to prevent these practices by our employees. However, our
existing safeguards and any future improvements may prove to be less than effective, and the employees, consultants, or sales agents of
our company may engage in conduct for which we might be held responsible.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Violations of the FCPA or
other anti-corruption laws may result in severe criminal or civil sanctions, and we may be subject to other liabilities, which could negatively
affect our business, operating results and financial condition. In addition, the United States government may seek to hold our company
liable for successor liability FCPA violations committed by companies in which we invest or that we acquire.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 80 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes or disruption in services supplies,
or transportation provided by third parties have impacted and could continue to impact or adversely affect our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">We depend on third parties
to provide supplies and services critical to our KetoAir business. We are heavily reliant on third-party ground and air travel for transport
of diagnostic testing supplies. A significant disruption to these travel systems, or our access to them, could have a material adverse
effect on our business. Disruptions to the continued supply, or increases in costs, of these products. may arise from export/import restrictions
or embargoes, political or economic instability, pressure from animal rights activists, adverse weather, natural disasters, public health
crises, transportation disruptions, cyber-attacks, or other causes, as well as from termination of relationships with suppliers or vendors
for their failure to follow our performance standards and requirements. Disruption of supply and services has impacted and could continue
to impact or have a material adverse effect on our business related to the sale of KetoAir.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risk Factors Related to Commercialization Activity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Some of our medical device products in the
future may face significant government regulation, and there is no guarantee that our medical devices will receive regulatory approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The manufacturing and marketing
of our potential medical device products such as our breathalyzer system may be subject to extensive regulation by the FDA and other regulatory
authorities in the United States, as well as by regulatory authorities in other countries. In the United States, our product candidates
are subject to regulation as biological products or as combination biological products/medical devices under the Federal Food, Drug and
Cosmetic Act, the Public Health Service Act and other statutes, as outlined in the Code of Federal Regulations. Different regulatory requirements
may apply to our products depending on how they are categorized by the FDA under these laws. These regulations can be subject to substantial
and significant interpretation, addition, amendment or revision by the FDA and by the legislative process. The FDA may determine that
we will need to undertake clinical trials beyond those currently planned. Furthermore, the FDA may determine that results of clinical
trials do not support approval for the product. Similar determinations may be encountered in foreign countries. The FDA will continue
to monitor products in the market after approval, if any, and may determine to withdraw its approval or otherwise seriously affect the
marketing efforts for any such product. The same possibilities exist for trials to be conducted outside of the United States that are
subject to regulations established by local authorities and local law. Any such determinations would delay or deny the introduction of
our product candidates to the market and have a material adverse effect on our business, financial condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain medical devices are
subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Agency, other federal agencies and corresponding state
agencies to ensure strict compliance with good manufacturing practices, and other government regulations and corresponding foreign standards.
We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards, nor can we guarantee that
we will maintain compliance with such regulations in regard to our own manufacturing processes. Other risks include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication, or field alerts to physicians and pharmacies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulatory authorities may withdraw their approval of the IND or the product or require us to take our approved products off the market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 81 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may be required to change the way the product is manufactured or administered and we may be required to conduct additional clinical trials or change the labeling of our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may have limitations on how we promote our products; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">we may be subject to litigation or product liability claims.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even if our medical devices
receive regulatory approval in the United States, we may never receive approval or commercialize our product candidates outside of the
United States. In order to market and commercialize any product candidate outside of the United States, we must establish and comply with
numerous and varying regulatory requirements of other countries regarding manufacturing, safety and efficacy. Approval procedures vary
among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval
in other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries may include
all of the risks detailed above regarding FDA approval in the United States as well as other risks. Regulatory approval in one country
does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative
effect on the regulatory approval process in others. Failure to obtain regulatory approval in other countries, or any delay or setback
in obtaining such approval, could have the same adverse effects detailed above regarding FDA approval in the United States. Such effects
include the risks that our product candidates may not be approved for all indications requested, which could limit the uses of our product
candidates and have an adverse effect on product sales and potential royalties, and that such approval may be subject to limitations on
the indicated uses for which the product may be marketed or require costly, post-marketing follow-up studies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if our medical devices receive regulatory
approval, we may still face future development and regulatory difficulties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even if U.S. regulatory approval
is obtained, the FDA may still impose significant restrictions on a product&#8217;s indicated uses or marketing, or impose ongoing requirements
for potentially costly post-approval studies. If any of our products were granted accelerated approval, FDA could require post-marketing
confirmatory trials to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. FDA
may withdraw approval of a drug or indication approved under the accelerated approval pathway if a trial required to verify the predicted
clinical benefit of the product fails to verify such benefit; other evidence demonstrates that the product is not shown to be safe or
effective under the conditions of use; the applicant fails to conduct any required post-approval trial of the drug with due diligence;
or the applicant disseminates false or misleading promotional materials relating to the product. In addition, the FDA currently requires
as a condition for accelerated approval the pre-approval of promotional materials, which could adversely impact the timing of the commercial
launch of the product.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Given the number of recent
high-profile adverse safety events with certain medical devices, the FDA may require, as a condition of approval, costly risk management
programs, which may include safety surveillance, restricted distribution and use, patient education, enhanced labeling, special packaging
or labeling, expedited reporting of certain adverse events, pre-approval of promotional materials, and restrictions on direct-to-consumer
advertising. Furthermore, heightened Congressional scrutiny on the adequacy of the FDA&#8217;s drug approval process and the FDA&#8217;s
efforts to assure the safety of marketed cell based therapy has resulted in the proposal of new legislation addressing drug safety issues.
If enacted, any new legislation could result in delays or increased costs during the period of product development, and regulatory review
and approval, as well as increased costs to assure compliance with any new post-approval regulatory requirements. Any of these restrictions
or requirements could force us to conduct costly studies or increase the time for us to become profitable. For example, any labeling approved
for any of our product candidates may include a restriction on the term of its use, or it may not include one or more of our intended
indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 82 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our product candidates will
also be subject to ongoing FDA requirements for the labeling, packaging, storage, advertising, promotion, record-keeping, and submission
of safety and other post-market information on the cell based therapy. New issues may arise during a product lifecycle that did not exist,
or were unknown, at the time of product approval, such as adverse events of unanticipated severity or frequency, or problems with the
facility where the product is manufactured. Since approved products, manufacturers, and manufacturers&#8217; facilities are subject to
continuous review and periodic inspections, these new issues post-approval may result in voluntary actions by us or may result in a regulatory
agency imposing restrictions on that product or us, including requiring withdrawal of the product from the market or for use in a clinical
study. If our product candidates fail to comply with applicable regulatory requirements, such as good manufacturing practices, a regulatory
agency may:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">issue warning letters;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions, and penalties for noncompliance;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">impose other civil or criminal penalties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">suspend regulatory approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">suspend any ongoing clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">refuse to approve pending applications or supplements to approved applications filed by us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">impose restrictions on operations, including costly new manufacturing requirements; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">seize or detain products or require a product recall.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we or current or future collaborators,
manufacturers, or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions
and substantial penalties, which could affect our ability to develop, market and sell our products and may harm our reputation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Although we currently are
only marketing KetoAir, once our medical devices are covered by federal health care programs, we will be subject to additional healthcare
statutory and regulatory requirements and enforcement by the federal, state and foreign governments of the jurisdictions in which we
conduct our business. Healthcare providers, physicians and third party payors play a primary role in the recommendation and prescription
of any medical devices for which we obtain marketing approval. Our future arrangements with third party payors and customers may expose
us to broadly applicable fraud and abuse, transparency, and other healthcare laws and regulations that may constrain the business or
financial arrangements and relationships through which we market, sell and distribute our therapeutic candidates for which we obtain
marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include, but are not limited to,
the following:</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing or ordering of an item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare or Medicaid;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">federal civil and criminal false claims laws and civil monetary penalty laws, such as the U.S. federal FCA, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against, individuals or entities for knowingly presenting or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 83 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">HIPAA includes a fraud and abuse provision referred to as the HIPAA All-Payor Fraud Law, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">HIPAA, as amended by HITECH, and its implementing regulations, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding, the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the federal Physician Payment Sunshine Act and the implementing regulations, also referred to as &#8220;Open Payments,&#8221; issued under the ACA, which require that manufacturers of pharmaceutical and biological drugs reimbursable under Medicare, Medicaid, and Children&#8217;s Health Insurance Programs report to the Department of Health and Human Services all consulting fees, travel reimbursements, research grants, and other payments, transfers of value or gifts made to physicians and teaching hospitals with limited exceptions; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The scope and enforcement
of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of
the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions
between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements
in the healthcare industry. Responding to investigations can be time-and resource-consuming and can divert management&#8217;s attention
from the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Ensuring that our business
arrangements with third-parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations
are found to be in violation of any such requirements, we may be subject to penalties, including civil or criminal penalties, monetary
damages, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement
or other government programs, including Medicare and Medicaid, any of which could adversely affect our financial results. Although effective
compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely
eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert
our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining
compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 84 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Any medical devices we develop may become
subject to unfavorable pricing regulations, third party coverage and reimbursement practices or healthcare reform initiatives, thereby
harming our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The regulations that govern
marketing approvals, pricing, coverage and reimbursement for new medical devices vary widely from country to country. Some countries require
approval of the sale price of a device before it can be marketed. In many countries, the pricing review period begins after marketing
or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental
control even after initial approval is granted. Although we intend to monitor these regulations, our programs are currently in earlier
stages of development and we will not be able to assess the impact of price regulations for a number of years. As a result, we might obtain
regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of
the product and negatively impact the revenues we are able to generate from the sale of the product in that country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ability to commercialize
any products successfully also will depend in part on the extent to which coverage and reimbursement for these products and related treatments
will be available from government health administration authorities, private health insurers and other organizations. However, there may
be significant delays in obtaining coverage for newly-approved medical devices. . Moreover, eligibility for coverage does not necessarily
signify that a cell based therapy will be reimbursed in all cases or at a rate that covers our costs, including research, development,
manufacture, sale and distribution costs. Also, interim payments for new cell based therapy if applicable, may be insufficient to cover
our costs and may not be made permanent. Thus, even if we succeed in bringing one or more products to the market, these products may not
be considered medically necessary or cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell
our products on a competitive basis. Because our programs are in earlier stages of development, we are unable at this time to determine
their cost effectiveness, or the likely level or method of reimbursement. In addition, obtaining coverage and reimbursement approval of
a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each
payor supporting scientific, clinical and cost-effectiveness data for the use of our product on a payor-by-payor basis, with no assurance
that coverage and adequate reimbursement will be obtained. A payor&#8217;s decision to provide coverage for a product does not imply that
an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure
that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to
maintain price levels sufficient to realize an appropriate return on our investment in product development. If reimbursement is not available
or is available only at limited levels, we may not be able to successfully commercialize any product candidate that we successfully develop.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Increasingly, the third party
payors who reimburse patients or healthcare providers, such as government and private insurance plans, are seeking greater upfront discounts,
additional rebates and other concessions to reduce the prices for pharmaceutical products. If the price we are able to charge for any
products we develop, or the reimbursement provided for such products, is inadequate in light of our development and other costs, our return
on investment could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the product is reasonable and necessary for the diagnosis or treatment of the illness or injury for which the product is administered according to accepted standards of medical practice;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the product is typically furnished incident to a physician&#8217;s services;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the indication for which the product will be used is included or approved for inclusion in certain Medicare-designated pharmaceutical compendia (when used for an off-label use); and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the product has been approved by the FDA.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 85 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Average prices for medical
devices may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future
relaxation of laws that presently restrict imports of medical devices from countries where they may be sold at lower prices than in the
U.S. Reimbursement rates under Medicare Part B would depend in part on whether the newly approved product would be eligible for a unique
billing code. It is difficult for us to predict how Medicare coverage and reimbursement policies will be applied to our products in the
future and coverage and reimbursement under different federal healthcare programs are not always consistent. Medicare reimbursement rates
may also reflect budgetary constraints placed on the Medicare program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Third party payors often rely
upon Medicare coverage policies and payment limitations in setting their own reimbursement rates. These coverage policies and limitations
may rely, in part, on compendia listings for approved therapeutics. Our inability to promptly obtain relevant compendia listings, coverage,
and adequate reimbursement from both government-funded and private payors for products that we develop and for which we obtain regulatory
approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products
and our financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect that these and other
healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and
in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or
other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment
measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products,
once marketing approval is obtained.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe that the efforts
of governments and third party payors to contain or reduce the cost of healthcare and legislative and regulatory proposals to broaden
the availability of healthcare will continue to affect the business and financial condition of pharmaceutical and biopharmaceutical companies.
A number of legislative and regulatory changes in the healthcare system in the U.S. and other major healthcare markets have been proposed,
and such efforts have expanded substantially in recent years. These developments could, directly or indirectly, affect our ability to
sell our products, if approved, at a favorable price. For example, in the United States, in 2010, the U.S. Congress passed the ACA, a
sweeping law intended to broaden access to health insurance, reduce or constrain the growth of health spending, enhance remedies against
fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the
health industry and impose additional policy reforms. Among the provisions of the ACA addressing coverage and reimbursement of pharmaceutical
products, of importance to our potential therapeutic candidates are the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Separately, pursuant to the
health reform legislation and related initiatives, the Centers for Medicare and Medicaid Services, or CMS, is working with various healthcare
providers to develop, refine, and implement Accountable Care Organizations, or ACOs, and other innovative models of care for Medicare
and Medicaid beneficiaries, including the Bundled Payments for Care Improvement Initiative, the Comprehensive Primary Care Initiative,
the Duals Demonstration, and other models. The continued development and expansion of ACOs and other innovative models of care will have
an uncertain impact on any future reimbursement we may receive for approved therapeutics administered by these organizations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The healthcare industry is heavily regulated
in the U.S. at the federal, state, and local levels, and our failure to comply with applicable requirements may subject us to penalties
and negatively affect our financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a healthcare company, our
operations and interactions with healthcare providers may be subject to extensive regulation in the U.S., particularly if we receive FDA
approval for any of its products in the future. For example, if we receive FDA approval for a product for which reimbursement is available
under a federal healthcare program (e.g., Medicare, Medicaid), it would be subject to a variety of federal laws and regulations, including
those that prohibit the filing of false or improper claims for payment by federal healthcare programs (e.g. the federal False Claims Act),
prohibit unlawful inducements for the referral of business reimbursable by federal healthcare programs (e.g. the federal Anti-Kickback
Statute), and require disclosure of certain payments or other transfers of value made to U.S.-licensed physicians and teaching hospitals
or Open Payments. We are not able to predict how third parties will interpret these laws and apply applicable governmental guidance and
may challenge our practices and activities under one or more of these laws. If our past or present operations are found to be in violation
of any of these laws, we could be subject to civil and criminal penalties, which could hurt our business, our operations and financial
condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The federal Anti-Kickback
Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any
remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering
or arranging for the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare
programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted
to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other.
There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions
and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing,
purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the
requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the
Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review
of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a statutory exception
or regulatory safe harbor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, the intent standard
under the Anti-Kickback Statute was amended by the ACA, to a stricter standard such that a person or entity no longer needs to have actual
knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law
that a claim including items or services resulting from a violation of the federal Anti- Kickback Statute constitutes a false or fraudulent
claim for purposes of the federal FCA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The civil monetary penalties
statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented
a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed
or is false or fraudulent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Federal false claims and false
statement laws, including the federal FCA, prohibit, among other things, any person or entity from knowingly presenting, or causing to
be presented, a false or fraudulent claim for payment to, or approval by, the federal healthcare programs, including Medicare and Medicaid,
or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal
government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. For instance,
historically, pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product
to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted
for causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, off-label, and thus
generally non-reimbursable, uses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 87 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">HIPAA prohibits, among other
offenses, knowingly and willfully executing a scheme to defraud any health care benefit program, including private payors, or falsifying,
concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery
of or payment for items or services under a health care benefit program. To the extent that we act as a business associate to a healthcare
provider engaging in electronic transactions, we may also be subject to the privacy and security provisions of HIPAA, as amended by HITECH,
which restricts the use and disclosure of patient-identifiable health information, mandates the adoption of standards relating to the
privacy and security of patient-identifiable health information, and requires the reporting of certain security breaches to healthcare
provider customers with respect to such information. Additionally, many states have enacted similar laws that may impose more stringent
requirements on entities like ours. Failure to comply with applicable laws and regulations could result in substantial penalties and adversely
affect our financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Many states also have similar
fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several
states, apply regardless of the payor. Additionally, to the extent that our product is sold in a foreign country, we may be subject to
similar foreign laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our products, once approved,
may be eligible for coverage under Medicare and Medicaid, among other government healthcare programs. Accordingly, we may be subject to
a number of obligations based on their participation in these programs, such as a requirement to calculate and report certain price reporting
metrics to the government, such as average sales price (ASP) and best price. Penalties may apply in some cases when such metrics are not
submitted accurately and timely. Further, these prices for medical devices may be reduced by mandatory discounts or rebates required by
government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of medical devices
from countries where they may be sold at lower prices than in the United States. It is difficult to predict how Medicare coverage and
reimbursement policies will be applied to our products in the future and coverage and reimbursement under different federal healthcare
programs are not always consistent. Medicare reimbursement rates may also reflect budgetary constraints placed on the Medicare program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order to distribute products
commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of medical devices
in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or
distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish
the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology
capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring
pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic
public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as
well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology
companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially
subject to federal and state consumer protection and unfair competition laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If our operations are found
to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to
us, we may be subject to penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement,
exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#8220;qui tam&#8221; actions
brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual
damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our
operations, any of which could adversely affect our ability to operate our business and our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 88 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to obtain reimbursement or funding
from the federal government may be impacted by possible reductions in federal spending.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">U.S. federal government agencies
currently face potentially significant spending reductions. The Budget Control Act of 2011, or the BCA, established a Joint Select Committee
on Deficit Reduction, which was tasked with achieving a reduction in the federal debt level of at least $1.2 trillion. That committee
did not draft a proposal by the BCA&#8217;s deadline. As a result, automatic cuts, referred to as sequestration, in various federal programs
were scheduled to take place, beginning in January 2013, although the American Taxpayer Relief Act of 2012 delayed the BCA&#8217;s automatic
cuts until March 1, 2013. While the Medicare program&#8217;s eligibility and scope of benefits are generally exempt from these cuts, Medicare
payments to providers and Part D health plans are not exempt. The BCA did, however, provide that the Medicare cuts to providers and Part
D health plans would not exceed two percent. President Obama issued the sequestration order on March 1, 2013, and cuts went into effect
on April 1, 2013. Additionally, the Bipartisan Budget Act of 2015 extended sequestration for Medicare through fiscal year 2027.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The U.S. federal budget remains
in flux, which could, among other things, cut Medicare payments to providers. The Trump Administration cost reduction initiatives may
impact Medicare and Medicaid reimbursement levels. Medicare program is frequently mentioned as a target for spending cuts. The full impact
on our business of any future cuts in Medicare or other programs is uncertain. In addition, we cannot predict any impact President Trump&#8217;s
administration and the U.S. Congress may have on the federal budget. If federal spending is reduced, anticipated budgetary shortfalls
may also impact the ability of relevant agencies, such as the FDA or the National Institutes of Health, to continue to function at current
levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of
relevant agencies to timely review and approve medical devises and development, manufacturing, and marketing activities, which may delay
our ability to develop, market and sell any products we may develop.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our officers, directors and principal stockholders
own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our officers, directors and
5% stockholders and their affiliates beneficially own a significant percentage of our outstanding common stock. As a result, these stockholders
have significant influence and may be able to determine all matters requiring stockholder approval. For example, these stockholders may
be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other
major corporate transactions. This concentration of ownership could delay or prevent any acquisition of our company on terms that other
stockholders may desire, and may adversely affect the market price of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 89 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to maintain listing of
our securities on The Nasdaq Capital Market or another reputable stock exchange, it may be more difficult for our stockholders to sell
their securities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Nasdaq requires listing issuers
to comply with certain standards in order to remain listed on its exchange. If Nasdaq should delist our securities from trading on its
exchange for any reason and we are unable to obtain listing on another reputable national securities exchange, a reduction in some or
all of the following may occur, each of which could materially adversely affect our stockholders. A delisting of our common stock is likely
to reduce the liquidity of our common stock and may inhibit or preclude our ability to raise additional financing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The price of our common stock may be volatile
and fluctuate substantially, which could result in substantial losses for our stockholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our common stock is listed
on the Nasdaq Capital Market under the symbol &#8220;ALBT.&#8221; The price of our common stock has been, and we expect it to continue
to be, volatile. The stock market in general and the market for smaller healthcare companies in particular have experienced extreme volatility
that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able
to sell your shares of common stock at or above the price you paid for your shares of common stock. The market price for our common stock
may be influenced by many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the success of competitive products or technologies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">developments related to our existing or any future collaborations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">regulatory or legal developments in the United States and other countries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the recruitment or departure of key personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">actual or anticipated changes in estimates as to financial results or recommendations by securities analysts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">changes in the structure of healthcare payment systems;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">market conditions in the healthcare, pharmaceutical and biotechnology sectors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">general economic, industry and market conditions; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future sales of our common stock or securities
convertible or exchangeable for our common stock may cause our stock price to decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If our existing stockholders
sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the price of our common stock could
decline. The perception in the market that these sales may occur could also cause the price of our common stock to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 90 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, as of March
31, 2025:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">1,451,425 shares of our common stock were issuable upon exercise of
outstanding stock options;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">171,163 shares of our common stock were issuable upon exercise of outstanding stock warrants;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">1,452,282 shares of our common stock issuable upon conversion of our outstanding Series C Preferred Stock;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">2,074,689 shares of our common stock issuable upon conversion of our outstanding Series D Preferred Stock; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">227,269 shares of our common stock issuable upon conversion of our outstanding convertible notes.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the shares we may issue
from time to time upon the exercise of outstanding options and warrants and the conversion of our outstanding Series C Preferred Stock
and Series D Preferred Stock are sold and outstanding convertible notes are issues, or if it is perceived that they will be sold, by the
award recipients in the public market, the price of our common stock could decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>You may experience dilution of your ownership
interests because of the future issuance of additional shares of our common or preferred stock or other securities that are convertible
into or exercisable for our common or preferred stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of the date of this filing,
we have issued an aggregate of (i) 3,500 shares of Series C Preferred Stock and (ii) 5,000 shares of Series D Preferred Stock. In the
future, we may issue our authorized but previously unissued equity securities, resulting in the dilution of the ownership interests of
our stockholders. We are authorized to issue an aggregate of 100,000,000 shares of common stock and 10,000,000 shares of &#8220;blank
check&#8221; preferred stock. We may issue additional shares of our common stock or other securities that are convertible into or exercisable
for our common stock in connection with hiring or retaining employees, future acquisitions, future sales of our securities for capital
raising purposes, or for other business purposes. The future issuance of any such additional shares of our common stock may create downward
pressure on the trading price of our common stock. We expect we will need to raise additional capital in the near future to meet our working
capital needs, and there can be no assurance that we will not be required to issue additional shares, warrants or other convertible securities
in the future in conjunction with these capital raising efforts, including at a price (or exercise prices) below the price you paid for
your stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The ability of our Board to issue additional
stock may prevent or make more difficult certain transactions, including a sale or merger.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Board is authorized to
issue up to 10,000,000 shares of preferred stock with powers, rights and preferences designated by it. Shares of voting or convertible
preferred stock could be issued, or rights to purchase such shares could be issued, to create voting impediments or to frustrate persons
seeking to effect a takeover or otherwise gain control of us. The rights of holders of our common stock are subject to the rights of the
holders of our preferred stock, including Series C Preferred Stock, Series D Preferred Stock and any preferred stock that may be issued.
The ability of the Board to issue such additional shares of preferred stock, with rights and preferences it deems advisable, could discourage
an attempt by a party to acquire control of us by tender offer or other means. Such issuances could therefore deprive stockholders of
benefits that could result from such an attempt, such as the realization of a premium over the market price for their shares in a tender
offer or the temporary increase in market price that such an attempt could cause. Moreover, the issuance of such additional shares of
preferred stock to persons friendly to the Board could make it more difficult to remove incumbent managers and directors from office even
if such change were to be favorable to stockholders generally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 91 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are incorporated in Delaware.
Certain anti-takeover provisions of Delaware law and our charter documents as currently in effect may make a change in control of us more
difficult, even if a change in control would be beneficial to the stockholders. Delaware law also prohibits corporations from engaging
in a business combination with any holders of 15% or more of their capital stock until the holder has held the stock for three years unless,
among other possibilities, our Board approves the transaction. Our Board may use these provisions to prevent changes in the management
and control of us. Also, under applicable Delaware law, our Board may adopt additional anti-takeover measures in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price
and trading volume could decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The trading market for our
common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. We
do not currently have and may never obtain research coverage by securities and industry analysts. If no or few securities or industry
analysts commence coverage of us, the trading price for our stock would be negatively impacted. In the event we obtain securities or industry
analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual
property or our stock performance, or if our operating results fail to meet the expectations of analysts, our stock price would likely
decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in
the financial markets, which in turn could cause our stock price or trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We do not anticipate paying dividends on
our common stock, and investors may lose the entire amount of their investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have never declared or
paid cash dividends on our common stock, and we do not anticipate such a declaration or payment for the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect to use future earnings,
if any, to fund business growth. Therefore, stockholders will not receive any funds absent a sale of their shares of our common stock.
We cannot assure stockholders of a positive return on their investment when they sell their shares, nor can we assure that stockholders
will not lose the entire amount of their investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Applicable regulatory requirements, including
those contained in and issued under the Sarbanes-Oxley Act of 2002, may make it difficult for us to retain or attract qualified officers
and directors, which could adversely affect the management of our business and our ability to obtain or retain listing of our common stock
on a national securities exchange.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may be unable to attract
and retain those qualified officers, directors and members of board committees required to provide for effective management because of
the rules and regulations that govern publicly held companies, including, but not limited to, certifications by principal executive officers.
The enactment of the Sarbanes-Oxley Act has resulted in the issuance of a series of related rules and regulations and the strengthening
of existing rules and regulations by the SEC, as well as the adoption of new and more stringent rules by national securities exchanges.
The perceived increased personal risk associated with these changes may deter qualified individuals from accepting roles as directors
and executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 92 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Further, some of these changes
heighten the requirements for board or committee membership, particularly with respect to an individual&#8217;s independence from the
corporation and level of experience in finance and accounting matters. We may have difficulty attracting and retaining directors with
the requisite qualifications. If we are unable to attract and retain qualified officers and directors, the management of our business
and our ability to obtain or retain listing of our shares of common stock on any national securities exchange could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Our failure to maintain compliance with
Nasdaq&#8217;s continued listing requirements could result in the delisting of our common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Our common stock is currently
listed for trading on The Nasdaq Capital Market. We must satisfy the continued listing requirements of The Nasdaq Stock Market LLC (or
Nasdaq) to maintain the listing of our common stock on The Nasdaq Capital Market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">On May 22, 2025, we received
notice from the Listing Qualifications Staff (the &#8220;Staff&#8221;) of Nasdaq indicating that we were not in compliance with the $2.5
million minimum stockholders&#8217; equity requirement for continued listing of our common stock on The Nasdaq Capital Market, as set
forth in Nasdaq Listing Rule 5550(b)(1) (the &#8220;Minimum Stockholders&#8217; Equity Rule&#8221;). In that regard, we reported stockholders&#8217;
equity of ($3,891,270), as reported in the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March 31, 2025 (we did
not then, and do not now, meet the alternative compliance standards relating to the market value of listed securities of $35 million
or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently
completed fiscal years).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">We intend to submit to
Nasdaq, within the requisite time period, a plan to regain compliance with the Minimum Stockholders&#8217; Equity Rule. There can be
no assurance that Nasdaq will accept our plan or that we will be able to regain compliance with the Minimum Stockholders&#8217; Equity
Rule or maintain compliance with any other Nasdaq requirement in the future. In the event that we are unable to regain compliance with
the Minimum Stockholders&#8217; Equity Rule, our common stock may be delisted from The Nasdaq Capital Market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">If our common stock were
delisted from The Nasdaq Capital Market, trading of our common stock would most likely take place on an over-the-counter market established
for unlisted securities, such as the OTCQB or the Pink Market maintained by OTC Markets Group Inc. An investor would likely find it less
convenient to sell, or to obtain accurate quotations in seeking to buy, our common stock on an over-the-counter market, and many investors
would likely not buy or sell our common stock due to difficulty in accessing over-the-counter markets, policies preventing them from
trading in securities not listed on a national exchange or other reasons. In addition, as a delisted security, our common stock would
be subject to SEC rules as a &#8220;penny stock,&#8221; which impose additional disclosure requirements on broker-dealers. The regulations
relating to penny stocks, coupled with the typically higher cost per trade to the investor of penny stocks due to factors such as broker
commissions generally representing a higher percentage of the price of a penny stock than of a higher-priced stock, would further limit
the ability of investors to trade in our common stock. Delisting would materially and adversely affect our ability to raise capital on
terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, suppliers, customers and employees
and fewer business development opportunities. In addition, the consummation of the pending merger is subject to the satisfaction or waiver
of a number of conditions set forth in the Merger Agreement, including the absence of any pending order or action from Nasdaq or any
Governmental Authority (as defined in the Merger Agreement) with respect to the status of the listing of our common stock, including
any delisting order. For these reasons and others, delisting would adversely affect the liquidity, trading volume and price of our common
stock, causing the value of an investment in us to decrease&#160;and having an adverse effect on our business, financial condition and
results of operations, including our ability to attract and retain qualified employees and to raise capital.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We could be subject to securities class
action litigation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the past, securities class
action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially
relevant for us because companies in our industry have experienced significant stock price volatility in recent years. If we face such
litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b><span style="clear: both; display: block;"><br/></span>
</b></span></p><div>

</div><div><a id="a_037"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">UNAUDITED PRO FORMA CONDENSED
COMBINED FINANCIAL INFORMATION</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following unaudited pro
forma condensed combined financial information presents the combination of the financial information of Avalon and YOOV adjusted to give
effect to the Merger and related transactions. The following unaudited pro forma condensed combined financial information has been prepared
in accordance with Article 11 of Regulation S-X. Defined terms included below have the same meaning as terms defined and included elsewhere
in this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Introduction</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following unaudited pro
forma condensed combined financial information is provided to aid you in your analysis of the financial aspects of the Merger. The following
unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of SEC Regulation S-X, as
amended by the final rule, Release No. 33-10786, <i>Amendments to Financial Disclosures about Acquired and Disposed Businesses</i>. Release
No. 33-10786 replaced the previous pro forma adjustment criteria with simplified requirements to depict the accounting for the Merger
(&#8220;Transaction Accounting Adjustments&#8221;) and present the reasonably estimable synergies and other transaction effects that have
occurred or are reasonably expected to occur (&#8220;Management&#8217;s Adjustments&#8221;). Management has elected not to present Management&#8217;s
Adjustments and will only be presenting Transaction Accounting Adjustments in the unaudited pro forma condensed combined financial information.
The adjustments presented in the unaudited pro forma condensed combined financial statements have been identified and presented to provide
relevant information necessary for an understanding of the combined company reflecting the Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV and Avalon have different
fiscal year ends. YOOV&#8217;s fiscal year end is March 31, and Avalon&#8217;s fiscal year end is December 31. Following the Merger, the
Combined Company will have a fiscal year end of March 31. The unaudited pro forma combined balance sheet as of December 31, 2024 gives
pro forma effect to the Merger as if it had been consummated as of that date. The unaudited pro forma combined statements of operations
for the year ended March 31, 2024 and for the nine months ended December 31, 2024 give pro forma effect to the Merger as if it had occurred
as of April 1, 2023. This information should be read together with YOOV and Avalon&#8217;s respective audited and unaudited financial
statements and related notes included elsewhere in this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The unaudited pro&#160;forma
condensed combined financial statements are provided for illustrative purposes only and are not necessarily indicative of what the actual
results of operations and financial position would have been had the Merger taken place on the dates indicated, nor are they indicative
of the future consolidated results of operations or financial position of the combined company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 94 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE
SHEET</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AS OF&#160;DECEMBER 31,
2024</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Scenario
    1</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Scenario
    2</span></td><td style="text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
    Closing Price less than or equal to&#160;&#160;$5.0</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Assuming
    Closing Price greater than $5.0</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Avalon
    (A)</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">YOOV
    (B)</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Pro
    Forma Adjustments</span></td><td style="padding-bottom: 1.5pt; text-align: center; white-space: nowrap; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Pro
    Forma Balance Sheet</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Pro
    Forma Adjustments</span></td><td style="padding-bottom: 1.5pt; text-align: center; white-space: nowrap; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Pro
    Forma Balance Sheet</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">CURRENT
    ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Cash</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,369,586</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,698,926</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(785,308</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)(2)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,433,204</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"/><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,433,204</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(850,000</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)(1)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"/><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accounts
    receivable, net</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">44,196,302</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">44,196,302</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"/><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">44,196,302</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Factoring
    receivables, net</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">509,751</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">509,751</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">509,751</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount
    due from related parties</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">10,300,228</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">10,300,228</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">10,300,228</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Rent
    receivable</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">81,854</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">81,854</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">81,854</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Receivable
    from sale of equity method investment, current portion</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">975,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">975,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">975,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Prepaid
    expense and other current assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">367,818</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">15,193,267</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">15,561,085</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">15,561,085</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
    Current Assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,794,258</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">72,898,474</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(1,635,308</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">74,057,424</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">74,057,424</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">NON-CURRENT
    ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Operating
    lease right-of-use assets, net</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">113,253</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">896,026</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,009,279</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,009,279</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Receivable
    from sale of equity method investment, noncurrent portion</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">675,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">675,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">675,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Property
    and equipment, net</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">10,660</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">466,283</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">476,943</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">476,943</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Intangible
    assets</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">42,416,410</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,500,000</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4)(b)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">43,916,410</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">43,916,410</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Insurance
    contracts</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Investment
    in real estate, net</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">6,980,551</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">5,519,449</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4)(b)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">12,500,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">12,500,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity
    method investment, net</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">64</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">64</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">64</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Goodwill</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">17,080,842</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4)(b)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">17,080,842</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">17,080,842</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Other
    non-current assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">36,067</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">36,067</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">36,067</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
    Non-current Assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,815,531</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">43,778,783</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">24,100,291</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">75,694,605</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">75,694,605</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
    Assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">10,609,789</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">116,677,257</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">22,464,983</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">149,752,029</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">149,752,029</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">LIABILITIES,
    MEZZANIEN EQUITY AND EQUITY</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">CURRENT
    LIABILITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accrued
    expenses and other payables</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,587,894</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,927,157</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">10,515,051</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">10,515,051</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accounts
    payable</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">371,060</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">371,060</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">371,060</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Note
    payable, net</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">5,745,254</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">5,745,254</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">5,745,254</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Deferred
    revenue</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">51,857,030</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">51,857,030</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">51,857,030</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Bank
    borrowing</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">20,298,334</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">20,298,334</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">20,298,334</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Income
    tax payable</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,825</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,825</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">30,825</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount
    due to related parties, current</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,428,078</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">5,216</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,433,294</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,433,294</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Operating
    lease liabilities, current</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">67,547</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">277,117</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">344,664</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">344,664</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Derivative
    liability</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">223,052</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">223,052</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">223,052</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Convertible
    note payable, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,397,528</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,397,528</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,397,528</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
    Current Labilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">14,449,353</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">80,766,739</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">95,216,092</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">95,216,092</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">NON-CURRENT
    LIABILITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Operating
    lease liabilities, non-current</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">51,706</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">650,067</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">701,773</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">701,773</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Deferred
    tax liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,731,360</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,731,360</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,731,360</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Long
    service payment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,384</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,384</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,384</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
    Non-current Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">51,706</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,389,811</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,441,517</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,441,517</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
    Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">14,501,059</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">83,156,550</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">97,657,609</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">97,657,609</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Commitment
    and Contingencies</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">MEZZANINE
    EQUITY</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Angel
    round redeemable convertible preferred shares</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,129,169</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,129,169</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)(3)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Series
    A redeemable convertible preferred shares</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">17,081,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(17,081,000</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)(3)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Series
    A1 redeemable convertible preferred shares</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">17,824,867</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(17,824,867</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)(3)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
    mezzanine equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">38,035,036</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(38,035,036</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(DEFICIT)/EQUITY</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Preferred
    stock,</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Series
    C Convertible Preferred Stock</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,500,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,500,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,500,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Series
    D Convertible Preferred Stock</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,837,527</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,837,527</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,837,527</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Common
    stock</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">166</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">20,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(166</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)(4)(a)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">6,166</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(600</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)(4)(e)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">5,566</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">166</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4)(c)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(20,000</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)(4)(c)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">6,000</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4)(e)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Additional
    paid-in capital</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">74,673,916</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">38,035,036</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">45,920,364</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">600</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4)(e)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">45,920,964</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(74,673,916</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)(4)(a)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,871,328</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4)(c)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">14,000</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4)(e)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Less:
    common stock held in treasury, at cost</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(522,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">522,500</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4)(a)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accumulated
    deficit</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(90,155,236</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4,630,229</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(850,000</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)(1)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(6,265,537</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(6,265,537</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(785,308</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)(2)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">90,155,236</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4)(a)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Statutory
    reserve</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">6,578</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(6,578</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)(4)(a)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accumulated
    other comprehensive loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(231,721</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(48,486</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">231,721</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4)(a)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(48,486</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(48,486</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
    Stockholders' (Deficit)/Equity Attributable to the company</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,891,270</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4,658,715</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">60,500,019</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">51,950,034</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">51,950,034</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Non-controlling
    interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">144,386</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">144,386</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">144,386</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
    Shareholders' (Deficit)/Equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,891,270</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(4,514,329</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">60,500,019</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">52,094,420</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">52,094,420</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total
    Liabilities, Mezzanine Equity and Equity</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">10,609,789</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">116,677,257</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">22,464,983</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">149,752,029</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right">&#160;&#160;&#160;&#8239;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">149,752,029</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">(A)</span></td><td style="text-align: justify"><span style="-keep: true">Derived from unaudited
                                            consolidated balance sheet of Avalon as of&#160;March 31, 2025.</span></td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(B)</td><td style="text-align: justify">Derived from unaudited consolidated balance sheet of YOOV as
of December 31, 2024.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 95 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT
OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FOR THE YEAR ENDED MARCH 31, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Scenario
    1</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Scenario
    2</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Assuming
    Closing Price less than or equal to $5.0</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Assuming
    Closing Price greater<br/> than $5.0</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Avalon<br/>
    (A)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Pro<br/>

    Forma<br/> Avalon</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Avalon<br/>
    Adjusted</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">YOOV
    <br/> (B)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Pro
    Forma Adjustments</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Pro
    Forma Income Statement</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Pro
    Forma Adjustments</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Pro
    Forma Income Statement</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; width: 36%; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Revenue</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="-keep: true">1,255,681</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"/><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="-keep: true">1,255,681</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="-keep: true">29,633,327</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"/><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="-keep: true">30,889,008</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"/><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="-keep: true">30,889,008</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Operating costs
    and expenses:</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Cost of revenues</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(10,735,837</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(10,735,837</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(10,735,837</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Operating expenses</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(1,017,493</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(1,017,493</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(1,017,493</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(1,017,493</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Loss from equity
    method investment</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(8,571,647</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">8,571,647</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">(1)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Selling and marketing
    expenses</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(1,666,721</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(1,666,721</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(10,399,877</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(12,066,598</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(12,066,598</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Administrative
    expenses</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(5,753,503</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(5,753,503</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(6,083,083</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(1,735,308</span></td><td style="white-space: nowrap; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)(2)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(13,671,894</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(13,671,894</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(100,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)(3)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Research
    and development expenses</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(612,733</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(612,733</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(612,733</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Total
    operating costs and expenses:</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(17,009,364</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">8,571,647</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(8,437,717</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(27,831,530</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(1,835,308</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(38,104,555</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(38,104,555</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">(Loss)/Income
    from operations</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(15,753,683</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">8,571,647</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(7,182,036</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">1,801,797</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(1,835,308</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(7,215,547</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(7,215,547</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Other income, net:</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Finance expense,
    net</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(1,351,502</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(1,351,502</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(383,593</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(1,735,095</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(1,735,095</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Other
    income, net</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">398,175</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">398,175</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">193,331</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">591,506</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">591,506</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Total other
    loss, net</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(953,327</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(953,327</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(190,262</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(1,143,589</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(1,143,589</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">(Loss) Income
    before income tax provision</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(16,707,010</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">8,571,647</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(8,135,363</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">1,611,535</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(1,835,308</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(8,359,136</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(8,359,136</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Income
    tax expenses</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(360,869</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(360,869</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(360,869</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Net
    (loss) income</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(16,707,010</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">8,571,647</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(8,135,363</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1,250,666</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(1,835,308</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(8,720,005</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(8,720,005</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Less: net income
    attributable to non-controlling interests</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">54,695</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">54,695</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">54,695</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Less: accretion of redemption value
    of preferred shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">264,391</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(264,391</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)(4)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Net loss attributable
    to the company's shareholders</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(16,707,010</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">8,571,647</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(8,135,363</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">931,580</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(1,570,917</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(8,774,700</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(8,774,700</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Weighted average shares outstanding</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Basic and diluted</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">701,932</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">701,932</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">200,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">59,800,000</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">(5)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">60,701,932</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(6,000,000</span></td><td style="white-space: nowrap; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)(5)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">54,701,932</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 8pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Net (loss)/income per ordinary
    share</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">Basic and diluted</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(23.80</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(11.59</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(0.14</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="-keep: true">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="-keep: true">(0.16</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="-keep: true">)</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(A)</td><td style="text-align: justify">Derived from audited consolidated statements of operations of
Avalon for the year ended December 31, 2023.</td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(B)</td><td style="text-align: justify">Derived from audited consolidated statement of operation of
YOOV for the year ended March 31, 2024.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 96 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b style="-keep: true">FOR THE NINE MONTHS
ENDED DECEMBER 31, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-decoration: none; text-align: center">&#160;</td><td style="text-decoration: none">&#160;</td>
    <td colspan="2" style="text-decoration: none; text-align: center">&#160;</td><td style="text-decoration: none">&#160;</td><td style="text-decoration: none">&#160;</td>
    <td colspan="2" style="text-decoration: none; text-align: center">&#160;</td><td style="text-decoration: none">&#160;</td><td style="text-decoration: none">&#160;</td>
    <td colspan="2" style="text-decoration: none; text-align: center">&#160;</td><td style="text-decoration: none">&#160;</td><td style="text-decoration: none">&#160;</td>
    <td colspan="2" style="text-decoration: none; text-align: center">&#160;</td><td style="text-decoration: none">&#160;</td><td style="font-weight: bold; text-decoration: none">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-decoration: none; text-align: center">Scenario 1</td><td style="font-weight: bold; text-decoration: none">&#160;</td><td style="font-weight: bold; text-decoration: none">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-decoration: none; text-align: center">Scenario 2</td><td style="font-weight: bold; text-decoration: none">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-decoration: none; text-align: center">&#160;</td><td style="text-decoration: none; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-decoration: none; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-decoration: none">&#160;</td><td style="text-decoration: none; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-decoration: none; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-decoration: none">&#160;</td><td style="text-decoration: none; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-decoration: none; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-decoration: none">&#160;</td><td style="text-decoration: none; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-decoration: none; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-decoration: none">&#160;</td><td style="font-weight: bold; text-decoration: none; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-decoration: none; text-align: center; border-bottom: Black 1.5pt solid">Assuming Closing
    Price less than or equal to&#160;&#160;$5.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none">&#160;</td><td style="font-weight: bold; text-decoration: none; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-decoration: none; text-align: center; border-bottom: Black 1.5pt solid">Assuming Closing
    Price greater than $5.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-decoration: none; text-align: center">&#160;</td><td style="font-weight: bold; text-decoration: none; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-decoration: none; text-align: center; border-bottom: Black 1.5pt solid">Avalon (A)</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none">&#160;</td><td style="font-weight: bold; text-decoration: none; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-decoration: none; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma
    Avalon</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none">&#160;</td><td style="font-weight: bold; text-decoration: none; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-decoration: none; text-align: center; border-bottom: Black 1.5pt solid">Avalon Adjusted</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none">&#160;</td><td style="font-weight: bold; text-decoration: none; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-decoration: none; text-align: center; border-bottom: Black 1.5pt solid">YOOV (B)</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none">&#160;</td><td style="font-weight: bold; text-decoration: none; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-decoration: none; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma
    Adjustments</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none">&#160;</td><td style="font-weight: bold; text-decoration: none; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-decoration: none; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma
    Income Statement</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none">&#160;</td><td style="font-weight: bold; text-decoration: none; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-decoration: none; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma
    Adjustments</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none">&#160;</td><td style="font-weight: bold; text-decoration: none; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-decoration: none; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma
    Income Statement</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-decoration: none">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-indent: -0.125in; padding-left: 0.125in">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">1,040,728</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">1,040,728</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">38,012,233</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">39,052,961</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">39,052,961</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Operating costs and expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,283,137</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,283,137</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,283,137</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(797,350</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(797,350</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(797,350</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(797,350</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Loss from equity method investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(232,043</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">232,043</td><td style="text-align: left">(1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Selling and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(201,161</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(201,161</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,523,469</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,724,630</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,724,630</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,197,256</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,197,256</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,589,367</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(75,000</td><td style="text-align: left">)(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,761,623</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,761,623</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(222,860</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(222,860</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(222,860</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Total operating
    costs and expenses:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">(5,427,810)</span></b></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">232,043</span></b></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">(5,195,767)</span></b></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">(35,618,833)</span></b></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">25,000</span></b></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">(40,789,600)</span></b></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">-</span></b></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">(40,789,600)</span></b></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">(Loss)/Income
    from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#12288;</span><span style="font-size: 8pt"><b>(4,387,082)</b></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#12288;</span><span style="font-size: 8pt"><b>232,043</b></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#12288;</span><span style="font-size: 8pt"><b>(4,155,039)</b></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">2,393,400</span></b></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">25,000</span></b></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">(1,736,639)</span></b></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">-</span></b></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">(1,736,639)</span></b></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Other income, net:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Finance expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,670,123</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,670,123</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(825,145</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,495,268</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,495,268</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(828,761</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(828,761</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">55,027</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(773,734</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(773,734</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Total other loss, net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">(2,498,884)</span></b></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">-</span></b></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">(2,498,884)</span></b></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">(770,118)</span></b></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">-</span></b></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">(3,269,002)</span></b></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">-</span></b></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#12288;</b></span><b><span style="font-size: 8pt">(3,269,002)</span></b></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">(Loss) Income before income tax provision</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(6,885,966</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">232,043</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(6,653,923</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,623,282</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">25,000</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(5,005,641</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(5,005,641</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Income tax expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(299,374</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(299,374</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(299,374</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">Net (loss) income</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(6,885,966</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">232,043</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(6,653,923</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,323,908</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5,305,015</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5,305,015</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Less: net income attributable to non-controlling interests</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,369</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,369</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,369</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Less: accretion of redemption value of preferred shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">215,959</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(215,959</td><td style="text-align: left">)(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Net loss attributable to the company's
    shareholders</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(6,885,966</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">232,043</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(6,653,923</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,036,580</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">240,959</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(5,376,384</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(5,376,384</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-indent: -0.125in; padding-left: 0.125in">Weighted average shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,138,370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,138,370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">59,800,000</p></td><td style="font-size: 8pt; text-align: left">(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,138,370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,000,000</td><td style="text-align: left">)(5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,138,370</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -0.125in; padding-left: 0.125in">Net (loss)/income per ordinary share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6.05</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5.85</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.09</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.10</td><td style="text-align: left">)</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">(A)</span></td><td style="text-align: justify"><span style="-keep: true">Derived from unaudited condensed consolidated statements of operation of Avalon for
                                                                                       the six months ended June 30, 2024, and the audited consolidated statements of operation of Avalon for the year ended December 31,
                                                                                       2024, and unaudited condensed consolidated statements of operation of Avalon for the three months ended March 31, 2025.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(B)</td><td style="text-align: justify">Derived from unaudited condensed consolidated statement of operation
of YOOV for the nine months ended December 31, 2024.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><!-- Field: Page; Sequence: 97 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED
FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in"><b>1.</b></td><td style="text-align: justify"><b>DESCRIPTION OF THE TRANSACTION</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25IN">On March 7, 2025, Avalon
GloboCare Corp. (&#8220;Avalon&#8221;), Nexus MergerSub Limited, a business company incorporated in the British Virgin Islands and a wholly
owned subsidiary of Avalon (&#8220;Merger Sub&#8221;), and YOOV Group Holding Limited, a business company incorporated in the British
Virgin Islands (&#8220;YOOV&#8221; or the &#8220;Company&#8221;), entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;)
pursuant to which Merger Sub will merge with and into YOOV, with YOOV surviving the merger and becoming a direct, wholly owned subsidiary
of Avalon (the &#8220;Merger&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25IN">Subject to the terms and
conditions of the Merger Agreement, immediately prior to the effective time of the Merger (the &#8220;Effective Time&#8221;), each then-outstanding
share of YOOV preferred shares, par value $0.10 per share, will either automatically be converted into shares of YOOV ordinary shares,
par value $0.10 per share (the &#8220;YOOV Ordinary Shares&#8221;) or canceled and cease to exist in accordance with their terms. At the
Effective Time, each then-outstanding YOOV Ordinary Share (other than any shares held in treasury and Dissenting Shares (as defined in
the Merger Agreement)) will be automatically converted into a number of shares of Avalon common stock, par value $0.0001 per share (the
&#8220;Avalon Common Stock&#8221;), equal to the Exchange Ratio. The &#8220;Exchange Ratio&#8221; will be the ratio (rounded to four decimal
places), determined as follows: if the closing price of the Avalon Common Stock on Nasdaq on the second trading day immediately preceding
the Effective Time is (x) less than or equal to $5.00, the Exchange Ratio shall be 60,000,000 divided by YOOV Outstanding Shares; or (y)
greater than $5.00, the Exchange Ratio shall be 54,000,000 divided by the Company Outstanding Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25IN">Pursuant to the terms of
the Merger Agreement, (i) each then-outstanding share of Avalon Common Stock will remain issued and outstanding after the Effective Time
and (ii) each then-outstanding option to purchase Avalon Common Stock, whether or not vested, will remain issued and outstanding after
the Effective Time. The then-outstanding shares of Series C Convertible Preferred Stock of Avalon and Series D Convertible Preferred Stock
of Avalon will remain outstanding in accordance with their terms. Additionally, at the Effective Time, the name of Avalon will be changed
to &#8220;YOOV, Inc.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25IN">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 22pt"><b>2.</b></td><td style="text-align: justify"><b>BASIS OF PRESENTATION</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt; background-color: white">While
Avalon will be the legal acquirer, the Merger will be accounted for as a reverse acquisition using the acquisition method of accounting
in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 805, &#8220;Business Combinations&#8221; (&#8220;ASC 805&#8221;).
YOOV will be deemed to be the acquirer for financial accounting purposes. Pursuant to the guidance under ASC 805, the following relevant
factors were considered in determining that YOOV is the accounting acquirer and Avalon is the accounting acquiree:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">YOOV stockholders will become stockholders of the combined company and will own approximately 97% to 98%
of the voting stock immediately after the Merger. Therefore, YOOV&#8217;s owners receive the largest portion of the voting rights in the
combined entity.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">YOOV will control corporate governance of the combined entity.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">YOOV&#8217;s size is significantly larger than Avalon&#8217;s as measured in terms of assets and revenues.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; background-color: white">&#160;</p><div>

</div><!-- Field: Page; Sequence: 98 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25IN">The unaudited pro forma
combined balance sheet as of December 31, 2024 gives pro forma effect to the Merger as if it had been consummated as of that date. The
unaudited pro forma combined statements of operations for the year ended March 31, 2024 and for the nine months ended December 31, 2024
give pro forma effect to the Business Combination as if it had occurred as of April 1, 2023. This information should be read together
with YOOV and Avalon&#8217;s respective audited and unaudited financial statements and related notes included elsewhere in this proxy
statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25IN">The unaudited pro forma
combined balance sheet as of December 31, 2024 has been prepared using the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25IN">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">Avalon&#8217;s
                                            unaudited consolidated balance sheet as of March 31, 2025 and the related notes included
                                            elsewhere in this proxy statement/prospectus; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">YOOV&#8217;s unaudited condensed consolidated balance sheet as of December 31, 2024 and the related notes
included elsewhere in this proxy statement/prospectus.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25IN">The unaudited pro forma
condensed combined statements of operations for the year ended March 31, 2024 have been prepared using, and should be read in conjunction
with, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Avalon&#8217;s audited consolidated statements of operations for the year ended December 31, 2023 and
the related notes included elsewhere in this proxy statement/prospectus; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">YOOV&#8217;s audited consolidated statements of operations for the year ended March 31, 2024 and the related
notes included elsewhere in this proxy statement/prospectus.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .25IN">The unaudited pro forma
condensed combined statements of operations for the nine months ended December 31, 2024 have been prepared using, and should be read in
conjunction with, the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">Avalon&#8217;s
                                            unaudited condensed consolidated statements of operations for the six months ended June 30,
                                            2024 in its Quarterly Report&#160;on&#160;Form&#160;10-Q&#160;for&#160;the quarter ended
                                            June 30, 2024, unaudited condensed consolidated statements of operations for the three months
                                            ended March 31, 2025, audited consolidated statements of operations for the year ended December
                                            31, 2024, and the related notes included elsewhere in this proxy statement/prospectus; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">YOOV&#8217;s unaudited condensed consolidated statements of operations for the nine months ended December
31, 2024 and the related notes included elsewhere in this proxy statement/prospectus.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The unaudited pro forma condensed combined financial
information has been prepared using the assumptions below with respect to closing price of the Avalon Common Stock on Nasdaq on the second
trading day immediately preceding the Effective Time:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b>Scenario
                                            1 - Assuming the closing price less than or equal to $5.00:</b> This presentation assumes
                                            that the closing price of the Avalon Common Stock on Nasdaq on the second trading day immediately
                                            preceding the Effective Time is less than or equal to $5.00, the Exchange Ratio shall be
                                            60,000,000 divided by YOOV Outstanding Shares;</p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 99 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true"><b>Scenario
                                            2 - Assuming the closing price greater than $5.00:</b> This presentation assumes that the
                                            closing price of the Avalon Common Stock on Nasdaq on the second trading day immediately
                                            preceding the Effective Time is greater than $5.00, the Exchange Ratio shall be 54,000,000
                                            divided by YOOV Outstanding Shares.</span></td></tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">All of the transaction
adjustments of the Merger shown in Scenario 1 also apply to Scenario 2, and Scenario 2 includes an additional adjustment to give effect
to differences in the Exchange Ratio between Scenarios 1 and 2.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">The unaudited pro forma condensed
combined financial information does not give effect to any anticipated synergies, operating efficiencies, tax savings or cost savings
that may be associated with the Merger. </span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The pro forma adjustments reflecting the consummation
of the Merger are based on certain currently available information and certain assumptions and methodologies that Avalon and YOOV believe
are reasonable under the circumstances. The unaudited condensed pro forma adjustments, which are described in the accompanying notes,
may be revised as additional information becomes available and is evaluated. Therefore, it is likely that the actual adjustments will
differ from the pro forma adjustments, and it is possible the difference may be material. The management of Avalon and YOOV believe that
their assumptions and methodologies provide a reasonable basis for presenting all of the significant effects of the Merger based on information
available to the management at this time and that the pro forma adjustments give appropriate effect to those assumptions and are properly
applied in the unaudited pro forma condensed combined financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>3. Merger Consideration Calculation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">The preliminary estimated
merger consideration shares, pro forma as of March 31, 2025, is 60,000,000 (assumed the closing price of the Avalon Common Stock on The
Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) on the second trading day immediately preceding the Effective Time is less than or equal
to $5.00).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">The fair value of the
Avalon common stock to be issued upon closing as merger consideration is $240,000,000. The fair value per share of Avalon&#8217;s common
stock was assumed for pro forma purposes to be $3.84 per share. This is the closing price of Avalon&#8217;s common stock on May 22, 2025.
Changes in the stock price of Avalon&#8217;s Common Stock will impact the fair value of total estimated purchase consideration transferred
and impact the estimated number of shares to be transferred to the YOOV stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">The final fair value
of the merger consideration will be based on the Avalon&#8217;s closing price per share immediately prior to the effective time of the
Merger. Accordingly, the fair value of the merger consideration and goodwill may change significantly if the trading price of Avalon&#8217;s
common stock fluctuates materially from the May 22, 2025, value of $3.84 per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 100 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>4. Reverse Acquisition and Purchase Price
Allocation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Fair Value of Total Estimated Consideration
Transferred</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">The
                                            fair value of preliminary purchase consideration expected to be transferred on the closing
                                            date includes the value of the estimated number of shares of the combined company to be owned
                                            by Avalon shareholders at closing of the Merger. The fair value per share of Avalon&#8217;s
                                            common stock was assumed for pro forma purposes to be $3.84 per share. This is the closing
                                            price of Avalon&#8217;s common stock on May 22, 2025.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">Purchase consideration</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Amounts</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="-keep: true">Number of Avalon common shares outstanding as of March 31, 2025</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">1,651,667</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Total shares of Avalon common shares assumed to be outstanding as of closing of the merger</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,651,667</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Avalon share price as of May 22, 2025</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">3.84</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">Preliminary estimate of fair value of common shares</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">6,342,401</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Preliminary estimate of fair value of Avalon Series C Convertible Preferred Stock(*)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">5,576,763</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Preliminary estimate of fair value of Avalon Series D Convertible Preferred Stock(*)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">7,966,805</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Preliminary estimate of fair value of share-based instruments (Avalon options
    and warrants)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">323,052</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Fair value of total estimated purchase consideration transferred</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">20,209,021</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">The Series C Convertible Preferred Stock and Series D Convertible Preferred Stock were valued
on the as converted method.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Purchase Price Allocation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt; background-color: white">The following is a preliminary
estimate of the allocation of the purchase price to acquired identifiable assets and assumed liabilities, which includes the preliminary
fair value of intangible assets acquired at the time of the Merger:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">Purchase Price Allocation</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Amounts</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-keep: true">Assets acquired</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 88%"><span style="-keep: true">Cash</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">1,369,586</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Prepaid expense and other current assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">449,672</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Receivable from sale of equity method investment</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,650,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Investment in real estate at fair value</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">12,500,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Other non-current assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">159,980</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Intangible assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,500,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Goodwill from the Merger</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">17,080,842</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total assets</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">34,710,080</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Liabilities assumed</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Accrued liabilities and other payables</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,807,147</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Advance from pending sale of noncontrolling interest</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">3,328,078</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Derivative liability</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">223,052</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Note payable, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,745,254</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Convertible note payable, net</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">2,397,528</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">14,501,059</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Fair value of total estimated consideration transferred</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">20,209,021</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt; background-color: white"><span style="background-color: white">The
acquired identified intangible assets are expected to be comprised of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">Intangible</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Estimated Useful Life</span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Estimated Fair Value at Closing</span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 86%; text-align: left; padding-left: 5.4pt"><span style="-keep: true">Patents</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 4%; text-align: right"><span style="-keep: true">15</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 4%; text-align: right"><span style="-keep: true">1,500,000</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="-keep: true">&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt; background-color: white"><span style="-keep: true">The
                                            fair value estimate for all identifiable intangible assets is preliminary and is based on
                                            assumptions that market participants would use in pricing an asset, based on the most advantageous
                                            market for the asset (i.e., its highest and best use). This preliminary fair value estimate
                                            could include assets that are not intended to be used, may be sold, or are intended to be
                                            used in a manner other than their best use. The useful lives estimate for all identifiable
                                            intangible assets is preliminary and is based on management&#8217;s best estimate of the
                                            distribution of the economic value of the identifiable intangible assets. The final determination
                                            of fair value of intangible assets, as well as estimated useful lives, remains subject to
                                            change. The finalization may have a material impact on the valuation of intangible assets
                                            and the purchase price allocation, which is expected to be finalized subsequent to the acquisition.
                                            No amortization or impairment of goodwill was considered in the unaudited pro forma condensed
                                            combined financial information.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt; background-color: white">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><!-- Field: Page; Sequence: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt; background-color: white"><span style="-keep: true">The
                                            final purchase consideration will be based on the Avalon closing price per share at the closing
                                            date. Accordingly, the purchase consideration and goodwill may change significantly if the
                                            trading price of Avalon&#8217;s common stock fluctuates materially from the May 22, 2025,
                                            value of $3.84 per share.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 20pt; background-color: white">



</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in"><b style="-keep: true">5.</b></td><td style="text-align: justify"><b style="-keep: true">ACCOUNTING POLICY</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon consummation of the Merger, the management
of Avalon and YOOV will perform a comprehensive review of the two entities&#8217; accounting policies. As a result of the review, the
management may identify differences between the accounting policies of the two entities which, when conformed, could have a material impact
on the financial statements of the post-combination company. Based on its initial analysis, the management did not identify any differences
that would have a material impact on the unaudited pro forma condensed combined financial information. As a result, the unaudited pro
forma condensed combined financial information does not assume any differences in accounting policies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in"><b style="-keep: true">6.</b></td><td style="text-align: justify"><b style="-keep: true">PRO FORMA ASSUMPTION AND ADJUSTMENTS</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25IN">The unaudited pro forma condensed combined financial
information has been prepared to illustrate the effect of the Merger and has been prepared for informational purposes only.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following unaudited pro forma condensed combined
financial information has been prepared in accordance with Article 11 of Regulation S-X as amended by the final rule, Release No. 33-10786
&#8220;Amendments to Financial Disclosures about Acquired and Disposed Businesses.&#8221; Release No. 33-10786 replaces the existing pro
forma adjustment criteria with simplified requirements to depict the accounting for the transaction (&#8220;Transaction Accounting Adjustments&#8221;)
and present the reasonably estimable synergies and other transaction effects that have occurred or are reasonably expected to occur (&#8220;Management&#8217;s
Adjustments&#8221;). Avalon and YOOV have elected not to present Management&#8217;s Adjustments and will only be presenting Transaction
Accounting Adjustments in the following unaudited pro forma condensed combined financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: .25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">Avalon and YOOV have not had any historical relationship
prior to the Merger. Accordingly, no transaction accounting adjustments were required to eliminate activities between the companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">All of the transaction
adjustments of the Merger shown in Scenario 1 also apply to Scenario 2, and Scenario 2 includes an additional adjustment to give effect
to differences in the Exchange Ratio between Scenarios 1 and 2.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 102 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Adjustments to Unaudited Pro Forma Condensed Combined Balance
Sheet</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Transaction Accounting Adjustments of Merger</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in"><span style="-keep: true">(1)</span></td><td style="text-align: justify"><span style="-keep: true">Reflects the settlement of approximately
                                            $850,000 of total Avalon&#8217;s estimated transaction costs related to the Merger, which
                                            were reflected as an adjustment to accumulated deficit as of December 31, 2024.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in"><span style="-keep: true">(2)</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Reflects
                                            the settlement of approximately $0.8 million of total YOOV&#8217;s estimated transaction
                                            costs related to the Merger, which were reflected as an adjustment to accumulated deficit
                                            as of December 31, 2024.</span></p></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Reflects
                                            the conversion of YOOV&#8217;s preferred shares from mezzanine equity to permanent equity.</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">(4)</span></td><td style="text-align: justify"><span style="-keep: true">Reflects the Merger adjustments including:</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">(a)</span></td><td style="text-align: justify"><span style="-keep: true">the elimination of the historical accumulated deficit and
other equity balance of Avalon, the accounting acquiree;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">(b)</span></td><td style="text-align: justify"><span style="-keep: true">change of fair value of investment in real estate, intangible
assets and goodwill recognized in the Merger;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">(c)</span></td><td style="text-align: justify"><span style="-keep: true">the purchase consideration of common stock and convertible
preferred stock of Avalon;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">(d)</span></td><td style="text-align: justify"><span style="-keep: true">the contribution of all the share capital in YOOV to Avalon,
and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">(<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</span></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
issuance of 60,000,0000 shares under Scenario 1 and 54,000,0000 shares under Scenario 2, respectively.</span></td>
</tr></table><div>



</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Adjustments to Unaudited Pro Forma Condensed
Combined Statement of Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Pro Forma Adjustment to Avalon</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Reflects
                                            the disposal of Avalon&#8217;s Lab Services MSO in February 2025 as if incurred on January
                                            1, 2023. On February 26, 2025, Avalon and Lab Services MSO entered into a Redemption and
                                            Abandonment Agreement (the &#8220;Redemption Agreement&#8221;), whereby Lab Services MSO
                                            redeemed the 40% equity interest in Lab Services MSO held by Avalon for cash and the surrender
                                            of its Series B Convertible Preferred Stock having a carrying value of $11,000,000. The loss
                                            from equity investment of Lab Services MSO was removed.</span></p></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Transaction Accounting Adjustments of Merger</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in">(2)</td><td style="text-align: justify">Reflects preliminary estimated Avalon and YOOV&#8217;s transaction costs that will be expensed upon the
closing of the Merger. These costs are reflected as if incurred on April 1, 2023, the date the Merger is deemed to have occurred for the
purposes of the unaudited pro forma condensed combined statement of operations. This is a non-recurring item.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in"><span style="-keep: true">(3)</span></td><td style="text-align: justify"><span style="-keep: true">Reflects the amortization of intangible
                                            assets recognized in the Merger assuming the amortization period was 15 years. The useful
                                            lives estimate for all identifiable intangible assets is preliminary and is based on management&#8217;s
                                            best estimate of the distribution of the economic value of the identifiable intangible assets.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in">(4)</td><td style="text-align: justify">Reflects the conversion of YOOV&#8217;s preferred shares from mezzanine equity to permanent equity as
if incurred on April 1, 2023.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in">(5)</td><td style="text-align: justify">The calculation of weighted average shares outstanding for basic and diluted net loss per share assumes
that the Merger as if it had been consummated on April 1, 2023. In addition, as the Merger is being reflected as if it had occurred on
this date, the calculation of weighted average shares outstanding for basic and diluted net loss per share assumes that the shares have
been outstanding for the entire period presented. For the year ended March 31, 2024, this calculation is retroactively adjusted to reflect
a 1-for-15 stock of Avalon&#8217;s outstanding shares of common stock on October 28, 2024.</td></tr></table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 103 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in"><b style="-keep: true">7.</b></td><td style="text-align: justify"><b style="-keep: true">NET LOSS PER SHARE</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Represents the loss per share calculated using the
historical weighted average shares outstanding, and the change in number of shares in connection with the Merger, assuming the shares
were outstanding since the beginning of the earliest period presented in the unaudited pro forma condensed combined statements of operations.
As the Merger and related transactions are being reflected as if they had occurred at the beginning of the period presented, the calculation
of weighted average shares outstanding for basic and diluted loss per share assumes that the shares issuable relating to the Merger have
been outstanding for the entire period presented.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The unaudited pro forma condensed combined statement
of operations and pro forma net loss per share have been prepared assuming: (a) Scenario 1: the closing price of Avalon Common Stock on
Nasdaq less than or equal to $5.00; and (b) Scenario 2: the closing price of Avalon Common Stock on Nasdaq greater than $5.00, for the
year ended March 31, 2024 and for the nine months ended December 31, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the year ended<br/> March 31,
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Assuming Closing<br/> Price less<br/>
    than or<br/> equal to $5.0</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Assuming Closing<br/> Price greater
    than $5.0</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-align: left"><span style="-keep: true">Pro forma net loss attributable to ordinary shareholders</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(8,774,700</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(8,774,700</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">Pro forma weighted average shares calculation - basic and diluted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Avalon&#8217;s ordinary shares</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">701,932</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">701,932</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Shares issued to YOOV&#8217;s shareholders in the Merger</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">60,000,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">54,000,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total weighted average shares outstanding - basic and diluted</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">60,701,932</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">54,701,932</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Pro forma net loss per share - basic and diluted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(0.14</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(0.16</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the nine months ended<br/>
    December 31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Assuming Closing Price less than
    or equal to $5.0</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Assuming Closing Price greater
    than $5.0</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-align: left"><span style="-keep: true">Pro forma net loss attributable to ordinary shareholders</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(5,376,384</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(5,376,384</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">Pro forma weighted average shares calculation - basic and diluted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Avalon&#8217;s ordinary shares</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,138,370</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,138,370</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Shares issued to YOOV&#8217;s shareholders in the Merger</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">60,000,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">54,000,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total weighted average shares outstanding - basic and diluted</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">61,138,370</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">55,138,370</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Pro forma net loss per share - basic and diluted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(0.09</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(0.10</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the year ended March 31, 2024, this calculation
is retroactively adjusted to reflect a 1-for-15 stock of Avalon&#8217;s outstanding shares of common stock on October 28, 2024. Since
the impact of Avalon&#8217;s warrants, convertible preferred shares, convertible notes, and options in the loss per share calculation
results in anti-dilutive, the effect of those instruments was not included in calculation of diluted loss per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 104 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><div><a id="a_038"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">THE SPECIAL MEETING OF AVALON
STOCKHOLDERS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><div><a id="a_039"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The Special Meeting</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon is furnishing this
proxy statement/prospectus to you as part of the solicitation of proxies by its board of directors for use at the Special Meeting, and
at any adjournment or postponement thereof. This proxy statement/prospectus is first being furnished to Avalon&#8217;s stockholders on
or about [<span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;</span>], 2025. This proxy statement/prospectus provides you
with information you need to know to be able to vote or instruct your vote to be cast at the Special Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_040"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Date, Time and Place of the Special Meeting</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Special Meeting will
be held in a virtual meeting format via live webcast only. The Special Meeting of stockholders of Avalon will be held at [&#8195;&#8195;],
Eastern time, on [&#8195;&#8195;], 2025, at [&#8195;&#8195;], or such other date, time and place to which such meeting may be adjourned or
postponed, for the purpose of considering and voting upon the proposals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On the day of the Special
Meeting, if you have properly registered, you may enter the Special Meeting by logging in using the event password you received via email
in your registration confirmation at [&#8195;&#8195;]. You will not be able to attend the Special Meeting in-person.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_041"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Purpose of the Special Meeting</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At the Special Meeting, Avalon
will ask the Avalon stockholders to vote in favor of the following proposals:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The &#8220;Nasdaq Proposal&#8221; - to approve, pursuant to the rules
    of the Nasdaq Stock Market, the issuance of the Merger Shares pursuant to the terms of the Merger Agreement; </span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The &#8220;Reverse Stock Split Proposal&#8221; - to approve an amendment
    to the Avalon Charter to effect a reverse stock split of only the outstanding shares of Avalon Common Stock and other outstanding
    securities of Avalon (with no change to the authorized capital stock of Avalon), at a ratio in the range from 1-for-2 to 1-for-20
    to 1-for-2 to 1-for-20, with such ratio to be determined by the Avalon Board and with such reverse stock split to be effected at
    such time and date as determined by the Avalon Board in its sole discretion, if necessary to be effectuated pursuant to the rules
    of The Nasdaq Capital Market to consummate the Merger; </span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The &#8220;Equity Plan Increase Proposal&#8221; - to approve an amendment
    to the Amended and Restated 2020 Plan to increase the number of shares available for issuance under the Amended and Restated 2020
    Plan by 2,500,000 shares;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">4.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The &#8220;Series C Preferred Stock Proposal&#8221; - to approve, pursuant
    to the rules of the Nasdaq Stock Market, the potential issuance of shares of Avalon Common Stock issuable upon conversion of the
    Avalon Series C Preferred Stock;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">5.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The &#8220;Series D Preferred Stock Proposal&#8221; - to approve, pursuant
    to the rules of the Nasdaq Stock Market, the potential issuance of shares of Avalon Common Stock issuable upon conversion of the
    Avalon Series D Preferred Stock;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">6.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The &#8220;Increase in Authorized Shares Proposal&#8221; - to approve
    an amendment to the Avalon Charter to increase the number of shares of Avalon Common Stock authorized for issuance thereunder from
    100,000,000 to 200,000,000;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">7.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The &#8220;Golden Parachute Proposal&#8221; - to approve on an advisory
    (non-binding) basis, certain compensation payments that will be made by Avalon to its named executive officer in connection with
    the Merger; and</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">8.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The &#8220;Adjournment Proposal&#8221; - to approve the adjournment
    of the Special Meeting in the event that the number of shares of Avalon Common Stock present or represented by proxy at the Special
    Meeting and voting &#8220;FOR&#8221; the adoption of Proposals No. 1 through 7 are insufficient to approve such proposals.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 105 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>


</div><div><a id="a_042"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Recommendation of the Avalon Board of Directors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The Avalon Board believes
that each of the proposals to be presented at the Special Meeting is in the best interests of Avalon and its stockholders and unanimously
recommends that its stockholders vote &#8220;<b>FOR</b>&#8221; each of the proposals as further described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">When you consider the recommendation
of the Avalon Board, you should keep in mind that certain of the Avalon Board and officers have interests in the Merger that are different
from, or in addition to, your interests as a stockholder. These interests include, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Avalon directors and officers beneficially owning approximately 26.1% of the shares of Avalon Common Stock
as of March 7, 2025;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Luisa Ingargiola, currently Avalon&#8217;s Chief Financial Officer, continuing as Chief Financial Officer
of the Combined Company following the Closing;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">Wenzhao
                                            Lu, Lourdes Felix and Steven A. Sanders, currently directors on the Avalon Board, will continue
                                            to serve as directors of the Combined Company following Closing;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Wenzhao Lu holding shares of Avalon Series D Preferred Stock, which shall remain outstanding and survive
the Merger;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Each of Avalon&#8217;s directors and executive officers holding Avalon Stock Options, which shall remain
outstanding and survive the Merger;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">The continued indemnification of current directors and officers of Avalon and the continuation of directors&#8217;
and officers&#8217; liability insurance after the Merger; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">The Key Avalon Stockholders, including Avalon directors and officers, entering into the Avalon Voting
Agreement in connection with the Merger.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_043"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Record Date and Voting</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">You will be entitled to vote
or direct votes to be cast at the Special Meeting if you owned shares of Avalon Common Stock at the close of business on [&#8195;&#8195;],
2025, which is the record date for the Special Meeting. Each share of Avalon Common Stock is entitled to one vote per share. If your shares
are held in &#8220;street name&#8221; or are in a margin or similar account, you should contact your broker, bank or other nominee to
ensure that votes related to the shares you beneficially own are properly counted. On the record date, there were [&#8195;&#8195;] shares
of Avalon Common Stock outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The Key Avalon Stockholders,
including each of Avalon&#8217;s officers and directors, have agreed, pursuant to the Avalon Voting Agreement, to vote all of their shares
of Avalon Common Stock in favor of, among other things, (a) the Nasdaq Proposal, (b) the Reverse Stock Split Proposal and (c) any other
proposals Avalon and YOOV mutually agree is necessary or desirable to consummate the transactions contemplated by the Merger Agreement.
As of March 7, 2025, the Key Avalon Stockholders, including Avalon directors and officers, beneficially owned approximately 26.1% of the
outstanding shares of Avalon Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_044"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Voting Your Shares</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Each share of Avalon Common
Stock that you own in your name entitles you to one vote on each of the proposals for the Special Meeting. Your proxy card shows the number
of shares of Avalon Common Stock that you own.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">If you are a holder of record,
there are different ways to vote your shares at the Special Meeting:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">You can vote by completing, signing and returning the enclosed proxy card in the postage-paid envelope
provided. If you hold your shares in &#8220;street name&#8221; through a bank, broker or other nominee, you will need to follow the instructions
provided to you by your bank, broker or other nominee to ensure that your shares are represented and voted at the Special Meeting. If
you vote by proxy card, your &#8220;proxy,&#8221; whose name is listed on the proxy card, will vote your shares as you instruct on the
proxy card. If you sign and return the proxy card but do not give instructions on how to vote your shares, your shares of Avalon Common
Stock will be voted as recommended by Avalon&#8217;s Board. With respect to proposals for the Special Meeting, that means: &#8220;<b>FOR</b>&#8221;
each of the proposals to be presented at the Special Meeting.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 106 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">You can vote via the Internet by following the instructions on the voting instruction form or proxy card
in your proxy materials.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">You can vote via telephone by following the instructions on the voting instruction form or proxy card
in your proxy materials.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">You can attend the Special Meeting and vote via live website. If you wish to vote your shares electronically
at the Special Meeting, there will be a live link provided during the Special Meeting. You will need the virtual control number assigned
to you in order to vote.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_045"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Who Can Answer Your Questions About Voting Your
Shares</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">If you have any questions
about how to vote or direct a vote in respect of your shares of Avalon Common Stock, you may contact Avalon GloboCare Corp., 400 Route
9 South, Suite 3100, Freehold, NJ&#160;07728, Attn.: Secretary, or by phone at (732)&#160;780-4400.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_046"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Quorum and Vote Required for the Proposals</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">A quorum of Avalon&#8217;s
stockholders is necessary to hold a valid meeting. The holders of at least one-third (1/3) of the voting power of the shares of capital
stock outstanding and entitled to vote at the meeting, as of the record date, present in person, present by remote communication, if applicable,
or represented by proxy, will constitute a quorum for the transaction of business at the Special Meeting. Avalon will include proxies
marked as abstentions and broker non-votes to determine the number of shares present at the Special Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The approval of each of the
Nasdaq Proposal, the Reverse Stock Split Proposal, the Equity Plan Increase Proposal, the Series C Preferred Stock Proposal, Series D
Preferred Stock Proposal, the Increase in Authorized Shares Proposal, the Golden Parachute Proposal (on an advisory (non-binding) basis)
and the Adjournment Proposal requires the affirmative vote of a majority of the total votes properly cast by the Avalon Stockholders at
the Special Meeting. Accordingly, abstentions and broker non-votes, if any, will have no effect on the outcome of the Nasdaq Proposal,
the Reverse Stock Split Proposal, the Equity Plan Increase Proposal, the Series C Preferred Stock Proposal, Series D Preferred Stock Proposal,
the Increase in Authorized Shares Proposal, the Golden Parachute Proposal and the Adjournment Proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">As of the Record Date,
the Key Avalon Stockholders, including Avalon directors and officers, beneficially owned approximately [ ]% of the outstanding shares
of Avalon Common Stock and, pursuant to the Voting Agreements, agreed to vote all of their shares of Avalon Common Stock in favor of
the approval of the Nasdaq Proposal, the Reverse Stock Split Proposal, the Equity Plan Increase Proposal, the Series C Preferred Stock
Proposal, Series D Preferred Stock Proposal, the Increase in Authorized Shares Proposal, the Golden Parachute Proposal (on an advisory
(non-binding) basis) and the Adjournment Proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_047"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Abstentions and Broker Non-Votes&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If your shares of Avalon
Common Stock are held by your broker as your nominee, that is, in &#8220;street name,&#8221; the enclosed voting instruction card is sent
by the institution that holds your shares. Please follow the instructions included on that proxy card regarding how to instruct your broker
to vote your shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If you do not give instructions
to your broker, the question of whether your broker or nominee will still be able to vote your shares depends on whether the NYSE deems
the particular proposal to be a &#8220;routine&#8221; matter and how your broker or nominee exercises any discretion they may have in
the voting of the shares that you beneficially own. Brokers and nominees can use their discretion to vote &#8220;uninstructed&#8221; shares
with respect to matters that are considered to be &#8220;routine,&#8221; but not with respect to &#8220;non-routine&#8221; matters. Under
the rules and interpretations of the NYSE, &#8220;non-routine&#8221; matters are matters that may substantially affect the rights or privileges
of stockholder, such as mergers, stockholder proposals, elections of directors (even if not contested), executive compensation (including
any advisory stockholder votes on executive compensation and on the frequency of stockholder votes on executive compensation), and certain
corporate governance proposals, even if management-supported.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><b>&#160;</b></p><div>

</div><!-- Field: Page; Sequence: 107 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For any proposal that is
considered a &#8220;routine&#8221; matter, your broker or nominee may vote your shares in its discretion either for or against the proposal
even in the absence of your instruction. For any proposal that is considered a &#8220;non-routine&#8221; matter for which you do not give
your broker instructions, the shares will be treated as broker non-votes. &#8220;Broker non-votes&#8221; occur when a beneficial owner
of shares held in street name does not give instructions to the broker or nominee holding the shares as to how to vote on matters deemed
&#8220;non-routine.&#8221; Broker non-votes will not be considered to be shares &#8220;entitled to vote&#8221; at the meeting and will
not be counted as having been voted on the applicable proposal. Therefore, if you are a beneficial owner and want to ensure that shares
you beneficially own are voted in favor or against any or all of the proposals to be presented at the Special Meeting, the only way you
can do so is to give your broker or nominee specific instructions as to how the shares are to be voted.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_048"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Revocability of Proxies</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If you have submitted a proxy
to vote your shares and wish to change your vote, you may do so by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">filing with Avalon&#8217;s Secretary, a letter revoking the proxy;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">submitting another signed proxy with a later date; or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">attending the Special Meeting and voting online, provided you file a written revocation with the Secretary
of the Special Meeting prior to the voting of such proxy.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_049"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Appraisal or Dissenters&#8217; Rights</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No appraisal or dissenters&#8217;
rights are available to holders of shares of Avalon Common Stock in connection with the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_050"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Solicitation of Proxies</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon will pay the cost
of soliciting proxies for the Special Meeting. Avalon also will reimburse banks, brokers and other custodians, nominees and fiduciaries
representing beneficial owners of shares of Avalon Common Stock for their expenses in forwarding soliciting materials to beneficial owners
of Avalon Common Stock and in obtaining voting instructions from those owners. Avalon&#8217;s directors, officer and employees may also
solicit proxies by telephone, by facsimile, by mail, on the Internet or in person. They will not be paid any additional amounts for soliciting
proxies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 108 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_051"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">THE MERGER</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><div><a id="a_052"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The Background of the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>The following chronology is a summary description
of the background of the negotiations and the proposed merger and does not purport to catalogue every conversation among representatives
of Avalon, YOOV and other parties. In addition to formal meetings of the Avalon Board, Avalon management had informal discussions with
the Avalon Board throughout the process and Avalon management held weekly calls with advisors, and ultimately with YOOV and its advisors.
The terms of the Merger Agreement are the result of extensive&#160;arm&#8217;s-length&#160;negotiations among Avalon&#8217;s and YOOV&#8217;s
management and members of the Avalon Board and the YOOV Board, along with Avalon&#8217;s and YOOV&#8217;s respective financial advisors
and legal counsel.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the ordinary course of
business, the Avalon Board, with the assistance of senior management and advisors, regularly reviewed the near-term and long-term strategy,
performance, positioning, and operating prospects of Avalon with a view toward maximizing stockholder value. These reviews included, from
time to time, discussions as to&#160;&#160;financing opportunities, possible acquisitions to expand the Avalon business, a possible business
combination with a third party or a possible sale of Avalon to a third party, and whether ultimately any of these opportunities could
offer the best opportunity to maximize stockholder value, as well as a review of the relative potential benefits and risks associated
with each such course of action.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November 3, 2023, the Nasdaq
staff notified Avalon that Avalon did not comply with the Minimum Bid Price Requirement for continued listing on The Nasdaq Capital Market
as set forth in Nasdaq Listing Rule 5550(a)(2) (the &#8220;Bid Price Notice&#8221;). Pursuant to the Bid Price Notice, Avalon had 180
calendar days from the date of the Bid Price Notice, or May 1, 2024, to regain compliance with the Minimum Bid Price Requirement. On May
2, 2024, Avalon received a letter from Nasdaq advising that Avalon had been granted a 180-day extension to October 28, 2024, to regain
compliance with the Minimum Bid Price Requirement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In September 2024, initial
outreach was conducted informally by Avalon&#8217;s Chief Financial Officer, Luisa Ingargiola, who reached out or was introduced to several&#160;merger
candidates, including YOOV.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During October 2024, management
of Avalon considered five (5) potential strategic candidates, including YOOV, a technology company (&#8220;Party A&#8221;), and a healthcare
solutions company (&#8220;Party B&#8221;) and three additional candidates that were likely not good merger candidates as a result of their
business profile, including a foreign gambling company and a foreign fuel company with limited revenues. The chief executive officer of
Party B is a member of the Avalon Board and Ms. Ingargiola is a member of Party B&#8217;s board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On October 25, 2024, in connection
with regaining compliance with the Minimum Bid Price Requirement, Avalon implemented a reverse stock split. However, on October 29, 2024,&#160;Avalon
received notice from the Nasdaq staff that it failed to regain compliance with the Minimum Bid Price Requirement because the reverse stock
split did not occur at least ten (10) business days prior to the deadline of on or before October 28, 2024, which served as basis for
the delisting of Avalon&#8217;s securities from Nasdaq.&#160;Following the receipt of the Nasdaq notice, Avalon requested and received
a hearing date to discuss the non-compliance notice with the Nasdaq staff.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On October 31, 2024, Ms.
Ingargiola and Meng Li, Avalon&#8217;s Chief Operating Officer, received a formal presentation from Wong Ling Yan Philip (&#8220;Phil
Wong&#8221;), YOOV&#8217;s Chief Executive Officer, and a representative from YOOV&#8217;s legal counsel, Lucosky Brookman LLP (&#8220;Lucosky&#8221;).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November 1, 2024, Ms. Ingargiola
received a formal business presentation from Party A&#8217;s Chief Executive Officer and discussed a potential transaction and on the
same day, Ms. Ingargiola held discussions with Party B&#8217;s Chief Executive Officer regarding a potential transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November 7, 2024, Mr. Wong
and YOOV representatives gave a presentation via Zoom to Avalon&#8217;s Chairman Wenzhao Lu and Ms. Li.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November&#160;12, 2024,
Avalon announced third quarter financial results, including cash and cash equivalents of approximately $1.0 million at September&#160;30,
2024. In addition to reiterating a substantial doubt about Avalon&#8217;s ability to continue as a going concern and the need for significant
additional capital to fund&#160;operations, Avalon also stated that if it is unable to obtain additional financing, it would be required
to cease operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 109 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November 19, 2024, Avalon
received a notice that it had regained compliance with Nasdaq&#8217;s Minimum Bid Price Requirement, as set forth in Nasdaq Listing Rule
5550(a)(2).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November 19, 2024, Avalon
received a draft term sheet from YOOV, which contemplated a reverse triangular merger whereby Avalon would issue to YOOV shareholders
58.8 million shares of Avalon common stock in the merger. The proposed transaction would be subject to certain conditions, including the
sale of certain assets of Avalon, the payoff of certain indebtedness of Avalon, the exchange of certain shares of preferred stock held
by Mr. Lu for a new series of preferred stock and the receipt by Avalon of financing in the amount of at least $3.5 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">From November 19, 2024 to
November 27, 2024, Ms. Ingargiola had discussions with management and Avalon&#8217;s legal counsel, Lowenstein Sandler LLP (&#8220;Lowenstein&#8221;),
regarding the terms of the term sheet and during such period, the parties negotiated and exchanged drafts of a non-binding letter of intent.
Avalon did not receive any term sheets or letters of intent with respect to Party A or Party B.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November 25, 2024, the
Avalon Board held a meeting and Ms. Ingargiola provided the Avalon Board with an overview of the business, financial position and potential
opportunities with respect to YOOV, Party A and Party B. In addition, Ms. Ingargiola reviewed the draft of the YOOV non-binding letter
of intent (a copy of which was previously delivered to the Avalon Board), with the Avalon Board. The Avalon Board then discussed the YOOV
non-binding letter of intent and the potential opportunities with YOOV, Party A and Party B and based on the business, growth potential,
unique business model, global customer reach and proprietary technology of YOOV, the Avalon Board authorized Avalon management to continue
negotiations with YOOV and to execute the non-binding letter of intent with YOOV.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On November 27, 2024, Avalon
and YOOV executed the non-binding letter of intent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 3, 2024, Avalon
engaged Roth Capital Partners, LLC (&#8220;Roth&#8221;) to provide a fairness opinion and to act as its financial advisor pursuant to
an engagement letter dated December 3, 2024, as amended on February 21, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 6, 2024, the Avalon
Board held a meeting to discuss the status of the proposed transaction with YOOV, including the timing to complete such potential transaction,
a proposed extension of Avalon&#8217;s outstanding convertible notes and the terms of a potential financing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 10, 2024, Avalon
and YOOV entered into a confidential disclosure agreement, as the parties were ready at such time to start to provide one another non-public
information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 15, 2024, Avalon
and the holder of Avalon&#8217;s outstanding convertible note in the principal amount of $2.8 million entered into an a consent and waiver
agreement pursuant to which the holder waived all amortization payments required to be made under the note, Avalon paid a waiver fee of
$150,000 to the holder and Avalon issued to the holder a common stock purchase warrant for the purchase of up to 150,000 shares of Avalon
common stock at an exercise price of $0.01 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 16, 2024, Avalon
engaged Koo, Li and Partners LLP (&#8220;Koo, Li&#8221;), as special counsel to conduct legal due diligence of YOOV and advise Avalon
with respect to matters concerning Hong Kong corporate law. In connection with Avalon&#8217;s review of the potential transaction with
YOOV, Avalon and its advisors, including Koo, Li, completed customary diligence, including, meetings with the management of YOOV, presentations
by the YOOV management team to the Avalon Board, customary legal review of YOOV business and contracts, and customary financial diligence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 19, 2024, Avalon
entered into that certain securities purchase agreement (the &#8220;Series C SPA&#8221;), with an accredited investor, pursuant to which
Avalon agreed to issue and sell, upon the terms and conditions set forth in the Series C SPA, up to 7,000 shares of Avalon Series C Preferred
Stock for up to an aggregate of $7,000,000. The first closing occurred on December 24, 2024, with respect to the purchase of 3,500 shares
of Series C Convertible Preferred Stock in exchange for $3,500,000. Pursuant to the Series C SPA, the investor had the right to invest
an additional $3.5 million within 120 days of the first closing. The investor did not exercise the option.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 3, 2025, Lowenstein
received an initial draft of the Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) from Lucosky.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 110 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 9, 2025, Avalon
entered into an exchange agreement with Mr. Lu pursuant to which he exchanged 9,000 shares of Avalon&#8217;s Series A Convertible Preferred
Stock (the &#8220;Series A Preferred Stock&#8221;) for 5,000 shares of Avalon Series D Preferred Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 14, 2025, Lowenstein
circulated an initial markup of the Merger Agreement to Lucosky.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 15, 2025, Ms. Ingargiola,
representatives from Lowenstein, representatives from YOOV and representatives from Lucosky met via video conference to discuss the transaction
generally, including the expected timing of the transaction, the revised draft of the Merger Agreement and the preparation of the Form
S-4 in connection with the proposed transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with Avalon&#8217;s
ongoing diligence process, on January 18, 2025, Ms. Ingargiola, Ms. Li and Mr. Lu, visited the YOOV Hong Kong office in person to meet
with YOOV management, including Mr. Phil Wong, Lai Kam Fu, the YOOV Chief Financial Officer, and Wong Ho Chi Mark (&#8220;Mark Wong&#8221;),
the Chief Technology Officer, as well as other YOOV employees. In addition, a member of Koo, Li, attended a portion of the meeting in
person.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 22, 2025, representatives
from Lowenstein held a video conference with representatives from Lucosky, together with representatives from Donohoe Advisory Associates
LLC for a discussion on possible structure, including potential Nasdaq considerations with respect to the continued listing of Avalon
and the issuance of the Merger Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 23, 2025, representatives
from Lowenstein held a video conference with representatives from Lucosky to further discuss open diligence items, the structure of the
transaction and the terms of the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 30, 2025, Mr.
Phil Wong, Mr. Lai, Mr. Mark Wong and Leung Hang Kin Karl, the Product Director of YOOV, held an introductory video conference call, during
which Mr. Phil Wong provided a corporate presentation of YOOV for the Avalon Board and executive officers and responded to questions from
the Avalon Board and executive officers. After the presentation, the YOOV representatives left the call, and the Avalon Board discussed
the potential transaction with representatives from Lowenstein.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 10, 2025, Lucosky
circulated a revised draft of the Merger Agreement to Lowenstein, and initial drafts of the Avalon Voting Agreement, YOOV Voting Agreement
and Lock-Up Agreement. Thereafter and continuing until the Merger Agreement was executed, the parties and their counsel negotiated the
terms of the Merger Agreement. Key terms of the Merger Agreement negotiated between the parties included (i) the circumstances in which
a termination fee would be payable by Avalon, (ii) whether YOOV should also pay a termination fee in certain circumstances, (iii) the
treatment of Avalon Stock Options under the Merger Agreement, (iv) the tail period for the directors and officers liability insurance
and (v) the terms of the Exchange Ratio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 18, 2025, Lowenstein
circulated the first draft of the Avalon Disclosure Schedules to Lucosky.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 20, 2025, Lowenstein
circulated revised drafts of the Avalon Voting Agreement and YOOV Voting Agreement to Lucosky, and Lucosky circulated a first draft of
the YOOV Disclosure Schedules (together with the Avalon Disclosure Schedules, the &#8220;Disclosure Schedules&#8221;). Key terms of the
Avalon Voting Agreement and YOOV Voting Agreement negotiated between the parties included (i) the circumstances in which the applicable
voting agreement would terminate&#894; and (ii) the restrictions on the ability of each stockholder party to the applicable voting agreement
to transfer such party&#8217;s shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 21, 2025, Ms.
Ingargiola, representatives from Lowenstein and representatives from Roth had a video conference call to discuss the contemplated exchange
ratio in the Merger Agreement. Roth advised that given the market volatility of Avalon Common Stock, it was for the benefit of Avalon
stockholders for Avalon to revise the exchange ratio by implementing a &#8220;collar&#8221; on the value of the stock consideration that
YOOV shareholders would receive.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February&#160;24,&#160;2025,
Mr. Phil Wong and representatives from Lucosky met in person with Ms. Ingargiola and representatives from Lowenstein to discuss the merger,
diligence matters and any possible challenges to executing such a merger, including the terms of the Exchange Ratio. The parties discussed
implementing a &#8220;collar&#8221; on the value of the stock consideration that YOOV shareholders would receive.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 27, 2025, the
Avalon Board met via video conference to discuss the current draft of the Merger Agreement. Representatives from Lowenstein and Ms. Ingargiola
provided the Avalon Board with an overview of the draft Merger Agreement and the open business items that were being negotiated, including
the tail period for the directors&#8217; and officers&#8217; liability insurance, the terms of the Exchange Raio and the circumstances
in which Avalon would be required to pay a termination fee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 111 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March 3, 2025, representatives
from Lowenstein and Lucosky meet via video conference to discuss the Exchange Ratio and agreed that if the closing price of the Avalon
Common Stock on NASDAQ on the second trading day before the closing of the merger is (x) less than or equal to $5.00 then the Exchange
Ratio shall be 60,000,000 divided by the YOOV Outstanding Shares or (y) greater than 5.000, the Exchange Ratio shall be 54,000,000 divided
by the YOOV Outstanding Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Between March 3, 2025 and
March 7, 2025, Lowenstein and Lucosky finalized the Merger Agreement, the Avalon Voting Agreement, the YOOV Voting Agreement, the&#160;Lock-Up&#160;Agreement
and the Disclosure Schedules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March 6, 2025, Ms. Ingargiola
circulated an updated draft of the Merger Agreement, the Avalon Voting Agreement, YOOV Voting Agreement, the&#160;Lock-Up&#160;Agreement
and the Disclosure Schedules to the Avalon Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March 7, 2025, the Avalon
Board held a meeting via video conference, with Ms. Ingargiola, as well as representatives of Lowenstein and Roth participating. Representatives
from Lowenstein provided an overview of the negotiations that had transpired related to the Merger Agreement, the Avalon Voting Agreement,
the YOOV Voting Agreement, the Lockup Agreement and the Disclosure Schedules. Representatives from Lowenstein then provided the Avalon
Board with an overview of fiduciary duties under Delaware law. Thereafter, at the request of the Avalon Board, Roth rendered its oral
opinion to the Avalon Board (which was subsequently confirmed in writing by delivery of Roth&#8217;s written opinion addressed to the
Avalon Board dated of the same date) as to the fairness, as of March 7, 2025, and subject to the various assumptions, qualifications
and limitations as set forth in its written opinion, from a financial point of view, the Exchange Ratio was fair to Avalon. After considering
the foregoing, and taking into consideration the factors described under &#8220;<i>The Merger - Avalon&#8217;s Reasons for the Merger</i>&#8221;
beginning on page 91 of this proxy statement/prospectus, the Avalon Board unanimously (i) determined that the Merger Agreement and the
transactions contemplated by the Merger Agreement, on the terms and subject to the conditions set forth in the Merger Agreement, are
fair to and in the best interests of Avalon and its stockholders, (ii) adopted, approved and declared it advisable that Avalon enter
the Merger Agreement, the Avalon Voting Agreement, the YOOV Voting Agreement and the Lock-Up Agreement, including the issuance of the
Merger Shares, and consummate the Merger and the transactions contemplated by the Merger Agreement in accordance with the BVI Companies
Act, and (iii) recommended that the Avalon stockholders approve (a) the issuance of the Merger Shares, (b) the Reverse Stock Split Proposal
and (c) any other proposals Avalon and YOOV mutually agree is necessary or desirable to consummate the transactions contemplated by the
Merger Agreement. Accordingly, the Avalon Board unanimously authorized and approved the issuance of the Merger Shares and the entry into
the Merger Agreement, the Avalon Voting Agreement, the YOOV Voting Agreement and the Lock-Up Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March 7, 2025, following
the meeting of the Avalon Board, Avalon, YOOV, and Merger Sub executed the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On the morning of March 10,
2025, prior to the market open on Nasdaq, Avalon issued a press release announcing entry into the Merger Agreement and filed a Form 8-K
with the SEC disclosing, among other things, the Merger Agreement, the Avalon Voting Agreement, the YOOV Voting Agreement and the Lock-Up
Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_053"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Avalon&#8217;s Reasons for the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Avalon Board unanimously
(i)&#160;determined that the Merger Agreement and the transactions contemplated by the Merger Agreement, on the terms and subject to the
conditions set forth in the Merger Agreement, are fair to and in the best interests of Avalon and its stockholders, (ii)&#160;adopted,
approved and declared it advisable that Avalon enter the Merger Agreement, the Avalon Voting Agreement, the YOOV Voting Agreement and
the Lock-Up Agreement, including the issuance of the Merger Shares, and consummate the Merger and the transactions contemplated by the
Merger Agreement in accordance with the BVI Companies Act, and (iii)&#160;recommended that the Avalon stockholders approve (a) the issuance
of the Merger Shares, (b) the Reverse Stock Split Proposal and (c) any other proposals Avalon and YOOV mutually agree is necessary or
desirable to consummate the transactions contemplated by the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 112 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Reasons for Recommendation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the course of reaching
its recommendation, the Avalon Board considered the following material factors relating to the Merger Agreement and the Merger, each of
which the Avalon Board believes supported its decision:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the strategic and transformative nature of the Merger considering YOOV&#8217;s proprietary AI technology;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the fact that the Combined Company is expected to have greater financial resources and flexibility to
create sustainable long-term growth;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the YOOV global customer reach which will allow greater revenue growth;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the YOOV historical revenue growth, indicating a potentially relevant product offering in comparison to
competitors;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the YOOV positive net income for 2024, demonstrating that the company will not need much cash to operate;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the alternatives reasonably available to Avalon, including remaining a standalone company or pursuing
other strategic alternatives, which the Avalon Board evaluated with the assistance of its financial and legal advisors, and the Avalon
Board&#8217; belief that the Merger created the best reasonably available opportunity to maximize value for Avalon stockholders given
the potential risks, rewards and uncertainties associated with other potential alternatives;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">if the Merger is not completed, Avalon may not have sufficient capital to continue to operate its business
in the short term and may become insolvent and be required to seek dissolution or the protection of the bankruptcy courts and, without
additional funding or a strategic transaction, would likely be delisted from Nasdaq;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the availability of capital from investors and the fact that as a one asset company and given the current
capital markets environment, accessing sufficient equity financing on attractive terms or at all would be difficult as a standalone company;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the fact that, because Avalon stockholders are expected to own approximately 2.7% to 3.0% of the Combined
Company, Avalon stockholders would continue to participate in the future performance of the Combined Company;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the historical market prices, volatility and trading information of Avalon Common Stock;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the fact that the Exchange Ratio was achieved through of a series of arms&#8217; length negotiations between
the parties;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the recommendation of Avalon&#8217;s management in favor of the Merger;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the fact that the Combined Company will be led by a board of directors comprised of five (5) directors
designated by YOOV and two (2) directors nominated by Avalon;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the terms and conditions of the Merger Agreement, including the commitments by Avalon and YOOV to complete
the Merger and the transactions contemplated thereby;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the Avalon Board&#8217; belief that, while the consummation of the Merger is subject to various approvals,
such approvals were likely to be obtained without a material adverse impact on the respective businesses of Avalon and YOOV;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the fact that the Merger Agreement does not preclude Avalon from responding to and negotiating certain
Takeover Proposals for Avalon from Third Parties made prior to the applicable approvals of the Avalon stockholders, should Avalon receive
a Superior Proposal;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the fact that the terms of the Merger Agreement provide that, prior to the applicable approvals of the
Avalon stockholders, the Avalon Board is permitted to change the Avalon Board Recommendation in response to a Superior Proposal or Intervening
Event that occur after the date of the Merger Agreement, subject to compliance with the terms and conditions of the Merger Agreement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 113 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the fact that the potential fluctuations in the Exchange Ratio under the Merger Agreement are fixed, but
will be subject to adjustment on a pro rata basis to account for the Reverse Stock Split, creating certainty as to the number of shares
of Avalon Common Stock to be issued;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the
                                            opinion of Roth, rendered orally on March 7, 2025 and subsequently confirmed in writing,
                                            to the Avalon Board that, as of that date and based upon and subject to certain assumptions,
                                            factors and qualifications set forth in the written opinion, the Exchange Ratio was fair,
                                            from a financial point of view, to Avalon, as more fully described below (please see the
                                            section entitled &#8220;<i>The Merger-Opinion of Avalon&#8217;s Financial Advisor</i>&#8221;);</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the
                                            course and history of competitive negotiations between Avalon and YOOV, as described in &#8220;<i>The
                                            Merger-Background of the Merger</i>&#8221; beginning on page 88 of this proxy statement/prospectus
                                            and the Avalon Board&#8217;s belief that it had obtained YOOV&#8217;s best and final offer;
                                            and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the Avalon Board&#8217;s view, after consultation with Avalon&#8217;s management and financial advisors,
that a strategic combination with YOOV was Avalon&#8217;s best available strategic alternative.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Avalon Board considered
these advantages and opportunities against a number of other factors identified in its deliberations weighing negatively against the Merger,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the difficulties of combining the businesses of Avalon and YOOV based on, among other things, the different
geographical locations and complexities of the two companies, and potential disruption associated with the transactions and integrating
the companies;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the challenges inherent in the management and operation of the Combined Company, including the risk that
integration costs may be greater than anticipated and may require greater than anticipated management attention and focus post-Closing;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the possibility that the consummation of the Merger might not occur, or might be delayed, despite the
companies&#8217; efforts, including by reason of a failure to obtain the approval of either the Avalon stockholders or the YOOV shareholders
or a failure of the parties to obtain the applicable approvals;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the risks and costs to Avalon in connection with the Merger (including if the Merger is not completed),
either during the pendency of the Merger or following the Closing, including the risks and costs associated with the potential diversion
of management and employee attention, potential employee attrition and the potential effect on business, operations and financial results;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the potential that the fixed Exchange Ratio with respect to the Merger Consideration could result in Avalon
delivering greater value to YOOV shareholders than had been anticipated by Avalon should the value of shares of Avalon Common Stock increase
disproportionately from the date of the Merger Agreement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the possibility that the anticipated benefits of the Merger may not be realized, including the commercial
or market opportunity of the YOOV business;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the restrictions in the Merger Agreement on Avalon&#8217;s ability to take certain actions outside the
ordinary course of business prior to the consummation of the Merger, which may delay or prevent Avalon from undertaking certain actions
or business opportunities that may arise prior to the consummation of the Merger;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the fact that under the terms of the Merger Agreement, Avalon is restrained from soliciting other Takeover
Proposals during the pendency of the Merger, except in certain circumstances;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the
                                            fact Avalon may be required to pay YOOV a termination fee of $1,000,000 if Avalon fails to
                                            consummate the Merger under specified circumstances (please see the section entitled &#8220;<i>The
                                            Merger Agreement-Termination and Termination Fee</i>&#8221;), and the effect this could have
                                            on Avalon, though the Avalon Board believed the termination fee was reasonable in amount;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the fact that regardless of whether the Avalon Board makes an Adverse Recommendation Change in response
to an Intervening Event that occur after the date of the Merger Agreement, Avalon may not terminate the Merger Agreement for this reasons
and may still be compelled to hold the Special Meeting and seek approvals of the proposals included herein;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 114 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the fact that, assuming the consummation of the Merger, the dilution to Avalon stockholders as stockholders
of the Combined Company due to the issuance of the Merger Shares to be issued in connection with the Merger;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the
                                            fact that the executive officers and directors of Avalon have interests in the Merger that
                                            may be different from, or in addition to, the interests of Avalon stockholders (please see
                                            the section entitled &#8220;<i>The Merger-Interests of Avalon&#8217;s Directors and Officers
                                            in the Merger</i>&#8221;); and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">various other risks associated with the Merger and the businesses of Avalon, YOOV and the Combined Company
described in the section entitled &#8220;<i>Risk Factors</i>.&#8221;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 10pt">The
foregoing discussion of the factors considered by the Avalon Board is not intended to be exhaustive, but rather includes the principal
factors considered by the Avalon Board in reaching its conclusion and recommendation in relation to the Merger and the Avalon Proposals
included herein. In view of the wide variety of factors considered in connection with its evaluation of the Merger and the complexity
of these matters, the Avalon Board did not find it useful and did not attempt to quantify or assign any relative or specific weights to
the various factors that it considered in reaching its determination to approve the Merger Agreement and to make its recommendations to
Avalon&#8217;s stockholders. In addition, individual members of the Avalon Board may have given differing weights to different factors.
The Avalon Board conducted an overall review of the factors described above, including thorough discussions with Avalon&#8217;s management
and outside legal and financial advisors. In considering the recommendation of the Avalon Board, Avalon&#8217;s stockholders should be
aware that Avalon&#8217;s directors may have interests in the Merger that are different from, or in addition to, those of the Avalon stockholders
generally. Please see the section entitled &#8220;<i>Interests of Avalon Directors and Executive Officer in the Merger</i>.</span>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_054"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">YOOV&#8217;s Reasons for the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The YOOV Board believes that
the merger between Avalon and YOOV would position YOOV within a diversified business framework, enhancing its long-term growth potential
by leveraging combined resources and expertise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additional factors the YOOV
Board considered included the following (which factors are not necessarily presented in any order of relative importance):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">YOOV&#8217;s shareholders will have the opportunity to participate in the growth of a publicly traded
company, benefiting from the expanded market presence and operational efficiencies that the integration is expected to deliver;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the Merger will potentially expand the access to capital and the range of investors available as a public
company to support the development of YOOV&#8217;s products and the expansion of its operations, compared to the capital and investors
YOOV could otherwise gain access to if it continued to operate as a privately-held company;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td>the potential benefits from increased public market awareness of YOOV and its AIaaS platform and other products and services;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the historical and current information concerning YOOV&#8217;s business, including its financial performance
and condition, operations and management;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the YOOV Board&#8217;s belief that no alternatives to the Merger were reasonably likely to create greater
value for YOOV shareholders, after considering the various financing and other strategic options to enhance shareholder value that were
considered by the YOOV Board;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the YOOV Board&#8217;s expectation that the Merger would be a higher probability and more cost-effective
means to access capital than other options considered, including an initial public offering;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the expected operations, management structure and operating plans of the Combined Company;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the business, history, operations, financial resources, assets, technology and credibility of Avalon;
and</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the terms and conditions of the Merger Agreement.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><!-- Field: Page; Sequence: 115 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_055"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Interests of Avalon&#8217;s Directors and Officer
in the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In considering the recommendation
of the Avalon Board with respect to issuing shares of Avalon Common Stock as contemplated by the Merger Agreement and the other matters
to be acted upon by Avalon stockholders at the Special Meeting, Avalon stockholders should be aware that Avalon&#8217;s directors and
officers have interests in the Merger that may be different from, or in addition to, the interests of Avalon stockholders. These interests
relate to or arise from the matters described below. Avalon&#8217;s directors are aware of these potential conflicts of interest and considered
them, among other matters, in reaching its decision to approve the Merger Agreement and the transactions contemplated thereby, and to
recommend, that Avalon stockholders approve the proposals to be presented to Avalon stockholders for consideration at the Special Meeting
as contemplated by this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_056"></a></div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Continued Service</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As described elsewhere in
this proxy statement/prospectus, Luisa Ingargiola, currently Avalon&#8217;s Chief Financial Officer, is expected to be Chief Financial
Officer of the Combined Company following the Closing, and Wenzhao Lu, the current Chairman of the Avalon Board, and Steven A. Sanders,
a current director of Avalon, will continue to serve as directors of the Combined Company following Closing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Treatment of Avalon Series D Preferred Stock
</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At the Effective Time, each
then-outstanding share of Avalon Series D Preferred Stock shall remain outstanding and survive the Merger. Wenzhao Lu, the holder of the
Avalon Series D Preferred Stock, is the Chairman of the Avalon Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Treatment of Avalon Stock Options</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each of Avalon&#8217;s directors
and executive officers holds Avalon Stock Options. At the Effective Time, each then-outstanding Avalon Stock Option, whether vested or
unvested, shall remain outstanding and survive the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_057"></a></div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Stock Ownership and Voting Agreements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of March 7, 2025, Avalon
directors and executive officer beneficially owned approximately 26.1% of the shares of Avalon Common Stock. Key Avalon Stockholders,
including the Avalon directors and executive officers have entered into the Avalon Voting Agreement in connection with the Merger. For
a more detailed discussion of the Avalon Voting Agreement, please see the section entitled &#8220;<i>Certain Agreements Related to the
Merger-Voting Agreements</i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_058"></a></div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indemnification and Insurance</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As described in this proxy
statement/prospectus, including in the section entitled &#8220;<i>Management After The Merger-Limitation on Liability and Indemnification
of Directors and Officers</i>,&#8221; certain of Avalon&#8217;s directors and officers will be entitled to certain ongoing rights of
indemnification and coverage under directors&#8217; and officers&#8217; liability insurance policies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Avalon Board was aware
of these interests and considered them, among other matters, in its decision to approve the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_059"></a></div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Golden Parachute Compensation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This section sets forth the
information required by Item 402(t) of Regulation S-K, which requires disclosure of information regarding compensation that is based on
or otherwise relates to the Merger for each of Avalon&#8217;s &#8220;named executive officers&#8221; whose compensation was disclosed
in the Annual Report on Form 10-K filed by Avalon on March 31, 2025. This compensation is referred to as &#8220;golden parachute&#8221;
compensation by the applicable SEC disclosure rules, and is subject to a non-binding advisory vote of the shareholders of Avalon. Luisa
Ingargiola, Avalon&#8217;s Chief Financial Officer, may be entitled to such types of compensation. David Jin, Avalon&#8217;s Chief Executive
Officer, and Meng Li, Avalon&#8217;s Chief Operating Officer, are not entitled to any compensation in connection with the Merger that
could be considered &#8220;golden parachute&#8221; compensation, so they are excluded from the discussion below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 116 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Ms. Ingargiola expects to
enter into an Executive Retention Agreement with the Combined Company, effective upon and subject to the Closing (the &#8220;Combined
Company Executive Retention Agreement&#8221;), which will supersede and replace Ms. Ingargiola&#8217;s current Executive Retention Agreement
(as amended, the &#8220;Ingargiola Executive Retention Agreement&#8221;), each as described in the section of this Form S-4 titled &#8220;<i>Avalon&#8217;s
Executive Compensation</i>.&#8221; The Combined Company Executive Retention Agreement will provide alternative compensation payable in
connection with the Merger in lieu of the compensation payable under the Ingargiola Executive Retention Agreement, as reflected in the
table below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">The amounts set forth in
the table below, which represent an estimate of Ms. Ingargiola&#8217;s golden parachute compensation as of June 6, 2025, calculated in
accordance with the SEC&#8217;s rules on disclosing golden parachute compensation, assume the following:</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">The Closing of the Merger constitutes a Change in Control (as defined in the Combined Company Executive
Retention Agreement) for purpose of the Combined Company Executive Retention Agreement;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">The Closing occurs on June 6, 2025, the latest practicable date prior to
the filing of this Form S-4 and hypothetical closing date used solely for purposes of estimating the value of these payments (the &#8220;Assumed
Date&#8221;);</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">The value per share of the Avalon Common Stock on the Assumed Date is $3.41
(the &#8220;Assumed Avalon Common Stock Price&#8221;);</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Ms. Ingargiola&#8217;s employment with Avalon is terminated without &#8220;Cause&#8221; or with &#8220;Good
Reason&#8221; (as each is defined in the Combined Company Executive Retention Agreement) on the Assumed Date immediately following the
Closing; and</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Ms. Ingargiola has complied with all requirements necessary in order to receive all payments and benefits.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Cash<br/>
 ($)(1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity ($)(2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Perquisites/<br/> Benefits<br/>
 ($)(3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other ($)(4)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/>
 ($)(5)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 65%; text-align: justify">Luisa Ingargiola</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">350,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">23,534</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">350,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">723,534</td><td style="width: 1%; text-align: left">(6)</td></tr>
  </table><div>



</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><!-- Field: Rule-Page --><!-- Field: /Rule-Page --><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Represents the cumulative severance payable pursuant to the Combined Company Executive Retention Agreement. The severance amount in this column is conditioned upon a termination without Cause or a resignation for Good Reason (as each is defined in the Combined Company Executive Retention Agreement).&#160;&#160;The amounts included in this column reflect payments of an amount equal to one year&#8217;s current base salary for Ms. Ingargiola ($350,000) plus an amount equal to her target bonus for the fiscal year in which her termination occurs ($0 for the fiscal year ending December 31, 2025) prorated for the full number of months during such year through the Assumed Date ($0). The severance benefits are contingent upon Ms. Ingargiola complying with the non-compete, non-solicitation, and confidentiality provisions set forth in the Combined Company Executive Retention Agreement. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">(2)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Under the Combined Company Executive Retention Agreement, all outstanding stock option and other stock awards granted to Ms. Ingargiola vest in the event of her involuntary termination without Cause or resignation for Good Reason (as such terms are defined in the Combined Company Executive Retention Agreement). &#160;The amounts shown in this column represent the excess of the Assumed Avalon Common Stock Price over the respective exercises prices of stock options that would become vested upon the Assumed Date, multiplied by the number of shares subject to such stock options which become vested on the Assumed Date.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">(3)</span></td>
    <td style="font-size: 10pt; text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Represents,
pursuant to the Combined Company Executive Retention Agreement, the estimated cost of continued health coverage to be provided to Ms.
Ingargiola by Avalon for twelve (12) months following her involuntary termination without Cause or a resignation for Good Reason (as
each is defined in the Combined Company Executive Retention Agreement).</span>&#160;</p></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">(4)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Represents the cash bonus expected to be payable pursuant to the Combined Company Executive Retention Agreement within ten (10) days of the Closing of the Merger.&#160;&#160;</span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in"><span style="font-size: 10pt">(5)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Does not reflect any reduction (i.e. a &#8220;cutback&#8221;) that may apply to the amounts otherwise payable to Ms. Ingargiola following a Change in Control in accordance with the Combined Company Executive Retention Agreement if such payments would cause an excise tax to imposed under Section 4999 of the Code. If the payments would trigger such an excise, the Company may elect to cutback the payments if doing so would cause Ms. Ingargiola to be in a better after-tax position than if such excise tax applied.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt"><span style="font-size: 10pt">(6)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Represents the aggregate dollar value of the sum of all amounts reported in prior columns. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><!-- Field: Page; Sequence: 117 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_060"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Interests of YOOV&#8217;s Directors and Officers
in the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In considering the recommendation
of the YOOV Board with respect to approving the Merger, YOOV shareholders should be aware that YOOV&#8217;s directors and executive officers
have interests in the Merger that are different from, or in addition to, the interests of YOOV shareholders generally. These interests
may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The YOOV Board was aware
of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement
and the Merger, and to recommend that the YOOV shareholders approve the Merger as contemplated by this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_061"></a></div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Ownership Interests</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">As of March 7, 2025,
YOOV&#8217;s current directors and executive officers beneficially owned, in the aggregate approximately 41.2% of the shares of YOOV
capital stock. The Key YOOV Shareholders have also entered into the YOOV Voting Agreement in connection with the Merger. For a more detailed
discussion of the YOOV Voting Agreement, please see the section titled &#8220;<i>Agreements Related to the Merger - Voting Agreements</i>&#8221;
beginning on page 125 of this proxy statement/prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain YOOV shareholders
affiliated with YOOV&#8217;s directors also currently hold shares of YOOV capital stock. The table below sets forth the beneficial ownership
of YOOV Ordinary Shares on an &#8220;as converted&#8221; basis taking into account YOOV Ordinary Shares and YOOV Preferred Shares convertible
into YOOV Ordinary Shares that are held by affiliates of YOOV&#8217;s directors as of March 31, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Stockholder</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of<br/> Shares of<br/> YOOV&#160;Common<br/> Stock&#160;held</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 93%; text-align: left; text-indent: -10pt; padding-left: 10pt">Facewell International Limited (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">118,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>



</div><p style="margin-top: 0; margin-bottom: 0"></p><div>
</div><!-- Field: Rule-Page --><!-- Field: /Rule-Page --><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt; background-color: white">YOOV&#8217;s </span><span style="font-size: 10pt">President and Chief Executive Officer, <span style="background-color: white">Wong Ling Yan Philip, who is the Shareholder and Director of </span>Facewell International Limited<span style="background-color: white">, has discretionary authority to vote and dispose of the shares held by </span>Facewell International Limited <span style="background-color: white">and may be deemed to be the beneficial owner of these shares. The business address of </span>Facewell International Limited <span style="background-color: white">is </span>1 Raffles Place, #31-62 One Raffles Place Tower 2, Singapore 048616<span style="background-color: white">.</span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify">&#160;</td>
    <td style="font-size: 10pt; text-align: justify">&#160;</td></tr>
  </table><div>
</div><div><a id="a_062"></a></div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Treatment of YOOV Preferred Shares</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the terms of the Merger
Agreement, immediately prior to the Effective Time, each then-outstanding YOOV Preferred Share will be converted into YOOV Ordinary Shares
in accordance with their terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_063"></a></div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Management After the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">As described in the section
captioned &#8220;<i>Management After the Merger</i>&#8221; beginning on page 212 of this proxy statement/prospectus, the Merger Agreement
provides that, immediately upon the Effective Time, the Combined Company Board will be comprised of seven (7) directors, five (5) of
which will be designated by YOOV and two (2) of which will be designated by Avalon. The individuals currently identified to serve as
directors of the Combined Company following the consummation of the Merger are Wenzhao Lu, the current Chairman of the Avalon Board,
and Steven A. Sanders, a current director of Avalon, designated by Avalon and Wong Ling Yan Philip, Devere Andrew Bryan, Lam Heung Yeung
Herman, Lourdes Felix and Kirsty Vanora Godfrey-Billy, designated by YOOV.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Additionally, immediately
following the Effective Time, the following individuals will be the officers of the Combined Company: Wong Ling Yan Philip, the current
President and Chief Executive Officer of YOOV, as President and Chief Executive Officer, Luisa Ingargiola, the current Chief Financial
Officer of Avalon, as Chief Financial Officer and Wong Ho Chi Mark, the current Chief Technology Officer of YOOV, as Chief Technology
Officer. Mr. Wong, Mr. Mark Wong and the Combined Company expect to enter into employment agreements, effective upon and subject to the
Closing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><b><i>&#160;</i></b></p><div>

</div><!-- Field: Page; Sequence: 118 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_064"></a></div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indemnification and Insurance</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For a discussion of the
indemnification and insurance provisions related to the YOOV directors and officers under the Merger Agreement, please see the section
titled &#8220;<i>The Merger Agreement - Indemnification and Insurance for Directors and Officers</i>&#8221; beginning on page 119 of
this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>YOOV Management Unaudited Prospective Financial
Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table presents
a summary of the YOOV financial projections that were prepared by YOOV and made available to Roth and the Avalon Board. Neither Avalon
nor YOOV, as a matter of course, publicly discloses forecasts, internal projections as to future performance, revenues, earnings or other
results of operations due to the inherent unpredictability and subjectivity of underlying assumptions and projections. However, YOOV&#8217;s
management prepared projections through the year ending December&#160;31, 2028 (the &#8220;Projections&#8221;) that were utilized in
connection with the Merger. The Projections are included in this proxy statement/prospectus only because (1)&#160;portions of the Projections
through the year ending December&#160;31, 2028 were made available to Avalon in connection with Avalon&#8217;s due diligence review of
YOOV; (2)&#160;the Projections were made available to the Avalon Board in connection with its consideration of the Merger; and (3)&#160;the
Projections were also made available to Roth, Avalon&#8217;s financial advisor, as more fully described below under the section titled
&#8220;<i>The Merger&#8201;&#8201;-&#8201;&#8201;Opinion of Avalon&#8217;s Financial Advisor</i>&#8221; beginning on page 100. The
Projections are not included in this proxy statement/ prospectus to influence any stockholder to make any investment decision with respect
to the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Projections are &#8220;forward-looking
statements&#8221; and actual results may differ materially and adversely from those set forth below. Important factors that may affect
actual results and cause the Projections not to be achieved include, but are not limited to, the risks and uncertainties described below
and those described in the sections titled &#8220;<i>Cautionary Note Regarding Forward-Looking Statements</i>&#8221; beginning on page
14 and &#8220;<i>Risk Factors</i>&#8221; beginning on page 17. Although the Projections are presented with numerical specificity, they
reflect numerous estimates and assumptions made by YOOV with respect to industry performance, general business, economic, regulatory,
market and financial conditions and other future events, as well as matters specific to YOOV&#8217;s business, all of which are difficult
or impossible to predict accurately and many of which are beyond YOOV&#8217;s control. The Projections reflect assumptions as to certain
potential business decisions that are subject to change. The Projections cover a number of&#160;years and such information by its nature
becomes less reliable with each successive year. The Projections were prepared on a standalone basis without giving effect to the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the view of YOOV&#8217;s
management, the information in the Projections was prepared on a reasonable basis and reflected the best estimates and judgments available
to YOOV&#8217;s management at the time. However, this information is not fact and should not be relied upon as being necessarily indicative
of future results. The Projections reflect subjective judgments and assumptions in many respects and thus are susceptible to multiple
interpretations and periodic revisions based on actual experience and business developments. As such, the Projections constitute forward-looking
information and are subject to many risks and uncertainties that could cause actual results to differ materially from the results forecasted
in the Projections, including, but not limited to, that YOOV may be adversely affected by other economic, business and/or competitive
factors, and risks related to YOOV&#8217;s financial condition, results of operations, business strategy, short-term and long-term business
operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties, and
assumptions, including those described under in the section titled &#8220;<i>Risk Factors</i>&#8221; beginning on page 17. Moreover,
YOOV operates in a competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for YOOV&#8217;s
management to predict all risks, nor can YOOV assess the effect of all factors on YOOV&#8217;s business or the extent to which any factor,
or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements YOOV
may make. There can be no assurance that the Projections will be realized or that actual results will not be significantly higher or
lower than forecasted. In addition, the Projections will be affected by YOOV&#8217;s ability to achieve its strategic goals, objectives
and targets over the applicable periods. The Projections cannot, therefore, be considered a guarantee of future operating results, and
this information should not be relied on as such.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Projections were prepared
by YOOV&#8217;s management for internal use, and were not prepared with a view toward public disclosure, or with a view toward compliance
with published guidelines of the SEC regarding projections, the guidelines established by the American Institute of Certified Public Accountants
for preparation and presentation of prospective financial information, or GAAP. None of YOOV, Avalon or their respective independent registered
public accounting firm, nor any other independent accountants, have compiled, examined or performed any procedures with respect to the
prospective financial information included below, or expressed any opinion or any other form of assurance with respect thereto or the
achievability of the results reflected in such projections, and none of the foregoing assumes any responsibility for such information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 119 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The inclusion of the Projections
should not be regarded as an indication that YOOV, Avalon, Roth, any of their respective affiliates, officers, directors, advisors or
other representatives or anyone who received this information then considered, or now considers, them a reliable prediction of future
events, and this information should not be relied upon as such. The inclusion of the Projections herein should not be deemed an admission
or representation by YOOV or Avalon that it views such Projections as material information. The inclusion of the Projections in this proxy
statement/prospectus should not be regarded as an indication that the Projections will necessarily be predictive of actual future events
given the inherent risks and uncertainties associated with such long-range forecasts. No representation is made by YOOV, Avalon or any
other person regarding the Projections or YOOV&#8217;s ultimate performance compared to such information, and no assurance can be provided
that the underlying estimates and assumptions of such Projections will be realized. The Projections should be evaluated, if at all, in
conjunction with the historical financial statements and other information about YOOV contained herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Projections included below
are not being included herein to influence Avalon&#8217;s stockholders&#8217; decision whether to vote in favor of any proposal contained
in this proxy statement/prospectus/information statement. In light of the foregoing factors and the uncertainties inherent in the Projections,
stockholders are cautioned not to place undue reliance on the Projections included in this proxy statement/prospectus/information statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Some of the Projections are
&#8220;non-GAAP financial measures,&#8221; which are financial performance measures that are not calculated in accordance with the published
guidelines of the SEC regarding projections or accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). These
non-GAAP financial measures should not be viewed as a substitute for GAAP financial measures, and may be different from non-GAAP financial
measures used by other companies. Furthermore, there are limitations inherent in non-GAAP financial measures, because they exclude charges
and credits that are required to be included in a GAAP presentation. Accordingly, these non-GAAP financial measures should be considered
together with, and not as an alternative to, financial measures prepared in accordance with GAAP. The financial measures included in the
Projections are not subject to SEC rules regarding disclosures of non-GAAP financial measures, which would otherwise require a reconciliation
of a non-GAAP financial measure to a GAAP financial measure. Reconciliations of non-GAAP financial measures to the most directly comparable
GAAP measure were not provided to or relied upon by the Avalon Board or Roth.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon&#8217;s management
team made certain assumptions relating to the Projections provided by YOOV&#8217;s management, which Roth used in its discounted cash
flow analysis. Those assumptions were as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Working capital assumptions were based on 2024 historical actuals and normalized for projected years,
assuming:</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">o</span></td><td style="text-align: justify">a 25% year-over-year decrease in days sales outstanding.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">o</span></td><td style="text-align: justify">a 15% year-over-year decrease in prepayments as a percentage of revenue. and</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">o</span></td><td style="text-align: justify">days payable outstanding was kept constant.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Depreciation and amortization for capital expenditures was based on a 20-year useful life, with YOOV management&#8217;s
projected capital expenditures amortized across the forecast period.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Projections, inclusive
of the above assumptions, are set forth below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Actual<sup>1</sup></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Projected</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Calendar Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024A</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025P</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2026P</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2027P</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2028P</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; padding-left: 0.75pt">Fiscal Year End Date</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><span style="font-size: 10pt"><i>12/31/2024</i></span></td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><span style="font-size: 10pt"><i>12/31/2025</i></span></td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><span style="font-size: 10pt"><i>12/31/2026</i></span></td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><span style="font-size: 10pt"><i>12/31/2027</i></span></td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><span style="font-size: 10pt"><i>12/31/2028</i></span></td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.75pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 65%; padding-left: 0.75pt">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">43.5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">64.1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">99.1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">153.3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">237.2</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; padding-left: 0.75pt">% Growth</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">47</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">55</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">55</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">55</td><td style="font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.75pt">Gross Profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50.7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78.3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187.4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; padding-left: 0.75pt">% Margin</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">62</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">79</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">79</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">79</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">79</td><td style="font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.75pt">EBIT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38.3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65.5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; padding-left: 0.75pt">% Margin</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">10</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">16</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">21</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">25</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">28</td><td style="font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.75pt">EBITDA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; padding-left: 0.75pt">% Margin</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">10</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">20</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">24</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">27</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">29</td><td style="font-style: italic; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.75pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.75pt">Net Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54.8</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; padding-left: 0.75pt">% Margin</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">8</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">14</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">18</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">21</td><td style="font-style: italic; text-align: left">%</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">23</td><td style="font-style: italic; text-align: left">%</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><i>1)</i></td><td style="text-align: justify"><i>Unaudited and calendarized to December 31<sup>st</sup>, 2024
fiscal year end</i></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><!-- Field: Page; Sequence: 120 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Opinion of Avalon&#8217;s Financial Advisor
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to an engagement
letter, dated December 3, 2024, as amended on February 21, 2025, the Avalon Board retained Roth to render its opinion to the Avalon Board
as to whether the Merger Consideration (as defined below) to be paid by Avalon in the Merger, as provided in the Merger Agreement, was
fair, from a financial point of view, to Avalon. On March 7, 2025, Roth rendered its opinion to the Avalon Board, which opinion was initially
rendered orally and subsequently confirmed in writing, that, as of the date of such opinion, and based upon the assumptions made, procedures
followed, matters considered, and qualifications and limitations of the review set forth in Roth&#8217;s written opinion, dated March
7, 2025 (the &#8220;Roth Fairness Opinion&#8221;), the Merger Consideration to be paid by Avalon in the Merger was fair, from a financial
point of view, to Avalon. For purposes of the Roth Fairness Opinion, the term &#8220;Merger Consideration&#8221; means the total number
of shares of Avalon Common Stock to be issued in the Merger as defined in the Roth Fairness Opinion. The full text of the Roth Fairness
Opinion, which sets forth the procedures followed, assumptions made, matters considered, and qualifications and limitations of the review
undertaken by Roth in rendering such opinion, is attached to this proxy statement/prospectus as <span style="text-decoration:underline">Annex B</span> and is incorporated by
reference in its entirety to this proxy statement/prospectus. The Roth Fairness Opinion was prepared for the information and use of the
Avalon Board (in its capacity as such) in connection with its consideration of the Merger. The Roth Fairness Opinion was not intended
to be used for any other purpose without Roth&#8217;s prior written approval in each instance, except as expressly provided for in the
Roth Fairness Opinion. Roth has consented to the use of the Roth Fairness Opinion in this proxy statement/prospectus. The Roth Fairness
Opinion did not address Avalon&#8217;s underlying business decision to enter into the Merger Agreement or complete the Merger, or the
relative merits of the Merger, as compared to any alternative transactions that were or may be available to Avalon, and does not constitute
a recommendation to the Avalon Board or to any stockholder of Avalon as to how such stockholder should vote with respect to the Merger
or any other matter. The following summary of the Roth Fairness Opinion is qualified in its entirety by reference to the full text of
such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For purposes of the Roth Fairness
Opinion and in connection with Roth&#8217;s review, Roth, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">reviewed a draft of the Merger Agreement;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">reviewed and analyzed certain information, including historic financial results and forecasts, relating
to the business, earnings, cash flow, assets, liabilities and prospects of YOOV and Avalon that were furnished to Roth by or through the
management team of Avalon;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">conducted discussions with members of the senior management of Avalon concerning the information described
in the preceding bullet;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">reviewed and analyzed certain publicly available information relating to Avalon, including reported prices
and trading activity for the Avalon Common Stock, Avalon&#8217;s recent annual report to stockholders, its annual report on Form 10-K
for the year ended December 31, 2023, the unaudited financial statements as of December 31, 2024 (on non-public-review basis), and the
most recent quarterly report on Form 10-Q for the three-month period ended September 30, 2024, as well as Avalon&#8217;s financial outlook
for 2025, provided by the management of Avalon;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">reviewed and analyzed the financial information and data, to the extent publicly available, of certain
acquisitions that Roth deemed relevant;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">compared certain publicly available financial and other information for certain public companies that
Roth deemed relevant;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">participated in certain discussions with management of Avalon, its legal advisors and the management of
YOOV;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">reviewed and analyzed the pro forma ownership structure of the combined entity resulting from the Merger
furnished to Roth by or through the management team of Avalon; and</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">performed such other analyses and considered such other factors as Roth deemed appropriate for the purpose
of reviewing the proposed Merger and arriving at their opinion.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the Roth Fairness Opinion,
Roth noted that the Merger Agreement provided that the number of shares of Avalon Common Stock issuable as Merger Consideration in the
Merger will be based on the following exchange ratio: (a) if the closing price of the Avalon Common Stock on the Nasdaq Capital Market
on the second (2<sup>nd</sup>) trading day immediately preceding the Effective Time is less than or equal to $5.00, then the exchange
ratio for each YOOV Ordinary Share will be equal to the ratio (rounded to four decimal places) of 60,000,000 divided by the number of
YOOV Outstanding Shares, or (b) if the closing price of the Avalon Common Stock on the Nasdaq Capital Market on the second (2<sup>nd</sup>)
trading day immediately preceding the Effective Time is greater than $5.00, then the Exchange Ratio for each YOOV Ordinary Share will
be equal to the ratio (rounded to four decimal places) of 54,000,000 divided by the number of YOOV Outstanding Shares. Additionally, prior
to the Effective Time, it is expected that YOOV will issue additional YOOV Ordinary Shares in respect of the conversion of certain YOOV
Preferred Shares in accordance with YOOV&#8217;s memorandum and articles of association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 121 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In rendering its opinion,
Roth assumed and relied upon, without independent verification, the accuracy and completeness of all information that was publicly available
or was supplied or otherwise made available to Roth by Avalon or YOOV or otherwise reviewed by Roth. With respect to information provided
to or reviewed by it, Roth was advised by the management of Avalon and the management of YOOV that such information does not contain an
untrue statement of material fact or omit to state a material fact required to be stated therein or necessary to make the any statement
contained therein not misleading in any material respect. With respect to the financial projections of Avalon and YOOV, Roth was advised
by the management of Avalon and the management of YOOV that such projections were reasonably prepared on bases reflecting the best currently
available estimates and judgments of the management of Avalon and the management of YOOV of the future financial performance of Avalon
and YOOV. Roth does not express any view as to the reasonableness of such financial forecasts, estimates or forward-looking information,
the assumptions on which they are based, or on the assumed probabilities associated with future events contemplated thereby.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Roth assumed that the final
executed Merger Agreement would not differ in any material respect from the draft Merger Agreement reviewed by Roth, and that the Merger
and other transactions contemplated by the Merger Agreement would be consummated in accordance with the terms set forth in the Merger
Agreement without any waiver, amendment or delay of any terms or conditions. Roth also assumed that all governmental, regulatory or other
approvals and consents required for the consummation of the Merger would be obtained without imposition of any delays, limitations, conditions
or restrictions that would have an adverse effect on Avalon or on the contemplated benefits expected to be derived in the proposed Merger.
Roth is not a legal, tax, accounting or regulatory advisor, and expressed no opinion as to legal, tax, accounting or regulatory matters.
Roth has relied upon, without independent verification, the assessment of Avalon and its legal, tax, accounting and regulatory advisors
with respect to legal, tax, accounting and regulatory matters. Accordingly, the Roth Fairness Opinion does not address any legal, tax,
accounting or regulatory matters, as to which Roth understood that Avalon had obtained such advice as it deemed necessary from qualified
professionals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Roth did not perform any independent
valuations or appraisals of any of the assets or liabilities (fixed, contingent or other) of Avalon or YOOV, and, except for the property
appraisal noted below under the heading &#8220;Management Liquidation Analysis&#8221;, Roth has not been furnished or provided with any
such appraisals or valuations. Additionally, Roth did not make any physical inspection of the properties or assets of Avalon or YOOV.
Roth did not evaluate the solvency of Avalon, YOOV or any of their respective subsidiaries (or the impact of the transactions contemplated
by the Merger Agreement thereon) under any state, federal or other laws relating to bankruptcy, insolvency or similar matters. Roth expresses
no view or opinion regarding the liquidation value of Avalon, YOOV or any other entity. Roth did not undertake any independent analysis
of any pending or threatened litigation, to which YOOV, Avalon or any of their respective affiliates is a party or may be subject, and
Roth did not make any assumptions concerning the possible assertion of claims, outcomes or damages arising out of any such matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Roth Fairness Opinion
was necessarily based on the economic, monetary, financial and other conditions as they existed and could have been evaluated as of the
date of the Roth Fairness Opinion. Events occurring after the date of the Roth Fairness Opinion could materially affect the assumptions
used in preparing the Roth Fairness Opinion. Roth does not have any obligation or responsibility to update, reaffirm or revise the Roth
Fairness Opinion or otherwise comment upon any circumstances, developments or events occurring after the date of the Roth Fairness Opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Roth is a nationally recognized
investment banking firm that provides financial advisory services and is continually engaged in the valuation of businesses and their
securities in connection with mergers and acquisitions, negotiated underwritings, private placements, secondary distributions of listed
and unlisted securities, and valuations for corporate, estate and other purposes. Roth was selected by Avalon based on Roth&#8217;s experience,
expertise, reputation and familiarity with Avalon. The Avalon Board did not impose any limitations on Roth with respect to the investigations
made or procedures followed in rendering its opinion. The Roth Fairness Opinion was approved by an authorized internal fairness committee
at Roth in accordance with its customary practice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The opinion of Roth was limited
to and addressed only the fairness of the consideration to be paid by Avalon to the extent expressly set forth in the Roth Fairness Opinion.
Roth was not asked to, nor did Roth offer any opinion on, and the Roth Fairness Opinion did not address, any other term, aspect or implication
of the Merger Agreement, including, without limitation, the form of the Merger, or any other agreements, arrangements or understandings
entered into in connection with the Merger Agreement or otherwise, including, without limitation, the fairness of the amount or nature
of any compensation to any officers, directors or employees of any party to the Merger Agreement, or any class of such persons, relative
to the Merger Consideration, or the fairness of the Merger to the holders of any class of securities, creditors or other constituencies
of Avalon. Further, Roth expressed no opinion as to the actual value of the shares of Avalon or the prices at which shares of Avalon,
in each case, including those shares of Avalon to be issued in the Merger, will trade at any time before or after the announcement of
the signing of the Merger Agreement or during the time between the announcement of signing of the Merger Agreement and the Closing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 122 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with its engagement
by the Avalon Board, Roth agreed to receive a fee of $100,000 upon the delivery of the Roth Fairness Opinion, which is payable in cash.
This fee was determined by Roth and proposed to the Avalon Board. In addition, Roth is entitled to receive an advisory fee for its services
as financial advisor to Avalon in connection with the Merger in an amount equal to $50,000, which is contingent upon the completion of
the Merger. The advisory fee is independent of any consideration for issuance of the Roth Fairness Opinion. Avalon has agreed to indemnify
Roth against certain liabilities. Roth will also be reimbursed for certain expenses in connection with its services up to a limit of $50,000
for all expenses, which limit may be modified with the consent of Avalon.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Roth is a full-service securities
firm engaged in securities trading and brokerage activities, as well as providing investment banking and other financial services. In
the ordinary course of business, Roth and its affiliates may acquire, hold or sell, for Roth&#8217;s or its affiliates&#8217; own accounts
and for the accounts of customers, equity, debt and other securities and financial instruments (including bank loans and other obligations)
of Avalon and the other parties to the Merger, and, accordingly, may at any time hold a long or a short position in such securities. Except
as described above or as set forth below, Roth has not had a material relationship with, nor has it otherwise received any fees from Avalon,
YOOV or any other parties to the Merger during the two (2) years preceding the date hereof. During the two (2) years prior to the date
hereof, Roth was engaged by Avalon to provide certain services under the following two engagements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">General financial advisory engagement under which Roth provided capital markets assistance, including
marketing a potential investment in Avalon to prospective debt financing sources. In June 2023, Avalon&#8217;s efforts to identify debt
financing sources were unsuccessful. Roth received $20,000 in compensation for these services. Additionally, under Roth&#8217;s engagement
letter relating to these advisory services, there was an additional amount of compensation due in the amount of $80,000 which was waived
by Roth in connection with the termination of the engagement. No fees associated with previous engagements are being paid in connection
with this merger, and no debt financing sources solicited under this prior engagement are participating in this merger.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Between July 2023 and August 2024, Roth also executed an at-the-market equity offering for Avalon and
received $104,797.30 in compensation for the services related thereto.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Summary of Material Financial Analyses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following is a summary
of material financial analyses prepared, or reviewed, by Roth and discussed with the Avalon Board in connection with the rendering of
the Roth Fairness Opinion:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">discounted cash flow analysis with respect to YOOV performed by Roth;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">selected publicly traded comparable companies analysis with respect to YOOV performed by Roth;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">selected precedent M&amp;A transactions analysis with respect to YOOV performed by Roth; and</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">liquidation analysis performed by the management of Avalon and provided to Roth.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The order in which the analyses
are listed above and described below does not represent the relative importance or weight given to the analyses by Roth. Some of the summaries
of financial analyses include information presented in tabular format. In order to fully understand the analyses, the tables must be read
together with the text of each summary. The tables alone do not constitute a complete description of Roth&#8217;s analyses. Considering
the data described below without considering the full narrative description of the financial analyses, including the methodologies and
assumptions underlying the analyses, could create a misleading or incomplete view of the analyses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except as otherwise noted,
the following quantitative information, to the extent that it is based on market data, is based on market data as it existed on or before
March 6, 2025 and is not necessarily indicative of current market conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Discounted Cash Flow Analysis</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The discounted cash flow analysis
is a &#8220;forward looking&#8221; methodology and is based on projected future cash flows to be generated by YOOV which are then discounted
back to March 6, 2025. This methodology has three primary components: (a) the present value of projected standalone unlevered, after-tax
free cash flows for a determined period, (b) the present value of the terminal value of cash flows (representing firm value beyond the
time horizon on the projection), and (c) the weighted average cost of capital (&#8220;WACC&#8221;) used to discount such future cash flows
and terminal value back to the present.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the discounted
cash flow analysis, Roth utilized YOOV management&#8217;s projected standalone unlevered, after-tax&#160;free cash flows for YOOV for
the calendar years ending December&#160;31, 2025 through December&#160;31, 2028, which were based on the  Projections. All of
the information used in Roth&#8217;s analysis was based on publicly available sources and the financial projections provided by YOOV&#8217;s
management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 123 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In performing its discounted
cash flow analysis, Roth calculated ranges of the estimated present values of the unlevered, after-tax free cash flows of YOOV forecasted
to generate for 2025 to 2028 by applying discount rates, as of March 6, 2025, ranging from 13.6% to 17.6%, reflecting Roth&#8217;s estimates
of the weighted-average cost of capital (&#8220;WACC&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The WACC was calculated by
adding (i) the estimated market value of equity as a percentage of the total market value of YOOV&#8217;s capital multiplied by YOOV&#8217;s
estimated cost of equity, and (ii) the estimated market value of debt as a percentage of the total market value of YOOV&#8217;s capital
multiplied by YOOV&#8217;s estimated after-tax market cost of debt. The estimated market value of YOOV&#8217;s debt and equity were calculated
using the average debt to equity ratios of the comparable publicly traded companies. The estimated cost of equity was calculated using
the capital asset pricing model, which took into account the betas of comparable publicly traded companies, the risk-free rate, a historical
equity market risk premium and a historical small capitalization risk premium, which risk premiums were sourced from the 2024 Kroll Cost
of Capital Module. The cost of equity also included a country risk premium which was based on an NYU Stern Country Risk Premium for Hong
Kong. The estimated cost of debt was based on publicly available data as of March 6, 2025. The following table sets forth the WACC calculation:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b>Weighted
Average Cost of Capital Calculation (WACC)</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>





</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Step 1- Calculate Average Portfolio Beta (a)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Average Levered Portfolio Equity Beta</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.29</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Step 2 - Calculate Unlevered Portfolio Beta (b)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Average Portfolio Equity Beta</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.29</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Average Debt-to-Equity Ratio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax Rate (c)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0.125in">Unlevered Portfolio Equity Beta</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1.10</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Step 3 - Arrive at YOOV Equity Beta (d)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Average Unlevered Portfolio Equity Beta</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">YOOV Debt-to-Equity Ratio (e)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax Rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0.125in">Levered YOOV Equity Beta</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1.60</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Step 4 - Calculate Cost of Equity Capital</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk Free Rate (f)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity Risk Premium (g)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Levered YOOV Equity Beta</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.60</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Country Risk Premium (h)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Size Premium (i)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.9</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left; padding-left: 0.125in">YOOV Adjusted Cost of Equity Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">19.6</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Step 5 - Calculate Cost of Debt Capital</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">10 Year Corporate Spread (j)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Risk Free Rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">YOOV Adjusted Cost of Debt Capital (k)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Tax Rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16.3</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left; padding-left: 0.125in">YOOV Adjusted After-tax Cost of Debt Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8.2</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Step 6 - Calculate WACC (l)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Debt-to-Capital Ratio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equity-to-Capital Ratio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">After-tax Cost of Debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of Equity Capital</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19.6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left; padding-left: 0.125in">YOOV Adjusted Cost of Equity Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">15.6</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td></tr>
  </table><div>



</div><p style="margin: 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">a)</td>
    <td style="text-align: justify">Beta was found using Capital IQ market data as of 3/6/2025 and derived from the average of selected comparable companies. Roth Capital uses mid-year convention to discount cash flows as Roth Capital assumes that cash flows come in continuously throughout the year.</td></tr>
  <tr style="vertical-align: top">
    <td>b)</td>
    <td style="text-align: justify">Unlevered Beta = Levered Beta / (1 + ((D/E) x (1 - T))</td></tr>
  <tr style="vertical-align: top">
    <td>c)</td>
    <td style="text-align: justify">Effective tax provided by YOOV&#8217;s management</td></tr>
  <tr style="vertical-align: top">
    <td>d)</td>
    <td style="text-align: justify">Levered Beta = Unlevered Beta* (1 + ((D/E) x (1 - T)) + P/E)</td></tr>
  <tr style="vertical-align: top">
    <td>e)</td>
    <td style="text-align: justify">Assumes debt as of 12/31/2024. Further assumes this amount of leverage persists as YOOV&#8217;s target leverage ratio.</td></tr>
  <tr style="vertical-align: top">
    <td>f)</td>
    <td style="text-align: justify">Source: 10-Year Treasury yield as of 3/6/2025</td></tr>
  <tr style="vertical-align: top">
    <td>g)</td>
    <td style="text-align: justify">Source: 2024 Kroll Cost of Capital Module</td></tr>
  <tr style="vertical-align: top">
    <td>h)</td>
    <td style="text-align: justify">Source: NYU Stern Country Risk Premium for Hong Kong</td></tr>
  <tr style="vertical-align: top">
    <td>i)</td>
    <td style="text-align: justify">Source: CRSP Deciles Size Study as of 12/31/2023</td></tr>
  <tr style="vertical-align: top">
    <td>j)</td>
    <td style="text-align: justify">Sourced from Capital IQ assumed BBB 10-year corporate spread as of 3/6/2025</td></tr>
  <tr style="vertical-align: top">
    <td>k)</td>
    <td style="text-align: justify">10 Year Corporate Spread - Risk Free Rate</td></tr>
  <tr style="vertical-align: top">
    <td>1)</td>
    <td style="text-align: justify">WACC = (Debt-to-Capital x Cost of Debt x (1 - Tax Rate)) + (Equity-to-Capital x Cost of Equity Capital)</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 124 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Roth calculated YOOV&#8217;s
implied enterprise value and implied equity value using the perpetuity growth method. Roth applied a selected range of perpetuity growth
rates of 2.0% to 4.0% to the projected unlevered free cash flow for the calendar year ending December 31, 2028, then divided the result
by the perpetuity growth rate minus a selected WACC range of 13.6% to 17.6%. The outcome was then discounted and added to the present
value of the projected unlevered free cash flows to determine the implied enterprise value. Finally, Roth derived the implied equity value
by subtracting total debt and adding cash as of calendar year ending December 31, 2024, based on figures provided by YOOV&#8217;s management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This analysis resulted in
the reference range of implied equity value for YOOV set forth below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Implied Equity Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify; border-bottom: Black 1.5pt solid">USD $ Million</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">High</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Discounted Cash Flow Analysis</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">168</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">301</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This analysis also resulted
in the reference range of implied enterprise value for YOOV set forth below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Implied Enterprise Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify; border-bottom: Black 1.5pt solid">USD $ Million</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">High</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Discounted Cash Flow Analysis</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">185</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">318</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Selected Public Companies Analysis</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Roth analyzed publicly available
financial and stock market data for eight (8) selected publicly traded companies operating in the AI-powered platform industry with market
capitalizations ranging from $78 million to $6.8 billion. Roth selected the following publicly traded companies that it considered generally
relevant for the analysis (collectively, the &#8220;selected companies&#8221;):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Appian Corporation</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Beta Systems Software AG</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Informatica Inc.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Innodata Inc.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Pegasystems Inc.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Sprinklr, Inc.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">UiPath Inc.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Upland Software, Inc.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Roth reviewed various financial
metrics of the selected companies, including enterprise values, which were calculated as fully diluted equity values based on the closing
stock prices on March 6, 2025, plus, if applicable for each company, total debt (excluding leases), preferred equity, and non-controlling
interests minus cash and cash equivalents. These enterprise values were analyzed as multiples of estimated Revenue and EBITDA for calendar
years 2025 and 2026. The financial data for the selected companies was sourced from publicly available data obtained from public filings
with the SEC and other data sources, while YOOV&#8217;s financial data was furnished to Roth by management and based on management of
YOOV&#8217;s forecasts and estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based on Roth&#8217;s judgment
and experience, the analysis excludes the highest and lowest 25% of Revenue and EBITDA multiples for the eight selected companies. After
excluding these data points, the following results were obtained:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.5in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the overall low to high calendar year 2025 and calendar year 2026 estimated Revenue multiples observed
for the selected companies were 1.9x to 3.7x (with an overall median of 3.3x) and 1.9x to 3.5x (with an overall median of 3.0x). Roth
applied the above selected ranges for projected calendar year 2025 and calendar year 2026 to corresponding data of YOOV.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.5in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the overall low to high calendar year 2025 and calendar year 2026 estimated EBITDA multiples observed
for the selected companies were 9.3x to 17.7x (with an overall median of 13.3x) and 9.0x to 18.5x (with an overall median of 13.4x). Roth
applied the above selected ranges for projected calendar year 2025 and calendar year 2026 to corresponding data of YOOV.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 125 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This analysis resulted in
the reference ranges of implied equity value for YOOV set forth below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Multiples</b></span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Implied Equity Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify; border-bottom: Black 1.5pt solid">USD $ Million</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">High</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">High</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">EV/CY 2025P Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.9</td><td style="width: 1%; text-align: left">x</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3.7</td><td style="width: 1%; text-align: left">x</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">106</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">221</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">EV/CY 2026P Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.9</td><td style="text-align: left">x</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.5</td><td style="text-align: left">x</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">328</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">EV/CY 2025P EBITDA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.3</td><td style="text-align: left">x</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17.7</td><td style="text-align: left">x</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">101</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">207</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">EV/CY 2026P EBITDA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.0</td><td style="text-align: left">x</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.5</td><td style="text-align: left">x</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">195</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">420</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Note: EV = Enterprise Value; CY = Calendar
Year</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Precedent Transaction Analysis</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Roth analyzed publicly available
financial information for eight (8) selected transactions involving target companies or businesses in the AI-powered platform industry.
These selected transactions were deemed relevant by Roth for purposes of this analysis (collectively, the &#8220;selected transactions&#8221;):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="text-align: left; border-bottom: Black 1.5pt solid; border-top: white 1pt solid; width: 23%; vertical-align: bottom"><b>Announced Date</b></td>
    <td style="text-align: left; padding-bottom: 1.5pt; width: 1%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 30%; text-align: left"><span style="font-size: 10pt"><b>Target</b></span></td>
    <td style="text-align: left; padding-bottom: 1.5pt; width: 1%; vertical-align: bottom">&#160;</td>
    <td style="border-top: White 1pt solid; border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 45%; text-align: left"><span style="font-size: 10pt"><b>Acquirer </b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Dec-24</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Windward Ltd.</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">FTV Management Company, L.P.; FTV VIII, L.P.</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Sep-24</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Esker SA</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">General Atlantic Ltd.; Bridgepoint Group plc</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Jun-24</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Augmento Labs Private Limited</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Saksoft Limited</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Mar-23</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">GK Software SE</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Fujitsu ND Solutions AG</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Sep-22</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Beta Systems Software AG</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Sparta AG</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Feb-22</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Bilot Oyj</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Vincit Oyj</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Dec-21</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">The Data Appeal Company S.P.A.</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Almawave S.p.A.</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Dec-20</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">RealPage, Inc.</span></td>
    <td style="text-align: left; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: left"><span style="font-size: 10pt">Thoma Bravo, L.P.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Roth noted that, although
the selected transactions were used for comparison purposes, no business of any selected company was either identical or directly comparable
to YOOV&#8217;s business. Accordingly, Roth&#8217;s comparison of selected companies to YOOV and analyses of the results of such comparisons
was not purely mathematical, but instead involved complex considerations and judgments concerning differences in financial and operating
characteristics and other factors that could affect the relative values of the selected companies and YOOV.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Roth reviewed, among other
information, and to the extent such information was publicly available, transaction values, calculated as the implied enterprise values
of the target companies based on the consideration payable in the selected transactions. These values were analyzed as multiples of the
revenue as of the last twelve (12) month period disclosed in public filings with the SEC for each target company as of the respective
announcement dates of the selected transactions. Financial data for the selected transactions was sourced from public filings with the
SEC and other publicly available information, while YOOV&#8217;s financial data was furnished to Roth by management and based on management
of YOOV&#8217;s forecasts and estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based on Roth&#8217;s judgment
and professional experience, the analysis excludes the highest and lowest 25% Revenue multiples for the eight selected transactions. After
excluding these data points, the overall low to high Revenue multiples observed for the selected transactions were 2.3x to 8.1x (with
an overall median of 5.0x). Roth applied the selected ranges above to corresponding data of YOOV.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This analysis resulted in
the reference ranges of implied equity value for YOOV set forth below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Multiples</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Implied Equity Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: justify; border-bottom: Black 1.5pt solid">USD $ Million</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">High</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">High</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">EV/CY 2024A Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.3</td><td style="width: 1%; text-align: left">x</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8.1</td><td style="width: 1%; text-align: left">x</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">83</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">333</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Note: EV = Enterprise Value; CY = Calendar
Year</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 126 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Management Liquidation Analysis&#160;&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Roth discussed a liquidation
analysis with the management of Avalon (the &#8220;Management Liquidation Analysis&#8221;). The Management Liquidation Analysis estimated
the potential proceeds that would be available for distribution to Avalon&#8217;s creditors and stockholders in the event of a hypothetical
liquidation under Chapter 7 of the Bankruptcy Code as of March 6, 2025. Roth considered this analysis to assess whether the value potentially
received by stockholders in connection with the proposed Merger exceeds the value they would receive in a hypothetical liquidation based
on the Management Liquidation Analysis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Roth noted that (i) the Management
Liquidation Analysis assumes the value of balance sheet items based on the book value for Avalon as of December 31, 2024, and (ii) the
book value items were adjusted by Avalon management with respect to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">sale of an investment, accounted for under the equity method;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">adjusted value of investment in real estate based on an independent appraisal used by management, dated
as of November 3, 2023; and</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the write-off of IP and Other Non-Current Assets.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Roth considered the conclusion
of the Management Liquidation Analysis, which provided that net proceeds available for distribution to stockholders in such a hypothetical
liquidation would be equal to an equity value per share of $2.36, as of a March 6, 2025 liquidation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Miscellaneous</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This summary is not a complete
description of the Roth Fairness Opinion or the underlying analyses and factors considered in connection with such opinion. The preparation
of a fairness opinion is a complex process involving the application of subjective business and financial judgment in determining the
most appropriate and relevant methods of financial analysis and the application of those methods to the particular circumstances and,
therefore, is not readily susceptible to a partial analysis or summary description. Roth believes that its analyses described above must
be considered as a whole and that considering any portion of such analyses or factors considered without considering all such analyses
and factors could create a misleading or incomplete view of the processes underlying Roth&#8217;s analyses and its opinion. In arriving
at its fairness determination, Roth considered the results of all of its analyses and did not attribute any particular weight to any factor
or analysis considered by it. Rather, it made its fairness determination on the basis of its experience and professional judgment after
considering the results of all of its analyses. In performing its analyses, Roth made numerous assumptions with respect to industry performance
and general business and economic conditions, such as industry growth, inflation, interest rates and many other matters, many of which
are beyond the control of Avalon, YOOV and their respective advisors. Any estimates used in Roth&#8217;s analyses, and the results derived
from such analyses, are not necessarily indicative of actual values or future results, which may be significantly more or less favorable
than suggested by such analyses. No company selected for the analyses described above is identical to Avalon or YOOV, and no transaction
selected for the analysis described above is identical to the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In
conducting its analyses and arriving at its opinion, Roth utilized a variety of valuation methods. The analyses were prepared solely for
the purpose of enabling Roth to provide its opinion to the Avalon Board as to the fairness, from a financial point of view, to Avalon
of the Merger Consideration to be paid by Avalon in the Merger, as of the date of the Roth Fairness Opinion and do not purport to be appraisals
or necessarily reflect the prices at which these companies or securities may actually be sold, which are inherently subject to uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The
terms of the Merger were determined through arm&#8217;s-length negotiations between Avalon and YOOV and were approved by the Avalon Board
and the YOOV Board. The decision to enter into the Merger Agreement by Avalon was solely that of the Avalon Board. Roth did not make any
recommendations as to any specific consideration to Avalon or the Avalon Board, or that any specific amount or type of consideration constituted
the only appropriate consideration for the Merger. In addition, Roth was not authorized to, and did not, solicit any expressions of interest
from any other parties with respect to any transaction involving Avalon or YOOV, or review other alternative business combinations or
transactions that Avalon could pursue. As described above, the Roth Fairness Opinion and the presentation of such opinion to the Avalon
Board by Roth were among a number of factors taken into consideration by the Avalon Board in making its determination to approve the Merger
Agreement, the Merger and the other transactions contemplated thereby, including the factors described elsewhere in this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 127 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><div><a id="a_065"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Regulatory Approvals Required for the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the United States, Avalon must comply with
applicable federal and state securities laws and the rules and regulations of Nasdaq in connection with the issuance of the Merger Shares
in connection with the Merger and the filing of this proxy statement/prospectus with the SEC.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_066"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Accounting Treatment of the Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although Avalon is the legal
acquirer and will issue shares of its common stock to effect the Merger with YOOV, if the Merger is completed it will be accounted for
as a &#8220;reverse acquisition&#8221; of Avalon by YOOV using the &#8220;acquisition&#8221; method of accounting. YOOV will record net
tangible and identifiable intangible assets acquired and liabilities assumed from Avalon at their respective fair values at the date of
the completion of the Merger. Any excess of the purchase price, which will equal the fair value of the aggregate amount of Avalon Common
Stock issued pursuant to the Merger Agreement on the date of the completion of the Merger, over the net fair value of such assets and
liabilities will be recorded as goodwill.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The financial condition and results of operations
of YOOV after completion of the Merger will reflect Avalon&#8217;s results but will not be restated retroactively to reflect the historical
financial condition or results of operations of Avalon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The earnings of YOOV following
the completion of the Merger will reflect the effect of acquisition accounting adjustments, including changes in the carrying values of
assets and liabilities and on depreciation and amortization expense. Intangible assets with indefinite useful lives and goodwill will
not be amortized but will be tested for impairment at least annually, and all assets including goodwill will be tested for impairment
when certain indicators are present. If in the future YOOV determines that tangible or intangible assets (including goodwill) are impaired,
YOOV would record an impairment charge at that time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_067"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Appraisal Rights and Dissenters&#8217; Rights</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Avalon</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are no appraisal rights
under the DGCL available to holders of shares of Avalon Common Stock and Avalon Preferred Stock in connection with the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>YOOV</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any holder of the Dissenting
Shares (other than those held in the treasury of YOOV, owned by YOOV or any of its direct or indirect wholly owned subsidiaries or by
Avalon or any of its affiliates at the Effective Time) is entitled to payment of the fair value of his Dissenting Shares upon dissenting
from the Merger in accordance with the BVI Companies Act.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 128 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><div><a id="a_068"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">THE MERGER AGREEMENT</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN"><i>The following is a summary
of the material terms of the Merger Agreement. A copy of the Merger Agreement is attached to this proxy statement/prospectus as <span style="text-decoration:underline">Annex
A</span> and is incorporated by reference into this proxy statement/prospectus. The Merger Agreement has been attached to this proxy statement/prospectus
to provide you with information regarding its terms. It is not intended to provide any other factual information about Avalon, YOOV or
Merger Sub. The following description does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement.
You should refer to the full text of the Merger Agreement for details of the Merger and the terms and conditions of the Merger Agreement.
</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN"><span style="background-color: white"><i>The
Merger Agreement and this summary of its terms have been included to provide you with information regarding the terms of the Merger Agreement.
Avalon is responsible for considering whether additional disclosure of material information is required to make the statements in this
proxy statement not misleading. Factual disclosures about Avalon contained in this proxy statement or Avalon&#8217;s public reports filed
with the SEC may supplement, update or modify the factual disclosures about Avalon contained in the Merger Agreement and described in
this summary. </i></span><i>The Merger Agreement contains representations and warranties that Avalon and Merger Sub, on the one hand,
and YOOV, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the
benefit of the other parties to the Merger Agreement and may be intended not as statements of fact but rather as a way of allocating the
risk to one of the parties if those statements prove to be incorrect. In addition, the assertions embodied in the representations and
warranties are qualified by information in confidential disclosure schedules exchanged by the parties in connection with signing the Merger
Agreement. While Avalon and YOOV do not believe that these disclosure schedules contain information required to be publicly disclosed
under the applicable securities laws, other than information that has already been so disclosed, the disclosure schedules do contain information
that modifies, qualifies and creates exceptions to the representations and warranties set forth in the attached Merger Agreement. Accordingly,
you should not rely on the representations and warranties as current characterizations of factual information about Avalon or YOOV, because
they were made as of specific dates and are modified by the disclosure schedules. </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Structure of the Merger</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">Subject to the terms and
conditions of the Merger Agreement, and in accordance with the British Virgin Islands Companies Act, 2004 (the &#8220;BVI Companies Act&#8221;),
at the Effective Time, Merger Sub, a wholly owned subsidiary of Avalon formed by Avalon in connection with the Merger, will merge with
and into YOOV, with YOOV surviving as a wholly owned subsidiary of Avalon (the &#8220;Surviving Corporation&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Completion and Effectiveness of the Merger
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">The Merger Agreement requires
the parties to consummate the Merger as promptly as practicable (and in any event within three (3) business days) after all of the conditions
to the consummation of the Merger contained in the Merger Agreement are satisfied or waived, including the adoption of the Merger Agreement
by the YOOV shareholders and the approval by the Avalon stockholders of the issuance of the Merger Shares and the other transactions proposed
under the Merger Agreement, other than those conditions that by their nature are to be satisfied at the Closing. The Merger will become
effective upon the filing and acceptance of an Articles of Merger with the Registrar of Corporate Affairs in the British Virgin Islands
(the &#8220;BVI Registry&#8221;). Neither Avalon nor YOOV can predict the exact timing of the consummation of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Merger Consideration </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">Immediately prior to the
Effective Time, each then-outstanding YOOV Preferred Share will either automatically be converted into YOOV Ordinary Shares or canceled
and cease to exist in accordance with their terms. At the Effective Time, upon the terms and subject to the conditions set forth in the
Merger Agreement, each then-outstanding YOOV Ordinary Share (other than shares held in treasury and Dissenting Shares) will be converted
into and become exchangeable for a number of shares of Avalon Common Stock equal to the Exchange Ratio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN"><span style="font-size: 10pt">No
fractional shares of Avalon Common Stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional
shares will be issued. Any fractional shares of Avalon Common Stock </span>r<span style="font-size: 10pt">esulting from the conversion
of shares of YOOV Ordinary Shares shall be rounded down to the nearest whole number of shares of Avalon Common Stock, if it is less than
the fraction of one-half (0.5) of one share of Avalon Common Stock, or rounded up to the nearest whole number of shares of Avalon Common
Stock if the said product is greater than or equal to the fraction of one-half (0.5) of one share of Avalon Common Stock. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN"></p><div>

</div><!-- Field: Page; Sequence: 129 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exchange Ratio </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">At the Effective Time, each
then-outstanding YOOV Ordinary Share (other than shares held in treasury and Dissenting Shares) will be converted into and become exchangeable
for a number of shares of Avalon Common Stock equal to the Exchange Ratio. The &#8220;Exchange Ratio&#8221; will be equal to the ratio
(rounded to four decimal places), determined as follows: if the closing price of the Avalon Common Stock on The Nasdaq Capital Market
on the second (2<sup>nd</sup>) trading day immediately preceding the Effective Time is (x) less than or equal to $5.00, the Exchange Ratio
shall be 60,000,000 divided by the YOOV Outstanding Shares; or (y) greater than $5.00, the Exchange Ratio shall be 54,000,000 divided
by the YOOV Outstanding Shares. For purposes of calculating the Exchange Ratio, &#8220;YOOV Outstanding Shares&#8221; means the total
number of YOOV Ordinary Shares outstanding immediately prior to the Effective Time expressed on a fully diluted and as-converted to YOOV
Ordinary Share basis, assuming, without limitation or duplication, and calculated using the treasury stock method (i) the conversion of
each YOOV Preferred Share into YOOV Ordinary Shares immediately prior to the Effective Time and in accordance with YOOV&#8217;s memorandum
and articles of association; (ii) the conversion of any YOOV Ordinary Share purchase warrants or other securities convertible or exchangeable
into YOOV Ordinary Shares; and (iii) the issuance of YOOV Ordinary Shares in respect of all other rights to receive such shares that will
be outstanding immediately after the Effective Time, in each case pursuant to the instruments governing such securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Exchange Ratio will be
adjusted equitably to reflect any change in the outstanding shares of capital stock of Avalon or YOOV which occurs as a result of any
reclassification, recapitalization, reorganization, stock split (including the Reverse Stock Split, if approved and if necessary to be
effectuated for the Combined Company to meet the $4.00 minimum bid price initial listing requirement following the Closing pursuant to
the rules of The Nasdaq Capital Market) or combination, exchange or readjustment of shares, or any stock dividend or distribution is declared
with a record date prior to the Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Treatment of YOOV Ordinary Shares and YOOV
Preferred Shares </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">Under the terms of the Merger
Agreement, immediately prior to the Effective Time, each then-outstanding YOOV Preferred Share will be converted into YOOV Ordinary Shares.
At the Effective Time, each then-outstanding YOOV Ordinary Share (other than shares held in treasury and Dissenting Shares) will be converted
into and become exchangeable for a number of shares of Avalon Common Stock equal to the Exchange Ratio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Treatment of Avalon Common Stock, Avalon Preferred
Stock, Avalon Stock Options </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">Each share of Avalon Common
Stock and Avalon Preferred Stock issued and outstanding at the Effective Time of the Merger will remain issued and outstanding. In addition,
each Avalon Stock Option that is outstanding immediately prior to the Effective Time, whether vested or unvested, will survive the Closing
and remain outstanding in accordance with its terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Based on the closing price
of Avalon Common Stock on Nasdaq of $3.41 on June 6, 2025, the latest practicable trading day prior to the date of this proxy statement/prospectus,
and the number of YOOV Outstanding Shares on such date, it is estimated that the Exchange Ratio will be approximately 121.8. Based on
the estimated Exchange Ratio, Avalon is expected to issue 60,000,000 shares of Avalon Common Stock to the YOOV shareholders. Upon completion
of the Merger, the current Avalon stockholders are expected to own approximately 2.7% to 3.0% of the common stock of the Combined Company
and the YOOV shareholders are expected to own approximately 97.0% to 97.3% of the common stock of the Combined Company. The Exchange
Ratio is an estimate only, and the actual Exchange Ratio and relative ownership interests of Avalon stockholders and YOOV shareholders
in the Combined Company immediately following the Merger will depend on the market price of Avalon&#8217;s Common Stock two (2) trading
days prior to the Merger and the number of YOOV Outstanding Shares on the Closing Date.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exchange and Payment </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">Promptly as practicable but
in no event later than two (2) Business Days after the Effective Time, Avalon will cause an exchange agent to send to each holder of shares
of YOOV Ordinary Shares, other than with respect shares held in treasury and Dissenting Shares, (a) a letter of transmittal specifying
that delivery of Avalon Common Stock to which such holder of shares of YOOV Ordinary Shares is entitled to receive, will be effected and
risk of loss and title will pass to such holder, upon proper delivery of a physical share certificate or in the case of YOOV Ordinary
Shares in book-entry form (&#8220;YOOV Book-Entry Shares&#8221;), upon adherence to the procedures set forth in the letter of transmittal
and (b) instructions for surrendering such physical share certificates or YOOV Book-Entry Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 130 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Directors and Officers of Avalon Following
the Merger </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN"><span style="-keep: true">Pursuant to the Merger
Agreement, each of the directors and officers of Avalon who will not continue as directors or officers of Avalon following the consummation
of the Merger will resign effective as of the Closing Date. Immediately upon the Effective Time, the Combined Company Board will be comprised
of seven (7) directors, five (5) of which will be designated by YOOV and two (2) of which will be designated by Avalon. The individuals
currently identified to serve as directors of the Combined Company following the consummation of the Merger are Wenzhao Lu, Avalon&#8217;s
current Chairman of the Board, and Steven A. Sanders, a current director of Avalon, designated by Avalon and Wong Ling Yan Philip, Devere
Andrew Bryan, Lam Heung Yeung Herman, Lourdes Felix and Kirsty Vanora Godfrey-Billy, designated by YOOV.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN"><span style="-keep: true">Additionally, immediately
following the consummation of the Merger, the following individuals will be the officers of the Combined Company: Wong Ling Yan Philip,
the current President and Chief Executive Officer of YOOV, as President and Chief Executive Officer, Luisa Ingargiola, the current Chief
Financial Officer of Avalon, as Chief Financial Officer and Wong Ho Chi Mark, the current Chief Technology Officer of YOOV, as Chief
Technology Officer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Amendment of the Avalon Charter </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">In connection with the Merger,
Avalon agreed to amend the Avalon Charter to (i) change Avalon&#8217;s name to &#8220;YOOV, Inc.&#8221; (ii) effectuate the Reverse Stock
Split, if necessary, and (iii) make such other changes as shall be mutually agreed by Avalon and YOOV prior to the filing of such amendment,
including the Increase in Authorized Shares Amendment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Representations and Warranties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">The Merger Agreement contains
customary representations and warranties of Avalon and YOOV for a transaction of this type relating to, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;">
<tr style="vertical-align: top">
<td style="width: 0.25in">&#160;</td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-size: 10pt">the
due organization, existence, good standing and qualification of Avalon and YOOV and their respective subsidiaries to carry on their respective
businesses;</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">organizational documents;</td></tr>
                                                                                                                                                                                                                         </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="background-color: white">required regulatory filings and authorizations and consents or approvals
of governmental authorities;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">non-contravention;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">authority to enter into the Merger Agreement and the related agreements;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">except as otherwise specifically disclosed in the Merger Agreement, the fact that the execution of the
Merger Agreement, the consummation of the Merger and other related transactions would not result in a violation or breach of, or default
under the organizational documents, certain laws, governmental authorizations or certain contracts of the parties; result in any liens
on the parties&#8217; assets or require the consent of any third party;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the capitalization of Avalon and YOOV and their respective subsidiaries;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">ownership in subsidiaries;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">financial statements and, with respect to Avalon, documents filed with the SEC;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">liabilities;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">material changes or events;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">litigation;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">material contracts;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">benefit plans;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 131 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">labor relations;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">taxes;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">environmental matters;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">intellectual property and data privacy;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">real and personal property;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">compliance with laws and permits;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">regulatory matters;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">insurance;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">transactions with affiliates;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">with respect to Avalon, its efforts with respect to ensuring the inapplicability of Section 203 of the
DGCL;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">only with respect to Avalon, the fact that there is no stockholder rights plan or similar device;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">only with respect to Avalon, the valid issuance of the Merger Consideration; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">brokers.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The representations and warranties
are, in many respects, qualified by materiality and knowledge, and will not survive the Merger, but their accuracy forms the basis of
one of the conditions to the obligations of Avalon and YOOV to complete the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Restrictive Covenants; Conduct of Business
Pending the Merger</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">Avalon has agreed that, except
as permitted by the Merger Agreement, as required by law, or unless YOOV has provided written consent, during the period commencing on
the date of the Merger Agreement and continuing until the earlier to occur of the Effective Time and the termination of the Merger Agreement,
Avalon and its subsidiaries will use commercially reasonable efforts to conduct their operations only in the ordinary course and in material
compliance with all applicable laws, regulations and material contracts. Avalon has also agreed that, subject to certain limited exceptions,
without the consent of YOOV (which consent will not be unreasonably withheld, delayed or conditioned), it will not, and will not cause
or permit any of its subsidiaries to, during the period commencing on the date of the Merger Agreement and continuing until the earlier
to occur of the Effective Time and the termination of the Merger Agreement:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">except as required to give effect to anything in contemplation of the Closing, amend the certificate of
incorporation, bylaws or other similar organizational documents of Avalon or its subsidiaries;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">make, declare, accrue, set aside or pay any dividend or distribution on any of its shares;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">other than with respect to the Reverse Stock Split (a) adjust, split, combine or reclassify its share
capital, (b) redeem, purchase or otherwise acquire, directly or indirectly, any of its shares of Avalon Common Stock or any securities
convertible or exchangeable into or exercisable for any of its shares of Avalon Common Stock, (c) issue, deliver or sell to any employee
of Avalon any additional shares of Avalon Common Stock or any securities convertible or exchangeable into or exercisable for any shares
of Avalon Common Stock, or (d) enter into any contract with respect to the voting or registration of its share capital;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">other than in the ordinary course of business, or in connection with the Equity Plan Increase Proposal,
(a) materially increase the compensation or benefits payable or to become payable to any employee, director or officer of Avalon or any
of its subsidiaries, (b) grant any severance or termination pay to any current or new employees, director or officer of Avalon or any
of its subsidiaries, (c) renew or enter into or amend any employment or severance agreement with any current or new employee, director
or officer of Avalon or any of its subsidiaries, (d) establish, adopt, enter into, materially amend or terminate any equity compensation
plan or any employee benefit plan, agreement, policy or program in effect on the date of the Merger Agreement, (e) enter into, terminate,
amend or negotiate any collective bargaining agreement or other agreement or contract with any labor organization, works council, trade
union, labor association or other employee representative, (f) implement any employee layoffs that could trigger any liability or notice
requirements under the WARN Act, or (g) take any action to accelerate the vesting, payment, or funding of any compensation or benefits
to any current or former employee, director or officer of Avalon or any of its subsidiaries, except, in each case, pursuant to the terms
of any Avalon equity compensation plan in effect on the date of the Merger Agreement that has been made available to YOOV;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 132 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">other than for obtaining &#8220;tail&#8221; insurance coverage in connection with Closing, terminate or
modify in any material respect, or fail to exercise renewal rights with respect to, any material insurance policy;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">sell, lease, license, transfer, pledge, encumber, grant or dispose of any Assets (as defined in the Merger
Agreement), including any intellectual property rights, the capital stock of any subsidiaries, that are material to Avalon and its respective
subsidiaries, taken as a whole other than (a) in connection with products or services offered or provided in the ordinary course of business,
(b) the disposition of used, obsolete or excess equipment in the ordinary course of business, or (c) expirations of any registered intellectual
property in accordance with the applicable statutory term, grants of non-exclusive licenses of Avalon-owned intellectual property, or
dispositions of non-material Avalon-owned intellectual property, in each case in the ordinary course of business;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">acquire, by merger, consolidation, acquisition of equity interests or assets, or otherwise, any business,
any material assets or properties, or any corporation, partnership, limited liability company, joint venture or other business organization
or division thereof, if the consideration paid by Avalon or its subsidiaries in connection with any such acquisition individually, or
all such acquisitions in the aggregate, would exceed $250,000;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">(a) enter into any contract which, if in effect as of the date of the Merger Agreement, would be a material
contract (as defined in the Merger Agreement) or real property lease, other than in the ordinary course of business (unless such contract
would otherwise be prohibited under another covenant in the Merger Agreement), (b) enter into any contract that would limit or otherwise
restrict Avalon or any of its subsidiaries or any of their successors, or that would, after the Effective Time, from engaging or competing
in any line of business or in any geographic area in any material respect, or (c) terminate, cancel, request any material change in, materially
amend or waive any material rights under any material contract or real property lease other than the expiration of any material contract
or real property in accordance with its terms in the ordinary course of business (unless such action would otherwise be prohibited under
another covenant in the Merger Agreement), or terminate, amend or waive any provisions of any confidentiality or standstill agreements
in place with any third parties;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">incur, assume or guarantee any indebtedness for borrowed money, other than (i) pursuant to any indebtedness
instrument outstanding as of the date of the Merger Agreement and made available to YOOV, and (ii) pursuant to promissory notes issued
in connection with any acquisition by Avalon or any of its subsidiaries, which is made pursuant to the terms set forth above, provided
that the indebtedness under any such promissory note taken individually, and all such promissory notes in the aggregate, does not exceed
$250,000;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">(a) make or forgive any loans, advances or capital contributions to (other than business advances in the
ordinary course of business), or investments in, any other person (including any of its executive officers, directors, employees, agents
or consultants), other than by Avalon or a wholly owned subsidiary of Avalon to, or in, Avalon or any of its wholly owned subsidiaries
in the ordinary course of business, or (b) make any material change in its existing borrowing or lending arrangements for or on behalf
of such persons;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">other than in the ordinary course of business, make or change or rescind any material tax election, file
any material amended tax return, change or adopt any material method of Tax accounting, settle any material Tax claim or assessment, surrender
in writing any right to claim a material refund of Taxes, consent to (or request) any extensions or waiver of the limitation period applicable
to any material tax claim or assessment, enter into any &#8220;closing agreement&#8221; within the meaning of Section&#160;7121 of the
Code (or any similar provision of state, local, or non-U.S. law) or any voluntary disclosure agreement with any governmental authority,
in each case, with respect to a material amount of taxes, incur any taxes outside of the ordinary course of business, or take any action,
or knowingly fail to take any action, where such action or failure to act could reasonably be expected to prevent the Merger from qualifying
as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code and the Treasury Regulations;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 133 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">materially change its accounting policies or procedures or any of its methods of reporting income, deductions
or other items for material accounting purposes or revalue any of its material assets other than as required by changes in GAAP or applicable
law after the date of the Merger Agreement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">commence, initiate, waive, release, assign, settle or compromise any legal action, or enter into any settlement
agreement or other understanding or agreement with any governmental authority (other than in the case of this clause, entry into commercial
agreements not relating to a dispute with such governmental authority in the ordinary course of business), relating to Avalon or any of
its subsidiaries, other than any such waiver, release, assignment, settlement or compromise with a person that is not a governmental authority
that is limited only to the payment of money or other form of value that, collectively in respect of such waiver, release, assignment,
settlement or compromise, is not in excess of $500,000 individually or $1,000,000 in the aggregate;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">enter into or amend any arrangement or contract with any affiliate, director, officer or stockholder of
Avalon that would reasonably be expected to materially delay or prevent the consummation of the Transactions or that would be required
to be described under Item 404 of Regulation S-K; or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">agree in writing or otherwise enter into a binding agreement to do any of the foregoing.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV has agreed that, except
as permitted by the Merger Agreement, as required by law, or unless Avalon shall have provided written consent, during the period commencing
on the date of the Merger Agreement and continuing until the earlier to occur of the Effective Time and the termination of the Merger
Agreement, YOOV will use commercially reasonable efforts to conduct its operations only in the ordinary course and in material compliance
with all applicable laws, regulations and material contracts. YOOV has also agreed that, subject to certain limited exceptions, without
the consent of Avalon (which consent will not be unreasonably withheld, delayed or conditioned), it will not, and will not cause or permit
its subsidiary to, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the Effective
Time and the termination of the Merger Agreement:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">amend the certificate of incorporation, bylaws or other similar organizational documents of YOOV or its
subsidiaries;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">make, declare, accrue, set aside or pay any dividend or distribution on any of its shares;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">other than with respect to the Reverse Stock Split (a) adjust, split, combine or reclassify its share
capital, (b) redeem, purchase or otherwise acquire, directly or indirectly, any of its shares of YOOV Ordinary Shares or any securities
convertible or exchangeable into or exercisable for any of its shares of YOOV Ordinary Shares, (c) issue, deliver or sell to any employee
of YOOV any additional shares of YOOV Ordinary Shares or any securities convertible or exchangeable into or exercisable for any shares
of YOOV Ordinary Shares, or (d) enter into any contract with respect to the voting or registration of its share capital;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">other than in the ordinary course of business, (a) materially increase the compensation or benefits payable
or to become payable to any employee, director or officer of YOOV or any of its subsidiaries, (b) grant any severance or termination pay
to any current or new employees, director or officer of YOOV or any of its subsidiaries, (c) renew or enter into or amend any employment
or severance agreement with any current or new employee, director or officer of YOOV or any of its subsidiaries, (d) establish, adopt,
enter into, materially amend or terminate any equity compensation plan or any employee benefit plan, agreement, policy or program in effect
on the date of the Merger Agreement, (e) enter into, terminate, amend or negotiate any collective bargaining agreement or other agreement
or contract with any labor organization, works council, trade union, labor association or other employee representative, (f) implement
any employee layoffs that could trigger any liability or notice requirements under the WARN Act, or (g) take any action to accelerate
the vesting, payment, or funding of any compensation or benefits to any current or former employee, director or officer of YOOV or any
of its subsidiaries, except, in each case, pursuant to the terms of any YOOV equity compensation plan in effect on the date of the Merger
Agreement that has been made available to YOOV;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">terminate or modify in any material respect, or fail to exercise renewal rights with respect to, any material
insurance policy;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">sell, lease, license, transfer, pledge, encumber, grant or dispose of any Assets (as defined in the Merger
Agreement), including any intellectual property rights, the capital stock of any subsidiaries, that are material to YOOV and its respective
subsidiaries, taken as a whole other than (a) in connection with products or services offered or provided in the ordinary course of business,
(b) the disposition of used, obsolete or excess equipment in the ordinary course of business, or (c) expirations of any registered intellectual
property in accordance with the applicable statutory term, grants of non-exclusive licenses of YOOV-owned intellectual property, or dispositions
of non-material YOOV-owned intellectual property, in each case in the ordinary course of business;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 134 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">acquire, by merger, consolidation, acquisition of equity interests or assets, or otherwise, any business,
any material assets or properties, or any corporation, partnership, limited liability company, joint venture or other business organization
or division thereof, if the consideration paid by YOOV or its subsidiaries in connection with any such acquisition individually, or all
such acquisitions in the aggregate, would exceed $250,000;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">(a) enter into any contract which, if in effect as of the date of the Merger Agreement, would be a material
contract (as defined in the Merger Agreement) or real property lease, other than in the ordinary course of business (unless such contract
would otherwise be prohibited under another covenant in the Merger Agreement), (b) enter into any contract that would limit or otherwise
restrict YOOV or any of its subsidiaries or any of their successors, or that would, after the Effective Time, from engaging or competing
in any line of business or in any geographic area in any material respect, or (c) terminate, cancel, request any material change in, materially
amend or waive any material rights under any material contract or real property lease other than the expiration of any material contract
or real property in accordance with its terms in the ordinary course of business (unless such action would otherwise be prohibited under
another covenant in the Merger Agreement), or terminate, amend or waive any provisions of any confidentiality or standstill agreements
in place with any third parties;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">incur, assume or guarantee any indebtedness for borrowed money in excess of $1,000,000, other than (i)
pursuant to any indebtedness instrument outstanding as of the date of the Merger Agreement and made available to YOOV, (ii) pursuant to
promissory notes issued in connection with any acquisition by YOOV or any of its subsidiaries, which is made pursuant to the terms set
forth above, provided that the indebtedness under any such promissory note taken individually, and all such promissory notes in the aggregate,
does not exceed $250,000 (iii) in connection with interest rate hedges on terms in the ordinary course of business consistent with past
practice, or (iv) pursuant to any letters of credit that YOOV enters into in the ordinary course of its business;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">(a) make or forgive any loans, advances or capital contributions to (other than business advances in the
ordinary course of business), or investments in, any other person (including any of its executive officers, directors, employees, agents
or consultants), other than by YOOV or a wholly owned subsidiary of YOOV to, or in, YOOV or any of its wholly owned subsidiaries in the
ordinary course of business, or (b) make any material change in its existing borrowing or lending arrangements for or on behalf of such
persons;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">other than in the ordinary course of business, make or change or rescind any material tax election, file
any material amended tax return, change or adopt any material method of Tax accounting, settle any material Tax claim or assessment, surrender
in writing any right to claim a material refund of Taxes, consent to (or request) any extensions or waiver of the limitation period applicable
to any material tax claim or assessment, enter into any &#8220;closing agreement&#8221; within the meaning of Section&#160;7121 of the
Code (or any similar provision of state, local, or non-U.S. law) or any voluntary disclosure agreement with any governmental authority,
in each case, with respect to a material amount of taxes, incur any taxes outside of the ordinary course of business, or take any action,
or knowingly fail to take any action, where such action or failure to act could reasonably be expected to prevent the Merger from qualifying
as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code and the Treasury Regulations;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">materially change its accounting policies or procedures or any of its methods of reporting income, deductions
or other items for material accounting purposes or revalue any of its material assets other than as required by changes in GAAP or applicable
law after the date of the Merger Agreement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">commence, initiate, waive, release, assign, settle or compromise any legal action, or enter into any settlement
agreement or other understanding or agreement with any governmental authority (other than in the case of this clause, entry into commercial
agreements not relating to a dispute with such governmental authority in the ordinary course of business), relating to YOOV or any of
its subsidiaries, other than any such waiver, release, assignment, settlement or compromise with a person that is not a governmental authority
that is limited only to the payment of money or other form of value that, collectively in respect of such waiver, release, assignment,
settlement or compromise, is not in excess of $1,000,000 individually or $3,000,000 in the aggregate;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 135 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">enter into or amend any arrangement or contract with any affiliate, director, officer or stockholder of
YOOV that would reasonably be expected to materially delay or prevent the consummation of the Transactions or that would be required to
be described under Item 404 of Regulation S-K; or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">agree in writing or otherwise enter into a binding agreement to do any of the foregoing.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Non-Solicitation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">Each of Avalon and YOOV have
agreed that, except as described below, Avalon and YOOV and any of their respective subsidiaries will not, nor will either party or any
of its subsidiaries authorize or knowingly permit any of the directors, officers, employees, consultants, accountants, legal counsel,
investment bankers or other financial advisors agents and other representatives retained by it or any of its subsidiaries to, directly
or indirectly:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">solicit, initiate or propose the making, submission or announcement of, or knowingly encourage, facilitate
or assist, any proposal or offer that constitutes, or could reasonably be expected to lead to, any Takeover Proposal (as defined below);</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 26.75pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">terminate, waive, amend or modify any provision of any existing confidentiality, standstill or similar
agreement with respect to a potential Takeover Proposal;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 26.75pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">enter into any letter of intent, memorandum of understanding, agreement in principle, acquisition agreement,
merger agreement or similar agreement (an &#8220;Alternative Acquisition Agreement&#8221;) providing for the consummation of a transaction
contemplated by any Takeover Proposal (other than a confidentiality agreement in connection with a Takeover Proposal from a Qualified
Person, as discussed below);</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">take any action that could reasonably be expected to lead to a Takeover Proposal;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 26.75pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">other than informing Persons (as defined in the Merger Agreement) of the existence of the provisions above,
enter into, continue or otherwise participate in any discussions or negotiations regarding, or furnish to any Person any non public information
of such party for the purpose of encouraging, facilitating or responding to, any Takeover Proposal or any proposal or inquiry that is
reasonably expected to lead to a Takeover Proposal; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">publicly propose to do any of the above.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">A &#8220;Takeover Proposal&#8221;
means, any proposal, offer, inquiry or indication of interest from a Third Party (as defined in the Merger Agreement) or &#8220;group&#8221;
(as defined in Section 13 of the Exchange Act) of Third Parties, whether involving a single or a series of related transactions made or
submitted to Avalon or YOOV relating to (i) a merger, consolidation, share exchange or business combination involving a party or any of
its subsidiaries representing 20% or more of such party&#8217;s assets, revenues, or earnings, (ii) a sale, lease, exchange, mortgage,
transfer or other disposition of 20% or more of a party&#8217;s assets, revenues or earnings, (iii) a direct or indirect purchase or sale
of shares of capital stock, share capital or other Stock Equivalents (as defined in the Merger Agreement) of a party (including the Avalon
Common Stock) representing 20% or more of the voting power of the capital stock or share capital of such party or any successor or parent
company thereto, including by way of a merger, business combination, share exchange, tender offer or exchange offer, (iv) a reorganization,
recapitalization, liquidation or dissolution of a party, or (v) any other transaction having a similar effect to those described in clauses
(i) through (iv), or any combination of the transactions in (i) through (iv) in each case other than the Merger and the transactions contemplated
by the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Notwithstanding the foregoing,
before obtaining the applicable approvals of the Avalon stockholders or YOOV shareholders required to consummate the Merger, each party
may furnish non-public information regarding such party and its subsidiaries to, and may enter into discussions or negotiations with,
any third party, pursuant to a confidentiality agreement not materially less restrictive than the Confidentiality Agreement (as defined
in the Merger Agreement), in response to a bona fide written Takeover Proposal from a Qualified Person (as defined below) if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">such party&#8217;s board of directors has determined in good faith based on the advice of outside legal
counsel, that the failure to take the actions contemplated by this section would be reasonably likely to result in a breach of the fiduciary
duties of the such party&#8217;s board of directors under applicable law;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">neither such party nor any Representative (as defined in the Merger Agreement) of such party has breached
the non-solicitation provisions of the Merger Agreement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 136 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">at least two (2) business days prior to furnishing any non-public information or entering into discussions
with a third party, such party gives the other party written notice of the identity of the third party and of that party&#8217;s intention
to furnish non-public information to, or enter into discussions with, such third party;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">substantially contemporaneously with furnishing any non-public information to a third party, such party
furnishes the same non-public information to the other party to the extent not previously furnished; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">such party shall continue to observe its obligations under the Confidentiality Agreement (as defined in
the Merger Agreement), including not furnishing any such Qualified Person with any confidential information of the other party.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">The Merger Agreement also
provides that each party will promptly (and in no event less than twenty-four (24) hours) advise the other party of (a) such party&#8217;s
receipt of any written or oral Takeover Proposal; (ii) a summary of the material terms and conditions of any such Takeover Proposal; (iii)
a copy of the Alternative Acquisition Agreement and other material written proposals or offers delivered with, or in connection with,
such Takeover Proposal; and (iv) the identity of the Person making any such Takeover Proposal (unless, in the case of clause (iv), such
disclosure is prohibited pursuant to the terms of any confidentiality agreement with such person that is in effect on the date of the
Merger Agreement).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A &#8220;Qualified Person&#8221;
means any Person making a bona fide Takeover Proposal that did not result from a breach of the non-solicitation provisions of the Merger
Agreement that the board of directors of such party receiving the Takeover Proposal determines in good faith (after consultation with
outside counsel and its financial advisor) is, or would reasonably be expected to lead to, a Superior Proposal (as defined below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Enforcement of Civil Liabilities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">YOOV is a British Virgin
Islands business company incorporated in the British Virgin Islands. YOOV is incorporated in the British Virgin Islands because of certain
benefits associated with being a British Virgin Islands exempted company, such as political and economic stability, an effective judicial
system, a favorable tax system, the absence of foreign exchange control or currency restrictions and the availability of professional
and support services. However, the British Virgin Islands has a less developed body of securities laws than the United States and provides
less protection for investors. In addition, British Virgin Islands companies may not have standing to sue before the federal courts of
the United States.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true"><span style="font-family: Times New Roman, Times, Serif">Substantially
all of </span>YOOV&#8217;s <span style="font-family: Times New Roman, Times, Serif">assets are located outside the United&#160;States.
In addition, after the Merger, some of the directors and executive officers of the Combined Company will be nationals or residents of
jurisdictions other than the United&#160;States and substantially all of their assets are located outside the United&#160;States. As
a result, it may be difficult or impossible for you to effect service of process within the United&#160;States upon us or these persons,
or to enforce judgments obtained in U.S.&#160;courts against us or them, including judgments predicated upon the civil liability provisions
of the securities laws of the United&#160;States, or any state in the United&#160;States. It may also be difficult for you to enforce
judgments obtained in U.S.&#160;courts based on the civil liability provisions of the U.S.&#160;federal securities laws against us and
our executive officers and directors after the Merger.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">British Virgin Islands</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">There is uncertainty
as to whether the British Virgin Islands Courts would:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.5in"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">recognize or enforce of the United
                                            States courts obtained against us based on certain civil liability provisions of U.S. securities
                                            laws; or</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.5in"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">entertain original actions brought
                                            in the BVI to impose liabilities against us based on certain civil liability provisions of
                                            U.S. federal securities laws.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">The United States and
the BVI do not have a treaty providing for reciprocal recognition and enforcement of judgments of courts of the United States in civil
and commercial matters and that a final judgment for the payment of money rendered by any general or state court in the United States
based on civil liability, whether or not predicated solely upon the U.S. federal securities laws, would not be automatically enforceable
in the BVI. Although the courts of the British Virgin Islands would treat a final and conclusive monetary judgment for a definitive sum
obtained against us in the U.S. federal or state courts as a cause of action in itself which may be sued upon as a debt at common law
so that no retrial of the issues would be necessary provided that:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 24pt"/><td style="width: 23.5pt"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">the U.S. federal or state court
                                            issuing the judgment had jurisdiction in the matter and the company either submitted to such
                                            jurisdiction or was resident or carrying on business within such jurisdiction and was duly
                                            served with process;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 24pt"/><td style="width: 23.5pt"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">the judgment given by the U.S. court
                                            was not in respect of penalties, taxes, fines or similar fiscal or revenue obligations of
                                            the company;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 24pt"/><td style="width: 23.5pt"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">in obtaining judgment there was
                                            no fraud on the part of the person in whose favor judgment was given or on the part of such
                                            U.S. federal or state court;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 24pt"/><td style="width: 23.5pt"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">recognition or enforcement of the
                                            judgment in the BVI would not be contrary to public policy in the British Virgin Islands;
                                            and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47.5pt; text-align: justify; text-indent: -23.5pt"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 24pt"/><td style="width: 23.5pt; text-align: left"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><span style="-keep: true">the proceedings
                                            pursuant to which judgment was obtained were not contrary to natural justice.<i>Hong Kong</i></span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 137 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Substantially all of
YOOV&#8217;s assets are located outside the United&#160;States, specifically in Hong Kong. In addition, after the Merger, some of directors
and officers of the Combined Company will be nationals or residents of jurisdictions other than the United&#160;States, specifically
in Hong Kong, and all or a substantial portion of their assets are located outside the United&#160;States, within Hong Kong. As a result,
it may be difficult for investors to effect service of process within the United&#160;States upon us or these persons.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">The director nominees of
the Combined Company, Wong Ling Yan Philip, Devere Andrew Bryan, Lam Heung Yeung Herman, Lourdes Felix and Kirsty Vanora Godfrey-Billy,
reside within Hong&#160;Kong.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">There is uncertainty
as to whether the courts of Hong&#160;Kong would (i)&#160;recognize or enforce judgments of U.S.&#160;courts obtained against the Combined
Company or its directors or officers predicated upon the civil liability provisions of the securities laws of the United&#160;States
or any state in the United&#160;States, or (ii)&#160;entertain original actions brought in Hong&#160;Kong against the Combined Company
or its directors or officers predicated upon the securities laws of the United&#160;States or any state in the United&#160;States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Foreign judgments can
be enforced under the Foreign Judgments (Reciprocal Enforcement) Ordinance (Cap..319 of the Laws of Hong Kong) or under common law. Foreign
judgments can be enforced through a statutory registration scheme under the Foreign Judgments (Reciprocal Enforcement) Ordinance based
on reciprocal recognition of judgment between Hong Kong and the foreign courts. The United States is not a designated country under the
Foreign Judgments (Reciprocal Enforcement) Ordinance. As a result, a judgment rendered by a court in the United States, including as
a result of administrative actions brought by regulatory authorities, such as the SEC, and other actions, cannot be registered and may
only be enforced at common law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">With respect to enforcing
a judgment of the U.S. court at common law, the U.S. court judgment will not be enforced directly by execution or any other process.
The U.S. court judgment itself may form the basis of a cause of action and the judgment will be regarded as creating a debt between the
parties to it. The judgment debtors liability arises on an implied promise to pay the amount of U.S. court judgment under a simple contract.
Being a promise under a contract, it is subject to the usual limitation period of 6 years for such legal action. Generally, for a U.S.
court judgment to be enforceable at common law in HK SAR, certain requirements must be met: (i) such a judgment must be for a debt or
a definite sum of money other than a sum payable in respect of taxes, penalties or similar charges; (ii) the judgment creditor has to
prove, among other things, that the U.S. court judgment is a final judgment conclusive upon the merits of the claim in the U.S. jurisdiction;
(iii) the U.S. court judgment must come from a &#8220;competent&#8221; court (as determined by the private international law rules applied
by the HK SAR courts); (iv) the U.S. court judgment was not obtained by fraud; (v) the U.S. court judgment was not contrary to Hong Kong
rules of public policy or notions of natural justice; (vi) the U.S. court judgment is not irreconcilable with the prior decision of the
Hong Kong court in an action between the same parties; and (vii) the judgment debtor submitted or agreed to submit to the jurisdiction
of the U.S. court.Consequently, after the Merger, our shareholders seeking to enforce a foreign judgment in Hong Kong courts may incur
substantial legal and other costs. They could potentially spend considerable time and resources on the recognition and enforcement procedure,
which poses a significant burden with no assurance of ultimate success. As a result, after the Merger, our shareholders may have more
difficulties in protecting their interests through actions against the Combined Company or its officers, directors or major shareholders
than would shareholders of a corporation incorporated in a jurisdiction in the United States.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Recommendation Change</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">Under the Merger Agreement,
subject to certain exceptions described below, (a) Avalon and YOOV each agreed that its board of directors may not (i) withhold, withdraw,
qualify or modify, or and publicly propose to withhold, amend, withdraw or modify, the Avalon Board Recommendation or the YOOV Board Recommendation
(as each is defined below), as applicable, in a manner adverse to the other party and (ii) adopt, approve, endorse or recommend, or publicly
announce an intention to adopt, approve, endorse or recommend, any Takeover Proposal or any proposal that is reasonably expected to lead
to a Takeover Proposal and (b) Avalon agreed that its board of directors (i) will include the Avalon Board Recommendation in the Registration
Statement and (ii) will not make or fail to make any recommendation or public statement in connection with a tender or exchange offer,
other than a recommendation against such offer or a &#8220;stop, look and listen&#8221; communication by the Avalon Board to the Avalon
stockholders pursuant to Rule 14d-9(f) promulgated under the Exchange Act (or any substantially similar communication) (any of the foregoing,
an &#8220;Adverse Recommendation Change&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Intervening Event</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">However, notwithstanding
the foregoing, before obtaining the applicable approvals of the Avalon stockholders or YOOV shareholders required to consummate the Merger,
the board of directors of either party may make an Adverse Recommendation Change in response to an Intervening Event (as defined below)
if such Party&#8217;s board of directors determines in good faith, after consultation with its outside legal counsel, that the failure
to do so would be a breach such board of director&#8217;s fiduciary duties under applicable law, only if all of the following conditions
are satisfied:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">such party shall have first provided the other party an Intervening Event Notice (as defined in the Merger
Agreement) at least five (5) business days in advance advising the other party that such party intends to make an Adverse Recommendation
Change, and specifying, in reasonable detail, the Intervening Event;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">during the applicable Intervening Event Notice Period (as defined in the Merger Agreement), or any mutually
agreed extension or continuation thereof, such party and its Representatives shall negotiate in good faith with the other party and its
Representatives to make revisions to the terms of the Merger Agreement as would cause such Intervening Event to cease to warrant an Adverse
Recommendation Change;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 138 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the other party does not make, within the applicable Intervening Event Notice Period (or any extension
or continuation thereof) after the receipt of such notice, a proposal that would, in the good faith judgment of the Avalon Board or YOOV
Board, as applicable, (after consultation with outside legal counsel), cause the failure to effect an Adverse Recommendation Change in
response to such Intervening Event to no longer be inconsistent with the such board of director&#8217;s fiduciary duties under applicable
law; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60.5pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">following the Intervening Event Notice Period, the Avalon Board or YOOV Board, as applicable, shall have
determined in good faith (after consultation with its outside legal counsel) that the failure to effect an Adverse Recommendation Change,
as applicable, in response to such Intervening Event would continue to be a breach of such board of director&#8217;s fiduciary duties
under applicable law.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#8220;Avalon Board Recommendation&#8221;
means the Avalon Board&#8217;s unanimous recommendation to the Avalon stockholders that they approve (a) the issuance of the Merger Shares,
(b) the Reverse Stock Split Proposal and (c) any other proposals Avalon and YOOV mutually agree is necessary or desirable to consummate
the transactions contemplated by the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#8220;Intervening Event&#8221;
means any material event, change, effect, development or occurrence occurring or arising after the date of the Merger Agreement that (i)
was not known by nor was reasonably foreseeable to the board of directors of any party or the executive officers of any party as of or
prior to the date of the Merger Agreement (or, if known, the consequences of which were not known or reasonably foreseeable to such persons
as of the date of the Merger Agreement) and results in the standalone financial condition of Avalon, YOOV and their respective subsidiaries,
taken as a whole, being materially more favorable to the Avalon stockholders or the YOOV shareholders, as applicable, than the Merger
Agreement and the transactions contemplated thereby, and (ii) does not relate to or involve a (A) Takeover Proposal or, (B) in the case
of Avalon, any changes in the market price, or change in trading volume, of the Avalon Common Stock, any change of the ratings or ratings
outlook for Avalon by any of the Rating Agencies (as defined in the Merger Agreement) and the consequences of any such ratings or outlook
changes, or Avalon exceeding any projections, forecasts, budgets, operational metrics or estimates (it being understood that the underlying
causes of any such changes or developments may, if they are not otherwise excluded from the definition of Intervening Event, be taken
into account in determining whether an Intervening Event has occurred).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#8220;YOOV Board Recommendation&#8221;
means the YOOV Board&#8217;s unanimous recommendation to the YOOV shareholders that they adopt the Merger Agreement, the plan of merger,
articles of merger and the Surviving Corporation amended and restated articles of association contemplated thereby, and thereby approve
the transactions contemplated by the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Superior Proposal</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">In addition, notwithstanding
the foregoing, before obtaining the applicable approvals of the Avalon stockholders or YOOV shareholders required to consummate the Merger,
if Avalon or YOOV receives a bona fide unsolicited written Takeover Proposal made by a Third Party after the date of the Merger Agreement
which does not arise from a breach of the non-solicitation provisions of the Merger Agreement and has not been withdrawn, the board of
directors of such party that received the Takeover Proposal determines in good faith (a) after consultation with outside legal counsel
and a financial advisor, that such Takeover Proposal constitutes a Superior Proposal, and (b) after consultation with outside legal counsel,
that the failure to make an Adverse Recommendation Change would be a breach of such party&#8217;s board of director&#8217;s fiduciary
duties under applicable law, then such party&#8217;s board of director&#8217;s may make an Adverse Recommendation Change only if, in either
such case, all of the following conditions are satisfied:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">such party shall have first provided to the other party a Superior Proposal Notice (as defined in the
Merger Agreement) at least five (5) business days in advance advising the other party that such party is prepared to effect an Adverse
Recommendation Change in response to a Superior Proposal (and specifying, in reasonable detail, the material terms and conditions of any
such Superior Proposal, including the identity of the Third Party making any such Superior Proposal) and providing the other Party with
a complete copy of any written request, proposal or offer, including any proposed Alternative Acquisition Agreement (and all schedules,
appendices, exhibits and other attachments relating thereto), and any other documents containing the material terms of such Superior Proposal;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">during the applicable Superior Proposal Notice Period (as defined in the Merger Agreement) (or any extension
or continuation thereof), prior to its effecting an Adverse Recommendation Change, such party and its Representatives shall negotiate
in good faith with the other party and its Representatives regarding changes to the terms of the Merger Agreement and any other proposals
intended to cause such Takeover Proposal to no longer constitute a Superior Proposal;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 139 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the other party does not make, within the applicable Superior Proposal Notice Period (or any mutually
agreed extension or continuation thereof) after the receipt of such notice, a proposal that would, in the good faith judgment of the board
of directors of such party (after consultation with outside legal counsel and a financial advisor), cause the offer previously constituting
a Superior Proposal to no longer constitute a Superior Proposal; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">following the Superior Proposal Notice Period, such party&#8217;s board of directors shall have determined
in good faith, in light of such Superior Proposal and taking into account any revised terms proposed by the other party, (a) after consultation
with outside legal counsel and a financial advisor, that such Takeover Proposal continues to constitute a Superior Proposal, and (b) after
consultation with outside legal counsel, that the failure to make an Adverse Recommendation Change would continue to be a breach of such
party&#8217;s board of director&#8217;s fiduciary duties under applicable law.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8220;Superior Proposal&#8221;
means a bona fide and unsolicited written Takeover Proposal (substituting &#8220;more than 50%&#8221; for &#8220;20%&#8221; in each instance
in the definition of Takeover Proposal), made by any Third Party or group (as defined in Section 13 of the Exchange Act) after the date
of the Merger, which did not result from a direct or indirect material breach of any provision of the Merger Agreement, including the
non-solicitation provisions of the Merger Agreement, and that the board of directors of the party receiving such Takeover Proposal determines
in good faith, in consultation with outside legal counsel and financial advisors and taking into account (with such weight and proportion
as determined by such board of directors in its sole discretion) all the terms and conditions and the financial, legal, regulatory, timing,
financing, conditionality and other aspects and risks of such Takeover Proposal and the Merger Agreement (after taking into account any
revisions to the terms and conditions to the Merger Agreement made or proposed in writing by the other party to the Merger Agreement in
accordance with Section 5.04), (i) are more favorable to the stockholders of Avalon or shareholders of the YOOV, as applicable (solely
in their capacities as such) than the Merger and the transactions contemplated by the Merger Agreement, and (ii) the board of directors
of Avalon or YOOV, as applicable, believes is reasonably likely to be consummated in accordance with its terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Required Stockholder Approvals</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">As promptly as reasonably
practicable after the effectiveness of the Registration Statement, Avalon shall establish the record date, and duly call, give notice
of, convene or hold the Special Meeting to consider and vote to approve (a) the issuance of the Merger Shares, (b) the Reverse Stock Split
Proposal and (c) any other proposals Avalon and YOOV mutually agree is necessary or desirable to consummate the transactions contemplated
by the Merger Agreement. The Special Meeting will be held as promptly as practicable after the Registration Statement is declared effective,
and in any event no later than forty-five (45) calendar days after the effective date of the Registration Statement.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">As soon as reasonably practicable
after the effectiveness of the Registration Statement, and no later than twenty-five (25) business days thereafter, YOOV is required to
either (a) call and hold a meeting of the shareholders of YOOV for the purpose of voting upon the approval and adoption of the Merger
Agreement, the Merger and all other transactions contemplated thereby or (b) solicit a majority written consent from its shareholders.
Reasonably promptly following receipt of such consents, YOOV will prepare, and cause to be mailed to its stockholders who did not execute
such consents, a notice in accordance with the BVI Companies Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Indemnification and Insurance for Directors
and Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">Under the Merger Agreement,
from the Closing Date through the sixth (6<sup>th</sup>) anniversary of the Closing Date, each of Avalon and YOOV, being the Surviving
Corporation in the Merger, agreed to jointly and severally indemnify and hold harmless any present or former, or who becomes prior to
the Effective Time, director or officer of Avalon or the Surviving Corporation, or their respective subsidiaries (each an &#8220;Indemnified
Party&#8221; and collectively, the &#8220;Indemnified Parties&#8221;) against all claims, losses, Liabilities (as defined in the Merger
Agreement), damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements (collectively,
&#8220;Costs&#8221;), incurred in connection with any Legal Action (as defined in the Merger Agreement) arising out of or pertaining to
the fact that the Indemnified Party is or was a director or officer of Avalon, the Surviving Company or their respective subsidiaries,
whether asserted or claimed prior to, at or at or after the Effective Time, in each case, to the fullest extent permitted under applicable
law. Each Indemnified Party will be entitled to advancement of Costs incurred in the defense of any such Legal Action from each of Avalon
and the Surviving Company upon receipt by Avalon or the Surviving Company from the Indemnified Party of a request therefor; provided that
any such Person to whom Costs are advanced provides an undertaking to Avalon, to the extent then required by the DGCL, to repay such advances
if it is ultimately determined that such Indemnified Party is not entitled to indemnification. Avalon shall cooperate with the Indemnified
Party in the defense of any such Legal Action and Avalon shall not settle, compromise or consent to the entry of any judgment in any Legal
Action pending or threatened in writing to which an Indemnified Party is a party (and in respect of which indemnification could be sought
by such Indemnified Party hereunder), unless such settlement, compromise or consent includes an unconditional release of such Indemnified
Party from all liability arising out of such Legal Action or such Indemnified Party otherwise consents in writing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 140 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">The Merger Agreement also
provides that the provisions of the Avalon Charter and the Avalon Bylaws with respect to indemnification, advancement of expenses and
exculpation of present and former directors and officers of Avalon that are presently set forth in the Avalon Charter and the Avalon Bylaws
will not be amended modified or repealed for a period of six (6) years from the Effective Time in a manner that would adversely affect
the rights thereunder of individuals who, at or prior to the Effective Time, were officers or directors of Avalon, unless such modification
is required by applicable law. The articles of association and bylaws of the Surviving Corporation will contain, provisions no less favorable
with respect to indemnification, advancement of Costs and exculpation of present and former directors and officers as those set forth
in the Avalon Charter and the Avalon Bylaws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">From and after the Effective
Time, Avalon will maintain director and officers&#8217; liability insurance policies, with an effective date as of the Closing Date, on
commercially available terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Avalon.
In addition, Avalon will secure and purchase a six (6) year &#8220;tail policy&#8221; on Avalon&#8217;s existing directors&#8217; and
officers&#8217; liability insurance policy with an effective date as of the Closing Date with respect to any claim related to any period
of time at or prior to the Effective Time with terms, conditions, retentions and limits of Liability that are no less favorable than the
coverage provided under the Avalon Charter and the Avalon Bylaws as of the date of the Merger Agreement with respect to any actual or
alleged error, misstatement, misleading statement, act, omission, neglect, breach of duty or any matter claimed against a director or
officer of Avalon or any of its subsidiaries by reason of him or her serving in such capacity that existed or occurred at or prior to
the Effective Time (including in connection with the Merger Agreement or the transactions contemplated thereby).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Additional Covenants</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">Each of Avalon and YOOV has
agreed to, and use reasonable best efforts to cause their respective affiliates to, use its reasonable best efforts to, take, or cause
to be taken, all actions and cooperate with the other parties to the Merger Agreement in doing all things necessary to consummate the
Merger and the other transactions contemplated by the Merger Agreement. In connection therewith Avalon agreed to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">(a) as promptly as practicable following the date of the Merger Agreement, prepare and file with the SEC
this Registration Statement and (b) to use commercially reasonable efforts to (i) respond to any comments on the Registration Statement
or requests for additional information from the SEC as soon as practicable after receipt of any such comments or requests, (b) have the
Registration Statement declared effective by the SEC as promptly as practicable following its filing, (c) set the record date for the
Special Meeting and (d) cause the Registration Statement to be mailed to Avalon stockholders as promptly as practicable after the SEC
confirms it has no further comments to the Registration Statement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">as promptly as practicable following the effectiveness of the Registration Statement, establish the record
date, and duly call, give notice of, convene or hold the Special Meeting in accordance with the DGCL and the Avalon Charter and the Avalon
Bylaws (and in any event within forty-five (45) days after the date thereof, unless otherwise required by applicable laws) to consider
and vote to approve (a) the issuance of the Merger Shares, (b) the Reverse Stock Split Proposal and (c) any other proposals Avalon and
YOOV mutually agree is necessary or desirable to consummate the transactions contemplated by the Merger Agreement; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">use commercially reasonable efforts to ensure the continued listing on The Nasdaq Capital Market of the
existing shares of Avalon Common Stock as of and from the date of the Merger Agreement through the Closing Date, including, to the extent
required, filing an initial listing application for Avalon Common Stock on The Nasdaq Capital Market; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">from the date of the Agreement through the Effective Time, use commercially reasonable efforts to negotiate
with the holders of certain Avalon Warrants to sell, assign or transfer such Avalon Warrants to a third party reasonably acceptable to
YOOV.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 141 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the Merger Agreement, Avalon and YOOV
have further agreed that each party shall:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">use its reasonable best efforts to satisfy the conditions precedent to the consummation of the transactions
contemplated by the Merger Agreement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">use its reasonable best efforts to make all necessary filings, registrations, declaration and other submissions
(if any) and give all notices (if any) required to be made and given by such party in connection with the transactions contemplated by
the Merger Agreement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">use commercially reasonable efforts to obtain all necessary and advisable actions or non-actions, waivers
and consents, (if any) (pursuant to any applicable law or contract, or otherwise) in connection with the Merger and the other transactions
contemplated by the Merger Agreement or for such contract to remain in full force and effect; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">use reasonable best efforts to lift any injunction prohibiting, or any other legal bar to, the transactions
contemplated by the Merger Agreement.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Conditions to the Completion of the Merger</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">The following contains a
description of all material conditions to the completion of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">Each party&#8217;s obligation
to complete the Merger is subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the
parties, at or prior to the closing, of various conditions, which include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the Avalon stockholders shall have approved (a) the issuance of the Merger Shares, (b) the Reverse Stock
Split Proposal and (c) any other proposals Avalon and YOOV mutually agree is necessary or desirable to consummate the transactions contemplated
by the Merger Agreement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the YOOV shareholders shall have approved the Plan of Merger, the Surviving Corporation amended and restated
articles of association, and the transactions contemplated by the Merger Agreement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the Registration Statement, of which this proxy statement/prospectus is a part, must have been declared
effective by the SEC in accordance with the Securities Act and no stop order suspending the effectiveness of the Registration Statement
shall have been issued and no proceeding for that purpose shall have been initiated or threatened in writing by the SEC or its staff;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the existing shares of Avalon Common Stock must be continually listed on The Nasdaq Capital Market, as
of the date of the Merger Agreement through the Closing Date, there shall be no pending order or action from Nasdaq or any governmental
authority with respect to the status of the listing of the Avalon Common Stock on The Nasdaq Capital Market, including without limitation,
any delisting order and the Merger Shares shall have been approved for listing on The Nasdaq Capital Market, subject only to official
notice of issuance; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the parties shall have received all approvals from any governmental authority necessary to consummate
the Merger and transaction contemplated by the Merger Agreement, and there must not have been issued, and remain in effect, any temporary
restraining order, preliminary or permanent injunction or other judgment, order or decree preventing the consummation of the Merger or
any of the other transactions contemplated by the Merger Agreement by any court of competent jurisdiction or other governmental authority
of competent jurisdiction, and no law, statute, rule, regulation, ruling or decree will be in effect which has the effect of making the
consummation of the Merger or any of the other transactions contemplated by the Merger Agreement illegal.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, each party&#8217;s
obligation to complete the Merger is further subject to the satisfaction or waiver by that party of the following additional conditions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the other party to the Merger Agreement must have performed or complied with in all material respects
all of such party&#8217;s agreements and covenants required to be performed or complied with by it under the Merger Agreement at or prior
to the Effective Time; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the other party must have delivered certain certificates and other documents required under the Merger
Agreement for the closing.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 142 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, the obligation
of Avalon and Merger Sub to complete the Merger is further subject to the satisfaction or waiver of the following conditions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the representations and warranties regarding certain matters related to the capitalization of YOOV in
the Merger Agreement must be true and correct in all respects as of the Closing with the same force and effect as if made on such date,
or, if such representations and warranties address matters as of a particular date, then as of that particular date, except for such inaccuracies
which are de minimis, individually or in the aggregate;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the representations and warranties regarding certain organization and power, corporate authorization and
brokers of YOOV in the Merger Agreement (A) that are not qualified by material or any other materiality qualifications must be true and
correct in all material respects as of the Closing with the same force and effect as if made on such date, or, if such representations
and warranties address matters as of a particular date, then as of that particular date, and (B) that are qualified by material or any
other materiality qualifications must be true and correct in all respects as of the Closing with the same force and effect as if made
on such date, or, if such representations and warranties address matters as of a particular date, then as of that particular date;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the remaining representations and warranties of YOOV in the Merger Agreement must be true and correct
as of the Closing with the same force and effect as if made on such date, and, if such representations and warranties address matters
as of a particular date, then as of that particular date, except in each case, or in the aggregate, where the failure to be so true and
correct would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect (as defined in the Merger
Agreement) on YOOV (without giving effect to any references therein to materiality qualifications); and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">there shall have been no Material Adverse Effect.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">In addition, the obligation
of YOOV to complete the Merger is further subject to the satisfaction or waiver of the following conditions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the representations and warranties regarding certain matters related to the capitalization of Avalon in
the Merger Agreement must be true and correct in all respects as of the Closing with the same force and effect as if made on such date,
or, if such representations and warranties address matters as of a particular date, then as of that particular date, except for such inaccuracies
which are de minimis, individually or in the aggregate;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the representations and warranties regarding certain organization and power, corporate authorization and
brokers of Avalon in the Merger Agreement (A) that are not qualified by material or any other materiality qualifications must be true
and correct in all material respects as of the Closing with the same force and effect as if made on such date, or, if such representations
and warranties address matters as of a particular date, then as of that particular date, and (B) that are qualified by material or any
other materiality qualifications must be true and correct in all respects as of the Closing with the same force and effect as if made
on such date, or, if such representations and warranties address matters as of a particular date, then as of that particular date;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the remaining representations and warranties of Avalon in the Merger Agreement must be true and correct
as of the Closing with the same force and effect as if made on such date, and, if such representations and warranties address matters
as of a particular date, then as of that particular date, except in each case, or in the aggregate, where the failure to be so true and
correct would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on Avalon (without giving
effect to any references therein to materiality qualifications);</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">there shall have been no Material Adverse Effect; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">each of the officers and directors of Avalon that are not going to continue as officers or directors of
the Combined Company after the Effective Time must deliver a written resignation and general release, in a form reasonably satisfactory
to YOOV, dated as of the Closing Date and effective as of the Effective Time.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">Each of Avalon and YOOV may
waive any or all of the conditions to the closing of the Merger that are for its benefit, to the extent permitted by applicable laws.
Avalon does not believe that applicable laws would permit it to waive the condition for obtaining approval from Avalon&#8217;s stockholders
of the issuance of the Merger Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 143 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Termination and Termination Fee</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Termination of the Merger Agreement </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">The Merger Agreement may
be terminated at any time before the Effective Time, whether before or after the required stockholder approvals to complete the Merger
have been obtained, as set forth below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(a)</td><td style="text-align: justify">by mutual written consent of Avalon and YOOV;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 26.75pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(b)</td><td style="text-align: justify">by either Avalon or YOOV, if any of the following circumstances shall occur:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(1)</td><td style="text-align: justify">if the Merger has not been consummated by March 7, 2026 (the &#8220;End Date&#8221;); provided, however,
that this right to terminate the Merger Agreement will not be available to any party whose action or failure to act has been a principal
cause of the failure of the Merger to occur on or before the End Date and such action or failure to act constitutes a breach of the Merger
Agreement; and provided, further, that such date will be extended by sixty (60) days by either party in the event that the SEC has not
declared effective the registration statement on Form S-4, of which this proxy statement/prospectus is a part, by the date which is sixty
(60) days following the End Date;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(2)</td><td style="text-align: justify">if the Special Meeting has been held and completed and Avalon stockholders have taken a final vote on
the Merger proposals set forth herein to be considered at the Special Meeting, and such proposals have not been approved by the Avalon
stockholders; provided that Avalon may not terminate the Merger Agreement pursuant to this provision if the failure to obtain the approval
of Avalon stockholders was caused by the action or failure to act of Avalon and such action or failure to act constitutes a material breach
by Avalon of the Merger Agreement; or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(3)</td><td style="text-align: justify">if any law or order is enacted, issued, promulgated or entered by a governmental authority of competent
jurisdiction (including Nasdaq) that permanently enjoins, or otherwise prohibits consummation of the Merger or the transactions contemplated
by the Merger Agreement, and (in the case of any order) such order has become final and nonappealable.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(c)</td><td style="text-align: justify">by YOOV, at any time prior to obtaining the approval by Avalon stockholders of the Merger proposals set
forth herein to be considered at the Special Meeting, if any of the following circumstances shall occur:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(1)</td><td style="text-align: justify">the Avalon Board approves, endorses or recommends to the Avalon stockholders a Superior Proposal or tender
offer or exchange offer for any outstanding shares of capital stock of Avalon is commenced before obtaining the approval by the Avalon
stockholders of the Merger proposals set forth herein to be considered at the Special Meeting, and the Avalon Board fails to recommend
against acceptance of such tender offer or exchange offer by its stockholders within ten (10) business days after commencement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(2)</td><td style="text-align: justify">Avalon breaches any of its representations, warranties, covenants or agreements contained in the Merger
Agreement, which breach would give rise to the failure of a closing condition set forth in the Merger Agreement and cannot be cured on
or before the End Date, or if curable, has not be cured by Avalon within the earlier of (a) thirty (30) days after Avalon&#8217;s receipt
of written notice of such breach from YOOV or (b) one business day prior to the End Date; or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(3)</td><td style="text-align: justify">all of the conditions to Closing have been satisfied (other than any condition the failure of which to
be satisfied has been principally caused by the breach of the Merger Agreement by Avalon or any of its respective affiliates and conditions
that, by their nature, are to be satisfied at Closing and which were, at the time of termination, capable of being satisfied) and Avalon
has failed to fulfill its obligation and agreement herein to consummate the Closing within three (3) business days following written notice
of such satisfaction from YOOV and that YOOV is ready, willing and able to consummate the Merger and transactions contemplated by the
Merger Agreement.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(d)</td><td style="text-align: justify">by Avalon, at any time prior to obtaining the YOOV shareholder approval, if any of the following circumstances
shall occur:&#160;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(1)</td><td style="text-align: justify">the Avalon Board approves, endorses or recommends to the Avalon stockholders a Superior Proposal prior
to the receipt of the approval of the Avalon stockholders of the Merger proposals set forth herein to be considered at the Special Meeting,
if and only if, prior to or substantially concurrent with such termination (a) Avalon shall have paid the termination fee to YOOV pursuant
to the Merger Agreement and (b) Avalon substantially concurrently with such termination, enters into a definitive agreement with respect
to the Superior Proposal that did not result from a material breach of the non-solicitation provisions of the Merger Agreement and that
remained a Superior Proposal following Avalon&#8217;s compliance with the provisions pertaining to Superior Proposals in the Merger Agreement;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 144 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(2)</td><td style="text-align: justify">YOOV breaches any of its representations, warranties, covenants or agreements contained in the Merger
Agreement, which breach would give rise to the failure of a closing condition set forth in the Merger Agreement and cannot be cured on
or before the End Date, or if curable, has not be cured by YOOV within the earlier of (a) thirty (30) days after Avalon&#8217;s receipt
of written notice of such breach from Avalon or (b) one business day prior to the End Date; or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in">(3)</td><td style="text-align: justify">all of the conditions to Closing have been satisfied (other than any condition the failure of which to
be satisfied has been principally caused by the breach of the Merger Agreement by YOOV or any of its respective affiliates and conditions
that, by their nature, are to be satisfied at Closing and which were, at the time of termination, capable of being satisfied) and YOOV
has failed to fulfill its obligation and agreement herein to consummate the Closing within three (3) business days following written notice
of such satisfaction from Avalon and that Avalon is ready, willing and able to consummate the Merger and transactions contemplated by
the Merger Agreement.&#160;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">The party desiring to terminate
the Merger Agreement will give the other party written notice of such termination, specifying the provisions hereof pursuant to which
such termination is made and the basis for termination described in reasonable detail.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Termination Fee Payable by Avalon </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">Avalon must pay YOOV a termination
fee of $1.0 million (a) upon the consummation of a Superior Transaction (as defined below), if (i) the Merger Agreement is terminated
by YOOV pursuant to clause (b)(2) above, (ii) a Superior Proposal with respect to Avalon shall have been publicly announced, disclosed
or otherwise communicated to Avalon or the Avalon Board at any time after the date of the Merger Agreement but prior to the termination
of the Merger Agreement (which shall not have been withdrawn) and (iii) within twelve (12) months after the date of such termination,
Avalon (1) consummates a transaction in respect of the Superior Proposal referred to in clause (ii) (the &#8220;Superior Transaction&#8221;)
or (2) the Superior Transaction is withdrawn, terminated or otherwise discontinued for any reason, (b) within ten (10) business days (i)
of such termination, if the Merger Agreement is terminated by Avalon pursuant to clause (d)(1) above, or (ii) after receiving written
notice of such termination, if the Merger Agreement is terminated by YOOV pursuant to clause (c)(1) above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Amendment and Waiver</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">The Merger Agreement may
not be amended, modified or supplemented except by an instrument in writing signed on behalf of each of YOOV, Merger Sub and Avalon. Such
amendment requires the approval of the respective boards of directors of YOOV, Merger Sub and Avalon at any time, except that after the
YOOV shareholder approval or the Avalon stockholder approval or adoption has been obtained, no amendment which by law requires further
approval by the YOOV shareholders or Avalon stockholders, as the case may be, may be made without such further approval or adoption.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">Any provision of the Merger
Agreement may be waived by any party solely on that party&#8217;s behalf, without the consent of any other party, except that after the
YOOV shareholder approval or the Avalon stockholder approval has been obtained, no waiver which by law requires further approval or adoption
by the YOOV shareholders or Avalon stockholders, as the case may be, may be made without such further approval or adoption. The waiver
must be expressly set forth in a written instrument duly executed and delivered on behalf of such party, which will only be valid in the
specific instance in which it is given. No failure or delay on the part of any party with respect to the exercise of any power, right,
privilege or remedy under the Merger Agreement will operate as a waiver of such power, right, privilege or remedy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fees and Expenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">The Merger Agreement provides
all fees and expenses incurred in connection with the Merger Agreement and the transactions contemplated thereby shall be paid by the
party incurring such expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 145 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="a_069"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">CERTAIN AGREEMENTS RELATED
TO THE MERGER</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>This section describes the material provisions
of certain additional agreements entered into or to be entered into pursuant to or in connection with the transactions contemplated by
the Merger Agreement, which are referred to as the &#8220;Related Agreements,&#8221; but does not purport to describe all of the terms
thereof. The descriptions below are qualified by reference to the actual text of these agreements. You are encouraged to read the Related
Agreements in their entirety. </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_070"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Voting Agreements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">Contemporaneously with the
execution of the Merger Agreement, on March 7, 2025, the Key Avalon Stockholders, solely in their capacities as stockholders of Avalon,
entered into the Avalon Voting Agreement pursuant to which each Key Avalon Stockholder agreed to vote all of their shares of Avalon Common
Stock (a) in favor of the approval of (i) the Nasdaq Proposal, (ii) the Reverse Stock Split Proposal, (iii) any other proposals Avalon
and YOOV mutually agree is necessary or desirable to consummate the transactions contemplated by the Merger Agreement, and (iv) the adjournment
of the Special Meeting as permitted under the terms of the Merger Agreement, and (b) against, (i) any action or agreement that would reasonably
be expected to prevent or materially delay the consummation of the transactions contemplated by the Merger Agreement and the Merger, or
the fulfillment of Avalon&#8217;s or YOOV&#8217;s respective conditions to close the Merger or the transactions contemplated thereby and
(ii) any Takeover Proposals. Additionally, the Key Avalon Stockholders agreed to not transfer their capital stock of Avalon, subject to
limited exceptions, which includes, if such Key Avalon Stockholder is an entity, to one or more partners or members of such Key Avalon
Stockholder or an affiliated corporation, trust or other entity under common control with such Key Avalon Stockholder, or if such Key
Avalon Stockholder is a trust, a transfer to a beneficiary, (ii) if such Key Avalon Stockholder is a natural person, a family member of
such Key Avalon Stockholder, (iii) to any other Key Avalon Stockholder a party to the Avalon Voting Agreement, (iv) as YOOV may otherwise
agree in writing in its sole discretion, (v) with respect to such Key Avalon Stockholder&#8217;s stock options which expire on or prior
to the termination of Avalon Voting Agreement, as payment for the (A) exercise price of such stock options and (B) taxes applicable to
the exercise of such stock options, and (vi) to any natural person or entity if and to the extent required by any non-consensual legal
order, by divorce decree or by will, intestacy or other similar law or for estate planning purposes; provided, that in the case of clause
(i) (ii) and (iii), such transfer shall only be permitted only if, as a precondition to such transfer, the transferee agrees in writing
(in form and substance reasonably satisfactory to YOOV) to be bound by all of the obligations of such Key Avalon Stockholder under the
terms of the Avalon Voting Agreement. Collectively, as of March 7, 2025, the Key Avalon Stockholders held approximately 26.1% of the outstanding
shares of Avalon Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN"><span style="-keep: true">Also on March 7, 2025,
the Key YOOV Shareholders, including Wong Ho Chi Mark, Facewell International Limited, Chan Ka Po, Rich Joy International Industrial
Limited, Topsoil (HK) Limited, and Pearl River Partners Limited, entered into the YOOV Voting Agreement pursuant to which such Key YOOV
Shareholders agreed to vote all of their YOOV Ordinary Shares (a) in favor of the approval and adoption of the Merger and the transactions
contemplated thereby and (b) against, (i) any action or agreement that would reasonably be expected to result in the conditions of the
transactions contemplated by the Merger Agreement not being fulfilled or a breach of a covenant, representation or warranty or any other
material obligation or agreement of YOOV contained in the Merger Agreement, (ii) any action, proposal, transaction or agreement that
would reasonably be expected to prevent or materially delay the consummation of the Merger and the transactions contemplated by the Merger,
or the fulfillment of YOOV&#8217;s or Avalon&#8217;s respective conditions to close the Merger and the transactions contemplated thereby,
and (iii) any Takeover Proposals. Additionally, such Key YOOV Shareholders have agreed not to transfer their capital stock of YOOV, subject
to limited exceptions, which includes, if such Key YOOV Shareholder is an entity, to one or more partners or members of such Key YOOV
Shareholder or an affiliated corporation, trust or other entity under common control with such Key YOOV Shareholder, or if such Key YOOV
Shareholder is a trust, a transfer to a beneficiary, (ii) if such Key YOOV Shareholder is a natural person, a family member of such Key
YOOV Shareholder, (iii) to any other Key YOOV Shareholder a party to the YOOV Voting Agreement, (iv) as Avalon may otherwise agree in
writing in its sole discretion, and (vi) to any natural person or entity if and to the extent required by any non-consensual legal order,
by divorce decree or by will, intestacy or other similar law or for estate planning purposes; provided, that in the case of clause (i)
(ii) and (iii), such transfer shall only be permitted only if, as a precondition to such transfer, the transferee agrees in writing (in
form and substance reasonably satisfactory to Avalon) to be bound by all of the obligations of such Key YOOV Shareholder under the terms
of the Avalon Voting Agreement. Collectively, as of March 7, 2025, the Key YOOV Shareholders held approximately 53.5% of the outstanding
shares of capital stock of YOOV.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 146 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">None of the Key Avalon Stockholders,
nor the Key YOOV Shareholders received any separate additional consideration in connection with their entering into the Avalon Voting
Agreement or the YOOV Voting Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">The foregoing descriptions
of the terms of the Avalon Voting Agreement and the YOOV Voting Agreement do not purport to be complete and are qualified in its entirety
by reference to the Form of Avalon Voting Agreement and the Form of YOOV Voting Agreement attached hereto as Exhibits A and B, respectively,
to the Merger Agreement, attached as <span style="text-decoration:underline">Annex A</span> to this proxy statement/prospectus and are incorporated herein by reference.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_071"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Lock-Up Agreements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN"><span style="-keep: true">Concurrently with the
execution of the Merger Agreement, certain Key YOOV Shareholders, namely, Facewell International Limited, Wong Ho Chi Mark, Chan Ka Po
and Rich Joy International Industrial Limited, and each of the Key Avalon Stockholders, entered into the Lock-Up Agreements, pursuant
to which, subject to specified exceptions, they have agreed not to offer, pledge, sell, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose
of, directly or indirectly, directly or indirectly, any YOOV Ordinary Shares or Avalon Common Stock, as applicable, or any securities
convertible into or exercisable or exchangeable for YOOV Ordinary Shares or Avalon Common Stock, as applicable, currently or thereafter
owned until one hundred eighty (180) days after the Effective Time of the Merger.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">As of March 7, 2025, the
(i) certain Key YOOV Shareholders who executed Lock-Up Agreements beneficially owned approximately 47.7% of the outstanding YOOV Ordinary
Shares and (ii) Key Avalon Stockholders beneficially owned approximately 26.1% of the outstanding Avalon Common Stock. Accordingly, after
the Effective Time, approximately 47.0% of common stock of the Combined
Company will be subject to the Lock-Up Agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">The foregoing
description of the terms of the Lock-Up Agreements does not purport to be complete and is qualified in its entirety by reference to
the Form of Lock-Up Agreement attached hereto as Exhibit C to the Merger Agreement, attached as <span style="text-decoration:underline">Annex A</span> to this proxy
statement/prospectus and is incorporated herein by reference.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 147 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><div><a id="a_072"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">CERTAIN MATERIAL U.S. FEDERAL
INCOME TAX CONSEQUENCES OF THE MERGER</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">The following discussion
is a summary of certain material U.S. federal income tax consequences of the Merger applicable to U.S. Holders (as defined below) who
exchange their YOOV Common Stock for Avalon Common Stock in the Merger or who hold Avalon Common Stock immediately prior to the Merger,
but does not purport to be a complete analysis of all potential tax effects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">This discussion and the discussion
of tax consequences elsewhere in this proxy statement/prospectus are limited to U.S. Holders who hold their YOOV Common Stock or Avalon
Common Stock as a &#8220;capital asset&#8221; within the meaning of Section 1221 of the Code (generally, property held for investment).
This summary does not address all aspects of U.S. federal income taxation that may be relevant to U.S. Holders in light of their particular
circumstances or to U.S. Holders who may be subject to special tax treatment under the Code, including, without limitation, dealers in
securities, commodities or foreign currency; banks, thrifts, insurance companies, and other financial institutions; traders that mark-to-market
their securities; tax-exempt organizations or governmental organizations; small business investment companies; regulated investment companies;
real estate investment trusts; tax-deferred or other retirement accounts; persons whose functional currency is not the U.S. dollar; persons
who hold YOOV Common Stock or Avalon Common Stock as part of a &#8220;straddle,&#8221; &#8220;hedge,&#8221; &#8220;conversion transaction&#8221;
or other risk reduction transaction; persons who hold or receive YOOV Common Stock or Avalon Common Stock pursuant to the exercise of
compensatory stock options, the vesting of previously restricted shares of stock or otherwise as compensation; persons holding YOOV Common
Stock who exercise dissenters&#8217; rights; persons whose shares constitute &#8220;qualified small business stock&#8221; for purposes
of Section 1202 of the Code; any entity or arrangement that is a partnership for U.S. federal income tax purposes; companies subject to
the &#8220;stapled stock&#8221; rules; &#8220;expatriated entities&#8221;; or certain former citizens or long-term residents of the United
States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">This discussion is based
on the Code, U.S. Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements
of the Internal Revenue Service, or IRS, in effect as of the date hereof, all of which are subject to change, possibly with retroactive
effect, or differing interpretations. Neither YOOV nor Avalon have sought any ruling from the IRS with respect to the statements made
and the conclusions reached in this discussion, and there can be no assurance that the IRS will agree with these statements and conclusions.
The effects of other U.S. federal tax laws, such as estate and gift tax laws, the alternative minimum tax and the 3.8% tax on net investment
income, and any applicable state, local, or foreign tax laws or the tax consequences occurring prior to, concurrently with or after the
merger (whether or not such transactions are in connection with the merger) are not discussed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">Each U.S. Holder is urged
to consult its own tax advisor with regard to the merger and the application of U.S. federal income tax laws, as well as the laws of any
state, local or foreign taxing jurisdictions, to its particular situation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">For purposes of this discussion,
a &#8220;U.S. Holder&#8221; is a beneficial owner of YOOV Common Stock or Avalon Common Stock that, for U.S. federal income tax purposes,
is or is treated as:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">an individual who is a citizen or resident of the United States;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">a corporation (or other entity taxable as a corporation for U.S. federal income purposes) created or organized
under the laws of the United States, any state thereof, or the District of Columbia;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">a trust if either a court within the United States is able to exercise primary supervision over the administration
of such trust and one or more United States persons (within the meaning of Section 7701(a)(30) of the Code, which we refer to as &#8220;United
States persons&#8221;) have the authority to control all substantial decisions of such trust, or the trust has a valid election in effect
under applicable Treasury Regulations to be treated as a United States person for U.S. federal income tax purposes.&#160;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an entity or arrangement
treated as a partnership for U.S. federal income tax purposes holds YOOV Common Stock or Avalon Common Stock, the tax treatment of a partner
in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the
partner level. Accordingly, partnerships holding YOOV Common Stock or Avalon Common Stock and the partners in such partnerships should
consult their tax advisors regarding the U.S. federal income tax consequences to them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISORS
WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF
THE MERGER ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION
OR UNDER ANY APPLICABLE INCOME TAX TREATY. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 148 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Material U.S. Federal Income Tax Consequences for U.S. Holders
of Avalon Common Stock</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon stockholders will not
sell, exchange or dispose of any shares of Avalon stock as a result of the Merger, so the Merger should not result in recognition of gain
or loss to the Avalon stockholders for U.S. federal income tax purposes in respect of their Avalon shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Material U.S. Federal Income Tax Consequences for U.S. Holders
of YOOV Common Stock</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the qualifications
and assumptions described in this proxy statement/prospectus, the Merger is intended to be treated for U.S. federal income tax purposes
as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended, for U.S. federal
income tax purposes. Neither Avalon nor YOOV has requested a ruling from the IRS regarding the qualification of the Merger as a reorganization
within the meaning of Section 368(a) of the Code. There is no guarantee that the IRS will treat the merger as a &#8220;reorganization&#8221;
within the meaning of Section 368(a) of the Code or that a court would not sustain a position that is contrary to any of the positions
set forth in this summary. Lucosky Brookman LLP, as counsel for YOOV, and Lowenstein Sandler LLP, as counsel for Avalon, believe that
the Merger will qualify as a reorganization within the meaning of Section 368(a) of the Code, based upon representations and covenants
received by each of Lucosky Brookman LLP and Lowenstein Sandler LLP from each of YOOV and Avalon in representation letters and assumptions
that (i) there will be no change in applicable law between the date of such opinions and the date of the Merger, (ii) the Merger will
be effected in accordance with the provisions of the Merger Agreement and (iii) the exercise of appraisal rights with respect to the Merger
will not be such as to prevent Avalon from acquiring interests in YOOV representing &#8220;control&#8221; of YOOV (generally defined as
voting shares representing at least 80% of the voting power of YOOV&#8217;s outstanding shares and at least 80% of each class of non-voting
shares of YOOV) for Avalon Common Stock. Should such an assumption or any of the representations or covenants set forth in the representation
letters from YOOV or Avalon not be accurate, then the Merger may not qualify as a reorganization within the meaning of Section 368(a)
of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Neither Avalon nor YOOV has
requested, and neither intends to request, a ruling from the IRS addressing the U.S. federal income tax consequences of the Merger. Consequently,
no assurance can be given that the IRS will not assert, or that a court would not sustain, a position contrary to the intended tax treatment
or any of the anticipated tax consequences set forth below, and accordingly, neither the Combined Company, Avalon, nor any other party
to the Merger Agreement makes any representations or provides any assurances regarding the qualification of the Merger as a reorganization.
Given this uncertainty, each holder of shares of Avalon Common Stock and YOOV Ordinary Shares is urged to consult its tax advisor with
respect to the particular tax consequence of the Merger to such holder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Assuming the Merger qualifies
as a reorganization within the meaning of Section 368(a) of the Code, in general, U.S. Holders (as defined herein) of YOOV Ordinary Shares
generally should not recognize gain or loss upon the exchange of YOOV Ordinary Shares for Avalon Common Stock pursuant to the Merger.
A shareholder&#8217;s aggregate tax basis in the shares of Avalon Common Stock received in the Merger will be the same as the aggregate
tax basis of the YOOV Ordinary Shares exchanged in the Merger, and the holding period of shares of Avalon Common Stock received in exchange
for YOOV Ordinary Shares will include the holding period of the YOOV Ordinary Shares exchanged for Avalon Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">However, there are many requirements
that must be satisfied in order for the Merger to be treated as a reorganization under Section 368(a) of the Code, some of which are based
upon factual determinations, and the reorganization treatment could be affected by actions taken after the Merger. If the Merger failed
to qualify as a reorganization under Section 368(a) of the Code, U.S. Holders of YOOV Ordinary Shares generally would recognize or loss
equal to the difference, if any, between the fair market value of YOOV Ordinary Shares and such U.S. Holders&#8217; adjusted tax basis
in their YOOV Ordinary Shares exchanged for Avalon Common Stock in the Merger. Long-term capital gain of certain non-corporate U.S. Holders
of YOOV Ordinary Shares (including individuals) is currently eligible for U.S. federal income taxation at preferential rates. The deductibility
of capital losses is subject to limitations. U.S. Holders that realize a loss should consult their tax advisors regarding any limitations
on the deductibility of such losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The discussion of material
U.S. federal income tax consequences contained in this proxy statement/prospectus is intended to provide only a general discussion and
is not a complete analysis or description of all potential U.S. federal income tax consequences of the Merger that may vary with, or are
dependent on, individual circumstances. In addition, the discussion does not address the effects of any foreign, state or local tax laws.
Accordingly, you should consult your tax advisor for a full understanding of the tax consequences of the Merger to you, including the
applicability and effect of federal, state, local and foreign income and other tax laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 149 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_073"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">PROPOSAL
NO. 1-THE NASDAQ PROPOSAL</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><div><a id="a_074"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Merger Shares</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">At the Special Meeting, Avalon
stockholders will be asked to approve (i) the issuance of the Merger Shares to the shareholders of YOOV pursuant to the Merger Agreement,
which Merger Shares will represent more than 20% of the shares of Avalon Common Stock outstanding immediately prior to the Merger and
(ii) the change of control of Avalon resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">Subject to the terms and
conditions of the Merger Agreement, immediately prior to the Effective Time, each then-outstanding YOOV Preferred Share will either automatically
be converted into YOOV Ordinary Shares or canceled and cease to exist in accordance with their terms. At the Effective Time, each then-outstanding
YOOV Ordinary Share (other than shares held in treasury and Dissenting Shares (as defined below)) will be converted into and become exchangeable
for a number of shares of Avalon Common Stock equal to the Exchange Ratio.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">The Exchange Ratio in the
Merger Agreement sets forth the number of shares of Avalon Common Stock that will be issuable for each YOOV Ordinary Share outstanding
in the Merger. The Exchange Ratio is subject to a collar mechanism and will be determined as follows: if the closing price of the Avalon
Common Stock on Nasdaq on the second (2<sup>nd</sup>) trading day immediately preceding the Effective Time is (x) less than or equal
to $5.00, the Exchange Ratio shall be 60,000,000 divided by the YOOV Outstanding Shares; or (y) greater than $5.00, the Exchange Ratio
shall be 54,000,000 divided by the YOOV Outstanding Shares. Based on the closing price of Avalon Common Stock on Nasdaq of $3.41 on June
6, 2025, the latest practicable trading day prior to the date of this proxy statement/prospectus, and the number of YOOV Outstanding
Shares on such date, it is estimated that the Exchange Ratio will be approximately 121.8. Based on the estimated Exchange Ratio, Avalon
is expected to issue 60,000,000 shares of Avalon Common Stock to the YOOV shareholders. Upon completion of the Merger, the current Avalon
stockholders are expected to own approximately 2.7% to 3.0% of the common stock of the Combined Company and the YOOV shareholders are
expected to own approximately 97.0% to 97.3% of the common stock of the Combined Company. The Exchange Ratio is an estimate only, and
the actual Exchange Ratio and relative ownership interests of Avalon stockholders and YOOV shareholders in the Combined Company immediately
following the Merger will depend on the market price of Avalon&#8217;s Common Stock two (2) trading days prior to the Merger and the
number of YOOV Outstanding Shares on the Closing Date.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">For more information about
the Merger and the issuance of the Merger Shares, please see the sections entitled &#8220;<i>The Merger</i>&#8221; and &#8220;<i>The
Merger Agreement-Merger Consideration</i>&#8221;, and the full text of the Merger Agreement included as <span style="text-decoration:underline">Annex A</span> hereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_075"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Approval of the Issuance of the Merger Shares</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">Under Nasdaq Listing Rule
5635(a)(1), a company listed on Nasdaq is required to obtain stockholder approval prior to the issuance of common stock, among other things,
in connection with the acquisition of another company&#8217;s stock, if the number of shares of common stock to be issued is in excess
of 20% of the number of shares of common stock then outstanding. The issuance of the Merger Shares is expected to result in an issuance
comprising more than 20% of the outstanding common stock of Avalon, or more than 20% of the voting power, in each case outstanding before
the issuance. In addition, under Nasdaq Listing Rule 5635(b), a company listed on Nasdaq is required to obtain stockholder approval prior
to the issuance of common stock where the issuance will result in a change of control of the company. The Avalon Board is requesting stockholder
approval of the Nasdaq Proposal to comply with Nasdaq Listing Rules 5635(a)(1) and 5635(b).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_076"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Vote Required for Approval</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">The approval of the Nasdaq
Proposal requires the affirmative vote of a majority of the total votes properly cast by the Avalon Stockholders at the Special Meeting.
Accordingly, abstentions and broker non-votes, if any, will have no effect on the outcome of the Nasdaq Proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">As of the Record Date,
the Key Avalon Stockholders, including Avalon directors and officers, beneficially owned approximately [ ]% of the outstanding shares
of Avalon Common Stock and, pursuant to the Voting Agreements, agreed to vote all of their shares of Avalon Common Stock in favor of
the approval of the Nasdaq Proposal.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE AVALON BOARD UNANIMOUSLY RECOMMENDS THAT
ITS STOCKHOLDERS VOTE &#8220;FOR&#8221; THE ISSUANCE OF THE MERGER SHARES AS SET FORTH IN THE NASDAQ PROPOSAL. </b></p><div>




</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 150 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_077"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">PROPOSAL
NO. 2-THE REVERSE STOCK SPLIT PROPOSAL</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">The Avalon Board has unanimously
approved a reverse stock split of the outstanding shares of Avalon Common Stock and other outstanding securities of Avalon, at a ratio
ranging from 1-for-2 to 1-for-20, inclusive (the &#8220;Reverse Stock Split&#8221;). &#160;A vote for this Reverse Stock Split Proposal
will constitute adoption and approval of an amendment to the Avalon Charter to effect the Reverse Stock Split (the &#8220;Reverse Split
Charter Amendment&#8221;) that, once effected by filing the Reverse Split Charter Amendment with the Secretary of State of the State of
Delaware, will combine between two (2) and twenty (20) shares of Avalon Common Stock into one share of Avalon Common Stock. If implemented,
the Reverse Stock Split will have the effect of decreasing the number of shares of Avalon Common Stock outstanding, but will have no effect
on the number of shares of Avalon Common Stock authorized for issuance pursuant to the Avalon Charter. The determination to effect the
Reverse Stock Split, including the ratio within the specified range and effective date of any such Reverse Stock Split, will be determined
by the Avalon Board in its sole discretion, if necessary to be effectuated pursuant to the rules of The Nasdaq Capital Market to consummate
the Merger. The Avalon Board has recommended that the proposed Reverse Stock Split be presented to, and approved by, the Avalon stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">The Reverse Stock Split,
if approved by Avalon stockholders at the Special Meeting, would become effective at the time and date set forth in the Reverse Split
Charter Amendment to be filed with the Secretary of State of the State of Delaware. The form of the proposed Reverse Split Charter Amendment
to effect the Reverse Stock Split is attached as <span style="text-decoration:underline">Annex C</span> to this proxy statement/prospectus. The Reverse Split Charter Amendment
to effect the Reverse Stock Split will include the Reverse Stock Split ratio fixed by the Avalon Board, within the range approved by Avalon
stockholders. Should Avalon receive the required stockholder approval for the Reverse Stock Split Proposal, the Avalon Board will have
the sole authority to determine, and without the need for any further action on the part of the Avalon stockholders, whether to effect
the Reverse Stock Split, the effective date of such Reverse Stock Split and the number of whole shares of Avalon Common Stock, between
and including two (2) and twenty (20), that will be combined into one share of Avalon Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN"><b>By approving the Reverse
Stock Split Proposal, Avalon&#8217;s stockholders will: (a) approve the Reverse Stock Split of Avalon Common Stock pursuant to which any
whole number of outstanding shares of Avalon Common Stock between and including two (2) and twenty (20) will be combined into one share
of Avalon Common Stock; and (b) authorize the Avalon Board to determine, at its option, whether to effect the Reverse Stock Split, the
effective date of the Reverse Stock Split and the ratio of the Reverse Stock Split within the specified range. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><div><a id="a_078"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Approval of Reverse Stock Split of Avalon Common
Stock</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">The Avalon Board has approved
and is recommending that its stockholders approve a Reverse Stock Split of Avalon Common Stock at a ratio in the range of 1-for-2 to 1-for-20,
inclusive. Avalon is proposing that the Avalon Board have the discretion to select the Reverse Stock Split ratio from within such range,
rather than proposing that stockholders approve a specific ratio at this time, in order to give the Avalon Board the flexibility to implement
a Reverse Stock Split at a ratio that reflects the Avalon Board&#8217;s then-current assessment of the factors described below under &#8220;Criteria
to be Used for Determining Whether to Implement the Reverse Stock Split.&#8221; If the Avalon Board decides to implement a Reverse Stock
Split, the Avalon Board will do so following the Special Meeting by resolution, which will include the effective date and ratio of the
Reverse Stock Split. Except for adjustments that may result from the treatment of fractional shares as described below, each of Avalon&#8217;s
stockholders will hold the same percentage of outstanding Avalon Common Stock immediately following the Reverse Stock Split as such stockholder
holds immediately prior to the Reverse Stock Split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_079"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Reasons for Reverse Stock Split</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN"><i>To meet the initial listing
requirements on The Nasdaq Capital Market in connection with the Merger. </i>In connection with the completion of the Merger, the Combined
Company will be required to meet the initial listing requirements of The Nasdaq Capital Market. These initial listing requirements are
more difficult to achieve than the continued listing requirements. Pursuant to the Merger Agreement, Avalon agreed, subject to Avalon
stockholder approval, to effect the Reverse Stock Split to ensure the Avalon Common Stock will be able to meet the $4.00 minimum bid
price initial listing requirement. If the Reverse Stock Split Proposal is not approved and Avalon is unable to otherwise effect a Reverse
Stock Split, the conditions to closing the Merger may not be achieved. Please see the section entitled &#8220;<i>The Merger Agreement-Conditions
to the Completion of the Merger</i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 151 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN"><i>To maintain Avalon&#8217;s
listing on The Nasdaq Capital Market if the Merger with YOOV is not consummated.</i> By potentially increasing Avalon&#8217;s stock price,
the Reverse Stock Split would reduce the risk that Avalon Common Stock could be delisted from The Nasdaq Capital Market in the event the
Merger with YOOV is not consummated. To continue Avalon&#8217;s listing on The Nasdaq Capital Market, Avalon must comply with Nasdaq Marketplace
Rules regarding continued listing requirements, which requirements include a minimum bid price of $1.00 per share. On November 3, 2023,
the Nasdaq staff notified Avalon that Avalon did not comply with the Minimum Bid Price Requirement for continued listing on The Nasdaq
Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2) (the &#8220;Bid Price Notice&#8221;). Pursuant to the Bid Price Notice,
Avalon had 180 calendar days from the date of the Bid Price Notice, or May 1, 2024, to regain compliance with the Minimum Bid Price Requirement.
On May 2, 2024, the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to October 28,
2024, to regain compliance with the Minimum Bid Price Requirement. In connection with regaining compliance with the Minimum Bid Price
Requirement, Avalon implemented a reverse stock split on October 25, 2024. However, on October 29, 2024,&#160;Avalon received notice from
the Nasdaq staff that it failed to regain compliance with the Minimum Bid Price Requirement because the reverse stock split did not occur
at least ten (10) business days prior to the deadline of on or before October 28, 2024, which served as basis for the delisting of Avalon&#8217;s
securities from Nasdaq.&#160;Following the receipt of the Nasdaq notice, Avalon requested and received a hearing date to discuss the non-compliance
notice with the Nasdaq staff. On November 19, 2024, prior to the date of the hearing, Avalon received a notice that it has regained compliance
with Nasdaq&#8217;s Minimum Bid Price Requirement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">However, there can be no
assurance that Avalon will be able to continue to maintain compliance with the Nasdaq continued listing requirements. The Avalon Board
has considered the potential harm to Avalon and its stockholders should Avalon be unable to maintain compliance with the continued listing
requirements, including the failure to consummate the Merger or delisting of Avalon Common Stock from The Nasdaq Capital Market. If the
Merger with YOOV is not consummated, the Avalon Common Stock price could decline, to the extent it reflects an assumption that Closing
will occur. In addition, delisting could adversely affect the liquidity of Avalon Common Stock, since alternatives, such as the OTC Market,
are generally considered to be less efficient markets. An investor likely would find it less convenient to sell, or to obtain accurate
quotations in seeking to buy, Avalon Common Stock on the OTC Market. Many investors likely would not buy or sell Avalon Common Stock due
to difficulty in accessing the OTC Market, policies preventing them from trading in securities not listed on a national exchange or for
other reasons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">Accordingly, even if the
Merger with YOOV is not consummated, the Avalon Board believes that the Reverse Stock Split may be a potentially effective means for Avalon
to maintain compliance with Nasdaq&#8217;s Minimum Bid Price Requirement, and to avoid, or at least mitigate, the likely adverse consequences
of Avalon Common Stock being delisted from The Nasdaq Capital Market by producing the immediate effect of increasing the bid price of
Avalon Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN">The Avalon Board believes
that maintaining the current number of authorized shares of Avalon Common Stock, irrespective of the Reverse Stock Split, is necessary
to provide Avalon with the flexibility to act in the future with respect to raising additional financing, potential strategic collaborations
and other corporate purposes without the delay and expense associated with obtaining special stockholder approval each time an opportunity
requiring the issuance of shares of Avalon Common Stock may arise. Such a delay might deny Avalon the flexibility that the Avalon Board
views as important and in the interests of the Company and its stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25IN"><i>To potentially improve
the marketability and liquidity of Avalon Common Stock should the Merger not occur.</i> The Avalon Board believes that the increased market
price of Avalon Common Stock expected as a result of implementing a Reverse Stock Split could improve the marketability and liquidity
of Avalon Common Stock and encourage interest and trading in Avalon Common Stock should the Merger not occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Stock Price Requirements: Many brokerage houses, institutional investors and funds have internal policies
and practices that either prohibit them from investing in low-priced stocks or tend to discourage individual brokers from recommending
low-priced stocks to their customers or by restricting or limiting the ability to purchase such stocks on margin. A Reverse Stock Split
could help increase analyst and broker interest in Avalon Common Stock, as their internal policies might discourage them from following
or recommending companies with low stock prices.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Stock Price Volatility: Because of the trading volatility often associated with low-priced stocks, many
brokerage houses and institutional investors have internal policies and practices that either prohibit them from investing in low-priced
stocks or tend to discourage individual brokers from recommending low-priced stocks to their customers. Some of those policies and practices
may make the processing of trades in low-priced stocks economically unattractive to brokers.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Transaction Costs: Investors may be dissuaded from purchasing stocks below certain prices because brokers&#8217;
commissions, as a percentage of the total transaction value, can be higher for low-priced stocks.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 152 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><div><a id="a_080"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Criteria to be Used for Determining Whether
to Implement Reverse Stock Split</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In determining whether to
implement the Reverse Stock Split and which Reverse Stock Split ratio to implement, The Avalon Board may consider, among other things,
various factors, such as:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the historical trading price and trading volume of Avalon Common Stock;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the then-prevailing trading price and trading volume of Avalon Common Stock and the expected impact of
the Reverse Stock Split on the trading market for Avalon Common Stock in the short- and long-term;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Avalon&#8217;s ability to maintain or continue its listing on The Nasdaq Capital Market;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Avalon&#8217;s ability to meet the initial listing requirements in The Nasdaq Capital Market in connection
with the Merger and satisfy the closing conditions to complete the Merger with YOOV;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">which Reverse Stock Split ratio would result in the least administrative cost to Avalon;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">prevailing general market and economic conditions; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">if Avalon stockholders approve this Reverse Stock Split Proposal, the additional authorized but unissued
shares of Avalon Common Stock that will result from the implementation of a Reverse Stock Split, will be available to provide flexibility
to use Avalon Common Stock for business and/or financial purposes.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_081"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Certain Risks and Potential Disadvantages Associated
with Reverse Stock Split</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon cannot assure you
that the Reverse Stock Split will increase its stock price and have the desired effect of meeting the initial listing requirements on
The Nasdaq Capital Market in connection with the Merger or maintaining compliance with the continued listing requirements of the Nasdaq
Listing Rules if the Merger is not consummated. Avalon expects that the Reverse Stock Split will increase the market price of Avalon Common
Stock so that Avalon may be able to meet the initial listing requirements in connection with the Merger. In addition, Avalon expects that
the Reverse Stock Split will increase the market price of Avalon Common Stock so that Avalon may be able to regain and/or maintain compliance
with the Nasdaq Minimum Bid Price Requirement, or to meet or maintain compliance with the Nasdaq Listing Rules required for Avalon&#8217;s
continued listing on The Nasdaq Capital Market should the Merger not be completed. However, the effect of the Reverse Stock Split upon
the market price of Avalon Common Stock cannot be predicted with any certainty, and the history of similar reverse stock splits for companies
in like circumstances is varied, particularly since some investors may view a reverse stock split negatively. It is possible that the
per share price of Avalon Common Stock after the Reverse Stock Split will not rise in proportion to the reduction in the number of shares
of Avalon Common Stock outstanding resulting from the Reverse Stock Split, and the market price per post-Reverse Stock Split share may
not exceed or remain in excess of the (i) $4.00 minimum bid price initial listing requirement in connection with the Merger, which requires
the Combined Company to have a minimum bid price of $4.00 per share, or (ii) $1.00 minimum bid price for a sustained period of time to
meet the continued listing requirements should the Merger not be completed and the stock price of the Avalon Common Stock falls below
the Nasdaq Minimum Bid Price Requirement, and the Reverse Stock Split may not result in a per share price that would attract brokers and
investors who do not trade in lower priced stocks. In addition, although Avalon believes the Reverse Stock Split may enhance the desirability
of Avalon Common Stock to certain potential investors, it is possible that, if implemented, Avalon Common Stock may not become more attractive
to institutional and other long-term investors. Even if Avalon implements the Reverse Stock Split, the market price of Avalon Common Stock
may decrease due to factors unrelated to the Reverse Stock Split. In any case, the market price of Avalon Common Stock may also be based
on other factors which may be unrelated to the number of shares outstanding, including Avalon&#8217;s future performance. If the Reverse
Stock Split is consummated and the trading price of the Avalon Common Stock declines, the percentage decline as an absolute number and
as a percentage of Avalon&#8217;s overall market capitalization may be greater than would occur in the absence of the Reverse Stock Split.
If the Merger is not completed, even if the market price per post-Reverse Stock Split share of Avalon Common Stock remains in excess of
$1.00 per share, Avalon may be delisted due to a failure to meet other continued listing requirements, including Nasdaq requirements related
to the minimum stockholders&#8217; equity requirement, the minimum number of shares that must be in the public float, the minimum market
value of the public float and the minimum number of &#8220;round lot&#8221; holders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>The proposed Reverse Stock
Split may decrease the liquidity of Avalon Common Stock and result in higher transaction costs if the Merger with YOOV is not consummated</i>.
The liquidity of Avalon Common Stock may be negatively impacted by a Reverse Stock Split, given the reduced number of shares that would
be outstanding after the Reverse Stock Split if the Merger with YOOV is not consummated, particularly if the stock price does not increase
as a result of the Reverse Stock Split. In addition, if a Reverse Stock Split is implemented, it will increase the number of Avalon stockholders
who own &#8220;odd lots&#8221; of fewer than 100 shares of Avalon Common Stock. Brokerage commission and other costs of transactions in
odd lots are generally higher than the costs of transactions of more than 100 shares of common stock. Accordingly, a Reverse Stock Split
may not achieve the desired results of increasing marketability and liquidity of Avalon Common Stock described above if the Merger with
YOOV is not consummated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 153 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>If Avalon stockholders
approve this Reverse Stock Split Proposal, the effective increase in the authorized number of shares of Avalon Common Stock as a result
of</i> the <i>Reverse Stock Split could have anti-takeover implications</i>. If Avalon stockholders approve this Reverse Stock Split Proposal,
the implementation of a Reverse Stock Split will result in an effective increase in the authorized number of shares of Avalon Common Stock,
which could, under certain circumstances, have anti-takeover implications. The additional shares of Avalon Common Stock that would become
available for issuance if this Reverse Stock Split Proposal is approved and a Reverse Stock Split is implemented could be used by Avalon
to oppose a hostile takeover attempt or to delay or prevent changes in control or our management. For example, without further stockholder
approval, the Avalon Board could adopt a &#8220;poison pill&#8221; which would, under certain circumstances related to an acquisition
of Avalon securities that is not approved by the Avalon Board, give certain holders the right to acquire additional shares of Avalon Common
Stock at a low price. The board of directors also could strategically sell shares of Avalon Common Stock in a private transaction to purchasers
who would oppose a takeover or favor the current Avalon Board. Although this Reverse Stock Split Proposal has been prompted by business
and financial considerations and not by the threat of any hostile takeover attempt (nor is the Avalon Board currently aware of any such
attempts directed at Avalon), Avalon stockholders should be aware that approval of this Reverse Stock Split Proposal could facilitate
future efforts by Avalon to deter or prevent changes in control, including transactions in which the Avalon stockholders might otherwise
receive a premium for their shares over then current market prices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_082"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Effective Reverse Stock Split Time</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The proposed Reverse Stock
Split would become effective as of the date and time determined by the Avalon Board and specified in the resolutions approving the Reverse
Stock Split (the &#8220;Effective Reverse Stock Split Time&#8221;). The proposed Reverse Stock Split will only occur if approved and if
necessary to be effectuated for the Combined Company to meet the $4.00 minimum bid price initial listing requirement following the Closing
pursuant to the rules of The Nasdaq Capital Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon will file the Reverse
Split Charter Amendment effecting the Reverse Stock Split with the Secretary of State of the State of Delaware, in substantially the form
attached as <span style="text-decoration:underline">Annex C</span> to this proxy statement/prospectus. Any Reverse Split Charter Amendment to effect the Reverse Stock Split will
include the Reverse Stock Split ratio fixed by Avalon&#8217;s Board, within the specified range approved by Avalon&#8217;s stockholders,
and the Effective Reverse Stock Split Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Effective as of the Effective
Reverse Stock Split Time, shares of Avalon Common Stock issued and outstanding immediately prior thereto will be combined, automatically
and without any action on the part of Avalon or its stockholders, into a lesser number of new shares of Avalon Common Stock in accordance
with the Reverse Stock Split ratio determined by the Avalon Board within the specified range approved by the Avalon stockholders pursuant
to this Reverse Stock Split Proposal See &#8220;<i>Treatment of Fractional Shares</i>&#8221; below regarding the treatment of any fractional
shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_083"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Effects of Reverse Stock Split</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">After the Effective Reverse
Stock Split Time, each Avalon stockholder will own a reduced number of shares of Avalon Common Stock as compared to immediately prior
to the Effective Reverse Stock Split Time. However, any Reverse Stock Split that is implemented by the Avalon Board would affect all Avalon
stockholders uniformly and would not affect any stockholder&#8217;s percentage ownership interests in Avalon, except for adjustments that
may result from the treatment of fractional shares as described below. Voting rights and other rights and preferences of the holders of
Avalon Common Stock will not be affected by a Reverse Stock Split (other than for adjustments that may result from the treatment of fractional
shares as described below). For example, a holder of 2% of the voting power of the outstanding shares of Avalon Common Stock immediately
prior to a Reverse Stock Split would continue to hold 2% (assuming there is no impact as a result of the treatment of fractional shares
as described below) of the voting power of the outstanding shares of Avalon Common Stock immediately after such Reverse Stock Split. The
number of stockholders of record will not be affected by a Reverse Stock Split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 154 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The principal effects of
a Reverse Stock Split that is implemented by the Avalon Board will be that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">depending on the Reverse Stock Split ratio selected by the Avalon Board, each two (2) to twenty (20) shares
of Avalon Common Stock owned by a stockholder will be combined into one post-split share of Avalon Common Stock;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">no fractional shares of Avalon Common Stock will be issued in connection with any Reverse Stock Split;
instead, holders of Avalon Common Stock who would otherwise hold a fractional share of Avalon Common Stock after giving effect to the
Reverse Stock Split will hold one whole post-split share as explained more fully below;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the total number of authorized shares of Avalon Common Stock will remain at 100,000,000 (or, if the Charter
Increase Proposal is approved, the authorized shares of Avalon Common Stock will be increased to 200,000,000), resulting in an effective
increase in the authorized number of shares of Avalon Common Stock;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">based upon the Reverse Stock Split ratio selected by the Avalon Board, proportionate adjustments will
be made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all then outstanding stock
options and warrants, which will result in a proportional decrease in the number of shares of Avalon Common Stock reserved for issuance
upon exercise or vesting of such stock options and warrants, and, in the case of stock options and warrants, a proportional increase in
the exercise price of all such stock options and warrants; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the number of shares then reserved for issuance under the Amended and Restated 2020 Plan (including the
shares reserved for issuance as a result of the Equity Plan Increase Proposal, if approved) will be reduced proportionately based upon
the Reverse Stock Split ratio selected by the board of directors.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">The
following table contains approximate information, based on share information as of [&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;], 2025, relating to outstanding Avalon Common Stock
based on the proposed Reverse Stock Split ratios (without giving effect to the treatment of fractional shares):</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Status</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Shares of<br/> Common Stock<br/> Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Shares of<br/> Common
    Stock<br/> Issued and<br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Shares of<br/> Common
    Stock<br/> Reserved for<br/> Future Issuance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Shares of<br/> Common
    Stock<br/> Authorized<br/> but Unissued<br/> and<br/> Unreserved</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify; text-indent: -10pt; padding-left: 10pt">Pre-Reverse Stock Split</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">100,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><span style="font-size: 10pt">[&#160;&#160;&#160;&#160;&#160;&#160;]</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><span style="font-size: 10pt">[<span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;</span>]</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><span style="font-size: 10pt">[<span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;</span>]</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt">Post-Reverse Stock Split 1-for-2</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">100,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">[<span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;</span>]</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">[<span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;</span>]</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">[&#160;&#160;&#160;&#160;&#160;&#160;]</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt">Post-Reverse Stock Split 1-for-10</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">100,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">[<span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;</span>]</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">[<span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;</span>]</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">[<span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;</span>]</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt">Post-Reverse Stock Split 1-for-20</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">100,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">[<span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;</span>]</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">[<span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;</span>]</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-size: 10pt">[<span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;</span>]</span></td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">After the Effective Reverse
Stock Split Time of any Reverse Stock Split that the Avalon Board elects to implement, Avalon Common Stock would have a new committee
on uniform securities identification procedures, or CUSIP number, a number used to identify Avalon Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon Common Stock is currently
registered under Section 12(b) of the Exchange Act, and Avalon is subject to the periodic reporting and other requirements of the Exchange
Act. The implementation of any proposed Reverse Stock Split will not affect the registration of Avalon Common Stock under the Exchange
Act. Avalon Common Stock would continue to be listed on The Nasdaq Capital Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_084"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Treatment of Fractional Shares</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No fractional shares of Avalon
Common Stock will be issued as a result of any Reverse Stock Split. Instead, in lieu of any fractional shares to which an Avalon stockholder
of record would otherwise be entitled as a result of the Reverse Stock Split, Avalon will issue to such stockholder such additional fraction
of a share as is necessary to increase such resulting fractional share to a full share of Avalon Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 155 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_085"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Record and Beneficial Stockholders</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this Reverse Stock Split
Proposal is approved by Avalon&#8217;s stockholders and the Avalon Board elects to implement a Reverse Stock Split, stockholders of record
holding all of their shares of Avalon Common Stock electronically in book-entry form under the direct registration system for securities
will be automatically exchanged by the exchange agent and will receive a transaction statement at their address of record indicating the
number of new post-split shares of Avalon Common Stock they hold after the Reverse Stock Split. Non-registered stockholders holding Avalon
Common Stock through a bank, broker or other nominee should note that such banks, brokers or other nominees may have different procedures
for processing the Reverse Stock Split than those that would be put in place by Avalon for registered stockholders. If you hold your shares
with such a bank, broker or other nominee and if you have questions in this regard, you are encouraged to contact your nominee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this Reverse Stock Split
Proposal is approved by Avalon&#8217;s stockholders and the Avalon Board elects to implement a Reverse Stock Split, stockholders of record
holding some or all of their shares in certificate form will receive a letter of transmittal from Avalon or its exchange agent, as soon
as practicable after the Effective Reverse Stock Split Time. The Avalon Transfer Agent is expected to act as &#8220;exchange agent&#8221;
for the purpose of implementing the exchange of stock certificates. Holders of pre-Reverse Stock Split shares will be asked to surrender
to the exchange agent certificates representing pre-Reverse Stock Split shares in exchange for post-Reverse Stock Split shares in accordance
with the procedures to be set forth in the letter of transmittal. No new post-Reverse Stock Split share certificates will be issued to
a stockholder until such stockholder has surrendered such stockholder&#8217;s outstanding certificate(s) together with the properly completed
and executed letter of transmittal to the exchange agent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON STOCKHOLDERS SHOULD NOT DESTROY ANY PRE-SPLIT
STOCK CERTIFICATE AND SHOULD NOT SUBMIT ANY CERTIFICATES UNTIL THEY ARE REQUESTED TO DO SO.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_086"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Accounting Consequences</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The par value per share of
Avalon Common Stock would remain unchanged at $0.0001 per share after any Reverse Stock Split. As a result, as of the Effective Reverse
Stock Split Time, the stated capital on Avalon&#8217;s balance sheet attributable to Avalon Common Stock would be reduced proportionally,
based on the actual Reverse Stock Split ratio, from its present amount, and the additional paid-in capital account would be credited with
the amount by which the stated capital would be reduced. The net income or loss per share of Avalon Common Stock would be increased because
there would be fewer shares of Avalon Common Stock outstanding. The Reverse Stock Split would be reflected retroactively and prospectively
in Avalon&#8217;s consolidated financial statements. Avalon does not anticipate that any other accounting consequences would arise as
a result of any Reverse Stock Split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_087"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">No Dissenter&#8217;s or Appraisal Rights</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon stockholders are not
entitled to dissenter&#8217;s or appraisal rights with respect to the proposed Reverse Stock Split under the DGCL. The Avalon Board expects
the Reverse Stock Split to occur prior to Closing only if approved and if necessary to be effectuated for the Combined Company to meet
the $4.00 minimum bid price initial listing requirement following the Closing pursuant to the rules of The Nasdaq Capital Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_088"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Certain Material U.S. Federal Income Tax Consequences
of the Reverse Stock Split</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following discussion
is a summary of certain material U.S. federal income tax consequences of the Reverse Stock Split to U.S. Holders (as defined above under
&#8220;<i>Certain Material U.S. Federal Income Tax Consequences of the Merger</i>&#8221;) that hold shares of Avalon Common Stock as capital
assets (generally, property held for investment) for U.S. federal income tax purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This summary does not address
all aspects of U.S. federal income taxation that may be relevant to stockholders in light of their particular circumstances or to stockholders
who may be subject to special tax treatment under the Code, including, without limitation dealers or traders in securities, commodities
or foreign currency; banks, thrifts, insurance companies, and other financial institutions; traders that mark-to-market their securities;
tax-exempt organizations or governmental organizations; small business investment companies; regulated investment companies; real estate
investment trusts; tax-deferred or other retirement accounts; persons whose functional currency is not the U.S. dollar; persons who hold
Avalon Common Stock as part of a &#8220;straddle,&#8221; &#8220;hedge,&#8221; &#8220;conversion transaction&#8221; or other risk reduction
transaction; persons who hold or receive Avalon Common Stock pursuant to the exercise of compensatory stock options, the vesting of previously
restricted shares of stock or otherwise as compensation; persons whose shares constitute &#8220;qualified small business stock&#8221;
for purposes of Section 1202 of the Code, any entity or arrangement that is a partnership for U.S. federal income tax purposes; companies
subject to the &#8220;stapled stock&#8221; rules; &#8220;expatriated entities&#8221;; certain former citizens or long-term residents of
the United States; or persons subject to the alternative minimum tax or the 3.8% tax on net investment income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 156 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This discussion is based
on the Code, U.S. Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements
of the IRS in effect as of the date hereof, all of which are subject to change, possibly with retroactive effect, or differing interpretations.
Any such change may cause the U.S. federal income tax consequences of a reverse stock split to vary substantially from the consequences
summarized below. Avalon has not sought any ruling from the IRS with respect to the statements made and the conclusions reached in this
discussion, and there can be no assurance that the IRS will agree with these statements and conclusions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The state, local and foreign
tax consequences of a Reverse Stock Split may vary as to each U.S. Holder of Avalon Common Stock, depending on the jurisdiction in which
such U.S. Holder resides. This discussion should not be considered as tax or investment advice, and the tax consequences of a reverse
stock split may not be the same for all U.S. Holders of Avalon Common Stock. U.S. Holders of Avalon Common Stock should consult their
own tax advisors to understand their individual U.S. federal, state, local and foreign tax consequences to them of the Reverse Stock Split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an entity or arrangement
treated as a partnership for U.S. federal income tax purposes holds shares of Avalon Common Stock, the tax treatment of a partner in the
partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner
level. Accordingly, partnerships holding shares of Avalon Common Stock and the partners in such partnerships should consult their tax
advisors regarding the U.S. federal income tax consequences to them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_089"></a></div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Tax Consequences of the Reverse Stock
Split Generally</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Reverse Stock Split is
expected to constitute a &#8220;recapitalization&#8221; for U.S. federal income tax purposes under Section 368(a)(1)(E) of the Code. As
a result, a U.S. Holder of Avalon Common Stock generally should not recognize any gain or loss for U.S. federal income tax purposes upon
the Reverse Stock Split, except possibly to the extent a U.S. Holder receives a whole share of Avalon Common Stock in lieu of a fractional
share of Avalon Common Stock, as discussed below. A U.S. Holder&#8217;s aggregate adjusted tax basis in shares of Avalon Common Stock
received in a Reverse Stock Split should equal the U.S. Holder&#8217;s aggregate adjusted tax basis in the shares of Avalon Common Stock
surrendered (increased by any income or gain recognized on receipt of a whole share in lieu of a fractional share). In addition, each
U.S. Holder&#8217;s holding period for the shares of Avalon Common Stock the U.S. Holder receives in a Reverse Stock Split should include
the U.S. Holder&#8217;s holding period for the shares of Avalon Common Stock exchanged in the Reverse Stock Split. Treasury Regulations
provide detailed rules for allocating the tax basis and holding period of the shares of Avalon Common Stock surrendered to the shares
of Avalon Common Stock received in a recapitalization pursuant to the Reverse Stock Split. U.S. Holders of shares of Avalon Common Stock
acquired on different dates and at different prices should consult their own tax advisors regarding the allocation of the tax basis and
holding period of such shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The treatment of fractional
shares of Avalon Common Stock being rounded up to the next whole share is uncertain, and a U.S. Holder that receives a whole share of
Avalon Common Stock in lieu of a fractional share of Avalon Common Stock may possibly recognize gain, which may be characterized as either
capital gain or as a dividend, in an amount not to exceed the excess of the fair market value of such whole share over the fair market
value of the fractional share to which the U.S. Holder was otherwise entitled. The holding period for the portion of a share of Avalon
Common Stock treated as a distribution or as to which a U.S. Holder recognizes gain might not include the holding period of pre-reverse
stock split shares of Avalon Common Stock surrendered. U.S. Holders should consult their tax advisors regarding the U.S. federal income
tax and other tax consequences of fractional shares being rounded to the next whole share. Backup withholding may apply to a stockholder
who receives a whole share of Avalon Common Stock in lieu of a fractional share unless the stockholder provides the exchange agent with
appropriate documentation establishing that backup withholding is not required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_090"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Vote Required for Approval</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The approval of the Reverse
Stock Split Proposal requires the affirmative vote of a majority of the total votes properly cast by the Avalon Stockholders at the Special
Meeting. Accordingly, abstentions and broker non-votes, if any, will have no effect on the outcome of the Reverse Stock Split Proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">As of the Record Date,
the Key Avalon Stockholders, including Avalon directors and officers, beneficially owned approximately [ ]% of the outstanding shares
of Avalon Common Stock and, pursuant to the Voting Agreements, agreed to vote all of their shares of Avalon Common Stock in favor of
the approval of the Reverse Stock Split Proposal.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>If the Nasdaq Proposal
is approved and the Reverse Stock Split Proposal is <span style="text-decoration:underline">not</span> approved, Avalon will be unlikely to meet the initial listing requirements
on The Nasdaq Capital Market in connection with the Merger, and may be unable to satisfy the conditions to Closing.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE AVALON BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
THAT ITS STOCKHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF A REVERSE STOCK SPLIT AS SET FORTH IN THE REVERSE STOCK SPLIT PROPOSAL. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 157 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_091"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">PROPOSAL
NO. 3-THE EQUITY PLAN INCREASE PROPOSAL</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Avalon Board is requesting
that stockholders approve an amendment to the Amended and Restated 2020 Plan, increasing the number of shares of the Avalon Common Stock
reserved for issuance under the Amended and Restated 2020 Plan by 2,500,000 shares. A copy of the amendment (the &#8220;Increase Amendment&#8221;)
is attached hereto as <span style="text-decoration:underline">Annex D</span>. The Avalon Board approved the Increase Amendment on February 11, 2025 and directed that the Increase
Amendment be submitted to Avalon stockholders for approval.&#160;On October 28, 2024, Avalon effectuated a reverse stock split of the
Avalon Common Stock at a ratio of 1-for-15. All amounts and values presented in this Proposal No. 3 have been retroactively adjusted to
reflect the reverse stock split for all periods presented, unless otherwise indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The primary purpose of the
Amended and Restated 2020 Plan is to provide a means whereby eligible employees, officers, non-employee directors and other individual
service providers develop a sense of proprietorship and personal involvement in the development and financial success of Avalon and to
encourage them to devote their best efforts to our business, thereby advancing the interests of Avalon and its stockholders. The Avalon
Board believes that the granting of stock options, restricted stock awards and similar kinds of equity-based compensation promotes continuity
of management and increases incentive and personal interest in the welfare of Avalon by those who are primarily responsible for shaping
and carrying out our long-range plans and securing our growth and financial success.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of March 31, 2025, 142,424
shares of Avalon Common Stock remained available for issuance under the Amended and Restated 2020 Plan. Avalon also maintains the Avalon
GloboCare Corp. 2019 Incentive Stock Plan (the &#8220;2019 Plan&#8221;). As of March 31, 2025, 6,213 shares of Avalon Common Stock remained
available for issuance under the 2019 Plan. If Avalon&#8217;s stockholders do not approve the Increase Amendment, Avalon will continue
to operate under the Amended and Restated 2020 Plan and under the 2019 Plan. However, if the authorized shares are depleted, Avalon would
not be able to continue to offer equity awards, which could put Avalon at a competitive disadvantage in recruiting and retaining talent,
and also make it more difficult for Avalon to align employee interests with those of Avalon stockholders through a program that includes
stock ownership.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Stockholder approval of the
Increase Amendment is necessary in order to satisfy certain legal requirements, including the rules and requirements of The Nasdaq Capital
Market, and to make awards under the Amended and Restated 2020 Plan eligible for beneficial tax treatment. In addition, the Avalon Board
regards stockholder approval of the Increase Amendment as desirable and consistent with good corporate governance practices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Description of the Amended and Restated 2020
Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following description
of the principal terms of the Amended and Restated 2020 Plan is a summary and is qualified in its entirety by the full text of the Amended
and Restated 2020 Plan, which is attached as Appendix A to Avalon&#8217;s definitive proxy statement filed on September 8, 2023. This
summary does not purport to be a complete description of all the provisions of the Amended and Restated 2020 Plan. The Amended and Restated
2020 Plan was adopted by the Avalon Board on August 29, 2023 and approved by the Avalon stockholders on October 12, 2023 at the 2023 Annual
Meeting of Stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Administration</i>.</b>&#160;The
Amended and Restated 2020 Plan is administered by the Compensation Committee of the Avalon Board (the &#8220;Compensation Committee&#8221;).
However, the entire Avalon Board may act in lieu of the Compensation Committee on any manner. The Compensation Committee has authority,
in its discretion, to approve the persons to whom awards may be granted, to make any combination of awards to participants, to accelerate
the exercisability or vesting of an award and to determine the specific terms and conditions of each award, subject to the provisions
of the Amended and Restated 2020 Plan. The Compensation Committee may also approve rules and regulations for the administration of the
Amended and Restated 2020 Plan and amendments or modifications of outstanding awards (except that options and Stock Appreciation Rights
(&#8220;SARs&#8221;) cannot be repriced without shareholder approval). The Compensation Committee may delegate authority to the Chief
Executive Officer and/or other officers to grant awards to employees (other than themselves), subject to applicable law and the Amended
and Restated 2020 Plan. No awards may be made under the Amended and Restated 2020 Plan on or after October 12, 2033 (the &#8220;Expiration
Date&#8221;), but the Amended and Restated 2020 Plan will continue thereafter while previously granted awards remain outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 158 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Eligibility</i>.</b>
Persons eligible to receive awards under the Amended and Restated 2020 Plan are all employees, officers, directors, consultants,
other advisors and other individual service providers of Avalon and its subsidiaries, who, in the opinion of the Compensation
Committee, are in a position to contribute to the success and growth of Avalon. Notwithstanding the foregoing, only Avalon employees
are eligible to receive grants of incentive stock option (&#8220;ISO&#8221;) that are intended to meet the requirements of
Section&#160;422 of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of March 31, 2025, Avalon
and its subsidiaries had a total of five (5) employees, including three (3) executive officers, six (6) non-employee directors, five (5)
consultants, five (5) other advisors, and fifteen (15) other individual service providers. In accordance with the Avalon Bylaws, directors
who are serving Avalon as employees and who receive compensation for their services as such, shall not be eligible to receive any other
compensation under the Amended and Restated 2020 Plan for their services as directors of Avalon. None of Avalon&#8217;s subsidiaries have
employees and none of the officers and directors of Avalon&#8217;s subsidiaries are eligible for awards under the Amended and Restated
2020 Plan other than those who are eligible as officers or directors of Avalon. Except for the Contingent Option Awards (as defined below),
awards under the Amended and Restated 2020 Plan are within the discretion of the Compensation Committee and Avalon cannot determine how
many individuals in each of the categories described above will receive awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Shares Subject to the
Amended and Restated 2020 Plan.&#160;</i></b>A total of 155,091 shares of Avalon Common Stock are currently authorized for issuance under
the Amended and Restated 2020 Plan, comprised of (i) 133,333 shares of Avalon Common Stock initially authorized under the Amended and
Restated 2020 Plan, (ii) 7,333 &#8220;evergreen shares&#8221; issued pursuant to the automatic increase on January 1, 2024 and (iii) 14,425
&#8220;evergreen shares&#8221; issued pursuant to the automatic increase on January 1, 2025. If the Increase Amendment is approved by
Avalon stockholders, the aggregate number of shares of Avalon Common Stock that will be authorized for issuance in connection with options
and other awards granted under the Amended and Restated 2020 Plan will be increased by 2,500,000 shares from 155,091 to 2,655,091 shares.
The number of shares of Avalon Common Stock authorized for issuance under the Amended and Restated 2020 Plan increases automatically each
January 1st until the Expiration Date in an amount equal to one percent (1%) of the total number of shares of Avalon Common Stock outstanding
on the December 31st of the preceding calendar year, unless the Avalon Board takes action prior to an automatic increase to provide that
there will not be an increase in the share reserve for such year or that the increase in the share reserve for such year will be of a
lesser number of shares of Avalon Common Stock than would otherwise occur. Shares attributable to these automatic increases are referred
to as &#8220;evergreen shares&#8221;. ISOs may be granted under the Amended and Restated 2020 Plan with respect to all of the 155,091
shares of Avalon Common Stock currently authorized for issuance under the Amended and Restated 2020 Plan. If the Increase Amendment is
approved by Avalon stockholders, the additional 2,500,000 shares that will be available under the Amended and Restated 2020 Plan may also
be granted as ISOs. Future evergreen shares would not be available for grant as ISOs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any option or SAR granted
under the Amended and Restated 2020 Plan terminates without having been exercised in full or if any award is forfeited, or if shares of
Avalon Common Stock are withheld to cover withholding taxes on options or other awards or applied to the payment of the exercise price
of an option or purchase price of an award, the number of shares of Avalon Common Stock as to which such option or award was forfeited,
withheld or paid, will be available for future grants under the Amended and Restated 2020 Plan. Awards settled in cash will not count
against the number of shares available for issuance under the Amended and Restated 2020 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The number of shares of Avalon
Common Stock authorized for issuance under the Amended and Restated 2020 Plan and the foregoing share limitations are subject to customary
adjustment for stock splits, stock dividends or similar transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Terms and Conditions
of Options.</i></b>&#160; Options granted under the Amended and Restated 2020 Plan may be either ISOs or &#8220;nonstatutory stock options&#8221;
that do not meet the requirements of Section 422 of the Code. The Compensation Committee will determine the exercise price of options
granted under the Amended and Restated 2020 Plan. The exercise price of stock options may not be less than the fair market value per share
of our common stock on the date of grant (or 110% of fair market value in the case of ISOs granted to a ten-percent stockholder).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">If on the date of grant the
Avalon Common Stock is listed on a stock exchange or is quoted on the automated quotation system of The Nasdaq Capital Market, the fair
market value will generally be the closing sale price on the date of grant (or the last trading day before the date of grant if no trades
occurred on the date of grant). If no such prices are available, the fair market value will be determined in good faith by the Compensation
Committee based on the reasonable application of a reasonable valuation method. On June 6, 2025, the closing sale price of a share of
Avalon Common Stock on The Nasdaq Capital Market was $3.41.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 159 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No option may be exercisable
for more than ten (10) years (five (5) years in the case of an ISO granted to a ten-percent (10%) stockholder) from the date of grant.
Options granted under the Amended and Restated 2020 Plan will be exercisable at such time or times as the Compensation Committee prescribes
at the time of grant. No employee may receive ISOs that first become exercisable in any calendar year in an amount exceeding $100,000.
The Compensation Committee may, in its discretion, permit a holder of a nonstatutory option to exercise the option before it has otherwise
become exercisable, in which case the shares of our common stock issued to the recipient will continue to be subject to the vesting requirements
that applied to the option before exercise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Generally, the option price
may be paid in cash or by certified check, bank draft or money order. The Compensation Committee may permit other methods of payment,
including (a)&#160;through delivery of shares of our common stock having a fair market value equal to the purchase price, (b)&#160;by
a full recourse, interest bearing promissory note having such terms as the Compensation Committee may permit, or (c)&#160;a combination
of these methods, as set forth in an award agreement or as otherwise determined by the Compensation Committee. The Compensation Committee
is authorized to establish a cashless exercise program and to permit the exercise price (or tax withholding obligations) to be satisfied
by reducing from the shares otherwise issuable upon exercise a number of shares having a fair market value equal to the exercise price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No option may be transferred
other than by will or by the laws of descent and distribution, and during a recipient&#8217;s lifetime an option may be exercised only
by the recipient. However, the Compensation Committee may permit the holder of a nonstatutory option to transfer the award to immediate
family members or a family trust for estate planning purposes. The Compensation Committee will determine the extent to which a holder
of a stock option may exercise the option following termination of service with Avalon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Stock Appreciation Rights</i>.</b>&#160;The
Compensation Committee may grant SARs independent of or in connection with an option. The Compensation Committee will determine the other
terms applicable to SARs. The exercise price per share of a SAR will not be less than 100% of the fair market value of a share of Avalon
Common Stock on the date of grant, as determined by the Compensation Committee. The maximum term of any SAR granted under the Amended
and Restated 2020 Plan is ten (10) years from the date of grant. Generally, each SAR will entitle a participant upon exercise to an amount
equal to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the excess of the fair market value on the exercise date
of one share of Avalon Common Stock</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">over the exercise price,&#160;<i>multiplied
by</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: justify; text-indent: -0.25in"><i>&#160;</i></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">the number of shares of Avalon Common Stock covered by the&#160;SAR.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Payment may be made in shares
of Avalon Common Stock, in cash, or partly in Avalon Common Stock and partly in cash, all as determined by the Compensation Committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Restricted Stock and
Restricted Stock Units</i></b><i>.</i>&#160; The Compensation Committee may award restricted common stock and/or restricted stock units
under the Amended and Restated 2020 Plan. Restricted stock awards consist of shares of Avalon Common Stock that are transferred to a participant
subject to restrictions that may result in forfeiture if specified conditions are not satisfied. Restricted stock units confer the right
to receive shares of Avalon Common Stock, cash, or a combination of shares of common stock and cash, at a future date upon or following
the attainment of certain conditions specified by the Compensation Committee. The restrictions and conditions applicable to each award
of restricted stock or restricted stock units may include performance-based conditions. Dividends or distributions with respect to restricted
stock may be paid to the holder of the shares as and when dividends are paid to stockholders or at the time that the restricted stock
vests, as determined by the Compensation Committee. If any dividends or distributions are paid in stock before the restricted stock vests,
they will be subject to the same restrictions. Dividend equivalent amounts may be deemed reinvested in additional restricted stock units
or paid with respect to restricted stock&#160;units either when cash dividends are paid to stockholders or when the&#160;units vest. Unless
the Compensation Committee determines otherwise, holders of restricted stock will have the right to vote the shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Performance Shares and
Performance Units</i></b><i>.</i>&#160;The Compensation Committee may award performance shares and/or performance units under the Amended
and Restated 2020 Plan to any eligible employee or other individual service provider other than a non-employee director of the Avalon
Board. Performance shares and performance units are awards, denominated in either shares of Avalon Common Stock or U.S. dollars, which
are earned during a specified performance period subject to the attainment of performance criteria, as established by the Compensation
Committee. The Compensation Committee will determine the restrictions and conditions applicable to each award of performance shares and
performance units.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Incentive Bonus Awards.&#160;</i></b>The
Compensation Committee may grant incentive bonus awards under the Amended and Restated 2020 Plan from time to time. The terms of incentive
bonus awards will be set forth in award agreements. Each award agreement will have such terms and conditions as the Compensation Committee
determines, including performance goals and amount of payment based on achievement of such goals. Incentive bonus awards are payable in
cash and/or shares of Avalon Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 160 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Other Stock-Based and
Cash-Based Awards</i></b><i>.</i>&#160;The Compensation Committee may award other types of equity-based or cash-based awards under the
Amended and Restated 2020 Plan, including the grant or offer for sale of shares of Avalon Common Stock that do not have vesting requirements
and the right to receive one or more cash payments subject to satisfaction of such conditions as the Compensation Committee may impose.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Effect of Certain Corporate
Transactions</i>.</b>&#160;The Compensation Committee may, at the time of the grant of an award provide for the effect of a Change in
Control (as defined in the Amended and Restated 2020 Plan) on any award, including (i) accelerating or extending the time periods for
exercising, vesting in, or realizing gain from any award, (ii) eliminating or modifying the performance or other conditions of an award,
or (iii) providing for the cash settlement of an award for an equivalent cash value, as determined by the Compensation Committee. The
Compensation Committee may, in its discretion and without the need for the consent of any recipient of an award, also take one or more
of the following actions contingent upon the occurrence of a Change in Control: (a) cause any or all outstanding options and SARs to become
immediately exercisable, in whole or in part; (b) cause any other awards<b>&#160;</b>to become non-forfeitable, in whole or in part; (c)
cancel any option or SAR in exchange for a substitute option; (d) cancel any award of restricted stock, restricted stock units, performance
shares or performance units in exchange for a similar award of the capital stock of any successor corporation; (e) redeem any restricted
stock for cash and/or other substitute consideration with a value equal to the fair market value of an unrestricted share of Avalon Common
Stock on the date of the Change in Control; (f) cancel any awards in exchange for cash and/or other property equal to the amount, if any,
that would have been attained upon the exercise of such award or realization of rights upon a Change in Control, but if the Change in
Control consideration with respect to any option or SAR does not exceed its exercise price, the option or SAR may be canceled without
payment of any consideration; or (g) take any other action the Compensation Committee deems necessary or appropriate to carry out the
terms of any definitive agreement controlling the terms and conditions of the Change in Control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Clawback/Recoupment.&#160;</i></b>Awards
granted under the Amended and Restated 2020 Plan will be subject to the requirement that the awards be forfeited or amounts repaid to
Avalon after they have been distributed to the participant (i)&#160;to the extent set forth in an award agreement or (ii)&#160;to the
extent covered by any clawback or recapture policy adopted by Avalon from time to time, or any applicable laws that impose mandatory forfeiture
or recoupment, under circumstances set forth in such applicable laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Amendment, Termination</i>.</b>&#160;The
Avalon Board may at any time amend, suspend or terminate the Amended and Restated 2020 Plan for the purpose of satisfying the requirements
of the Code, or other applicable law or regulation or for any other legal purpose, provided that, without the consent of the Avalon stockholders,
the Board may not (i) increase the number of shares of common stock available under the Amended and Restated 2020 Plan, (ii) change the
group of individuals eligible to receive awards, or (iii) extend the term of the Amended and Restated 2020 Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>New Plan Benefits </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="background-color: white">The
following table sets forth grants of options approved by the Avalon Board on </span>February 11, 2025 <span style="background-color: white">that
are contingent upon shareholder approval of this Proposal </span>(the &#8220;Contingent Option Awards&#8221;)<span style="background-color: white">.
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Name and Position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Units(1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">David Jin, Chief Executive Officer</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Luisa Ingargiola, Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Meng Li, Chief Operating Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Steven Sanders, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lourdes Felix, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">William Stilley, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tevi Troy, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Wilbert Tauzin III, Director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">All current executive officers as a group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">900,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">All current directors who are not executive officers as a group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">All employees, including all current officers who are not executive officers, as
    a group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in">(1)</td><td style="text-align: justify"><span style="background-color: white">Awards granted under the
                                         Plan to our executive officers and other employees are discretionary and are not subject to
                                         set benefits or amounts under the terms of the Amended and Restated 2020 Plan. Accordingly,
                                         except as noted below, the benefits or amounts that will be received by or allocated to our
                                         executive officers and other employees under the Plan in the future are not determinable. On
                                         </span>February 11, 2025<span style="background-color: white">, the Avalon Board approved the
                                         grant of stock options under the Amended and Restated 2020 Plan to certain of our current executive
                                         officers and directors, contingent upon stockholder approval of this Proposal. The number of
                                         units in the table above is the number of shares of Avalon Common Stock subject to each option
                                         that is contingent upon stockholder approval of this Proposal. Please refer to &#8220;Executive
                                         Compensation&#8221; in this proxy statement/prospectus, which provides information on the grants
                                         made in the previous fiscal year (including those listed above) and please refer to the description
                                         of grants made to our non-employee directors in the last previous year under the heading &#8220;Avalon
                                         Executive Compensation <i>- Director Compensation</i>&#8221; in this proxy statement/prospectus.
                                         </span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in">(2)</td><td style="text-align: justify"><span style="background-color: white">Each option was granted with an exercise price per share of $</span>3.53<span style="background-color: white">.
The actual value realized upon exercise of an option will depend on the excess, if any, of the stock price over the exercise price on
the date of exercise.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 161 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Plan Benefits</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Since the adoption of Amended
and Restated 2020 Plan through June 6, 2025, we have granted the following stock options under the Amended and Restated 2020 Plan to
the individuals and groups listed below. In all cases, the securities underlying such stock options were shares of Avalon Common Stock.
These share numbers do not take into account the effect of awards that have been cancelled or forfeited. As of the date hereof, we have
granted only stock options and Avalon Common Stock and no other type of award under the Amended and Restated 2020 Plan.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Name and Position</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Number of Shares</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Subject to Stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Options (1)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: justify">Named Executive Officers</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">David Jin, Chief Executive Officer</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#822;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Luisa Ingargiola, Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#822;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Meng Li, Chief Operating Officer</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#822;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">All current executive officers, as a group (2)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#822;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-weight: bold; text-align: justify">All current directors who are not executive officers, as a group (3)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: right">533</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Associates of any of such directors, executive officers or nominees</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: right">1,334</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Each other person who received or is to receive five percent of such options</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#822;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">All employees who are not executive officers, as a group</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">&#822;</span></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Does not include, as applicable, the Contingent Option Awards. Number of shares of Avalon Common Stock underlying stock options reflects the 1-for-15 reverse stock split of our issued and outstanding common stock, which became effective on October 25, 2024.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes common stock underlying stock options listed separately for Dr. Jin, Ms. Ingargiola and Ms. Li.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes common stock underlying stock options for Wenzhao Lu, Steven A. Sanders, Wilbert J. Tauzin II, William B. Stilley III, Tevi Troy and Lourdes Felix. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Material Federal Income Tax Consequences</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">THE FOLLOWING IS A BRIEF SUMMARY
OF THE EFFECT OF FEDERAL INCOME TAXATION UPON THE PARTICIPANTS AND THE COMPANY WITH RESPECT TO THE PURCHASE OF SHARES UNDER THE AMENDED
AND RESTATED PLAN. THIS SUMMARY DOES NOT PURPORT TO BE COMPLETE AND DOES NOT ADDRESS THE FEDERAL INCOME TAX CONSEQUENCES TO TAXPAYERS
WITH SPECIAL TAX STATUS. IN ADDITION, THIS SUMMARY DOES NOT DISCUSS THE PROVISIONS OF THE INCOME TAX LAWS OF ANY MUNICIPALITY, STATE OR
FOREIGN COUNTRY IN WHICH THE PARTICIPANT MAY RESIDE, AND DOES NOT DISCUSS ESTATE, GIFT OR OTHER TAX CONSEQUENCES OTHER THAN INCOME TAX
CONSEQUENCES. THE COMPANY ADVISES EACH PARTICIPANT TO CONSULT HIS OR HER OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF PARTICIPATION
IN THE AMENDED AND RESTATED PLAN AND FOR REFERENCE TO APPLICABLE PROVISIONS OF THE CODE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 162 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Treatment of Options</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Code treats ISOs and nonstatutory
stock options differently. However, as to both types of options, no income will be recognized to the optionee at the time of the grant
of the options under the Amended and Restated 2020 Plan, nor will Avalon be entitled to a tax deduction at that time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Generally, upon exercise of
a nonstatutory stock option (including an option intended to be an incentive stock option but which has not continued to so qualify at
the time of exercise), an optionee will recognize ordinary income tax on the excess of the fair market value of the stock on the exercise
date over the option price. Avalon will be entitled to a tax deduction in an amount equal to the ordinary income recognized by the optionee
in the fiscal year which includes the end of the optionee&#8217;s taxable year. We will be required to satisfy applicable withholding
requirements in order to be entitled to a tax deduction. In general, if an optionee, in exercising a nonstatutory stock option, tenders
shares of Avalon Common Stock in partial or full payment of the option price, no gain or loss will be recognized on the tender. However,
if the tendered shares were previously acquired upon the exercise of an ISO and the tender is within two years from the date of grant
or one year after the date of exercise of the ISO, the tender will be a disqualifying disposition of the shares acquired upon exercise
of the ISO.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For ISOs, there is no taxable
income to an optionee at the time of exercise. However, the excess of the fair market value of the stock on the date of exercise over
the exercise price will be taken into account in determining whether the &#8220;alternative minimum tax&#8221; will apply for the year
of exercise. If the shares acquired upon exercise are held until at least two (2) years from the date of grant and more than one year
from the date of exercise, any gain or loss upon the sale of such shares, if held as capital assets, will be long-term capital gain or
loss (measured by the difference between the sales price of the stock and the exercise price). Under current federal income tax law, a
long-term capital gain will be taxed at a rate which is less than the maximum rate of tax on ordinary income. If the two (2)-year and
one year holding period requirements are not met (a &#8220;Disqualifying Disposition&#8221;), an optionee will recognize ordinary income
in the year of disposition in an amount equal to the lesser of (i) the fair market value of the stock on the date of exercise minus the
exercise price or (ii) the amount realized on disposition minus the exercise price. The remainder of the gain will be treated as long-term
capital gain, depending upon whether the stock has been held for more than a year. If an optionee makes a Disqualifying Disposition, Avalon
will be entitled to a tax deduction equal to the amount of ordinary income recognized by the optionee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In general, if an optionee,
in exercising an ISO, tenders shares of common stock in partial or full payment of the option price, no gain or loss will be recognized
on the tender. However, if the tendered shares were previously acquired upon the exercise of another ISO and the tender is within two
years from the date of grant or one year after the date of exercise of the other option, the tender will be a Disqualifying Disposition
of the shares acquired upon exercise of the other option.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As noted above, the exercise
of an ISO could subject an optionee to the alternative minimum tax. The application of the alternative minimum tax to any particular optionee
depends upon the particular facts and circumstances which exist with respect to the optionee in the year of exercise. However, as a general
rule, the amount by which the fair market value of the common stock on the date of exercise of an option exceeds the exercise price of
the option will constitute an item of &#8220;adjustment&#8221; for purposes of determining the alternative minimum taxable income on which
the alternative tax may be imposed. As such, this item will enter into the tax base on which the alternative minimum tax is computed,
and may therefore cause the alternative minimum tax to become applicable in any given year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Treatment of Stock Appreciation Rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Generally, the recipient of
a SAR will not recognize any income upon grant of the SAR, nor will Avalon be entitled to a deduction at that time. Upon exercise of a
SAR, the holder will recognize ordinary income, and Avalon generally will be entitled to a corresponding deduction, equal to the fair
market value of our common stock at that time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 163 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Treatment of Stock Awards</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Generally, absent an election
to be taxed currently under Section 83(b) of the Code (a &#8220;Section 83(b) Election&#8221;), there will be no federal income tax consequences
to either the recipient or Avalon upon the grant of a restricted stock award. At the expiration of the restriction period and the satisfaction
of any other restrictions applicable to the restricted shares, the recipient will recognize ordinary income and Avalon generally will
be entitled to a corresponding deduction equal to the fair market value of the common stock at that time. If a Section 83(b) Election
is made within 30 days after the date the restricted stock award is granted, the recipient will recognize an amount of ordinary income
at the time of the receipt of the restricted shares, and Avalon generally will be entitled to a corresponding deduction, equal to the
fair market value (determined without regard to applicable restrictions) of the shares at such time, less any amount paid by the recipient
for the shares. If a Section 83(b) Election is made, no additional income will be recognized by the recipient upon the lapse of restrictions
on the shares (and prior to the sale of such shares), but, if the shares are subsequently forfeited, the recipient may not deduct the
income that was recognized pursuant to the Section 83(b) Election at the time of the receipt of the shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The recipient of an unrestricted
stock award will recognize ordinary income, and Avalon generally will be entitled to a corresponding deduction, equal to the fair market
value of Avalon Common Stock that is the subject of the award when the award is made.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The recipient of a restricted
stock unit will recognize ordinary income as and when the units vest and shares of Avalon Common Stock are issued. The amount of the income
will be equal to the fair market value of the shares of Avalon Common Stock issued at that time, and Avalon will be entitled to a corresponding
deduction. The recipient of a restricted stock unit will not be permitted to make a Section 83(b) Election with respect to such award.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The federal income tax consequences
of performance share awards, performance unit awards, incentive bonus awards, other cash-based awards and other stock-based awards will
depend on the terms and conditions of those awards but, in general, participants will be required to recognize ordinary income in an amount
equal to the cash and the fair market value of any fully vested shares of Avalon Common Stock paid, determined at the time of such payment,
in connection with such awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Treatment of Incentive Bonus Awards and
Other Stock or Cash-Based Awards</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Generally, the recipient of
an incentive bonus or other stock or cash-based award will not recognize any income upon grant of the award, nor will Avalon be entitled
to a deduction at that time. Upon payment with respect to such an award, the recipient will recognize ordinary income, and Avalon generally
will be entitled to a corresponding deduction, equal to the amount of cash paid and/or the fair market value of Avalon Common Stock issued
at that time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Section 409A</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an award is subject to
Section&#160;409A of the Code but does not comply with the requirements of Section&#160;409A or meet an exemption to Section 409A, the
taxable events as described above could apply earlier than described and could result in the imposition of additional taxes and penalties.
Participants are urged to consult with their tax advisors regarding the applicability of Section&#160;409A to their awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 164 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Potential Limitation on Company Deductions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section 162(m) of the Code
generally disallows a tax deduction for compensation in excess of $1 million paid in a taxable year by a publicly held corporation to
its chief executive officer and certain other &#8220;covered employees&#8221;. The Avalon Board and the Compensation Committee intend
to consider the potential impact of Section 162(m) on grants made under the Amended and Restated 2020 Plan, but reserve the right to approve
grants of awards for an executive officer that exceeds the deduction limit of Section 162(m).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Restrictions on Resale</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain officers and directors
of Avalon may be deemed to be &#8220;affiliates&#8221; of Avalon as that term is defined under the Securities Act. The common stock acquired
under the Amended and Restated 2020 Plan by an affiliate may be reoffered or resold only pursuant to an effective registration statement
or pursuant to Rule 144 under the Securities Act or another exemption from the registration requirements of the Securities Act. It is
intended that the shares issuable pursuant to the Amended and Restated 2020 Plan will be registered under the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Tax Withholding</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As and when appropriate, we
shall have the right to require each optionee purchasing shares of common stock and each grantee receiving an award of shares of common
stock under the Amended and Restated 2020 Plan to pay any federal, state or local taxes required by law to be withheld.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Securities Issuable Pursuant to Other Equity Compensation Plans</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For information regarding
securities issuable pursuant to our 2019 Plan, please see the information in this proxy statement/prospectus set forth under the caption
&#8220;AVALON EXECUTIVE COMPENSATION <i>- Equity Compensation Plan Information</i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_092"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Vote Required for Approval</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The approval of the Equity
Plan Increase Proposal requires the affirmative vote of a majority of the total votes properly cast by the Avalon Stockholders at the
Special Meeting. Accordingly, abstentions and broker non-votes, if any, will have no effect on the outcome of the Equity Plan Increase
Proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">As of the Record Date,
the Key Avalon Stockholders, including Avalon directors and officers, beneficially owned approximately [ ]% of the outstanding shares
of Avalon Common Stock and, pursuant to the Voting Agreements, agreed to vote all of their shares of Avalon Common Stock in favor of
the approval of the Equity Plan Increase Proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE AVALON BOARD OF DIRECTORS RECOMMENDS THAT
THE AVALON STOCKHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE EQUITY PLAN INCREASE PROPOSAL. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 165 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_093"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">PROPOSAL
NO. 4-THE SERIES C PREFERRED STOCK PROPOSAL</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Background and Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">On December 19, 2024,
Avalon entered into a securities purchase agreement (the &#8220;Series C Securities Purchase Agreement&#8221;) with an accredited investor,
York Sun Investment Holding Limited, a British Virgin islands company, (the &#8220;Series C Investor&#8221;) pursuant to which Avalon
agreed to issue and sell to the Series C Investor, upon the terms and conditions set forth in the Series C Securities Purchase Agreement,
up to 7,000 shares of Avalon&#8217;s Series C Convertible Preferred Stock, par value $0.0001 per share (the &#8220;Series C Preferred
Stock&#8221;), for up to an aggregate of $7,000,000 (the &#8220;Series C Offering&#8221;). The first closing occurred on December 24,
2024, with respect to the Investor&#8217;s purchase of 3,500 shares of Series C Preferred Stock in exchange for $3,500,000. Pursuant
to the Series C Securities Purchase Agreement, the Series C Investor had the right to invest an additional $3,500,000 within 120 days
of the first closing. The Investor did not exercise the option. On June 4, 2025, Avalon entered into an additional securities purchase
agreement with the Series C Investor, whereby Avalon agreed to issue to the Series C Investor 41,643 shares of&#160;Avalon Common Stock
in exchange for $500,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each share of Series C Preferred
Stock is convertible into Avalon Common Stock (the &#8220;Series C Conversion Shares&#8221;) at a conversion price per share equal to
$2.41, at the option of the holder, at any time after the later of (i) the date of the stockholder approval of the issuance of the Series
C Conversion Shares pursuant to the rules of the Nasdaq Stock Market (the &#8220;Series C Stockholder Approval&#8221;) and (ii) the one
year anniversary of the date of the first issuance of any shares of the Series C Preferred Stock. Avalon shall not be required to issue
any Series C Conversion Shares until the Series C Stockholder Approval is obtained by Avalon. The Series C Investor shall also have a
right of first refusal during the period beginning on the date of the Series C Securities Purchase Agreement and continuing until the
Series C Stockholder Approval is obtained, on all issuances of convertible preferred stock of Avalon, excluding agreements that are in
place prior to the date of the Series C Securities Purchase Agreement and issuances of new classes of convertible preferred stock in exchange
for existing classes of convertible preferred stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">In connection with the
Series C Securities Purchase Agreement, Avalon filed a certificate of designation of preferences, rights and limitations of Series C
Convertible Preferred Stock (as amended, the &#8220;Series C Certificate of Designations&#8221;) which provides for the designation of
10,000 shares of Series C Preferred Stock upon the terms and conditions set forth in the Series C Certificate of Designations. Each share
of Series C Preferred Stock has a stated value of $1,000 (the &#8220;Series C Stated Value&#8221;). The Series C Preferred Stock shall
rank (i) senior to Avalon Common Stock and any other class or series of capital stock of Avalon created hereafter, the terms of which
specifically provide that such class or series shall rank junior to the Series C Preferred Stock and (ii) pari passu with any class or
series of capital stock of Avalon created hereafter specifically ranking, by its terms, on par with the Series C Preferred Stock. Holders
of the Series C Preferred Stock shall be entitled to receive, and Avalon shall pay, dividends on shares of Series C Preferred Stock equal
(on an as-if-converted-to-Avalon Common Stock basis, disregarding for such purpose any conversion limitations hereunder) to and in the
same form as dividends actually paid on shares of the Avalon Common Stock when, as and if such dividends are paid on shares of the Avalon
Common Stock. Holders of the Series C Preferred Stock have no voting power except as otherwise required by the Delaware General Corporation
Law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon any liquidation, dissolution
or winding-up of Avalon, whether voluntary or involuntary, the holders of the Series C Preferred Stock shall be entitled to receive out
of the assets available for distribution to stockholders, (i) after and subject to the payment in full of all amounts required to be distributed
to the holders of another class or series of stock of Avalon ranking on liquidation prior and in preference to the Series C Preferred
Stock, (ii) ratably with any class or series of stock ranking on liquidation on parity with the Series C Preferred Stock and (iii) in
preference and priority to the holders of the shares of Avalon Common Stock, an amount equal to 100% of the Stated Value of the Series
C Preferred Stock, in proportion to the full and preferential amount that all shares of the Series C Preferred Stock are entitled to receive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Why We Need Stockholder Approval</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are seeking stockholder
approval in order to comply with Nasdaq Listing Rules 5635(b) and 5635(d).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to Nasdaq Listing
Rule 5635(b), stockholder approval is required prior to the issuance of securities that could result in a &#8220;change of control&#8221;
of a listed company, which for Nasdaq purposes in generally deemed to occur when, as a result of an issuance, an investor or group of
investors acquires, or has the right to acquire, 20% or more of the outstanding equity or voting power of the company and such ownership
or voting power would be the company&#8217;s largest ownership position.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 166 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to Nasdaq Listing
Rule 5635(d), stockholder approval is required prior to the issuance of common stock, or securities convertible into or exercisable for
common stock, at a price less than the &#8220;Minimum Price&#8221; (as defined in Nasdaq Listing Rule 5635(d)(1)) in an amount equal to
20% or more of the common stock or voting power outstanding before such issuance, unless the issuance is in a public offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As December 19, 2024, which
is the time of our entry into the Securities Purchase Agreement, the &#8220;Minimum Price&#8221; of our Common Stock was approximately
$3.89 per share. By contrast, the conversion price of the Series C Preferred Stock is $2.41 per share which is lower than the &#8220;Minimum
Price&#8221; under Nasdaq Rule 5635(d) and related guidance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, the Series C
Offering does not qualify as a public offering under Nasdaq Rule 5635(d) and related guidance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accordingly, in order to comply
with the 20% limitation set forth in Nasdaq Rule 5635(d) and related guidance, the Series C Certificate of Designations provides that
the Series C Preferred Stock is not convertible until the later of (i) the Series C Stockholder Approval and (ii) the one year anniversary
of the date of the first issuance of any shares of Series C Preferred Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Without giving effect to such
limitations on conversion or exercise, and assuming the issuance of all 7,000 shares of Series C Preferred Stock to the Investor, up to
an aggregate of 2,904,565 shares of Common Stock are potentially issuable in respect of the Series C Offering described herein. Such amount
is well in excess of the 20% limitation under Nasdaq Listing Rules 5635(b) and 5635(d), which as of December 19, 2024 was approximately
289,000 shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are therefore seeking stockholder
approval, in connection with the Series C Offering, for the sale and issuance of the shares of Series C Conversion Share to satisfy the
requirements of Nasdaq Listing Rules 5635(b) and 5635(d) described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Effect of this Proposal on Current Avalon Stockholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this Proposal is adopted
by our stockholders, we will have the right to issue the Series C Conversion Shares and issue such shares in excess of 19.99% of the issued
and outstanding Avalon Common Stock upon conversion of the Series C Preferred Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The issuance of Avalon Common
Stock upon the conversion of the Series C Preferred Stock will result in certain dilution to our stockholders, and would afford our stockholders
a smaller percentage interest in our voting power, liquidation value and aggregate book value. The sale or any resale of the Avalon Common
Stock issued upon conversion of the Series C Preferred Stock could cause the market price of Avalon Common Stock to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If&#160;our stockholders do
not&#160;approve this Proposal, we may not issue, upon conversion of shares of Series C Preferred Stock, a number of shares of Avalon
Common Stock in excess of 19.99% of our issued and outstanding shares of Avalon Common Stock on December 19, 2024.&#160;The Series C Preferred
Stock would remain outstanding upon the terms and conditions described herein, and pursuant to the Series C Certificate of Designations,
Avalon will be restricted from taking certain corporate actions as specified in the Series C Certificate of Designations including transferring
any of its assets or changing the nature of the business until the Series C Stockholder Approval has been obtained.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are not seeking stockholder
approval to authorize the Series C Offering, the entry into or the closing of the transactions related thereto, or the execution of the
related transaction documents, as we have already entered into and closed the transaction and executed the related transaction documents,
which are binding obligations on us. The failure of our stockholders to approve this Proposal will not negate the existing terms of such
transaction documents or any other documents relating to the Series C Offering. The Series&#160;C Preferred Stock issued at the closing
of the Series C Offering will remain outstanding and the terms of the Series&#160;C Preferred Stock will remain our binding obligation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_094"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Vote Required for Approval</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The approval of the Series
C Preferred Stock Proposal requires the affirmative vote of a majority of the total votes properly cast by the Avalon Stockholders at
the Special Meeting. Accordingly, abstentions and broker non-votes, if any, will have no effect on the outcome of the Series C Preferred
Stock Proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">As of the Record Date,
the Key Avalon Stockholders, including Avalon directors and officers, beneficially owned approximately [ ]% of the outstanding shares
of Avalon Common Stock and, pursuant to the Voting Agreements, agreed to vote all of their shares of Avalon Common Stock in favor of
the approval of the Series C Preferred Stock Proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE AVALON BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
THAT ITS STOCKHOLDERS VOTE &#8220;FOR&#8221; THE SERIES C PREFERRED STOCK PROPOSAL. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 167 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_095"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">PROPOSAL
NO. 5-THE SERIES D PREFERRED STOCK PROPOSAL</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><div><a id="a_096"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Background and Overview</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 9, 2025, Avalon
entered into an exchange agreement (the &#8220;Exchange Agreement&#8221;) with Wenzhao Lu, the Chairman of Avalon&#8217;s Board, pursuant
to which Mr. Lu exchanged 9,000 shares of the Series A Preferred Stock for 5,000 shares of Series D Convertible Preferred Stock of Avalon
(the &#8220;Series D Preferred Stock&#8221;) pursuant to an exemption from registration under Section 3(a)(9) of the Securities Act (the
&#8220;Exchange&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 6, 2025, Avalon
filed a certificate of designations of preferences, rights and limitations of the Series D Preferred Stock (the &#8220;Series D Certificate
of Designations&#8221;) which provides for the designation of 5,000 shares of Series D Preferred Stock, par value $0.0001 per share, upon
the terms and conditions as set forth in the Series D Certificate of Designations. Each share of Series D Preferred Stock has a stated
value of $1,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Series D Preferred Stock
ranks senior to the Avalon Common Stock and any other class or series of capital stock of Avalon created hereafter, the terms of which
specifically provide that such class or series shall rank junior to the Series D Preferred Stock, (ii) pari passu with any class or series
of capital stock of Avalon created hereafter specifically ranking, by its terms, on par with the Series D Preferred Stock, and (iii) pari
passu with the Series C Preferred Stock. Holders of the Series D Preferred Stock have no voting power except as otherwise required by
the Delaware General Corporation Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon any liquidation, dissolution
or winding-up of Avalon, whether voluntary or involuntary, the holders of the Series D Preferred Stock shall be entitled to receive out
of the assets available for distribution to stockholders, (i) after and subject to the payment in full of all amounts required to be distributed
to the holders of another class or series of stock of Avalon ranking on liquidation prior and in preference to the Series D Preferred
Stock, (ii) ratably with any class or series of stock ranking on liquidation on parity with the Series D Preferred Stock and (iii) in
preference and priority to the holders of the shares of Avalon Common Stock, an amount equal to 100% of the Stated Value of the Series
D Preferred Stock, in proportion to the full and preferential amount that all shares of the Series D Preferred Stock are entitled to receive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each share of Series D Preferred
Stock shall be convertible into Avalon Common Stock (the &#8220;Series D Conversion Shares&#8221;) at a conversion per share equal to
$2.41, at the option of the holder, at any time after Avalon has obtained stockholder approval for the issuance of the Series D Conversion
Shares pursuant to the rules of the Nasdaq Stock Market (the &#8220;Series D Stockholder Approval&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Why We Need Stockholder Approval</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are seeking stockholder
approval in order to comply with Nasdaq Listing Rules 5635(b) and 5635(d).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to Nasdaq Listing
Rule 5635(b), stockholder approval is required prior to the issuance of securities that could result in a &#8220;change of control&#8221;
of a listed company, which for Nasdaq purposes in generally deemed to occur when, as a result of an issuance, an investor or group of
investors acquires, or has the right to acquire, 20% or more of the outstanding equity or voting power of the company and such ownership
or voting power would be the company&#8217;s largest ownership position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to Nasdaq Listing
Rule 5635(d), stockholder approval is required prior to the issuance of common stock, or securities convertible into or exercisable for
common stock, at a price less than the &#8220;Minimum Price&#8221; (as defined in Nasdaq Listing Rule 5635(d)(1)) in an amount equal to
20% or more of the common stock or voting power outstanding before such issuance, unless the issuance is in a public offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of January 9, 2025, which
is the time of our entry into the Exchange Agreement, the &#8220;Minimum Price&#8221; of the Avalon Common Stock was approximately $3.54
per share. By contrast, the conversion price of the Series D Preferred Stock is $2.41 per share which is lower than the &#8220;Minimum
Price&#8221; under Nasdaq Rule 5635(d) and related guidance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, the Exchange
does not qualify as a public offering under Nasdaq Rule 5635(d) and related guidance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accordingly, in order to comply
with the 20% limitation set forth in Nasdaq Rule 5635(d) and related guidance, the Series D Certificate of Designations provides that
the Series D Preferred Stock is not convertible until the Series D Stockholder Approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 168 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Without giving effect to limitations
on conversion or exercise, and assuming the issuance of all 5,000 shares of Series D Preferred Stock to Mr. Lu, up to an aggregate of
2,074,689 shares of Avalon Common Stock are potentially issuable in respect of the Exchange described herein. Such amount is well in excess
of the 20% limitation under Nasdaq Listing Rules 5635(b) and 5635(d), which as of January 9, 2025 was approximately 289,000 shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are therefore seeking stockholder
approval, in connection with the Exchange, for the sale and issuance of the shares of Series D Conversion Share to satisfy the requirements
of Nasdaq Listing Rules 5635(b) and 5635(d) described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Effect of this Proposal on Current Avalon Stockholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this Proposal is adopted
by our stockholders, we will have the right to issue the Series D Conversion Shares and issue such shares in excess of 19.99% of the issued
and outstanding Avalon Common Stock upon conversion of the Series D Preferred Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The issuance of Avalon Common
Stock upon the conversion of the Series D Preferred Stock will result in certain dilution to our stockholders, and would afford our stockholders
a smaller percentage interest in our voting power, liquidation value and aggregate book value. The sale or any resale of the Avalon Common
Stock issued upon conversion of the Series D Preferred Stock could cause the market price of Avalon Common Stock to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If&#160;our stockholders do
not&#160;approve this Proposal, we may not issue, upon conversion of shares of Series D Preferred Stock, a number of shares of Avalon
Common Stock in excess of 19.99% of our issued and outstanding shares of Avalon Common Stock on January 9, 2025.&#160;The Series D Preferred
Stock would remain outstanding upon the terms and conditions described herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are not seeking stockholder
approval to authorize the Exchange, the entry into or the closing of the transactions related thereto, or the execution of the related
transaction documents, as we have already entered into and closed the transaction and executed the related transaction documents, which
are binding obligations on us. The failure of our stockholders to approve this Proposal will not negate the existing terms of such transaction
documents or any other documents relating to the Exchange. The Series&#160;D Preferred Stock issued in the Exchange will remain outstanding
and the terms of the Series&#160;D Preferred Stock will remain our binding obligation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_097"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Vote Required for Approval</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The approval of the Series
D Preferred Stock Proposal requires the affirmative vote of a majority of the total votes properly cast by the Avalon Stockholders at
the Special Meeting. Accordingly, abstentions and broker non-votes, if any, will have no effect on the outcome of the Series D Preferred
Stock Proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">As of the Record Date,
the Key Avalon Stockholders, including Avalon directors and officers, beneficially owned approximately [ ]% of the outstanding shares
of Avalon Common Stock and, pursuant to the Voting Agreements, agreed to vote all of their shares of Avalon Common Stock in favor of
the approval of the Series D Preferred Stock Proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE AVALON BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
THAT ITS STOCKHOLDERS VOTE &#8220;FOR&#8221; THE SERIES D PREFERRED STOCK PROPOSAL. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 169 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_098"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">PROPOSAL
NO. 6-THE INCREASE IN AUTHORIZED SHARES PROPOSAL</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>APPROVAL OF AMENDMENT TO CERTIFICATE OF INCORPORATION
TO INCREASE THE TOTAL NUMBER OF AUTHORIZED SHARES FROM 100,000,000 SHARES TO 200,000,000 SHARES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Avalon Board is asking
stockholders to adopt and approve an amendment to the Avalon Charter to increase the total number of authorized shares of Avalon common
stock from 100,000,000&#160;shares to 200,000,000&#160;shares (the&#160;&#8220;Increase in Authorized Shares Amendment&#8221;). On April 21,
2025, the Avalon Board unanimously approved and declared advisable the proposed Increase in Authorized Shares Amendment, and recommends
that stockholders adopt and approve Proposal&#160;No. 6 and the proposed Increase in Authorized Shares Amendment. If this Proposal&#160;No.
6 is approved by stockholders, this Proposal&#160;No. 6 will authorize the amendment of the Avalon Charter to effectuate the Authorized
Share Increase, increasing our authorized shares of common stock from 100,000,000&#160;shares of common stock to 200,000,000&#160;shares
of common stock. The form of amendment to the Avalon Charter relating to this Proposal No. 6 is attached as <span style="text-decoration:underline">Annex E</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Assuming stockholders approve
this Proposal&#160;No.&#160;6, the effective date of the Authorized Share Increase will be determined at the sole discretion of the Avalon
Board, and may occur as soon as the&#160;day of the Special Meeting. The effective date of the Authorized Share Increase will be publicly
announced by us. The Avalon Board may determine, in its sole discretion, not to effectuate the Authorized Share Increase and not to file
any amendment to the Avalon Charter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Avalon Board believes
authorizing 200,000,000 shares would allow for an appropriate number of available authorized shares to allow the Combined Company to raise
necessary capital need to accomplish its corporate goals and be responsive to potential investors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Avalon Board does not
have any definitive plans, arrangements, understandings or agreements regarding the potential implications of increasing the authorized
shares of Avalon common stock. The Avalon Board is asking stockholders to approve the Increase in Authorized Shares Amendment which, if
approved by stockholders, will authorize the amendment of the Avalon Charter to effectuate the Authorized Share Increase from 100,000,000&#160;shares
of common stock to 200,000,000&#160;shares of common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The adoption of the Increase
in Authorized Shares Amendment would not have any immediate accretive effect on the proportionate voting power or other rights of existing
stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Discretion to Implement the Authorized
Share Increase</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Avalon Board believes
that stockholder adoption and approval of the Authorized Share Increase is in the best interests of our stockholders. If our stockholders
approve this Proposal&#160;No.&#160;6, the Board will implement the Authorized Share Increase only upon the&#160;approval of the Nasdaq
Proposal by stockholders and a determination that the Authorized Share Increase is in the best interests of the stockholders at that time.
The Board may abandon the Authorized Share Increase in its sole discretion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Effective Time</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The effective time of the
Authorized Share Increase (if the Nasdaq Proposal is approved by stockholders, the proposed Increase in Authorized Shares Amendment is
adopted and approved by stockholders, and the Authorized Share Increase is implemented at the discretion of the Avalon Board) will be
the date and time that the Avalon Charter amendment effectuating the Authorized Share Increase is filed with the Delaware Secretary of
State or such later time as is specified therein. Such filing may occur as soon as the&#160;day of the Special Meeting or at any time
prior to the one year anniversary of the Special Meeting. The exact timing of the Authorized Share Increase will be determined by the
Avalon Board based on its evaluation as to when such action will be the most advantageous to the Company and its stockholders, and the
effective date will be publicly announced by the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Authorized Share Increase
may be delayed or abandoned without further action by the stockholders at any time prior to effectiveness of the relevant Avalon Charter
amendment with the Delaware Secretary of State, notwithstanding stockholder adoption and approval of the Increase in Authorized Shares
Amendment if the Avalon Board, in its sole discretion, determines that it is in the best interests of the Company and its stockholders
to delay or abandon the Authorized Share Increase. If the Avalon Charter amendment implementing the Authorized Share Increase is not effective
with the Delaware Secretary of State on or before the one year anniversary of the Special Meeting, the Avalon Board will be deemed to
have abandoned the Authorized Share Increase.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_099"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Vote Required for Approval</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The approval of the Increase
in Authorized Shares Proposal requires the affirmative vote of a majority of the total votes properly cast by the Avalon Stockholders
at the Special Meeting. Accordingly, abstentions and broker non-votes, if any, will have no effect on the outcome of the Increase in Authorized
Shares Proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">As of the Record Date,
the Key Avalon Stockholders, including Avalon directors and officers, beneficially owned approximately [ ]% of the outstanding shares
of Avalon Common Stock and, pursuant to the Voting Agreements, agreed to vote all of their shares of Avalon Common Stock in favor of
the approval of the Increase in Authorized Shares Proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE AVALON BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
THAT ITS STOCKHOLDERS VOTE &#8220;FOR&#8221; THE INCREASE IN AUTHORIZED SHARES PROPOSAL. </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 170 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_100"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">PROPOSAL
NO. 7-THE GOLDEN PARACHUTE PROPOSAL</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><div><a id="a_101"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">General</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As required by Item 402(t)
of Regulation S-K and Section 14A of the Exchange Act, Avalon is providing its stockholders with the opportunity to cast a non-binding,
advisory vote to approve certain compensation payments that may or will be made to Luisa Ingargiola, Avalon&#8217;s Chief Financial Officer,
in connection with the Merger, as disclosed pursuant to Item 402(t) of Regulation S-K in the &#8220;Golden Parachute Compensation&#8221;
table and the footnote to that table contained in the section captioned &#8220;<i>The Merger - Interests of Avalon&#8217;s Directors
and Officers in the Merger - Golden Parachute Compensation.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon believes that those
certain compensation payments that may or will be made to Ms. Ingargiola in connection with the Merger are reasonable and further the
goals of Avalon&#8217;s executive compensation program by ensuring the retention of talented executive officers and aligning their interests
with the long-term interests of Avalon&#8217;s stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon asks that its stockholders
vote &#8220;<b>FOR</b>&#8221; the following resolution:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#8220;RESOLVED, that
certain compensation payments that may or will be made to Luisa Ingargiola Avalon&#8217;s Chief Financial Officer in connection with
the Merger, as disclosed pursuant to Item 402(t) of Regulation S-K in the &#8220;Golden Parachute Compensation&#8221; table and the footnote
to that table contained in the section captioned &#8220;The Merger - Interests of Avalon&#8217;s Directors and Officers in the Merger
- Golden Parachute Compensation,&#8221; is hereby APPROVED on a non-binding, advisory basis.&#8221; </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This vote is advisory and,
therefore, it will not be binding on Avalon, nor will it overrule any prior decision or require the Avalon Board (or any committee thereof)
to take any action. Accordingly, regardless of the outcome of the advisory vote, Ms. Ingargiola may be or become entitled to certain compensation
payments in connection with the Merger, as disclosed in this proxy statement/prospectus. However, the Avalon Board values the opinions
of Avalon&#8217;s stockholders, and to the extent that there is any significant vote against the Golden Parachute Compensation Proposal,
the Avalon Board will consider Avalon&#8217;s stockholders&#8217; concerns and will evaluate whether any actions are necessary to address
those concerns. The Avalon Board will consider the vote of a majority of the votes properly cast &#8220;<b>FOR</b>&#8221; the foregoing
resolution as non-binding, advisory approval of certain compensation arrangements that will be made to Avalon&#8217;s named executive
officer in connection with the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_102"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Vote Required for Approval</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The approval of the Golden
Parachute Proposal requires the affirmative vote of a majority of the total votes properly cast by the Avalon Stockholders at the Special
Meeting. Accordingly, abstentions and broker non-votes, if any, will have no effect on the outcome of the Golden Parachute Proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">As of the Record Date,
the Key Avalon Stockholders, including Avalon directors and officers, beneficially owned approximately [ ]% of the outstanding shares
of Avalon Common Stock and, pursuant to the Voting Agreements, agreed to vote all of their shares of Avalon Common Stock in favor of
the approval of the Golden Parachute Proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE AVALON BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
THAT ITS STOCKHOLDERS VOTE &#8220;FOR&#8221; THE GOLDEN PARACHUTE PROPOSAL. </b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 171 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_103"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">PROPOSAL
NO. 8-THE ADJOURNMENT PROPOSAL</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If Avalon fails to receive
a sufficient number of votes to approve any of Proposals No. 1 through 7, Avalon may propose to adjourn the Special Meeting for the purpose
of soliciting additional proxies to approve such proposals. Avalon currently does not intend to propose adjournment at the Special Meeting
if there are sufficient votes to approve the proposals to be presented at the Special Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If on the date of the Special
Meeting, or a date preceding the date on which the Special Meeting is scheduled, Avalon reasonably believes that (i) it will not receive
proxies sufficient to obtain the required vote to approve any of the foregoing proposals, whether or not a quorum would be present or
(ii) it will not have sufficient shares of Avalon Common Stock represented (whether in person or by proxy) to constitute a quorum necessary
to conduct the business of the Special Meeting, Avalon may postpone or adjourn, or make one or more successive postponements or adjournments
of, the Special Meeting as long as the date of the Special Meeting is not postponed or adjourned more than an aggregate of thirty (30)
calendar days in connection with any postponements or adjournments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_104"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Vote Required for Approval</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The approval of the Adjournment
Proposal requires the affirmative vote of a majority of the total votes properly cast by the Avalon Stockholders at the Special Meeting.
Accordingly, abstentions and broker non-votes, if any, will have no effect on the outcome of the Adjournment Proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">As of the Record Date,
the Key Avalon Stockholders, including Avalon directors and officers, beneficially owned approximately [ ]% of the outstanding shares
of Avalon Common Stock and, pursuant to the Voting Agreements, agreed to vote all of their shares of Avalon Common Stock in favor of
the approval of the Adjournment Proposal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE AVALON BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS
THAT ITS STOCKHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE ADJOURNMENT PROPOSAL </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 172 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><div><a id="a_105"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">INFORMATION ABOUT YOOV</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><div><a id="a_106"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">BUSINESS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">YOOV Group Holding Limited
(&#8220;YOOV&#8221;) is a prominent provider of Artificial Intelligence-as-a-Service (AIaaS) solutions, specializing in intelligent business
automation. AIaaS enables businesses to incorporate AI technologies and capabilities through a cloud platform without the need for significant
infrastructure investment. This model provides a more accessible and cost-effective way for businesses to bring AI into their applications
and processes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">YOOV&#8217;s mission
is to make advanced AI and automation technologies accessible to businesses without requiring technical expertise. By integrating AI
technologies into with its no-code workflow automation platform, YOOV enables businesses to automate complex workflows and tasks across
diverse industries, empowering businesses of all sizes to optimize operations, reduce costs, and enhance service delivery through its
AIaaS solutions. To cope with the global expansion plan, YOOV&#8217;s solutions are designed to address the challenges of modern businesses
while fostering efficiency, scalability, and growth. In addition, YOOV operates subsidiaries in financial and insurance services, including
YOOV Capital Limited and YOOV Insurance Services Limited.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">YOOV is a holding company
incorporated in the British Virgin Islands with no material operations of its own. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Headquartered
in Singapore, YOOV operates its sales and operations offices in Australia, Hong Kong, Malaysia, and Taiwan. YOOV derives the vast majority
of its revenues from operations in Hong Kong, which accounted for approximately 77.9% and 83.2% of total revenue for the year ended 2024
and nine months ended December 31, 2024. A significant portion of its management, employees, and business operations are based in Hong
Kong. As of April 30, 2025, YOOV employed 52 full time employees in Hong Kong, representing 94% of its total workforce, including functions
of CEO and management, investor relations, business development and marketing, research and development, etc. YOOV conducts its business
through its Hong Kong subsidiaries, including, but limited to, YOOV Internet Technology (Asia) Limited, <span style="background-color: white">YOOV
Capital Limited and YOOV Insurance Services Limited</span>, which are integral to its core operations.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.25in"><b style="-keep: true">Corporate
Structure</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_004.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate History</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV was founded in 2016 with
the mission of transforming business operations through innovative automation solutions. Initially launched as an office automation platform
with the market position as a Software-as-a-Service (SaaS) provider, offering cloud-based software with quick and easy deployment. YOOV
then quickly evolved into a no-code workflow automation platform that further strengthens its service offerings with flexibility, scalability
and sustainability, empowering businesses of all sizes to customize and manage their operations without the need for extensive resources
or technical expertise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In recent years, YOOV has
transitioned into an AIaaS provider, integrating cutting-edge AI technologies to deliver intelligent business automation solutions. By
offering scalable, cloud-based AI tools, YOOV enables seamless automation, allowing businesses to implement AI-powered solutions efficiently
and cost-effectively. This on-demand model accelerates innovation and optimizes operations. YOOV&#8217;s evolution underscores its commitment
to staying at the forefront of technological innovation and addressing the diverse needs of its clients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In 2020, YOOV expanded its
operations into the financial and insurance sectors by establishing its subsidiaries YOOV Capital Limited (&#8220;YOOV Capital&#8221;)
and YOOV Insurance Services Limited (&#8220;YOOV Insurance&#8221;). Leveraging extensive commercial data generated by its corporate client
base, YOOV introduced solutions for credit evaluation and insurance policy applications. These offerings enable businesses to achieve
faster, more accurate results while fostering a comprehensive YOOV ecosystem. As the financial and insurance sectors rely heavily on
data analysis, automation, and decision-making - areas where YOOV&#8217;s expertise excels, this expansion is a natural extension of
YOOV&#8217;s AI platform business. By integrating these services, YOOV enhances its ecosystem, creating synergies that allow businesses
to streamline operations while accessing tailored financial and insurance solutions. The interconnected offerings foster cross-selling
opportunities and deliver greater value to clients, positioning YOOV as a comprehensive and efficient partner across multiple industries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In 2025, following the global
expansion strategy, YOOV has relocated its Headquarters from Hong Kong to Singapore.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 173 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Business Description</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">YOOV is an innovative
AIaaS platform and SaaS provider that empowers businesses of all sizes to easily access and benefit from intelligent business automation.
By seamlessly integrating advanced AI technologies with no-code workflow automation platform, YOOV offers AIaaS solutions that allows
businesses to automate complex processes and enhance operational efficiency without requiring extensive technical expertise or resources.
This user-friendly approach ensures that even smaller enterprises with limited IT capabilities can leverage AI-powered automation to
streamline operations, reduce costs, and improve service delivery. Unlike traditional business automation solutions that follow predefined
rules and static workflows, YOOV&#8217;s AIaaS solutions are operated on a no-code development platform that dynamically adapt, predict
outcomes, and improve performance through continuous learning. YOOV&#8217;s flexibility and scalability make it suitable not only for
small and medium-sized enterprises but also for larger organizations seeking practical solutions to complex challenges. With a strong
emphasis on customization, YOOV enables businesses to adapt their platforms to their specific needs, thereby maximizing the impact of
automation across various sectors. Its commitment to accessibility positions it strongly in the market, enabling companies worldwide
to transform their operations and thrive in a competitive landscape.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV stands out in the AI
landscape by seamlessly integrating AI, Process and Data together, creating a unique ecosystem that goes beyond simple question-and-answer
interactions. Unlike many AI solutions that offer a plethora of models yet struggle with practical applications, YOOV offers an AIaaS
framework, enabling businesses to deploy business AI solutions on demand easily that fit their specific needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">With YOOV, users can directly
engage with their data and delegate a wide range of business tasks, ensuring smooth and efficient process execution. By integrating advanced
AI technologies with the comprehensive no-code workflow automation platform, YOOV combines the strengths of AI and automation to create
specialized modules, including Operations AI, People AI, Sales AI, and Customer Service AI to automate various business processes tailored
for diverse industries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV also features robust
application programming interface (API) that allows businesses to easily access AI functionalities. Users can integrate their existing
applications or systems with YOOV&#8217;s AI platform using a no-code approach, unlocking powerful features that enhance their software
ecosystems. This innovative approach enables users to harness multiple AI models effectively, transforming the way organizations operate
by facilitating intelligent decision-making and automating complex processes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Beyond its core AI-driven
automation solutions, YOOV extends its offerings into financial and insurance services through its subsidiaries, YOOV Capital and YOOV
Insurance. YOOV Capital&#8217;s main offering is Factoring, also known as Invoice Finance, which is a flexible and efficient cash flow
solution for businesses, allowing them to quickly access cash tied up in outstanding invoices and turn accounts receivables into working
capital for business growth. YOOV Insurance provides commercial insurance intermediary services to enterprises. Based on customer&#8217;s
needs and requirements, the professional commercial insurance team collects proposals or quotations from insurance service providers for
customers to compare and select the suitable insurance package. These subsidiaries leverage YOOV&#8217;s commercial data insights to provide
credit evaluation and insurance brokerage services, further enhancing the YOOV ecosystem and delivering added value to clients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Technology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At YOOV, the technology
systems are the cornerstone of success, meticulously designed to enhance efficiency and scalability across customers&#8217; business
operations. YOOV&#8217;s dedicated research and development team, along with its proprietary technology infrastructure, drive continuous
improvements in technological capabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">YOOV does not develop
core AI technologies in-house. Instead, it leverages external AI vendors to embed AI capabilities into its platform. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">YOOV
focuses on integration, customization, and workflow orchestration through its no-code AIaaS platform, enabling seamless deployment of
third-party AI tools for business automation. Full transparency regarding third-party AI dependencies is also maintained in client service
agreements. This empowers YOOV to maintain reliability, scalability, and flexibility in all aspects of its business.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 174 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Proprietary AIaaS Platform</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV provides Business AI
Automation solutions via its AIaaS platform, which is a no-code workflow automation platform that integrates advanced AI technologies,
emphasizing three key areas of business digitalization: AI, Process, and Data. AI technologies maximize the impact of business automation;
Process automation raises productivity at lower costs; Data empowers businesses to make smarter decisions. With this concept in mind,
YOOV&#8217;s AIaaS platform consists of below products that are flexibly customized according to the needs of each business:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>AI CHAIN</b>: A generative AIaaS platform with built-in capabilities such as chatbots, workflows, large
models, and knowledge search cover the entire process of model selection, application development, and deployment, making it easy to build
AI applications.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>NEXA</b>: A Business AI assistant offers voice-activated assistance for various business tasks, including
scheduling, reminders, and data retrieval. It utilizes advanced AI algorithms to understand and respond to natural language queries. NEXA
enhances productivity through AI-driven assistance, integrating with other YOOV products for a cohesive user experience. YOOV has been
awarded Gold Award in the Hong Kong ICT Awards 2024: Smart Business (Emerging Technologies) Award with NEXA as the entry.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>YOOV PLUS:</b> A no-code workflow automation platform allows businesses to create customized applications
without extensive coding knowledge. YOOV PLUS features a user-friendly interface with drag-and-drop functionalities for rapid deployment
and easy modifications. It enables businesses in all sizes and industries to develop scalable and flexible solutions tailored to their
specific needs. YOOV has been awarded Gold Award in the Hong Kong ICT Awards 2022: Smart Business (Solution for SME) Award with YOOV PLUS
as the entry.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>YOOV WORK</b>: A Human Resources Management (HRM) and Workflow Automation system developed with the
aim to streamlining HRM operations such as payroll, attendance, leave management, and employee records. It integrates seamlessly with
other business systems for better data management and provides a mobile app for on-the-go management. YOOV Work optimizes daily HRM operations,
enhances business efficiency, and provides advanced analytics for better decision-making.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Integration of Third-Party Technologies</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">While developing the proprietary
AIaaS platform, YOOV also strategically licenses and integrates third-party technologies to complement its solutions. Instead of developing
its own AI model, YOOV leverages widely recognized AI models, such as ChatGPT, Large Language Models (LLM), Natural Language Processing
(NLP), Computer Vision and Optical Character Recognition (OCR), incorporating these models into YOOV&#8217;s AIaaS platform to provide
tailored solution for each customer. This hybrid approach allows YOOV to offer a comprehensive technology stack that simplifies and enhances
the user experience while maintaining robust operational capabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Data-Driven Innovations </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The large volume of data generated
and collected on YOOV&#8217;s AIaaS platform is pivotal in driving continuous improvements. The advanced data analytics capabilities enable
YOOV to gain actionable insights, optimize processes, and predict trends, ensuring that our technology remains at the cutting edge of
innovation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operational Enhancements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV's technology infrastructure
is designed to streamline fulfilment processes, optimize financial operations, and enhance customer service. By automating routine tasks
and providing real-time data access, the systems improve operational efficiency and scalability, allowing YOOV to better serve its customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>R&amp;D Strategy and Maintenance of
Platform</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">YOOV&#8217;s research
and development strategy is driven by comprehensive market and industry trend analysis, which informs the company&#8217;s product development
roadmap. Based on these insights, YOOV determines the strategic direction for its proprietary solutions and selectively outsources specialized
development components to trusted third-party partners. YOOV&#8217;s no-code AIaaS cloud platform is hosted on secure and scalable infrastructure
provided by AWS (Amazon Web Services), ensuring high availability, enterprise-grade security, and global accessibility.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 175 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Customer Experience Enhancements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV&#8217;s technology not
only improves internal operations but also significantly enhances the customer experience. With products like NEXA, YOOV offers AI-powered
assistance that simplifies interactions and provides instant support. Additionally, seamless integration across different platforms ensures
consistent and efficient user experience.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future Technology Strategy</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV is committed to continuous
innovation and technological advancement. The future strategy includes expanding AI capabilities, developing more intuitive and integrated
solutions, and exploring new technologies to further enhance our offerings. YOOV is dedicated to staying ahead of industry trends and
delivering cutting-edge solutions to customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Industry Overview and Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Industry Overview</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">The business automation
market is experiencing significant growth, driven by the increasing adoption of advanced technologies such as artificial intelligence,
robotic process automation, and no-code platforms. According to Grand View Research, the global Robotics Process Automation (&#8220;RPA&#8221;)
market was valued at $10.01 billion in 2022 and is projected to expand at a compound annual growth rate (&#8220;CAGR&#8221;) of 39.9%
from 2023 to 2030, fueled by rising demand for automating repetitive business processes and improving operational efficiency.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In parallel, the AI as a Service
market is also seeing robust growth. According to Mordor Intelligence, the AIaaS market size is estimated to grow at a CAGR of 36.78%
from 2025 to 2030, driven by the increasing need for scalable AI tools and cloud-based solutions across industries like healthcare, BFSI,
and retail.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This robust growth is driven
by organizations seeking to enhance operational efficiency, reduce costs, and improve service delivery. AIaaS platforms, in particular,
are transforming the market by making AI-powered automation accessible to businesses of all sizes, enabling them to streamline workflows,
automate complex processes, and leverage data insights without requiring extensive technical expertise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The rise of no-code and low-code
platforms has further democratized automation, empowering small and medium enterprises (&#8220;SMEs&#8221;) to adopt advanced technologies
that were previously out of reach. Gartner predicts that by 2025, 70% of new enterprise applications will be developed using low-code
or no-code technologies, signifying a paradigm shift toward more accessible automation tools.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Global demand for business
automation is especially strong in industries such as finance, insurance, manufacturing, retail, and logistics. Automation solutions address
challenges related to labor shortages, cost pressures, and the need for enhanced customer experiences. McKinsey &amp; Company estimates
that 60% of all occupations have at least 30% of activities that could be automated, underscoring the vast potential for automation adoption.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 176 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i>Customers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">YOOV<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8217;s
customer base consists entirely of corporate clients, ranging from small and medium-sized enterprises (SMEs) to large conglomerates located
mainly in Hong Kong, Japan, Malaysia and Taiwan. YOOV serves a wide range of industries that require systems and workflow automation,
offering subscriptions and customized solutions tailored to the specific needs of each business.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Competition</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The market for business AI
automation is highly competitive, with established players and emerging challengers vying for market share. As businesses across various
industries seek to leverage automation technologies to drive efficiency and gain a strategic advantage, competition in this space is intensifying.
The business AI automation market comprises a diverse range of players offering solutions tailored to different industries and business
sizes. Key groups of competitors include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>Large Enterprise Software Companies</b> are enhancing their capabilities by integrating automation
tools into their software suites, leveraging existing customer relationships to promote AIaaS solutions. They offer user-friendly, no-code
approach for automating workflows and integrate well within the existing IT ecosystem, though it may not appeal to businesses with diverse
technology stacks. They also focus on data analysis, natural language processing, and machine learning, providing extensive AI capabilities
and strong brand recognition. However, its complexity and enterprise-oriented design may limit its suitability for smaller businesses,
highlighting the different audiences and use cases each platform serves.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>AI Model or Solution Providers</b> offer AI platforms tailored for business applications. Unlike YOOV,
these platforms primarily focus on providing AI models and tools rather than comprehensive end-to-end automation solutions.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>Specialized AIaaS or Traditional RPA Providers </b>lead the RPA market with robust solutions focused
on intelligent automation, leveraging advanced AI and machine learning. However, these platforms often require significant technical expertise
and primarily focus on task-based automation, limiting accessibility for businesses with limited IT resources. UiPath, while offering
a comprehensive automation platform, has a strong RPA focus that may restrict advanced AI integration and often involve complex deployment.
Similarly, Automation Anywhere's cloud-native platform enhances decision-making but also demands substantial resources and lacks a no-code
approach. In contrast, YOOV differentiates itself by providing a no-code, AI-driven platform that is accessible to all businesses, regardless
of their technical capabilities.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>No-Code Workflow Platforms</b> cater to companies seeking customizable workflow automation. These platforms
are user-friendly and offer a wide range of integrations, making them ideal choices for businesses seeking quick and simple automation
solutions. However, they usually lack advanced AI capabilities, focusing primarily on task automation rather than intelligent decision-making.
Also, it is limited in handling complex business processes. YOOV stands out with its unique AIaaS capabilities, delivering specialized
modules such as Operations AI, People AI, and Sales AI to address complex business needs.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>System Integrators and Consulting Firms </b>are leading global professional services firms that specialize
in technology and consulting. They provide a wide range of services, including IT solutions, digital transformation, and strategic consulting,
helping organizations leverage advanced technologies to drive growth and efficiency. YOOV stands out among system integrators and consulting
firms with its AI powered no-code, user-friendly platform allows users with varying technical skills to automate processes easily, enabling
rapid deployment and reducing project timelines. Additionally, YOOV offers competitive pricing, making advanced automation affordable
for smaller businesses, and provides high levels of customization to fit unique workflows</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>Industry-Specific Solutions</b>: Various niche providers that cater to specific sectors, such as finance
or insurance. YOOV distinguishes itself by offering a comprehensive ecosystem that integrates automation with financial credit evaluation
and insurance brokerage services, creating added value for clients.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 177 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competitive Advantages</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">YOOV differentiates itself
through its AIaaS platform, which uniquely integrates advanced AI technologies with no-code workflow automation. The ability to provide
end-to-end business solutions in the form of an integrated suite spanning HRM, CRM, and specialized industry applications makes it better
positioned to address a wide range of customer needs than many of its rivals. By empowering businesses to leverage advanced AI technologies
without technical barriers, YOOV addresses a critical gap in the market, making it a preferred choice for businesses worldwide. YOOV maintains
its market-leading position through the continual refinement of key competitive advantages:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>Innovative AIaaS Solution Offerings</b>: YOOV offers a
wide range of innovative and diverse AIaaS solutions addressing customers&#8217; different needs. This includes a comprehensive no-code
platform offering a holistic suite of automation capabilities and workflow orchestration, ready-to-use AI-powered solutions tackling
common pain points of various industries and niche market segments. With specialized AI modules, such as Operations AI, People AI, Sales
AI, and Customer Service AI, YOOV delivers versatile solutions that cater to the specific needs of businesses in all sizes and industries.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>Industry Expertise</b>: YOOV has a deep understanding
of various industries such as property management, health care, retail and F&amp;B, reflected in the tailored solutions it provides that
address specific business challenges. The Company's extensive experience in sectors such as finance, retail, and manufacturing enable
it to offer highly specialized and relevant AI automation tools. YOOV's industry expertise is further instilled in a professional team
of people with extensive experience in their respective fields, ensuring that the most appropriate and efficient solutions are presented
to clients. By offering highly specialized and relevant AI automation tools to customers, YOOV meets and even exceeds the expectations
of its clients, positioning the company as a trusted partner in their digital transformation journey.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>Highly Scalable and Customizable AIaaS Platform</b>: YOOV&#8217;s
architecture allows for scalability, allowing businesses to grow their AI capabilities as needed. This adaptability is often lacking
in rigid platforms that require substantial changes to accommodate growth. YOOV&#8217;s AIaaS platform can be scaled up or down based
on customer's evolving business needs, with the ability to easily add or modify components of systems and applications, as well as workflows,
seamlessly integrate with existing IT systems and applications, and support both attended and unattended automation modes.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>Robust Application Programming Interfaces (APIs) Accessibility</b>:
YOOV&#8217;s AIaaS platform features powerful APIs that allows businesses to easily access and integrate AI functionalities. This flexibility
enables organizations to enhance their existing software ecosystems seamlessly, reducing complexity and implementation time.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>Empowerment Through Accessibility</b>: YOOV&#8217;s mission
to empower businesses of all sizes means that even small and medium sized enterprises can access advanced AI technologies without the
need for extensive resources. This accessibility is a significant advantage over competitors that may target only larger organizations.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>Enhanced Data Interaction</b>: With YOOV&#8217;s AIaaS
platform, users can interact directly with their data and delegate a wide range of business tasks, facilitating seamless execution of
processes. This direct interaction allows for more intuitive decision-making and operational agility compared to other platforms that
may rely on predefined scripts or limited interactions.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>Pricing</b>: YOOV offers competitive pricing to customers.
YOOV is committed to delivering exceptional value to its customers by offering competitive pricing structures without compromising the
quality of any service. The company builds efficient operational models and strategic partnerships in which costs incurred are minimized,
and it passes these savings down to the customers. YOOV&#8217;s pricing strategy is designed to be flexible, catering to businesses of
all sizes. By providing a range of pricing options, YOOV ensures that its solutions are accessible and affordable for business uptake
and scaling AI automation.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>Customer service and support</b>: YOOV's business philosophy
upholds customer service and support as critical in building long-term client relationships. The Company offers comprehensive customer
support, promptly addressing any issues or queries. YOOV's support team comprises knowledgeable and responsive professionals committed
to helping clients maximize the benefits of their AI automation solutions. Apart from technical support, YOOV provides comprehensive
training and resources to help customers fully understand and utilize their products. This commitment to customer satisfaction is a key
differentiator for YOOV in the competitive market.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>Brand recognition and reputation</b>: YOOV has won numerous
industry awards, including the Hong Kong ICT Awards 2022 and 2024, Gold Award in Smart Business (Solution for SME) Award and Gold Award
in Smart Business (Emerging Technologies) Award respectively, further emphasizing its innovation and leadership in the business AI space.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 178 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>Synergy of the YOOV Ecosystem</b>: YOOV's ecosystem is
not limited to AIaaS solutions but incorporates financial and insurance services through its subsidiaries, YOOV Capital and YOOV Insurance,
respectively. This would then create smooth customer experience with cross-selling opportunities and better customer retention. The YOOV
ecosystem enables customers to enjoy tailored financial advisory services and insurance packages, improving their risk management and
financial well-being. This value proposition helps YOOV to establish stronger customer loyalty, drive sustainable growth and solidify
its competitive position in the market.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As the business AI automation
market continues to evolve, YOOV must stay agile, innovate rapidly, and deliver comprehensive solutions to maintain a competitive edge
and capitalize on the growing demand for intelligent automation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Models</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">YOOV&#8217;s revenues
primarily consist of (1) AIaaS services, (2) insurance brokerage services, (3) factoring services, and (4) others such as sales of office
supplies and others.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true"><b>(1) </b>The below fees generated
from AIaaS services:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><b style="-keep: true">1.</b></td><td style="text-align: justify"><span style="-keep: true"><b>Implementation service. </b>YOOV
                                            provides customized setup, configuration, and deployment of the AIaaS platform to enable
                                            YOOV Customers' access, including data migration, user training, system integration..</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><b style="-keep: true">2.</b></td><td style="text-align: justify"><span style="-keep: true"><b>AIaaS in the subscription
                                            periods. </b>YOOV provides ongoing access to the cloud-based AI platform during the subscription
                                            period (e.g., model training, API access, analytics).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><b style="-keep: true">3.</b></td><td style="text-align: justify"><span style="-keep: true"><b>Maintenance and unspecified
                                            upgrades services. </b>YOOV provides routine support, bug fixes, and unspecified feature
                                            enhancements to ensure platform reliability and performance.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>(2) Insurance brokerage services</b>
refers to revenues generated by the subsidiary, YOOV Insurance, which includes commission from insurance companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true"><b>(3) Factoring services</b> refers
to revenues generated by the subsidiary, YOOV Capital which includes: (i) set up fee; (ii) discount fee; and (iii) factoring commission.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true"><b>(4) Other streams of revenue,
such as sales of office supplies </b>refers to revenues generated exclusive from the above, such as sales of office supplies and others.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Growth Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV aims to enhance its
position as a leading AIaaS solutions provider and to continue to expand globally and into new related businesses. The growth strategy
is focused on capitalizing on the rapidly expanding markets for automation technologies. By leveraging innovative solutions, market expertise,
and strategic investments, YOOV aims to drive sustainable, long-term growth. YOOV plans to achieve this through the following strategies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>&#9679;</b></td><td style="text-align: justify"><b>Expanding Market Presence in High-Growth Segments</b></td>
</tr></table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">YOOV is strategically positioned to
benefit from the robust growth in the AIaaS market. According to Mordor Intelligence, the AIaaS market size is estimated to grow at a
CAGR of 36.78% from 2025 to 2030, driven by the increasing need for scalable AI tools and cloud-based solutions across industries like
healthcare, BFSI, and retail, represents a significant opportunity. YOOV will continue to enhance product offerings and scale operations
to meet the growing demand for automation solutions across industries such as finance, healthcare, retail, and manufacturing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 179 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><b>Expanding Globally into New Markets for Broader Customer Base and Geographic Reach</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Recognizing the tremendous potential
of AI technologies, we plan to further expand into new markets. The initial focus will be on the Southeast Asian markets, including but
not limited to Singapore, Malaysia, Indonesia, Vietnam, Thailand, and the Philippines. Following this, YOOV plans to expand its presence
in Australia, New Zealand and Middle Eastern markets. With the intension to grow customer base by targeting enterprises of all sizes and
deepening penetration into underserved markets, YOOV&#8217;s geographic expansion strategy includes entering emerging markets with increasing
demand for automation solutions. This approach will allow YOOV to capture new revenue streams while further diversifying its global footprint.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Enhancing Product Innovation and Capabilities</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">YOOV is committed to continuous innovation,
with a focus on enabling enterprises to adopt AI automation technologies seamlessly. This includes investments in advanced AI-driven capabilities
and low-code/no-code platforms, which Gartner predicts will power 70% of new enterprise applications by 2025. YOOV will continue to invest
in research and development to enhance its core AI technologies and product capabilities. By reducing the technical barriers to entry
for customers, YOOV aims to drive greater adoption of our solutions and capture a larger share of the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Pursuing Strategic Partnership and Strengthening Distribution Network</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">YOOV&#8217;s growth strategy includes
establishing a strong network by forging strategic partnership with leading technology providers, system integrators, and cloud platform
providers. By doing so, YOOV gains the capability to create a robust ecosystem that delivers comprehensive automation solutions, expand
market exposure and accelerate market acquisition to secure stable sale volume and revenue in long-term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Driving Operational Efficiency</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As automation increasingly becomes a
priority for organizations, YOOV is focused on demonstrating the value of its solutions in improving operational efficiency. According
to McKinsey &amp; Company, up to 60% of all occupations have at least 30% of activities that can be automated. By aligning our offerings
with the specific needs of customers, YOOV aims to drive widespread adoption and maximize customer satisfaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Seizing Opportunities in Economic and Regulatory Trends</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">YOOV will continue to monitor and adapt
to macroeconomic and regulatory trends that influence the adoption of automation technologies. YOOV&#8217;s AIaaS solutions are well-suited
to address challenges such as labor shortages, rising operational costs, and stricter compliance requirements, positioning YOOV as a trusted
partner for enterprises navigating these complexities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Targeted Mergers and Acquisitions</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">YOOV plans to pursue strategic acquisitions
to complement organic growth initiatives. These acquisitions will focus on expanding our technological capabilities, entering new markets,
and enhancing competitive positioning. YOOV disciplined approach to mergers and acquisitions is designed to create shareholder value while
accelerating long-term growth objectives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 180 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->159<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Strengthening Brand Recognition and Thought Leadership</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-keep: true">YOOV sells and markets its platform
primarily through sales agents. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">YOOV invests in marketing campaigns
for brand exposure and lead generation in target markets. These marketing campaigns cover both online and offline channels, including
search engines, social media, affiliated networks and broadcasting channels, as well as physical events such as seminars, summits and
exhibitions. YOOV encourages its key talents to engage in AI events and summits to actively promote its expertise and vision, establishing
YOOV as a trusted and innovative market leader.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">By executing these strategic
priorities, YOOV is confident in our ability to deliver sustainable revenue growth, expand profitability, and create long-term value for
our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b style="-keep: true">Sales
Flow and Customer Support</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">To ensure a timely and
smooth client onboarding process, YOOV has set out a standard operating procedure (SOP) which covers the key steps and responsibilities
from client intake through deployment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="margin: 0pt 0 0pt 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left"><b style="-keep: true">Procedure:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid; text-align: center; width: 5%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="border-top: Black 1pt solid; width: 20%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Client
    Intake</span></td>
    <td style="border-left: Black 1pt solid; border-top: Black 1pt solid; text-align: center; width: 5%"><span style="-keep: true">a.</span></td>
    <td style="border-right: Black 1pt solid; border-top: Black 1pt solid; text-align: justify; width: 70%"><span style="-keep: true">Sales agents gather relevant
    client information, including company details, key contacts, project requirements, and timeline.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-left: Black 1pt solid; text-align: center"><span style="-keep: true">b.</span></td>
    <td style="border-right: Black 1pt solid; text-align: justify"><span style="-keep: true">Sales agents provide the client with an onboarding checklist and
    schedule an onboarding kickoff meeting.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Onboarding Kickoff Meeting</span></td>
    <td style="border-left: Black 1pt solid; text-align: center"><span style="-keep: true">a.</span></td>
    <td style="border-right: Black 1pt solid; text-align: justify"><span style="-keep: true">Attend the kickoff meeting with the client, including representatives
    of sales agents, customer support team, and relevant subject matter experts.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-left: Black 1pt solid; text-align: center"><span style="-keep: true">b.</span></td>
    <td style="border-right: Black 1pt solid; text-align: justify"><span style="-keep: true">Review the client's project requirements, timeline, and objectives.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-left: Black 1pt solid; text-align: center"><span style="-keep: true">c.</span></td>
    <td style="border-right: Black 1pt solid; text-align: justify"><span style="-keep: true">Establish clear communication protocols, including points of contact,
    meeting cadence, and escalation procedures.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-left: Black 1pt solid; text-align: center"><span style="-keep: true">d.</span></td>
    <td style="border-right: Black 1pt solid"><span style="-keep: true">Outline the roles and responsibilities of all parties.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-left: Black 1pt solid; text-align: center"><span style="-keep: true">e.</span></td>
    <td style="border-right: Black 1pt solid"><span style="-keep: true">Agree on the project milestones, deliverables, and success criteria.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-left: Black 1pt solid; text-align: center"><span style="-keep: true">f.</span></td>
    <td style="border-right: Black 1pt solid"><span style="-keep: true">Discuss any potential risks or challenges and develop strategies.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font-size: 10pt"><span style="-keep: true">Solution Design and Configuration</span></td>
    <td style="border-left: Black 1pt solid; text-align: center"><span style="-keep: true">a.</span></td>
    <td style="border-right: Black 1pt solid; text-align: justify"><span style="-keep: true">Assign a dedicated project manager from the customer support team
    to oversee the implementation process.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-left: Black 1pt solid; text-align: center"><span style="-keep: true">b.</span></td>
    <td style="border-right: Black 1pt solid; text-align: justify"><span style="-keep: true">Collaborate with the client to finalize the solution design, incorporating
    their feedback and requirements.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-left: Black 1pt solid; text-align: center"><span style="-keep: true">c.</span></td>
    <td style="border-right: Black 1pt solid; text-align: justify"><span style="-keep: true">Configure the solution, including data integration, model training,
    and deployment, according to the agreed-upon specifications.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-left: Black 1pt solid; text-align: center"><span style="-keep: true">d.</span></td>
    <td style="border-right: Black 1pt solid; text-align: justify"><span style="-keep: true">Conduct internal testing and quality assurance checks to ensure
    the solution meets the client's requirements.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Training Session (If training
    session is subscribed)</span></td>
    <td style="border-left: Black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="border-right: Black 1pt solid; text-align: justify; font-size: 10pt"><span style="-keep: true">Coordinate the deployment of the solution and
    provide the client with comprehensive user training.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">User Acceptance</span></td>
    <td style="border-left: Black 1pt solid; text-align: center"><span style="-keep: true">a.</span></td>
    <td style="border-right: Black 1pt solid; text-align: justify"><span style="-keep: true">Schedule a UAT session with the client to validate the functionality
    and performance of the solution. &#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt"><span style="-keep: true">Testing (UAT) and</span></td>
    <td style="border-left: Black 1pt solid; text-align: center"><span style="-keep: true">b.</span></td>
    <td style="border-right: Black 1pt solid"><span style="-keep: true">Incorporate client feedback and make any necessary adjustments to the solution.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt"><span style="-keep: true">Onboarding</span></td>
    <td style="border-left: Black 1pt solid; text-align: center"><span style="-keep: true">c.</span></td>
    <td style="border-right: Black 1pt solid"><span style="-keep: true">Obtain the client's formal acceptance and sign-off on the solution.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ongoing Support and</span></td>
    <td style="border-left: Black 1pt solid; text-align: center"><span style="-keep: true">a.</span></td>
    <td style="border-right: Black 1pt solid"><span style="-keep: true">Assign a dedicated representative from the customer support team for the client. &#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt"><span style="-keep: true">Relationship</span></td>
    <td style="border-left: Black 1pt solid; text-align: center"><span style="-keep: true">b.</span></td>
    <td style="border-right: Black 1pt solid; text-align: justify"><span style="-keep: true">Regularly review the client's satisfaction, usage, and performance
    metrics, and address any concerns or issues promptly.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt"><span style="-keep: true">Management (If Support Plan is subscribed)</span></td>
    <td style="border-left: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><span style="-keep: true">c.</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><span style="-keep: true">Explore opportunities for solution
    expansion, feature enhancements, or additional services to further support the client's evolving needs.</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><b style="-keep: true">Responsibilities:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><b style="-keep: true">Sales <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">agents:
                                            </span></b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Responsible
                                            for client intake and onboarding kickoff meeting.</span></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><b style="-keep: true">Customer <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">support
                                            team:</span></b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            Responsible for solution design, configuration, and implementation, ongoing support and relationship
                                            management.</span></td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: justify"><span style="-keep: true">&#160;</span></td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#9679;</span></td><td style="text-align: justify"><b style="-keep: true">Subject matter experts:</b> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide
                                            technical expertise and support throughout the onboarding process.</span></td></tr>
     </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 181 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->160<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a provider of AIaaS and
business workflow automation solutions, YOOV operates within complex regulatory environments that vary across jurisdictions and industries.
The Company is subject to a range of government regulations that impact its operations, particularly in the areas of data protection,
privacy, financial services, and the use of artificial intelligence technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Data Protection and Privacy Compliance:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">YOOV processes and stores substantial
amounts of data on behalf of its customers, including sensitive business and operational information. As such, the Company is subject
to stringent data protection laws, such as the General Data Protection Regulation (GDPR) in the European Union, the California Consumer
Privacy Act (CCPA) in the United States, and other local privacy regulations in the jurisdictions where it operates. These regulations
require YOOV to implement robust data security measures, provide transparency around data collection and usage, and ensure that customers
retain control over their data. Non-compliance with these regulations could result in significant fines, reputational damage, and operational
challenges.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Given the cybersecurity risks associated
with AI systems, YOOV must adhere to cybersecurity regulations issued by the jurisdictions where it operates. These regulations set standards
for access controls, incident response, and other measures to protect critical information infrastructure. YOOV strives to align its AI
practices with guidance and frameworks related to the ethical and responsible development of AI.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Competition Law:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">YOOV&#8217;s operations are influenced
by the competition law, which prohibits anti-competitive conduct, such as price fixing, market sharing, and abuse of market dominance.
As YOOV&#8217;s technologies and services may impact market competition, YOOV must ensure its business practices comply with the requirements
of the competition law in the jurisdictions where it operates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Sector-Specific Regulations:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In industries such as finance and insurance,
YOOV&#8217;s solutions must comply with sector-specific regulations, including those related to credit evaluation, financial reporting,
and risk management. For example, YOOV Capital and YOOV Insurance are subject to oversight by financial regulatory authorities, requiring
them to meet strict standards for data accuracy, transparency, and consumer protection. These regulations also mandate regular reporting
and adherence to anti-money laundering (AML) and know-your-customer (KYC) protocols.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">YOOV Capital is a Money Lender License
Holder, subject to regulation by the Companies Registry, which oversees the Money Lenders Ordinance. The Money Lenders Ordinance sets
out specific conduct regulations for money lenders, including requirements around loan agreement terms, disclosure of interest rates,
and fair treatment of borrowers. As a financial institution, YOOV Capital must comply with Hong Kong's comprehensive AML, counter-terrorist
financing regulations and KYC protocols, which are enforced by the Companies Registry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">YOOV Insurance is subject to extensive
regulation and supervision by the Insurance Authority (IA), the primary regulatory body for the insurance industry in Hong Kong. The IA
is responsible for administering the Insurance Ordinance and other relevant laws and regulations that govern the licensing, solvency requirements,
business conduct, and other aspects of insurance companies operating in Hong Kong.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 182 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->161<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Artificial Intelligence and Automation Oversight:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The use of AI technologies in business
automation is increasingly scrutinized by regulatory bodies to ensure ethical and fair deployment. YOOV actively monitors legislative
developments to align its AI-driven solutions with emerging guidelines and standards. For instance, the European Commission has proposed
an Artificial Intelligence Act, which could impose stricter requirements on the use of high-risk AI systems. YOOV&#8217;s commitment to
transparency and ethical AI development positions it to comply with such regulations as they evolve.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Cross-Border Operations and Trade Compliance:</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As YOOV serves customers globally, it
is subject to international trade laws, export controls, and sanctions regulations. The Company ensures compliance with relevant laws
to prevent unauthorized or improper use of its software or services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Security and Data Protection</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV and its subsidiaries,
YOOV Capital and YOOV Insurance, recognize the critical importance of safeguarding customer data and ensuring the integrity of their platforms.
To address security challenges, the Company has implemented a comprehensive security framework designed to protect against data breaches,
cyberattacks, and other threats that could compromise its operations or customer trust. Key elements of YOOV&#8217;s security strategy
include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Data Encryption and Secure Storage</b>:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">YOOV employs advanced encryption protocols
to protect customer data both in transit and at rest. Confidential information concerning YOOV&#8217;s customers and partners is encrypted
using SSL encryption software and securely stored in compliance with industry standards, ensuring that sensitive information is safeguarded
against unauthorized access. These security measures apply across all YOOV platforms, including financial and insurance services offered
by YOOV Capital and YOOV Insurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Authentication and Access Controls</b>:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">YOOV implements multi-factor authentication
(MFA) and role-based access controls (RBAC) across all platforms to prevent unauthorized access. These measures ensure that only authorized
personnel and customers can access specific data and system functions, with enhanced controls for sensitive financial and insurance information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Regular Security Audits and Penetration Testing</b>:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">YOOV conducts regular security audits
and penetration testing to identify and address system vulnerabilities. These proactive measures are applied to the core AIaaS platform
and to the systems supporting YOOV Capital and YOOV Insurance, ensuring the security and reliability of all services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Compliance with Security Standards</b>:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">YOOV&#8217;s security protocols adhere
to internationally recognized standards, including ISO/IEC 27001 for information security management and SOC 2 (Service Organization Control)
for data protection and operational controls. Both YOOV Capital and YOOV Insurance comply with these standards to maintain the security
of financial and insurance-related data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Incident Response and Business Continuity</b>:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">YOOV has established a robust incident
response plan to address potential security breaches or disruptions. This plan includes rapid detection, containment, and recovery processes
to minimize the impact of security incidents on customers and business operations. Additionally, YOOV maintains comprehensive business
continuity and disaster recovery protocols to ensure uninterrupted service delivery, including for YOOV Capital and YOOV Insurance clients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Customer Education and Support</b>:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Recognizing the shared responsibility
for security, YOOV provides customers with resources and tools to strengthen their security practices. These include training materials,
user guides, and support for implementing best practices in data protection and secure automation. Additionally, YOOV Capital and YOOV
Insurance clients receive specific guidance on safeguarding sensitive financial and insurance data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 183 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->162<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>AI Security and Ethical Standards</b>:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">YOOV&#8217;s AI-driven solutions are
designed with security and ethical considerations at the forefront. The Company trains its AI models on diverse datasets to minimize bias
and ensures compliance with relevant legal and ethical standards. Additionally, YOOV provides transparency around the decision-making
processes of its AI systems, enabling customers to understand and trust the outcomes generated by its platforms, including YOOV Capital&#8217;s
credit evaluations and YOOV Insurance&#8217;s policy recommendations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Network Security and Facility Protection</b>:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">YOOV implements multiple layers of network
segregation and advanced firewall technology to prevent attacks or unauthorized access to its networks, servers and databases. YOOV operates
in a secured facility with physical access controls, where all employees must check in with facial recognition for access.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><b>Privacy Policy and Data Use Practices</b>:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">YOOV has implemented a comprehensive
privacy policy that outlines its data use practices and commitment to protecting user privacy. The policy specifies the extent to which
other YOOV users may access certain information. YOOV requires users to acknowledge and expressly agree to this policy when registering
with its platforms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">By prioritizing regulatory
compliance and security, YOOV and its subsidiaries aim to build and maintain trust with customers, partners, and stakeholders. The Company
remains committed to proactively adapting to regulatory changes and emerging security threats, ensuring the continued integrity and reliability
of its solutions, including the specialized services offered by YOOV Capital and YOOV Insurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024, YOOV
employed a total of 52 full-time employees. YOOV maintains good working relationships with its employees and does not foresee any difficulties
in the recruitment and retention of experienced staff.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The following table provides a summary of
the Company&#8217;s full-time employees by function as of December 31, 2024.<b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 90%"><span style="font-size: 10pt"><b>Function</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: center"><span style="font-size: 10pt"><b>Number of <br/>
    Employees</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">CEO and Management Office</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Finance</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">6</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Human Resources</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">2</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Investor Relations</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Business Development and Partnership</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">11</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Marketing</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">4</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Customer Services and Support</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">4</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">Research and Development</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">10</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">YOOV Capital</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">YOOV Insurance</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">4</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">52</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Facilities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of Mar 31, 2025, YOOV leased
the following principal facilities:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify"><b>Description of Use</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Approximate <br/> Square Footage</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Geographic<br/> Location</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Lease Expiration </b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: justify">Corporate Office Facilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,352</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">Hong Kong</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">01/11/2024 31/10/2027</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">through</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Corporate Office Facilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Singapore</td><td>&#160;</td>
    <td style="text-align: center">01/03/2025 28/02/2028</td><td>&#160;</td>
    <td style="text-align: center">through</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Corporate Office Facilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,035</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Malaysia</td><td>&#160;</td>
    <td style="text-align: center">04/11/2024 03/11/2025</td><td>&#160;</td>
    <td style="text-align: center">through</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Corporate Office Facilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Australia</td><td>&#160;</td>
    <td style="text-align: center">01/11/2024 30/04/2025</td><td>&#160;</td>
    <td style="text-align: center">through</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV&#8217;s corporate headquarters
is located in Singapore. YOOV also leases additional corporate office facilities in other locations as sales and operations offices. YOOV
periodically evaluates its facility requirements as necessary and believes its existing and planned facilities will be sufficient for
its needs for at least the next twelve months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 184 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->163<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Insurance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV complies with all Labor
Insurance regulations, ensuring that employees receive the necessary protections and benefits as mandated by law. This coverage underscores
our commitment to safeguarding the health and welfare of our workforce. YOOV is also fully covered under a comprehensive Group Medical
Insurance plan, which provides essential health benefits to all eligible employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV&#8217;s trademarks, intellectual
property, and intangible assets form the foundation of its operations and competitive position. The company leverages these assets to
deliver its innovative solutions, including its AIaaS platform, workflow automation tools, and financial and insurance services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV safeguards its intellectual
property through copyrights, trade secrets, and contractual safeguards. Confidentiality agreements, non-compete clauses, and intellectual
property clauses in contracts with employees, contractors, and partners ensure the protection of its proprietary technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV&#8217;s intellectual
property portfolio includes numerous domain names for websites that it uses in its business. YOOV has registered the domain names yoov.com,
yoov.asia and yoov.co and their variations. YOOV&#8217;s &#8220;YOOV&#8221; trademark and logo have also been registered with the relevant
authorities in Australia, Canada, Hong Kong, Macau, Taiwan and United Kingdom.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Trademarks</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV owns four registered
trademarks and service marks that are central to its brand identity and customer recognition. From time to time, YOOV monitors the use
of the trademarks across all markets and takes proactive measures to prevent infringement or dilution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are not involved in any
disputes and do not have any litigation matters pending that we believe could have a materially adverse effect on its financial condition
or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">From time to time, however,
we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of our business. Litigation is subject
to inherent uncertainties, and an adverse result in any such matters may arise from time to time that may harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 185 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->164<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><div><a id="a_107"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">YOOV EXECUTIVE COMPENSATION</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table summarizes
all compensation earned by YOOV&#8217;s Chief Executive Officer and two most highly compensation executive officers (other than our chief
executive officer) who were serving as executive officers as of March 31, 2025 and 2024 (the &#8220;Named Executive Officers&#8221;),
for services rendered as executive officers for the years ended March 31, 2025 and 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Summary Compensation Table</b>

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="8" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Compensation Paid(1)</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold"/><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Fiscal</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary</b></span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus</b></span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>Name and Principal Position</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">($)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">($)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">($)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Mr. Wong Ling Yan Philip </td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">2025</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">299,146</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">299,146</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">President and Chief Executive Officer </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">299,238</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">299,238</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mr. Wong Ho Chi Mark </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">153,337</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">153,337</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chief Technology Officer </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">153,337</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">153,337</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mr. Lai Kam Fu </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">153,359</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">153,869</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chief Financial Officer </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130,018</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,861</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,879</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The average exchange rates used
for US$ during the year ended March 31, 2024 and 2025, are based on the noon-buying&#160;rate certified for custom purposes by the U.S.
Federal Reserve Bank of New York set forth in the H.10 statistical release of the Federal Reserve Board, were 0.1277 and 0.1277 per HK$,
respectively.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employment Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On July 29, 2019, YOOV and
Mr. Wong Ling Yan Philip entered into an employment agreement pursuant to which Mr. Wong Ling Yan Philip serves as YOOV&#8217;s Chief
Executive Officer. The agreement provides that Mr. Wong Ling Yan Philip&#8217;s employment is &#8220;at will&#8221; and that either party
has the right to terminate his employment at any time and for any or for no reason upon one month&#8217;s notice. Mr. Wong Ling Yan Philip&#8217;s
employment agreement provides that he will receive an annual salary of HK$1,140,000 (approximately USD 145,547). Additionally, Mr. Wong
Ling Yan Philip is eligible for a discretionary performance incentive commission. The agreement also contains non-competition and confidentiality
provisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On June 1, 2017, YOOV and
Mr. Wong Ho Chi Mark entered into an employment agreement pursuant to which Mr. Wong Ho Chi Mark serves as YOOV&#8217;s Technical Director.
The agreement provides that Mr. Wong Ho Chi Mark&#8217;s employment is &#8220;at will&#8221; and that either party has the right to terminate
his employment at any time and for any or for no reason upon 30 days&#8217; notice or salary in lieu of notice. Mr. Wong Ho Chi Mark&#8217;s
employment agreement provides that he will receive an annual salary of HK$720,000 (approximately USD 91,925). Additionally, Mr. Wong Ho
Chi Mark is eligible for a discretionary performance incentive commission. The agreement also contains confidentiality provisions. On
August 2, 2021, Mr. Wong Ho Chi Mark was appointed as Chief Technology Officer of YOOV, with an annual salary of USD 107,692. No employment
agreement was entered into between YOOV and Mr. Wong Ho Chi Mark in connection with this appointment. On February 13, 2023, Mr. Wong Ho
Chi Mark&#8217;s annual salary was adjusted to USD 153,846.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 186 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->165<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March 10, 2023, YOOV and
Mr. Lai Kam Fu entered into an employment agreement pursuant to which Mr. Lai Kam Fu serves as YOOV&#8217;s Chief Financial Officer. The
agreement provides that Mr. Lai Kam Fu&#8217;s employment is &#8220;at will&#8221; and that either party has the right to terminate his
employment at any time and for any or for no reason upon one month&#8217;s notice. Mr. Lai Kam Fu&#8217;s employment agreement provides
that he will receive an annual salary of HK$1,020,000 (approximately USD 129,938). Additionally, Mr. Lai Kam Fu is eligible for an annual
guaranteed and discretionary bonus, as well as additional IPO project bonus. The agreement also contains non-competition and confidentiality
provisions.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Option Exercises and Stock Vested</b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">There were no options exercised by our executive
officers or stock vested to YOOV&#8217;s executive officers during the year ended March 31, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Outstanding Equity Awards at 2024 Fiscal Year
End</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">As of the date of this proxy statement/prospectus,
YOOV has not granted any equity awards to its executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>No Pension Benefits</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV does not maintain any
plan that provides for payments or other benefits to its executive officers at, following or in connection with retirement and including,
without limitation, any tax-qualified defined benefit plans or supplemental executive retirement plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>No Nonqualified Deferred Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV does not maintain any
defined contribution or other plan that provides for the deferral of compensation on a basis that is not tax-qualified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b>Director Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">Prior to the Merger, YOOV did not have a formal
policy to provide any cash or equity compensation to its non-employee directors for their service on the YOOV Board or committees of the
YOOV Board. YOOV has not paid any compensation to its non-employee directors for their service on the YOOV Board or committees of the
YOOV Board</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 187 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->166<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_108"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">YOOV MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><i>The following discussion
and analysis of YOOV&#8217;s financial condition and results of operations should be read together with YOOV&#8217;s consolidated financial
statements and the related notes appearing elsewhere in this proxy statement/prospectus. This discussion and other parts of this proxy
statement/prospectus contain forward-looking statements that involve risks and uncertainties, such as statements regarding YOOV&#8217;s
plans, objectives, expectations, intentions and projections. YOOV&#8217;s actual results could differ materially from those described
in or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited
to, those discussed in the &#8220;Risk Factors&#8221; section of this proxy statement/prospectus</i>. <i>Throughout this section, unless
otherwise noted or the context requires otherwise, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Company&#8221;
refer to YOOV and its consolidated subsidiaries, and in references to monetary amounts, &#8220;dollars&#8221; and &#8220;$&#8221; refer
to U.S. Dollars.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV is a prominent provider
of Artificial Intelligence-as-a-Service (AIaaS) solutions, specializing in intelligent business automation. YOOV has transformed from
an office automation platform into a comprehensive no-code AI-driven workflow automation platform. </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">YOOV&#8217;s mission is
to make advanced AI technologies accessible to businesses without requiring technical expertise. By integrating AI with its no-code
workflow automation platform, YOOV enables businesses to automate complex workflows and tasks across diverse industries, empowering
businesses of all sizes to optimize operations, reduce costs, and enhance service delivery through its AIaaS solutions. To cope with
the global expansion plan, YOOV&#8217;s solutions are designed to address the challenges of modern businesses while fostering
efficiency, scalability, and growth. In addition, YOOV operates subsidiaries in financial and insurance services, including YOOV
Capital Limited and YOOV Insurance Services Limited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Key Factors Affecting Our Results</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe that the key factors affecting our performance
and financial performance include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our ability to attract new customers and retain existing customers</i></b><i>.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order to maintain and increase
our revenue, we need to continue to retain and attract new customers by means of strategic alliance marketing, inbound marketing, and
outbound marketing. A number of factors could adversely impact our ability to successfully implement our marketing efforts, such as difficulty
of our sales and marketing team to effectively interact with potential customers, or potential customers do not find our products and
services sufficient to meet their needs. If we are unable to successfully market our solutions, whether due to failure to maintain and
expand relationships with our partners and alliances and/or failure to adjust our strategy in order to meet the needs of current and potential
customers, our ability to retain and attract new customers may be undermined, which would adversely affect our business and results of
operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We retain and attract customers
through a multitude of avenues, including industry trade shows and collaboration with relevant partners such as sales agents. We routinely
communicate with customers to keep ourselves informed of their evolving business needs and develop the product and service offerings with
tailored functions and features accordingly. With these approaches, we have successfully built our brand, increase customer stickiness
and expanded our customer base. Our business has experienced steady growth during the past few years.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a result of these close
and stable relationships with our existing customers, we are able to receive recurring businesses from the existing customers. If we are
unable to maintain close and stable relationships with our existing customers, our business and results of operations may be adversely
affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 188 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->167<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our ability to help our customers to automate complex workflows
and tasks</i></b><i>.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The engagement and adoption
of YOOV&#8217;s platform by businesses directly impacts our growth and operational performance. As an AIaaS provider, YOOV offers a no-code
automation solution that integrates advanced AI and RPA technologies, enabling organizations of all sizes to streamline operations, reduce
costs, and enhance service delivery without requiring significant IT resources. Our modular offerings-such as Operations AI, People AI,
Sales AI, and Customer Service AI-are designed to address the diverse needs of businesses across industries, making intelligent automation
both accessible and effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To support customer success,
YOOV provides analytical tools that track key usage metrics, such as workflow execution rates, user engagement, AI task performance, and
API integration activity. These insights help businesses optimize their use of the platform, identify opportunities for improvement, and
tailor automation strategies to their specific needs. By combining powerful technology with actionable data, YOOV empowers customers to
unlock the full potential of AI-driven business automation.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our ability to manage our cost of revenues</i></b><i>
<b>and expenses.</b></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our results of operations
depend on our ability to manage our costs and expenses. Our cost of revenues primarily of commission paid to third-party sales agents, amortization expenses
related to our AIaaS related software and systems, salaries and benefits of relevant operations and support personnel and other direct
service costs, and our operating expenses primarily consisted of advertising and marketing expenses
of marketing our products and services, staff costs for our marketing and sales department, staff cost for our administrative personnel,
consulting and professional service fees; depreciation  relating to our property, and equipment; and other
administrative expenses, and research and development expenses. If we are unable to control such costs, our financial performance may be adversely affected.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our ability to further advance our technological capabilities
and infrastructure</i></b><i>.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our strong technological
capabilities and infrastructure, in particular our AIaaS platform and third-party technologies integrated into our AIaaS platform, support
our business development. Our ability to effectively invest in these technologies allows us to create a superior user experience and
to timely identify new trends. We must continue to innovate to keep pace with the growth of our business and bring forward new technologies.
If our technologies or solutions are unable to satisfy our customers due to complexity of their requirements, our ability to retain existing
customers and attract new customers may be undermined, which would adversely affect our business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Key components of results of operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our revenues primarily consist
of (1) Artificial Intelligence-as-a-Service (&#8220;AIaaS&#8221;) services, (2) insurance brokerage services, (3) factoring services,
and (4) others such as sales of office supplies and others. For the nine months ended December 31, 2024 and 2023, our total revenues were
USD38.0 million and USD21.7 million, respectively. For the years ended March 31, 2024 and 2023, our total revenues were USD29.6 million
and USD21.5 million, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets forth
a breakdown of our revenues, each expressed in the absolute amount and as a percentage of our total revenues, for the period indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the nine months ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended March 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">Revenues</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">%</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">%</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">%</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 24%; text-align: left">AIaaS services &#12288;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">37,560,885</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98.7</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">21,321,547</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98.0</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">29,088,722</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98.2
</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">21,092,035</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">98.3</td><td style="width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Insurance brokerage services &#12288;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">286,342</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224,870</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">292,580</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,793</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Factoring services &#12288;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135,663</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.4</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.5</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">227,215</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Others &#12288;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,343</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,711</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,311</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,911</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total &#12288;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">38,012,233</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>100.0</b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">21,745,878</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>100.0</b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">29,633,327</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>100.0</b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">21,456,954</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 189 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->168<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">AIaaS services</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.3pt">We offer AIaaS services by
operating four core products, each designed to address specific enterprise needs:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"/><td style="text-align: justify; width: 0.25in">(1)</td><td style="text-align: justify"><b>AI CHAIN</b>: A generative AIaaS platform with built-in capabilities such as chatbots, workflows, large
models, and knowledge search cover the entire process of model selection, application development, and deployment, making it easy to build
AI applications.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"/><td style="text-align: justify; width: 0.25in">(2)</td><td style="text-align: justify"><b>NEXA</b>: A Business AI assistant offers voice-activated assistance for various business tasks, including
scheduling, reminders, and data retrieval. It utilizes advanced AI algorithms to understand and respond to natural language queries. NEXA
enhances productivity through AI-driven assistance, integrating with other YOOV products for a cohesive user experience. YOOV has been
awarded Gold Award in the Hong Kong ICT Awards 2024: Smart Business (Emerging Technologies) Award with NEXA as the entry.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"/><td style="text-align: justify; width: 0.25in">(3)</td><td style="text-align: justify"><b>YOOV PLUS:</b> A no-code workflow automation platform allows businesses to create customized applications
without extensive coding knowledge. YOOV PLUS features a user-friendly interface with drag-and-drop functionalities for rapid deployment
and easy modifications. It enables businesses in all sizes and industries to develop scalable and flexible solutions tailored to their
specific needs. YOOV has been awarded Gold Award in the Hong Kong ICT Awards 2022: Smart Business (Solution for SME) Award with YOOV PLUS
as the entry.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="text-align: justify; width: 0.5in"/><td style="text-align: justify; width: 0.25in">(4)</td><td style="text-align: justify"><b>YOOV WORK</b>: A Human Resources Management (HRM) and Workflow Automation system developed with the
aim to streamlining HRM operations such as payroll, attendance, leave management, and employee records. It integrates seamlessly with
other business systems for better data management and provides a mobile app for on-the-go management. YOOV Work optimizes daily HRM operations,
enhances business efficiency, and provides advanced analytics for better decision-making.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.3pt">As we execute on our long-term
growth strategies and deliver product innovation, we have continued to experience growth in AIaaS services revenue across our portfolio
of offerings. Revenue from our AIaaS services amounted to USD37.6 million and USD21.3 million for the nine months ended December 31, 2024
and 2023, which accounted for 98.7% and 98.0% of the total revenues, respectively. Revenue from our AIaaS services amounted to USD29.1
and USD21.1 million for the years ended March 31, 2024 and 2023, which accounted for 98.2% and 98.3% of the total revenues, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Insurance brokerage service</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As an agent, we provide insurance
brokerage service on behalf of insurance companies, including the distribution of insurance policies, and earn commissions determined
as a percentage of premiums paid by the insured. Our primary service is for AXA General Insurance Hong Kong Limited, and the commission
rates vary depending on the type of insurance, typically ranging from 15% to 55%. The revenue generated from our insurance brokerage services
amounted to USD0.3 million and USD0.2 million for the nine months ended December 31, 2024 and 2023, respectively. The revenue generated
from our insurance brokerage services amounted to USD0.3 million and USD0.1 million for the year ended March&#160;31, 2024 and 2023, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Factoring services</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We also generated revenue
from the provision of factoring services, whereby customers sell or transfer their accounts receivable to us in exchange for immediate
funding. This service is typically used to alleviate working capital shortages and to support corporate customers in managing liquidity,
whether for suppliers payment, operating expenses, or investing in growth. For the nine months ended December 31, 2024 and 2023, revenue
from factoring services amounted to USD0.1 million and USD0.1 million, respectively. For the years ended March 31, 2024 and 2023, revenue
from factoring services amounted to USD0.2 million and USD0.2 million, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cost of revenue</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our cost of revenue primarily
consists of the following: (i)&#160;amortization of AIaaS related software; (ii)&#160;sales commission paid to sales agents which are
amortized over the contract period, and (iii)&#160;others such as costs of goods sold.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 190 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->169<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets forth
a breakdown of our cost of revenues, each expressed in the absolute amount and as a percentage of our total cost of revenues, for the
period indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">For the nine months ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended March 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">Cost of revenues</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">%</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">%</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">%</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 24%; text-align: left">Sales commissions &#12288;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">9,879,607</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74.4</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">5,581,859</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71.8</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">7,688,486</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71.6</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">5,351,190</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">71.5</td><td style="width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Amortization of AIaaS related software </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,371,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,087,745</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26.9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,940,699</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,881,495</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Others &#12288;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32,230</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.2</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">99,479</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">106,652</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.0
</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">255,473</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Total </td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">13,283,137</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">7,769,083</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">10,735,837</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">7,488,158</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets forth
a breakdown of our operating expenses, each expressed in the absolute amount and as a percentage of our total operating expenses, for
the period indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">For the nine months ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended March 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">Operating expenses</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">%</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">%</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">%</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 24%; text-align: left">Selling and marketing expenses &#12288;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">18,523,469</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">82.9</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">8,436,295</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66.9</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">10,399,877</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60.8</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">6,433,443</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">45.6</td><td style="width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Administrative expenses </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,589,367</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,613,649</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,083,083</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,510,772</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46.1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">222,860</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.0</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">570,141</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5 </span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">612,733</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,174,942</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8.3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Total </td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">22,335,696</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">12,620,085</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">17,095,693</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,119,157</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Selling and marketing expenses</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Selling and marketing expenses
primarily consist of (i) advertising and marketing expenses of marketing our products and services and (ii) staff costs for our marketing
and sales department.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Administrative expenses</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Administrative expenses primarily
consist of: (i)&#160;staff cost for our administrative personnel; (ii) consulting and professional service fees; (iii)&#160;depreciation expenses relating to our property and equipment; and (iv)&#160;other expenses which primarily include credit losses,
utilities, traveling, repair and maintenance, rental and other miscellaneous administrative expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Research and development (&#8220;R&amp;D&#8221;)
expenses</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Research and development expenses
primarily include&#160;(i)&#160;staff cost paid to R&amp;D employees; and (ii) other costs incurred during the research stage.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other loss, net</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other loss, net, primarily
consists of: (i)&#160;finance income generated from cash deposit in bank; (ii)&#160;finance expenses generated from borrowings from bank
and third parties; (iii)&#160;other non-operating income, inclusive of cash surrender value changes of insurance contracts, government
subsidy, etc.; and (iv)&#160;other non-cancellable income/expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income tax expenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>British Virgin Islands (&#8220;BVI&#8221;)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the current laws of
BVI, we are not subject to income or capital gains taxes. In addition, dividend payments are not subject to withholdings tax in BVI.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 191 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->170<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Hong&#160;Kong</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">According to Tax (Amendment)
(No. 3) Ordinance 2019 published by Hong&#160;Kong government, effective April&#160;1, 2019, under the two-tiered profits tax rates regime,
the profits tax rate for the first approximately $256,410 of assessable profits was reduced to 8.25% (half of the rate specified in Schedule&#160;8
to the Inland Revenue Ordinance (IRO)) for corporations, while the remaining profits will continue to be taxed at the existing 16.5% tax
rate. All of our subsidiaries were subject to Hong&#160;Kong profit tax during the periods presented.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Comparison of Results of Operations for the&#160;Nine
Months Ended December&#160;31, 2024 and 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets forth
a summary of our consolidated results of operations for the periods indicated. This information should be read together with our unaudited
condensed consolidated financial statements and related notes included elsewhere in this proxy statements/prospectus. The operating results
in any period are not necessarily indicative of the results that may be expected for any future period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Variance</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">38,012,233</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21,745,878</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16,266,355</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">74.8</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Cost of revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,283,137</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,769,083</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,514,054</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71.0</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">24,729,096</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">13,976,795</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">10,752,301</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">76.9</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,523,469</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,436,295</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,087,174</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">119.6</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,589,367</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,613,649</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,282</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.7</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(222,860</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(570,141</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">347,281</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60.9</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total operating expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(22,335,696</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(12,620,085</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(9,715,611</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">77.0</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#12288;</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#12288;</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income from operations</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,393,400</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,356,710</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,036,690</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">76.4</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other loss, net:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(825,145</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(309,800</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(515,345</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166.3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(84</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100.0</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">55,027</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62,756</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,729</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12.3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total other loss, net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(770,118</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(247,128</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(522,990</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">211.6</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#12288;</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#12288;</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income before income tax provision</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,623,282</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,109,582</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">513,700</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">46.3</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(299,374</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(230,663</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(68,711</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29.8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net income</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,323,908</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">878,919</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">444,989</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">50.6</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets forth
a breakdown of our revenues, each expressed in the absolute amount and as a percentage of our total revenues, for the period indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">2024 &#12288;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Variance</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">Revenues</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">AIaaS services &#12288;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">37,560,885</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98.7</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21,321,547</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98.0</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16,239,338</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">76.2</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Insurance brokerage services &#12288;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">286,342</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.8</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224,870</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.0</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,472</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27.3</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Factoring services &#12288;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135,663</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.4</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,913</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Others &#12288;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,343</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.1</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,711</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.4</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(48,368</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(62.2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total &#12288;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">38,012,233</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>100.0</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">21,745,878</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>100.0</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">16,266,355</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">74.8</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 192 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->171<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">AIaaS services</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Revenue generated from our
AIaaS services increased by USD16.2 million, or 76.2%, from USD21.3 million for the nine months ended December 31, 2023, to USD37.5 million
for the nine months ended December 31, 2024. This accounted for 98.7% and 98.0% of the total revenues for the nine months periods in 2024
and 2023, respectively. This significant growth was primarily driven by the expansion of our customer base and continued penetration into
overseas markets, facilitated by our ongoing implementation of a product-led growth strategy. Revenues generated from Hong Kong amounted
to USD31.3 million and USD17.8 million for the nine months ended December 31, 2024 and 2023, respectively. Revenues generated from AIaaS
services outside Hong Kong amounted to USD6.3 million and USD3.5 million for the nine months ended December 31, 2024 and 2023, respectively,
which accounted for 16.8% and 16.6% of our AIaaS services revenues for both nine months periods in 2024 and 2023, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets forth
a breakdown of our revenues from AIaaS services by geographic areas, each expressed in the absolute amount and as a percentage of our
revenues generated from AIaaS services, for the period indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">2024 &#12288;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Variance</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">Revenues from AIaaS services by geographic areas</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong <b>&#12288;</b></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">31,251,275</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83.2</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">17,776,010</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83.4</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,475,265</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">75.8</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Others (1) </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,309,610</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,545,537</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,764,073</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78.0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total </td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">37,560,885</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">100.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">21,321,547</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">100.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">16,239,338</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">76.2</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Other geographic areas include Taiwan, Malaysia,
and Japan etc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Insurance brokerage service</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Revenue generated from our
insurance brokerage service increased by USD0.1 million, or 27.3%, from USD0.2 million for the nine months ended December 31, 2023 to
USD0.3 million for the nine months ended December 31, 2024, primarily due to an increase sales volume in insurance policies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Factoring services</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Revenue generated from factoring
services amounted to USD0.1 million for both nine months ended December 31, 2024 and 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cost of revenues</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our cost of revenues increased
by USD5.5 million, or 71.0%, from USD7.8 million for the nine months ended December 31, 2023, to USD13.3 million for the nine months ended
December 31, 2024, primarily due to the increase of sales commissions and amortization of AIaaS related software. This mirrors the trend
observed in the AIaaS industry, where companies often experience increased sales costs as they scale up their operations and invest in
the growth of their cloud-based service offerings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Sales commissions increased
by USD4.3 million, or 77.0%, from USD5.6 million for the nine months ended December 31, 2023 to USD9.9 million for the nine months ended
December 31, 2024, basically proportionate to the changes in the revenue stream, primarily due to our market expansion which required
more sales commissions paid to the sales agents in both domestic and newly developed overseas markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The amortization of AIaaS-related
software increased by USD1.3 million, or 61.5%, from USD2.1 million for the nine months ended December 31, 2023, to USD3.4 million for
the nine months ended December 31, 2024, primarily due to the addition of AIaaS-related software.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Gross profit and gross profit margin</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Gross profit represents our
revenues less cost of revenues. Our gross profit margin represents our gross profit as a percentage of our revenues. For the nine months
ended December 31, 2024 and 2023, our gross profit was USD24.7&#160;million and USD14.0&#160;million, respectively, and our gross profit
margin was 65.1% and 64.3%, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Selling and marketing expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our selling and marketing
expenses increased by USD10.1 million, or 119.6%, from USD8.4 million for the nine months ended December 31, 2023, to USD18.5 million
for the nine months ended December 31, 2024, which was primarily due to&#160;our business expansion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 193 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->172<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Administrative expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our administrative expenses
remained stable at USD3.6&#160;million for both nine months ended December 31, 2024 and 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>R&amp;D expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our research and development
expenses decreased by USD0.4&#160;million, from USD0.6 million for the nine months ended December 31, 2023, to USD0.2&#160;million for
the nine months ended December 31, 2024, as we reallocated R&amp;D efforts from internal development to collaboration with a leading external
technology company. This shift reduced the need for in-house R&amp;D staff, thereby lowing overall R&amp;D costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other loss, net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other loss increased by USD0.5&#160;million
from USD0.2&#160;million for the nine months ended December 31, 2023 to USD0.7&#160;million for the nine months ended December 31, 2024,
which was primarily due to an increase in finance expenses of USD0.5 million due to the increase of borrowings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Income tax expenses </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our income tax expenses increased
by USD0.1 million from USD0.2 million for the for the nine months ended December 31, 2023, to USD0.3 million for the for the nine months
ended December 31, 2024, which was due to the increase in the deferred income tax expenses, arising from the increase in deferred tax
liabilities related to accelerated depreciation and amortization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net income</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Consequently, our net income
increased by USD0.4 million from USD0.9 million for the nine months ended December 31, 2023 to USD1.3&#160;million for the for the nine
months ended December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Comparison of Results of Operations for the&#160;Years
Ended March&#160;31, 2024 and 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets forth
a summary of our consolidated results of operations for the periods indicated. This information should be read together with our consolidated
financial statements and related notes included elsewhere in this proxy statements/prospectus. The operating results in any period are
not necessarily indicative of the results that may be expected for any future period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended March 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Variance</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">29,633,327</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21,456,954</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,176,373</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">38.1</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Cost of revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,735,837</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,488,158</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,247,679</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43.4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">18,897,490</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">13,968,796</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">4,928,694</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">35.3</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,399,877</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,433,443</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,966,434</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61.7</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,083,083</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,510,772</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">427,689</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6.6</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(612,733</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,174,942</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">562,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47.8</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total operating expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(17,095,693</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(14,119,157</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(2,976,536</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">21.1</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income/(loss) from operations</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,801,797</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(150,361</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,952,158</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,298.3</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other loss, net:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(383,593</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(285,271</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(98,322</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34.5</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(84</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(235</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">151</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(64.3</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">193,331</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">127,678</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">65,653</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51.4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total other loss, net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(190,346</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(157,828</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(32,518</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">20.6</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income/(loss) before income tax provision</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,611,451</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(308,189</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,919,640</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(622.9</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(360,869</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(119,353</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(241,516</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">202.4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net income/(loss)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,250,582</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(427,542</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,678,124</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(392.5</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 194 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->173<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets forth
a breakdown of our revenues, each expressed in the absolute amount and as a percentage of our total revenues, for the period indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">2024 &#12288;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Variance</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">Revenues</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">AIaaS services &#12288;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">29,088,722</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98.2</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21,092,035</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98.3</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,996,687</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">37.9</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Insurance brokerage services &#12288;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">292,580</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.0</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,793</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.5</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">174,787</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148.4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Factoring services &#12288;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.5</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">227,215</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(68,501</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30.1</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Others &#12288;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,311</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.3</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,911</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.1</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">73,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">368.6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total &#12288;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">29,633,327</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>100.0</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">21,456,954</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>100.0</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,176,373</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">38.1</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">AIaaS services</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Revenue generated from our
AIaaS services increased by USD8.0 million, or 37.9%, from USD21.1 million for the year ended March&#160;31, 2023, to USD29.1 million
for the year ended March 31, 2024. This accounted for approximately 98% of the total revenues for both years. This growth was primarily
attributed to our expanded new customer base and the continued development of overseas markets, facilitated by our ongoing implementation
of a product-led growth strategy. Notably, during the fiscal year 2024, we actively developed new international markets such as Taiwan
and Malaysia, through the in-depth research on potential market. These efforts enable us to tailor our go-to-market strategy and enhance
our brand visibility. As a result, we successfully entered these markets and unlocked new revenue streams, further solidifying our international
footprint. Revenues generated from Hong Kong amounted to USD22.7 million and USD21.1 million for the years ended March 31, 2024 and 2023,
respectively. Revenues generated from AIaaS services outside Hong Kong amounted to USD6.4 million for the year ended March 31, 2024, which
accounted for 22.1% of our AIaaS services revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets forth
a breakdown of our revenues from AIaaS services by geographic areas, each expressed in the absolute amount and as a percentage of our
revenues generated from AIaaS services, for the period indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="22" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended March 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Variance</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">Revenues from AIaaS services by geographic areas</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong <b>&#12288;</b></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">22,671,557</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77.9 <b>&#12288;</b></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21,092,035</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100.0 <b>&#12288;</b></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,579,522</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.5</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Others(1) </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,417,165</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,417,165</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100.0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Total </td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">29,088,722</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">100.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">21,092,035</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">100.0</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7,996,687</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">37.9</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Other geographic areas include Taiwan, Malaysia,
and Japan etc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Insurance brokerage service</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Revenue generated from our
insurance brokerage service increased by USD0.2 million, or 148.4%, from USD0.1 million for the year ended March 31, 2023 to USD0.3 million
for the year ended March&#160;31, 2024, primarily due to an increase sales volume in insurance policies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Factoring services</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Revenue generated from factoring
services amounted to USD0.2 million and USD0.2 million for the year ended March&#160;31, 2024 and 2023, respectively .</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cost of revenues</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our cost of revenues increased
by USD3.2 million, or 43.4%, from USD7.5 million for the year ended March 31, 2023, to USD10.7 million for the year ended March 31, 2024,
primarily due to the increase of sales commissions and amortization of AIaaS related software. This mirrors the trend observed in the
AIaaS industry, where companies often experience increased sales costs as they scale up their operations and invest in the growth of their
cloud-based service offerings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 195 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->174<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b>&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Sales commissions increased
by USD2.3 million, or 43.7%, from USD5.4 million for the year ended March&#160;31, 2023 to USD7.7 million for the year ended March 31,
2024, basically proportionate to the changes in the revenue stream. The rise in commissions was mainly due to intensified sales activities
associated with our geographic expansion and increased sales agent coverage, particularly in newly entered markets such as Taiwan and
Malaysia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The amortization of AIaaS-related
software increased by USD1.1 million, or 56.3%, from USD1.9 million for the year ended March&#160;31, 2023, to USD3.0 million for the
year ended March 31, 2024, primarily due to the addition of AIaaS-related software.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Gross profit and gross profit margin</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Gross profit represents our
revenues less cost of revenues. Our gross profit margin represents our gross profit as a percentage of our revenues. For the years ended
March&#160;31, 2024 and 2023, our gross profit was USD18.9&#160;million and USD14.0&#160;million, respectively, and our gross profit margin
was 63.8% and 65.1%, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Selling and marketing expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our selling and marketing
expenses increased by USD4.0 million, or 61.7%, from USD6.4 million for the year ended March 31, 2023, to USD10.4 million for the year
ended March 31, 2024, which was primarily attributable to&#160;our business expansion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Administrative expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our administrative expenses
decreased by USD0.4&#160;million, or 6.6%, from USD6.5&#160;million for the year ended March&#160;31, 2023, to USD6.1&#160;million for
the year ended March&#160;31, 2024, which was primarily attributable to (i) an increase of reversal of credit losses of USD1.4 million
due to collection, which was deducted from administrative expenses, (ii) a decrease of professional service fees of USD 0.5 million, and
partially offset by (iii) an increase of USD1.3&#160;million in staff cost due to newly hired management and increased performance bonuses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>R&amp;D expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our research and development
expenses decreased by 47.8%, or USD0.6&#160;million, from USD1.2&#160;million for the year ended March&#160;31, 2023, to USD0.6&#160;million
for the year ended March&#160;31, 2024, which was primarily attributable to&#160;a decrease in salaries for R&amp;D employees of USD0.5&#160;million,
as we reallocated R&amp;D efforts from internal development to collaboration with a leading external technology company. This shift reduced
the need for in-house R&amp;D staff, thereby lowing overall R&amp;D costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other loss, net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other loss increased by USD0.03&#160;million
from USD0.16&#160;million in fiscal year 2023 to USD0.19&#160;million in fiscal year 2024, which was primarily attributable to an increase
in finance expenses of USD0.1 million due to the increase of borrowings; partially offset by a decrease of USD0.2&#160;million in government
subsidy and an increase of USD0.2 million in cash surrender value changes of insurance contracts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Income tax expenses </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our income tax expenses increased
by USD0.2 million from USD0.1 million for the year ended March 31, 2023, to USD0.3 million for the year ended March 31, 2024, which was
due to the increase in the deferred income tax expenses, arising from the increase in deferred tax liabilities related to accelerated
depreciation and amortization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net income</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Consequently, our net income
increased by USD1.7 million, from net loss of USD0.4 million for the year ended March&#160;31, 2023, to net income of USD1.3&#160;million
for the year ended March&#160;31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our primary liquidity sources
have comprised operational cash flows, financing from third-party investors, related parties and bank borrowings. As of December&#160;31,
2024 and March&#160;31, 2024, we had USD2.7million and USD1.4&#160;million in cash in Hong Kong respectively. We generated USD5.4 million
in cash from operating activities for the nine months ended December 31, 2024. Most of our cash resources were used to pay for the development
of intangible assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Accounts
                                            receivable amounted to USD44.2 million as of December 31, 2024, compared to USD19.8 million
                                            as of March 31, 2024. The increase of USD24.4 million was primarily attributable to the significant
                                            growth in revenue generated from AIaaS services, which surged by 76.2% during the nine months
                                            ended December 31, 2024, compared with the same period in 2023. This revenue growth underscores
                                            our robust business momentum, increased contract volumes, and ongoing penetration into overseas
                                            markets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">The increase in accounts
receivable as at December 31, 2024 was also influenced by a higher volume of revenue generated in the calendar year end, as many customers
tend to settle the payments after year-end closing activities, leading to a temporary accumulation of receivables. . The increase in
days sales outstanding (&#8220;DSO&#8221;) was largely the result of the revenue increased toward the third quarter in the fiscal year
of 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 196 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->175<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">The Company estimated
the DSO as at March 31, 2025 will stabilize at similar levels, compared with the same period in 2024. We continue to monitor account
receivable and cash collection trends closely, and to date, have not observed a material increase in delinquency or credit risk. Approximately
33.9%, or USD15million, of the December 31, 2024 accounts receivable balance has been subsequently collected as of the date of this prospectus.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December&#160;31, 2024
and March&#160;31, 2024, we had balances due from a director of USD10.3&#160;million and USD4.6&#160;million, respectively. The director
authorized the use of his bank account for our collection and payments activities, aiming to improve business efficiency, covering the
payment of development of intangible assets, collection of investment, and receivables, etc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December&#160;31, 2024
and March&#160;31, 2024, we had mezzanine equity of USD38.0&#160;million and USD37.5&#160;million, respectively. These were redeemable
at the option of holders after the lock-up periods, or if a Qualified IPO or a Trade Sale was not consummate by December 31, 2026, or
the Group failed to meet the revenue target from the fiscal years March 31, 2023 to 2026, according to the terms of different series investments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December&#160;31, 2024
and March&#160;31, 2024, our borrowings amounted to USD20.3 million and USD7.0&#160;million, respectively. These loans were obtained from
banks in Hong&#160;Kong and from third parties, secured by accounts receivable, for working capital purposes. We anticipate being able
to renew all of our existing bank loans upon their maturity or to secure additional new loans from financial institutions, based on past
experience and our solid credit history.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024, we
had working capital deficit of USD7.9&#160;million. We believe that our current cash reserves and anticipated cash flows from operations
will be sufficient to meet our anticipated working capital requirements, capital expenditures, and debt repayment obligations for at least
the next 12&#160;months following the date our unaudited condensed consolidated financial statements for the nine months ended December
31, 2024 were released.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash Flows</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash Flows for the Nine Months Ended December&#160;31,
2024, compared to the Nine Months Ended December&#160;31, 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets forth
a summary of our cash flows for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Variance</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Net cash provided by operating activities &#12288;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,378,530</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;3,642,395</span></td>
    <td style="width: 1%; text-align: right">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,736,135</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">47.7</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash used in investing activities &#12288;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,851,759</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;(4,669,345</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,182,414</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260.9</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by financing activities &#12288;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,786,876</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;1,391,197</span></td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,395,679</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">819.1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of exchange rate changes on cash &#12288;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,271</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;(69,660</span></td>
    <td style="padding-bottom: 2pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">84,931</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(121.9</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net change in cash &#12288;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,328,918</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#12288;294,587</b></span></td>
    <td style="text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,034,331</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">351.1</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash at beginning of the period &#12288;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,370,008</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#12288;998,948</b></span></td>
    <td style="text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">371,060</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">37.1</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash at end of the period &#12288;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,698,926</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#12288;1,293,535</b></span></td>
    <td style="text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,405,391</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">108.6</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Operating activities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the nine months ended
December 31, 2024, our net cash provided by operating activities was USD5.4&#160;million, primarily attributable to (i)&#160;a net income
of USD1.3&#160;million, adjusted for depreciation and amortization of USD3.5&#160;million; (ii)&#160;an increase in deferred revenues
of USD34.7 million due to our expansion of AIaaS services; (iii) an increase in accruals and other payables of USD5.5 million due to increasing
in accrual expenses such as payable advertising fees and payable commission fees related to our business expansion; partially offset by
(i) an increase in accounts receivables of USD24.4 million due to increased sales; (ii) an increase in prepayment, deposits and other
receivables of USD10.4 million due to prepayment for obtaining contract increased resulting from our expansion of AIaaS services and (iii)
an increase in amount due from related parties of USD5.6 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the nine months ended December 31, 2023, our net cash provided
by operating activities was USD3.6&#160;million, primarily attributable to (i) a&#160;net income of USD0.9&#160;million, adjusted for
depreciation and amortization of USD2.3&#160;million; (ii)&#160;an increase in deferred revenues of USD1.6 million due to our expansion
of AIaaS services; (iii) an increase in accruals and other payables of USD2.4 million due to increasing in accrual expenses such as payable
advertising fees and payable commission fees related to our business expansion; and partially offset by (i) an increased in accounts receivable
of USD2.9 million due to increased sales, and (ii) an increase in prepaid expenses and other current asset of USD1.0 million due to prepayment
for obtaining contract increased resulting from our expansion of AIaaS services. </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 197 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->176<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Investing activities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our net cash used in investing
activities was USD16.9&#160;million for the nine months ended December 31, 2024, primarily attributable to the purchase of intangible
assets of USD17.3&#160;million for the provision of AIaaS services and partially offset by proceeds from the surrender of insurance contract
of USD0.7 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our net cash used in investing
activities was USD4.7&#160;million for the nine months ended December 31, 2023, primarily attributable to the purchase of intangible assets
of USD4.9&#160;million, partially offset by proceeds from the surrender of insurance contract of USD0.2 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Financing activities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the nine months ended
December 31, 2024, our net cash provided by financing activities was USD12.8&#160;million, which consisted of proceeds from borrowings
of USD17.9&#160;million, partially offset by the repayments of borrowings of USD5.1&#160;million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the nine months ended December 31, 2023, our net cash provided
by financing activities was USD1.4&#160;million, which consisted of proceeds from borrowings of USD4.5&#160;million and proceeds from
mezzanine equity of USD2.0 million, partially offset by the repayment of borrowings of USD5.1&#160;million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash Flows for the Year Ended March&#160;31,
2024, compared to the Year Ended March&#160;31, 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets forth
a summary of our cash flows for the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">%</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Net cash provided by/(used in) operating activities &#12288;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,883,639</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;(461,721</span></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,345,360</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(1,374.3</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash used in investing activities &#12288;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,715,029</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;(10,436,423</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,721,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16.5</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by financing activities &#12288;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,289,582</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;7,485,170</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,195,588</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(56.1</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of exchange rate changes on cash &#12288;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(87,132</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#12288;298,202</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(385,334</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(129.2</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net change in cash &#12288;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>371,060</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#12288;(3,114,772</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,485,832</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(111.9</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash at beginning of the year &#12288;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>998,948</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#12288;4,113,720</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(3,114,772</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(75.7</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash at end of the year &#12288;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1,370,008</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#12288;998,948</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">371,060</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">37.1</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Operating activities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the year ended March&#160;31,
2024, our net cash provided by operating activities was USD5.9&#160;million, primarily attributable to (i)&#160;a net income of USD1.3&#160;million,
adjusted for depreciation and amortization of USD3.2&#160;million; (ii)&#160;an increase in deferred revenues of USD2.7 million due to
our expansion of AIaaS services; (iii) a decreased in amounts due from a related party of USD5.0 million; partially offset by an increase
in accounts receivables of USD6.6 million, due to increased sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 198 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->177<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the year ended March&#160;31,
2023, our net cash used in operating activities was USD0.5&#160;million, primarily attributable to (i) a&#160;net loss of USD0.4&#160;million,
adjusted for depreciation and amortization of USD2.1&#160;million and provision of credit losses of USD0.8 million; (ii)&#160;an increase
in accounts receivable of USD9.9&#160;million, resulting from increased sales; and partially offset by an increase in deferred revenues
of USD4.7 million and a decreased in amounts due from a related party of USD2.6 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Investing activities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our net cash used in investing
activities was USD8.7&#160;million and USD10.4&#160;million for the years ended March&#160;31, 2024 and 2023, respectively. The cash flow
in fiscal year 2024 primarily reflected the purchase of intangible assets of USD8.9&#160;million for the provision of AIaaS services and
the surrender of insurance contract of USD0.2 million. The cash flow in fiscal year 2023 was primarily attributable to the purchase of
intangible assets and property and equipment, totaling USD9.5&#160;million, along with the purchase of insurance contract for USD0.9 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Financing activities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the year ended March&#160;31,
2024, our net cash provided by financing activities was USD3.3&#160;million, which consisted of proceeds from borrowings of USD6.8&#160;million
and proceeds from mezzanine equity of USD2.0 million, partially offset by the repayments of borrowings of USD5.5&#160;million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the year ended March 31, 2023, our net cash provided by financing
activities was USD7.5 million, which consisted of proceeds from borrowings of USD7.4 million and proceeds from mezzanine equity of USD5.0
million, partially offset by the repayment of borrowings of USD5.0 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Tabular Disclosure of Contractual Obligations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets forth
our contractual obligations as of December 31, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Payment Due by Period-December 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than<br/>
 1 year</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">More than<br/>
 1 year</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Amounts expressed in USD)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Borrowings &#12288;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20,298,334</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20,298,334</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lease obligations </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">999,653</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">317,340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">682,313</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Long service payment &#12288;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,384</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,384</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Total </td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">21,306,371</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">20,615,674</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">690,697</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Borrowings consist of borrowings
from banks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Operating lease obligations
consist of leases in relation to certain offices for our daily operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Long service payment is a
provision figure for statutory benefits under the Employment Ordinance in Hong Kong, applicable to involuntary termination of service,
including retirement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other than those shown above,
we did not have any significant capital and other commitments, long-term obligations, or guarantees as of December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Off-Balance Sheet Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have not entered into any
off-balance sheet financial guarantees or other off-balance sheet commitments to guarantee the payment obligations of any third parties.
We have not entered into any derivative contracts that are indexed to our shares and classified as shareholder&#8217;s equity or that
are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interests in assets
transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable
interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging
or product development services with us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 199 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->178<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT
MARKET RISKS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign currency exchange rate risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Foreign currency risk is the
risk that the holding of foreign currency assets will affect the Company&#8217;s financial position as a result of a change in foreign
currency exchange rates. Our function currency is HKD and our consolidated financial statements are presented in USD. Our sales, operation
activities and assets and liabilities are predominately denominated in the function currency. We consider the foreign exchange risk in
relation to transactions denominated in HKD with respect to USD is not significant as HKD is pegged to USD. Hong&#160;Kong Monetary Authority
guarantees to exchange USD into HKD, or vice versa, at a rate close to HKD7.80 to USD1.00. Our cash denominated in HKD amounted to USD
1,376,830 and USD721,027 as of December 31, 2024 and March 31, 2024, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Interest rate risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are exposed to interest
rate risk on our interest-bearing assets and liabilities. As part of our asset and liability risk management, we review and take appropriate
steps to manage our interest rate exposures on our interest-bearing assets and liabilities. We have not been exposed to material risks
due to changes in market interest rates, and not used any derivative financial instruments to manage the interest risk exposure during
the nine months ended December 31, 2024 and 2023, and for the years ended March&#160;31, 2024 and 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inflation risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Whilst inflation has been
a global issue impacting many countries around the globe, inflation in Hong Kong has not materially affected our results of operations
in recent years. According to the Census and Statistics Department of Hong Kong, the year-over-year percent changes in the consumer price
index rise by 1.7% in 2024, compared with the same period in 2023. Although we have not been affected by inflation at this point in time,
we may be affected if Hong Kong and any other jurisdiction where we operate in the future experience higher rates of inflation in the
future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Credit Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Financial instruments that
potentially subject us to the credit risks consist of cash, accounts receivable, factoring receivable, amounts due from related parties
and prepayment, deposits and other receivables. The maximum exposures of such assets to credit risk are their carrying amounts as of the
balance sheet dates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We deposit our cash with reputable
banks located in Hong Kong. As of December 31, 2024 and March 31, 2024, USD2,696,899 and USD1,369,862 were deposited with these banks,
respectively. Balances maintained with banks in Hong Kong are insured under the Deposit Protection Scheme introduced by the Hong Kong
Government for a maximum amount of HK$800,000 (equivalent to USD102,991) since October 1, 2024, whilst the balances maintained by us may
at times exceed the insured limits. Cash balances maintained with banks in Hong Kong are not otherwise insured by the Federal Deposit
Insurance Corporation or other programs. We have not experienced any losses in these bank accounts and we believe that we are not exposed
to any significant credit risk on cash.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Assets that potentially subject
us to a significant credit risk primarily consist of accounts receivable, factoring receivable, amounts due from related parties and prepayment,
deposits and other receivables. We perform regular and ongoing credit assessments of the counterparts&#8217; financial conditions and
credit histories. We also assess historical collection trends, aging of receivables and general economic conditions. We consider that
we have adequate controls over these receivables in order to minimize the related credit risk. For the nine months ended December&#160;31,
2024 and 2023, the allowance for credit losses was USD230,825 and a reversal for credit losses was USD622,464, respectively. For the years
ended March&#160;31, 2024 and 2023, the reversal for credit losses was USD596,209 and the allowance for credit losses was USD772,224,
respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 200 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->179<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Liquidity Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are also exposed to liquidity
risk, which is risk that we will be unable to provide sufficient capital resources and liquidity to meet our commitments and business
needs. Liquidity risk is controlled by the application of financial position analysis and monitoring procedures. When necessary, we will
turn to other financial institutions and related parties to obtain short-term funding to cover any liquidity shortage</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Estimates </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We prepared the consolidated
financial statements in accordance with U.S. GAAP. When reviewing our financial statements, you should consider our selection of critical
accounting policies, our judgments and other uncertainties affecting our applications of those policies and the sensitivity of reported
results to changes of such policies, judgments and uncertainties. We continually evaluate these judgments, estimates and assumptions based
on our own historical experience, knowledge and assessment of current business and other conditions and our expectations regarding the
future based on available information, which together form our basis for making judgments about matters that are not readily apparent
from other sources. Since the use of estimates is an integral component of the financial reporting process, our actual results could differ
from those estimates. Some of our accounting policies require a higher degree of judgment than others in their application.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">When reading our consolidated
financial statements, you should consider our selection of critical accounting policies, the judgment and other uncertainties affecting
the application of such policies and the sensitivity of reported results to changes in conditions and assumptions. Our critical accounting
policies and practices see Note 2 - Summary of Significant Accounting Policies to our consolidated financial statements for the disclosure
of these accounting policies. We believe the following accounting estimates involve the most significant judgments used in the preparation
of our financial statements. When reviewing its financial statements, you should consider:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify">&#9679;</td><td style="text-align: justify">Our selection of critical accounting policies;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1.5pt; text-indent: 22.3pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify">&#9679;</td><td style="text-align: justify">the judgments and other uncertainties affecting the application
of such policies;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1.5pt; text-indent: 22.3pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify">&#9679;</td><td style="text-align: justify">the sensitivity of reported results to changes in conditions
and assumptions.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Estimated allowance for credit losses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accounts receivable, net are
stated at the original amount less allowances for credit losses. Accounts receivable are recognized in the period when we have provided
services to our customers and when our right to consideration is unconditional. We assess collectability by reviewing accounts receivable
on a collective basis where similar characteristics exist, primarily based on similar business lines, and on an individual basis when
we identify specific customers with known disputes or collectability issues. In determining the amount of the allowance for credit losses,
we consider historical collectability based on past due status, the age of the accounts receivable balances, credit quality of our customers
based on ongoing credit evaluations, current economic conditions, reasonable and supportable forecasts of future economic conditions,
and other factors that may affect our ability to collect from customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We recognized credit losses
of USD0.2 million and reversed credit losses of USD0.6 million for the nine months ended December 31, 2024 and 2023, respectively. A 10%
increase in our provision for credit losses would have decreased our income before income tax provision by 1.4% for the nine months ended
December 31, 2024, and a 10% increase in our reversal for credit losses increased our income before income tax provision by 5.6% for the
nine months ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 201 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->180<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We reversed credit losses
of USD0.6 million and recognized credit losses of USD0.8 million for the years ended March 31, 2024 and 2023, respectively. A 10% increase
in our reversal of credit losses would have increased our income before income tax provision by 3.7% for the year ended March 31, 2024,
and a 10% increase in our provision for credit losses would have increased our loss before income tax provision by 25.1% for the year
ended March 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Estimated useful lives of intangible assets</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our intangible assets refer
to AIaaS related software including HR resources management and workflow approval system, CRM and data management system and an AI business
assistant with diverse platforms and enterprise systems. The AIaaS related software have a finite useful life which is based on the management&#8217;s
best estimation. The estimated useful lives are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: justify"><span style="font-size: 10pt"><b>Category</b></span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 67%; text-align: justify"><span style="font-size: 10pt"><b>Estimated useful lives</b></span></td>
    </tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">AIaaS related software</span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt">10 years</span></td>
    </tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Estimate of the valuation allowance of deferred
tax assets</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Deferred tax assets are reduced
by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets
will not be realized. We consider positive and negative evidence when determining whether a portion or all of our deferred tax assets
will more likely than not be realized. This assessment considers, among other matters, the nature, frequency and severity of current and
cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, our experience with tax attributes
expiring unused, and our tax planning strategies. The ultimate realization of deferred tax assets is dependent upon our ability to generate
sufficient future taxable income within the carry-forward periods provided for in the tax law and during the periods in which the temporary
differences become deductible. When assessing the realization of deferred tax assets, we have considered possible sources of taxable income
including (i) future reversals of existing taxable temporary differences, (ii) future taxable income exclusive of reversing temporary
differences and carry-forwards, (iii) future taxable income arising from implementing tax planning strategies, and (iv) specific known
trend of profits expected to be reflected within the industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For the nine months ended
December 31, 2024 and 2023, we recognized valuation allowance of deferred tax assets of USD0.1 million and USD0.1 million, respectively.
A 10% increase in our valuation allowance of deferred tax assets would have decreased our net income by 0.5% and 1.0% for the nine months
ended December 31, 2024 and 2023, respectively.</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For the years ended March 31, 2024 and 2023, we
recognized valuation allowance of deferred tax assets of USD0.1 million and USD0.2 million, respectively. A 10% increase in our valuation
allowance of deferred tax assets would have decreased our net income by 1.1% and increased our net loss by 5.2% for the years ended March
31, 2024 and 2023, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 202 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->181<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_109"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CERTAIN YOOV RELATIONSHIPS
AND RELATED PARTY TRANSACTIONS</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">SEC rules require us to disclose
any transaction since the beginning of our last fiscal year or any currently proposed transaction in which we are a participant in which
the amount involved exceeded or will exceed $120,000 and in which any related person has or will have a direct or indirect material interest.
A related person is any executive officer, director, nominee for director, or holder of 5% or more of our common stock, or an immediate
family member of any of those persons.</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other than the compensation
arrangements with YOOV&#8217;s directors and executive officers discussed in &#8220;YOOV Executive Compensation&#8221; and &#8220;YOOV
Director Compensation&#8221;, such transactions are as follows:</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Wong Ling Yan Philip, Chief
Executive Officer, President and Chairman of the Board of YOOV, authorized the use of his bank account by YOOV through its wholly-owned
subsidiaries (collectively, the &#8220;Group&#8221;), for the purpose of collection and payments activities to improve business efficiency,
including the purchase of intangible assets, collection of investment and receivables, etc. The Group has evaluated the subsequent settlement
of amount due from Philip from December 31, 2024 through the date of the prospectus and the balance has not been settled.</p><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, during the years
ended March 31, 2024 and 2023, certain expenses incurred by companies owned by Mr. Wong Ling Yan Philip that are outside the Group were
settled by the Group.</p><div>
</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">On September 17, 2024,
the Group entered into a Factoring Agreement with Qupital Ltd. to obtain borrowings secured by accounts receivable and guaranteed by
Mr. Wong Ling Yan Philip, Portwin International Limited and YOOV Group Holding Limited for the purpose of business financing with interest
rates based on overnight secured overnight financing rate.</span></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Further, during the years
ended March 31, 2024 and 2023, certain expenses for the settlement of company fees of Good Staywell HK Limited was incurred by Good On
Time Company Limited, a minority shareholder of Good Staywell HK Limited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the nine months ended
December 31, 2024, Lee Kar Man Montina, a director of YOOV Capital, paid expenses incurred by YOOV Capital on behalf of YOOV Capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Amounts due to and from related
parties consisted of the following as of the periods indicated:</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Related parties:</i></b></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="white-space: nowrap; border-bottom: black 1.5pt solid; width: 32%"><span style="font-size: 10pt"><b>Names of related
    parties</b></span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="white-space: nowrap; border-bottom: black 1.5pt solid; width: 67%"><span style="font-size: 10pt"><b>Relationship</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Wong Ling Yan Philip</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt">Director and controlling shareholder of the Company</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Good Staywell HK Limited</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-size: 10pt">An equity investee of Good On Time Company Limited, a subsidiary of the Company</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Lee Kar Man Montina</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-size: 10pt">Director of YOOV Capital, a subsidiary of the Company</span></td></tr>
  </table><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Amount due from related parties:</i></b></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD (Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 0.85pt">Wong Ling Yan Philip</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,632,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,588,036</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,299,059</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Good Staywell HK Limited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,160</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">876</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,169</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.85pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,633,560</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,588,912</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">10,300,228</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Amount due to a related party:</i></b></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Lee Kar Man Montina</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">5,216</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,216</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>




</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 203 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->182<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Significant related party transactions:</i></b></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the years ended <br/>
March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.85pt">Advance payment to the director for intangible assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,946,433</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,195,447</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">Intangible assets payment paid by the director on behalf of the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,946,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,031,340</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.85pt">Mezzanine equity received by the director on behalf of the Group to offset intangible assets payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,164,107</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">Mezzanine equity received by the director on behalf of the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,508,783</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.85pt">Mezzanine equity received by the director on behalf of the Group and repaid to the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,994,509</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">Accounts receivable received by the director on behalf of the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,393,388</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,946</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.85pt">Accounts receivable received by the director and repaid to the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,158,547</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,431,519</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">Expenses paid by the Group on behalf of the director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,185,943</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">887,516</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.85pt">Expenses paid by the director on behalf of the Company</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">417,363</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,100</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.85pt">Others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">966</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,375</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended<br/>
 December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Advance payment to the director for intangible assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">17,314,798</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,900,749</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Intangible assets payment paid by the director on behalf of the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,314,798</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,900,749</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mezzanine equity received by the director on behalf of the Group and repaid to the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,994,178</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts receivable received by the director on behalf of the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,164,698</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">677,360</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts receivable received by the director and repaid to the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,906,058</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,607,815</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expenses paid by the Group on behalf of the director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,492,915</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">818,564</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expenses paid by the director on behalf of the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,146,182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,586</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 204 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->183<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_110"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">INFORMATION ABOUT AVALON</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">All
references in the &#8220;Business&#8221;, &#8220;Avalon Executive Compensation&#8221;, &#8220;Avalon Management&#8217;s Discussion
and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Certain Avalon Relationships and Related Party
Transactions&#8221; sections to &#8220;Avalon,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or
&#8220;our&#8221; mean Avalon and its subsidiaries unless we state otherwise, or the context otherwise indicates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="g_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>BUSINESS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="-keep: true">We
are a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products. We are currently marketing
the KetoAir breathalyzer device and plan to develop additional diagnostic uses of the breathalyzer technology. We also provided laboratory
services in 2024 and 2023, offering a broad portfolio of diagnostic tests, including drug testing, toxicology, and a broad array of test
services, from general bloodwork to anatomic pathology, and urine toxicology. We completed an acquisition of a 40% membership interest
in Laboratory Services MSO, LLC (&#8220;Lab Services MSO&#8221;), which closed in February 2023. During 2025, to preserve cash, the Company
entered into discussions with Lab Services MSO for the potential redemption of our investment and on February 26, 2025, we and Lab Services
MSO entered into a Redemption and Abandonment Agreement, whereby Lab Services MSO redeemed the 40% equity interest in Lab Services MSO
held by us. Accordingly, beginning in February 2025, we no longer offer laboratory services.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="-keep: true">In
2024, we initiated sales of our first diagnostic consumer product, KetoAir, a device that tests ketosis levels.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
had the following areas of focus in 2024 and 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Laboratory Acquisitions</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
had embarked on a laboratory rollup strategy focused on forming joint ventures and acquiring laboratories that were accretive to our commercial
strategy. As a first step, in February 2023, we acquired a 40% membership interest in Lab Services MSO. Among other things, Lab Services
MSO provides toxicology and wellness testing services, a broad portfolio of diagnostic tests, and a broad array of test services. During
2025, to preserve cash, the Company entered into discussions with Lab Services MSO for the potential redemption of our investment and
on February 26, 2025, we and Lab Services MSO entered into a Redemption and Abandonment Agreement, whereby Lab Services MSO redeemed the
40% equity interest in Lab Services MSO held by us. Accordingly, beginning in February 2025, we no longer offer laboratory services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Research and Development</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
are focused on bringing forward intellectual property through joint patent filings with the Massachusetts Institute of Technology (&#8220;MIT&#8221;).
We completed a sponsored research and co-development project with MIT led by Professor Shuguang Zhang as Principal Investigator. Using
the unique QTY code protein design platform, six water-soluble variant cytokine receptors have been successfully designed and tested to
show binding affinity to the respective cytokines. We currently are focused on bringing forward the intellectual property associated with
this program through joint patent submissions, new research and development has been suspended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Product Commercialization</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
have begun the commercialization and development of a versatile breathalyzer system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
were granted exclusive distributorship rights for the KetoAir from Qi Diagnostics for the following territories: North America, South
America, the EU and the UK. For our commercialization strategy, we intend to target the diabetes and obesity markets. We sell the product
through the KetoAir website and social media. We believe the KetoAir device has some competitive advantages to other methods for measuring
ketosis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 205 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->184<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
KetoAir device is a handheld device that allows the user to detect acetone levels in exhaled breath. The acetone level is in concentration
units (ppm, part-per-million) such that the user will know his/her real-time ketosis status: inadequate ketosis (0-3.99 ppm), mild ketosis
(4-9.99 ppm), optimal ketosis (10-40 ppm), or alarming level (&gt; 40 ppm). The KetoAir is registered with the United States Food and
Drug Administration as a Class I medical device. The device is also paired with an &#8220;AI Nutritionist&#8221; software program (via
Bluetooth connection) which is downloadable from Google Play (for Android mobile phones, approved) and iPhone It helps users monitor and
manage their ketogenic diet and related programs. We believe the KetoAir can be an essential tool to help diabetic patients adhere to
their therapeutic programs and optimize their ketogenic dietary management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>China Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Due to the winding down of
the medical related consulting services segment, in November 2022, we decided to cease all operations in the People&#8217;s Republic of
China (the &#8220;PRC&#8221;) with the exception of a small administrative office, in Beijing. We do not expect nor do we plan that we
will further operate in the PRC or generate revenue from PRC operations for the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements reflect the activities of the Company and each of the following entities:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: white">
    <td style="width: 28%; border-bottom: black 1.5pt solid; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>Name
    of Subsidiary</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Place and Date of<br/>
    Incorporation</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Percentage of<br/>
    Ownership</b></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="width: 37%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Principal Activities</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Avalon Healthcare System, Inc. (&#8220;AHS&#8221;)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Delaware<br/>
May 18, 2015</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">100% held by Company</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Holding company for payroll and other expenses</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Avalon RT 9 Properties, LLC (&#8220;Avalon RT 9&#8221;)</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">New Jersey February 7, 2017</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">100% held by Company</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Owns and operates an income-producing real property and holds and manages the corporate headquarters</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Avalon (Shanghai) Healthcare Technology Co., Ltd. (&#8220;Avalon Shanghai&#8221;)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">PRC April 29, 2016</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">100% held by AHS</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Is not considered an operating entity</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Genexosome Technologies Inc. (&#8220;Genexosome&#8221;)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Nevada July 31, 2017</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">60% held by Company</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">No current activities to report, dormant</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Avactis Biosciences Inc. (&#8220;Avactis&#8221;)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Nevada <br/>
July 18, 2018</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">60% held by Company</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dormant,</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">is in process of being dissolved</p></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Avactis Nanjing Biosciences Ltd. (&#8220;Avactis Nanjing&#8221;)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">PRC<br/>
May 8, 2020</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">100% held by Avactis</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dormant,</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">is in process of being dissolved</p></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Avalon Laboratory Services, Inc. (&#8220;Avalon Lab&#8221;)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">Delaware<br/>
October 14, 2022</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">100% held by Company</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Laboratory holding company with a 40% membership interest in Lab Services MSO as of December 31, 2024 (1)</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 0.15in; text-indent: -0.15in"><span style="font-size: 10pt">Q&amp;A Distribution LLC<br/>
(&#8220;Q&amp;A Distribution&#8221;)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Texas</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">May 1, 2024</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-size: 10pt">100% held by Company</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Distributes KetoAir device</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">On February 26, 2025, we and Lab Services MSO entered into a
Redemption and Abandonment Agreement, whereby Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by us.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Sales and Marketing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We launched sales of the KetoAir
in the U.S. in 2024. We have retained a marketing expert to assist us to bring this product to market through social media, influencer
promotion and our website. We launched this product at the 2024 &#8220;KetoCon&#8221; convention which took place May 31, 2024 in Austin
Texas.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 206 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->185<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Markets</b>

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Laboratory Services</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During 2024 and 2023 and until
February 2025, through our membership interest in Lab Services MSO, we were focused on delivering high quality services related to toxicology
and wellness testing. The panels that we tested for were thyroid panel, comprehensive metabolic panel, kidney profile, liver function
tests, and other individual tests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We offered our laboratory
services in California, Texas and Arizona. During 2025, to preserve cash, the Company entered into discussions with Lab Services MSO for
the potential redemption of our investment and on February 26, 2025, we and Lab Services MSO entered into a Redemption and Abandonment
Agreement, whereby Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by us. Accordingly, beginning in February
2025, we no longer offer laboratory services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Breathalyzer System (KetoAir)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our current area of focus
for the launch of the KetoAir is within the U.S. We are focused on the population within the U.S. that is using the Keto Diet approach
to weight loss and diabetic management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Avalon RT 9 Properties, LLC</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We own commercial property
located in Freehold, New Jersey. This property serves as our corporate headquarters and contains several commercial tenants that generate
revenue through rental income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Strategic Development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In late 2024, we launched
an initiative seeking transformational merger candidates. The Company determined that it had limited access to cash and it was in the
best interest of shareholders to seek a strategic merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our goal is to obtain, maintain
and enforce patent rights for our products, formulations, processes, methods of use and other proprietary technologies, preserve our trade
secrets, and operate without infringing on the proprietary rights of other parties, both in the United States and abroad. Our policy is
to actively seek to obtain, where appropriate, the broadest intellectual property protection possible for our current product candidates
and any future product candidates, proprietary information and proprietary technology through a combination of contractual arrangements
and patents, both in the United States and abroad. Even patent protection, however, may not always afford us with complete protection
against competitors who seek to circumvent our patents. If we fail to adequately protect or enforce our intellectual property rights or
secure rights to patents of others, the value of our intellectual property rights would diminish. To this end, we require all of our employees,
consultants, advisors and other contractors to enter into confidentiality agreements that prohibit the disclosure and use of confidential
information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions relevant
to our technologies and important to our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Many of our existing and potential
future competitors have significantly greater financial resources and expertise in operations, research and development, manufacturing,
obtaining marketing approvals and marketing approved products than we do. Mergers and acquisitions may result in even more resources being
concentrated among a smaller number of our competitors. Smaller, or early stage, companies may also prove to be significant competitors,
particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting
and retaining qualified scientific and management personnel, as well as in acquiring technologies complementary to, or necessary for,
our programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect that our ability
to compete effectively will depend upon our ability to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">maintain a proprietary position
for our manufacturing processes and other technology;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">produce our products in accordance
with FDA and international regulatory guidelines;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">attract and retain key personnel;
and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: justify; width: 0.25in"/><td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">build or access an adequate
sales and marketing infrastructure for any approved products.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Failure to do one or more
of these activities could have an adverse effect on our business, financial condition or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt"></p><div>

</div><!-- Field: Page; Sequence: 207 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->186<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Avalon RT 9 Properties, LLC</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We own commercial property
located in Freehold, New Jersey. This property serves as our corporate headquarters and contains several commercial tenants that generate
revenue through rental income. The property is located on a major highway and is one of the largest buildings in the surrounding areas.
It is centrally located and maintains high occupancy. There are other commercial properties in the vicinity that offer similar amenities.
However, premier executive offices are limited and as such, we expect to continue to maintain high occupancy in the near term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of March 31, 2025, we employed
five employees, four of which are full time employees. None of our employees is represented by a collective bargaining arrangement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Overview</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The healthcare industry in
the U.S. is highly regulated and subject to changing political, legislative, regulatory, and other influences. Further, the healthcare
industry is currently undergoing rapid change. We are uncertain how, when or in what context these new changes will be adopted or implemented.
These new regulations could create unexpected liabilities for us, could cause us or our members to incur additional costs and could restrict
our or our clients&#8217; operations. Many of the laws are complex and their application to us, our clients, or the specific services
and relationships we have with our members are not always clear. Our failure to anticipate accurately the application of these laws and
regulations, or our other failure to comply, could create liability for us, result in adverse publicity, and otherwise negatively affect
our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Holding Foreign Companies Accountable Act
Compliance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Holding Foreign Companies
Accountable Act, or the HFCA Act, was enacted on December 18, 2020. According to the HFCA Act, if the SEC determines that Avalon has filed
audit reports issued by a registered public accounting firm that has not been subject to inspection by the PCAOB for three consecutive
years beginning in 2021, the SEC will prohibit Avalon&#8217;s securities from being traded on a national securities exchange or in the
over-the-counter trading market in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 16, 2021, the
PCAOB issued a Determination Report which reported that the PCAOB is unable to inspect or investigate completely registered public accounting
firms headquartered in: (1) mainland China of the People&#8217;s Republic of China, because of a position taken by one or more authorities
in mainland China; and (2) Hong Kong, a Special Administrative Region of the PRC, because of a position taken by one or more authorities
in Hong Kong.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon&#8217;s auditor is
M&amp;K CPAS PLLC (M&amp;K&#8221;), based in Texas. M&amp;K is registered with the PCAOB and is subject to laws in the United States pursuant
to which the PCAOB conducts regular inspections to assess their compliance with the applicable professional standards. Since M&amp;K is
located in the United States, the PCAOB has been able to conduct inspections of M&amp;K. In addition, M&amp;K is not among the PCAOB registered
public accounting firms registered in mainland China or Hong Kong that are subject to PCAOB&#8217;s determination on December 16, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Healthcare Fraud and Abuse Laws</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the U.S., our activities
are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited
to, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services (such
as the Office of Inspector General and the Health Resources and Service Administration), the U.S. Department of Justice, or the DOJ, and
individual U.S. Attorney offices within the DOJ, and state and local governments. For example, sales, marketing and scientific/educational
grant programs may have to comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the privacy
and security provisions of the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws, each as amended,
as applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 208 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->187<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The federal Anti-Kickback
Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying, soliciting or receiving any
remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering
or arranging for the purchase, lease or order of any item or service reimbursable, in whole or in part, under Medicare, Medicaid or other
federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute
has been interpreted to apply to arrangements between therapeutic product manufacturers on one hand and prescribers, purchasers, and formulary
managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution.
The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce
prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to
meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se
illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a
cumulative review of all of its facts and circumstances. Additionally, the intent standard under the Anti-Kickback Statute was amended
by the ACA to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent
to violate it in order to have committed a violation. In addition, the ACA codified case law that a claim including items or services
resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False
Claims Act, or FCA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The federal false claims and
civil monetary penalty laws, including the FCA, which imposes significant penalties and can be enforced by private citizens through civil
qui tam actions, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false or
fraudulent claim for payment to, or approval by, the federal healthcare programs, including Medicare and Medicaid, or knowingly making,
using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A
claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. For instance, historically,
pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers
with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing
false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, off-label, and thus generally non-reimbursable,
uses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">HIPAA created additional federal
criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud
or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control
or custody of, any healthcare benefit program, including private third-party payors, willfully obstructing a criminal investigation of
a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or
making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits,
items or services. Like the Anti-Kickback Statute, the ACA amended the intent standard for certain healthcare fraud statutes under HIPAA
such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have
committed a violation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Many states have similar,
and typically more prohibitive, fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and
other state programs, or, in several states, apply regardless of the payor. Additionally, to the extent that our product candidates may
in the future be sold in a foreign country, we may be subject to similar foreign laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may be subject to data
privacy and security regulations by both the federal government and the states in which we conduct our business. HIPAA, as amended by
the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes requirements
relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s
privacy and security standards directly applicable to business associates, independent contractors, or agents of covered entities that
receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created
four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates,
and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and
seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, many state laws govern the privacy and
security of health information in specified circumstances, many of which differ from each other in significant ways, are often not pre-empted
by HIPAA, and may have a more prohibitive effect than HIPAA, thus complicating compliance efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 209 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->188<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.2pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect our product, after
approval, may be eligible for coverage under Medicare, the federal health care program that provides health care benefits to the aged
and disabled, and covers outpatient services and supplies, including certain pharmaceutical products, that are medically necessary to
treat a beneficiary&#8217;s health condition. In addition, the product may be covered and reimbursed under other government programs,
such as Medicaid and the 340B Drug Pricing Program. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into
and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states
to receive federal matching funds for the manufacturer&#8217;s outpatient drugs furnished to Medicaid patients. Under the 340B Drug Pricing
Program, the manufacturer must extend discounts to entities that participate in the program. As part of the requirements to participate
in certain government programs, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government,
such as average manufacturer price, or AMP, and best price. Penalties may apply in some cases when such metrics are not submitted accurately
and timely.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, the federal
Physician Payments Sunshine Act, or the Sunshine Act, within the ACA, and its implementing regulations, require that certain manufacturers
of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health
Insurance Program (with certain exceptions) report annually to CMS information related to certain payments or other transfers of value
made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of,
the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate
family members. Failure to report accurately could result in penalties. In addition, many states also govern the reporting of payments
or other transfers of value, many of which differ from each other in significant ways, are often not pre-empted, and may have a more prohibitive
effect than the Sunshine Act, thus further complicating compliance efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>New Legislation and Regulations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">From time to time, legislation
is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the testing, approval,
manufacturing and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations and policies are often revised
or interpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether
further legislative changes will be enacted or whether FDA regulations, guidance, policies or interpretations will be changed or what
the effect of such changes, if any, may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Developments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Mortgage and Security
Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">On
March 27, 2024, the Company entered into a Mortgage and Security Agreement (the &#8220;Mast Hill Mortgage&#8221;) with Mast Hill Fund
L.P. (&#8220;Mast Hill&#8221;) to secure the payment performance and obligation under certain follow-up financing agreements described
below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">In
March 2024, the Company entered into follow-up financing agreements with Mast Hill, which included the issuance of 13% senior secured
promissory notes totaling $700,000 convertible into common stock, as well as the issuance of up to 7,000 shares of common stock as a commitment
fee, and warrants for the purchase of up to 8,750 shares of common stock at an initial price per share of $30.00, and common share purchase
warrants for the purchase of up to 8,077 shares of common stock at an initial price per share of $19.50, with a total purchase price of
$665,000 (the &#8220;2024 Financing Agreements&#8221;). These agreements were made under the same terms and conditions of the prior rounds
of convertible note financing in October 2023 and May 2023 (the &#8220;2023 Financing Agreements&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">On
March 27, 2024, the Company also entered into a Mortgage and Security Agreement (the &#8220;Firstfire Mortgage&#8221;) with Firstfire
Global Opportunities Fund, LLC (&#8220;Firstfire&#8221;) to secure the payment performance and obligation under the 2023 Financing Agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 210 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->189<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Convertible Note
Financing and Mortgage and Security Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">On
June 5, 2024, the Company entered into securities purchase agreements (the &#8220;Securities Purchase Agreements&#8221;) with Mast Hill
for the issuance of 13% senior secured promissory notes in the aggregate principal amount of $2,845,000 (collectively, the &#8220;Notes&#8221;)
convertible into shares of the Company&#8217;s common stock, as well as the issuance of up to 26,800 shares of common stock as a commitment
fee and warrants for the purchase of up to 146,667 shares of common stock (the &#8220;Convertible Note Financing&#8221;). The Company
and its subsidiaries entered into those certain security agreements (the &#8220;Security Agreements&#8221;), creating a security interest
in certain property of the Company and its subsidiaries to secure the prompt payment, performance and discharge in full of all of the
Company&#8217;s obligations under the Notes. The transaction closed on June 5, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Mast
Hill&#160;acquired the Notes with principal amount of $2,845,000 and paid the purchase price of $2,702,750 after an original issue discount
of $142,250, with a conversion price of $11.25, subject to adjustment as provided in Notes. Also on June 5, 2024, the Company issued (i)
a warrant to purchase 66,667 shares of common stock with an exercise price of $9.75 exercisable until June 5, 2029 (the &#8220;First Warrant&#8221;),
(ii) a warrant to purchase 80,000 shares of common stock with an exercise price of $7.50 exercisable until June 5, 2029, which warrant
shall be cancelled and extinguished against payment of the Notes (the &#8220;Second Warrant&#8221; and collectively with the First Warrant,
the &#8220;Warrants&#8221;), and (iii) 26,800 shares of common stock to&#160;Mast Hill as additional consideration for the purchase of
the Note ( the &#8220;Commitment Shares&#8221;), which were earned in full as of June 5, 2024. On the closing date, the Company delivered
such duly executed Notes, warrants and common stock to&#160;Mast Hill against delivery of such purchase price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
Company used the proceeds from the Convertible Note Financing to pay off all previously issued convertible notes to Mast Hill and Firstfire.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">On
June 5, 2024, the Company also entered into a Mortgage and Security Agreement (the &#8220;Mortgage&#8221;) with Mast Hill to secure the
payment, performance, and obligations under the above-mentioned Convertible Note Financing. As of June 5, 2024, the Company was indebted
to Mast Hill in the combined principal sum of $2,845,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="background-color: white">On
December 15, 2024, the Company and Mast Hill entered into that certain consent, acknowledgement, and waiver agreement, pursuant to which
Mast Hill waived all amortization payments required to be made under the Note, the Company paid a waiver fee of $150,000 to Mast Hill,
and the Company issued to Mast Hill a common stock purchase warrant for the purchase of up to 150,000 shares of the Company&#8217;s common
stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>At-the-Market
Offering</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="background-color: white">In
June 2023, the Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Roth Capital Partners, LLC (&#8220;Roth&#8221;)
under which the Company could offer and sell from time to time shares of its common stock having an aggregate offering price of up to
$3.5&#160;million. From July 1, 2023 to August 16, 2024, we sold an aggregate of 312,285 shares of our common stock at an average price
of $11.19 per share to investors pursuant to the Sales Agreement, and received net cash proceeds of $3,388,251, net of cash paid for Roth&#8217;s
commissions and other fees of $104,992.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reverse Stock Split &amp; Decrease in Authorized
Shares </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">On
October 23, 2024, the Company filed a certificate of amendment (the &#8220;Amendment&#8221;) to its Certificate of Incorporation with
the Secretary of State of the State of Delaware to effectuate a reverse stock split of the Company&#8217;s common stock at a ratio of
1-for-15 (the &#8220;Reverse Stock Split&#8221;), as well as the decrease in the number of shares of common stock authorized for issuance
from 490,000,000 to 100,000,000. The Amendment became effective at 5:00 p.m. ET on October 25, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 211 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->190<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Series C Convertible
Preferred Stock</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">On
December 13, 2024, the Company filed a certificate of designations of preferences, rights, and limitations of Series C Convertible Preferred
Stock (the &#8220;Series C Certificate of Designations&#8221;) with the State of Delaware which provides for the designation of 10,000
shares of Series C preferred stock of the Company, par value $0.0001 per share, upon the terms and conditions as set forth in the Series
C Certificate of Designations. Each share of Series C Preferred Stock has a stated value of $1,000 (the &#8220;Stated Value&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
Series C Preferred Stock shall rank (i) senior to the Company&#8217;s common stock (the &#8220;Common Stock&#8221;) and any other class
or series of capital stock of the Company created hereafter, the terms of which specifically provide that such class or series shall rank
junior to the Series C Preferred Stock, (ii) pari passu with any class or series of capital stock of the Company created hereafter specifically
ranking, by its terms, on par with the Series C Preferred Stock, (iii) pari passu with Series B Convertible Preferred Stock of the Company
(the &#8220;Series B Preferred Stock&#8221;) with respect to its rights, preferences and restrictions, and (iv) subordinate to the Series
A Convertible Preferred Stock of the Company (the &#8220;Series A Preferred Stock&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Holders
of the Series C Preferred Stock shall be entitled to receive, and the Company shall pay, dividends on shares of Series C Preferred Stock
equal (on an as-if-converted-to-common-stock basis, disregarding for such purpose any conversion limitations hereunder) to and in the
same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of the common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Holders
of the Series C Preferred Stock have no voting power except as otherwise required by the Delaware General Corporation Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Upon
any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary (a &#8220;Liquidation&#8221;), the holders
of the Series C Preferred Stock shall be entitled to receive out of the assets available for distribution to stockholders, (i) after and
subject to the payment in full of all amounts required to be distributed to the holders of another class or series of stock of the Company
ranking on liquidation prior and in preference to the Series C Preferred Stock, (ii) ratably with any class or series of stock ranking
on liquidation on parity with the Series C Preferred Stock and (iii) in preference and priority to the holders of the shares of common
stock, an amount equal to 100% of the Stated Value of the Series C Preferred Stock, in proportion to the full and preferential amount
that all shares of the Series C Preferred Stock are entitled to receive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Each
share of Series C Preferred Stock shall be convertible into common stock (the &#8220;Conversion Shares&#8221;) at a conversion per share
equal to $2.41, at the option of the holder, at any time after the later of (i) the date of the shareholder approval of the issuance of
the Conversion Shares pursuant to the rules of the Nasdaq Stock Market and (ii) the one year anniversary of the date of the first issuance
of any shares of the Series C Preferred Stock. In addition, the holder shall not have the right to convert any portion of the Series C
Preferred Stock if, after giving effect to the conversion, such holder (together with its affiliates) would beneficially own in excess
of 19.99% of the number of shares of the common stock outstanding immediately after giving effect to the issuance of the respective Conversion
Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>York Sun Securities
Purchase Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">On
December 19, 2024, the Company entered into that certain securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;),
with an accredited investor, York Sun Investment Holding Limited (the &#8220;Investor&#8221;), pursuant to which the Company agreed to
issue and sell to the Investor, upon the terms and conditions set forth in the Securities Purchase Agreement, up to 7,000 shares of Series
C Convertible Preferred Stock for up to an aggregate of $7,000,000 (the &#8220;Purchase Price&#8221;), which is equal to $1,000 per share.
The first closing occurred on December 24, 2024, with respect to the Investor&#8217;s purchase of 3,500 shares of Series C Convertible
Preferred Stock in exchange for $3,500,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 212 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->191<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
Investor shall also have a right of first refusal during the period beginning on the date of the Securities Purchase Agreement and continuing
until such shareholder approval is obtained, on all issuances of convertible preferred stock of the Company, excluding agreements that
are in place prior to the date of the Securities Purchase Agreement and issuances of new classes of convertible preferred stock in exchange
for existing classes of convertible preferred stock. Additionally, the Investor has the right, pursuant to the Securities Purchase Agreement
to appoint one member to, or to replace one member of, the Company&#8217;s board of directors, subject to all applicable Nasdaq rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
Investor&#8217;s purchase of the remaining 3,500 shares of Series C Convertible Preferred Stock under the Securities Purchase Agreement
in exchange for an additional $3,500,000 is required to occur within 120 calendar days of the date of the Securities Purchase Agreement,
subject to the satisfaction of customary closing conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Series D Convertible Preferred Stock</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 6, 2025, the Company
filed a certificate of designations of preferences, rights, and limitations of Series D Convertible Preferred Stock (the &#8220;Series
D Certificate of Designations&#8221;) with the Department of State, Division of Corporations, of the State of Delaware, which provides
for the designation of 5,000 shares of Series D Preferred Stock of the Company, par value $0.0001 per share, upon the terms and conditions
as set forth in the Series D Certificate of Designations. Each share of Series D Preferred Stock has a stated value of $1,000 (the &#8220;Stated
Value&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Series D Preferred Stock
shall rank (i) senior to the Company&#8217;s common stock and any other class or series of capital stock of the Company created hereafter,
the terms of which specifically provide that such class or series shall rank junior to the Series D Preferred Stock, (ii) pari passu with
any class or series of capital stock of the Company created hereafter specifically ranking, by its terms, on par with the Series D Preferred
Stock, (iii) pari passu with the Series B Convertible Preferred Stock of the Company (the &#8220;Series B Preferred Stock&#8221;) with
respect to its rights, preferences and restrictions, and (iv) pari passu with the Series C Convertible Preferred Stock of the Company
(the &#8220;Series C Preferred Stock&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Holders of the Series D Preferred
Stock have no voting power except as otherwise required by the Delaware General Corporation Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon any liquidation, dissolution
or winding-up of the Company, whether voluntary or involuntary (a &#8220;Liquidation&#8221;), the holders of the Series D Preferred Stock
shall be entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to the payment in full
of all amounts required to be distributed to the holders of another class or series of stock of the Company ranking on liquidation prior
and in preference to the Series D Preferred Stock, (ii) ratably with any class or series of stock ranking on liquidation on parity with
the Series D Preferred Stock and (iii) in preference and priority to the holders of the shares of Common Stock, an amount equal to 100%
of the Stated Value of the Series D Preferred Stock, in proportion to the full and preferential amount that all shares of the Series D
Preferred Stock are entitled to receive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each share of Series D Preferred
Stock shall be convertible into common stock (the &#8220;Conversion Shares&#8221;) at a conversion per share equal to $2.41, at the option
of the holder, at any time after the Company has obtained shareholder approval for the issuance of the Conversion Shares pursuant to the
rules of the Nasdaq Stock Market. In addition, the holder shall not have the right to convert any portion of the Series D Preferred Stock
if, after giving effect to the conversion, such holder (together with its affiliates) would beneficially own in excess of 4.99% of the
number of shares of the common stock outstanding immediately after giving effect to the issuance of the respective Conversion Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 213 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->192<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Wenzhao Lu Exchange Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 9, 2025, the Company
entered into an exchange agreement with Wenzhao Lu, the Chairman of the Board of Directors of the Company, pursuant to which Mr. Lu exchanged
9,000 shares of Series A Preferred Stock of the Company for 5,000 shares of Series D Preferred Stock of the Company pursuant to an exemption
from registration under Section 3(a)(9) of the Securities Act of 1933, as amended (the &#8220;Exchange&#8221;). Upon consummation of the
Exchange, there were no shares of Series A Preferred Stock of the Company outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Redemption Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During 2025, to preserve cash,
the Company entered into discussions with Lab Services MSO for the potential redemption of our investment and on February 26, 2025, the
Company, Avalon Lab, Laboratory Services MSO, and the other parties signatory thereto, entered into a Redemption and Abandonment Agreement
(the &#8220;Redemption Agreement&#8221;), whereby Laboratory Services MSO redeemed the 40% equity interest in Laboratory Services MSO
held by Avalon Lab (the &#8220;Redemption&#8221;). The aggregate cash amount paid to Avalon Lab for the Redemption was $1,745,000, to
be paid as follows: one payment of $95,000 at the closing of the Redemption and, beginning in March 2025, monthly payments of $75,000
until December 2026. In addition, pursuant to the terms of the Redemption Agreement, all shares of Avalon&#8217;s Series B Convertible
Preferred Stock previously issued to SCBC Holdings LLC as partial consideration for the equity interests of Laboratory Services MSO, were
permanently surrendered and relinquished to Avalon for no additional consideration. As a result of the Redemption, beginning in February
2025, we no longer offer laboratory services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Certificates of Elimination</i></b></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">On
March 7, 2025, the Company filed a Certificate of Elimination relating to each of the Series A Preferred Stock and the Series B Preferred
Stock (the &#8220;Eliminations of Designation&#8221;) with the Secretary of State of the State of Delaware, thereby terminating the designations
of the Series A Preferred Stock and the Series B Preferred Stock. The Eliminations of Designation were effective upon filing and eliminated
from the Company&#8217;s Amended and Restated Certificate of Incorporation all matters set forth in the previously-filed Certificates
of Designations with respect to the previously designated Series A Preferred Stock and Series B Preferred Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Bylaws Amendment</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">On
March 7, 2025, the Board approved and adopted an amendment (the&#160;&#8220;Amendment&#8221;) to the Company&#8217;s Amended and Restated
Bylaws (the&#160;&#8220;Bylaws&#8221;).&#160;The Amendment reduces the quorum at any meeting of stockholders, except as otherwise required
by law or by the Company&#8217;s Amended and Restated Certificate of Incorporation or the Bylaws, to one-third of the voting power of
the shares of capital stock outstanding and entitled to vote at the meeting, present in person, present by remote communication, if applicable,
or represented by proxy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Corporate and Available Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We were incorporated in Delaware.
Our website is located at <i>http://www.avalon-globocare.com.</i> On our website, investors can obtain, free of charge, a copy of our
Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, our Code of Conduct and Business Ethics, including
disclosure related to any amendments or waivers thereto, and other reports and any amendments thereto filed or furnished pursuant to
Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we file such material electronically with, or furnish
it to, the SEC. None of the information posted on our website is incorporated by reference into this Annual Report on Form 10-K. The
SEC also maintains a website at <i>http://www.sec.gov</i> that contains reports, proxy and information statements and other information
regarding us and other companies that file materials with the SEC electronically.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 214 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->193<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><div><a id="a_111"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">AVALON EXECUTIVE COMPENSATION</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are currently a &#8220;smaller
reporting company,&#8221; as such term is defined in the rules promulgated under the Securities Act. We have opted to comply with the
scaled down disclosure rules applicable to smaller reporting companies which require certain compensation disclosure for (i) our principal
executive officer, (ii) our two most highly compensated executive officers, other than the principal executive officer, whose total compensation
for 2024 exceeded $100,000 and who were serving as executive officers as of December 31, 2024, and (iii) up to two additional individuals
for whom disclosure would have been provided pursuant to the foregoing clause (ii) but for the fact that the individual was not serving
as an executive officer as of December 31, 2024. We refer to these individuals as &#8220;named executive officers.&#8221; Our named executive
officers for the year ended December 31, 2024 were Dr. David Jin, Luisa Ingargiola and Meng Li. Certain information regarding their 2024
compensation is included below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>2024 Summary Compensation Table</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Name and principal position</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Year</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Salary</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Stock<br/>
    awards</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Option<br/>
    Awards</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Nonequity<br/>
    incentive plan<br/>
    compensation</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Nonqualified<br/>
    deferred<br/>
    compensation<br/>
    earnings</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>All other<br/>
    compensation</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Total</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>($)</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>($)</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>($)</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>($)</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>($)</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>($)</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>($)</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Dr. David Jin</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">180,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">180,000</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; width: 19%; padding-left: 9.25pt"><span style="font-size: 10pt">CEO</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 10%; text-align: center"><span style="font-size: 10pt">2023</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%; text-align: right"><span style="font-size: 10pt">330,000</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%; text-align: right"><span style="font-size: 10pt">&#160;-</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;-</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;-</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;-</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 7%; text-align: right"><span style="font-size: 10pt">330,000</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Luisa Ingargiola</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">350,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">350,000</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom; padding-left: 9.25pt"><span style="font-size: 10pt">CFO</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2023</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">350,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">350,000</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Meng Li</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2024</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">205,471</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">205,471</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: bottom; padding-left: 9.25pt"><span style="font-size: 10pt">COO</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">2023</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">280,244</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-size: 10pt">280,244</span></td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employment Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>David Jin</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 1, 2016, the Company
entered into an Executive Employment Agreement with David Jin, the Company&#8217;s CEO and President. Pursuant to the agreement, Mr. Jin
was employed as President and Chief Executive Officer of the Company, which agreement had a term initially through November 30, 2017 unless
earlier terminated pursuant to the terms of the agreement. On February 20, 2020, the Company entered into a Letter Agreement with Dr.
Jin pursuant to which the term of Dr. Jin&#8217;s Executive Employment Agreement was extended an additional three years. During the term
of the agreement, Dr. Jin is entitled to a base salary and will be eligible for a discretionary performance bonus, equity awards and to
participate in employee benefits plans as the Company may institute from time to time at the discretion of the Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 3, 2019, the Company
entered into a Letter Agreement with Dr. Jin, pursuant to which his annual base salary set forth in his employment agreement was increased
to $360,000, effective January 1, 2019. Pursuant to the agreement, Mr. Jin may be terminated for &#8220;cause&#8221; as defined and Mr.
Jin may resign for &#8220;good reason&#8221; as defined. In the event Mr. Jin is terminated without cause or resigns for good reason,
the Company will be required to pay Mr. Jin all accrued salary and bonuses, reimbursement for all business expenses and Mr. Jin&#8217;s
salary for one year. In the event Mr. Jin is terminated with cause, resigns without good reason, dies or is disabled, the Company will
be required to pay Mr. Jin all accrued salary and bonuses and reimbursement for all business expenses. Under the agreement Mr. Jin is
subject to confidentiality, non-compete and non-solicitation restrictions. This agreement has not been extended, however Dr. Jin is continuing
his employment with the Company at will and otherwise under the same terms and conditions, except that Dr. Jin agreed to a salary reduction
as set forth in the table above for the years ended December 31, 2024 and 2023 as part of the Company&#8217;s cost reduction measures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Luisa Ingargiola</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On February 21, 2017, Ms.
Ingargiola and the Company entered into an Executive Retention Agreement effective February 9, 2017, pursuant to which Ms. Ingargiola
agreed to serve as Chief Financial Officer in consideration of an annual salary. On January 3, 2019, the Company entered into a Letter
Agreement with Ms. Ingargiola, pursuant to which her annual base salary set forth in her employment agreement was increased to $350,000
effective January 1, 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The employment of Ms. Ingargiola
is at will and may be terminated at any time, with or without formal cause. Pursuant to the terms of Executive Retention Agreement with
Ms. Ingargiola, the Company has agreed to provide specified severance and bonus amounts and to accelerate the vesting on her equity awards
upon termination upon a change of control or an involuntary termination, as each term is defined in the agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 215 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->194<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the event of a termination
upon a change of control, Ms. Ingargiola is entitled to receive an amount equal to 12 months of her base salary and the target bonus then
in effect for the executive officer for the year in which such termination occurs, such bonus payment to be pro-rated to reflect the full
number of months the executive remained in the Company&#8217;s employ. In addition, the vesting on any stock option held by the executive
officer will be accelerated in full. At the election of the executive officer, the Company will also continue to provide health related
employee insurance coverage for twelve months, at the Company&#8217;s expense.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the event of an involuntary
termination, Ms. Ingargiola is entitled to receive an amount equal to six months of her base salary and the target bonus then in effect
for the executive officer for the six months in which such termination occurs, such bonus payment to be pro-rated to reflect the full
number of months the executive remained in the Company&#8217;s employ. Such payment will be increased to 12 months upon the one-year anniversary
of the retention agreement. In addition, the vesting on any stock option held by the executive officer will be accelerated in full. At
the election of the executive officer, the Company will also continue to provide health related employee insurance coverage for twelve
months, at the Company&#8217;s expense.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Meng Li</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January 11, 2017, Avalon
Shanghai entered into an Executive Employment Agreement with Meng Li, the Company&#8217;s COO and Secretary. Pursuant to the agreement,
Ms. Li was employed as Chief Operating Officer and President of Avalon Shanghai initially through November 30, 2019, unless earlier terminated
pursuant to the terms of the agreement. On February 20, 2020, the Company entered into a Letter Agreement with Meng Li pursuant to which
the term of Ms. Li&#8217;s Executive Employment Agreement entered between the Company&#8217;s subsidiary and Ms. Li dated January 11,
2017 was extended an additional three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the term of the agreement,
Ms. Li is entitled to a base salary and will be eligible for a discretionary performance bonus, equity awards and to participate in employee
benefits plans as the Avalon Shanghai may institute from time to time at the discretion of its Board of Directors. On January 3, 2019,
the Company entered into a Letter Agreement with Ms. Li, pursuant to which her annual base salary set forth in her employment agreement
was increased to $340,000 effective January 1, 2019, except that Ms. Li agreed to a salary reduction as set forth in the table above for
the years ended December 31, 2024 and 2023 as part of the Company&#8217;s cost reduction measures. Pursuant to the agreement, Ms. Li may
be terminated for &#8220;cause&#8221; as defined and Ms. Li may resign for &#8220;good reason&#8221; as defined. In the event Ms. Li is
terminated without cause or resigns for good reason, Avalon Shanghai will be required to pay Ms. Li all accrued salary and bonuses, reimbursement
for all business expenses and Ms. Li&#8217;s salary for one year. In the event Ms. Li is terminated with cause, resigns without good reason,
dies or is disabled, Avalon Shanghai will be required to pay Ms. Li all accrued salary and bonuses and reimbursement for all business
expenses. Under the agreement Ms. Li is subject to confidentiality, non-compete and non-solicitation restrictions. This agreement has
not been extended, however Ms. Li is continuing her employment with the Company at will and otherwise under the same terms and conditions,
except that Ms. Li agreed to a salary reduction as set forth in the table above for the years ended December 31, 2024 and 2023 as part
of the Company&#8217;s cost reduction measures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Option Exercises and Stock Vested</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There were no options exercised
by our executive officers or stock vested to our executive officers during the year ended December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 216 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->195<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Outstanding Equity Awards at 2024 Fiscal Year
End</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets forth
information with respect to the outstanding equity awards of our named executive officers at December 31, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="32" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Outstanding Equity
    Awards</b></span></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="16" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Option Awards</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Stock Awards</b></span></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of<br/>
    securities<br/>
    underlying<br/>
    unexercised<br/>
    options<br/>
    (#) (Exercisable)</b></span></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of<br/>
    securities<br/>
    underlying<br/>
    unexercised<br/>
    options<br/>
    (#) (Unexercisable)</b></span></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Equity<br/>
    incentive<br/>
    plan<br/>
    awards:<br/>
    Number of<br/>
    securities<br/>
    underlying<br/>
    unexercised unearned <br/>
    options <br/>
    (#)</b></span></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Options<br/>
    exercise<br/>
    price <br/>
    ($)</b></span></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Option<br/>
    expiration<br/>
    Date</b></span></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of<br/>
    shares<br/>
    or units<br/>
    of stock<br/>
    that<br/>
    have not<br/>
    vested<br/>
    (#)</b></span></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Market<br/>
    value of<br/>
    shares or<br/>
    units of<br/>
    stock<br/>
    that<br/>
    have<br/>
    not<br/>
    vested<br/>
    ($)</b></span></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Equity<br/>
    incentive<br/>
    plan<br/>
    awards:<br/>
    Number of<br/>
    unearned<br/>
    shares,<br/>
    units or<br/>
    other<br/>
    rights<br/>
    that have<br/>
    not vested<br/>
    (#)</b></span></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Equity<br/>
    incentive<br/>
    plan<br/>
    awards:<br/>
    Market or<br/>
    payout<br/>
    value of<br/>
    unearned<br/>
    shares,<br/>
    units or<br/>
    other<br/>
    rights<br/>
    that have<br/>
    not vested<br/>
    ($)</b></span></td>
    <td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 50%"><span style="font-size: 10pt">David Jin</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%; text-align: right"><span style="font-size: 10pt">2,667</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%; text-align: right"><span style="font-size: 10pt">2,667</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%; text-align: right"><span style="font-size: 10pt">228</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center"><span style="font-size: 10pt">2/18/2030</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: right"><span style="font-size: 10pt">&#160;&#160;&#160;&#160;-</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Luisa </span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">13,333</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">13,333</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">75</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2/8/2027</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-size: 10pt">Ingargiola</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2,667</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2,667</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">228</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2/18/2030</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-size: 10pt">Meng Li</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">2,000</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">228</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">2/18/2030</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Policies and Practices Related to the Grant
of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not have any formal
policy that requires us to grant, or avoid granting, stock options at particular times. Consistent with its annual compensation cycle,
if options are to be granted, the Compensation Committee generally seeks to grant annual stock option awards after its Annual Report on
Form 10-K has been filed. The timing of any stock option grants in connection with new hires, promotions, or other non-routine grants
is tied to the event giving rise to the award (such as an employee&#8217;s commencement of employment or promotion effective date). As
a result, in all cases, the timing of grants of stock options occurs independent of the release of any material nonpublic information,
and we do not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No stock options were issued
to executive officers in 2024 during any period beginning four business days before the filing of a periodic report or current report
disclosing material non-public information and ending one business day after the filing or furnishing of such report with the SEC.&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>No Pension Benefits</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not maintain any plan
that provides for payments or other benefits to its executive officers at, following or in connection with retirement and including, without
limitation, any tax-qualified defined benefit plans or supplemental executive retirement plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>No Nonqualified Deferred Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not maintain any defined
contribution or other plan that provides for the deferral of compensation on a basis that is not tax-qualified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 217 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->196<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2024 Director Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets forth
information concerning the compensation earned or paid to certain of our non-employee directors during the fiscal year ended December
31, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><b>Name</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Fees<br/> Earned or Paid in<br/> Cash<br/> $</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Stock<br/> Awards<br/> $</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Option<br/> Awards<br/> $</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Non-equity<br/> Incentive Plan<br/> Compensation<br/>
    $</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Change in<br/> Pension Value<br/> and Non-<br/> Qualified<br/>
    Deferred<br/> Compensation<br/> Earnings <br/> $</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>All Other<br/> Compensation<br/> $</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Total <br/> $</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 51%; text-align: left; text-indent: -9pt; padding-left: 9.25pt">Wenzhao Lu</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">100,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 4%; text-align: right">100,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9.25pt">Lourdes Felix (1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,697</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9.25pt">Steven A. Sanders (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,697</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9.25pt">William B. Stilley, III (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,697</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9.25pt">Wilbert J. Tauzin II (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,697</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9.25pt">Tevi Troy (5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,697</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Ms. Felix&#8217;s 2024 compensation
consisted of cash of $70,000 and 533 stock options vested and valued at $2,697.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Mr. Sanders&#8217;s 2024 compensation
consisted of cash of $70,000 and 533 options vested and valued at $2,697.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Mr. Stilley&#8217;s 2024 compensation
consisted of cash of $70,000 and 533 options vested and valued at $2,697.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Mr. Tauzin&#8217;s 2024 compensation
consisted of cash of $25,000 and 1,333 options vested and valued at $4,697.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Mr. Troy&#8217;s 2024 compensation
consisted of cash of $60,000 and 533 options vested and valued at $2,697.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 218 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->197<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_112"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">AVALON MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
following discussion and analysis of our financial condition and results of operations for the years ended December 31, 2024 and 2023
should be read in conjunction with our consolidated financial statements and related notes to those consolidated financial statements
that are included elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking
statements that involve risks and uncertainties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Special Note Regarding
Forward-looking Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">All
statements other than statements of historical fact included in this Annual Report Form 10-K including, without limitation, statements
under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; regarding our financial
position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. When used
in this Annual Report on Form 10-K, words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221;
&#8220;intend&#8221; and similar expressions, as they relate to us or our management, identify forward-looking statements. Such forward-looking
statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, our management.
Actual results could differ materially from those contemplated by the forward-looking statements as a result of a number of factors, including
those set forth under the risk factors and business sections in this Annual Report on Form 10-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="-keep: true">We
are a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products and the advancement of intellectual
property in cellular therapy. We are currently marketing the KetoAir&#8482; breathalyzer device and plan to develop additional diagnostic
uses of the breathalyzer technology. The KetoAir<sup>TM</sup>&#160;is registered with the U.S. Food and Drug Administration as a Class
I medical device. In addition, we own and operate commercial real estate at our headquarters in Freehold, NJ.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="-keep: true">We
had the following areas of focus in the three months ended March 31, 2025 and 2024:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Research and Development</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
are focused on bringing forward intellectual property through joint patent filings with the Massachusetts Institute of Technology (&#8220;MIT&#8221;).
We completed a sponsored research and co-development project with MIT led by Professor Shuguang Zhang as Principal Investigator. Using
the unique QTY code protein design platform, six water-soluble variant cytokine receptors have been successfully designed and tested to
show binding affinity to the respective cytokines. We currently are focused on bringing forward the intellectual property associated with
this program through joint patent submissions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Product Commercialization</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
have begun the commercialization and development of a versatile breathalyzer system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
were granted exclusive distributorship rights for the KetoAir from Qi Diagnostics for the following territories: North America, South
America, the EU and the UK. For our commercialization strategy, we intend to target the diabetes and obesity markets. We sell the product
through the KetoAir website and social media. We believe the KetoAir device has some competitive advantages to other methods for measuring
ketosis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 219 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->198<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
KetoAir is a handheld device that allows the user to detect acetone levels in exhaled breath. The acetone level is in concentration units
(ppm, part-per-million) such that the user will know his/her real-time ketosis status: inadequate ketosis (0-3.99 ppm), mild ketosis (4-9.99
ppm), optimal ketosis (10-40 ppm), or alarming level (&gt; 40 ppm). The KetoAir is registered with the United States Food and Drug Administration
as a Class I medical device. The device is also paired with an &#8220;AI Nutritionist&#8221; software program (via Bluetooth connection)
which is downloadable from Google Play (for Android mobile phones, approved) and iPhone (the app is currently being reviewed by Apple
iOS AppStore). It helps users monitor and manage their ketogenic diet and related programs. We believe the KetoAir can be an essential
tool to help diabetic patients adhere to their therapeutic programs and optimize their ketogenic dietary management.<i>&#160;</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Laboratory Acquisitions</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">We
had embarked on a laboratory rollup strategy focused on forming joint ventures and acquiring laboratories that were accretive to our
commercial strategy. As a first step, in February 2023, we acquired a 40% membership interest in Lab Services MSO. Among other things,
Lab Services MSO provides toxicology and wellness testing services, a broad portfolio of diagnostic tests, and a broad array of test
services. During the first quarter of 2025, to preserve cash, the Company entered into discussions with Lab Services MSO for the potential
redemption of our investment and on February 26, 2025, we and Lab Services MSO entered into a Redemption and Abandonment Agreement, whereby
Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by us. Accordingly, beginning in February 2025, we no longer
offer laboratory services.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><i style="-keep: true">&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i style="-keep: true">Other Areas</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="-keep: true">In
order to preserve cash and focus on and product commercialization, we have currently suspended all research and development efforts related
to cellular therapy in order to redirect our funding efforts to our core business strategies outlined above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">We are a commercial-stage
company dedicated to developing and delivering precision diagnostic consumer products. We are currently marketing the KetoAir breathalyzer
device and plan to develop additional diagnostic uses of the breathalyzer technology.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="background-color: white">In
addition, we own commercial real estate that houses our headquarters in Freehold, New Jersey. These consolidated financial statements
have been prepared assuming that we will continue as a going concern, which contemplates, among other things, the realization of assets
and the satisfaction of liabilities in the normal course of business.</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="-keep: true">As
reflected in the accompanying consolidated financial statements, we had working capital deficit of approximately $10,646,000 at December
31, 2024 and approximately $11,655,000 at March 31, 2025, and had incurred recurring net losses and generated negative cash flow from
operating activities of approximately $7,903,000 and $4,969,000 for the year ended December 31, 2024, respectively and approximately
$2,482,000 and $1,802,000 for the three months ended March 31, 2025, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
have a limited operating history and our continued growth is dependent upon the continuation of generating rental revenue from our income-producing
real estate property in New Jersey and obtaining additional financing to fund future obligations and pay liabilities arising from ordinary
course business operations. In addition, the current cash balance cannot be projected to cover our operating expenses for the next twelve
months from the release date of this report. These matters raise substantial doubt about our ability to continue as a going concern. Our
ability to continue as a going concern is dependent on our ability to raise additional capital, implement our business plan, and generate
sufficient revenues. There are no assurances that we will be successful in our efforts to generate sufficient revenues, maintain sufficient
cash balance or report profitable operations or to continue as a going concern. We plan on raising capital through the sale of equity
to implement our business plan. However, there is no assurance these plans will be realized and that any additional financings will be
available to us on satisfactory terms and conditions, or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The accompanying consolidated
financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts
and classification of liabilities that may result should we be unable to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Critical
Accounting Policies</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white"><b><i>Use
of Estimates</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States
of America (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period. Changes in these estimates and assumptions may have a material impact on the consolidated
financial statements and accompanying notes. Making estimates requires management to exercise significant judgment. It is at least reasonably
possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements,
which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly,
the actual results could differ significantly from those estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Significant
estimates during the years ended December 31, 2024 and 2023 include the useful life of investment in real estate and intangible assets,
the assumptions used in assessing impairment of long-term assets, the valuation of deferred tax assets and the associated valuation allowances,
the valuation of stock-based compensation, the assumptions used to determine fair value of warrants and embedded conversion features of
convertible note payable, and the fair value of the consideration given and assets acquired in the purchase of our equity interest in
Lab Services MSO.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 220 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->199<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Investment in Unconsolidated
Companies</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
use the equity method of accounting for our investment in, and earning or loss of, company that we do not control but over which we do
exert significant influence. We apply the equity method by initially recording these investments at cost, as equity method investments,
subsequently adjusted for equity in earnings and cash distributions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
consider whether the fair value of our equity method investment has declined below its carrying value whenever adverse event or change
in circumstance indicates that recorded value may not be recoverable. If we consider any decline to be other than temporary (based on
various factors, including historical financial results and the overall health of the investee), then a write-down would be recorded to
estimated fair value. Impairment of equity method investment amounted to $259,579 and $9,651,361 for the years ended December 31, 2024
and 2023, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
classify distributions received from equity method investments using the cumulative earnings approach. Distributions received are considered
returns on the investment and classified as cash inflows from operating activities. If, however, the investor&#8217;s cumulative distributions
received, less distributions received in prior periods determined to be returns of investment, exceeds cumulative equity in earnings recognized,
the excess is considered a return of investment and is classified as cash inflows from investing activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Real Property Rental</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
have determined that the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;)
606 does not apply to rental contracts, which are within the scope of other revenue recognition accounting standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Rental
income from operating leases is recognized on a straight-line basis under the guidance of ASC 842. Lease payments under tenant leases
are recognized on a straight-line basis over the term of the related leases. The cumulative difference between lease revenue recognized
under the straight-line method and contractual lease payments are included in rent receivable on the consolidated balance sheets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Income Taxes</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="background-color: white">We
are governed by the income tax laws of China and the United States. Income taxes are accounted for pursuant to ASC 740 &#8220;Accounting
for Income Taxes,&#8221; which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. The charge for
taxes is based on the results for the period as adjusted for items, which are non-assessable or disallowed. It is calculated using tax
rates that have been enacted or substantively enacted by the balance sheet date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="background-color: white">Deferred
tax is accounted for using the balance sheet liability method in respect of temporary differences arising from differences between the
carrying amount of assets and liabilities in the financial statements and the corresponding tax basis used in the computation of assessable
tax profit. In principle, deferred tax liabilities are recognized for all taxable </span>temporary differences, and deferred tax assets
are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences
can be utilized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Deferred
tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the liability is settled. Deferred
tax is charged or credited in the income statement, except when it is related to items credited or charged directly to equity, in which
case the deferred tax is changed to equity. Deferred tax assets and liabilities are offset when they related to income taxes levied by
the same taxation authority and we intend to settle its current tax assets and liabilities on a net basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 221 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->200<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Accounting Standards&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For details of applicable
new accounting standards, please, refer to Recent Accounting Standards in Note 3 of our consolidated financial statements accompanying
this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>RESULTS OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Comparison of Results of Operations for the
Years Ended December 31, 2024 and 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white"><b><i>Real
Property Rental Revenue</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="background-color: white">For
the year ended December 31, 2024, we had real property rental revenue of $1,333,403, as compared to $1,255,681 for the year ended December
31, 2023, an increase of $77,722, or 6.2%. The increase was primarily attributable to the increase in the number of tenants occupying
the building in the year ended December 31, 2024 as compared to the year ended December 31, 2023. We expect that our revenue from real
property rent will remain at its current level with minimal increase in the near future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Real Property Operating
Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Real
property operating expenses consist of property management fees, property insurance, real estate taxes, depreciation, repairs and maintenance
fees, utilities and other expenses related to our rental properties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">For
the year ended December 31, 2024, our real property operating expenses amounted to $1,065,574, as compared to $1,017,493 for the year
ended December 31, 2023, an increase of $48,081, or 4.7%. The increase was primarily attributable to an increase in electric fee of approximately
$40,000 and an increase in other miscellaneous items of approximately $8,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Real Property Operating
Income</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Our
real property operating income for the year ended December 31, 2024 was $267,829, representing an increase of $29,641, or 12.4%, as compared
to $238,188 for the year ended December 31, 2023. The increase was primarily attributable to the increase in real property rental revenue
as described above. We expect our real property operating income will remain at its current level with minimal increase in the near future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b style="-keep: true"><i>Loss from Equity
Method Investment - Lab Services MSO</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">For
the year ended December 31, 2024, we had loss from our investment in Lab Services MSO of $846,588, which consists of our share of Lab
Services MSO&#8217;s net income of $79,923, and amortization of identifiable intangible assets acquired from Lab Services MSO acquisition
of $666,932, and impairment of goodwill acquired from Lab Services MSO acquisition of $259,579, which was primarily attributable to Lab
Services MSO&#8217;s lower revenues and net incomes than anticipated and the decline in our stock price and market capitalization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">For
the year ended December 31, 2023, we had loss from our investment in Lab Services MSO of $8,571,647, which consists of our share of Lab
Services MSO&#8217;s net income of $1,236,391, and amortization of identifiable intangible assets acquired from Lab Services MSO acquisition
of $611,356, and impairment of goodwill acquired from Lab Services MSO acquisition of $9,196,682, which was primarily attributable to
Lab Services MSO&#8217;s lower revenues and net incomes than anticipated and the decline in our stock price and market capitalization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 222 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->201<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Operating Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="background-color: white">For
the years ended December 31, 2024 and 2023, other operating expenses consisted of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Years Ended December 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Advertising and marketing expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">237,671</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,666,721</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,822,105</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,076,477</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Compensation and related benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,431,328</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,768,449</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Miscellaneous taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">233,488</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,290</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109,618</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Directors and officers&#8217; liability insurance premium</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">212,898</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">349,745</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Travel and entertainment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109,244</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166,921</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Rent and related utilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62,294</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,149</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impairment of laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111,033</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other general and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">128,912</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,854</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,348,973</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,420,224</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">For the year ended December 31, 2024, advertising and marketing expenses decreased by $1,429,050, or 85.7%, as compared to the year ended December 31, 2023. The decrease was primarily due to decreased advertising activities in the year ended December 31, 2024. We expect that our advertising and marketing expenses will decrease in the near future as we conserve cash.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; background-color: white">Professional fees primarily consisted of accounting fees, audit fees, legal service fees, consulting fees, investor relations service charges, valuation service fees and other fees. For the year ended December 31, 2024, professional fees decreased by $1,254,372, or 40.8%, as compared to the year ended December 31, 2023, which was primarily attributable to a decrease in consulting fees of approximately $352,000, mainly due to the decrease in use of consulting service providers related to our acquisition of Lab Services MSO, a decrease in audit fees of approximately $174,000, due to the decreased audit services related to our acquisition of Lab Services MSO, a decrease in accounting fees of approximately $431,000, mainly due to the decreased accounting services related to our acquisition of Lab Services MSO, a decrease in legal service fees of approximately $385,000, mainly due to the decreased legal services related to our acquisition of Lab Services MSO, and a decrease in other miscellaneous items of approximately $47,000, offset by an increase in valuation fee for our equity method investment on Lab Services MSO of $135,000. We expect that our professional fees will likely remain at their current level with minimal increase in the near future.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; background-color: white">For the year ended December 31, 2024, compensation and related benefits decreased by $337,121, or 19.1%, as compared to the year ended December 31, 2023. The decrease was primarily attributable to the decreased compensation for two of our executive officers, David Jin and Meng Li. We expect that our compensation and related benefits will remain relatively steady, with minimal increase, in the near future</span><span style="font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">For the year ended December 31, 2024, miscellaneous taxes increased by $176,198, or 307.6%, as compared to the year ended December 31, 2023. The increase was primarily attributable to increased Delaware state franchise tax. We expect that our miscellaneous taxes will decrease in the near future.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; background-color: white">For the year ended December 31, 2024, research and development expenses decreased by $109,618, or 100.0%, as compared to the year ended December 31, 2023. In the year ended December 31, 2024, we did not incur any activity with respect to research and development projects as we redirected our funding efforts to our core business strategies discussed above.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; background-color: white">For the year ended December 31, 2024, directors&#8217; and officers&#8217; liability insurance premium decreased by $136,847, or 39.1%, as compared to the year ended December 31, 2023. The decrease was mainly due to our switching to a different insurance provider, resulting in a lower premium.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">For <span style="background-color: white">the year ended December 31, 2024, travel and entertainment expense decreased by $57,677, or 34.6%, as compared to the year ended December 31, 2023. The decrease was mainly due to decreased business travel activities in the year ended December 31, 2024 as compared to the year ended December 31, 2023.</span></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">For <span style="background-color: white">the year ended December 31, 2024, rent and related utilities expenses decreased by $1,855, or 2.9%, as compared to the year ended December 31, 2023. </span></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 223 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->202<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">In December 2024, we assessed our laboratory equipment for any impairment and concluded that there were indicators of impairment as of December 31, 2024 and we calculated that the estimated undiscounted cash flows were less than the carrying amount of the laboratory equipment. Based on our analysis, we recognized an impairment loss of $111,033 for the year ended December 31, 2024, which reduced the value of laboratory equipment to zero. We did not record any impairment charge for the year ended December 31, 2023.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Other <span style="background-color: white">general and administrative expenses mainly consisted of NASDAQ listing fee, office supplies, and other miscellaneous items. For the year ended December 31, 2024, other general and administrative expenses decreased by $31,942, or 19.9%, as compared to the year ended December 31, 2023, which was mainly attributable to a decrease in office supplies of approximately $12,000, and a decrease in other miscellaneous items of approximately $20,000 due to our efforts at stricter controls on corporate expenditure.</span></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Loss from Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">As
a result of the foregoing, for the year ended December 31, 2024, loss from operations amounted to $4,927,732, as compared to $15,753,683
for the year ended December 31, 2023, representing a decrease of $10,825,951, or 68.7%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Other (Expense)
Income</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Other
(expense) income mainly includes third party and related party interest expense, debt modification charge, change in fair value of derivative
liability, impairment of equity method investment on Epicon, gain on debts extinguishment, and other miscellaneous expense.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Other
expense, net, totaled $2,975,662 for the year ended December 31, 2024, as compared to $953,327 for the year ended December 31, 2023,
an increase of $2,022,335, or 212.1%, which was primarily attributable to an increase in third party interest expense of approximately
$1,077,000, mainly driven by the increase in amortization of debt discount and debt issuance costs of approximately $867,000 and the
increased interest expense of approximately $210,000 from third party debts, an increase in interest expense - related party of approximately
$9,000, an increase in debt modification charge of approximately $839,000, a decrease in gain on debts extinguishment of approximately
$683,000, and an increase in other expense of approximately $56,000, offset by an increase in gain from change in fair value of derivative
liability of approximately $186,000, a decrease in impairment of equity method investment on Epicon of approximately $455,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Income Taxes</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="background-color: white">We
did not have any income taxes expense for the years ended December 31, 2024 and 2023, since we incurred losses in these periods.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Net Loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="background-color: white">As
a result of the factors described above, our net loss was $7,903,394 for the year ended December 31, 2024, as compared to $16,707,010
for the year ended December 31, 2023, a decrease of $8,803,616, or 52.7%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Net Loss Attributable
to Avalon GloboCare Corp. Common Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="background-color: white">The
net loss attributable to our common shareholders was $7,903,394, or $8.44 per share (basic and diluted), for the year ended December 31,
2024, as compared to $16,707,010, or $23.80 per share (basic and diluted), for the year ended December 31, 2023, a decrease of $8,803,616,
or 52.7%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Foreign Currency
Translation Adjustment</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="background-color: white">Our
reporting currency is the U.S. dollar. The functional currency of our parent company, AHS, Avalon RT 9, Avalon Lab, and Q&amp;A Distribution
is the U.S. dollar and the functional currency of Avalon Shanghai is the Chinese Renminbi (&#8220;RMB&#8221;). The financial statements
of our subsidiary whose functional currency is the RMB are translated to U.S. dollars using period end rate of exchange for assets and
liabilities, average rate of exchange for revenues, costs, and expenses and cash flows, and at historical exchange rate for equity. Net
gains and losses resulting from foreign exchange transactions are included in the results of operations. As a result of foreign currency
translations, which are a non-cash adjustment, we reported a foreign currency translation loss of $273 and $18,590 for the years ended
December 31, 2024 and 2023, respectively. This non-cash loss had the effect of increasing our reported comprehensive loss in each respective
period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 224 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->203<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Comprehensive Loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="background-color: white">As
a result of our foreign currency translation adjustment, we had comprehensive loss of $7,903,667 and $16,725,600 for the years ended December
31, 2024 and 2023, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">RESULTS OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Comparison of Results of Operations for
the Three Months Ended March 31, 2025 and 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Real Property Rental Revenue</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="-keep: true">For the three months
ended March 31, 2025, we had real property rental revenue of $349,800, as compared to $314,588 for the three months ended March 31, 2024,
an increase of $35,212, or 11.2%. The increase was primarily attributable to the increase in the number of tenants occupying the building
in the three months ended March 31, 2025 as compared to the three months ended March 31, 2024. We expect that our revenue from real property
rent will remain at its current level with minimal increase in the near future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Real Property Operating Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="-keep: true">Real property operating
expenses consist of property management fees, property insurance, real estate taxes, depreciation, repairs and maintenance fees, utilities
and other expenses related to our rental properties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="-keep: true">For the three months
ended March 31, 2025, our real property operating expenses amounted to $280,390, as compared to $263,126 for the three months ended March
31, 2024, an increase of $17,264, or 6.6%. The increase was primarily attributable to an increase in utilities of approximately $23,000,
offset by a decrease in other miscellaneous items of approximately $6,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Real Property Operating Income</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="-keep: true">Our real property operating
income for the three months ended March 31, 2025 was $69,410, representing an increase of $17,948, or 34.9%, as compared to $51,462 for
the three months ended March 31, 2024. The increase was primarily attributable to the increase in real property rental revenue as described
above. We expect our real property operating income will remain at its current level with minimal increase in the near future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Income from Equity Method Investment
- Lab Services MSO</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="-keep: true">For the three months
ended March 31, 2025, we had income from our investment in Lab Services MSO of $392,677, which consists of our share of Lab Services
MSO&#8217;s net income of $503,833 and amortization of identifiable intangible assets acquired from Lab Services MSO acquisition of $111,156.
We sold our ownership of 40% of Lab Services MSO on February 26, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="-keep: true">For the three months
ended March 31, 2024, we had income from our investment in Lab Services MSO of $107,469, which consists of our share of Lab Services
MSO&#8217;s net income of $274,202 and amortization of identifiable intangible assets acquired from Lab Services MSO acquisition of $166,733.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Other Operating Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">For the three months
ended March 31, 2025 and 2024, other operating expenses consisted of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Three Months Ended<br/>
 March 31,</span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Advertising and marketing expenses</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">71,150</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">45,000</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Professional fees</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,691,579</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">442,335</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Compensation and related benefits</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">340,420</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">353,571</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Miscellaneous taxes</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">40,245</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">29,341</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Directors&#8217; and officers&#8217; liability insurance premium</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">35,517</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">69,307</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Travel and entertainment</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">44,661</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">22,323</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Rent and related utilities</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">15,327</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td>&#160;</td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">15,592</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Other general and administrative</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">29,963</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">24,524</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">2,268,862</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1,001,993</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">For
                                            the three months ended March 31, 2025, advertising and marketing expenses increased by $26,150,
                                            or 58.1%, as compared to the three months ended March 31, 2024. The increase was primarily
                                            due to increased advertising activities in the three months ended March 31, 2025. We expect
                                            that our advertising and marketing expenses will likely remain at their current level with
                                            minimal increase in the near future.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 225 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->204<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Professional
                                            fees primarily consisted of accounting fees, audit fees, legal service fees, consulting fees,
                                            investor relations service charges, fairness opinion charge, valuation service fees and other
                                            fees. For the three months ended March 31, 2025, professional fees increased by $1,249,244
                                            or 282.4%, as compared to the three months ended March 31, 2024, which was primarily attributable
                                            to an increase in consulting fees of approximately $717,000, mainly due to the increase in
                                            use of consulting service providers related to our potential merger with YOOV Group Holding
                                            Limited, a business company incorporated in the British Virgin Islands (&#8220;YOOV&#8221;),
                                            an increase in legal service fees of approximately $498,000, mainly due to the increased
                                            legal services related to our potential merger with YOOV, an increase in fairness opinion
                                            charge of approximately $129,000 resulting from the increased fairness opinion services related
                                            to our potential merger with YOOV, offset by a decrease in other miscellaneous items of approximately
                                            $95,000. We expect that our professional fees will decrease in the near future.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">For
                                            the three months ended March 31, 2025, compensation and related benefits decreased by $13,151,
                                            or 3.7%, as compared to the three months ended March 31, 2024. The decrease was primarily
                                            attributable to the decreased compensation for our executive officer, David Jin. We expect
                                            that our compensation and related benefits will increase in the near future.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">For
                                            the three months ended March 31, 2025, miscellaneous taxes increased by $10,904, or 37.2%,
                                            as compared to the three months ended March 31, 2024. The increase was primarily attributable
                                            to increased Delaware state franchise tax. We expect that our miscellaneous taxes will remain
                                            relatively steady, with minimal increase, in the near future.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">For
                                            the three months ended March 31, 2025, directors&#8217; and officers&#8217; liability insurance
                                            premium decreased by $33,790, or 48.8%, as compared to the three months ended March 31, 2024.
                                            The decrease was mainly due to our switching to a different insurance provider, resulting
                                            in a lower premium.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">For
                                            the three months ended March 31, 2025, travel and entertainment expense increased by $22,338,
                                            or 100.1%, as compared to the three months ended March 31, 2024. The increase was mainly
                                            due to increased business travel activities in the three months ended March 31, 2025 as compared
                                            to the three months ended March 31, 2024.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">For
                                            the three months ended March 31, 2025, rent and related utilities expenses decreased by $265,
                                            or 1.7%, as compared to the three months ended March 31, 2024.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Other
                                            general and administrative expenses mainly consisted of NASDAQ listing fee, office supplies,
                                            and other miscellaneous items. For the three months ended March 31, 2025, other general and
                                            administrative expenses increased by $5,439, or 22.2%, as compared to the three months ended
                                            March 31, 2024, which was mainly attributable to an increase in service fee related to setting
                                            up our British Virgin Islands company for our potential merger with YOOV of approximately
                                            $4,000, and an increase in other miscellaneous items of approximately $1,000.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Loss from Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="-keep: true">As a result of the foregoing,
for the three months ended March 31, 2025, loss from operations amounted to $1,806,775, as compared to $843,062 for the three months
ended March 31, 2024, representing an increase of $963,713, or 114.3%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Other (Expense) Income</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="-keep: true">Other (expense) income
mainly includes third party and related party interest expense, change in fair value of derivative liability, and other miscellaneous
expense.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="-keep: true">Other expense, net, totaled
$675,336 for the three months ended March 31, 2025, as compared to $524,451 for the three months ended March 31, 2024, an increase of
$150,885, or 28.8%, which was primarily attributable to an increase in third party interest expense of approximately $52,000, mainly
driven by the increase in amortization of debt discount and debt issuance costs of approximately $42,000 and the increased interest expense
of approximately $10,000 from third party debts, a decrease in gain from change in fair value of derivative liability of approximately
$146,000, offset by a decrease in interest expense - related party of approximately $11,000, and a decrease in other expense of approximately
$36,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Income Taxes</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="-keep: true">We did not have any income
taxes expense for the three months ended March 31, 2025 and 2024 since we incurred losses in these periods.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Net Loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="-keep: true">As a result of the factors
described above, our net loss was $2,482,111 for the three months ended March 31, 2025, as compared to $1,367,513 for the three months
ended March 31, 2024, an increase of $1,114,598, or 81.5%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Net Loss Attributable to Avalon GloboCare
Corp. Common Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="-keep: true">The net loss attributable
to our common shareholders (after taking into effect $162,473 in deemed contribution) was $2,319,638, or $1.43 per share (basic and diluted),
for the three months ended March 31, 2025, as compared to $1,367,513, or $1.86 per share (basic and diluted), for the three months ended
March 31, 2024, an increase of $952,125, or 69.6%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Foreign Currency Translation Adjustment</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="-keep: true">Our reporting currency
is the U.S. dollar. The functional currency of our parent company, AHS, Avalon RT 9, Avalon Lab, and Q&amp;A Distribution is the U.S.
dollar and the functional currency of Avalon Shanghai is the Chinese Renminbi (&#8220;RMB&#8221;). The financial statements of our subsidiary
whose functional currency is the RMB are translated to U.S. dollars using period end rate of exchange for assets and liabilities, average
rate of exchange for revenues, costs, and expenses and cash flows, and at historical exchange rate for equity. Net gains and losses resulting
from foreign exchange transactions are included in the results of operations. As a result of foreign currency translations, which are
a non-cash adjustment, we reported a foreign currency translation gain of $279 and a foreign currency translation loss of $2,920 for
the three months ended March 31, 2025 and 2024, respectively. This non-cash gain/loss had the effect of decreasing/increasing our reported
comprehensive loss in each respective period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 226 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->205<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Comprehensive Loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><span style="-keep: true">As a result of our foreign
currency translation adjustment, we had comprehensive loss of $2,481,832 and $1,370,433 for the three months ended March 31, 2025 and
2024, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b style="-keep: true">Liquidity and
Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true"><span style="background-color: white">We
have a limited operating history and our continued growth is dependent upon the continuation of generating </span>We have a limited operating
history and our continued growth is dependent upon the continuation of generating rental revenue from our income-producing real estate
property in New Jersey, generating revenue for selling of KetoAir, as well as obtaining additional financing to fund future obligations
and pay liabilities arising from ordinary course business operations. In addition, the current cash balance cannot be projected to cover
our operating expenses for the next twelve months from the release date of this report. These matters raise substantial doubt about our
ability to continue as a going concern. Our ability to continue as a going concern is dependent on our ability to raise additional capital,
implement our business plan, and generate sufficient revenues. There are no assurances that we will be successful in our efforts to generate
sufficient revenues, maintain sufficient cash balance or report profitable operations or to continue as a going concern. We plan to raise
capital in the future through the sale of equity or debt to implement our business plan. However, there is no assurance these plans will
be realized and that any additional financings will be available to us on satisfactory terms and conditions, if at all.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Liquidity is the ability
of a company to generate funds to support its current and future operations, satisfy its obligations as they come due and otherwise operate
on an ongoing basis. At March 31, 2025 and December 31, 2024, we had a cash balance of approximately $1,370,000 and $2,856,000, respectively.
These funds are kept in financial institutions located as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><span style="-keep: true">Country:</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b style="-keep: true">March 31, <br/> 2025</b></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b style="-keep: true">December 31, <br/> 2024</b></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="-keep: true">United States</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">1,351,923</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">98.7</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">%</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">2,844,522</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">99.6</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">China</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">17,663</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">1.3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">11,787</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">0.4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Total cash</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">1,369,586</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">100.0</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">%</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">2,856,309</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">100.0</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">%</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The
following table sets forth a summary of changes in our working capital deficit from December 31, 2024 to March 31, 2025:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><b style="-keep: true">March 31,</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><b style="-keep: true">December&#160;31,</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b style="-keep: true">Changes in</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b style="-keep: true">&#160;</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b style="-keep: true">2025</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b style="-keep: true">2024</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b style="-keep: true">Amount</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td><td style="padding-bottom: 1.5pt"><b style="-keep: true">&#160;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b style="-keep: true">Percentage</b></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-keep: true">Working capital deficit:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="-keep: true">Total current assets</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">2,794,258</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">3,236,498</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(442,240</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(13.7</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total current liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">14,449,353</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">13,882,555</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">566,798</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">4.1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Working capital deficit</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(11,655,095</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(10,646,057</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(1,009,038</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">9.5</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">%</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Our working capital deficit
increased by $1,009,038 to $11,655,095 at March 31, 2025 from $10,646,057 at December 31, 2024. The increase in working capital deficit
was primarily attributable to a decrease in cash of approximately $1,487,000, an increase in accrued professional fees of approximately
$373,000 which was mainly attributable to the increase in professional services related to our potential merger with YOOV, an increase
in advance from pending sale of noncontrolling interest - related party of approximately $220,000 resulting from advance received in
connection with the membership interest purchase agreement entered into in November 2023 in three months ended March 31, 2025, and an
increase in convertible note payable, net, of approximately $284,000 driven by the amortization of debt discount and debt issuance costs
of approximately $284,000 in the three months ended March 31, 2025, offset by an increase in current portion of receivable from sale
of equity method investment of $975,000 resulting from execution of the Redemption Agreement signed on February 26, 2025 as described
elsewhere in this report, and a decrease in accrued liabilities and other payables - related parties of approximately $633,000 which
was extinguished upon our sale of equity method investment in the first quarter of 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="text-indent: 0.25in; text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Because the exchange
rate conversion is different for the condensed consolidated balance sheets and the condensed consolidated statements of cash flows, the
changes in assets and liabilities reflected on the condensed consolidated statements of cash flows are not necessarily identical with
the comparable changes reflected on the condensed consolidated balance sheets.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 227 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->206<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white"><b>Cash
Flows for the Year Ended December 31, 2024 Compared to the Year Ended December 31, 2023 and Three Months Ended March 31, 2025 and 2024</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="background-color: white">The
following table summarizes the key components of our cash flows for the years ended December 31, 2024 and 2023:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Years Ended December 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,969,205</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(6,504,718</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(100,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,159</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,638,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,825,337</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Effect of exchange rate on cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,447</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,970</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net increase (decrease) in cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,570,909</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,705,510</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="background-color: white">Net
cash flow used in operating activities for the year ended December 31, 2024 was $4,969,205, which primarily reflected our consolidated
net loss of approximately $7,903,000, and the non-cash item adjustment, consisting of change in fair market value of derivative liability
of approximately $374,000, and the changes in operating assets and liabilities, primarily consisting of a decrease in accrued liabilities
and other payables of approximately $1,165,000 resulting from payments made to our vendors in the year ended December 31, 2024, and a
decrease in operating lease obligation of approximately $123,000, offset by a decrease in rent receivable of approximately $131,000 driven
by our collection efforts, and the non-cash items adjustment, primarily consisting of depreciation of approximately $178,000, amortization
of operating lease right-of-use asset of approximately $123,000, stock-based compensation and service expense of approximately $522,000,
loss from equity method investments of approximately $847,000 which was mainly attributable to the amortization of identifiable intangible
assets acquired from Lab Services MSO acquisition of approximately $667,000 and the impairment of goodwill acquired from Lab Services
MSO acquisition of approximately $260,000, resulting from Lab Services MSO&#8217;s lower revenues and net incomes than anticipated and
the decline in our stock price and market capitalization, distribution of earnings from equity method investment of </span>approximately
$612,000, amortization of debt issuance costs and debt discount of approximately $1,411,000, impairment of laboratory equipment of approximately
$111,000, and debt modification charge of approximately $689,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="background-color: white">Net
cash flow used in operating activities for the year ended December 31, 2023 was $6,504,718, which primarily reflected our consolidated
net loss of approximately $16,707,000, and the changes in operating assets and liabilities, primarily consisting of a decrease in operating
lease obligation of approximately $113,000, and the non-cash items adjustment, consisting of change in fair market value of derivative
liability of approximately $188,000, and gain on debts extinguishment of approximately $683,000, offset by depreciation of approximately
$212,000, amortization of operating lease right-of-use asset of approximately $118,000, stock-based compensation and service expense
of approximately $1,180,000, loss from equity method investments of approximately $8,590,000 mainly due to the impairment of goodwill
acquired from Lab Services MSO acquisition resulting from Lab Services MSO&#8217;s lower revenues and net incomes than anticipated and
the decline in our stock price and market capitalization, impairment of equity method investment - Epicon of approximately $455,000 due
to Epicon&#8217;s series of operating losses and the joint venture partner unable to obtain funds to commence operations, and amortization
of debt issuance costs and debt discount of approximately $544,000 resulting from our outstanding convertible debt and note payable,
and the changes in operating assets and liabilities, primarily consisting of an increase in accrued liabilities and other payables -
related parties of approximately $106,000 driven by the increased accrued interest for related party.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
expect our cash used in operating activities to increase in the next 12 months due to the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; background-color: white">the development and commercialization of new products; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; background-color: white">an </span><span style="font-size: 10pt">increase in public relations and/or sales promotions for existing and/or new brands as we expand within existing markets or enter new markets.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="background-color: white">Net
cash flow used in investing activities was $100,000 for the year ended December 31, 2024, as compared to $22,159 for the year ended December
31, 2023. During the year ended December 31, 2024, we paid $100,000 for the acquisition of a 40% interest in Lab Services MSO. During
the year ended December 31, 2023, we made payment for purchase of property and equipment of approximately $22,000.&#160;&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 228 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->207<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="background-color: white">Net
cash flow provided by financing activities was $7,638,667 for the year ended December 31, 2024, as compared to $4,825,337 for the year
ended December 31, 2023. During the year ended December 31, 2024, we received net proceeds from the issuance of convertible debts and
warrants of approximately $3,085,000 (net of original issue discount of approximately $177,000 and cash paid for convertible note issuance
costs of approximately $283,000), an advance from the pending sale of a noncontrolling interest in a subsidiary of approximately $2,122,000,
net proceeds from equity offering of approximately $2,719,000 (net of cash paid for commission and other offering costs of approximately
$138,000), and proceeds from issuance of convertible preferred stock of $3,500,000, offset by repayments made for loan payable - related
party of $400,000, and made for convertible debts of approximately $3,388,000. During the year ended December 31, 2023, we received proceeds
from related party borrowings of $850,000, and net proceeds from issuance of convertible debt and warrants of approximately $2,238,000
(net of original issue discount of $135,000 and cash paid for convertible note issuance costs of approximately $327,000), and net proceeds
from issuance of balloon promissory note of approximately $936,000 (net of cash paid for promissory note issuance costs of approximately
$64,000), and net proceeds from equity offering of approximately $616,000 (net of cash paid for commission and other offering costs of
approximately $19,000), and advance from pending sale of noncontrolling interest in subsidiary of approximately $486,000, offset by repayments
made for convertible debt of $300,000. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="-keep: true">Net
cash flow provided by financing activities was $219,972 for the three months ended March 31, 2025, as compared to $936,772 for the three
months ended March 31, 2024. During the three months ended March 31, 2025, we received advance from sale of noncontrolling interest in
subsidiary of approximately $220,000. During the three months ended March 31, 2024, we received net proceeds from issuance of convertible
debt and warrants of approximately $592,000 (net of original issue discount of $35,000 and cash paid for convertible note issuance costs
of approximately $73,000), and advance from sale of noncontrolling interest in subsidiary of approximately $1,210,000, offset by repayments
made for convertible debt of $866,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
following trends are reasonably likely to result in a material decrease in our liquidity over the near to long term:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">an increase in working capital requirements to finance our current business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the use of capital for acquisitions and the development of business opportunities; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the cost of being a public company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="-keep: true">In
addition, the impact that the imposition of tariffs and changes to global trade policies could have on our results of operations is uncertain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="-keep: true">We
estimate that, based on current plans and assumptions, our available cash will be insufficient to satisfy our cash requirements under
our present operating expectations through cash flow provided by operations and sales of equity. Other than funds received as described
above and cash resources generated from our operations, we presently have no other significant alternative source of working capital.
We have used these funds to fund our operating expenses, pay our obligations and grow our company. We will need to raise significant
additional capital to fund our operations and to provide working capital for our ongoing operations and obligations. Therefore, our future
operation is dependent on our ability to secure additional financing. Financing transactions may include the issuance of equity or debt
securities, obtaining credit facilities, or other financing mechanisms. However, there can be no assurance that financing will be available
in amounts or on terms acceptable to the Company. Additionally, the trading price of our common stock and a downturn in the U.S. equity
and debt markets could make it more difficult to obtain financing through the issuance of equity or debt securities. Even if we are able
to raise the funds required, it is possible that we could incur unexpected costs and expenses or experience unexpected cash requirements
that would force us to seek alternative financing. Furthermore, if we issue additional equity or debt securities, stockholders may experience
additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our
common stock. The inability to obtain additional capital may restrict our ability to grow and may reduce our ability to continue to conduct
business operations. If we are unable to obtain additional financing, we will be required to cease our operations. To date, we have not
considered this alternative, nor do we view it as a likely occurrence.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>August 2019 Credit
Facility</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">In
the third quarter of 2019, we entered into a $20 million credit facility (the &#8220;Line of Credit&#8221;) provided by our Chairman of
the Board and a significant (and our largest) stockholder, Wenzhao Lu. The Line of Credit allowed us to request loans thereunder and to
use the proceeds of such loans for working capital and operating expense purposes until the facility matured on December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>At-the-Market Offering</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">In
June 2023, we entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Roth Capital Partners, LLC (&#8220;Roth&#8221;)
under which we may offer and sell from time to time shares of our common stock having an aggregate offering price of up to $3.5 million.
From July 1, 2023 to August 16, 2024, we sold an aggregate of 312,285 shares of our common stock at an average price of $11.19 per share
to investors pursuant to the Sales Agreement, and received net cash proceeds of $3,388,251, net of cash paid for Roth&#8217;s commissions
and other fees of $104,992.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>March 2024 Convertible
Note Financing</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">In
March 2024, we entered into a security purchase agreement with a lender (the &#8220;March 2024 Lender&#8221;) and closed on the issuance
of a 13.0% senior secured convertible promissory note in the principal amount of $700,000 (the &#8220;March 2024 Convertible Note&#8221;),
as well as the issuance of 7,000 shares of common stock as a commitment fee and warrants for the purchase of up to 16,827 shares of our
common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 229 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->208<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>June 2024 Convertible
Note Financing</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">In
June 2024, we entered into a security purchase agreement with a lender (the &#8220;June 2024 Lender&#8221;) and closed on the issuance
of a 13.0% senior secured convertible promissory note in the principal amount of $2,845,000 (the &#8220;June 2024 Convertible Note&#8221;),
as well as the issuance of 26,800 shares of common stock as a commitment fee and warrants for the purchase of up to 146,667 shares of
our common stock. We and our subsidiaries also entered into security agreements in connection with issuance of the June 2024 Convertible
Note, creating a security interest in certain property of the Company and its subsidiaries to secure the prompt payment, performance and
discharge in full of all of our obligations under the June 2024 Convertible Note.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Series C Convertible
Preferred Stock Sold Pursuant to Securities Purchase Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">On
December 19, 2024, the Company entered into that certain securities purchase agreement (the &#8220;Securities Purchase Agreement&#8221;),
with an accredited investor, York Sun Investment Holding Limited, a British Virgin Islands company (the &#8220;Investor&#8221;), pursuant
to which the Company agreed to issue and sell to the Investor, upon the terms and conditions set forth in the Securities Purchase Agreement,
up to 7,000 shares of Series C Convertible Preferred Stock for up to an aggregate of $7,000,000 (the &#8220;Purchase Price&#8221;), which
is equal to $1,000 per share. The first closing occurred on December 24, 2024, with respect to the Investor&#8217;s purchase of 3,500
shares of Series C Convertible Preferred Stock in exchange for $3,500,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Each
share of Series C Convertible Preferred Stock is convertible into common stock of the Company (the &#8220;Conversion Shares&#8221;) at
a conversion per share equal to $2.41, at the option of the holder, at any time after the later of (i) the date of the shareholder approval
of the issuance of the Conversion Shares pursuant to the rules of the Nasdaq Stock Market (the &#8220;Shareholder Approval&#8221;) and
(ii) the one year anniversary of the date of the first issuance of any shares of the Series C Convertible Preferred Stock. The Company
shall not be required to issue any Conversion Shares until the Shareholder Approval is obtained by the Company. The Investor shall also
have a right of first refusal during the period beginning on the date of the Securities Purchase Agreement and continuing until such shareholder
approval is obtained, on all issuances of convertible preferred stock of the Company, excluding agreements that are in place prior to
the date of the Securities Purchase Agreement and issuances of new classes of convertible preferred stock in exchange for existing classes
of convertible preferred stock. Additionally, the Investor has the right, pursuant to the Securities Purchase Agreement to appoint one
member to, or to replace one member of, the Company&#8217;s board of directors, subject to all applicable Nasdaq rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
Investor&#8217;s purchase of the remaining 3,500 shares of Series C Convertible Preferred Stock under the Securities Purchase Agreement
in exchange for an additional $3,500,000 is required to occur within 120 calendar days of the date of the Securities Purchase Agreement,
subject to the satisfaction of customary closing conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We
estimate that, based on current plans and assumptions, our available cash will be insufficient to satisfy our cash requirements under
our present operating expectations through cash flow provided by operations and sales of equity. Other than funds received as described
above and cash resources generated from our operations, we presently have no other significant alternative source of working capital.
We have used these funds to fund our operating expenses, pay our obligations and grow our company. We will need to raise significant additional
capital to fund our operations and to provide working capital for our ongoing operations and obligations. Therefore, our future operation
is dependent on our ability to secure additional financing. Financing transactions may include the issuance of equity or debt securities,
obtaining credit facilities, or other financing mechanisms. However, the trading price of our common stock and a downturn in the U.S.
equity and debt markets could make it more difficult to obtain financing through the issuance of equity or debt securities. Even if we
are able to raise the funds required, it is possible that we could incur unexpected costs and expenses or experience unexpected cash requirements
that would force us to seek alternative financing. Furthermore, if we issue additional equity or debt securities, stockholders may experience
additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our
common stock. The inability to obtain additional capital may restrict our ability to grow and may reduce our ability to continue to conduct
business operations. If we are unable to obtain additional financing, we will be required to cease our operations. To date, we have not
considered this alternative, nor do we view it as a likely occurrence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Currency Exchange Rate Risk </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="-keep: true">We
                                            ceased all operations in China in 2022, with the exception of a small administrative office.
                                            We did not during the year ended December 31, 2024 and three months ended March 31, 2025,
                                            and do not expect in the foreseeable future, to generate any additional revenue from PRC
                                            operations. Thus, exchange rate fluctuations between the RMB and the U.S. dollar do not,
                                            and are not expected to, have a material effect on us. For the years ended December 31, 2024
                                            and 2023, we had an unrealized foreign currency translation loss of approximately $300 and
                                            $18,600, respectively, because of changes in the exchange rate. For the three months ended
                                            March 31, 2025 and 2024, we had an unrealized foreign currency translation gain of approximately
                                            $300 and an unrealized foreign currency translation loss of approximately $3,000, respectively,
                                            because of changes in the exchange rate.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Inflation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="-keep: true">The
effect of inflation on our revenues and operating results was not significant for the years ended December 31, 2024 and 2023 and the
three months ended March 31, 2025 and 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&#160;</p><div>


</div><!-- Field: Page; Sequence: 230 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->209<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_113"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CERTAIN AVALON RELATIONSHIPS
AND RELATED PARTY TRANSACTIONS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other than compensation arrangements
for our named executive officers and directors, we describe below each transaction or series of similar transactions, since January 1,
2023 to which we were a party or will be a party, in which:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the amounts involved exceeded or will exceed the lesser of (i) $120,000 or (ii) 1% of the average total assets of the Company at year end for the last two completed fiscal years; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any of our directors, executive officers, promoters or holders of more than 5% of our capital stock, or any member of the immediate family of the foregoing persons, had or will have a direct or indirect material interest.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Compensation arrangements
for our named executive officers and directors are described in the section entitled &#8220;Information About Avalon - Avalon&#8217;s
Executive Compensation.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Rental
Revenue from Related Party and Rent Receivable - Related Party</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company leases space of
its commercial real property located in New Jersey to D.P. Capital Investments LLC, which is controlled by Wenzhao Lu, the Company&#8217;s
chairman of the Board of Directors. The term of the related party lease agreement is five years commencing on May 1, 2021 and will expire
on April 30, 2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="background-color: white">For
both the years ended December 31, 2024 and 2023, the related party rental revenue amounted to $50,400 and has been included in real property
rental revenue on the accompanying consolidated statements of operations and comprehensive loss. At December 31, 2024 and 2023, the related
party rent receivable totaled $0 and $124,500, respectively, which has been included in rent receivable on the accompanying consolidated
balance sheets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Services
Provided by Related Party</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">From time to time, Wilbert
Tauzin, a director of the Company, and his son provide consulting services to the Company. As compensation for professional services provided,
the Company recognized consulting expenses of $63,644 and $86,528 for the years ended December 31, 2024 and 2023, respectively, which
have been included in professional fees on the accompanying consolidated statements of operations and comprehensive loss. As of both December
31, 2024 and 2023, the accrued and unpaid services charge related to this director&#8217;s son amounted to $15,000, which have been included
in accrued professional fees on the accompanying consolidated balance sheets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Accrued Liabilities and Other Payables
- Related Parties</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b style="-keep: true">&#160;</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">In 2017, the Company
acquired Beijing Genexosome for a cash payment of $450,000. As of both December 31, 2024 and 2023, the unpaid acquisition consideration
of $100,000, was payable to Dr. Yu Zhou, former director and former co-chief executive officer and 40% owner of Genexosome, and has been
included in accrued liabilities and other payables - related parties on the accompanying consolidated balance sheets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">From time to time, Lab
Services MSO paid shared expense on behalf of the Company. In addition, Lab Services MSO made a payment of $566,667 for equity method
investment payable on behalf of the Company in the year ended December 31, 2024. As of December 31, 2024 and 2023, the balance due to
Lab Services MSO amounted to $632,916 and $72,746, respectively, which has been included in accrued liabilities and other payables -
related parties on the accompanying consolidated balance sheets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">As of December 31, 2024
and 2023, $0 and $33,712 of accrued and unpaid interest related to borrowings from Wenzhao Lu, the Company&#8217;s chairman of the Board
of Directors, respectively, have been included in accrued liabilities and other payables - related parties on the accompanying consolidated
balance sheets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 231 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->210<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Borrowings from Related Party</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Line of Credit </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On August 29, 2019, the Company
entered into a Line of Credit Agreement (the &#8220;Line of Credit Agreement&#8221;) providing the Company with a $20 million line of
credit (the &#8220;Line of Credit&#8221;) from Mr. Lu, the Company&#8217;s chairman of the Board of Directors. The Line of Credit allowed
the Company to request loans thereunder and to use the proceeds of such loans for working capital and operating expense purposes until
the facility matured on December 31, 2024. The loans are unsecured and are not convertible into equity of the Company. Loans drawn under
the Line of Credit bear interest at an annual rate of 5% and each individual loan is payable three years from the date of issuance. The
Company has a right to draw down on the line of credit and not at the discretion of Mr. Lu, the related party lender. The Company may,
at its option, prepay any borrowings under the Line of Credit, in whole or in part at any time prior to maturity, without premium or penalty.
The Line of Credit Agreement includes customary events of default. If any such event of default occurs, Mr. Lu may declare all outstanding
loans under the Line of Credit to be due and payable immediately.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the years ended December
31, 2024 and 2023, activity recorded for the Line of Credit is summarized in the following table:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Outstanding principal under the Line of Credit at January 1, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: justify; padding-bottom: 1.5pt">Draw down from Line of Credit</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">850,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Outstanding principal under the Line of Credit at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">850,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Repayment of Line of Credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(400,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Reclassification of Line of Credit to advance from related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(450,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding principal under the Line of Credit at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">For the years ended December
31, 2024 and 2023, the interest expense related to related party borrowing amounted to $42,445 and $33,712, respectively, and has been
reflected as interest expense - related party on the accompanying consolidated statements of operations and comprehensive loss.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">As of December 31, 2024
and 2023, the related accrued and unpaid interest for Line of Credit was $0 and $33,712, respectively, and has been included in accrued
liabilities and other payables - related parties on the accompanying consolidated balance sheets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Membership Interest Purchase Agreement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">On
                                            November 17, 2023, the Company entered into a Membership Interest Purchase Agreement (the
                                            &#8220;Purchase Agreement&#8221;) with Mr. Lu, the Company&#8217;s chairman of the Board
                                            of Directors, pursuant to which (i) Mr. Lu will acquire from the Company 30% of the total
                                            outstanding membership interests of Avalon RT 9, a wholly owned subsidiary of the Company,
                                            for a cash purchase price of $3,000,000 (the &#8220;Acquisition&#8221;), and (ii) for a period
                                            of twelve months following the closing of the Acquisition, Mr. Lu shall have the option to
                                            purchase from the Company up to an additional 70% of the outstanding membership interests
                                            of Avalon RT 9 for a purchase price of up to $7,000,000 (the &#8220;Option&#8221;), subject
                                            to the terms and conditions of a membership interest purchase agreement to be negotiated
                                            and entered into between the Purchaser and the Company at such time that the Purchaser desires
                                            to exercise the Option. The Company received $3,108,106 and $485,714 from Wenzhao Lu as of
                                            December 31, 2024 and 2023, respectively, which was recorded as advance from pending sale
                                            of noncontrolling interest - related party on the accompanying consolidated balance sheets.
                                            The Acquisition is expected to be closed in the fourth quarter of 2025.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Policies and Procedures for Related Party Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Avalon Board has adopted
a policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class of
our common stock, any members of the immediate family of any of the foregoing persons and any firms, corporations or other entities in
which any of the foregoing persons is employed or is a partner or principal or in a similar position or in which such person has a 5%
or greater beneficial ownership interest, are not permitted to enter into a transaction with us without the prior consent of our Board
acting through the Audit Committee or, in certain circumstances, the Chairman of the Audit Committee. Any request for us to enter into
a transaction with a related party, in which the amount involved exceeds $100,000 and such related party would have a direct or indirect
interest must first be presented to our Audit Committee, or in certain circumstances the Chairman of our Audit Committee, for review,
consideration and approval. In approving or rejecting any such proposal, our Audit Committee, or the Chairman of our Audit Committee,
is to consider the material facts of the transaction, including, but not limited to, whether the transaction is on terms no less favorable
than terms generally available to an unaffiliated third party under the same or similar circumstances, the extent of the benefits to us,
the availability of other sources of comparable products or services and the extent of the related party&#8217;s interest in the transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 232 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->211<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_114"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">MANAGEMENT AFTER THE MERGER</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><div><a id="a_115"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="-keep: true">E<b>xecutive Officers,
Directors and Key Employees of the Combined Company Following the Merger</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Pursuant to the Merger
Agreement, immediately after the Effective Time of the Merger, the Combined Company&#8217;s board of directors will be fixed at seven
(7) members, five (5) of whom will be directors designated by YOOV and is expected to include Wong Ling Yan Philip, Devere Andrew Bryan,
Lam Heung Yeung Herman, Lourdes Felix and Kirsty Vanora Godfrey-Billy. The remaining directors will be designated by Avalon, and are
expected to be Wenzhao Lu and Steve A. Sanders, each of whom are current directors of Avalon.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Following the Merger,
the management team of the Combined Company is expected to be led by Wong Ling Yan Philip, as President and Chief Executive Officer of
YOOV, Luisa Ingargiola, Chief Financial Officer of Avalon and Wong Ho Chi Mark, as Chief Technology Officer of YOOV. Wong Ling Yan Philip,
Luisa Ingargiola and Wong Ho Chi Mark will enter into employment agreements with the Combined Company, as described below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">The following table lists
the names and positions of all individuals, together with their respective ages as of March 31, 2025, who are expected to serve as executive
officers and directors of the Combined Company upon the completion of the Merger:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 53%"><span style="font-size: 10pt"><b>Position(s)</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Wong Ling Yan Philip(1)</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">44</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Chief Executive Officer, President and Chairman of the Board</span></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top"><span style="font-size: 10pt">Luisa Ingargiola</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">57</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="background-color: #CCECFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Wong Ho Chi Mark</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">32</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Chief Technology Officer</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Devere Andrew Bryan(1)</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">49</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="background-color: #CCECFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Lam Heung Yeung Herman(1)</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">59</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Director</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Lourdes Felix(1)</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">57</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="background-color: #CCECFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Kirsty Vanora Godfrey-Billy(1)</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">53</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Director</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Wenzhao Lu(2)</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">67</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="background-color: #CCECFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">Steven A. Sanders(2)</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">79</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Director</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">YOOV designee</td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Avalon designee</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Each
                                            executive officer will serve at the discretion of the Combined Company&#8217;s board of directors
                                            and holds office until his or her successor is duly elected and qualified or until his or
                                            her earlier resignation or removal. There are no family relationships among any of the proposed
                                            directors or executive officers of the Combined Company. All of Avalon&#8217;s current directors,
                                            other than Wenzhao Lu, Lourdes Felix and Steven A. Sanders, and all of Avalon&#8217;s current
                                            officers, except for Ms. Ingargiola, are expected to resign from their positions as directors
                                            or executive officers, as applicable, of Avalon, effective as of the Effective Time.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_116"></a></div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Executive Officers</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Wong Ling Yan Philip, Chief Executive Officer, President and Chairman
of the Board</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Wong Ling Yan Philip,
age 44, has served as the Chairman of the Board and Chief Executive Officer of YOOV since 2016. Mr. Wong is also the Co-founder of YOOV.
Mr. Wong has deep insights into Internet Technology development and brings over 10 years of hands-on industry expertise. He began his
career in the corporate and investment banking division with Wachovia Bank and Wells Fargo Bank. In 2012, Mr. Wong transitioned from
the finance industry to pursue an entrepreneurial venture in the education sector. From 2012 to 2015, Mr. Wong owned 3 education centers
in Hong Kong and successfully sold them at nearly USD2 million. Mr. Wong holds a Master&#8217;s in Business Administration from the Chinese
University of Hong Kong and is a registered surveyor.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Mr. Wong and the Combined
Company expect to enter into an executive retention agreement (the &#8220;Wong Combined Company Executive Retention Agreement&#8221;),
effective upon and subject to the Closing, as described below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 233 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->212<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Luisa Ingargiola, Chief Financial Officer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Luisa Ingargiola, age 57,
has served as Avalon&#8217;s Chief Financial Officer since February 21, 2017. Ms. Ingargiola has significant experience serving as Chief
Financial Officer or Audit Chair for multiple Nasdaq and New York Stock Exchange companies. She currently serves as Director and Audit
Chair for several public companies, including ElectraMeccanica (Nasdaq:SOLO), Dragonfly Energy (Nasdaq: DFLI) and Vision Marine (Nasdaq:
VMAR). From 2007 through 2016, Ms. Ingargiola served as the Chief Financial Officer and then a member of the board of directors at MagneGas
Corporation (Nasdaq: MNGA). Prior to 2007, Ms. Ingargiola held various roles as Budget Director and Investment Analyst in several private
companies. Ms. Ingargiola graduated in 1989 from Boston University with a Bachelor&#8217;s degree in Business Administration and a concentration
in Finance. In 1996, she received her MBA in Health Administration from the University of South Florida. Ms. Ingargiola is qualified to
serve as a Chief Financial Officer because of her extensive knowledge regarding corporate governance, regulatory requirements, executive
leadership and financing and M&amp;A transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Ms.
                                            Ingargiola and the Combined Company expect to enter into the Ingargiola Combined Company
                                            Executive Retention Agreement, effective upon and subject to the Closing, as described below,
                                            which will supersede and replace the Ingargiola Executive Retention Agreement described in
                                            the section titled &#8220;AVALON EXECUTIVE COMPENSATION.&#8221; For a more detailed discussion
                                            of the compensation payable to Ms. Ingargiola in connection with the Merger pursuant to the
                                            Combined Company Executive Retention Agreement, please see the section entitled &#8220;BACKGROUND
                                            OF THE MERGER - Interests of Avalon&#8217;s Directors and Officer in the Merger - <i>Golden
                                            Parachute Compensation.&#8221;</i></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Wong Ho Chi Mark, Chief Technology Officer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Wong Ho Chi Mark, age
32, has served as YOOV's Chief Technology Officer since 2021 and is a Co-Founder of YOOV. Mr. Mark Wong has over 15 years of experience
developing enterprise systems for large corporations across the APAC region, leading distributed engineering teams throughout the Asia-Pacific
region.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">From 2011 to 2012, Mr.
Mark Wong was a Web Developer at Mr. Web Limited. From 2012 to 2016, Mr. Mark Wong was a Freelance Developer, providing web development
services and system solutions to various clients. From 2016 to Present, Mr. Mark Wong has served as Co-founder of YOOV and Chief Technology
Officer since 2021. As Co-founder and Chief Technology Officer of YOOV, Mr. Mark Wong focuses on product strategy and solving complex
technical challenges in SaaS platforms to optimize business workflows. Mark was selected to serve as Chief Technology Officer because
of his expertise in distributed systems, cloud infrastructure, and enterprise-grade solutions. Mr. Mark Wong holds a BSc in Information
Systems and Web Technologies from the School of Professional Education and Executive Development, The Hong Kong Polytechnic University
(currently pursuing), and completed two years of Computer Science and Information Engineering at National Formosa University, Taiwan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Mr. Mark Wong and the
Combined Company expect to enter into an executive retention agreement (the &#8220;Mark Wong Combined Company Executive Retention Agreement&#8221;),
effective upon and subject to the Closing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Key Employees</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Leung Hang Kin Karl, Product Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Mr. Leung is a seasoned
product leader with a strong background in product development, system architecture, and data-driven growth strategies. Formerly serving
as Senior Growth Manager at ZA Bank, he led cross-functional teams of over 80 members, driving large-scale digital transformation initiatives.
Mr. Leung holds a Bachelor&#8217;s degree in Electrical Engineering and brings a unique combination of technical insight and strategic
vision to the role.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Au Kai Yuen, Senior System Analyst </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Mr. Au has 20 years of
proven experience in leading technical innovation and product development initiatives, specializing in system design and software development.
He directs the software development cycle and focuses on YOOV&#8217;s AI product development. His extensive expertise positions him to
drive breakthrough solutions and strategic R&amp;D initiatives. Xavier holds a Bachelor&#8217;s degree in Science with a focus on Physics
and Mathematics.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Executive Employment Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="-keep: true">Following the Closing, the Combined Company
and each of the executive officers listed above will enter into employment agreements, effective upon and subject to the Closing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-keep: true">Ingargiola Combined Company Executive Retention Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-keep: true">&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Effective upon and subject
to the Closing, Ms. Ingargiola will serve as the Chief Financial Officer of the Combined Company pursuant to the Ingargiola Combined
Company Executive Retention Agreement, in exchange for an annual salary of $350,000, subject to periodic review and modification by the
Combined Company Board (as defined below) or Compensation Committee of the Combined Company Board. Ms. Ingargiola will be entitled to
performance bonuses, as determined by the Combined Company Board or Compensation Committee of the Combined Company Board, and a one-time
lump sum payment of $350,000, payable on or within ten (10) says following the Closing. In addition, Ms. Ingargiola may be eligible for
equity incentive grants, subject to her continued employment and satisfactory job performance, which may be made from time to time, by
the Combined Company Board or Compensation Committee of the Combined Company Board. Within thirty (30) days following the effective date
of the Ingargiola Combined Company Executive Retention Agreement, Ms. Ingargiola shall be granted an option to purchase 600,000 shares
of the Combined Company&#8217;s common stock, vesting over three (3) years, one third on the first anniversary of the effective date
of the Ingargiola Combined Company Executive Retention Agreement and the balance in equal quarterly installments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 234 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->213<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The employment of Ms.
Ingargiola is at will and may be terminated at any time, with or without formal cause. Pursuant to the terms of Ingargiola Combined Company
Executive Retention Agreement, the Combined Company has agreed to provide specified severance and bonus amounts and to accelerate the
vesting on her equity awards upon termination upon a change of control or an involuntary termination, as each term is defined in the
Ingargiola Combined Company Executive Retention Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">In the event of an involuntary
termination or termination upon a change of control, Ms. Ingargiola is entitled to receive an amount equal to twelve (12) months of her
base salary and 100% of (a) any actual bonus amount earned with respect to a previous year to the extent that all the conditions for
payment of such bonus have been satisfied and (b) the target bonus then in effect for Ms. Ingargiola for the year in which such termination
occurs, such payment to be prorated to reflect the number of days Ms. Ingargiola remained in the employ of the Combined Company. In addition,
the vesting and exercisability of all then outstanding stock options and shares of restricted stock (or any other equity award) granted
to Ms. Ingargiola shall be accelerated as to 100% of the shares subject to any such equity awards granted to Ms. Ingargiola and the applicable
exercise period of Ms. Ingargiola&#8217;s stock options shall be extended so as to expire on the last day of the term applicable to such
stock option, as measured from the date of the involuntary termination or termination upon a change of control.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-keep: true">Wong Combined Company Executive Retention Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-keep: true">&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Effective upon and subject
to the Closing, Mr. Wong will serve as the Chief Executive Officer of the Combined Company pursuant to the Wong Combined Company Executive
Retention Agreement, in exchange for an annual salary of $360,000, subject to periodic review and modification by the Combined Company
Board or Compensation Committee of the Combined Company Board. Mr. Wong will be entitled to performance bonuses, as determined by the
Combined Company Board or Compensation Committee of the Combined Company Board, and a one-time lump sum payment of $150,000, payable
on or within ten (10) says following the Closing. In addition, Mr. Wong may be eligible for equity incentive grants, subject to his continued
employment and satisfactory job performance, which may be made from time to time, by the Combined Company Board or Compensation Committee
of the Combined Company Board. Within thirty (30) days following the effective date of the Wong Combined Company Executive Retention
Agreement, Mr. Wong shall be granted an option to purchase 1,000,000 shares of the Combined Company&#8217;s common stock, vesting over
three (3) years, one third on the first anniversary of the effective date of the Wong Combined Company Executive Retention Agreement
and the balance in equal quarterly installments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The employment of Mr.
Wong is at will and may be terminated at any time, with or without formal cause. Pursuant to the terms of Wong Combined Company Executive
Retention Agreement, the Combined Company has agreed to provide specified severance and bonus amounts and to accelerate the vesting on
his equity awards upon termination upon a change of control or an involuntary termination, as each term is defined in the Wong Combined
Company Executive Retention Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">In the event of involuntary
termination or termination upon a change of control, Mr. Wong is entitled to receive an amount equal to twenty-four (24) months of his
base salary and 100% of (a) any actual bonus amount earned with respect to a previous year to the extent that all the conditions for
payment of such bonus have been satisfied and (b) the target bonus then in effect for Mr. Wong for the year in which such termination
occurs, such payment to be prorated to reflect the number of days Mr. Wong remained in the employ of the Combined Company. In addition,
the vesting and exercisability of all then outstanding stock options and shares of restricted stock (or any other equity award) granted
to Mr. Wong shall be accelerated as to 100% of the shares subject to any such equity awards granted to Mr. Wong and the applicable exercise
period of Mr. Wong&#8217;s stock options shall be extended so as to expire on the last day of the term applicable to such stock option,
as measured from the date of the involuntary termination or termination upon a change of control.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-keep: true">&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-keep: true">Mark Wong Combined Company Executive Retention Agreement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Effective upon and subject
to the Closing, Mr. Mark Wong will serve as the Chief Technology Officer of the Combined Company pursuant to the Mark Wong Combined Company
Executive Retention Agreement, in exchange for an annual salary of $150,000, subject to periodic review and modification by the Combined
Company Board or Compensation Committee of the Combined Company Board. Mr. Mark Wong will be entitled to performance bonuses, as determined
by the Combined Company Board or Compensation Committee of the Combined Company Board, and a one-time lump sum payment of $150,000, payable
on or within ten (10) says following the Closing. In addition, Mr. Mark Wong may be eligible for equity incentive grants, subject to
his continued employment and satisfactory job performance, which may be made from time to time, by the Combined Company Board or Compensation
Committee of the Combined Company Board. Within thirty (30) days following the effective date of the Mark Wong Combined Company Executive
Retention Agreement, Mr. Mark Wong shall be granted an option to purchase 1,000,000 shares of the Combined Company&#8217;s common stock,
vesting over three (3) years, one third on the first anniversary of the effective date of the Mark Wong Combined Company Executive Retention
Agreement and the balance in equal quarterly installments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The employment of Mr.
Mark Wong is at will and may be terminated at any time, with or without formal cause. Pursuant to the terms of Mark Wong Combined Company
Executive Retention Agreement, the Combined Company has agreed to provide specified severance and bonus amounts and to accelerate the
vesting on his equity awards upon termination upon a change of control or an involuntary termination, as each term is defined in the
Mark Wong Combined Company Executive Retention Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">In the event of involuntary
termination or termination upon a change of control, Mr. Mark Wong is entitled to receive an amount equal to twenty-four (24) months
of his base salary and 100% of (a) any actual bonus amount earned with respect to a previous year to the extent that all the conditions
for payment of such bonus have been satisfied and (b) the target bonus then in effect for Mr. Mark Wong for the year in which such termination
occurs, such payment to be prorated to reflect the number of days Mr. Mark Wong remained in the employ of the Combined Company. In addition,
the vesting and exercisability of all then outstanding stock options and shares of restricted stock (or any other equity award) granted
to Mr. Mark Wong shall be accelerated as to 100% of the shares subject to any such equity awards granted to Mr. Mark Wong and the applicable
exercise period of Mr. Mark Wong&#8217;s stock options shall be extended so as to expire on the last day of the term applicable to such
stock option, as measured from the date of the involuntary termination or termination upon a change of control.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 235 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->214<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_117"></a></div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Non-Employee Directors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Devere Andrew Bryan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Devere Andrew Bryan, age 49,
combines over 25 years of experience in telecommunications, fintech, and IT sectors. With strengths in marketing expansion and corporate
development, Mr. Bryan has held key positions in multiple international companies including Chief Operating Officer, Regional General
Manager, and Executive Director. He is currently a member of the Executive leadership team and the Group General Manager at First Digital
Trust, which issues the third largest USD-backed stablecoin (FDUSD). He is also the Chief Revenue Officer at Payment Asia. Previously,
Devere joined IDT Corporation in 1999 and then served as the Regional Director since 2004 in IDT Global (NYSE:IDT) to lead the APAC retail
expansion. In 2015, he served as the Chief Operating Officer for Bux Global. From 2018 to 2022, he was the Regional General Manager of
Partnerships at Xero (ASX:XRO). Mr. Bryan holds an MS in Global Management and is a member and alumnus of the Hong Kong FinTech Association,
Monetary Authority of Singapore Payments Council, and a number of Artistic and Corporate Executive networks. Mr. Bryan was selected to
serve as a director because of his extensive operational knowledge of, and executive level management experience in, the telecommunications,
fintech, and IT sectors industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Lam Heung Yeung Herman</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Lam Heung Yeung Herman, age
59, has over 20 years of experience in the technology and IT sectors, held various senior management positions, including CEO, Managing
Director and General Manager, across multiple international organizations including Microsoft and Cisco. Mr. Lam is currently an Independent
Non-Executive Director of Principal Trust Company (Asia) Limited, a financial services trustee company. From 2018 to 2024, he has served
as Managing Director for Cisco Systems Hong Kong Limited and led the Cisco Greater China Partner Organization since 2019. From 2010 to
2018, he was the CEO of Hong Kong Cyberport Management Company Limited, a government-supported innovation and technology hub. From 1996
to 2009, Herman joined Microsoft Hong Kong Limited and took up key roles as Senior Director, as well as General Manager of Hong Kong and
Macau. Mr. Lam holds a Bachelor&#8217;s degree and an MBA from the University of North Texas. Mr. Lam was selected to serve as a director
because of his experience working in senior management positions of companies in the technology and IT sectors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b style="-keep: true">Lourdes Felix</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Lourdes Felix has served
as a member of the Board since January 9, 2023. Ms. Felix is an entrepreneur and corporate finance executive with 30 years of combined
experience in capital markets, public accounting and in the private sector. Since April 2024, Ms. Felix has served as a director and
audit committee chair of La Rosa Holdings Corp (Nasdaq: LRHC). She also presently serves as Chief Executive Officer, Chief Financial
Officer, and a member of the board of directors of BioCorRx Inc., a company focused on addiction treatment solutions and related disorders.
She has been with BioCorRx Inc. since October 2012. Ms. Felix is one of the founders and President of BioCorRx Pharmaceuticals Inc.,
a majority owned subsidiary of BioCorRx Inc. Prior to joining BioCorRx Inc., her experience was in the private sector and public accounting.
Ms. Felix has expertise in finance, accounting, company-wide operations, budgeting, and internal control principles, including U.S. GAAP,
SEC, and SOX compliance. She has thorough knowledge of federal and state regulations and has successfully managed and produced SEC regulatory
filings. She also has extensive experience in developing and managing financial operations. Ms. Felix holds a Bachelor of Science degree
in Accounting from the University of Phoenix. She continued her education and is an MBA candidate at D&#8217;Amore-McKim School of Business,
Northeastern University. Ms. Felix was selected to serve as a director because of her extensive public company and executive level management
experience.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 236 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->215<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Kirsty Vanora Godfrey-Billy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Kirsty Vanora Godfrey-Billy,
age 53, has over 25 years of global experience in the finance and technology sectors across New Zealand, Australia and the UK at companies
including PwC, BBC Technology, Jade and Siemens, holding positions including Chief Financial Officer, Commercial Manager, and board member.
From 2016 through 2025, Ms. Godfrey-Billy served as the Chief Financial Officer for Xero (UK) Limited, a cloud accounting software company.
From 2011 to 2016, she was a Partner of PwC New Zealand, a professional services firm that focused on business advisory and accounting
services. Ms. Godfrey-Billy is also currently a director of NZ Hi-Tech Trust, a non-profit organization advancing New Zealand&#8217;s technology
sector. She holds an undergraduate degree from Lincoln University (NZ) and is a Fellow Chartered Accountant (FCA) from Chartered Accountants
Australia and New Zealand. Ms. Godfrey-Billy was selected to serve as a director because of her expansive finance experience in the technology
sector.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Wenzhao Lu</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Mr. Wenzhao Lu has served
as the Chairman of the Avalon Board since October 10, 2016. He is a seasoned healthcare entrepreneur with extensive operational knowledge
and experience in the U.S. and Asia. He served as Chairman of the board of directors of the Daopei Medical Group (&#8220;DPMG&#8221;),
from 2010 to December 2021. Under his leadership, DPMG operated three top-ranked private hospitals (located in Beijing and Hebei), specialty
hematology laboratories, and a hematology research institute, with more than 100 partnering and collaborating hospitals in China. DPMG
was founded by Professor Daopei Lu, a renowned hematologist pioneering in hematopoietic stem cell transplant and a member of the Academy
of Engineering in China. Mr. Lu received a Bachelor of Arts from Temple University Tyler School of Arts in 1988 and subsequently worked
as senior Art Director at Ogilvy &amp; Mather Advertising Company. Prior to joining DPMG, in 2009, Mr. Lu served as Chief Operating Officer
of BioTime Asia Limited, a subsidiary of BioTime, Inc. (NYSE American: BTX). Mr. Lu was selected as a director because of his extensive
public company experience.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Steven A. Sanders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Steven A. Sanders has served
as a member of the Avalon Board since July 30, 2018. Since January 2017, Mr. Sanders has been Of Counsel to the law firm of Ortoli Rosenstadt
LLP. From July 2007 until January 2017, Mr. Sanders was a Senior Partner at Ortoli Rosenstadt LLP. From January 1, 2004 until June 30,
2007, he was Of Counsel to the law firm of Rubin, Bailin, Ortoli, LLP. From January 1, 2001 to December 31, 2003, he was Counsel at the
law firm of Spitzer &amp; Feldman PC. Mr. Sanders also serves as a member of the board of directors of Helijet International, Inc. and
served as a member of the board of directors of Electrameccanica Vehicles Corp. (Nasdaq: SOLO). Additionally, since October 2013, he has
been a member of the board of directors at the American Academy of Dramatic Arts, and, since February 2015, has been a member of the board
of directors of the Bay Street Theater. Mr. Sanders received his JD from Cornell University and his BBA from The City College of New York.
Mr. Sanders was selected as a director because of his extensive public company experience.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_118"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Board Composition</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The board of directors of
the Combined Company will consist of seven (7) members upon the Closing (the &#8220;Combined Company Board&#8221;). The Combined Company
Charter provides that directors are to be elected at each annual meeting of stockholders to hold office until the expiration of the term
for which elected and until such director&#8217;s successor is elected and qualified or until such director&#8217;s earlier death, resignation,
or removal. Following the Closing, Wong Ling Yan Philip is expected to serve as Chair of the Combined Company Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_119"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Director Independence</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based on information provided
by each director concerning their background, employment and affiliations, upon the consummation of the Merger, Avalon and YOOV anticipate
that each of the directors on the Combined Company Board, other than [&#160;&#160; ], will qualify as independent directors as defined under the rules
of the SEC and Nasdaq listing rules relating to director independence requirements. In addition, the Combined Company will be subject
to the rules of the SEC and Nasdaq relating to the membership, qualifications, and operations of certain committees of the Combined Company
Board, as discussed below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 237 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->216<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_120"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Committees of the Board of Directors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following the Closing, the
Combined Company Board will establish an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee,
each of which will operate pursuant to a Charter adopted by the Combined Company Board, which will be available on the Combined Company&#8217;s
website, [ ]. The Combined Company Board may also establish other committees from time to time to assist the Combined Company and the
Combined Company Board. Each of the Audit Committee, Compensation Committee and the Nominating and Corporate Governance Committee is expected
to have the responsibilities described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_121"></a></div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Audit Committee</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Audit Committee will
oversee and monitor the Combined Company&#8217;s financial reporting process and internal control system, review and evaluate the audit
performed by our registered independent public accountants and report to the Combined Company Board any substantive issues found during
the audit. The Audit Committee will be directly responsible for the appointment, compensation and oversight of the work of the Combined
Company&#8217;s registered independent public accountants. The Audit Committee will review and approve all transactions with affiliated
parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following the Merger, the
Audit Committee will consist of [ ], [ ], and [ ], who will serve as the chair of the committee. In addition, the Combined Company Board
is expected to determine that [ ] is an &#8220;audit committee financial expert&#8221; as defined under the rules of the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To qualify as independent
to serve on the Combined Company&#8217;s Audit Committee, listing standards of Nasdaq and the applicable SEC rules require that a director
not accept any consulting, advisory or other compensatory fee from the Combined Company, other than for service as a director, or be an
affiliated person of the Combined Company. Avalon and YOOV believe that, following the completion of the Merger, the composition of the
Audit Committee will comply with the applicable requirements of the rules and regulations of Nasdaq and the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_122"></a></div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Compensation Committee</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Compensation Committee
will assist the Combined Company Board in fulfilling its oversight responsibilities relating to (i) corporate governance practices and
policies and (ii) compensation matters, including compensation of the directors and senior management and the administration of compensation
plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following the Merger, the
Combined Company&#8217;s Compensation Committee will consist of [ ], [ ], and [ ], who will serve as the chair of the committee. Each
member of the Compensation Committee will be a &#8220;non-employee&#8221; director within the meaning of Rule 16b-3 of the rules promulgated
under the Exchange Act and independent within the meaning of the independent director guidelines of Nasdaq. Avalon and YOOV believe that,
following the completion of the Merger, the composition of the Compensation Committee will comply with the applicable requirements of
the rules and regulations of Nasdaq and the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><div><a id="a_123"></a></div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Nominating and Corporate Governance Committee</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Nominating and Corporate
Governance Committee will assess potential candidates to fill perceived needs of the Combined Company Board for required skills, expertise,
independence and other factors. A director candidate nominated by stockholders will be considered in the same manner as a nominee recommended
by a board member, management or other sources. The Nominating and Corporate Governance Committee will have discretion to decide which
individuals to recommend for nomination as directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 238 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->217<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Following
                                            the Merger, the Nominating and Corporate Governance Committee will consist of [&#160;&#160;
                                            ], [ &#160;&#160;], and [ &#160;&#160;], who will serve as the chair of the committee.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon and YOOV believe that,
after the completion of the Merger, the composition of the Nominating and Corporate Governance Committee will meet the requirements for
independence under, and the functioning of such Nominating and Corporate Governance Committee will comply with, any applicable requirements
of the rules and regulations of Nasdaq and the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_124"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Compensation Committee Interlocks and Insider
Participation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each member of the Compensation
Committee following the closing of the Merger will be a &#8220;non-employee&#8221; director within the meaning of Rule 16b-3 of the rules
promulgated under the Exchange Act and independent within the meaning of the independent director guidelines of Nasdaq. None of the proposed
Combined Company&#8217;s executive officers serve as a member of the board of directors or compensation committee of any entity that has
one or more executive officers who is proposed to serve on the Combined Company Board or Compensation Committee following the completion
of the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_125"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Director Compensation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Prior to the Merger, YOOV
did not have a formal policy to provide any cash or equity compensation to its non-employee directors for their service on its board of
directors or committees of its board of directors. YOOV&#8217;s non-employee director compensation is described under &#8220;<i>YOOV&#8217;s
Director Compensation</i>&#8221; in this proxy statement/prospectus. The determinations with respect to director compensation after the
Closing have not yet been made, provided it is expected that the Combined Company Board will, promptly following the completion of the
Merger, adopt a non-employee director compensation policy designed to enable the Combined Company to attract and retain, on a long-term
basis, highly qualified non-employee directors and align its directors&#8217; interests with those of its stockholders. It is anticipated
that each director who is not an employee will be paid cash compensation in an amount to be determined. In addition, each non-employee
elected or appointed to the Combined Company Board is expected be granted an initial stock option award and an annual stock option award,
the amount and terms of which have not yet been determined.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Combined Company will
also reimburse its non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with attending the board
of director and committee meetings. It is anticipated that employee directors will not receive additional compensation for their services
as directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_126"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Limitation on Liability and Indemnification
of Directors and Officers</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Combined Company Bylaws
will provide that the Combined Company will indemnify the Combined Company&#8217;s directors and officers, and may indemnify other employees
and agents under certain circumstances. Any indemnified person is also entitled, subject to certain limitations, to direct payment or
reimbursement of costs, charges and expenses incurred by such person in an action or proceeding to which such director, officer, employee
or agent is or are made a party by reason of his or her being or having been a director, officer, employee or agent of the Combined Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 239 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->218<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, the Combined
Company expects to enter into separate indemnification agreements with the Combined Company&#8217;s directors and executive officers.
These agreements, subject to limitations contained therein, will obligate the Combined Company to indemnify the directors and executive
officers to the fullest extent permitted by applicable law, for certain expenses, including attorneys&#8217; fees, judgments, penalties,
fines and settlement amounts actually and reasonably incurred by them in any threatened, pending or completed action, suit, claim, investigation,
inquiry, administrative hearing, arbitration or other proceeding arising out of their services as a director or executive officer. Subject
to certain limitations, the indemnification agreements will provide for the advancement of expenses incurred by the indemnitee, and the
repayment to the Combined Company of the amounts advanced to the extent that it is ultimately determined that the indemnitee is not entitled
to be indemnified by the Combined Company. The indemnification agreements will also create certain rights in favor of the Combined Company,
including the right to assume the defense of claims and to consent to settlements. The indemnification agreements will not exclude any
other rights to indemnification or advancement of expenses to which the indemnitee may be entitled under applicable law, the Combined
Company Charter or the Combined Company Bylaws, any agreement, or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Combined Company will
maintain a directors&#8217; and officers&#8217; insurance policy pursuant to which the Combined Company&#8217;s directors and officers
will be insured against liability for actions taken in their capacities as directors and officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Combined Company pursuant
to the foregoing provisions, the Combined Company been informed that, in the opinion of the SEC, such indemnification is against public
policy as expressed in the Securities Act and is therefore unenforceable. In the event that a claim for indemnification against such liabilities
(other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the Combined Company
in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, the Combined Company will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by the Combined Company is against
public policy as expressed hereby in the Securities Act and the Combined Company will be governed by the final adjudication of such issue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Insider Trading Arrangements and Policies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following the Closing, the
Combined Company will adopt an insider trading policy that governs the purchase, sale, and/or other transactions of our securities by
the Combined Company directors, officers and employees. In addition, with regard to the Combined Company trading in its own securities,
it will be the Combined Company&#8217;s policy to comply with the federal securities laws and the applicable exchange listing requirements
in all respects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_127"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Code of Business Conduct and Ethics for Employees,
Executive Officers, and Directors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following the Closing, the
Combined Company will adopt a Code of Ethics and Business Conduct that applies to all of its executive officers, financial and accounting
officers, its directors, financial managers and all employees. Each of the Avalon Board and the YOOV Board are committed to a high standard
of corporate governance practices and, through their respective oversight roles, encourage and promote a culture of ethical business conduct.
A copy of the Combined Company&#8217;s Code of Ethics and Business Conduct, will be posted under the &#8220;Investors&#8221; tab on Combined
Company&#8217;s website, which is located at [&#160;&#160; ]. The Combined Company intends to disclose any amendments to the Code of Ethics and Business
Conduct, or any waivers of its requirements, on its website to the extent required by applicable rules. Information contained on, or that
can be accessed through, the Combined Company&#8217;s website is not incorporated by reference into this proxy statement/prospectus, and
you should not consider information on the Combined Company&#8217;s website to be part of this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 240 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->219<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_128"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">DESCRIPTION OF AVALON&#8217;S
SECURITIES</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All references in this section
to &#8220;Avalon,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221; mean Avalon and its subsidiaries
unless we state otherwise, or the context otherwise indicates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following summary, which
includes applicable provisions of the DGCL describes material provisions of the capital stock of Avalon GloboCare Corp., a Delaware corporation,
and is intended as a summary only and therefore is not a complete description of our capital stock. The description of our capital stock
and provisions of our amended and restated certificate of incorporation, as amended (the &#8220;Certificate of Incorporation&#8221;),
and our amended and restated bylaws, as amended (the &#8220;Bylaws&#8221;), are summaries and are qualified entirely by reference to the
Certificate of Incorporation and Bylaws, which are included as exhibits to our Annual Report on Form 10-K, of which this Exhibit 4.9 is
a part. You should review these documents for a description of the rights, restrictions and obligations relating to our capital stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>General</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have one class of securities
registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), which is the Avalon Common
Stock, par value $0.0001 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Avalon Charter authorizes
us to issue 110,000,000 shares of capital stock, par value $0.0001 per share, of which (i) 100,000,000 shares are designated as Avalon
Common Stock, and (ii) 10,000,000 shares are designated as preferred stock. Of the 10,000,000 shares of preferred stock, (x) 10,000 shares
have been designated as Series C Preferred Stock, at a stated value equal to $1,000 per share, and (y) 5,000 shares have been designated
as Series D Preferred Stock, at a stated value equal to $1,000 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Common Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Dividends</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Dividends may be declared
and paid or set apart for payment upon the Avalon Common Stock out of any assets or funds of the Company legally available for the payment
of dividends, but only when and as declared by the Avalon Board or any authorized committee of thereof, subject to any preferential dividend
or other rights of the then outstanding preferred stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Voting Rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each share of Avalon Common
Stock entitles the holders of Avalon Common Stock to one vote per share on all matters submitted to a vote by our stockholders, including
the election of directors; provided, that, unless otherwise required by law, holders of Avalon Common Stock are not entitled to vote on
any amendment to the Avalon Charter (or on any amendment to a certificate of designations of any series of undesignated preferred stock)
that relates solely to the terms of one or more outstanding series of our preferred stock, if the holders of such affected series are
entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon pursuant to the
Avalon Charter. Holders of Avalon Common Stock do not have cumulative voting rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Rights Upon Liquidation and Dissolution</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon the voluntary or involuntary
liquidation, dissolution or winding up of the Company, the net assets of the Company shall be distributed pro rata to the holders of Avalon
Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 241 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->220<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Holders Avalon Common Stock
have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of Avalon Common
Stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may
designate and issue in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Preferred Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In accordance with the Avalon
Charter, the Avalon Board is authorized to direct us to issue shares of undesignated preferred stock in one or more series without stockholder
approval. The Avalon Board has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights,
dividend rights, conversion rights, repurchase rights, redemption privileges and liquidation preferences, of each series of preferred
stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The purpose of authorizing
the Avalon Board to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder
vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future
financings and other corporate purposes, could have the effect of making it more difficult for a third-party to acquire, or could discourage
a third-party from seeking to acquire, a majority of our outstanding voting stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Series C Preferred Stock</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
Series C Preferred Stock shall rank (i) senior to the Avalon Common Stock and any other class or series of capital stock of the Company
created hereafter, the terms of which specifically provide that such class or series shall rank junior to the Series C Preferred Stock
and (ii) pari passu with any class or series of capital stock of the Company created hereafter specifically ranking, by its terms, on
par with the Series C Preferred Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Holders
of the Series C Preferred Stock shall be entitled to receive, and the Company shall pay, dividends on shares of Series C Preferred Stock
equal (on an as-if-converted-to-common-stock basis, disregarding for such purpose any conversion limitations hereunder) to and in the
same form as dividends actually paid on shares of the Avalon Common Stock when, as and if such dividends are paid on shares of the Avalon
Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Holders
of the Series C Preferred Stock have no voting power except as otherwise required by the DGCL.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Upon
any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary (a &#8220;Liquidation&#8221;), the holders
of the Series C Preferred Stock shall be entitled to receive out of the assets available for distribution to stockholders, (i) after and
subject to the payment in full of all amounts required to be distributed to the holders of another class or series of stock of the Company
ranking on liquidation prior and in preference to the Series C Preferred Stock, (ii) ratably with any class or series of stock ranking
on liquidation on parity with the Series C Preferred Stock and (iii) in preference and priority to the holders of the shares of the Avalon
Common Stock, an amount equal to 100% of the Stated Value of the Series C Preferred Stock, in proportion to the full and preferential
amount that all shares of the Series C Preferred Stock are entitled to receive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Each
share of Series C Preferred Stock shall be convertible into Avalon Common Stock (the &#8220;Series C Conversion Shares&#8221;) at a conversion
per share equal to $2.41, at the option of the holder, at any time after the later of (i) the date of the shareholder approval of the
issuance of the Series C Conversion Shares pursuant to the rules of the Nasdaq Stock Market and (ii) the one year anniversary of the date
of the first issuance of any shares of the Series C Preferred Stock. In addition, the holder shall not have the right to convert any portion
of the Series C Preferred Stock if, after giving effect to the conversion, such holder (together with its affiliates) would beneficially
own in excess of 19.99% of the number of shares of the Avalon Common Stock outstanding immediately after giving effect to the issuance
of the respective Series C Conversion Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 242 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->221<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Series D Preferred Stock</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
Series D Preferred Stock shall rank (i) senior to the Avalon Common Stock and any other class or series of capital stock of the Company
created hereafter, the terms of which specifically provide that such class or series shall rank junior to the Series D Preferred Stock
and (ii) pari passu with any class or series of capital stock of the Company created hereafter specifically ranking, by its terms, on
par with the Series D Preferred Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Holders
of the Series D Preferred Stock have no voting power except as otherwise required by the DGCL.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Upon
any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary (a &#8220;Liquidation&#8221;), the holders
of the Series D Preferred Stock shall be entitled to receive out of the assets available for distribution to stockholders, (i) after and
subject to the payment in full of all amounts required to be distributed to the holders of another class or series of stock of the Company
ranking on liquidation prior and in preference to the Series D Preferred Stock, (ii) ratably with any class or series of stock ranking
on liquidation on parity with the Series D Preferred Stock and (iii) in preference and priority to the holders of the shares of the Avalon
Common Stock, an amount equal to 100% of the Stated Value of the Series D Preferred Stock, in proportion to the full and preferential
amount that all shares of the Series D Preferred Stock are entitled to receive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each share of Series D Preferred
Stock shall be convertible into Avalon Common Stock (the &#8220;Series D Conversion Shares&#8221;) at a conversion per share equal to
$2.41, at the option of the holder, at any time after the Company has obtained shareholder approval for the issuance of the Series D Conversion
Shares pursuant to the rules of the Nasdaq Stock Market. In addition, the holder shall not have the right to convert any portion of the
Series D Preferred Stock if, after giving effect to the conversion, such holder (together with its affiliates) would beneficially own
in excess of 4.99% of the number of shares of the Avalon Common Stock outstanding immediately after giving effect to the issuance of the
respective Series D Conversion Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Effects of Authorized but Unissued Stock</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our authorized but unissued
shares of Avalon Common Stock and preferred stock are available for future issuance without stockholder approval, subject to any limitations
imposed by the listing requirements of the Nasdaq Stock Market. These additional shares may be used for a variety of corporate finance
transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved Avalon Common Stock and
preferred stock could make it more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer,
merger or otherwise. In addition, if we issue preferred stock in the future, the issuance could adversely affect the voting power of holders
of the Avalon Common Stock and the likelihood that such holders will receive dividend payments and payments upon liquidation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Anti-Takeover Provisions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The DGCL, the Avalon Charter
and the Avalon Bylaws contain provisions that could have the effect of delaying, deferring or discouraging another party from acquiring
control of us. The purpose of these provisions, which are summarized below, is to discourage coercive takeover practices and inadequate
takeover bids. These provisions are also designed to encourage persons seeking to acquire control of the Company to first negotiate with
the Avalon Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Special Meetings.</i> Except
as otherwise required by statute and subject to the rights, if any, of the holders of any series of our undesignated preferred stock,
special meetings of our stockholders may be called only by the Avalon Board acting pursuant to a resolution approved by the affirmative
vote of a majority of the directors then in office. The order of business and all other matters of procedure at any meeting of the stockholders
will be determined by a presiding officer designated by the Avalon Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="background-color: white"><i>Removal
of Directors.</i> The Avalon Charter provides that our directors may be removed only by the affirmative vote of a majority of the voting
power of the outstanding shares of capital stock then entitled to vote at an election of directors. In addition, at least forty-five (45)
days prior to any annual or special meeting of stockholders at which it is proposed that a director be removed from office, written notice
of such proposed removal and the alleged grounds thereof must be sent to the director whose removal will be considered at the meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 243 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->222<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Stockholder Action by Written
Consent.</i> Any action that is permitted to be taken by our stockholders by written consent without a meeting must first satisfy the
requirements and procedures set forth in the Avalon Charter and the Avalon Bylaws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Advance Notice Requirements
for Stockholder Proposals.</i> The Avalon Bylaws establish an advance notice procedure for stockholder proposals to be brought before
an annual meeting of stockholders, including proposed nominations of persons for election to the Avalon Board. Stockholders at an annual
meeting are only able to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the
direction of the Avalon Board or by a stockholder of record on the record date for the meeting who is entitled to vote at the meeting
and who has delivered timely written notice in proper form to our secretary of the stockholder&#8217;s intention to bring such business
before the meeting. These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are
favored by the holders of a majority of our outstanding shares entitled to vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Delaware Business Combination
Statute.</i> We are subject to Section 203 of the DGCL. Subject to certain exceptions, Section 203 of the DGCL prevents a publicly held
Delaware corporation from engaging in a &#8220;business combination&#8221; with any &#8220;interested stockholder&#8221; for three (3)
years following the date that the person became an interested stockholder, unless the interested stockholder attained such status with
the approval of our board of directors or unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221;
includes, among other things, a merger or consolidation involving us and the &#8220;interested stockholder&#8221; and the sale of more
than 10% of our assets. In general, an &#8220;interested stockholder&#8221; is any entity or person beneficially owning 15% or more of
our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Amendment of Certificate
of Incorporation and Bylaws.</i> The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on
any matter is required to amend a corporation&#8217;s certificate of incorporation or by-laws, unless a corporation&#8217;s certificate
of incorporation or by-laws, as the case may be, requires a greater percentage. The Avalon Bylaws may be amended or repealed by the affirmative
vote of a majority vote of our board of directors then in office or the affirmative vote of the holders of at least seventy-five percent
(75%) of the voting power of the outstanding shares entitled to vote on such amendment or repeal, voting as a single class; provided,
however, that if the Avalon Board recommends that stockholders approve such amendment or repeal at such meeting of stockholders, such
amendment or repeal will only require the affirmative vote of the majority of the voting power of the outstanding shares entitled to vote
on such amendment or repeal, voting together as a single class. In addition, the Company reserves the right to amend or repeal the Avalon
Charter in the manner now or hereafter prescribed by statute and by the Avalon Charter, and any rights conferred upon the stockholders
in the Avalon Charter are granted subject to this reservation. Whenever any vote of the holders of our capital stock is required to amend
or repeal any provision of the Avalon Charter, and in addition to any other vote of holders of capital stock that is required by the Avalon
Charter or the Avalon Bylaws, such amendment or repeal will require the affirmative vote of the majority of the voting power of the outstanding
shares of capital stock entitled to vote on such amendment or repeal, and the affirmative vote of the majority of the voting power of
the outstanding shares of each class entitled to vote thereon as a class, at a duly constituted meeting of stockholders called expressly
for such purpose.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Exclusive Forum Selection.</i>
The Avalon Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery in the State
of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any
action asserting a claim of breach of a fiduciary duty owed by any director, officer, stockholder or other employee of the Company to
the Company or the Company&#8217;s stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL or the
Avalon Charter or the Avalon Bylaws, or (iv) any action asserting a claim against the Company governed by the internal affairs doctrine.
Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Company shall be deemed to have
notice of and consented to the provisions of our exclusive forum selection as set forth in the Avalon Bylaws under &#8220;<i>Exclusive
Jurisdiction of Delaware Courts</i>.&#8221; Although the Avalon Bylaws contain the choice of forum provision described above, it is possible
that a court could rule that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Transfer Agent and Registrar</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Vstock Transfer LLC is the
transfer agent and registrar for the Avalon Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Listing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Avalon Common Stock is
listed on the Nasdaq Capital Market under the symbol &#8220;ALBT.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 244 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->223<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_129"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">COMPARISON OF RIGHTS OF
HOLDERS OF AVALON STOCK AND YOOV STOCK</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon is incorporated under
the laws of the state of Delaware and YOOV is incorporated under the laws of the British Virgin Islands. Accordingly, the rights of Avalon
stockholders and YOOV shareholders are governed by the laws of the State of Delaware and the laws of the British Virgin Islands, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Based
                                            on the closing price of Avalon Common Stock on Nasdaq of $3.41 on June 6, 2025, the latest
                                            practicable trading day prior to the date of this proxy statement/prospectus, and the number
                                            of YOOV Outstanding Shares on such date, it is estimated that, following the Closing, the
                                            shareholders of YOOV would own approximately 97.0% to 97.3% of the common stock of the Combined
                                            Company. The rights of the former YOOV shareholders and former Avalon stockholders will thereafter
                                            be governed by the DGCL, the Combined Company Charter and the Combined Company Bylaws.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The summary table below describes
the material differences between the rights of Avalon stockholders and YOOV shareholders before the Merger. Avalon has filed its Governance
Documents with the SEC and will send copies to you without charge, upon your request. YOOV will also send copies of its charter documents
referred to in this proxy statement/prospectus to you upon your request. Please see the section titled &#8220;<i>Where You Can Find More
Information</i>&#8221; in this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; width: 16%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 42%"><span style="font-size: 10pt"><b>Rights of Avalon stockholders</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 39%"><span style="font-size: 10pt"><b>Rights of YOOV shareholders</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Authorized<br/>
</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Capital Stock</b></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The Avalon Charter provides that the authorized capital stock of Avalon consists of 100,000,000 shares of common stock, par value $0.0001 per share and 10,000,000 shares of preferred stock, par value $0.0001. </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The memorandum and articles of association of YOOV provide that YOOV is authorized to issue a maximum of 1,000,000 voting shares and 1,000,000 non-voting shares, par value $0.10 per share. The shares may be divided into such number of classes and series of shares as may be determined from time to time by resolution of directors or resolution of members and currently comprise three classes of voting shares, namely: ordinary shares, series A ordinary shares and redeemable convertible preferred shares. </span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Stockholder<br/>
 Action by Written<br/>
 Consent</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The Avalon Charter provides that any action required or permitted to be taken by the Avalon stockholders may be effected by the consent in writing of the holders of a majority of the total voting power of the outstanding shares of capital stock of Avalon entitled to vote thereon, voting together as a single class in lieu of a duly called annual or special meeting of stockholders.</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The memorandum and articles of association of YOOV provide that an action that may be taken by members at a meeting of members may also be taken by a resolution consented to in writing, without the need for any notice. Such resolution shall be duly consented to in writing by members representing a majority of the votes of shares entitled to vote on the resolution in accordance with the memorandum and articles of association of YOOV.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Number of<br/>
</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Directors</b></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The number of directors shall be fixed solely and exclusively by resolution duly adopted from time to time by the Avalon Board. There are currently seven (7) directors serving on the Avalon Board</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">There is no limit on the number of directors pursuant to the memorandum and articles of association of YOOV. There are currently four (4) directors serving on the board of directors of YOOV.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 245 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->224<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; width: 16%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 42%; text-align: center"><span style="font-size: 10pt"><b>Rights of Avalon stockholders</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 39%; text-align: center"><span style="font-size: 10pt"><b>Rights of YOOV shareholders</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Stockholder<br/>
 Nominations and<br/>
 Proposals</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The Avalon Bylaws provide that, at a meeting of the stockholders, only such nominations of persons for the election of directors and such other business shall be conducted as shall have been properly brought before the meeting. To be properly brought before an annual meeting, nominations or such other business must be: (A) specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board or any committee thereof; (B) otherwise properly brought before the meeting by or at the direction of the Board or any committee thereof; or (C) otherwise properly brought before an annual meeting by a stockholder who is a stockholder of record of Avalon at the time such notice of meeting is delivered, who is entitled to vote at the meeting, and who complies with the notice and nomination procedures set forth in the Avalon Bylaws.</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The memorandum and articles of association of YOOV provide that directors may be appointed and removed by a resolution of directors or resolution of members.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Directors&#8217; Terms</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>of Office;<br/>
 Removal</b></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The Avalon Charter provides that directors shall be elected for a term expiring at the next annual meeting of stockholders after their election. Directors shall hold office until their successors are duly elected and qualified or until their earlier resignation, death or removal. Any director may be removed from office (i) with or without cause and (ii) only by the affirmative vote of the holders of a majority of the voting power of the outstanding shares of capital stock then entitled to vote at an election of directors. At least forty-five (45) days prior to any annual or special meeting of stockholders at which it is proposed that any director be removed from office, written notice of such proposed removal and the alleged grounds thereof shall be sent to the director whose removal will be considered at the meeting.</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The memorandum and articles of association of YOOV provide that a director shall be appointed for such term as may be specified on his appointment or, failing any term specified, shall be deemed to be appointed indefinitely. Each director holds office until (i) his disqualification to act as a director in accordance with the BVI Companies Act; (ii) his death or, in the case of a director that is not an individual, its ceasing to exist; (iii) his resignation; (iv) the expiry of the term of office (if any) specified on his appointment or as the directors or members may have determined; or (v) the effective date of his removal by resolution of directors or resolution of members.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Annual Meetings<br/>
 of the<br/>
 Stockholders</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The Avalon Bylaws provide that the annual meeting of stockholders shall be held at the hour, date and place within or without the United States which is fixed by the Avalon Board, which time, date and place may subsequently be changed at any time by vote of the Avalon Board.</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The memorandum and articles of association of YOOV do not require annual meetings of the members to be held.</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Cumulative<br/>
 Voting</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The Avalon Charter does not provide for cumulative voting rights in the election of its directors. Under the DGCL, cumulative voting is permitted only when authorized in the certificate of incorporation.</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The memorandum and articles of association of YOOV do not provide for cumulative voting rights in the election of its directors.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>

<tr>
    <td style="vertical-align: top; width: 16%"><span style="font-size: 10pt"><b>Voting</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; text-align: justify; width: 42%"><span style="font-size: 10pt">The Avalon Charter provides that each share of Avalon&#8217;s common stock entitles the holder thereof to one vote on each matter properly submitted to the stockholders of the corporation for their vote.</span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; text-align: justify; width: 39%"><span style="font-size: 10pt">The memorandum and articles of association of YOOV provide that each voting share in YOOV confers on the holder the right to one vote on any resolution of members.</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 246 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->225<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="padding-bottom: 1.5pt; vertical-align: top; width: 16%">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 42%; text-align: center"><span style="font-size: 10pt"><b>Rights of Avalon stockholders</b></span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 39%; text-align: center"><span style="font-size: 10pt"><b>Rights of YOOV shareholders</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Vacancies</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The Avalon Charter provides that any and all vacancies and newly created directorships in the Board, however occurring, including, without limitation, by reason of an increase in the size of the Board, or the death, resignation, disqualification or removal of a director, shall be filled solely and exclusively by the affirmative vote of a majority of the remaining directors then in office, even if less than a quorum of the Board, and not by the stockholders. Any director appointed in accordance with the preceding sentence shall hold office for the remainder of the full term and until such director&#8217;s successor shall have been duly elected and qualified or until his or her earlier resignation, death or removal. In the event of a vacancy in the Board, the remaining directors, except as otherwise provided by law, shall exercise the powers of the full Board until the vacancy is filled.</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The memorandum and articles of association of YOOV provide that the directors may, by resolution of directors, appoint a director to fill a vacancy on the board of directors of YOOV.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Election of<br/>
 Directors</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The Avalon Bylaws provide that any election of directors by stockholders shall be determined by a plurality of the votes properly cast on the election of directors.</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The memorandum and articles of association of YOOV provide that directors may be appointed and removed by a resolution of directors or resolution of members. A resolution of members means either (i) a resolution passed at a meeting of members either on a show of hands or by a poll in accordance with the articles of association of YOOV; or (ii) a resolution duly consented to in writing by members representing a majority of the votes of shares entitled to vote on the resolution in accordance with the memorandum and articles of association of YOOV.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Quorum</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The Avalon Bylaws provide that at least one-third (1/3) of the voting power of the shares of capital stock outstanding and entitled to vote at the meeting, as of the record date, present in person, present by remote communication, if applicable, or represented by proxy, shall constitute a quorum at any meeting of stockholders.</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The memorandum and articles of association of YOOV provide that no business shall be transacted at any meeting of members unless a quorum of members is present at the time when the meeting proceeds to business. A quorum shall consist of the holder or holders present in person or by proxy entitled to exercise at least fifty (50) percent of the voting rights of the shares.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>

<tr>
    <td style="vertical-align: top; width: 16%"><span style="font-size: 10pt"><b>Notice of<br/>
Stockholder<br/>
 Meetings</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 42%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notice of each meeting of stockholders shall
state the hour, date and place, if any, of such stockholder meeting and the means of remote communication, if any, by which stockholders
and proxy holders may be deemed to be present in person and vote at such meeting, shall be given in the manner permitted by the Avalon
Bylaws to each stockholder entitled to vote thereat as of the record date for determining the stockholders entitled to notice of the
meeting, by the Company not less than 10 nor more than 60 days before the date of the meeting unless otherwise required by the DGCL.&#160;</p></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; text-align: justify; width: 39%"><span style="font-size: 10pt">The memorandum and articles of association of YOOV provide that not less than seven (7) days&#8217; notice specifying at least the place, the day and the hour of the meeting and general nature of the business to be conducted shall be given in the manner specified in the memorandum and articles of association of YOOV to such persons whose names on the date the notice is given appear as members in YOOV&#8217;s register of members and are entitled to vote at the meeting.</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 247 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->226<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="padding-bottom: 1.5pt; vertical-align: top; width: 16%">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 42%; text-align: center"><span style="font-size: 10pt"><b>Rights of Avalon stockholders</b></span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 39%; text-align: center"><span style="font-size: 10pt"><b>Rights of YOOV shareholders</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Conversion<br/>
Rights and<br/>
Protective Provisions</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The Avalon Charter does not provide that holders of Avalon stock shall have preemptive, conversion or other protective rights, except that the holders of Series C Preferred Stock and Series D Preferred Stock shall be entitled to convert such shares pursuant to the terms of the certificate of incorporation and respective certificate of designations.</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The memorandum and articles of association of YOOV provide that the shares issued of one class or series may be converted to another class or series.</span></td></tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Indemnification<br/>
of Officers and<br/>
Directors</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the DGCL, a Delaware corporation must indemnify
    its present or former directors and officers against expenses (including attorneys&#8217; fees) actually and reasonably incurred to the
    extent that the officer or director has been successful on the merits or otherwise in defense of any action, suit or proceeding brought
    against him or her by reason of the fact that he or she is or was a director or officer of the corporation.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Delaware law provides that a corporation may indemnify
    its present and former directors, officers, employees and agents, as well as any individual serving with another corporation in that capacity
    at the corporation&#8217;s request against expenses (including attorney&#8217;s fees), judgments, fines and amounts paid in settlement
    of actions taken, if the individual acted in good faith and in a manner reasonably believed to be in, or not opposed to, the best interests
    of the corporation and, in the case of a criminal proceeding, the individual had no reasonable cause to believe the individual&#8217;s
    conduct was unlawful. However, with respect to actions by or in the rights of the corporation, no indemnification may be paid for judgments
    and settlements or to the extent the person is adjudged to be liable to the corporation unless a court approves the indemnity. The DGCL
    permits a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent
    of a corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation,
    partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in
    any such capacity, or arising out of such person&#8217;s status as such.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the DGCL, the Avalon Bylaws
    provide that each director and officer shall be indemnified and held harmless by the corporation to the fullest extent authorized by the
    DGCL, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits
    the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment),
    in connection with actions, suits and proceedings for actions taken in good faith and in a manner reasonably believed to be in the best
    interests of Avalon, such indemnification to continue as to a director or officer after he or she has ceased to be a director or officer
    and shall inure to the benefit of his or her heirs, executors, administrators and personal representatives.</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The BVI Companies Act provides that a company
    may indemnify against all expenses, including legal fees, and against all judgements, fines and amounts paid in settlement and reasonably
    incurred in connection with legal, administrative or investigative proceedings any person who (i) is or was a party or is threatened to
    be made a party to any threatened, pending or completed proceedings, whether civil, criminal, administrative or investigative, by reason
    of the fact that the person is or was a director of the company; or (ii) is or was, at the request of the company, serving as a director
    of, or in any other capacity is or was acting for, another body corporate or a partnership, joint venture, trust or other enterprise.
    The aforesaid does not apply to a person referred to in the aforesaid unless the person acted honestly and in good faith and in what he
    or she believed to be in the best interests of the company and, in the case of criminal proceedings, the person had no reasonable cause
    to believe that his conduct was unlawful.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with the BVI Companies Act, the
    memorandum and articles of association of YOOV provide that subject to the provisions of the BVI Companies Act, every director and officer
    of YOOV (which for the avoidance of doubt, shall not include auditors of YOOV), together with every former director and former officer
    of YOOV (each an &#8220;Indemnified Person&#8221;) shall be indemnified out of the assets of YOOV against any liability, action, proceeding,
    claim, demand, costs, damages or expenses, including legal expenses, whatsoever which they or any of them may incur as a result of any
    act or failure to act in carrying out their functions other than such liability (if any) that they may incur by reason of their own actual
    fraud or wilful default. No Indemnified Person shall be liable to YOOV for any loss or damage incurred by YOOV as a result (whether direct
    or indirect) of the carrying out of their functions unless that liability arises through the actual fraud or wilful default of such Indemnified
    Person. No person shall be found to have committed actual fraud or wilful default unless or until a court of competent jurisdiction shall
    have made a finding to that effect.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 248 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->227<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="padding-bottom: 1.5pt; vertical-align: top; width: 16%">&#160;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 42%; text-align: center"><span style="font-size: 10pt"><b>Rights of Avalon stockholders</b></span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 39%; text-align: center"><span style="font-size: 10pt"><b>Rights of YOOV shareholders</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Declaration and<br/>
Payment of<br/>
 Dividends</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">The Avalon Charter provides that dividends may be declared and paid or set apart for payment upon the Avalon common stock out of any assets or funds of the corporation legally available for the payment of dividends, but only when and as declared by the Board or any authorized committee thereof. The Series C Preferred Stock shall be entitled to receive dividends equal to and in the same form as dividends actually paid on shares of Avalon common stock when, as and if such dividends are paid on shares of Avalon common stock.</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Subject to the BVI Companies Act, the memorandum and articles of association of YOOV provide that the directors may, by resolution of directors, authorize a distribution by YOOV at a time, and of an amount, and to any members they think fit if they are satisfied, on reasonable grounds that, immediately after the distribution, the value of YOOV&#8217;s assets will exceed YOOV&#8217;s liabilities and YOOV will be able to pay its debts as they fall due. Distributions, including dividends, may be declared and paid in cash or in specie, in shares or other assets and the directors may for such purpose set such value as they deem fair upon any such assets.</span></td></tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Amendments;<br/>
General Provisions</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Avalon Bylaws may be amended or repealed by
    the Board by the affirmative vote of a majority of the directors then in office. The bylaws may be amended or repealed at any annual meeting
    of stockholders, or special meeting of stockholders called for such purpose in accordance with the bylaws by the affirmative vote of a
    least seventy-five percent (75%) of the voting power of the outstanding shares entitled to vote on such amendment or repeal, voting together
    as a single class; provided, however, that if the Board recommends that stockholders approve such amendment or repeal at such meeting
    of stockholders, such amendment or repeal shall only require the affirmative vote of a majority of the voting power of the outstanding
    shares entitled to vote on such amendment or repeal, voting together as a single class.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Avalon Charter provides that the corporation
    reserves the right to amend or repeal the certificate of incorporation in the manner now or hereafter prescribed by statute and certificate
    of incorporation, and all rights conferred upon stockholders therein are granted subject to this reservation. Whenever any vote of the
    holders of capital stock of Avalon is required to amend or repeal any provision of the certificate of incorporation, and in addition to
    any other vote of holders of capital stock that is required by the certificate of incorporation or by law, such amendment or repeal shall
    require the affirmative vote of the majority of the voting power of the outstanding shares of capital stock entitled to vote on such amendment
    or repeal, and the affirmative vote of the majority of the voting power of the outstanding shares of each class entitled to vote thereon
    as a class, at a duly constituted meeting of stockholders called expressly for such purpose.</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The memorandum and articles of association of
    YOOV provide that subject to the provisions of the BVI Companies Act, the directors or members may from time to time amend the memorandum
    of association or the articles of association by resolution of directors or resolution of members. The directors shall give notice of
    such resolution to the registered agent of the Company, for the registered agent to file with the Registrar of Corporate Affairs a notice
    of the amendment to the memorandum of association or the articles of association, or a restated memorandum and articles of association
    incorporating the amendment(s) made, and any such amendment(s) to the memorandum of association or the articles of association will take
    effect from the date of the registration by the Registrar of Corporate Affairs of the notice of amendment or restated memorandum and articles
    of association incorporating the amendment(s) made.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding any provision to the contrary
    in the memorandum of association or the articles of association, the directors shall not have the power to amend the memorandum of association
    or the articles of association (i) to restrict the rights or powers of the members to amend the memorandum of association or the articles
    of association; (ii) to change the percentage of members required to pass a resolution to amend the memorandum of association or the articles
    of association; or (iii) in circumstances where the memorandum of association or the articles of association cannot be amended by the
    members.</p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 249 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->228<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><div><a id="a_130"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><div><a id="a_131"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">YOOV</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets
forth certain information known to YOOV regarding beneficial ownership of YOOV capital stock on a converted basis as of March 31, 2025
(the &#8220;Beneficial Ownership Date&#8221;), for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">each person or group of affiliated persons, who is known by YOOV to be the beneficial owner of more than
5% of YOOV capital stock;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">each of YOOV&#8217;s directors;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">each of YOOV&#8217;s named executive officers; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">all of YOOV&#8217;s directors and executive officers and directors as a group.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Beneficial ownership is determined
in accordance with the rules of the SEC and thus represents voting or investment power with respect to YOOV&#8217;s securities. Under
such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as
well as any shares that the individual has the right to acquire within 60 days of the Beneficial Ownership Date. YOOV Ordinary Shares
that an individual has the right to acquire within 60 days of the Beneficial Ownership Date are deemed to be outstanding and beneficially
owned by the individual for the purpose of computing the percentage ownership of that individual, but they are not treated as outstanding
for the purpose of computing the percentage ownership of any other person. To YOOV&#8217;s knowledge and subject to applicable community
property rules, and except as otherwise indicated below, the persons and entities named in the table have sole voting and sole investment
power with respect to all shares beneficially owned.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Effective as of immediately
prior to the Effective Time, each then-outstanding YOOV Preferred Shares will automatically convert, pursuant to its terms, into an aggregate
of 373,208 YOOV Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The percentage of beneficial
ownership shown prior to the Merger in the table below is based on March 31, 2025 YOOV Ordinary Shares deemed to be outstanding as of the Beneficial
Ownership Date, assuming the conversion of the YOOV Preferred Shares into YOOV Ordinary Shares described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise indicated
in the footnotes below, the address of each beneficial owner listed in the table below is 1 Raffles Place, #31-62 One Raffles Place Tower
2, Singapore 048616.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name of Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/> Shares <br/> Beneficially <br/> Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage of<br/> Shares <br/> Outstanding <br/> Beneficially <br/> Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-style: italic">Directors &amp; Executive Officers</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Wong Ling Yan Philip (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">118,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">31.6</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Kwok Chi Yin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sze Kin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tsui Hoi Yee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Wong Ho Chi Mark</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lai Kam Fu</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Directors and Executive Officers as a Group (6&#160;Total)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">138,000</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">37.0</td><td style="font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">5% or Greater Holders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">HHG Investment Fund SPC (for the account of HHG Capital Fund SP) (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,668</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.3</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Consists of 118,000 YOOV Ordinary Shares held by Facewell International
Limited<span style="background-color: white">. Wong Ling Yan Philip, Director of Facewell International Limited, has discretionary authority
to vote and dispose of the shares held by Facewell International Limited and may be deemed to be the beneficial owner of these shares.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 250 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->229<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Consists of 40,668 YOOV Ordinary Shares issuable upon conversion of YOOV Preferred Shares
                                                                                immediately prior to the Merger. Based upon information provided by HHG Investment Fund SPC, Yeung Wai Tin, Hong Zhaochun and Qiu
                                                                                Yuying, the majority ultimate shareholders of HHG Investment Fund SPC are the beneficial owners of 40,668 YOOV Ordinary Shares,
                                                                                beneficially owned by HHG Investment Fund SPC. The address of HHG Investment Fund SPC is Suite 102, Cannon Place, P.O. Box 712,
                                                                                North Sound Rd., George Town, Grand Cayman, KY1-9006 Cayman Island.</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><div>

</div><div><a id="a_132"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Shareholders Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 1, 2022, YOOV
entered into an amended and restated shareholders&#8217; agreement, as amended on the same day (together, the &#8220;Shareholders&#8217;
Agreement&#8221;) with each of the investors of YOOV Preferred Shares (collectively, &#8220;Preferred Shareholders&#8221;), which modified
the redemption and conversion terms of Series A Preferred Shares and changed the Series A Ordinary Shares to Series A Preferred Shares.
Pursuant to the Shareholders&#8217; Agreement, the YOOV Board shall be comprised of members appointed by the Preferred Shareholders, and
the Preferred Shareholders shall have anti-dilution rights pre-emption rights if YOOV issues any YOOV Ordinary Shares, or any other securities
that are convertible or exchangeable into the YOOV Ordinary Shares, at a price less than $368.84 per share. The Preferred Shareholders
shall also have tag along rights in the event that the number of shares to be disposed of by the proposed transferor represent 50% or
more of the outstanding and issued share capital of YOOV, on a fully diluted basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">YOOV plans to terminate the Shareholders&#8217;
Agreement upon effectiveness of this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_133"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Avalon</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table
sets forth information regarding (i) the actual beneficial ownership of Avalon Common Stock as of March 31, 2025 and (ii) expected
beneficial ownership of Avalon Common Stock immediately following the Closing based on the 62,132,236 shares of Avalon Common Stock
outstanding immediately after the consummation of the Merger (without giving effect to the anticipated Reverse Stock Split, if
approved and if necessary to be effectuated for the Combined Company to meet the $4.00 minimum bid price initial listing requirement
following the completion pursuant to the rules of The Nasdaq Capital Market) by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">each person who is, or is expected to be, the beneficial owner of more than 5% of issued and outstanding
shares of Avalon Common Stock before and after the Closing;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">each of our current named executive officers and directors;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">each person who will become a named executive officer or director of Avalon after the Closing; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">all executive officers and directors of Avalon as a group before and after the Closing.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Beneficial ownership is determined
according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses
sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable
within 60 days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 251 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->230<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The expected beneficial
ownership of shares of Avalon Common Stock after the Closing has been determined based upon the following: (i) that 60,000,000
shares of Avalon Common Stock are issued to the YOOV shareholders in connection with the Merger and (ii) there will be an aggregate
of 1,651,667 shares of Avalon Common Stock issued and outstanding at Closing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
    the Closing</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
    the Closing</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Beneficial Owner(1)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common<br/>
    Stock<br/> Beneficially<br/>
    Owned</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%(2)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common<br/>
    Stock<br/> Beneficially<br/>
    Owned</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    Directors and Executive Officers of Avalon:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wenzhao
    Lu (3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">238,928</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">238,928</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Jin, MD, PhD (4)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105,667</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105,667</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Meng
    Li (5)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,334</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,334</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Luisa
    Ingargiola (6)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven
    A. Sanders (7)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,665</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,665</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wilbert
    J. Tauzin II (8)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,570</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,570</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    B. Stilley III (9)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,665</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,665</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tevi
    Troy (10)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,665</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,665</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lourdes
    Felix (11)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,053</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,053</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    Current Directors and Executive Officers of Avalon as a Group (9 Total)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">411,547</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.4</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">411,547</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5%
    or Greater Holders</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vision
    Capital NY Inc. (12)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
    and Officers of Combined Company After Closing</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wong
    Ling Yan Philip</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-&#8194;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-&#8194;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,970,860</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Luisa
    Ingargiola</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wong
    Ho Chi Mark</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,193,102</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devere
    Andrew Bryan</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lam
    Heung Yeung Herman</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lourdes
    Felix</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,053</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,053</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kirsty
    Vanora Godfrey-Billy</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wenzhao
    Lu</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">238,928</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">238,928</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven
    A. Sanders</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,665</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,665</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    Officers and Directors of Combined Company after Closing as a Group (9 Total)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,422,608</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.7</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5%
    or Greater Holders</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HHG
    Investment Fund SPC (for the account of HHG Capital Fund SP)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,538,194</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left">*</td><td style="text-align: justify">Less than 1%</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left">(1)</td><td style="text-align: justify">Except as otherwise indicated, the address of each beneficial
owner is c/o Avalon GloboCare Corp., 4400 Route 9 South, Suite 3100, Freehold, New Jersey 07728.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 252 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->231<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left">(2)</td><td style="text-align: justify">Applicable percentage ownership is based on 1,651,667 shares
of Avalon Common Stock outstanding as of March 31, 2025, together with securities exercisable or convertible into shares of Avalon Common
Stock within 60 days of March 31, 2025 for each stockholder. Beneficial ownership is determined in accordance with the rules of the SEC
and generally includes voting or investment power with respect to securities. Shares of common stock that are currently exercisable or
exercisable within 60 days of March 31, 2025 are deemed to be beneficially owned by the person holding such securities for the purpose
of computing the percentage of ownership of such person, but are not treated as outstanding for the purpose of computing the percentage
ownership of any other person.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left">(3)</td><td style="text-align: justify">Wenzhao Lu holds 238,928 shares of Avalon Common Stock.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left">(4)</td><td style="text-align: justify">David Jin holds (i) 103,000 shares of Avalon Common Stock and
(ii) 2,667 vested options to acquire 2,667 shares of Avalon Common Stock.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left">(5)</td><td style="text-align: justify">Meng Li holds (i) 34,334 shares of Avalon Common Stock and (ii)
2,000 vested options to acquire 2,000 shares of Avalon Common Stock.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left">(6)</td><td style="text-align: justify">Represents 16,000 vested options to acquire 16,000 shares of
Avalon Common Stock.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left">(7)</td><td style="text-align: justify">Represents 2,665 vested options to acquire 2,665 shares of Avalon
Common Stock.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left">(8)</td><td style="text-align: justify">Wilbert J. Tauzin II holds (i) 1,037 shares of Avalon Common
Stock and (ii) 4,533 vested options to acquire 4,533 shares of Avalon Common Stock.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left">(9)</td><td style="text-align: justify">Represents 2,665 vested options to acquire 2,665 shares of Avalon
Common Stock.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left">(10)</td><td style="text-align: justify">Represents 2,665 vested options to acquire 2,665 shares of Avalon
Common Stock.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left">(11)</td><td style="text-align: justify">Represents 1,053 vested options to acquire 1,053 shares of Avalon
Common Stock.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.35in; text-align: left">(12)</td><td style="text-align: justify">Vision Capital NY Inc. holds 100,000 shares of Avalon Common
Stock. Vision Capital NY Inc.&#8217;s address is 600 Pine Hollow Road #16-5B, East Norwich, NY 11732.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 253 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->232<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_134"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">LEGAL MATTERS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The validity of the shares
of Avalon Common Stock to be issued in connection with the Merger will be passed upon for Avalon by Lowenstein Sandler LLP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_135"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXPERTS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The consolidated financial
statements of YOOV as of March 31, 2024 and 2023, and for the years then ended, included in the proxy statement/prospectus have been audited
by ARK Pro CPA &amp; Co., an independent registered accounting firm, as stated in their report. Such financial statements are included
in reliance upon the report of such firm given their authority as experts in accounting and auditing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The consolidated financial
statements of Avalon as of December 31, 2024, and for the year then ended, included in the proxy statement/prospectus, which is referred
to and made a part this Registration Statement on Form S-4, have been audited by M&amp;K CPAS, PLLC, independent registered public accounting
firm, as set forth in their report appearing elsewhere herein, and are included in reliance upon such report given on the authority of
such firm as experts in accounting and auditing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The consolidated
financial statements of Avalon as of December 31, 2023, and for the year then ended, included in the proxy statement/prospectus,
which is referred to and made a part this Registration Statement on Form S-4, have been audited by Marcum LLP, independent
registered public accounting firm, as set forth in their report, which contains an explanatory paragraph relating to the
Company&#8217;s ability to continue as a going concern as described in Note 2 to the financial statements, appearing elsewhere
herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 254 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->233<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_136"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ADDITIONAL INFORMATION</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><div><a id="a_137"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Annual Report</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Copies of our Annual Report
on Form 10-K (including our audited financial statements) filed with the SEC may be obtained without charge by writing to Avalon GloboCare
Corp., 400 Route 9 South, Suite 3100, Freehold, NJ&#160;07728, Attn.: Secretary, or by phone at (732)&#160;780-4400. Exhibits to the Form
10-K will be mailed upon similar request and payment of specified fees to cover the costs of copying and mailing such materials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our audited financial statements
for the fiscal year ended December 31, 2024 and certain other related financial and business information are contained in our Annual Report
on Form 10-K, which is being made available to our stockholders along with this proxy statement, but which is not deemed a part of the
proxy soliciting material.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_138"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Submitting Proxy Proposals and Director Nominations
for the 2025 Annual Meeting</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Proposals to be Considered for Inclusion in
Avalon&#8217;s 2025 Proxy Materials </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order for a stockholder
proposal to be eligible to be included in Avalon&#8217;s proxy statement and proxy card for the 2025 Annual Meeting of Stockholders, the
proposal must (1) be received by Avalon at our principal executive offices, 400 Route 9 South, Suite 3100, Freehold, NJ&#160;07728, Attn.:
Secretary, on or before May&#160;9, 2025, and (2) concern a matter that may be properly considered and acted upon at the annual meeting
in accordance with applicable laws, regulations and the Avalon Bylaws and policies, and must otherwise comply with Rule 14a-8 of the Exchange
Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Director Nominations and Other Business to
be Brought Before the 2025 Annual Meeting of Stockholders </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Notice of any director nomination
or the proposal of other business that stockholders intend to present at the 2025 Annual Meeting of Stockholders, but do not intend to
have included in Avalon&#8217;s proxy statement and form of proxy relating to the 2025 Annual Meeting of Stockholders, must be received
by Avalon at our principal executive offices, 400 Route 9 South, Suite 3100, Freehold, NJ&#160;07728, Attn.: Secretary, not earlier than
the close of business on June&#160;9, 2025 and not later than the close of business on July&#160;9, 2025. In the event that the date of
the 2025 Annual Meeting of Stockholders is more than 25 days before or after the anniversary date of the 2024 Annual Meeting of Stockholders,
the notice must be delivered to Avalon not earlier than the 120th day prior to the 2025 Annual Meeting of Stockholders and not later than
the later of the 90th day prior to such annual meeting or the 10th day following the day on which public announcement of the date of such
annual meeting is first made by Avalon. In addition, a stockholder&#8217;s notice must include the information required by the Avalon
Bylaws with respect to each director nomination or proposal of other business that such stockholder intends to present at the 2025 Annual
Meeting of Stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to satisfying
the foregoing requirements pursuant to the Avalon Bylaws, to comply with the universal proxy rules, stockholders who intend to solicit
proxies in support of director nominees other than Avalon&#8217;s nominees must provide notice that sets forth the information required
by Rule 14a-19 under the Exchange Act by August&#160;8, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_139"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="-keep: true">H<b>ouseholding-Delivery
of Documents to Stockholders</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Some banks, brokers and other
nominee record holders may be participating in the practice of &#8220;householding&#8221; proxy statements. This means that only one copy
of this proxy statement and Annual Report may have been sent to multiple stockholders in the same household. We will promptly deliver
a separate copy of this proxy statement to any stockholder upon written or oral request to: Avalon GloboCare Corp., 400 Route 9 South,
Suite 3100, Freehold, NJ&#160;07728, Attn.: Secretary, or by phone at (732)&#160;780-4400. Any stockholder who wants to receive a separate
copy of this proxy statement or Annual Report, or of the Company&#8217;s proxy statements or annual reports in the future, or any stockholder
who is receiving multiple copies and would like to receive only one copy per household, should contact the stockholder&#8217;s bank, broker,
or other nominee record holder, or the stockholder may contact us at the address and phone number above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 255 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->234<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_140"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">WHERE YOU CAN FIND MORE
INFORMATION</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon files reports, proxy
statements and other information with the SEC as required by the Exchange Act. The SEC maintains a website that contains reports, proxy
statements and other information about Avalon. You can read Avalon&#8217;s SEC filings, including this proxy statement/prospectus, over
the Internet at the SEC&#8217;s website at http://www.sec.gov. The reports and other information filed by Avalon with the SEC are also
available at Avalon&#8217;s website, which is https://www.avalon-globocare.com/. Information on Avalon&#8217;s website is not part of
this proxy statement/prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If you would like additional
copies of this proxy statement/prospectus or if you have questions about the Merger or the proposals to be presented at the Special Meeting,
you should contact Avalon by telephone or in writing:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Avalon GloboCare Corp.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">400 Route 9 South, Suite 3100</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Freehold, NJ 07728</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Telephone: (732)&#160;780-4400</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Attention: Secretary</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If you are a stockholder
of Avalon and would like to request documents, please do so by [__], 2025 to receive them before the Special Meeting. If you request any
documents from us, Avalon will mail them to you by first class mail, or another equally prompt means.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All information contained
in this proxy statement/prospectus relating to Avalon has been supplied by Avalon, and all such information relating to YOOV has been
supplied by YOOV. Information provided by either Avalon or YOOV does not constitute any representation, estimate or projection of any
other party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">You should rely only on the
information contained in this proxy statement/prospectus or that Avalon have referred to you. None of Avalon or YOOV has authorized anyone
to provide you with any additional information. This proxy statement/prospectus is dated as of the date listed on the cover page. You
should not assume that the information contained in this proxy statement/prospectus is accurate as of any date other than such date, and
neither the mailing or posting of this proxy statement/prospectus to stockholders of Avalon or shareholders of YOOV shall create any implication
to the contrary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 256 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->235<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_141"></a></div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>INDEX TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>YOOV Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; padding-right: 0pt; width: 91%; padding-left: 0.125in; text-indent: -0.125in"><span style="font-size: 10pt"><b>CONTENTS</b></span></td>
    <td style="padding-right: 0pt; white-space: nowrap; width: 1%; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; padding-right: 0pt; width: 8%; text-align: center; padding-left: 0.125in; text-indent: -0.125in"><span style="font-size: 10pt"><b>PAGE</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-right: 0pt; padding-left: 0.125in; text-indent: -0.125in"><a href="#a_142"><span style="font-size: 10pt">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB ID: 3299)</span></a></td>
    <td style="padding-right: 0pt; white-space: nowrap; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-right: 0pt; text-align: center; padding-left: 0.125in; text-indent: -0.125in"><span style="font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-right: 0pt; padding-left: 0.125in; text-indent: -0.125in"><a href="#F_001"><span style="font-size: 10pt">CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2024 AND 2023</span></a></td>
    <td style="padding-right: 0pt; white-space: nowrap; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-right: 0pt; text-align: center; padding-left: 0.125in; text-indent: -0.125in"><span style="font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-right: 0pt; padding-left: 0.125in; text-indent: -0.125in"><a href="#F_002"><span style="font-size: 10pt">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME/(LOSS) FOR THE YEARS ENDED MARCH 31, 2024 AND 2023</span></a></td>
    <td style="padding-right: 0pt; white-space: nowrap; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-right: 0pt; text-align: center; padding-left: 0.125in; text-indent: -0.125in"><span style="font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-right: 0pt; padding-left: 0.125in; text-indent: -0.125in"><a href="#F_003"><span style="font-size: 10pt">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY/(DEFICIT) FOR THE YEARS ENDED MARCH 31, 2024 AND 2023</span></a></td>
    <td style="padding-right: 0pt; white-space: nowrap; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-right: 0pt; text-align: center; padding-left: 0.125in; text-indent: -0.125in"><span style="font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-right: 0pt; padding-left: 0.125in; text-indent: -0.125in"><a href="#F_004"><span style="font-size: 10pt">CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED MARCH 31, 2024 AND 2023</span></a></td>
    <td style="padding-right: 0pt; white-space: nowrap; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-right: 0pt; text-align: center; padding-left: 0.125in; text-indent: -0.125in"><span style="font-size: 10pt">F-6</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-right: 0pt; padding-left: 0.125in; text-indent: -0.125in"><a href="#F_005"><span style="font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></a></td>
    <td style="padding-right: 0pt; white-space: nowrap; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="padding-right: 0pt; text-align: center; padding-left: 0.125in; text-indent: -0.125in"><span style="font-size: 10pt">F-7</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>YOOV Unaudited Condensed Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; padding-right: 0pt; width: 91%; padding-left: 0pt; text-indent: 0pt"><b>CONTENTS</b></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="width: 8%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>PAGE</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-right: 0pt; vertical-align: bottom; padding-left: 0.125in; text-indent: -0.125in"><a href="#N_001"><span style="font-size: 10pt">CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2024 AND MARCH 31, 2024 (UNAUDITED)</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">F-29</span></td></tr>
  <tr>
    <td style="padding-right: 0pt; vertical-align: bottom; padding-left: 0.125in; text-indent: -0.125in"><a href="#N_002"><span style="font-size: 10pt">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME FOR THE NINE MONTHS ENDED DECEMBER 31, 2024 AND 2023</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">F-30</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-right: 0pt; vertical-align: bottom; padding-left: 0.125in; text-indent: -0.125in"><a href="#N_003"><span style="font-size: 10pt">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; DEFICIT FOR THE NINE MONTHS ENDED DECEMBER 31, 2024 AND 2023</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">F-31</span></td></tr>
  <tr>
    <td style="padding-right: 0pt; vertical-align: bottom; padding-left: 0.125in; text-indent: -0.125in"><a href="#N_004"><span style="font-size: 10pt">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED DECEMBER 31, 2024 AND 2023</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">F-32</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="padding-right: 0pt; vertical-align: bottom; padding-left: 0.125in; text-indent: -0.125in"><a href="#N_005"><span style="font-size: 10pt">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></a></td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">F-33</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Avalon Consolidated Financial Statements</b></p><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; width: 91%"><b>CONTENTS</b></td>
    <td style="padding-bottom: 1.5pt; width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PAGE</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#b_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB NO. 2738)</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-52</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#b_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB NO. 688)</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-53</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED FINANCIAL STATEMENTS:</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><a href="#b_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED BALANCE SHEETS - AS OF DECEMBER 31, 2024 AND 2023</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-54</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in"><a href="#b_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F55</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in"><a href="#b_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F56</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in"><a href="#b_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED STATEMENTS OF CASH FLOWS - FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-57</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in"><a href="#b_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-58</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">Avalon Unaudited Condensed Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; border-bottom: Black 1.5pt solid; vertical-align: top; width: 91%"><span style="font-size: 10pt"><b>CONTENTS</b>&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 8%"><span style="font-size: 10pt"><b>PAGE</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#s1_001"><span style="font-size: 10pt">CONDENSED CONSOLIDATED
    BALANCE SHEETS - AT MARCH 31, 2025 (UNAUDITED) AND DECEMBER 31, 2024</span></a></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-101</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#s1_002"><span style="font-size: 10pt">CONDENSED CONSOLIDATED
    STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024</span></a></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">F-102</span></td>
  </tr><tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#s1_003"><span style="font-size: 10pt">CONDENSED CONSOLIDATED
    STATEMENTS OF CHANGES IN (DEFICIT) EQUITY (UNAUDITED) - FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024</span></a></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">F-103</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#s1_005"><span style="font-size: 10pt">CONDENSED CONSOLIDATED
    STATEMENTS OF CASH FLOWS (UNAUDITED) - FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024</span></a></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">F-105</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><a href="#s1_006"><span style="font-size: 10pt">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></a></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">F-106</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>


</div><!-- Field: Page; Sequence: 257; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_142"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">YOOV FINANCIAL STATEMENTS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="fin_001.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To: the Board of Directors and Stockholders of</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">YOOV Group Holding Limited</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Opinion on the Financial Statements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of YOOV Group Holding Limited and its subsidiaries (&#8220;the Company&#8221;) as of March 31, 2024 and 2023, and related
consolidated statement of operations and comprehensive income, consolidated statement of changes in equity and consolidated statement
of cash flows for each of the year in the two years period ended March 31, 2024, and the related notes (collectively referred to as the
&#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material
respects, the consolidated financial position of the Company as of March 31, 2024 and 2023, and the results of its operations and its
cash flows for each of the year in the two years period ended March 31, 2024, in conformity with accounting principles generally accepted
in the United States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basis for Opinion</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These consolidated financial statements are the
responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements
based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules
and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audit in accordance with standards
of the PCAOB. &#160;Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit included performing procedures to assess
the risks of material misstatements of the consolidated financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis
for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1pt; width: 40%; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ ARK Pro CPA &amp; Co</span></td>
    <td style="width: 60%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARK Pro CPA &amp; Co</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have served as the Company&#8217;s auditor since 2024.</span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hong Kong, China</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">April 24, 2025</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 258 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="F_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YOOV GROUP HOLDING LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -22pt">(In U.S. dollars,
except for the number of shares data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -22pt">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">As of March 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="-keep: true">USD</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="-keep: true">USD</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-keep: true">ASSETS</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-keep: true">Current assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="-keep: true">Cash</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">1,370,008</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">998,948</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Accounts receivable, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">19,799,764</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">12,580,049</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Factoring receivables, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">323,828</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">457,904</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Prepayment, deposits and other receivables, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,755,118</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,585,861</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Amount due from related parties</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">4,633,560</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">11,588,912</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total current assets</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">30,882,278</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">33,211,674</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Non-current assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Property and equipment, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">451,373</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">716,742</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Operating lease right-of-use asset</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">279,706</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">680,223</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Intangible assets, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">28,191,671</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">18,274,509</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Investment in insurance contracts</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">835,540</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,032,529</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Investment in associate</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">63</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">147</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total non-current assets</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">29,758,353</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">20,704,150</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">TOTAL ASSETS</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">60,640,631</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">53,915,824</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS&#8217; DEFICIT</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Current liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Accounts payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">269,233</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">153,317</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Accruals and other payables</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,807,703</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,593,180</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Deferred revenue</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">16,850,228</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">14,083,796</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Short-term borrowings</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,002,759</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,690,449</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Operating lease liabilities, current</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">301,003</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">395,003</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Income tax payable</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">9,282</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total current liabilities</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">27,240,208</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">21,915,745</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Non-current liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Operating lease liabilities, non-current</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">300,082</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Deferred tax liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,441,519</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,086,659</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Long service payment</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">6,556</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">5,231</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total non-current liabilities</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">1,448,075</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">1,391,972</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">TOTAL LIABILITIES</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">28,688,283</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">23,307,717</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Commitments and contingencies</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Mezzanine equity</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Angel round redeemable convertible preferred shares, USD0.1 par value, 71,119
    and 71,119 shares issued and outstanding as of March 31, 2024 and 2023, respectively.</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">2,890,728</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">2,618,351</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Series A redeemable convertible preferred shares, USD0.1 par value, 54,224
    and 54,224 shares issued and outstanding as of March 31, 2024 and 2023, respectively.</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">16,953,971</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">16,902,137</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Series A1 redeemable convertible preferred shares, USD0.1 par value, 47,865
    and 47,865 shares issued and outstanding as of March 31, 2024 and 2023, respectively.</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">17,692,306</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">17,638,214</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">TOTAL MEZZANINE EQUITY</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">37,537,005</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">37,158,702</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Shareholders&#8217; deficit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Ordinary shares, USD0.1 par value, 2,000,000 shares authorized, 200,000 and 200,000 shares issued and outstanding as of March
    31, 2024 and 2023, respectively</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">20,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">20,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Accumulated deficit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(5,666,809</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(6,598,305</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Accumulated other comprehensive (loss)/income</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(12,120</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">7,333</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Deficit attributable to the shareholders of the Company</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(5,658,929</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(6,570,972</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Non-controlling interests</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">74,272</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">20,377</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total shareholders' deficit</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">(5,584,657</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">(6,550,595</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS&#8217;
    DEFICIT</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">60,640,631</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">53,915,824</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes
are an integral part of these consolidated financial statements.</p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 259 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="F_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YOOV GROUP HOLDING LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
INCOME/(LOSS)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -22pt">(In U.S. dollars,
except for the number of shares data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -22pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended<br/>
    March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">29,633,327</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21,456,954</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Cost of revenues</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,735,837</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,488,158</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Gross profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">18,897,490</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">13,968,796</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Selling and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,399,877</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,433,443</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,083,083</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,510,772</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(612,733</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,174,942</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Total operating
    expenses</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(17,095,693</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(14,119,157</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td><td>&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Income/(loss) from operations</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,801,797</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(150,361</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Other loss, net:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Finance expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(383,593</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(285,271</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Investment loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(84</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(235</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Other income, net</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">193,331</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">127,678</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Total other
    loss, net</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(190,346</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(157,828</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td><td>&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Income/(loss) before income tax provision</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,611,451</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(308,189</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Income tax expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(360,869</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(119,353</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Net income/(loss)</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,250,582</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(427,542</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Less: net income/(loss) attributable to non-controlling
    interests</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,695</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(217,368</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Less: accretion of redemption value of preferred shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">264,391</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Less: deemed dividend under the modification and extinguishment</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,035,985</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Net income/(loss) attributable to YOOV
    Group Holding Limited&#8217;s shareholders</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">931,496</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(9,485,826</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Other comprehensive (loss)/income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Foreign currency translation change, net of nil income
    taxes</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,253</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,148</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Total other comprehensive (loss)/income</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,253</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,148</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Total comprehensive income/(loss)</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,230,329</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(350,394</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Total comprehensive income/(loss) attributable to non-controlling
    interests</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">53,895</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(216,968</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Total comprehensive income/(loss) attributable to YOOV
    Group Holding Limited shareholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,176,434</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(133,426</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Loss per ordinary share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">- Basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47.43</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Weighted average shares used in calculating loss per
    share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">- Basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-indent: -22pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes
are an integral part of these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -22pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -22pt"></p><div>

</div><!-- Field: Page; Sequence: 260 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -22pt">&#160;</p><div>





</div><div><a id="F_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YOOV GROUP HOLDING LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217;
EQUITY/(DEFICIT)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -22pt">(In U.S. dollars,
except for the number of shares data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-indent: -22pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated other comprehensive (loss)/income</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total YOOV<br/>
 Group Holding<br/>
 Limited <br/>
shareholders&#8217; equity/(deficit)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-controlling interests</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/>
 shareholders&#8217; equity/(deficit)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Numbers</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; width: 37%; font-weight: bold; padding-left: 0.125in">Balance as of March 31, 2022</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right">200,000</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right">20,000</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right">2,887,521</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right">(69,415</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right">2,838,106</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right">103,324</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 6%; font-weight: bold; text-align: right">2,941,430</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(210,174</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(210,174</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(217,368</td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(427,542</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Capital injection</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134,021</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">134,021</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,748</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">76,748</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">400</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">77,148</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Deemed dividend under the modification and extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,035,985</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(9,035,985</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(9,035,985</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Accretion on convertible redeemable preferred shares to redemption value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(239,667</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(239,667</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(239,667</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; font-weight: bold; padding-bottom: 1.5pt; padding-left: 0.125in">Balance as of March 31, 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">200,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">20,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(6,598,305</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7,333</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(6,570,972</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">20,377</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(6,550,595</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Net income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,195,887</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,195,887</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,695</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,250,582</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,453</td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(19,453</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(800</td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(20,253</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Accretion on convertible redeemable preferred shares to redemption value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(264,391</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(264,391</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(264,391</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.125in">Balance as of March 31, 2024</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">200,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">20,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(5,666,809</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(12,120</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(5,658,929</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">74,272</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(5,584,657</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -22pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -22pt">The accompanying notes
are an integral part of these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -22pt"></p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 261 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="F_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YOOV GROUP HOLDING LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -22pt">(In U.S. dollars,
except for the number of shares data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -22pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended<br/>
 March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 82%; text-align: left">Net profit/(loss)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">1,250,582</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">(427,542</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-style: italic; text-align: left">Adjustments to reconcile net profit/(loss) to net cash provided by/(used in) operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">(Reversal)/provision of credit losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(596,209</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">772,224</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,185,969</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,127,010</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Amortization of operating lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">402,670</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">419,019</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">351,586</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">119,353</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Investment loss in associate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">235</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Cash surrender value changes of insurance contracts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,921</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(152,141</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-style: italic; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,588,221</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,907,625</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Factoring receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,604</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309,781</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Prepaid expenses and other current asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(694,212</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,380,679</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115,464</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(914</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Deferred revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,723,693</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,736,439</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">923,851</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">705,616</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(396,280</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(417,767</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Income tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,283</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Long service payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,309</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">738</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Amounts due from related parties</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,997,544</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,634,532</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Net cash provided by/(used in) operating activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">5,883,638</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(461,721</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Purchase of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,946,433</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,031,340</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Purchase of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(472,976</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Purchase of insurance contract</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(932,107</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Proceeds from surrender of insurance contract</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">231,404</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Net cash used in investing activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(8,715,029</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(10,436,423</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">CASH FLOWS FORM FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Proceeds from borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,834,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,384,425</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Repayments of borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,539,094</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,008,390</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Proceeds from capital contribution from non-controlling interests</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,947</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Proceeds from mezzanine equity</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,994,509</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,975,188</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Net cash provided by financing activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">3,289,582</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">7,485,170</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Effect of exchange rate changes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(87,131</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">298,202</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 10pt">&#12288;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net change in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">371,060</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,114,772</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Cash at beginning of the period</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">998,948</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,113,720</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Cash at end of the period</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,370,008</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">998,948</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Interest paid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">237,699</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">201,345</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Income tax paid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Supplemental schedule of non-cash financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Accretion of mezzanine equity to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">264,391</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Deemed dividend under modification and extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">9,035,985</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Mezzanine equity received by the director on behalf of the Company to offset IA payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,164,107</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Mezzanine equity received by the director on behalf of the Company</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,508,783</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">The accompanying notes are an integral
part of these consolidated financial statements.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 262 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="F_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YOOV GROUP HOLDING LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FOR THE YEARS ENDED MARCH 31, 2024 AND 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -22pt">(In U.S. dollars,
except for the number of shares data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>1.</b></td><td style="text-align: justify"><b>ORGANIZATION AND PRINCIPAL ACTIVITIES</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">YOOV Group Holding Limited. (the &#8220;Company&#8221;),
through its wholly-owned subsidiaries (collectively, the &#8220;Group&#8221;) primarily engages in providing Artificial Intelligence-as-a-Service
(&#8220;AIaaS&#8221;) services, which integrates cutting-edge AI technologies to deliver intelligent business automation solutions to
the customers, factoring services, insurance brokerage services and other services in Hong Kong (&#8220;HK&#8221;). The Company was incorporated
under the laws of British Virgin Islands (&#8220;BVI&#8221;) on August 1, 2017.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2024, the Company&#8217;s major
subsidiaries are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left; font-weight: bold"><span style="-keep: true">Name</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-keep: true">Date of Incorporation</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-keep: true">Place of Incorporation</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-keep: true">Percentage of<br/>
    Equity Interest</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold"><span style="-keep: true">Principal Activities</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 38%; text-align: left"><span style="-keep: true">YOOV Internet Technology
    Limited <br/>(&#8220;YOOV Internet&#8221;)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; white-space: nowrap; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    19, 2012</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 13%; text-align: right"><span style="-keep: true">100</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">%</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; width: 22%; text-align: center"><span style="-keep: true">AIaaS services</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left"><span style="-keep: true">Portwin International Limited</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    12, 2021</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BVI</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">100</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">Holding company</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="-keep: true">YOOV Internet Technology (Asia) Limited</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    4, 2020</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">100</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">AIaaS services</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left"><span style="-keep: true">YOOV Capital Limited</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    4, 2020</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">100</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">Factoring services</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="-keep: true">Jump Group Limited</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    4, 2020</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">100</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">Other services</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left"><span style="-keep: true">BYOB Group Limited</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    4, 2020</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">100</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">AIaaS services</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="-keep: true">YOOV Insurance Services Limited</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    4, 2020</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">65</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">Insurance brokerage service</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left"><span style="-keep: true">Good On Time Limited (&#8220;Good On Time&#8221;)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    9, 2021</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="-keep: true">75</span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">AIaaS services</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><span style="-keep: true">Interactive Union Limited</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    21, 2021</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70% owned by Good On Time</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">Other services</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left"><span style="-keep: true">Solar Pump Limited</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    12, 2021</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51% owned by Good On Time</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">Other services</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>2.</b></td><td style="text-align: justify"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(a).</i></b></td><td style="text-align: justify"><b><i>Basis of Presentation</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(b).</i></b></td><td style="text-align: justify"><b><i>Principles of consolidation</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include
the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances have been eliminated
upon consolidation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(c).</i></b></td><td style="text-align: justify"><b><i>Use of estimates</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial
statements in conformity with US GAAP requires management of the Group to make certain estimates and assumptions that affect the reported
amounts of assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses
during the reporting period. The Group&#8217;s management based on their estimates on historical experience and various other factors
believed to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value
of assets and liabilities that are not readily apparent from other sources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant accounting estimates reflected in
the Group&#8217;s consolidated financial statements include, but not limited to revenue recognition, provision for credit losses, the
useful lives and impairment of long-lived assets and valuation allowance for deferred tax assets. Changes in facts and circumstances may
result in revised estimates. Actual results could differ from those estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 263 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(d).</i></b></td><td style="text-align: justify"><b><i>Foreign currency translations and transactions</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s reporting currency is the United
States dollar (&#8220;USD&#8221;). The functional currency of the Group and its subsidiary which is incorporated in Hong Kong is HKD,
which is its respective local currency based on the criteria of ASC 830, &#8220;Foreign Currency Matters&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s financial statements are reported
using USD. The results of operations and the consolidated statements of cash flows denominated in foreign currency are translated at the
average rate of exchange during the reporting period. Assets and liabilities denominated in foreign currencies at the balance sheet date
are translated at the applicable rates of exchange in effect at that date. The equity denominated in the functional currency is translated
at the historical rate of exchange at the time of capital contribution. Because cash flows are translated based on the average translation
rate, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with
changes in the corresponding balances on the consolidated balance sheets. Translation adjustments arising from the use of different exchange
rates from period to period are included as a separate component of accumulated other comprehensive income (loss) included in consolidated
statements of changes in equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Translation of amounts from HKD into USD has been
made at the following exchange rates:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 1.4pt">Period end USD: HKD exchange rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8259</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8499</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended <br/>
March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 1.4pt">Average USD: HKD exchange rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8246</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8389</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(e).</i></b></td><td style="text-align: justify"><b><i>Cash</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash comprise cash at bank and on hand which are
unrestricted as to withdrawal or use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(f).</i></b></td><td style="text-align: justify"><b><i>Accounts receivable, net</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable are stated at the original
amount less an allowance for credit losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable are recognized in the period
when the Group has provided services to its customers and when its right to consideration is unconditional. On April 1, 2022, the Group
adopted ASU 2016-13, &#8220;Financial Instruments-Credit Losses (Topic 326): Measurement on Credit Losses on Financial Instruments&#8221;,
including certain subsequent amendments, transitional guidance and other interpretive guidance within ASU 2018-19, ASU 2019-04, ASU 2019-05,
ASU 2019-11, ASU 2020-02 and ASU 2020-03 (collectively, including ASU 2016-13, &#8220;ASC 326&#8221;). ASC 326 introduces an approach
based on expected losses to estimate the allowance for credit losses, replacing the previous incurred loss impairment model, which makes
allowances when there is substantial doubt as to the collectability and a loss is determined to be probable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group adopts the current expected credit loss
model (&#8220;CECL model&#8221;) to estimate the expected credit losses, which is determined by multiplying the probability of default.
In determining the probability of default, the Group mainly considers factors such as aging schedule of receivables, migration rate of
receivables, assessment of receivables due from specific identifiable counterparties that are considered at risk or uncollectible, current
market conditions, as well as reasonable and supportable forecasts of future economic conditions. The Group concludes that there is no
impact over the initial adoption of CECL model, which should be treated as cumulative-effect adjustment on accumulated deficits as of
April 1, 2022. Accounts receivable balances are written off after all collection efforts have been exhausted.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 264 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(g).</i></b></td><td style="text-align: justify"><b><i>Factoring receivables, net</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Factoring receivables, net mainly represent amounts
due from customers, including the funds extended by the Group to qualified customers, including the merchants, through its factoring arrangements
and are recorded net of allowance for credit losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group adopts the CECL model to estimate the
expected credit losses on a collective (pooled) basis that share similar risk characteristics. The assumptions considered when determining
the allowance for credit losses for factoring receivables include probability of default (&#8220;PD&#8221;) and loss given default (&#8220;LGD&#8221;),
adjusted for forward-looking macroeconomic conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2024 and 2023, the balance credit
losses of the factoring receivables was USD2,792 and USD4,878, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(h).</i></b></td><td style="text-align: justify"><b><i>Related parties</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Related parties, which can be a corporation or
individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise
significant influence over the other party in making financial and operational decisions. Companies are also considered to be related
if they are subject to common control or common significant influence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Transactions between related parties commonly
occurring in the normal course of business are considered to be related party transactions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(i).</i></b></td><td style="text-align: justify"><b><i>Property and equipment, net</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment, net are stated at cost
less accumulated depreciation and impairment, if any, and depreciated on a straight-line basis over the estimated useful lives of the
assets. Cost represents the purchase price of the asset and other costs incurred to bring the asset into its intended use. Estimated useful
lives and residual value are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 40%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Category</b></p></td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 59%; font-weight: bold; text-align: left">Estimated useful lives</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Solar pump system</td><td>&#160;</td>
    <td>11 years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Electronic office equipment</td><td>&#160;</td>
    <td>5 years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td>5 years</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">Over the shorter of lease term or the estimated useful lives of the assets</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Repair and maintenance costs are charged to expenses
as incurred, whereas the cost of renewals and betterment that extends the useful lives of property and equipment are capitalized as additions
to the related assets. Retirements, sales and disposals of assets are recorded by removing the costs, accumulated depreciation and impairment
with any resulting gain or loss recognized in the consolidated statements of income and comprehensive income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(j).</i></b></td><td style="text-align: justify"><b><i>Intangible assets, net</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intangible assets, net that are acquired by the
Group are stated at cost less accumulated amortization (where the estimated useful life is finite) and accumulated impairment losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Amortization
                                            is calculated write off the cost of intangible assets with finite useful lives using straight-line
                                            method over their estimated useful lives and is generally recognized in profit or loss. The
                                            Group&#8217;s intangible assets is AIaaS related software, integrating cutting-edge AI technologies
                                            to deliver intelligent business automation solutions, including HR resources management and
                                            workflow approval system, CRM and data management system and an AI business assistant with
                                            diverse platforms and enterprise systems. AIaaS-related software, which is acquired in the
                                            course of business operations, is defined as internal-use software, as the Group delivers
                                            its software as a cloud-based solution and customers cannot take possession of the software
                                            during the hosting or subscription period without significant penalty. Subsequent to the
                                            initial release, costs incurred for software updates and enhancements that added significant
                                            new features or improved functionality were capitalized, while routine maintenance and minor
                                            upgrades were expensed as incurred. The AIaaS related software have a finite useful life
                                            that is dependent to the AIaaS interactive marketing business of the Group. The estimated
                                            useful lives are as follows:</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 40%; font-weight: bold; text-align: justify">Category</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 59%; font-weight: bold; text-align: justify">Estimated useful lives</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">AIaaS related software</td><td>&#160;</td>
    <td style="text-align: justify">10 years</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 265 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(k).</i></b></td><td style="text-align: justify"><b><i>Impairment of long-lived assets</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group reviews its long-lived assets for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. When these events
occur, the Group measures impairment by comparing the carrying value of the long-lived assets to the estimated undiscounted future cash
flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flow
is less than the carrying amount of the assets, the Group would recognize an impairment loss, which is the excess of carrying amount over
the fair value of the assets, which is determined through various valuation techniques including discounted cash flow models, quoted market
values and third-party independent appraisals, as considered necessary. The Group did not record any impairment loss of long-lived assets
for the years ended March 31, 2024 and 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(l).</i></b></td><td style="text-align: justify"><b><i>Lease</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group has entered into lease agreement to
secure office space. Effective April 1, 2022, the Group adopted ASC&#160;842, which requires that lessees shall recognize assets and liabilities
on the balance sheet for most leases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At inception of a contract, the Group assesses
whether a contract is, or contains, a lease. A contract is or contains a lease if it conveys the right to control the use of an identified
asset for a period of time in exchange of a consideration. To assess whether a contract is or contains a lease, the Group assess whether
the contract involves the use of an identified asset, whether it has the right to obtain substantially all the economic benefits from
the use of the asset and whether it has the right to control the use of the asset.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Right-of-use (&#8220;ROU&#8221;) assets represent
the Group&#8217;s rights to use underlying assets for the lease term and lease liabilities represent the Group&#8217;s obligation to make
lease payments arising from the lease. Operating lease ROU assets and lease liabilities are recognized at commencement date. Lease expense
for lease payments is recognized on a straight-line basis over the lease term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Operating lease ROU assets</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The right-of-use assets are initially measured
at cost, which comprise the initial amounts of the lease liabilities adjusted for any lease payments made at or before the commencement
date, plus any initial direct costs incurred and less any lease incentive received.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Operating lease liabilities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lease liabilities are initially measured at the
present value of the outstanding lease payments at the commencement date, discounted using the discount rate for the leases. As most of
the Group&#8217;s leases do not provide an implicit rate, the Group uses its incremental borrowing rate based on the information available
at lease commencement date in determining the present value of lease payments. The Group&#8217;s lease terms may include options to extend
or terminate the lease when it is reasonably certain that the Group will exercise that option.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lease liabilities are measured at amortized cost
using the effective interest rate method. They are re-measured when there is a change in future lease payments, if there is a change in
the estimate of the amount expected to be payable under a residual value guarantee, or if there is any change in the Group assessment
of option purchases, contract extensions or termination options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(m).</i></b></td><td style="text-align: justify"><b><i>Investment in insurance contracts</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group invests in life insurance contracts
for key management. The insurance contracts are initially recognized at the amount of premium paid, and subsequently measured at end of
each reporting period at the cash surrender value that could be realized under the insurance policy, which is primarily based on the guaranteed
cash value stated on the annual statement from the insurance company. Changes to the cash surrender value at end of each reporting period
will be recognized in other income or other expenses in the consolidated statements of income. Any gain or loss on the derecognition of
the investment in the event of death of the insured person, the surrender of the policy, or upon the maturity of the policy, will be recognized
in other income or other expenses in the consolidated statements of income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(n).</i></b></td><td style="text-align: justify"><b><i>Short-term borrowings</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Short-term borrowings represent the Group&#8217;s
borrowings from commercial banks for the Group&#8217;s working capital. Short-term borrowings include borrowings with maturity terms shorter
than one year.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 266 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(o).</i></b></td><td style="text-align: justify"><b><i>Ordinary shares</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ordinary shares are classified as equity. Incremental
costs directly attributable to the issuance of new shares are recognized in equity as a deduction, net of tax, from the proceeds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(p).</i></b></td><td style="text-align: justify"><b><i>Non-controlling interests</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Group&#8217;s majority-owned subsidiaries,
a non-controlling interest is recognized to reflect the portion of their equity which is not attributable, directly or indirectly, to
the Group. Consolidated net loss on the consolidated statements of operation and comprehensive loss includes the net loss attributable
to non-controlling interests. The cumulative results of operations attributable to non-controlling interests, are recorded as non-controlling
interests in the Group&#8217;s consolidated balance sheets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(q).</i></b></td><td style="text-align: justify"><b><i>Employee benefits</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><i>(i)</i></td><td style="text-align: justify"><i>Short-term employee benefits</i></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 44pt; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Short-term employee benefits are expensed
as the related service is provided. A liability is recognized for the amount expected to be paid if the Group has a present legal or constructive
obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 44pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><i>(ii)</i></td><td style="text-align: justify"><i>Contributions to defined contribution plans</i></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 44pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Group participates in a pension scheme
under the rules and regulations of the Mandatory Provident Fund Scheme Ordinance (the &#8220;MPF Scheme&#8221;) for all employees in Hong
Kong, which is a defined contribution retirement scheme. The contributions to the MPF Scheme are based on minimum statutory contribution
requirement of 5% of eligible employees&#8217; relevant aggregate income. Contributions to the plan vest immediately. There are no forfeited
contributions for the MPF Scheme as the contributions are fully vested to the employees upon payment to the scheme. The assets of this
pension scheme are held separately from those of the Group in independently administered funds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(r).</i></b></td><td style="text-align: justify"><b><i>Fair value measurement</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group applies ASC 820, Fair Value Measurements
and Disclosures (&#8220;ASC 820&#8221;). ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures
about fair value measurements. ASC 820 requires disclosures to be provided on fair value measurement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820 establishes a three-tier fair value hierarchy,
which prioritizes the inputs used in measuring fair value as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1-Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities
                                            in active markets;</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2-Include other inputs other than quoted prices in active market; and</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3-Unobservable inputs which are supported by little or no market activity that are significant
                                            to the fair value of the assets and liabilities. This includes certain pricing models, discounted
                                            cash flow methodologies and similar techniques that use significant unobservable inputs.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820 describes three main approaches to measuring
the fair value of assets and liabilities: (1) market approach; (2) income approach and (3) cost approach. The market approach uses prices
and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income
approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated
by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to
replace an asset.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial assets and liabilities of the Group
primarily consisted of cash, accounts receivable, factoring receivable, prepayment, deposits and other receivables, amounts due from related
parties, investment in insurance contracts, accounts payable, accruals and other payables, amounts due to related parties and short-term
borrowings. As of March 31, 2024 and 2023, the carrying amounts of the Group&#8217;s financial instruments approximated to their fair
value of the respective assets and liabilities based upon the short-term nature of these assets and liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 267 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(s).</i></b></td><td style="text-align: justify"><b><i>Revenue recognition</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 606 Revenue from Contracts with Customers
(&#8220;ASC 606&#8221;) establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and
cash flows arising from the entity&#8217;s contracts to provide goods or services to customers. The core principle requires an entity
to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects
to be entitled to receive in exchange for those goods or services recognized as performance obligations are satisfied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To determine revenue recognition for contracts
with customers, the Group performs the following five steps:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">Step</td><td style="text-align: justify">1: &#160;&#160;&#160;&#160;&#160;&#160;&#160;Identify the contract with the customer</td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">Step</td><td style="text-align: justify">2:  &#160;&#160;&#160;&#160;&#160;&#160;&#160;Identify the performance obligations in the contract</td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">Step</td><td style="text-align: justify">3:  &#160;&#160;&#160;&#160;&#160;&#160;&#160;Determine the transaction price</td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">Step</td><td style="text-align: justify">4:  &#160;&#160;&#160;&#160;&#160;&#160;&#160;Allocate the transaction price to the performance obligations
in the contract</td>
</tr></table><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">Step</td><td style="text-align: justify">5:  &#160;&#160;&#160;&#160;&#160;&#160;&#160;Recognize revenue when the company satisfies a performance
obligation</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">AIaaS services</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Group offers AIaaS services to the customers
through HR resources management and workflow approval system, CRM and data management system and an AI business assistant with diverse
platforms and enterprise systems. The Group has identified that the nature of its overall promise to customers includes (i) implementation
service, (ii) AIaaS in the subscription periods, and (iii) maintenance and unspecific upgrades service. The promises are highly interrelated
to provide a combined output of smooth and high-quality AIaaS service during the subscription period. Therefore, the Group identifies
only one performance obligation to provide AIaaS service.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue from AIaaS services is recognized ratably
over time over the contract term beginning on the date that the AIaaS service is made available to the customer, whereby the Group considers
that its customers simultaneously receive and consume the benefits provided by the use of existing applications. The Group does not have
other right to consideration in exchange for goods or service that the Group has transferred to a customer when that right is conditional
on something other than the passage of time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The contract terms generally consist of one-year
subscription period. Payments received in advance of services being rendered are recorded as deferred revenue. The contract payment is
not subject to any variable consideration, refund, cancellation or termination provision. The Group takes the practical expedient and
will not adjust the impact of a financing component for deferred revenue which will be earned within one year. Revenue is recognized
ratably over time, over the requisite service period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Insurance brokerage services</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group provides insurance brokerage service
distributing on behalf of insurance companies. As an agent of the insurance company, the Company sells insurance policies, primarily short-term
insurance products, on behalf of the insurance company and earns commissions determined as a percentage of premiums paid by the insured.
Revenue from insurance brokerage services is recognized at a point in time when the brokered insurance policies are executed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Factoring services</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group generated revenue from factoring services
that the customer sells or transfers its accounts receivable to the Group in exchange for immediate funds. The Group generated non-interest
income including factoring commission, set up fee etc., under ASC 606 and interest income under ASC 310 Receivables (&#8220;ASC 310&#8221;).
The non-interest income is recognized at a point in time upon commencement of factoring transaction. The interest income, using effective
interest method under ASC 310, is recognized over time over the recourse period beginning on the date that the advance payment to the
customers and ends upon the withdraw of the factoring receivable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Others</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group also derives revenues from other products
and services such as sales of office supplies and others. The Group recognizes revenue at a point in time when title and risk of loss
passes and the customer accepts the goods or services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 268 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table disaggregates the Group&#8217;s
revenue for the years ended March 31, 2024 and 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended<br/>
 March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">By revenue stream</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.85pt">AIaaS services</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">29,088,722</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21,092,035</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">Insurance brokerage services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">292,580</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117,793</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.85pt">Factoring services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">158,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">227,215</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 0.85pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,311</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,911</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.85pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">29,633,327</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">21,456,954</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended<br/>
 March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">By revenue recognition time</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.85pt">Over time</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">29,226,712</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21,202,701</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">At a point in time</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">406,615</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">254,253</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.85pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">29,633,327</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">21,456,954</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration:underline">Contract balances</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Timing of revenue recognition may differ from
the timing of invoicing to customers. Accounts receivable represent amounts invoiced and revenue recognized prior to invoicing when the
Group has satisfied its performance obligations and has the unconditional right to payment. The Group normally does not have contract
assets, which are primarily unbilled accounts receivable that are conditional on something other than the passage of time. The Group did
not have contract assets as of March 31, 2024 and 2023, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A contract liability is recognized when the customer
pays non-refundable consideration before the Group recognizes the related revenue. A contract liability would also be recognized if the
Group has an unconditional right to receive non-refundable consideration before the Group recognizes the related revenue. In such cases,
a corresponding receivable would also be recognized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a single contract with the customer, either
a net contract asset or a net contract liability is presented. For multiple contracts, contract assets and contract liabilities of unrelated
contracts are not presented on a net basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred revenue amounted to USD16,850,228 and
USD14,083,796 as of March 31, 2024 and 2023, respectively. Revenue included in the beginning balance of deferred revenue and recognized
in the&#160;period ended March 31, 2024 and 2023&#160;amounted to USD14,083,796&#160;and USD9,374,774, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(t).</i></b></td><td style="text-align: justify"><b><i>Cost of revenues</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost of revenues primarily comprises (i) commission
paid to third-party sales agents, (ii) amortization expenses related to the Group&#8217;s software and systems, (iii) salaries and benefits
of relevant operations and support personnel, and (iv) other direct service costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(u).</i></b></td><td style="text-align: justify"><b><i>Selling and marketing expenses</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Selling and marketing expenses consist primarily
of (i)&#160;advertising and promotion expenses, and (ii)&#160;salary and welfare for sales and marketing personnel.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 269 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(v).</i></b></td><td style="text-align: justify"><b><i>Administrative expenses</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses consist primarily
of (i)&#160;salary and welfare for administrative personnel, (ii)&#160;professional service fees, (iii) depreciation of fixed assets,
(iv) lease expenses, and (v)&#160;allowance for credit losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(w).</i></b></td><td style="text-align: justify"><b><i>Research and development expenses</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses consist primarily
of (i)&#160;salary and welfare for research and development personnel and (ii) costs incurred during the research stage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(x).</i></b></td><td style="text-align: justify"><b><i>Income tax</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group accounts for income taxes under ASC
740. Provision for income taxes consists of current taxes and deferred taxes. Current tax is recognized based on the results for the year
as adjusted for items which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively
enacted by the balance sheet date. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to
differences between the combined financial statement carrying amounts of existing assets and liabilities and their respective tax bases
that will be in effect when the differences are expected to reverse. Deferred tax assets and liabilities are measured using enacted tax
rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The
effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period including the enactment date.
Valuation allowances are established, based on a more-likely-than-not threshold, to reduce deferred tax assets to the amount expected
to be realized. The Group&#8217;s ability to realize deferred tax assets depends on each individual entity&#8217;s ability to generate
sufficient taxable income within the carry forward periods provided for in the tax law. Current income taxes are provided for in accordance
with the laws of the relevant taxing authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The provisions of ASC 740-10-25, &#8220;Accounting
for Uncertainty in Income Taxes&#8221;, prescribe a more-likely-than-not threshold for combined financial statement recognition and measurement
of a tax position taken (or expected to be taken) in a tax return. This interpretation also provides guidance on the recognition of income
tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties
associated with tax positions, and related disclosures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group did not accrue any liability, interest
or penalties related to uncertain tax positions in its provision for income taxes line of its consolidated statements of income for the
years ended March 31, 2024 and 2023, respectively. The Group does not expect that its assessment regarding unrecognized tax positions
will materially change over the next 12 months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(y).</i></b></td><td style="text-align: justify"><b><i>Earnings/(loss) per share</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0in; text-align: justify">The Company computes earnings per share
(&#8220;EPS&#8221;) in accordance with ASC 260, &#8220;Earnings per Share&#8221; (&#8220;ASC 260&#8221;). ASC 260 requires companies with
complex capital structures to present basic and diluted EPS. Basic EPS are computed by dividing income available to ordinary shareholders
of the Company by the weighted average ordinary shares outstanding during the period. The Group&#8217;s convertible redeemable preferred
shares are participating securities as they participate in undistributed earnings on an as-if-converted basis. Accordingly, the Group
uses the two-class method whereby undistributed net income is allocated on a pro rata basis to the ordinary shares and preferred shares
to the extent that each class may share in income for the period; whereas the undistributed net loss for the period is allocated to ordinary
shares only because the convertible redeemable preferred shares are not contractually obligated to share the loss. Diluted EPS takes into
account the potential dilution that could occur if securities or other contracts to issue ordinary shares were exercised and converted
into ordinary shares. Potential dilutive securities are excluded from the calculation of diluted loss per share in loss periods as their
effect would be anti-dilutive. As of March 31, 2024 and 2023, there were nil and nil dilutive potential ordinary shares of the Group,
respectively.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 270 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b><i>(z).</i></b></td><td style="text-align: justify"><b><i>Segment reporting</i></b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating segments, and the amounts of each segment
item reported in the financial statements, are identified from the financial information provided regularly to the Group&#8217;s most
senior executive management for the purposes of allocating resources to, and assessing the performance of, the Group&#8217;s various lines
of business and geographical locations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Individually material operating segments are not
aggregated for financial reporting purposes unless the segments have similar economic characteristics and are similar in respect of the
nature of products and services, the type or class of customers, the methods used to distribute the products or provide the services,
and the nature of the regulatory environment. Operating segments which are not individually material may be aggregated if they share a
majority of these criteria.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group operates in only one segment. As the
Group&#8217;s long-lived assets are substantially located in the HK and the majority of the Group&#8217;s revenue are derived from the
HK with all operation being carried out in the HK, no geographical segments are presented.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 22pt"><b><i>(aa).</i></b></td><td style="text-align: justify"><b><i>Recently issued accounting pronouncements </i></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is an &#8220;emerging growth company&#8221;
(&#8220;EGC&#8221;) as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, EGC
can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards
apply to private companies. The Group does not opt out of extended transition period for complying with any new or revised financial accounting
standards. Therefore, the Company&#8217;s financial statements may not be comparable to companies that comply with public company effective
dates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In
                                            August 2020, the FASB issued ASU 2020-06, Debt-Debt with Conversion and Other Options (Subtopic
                                            470-20) and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815
                                            40). The ASU simplifies the accounting for certain financial instruments with characteristics
                                            of liabilities and equity. The FASB reduced the number of accounting models for convertible
                                            debt and convertible preferred stock instruments and made certain disclosure amendments to
                                            improve the information provided to users. In addition, the FASB amended the derivative guidance
                                            for the &#8220;own stock&#8221; scope exception and certain aspects of the EPS guidance.
                                            For public business entities that meet the definition of an SEC filer, excluding entities
                                            eligible to be smaller reporting companies as defined by the SEC, the guidance is effective
                                            for fiscal years beginning after December 15, 2021, including interim periods within those
                                            fiscal years. For all other entities, the guidance is effective for fiscal years beginning
                                            after December 15, 2023, including interim periods within those fiscal years. Early adoption
                                            is permitted, but no earlier than fiscal years beginning after December 15, 2020, including
                                            interim periods within those fiscal years. The Group elects to early adopt ASU2020-06 from
                                            April 1, 2021.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2023, the FASB issued ASU 2023-06,
&#8220;Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative.&#8221;
This ASU incorporates certain U.S. Securities and Exchange Commission (SEC) disclosure requirements into the FASB Accounting Standards
Codification. The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of Codification
Topics, allow users to more easily compare entities subject to the SEC&#8217;s existing disclosures with those entities that were not
previously subject to the requirements, and align the requirements in the Codification with the SEC&#8217;s regulations. For entities
subject to the SEC&#8217;s existing disclosure requirements and for entities required to file or furnish financial statements with or
to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer,
the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. For all other
entities, the amendments will be effective two years later. However, if by June 30, 2027, the SEC has not removed the related disclosure
from its regulations, the amendments will be removed from the Codification and not become effective for any entity. The Company does not
expect the adoption of ASU 2023-06 to have a material impact on its consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2023, the FASB issued ASU 2023-07,
which modifies the disclosure and presentation requirements of reportable segments. The new guidance requires the disclosure of significant
segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported
measure of segment profit and loss. In addition, the new guidance enhances interim disclosure requirements, clarifies circumstances in
which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with
a single reportable segment, and contains other disclosure requirements. The update is effective for annual periods beginning after December
15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not
expect that the adoption of ASU 2023-07 will have a material impact on its consolidated financial statements disclosures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 271 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09,
Improvement to Income Tax Disclosure. This standard requires more transparency about income tax information through improvements to income
tax disclosures primarily related to the rate reconciliation and income taxes paid information. This standard also includes certain other
amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for public business entities, for annual periods
beginning after December 15, 2024. For entities other than public business entities, the amendments are effective for annual periods beginning
after December 15, 2025. The Company is in the process of evaluation the impact of adopting this new guidance on its consolidated financial
statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2024, the FASB issued ASU 2024-03,
Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40), to improve the disclosures about
an entity&#8217;s expenses including more detailed information about the types of expenses in commonly presented expense captions (&#8220;ASU
2024-03&#8221;). In January 2025, the FASB issued ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation
Disclosures (Subtopic 220-40): Clarifying the Effective Date (&#8220;ASU 2025-01&#8221;). At each interim and annual reporting period,
entities will disclose in tabular format disaggregating information about prescribed categories underlying relevant income statement captions,
as well as the total amount of selling expense and a description of the composition of its selling expense. ASU 2024-03, as clarified
by&#160;ASU 2025-01, is effective for annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting
periods beginning after December 15, 2027.&#160;The Company will adopt the amendments in this ASU for its fiscal year beginning on January
1, 2027. The Company is in the process of evaluation the impact of adopting this new guidance on its consolidated financial statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other accounting standards that have been issued
by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements
upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on, or are unrelated to,
its consolidated financial condition, results of operations, cash flows or disclosures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>3.</b></td><td style="text-align: justify"><b>ACCOUNTS RECEIVABLE, NET</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounts receivable, net consisted of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.85pt">Account receivables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20,030,075</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,401,848</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Less: provision for credit losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(230,311</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(821,799</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.85pt">Total accounts receivable, net</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">19,799,764</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">12,580,049</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 2, 2024, the Group entered into an
accounts receivable factoring agreement with Intrabase Financial Services Limited (&#8220;Intrabase&#8221;) with recourse right (the &#8220;Factoring
Agreement&#8221;). The Factoring Agreement allowed for a prepayment of USD3,191,965, which were collateralized by assigned eligible accounts
receivable of USD7,232,257, with an interest rate of 12% per annum. The Group has continuing involvement with the assigned accounts receivable
due to the recourse rights, which did not meet the derecognition criteria to derecognize the assigned accounts receivable. Therefore,
proceeds from the factoring were accounted for as a secured borrowing with the pledge of collateral.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Details of the movements of provision of credit losses are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended<br/>
 March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.85pt">Balance at beginning of the years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">821,799</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">46,073</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">(Reversal)/provision of credit losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(594,108</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">776,917</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,620</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,191</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.85pt">Balance at end of the years</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">230,311</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">821,799</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 272 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>4.</b></td><td style="text-align: justify"><b>FACTORING RECEIVABLES, NET</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Factoring receivables, net consisted of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.85pt">Factoring receivables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">326,620</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">462,782</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Less: provision of credit losses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,792</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,878</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.85pt">Total factoring receivables, net</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">323,828</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">457,904</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Details of the movements of provision of credit losses are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended<br/>
 March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-align: left; padding-left: 0.85pt">Balance at beginning of the years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,878</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,585</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">Reversal of credit losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,101</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,693</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.85pt">Balance at end of the years</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,792</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,878</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>5.</b></td><td style="text-align: justify"><b>PREPAYMENT, DEPOSITS AND OTHER RECEIVABLES, NET</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prepayment, deposits and other receivables, net consisted of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.85pt">Prepayment for technology services</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,537,255</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepayment for obtaining contract <sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,555,894</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,772,159</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.85pt">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161,254</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,582</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">Prepayment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,912</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,865</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.85pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,058</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.85pt">Total prepayment, deposits and other receivables, net</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,755,118</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">7,585,861</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="-keep: true">(1)</span></td><td style="text-align: justify"><span style="-keep: true">The prepayment consisted
                                            of sales commission to sales agents for obtaining sales contracts, which was charged into
                                            cost of revenues on a ratable basis in line with the revenue recognition.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>6.</b></td><td style="text-align: justify"><b>PROPERTY AND EQUIPMENT, NET</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and equipment, net consisted of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.85pt">Leasehold improvement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">671,266</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">669,213</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">Solar pump system</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">245,721</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">244,969</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.85pt">Electronic office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196,356</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">195,755</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,697</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(667,684</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(398,892</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.85pt">Property and equipment, net</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">451,373</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">716,742</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Depreciation expenses were USD267,612 and USD252,949 for the years
ended March 31, 2024 and 2023, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 273 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>7.</b></td><td style="text-align: justify"><b>INTANGIBLE ASSETS, NET</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 0.85pt">Software</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">35,778,632</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">22,929,323</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,586,961</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,654,814</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.85pt">Intangible assets, net</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">28,191,671</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">18,274,509</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amortization expenses were USD2,918,357 and USD1,874,061 for the years
ended March 31, 2024 and 2023, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Future estimated amortization expenses of intangible assets are as
follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">For the years ending March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.85pt">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,917,872</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,917,872</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.85pt">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,917,872</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,917,872</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.85pt">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,917,872</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,602,311</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.85pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">28,191,671</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>8.</b></td><td style="text-align: justify"><b>INVESTMENT IN INSURANCE CONTRACTS</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group entered into a key management insurance
policy for the founder to secure that the operation of the Group will not be affected by the death and loss of position of the founder.
The fair value of the investment in key management insurance policy is determined at end of each reporting period at the cash surrender
value that could be realized under the insurance policy, which is primarily based on the guaranteed cash value stated on the annual statement
from the insurance company. The fair value measurement of the investment in key management insurance policy has been categorized as Level
3 based on the inputs to the valuation technique used and is positively correlated to the surrender cash value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-align: left; padding-left: 0.85pt">Balance at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,032,529</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">252,897</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.85pt">Purchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">932,107</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.85pt">Surrender</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(231,404</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">Cash surrender value changes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,921 </td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(152,141</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Foreign exchange impact</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,506</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(334</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.85pt">Balance at end of the year</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">835,540</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,032,529</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 274 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in"><b>9.</b></td><td style="text-align: justify"><b>ACCRUALS AND OTHER PAYABLES</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Accruals and other payables consisted of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.85pt">Accrued salaries</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,558,047</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">604,806</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses <sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,094,259</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">804,660</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.85pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">155,397</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">183,714</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.85pt">Accruals and other payables</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,807,703</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,593,180</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Accrued expenses as of March 31, 2024 and 2023 mainly included
payable professional fees, payable advertising fees, payable commission fees, payable rental expenses and other miscellaneous expenses
such as utilities and office expenses for daily operations.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>10.</b></td><td style="text-align: justify"><b>SHORT-TERM BORROWINGS</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">As of March 31, 2024 and 2023, short-term borrowings consisted
of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>Lender</b></td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"><b>Types of loans</b></td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"><b>Maturity date</b></td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom"><b>Interest Rate</b></td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; text-align: left; font-weight: bold"/><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td>
    <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: center; font-weight: bold"/><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td>
    <td style="vertical-align: top; padding-bottom: 1.5pt; font-weight: bold; text-align: center"/><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"/><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; padding-bottom: 1.5pt"><b>USD</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="text-align: center; padding-bottom: 1.5pt"><b>USD</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; width: 26%; text-align: left; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intrabase Financial Services Limited&#160;<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 20%; text-align: center; padding-left: 0.85pt">Loans from third parties</td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 13%; text-align: center; padding-left: 0.85pt">N/A</td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 13%; text-align: center">12.0%</td><td style="width: 1%; text-align: left"/><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,191,965</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Leon Cheng</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">Loans from third parties</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">2025-01-11</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">12.0%</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">511,123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Leon Cheng</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">Loans from third parties</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">2024-04-15</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">12.0%</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191,671</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">ORIX Asia Limited</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">Loans from third parties</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">2024-03-28</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7% - 8.5%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">457,813</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">IACF (Hong Kong) limited</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">Loans from third parties</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">2024-01-12</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.4% - 19.4%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">447,140</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Standard Chartered Bank (Hong Kong) Limited <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">Revolving Loan</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">2024-04-29</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">7.3%</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">894,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Heng Seng Bank Limited <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">Revolving Loan</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">2029-04-13</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hongkong Inter-Bank Offered Rate (&#8220;HIBOR&#8221;) +2.5%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">319,452</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">318,475</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Heng Seng Bank Limited <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">Revolving Loan</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">2029-04-13</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIBOR+2.5%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191,671</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191,085</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Heng Seng Bank Limited <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">Revolving Loan</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">2029-04-13</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIBOR+2.5%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,781</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,390</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Standard Chartered Bank (Hong Kong) Limited <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">Revolving Loan</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">2023-11-27</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIBOR+2.5%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">891,731</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Heng Seng Bank Limited <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">Revolving Loan</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">2023-04-28</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIBOR+3.5%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">445,866</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DBS Bank (Hong Kong) Limited <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">Installment Loan</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">2027-06-27</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5% p.a. below Prime rate</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">662,947</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">687,596</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Heng Seng Bank Limited</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">Term Loan</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">2029-02-25</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">3.6%</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">592,665</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">628,957</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Heng Seng Bank Limited</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">Term Loan</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">2029-07-15</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">3.6%</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">126,773</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,390</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Heng Seng Bank Limited</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">Term Loan</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">2025-12-11</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HBR+3.5%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420,388</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Heng Seng Bank Limited</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">Term Loan</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">2025-05-27</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">5.0%</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">354,938</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Heng Seng Bank Limited</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">Term Loan</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">2025-05-02</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">5.4%</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">187,906</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in">Heng Seng Bank Limited</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">Term Loan</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">2027-04-27</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">2.0%</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,964</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DBS Bank (Hong Kong) Limited <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: center; padding-left: 0.85pt; vertical-align: top">Overdraft</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-left: 0.85pt">N/A</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">arrears at 3% per annum below USD Prime Rate</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192,245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,990</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">DBS Bank (Hong Kong) Limited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 0.85pt; vertical-align: top">Overdraft</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 1.5pt; padding-left: 0.85pt">N/A</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5% p.a. below Prime rate</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">101,820</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 0.85pt; vertical-align: top">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-bottom: 2.5pt; padding-left: 0.85pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="vertical-align: top; padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">7,002,759</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,690,449</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.5in">(1)</td><td style="text-align: justify">On February 2, 2024, the Group entered into Factoring Agreement with Intrabase (See Note 3) to obtain
borrowings secured by accounts receivable for the purpose of business financing with interest rates of 12.0%. Since the Factoring Agreement
was with recourse, the accounts receivable factoring transaction did not qualify as a transfer of financial assets to be considered as
a sale under ASC860, and was accounted for as short-term borrowings without derecognition of accounts receivable. The assigned eligible
accounts receivable collateralized were USD7,232,257.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 275 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.5in">(2)</td><td style="text-align: justify">For the years ended March 31, 2024 and 2023, the Group entered into agreements with DBS Bank (Hong Kong)
Limited, Heng Seng Bank Limited and Standard Chartered Bank (Hong Kong) Limited to obtain revolving loan with interest rates range from
2.5%-3.5% per annum over HIBOR.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 20pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.5in">(3)</td><td style="text-align: justify">On June 21, 2022, the Group entered into an agreement with DBS Bank (Hong Kong) Limited ("DBS")
for an overdraft facility of HKD1,500,000 (USD191,671) with an interest rate of 2.5% per annum below Prime Rate and an installment loan
of USD715,859 with an interest rate of 3% per annum below USD Prime Rate.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The interest expenses of short-term borrowings
were USD384,718 and USD285,571 for the years ended March 31, 2024 and 2023, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>11.</b></td><td style="text-align: justify"><b>MEZZANINE EQUITY</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Issuance of Redeemable Convertible Preferred
Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From 2017 to 2023, the Company has completed several
rounds of equity financing by issuing redeemable convertible preferred shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2017 and February 2018, YOOV Internet,
the subsidiary of the Company, entered into share subscription agreements to issue 71,119 Angel Round redeemable convertible preferred
shares (&#8220;Angel Round Preferred Shares&#8221;) at a price of USD22.44 per share. In July, 2021, the holders of Angel Round Preferred
Shares entered into application for shares with YOOV Internet and the Company. Since the Angel Round Preferred Shares were initially issued
by YOOV Internet in 2017 and 2018, and the core business was transferred from YOOV Internet to the Company, the holders therefore, request
the YOOV Internet to transfer the Angel Round Preferred Shares to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2021, the Company entered into subscription
agreements to issue 20,334 Series A redeemable convertible preferred shares (&#8220;Series A Preferred Shares&#8221;), and 13,556 Series
A redeemable ordinary shares (&#8220;Series A Ordinary Shares&#8221;), at a consideration of USD147.54 and USD147.54 per share, respectively.
In connection with the issuance of Series A Preferred Shares, the Company issued warrant of option for the holder to exercise to further
subscribe 20,334 Series A Preferred Shares at the same subscription price of USD147.54 per share within one year. The warrant was fully
exercised in July 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2022, the Company entered into subscription
agreements to issue 47,865 Series A1 redeemable convertible preferred shares (&#8220;Series A1 Preferred Shares&#8221;) at a consideration
of USD368.87 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><b><i>Modification</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">In December 2022, the Company entered into the Amended Shareholders
Agreement with all investors at the date (collectively, &#8220;Preferred Shareholders&#8221;). The Amended Shareholders Agreement modified
the redemption and conversion terms of Series A Preferred Shares, and changed the Series A Ordinary Shares to Series A Preferred Shares
(collectively, &#8220;Modified Series A Preferred Shares&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The following table summarizes the issuance of redeemable convertible
preferred shares (collectively, &#8220;Redeemable Convertible Preferred Shares&#8221;):</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Original Issuance Price per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Consideration</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Angel Round Preferred Shares</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">22.44</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">71,119</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,595,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Modified Series A Preferred Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">147.54</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,224</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Series A1 Preferred Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">368.87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,865</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,654,900</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>


</div><!-- Field: Page; Sequence: 276 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The rights, preferences and privileges of the
Redeemable Convertible Preferred Shares are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Voting Rights</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At all general meetings of the Company and on
all matters with respect to which the shareholders are entitled to vote, the holder of Preferred Shareholders shall have voting rights.
For the purposes of voting at any general meeting of the Company, the Preferred Shareholder shall (i) have one (1) vote per share and
(ii) vote together with the holders of the Common Shares as a single class, except as stipulated in the applicable laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dividend Rights</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Preferred Shareholders shall be entitled to
an annual per share cash dividend equal to 5.0% of the issue price of the relevant Redeemable Convertible Preferred Shares prior to the
payment of any dividend with respect to the ordinary shares, payable when and if declared by the board of directors of the Company and
the Shareholders&#8217; meeting. After payment of the preferential dividend to the Preferred Shareholders, any further dividends would
be paid pari passu to the Preferred Shareholders, and the ordinary shareholders of the Company on a pro rata, as-converted basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Conversion Rights</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For holders of Angel Round Preferred Shares and
Series A Preferred Shares before Modification, the holders shall have the right to convert all or part of its Redeemable Convertible Preferred
Shares into certain number of ordinary shares, exercisable at any time and from time to time during the period beginning on the day after
the closing date and ending on the 5th anniversary of the closing date. The initial conversion price shall be the issue price, and the
initial conversion ratio of a preferred share to ordinary share shall be approximately 1:1. The conversion price shall be subject to adjustment
pursuant to certain issuances, splits and combinations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For holders of Modified Series A and Series A1
Preferred Shares, the holders shall have the right to convert all or part of its Redeemable Convertible Preferred Shares into a certain
number of ordinary shares, exercisable at any time before the third anniversary date of such Redeemable Convertible Preferred Shares.
The number of ordinary shares issuable upon conversion of one share of Redeemable Convertible Preferred Shares shall be one. The conversion
ratio is not subject to any adjustments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Redemption Rights</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For
holders of Angel Round Preferred Shares and Series A Preferred Shares before Modification, holders may request the Company to redeem the
preferred shares, in whole or in part, at any time and from time to time after 4-year anniversary of the closing date. The redemption
price for each share of the Redeemable Convertible Preferred Shares shall be the amount which shall result in an internal rate of return
(</span>&#8220;<span style="font-family: Times New Roman, Times, Serif">IRR</span>&#8221;<span style="font-family: Times New Roman, Times, Serif">),
net of any and all taxes, fees and expenses incurred or to be incurred by the holder of 10% of the issue price for each Redeemable Convertible
Preferred Shares, compounded annually and calculated on the basis of a 365-day year for the actual number of days elapsed from and excluding
the closing date to and including the date of payment of the redemption price (as appropriately adjusted for any bonus issue, stock splits,
stock dividend, consolidation, subdivision, reclassification and the like of the Preferred Shares subsequent to its issuance).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For holders of Series A Ordinary Shares, holders
may request the Company to redeem the ordinary shares after 2 calendar years from the completion date (&#8220;Lock-up Period&#8221;).
At any time after the expiry of the Lock-up Period, the Company shall be required to repurchase any or all of the shares at a unite price
equal to the amount subscription price paid by the investor in return for such subscription shares plus an interest at the rate of 12%
per annum calculated on a non-compounded basis and on the basis of a year of 360 days accruing from the completion date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For holders of Modified Series A Preferred Shares,
holders may require the Company to repurchase any or all of the holders&#8217; Modified Series A Preferred Shares, at any time after October
21, 2023, at a unit share price equal to the issue price of such shares plus an interest at the rate of 12% per annum calculated on a
non-compounded basis and on the basis of a year of 360 days accruing from the completion date within 10 business days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 277 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company fails to pay the redemption price
for the aforementioned scenarios in full within 1 month after receiving the redemption notice from the Preferred Shareholder, the outstanding
amount of the redemption price shall accrue interest at the rate of 20% per annum compounded annually from the date immediately following
the redemption date until the date on which such Preferred Shareholder receives full payment of the outstanding redemption price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For holders of Series A1 Redeemable Convertible
Preferred Shares, holders may request the Company to redeem the shares (&#8220;Put Option&#8221;) if the Company fails to consummate a
Qualified IPO or a Trade Sale by 31 December 2026; or the revenue target of the Group from the fiscal years March 31, 2023 to 2026. The
redemption price equals to the issue price plus an interest at the rate of 12% per annum calculated on a non-compounded basis since the
date of exercise of the Put Option.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Liquidation Preferences </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to Amended Shareholders&#8217; Agreement
dated in December 2022, the liquidation preference of Redeemable Convertible Preferred Shares was as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(i)</td><td style="text-align: justify">After payment of all creditors, including the repayment of bank borrowings, a holder of Angel Round Preferred
Shares then in issue shall be entitled to a distribution of the surplus assets of the Company available for distribution among the holders
of Angel Round Preferred Shares in priority to the holders of Modified Series A Preferred Shares, Series A1 Preferred Shares, and ordinary
shares, based on its shareholding percentage of all the Redeemable Convertible Preferred Shares at the time of the relevant distribution,
up to, in respect of a Preferred Shareholder, the aggregate Issue Price for such holder's Angel Round Redeemable Convertible Preferred
Shares plus such amount that represents a total IRR of 10%;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(ii)</td><td style="text-align: justify">The Modified Series A Preferred Shares, the distribution should be up to the aggregate Issue Price for
such holder&#8217;s Modified Series A Preferred Shares plus such amount that represents a total simple, non-compounding rate of return
of 12%;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(iii)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Series A1 Preferred Shares, the distribution
should be up to the aggregate Issue Price for such holder</span>&#8217;<span style="font-family: Times New Roman, Times, Serif">s Modified
Series A Preferred Shares plus sch amount that represents a total simple, non-compounding rate of return of 12%.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Accounting of Redeemable Convertible Preferred
Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company elects to early adopt ASU2020-06 from
April 1, 2021, which reduced the number of accounting models for convertible preferred stock instruments. The Redeemable Convertible Preferred
Shares are equity host. The Company accounted for the Redeemable Convertible Preferred Shares as mezzanine equity under the section of
the Consolidated Balance Sheets because they were redeemable at the holders&#8217; option any time after a certain date, or were contingently
redeemable upon the occurrence of certain events outside of the Company&#8217;s control. The Redeemable Convertible Preferred Shares were
recorded initially at fair value, net of issuance costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records accretion on the Redeemable
Convertible Preferred Shares, where applicable, to the redemption value pursuant to the redemption terms. The accretion, calculated using
the effective interest method, is recorded against retained earnings, or in the absence of retained earnings, by charging against additional
paid-in capital. For the years ended March 31, 2024 and 2023, the accretions of Redeemable Convertible Preferred Shares were US$264,391and
US$239,667, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Amended Shareholders Agreement in December
2022 modified certain terms of Series A Redeemable Convertible Preferred Shares and Series A Redeemable Ordinary Shares. The amendment
of Series A Redeemable Ordinary Shares was accounted for as extinguishment as the fair value of the Series A Redeemable Ordinary Shares
immediately before and after the amendment was significantly different, while the amendment of Series A Redeemable Convertible Preferred
Shares was accounted for as modification. The Company accounted for the modification and extinguishment that resulted in an increase to
the fair value of the modified Series A Redeemable Convertible Preferred Shares of US$9,035,985 as deemed dividends during the year ended
March 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 278 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s Redeemable Convertible Preferred
Shares activities for the years ended March 31, 2024 and 2023 were summarized below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amounts</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold">Balance as of March 31, 2022</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">105,009</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">7,363,559</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accretion to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,199</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,619,144</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Modification and Extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,035,985</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign exchange impact</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(99,653</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Balance as of March 31, 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">173,208</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">37,158,702</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accretion to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">264,391</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign exchange impact</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">113,912</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance as of March 31, 2024</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">173,208</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">37,537,005</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>12.</b></td><td style="text-align: justify"><b>INCOME TAXES</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>British Virgin Islands (&#8220;BVI&#8221;)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the current laws of BVI, the Company is
not subject to income or capital gains taxes. In addition, dividend payments are not subject to withholdings tax in BVI.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Hong&#160;Kong</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to Tax (Amendment) (No. 3) Ordinance
2019 published by Hong&#160;Kong government, effective April&#160;1, 2019, under the two-tiered profits tax rates regime, the profits
tax rate for the first HK$ 2&#160;million of assessable profits was reduced to 8.25% (half of the rate specified in Schedule&#160;8 to
the Inland Revenue Ordinance (IRO)) for corporations, while the remaining profits will continue to be taxed at the existing 16.5% tax
rate. All subsidiaries were subject to Hong&#160;Kong profit tax during the periods presented.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The income tax provision consisted of the following
components:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended<br/>
 March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.85pt">Current income tax expense</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(9,282</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Deferred income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(351,587</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(119,353</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.85pt">Total income tax expense</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(360,869</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(119,353</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation between the Group&#8217;s actual
provision for income taxes and the provision under the HK statutory rate is as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended <br/>
March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.85pt">Profits/(loss) before tax</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,611,451</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(308,189</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">Tax calculated at 16.5%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">266,256</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(50,571</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.85pt">Income not subject to tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,321</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(45,913</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">Expenses not deductible for tax purposes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,219</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">394</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">109,715</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">215,443</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.85pt">Income tax expense</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">360,869</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">119,353</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 279 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March&#160;31, 2024 and 2023, the significant
components of the deferred tax assets and liabilities were summarized below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.85pt">Net operating loss carried forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,533,449</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,048,630</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">Allowance of credit losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,644</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,239</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Cash surrender value changes of insurance contracts</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,425</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,068</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0.85pt">Total deferred tax assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">3,578,518</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">2,200,937</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(368,245</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(257,758</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Deferred tax assets, net</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,210,273</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,943,179</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right; padding-left: 0.85pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0.85pt">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Accelerated depreciation and amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,651,792</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,029,838</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Deferred tax liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,651,792</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(3,029,838</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.85pt">Net deferred tax liabilities</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,441,519</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,086,659</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Changes in valuation allowance are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-align: left; padding-left: 0.85pt">Balance at beginning of the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">257,758</p></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">42,617</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.85pt">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,017</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">221,343</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.85pt">Decrease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23,302</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,901</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Foreign exchange difference</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">772</p></td><td style="padding-bottom: 1.5pt; text-align: left"/><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(301</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.85pt">Balance at end of the year</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">368,245</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">257,758</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2024 and 2023, the Group had indefinite
loss carryforwards of USD21,413,651 and USD12,426,410, respectively, which arose from the Group&#8217;s subsidiaries in HK.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 280 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>13.</b></td><td style="text-align: justify"><b>LEASE</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company has an operating lease for office as a lessee. Supplemental
balance sheet information related to operating lease was as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-align: left; padding-left: 0.85pt">Operating lease right-of-use asset</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">279,706</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">680,223</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: right; padding-left: 0.85pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.85pt">Operating lease liabilities, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301,003</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">395,003</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Operating lease liabilities, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">300,082</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.85pt">Total lease liabilities</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">301,003</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">695,085</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The discount rate for the operating lease was 5.00% both for the years
ended March 31, 2024 and 2023. The remaining lease term was 8 months as of March 31, 2024</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the years ended March 31, 2024 and 2023, the lease expense was
as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended <br/>
March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.85pt">Operating lease expenses excluding short-term rental expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">428,137</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">464,088</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Short-term lease expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,102</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,450</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.85pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">429,239</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">467,538</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a schedule of future minimum payments under the Company&#8217;s
operating leases as of March 31, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">For the fiscal year ended</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">2025</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">306,674</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0.85pt">Total lease payments</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">306,674</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,671</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.85pt">Total operating lease liabilities, net of interest</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">301,003</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 281 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>14.</b></td><td style="text-align: justify"><b>LOSS PER SHARE</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The following table sets forth the basic and diluted net loss per share
computation and provides a reconciliation of the numerator and denominator for the years presented:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended <br/>
    March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Numerator:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Net income/(loss)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,250,582</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(427,542</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Less: net income/(loss) attributable to non-controlling
    interests</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,695</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(217,368</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Less: deemed dividend of preferred shares' modification
    and extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,035,985</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Less: accretion of redemption value of preferred shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">264,391</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Less: non-cumulative dividend to
    preferred shares prior to any payment of dividend to ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">931,496</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net loss attributable
    to the Company's ordinary shareholders</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(9,485,826</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Weighted average number of ordinary shares - basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Loss per ordinary share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">- Basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47.43</td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The redeemable convertible preferred shares were anti-diluted for the
years ended March 31, 2024 and 2023 since their accretion per common share obtainable on conversion exceeds basic EPS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>15.</b></td><td style="text-align: justify"><b>RELATED PARTY TRANSACTIONS</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Related parties:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; width: 29%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Names of related parties</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wong Ling Yan (Philip)</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director and controlling shareholder of the Company</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Good Staywell HK Limited</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An equity investee of Good On Time</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Amount due from related parties:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.85pt">Wong Ling Yan (Philip)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,632,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,588,036</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.85pt">Good Staywell HK Limited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,160</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">876</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.85pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,633,560</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,588,912</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 282 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Significant related party transactions:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended <br/>
March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.85pt">Advance payment to the director for intangible assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,946,433</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,195,447</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">Intangible assets payment paid by the director on behalf of the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,946,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,031,340</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.85pt">Mezzanine equity received by the director on behalf of the Group to offset intangible assets payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,164,107</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">Mezzanine equity received by the director on behalf of the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,508,783</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.85pt">Mezzanine equity received by the director on behalf of the Group and repaid to the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,994,509</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">Accounts receivable received by the director on behalf of the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,393,388</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,946</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.85pt">Accounts receivable received by the director and repaid to the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,158,547</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,431,519</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">Expenses paid by the Group on behalf of the director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,185,943</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">887,516</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.85pt">Expenses paid by the director on behalf of the Company</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">417,363</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59,100</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.85pt">Others</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">966</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,375</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">The director authorized his bank account to the Group for the
purpose of collection and payments activities to improve business efficiency, including the purchase of intangible assets, collection
of investment and receivables, etc. </td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">To ensure business continuity and the smooth settlement since the
Company faced operational challenges in establishing fully functional corporate banking infrastructure to support time-sensitive transactional
needs, the director voluntarily agreed to temporarily authorize his personal bank account for these activities. This was a transitional
measure to avoid disruptions to critical business operations during a period of organizational and regulatory ramp-up.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>16.</b></td><td><b>SIGNIFICANT RISKS </b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Credit risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially expose
the Group to the concentration of credit risk consist primarily of cash, accounts receivable, factoring receivables, amounts from related
parties, and other receivables and prepayments. As of March 31, 2024 and 2023, the Group places its cash with major financial institutions
located in the Hong Kong S.A.R, which management considers to be of high credit quality. Concentration of credit risks with respect to
accounts receivable, factoring receivables, amounts from related parties, and other receivables and prepayments, to manage credit risk,
the Group performs ongoing credit evaluations of customers&#8217; and suppliers&#8217;, as well as related parties&#8217; financial condition.
There is no significant credit risk for the years ended March 31, 2024 and 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2024 and 2023, HKD10,720,403 (USD1,369,862)
and HKD7,837,736 (USD998,450) of the Group&#8217;s cash was on deposit at financial institutions in Hong&#160;Kong, respectively. In accordance
with the relevant regulations in Hong&#160;Kong, the maximum insured bank deposit amount is HKD500,000 for each financial institution.
Accordingly, the Group&#8217;s total unprotected cash held in banks amounted to HKD8,720,403 (USD1,114,300) and HKD6,837,736 (USD871,060)
as of March 31, 2024 and 2023, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 283 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Concentration risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There was no single customers which individually represented greater
than 10% of the total revenues of the Group for the years ended March 31, 2024 and 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group collected accounts receivables from customers through sales
agents. The following parties represent more than 10% of the Group&#8217;s accounts receivable as of March 31, 2024 and 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Percentage of the Company&#8217;s accounts receivables</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 0.85pt">A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">34.4</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16.4</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.85pt">B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.85pt">C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.9</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">represents percentage less than 10%.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The suppliers which individually represented greater than 10% of the
total purchases of the Group for the years ended March 31, 2024 and 2023 were as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the years ended <br/>
March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Percentage of the Company&#8217;s total purchase</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Supplier E</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Supplier F</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following suppliers represent more than 10% of the Group&#8217;s
accounts payable s of March 31, 2024 and 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Percentage of the Company&#8217;s accounts payable</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.85pt">Supplier A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.3</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11.9</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">Supplier B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.85pt">Supplier C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.85pt">Supplier D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.0</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">represents percentage less than 10%.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>17.</b></td><td><b>COMMITMENTS AND CONTINGENCIES</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="-keep: true">The Company follows subtopic 450-20 of the
FASB Accounting Standards Codification to report accounting for contingencies. The Company records a loss contingency, consistent with
ASC 450, when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. If a potential
material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the
contingent liability, together with an estimate of the range of possible loss if determinable and material, is disclosed. Accounting
for contingencies requires us to use judgement related to both the likelihood of a loss and the estimate of the amount or range of loss.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Except for leases which were disclosed in Note 13, there are not any
other known commitments or contingencies as of March 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>18.</b></td><td><b>SUBSEQUENT EVENTS</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Company has evaluated events from the year ended March 31, 2024
through April 24, 2025 the date the financial statements were issued. The Company did not identify any subsequent events with a material
financial impact on the Company&#8217;s consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 284 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="N_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YOOV GROUP HOLDING LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in">(In U.S. dollars,
except for the number of shares data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">As of</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">December 31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">March 31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">USD</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">USD</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">(Unaudited)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"><span style="-keep: true">ASSETS</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"><span style="-keep: true">Current assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; width: 76%; padding-left: 0.125in"><span style="-keep: true">Cash</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">2,698,926</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">1,370,008</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="-keep: true">Accounts receivable, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">44,196,302</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">19,799,764</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="-keep: true">Factoring receivables, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">509,751</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">323,828</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="-keep: true">Prepayment, deposits and other receivables, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">15,193,267</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">4,755,118</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">Amount due from related parties</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">10,300,228</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">4,633,560</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">Total current
    assets</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">72,898,474</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">30,882,278</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-left: 0.125in"><span style="-keep: true">Non-current assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="-keep: true">Property and equipment, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">466,283</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">451,373</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="-keep: true">Operating lease right-of-use assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">896,026</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">279,706</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="-keep: true">Intangible assets, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">42,416,410</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">28,191,671</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="-keep: true">Investment in insurance contracts</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">835,540</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">Investment in associate</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">64</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">63</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">Total non-current
    assets</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">43,778,783</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">29,758,353</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"><span style="-keep: true">TOTAL ASSETS</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">116,677,257</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">60,640,631</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-left: 0.125in"><span style="-keep: true">LIABILITIES, MEZZANIEN EQUITY AND
    SHAREHOLDERS&#8217; DEFICIT</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-left: 0.125in"><span style="-keep: true">Current liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="-keep: true">Accounts payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">371,060</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">269,233</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="-keep: true">Accruals and other payables</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,927,157</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,807,703</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="-keep: true">Deferred revenue</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">51,857,030</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">16,850,228</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="-keep: true">Short-term borrowings</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">20,298,334</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,002,759</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="-keep: true">Operating lease liabilities, current</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">277,117</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">301,003</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="-keep: true">Amount due to a related party</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">5,216</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">Income tax payable</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">30,825</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">9,282</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">Total current
    liabilities</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">80,766,739</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">27,240,208</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-left: 0.125in"><span style="-keep: true">Non-current liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="-keep: true">Operating lease liabilities, non-current</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">650,067</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="-keep: true">Deferred tax liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,731,360</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,441,519</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">Long service payment</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">8,384</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">6,556</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">Total non-current
    liabilities</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">2,389,811</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">1,448,075</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">TOTAL LIABILITIES</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">83,156,550</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">28,688,283</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-left: 0.125in"><span style="-keep: true">Commitments and contingencies</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-left: 0.125in"><span style="-keep: true">Mezzanine equity</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">Angel round redeemable convertible
    preferred shares, USD0.1 par value, 71,119 and 71,119 shares issued and outstanding as of December 31 and March 31, 2024, respectively.</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">3,129,169</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">2,890,728</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">Series A redeemable convertible
    preferred shares, USD0.1 par value, 54,224 and 54,224 shares issued and outstanding as of <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31 and March 31, 2024, respectively.</span></span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">17,081,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">16,953,971</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">Series A1 redeemable convertible
    preferred shares, USD0.1 par value, 47,865 and 47,865 shares issued and outstanding as of December 31 and March 31, 2024, respectively.</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-keep: true">17,824,867</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-keep: true">17,692,306</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">TOTAL MEZZANINE
    EQUITY</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">38,035,036</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">37,537,005</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-left: 0.125in"><span style="-keep: true">Shareholders&#8217; deficit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Ordinary share, USD0.1 par value, 2,000,000 shares authorized, 200,000
    and 200,000 shares issued and outstanding as of December 31, 2024 and March 31, 2024, respectively</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">20,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">20,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.125in"><span style="-keep: true">Accumulated deficit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(4,630,229</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(5,666,809</span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">Accumulated other comprehensive
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(48,486</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(12,120</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-left: 0.125in"><span style="-keep: true">Deficit attributable to the shareholders
    of the Company</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(4,658,715</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-keep: true">(5,658,929</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">Non-controlling interests</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">144,386</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">74,272</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-keep: true">Total shareholders'
    deficit</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">(4,514,329</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">)</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">(5,584,657</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in"><span style="-keep: true">TOTAL LIABILITIES,
    MEZZANINE EQUITY AND SHAREHOLDERS&#8217; DEFICIT</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">116,677,257</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">60,640,631</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in">The accompanying notes
are an integral part of these unaudited condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in">&#160;</p><div>



</div><!-- Field: Page; Sequence: 285 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="N_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YOOV GROUP HOLDING LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS AND COMPREHENSIVE INCOME</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in">(In U.S. dollars,
except for the number of shares data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended<br/>
    December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%">Revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">38,012,233</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21,745,878</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Cost of revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,283,137</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,769,083</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Gross profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">24,729,096</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">13,976,795</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Selling and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,523,469</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,436,295</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,589,367</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,613,649</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(222,860</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(570,141</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Total operating expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(22,335,696</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(12,620,085</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income from
    operations</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,393,400</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,356,710</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Other loss, net:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Finance expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(825,145</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(309,800</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Investment loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(84</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">55,027</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">62,756</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Total other loss, net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(770,118</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(247,128</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income before
    income tax provision</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,623,282</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,109,582</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Income tax expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(299,374</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(230,663</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net income</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,323,908</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">878,919</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Less: net income attributable to non-controlling interests</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,369</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,999</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Less: accretion of redemption value of preferred shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">215,959</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196,274</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net income attributable to YOOV Group Holding Limited
    shareholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,036,580</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">612,646</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Foreign currency translation change,
    net of nil income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37,621</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(31,396</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other
    comprehensive loss</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(37,621</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(31,396</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive
    income</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,286,287</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">847,523</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Total comprehensive income attributable to non-controlling
    interests</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,114</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,844</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Total comprehensive income attributable to YOOV Group
    Holding Limited shareholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,216,173</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">778,679</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Earnings per ordinary share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">- Basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Weighted average shares used in calculating earnings
    per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">- Basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in">The accompanying notes
are an integral part of these unaudited condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in">&#160;</p><div>



</div><!-- Field: Page; Sequence: 286 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="N_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YOOV GROUP HOLDING LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF CHANGES IN SHAREHOLDERS&#8217; DEFICIT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in">(In U.S. dollars,
except for the number of shares data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><b>&#160;</b></td><td style="font-weight: bold"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><b>Ordinary Shares</b></td><td style="font-weight: bold"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Accumulated</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Accumulated other comprehensive</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Total YOOV Group&#160;Holding Limited shareholders&#8217;</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Non-controlling</b></td><td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="2" style="text-align: center"><b>Total shareholders&#8217;</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> income/(loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> interests</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Numbers</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 16%; font-weight: bold">Balance as of March 31, 2023</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">200,000</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">20,000</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(6,598,305</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">7,333</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(6,570,972</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">20,377</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">(6,550,595</td><td style="width: 1%; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">808,920</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">808,920</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,999</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">878,919</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30,241</td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(30,241</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,155</td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(31,396</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Accretion on convertible redeemable preferred shares to redemption value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(196,274</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(196,274</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(196,274</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; padding-bottom: 1.5pt">Balance as of December 31, 2023 (Unaudited)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">200,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">20,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(5,985,659</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(22,908</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(5,988,567</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">89,221</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(5,899,346</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Balance as of March<br/> &#160;31, 2024</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">200,000</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">20,000</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(5,666,809</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(12,120</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(5,658,929</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">74,272</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(5,584,657</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Net income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,252,539</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,252,539</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,369</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,323,908</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36,366</td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(36,366</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,255</td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(37,621</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Accretion on convertible redeemable preferred shares to redemption value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(215,959</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(215,959</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(215,959</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; padding-bottom: 2.5pt">Balance as of December 31, 2024 (Unaudited)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">200,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">20,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(4,630,229</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(48,486</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(4,658,715</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">144,386</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(4,514,329</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in">The accompanying notes
are an integral part of these unaudited condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in">&#160;</p><div>



</div><!-- Field: Page; Sequence: 287 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="N_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YOOV GROUP HOLDING LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in">(In U.S. dollars,
except for the number of shares data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended<br/>
 December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net profit</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,323,908</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">878,919</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Adjustments to reconcile net profit to net cash provided by operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Provision/(Reversal) of credit losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">230,825</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(622,464</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,536,387</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,271,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amortization of operating lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">329,624</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,270</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(520,705</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">277,981</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">751,369</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investment loss in associate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash surrender value changes of insurance contracts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">182,178</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,433</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(24,388,160</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,949,173</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Factoring receivables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(181,601</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">246,828</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses and other current asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,363,031</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,011,912</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99,432</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">271,104</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,748,137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,553,572</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,485,016</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,399,495</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Amounts due to a related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,197</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(319,958</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(285,895</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long service payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,772</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,108</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Amounts due from related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,610,570</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">305,695</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net cash provided by operating activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">5,378,530</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">3,642,395</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Purchase of intangible asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,314,798</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,900,749</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Purchase of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(193,387</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Proceeds from surrender of insurance contract</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">656,426</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">231,404</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net cash used in investing activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(16,851,759</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(4,669,345</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,889,083</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,502,349</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Repayments of borrowings</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,102,207</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,105,330</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Proceeds from mezzanine equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,994,178</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net cash provided by financing activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">12,786,876</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">1,391,197</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Effect of exchange rate changes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,271</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(69,660</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#12288;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">&#12288;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net change in cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,328,918</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">294,587</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash at beginning of the period</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,370,008</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">998,948</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash at end of the period</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,698,926</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,293,535</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest paid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">340,477</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">195,264</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income tax paid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,695</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental schedule of non-cash financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accretion of mezzanine equity to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">215,959</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196,274</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Obtaining right-of-use assets in exchange for operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">941,516</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in">The accompanying notes
are an integral part of these unaudited condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in">&#160;</p><div>



</div><!-- Field: Page; Sequence: 288 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="N_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>YOOV GROUP HOLDING LIMITED</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FOR THE NINE MONTHS ENDED DECEMBER 31, 2024
AND 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: center; text-indent: -0.25in">(In U.S. dollars,
except for the number of shares data)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>1.</b></td><td style="text-align: justify"><b>ORGANIZATION AND PRINCIPAL ACTIVITIES</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">YOOV Group Holding Limited. (the &#8220;Company&#8221;), through its
wholly-owned subsidiaries (collectively, the &#8220;Group&#8221;) primarily engages in providing Artificial Intelligence-as-a-Service
(&#8220;AIaaS&#8221;) services, which integrates cutting-edge AI technologies to deliver intelligent business automation solutions to
the customers, factoring services, insurance brokerage services and other services in Hong Kong (&#8220;HK&#8221;). The Company was incorporated
under the laws of British Virgin Islands (&#8220;BVI&#8221;) on August 1, 2017.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2024, the Company&#8217;s major subsidiaries are
as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
    of Incorporation</b></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Place
    of Incorporation</b></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage
    of Equity Interest</b></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
    Activities</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="vertical-align: top; text-align: left; width: 39%"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-indent: -0.25in; margin-top: 0pt; margin-bottom: 0pt"><span style="-keep: true">YOOV
    Internet Technology Limited (&#8220;YOOV Internet&#8221;)</span></p></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 19,
    2012</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIaaS services</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portwin
    International Limited</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    12, 2021</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BVI</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holding company</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">YOOV
    Internet Technology (Asia) Limited</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    4, 2020</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIaaS services</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">YOOV
    Capital Limited</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    4, 2020</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Factoring services</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jump
    Group Limited</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    4, 2020</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other services</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BYOB
    Group Limited</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    4, 2020</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIaaS services</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">YOOV
    Insurance Services Limited</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    4, 2020</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65%</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance brokerage
    service</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Good
    On Time Limited (&#8220;Good On Time&#8221;)</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    9, 2021</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75%</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIaaS services</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interactive
    Union Limited</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    21, 2021</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70% owned by Good On
    Time</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other services</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solar
    Pump Limited</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    12, 2021</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51% owned by Good On
    Time</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other services</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">YOOV
    Internet Technology (HK) Limited </span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    20, 2024</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AIaaS services</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>2.</b></td><td style="text-align: justify"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b><i>(a).</i></b></td><td style="text-align: justify"><b><i>Basis of Presentation</i></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited condensed consolidated financial
statements have been prepared in accordance with the rules and regulations of the Security and Exchange Commission and accounting principles
generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial reporting. Certain information and
footnote disclosures normally included in financial statements prepared in conformity with U.S. GAAP have been condensed or omitted pursuant
to such rules and regulations. Accordingly, these statements should be read in conjunction with the Group&#8217;s audited consolidated
financial statements for the years ended March 31, 2024 and 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the opinion of the management, the accompanying
unaudited condensed consolidated financial statements reflect all normal recurring adjustments, which are necessary for a fair presentation
of financial results for the interim periods presented. The Group believes that the disclosures are adequate to make the information presented
not misleading. The accompanying unaudited condensed consolidated financial statements have been prepared using the same accounting policies
as used in the preparation of the Group&#8217;s consolidated financial statements for the years ended March 31, 2024 and 2023. The results
of operations for the nine months ended December 31, 2024 and 2023 are not necessarily indicative of the results for the full year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 289 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b><i>(b).</i></b></td><td style="text-align: justify"><b><i>Principles of consolidation</i></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited condensed consolidated financial
statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances
have been eliminated upon consolidation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b><i>(c).</i></b></td><td style="text-align: justify"><b><i>Use of estimates</i></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the unaudited condensed consolidated
financial statements in conformity with US GAAP requires management of the Group to make certain estimates and assumptions that affect
the reported amounts of assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported
amounts of revenues and expenses during the reporting period. The Group&#8217;s management based on their estimates on historical experience
and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgements
about the carrying value of assets and liabilities that are not readily apparent from other sources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant accounting estimates reflected in
the Group&#8217;s unaudited condensed consolidated financial statements include, but not limited to revenue recognition, provision for
credit losses, the useful lives and impairment of long-lived assets and valuation allowance for deferred tax assets. Changes in facts
and circumstances may result in revised estimates. Actual results could differ from those estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b><i>(d).</i></b></td><td style="text-align: justify"><b><i>Foreign currency translations and transactions</i></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s reporting currency is the United
States dollar (&#8220;USD&#8221;). The functional currency of the Group and its subsidiary which is incorporated in Hong Kong is HKD,
which is its respective local currency based on the criteria of ASC 830, &#8220;Foreign Currency Matters&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group&#8217;s unaudited condensed financial
statements are reported using USD. The results of operations and the unaudited condensed consolidated statements of cash flows denominated
in foreign currency are translated at the average rate of exchange during the reporting period. Assets and liabilities denominated in
foreign currencies at the balance sheet date are translated at the applicable rates of exchange in effect at that date. The equity denominated
in the functional currency is translated at the historical rate of exchange at the time of capital contribution. Because cash flows are
translated based on the average translation rate, amounts related to assets and liabilities reported on the unaudited condensed consolidated
statements of cash flows will not necessarily agree with changes in the corresponding balances on the unaudited condensed consolidated
balance sheets. Translation adjustments arising from the use of different exchange rates from period to period are included as a separate
component of accumulated other comprehensive income (loss) included in unaudited condensed consolidated statements of changes in deficit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Translation of amounts from HKD into USD has been
made at the following exchange rates:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Period end USD: HKD exchange rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.7677</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8259</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended <br/>
December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Average USD: HKD exchange rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.7973</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.8259</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 290 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b><i>(e).</i></b></td><td style="text-align: justify"><b><i>Fair value measurement</i></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group applies ASC 820, Fair Value Measurements
and Disclosures (&#8220;ASC 820&#8221;). ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures
about fair value measurements. ASC 820 requires disclosures to be provided on fair value measurement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820 establishes a three-tier fair value hierarchy,
which prioritizes the inputs used in measuring fair value as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1-Observable inputs
    that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2-Include other inputs
    other than quoted prices in active market; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3-Unobservable inputs
    which are supported by little or no market activity that are significant to the fair value of the assets and liabilities. This includes
    certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 820 describes three main approaches to measuring
the fair value of assets and liabilities: (1) market approach; (2) income approach and (3) cost approach. The market approach uses prices
and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income
approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated
by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to
replace an asset.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial assets and liabilities of the Group
primarily consisted of cash, accounts receivable, factoring receivable, prepayment, deposits and other receivables, amounts due from related
parties, investment in insurance contracts, accounts payable, accruals and other payables, amounts due to related parties and short-term
borrowings. As of December 31, 2024 and March 31, 2024, the carrying amounts of the Group&#8217;s financial instruments approximated to
their fair value of the respective assets and liabilities based upon the short-term nature of these assets and liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b><i>(f).</i></b></td><td style="text-align: justify"><b><i>Revenue recognition </i></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 606 Revenue from Contracts with Customers
(&#8220;ASC 606&#8221;) establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and
cash flows arising from the entity&#8217;s contracts to provide goods or services to customers. The core principle requires an entity
to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration that it expects
to be entitled to receive in exchange for those goods or services recognized as performance obligations are satisfied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To determine revenue recognition for contracts
with customers, the Company performs the following five steps:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">Step</td><td style="text-align: justify">1: Identify the contract with the customer</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">Step</td><td style="text-align: justify">2: Identify the performance obligations in the contract</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">Step</td><td style="text-align: justify">3: Determine the transaction price</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">Step</td><td style="text-align: justify">4: Allocate the transaction price to the performance obligations in the contract</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">Step</td><td style="text-align: justify">5: Recognize revenue when the company satisfies a performance obligation</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">AIaaS services</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Group offers AIaaS services to the customers
through HR resources management and workflow approval system, CRM and data management system and an AI business assistant with diverse
platforms and enterprise systems. The Group has identified that the nature of its overall promise to customers includes (i) implementation
service, (ii) AIaaS in the subscription periods, and (iii) maintenance and unspecific upgrades service. The promises are highly interrelated
to provide a combined output of smooth and high-quality AIaaS service during the subscription period. Therefore, the Group identifies
only one performance obligation to provide AIaaS service.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue from AIaaS services is recognized ratably
over time over the contract term beginning on the date that the AIaaS service is made available to the customer, whereby the Group considers
that its customers simultaneously receive and consume the benefits provided by the use of existing applications. The Group does not have
other right to consideration in exchange for goods or service that the Group has transferred to a customer when that right is conditional
on something other than the passage of time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 291 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The
                                            contract terms generally consist of one-year subscription period. Payments received in advance
                                            of services being rendered are recorded as deferred revenue. The contract payment is not
                                            subject to any variable consideration, refund, cancellation or termination provision. The
                                            Group takes the practical expedient and will not adjust the impact of a financing component
                                            for deferred revenue which will be earned within one year. Revenue is recognized ratably over
                                            time, over the requisite service period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Insurance brokerage services</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group provides insurance brokerage service
distributing on behalf of insurance companies. As an agent of the insurance company, the Company sells insurance policies, primarily short-term
insurance products, on behalf of the insurance company and earns commissions determined as a percentage of premiums paid by the insured.
Revenue from insurance brokerage services is recognized at a point in time when the brokered insurance policies are executed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Factoring services</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group generated revenue from factoring services
that the customer sells or transfers its accounts receivable to the Group in exchange for immediate funds. The Group generated non-interest
income including factoring commission, set up fee etc., under ASC 606 and interest income under ASC 310 Receivables (&#8220;ASC 310&#8221;).
The non-interest income is recognized at a point in time upon commencement of factoring transaction. The interest income, using effective
interest method under ASC 310, is recognized over time over the recourse period beginning on the date that the advance payment to the
customers and ends upon the withdraw of the factoring receivable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Others</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group also derives revenues from other products
and services such as sales of office supplies and others. The Group recognizes revenue at a point in time when title and risk of loss
passes and the customer accepts the goods or services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table disaggregates the Group&#8217;s
revenue for the nine months ended December 31, 2024 and 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">By revenue stream</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">AIaaS services</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">37,560,885</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21,321,547</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Insurance brokerage services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">286,342</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224,870</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Factoring services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135,663</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,750</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29,343</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,711</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">38,012,233</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">21,745,878</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">By revenue recognition time</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Over time</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">37,647,338</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21,428,962</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">At a point in time</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">364,895</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">316,916</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">38,012,233</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">21,745,878</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 292 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration:underline">Contract balances</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Timing of revenue recognition may differ from
the timing of invoicing to customers. Accounts receivable represent amounts invoiced and revenue recognized prior to invoicing when the
Group has satisfied its performance obligations and has the unconditional right to payment. The Group normally does not have contract
assets, which are primarily unbilled accounts receivable that are conditional on something other than the passage of time. The Group did
not have contract assets as of December 31, 2024 and March 31, 2024, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A contract liability is recognized when the customer
pays non-refundable consideration before the Group recognizes the related revenue. A contract liability would also be recognized if the
Group has an unconditional right to receive non-refundable consideration before the Group recognizes the related revenue. In such cases,
a corresponding receivable would also be recognized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a single contract with the customer, either
a net contract asset or a net contract liability is presented. For multiple contracts, contract assets and contract liabilities of unrelated
contracts are not presented on a net basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred revenue amounted to USD51,857,030 and
USD16,850,228 as of December 31, 2024 and March 31, 2024, respectively. Revenue included in the beginning balance of deferred revenue
and recognized in the&#160;nine months ended December 31, 2024 and 2023&#160;amounted to USD8,270,846 and USD7,087,316, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b><i>(g).</i></b></td><td style="text-align: justify"><b><i>Recently issued accounting pronouncements </i></b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is an &#8220;emerging growth company&#8221;
(&#8220;EGC&#8221;) as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). Under the JOBS Act, EGC
can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards
apply to private companies. The Group does not opt out of extended transition period for complying with any new or revised financial accounting
standards. Therefore, the Company&#8217;s unaudited condensed financial statements may not be comparable to companies that comply with
public company effective dates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2023, the FASB issued ASU 2023-06,
&#8220;Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative.&#8221;
This ASU incorporates certain U.S. Securities and Exchange Commission (SEC) disclosure requirements into the FASB Accounting Standards
Codification. The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of Codification
Topics, allow users to more easily compare entities subject to the SEC&#8217;s existing disclosures with those entities that were not
previously subject to the requirements, and align the requirements in the Codification with the SEC&#8217;s regulations. For entities
subject to the SEC&#8217;s existing disclosure requirements and for entities required to file or furnish financial statements with or
to the SEC in preparation for the sale of or for purposes of issuing securities that are not subject to contractual restrictions on transfer,
the effective date for each amendment will be the date on which the SEC removes that related disclosure from its rules. For all other
entities, the amendments will be effective two years later. However, if by June 30, 2027, the SEC has not removed the related disclosure
from its regulations, the amendments will be removed from the Codification and not become effective for any entity. The Company does not
expect the adoption of ASU 2023-06 to have a material impact on its unaudited condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2023, the FASB issued ASU 2023-07,
which modifies the disclosure and presentation requirements of reportable segments. The new guidance requires the disclosure of significant
segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported
measure of segment profit and loss. In addition, the new guidance enhances interim disclosure requirements, clarifies circumstances in
which an entity can disclose multiple segment measures of profit or loss, provides new segment disclosure requirements for entities with
a single reportable segment, and contains other disclosure requirements. The update is effective for annual periods beginning after December
15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not
expect that the adoption of ASU 2023-07 will have a material impact on its unaudited condensed consolidated financial statements disclosures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09,
Improvement to Income Tax Disclosure. This standard requires more transparency about income tax information through improvements to income
tax disclosures primarily related to the rate reconciliation and income taxes paid information. This standard also includes certain other
amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for public business entities, for annual periods
beginning after December 15, 2024. For entities other than public business entities, the amendments are effective for annual periods beginning
after December 15, 2025. The Company is in the process of evaluation the impact of adopting this new guidance on its unaudited condensed
consolidated financial statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 293 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2024, the FASB issued ASU 2024-03,
Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40), to improve the disclosures about
an entity&#8217;s expenses including more detailed information about the types of expenses in commonly presented expense captions (&#8220;ASU
2024-03&#8221;). In January 2025, the FASB issued ASU 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation
Disclosures (Subtopic 220-40): Clarifying the Effective Date (&#8220;ASU 2025-01&#8221;). At each interim and annual reporting period,
entities will disclose in tabular format disaggregating information about prescribed categories underlying relevant income statement captions,
as well as the total amount of selling expense and a description of the composition of its selling expense. ASU 2024-03, as clarified
by ASU 2025-01, is effective for annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting
periods beginning after December 15, 2027. The Company will adopt the amendments in this ASU for its fiscal year beginning on January
1, 2027. The Company is in the process of evaluation the impact of adopting this new guidance on its unaudited condensed consolidated
financial statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other accounting standards that have been issued
by FASB that do not require adoption until a future date are not expected to have a material impact on the unaudited condensed consolidated
financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on,
or are unrelated to, its unaudited condensed consolidated financial condition, results of operations, cash flows or disclosures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>3.</b></td><td style="text-align: justify"><b>ACCOUNTS RECEIVABLE, NET</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accounts receivable, net consisted of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Account receivables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">44,661,246</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20,030,075</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: provision of credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(464,944</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(230,311</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total accounts receivable, net</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">44,196,302</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">19,799,764</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 18, 2024, the Group entered into a
Factoring Agreement with Olea Global Pte. Ltd. (&#8220;Olea&#8221;) to obtain borrowings secured by accounts receivable for the purpose
of business financing with interest rates based on SOFR or Hongkong Inter-Bank Offered Rate (&#8220;HIBOR&#8221;). Since the Factoring
Agreement was with recourse, the accounts receivable factoring transaction did not qualify as a transfer of financial assets to be considered
as a sale under ASC860, and was accounted for as short-term borrowings without derecognition of accounts receivable. The assigned eligible
accounts receivable collateralized were USD12,297,708.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 17, 2024, the Group entered into
a Factoring Agreement with Qupital Ltd. (&#8220;Qupital&#8221;) to obtain borrowings secured by accounts receivable and guaranteed by
WONG Ling Yan Philip, Portwin International Limited and YOOV Group Holding Limited for the purpose of business financing with interest
rates based on the secured overnight financing rate (&#8220;SOFR&#8221;). Since the Factoring Agreement was with recourse, the accounts
receivable factoring transaction did not qualify as a transfer of financial assets to be considered as a sale under ASC860, and was accounted
for as short-term borrowings without derecognition of accounts receivable. The assigned eligible accounts receivable collateralized were
USD8,888,972.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Details of the movements of provision of credit
losses are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended <br/>
December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of the periods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">230,311</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">821,799</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Provision/(reversal) of credit loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">232,024</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(618,826</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,609</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,916</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance at end of the periods</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">464,944</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">205,889</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 294 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>4.</b></td><td style="text-align: justify"><b>FACTORING RECEIVABLES, NET</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Factoring receivables, net consisted of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Factoring receivables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">511,361</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">326,620</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: provision of credit loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,610</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,792</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total factoring receivables, net</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">509,751</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">323,828</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Details of the movements of provision of credit losses are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Balance at beginning of the periods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,792</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,878</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reversal of credit loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,199</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,638</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance at end of the periods</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,610</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,257</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>5.</b></td><td style="text-align: justify"><b>PREPAYMENT, DEPOSITS AND OTHER RECEIVABLES, NET</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prepayment, deposits and other receivables, net consisted of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepayment for obtaining contract <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">14,784,314</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,555,894</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">288,408</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161,254</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepayment expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,912</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">85,520</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,058</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total prepayment, deposits and other receivables, net</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">15,193,267</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,755,118</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="-keep: true">(1)</span></td><td style="text-align: justify"><span style="-keep: true">The prepayment consisted of sales commission
                                            to sales agents obtaining sales contracts, which was charged into cost of revenues on a ratable
                                            basis in line with the revenue recognition.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 295 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>6.</b></td><td style="text-align: justify"><b>PROPERTY AND EQUIPMENT, NET</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and equipment, net consisted of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Leasehold improvement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">870,419</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">671,266</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Solar pump system</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">247,562</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">245,721</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Electronic office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">197,827</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196,356</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,757</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,714</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(855,282</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(667,684</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">466,283</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">451,373</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Depreciation expense was USD181,902 and USD200,675 for the nine months
ended December 31, 2024 and 2023, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>7.</b></td><td style="text-align: justify"><b>INTANGIBLE ASSETS, NET</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Software</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">53,427,485</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">35,778,632</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,011,075</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,586,961</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Intangible assets, net</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">42,416,410</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">28,191,671</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Amortization expenses were USD3,354,485 and USD2,070,992 for the nine
months ended December 31, 2024 and 2023, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Future estimated amortization expenses of intangible assets are as
follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">For the years ending March 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 88%">Remaining of 2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">891,187</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,564,747</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,564,747</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,585,345</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,293,771</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">27,516,613</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">42,416,410</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 296 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>8.</b></td><td style="text-align: justify"><b>INVESTMENT IN INSURANCE CONTRACTS</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Group entered into a key management insurance
policy for the founder to secure that the operation of the Group will not be affected by the death and loss of position of the founder.
The fair value of the investment in key management insurance policy is determined at end of each reporting period at the cash surrender
value that could be realized under the insurance policy, which is primarily based on the guaranteed cash value stated on the annual statement
from the insurance company. The fair value measurement of the investment in key management insurance policy has been categorized as Level
3 based on the inputs to the valuation technique used and is positively correlated to the surrender cash value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-align: left">Balance at beginning of the periods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">835,540</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,032,529</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Surrender</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(656,426</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(231,404</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash surrender value changes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(182,178</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,921</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign exchange impact</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,064</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,506</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance at end of the periods</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">835,540</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>9.</b></td><td style="text-align: justify"><b>ACCRUALS AND OTHER PAYABLES</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Accruals and other payables consisted of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued salaries</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,743,110</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,558,047</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses <sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,155,896</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,094,259</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28,151</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">155,397</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Accruals and other payables</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">7,927,157</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,807,703</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Accrued expenses as of December 31, 2024 and March 31, 2024
mainly included payable professional fees, payable advertising fees, payable commission fees, payable rental expenses and other miscellaneous
expenses such as utilities and office expenses for daily operations.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 297 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>10.</b></td><td style="text-align: justify"><b>SHORT-TERM BORROWINGS</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0in 0.25in">As of December 31, 2024 and March 31, 2024, short-term borrowings
consisted of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 20pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; padding-left: 0.125in"><b>Lender</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Types of loans</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Maturity date</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Interest Rate</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>December 31, <br/>
    2024</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>March 31,<br/>
 2024</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; text-align: center"/><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"/><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"/><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"/><td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><b>USD</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><b>USD</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 25%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Olea Global Pte. Ltd. <sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: left">Loans from third parties</td><td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 13%">N/A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">based on SOFR or HIBOR</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,600,361</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qupital Ltd. <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">Loans from third parties</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overnight SOFR</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,183,361</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Hung Mei Lih</td><td>&#160;</td>
    <td style="text-align: left">Loans from third parties</td><td>&#160;</td>
    <td style="text-align: center">2025-10-08</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8%, 7%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">193,107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Intrabase Financial Services limited</td><td>&#160;</td>
    <td style="text-align: left">Loans from third parties</td><td>&#160;</td>
    <td style="text-align: center">N/A</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">12.0%</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,191,965</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Leon Cheng</td><td>&#160;</td>
    <td style="text-align: left">Loans from third parties</td><td>&#160;</td>
    <td style="text-align: center">2025-01-11</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">12.0%</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">514,953</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">511,123</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Leon Cheng</td><td>&#160;</td>
    <td style="text-align: left">Loans from third parties</td><td>&#160;</td>
    <td style="text-align: center">2025-04-16</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">12.0%</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">193,107</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191,671</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Standard Chartered Bank (Hong Kong) Limited</td><td>&#160;</td>
    <td style="text-align: left">Revolving Loan</td><td>&#160;</td>
    <td style="text-align: center">2025-05-29</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">7.3%</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">901,168</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">894,466</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Heng Seng Bank Limited</td><td>&#160;</td>
    <td style="text-align: left">Revolving Loan</td><td>&#160;</td>
    <td style="text-align: center">2029-04-13</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIBOR+2.5%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">319,452</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Heng Seng Bank Limited</td><td>&#160;</td>
    <td style="text-align: left">Revolving Loan</td><td>&#160;</td>
    <td style="text-align: center">2029-04-13</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIBOR+2.5%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">191,671</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Heng Seng Bank Limited</td><td>&#160;</td>
    <td style="text-align: left">Revolving Loan</td><td>&#160;</td>
    <td style="text-align: center">2029-04-13</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIBOR+2.5%</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">127,781</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">DBS Bank (Hong Kong) Limited</td><td>&#160;</td>
    <td style="text-align: left">Installment Loan</td><td>&#160;</td>
    <td style="text-align: center">2027-06-27</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5% p.a. below Prime rate</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">662,947</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">The Hongkong and Shanghai Banking Corporation Limited</td><td>&#160;</td>
    <td style="text-align: left">Term Loan</td><td>&#160;</td>
    <td style="text-align: center">2029-02-25</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3.6%</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">586,756</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">592,665</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">The Hongkong and Shanghai Banking Corporation Limited</td><td>&#160;</td>
    <td style="text-align: left">Term Loan</td><td>&#160;</td>
    <td style="text-align: center">2029-07-15</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3.6%</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125,521</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">126,773</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">DBS Bank (Hong Kong) Limited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">Overdraft</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">N/A</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">arrears at 3% per annum below USD Prime Rate</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">192,245</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: center">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">20,298,334</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">7,002,759</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 20pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in">(1)</td><td style="text-align: justify">On October 18, 2024, the Group entered into a Factoring Agreement with Olea (See Note 3) to obtain borrowings
secured by accounts receivable for the purpose of business financing with interest rates based on SOFR or HIBOR. Since the Factoring Agreement
was with recourse, the accounts receivable factoring transaction did not qualify as a transfer of financial assets to be considered as
a sale under ASC860, and was accounted for as short-term borrowings without derecognition of accounts receivable. The assigned eligible
accounts receivable collateralized were USD12,297,708.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in">(2)</td><td style="text-align: justify">On September 17, 2024, the Group entered into a Factoring Agreement with Qupital (See Note 3) to obtain
borrowings secured by accounts receivable and guaranteed by WONG Ling Yan Philip, Portwin International Limited and YOOV Group Holding
Limited for the purpose of business financing with interest rates based on overnight SOFR. Since the Factoring Agreement was with recourse,
the accounts receivable factoring transaction did not qualify as a transfer of financial assets to be considered as a sale under ASC860,
and was accounted for as short-term borrowings without derecognition of accounts receivable. The assigned eligible accounts receivable
collateralized were USD8,888,972.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The interest expenses of short-term borrowings were USD827,204 and
USD310,550 for the nine months ended December 31, 2024 and 2023, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 298 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>11.</b></td><td style="text-align: justify"><b>MEZZANINE EQUITY</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Issuance of Redeemable Convertible Preferred
Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From 2017 to 2023, the Company has completed several
rounds of equity financing by issuing redeemable convertible preferred shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2017 and February 2018, YOOV Internet,
the subsidiary of the Company, entered into share subscription agreements to issue 71,119 Angel Round redeemable convertible preferred
shares (&#8220;Angel Round Preferred Shares&#8221;) at a price of USD22.44 per share. In July, 2021, the holders of Angel Round Preferred
Shares entered into application for shares with YOOV Internet and the Company. Since the Angel Round Preferred Shares were initially issued
by YOOV Internet in 2017 and 2018, and the core business was transferred from YOOV Internet to the Company, the holders therefore, request
the YOOV Internet to transfer the Angel Round Preferred Shares to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2021, the Company entered into subscription
agreements to issue 20,334 Series A redeemable convertible preferred shares (&#8220;Series A Preferred Shares&#8221;), and 13,556 Series
A redeemable ordinary shares (&#8220;Series A Ordinary Shares&#8221;), at a consideration of USD147.54 and USD147.54 per share, respectively.
In connection with the issuance of Series A Preferred Shares, the Company issued warrant of option for the holder to exercise to further
subscribe 20,334 Series A Preferred Shares at the same subscription price of USD147.54 per share within one year. The warrant was fully
exercised in July 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2022, the Company entered into subscription
agreements to issue 47,865 Series A1 redeemable convertible preferred shares (&#8220;Series A1 Preferred Shares&#8221;) at a consideration
of USD368.87 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Modification</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2022, the Company entered into the
Amended Shareholders Agreement with all investors at the date (collectively, &#8220;Preferred Shareholders&#8221;). The Amended Shareholders
Agreement modified the redemption and conversion terms of Series A Preferred Shares, and changed the Series A Ordinary Shares to Series
A Preferred Shares (collectively, &#8220;Modified Series A Preferred Shares&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the issuance of
redeemable convertible preferred shares (collectively, &#8220;Redeemable Convertible Preferred Shares&#8221;):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Original Issuance Price per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Consideration</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Angel Round Preferred Shares</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">22.44</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">71,119</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,595,910</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Modified Series A Preferred Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">147.54</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,224</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Series A1 Preferred Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">368.87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,865</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,654,900</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The rights, preferences and privileges of the Redeemable Convertible
Preferred Shares are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Voting Rights</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At all general meetings of the Company and on
all matters with respect to which the shareholders are entitled to vote, the holder of Preferred Shareholders shall have voting rights.
For the purposes of voting at any general meeting of the Company, the Preferred Shareholder shall (i) have one (1) vote per share and
(ii) vote together with the holders of the Common Shares as a single class, except as stipulated in the applicable laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dividend Rights</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Preferred Shareholders shall be entitled to
an annual per share cash dividend equal to 5.0% of the issue price of the relevant Redeemable Convertible Preferred Shares prior to the
payment of any dividend with respect to the ordinary shares, payable when and if declared by the board of directors of the Company and
the Shareholders&#8217; meeting. After payment of the preferential dividend to the Preferred Shareholders, any further dividends would
be paid pari passu to the Preferred Shareholders, and the ordinary shareholders of the Company on a pro rata, as-converted basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 299 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Conversion Rights</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For holders of Angel Round Preferred Shares and
Series A Preferred Shares before Modification, the holders shall have the right to convert all or part of its Redeemable Convertible Preferred
Shares into certain number of ordinary shares, exercisable at any time and from time to time during the period beginning on the day after
the closing date and ending on the 5th anniversary of the closing date. The initial conversion price shall be the issue price, and the
initial conversion ratio of a preferred share to ordinary share shall be approximately 1:1. The conversion price shall be subject to adjustment
pursuant to certain issuances, splits and combinations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For holders of Modified Series A and Series A1
Preferred Shares, the holders shall have the right to convert all or part of its Redeemable Convertible Preferred Shares into a certain
number of ordinary shares, exercisable at any time before the third anniversary date of such Redeemable Convertible Preferred Shares.
The number of ordinary shares issuable upon conversion of one share of Redeemable Convertible Preferred Shares shall be one. The conversion
ratio is not subject to any adjustments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Redemption Rights</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For
holders of Angel Round Preferred Shares and Series A Preferred Shares before Modification, holders may request the Company to redeem the
preferred shares, in whole or in part, at any time and from time to time after 4-year anniversary of the closing date. The redemption
price for each share of the Redeemable Convertible Preferred Shares shall be the amount which shall result in an internal rate of return
(</span>&#8220;<span style="font-family: Times New Roman, Times, Serif">IRR</span>&#8221;<span style="font-family: Times New Roman, Times, Serif">),
net of any and all taxes, fees and expenses incurred or to be incurred by the holder of 10% of the issue price for each Redeemable Convertible
Preferred Shares, compounded annually and calculated on the basis of a 365-day year for the actual number of days elapsed from and excluding
the closing date to and including the date of payment of the redemption price (as appropriately adjusted for any bonus issue, stock splits,
stock dividend, consolidation, subdivision, reclassification and the like of the Preferred Shares subsequent to its issuance).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For holders of Series A Ordinary Shares, holders
may request the Company to redeem the ordinary shares after 2 calendar years from the completion date (&#8220;Lock-up Period&#8221;).
At any time after the expiry of the Lock-up Period, the Company shall be required to repurchase any or all of the shares at a unite price
equal to the amount subscription price paid by the investor in return for such subscription shares plus an interest at the rate of 12%
per annum calculated on a non-compounded basis and on the basis of a year of 360 days accruing from the completion date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For holders of Modified Series A Preferred Shares,
holders may require the Company to repurchase any or all of the holders&#8217; Modified Series A Preferred Shares, at any time after October
21, 2023, at a unit share price equal to the issue price of such shares plus an interest at the rate of 12% per annum calculated on a
non-compounded basis and on the basis of a year of 360 days accruing from the completion date within 10 business days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company fails to pay the redemption price
for the aforementioned scenarios in full within 1 month after receiving the redemption notice from the Preferred Shareholder, the outstanding
amount of the redemption price shall accrue interest at the rate of 20% per annum compounded annually from the date immediately following
the redemption date until the date on which such Preferred Shareholder receives full payment of the outstanding redemption price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For holders of Series A1 Redeemable Convertible
Preferred Shares, holders may request the Company to redeem the shares (&#8220;Put Option&#8221;) if the Company fails to consummate a
Qualified IPO or a Trade Sale by 31 December 2026; or the revenue target of the Group from the fiscal years March 31, 2023 to 2026. The
redemption price equals to the issue price plus an interest at the rate of 12% per annum calculated on a non-compounded basis since the
date of exercise of the Put Option.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 300 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Liquidation Preferences </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to Amended Shareholders&#8217; Agreement
dated in December 2022, the liquidation preference of Redeemable Convertible Preferred Shares was as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">(i)</td><td style="text-align: justify">After payment of all creditors, including the repayment of bank borrowings, a holder of Angel Round Preferred
Shares then in issue shall be entitled to a distribution of the surplus assets of the Company available for distribution among the holders
of Angel Round Preferred Shares in priority to the holders of Modified Series A Preferred Shares, Series A1 Preferred Shares, and ordinary
shares, based on its shareholding percentage of all the Redeemable Convertible Preferred Shares at the time of the relevant distribution,
up to, in respect of a Preferred Shareholder, the aggregate Issue Price for such holder's Angel Round Redeemable Convertible Preferred
Shares plus such amount that represents a total IRR of 10%;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(ii)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Modified Series A Preferred Shares, the distribution
should be up to the aggregate Issue Price for such holder</span>&#8217;<span style="font-family: Times New Roman, Times, Serif">s Modified
Series A Preferred Shares plus sch amount that represents a total simple, non-compounding rate of return of 12%;</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">(iii)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Series A1 Preferred Shares, the distribution
should be up to the aggregate Issue Price for such holder</span>&#8217;<span style="font-family: Times New Roman, Times, Serif">s Modified
Series A Preferred Shares plus sch amount that represents a total simple, non-compounding rate of return of 12%.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Accounting of Redeemable Convertible Preferred
Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company elects to early adopt ASU2020-06 from
April 1, 2021, which reduced the number of accounting models for convertible preferred stock instruments. The Redeemable Convertible Preferred
Shares are equity host. The Company accounted for the Redeemable Convertible Preferred Shares as mezzanine equity under the section of
the Consolidated Balance Sheets because they were redeemable at the holders&#8217; option any time after a certain date, or were contingently
redeemable upon the occurrence of certain events outside of the Company&#8217;s control. The Redeemable Convertible Preferred Shares were
recorded initially at fair value, net of issuance costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records accretion on the Redeemable
Convertible Preferred Shares, where applicable, to the redemption value pursuant to the redemption terms. The accretion, calculated using
the effective interest method, is recorded against retained earnings, or in the absence of retained earnings, by charging against additional
paid-in capital. For the nine months ended December 31, 2024 and 2023, the accretions of Redeemable Convertible Preferred Shares were
US$215,959 and US$196,274, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&#8217;s Redeemable Convertible Preferred Shares activities
for the nine months ended December 31, 2024 and 2023 were summarized below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amounts</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold">Balance as of March 31, 2023</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">173,208</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">37,158,702</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accretion to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196,274</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign exchange impact</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">185,912</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Balance as of December 31, 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">173,208</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">37,540,888</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Balance as of March 31, 2024</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">173,208</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">37,537,005</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accretion to redemption value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">215,959</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign exchange impact</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">282,072</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">173,208</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">38,035,036</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 301 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><b>12.</b></td><td style="text-align: justify"><b>INCOME TAXES</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>British Virgin Islands (&#8220;BVI&#8221;)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the current laws of BVI, the Company is
not subject to income or capital gains taxes. In addition, dividend payments are not subject to withholdings tax in BVI.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Hong&#160;Kong</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to Tax (Amendment) (No. 3) Ordinance
2019 published by Hong&#160;Kong government, effective April&#160;1, 2019, under the two-tiered profits tax rates regime, the profits
tax rate for the first HK$ 2&#160;million of assessable profits was reduced to 8.25% (half of the rate specified in Schedule&#160;8 to
the Inland Revenue Ordinance (IRO)) for corporations, while the remaining profits will continue to be taxed at the existing 16.5% tax
rate. All subsidiaries were subject to Hong&#160;Kong profit tax during the periods presented.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The income tax provision consisted of the following
components:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended <br/>
December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current income tax expense</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21,393</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(277,981</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(230,663</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total income tax expense</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(299,374</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(230,663</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation between the Group&#8217;s actual
provision for income taxes and the provision under the HK statutory rate is as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended <br/>
December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Profits before Tax</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,623,282</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,109,582</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax calculated at 16.5%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">268,944</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">183,163</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income not subject to tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(492</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(163</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expenses not deductible for tax purposes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,601</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">504</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24,321</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47,159</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income tax expense</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">299,374</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">230,663</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 302 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024 and March 31, 2024, the
significant components of the deferred tax assets and liabilities were summarized below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/>
 2024</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss carried forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,592,252</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,533,449</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Allowance of credit losses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,721</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,644</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash surrender value changes of insurance contracts</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,425</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Total deferred tax assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">5,659,973</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">3,578,518</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: valuation allowance</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(395,418</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(368,245</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Deferred tax assets, net</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,264,555</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,210,273</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accelerated depreciation and amortization</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,995,915</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,651,792</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Deferred tax liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(6,995,915</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,651,792</td><td style="font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net deferred tax liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,731,360</td><td style="font-weight: bold; text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,441,519</td><td style="font-weight: bold; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Changes in valuation allowance are as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/>
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-align: left; padding-left: 1.4pt">Balance at beginning of the periods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">368,245</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">257,758</p></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 1.4pt">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,663</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,017</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 1.4pt">Decrease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36,342</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23,302</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 1.4pt">Foreign exchange difference</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,852</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">772</p></td><td style="padding-bottom: 1.5pt; text-align: left"/></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 1.4pt">Balance at end of the periods</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">395,418</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">368,245</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024 and March 31, 2024, the
Group had indefinite loss carryforwards of USD33,763,388 and USD21,413,651, respectively, which arose from the Group&#8217;s subsidiaries
in HK.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>13.</b></td><td style="text-align: justify"><b>LEASES</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has two operating leases for office as a lessee. Supplemental
balance sheet information related to operating leases was as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/>
 2024</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-align: left">Operating lease right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">896,026</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">279,706</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">277,117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301,003</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease liabilities, non-current</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">650,067</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total lease liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">927,184</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">301,003</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 303 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The discount rate for the operating lease
was 5.00% both for the nine months ended December 31, 2024 and 2023. The remaining lease term was 34 months as of December 31, 2024
For the nine months ended December 31, 2024 and 2023, the lease expense was as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended<br/>
 December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease expenses excluding short-term rental expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">343,178</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">321,049</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Short-term lease expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,101</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">343,178</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">322,150</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a schedule of future minimum payments under the Company&#8217;s
operating leases as of December 31, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">For the fiscal year ended</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 88%">Remaining of 2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">77,436</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">328,733</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">368,191</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028 and thereafter</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">225,292</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total lease payments</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">999,652</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: imputed interest</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(72,468</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Total operating liabilities, net of interest</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">927,184</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>14.</b></td><td style="text-align: justify"><b>EARNINGS PER SHARE</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the basic and diluted net profit per
share computation and provides a reconciliation of the numerator and denominator for the periods presented:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-keep: true">For the nine months ended<br/>
    December 31,</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-keep: true">2024</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-keep: true">2023</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="-keep: true">USD</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="text-align: center; font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center; font-weight: bold"><span style="-keep: true">USD</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="text-align: center; font-weight: bold"><span style="-keep: true">(Unaudited)</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"><span style="-keep: true">Numerator:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left"><span style="-keep: true">Net income</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">1,323,908</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">878,919</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="-keep: true">Less: net income attributable to non-controlling interests</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">71,369</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">69,999</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="-keep: true">Less: accretion of redemption value of preferred shares</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">215,959</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">196,274</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="-keep: true">Less: non-cumulative dividend to preferred shares prior
    to any payment of dividend to ordinary shares</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">1,021,905</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">612,646</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="-keep: true">Less: net income attributable to preferred shareholders</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">6,811</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="-keep: true">Net income attributable to the Company's
    ordinary shareholders</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">7,864</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true">-</span></td><td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="-keep: true">Denominator:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="-keep: true">Weighted average number of ordinary shares - basic and diluted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">200,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">200,000</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="-keep: true">Earnings per ordinary share</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="-keep: true">- Basic and diluted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0.04</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The redeemable convertible preferred shares were anti-diluted for the
nine months ended December 31, 2024 and 2023 since their accretion per common share obtainable on conversion exceeds basic EPS.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 304 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 22pt"><b>15.</b></td><td style="text-align: justify"><b>RELATED PARTY TRANSACTIONS</b></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Related parties:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; text-decoration: none; width: 50%; font-weight: bold; text-align: left"><span style="text-decoration: none">Names
    of related parties</span></td><td style="text-decoration: none; padding-bottom: 1.5pt; width: 1%; font-weight: bold"><span style="text-decoration: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-decoration: none; width: 49%; font-weight: bold"><span style="text-decoration: none">Relationship</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Wong Ling Yan (Philip)</td><td>&#160;</td>
    <td style="text-align: left">Director and controlling shareholder of the Company</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Good Staywell HK Limited</td><td>&#160;</td>
    <td style="text-align: left">An equity investee of Good On Time</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lee Kar Man Montina</td><td>&#160;</td>
    <td style="text-align: left">Director of YOOV Capital</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Amount due from related parties:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/>
 2024</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Wong Ling Yan (Philip)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10,299,059</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,632,400</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Good Staywell HK Limited</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,169</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,160</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">10,300,228</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,633,560</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Amount due to a related party:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/>
 2024</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Lee Kar Man Montina</td><td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">5,216</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">Total</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,216</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Significant related party transactions:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended<br/>
 December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">USD</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Advance payment to the director for intangible assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">17,314,798</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,900,749</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Intangible assets payment paid by the director on behalf of the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,314,798</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,900,749</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Mezzanine equity received by the director on behalf of the Group and repaid to the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,994,178</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounts receivable received by the director on behalf of the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,164,698</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">677,360</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts receivable received by the director and repaid to the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,906,058</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,607,815</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expenses paid by the Group on behalf of the director</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,492,915</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">818,564</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expenses paid by the director on behalf of the Group</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,146,182</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,586</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The director authorized his bank account to the
Group for the purpose of collection and payments activities to improve business efficiency, including the purchase of intangible assets,
collection of investment and receivables, etc. The Group has evaluated the subsequent settlement of amount due from Philip from December
31, 2024 through April 24, 2025, the date the unaudited condensed financial statements were issued, the balance has not been repaid to
the Group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 305 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>16.</b></td><td style="text-align: justify"><b>SIGNIFICANT RISKS</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Credit risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially expose
the Group to the concentration of credit risk consist primarily of cash, accounts receivable, factoring receivables, amounts from related
parties, and other receivables and prepayments. As of December 31, 2024 and March 31, 2024, the Group places its cash with major financial
institutions located in the Hong Kong S.A.R, which management considers to be of high credit quality. Concentration of credit risks with
respect to accounts receivable, factoring receivables, amounts from related parties, and other receivables and prepayments, to manage
credit risk, the Group performs ongoing credit evaluations of customers&#8217; and suppliers&#8217;, as well as related parties&#8217;
financial condition. There is no significant credit risk for the nine months ended December 31, 2024 and 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024 and March 31, 2024, HKD20,948,703
(USD2,696,899) and HKD10,720,403 (USD1,369,862) of the Group&#8217;s cash was on deposit at financial institutions in Hong&#160;Kong,
respectively. In accordance with the relevant regulations in Hong&#160;Kong, the maximum insured bank deposit amount is HKD500,000 for
each financial institution and it has been enhanced to HKD 800,000 since October 1, 2024. Accordingly, the Group&#8217;s total unprotected
cash held in banks amounted to HKD16,948,703 (USD2,181,946) and HKD8,720,403 (USD1,114,300) as of December 31, 2024 and March 31, 2024,
respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Concentration risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">There was no single customers which individually represented greater
than 10% of the total revenues of the Group for the nine months ended December 31, 2024 and 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The Group collected accounts receivables from customers through sales
agents. The following parties represent more than 10% of the Group&#8217;s accounts receivable as of December 31, 2024 and March 31, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/>
 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Percentage of the Company&#8217;s accounts receivables</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 1.4pt">A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.2</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">34.4</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 1.4pt">B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">represents percentage less than 10%.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 306 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The suppliers which individually represented greater than 10% of the
total purchases of the Group for the nine months ended December 31, 2024 and 2023 were as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the nine months ended<br/>
 December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Percentage of the Company&#8217;s total purchase</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Supplier B</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">22.6</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10.3</td><td style="width: 1%; text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following suppliers represent more than 10% of the Group&#8217;s
accounts payable as of December 31, 2024 and March 31, 2024:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/>
 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">March 31,<br/>
 2024</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Percentage of the Company&#8217;s accounts payable</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Supplier A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18.1</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.3</td><td style="width: 1%; text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>17.</b></td><td style="text-align: justify"><b>COMMITMENTS AND CONTINGENCIES</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The
                                            Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting
                                            for contingencies. The Company records a loss contingency, consistent with ASC 450, when
                                            it is probable that a liability has been incurred and the amount of the loss can be reasonably
                                            estimated. If a potential material loss contingency is not probable but is reasonably possible,
                                            or is probable but cannot be estimated, then the nature of the contingent liability, together
                                            with an estimate of the range of possible loss if determinable and material, is disclosed.
                                            Accounting for contingencies requires us to use judgement related to both the likelihood
                                            of a loss and the estimate of the amount or range of loss.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except for leases which were disclosed in Note
13, there are not any other known commitments or contingencies as of December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><b>18.</b></td><td style="text-align: justify"><b>SUBSEQUENT EVENTS</b></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated events from the nine
months ended December 31, 2024 through April 24, 2025 the date the financial statements were issued. The Company did not identify any
subsequent events with a material financial impact on the Company&#8217;s unaudited condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 307 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_143"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>AVALON FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;&#160;</p><div>

</div><div><a id="b_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Directors and Stockholders of Avalon GloboCare
Corp.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Opinion on the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Avalon GloboCare Corp. (the Company) as of December 31, 2024, and the related consolidated statements of operations
and comprehensive loss, changes in equity, and cash flows for the year ended December 31, 2024, and the related notes (collectively referred
to as the financial statements). We have audited the reverse stock split presentation for year-end December 31, 2023. We have audited
note 20 in regards to the presentation of segment information for the year-ended December 31, 2023. In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations
and its cash flows for the year ended December 31, 2024, in conformity with accounting principles generally accepted in the United States
of America. The financial statements of Avalon GloboCare Corp., as of December 31, 2023, were audited by other auditors whose report dated
April 15, 2024, expressed an unqualified opinion on those financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared assuming the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has yet
to achieve profitable operations, has negative cash flows from operating activities, and is dependent upon future issuances of equity
or other financings to fund ongoing operations all of which raises substantial doubt about its ability to continue as a going concern.
Management&#8217;s plans regarding these matters are also described in Note 2. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations
of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audit in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Audit Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The critical audit matter communicated below is
a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the
audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially
challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the
financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions
on the critical audit matter or on the accounts or disclosures to which it relates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Investments</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As discussed in the notes to the financial statements,
the Company has an equity method investment in an unconsolidated subsidiary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Auditing management&#8217;s valuation of the carrying value of the
investment involves significant judgements and estimates to determine the proper value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">To evaluate the appropriateness of the valuation of the investment,
we evaluated management&#8217;s significant judgments and estimates to determine that the investment is properly valued.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ M&amp;K CPAS, PLLC</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Woodlands, TX</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 31, 2025</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 308 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="b_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Shareholders and Board of Directors of</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Avalon GloboCare Corp.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Opinion on the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">We have audited,
before the effects of the adjustments to retrospectively apply the reverse stock split described in Note 3, and before the effects of
the retrospective adjustment for the adoption of ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>
(&#8220;ASU 2023-07&#8221;) discussed in Note 3 and Note 20 to the consolidated financial statements, the accompanying consolidated balance
sheet of </span>Avalon GloboCare Corp. <span style="font-size: 10pt">(the &#8220;Company&#8221;) as of December 31, 2023, and the related
consolidated statements of operations and comprehensive loss, changes in equity and cash flows the year ended December 31, 2023, and the
related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements, before the
effects of the adjustments to retrospectively apply the reverse stock split described in Note 3, and before the effects of the retrospective
adjustment for the adoption of ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i> (&#8220;ASU
2023-07&#8221;) discussed in Note 3 and Note 20 to the consolidated financial statements, present fairly, in all material respects, the
financial position of the Company as of December 31, 2023, and the results of its operations and its cash flows for the year ended December
31, 2023, in conformity with accounting principles generally accepted in the United States of America.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were not engaged to audit, review, or apply
any procedures to the retrospective reverse stock split described in Note 3, or retrospective adjustment for the adoption of ASU 2023-07
discussed in Note 3 and Note 20 to the consolidated financial statements, and accordingly, we do not express an opinion or any other form
of assurance about whether such retrospective adjustments are appropriate and have been properly applied. Those retrospective adjustments
were audited by other auditors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Explanatory Paragraph - Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company has a significant
working capital deficiency, has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its
operations. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in
regard tao these matters are also described in Note 2. The financial statements do not include any adjustments that might result from
the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We
are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audit in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal
control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Marcum <span style="font-variant: small-caps">llp</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marcum <span style="font-variant: small-caps">llp</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-variant: small-caps">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor from 2019 to 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY<b><br/>
</b>April 15, 2024</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 309 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><div><a id="b_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CONSOLIDATED BALANCE
SHEETS</b></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">CURRENT ASSETS:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-88775">2,856,309</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-88776">285,400</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Rent receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-88777">80,829</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-88778">197,473</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Prepaid expense and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-88779">299,360</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-88780">367,994</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total Current Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-88781">3,236,498</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-88782">850,867</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">NON-CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Operating lease right-of-use assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-88783">4,709</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-88784">128,250</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-88785">12,912</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-88786">38,083</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Investment in real estate, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RealEstateInvestments" scale="0" unitRef="usd" id="ixv-88787">7,022,721</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RealEstateInvestments" scale="0" unitRef="usd" id="ixv-88788">7,191,404</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Equity method investments, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-88789">10,636,544</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-88790">12,095,020</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-88791">71,794</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-88792">278,912</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total Non-current Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-88793">17,748,680</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-88794">19,731,669</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-88795">20,985,178</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-88796">20,582,536</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">LIABILITIES AND EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Accrued professional fees</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" unitRef="usd" id="ixv-88797">611,462</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" unitRef="usd" id="ixv-88798">1,804,100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Accrued research and development fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="avco:AccruedResearchAndDevelopmentsFees" scale="0" unitRef="usd" id="ixv-88799">153,772</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="avco:AccruedResearchAndDevelopmentsFees" scale="0" unitRef="usd" id="ixv-88800">208,772</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Accrued payroll liability and compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedPayrollTaxesCurrent" scale="0" unitRef="usd" id="ixv-88801">501,258</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedPayrollTaxesCurrent" scale="0" unitRef="usd" id="ixv-88802">588,722</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Accrued litigation settlement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LitigationReserveCurrent" scale="0" unitRef="usd" id="ixv-88803">373,450</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LitigationReserveCurrent" scale="0" unitRef="usd" id="ixv-88804">450,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Accrued liabilities and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-88805">434,117</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-88806">272,915</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Accrued liabilities and other payables - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-88807">732,916</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-88808">206,458</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Operating lease obligation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-88809">10,709</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-88810">129,396</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Advance from pending sale of noncontrolling interest - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" scale="0" unitRef="usd" id="ixv-88811">3,108,106</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" scale="0" unitRef="usd" id="ixv-88812">485,714</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Equity method investment payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="avco:EquityMethodInvestmentPayableCurrent" scale="0" unitRef="usd" id="ixv-88813">666,667</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-88814">127,545</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-88815">24,796</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Note payable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableToBankCurrent" scale="0" unitRef="usd" id="ixv-88816">5,715,447</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Convertible note payable, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-88817">2,113,773</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-88818">1,925,146</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total Current Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-88819">13,882,555</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-88820">6,762,686</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">NON-CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Operating lease obligation - noncurrent portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-88821">4,855</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Note payable, net - noncurrent portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermNotesPayable" scale="0" unitRef="usd" id="ixv-88822">5,596,219</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Loan payable - related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermLoansPayable" scale="0" unitRef="usd" id="ixv-88823">850,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total Non-current Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-88824">6,451,074</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-88825">13,882,555</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-88826">13,213,760</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Commitments and Contingencies (Note 21)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>EQUITY:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">Preferred stock, $<ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-88827"><ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-88828">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-88829"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-88830">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"><div style="-sec-ix-hidden: hidden-fact-11">Series A Convertible Preferred Stock, <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-88831"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-88832"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-88833"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-88834">9,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2024 and 2023&#8239;Liquidation preference $<ix:nonFraction contextRef="c5" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreferenceValue" scale="6" unitRef="usd" id="ixv-88835">9</ix:nonFraction> million at December 31, 2024 </div></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-88836">9,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-88837">9,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left"><div style="-sec-ix-hidden: hidden-fact-12">Series B Convertible Preferred Stock, <ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-88838"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-88839"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-88840"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-88841">11,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2024 and 2023 Liquidation preference $<ix:nonFraction contextRef="c7" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreferenceValue" scale="6" unitRef="usd" id="ixv-88842">11</ix:nonFraction> million at December 31, 2024</div></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-88843">11,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-88844">11,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Series C Convertible Preferred Stock, <ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-88845"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-88846"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-88847"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-88848">3,500</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares&#8239;issued and outstanding at December 31, 2024&#8239;Liquidation preference $<ix:nonFraction contextRef="c9" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreferenceValue" scale="6" unitRef="usd" id="ixv-88849">3.5</ix:nonFraction> million at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-88850">3,500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13"><span style="-sec-ix-hidden: hidden-fact-14">-</span></div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in">Common stock, $<ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-88851"><ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-88852">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-88853"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-88854">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized;&#8239;<ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-88855">1,445,979</ix:nonFraction> shares issued and <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-88856">1,442,512</ix:nonFraction> shares outstanding at December 31, 2024;&#8239;<ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-88857">736,769</ix:nonFraction> shares issued and <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-88858">733,302</ix:nonFraction> shares outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-88859">145</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-88860">74</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-88861">72,023,525</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-88862">67,886,082</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: common stock held in treasury, at cost;&#8239; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" unitRef="shares" id="ixv-88863"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" unitRef="shares" id="ixv-88864">3,467</ix:nonFraction></ix:nonFraction> shares at December 31, 2024 and 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonValue" scale="0" unitRef="usd" id="ixv-88865">522,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonValue" scale="0" unitRef="usd" id="ixv-88866">522,500</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-88867">87,673,125</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-88868">79,769,731</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Statutory reserve</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" scale="0" unitRef="usd" id="ixv-88869">6,578</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" scale="0" unitRef="usd" id="ixv-88870">6,578</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated other comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-88871">232,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-88872">231,727</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total Avalon GloboCare Corp. stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-88873">7,102,623</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-88874">7,368,776</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Noncontrolling interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-88875">7,102,623</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-88876">7,368,776</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-88877">20,985,178</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-88878">20,582,536</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">See accompanying notes to the consolidated financial statements</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 310 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="b_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS</b></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>For the Years Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">REAL PROPERTY RENTAL REVENUE</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-88879">1,333,403</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-88880">1,255,681</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">REAL PROPERTY OPERATING EXPENSES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-88881">1,065,574</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-88882">1,017,493</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">REAL PROPERTY OPERATING INCOME</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd" id="ixv-88883">267,829</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd" id="ixv-88884">238,188</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">LOSS FROM EQUITY METHOD INVESTMENT - LAB SERVICES MSO</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="0" sign="-" unitRef="usd" id="ixv-88885">846,588</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="0" sign="-" unitRef="usd" id="ixv-88886">8,571,647</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">OTHER OPERATING EXPENSES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Advertising and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MarketingAndAdvertisingExpense" scale="0" unitRef="usd" id="ixv-88887">237,671</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MarketingAndAdvertisingExpense" scale="0" unitRef="usd" id="ixv-88888">1,666,721</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-88889">1,822,105</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-88890">3,076,477</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Compensation and related benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="0" unitRef="usd" id="ixv-88891">1,431,328</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="0" unitRef="usd" id="ixv-88892">1,768,449</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-88893">857,869</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-88894">908,577</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total Other Operating Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" unitRef="usd" id="ixv-88895">4,348,973</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" unitRef="usd" id="ixv-88896">7,420,224</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">LOSS FROM OPERATIONS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-88897">4,927,732</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-88898">15,753,683</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">OTHER (EXPENSE) INCOME</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Interest expense - amortization of debt discount and debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="0" unitRef="usd" id="ixv-88899">1,411,042</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="0" unitRef="usd" id="ixv-88900">544,010</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Interest expense - other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-88901">983,486</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-88902">773,780</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Interest expense - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd" id="ixv-88903">42,445</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd" id="ixv-88904">33,712</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Debt modification charge</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:DebtModificationCharge" scale="0" sign="-" unitRef="usd" id="ixv-88905">838,794</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" sign="-" unitRef="usd" id="ixv-88906">374,365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" sign="-" unitRef="usd" id="ixv-88907">188,374</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Impairment of equity method investment - Epicon</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="0" unitRef="usd" id="ixv-88908">454,679</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Gain on debts extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" unitRef="usd" id="ixv-88909">682,979</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="0" unitRef="usd" id="ixv-88910">74,260</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="0" unitRef="usd" id="ixv-88911">18,499</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total Other Expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-88912">2,975,662</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-88913">953,327</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">LOSS BEFORE INCOME TAXES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-88914">7,903,394</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-88915">16,707,010</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">INCOME TAXES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">NET LOSS</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-88916">7,903,394</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-88917">16,707,010</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-88918">7,903,394</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-88919">16,707,010</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c18" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-88920"><ix:nonFraction contextRef="c18" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-88921">8.44</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c19" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-88922"><ix:nonFraction contextRef="c19" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-88923">23.80</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-88924"><ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-88925">936,614</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-88926"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-88927">701,932</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">COMPREHENSIVE LOSS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">NET LOSS</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-88928">7,903,394</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-88929">16,707,010</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">OTHER COMPREHENSIVE LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Unrealized foreign currency translation loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" scale="0" unitRef="usd" id="ixv-88930">273</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" scale="0" unitRef="usd" id="ixv-88931">18,590</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">COMPREHENSIVE LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-88932">7,903,667</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-88933">16,725,600</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">LESS: COMPREHENSIVE LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt">COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-88934">7,903,667</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-88935">16,725,600</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>


</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes to the consolidated financial statements</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 311 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="b_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
STATEMENTS OF CHANGES IN EQUITY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Years Ended December 31, 2024 and 2023</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="font-size: 8pt; vertical-align: bottom"> <td colspan="65" style="font-size: 8pt; text-align: center"/></tr> <tr style="font-size: 8pt; vertical-align: bottom"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="54" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Avalon GloboCare Corp. Stockholders&#8217; Equity</b></span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom"> <td style="font-size: 8pt; text-align: center; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="6" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Series A <br/> Preferred Stock</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="6" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Series B <br/> Preferred Stock</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="6" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Series C <br/> Preferred Stock</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="6" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Common Stock</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;Additional</b></span><span style="-keep: true; display: block;"><br/></span> <span style="font-size: 8pt"><b>Paid-in</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="6" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Treasury Stock</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Accumulated</b></span><span style="font-size: 8pt"><br/> <span style="font-family: Times New Roman, Times, Serif"><b>Other</b></span></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom"> <td style="font-size: 8pt; text-align: center; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Number&#160;of</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Number&#160;of</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Number&#160;of</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Number&#160;of</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"/><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Number&#160;of</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Accumulated</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Statutory</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-size: 8pt"><b>Comprehensive</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Noncontrolling</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Total</b></span></td><td style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom"> <td style="font-size: 8pt; text-align: center; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Shares</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amount</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Shares</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amount</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Shares</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amount</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Shares</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amount</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Capital</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Shares</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amount</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Deficit</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Reserve</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Loss</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Interest</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td> <td colspan="2" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Equity</b></span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom"> <td style="font-size: 8pt; text-align: center; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td colspan="2" style="font-size: 8pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; width: 26.1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance, January 1, 2023</span></td><td style="font-size: 8pt; width: 0.2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c22" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-88936">9,000</ix:nonFraction></span></td><td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-88937">9,000,000</ix:nonFraction></span></td><td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-88938">667,572</ix:nonFraction></span></td><td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-88939">67</ix:nonFraction></span></td><td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-88940">65,950,661</ix:nonFraction></span></td><td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-88941">3,467</ix:nonFraction></span></td><td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font-size: 8pt; width: 0.2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-88942">522,500</ix:nonFraction></span></td><td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font-size: 8pt; width: 0.2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-88943">63,062,721</ix:nonFraction></span></td><td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font-size: 8pt; width: 0.2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-88944">6,578</ix:nonFraction></span></td><td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-88945">213,137</ix:nonFraction></span></td><td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font-size: 8pt; width: 0.2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; width: 0.2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-88946">11,158,948</ix:nonFraction></span></td><td style="font-size: 8pt; width: 0.2%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">To correct shares issued for adjustments for <ix:nonNumeric contextRef="c19" name="us-gaap:StockholdersEquityReverseStockSplit" id="ixv-88947">1:10</ix:nonNumeric> reverse split</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c36" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" unitRef="shares" id="ixv-88948">3,333</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance of Series B Convertible Preferred Stock for equity method investment</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c34" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares" id="ixv-88949">11,000</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-88950">11,000,000</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-66"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd" id="ixv-88951">11,000,000</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance of common stock as convertible note payable commitment fee</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c36" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-88952">11,333</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-88953">1</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-88954">236,399</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-88955">236,400</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Sale of common stock, net</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c36" decimals="INF" format="ixt:num-dot-decimal" name="avco:StockIssuedDuringPeriodSharesSaleOfCommonStockNet" scale="0" unitRef="shares" id="ixv-88956">30,442</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" scale="0" unitRef="usd" id="ixv-88957">3</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" scale="0" unitRef="usd" id="ixv-88958">414,393</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" scale="0" unitRef="usd" id="ixv-88959">414,396</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance of common stock for services</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c36" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-88960">24,089</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-88961">3</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-88962">999,652</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-88963">999,655</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based compensation</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-88964">284,977</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-97"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-88965">284,977</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
<tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Foreign currency translation adjustment</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" sign="-" unitRef="usd" id="ixv-88966">18,590</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" sign="-" unitRef="usd" id="ixv-88967">18,590</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
<tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
<tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net loss for the year</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-110"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-88968">16,707,010</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-112"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-88969">16,707,010</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
<tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance, December 31, 2023</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c42" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-88970">9,000</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-88971">9,000,000</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c43" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-88972">11,000</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-88973">11,000,000</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-88974">736,769</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-88975">74</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-88976">67,886,082</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c47" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-88977">3,467</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-88978">522,500</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-88979">79,769,731</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-88980">6,578</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-88981">231,727</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-88982">7,368,776</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
<tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance of common stock as convertible note payable commitment fee</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"/><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c55" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-88983">33,800</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-88984">3</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-88985">320,543</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-88986">320,546</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Sale of common stock, net</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c55" decimals="INF" format="ixt:num-dot-decimal" name="avco:StockIssuedDuringPeriodSharesSaleOfCommonStockNet" scale="0" unitRef="shares" id="ixv-88987">281,843</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" scale="0" unitRef="usd" id="ixv-88988">28</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" scale="0" unitRef="usd" id="ixv-88989">2,544,283</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-129"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-130"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" scale="0" unitRef="usd" id="ixv-88990">2,544,311</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance of common stock upon cashless exercise of stock warrants</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c55" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-88991">42,381</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-88992">4</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" sign="-" unitRef="usd" id="ixv-88993">4</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance of common stock for services</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c55" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-88994">145,153</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-88995">15</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-88996">530,335</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-143"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-88997">530,350</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Reclassification of derivative liability to equity</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-149"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="0" unitRef="usd" id="ixv-88998">2,354</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="0" unitRef="usd" id="ixv-88999">2,354</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Sale of Series C Convertible Preferred Stock</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c54" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares" id="ixv-89000">3,500</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="0" unitRef="usd" id="ixv-89001">3,500,000</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="0" unitRef="usd" id="ixv-89002">3,500,000</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance of pre-funded warrants</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-164"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-165"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-166"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" unitRef="usd" id="ixv-89003">688,794</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-167"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-169"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" unitRef="usd" id="ixv-89004">688,794</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based compensation</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-174"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-89005">51,159</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-175"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-176"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-89006">51,159</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Shares issued for adjustments for 1:15 reverse split</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-181"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c55" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" unitRef="shares" id="ixv-89007">206,033</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" scale="0" unitRef="usd" id="ixv-89008">21</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" scale="0" sign="-" unitRef="usd" id="ixv-89009">21</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-182"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-183"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-185"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-186"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Foreign currency translation adjustment</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-187"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-188"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-189"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-190"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-191"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-192"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-193"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" sign="-" unitRef="usd" id="ixv-89010">273</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-194"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" sign="-" unitRef="usd" id="ixv-89011">273</ix:nonFraction></span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net loss for the year</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-195"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-196"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-197"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-198"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-199"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-89012">7,903,394</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-200"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-201"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-202"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-89013">7,903,394</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: White"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr> <tr style="font-size: 8pt; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 8pt; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance, December 31, 2024</span></td><td style="font-size: 8pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c61" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-89014">9,000</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-89015">9,000,000</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c62" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-89016">11,000</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-89017">11,000,000</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c63" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-89018">3,500</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-89019">3,500,000</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c64" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-89020">1,445,979</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-89021">145</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-89022">72,023,525</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c66" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-89023">3,467</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font-size: 8pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-89024">522,500</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font-size: 8pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-89025">87,673,125</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font-size: 8pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-89026">6,578</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-89027">232,000</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td><td style="font-size: 8pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-203"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></div></td><td style="font-size: 8pt; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td><td style="font-size: 8pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td> <td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td><td style="font-size: 8pt; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-89028">7,102,623</ix:nonFraction></span></td><td style="font-size: 8pt; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">See accompanying notes to the consolidated
financial statements.</span></p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 312 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"></p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><div><a id="b_006"></a></div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>AVALON GLOBOCARE
CORP. AND SUBSIDIARIES</b></span></p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></span></p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="6" style="text-align: center"><b>For the Years Ended</b></td><td><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>December 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-89029">7,903,394</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-89030">16,707,010</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-89031">177,917</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-89032">211,720</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Change in straight-line rent receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StraightLineRent" scale="0" sign="-" unitRef="usd" id="ixv-89033">46,607</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StraightLineRent" scale="0" sign="-" unitRef="usd" id="ixv-89034">10,496</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Amortization of operating lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd" id="ixv-89035">122,553</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd" id="ixv-89036">118,226</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Stock-based compensation and service expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-89037">521,509</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-89038">1,179,761</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Loss from equity method investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" sign="-" unitRef="usd" id="ixv-89039">846,588</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" sign="-" unitRef="usd" id="ixv-89040">8,589,822</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Distribution of earnings from equity method investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:DistributionOfEarningsFromEquityMethodInvestment" scale="0" sign="-" unitRef="usd" id="ixv-89041">611,888</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-284">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Impairment of equity method investment - Epicon</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-285">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="0" unitRef="usd" id="ixv-89042">454,679</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Amortization of debt issuance costs and debt discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:BeneficialConversionFeatureRelatedToConvertibleNotePayable" scale="0" sign="-" unitRef="usd" id="ixv-89043">1,411,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="avco:BeneficialConversionFeatureRelatedToConvertibleNotePayable" scale="0" sign="-" unitRef="usd" id="ixv-89044">544,010</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Change in fair market value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" sign="-" unitRef="usd" id="ixv-89045">374,365</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" sign="-" unitRef="usd" id="ixv-89046">188,374</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Impairment of laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:ImpairmentOfLaboratoryEquipment" scale="0" unitRef="usd" id="ixv-89047">111,033</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-286">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Debt modification charge</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnRestructuringOfDebt" scale="0" sign="-" unitRef="usd" id="ixv-89048">688,794</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-287">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Gain on debts extinguishment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-288">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" unitRef="usd" id="ixv-89049">682,979</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Rent receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" sign="-" unitRef="usd" id="ixv-89050">130,739</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" unitRef="usd" id="ixv-89051">46,220</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Security deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-289">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInSecurityDeposits" scale="0" unitRef="usd" id="ixv-89052">396</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Deferred leasing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:IncreaseDecreaseInDeferredLeasingCosts" scale="0" unitRef="usd" id="ixv-89053">33,402</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="avco:IncreaseDecreaseInDeferredLeasingCosts" scale="0" unitRef="usd" id="ixv-89054">33,402</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Prepaid expense and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd" id="ixv-89055">91,496</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" sign="-" unitRef="usd" id="ixv-89056">411</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Accrued liabilities and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-89057">1,165,418</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-89058">16,601</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Accrued liabilities and other payables - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:AccruedLiabilitiesAndOtherPayablesRelatedParties" scale="0" unitRef="usd" id="ixv-89059">14,051</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="avco:AccruedLiabilitiesAndOtherPayablesRelatedParties" scale="0" sign="-" unitRef="usd" id="ixv-89060">106,458</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Operating lease obligation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd" id="ixv-89061">122,553</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd" id="ixv-89062">112,915</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">NET CASH USED IN OPERATING ACTIVITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-89063">4,969,205</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-89064">6,504,718</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Purchase of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-290">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-89065">22,159</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Payment for equity interest purchase</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="0" unitRef="usd" id="ixv-89066">100,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-291">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">NET CASH USED IN INVESTING ACTIVITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-89067">100,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-89068">22,159</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Proceeds from loan payable - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-292">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-89069">850,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Repayments of loan payable - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd" id="ixv-89070">400,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-293">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Proceeds from issuance of convertible debts and warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-89071">3,367,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-89072">2,565,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Payments of convertible debts issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" unitRef="usd" id="ixv-89073">282,700</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" unitRef="usd" id="ixv-89074">327,200</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Repayments of convertible debts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="0" unitRef="usd" id="ixv-89075">3,388,222</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="0" unitRef="usd" id="ixv-89076">300,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Proceeds from issuance of balloon promissory note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-294">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="0" unitRef="usd" id="ixv-89077">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Payments of balloon promissory note issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-295">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" unitRef="usd" id="ixv-89078">64,436</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Advance from pending sale of noncontrolling interest in subsidiary</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" scale="0" unitRef="usd" id="ixv-89079">2,122,392</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" scale="0" unitRef="usd" id="ixv-89080">485,714</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Proceeds from equity offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromOtherEquity" scale="0" unitRef="usd" id="ixv-89081">2,857,852</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromOtherEquity" scale="0" unitRef="usd" id="ixv-89082">635,391</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Disbursements for equity offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" scale="0" unitRef="usd" id="ixv-89083">138,405</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" scale="0" unitRef="usd" id="ixv-89084">19,132</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Proceeds from issuance of convertible preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="0" unitRef="usd" id="ixv-89085">3,500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-296">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">NET CASH PROVIDED BY FINANCING ACTIVITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-89086">7,638,667</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-89087">4,825,337</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">EFFECT OF EXCHANGE RATE ON CASH</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-89088">1,447</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" sign="-" unitRef="usd" id="ixv-89089">3,970</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">NET INCREASE (DECREASE) IN CASH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd" id="ixv-89090">2,570,909</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-89091">1,705,510</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">CASH - beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-89092">285,400</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-89093">1,990,910</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">CASH - end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-89094">2,856,309</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-89095">285,400</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in">Cash paid for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0.25in">Interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-89096">1,088,512</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-89097">718,753</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">NON-CASH INVESTING AND FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt">Common stock issued for accrued liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:CommonStockIssuedForAccruedLiabilities" scale="0" unitRef="usd" id="ixv-89098">60,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="avco:CommonStockIssuedForAccruedLiabilities" scale="0" unitRef="usd" id="ixv-89099">164,871</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Reclassification of advances for equity interest purchase to equity method investment</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-297">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="avco:ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment" scale="0" unitRef="usd" id="ixv-89100">9,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Series B Convertible Preferred Stock issued related to equity method investment</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-298">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="avco:WarrantsIssuedWithConvertibleNotePayable" scale="0" unitRef="usd" id="ixv-89101">11,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Accrued purchase price related to equity method investment</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-299">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="avco:AccruedPurchasePriceRelatedToEquityMethodInvestment" scale="0" unitRef="usd" id="ixv-89102">666,667</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Warrants issued as convertible notes payable finder&#8217;s fee</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:WarrantsIssuedAsConvertibleNotePayableFindersFee" scale="0" unitRef="usd" id="ixv-89103">40,900</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="avco:WarrantsIssuedAsConvertibleNotePayableFindersFee" scale="0" unitRef="usd" id="ixv-89104">16,977</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Warrants issued with convertible notes payable recorded as debt discount</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount" scale="0" unitRef="usd" id="ixv-89105">438,568</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="avco:WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount" scale="0" unitRef="usd" id="ixv-89106">196,193</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Common stock issued as convertible notes payable commitment fee</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock" scale="0" unitRef="usd" id="ixv-89107">320,546</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="avco:ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock" scale="0" unitRef="usd" id="ixv-89108">236,400</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Deferred financing costs in accrued liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-300">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="avco:DeferredFinancingCostsInAccruedLiabilities" scale="0" unitRef="usd" id="ixv-89109">202,892</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Equity method investment payable paid by a related party</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-89110">566,667</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-301">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Reclassification of deferred offering costs</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SupplementalDeferredPurchasePrice" scale="0" unitRef="usd" id="ixv-89111">175,136</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-302">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Settlement of derivative liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:SettlementsOfDerivativeLiability" scale="0" unitRef="usd" id="ixv-89112">2,354</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-303">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.375in">Reclassification of related party loan payable and accrued expenses to advance from related party</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty" scale="0" unitRef="usd" id="ixv-89113">500,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-304">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Issuance of common stock upon cashless exercise of stock warrants</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant" scale="0" unitRef="usd" id="ixv-89114">4</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-305">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Shares issued for adjustments for 1:15 reverse split</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="0" unitRef="usd" id="ixv-89115">21</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-306">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>







</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the consolidated financial statements.</span></p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 313 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><div><a id="b_007"></a></div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>AVALON GLOBOCARE
CORP. AND SUBSIDIARIES<br/>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c18" continuedAt="_NatureOfOperations-c18_cont_1" escape="true" name="us-gaap:NatureOfOperations" id="ixv-58929"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 - <span style="text-decoration:underline">ORGANIZATION AND NATURE
OF OPERATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Avalon GloboCare Corp. (the &#8220;Company&#8221;
or &#8220;ALBT&#8221;) was incorporated under the laws of the State of Delaware on July 28, 2014.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company is a commercial-stage company dedicated
to developing and delivering precision diagnostic consumer products. The Company is currently marketing the KetoAir breathalyzer device
and plans to develop additional diagnostic uses of the breathalyzer technology. The Company also provided laboratory services in 2024
and 2023, offering a broad portfolio of diagnostic tests, including drug testing, toxicology, and a broad array of test services, from
general bloodwork to anatomic pathology, and urine toxicology.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 18, 2015, Avalon Healthcare System, Inc.
(&#8220;AHS&#8221;) was incorporated under the laws of the State of Delaware. AHS owns <ix:nonFraction contextRef="c111" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-89116">100</ix:nonFraction>% of the capital stock of Avalon (Shanghai)
Healthcare Technology Co., Ltd. (&#8220;Avalon Shanghai&#8221;), which is a wholly foreign-owned enterprise organized under the laws of
the People&#8217;s Republic of China (&#8220;PRC&#8221;). Avalon Shanghai was incorporated on April 29, 2016, and was engaged in medical
related consulting services for customers. Due to the winding down of the medical related consulting services in 2022, the Company decided
to cease all operations of Avalon Shanghai and no longer has any material revenues or expenses in Avalon Shanghai. As a result, Avalon
Shanghai is no longer an operating entity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 7, 2017, the Company formed Avalon
RT 9 Properties, LLC (&#8220;Avalon RT 9&#8221;), a New Jersey limited liability company. On May 5, 2017, Avalon RT 9 purchased a real
property located in Township of Freehold, County of Monmouth, State of New Jersey, having a street address of 4400 Route 9 South, Freehold,
NJ 07728. This property was purchased to serve as the Company&#8217;s world-wide headquarters for all corporate administration and operations.
In addition, the property generates rental income. Avalon RT 9 owns this office building. Avalon RT 9&#8217;s business consists of the
ownership and operation of the income-producing real estate property in New Jersey. As of December 31, 2024, the occupancy rate of the
building is <ix:nonFraction contextRef="c112" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-89117">98.5</ix:nonFraction>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 18, 2018, the Company formed a wholly
owned subsidiary, Avactis Biosciences Inc. (&#8220;Avactis&#8221;), a Nevada corporation, which is a patent holding company. Commencing
on April 6, 2022, the Company owns <ix:nonFraction contextRef="c113" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-89118">60</ix:nonFraction>% of Avactis and Arbele Biotherapeutics Limited (&#8220;Arbele Biotherapeutics&#8221;) owns <ix:nonFraction contextRef="c114" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-89119">40</ix:nonFraction>% of
Avactis. Avactis owns <ix:nonFraction contextRef="c115" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-89120">100</ix:nonFraction>% of the capital stock of Avactis Nanjing Biosciences Ltd., a company incorporated in the PRC on May 8, 2020
(&#8220;Avactis Nanjing&#8221;), which only owns a patent and is not considered an operating entity. Currently, Avactis and Avactis Nanjing
are dormant and are in process of being dissolved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 14, 2022, the Company formed a wholly
owned subsidiary, Avalon Laboratory Services, Inc. (&#8220;Avalon Lab&#8221;), a Delaware company. On February 9, 2023, Avalon Lab purchased
<ix:nonFraction contextRef="c116" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-89121">40</ix:nonFraction>% of the issued and outstanding equity interests of Laboratory Services MSO, LLC, a private limited company formed under the laws of
the State of Delaware on September 6, 2019 (&#8220;Lab Services MSO&#8221;), and its subsidiaries. Lab Services MSO, through its subsidiaries,
is engaged in providing laboratory testing services. During 2025, to preserve cash, the Company entered into discussions with Lab Services
MSO for the potential redemption of our investment and on February 26, 2025, Lab Services MSO redeemed the <ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-89122">40</ix:nonFraction>% equity interest in Lab
Services MSO held by Avalon Lab. See Note 22 - Subsequent Events - Redemption Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On May 1,
2024, the Company formed a wholly owned subsidiary, Q&amp;A Distribution LLC (&#8220;Q&amp;A Distribution&#8221;), a Texas company. Q&amp;A
Distribution is engaged in distribution of KetoAir device.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 314 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES<br/>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 - <span style="text-decoration:underline">ORGANIZATION AND NATURE OF
OPERATIONS (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" id="ixv-58978"><ix:continuation id="_NatureOfOperations-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Details of the Company&#8217;s subsidiaries which
are included in these consolidated financial statements as of December 31, 2024 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; width: 30%; text-align: left">Name of Subsidiary</td> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 17%; text-align: center">Place and date of<br/> Incorporation</td> <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 2%; text-align: center">&#160;</td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 15%; text-align: center">Percentage of<br/> Ownership</td> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center">Principal Activities</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Avalon Healthcare System, Inc. (&#8220;AHS&#8221;)</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top"><ix:nonNumeric contextRef="c119" name="avco:EquityMethodInvestmentPlaceAndDateOfIncorporation" id="ixv-58997">Delaware <br/>
May 18, 2015</ix:nonNumeric></td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center"><ix:nonFraction contextRef="c119" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-89123">100</ix:nonFraction>% held by ALBT</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c119" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-89124">Holding company for payroll and other expenses</ix:nonNumeric></td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Avalon RT 9 Properties LLC (&#8220;Avalon RT 9&#8221;) &#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top"><ix:nonNumeric contextRef="c120" name="avco:EquityMethodInvestmentPlaceAndDateOfIncorporation" id="ixv-59015">New Jersey<br/> February 7, 2017</ix:nonNumeric> &#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top"><ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-89125">100</ix:nonFraction>% held by ALBT &#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c120" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-89126">Owns and operates an income-producing real property and holds and manages the corporate headquarters</ix:nonNumeric></td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Avalon (Shanghai) Healthcare Technology Co., Ltd. (&#8220;Avalon Shanghai&#8221;)</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top"><ix:nonNumeric contextRef="c121" name="avco:EquityMethodInvestmentPlaceAndDateOfIncorporation" id="ixv-59033">PRC <br/>
April 29, 2016</ix:nonNumeric> &#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top"><ix:nonFraction contextRef="c121" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-89127">100</ix:nonFraction>% held by AHS &#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top"><ix:nonNumeric contextRef="c121" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-89128">Is not considered an operating entity</ix:nonNumeric> &#160; &#160;</td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Genexosome Technologies Inc. (&#8220;Genexosome&#8221;)</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top"><ix:nonNumeric contextRef="c122" name="avco:EquityMethodInvestmentPlaceAndDateOfIncorporation" id="ixv-59051">Nevada<br/> July 31, 2017</ix:nonNumeric></td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center"><ix:nonFraction contextRef="c122" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-89129">60</ix:nonFraction>% held by ALBT</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top"><ix:nonNumeric contextRef="c122" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-89130">No current activities to report, dormant</ix:nonNumeric> &#160;</td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Avactis Biosciences Inc. (&#8220;Avactis&#8221;)</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top"><ix:nonNumeric contextRef="c123" name="avco:EquityMethodInvestmentPlaceAndDateOfIncorporation" id="ixv-59069">Nevada<br/> July 18, 2018</ix:nonNumeric></td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center"><ix:nonFraction contextRef="c123" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-89131">60</ix:nonFraction>% held by ALBT</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top"><ix:nonNumeric contextRef="c123" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-89132">Dormant, is in process of being dissolved</ix:nonNumeric></td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Avactis Nanjing Biosciences Ltd. (&#8220;Avactis Nanjing&#8221;)</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top"><ix:nonNumeric contextRef="c124" name="avco:EquityMethodInvestmentPlaceAndDateOfIncorporation" id="ixv-59079">PRC <br/>
May 8, 2020</ix:nonNumeric></td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center"><ix:nonFraction contextRef="c124" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-89133">100</ix:nonFraction>% held by Avactis</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top"><ix:nonNumeric contextRef="c124" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-89134">Dormant, is in process of being dissolved</ix:nonNumeric></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Avalon Laboratory Services, Inc. (&#8220;Avalon Lab&#8221;)</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top"><ix:nonNumeric contextRef="c125" name="avco:EquityMethodInvestmentPlaceAndDateOfIncorporation" id="ixv-59097">Delaware<br/> October 14, 2022</ix:nonNumeric></td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center"><ix:nonFraction contextRef="c125" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-89135">100</ix:nonFraction>% held by ALBT</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c125" id="ix_0_fact" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose">Laboratory holding company with a 40% membership interest in Lab Services MSO (1)</ix:nonNumeric></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left; vertical-align: top">Q&amp;A Distribution LLC (&#8220;Q&amp;A Distribution&#8221;)</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: top"><ix:nonNumeric contextRef="c126" name="avco:EquityMethodInvestmentPlaceAndDateOfIncorporation" id="ixv-59115">Texas <br/>
May 1, 2024</ix:nonNumeric></td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: top"><ix:nonFraction contextRef="c126" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-89137">100</ix:nonFraction>% held by ALBT</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="padding-bottom: 1pt; vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c126" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-89138">Distributes KetoAir device</ix:nonNumeric></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in">(1)</td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US">On February 26, 2025, the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement,
whereby Lab Services MSO redeemed the <ix:nonFraction contextRef="c118" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-89140">40</ix:nonFraction>% equity interest in Lab Services MSO held by the Company.</ix:footnote></td></tr></table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c18" continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c18_cont_1" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="ixv-59129"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="background-color: white"><b>NOTE
2 - <span style="text-decoration:underline">BASIS OF PRESENTATION AND GOING CONCERN CONDITION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S.
GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission for financial information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s consolidated financial statements
include the accounts of the Company and its subsidiaries. All significant intercompany accounts and transactions have been eliminated
in consolidation.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 315 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES<br/>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="background-color: white"><b>NOTE
2 - <span style="text-decoration:underline">BASIS OF PRESENTATION AND GOING CONCERN CONDITION (continued)</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company is a commercial-stage company dedicated
to developing and delivering precision diagnostic consumer products. The Company is currently marketing the KetoAir breathalyzer device
and plans to develop additional diagnostic uses of the breathalyzer technology. In addition, the Company owns commercial real estate
that houses its headquarters in Freehold, New Jersey. These consolidated financial statements have been prepared assuming that the Company
will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities
in the normal course of business.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As reflected in the accompanying consolidated
financial statements, the Company had a working capital deficit of approximately $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="avco:WorkingCapitalDeficit" scale="0" unitRef="usd" id="ixv-89141">10,646,000</ix:nonFraction> at December 31, 2024 and had incurred recurring
net losses and generated negative cash flow from operating activities of approximately $<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-89142">7,903,000</ix:nonFraction> and $<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-89143">4,969,000</ix:nonFraction> for the year ended December
31, 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a limited operating history and
its continued growth is dependent upon the continuation of generating rental revenue from its income-producing real estate property in
New Jersey and obtaining additional financing to fund future obligations and pay liabilities arising from normal business operations.
In addition, the current cash balance cannot be projected to cover the operating expenses for the next twelve months from the release
date of this report. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The ability
of the Company to continue as a going concern is dependent on the Company&#8217;s ability to raise additional capital, implement its business
plan, and generate significant revenue. There are no assurances that the Company will be successful in its efforts to generate significant
revenue, maintain sufficient cash balance or report profitable operations or to continue as a going concern. The Company plans on raising
capital through the sale of equity to implement its business plan. However, there is no assurance these plans will be realized and that
any additional financings will be available to the Company on satisfactory terms and conditions, if any.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification
of liabilities that may result should the Company be unable to continue as a going concern.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:nonNumeric contextRef="c18" continuedAt="_SignificantAccountingPoliciesTextBlock-c18_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-59185"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 - <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" continuedAt="_UseOfEstimates-c18_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-59190"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Use of Estimates</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation continuedAt="_UseOfEstimates-c18_cont_2" id="_UseOfEstimates-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The preparation
of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting period. Changes in these estimates and assumptions may have a material
impact on the consolidated financial statements and accompanying notes. Making estimates requires management to exercise significant judgment.
It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the
date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or
more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation id="_UseOfEstimates-c18_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant estimates during the years ended December
31, 2024 and 2023 include the useful life of investment in real estate and intangible assets, the assumptions used in assessing impairment
of long-term assets, the valuation of deferred tax assets and the associated valuation allowances, the valuation of stock-based compensation,
the assumptions used to determine fair value of warrants and embedded conversion features of convertible note payable, and the fair value
of the consideration given and assets acquired in the purchase of <ix:nonFraction contextRef="c127" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" unitRef="pure" id="ixv-89144">40</ix:nonFraction>% of Lab Services MSO.</p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 316 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES<br/>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 - <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c18_cont_2" id="_SignificantAccountingPoliciesTextBlock-c18_cont_1"><ix:nonNumeric contextRef="c18" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-59229"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Fair Value of Financial Instruments and
Fair Value Measurements</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>&#160;</i></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company adopted the guidance of Accounting Standards Codification (&#8220;ASC&#8221;) 820 for fair value measurements which clarifies
the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs
used in measuring fair value as follows</span>:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Level <span style="background-color: white">1-Inputs are
unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.</span></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Level <span style="background-color: white">2-Inputs are
unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities
in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable
market data.</span></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Level <span style="background-color: white">3-Inputs are
unobservable inputs which reflect the reporting entity&#8217;s own assumptions on what assumptions the market participants would use
in pricing the asset or liability based on the best available information.</span></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the Company&#8217;s assets and
liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying
amounts represented in the accompanying consolidated financial statements, primarily due to their short-term nature<span style="background-color: white">.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_7" id="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Assets
and liabilities measured at fair value on a recurring basis.</i></b><i>&#160;</i></span>Certain assets and liabilities are measured at
fair value on a recurring basis. These assets and liabilities are measured at fair value on an ongoing basis. These assets and liabilities
include derivative liability<span style="background-color: white">.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_8" id="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><i>Derivative
liability.</i>&#160;Derivative liability is carried at fair value and measured on an ongoing basis.&#160;<ix:nonNumeric contextRef="c18" continuedAt="_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock-c18_cont_1" escape="true" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="ixv-89145">The table below reflects the
activity of derivative liability measured at fair value for the years ended December 31, 2024 and 2023:</ix:nonNumeric></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation id="_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock-c18_cont_1"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_9" id="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_8"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Significant Unobservable Inputs <br/>
(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance of derivative liability as of January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-329">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: left">Initial fair value of derivative liability attributable to warrants issuance with May, July, and October 2023 fund raises</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="avco:InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise" scale="0" unitRef="usd" id="ixv-89146">213,170</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain from change in the fair value of derivative liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89147">188,374</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Balance of derivative liability as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-89148">24,796</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Initial fair value of derivative liability attributable to warrants issuance with March and June 2024 fund raises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="avco:InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise" scale="0" unitRef="usd" id="ixv-89149">479,468</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reclassification of additional paid-in capital upon conversion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="0" unitRef="usd" id="ixv-89150">2,354</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain from change in the fair value of derivative liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89151">374,365</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance of derivative liability as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-89152">127,545</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_10" id="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Assets
and liabilities measured at fair value on a nonrecurring basis.</i></b>&#160;Certain assets and liabilities are measured at fair value
on a nonrecurring basis. These assets and liabilities are not measured at fair value on an ongoing basis, but are subject to fair value
adjustments in certain circumstances. These assets and liabilities can include equipment held for sale and equity method investment that
are written down to fair value when they are impaired.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_11" id="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><i>Laboratory
equipment. </i>The Company conducted an impairment assessment on its laboratory equipment based on the guidelines established in Financial
Accounting Standards Board (&#8220;FASB&#8221;) ASC Topic 360 to determine the estimated fair market value of its laboratory equipment
as of December 31, 2024. Upon completion of its 2024 impairment analysis, the Company determined that the carrying value exceeded the
fair market value of laboratory equipment. The fair market value of laboratory equipment is a level 3 valuation. The Company recorded
an impairment charge of $<ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="0" unitRef="usd" id="ixv-89153">111,033</ix:nonFraction> for the year ended December 31, 2024, which was included in other general and administrative expenses
on the accompanying consolidated statements of operations and comprehensive loss.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 317 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES<br/>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 3 - <span style="text-decoration:underline">SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Fair Value of Financial
Instruments and Fair Value Measurements (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c18_cont_3" id="_SignificantAccountingPoliciesTextBlock-c18_cont_2"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_12" id="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><i>Equity
method investment in Epicon Biotech Co., Ltd.</i>&#160;The factors used to determine fair value are subject to management&#8217;s judgment
and expertise and include, but are not limited to, the investee&#8217;s series of operating losses and the joint venture partner unable
to obtain funds to commence operations. These assumptions represent Level 3 inputs. Impairment of equity method investment in Epicon Biotech
Co., Ltd. for the year ended December 31, 2023 was $<ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="0" unitRef="usd" id="ixv-89154">454,679</ix:nonFraction>. There is no comparative impairment for the year ended December 31, 2024 since
the investment was fully impaired at December 31, 2023.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_13" id="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><i>Equity
method investment in </i></span><i>Laboratory Services MSO, LLC </i><span style="background-color: white">The factors used to determine
fair value are subject to management&#8217;s judgment and expertise. These assumptions represent Level 3 inputs. Impairment of equity
method investment in Laboratory Services MSO, LLC for the years ended December 31, 2024 and 2023 was $<ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-89155">259,579</ix:nonFraction> and $<ix:nonFraction contextRef="c131" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-89156">9,196,682</ix:nonFraction>, respectively,
which have been included in loss from equity method investment - Lab Services MSO on the accompanying consolidated statements of
operations and comprehensive loss.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c18_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">ASC
825-10 &#8220;Financial Instruments&#8221;, allows entities to voluntarily choose to measure certain financial assets and liabilities
at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless
a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should
be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding
instruments.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c18_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-59405"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Cash and Cash Equivalents</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="ixv-59409"><ix:continuation continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c18_cont_2" id="_CashAndCashEquivalentsPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2024 and 2023, the Company&#8217;s
cash balances by geographic area were as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c18_cont_3" id="_CashAndCashEquivalentsPolicyTextBlock-c18_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Country:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-89157">2,844,522</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c152" decimals="3" format="ixt:num-dot-decimal" name="avco:CashPercentage" scale="-2" unitRef="pure" id="ixv-89158">99.6</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-89159">280,197</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c142" decimals="3" format="ixt:num-dot-decimal" name="avco:CashPercentage" scale="-2" unitRef="pure" id="ixv-89160">98.2</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">China</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-89161">11,787</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c140" decimals="3" format="ixt:num-dot-decimal" name="avco:CashPercentage" scale="-2" unitRef="pure" id="ixv-89162">0.4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-89163">5,203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c141" decimals="3" format="ixt:num-dot-decimal" name="avco:CashPercentage" scale="-2" unitRef="pure" id="ixv-89164">1.8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-89165">2,856,309</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="3" format="ixt:num-dot-decimal" name="avco:CashPercentage" scale="-2" unitRef="pure" id="ixv-89166">100.0</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-89167">285,400</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="avco:CashPercentage" scale="-2" unitRef="pure" id="ixv-89168">100.0</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table></ix:continuation></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c18_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the consolidated statements of
cash flows, the Company considers all highly liquid instruments with a maturity of three months or less when purchased and money market
accounts to be cash equivalents. The Company had no cash equivalents at December 31, 2024 and 2023.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" continuedAt="_ConcentrationRiskCreditRisk-c18_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-59481"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Credit Risk and Uncertainties</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c18_cont_2" id="_ConcentrationRiskCreditRisk-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
maintains a portion of its cash on deposits with bank and financial institution within the U.S. that at times may exceed federally-insured
limits of $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashFDICInsuredAmount" scale="0" unitRef="usd" id="ixv-89169">250,000</ix:nonFraction>. The Company manages this credit risk by concentrating its cash balances in high quality financial institutions and
by periodically evaluating the credit quality of the primary financial institutions holding such deposits. The Company has not experienced
any losses in such bank accounts and believes it is not exposed to any risks on its cash in bank accounts. At December 31, 2024, the Company&#8217;s
cash balances in United States bank accounts had approximately $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FederalReserveBankStock" scale="0" unitRef="usd" id="ixv-89170">2,413,000</ix:nonFraction> in excess of the federally-insured limits.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation id="_ConcentrationRiskCreditRisk-c18_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company&#8217;s
concentrations of credit risk with respect to its rent receivable is limited due to short-term payment terms. The Company also performs
ongoing credit evaluations of its tenants to help further reduce credit risk.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p>

<ix:nonNumeric contextRef="c18" continuedAt="_RevenueRecognitionPolicyTextBlock-c18_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="ixv-59493"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Rent Receivable and Reserve for Credit
Losses</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c18_cont_2" id="_RevenueRecognitionPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Rent receivable
is presented net of reserve for credit losses. Rent receivable balance consists of base rents, tenant reimbursements and receivables arising
from straight-lining of rents represent amounts accrued and unpaid from tenants in accordance with the terms of the respective leases,
subject to the Company&#8217;s revenue recognition policy. A reverse for the uncollectible portion of rent receivable is determined based
upon an analysis of the tenant&#8217;s payment history, the financial condition of the tenant, business conditions in the industry in
which the tenant operates and economic conditions in Freehold, New Jersey in which the property is located.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_RevenueRecognitionPolicyTextBlock-c18_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Management
believes that the rent receivable is fully collectable. Therefore, no material reverse for credit losses is deemed to be required on its
rent receivable at December 31, 2024 and 2023.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 318 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES<br/>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 - <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c18_cont_4" id="_SignificantAccountingPoliciesTextBlock-c18_cont_3"><ix:nonNumeric contextRef="c18" continuedAt="avco_DeferredOfferingCostsPolicyTextBlock-c18_cont_1" escape="true" name="avco:DeferredOfferingCostsPolicyTextBlock" id="ixv-59533"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Deferred Offering Costs</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation id="avco_DeferredOfferingCostsPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred offering costs consist of legal, accounting
and other costs that are directly related to the Company&#8217;s open market sale equity financing and will be charged to stockholders&#8217;
equity upon completion of the equity offering. As of December 31, 2024 and 2023, deferred offering costs amounted to $<ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="0" unitRef="usd" id="ixv-89171">0</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="0" unitRef="usd" id="ixv-89172">175,136</ix:nonFraction>,
respectively, which were included in prepaid expense and other current assets.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c18" continuedAt="_LesseeLeasesPolicyTextBlock-c18_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-59542"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Deferred Leasing Costs</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Costs incurred
to obtain tenant leases are amortized using the straight-line method over the term of the related lease agreement. Such costs include
lease incentives and leasing commissions. If the lease is terminated early, the remaining unamortized deferred leasing cost is written
off.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="c18" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c18_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-59550"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Property and Equipment</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are carried at cost less
accumulated depreciation, and are depreciated on a straight-line basis over the estimated useful lives of the assets. The cost of repairs
and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of,
the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the period
of disposition. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances
reflect the fact that their recorded value may not be recoverable.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" continuedAt="avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock-c18_cont_1" escape="true" name="avco:InvestmentInRealEstateAndDepreciationPolicyTextBlock" id="ixv-59558"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Investment In Real
Estate and Depreciation</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation id="avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investment in real estate is carried at cost less
accumulated depreciation, and consists of building and improvement. The Company depreciates real estate building and improvement on a
straight-line basis over estimated useful life. Expenditures for ordinary repair and maintenance costs are charged to expense as incurred.
Expenditure for improvements, renovations, and replacements of real estate asset is capitalized and depreciated over its estimated useful
life if the expenditure qualifies as betterment.&#160;</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c18_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ixv-59565"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Impairment of Long-lived Assets</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c18_cont_2" id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC Topic 360, the Company
reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may
not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future
cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset&#8217;s
estimated fair value and its book value.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c18_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">For the
year ended December 31, 2024, the Company incurred impairment charges in operations of $<ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="0" unitRef="usd" id="ixv-89173">111,033</ix:nonFraction> on its laboratory equipment. The valuation
of the laboratory equipment, and the amount of the impairment charge, were based on impairment assessment conducted on the equipment at
December 31, 2024.&#160;&#160;</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" continuedAt="_InvestmentPolicyTextBlock-c18_cont_1" escape="true" name="us-gaap:InvestmentPolicyTextBlock" id="ixv-59576"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Investment in Unconsolidated
Companies</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_InvestmentPolicyTextBlock-c18_cont_2" id="_InvestmentPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the equity method of accounting
for its investment in, and earning or loss of, investees that it does not control but over which it does exert significant influence.
The Company applies the equity method by initially recording these investments at cost, as equity method investments, subsequently adjusted
for equity in earnings and cash distributions.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_InvestmentPolicyTextBlock-c18_cont_3" id="_InvestmentPolicyTextBlock-c18_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers whether the fair value of
its equity method investment has declined below its carrying value whenever adverse events or changes in circumstances indicate that recorded
value may not be recoverable. If the Company considers any decline to be other than temporary (based on various factors, including historical
financial results and the overall health of the investee), then a write-down would be recorded to estimated fair value. Impairment of
equity method investment amounted to $<ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetImpairmentCharges" scale="0" unitRef="usd" id="ixv-89174">259,579</ix:nonFraction> and $<ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetImpairmentCharges" scale="0" unitRef="usd" id="ixv-89175">9,651,361</ix:nonFraction> for the years ended December 31, 2024 and 2023, respectively. See Note 8
for discussion of equity method investments.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_InvestmentPolicyTextBlock-c18_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies distributions received
from equity method investments using the cumulative earnings approach. Distributions received are considered returns on the investment
and classified as cash inflows from operating activities. If, however, the investor&#8217;s cumulative distributions received, less distributions
received in prior periods determined to be returns of investment, exceeds cumulative equity in earnings recognized, the excess is considered
a return of investment and is classified as cash inflows from investing activities.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 319 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES<br/>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 - <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c18_cont_5" id="_SignificantAccountingPoliciesTextBlock-c18_cont_4"><ix:nonNumeric contextRef="c18" continuedAt="avco_DeferredRentalIncomePolicyTextBlock-c18_cont_1" escape="true" name="avco:DeferredRentalIncomePolicyTextBlock" id="ixv-59616"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Deferred Rental Income</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation id="avco_DeferredRentalIncomePolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred rental income represents rental income
collected but not earned as of the reporting date. The Company defers the revenue related to lease payments received from tenants in advance
of their due dates. As of December 31, 2024 and 2023, deferred rental income totaled $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncome" scale="0" unitRef="usd" id="ixv-89176">38,346</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncome" scale="0" unitRef="usd" id="ixv-89177">11,429</ix:nonFraction>, respectively, which were included
in accrued liabilities and other payables on the accompanying consolidated balance sheets.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c18" continuedAt="avco_RealPropertyRentalRevenuePolicyTextBlock-c18_cont_1" escape="true" name="avco:RealPropertyRentalRevenuePolicyTextBlock" id="ixv-59624"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>Real Property Rental Revenue</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation continuedAt="avco_RealPropertyRentalRevenuePolicyTextBlock-c18_cont_2" id="avco_RealPropertyRentalRevenuePolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
has determined that ASC 606 does not apply to rental contracts, which are within the scope of other revenue recognition accounting standards.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="avco_RealPropertyRentalRevenuePolicyTextBlock-c18_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rental income from operating leases is recognized
on a straight-line basis under the guidance of ASC 842. Lease payments under tenant leases are recognized on a straight-line basis over
the term of the related leases. The cumulative difference between lease revenue recognized under the straight-line method and contractual
lease payments are included in rent receivable on the consolidated balance sheets<span style="background-color: white">.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="c18" continuedAt="_LessorLeasesPolicyTextBlock-c18_cont_1" escape="true" name="us-gaap:LessorLeasesPolicyTextBlock" id="ixv-59637"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Office Lease</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_LessorLeasesPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When a lease contains &#8220;rent holidays&#8221;,
the Company records rental expense on a straight-line basis over the term of the lease. The Company begins recording rent expense on the
lease possession date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" continuedAt="_RealEstatePolicyTextBlock-c18_cont_1" escape="true" name="us-gaap:RealEstatePolicyTextBlock" id="ixv-59644"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Real Property Operating Expenses</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<ix:continuation id="_RealEstatePolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Real property operating expenses consist of property
management fees, property insurance, real estate taxes, depreciation, repairs and maintenance fees, utilities and other expenses related
to the Company&#8217;s rental properties.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c18" continuedAt="_ResearchAndDevelopmentExpensePolicy-c18_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-59652"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expenditures for research and product development
costs are expensed as incurred. The Company incurred research and development expense of $<ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-89178">0</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-89179">109,618</ix:nonFraction>&#160;in the years ended
December 31, 2024 and 2023, respectively.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c18" continuedAt="_AdvertisingCostsPolicyTextBlock-c18_cont_1" escape="true" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="ixv-59661"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Advertising and Marketing Costs</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_AdvertisingCostsPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All costs related to advertising and marketing
are expensed as incurred. For the years ended December 31, 2024 and 2023, advertising and marketing costs amounted to $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredAdvertisingCosts" scale="0" unitRef="usd" id="ixv-89180">237,671</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredAdvertisingCosts" scale="0" unitRef="usd" id="ixv-89181">1,666,721</ix:nonFraction>,
respectively.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c18_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-59668"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-based Compensation</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c18_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
accounts for its stock-based compensation awards in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718, Compensation-Stock
Compensation (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees and non-employees including grants of stock
options, to be recognized as expense in the statements of operations based on their grant date fair values. The Company estimates the
grant date fair value of each option award using the Black-Scholes option-pricing model.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c18_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
periodically issues common stock and common stock options to consultants for various services. Costs of these transactions are measured
at the fair value of the service received or the fair value of the equity instruments issued, whichever is more reliably measurable. The
value of the common stock is measured at the earlier of (i) the date at which a firm commitment for performance by the counterparty to
earn the equity instruments is reached or (ii) the date at which the counterparty&#8217;s performance is complete.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 320 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES<br/>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 - <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c18_cont_6" id="_SignificantAccountingPoliciesTextBlock-c18_cont_5"><ix:nonNumeric contextRef="c18" continuedAt="avco_DebtModificationsAndExtinguishmentsPolicyTextBlock-c18_cont_1" escape="true" name="avco:DebtModificationsAndExtinguishmentsPolicyTextBlock" id="ixv-59709"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Debt
Modifications and Extinguishments</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation continuedAt="avco_DebtModificationsAndExtinguishmentsPolicyTextBlock-c18_cont_2" id="avco_DebtModificationsAndExtinguishmentsPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">When the
Company modifies or extinguishes debt, it first evaluates whether the modification qualifies as a troubled debt restructuring (TDR) under
ASC Topic 470-60, which requires debt modifications to be evaluated to determine if (1) the borrower is experiencing financial difficulty,
and (2) the lender grants the borrower a concession. If a TDR is determined not to have occurred, the Company evaluates the modification
in accordance with ASC Topic 470-50-40, which requires modification to debt instruments to be evaluated to assess whether debt modification
or debt extinguishment accounting is applicable. This evaluation includes analyzing whether there are significant and consequential changes
to the economic substance of the note. If the change is deemed insignificant then the change is considered a debt modification, whereas
if the change is substantial the change is reflected as a debt extinguishment.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="avco_DebtModificationsAndExtinguishmentsPolicyTextBlock-c18_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">If debt
extinguishment guidance applies, the previous debt principal amount is removed, the previously capitalized debt issuance costs are expensed,
the value of instruments exchanged are recorded, including cash, new debt, warrants and common stock, and a gain or loss on extinguishment
of debt is recorded. If debt modification guidance applies, no gain or loss is recorded and the effective interest rate of the debt is
updated based on the carrying value of the debt and the revised future cash flows. Any previously capitalized debt issuance costs in a
debt modification are amortized as interest expense over the term of the new debt instrument.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c18" continuedAt="_IncomeTaxPolicyTextBlock-c18_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-59724"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c18_cont_2" id="_IncomeTaxPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
is governed by the income tax laws of China and the United States. The Company accounts for income taxes using the asset/liability method
prescribed by ASC 740, &#8220;Income Taxes.&#8221; Under this method, deferred tax assets and liabilities are determined based on the
difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the
period in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if, based
on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized.
The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c18_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
follows the accounting guidance for uncertainty in income taxes using the provisions of ASC 740 &#8220;Income Taxes&#8221;. Using that
guidance, the benefit for tax positions taken can only be recognized in the financial statements when it is more likely than not the position
will be sustained upon examination by the tax authorities. As of December 31, 2024 and 2023, the Company had no significant uncertain
tax positions which would require either recognition of a liability or disclosure in the financial statements. For United States entities,
tax year that remains subject to examination is the years ended December 31, 2024, 2023, 2022 and 2021. For China entities, income tax
returns for the tax years ended December 31, 2020 through December 31, 2024 remain open for statutory examination by PRC tax authorities.
The Company recognizes interest and penalties related to significant uncertain income tax positions in income tax expense. However, no
such interest and penalties were recorded as of December 31, 2024 and 2023.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c18" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c18_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="ixv-59736"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Foreign Currency Translation</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c18_cont_2" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The reporting
currency of the Company is the U.S. dollar. The functional currency of the parent company, AHS, Avalon RT 9, Avalon Lab, and Q&amp;A Distribution
is the U.S. dollar and the functional currency of Avalon Shanghai is the Chinese Renminbi (&#8220;RMB&#8221;). For Avalon Shanghai whose
functional currency is the RMB, result of operations and cash flows are translated at average exchange rates during the period, assets
and liabilities are translated at the unified exchange rate at the end of the period, and equity is translated at historical exchange
rates. As a result, amounts relating to assets and liabilities reported on the statements of cash flows may not necessarily agree with
the changes in the corresponding balances on the balance sheets. Translation adjustments resulting from the process of translating the
local currency financial statements into U.S. dollars are included in determining comprehensive income/loss. Transactions denominated
in foreign currencies are translated into the functional currency at the exchange rates prevailing on the transaction dates. Assets and
liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the balance
sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency
other than the functional currency are included in the results of operations as incurred. All of the Company&#8217;s revenue transactions
are transacted in the functional currency of the operating subsidiaries. The Company does not enter into any material transaction in foreign
currencies. Transaction gains or losses have not had, and are not expected to have, a material effect on the results of operations of
the Company.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;&#160;</span></p>

<ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c18_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Asset and
liability accounts at December 31, 2024 and 2023 were translated at <ix:nonFraction contextRef="c137" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-89182">7.2980</ix:nonFraction> RMB and <ix:nonFraction contextRef="c138" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-89183">7.0786</ix:nonFraction> RMB to $<ix:nonFraction contextRef="c139" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-89184">1.00</ix:nonFraction>, respectively, which were the exchange
rates on the balance sheet dates. Equity accounts were stated at their historical rates. The average translation rates applied to the
statements of operations for the years ended December 31, 2024 and 2023 were <ix:nonFraction contextRef="c140" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-89185">7.1889</ix:nonFraction> RMB and <ix:nonFraction contextRef="c141" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-89186">7.0752</ix:nonFraction> RMB to $<ix:nonFraction contextRef="c142" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" unitRef="pure" id="ixv-89187">1.00</ix:nonFraction>, respectively. Cash flows
from the Company&#8217;s operations are calculated based upon the local currencies using the average translation rate.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 321 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="background-color: white"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 - <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c18_cont_7" id="_SignificantAccountingPoliciesTextBlock-c18_cont_6"><ix:nonNumeric contextRef="c18" continuedAt="_ComprehensiveIncomePolicyPolicyTextBlock-c18_cont_1" escape="true" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="ixv-59781"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Comprehensive Loss</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<ix:continuation id="_ComprehensiveIncomePolicyPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comprehensive loss is comprised of net loss and
all changes to the statements of equity, except those due to investments by stockholders, changes in paid-in capital and distributions
to stockholders. For the Company, comprehensive loss for the years ended December 31, 2024 and 2023 consisted of net loss and unrealized
loss from foreign currency translation adjustment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c18" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c18_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="ixv-59789"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Commitments
and Contingencies</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In the normal
course of business, the Company is subject to contingencies, such as legal proceedings and claims arising out of its business, that cover
a wide range of matters. Liabilities for such contingencies are recorded when it is probable that a liability has been incurred and the
amount of the assessment can be reasonably estimated.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c18" continuedAt="_EarningsPerSharePolicyTextBlock-c18_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-59799"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Per Share Data</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c18_cont_2" id="_EarningsPerSharePolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC Topic 260 &#8220;Earnings per Share,&#8221;
requires presentation of both basic and diluted earnings per share (&#8220;EPS&#8221;) with a reconciliation of the numerator and denominator
of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c18_cont_3" id="_EarningsPerSharePolicyTextBlock-c18_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per share is computed by dividing
net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents
and potentially dilutive securities outstanding during each period. For the years ended December 31, 2024 and 2023, potentially dilutive
common shares consist of the common shares issuable upon the conversion of convertible preferred stock and convertible notes (using the
if-converted method) and exercise of common stock options and warrants (using the treasury stock method). Common stock equivalents are
not included in the calculation of diluted net loss per share if their effect would be anti-dilutive. In a period in which the Company
has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares outstanding as they would have
had an anti-dilutive impact.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c18_cont_4" id="_EarningsPerSharePolicyTextBlock-c18_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The calculation of basic and diluted net loss
per common share attributable to the Company common shareholders includes <ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-89188">150,000</ix:nonFraction> of the pre-funded warrants that remain outstanding as
of December 31, 2024.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-59812"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c18_cont_5" id="_EarningsPerSharePolicyTextBlock-c18_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the securities
that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c18_cont_6" id="_EarningsPerSharePolicyTextBlock-c18_cont_5"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended<br/>
 December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Options to purchase common stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c153" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-89189">52,479</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c154" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-89190">56,880</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrants to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c155" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-89191">182,996</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c156" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-89192">43,035</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series A convertible preferred stock <sup>(*)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c157" decimals="INF" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">60,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c158" decimals="INF" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">60,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series B convertible preferred stock <sup>(**)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c159" decimals="INF" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">194,004</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c160" decimals="INF" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">194,004</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series C convertible preferred stock <sup>(***)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c161" decimals="INF" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">1,452,282</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-330">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Convertible notes <sup>(****)</sup></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c163" decimals="INF" format="ixt:num-dot-decimal" id="ix_6_fact" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">227,269</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c164" decimals="INF" format="ixt:num-dot-decimal" id="ix_7_fact" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">60,740</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-89200">2,169,030</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-89201">414,659</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c18_cont_7" id="_EarningsPerSharePolicyTextBlock-c18_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US">Assumed the Series A convertible preferred stock was converted
into shares of common stock of the Company at a conversion price of $<ix:nonFraction contextRef="c144" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-89202">150.00</ix:nonFraction> per share<span style="background-color: white">.</span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c18_cont_8" id="_EarningsPerSharePolicyTextBlock-c18_cont_7"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="background-color: white">(**)</span></td><td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="background-color: white">Assumed the Series
B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-89203">56.70</ix:nonFraction> per share.</span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c18_cont_9" id="_EarningsPerSharePolicyTextBlock-c18_cont_8"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="background-color: white">(***)</span></td><td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US"><span style="background-color: white">Assumed the Series
C convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $<ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-89204">2.41</ix:nonFraction> per share.</span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c18_cont_9"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="background-color: white">(****)</span></td><td style="text-align: justify"><ix:footnote id="ix_4_footnote" xml:lang="en-US"><span style="background-color: white">Assumed the convertible
notes were converted into shares of common stock of the Company at a conversion price of $<ix:nonFraction contextRef="c18" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceIncrease" scale="0" unitRef="usdPershares" id="ixv-89205">11.25</ix:nonFraction> per share for the year ended December
31, 2024. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $<ix:nonFraction contextRef="c36" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceIncrease" scale="0" unitRef="usdPershares" id="ixv-89206">67.50</ix:nonFraction> and
$<ix:nonFraction contextRef="c19" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceIncrease" scale="0" unitRef="usdPershares" id="ixv-89207">22.50</ix:nonFraction> per share for the year ended December 31, 2023.</span></ix:footnote></td>
</tr></table></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 322 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES<br/>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 - <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c18_cont_8" id="_SignificantAccountingPoliciesTextBlock-c18_cont_7"><ix:nonNumeric contextRef="c18" continuedAt="avco_NoncontrollingInterestPolicyTextBlock-c18_cont_1" escape="true" name="avco:NoncontrollingInterestPolicyTextBlock" id="ixv-59974"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Noncontrolling Interest</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<ix:continuation id="avco_NoncontrollingInterestPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024, Dr. Yu Zhou, former director
and former Co-Chief Executive Officer of Genexosome, who owns <ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-89208">40</ix:nonFraction>% of the equity interests of Genexosome, which is not under the Company&#8217;s
control. Since the fourth quarter of 2019, the non-controlling interest has remained inactive.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" continuedAt="_PriorPeriodReclassificationAdjustmentDescription-c18_cont_1" escape="true" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="ixv-59982"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Reclassification</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<ix:continuation id="_PriorPeriodReclassificationAdjustmentDescription-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Certain prior period
amounts have been reclassified to conform to the current period presentation. These reclassifications have no effect on the previously
reported financial position, results of operations and cash flows.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c18" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c18_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-59991"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Segment Reporting</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c18_cont_2" id="_SegmentReportingPolicyPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The segment
reporting structure uses the Company&#8217;s management reporting structure as its foundation to reflect how the Company manages the businesses
internally and is mainly organized by services. The Company is organized into two services-oriented strategic business units: real property
rental services and laboratory testing services - which are led by our strategic business unit managers. Operating segments are
defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating
decision maker (&#8220;CODM&#8221;) in deciding how to make operating decisions, allocate resources and assess performance.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c18_cont_3" id="_SegmentReportingPolicyPolicyTextBlock-c18_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 9, 2023, the Company purchased <ix:nonFraction contextRef="c146" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-89209">40</ix:nonFraction>%
of Lab Services MSO. Commencing from the purchase date, February 9, 2023, the Company is active in the management of Lab Services MSO.
During the years ended December 31, 2024 and 2023, the Company operated in two reportable business segments: (1) the real property operating
segment, and (2) laboratory testing services segment (which commenced with the purchase date, February 9, 2023) since Lab Services MSO&#8217;s
operating results are regularly reviewed by the Company&#8217;s chief operating decision maker to determine the resources to be allocated
to the segment and assess its performance. The Company regularly reviews the operating results and performance of Lab Services MSO, for
which the Company accounts for under the equity method.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c18_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s President and Chief Executive
Officer is its CODM. The Company reports operational data to its CODM at the segment level, which he uses to evaluate performance and
allocate resources based on real property operating income and loss from equity method investment - Lab Services MSO.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c18" continuedAt="_FiscalPeriod-c18_cont_1" escape="true" name="us-gaap:FiscalPeriod" id="ixv-60006"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Fiscal Year End</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<ix:continuation id="_FiscalPeriod-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company has adopted a fiscal year end of December 31st.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c18" continuedAt="avco_ReverseStockSplitPolicyTextBlock-c18_cont_1" escape="true" name="avco:ReverseStockSplitPolicyTextBlock" id="ixv-60015"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Reverse Stock Split</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation id="avco_ReverseStockSplitPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
effectuated a <ix:nonNumeric contextRef="c18" name="us-gaap:StockholdersEquityReverseStockSplit" id="ixv-89210">1-for-15</ix:nonNumeric> reverse stock split of its outstanding shares of common stock on October 28, 2024. The reverse split did not change
the par value of common stock. All references in these consolidated financial statements to shares, share prices, exercise prices, and
other per share information in all periods have been adjusted, on a retroactive basis, to reflect the reverse stock split.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c18_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-60023"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Recent Accounting
Standards</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c18_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In August
2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic
470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40), to simplify accounting for certain
financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion
features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts
in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments
that are indexed to and settled in an entity&#8217;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including
the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after
December 15, 2022, including interim periods within those fiscal years, with early adoption permitted. The adoption of ASU 2020-06 did
not have a material effect on the Company&#8217;s consolidated financial statements and related disclosures.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 323 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES<br/>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 - <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Recent Accounting
Standards (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c18_cont_8"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c18_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c18_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In November
2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280). The amendments in this update improve reportable segment disclosure
requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 became effective for the Company&#8217;s
annual period beginning on January 1, 2024 and interim periods beginning after January 1, 2025. The Company adopted this guidance in the
fourth quarter of 2024. Refer to Note 20 - Segment Information. The Company&#8217;s results of operations, cash flows, and financial condition
were not impacted by the adoption of this ASU.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c18_cont_4" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c18_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In December
2023, the FASB ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This guidance is intended to enhance the
transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income
tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign
jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to
apply the standard retrospectively. Early adoption is permitted. The adoption of ASU 2023-09 did not have a material effect on the Company&#8217;s
consolidated financial statements and related disclosures.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c18_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Other accounting
standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material
impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated
to have an impact on or are unrelated to its consolidated financial condition, results of operations, cash flows or disclosures.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock" id="ixv-60079"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 4 -&#160;<span style="text-decoration:underline">PREPAID EXPENSE
AND OTHER CURRENT ASSETS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="ixv-60084"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">At December 31, 2024 and 2023, prepaid expense
and other current assets consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>
2024</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>
2023</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid professional fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="avco:PrepaidProfessionalFees" scale="0" unitRef="usd" id="ixv-89211">33,665</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="avco:PrepaidProfessionalFees" scale="0" unitRef="usd" id="ixv-89212">33,062</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid directors and officers&#8217; liability insurance premium</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidReinsurancePremiums" scale="0" unitRef="usd" id="ixv-89213">9,741</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidReinsurancePremiums" scale="0" unitRef="usd" id="ixv-89214">27,192</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-331">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="0" unitRef="usd" id="ixv-89215">175,136</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred leasing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCostsLeasingNet" scale="0" unitRef="usd" id="ixv-89216">31,587</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCostsLeasingNet" scale="0" unitRef="usd" id="ixv-89217">33,402</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Security deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="0" unitRef="usd" id="ixv-89218">17,654</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-332">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Due from broker</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromCorrespondentBrokers" scale="0" unitRef="usd" id="ixv-89219">32,885</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromCorrespondentBrokers" scale="0" unitRef="usd" id="ixv-89220">37,187</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finished goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd" id="ixv-89221">92,230</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-333">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Recoverable VAT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ValueAddedTaxReceivable" scale="0" unitRef="usd" id="ixv-89222">9,245</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ValueAddedTaxReceivable" scale="0" unitRef="usd" id="ixv-89223">6,218</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-89224">72,353</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-89225">55,797</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-89226">299,360</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-89227">367,994</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-60204"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 5 -&#160;<span style="text-decoration:underline">PROPERTY AND EQUIPMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-60209"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">At December 31, 2024
and 2023, property and equipment consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Useful Life</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center"><ix:nonNumeric contextRef="c165" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-89228">5</ix:nonNumeric> Years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-334">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c166" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-89229">100,548</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Office equipment and furniture</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c167" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-89230">3</ix:nonNumeric> - <ix:nonNumeric contextRef="c168" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-89231">10</ix:nonNumeric> Years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-89232">54,499</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-89233">54,797</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-89234">54,499</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-89235">155,345</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-89236">41,587</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-89237">117,262</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-89238">12,912</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-89239">38,083</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For the years ended December
31, 2024 and 2023, depreciation expense of property and equipment amounted to $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" scale="0" unitRef="usd" id="ixv-89240">9,234</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation" scale="0" unitRef="usd" id="ixv-89241">43,037</ix:nonFraction>, respectively, of which, $<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="0" unitRef="usd" id="ixv-89242">8,623</ix:nonFraction> and $<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="0" unitRef="usd" id="ixv-89243">7,221</ix:nonFraction>
was included in real property operating expenses, $<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:OtherOperatingExpense" scale="0" unitRef="usd" id="ixv-89244">611</ix:nonFraction> and $<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="avco:OtherOperatingExpense" scale="0" unitRef="usd" id="ixv-89245">417</ix:nonFraction> was included in other operating expenses, and $<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" unitRef="usd" id="ixv-89246">0</ix:nonFraction> and $<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" unitRef="usd" id="ixv-89247">35,399</ix:nonFraction> was included
in research and development expense, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 324 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock" id="ixv-60308"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>NOTE
6 - <span style="text-decoration:underline">EQUIPMENT HELD FOR SALE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company measures
long-lived assets to be disposed of by sale at the lower of carrying amount or fair value, less associated costs to sell these assets.
The assets held for sale is no longer subject to depreciation as they are not used in operations. As of December 31, 2024, the Company
committed to a plan to sell certain laboratory equipment that was used to research and development as equipment held for sale, which was
included in &#8220;Other non-current assets&#8221; on the accompanying consolidated balance sheets. The Company evaluated equipment for
impairment at December 31, 2024. The Company compared the estimated fair value of the equipment to its carrying value with impairment
indicators and recorded an impairment charge for the excess of carrying value over fair value. For the year ended December 31, 2024, the
Company incurred an impairment charge in operations of $<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:ImpairmentOfLaboratoryEquipment" scale="0" unitRef="usd" id="ixv-89248">111,033</ix:nonFraction> on laboratory equipment. Although the Company is actively seeking and
negotiating with potential buyers, the Company can give no assurances that the sale process will be successful and, if it were successful,
there are no assurances as to the amount or timing of any potential proceeds.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:RealEstateDisclosureTextBlock" id="ixv-60318"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>NOTE
7 - <span style="text-decoration:underline">INVESTMENT IN REAL ESTATE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock" id="ixv-60325"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">At December 31, 2024
and 2023, investment in real estate consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Useful Life</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Commercial real property building</td><td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: center"><ix:nonNumeric contextRef="c171" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-89249">39</ix:nonNumeric> Years</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RealEstateInvestmentPropertyAtCost" scale="0" unitRef="usd" id="ixv-89250">7,708,571</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RealEstateInvestmentPropertyAtCost" scale="0" unitRef="usd" id="ixv-89251">7,708,571</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Improvement</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c173" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-89252">12</ix:nonNumeric> Years</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RealEstateInvestmentPropertyAtCost" scale="0" unitRef="usd" id="ixv-89253">529,372</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RealEstateInvestmentPropertyAtCost" scale="0" unitRef="usd" id="ixv-89254">529,372</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RealEstateInvestmentPropertyAtCost" scale="0" unitRef="usd" id="ixv-89255">8,237,943</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RealEstateInvestmentPropertyAtCost" scale="0" unitRef="usd" id="ixv-89256">8,237,943</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOwnedAccumulatedDepreciation" scale="0" unitRef="usd" id="ixv-89257">1,215,222</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOwnedAccumulatedDepreciation" scale="0" unitRef="usd" id="ixv-89258">1,046,539</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RealEstateInvestmentPropertyNet" scale="0" unitRef="usd" id="ixv-89259">7,022,721</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RealEstateInvestmentPropertyNet" scale="0" unitRef="usd" id="ixv-89260">7,191,404</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For both the years ended
December 31, 2024 and 2023, depreciation expense of this commercial real property amounted to $<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDepreciationAndAmortization" scale="0" unitRef="usd" id="ixv-89261"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDepreciationAndAmortization" scale="0" unitRef="usd" id="ixv-89262">168,683</ix:nonFraction></ix:nonFraction>, which was included in real property
operating expenses.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c18" continuedAt="_EquityMethodInvestmentsDisclosureTextBlock-c18_cont_1" escape="true" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="ixv-60406"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 8 -&#160;<span style="text-decoration:underline">EQUITY
METHOD INVESTMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Investment in&#160;Epicon
Biotech Co., Ltd.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As of December 31, 2023,
the equity method investment in Epicon Biotech Co., Ltd. (&#8220;Epicon&#8221;) amounted to $<ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-89263">0</ix:nonFraction>. The investment represents the Company&#8217;s
subsidiary, Avalon Shanghai&#8217;s interest in Epicon. Epicon was incorporated on August 14, 2018 in PRC. Avalon Shanghai and an unrelated
company, Jiangsu Unicorn Biological Technology Co., Ltd. (&#8220;Unicorn&#8221;), have an ownership interest in Epicon of <ix:nonFraction contextRef="c176" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-89264">40</ix:nonFraction>% and <ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-89265">60</ix:nonFraction>%,
respectively. Epicon is focused on cell preparation, third party testing, biological sample repository for commercial and scientific research
purposes and clinical transformation of scientific achievements. The Company is not involved in the management of Epicon. Therefore, it
is a passive investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In June 2023, the Company
assessed its equity method investment in Epicon for any impairment and concluded that there were indicators of impairment as of June 30,
2023. The impairment is due to the Company&#8217;s conclusion that it will be unable to recover the carrying amount of the investment
due to the investee&#8217;s series of operating losses and the inability of Avalon Shanghai&#8217;s joint venture partner (Unicorn) to
obtain adequate funding to commence operations. The Company calculated that the estimated undiscounted cash flows were less than the carrying
amount related to the equity method investment. The Company has recognized an impairment loss of $<ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetImpairmentCharges" scale="0" sign="-" unitRef="usd" id="ixv-89266">454,679</ix:nonFraction> related to the equity method
investment for the year ended December 31, 2023, which reduced the investment value to zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Under the equity method,
if there is a commitment for the Company to fund the losses of its equity method investees, the Company would continue to record its share
of losses resulting in a negative equity method investment, which would be presented as a liability on the consolidated balance sheets.
Commitments may be explicit and may include formal guarantees, legal obligations, or arrangements by contract. Implicit commitments may
arise from reputational expectations, intercompany relationships, statements by the Company of its intention to provide support, a history
of providing financial support or other facts and circumstances. When the Company has no commitment to fund the losses of its equity method
investees, the carrying value of its equity method investments will not be reduced below zero. The Company has no commitment to fund additional
losses of its equity method investments.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 325 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 8 - <span style="text-decoration:underline">EQUITY
METHOD INVESTMENTS (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_EquityMethodInvestmentsDisclosureTextBlock-c18_cont_2" id="_EquityMethodInvestmentsDisclosureTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Investment in Laboratory
Services MSO, LLC</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On February 9, 2023 (the
&#8220;Closing Date&#8221;), the Company entered into and closed an Amended and Restated Membership Interest Purchase Agreement (the &#8220;Amended
MIPA&#8221;), by and among Avalon Lab, SCBC Holdings LLC (the &#8220;Seller&#8221;), the Zoe Family Trust, Bryan Cox and Sarah Cox as
individuals (each an &#8220;Owner&#8221; and collectively, the &#8220;Owners&#8221;), and Lab Services MSO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the terms
and conditions set forth in the Amended MIPA, Avalon Lab acquired from the Seller,&#160;<ix:nonFraction contextRef="c179" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-89267">40</ix:nonFraction>% of the issued and outstanding equity interests
of Lab Services MSO (the &#8220;Purchased Interests&#8221;). The consideration paid by Avalon Lab to Seller for the Purchased Interests
consisted of $<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="0" unitRef="usd" id="ixv-89268">20,666,667</ix:nonFraction>, which was comprised of (i) $<ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-89269">9,000,000</ix:nonFraction>&#160;in cash, (ii) $<ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-89270">11,000,000</ix:nonFraction>&#160;pursuant to the issuance of&#160;<ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-89271">11,000</ix:nonFraction>&#160;shares
of the Company&#8217;s Series B Convertible Preferred Stock (the &#8220;Series B Preferred Stock&#8221;), stated value $<ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-89272">1,000</ix:nonFraction>&#160;(the
&#8220;Series B Stated Value&#8221;), which approximated the fair value, and (iii) a $<ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="avco:EquityMethodInvestmentPayableCurrent" scale="0" unitRef="usd" id="ixv-89273">666,667</ix:nonFraction>&#160;cash payment on February 9, 2024. The
Series B Preferred Stock is convertible into shares of the Company&#8217;s common stock at a conversion price per share equal to $<ix:nonFraction contextRef="c181" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-89274">56.70</ix:nonFraction>,
which approximated the market price at the date of closing, or an aggregate of&#160;<ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="avco:AggregateOfCommonStock" scale="0" unitRef="shares" id="ixv-89275">194,004</ix:nonFraction>&#160;shares of the Company&#8217;s common
stock, which are subject to a lock-up period and restrictions on sale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Lab Services MSO, through
its subsidiaries, is engaged in providing laboratory testing services. Avalon Lab and an unrelated company, have an ownership interest
in Lab Services MSO of&#160;<ix:nonFraction contextRef="c184" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-89276">40</ix:nonFraction>% and&#160;<ix:nonFraction contextRef="c185" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-89277">60</ix:nonFraction>%, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In accordance with ASC
810, the Company determined that Lab Services MSO does not qualify as a variable interest entity, nor does it have a controlling financial
interest over the legal entity. However, the Company determined that it does have significant influence as a result of its board representation.
Therefore, the Company treats the equity investment in the consolidated financial statements under the equity method. Under the equity
method, the investment is initially recorded at cost, adjusted for any excess of the Company&#8217;s share of the purchased-date fair
values of the investee&#8217;s identifiable net assets over the cost of the investment (if any). At February 9, 2023 (date of investment),
the excess of the Company&#8217;s share of the fair values of the investee&#8217;s identifiable net assets over the cost of the investment
was approximately $<ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedAtCost" scale="0" unitRef="usd" id="ixv-89278">19,460,000</ix:nonFraction>&#160;which was attributable to intangible assets and goodwill. Thereafter, the investment is adjusted for
the post purchase change in the Company&#8217;s share of the investee&#8217;s net assets and any impairment loss relating to the investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Intangible assets consist
of the valuation of identifiable intangible assets acquired, representing trade names and customers relationships, which are being amortized
on a straight-line method over the estimated useful life of&#160;<ix:nonNumeric contextRef="c1" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-89279">15</ix:nonNumeric>&#160;years. The straight-line method of amortization represents the
Company&#8217;s best estimate of the distribution of the economic value of the identifiable intangible assets. For the year ended December
31, 2024 and for the period from February 9, 2023 (date of investment) through December 31, 2023, amortization expense of these intangible
assets amounted to $<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-89280">666,932</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-89281">611,356</ix:nonFraction>, respectively, which was included in loss from equity method investment - Lab Services
MSO in the accompanying consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Goodwill represents the
excess of the purchase price paid over the fair value of net assets acquired in the business acquisition of Lab Services MSO incurred
on February 9, 2023. Goodwill is not amortized but is tested for impairment at least once annually, or more frequently if events or changes
in circumstances indicate that the asset might be impaired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In September 2024 and
December 2023, the Company assessed its equity method investment in Laboratory Services MSO, LLC for any impairment and concluded that
there were indicators of impairment as of September 30, 2024 and December 31, 2023, respectively. The Company calculated that the estimated
undiscounted cash flows of goodwill were less than the carrying amount of goodwill related to the equity method investment. The Company
has recognized impairment loss of $<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillImpairmentLoss" scale="0" unitRef="usd" id="ixv-89282">259,579</ix:nonFraction> and $<ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillImpairmentLoss" scale="0" unitRef="usd" id="ixv-89283">9,196,682</ix:nonFraction>&#160;related to the equity method investment for the year ended December 31,
2024 and for the period from February 9, 2023 (date of investment) through December 31, 2023, respectively, which was included in loss
from equity method investment - Lab Services MSO in the accompanying consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For the year ended December
31, 2024 and for the period from February 9, 2023 (date of investment) through December 31, 2023, the Company&#8217;s share of Lab Services
MSO&#8217;s net income was $<ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="avco:LabServicesMSOsNetIncomeAttributableToTheCompany" scale="0" unitRef="usd" id="ixv-89284">79,923</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" name="avco:LabServicesMSOsNetIncomeAttributableToTheCompany" scale="0" unitRef="usd" id="ixv-89285">1,236,391</ix:nonFraction>, respectively, which was included in loss from equity method investment -
Lab Services MSO in the accompanying consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company classifies
distributions received from its investment on Lab Services MSO using the cumulative earnings approach. Distributions received are considered
returns on the investment and classified as cash inflows from operating activities. For the year ended December 31, 2024 and for the
period from February 9, 2023 (date of investment) through December 31, 2023, distribution of earnings from the Company&#8217;s investment
on Lab Services MSO amounted to $<ix:nonFraction contextRef="c189" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="0" unitRef="usd" id="ixv-89286">611,888</ix:nonFraction> and $<ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="0" unitRef="usd" id="ixv-89287">0</ix:nonFraction>, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><!-- Field: Page; Sequence: 326 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AVALON GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 8 -&#160;<span style="text-decoration:underline">EQUITY
METHOD INVESTMENTS (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Investment in Laboratory
Services MSO, LLC (continued)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:continuation id="_EquityMethodInvestmentsDisclosureTextBlock-c18_cont_2"><ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:EquityMethodInvestmentsTextBlock" id="ixv-60507"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In the years ended December
31, 2024 and 2023, activity recorded for the Company&#8217;s equity method investment in Lab Services MSO is summarized in the following
table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Equity investment carrying amount at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-335">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Payment for equity method investment:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">The Company&#8217;s interest in the fair value of Lab Services MSO&#8217;s net assets at February 9, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets" scale="0" unitRef="usd" id="ixv-89288">1,206,406</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">The Company&#8217;s interest in the net excess of Lab Services MSO&#8217;s fair value over net assets which was attributable to identifiable intangible assets at February 9, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="avco:EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets" scale="0" unitRef="usd" id="ixv-89289">10,004,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">The Company&#8217;s interest in the net excess of Lab Services MSO&#8217;s fair value over net assets which was attributable to goodwill at February 9, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="avco:EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets" scale="0" unitRef="usd" id="ixv-89290">9,456,261</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Total payment for equity method investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="0" unitRef="usd" id="ixv-89291">20,666,667</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Lab Services MSO&#8217;s net income attributable to the Company</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="avco:LabServicesMSOsNetIncomeAttributableToTheCompany" scale="0" unitRef="usd" id="ixv-89292">1,236,391</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Intangible assets amortization amount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-89293">611,356</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Impairment of goodwill</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillImpairmentLoss" scale="0" unitRef="usd" id="ixv-89294">9,196,682</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Equity investment carrying amount at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-89295">12,095,020</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Lab Services MSO&#8217;s net income attributable to the Company</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="avco:LabServicesMSOsNetIncomeAttributableToTheCompany" scale="0" unitRef="usd" id="ixv-89296">79,923</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Intangible assets amortization amount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-89297">666,932</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Distribution of earnings from equity investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="0" unitRef="usd" id="ixv-89298">611,888</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Impairment of goodwill</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillImpairmentLoss" scale="0" unitRef="usd" id="ixv-89299">259,579</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Equity investment carrying amount at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-89300">10,636,544</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024, the Company&#8217;s carrying
value of the identified intangible assets and goodwill which are included in the equity investment carrying amount was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-89301">8,725,712</ix:nonFraction>&#160;and
$<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillFairValueDisclosure" scale="0" unitRef="usd" id="ixv-89302">0</ix:nonFraction>, respectively. As of December 31, 2023, the Company&#8217;s carrying value of the identified intangible assets and goodwill which are
included in the equity investment carrying amount was $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-89303">9,392,644</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillFairValueDisclosure" scale="0" unitRef="usd" id="ixv-89304">259,579</ix:nonFraction>, respectively.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" escape="true" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock" id="ixv-60605"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tables below present the summarized financial
information, as provided to the Company by the investee, for the unconsolidated company:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-89305">2,917,880</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-89306">4,930,254</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Noncurrent assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-89307">4,509,185</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-89308">5,228,044</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-89309">611,391</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-89310">828,713</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Noncurrent liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-89311">4,346,725</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-89312">4,104,183</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-89313">2,468,949</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-89314">5,225,402</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:nonNumeric contextRef="c18" escape="true" name="srt:ScheduleOfCondensedIncomeStatementTableTextBlock" id="ixv-60670"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">For the year Ended December 31, 2024</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">For the Period from<br/>
February 9,<br/>
 2023 (Date of Investment) through December 31, 2023</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-89315">13,558,711</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-89316">12,699,683</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-89317">3,534,503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-89318">4,744,277</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">(Loss) income from operation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-89319">265,754</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-89320">2,393,830</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-89321">199,808</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-89322">3,090,977</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2025, to preserve cash, the Company entered
into discussions with Lab Services MSO for the potential redemption of our investment and on February 26, 2025, the Company and Lab Services
MSO entered into a Redemption and Abandonment Agreement (the &#8220;Redemption Agreement&#8221;), whereby Lab Services MSO redeemed the
40% equity interest in Lab Services MSO held by the Company. See Note 22 - Subsequent Events - Redemption Agreement.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 327 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="ixv-60747"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9 -&#160;<span style="text-decoration:underline">ACCRUED LIABILITIES
AND OTHER PAYABLES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="ixv-60753"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">At December 31, 2024
and 2023, accrued liabilities and other payables consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>
2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,<br/>
 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued tenants&#8217; improvement reimbursement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="avco:AccruedTenantsImprovementReimbursement" scale="0" unitRef="usd" id="ixv-89323">43,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="avco:AccruedTenantsImprovementReimbursement" scale="0" unitRef="usd" id="ixv-89324">43,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tenants&#8217; security deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Deposits" scale="0" unitRef="usd" id="ixv-89325">81,233</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Deposits" scale="0" unitRef="usd" id="ixv-89326">81,233</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued business expense reimbursement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="avco:AccruedBusinessExpenseReimbursement" scale="0" unitRef="usd" id="ixv-89327">34,781</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="avco:AccruedBusinessExpenseReimbursement" scale="0" unitRef="usd" id="ixv-89328">25,061</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued utilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedUtilitiesCurrent" scale="0" unitRef="usd" id="ixv-89329">26,075</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedUtilitiesCurrent" scale="0" unitRef="usd" id="ixv-89330">15,166</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred rental income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncome" scale="0" unitRef="usd" id="ixv-89331">38,346</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncome" scale="0" unitRef="usd" id="ixv-89332">11,429</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued real property cleaning service fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="avco:AccruedRealPropertyCleaningServiceFee" scale="0" unitRef="usd" id="ixv-89333">9,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="avco:AccruedRealPropertyCleaningServiceFee" scale="0" unitRef="usd" id="ixv-89334">7,570</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPayableCurrent" scale="0" unitRef="usd" id="ixv-89335">55,027</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd" id="ixv-89336">177,724</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="0" unitRef="usd" id="ixv-89337">11,794</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="0" unitRef="usd" id="ixv-89338">23,258</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="0" unitRef="usd" id="ixv-89339">22,135</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-89340">434,117</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-89341">272,915</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c18" continuedAt="_LongTermDebtTextBlock-c18_cont_1" escape="true" name="us-gaap:LongTermDebtTextBlock" id="ixv-60871"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 10 - <span style="text-decoration:underline">CONVERTIBLE NOTE PAYABLE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>May 2023 Convertible
Note</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On May 23, 2023, the
Company entered into securities purchase agreements with Mast Hill Fund, L.P. (&#8220;Mast Hill&#8221;) for the issuance of&#160;<ix:nonFraction contextRef="c200" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure" id="ixv-89342">13.0</ix:nonFraction>%
senior secured promissory notes in the aggregate principal amount of $<ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-89343">1,500,000</ix:nonFraction>&#160;(collectively, the &#8220;May 2023 Convertible Note&#8221;)
convertible into shares of the Company&#8217;s common stock, as well as the issuance of&#160;<ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-89344">5,000</ix:nonFraction>&#160;shares of common stock as a commitment
fee and warrants for the purchase of&#160;<ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89345">15,366</ix:nonFraction>&#160;shares of common stock of the Company. The Company and its subsidiaries also entered
into a security agreement, creating a security interest in certain property of the Company and its subsidiaries to secure the prompt payment,
performance and discharge in full of all of the Company&#8217;s obligations under the May 2023 Convertible Note. Principal amount and
interest under the May 2023 Convertible Note were convertible into shares of common stock of the Company at a conversion price of $<ix:nonFraction contextRef="c203" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-89346">67.50</ix:nonFraction>&#160;per
share unless the Company failed to make an amortization payment when due, in which case the conversion price would be the lower of $<ix:nonFraction contextRef="c204" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-89347">67.50</ix:nonFraction>&#160;or
the trading price of the shares, subject to a floor of $<ix:nonFraction contextRef="c201" decimals="2" format="ixt:num-dot-decimal" name="avco:DebtInstrumentConvertibleFloorPrice" scale="0" unitRef="usdPershares" id="ixv-89348">22.50</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Mast Hill acquired the
May 2023 Convertible Note with principal amount of $<ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-89349">1,500,000</ix:nonFraction>&#160;and paid the purchase price of $<ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="0" unitRef="usd" id="ixv-89350">1,425,000</ix:nonFraction>&#160;after an original issue
discount of $<ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-89351">75,000</ix:nonFraction>. On May 23, 2023, the Company issued (i) a warrant to purchase&#160;<ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89352">8,333</ix:nonFraction>&#160;shares of common stock with an exercise
price of $<ix:nonFraction contextRef="c205" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89353">67.50</ix:nonFraction>&#160;exercisable until the five-year anniversary of May 23, 2023 (&#8220;First Warrant&#8221;), (ii) a warrant to purchase&#160;<ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89354">7,033</ix:nonFraction>&#160;shares
of common stock with an exercise price of $<ix:nonFraction contextRef="c206" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89355">48.00</ix:nonFraction>&#160;exercisable until the five-year anniversary of May 23, 2023 (&#8220;Second Warrant&#8221;).The
Second Warrant was never fair valued and was cancelled and extinguished against payment of the May 2023 Convertible Note, and (iii)&#160;<ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-89356">5,000</ix:nonFraction>&#160;shares
of common stock as a commitment fee for the purchase of the May 2023 Convertible Note, which were earned in full as of May 23, 2023. On
May 23, 2023, the Company delivered such duly executed May 2023 Convertible Note, warrants and common stock to Mast Hill against delivery
of such purchase price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company was obligated
to make amortization payments in cash to Mast Hill toward the repayment of the May 2023 Convertible Note, as described in the May 2023
Convertible Note. As of December 31, 2024, the May 2023 Convertible Note was repaid in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
issuance of the May 2023 Convertible Note, the Company incurred debt issuance costs of $<ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" unitRef="usd" id="ixv-89357">175,162</ix:nonFraction>&#160;(including the issuance of&#160;<ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-89358">667</ix:nonFraction>&#160;warrants
as a finder&#8217;s fee) which was capitalized and was amortized into interest expense over the term of the May 2023 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Based upon the Company&#8217;s
analysis of the criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a
finder&#8217;s fee met the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances.
Accordingly, the fair value of the&#160;<ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89359">9,000</ix:nonFraction>&#160;warrants with an exercise price of $<ix:nonFraction contextRef="c210" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-89360">67.50</ix:nonFraction>&#160;exercisable until the five-year anniversary
of May 23, 2023 was classified as derivative liability on May 23, 2023. The fair values of the&#160;<ix:nonFraction contextRef="c211" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89361">9,000</ix:nonFraction>&#160;warrants with an exercise
price of $<ix:nonFraction contextRef="c211" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-89362">67.50</ix:nonFraction>&#160;exercisable until the five-year anniversary of May 23, 2023 issued on May 23, 2023 were computed using the Black-Scholes
option-pricing model with the following assumptions: stock price of $<ix:nonFraction contextRef="c212" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89363">29.40</ix:nonFraction>, volatility of&#160;<ix:nonFraction contextRef="c213" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89364">88.80</ix:nonFraction>%, risk-free rate of&#160;<ix:nonFraction contextRef="c214" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89365">3.76</ix:nonFraction>%, annual
dividend yield of&#160;<ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89366">0</ix:nonFraction>% and expected life of&#160;<ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89367">5</ix:nonFraction>&#160;years.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 328 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 10 - <span style="text-decoration:underline">CONVERTIBLE NOTE PAYABLE
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>May 2023 Convertible
Note (continued)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_LongTermDebtTextBlock-c18_cont_2" id="_LongTermDebtTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 470-20-25-2, proceeds from
the sale of a debt instrument with stock purchase warrants are allocated to the two elements based on the&#160;relative fair values&#160;of
the debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds allocated to
the warrants are accounted for as derivative liability. The remainder of the proceeds are allocated to the debt instrument portion of
the transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company recorded
a total debt discount of $<ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-89368">349,654</ix:nonFraction>&#160;related to the original issue discount, common shares issued and warrants issued to Mast Hill,
which was amortized over the term of the May 2023 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>July&#160;2023 Convertible
Note</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On July 6, 2023, the
Company entered into securities purchase agreements with FirstFire Global Opportunities Fund, LLC (&#8220;FirstFire&#8221;) for the issuance
of <ix:nonFraction contextRef="c217" decimals="3" format="ixt:num-dot-decimal" name="avco:PercentageOfPromissoryNotes" scale="-2" unitRef="pure" id="ixv-89369">13.0</ix:nonFraction>% senior secured promissory notes in the aggregate principal amount of $<ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-89370">500,000</ix:nonFraction> (collectively, the &#8220;July 2023 Convertible
Note&#8221;) convertible into shares of the Company&#8217;s common stock, as well as the issuance of <ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-89371">1,667</ix:nonFraction> shares of common stock as a
commitment fee and warrants for the purchase of <ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-89372">5,122</ix:nonFraction> shares of common stock of the Company. The Company and its subsidiaries also entered
into a security agreement, creating a security interest in certain property of the Company and its subsidiaries to secure the prompt payment,
performance and discharge in full of all of the Company&#8217;s obligations under the July 2023 Convertible Note. Principal amount and
interest under the July 2023 Convertible Note were convertible into shares of common stock of the Company at a conversion price of $<ix:nonFraction contextRef="c219" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-89373">67.50</ix:nonFraction>
per share unless the Company failed to make an amortization payment when due, in which case the conversion price would be the lower of
$<ix:nonFraction contextRef="c217" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceDecrease" scale="0" unitRef="usdPershares" id="ixv-89374">67.50</ix:nonFraction> or the trading price of the shares, subject to a floor of $<ix:nonFraction contextRef="c220" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceDecrease" scale="0" unitRef="usdPershares" id="ixv-89375">22.50</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">FirstFire acquired the
July 2023 Convertible Note with principal amount of $<ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-89376">500,000</ix:nonFraction> and paid the purchase price of $<ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="0" unitRef="usd" id="ixv-89377">475,000</ix:nonFraction> after an original issue discount
of $<ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-89378">25,000</ix:nonFraction>. On July 6, 2023, the Company issued (i) a warrant to purchase <ix:nonFraction contextRef="c223" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" unitRef="shares" id="ixv-89379">2,778</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction contextRef="c224" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89380">67.50</ix:nonFraction>
exercisable until the five-year anniversary of July 6, 2023 (&#8220;First Warrant&#8221;), (ii) a warrant to purchase <ix:nonFraction contextRef="c225" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" unitRef="shares" id="ixv-89381">2,344</ix:nonFraction> shares of
common stock with an exercise price of $<ix:nonFraction contextRef="c226" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89382">48.00</ix:nonFraction> exercisable until the five-year anniversary of July 6, 2023 (&#8220;Second Warrant&#8221;).
The Second Warrant was never fair valued and was cancelled and extinguished against payment of the July 2023 Convertible Note, and (iii)
<ix:nonFraction contextRef="c227" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-89383">1,667</ix:nonFraction> shares of common stock as a commitment fee for the purchase of the July 2023 Convertible Note, which were earned in full as of July
6, 2023. On July 6, 2023, the Company delivered such duly executed July 2023 Convertible Note, warrants and common stock to FirstFire
against delivery of such purchase price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company was obligated
to make amortization payments in cash to FirstFire toward the repayment of the July 2023 Convertible Note, as described in the July 2023
Convertible Note. As of December 31, 2024, the July 2023 Convertible Note was repaid in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
issuance of the July 2023 Convertible Note, the Company incurred debt issuance costs of $<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" unitRef="usd" id="ixv-89384">74,204</ix:nonFraction>&#160;(including the issuance of&#160;<ix:nonFraction contextRef="c228" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-89385">222</ix:nonFraction>&#160;warrants
as a finder&#8217;s fee), which was capitalized and was amortized into interest expense over the term of the July 2023 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Based upon the Company&#8217;s
analysis of the criteria contained in ASC 815, the Company determined that all the warrants issued to Firstfire and a third party as a
finder&#8217;s fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances.
Accordingly, the fair value of the&#160;<ix:nonFraction contextRef="c229" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89386">3,000</ix:nonFraction>&#160;warrants with an exercise price of $<ix:nonFraction contextRef="c229" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-89387">67.50</ix:nonFraction>&#160;exercisable until the five-year anniversary
of July 6, 2023 was classified as a derivative liability on July 6, 2023. The fair values of the&#160;<ix:nonFraction contextRef="c227" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89388">3,000</ix:nonFraction>&#160;warrants with an exercise
price of $<ix:nonFraction contextRef="c227" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-89389">67.50</ix:nonFraction>&#160;exercisable until the five-year anniversary of July 6, 2023 issued on July 6, 2023 were computed using the Black-Scholes
option-pricing model with the following assumptions: stock price of $<ix:nonFraction contextRef="c230" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89390">21.30</ix:nonFraction>, volatility of&#160;<ix:nonFraction contextRef="c231" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89391">88.52</ix:nonFraction>%, risk-free rate of&#160;<ix:nonFraction contextRef="c232" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89392">4.37</ix:nonFraction>%, annual
dividend yield of&#160;<ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89393">0</ix:nonFraction>% and expected life of&#160;<ix:nonFraction contextRef="c234" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89394">5</ix:nonFraction>&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="-keep: true">In accordance with
ASC 470-20-25-2, proceeds from the sale of a debt instrument with stock purchase warrants are allocated to the two elements based on
the relative fair values of the debt instrument without the warrants and of the warrants themselves at time of issuance. The portion
of the proceeds allocated to the warrants are accounted for as derivative liability. The remainder of the proceeds are allocated to the
debt instrument portion of the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded a total debt discount of
$<ix:nonFraction contextRef="c235" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-89395">89,191</ix:nonFraction>&#160;related to the original issue discount, common shares issued and warrants issued to Firstfire, which was amortized over the
term of the July 2023 Convertible Note.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 329 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 10 - <span style="text-decoration:underline">CONVERTIBLE NOTE PAYABLE
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_LongTermDebtTextBlock-c18_cont_3" id="_LongTermDebtTextBlock-c18_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>October&#160;2023
Convertible Note</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On October 9, 2023, the
Company entered into securities purchase agreements with Mast Hill and FirstFire for the issuance of <ix:nonFraction contextRef="c236" decimals="3" format="ixt:num-dot-decimal" name="avco:PercentageOfPromissoryNotes" scale="-2" unitRef="pure" id="ixv-89396">13.0</ix:nonFraction>% senior secured promissory notes
in the aggregate principal amount of $<ix:nonFraction contextRef="c236" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-89397">700,000</ix:nonFraction> (collectively, the &#8220;October 2023 Convertible Note&#8221;) convertible into shares
of the Company&#8217;s common stock, as well as the issuance of <ix:nonFraction contextRef="c236" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-89398">4,666</ix:nonFraction> shares of common stock as a commitment fee and warrants for the
purchase of <ix:nonFraction contextRef="c237" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89399">12,834</ix:nonFraction> shares of common stock of the Company. The Company and its subsidiaries also entered into that certain security agreements,
creating a security interest in certain property of the Company and its subsidiaries to secure the prompt payment, performance and discharge
in full of all of the Company&#8217;s obligations under the October 2023 Convertible Note. Principal amount and interest under the October
2023 Convertible Note were convertible into shares of common stock of the Company at a conversion price of $<ix:nonFraction contextRef="c238" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-89400">22.50</ix:nonFraction> per share unless the
Company failed to make an amortization payment when due, in which case the conversion price would be the lower of $<ix:nonFraction contextRef="c239" decimals="2" format="ixt:num-dot-decimal" name="avco:TradingPrice" scale="0" unitRef="usdPershares" id="ixv-89401">22.50</ix:nonFraction> or the market
price (as defined in the October 2023 Convertible Note) of the shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Mast Hill acquired the
October 2023 Convertible Note with principal amount of $<ix:nonFraction contextRef="c240" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-89402">350,000</ix:nonFraction>&#160;and paid the purchase price of $<ix:nonFraction contextRef="c241" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="0" unitRef="usd" id="ixv-89403">332,500</ix:nonFraction>&#160;after an original issue
discount of $<ix:nonFraction contextRef="c242" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-89404">17,500</ix:nonFraction>. On October 9, 2023, the Company issued (i) a warrant to purchase&#160;<ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89405">3,500</ix:nonFraction>&#160;shares of common stock with an exercise
price of $<ix:nonFraction contextRef="c243" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89406">37.50</ix:nonFraction>&#160;exercisable until the five-year anniversary of October 9, 2023 (&#8220;First Warrant&#8221;), (ii) a warrant to purchase&#160;<ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89407">2,917</ix:nonFraction>&#160;shares
of common stock with an exercise price of $<ix:nonFraction contextRef="c244" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89408">27.00</ix:nonFraction>&#160;exercisable until the five-year anniversary of October 9, 2023 (&#8220;Second Warrant&#8221;).
The Second Warrant was never fair valued and was cancelled and extinguished against payment of the October 2023 Convertible Note, and
(iii)&#160;<ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-89409">2,333</ix:nonFraction>&#160;shares of common stock as a commitment fee for the purchase of the October 2023 Convertible Note, which were earned
in full as of October 9, 2023. On October 9, 2023, the Company delivered such duly executed October 2023 Convertible Note, warrants and
common stock to Mast Hill against delivery of such purchase price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company was obligated to make amortization
payments in cash to Mast Hill toward the repayment of the October 2023 Convertible Note, as described in the October 2023 Convertible
Note. As of December 31, 2024, the October 2023 Convertible Note was repaid in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">FirstFire&#160;acquired
the October 2023 Convertible Note with principal amount of $<ix:nonFraction contextRef="c246" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-89410">350,000</ix:nonFraction>&#160;and paid the purchase price of $<ix:nonFraction contextRef="c247" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="0" unitRef="usd" id="ixv-89411">332,500</ix:nonFraction>&#160;after an original
issue discount of $<ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-89412">17,500</ix:nonFraction>. On October 9, 2023, the Company issued (i) a warrant to purchase&#160;<ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89413">3,500</ix:nonFraction>&#160;shares of common stock with
an exercise price of $<ix:nonFraction contextRef="c237" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89414">37.50</ix:nonFraction>&#160;exercisable until the five-year anniversary of October 9, 2023 (&#8220;First Warrant&#8221;), (ii) a
warrant to purchase&#160;<ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89415">2,917</ix:nonFraction>&#160;shares of common stock with an exercise price of $<ix:nonFraction contextRef="c250" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89416">27.00</ix:nonFraction>&#160;exercisable until the five-year anniversary
of October 9, 2023 (&#8220;Second Warrant&#8221;). The Second Warrant was never fair valued and was cancelled and extinguished against
payment of the October 2023 Convertible Note, and (iii)&#160;<ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89417">2,333</ix:nonFraction>&#160;shares of common stock as a commitment fee for the purchase of
the October 2023 Convertible Note, which were earned in full as of October 9, 2023. On October 9, 2023, the Company delivered such duly
executed October 2023 Convertible Note, warrants and common stock to FirstFire against delivery of such purchase price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company was obligated to make amortization
payments in cash to FirstFire toward the repayment of the October 2023 Convertible Note, as described in the October 2023 Convertible
Note. As of December 31, 2024, the October 2023 Convertible Note was repaid in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the issuance of the October
2023 Convertible Note, the Company incurred debt issuance costs of $<ix:nonFraction contextRef="c238" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" unitRef="usd" id="ixv-89418">95,349</ix:nonFraction>&#160;(including the issuance of&#160;<ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-89419">560</ix:nonFraction>&#160;warrants as a
finder&#8217;s fee), which was capitalized and was amortized into interest expense over the term of the October 2023 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon the Company&#8217;s analysis of the
criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and Firstfire and a third party as a finder&#8217;s
fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances. Accordingly,
the fair value of the&#160;<ix:nonFraction contextRef="c236" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89420">7,560</ix:nonFraction>&#160;warrants with an exercise price of $<ix:nonFraction contextRef="c236" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-89421">37.50</ix:nonFraction>&#160;exercisable until the five-year anniversary of October
9, 2023 was classified as a derivative liability on October 9, 2023. The fair values of the&#160;<ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89422">7,560</ix:nonFraction>&#160;warrants with an exercise
price of $<ix:nonFraction contextRef="c252" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-89423">37.50</ix:nonFraction>&#160;exercisable until the five-year anniversary of October 9, 2023 issued on October 9, 2023 were computed using the
Black-Scholes option-pricing model with the following assumptions: stock price of $<ix:nonFraction contextRef="c253" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89424">11.55</ix:nonFraction>, volatility of&#160;<ix:nonFraction contextRef="c254" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89425">89.70</ix:nonFraction>%, risk-free rate of&#160;<ix:nonFraction contextRef="c255" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89426">4.75</ix:nonFraction>%,
annual dividend yield of&#160;<ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89427">0</ix:nonFraction>% and expected life of&#160;<ix:nonFraction contextRef="c257" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89428">5</ix:nonFraction>&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In accordance with ASC 470-20-25-2, proceeds
from the sale of a debt instrument with stock purchase warrants are allocated to the two elements based on the relative fair values of
the debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds allocated to
the warrants are accounted for as derivative liability. The remainder of the proceeds are allocated to the debt instrument portion of
the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded a total debt discount of
$<ix:nonFraction contextRef="c258" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-89429">128,748</ix:nonFraction>&#160;related to the original issue discount, common shares issued and warrants issued to Mast Hill and Firstfire, which was amortized
over the term of the October 2023 Convertible Note.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 330 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 10 - <span style="text-decoration:underline">CONVERTIBLE NOTE PAYABLE
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_LongTermDebtTextBlock-c18_cont_4" id="_LongTermDebtTextBlock-c18_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>March 2024 Convertible
Note</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On March 7, 2024, the
Company entered into securities purchase agreements with Mast Hill for the issuance of&#160;<ix:nonFraction contextRef="c259" decimals="3" format="ixt:num-dot-decimal" name="avco:PercentageOfPromissoryNotes" scale="-2" unitRef="pure" id="ixv-89430">13.0</ix:nonFraction>% senior secured promissory notes in the
aggregate principal amount of $<ix:nonFraction contextRef="c259" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-89431">700,000</ix:nonFraction>&#160;(collectively, the &#8220;March 2024 Convertible Note&#8221;) convertible into shares of the
Company&#8217;s common stock, as well as the issuance of&#160;<ix:nonFraction contextRef="c259" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-89432">7,000</ix:nonFraction>&#160;shares of common stock as a commitment fee and warrants for the
purchase of&#160;<ix:nonFraction contextRef="c260" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-89433">16,827</ix:nonFraction>&#160;shares of common stock of the Company. The Company and its subsidiaries also entered into a security agreement,
creating a security interest in certain property of the Company and its subsidiaries to secure the prompt payment, performance and discharge
in full of all of the Company&#8217;s obligations under the March 2024 Convertible Note. Principal amount and interest under the March
2024 Convertible Note were convertible into shares of common stock of the Company at a conversion price of $<ix:nonFraction contextRef="c261" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-89434">15.00</ix:nonFraction>&#160;per share unless
the Company failed to make an amortization payment when due, in which case the conversion price would be the lower of $<ix:nonFraction contextRef="c261" decimals="2" format="ixt:num-dot-decimal" name="avco:TradingPrice" scale="0" unitRef="usdPershares" id="ixv-89435">15.00</ix:nonFraction>&#160;or the
market price (as defined in the March 2024 Convertible Note) of the shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Mast Hill acquired the
March 2024 Convertible Note with principal amount of $<ix:nonFraction contextRef="c259" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-89436">700,000</ix:nonFraction>&#160;and paid the purchase price of $<ix:nonFraction contextRef="c259" decimals="0" format="ixt:num-dot-decimal" name="avco:PurchasePriceOfConvertibleNote" scale="0" unitRef="usd" id="ixv-89437">665,000</ix:nonFraction>&#160;after an original issue
discount of $<ix:nonFraction contextRef="c261" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-89438">35,000</ix:nonFraction>. On March 7, 2024, the Company issued (i) a warrant to purchase&#160;<ix:nonFraction contextRef="c262" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" unitRef="shares" id="ixv-89439">8,750</ix:nonFraction>&#160;shares of common stock with an exercise
price of $<ix:nonFraction contextRef="c262" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-89440">30.00</ix:nonFraction>&#160;exercisable until the five-year anniversary of March 7, 2024 (&#8220;First Warrant&#8221;), (ii) a warrant to purchase&#160;<ix:nonFraction contextRef="c259" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" unitRef="shares" id="ixv-89441">8,077</ix:nonFraction>&#160;shares
of common stock with an exercise price of $<ix:nonFraction contextRef="c263" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-89442">19.50</ix:nonFraction>&#160;exercisable until the five-year anniversary of March 7, 2024 (&#8220;Second Warrant&#8221;).
The Second Warrant was never fair valued and was cancelled and extinguished against payment of the March 2024 Convertible Note, and (iii)&#160;<ix:nonFraction contextRef="c264" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonUnitOutstanding" scale="0" unitRef="shares" id="ixv-89443">7,000</ix:nonFraction>&#160;shares
of common stock as a commitment fee for the purchase of the March 2024 Convertible Note, which were earned in full as of March 7, 2024.
On March 7, 2024, the Company delivered such duly executed March 2024 Convertible Note, warrants and common stock to Mast Hill against
delivery of such purchase price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company was obligated to make amortization
payments in cash to Mast Hill toward the repayment of the March 2024 Convertible Note, as described in the March 2024 Convertible Note.
As of December 31, 2024, the March 2024 Convertible Note was repaid in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the issuance of the March 2024
Convertible Note, the Company incurred debt issuance costs of $<ix:nonFraction contextRef="c261" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" unitRef="usd" id="ixv-89444">74,379</ix:nonFraction>&#160;(including the issuance of&#160;<ix:nonFraction contextRef="c261" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-89445">700</ix:nonFraction>&#160;warrants as a finder&#8217;s
fee) which was capitalized and was amortized into interest expense over the term of the March 2024 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon the Company&#8217;s analysis of the
criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a finder&#8217;s
fee met the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances. Accordingly,
the fair value of the&#160;<ix:nonFraction contextRef="c265" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89446">9,450</ix:nonFraction>&#160;warrants with an exercise price of $<ix:nonFraction contextRef="c265" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-89447">30.00</ix:nonFraction>&#160;exercisable until the five-year anniversary of March
7, 2024 was classified as derivative liability on March 7, 2024. The fair values of the&#160;<ix:nonFraction contextRef="c266" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89448">9,450</ix:nonFraction>&#160;warrants with an exercise price
of $<ix:nonFraction contextRef="c266" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-89449">30.00</ix:nonFraction>&#160;exercisable until the five-year anniversary of March 7, 2024 issued on March 7, 2024 were computed using the Black-Scholes
option-pricing model with the following assumptions: stock price of $<ix:nonFraction contextRef="c267" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89450">6.00</ix:nonFraction>, volatility of&#160;<ix:nonFraction contextRef="c268" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89451">85.24</ix:nonFraction>%, risk-free rate of&#160;<ix:nonFraction contextRef="c269" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89452">4.07</ix:nonFraction>%, annual
dividend yield of&#160;<ix:nonFraction contextRef="c270" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89453">0</ix:nonFraction>% and expected life of&#160;<ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89454">5</ix:nonFraction>&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 470-20-25-2, proceeds from
the sale of a debt instrument with stock purchase warrants are allocated to the two elements based on the relative fair values of the
debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds allocated to the
warrants are accounted for as derivative liability. The remainder of the proceeds are allocated to the debt instrument portion of the
transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded a total debt discount of
$<ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-89455">97,374</ix:nonFraction>&#160;related to the original issue discount, common shares issued and warrants issued to Mast Hill, which was amortized over the
term of the March 2024 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>June 2024 Convertible
Note</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On June 5, 2024, the
Company entered into securities purchase agreements with Mast Hill for the issuance of&#160;<ix:nonFraction contextRef="c273" decimals="3" format="ixt:num-dot-decimal" name="avco:PercentageOfPromissoryNotes" scale="-2" unitRef="pure" id="ixv-89456">13.0</ix:nonFraction>% senior secured promissory notes in the
aggregate principal amount of $<ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-89457">2,845,000</ix:nonFraction>&#160;(collectively, the &#8220;June 2024 Convertible Note&#8221;) convertible into shares of
the Company&#8217;s common stock, as well as the issuance of&#160;<ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-89458">26,800</ix:nonFraction>&#160;shares of common stock as a commitment fee and warrants
for the purchase of&#160;<ix:nonFraction contextRef="c274" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89459">146,667</ix:nonFraction>&#160;shares of common stock of the Company. The Company and its subsidiaries have also entered into a
security agreement, creating a security interest in certain property of the Company and its subsidiaries to secure the prompt payment,
performance and discharge in full of all of the Company&#8217;s obligations under the June 2024 Convertible Note. Principal amount and
interest under the June 2024 Convertible Note are convertible into shares of common stock of the Company at a conversion price of $<ix:nonFraction contextRef="c273" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPriceIncrease" scale="0" unitRef="usdPershares" id="ixv-89460">11.25</ix:nonFraction>&#160;per
share unless the Company fails to make an amortization payment when due, in which case the conversion price shall be the lesser of $<ix:nonFraction contextRef="c273" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPriceDecrease" scale="0" unitRef="usdPershares" id="ixv-89461">11.25</ix:nonFraction>&#160;or
the market price (as defined in the June 2024 Convertible Note).</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 331 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 10 - <span style="text-decoration:underline">CONVERTIBLE NOTE PAYABLE
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>June 2024 Convertible
Note (continued)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:continuation continuedAt="_LongTermDebtTextBlock-c18_cont_5" id="_LongTermDebtTextBlock-c18_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Mast Hill acquired the
June 2024 Convertible Note with principal amount of $<ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-89462">2,845,000</ix:nonFraction>&#160;and paid the purchase price of $<ix:nonFraction contextRef="c274" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="0" unitRef="usd" id="ixv-89463">2,702,750</ix:nonFraction>&#160;after an original issue
discount of $<ix:nonFraction contextRef="c274" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-89464">142,250</ix:nonFraction>. On June 5, 2024, the Company issued (i) a warrant to purchase&#160;<ix:nonFraction contextRef="c275" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" unitRef="shares" id="ixv-89465">66,667</ix:nonFraction>&#160;shares of common stock with an exercise
price of $<ix:nonFraction contextRef="c276" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89466">9.75</ix:nonFraction>&#160;exercisable until the five-year anniversary of June 5, 2024 (&#8220;First Warrant&#8221;), (ii) a warrant to purchase&#160;<ix:nonFraction contextRef="c277" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" unitRef="shares" id="ixv-89467">80,000</ix:nonFraction>&#160;shares
of common stock with an exercise price of $<ix:nonFraction contextRef="c278" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89468">7.50</ix:nonFraction>&#160;exercisable until the five-year anniversary of June 5, 2024 (&#8220;Second Warrant&#8221;).
The Second Warrant will not be fair valued and shall be cancelled and extinguished against payment of the June 2024 Convertible Note,
and (iii)&#160;<ix:nonFraction contextRef="c277" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-89469">26,800</ix:nonFraction>&#160;shares of common stock as a commitment fee for the purchase of the June 2024 Convertible Note, which were earned
in full as of June 5, 2024. On June 5, 2024, the Company delivered such duly executed June 2024 Convertible Note, warrants and common
stock to Mast Hill against delivery of such purchase price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company received
net cash amount of $<ix:nonFraction contextRef="c279" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NontradeReceivables" scale="0" unitRef="usd" id="ixv-89470">881,210</ix:nonFraction>&#160;from the June 2024 Convertible Note financing after using the proceeds to pay off all previously issued
convertible notes to Mast Hill of $<ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd" id="ixv-89471">1,206,867</ix:nonFraction>&#160;and FirstFire of $<ix:nonFraction contextRef="c281" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd" id="ixv-89472">454,673</ix:nonFraction>, respectively, and to pay finder&#8217;s fee of $<ix:nonFraction contextRef="c282" decimals="0" format="ixt:num-dot-decimal" name="avco:PaymentForCommission" scale="0" unitRef="usd" id="ixv-89473">120,000</ix:nonFraction>&#160;and
lender&#8217;s costs of $<ix:nonFraction contextRef="c282" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="0" unitRef="usd" id="ixv-89474">40,000</ix:nonFraction>&#160;related to this financing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="ixv-61099"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company is obligated
to make amortization payments in cash to Mast Hill toward the repayment of the June 2024 Convertible Note, as provided in the following
table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 30%">Payment Date:</td> <td style="padding-bottom: 1.5pt; white-space: nowrap; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 68%">Payment Amount:</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap">December 5, 2024</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap"><ix:nonNumeric contextRef="c294" name="us-gaap:DebtInstrumentDescription" id="ixv-89475">$284,500 plus accrued interest through December 5, 2024</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap">January 5, 2025</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap"><ix:nonNumeric contextRef="c295" name="us-gaap:DebtInstrumentDescription" id="ixv-89476">$284,500 plus accrued interest through January 5, 2025</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap">February 5, 2025</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap"><ix:nonNumeric contextRef="c296" name="us-gaap:DebtInstrumentDescription" id="ixv-89477">$379,336 plus accrued interest through February 5, 2025</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap">March 5, 2025</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap"><ix:nonNumeric contextRef="c297" name="us-gaap:DebtInstrumentDescription" id="ixv-89478">$474,167 plus accrued interest through March 5, 2025</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap">April 5, 2025</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap"><ix:nonNumeric contextRef="c298" name="us-gaap:DebtInstrumentDescription" id="ixv-89479">$474,167 plus accrued interest through April 5, 2025</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap">May 5, 2025</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap"><ix:nonNumeric contextRef="c299" name="us-gaap:DebtInstrumentDescription" id="ixv-89480">$569,000 plus accrued interest through May 5, 2025</ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap">June 5, 2025</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap"><ix:nonNumeric contextRef="c300" name="us-gaap:DebtInstrumentDescription" id="ixv-89481">The entire remaining outstanding balance of the June 2024 Convertible Note</ix:nonNumeric></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
issuance of the June 2024 Convertible Note, the Company incurred debt issuance costs of $<ix:nonFraction contextRef="c279" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" unitRef="usd" id="ixv-89482">224,221</ix:nonFraction>&#160;(including the issuance of&#160;<ix:nonFraction contextRef="c283" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-89483">5,333</ix:nonFraction>&#160;warrants
as a finder&#8217;s fee) which is capitalized and will be amortized into interest expense over the term of the June 2024 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Based upon the Company&#8217;s
analysis of the criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a
finder&#8217;s fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances.
Management determined the probability of failing to make an amortization payment when due to be remote and as such the fair value of the&#160;<ix:nonFraction contextRef="c284" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-89484">80,000</ix:nonFraction>&#160;warrants
with an exercise price of $<ix:nonFraction contextRef="c274" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89485">7.50</ix:nonFraction>&#160;exercisable until the five-year anniversary of June 5, 2024, which warrant shall be cancelled and
extinguished against payment of the June 2024 Convertible Note, has been estimated to be zero. Accordingly, the fair value of the&#160;<ix:nonFraction contextRef="c284" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89486">72,000</ix:nonFraction>&#160;warrants
with an exercise price of $<ix:nonFraction contextRef="c284" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89487">9.75</ix:nonFraction>&#160;exercisable until the five-year anniversary of June 5, 2024 was classified as derivative liability
on June 5, 2024. The fair values of the&#160;<ix:nonFraction contextRef="c284" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89488">72,000</ix:nonFraction>&#160;warrants with an exercise price of $<ix:nonFraction contextRef="c284" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89489">9.75</ix:nonFraction>&#160;exercisable until the five-year
anniversary of June&#160;<ix:nonFraction contextRef="c285" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89490">5</ix:nonFraction>, 2024 issued on June 5, 2024 were computed using the Black-Scholes option-pricing model with the following
assumptions: stock price of $<ix:nonFraction contextRef="c286" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89491">10.39</ix:nonFraction>, volatility of&#160;<ix:nonFraction contextRef="c287" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89492">85.72</ix:nonFraction>%, risk-free rate of&#160;<ix:nonFraction contextRef="c288" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89493">4.31</ix:nonFraction>%, annual dividend yield of&#160;<ix:nonFraction contextRef="c289" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89494">0</ix:nonFraction>% and expected
life of 5 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In accordance with ASC
470-20-25-2, proceeds from the sale of a debt instrument with stock purchase warrants are allocated to the two elements based on the relative
fair values of the debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds
allocated to the warrants are accounted for as derivative liability. The remainder of the proceeds are allocated to the debt instrument
portion of the transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In accordance with ASC
480-10-25-14, the Company determined that the conversion provisions contain an embedded derivative feature and the Company valued the
derivative feature separately, recording debt discount and derivative liability in accordance with the provisions of the convertible debt
(see Note 11). However, management determined the probability of failing to make an amortization payment when due to be remote and as
such the fair value of the embedded conversion feature has been estimated to be zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company recorded
a total debt discount of $<ix:nonFraction contextRef="c279" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-89495">838,990</ix:nonFraction>&#160;related to the original issue discount, common shares issued and warrants issued to Mast Hill,
which will be amortized over the term of the June 2024 Convertible Note.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 332 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 10 - <span style="text-decoration:underline">CONVERTIBLE NOTE PAYABLE
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>June 2024 Convertible
Note (continued)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:continuation id="_LongTermDebtTextBlock-c18_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On December 15, 2024,
the Company and Mast Hill entered into that certain consent, acknowledgement, and waiver agreement (&#8220;Agreement&#8221;), pursuant
to which Mast Hill waived all amortization payments required to be made under the June 2024 Convertible Note, the Company paid a waiver
fee of $<ix:nonFraction contextRef="c290" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFeeAmount" scale="0" unitRef="usd" id="ixv-89496">150,000</ix:nonFraction> to Mast Hill, and the Company issued to Mast Hill a common stock purchase warrant for the purchase of up to <ix:nonFraction contextRef="c291" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-89497">150,000</ix:nonFraction> shares
of the Company&#8217;s common stock (&#8220;Pre-Funded Warrants&#8221;). The Pre-Funded Warrants are immediately exercisable at issuance
and until the Pre-Funded Warrants are exercised in full and have an exercise price of $<ix:nonFraction contextRef="c292" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-89498">0.01</ix:nonFraction> per share. The Pre-Funded Warrants were classified
as a component of permanent equity on the accompanying consolidated balance sheets as they are freestanding financial instrument that
is immediately exercisable, does not embody an obligation for the Company to repurchase its own shares and permit the holder to receive
a fixed number of shares of common stock upon exercise. All of the shares underlying the Pre-Funded Warrants have been included in the
weighted-average number of shares of common stock used to calculate net loss per share, basic and diluted, attributable to the Company&#8217;s
common stockholders because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original
issuance date of the Pre-Funded Warrants. Based on the Company&#8217;s assess, this arrangement was accounted for as a modification of
debt and, as such, $<ix:nonFraction contextRef="c293" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFeeAmount" scale="0" unitRef="usd" id="ixv-89499">838,794</ix:nonFraction> related to the waiver fee and Pre-Fund Warrants issued to Mast Hill were expensed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:ConvertibleDebtTableTextBlock" id="ixv-61182"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">The
convertible note payable as of December 31, 2024 and 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Principal amount</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c301" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-89500">2,556,777</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c302" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-89501">2,400,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: unamortized debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c301" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="0" unitRef="usd" id="ixv-89502">93,425</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c302" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="0" unitRef="usd" id="ixv-89503">183,840</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: unamortized debt discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c301" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" scale="0" unitRef="usd" id="ixv-89504">349,579</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c302" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" scale="0" unitRef="usd" id="ixv-89505">291,014</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Convertible note payable, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c301" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-89506">2,113,773</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c302" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-89507">1,925,146</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For the years ended December
31, 2024 and 2023, amortization of debt discount and debt issuance costs related to convertible note payable amounted to $<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd" id="ixv-89508">1,291,814</ix:nonFraction>&#160;and
$<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd" id="ixv-89509">437,453</ix:nonFraction>, respectively, which have been included in interest expense - amortization of debt discount and debt issuance costs on
the accompanying consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For the years ended December
31, 2024 and 2023, interest expense related to convertible note payable amounted to $<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd" id="ixv-89510">325,486</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd" id="ixv-89511">167,058</ix:nonFraction>, respectively, which have
been included in interest expense - other on the accompanying consolidated statements of operations and comprehensive loss.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:nonNumeric contextRef="c18" continuedAt="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c18_cont_1" escape="true" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="ixv-61242"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 11 -&#160;<span style="text-decoration:underline">DERIVATIVE LIABILITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As stated
in Note 10, June 2024 Convertible Note, the Company determined that the convertible note payable contains an embedded derivative feature
in the form of a conversion provision which is adjustable based on future prices of the Company&#8217;s common stock. In accordance with
ASC 815-10-25, each derivative feature is initially recorded at its fair value using the Black-Scholes option valuation method and then
re-value at each reporting date, with changes in the fair value reported in the statements of operations. However, on June 5, 2024 and
December 31, 2024, management determined the probability of failing to make an amortization payment and repayment, respectively, when
due to be remote and as such the fair value of the embedded conversion feature has been estimated to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 23, 2023, the Company issued <ix:nonFraction contextRef="c303" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-89512">9,000</ix:nonFraction> warrants
with an exercise price of $<ix:nonFraction contextRef="c304" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89513">67.50</ix:nonFraction> exercisable until the five-year anniversary of May 23, 2023 to Mast Hill and a third party as a finder&#8217;s
fee. Upon evaluation, the warrants meet the definition of a derivative liability under FASB ASC 815, as the Company cannot avoid a net
cash settlement under certain circumstances. Accordingly, the fair value of the <ix:nonFraction contextRef="c305" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89514">9,000</ix:nonFraction> warrants was classified as a derivative liability
on May 23, 2023. On December 31, 2023, the estimated fair value of the <ix:nonFraction contextRef="c306" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-89515">9,000</ix:nonFraction> warrants was $<ix:nonFraction contextRef="c307" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89516">14,805</ix:nonFraction>. The estimated fair value of the warrants
was computed as of December 31, 2023 using Black-Scholes option-pricing model, with the following assumptions: stock price of $<ix:nonFraction contextRef="c308" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89517">7.24</ix:nonFraction>, volatility
of <ix:nonFraction contextRef="c309" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89518">83.96</ix:nonFraction>%, risk-free rate of <ix:nonFraction contextRef="c310" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89519">3.84</ix:nonFraction>%, annual dividend yield of <ix:nonFraction contextRef="c311" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89520">0</ix:nonFraction>% and expected life of <ix:nonFraction contextRef="c312" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89521">4.4</ix:nonFraction> years. On December 31, 2024, the estimated fair
value of the <ix:nonFraction contextRef="c313" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89522">9,000</ix:nonFraction> warrants was $<ix:nonFraction contextRef="c313" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightUnissued" scale="0" unitRef="shares" id="ixv-89523">3,714</ix:nonFraction>. The estimated fair value of the warrants was computed as of December 31, 2024 using Black-Scholes
option-pricing model, with the following assumptions: stock price of $<ix:nonFraction contextRef="c314" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89524">3.26</ix:nonFraction>, volatility of <ix:nonFraction contextRef="c315" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89525">97.00</ix:nonFraction>%, risk-free rate of <ix:nonFraction contextRef="c316" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89526">4.27</ix:nonFraction>%, annual dividend
yield of <ix:nonFraction contextRef="c317" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89527">0</ix:nonFraction>% and expected life of <ix:nonFraction contextRef="c318" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89528">3.4</ix:nonFraction> years.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 333 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 11 -&#160;<span style="text-decoration:underline">DERIVATIVE LIABILITY
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2023, the Company issued&#160;<ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-89529">3,000</ix:nonFraction>&#160;warrants
with an exercise price of $<ix:nonFraction contextRef="c319" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89530">67.50</ix:nonFraction>&#160;exercisable until the five-year anniversary of July 6, 2023 to FirstFire and a third party as a
finder&#8217;s fee. Upon evaluation, the warrants meet the definition of a derivative liability under ASC 815, as the Company cannot avoid
a net cash settlement under certain circumstances. Accordingly, the fair value of the&#160;<ix:nonFraction contextRef="c320" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89531">3,000</ix:nonFraction>&#160;warrants was classified as a derivative
liability on July 6, 2023. On December 31, 2023, the estimated fair value of the&#160;<ix:nonFraction contextRef="c321" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89532">3,000</ix:nonFraction>&#160;warrants was $<ix:nonFraction contextRef="c321" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightUnissued" scale="0" unitRef="shares" id="ixv-89533">5,098</ix:nonFraction>.&#160;The estimated
fair value of the warrants was computed as of December 31, 2023 using Black-Scholes&#160;option-pricing model, with the following assumptions:
stock price of $<ix:nonFraction contextRef="c322" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89534">7.24</ix:nonFraction>, volatility of&#160;<ix:nonFraction contextRef="c323" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89535">83.66</ix:nonFraction>%, risk-free rate of&#160;<ix:nonFraction contextRef="c324" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89536">3.84</ix:nonFraction>%, annual dividend yield of&#160;<ix:nonFraction contextRef="c325" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89537">0</ix:nonFraction>% and expected life of&#160;<ix:nonFraction contextRef="c326" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89538">4.5</ix:nonFraction>&#160;years.
On November 18, 2024, <ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="avco:WarrantsOfCashlessExercised" scale="0" unitRef="shares" id="ixv-89539">2,778</ix:nonFraction> warrants held by FirstFire were cashless exercised. On December 31, 2024, the estimated fair value of the&#160;rest
of <ix:nonFraction contextRef="c328" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-89540">222</ix:nonFraction>&#160;warrants was $<ix:nonFraction contextRef="c329" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89541">94</ix:nonFraction>. The estimated fair value of the warrants was computed as of December 31, 2024 using Black-Scholes option-pricing
model, with the following assumptions: stock price of $<ix:nonFraction contextRef="c330" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89542">3.26</ix:nonFraction>, volatility of&#160;<ix:nonFraction contextRef="c331" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89543">95.85</ix:nonFraction>%, risk-free rate of&#160;<ix:nonFraction contextRef="c332" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89544">4.27</ix:nonFraction>%, annual dividend
yield of&#160;<ix:nonFraction contextRef="c333" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89545">0</ix:nonFraction>% and expected life of&#160;<ix:nonFraction contextRef="c334" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89546">3.5</ix:nonFraction>&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 9, 2023, the Company issued&#160;<ix:nonFraction contextRef="c335" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-89547">7,560</ix:nonFraction>&#160;warrants
with an exercise price of $<ix:nonFraction contextRef="c237" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89548">37.50</ix:nonFraction>&#160;exercisable until the five-year anniversary of October 9, 2023 to Mast Hill and FirstFire and a
third party as a finder&#8217;s fee. Upon evaluation, the warrants meet the definition of a derivative liability under ASC 815, as the
Company cannot avoid a net cash settlement under certain circumstances. Accordingly, the fair value of the&#160;<ix:nonFraction contextRef="c336" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89549">7,560</ix:nonFraction>&#160;warrants was
classified as a derivative liability on October 9, 2023. On December 31, 2023, the estimated fair value of the&#160;<ix:nonFraction contextRef="c337" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89550">7,560</ix:nonFraction>&#160;warrants
was $<ix:nonFraction contextRef="c337" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightUnissued" scale="0" unitRef="shares" id="ixv-89551">20,920</ix:nonFraction>.&#160;The estimated fair value of the warrants was computed as of December 31, 2023 using Black-Scholes&#160;option-pricing
model, with the following assumptions: stock price of $<ix:nonFraction contextRef="c322" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89552">7.24</ix:nonFraction>, volatility of&#160;<ix:nonFraction contextRef="c338" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89553">86.33</ix:nonFraction>%, risk-free rate of&#160;<ix:nonFraction contextRef="c339" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89554">3.84</ix:nonFraction>%, annual dividend
yield of&#160;<ix:nonFraction contextRef="c340" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89555">0</ix:nonFraction>% and expected life of&#160;<ix:nonFraction contextRef="c341" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89556">4.8</ix:nonFraction>&#160;years. On November 18, 2024, <ix:nonFraction contextRef="c342" decimals="0" format="ixt:num-dot-decimal" name="avco:WarrantsOfCashlessExercised" scale="0" unitRef="shares" id="ixv-89557">3,500</ix:nonFraction> warrants held by FirstFire were cashless exercised.
On December 31, 2024, the estimated fair value of the&#160;rest of <ix:nonFraction contextRef="c343" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightUnissued" scale="0" unitRef="shares" id="ixv-89558">4,060</ix:nonFraction>&#160;warrants was $<ix:nonFraction contextRef="c344" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89559">2,880</ix:nonFraction>. The estimated fair value of the warrants
was computed as of December 31, 2024 using Black-Scholes option-pricing model, with the following assumptions: stock price of $<ix:nonFraction contextRef="c345" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89560">3.26</ix:nonFraction>, volatility
of&#160;<ix:nonFraction contextRef="c346" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89561">93.90</ix:nonFraction>%, risk-free rate of&#160;<ix:nonFraction contextRef="c347" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89562">4.27</ix:nonFraction>%, annual dividend yield of&#160;<ix:nonFraction contextRef="c348" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89563">0</ix:nonFraction>% and expected life of&#160;<ix:nonFraction contextRef="c349" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89564">3.8</ix:nonFraction>&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On March 7, 2024, the
Company issued&#160;<ix:nonFraction contextRef="c350" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-89565">9,450</ix:nonFraction>&#160;warrants with an exercise price of $<ix:nonFraction contextRef="c264" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89566">30.00</ix:nonFraction>&#160;exercisable until the five-year anniversary of March 7,
2024 to Mast Hill and a third party as a finder&#8217;s fee. Upon evaluation, the warrants meet the definition of a derivative liability
under FASB ASC 815, as the Company cannot avoid a net cash settlement under certain circumstances. Accordingly, the fair value of the&#160;<ix:nonFraction contextRef="c351" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89567">9,450</ix:nonFraction>&#160;warrants
was classified as a derivative liability on March 7, 2024. On December 31, 2024, the estimated fair value of the&#160;<ix:nonFraction contextRef="c352" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89568">9,450</ix:nonFraction>&#160;warrants
was $<ix:nonFraction contextRef="c352" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightUnissued" scale="0" unitRef="shares" id="ixv-89569">8,191</ix:nonFraction>. The estimated fair value of the warrants was computed as of December 31, 2024 using Black-Scholes option-pricing model, with
the following assumptions: stock price of $<ix:nonFraction contextRef="c353" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89570">3.26</ix:nonFraction>, volatility of&#160;<ix:nonFraction contextRef="c354" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89571">90.43</ix:nonFraction>%, risk-free rate of&#160;<ix:nonFraction contextRef="c355" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89572">4.38</ix:nonFraction>%, annual dividend yield of&#160;<ix:nonFraction contextRef="c356" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89573">0</ix:nonFraction>%
and expected life of&#160;<ix:nonFraction contextRef="c357" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89574">4.2</ix:nonFraction>&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On June 5, 2024, the
Company issued&#160;<ix:nonFraction contextRef="c358" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-89575">152,000</ix:nonFraction>&#160;warrants to Mast Hill and a third party as a finder&#8217;s fee (see Note 10). Upon evaluation, the warrants
meet the definition of a derivative liability under ASC 815, as the Company cannot avoid a net cash settlement under certain circumstances.
Management determined the probability of failing to make an amortization payment when due to be remote and as such the fair value of the&#160;<ix:nonFraction contextRef="c359" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89576">80,000</ix:nonFraction>&#160;warrants
with an exercise price of $<ix:nonFraction contextRef="c274" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89577">7.50</ix:nonFraction>&#160;exercisable until the five-year anniversary of June 5, 2024, which warrant shall be cancelled and
extinguished against payment of the June 2024 Convertible Note, has been estimated to be zero. Accordingly, the fair value of the&#160;<ix:nonFraction contextRef="c360" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89578">72,000</ix:nonFraction>&#160;warrants
with an exercise price of $<ix:nonFraction contextRef="c360" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89579">9.75</ix:nonFraction>&#160;exercisable until the five-year anniversary of June 5, 2024 was classified as a derivative liability
on June 5, 2024. On December 31, 2024, the estimated fair value of the&#160;<ix:nonFraction contextRef="c361" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89580">72,000</ix:nonFraction>&#160;warrants with an exercise price of $<ix:nonFraction contextRef="c362" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89581">9.75</ix:nonFraction>&#160;exercisable
until the five-year anniversary of June 5, 2024 as derivative liability was $<ix:nonFraction contextRef="c360" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-89582">112,666</ix:nonFraction>. The estimated fair value of the warrants was computed
as of December 31, 2024 using Black-Scholes option-pricing model, with the following assumptions: stock price of $<ix:nonFraction contextRef="c363" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89583">3.26</ix:nonFraction>, volatility of&#160;<ix:nonFraction contextRef="c364" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89584">88.64</ix:nonFraction>%,
risk-free rate of&#160;<ix:nonFraction contextRef="c365" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89585">4.38</ix:nonFraction>%, annual dividend yield of&#160;<ix:nonFraction contextRef="c366" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89586">0</ix:nonFraction>% and expected life of&#160;<ix:nonFraction contextRef="c367" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-89587">4.4</ix:nonFraction>&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Increases or decreases
in fair value of the derivative liability are included as a component of total other (expenses) income in the accompanying consolidated
statements of operations and comprehensive loss. The changes to the derivative liability resulted in a decrease of $<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" sign="-" unitRef="usd" id="ixv-89588">374,365</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" sign="-" unitRef="usd" id="ixv-89589">188,374</ix:nonFraction>&#160;in
the derivative liability and the corresponding increase in other income as a gain for the years ended December 31, 2024 and 2023, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:nonNumeric contextRef="c18" continuedAt="_DebtDisclosureTextBlock-c18_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-61293"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 12 -&#160;<span style="text-decoration:underline">NOTE PAYABLE, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">On
September 1, 2022, the Company issued a balloon promissory note in the form of a mortgage on its headquarters to a third party company
in the principal amount of $<ix:nonFraction contextRef="c368" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-89590">4,800,000</ix:nonFraction>, which carries interest of <ix:nonFraction contextRef="c369" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" scale="-2" unitRef="pure" id="ixv-89591">11.0</ix:nonFraction>% per annum. Interest is due in monthly payments of $<ix:nonFraction contextRef="c370" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="0" unitRef="usd" id="ixv-89592">44,000</ix:nonFraction> beginning
November 1, 2022 and payable monthly thereafter until September 1, 2025 when the principal outstanding and all remaining interest is due.
The principal of $<ix:nonFraction contextRef="c371" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-89593">4,800,000</ix:nonFraction> can be extended for an additional 36 months, provided that the Company has not defaulted. The Company may
not prepay the principal of $<span style="-sec-ix-hidden: hidden-fact-338">4,800,00</span> for a period of 12 months. The principal of $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecuredDebt" scale="0" unitRef="usd" id="ixv-89594">4,800,000</ix:nonFraction> is secured by a first mortgage on the Company&#8217;s
real property located in Township of Freehold, County of Monmouth, State of New Jersey, having a street address of 4400 Route 9 South,
Freehold, NJ 07728.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 334 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 12 -&#160;<span style="text-decoration:underline">NOTE PAYABLE, NET
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In May 2023, the Company
borrowed $<ix:nonFraction contextRef="c372" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="0" unitRef="usd" id="ixv-89595">1,000,000</ix:nonFraction> from the same lender. The principal of $<ix:nonFraction contextRef="c373" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd" id="ixv-89596">1,000,000</ix:nonFraction> accrues interest at an annual rate of <ix:nonFraction contextRef="c373" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-89597">13.0</ix:nonFraction>% and is payable in monthly
installments of interest-only in the amount of $<ix:nonFraction contextRef="c373" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="0" unitRef="usd" id="ixv-89598">10,833</ix:nonFraction>, commencing in June 2023 and continuing through October 2025 (at which point any
unpaid balance of principal, interest and other charges are due and payable). The loan is secured by a second-lien mortgage on certain
real property and improvements located at 4400 Route 9, Freehold, Monmouth County, New Jersey.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:ScheduleOfDebtTableTextBlock" id="ixv-61337"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">The
note payable as of December 31, 2024 and 2023 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Principal amount</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-89599">5,800,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-89600">5,800,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: unamortized debt issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="0" unitRef="usd" id="ixv-89601">84,553</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="0" unitRef="usd" id="ixv-89602">203,781</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Note payable, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-89603">5,715,447</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-89604">5,596,219</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current portion</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd" id="ixv-89605">5,715,447</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-336">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Noncurrent portion</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-337">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermNotesPayable" scale="0" unitRef="usd" id="ixv-89606">5,596,219</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For the years ended December
31, 2024 and 2023, amortization of debt issuance costs related to note payable amounted to $<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd" id="ixv-89607">119,228</ix:nonFraction> and $<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd" id="ixv-89608">106,557</ix:nonFraction>, respectively, which
have been included in interest expense - amortization of debt discount and debt issuance costs on the accompanying consolidated
statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For the years ended December
31, 2024 and 2023, interest expense related to note payable amounted to $<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseShortTermBorrowings" scale="0" unitRef="usd" id="ixv-89609">658,000</ix:nonFraction> and $<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseShortTermBorrowings" scale="0" unitRef="usd" id="ixv-89610">606,722</ix:nonFraction>, respectively, which have been included
in interest expense - other on the accompanying consolidated statements of operations and comprehensive loss.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:nonNumeric contextRef="c18" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c18_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-61409"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 13 -&#160;<span style="text-decoration:underline">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Rental
Revenue from Related Party and Rent Receivable - Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company leases space of its commercial real
property located in New Jersey to D.P. Capital Investments LLC, which is controlled by Wenzhao Lu, the Company&#8217;s chairman of the
Board of Directors. The term of the related party lease agreement is five years commencing on May 1, 2021 and will expire on April 30,
2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">For both
the years ended December 31, 2024 and 2023, the related party rental revenue amounted to $<ix:nonFraction contextRef="c374" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RentalIncomeNonoperating" scale="0" unitRef="usd" id="ixv-89611"><ix:nonFraction contextRef="c375" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RentalIncomeNonoperating" scale="0" unitRef="usd" id="ixv-89612">50,400</ix:nonFraction></ix:nonFraction> and has been included in real property
rental revenue on the accompanying consolidated statements of operations and comprehensive loss. At December 31, 2024 and 2023, the related
party rent receivable totaled $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="0" unitRef="usd" id="ixv-89613">0</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="0" unitRef="usd" id="ixv-89614">124,500</ix:nonFraction>, respectively, which has been included in rent receivable on the accompanying consolidated
balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Services
Provided by Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, Wilbert Tauzin, a director
of the Company, and his son provide consulting services to the Company. As compensation for professional services provided, the Company
recognized consulting expenses of $<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralExpense" scale="0" unitRef="usd" id="ixv-89615">63,644</ix:nonFraction> and $<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralExpense" scale="0" unitRef="usd" id="ixv-89616">86,528</ix:nonFraction> for the years ended December 31, 2024 and 2023, respectively, which have been included
in professional fees on the accompanying consolidated statements of operations and comprehensive loss. As of both December 31, 2024 and
2023, the accrued and unpaid services charge related to this director&#8217;s son amounted to $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="avco:AccruedAndUnpaidServicesCharge" scale="0" unitRef="usd" id="ixv-89617"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="avco:AccruedAndUnpaidServicesCharge" scale="0" unitRef="usd" id="ixv-89618">15,000</ix:nonFraction></ix:nonFraction>, which have been included in accrued
professional fees on the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Accrued Liabilities and Other Payables -
Related Parties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b>&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2017, the Company acquired Beijing Genexosome
for a cash payment of $<ix:nonFraction contextRef="c376" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-89619">450,000</ix:nonFraction>. As of both December 31, 2024 and 2023, the unpaid acquisition consideration of $<ix:nonFraction contextRef="c377" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" unitRef="usd" id="ixv-89620"><ix:nonFraction contextRef="c378" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" unitRef="usd" id="ixv-89621">100,000</ix:nonFraction></ix:nonFraction>, was payable to
Dr. Yu Zhou, former director and former co-chief executive officer and <ix:nonFraction contextRef="c379" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-89622">40</ix:nonFraction>% owner of Genexosome, and has been included in accrued liabilities
and other payables - related parties on the accompanying consolidated balance sheets.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 335 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 13 -&#160;<span style="text-decoration:underline">RELATED PARTY TRANSACTIONS
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Accrued Liabilities and Other Payables -
Related Parties (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, Lab Services MSO paid shared
expense on behalf of the Company. In addition, Lab Services MSO made a payment of $<ix:nonFraction contextRef="c380" decimals="0" format="ixt:num-dot-decimal" name="avco:EquityMethodInvestmentPayableCurrent" scale="0" unitRef="usd" id="ixv-89623">566,667</ix:nonFraction> for equity method investment payable on behalf
of the Company in the year ended December 31, 2024. As of December 31, 2024 and 2023, the balance due to Lab Services MSO amounted to
$<ix:nonFraction contextRef="c380" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="0" unitRef="usd" id="ixv-89624">632,916</ix:nonFraction> and $<ix:nonFraction contextRef="c381" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="0" unitRef="usd" id="ixv-89625">72,746</ix:nonFraction>, respectively, which has been included in accrued liabilities and other payables - related parties on the accompanying
consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024 and 2023, $<ix:nonFraction contextRef="c382" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="0" unitRef="usd" id="ixv-89626">0</ix:nonFraction> and $<ix:nonFraction contextRef="c383" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="0" unitRef="usd" id="ixv-89627">33,712</ix:nonFraction>
of accrued and unpaid interest related to borrowings from Wenzhao Lu, the Company&#8217;s chairman of the Board of Directors, respectively,
have been included in accrued liabilities and other payables - related parties on the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Borrowings from Related Party</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Line of Credit </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 29, 2019, the Company entered into a
Line of Credit Agreement (the &#8220;Line of Credit Agreement&#8221;) providing the Company with a $<ix:nonFraction contextRef="c384" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="6" unitRef="usd" id="ixv-89628">20</ix:nonFraction> million line of credit (the &#8220;Line
of Credit&#8221;) from Mr. Lu, the Company&#8217;s chairman of the Board of Directors. The Line of Credit allowed the Company to request
loans thereunder and to use the proceeds of such loans for working capital and operating expense purposes until the facility matured on
<ix:nonNumeric contextRef="c384" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-89629">December 31, 2024</ix:nonNumeric>. The loans are unsecured and are not convertible into equity of the Company. Loans drawn under the Line of Credit bear
interest at an annual rate of <ix:nonFraction contextRef="c384" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-89630">5</ix:nonFraction>% and each individual loan is payable three years from the date of issuance. The Company has a right to
draw down on the line of credit and not at the discretion of Mr. Lu, the related party lender. The Company may, at its option, prepay
any borrowings under the Line of Credit, in whole or in part at any time prior to maturity, without premium or penalty. The Line of Credit
Agreement includes customary events of default. If any such event of default occurs, Mr. Lu may declare all outstanding loans under the
Line of Credit to be due and payable immediately.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="ixv-61483"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the years ended December 31, 2024 and 2023,
activity recorded for the Line of Credit is summarized in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Outstanding principal under the Line of Credit at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-339">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Draw down from Line of Credit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:DrawDownFromLineOfCredit" scale="0" unitRef="usd" id="ixv-89631">850,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding principal under the Line of Credit at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" scale="0" unitRef="usd" id="ixv-89632">850,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Repayment of Line of Credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="0" unitRef="usd" id="ixv-89633">400,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Reclassification of Line of Credit to advance from related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:ReclassificationOfLineOfCreditToAdvanceFromRelatedParty" scale="0" sign="-" unitRef="usd" id="ixv-89634">450,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Outstanding principal under the Line of Credit at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2024 and 2023,
the interest expense related to related party borrowing amounted to $<ix:nonFraction contextRef="c374" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-89635">42,445</ix:nonFraction> and $<ix:nonFraction contextRef="c375" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-89636">33,712</ix:nonFraction>, respectively, and has been reflected as interest
expense - related party on the accompanying consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024 and 2023, the related
accrued and unpaid interest for Line of Credit was $<ix:nonFraction contextRef="c385" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityIncreaseAccruedInterest" scale="0" unitRef="usd" id="ixv-89637">0</ix:nonFraction> and $<ix:nonFraction contextRef="c386" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityIncreaseAccruedInterest" scale="0" unitRef="usd" id="ixv-89638">33,712</ix:nonFraction>, respectively, and has been included in accrued liabilities and other
payables - related parties on the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Membership Interest
Purchase Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On November 17, 2023,
the Company entered into a Membership Interest Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Mr. Lu, the Company&#8217;s
chairman of the Board of Directors, pursuant to which (i) Mr. Lu will acquire from the Company <ix:nonFraction contextRef="c387" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" unitRef="pure" id="ixv-89639">30</ix:nonFraction>% of the total outstanding membership
interests of Avalon RT 9, a wholly owned subsidiary of the Company, for a cash purchase price of $<ix:nonFraction contextRef="c388" decimals="0" format="ixt:num-dot-decimal" name="avco:PurchasePrice" scale="0" unitRef="usd" id="ixv-89640">3,000,000</ix:nonFraction> (the &#8220;Acquisition&#8221;),
and (ii) for a period of twelve months following the closing of the Acquisition, Mr. Lu shall have the option to purchase from the Company
up to an additional <ix:nonFraction contextRef="c389" decimals="2" format="ixt:num-dot-decimal" name="avco:BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage" scale="-2" unitRef="pure" id="ixv-89641">70</ix:nonFraction>% of the outstanding membership interests of Avalon RT 9 for a purchase price of up to $<ix:nonFraction contextRef="c390" decimals="0" format="ixt:num-dot-decimal" name="avco:PurchasePrice" scale="0" unitRef="usd" id="ixv-89642">7,000,000</ix:nonFraction> (the &#8220;Option&#8221;),
subject to the terms and conditions of a membership interest purchase agreement to be negotiated and entered into between the Purchaser
and the Company at such time that the Purchaser desires to exercise the Option. The Company received $<ix:nonFraction contextRef="c382" decimals="0" format="ixt:num-dot-decimal" name="avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" scale="0" unitRef="usd" id="ixv-89643">3,108,106</ix:nonFraction> and $<ix:nonFraction contextRef="c383" decimals="0" format="ixt:num-dot-decimal" name="avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" scale="0" unitRef="usd" id="ixv-89644">485,714</ix:nonFraction> from Wenzhao
Lu as of December 31, 2024 and 2023, respectively, which was recorded as advance from pending sale of noncontrolling interest -
related party on the accompanying consolidated balance sheets. The Acquisition is expected to be closed in the fourth quarter of 2025.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 336 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:nonNumeric contextRef="c18" continuedAt="_IncomeTaxDisclosureTextBlock-c18_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-61556"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 14 -&#160;<span style="text-decoration:underline">INCOME
TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
is governed by the Income Tax Law of the PRC and the U.S. Internal Revenue Code of 1986, as amended. Under the Income Tax Laws of PRC,
Chinese companies are generally subject to an income tax at an effective rate of <ix:nonFraction contextRef="c18" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" scale="-2" unitRef="pure" id="ixv-89645">25</ix:nonFraction>% on income reported in the statutory financial statements
after appropriate tax adjustments. The Company has a cumulative deficit from its foreign subsidiary of $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="0" unitRef="usd" id="ixv-89646">3,399,273</ix:nonFraction> as of December 31, 2024,
which is included in the consolidated accumulated deficit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="ixv-61564"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company&#8217;s
loss before income taxes includes the following components:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">United States loss before income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="0" unitRef="usd" id="ixv-89647">7,639,148</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="0" unitRef="usd" id="ixv-89648">15,928,780</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">China loss before income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="0" unitRef="usd" id="ixv-89649">264,246</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="0" unitRef="usd" id="ixv-89650">778,230</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0.125in; text-align: left">Total loss before income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd" id="ixv-89651">7,903,394</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd" id="ixv-89652">16,707,010</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="ixv-61613"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Components of income taxes expense (benefit) consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">U.S. federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-340">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-341">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">U.S. state and local</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-342">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-343">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">China</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-344">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-345">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left">Total current income taxes expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-346">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-347">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">U.S. federal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-89653">4,874</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-89654">3,256,007</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">U.S. state and local</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-89655">1,650</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-89656">1,102,392</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">China</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-89657">93,437</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-89658">183,443</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Total deferred income taxes (benefit)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-89659">86,913</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd" id="ixv-89660">4,541,842</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" unitRef="usd" id="ixv-89661">86,913</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" sign="-" unitRef="usd" id="ixv-89662">4,541,842</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Total income taxes expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-348">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-349">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-61760"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below summarizes the differences between
the U.S. statutory rate and the Company&#8217;s effective tax rate for the years ended December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">U.S. federal rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c18" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-89663">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c19" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-89664">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">U.S. state rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" unitRef="pure" id="ixv-89665">6.4</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" unitRef="pure" id="ixv-89666">6.7</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent difference</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" scale="-2" sign="-" unitRef="pure" id="ixv-89667">1.3</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" scale="-2" sign="-" unitRef="pure" id="ixv-89668">0.1</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-US rate differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" unitRef="pure" id="ixv-89669">0.1</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" unitRef="pure" id="ixv-89670">0.2</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">True ups</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" scale="-2" sign="-" unitRef="pure" id="ixv-89671">27.3</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" scale="-2" sign="-" unitRef="pure" id="ixv-89672">0.6</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">U.S. valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c18" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" unitRef="pure" id="ixv-89673">1.1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c19" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitRef="pure" id="ixv-89674">27.2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-89675">0.0</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-89676">0.0</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2024 and 2023,
the Company did not incur any income taxes expense since it did not generate any taxable income in those periods. The Company&#8217;s
foreign entity did not pay any income taxes during the years ended December 31, 2024 and 2023.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 337 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 14 -&#160;<span style="text-decoration:underline">INCOME TAXES (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c18_cont_1"><ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-61879"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s components of deferred taxes
as of December 31, 2024 and 2023 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,<br/>
 2024</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>
2023</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Stock-based compensation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" unitRef="usd" id="ixv-89677">1,598,257</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" unitRef="usd" id="ixv-89678">3,501,507</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Disallowed business interest deduction</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-350">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetInterestCarryforward" scale="0" unitRef="usd" id="ixv-89679">9,476</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Research and development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="0" unitRef="usd" id="ixv-89680">106,783</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="0" unitRef="usd" id="ixv-89681">130,823</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Accrued directors&#8217; compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="0" unitRef="usd" id="ixv-89682">104,977</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="0" unitRef="usd" id="ixv-89683">165,490</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Accrued settlement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="0" unitRef="usd" id="ixv-89684">140,904</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="0" unitRef="usd" id="ixv-89685">126,496</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Partnership Investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="avco:DeferredTaxAssetsPartnershipInvestment" scale="0" unitRef="usd" id="ixv-89686">2,167,965</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="avco:DeferredTaxAssetsPartnershipInvestment" scale="0" unitRef="usd" id="ixv-89687">2,422,744</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" unitRef="usd" id="ixv-89688">1,687</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" unitRef="usd" id="ixv-89689">20,935</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Capital loss limitation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="0" unitRef="usd" id="ixv-89690">149,394</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="0" unitRef="usd" id="ixv-89691">149,394</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net operating loss carryforward</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-89692">17,648,077</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-89693">15,493,570</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left">Total deferred tax assets, gross</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd" id="ixv-89694">21,918,044</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" unitRef="usd" id="ixv-89695">22,020,435</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-89696">21,784,638</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-89697">21,871,551</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total deferred tax assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" unitRef="usd" id="ixv-89698">133,406</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" unitRef="usd" id="ixv-89699">148,884</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Fixed assets and intangible assets book/tax basis difference</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesOtherFiniteLivedAssets" scale="0" unitRef="usd" id="ixv-89700">133,406</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesOtherFiniteLivedAssets" scale="0" unitRef="usd" id="ixv-89701">129,636</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-351">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesRegulatoryAssets" scale="0" unitRef="usd" id="ixv-89702">19,248</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilities" scale="0" unitRef="usd" id="ixv-89703">133,406</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilities" scale="0" unitRef="usd" id="ixv-89704">148,884</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-352">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-353">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As of December
31, 2024 and 2023, the Company&#8217;s both federal and state net operating loss carryforwards amounted to $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-89705">60,926,204</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-89706">52,929,248</ix:nonFraction>,
respectively. As of December 31, 2024, the Company has $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="0" unitRef="usd" id="ixv-89707">58,438,649</ix:nonFraction> of U.S. federal net operating loss carryovers that have no expiration
date, and $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="0" unitRef="usd" id="ixv-89708">2,487,555</ix:nonFraction> of the federal net operating loss and state net operating loss carry-forwards begin to expire in 2034.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024, the Company had net operating
loss carryforwards in China of $<ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="0" unitRef="usd" id="ixv-89709">2,086,886</ix:nonFraction>&#160;that begin to expire in 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Additionally,
as of December 31, 2024, $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="0" unitRef="usd" id="ixv-89710">61,847</ix:nonFraction> of the future utilization of the net operating loss carryforward to offset future taxable income is subject
to special tax rules which may limit their usage under IRS Section 382 (Change of Ownership) and possibly the Separate Return Limitation
Year (&#8220;SRLY&#8221;) rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A full valuation allowance has been provided against
the Company&#8217;s deferred tax assets at December 31, 2024 as the Company believes it is more likely than not that sufficient taxable
income will not be generated to realize these temporary differences.<span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
has been notified and assessed an IRS Section 6038 penalty of <ix:nonNumeric contextRef="c18" name="us-gaap:DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries" id="ixv-89711">$10,000</ix:nonNumeric> for failure to file a foreign entity tax disclosure. The Company
has appealed the penalty and awaits the Internal Revenue Service&#8217;s review of the appeal. There is no assurance such appeal will
be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
has not been audited by any jurisdiction since its inception. The Company is open for audit by the U.S. Internal Revenue Service and U.S.
state tax jurisdictions from 2021 to 2024, and open for audit by the Chinese Ministry of Finance from 2020 to 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">There were
no material uncertain tax positions as of December 31, 2024 and 2023. The Company recognizes interest and penalties related to unrecognized
tax benefits as income tax expense, if any. The Company does not have any significant uncertain tax positions or events leading to uncertainty
in a tax position.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 338 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c18" continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_1" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="ixv-62118"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 15 -&#160;<span style="text-decoration:underline">EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company is authorized
to issue an aggregate of&#160;<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-89712">100,000,000</ix:nonFraction>&#160;shares of common stock and&#160;<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-89713">10,000,000</ix:nonFraction>&#160;shares of &#8220;blank check&#8221; preferred
stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Series A Convertible
Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company designated
up to <ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-89714">15,000</ix:nonFraction> shares of its previously undesignated preferred stock as Series A Preferred Stock. Each share of Series A Preferred Stock
has a par value of $<ix:nonFraction contextRef="c61" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-89715">0.0001</ix:nonFraction> per share and a stated value equal to $<ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-89716">1,000</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The shares of Series
A Preferred Stock have identical terms and include the terms as set forth below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dividends.</i>&#160;The Series A Holders are
entitled to receive, and the Company shall pay, dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-common-stock
basis, disregarding for such purpose any conversion limitations set forth in the Series A Certificate of Designations) to and in the same
form as dividends actually paid on shares of the Company&#8217;s common stock when, as and if such dividends are paid on shares of the
common stock. No other dividends shall be paid on shares of Series A Preferred Stock. The Company will not pay any dividends on its common
stock unless the Company simultaneously complies with the terms set forth in the Series A Certificate of Designation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Liquidation.</i>&#160;Upon any dissolution,
liquidation or winding-up of the Company, whether voluntary or involuntary (a &#8220;Liquidation&#8221;), the Series A Holders will be
entitled to receive out of the assets available for distribution to the stockholders, (i) after and subject to the payment in full of
all amounts required to be distributed to the holders of another class or series of stock of the Company ranking on liquidation prior
and in preference to the Series A Preferred Stock, (ii) ratably with any class or series of stock ranking on liquidation on parity with
the Series A Preferred Stock and (iii) in preference and priority to the holders of the shares of the Company&#8217;s common stock, an
amount equal to <ix:nonFraction contextRef="c391" decimals="2" format="ixt:num-dot-decimal" name="avco:PercentageOfCommonStockIssuedAndOutstanding" scale="-2" unitRef="pure" id="ixv-89717">100</ix:nonFraction>% of the Series A Stated Value, and no more, in proportion to the full and preferential amount that all shares of the
Series A Preferred Stock are entitled to receive. The Company shall mail written notice of any Liquidation not less than twenty (20) days
prior to the payment date stated therein, to each Series A Holder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Conversion.</i>&#160;Each share of Series A
Preferred Stock shall be convertible, at any time and from time to time from and after the later of (i) the date of the stockholder approval
as described above, in accordance with the Nasdaq Stock Market Listing Rules, and (ii) the&#160;nine&#160;(9) month anniversary of the
Closing (the &#8220;Initial Conversion Date&#8221;), at the option of the Series A Holder, into that number of shares of common stock
(subject to the limitations set forth in Series A Certificate of Designations, determined by dividing the Stated Value of such share of
Series A Preferred Stock by the Conversion Price (as defined below)). The Series A Holders may effect conversions by providing the Company
with the form of conversion notice attached as Annex A to the Series A Certificate of Designation. The Series A Holders may convert such
shares into shares of the Company&#8217;s common stock at a conversion price per share equal to the greater of (i) one hundred fifty dollars
($<ix:nonFraction contextRef="c5" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-89718">150.0</ix:nonFraction>) and (ii) ninety percent (<ix:nonFraction contextRef="c391" decimals="2" format="ixt:num-dot-decimal" name="avco:ConversionPricePercentage" scale="-2" sign="-" unitRef="pure" id="ixv-89719">90</ix:nonFraction>%) of the closing price of the Company&#8217;s common stock on Nasdaq on the day prior to receipt
of a conversion notice (collectively, the &#8220;Conversion Price&#8221;), subject to adjustment for stock splits and similar matters.
In addition, following the Initial Conversion Date, each Series A Holder agrees that it shall not be entitled to in any calendar month,
sell a number of Series A Conversion Shares into the open market in an amount exceeding more than ten percent (<ix:nonFraction contextRef="c392" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentRate" scale="-2" unitRef="pure" id="ixv-89720">10</ix:nonFraction>%) of the number of Series
A Conversion Shares issuable upon conversion of the Series A Preferred Stock then held by such Series A Holder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Conversion Price Adjustment:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stock Dividends and Stock Splits.</i>&#160;If
the Company, at any time while the Series A Preferred Stock is outstanding: (i) pays a stock dividend or otherwise makes a distribution
or distributions payable in shares of common stock on shares of common stock or any other common stock equivalents (which, for avoidance
of doubt, shall not include any shares of common stock issued by the Company upon conversion of, or payment of a dividend on, the Series
A Preferred Stock), (ii) subdivides outstanding shares of common stock into a larger number of shares, (iii) combines (including by way
of a reverse stock split) outstanding shares of common stock into a smaller number of shares, or (iv) issues, in the event of a reclassification
of shares of the common stock, any shares of capital stock of the Company, then the conversion price of the Series A Preferred Stock shall
be multiplied by a fraction of which the numerator shall be the number of shares of common stock (excluding any treasury shares of the
Company) outstanding immediately before such event, and of which the denominator shall be the number of shares of common stock outstanding
immediately after such event. Any of the foregoing adjustments shall become effective immediately after the record date for the determination
of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the
case of a subdivision, combination or re-classification.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 339 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 15 -&#160;<span style="text-decoration:underline">EQUITY
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Series A Convertible
Preferred Stock (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Conversion Price Adjustment: (continued)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_2" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fundamental Transaction.</i>&#160;If, at any
time while the Series A Preferred Stock is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another individual or corporation, partnership, trust, incorporated or unincorporated
association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other
entity of any kind (a &#8220;Person&#8221;), (ii) the Company (and all of its subsidiaries, taken as a whole), directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company
or another Person) is completed pursuant to which holders of the Company&#8217;s common stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of fifty percent (<ix:nonFraction contextRef="c18" decimals="2" format="ixt:num-dot-decimal" name="avco:PercentageOfCommonStockIssuedAndOutstanding" scale="-2" sign="-" unitRef="pure" id="ixv-89721">50</ix:nonFraction>%) or more of the outstanding
common stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the common stock or any compulsory share exchange pursuant to which the common stock is effectively converted into
or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates
a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than fifty percent (<ix:nonFraction contextRef="c55" decimals="2" format="ixt:num-dot-decimal" name="avco:PercentageOfCommonStockIssuedAndOutstanding" scale="-2" sign="-" unitRef="pure" id="ixv-89722">50</ix:nonFraction>%) of the outstanding
shares of common stock (not including any shares of common stock held by the other Person or other Persons making or party to, or associated
or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a
&#8220;Fundamental Transaction&#8221;), then, the Series A Holder shall have the right to receive, for each conversion share that would
have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation
set forth in the Series A Certificate of Designation on the conversion of the Series A Preferred Stock), the number of shares of common
stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and/or any additional consideration
(the &#8220;Alternate Consideration&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares
of common stock for which the Series A Preferred Stock is convertible immediately prior to such Fundamental Transaction (without regard
to the limitations set forth in the Series A Certificate of Designation on the conversion of the Series A Preferred Stock). For purposes
of any such conversion, the determination of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of <ix:nonFraction contextRef="c55" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares" id="ixv-89723">one</ix:nonFraction> share of common stock in such Fundamental Transaction, and the
Company shall apportion the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of
any different components of the Alternate Consideration. If holders of common stock are given any choice as to the securities, cash or
property to be received in a Fundamental Transaction, then the Series A Holder shall be given the same choice as to the Alternate Consideration
it receives upon such Fundamental Transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Voting Rights.</i>&#160;The Series A Holders
will have no voting rights, except as otherwise required by the Delaware General Corporation Law. Notwithstanding the foregoing, as long
as any shares of Series A Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority
of the then outstanding shares of Series A Preferred Stock, voting as a separate class, (a) alter or change adversely the powers, preferences
or rights given to the Series A Preferred Stock in the Series A Certificate of Designation, (b) increase the number of authorized shares
of Series A Preferred Stock, (c) authorize or issue an additional class or series of capital stock that ranks senior to the Series A Preferred
Stock with respect to the distribution of assets on liquidation or (d) enter into any agreement with respect to any of the foregoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Fractional Shares.</i>&#160;No
fractional shares or scrip representing fractional shares shall be issued upon the conversion of the Series A Preferred Stock. As to any
fraction of a share of Company common stock which a Series A Holder would otherwise be entitled to upon such conversion, the Company will,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Conversion Price or round up to the next whole share. Notwithstanding the foregoing, nothing shall prevent any Series A Holder from converting
fractional shares of Series A Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As of December 31, 2024
and 2023, <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-89724"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-89725"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-89726"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-89727">9,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of Series A Preferred Stock were issued and outstanding. On January 9, 2025, the <ix:nonFraction contextRef="c393" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-89728">9,000</ix:nonFraction> shares of Series A Preferred
Stock were exchanged for <ix:nonFraction contextRef="c394" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-89729">5,000</ix:nonFraction> shares of Series D Preferred Stock of the Company (see Note 22 - Subsequent Events - Series D Convertible
Preferred Stock).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Series B Convertible
Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company designated
up to <ix:nonFraction contextRef="c395" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-89730">15,000</ix:nonFraction> shares of its previously undesignated preferred stock as Series B Preferred Stock. Each share of Series B Preferred Stock
has a par value of $<ix:nonFraction contextRef="c396" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-89731">0.0001</ix:nonFraction> per share and a stated value equal to $<ix:nonFraction contextRef="c396" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-89732">1,000</ix:nonFraction>.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 340 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 15 -&#160;<span style="text-decoration:underline">EQUITY
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Series B Convertible
Preferred Stock (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_3" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The shares of Series
B Preferred Stock have identical terms and include the terms as set forth below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dividends.</i>&#160;The Series B Holders shall
be entitled to receive, and the Company shall pay, dividends on shares of Series B Preferred Stock equal (on an as-if-converted-to-common-stock
basis, disregarding for such purpose any conversion limitations set forth in the Series B Certificate of Designations) to and in the same
form as dividends actually paid on shares of the Company&#8217;s common stock when, as and if such dividends are paid on shares of the
common stock. No other dividends shall be paid on shares of Series B Preferred Stock. The Company will not pay any dividends on its common
stock unless the Company simultaneously complies with the terms set forth in the Series B Certificate of Designation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Rank.</i>&#160;The Series B Preferred Stock
will rank subordinate to the shares of the Company&#8217;s Series A Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Liquidation.&#160;</i>Upon any Liquidation,
the Series B Holders will be entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to
the payment in full of all amounts required to be distributed to the holders of another class or series of stock of the Company ranking
on liquidation prior and in preference to the Series B Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any
class or series of stock ranking on liquidation on parity with the Series B Preferred Stock and (iii) in preference and priority to the
holders of the shares of common stock, an amount equal to one hundred percent (<ix:nonFraction contextRef="c397" decimals="2" format="ixt:num-dot-decimal" name="avco:PercentageOfCommonStockIssuedAndOutstanding" scale="-2" sign="-" unitRef="pure" id="ixv-89733">100</ix:nonFraction>%) of the Series B Stated Value and no more, in proportion
to the full and preferential amount that all shares of the Series B Preferred Stock are entitled to receive. The Company shall mail written
notice of any such Liquidation not less than twenty (20) days prior to the payment date stated therein, to each Series B Holder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Conversion.</i>&#160;Each share of Series B
Preferred Stock shall be convertible, at any time and from time to time from and after the later of (i) the date of the stockholder approval
and (ii) the one year anniversary of the Closing Date (the &#8220;Lock Up Period&#8221;), at the option of the Series B Holder thereof,
into that number of shares of common stock (subject to the limitations set forth in Series B Certificate of Designation determined by
dividing the Series B Stated Value of such share of Series B Preferred Stock by the conversion price of the Series B Preferred Stock).
Series B Holders may effect conversions by providing the Company with the form of conversion notice attached as Annex A to the Series
B Certificate of Designation. The Series B Preferred Stock will be convertible into shares of the Company&#8217;s common stock at a conversion
price per share equal to $<ix:nonFraction contextRef="c397" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceIncrease" scale="0" unitRef="usdPershares" id="ixv-89734">56.70</ix:nonFraction>, subject to the adjustments set forth in the Series B Certificate of Designation. Notwithstanding the
foregoing or the transactions contemplated by the Amended MIPA, until the consummation of the Lock Up Period, the Series B Holders shall
not, directly or indirectly, sell, transfer or otherwise dispose of any Series B Preferred Stock issued upon conversion of the Series
B Conversion Shares or pursuant to the Equity Earnout Payment (the &#8220;Restricted Securities&#8221;) without Company&#8217;s prior
written consent; provided, however, the Series B Holders may sell, transfer or otherwise dispose of Restricted Securities to an Affiliate,
as defined in the Amended MIPA, of a Series B Holder without Company&#8217;s prior written consent; provided, further, that such Series
B Holder provide prompt written notice to Company of such transfer, including the name and contact information of the Affiliate transferee,
and such Affiliate transferee agrees in writing to be bound by the terms of the transaction documents contemplated by the Amended MIPA
to which the Series B Holder is a party (which agreement shall also be provided to Company with such notice). After the expiration of
the Lock Up Period, the Series B Holder agrees that it and any of its Affiliate transferees shall not be entitled to in any calendar month,
sell a number of shares of Company common stock into the open market in an amount exceeding more than ten percent (10%) of the total number
of shares of Company common stock issuable upon conversion of the Company common stock then held by the Seller and its Affiliates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Conversion Price Adjustment:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stock Dividends and Stock Splits.</i>&#160;If
the Company, at any time while the Series B Preferred Stock is outstanding: (i) pays a stock dividend or otherwise makes a distribution
or distributions payable in shares of common stock on shares of common stock or any other common stock equivalents (which, for avoidance
of doubt, shall not include any shares of common stock issued by the Company upon conversion of, or payment of a dividend on, the Series
B Preferred Stock), (ii) subdivides outstanding shares of common stock into a larger number of shares, (iii) combines (including by way
of a reverse stock split) outstanding shares of common stock into a smaller number of shares, or (iv) issues, in the event of a reclassification
of shares of the common stock, any shares of capital stock of the Company, then the conversion price of the Series B Preferred Stock shall
be multiplied by a fraction of which the numerator shall be the number of shares of common stock (excluding any treasury shares of the
Company) outstanding immediately before such event, and of which the denominator shall be the number of shares of common stock outstanding
immediately after such event. Any of the foregoing adjustments shall become effective immediately after the record date for the determination
of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the
case of a subdivision, combination or re-classification.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 341 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 15 -&#160;<span style="text-decoration:underline">EQUITY
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Series B Convertible
Preferred Stock (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Conversion Price
Adjustment: (continued)</i>

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_4" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fundamental Transaction.</i>&#160;If, at any
time while the Series B Preferred Stock is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another Person, (ii) the Company (and all of its subsidiaries, taken as a whole),
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of the Company&#8217;s common stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of fifty percent
(<ix:nonFraction contextRef="c398" decimals="2" format="ixt:num-dot-decimal" name="avco:PercentageOfCommonStockIssuedAndOutstanding" scale="-2" sign="-" unitRef="pure" id="ixv-89735">50</ix:nonFraction>%) or more of the outstanding common stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any
reclassification, reorganization or recapitalization of the common stock or any compulsory share exchange pursuant to which the common
stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in
one or more related transactions consummates a Fundamental Transaction, then, at the closing of such Fundamental Transaction, without
any action on the part of the Series B Holder, the Series B Holder shall have the right to receive, for each conversion share that would
have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation
in the Series B Certificate of Designation on the conversion of the Series B Preferred Stock), the number of shares of common stock of
the successor or acquiring corporation or of the Company, if it is the surviving corporation, and/or any Alternate Consideration receivable
as a result of such Fundamental Transaction by a holder of the number of shares of common stock for which the Series B Preferred Stock
is convertible immediately prior to such Fundamental Transaction (without regard to the limitations set forth in the Series B Certificate
of Designation on the conversion of the Series B Preferred Stock). For purposes of any such conversion, the determination of the conversion
price of the Series B Preferred Stock shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of
Alternate Consideration issuable in respect of one share of common stock in such Fundamental Transaction, and the Company shall apportion
the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of common stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Series B Holder shall be given the same choice as to the Alternate Consideration it receives upon
such Fundamental Transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Voting Rights</i>. The Series B Holders will
have no voting rights, except as otherwise required by the Delaware General Corporation Law. Notwithstanding the foregoing, in addition,
as long as any shares of Series B Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders
of a majority of the then outstanding shares of the Series B Preferred Stock, voting as a separate class, (a) alter or change adversely
the powers, preferences or rights given to the Series B Preferred Stock in the Series B Certificate of Designation, (b) increase the number
of authorized shares of Series B Preferred Stock, (c) except with respect to the Series A Preferred Stock, authorize or issue an additional
class or series of capital stock that ranks senior to the Series B Preferred Stock with respect to the distribution of assets on liquidation
or (d) enter into any agreement with respect to any of the foregoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Fractional Shares.</i>
No fractional shares or scrip representing fractional shares shall be issued upon the conversion of the Series B Preferred Stock. As to
any fraction of a share which a Series B Holder would otherwise be entitled to upon such conversion, the Company shall at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price
or round up to the next whole share. Notwithstanding the foregoing, nothing shall prevent any Series B Holder from converting fractional
shares of Series B Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As of December 31, 2024
and 2023, <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-89736"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-89737"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-89738"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-89739">11,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of Series B Preferred Stock were issued and outstanding. On February 26, 2025, all shares of the Company&#8217;s
Series B Convertible Preferred Stock were permanently surrendered and relinquished to the Company for no additional consideration (see
Note 22 - Subsequent Events - Redemption Agreement).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Series C Convertible
Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On December 13, 2024,
the Company filed a certificate of designations of preferences, rights, and limitations of Series C Convertible Preferred Stock (the &#8220;Series
C Certificate of Designations&#8221;) with the Department of State, Division of Corporations, of the State of Delaware, which provides
for the designation of <ix:nonFraction contextRef="c399" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-89740">10,000</ix:nonFraction> shares of Series C Preferred Stock of the Company, par value $<ix:nonFraction contextRef="c399" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-89741">0.0001</ix:nonFraction> per share. Each share of Series C Preferred
Stock has a stated value of $<ix:nonFraction contextRef="c399" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-89742">1,000</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Series C Preferred
Stock shall rank (i) senior to the Company&#8217;s common stock (the &#8220;Common Stock&#8221;) and any other class or series of capital
stock of the Company created hereafter, the terms of which specifically provide that such class or series shall rank junior to the Series
C Preferred Stock, (ii) pari passu with any class or series of capital stock of the Company created hereafter specifically ranking, by
its terms, on par with the Series C Preferred Stock, (iii) pari passu with Series B Convertible Preferred Stock of the Company (the &#8220;Series
B Preferred Stock&#8221;) with respect to its rights, preferences and restrictions, and (iv) subordinate to the Series A Convertible Preferred
Stock of the Company (the &#8220;Series A Preferred Stock&#8221;).</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 342 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 15 -&#160;<span style="text-decoration:underline">EQUITY
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Series C Convertible
Preferred Stock (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_5" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Holders of the Series
C Preferred Stock shall be entitled to receive, and the Company shall pay, dividends on shares of Series C Preferred Stock equal (on an
as-if-converted-to-Common-Stock basis, disregarding for such purpose any conversion limitations hereunder) to and in the same form as
dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Holders of the Series
C Preferred Stock have no voting power except as otherwise required by the Delaware General Corporation Law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Upon any liquidation,
dissolution or winding-up of the Company, whether voluntary or involuntary (a &#8220;Liquidation&#8221;), the holders of the Series C
Preferred Stock shall be entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to the
payment in full of all amounts required to be distributed to the holders of another class or series of stock of the Company ranking on
liquidation prior and in preference to the Series C Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any class
or series of stock ranking on liquidation on parity with the Series C Preferred Stock and (iii) in preference and priority to the holders
of the shares of Common Stock, an amount equal to <ix:nonFraction contextRef="c400" decimals="2" format="ixt:num-dot-decimal" name="avco:PercentageOfCommonStockIssuedAndOutstanding" scale="-2" unitRef="pure" id="ixv-89743">100</ix:nonFraction>% of the Stated Value of the Series C Preferred Stock, in proportion to the full
and preferential amount that all shares of the Series C Preferred Stock are entitled to receive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Each share of Series
C Preferred Stock shall be convertible into Common Stock (the &#8220;Conversion Shares&#8221;) at a conversion per share equal to $<ix:nonFraction contextRef="c9" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-89744">2.41</ix:nonFraction>,
at the option of the holder, at any time after the later of (i) the date of the shareholder approval of the issuance of the Conversion
Shares pursuant to the rules of the Nasdaq Stock Market and (ii) the one year anniversary of the date of the first issuance of any shares
of the Series C Preferred Stock. In addition, the holder shall not have the right to convert any portion of the Series C Preferred Stock
if, after giving effect to the conversion, such holder (together with its affiliates) would beneficially own in excess of <ix:nonFraction contextRef="c401" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-89745">19.99</ix:nonFraction>% of the
number of shares of the Common Stock outstanding immediately after giving effect to the issuance of the respective Conversion Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As of December 31, 2024,
<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-89746"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-89747">3,500</ix:nonFraction></ix:nonFraction> shares of Series C Preferred Stock were issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Series B Convertible
Preferred Stock Issued for Equity Method Investment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 9, 2023, the Company issued <ix:nonFraction contextRef="c402" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-89748">11,000</ix:nonFraction> shares of its Series
B Convertible Preferred Stock as a part of consideration for the purchase of <ix:nonFraction contextRef="c403" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-89749">40</ix:nonFraction>% of equity interest of Lab Services MSO. The Series B
Preferred Stock is convertible into shares of the Company&#8217;s common stock at a conversion price per share equal to $<ix:nonFraction contextRef="c402" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-89750">56.70</ix:nonFraction>, which
approximated the market price at the date of closing, or an aggregate of <ix:nonFraction contextRef="c402" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-89751">194,004</ix:nonFraction> shares of the Company&#8217;s common stock and are subject
to a lock-up period and restrictions on sale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Series C Convertible
Preferred Stock Sold for Cash</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During the year ended December 31, 2024, the Company sold an aggregate
of <ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-89752">3,500</ix:nonFraction> shares of Series C Convertible Preferred stock and received proceeds of $<ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="0" unitRef="usd" id="ixv-89753">3,500,000</ix:nonFraction>. Each share of Series C Convertible Preferred
Stock is convertible into common stock of the Company (the &#8220;Conversion Shares&#8221;) at a conversion per share equal to $<ix:nonFraction contextRef="c63" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-89754">2.41</ix:nonFraction>,
which approximated the market price at the date of transaction, at the option of the holder, at any time after the later of (i) the date
of the shareholder approval of the issuance of the Conversion Shares pursuant to the rules of the Nasdaq Stock Market (the &#8220;Shareholder
Approval&#8221;) and (ii) the one year anniversary of the date of the first issuance of any shares of the Series C Convertible Preferred
Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company evaluated
the features of the Series C Convertible Preferred Stock under ASC 480, and classified them as permanent equity because the Series C Convertible
Preferred Stock is not mandatorily or contingently redeemable at the stockholder&#8217;s option and the liquidation preference that exists
does not fall within the guidance of SEC Accounting Series Release No. 268 -&#160;<i>Presentation in Financial Statements of &#8220;Redeemable
Preferred Stocks&#8221;</i>&#160;(&#8220;ASR 268&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Common Shares Issued
as Convertible Note Payable Commitment Fee</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During the year ended
December 31, 2023, the Company issued a total of <ix:nonFraction contextRef="c404" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-89755">11,333</ix:nonFraction> shares of its common stock as commitment fee for the purchases of May 2023 Convertible
Note, July 2023 Convertible Note, and October 2023 Convertible Note. These shares were valued at $<ix:nonFraction contextRef="c404" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-89756">236,400</ix:nonFraction>, the fair market values on the
grant dates using the reported closing share prices on the dates of grant, and the Company recorded it as debt discount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During the year ended
December 31, 2024, the Company issued a total of&#160;<ix:nonFraction contextRef="c405" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-89757">33,800</ix:nonFraction>&#160;shares of its common stock as commitment fee for the purchase of March
2024 Convertible Note and June 2024 Convertible Note. These shares were valued at $<ix:nonFraction contextRef="c405" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-89758">320,546</ix:nonFraction>, the fair market value on the grant dates using
the reported closing share prices on the dates of grant, and the Company recorded it as debt discount.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 343 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AVALON GLOBOCARE CORP.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 15 -&#160;<span style="text-decoration:underline">EQUITY
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_6" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Common Shares Sold
for Cash</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2023, the Company entered into a sales
agreement (the &#8220;Sales Agreement&#8221;) with Roth Capital Partners, LLC (&#8220;Roth&#8221;) under which the Company may offer and
sell from time to time shares of its common stock having an aggregate offering price of up to $<ix:nonFraction contextRef="c406" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" unitRef="usd" id="ixv-89759">3.5</ix:nonFraction>&#160;million. During the year ended
December 31, 2023, Roth sold an aggregate of&#160;<ix:nonFraction contextRef="c407" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-89760">30,442</ix:nonFraction>&#160;shares of common stock at an average price of $<ix:nonFraction contextRef="c407" decimals="2" format="ixt:num-dot-decimal" name="avco:CommonStockOfAveragePrice" scale="0" unitRef="usdPershares" id="ixv-89761">20.85</ix:nonFraction>&#160;per share to investors
and the Company recorded net proceeds of $<ix:nonFraction contextRef="c407" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromOtherEquity" scale="0" unitRef="usd" id="ixv-89762">414,396</ix:nonFraction>, net of commission and other offering costs of $<ix:nonFraction contextRef="c408" decimals="0" format="ixt:num-dot-decimal" name="avco:OfferingCost" scale="0" unitRef="usd" id="ixv-89763">220,995</ix:nonFraction>.&#160;During the year ended
December 31, 2024, Roth sold an aggregate of&#160;<ix:nonFraction contextRef="c409" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-89764">281,843</ix:nonFraction>&#160;shares of common stock at an average price of $<ix:nonFraction contextRef="c410" decimals="2" format="ixt:num-dot-decimal" name="avco:CommonStockOfAveragePrice" scale="0" unitRef="usdPershares" id="ixv-89765">10.14</ix:nonFraction>&#160;per share to
investors and the Company recorded net proceeds of $<ix:nonFraction contextRef="c410" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromOtherEquity" scale="0" unitRef="usd" id="ixv-89766">2,544,311</ix:nonFraction>, net of commission and other offering costs of $<ix:nonFraction contextRef="c411" decimals="0" format="ixt:num-dot-decimal" name="avco:OfferingCost" scale="0" unitRef="usd" id="ixv-89767">313,541</ix:nonFraction>.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Shares Issued for Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">During the
year ended December 31, 2023, the Company issued a total of <ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-89768">24,089</ix:nonFraction> shares of its common stock for services rendered. These shares were
valued at $<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="avco:FairMarketValuesOfGrantDates" scale="0" unitRef="usd" id="ixv-89769">999,655</ix:nonFraction>, the fair market values on the grant dates using the reported closing share prices on the dates of grant, and the Company
recorded stock-based compensation expense of $<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-89770">834,784</ix:nonFraction> for the year ended December 31, 2023 and reduced accrued liabilities of $<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" unitRef="usd" id="ixv-89771">164,871</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2024, the Company
issued a total of <ix:nonFraction contextRef="c412" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-89772">145,153</ix:nonFraction> shares of its common stock for services rendered. These shares were valued at $<ix:nonFraction contextRef="c412" decimals="0" format="ixt:num-dot-decimal" name="avco:FairMarketValuesOfGrantDates" scale="0" unitRef="usd" id="ixv-89773">530,350</ix:nonFraction>, the fair market values
on the grant dates using the reported closing share prices on the dates of grant, and the Company recorded stock-based compensation expense
of $<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-89774">470,350</ix:nonFraction> for the year ended December 31, 2024 and reduced accrued liabilities of $<ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" unitRef="usd" id="ixv-89775">60,000</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Common Shares Issued
for Warrant Exercise</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On November 18, 2024,
the Company issued <ix:nonFraction contextRef="c413" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-89776">42,381</ix:nonFraction> shares of its common stock upon cashless exercise of warrants to purchase <ix:nonFraction contextRef="c414" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89777">6,278</ix:nonFraction> shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Common Shares Issued
for Adjustment for 1:15 Reverse Split</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company issued <ix:nonFraction contextRef="c415" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-89778">206,033</ix:nonFraction>
shares of its common stock, resulting from the rounding up of the fractional shares at the one-for-fifteen reverse stock split effected
on October 28, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Pre-Funded Warrants
Issued for Debt Modification</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On December 15, 2024,
the Company issued to Mast Hill a common stock purchase warrant for the purchase of up to <ix:nonFraction contextRef="c416" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89779">150,000</ix:nonFraction> shares of the Company&#8217;s common
stock. The Pre-Funded Warrants are immediately exercisable at issuance and until the Pre-Funded Warrants are exercised in full and have
an exercise price of $<ix:nonFraction contextRef="c417" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89780">0.01</ix:nonFraction> per share. The Pre-Funded Warrants were classified as a component of permanent equity as they are freestanding
financial instrument that is immediately exercisable, does not embody an obligation for the Company to repurchase its own shares and permit
the holder to receive a fixed number of shares of common stock upon exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="ixv-62463"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table summarizes
the shares of the Company&#8217;s common stock issuable upon exercise of options outstanding at December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Options Outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Options Exercisable</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Range<br/> of Exercise <br/> Price</td> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number <br/>
Outstanding at<br/> December 31, <br/>
2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted Average</p> <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number Exercisable at<br/> December 31, <br/>
2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise <br/>Price</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right"><ix:nonFraction contextRef="c471" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" unitRef="usdPershares" id="ixv-89781">2.93</ix:nonFraction> - <ix:nonFraction contextRef="c471" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" unitRef="usdPershares" id="ixv-89782">31.20</ix:nonFraction></td> <td style="width: 1%">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction contextRef="c472" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-89783">20,198</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><ix:nonNumeric contextRef="c471" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-89784">3.54</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction contextRef="c472" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89785">14.76</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><ix:nonFraction contextRef="c472" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-89786">14,591</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction contextRef="c472" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-89787">16.38</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c473" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" unitRef="usdPershares" id="ixv-89788">48.75</ix:nonFraction> - <ix:nonFraction contextRef="c473" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" unitRef="usdPershares" id="ixv-89789">123.00</ix:nonFraction></td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c474" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-89790">20,517</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c473" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-89791">2.04</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c474" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89792">78.91</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c474" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-89793">20,517</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c474" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-89794">78.91</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c475" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" unitRef="usdPershares" id="ixv-89795">154.50</ix:nonFraction> - <ix:nonFraction contextRef="c475" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" unitRef="usdPershares" id="ixv-89796">289.50</ix:nonFraction></td> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c476" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-89797">11,764</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonNumeric contextRef="c475" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-89798">3.44</ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c476" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89799">218.21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c476" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-89800">11,764</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c476" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-89801">218.21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c477" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" unitRef="usdPershares" id="ixv-89802">2.93</ix:nonFraction> - <ix:nonFraction contextRef="c477" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" unitRef="usdPershares" id="ixv-89803">289.50</ix:nonFraction></td> <td>&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c478" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-89804">52,479</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c477" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-89805">2.93</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c478" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89806">85.45</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c478" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-89807">46,872</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c478" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-89808">94.41</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table></ix:nonNumeric></ix:continuation><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 344 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 15 -&#160;<span style="text-decoration:underline">EQUITY
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Options (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_7" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_6"><ix:nonNumeric contextRef="c18" continuedAt="_ScheduleOfShareBasedCompensationActivityTableTextBlock-c18_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="ixv-62634"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Stock option activity
for the years ended December 31, 2024 and 2023 was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Options</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c479" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-89809">53,357</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c479" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89810">195.45</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c480" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-89811">12,452</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c480" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89812">35.25</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c480" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" unitRef="shares" id="ixv-89813">8,929</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c480" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89814">267.90</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c481" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-89815">56,880</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c481" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89816">149.03</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c482" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-89817">10,265</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c482" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89818">4.13</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c482" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" unitRef="shares" id="ixv-89819">14,666</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c482" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89820">275.14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c483" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-89821">52,479</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c483" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89822">85.45</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Options exercisable at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c483" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-89823">46,872</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c483" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89824">94.41</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options expected to vest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c483" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-89825">5,607</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c483" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89826">10.56</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value of stock options
outstanding and stock options exercisable at December 31, 2024 was approximately $<ix:nonFraction contextRef="c418" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" unitRef="usd" id="ixv-89827">1,900</ix:nonFraction>&#160;an $<ix:nonFraction contextRef="c418" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" unitRef="usd" id="ixv-89828">900</ix:nonFraction>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The fair values of options granted during
the year ended December 31, 2024 were estimated at the date of grant using the Black-Scholes option-pricing model with the following
assumptions: volatility of&#160;<ix:nonFraction contextRef="c419" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-89829">83.10</ix:nonFraction>% -&#160;<ix:nonFraction contextRef="c420" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-89830">96.36</ix:nonFraction>%, risk-free rate of&#160;<ix:nonFraction contextRef="c419" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-89831">3.47</ix:nonFraction>% -&#160;<ix:nonFraction contextRef="c420" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-89832">4.79</ix:nonFraction>%, annual dividend yield of&#160;<ix:nonFraction contextRef="c18" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-89833">0</ix:nonFraction>%, and
expected life of&#160;<ix:nonNumeric contextRef="c419" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-89834">3.00</ix:nonNumeric> - <ix:nonNumeric contextRef="c420" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-89835">5.00</ix:nonNumeric>&#160;years. The aggregate fair value of the options granted during the year ended December 31, 2024
was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" unitRef="usd" id="ixv-89836">28,694</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The fair values of options granted during
the year ended December 31, 2023 were estimated at the date of grant using the Black-Scholes option-pricing model with the following
assumptions: volatility of&#160;<ix:nonFraction contextRef="c421" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-89837">79.76</ix:nonFraction>% -&#160;<ix:nonFraction contextRef="c422" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-89838">96.37</ix:nonFraction>%, risk-free rate of&#160;<ix:nonFraction contextRef="c421" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-89839">3.58</ix:nonFraction>% -&#160;<ix:nonFraction contextRef="c422" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-89840">4.76</ix:nonFraction>%, annual dividend yield of&#160;<ix:nonFraction contextRef="c19" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-89841">0</ix:nonFraction>%, and
expected life of&#160;<ix:nonNumeric contextRef="c421" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-89842">3.00</ix:nonNumeric>&#160;-&#160;<ix:nonNumeric contextRef="c422" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-89843">5.00</ix:nonNumeric>&#160;years. The aggregate fair value of the options granted during the year ended December
31, 2023 was $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" unitRef="usd" id="ixv-89844">319,380</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2024 and 2023,
stock-based compensation expense associated with stock options granted amounted to $<ix:nonFraction contextRef="c423" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-89845">51,159</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c424" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-89846">284,977</ix:nonFraction>, of which, $<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd" id="ixv-89847">19,878</ix:nonFraction>&#160;and
$<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd" id="ixv-89848">172,943</ix:nonFraction>&#160;was recorded as compensation and related benefits, $<ix:nonFraction contextRef="c423" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-89849">31,281</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c424" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-89850">106,565</ix:nonFraction>&#160;was recorded as professional fees, and
$<ix:nonFraction contextRef="c423" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-89851">0</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c424" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-89852">5,469</ix:nonFraction>&#160;was recorded as research and development expenses, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="c18" continuedAt="_ScheduleOfNonvestedShareActivityTableTextBlock-c18_cont_1" escape="true" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="ixv-62747"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the status of the Company&#8217;s
nonvested stock options granted as of December 31, 2024 and changes during the years ended December 31, 2024 and 2023 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Options</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Nonvested at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c489" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares" id="ixv-89853">1,334</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c489" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-89854">64.35</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c490" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-89855">12,452</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c490" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-89856">35.25</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c490" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-89857">8,475</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c490" decimals="2" format="ixt:num-dot-decimal" name="avco:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues" scale="0" sign="-" unitRef="usdPershares" id="ixv-89858">47.14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Nonvested at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c491" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares" id="ixv-89859">5,311</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c491" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-89860">23.55</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c492" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-89861">10,265</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c492" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-89862">4.13</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c492" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-89863">9,969</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c492" decimals="2" format="ixt:num-dot-decimal" name="avco:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues" scale="0" sign="-" unitRef="usdPershares" id="ixv-89864">10.90</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Nonvested at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c493" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares" id="ixv-89865">5,607</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c493" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-89866">10.56</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 345 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 15 -&#160;<span style="text-decoration:underline">EQUITY
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_8" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants (Except Pre-Funded Warrants)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" continuedAt="_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-c18_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="ixv-62868"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the shares of the
Company&#8217;s common stock issuable upon exercise of warrants outstanding at December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants Exercisable</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Range of<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">Number<br/> Outstanding at <br/>
December 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average<br/> Remaining<br/> Contractual<br/> Life (Years)</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">Weighted<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">Number<br/> Exercisable at<br/> December 31<br/>
, 2024</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Weighted Average Exercise</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Price</p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 13.5%; text-align: right"><ix:nonFraction contextRef="c499" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" unitRef="usdPershares" id="ixv-89867">7.50</ix:nonFraction> - <ix:nonFraction contextRef="c499" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" unitRef="usdPershares" id="ixv-89868">37.50</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c500" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-89869">165,510</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonNumeric contextRef="c499" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-89870">4.40</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 13.5%; text-align: right"><ix:nonFraction contextRef="c500" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89871">10.50</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13.5%; text-align: right"><ix:nonFraction contextRef="c500" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-89872">85,510</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 13.5%; text-align: right"><ix:nonFraction contextRef="c500" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-89873">13.31</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c501" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89874">67.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c501" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-89875">9,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c502" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-89876">3.40</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c501" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89877">67.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c501" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-89878">9,222</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c501" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-89879">67.50</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c503" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89880">187.50</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c503" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-89881">8,264</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonNumeric contextRef="c504" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-89882">2.30</ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c503" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89883">187.50</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c503" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-89884">8,264</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c503" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-89885">187.50</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c505" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" unitRef="usdPershares" id="ixv-89886">7.50</ix:nonFraction> - <ix:nonFraction contextRef="c505" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" unitRef="usdPershares" id="ixv-89887">187.50</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c506" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-89888">182,996</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c505" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-89889">4.25</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c506" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89890">21.37</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c506" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-89891">102,996</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c506" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-89892">32.13</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation id="_ScheduleOfShareBasedCompensationActivityTableTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Stock warrant activity
for the years ended December 31, 2024 and 2023 was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Warrants</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c484" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-89893">8,264</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c484" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89894">187.50</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Issued</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c485" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-89895">34,771</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c485" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89896">48.90</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c486" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-89897">43,035</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c486" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89898">75.53</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c487" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-89899">169,527</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c487" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89900">10.28</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c487" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares" id="ixv-89901">23,288</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c487" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89902">32.85</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c487" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-89903">6,278</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c487" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89904">50.77</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c488" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-89905">182,996</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c488" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89906">21.37</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants exercisable at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c488" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-89907">102,996</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c488" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89908">32.13</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants expected to vest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c488" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-89909">80,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c488" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89910">7.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-c18_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Second Warrant, which was issued on May 23, 2023, July 6,
2023, October 9, 2023, and March 7, 2024, was cancelled in June 2024. Second Warrant, which was issued on June 5, 2024, is still outstanding
as of December 31, 2024.</td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value of both stock warrants
outstanding and stock warrants exercisable at December 31, 2024 was $<ix:nonFraction contextRef="c425" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" unitRef="usd" id="ixv-89911">0</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Warrants Issued in
May 2023</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
issuance of May 2023 Convertible Note (See Note 10), the Company issued <ix:nonNumeric contextRef="c426" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees" id="ixv-89912">(i) a warrant to purchase 8,333 shares of common stock with an
exercise price of $67.50 exercisable until the five-year anniversary of May 23, 2023, and (ii) a warrant to purchase 7,033 shares of common
stock with an exercise price of $48.00 exercisable until the five-year anniversary of May 23, 2023, which warrant was never fair valued
and was cancelled and extinguished against payment of the May 2023 Convertible Note, to Mast Hill; and issued a warrant to purchase 667
shares of common stock with an exercise price of $67.50 exercisable until the five-year anniversary of May 23, 2023 to a third party as
a finder&#8217;s fee.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Based upon the Company&#8217;s
analysis of the criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a
finder&#8217;s fee meet the definition of derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances.
Accordingly, the fair value of the <ix:nonFraction contextRef="c427" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89913">9,000</ix:nonFraction> warrants with an exercise price of $<ix:nonFraction contextRef="c427" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89914">67.50</ix:nonFraction> exercisable until the five-year anniversary of May
23, 2023 was classified as derivative liability on May 23, 2023. The fair values of the <ix:nonFraction contextRef="c428" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89915">9,000</ix:nonFraction> warrants with an exercise price of $<ix:nonFraction contextRef="c428" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89916">67.50</ix:nonFraction>
exercisable until the five-year anniversary of May 23, 2023 issued on May 23, 2023 were computed using the Black-Scholes option-pricing
model with the following assumptions: stock price of $<ix:nonFraction contextRef="c429" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-89917">29.40</ix:nonFraction>, volatility of <ix:nonFraction contextRef="c430" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" unitRef="pure" id="ixv-89918">88.80</ix:nonFraction>%, risk-free rate of <ix:nonFraction contextRef="c430" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" unitRef="pure" id="ixv-89919">3.76</ix:nonFraction>%, annual dividend yield of <ix:nonFraction contextRef="c430" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-89920">0</ix:nonFraction>%
and expected life of <ix:nonNumeric contextRef="c430" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-89921">5</ix:nonNumeric> years.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 346 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 15 -&#160;<span style="text-decoration:underline">EQUITY
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants (Except Pre-Funded Warrants) (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Warrants Issued in
May 2023 (continued)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_9" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The warrants with an
exercise price of $<ix:nonFraction contextRef="c431" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89922">67.50</ix:nonFraction> exercisable until the five-year anniversary of May 23, 2023 issued to Mast Hill to purchase <ix:nonFraction contextRef="c431" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89923">8,333</ix:nonFraction> shares of the
Company&#8217;s common stock were treated as a discount on the convertible note payable and were valued at $<ix:nonFraction contextRef="c305" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd" id="ixv-89924">127,654</ix:nonFraction> and were amortized
over the term of the May 2023 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The warrants with an
exercise price of $<ix:nonFraction contextRef="c432" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89925">67.50</ix:nonFraction> exercisable until the five-year anniversary of May 23, 2023 issued to a third party as a finder&#8217;s fee to
purchase <ix:nonFraction contextRef="c432" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89926">667</ix:nonFraction> shares of the Company&#8217;s common stock were treated as convertible debt issuance costs and were valued at $<ix:nonFraction contextRef="c433" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd" id="ixv-89927">11,162</ix:nonFraction> and
were amortized over the term of the May 2023 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Warrants Issued in
July 2023</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
issuance of July 2023 Convertible Note (See Note 10), the Company issued <ix:nonNumeric contextRef="c434" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees" id="ixv-89928">(i) a warrant to purchase 2,778 shares of common stock with an
exercise price of $67.50 exercisable until the five-year anniversary of July 6, 2023, and (ii) a warrant to purchase 2,344 shares of common
stock with an exercise price of $48.00 exercisable until the five-year anniversary of July 6, 2023, which warrant was never fair valued
and was cancelled and extinguished against payment of the July 2023 Convertible Note, to Firstfire; and issued a warrant to purchase 222
shares of common stock with an exercise price of $67.50 exercisable until the five-year anniversary of July 6, 2023 to a third party as
a finder&#8217;s fee.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Based upon the Company&#8217;s
analysis of the criteria contained in ASC 815, the Company determined that all the warrants issued to Firstfire and a third party as a
finder&#8217;s fee meet the definition of derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances.
Accordingly, the fair value of the <ix:nonFraction contextRef="c435" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89929">3,000</ix:nonFraction> warrants with an exercise price of $<ix:nonFraction contextRef="c436" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89930">67.50</ix:nonFraction> exercisable until the five-year anniversary of July
6, 2023 was classified as derivative liability on July 6, 2023. The fair values of the <ix:nonFraction contextRef="c437" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89931">3,000</ix:nonFraction> warrants with an exercise price of $<ix:nonFraction contextRef="c438" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89932">67.50</ix:nonFraction>
exercisable until the five-year anniversary of July 6, 2023 issued on July 6, 2023 were computed using the Black-Scholes option-pricing
model with the following assumptions: stock price of $<ix:nonFraction contextRef="c439" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-89933">21.30</ix:nonFraction>, volatility of <ix:nonFraction contextRef="c220" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" unitRef="pure" id="ixv-89934">88.52</ix:nonFraction>%, risk-free rate of <ix:nonFraction contextRef="c220" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" unitRef="pure" id="ixv-89935">4.37</ix:nonFraction>%, annual dividend yield of <ix:nonFraction contextRef="c220" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-89936">0</ix:nonFraction>%
and expected life of <ix:nonNumeric contextRef="c220" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-89937">5</ix:nonNumeric> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The warrants with an
exercise price of $<ix:nonFraction contextRef="c440" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89938">67.50</ix:nonFraction> exercisable until the five-year anniversary of July 6, 2023 issued to Firstfire to purchase <ix:nonFraction contextRef="c440" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89939">2,778</ix:nonFraction> shares of the
Company&#8217;s common stock were treated as a discount on the convertible note payable and were valued at $<ix:nonFraction contextRef="c441" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd" id="ixv-89940">28,691</ix:nonFraction> and were amortized
over the term of the July 2023 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants with an exercise price of $<ix:nonFraction contextRef="c319" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89941">67.50</ix:nonFraction>
exercisable until the five-year anniversary of July 6, 2023 issued to a third party as a finder&#8217;s fee to purchase <ix:nonFraction contextRef="c319" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89942">222</ix:nonFraction> shares of
the Company&#8217;s common stock were treated as convertible debt issuance costs and were valued at $<ix:nonFraction contextRef="c442" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd" id="ixv-89943">2,435</ix:nonFraction> and were amortized over the
term of the July 2023 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Warrants Issued in
October 2023</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
issuance of October 2023 Convertible Note (See Note 10), the Company issued <ix:nonNumeric contextRef="c443" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees" id="ixv-89944">(i) a warrant to purchase 7,000 shares of common stock with
an exercise price of $37.50 exercisable until the five-year anniversary of October 9, 2023, (ii) a warrant to purchase 5,834 shares of
common stock with an exercise price of $27.00 exercisable until the five-year anniversary of October 9, 2023, which warrant was never
fair valued and was cancelled and extinguished against payment of the October 2023 Convertible Note, to Mast Hill and Firstfire; and issued
a warrant to purchase 560 shares of common stock with an exercise price of $37.50 exercisable until the five-year anniversary of October
9, 2023 to a third party as a finder&#8217;s fee.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon the Company&#8217;s analysis of the
criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and Firstfire and a third party as a finder&#8217;s
fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances. Accordingly,
the fair value of the <ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89945">7,560</ix:nonFraction> warrants with an exercise price of $<ix:nonFraction contextRef="c444" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89946">37.50</ix:nonFraction> exercisable until the five-year anniversary of October 9, 2023 was
classified as a derivative liability on October 9, 2023. The fair values of the <ix:nonFraction contextRef="c445" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89947">7,560</ix:nonFraction> warrants with an exercise price of $<ix:nonFraction contextRef="c446" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89948">37.50</ix:nonFraction> exercisable
until the five-year anniversary of October 9, 2023 issued on October 9, 2023 were computed using the Black-Scholes option-pricing model
with the following assumptions: stock price of $<ix:nonFraction contextRef="c447" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-89949">11.55</ix:nonFraction>, volatility of <ix:nonFraction contextRef="c448" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" unitRef="pure" id="ixv-89950">89.70</ix:nonFraction>%, risk-free rate of <ix:nonFraction contextRef="c448" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" unitRef="pure" id="ixv-89951">4.75</ix:nonFraction>%, annual dividend yield of <ix:nonFraction contextRef="c448" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-89952">0</ix:nonFraction>% and
expected life of <ix:nonNumeric contextRef="c448" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-89953">5</ix:nonNumeric> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The warrants with an
exercise price of $<ix:nonFraction contextRef="c449" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89954">37.50</ix:nonFraction> exercisable until the five-year anniversary of October 9, 2023 issued to Mast Hill and Firstfire to purchase
<ix:nonFraction contextRef="c449" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89955">7,000</ix:nonFraction> shares of the Company&#8217;s common stock were treated as a discount on the convertible note payable and were valued at $<ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd" id="ixv-89956">39,848</ix:nonFraction>
and were amortized over the term of the October 2023 Convertible Note.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 347 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 15 -&#160;<span style="text-decoration:underline">EQUITY
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants (Except Pre-Funded Warrants) (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Warrants Issued in
October 2023 (continued)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_10" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants with an exercise price of $<ix:nonFraction contextRef="c444" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89957">37.50</ix:nonFraction>
exercisable until the five-year anniversary of October 9, 2023 issued to a third party as a finder&#8217;s fee to purchase <ix:nonFraction contextRef="c444" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89958">560</ix:nonFraction> shares
of the Company&#8217;s common stock were treated as convertible debt issuance costs and were valued at $<ix:nonFraction contextRef="c445" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd" id="ixv-89959">3,380</ix:nonFraction> and were amortized over
the term of the October 2023 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Warrants Issued in
March 2024</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
issuance of March 2024 Convertible Note (See Note 10), the Company issued&#160;<ix:nonNumeric contextRef="c450" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees" id="ixv-89960">(i) a warrant to purchase 8,750 shares of common stock
with an exercise price of $30.00 exercisable until the five-year anniversary of March 7, 2024 (&#8220;First Warrant&#8221;), (ii) a warrant
to purchase 8,077 shares of common stock with an exercise price of $19.50 (&#8220;Second Warrant&#8221;), which warrant was never fair
valued and was cancelled and extinguished against payment of the March 2024 Convertible Note, to Mast Hill; and issued a warrant to purchase
700 shares of common stock with an exercise price of $30.00 exercisable until the five-year anniversary of March 7, 2024 to a third party
as a finder&#8217;s fee.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Based upon the Company&#8217;s
analysis of the criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a
finder&#8217;s fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances.
The fair value of the&#160;<ix:nonFraction contextRef="c451" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89961">9,450</ix:nonFraction>&#160;warrants with an exercise price of $<ix:nonFraction contextRef="c452" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89962">30.00</ix:nonFraction>&#160;exercisable until the five-year anniversary of March
7, 2024 was classified as a derivative liability on March 7, 2024. The fair values of the&#160;<ix:nonFraction contextRef="c453" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89963">9,450</ix:nonFraction>&#160;warrants with an exercise price
of $<ix:nonFraction contextRef="c452" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89964">30.00</ix:nonFraction>&#160;exercisable until the five-year anniversary of March 7, 2024 issued on March 7, 2024 were computed using the Black-Scholes
option-pricing model with the following assumptions: stock price of $<ix:nonFraction contextRef="c452" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-89965">6.00</ix:nonFraction>, volatility of&#160;<ix:nonFraction contextRef="c453" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" unitRef="pure" id="ixv-89966">85.24</ix:nonFraction>%, risk-free rate of&#160;<ix:nonFraction contextRef="c453" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" unitRef="pure" id="ixv-89967">4.07</ix:nonFraction>%, annual
dividend yield of&#160;<ix:nonFraction contextRef="c453" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-89968">0</ix:nonFraction>% and expected life of&#160;<ix:nonNumeric contextRef="c453" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-89969">5</ix:nonNumeric>&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The warrants with an
exercise price of $<ix:nonFraction contextRef="c454" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89970">30.00</ix:nonFraction>&#160;exercisable until the five-year anniversary of March 7, 2024 issued to Mast Hill to purchase&#160;<ix:nonFraction contextRef="c454" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89971">8,750</ix:nonFraction>&#160;shares
of the Company&#8217;s common stock were treated as a discount on the convertible note payable and were valued at $<ix:nonFraction contextRef="c454" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd" id="ixv-89972">20,374</ix:nonFraction>&#160;and were
amortized over the term of the March 2024 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The warrants with an
exercise price of $<ix:nonFraction contextRef="c455" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89973">30.00</ix:nonFraction>&#160;exercisable until the five-year anniversary of March 7, 2024 issued to a third party as a finder&#8217;s
fee to purchase&#160;<ix:nonFraction contextRef="c455" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89974">700</ix:nonFraction>&#160;shares of the Company&#8217;s common stock were treated as convertible debt issuance costs and were valued
at $<ix:nonFraction contextRef="c456" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd" id="ixv-89975">1,679</ix:nonFraction>&#160;and were amortized over the term of the March 2024 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Warrants Issued in
June 2024</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the issuance of June 2024 Convertible
Note (See Note 10), the Company issued&#160;<ix:nonNumeric contextRef="c457" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees" id="ixv-89976">(i) a warrant to purchase 66,667 shares of common stock with an exercise price of $9.75 exercisable
until the five-year anniversary of June 5, 2024 (&#8220;First Warrant&#8221;), (ii) a warrant to purchase 80,000 shares of common stock
with an exercise price of $7.50 exercisable until the five-year anniversary of June 5, 2024 (&#8220;Second Warrant&#8221;), which warrant
shall be cancelled and extinguished against payment of the June 2024 Convertible Note, to Mast Hill; and issued a warrant to purchase
5,333 shares of common stock with an exercise price of $9.75 exercisable until the five-year anniversary of June 5, 2024 to a third party
as a finder&#8217;s fee.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon the Company&#8217;s analysis of the
criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a finder&#8217;s
fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances. Management
determined the probability of failing to make an amortization payment when due to be remote and as such the fair value of the&#160;<ix:nonFraction contextRef="c458" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-89977">80,000</ix:nonFraction>&#160;warrants
with an exercise price of $<ix:nonFraction contextRef="c458" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89978">7.50</ix:nonFraction>&#160;exercisable until the five-year anniversary of June 5, 2024, which warrant shall be cancelled and
extinguished against payment of the June 2024 Convertible Note, has been estimated to be zero. Accordingly, the fair value of the&#160;<ix:nonFraction contextRef="c459" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89979">72,000</ix:nonFraction>&#160;warrants
with an exercise price of $<ix:nonFraction contextRef="c460" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89980">9.75</ix:nonFraction>&#160;exercisable until the five-year anniversary of June 5, 2024 was classified as a derivative liability
on June 5, 2024. The fair values of the&#160;<ix:nonFraction contextRef="c461" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-89981">72,000</ix:nonFraction>&#160;warrants with an exercise price of $<ix:nonFraction contextRef="c462" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89982">9.75</ix:nonFraction>&#160;exercisable until the five-year
anniversary of June <ix:nonNumeric contextRef="c463" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-89983">5</ix:nonNumeric>, 2024 issued on June 5, 2024 were computed using the Black-Scholes option-pricing model with the following assumptions:
stock price of $<ix:nonFraction contextRef="c464" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-89984">10.39</ix:nonFraction>, volatility of&#160;<ix:nonFraction contextRef="c463" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" unitRef="pure" id="ixv-89985">85.72</ix:nonFraction>%, risk-free rate of&#160;<ix:nonFraction contextRef="c463" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" unitRef="pure" id="ixv-89986">4.31</ix:nonFraction>%, annual dividend yield of&#160;<ix:nonFraction contextRef="c463" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-89987">0</ix:nonFraction>% and expected life of&#160;5&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants with an exercise price of $<ix:nonFraction contextRef="c465" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89988">9.75</ix:nonFraction>&#160;exercisable
until the five-year anniversary of June 5, 2024 issued to Mast Hill to purchase&#160;<ix:nonFraction contextRef="c466" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89989">66,667</ix:nonFraction>&#160;shares of the Company&#8217;s common
stock were treated as a discount on the convertible note payable and were valued at $<ix:nonFraction contextRef="c466" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd" id="ixv-89990">418,194</ix:nonFraction>&#160;and will be amortized over the term
of the June 2024 Convertible Note.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 348 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 15 -&#160;<span style="text-decoration:underline">EQUITY
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants (Except Pre-Funded Warrants) (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Warrants Issued in
June 2024 (continued)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c18_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants with an exercise price of $<ix:nonFraction contextRef="c467" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-89991">9.75</ix:nonFraction>&#160;exercisable
until the five-year anniversary of June 5, 2024 issued to a third party as a finder&#8217;s fee to purchase&#160;<ix:nonFraction contextRef="c467" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-89992">5,333</ix:nonFraction>&#160;shares of
the Company&#8217;s common stock were treated as convertible debt issuance costs and were valued at $<ix:nonFraction contextRef="c468" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd" id="ixv-89993">39,221</ix:nonFraction>&#160;and will be amortized
over the term of the June 2024 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Warrants Cancelled
in June 2024</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As of June 5, 2024, the
Company paid in full of its outstanding May 2023 Convertible Note, July 2023 Convertible Note, October 2023 Convertible Note, and March
2024 Convertible Note and cancelled&#160;<ix:nonFraction contextRef="c469" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares" id="ixv-89994">23,288</ix:nonFraction>&#160;warrants since these convertible notes were fully extinguished.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Warrants Exercised
in November 2024</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On November 18, 2024,
<ix:nonFraction contextRef="c470" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-89995">6,278</ix:nonFraction> warrants were cashless exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:continuation id="_ScheduleOfNonvestedShareActivityTableTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">A summary of the status
of the Company&#8217;s nonvested stock warrants issued as of December 31, 2024 and changes during the years ended December 31, 2024 and
2023 was presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Warrants</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Nonvested at January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-354">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-355">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%">Issued</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c495" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" unitRef="shares" id="ixv-89996">34,771</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c495" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-89997">48.90</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c495" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-89998">19,560</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c495" decimals="2" format="ixt:num-dot-decimal" name="avco:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues" scale="0" unitRef="usdPershares" id="ixv-89999">55.95</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Nonvested at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c496" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares" id="ixv-90000">15,211</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c496" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-90001">39.90</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c497" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" unitRef="shares" id="ixv-90002">169,527</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c497" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90003">10.28</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c497" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares" id="ixv-90004">23,288</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c497" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-90005">32.85</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c497" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-90006">81,450</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c497" decimals="2" format="ixt:num-dot-decimal" name="avco:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues" scale="0" sign="-" unitRef="usdPershares" id="ixv-90007">12.10</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Nonvested at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c498" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares" id="ixv-90008">80,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c498" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-90009">7.50</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c18" escape="true" name="avco:StatutoryReserveAndRestrictedNetAssetsTextBlock" id="ixv-63411"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 16 - <span style="text-decoration:underline">STATUTORY
RESERVE AND RESTRICTED NET ASSETS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company&#8217;s PRC
subsidiary, Avalon Shanghai, is restricted in its ability to transfer a portion of its net asset to the Company. The payment of dividends
by entities organized in China is subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment
of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company is required
to make appropriations to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus reserve, based
on after-tax net income determined in accordance with generally accepted accounting principles of the PRC (&#8220;PRC GAAP&#8221;). Appropriations
to the statutory surplus reserve are required to be at least&#160;<ix:nonFraction contextRef="c18" decimals="2" format="ixt:num-dot-decimal" name="avco:StatutoryReservePercent" scale="-2" unitRef="pure" id="ixv-90010">10</ix:nonFraction>% of the after-tax net income determined in accordance with PRC GAAP
until the reserve is equal to&#160;<ix:nonFraction contextRef="c18" decimals="2" format="ixt:num-dot-decimal" name="avco:RegisteredCapitalPercentage" scale="-2" unitRef="pure" id="ixv-90011">50</ix:nonFraction>% of the entity&#8217;s registered capital. Appropriations to the discretionary surplus reserve are
made at the discretion of the Board of Directors. The statutory reserve may be applied against prior year losses, if any, and may be used
for general business expansion and production or increase in registered capital, but are not distributable as cash dividends. The Company
did not make any appropriation to statutory reserve for Avalon Shanghai during the years ended December 31, 2024 and 2023 as it incurred
net loss in the periods. As of both December 31, 2024 and 2023, the restricted amount as determined pursuant to PRC statutory laws totaled
$<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="avco:StatutoryReserve" scale="0" unitRef="usd" id="ixv-90012"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="avco:StatutoryReserve" scale="0" unitRef="usd" id="ixv-90013">6,578</ix:nonFraction></ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Relevant PRC laws and
regulations restrict the Company&#8217;s PRC subsidiary, Avalon Shanghai, from transferring a portion of its net assets, equivalent to
its statutory reserve and its share capital, to the Company&#8217;s shareholders in the form of loans, advances or cash dividends. Only
PRC entity&#8217;s accumulated profit may be distributed as dividend to the Company&#8217;s shareholders without the consent of a third
party. As of December 31, 2024 and 2023, total restricted net assets amounted to $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherRestrictedAssets" scale="0" unitRef="usd" id="ixv-90014">1,206,578</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherRestrictedAssets" scale="0" unitRef="usd" id="ixv-90015">1,106,578</ix:nonFraction>, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 349 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:MinorityInterestDisclosureTextBlock" id="ixv-63444"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 17 - <span style="text-decoration:underline">NONCONTROLLING
INTEREST</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As of December
31, 2024, Dr. Yu Zhou, former director and former co-chief executive officer of Genexosome, who owns <ix:nonFraction contextRef="c507" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-90016">40</ix:nonFraction>% of the equity interests of Genexosome,
which is not under the Company&#8217;s control. During the years ended December 31, 2024 and 2023, the Company did not allocate any net
loss and foreign currency translation adjustment to the noncontrolling interest holder due to its inability to satisfy these deficits.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" id="ixv-63454"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 18 - <span style="background-color: white"><span style="text-decoration:underline">CONDENSED
FINANCIAL INFORMATION OF THE PARENT COMPANY</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the requirements
of Rule 12-04(a), 5-04(c) and 4-08(e)(3) of Regulation S-X, the condensed financial information of the parent company shall be filed when
the restricted net assets of consolidated subsidiary exceed <ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="avco:RestrictedNetAssetsOfSubsidiaryExceedNetAssets" scale="-2" unitRef="pure" id="ixv-90017">25</ix:nonFraction>% of consolidated net assets as of the end of the most recently completed
fiscal year. For purposes of this test, restricted net assets of consolidated subsidiary shall mean that amount of the Company&#8217;s
proportionate share of net assets of consolidated subsidiary (after intercompany eliminations) which as of the end of the most recent
fiscal year may not be transferred to the parent company by subsidiary in the form of loans, advances or cash dividends without the consent
of a third party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company performed
a test on the restricted net assets of consolidated subsidiary in accordance with such requirement and concluded that it was not applicable
to the Company as the restricted net assets of the Company&#8217;s PRC subsidiary did not exceed <ix:nonFraction contextRef="c508" decimals="2" format="ixt:num-dot-decimal" name="avco:RestrictedNetAssetsPRCSubsidiaryDidNotExceed" scale="-2" unitRef="pure" id="ixv-90018">25</ix:nonFraction>% of the consolidated net assets of
the Company, therefore, the condensed financial statements for the parent company have not been required.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="ixv-63466"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 19 -&#160;<span style="text-decoration:underline">CONCENTRATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Customers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="ixv-63475"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The following
table sets forth information as to each customer that accounted for <ix:nonFraction contextRef="c509" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90019"><ix:nonFraction contextRef="c510" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90020">10</ix:nonFraction></ix:nonFraction>% or more of the Company&#8217;s revenues for the years ended December
31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">Customer</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c517" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90021">29</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c518" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90022">30</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c519" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90023">17</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c520" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90024">18</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c521" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90025">11</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c522" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90026">12</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">One customer, which is
a third party, whose outstanding receivable accounted for <ix:nonFraction contextRef="c511" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90027">10</ix:nonFraction>% or more of the Company&#8217;s total outstanding rent receivable at December
31, 2024, accounted for <ix:nonFraction contextRef="c512" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90028">76.9</ix:nonFraction>% of the Company&#8217;s total outstanding rent receivable at December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Two customers, of which
one is a related party and the other is a third party, whose outstanding receivables accounted for <ix:nonFraction contextRef="c513" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90029">10</ix:nonFraction>% or more of the Company&#8217;s
total outstanding rent receivable at December 31, 2023, accounted for <ix:nonFraction contextRef="c514" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90030">80.6</ix:nonFraction>% of the Company&#8217;s total outstanding rent receivable at
December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Suppliers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">No supplier
accounted for <ix:nonFraction contextRef="c515" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90031"><ix:nonFraction contextRef="c516" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90032">10</ix:nonFraction></ix:nonFraction>% or more of the Company&#8217;s purchase during the years ended December 31, 2024 and 2023.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c18" continuedAt="_SegmentReportingDisclosureTextBlock-c18_cont_1" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock" id="ixv-63536"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>NOTE
20 -&#160;<span style="text-decoration:underline">SEGMENT INFORMATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The segment reporting structure uses the Company&#8217;s
management reporting structure as its foundation to reflect how the Company manages the businesses internally. The management reporting
structure is composed of two strategic business units, mainly organized by services, led by the Company&#8217;s President and Chief Executive
Officer, who is its Chief Operating Decision Maker. Using the accounting guidance on segment reporting, the Company determined that its
<ix:nonFraction contextRef="c18" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="segments" id="ixv-90033">two</ix:nonFraction> operating segments are aligned with its <ix:nonFraction contextRef="c18" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="segments" id="ixv-90034">two</ix:nonFraction> reportable segments corresponding to its strategic business units.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 350 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 20 -&#160;<span style="text-decoration:underline">SEGMENT
INFORMATION (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c18_cont_2" id="_SegmentReportingDisclosureTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 9, 2023, the Company purchased <ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="avco:PurchasedServicesPercentage" scale="-2" unitRef="pure" id="ixv-90035">40</ix:nonFraction>%
of Lab Services MSO. Commencing from the purchase date, February 9, 2023, the Company was active in the management of Lab Services MSO.
During the years ended December 31, 2024 and 2023, the Company operated in <ix:nonFraction contextRef="c18" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="segments" id="ixv-90036"><ix:nonFraction contextRef="c18" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="segments" id="ixv-90037">two</ix:nonFraction></ix:nonFraction> reportable business segments: (1) the real property operating
segment, and (2) laboratory testing services segment (which commenced with the purchase date, February 9, 2023) since Lab Services MSO&#8217;s
operating results are regularly reviewed by the Company&#8217;s chief operating decision maker to make decisions about resources to be
allocated to the segment and assess its performance. The Company regularly reviews the operating results and performance of Lab Services
MSO, which is the Company&#8217;s equity method investee. See Note 22-Subsequent Events-Redemption Agreement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accounting policies for the segments are the
same as those described in Note 3. Our reportable segments are aligned principally around the differences in services. Real property operating
income is calculated by subtracting real property operating expenses from real property rental revenue; loss from equity method investment
- Lab Services MSO is calculated by subtracting amortization of intangible assets acquired from acquisition and impairment of goodwill
acquired from acquisition and distribution of earnings from equity investment from the Company&#8217;s share of Lab Services MSO&#8217;s
net income. The assets and certain expenses related to corporate activities are not allocated to the segments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="ixv-63577"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information with respect to these reportable business
segments for the years ended December 31, 2024 and 2023 was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ended December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Real Property Operations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Lab Services MSO</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Corporate / Other</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Real property rental revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c523" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-90038">1,333,403</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-356">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-357">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-90039">1,333,403</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Real property operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c523" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-90040">1,065,574</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-358">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-359">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-90041">1,065,574</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Real property operating income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c523" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd" id="ixv-90042">267,829</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-360">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-361">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd" id="ixv-90043">267,829</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from equity method investment - Lab Services MSO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-362">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c524" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="0" sign="-" unitRef="usd" id="ixv-90044">846,588</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-363">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="0" sign="-" unitRef="usd" id="ixv-90045">846,588</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c523" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" unitRef="usd" id="ixv-90046">354,311</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-364">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c525" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" unitRef="usd" id="ixv-90047">3,994,662</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" unitRef="usd" id="ixv-90048">4,348,973</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other (expense) income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;&#160;Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c523" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-90049">777,228</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-365">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c525" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-90050">1,659,745</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-90051">2,436,973</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;&#160;Other expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c523" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" sign="-" unitRef="usd" id="ixv-90052">80</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-366">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c525" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" sign="-" unitRef="usd" id="ixv-90053">538,609</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" sign="-" unitRef="usd" id="ixv-90054">538,689</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c523" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-90055">863,790</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c524" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-90056">846,588</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c525" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-90057">6,193,016</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-90058">7,903,394</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ended December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Real Property Operations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Lab Services MSO</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Corporate / Other</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Real property rental revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c526" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-90059">1,255,681</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-367">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-368">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-90060">1,255,681</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Real property operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c526" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-90061">1,017,493</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-369">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-370">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-90062">1,017,493</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Real property operating income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c526" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd" id="ixv-90063">238,188</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-371">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-372">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd" id="ixv-90064">238,188</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from equity method investment - Lab Services MSO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-373">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c527" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="0" sign="-" unitRef="usd" id="ixv-90065">8,571,647</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-374">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="0" sign="-" unitRef="usd" id="ixv-90066">8,571,647</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c526" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" unitRef="usd" id="ixv-90067">347,356</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-375">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c528" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" unitRef="usd" id="ixv-90068">7,072,868</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" unitRef="usd" id="ixv-90069">7,420,224</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other (expense) income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;&#160;Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c526" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-90070">918,885</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-376">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c528" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-90071">432,617</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-90072">1,351,502</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;&#160;Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c526" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd" id="ixv-90073">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-377">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c528" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd" id="ixv-90074">398,160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd" id="ixv-90075">398,175</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c526" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-90076">1,028,038</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c527" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-90077">8,571,647</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c528" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-90078">7,107,325</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-90079">16,707,010</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 351 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>AVALON
                                            GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 20 -&#160;<span style="text-decoration:underline">SEGMENT
INFORMATION (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><ix:continuation id="_SegmentReportingDisclosureTextBlock-c18_cont_2"><ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="ixv-64003"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Identifiable long-lived tangible assets at December 31, 2024 and 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Real property operations</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c529" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90080">7,034,335</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c530" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90081">7,211,641</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Corporate/Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c531" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90082">1,298</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c532" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90083">17,846</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;&#160;&#160;Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90084">7,035,633</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90085">7,229,487</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" id="ixv-64044"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Identifiable long-lived tangible assets at December 31, 2024 and 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90086">7,034,335</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90087">7,227,533</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">China</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90088">1,298</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90089">1,954</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;&#160;Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90090">7,035,633</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90091">7,229,487</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c18" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c18_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-64088"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 21 -&#160;<span style="text-decoration:underline">COMMITMENTS
AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Litigation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company is subject to ordinary routine litigation incidental to its normal business operations. The Company
is not currently a party to, and its property is not subject to, any material legal proceedings, except as set forth below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October
25, 2017, Genexosome entered into and closed a Stock Purchase Agreement with Beijing Genexosome and Yu Zhou, MD, PhD, the sole shareholder
of Beijing Genexosome, pursuant to which Genexosome acquired all of the issued and outstanding securities of Beijing Genexosome in consideration
of a cash payment in the amount of $<ix:nonFraction contextRef="c533" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-90092">450,000</ix:nonFraction>, of which $<ix:nonFraction contextRef="c534" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansPayable" scale="0" unitRef="usd" id="ixv-90093">100,000</ix:nonFraction> is still owed. Further, on October 25, 2017, Genexosome entered into and
closed an Asset Purchase Agreement with Dr. Zhou, pursuant to which the Company acquired all assets, including all intellectual property
and exosome separation systems, held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies.
In consideration of the assets, Genexosome paid Dr. Zhou $<ix:nonFraction contextRef="c535" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-90094">876,087</ix:nonFraction> in cash, transferred <ix:nonFraction contextRef="c536" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-90095">3,333</ix:nonFraction> shares of common stock of the Company to
Dr. Zhou and issued Dr. Zhou <ix:nonFraction contextRef="c537" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-90096">400</ix:nonFraction> shares of common stock of Genexosome. Further, the Company had not been able to realize the financial
projections provided by Dr. Zhou at the time of the acquisition and has decided to impair the intangible asset associated with this acquisition
to zero. Dr. Zhou was terminated as Co-CEO of Genexosome on August 14, 2019. Further, on October 28, 2019, Research Institute at Nationwide
Children&#8217;s Hospital (&#8220;Research Institute&#8221;) filed a Complaint in the United States District Court for the Southern District
of Ohio Eastern Division against Dr. Zhou, Li Chen, the Company and Genexosome with various claims against the Company and Genexosome.
The criminal proceedings against Dr. Zhou and Li Chen have been concluded. The Company, Genexosome and the Research Institute entered
into a Settlement Agreement dated June 7, 2022 (the &#8220;Settlement Date&#8221;) whereby the Company agreed to pay the Research Institute
$<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LitigationReserve" scale="0" unitRef="usd" id="ixv-90097">450,000</ix:nonFraction> on each of the sixty-day, one year and two-year anniversaries of the Settlement Date. In addition, the Company agreed to pay
the Research Institute <ix:nonFraction contextRef="c18" decimals="2" format="ixt:num-dot-decimal" name="avco:PercentageOfPretaxProfit" scale="-2" unitRef="pure" id="ixv-90098">30</ix:nonFraction>% of the Company&#8217;s initial pre-tax profit of $<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:PreTaxProfit" scale="0" unitRef="usd" id="ixv-90099">3,333,333</ix:nonFraction>, <ix:nonFraction contextRef="c538" decimals="2" format="ixt:num-dot-decimal" name="avco:PercentageOfPretaxProfit" scale="-2" unitRef="pure" id="ixv-90100">20</ix:nonFraction>% of the Company&#8217;s second pre-tax profit
of $<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:PreTaxProfit" scale="0" unitRef="usd" id="ixv-90101">3,333,333</ix:nonFraction> and <ix:nonFraction contextRef="c539" decimals="2" format="ixt:num-dot-decimal" name="avco:PercentageOfPretaxProfit" scale="-2" unitRef="pure" id="ixv-90102">10</ix:nonFraction>% of the Company&#8217;s third pre-tax profit of $<ix:nonFraction contextRef="c539" decimals="0" format="ixt:num-dot-decimal" name="avco:PreTaxProfit" scale="0" unitRef="usd" id="ixv-90103">3,333,333</ix:nonFraction>. The parties provided a mutual release as well. As of
December 31, 2024, the accrued litigation settlement amounted to $<ix:nonFraction contextRef="c540" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LitigationReserve" scale="0" unitRef="usd" id="ixv-90104">373,450</ix:nonFraction>.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 352 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>AVALON
                                            GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 21 -&#160;<span style="text-decoration:underline">COMMITMENTS
AND CONTINGENCIES (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c18_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Operating
Leases Commitment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
is a party to leases for office space. These lease agreements expired through February 2025. Rent expense under all operating leases amounted
to approximately $<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd" id="ixv-90105">127,000</ix:nonFraction> and $<ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd" id="ixv-90106">129,000</ix:nonFraction> for the years ended December 31, 2024 and 2023, respectively.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-64138"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Supplemental
cash flow information related to leases for the years ended December 31, 2024 and 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">&#160;&#160;Operating cash flows paid for operating lease</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-90107">125,076</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-90108">125,929</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;&#160;Operating lease</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-378">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="avco:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities" scale="0" unitRef="usd" id="ixv-90109">235,893</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the lease term
and discount rate for the Company&#8217;s operating lease as of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Operating Lease</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Weighted average remaining lease term (in years)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-90110">0.08</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted average discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-90111">11.0</ix:nonFraction></td><td style="text-align: left">%</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c18" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-64217"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the maturity of lease liabilities under
operating lease as of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">For the Year Ending December 31:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Operating Lease</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" unitRef="usd" id="ixv-90112">10,753</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2026 and thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-379">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd" id="ixv-90113">10,753</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Amount of lease payments representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" unitRef="usd" id="ixv-90114">44</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total present value of operating lease liabilities (current liability)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-90115">10,709</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 353 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 21 -&#160;<span style="text-decoration:underline">COMMITMENTS
AND CONTINGENCIES (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c18_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Joint Venture - Avactis Biosciences Inc.</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On July 18, 2018, the
Company formed a wholly owned subsidiary, Avactis Biosciences Inc. (&#8220;Avactis&#8221;), a Nevada corporation, which focuses on accelerating
commercial activities related to cellular therapies as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others. When
formed, Avactis was designed to integrate and optimize the Company&#8217;s global scientific and clinical resources to further advance
the use of cellular therapies to treat certain cancers, however the Company is no longer pursuing any commercial activities with respect
to cellular immunotherapy and CAR-T, in particular. As of April 6, 2022, the Company owns <ix:nonFraction contextRef="c541" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-90116">60</ix:nonFraction>% of Avactis and Arbele Biotherapeutics Limited
(&#8220;Arbele Biotherapeutics&#8221;) owns <ix:nonFraction contextRef="c542" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-90117">40</ix:nonFraction>% of Avactis. Avactis owns <ix:nonFraction contextRef="c543" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-90118">100</ix:nonFraction>% of the capital stock of Avactis Nanjing Biosciences Ltd.,
a company incorporated in the PRC on May 8, 2020 (&#8220;Avactis Nanjing&#8221;), which only owns a patent and is not considered an operating
entity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company is required
to contribute $<ix:nonFraction contextRef="c18" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashFlowsBetweenTransfereeAndTransferorServicingFees" scale="6" unitRef="usd" id="ixv-90119">10</ix:nonFraction> million (or equivalent in RMB) in cash and/or services, which shall be contributed in tranches based on milestones to
be determined jointly by Avactis and the Company in writing subject to the Company&#8217;s cash reserves. Within 30 days, Arbele Biotherapeutics
shall make contribution of $<ix:nonFraction contextRef="c544" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:NoncashContributionExpense" scale="6" unitRef="usd" id="ixv-90120">6.66</ix:nonFraction> million in the form of entering into a License Agreement with Avactis granting Avactis an exclusive right
and license in China to its technology and intellectual property pertaining to CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy technology
and any additional technology developed in the future with terms and conditions to be mutually agreed upon the Company and Avactis and
services. As of the date hereof, the License Agreement has not been finalized by the parties.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In addition, the Company
is responsible for contributing registered capital of RMB <ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="avco:WorkingCapital" scale="0" unitRef="cny" id="ixv-90121">5,000,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c18" decimals="-5" format="ixt:num-dot-decimal" name="avco:WorkingCapital" scale="6" unitRef="usd" id="ixv-90122">0.7</ix:nonFraction> million) for working capital purposes as required
by local regulation, which is not required to be contributed immediately and will be contributed subject to the Company&#8217;s discretion.
As of the date hereof, Avactis&#8217; activities have been limited to that of a patent holding company and there is no other activity
or planned contributions in 2025 or into the foreseeable future.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c18" continuedAt="_SubsequentEventsTextBlock-c18_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-64300"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 22 - <span style="text-decoration:underline">SUBSEQUENT
EVENTS</span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company evaluated
subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued.
Based upon this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment
or disclosure in the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Series D Convertible
Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On January 6, 2025, the
Company filed a certificate of designations of preferences, rights, and limitations of Series D Convertible Preferred Stock (the &#8220;Series
D Certificate of Designations&#8221;) with the Department of State, Division of Corporations, of the State of Delaware, which provides
for the designation of <ix:nonFraction contextRef="c545" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-90123">5,000</ix:nonFraction> shares of Series D Preferred Stock of the Company, par value $<ix:nonFraction contextRef="c546" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-90124">0.0001</ix:nonFraction> per share, upon the terms and conditions
as set forth in the Series D Certificate of Designations. Each share of Series D Preferred Stock has a stated value of $<ix:nonFraction contextRef="c546" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-90125">1,000</ix:nonFraction> (the &#8220;Stated
Value&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Series D Preferred
Stock shall rank (i) senior to the Company&#8217;s common stock (the &#8220;Common Stock&#8221;) and any other class or series of capital
stock of the Company created hereafter, the terms of which specifically provide that such class or series shall rank junior to the Series
D Preferred Stock, (ii) pari passu with any class or series of capital stock of the Company created hereafter specifically ranking, by
its terms, on par with the Series D Preferred Stock, (iii) pari passu with the Series B Convertible Preferred Stock of the Company (the
&#8220;Series B Preferred Stock&#8221;) with respect to its rights, preferences and restrictions, and (iv) pari passu with the Series
C Convertible Preferred Stock of the Company (the &#8220;Series C Preferred Stock&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Holders of the Series
D Preferred Stock have no voting power except as otherwise required by the Delaware General Corporation Law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Upon any liquidation,
dissolution or winding-up of the Company, whether voluntary or involuntary (a &#8220;Liquidation&#8221;), the holders of the Series D
Preferred Stock shall be entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to the
payment in full of all amounts required to be distributed to the holders of another class or series of stock of the Company ranking on
liquidation prior and in preference to the Series D Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any class
or series of stock ranking on liquidation on parity with the Series D Preferred Stock and (iii) in preference and priority to the holders
of the shares of Common Stock, an amount equal to <ix:nonFraction contextRef="c547" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" unitRef="pure" id="ixv-90126">100</ix:nonFraction>% of the Stated Value of the Series D Preferred Stock, in proportion to the full
and preferential amount that all shares of the Series D Preferred Stock are entitled to receive.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 354 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 22 - <span style="text-decoration:underline">SUBSEQUENT
EVENTS (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Series D Convertible
Preferred Stock (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c18_cont_2" id="_SubsequentEventsTextBlock-c18_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Each share of Series
D Preferred Stock shall be convertible into Common Stock (the &#8220;Conversion Shares&#8221;) at a conversion per share equal to $<ix:nonFraction contextRef="c17" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-90127">2.41</ix:nonFraction>,
at the option of the holder, at any time after the Company has obtained shareholder approval for the issuance of the Conversion Shares
pursuant to the rules of the Nasdaq Stock Market. In addition, the holder shall not have the right to convert any portion of the Series
D Preferred Stock if, after giving effect to the conversion, such holder (together with its affiliates) would beneficially own in excess
of <ix:nonFraction contextRef="c17" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedPercentOfNetAssets" scale="-2" unitRef="pure" id="ixv-90128">4.99</ix:nonFraction>% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of the respective Conversion
Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On January 9, 2025, the
Company entered into an exchange agreement with Wenzhao Lu, the Company&#8217;s chairman of the Board of Directors, pursuant to which
Mr. Lu exchanged <ix:nonFraction contextRef="c548" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-90129">9,000</ix:nonFraction> shares of Series A Preferred Stock of the Company for <ix:nonFraction contextRef="c549" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-90130">5,000</ix:nonFraction> shares of Series D Preferred Stock of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Redemption Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During 2025, to preserve
cash, the Company entered into discussions with Lab Services MSO for the potential redemption of our investment and on February 26, 2025,
the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement (the &#8220;Redemption Agreement&#8221;), whereby
Lab Services MSO redeemed the <ix:nonFraction contextRef="c550" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-90131">40</ix:nonFraction>% equity interest in Lab Services MSO held by the Company for cash and the surrender of its Series B Convertible
Preferred Stock having a carrying value of $<ix:nonFraction contextRef="c551" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-90132">11,000,000</ix:nonFraction>. The aggregate cash amount to the Company for the redemption was $<ix:nonFraction contextRef="c552" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RedemptionPremium" scale="0" unitRef="usd" id="ixv-90133">1,745,000</ix:nonFraction>, to
be paid as follows: one payment of $<ix:nonFraction contextRef="c553" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RedemptionPremium" scale="0" unitRef="usd" id="ixv-90134">95,000</ix:nonFraction> at the closing of the redemption and, beginning in March 2025, monthly payments of $75,000
until December 2026. In addition, pursuant to the terms of the Redemption Agreement, all shares of the Company&#8217;s Series B Convertible
Preferred Stock previously issued to SCBC Holdings LLC as partial consideration for the equity interests of Laboratory Services MSO, were
permanently surrendered and relinquished to the Company for no additional consideration. Accordingly, beginning in February 2025, the
Company no longer offers laboratory services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Agreement and Plan
of Merger</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On March 7, 2025, the
Company, Nexus MergerSub Limited, a business company incorporated in the British Virgin Islands and a wholly owned subsidiary of the Company
(&#8220;Merger Sub&#8221;), and YOOV Group Holding Limited, a business company incorporated in the British Virgin Islands (&#8220;YOOV&#8221;),
entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) pursuant to which Merger Sub will merge with and into
YOOV, with YOOV surviving the merger and becoming a direct, wholly owned subsidiary of the Company (the &#8220;Merger&#8221;). The Merger
is expected to be completed in the third quarter of 2025, subject to customary closing conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms and conditions of the Merger
Agreement, immediately prior to the effective time of the Merger (the &#8220;Effective Time&#8221;), each then-outstanding share of YOOV
preferred shares, par value $<ix:nonFraction contextRef="c554" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-90135">0.10</ix:nonFraction> per share, will either automatically be converted into shares of YOOV ordinary shares, par value $<ix:nonFraction contextRef="c555" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-90136">0.10</ix:nonFraction>
per share (the &#8220;YOOV Ordinary Shares&#8221;) or canceled and cease to exist in accordance with their terms. At the Effective Time,
each then-outstanding YOOV Ordinary Share (other than any shares held in treasury and Dissenting Shares (as defined in the Merger Agreement))
will be automatically converted into a number of shares of the Company&#8217;s common stock, par value $<ix:nonFraction contextRef="c18" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceDecrease" scale="0" unitRef="usdPershares" id="ixv-90137">0.0001</ix:nonFraction> per share (the &#8220;Avalon
Common Stock&#8221;), equal to the Exchange Ratio. The &#8220;Exchange Ratio&#8221; will be the ratio (rounded to four decimal places),
determined as follows: if the closing price of the Avalon Common Stock on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) on the second
trading day immediately preceding the Effective Time is (x) less than or equal to $<ix:nonFraction contextRef="c18" decimals="2" format="ixt:num-dot-decimal" name="avco:ExchangeRatioPerShare" scale="0" unitRef="usdPershares" id="ixv-90138">5.00</ix:nonFraction>, the Exchange Ratio shall be <ix:nonFraction contextRef="c556" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-90139">60,000,000</ix:nonFraction> divided
by YOOV Outstanding Shares (as defined in the Merger Agreement); or (y) greater than $<ix:nonFraction contextRef="c557" decimals="2" format="ixt:num-dot-decimal" name="avco:ExchangeRatioPerShare" scale="0" unitRef="usdPershares" id="ixv-90140">5.00</ix:nonFraction>, the Exchange Ratio shall be <ix:nonFraction contextRef="c558" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-90141">54,000,000</ix:nonFraction> divided
by YOOV Outstanding Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Merger Agreement,
(i) each then-outstanding share of Avalon Common Stock will remain issued and outstanding after the Effective Time and (ii) each then-outstanding
option to purchase Avalon Common Stock, whether or not vested, will remain issued and outstanding after the Effective Time. The then-outstanding
shares of Series C Convertible Preferred Stock of the Company and Series D Convertible Preferred Stock of the Company will remain outstanding
in accordance with their terms. Additionally, at the Effective Time, the name of the Company will be changed to &#8220;YOOV, Inc.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Merger, the Company will
seek approval of its stockholders to, among other things, (i) approve the issuance of the shares of Avalon Common Stock to be issued to
YOOV shareholders in connection with the Merger pursuant to the rules of Nasdaq and (ii) amend the Company&#8217;s certificate of incorporation
to effect a reverse stock split of the Avalon Common Stock to the extent the Company and YOOV mutually agree implementing such reverse
stock split is necessary to meet Nasdaq&#8217;s listing requirements (collectively, the &#8220;Avalon Stockholder Matters&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the Company and YOOV have made customary
representations, warranties and covenants in the Merger Agreement, including, among other things, covenants relating to (i) obtaining
the requisite approval of its respective stockholders, (ii) non-solicitation or facilitation of any Takeover Proposal or Superior Proposal
(as each is defined in the Merger Agreement), (iii) the conduct of its respective business during the period between the signing of the
Merger Agreement and the closing of the Merger, and (iv) the Company filing with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;)
and causing to become effective a registration statement on Form S-4 (the &#8220;Registration Statement&#8221;) to register the shares
of Avalon Common Stock to be issued in connection with the Merger.</p></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 355 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><b>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 22 - <span style="text-decoration:underline">SUBSEQUENT
EVENTS (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Agreement and Plan
of Merger (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c18_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consummation of the Merger is subject to certain
closing conditions, including, among other things, (i) approval of the Avalon Stockholder Matters by the requisite the Company stockholders,
(ii) adoption and approval of the Merger Agreement, and the transactions contemplated thereby, by the requisite YOOV shareholders, (iii)
the effectiveness of the Registration Statement and (iv) the listing of the Avalon Common Stock issuable in connection with the Merger
on Nasdaq. Each party&#8217;s obligation to consummate the Merger is also subject to other specified customary conditions, including regarding
the accuracy of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance
in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the
Effective Time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Merger Agreement contains certain termination
rights for both the Company and YOOV, including the right to terminate the Merger Agreement at any time before the Effective Time, whether
before or after the Avalon Stockholder Matters have been approved, by mutual written consent of the parties. In addition, the Merger Agreement
may be terminated at any time by either party if the Merger is not consummated on or before March 7, 2026 (the &#8220;End Date&#8221;),
provided that the End Date may be extended by either party for up to 60 days in the event that the SEC has not declared effective the
Registration Statement by the date which is 60 days prior to the End Date. Upon termination of the Merger Agreement under specified circumstances,
the Company may be required to pay YOOV a termination fee of $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" scale="6" unitRef="usd" id="ixv-90142">1.0</ix:nonFraction> million; however, YOOV is not required to pay the Company a termination
fee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Effective Time, the board of directors
of the Company (the &#8220;Avalon Board&#8221;) is expected to consist of seven (7) members, five (5) of whom will be designated by YOOV
and two (2) of whom will be designated by the Company, as provided in the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Voting and Support Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrently with the execution of the Merger
Agreement, (i) the officers, directors and certain shareholders of YOOV (solely in their respective capacities as YOOV shareholders) have
entered into voting and support agreements with the Company and YOOV, pursuant to which such YOOV shareholders agree, among other things
to, (a) not transfer their capital stock of YOOV, subject to certain limited exceptions and (b) vote all of their shares of capital stock
of YOOV in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and against, among other
things, any Takeover Proposals (the &#8220;YOOV Voting Agreement&#8221;) and (ii) the officers, directors and certain stockholders of
the Company (solely in their respective capacities as Avalon Stockholders) have entered into voting and support agreements with the Company
and YOOV, pursuant to which such the Company stockholders agree, among other things to, (a) not transfer their capital stock of the Company,
subject to certain limited exceptions and (b) vote all of their shares of capital stock of the Company in favor of, among other things,
the Avalon Stockholder Matters and against, among other things, any Takeover Proposals (the &#8220;Avalon Voting Agreement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Lock-Up Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrently with the execution of the Merger
Agreement, certain directors, officers and stockholders of each of the Company and YOOV have entered into lock-up agreements (the &#8220;Lock-Up
Agreement&#8221;), pursuant to which, subject to specified exceptions, they have agreed not to transfer their shares of Avalon Common
Stock, during the 180-day period following the Effective Time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Certificates of Elimination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company previously designated (i) <ix:nonFraction contextRef="c559" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-90143">15,000</ix:nonFraction> shares
of preferred stock as Series A Convertible Preferred Stock (the &#8220;Series A Preferred Stock&#8221;), of which no shares remain outstanding
as a result of the exchange agreement entered with Wenzhao Lu on January 9, 2025 and (ii) <ix:nonFraction contextRef="c560" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-90144">15,000</ix:nonFraction> shares of Series B Preferred Stock, of
which no shares remain outstanding as a result of the surrender of the Series B Preferred Stock in connection with the redemption and
abandonment agreement with the Company, Avalon Laboratory Services, Inc., Laboratory Services MSO, LLC and the other parties signatory
thereto on February 26, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2025, the Company filed a Certificate
of Elimination relating to each of the Series A Preferred Stock and the Series B Preferred Stock (the &#8220;Eliminations of Designation&#8221;)
with the Secretary of State of the State of Delaware, thereby terminating the designations of the Series A Preferred Stock and the Series
B Preferred Stock. The Eliminations of Designation were effective upon filing and eliminated from the Company&#8217;s Amended and Restated
Certificate of Incorporation (as amended and/or restated from time to time, the &#8220;Avalon Charter&#8221;) all matters set forth in
the previously-filed Certificates of Designations with respect to the previously designated Series A Preferred Stock and Series B Preferred
Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Bylaws Amendment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2025, the Avalon Board approved and
adopted an amendment (the&#160;&#8220;Amendment&#8221;) to the Company&#8217;s Amended and Restated Bylaws (the&#160;&#8220;Avalon Bylaws&#8221;).&#160;The
Amendment reduces the quorum at any meeting of stockholders, except as otherwise required by law or by the Avalon Charter or the Avalon
Bylaws, to one-third of the voting power of the shares of capital stock outstanding and entitled to vote at the meeting, present in person,
present by remote communication, if applicable, or represented by proxy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Shares Issued for Warrant Exercise</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2025, the Company issued <ix:nonFraction contextRef="c561" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-90145">186,877</ix:nonFraction> shares
of its common stock upon cashless exercise of warrants to purchase <ix:nonFraction contextRef="c562" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-90146">11,833</ix:nonFraction> shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Shares Issued for Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2025, the Company issued a total of <ix:nonFraction contextRef="c563" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-90147">22,278</ix:nonFraction>
shares of its common stock for services rendered and to be rendered. These shares were valued at $<ix:nonFraction contextRef="c564" decimals="0" format="ixt:num-dot-decimal" name="avco:FairMarketValuesOfGrantDates" scale="0" unitRef="usd" id="ixv-90148">113,847</ix:nonFraction>, the fair market values on the
grant dates using the reported closing share prices on the dates of grant.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 356 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><div><a id="s1_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">CONDENSED CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><b style="-keep: true">March 31,</b></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><b style="-keep: true">December 31,</b></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b style="-keep: true">2025</b></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b style="-keep: true">2024</b></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">(Unaudited)</span></td><td><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">ASSETS</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td colspan="2" style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt">&#160;</td><td style="font-size: 12pt">&#160;</td>
    <td colspan="2" style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">CURRENT ASSETS:</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 9.25pt"><span style="-keep: true">Cash</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-90149">1,369,586</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd" id="ixv-90150">2,856,309</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Rent receivable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-90151">81,854</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-90152">80,829</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Receivable from sale of equity method investment, current portion</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-90153">975,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt"><span style="-keep: true">Prepaid expense and other current assets</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-90154">367,818</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-90155">299,360</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 18.25pt"><span style="-keep: true">Total Current Assets</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-90156">2,794,258</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-90157">3,236,498</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">NON-CURRENT ASSETS:</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Operating lease right-of-use assets, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-90158">113,253</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-90159">4,709</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Receivable from sale of equity method investment, noncurrent portion</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestmentsAndReceivablesNet" scale="0" unitRef="usd" id="ixv-90160">675,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Property and equipment, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-90161">10,660</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-90162">12,912</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Investment in real estate, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RealEstateInvestments" scale="0" unitRef="usd" id="ixv-90163">6,980,551</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RealEstateInvestments" scale="0" unitRef="usd" id="ixv-90164">7,022,721</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Equity method investments, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-90165">10,636,544</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt"><span style="-keep: true">Other non-current assets</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-90166">36,067</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-90167">71,794</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 18.25pt"><span style="-keep: true">Total Non-current Assets</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-90168">7,815,531</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-90169">17,748,680</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 18.25pt"><span style="-keep: true">Total Assets</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-90170">10,609,789</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-90171">20,985,178</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><span style="-keep: true">LIABILITIES AND (DEFICIT) EQUITY</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">CURRENT LIABILITIES:</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Accrued professional fees</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" unitRef="usd" id="ixv-90172">984,869</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" unitRef="usd" id="ixv-90173">611,462</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Accrued research and development fees</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="avco:AccruedResearchAndDevelopmentsFees" scale="0" unitRef="usd" id="ixv-90174">153,772</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="avco:AccruedResearchAndDevelopmentsFees" scale="0" unitRef="usd" id="ixv-90175">153,772</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Accrued payroll liability and compensation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedPayrollTaxesCurrent" scale="0" unitRef="usd" id="ixv-90176">550,931</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedPayrollTaxesCurrent" scale="0" unitRef="usd" id="ixv-90177">501,258</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Accrued litigation settlement</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LitigationReserveCurrent" scale="0" unitRef="usd" id="ixv-90178">373,450</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LitigationReserveCurrent" scale="0" unitRef="usd" id="ixv-90179">373,450</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Accrued liabilities and other payables</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-90180">524,872</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-90181">434,117</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Accrued liabilities and other payables - related parties</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-90182">100,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-90183">732,916</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Operating lease obligation, current portion</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-90184">67,547</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-90185">10,709</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Advance from pending sale of noncontrolling interest - related party</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" scale="0" unitRef="usd" id="ixv-90186">3,328,078</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" scale="0" unitRef="usd" id="ixv-90187">3,108,106</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Derivative liability</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-90188">223,052</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-90189">127,545</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Note payable, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableToBankCurrent" scale="0" unitRef="usd" id="ixv-90190">5,745,254</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableToBankCurrent" scale="0" unitRef="usd" id="ixv-90191">5,715,447</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt"><span style="-keep: true">Convertible note payable, net</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-90192">2,397,528</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-90193">2,113,773</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 18.25pt"><span style="-keep: true">Total Current Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-90194">14,449,353</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-90195">13,882,555</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">NON-CURRENT LIABILITIES:</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt"><span style="-keep: true">Operating lease obligation, noncurrent portion</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-90196">51,706</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-20"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 18.25pt"><span style="-keep: true">Total Non-current Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-90197">51,706</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-21"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 18.25pt"><span style="-keep: true">Total Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-90198">14,501,059</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-90199">13,882,555</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Commitments and Contingencies (Note 15)</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-22"><span style="-keep: true">&#160;</span></div></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-23"><span style="-keep: true">&#160;</span></div></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">(DEFICIT) EQUITY:</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9.25pt"><span style="-keep: true">Preferred stock, $<ix:nonFraction contextRef="c11" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-90200"><ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-90201">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-90202"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-90203">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24"><span style="-keep: true">&#160;</span></div></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25"><span style="-keep: true">&#160;</span></div></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27.25pt"><span style="-keep: true">Series A convertible preferred stock, <ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-90204"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-90205">0</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-90206"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-90207">9,000</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-90208">9,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27.25pt"><span style="-keep: true">Series B convertible preferred stock, <ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-90209"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-90210">0</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-90211"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-90212">11,000</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-90213">11,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27.25pt"><span style="-keep: true">Series C convertible preferred stock, <ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-90214"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-90215"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-90216"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-90217">3,500</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2025 and December 31, 2024; Liquidation preference $<ix:nonFraction contextRef="c15" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreferenceValue" scale="6" unitRef="usd" id="ixv-90218">3.5</ix:nonFraction> million at March 31, 2025</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-90219">3,500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-90220">3,500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27.25pt"><span style="-keep: true">Series D convertible preferred stock, <ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-90221"><ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-90222">5,000</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-90223"><ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-90224">0</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively; Liquidation preference $<ix:nonFraction contextRef="c16" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreferenceValue" scale="6" unitRef="usd" id="ixv-90225">5</ix:nonFraction> million at March 31, 2025</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-90226">8,837,527</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 9.25pt"><span style="-keep: true">Common stock, $<ix:nonFraction contextRef="c11" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-90227"><ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-90228">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-90229"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-90230">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 27.25pt"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-90231">1,655,134</ix:nonFraction> shares issued and <ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-90232">1,651,667</ix:nonFraction> shares outstanding at March 31, 2025; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-90233">1,445,979</ix:nonFraction> shares issued and <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-90234">1,442,512</ix:nonFraction> shares outstanding at December 31, 2024</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-90235">166</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-90236">145</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Additional paid-in capital</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-90237">74,673,916</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd" id="ixv-90238">72,023,525</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Less: common stock held in treasury, at cost;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 18.25pt"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" unitRef="shares" id="ixv-90239"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" unitRef="shares" id="ixv-90240">3,467</ix:nonFraction></ix:nonFraction> shares at March 31, 2025 and December 31, 2024</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonValue" scale="0" unitRef="usd" id="ixv-90241">522,500</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonValue" scale="0" unitRef="usd" id="ixv-90242">522,500</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Accumulated deficit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-90243">90,155,236</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-90244">87,673,125</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Statutory reserve</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" scale="0" unitRef="usd" id="ixv-90245">6,578</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" scale="0" unitRef="usd" id="ixv-90246">6,578</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt"><span style="-keep: true">Accumulated other comprehensive loss</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-90247">231,721</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-90248">232,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt"><span style="-keep: true">Total Avalon GloboCare Corp. stockholders&#8217; (deficit) equity</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-90249">3,891,270</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-90250">7,102,623</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt"><span style="-keep: true">Noncontrolling interest</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 18.25pt"><span style="-keep: true">Total (Deficit) Equity</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-90251">3,891,270</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90252">7,102,623</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-size: 12pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 18.25pt"><span style="-keep: true">Total Liabilities and (Deficit) Equity</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-90253">10,609,789</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-90254">20,985,178</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">See accompanying notes to the condensed consolidated
financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 357; Options: NewSection; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>



</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><div><a id="s1_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b style="-keep: true">AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b style="-keep: true">CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b style="-keep: true">(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center"><span style="-keep: true">For the Three Months Ended</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">March 31,</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">REAL PROPERTY RENTAL REVENUE</span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-90255">349,800</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-90256">314,588</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">REAL PROPERTY OPERATING EXPENSES</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-90257">280,390</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-90258">263,126</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">REAL PROPERTY OPERATING INCOME</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd" id="ixv-90259">69,410</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd" id="ixv-90260">51,462</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">INCOME FROM EQUITY METHOD INVESTMENT - LAB SERVICES MSO</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="0" unitRef="usd" id="ixv-90261">392,677</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="0" unitRef="usd" id="ixv-90262">107,469</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">OTHER OPERATING EXPENSES:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-keep: true">Advertising and marketing expenses</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MarketingAndAdvertisingExpense" scale="0" unitRef="usd" id="ixv-90263">71,150</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MarketingAndAdvertisingExpense" scale="0" unitRef="usd" id="ixv-90264">45,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-keep: true">Professional fees</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-90265">1,691,579</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-90266">442,335</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-keep: true">Compensation and related benefits</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="0" unitRef="usd" id="ixv-90267">340,420</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="0" unitRef="usd" id="ixv-90268">353,571</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt"><span style="-keep: true">Other general and administrative expenses</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-90269">165,713</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-90270">161,087</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 18.25pt"><span style="-keep: true">Total Other Operating Expenses</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" unitRef="usd" id="ixv-90271">2,268,862</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" unitRef="usd" id="ixv-90272">1,001,993</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">LOSS FROM OPERATIONS</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-90273">1,806,775</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-90274">843,062</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">OTHER (EXPENSE) INCOME</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-keep: true">Interest expense - amortization of debt discount and debt
    issuance costs</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="0" unitRef="usd" id="ixv-90275">313,562</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="0" unitRef="usd" id="ixv-90276">272,196</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-keep: true">Interest expense - other</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-90277">246,456</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd" id="ixv-90278">236,215</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-keep: true">Interest expense - related party</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">-</span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="0" unitRef="usd" id="ixv-90279">10,596</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-keep: true">Change in fair value of derivative liability</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-90280">114,360</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" sign="-" unitRef="usd" id="ixv-90281">31,212</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt"><span style="-keep: true">Other expense</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="0" unitRef="usd" id="ixv-90282">958</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="0" unitRef="usd" id="ixv-90283">36,656</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 18.25pt"><span style="-keep: true">Total Other Expense, net</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-90284">675,336</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-90285">524,451</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">LOSS BEFORE INCOME TAXES</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-90286">2,482,111</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-90287">1,367,513</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">INCOME TAXES</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-40"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">NET LOSS</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-90288">2,482,111</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-90289">1,367,513</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">NET LOSS AFTER NONCONTROLLING INTEREST</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-90290">2,482,111</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-90291">1,367,513</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">DEEMED CONTRIBUTION ON EXCHANGE OF EQUITY INSTRUMENTS</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="avco:DeemedContributionOnExchangeOfEquityInstruments" scale="0" unitRef="usd" id="ixv-90292">162,473</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd" id="ixv-90293">2,319,638</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd" id="ixv-90294">1,367,513</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 9.25pt"><span style="-keep: true">NET LOSS PER COMMON SHARE ATTRIBUTABLE
    TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 9.25pt"><span style="-keep: true">Basic and diluted</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c20" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-90295"><ix:nonFraction contextRef="c20" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-90296">1.43</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c21" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-90297"><ix:nonFraction contextRef="c21" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-90298">1.86</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt"><span style="-keep: true">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 9.25pt"><span style="-keep: true">Basic and diluted</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-90299"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-90300">1,624,629</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-90301"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-90302">735,225</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">COMPREHENSIVE LOSS:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-keep: true">NET LOSS</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-90303">2,482,111</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-90304">1,367,513</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-keep: true">OTHER COMPREHENSIVE INCOME (LOSS)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 18.25pt"><span style="-keep: true">Unrealized foreign currency translation
    gain (loss)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" scale="0" sign="-" unitRef="usd" id="ixv-90305">279</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" scale="0" unitRef="usd" id="ixv-90306">2,920</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-keep: true">COMPREHENSIVE LOSS</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-90307">2,481,832</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-90308">1,370,433</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt"><span style="-keep: true">LESS: COMPREHENSIVE LOSS ATTRIBUTABLE
    TO NONCONTROLLING INTEREST</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 18.25pt"><span style="-keep: true">COMPREHENSIVE LOSS
    ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-90309">2,481,832</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd" id="ixv-90310">1,370,433</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">See accompanying notes to the condensed consolidated
financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 358; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><div><a id="s1_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b style="-keep: true">AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b style="-keep: true">CONDENSED CONSOLIDATED
STATEMENTS OF CHANGES IN (DEFICIT) EQUITY</b></p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-size: 10pt"><b>For
the Three Months Ended March 31, 2025</b></span><b style="-keep: true"><span style="font-size: 8pt">&#160;</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b style="-keep: true">(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="62" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Avalon GloboCare Corp. Stockholders&#8217;
    (Deficit) Equity</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Series A<br/> Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Series B<br/> Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Series C Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Series D Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Common Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 8pt">&#160;<b>Additional</b></span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Treasury Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;<b>Accumulated
    Other</b></span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number&#160;of Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number&#160;of Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number&#160;of Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number&#160;of Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number&#160;of Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Paid-in Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number&#160;of Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Accumulated Deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Statutory Reserve</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Comprehensive Loss (Deficit)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Noncontrolling Interest</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Total &#160; Equity</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Balance, January 1, 2025</span></td><td style="width: 0%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 4%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c61" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-90311">9,000</ix:nonFraction></span></td><td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 0%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 4%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90312">9,000,000</ix:nonFraction></span></td><td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 0%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 4%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c62" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-90313">11,000</ix:nonFraction></span></td><td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 0%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 4%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90314">11,000,000</ix:nonFraction></span></td><td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 0%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 4%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c63" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-90315">3,500</ix:nonFraction></span></td><td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 0%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 4%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90316">3,500,000</ix:nonFraction></span></td><td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 0%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 4%; text-align: right"><span style="-keep: true">-</span></td><td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 0%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 4%; text-align: right"><span style="-keep: true">-</span></td><td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 0%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 4%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c64" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-90317">1,445,979</ix:nonFraction></span></td><td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 0%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 4%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90318">145</ix:nonFraction></span></td><td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 0%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 4%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90319">72,023,525</ix:nonFraction></span></td><td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 0%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 4%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c66" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-90320">3,467</ix:nonFraction></span></td><td style="width: 0%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 0%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 4%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-90321">522,500</ix:nonFraction></span></td><td style="width: 0%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 0%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 4%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-90322">87,673,125</ix:nonFraction></span></td><td style="width: 0%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 0%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 4%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90323">6,578</ix:nonFraction></span></td><td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 0%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 4%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90324">7,102,623</ix:nonFraction></span></td><td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 0%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 4%; text-align: right"><span style="-keep: true">-</span></td><td style="width: 0%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 0%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 0%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 4%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-90325">232,000</ix:nonFraction></span></td><td style="width: 0%; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Issuance of common stock upon cashless exercise of
    stock warrants</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-204"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-205"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-206"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c74" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-90326">186,877</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-90327">19</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" sign="-" unitRef="usd" id="ixv-90328">19</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Issuance of common stock for services</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-208"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c74" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-90329">22,278</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-90330">2</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-90331">111,230</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd" id="ixv-90332">111,232</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Reclassification of derivative liability to equity</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-210"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-211"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="0" unitRef="usd" id="ixv-90333">18,853</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="0" unitRef="usd" id="ixv-90334">18,853</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Series D Convertible Preferred Stock issued in exchange
    of Series A Convertible Preferred Stock</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c71" decimals="INF" format="ixt:num-dot-decimal" name="avco:StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" scale="0" sign="-" unitRef="shares" id="ixv-90335">9,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" scale="0" sign="-" unitRef="usd" id="ixv-90336">9,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-215"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-216"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c77" decimals="INF" format="ixt:num-dot-decimal" name="avco:StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" scale="0" unitRef="shares" id="ixv-90337">5,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" scale="0" unitRef="usd" id="ixv-90338">8,837,527</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-217"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-218"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" scale="0" unitRef="usd" id="ixv-90339">162,473</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-219"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-220"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-221"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-222"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-223"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Series B Convertible Preferred Stock extinguished related
    to sale of equity method investment</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c72" decimals="INF" format="ixt:num-dot-decimal" name="avco:SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments" scale="0" sign="-" unitRef="shares" id="ixv-90340">11,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="avco:SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment" scale="0" sign="-" unitRef="usd" id="ixv-90341">11,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="avco:SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment" scale="0" unitRef="usd" id="ixv-90342">2,348,695</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="avco:SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment" scale="0" sign="-" unitRef="usd" id="ixv-90343">8,651,305</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Stock-based compensation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-224"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-225"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-226"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-228"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-90344">9,159</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-229"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-230"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-90345">9,159</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-231"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-232"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Foreign currency translation adjustment</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-233"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-234"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-235"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-236"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-237"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-238"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-239"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-240"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" unitRef="usd" id="ixv-90346">279</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-241"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" unitRef="usd" id="ixv-90347">279</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Net loss for the three months ended March 31,
    2025</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-242"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-243"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-244"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-245"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-246"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-247"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-90348">2,482,111</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-248"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-90349">2,482,111</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-249"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Balance, March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-250"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-251"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-252"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-253"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c83" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-90350">3,500</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90351">3,500,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c84" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-90352">5,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90353">8,837,527</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c85" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-90354">1,655,134</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90355">166</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90356">74,673,916</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c87" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-90357">3,467</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-90358">522,500</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-90359">90,155,236</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90360">6,578</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-90361">3,891,270</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-254"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-90362">231,721</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  </table><div>


</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">See accompanying notes to the condensed consolidated
financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 359; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><div><a id="s1_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES
IN EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">For the Three Months Ended March 31, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="47" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-keep: true">Avalon GloboCare Corp. Stockholders&#8217; Equity</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 8pt">Series A<br/>
    Preferred Stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 8pt">Series B<br/>
    Preferred Stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 8pt">Common Stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;Additional</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 8pt">Treasury Stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">Accumulated Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 8pt">&#160;</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 8pt">Number&#160;of Shares</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 8pt">Number&#160;of Shares</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 8pt">Number of Shares</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-size: 8pt; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 8pt">Paid-in
    Capital</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 8pt">Number&#160;of Shares</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 8pt">Accumulated Deficit</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 8pt">Statutory Reserve</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 8pt">Comprehensive Loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 8pt">Noncontrolling Interest</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-size: 8pt">Total Equity</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 23%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Balance, January
    1, 2024</span></td><td style="width: 0.5%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c42" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-90363">9,000</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.5%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90364">9,000,000</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.5%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c43" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-90365">11,000</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.5%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90366">11,000,000</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.5%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c45" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-90367">736,769</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.5%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90368">74</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.5%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90369">67,886,082</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.5%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c47" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-90370">3,467</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 0.5%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-90371">522,500</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">)</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.5%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-90372">79,769,731</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 0.5%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90373">6,578</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.5%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-90374">231,727</ix:nonFraction></span></td><td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 0.5%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255"><span style="font-size: 8pt">&#160;&#160;&#160;&#160;-</span></div></td><td style="width: 0.5%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.5%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right; width: 4%"><span style="font-size: 8pt">$<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90375">7,368,776</ix:nonFraction></span></td>
    <td style="width: 0.5%"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Issuance of common stock
    as convertible note payable commitment fee</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-256"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-257"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c94" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-90376">7,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-90377">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-90378">41,999</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-258"><span style="font-size: 8pt">&#160;</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-259"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-260"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-261"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-90379">42,000</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Stock-based compensation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-262"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-263"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-264"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-90380">13,533</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-265"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-266"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-267"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-268"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-90381">13,533</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Foreign currency translation
    adjustment</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-269"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-270"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-271"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-272"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-273"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-274"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" sign="-" unitRef="usd" id="ixv-90382">2,920</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-275"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="0" sign="-" unitRef="usd" id="ixv-90383">2,920</ix:nonFraction>)</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Net
    loss for the three months ended March 31, 2024</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-276"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-277"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-278"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-279"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-90384">1,367,513</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-280"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-281"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-282"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-90385">1,367,513</ix:nonFraction>)</span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Balance,
    March 31, 2024</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c101" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-90386">9,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90387">9,000,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c102" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-90388">11,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90389">11,000,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c103" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-90390">743,769</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90391">75</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90392">67,941,614</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c105" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-90393">3,467</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-90394">522,500</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-90395">81,137,244</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90396">6,578</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-90397">234,647</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-283"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">$<ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd" id="ixv-90398">6,053,876</ix:nonFraction></span></td>
    <td><span style="font-size: 8pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">See accompanying notes to the condensed consolidated
financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 360; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><div><a id="s1_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center"><span style="-keep: true">For the Three Months Ended</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">March 31,</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left"><span style="-keep: true">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 76%; font-size: 10pt; text-align: left"><span style="-keep: true">Net loss</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-90399">2,482,111</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-90400">1,367,513</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left"><span style="-keep: true">Adjustments to reconcile net loss to
    net cash used in operating activities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-size: 10pt"><span style="-keep: true">Depreciation</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-90401">44,428</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-90402">44,481</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-size: 10pt; text-align: left"><span style="-keep: true">Change in straight-line rent receivable</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StraightLineRent" scale="0" sign="-" unitRef="usd" id="ixv-90403">29,288</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StraightLineRent" scale="0" sign="-" unitRef="usd" id="ixv-90404">20,548</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-size: 10pt; text-align: left"><span style="-keep: true">Amortization of operating lease right-of-use
    asset</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd" id="ixv-90405">18,956</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd" id="ixv-90406">29,448</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-size: 10pt; text-align: left"><span style="-keep: true">Stock-based compensation and service
    expense</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-90407">26,371</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-90408">45,746</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-size: 10pt; text-align: left"><span style="-keep: true">Income from equity method investment</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd" id="ixv-90409">392,677</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" unitRef="usd" id="ixv-90410">107,469</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-size: 10pt; text-align: left"><span style="-keep: true">Distribution of earnings from equity
    method investment</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-307"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="avco:DistributionOfEarningsFromEquityMethodInvestment" scale="0" sign="-" unitRef="usd" id="ixv-90411">160,788</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-size: 10pt; text-align: left"><span style="-keep: true">Amortization of debt issuance costs
    and debt discount</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="avco:BeneficialConversionFeatureRelatedToConvertibleNotePayable" scale="0" sign="-" unitRef="usd" id="ixv-90412">313,562</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="avco:BeneficialConversionFeatureRelatedToConvertibleNotePayable" scale="0" sign="-" unitRef="usd" id="ixv-90413">272,196</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-size: 10pt; text-align: left"><span style="-keep: true">Change in fair market value of derivative
    liability</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-90414">114,360</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" sign="-" unitRef="usd" id="ixv-90415">31,212</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left"><span style="-keep: true">Changes in operating assets and liabilities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-size: 10pt; text-align: left"><span style="-keep: true">Rent receivable</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-308"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="0" sign="-" unitRef="usd" id="ixv-90416">113,024</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-size: 10pt; text-align: left"><span style="-keep: true">Security deposit</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInSecurityDeposits" scale="0" unitRef="usd" id="ixv-90417">5,473</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-309"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-size: 10pt; text-align: left"><span style="-keep: true">Deferred leasing costs</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="avco:IncreaseDecreaseInDeferredLeasingCosts" scale="0" unitRef="usd" id="ixv-90418">8,021</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="avco:IncreaseDecreaseInDeferredLeasingCosts" scale="0" unitRef="usd" id="ixv-90419">8,350</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-size: 10pt; text-align: left"><span style="-keep: true">Prepaid expense and other assets</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd" id="ixv-90420">24,698</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd" id="ixv-90421">3,739</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-size: 10pt; text-align: left"><span style="-keep: true">Accrued liabilities and other payables</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-90422">556,057</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" scale="0" sign="-" unitRef="usd" id="ixv-90423">14,758</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-size: 10pt; text-align: left"><span style="-keep: true">Accrued liabilities and other payables
    - related parties</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-310"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="avco:AccruedLiabilitiesAndOtherPayablesRelatedParties" scale="0" unitRef="usd" id="ixv-90424">62,151</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Operating lease
    obligation</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd" id="ixv-90425">18,956</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="0" sign="-" unitRef="usd" id="ixv-90426">23,448</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">NET CASH USED
    IN OPERATING ACTIVITIES</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-90427">1,801,926</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-90428">915,709</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left"><span style="-keep: true">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Proceeds from
    sale of equity method investment</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="0" unitRef="usd" id="ixv-90429">95,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-311"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">NET CASH PROVIDED
    BY INVESTING ACTIVITIES</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" unitRef="usd" id="ixv-90430">95,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-312"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left"><span style="-keep: true">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left"><span style="-keep: true">Proceeds from issuance of convertible
    debt and warrants</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-313"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="avco:ProceedsFromIssuanceOfConvertibleDebtAndWarrants" scale="0" sign="-" unitRef="usd" id="ixv-90431">665,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left"><span style="-keep: true">Payments of convertible debt issuance
    costs</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-314"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="avco:PaymentsOfConvertibleDebtIssuanceCosts" scale="0" unitRef="usd" id="ixv-90432">72,700</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left"><span style="-keep: true">Repayments of convertible debt</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-315"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="0" unitRef="usd" id="ixv-90433">866,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Advance from
    pending sale of noncontrolling interest in subsidiary</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" scale="0" unitRef="usd" id="ixv-90434">219,972</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" scale="0" unitRef="usd" id="ixv-90435">1,210,472</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">NET CASH PROVIDED
    BY FINANCING ACTIVITIES</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-90436">219,972</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-90437">936,772</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">EFFECT OF EXCHANGE
    RATE ON CASH</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-90438">231</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" sign="-" unitRef="usd" id="ixv-90439">995</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left"><span style="-keep: true">NET (DECREASE) INCREASE IN CASH</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-90440">1,486,723</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd" id="ixv-90441">20,068</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">CASH - beginning of period</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-90442">2,856,309</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-90443">285,400</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">CASH - end of period</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-90444">1,369,586</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-90445">305,468</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left"><span style="-keep: true">SUPPLEMENTAL DISCLOSURE OF CASH FLOW
    INFORMATION:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left"><span style="-keep: true">Cash paid for:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">Interest</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-90446">164,500</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-90447">238,782</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-size: 10pt; text-align: left"><span style="-keep: true">NON-CASH INVESTING AND FINANCING ACTIVITIES:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Common stock issued
    for future services</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockAmountIssued1" scale="0" unitRef="usd" id="ixv-90448">51,635</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-316"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Common stock issued
    for accrued liabilities</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="avco:CommonStockIssuedForAccruedLiabilities" scale="0" unitRef="usd" id="ixv-90449">42,385</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-317"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Receivable related
    to sale of equity method investment</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="avco:ReceivableRelatedToSaleOfEquityMethodInvestment" scale="0" unitRef="usd" id="ixv-90450">1,745,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-318"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Related party
    payable extinguished upon sale of equity method investment</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="avco:RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment" scale="0" unitRef="usd" id="ixv-90451">632,916</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-319"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Series B Convertible
    Preferred Stock extinguished related to sale of equity method investment</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="avco:SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment" scale="0" unitRef="usd" id="ixv-90452">11,000,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-320"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Series D Convertible
    Preferred Stock issued in exchange of Series A Convertible Preferred Stock</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="avco:SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" scale="0" unitRef="usd" id="ixv-90453">9,000,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-321"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Warrants issued
    as convertible note payable finder&#8217;s fee</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-322"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="avco:WarrantsIssuedAsConvertibleNotePayableFindersFee" scale="0" unitRef="usd" id="ixv-90454">1,679</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Warrants issued
    with convertible note payable recorded as debt discount</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-323"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="avco:WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount" scale="0" unitRef="usd" id="ixv-90455">20,374</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Common stock issued
    as convertible note payable commitment fee</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-324"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="avco:CommonStockIssuedAsConvertibleNotePayableCommitmentFee" scale="0" unitRef="usd" id="ixv-90456">42,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Equity method
    investment payable paid by a related party</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-325"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd" id="ixv-90457">666,667</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Settlement of
    derivative liability</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="avco:SettlementsOfDerivativeLiability" scale="0" unitRef="usd" id="ixv-90458">18,853</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-326"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Issuance of common
    stock upon cashless exercise of stock warrants</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="avco:IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant" scale="0" unitRef="usd" id="ixv-90459">19</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-327"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Initial ROU asset
    and lease liability</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-90460">127,486</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-328"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">See accompanying notes to the condensed consolidated
financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 361; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><div><a id="s1_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP.
AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_NatureOfOperations-c0_cont_1" escape="true" name="us-gaap:NatureOfOperations" id="ixv-72279"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 1 - <span style="text-decoration:underline">ORGANIZATION AND NATURE OF OPERATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Avalon GloboCare Corp. (the &#8220;Company&#8221;
or &#8220;ALBT&#8221;) was incorporated under the laws of the State of Delaware on July 28, 2014.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">The Company is a
commercial-stage company dedicated to developing and delivering precision diagnostic consumer products and the advancement of intellectual
property in cellular therapy. The Company is currently marketing the KetoAir&#8482; breathalyzer device and plans to develop additional
diagnostic uses of the breathalyzer technology. The KetoAir</span><span style="font-size: 12.5pt"><sup>TM</sup></span> <span style="font-size: 10pt">is
registered with the U.S. Food and Drug Administration as a Class I medical device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On May 18, 2015, Avalon Healthcare System, Inc.
(&#8220;AHS&#8221;) was incorporated under the laws of the State of Delaware. AHS owns <ix:nonFraction contextRef="c565" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-90461">100</ix:nonFraction>% of the capital stock of Avalon (Shanghai)
Healthcare Technology Co., Ltd. (&#8220;Avalon Shanghai&#8221;), which is a wholly foreign-owned enterprise organized under the laws
of the People&#8217;s Republic of China (&#8220;PRC&#8221;). Avalon Shanghai was incorporated on April 29, 2016, and was engaged in medical
related consulting services for customers. Due to the winding down of the medical related consulting services in 2022, the Company decided
to cease all operations of Avalon Shanghai and no longer has any material revenues or expenses in Avalon Shanghai. As a result, Avalon
Shanghai is no longer an operating entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On February 7, 2017, the Company formed Avalon
RT 9 Properties, LLC (&#8220;Avalon RT 9&#8221;), a New Jersey limited liability company. On May 5, 2017, Avalon RT 9 purchased a real
property located in Township of Freehold, County of Monmouth, State of New Jersey, having a street address of 4400 Route 9 South, Freehold,
NJ 07728. This property was purchased to serve as the Company&#8217;s world-wide headquarters for all corporate administration and operations.
In addition, the property generates rental income. Avalon RT 9 owns this office building. Avalon RT 9&#8217;s business consists of the
ownership and operation of the income-producing real estate property in New Jersey. As of March 31, 2025, the occupancy rate of the building
is <ix:nonFraction contextRef="c566" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-90462">96.2</ix:nonFraction>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On July 18, 2018, the Company formed a wholly
owned subsidiary, Avactis Biosciences Inc. (&#8220;Avactis&#8221;), a Nevada corporation, which is a patent holding company. Commencing
on April 6, 2022, the Company owns <ix:nonFraction contextRef="c113" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-90463">60</ix:nonFraction>% of Avactis and Arbele Biotherapeutics Limited (&#8220;Arbele Biotherapeutics&#8221;) owns <ix:nonFraction contextRef="c567" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-90464">40</ix:nonFraction>%
of Avactis. Avactis owns <ix:nonFraction contextRef="c568" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-90465">100</ix:nonFraction>% of the capital stock of Avactis Nanjing Biosciences Ltd., a company incorporated in the PRC on May 8, 2020
(&#8220;Avactis Nanjing&#8221;), which only owns a patent and is not considered an operating entity. Currently, Avactis and Avactis Nanjing
are dormant and are in process of being dissolved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On October 14, 2022, the Company formed a wholly
owned subsidiary, Avalon Laboratory Services, Inc. (&#8220;Avalon Lab&#8221;), a Delaware company. On February 9, 2023, Avalon Lab purchased
<ix:nonFraction contextRef="c116" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-90466">40</ix:nonFraction>% of the issued and outstanding equity interests of Laboratory Services MSO, LLC, a private limited company formed under the laws of
the State of Delaware on September 6, 2019 (&#8220;Lab Services MSO&#8221;), and its subsidiaries. Lab Services MSO, through its subsidiaries,
is engaged in providing laboratory testing services. During the first quarter of 2025, to preserve cash, the Company entered into discussions
with Lab Services MSO for the potential redemption of our investment and on February 26, 2025, Lab Services MSO redeemed the <ix:nonFraction contextRef="c569" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-90467">40</ix:nonFraction>% equity
interest in Lab Services MSO held by Avalon Lab.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On May 1, 2024, the Company formed a wholly owned
subsidiary, Q&amp;A Distribution LLC (&#8220;Q&amp;A Distribution&#8221;), a Texas company. Q&amp;A Distribution is engaged in distribution
of KetoAir device.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 362; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 1 - <span style="text-decoration:underline">ORGANIZATION AND NATURE OF OPERATIONS
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" id="ixv-72344"><ix:continuation id="_NatureOfOperations-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Details of the Company&#8217;s subsidiaries which
are included in these condensed consolidated financial statements as of March 31, 2025 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 29%"><span style="font-size: 10pt">Name of Subsidiary</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-bottom: 1.5pt; padding-left: 5.65pt; text-align: center; width: 2%"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 15%"><span style="font-size: 10pt">Place and Date of Incorporation</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-bottom: 1.5pt; padding-left: 5.65pt; text-align: center; width: 2%"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 15%"><span style="font-size: 10pt">Percentage of Ownership</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-bottom: 1.5pt; padding-left: 5.65pt; text-align: center; width: 2%"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 35%"><span style="font-size: 10pt">Principal Activities</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-size: 10pt">Avalon Healthcare System, Inc. (&#8220;AHS&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><ix:nonNumeric contextRef="c570" name="avco:EquityMethodInvestmentPlaceAndDateOfIncorporation" id="ixv-72372"><span style="font-size: 10pt">Delaware May 18, 2015</span></ix:nonNumeric></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c570" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-90468">100</ix:nonFraction>% held by ALBT</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><ix:nonNumeric contextRef="c570" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-72381"><span style="font-size: 10pt">Holding company for payroll and other expenses</span></ix:nonNumeric></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-size: 10pt">Avalon RT 9 Properties LLC (&#8220;Avalon RT 9&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><ix:nonNumeric contextRef="c571" name="avco:EquityMethodInvestmentPlaceAndDateOfIncorporation" id="ixv-72404"><span style="font-size: 10pt">New Jersey February 7, 2017</span></ix:nonNumeric></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c571" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-90469">100</ix:nonFraction>% held by ALBT</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><ix:nonNumeric contextRef="c571" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-72413"><span style="font-size: 10pt">Owns and operates an income-producing real property and holds and manages the corporate headquarters</span></ix:nonNumeric></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-size: 10pt">Avalon (Shanghai) Healthcare Technology Co., Ltd. (&#8220;Avalon Shanghai&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><ix:nonNumeric contextRef="c572" name="avco:EquityMethodInvestmentPlaceAndDateOfIncorporation" id="ixv-72436"><span style="font-size: 10pt">PRC April 29, 2016</span></ix:nonNumeric></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c572" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-90470">100</ix:nonFraction>% held by AHS</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><ix:nonNumeric contextRef="c572" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-72445"><span style="font-size: 10pt">Not considered an operating entity</span></ix:nonNumeric></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-size: 10pt">Genexosome Technologies Inc. (&#8220;Genexosome&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><ix:nonNumeric contextRef="c573" name="avco:EquityMethodInvestmentPlaceAndDateOfIncorporation" id="ixv-72468"><span style="font-size: 10pt">Nevada July 31, 2017</span></ix:nonNumeric></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c573" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-90471">60</ix:nonFraction>% held by ALBT</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><ix:nonNumeric contextRef="c573" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-72477"><span style="font-size: 10pt">No current activities to report; dormant</span></ix:nonNumeric></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-size: 10pt">Avactis Biosciences Inc. (&#8220;Avactis&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><ix:nonNumeric contextRef="c574" name="avco:EquityMethodInvestmentPlaceAndDateOfIncorporation" id="ixv-72500"><span style="font-size: 10pt">Nevada July 18, 2018</span></ix:nonNumeric></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c574" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-90472">60</ix:nonFraction>% held by ALBT</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><ix:nonNumeric contextRef="c574" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-72509"><span style="font-size: 10pt">Dormant; in process of being dissolved</span></ix:nonNumeric></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-size: 10pt">Avactis Nanjing Biosciences Ltd. (&#8220;Avactis Nanjing&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><ix:nonNumeric contextRef="c575" name="avco:EquityMethodInvestmentPlaceAndDateOfIncorporation" id="ixv-72532"><span style="font-size: 10pt">PRC May 8, 2020</span></ix:nonNumeric></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c575" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-90473">100</ix:nonFraction>% held by Avactis</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><ix:nonNumeric contextRef="c575" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-72541"><span style="font-size: 10pt">Dormant; in process of being dissolved</span></ix:nonNumeric></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-size: 10pt">Avalon Laboratory Services, Inc. (&#8220;Avalon Lab&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><ix:nonNumeric contextRef="c576" name="avco:EquityMethodInvestmentPlaceAndDateOfIncorporation" id="ixv-72564"><span style="font-size: 10pt">Delaware October 14, 2022</span></ix:nonNumeric></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c576" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-90474">100</ix:nonFraction>% held by ALBT</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><ix:nonNumeric contextRef="c576" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-72573"><span style="font-size: 10pt">No current activities to report; dormant</span></ix:nonNumeric></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-size: 10pt">Q&amp;A Distribution LLC (&#8220;Q&amp;A Distribution&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><ix:nonNumeric contextRef="c577" name="avco:EquityMethodInvestmentPlaceAndDateOfIncorporation" id="ixv-72596"><span style="font-size: 10pt">Texas May 1, 2024</span></ix:nonNumeric></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="font-size: 10pt"><ix:nonFraction contextRef="c577" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" scale="-2" unitRef="pure" id="ixv-90475">100</ix:nonFraction>% held by ALBT</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><ix:nonNumeric contextRef="c577" name="us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" id="ixv-72605"><span style="font-size: 10pt">Distributes KetoAir device</span></ix:nonNumeric></td></tr> </table></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_1" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="ixv-72611"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">NOTE 2 - <span style="text-decoration:underline">BASIS OF PRESENTATION AND GOING CONCERN CONDITION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">Basis of Presentation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">These interim condensed consolidated financial
statements of the Company and its subsidiaries are unaudited. In the opinion of management, all adjustments (consisting of normal recurring
accruals) and disclosures necessary for a fair presentation of these interim condensed consolidated financial statements have been included.
The results reported in the condensed consolidated financial statements for any interim periods are not necessarily indicative of the
results that may be reported for the entire year. The accompanying condensed consolidated financial statements have been prepared in
accordance with the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) and do not include all information
and footnotes necessary for a complete presentation of financial statements in conformity with accounting principles generally accepted
in the United States (&#8220;U.S. GAAP&#8221;). The Company&#8217;s condensed consolidated financial statements include the accounts
of the Company and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Certain information and footnote disclosures normally
included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These
condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements
and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC
on March 31, 2025.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 363; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">NOTE 2 - <span style="text-decoration:underline">BASIS OF PRESENTATION AND GOING CONCERN CONDITION (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">&#160;</b></p><div>

</div><ix:continuation id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company is a commercial-stage company dedicated
to developing and delivering precision diagnostic consumer products. The Company is currently marketing the KetoAir breathalyzer device
and plans to develop additional diagnostic uses of the breathalyzer technology. In addition, the Company owns commercial real estate
that houses its headquarters in Freehold, New Jersey. These condensed consolidated financial statements have been prepared assuming that
the Company will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction
of liabilities in the normal course of business.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">As reflected in the accompanying condensed consolidated
financial statements, the Company had a working capital deficit of approximately $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="avco:WorkingCapitalDeficit" scale="0" unitRef="usd" id="ixv-90476">11,655,000</ix:nonFraction> at March 31, 2025 and had incurred recurring
net losses and generated negative cash flow from operating activities of approximately $<ix:nonFraction contextRef="c578" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-90477">2,482,000</ix:nonFraction> and $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-90478">1,802,000</ix:nonFraction> for the three months
ended March 31, 2025, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company has a limited operating history and
its continued growth is dependent upon the continuation of generating rental revenue from its income-producing real estate property in
New Jersey, generating revenue for selling of KetoAir, and obtaining additional financing to fund future obligations and pay liabilities
arising from normal business operations. In addition, the current cash balance cannot be projected to cover the operating expenses for
the next twelve months from the release date of this report. These matters raise substantial doubt about the Company&#8217;s ability
to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company&#8217;s ability
to raise additional capital, implement its business plan, and generate significant revenue. There are no assurances that the Company
will be successful in its efforts to generate significant revenue, maintain sufficient cash balance or report profitable operations or
to continue as a going concern. The Company plans on raising capital through the sale of equity to implement its business plan. However,
there is no assurance these plans will be realized and that any additional financings will be available to the Company on satisfactory
terms and conditions, if any.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The accompanying condensed consolidated financial
statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and
classification of liabilities that may result should the Company be unable to continue as a going concern.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-72682"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 3 - <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-72688"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Use of Estimates</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i style="-keep: true">&#160;</i></p>

<ix:continuation continuedAt="_UseOfEstimates-c0_cont_2" id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The preparation of condensed consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Changes in these estimates and assumptions may have a material impact on the condensed
consolidated financial statements and accompanying notes. Making estimates requires management to exercise significant judgment. It is
at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date
of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more
future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_UseOfEstimates-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Significant estimates during the three months
ended March 31, 2025 and 2024 include the useful life of investment in real estate and intangible assets, the assumptions used in assessing
impairment of long-term assets, the valuation of deferred tax assets and the associated valuation allowances, the valuation of stock-based
compensation, the valuation of Series D convertible preferred stock (&#8220;Series D Preferred Stock&#8221;), and the assumptions used
to determine fair value of warrants and embedded conversion features of convertible note payable.</span></p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 364; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 3 - <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-72732"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">Fair Value of Financial Instruments and Fair Value Measurements</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i style="-keep: true">&#160;</i></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company adopted the guidance of the Financial
Accounting Standards Board&#8217;s (the &#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820 for fair value
measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value
hierarchy to classify the inputs used in measuring fair value as follows:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 1-Inputs are unadjusted quoted prices in active markets for
    identical assets or liabilities available at the measurement date.</span></td></tr>
</table></ix:continuation>

<p style="margin: 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 2-Inputs are unadjusted quoted prices for similar assets and
    liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs
    other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.</span></td></tr>
</table></ix:continuation>

<p style="margin: 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Level 3-Inputs are unobservable inputs which reflect the reporting
    entity&#8217;s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the
    best available information.</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The fair value of the Company&#8217;s assets and
liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying
amounts represented in the accompanying condensed consolidated financial statements, primarily due to their short-term nature.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true"><b><i>Assets and liabilities measured at fair
value on a recurring basis. </i></b>Certain assets and liabilities are measured at fair value on a recurring basis. These assets and
liabilities are measured at fair value on an ongoing basis. These assets and liabilities include derivative liability.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_8" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true"><i>Derivative liability. </i>Derivative liability
is carried at fair value and measured on an ongoing basis. <ix:nonNumeric contextRef="c0" continuedAt="_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="ixv-90479">The table below reflects the activity of derivative liability measured at
fair value for the three months ended March 31, 2025:</ix:nonNumeric></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock-c0_cont_1"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_9" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_8"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Significant <br/>
    Unobservable Inputs<br/> (Level 3)</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-size: 10pt"><span style="-keep: true">Balance of derivative liability as of January 1, 2025</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-90480">127,545</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Reclassification of additional paid-in capital upon conversion</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c585" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="0" unitRef="usd" id="ixv-90481">18,853</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Loss from change in the fair value of derivative liability</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c585" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" sign="-" unitRef="usd" id="ixv-90482">114,360</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">Balance of derivative liability as of March 31, 2025</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c586" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-90483">223,052</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">ASC 825-10 &#8220;Financial Instruments&#8221;,
allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair
value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value
option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent
reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-72858"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Cash and Cash Equivalents</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="ixv-72863"><ix:continuation continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_2" id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">At March 31, 2025 and December 31, 2024, the Company&#8217;s
cash balances by geographic area were as follows:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<ix:continuation continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_3" id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_2"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1.5pt solid"><span style="-keep: true">Country:</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">March 31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">December 31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-size: 10pt; text-align: left"><span style="-keep: true">United States</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c587" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-90484">1,351,923</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c587" decimals="3" format="ixt:num-dot-decimal" name="avco:CashPercentage" scale="-2" unitRef="pure" id="ixv-90485">98.7</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">%</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-90486">2,844,522</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c152" decimals="3" format="ixt:num-dot-decimal" name="avco:CashPercentage" scale="-2" unitRef="pure" id="ixv-90487">99.6</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">China</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c588" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-90488">17,663</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c588" decimals="3" format="ixt:num-dot-decimal" name="avco:CashPercentage" scale="-2" unitRef="pure" id="ixv-90489">1.3</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">%</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-90490">11,787</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c140" decimals="3" format="ixt:num-dot-decimal" name="avco:CashPercentage" scale="-2" unitRef="pure" id="ixv-90491">0.4</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Total cash</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-90492">1,369,586</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="3" format="ixt:num-dot-decimal" name="avco:CashPercentage" scale="-2" unitRef="pure" id="ixv-90493">100.0</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">%</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-90494">2,856,309</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="3" format="ixt:num-dot-decimal" name="avco:CashPercentage" scale="-2" unitRef="pure" id="ixv-90495">100.0</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">%</span></td></tr>
  </table></ix:continuation></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">For purposes of the condensed consolidated statements
of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less when purchased and money market
accounts to be cash equivalents. The Company had no cash equivalents at March 31, 2025 and December 31, 2024.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 365; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 3 - <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-73029"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Credit Risk and Uncertainties</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company maintains a portion of its cash on
deposits with bank and financial institution within the U.S. that at times may exceed federally-insured limits of $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashFDICInsuredAmount" scale="0" unitRef="usd" id="ixv-90496">250,000</ix:nonFraction>. The Company
manages this credit risk by concentrating its cash balances in high quality financial institutions and by periodically evaluating the
credit quality of the primary financial institutions holding such deposits. The Company has not experienced any losses in such bank accounts
and believes it is not exposed to any risks on its cash in bank accounts. At March 31, 2025, the Company&#8217;s cash balances in United
States bank accounts had approximately $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FederalReserveBankStock" scale="0" unitRef="usd" id="ixv-90497">840,000</ix:nonFraction> in excess of the federally-insured limits.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company&#8217;s concentrations of credit risk
with respect to its rent receivable is limited due to short-term payment terms. The Company also performs ongoing credit evaluations
of its tenants to help further reduce credit risk.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_InvestmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentPolicyTextBlock" id="ixv-73044"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Investment in Unconsolidated Company</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_InvestmentPolicyTextBlock-c0_cont_2" id="_InvestmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company uses the equity method of accounting
for its investment in, and earning or loss of, investees that it does not control but over which it does exert significant influence.
The Company applies the equity method by initially recording these investments at cost, as equity method investments, subsequently adjusted
for equity in earnings and cash distributions.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_InvestmentPolicyTextBlock-c0_cont_3" id="_InvestmentPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company considers whether the fair value of
its equity method investment has declined below its carrying value whenever adverse events or changes in circumstances indicate that
recorded value may not be recoverable. If the Company considers any decline to be other than temporary (based on various factors, including
historical financial results and the overall health of the investee), then a write-down would be recorded to estimated fair value. See
Note 5 for discussion of equity method investment.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_InvestmentPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company classifies distributions received
from equity method investments using the cumulative earnings approach. Distributions received are considered returns on the investment
and classified as cash inflows from operating activities. If, however, the investor&#8217;s cumulative distributions received, less distributions
received in prior periods determined to be returns of investment, exceeds cumulative equity in earnings recognized, the excess is considered
a return of investment and is classified as cash inflows from investing activities.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-73064"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Receivable from Sale of Equity Method Investment</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">During the first quarter of 2025, to preserve
cash, the Company entered into discussions with Lab Services MSO for the potential redemption of our investment and on February 26, 2025,
the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement (the &#8220;Redemption Agreement&#8221;), whereby
Lab Services MSO redeemed the <ix:nonFraction contextRef="c579" decimals="2" format="ixt:num-dot-decimal" name="avco:EquityInterestPercent" scale="-2" unitRef="pure" id="ixv-90498">40</ix:nonFraction>% equity interest in Lab Services MSO held by the Company for cash and the surrender of its Series B
convertible preferred stock (&#8220;Series B Preferred Stock&#8221;) having a carrying value of $<ix:nonFraction contextRef="c580" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="0" unitRef="usd" id="ixv-90499">11,000,000</ix:nonFraction>. The aggregate cash amount
to the Company for the redemption was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="0" unitRef="usd" id="ixv-90500">1,745,000</ix:nonFraction>, to be paid as follows: one payment of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="avco:PaymentOfEquityInvestment" scale="0" unitRef="usd" id="ixv-90501">95,000</ix:nonFraction> at the closing of the redemption and,
beginning in March 2025, monthly payments of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="avco:RegularPaymentsOnEquityInvestments" scale="0" unitRef="usd" id="ixv-90502">75,000</ix:nonFraction> until December 2026. In addition, pursuant to the terms of the Redemption Agreement,
all shares of the Company&#8217;s Series B Preferred Stock previously issued to SCBC Holdings LLC as partial consideration for the equity
interests of Laboratory Services MSO, were permanently surrendered and relinquished to the Company for no additional consideration. The
difference of $<ix:nonFraction contextRef="c581" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="0" unitRef="usd" id="ixv-90503">2,348,695</ix:nonFraction> between the carrying value of the extinguished Series B Preferred Stock, the aggregate cash amount to the Company
for the redemption, net of the payables due to Lab Services MSO of $<ix:nonFraction contextRef="c580" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="0" unitRef="usd" id="ixv-90504">632,916</ix:nonFraction>, totaling $<ix:nonFraction contextRef="c582" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="0" unitRef="usd" id="ixv-90505">13,377,916</ix:nonFraction>, and the carrying value of the equity
method investment of $<ix:nonFraction contextRef="c580" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="0" unitRef="usd" id="ixv-90506">11,029,221</ix:nonFraction> was accounted for as an increase to additional paid-in capital (See Note 10 - Series B Convertible Preferred
Stock Extinguished Related to Sale of Equity Method Investment). Accordingly, beginning in February 2025, the Company no longer offers
laboratory services. As of March 31, 2025, the receivable from sale of equity method investment amounted to $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReceivableInvestmentSale" scale="0" unitRef="usd" id="ixv-90507">1,650,000</ix:nonFraction>, of which $<ix:nonFraction contextRef="c579" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-90508">975,000</ix:nonFraction>
was included in current assets and $<ix:nonFraction contextRef="c579" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="0" unitRef="usd" id="ixv-90509">675,000</ix:nonFraction> was included in non-current assets. Management believes that the receivable is fully collectable.
Therefore, no material allowance for doubtful accounts was deemed to be required on the receivable at March 31, 2025.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-73074"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Per Share Data</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">ASC Topic 260 &#8220;Earnings per Share,&#8221;
requires presentation of both basic and diluted earnings per share (&#8220;EPS&#8221;) with a reconciliation of the numerator and denominator
of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 366; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 3 - <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Per Share Data (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Basic net loss per share is computed by dividing
net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents
and potentially dilutive securities outstanding during each period. The Company had $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DilutiveSecurities" scale="0" unitRef="usd" id="ixv-90510">162,473</ix:nonFraction> in deemed contribution during the three
months ended March 31, 2025, which increases the numerator in the net loss per share calculation. For the three months ended March 31,
2025 and 2024, potentially dilutive common shares consisted of the common shares issuable upon the conversion of convertible preferred
stock and convertible notes (using the if-converted method) and exercise of common stock options and warrants (using the treasury stock
method). Common stock equivalents are not included in the calculation of diluted net loss per share if their effect would be anti-dilutive.
In a period in which the Company has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares
outstanding as they would have had an anti-dilutive impact.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_4" id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The calculation of basic and diluted net loss
per common share attributable to the Company common shareholders includes <ix:nonFraction contextRef="c583" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-90511">150,000</ix:nonFraction> of the pre-funded warrants that remained outstanding
as of March 31, 2025.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-73129"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_5" id="_EarningsPerSharePolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The following table summarizes the securities
that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_6" id="_EarningsPerSharePolicyTextBlock-c0_cont_5"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Three Months Ended March 31,</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-keep: true">Options to purchase common stock</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c589" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-90512">1,451,425</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c590" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-90513">47,287</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Warrants to purchase common stock</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c591" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-90514">171,163</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c592" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-90515">60,562</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Series A convertible preferred stock </span><span style="font-size: 12.5pt"><sup>(*)</sup></span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-380"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c594" decimals="INF" format="ixt:num-dot-decimal" id="ix_8_fact" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">60,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Series B convertible preferred stock </span><span style="font-size: 12.5pt"><sup>(**)</sup></span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-381"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c596" decimals="INF" format="ixt:num-dot-decimal" id="ix_9_fact" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">194,004</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Series C convertible preferred stock </span><span style="font-size: 12.5pt"><sup>(***)</sup></span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c597" decimals="INF" format="ixt:num-dot-decimal" id="ix_10_fact" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">1,452,282</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-382"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Series D convertible preferred stock (****)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c599" decimals="INF" format="ixt:num-dot-decimal" id="ix_11_fact" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">2,074,689</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-383"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Convertible notes and related accrued interest
    </span><span style="font-size: 12.5pt"><sup>(*****)</sup></span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c601" decimals="INF" format="ixt:num-dot-decimal" id="ix_12_fact" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">234,554</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c602" decimals="INF" format="ixt:num-dot-decimal" id="ix_13_fact" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">90,133</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Potentially dilutive securities</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-90522">5,384,113</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-90523">451,986</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_7" id="_EarningsPerSharePolicyTextBlock-c0_cont_6"><table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="font-size: 10pt">(*)</span></td> <td style="text-align: justify"><ix:footnote id="ix_5_footnote" xml:lang="en-US"><span style="font-size: 10pt">Assumed the Series A convertible preferred stock (&#8220;Series A Preferred Stock&#8221;) was converted into shares of common stock of the Company at a conversion price of $<ix:nonFraction contextRef="c13" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-90524">150.00</ix:nonFraction> per share.</span></ix:footnote></td></tr> </table></ix:continuation>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_8" id="_EarningsPerSharePolicyTextBlock-c0_cont_7"><table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="font-size: 10pt">(**)</span></td> <td style="text-align: justify"><ix:footnote id="ix_6_footnote" xml:lang="en-US"><span style="font-size: 10pt">Assumed the Series B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $<ix:nonFraction contextRef="c14" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-90525">56.70</ix:nonFraction> per share.</span></ix:footnote></td></tr> </table></ix:continuation>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_9" id="_EarningsPerSharePolicyTextBlock-c0_cont_8"><table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="font-size: 10pt">(***)</span></td> <td style="text-align: justify"><ix:footnote id="ix_7_footnote" xml:lang="en-US"><span style="font-size: 10pt">Assumed the Series C convertible preferred stock (&#8220;Series C Preferred Stock&#8221;) was converted into shares of common stock of the Company at a conversion price of $<ix:nonFraction contextRef="c15" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-90526">2.41</ix:nonFraction> per share.</span></ix:footnote></td></tr> </table></ix:continuation>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_10" id="_EarningsPerSharePolicyTextBlock-c0_cont_9"><table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="font-size: 10pt">(****)</span></td> <td style="text-align: justify"><ix:footnote id="ix_8_footnote" xml:lang="en-US"><span style="font-size: 10pt">Assumed the Series D convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $<ix:nonFraction contextRef="c16" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-90527">2.41</ix:nonFraction> per share.</span></ix:footnote></td></tr> </table></ix:continuation>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_10"><table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="font-size: 10pt">(*****)</span></td> <td style="text-align: justify"><ix:footnote id="ix_9_footnote" xml:lang="en-US"><span style="font-size: 10pt">Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceIncrease" scale="0" unitRef="usdPershares" id="ixv-90528">11.25</ix:nonFraction> per share for the three months ended March 31, 2025. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $<ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-90529">67.50</ix:nonFraction> and $<ix:nonFraction contextRef="c82" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-90530">22.50</ix:nonFraction> and $<ix:nonFraction contextRef="c83" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-90531">15.00</ix:nonFraction> per share for the three months ended March 31, 2024.</span></ix:footnote></td></tr> </table></ix:continuation></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="avco_RealPropertyRentalRevenuePolicyTextBlock-c0_cont_1" escape="true" name="avco:RealPropertyRentalRevenuePolicyTextBlock" id="ixv-73377"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Real Property Rental Revenue</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="avco_RealPropertyRentalRevenuePolicyTextBlock-c0_cont_2" id="avco_RealPropertyRentalRevenuePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company has determined that ASC 606 does not
apply to rental contracts, which are within the scope of other revenue recognition accounting standards.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="avco_RealPropertyRentalRevenuePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Rental income from operating leases is recognized
on a straight-line basis under the guidance of ASC 842. Lease payments under tenant leases are recognized on a straight-line basis over
the term of the related leases. The cumulative difference between lease revenue recognized under the straight-line method and contractual
lease payments are included in rent receivable on the condensed consolidated balance sheets.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 367; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 3 - <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="ixv-73421"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Commitments and Contingencies</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">In the normal course of business, the Company
is subject to contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters. Liabilities
for such contingencies are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably
estimated.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-73431"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Segment Reporting</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i style="-keep: true">&#160;</i></p>

<ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_2" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The segment reporting structure uses the Company&#8217;s
management reporting structure as its foundation to reflect how the Company manages the businesses internally and was mainly organized
by services. During the three months ended March 31, 2025 and 2024, the Company is organized into two services-oriented strategic business
units: real property rental services and laboratory testing services (which ended on the redemption date, February 26, 2025) - which
are led by our strategic business unit managers. Operating segments are defined as components of an enterprise for which separate financial
information is available and evaluated regularly by the chief operating decision maker (&#8220;CODM&#8221;) in deciding how to make operating
decisions, allocate resources and assess performance.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_3" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On February 9, 2023, the Company purchased <ix:nonFraction contextRef="c146" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-90532">40</ix:nonFraction>%
of Lab Services MSO. During the first quarter of 2025, to preserve cash, the Company entered into discussions with Lab Services MSO for
the potential redemption of Avalon Lab&#8217;s investment and on February 26, 2025, Lab Services MSO redeemed the <ix:nonFraction contextRef="c584" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-90533">40</ix:nonFraction>% equity interest
in Lab Services MSO held by Avalon Lab. Commencing from the purchase date, February 9, 2023, through the redemption date, February 26,
2025, the Company was active in the management of Lab Services MSO. During the three months ended March 31, 2025 and 2024, the Company
operated in two reportable business segments: (1) the real property operating segment, and (2) laboratory testing services segment (which
ended on the redemption date, February 26, 2025) since Lab Services MSO&#8217;s operating results are regularly reviewed by the Company&#8217;s
chief operating decision maker to determine the resources to be allocated to the segment and assess its performance. Prior to February
26, 2025, the Company regularly reviewed the operating results and performance of Lab Services MSO, for which the Company accounted for
under the equity method.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company&#8217;s President and Chief Executive
Officer is its CODM. The Company reports operational data to its CODM at the segment level, which he uses to evaluate performance and
allocate resources based on real property operating income and income from equity method investment - Lab Services MSO.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="avco_ReverseStockSplitPolicyTextBlock-c0_cont_1" escape="true" name="avco:ReverseStockSplitPolicyTextBlock" id="ixv-73451"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Reverse Stock Split</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<ix:continuation id="avco_ReverseStockSplitPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company effectuated a <ix:nonNumeric contextRef="c0" name="us-gaap:StockholdersEquityReverseStockSplit" id="ixv-90534">1-for-15</ix:nonNumeric> reverse stock
split of its outstanding shares of common stock on October 28, 2024. The reverse split did not change the par value of common stock.
All references in these condensed consolidated financial statements to shares, share prices, exercise prices, and other per share information
in all periods have been adjusted, on a retroactive basis, to reflect the reverse stock split.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-73461"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Recent Accounting Standards</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">In August 2020, the FASB issued Accounting Standards
Update (&#8220;ASU&#8221;) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts
in Entity&#8217;s Own Equity (Subtopic 815-40), to simplify accounting for certain financial instruments. ASU 2020-06 eliminated the
then-current models that required separation of beneficial conversion and cash conversion features from convertible instruments and simplified
the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#8217;s own equity. ASU 2020-06
also introduced additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#8217;s
own equity. ASU 2020-06 amended the diluted earnings per share guidance, including the requirement to use the if-converted method for
all convertible instruments. ASU 2020-06 was effective for fiscal years beginning after December 15, 2023, including interim periods
within those fiscal years, with early adoption permitted. The adoption of ASU 2020-06 did not have a material effect on the Company&#8217;s
condensed consolidated financial statements and related disclosures.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">In November 2023, the FASB issued ASU 2023-07,
Segment Reporting (Topic 280). The amendments in this update improve reportable segment disclosure requirements, primarily through enhanced
disclosures about significant segment expenses. ASU 2023-07 became effective for the Company&#8217;s annual period beginning on January
1, 2024 and interim periods beginning after January 1, 2025. The Company adopted this guidance in the fourth quarter of 2024. The Company&#8217;s
results of operations, cash flows, and financial condition were not impacted by the adoption of this ASU.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 368; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 3 - <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Recent Accounting Standards (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">In December 2023, the FASB issued ASU 2023-09,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This guidance was intended to enhance the transparency and decision-usefulness
of income tax disclosures. The amendments in ASU 2023-09 addressed investor requests for enhanced income tax information primarily through
changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09
was effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively.
Early adoption was permitted. The adoption of ASU 2023-09 did not have a material effect on the Company&#8217;s condensed consolidated
financial statements and related disclosures.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Other accounting standards that have been issued
or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the condensed consolidated
financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on
or are unrelated to its condensed consolidated financial condition, results of operations, cash flows or disclosures.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock" id="ixv-73523"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">NOTE 4 - <span style="text-decoration:underline">PREPAID EXPENSE AND OTHER CURRENT ASSETS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="ixv-73529"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">At March 31, 2025 and December 31, 2024, prepaid expense and other
current assets consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">March 31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">December 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-keep: true">Prepaid professional fees</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="avco:PrepaidProfessionalFees" scale="0" unitRef="usd" id="ixv-90535">90,431</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="avco:PrepaidProfessionalFees" scale="0" unitRef="usd" id="ixv-90536">33,665</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Prepaid directors&#8217; and officers&#8217; liability insurance premium</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidReinsurancePremiums" scale="0" unitRef="usd" id="ixv-90537">12,834</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidReinsurancePremiums" scale="0" unitRef="usd" id="ixv-90538">9,741</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Prepaid NASDAQ listing fee</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseOtherNoncurrent" scale="0" unitRef="usd" id="ixv-90539">39,750</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-384"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Deferred leasing costs</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCostsLeasingNet" scale="0" unitRef="usd" id="ixv-90540">28,980</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredCostsLeasingNet" scale="0" unitRef="usd" id="ixv-90541">31,587</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Security deposit</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="0" unitRef="usd" id="ixv-90542">12,256</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="0" unitRef="usd" id="ixv-90543">17,654</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Due from broker</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromCorrespondentBrokers" scale="0" unitRef="usd" id="ixv-90544">33,160</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromCorrespondentBrokers" scale="0" unitRef="usd" id="ixv-90545">32,885</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Finished goods</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd" id="ixv-90546">90,116</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd" id="ixv-90547">92,230</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Recoverable value-added tax</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ValueAddedTaxReceivable" scale="0" unitRef="usd" id="ixv-90548">10,094</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ValueAddedTaxReceivable" scale="0" unitRef="usd" id="ixv-90549">9,245</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">Others</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-90550">50,197</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-90551">72,353</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-90552">367,818</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-90553">299,360</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_EquityMethodInvestmentsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="ixv-73747"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">NOTE 5 - <span style="text-decoration:underline">EQUITY METHOD INVESTMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On February 9, 2023, the Company entered into
and closed an Amended and Restated Membership Interest Purchase Agreement (the &#8220;Amended MIPA&#8221;), by and among Avalon Lab,
SCBC Holdings LLC (the &#8220;Seller&#8221;), the Zoe Family Trust, Bryan Cox and Sarah Cox as individuals (each an &#8220;Owner&#8221;
and collectively, the &#8220;Owners&#8221;), and Lab Services MSO. <b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Pursuant to the terms and conditions set forth
in the Amended MIPA, Avalon Lab acquired from the Seller, <ix:nonFraction contextRef="c603" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-90554">40</ix:nonFraction>% of the issued and outstanding equity interests of Lab Services MSO (the
&#8220;Purchased Interests&#8221;). The consideration paid by Avalon Lab to Seller for the Purchased Interests consisted of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="0" unitRef="usd" id="ixv-90555">20,666,667</ix:nonFraction>,
which was comprised of (i) $<ix:nonFraction contextRef="c604" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-90556">9,000,000</ix:nonFraction> in cash, (ii) $<ix:nonFraction contextRef="c605" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-90557">11,000,000</ix:nonFraction> pursuant to the issuance of <ix:nonFraction contextRef="c605" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-90558">11,000</ix:nonFraction> shares of the Company&#8217;s Series
B Preferred Stock, stated value $<ix:nonFraction contextRef="c606" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-90559">1,000</ix:nonFraction> (the &#8220;Series B Stated Value&#8221;), which approximated the fair value, and (iii) a $<ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="avco:EquityMethodInvestmentPayableCurrent" scale="0" unitRef="usd" id="ixv-90560">666,667</ix:nonFraction>
cash payment on February 9, 2024. The Series B Preferred Stock was convertible into shares of the Company&#8217;s common stock at a conversion
price per share equal to $<ix:nonFraction contextRef="c605" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-90561">56.70</ix:nonFraction>, which approximated the market price at the date of closing, or an aggregate of <ix:nonFraction contextRef="c605" decimals="0" format="ixt:num-dot-decimal" name="avco:AggregateOfCommonStock" scale="0" unitRef="shares" id="ixv-90562">194,004</ix:nonFraction> shares of the
Company&#8217;s common stock, which were subject to a lock-up period and restrictions on sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">During the first quarter of 2025, to preserve
cash, the Company entered into discussions with Lab Services MSO for the potential redemption of the Company&#8217;s investment and on
February 26, 2025, the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement, whereby Lab Services MSO redeemed
the <ix:nonFraction contextRef="c607" decimals="0" format="ixt:num-dot-decimal" name="avco:LabServicesMSOsNetIncomeAttributableToTheCompany" scale="0" unitRef="usd" id="ixv-90563">40</ix:nonFraction>% equity interest in Lab Services MSO held by the Company (See Note 3 - Receivable from Sale of Equity Method Investment).</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 369; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">NOTE 5 - <span style="text-decoration:underline">EQUITY METHOD INVESTMENT (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation continuedAt="_EquityMethodInvestmentsDisclosureTextBlock-c0_cont_2" id="_EquityMethodInvestmentsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Lab Services MSO, through its subsidiaries, was
engaged in providing laboratory testing services. During the period from February 9, 2023 (date of investment) through February 26, 2025
(date of sale), Avalon Lab and an unrelated company, had an ownership interest in Lab Services MSO of <ix:nonFraction contextRef="c608" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-90564">40</ix:nonFraction>% and <ix:nonFraction contextRef="c609" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-90565">60</ix:nonFraction>%, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">In accordance with ASC 810, the Company determined
that Lab Services MSO did not qualify as a variable interest entity, nor did it have a controlling financial interest over the legal
entity. However, the Company determined that it does have significant influence as a result of its board representation. Therefore, the
Company treats the equity investment in the condensed consolidated financial statements under the equity method. Under the equity method,
the investment is initially recorded at cost, adjusted for any excess of the Company&#8217;s share of the purchased-date fair values
of the investee&#8217;s identifiable net assets over the cost of the investment (if any). At February 9, 2023 (date of investment), the
excess of the Company&#8217;s share of the fair values of the investee&#8217;s identifiable net assets over the cost of the investment
was approximately $<ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentOwnedAtCost" scale="0" unitRef="usd" id="ixv-90566">19,460,000</ix:nonFraction> which was attributable to intangible assets and goodwill. Thereafter, the investment was adjusted for the
post purchase change in the Company&#8217;s share of the investee&#8217;s net assets and any impairment loss relating to the investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Intangible assets consisted of the valuation of
identifiable intangible assets acquired, representing trade names and customers relationships, which were being amortized on a straight-line
method over the estimated useful life of <ix:nonNumeric contextRef="c11" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-90567">15</ix:nonNumeric> years. The straight-line method of amortization represents the Company&#8217;s best estimate
of the distribution of the economic value of the identifiable intangible assets. For the period from January 1, 2025 through February
26, 2025 (date of sale) and for the three months ended March 31, 2024, amortization expense of these intangible assets amounted to $<ix:nonFraction contextRef="c610" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-90568">111,156</ix:nonFraction>
and $<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-90569">166,733</ix:nonFraction>, respectively, which was included in income from equity method investment - Lab Services MSO in the accompanying condensed
consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Goodwill represents the excess of the purchase
price paid over the fair value of net assets acquired in the business acquisition of Lab Services MSO incurred on February 9, 2023. Goodwill
is not amortized but is tested for impairment at least once annually, or more frequently if events or changes in circumstances indicate
that the asset might be impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">For the period from January 1, 2025 through February
26, 2025 (date of sale) and for the three months ended March 31, 2024, the Company&#8217;s share of Lab Services MSO&#8217;s net income
was $<ix:nonFraction contextRef="c610" decimals="0" format="ixt:num-dot-decimal" name="avco:LabServicesMSOsNetIncomeAttributableToTheCompany" scale="0" unitRef="usd" id="ixv-90570">503,833</ix:nonFraction> and $<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="avco:LabServicesMSOsNetIncomeAttributableToTheCompany" scale="0" unitRef="usd" id="ixv-90571">274,202</ix:nonFraction>, respectively, which was included in income from equity method investment - Lab Services MSO in the accompanying
condensed consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company classifies distributions received
from its investment on Lab Services MSO using the cumulative earnings approach. Distributions received are considered returns on the
investment and classified as cash inflows from operating activities. For the period from January 1, 2025 through February 26, 2025 (date
of sale) and for the three months ended March 31, 2024, distribution of earnings from the Company&#8217;s investment on Lab Services
MSO amounted to $<ix:nonFraction contextRef="c611" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillImpairmentLoss" scale="0" unitRef="usd" id="ixv-90572">0</ix:nonFraction> and $<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillImpairmentLoss" scale="0" unitRef="usd" id="ixv-90573">160,788</ix:nonFraction>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:EquityMethodInvestmentsTextBlock" id="ixv-73819"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">In the three months ended March 31, 2025, activity
recorded for the Company&#8217;s equity method investment in Lab Services MSO is summarized in the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="-keep: true">Equity investment carrying amount at January 1, 2025</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-90574">10,636,544</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Lab Services MSO&#8217;s net income attributable to the Company</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c612" decimals="0" format="ixt:num-dot-decimal" name="avco:LabServicesMSOsNetIncomeAttributableToTheCompany" scale="0" unitRef="usd" id="ixv-90575">503,833</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Intangible assets amortization amount</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c612" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-90576">111,156</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Sale of equity investment</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c612" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="0" unitRef="usd" id="ixv-90577">11,029,221</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Equity investment carrying amount at March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-385"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">As of December 31, 2024, the Company&#8217;s carrying
value of the identified intangible assets and goodwill which are included in the equity investment carrying amount was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="0" unitRef="usd" id="ixv-90578">8,725,712</ix:nonFraction> and
$<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillFairValueDisclosure" scale="0" unitRef="usd" id="ixv-90579">0</ix:nonFraction>, respectively.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 370; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">NOTE 5 - <span style="text-decoration:underline">EQUITY METHOD INVESTMENT (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="srt:ScheduleOfCondensedIncomeStatementTableTextBlock" id="ixv-73915"><ix:continuation id="_EquityMethodInvestmentsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The tables below present the summarized financial
information, as provided to the Company by the investee, for the unconsolidated company:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the Period<br/> from January
    1,<br/> 2025 through<br/> February 26,<br/> 2025 <br/> (Date of Sale)</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the Three<br/> Months Ended <br/>
    March 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-keep: true">Net revenue</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c614" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-90580">4,241,732</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c615" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-90581">3,376,372</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Gross profit</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c614" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-90582">2,155,760</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c615" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-90583">1,003,789</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Income from operation</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c614" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-90584">1,513,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c615" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-90585">275,026</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Net income</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c614" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-90586">1,259,582</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c615" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-90587">685,504</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LongTermDebtTextBlock-c0_cont_1" escape="true" name="us-gaap:LongTermDebtTextBlock" id="ixv-74025"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">NOTE 6 - <span style="text-decoration:underline">CONVERTIBLE NOTE PAYABLE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i style="-keep: true">June 2024 Convertible Note</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On June 5, 2024, the Company entered into securities
purchase agreements with Mast Hill Fund L.P. (&#8220;Mast Hill&#8221;) for the issuance of <ix:nonFraction contextRef="c616" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure" id="ixv-90588">13.0</ix:nonFraction>% senior secured promissory notes in the
aggregate principal amount of $<ix:nonFraction contextRef="c617" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-90589">2,845,000</ix:nonFraction> (collectively, the &#8220;June 2024 Convertible Note&#8221;) convertible into shares of the
Company&#8217;s common stock, as well as the issuance of <ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-90590">26,800</ix:nonFraction> shares of common stock as a commitment fee and warrants for the purchase
of <ix:nonFraction contextRef="c618" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-90591">146,667</ix:nonFraction> shares of common stock of the Company. The Company and its subsidiaries have also entered into a security agreement, creating
a security interest in certain property of the Company and its subsidiaries to secure the prompt payment, performance and discharge in
full of all of the Company&#8217;s obligations under the June 2024 Convertible Note. Principal amount and interest under the June 2024
Convertible Note are convertible into shares of common stock of the Company at a conversion price of $<ix:nonFraction contextRef="c274" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-90592">11.25</ix:nonFraction> per share unless the Company
fails to make an amortization payment when due, in which case the conversion price shall be the lesser of $<ix:nonFraction contextRef="c619" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-90593">11.25</ix:nonFraction> or the market price
(as defined in the June 2024 Convertible Note).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Mast Hill acquired the June 2024 Convertible Note
with principal amount of $<ix:nonFraction contextRef="c620" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-90594">2,845,000</ix:nonFraction> and paid the purchase price of $<ix:nonFraction contextRef="c621" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="0" unitRef="usd" id="ixv-90595">2,702,750</ix:nonFraction> after an original issue discount of $<ix:nonFraction contextRef="c621" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-90596">142,250</ix:nonFraction>. On June 5,
2024, the Company issued (i) a warrant to purchase <ix:nonFraction contextRef="c622" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-90597">66,667</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction contextRef="c622" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-90598">9.75</ix:nonFraction> exercisable until June
5, 2029 (&#8220;First Warrant&#8221;), (ii) a warrant to purchase <ix:nonFraction contextRef="c623" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-90599">80,000</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction contextRef="c623" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-90600">7.50</ix:nonFraction> exercisable
until June 5, 2029 (&#8220;Second Warrant&#8221;), and (iii) <ix:nonFraction contextRef="c624" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-90601">26,800</ix:nonFraction> shares of common stock as a commitment fee for the purchase of the
June 2024 Convertible Note, which were earned in full as of June 5, 2024. The Second Warrant is not fair valued and shall be cancelled
and extinguished against payment of the June 2024 Convertible Note. On June 5, 2024, the Company delivered such duly executed June 2024
Convertible Note, warrants and common stock to Mast Hill against delivery of the purchase price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company received net cash amount of $<ix:nonFraction contextRef="c625" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NontradeReceivables" scale="0" unitRef="usd" id="ixv-90602">881,210</ix:nonFraction>
from the June 2024 Convertible Note financing after using the proceeds to pay off all previously issued convertible notes of $<ix:nonFraction contextRef="c626" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd" id="ixv-90603">1,661,540</ix:nonFraction>,
and to pay finder&#8217;s fee of $<ix:nonFraction contextRef="c627" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd" id="ixv-90604">120,000</ix:nonFraction> and lender&#8217;s costs of $<ix:nonFraction contextRef="c628" decimals="0" format="ixt:num-dot-decimal" name="avco:PaymentForCommission" scale="0" unitRef="usd" id="ixv-90605">40,000</ix:nonFraction> related to this financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="ixv-74047"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company is obligated to make amortization
payments in cash to Mast Hill toward the repayment of the June 2024 Convertible Note, as provided in the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: black 1.5pt solid; width: 49%"><span style="font-size: 10pt"><b>Payment Date</b></span></td> <td style="white-space: nowrap; padding-bottom: 1.5pt; width: 2%"><span style="-keep: true">&#160;</span></td> <td style="white-space: nowrap; border-bottom: black 1.5pt solid; width: 49%"><span style="font-size: 10pt"><b>Payment Amount</b></span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="white-space: nowrap"><span style="font-size: 10pt">December 5, 2024</span></td> <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td> <td style="white-space: nowrap"><ix:nonNumeric contextRef="c631" name="us-gaap:DebtInstrumentDescription" id="ixv-74070"><span style="font-size: 10pt">$284,500 plus accrued interest through December 5, 2024</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><span style="font-size: 10pt">January 5, 2025</span></td> <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td> <td style="white-space: nowrap"><ix:nonNumeric contextRef="c632" name="us-gaap:DebtInstrumentDescription" id="ixv-74078"><span style="font-size: 10pt">$284,500 plus accrued interest through January 5, 2025</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="white-space: nowrap"><span style="font-size: 10pt">February 5, 2025</span></td> <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td> <td style="white-space: nowrap"><ix:nonNumeric contextRef="c633" name="us-gaap:DebtInstrumentDescription" id="ixv-74086"><span style="font-size: 10pt">$379,336 plus accrued interest through February 5, 2025</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><span style="font-size: 10pt">March 5, 2025</span></td> <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td> <td style="white-space: nowrap"><ix:nonNumeric contextRef="c634" name="us-gaap:DebtInstrumentDescription" id="ixv-74094"><span style="font-size: 10pt">$474,167 plus accrued interest through March 5, 2025</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="white-space: nowrap"><span style="font-size: 10pt">April 5, 2025</span></td> <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td> <td style="white-space: nowrap"><ix:nonNumeric contextRef="c635" name="us-gaap:DebtInstrumentDescription" id="ixv-74102"><span style="font-size: 10pt">$474,167 plus accrued interest through April 5, 2025</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><span style="font-size: 10pt">May 5, 2025</span></td> <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td> <td style="white-space: nowrap"><ix:nonNumeric contextRef="c636" name="us-gaap:DebtInstrumentDescription" id="ixv-74110"><span style="font-size: 10pt">$569,000 plus accrued interest through May 5, 2025</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="white-space: nowrap"><span style="font-size: 10pt">June 5, 2025</span></td> <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td> <td style="white-space: nowrap"><ix:nonNumeric contextRef="c637" name="us-gaap:DebtInstrumentDescription" id="ixv-74118"><span style="font-size: 10pt">The entire remaining outstanding balance of the June 2024 Convertible Note</span></ix:nonNumeric></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">In connection with the issuance of the June 2024
Convertible Note, the Company incurred debt issuance costs of $<ix:nonFraction contextRef="c625" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" unitRef="usd" id="ixv-90606">224,221</ix:nonFraction> (including the issuance of <ix:nonFraction contextRef="c629" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-90607">5,333</ix:nonFraction> warrants as a finder&#8217;s
fee) which is capitalized and will be amortized into interest expense over the term of the June 2024 Convertible Note.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 371; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 6 - <span style="text-decoration:underline">CONVERTIBLE NOTE PAYABLE (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i style="-keep: true">June 2024 Convertible Note (continued)</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation id="_LongTermDebtTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Based upon the Company&#8217;s analysis of the
criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a finder&#8217;s
fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances. Management
determined the probability of failing to make an amortization payment when due to be remote and as such the fair value of the <ix:nonFraction contextRef="c284" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-90608">80,000</ix:nonFraction>
warrants with an exercise price of $<ix:nonFraction contextRef="c274" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-90609">7.50</ix:nonFraction> exercisable until June 5, 2029, which warrant shall be cancelled and extinguished against payment
of the June 2024 Convertible Note, has been estimated to be zero. Accordingly, the fair value of the <ix:nonFraction contextRef="c630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-90610">72,000</ix:nonFraction> warrants with an exercise
price of $<ix:nonFraction contextRef="c630" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-90611">9.75</ix:nonFraction> exercisable until June 5, 2029 was classified as derivative liability on June 5, 2024. The fair values of the <ix:nonFraction contextRef="c284" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-90612">72,000</ix:nonFraction> warrants
with an exercise price of $<ix:nonFraction contextRef="c284" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-90613">9.75</ix:nonFraction> exercisable until June <ix:nonFraction contextRef="c285" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90614">5</ix:nonFraction>, 2029 issued on June 5, 2024 were computed using the Black-Scholes option-pricing
model with the following assumptions: stock price of $<ix:nonFraction contextRef="c286" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90615">10.39</ix:nonFraction>, volatility of <ix:nonFraction contextRef="c287" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90616">85.72</ix:nonFraction>%, risk-free rate of <ix:nonFraction contextRef="c288" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90617">4.31</ix:nonFraction>%, annual dividend yield of
<ix:nonFraction contextRef="c289" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90618">0</ix:nonFraction>% and expected life of 5 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">In accordance with ASC 470-20-25-2, proceeds from
the sale of a debt instrument with stock purchase warrants are allocated to the two elements based on the relative fair values of the
debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds allocated to the
warrants are accounted for as derivative liability. The remainder of the proceeds are allocated to the debt instrument portion of the
transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">In accordance with ASC 480-10-25-14, the Company
determined that the conversion provisions contain an embedded derivative feature and the Company valued the derivative feature separately,
recording debt discount and derivative liability in accordance with the provisions of the convertible debt (see Note 7). However, management
determined the probability of failing to make an amortization payment when due to be remote and as such the fair value of the embedded
conversion feature has been estimated to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company recorded a total debt discount of
$<ix:nonFraction contextRef="c625" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="0" unitRef="usd" id="ixv-90619">838,990</ix:nonFraction> related to the original issue discount, common shares issued and warrants issued to Mast Hill, which will be amortized over
the term of the June 2024 Convertible Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On December 15, 2024, the Company and Mast Hill
entered into that certain consent, acknowledgement, and waiver agreement, pursuant to which Mast Hill waived all amortization payments
required to be made under the June 2024 Convertible Note, the Company paid a waiver fee of $<ix:nonFraction contextRef="c290" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFeeAmount" scale="0" unitRef="usd" id="ixv-90620">150,000</ix:nonFraction> to Mast Hill, and the Company issued
to Mast Hill a common stock purchase warrant for the purchase of up to <ix:nonFraction contextRef="c291" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-90621">150,000</ix:nonFraction> shares of the Company&#8217;s common stock (&#8220;Pre-Funded
Warrants&#8221;). The Pre-Funded Warrants are immediately exercisable at issuance and until the Pre-Funded Warrants are exercised in
full and have an exercise price of $<ix:nonFraction contextRef="c292" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-90622">0.01</ix:nonFraction> per share. The Pre-Funded Warrants were classified as a component of permanent equity on the
accompanying consolidated balance sheets as they are freestanding financial instruments that are immediately exercisable, do not embody
an obligation for the Company to repurchase its own shares and permit the holder to receive a fixed number of shares of common stock
upon exercise. All of the shares underlying the Pre-Funded Warrants have been included in the weighted-average number of shares of common
stock used to calculate net loss per share, basic and diluted, attributable to the Company&#8217;s common stockholders because the shares
may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the Pre-Funded
Warrants. Based on the Company&#8217;s assess, this arrangement was accounted for as a modification of debt and, as such, $<ix:nonFraction contextRef="c293" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFeeAmount" scale="0" unitRef="usd" id="ixv-90623">838,794</ix:nonFraction> related
to the waiver fee and Pre-Fund Warrants issued to Mast Hill were expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ConvertibleDebtTableTextBlock" id="ixv-74181"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The convertible note payable as of March 31, 2025
and December 31, 2024 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">March 31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">December 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Principal amount</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c638" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-90624">2,556,777</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c301" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-90625">2,556,777</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Less: unamortized debt issuance costs</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c638" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="0" unitRef="usd" id="ixv-90626">33,584</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c301" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnamortizedDebtIssuanceExpense" scale="0" unitRef="usd" id="ixv-90627">93,425</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Less: unamortized debt discount</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c638" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" scale="0" unitRef="usd" id="ixv-90628">125,665</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c301" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" scale="0" unitRef="usd" id="ixv-90629">349,579</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Convertible note payable, net</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c638" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-90630">2,397,528</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c301" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="0" unitRef="usd" id="ixv-90631">2,113,773</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">For the three months ended March 31, 2025 and
2024, amortization of debt discount and debt issuance costs related to convertible note payable amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd" id="ixv-90632">283,755</ix:nonFraction> and $<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" unitRef="usd" id="ixv-90633">242,389</ix:nonFraction>, respectively,
which have been included in interest expense - amortization of debt discount and debt issuance costs on the accompanying condensed consolidated
statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">For the three months ended March 31, 2025 and
2024, interest expense related to convertible note payable amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd" id="ixv-90634">81,956</ix:nonFraction> and $<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd" id="ixv-90635">71,715</ix:nonFraction>, respectively, which have been included in
interest expense - other on the accompanying condensed consolidated statements of operations and comprehensive loss.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 372; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="ixv-74311"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 7 - <span style="text-decoration:underline">DERIVATIVE LIABILITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">As stated in Note 6, June 2024 Convertible Note,
the Company determined that the convertible note payable contains an embedded derivative feature in the form of a conversion provision
which is adjustable based on future prices of the Company&#8217;s common stock. In accordance with ASC 815-10-25, each derivative feature
is initially recorded at its fair value using the Black-Scholes option valuation method and then re-value at each reporting date, with
changes in the fair value reported in the statements of operations. However, on June 5, 2024 and March 31, 2025, management determined
the probability of failing to make an amortization payment and repayment, respectively, when due to be remote and as such the fair value
of the embedded conversion feature has been estimated to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On May 23, 2023, the Company issued <ix:nonFraction contextRef="c303" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-90636">9,000</ix:nonFraction> warrants
with an exercise price of $<ix:nonFraction contextRef="c304" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-90637">67.50</ix:nonFraction> exercisable until May 23, 2028 to Mast Hill and a third party as a finder&#8217;s fee. Upon evaluation,
the warrants meet the definition of a derivative liability under ASC 815, as the Company cannot avoid a net cash settlement under certain
circumstances. Accordingly, the fair value of the <ix:nonFraction contextRef="c639" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-90638">9,000</ix:nonFraction> warrants was classified as a derivative liability on May 23, 2023. In March 2025,
<ix:nonFraction contextRef="c639" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-90639">8,333</ix:nonFraction> warrants held by Mast Hill were cashless exercised. On March 31, 2025, the estimated fair value of the rest of <ix:nonFraction contextRef="c640" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-90640">667</ix:nonFraction> warrants was
$<ix:nonFraction contextRef="c641" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-90641">701</ix:nonFraction>. The estimated fair value of the warrants was computed as of March 31, 2025 using Black-Scholes option-pricing model, with the following
assumptions: stock price of $<ix:nonFraction contextRef="c642" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90642"><ix:nonFraction contextRef="c642" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90643">4.80</ix:nonFraction></ix:nonFraction>, volatility of <ix:nonFraction contextRef="c643" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90644">108.28</ix:nonFraction>%, risk-free rate of <ix:nonFraction contextRef="c644" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90645">3.89</ix:nonFraction>%, annual dividend yield of <ix:nonFraction contextRef="c645" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90646">0</ix:nonFraction>% and expected life of <ix:nonFraction contextRef="c646" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90647">3.1</ix:nonFraction>
years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On July 6, 2023, the Company issued <ix:nonFraction contextRef="c647" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-90648">222</ix:nonFraction> warrants
with an exercise price of $<ix:nonFraction contextRef="c319" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-90649">67.50</ix:nonFraction> exercisable until July 6, 2028 to a third party as a finder&#8217;s fee. Upon evaluation, the warrants
meet the definition of a derivative liability under ASC 815, as the Company cannot avoid a net cash settlement under certain circumstances.
Accordingly, the fair value of the <ix:nonFraction contextRef="c648" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-90650">222</ix:nonFraction> warrants was classified as a derivative liability on July 6, 2023. On March 31, 2025, the estimated
fair value of the <ix:nonFraction contextRef="c649" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-90651">222</ix:nonFraction> warrants was $<ix:nonFraction contextRef="c650" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-90652">237</ix:nonFraction>. The estimated fair value of the warrants was computed as of March 31, 2025 using Black-Scholes
option-pricing model, with the following assumptions: stock price of $<ix:nonFraction contextRef="c651" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90653">4.80</ix:nonFraction>, volatility of <ix:nonFraction contextRef="c652" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90654">106.65</ix:nonFraction>%, risk-free rate of <ix:nonFraction contextRef="c653" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90655">3.89</ix:nonFraction>%, annual dividend
yield of <ix:nonFraction contextRef="c654" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90656">0</ix:nonFraction>% and expected life of <ix:nonFraction contextRef="c655" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90657">3.3</ix:nonFraction> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On October 9, 2023, the Company issued <ix:nonFraction contextRef="c656" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-90658">4,060</ix:nonFraction> warrants
with an exercise price of $<ix:nonFraction contextRef="c237" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-90659">37.50</ix:nonFraction> exercisable until October 9, 2028 to Mast Hill and a third party as a finder&#8217;s fee. Upon evaluation,
the warrants meet the definition of a derivative liability under ASC 815, as the Company cannot avoid a net cash settlement under certain
circumstances. Accordingly, the fair value of the <ix:nonFraction contextRef="c657" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-90660">4,060</ix:nonFraction> warrants was classified as a derivative liability on October 9, 2023. On March
26, 2025, <ix:nonFraction contextRef="c658" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-90661">3,500</ix:nonFraction> warrants held by Mast Hill were cashless exercised. On March 31, 2025, the estimated fair value of the rest of <ix:nonFraction contextRef="c659" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-90662">560</ix:nonFraction> warrants
was $<ix:nonFraction contextRef="c660" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-90663">866</ix:nonFraction>. The estimated fair value of the warrants was computed as of March 31, 2025 using Black-Scholes option-pricing model, with the
following assumptions: stock price of $<ix:nonFraction contextRef="c661" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90664">4.80</ix:nonFraction>, volatility of <ix:nonFraction contextRef="c662" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90665">103.38</ix:nonFraction>%, risk-free rate of <ix:nonFraction contextRef="c663" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90666">3.89</ix:nonFraction>%, annual dividend yield of <ix:nonFraction contextRef="c664" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90667">0</ix:nonFraction>% and expected
life of <ix:nonFraction contextRef="c665" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90668">3.5</ix:nonFraction> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On March 7, 2024, the Company issued <ix:nonFraction contextRef="c350" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-90669">9,450</ix:nonFraction> warrants
with an exercise price of $<ix:nonFraction contextRef="c264" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-90670">30.00</ix:nonFraction> exercisable until March 7, 2029 to Mast Hill and a third party as a finder&#8217;s fee. Upon evaluation,
the warrants meet the definition of a derivative liability under FASB ASC 815, as the Company cannot avoid a net cash settlement under
certain circumstances. Accordingly, the fair value of the <ix:nonFraction contextRef="c351" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-90671">9,450</ix:nonFraction> warrants was classified as a derivative liability on March 7, 2024. On
March 31, 2025, the estimated fair value of the <ix:nonFraction contextRef="c649" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-90672">9,450</ix:nonFraction> warrants was $<ix:nonFraction contextRef="c666" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-90673">17,134</ix:nonFraction>. The estimated fair value of the warrants was computed as
of March 31, 2025 using Black-Scholes option-pricing model, with the following assumptions: stock price of $<ix:nonFraction contextRef="c667" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90674">4.80</ix:nonFraction>, volatility of <ix:nonFraction contextRef="c668" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90675">99.62</ix:nonFraction>%,
risk-free rate of <ix:nonFraction contextRef="c669" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90676">3.89</ix:nonFraction>%, annual dividend yield of <ix:nonFraction contextRef="c670" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90677">0</ix:nonFraction>% and expected life of <ix:nonFraction contextRef="c671" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90678">3.9</ix:nonFraction> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On June 5, 2024, the Company issued <ix:nonFraction contextRef="c358" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-90679">152,000</ix:nonFraction> warrants
to Mast Hill and a third party as a finder&#8217;s fee (see Note 6). Upon evaluation, the warrants meet the definition of a derivative
liability under ASC 815, as the Company cannot avoid a net cash settlement under certain circumstances. Management determined the probability
of failing to make an amortization payment when due to be remote and as such the fair value of the <ix:nonFraction contextRef="c359" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-90680">80,000</ix:nonFraction> warrants with an exercise price
of $<ix:nonFraction contextRef="c274" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-90681">7.50</ix:nonFraction> exercisable until June 5, 2029, which warrant shall be cancelled and extinguished against payment of the June 2024 Convertible
Note, has been estimated to be zero. Accordingly, the fair value of the <ix:nonFraction contextRef="c672" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90682">72,000</ix:nonFraction> warrants with an exercise price of $<ix:nonFraction contextRef="c673" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90683">9.75</ix:nonFraction> exercisable until
June 5, 2029 was classified as a derivative liability on June 5, 2024. On March 31, 2025, the estimated fair value of the <ix:nonFraction contextRef="c674" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-90684">72,000</ix:nonFraction> warrants
with an exercise price of $<ix:nonFraction contextRef="c675" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-90685">9.75</ix:nonFraction> exercisable until the five-year anniversary of June 5, 2024 as derivative liability was $<ix:nonFraction contextRef="c676" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-90686">204,114</ix:nonFraction>. The
estimated fair value of the warrants was computed as of March 31, 2025 using Black-Scholes option-pricing model, with the following assumptions:
stock price of $<ix:nonFraction contextRef="c677" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90687">4.80</ix:nonFraction>, volatility of <ix:nonFraction contextRef="c678" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90688">97.66</ix:nonFraction>%, risk-free rate of <ix:nonFraction contextRef="c679" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90689">3.96</ix:nonFraction>%, annual dividend yield of <ix:nonFraction contextRef="c680" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90690">0</ix:nonFraction>% and expected life of <ix:nonFraction contextRef="c681" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-90691">4.2</ix:nonFraction> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Increases or decreases in fair value of the derivative
liability are included as a component of total other (expenses) income in the accompanying condensed consolidated statements of operations
and comprehensive loss. The changes to the derivative liability resulted in an increase of $<ix:nonFraction contextRef="c649" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="0" unitRef="usd" id="ixv-90692">114,360</ix:nonFraction> in the derivative liability and the
corresponding increase in other expense as a loss for the three months ended March 31, 2025. The changes to the derivative liability
resulted in a decrease of $<ix:nonFraction contextRef="c682" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" unitRef="usd" id="ixv-90693">31,212</ix:nonFraction> in the derivative liability and the corresponding increase in other income as a gain for the three
months ended March 31, 2024.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 373; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-74366"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">NOTE 8 - <span style="text-decoration:underline">NOTE PAYABLE, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On September 1, 2022, the Company issued a balloon
promissory note in the form of a mortgage on its headquarters to a third party company in the principal amount of $<ix:nonFraction contextRef="c368" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-90694">4,800,000</ix:nonFraction>, which carries
interest of <ix:nonFraction contextRef="c369" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" scale="-2" unitRef="pure" id="ixv-90695">11.0</ix:nonFraction>% per annum. Interest is due in monthly payments of $<ix:nonFraction contextRef="c370" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="0" unitRef="usd" id="ixv-90696">44,000</ix:nonFraction> beginning November 1, 2022 and payable monthly thereafter
until September 1, 2025 when the principal outstanding and all remaining interest is due. The principal of $<ix:nonFraction contextRef="c683" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-90697">4,800,000</ix:nonFraction> can be extended
for an additional 36 months, provided that the Company has not defaulted. The Company may not prepay the principal of $<ix:nonFraction contextRef="c683" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" scale="0" unitRef="usd" id="ixv-90698">4,800,000</ix:nonFraction> for
a period of 12 months. The principal of $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecuredDebt" scale="0" unitRef="usd" id="ixv-90699">4,800,000</ix:nonFraction> is secured by a first mortgage on the Company&#8217;s real property located at 4400
Route 9 South, Freehold, Monmouth County, New Jersey..</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">In May 2023, the Company borrowed $<ix:nonFraction contextRef="c372" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="0" unitRef="usd" id="ixv-90700">1,000,000</ix:nonFraction> from
the same lender. The principal of $<ix:nonFraction contextRef="c373" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd" id="ixv-90701">1,000,000</ix:nonFraction> accrues interest at an annual rate of <ix:nonFraction contextRef="c373" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-90702">13.0</ix:nonFraction>% and is payable in monthly installments of interest-only
in the amount of $<ix:nonFraction contextRef="c373" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" scale="0" unitRef="usd" id="ixv-90703">10,833</ix:nonFraction>, commencing in June 2023 and continuing through October 2025 (at which point any unpaid balance of principal,
interest and other charges are due and payable). The loan is secured by a second-lien mortgage on certain real property and improvements
located at 4400 Route 9 South, Freehold, Monmouth County, New Jersey.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDebtTableTextBlock" id="ixv-74380"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The note payable as of March 31, 2025 and December
31, 2024 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><b style="-keep: true">March 31,<br/> 2025</b></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><b style="-keep: true">December
    31, <br/> 2024</b></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-keep: true">Principal amount</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-90704">5,800,000</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-90705">5,800,000</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Less: unamortized debt issuance costs</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="0" unitRef="usd" id="ixv-90706">54,746</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="0" unitRef="usd" id="ixv-90707">84,553</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-keep: true">Note payable, net</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd" id="ixv-90708">5,745,254</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="0" unitRef="usd" id="ixv-90709">5,715,447</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">For the three months ended March 31, 2025 and
2024, amortization of debt issuance costs related to note payable amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd" id="ixv-90710">29,807</ix:nonFraction> and $<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd" id="ixv-90711">29,807</ix:nonFraction>, respectively, which have been included
in interest expense - amortization of debt discount and debt issuance costs on the accompanying condensed consolidated statements of
operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">For the three months ended March 31, 2025 and
2024, interest expense related to note payable amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseShortTermBorrowings" scale="0" unitRef="usd" id="ixv-90712">164,500</ix:nonFraction> and $<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseShortTermBorrowings" scale="0" unitRef="usd" id="ixv-90713">164,500</ix:nonFraction>, respectively, which have been included in interest
expense - other on the accompanying condensed consolidated statements of operations and comprehensive loss.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-74472"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">NOTE 9 - <span style="text-decoration:underline">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Rental Revenue from Related Party and Rent
Receivable - Related Party</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company leases space of its commercial real
property located in New Jersey to D.P. Capital Investments LLC, which is controlled by Wenzhao Lu, the Company&#8217;s chairman of the
Board of Directors. The term of the related party lease agreement is five years commencing on May 1, 2021 and will expire on April 30,
2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">For both the three months ended March 31, 2025
and 2024, the related party rental revenue amounted to $<ix:nonFraction contextRef="c684" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RentalIncomeNonoperating" scale="0" unitRef="usd" id="ixv-90714"><ix:nonFraction contextRef="c685" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RentalIncomeNonoperating" scale="0" unitRef="usd" id="ixv-90715">12,600</ix:nonFraction></ix:nonFraction> and has been included in real property rental revenue on the accompanying
condensed consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Services Provided by Related Party</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">From time to time, Wilbert Tauzin, a director
of the Company, and his son provide consulting services to the Company. As compensation for professional services provided, the Company
recognized consulting expenses of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralExpense" scale="0" unitRef="usd" id="ixv-90716">15,597</ix:nonFraction> and $<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralExpense" scale="0" unitRef="usd" id="ixv-90717">16,731</ix:nonFraction> for the three months ended March 31, 2025 and 2024, respectively, which have been
included in professional fees on the accompanying condensed consolidated statements of operations and comprehensive loss. As of March
31, 2025 and December 31, 2024, the accrued and unpaid services charge related to this director&#8217;s son amounted to $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="avco:AccruedAndUnpaidServicesCharge" scale="0" unitRef="usd" id="ixv-90718">2,615</ix:nonFraction> and $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="avco:AccruedAndUnpaidServicesCharge" scale="0" unitRef="usd" id="ixv-90719">15,000</ix:nonFraction>,
respectively, which have been included in accrued professional fees on the accompanying condensed consolidated balance sheets.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 374; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">NOTE 9 - <span style="text-decoration:underline">RELATED PARTY TRANSACTIONS (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Accrued Liabilities and Other Payables - Related
Parties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">In 2017, the Company acquired Beijing Jieteng
(Genexosome) Biotech Co., Ltd. (&#8220;Beijing GenExosome&#8221;) for a cash payment of $<ix:nonFraction contextRef="c686" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAcquiredFromAcquisition" scale="0" unitRef="usd" id="ixv-90720">450,000</ix:nonFraction>. As of both March 31, 2025 and December
31, 2024, the unpaid acquisition consideration of $<ix:nonFraction contextRef="c687" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" unitRef="usd" id="ixv-90721"><ix:nonFraction contextRef="c377" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" unitRef="usd" id="ixv-90722">100,000</ix:nonFraction></ix:nonFraction>, was payable to Dr. Yu Zhou, former director and former co-chief executive
officer and <ix:nonFraction contextRef="c688" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-90723">40</ix:nonFraction>% owner of Genexosome, and has been included in accrued liabilities and other payables - related parties on the accompanying
condensed consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">From time to time, Lab Services MSO paid shared
expense on behalf of the Company. In addition, Lab Services MSO made a payment of $<ix:nonFraction contextRef="c689" decimals="0" format="ixt:num-dot-decimal" name="avco:EquityMethodInvestmentPayableCurrent" scale="0" unitRef="usd" id="ixv-90724">566,667</ix:nonFraction> for equity method investment payable on behalf
of the Company in 2024. During the first quarter of 2025, to preserve cash, the Company entered into discussions with Lab Services MSO
for the potential redemption of our investment and on February 26, 2025, the Company and Lab Services MSO entered into a Redemption and
Abandonment Agreement, whereby Lab Services MSO redeemed the <ix:nonFraction contextRef="c690" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-90725">40</ix:nonFraction>% equity interest in Lab Services MSO held by the Company for cash and
the surrender of its Series B Preferred Stock having a carrying value of $<ix:nonFraction contextRef="c691" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-90726">11,000,000</ix:nonFraction>. The aggregate cash amount to the Company for the
redemption was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="0" unitRef="usd" id="ixv-90727">1,745,000</ix:nonFraction>, to be paid as follows: one payment of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireLoansHeldForInvestment" scale="0" unitRef="usd" id="ixv-90728">95,000</ix:nonFraction> at the closing of the redemption and, beginning in March 2025,
monthly payments of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="avco:RegularPaymentsOnEquityInvestments" scale="0" unitRef="usd" id="ixv-90729">75,000</ix:nonFraction> until December 2026. In addition, pursuant to the terms of the Redemption Agreement, all shares of the Company&#8217;s
Series B Preferred Stock previously issued to SCBC Holdings LLC as partial consideration for the equity interests of Laboratory Services
MSO, were permanently surrendered and relinquished to the Company for no additional consideration. The difference of $<ix:nonFraction contextRef="c581" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="0" unitRef="usd" id="ixv-90730">2,348,695</ix:nonFraction> between
the carrying value of the extinguished Series B Preferred Stock, the aggregate cash amount to the Company for the redemption, net of
payables due to Lab Services MSO of $<ix:nonFraction contextRef="c692" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="0" unitRef="usd" id="ixv-90731">632,916</ix:nonFraction>, totaling $<ix:nonFraction contextRef="c692" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="0" unitRef="usd" id="ixv-90732">13,377,916</ix:nonFraction>, and the carrying value of the equity method investment of $<ix:nonFraction contextRef="c689" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ReceivableInvestmentSale" scale="0" unitRef="usd" id="ixv-90733">11,029,221</ix:nonFraction>
was accounted for as an increase to additional paid-in capital (See Note 10 - Series B Convertible Preferred Stock Extinguished Related
to Sale of Equity Method Investment). As of March 31, 2025 and December 31, 2024, the balance due to Lab Services MSO amounted to <ix:nonFraction contextRef="c689" decimals="0" format="ixt:fixed-zero" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-90734">$0</ix:nonFraction>
and $<ix:nonFraction contextRef="c693" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNotesPayable" scale="0" unitRef="usd" id="ixv-90735">632,916</ix:nonFraction>, respectively, which has been included in accrued liabilities and other payables - related parties on the accompanying condensed
consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Membership Interest Purchase Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On November 17, 2023, the Company entered into
a Membership Interest Purchase Agreement with Mr. Lu, the Company&#8217;s chairman of the Board of Directors, pursuant to which (i) Mr.
Lu will acquire from the Company <ix:nonFraction contextRef="c694" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" unitRef="pure" id="ixv-90736">30</ix:nonFraction>% of the total outstanding membership interests of Avalon RT 9, a wholly owned subsidiary of the Company,
for a cash purchase price of $<ix:nonFraction contextRef="c695" decimals="0" format="ixt:num-dot-decimal" name="avco:PurchasePrice" scale="0" unitRef="usd" id="ixv-90737">3,000,000</ix:nonFraction> (the &#8220;Acquisition&#8221;), and (ii) for a period of twelve months following the closing
of the Acquisition, Mr. Lu shall have the option to purchase from the Company up to an additional <ix:nonFraction contextRef="c696" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" unitRef="pure" id="ixv-90738">70</ix:nonFraction>% of the outstanding membership interests
of Avalon RT 9 for a purchase price of up to $<ix:nonFraction contextRef="c697" decimals="0" format="ixt:num-dot-decimal" name="avco:PurchasePrice" scale="0" unitRef="usd" id="ixv-90739">7,000,000</ix:nonFraction> (the &#8220;Option&#8221;), subject to the terms and conditions of a membership
interest purchase agreement to be negotiated and entered into between Mr. Lu and the Company at such time that Mr. Lu desires to exercise
the Option. The Company received $<ix:nonFraction contextRef="c698" decimals="0" format="ixt:num-dot-decimal" name="avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" scale="0" unitRef="usd" id="ixv-90740">3,328,078</ix:nonFraction> and $<ix:nonFraction contextRef="c699" decimals="0" format="ixt:num-dot-decimal" name="avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" scale="0" unitRef="usd" id="ixv-90741">3,108,106</ix:nonFraction> from Mr. Lu as of March 31, 2025 and December 31, 2024, respectively, which
was recorded as advance from pending sale of noncontrolling interest - related party on the accompanying condensed consolidated balance
sheets. The Acquisition is expected to close in the fourth quarter of 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Series D Convertible Preferred Stock Issued
in Exchange of Series A Convertible Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On January 9, 2025, the Company entered into an
exchange agreement with Wenzhao Lu, the Company&#8217;s chairman of the Board of Directors, pursuant to which Mr. Lu exchanged <ix:nonFraction contextRef="c700" decimals="0" format="ixt:num-dot-decimal" name="avco:ExchangeShare" scale="0" unitRef="shares" id="ixv-90742">9,000</ix:nonFraction>
shares of Series A Preferred Stock of the Company, having a carrying value of $<ix:nonFraction contextRef="c701" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-90743">9,000,000</ix:nonFraction>, for <ix:nonFraction contextRef="c702" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-90744">5,000</ix:nonFraction> shares of Series D Preferred Stock
of the Company. The Company determined that the exchange of the Series A Preferred Stock for the Series D Preferred Stock resulted in
the extinguishment of the Series A Preferred Stock. As a result, the difference between the carrying amount of the Series A Preferred
Stock and the fair value of the Series D Preferred Stock of $<ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-90745">162,473</ix:nonFraction> was recognized as a deemed contribution in the three months ended
March 31, 2025 that increased additional paid-in capital and income available to common shareholders in calculating earnings per share
(See Note 10 - Series D Convertible Preferred Stock Issued in Exchange of Series A Convertible Preferred Stock).</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 375; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="ixv-74576"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 10 - <span style="text-decoration:underline">EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company is authorized to issue an aggregate
of <ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-90746">100,000,000</ix:nonFraction> shares of common stock and <ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-90747">10,000,000</ix:nonFraction> shares of &#8220;blank check&#8221; preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Series A Convertible Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company designated up to <ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-90748">15,000</ix:nonFraction> shares of
its previously undesignated preferred stock as Series A Preferred Stock. Each share of Series A Preferred Stock has a par value of $<ix:nonFraction contextRef="c81" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-90749">0.0001</ix:nonFraction>
per share and a stated value equal to $<ix:nonFraction contextRef="c703" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-90750">1,000</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The shares of Series A Preferred Stock have identical
terms and include the terms as set forth below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true"><i>Dividends.</i> Holders of Series A Preferred
Stock (each, a &#8220;Series A Holder&#8221; and collectively, the &#8220;Series A Holders&#8221;) are entitled to receive, and the Company
shall pay, dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-common-stock basis, disregarding for such
purpose any conversion limitations set forth in the Series A Certificate of Designations) to and in the same form as dividends actually
paid on shares of the Company&#8217;s common stock when, as and if such dividends are paid on shares of the common stock. No other dividends
shall be paid on shares of Series A Preferred Stock. The Company will not pay any dividends on its common stock unless the Company simultaneously
complies with the terms set forth in the Series A Certificate of Designations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true"><i>Liquidation.</i> Upon any dissolution, liquidation
or winding-up of the Company, whether voluntary or involuntary (a &#8220;Liquidation&#8221;), the Series A Holders will be entitled to
receive out of the assets available for distribution to the stockholders, (i) after and subject to the payment in full of all amounts
required to be distributed to the holders of another class or series of stock of the Company ranking on liquidation prior and in preference
to the Series A Preferred Stock, (ii) ratably with any class or series of stock ranking on liquidation on parity with the Series A Preferred
Stock and (iii) in preference and priority to the holders of the shares of the Company&#8217;s common stock, an amount equal to <ix:nonFraction contextRef="c704" decimals="2" format="ixt:num-dot-decimal" name="avco:PercentageOfCommonStockIssuedAndOutstanding" scale="-2" unitRef="pure" id="ixv-90751">100</ix:nonFraction>%
of the Series A Stated Value, and no more, in proportion to the full and preferential amount that all shares of the Series A Preferred
Stock are entitled to receive. The Company shall mail written notice of any Liquidation not less than twenty (20) days prior to the payment
date stated therein, to each Series A Holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true"><i>Conversion.</i> Each share of Series A Preferred
Stock shall be convertible, at any time and from time to time from and after the later of (i) the date of the stockholder approval as
described above, in accordance with the Nasdaq Stock Market Listing Rules, and (ii) the nine (9) month anniversary of the Closing (the
&#8220;Initial Conversion Date&#8221;), at the option of the Series A Holder, into that number of shares of common stock (subject to
the limitations set forth in Series A Certificate of Designations, determined by dividing the Stated Value of such share of Series A
Preferred Stock by the conversion price (as defined below)). The Series A Holders may effect conversions by providing the Company with
the form of conversion notice attached as Annex A to the Series A Certificate of Designations. The Series A Holders may convert such
shares into shares of the Company&#8217;s common stock at a conversion price per share equal to the greater of (i) one hundred fifty
dollars ($<ix:nonFraction contextRef="c13" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-90752">150.0</ix:nonFraction>) and (ii) ninety percent (<ix:nonFraction contextRef="c704" decimals="2" format="ixt:num-dot-decimal" name="avco:ConversionPricePercentage" scale="-2" sign="-" unitRef="pure" id="ixv-90753">90</ix:nonFraction>%) of the closing price of the Company&#8217;s common stock on Nasdaq on the day prior to
receipt of a conversion notice, subject to adjustment for stock splits and similar matters. In addition, following the Initial Conversion
Date, each Series A Holder agrees that it shall not be entitled to in any calendar month, sell a number of Series A conversion shares
into the open market in an amount exceeding more than ten percent (<ix:nonFraction contextRef="c705" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentRate" scale="-2" unitRef="pure" id="ixv-90754">10</ix:nonFraction>%) of the number of Series A conversion shares issuable upon conversion
of the Series A Preferred Stock then held by such Series A Holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i style="-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i style="-keep: true">Conversion Price Adjustment:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true"><i>Stock Dividends and Stock Splits.</i> If the
Company, at any time while the Series A Preferred Stock is outstanding: (i) pays a stock dividend or otherwise makes a distribution or
distributions payable in shares of common stock on shares of common stock or any other common stock equivalents (which, for avoidance
of doubt, shall not include any shares of common stock issued by the Company upon conversion of, or payment of a dividend on, the Series
A Preferred Stock), (ii) subdivides outstanding shares of common stock into a larger number of shares, (iii) combines (including by way
of a reverse stock split) outstanding shares of common stock into a smaller number of shares, or (iv) issues, in the event of a reclassification
of shares of the common stock, any shares of capital stock of the Company, then the conversion price of the Series A Preferred Stock
shall be multiplied by a fraction of which the numerator shall be the number of shares of common stock (excluding any treasury shares
of the Company) outstanding immediately before such event, and of which the denominator shall be the number of shares of common stock
outstanding immediately after such event. Any of the foregoing adjustments shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 376; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 10 - <span style="text-decoration:underline">EQUITY (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Series A Convertible Preferred Stock (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_2" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true"><i>Fundamental Transaction.</i> If, at any time
while the Series A Preferred Stock is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another individual or corporation, partnership, trust, incorporated or unincorporated
association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other
entity of any kind (a &#8220;Person&#8221;), (ii) the Company (and all of its subsidiaries, taken as a whole), directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in
one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the
Company or another Person) is completed pursuant to which holders of the Company&#8217;s common stock are permitted to sell, tender or
exchange their shares for other securities, cash or property and has been accepted by the holders of fifty percent (<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="avco:PercentageOfCommonStockIssuedAndOutstanding" scale="-2" sign="-" unitRef="pure" id="ixv-90755">50</ix:nonFraction>%) or more of the
outstanding common stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the common stock or any compulsory share exchange pursuant to which the common stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than fifty percent (<ix:nonFraction contextRef="c74" decimals="2" format="ixt:num-dot-decimal" name="avco:PercentageOfCommonStockIssuedAndOutstanding" scale="-2" sign="-" unitRef="pure" id="ixv-90756">50</ix:nonFraction>%)
of the outstanding shares of common stock (not including any shares of common stock held by the other Person or other Persons making
or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business
combination) (each a &#8220;Fundamental Transaction&#8221;), then, the Series A Holder shall have the right to receive, for each conversion
share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without
regard to any limitation set forth in the Series A Certificate of Designations on the conversion of the Series A Preferred Stock), the
number of shares of common stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and/or
any additional consideration (the &#8220;Alternate Consideration&#8221;) receivable as a result of such Fundamental Transaction by a
holder of the number of shares of common stock for which the Series A Preferred Stock is convertible immediately prior to such Fundamental
Transaction (without regard to the limitations set forth in the Series A Certificate of Designations on the conversion of the Series
A Preferred Stock). For purposes of any such conversion, the determination of the conversion price shall be appropriately adjusted to
apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of <ix:nonFraction contextRef="c74" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares" id="ixv-90757">one</ix:nonFraction> share of common stock
in such Fundamental Transaction, and the Company shall apportion the conversion price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of common stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Series A Holder shall be given
the same choice as to the Alternate Consideration it receives upon such Fundamental Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true"><i>Voting Rights.</i> The Series A Holders will
have no voting rights, except as otherwise required by the Delaware General Corporation Law. Notwithstanding the foregoing, as long as
any shares of Series A Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority
of the then outstanding shares of Series A Preferred Stock, voting as a separate class, (a) alter or change adversely the powers, preferences
or rights given to the Series A Preferred Stock in the Series A Certificate of Designations, (b) increase the number of authorized shares
of Series A Preferred Stock, (c) authorize or issue an additional class or series of capital stock that ranks senior to the Series A
Preferred Stock with respect to the distribution of assets on liquidation or (d) enter into any agreement with respect to any of the
foregoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true"><i>Fractional Shares.</i> No fractional shares
or scrip representing fractional shares shall be issued upon the conversion of the Series A Preferred Stock. As to any fraction of a
share of Company common stock which a Series A Holder would otherwise be entitled to upon such conversion, the Company will, at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the conversion price
or round up to the next whole share. Notwithstanding the foregoing, nothing shall prevent any Series A Holder from converting fractional
shares of Series A Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">As of December 31, 2024, <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-90758"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-90759">9,000</ix:nonFraction></ix:nonFraction> shares of Series
A Preferred Stock were issued and outstanding. On January 9, 2025, the Company entered into an exchange agreement with Wenzhao Lu, the
Company&#8217;s chairman of the Board of Directors, pursuant to which Mr. Lu exchanged <ix:nonFraction contextRef="c701" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-90760">9,000</ix:nonFraction> shares of Series A Preferred Stock of the
Company for <ix:nonFraction contextRef="c702" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-90761">5,000</ix:nonFraction> shares of Series D Preferred Stock of the Company (See Note 10 - Series D Convertible Preferred Stock Issued in Exchange
of Series A Convertible Preferred Stock). As of March 31, 2025, there were no shares of Series A Preferred Stock remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Series B Convertible Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company designated up to <ix:nonFraction contextRef="c706" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-90762">15,000</ix:nonFraction> shares of
its previously undesignated preferred stock as Series B Preferred Stock. Each share of Series B Preferred Stock has a par value of $<ix:nonFraction contextRef="c707" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-90763">0.0001</ix:nonFraction>
per share and a stated value equal to $<ix:nonFraction contextRef="c707" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-90764">1,000</ix:nonFraction>.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 377; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 10 - <span style="text-decoration:underline">EQUITY (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Series B Convertible Preferred Stock (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_3" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The shares of Series B Preferred Stock have identical
terms and include the terms as set forth below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true"><i>Dividends.</i> The holders of Series B Preferred
Stock (each, a &#8220;Series B Holder&#8221; and collectively, the &#8220;Series B Holders&#8221;) shall be entitled to receive, and
the Company shall pay, dividends on shares of Series B Preferred Stock equal (on an as-if-converted-to-common-stock basis, disregarding
for such purpose any conversion limitations set forth in the Series B Certificate of Designations) to and in the same form as dividends
actually paid on shares of the Company&#8217;s common stock when, as and if such dividends are paid on shares of the common stock. No
other dividends shall be paid on shares of Series B Preferred Stock. The Company will not pay any dividends on its common stock unless
the Company simultaneously complies with the terms set forth in the Series B Certificate of Designations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true"><i>Rank.</i> The Series B Preferred Stock will
rank subordinate to the shares of the Company&#8217;s Series A Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true"><i>Liquidation. </i>Upon any Liquidation, the
Series B Holders will be entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to the
payment in full of all amounts required to be distributed to the holders of another class or series of stock of the Company ranking on
liquidation prior and in preference to the Series B Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any class
or series of stock ranking on liquidation on parity with the Series B Preferred Stock and (iii) in preference and priority to the holders
of the shares of common stock, an amount equal to one hundred percent (<ix:nonFraction contextRef="c581" decimals="2" format="ixt:num-dot-decimal" name="avco:PercentageOfCommonStockIssuedAndOutstanding" scale="-2" unitRef="pure" id="ixv-90765">100</ix:nonFraction>%) of the Series B Stated Value and no more, in proportion
to the full and preferential amount that all shares of the Series B Preferred Stock are entitled to receive. The Company shall mail written
notice of any such Liquidation not less than twenty (20) days prior to the payment date stated therein, to each Series B Holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true"><i>Conversion.</i> Each share of Series B Preferred
Stock shall be convertible, at any time and from time to time from and after the later of (i) the date of the stockholder approval and
(ii) February 9, 2024 (the &#8220;Lock Up Period&#8221;), at the option of the Series B Holder thereof, into that number of shares of
common stock (subject to the limitations set forth in Series B Certificate of Designations determined by dividing the Series B Stated
Value of such share of Series B Preferred Stock by the conversion price of the Series B Preferred Stock). Series B Holders may effectuate
conversions by providing the Company with the form of conversion notice attached as Annex A to the Series B Certificate of Designations.
The Series B Preferred Stock will be convertible into shares of the Company&#8217;s common stock at a conversion price per share equal
to $<ix:nonFraction contextRef="c581" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceIncrease" scale="0" unitRef="usdPershares" id="ixv-90766">56.70</ix:nonFraction>, subject to the adjustments set forth in the Series B Certificate of Designations. Notwithstanding the foregoing or the transactions
contemplated by the Amended MIPA, until the consummation of the Lock Up Period, the Series B Holders shall not, directly or indirectly,
sell, transfer or otherwise dispose of any Series B Preferred Stock issued upon conversion of the Series B conversion shares or pursuant
to the Equity Earnout Payment (the &#8220;Restricted Securities&#8221;) without Company&#8217;s prior written consent; provided, however,
the Series B Holders may sell, transfer or otherwise dispose of Restricted Securities to an Affiliate, as defined in the Amended MIPA,
of a Series B Holder without Company&#8217;s prior written consent; provided, further, that such Series B Holder provide prompt written
notice to Company of such transfer, including the name and contact information of the Affiliate transferee, and such Affiliate transferee
agrees in writing to be bound by the terms of the transaction documents contemplated by the Amended MIPA to which the Series B Holder
is a party (which agreement shall also be provided to Company with such notice). After the expiration of the Lock Up Period, the Series
B Holder agrees that it and any of its Affiliate transferees shall not be entitled to in any calendar month, sell a number of shares
of Company common stock into the open market in an amount exceeding more than ten percent (10%) of the total number of shares of Company
common stock issuable upon conversion of the Company common stock then held by the Seller and its Affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i style="-keep: true">Conversion Price Adjustment:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true"><i>Stock Dividends and Stock Splits.</i> If the
Company, at any time while the Series B Preferred Stock is outstanding: (i) pays a stock dividend or otherwise makes a distribution or
distributions payable in shares of common stock on shares of common stock or any other common stock equivalents (which, for avoidance
of doubt, shall not include any shares of common stock issued by the Company upon conversion of, or payment of a dividend on, the Series
B Preferred Stock), (ii) subdivides outstanding shares of common stock into a larger number of shares, (iii) combines (including by way
of a reverse stock split) outstanding shares of common stock into a smaller number of shares, or (iv) issues, in the event of a reclassification
of shares of the common stock, any shares of capital stock of the Company, then the conversion price of the Series B Preferred Stock
shall be multiplied by a fraction of which the numerator shall be the number of shares of common stock (excluding any treasury shares
of the Company) outstanding immediately before such event, and of which the denominator shall be the number of shares of common stock
outstanding immediately after such event. Any of the foregoing adjustments shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 378; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 10 - <span style="text-decoration:underline">EQUITY (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Series B Convertible Preferred Stock (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_4" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true"><i>Fundamental Transaction.</i> If, at any time
while the Series B Preferred Stock is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another Person, (ii) the Company (and all of its subsidiaries, taken as a whole),
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of the Company&#8217;s common stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of fifty percent
(<ix:nonFraction contextRef="c708" decimals="2" format="ixt:num-dot-decimal" name="avco:PercentageOfCommonStockIssuedAndOutstanding" scale="-2" unitRef="pure" id="ixv-90767">50</ix:nonFraction>%) or more of the outstanding common stock, (iv) the Company, directly or indirectly, in one or more related transactions effects
any reclassification, reorganization or recapitalization of the common stock or any compulsory share exchange pursuant to which the common
stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a Fundamental Transaction, then, at the closing of such Fundamental Transaction, without
any action on the part of the Series B Holder, the Series B Holder shall have the right to receive, for each conversion share that would
have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation
in the Series B Certificate of Designations on the conversion of the Series B Preferred Stock), the number of shares of common stock
of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and/or any Alternate Consideration receivable
as a result of such Fundamental Transaction by a holder of the number of shares of common stock for which the Series B Preferred Stock
is convertible immediately prior to such Fundamental Transaction (without regard to the limitations set forth in the Series B Certificate
of Designations on the conversion of the Series B Preferred Stock). For purposes of any such conversion, the determination of the conversion
price of the Series B Preferred Stock shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of
Alternate Consideration issuable in respect of one share of common stock in such Fundamental Transaction, and the Company shall apportion
the conversion price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of common stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Series B Holder shall be given the same choice as to the Alternate Consideration it receives upon
such Fundamental Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true"><i>Voting Rights</i>. The Series B Holders will
have no voting rights, except as otherwise required by the Delaware General Corporation Law. Notwithstanding the foregoing, in addition,
as long as any shares of Series B Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders
of a majority of the then outstanding shares of the Series B Preferred Stock, voting as a separate class, (a) alter or change adversely
the powers, preferences or rights given to the Series B Preferred Stock in the Series B Certificate of Designations, (b) increase the
number of authorized shares of Series B Preferred Stock, (c) except with respect to the Series A Preferred Stock, authorize or issue
an additional class or series of capital stock that ranks senior to the Series B Preferred Stock with respect to the distribution of
assets on liquidation or (d) enter into any agreement with respect to any of the foregoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true"><i>Fractional Shares.</i> No fractional shares
or scrip representing fractional shares shall be issued upon the conversion of the Series B Preferred Stock. As to any fraction of a
share which a Series B Holder would otherwise be entitled to upon such conversion, the Company shall at its election, either pay a cash
adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the conversion price or round up to the
next whole share. Notwithstanding the foregoing, nothing shall prevent any Series B Holder from converting fractional shares of Series
B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">As of December 31, 2024, <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-90768"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-90769">11,000</ix:nonFraction></ix:nonFraction> shares of Series
B Preferred Stock were issued and outstanding. During the first quarter of 2025, to preserve cash, the Company entered into discussions
with Lab Services MSO for the potential redemption of our investment and on February 26, 2025, the Company and Lab Services MSO entered
into a Redemption and Abandonment Agreement, whereby Lab Services MSO redeemed the <ix:nonFraction contextRef="c709" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-90770">40</ix:nonFraction>% equity interest in Lab Services MSO held by the
Company for cash and the surrender of its Series B Preferred Stock having a carrying value of $<ix:nonFraction contextRef="c710" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-90771">11,000,000</ix:nonFraction>. Pursuant to the terms of the
Redemption Agreement, all shares of the Company&#8217;s Series B Preferred Stock previously issued to SCBC Holdings LLC as partial consideration
for the equity interests of Laboratory Services MSO, were permanently surrendered and relinquished to the Company for no additional consideration
(See Note 10 - Series B Convertible Preferred Stock Extinguished Related to Sale of Equity Method Investment). As of March 31, 2025,
there were no shares of Series B Preferred Stock remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Series C Convertible Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On December 13, 2024, the Company filed a certificate
of designations of preferences, rights, and limitations of Series C Preferred Stock (the &#8220;Series C Certificate of Designations&#8221;)
with the Department of State, Division of Corporations, of the State of Delaware, which provides for the designation of <ix:nonFraction contextRef="c399" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-90772">10,000</ix:nonFraction> shares
of Series C Preferred Stock of the Company, par value $<ix:nonFraction contextRef="c399" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-90773">0.0001</ix:nonFraction> per share. Each share of Series C Preferred Stock has a stated value of
$<ix:nonFraction contextRef="c399" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-90774">1,000</ix:nonFraction>.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 379; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 10 - <span style="text-decoration:underline">EQUITY (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Series C Convertible Preferred Stock (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_5" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Series C Preferred Stock shall rank (i) senior
to the Company&#8217;s common stock and any other class or series of capital stock of the Company created hereafter, the terms of which
specifically provide that such class or series shall rank junior to the Series C Preferred Stock, (ii) pari passu with any class or series
of capital stock of the Company created hereafter specifically ranking, by its terms, on par with the Series C Preferred Stock, (iii)
pari passu with Series B Preferred Stock of the Company with respect to its rights, preferences and restrictions, and (iv) subordinate
to the Series A Preferred Stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Holders of the Series C Preferred Stock shall
be entitled to receive, and the Company shall pay, dividends on shares of Series C Preferred Stock equal (on an as-if-converted-to-common-stock
basis, disregarding for such purpose any conversion limitations hereunder) to and in the same form as dividends actually paid on shares
of the common stock when, as and if such dividends are paid on shares of the common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Holders of the Series C Preferred Stock have no
voting power except as otherwise required by the Delaware General Corporation Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Upon any liquidation, dissolution or winding-up
of the Company, whether voluntary or involuntary (a &#8220;Liquidation&#8221;), the holders of the Series C Preferred Stock shall be
entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to the payment in full of all
amounts required to be distributed to the holders of another class or series of stock of the Company ranking on liquidation prior and
in preference to the Series C Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any class or series of stock
ranking on liquidation on parity with the Series C Preferred Stock and (iii) in preference and priority to the holders of the shares
of common stock, an amount equal to <ix:nonFraction contextRef="c711" decimals="2" format="ixt:num-dot-decimal" name="avco:PercentageOfCommonStockIssuedAndOutstanding" scale="-2" unitRef="pure" id="ixv-90775">100</ix:nonFraction>% of the Stated Value of the Series C Preferred Stock, in proportion to the full and preferential
amount that all shares of the Series C Preferred Stock are entitled to receive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Each share of Series C Preferred Stock shall be
convertible into common stock (the &#8220;Series C Conversion Shares&#8221;) at a conversion per share equal to $<ix:nonFraction contextRef="c15" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-90776">2.41</ix:nonFraction>, at the option
of the holder, at any time after the later of (i) the date of the shareholder approval of the issuance of the Series C Conversion Shares
pursuant to the rules of the Nasdaq Stock Market and (ii) the one year anniversary of the date of the first issuance of any shares of
the Series C Preferred Stock. In addition, the holder shall not have the right to convert any portion of the Series C Preferred Stock
if, after giving effect to the conversion, such holder (together with its affiliates) would beneficially own in excess of <ix:nonFraction contextRef="c712" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-90777">19.99</ix:nonFraction>% of the
number of shares of the common stock outstanding immediately after giving effect to the issuance of the respective Series C Conversion
Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">As of both March 31, 2025 and December 31, 2024,
<ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-90778"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-90779">3,500</ix:nonFraction></ix:nonFraction> shares of Series C Preferred Stock were issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Series D Convertible Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On January 6, 2025, the Company filed a certificate
of designations of preferences, rights, and limitations of Series D Preferred Stock (the &#8220;Series D Certificate of Designations&#8221;)
with the Department of State, Division of Corporations, of the State of Delaware, which provides for the designation of <ix:nonFraction contextRef="c713" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-90780">5,000</ix:nonFraction> shares
of Series D Preferred Stock of the Company, par value $<ix:nonFraction contextRef="c713" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-90781">0.0001</ix:nonFraction> per share, upon the terms and conditions as set forth in the Series D Certificate
of Designations. Each share of Series D Preferred Stock has a stated value of $<ix:nonFraction contextRef="c713" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-90782">1,000</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Series D Preferred Stock shall rank (i) senior
to the Company&#8217;s common stock and any other class or series of capital stock of the Company created hereafter, the terms of which
specifically provide that such class or series shall rank junior to the Series D Preferred Stock, (ii) pari passu with any class or series
of capital stock of the Company created hereafter specifically ranking, by its terms, on par with the Series D Preferred Stock, (iii)
pari passu with the Series B Preferred Stock of the Company with respect to its rights, preferences and restrictions, and (iv) pari passu
with the Series C Preferred Stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Holders of the Series D Preferred Stock have no
voting power except as otherwise required by the Delaware General Corporation Law.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 380; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 10 - <span style="text-decoration:underline">EQUITY (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Series D Convertible Preferred Stock (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_6" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Upon any liquidation, dissolution or winding-up
of the Company, whether voluntary or involuntary (a &#8220;Liquidation&#8221;), the holders of the Series D Preferred Stock shall be
entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to the payment in full of all
amounts required to be distributed to the holders of another class or series of stock of the Company ranking on liquidation prior and
in preference to the Series D Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any class or series of stock
ranking on liquidation on parity with the Series D Preferred Stock and (iii) in preference and priority to the holders of the shares
of common stock, an amount equal to <ix:nonFraction contextRef="c714" decimals="2" format="ixt:num-dot-decimal" name="avco:PercentageOfCommonStockIssuedAndOutstanding" scale="-2" unitRef="pure" id="ixv-90783">100</ix:nonFraction>% of the Stated Value of the Series D Preferred Stock, in proportion to the full and preferential
amount that all shares of the Series D Preferred Stock are entitled to receive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Each share of Series D Preferred Stock shall be
convertible into common stock (the &#8220;Series D Conversion Shares&#8221;) at a conversion per share equal to $<ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-90784">2.41</ix:nonFraction>, at the option
of the holder, at any time after the Company has obtained shareholder approval for the issuance of the Series D Conversion Shares pursuant
to the rules of the Nasdaq Stock Market. In addition, the holder shall not have the right to convert any portion of the Series D Preferred
Stock if, after giving effect to the conversion, such holder (together with its affiliates) would beneficially own in excess of <ix:nonFraction contextRef="c715" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-90785">4.99</ix:nonFraction>%
of the number of shares of the common stock outstanding immediately after giving effect to the issuance of the respective Series D Conversion
Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">As of March 31, 2025, <ix:nonFraction contextRef="c712" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-90786"><ix:nonFraction contextRef="c712" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-90787">5,000</ix:nonFraction></ix:nonFraction> shares of Series D
Preferred Stock were issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Series D Convertible Preferred Stock Issued
in Exchange of Series A Convertible Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On January 9, 2025, the Company entered into an
exchange agreement with Wenzhao Lu, the Company&#8217;s chairman of the Board of Directors, pursuant to which Mr. Lu exchanged <ix:nonFraction contextRef="c716" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-90788">9,000</ix:nonFraction>
shares of Series A Preferred Stock of the Company, having a carrying value of $<ix:nonFraction contextRef="c702" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-90789">9,000,000</ix:nonFraction>, for <ix:nonFraction contextRef="c702" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-90790">5,000</ix:nonFraction> shares of Series D Preferred Stock
of the Company. The Company determined that the exchange of the Series A Preferred Stock for the Series D Preferred Stock resulted in
the extinguishment of the Series A Preferred Stock. As a result, the difference between the carrying amount of the Series A Preferred
Stock and the fair value of the Series D Preferred Stock of $<ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-90791">162,473</ix:nonFraction> was recognized as a deemed contribution in the three months ended
March 31, 2025 that increased additional paid-in capital and income available to common shareholders in calculating earnings per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Each share of Series D Preferred Stock is convertible
into common stock of the Company (the &#8220;Series D Conversion Shares&#8221;) at a conversion per share equal to $<ix:nonFraction contextRef="c16" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-90792">2.41</ix:nonFraction>, which approximated
the market price at the date of transaction, at the option of the holder, at any time after the Company has obtained shareholder approval
for the issuance of the Series D Conversion Shares pursuant to the rules of the Nasdaq Stock Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company evaluated the features of the Series
D Preferred Stock under ASC 480, and classified them as permanent equity because the Series D Preferred Stock is not mandatorily or contingently
redeemable at the stockholder&#8217;s option and the liquidation preference that exists does not fall within the guidance of SEC Accounting
Series Release No. 268 - <i>Presentation in Financial Statements of &#8220;Redeemable Preferred Stocks&#8221;</i> (&#8220;ASR 268&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Series B Convertible Preferred Stock Extinguished
Related to Sale of Equity Method Investment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">During the first quarter of 2025, to preserve
cash, the Company entered into discussions with Lab Services MSO for the potential redemption of our investment and on February 26, 2025,
the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement, whereby Lab Services MSO redeemed the <ix:nonFraction contextRef="c717" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-90793">40</ix:nonFraction>% equity
interest in Lab Services MSO held by the Company for cash and the surrender of its Series B Preferred Stock having a carrying value of
$<ix:nonFraction contextRef="c718" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-90794">11,000,000</ix:nonFraction>. The aggregate cash amount to the Company for the redemption was $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockRedemptionAmount" scale="0" unitRef="usd" id="ixv-90795">1,745,000</ix:nonFraction>, to be paid as follows: one payment of $<ix:nonFraction contextRef="c707" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockRedemptionAmount" scale="0" unitRef="usd" id="ixv-90796">95,000</ix:nonFraction>
at the closing of the redemption and, beginning in March 2025, monthly payments of $<ix:nonFraction contextRef="c706" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockRedemptionAmount" scale="0" unitRef="usd" id="ixv-90797">75,000</ix:nonFraction> until December 2026. In addition, pursuant
to the terms of the Redemption Agreement, all shares of the Company&#8217;s Series B Preferred Stock previously issued to SCBC Holdings
LLC as partial consideration for the equity interests of Laboratory Services MSO, were permanently surrendered and relinquished to the
Company for no additional consideration. The difference of $<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="0" unitRef="usd" id="ixv-90798">2,348,695</ix:nonFraction> between the carrying value of the extinguished Series B preferred
stock, the aggregate cash amount to the Company for the redemption, net of payables due to Lab Services MSO of $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="avco:RedemptionNetOfPayablesDueToLabServices" scale="0" unitRef="usd" id="ixv-90799">632,916</ix:nonFraction>, totaling $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockRedemptionPremium" scale="0" unitRef="usd" id="ixv-90800">13,377,916</ix:nonFraction>,
and the carrying value of the equity method investment of $<ix:nonFraction contextRef="c707" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd" id="ixv-90801">11,029,221</ix:nonFraction> was accounted for as an increase to additional paid-in capital.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 381; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 10 - <span style="text-decoration:underline">EQUITY (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_7" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Common Shares Issued for Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">During the three months ended March 31, 2025,
the Company issued a total of <ix:nonFraction contextRef="c719" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-90802">22,278</ix:nonFraction> shares of its common stock for services rendered and to be rendered. These shares were valued at
$<ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="avco:FairMarketValues" scale="0" unitRef="usd" id="ixv-90803">111,232</ix:nonFraction>, the fair market values on the grant dates using the reported closing share prices on the dates of grant, and the Company recorded
stock-based compensation expense of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-90804">17,212</ix:nonFraction> for the three months ended March 31, 2025 and reduced accrued liabilities of $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-90805">42,385</ix:nonFraction> and
recorded prepaid expense of $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-90806">51,635</ix:nonFraction> as of March 31, 2025 which will be amortized over the rest of corresponding service periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Common Shares Issued for Warrant Exercise</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">In March 2025, pursuant to the terms of related
warrant agreements, the Company issued <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-90807">186,877</ix:nonFraction> shares of its common stock upon cashless exercise of warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<ix:nonNumeric contextRef="c725" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="ixv-75010"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The following table summarizes the shares of the
Company&#8217;s common stock issuable upon exercise of options outstanding at March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: White"> <td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">Options Outstanding</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-keep: true">&#160;</span></td><td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options Exercisable</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">Range of<br/> Exercise<br/> Price</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number <br/> Outstanding<br/> at March 31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted <br/> Average <br/> Remaining <br/> Contractual Life <br/> (Years)</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted <br/> Average<br/> Exercise<br/> Price</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number <br/> Exercisable at <br/> March 31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted <br/> Average<br/> Exercise <br/> Price</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: right"><span style="-keep: true">$</span></td> <td style="width: 24%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c726" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" unitRef="usdPershares" id="ixv-90808">2.93</ix:nonFraction> - <ix:nonFraction contextRef="c726" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" unitRef="usdPershares" id="ixv-90809">31.20</ix:nonFraction></span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 12%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c727" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-90810">21,010</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 12%; text-align: right"><ix:nonNumeric contextRef="c726" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-75108"><span style="-keep: true">3.48</span></ix:nonNumeric></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 12%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c727" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90811">12.19</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 12%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c727" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-90812">17,078</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 12%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c727" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-90813">14.28</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;<span style="font-size: 10pt"><ix:nonFraction contextRef="c728" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" unitRef="usdPershares" id="ixv-90814">48.75</ix:nonFraction> - <ix:nonFraction contextRef="c728" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" unitRef="usdPershares" id="ixv-90815">123.00</ix:nonFraction>&#160;</span></span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c729" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-90816">20,517</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><ix:nonNumeric contextRef="c728" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-75153"><span style="-keep: true">1.79</span></ix:nonNumeric></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c729" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90817">78.91</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c729" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-90818">20,517</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c729" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-90819">78.91</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="2" style="text-align: right; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;<span style="font-size: 10pt"><ix:nonFraction contextRef="c730" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" unitRef="usdPershares" id="ixv-90820">154.50</ix:nonFraction> - <ix:nonFraction contextRef="c730" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" unitRef="usdPershares" id="ixv-90821">264.00</ix:nonFraction>&#160;</span></span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c731" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-90822">9,898</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonNumeric contextRef="c730" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-75198"><span style="-keep: true">3.82</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c731" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90823">214.71</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c731" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-90824">9,898</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c731" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-90825">214.71</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-top: Black 1.5pt solid; text-align: right; padding-bottom: 2.5pt; border-bottom: Black 4pt double"><span style="-keep: true">$</span></td> <td style="border-top: Black 1.5pt solid; text-align: right; padding-bottom: 2.5pt; border-bottom: Black 4pt double"><span style="-keep: true"><ix:nonFraction contextRef="c732" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" unitRef="usdPershares" id="ixv-90826">2.93</ix:nonFraction> - <ix:nonFraction contextRef="c732" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" unitRef="usdPershares" id="ixv-90827">264.00</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c733" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-90828">51,425</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c732" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-75244"><span style="-keep: true">2.87</span></ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c733" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90829">77.79</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c733" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-90830">47,493</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c733" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-90831">83.97</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr> </table></ix:nonNumeric>


<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="ixv-75274"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Stock option activity for the three months ended
March 31, 2025 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number of <br/> Options</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted <br/> Average <br/> Exercise
    <br/> Price</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; font-size: 10pt"><span style="-keep: true">Outstanding at January 1, 2025</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c483" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-90832">52,479</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c483" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90833">85.45</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt"><span style="-keep: true">Granted</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c734" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-90834">2,665</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c734" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90835">3.26</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Expired / cancelled</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c734" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares" id="ixv-90836">3,719</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c734" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90837">132.47</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">Outstanding at March 31, 2025</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c735" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-90838">51,425</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c735" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90839">77.79</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="-keep: true">Options exercisable at March 31, 2025</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c735" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-90840">47,493</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c735" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90841">83.97</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Options expected to vest</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c735" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-90842">3,932</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c735" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90843">3.13</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The aggregate intrinsic value of stock options
outstanding and stock options exercisable at March 31, 2025 was approximately $<ix:nonFraction contextRef="c720" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" unitRef="usd" id="ixv-90844">17,000</ix:nonFraction> an $<ix:nonFraction contextRef="c720" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" unitRef="usd" id="ixv-90845">10,000</ix:nonFraction>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The fair values of options granted during the
three months ended March 31, 2025 were estimated at the date of grant using the Black-Scholes option-pricing model with the following
assumptions: volatility of <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-90846">105.10</ix:nonFraction>%, risk-free rate of <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-90847">4.29</ix:nonFraction>%, annual dividend yield of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-90848">0</ix:nonFraction>%, and expected life of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-90849">3.00</ix:nonNumeric> years. The aggregate
fair value of the options granted during the three months ended March 31, 2025 was $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" unitRef="usd" id="ixv-90850">6,115</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The fair values of options granted during the
three months ended March 31, 2024 were estimated at the date of grant using the Black-Scholes option-pricing model with the following
assumptions: volatility of <ix:nonFraction contextRef="c100" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-90851">91.17</ix:nonFraction>%, risk-free rate of <ix:nonFraction contextRef="c100" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-90852">3.93</ix:nonFraction>%, annual dividend yield of <ix:nonFraction contextRef="c100" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-90853">0</ix:nonFraction>%, and expected life of <ix:nonNumeric contextRef="c100" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-90854">5.00</ix:nonNumeric> years. The aggregate
fair value of the options granted during the three months ended March 31, 2024 was $<ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" unitRef="usd" id="ixv-90855">12,137</ix:nonFraction>.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 382; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 10 - <span style="text-decoration:underline">EQUITY (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Options (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_8" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">For the three months ended March 31, 2025 and
2024, stock-based compensation expense associated with stock options granted amounted to $<ix:nonFraction contextRef="c721" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-90856">9,159</ix:nonFraction> and $<ix:nonFraction contextRef="c722" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-90857">13,533</ix:nonFraction>, of which, $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd" id="ixv-90858">4,858</ix:nonFraction> and $<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd" id="ixv-90859">5,103</ix:nonFraction>
was recorded as compensation and related benefits, $<ix:nonFraction contextRef="c721" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-90860">4,301</ix:nonFraction> and $<ix:nonFraction contextRef="c722" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd" id="ixv-90861">8,430</ix:nonFraction> was recorded as professional fees, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfNonvestedShareActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="ixv-75466"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">A summary of the status of the Company&#8217;s
nonvested stock options granted as of March 31, 2025 and changes during the three months ended March 31, 2025 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number of <br/> Options</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted <br/> Average <br/> Exercise
    <br/> Price</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt"><span style="-keep: true">Nonvested at January 1, 2025</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c738" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares" id="ixv-90862">5,943</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c738" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-90863">11.54</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="-keep: true">Granted</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c739" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-90864">2,665</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c739" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-90865">3.26</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt"><span style="-keep: true">Cancelled</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c739" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares" id="ixv-90866">1,853</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c739" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-90867">27.40</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">Vested</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c739" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-90868">2,823</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c739" decimals="2" format="ixt:num-dot-decimal" name="avco:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues" scale="0" sign="-" unitRef="usdPershares" id="ixv-90869">5.03</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">Nonvested at March 31, 2025</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c740" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares" id="ixv-90870">3,932</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c740" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-90871">3.13</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Warrants (Except Pre-Funded Warrants)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c741" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="ixv-75592"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The following table summarizes the shares of the
Company&#8217;s common stock issuable upon exercise of warrants outstanding at March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="-keep: true">&#160;</span></td> <td colspan="12" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">Warrants Outstanding</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">Warrants Exercisable</span></td> <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">Range of<br/> Exercise<br/> Price</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">Number <br/> Outstanding<br/> at March 31,<br/> 2025</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">Weighted <br/> Average <br/> Remaining <br/> Contractual Life <br/> (Years)</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">Weighted <br/> Average<br/> Exercise<br/> Price</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">Number <br/> Exercisable at <br/> March 31,<br/> 2025</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">Weighted <br/> Average<br/> Exercise<br/> Price</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c742" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" unitRef="usdPershares" id="ixv-90872">7.50</ix:nonFraction> - <ix:nonFraction contextRef="c742" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" unitRef="usdPershares" id="ixv-90873">37.50</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c743" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-90874">162,010</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><ix:nonNumeric contextRef="c742" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-75680"><span style="font-size: 10pt">4.17</span></ix:nonNumeric></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c743" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90875">9.92</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c743" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-90876">82,010</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c743" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-90877">12.27</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c744" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90878">67.50</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c744" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-90879">889</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><ix:nonNumeric contextRef="c745" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-75726"><span style="font-size: 10pt">3.18</span></ix:nonNumeric></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c744" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90880">67.50</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c744" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-90881">889</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td><span style="-keep: true">&#160;</span></td> <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c744" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-90882">67.50</ix:nonFraction></span></td> <td><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c746" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90883">187.50</ix:nonFraction></span></td> <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c746" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-90884">8,264</ix:nonFraction></span></td> <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><ix:nonNumeric contextRef="c747" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-75772"><span style="font-size: 10pt">2.06</span></ix:nonNumeric></td> <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c746" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90885">187.50</ix:nonFraction></span></td> <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c746" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-90886">8,264</ix:nonFraction></span></td> <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c746" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-90887">187.50</ix:nonFraction></span></td> <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c748" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" unitRef="usdPershares" id="ixv-90888">7.50</ix:nonFraction> - <ix:nonFraction contextRef="c748" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" unitRef="usdPershares" id="ixv-90889">187.50</ix:nonFraction></span></td> <td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c749" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-90890">171,163</ix:nonFraction></span></td> <td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><ix:nonNumeric contextRef="c748" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-75818"><span style="font-size: 10pt">4.06</span></ix:nonNumeric></td> <td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c749" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90891">18.79</ix:nonFraction></span></td> <td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c749" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-90892">91,163</ix:nonFraction></span></td> <td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c749" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-90893">28.70</ix:nonFraction></span></td> <td style="padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_ScheduleOfShareBasedCompensationActivityTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Stock warrant activity for the three months ended
March 31, 2025 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number of <br/> Warrants</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted <br/>
    Average <br/> Exercise <br/> Price</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt"><span style="-keep: true">Outstanding at January 1, 2025</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c488" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-90894">182,996</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c488" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90895">21.37</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">Exercised</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c736" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-90896">11,833</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c736" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90897">58.63</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">Outstanding at March 31, 2025</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c737" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-90898">171,163</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c737" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90899">18.79</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="-keep: true">Warrants exercisable at March 31, 2025</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c737" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-90900">91,163</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c737" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90901">28.70</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Warrants expected to vest</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c737" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-90902">80,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c737" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-90903">7.50</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The aggregate intrinsic value of both stock warrants
outstanding and stock warrants exercisable at March 31, 2025 was $<ix:nonFraction contextRef="c723" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" unitRef="usd" id="ixv-90904">0</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i style="-keep: true">Warrants Exercised in March 2025</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i style="-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">In March 2025, pursuant to the terms of related
warrant agreements, the Company issued <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-90905">186,877</ix:nonFraction> shares of its common stock upon cashless exercise of warrants.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 383; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 10 - <span style="text-decoration:underline">EQUITY (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Warrants (Except Pre-Funded Warrants) (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_8"><ix:continuation id="_ScheduleOfNonvestedShareActivityTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">A summary of the status of the Company&#8217;s
nonvested stock warrants issued as of March 31, 2025 and changes during the three months ended March 31, 2025 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Number of <br/> Warrants</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Weighted <br/> Average <br/> Exercise<br/>
    Price</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt"><span style="-keep: true">Nonvested at January 1, 2025</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="white-space: nowrap; width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares" id="ixv-90906">80,000</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-90907">7.50</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">Vested</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-386"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-387"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">Nonvested at March 31, 2025</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares" id="ixv-90908">80,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-90909">7.50</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Pre-Funded Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">As of March 31, 2025, there were <ix:nonFraction contextRef="c724" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-90910">150,000</ix:nonFraction> pre-funded
warrants outstanding with an exercise price of $<ix:nonFraction contextRef="c724" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-90911">0.01</ix:nonFraction> per share. There was no activity related to these warrants during the three months
ended March 31, 2025.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="avco:StatutoryReserveAndRestrictedNetAssetsTextBlock" id="ixv-76113"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 11 - <span style="text-decoration:underline">STATUTORY RESERVE AND RESTRICTED
NET ASSETS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company&#8217;s PRC subsidiary, Avalon Shanghai,
is restricted in its ability to transfer a portion of its net asset to the Company. The payment of dividends by entities organized in
China is subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment of dividends only out of
accumulated profits as determined in accordance with accounting standards and regulations in China.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company is required to make appropriations
to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus reserve, based on after-tax net income
determined in accordance with generally accepted accounting principles of the PRC (&#8220;PRC GAAP&#8221;). Appropriations to the statutory
surplus reserve are required to be at least <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="avco:StatutoryReservePercent" scale="-2" unitRef="pure" id="ixv-90912">10</ix:nonFraction>% of the after-tax net income determined in accordance with PRC GAAP until the reserve
is equal to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="avco:RegisteredCapitalPercentage" scale="-2" unitRef="pure" id="ixv-90913">50</ix:nonFraction>% of the entity&#8217;s registered capital. Appropriations to the discretionary surplus reserve are made at the discretion
of the Board of Directors. The statutory reserve may be applied against prior year losses, if any, and may be used for general business
expansion and production or increase in registered capital, but are not distributable as cash dividends. The Company did not make any
appropriation to statutory reserve for Avalon Shanghai during the three months ended March 31, 2025 as it incurred net loss in the period.
As of both March 31, 2025 and December 31, 2024, the restricted amount as determined pursuant to PRC statutory laws totaled $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" scale="0" unitRef="usd" id="ixv-90914"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" scale="0" unitRef="usd" id="ixv-90915">6,578</ix:nonFraction></ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Relevant PRC laws and regulations restrict the
Company&#8217;s PRC subsidiary, Avalon Shanghai, from transferring a portion of its net assets, equivalent to its statutory reserve and
its share capital, to the Company&#8217;s shareholders in the form of loans, advances or cash dividends. Only PRC entity&#8217;s accumulated
profit may be distributed as dividend to the Company&#8217;s shareholders without the consent of a third party. As of both March 31,
2025 and December 31, 2024, total restricted net assets amounted to $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherRestrictedAssets" scale="0" unitRef="usd" id="ixv-90916"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherRestrictedAssets" scale="0" unitRef="usd" id="ixv-90917">1,206,578</ix:nonFraction></ix:nonFraction>.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" id="ixv-76133"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 12 - <span style="text-decoration:underline">CONDENSED FINANCIAL INFORMATION
OF THE PARENT COMPANY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Pursuant to the requirements of Rule 12-04(a),
5-04(c) and 4-08(e)(3) of Regulation S-X, the condensed financial information of the parent company shall be filed when the restricted
net assets of consolidated subsidiary exceed <ix:nonFraction contextRef="c11" decimals="2" format="ixt:num-dot-decimal" name="avco:RestrictedNetAssetsOfSubsidiaryExceedNetAssets" scale="-2" unitRef="pure" id="ixv-90918">25</ix:nonFraction>% of consolidated net assets as of the end of the most recently completed fiscal year.
For purposes of this test, restricted net assets of consolidated subsidiary shall mean that amount of the Company&#8217;s proportionate
share of net assets of consolidated subsidiary (after intercompany eliminations) which as of the end of the most recent fiscal year may
not be transferred to the parent company by subsidiary in the form of loans, advances or cash dividends without the consent of a third
party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company performed a test on the restricted
net assets of consolidated subsidiary in accordance with such requirement and concluded that it was not applicable to the Company as
the restricted net assets of the Company&#8217;s PRC subsidiary did not exceed <ix:nonFraction contextRef="c750" decimals="2" format="ixt:num-dot-decimal" name="avco:RestrictedNetAssetsPRCSubsidiaryDidNotExceed" scale="-2" unitRef="pure" id="ixv-90919">25</ix:nonFraction>% of the consolidated net assets of the Company, therefore,
the condensed financial statements for the parent company have not been required.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><!-- Field: Page; Sequence: 384; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p><div>






</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="ixv-76169"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 13 - <span style="text-decoration:underline">CONCENTRATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">Customers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="ixv-76179"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The following table sets forth information as
to each customer that accounted for 10% or more of the Company&#8217;s revenue for the three months ended March 31, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Three Months Ended March 31,</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1.5pt solid"><span style="-keep: true">Customer</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt"><span style="-keep: true">A</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c752" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90920">28</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">%</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c753" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90921">28</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="-keep: true">B</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c754" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90922">17</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">%</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c755" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90923">18</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt"><span style="-keep: true">C</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c756" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90924">11</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">%</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c757" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90925">12</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">%</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">One customer, which is a third party, whose outstanding
receivable accounted for 10% or more of the Company&#8217;s total outstanding rent receivable at March 31, 2025, accounted for <ix:nonFraction contextRef="c751" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90926">79.8</ix:nonFraction>%
of the Company&#8217;s total outstanding rent receivable at March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">One customer, which is a third party, whose outstanding
receivable accounted for 10% or more of the Company&#8217;s total outstanding rent receivable at December 31, 2024, accounted for <ix:nonFraction contextRef="c512" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-90927">76.9</ix:nonFraction>%
of the Company&#8217;s total outstanding rent receivable at December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-keep: true">Suppliers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">No supplier accounted for 10% or more of the Company&#8217;s
purchase during the three months ended March 31, 2025 and 2024.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock" id="ixv-76286"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 14 - <span style="text-decoration:underline">SEGMENT INFORMATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The segment reporting structure uses the Company&#8217;s
management reporting structure as its foundation to reflect how the Company manages the businesses internally. During the three months
ended March 31, 2025 and 2024, the management reporting structure was composed of two strategic business units, mainly organized by services,
led by the Company&#8217;s President and Chief Executive Officer, who is its Chief Operating Decision Maker. Using the accounting guidance
on segment reporting, the Company determined that its <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="segments" id="ixv-90928">two</ix:nonFraction> operating segments were aligned with its <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="segments" id="ixv-90929">two</ix:nonFraction> reportable segments corresponding
to its strategic business units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On February 9, 2023, the Company purchased <ix:nonFraction contextRef="c146" decimals="2" format="ixt:num-dot-decimal" name="avco:PurchasedServicesPercentage" scale="-2" unitRef="pure" id="ixv-90930">40</ix:nonFraction>%
of Lab Services MSO. During the first quarter of 2025, to preserve cash, the Company entered into discussions with Lab Services MSO for
the potential redemption of our investment and on February 26, 2025, the Company and Lab Services MSO entered into a Redemption and Abandonment
Agreement, whereby Lab Services MSO redeemed the <ix:nonFraction contextRef="c758" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-90931">40</ix:nonFraction>% equity interest in Lab Services MSO held by the Company. During the three months
ended March 31, 2025 and 2024, the Company operated in <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="segments" id="ixv-90932"><ix:nonFraction contextRef="c100" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="segments" id="ixv-90933">two</ix:nonFraction></ix:nonFraction> reportable business segments: (1) the real property operating segment, and
(2) laboratory testing services segment (which ended on February 26, 2025) since Lab Services MSO&#8217;s operating results were regularly
reviewed by the Company&#8217;s chief operating decision maker to make decisions about resources to be allocated to the segment and assess
its performance. The Company regularly reviewed the operating results and performance of Lab Services MSO, which was the Company&#8217;s
equity method investee.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>




</div><!-- Field: Page; Sequence: 385; Options: NewSection; Value: 129 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><ix:continuation continuedAt="_SegmentReportingDisclosureTextBlock-c0_cont_2" id="_SegmentReportingDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The accounting policies for the segments are the
same as those described in Note 3. Our reportable segments are aligned principally around the differences in services. Real property
operating income is calculated by subtracting real property operating expenses from real property rental revenue; income from equity
method investment - Lab Services MSO is calculated by subtracting amortization of intangible assets acquired from acquisition and distribution
of earnings from equity investment from the Company&#8217;s share of Lab Services MSO&#8217;s net income. The assets and certain expenses
related to corporate activities are not allocated to the segments. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="ixv-90934">Information with respect to these reportable business segments for
the three months ended March 31, 2025 and 2024 was as follows:</ix:nonNumeric></span></p></ix:continuation><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 14 - <span style="text-decoration:underline">SEGMENT INFORMATION (continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation id="_SegmentReportingDisclosureTextBlock-c0_cont_2"><ix:continuation id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="14" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Three Months Ended March 31, 2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Real Property Operations</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Lab Services<br/>
 MSO</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Corporate /<br/>
 Other</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-size: 10pt; text-align: left"><span style="-keep: true">Real property rental revenue</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c759" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-90935">349,800</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-388"><span style="-keep: true">-</span></div></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-389"><span style="-keep: true">-</span></div></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-90936">349,800</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Real property operating expenses</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c759" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-90937">280,390</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-390"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-391"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-90938">280,390</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Real property operating income</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c759" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd" id="ixv-90939">69,410</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-392"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-393"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd" id="ixv-90940">69,410</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Income from equity method investment - Lab Services MSO</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-394"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c760" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="0" unitRef="usd" id="ixv-90941">392,677</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-395"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="0" unitRef="usd" id="ixv-90942">392,677</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Other operating expenses</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c759" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" unitRef="usd" id="ixv-90943">90,762</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-396"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c761" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" unitRef="usd" id="ixv-90944">2,178,100</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" unitRef="usd" id="ixv-90945">2,268,862</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Other (expense) income:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-keep: true">Interest expense</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c759" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-90946">194,307</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-397"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c761" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-90947">365,711</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-90948">560,018</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-keep: true">Other income (expense)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c759" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd" id="ixv-90949">228</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-398"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c761" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" sign="-" unitRef="usd" id="ixv-90950">115,546</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" sign="-" unitRef="usd" id="ixv-90951">115,318</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Net (loss) income</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c759" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-90952">215,431</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c760" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-90953">392,677</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c761" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-90954">2,659,357</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-90955">2,482,111</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="14" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Three Months Ended March 31, 2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Real Property Operations</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Lab Services<br/>
 MSO</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Corporate /<br/>
 Other</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-size: 10pt; text-align: left"><span style="-keep: true">Real property rental revenue</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c762" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-90956">314,588</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-399"><span style="-keep: true">-</span></div></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-400"><span style="-keep: true">-</span></div></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-90957">314,588</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Real property operating expenses</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c762" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-90958">263,126</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-401"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-402"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-90959">263,126</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Real property operating income</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c762" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd" id="ixv-90960">51,462</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-403"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-404"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd" id="ixv-90961">51,462</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Income from equity method investment - Lab Services MSO</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-405"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c763" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="0" unitRef="usd" id="ixv-90962">107,469</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-406"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="0" unitRef="usd" id="ixv-90963">107,469</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Other operating expenses</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c762" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" unitRef="usd" id="ixv-90964">114,287</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-407"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c764" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" unitRef="usd" id="ixv-90965">887,706</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingCostsAndExpenses" scale="0" unitRef="usd" id="ixv-90966">1,001,993</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Other (expense) income:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-keep: true">Interest expense</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c762" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-90967">194,307</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-408"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c764" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-90968">324,700</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="0" unitRef="usd" id="ixv-90969">519,007</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-keep: true">Other income (expense)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c762" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd" id="ixv-90970">4</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-409"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c764" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" sign="-" unitRef="usd" id="ixv-90971">5,448</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" sign="-" unitRef="usd" id="ixv-90972">5,444</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Net (loss) income</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c762" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-90973">257,128</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c763" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" unitRef="usd" id="ixv-90974">107,469</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c764" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-90975">1,217,854</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd" id="ixv-90976">1,367,513</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="ixv-77075"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1.5pt solid"><span style="-keep: true">Identifiable long-lived tangible assets at March 31, 2025 and December
    31, 2024</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">March 31, <br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">December 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-keep: true">Real property operations</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c765" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90977">6,990,058</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c529" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90978">7,034,335</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">Corporate/Other</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c766" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90979">1,153</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c531" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90980">1,298</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 9.25pt"><span style="-keep: true">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90981">6,991,211</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90982">7,035,633</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" id="ixv-77153"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1.5pt solid"><span style="-keep: true">Identifiable long-lived tangible assets at March 31, 2025 and December
    31, 2024</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">March 31, <br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">December 31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-keep: true">United States</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c587" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90983">6,990,058</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90984">7,034,335</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">China</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c588" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90985">1,153</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90986">1,298</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 9.25pt"><span style="-keep: true">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90987">6,991,211</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoncurrentAssets" scale="0" unitRef="usd" id="ixv-90988">7,035,633</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>




</div><!-- Field: Page; Sequence: 386; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-77252"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 15 - <span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Litigation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">From time to time, the Company is subject to ordinary
routine litigation incidental to its normal business operations. The Company is not currently a party to, and its property is not subject
to, any material legal proceedings, except as set forth below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On October 25, 2017, Genexosome entered into and
closed a Stock Purchase Agreement with Beijing Genexosome and Yu Zhou, MD, PhD, the sole shareholder of Beijing Genexosome, pursuant
to which Genexosome acquired all of the issued and outstanding securities of Beijing Genexosome in consideration of a cash payment in
the amount of $<ix:nonFraction contextRef="c767" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" unitRef="usd" id="ixv-90989">450,000</ix:nonFraction>, of which $<ix:nonFraction contextRef="c534" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansPayable" scale="0" unitRef="usd" id="ixv-90990">100,000</ix:nonFraction> is still owed. Further, on October 25, 2017, Genexosome entered into and closed an Asset Purchase
Agreement with Dr. Zhou, pursuant to which the Company acquired all assets, including all intellectual property and exosome separation
systems, held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies. In consideration
of the assets, Genexosome paid Dr. Zhou $<ix:nonFraction contextRef="c768" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" unitRef="usd" id="ixv-90991">876,087</ix:nonFraction> in cash, transferred <ix:nonFraction contextRef="c536" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-90992">3,333</ix:nonFraction> shares of common stock of the Company to Dr. Zhou and issued
Dr. Zhou <ix:nonFraction contextRef="c537" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-90993">400</ix:nonFraction> shares of common stock of Genexosome. Dr. Zhou was terminated as Co-CEO of Genexosome on August 14, 2019. Further, on October
28, 2019, Research Institute at Nationwide Children&#8217;s Hospital (&#8220;Research Institute&#8221;) filed a Complaint in the United
States District Court for the Southern District of Ohio Eastern Division against Dr. Zhou, Li Chen, the Company and Genexosome with various
claims against the Company and Genexosome. The Company, Genexosome and the Research Institute entered into a Settlement Agreement dated
June 7, 2022 (the &#8220;Settlement Date&#8221;) whereby the Company agreed to pay the Research Institute $<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LitigationReserve" scale="0" unitRef="usd" id="ixv-90994">450,000</ix:nonFraction> on each of the sixty-day,
one year and two-year anniversaries of the Settlement Date. In addition, the Company agreed to pay the Research Institute <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="avco:PercentageOfPretaxProfit" scale="-2" unitRef="pure" id="ixv-90995">30</ix:nonFraction>% of the
Company&#8217;s initial pre-tax profit of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="avco:PreTaxProfit" scale="0" unitRef="usd" id="ixv-90996">3,333,333</ix:nonFraction>, <ix:nonFraction contextRef="c769" decimals="2" format="ixt:num-dot-decimal" name="avco:PercentageOfPretaxProfit" scale="-2" unitRef="pure" id="ixv-90997">20</ix:nonFraction>% of the Company&#8217;s second pre-tax profit of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="avco:PreTaxProfit" scale="0" unitRef="usd" id="ixv-90998">3,333,333</ix:nonFraction> and <ix:nonFraction contextRef="c770" decimals="2" format="ixt:num-dot-decimal" name="avco:PercentageOfPretaxProfit" scale="-2" unitRef="pure" id="ixv-90999">10</ix:nonFraction>% of the Company&#8217;s
third pre-tax profit of $<ix:nonFraction contextRef="c770" decimals="0" format="ixt:num-dot-decimal" name="avco:PreTaxProfit" scale="0" unitRef="usd" id="ixv-91000">3,333,333</ix:nonFraction>. The parties provided a mutual release as well. As of both March 31, 2025 and December 31, 2024, the
accrued litigation settlement amounted to $<ix:nonFraction contextRef="c771" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LitigationReserve" scale="0" unitRef="usd" id="ixv-91001"><ix:nonFraction contextRef="c772" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LitigationReserve" scale="0" unitRef="usd" id="ixv-91002">373,450</ix:nonFraction></ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Operating Leases Commitment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company is a party to leases for office space.
These lease agreements expire through December 2025. Rent expense under all operating leases amounted to approximately $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd" id="ixv-91003"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd" id="ixv-91004">32,000</ix:nonFraction></ix:nonFraction> for both
the three months ended March 31, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-77278"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">Supplemental cash flow information related to
leases for the three months ended March 31, 2025 and 2024 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Three Months Ended March 31,</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="-keep: true">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-keep: true">Operating cash flows paid for operating lease</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-91005">27,535</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-91006">26,533</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Right-of-use assets obtained in exchange for lease obligation:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-keep: true">Operating lease</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-91007">127,486</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-410"><span style="-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The following table summarizes the lease term
and discount rate for the Company&#8217;s operating lease as of March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>



<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Operating <br/> Lease</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; font-size: 10pt; text-align: left"><span style="-keep: true">Weighted average remaining lease term (in years)</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><ix:nonNumeric contextRef="c1" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-77406"><span style="-keep: true">1.75</span></ix:nonNumeric></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"><span style="-keep: true">Weighted average discount rate</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td> <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-91008">13.0</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">%</span></td></tr> </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>




</div><!-- Field: Page; Sequence: 387; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">AVALON GLOBOCARE CORP. AND SUBSIDIARIES<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(Unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b style="-keep: true">&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 15 - <span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES
(continued)</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Operating Leases Commitment (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-77458"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">The following table summarizes the maturity of lease liabilities under
operating lease as of March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the Twelve-month Period Ending March 31:</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Operating <br/> Lease</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-size: 10pt; text-align: left"><span style="-keep: true">2026</span></td><td style="width: 1%; font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" unitRef="usd" id="ixv-91009">78,000</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">2027</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" unitRef="usd" id="ixv-91010">54,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">2028 and thereafter</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-411"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Total lease payments</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd" id="ixv-91011">132,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Amount of lease payments representing interest</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" unitRef="usd" id="ixv-91012">12,747</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Total present value of operating lease liabilities</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-91013">119,253</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">Current portion</span></td><td style="font-size: 10pt"><span style="-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-91014">67,547</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Long-term portion</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-91015">51,706</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-91016">119,253</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Joint Venture - Avactis Biosciences Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">On July 18, 2018, the Company formed a wholly
owned subsidiary, Avactis Biosciences Inc. (&#8220;Avactis&#8221;), a Nevada corporation, which focuses on accelerating commercial activities
related to cellular therapies as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others. When formed, Avactis was designed
to integrate and optimize the Company&#8217;s global scientific and clinical resources to further advance the use of cellular therapies
to treat certain cancers; however the Company is no longer pursuing any commercial activities with respect to cellular immunotherapy
and CAR-T, in particular. Commencing on April 6, 2022, the Company owns <ix:nonFraction contextRef="c541" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-91017">60</ix:nonFraction>% of Avactis and Arbele Biotherapeutics Limited (&#8220;Arbele
Biotherapeutics&#8221;) owns <ix:nonFraction contextRef="c542" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-91018">40</ix:nonFraction>% of Avactis. Avactis owns <ix:nonFraction contextRef="c543" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-91019">100</ix:nonFraction>% of the capital stock of Avactis Nanjing Biosciences Ltd., a company incorporated
in the PRC on May 8, 2020 (&#8220;Avactis Nanjing&#8221;), which only owns a patent and is not considered an operating entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company is required to contribute $<ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashFlowsBetweenTransfereeAndTransferorServicingFees" scale="6" unitRef="usd" id="ixv-91020">10</ix:nonFraction> million
(or equivalent in RMB) in cash and/or services, which shall be contributed in tranches based on milestones to be determined jointly by
Avactis and the Company in writing subject to the Company&#8217;s cash reserves. Within 30 days, Arbele Biotherapeutics shall make contribution
of $<ix:nonFraction contextRef="c773" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:NoncashContributionExpense" scale="6" unitRef="usd" id="ixv-91021">6.66</ix:nonFraction> million in the form of entering into a License Agreement with Avactis granting Avactis an exclusive right and license in China
to its technology and intellectual property pertaining to CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy technology and any additional
technology developed in the future with terms and conditions to be mutually agreed upon the Company and Avactis and services. As of the
date hereof, the License Agreement has not been finalized by the parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">In addition, the Company is responsible for contributing
registered capital of RMB <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="avco:WorkingCapital" scale="0" unitRef="cny" id="ixv-91022">5,000,000</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="avco:WorkingCapital" scale="6" unitRef="usd" id="ixv-91023">0.7</ix:nonFraction> million) for working capital purposes as required by local regulation, which
is not required to be contributed immediately and will be contributed subject to the Company&#8217;s discretion. As of the date hereof,
Avactis&#8217; activities have been limited to that of a patent holding company and there is no other activity or planned contributions
in the rest of 2025 or into the foreseeable future.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-77605"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">NOTE 16 - <span style="text-decoration:underline">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">The Company evaluated subsequent events and transactions
that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than
as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">Common Shares Issued for Warrant Exercise</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">In April 2025, the Company issued <ix:nonFraction contextRef="c774" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-91024">242,304</ix:nonFraction> shares
of its common stock upon the exercise of warrants on a cashless basis.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 388; Value: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>



</div><div><a id="a_144"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="text-decoration:underline">ANNEX A: MERGER AGREEMENT</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">AGREEMENT AND PLAN OF MERGER</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">by and among</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">YOOV GROUP HOLDING LIMITED, AVALON
GLOBOCARE CORP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NEXUS MERGERSUB LIMITED</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Dated as of March 7, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 389; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>




</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1.5pt; width: 8%; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 10%; text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 74%; text-align: justify">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 8%; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: justify"><span style="font-size: 10pt">ARTICLE I. THE MERGER</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 1.01</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The Merger</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 1.02</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Closing</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 1.03</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Effective Time</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 1.04</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Effects of the Merger</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">8</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 1.05</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Organizational Documents</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">9</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 1.06</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Directors and Officers</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">9</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 1.07</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tax Treatment</span></td>
    <td style="text-align: center">9</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: justify"><span style="font-size: 10pt">ARTICLE II. EFFECT OF THE MERGER ON SHARE CAPITAL</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">9</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 2.01</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Conversion of Share Capital</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">9</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 2.02</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Surrender and Payment</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">11</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 2.03</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Treatment of Equity Awards</span></td>
    <td style="text-align: center">12</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 2.04</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Dissenting Shares</span></td>
    <td style="text-align: center">13</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: justify"><span style="font-size: 10pt">ARTICLE III. REPRESENTATIONS AND WARRANTIES OF THE COMPANY</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">13</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.01</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Organization and Power</span></td>
    <td style="text-align: center">13</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.02</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Organizational Documents</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">13</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.03</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Governmental Authorizations</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">14</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.04</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Corporate Authorization</span></td>
    <td style="text-align: center">14</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.05</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Non-Contravention</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">14</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.06</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Capitalization</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">15</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.07</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Subsidiaries</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">15</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.08</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial Statements</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">16</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.09</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Undisclosed Liabilities</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">17</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.10</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Absence of Certain Changes</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">17</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.11</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Litigation</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">17</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.12</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Material Contracts</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">17</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.13</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Benefit Plans</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">18</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 390 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 8%; text-align: justify">&#160;</td>
    <td style="width: 10%; text-align: justify"><span style="font-size: 10pt">Section 3.14</span></td>
    <td style="width: 74%; text-align: justify"><span style="font-size: 10pt">Labor Relations</span></td>
    <td style="width: 8%; text-align: center"><span style="font-size: 10pt">19</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.15</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Taxes</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">20</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.16</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Environmental Matters</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">21</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.17</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Intellectual Property; Data Privacy</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">22</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.18</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Real Property; Personal Property</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">23</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.19</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Permits; Compliance with Law</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">24</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.20</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Regulatory Matters</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">24</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.21</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">[Intentionally Left Blank]</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">25</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.22</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Takeover Law</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">25</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.23</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Transactions with Affiliates</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">25</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.24</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Insurance</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">25</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.25</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Brokers</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">25</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 3.26</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No Other Representations and Warranties</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">25</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: justify"><span style="font-size: 10pt">ARTICLE IV. REPRESENTATIONS AND WARRANTIES OF PUBCO ENTITIES</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">25</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.01</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Organization and Power</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">26</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.02</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Organizational Documents</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">26</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.03</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Governmental Authorizations</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">26</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.04</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Corporate Authorization</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">26</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.05</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Non-Contravention</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">27</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.06</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Capitalization</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">27</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.07</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Subsidiaries</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">28</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.08</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">SEC Filings and the Sarbanes-Oxley Act</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">29</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.09</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial Statements; Internal Controls</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">30</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.10</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Undisclosed Liabilities</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">31</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.11</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Absence of Certain Changes</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">31</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.12</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Litigation</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">31</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.13</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Material Contracts</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">31</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.14</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Benefit Plans</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">33</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.15</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Labor Relations</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">34</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 391 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 8%; text-align: justify">&#160;</td>
    <td style="width: 10%; text-align: justify"><span style="font-size: 10pt">Section 4.16</span></td>
    <td style="width: 74%; text-align: justify"><span style="font-size: 10pt">Taxes</span></td>
    <td style="width: 8%; text-align: center"><span style="font-size: 10pt">35</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.17</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Environmental Matters</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">36</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.18</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Intellectual Property</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">37</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.19</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Real Property; Personal Property</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">38</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.20</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Permits; Compliance with Law</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">39</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.21</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Regulatory Matters</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">39</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.22</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Takeover Statutes</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">39</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.23</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Transactions with Affiliates</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">40</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.24</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Insurance</span></td>
    <td style="text-align: center">40</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.25</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Valid Issuance</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">40</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.26</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Brokers</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">40</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 4.27</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No Other Representations or Warranties</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">40</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: justify"><span style="font-size: 10pt">ARTICLE V. COVENANTS</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">40</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.01</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Conduct of Business of the Company</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">40</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.02</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Conduct of Business of PubCo</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">43</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.03</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Access to Information; Confidentiality</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">45</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.04</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No Solicitation</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">45</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.05</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">PubCo Registration Statement and Proxy</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">49</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.06</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">PubCo Stockholders Meeting</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">50</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.07</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Listing</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">50</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.08</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Directors&#8217; and Officers&#8217; Indemnification and Insurance</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">50</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.09</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Reasonable Best Efforts</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">51</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.10</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Consents; Filings; Further Action</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">51</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.11</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Public Announcements</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">52</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.12</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Fees and Expenses</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">53</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.13</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Takeover Statutes</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">53</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.14</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Rule 16b-3</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">53</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.15</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Succession of Officers and Directors</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">53</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.16</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Notification of Certain Matters</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">53</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 392 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 8%; text-align: justify">&#160;</td>
    <td style="width: 10%; text-align: justify"><span style="font-size: 10pt">Section 5.17</span></td>
    <td style="width: 74%; text-align: justify"><span style="font-size: 10pt">Certain Litigation</span></td>
    <td style="width: 8%; text-align: center"><span style="font-size: 10pt">53</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.18</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Requisite Company Approval</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">54</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.19</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Lock-Up Agreements</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">54</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.20</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Tax Matters</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">54</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.21</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Legends</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">55</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.22</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Financial Statements</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">55</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 5.23</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Outstanding PubCo Warrants</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">55</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: justify"><span style="font-size: 10pt">ARTICLE VI. CONDITIONS</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">55</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 6.01</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Conditions to Each Party&#8217;s Obligation to Consummate the Transactions</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">55</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 6.02</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Conditions to Obligations of PubCo Entities</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">56</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 6.03</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Conditions to Obligation of the Company</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">57</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 6.04</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Frustration of Closing Conditions</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">57</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: justify"><span style="font-size: 10pt">ARTICLE VII. TERMINATION, AMENDMENT AND WAIVER</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">58</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 7.01</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Termination by Mutual Consent</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">58</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 7.02</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Termination by Either PubCo or the Company</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">58</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 7.03</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Termination by the Company</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">58</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 7.04</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Termination by PubCo</span></td>
    <td style="text-align: center">59</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 7.05</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Effect of Termination</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">59</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 7.06</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Fees and Expenses Following Termination</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">59</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: justify"><span style="font-size: 10pt">ARTICLE VIII. [INTENTIONALLY LEFT BLANK]</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">60</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: justify"><span style="font-size: 10pt">ARTICLE IX. MISCELLANEOUS</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">60</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 9.01</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Certain Definitions</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">60</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 9.02</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Interpretation</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">68</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 9.03</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No Survival</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">68</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 9.04</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Governing Law</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">68</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 9.05</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Submission to Jurisdiction; Service</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">69</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 9.06</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">WAIVER OF JURY TRIAL</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">69</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 9.07</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Notices</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">69</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 9.08</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Amendment</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">70</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 393 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 8%; text-align: justify">&#160;</td>
    <td style="width: 10%; text-align: justify"><span style="font-size: 10pt">Section 9.09</span></td>
    <td style="width: 74%; text-align: justify"><span style="font-size: 10pt">Extension; Waiver</span></td>
    <td style="width: 8%; text-align: center"><span style="font-size: 10pt">70</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 9.10</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Entire Agreement</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">70</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 9.11</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No Third-Party Beneficiaries</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">70</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 9.12</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Severability</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">70</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 9.13</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Rules of Construction</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">70</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 9.14</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Assignment</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">71</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 9.15</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Remedies</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">71</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 9.16</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Specific Performance</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">71</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 9.17</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Counterparts; Effectiveness</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">72</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Section 9.18</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Non-Recourse</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">72</span></td></tr>
  </table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Disclosure Letters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Company Disclosure Letter PubCo Disclosure Letter</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exhibits</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exhibit A: Form of PubCo Voting Agreement Exhibit
B: Form of Lockup Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Exhibit C: Form of Company Voting Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 394 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AGREEMENT AND PLAN OF MERGER</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS AGREEMENT AND PLAN OF
MERGER, dated as of March 7, 2025 (this &#8220;<span style="text-decoration:underline">Agreement</span>&#8221;), by and among Avalon GloboCare Corp., a Delaware corporation (&#8220;<span style="text-decoration:underline">PubCo</span>&#8221;),
Nexus MergerSub Limited, a business company incorporated in the British Virgin Islands and a wholly owned subsidiary of PubCo (&#8220;<span style="text-decoration:underline">Merger
Sub</span>&#8221;, and together with PubCo, the &#8220;<span style="text-decoration:underline">PubCo Entities</span>&#8221;), and YOOV Group Holding Limited, a business company
incorporated in the British Virgin Islands (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;, and collectively with PubCo and Merger Sub, the &#8220;<span style="text-decoration:underline">Parties</span>&#8221;
and each individually, a &#8220;<span style="text-decoration:underline">Party</span>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>RECITALS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Parties intend
that on the Closing Date, upon the terms and subject to the conditions of this Agreement and in accordance with the BVI Business Companies
Act, 2004 (as revised) (the &#8220;<span style="text-decoration:underline">BVI Companies Act</span>&#8221;), Merger Sub will merge with and into the Company (the &#8220;<span style="text-decoration:underline">Merger</span>&#8221;,
and together with the other transactions contemplated hereby, the &#8220;<span style="text-decoration:underline">Transactions</span>&#8221;), with the Company surviving the Merger
as a wholly owned subsidiary of PubCo;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, for United States
federal income tax purposes, it is intended that (i) the Merger shall qualify for the Intended Tax Treatment and (ii) this Agreement shall
constitute a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations Sections 1.368-2(g) and 1.368-3(a);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the board of directors
of PubCo (the &#8220;<span style="text-decoration:underline">PubCo Board</span>&#8221;) has unanimously (a) approved, adopted and declared advisable this Agreement and the Transactions,
including the issuance of PubCo Common Stock to the Company Shareholders, (b) declared that it is fair to, advisable and in the best interests
of PubCo and the stockholders of PubCo (the &#8220;<span style="text-decoration:underline">PubCo Stockholders</span>&#8221;) that PubCo enter into this Agreement and consummate
the Transactions, on the terms and subject to the conditions set forth in this Agreement and (c) recommended to the PubCo Stockholders
that they approve the PubCo Stockholder Matters (the &#8220;<span style="text-decoration:underline">PubCo Board Recommendation</span>&#8221;);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the board of directors
of the Company (the &#8220;<span style="text-decoration:underline">Company Board</span>&#8221;) has (a) approved and declared advisable this Agreement, the Plan of Merger, the
Articles of Merger, the Surviving Company Restated Articles and the Transactions, including the Merger, in accordance with the memorandum
and articles of association of the Company then in effect, (b) declared that it is fair to, advisable and in the best interests of the
Company and the shareholders of the Company (the &#8220;<span style="text-decoration:underline">Company Shareholders</span>&#8221;) that the Company enter into this Agreement,
the Plan of Merger, the Articles of Merger and the Surviving Company Restated Article and to consummate the Transactions, including the
Merger, on the terms and subject to the conditions set forth in this Agreement, (c) directed that the adoption of this Agreement be submitted
to a vote of the Company Shareholders either through a written consent or at a meeting of the Company Shareholders, and (d) recommended
to the Company Shareholders that they adopt this Agreement, the Plan of Merger, the Articles of Merger, the Surviving Company Restated
Articles and thereby approve the Transactions (the &#8220;<span style="text-decoration:underline">Company Board Recommendation</span>&#8221;);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the board of directors
of Merger Sub has (a) approved and declared advisable this Agreement and the Transactions, including the Merger, (b) declared that it
is fair to, advisable and in the best interests of Merger Sub and the sole shareholder of Merger Sub that Merger Sub enter into this Agreement
and consummate the Transactions, including the Merger, on the terms and subject to the conditions set forth in this Agreement, (c) recommended
to the sole shareholder of Merger Sub that it adopts this Agreement and thereby approve the contemplated Transactions on the terms and
conditions set forth in this Agreement, and (d) PubCo, in its capacity as the sole shareholder of Merger Sub will, approve and adopt this
Agreement by written resolution immediately thereafter;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, concurrently with
the execution and delivery of this Agreement and as a condition and inducement to the Company&#8217;s willingness to enter into this Agreement,
(a) the directors, officers and the PubCo Stockholder listed on Schedule A-1 of the PubCo Disclosure Letter have (solely in their capacity
as PubCo Stockholders) entered into a voting agreement with PubCo and the Company in substantially the form attached hereto as <span style="text-decoration:underline">Exhibit
A</span> (each, a &#8220;<span style="text-decoration:underline">PubCo Voting Agreement</span>&#8221;) pursuant to which such directors, officers and PubCo Stockholders agree to
vote in favor of the adoption of this Agreement and to take (and refrain from taking) certain other actions in connection with the Transactions,
in each case, on the terms therein, and (b) the directors, officers and the PubCo Stockholders listed on Schedule A-2 of the PubCo Disclosure
Letter have entered into a lockup agreement in substantially the form attached hereto as <span style="text-decoration:underline">Exhibit B</span> (each, a &#8220;<span style="text-decoration:underline">Lockup Agreement</span>&#8221;);
and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 395 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, concurrently with
the execution and delivery of this Agreement and as a condition and inducement to PubCo&#8217;s willingness to enter into this Agreement,
the directors, officers and Company Shareholders listed on Schedule A-1 of the Company Disclosure Letter have (solely in their capacity
as Company Shareholders) (a) entered into a voting agreement with the Company and PubCo in substantially the form attached hereto as <span style="text-decoration:underline">Exhibit
C</span> (each, a &#8220;<span style="text-decoration:underline">Company Voting Agreement</span>&#8221;) pursuant to which such directors, officers and Company Shareholders agree
to, as promptly as practicable following the effectiveness of the PubCo Registration Statement, (i) approve by vote at a duly held meeting
of the Company Shareholders the execution, delivery and performance of this Agreement and the Transactions, and (ii) adopt this Agreement
and to take (and refrain from taking) certain other actions in connection with the Transactions, in each case, on the terms therein, and
(b) entered into the Lockup Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the mutual representations, warranties, covenants and agreements set forth herein and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows:</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE I. THE MERGER</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>Section 1.01 <span style="text-decoration:underline">The
Merger</span></b>. Upon the terms and subject to the conditions set forth in this Agreement, on the Closing Date, Merger Sub shall be merged
with and into the Company in accordance with the applicable provisions of the BVI Companies Act. As a result of the Merger, Merger Sub
shall cease to exist, and the Company shall continue as the surviving corporation of the Merger (the &#8220;<span style="text-decoration:underline">Surviving Company</span>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>Section 1.02 <span style="text-decoration:underline">Closing</span></b>.
Unless this Agreement is earlier terminated pursuant to <span style="text-decoration:underline">Article VII</span>, and subject to the satisfaction or waiver of all of the conditions
to closing contained in <span style="text-decoration:underline">Article VI</span>, the closing of the Merger (the &#8220;<span style="text-decoration:underline">Closing</span>&#8221;) shall take place (a) remotely
by exchange of documents and signatures (or their electronic counterparts) on the third Business Day after the day on which the conditions
set forth in <span style="text-decoration:underline">Article VI</span> (other than any conditions that by their nature are to be satisfied at the Closing, but subject to the
satisfaction or waiver of those conditions) are satisfied or waived in accordance with this Agreement or (b) at such other place and time
as PubCo and the Company may mutually agree in writing. The date on which the Closing occurs is referred to as the &#8220;<span style="text-decoration:underline">Closing Date.</span>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>Section 1.03 <span style="text-decoration:underline">Effective
Time</span></b>. Upon the terms and subject to the conditions set forth in this Agreement, as soon as practicable on the Closing Date, the
Parties shall execute a plan of merger (the &#8220;<span style="text-decoration:underline">Plan of Merger</span>&#8221;) and articles of merger (the &#8220;<span style="text-decoration:underline">Articles of Merger</span>&#8221;),
and shall cause the Merger to be consummated by filing the Articles of Merger (appending the Plan of Merger) and other documents required
by the BVI Companies Act with the Registrar of Corporate Affairs in the British Virgin Islands (&#8220;<span style="text-decoration:underline">BVI Registry</span>&#8221;) in
accordance with the relevant provisions of the BVI Companies Act, and shall make all other filings, recordings or publications required
under the BVI Companies Act in connection with the Merger. The Merger shall become effective at the time that the properly executed copy
of the Articles of Merger is filed and accepted by the BVI Registry or, to the extent permitted by applicable Law, at such later time
as specified in the Articles of Merger (the time at which the Merger becomes effective is herein referred to as the &#8220;<span style="text-decoration:underline">Effective
Time</span>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>Section 1.04 <span style="text-decoration:underline">Effects
of the Merger</span></b>. At the Effective Time, the effect of the Merger shall be as provided in the applicable provisions of the BVI Companies
Act, this Agreement and the Articles of Merger. Without limiting the generality of the foregoing, and subject thereto, at the Effective
Time, all the property, rights, privileges, agreements, powers and franchises, debts, liabilities, duties and obligations of each of the
Company and the Merger Sub shall become the property, rights, privileges, agreements, powers and franchises, debts, liabilities, duties
and obligations of the Surviving Company, which will include the assumption by the Surviving Company of any and all agreements, covenants,
duties and obligations of the Company and the Merger Sub set forth in this Agreement to be performed after the Effective Time. As a result
of the Merger, the Surviving Company will become a wholly owned subsidiary of PubCo.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"></p><div>

</div><!-- Field: Page; Sequence: 396 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
1.05 <span style="text-decoration:underline">Organizational Documents</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Surviving
Company Organizational Documents</span>. The memorandum and articles of association of the Company in effect at the Effective Time shall
be the memorandum and articles of association of the Surviving Company immediately after the Effective Time, except such memorandum and
articles of association shall be amended and restated as may be necessary (the &#8220;<span style="text-decoration:underline">Surviving Company Restated Articles</span>&#8221;),
until amended in accordance with applicable Law, and the Parties shall approve and adopt the Surviving Company Restated Articles, and
make any required filings with the BVI Registry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="text-decoration:underline">PubCo
Organizational Documents</span>. The certificate of incorporation of PubCo shall be identical to the certificate of incorporation of PubCo
immediately prior to the Effective Time, until thereafter amended in accordance with such certificate of incorporation and applicable
Law; provided, however, that at or immediately prior to the Effective Time, PubCo shall file an amendment to its certificate of incorporation
to (i) change the name of PubCo to &#8220;YOOV, Inc.&#8221; or such other name chosen by the Company and approved, in writing, by PubCo
(which approval shall not be unreasonably withheld, delayed or conditioned), (ii) effectuate the Reverse Stock Split, if necessary, and
(iii) make such other changes as shall be mutually agreed upon by the Company and PubCo prior to the filing of such amendment. The bylaws
of PubCo shall be identical to the bylaws of PubCo as in effect as of the Effective Time, except such bylaws shall be deemed amended to
change the name of PubCo stated therein to &#8220;YOOV, Inc.,&#8221; until thereafter amended in accordance with such bylaws and applicable
Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
1.06 <span style="text-decoration:underline">Directors and Officers.</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">PubCo
Board</span>. The Parties shall take all necessary actions such that as of the Effective Time and until successors are duly elected or appointed
and qualified in accordance with applicable Law, or until their earlier death, resignation or removal in accordance with the organizational
documents of PubCo, the PubCo Board shall be comprised of seven (7) individuals, five (5) such individuals shall be as designated by the
Company in a written notice to PubCo prior to the Closing, and two (2) individuals from the existing PubCo Board as of immediately prior
to the Closing shall be retained (or as may be otherwise designated by the pre-Closing PubCo Board), provided, that such individuals are
reasonably acceptable to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="text-decoration:underline">Officers
of PubCo</span>. The Parties shall take all necessary actions such that, from and after the Effective Time, until successors are duly elected
or appointed and qualified in accordance with applicable Law, or until their earlier death, resignation or removal in accordance with
the organizational documents of PubCo, the officers of PubCo shall be designated by the Company in a written notice to PubCo prior to
the Closing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;<span style="text-decoration:underline">Directors
and Officers of the Surviving Company</span>. The Parties shall take all necessary actions such that, from and after the Effective Time,
until successors are duly elected or appointed and qualified in accordance with applicable Law, or until their earlier death, resignation
or removal in accordance with the organizational documents of the Surviving Company, (i) the directors of the Surviving Company, and (ii)
the officers of the Surviving Company shall, in each case, be designated by the Company in a written notice to PubCo prior to the Closing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>Section 1.07 <span style="text-decoration:underline">Tax
Treatment</span></b>. Each of the Parties intends that, for U.S. federal income tax, and as applicable, state and local Tax purposes, (i)
the Merger shall qualify as a reorganization under Section 368(a) of the Code and, in the event that the former shareholders of the Company
are in &#8220;control&#8221; of PubCo immediately after the Effective Time within the meaning of Section 368(c) of the Code, shall also
qualify as an exchange of Company Ordinary Shares for shares of PubCo Common Stock within the meaning of Section 351(a) of the Code (the
&#8220;<span style="text-decoration:underline">Intended Tax Treatment</span>&#8221;), and (ii) this Agreement shall constitute, and is hereby adopted as, a &#8220;plan of reorganization&#8221;
within the meaning of Treasury Regulations Sections 1.368-2(g) and 1.368-3(a).</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE II. EFFECT OF THE MERGER ON SHARE
CAPITAL</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
2.01 <span style="text-decoration:underline">Conversion of Share Capital</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Treatment
of Company Convertible Securities</span>. Immediately prior to the Effective Time, each Company Preferred Share and any ordinary share purchase
warrants or other securities convertible or exchangeable into shares of Company Ordinary Shares (such warrants or securities, the &#8220;<span style="text-decoration:underline">Company
Convertible Securities</span>&#8221;) shall be (i) converted into Company Ordinary Shares (the &#8220;<span style="text-decoration:underline">Company Convertible Securities Conversion</span>&#8221;),
or (ii) cancelled and shall cease to exist in accordance with their terms. The Company&#8217;s issued and outstanding Ordinary Shares
shall be subject to <span style="text-decoration:underline">Section 2.01(c)</span> below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 397 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="text-decoration:underline">Merger</span>.
At the Effective Time, by virtue of the Merger and without any additional action on the part of either PubCo Entity, the Company, the
PubCo Stockholders or the Company Shareholders:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)&#160;<span style="text-decoration:underline">Company
Ordinary Share</span>. Each Company Ordinary Share issued and outstanding immediately prior to the Effective Time (and, for the avoidance
of doubt, (A) following the conversion of any Company Convertible Securities Conversion, and (B) other than Dissenting Shares or Excluded
Company Shares) shall automatically be converted into the right to receive a number of validly issued, fully paid and nonassessable shares
of PubCo Common Stock equal to the Exchange Ratio (the &#8220;<span style="text-decoration:underline">Merger Consideration</span>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)&#160;<span style="text-decoration:underline">PubCo
Common Stock</span>. Each share of PubCo Common Stock issued and outstanding immediately prior to the Effective Time shall remain outstanding.
Immediately following the Effective Time, shares of PubCo Common Stock, if any, owned by the Surviving Company shall be surrendered to
PubCo without payment therefor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii)&#160;<span style="text-decoration:underline">Merger
Sub Ordinary Shares</span>. Each Merger Sub Ordinary Share issued and outstanding immediately prior to the Effective Time shall automatically
be converted into and exchanged for one validly issued, fully paid and nonassessable share of the Surviving Company, which shall constitute
the only outstanding shares of the Surviving Company and shall be solely owned by the PubCo.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iv)&#160;<span style="text-decoration:underline">Treasury
Stock of the Company</span>. Each share of the Company Share Capital held in the treasury of the Company, owned by the Company or any of
its direct or indirect wholly owned Subsidiaries or by PubCo or any of its Affiliates at the Effective Time (collectively, the &#8220;<span style="text-decoration:underline">Excluded
Company Shares</span>&#8221;) shall be canceled automatically and shall cease to exist, and no consideration shall be paid for those Excluded
Company Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;<span style="text-decoration:underline">Conversion
of Company Securities</span>. All Company Ordinary Shares (including Company Ordinary Shares issued upon any Company Convertible Securities
Conversion) that have been converted pursuant to <span style="text-decoration:underline">Section 2.01(b)</span> shall be canceled automatically and shall cease to exist, and
the holders of (i) certificates which immediately before the Effective Time represented such shares (the &#8220;<span style="text-decoration:underline">Company Share Certificates</span>&#8221;)
or (ii) shares represented by book-entry (the &#8220;<span style="text-decoration:underline">Company Book-Entry Shares</span>&#8221;) shall cease to have any rights with respect
to those shares, other than the right to receive the Merger Consideration in accordance with <span style="text-decoration:underline">Section 2.02</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;<span style="text-decoration:underline">Equitable
Adjustment</span>. If at any time during the period between the date of this Agreement and the Effective Time, any change in the outstanding
shares of capital stock of PubCo or the Company shall occur as a result of any reclassification, recapitalization, reorganization, stock
split (including a reverse stock split only to the extent such split has not been previously taken into account in calculating the Exchange
Ratio) or combination, exchange or readjustment of shares, or any stock dividend or stock distribution is declared with a record date
during such period, the Exchange Ratio (and the determination thereof) shall be equitably adjusted to reflect such change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;<span style="text-decoration:underline">Fractional
Shares</span>. No fractional shares of PubCo Common Stock shall be issued in connection with the Merger, and no certificates or scrip for
any such fractional shares shall be issued, and such fractional share interests shall not entitle the owner thereof to vote or to any
rights as a holder of PubCo Common Stock. If the product of the number of shares a Company Shareholder holds immediately prior to the
Effective Time multiplied by the Exchange Ratio would result in the issuance of a fractional share of PubCo Common Stock, that product
will be rounded down to the nearest whole number of shares of PubCo Common Stock, if it is less than the fraction of one-half (0.5) of
one share of PubCo Common Stock, or rounded up to the nearest whole number of shares of PubCo Common Stock if the said product is greater
than or equal to the fraction of one-half (0.5) of one share of PubCo Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"></p><div>

</div><!-- Field: Page; Sequence: 398 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
2.02 <span style="text-decoration:underline">Surrender and Payment</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Exchange
Agent</span>. Prior to the Effective Time, PubCo and the Company shall appoint a firm, bank or trust company acceptable to the Company to
serve as exchange and payment agent (the &#8220;<span style="text-decoration:underline">Exchange Agent</span>&#8221;), for the purpose of issuing and sending to each Company
Shareholder, other than with respect to Excluded Company Shares or Dissenting Shares, the Merger Consideration. PubCo will enter into
an agreement with such Exchange Agent on terms reasonably satisfactory to PubCo and the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="text-decoration:underline">Exchange
Fund</span>. On or prior to the Closing Date, PubCo and the Company shall cause to be deposited with the Exchange Agent, in trust for the
benefit of the holders of Company Ordinary Share, the aggregate Merger Consideration (which shall be in book-entry form unless a physical
certificate is requested) issuable pursuant to this Agreement. All book-entry shares representing PubCo Common Stock deposited by PubCo
with the Exchange Agent for distribution to the Company Shareholders pursuant to this <span style="text-decoration:underline">Article II</span> are referred to in this Agreement
as the &#8220;<span style="text-decoration:underline">Exchange Fund</span>.&#8221; The Exchange Fund shall not be used for any other purpose.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117.95pt; text-align: justify; text-indent: -35.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) <span style="text-decoration:underline">Exchange Procedures</span>.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.95pt; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)&#160;<span style="text-decoration:underline">Letter
of Transmittal</span>. As promptly as practicable but in no event later than two (2) Business Days following the Effective Time, PubCo shall,
or shall cause the Exchange Agent to, mail to each holder of record of a share of Company Ordinary Share, (A) a letter of transmittal
in customary form, specifying that delivery shall be effected, and risk of loss and title to such holder&#8217;s shares shall pass, only
upon proper delivery of the Company Share Certificate, as applicable, to the Exchange Agent or, in the case of Company Book-Entry Shares,
upon adherence to the procedures set forth in the letter of transmittal, and (B) instructions for surrendering such Company Share Certificates
or Company Book-Entry Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.95pt; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)&#160;<span style="text-decoration:underline">Surrender
of Shares of Company Stock</span>. Upon surrender of a Company Share Certificate or of a Company Book-Entry Share for cancellation to the
Exchange Agent in accordance with the instructions provided by the Exchange Agent pursuant to <span style="text-decoration:underline">Section 2.02(c)(i)</span> above, together
with a duly executed and completed letter of transmittal and any other documents reasonably required by the Exchange Agent, the holder
of that Company Share Certificate or Company Book-Entry Share shall be entitled to receive, and the Exchange Agent shall issue in exchange
therefor, that number of whole shares of PubCo Common Stock to which such Company Shareholder shall have become entitled on the account
of Merger Consideration pursuant to the provisions of <span style="text-decoration:underline">Section 2.01</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii)&#160;<span style="text-decoration:underline">Unregistered
Transferees</span>. If any Merger Consideration is to be paid to a Person other than the Person in whose name the share of Company Ordinary
Share is registered, then the Merger Consideration may be paid to such a transferee so long as (A) the surrendered Company Share Certificate
or Company Book-Entry Share is accompanied by all documents required by PubCo or the Company, as applicable, to evidence that such Company
Ordinary Share has been properly transferred and (B) the Person requesting such payment (1) pays any applicable transfer taxes or (2)
establishes to the reasonable satisfaction of PubCo and the Exchange Agent that any such transfer taxes have already been paid or are
not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iv)&#160;<span style="text-decoration:underline">No
Other Rights</span>. Until surrendered in accordance with this <span style="text-decoration:underline">Section 2.02(c)</span>, each Company Share Certificate and each Company Book-Entry
Share shall be deemed, from and after the Effective Time, to represent only the right to receive the Merger Consideration. Any Merger
Consideration paid upon the surrender of any Company Share Certificate or Company Book-Entry Share shall be deemed to have been paid in
full satisfaction of all rights pertaining to such Company Share Certificate or Company Book-Entry Share and the Company Ordinary Shares
formerly represented by it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.5pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;<span style="text-decoration:underline">Lost,
Stolen or Destroyed Certificates</span>. If any Company Share Certificate is lost, stolen or destroyed, upon the making of an affidavit of
that fact by the Person claiming such Company Share Certificate to be lost, stolen or destroyed and, if required by PubCo, the posting
by such Person of a bond, in such reasonable amount as PubCo may direct, as indemnity against any claim that may be made against it with
respect to such Company Share Certificate, the Exchange Agent shall pay, in exchange for such affidavit claiming such Company Share Certificate
is lost, stolen or destroyed, the Merger Consideration, to such Person in respect of the Company Ordinary Shares represented by such Company
Share Certificate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.55pt; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.55pt; text-align: justify; text-indent: 71.95pt"></p><div>

</div><!-- Field: Page; Sequence: 399 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.55pt; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;<span style="text-decoration:underline">No
Further Transfers</span>. At the Effective Time, the stock transfer books of the Company shall be closed and there shall be no further registration
of transfers of the Company Ordinary Shares that were outstanding immediately before the Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.55pt; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;<span style="text-decoration:underline">Required
Withholding</span>. Insofar as applicable, each of PubCo, the Surviving Company and the Exchange Agent shall be entitled to deduct and withhold
from any consideration otherwise payable under this Agreement such amounts as may be required to be deducted or withheld therefrom under
the Internal Revenue Code of 1986, as amended (the &#8220;<span style="text-decoration:underline">Code</span>&#8221;), or any other applicable state, local or foreign Law. To
the extent that any amounts are so deducted and withheld and paid to the appropriate Governmental Authorities, those amounts shall be
treated as having been paid to the Person in respect of whom such deduction or withholding was made.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.5pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;<span style="text-decoration:underline">No
Liability</span>. None of PubCo, the Surviving Company or the Exchange Agent (or any of their respective officers, directors, employees,
agents or Affiliates) shall be liable to any Company Shareholder for any amount properly paid to a public official under any applicable
abandoned property, escheat or similar Law. If any shares Company Ordinary Share shall not have been allocated their Merger Consideration
prior to two (2) years after the Effective Time (or immediately prior to such earlier date on which the related Merger Consideration (and
all dividends or other distributions with respect to shares of PubCo Common Stock) would otherwise escheat to or become the property of
any Governmental Authority), any such Merger Consideration (and such dividends, distributions and cash) in respect thereof shall, to the
extent permitted by applicable Law, become the property of the PubCo, free and clear of all claims or interest of any Person previously
entitled thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.5pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#160;<span style="text-decoration:underline">Termination of
Exchange Fund</span>. Any portion of the Exchange Fund that remains unclaimed by the holders of Company Share Certificates or Company Book-Entry
Shares one year after the Effective Time shall be delivered by the Exchange Agent to PubCo upon demand. Thereafter, any holder of Company
Share Certificates or Company Book-Entry Shares who has not theretofore complied with this <span style="text-decoration:underline">Article II</span> shall look only to the PubCo
for, and the PubCo shall remain liable for, payment of the applicable Merger Consideration pursuant to the terms of this <span style="text-decoration:underline">Article II</span>,
subject to any applicable abandoned property, escheat or similar Law, without interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
2.03 <span style="text-decoration:underline">Treatment of Equity Awards</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">PubCo
Stock Options</span>. Following the Effective Time, each PubCo Stock Option that is outstanding immediately prior to the Effective Time,
whether or not then vested or exercisable, shall, without any action on the part of the holder thereof or any other Person, continue to
be outstanding and have, and shall continue to be subject to, the same terms and conditions as applied to such PubCo Stock Option as of
immediately prior to the Effective Time; provided, that, in no event shall such total PubCo Stock Option, whether or not vested or exercisable,
on an as-converted and fully diluted basis, be exercised or excisable for more than 4% of the aggregate PubCo Common Stock reserved for
issuance under such equity plan of PubCo adopted or becomes effective after the Effective Time. Notwithstanding any other provision of
this Agreement, all PubCo Stock Options shall be treated in a manner so as not to result in the incurrence of a penalty tax under Section
409A of the Code. For the avoidance of doubt, the PubCo Stock Options outstanding at the Effective Time shall not in any way change or
otherwise alter the percentage ownership interest of the PubCo Stockholders and the Company Shareholders, respectively, as contemplated
under this Agreement. Prior to the Effective Time, PubCo shall take all necessary action, if any, to give effect to the terms of this
<span style="text-decoration:underline">Section 2.03(a)</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="text-decoration:underline">Amendment
to PubCo Equity Plan</span>. PubCo shall undertake to amend the PubCo Equity Plan, in such form that is reasonably acceptable to the Company,
to increase the number of PubCo Common Stock reserved and issuable under the PubCo Equity Plan after the Effective Time (the &#8220;<span style="text-decoration:underline">PubCo
Equity Plan Amendment</span>&#8221;). PubCo shall take all necessary action to submit the PubCo Equity Plan Amendment to the PubCo Board
for approval and, upon its approval, the PubCo Board shall submit the PubCo Equity Plan Amendment for stockholder approval at the PubCo
Stockholders Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"></p><div>

</div><!-- Field: Page; Sequence: 400 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
2.04 <span style="text-decoration:underline">Dissenting Shares</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Notwithstanding
any provision of this Agreement to the contrary, any shares of Company Share Capital (other than Excluded Company Shares) for which the
holder thereof (the &#8220;<span style="text-decoration:underline">Dissenting Shareholder</span>&#8221;) (i) has not voted in favor of the Merger or consented in writing and
(ii) has validly exercised the rights to dissent from the Merger in accordance with, and has complied in all respects with, the BVI Companies
Act (collectively, the &#8220;<span style="text-decoration:underline">Dissenting Shares</span>&#8221;), shall not be converted into the right to receive the Merger Consideration
in accordance with <span style="text-decoration:underline">Section 2.01</span>. Each Dissenting Shareholder shall be entitled to receive only the payment resulting from the procedure
in Section 179 of BVI Companies Act with respect to the Dissenting Shares owned by such Dissenting Shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 71.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Notwithstanding
the provisions of <span style="text-decoration:underline">Section 2.04(a)</span>, if any Dissenting Shareholder effectively waives, withdraws or loses such rights to dissent
from the Merger (through failure to perfect such rights or otherwise in accordance with the BVI Companies Act), then such holder&#8217;s
shares (i) shall be deemed no longer to be Dissenting Shares, and (ii) shall be treated as if they had been converted automatically at
the Effective Time into the right to receive the Merger Consideration upon surrender of the Company Share Certificate or Company Book-Entry
Share formerly representing such shares in accordance with <span style="text-decoration:underline">Section 2.02</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;The
Company shall give PubCo (i) notice of any written demands for exercise of the rights to dissent from the Merger of any shares of Company
Share Capital, the withdrawals of such demands and any other related instrument served on the Company under the BVI Companies Act and
(ii) the right to participate in, and at PubCo&#8217;s election and expense, direct all negotiations and proceedings with respect to such
demands for exercise of the rights to dissent from the Merger. The Company shall not (or cause or permit any Person on its behalf to)
offer to make or make any payment or settle, compromise, or offer to settle or compromise, or otherwise negotiate with respect to any
such demands for exercise of the rights to dissent from the Merger without the prior written consent of PubCo, which consent shall not
be unreasonably withheld, conditioned or delayed.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE III. REPRESENTATIONS AND WARRANTIES
OF THE COMPANY</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth in the
corresponding sections of the disclosure letter delivered by the Company to the PubCo Entities concurrently with the execution of this
Agreement (the &#8220;<span style="text-decoration:underline">Company Disclosure Letter</span>&#8221;), it being agreed that disclosure of any item in any section of the Company
Disclosure Letter (whether or not an explicit cross reference appears) shall be deemed to be disclosure with respect to any other section
to which the relevance of such item is reasonably apparent, the Company represents and warrants to each PubCo Entity that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>Section 3.01 <span style="text-decoration:underline">Organization
and Power</span></b>. Each of the Company and its Subsidiaries is duly organized, validly existing and in good standing under the Law of
its jurisdiction of organization. The Company has the requisite corporate power and authority to own, lease and operate its assets and
properties and to carry on its business as now conducted and to perform its obligations under all Contracts by which it is bound. Each
of the Company&#8217;s Subsidiaries has the requisite power and authority to own, lease and operate its assets and properties, to carry
on its business as now conducted, except where the failure to have such requisite power or authority would not, individually or in the
aggregate, reasonably be expected to have a Company Material Adverse Effect. Each of the Company and its Subsidiaries is duly qualified
to do business as a foreign corporation, limited liability company or other legal entity and is in good standing in each jurisdiction
where such qualification is necessary, except where the failure to be so qualified or in good standing would not, individually or in the
aggregate, reasonably be expected to have a Company Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>Section 3.02 <span style="text-decoration:underline">Organizational
Documents</span></b>. The Company has made available to PubCo true and complete copies of the memorandum and articles of association and
all other similar constitutional documents adopted or filed in connection with the creation, formation, organization or governance of
the Company as in effect on the date of this Agreement (collectively, the &#8220;<span style="text-decoration:underline">Company Organizational Documents</span>&#8221;), and
(i) the Company Organizational Documents are in full force and effect and (ii) the Company is not in violation in any material respects
of any provision of the Company Organizational Documents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"></p><div>

</div><!-- Field: Page; Sequence: 401 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>Section 3.03 <span style="text-decoration:underline">Governmental
Authorizations</span></b>. Assuming that the representations and warranties of the PubCo Entities contained in <span style="text-decoration:underline">Section 4.04</span> are true
and correct, the execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the Transactions,
including the Merger, do not and will not require any consent, approval or other authorization of, or registration or filing with or notification
to any Governmental Authority (collectively, &#8220;<span style="text-decoration:underline">Governmental Authorizations</span>&#8221;), other than:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;the
filing of the Articles of Merger (appending the Plan of Merger) and other documents required by the BVI Companies Act to effect the Merger,
with the BVI Registry, and the adoption and filing the Surviving Company Restated Articles, with the BVI Registry, as may be required;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;any
other filings or reports that may be required in connection with this Agreement and the Transactions under the Securities Exchange Act
of 1934 (the &#8220;<span style="text-decoration:underline">Exchange Act</span>&#8221;), the Securities Act or any other state or federal securities, takeover or &#8220;blue
sky&#8221; Laws; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;such
other Governmental Authorizations, where the failure to obtain such Governmental Authorizations would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
3.04 <span style="text-decoration:underline">Corporate Authorization</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;The
Company Board has (i) approved and declared advisable this Agreement, the Plan of Merger, the Articles of Merger and the Transactions,
including the Merger, in accordance with the memorandum and articles of association of the Company then in effect (ii) declared that it
is fair to, advisable and in the best interests of the Company and the Company Shareholders that the Company enter into this Agreement,
the Plan of Merger and the Articles of Merger and consummate the Transactions, including the Merger, on the terms and subject to the conditions
set forth in this Agreement, (iii) directed that the adoption of this Agreement, the Plan of Merger and the Surviving Company Restated
Articles be submitted to the Company Shareholders, and (iv) recommended to the Company Shareholders that they adopt this Agreement, the
Plan of Merger and the Surviving Company Restated Articles. Except as set forth in <span style="text-decoration:underline">Section 3.04</span> of the Company Disclosure Letter,
the Requisite Company Vote is the only vote of the Company Shareholders necessary to adopt this Agreement and approve the Transactions.
Each Person that executes the Company Voting Agreement is an executive officer, director, affiliate, founder or family member of a founder
or holder of at least five percent of the voting equity securities of the Company, in each case, within the meaning of the SEC&#8217;s
Compliance and Disclosure Interpretation 239.13.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(b)&#160;Except
as set forth in <span style="text-decoration:underline">Section 3.04</span> of the Company Disclosure Letter, the Company has all necessary corporate power and authority to enter
into this Agreement, the Plan of Merger and the Articles of Merger, and assuming the Company Shareholder Approval is received, to consummate
the Transactions. The execution, delivery and performance of this Agreement, the Plan of Merger and the Articles of Merger by the Company
and, subject to the receipt of the Company Shareholder Approval, the consummation by the Company of the Transactions have been duly and
validly authorized by all necessary corporate action on the part of the Company. This Agreement constitutes a legal, valid and binding
agreement of the Company enforceable against the Company in accordance with its terms (except as such enforceability may be limited by
bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws of general applicability relating to or
affecting creditor&#8217;s rights, and to general equitable principles).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>Section 3.05 <span style="text-decoration:underline">Non-Contravention</span></b>.
Except as set forth in <span style="text-decoration:underline">Section 3.05</span> of the Company Disclosure Letter, and subject to obtaining the Company Shareholder Approval
and the Governmental Authorizations applicable to the Company or its Subsidiaries, the execution, delivery and performance of this Agreement
by the Company and the consummation of the Transactions do not and will not (a) contravene or conflict with, or result in any material
violation or breach of, any provision of (i) the Company Organizational Documents, or (ii) the comparable organizational or governing
documents of any of the Subsidiaries of the Company, (b) contravene or conflict with, or result in any material violation or breach of,
any Law applicable to the Company or any of its Subsidiaries or by which any Company Assets are bound, (c) except as set forth in <span style="text-decoration:underline">Section
3.05</span> of the Company Disclosure Letter, result in any violation, termination, acceleration of any material obligation, cancellation,
material payment or material breach of, or constitute a default (with or without notice or lapse of time or both) or require any notice
or consent under, any Company Material Contracts or Company Real Property Leases (as defined below) to which the Company or any of its
Subsidiaries is a party or by which any Company Assets are bound, or (d) result in the creation of any Liens (other than Permitted Liens)
upon any of the Company Assets, except, in the case of clauses (a)(ii), (b), (c), and (d), as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"></p><div>

</div><!-- Field: Page; Sequence: 402 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
3.06 <span style="text-decoration:underline">Capitalization</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;As
of the date of this Agreement, the capitalization of the Company is as set forth in <span style="text-decoration:underline">Section 3.06(a)</span> of the Company Disclosure Letter,
which reflects in all material respects all of the issued and outstanding Company Share Capital and all rights to acquire share capital
or securities of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Except
as set forth in the capitalization table under <span style="text-decoration:underline">Section 3.06(a)</span> of the Company Disclosure Letter, to the extent expressly permitted
under <span style="text-decoration:underline">Section 5.01</span> (including as required by applicable Law), or as set forth in <span style="text-decoration:underline">Section 3.06(g)</span> of the Company Disclosure
Letter, (i) there are no other outstanding shares of the Company, (ii) there are no outstanding subscriptions, options, warrants, calls,
convertible securities, rights of first refusal, preemptive rights, or other similar rights (whether or not currently exercisable), agreements
or commitments (other than this Agreement) relating to the issuance or acquisition of share capital to which the Company or any of its
Subsidiaries is a party obligating the Company or any of its Subsidiaries to (A) issue, transfer or sell any shares of the Company or
other equity interests of the Company or any of its Subsidiaries or securities convertible into or exchangeable for such shares or equity
interests, (B) grant, extend or enter into any such subscription, option, warrant, call, convertible securities or other similar right,
agreement or arrangement, (C) redeem, repurchase or otherwise acquire any such shares of the Company or other equity interests, or (D)
provide an amount of funds to, or make any investment (in the form of a loan, capital contribution or otherwise) in the Company or any
of its Subsidiaries or any other Person, and (iii) other than pursuant to this Agreement, there is no condition or circumstance that could
be reasonably likely to give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled
to acquire or receive any shares of the Company. There are no outstanding or authorized stock appreciation, phantom stock, profit participation
or other similar rights with respect to the Company or its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;All
outstanding shares of the Company Share Capital have been duly authorized and are validly issued, fully paid and non-assessable and not
subject to any pre-emptive rights, right of participation, right of maintenance or any similar right. All outstanding shares of the Company
Share Capital were issued or sold in compliance in all material respects with (i) applicable securities Laws, (ii) the Company Organizational
Documents, and (iii) any Contract.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;Each
outstanding share or other equity interests of each Subsidiary is duly authorized, validly issued, fully paid and non-assessable and is
not subject to any pre-emptive rights, right of participation, right of maintenance, or any similar right.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;Except
as set forth in the Company Organizational Documents and <span style="text-decoration:underline">Section 3.06(b)</span> of the Company Disclosure Letter, there are no outstanding
contractual obligations of the Company or any of its Subsidiaries to repurchase, redeem or otherwise acquire any shares of the Company
Share Capital or shares of any Subsidiary, if any, of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(f)&#160;There
are no voting trusts, proxies or similar agreements, arrangements or commitments to which the Company or any of its Subsidiaries is a
party with respect to the voting of any shares of the Company or any of its Subsidiaries. There are no bonds, debentures, notes or other
instruments of indebtedness of the Company or any of its Subsidiaries that entitle the holder of such instruments of indebtedness to vote
together with shareholders of the Company on any matters with respect to the Company or any Subsidiary, if any.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(g)&#160;The
Company does not have any share option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation
for any Person that are currently in effect or outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
3.07 <span style="text-decoration:underline">Subsidiaries</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Section
3.07</span> of the Company Disclosure Letter sets forth a complete and accurate organization chart of the Company with each Subsidiary of
the Company. The Company has made available to PubCo the organizational documents of each Subsidiary of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 403 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Each
of the Subsidiaries of the Company is wholly owned by the Company, directly or indirectly, free and clear of any Liens (other than Permitted
Liens) or restrictions on transfer (other than restrictions under applicable Law). Other than the Subsidiaries listed on <span style="text-decoration:underline">Section 3.07</span>
of the Company Disclosure Letter, the Company does not own, directly or indirectly, any equity, membership interest, partnership interest,
joint venture interest, or other equity or voting interest in, or any interest convertible into, exercisable or exchangeable for any of
the foregoing, nor is it under any current or prospective obligation to form or participate in, provide funds to, make any loan, capital
contribution, guarantee, credit enhancement or other investment in, or assume any liability or obligation of, any Person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Except
as set forth on <span style="text-decoration:underline">Section 3.07(c)</span> of the Company Disclosure Letter, neither the Company nor any of its Subsidiaries is a party to,
has any commitment to become a party to, any joint venture, off balance sheet partnership or any similar Contract (including any Contract
or arrangement relating to any transaction or relationship between or among the Company and its Subsidiaries, on the one hand, and any
unconsolidated Affiliate, including any structured finance, special purpose or limited purpose entity or Person, on the other hand, or
any &#8220;off balance sheet arrangements&#8221; (as defined in Item 303(a) of Regulation S-K under the Exchange Act)).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
3.08 <span style="text-decoration:underline">Financial Statements</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Section
3.08</span> of the Company Disclosure Letter contains true, correct and complete copies of (i) the unaudited consolidated financial statements
for the twelve (12) month periods ended on March 31, 2023 and March 31, 2024, consisting of the balance sheet, and the related statements
of income, shareholders&#8217; equity and cash flows of the Company and its Subsidiaries, and (ii) the unaudited consolidated financial
statements for the six (6) month period ended on September 30, 2024 (the &#8220;<span style="text-decoration:underline">Balance Sheet Date</span>&#8221;), consisting of the balance
sheet, and the related statements of income, shareholders&#8217; equity and cash flows of the Company and its Subsidiaries. The financial
statements contemplated under the aforementioned sub-paragraphs (i) and (ii) shall be collectively referred to as the &#8220;<span style="text-decoration:underline">Company
Unaudited Financial Statements</span>&#8221;. The Company Unaudited Financial Statements fairly present, in all material respects, the financial
condition and results of operations of the Company and its consolidated Subsidiaries as of the times and for the periods referred to therein
and have been prepared in conformity with GAAP. There are no &#8220;off-balance sheet arrangements&#8221; (as defined in Item 303(c) of
Regulation S-K under the Exchange Act) to which the Company or any of its Subsidiaries is a party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;The
books of account and financial records of the Company and its Subsidiaries are true and correct and have been prepared and are maintained
in accordance with sound accounting practice. The Company maintains a system of internal accounting controls reasonably sufficient to
provide reasonable assurance that (i) that transactions are recorded as necessary to permit preparation of financial statements in conformity
with GAAP consistently applied, (ii) that transactions are executed only in accordance with the authorization of management, and (iii)
regarding prevention or timely detection of the unauthorized acquisition, use or disposition of Company Assets that could have a material
effect on the financial statements. The Company maintains internal control over financial reporting that provides reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
GAAP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;There
have been no formal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated
at the direction of the chief executive officer, chief financial officer, principal accounting officer or general counsel of the Company,
the Company Board or any committee thereof, other than ordinary course audits or reviews of accounting policies and practices or internal
controls required by the Sarbanes-Oxley Act or any other applicable Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"></p><div>

</div><!-- Field: Page; Sequence: 404 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>Section 3.09 <span style="text-decoration:underline">Undisclosed
Liabilities</span></b>. As of the date of this Agreement, except as set forth in <span style="text-decoration:underline">Section 3.09</span> of the Company Disclosure Letter, there
are no liabilities, indebtedness, obligations or expense of any of any kind, whether accrued, contingent, absolute, matured or otherwise
(collectively, &#8220;<span style="text-decoration:underline">Liabilities</span>&#8221;) of the Company or any of its Subsidiaries, individually or in the aggregate, that are
required to be reflected in the financial statements under GAAP other than:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Liabilities
reflected or reserved against in the Company Interim Financial Statements as of the Balance Sheet Date or the footnotes thereto;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Liabilities
that have been incurred since the Balance Sheet Date in the ordinary course of business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Liabilities
incurred in connection with the Transactions or as permitted or contemplated expressly by this Agreement;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;Liabilities
incurred pursuant to Company Material Contracts binding on the Company or any of its Subsidiaries (other than those resulting from any
breach or default under such Company Material Contract); and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;Liabilities
that would not, individually or in aggregate, reasonably be expected to have a Company Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>Section 3.10 <span style="text-decoration:underline">Absence
of Certain Changes</span></b>. Except as otherwise expressly contemplated or required by this Agreement, or as set forth in <span style="text-decoration:underline">Section 3.10</span>
of the Company Disclosure Letter, since the Balance Sheet Date to the date of this Agreement, (a) the business of the Company and each
of its Subsidiaries has been conducted, in all material respects, in the ordinary course of business, excluding the exaction and performance
of this Agreement and the discussion, negotiations and transactions related thereto, (b) there has not been any Company Material Adverse
Effect, and (c) there has not been or occurred any event, condition, action or effect that, if taken during this period, would constitute
a breach of <span style="text-decoration:underline">Section 5.01</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>Section 3.11 <span style="text-decoration:underline">Litigation</span></b>.
Except as set forth in <span style="text-decoration:underline">Section 3.11</span> of the Company Disclosure Letter, from the Balance Sheet Date through the date of this Agreement,
(a) there are no legal actions, claims, demands, arbitrations, hearings, charges, complaints, sanctions investigations, examinations,
indictments, litigations, suits or other civil, criminal, administrative or investigative proceedings before a Governmental Authority
(collectively, &#8220;<span style="text-decoration:underline">Legal Actions</span>&#8221;) pending or, to the Knowledge of the Company, threatened against the Company or any
of its Subsidiaries, or any of its or their assets or properties that would, individually or in the aggregate, reasonably be expected
to have a Company Material Adverse Effect, and (b) there are no Orders outstanding against the Company or any of its Subsidiaries or any
of its or their assets or properties that would, individually or in the aggregate, reasonably be expected to have a Company Material Adverse
Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
3.12 <span style="text-decoration:underline">Material Contracts</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Section
3.12</span> of the Company Disclosure Letter sets forth a list of each of the following Contracts to which, as of the date of this Agreement,
the Company or any of its Subsidiaries is a party (each, a &#8220;<span style="text-decoration:underline">Company Material Contract</span>&#8221;):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)&#160;Each
contract that would constitute a &#8220;material contract&#8221; (as such term is defined in Item 601(b)(10) of Regulation S-K under the
Securities Act), with respect to the Company or any of its Subsidiaries (assuming the Company was subject to the requirements of the Exchange
Act);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 71.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 71.3pt">(ii)&#160;each
Contract (A) not to (or otherwise restricting or limiting the ability of the Company or any of its Subsidiaries to) compete in any line
of business or geographic area or (B) to restrict the ability of the Company or any of its Subsidiaries to conduct business in any geographic
area;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii)&#160;each
Contract (other than any Company Benefit Plan) that is reasonably likely to require, during the remaining term of such Contract, annual
payments by the Company or any of its Subsidiaries that exceed $250,000;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iv)&#160;all
Contracts granting to any Person an option or a first refusal, first offer or similar preferential right to purchase or acquire any material
Company Assets;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 405 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(v)&#160;all
material Contracts for the granting or receiving of a license, sublicense or franchise or under which any Person is obligated to pay or
has the right to receive a royalty, license fee, franchise fee or similar payment (other than agreements with employees, non-exclusive
licenses granted to the Company&#8217;s or its Subsidiaries&#8217; customers, and non-exclusive licenses to commercially available, off-the-shelf
Software that have been granted on standardized, generally available terms);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vi)&#160;all
partnership, joint venture or other similar agreements or arrangements;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vii)&#160;any
agreement relating to indebtedness for borrowed money or the deferred purchase price of property (in either case, whether incurred, assumed,
guaranteed or secured by any asset), except any such agreement (or a series of related agreements) with an aggregate outstanding principal
amount not exceeding $1,000,000;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 71.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 71.3pt">(viii)&#160;any
agreement for the disposition or acquisition by the Company or any of its Subsidiaries with material obligations of the Company or any
of its Subsidiaries (other than confidentiality obligations) remaining to be performed or material Liabilities of the Company or any of
its Subsidiaries continuing after the date of this Agreement, of any material business or any material amount of assets other than in
the ordinary course of business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ix)&#160;any
agreement with (A) the top 10 customers of the Company and its Subsidiaries taken as a whole, as applicable, and (B) the top 10 suppliers
of the Company and its Subsidiaries taken as a whole, as applicable, in each case, for the 2024 fiscal year measured by the aggregate
obligations paid or agreed to pay to or by the Company, as applicable;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(x)&#160;any
agreement restricting or limiting the payment of dividends or the making of distributions to shareholders, including intercompany dividends
or distributions other than such restrictions or limitations that are required by applicable Law;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xi)&#160;any
Contract for the development of Intellectual Property, other than those entered into in the ordinary course of business with Company employees
and contractors on the Company&#8217;s standard form for such Contracts; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xii)&#160;all
material agreements with any Governmental Authority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(b)&#160;Each
Company Material Contract is a valid and binding agreement of the Company or its applicable Subsidiary, except where the failure to be
valid and binding would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. Except
as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, (i) neither the Company
or such Subsidiary nor, to the Knowledge of the Company, any other party thereto, is in breach of or default under any such Company Material
Contract, (ii) as of the date of this Agreement, there are no material disputes in connection with any such Company Material Contract,
and (iii) as of the date of this Agreement no party under any Company Material Contract has given written notice of its intent to terminate
or otherwise seek a material amendment to such Company Material Contract.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
3.13 <span style="text-decoration:underline">Benefit Plans</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Section
3.13(a)</span> of the Company Disclosure Letter lists all material Company Benefit Plans. For purposes of this Agreement a &#8220;Company
Benefit Plan&#8221; is, whether or not written, (i) any compensation, stock purchase, stock option, equity or equity-based compensation,
severance, employment, consulting, change-of-control, bonus, incentive, deferred compensation and other employee benefit plan, agreement,
program or policy, (ii) any plan, agreement, program or policy providing vacation benefits, insurance (including any self-insured arrangements),
medical, dental, vision or prescription benefits, disability or sick leave benefits, life insurance, employee assistance program, workers&#8217;
compensation, supplemental unemployment benefits and post-employment or retirement benefits (including compensation, pension or insurance
benefits), or (iii) any loan to or for the benefit of an officer of the Company or any of its Subsidiaries, in each case (A) under which
any current or former director, officer, employee or independent contractor of the Company or any of its Subsidiaries has any right to
benefits, or (B) which are maintained, sponsored or contributed to by the Company or any of its Subsidiaries or to which the Company or
any of its Subsidiaries makes or is required to make contributions or with respect to which the Company or any of its Subsidiaries has
any material Liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"></p><div>

</div><!-- Field: Page; Sequence: 406 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt">(b)&#160;With
respect to each Company Benefit Plan that is subject to the Laws of a jurisdiction other than the United States (whether or not United
States Law also applies) (each such plan, a &#8220;<span style="text-decoration:underline">Foreign Plan</span>&#8221;): (i) all required employer and employee contributions have
been calculated, deposited or made or properly accrued in a material respects; (ii) each Foreign Plan required to be registered has been
registered and has been maintained in good standing with applicable regulatory authorities and, if intended to qualify for special tax
treatment, meets all of the requirements for such treatment; (iii) no Foreign Plan is a defined benefit plan or an arrangement providing
a stated level of benefits calculated by reference to an employee&#8217;s (or former employee&#8217;s) length of service and salary; (iv)
no unfunded or underfunded liabilities exist with respect to any Foreign Plan and no rights or entitlements (including but not limited
to any entitlements to enhanced or additional benefits) exist in relation to any employee or former employee of the Company or any of
the Company Subsidiaries other than pursuant to the terms of the plan documents governing the Foreign Plans, and (v) no notice of default
or show cause notice has been received regarding any non-compliance or inadequate compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;The
execution and delivery of this Agreement and the consummation of the Transactions will not (either alone or in combination with another
event) (i) result in any payment from The Company or any of its Subsidiaries becoming due, or increase the amount of any compensation
due, to any current or former employee, director or independent contractor of the Company or any of its Subsidiaries, (ii) increase any
benefits otherwise payable under any Company Benefit Plan, (iii) result in the acceleration of the time of payment, vesting of any compensation
or benefits or forgiveness of indebtedness with respect to any current or former employee, director or independent contractor of the Company
or any of its Subsidiaries, (iv) result in any funding, through a grantor trust or otherwise, of any compensation or benefits to any current
or former employee, director or independent contractor of the Company or any of its Subsidiaries under any Company Benefit Plan, (v) cause
any amount to fail to be deductible by reason of Section 280G of the Code or be characterized as an &#8220;excess parachute payment&#8221;
(as such term is defined in Section 280G(b)(1) of the Code), or (vi) result in any breach or violation of or default under any Company
Benefit Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;There
are no pending, or, to the Knowledge of the Company, threatened, material Legal Actions against or involving any Company Benefit Plan,
other than ordinary claims for benefits by participants and beneficiaries. Each Company Benefit Plan can be terminated at any time for
any or no reason by the Company and its Subsidiaries without any past, present or future Liability or obligation to the Company or any
of its Subsidiaries (other than solely administrative expenses related to such termination).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
3.14 <span style="text-decoration:underline">Labor Relations</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;(i)
No employee of the Company or any of its Subsidiaries is represented by a union or is covered by an effective or pending collective bargaining
agreement or similar labor agreement and, to the Knowledge of the Company, no labor union, or similar employee group to organize any employees,
organizing efforts are currently being conducted, (ii) neither the Company nor any of its Subsidiaries is a party to, and is not currently
negotiating any entry into, any collective bargaining agreement or other labor Contract, and (iii) no strike, picket, work stoppage, work
slowdown or other organized labor dispute exists in respect of the Company or any of its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;The
Company and its Subsidiaries is, and has been since the January 1, 2023, in compliance in all material respects with all federal, state,
local or foreign Laws regarding labor, employment and employment practices that are applicable to the Company and its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Since
January 1, 2023, there have been no material Legal Actions against the Company or any of its Subsidiaries or, to the Company&#8217;s Knowledge,
investigations pending or threatened related to any allegations of sexual harassment, discrimination or other misconduct against the Company
or any of its respective current or former directors, officers or senior level management employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.3pt"></p><div>

</div><!-- Field: Page; Sequence: 407 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.3pt">(d)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, there are no pending
or, to the Company&#8217;s Knowledge, threatened claims, suits, actions or other legal proceeding against the Company or any of its Subsidiaries
brought by or on behalf of any applicant for employment, any current or former employees or other individual service providers of the
Company or any of its Subsidiaries, any current or former leased employee, intern, volunteer or &#8220;temp&#8221; of the Company or any
of its Subsidiaries, or any person alleging to be a current or former employee, or any group or class of the foregoing, or any Governmental
Authority, alleging: (i) violation of any labor or employment Laws; (ii) breach of any collective bargaining agreement; (iii) breach of
any express or implied contract of employment; (iv) wrongful termination of employment; or (v) any other discriminatory, wrongful or tortious
conduct in connection with any employment relationship, including before the Equal Employment Opportunity Commission.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
3.15 <span style="text-decoration:underline">Taxes</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;(i)
All income and other material Tax Returns required to be filed by or with respect to the Company or any of its Subsidiaries have been
timely filed (taking into account all applicable extensions), and all such Tax Returns are true, complete and correct in all material
respects, (ii) the Company and its Subsidiaries have fully and timely paid (or have had paid on their behalf) all material Taxes due and
payable (whether or not shown to be due on any Tax Return) and have made adequate provision in accordance with GAAP for all material Taxes
not yet due and payable in the most recent financial statements of the Company and its Subsidiaries, and (iii) the Company and its Subsidiaries
have complied in all material respects with all applicable Laws relating to the withholding and payment over to the appropriate Governmental
Authority of all Taxes required to be withheld by the Company and its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;(i)
There are no outstanding agreements extending or waiving the statutory period of limitations applicable to any claim for, or the period
for the collection, assessment or reassessment of, any material Taxes due from the Company or any of its Subsidiaries for any taxable
period and no request for any such waiver or extension is currently pending, (ii) to the Company&#8217;s Knowledge, no audit is presently
in progress, pending or threatened in writing with respect to any material Taxes due from or with respect to the Company or any of its
Subsidiaries, (iii) no claim in writing has been made by any Governmental Authority in a jurisdiction where the Company and its Subsidiaries
does not file Tax Returns that it is or may be subject to taxation by that jurisdiction, and (iv) all material deficiencies for Taxes
asserted or assessed in writing against the Company or any of its Subsidiaries have been fully and timely paid or properly reflected under
GAAP in the most recent financial statements of the Company and its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;There
are no Liens for Taxes upon the assets or properties of the Company or any of its Subsidiaries, except for Liens for current Taxes and
assessments not yet past due.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;Neither
the Company nor any of its Subsidiaries has participated in any listed transaction within the meaning of Treasury Regulations Section
1.6011-4(b) (or any similar provision of state, local or non-U.S. Tax Law).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;The
Company has not been a &#8220;controlled corporation&#8221; or a &#8220;distributing corporation&#8221; in any distribution occurring
during the three-year period ending on the date hereof that was purported or intended to be governed by Section 355 of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;Neither
the Company nor any of its Subsidiaries (i) is or has been a member of a group (other than a group the common parent of which is the Company)
filing a consolidated, combined, affiliated, unitary or similar income Tax Return or (ii) has any Liability for the Taxes of any Person
(other than any of the Company or its Subsidiaries) under Treasury Regulation Section 1.1502-6 (or any similar provision of state, local,
or foreign Law), as a transferee, successor, by Contract (other than pursuant to any ordinary course Contract, the principal purpose of
which does not relate to Taxes) or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt"></p><div>

</div><!-- Field: Page; Sequence: 408 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt">(g)&#160;Neither
the Company nor any of its Subsidiaries will be required to include any item of material income in, or exclude any item of material deduction
from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of (i) any change in, or use
of improper, method of accounting adopted, requested or initiated at or prior to the Closing for a taxable period ending on or prior to
the Closing Date, (ii) any intercompany transaction or any excess loss account described in Treasury Regulations under Section 1502 of
the Code (or any similar provision of state, local or foreign income Tax law), (iii) any installment sale or open transaction disposition
made at or prior to the Closing, (iv) any item of deferred revenue, (v) any election under Section 965 of the Code, (vi) any prepaid amounts
received on or prior to the Closing Date, or (vii) any agreement entered into with any Governmental Authority with respect to Taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#160;No
private letter rulings, technical advice memoranda or similar material agreements or rulings have been requested, entered into or issued
by any taxing authority with respect to the Company or any of its Subsidiaries which rulings remain in effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#160;Neither
the Company nor any of its Subsidiaries has been a United States real property holding corporation, as defined in Section 897(c)(2) of
the Code during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#160;To
the Knowledge of the Company, each of the Company and its Subsidiaries has not been, is not, and immediately prior to the Effective Time
will not be, treated as an &#8220;investment company&#8221; within the meaning of Section 368(a)(2)(F) of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&#160;Neither
the Company nor any of its Subsidiaries has taken any action that could reasonably be expected to prevent the Merger from qualifying for
the Intended Tax Treatment. To the Knowledge of the Company, there are no facts or circumstances, other than any facts and circumstances
to the extent that such facts and circumstances exist or arise as a result of or related to any act or omission occurring after the date
of this Agreement of any PubCo Entity or any of its Affiliates not contemplated by this Agreement, that could reasonably be expected to
prevent the Merger from qualifying for the Intended Tax Treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&#160;The
Company is and has been since its date of formation, a C corporation for U.S. federal income tax purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)&#160;Neither
the Company nor any of its Subsidiaries (i) is a &#8220;controlled foreign corporation&#8221; as defined in Section 957 of the Code, (ii)
is a &#8220;passive foreign investment company&#8221; within the meaning of Section 1297 of the Code, or (iii) has a permanent establishment
(with the meaning of an applicable Tax treaty) or otherwise has an office or fixed place of business in a country other than the country
in which it is organized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>Section 3.16 <span style="text-decoration:underline">Environmental
Matters</span></b>. Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.1pt">(a)&#160;The
Company and its Subsidiaries comply and have complied with all applicable Environmental Laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.1pt">(b)&#160;The
Company and its Subsidiaries possess all Permits required under Environmental Laws necessary for their respective operations as currently
conducted, and are in compliance with such Permits, which are, and through the Closing Date shall remain, in full force and effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Neither
the Company nor any Subsidiary has received any written notice or request for information from any Governmental Authority or other third
party related to any actual or alleged Liability under Environmental Law, including any investigatory, remedial or corrective obligations
or otherwise pertaining to Hazardous Substances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.1pt">(d)&#160;To
the Knowledge of the Company, as of the date of this Agreement, no condition exists on any property owned or operated by the Company and
its Subsidiaries or any other location which has given rise to, or would reasonably be expected to give rise to, any Liability relating
to environmental or Hazardous Substances matters or Environmental Laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.1pt">(e)&#160;To
the Knowledge of the Company, the Transactions do not require notice to, or approval from, any Governmental Authority under any Environmental
Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"></p><div>

</div><!-- Field: Page; Sequence: 409 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
3.17 <span style="text-decoration:underline">Intellectual Property; Data Privacy</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Each
of the Company and its Subsidiaries owns, is licensed to use, pursuant to valid, enforceable and binding Contracts, or otherwise has the
right to use all Intellectual Property used, held for use or necessary for the operation of the business of the Company and its Subsidiaries
(collectively, the &#8220;<span style="text-decoration:underline">Company Intellectual Property</span>&#8221;) free and clear of all Liens (other than Permitted Liens), except
as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect. <span style="text-decoration:underline">Section 3.17(a)</span>
of the Company Disclosure Letter sets forth a true and complete list of the following which are owned or purported to be owned by the
Company and its Subsidiaries: (i) patents and patent applications, (ii) registered trademarks and applications therefor, (iii) registered
copyrights and applications therefor, and (iv) domain name registrations ((i) - (iv), the &#8220;<span style="text-decoration:underline">Company Registered IP</span>&#8221;).
Except as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, the execution,
delivery and performance of this Agreement by the Company and the consummation by the Company of the Transactions do not and will not
encumber, impair or extinguish any of the Company Intellectual Property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: 75.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, (i) none of the Company
Intellectual Property owned or purported to be owned by the Company or any of its Subsidiaries (&#8220;<span style="text-decoration:underline">Company Owned Intellectual Property</span>&#8221;)
(A) has been adjudged invalid or unenforceable in whole or in part, or (B) is the subject of any cancellation or reexamination proceeding
or any other proceeding challenging its ownership, use, registrability, validity and enforceability, and (ii) to the Knowledge of the
Company, all Company Registered IP is subsisting, in full force and effect, and, to the Knowledge of the Company, valid and enforceable,
and all renewal fees and other maintenance fees have been paid. There exist no material contractual restrictions on the disclosure, use,
license or transfer of any Company Owned Intellectual Property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Except
as set forth in <span style="text-decoration:underline">Section 3.17(c)</span> of the Company Disclosure Letter, or as would not, individually or in the aggregate, reasonably
be expected to have a Company Material Adverse Effect, (i) the conduct of the business of the Company and its Subsidiaries does not infringe
upon, misappropriate or otherwise violate, and has not, since January 1, 2023 infringed upon, misappropriated, or otherwise violated,
the Intellectual Property rights of any Third Party, and (ii) no Legal Action is pending, asserted in writing, or to the Knowledge of
the Company, threatened against the Company or any of its Subsidiaries that the conduct of the business of the Company or its Subsidiaries
infringes upon, misappropriates or otherwise violates the Intellectual Property rights of any Third Party. To the Knowledge of the Company,
no Person is infringing upon, misappropriating or otherwise violating, or has, since January 1, 2023, infringed upon, misappropriated,
or otherwise violated, any Intellectual Property owned or purported to be owned by the Company or any of its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, the Company and its
Subsidiaries have taken reasonable steps in accordance with normal industry practice to maintain and protect the confidentiality of all
Company Intellectual Property that is material to the business of the Company and its Subsidiaries, and the value of which is contingent
upon maintaining the confidentiality thereof. Except as would not, individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect, none of the Company Owned Intellectual Property that is material to the business of the Company and its
Subsidiaries and the value of which is contingent upon maintaining the confidentiality thereof, has been disclosed other than to Third
Parties that are bound by customary, written confidentiality agreements entered into in the ordinary course of business consistent with
past practice and that are, to the Knowledge of the Company, valid and enforceable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, all Persons who have
contributed, developed or conceived any Company Owned Intellectual Property have done so pursuant to a valid and enforceable Contract
(subject to enforceability exceptions for bankruptcy and insolvency and subject to principles of equity) that protects the confidential
information of the Company and its Subsidiaries and assigns to the Company (or one of its Subsidiaries, as applicable) exclusive ownership
of the Person&#8217;s contribution, development or conception, other than Intellectual Property excluded by Law or non-assignable moral
rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 410 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, (i) the Company and
its Subsidiaries have sufficient rights to use all Software, including middleware, databases, and systems, information technology equipment,
and associated documentation used or held for use in connection with the operation of the business of the Company and its Subsidiaries
(&#8220;<span style="text-decoration:underline">IT Assets</span>&#8221;), (ii) in each case, the IT Assets operate and perform in all material respects in accordance with their
documentation and functional specifications and are sufficient or configurable to effectively perform all operations necessary for the
current operation of the business of the Company and its Subsidiaries, and all IT Assets are owned or licensed under valid licenses and
operated by and are under the control of the Company and its Subsidiaries, (iii) the IT Assets have not materially malfunctioned or failed
since January 1, 2023, to the Knowledge of the Company, do not contain any viruses, bugs, faults or other devices or effects that (A)
enable or assist any Person to access without authorization or disable or erase the IT Assets, or (B) otherwise materially adversely affect
the functionality of the IT Assets, (iv) the Company and its Subsidiaries have taken commercially reasonable steps to provide for the
remote-site back-up of data and information critical to the conduct of the business of the Company and its Subsidiaries and have in place
commercially reasonable disaster recovery and business continuity plans, procedures and facilities, (v) no Person has gained unauthorized
access to any IT Assets since January 1, 2023, (vi) the Company and its Subsidiaries have maintained, continue to maintain, and caused
their vendors to maintain, safeguards, security measures and procedures against the unauthorized access, disclosure, destruction, loss,
or alteration of customer data or information (including any personal or device-specific information) in its possession or control that
comply with any applicable contractual and legal requirements and meet industry standards, and (vii) the Company and its Subsidiaries
have in place with the third-party owners and operators of all data centers which provide services related to the business of the Company
and its Subsidiaries written agreements that ensure that such Third Parties adhere to and are in compliance with commercially reasonable
standards and requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 70.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;Except as set forth
in <span style="text-decoration:underline">Section 3.17(g)</span> of the Company Disclosure Letter, each of the Company and its Subsidiaries is in compliance in all material
respects with all applicable Laws pertaining to (i) data security, cybersecurity, privacy, and (ii) the collection, storage, use, access,
disclosure, processing, security, and transfer of personal data or any other information that alone or in combination with other information
can be used to identify an individual (&#8220;<span style="text-decoration:underline">Personal Information</span>&#8221;), to the extent that it is subject to same. During the
past two (2) years, no claims have been asserted or, to the Knowledge of the Company, threatened in writing against the Company or any
of its Subsidiaries alleging a violation of any Person&#8217;s privacy or Personal Information. Each of the Company and its Subsidiaries
has taken commercially reasonable steps to protect the Personal Information collected, used or held for use by the Company or any of
its Subsidiaries against loss and unauthorized access, use, modification, disclosure or other misuse.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#160;To
the Knowledge of the Company, no government funding, facilities or resources of a university, college, other educational institution or
research center was used in the development of the Company Owned Intellectual Property, to the Knowledge of the Company, exclusively licensed
to the Company or any of its Subsidiaries, and no Governmental Authority, university, college, other educational institution or research
center has, to the knowledge of the Company, any claim or right in or to such Intellectual Property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
3.18 <span style="text-decoration:underline">Real Property; Personal Property</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, (i) the Company and
its Subsidiaries have good and marketable title to, or have a valid and enforceable right to use or a valid and enforceable leasehold
interest in, all real property (including all buildings, fixtures and other improvements thereto) used by the business of the Company
and its Subsidiaries (the &#8220;<span style="text-decoration:underline">Company Real Property</span>&#8221;), and (ii) the ownership of or leasehold interest in any Company
Real Property is not subject to any Lien (except in all cases for Permitted Liens). Except as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect, neither the Company nor any of its Subsidiaries has leased, subleased,
licensed, sublicensed or otherwise granted to any Person the right to use or occupy any Company Real Property or any portion thereof,
other than the right of PubCo pursuant to this Agreement, there are no outstanding options, rights of first offer or rights of first refusal
to purchase any Company Real Property or any portion thereof or interest therein, and except for this Agreement, neither the Company nor
any of its Subsidiaries is a party to any Contract to sell, transfer, or encumber any Company Real Property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 411 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, each of the material
leases, subleases and other agreements under which the Company or any of its Subsidiaries use or occupy or have the right to use or occupy,
now or in the future, any material real property (the &#8220;<span style="text-decoration:underline">Company Real Property Leases</span>&#8221;) is valid, binding and in full
force and effect (except as may be limited by bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar
laws of general applicability relating to or affecting creditor&#8217;s rights, and to general equitable principles), and no termination
event or condition or uncured default on the part of the Company or its Subsidiaries exists under any Company Real Property Lease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, (i) the Company and
its Subsidiaries have good and marketable title to, or a valid and enforceable leasehold interest in, all Company Assets, (ii) the Company
Assets are in good working order (reasonable wear and tear excepted) and is suitable and adequate for the uses for which it is intended
or is being used, and (iii) none of the Company&#8217;s or any of its Subsidiaries&#8217; ownership of or leasehold interest in any such
Company Assets is subject to any Liens (except in all cases for Permitted Liens).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
3.19 <span style="text-decoration:underline">Permits; Compliance with Law</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, each of the Company
and its Subsidiaries is in possession of all material franchises, grants, authorizations, licenses, easements, variances, exceptions,
consents, certificates, approvals, waivers, notices, and other permits of any Governmental Authority (&#8220;<span style="text-decoration:underline">Permits</span>&#8221;) necessary
for each of the Company and its Subsidiaries to own, lease and operate their respective properties and assets or to carry on their respective
business as it is now being conducted (collectively, the &#8220;<span style="text-decoration:underline">Company Permits</span>&#8221;). All such Company Permits are in full force
and effect in all material respects and no suspension or cancellation of any of the Company Permits is pending or, to the Knowledge of
the Company, has been threatened in writing against the Company or any of its Subsidiaries. The rights and benefits of each Company Permit
will be available to the Surviving Company or its Subsidiaries, as applicable, immediately after the Effective Time on terms substantially
identical to those enjoyed by the Company as of the date of this Agreement and immediately prior to the Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, each of the Company
and its Subsidiaries has at all times since January 1, 2023 been in compliance with (i) all Laws applicable to the Company or such Subsidiary
or by which any of the Company Assets is bound and (ii) all Laws applicable to, and the terms and conditions of, any Company Permits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
3.20 <span style="text-decoration:underline">Regulatory Matters</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, (i) the Company and
its Subsidiaries currently conduct, and have at all times since January 1, 2023, conducted their respective businesses in compliance with
all Laws applicable to their respective operations, activities or services and any Orders to which they are a party or are subject, including
any settlement agreements or corporate integrity agreements, (ii) except for routine matters arising in the ordinary course of business,
none of the Company or any of its Subsidiaries has received any written notice, citation, suspension, revocation, limitation, warning,
or request for repayment or refund issued by a Governmental Authority which alleges or asserts that the Company or any of its Subsidiaries
has violated any Laws or which requires or seeks to adjust, modify or alter the Company&#8217;s or any of its Subsidiary&#8217;s operations,
activities, services or financial condition that has not been fully and finally resolved to the Governmental Authority&#8217;s satisfaction
without further Liability to the Company and its Subsidiaries, and (iii) there are no restrictions imposed by any Governmental Authority
upon the Company&#8217;s or any of its Subsidiaries&#8217; business, activities or services which would restrict or prevent the Company
or any of its Subsidiaries from operating as it currently operates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.75pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;As
of the date of this Agreement, except as would not reasonably be expected to have, individually or in the aggregate, a Company Material
Adverse Effect, (i) the Company and each of its Subsidiaries, and (ii) to the Knowledge of the Company, all of their respective directors,
officers, agents and employees, are in compliance in all material respects with, to the extent applicable, all Laws.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 412 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
3.21</b></span> [Intentionally Left Blank].</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>Section 3.22 <span style="text-decoration:underline">Takeover
Law</span></b>. The Company Board has taken all actions necessary to ensure that the Takeover Laws are, and will be, inapplicable to the
execution, delivery and performance of this Agreement and the timely consummation of the Transactions, including the Merger, and will
not restrict, impair or delay the ability of PubCo, after the Effective Time, to vote or otherwise exercise all rights as a shareholder
of the Company. &#8220;Takeover Laws&#8221; shall mean any &#8220;moratorium,&#8221; &#8220;control share acquisition,&#8221; &#8220;affiliated
transactions,&#8221; &#8220;business combination,&#8221; &#8220;fair price&#8221; or other form of anti-takeover Laws of any jurisdiction
or other applicable Laws that purport to limit or restrict mergers or business combinations or the ability to limit or restrict mergers
or business combinations or the ability to acquire or to vote shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>Section 3.23 <span style="text-decoration:underline">Transactions
with Affiliates</span></b>. There are no transactions, arrangements or Contracts between the Company or any Subsidiary of the Company, on
the one hand, and any shareholder, officer, director, Affiliate, or any &#8220;related person&#8221; (within the meaning of Item 404 of
Regulation S-K under the Securities Act) of the Company, on the other hand, that is of the type that would be required to be disclosed
under Item 404 of Regulation S-K under the Securities Act (assuming the Company was subject to the requirements of the Securities Act).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>Section 3.24 <span style="text-decoration:underline">Insurance</span></b>.
The Company and its Subsidiaries are covered by valid and currently effective insurance policies and all premiums payable under such policies
have been duly paid to date. As of the date of this Agreement, none of the Company or any of its Subsidiaries have received any written
notice of default or cancellation of any such policy. All material fire and casualty, general liability, business interruption, product
liability, and sprinkler and water damage insurance policies maintained by or on behalf of the Company or any of its Subsidiaries (&#8220;<span style="text-decoration:underline">Insurance
Policies</span>&#8221;) provide adequate coverage for all normal risks incident to the business of the Company and its Subsidiaries and their
respective properties and assets, except for any such failures to maintain Insurance Policies that, individually or in the aggregate,
are not reasonably be expected to have a Company Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>Section 3.25 <span style="text-decoration:underline">Brokers</span></b>.
Except as set forth in <span style="text-decoration:underline">Section 3.25</span> of the Company Disclosure Letter, no broker, finder, adviser or investment banker is entitled
to any brokerage, success, finder&#8217;s or other similar fee or commission in connection with the Transactions based upon arrangements
made by or on behalf of the Company or any of its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: .75in"><b>Section 3.26 <span style="text-decoration:underline">No
Other Representations and Warranties</span></b>. The Company acknowledges and agrees that, except for the representations and warranties
of PubCo and Merger Sub set forth in <span style="text-decoration:underline">Article IV</span> or in any certificate delivered by PubCo or Merger Sub to the Company pursuant
to this Agreement, neither the Company nor its Subsidiaries or any of their respective Affiliates or its Representatives, is relying on
any other representation or warranty of PubCo, Merger Sub, any of their Affiliates or Representatives or any other Person made outside
of <span style="text-decoration:underline">Article IV</span> or such certificate, including regarding the accuracy or completeness of any such other representations or warranties
or the omission of any material information, whether express or implied.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE IV. REPRESENTATIONS AND WARRANTIES
OF PUBCO ENTITIES</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as (i) set forth in
the corresponding sections of the disclosure letter delivered by the PubCo Entities to the Company concurrently with the execution of
this Agreement (the &#8220;<span style="text-decoration:underline">PubCo Disclosure Letter</span>&#8221;), it being agreed that disclosure of any item in any section of the PubCo
Disclosure Letter (whether or not an explicit cross reference appears) shall be deemed to be disclosure with respect to any other section
to which the relevance of such item is reasonably apparent or (ii) disclosed in any of the PubCo SEC Reports prior to the date hereof
and publicly available on the SEC&#8217;s Electronic Data Gathering Analysis and Retrieval system (excluding any disclosures contained
under the headings &#8220;Risk Factors,&#8221; &#8220;Disclosure Regarding Forward Looking Statements&#8221; or &#8220;Quantitative and
Qualitative Disclosures about Market Risk&#8221;, or in any other sections to the extent such disclosures are prospective or forward-looking
statements or cautionary, predictive or forward-looking in nature), <span style="text-decoration:underline">provided</span>, that nothing disclosed in the PubCo SEC Reports shall
be deemed to be a qualification of, or modification to, the representations and warranties set forth in <span style="text-decoration:underline">Section 4.01</span>, <span style="text-decoration:underline">Section
4.02</span>, <span style="text-decoration:underline">Section 4.03</span>, <span style="text-decoration:underline">Section 4.04</span>, <span style="text-decoration:underline">Section 4.05</span>, and <span style="text-decoration:underline">Section</span> 4.26, the PubCo Entities, jointly and severally,
represent and warrant to the Company that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 413 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 4.01 <span style="text-decoration:underline">Organization
and Power</span></b>. Each of the PubCo Entities and their respective Subsidiaries is duly organized, validly existing and in good standing
under the Law of its jurisdiction of organization. Each PubCo Entity has the requisite corporate power and authority to own, lease and
operate its assets and properties and to carry on its business as now conducted and to perform its obligations under all Contracts by
which it is bound. Each of the Subsidiaries of the PubCo Entities has the requisite power and authority to own, lease and operate its
assets and properties and to carry on its business as now conducted, except where the failure to have such requisite power or authority
would not, individually or in the aggregate, reasonably be expected to have a PubCo Material Adverse Effect. Each of the PubCo Entities
and their respective Subsidiaries is duly qualified to do business as a foreign corporation, limited liability company or other legal
entity and is in good standing in each jurisdiction where such qualification is necessary, except where the failure to be so qualified
or in good standing would not, individually or in the aggregate, reasonably be expected to have a PubCo Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 4.02 <span style="text-decoration:underline">Organizational
Documents</span></b>. Each PubCo Entity has made available to the Company true and complete copies of the certificate of incorporation, bylaws
and all other similar constitutional documents adopted or filed in connection with the creation, formation, organization or governance
of the PubCo Entities as in effect on the date of this Agreement (collectively, the &#8220;<span style="text-decoration:underline">PubCo Organizational Documents</span>&#8221;).
Neither PubCo nor Merger Sub is in breach in any material respect of the PubCo Organizational Documents governing PubCo and Merger Sub,
respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 4.03 <span style="text-decoration:underline">Governmental
Authorizations</span></b>. Assuming that the representations and warranties of the Company contained in <span style="text-decoration:underline">Section 3.04</span> are true and
correct, the execution, delivery and performance of this Agreement by each PubCo Entity and the consummation by each of the PubCo Entities
of the Transactions do not and will not require any Governmental Authorizations, other than:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;the
filing of the Articles of Merger (appending the Plan of Merger) and other documents required by the BVI Companies Act to effect the Merger,
with the BVI Registry, as may be required;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;the
filing with the Securities and Exchange Commission (the &#8220;<span style="text-decoration:underline">SEC</span>&#8221;) of a registration statement on Form S-4 (together with
all amendments and supplements thereto, and including the Proxy Statement contained therein, the &#8220;<span style="text-decoration:underline">PubCo Registration Statement</span>&#8221;);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;any
other filings or reports that may be required in connection with this Agreement and the Transactions under the Exchange Act, the Securities
Act or any other state or federal securities, takeover or &#8220;blue sky&#8221; Laws;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118pt; text-align: justify; text-indent: -0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"> (d) compliance with Nasdaq rules and regulations; and</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;such
other Governmental Authorizations, where the failure to obtain such Governmental Authorizations would not, individually or in the aggregate,
reasonably be expected to have a PubCo Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 4.04 <span style="text-decoration:underline">Corporate
Authorization</span></b>. Each PubCo Entity has all necessary corporate power and authority to enter into this Agreement and, subject to
the receipt of the Requisite PubCo Vote, to consummate the Transactions, including the issuance of stock to the Company Shareholders.
The PubCo Board has unanimously (a) approved and declared advisable this Agreement and the Transactions, including the issuance of PubCo
Common Stock to the Company Shareholders, (b) declared that it is fair to, advisable and in the best interests of PubCo and the PubCo
Stockholder that PubCo enter into this Agreement and consummate the Transactions, including the Merger, on the terms and subject to the
conditions set forth in this Agreement and (c) recommended to the PubCo Stockholders that they approve the PubCo Stockholder Matters.
The execution, delivery and performance of this Agreement by each PubCo Entity and, assuming that the Requisite PubCo Vote is received,
the consummation by each PubCo Entity of the Transactions have been duly and validly authorized by all necessary corporate action on the
part of each PubCo Entity. This Agreement has been duly and validly executed and delivered by the PubCo Entities and constitutes a legal,
valid and binding agreement of each PubCo Entity enforceable against each PubCo Entity in accordance with its terms (except as such enforceability
may be limited by bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws of general applicability
relating to or affecting creditor&#8217;s rights, and to general equitable principles). The Requisite PubCo Vote is the only vote of the
holders of any class or series of capital stock of PubCo required to approve and adopt this Agreement and the Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 414 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 4.05 <span style="text-decoration:underline">Non-Contravention</span></b>.
Except as set forth in <span style="text-decoration:underline">Section 4.05</span> of the PubCo Disclosure Letter, and subject to receiving the Requisite PubCo Vote and the Governmental
Authorizations applicable to PubCo, the execution, delivery and performance of this Agreement by each PubCo Entity and the consummation
of the Transactions do not and will not (a) contravene or conflict with, or result in any violation or breach of, any provision of (i)
the PubCo Organizational Documents, or (ii) the comparable organizational or governing documents of any of the Subsidiaries of the PubCo
Entities, (b) contravene or conflict with, or result in any material violation or breach of, any Law applicable to any of the PubCo Entities
or any of their respective Subsidiaries or by which any PubCo Assets are bound, (c) result in any violation, termination, acceleration
of any material obligation, cancellation, material payment or breach of, or constitute a default (with or without notice or lapse of time
or both) or require any notice or consent under, any PubCo Material Contracts or PubCo Real Property Leases to which the PubCo Entities
or any of their respective Subsidiaries is a party or by which any PubCo Assets are bound, or (d) result in the creation of any Liens
(other than Permitted Liens) upon any of the PubCo Assets, except, in the case of clauses (a)(ii), (b), (c), and (d), as would not, individually
or in the aggregate, reasonably be expected to have a PubCo Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
4.06</b></span> Capitalization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;As
of the date of this Agreement, PubCo&#8217;s authorized capital stock consists solely of (i) 100,000,000 shares of PubCo Common Stock,
and (ii) 10,000,000 shares of PubCo Preferred Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Except
as set forth in <span style="text-decoration:underline">Section 4.06(a)</span> of the PubCo Disclosure Letter, to the extent expressly permitted under <span style="text-decoration:underline">Section 5.02</span> (including
as required by applicable Law) or as set forth in <span style="text-decoration:underline">Section 4.06(g)</span> of the PubCo Disclosure Letter, (i) there are no outstanding
shares of capital stock of any PubCo Entity (subject to any exercise of PubCo Stock Options after the date of this Agreement each in accordance
with their terms), (ii) there are no outstanding subscriptions, options, warrants, calls, convertible securities, rights of first refusal,
preemptive rights, or other similar rights (whether or not currently exercisable), agreements or commitments (other than this Agreement)
relating to the issuance or acquisition of capital stock to which any of the PubCo Entities or any of their respective Subsidiaries is
a party obligating the PubCo Entities or any of their respective Subsidiaries to (A) issue, transfer or sell any shares of capital stock
or other equity interests of any of the PubCo Entities or any of their respective Subsidiaries or securities convertible into or exchangeable
for such shares or equity interests, or (B) grant, extend or enter into any such subscription, option, warrant, call, convertible securities
or other similar right, agreement or arrangement, (C) redeem, repurchase or otherwise acquire any such shares of capital stock or other
equity interests, or (D) provide an amount of funds to, or make any investment (in the form of a loan, capital contribution or otherwise)
in PubCo or any of its Subsidiaries or any other Person, and (iii) other than pursuant to this Agreement, there is no condition or circumstance
that could be reasonably likely to give rise to or provide a basis for the assertion of a claim by any Person to the effect that such
Person is entitled to acquire or receive any shares of PubCo Capital Stock. There are no outstanding or authorized stock appreciation,
phantom stock, profit participation or other similar rights with respect to the Company or its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 1.05in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;All
outstanding shares of PubCo Common Stock have been duly authorized and are validly issued, fully paid and non-assessable and not subject
to any pre-emptive rights, right of participation, right of maintenance or any similar right. All outstanding shares of PubCo Common Stock
and PubCo Stock Options were offered, sold and issued in compliance in all material respects with applicable securities Laws and were
not issued in violation in any material respect of (i) the PubCo Organizational Documents or (ii) any Contract.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;Each
outstanding share of capital stock or other equity interests of each Subsidiary of the PubCo Entities is duly authorized, validly issued,
fully paid and non-assessable, in each case, to the extent such concepts are applicable to such capital stock or other equity interests,
and not subject to any pre-emptive rights, right of participation, right of maintenance, or any similar right.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 415 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;Except
as set forth in this <span style="text-decoration:underline">Section 4.06</span>, there are no outstanding contractual obligations of the PubCo Entities or any of their respective
Subsidiaries to repurchase, redeem or otherwise acquire any capital stock of the PubCo Entities, including shares of PubCo Common Stock,
or capital stock of any Subsidiary of PubCo.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;There
are no voting trusts, proxies or similar agreements, arrangements or commitments to which the PubCo Entities or any of their respective
Subsidiaries is a party with respect to the voting of any shares of capital stock of any of the PubCo Entities or any of their respective
Subsidiaries. There are no bonds, debentures, notes or other instruments of indebtedness of the PubCo Entities or any of their respective
Subsidiaries that entitle the holder of such instruments of indebtedness to vote together with stockholders of the PubCo Entities on any
matters with respect to the PubCo Entities or any of their respective Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 75.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;Except
for the PubCo Equity Plans, PubCo does not have any stock option plan or any other plan, program, agreement or arrangement providing for
any equity-based compensation for any Person. <span style="text-decoration:underline">Section 4.06(g)</span> of the PubCo Disclosure Letter sets forth the following information
with respect to each PubCo Stock Option outstanding as of the date of this Agreement: (i) the name of the optionee; (ii) the number of
shares of PubCo Common Stock subject to such PubCo Stock Option at the time of grant; (iii) the number of shares of PubCo Common Stock
subject to such PubCo Stock Option as of the date of this Agreement; (iv) the exercise price of such PubCo Stock Option; (v) the date
on which such PubCo Stock Option was granted; (vi) the applicable vesting schedule, including the number of vested and unvested shares
as of the date of this Agreement and any acceleration provisions; (vii) the date on which such PubCo Stock Option expires; and (viii)
whether such PubCo Stock Option is intended to constitute an &#8220;incentive stock option&#8221; (as defined in the Code) or a non-qualified
stock option. PubCo has made available to the Company an accurate and complete copy of the PubCo Equity Plan and a form of stock option
agreement that is consistent in all material respects with the stock option agreements evidencing outstanding options granted thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 75.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
4.07 <span style="text-decoration:underline">Subsidiaries</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Section
4.07(a)</span> of the PubCo Disclosure Letter sets forth a complete and accurate list of each Subsidiary of PubCo. PubCo has made available
to the Company the organizational documents of each Subsidiary of the PubCo Entities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 70.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;All
of the issued and outstanding shares of capital stock of each Subsidiary of PubCo have been duly authorized and are validly issued, fully
paid, and non-assessable. Each of the Subsidiaries of PubCo is wholly owned by PubCo, directly or indirectly, free and clear of any Liens
(other than Permitted Liens) or restrictions on transfer (other than restrictions under applicable Law). Other than the Subsidiaries listed
in <span style="text-decoration:underline">Section 4.07(a)</span> of the PubCo Disclosure Letter or as set forth in <span style="text-decoration:underline">Section 4.07(b)</span> of the PubCo Disclosure Letter, PubCo
does not own, directly or indirectly, any equity, membership interest, partnership interest, joint venture interest, or other equity or
voting interest in, or any interest convertible into, exercisable or exchangeable for any of the foregoing, nor is it under any current
or prospective obligation to form or participate in, provide funds to, make any loan, capital contribution, guarantee, credit enhancement
or other investment in, or assume any liability or obligation of, any Person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Except
as set forth on <span style="text-decoration:underline">Section 4.07(c)</span> of the PubCo Disclosure Letter, neither PubCo nor any of its Subsidiaries is a party to, has any
commitment to become a party to, any joint venture, off balance sheet partnership or any similar Contract (including any Contract or arrangement
relating to any transaction or relationship between or among the PubCo Entities and their respective Subsidiaries, on the one hand, and
any unconsolidated Affiliate, including any structured finance, special purpose or limited purpose entity or Person, on the other hand,
or any &#8220;off balance sheet arrangements&#8221; (as defined in Item 303(a) of Regulation S-K under the Exchange Act)).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 416 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
4.08 <span style="text-decoration:underline">SEC Filings and the Sarbanes-Oxley Act</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;PubCo
has filed with or furnished to the SEC (subject to extensions pursuant to Exchange Act Rule 12b-25) each report, statement, schedule,
form, certification or other document (including exhibits and all other information incorporated therein) or filing required by applicable
Law to be filed with or furnished by PubCo to the SEC in a timely manner. PubCo has delivered to the Company accurate and complete copies
of all reports, statements (including registration and proxy statements), schedules, forms, certifications or other document (including
exhibits and all other information incorporated therein) filed by PubCo with the SEC since January 1, 2023 (the documents referred to
in this <span style="text-decoration:underline">Section 4.08(a)</span>, as they may have been supplemented, modified or amended since the initial filing date and together with
all exhibits thereto and information incorporated by reference therein, the &#8220;<span style="text-decoration:underline">PubCo SEC Reports</span>&#8221;), other than such documents
that can be obtained on the SEC&#8217;s website at www.sec.gov. No Subsidiary of PubCo is required to file or furnish any report, statement,
schedule, form, registration statement, proxy statement, certification or other document with, or make any other filing with, or furnish
any other material to, the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;As
of its filing date (or, if amended, supplemented, modified or superseded by a filing prior to the date of this Agreement, on the date
of such filing), each PubCo SEC Report complied, and each such PubCo SEC Report filed subsequent to the date of this Agreement and prior
to the Effective Time will comply in all material respects with the applicable requirements of the Securities Act, the Exchange Act and
the Sarbanes-Oxley Act and the rules and regulations of the SEC promulgated thereunder applicable to each such PubCo SEC Report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;As
of its filing date (or, if amended, supplemented, modified or superseded by another filing prior to the date of this Agreement, on the
date of such filing), each PubCo SEC Report filed on or prior to the date hereof did not, and each such PubCo SEC Report filed subsequent
to the date of this Agreement and prior to the Effective Time will not, contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances
under which they were made, not misleading. Each PubCo SEC Report that is a registration statement, as amended or supplemented, if applicable,
filed pursuant to the Securities Act, as of the date such registration statement, amendment or supplement became effective, did not, and
each such PubCo SEC Report filed subsequent to the date of this Agreement and prior to the Effective Time, as of the date such registration
statement, amendment or supplement becomes effective, will not, contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein not misleading.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;As
of the date of this Agreement, PubCo has not received, and there are no outstanding or unresolved comments in, any comment letters received
by PubCo from the SEC with respect to the PubCo SEC Reports and to PubCo&#8217;s Knowledge, none of the PubCo SEC Reports have been the
subject of any review of, or is the subject of any ongoing review by, the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;With
respect to each annual report on Form 10-K and each quarterly report on Form 10-Q (and any amendments to such Form 10-K or 10-Q) included
in the PubCo SEC Reports, the chief executive officer and chief financial officer of PubCo have made all certifications required by the
Sarbanes-Oxley Act and any related rules and regulations promulgated by the SEC (including certifications required by Rules 13a-14 and
15d-14 under the Exchange Act and Sections 302 and 906 of the Sarbanes-Oxley Act), and (i) the statements contained in any such certifications
were complete and correct and (ii) such certifications complied with the applicable provisions of the Sarbanes-Oxley Act, in each case,
in all material respects as of their respective dates. As of the date of this Agreement, PubCo has not received written notice from the
SEC challenging or questioning the accuracy, completeness, form or manner of filing of such certifications made with respect to the PubCo
SEC Reports filed prior to the date of this Agreement. PubCo is in compliance in all material respects with all current listing and corporate
governance requirements of Nasdaq and is in compliance in all material respects with all applicable provisions, rules, regulations and
requirements of the Sarbanes-Oxley Act. PubCo has not received any correspondence from any officials of Nasdaq or the staff thereof relating
to the delisting or maintenance of listing of the PubCo Common Stock on Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 417 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
4.09 <span style="text-decoration:underline">Financial Statements; Internal Controls</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;The
audited consolidated financial statements and unaudited consolidated interim financial statements of PubCo and its consolidated Subsidiaries
included in the PubCo SEC Reports:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)&#160;complied
in all material respects with applicable accounting requirements and the rules and regulations of the SEC;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)&#160;were
prepared in accordance with GAAP applied on a consistent basis (except as may be indicated in the notes to those financial statements);
and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 71.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 71.3pt">(iii)&#160;fairly
presented in all material respects the consolidated financial position of PubCo and its consolidated Subsidiaries as of the dates thereof
and their consolidated results of operations and cash flows for the periods then ended (subject, in the case of any unaudited interim
financial statements, to normal year-end adjustments and the absence of notes). PubCo maintains and since January 1, 2023, has maintained
disclosure controls and procedures required by Rule 13a-15 or Rule 15d-15 under the Exchange Act. Such disclosure controls and procedures
are reasonably designed and reasonably effective to ensure that all information (both financial and non-financial) relating to the PubCo
Entities and their respective Subsidiaries required to be disclosed in PubCo&#8217;s periodic reports under the Exchange Act is made known
to the PubCo&#8217;s principal executive officer and its principal financial officer by others within the PubCo Entities or any of their
respective Subsidiaries, and such disclosure controls and procedures are effective in timely alerting the PubCo&#8217;s principal executive
officer and its principal financial officer to such information required to be included in the PubCo&#8217;s periodic reports required
under the Exchange Act. PubCo maintains a system of &#8220;internal control over financial reporting&#8221; (as defined in Rules 13a-15(f)
and 15d-15(f) under the Exchange Act) reasonably sufficient (i) to provide reasonable assurance (A) that transactions are recorded as
necessary to permit preparation of financial statements in conformity with GAAP consistently applied, (B) that transactions are executed
only in accordance with the authorization of management, and (C) regarding prevention or timely detection of the unauthorized acquisition,
use or disposition of PubCo&#8217;s properties or assets that could have a material effect on the financial statements, and (ii) such
that all material information is accumulated and communicated to its management as appropriate to allow timely decisions regarding required
disclosure and to make the certifications required pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act. From January 1, 2023, until
the date of this Agreement, PubCo has disclosed to PubCo&#8217;s auditors and the audit committee of the PubCo Board and made available
to the Company prior to the date of this Agreement (i) all significant deficiencies and material weaknesses in the design or operation
of internal controls over financial reporting which are reasonably likely to adversely affect PubCo&#8217;s or any of its Subsidiaries&#8217;
ability to record, process, summarize and report financial information in any material respect, and (ii) any fraud, whether or not material,
that involves management or other employees who have a significant role in the PubCo internal controls, in each case, if any. From January
1, 2023, until the date of this Agreement, to the Knowledge of PubCo, neither PubCo nor any of its Subsidiaries has received any written
complaint, allegation, assertion or claim regarding the accounting or auditing practices, procedures, methodologies or methods of PubCo
or its Subsidiaries or their respective internal accounting controls.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;There
are no off-balance sheet arrangements to which the PubCo Entities or any of their respective Subsidiaries is a party of any type required
to be disclosed in the PubCo SEC Reports pursuant to Item 303(a)(4) of Regulation S-K promulgated under the Securities Act that have not
been so described in the PubCo SEC Reports.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71pt">(c)&#160;To
the Knowledge of PubCo, PubCo&#8217;s independent registered accounting firm has at all times since the date PubCo became subject to the
applicable provisions of the Sarbanes-Oxley Act been: (i) a registered public accounting firm (as defined in Section 2(a)(12) of the Sarbanes-Oxley
Act); (ii) &#8220;Independent&#8221; with respect to PubCo within the meaning of Regulation S-X under the Exchange Act; and (iii) in compliance
with subsections (g) through (l) of Section 10A of the Exchange Act and the rules and regulations promulgated by the SEC and the Public
Company Accounting Oversight Board thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;There
have been no formal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated
at the direction of the chief executive officer, chief financial officer, principal accounting officer or general counsel of PubCo, the
PubCo Board or any committee thereof, other than ordinary course audits or reviews of accounting policies and practices or internal controls
required by the Sarbanes-Oxley Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt"></p><div>

</div><!-- Field: Page; Sequence: 418 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(e)&#160;Each
director and executive officer of PubCo has filed with the SEC on a timely basis all statements required by Section 16(a) of the Exchange
Act and the rules and regulations promulgated thereunder. PubCo has not taken any action prohibited by Section 402 of the Sarbanes-Oxley
Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 4.10 <span style="text-decoration:underline">Undisclosed
Liabilities</span></b>. As of the date of this Agreement, except as set forth in <span style="text-decoration:underline">Section 4.10</span> of the PubCo Disclosure Letter and PubCo
SEC Reports, there are no Liabilities of the PubCo Entities or any of their respective Subsidiaries, individually or in the aggregate,
other than:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Liabilities
reflected or reserved against in the consolidated balance sheet of PubCo and its consolidated Subsidiaries as of the PubCo Balance Sheet
Date or the footnotes thereto set forth in the PubCo SEC Reports;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Liabilities
incurred since the PubCo Balance Sheet Date in the ordinary course of business (none of which is a Liability for tort, breach of contract
or environmental Liability);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Liabilities
incurred in connection with the Transactions or as permitted or contemplated expressly by this Agreement;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;Liabilities
incurred pursuant to PubCo Material Contracts binding on PubCo or any of its Subsidiaries (other than those resulting from any breach
or default under such PubCo Material Contract); and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;Liabilities
that would not, individually or in aggregate, reasonably be expected to be material to the PubCo Entities and their respective Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 4.11 <span style="text-decoration:underline">Absence
of Certain Changes</span></b>. Except as otherwise expressly contemplated or required by this Agreement, or as set forth in <span style="text-decoration:underline">Section 4.11</span>
of the PubCo Disclosure Letter, since the Balance Sheet Date to the date of this Agreement, (a) the business of PubCo and each of its
Subsidiaries has been conducted, in all material respects, in the ordinary course of business, (b) there has not been any PubCo Material
Adverse Effect, and (c) there has not been or occurred any event, condition, action or effect that, if taken during this period, would
constitute a breach of <span style="text-decoration:underline">Section 5.02</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 4.12 <span style="text-decoration:underline">Litigation</span></b>.
Except as set forth in <span style="text-decoration:underline">Section 4.12</span> of the PubCo Disclosure Letter, from the Balance Sheet Date through the date of this Agreement,
(a) there are no Legal Actions pending or, to the Knowledge of PubCo, threatened against the PubCo Entities or any of their respective
Subsidiaries or any of their assets or properties that would, individually or in the aggregate, reasonably be expected to be material
to the PubCo Entities and their respective Subsidiaries, and (b) there are no Orders outstanding against the PubCo Entities or any of
their respective Subsidiaries or any of their assets or properties that would, individually or in the aggregate, reasonably be expected
to be material to the PubCo Entities and their respective Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
4.13 <span style="text-decoration:underline">Material Contracts</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Section
4.13</span> of the PubCo Disclosure Letter sets forth a list of each of the following Contracts to which, as of the date of this Agreement,
the PubCo Entities or any of their respective Subsidiaries is a party (each, a &#8220;<span style="text-decoration:underline">PubCo Material Contract</span>&#8221;):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 81.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)&#160;any
&#8220;material contract&#8221; (as such term is defined in Item 601(b)(10) of Regulation S-K of the SEC as determined as of the date
of this Agreement, other than those agreements and arrangements described in Item 601(b)(10)(iii)) with respect to PubCo;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 81.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)&#160;each
Contract (A) not to (or otherwise restricting or limiting the ability of the PubCo Entities or any of their respective Subsidiaries to)
compete in any line of business or geographic area or (B) to restrict the ability of the PubCo Entities or any of their respective Subsidiaries
to conduct business in any geographic area;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 81.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 81.95pt"></p><div>

</div><!-- Field: Page; Sequence: 419 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 81.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii)&#160;each
Contract (other than any PubCo Benefit Plan) providing for or resulting in payments by the PubCo Entities or any of their respective Subsidiaries
that exceeded annual payments by a PubCo Entity or any of their Subsidiaries that exceed $250,000;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 81.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iv)&#160;all
Contracts granting to any Person an option or a first refusal, first offer or similar preferential right to purchase or acquire any material
PubCo Assets;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 81.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(v)&#160;all
material Contracts (A) for the granting or receiving of a license, sublicense or franchise (in each case, including any such Contracts
relating to any Intellectual Property) providing for or resulting in a payment in excess of $250,000 per year or (B) under which any Person
is obligated to pay or has the right to receive a royalty, license fee, franchise fee or similar payment in which it is reasonably expected
to pay or receive a royalty, license fee, franchise fee or similar payment in excess of $250,000, in each case of <span style="text-decoration:underline">clause (A)</span> and
<span style="text-decoration:underline">(B)</span>, other than agreements with employees, non-exclusive licenses granted to a PubCo Entity&#8217;s or its Subsidiaries&#8217;
customers, and non-exclusive licenses to commercially available, off-the-shelf Software that have been granted on standardized, generally
available terms;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 81.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vi)&#160;all
partnership, joint venture or other similar agreements or arrangements;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 81.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vii)&#160;any
agreement with any director, officer or stockholder of PubCo or any Subsidiary that is required to be described under Item 404 of Regulation
S-K of the SEC in the PubCo SEC Reports;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 81.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(viii)&#160;any
agreement relating to indebtedness for borrowed money or the deferred purchase price of property (in either case, whether incurred, assumed,
guaranteed or secured by any asset), except any such agreement with an aggregate outstanding principal amount not exceeding $1,000,000;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 81.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ix)&#160;any
agreement for the disposition or acquisition by the PubCo Entities or any of their respective Subsidiaries, with material obligations
of the PubCo Entities or any of their respective Subsidiaries (other than confidentiality obligations) remaining to be performed or material
Liabilities of the PubCo Entities or any of their respective Subsidiaries continuing after the date of this Agreement, of any material
business or any material amount of assets other than in the ordinary course of business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 81.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(x)&#160;any
agreement restricting or limiting the payment of dividends or the making of distributions to stockholders, including intercompany dividends
or distributions other than such restrictions or limitations that are required by applicable Law; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 81.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xi)&#160;all
material agreements with any Governmental Authority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;A
true and complete copy of each PubCo Material Contract (including any related amendments) entered into prior to the date of this Agreement
has been filed as an exhibit (by reference or otherwise) to a PubCo Annual Report on Form 10-K, or disclosed by PubCo in a subsequent
PubCo SEC Report or made available to the Company prior to the date of this Agreement. Each PubCo Material Contract is a valid and binding
agreement of PubCo or its applicable Subsidiary, except where the failure to be valid and binding would not, individually or in the aggregate,
reasonably be expected to have a PubCo Material Adverse Effect. Except as would not, be material to PubCo, (i) neither PubCo or such Subsidiary
nor, to the Knowledge of PubCo, any other party, is in breach of or default under any such PubCo Material Contract, (ii) as of the date
of this Agreement, there are no material disputes with respect to any such PubCo Material Contract, (iii) as of the date of this Agreement,
there are no material Liabilities incurred under PubCo Material Contracts binding on PubCo or any of its Subsidiaries that resulted from
the breach or failure to perform by the Company or any of its Subsidiaries, and (iv) as of the date of this Agreement, no party under
any PubCo Material Contract has given written notice of its intent to terminate or otherwise seek a material amendment to such PubCo Material
Contract.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 420 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
4.14 <span style="text-decoration:underline">Benefit Plans</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt">(a)&#160;<span style="text-decoration:underline">Section
4.14(a)</span> of the PubCo Disclosure Letter lists all material PubCo Benefit Plans. For purposes of this Agreement a &#8220;<span style="text-decoration:underline">PubCo Benefit
Plan</span>&#8221; is, whether or not written, (i) any &#8220;employee benefit plan&#8221; within the meaning of Section 3(3) of ERISA, (ii)
any compensation, stock purchase, stock option, equity or equity-based compensation, severance, employment, consulting, change-of-control,
bonus, incentive, deferred compensation and other employee benefit plan, agreement, program or policy, whether or not subject to ERISA,
(iii) any plan, agreement, program or policy providing vacation benefits, insurance (including any self-insured arrangements), medical,
dental, vision or prescription benefits, disability or sick leave benefits, life insurance, employee assistance program, workers&#8217;
compensation, supplemental unemployment benefits and post-employment or retirement benefits (including compensation, pension or insurance
benefits), or (iv) any loan to or for the benefit of an officer of any PubCo Entity or any of its Subsidiaries, in each case (A) under
which any current or former director, officer, employee or independent contractor of PubCo or any of its Subsidiaries has any right to
benefits, or (B) which are maintained, sponsored or contributed to by any PubCo Entity or any of its Subsidiaries or to which any PubCo
Entity or any of its Subsidiaries makes or is required to make contributions or with respect to which any PubCo Entity or any of its Subsidiaries
has any material Liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt">(b)&#160;With
respect to each material PubCo Benefit Plan, if applicable, PubCo has made available to the Company true and complete copies of (i) the
plan document and any amendments thereto and for any unwritten plan, a summary of the material terms, (ii) the most recent summary plan
description, (iii) the most recent annual report on Form 5500 (including all schedules), (iv) the most recent annual audited financial
statements, (v) if the PubCo Benefit Plan is intended to qualify under Section 401(a) of the Code, the most recent determination or opinion
letter received from the Internal Revenue Service, (vi) any related trust or funding agreements or insurance policies, and (vii) all material
non-routine correspondence with respect to any Parent Benefit Plan with a Governmental Authority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Neither
PubCo, nor any of its Subsidiaries nor any of their respective ERISA Affiliates maintains, sponsors, administers or contributes to (or
is required to sponsor, maintain, administer or contribute to), or has within the preceding six years maintained, sponsored or contributed
to, or has any Liability under or with respect to, (i) any employee benefit plan subject to Section 412 or Section 430 of the Code or
Title IV of ERISA, (ii) any multiemployer plan (as defined in Section 3(37) of ERISA and 4001(a)(3) of ERISA), (iii) any multiple employer
plan (within the meaning of Section 210 of ERISA or Section 413(c) of the Code) or that is or has been subject to Section 4063 or 4064
of ERISA, or (iv) any multiple employer welfare arrangement (as defined in Section 3(40)(A) of ERISA). Neither PubCo nor its Affiliates
have ever incurred any liability under Title IV of ERISA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;Each
PubCo Benefit Plan is in compliance in all material respects with all applicable requirements of ERISA, the Code and other applicable
Laws and has been administered in all material respects in accordance with its terms and such Laws. With respect to each PubCo Benefit
Plan that is intended to qualify under Section 401(a) of the Code, (i) such PubCo Benefit Plan has received a favorable determination
or opinion letter has been issued by the Internal Revenue Service with respect to such qualification, (ii) its related trust has been
determined to be exempt from taxation under Section 501(a) of the Code, and (iii) to the Knowledge of the PubCo, no event has occurred
since the date of such qualification or exemption that would reasonably be expected to adversely affect such qualification or exemption.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;Neither
PubCo nor any of its Subsidiaries has any current or projected Liability with respect to, and no PubCo Benefit Plan provides, health,
medical, life insurance or death benefits to current or former employees or other individual service providers of any PubCo Entity or
any of its Subsidiaries beyond their retirement or other termination of service, other than coverage mandated by COBRA or Section 4980B
of the Code, or any similar state group health plan continuation Law, the cost of which is fully paid by such current or former employees
or other individual service providers or their dependents. No PubCo Benefit Plan is maintained (or governed by the Laws) outside of the
United States or provides benefits to any service provider who is based or provides substantial services (in whole or in part) outside
of the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.3pt"></p><div>

</div><!-- Field: Page; Sequence: 421 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.3pt">(f)&#160;The
execution and delivery of this Agreement and the consummation of the Transactions will not (either alone or in combination with another
event) (i) result in any payment from any PubCo Entity or any of its Subsidiaries becoming due, or increase the amount of any compensation
due, to any current or former employee, director or independent contractor of any PubCo Entity or any of its Subsidiaries, (ii) increase
any benefits otherwise payable under any PubCo Benefit Plan, (iii) result in the acceleration of the time of payment, vesting of any compensation
or benefits or forgiveness of indebtedness with respect to any current or former employee, director or independent contractor of any PubCo
Entity or any of its Subsidiaries, (iv) result in any funding, through a grantor trust or otherwise, of any compensation or benefits to
any current or former employee, director or independent contractor of any PubCo Entity or any of its Subsidiaries under any PubCo Benefit
Plan, (v) cause any amount to fail to be deductible by reason of Section 280G of the Code or be characterized as an &#8220;excess parachute
payment&#8221; (as such term is defined in Section 280G(b)(1) of the Code), or (vi) result in any breach or violation of or default under
or limit PubCo&#8217;s, Merger Sub&#8217;s or the Company&#8217;s right to amend, modify or terminate any PubCo Benefit Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;Each
PubCo Benefit Plan is, and has been at all times since January 1, 2023, in compliance in all material respects with Section 409A of the
Code. No person is entitled to any gross-up, make-whole or other additional payment from any PubCo Entity or any of its Subsidiaries in
respect of any Tax (including taxes imposed under Section 4999 or 409A of the Code).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#160;Since
January 1, 2023, there have been no pending, or, to the Knowledge of PubCo, threatened, material claims, investigations, audits or litigation
against or involving any PubCo Benefit Plan, other than ordinary claims for benefits by participants and beneficiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#160;Each
PubCo Benefit Plan can be terminated at any time for any or no reason by PubCo and its Subsidiaries without any past, present or future
Liability or obligation to any PubCo Entity or any of its Subsidiaries (other than solely administrative expenses related to such termination).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
4.15</b></span> Labor Relations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(a)&#160;(i)
No employee of any PubCo Entity or any of its Subsidiaries is represented by a union or is covered by an effective or pending collective
bargaining agreement or similar labor agreement and, to the Knowledge of PubCo, no labor union, or similar employee group to organize
any employees, organizing efforts are currently being conducted, (ii) neither any PubCo Entity nor any of its respective Subsidiaries
is a party to, and is not currently negotiating any entry into, any collective bargaining agreement or other labor Contract, and (iii)
no strike, picket, work stoppage, work slowdown or other organized labor dispute exists in respect of any PubCo Entity or any of its respective
Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71pt">(b)&#160;Each
of the PubCo Entities and their respective Subsidiaries is, and has been since January 1, 2023, in compliance in all material respects
with all federal, state, local and foreign Laws regarding labor, employment and employment practices, including but not limited to all
Laws relating to: (i) the hiring, promotion, assignment and termination of employees (including but not limited to timing and usage of
employment applications, drug testing and pre-employment testing); (ii) discrimination; (iii) harassment; (iv) retaliation; (v) equal
employment opportunities; (vi) disability; (vii) labor relations; (viii) wages and hours; (ix) the FLSA; (x) hours of work; (xi) payment
of wages (including but not limited to the timing of payments, recordkeeping and reporting of wages to employees); (xii) immigration;
(xiii) workers&#8217; compensation; (xiv) employee benefits; (xv) background and credit checks; (xvi) working conditions; (xvii) occupational
safety and health; (xviii) family and medical leave; (xix) classification of employees; (xx) unfair competition/noncompetition; and (xxi)
any bargaining or other obligations under the National Labor Relations Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(c)&#160;Neither
PubCo nor any of its Subsidiaries has incurred any material Liability or obligation under the WARN Act that remains unsatisfied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.9pt">(d)&#160;Since
January 1, 2023, there are no material Legal Actions against PubCo or any of its Subsidiaries or, to PubCo&#8217;s Knowledge, investigations
pending or threatened related to any allegations of sexual harassment, discrimination or other misconduct against PubCo or any of its
respective current or former directors, officers or senior level management employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.3pt"></p><div>

</div><!-- Field: Page; Sequence: 422 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.3pt">(e)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to result in a PubCo Material Adverse Effect, there are no pending
or, to PubCo&#8217;s Knowledge, threatened claims, suits, actions or other legal proceeding against any PubCo Entity or any of its Subsidiaries
brought by or on behalf of any applicant for employment, any current or former employees or other individual service providers of any
PubCo Entity or any of its Subsidiaries, any current or former leased employee, intern, volunteer or &#8220;temp&#8221; of any PubCo Entity
or any of its Subsidiaries, or any person alleging to be a current or former employee, or any group or class of the foregoing, or any
Governmental Authority, alleging: (i) violation of any labor or employment Laws; (ii) breach of any collective bargaining agreement; (iii)
breach of any express or implied contract of employment; (iv) wrongful termination of employment; or (v) any other discriminatory, wrongful
or tortious conduct in connection with any employment relationship, including before the Equal Employment Opportunity Commission.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;Since
January 1, 2023 and to PubCo&#8217;s Knowledge, all individuals who perform or have performed services for any PubCo Entity or any of
its Subsidiaries have been properly classified under applicable Law in all material respects (i) as employees or individual independent
contractors, and (ii) for employees, as an &#8220;exempt&#8221; employee or a &#8220;non-exempt&#8221; employee (within the meaning of
the FLSA and state Law), and no such individual has been improperly included or excluded from any PubCo Benefit Plan, and neither PubCo
nor any of its Subsidiaries has notice of any pending or, to PubCo&#8217;s Knowledge, threatened inquiry or audit from any Governmental
Authority concerning any such classifications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
4.16 <span style="text-decoration:underline">Taxes</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.3pt">(a)&#160;(i)
All income and other material Tax Returns required to be filed by or with respect to the PubCo Entities and their respective Subsidiaries
have been timely filed (taking into account all applicable extensions), and all such Tax Returns are true, complete and correct in all
material respects, (ii) the PubCo Entities and their respective Subsidiaries have fully and timely paid (or have had paid on their behalf)
all material Taxes due and payable (whether or not shown to be due on any Tax Return) and have made adequate provision in accordance with
GAAP for all material Taxes not yet due and payable in the most recent financial statements contained in the PubCo SEC Reports, and (iii)
the PubCo Entities and their respective Subsidiaries have complied in all material respects with all applicable Laws relating to the withholding
and payment over to the appropriate Governmental Authority of all Taxes required to be withheld by the Company and its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;(i)
There are no outstanding agreements extending or waiving the statutory period of limitations applicable to any claim for, or the period
for the collection, assessment or reassessment of, any material Taxes due from the PubCo Entities and their respective Subsidiaries for
any taxable period and no request for any such waiver or extension is currently pending, (ii) no audit is presently in progress, pending
or threatened in writing with respect to any material Taxes due from or with respect to the PubCo Entities and their respective Subsidiaries,
(iii) no claim in writing has been made by any Governmental Authority in a jurisdiction where the PubCo Entities and their respective
Subsidiaries do not file Tax Returns that it is or may be subject to taxation by that jurisdiction, and (iv) all material deficiencies
for Taxes asserted or assessed in writing against the PubCo Entities or any of their respective Subsidiaries have been fully and timely
paid or properly reflected under GAAP in the most recent financial statements contained in the PubCo SEC Reports.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;There
are no Liens for Taxes upon the assets or properties of the PubCo Entities and their respective Subsidiaries, except for Permitted Liens.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;Neither
the PubCo Entities nor their respective Subsidiaries has participated in any listed transaction within the meaning of Treasury Regulations
Section 1.6011-4(b) (or any similar provision of state, local or non-U.S. Tax Law).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;The
PubCo has not been a &#8220;controlled corporation&#8221; or a &#8220;distributing corporation&#8221; in any distribution occurring during
the three-year period ending on the date hereof that was purported or intended to be governed by Section 355 of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(f)&#160;Neither
the PubCo Entities nor their respective Subsidiaries (i) is or has been a member of a group (other than a group the common parent of which
is a PubCo Entity) filing a consolidated, combined, affiliated, unitary or similar income Tax Return, or (ii) has any Liability for the
Taxes of any Person (other than any of the PubCo Entities and their respective Subsidiaries) under Treasury Regulation Section 1.1502-6
(or any similar provision of state, local, or foreign Law), as a transferee, successor, by Contract (other than pursuant to any ordinary
course Contract, the principal purpose of which does not relate to Taxes) or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 423 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;Neither
the PubCo Entities nor their respective Subsidiaries will be required to include any material item of income in, or exclude any material
item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of (i) any
change in, or use of improper, method of accounting adopted, requested or initiated at or prior to the Closing for a taxable period ending
on or prior to the Closing Date, (ii) any intercompany transaction or any excess loss account described in Treasury Regulations under
Section 1502 of the Code (or any similar provision of state, local or foreign income Tax law), (iii) any installment sale or open transaction
disposition made at or prior to the Closing, (iv) any item of deferred revenue, (v) any election under Section 965 of the Code, (vi) any
prepaid amounts received on or prior to the Closing Date, or (vii) any agreement entered into with any Governmental Authority with respect
to Taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#160;No
private letter rulings, technical advice memoranda or similar material agreements or rulings have been requested, entered into or issued
by any taxing authority with respect to the PubCo Entities or their respective Subsidiaries which rulings remain in effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#160;Neither
the PubCo Entities nor their respective Subsidiaries has been a United States real property holding corporation, as defined in Section
897(c)(2) of the Code during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(j)&#160;To
the Knowledge of the PubCo Entities and their respective Subsidiaries, each of the PubCo Entities and their respective Subsidiaries has
not been, is not, and immediately prior to the Effective Time will not be, treated as an &#8220;investment company&#8221; within the meaning
of Section 368(a)(2)(F) of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&#160;PubCo
is, and has been since its date of formation, a C corporation for U.S. federal income tax purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(l)&#160;Neither
the PubCo Entities nor any of their respective Subsidiaries has taken any action that could reasonably be expected to prevent the Merger
from qualifying for the Intended Tax Treatment. To the Knowledge of the PubCo Entities and their respective Subsidiaries, there are no
facts or circumstances, other than any facts and circumstances to the extent that such facts and circumstances exist or arise as a result
of or related to any act or omission occurring after the date of this Agreement of the Company or any of its Affiliates not contemplated
by this Agreement, that could reasonably be expected to prevent the Merger from qualifying for the Intended Tax Treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 4.17 <span style="text-decoration:underline">Environmental
Matters</span></b>. Except would not, individually or in the aggregate, reasonably be expected to have a PubCo Material Adverse Effect:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;PubCo
and its Subsidiaries comply and have complied with all applicable Environmental Laws, in all material respects;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;PubCo
and its Subsidiaries possess all material Permits required under Environmental Laws necessary for their respective operations as currently
conducted, and are in compliance with such Permits, which are, and through the Closing Date shall remain, in full force and effect;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(c)&#160;Neither
PubCo nor any Subsidiary has received any notice or request for information from any Governmental Authority or other Third Party related
to any actual or alleged Liability under Environmental Law, including any investigatory, remedial or corrective obligations or otherwise
pertaining to Hazardous Substances;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;To
the Knowledge of PubCo, no condition exists on any property owned or operated by PubCo and its Subsidiaries or any other location which
has given rise to, or would reasonably be expected to give rise to, any Liability relating to environmental or Hazardous Substances matters
or Environmental Laws; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(e)&#160;To
the Knowledge of PubCo, the Transactions do not require notice to, or approval from, any Governmental Authority under any Environmental
Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 424 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
4.18 <span style="text-decoration:underline">Intellectual Property</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(a)&#160;Each
of the PubCo Entities and their respective Subsidiaries owns, is licensed to use, pursuant to valid, enforceable and binding Contracts,
or otherwise has the right to use all Intellectual Property used, held for use or necessary for the operation of the business of the PubCo
Entities and their respective Subsidiaries (collectively, the &#8220;<span style="text-decoration:underline">PubCo Intellectual Property</span>&#8221;) free and clear of all
Liens (other than Permitted Liens), except as would not, individually or in the aggregate, reasonably be expected to have a PubCo Material
Adverse Effect. <span style="text-decoration:underline">Section 4.18(a)</span> of the PubCo Disclosure Letter sets forth a true and complete list of the following which are owned
or purported to be owned by any PubCo Entity or any of its Subsidiaries: (i) patents and patent applications, (ii) registered trademarks
and applications therefor, (iii) registered copyrights and applications therefor, and (iv) domain name registrations ((i) - (iv), the
&#8220;<span style="text-decoration:underline">PubCo Registered IP</span>&#8221;). Except as would not, individually or in the aggregate, reasonably be expected to have a PubCo
Material Adverse Effect, the execution, delivery and performance of this Agreement by the PubCo Entities and the consummation by PubCo
Entities of the Transactions do not and will not encumber, impair or extinguish any of the PubCo Intellectual Property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(b)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a PubCo Material Adverse Effect, none (i) of the PubCo
Intellectual Property owned or purported to be owned by any PubCo Entity or any of its Subsidiaries (&#8220;<span style="text-decoration:underline">PubCo Owned Intellectual
Property</span>&#8221;) (A) has been adjudged invalid or unenforceable in whole or in part, or (B) is the subject of any cancellation or
reexamination proceeding or any other proceeding challenging its ownership, use, registrability, validity and enforceability, and (ii)
to the Knowledge of PubCo, all PubCo Registered IP is subsisting, in full force and effect, and, to the Knowledge of PubCo, valid and
enforceable, and all renewal fees and other maintenance fees have been paid. There exist no material contractual restrictions on the disclosure,
use, license or transfer of any PubCo Owned Intellectual Property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 71.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(c)&#160;(i)
To the Knowledge of the PubCo Entities, the conduct of the business of the PubCo Entities and their respective Subsidiaries does not infringe
upon, misappropriate or otherwise violate, and has not, since January 1, 2023, infringed upon, misappropriated, or otherwise violated,
the Intellectual Property rights of any Third Party, (ii) no Legal Action is pending, asserted in writing, or to the Knowledge of PubCo,
threatened against any PubCo Entity or any of its Subsidiaries that the conduct of the business of any PubCo Entity or any of its Subsidiaries
infringes upon, misappropriates or otherwise violates the Intellectual Property rights of any Third Party, and (iii) to the Knowledge
of PubCo, no Person is infringing upon, misappropriating or otherwise violating, or has, since January 1, 2023, infringed upon, misappropriated,
or otherwise violated, any Intellectual Property owned by any PubCo Entity or any of its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(d)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a Company Material Adverse Effect, the PubCo Entities and
their respective Subsidiaries have taken reasonable steps in accordance with normal industry practice to maintain and protect the confidentiality
of all PubCo Intellectual Property s and the value of which is contingent upon maintaining the confidentiality thereof. Except as would
not, individually or in the aggregate, reasonably be expected to have a PubCo Material Adverse Effect, none of the PubCo Owned Intellectual
Property that is material to the business of the PubCo Entities and their respective Subsidiaries and the value of which is contingent
upon maintaining the confidentiality thereof, has been disclosed other than to Third Parties that are bound by customary, written confidentiality
agreements entered into in the ordinary course of business consistent with past practice and that are valid and enforceable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(e)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a PubCo Material Adverse Effect, all Persons who have contributed,
developed or conceived any PubCo Owned Intellectual Property have done so pursuant to a valid and enforceable Contract (subject to enforceability
exceptions for bankruptcy and insolvency and subject to principles of equity) that protects the confidential information of the PubCo
Entities and their respective Subsidiaries and assigns to PubCo (or one of its Subsidiaries, as applicable) exclusive ownership of the
Person&#8217;s contribution, development or conception, other than Intellectual Property excluded by Law or non-assignable moral rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 71.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 71.3pt"></p><div>

</div><!-- Field: Page; Sequence: 425 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 71.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(f)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a PubCo Material Adverse Effect, (i) PubCo and its Subsidiaries
have sufficient rights to use all of the IT Assets used or held for use in connection with the operation of the business of PubCo and
its Subsidiaries, (ii) in each case, the IT Assets operate and perform in all material respects in accordance with their documentation
and functional specifications and are sufficient or configurable to effectively perform all operations necessary for the current operation
of the business of PubCo and its Subsidiaries, and all IT Assets are owned or licensed under valid licenses and operated by and are under
the control of the Company and its Subsidiaries, (iii) the IT Assets have not materially malfunctioned or failed since January 1, 2023,
to the Knowledge of PubCo, do not contain any viruses, bugs, faults or other devices or effects that (A) enable or assist any Person to
access without authorization or disable or erase the IT Assets, or (B) otherwise materially adversely affect the functionality of the
IT Assets, (iv) PubCo and its Subsidiaries have taken commercially reasonable steps to provide for the remote-site back-up of data and
information critical to the conduct of the business of PubCo and its Subsidiaries and have in place commercially reasonable disaster recovery
and business continuity plans, procedures and facilities, (v) no Person has gained unauthorized access to any IT Assets since January
1, 2023, (vi) PubCo and its Subsidiaries have maintained, continue to maintain, and caused their vendors to maintain, safeguards, security
measures and procedures against the unauthorized access, disclosure, destruction, loss, or alteration of customer data or information
(including any personal or device-specific information) in its possession or control that comply with any applicable contractual and legal
requirements and meet industry standards, and (vii) PubCo and its Subsidiaries have in place with the third-party owners and operators
of all data centers which provide services related to the business of PubCo and its Subsidiaries written agreements that ensure that such
Third Parties adhere to and are in compliance with commercially reasonable standards and requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(g)&#160;Except
as set forth in <span style="text-decoration:underline">Section 4.18(g)</span> of the PubCo Disclosure Letter, each of the PubCo Entities is in compliance in all material respects
with all applicable Laws pertaining to (i) data security, cybersecurity, privacy, and (ii) the collection, storage, use, access, disclosure,
processing, security, and transfer of Personal Information, to the extent that it is subject to same. During the past two (2) years, no
claims have been asserted or, to the Knowledge of PubCo, threatened in writing against the PubCo Entities alleging a violation of any
Person&#8217;s privacy or Personal Information. Each of the PubCo Entities has taken commercially reasonable steps to protect the Personal
Information collected, used or held for use by the PubCo Entities against loss and unauthorized access, use, modification, disclosure
or other misuse.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(h)&#160;To
the Knowledge of PubCo, no government funding, facilities or resources of a university, college, other educational institution or research
center was used in the development of the PubCo Owned Intellectual Property, to the Knowledge of PubCo, exclusively licensed to the PubCo
Entities, and no Governmental Authority, university, college, other educational institution or research center has, to the knowledge of
PubCo, any claim or right in or to such Intellectual Property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
4.19 <span style="text-decoration:underline">Real Property; Personal Property</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(a)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a PubCo Material Adverse Effect, (i) the PubCo Entities
and their respective Subsidiaries have good and marketable title to, or have a valid and enforceable right to use or a valid and enforceable
leasehold interest in, all real property (including all buildings, fixtures and other improvements thereto) used by the business of the
PubCo Entities and their respective Subsidiaries (the &#8220;<span style="text-decoration:underline">PubCo Real Property</span>&#8221;), and (ii) the ownership of or leasehold
interest in any PubCo Real Property is not subject to any Lien (except in all cases for Permitted Liens). Except as would not, individually
or in the aggregate, reasonably be expected to have a PubCo Material Adverse Effect, neither PubCo nor any of its Subsidiaries has leased,
subleased, licensed, sublicensed or otherwise granted to any Person the right to use or occupy any PubCo Real Property or any portion
thereof, other than the right of the Company pursuant to this Agreement, there are no outstanding options, rights of first offer or rights
of first refusal to purchase any PubCo Real Property or any portion thereof or interest therein, and except for this Agreement, neither
the Company nor any of its Subsidiaries is a party to any Contract to sell, transfer, or encumber any PubCo Real Property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(b)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a PubCo Material Adverse Effect, each of the material leases,
subleases and other agreements under which the Company or any of its Subsidiaries use or occupy or have the right to use or occupy, now
or in the future, any material real property (the &#8220;<span style="text-decoration:underline">PubCo Real Property Leases</span>&#8221;) is valid, binding and in full force
and effect (except as may be limited by bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other similar laws
of general applicability relating to or affecting creditor&#8217;s rights, and to general equitable principles), and no termination event
or condition or uncured default on the part of the Company or its Subsidiaries exists under any PubCo Real Property Lease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 426 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(c)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a PubCo Material Adverse Effect, (i) the PubCo Entities
and their respective Subsidiaries have good and marketable title to, or a valid and enforceable leasehold interest in, all material PubCo
Assets, (ii) the Company Assets are in good working order (reasonable wear and tear excepted) and is suitable and adequate for the uses
for which it is intended or is being used, and (iii) none of PubCo&#8217;s or any of its Subsidiaries&#8217; ownership of or leasehold
interest in any such material PubCo Assets is subject to any Liens (except in all cases for Permitted Liens).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
4.20 <span style="text-decoration:underline">Permits; Compliance with Law</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(a)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a PubCo Material Adverse Effect, each of the PubCo Entities
and their respective Subsidiaries is in possession of all material Permits necessary for each of the PubCo Entities and their respective
Subsidiaries to own, lease and operate their respective properties and assets or to carry on their respective business as it is now being
conducted (collectively, the &#8220;<span style="text-decoration:underline">PubCo Permits</span>&#8221;). All such PubCo Permits are in full force and effect in all material
respects and no suspension or cancellation of any of the PubCo Permits is pending or, to the Knowledge of PubCo, has been threatened in
writing against any PubCo Entity or any of its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(b)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a PubCo Material Adverse Effect, each of the PubCo Entities
and their respective Subsidiaries has at all times since January 1, 2023 been in compliance in all material respects with (i) all Laws
applicable to PubCo or such Subsidiary or by which any of the PubCo Assets is bound, and (ii) all Laws applicable to, and the terms and
conditions of, any PubCo Permits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
4.21 <span style="text-decoration:underline">Regulatory Matters</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(a)&#160;Except
as would not, individually or in the aggregate, reasonably be expected to have a PubCo Material Adverse Effect, (i) the PubCo Entities
and their respective Subsidiaries currently conduct, and have at all times since January 1, 2023, conducted their respective business
in compliance in compliance with all Laws applicable to their respective operations, activities or services and any Orders to which they
are a party or are subject, including any settlement agreements or corporate integrity agreements, (ii) except for routine matters arising
in the ordinary course of business, none of any PubCo Entity or any of its Subsidiaries has received any written notice, citation, suspension,
revocation, limitation, warning, or request for repayment or refund issued by a Governmental Authority which alleges or asserts that any
PubCo Entity or any of its Subsidiaries has violated any Laws or which requires or seeks to adjust, modify or alter PubCo&#8217;s or any
of its Subsidiary&#8217;s operations, activities, services or financial condition that has not been fully and finally resolved to the
Governmental Authority&#8217;s satisfaction without further Liability to the PubCo Entities and their respective Subsidiaries, and (iii)
there are no restrictions imposed by any Governmental Authority upon PubCo&#8217;s or any of its Subsidiaries&#8217; business, activities
or services which would restrict or prevent any PubCo Entity or any of its Subsidiaries from operating as it currently operates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.1pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(b)&#160;As
of the date of this agreement and except as would not, individually or in the aggregate, reasonably be expected to have a PubCo Material
Adverse Effect, PubCo and each of its Subsidiaries, and to the Knowledge of PubCo, all of their respective directors, officers, agents
and employees, are in compliance in all material respects with, and the PubCo and each of its Subsidiaries have compliance programs including
policies and procedures reasonably designed to cause the PubCo Entities and their respective Subsidiaries and their respective directors,
officers, agents and employees to be in compliance in all material respects with, to the extent applicable, all Laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 4.22 <span style="text-decoration:underline">Takeover
Statutes</span></b>. The PubCo Board has taken all necessary action to ensure that the restrictions on business combinations that are set
forth in Section 203 of the Delaware General Corporation Law (DGCL), and any other similar Law applicable to PubCo, will not apply to
this Agreement, the Transactions, including by approving this Agreement, the Merger and the other Transactions. There is no stockholder
rights plan, &#8220;poison pill&#8221; anti-takeover plan or other similar plan, device or arrangement to which PubCo or any of its Subsidiaries
is a party or by which it or they are bound with respect to any capital stock of PubCo or any of its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 427 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 4.23 <span style="text-decoration:underline">Transactions
with Affiliates</span></b>. Except as disclosed in the PubCo SEC Reports, since PubCo&#8217;s last proxy statement, no event has occurred
that would be required to be reported by PubCo pursuant to Item 404 of Regulation S-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 4.24 <span style="text-decoration:underline">Insurance</span></b>.
The PubCo Entities and their respective Subsidiaries are covered by valid and currently effective insurance policies and all premiums
payable under such policies have been duly paid to date. None of the PubCo Entities or any of its Subsidiaries have received any written
notice of default or cancellation of any such policy. All material fire and casualty, general Liability, business interruption, product
Liability, and sprinkler and water damage insurance policies maintained by or on behalf of any PubCo Entity or any of its Subsidiaries
(&#8220;<span style="text-decoration:underline">PubCo Insurance Policies</span>&#8221;) provide adequate coverage for all normal risks incident to the business of the PubCo Entities
and their respective Subsidiaries and their respective properties and assets, except for any such failures to maintain PubCo Insurance
Policies that, individually or in the aggregate, are not reasonably be expected to have a PubCo Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 4.25 <span style="text-decoration:underline">Valid
Issuance</span></b>. The PubCo Common Stock to be issued in the Merger will, when issued in accordance with the provisions of this Agreement,
be validly issued, fully paid and nonassessable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 4.26 <span style="text-decoration:underline">Brokers</span></b>.
Except for the PubCo Financial Advisor, no broker, finder, adviser or investment banker, is entitled to any brokerage, success, finder&#8217;s
or other similar fee or commission in connection with the Transactions based upon arrangements made by or on behalf of any PubCo Entity
or any of its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
4.27 <span style="text-decoration:underline">No Other Representations or Warranties</span></b>. PubCo acknowledges and agrees that, except for the representations and warranties
of the Company set forth in <span style="text-decoration:underline">Article III</span> or in any certificate delivered by the Company to PubCo pursuant to this Agreement, neither
PubCo nor its Subsidiaries or their respective Affiliates or Representatives, is relying on any other representation or warranty of the
Company, any of its Affiliates or Representatives or any other Person made outside of <span style="text-decoration:underline">Article III</span> or such certificate, including
regarding the accuracy or completeness of any such other representations or warranties or the omission of any material information, whether
express or implied.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE V. COVENANTS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 5.01 <span style="text-decoration:underline">Conduct
of Business of the Company</span></b>. From and after the date of this Agreement and prior to the Effective Time or the date, if any, on
which this Agreement is earlier terminated pursuant to <span style="text-decoration:underline">Article VII</span>, except (i) as expressly contemplated or permitted by this Agreement,
(ii) as set forth in <span style="text-decoration:underline">Section 5.01</span> of the Company Disclosure Letter, (iii) as required by Law, or (iv) with the prior written consent
of PubCo (such consent not to be unreasonably withheld, conditioned or delayed), the Company shall, and shall cause each of its Subsidiaries
to, use commercially reasonable efforts to conduct its operations only in the ordinary course of business and in material compliance with
all applicable Law and the requirements of all Contracts that constitute Company Material Contracts. Without limiting the generality of
the foregoing, and except (i) as otherwise expressly contemplated or permitted by this Agreement, (ii) as set forth in <span style="text-decoration:underline">Section 5.01</span>
of the Company Disclosure Letter, (iii) as required by applicable Law, or (iv) with the prior written consent of PubCo (such consent not
to be unreasonably withheld, conditioned or delayed), from and after the date of this Agreement and prior to the Effective Time or the
date, if any, on which this Agreement is earlier terminated pursuant to <span style="text-decoration:underline">Article VII</span>, the Company shall not, and shall not permit
any of its Subsidiaries to, take any of the following actions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Organizational
Documents</span>. Amend any of the Company Organizational Documents or any of the comparable organizational documents of any of the Company&#8217;s
Subsidiaries (including partnership agreements and limited liability company agreements);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="text-decoration:underline">Dividends</span>.
Make, declare, accrue, set aside or pay any dividend or distribution on any of its shares;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;<span style="text-decoration:underline">Share
Capital</span>. (i) Adjust, split, combine or reclassify its share capital, (ii) redeem, purchase or otherwise acquire, directly or indirectly,
any of its shares or any securities convertible or exchangeable into or exercisable for any of its shares, (iii) issue, deliver or sell
to any employee of the Company any additional shares of the Company (or any Subsidiary thereof) or any securities convertible or exchangeable
into or exercisable for any shares of the Company (or any Subsidiary thereof) or such securities, or (iv) enter into any Contract with
respect to the voting or registration of its share capital;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 428 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;<span style="text-decoration:underline">Compensation
and Benefits</span>. Other than in the ordinary course of business, (i) materially increase the compensation or benefits payable or to become
payable to any employee, director or officer of the Company or any of its Subsidiaries, (ii) grant any severance or termination pay to
any current or new employees, director or officer of the Company or any of its Subsidiaries, (iii) renew or enter into or amend any employment
or severance agreement with any current or new employee, director or officer of the Company or any of its Subsidiaries, (iv) establish,
adopt, enter into, materially amend or terminate any Company Benefit Plan or any employee benefit plan, agreement, policy or program that,
if in effect on the date of this Agreement, would be a Company Benefit Plan, (v) enter into, terminate, amend or negotiate any collective
bargaining agreement or other agreement or Contract with any labor organization, works council, trade union, labor association or other
employee representative, (vi) implement any employee layoffs that could trigger any Liability or notice requirements under the WARN Act,
or (vii) take any action to accelerate the vesting, payment, or funding of any compensation or benefits to any current or former employee,
director or officer of the Company or any of its Subsidiaries, except, in each case, pursuant to the terms of any Company Benefit Plan
in effect on the date of this Agreement that has been made available to PubCo as of the date hereof;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;<span style="text-decoration:underline">Insurance</span>.
Terminate or modify in any material respect, or fail to exercise renewal rights with respect to, any material insurance policy;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;<span style="text-decoration:underline">Dispositions</span>.
Sell, lease, license, transfer, pledge, encumber, grant or dispose of any Company Assets, including any Intellectual Property rights and
the share capital of Subsidiaries of the Company, that are material to the Company and its Subsidiaries, taken as a whole other than (A)
in connection with products or services offered or provided in the ordinary course of business, (B) the disposition of used, obsolete
or excess equipment in the ordinary course of business, or (C) expirations of Company Registered IP in accordance with the applicable
statutory term, grants of non-exclusive licenses of PubCo Owned Intellectual Property, or dispositions of non-material Company Owned Intellectual
Property, in each case in the ordinary course of business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;<span style="text-decoration:underline">Acquisitions</span>.
Acquire, by merger, consolidation, acquisition of equity interests or assets, or otherwise, any business, any material assets or properties,
or any corporation, partnership, limited liability company, joint venture or other business organization or division thereof, if the consideration
paid by the Company in connection with any such acquisition individually, or all such acquisitions in the aggregate, would exceed $250,000;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#160;<span style="text-decoration:underline">Contracts</span>.
(i) Enter into any Contract which if in effect as of the date of this Agreement would be a Company Material Contract or Company Real Property
Lease, (ii) enter into any Contract that would limit or otherwise restrict the Company or any of its Subsidiaries or any of their successors,
or that would, after the Effective Time, from engaging or competing in any line of business or in any geographic area in any material
respect, or (iii) terminate, cancel, request any material change in, materially amend or waive any material rights under any Company Material
Contract or Company Real Property Lease other than the expiration of any Company Material Contract or Company Real Property Lease in accordance
with its terms in the ordinary course of business (unless such action would otherwise be prohibited under another subsection of this <span style="text-decoration:underline">Section
5.01</span>), or terminate, amend or waive any provisions of any confidentiality or standstill agreements in place with any Third Parties;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#160;<span style="text-decoration:underline">Indebtedness;
Guarantees</span>. Incur, assume or guarantee any indebtedness for borrowed money in excess of $1,000,000, other than: (i) pursuant to any
indebtedness instrument outstanding as of the date of this Agreement and made available to PubCo, (ii) pursuant to promissory notes issued
in connection with any acquisition by the Company, which is made pursuant to the terms set forth in <span style="text-decoration:underline">Section 5.01(g)</span>, provided that
the indebtedness under any such promissory note taken individually, and all such promissory notes in the aggregate, does not exceed $250,000,
(iii) in connection with interest rate hedges on terms in the ordinary course of business consistent with past practice, or (iv) pursuant
to any letters of credit that the Company enters into in the ordinary course of its business;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 429 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#160;<span style="text-decoration:underline">Loans</span>.
(i) Make or forgive any loans, advances or capital contributions to (other than business advances in the ordinary course of business),
or investments in, any other Person (including any of its executive officers, directors, employees, agents or consultants), other than
by the Company or a wholly owned Subsidiary of the Company to, or in, the Company or any of its wholly owned Subsidiaries in the ordinary
course of business, or (ii) make any material change in its existing borrowing or lending arrangements for or on behalf of such Persons;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k) <span style="text-decoration:underline">Tax</span>. Other than in the ordinary course of business: make
or change or rescind any material Tax election, file any material amended Tax Return, change or adopt any material method of Tax accounting,
settle any material Tax claim or assessment, surrender in writing any right to claim a material refund of Taxes, consent to (or request)
any extensions or waiver of the limitation period applicable to any material Tax claim or assessment, enter into any &#8220;closing agreement&#8221;
within the meaning of Section 7121 of the Code (or any similar provision of state, local, or non-U.S. Law) or any voluntary disclosure
agreement with any Governmental Authority, in each case, with respect to a material amount of Taxes, incur any Taxes outside of the ordinary
course of business, or take any action, or knowingly fail to take any action, where such action or failure to act could reasonably be
expected to prevent the Merger from qualifying as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code and
the Treasury Regulations;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&#160;<span style="text-decoration:underline">Legal
Actions</span>. Commence, initiate, waive, release, assign, settle or compromise any Legal Action, or enter into any settlement agreement
or other understanding or agreement with any Governmental Authority (other than in the case of this clause, entry into commercial agreements
not relating to a dispute with such Governmental Authority in the ordinary course of business), relating to the Company or any of its
Subsidiaries, other than any such waiver, release, assignment, settlement or compromise with a Person that is not a Governmental Authority
that is limited only to the payment of money or other form of value that, collectively in respect of such waiver, release, assignment,
settlement or compromise, is not in excess of $1,000,000 individually or $3,000,000 in the aggregate;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)&#160;<span style="text-decoration:underline">Accounting</span>.
Materially change its accounting policies or procedures or any of its methods of reporting income, deductions or other items for material
accounting purposes or revalue any of its material assets other than as required by changes in GAAP or applicable Law after the date hereof;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)&#160;<span style="text-decoration:underline">Affiliate
Transactions</span>. Enter into or amend any arrangement or Contract with any Affiliate, director, officer or shareholder of the Company
that would reasonably be expected to materially delay or prevent the consummation of the Transactions;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o)&#160;<span style="text-decoration:underline">Inhibiting
Transactions</span>. Take any action that would reasonably be expected to result in any of the conditions to the Transactions set forth in
<span style="text-decoration:underline">Article VI</span> of this Agreement not being satisfied or satisfaction of those conditions being materially delayed; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(p)&#160;<span style="text-decoration:underline">Related
Actions</span>. Agree in writing or otherwise enter into a binding agreement to do any of the foregoing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Nothing contained in this Agreement shall
give PubCo, directly or indirectly, the right to control or direct the operations of the Company prior to the Effective Time. Prior to
the Effective Time, the Company shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control
and supervision over its business operations. Notwithstanding anything to the contrary set forth in this Agreement, no consent of the
PubCo shall be required with respect to any matter set forth in this <span style="text-decoration:underline">Section&#160;5.01</span> or elsewhere in this Agreement to the extent
that the requirement of such consent could violate any applicable Laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 430 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 5.02 <span style="text-decoration:underline">Conduct
of Business of PubCo</span></b>. From and after the date of this Agreement and prior to the Effective Time or the date, if any, on which
this Agreement is earlier terminated pursuant to <span style="text-decoration:underline">Article VII</span>, except (i) as expressly contemplated or permitted by this Agreement,
(ii) as set forth in <span style="text-decoration:underline">Section&#160;5.02</span> of the PubCo Disclosure Letter, (iii) as required by Law, or (iv) with the prior written
consent of the Company (such consent not to be unreasonably withheld, conditioned or delayed), PubCo shall, and shall cause each of its
Subsidiaries to, use commercially reasonable efforts to conduct its operations only in the ordinary course of business and in material
compliance with all applicable Law and the requirements of all Contracts that constitute PubCo Material Contracts. Without limiting the
generality of the foregoing, and except (i) as otherwise expressly contemplated or permitted by this Agreement, (ii) as set forth in <span style="text-decoration:underline">Section&#160;5.02</span>
of the PubCo Disclosure Letter, (iii) as required by applicable Law, or (iv) with the prior written consent of PubCo (such consent not
to be unreasonably withheld conditioned or delayed), from and after the date of this Agreement and prior to the Effective Time or the
date, if any, on which this Agreement is earlier terminated pursuant to <span style="text-decoration:underline">Article VII</span>, PubCo shall not, and shall not permit any
of its Subsidiaries to, take any of the following actions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">Organizational
Documents</span>. Amend any of the PubCo Organizational Documents or any of the comparable organizational documents of any of PubCo&#8217;s
Subsidiaries (including partnership agreements and limited liability company agreements); <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that immediately
prior to the Effective Time, PubCo shall be permitted to amend its certificate of incorporation pursuant to <span style="text-decoration:underline">Section&#160;1.05(b)</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="text-decoration:underline">Dividends</span>.
Make, declare, accrue, set aside or pay any dividend or distribution on any shares of its capital stock;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;<span style="text-decoration:underline">Capital
Stock</span>. Other than with respect to the Reverse Stock Split, (i) adjust, split, combine or reclassify its capital stock, (ii) redeem,
purchase or otherwise acquire, directly or indirectly, any shares of its capital stock or any securities convertible or exchangeable into
or exercisable for any shares of its capital stock, (iii) issue, deliver or sell to any PubCo Employee any additional shares of its capital
stock or any securities convertible or exchangeable into or exercisable for any shares of its capital stock or such securities (other
than pursuant to the exercise of PubCo Stock Options outstanding as of the date of this Agreement and in accordance with their terms),
or (iv) enter into any Contract with respect to the sale, voting, registration or repurchase of its capital stock;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;<span style="text-decoration:underline">Compensation
and Benefits</span>. (i) Materially increase the compensation or benefits payable or to become payable to any current or new PubCo Employee
or any directors or officers, (ii) grant any severance or termination pay to any PubCo Employee or any directors or officers, (iii) renew
or enter into or amend any employment or severance agreement with any PubCo Employee or any directors or officers, (iv) establish, adopt,
enter into, materially amend or terminate any PubCo Benefit Plan or any employee benefit plan, agreement, policy or program that, if in
effect on the date of this Agreement, would be a PubCo Benefit Plan, (v) enter into, terminate, amend or negotiate any collective bargaining
agreement or other agreement or Contract with any labor organization, works council, trade union, labor association or other employee
representative, (vi) implement any employee layoffs that could trigger any Liability or notice requirements under the WARN Act, or (vii)
take any action to accelerate the vesting, payment, or funding of any compensation or benefits to any current or former PubCo Employee
or any directors or officers, except, in each case, to the extent required by applicable Law, this Agreement or in terms of any PubCo
Benefit Plan in effect on the date of this Agreement that has been made available to the Company as of the date hereof;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;<span style="text-decoration:underline">Insurance</span>.
Other than for the avoidance of doubt, obtaining &#8220;tail&#8221; insurance coverage in connection with Closing, terminate or modify
in any material respect, or fail to exercise renewal rights with respect to, any material insurance policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;<span style="text-decoration:underline">Dispositions</span>.
Except as the Parties may otherwise agree, sell, lease, license, transfer, pledge, encumber, grant or dispose of any PubCo Assets, including
any Intellectual Property rights, the capital stock of Subsidiaries of PubCo, that are material to the PubCo Entities and their respective
Subsidiaries, taken as a whole other than (A) in connection with products or services offered or provided in the ordinary course of business,
(B) the disposition of used, obsolete or excess equipment in the ordinary course of business, or (C) expirations of PubCo Registered IP
in accordance with the applicable statutory term, grants of non-exclusive licenses of PubCo Owned Intellectual Property, or dispositions
of non-material Company Owned Intellectual Property, in each case in the ordinary course of business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;<span style="text-decoration:underline">Acquisitions</span>.
Acquire, by merger, consolidation, acquisition of equity interests or assets, or otherwise, any business, any material assets or properties,
or any corporation, partnership, limited liability company, joint venture or other business organization or division thereof, if the consideration
paid by the PubCo Entities in connection with any such acquisition individually, or all such acquisitions in the aggregate, would exceed
$250,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 431 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h) <span style="text-decoration:underline">Contracts</span>. (i) Enter
into any Contract which if in effect as of the date of this Agreement would be a PubCo Material Contract or PubCo Real Property Lease,
other than in the ordinary course of business (unless such Contract would otherwise be prohibited under another subsection of this <span style="text-decoration:underline">Section
5.02</span>), (ii) enter into any Contract that would limit or otherwise restrict PubCo or any of its Subsidiaries or any of their successors,
or that would, after the Effective Time, from engaging or competing in any line of business or in any geographic area in any material
respect, or (iii) terminate, cancel, request any material change in, materially amend or waive any material rights under any PubCo Material
Contract or PubCo Real Property Lease other than the expiration of any PubCo Material Contract or PubCo Real Property Lease in accordance
with its terms in the ordinary course of business (unless such action would otherwise be prohibited under another subsection of this <span style="text-decoration:underline">Section
5.02</span>), or terminate, amend or waive any provisions of any confidentiality or standstill agreements in place with any Third Parties;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="-keep: true">(i) <span style="text-decoration:underline">Indebtedness; Guarantees</span>.
Incur, assume or guarantee any indebtedness for borrowed money, other than (i) pursuant to any indebtedness instrument outstanding as
of the date of this Agreement and made available to the Company, and (ii) pursuant to promissory notes issued in connection with any
acquisition by the PubCo Entities, which is made pursuant to the terms set forth in <span style="text-decoration:underline">Section 5.02(g)</span>, provided that the indebtedness
under any such promissory note taken individually, and all such promissory notes in the aggregate, does not exceed $250,000;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="-keep: true">(j) <span style="text-decoration:underline">Loans</span>. (i) Make
or forgive any loans, advances or capital contributions to (other than business advances in the ordinary course of business), or investments
in, any other Person (including any of its executive officers, directors, employees, agents or consultants), other than by PubCo or a
wholly owned Subsidiary of PubCo to, or in, PubCo or any of its wholly owned Subsidiaries in the ordinary course of business, or (ii)
make any material change in its existing borrowing or lending arrangements for or on behalf of such Persons;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="-keep: true">(k) <span style="text-decoration:underline">Tax</span>. Other than
in the ordinary course of business: make or change or rescind any material Tax election, file any material amended Tax Return, change
or adopt any material method of Tax accounting, settle any material Tax claim or assessment, surrender in writing any right to claim
a material refund of Taxes, consent to (or request) any extensions or waiver of the limitation period applicable to any material Tax
claim or assessment, enter into any &#8220;closing agreement&#8221; within the meaning of Section 7121 of the Code (or any similar provision
of state, local, or non-U.S. Law) or any voluntary disclosure agreement with any Governmental Authority, in each case, with respect to
a material amount of Taxes, incur any Taxes outside of the ordinary course of business, or take any action, or knowingly fail to take
any action, where such action or failure to act could reasonably be expected to prevent the Merger from qualifying as a &#8220;reorganization&#8221;
within the meaning of Section 368(a) of the Code and the Treasury Regulations;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l) <span style="text-decoration:underline">Accounting</span>. Materially
change its accounting policies or procedures or any of its methods of reporting income, deductions or other items for material accounting
purposes or revalue any of its material assets other than as required by changes in GAAP or applicable Law after the date hereof;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m) <span style="text-decoration:underline">Legal Actions</span>. Commence,
initiate, waive, release, assign, settle or compromise any Legal Action, or enter into any settlement agreement or other understanding
or agreement with any Governmental Authority (other than in the case of this clause, entry into commercial agreements not relating to
a dispute with such Governmental Authority in the ordinary course of business), relating to PubCo or any of its Subsidiaries, other than
any such waiver, release, assignment, settlement or compromise with a Person that is not a Governmental Authority that is limited only
to the payment of money or other form of value that, collectively in respect of such waiver, release, assignment, settlement or compromise,
is not in excess of $500,000 individually or $1,000,000 in the aggregate;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n) <span style="text-decoration:underline">Affiliate Transactions</span>.
Enter into or amend any arrangement or Contract with any Affiliate, director, officer or stockholder of PubCo that would reasonably be
expected to materially delay or prevent the consummation of the Transactions or that would be required to be described under Item 404
of Regulation S-K of the SEC;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o) <span style="text-decoration:underline">Inhibiting Transactions</span>.
Take any action that would reasonably be expected to result in any of the conditions to the Transactions set forth in <span style="text-decoration:underline">Article VI</span>
of this Agreement not being satisfied or satisfaction of those conditions being materially delayed; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(p) <span style="text-decoration:underline">Related Actions</span>.
Agree in writing or otherwise enter into a binding agreement to do any of the foregoing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Nothing contained in this Agreement
shall give the Company, directly or indirectly, the right to control or direct the operations of PubCo prior to the Effective Time. Prior
to the Effective Time, PubCo shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and
supervision over its business operations. Notwithstanding anything to the contrary set forth in this Agreement, no consent of the Company
shall be required with respect to any matter set forth in this <span style="text-decoration:underline">Section 5.02</span> or elsewhere in this Agreement to the extent that the
requirement of such consent could violate any applicable Laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 432 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
5.03 <span style="text-decoration:underline">Access to Information; Confidentiality</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-size: 10pt">(a)&#160;From
the date of this Agreement through the Effective Time (or if earlier, the date on which this Agreement is terminated pursuant to <span style="text-decoration:underline">Article
VII</span>), the Company shall, and shall cause its Subsidiaries to use commercially reasonable efforts to, upon reasonable notice, (i)
provide to PubCo and its Representatives reasonable access during normal business hours to the officers, employees, properties, books,
records, work papers and other documents and information relating to the Company and its Subsidiaries, (ii) furnish promptly such information,
including copies of books, records, work papers, Tax Returns and other documents and information relating to the Company and its Subsidiaries,
as PubCo or its Representatives may reasonably request, (iii) permit PubCo&#8217;s officers and other employees to meet, upon reasonable
notice and during normal business hours, with the chief financial officer and other officers and managers of the Company that are responsible
for the Company&#8217;s financial statements and internal controls to discuss such matters as the other party may reasonably request,
and (iv) make available to PubCo copies of any material notice, report or other document filed with or sent to or received from any Governmental
Authority in connection with the Transactions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;From
the date of this Agreement through the Effective Time (or if earlier, the date on which this Agreement is terminated pursuant to <span style="text-decoration:underline">Article
VII</span>), PubCo shall, and shall cause its Subsidiaries to use commercially reasonable efforts to, upon reasonable notice, (i) provide
to the Company and its Representatives reasonable access during normal business hours to the officers, employees, properties, books, records,
work papers and other documents and information relating to PubCo and its Subsidiaries, (ii) furnish promptly such information, including
copies of books, records, work papers, Tax Returns and other documents and information relating to PubCo and its Subsidiaries, as the
Company or its Representatives may reasonably request, (iii) permit the Company&#8217;s officers and other employees to meet, upon reasonable
notice and during normal business hours, with the chief financial officer and other officers and managers of PubCo that are responsible
for PubCo&#8217;s financial statements and internal controls to discuss such matters as the other party may reasonably request, and (iv)
make available to the Company copies of any material notice, report or other document filed with or sent to or received from any Governmental
Authority in connection with the Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;Notwithstanding
the foregoing, neither PubCo nor the Company shall be required to provide such access if it reasonably determines that it would (i) materially
disrupt or impair the business or operations of PubCo or the Company, as applicable, or any of their respective Subsidiaries, or (ii)
constitute a violation of any applicable Law. Nothing herein shall require the Company or PubCo or any of their respective Subsidiaries
to disclose information to the extent such information would result in a waiver of attorney-client privilege, work product doctrine or
similar privilege or violate any confidentiality obligation of such Party existing as of the date of this Agreement (provided that such
Party shall use reasonable best efforts to permit such disclosure to be made in a manner consistent with the protection of such privilege
or to obtain any consent required to permit such disclosure to be made without violation of such confidentiality obligations, as applicable).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;PubCo
and the Company shall comply with and shall use their reasonable best efforts to cause their respective Representatives to comply with,
all of their respective obligations under the Confidentiality Agreement, with respect to the information disclosed under this <span style="text-decoration:underline">Section
5.03</span>. The Company acknowledges that the information provided to it is subject to the terms of the Confidentiality Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
5.04 <span style="text-decoration:underline">No Solicitation</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">No
Solicitation or Facilitation of Proposals</span>. Except as permitted by this <span style="text-decoration:underline">Section&#160;5.04</span>, at any time prior to the Specified
Time, neither PubCo, PubCo&#8217;s Subsidiaries, the Company, or the Company&#8217;s Subsidiaries shall, and PubCo and the Company shall
instruct and use reasonable best efforts to cause its Representatives not to, and shall not authorize or knowingly permit any of its Representatives
to, directly or indirectly:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#160;solicit,
initiate or propose the making, submission or announcement of, or knowingly encourage, facilitate or assist, any proposal or offer that
constitutes, or could reasonably be expected to lead to, any Takeover Proposal;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 433 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&#160;terminate,
waive, amend or modify any provision of any existing confidentiality, standstill or similar agreement with respect to a potential Takeover
Proposal;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&#160;enter
into any letter of intent, memorandum of understanding, agreement in principle, acquisition agreement, merger agreement or similar agreement
(an &#8220;<span style="text-decoration:underline">Alternative Acquisition Agreement</span>&#8221;) providing for the consummation of a transaction contemplated by any Takeover
Proposal (other than a confidentiality agreement referred to in this <span style="text-decoration:underline">Section 5.04(a)</span> entered into in the circumstances referred
to in this <span style="text-decoration:underline">Section 5.04(a)</span>);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)&#160;take
any action that would reasonably be expected to lead to Takeover Proposal;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)&#160;other
than informing Persons of the existence of the provisions of this <span style="text-decoration:underline">Section&#160;5.04</span>, enter into, continue or otherwise participate
in any discussions or negotiations regarding, or furnish to any Person any non-public information of such Party for the purpose of encouraging,
facilitating or responding to, any Takeover Proposal or any proposal or inquiry that is reasonably expected to lead to a Takeover Proposal;
and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vi)&#160;publicly
propose to do any of the foregoing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">Notwithstanding the foregoing
or anything to the contrary set forth in this Agreement and subject to compliance with this <span style="text-decoration:underline">Section 5.04</span>, prior to the Specified
Time, a Party may, in response to an unsolicited bona fide written Takeover Proposal from a Qualified Person, (A) furnish non-public information
with respect to such Party and its Subsidiaries to such Qualified Person (and the Representatives of such Qualified Person), pursuant
to a confidentiality agreement not materially less restrictive with respect to the obligations (including confidentiality obligations,
use restrictions, non-solicit provisions, no hire provisions and standstill provisions) of such Qualified Person than the Confidentiality
Agreement, <span style="text-decoration:underline">provided</span> that such confidentiality agreement shall not (x) grant any exclusive right to negotiate with such counterparty,
(y) prohibit such Party from satisfying its obligations hereunder, or (z) require the such Party to pay or reimburse the counterparty&#8217;s
fees, costs or expenses, (B) engage in discussions or negotiations (including solicitation of revised Takeover Proposals) with any such
Qualified Person (and the Representatives of such Qualified Person) regarding any Takeover Proposal, and (C) amend, or grant a waiver
or release under, any standstill or similar agreement with respect to any PubCo Common Stock or any Company Ordinary Shares, as applicable,
with any Qualified Person; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that (A) the board of directors of such Party has determined in good faith
based on the advice of outside legal counsel, that the failure to take the actions contemplated by this sentence would be reasonably likely
to result in a breach of the fiduciary duties of the such Party&#8217;s board of directors under applicable Law, (B) neither such applicable
Party nor its Representative has breached this <span style="text-decoration:underline">Section 5.04</span>, (C) at least two Business Days prior to furnishing any such non-public
information to, or entering into discussions with, any such Qualified Person, such Party gives the other Party written notice of the identity
of such Qualified Person (unless, in the case of clause (iv), such disclosure is prohibited pursuant to the terms of any confidentiality
agreement with such Person that is in effect on the date of this Agreement) and of such Party&#8217;s intention to furnish non-public
information to, or enter into discussions with, such Qualified Person, (D) substantially contemporaneously with furnishing any non-public
information to any such Qualified Person, such Party furnishes such non-public information to the other Party (to the extent such information
has not been previously furnished by such Party to the other Party), and (E) notwithstanding anything to the contrary set forth in this
Agreement, such Party shall continue to observe its obligations under the Confidentiality Agreement including not furnishing any such
Qualified Person with any confidential information of the other Party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="text-decoration:underline">Notice</span>.
PubCo or the Company, as applicable, shall promptly (and in any event within 24 hours) advise the other Party orally, with written confirmation
to promptly follow, of: (i) such Party&#8217;s receipt of any written or oral Takeover Proposal; (ii) a summary of the material terms
and conditions of any such Takeover Proposal; (iii) a copy of the Alternative Acquisition Agreement and other material written proposals
or offers delivered with, or in connection with, such Takeover Proposal; and (iv) the identity of the Person making any such Takeover
Proposal (unless, in the case of clause (iv), such disclosure is prohibited pursuant to the terms of any confidentiality agreement with
such Person that is in effect on the date of this Agreement). Such Party shall keep the other Party reasonably informed in all material
respects of any material developments with respect to any Takeover Proposal (and any subsequent amendments or modifications or proposed
amendments or modifications thereto), in each case, as soon as is reasonably practicable and in any event within 24 hours of receipt,
provision or occurrence thereof. Such Party shall keep the other Party reasonably informed with respect to the status and terms of any
such Takeover Proposal and any material modification or material proposed modification thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;<span style="text-decoration:underline">No
Change in Recommendation or Alternative Acquisition Agreement</span>. At any time prior to the Specified Time:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#160;the
board of directors of either Party shall not, except as permitted in this <span style="text-decoration:underline">Section&#160;5.04</span>, withhold, withdraw, qualify or modify,
or and publicly propose to withhold, amend, withdraw or modify, the PubCo Board Recommendation or the Company Board Recommendation, as
applicable, in a manner adverse to the other Party;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46pt; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 434 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&#160;the
PubCo Board shall include the PubCo Board Recommendation in the PubCo Registration Statement and the Proxy Statement;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.95pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&#160;the
PubCo Board (or any committee thereof) shall not make or fail to make any recommendation or public statement in connection with a tender
or exchange offer, other than a recommendation against such offer or a &#8220;stop, look and listen&#8221; communication by the PubCo
Board (or a committee thereof) to the PubCo Stockholders pursuant to Rule 14d-9(f) promulgated under the Exchange Act (or any substantially
similar communication) (it being understood that the PubCo Board (or a committee thereof) may refrain from taking a position with respect
to a Takeover Proposal until the close of business on the 10<sup>th</sup> Business Day after the commencement of a tender or exchange
offer in connection with such Takeover Proposal without such action being considered a violation of this <span style="text-decoration:underline">Section 5.04(c)</span> or a PubCo
Adverse Recommendation Change); and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)&#160;the
board of directors of either Party shall not, except as set forth in this <span style="text-decoration:underline">Section 5.04</span>, adopt, approve, endorse or recommend, or
publicly announce an intention to adopt, approve, endorse or recommend, any Takeover Proposal or any proposal that is reasonably expected
to lead to a Takeover Proposal (any action described in clauses (i) through (iv), in the case of PubCo, a &#8220;<span style="text-decoration:underline">PubCo Adverse Recommendation
Change</span>&#8221; or in the case of the Company, a &#8220;<span style="text-decoration:underline">Company Adverse Recommendation Change</span>,&#8221; and in either case, as
applicable, an &#8220;<span style="text-decoration:underline">Adverse Recommendation Change</span>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.1pt; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)&#160;Notwithstanding
anything to the contrary contained in this Agreement, at any time prior to the Specified Time, the board of directors of either Party
may make an Adverse Recommendation Change in response to an Intervening Event if such Party&#8217;s board of directors determines in good
faith, after consultation with its outside legal counsel, that the failure to do so would be a breach such board of director&#8217;s fiduciary
duties under applicable Law, only if all of the following conditions are satisfied:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(A)&#160;Such
Party shall have first provided the other Party an Intervening Event Notice at least five Business Days in advance advising the other
Party that such Party intends to make an Adverse Recommendation Change (it being understood and hereby agreed that the delivery and receipt
of any such Intervening Event Notice shall not, in and of itself, be deemed to be an Adverse Recommendation Change) and specifying, in
reasonable detail, the Intervening Event;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(B)&#160;during
the applicable Intervening Event Notice Period (or any mutually agreed extension or continuation thereof), such Party and its Representatives
shall negotiate in good faith with the other Party and its Representatives to make revisions to the terms of this Agreement as would cause
such Intervening Event to cease to warrant an Adverse Recommendation Change;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(C)&#160;the
other Party does not make, within the applicable Intervening Event Notice Period (or any extension or continuation thereof) after the
receipt of such notice, a proposal that would, in the good faith judgment of the PubCo Board or Company Board, as applicable, (after consultation
with outside legal counsel), cause the failure to effect an Adverse Recommendation Change in response to such Intervening Event to no
longer be inconsistent with the such board of director&#8217;s fiduciary duties under applicable Law (it being understood and agreed that
any material change in any event, occurrence or facts relating to such Intervening Event shall require a new Intervening Event Notice
with a new Intervening Event Notice Period ending on the day that is three Business Days after such material change); and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(D)&#160;following
the Intervening Event Notice Period, the PubCo Board or Company Board, as applicable, shall have determined in good faith (after consultation
with its outside legal counsel) that the failure to effect an Adverse Recommendation Change, as applicable, in response to such Intervening
Event would continue to be a breach of such board of director&#8217;s fiduciary duties under applicable Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 435 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vi)&#160;Notwithstanding
anything to the contrary contained in this Agreement, at any time prior to the Specified Time if, in response to a <i>bona fide </i>unsolicited
written Takeover Proposal made by a Third Party after the date of this Agreement which does not arise from a breach of this <span style="text-decoration:underline">Section
5.04</span> and has not been withdrawn, the board of directors of such Party that received the Takeover Proposal determines in good faith
(1) after consultation with outside legal counsel and a financial advisor, that such Takeover Proposal constitutes a Superior Proposal,
and (2) after consultation with outside legal counsel, that the failure to make an Adverse Recommendation Change, would be a breach of
such Party&#8217;s board of director&#8217;s fiduciary duties under applicable Law, then such Party&#8217;s board of director&#8217;s
may make an Adverse Recommendation Change only if, in either such case, all of the following conditions are satisfied:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(A)&#160;Such
party shall have first provided to the other Party a Superior Proposal Notice at least five Business Days in advance advising the other
Party that such Party is prepared to effect an Adverse Recommendation Change in response to a Superior Proposal (and specifying, in reasonable
detail, the material terms and conditions of any such Superior Proposal, including the identity of the Third Party making any such Superior
Proposal) (it being understood and hereby agreed that the delivery and receipt of any such Superior Proposal Notice shall not, in and
of itself, be deemed to be an Adverse Recommendation Change) and providing the other Party with a complete copy of any written request,
proposal or offer, including any proposed Alternative Acquisition Agreement (and all schedules, appendices, exhibits and other attachments
relating thereto), and any other documents containing the material terms of such Superior Proposal; during the applicable Superior Proposal
Notice Period (or any extension or continuation thereof), prior to its effecting an Adverse Recommendation Change, such Party and its
Representatives shall negotiate in good faith with the other Party and its Representatives regarding changes to the terms of this Agreement
and any other proposals intended to cause such Takeover Proposal to no longer constitute a Superior Proposal;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(B)&#160;the
other Party does not make, within the applicable Superior Proposal Notice Period (or any mutually agreed extension or continuation thereof)
after the receipt of such notice, a proposal that would, in the good faith judgment of the board of directors of such Party (after consultation
with outside legal counsel and a financial advisor), cause the offer previously constituting a Superior Proposal to no longer constitute
a Superior Proposal (it being understood and agreed that any material amendment or modification of such Superior Proposal shall require
a new Superior Proposal Notice with a new Superior Proposal Notice Period of five Business Days); and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(C)&#160;following
the Superior Proposal Notice Period, such Party&#8217;s board of directors shall have determined in good faith, in light of such Superior
Proposal and taking into account any revised terms proposed by the other Party, (x) after consultation with outside legal counsel and
a financial advisor, that such Takeover Proposal continues to constitute a Superior Proposal, and (y) after consultation with outside
legal counsel, that the failure to make an Adverse Recommendation Change would continue to be a breach of the such board of director&#8217;s
fiduciary duties under applicable Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;<span style="text-decoration:underline">Certain
Permitted Disclosure</span>. Notwithstanding anything to the contrary in this Agreement, nothing contained in this Agreement shall prohibit
PubCo, any of its Subsidiaries or the PubCo Board from (i) taking and disclosing to its stockholders a position with respect to a tender
offer contemplated by Rule 14d-9 or Rule 14e-2 promulgated under the Exchange Act, or from issuing a &#8220;stop, look and listen&#8221;
statement pending disclosure of its position thereunder (none of which, in and of itself, shall be deemed to constitute a PubCo Adverse
Recommendation Change), or (ii) making any disclosure to PubCo&#8217;s stockholders if, in the good faith judgment of the PubCo Board,
after consultation with outside counsel, failure to so disclose would reasonably likely to result in a breach of its fiduciary duties
under applicable Law, it being understood that nothing in the foregoing shall be deemed to permit PubCo or the PubCo Board (or a committee
thereof) to effect a PubCo Adverse Recommendation Change other than in accordance with <span style="text-decoration:underline">Section 5.04(c)</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;<span style="text-decoration:underline">Cessation
of Ongoing Discussions</span>. PubCo and the Company shall, and shall cause their respective Representatives to: (i) cease immediately all
discussions and negotiations that commenced prior to the date of this Agreement regarding any proposal that would constitute (if made
after the date of this Agreement), or could reasonably be expected to lead to, an Takeover Proposal, (ii) within two Business Days of
the date of this Agreement, request the prompt return or destruction of all non-public information concerning PubCo or its Subsidiaries
theretofore furnished to any Person with whom a confidentiality agreement in contemplation of an acquisition transaction was entered into
at any time within the 12-month period immediately preceding the date hereof, and (iii) immediately terminate all access granted to any
such Persons or their respective Representatives referenced in clauses (i) and (ii) to any physical or electronic data room; provided,
however, that the foregoing shall not in any way limit or modify any of PubCo&#8217;s rights under the other provisions of this <span style="text-decoration:underline">Section
5.04</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 436 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
5.05 <span style="text-decoration:underline">PubCo Registration Statement and Proxy</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;As
promptly as practicable following the date of this Agreement, PubCo shall prepare and file with the SEC the PubCo Registration Statement
relating to the registration of the shares of PubCo Common Stock to be issued to the Company Shareholders, which will contain the Proxy
Statement. The PubCo Registration Statement and Proxy Statement shall comply as to form in all material respects with the applicable provisions
of the Securities Act and the Exchange Act and other applicable Laws. The Company shall provide to PubCo all information, including certificates
or other statements, concerning the Company as may be reasonably requested by PubCo in connection with the PubCo Registration Statement
and Proxy Statement and shall otherwise reasonably assist and cooperate with PubCo in the preparation of the PubCo Registration Statement
and Proxy Statement and resolution of any comments referred to below; provided, that PubCo shall provide the Company with a reasonable
opportunity to review and comment on any drafts of the PubCo Registration Statement and Proxy Statement and related correspondence and
filings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;PubCo
covenants and agrees that none of the information to be included or incorporated by reference in the PubCo Registration Statement, the
Proxy Statement and any pro forma financial statements included therein, will, at the date it is first mailed to the PubCo Stockholders
or at the time of any amendment or supplement thereof, contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are
made, not misleading; provided, however, that no representation or warranty is made by PubCo with respect to statements made or incorporated
by reference therein to the extent based on information supplied by or on behalf of the Company or any Affiliate of the Company in connection
with the preparation of the PubCo Registration Statement and the Proxy Statement for inclusion or incorporation by reference therein.
The Company hereby covenants and agrees that none of the information to be supplied by or on behalf of the Company or any Affiliate thereof
for inclusion or incorporation by reference in the PubCo Registration Statement and the Proxy Statement, shall, at the date it is first
mailed to the PubCo Stockholders or at the time of any amendment or supplement thereof, contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they are made, not misleading; provided, however, that no representation or warranty is made by the Company
with respect to statements made or incorporated by reference therein to the extent based on information supplied by any PubCo Entity or
any Affiliate thereof in connection with the preparation of the PubCo Registration Statement or the Proxy Statement for inclusion or incorporation
by reference therein. PubCo and the Company shall use their respective commercially reasonable best efforts to ensure that the PubCo Registration
Statement complies in all material respects with the applicable provisions of the Exchange Act and the rules and regulations promulgated
thereunder and to satisfy all rules of Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;PubCo
shall use its commercially reasonable best efforts to (i) respond to any comments on the PubCo Registration Statement or requests for
additional information from the SEC as soon as practicable after receipt of any such comments or requests, provide the SEC with all information
reasonably necessary to amend the PubCo Registration Statement), (ii) have the PubCo Registration Statement cleared by the SEC as promptly
as practicable following its filing with the SEC, (iii) set a record date for the PubCo Stockholders Meeting, and (iv) cause the PubCo
Registration Statement to be mailed to the PubCo Stockholders as promptly as practicable after the SEC confirms that it has no further
comments on the PubCo Registration Statement. PubCo shall promptly (A) notify the Company upon the receipt of any such comments or requests,
and (B) provide the Company with copies of all correspondence relating to the PubCo Registration Statement between PubCo and its Representatives,
on the one hand, and the SEC and its staff, on the other hand. Before responding to any such comments or requests or the filing or mailing
of the PubCo Registration Statement, PubCo shall provide the Company with a reasonable opportunity to review and comment on any drafts
of the PubCo Registration Statement and related correspondence and filings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;The
PubCo Registration Statement shall include the PubCo Board Recommendation unless the PubCo Board has made a PubCo Adverse Recommendation
Change in accordance with <span style="text-decoration:underline">Section 5.04</span> of this Agreement. The PubCo Registration Statement shall not, when sent to PubCo&#8217;s
stockholders, contain any other proposal or request for stockholder approval of a Takeover Proposal other than the Requisite PubCo Vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;PubCo
and the Company shall reasonably cooperate in good faith and use its respective commercially reasonable best efforts to cause the shares
of PubCo Common Stock to be issued in the Transactions to be approved for listing on Nasdaq, subject to official notice of issuance, prior
to the Closing Date. PubCo shall also use its commercially reasonable best efforts to obtain, and the Company shall reasonably cooperate
in good faith with PubCo to assist PubCo in obtaining, all necessary state securities law or &#8220;blue sky&#8221; permits and approvals
necessary to ensure that the PubCo Common Stock to be issued in the Transactions (to the extent required) shall be registered or qualified
or exempt from registration or qualification under the securities law of every jurisdiction of the United States in which any registered
holder of Company Ordinary Share or Company Preferred Share has an address of record on the applicable record date for determining the
holders of Company Ordinary Share or Company Preferred Share entitled to notice and to vote pursuant to the Company Shareholder Approval,
to the extent applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 437 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 5.06 <span style="text-decoration:underline">PubCo
Stockholders Meeting</span></b>. Subject to <span style="text-decoration:underline">Section 5.04</span>, as promptly as practicable following the effectiveness of the PubCo Registration
Statement, PubCo shall establish the record date, and duly call, give notice of, convene or hold the PubCo Stockholders Meeting in accordance
with the DGCL and the PubCo Organizational Documents (and in any event within forty-five (45) days after the date thereof, unless otherwise
required by applicable Laws) to consider and vote to approve the PubCo Stockholder Matters. PubCo shall take reasonable measures to ensure
that all proxies solicited in connection with the PubCo Stockholder Meeting are solicited in compliance with all applicable Law. Notwithstanding
anything to the contrary contained herein, PubCo may postpone or adjourn the PubCo Stockholders Meeting: (i) with the consent of the Company
(which consent shall not be unreasonably withheld, delayed or conditioned); (ii) it will not receive proxies sufficient to obtain the
Requisite PubCo Vote, whether or not a quorum would be present; (iii) for the absence of a quorum; (iv) to allow reasonable additional
time (not to exceed 20 days) for the filing and distribution of any supplemental or amended disclosure with respect to the Transactions,
which the PubCo Board has determined in good faith (after consultation with its outside legal counsel) is necessary under applicable Laws
and for such supplemental or amended disclosure to be disseminated to and reviewed by the PubCo Stockholders prior to the PubCo Stockholders
Meeting; or (v) as reasonably necessary in connection with PubCo taking any of the actions permitted by <span style="text-decoration:underline">Section 5.04</span> in response
to a Takeover Proposal. Without limiting the generality of the foregoing, PubCo&#8217;s requirement to call and hold the PubCo Stockholder
Meeting shall not be affected by the commencement, public proposal, public disclosure or communication to PubCo of any Takeover Proposal,
Intervening Event or the PubCo Board making a PubCo Adverse Recommendation Change. Subject to <span style="text-decoration:underline">Section 5.04</span>, the PubCo Board shall
recommend that the PubCo Stockholders vote to approve the PubCo Stockholder Matters. Prior to the mailing of the PubCo Registration Statement,
PubCo shall be entitled to engage a proxy solicitor that is reasonably satisfactory to the Company, and PubCo shall keep the Company reasonably
informed regarding its solicitation efforts and proxy tallies following the mailing of the PubCo Registration Statement. If, at any time
after PubCo has obtained the Requisite PubCo Vote, the Company issues and sells shares of Company Preferred Share in accordance with <span style="text-decoration:underline">Section
5.01(c)</span>, the Company shall provide PubCo written notice of such issuance and sale within three Business Days following the consummation
of any such issuance sale. Promptly following the receipt of such written notice, PubCo shall take all actions necessary to ensure that
PubCo, as of the Effective Time, will be able to issue the Merger Consideration in accordance with the terms of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
5.07 <span style="text-decoration:underline">Listing</span></b>. PubCo shall use commercially reasonable efforts to ensure that the existing shares of PubCo Common Stock shall
have been continually listed on Nasdaq as of and from the date of this Agreement through the Closing Date. PubCo and the Company shall
reasonably cooperate in good faith to (i) effectuate the Reverse Stock Split, and (ii) cause the shares of PubCo Common Stock being issued
in connection with the Transactions to be approved for listing (subject to notice of issuance) on Nasdaq to be approved for issuance
(subject to official notice of issuance) at or after the Effective Time pursuant to Nasdaq rules and regulations. To the extent required
by Nasdaq Marketplace Rule 5110, PubCo shall use its commercially reasonable efforts to prepare and file an initial listing application
for the PubCo Common Stock on Nasdaq (the &#8220;<span style="text-decoration:underline">Nasdaq Listing Application</span>&#8221;) and to cause such Nasdaq Listing Application
to be conditionally approved prior to the Effective Time. The Company will cooperate with PubCo as reasonably requested by PubCo with
respect to the Nasdaq Listing Application and promptly furnish to PubCo all information concerning the Company and the Company Shareholders
that may be required or reasonably requested in connection with any action contemplated by this <span style="text-decoration:underline">Section 5.07</span>. All fees associated
with the Nasdaq Listing Application shall be paid by the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
5.08 <span style="text-decoration:underline">Directors&#8217; and Officers&#8217; Indemnification and Insurance</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;From
the Closing Date through the sixth anniversary of the Closing Date, each of PubCo and the Surviving Company, jointly and severally, shall
indemnify and hold harmless any present or former, or who becomes prior to the Effective Time, director or officer of PubCo or the Surviving
Company, or their respective Subsidiaries (the &#8220;<span style="text-decoration:underline">Indemnified Parties</span>&#8221;) against all claims, losses, Liabilities, damages,
judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements (collectively, &#8220;<span style="text-decoration:underline">Costs</span>&#8221;),
incurred in connection with any Legal Action arising out of or pertaining to the fact that the Indemnified Party is or was a director
or officer of PubCo, the Surviving Company or their respective Subsidiaries, whether asserted or claimed prior to, at or at or after the
Effective Time, in each case, to the fullest extent permitted under applicable Law. Each Indemnified Party will be entitled to advancement
of Costs incurred in the defense of any such Legal Action from each of PubCo and the Surviving Company upon receipt by PubCo or the Surviving
Company from the Indemnified Party of a request therefor; <span style="text-decoration:underline">provided</span> that any such Person to whom Costs are advanced provides an
undertaking to PubCo, to the extent then required by the DGCL, to repay such advances if it is ultimately determined that such Person
is not entitled to indemnification. PubCo shall cooperate with the Indemnified Party in the defense of any such Legal Action and PubCo
shall not settle, compromise or consent to the entry of any judgment in any Legal Action pending or threatened in writing to which an
Indemnified Party is a party (and in respect of which indemnification could be sought by such Indemnified Party hereunder), unless such
settlement, compromise or consent includes an unconditional release of such Indemnified Party from all liability arising out of such Legal
Action or such Indemnified Party otherwise consents in writing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;The
provisions presently set forth in the certificate of incorporation and bylaws of PubCo with respect to indemnification, advancement of
Costs and exculpation of present and former directors and officers of PubCo shall not be amended, modified or repealed for a period of
six (6) years from the Effective Time in a manner that would adversely affect the rights thereunder of individuals who, at or prior to
the Effective Time, were officers or directors of PubCo. The certificate of incorporation and bylaws of the Surviving Company shall contain,
and PubCo shall cause the certificate of incorporation and bylaws of the Surviving Company to so contain, provisions no less favorable
with respect to indemnification, advancement of Costs and exculpation of present and former directors and officers as those presently
set forth in the certificate of incorporation and bylaws of PubCo.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 438 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;From
and after the Effective Time, (i) the Surviving Company shall fulfill and honor in all respects the obligations of the Company to its
Indemnified Parties as of immediately prior to the Effective Time pursuant to any indemnification provisions under the Company&#8217;s
Organizational Documents and pursuant to any indemnification agreements between the Company and such Indemnified Parties, with respect
to claims arising out of matters occurring at or prior to the Effective Time, and (ii) PubCo shall fulfill and honor in all respects the
obligations of PubCo to its Indemnified Parties as of immediately prior to the Effective Time pursuant to any indemnification provisions
under PubCo&#8217;s Organizational Documents and pursuant to any indemnification agreements between PubCo and such Indemnified Parties,
with respect to claims arising out of matters occurring at or prior to the Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;From
and after the Effective Time, PubCo shall maintain a directors&#8217; and officers&#8217; Liability insurance policy, with an effective
date as of the Closing Date on commercially available terms and conditions and with coverage limits customary for U.S. public companies
similarly situated to PubCo. In addition, PubCo shall also purchase and maintain, following consultation with, and subject to the approval
of, and at the expense of, the Company, a non-cancellable extension of the directors&#8217; and officers&#8217; Liability coverage of
PubCo&#8217;s existing directors&#8217; and officers&#8217; insurance policies for a claims reporting or discovery period of at least
six years from and after the Effective Time with respect to any claim related to any period of time at or prior to the Effective Time
with terms, conditions, retentions and limits of Liability that are no less favorable than the coverage provided under PubCo&#8217;s existing
policies as of the date of this Agreement with respect to any actual or alleged error, misstatement, misleading statement, act, omission,
neglect, breach of duty or any matter claimed against a director or officer of PubCo or any of its Subsidiaries by reason of him or her
serving in such capacity that existed or occurred at or prior to the Effective Time (including in connection with this Agreement or the
Transactions).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;The
covenants contained in this <span style="text-decoration:underline">Section 5.08</span> are intended to be in addition to the rights otherwise available to the Indemnified Parties
by Law, charter, statute, bylaw or agreement, and are for the benefit of, and shall be enforceable by, each of the Indemnified Parties
and their respective heirs and legal representatives and shall not be deemed exclusive of any other rights to which an Indemnified Party
is entitled, whether pursuant to Law, Contract or otherwise. For the avoidance of the doubt, the Indemnified Parties and their respective
heirs and legal representatives shall be third-party beneficiaries with respect to the covenants contained in this <span style="text-decoration:underline">Section 5.08</span>.
From and after the Effective Time, PubCo shall pay all Costs, including reasonable attorneys&#8217; fees, that are incurred by any Indemnified
Party in enforcing the indemnity and other obligations provided in this <span style="text-decoration:underline">Section 5.08</span>, except to the extent that it is ultimately
determined by a Governmental Authority with valid jurisdiction that such Indemnified Party is not entitled to be indemnified pursuant
to this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;In
the event that PubCo, the Surviving Company or any of their respective successors or assigns (i) consolidates with or merges into any
other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger, or (ii) transfers or
conveys all or substantially all of its properties and assets to any Person, then, and in each such case, PubCo or the Surviving Company,
as applicable, shall take all necessary action so that the successors or assigns of PubCo or the Surviving Company, as the case may be,
shall succeed to the obligations set forth in this <span style="text-decoration:underline">Section&#160;5.08</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 5.09 <span style="text-decoration:underline">Reasonable
Best Efforts</span></b>. Upon the terms and subject to the conditions set forth in this Agreement and in accordance with applicable Law,
each of the Parties shall, and shall use reasonable best efforts to cause its Affiliates to, use its reasonable best efforts to take,
or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable to ensure that the conditions
applicable to such Party set forth in <span style="text-decoration:underline">Article VI</span> are satisfied and to consummate the Transactions as promptly as practicable in
accordance with its terms. The terms of this <span style="text-decoration:underline">Section 5.09</span> shall not limit the applicable rights of PubCo or the Company set forth
in <span style="text-decoration:underline">Section 5.04</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
5.10 <span style="text-decoration:underline">Consents; Filings; Further Action</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Subject
to the terms and conditions of this Agreement, PubCo and the Company shall (and shall cause their respective Subsidiaries to) each use
their reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, and to assist and reasonably
cooperate with the other Parties in doing all things necessary, proper or advisable under applicable Laws to (i) make any necessary filings
promptly after signing of this Agreement and obtain all necessary actions, waivers, registrations, permits, authorizations, Orders, consents
and approvals from Governmental Authorities, the expiry or early termination of any applicable waiting periods, and make all necessary
registrations and filings (including filings with Governmental Authorities, if any) and take all steps as may be reasonably necessary
to obtain an approval or waiver from, or to avoid an action or proceeding by, any Governmental Authorities, in order to consummate the
Transactions as promptly as practicable and in any event prior to the Termination Date, and (ii) deliver required notices or any necessary
additional instruments to, and obtain required consents, waivers or any additional instruments necessary from, Third Parties in order
to consummate the Transactions as promptly as practicable and in any event prior to the Termination Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 439 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;Subject
to applicable Laws and the requirements of applicable Governmental Authorities, PubCo and the Company and their respective counsel shall
(i) cooperate in all respects with each other in connection with any filing or submission with a Governmental Authority in connection
with the Transactions and in connection with any investigation or other inquiry by or before a Governmental Authority relating to the
Transactions, including any proceeding initiated by a private Person, (ii) to the extent legally permissible, have the right to review
in advance, and each shall consult the other on, any material filing made with, or written materials to be submitted to, any Governmental
Authority in connection with the Transactions and of any material communication received or given in connection with any proceeding by
a private Person, in each case regarding any of the Transactions, (iii) promptly inform each other of any material communication (or any
other material correspondence or memoranda) received from, or given to, the DOJ or the FTC or any other applicable Governmental Authority,
and (iv) where legally permissible, promptly furnish each other with copies of all correspondence, filings and written communications
between them or their Subsidiaries or Affiliates, on the one hand, and any Governmental Authority or its respective staff, on the other
hand, with respect to the Transactions. In furtherance of the foregoing and subject to applicable Laws and the requirements of Governmental
Authorities, PubCo and the Company shall (with respect to any in-person discussion or meeting, remote video meeting or substantive telephonic
discussion or meeting), provide the other Party and its counsel with advance notice of and the opportunity to participate in any material
discussion or meeting with any Governmental Authority in respect of any filing, investigation or other inquiry in connection with the
Transactions. Notwithstanding anything to the contrary in this <span style="text-decoration:underline">Section 5.10(b)</span>, PubCo and the Company may, as each deems advisable
and necessary, (x) reasonably designate any competitively sensitive material provided to the other under this <span style="text-decoration:underline">Section 5.10</span> as &#8220;Antitrust
Counsel Only Material;&#8221; and (y) redact materials to be provided to the other Party as necessary to comply with contractual arrangement,
to address good faith legal privilege or confidentiality concerns, to comply with applicable Law, or to remove references concerning the
valuation of PubCo or Company and their respective Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;In
furtherance of the undertakings under this <span style="text-decoration:underline">Section 5.10</span>, PubCo and the Company, along with their respective Subsidiaries, shall
use their reasonable best efforts to obtain clearance under any applicable Antitrust Laws so as to enable the Parties to consummate the
Transactions as promptly as practicable, and in any event prior to the Termination Date, which shall include using reasonable best efforts
to propose, negotiate, commit to and effect, by consent decree, hold separate order or otherwise, the sale, divestiture, disposition,
license or other disposition of such of its and its Subsidiaries&#8217; assets, properties or businesses or of the assets, properties
or businesses, and enter into such other arrangements, as are necessary or advisable in order to avoid the entry of, and the commencement
of litigation seeking the entry of, or to effect the dissolution of, any injunction, temporary restraining order or other Order in any
proceeding by a Governmental Authority or any other Person under applicable Antitrust Laws, that would otherwise have the effect of preventing
or materially delaying the consummation of the Transactions. PubCo shall not, unless requested to do so by the Company, commit to or effect
any action contemplated in the immediately preceding sentence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;Each
of PubCo and the Company shall consult with the other Party and consider in good faith the views of the other Party with respect to the
appropriate strategy relating to any matters relating to the Antitrust Laws, including with respect to any filings, notifications, submissions
and communications with or to any Governmental Authority and the nature and timing of any divestitures or other remedial undertakings
made for purposes of securing any required approvals under the Antitrust Laws; provided that, notwithstanding any other provisions of
this Agreement to the contrary, the Company shall, on behalf of the Parties, control and direct all aspects of the Parties&#8217; efforts
with respect to applicable Antitrust Laws and any authorization, consent, notice or approval to be obtained from a Governmental Authority
or Third Party with respect to the Transactions, including having principal responsibility for devising, implementing, and making the
final determination as to such appropriate strategy, and shall have the right, in its sole discretion, to determine the nature and timing
of any such divestitures or other remedial undertakings to the extent any such divestitures or other remedial undertakings would be conditioned
upon and only be effective after the Closing. PubCo shall cooperate in good faith with the Company in the Parties&#8217; efforts to obtain
any clearance, approval, waiver or expiry or early termination of any applicable waiting periods with respect to any Antitrust Laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 5.11 <span style="text-decoration:underline">Public
Announcements</span></b>. The Parties shall consult with each other before issuing any press release or otherwise making any public statements
about this Agreement or any of the Transactions. No Party shall issue any such press release or make any such public statement prior to
receiving the written consent (not to be unreasonably conditioned, withheld or delayed) of the other Party, except to the extent required
by applicable Law or Nasdaq rules, in which case that Party shall use its commercially best efforts to consult with the other party before
issuing any such release or making any such public statement; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that such consent shall not be required,
and no Party shall be required to consult with any other Party in connection with, or provide the other an opportunity to review or comment
upon, any press release or other public statement or comment to be issued or made with respect to any Takeover Proposal. Notwithstanding
the foregoing, without the prior consent of the other parties, the Company or PubCo may (a) communicate with its respective customers,
vendors, suppliers, financial analysts, investors and media representatives in a manner consistent with its past practice in compliance
with applicable Law to the extent such communications consist of information included in a press release or other document previously
approved for external distribution by the other Party, and (b) issue public statements or disseminate information to the extent solely
related to the operation of the business of such Party. PubCo and the Company will each issue a press release announcing the execution
of this Agreement, each of which shall be reasonably acceptable to the other Party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"></p><div>

</div><!-- Field: Page; Sequence: 440 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 5.12 <span style="text-decoration:underline">Fees
and Expenses</span></b>. Except as explicitly provided otherwise in this Agreement, whether or not the Transactions are consummated, all
expenses (including those payable to Representatives) incurred by any Party or on its behalf in connection with this Agreement and the
Transactions (&#8220;<span style="text-decoration:underline">Expenses</span>&#8221;) shall be paid by the Party incurring those Expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 5.13 <span style="text-decoration:underline">Takeover
Statutes</span></b>. Unless the PubCo Board has made a PubCo Adverse Recommendation Change in accordance with this Agreement, if any takeover
statute is or becomes applicable to this Agreement or any Transaction, each of PubCo, the Company and their respective boards of directors
shall use reasonable best efforts (a) to ensure that such transactions may be consummated as promptly as practicable upon the terms and
subject to the conditions set forth in this Agreement, and (b) to otherwise act to eliminate or minimize the effects of such takeover
statute.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 5.14 <span style="text-decoration:underline">Rule
16b-3</span></b>. Prior to the Effective Time, PubCo shall take such further actions, if any, as may be necessary or appropriate to ensure
that the dispositions of equity securities of PubCo (including derivative securities) pursuant to the Transactions by any Person who is
subject to Section 16 of the Exchange Act are exempt under Rule 16b-3 promulgated under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
5.15 <span style="text-decoration:underline">Succession of Officers and Directors</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;At
the Closing, PubCo shall deliver to the Company evidence reasonably satisfactory to the Company of the resignation of all directors of
PubCo effective as of the Effective Time (other than those directors remaining on the PubCo Board pursuant to Section 1.06(a)).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;The
officers of the Surviving Company immediately prior to the Effective Time shall be, from and after the Effective Time, the officers of
PubCo until their successors are duly elected or appointed and qualified or until their earlier death, resignation or removal in accordance
with the organizational documents of PubCo.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;As
of the Effective Time, PubCo shall take all action necessary to (i) cause (A) the number of members of the PubCo Board to be fixed at
seven, and (B) cause to be appointed to the PubCo Board, as directors, up to five persons chosen by the Company in its sole discretion
and as set forth on <span style="text-decoration:underline">Section 1.06(a)</span> of the Company Disclosure Letter. If any person identified by the Company to serve on the PubCo
Board in accordance with this <span style="text-decoration:underline">Section 5.15(c)</span> is unable or unwilling to serve in such capacity, the Company may designate a successor
but not less than five days in advance of the Closing or such earlier period as may be required by disclosure requirements under applicable
Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 5.16 <span style="text-decoration:underline">Notification
of Certain Matters</span></b>. The Company shall give prompt notice to PubCo, and PubCo shall give prompt notice to the Company, of (a) the
occurrence of any event known to it which would reasonably be expected to, individually or in the aggregate, (i) in the case of the Company,
have a Company Material Adverse Effect, or, in the case of PubCo, have a PubCo Material Adverse Effect, (ii) cause any condition set forth
in <span style="text-decoration:underline">Article VI</span> to be unsatisfied in any material respect at any time prior to the Effective Time, or (iii) cause any authorization,
consent, Order, declaration or approval of any Governmental Authority or Third Party necessary for the consummation of the Transactions
to not be obtained by the Termination Date, or (b) any action, suit, proceeding, inquiry or investigation pending or, to the Knowledge
of the Company or PubCo, threatened which questions or challenges the validity of this Agreement or the ability of any party to consummate
the Transactions; <span style="text-decoration:underline">provided</span>, <span style="text-decoration:underline">however</span>, that the delivery of any notice pursuant to this <span style="text-decoration:underline">Section 5.16</span> shall not limit
or otherwise affect the remedies available hereunder to the party receiving such notice nor shall the party giving such notice be prejudiced
with respect to any such matters solely by virtue of having given such notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
5.17 <span style="text-decoration:underline">Certain Litigation</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;PubCo
shall assume the control and defense at its own expense of all stockholder litigation against PubCo, any of its Subsidiaries or any of
the directors or officers of PubCo or its Subsidiaries (such Persons, the &#8220;<span style="text-decoration:underline">Covered Persons</span>&#8221;), in each case, arising
out of or in connection with this Agreement or the Transactions (collectively, the &#8220;<span style="text-decoration:underline">Stockholder Litigation</span>&#8221;); provided,
that (i) PubCo shall promptly as practicable notify the Company of such Stockholder Litigation, (ii) PubCo shall keep the Company reasonably
informed with respect to the status thereof, and (iii) the Company shall have the opportunity to consult with PubCo in connection with
such proceedings, negotiations and settlement decisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;PubCo
shall obtain the prior written consent of the Company and the Covered Persons (which shall not be unreasonably withheld, conditioned or
delayed) before entering into any settlement, understanding or other agreement relating to such Stockholder Litigation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.55pt">(c)&#160;Each
Party shall cooperate, and cause its Affiliates to cooperate, in the defense of any Stockholder Litigation and shall furnish or cause
to be furnished such records, information and testimony, and attend, at each Party&#8217;s own expense, such conferences, discovery proceedings,
hearings, trials or appeals, as may be reasonably requested in connection therewith.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.55pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.55pt"></p><div>

</div><!-- Field: Page; Sequence: 441 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.55pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 5.18 <span style="text-decoration:underline">Requisite
Company Approval</span></b>. Upon the terms set forth in this Agreement and the Company Voting Agreement, the Company shall either: (i) call
and hold a meeting of the shareholders of the Company for the purpose of voting upon the approval and adoption of this Agreement, the
Merger and all other Transactions including the conversion of the Company Convertible Securities described in <span style="text-decoration:underline">Section 2.01(a)</span>,
or (ii) solicit a majority written consent from its shareholder, (the &#8220;<span style="text-decoration:underline">Company Shareholder Approval</span>&#8221;) as soon as reasonably
practicable after the PubCo Registration Statement becomes effective, and in any event within 25 Business Days after the PubCo Registration
Statement becomes effective. In connection therewith, the Company, as promptly as practicable (A) shall establish the record date (which
record date shall be mutually agreed with PubCo) for determining the Company Shareholders entitled to provide such written consent, and
(B) shall use commercially reasonable best efforts to obtain proxies from the Company Shareholders to give the Company Shareholder Approval.
The Company Board shall make the Company Board Recommendation available to shareholders of the Company. Neither the Company Board nor
any committee thereof shall withhold, withdraw or modify, or publicly propose or resolve to withhold, withdraw or modify in a manner adverse
to PubCo the Company Board Recommendation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 5.19 <span style="text-decoration:underline">Lock-Up
Agreements</span></b>. Prior to the Effective Time, (i) PubCo shall cause those individuals listed on Schedule A-2 of the PubCo Disclosure
Letter, and (ii) the Company shall cause those individuals listed on Schedule A-1 of the Company Disclosure Letter, to each enter into
a Lockup Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
5.20 <span style="text-decoration:underline">Tax Matters</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;Each
of PubCo and the Company will (and will cause their respective Affiliates to) (i) use all reasonable best efforts to cause the Merger
to constitute as a transaction qualifying for the Intended Tax Treatment, and (ii) not take any action not required by this Agreement
or fail to take any action required by this Agreement that could reasonably be expected to prevent or impede the Merger from qualifying
as a transaction qualifying for the Intended Tax Treatment. Except as otherwise required by applicable law, PubCo shall not file (or cause
its Affiliates, including the Company, to file) any U.S. federal, state or local Tax Return after the Closing Date in a manner that is
inconsistent with the treatment of the Merger as a transaction qualifying for the Intended Tax Treatment for U.S. federal, state income
and other relevant Tax purposes, and shall not take any inconsistent position during the course of any audit, litigation or other proceeding
with respect to Taxes, in each case, unless otherwise required by a determination within the meaning of Section 1313(a) of the Code or
a corresponding event with respect to state or local income Tax law. Notwithstanding the foregoing or anything herein to the contrary,
(i) PubCo makes no representations or warranties to any other Person or to any Company Shareholder regarding the Intended Tax Treatment
of the Merger or any of the other Transactions, and (ii) the Company and each Company Shareholder will rely solely on their own Tax advisors
in connection with this Agreement and the Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;If,
in connection with the preparation and filing of the PubCo Registration Statement, the SEC requests or requires that tax opinions be prepared
and submitted in such connection, PubCo and the Company shall deliver to Lowenstein Sandler LLP and Lucosky Brookman LLP, as applicable,
customary Tax representation letters satisfactory to counsel, dated and executed as of the date the PubCo Registration Statement shall
have been declared effective by the SEC and such other date(s) as determined reasonably necessary by such counsel in connection with the
preparation and filing of the PubCo Registration Statement, and, if required by the SEC, both Lowenstein Sandler LLP and Lucosky Brookman
LLP shall furnish an opinion, subject to customary assumptions and limitations, with respect to the Intended Tax Treatment as it applies
to the Merger.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;All
transfer, documentary, sales, use, stamp, registration, excise, recording, registration value added and other such similar Taxes and fees
(including any penalties and interest) that become payable in connection with or by reason of the execution of this Agreement and the
Transactions shall be borne and paid by the Company. Unless otherwise required by applicable law, the Company shall timely file any Tax
Return or other document with respect to such Taxes or fees (and PubCo shall reasonably cooperate with respect thereto as necessary).
PubCo shall timely file any Tax Return or other document with respect to such Taxes or fees that it is required to file under applicable
law (and the Company shall reasonably cooperate with respect thereto as necessary).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 442 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 5.21 <span style="text-decoration:underline">Legends</span></b>.
PubCo shall be entitled to place appropriate legends on the book entries and/or certificates evidencing any shares of PubCo Common Stock
to be received in the Merger by equity holders of the Company who may be considered &#8220;affiliates&#8221; of PubCo for purposes of
Rules 144 and 145 under the Securities Act reflecting the restrictions set forth in Rules 144 and 145 and to issue appropriate stop transfer
instructions to the transfer agent for PubCo Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 5.22 <span style="text-decoration:underline">Financial
Statements</span></b>. As promptly as reasonably practicable following the date of this Agreement, the Company will furnish to PubCo (a)
audited financial statements for the fiscal years ended December 31, 2023 and December 31, 2024 for inclusion in the Proxy Statement and
the PubCo Registration Statement (the &#8220;Company Audited Financial Statements&#8221;), and (b) unaudited interim financial statements
for each interim period completed prior to Closing that would be required to be included in the PubCo Registration Statement or any periodic
report due prior to the Closing if the Company were subject to the periodic reporting requirements under the Securities Act or the Exchange
Act (the &#8220;Company Interim Financial Statements&#8221;). Each of the Company Audited Financial Statements and the Company Interim
Financial Statements will be suitable for inclusion in the Proxy Statement and the PubCo Registration Statement and prepared in accordance
with GAAP as applied on a consistent basis during the periods involved (except in each case as described in the notes thereto) and on
that basis will present fairly, in all material respects, the financial position and the results of operations, changes in members&#8217;
equity, and cash flows of the Company as of the dates of and for the periods referred to in the Company Audited Financial Statements or
the Company Interim Financial Statements, as the case may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 5.23 <span style="text-decoration:underline">Outstanding
PubCo Warrants</span></b>. From the date of this Agreement through the Effective Time, PubCo shall use its commercially reasonable best efforts
to negotiate with the holders of the warrants set forth on Section 5.23 of the PubCo Disclosure Letter to sell, assign or transfer such
warrants to a third party reasonably acceptable to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE VI. CONDITIONS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 6.01 <span style="text-decoration:underline">Conditions
to Each Party&#8217;s Obligation to Consummate the Transactions</span></b>. The respective obligation of each Party to effect the Transactions,
including the Merger, is subject to the satisfaction on or before the Closing Date of each of the following conditions, unless waived
in writing by each of PubCo and the Company:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">PubCo
Stockholder Approval</span>. The PubCo Stockholder Matters shall have been duly adopted by the holders of shares of PubCo Common Stock constituting
the Requisite PubCo Vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="text-decoration:underline">Company
Shareholder Approval</span>. This Agreement, the Plan of Merger and the Surviving Company Restated Articles and the transactions contemplated
by this Agreement shall have been duly adopted by the holders of shares of the Company constituting the Requisite Company Vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;<span style="text-decoration:underline">Registration
Statements</span>. The PubCo Registration Statement shall have become effective under the Securities Act and no stop order suspending the
effectiveness of the PubCo Registration Statement shall have been issued and no proceeding for that purpose shall have been initiated
or threatened in writing by the SEC or its staff.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;<span style="text-decoration:underline">Listings</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(i)&#160;The
existing shares of PubCo Common Stock shall have been continually listed on Nasdaq as of and from the date of this Agreement through the
Closing Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(ii)&#160;There
are no pending order or action from Nasdaq or any Governmental Authority with respect to the status of the listing of PubCo Common Stock
on Nasdaq, including without limitation, any delisting order.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(iii)&#160;The
shares of PubCo Common Stock to be issued pursuant to <span style="text-decoration:underline">Article II</span> shall have been approved for listing on Nasdaq, subject only to
official notice of issuance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;<span style="text-decoration:underline">Approvals</span>.
The Parties shall have received all approvals from any Governmental Authority necessary to consummate the transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;<span style="text-decoration:underline">No
Orders</span>. There shall not have been enacted, promulgated or made effective after the date of this Agreement any Law or Orders by a Governmental
Authority of competent jurisdiction that enjoins or otherwise prohibits or makes illegal, or any Legal Action by any Governmental Authority
seeking to enjoin or prohibit or make illegal, consummation of the Transactions and there shall not be in effect any injunction (whether
temporary, preliminary or permanent) by any Governmental Authority of competent jurisdiction that enjoins or otherwise prohibits consummation
of the Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 443 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 6.02 <span style="text-decoration:underline">Conditions
to Obligations of PubCo Entities</span></b>. The obligations of each of PubCo Entity to effect the Transactions, including the Merger, are
also subject to the satisfaction on or before the Closing Date of the following conditions, unless waived in writing by PubCo:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-indent: 0in; text-align: justify">(a)
<span style="text-decoration:underline">Representations and Warranties</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(i)&#160;Each
of the representations and warranties of the Company set forth in <span style="text-decoration:underline">Section 3.06(a)</span>, <span style="text-decoration:underline">Section 3.06(b)</span> and <span style="text-decoration:underline">Section 3.06(g)</span>
shall be true and correct in all respects (except for (A) any inaccuracies that individually or in the aggregate are <i>de minimis </i>or
(B) to the extent any such representation and warranty expressly speaks as of a specified date, in which case, subject to the qualifications
as set forth in the preceding clause (A), as of such date) as of the Closing as though then made on such date;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(ii)&#160;Each
of the representations and warranties of the Company set forth in <span style="text-decoration:underline">Section 3.01</span> (Organization and Power), <span style="text-decoration:underline">Section 3.04</span> (Corporate
Authorizations), and <span style="text-decoration:underline">Section 3.25</span> (Brokers) (A) that are not qualified by references to &#8220;material&#8221; or any other materiality
qualifications shall be true and correct in all material respects as of the Closing as though made on such date (except to the extent
any such representation and warranty expressly speaks as of a specified date, in which case as of such date), and (B) that are qualified
by references to &#8220;material&#8221; or any other materiality qualifications shall be true and correct in all respects as of the Closing
as though made on such date (except to the extent any such representation and warranty expressly speaks as of a specified date, in which
case as of such date);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(iii)&#160;The
remaining representations and warranties of the Company contained in <span style="text-decoration:underline">Article III</span> (Representations and Warranties of the Company)
shall be true and correct, in each case as of the Closing as though made on such date (except to the extent any such representation and
warranty expressly speaks as of a specified date, in which case as of such date), except, in the case of this clause <span style="text-decoration:underline">(iii)</span> only,
where the failure of any such representations and warranties to be so true and correct (without regard to any materiality, in all material
respects, Company Material Adverse Effect, or similar qualifications set forth in any such representation or warranty) would not, individually
or in the aggregate, reasonably be expected to have a Company Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="text-decoration:underline">Performance
of Obligations</span>. The Company shall have performed in all material respects all obligations and covenants required to be performed by
it under this Agreement at or before the Closing Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;<span style="text-decoration:underline">Absence
of Company Material Adverse Effect</span>. No event, circumstance, development, change or effect shall (i) have occurred since the date of
this Agreement that, individually or in the aggregate, has caused a Company Material Adverse Effect, or (ii) continue to occur that would
reasonably be expected to cause, individually or in the aggregate, a Company Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;<span style="text-decoration:underline">FIRPTA
Certificate</span>. PubCo shall have received (i) an original signed statement from the Company that the Company is not, and has not been
at any time during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code, a &#8220;United States real property holding
corporation,&#8221; as defined in Section 897(c)(2) of the Code, conforming to the requirements of Treasury Regulations Section 1.1445-2(c)(3)
and 1.897-2(h), and (ii) an original signed notice to be delivered to the Internal Revenue Service in accordance with the provisions of
Treasury Regulations Section 1.897-2(h)(2), together with written authorization for PubCo to deliver such notice to the Internal Revenue
Service on behalf of the Company following the Closing, each dated as of the Closing Date, duly executed by an authorized officer of the
Company, and in form and substance reasonably acceptable to PubCo.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;<span style="text-decoration:underline">Officer&#8217;s
Certificate</span>. PubCo shall have received a certificate, signed by an executive officer of the Company, certifying as to the matters
set forth in <span style="text-decoration:underline">Section 6.02(a)</span>, <span style="text-decoration:underline">Section 6.02(b)</span>, <span style="text-decoration:underline">Section 6.02(c)</span>, and <span style="text-decoration:underline">Section 6.02(d)</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 444 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 6.03 <span style="text-decoration:underline">Conditions
to Obligation of the Company</span></b>. The obligation of the Company to effect the Transactions, including the Merger, is also subject
to the satisfaction on or before the Closing Date of the following conditions, unless waived in writing by the Company:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in; text-indent: 0in; text-align: justify">(a)
<span style="text-decoration:underline">Representations and Warranties</span>.</p><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(i)&#160;Each
of the representations and warranties of the PubCo Entities set forth in <span style="text-decoration:underline">Section 4.06(a), Section 4.06(b)</span> and <span style="text-decoration:underline">Section 4.06(g)</span>
shall be true and correct in all respects (except for (A) any inaccuracies that individually or in the aggregate are <i>de minimis</i>,
or (B) to the extent any such representation and warranty expressly speaks as of a specified date, in which case, subject to the qualifications
as set forth in the preceding clause (A), as of such date) as of the Closing as though then made on such date;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(ii)&#160;Each
of the representations and warranties of the PubCo Entities set forth in <span style="text-decoration:underline">Section 4.01</span> (Organization and Power), <span style="text-decoration:underline">Section 4.04</span>
(Corporate Authorization), and <span style="text-decoration:underline">Section&#160;4.26</span> (Brokers) (A) that are not qualified by references to &#8220;material&#8221; or
any other materiality qualifications shall be true and correct in all material respects as of the Closing as though made on such date
(except to the extent any such representation and warranty expressly speaks as of a specified date, in which case as of such date), and
(B) that are qualified by references to &#8220;material&#8221; or any other materiality qualifications shall be true and correct in all
respects as of the Closing as though made on such date (except to the extent any such representation and warranty expressly speaks as
of a specified date, in which case as of such date);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(iii)&#160;The
remaining representations and warranties of the PubCo Entities contained in <span style="text-decoration:underline">Article IV</span> (Representations and Warranties of the PubCo
Entities) shall be true and correct, in each case as of the Closing as though made on such date (except to the extent any such representation
and warranty expressly speaks as of a specified date, in which case as of such date), except, in the case of this clause <span style="text-decoration:underline">(iii)</span>
only, where the failure of any such representations and warranties to be so true and correct (without regard to any materiality, in all
material respects, PubCo Material Adverse Effect, or similar qualifications set forth in any such representation or warranty) would not,
individually or in the aggregate, reasonably be expected to have a PubCo Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="text-decoration:underline">Performance
of Obligations</span>. Each PubCo Entity shall have performed in all material respects all obligations and covenants required to be performed
by it under this Agreement at or before the Closing Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;<span style="text-decoration:underline">Absence
of PubCo Material Adverse Effect</span>. No event, circumstance, development, change or effect shall have occurred since the date of this
Agreement that, individually or in the aggregate, has had, or would reasonably be expected to have, a PubCo Material Adverse Effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;<span style="text-decoration:underline">Officer&#8217;s
Certificate</span>. The Company shall have received a certificate, signed by an executive officer of PubCo, certifying as to the matters
set forth in <span style="text-decoration:underline">Section 6.03(a)</span>, <span style="text-decoration:underline">Section 6.03(b)</span>, and <span style="text-decoration:underline">Section 6.03(c)</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;<span style="text-decoration:underline">Resignation
and Releases</span>. A written resignation and general release, in a form reasonably satisfactory to the Company, dated as of the Closing
Date and effective as of the Closing, by and for each of the officers and directors of PubCo who are not going to continue as officers
or directors of PubCo after the Closing pursuant to <span style="text-decoration:underline">Section 5.15(a)</span> hereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 6.04 <span style="text-decoration:underline">Frustration
of Closing Conditions</span></b>. Neither the Company, on the one hand, nor any PubCo Entity, on the other hand, may rely, either as a basis
for not consummating the Transactions or for terminating this Agreement and abandoning the Transactions, on the failure of any condition
set forth in <span style="text-decoration:underline">Section 6.01</span>, <span style="text-decoration:underline">Section 6.02</span>, or <span style="text-decoration:underline">Section 6.03</span>, as the case may be, to be satisfied if such failure was
principally caused by such Party&#8217;s breach of any provision of this Agreement or failure to use the efforts to consummate the Transactions,
as required by and subject to this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"></p><div>

</div><!-- Field: Page; Sequence: 445 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE VII. TERMINATION, AMENDMENT AND WAIVER</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 7.01 <span style="text-decoration:underline">Termination
by Mutual Consent</span></b>. This Agreement may be terminated at any time before the Effective Time, whether before or after obtaining the
Requisite PubCo Vote, by mutual written consent of PubCo and the Company.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 7.02 <span style="text-decoration:underline">Termination
by Either PubCo or the Company</span></b>. This Agreement may be terminated by either PubCo or the Company at any time before the Effective
Time:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.55pt">(a)&#160;if
the Transactions have not been consummated by March 7, 2026 (the &#8220;<span style="text-decoration:underline">Termination Date</span>&#8221;), except that the right to terminate
this Agreement under this <span style="text-decoration:underline">Section 7.02(a)</span> shall not be available to any Party whose breach of this Agreement has been a principal
cause of, or principal reason for, the failure to consummate the Transactions by such date, provided, that, absent any such breach and
in the event that the SEC has not declared the Registration Statement effective under the Securities by the date which is sixty (60) days
prior to the Termination Date, then either the Company or PubCo shall be entitled to extend the Termination Date for an additional sixty
(60) days upon written notice to the other Party;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 70.55pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;if
this Agreement has been submitted to the PubCo Stockholders for adoption at a duly convened PubCo Stockholders Meeting (or adjournment
or postponement thereof) and the Requisite PubCo Vote is not obtained upon a vote taken thereon, except that the right to terminate this
Agreement under this <span style="text-decoration:underline">Section 7.02(b)</span> shall not be available to PubCo where the failure to obtain the Requisite PubCo Vote has been
caused by the action or failure to act of any of the PubCo Entities and such action or failure to act constitutes a material breach by
the PubCo Entities of this Agreement; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;if
any Law or Order is enacted, issued, promulgated or entered by a Governmental Authority of competent jurisdiction (including Nasdaq) that
permanently enjoins, or otherwise prohibits consummation of the Transactions, and (in the case of any Order) such Order has become final
and nonappealable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 7.03 <span style="text-decoration:underline">Termination
by the Company</span></b>. This Agreement may be terminated by the Company:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;if
(i) the PubCo Board publicly approves, endorses or recommends to the PubCo Stockholders a Superior Proposal, or (ii) a tender offer or
exchange offer for any outstanding shares of capital stock of PubCo is commenced before obtaining the Requisite PubCo Vote and the PubCo
Board fails to recommend against acceptance of such tender offer or exchange offer by its stockholders within ten Business Days after
commencement;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;if
any PubCo Entity breaches any of its representations, warranties, covenants or agreements contained in this Agreement, which breach would
give rise to the failure of a condition set forth in <span style="text-decoration:underline">Section 6.01</span> or <span style="text-decoration:underline">Section 6.03</span> and cannot be cured by the Termination
Date, or, if curable, has not been cured by the PubCo Entities within the earlier of (i) 30 days after PubCo&#8217;s receipt of written
notice of such breach from the Company, and (ii) one Business Day prior to the Termination Date; provided the Company shall not have the
right to terminate this Agreement pursuant to this <span style="text-decoration:underline">Section 7.03(b)</span> if the Company is then in breach of any of their representations,
warranties, covenants or agreements contained in this Agreement that would result in the conditions to Closing set forth in <span style="text-decoration:underline">Section
6.01</span> or <span style="text-decoration:underline">Section 6.02</span> not being satisfied; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;if
all of the conditions set forth in <span style="text-decoration:underline">Section 6.01</span> and <span style="text-decoration:underline">Section 6.02</span> have been satisfied (other than any condition the failure
of which to be satisfied has been principally caused by the breach of this Agreement by any PubCo Entity or any of their respective Affiliates
and conditions that, by their nature, are to be satisfied at Closing and which were, at the time of termination, capable of being satisfied)
and PubCo has failed to fulfill its obligation and agreement herein to consummate the Closing within three Business Days following written
notice of such satisfaction from the Company and that the Company is ready, willing and able to consummate the Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 446 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 7.04 <span style="text-decoration:underline">Termination
by PubCo</span></b>. This Agreement may be terminated by PubCo at any time before the Effective Time:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;if
the PubCo Board approves, endorses or recommends to the PubCo Stockholders a Superior Proposal prior to the receipt of the Requisite PubCo
Vote, if and only if prior to or substantially concurrent with such termination, (i) PubCo shall have paid the PubCo Termination Fee to
the Company pursuant to <span style="text-decoration:underline">Section 7.06</span>, and (ii) PubCo substantially concurrently with such termination enters into a definitive
agreement with respect to the Superior Proposal that did not result from a material breach of <span style="text-decoration:underline">Section 5.04</span> and that remained a
Superior Proposal following PubCo&#8217;s compliance with the provisions set forth in <span style="text-decoration:underline">Section 5.04</span>;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;if
the Company breaches any of its representations, warranties, covenants or agreements contained in this Agreement, which breach (i) would
give rise to the failure of a condition set forth in <span style="text-decoration:underline">Section 6.01</span> or <span style="text-decoration:underline">Section 6.02</span>, and (ii) cannot be cured by the Termination
Date, or, if curable, has not been cured by the Company within the earlier of (A) 30 days after the Company&#8217;s receipt of written
notice of such breach from PubCo, and (B) one Business Day prior to the Termination Date; provided PubCo shall not have the right to terminate
this Agreement pursuant to this <span style="text-decoration:underline">Section 7.04(b)</span> if any PubCo Entity is then in breach of any of its representations, warranties,
covenants or agreements contained in this Agreement that would result in the conditions to Closing set forth in <span style="text-decoration:underline">Section 6.01</span> or
<span style="text-decoration:underline">Section 6.03</span> not to be satisfied; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;if
all of the conditions set forth in <span style="text-decoration:underline">Section 6.01</span> and <span style="text-decoration:underline">Section 6.03</span> have been satisfied (other than any condition the failure
of which to be satisfied has been principally caused by the breach of this Agreement by the Company or any of its Affiliates and conditions
that, by their nature, are to be satisfied at Closing and which were, at the time of termination, capable of being satisfied) and the
Company has failed to fulfill its obligation and agreement herein to consummate the Closing within three Business Days following written
notice of such satisfaction from PubCo and that PubCo is ready, willing and able to consummate the Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 7.05 <span style="text-decoration:underline">Effect
of Termination</span></b>. If this Agreement is validly terminated pursuant to this <span style="text-decoration:underline">Article VII</span>, except as set forth in this <span style="text-decoration:underline">Section
7.05</span>, it shall become void and of no further force and effect, with no Liability (except as provided in <span style="text-decoration:underline">Section 7.06</span>) on the
part of any Party (or any stockholder or Representative of such Party), except that, subject to <span style="text-decoration:underline">Section 7.06</span>, the termination of
this Agreement shall not relieve any Party of Liability if such termination results from (a) fraud, or (b) the willful and material (i)
failure of any Party to perform its covenants, obligations or agreements contained in this Agreement, or (ii) breach by any Party of its
representations or warranties contained in this Agreement. The provisions of <span style="text-decoration:underline">Section 5.03(d)</span> (Confidentiality), <span style="text-decoration:underline">Section 5.12</span>
(Fees and Expenses), this <span style="text-decoration:underline">Section 7.05</span> (Effect of Termination), <span style="text-decoration:underline">Section 7.06</span> (Fees and Expenses Following Termination),
<span style="text-decoration:underline">Article IX</span> (Miscellaneous), and the definitions of defined terms in such Sections shall survive any valid termination of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-size: 10pt"><b>Section
7.06 <span style="text-decoration:underline">Fees and Expenses Following Termination</span></b></span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;<span style="text-decoration:underline">PubCo
Termination Fee</span>. Notwithstanding anything in this Agreement to the contrary:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(i)&#160;if
(A) this Agreement is terminated by the Company pursuant to <span style="text-decoration:underline">Section&#160;7.02(b)</span>, (B) a Superior Proposal with respect to PubCo
shall have been publicly announced, disclosed or otherwise communicated to PubCo or the PubCo Board at any time after the date of this
Agreement but prior to the termination of this Agreement (which shall not have been withdrawn) and (C) within twelve (12) months after
the date of such termination, PubCo (1) consummates a transaction in respect of the Superior Proposal referred to in clause (B) (the &#8220;<span style="text-decoration:underline">Superior
Transaction</span>&#8221;) or (2) the Superior Transaction is withdrawn, terminated or otherwise discontinued for any reason, then PubCo
shall pay to the Company the PubCo Termination Fee upon the consummation, withdrawal, termination or other discontinuation, as applicable,
of the Superior Transaction;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(ii)&#160;if
this Agreement is terminated by PubCo pursuant to <span style="text-decoration:underline">Section 7.04(a)</span> then PubCo shall pay to the Company the PubCo Termination Fee
within ten Business Days of such termination; or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(iii)&#160;if
this Agreement is terminated by the Company pursuant to <span style="text-decoration:underline">Section&#160;7.03(a)</span>, then PubCo shall pay to the Company the PubCo Termination
Fee within ten Business Days after receiving written notice of such termination from the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 447 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;<span style="text-decoration:underline">Payment
of PubCo Termination Fee</span>. The payment of any PubCo Termination Fee required to be made pursuant to <span style="text-decoration:underline">Section 7.06(a)</span> shall be
made by wire transfer of immediately available funds to the account(s) designated by the Company as set forth on <span style="text-decoration:underline">Schedule 7.06(b)</span>
of the Company Disclosure Letter or to such other account(s) designated by the Company in writing to PubCo after the date hereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;<span style="text-decoration:underline">Others
Fees and Expenses Following Termination</span>. Notwithstanding anything in this Agreement to the contrary:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(i)&#160;the
Company shall not be required to pay any termination fee upon termination of this Agreement;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(ii)&#160;PubCo
acknowledges and agrees that the provisions of this <span style="text-decoration:underline">Section 7.06</span> are an integral part of the Transactions (including the Merger),
and that without such provisions the Company would not have entered into this Agreement. If PubCo shall fail to pay in a timely manner
the amount due pursuant to this <span style="text-decoration:underline">Section 7.06</span>, and, in order to obtain such overdue amount and enforce its rights under this <span style="text-decoration:underline">Section
7.06</span>, the Company makes a claim against PubCo that results in a judgment against PubCo, then PubCo shall pay to the Company the reasonable
and documented out-of-pocket costs and expenses of the Company (including its reasonable and documented attorneys&#8217; fees and expenses)
incurred or accrued in connection with such suit, provided that any such attorneys&#8217; fees are based upon actual hours worked by an
attorney at such attorney&#8217;s normal hourly billing rate and not upon any percentage of any amount in dispute, premium, results achieved
or any non-hourly charge; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">(iii)&#160;except
in the case of a willful breach of any representation, warranty, covenant, obligation or other provision contained in this Agreement or
fraud by any of the PubCo Entities (in which case the Company shall be entitled to seek monetary damages, recovery or award from PubCo),
(A) the parties agree that the Company&#8217;s right to receive payment from PubCo of the PubCo Termination Fee pursuant to <span style="text-decoration:underline">Section
7.06</span> shall constitute the sole and exclusive monetary remedy of the Company against the PubCo Entities for all losses and damages
suffered as a result of the failure of the Transactions contemplated by this Agreement to be consummated or for a breach or failure to
perform hereunder, and upon payment of such PubCo Termination Fee, none of the PubCo Entities shall have any further liability or obligation
relating to or arising out of this Agreement or the transactions contemplated by this Agreement (except with respect to this <span style="text-decoration:underline">Section&#160;7.6</span>)
and (ii) the Parties hereby agree that if actually paid in full, the PubCo Termination Fee shall represent the sole and exclusive remedy
of the Company in the circumstances in which such fee is payable and the Company shall not be entitled to bring or maintain any other
claim, action or proceeding against PubCo, shall be precluded from any other remedy against PubCo, at law, in equity, in contract, in
tort or otherwise, and shall not seek to obtain any recovery or judgment against PubCo, in connection with or arising out of the termination
of any of the this Agreement or any other agreement entered into connection with the Transactions (the &#8220;<span style="text-decoration:underline">Transaction Documents</span>&#8221;),
any breach by PubCo giving rise to such termination, the failure of the Transactions to be consummated, the failure by PubCo to perform
its obligations under this Agreement or the other Transaction Documents (other than the Confidentiality Agreement) or failure by PubCo
to perform any obligation under Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE VIII. [INTENTIONALLY LEFT BLANK]</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE IX. MISCELLANEOUS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 9.01 <span style="text-decoration:underline">Certain
Definitions</span></b>. For purposes of this Agreement:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;&#8220;<span style="text-decoration:underline">Affiliate</span>&#8221;
means, with respect to any Person, any other Person that directly or indirectly controls, is controlled by or is under common control
with, such first Person. For the purposes of this definition, &#8220;control&#8221; (including, with correlative meanings, the terms &#8220;controlling,&#8221;
&#8220;controlled by&#8221; and &#8220;under common control with&#8221;), when used with respect to any Person, means the power to direct
or cause the direction of the management or policies of such Person, directly or indirectly, whether through the ownership of voting securities,
by Contract or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 448 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;&#8220;<span style="text-decoration:underline">Antitrust
Laws</span>&#8221; means the HSR Act, the Federal Trade Commission Act, the Sherman Act, the Clayton Act, and any applicable foreign antitrust
Laws and all other applicable Laws that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect
of monopolization or restraint of trade or lessening of competition through merger or acquisition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;&#8220;<span style="text-decoration:underline">Business
Day</span>&#8221; means any day other than Saturday, Sunday or a day on which commercial banks in Hong Kong and New York, New York are authorized
or required by Law to close.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;&#8220;<span style="text-decoration:underline">Company
Assets</span>&#8221; means any assets of the Company or any of its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.05pt">(e)&#160;&#8220;<span style="text-decoration:underline">Company
Material Adverse Effect</span>&#8221; means any change, event, violation, inaccuracy, effect or circumstance (each, an &#8220;<span style="text-decoration:underline">Effect</span>&#8221;)
that, individually or in the aggregate with any one or more other Effects, would reasonably be expected to (x) result in a material adverse
effect on the business, assets, liabilities, results of operations or financial condition of the Company and its Subsidiaries, taken as
a whole, or (y) prevent, or materially impair or delay, the ability of the Company to consummate the Transactions or otherwise perform
any of its obligations under this Agreement, taken as a whole; provided, however, no Effect (by itself or when aggregated or taken together
with any and all other Effects) resulting or arising from any of the following shall be taken into account when determining whether a
&#8220;<span style="text-decoration:underline">Company Material Adverse Effect</span>&#8221; has occurred: (a) general economic conditions (or changes in such conditions) in
the United States or any other country or region in the world, or conditions in the global economy generally, affecting the industry in
which the Company operates; (b) conditions (or changes in such conditions) in the securities markets, credit markets, currency or other
financial markets in the United States or any other country or region in the world; (c) conditions (or changes in such conditions) in
the industries in which the Company and its Subsidiaries conduct business; (d) changes in political conditions in the United States or
any other country or region in the world or acts of war, sabotage or terrorism (including any escalation or general worsening of any such
acts of war, sabotage or terrorism) in the United States or any other country or region in the world; (e) earthquakes, hurricanes, tsunamis,
tornadoes, floods, mudslides, wild fires or other natural disasters, weather conditions and other force majeure events in the United States
or any other country or region in the world; (f) pandemics, epidemics or disease outbreaks or any escalation or worsening of any of the
foregoing (including, for the avoidance of doubt, any effect resulting from, arising out of or otherwise related to a pandemic (including
any impact of any associated shutdown, shelter in place or non-essential business order or other similar measures mandated or recommended
by any applicable Governmental Authority); (g) the announcement of this Agreement or the pendency or consummation of the Transactions;
(h) changes in Law or other legal or regulatory conditions, or the interpretation thereof, or changes in GAAP or other accounting standards
(or the interpretation thereof), or that result from any action taken for the purpose of complying with any of the foregoing; or (i) any
specific action taken (or omitted to be taken) by the Company that is required by this Agreement; provided, further, that any Effect relating
to or arising out of or resulting from any change or event referred to in clauses (a) through (f) or (h) above may constitute, and be
taken into account in determining the occurrence of, a Company Material Adverse Effect if and only to the extent that such change or event
has a disproportionate impact on the Company and its Subsidiaries as compared to other participants that operate in the industry in which
the Company and its Subsidiaries operate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.05pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.05pt"></p><div>

</div><!-- Field: Page; Sequence: 449 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.05pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;&#8220;<span style="text-decoration:underline">Company
Ordinary Shares</span>&#8221; means the ordinary shares, par value $0.10 per share, of the Company of any series or class.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;&#8220;<span style="text-decoration:underline">Company
Outstanding Shares</span>&#8221; means the total number of shares of Company Ordinary Shares outstanding immediately prior to the Effective
Time expressed on a fully diluted and as-converted to Company Ordinary Share basis, assuming, without limitation or duplication, and calculated
using the treasury stock method (i) the conversion of each Company Preferred Share into shares of Company Ordinary Shares immediately
prior to the Effective Time and in accordance with the Company&#8217;s memorandum and articles of association; (ii) the Company Convertible
Securities Conversion; and (iii) the issuance of Company Ordinary Shares in respect of all other rights to receive such shares that will
be outstanding immediately after the Effective Time, in each case pursuant to the instruments governing such securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#160;&#8220;<span style="text-decoration:underline">Company
Preferred Shares</span>&#8221; means the redeemable convertible preferred shares of the Company, par value $0.10.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#160;&#8220;<span style="text-decoration:underline">Company
Share Capital</span>&#8221; means the Company Ordinary Shares together with the Company Preferred Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#160;&#8220;<span style="text-decoration:underline">Confidentiality
Agreement</span>&#8221; means that certain mutual non-disclosure and confidentiality agreement, dated as of December 10, 2024, by and between
PubCo and YOOV Internet Technology (Asia) Limited, a Hong Kong company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&#160;&#8220;<span style="text-decoration:underline">Contract</span>&#8221;
means any written or oral contract, agreement, indenture, note, bond, loan, lease, sublease, mortgage, license, sublicense, obligation
or other binding arrangement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&#160;&#8220;<span style="text-decoration:underline">DOJ</span>&#8221;
means the U.S. Department of Justice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)&#160;&#8220;<span style="text-decoration:underline">Environmental
Laws</span>&#8221; means all Laws relating to (i) pollution, contamination, protection of the (indoor or outdoor) environment or health and
safety, (ii) emissions, discharges, disseminations, releases or threatened releases of Hazardous Substances into the environment, including
air (indoor or outdoor), surface water, groundwater, soil, land surface or subsurface, buildings, facilities, real or personal property
or fixtures, or (iii) the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of, or exposure
to, Hazardous Substances. &#8220;<span style="text-decoration:underline">Environmental Laws</span>&#8221; includes the Comprehensive Environmental Response, Compensation and
Liability Act, 42 U.S.C. &#167; 9601 et seq., the Clean Water Act, 33 U.S.C. &#167; 1251 et seq., the Clean Air Act, 42 U.S.C. &#167;
7401 et seq., the Toxic Substances Control Act, 15 U.S.C. &#167; 2601 et seq., the Federal Insecticide, Fungicide, and Rodenticide Act,
7 U.S.C. &#167; 136 et seq., the Oil Pollution Act of 1990, 33 U.S.C. &#167; 2701 et seq., the Emergency Planning and Community Right-to-Know
Act of 1986, 42 U.S.C. &#167; 11001 et seq., the Safe Drinking Water Act, 42 U.S.C. &#167; 300f et seq., the Endangered Species Act, 16
U.S.C. &#167; 1531 et seq., the Solid Waste Disposal Act, as amended by the Resource Conservation and Control Act, 42 U.S.C. &#167; 6901
et seq. and all applicable analogous state or local statutes or ordinances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(n)&#160;&#8220;<span style="text-decoration:underline">ERISA
Affiliate</span>&#8221; means, with respect to any Person, any trade or business (whether or not incorporated) that is treated as a single
employer with such Person within the meaning of Section 4001 of ERISA or Sections 414(b), (c), (m), or (o) of the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(o)&#160;&#8220;<span style="text-decoration:underline">Exchange
Ratio</span>&#8221; means the ratio (rounded to four decimal places), determined as follows, if the closing price of the PubCo Common Stock
on NASDAQ on the second trading day immediately preceding the Effective Time is (x) less than or equal to $5.00, the Exchange Ratio shall
be 60,000,000 divided by the Company Outstanding Shares; or (y) greater than $5.00, the Exchange Ratio shall be 54,000,000 divided by
the Company Outstanding Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(p)&#160;&#8220;<span style="text-decoration:underline">FTC</span>&#8221;
means the U.S. Federal Trade Commission.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(q)&#160;&#8220;<span style="text-decoration:underline">GAAP</span>&#8221;
generally accepted accounting principles and practices in effect from time to time within the United States applied consistently throughout
the period involved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 450 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(r)&#160;&#8220;<span style="text-decoration:underline">Governmental
Authority</span>&#8221; means (i) any federal, state, local, foreign or international government or governmental authority, regulatory or
administrative agency, governmental commission, department, board, bureau, agency or instrumentality, court, tribunal, arbitrator or arbitral
body (public or private); and (ii) any self-regulatory organization (including Nasdaq); (iii) any political subdivision of any of the
foregoing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(s)&#160;&#8220;<span style="text-decoration:underline">Hazardous
Substances</span>&#8221; means any material, substance, chemical, waste, product, derivative, compound, mixture, solid, liquid, mineral,
or gas, in each case, whether naturally occurring or manmade, that presents a risk to human health or the environment or is hazardous,
acutely hazardous, toxic, or words of similar import or regulatory effect under any Environmental Law or is otherwise governed, defined,
regulated, or for which Liability or standards of conduct may be imposed under any Environmental Law including but not limited to any
petroleum or petroleum-derived products, radon, radioactive materials or wastes, asbestos in any form, lead or lead-containing materials,
urea formaldehyde foam insulation, polychlorinated biphenyls, mold, and perfluoroalkyl and polyfluoroalkyl substances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(t)&#160;&#8220;<span style="text-decoration:underline">HSR
Act</span>&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(u)&#160;&#8220;<span style="text-decoration:underline">Intellectual
Property</span>&#8221; means all intellectual property and other similar proprietary rights in any jurisdiction throughout the world, including
any and all (i) inventions (whether or not patentable), invention disclosures, patents and patent applications (including divisionals,
provisionals, continuations, continuations-in-part, and renewal applications), and any renewals, extensions, or reissues thereof; (ii)
trademarks, service marks, trade dress, logos, slogans, trade names, assumed names, corporate names, domain names and other source identifiers,
including all registrations and applications for registration of the foregoing, and all goodwill associated with any of the foregoing;
(iii) copyrights (including all registrations and applications for registration), copyrightable subject matter, original works of authorship,
and moral rights; (iv) rights in Software, (v) trade secrets, including confidential and proprietary information and know-how (including
processes, formulae, techniques, methods, algorithms, data, databases, designs, drawings, specifications, and material proprietary customer
and business data); and (vi) rights to sue and recover and retain damages, costs and attorneys&#8217; fees for the past, present and future
infringement, misappropriation or other violation of any of the foregoing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)&#160;&#8220;<span style="text-decoration:underline">Intervening
Event</span>&#8221; means any material event, change, effect, development or occurrence occurring or arising after the date of this Agreement
that (i) was not known by nor was reasonably foreseeable to the board of directors of any Party or the executive officers of any Party
as of or prior to the date of this Agreement (or, if known, the consequences of which were not known or reasonably foreseeable to such
Persons as of the date of this Agreement) and results in the standalone financial condition of PubCo, the Company and their respective
Subsidiaries, taken as a whole, being materially more favorable to the PubCo Stockholders or the Company Shareholders, as applicable,
than this Agreement and the Transactions, and (ii) does not relate to or involve a (A) Takeover Proposal or, (B) in the case of PubCo,
any changes in the market price, or change in trading volume, of the PubCo Common Stock, any change of the ratings or ratings outlook
for PubCo by any of the Rating Agencies and the consequences of any such ratings or outlook changes, or PubCo exceeding any projections,
forecasts, budgets, operational metrics or estimates (it being understood that the underlying causes of any such changes or developments
may, if they are not otherwise excluded from the definition of Intervening Event, be taken into account in determining whether an Intervening
Event has occurred).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(w)&#160;&#8220;<span style="text-decoration:underline">Intervening
Event Notice</span>&#8221; means a prior written notice of an Intervening Event delivered by one Party to the other Party in accordance with
<span style="text-decoration:underline">Section 5.04(c)(v)</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(x)&#160;&#8220;<span style="text-decoration:underline">Intervening
Event Notice Period</span>&#8221; means five Business Days (as modified, extended or continued in accordance with <span style="text-decoration:underline">Section 5.04(c)(v)</span>).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(y)&#160;&#8220;<span style="text-decoration:underline">Knowledge</span>&#8221;
means, when used with respect to PubCo or the Company, the actual knowledge of the Persons set forth in <span style="text-decoration:underline">Section 9.01(aa)</span> of the
PubCo Disclosure Letter or Company Disclosure Letter, respectively and such Persons on the PubCo Disclosure Letter referred to as the
&#8220;<span style="text-decoration:underline">PubCo Knowledge Persons</span>,&#8221; and such Persons on the Company Disclosure Letter referred to as the &#8220;<span style="text-decoration:underline">Company Knowledge
Persons</span>,&#8221; in each case, after reasonable investigation of each such individual.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(z)&#160;&#8220;<span style="text-decoration:underline">Law</span>&#8221;
means any federal, state, national, material local or municipal or other law, statute, ordinance, code, regulation, rule, the common law
or other requirement of any Governmental Authority, and any Orders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 451 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(aa) &#8220;<span style="text-decoration:underline">Liens</span>&#8221;
means any mortgages, deeds of trust, liens, pledges, security interests, leases, subleases, licenses, covenants, claims, hypothecations,
options, rights of first offer or refusal, charges or other encumbrances in respect of any property or asset.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(bb) &#8220;<span style="text-decoration:underline">Merger
Sub Ordinary Shares</span>&#8221; means the ordinary shares, no par value per share, of Merger Sub of any series or class.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(cc) &#8220;<span style="text-decoration:underline">Nasdaq</span>&#8221;
means the Nasdaq Stock Market LLC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(dd) &#8220;<span style="text-decoration:underline">Orders</span>&#8221;
means any orders, decisions, judgments, writs, injunctions, decrees, awards or other determinations of any Governmental Authority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ee) &#8220;<span style="text-decoration:underline">Permitted
Liens</span>&#8221; means (i) statutory Liens for Taxes, assessments or other charges by Governmental Authorities not yet due and payable
or the amount or validity of which is being contested in good faith and by appropriate proceedings, and for which adequate reserves have
been made on the Company Balance Sheet and PubCo Balance Sheet, (ii) mechanics&#8217;, materialmen&#8217;s, carriers&#8217;, workmen&#8217;s,
warehouseman&#8217;s, repairmen&#8217;s, landlords&#8217; and similar Liens granted or which arise in the ordinary course of business
that are not material in amount and do not materially detract from the value of or materially impair the existing use of the property
affected by such Lien, (iii) zoning, entitlement, building and other land use Liens applicable to real property which are not violated
by the current use, occupancy or operation of such real property, (iv) Liens arising under worker&#8217;s compensation, unemployment insurance,
social security, retirement and similar Laws, (v) Liens on goods in transit incurred pursuant to documentary letters of credit, and (vi)
non-exclusive, non-perpetual licenses of Intellectual Property granted by the applicable Party in the ordinary course of business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ff) &#8220;<span style="text-decoration:underline">Person</span>&#8221;
means any natural person, corporation, company, partnership, association, limited liability company, limited partnership, limited liability
partnership, trust or other legal entity or organization, including a Governmental Authority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(gg) &#8220;<span style="text-decoration:underline">Proxy
Statement</span>&#8221; means the proxy statement to be sent to PubCo Stockholders in connection with the PubCo Stockholders Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(hh) &#8220;<span style="text-decoration:underline">PubCo
Assets</span>&#8221; means any assets of PubCo or any of its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&#160;&#8220;<span style="text-decoration:underline">PubCo
Balance Sheet</span>&#8221; means the unaudited balance sheet of PubCo as of September 30, 2024 (the &#8220;<span style="text-decoration:underline">PubCo Balance Sheet Date</span>&#8221;),
included in PubCo&#8217;s Report on Form 10-Q for the quarterly period ended September 30, 2024, as filed with the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(jj) &#8220;<span style="text-decoration:underline">PubCo
Capital Stock</span>&#8221; means PubCo Common Stock and PubCo Preferred Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">(kk) &#8220;<span style="text-decoration:underline">PubCo Common
Stock</span>&#8221; means the Common Stock, par value $0.01 per share, of PubCo.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">(ll) &#8220;<span style="text-decoration:underline">PubCo Employee</span>&#8221;
each individual who is an employee, independent contractor or other individual service provider of PubCo and its Subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">(mm) &#8220;<span style="text-decoration:underline">PubCo Equity
Plan</span>&#8221; means Amended and Restated 2020 Stock Incentive Plan, as adopted on October 12, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt"></p><div>

</div><!-- Field: Page; Sequence: 452 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">(nn) &#8220;<span style="text-decoration:underline">PubCo Financial
Advisor</span>&#8221; means Roth Capital Partners, LLC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">(oo)&#160;&#8220;<span style="text-decoration:underline">PubCo
Material Adverse Effect</span>&#8221; means any Effect that, individually or in the aggregate with any one or more other Effects, would reasonably
be expected to (x) result in a material adverse effect on the business, assets, Liabilities, results of operations or condition (financial
or otherwise) of the PubCo Entities and their Subsidiaries, taken as a whole, or (y) prevent, or materially impair or delay, the ability
of the PubCo Entities to consummate the Transactions or otherwise perform any of its obligations under this Agreement, taken as a while;
provided, however, no Effect (by itself or when aggregated or taken together with any and all other Effects) resulting or arising from
any of the following shall be taken into account when determining whether a &#8220;<span style="text-decoration:underline">PubCo Material Adverse Effect</span>&#8221; has occurred:
(a) general economic conditions (or changes in such conditions) in the United States or any other country or region in the world, or conditions
in the global economy generally, affecting the industry in which PubCo operates; (b) conditions (or changes in such conditions) in the
securities markets, credit markets, currency markets or other financial markets in the United States or any other country or region in
the world; (c) conditions (or changes in such conditions) in the industries in which PubCo Entities and their Subsidiaries conduct business;
(d) changes in political conditions in the United States or any other country or region in the world or acts of war, sabotage or terrorism
(including any escalation or general worsening of any such acts of war, sabotage or terrorism) in the United States or any other country
or region in the world; (e) earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, wild fires or other natural disasters, weather
conditions and other force majeure events in the United States or any other country or region in the world; (f) pandemics, epidemics or
disease outbreaks or any escalation or worsening of any of the foregoing (including, for the avoidance of doubt, any effect resulting
from, arising out of or otherwise related to any the impact of any associated shutdown, shelter in place or non-essential business order
or other similar measures mandated or recommended by any applicable Governmental Authority); (g) the announcement of this Agreement or
the pendency or consummation of the Transactions; (h) changes in Law or other legal or regulatory conditions, or the interpretation thereof,
or changes in GAAP or other accounting standards (or the interpretation thereof), or that result from any action taken for the purpose
of complying with any of the foregoing; (i) any specific action taken (or omitted to be taken) by PubCo that is required by this Agreement;
or (j) any failure by PubCo or any of its Subsidiaries to meet any internal or external projections or forecasts or any decline in the
price of PubCo Common Stock (but excluding, in each case, the underlying causes of such failure or decline, as applicable, which may themselves
constitute or be taken into account in determining whether there has been, or would be, a PubCo Material Adverse Effect); provided, further,
that any Effect relating to or arising out of or resulting from any change or event referred to in clauses (a) through (f) or (h) above
may constitute, and be taken into account in determining the occurrence of, a PubCo Material Adverse Effect if and only to the extent
that such change or event has a disproportionate impact on the PubCo Entities and their Subsidiaries as compared to other participants
that operate in the industry in which the PubCo Entities and their Subsidiaries operate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">(pp) &#8220;<span style="text-decoration:underline">PubCo Preferred
Stock</span>&#8221; means the preferred stock of PubCo, $0.0001 par value; 10,000,000 shares authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">(qq) &#8220;<span style="text-decoration:underline">PubCo RSUs</span>&#8221;
means restricted stock units issued by PubCo.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">(rr) &#8220;<span style="text-decoration:underline">PubCo Stock
Issuance</span>&#8221; means the issuance, on the terms and subject to the conditions set forth in this Agreement, of the shares of PubCo
Common Stock that represent more than twenty percent (20%) of the shares of PubCo Common Stock outstanding immediately prior to the Merger
to the Company Shareholders in connection with the transactions contemplated by this Agreement and the change of control of PubCo resulting
from the transactions contemplated by this Agreement, in each case pursuant to the Nasdaq rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">(ss) &#8220;<span style="text-decoration:underline">PubCo Stock
Option</span>&#8221; means a stock option to purchase shares of PubCo Common Stock issued by PubCo pursuant to the PubCo Equity Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt"></p><div>

</div><!-- Field: Page; Sequence: 453 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.7pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(tt) &#8220;<span style="text-decoration:underline">PubCo
Stockholder Matters</span>&#8221; means (i) the amendment of PubCo&#8217;s certificate of incorporation to effect the Reverse Stock Split
(to the extent PubCo and the Company mutually agree is applicable and necessary to meet the requirements, if any, for the Nasdaq Listing
Application), (ii) the PubCo Stock Issuance and (iii) any other proposals PubCo and the Company mutually agree is necessary or desirable
to consummate the transactions contemplated by this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(uu) &#8220;<span style="text-decoration:underline">PubCo
Stockholders Meeting</span>&#8221; means the special meeting of the PubCo Stockholders to be held to consider the approval of this Agreement
and the Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vv) &#8220;<span style="text-decoration:underline">PubCo
Termination Fee</span>&#8221; means a one-time fee in an amount equal to $1,000,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ww) &#8220;<span style="text-decoration:underline">Qualified
Person</span>&#8221; means any Person making a <i>bona fide </i>Takeover Proposal that did not result from a breach of <span style="text-decoration:underline">Section 5.04</span>
that the board of directors of such Party receiving the Takeover Proposal determines in good faith (after consultation with outside counsel
and its financial advisor) is, or would reasonably be expected to lead to, a Superior Proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 73pt">(xx)&#160;&#8220;<span style="text-decoration:underline">Rating
Agencies</span>&#8221; means Standard &amp; Poor&#8217;s Ratings Service and A.M. Best Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 73pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 73pt">(yy) &#8220;<span style="text-decoration:underline">Representatives</span>&#8221;
means, when used with respect to any Person, the directors, officers, employees, consultants, accountants, legal counsel, investment bankers
or other financial advisors, agents and other representatives of such Person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 73pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 73pt">(zz) &#8220;<span style="text-decoration:underline">Requisite
Company Vote</span>&#8221; means the written consent or affirmative vote of (i) the holders of a majority of the outstanding Company Ordinary
Shares, and (ii) the holders of a majority of the outstanding shares of Company Preferred Share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 73pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(aaa) &#8220;<span style="text-decoration:underline">Requisite
PubCo Vote</span>&#8221; means the adoption of this Agreement and the Transactions by the affirmative vote of holders of a majority of the
outstanding shares of PubCo Common Stock as of the record date for the PubCo Stockholders Meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(bbb) &#8220;<span style="text-decoration:underline">Reverse
Stock Split</span>&#8221; means a reverse stock split of the PubCo Common Stock, with the final ratio to be designated by the Company and
effective by PubCo prior to the Effective Time in accordance with the terms hereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ccc) &#8220;<span style="text-decoration:underline">Securities
Act</span>&#8221; means the Securities Act of 1933, as amended, and the rules promulgated thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ddd) &#8220;<span style="text-decoration:underline">Software</span>&#8221;
means all computer software (in object code or source code format), libraries, data and databases, and related specifications, documentation
and materials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(eee) &#8220;<span style="text-decoration:underline">Specified
Time</span>&#8221; means the earlier of (i) the time that this Agreement is terminated in accordance with the terms hereof, and (ii) receipt
of the Requisite PubCo Vote and Requisite Company Vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(fff) &#8220;<span style="text-decoration:underline">Stock
Equivalent</span>&#8221; means, with respect to any Person, any option or other security or obligation that is by its terms, directly or
indirectly, convertible into or exchangeable or exercisable for shares of Company, and any option, warrant or other right to subscribe
for, purchase or acquire shares of such Person&#8217;s capital stock or Stock Equivalents (disregarding any restrictions or limitations
on the exercise of such rights).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ggg) &#8220;<span style="text-decoration:underline">Subsidiary</span>&#8221;
means, when used with respect to any Person, any other Person that such Person directly or indirectly owns or has the power to vote or
control more than 50% of the voting stock or other interests the holders of which are generally entitled to vote for the election of the
board of directors or other applicable governing body of such other Person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 454 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(hhh) &#8220;<span style="text-decoration:underline">Superior
Proposal</span>&#8221; means a bona fide and unsolicited written Takeover Proposal (substituting &#8220;more than 50%&#8221; for &#8220;20%&#8221;
in each instance in the definition of Takeover Proposal), made by any Third Party or group (as defined in Section 13 of the Exchange Act)
after the date of this Agreement, which did not result from a direct or indirect material breach of any provision of this Agreement, including
<span style="text-decoration:underline">Section 5.04</span>, and that the board of directors of the Party receiving such Takeover Proposal determines in good faith, in consultation
with outside legal counsel and financial advisors and taking into account (with such weight and proportion as determined by such board
of directors in its sole discretion) all the terms and conditions and the financial, legal, regulatory, timing, financing, conditionality
and other aspects and risks of such Takeover Proposal and this Agreement (after taking into account any revisions to the terms and conditions
to this Agreement made or proposed in writing by the other Party to the Agreement in accordance with <span style="text-decoration:underline">Section 5.04</span>), (i) are more
favorable to the stockholders of PubCo or shareholders of the Company, as applicable (solely in their capacities as such) than the Transactions,
and (ii) the board of directors of PubCo or the Company, as applicable, believes is reasonably likely to be consummated in accordance
with its terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&#160;&#8220;<span style="text-decoration:underline">Superior
Proposal Notice</span>&#8221; means a prior written notice of a Superior Proposal delivered by one Party to the other Party in accordance
with <span style="text-decoration:underline">Section 5.04(c)(vi)</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(jjj) &#8220;<span style="text-decoration:underline">Superior Proposal
Notice Period</span>&#8221; means five Business Days (as modified, extended or continued in accordance with <span style="text-decoration:underline">Section 5.04(c)(vi))</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(kkk) &#8220;<span style="text-decoration:underline">Takeover
Proposal</span>&#8221; means any proposal, offer, inquiry or indication of interest from a Third Party or &#8220;group&#8221; (as defined
in Section 13 of the Exchange Act) of Third Parties, whether involving a single or a series of related transactions made or submitted
to PubCo or the Company relating to (i) a merger, consolidation, share exchange or business combination involving a Party or any of its
Subsidiaries representing 20% or more of such Party&#8217;s assets, revenues, or earnings, (ii) a sale, lease, exchange, mortgage, transfer
or other disposition of 20% or more of a Party&#8217;s assets, revenues or earnings, (iii) a direct or indirect purchase or sale of shares
of capital stock, share capital or other Stock Equivalents of a Party (including the PubCo Common Stock) representing 20% or more of the
voting power of the capital stock or share capital of such Party or any successor or parent company thereto, including by way of a merger,
business combination, share exchange, tender offer or exchange offer, (iv) a reorganization, recapitalization, liquidation or dissolution
of a Party, or (v) any other transaction having a similar effect to those described in clauses (i) through (iv), or any combination of
the transactions in (i) through (iv) in each case other than the Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(lll) &#8220;<span style="text-decoration:underline">Tax Returns</span>&#8221;
means any and all reports, returns, declarations, claims for refund, elections, disclosures, estimates, information reports or returns
or statements required to be supplied to a Governmental Authority in connection with Taxes, including any schedule or attachment thereto
or amendment thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(mmm) &#8220;<span style="text-decoration:underline">Taxes</span>&#8221;
means (i) any and all federal, state, provincial, local, foreign and other taxes, levies, fees, imposts, duties, and similar governmental
charges (including any interest, fines, assessments, penalties or additions to tax imposed in connection therewith or with respect thereto)
including (x) taxes imposed on, or measured by, income, franchise, profits or gross receipts, and (y) ad valorem, value added, capital
gains, sales, goods and services, use, real or personal property, capital stock, share capital, license, branch, payroll, estimated withholding,
employment, social security (or similar), unemployment, compensation, escheat, abandoned and unclaimed property, utility, severance, production,
excise, stamp, occupation, premium, windfall profits, transfer and gains taxes, and customs duties, (ii) any and all Liability for the
payment of any items described in clause (i) above as a result of being (or ceasing to be) a member of an affiliated, consolidated, combined,
unitary or aggregate group (or being included (or being required to be included) in any Tax Return related to such group), including pursuant
to Treasury Regulations Section 1.1502-6 (or comparable provision of state, local or non-U.S. Tax Law), and (iii) any and all Liability
for the payment of any amounts described in clause (i) or (ii) above as a result of any express or implied obligation to indemnify any
other person, or any successor or transferee Liability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 73pt">(nnn) &#8220;<span style="text-decoration:underline">Third Party</span>&#8221;
means any Person or group other than the Company and its Affiliates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 73pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 73pt"></p><div>

</div><!-- Field: Page; Sequence: 455 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 73pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 9.02 <span style="text-decoration:underline">Interpretation</span></b>.
Unless the express context otherwise requires:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#160;the
words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import, when used in this Agreement,
shall refer to this Agreement as a whole and not to any particular provision of this Agreement;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&#160;terms
defined in the singular shall have a comparable meaning when used in the plural, and vice versa;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&#160;the
terms &#8220;Dollars&#8221; and &#8220;$&#8221; mean U.S. dollars;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)&#160;references
herein to a specific Section, Subsection, Recital, Schedule or Exhibit shall refer, respectively, to Sections, Subsections, Recitals,
Schedules or Exhibits of this Agreement unless otherwise indicated;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)&#160;wherever
the word &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; is used in this Agreement, it shall be deemed to be
followed by the words &#8220;without limitation&#8221;;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)&#160;references
herein to any gender shall include each other gender;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)&#160;references
herein to a Person in a particular capacity or capacities shall exclude such Person in any other capacity;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)&#160;the
word &#8220;or&#8221; shall be disjunctive but not exclusive;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#160;references
herein to any Law shall be deemed to refer to such Law as amended, modified, codified, reenacted, supplemented or superseded in whole
or in part and in effect from time to time, and also to all rules and regulations promulgated thereunder;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)&#160;the
headings contained in this Agreement are intended solely for convenience and shall not affect the rights of the Parties;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)&#160;if
the last day for the giving of any notice or the performance of any act required or permitted under this Agreement is a day that is not
a Business Day, then the time for the giving of such notice or the performance of such action shall be extended to the next succeeding
Business Day; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)&#160;references
herein to &#8220;ordinary course of business&#8221; shall refer to ordinary course of business consistent with past practice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 9.03 <span style="text-decoration:underline">No
Survival</span></b>. None of the representations and warranties contained in this Agreement or in any instrument delivered under this Agreement
shall survive the Effective Time. This <span style="text-decoration:underline">Section 9.03</span> shall not limit any covenant or agreement of the Parties which, by its terms,
contemplates performance after the Effective Time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 9.04 <span style="text-decoration:underline">Governing
Law</span></b>. All matters arising out of or relating to this Agreement and the Transactions (including its interpretation, construction,
performance and enforcement) shall be governed by and construed in accordance with the Law of the State of Delaware without giving effect
to any choice or conflict of law provision or rule that would cause the application of Laws of any jurisdictions other than those of the
State of Delaware.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"></p><div>

</div><!-- Field: Page; Sequence: 456 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 9.05 <span style="text-decoration:underline">Submission
to Jurisdiction; Service</span></b>. Each Party (a) irrevocably and unconditionally submits to the personal jurisdiction of the federal courts
of the United States of America located in the State of Delaware and the Court of Chancery of the State of Delaware, (b) agrees to assert,
by way of motion or as a defense, counterclaim or otherwise, (i) any claim that it is not personally subject to the jurisdiction of the
courts in Delaware as described herein for any reason, or (ii) any claim that it or its property is exempt or immune from jurisdiction
of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment,
attachment in aid of execution of judgment, execution of judgment or otherwise), (c) agrees that any actions or proceedings arising in
connection with this Agreement or the Transactions shall be brought, tried and determined only in the Delaware Court of Chancery (or,
only if the Delaware Court of Chancery declines to accept jurisdiction over a particular matter, any state or federal court within the
State of Delaware), (d) waives any claim of improper venue or any claim that those courts are an inconvenient forum, and (e) agrees that
it will not bring any action relating to this Agreement or the Transactions in any court other than the aforesaid courts. The Parties
agree that mailing of process or other papers in connection with any such Legal Action or proceeding in the manner provided in <span style="text-decoration:underline">Section
9.07</span> or in such other manner as may be permitted by applicable Law, shall be valid and sufficient service thereof. Each of the parties
hereby irrevocably submits to the jurisdiction of the aforesaid courts for itself and with respect to its property, generally and unconditionally,
with regard to any such action or proceeding arising out of or relating to this Agreement and the Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 9.06 <span style="text-decoration:underline">WAIVER
OF JURY TRIAL</span></b>. EACH OF THE PARTIES HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING
OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 9.07 <span style="text-decoration:underline">Notices</span></b>.
All notices and other communications hereunder shall be in writing and shall be addressed as follows (or at such other address for a Party
as shall be specified by like notice):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify"><i>If to any PubCo Entity, to:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify">Avalon GloboCare Corp.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify">4400 Route 9 South, Suite 3100</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify">Freehold, New Jersey 07728</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify">Attn: Luisa Ingargiola (email:
[***])</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify"><i>With a copy which shall not constitute
notice to:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify">Lowenstein Sandler LLP</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118pt; text-align: justify">1251 Avenue of the Americas</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118pt; text-align: justify">New York, New York 10020</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify">Attn: Steven Skolnick, Esq. (email:
[***])</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify"><i>If to the Company, to:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify">YOOV Group Holding Limited</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify">1 Raffles Place</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify">#31-62 One Raffles
Place Tower 2</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify">Singapore 048616</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify">Attn: Phil Wong (email: [***])</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify"><i>With a copy which shall not constitute
notice to:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify">Lucosky Brookman LLP</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118pt; text-align: justify">101 Wood Avenue South, 5th Floor</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118pt; text-align: justify">Iselin, New Jersey 08830</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify">Attn: Joseph M. Lucosky, Esq. (email:
[***])</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 153pt; text-align: justify">Scott Linsky, Esq. (email: [***])</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 153pt; text-align: justify">Ian Liao, Esq. (email: [***])</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 153pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">All such notices or communications
shall be deemed to have been delivered and received: (a) if delivered in person, on the day of such delivery, (b) if by electronic mail,
on the day on which such electronic mail was sent; <span style="text-decoration:underline">provided</span>, written confirmation of receipt by e-mail or otherwise is confirmed,
(c) if by certified or registered mail (return receipt requested, postage prepaid), on the third Business Day after the mailing thereof,
or (d) if by reputable overnight delivery service, on the first Business Day after the sending thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"></p><div>

</div><!-- Field: Page; Sequence: 457 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 9.08 <span style="text-decoration:underline">Amendment</span></b>.
This Agreement may be amended by the Parties at any time before the Effective Time, whether before or after obtaining the Requisite PubCo
Vote, so long as (a) no amendment that requires further stockholder approval under applicable Law after stockholder approval hereof shall
be made without such required further approval, and (b) such amendment has been duly approved by the board of directors of each of PubCo
Entity and the Company. This Agreement may not be amended except by an instrument in writing signed by each of the Parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 9.09 <span style="text-decoration:underline">Extension;
Waiver</span></b>. At any time before the Effective Time, PubCo Entities, on the one hand, and the Company, on the other hand, may (a) extend
the time for the performance of any of the obligations of the other Party, (b) waive any inaccuracies in the representations and warranties
of the other Party contained in this Agreement or in any document delivered under this Agreement, or (c) subject to applicable Law, waive
compliance with any of the covenants or conditions contained in this Agreement; provided, however, that after the approval of the stockholders
of PubCo or the Company has been obtained, no waiver may be made that pursuant to applicable Law requires further approval or adoption
by the shareholders of the Company or stockholders of PubCo, as applicable, without such further approval or adoption. Any agreement on
the part of a Party to any extension or waiver shall be valid only if set forth in an instrument in writing signed by such Party. The
failure of any Party to assert any of its rights under this Agreement or otherwise shall not constitute a waiver of such rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 9.10 <span style="text-decoration:underline">Entire
Agreement</span></b>. This Agreement (and the exhibits hereto), the Company Disclosure Letter, the PubCo Disclosure Letter, the certificates
delivered hereunder, the PubCo Voting Agreements, the Company Voting Agreements, and the Confidentiality Agreement contain all of the
terms, conditions and representations and warranties agreed to by the Parties relating to the subject matter of this Agreement and supersede
all prior or contemporaneous agreements, negotiations, correspondence, undertakings, understandings, representations and warranties, both
written and oral, among the Parties with respect to the subject matter of this Agreement. No representation, warranty, inducement, promise,
understanding or condition not set forth in such documents has been made or relied upon by any of the Parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 9.11 <span style="text-decoration:underline">No
Third-Party Beneficiaries</span></b>. Except (a) for the Parties, (b) as provided in <span style="text-decoration:underline">Section 5.08</span> (Directors&#8217; and Officers&#8217;
Indemnification and Insurance), and (c) the rights of Covered Persons under <span style="text-decoration:underline">Section 5.17</span>, nothing in this Agreement, express or
implied, is intended to or shall confer upon any Person other than the parties and their respective successors and permitted assigns any
legal or equitable right, benefit or remedy of any nature under or by reason of this Agreement. The representations and warranties in
this Agreement are the product of negotiations among the Parties and are for the sole benefit of the Parties. Any inaccuracies in such
representations and warranties are subject to waiver by the parties hereto in accordance with <span style="text-decoration:underline">Section 9.09</span> without notice or liability
to any other Person. In some instances, the representations and warranties in this Agreement may represent an allocation among the parties
hereto of risks associated with particular matters regardless of the knowledge of any of the parties hereto. Consequently, Persons other
than the parties hereto may not rely upon the representations and warranties in this Agreement as characterizations of actual facts or
circumstances as of the date of this Agreement or as of any other date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 9.12 <span style="text-decoration:underline">Severability</span></b>.
The provisions of this Agreement shall be deemed severable, and the invalidity or unenforceability of any provision shall not affect the
validity or enforceability of the other provisions of this Agreement. If any provision of this Agreement, or the application of that provision
to any Person or any circumstance, is invalid or unenforceable, (a) a suitable and equitable provision shall be substituted for that provision
in order to carry out, so far as may be valid and enforceable, the intent and purpose of the invalid or unenforceable provision, and (b)
the remainder of this Agreement and the application of that provision to other Persons or circumstances shall not be affected by such
invalidity or unenforceability, nor shall such invalidity or unenforceability affect the validity or enforceability of that provision,
or the application of that provision, in any other jurisdiction. Upon such a determination, the Parties shall negotiate in good faith
to modify this Agreement so as to effect the original intent of the Parties as closely as possible in a reasonably acceptable manner so
that the Transactions may be consummated as originally contemplated to the fullest extent possible.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><b>Section 9.13 <span style="text-decoration:underline">Rules
of Construction</span></b>. The Parties have participated jointly in negotiating and drafting this Agreement. If an ambiguity or a question
of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties, and no presumption or burden
of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provision of this Agreement. Subject to and
without limiting the introductory language to <span style="text-decoration:underline">Article III</span> and <span style="text-decoration:underline">Article IV</span>, each Party has or may have set forth information
in the Company Disclosure Letter and PubCo Disclosure Letter, as applicable, in a section of such disclosure letter that corresponds to
the section of this Agreement to which it relates. The fact that any item of information is disclosed in the Company Disclosure Letter
or PubCo Disclosure Letter shall not constitute an admission by the Company or PubCo, respectively, that such item is material, that such
item has had or would have a Company Material Adverse Effect or PubCo Material Adverse Effect, as the case may be, or that the disclosure
of such be construed to mean that such information is required to be disclosed by this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"></p><div>

</div><!-- Field: Page; Sequence: 458 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;text-indent: 0.75in"><b>Section 9.14 <span style="text-decoration:underline">Assignment</span></b>.
This Agreement shall be binding upon and shall inure to the benefit of the Parties and their permitted successors and assigns. No
Party may assign or delegate, by operation of law or otherwise, all or any portion of its rights or Liabilities under this Agreement
without the prior written consent of the other Parties, and any attempted or purported assignment or delegation in violation of this <span style="text-decoration:underline">Section
9.13</span> shall be null and void.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;text-indent: 0.75in"><b>Section 9.15 <span style="text-decoration:underline">Remedies</span></b>.
No failure or delay on the part of any Party in the exercise of any right hereunder shall impair such right or be construed to be a waiver
of, or acquiescence in, any breach of any representation, warranty or agreement herein, nor shall any single or partial exercise of any
such right preclude any other or further exercise thereof or of any other right. All rights and remedies existing under this Agreement
are cumulative to, and not exclusive of, any rights or remedies otherwise available except as otherwise provided <span style="text-decoration:underline">Section 9.15</span>,
the exercise by a Party of any one remedy hereunder shall not preclude the exercise by it of any other remedy hereunder to the extent
permitted herein; provided, however, that, without limiting the ability of the Company to pursue both specific performance pursuant to
<span style="text-decoration:underline">Section 9.15</span> (subject to the terms and conditions therein) prior to a valid termination of this Agreement and payment of the PubCo
Termination Fee, under no circumstances shall the Company be permitted or entitled to receive both a grant of (a) specific performance
pursuant to <span style="text-decoration:underline">Section 9.15</span> (subject to the terms and conditions therein), and (b) the payment the PubCo Termination Fee. For the
avoidance of doubt, in the event the Company seeks, but does not granted the remedy of specific performance pursuant to <span style="text-decoration:underline">Section 9.16</span>,
the Company will still be entitled to receive payment of the Termination Fee pursuant to <span style="text-decoration:underline">Section 7.06</span> (subject to the terms and
conditions therein).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;text-indent: 0.75in"><b>Section 9.16 <span style="text-decoration:underline">Specific
Performance</span></b>. The Parties agree that irreparable injury would occur if any of the provisions of this Agreement are not performed
in accordance with their specific terms or are otherwise breached, and further agree that the right of specific performance is an integral
part of this Agreement and without that right the Parties would not have entered into this Agreement. Further, it is explicitly agreed
that the Parties shall have the right to an injunction or specific performance to the other Party&#8217;s obligations to consummate the
Transactions. It is further agreed that the Parties shall be entitled to an injunction or injunctions, specific performance or other equitable
relief to prevent breaches or threatened breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement
in the Court of Chancery of the State of Delaware or other court of the United States as specified in <span style="text-decoration:underline">Section 9.05</span>, and the Parties
hereby waive any requirement for the posting of any bond or similar collateral in connection therewith. Each Party agrees that it will
not oppose the granting of an injunction or specific performance on the basis that (i) any other Party has an adequate remedy at law,
or (ii) an award of specific performance is not an appropriate remedy for any reason at law or equity. Notwithstanding the foregoing,
the Parties agree that their respective rights under this <span style="text-decoration:underline">Section 9.15</span> shall terminate upon the Company&#8217;s receipt of the
PubCo Termination Fee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"></p><div>

</div><!-- Field: Page; Sequence: 459 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;text-indent: 0.75in"><b>Section 9.17 <span style="text-decoration:underline">Counterparts;
Effectiveness</span></b>. This Agreement may be executed in any number of counterparts, each such counterpart being deemed to be an original
instrument, and all such counterparts shall together constitute the same agreement. The exchange of copies of this Agreement and signature
pages by email in .pdf or .tif format (including any electronic signature complying with the U.S. ESIGN Act of 2000, e.g., www.docusign.com),
or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, or by combination of
such means, shall constitute effective execution and delivery of this Agreement as to the Parties and may be used in lieu of the original
Agreement for all purposes. Such execution and delivery shall be considered valid, binding and effective for all purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;text-indent: 0.75in"><b>Section 9.18 <span style="text-decoration:underline">Non-Recourse</span></b>.
This Agreement may only be enforced against the named Parties. All legal proceedings, Legal Actions, obligations, losses, damages, claims
or causes of action (whether in contract, in tort, in law or in equity, or granted by statute whether by or through attempted piercing
of the corporate, limited partnership or limited liability company veil or otherwise) that may be based upon, arise under, out or by reason
of, be connected with, or relate in any manner to (i) this Agreement or any of the other agreements or documents contemplated hereby,
(ii) the negotiation, execution or performance of this Agreement or any of the documents contemplated hereby (including any representation
or warranty made in connection with, or as an inducement to, this Agreement or any of the other agreements or documents contemplated hereby),
(iii) any breach or violation of this Agreement (including the failure of any representation and warranty to be true or accurate) or any
of the other agreements or documents contemplated hereby, and (iv) any failure of the Transactions or the other agreements or documents
contemplated hereby to be consummated, in the case of clauses (i) and (iv), may be made only against (and are those solely of) the Persons
that are expressly named as parties to this Agreement, the PubCo Voting Agreements, and the Confidentiality Agreement, and then only to
the extent of the specific obligations of such Persons set forth in this Agreement, the PubCo Voting Agreements, or the Confidentiality
Agreement, as applicable. In furtherance and not in limitation of the foregoing, and notwithstanding any other provision of this Agreement
to the contrary, each Party covenants, agrees and acknowledges that (except to the extent named as a party, the PubCo Voting Agreements,
or the Confidentiality Agreement, and then only to the extent of the specific obligations of such parties set forth in this Agreement,
the PubCo Voting Agreements, or the Confidentiality Agreement, as applicable) no recourse under this Agreement, any related document or
any documents or instruments delivered in connection with this Agreement or any related document shall be had against any Company Related
Party or PubCo Related Party, whether in contract, tort, equity, law or granted by statute whether by or through attempted piercing of
the corporate, limited partnership or limited liability company veil or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;text-indent: 0.75in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<i>Signature Pages Follow</i>]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 135.05pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 135.05pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 460 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 135.05pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.95pt">IN WITNESS WHEREOF, the
Parties have caused this Agreement to be executed as of the date first above written.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><b>PUBCO</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">AVALON GLOBOCARE CORP.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1.5pt; width: 60%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 5%">By:</td>
    <td style="border-bottom: Black 1.5pt solid; width: 35%"><i>/s/ Luisa Ingargiola</i></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Name:&#160;</td>
    <td>Luisa Ingargiola</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Title</td>
    <td>Chief Financial Officer</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><b>COMPANY</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">YOOV GROUP HOLDING LIMITED</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1.5pt; width: 60%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 5%">By:</td>
    <td style="border-bottom: Black 1.5pt solid; width: 35%"><i>/s/ Phil Wong</i></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Name:&#160;</td>
    <td> Phil Wong</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Title</td>
    <td>Chief Executive Officer</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><b>MERGER SUB</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">NEXUS MERGERSUB LIMITED</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1.5pt; width: 60%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 5%">By:</td>
    <td style="border-bottom: Black 1.5pt solid; width: 35%"><i>/s/ Luisa Ingargiola</i></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Name:&#160;</td>
    <td> Luisa Ingargiola</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Title:</td>
    <td> Director</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 461 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration:underline">EXHIBIT A</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Form of PubCo Voting Agreement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>See Attached.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 462 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM OF VOTING AND SUPPORT AGREEMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This PubCo Voting and Support
Agreement (this &#8220;<b>Agreement</b>&#8221;), dated as of March 7, 2025, is entered into by and among Avalon GloboCare Corp., a Delaware
corporation ( &#8220;<b>PubCo</b>&#8221;), YOOV Group Holding Limited, a British Virgin Islands company (the &#8220;<b>Company</b>&#8221;),
and the persons listed on the attached <span style="text-decoration:underline">Schedule A</span> who are signatories to this Agreement and holders of securities of PubCo (each,
a &#8220;<b>Stockholder</b>&#8221;, and collectively, the &#8220;<b>Stockholders</b>&#8221;). Terms used herein and not defined herein
shall have the meaning ascribed to them in the Merger Agreement (as defined below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>RECITALS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, PubCo, the Company,
and Nexus MergerSub Limited, a British Virgin Islands company and wholly owned subsidiary of PubCo (&#8220;<b>Merger Sub</b>&#8221;),
have entered into an Agreement and Plan of Merger, dated as of March 7, 2025 (the &#8220;<b>Merger Agreement</b>&#8221;), providing that,
among other things, all outstanding Company Ordinary Shares will be exchanged for shares of PubCo Common Stock based on the terms and
conditions of the Merger Agreement;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, as of the date of
this Agreement, each Stockholder is the record and/or &#8220;beneficial owner&#8221; (within the meaning of Rule 13d-3 under the Exchange
Act) of the number of shares of PubCo Common Stock, PubCo Preferred Stock and PubCo Stock Options set forth on <span style="text-decoration:underline">Schedule A</span> opposite
such Stockholder&#8217;s name (all of the shares of PubCo Common Stock and PubCo Preferred Stock owned of record or beneficially by such
Stockholder as of the date of this Agreement, the &#8220;<b>Owned Shares</b>&#8221; and, together with any additional shares of PubCo
Common Stock or other voting securities of the Company of which such Stockholder acquires record or beneficial ownership after the date
of this Agreement, including by purchase, as a result of a stock dividend, stock split, recapitalization, combination, consolidation,
reclassification, exchange or change of such shares, or other similar transaction, or upon exercise, vesting or conversion of any securities,
such Stockholder&#8217;s &#8220;<b>Covered Shares</b>&#8221;);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, as a condition and
inducement to the willingness of the parties to enter into the Merger Agreement and consummate the transactions contemplated thereby,
including the Merger, the Stockholders are entering into this Agreement; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Stockholders
acknowledge that each of PubCo and the Company desire to enter into the Merger Agreement in reliance on the representations, warranties,
covenants and other agreements of the Stockholders set forth in this Agreement and would not enter into the Merger Agreement if the Stockholders
did not enter into this Agreement</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 463 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">AGREEMENT</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing and the respective representations, warranties, covenants and agreements set forth below and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, do hereby
agree as follows:</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
I. Certain Definitions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All capitalized terms that
are used but not defined herein have the respective meanings ascribed to them in the Merger Agreement. For all purposes of and under this
Agreement, the following terms have the following respective meanings:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 1.01 </b>&#8220;<span style="text-decoration:underline">Entity</span>&#8221;
means a corporation (including any non-profit corporation), partnership (including any general partnership, limited partnership or limited
liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint
stock company), firm, society or other enterprise, association, organization or entity, and each of its successors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 1.02 </b>&#8220;<span style="text-decoration:underline">family
member</span>&#8221; means of any natural person means (i) such individual&#8217;s spouse (former or current), (ii) such individual&#8217;s
parents and grandparents (in each case, natural or adoptive, of the whole or half-blood), (iii) such individual&#8217;s children and grandchildren
(in each case, natural or adoptive, of the whole or half-blood), (iv) such individual&#8217;s sons-in-law and daughters-in-law (in each
case, former or current), (v) any other ascendants and descendants (natural or adoptive, of the whole or half-blood) of such individual&#8217;s
parents or of the parents of such individual&#8217;s spouse (former or current) and (vi) any lineal descendants (natural or adoptive,
of the whole or half-blood) of such individual&#8217;s spouse.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 1.03 </b>&#8220;<span style="text-decoration:underline">Permitted
Liens</span>&#8221; means (i) Liens for Taxes that (A) are not yet due and payable or (B) are being contested in good faith by appropriate
proceedings, (ii) Liens for assessments and other governmental charges or landlords&#8217;, carriers&#8217;, warehousemen&#8217;s, mechanics&#8217;,
repairmen&#8217;s, workers&#8217; and other similar common law or statutory Liens arising or incurred in the ordinary course of business
consistent with past practice, in each case that (A) relate to obligations that are not delinquent or (B) the applicable Stockholder or
any of such Stockholder&#8217;s Affiliates is contesting in good faith by appropriate proceedings, and (iii) Liens that are or may be
imposed pursuant to this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 1.04 </b>&#8220;<span style="text-decoration:underline">Termination
Date</span>&#8221; means the earliest to occur of (i) the closing of the Merger, (ii) the occurrence of a PubCo Adverse Recommendation Change
with respect to an Intervening Event and (iii)&#160;the termination of the Merger Agreement in accordance with its terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 1.05 </b>A Person
will be deemed to have effected a &#8220;<span style="text-decoration:underline">Transfer</span>&#8221; of a security if such Person, whether voluntarily or involuntarily, directly
or indirectly, (i) sells, pledges, encumbers, hypothecates, leases, assigns, gifts, grants an option with respect to, transfers, exchanges,
tenders or disposes (by merger, by testamentary disposition, by operation of law or otherwise) of such security or any interest in such
security, (ii) creates or permits to exist any Liens, (iii) deposits such security into a voting trust or enters into a voting agreement
or arrangement or grants any proxy, power of attorney or other authorization with respect thereto that is inconsistent with this Agreement
or (iv) enters into an agreement, option, commitment or other arrangement to take any of the actions referred to in the foregoing clauses
(i) through (iii).</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
II. Transfer Restrictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From the date of this Agreement
until the Termination Date, Stockholder shall not Transfer (or cause or permit the Transfer of) any of such Stockholder&#8217;s Covered
Shares. Notwithstanding anything to the contrary in this Agreement, this <span style="text-decoration:underline">Article II</span> shall not prohibit a Transfer of Covered Shares
by a Stockholder (i) if Stockholder is an Entity, to one or more partners or members of Stockholder or an Affiliated corporation, trust
or other Entity under common control with Stockholder, or if Stockholder is a trust, a transfer to a beneficiary, (ii) if Stockholder
is a natural person, a family member of such Stockholder, (iii) to any other Stockholder a party to this Agreement, (iv) as the Company
may otherwise agree in writing in its sole discretion, (v) with respect to Stockholder&#8217;s PubCo Stock Options which expire on or
prior to the Termination Date, as payment for the (A) exercise price of Stockholder&#8217;s PubCo Stock Options and (B) taxes applicable
to the exercise of Stockholder&#8217;s PubCo Stock Options, (vi) to any natural person or Entity if and to the extent required by any
non-consensual legal order, by divorce decree or by will, intestacy or other similar law or for estate planning purposes; <span style="text-decoration:underline">provided</span>
that in the case of (i), (ii) and (iii), such a Transfer shall be permitted only if, as a precondition to such Transfer, the transferee
agrees in writing (in form and substance reasonably satisfactory to PubCo) to be bound by all of the obligations of such Stockholder under
this Agreement with respect to such Covered Shares being Transferred. If any voluntary or involuntary Transfer of any Covered Shares occurs,
the transferee (which term, as used herein, shall include any and all transferees and subsequent transferees of the initial transferee)
shall take and hold such Covered Shares subject to all of the restrictions, Liabilities and rights under this Agreement, which shall continue
in full force and effect, notwithstanding that such transferee is not a Stockholder and has not executed a counterpart hereof or joinder
hereto. Any Transfer or attempted Transfer of any Covered Shares in violation of this <span style="text-decoration:underline">Article II</span> shall be null and void and of
no effect whatsoever.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 464 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
III. Agreement to Vote.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 3.01 </b>From
the date of this Agreement until the Termination Date, at the PubCo Stockholders Meeting and any other meeting of the stockholders of
PubCo (and at every adjournment or postponement thereof) to vote on any matter contemplated by this Agreement, however called, each Stockholder
unconditionally and irrevocably agrees to vote, or cause to be voted, all such Stockholder&#8217;s Covered Shares held at that time:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) in
favor of the PubCo Stockholder Matters;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) in
favor of any other proposal or proposals that PubCo reasonably deems necessary or desirable to consummate the Transactions contemplated
by the Merger Agreement;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) in
favor of the adjournment of the PubCo Stockholders Meeting as permitted by <span style="text-decoration:underline">Section 5.06</span> of the Merger Agreement;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) against
any action or agreement that would reasonably be expected to result in the conditions of the Transactions contemplated by the Merger Agreement
not being fulfilled or a breach of a covenant, representation or warranty or any other material obligation or agreement of PubCo contained
in the Merger Agreement;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e) against
any action, proposal, transaction or agreement that would reasonably be expected to prevent or materially delay the consummation of the
Transactions and the Merger, or the fulfillment of PubCo&#8217;s or the Company&#8217;s respective conditions to close the Merger and
Transactions; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">(h) against any Takeover
Proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 3.02 </b>From
the date of this Agreement until the Termination Date, each Stockholder shall appear, or shall cause the applicable entity that is the
record holder of any of such Stockholder&#8217;s Covered Shares, as applicable (in person, by proxy or by any other means permitted by
the bylaws of PubCo) at each meeting of the stockholders of PubCo, or adjournment or postponement thereof, to vote on any matter contemplated
by this Agreement and shall cause all such Stockholder&#8217;s Covered Shares to be counted as present thereat for purposes of calculating
a quorum and shall vote all such Stockholder&#8217;s Covered Shares in accordance with this <span style="text-decoration:underline">Article III</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 3.03</b> Nothing
in this Agreement, including this <span style="text-decoration:underline">Article III</span>, limits or restricts any Stockholder, or any Affiliate or designee of any Stockholder
who serves as a member of the PubCo Board in acting or voting in his or her capacity as a director of PubCo and exercising his or her
fiduciary duties and responsibilities, it being understood that this Agreement applies to each Stockholder solely in such Stockholder&#8217;s
capacity as a stockholder of PubCo and does not apply to such Stockholder&#8217;s or any such Affiliate&#8217;s or designee&#8217;s actions,
judgments or decisions as a director of PubCo, and such actions (or failures to act) shall not be deemed to constitute a breach of this
Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
IV. No Inconsistent Agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Stockholder hereby represents,
covenants and agrees that, except as contemplated by this Agreement, such Stockholder (a) has not entered into, and shall not enter into
at any time prior to the Termination Date, any voting agreement or voting trust with respect to any of such Stockholder&#8217;s Covered
Shares and (b) has not granted, and shall not grant at any time prior to the Termination Date of this Agreement, a proxy or power of attorney
with respect to any of such Stockholder&#8217;s Covered Shares, in either case, that is inconsistent with such Stockholder&#8217;s obligations
pursuant to this Agreement.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 465 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
V. Representations and Warranties of each Stockholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Stockholder hereby represents
and warrants to PubCo, Merger Sub and the Company, solely as to itself and not as to any other Stockholder or other Person, as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.01 </b><span style="text-decoration:underline">Power;
Organization; Binding Agreement</span>. If such Stockholder is an Entity: (i) Stockholder is duly organized, validly existing and in good
standing under the laws of the jurisdiction in which it is incorporated, organized or constituted, (ii) Stockholder has all necessary
power and authority to execute and deliver this Agreement, to perform Stockholder&#8217;s obligations hereunder and to consummate the
transactions contemplated hereby, and (iii) the execution and delivery of this Agreement, performance of Stockholder&#8217;s obligations
hereunder and the consummation of the transactions contemplated hereby by Stockholder have been duly authorized by all necessary action
on the part of Stockholder and no other proceedings on the part of Stockholder are necessary to authorize this Agreement, or to consummate
the transactions contemplated hereby. If such Stockholder is an individual, Stockholder has the capacity to execute and deliver this Agreement,
to perform such Stockholder&#8217;s obligations hereunder and to consummate the transactions contemplated hereby. This Agreement has been
duly executed and delivered by such Stockholder, and, assuming due authorization, execution and delivery by PubCo and the Company, this
Agreement is enforceable against such Stockholder in accordance with its terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.02 </b><span style="text-decoration:underline">No
Conflicts</span>. None of the execution and delivery by such Stockholder of this Agreement, the performance by such Stockholder of such Stockholder&#8217;s
obligations hereunder or the consummation by such Stockholder of the transactions contemplated hereby will (i) require any consent or
approval under, or result in a violation or breach of, any agreement to which such Stockholder is a party or by which such Stockholder
may be bound, including any voting agreement or voting trust, (ii) result in the creation of any Lien on any of the assets or properties
of such Stockholder, (iii) violate any applicable Law or Judgment or (iv) with respect to a Stockholder that is not a natural person,
violate the organizational documents of such Stockholder, in each case, except for such consents, approvals, breaches, Liens or violations
that would not, individually or in the aggregate, prevent or materially delay such Stockholder from performing such Stockholder&#8217;s
obligations under this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.03 </b><span style="text-decoration:underline">Ownership
of Covered Shares</span>. Such Stockholder is the beneficial owner of such Stockholder&#8217;s Covered Shares. All such Stockholder&#8217;s
Covered Shares are owned free and clear of any Liens other than Permitted Liens, and no Person has a right to acquire any of such Covered
Shares, in each case other than pursuant to this Agreement, the Merger Agreement, under applicable federal or state securities laws or
pursuant to any written policies of PubCo only with respect to restrictions upon the trading of securities under applicable securities
laws. As of the date of this Agreement, except as set forth on <span style="text-decoration:underline">Schedule A</span>, other than such Stockholder&#8217;s Owned Shares, such
Stockholder does not own beneficially or of record any (i) shares of capital stock or voting securities of PubCo, (ii) securities of PubCo
convertible into or exchangeable for shares of capital stock or voting securities of PubCo or (iii) options or other rights to acquire
from PubCo any capital stock, voting securities or securities convertible into or exchangeable for capital stock or voting securities
of PubCo.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.04 </b><span style="text-decoration:underline">Voting
Power</span>. Such Stockholder has the requisite voting power, power of disposition, power to issue instructions with respect to the matters
set forth herein and power to agree to all of the matters set forth in this Agreement necessary to take all actions required under this
Agreement, in each case with respect to all of the securities subject to this Agreement owned by such Stockholder, with no limitations,
qualifications or restrictions on such rights, subject to applicable federal securities laws and those arising under the terms of this
Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.05 </b><span style="text-decoration:underline">Reliance
by the Company, PubCo and Merger Sub</span>. Such Stockholder understands and acknowledges that each of the Company, PubCo and Merger Sub
is entering into the Merger Agreement in reliance upon such Stockholder&#8217;s execution and delivery of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.06 </b><span style="text-decoration:underline">Consents
and Approvals</span>. The execution and delivery of this Agreement by such Stockholder does not, and the performance by such Stockholder
of such Stockholder&#8217;s obligations under this Agreement and the consummation of the transactions contemplated hereby will not, require
such Stockholder to obtain any consent, approval, authorization or permit of, or to make any filing with or notification to, any Governmental
Authority, except in each case for filings with the SEC or where the failure to obtain such consents, approvals, authorizations or permits,
or to make such filings and notifications, would not, either individually or in the aggregate, prevent or materially delay the performance
by such Stockholder of any of such Stockholder&#8217;s obligations hereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 466 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.07 </b><span style="text-decoration:underline">Litigation</span>.
As of the date of this Agreement, there is no Legal Action pending or, to the knowledge of such Stockholder, threatened against such Stockholder
that would reasonably be expected to prevent or delay the performance by such Stockholder of his, her or its obligations under this Agreement
in any material respect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.08 </b><span style="text-decoration:underline">Brokers</span>.
No investment banker, broker, finder or other intermediary is entitled to a fee or commission from PubCo or the Company in respect of
this Agreement based upon any contract made by or on behalf of Stockholder</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
VI. Additional Covered Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the avoidance of doubt,
prior to the Termination Date, in the event that a Stockholder acquires record or beneficial ownership of, or the power to vote or direct
the voting of, any additional shares of PubCo Common Stock, PubCo Preferred Stock or other voting interests with respect to PubCo, such
shares of PubCo Common Stock, PubCo Preferred Stock, or other voting interests will, without further action of the parties, be deemed
Covered Shares held by such Stockholder and subject to the provisions of this Agreement, the number of shares of PubCo Common Stock held
by such Stockholder will be deemed amended accordingly, and such shares of PubCo Common Stock or voting interests will automatically become
subject to the terms of this Agreement as Covered Shares. Notwithstanding the foregoing, nothing in this Agreement shall require a Stockholder
to (i) convert, exercise or exchange any options, warrants or convertible securities in order to obtain underlying shares of PubCo Common
Stock or (ii) vote, or execute any consent with respect to, any shares of PubCo Common Stock underlying such options, warrants or convertible
securities that have not yet been issued as of the applicable record date for such vote or consent.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
VII. irrevocable proxy</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the final sentence
of this <span style="text-decoration:underline">Article VII</span>, by execution of this Agreement, such Stockholder does hereby appoint PubCo and any of its designees with full
power of substitution and resubstitution, as Stockholder&#8217;s true and lawful attorney and irrevocable proxy, to the fullest extent
of Stockholder&#8217;s rights with respect to the Covered Shares, to vote and exercise all voting and related rights, including the right
to sign such Stockholder&#8217;s name (solely in its capacity as a stockholder) to any stockholder consent, if Stockholder is unable to
perform or otherwise does not perform his, her or its obligations under this Agreement, with respect to such Covered Shares solely with
respect to the matters set forth in <span style="text-decoration:underline">Section 3.01</span>. Such Stockholder intends this proxy to be irrevocable and coupled with an interest
hereunder until the Termination Date, hereby revokes any proxy previously granted by Stockholder with respect to the Covered Shares and
represents that none of such previously-granted proxies are irrevocable. The irrevocable proxy and power of attorney granted herein shall
survive the death or incapacity of Stockholder and the obligations of Stockholder shall be binding on Stockholder&#8217;s heirs, personal
representatives, successors, transferees and assigns. Stockholder hereby agrees not to grant any subsequent powers of attorney or proxies
with respect to any Covered Shares with respect to the matters set forth in <span style="text-decoration:underline">Section 3.01</span> until after the Termination Date. Such
Stockholder hereby affirms that the proxy set forth in this <span style="text-decoration:underline">Article VII</span> is given in connection with and granted in consideration
of and as an inducement to the Company, PubCo and Merger Sub to enter into the Merger Agreement and that such proxy is given to secure
the obligations of Stockholder under <span style="text-decoration:underline">Section 3.01</span>. Notwithstanding anything contained herein to the contrary, this irrevocable
proxy shall automatically terminate upon the Termination Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
VIII. Stockholder Litigation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Stockholder agrees not
to commence or participate in, and to take all actions necessary to opt out of any class in any class action with respect to, any claim,
derivative or otherwise, that may be brought against PubCo or any of its successors and assigns relating to the negotiation, execution
or delivery of this Agreement, the Merger Agreement or the consummation of the transactions contemplated hereby and thereby; <span style="text-decoration:underline">provided</span>
that this <span style="text-decoration:underline">Article VIII</span> shall not be deemed a waiver of any rights of any Stockholder or such Stockholder&#8217;s Affiliates for
any breach of this Agreement or the Merger Agreement by PubCo.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
IX. Stop Transfer Instructions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At all times commencing with
the execution and delivery of this Agreement and continuing until the Termination Date, in furtherance of this Agreement, each Stockholder
hereby authorizes PubCo or its counsel to instruct PubCo&#8217;s transfer agent to put in place a stop transfer order with respect to
all of the securities of PubCo held of record by such Stockholder (and that this Agreement places limits on the voting and transfer of
such securities) except with respect to Transfers of any Covered Shares in accordance with <span style="text-decoration:underline">Article II</span>.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 467 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
X. Termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement and all rights
and obligations of the parties hereunder will terminate and have no further force or effect as of the Termination Date; <span style="text-decoration:underline">provided</span>
that this <span style="text-decoration:underline">Article X</span> and <span style="text-decoration:underline">Article XI</span> shall survive the termination of this Agreement. Notwithstanding the foregoing, nothing
set forth in this <span style="text-decoration:underline">Article X</span> or elsewhere in this Agreement relieves any party hereto from liability, or otherwise limits the liability
of any party hereto, for any breach of this Agreement prior to such termination hereof or such party&#8217;s fraud.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
XI. Miscellaneous.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.01 </b><span style="text-decoration:underline">Severability</span>.
If any term, provision, covenant or restriction of this Agreement or the application of any such provision to any person or circumstance
shall be held invalid, illegal, void or unenforceable in any respect by a court of competent jurisdiction or other Governmental Authority,
the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in
no way be affected, impaired or invalidated. Upon such a holding, the parties hereto agree to negotiate in good faith to modify this Agreement
so as to effect the original intent of the parties as closely as possible in an acceptable manner, in order that the transactions contemplated
by this Agreement be consummated as originally contemplated to the fullest extent possible.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.02 </b><span style="text-decoration:underline">Assignment</span>.
Except in connection with a Transfer of any Covered Shares in accordance with <span style="text-decoration:underline">Article II</span>, neither this Agreement nor any of the
rights, interests or obligations hereunder shall be assigned, in whole or in part, by operation of Law or otherwise by any of the parties
without the prior written consent of the other parties and any purported assignment in violation hereof shall be null and void <i>ab initio</i>.
Subject to the immediately preceding sentence, this Agreement shall be binding upon, inure to the benefit of and be enforceable by, the
parties hereto and their respective successors and assigns.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.03 </b><span style="text-decoration:underline">Amendment
and Modification; Waiver</span>. This Agreement may be amended or waived by any party only if such amendment or waiver is in writing and
is signed, in the case of an amendment, by each party to this Agreement or, in the case of a waiver, by each party against whom the waiver
is to be effective. Any failure of any of the parties to comply with any obligation, covenant, agreement or condition in this Agreement
may be waived by any of the parties entitled to the benefit thereof only by a written instrument signed by each such party granting such
waiver. No failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall
any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege.
The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by applicable Law or
in equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.04 </b><span style="text-decoration:underline">Specific
Performance</span>. The parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy,
would occur and that the parties would not have any adequate remedy at law in the event that any of the provisions of this Agreement were
not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that, in addition to any other
remedy to which the parties are entitled at law or in equity, (i) the parties shall be entitled to an injunction or injunctions, specific
performance or other equitable relief, to prevent breaches or threatened or anticipated breaches of this Agreement and to enforce specifically
the terms and provisions of this Agreement in the courts described in <span style="text-decoration:underline">Section 11.08</span>, without proof of damages or otherwise, and
(ii)&#160;the right of specific performance is an integral part of the transactions contemplated hereby and without that right, none of
the parties would have entered into this Agreement. Each of the parties agrees that it waives the defense of adequacy of a remedy at law
and will not oppose the granting of an injunction or injunctions, specific performance or other equitable relief on the basis that (A)
the other parties have an adequate remedy at law or (B) an award of an injunction, specific Performance or other equitable relief is not
an appropriate remedy for any reason at law or equity. The parties acknowledge and agree that any party seeking an injunction or injunctions
to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in accordance with this <span style="text-decoration:underline">Section
11.04</span> shall not be required to provide any bond or other security in connection with any such order or injunction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><!-- Field: Page; Sequence: 468 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.05 </b><span style="text-decoration:underline">Notices</span>.
All notices or other communications required or permitted under, or otherwise given in connection with, this Agreement shall be in writing
and shall be deemed to have been duly given (i) when delivered, if delivered in person, (ii) on the next Business Day if transmitted by
national overnight courier (with confirmation of delivery) or (iii) on the date transmitted if sent by email (<span style="text-decoration:underline">provided</span> that no
&#8220;bounce back&#8221; or similar message of non-delivery is received with respect thereto), as follows (or at such other address for
a party as shall be specified by notice given in accordance with this <span style="text-decoration:underline">Section 11.05</span>):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If to the Stockholders, to
the address for notice set forth on <span style="text-decoration:underline">Schedule A</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><i>If to PubCo, to:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Avalon GloboCare Corp.<br/>
4400 Route 9 South, Suite 3100<br/>
Freehold, New Jersey 07728</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Attn: Luisa Ingargiola (email: [***])</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><i>With a copy which shall not constitute
notice to:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Lowenstein Sandler LLP<br/>
1251 Avenue of the Americas<br/>
New York, New York 10020</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Attn: Steven Skolnick, Esq. (email: [***])</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><i>If to the Company, to:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">YOOV Group Holding Limited</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">1 Raffles Place</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">#31-62 One Raffles
Place Tower 2</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Singapore 048616</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Attn: Phil Wong (email: [***])</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 118.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><i>With a copy which shall not constitute
notice to:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Lucosky Brookman LLP<br/>
101 Wood Avenue South, 5th Floor<br/>
Iselin, New Jersey 08830</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: -0.5in">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 1in"/><td style="width: 0.4in">Attn:</td><td>Joseph M. Lucosky, Esq. (email: [***])<br/>
Scott Linsky, Esq. (email: [***])<br/>
Ian Liao, Esq. (email:
[***])</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything in
this Agreement to the contrary, any notice given in accordance with the foregoing clauses (i) or (ii) of this <span style="text-decoration:underline">Section 11.05</span> shall
only be effective if a duplicative copy of such notice is also given by email in the method described in this <span style="text-decoration:underline">Section 11.05</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.06 </b><span style="text-decoration:underline">No
Third Party Beneficiaries</span>. This Agreement is not intended to confer upon any person other than the parties hereto (and their respective
successors and permitted assigns) any rights (legal, equitable or otherwise) or remedies, whether as third-party beneficiaries or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.07 </b><span style="text-decoration:underline">Governing
Law</span>. This Agreement and all Legal Actions arising out of or relating to this Agreement shall be governed by, and construed in accordance
with, the Laws of the State of Delaware, regardless of the laws that might otherwise govern under any applicable conflict of laws principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><!-- Field: Page; Sequence: 469 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.08 </b><span style="text-decoration:underline">Jurisdiction</span>.
In any action or proceeding between any of the parties arising out of or relating to this Agreement, each of the parties: (i) irrevocably
and unconditionally consents and submits to the exclusive jurisdiction and venue of the federal courts located in the State of Delaware
and the Court of Chancery of the State of Delaware (collectively with any appellate courts thereof, the &#8220;<b>Courts</b>&#8221;);
(ii) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause
(i) of this <span style="text-decoration:underline">Section 11.08</span>; (iii) waives any objection to laying venue in any such action or proceeding in such Courts; (iv) waives
any objection that such Courts are an inconvenient forum or do not have jurisdiction over any Party; (v) agrees that service of process
upon such party in any such action or proceeding shall be effective if notice is given in accordance with <span style="text-decoration:underline">Section 11.05</span> of this
Agreement; and (vi) irrevocably and unconditionally waives the right to trial by jury. This Agreement, and any certificates, documents,
instruments and writings that are delivered pursuant hereto, constitutes the entire agreement and understanding of the Parties in respect
of the subject matter hereof and supersedes all prior understandings, agreements or representations by or among the Parties, written or
oral, to the extent they relate in any way to the subject matter hereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239; <b>Section 11.09 </b><span style="text-decoration:underline">WAIVER
OF JURY TRIAL</span>. EACH PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE
COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE
LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT
OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY HERETO CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE, AGENT OR ATTORNEY OF
ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE
THE FOREGOING WAIVER, (B) IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVER, (C) IT MAKES SUCH WAIVER VOLUNTARILY AND
(D) IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVER AND CERTIFICATIONS IN THIS <span style="text-decoration:underline">SECTION 11.09</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.10 </b><span style="text-decoration:underline">Rules
of Construction</span>. Each of the parties hereto acknowledges that such party has been represented by counsel of such party&#8217;s choice
throughout all negotiations that have preceded the execution of this Agreement, and that such party has executed the same with the advice
of such counsel. Each party and such party&#8217;s counsel cooperated and participated in the drafting and preparation of this Agreement
and the documents referred to in this Agreement, and any and all drafts relating thereto exchanged among the parties shall be deemed the
work product of all of the parties and may not be construed against any party by reason of such party&#8217;s drafting or preparation.
Accordingly, any rule of law or any legal decision that would require interpretation of any ambiguities in this Agreement against any
party that drafted or prepared it is of no application and is hereby expressly waived by each of the parties hereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.11 </b><span style="text-decoration:underline">Entire
Agreement</span>. This Agreement, taken together with the Schedules attached hereto, and the Merger Agreement to the extent referenced herein,
constitutes the entire agreement among the parties hereto with respect to the subject matter hereof, and supersedes all prior agreements
and understandings, both written and oral, among the parties hereto with respect thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.12 </b><span style="text-decoration:underline">Interpretation</span>.
The rules of interpretation set forth in Section 9.02 of the Merger Agreement shall apply to this Agreement, <i>mutatis mutandis</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.13 </b><span style="text-decoration:underline">Expenses</span>.
Except as otherwise expressly provided in this Agreement and the Merger Agreement, all fees and expenses incurred in connection with this
Agreement and the transactions contemplated hereby shall be paid by the party hereto incurring such fees or expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.14 </b><span style="text-decoration:underline">No
Recourse</span>. This Agreement may only be enforced against, and any claims or causes of action that may be based upon, arise out of or
relate to this Agreement, or the negotiation, execution or performance of this Agreement, may only be made against, the Persons that are
expressly identified as parties hereto and no former, current or future equity holders, controlling persons, directors, officers, employees,
agents or Affiliates of any party hereto or any former, current or future stockholder, controlling person, director, officer, employee,
general or limited partner, member, manager, agent or Affiliate of any of the foregoing shall have any liability for any obligations or
liabilities of the parties to this Agreement or for any claim (whether in tort, contract or otherwise) based on, in respect of, or by
reason of, the transactions contemplated hereby or in respect of any representations made or alleged to be made in connection herewith.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 470 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: -0.25in"></p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
XII. Counterparts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement may be signed
in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon
the same instrument. This Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by all
of the other parties hereto, it being understood and agreed that all parties hereto need not sign the same counterpart. Until and unless
each party has received a counterpart hereof signed by each other party hereto, this Agreement shall have no effect and no party shall
have any right or obligation hereunder (whether by virtue of any other oral or written agreement or other communication). Signatures to
this Agreement (which need not be on the same counterpart) transmitted by electronic mail in PDF form, or by any other electronic means
designed to preserve the original graphic and pictorial appearance of a document (including DocuSign), will be deemed to have the same
effect as physical delivery of the paper document bearing the original signatures.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
XIII. Stockholder Obligation Several and Not Joint.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The obligations of each Stockholder
hereunder shall be several and not joint, and no Stockholder shall be liable for any breach of the terms of this Agreement by any other
Stockholder.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
XIV. No Ownership Interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Stockholder, solely as
to itself and not as to any other Stockholder or other Person, has agreed to enter into this Agreement and act in the manner specified
in this Agreement for consideration. Except as expressly set forth in this Agreement, all rights and all ownership and economic benefits
of and relating to each Stockholder&#8217;s Covered Shares will remain vested in and belong to such Stockholder, and nothing herein will,
or will be construed to, grant PubCo, Merger Sub or the Company any power, sole or shared, to direct or control the voting or disposition
of any of such Covered Shares. Nothing in this Agreement will be interpreted as creating or forming a &#8220;group&#8221; with any other
Person, including other holders listed on <span style="text-decoration:underline">Schedule A</span>, for purposes of Rule 13d-5(b)(1) of the Exchange Act or any other similar
provision of applicable Law.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
XV. Disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Stockholder hereby (a)
authorizes PubCo and the Company to publish and disclose in any announcement or disclosure required by the SEC or other applicable Law
and in the Proxy Statement such Stockholder&#8217;s identity and ownership of the Covered Shares and the nature of such Stockholder&#8217;s
obligations under this Agreement and (b) agrees to promptly give to PubCo and Company any information it may reasonably require for the
preparation of any such announcement or disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[S<i>ignature pages follow</i>]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 471 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have executed this Agreement as of the date first written above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>PUBCO</b>:</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>AVALON GLOBOCARE CORP.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 60%">&#160;</td>
    <td style="text-align: justify; width: 3%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify; width: 37%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Name:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Title:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<i>Signature Page to Company Voting Agreement</i>]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"></p><div>

</div><!-- Field: Page; Sequence: 472 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have executed this Agreement as of the date first written above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>COMPANY</b>:</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>YOOV GROUP HOLDING LIMITED</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 60%">&#160;</td>
    <td style="text-align: justify; width: 3%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: justify; width: 37%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Name:</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Title:</span></td></tr>
  </table><div>
</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">[<i>Signature Page to Company Voting Agreement</i>]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"></p><div>

</div><!-- Field: Page; Sequence: 473 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have executed this Agreement as of the date first written above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>STOCKHOLDER</b>:</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">By: </span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 35%">&#160;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Name: </span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title:</span></td>
    <td>&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">[<i>Signature Page to Company Voting Agreement</i>]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 474 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">EXHIBIT B</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Form of Lockup Agreement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>See attached</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 475 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF LOCK-UP AGREEMENT</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This LOCK-UP AGREEMENT (this
&#8220;<b>Lock-Up <span style="text-decoration:underline">Agreement</span></b>&#8221;), dated as of March 7, 2025, is entered into by and among (i) Avalon GloboCare Corp., a
Delaware corporation (&#8220;<b>PubCo</b>&#8221;), (ii) certain holders of securities of PubCo as set forth on&#160;<span style="text-decoration:underline">Schedule&#160;A</span>&#160;hereto
(collectively, the &#8220;<b>PubCo Lock-Up Equityholders</b>&#8221;), and (iii) the equityholders of YOOV Group Holding Limited, a British
Virgin Islands company (the &#8220;<b>Company</b>&#8221;), as set forth on&#160;<span style="text-decoration:underline">Schedule&#160;B</span><b>&#160;</b>hereto (collectively,
the &#8220;<b>Company Lock-Up <span style="text-decoration:underline">Equityholders</span></b>&#8221; and together with the PubCo Lock-Up Equityholders, the &#8220;<b>Holders</b>,&#8221;
and the Holders, together with PubCo, the &#8220;<b>Parties</b>&#8221; and each individually a &#8220;<b><span style="text-decoration:underline">Party</span></b>&#8221;) All
terms used but not defined in this Lock-Up Agreement shall have the same meanings set forth in the Merger Agreement (as defined below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><b>WHEREAS</b>, the Parties
are entering this Lock-Up Agreement pursuant to that certain Agreement and Plan of Merger (the &#8220;<b>Merger Agreement</b>&#8221;),
dated as of March 7, 2025, by and among PubCo, Nexus MergerSub Limited, a wholly owned subsidiary of PubCo (&#8220;<b>Merger Sub</b>&#8221;,
and together with PubCo, the &#8220;<b>PubCo Entities</b>&#8221;), and the Company, pursuant to which, and subject to the terms and conditions
set forth therein, Merger Sub will merger with and into the Company (the &#8220;<b>Merger</b>&#8221;), with the Company surviving the
Merger as a wholly owned subsidiary of PubCo; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><b>WHEREAS</b>, as a condition
to the Closing, the Parties are entering into this Lock-Up Agreement effective as of the Closing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><b>NOW, THEREFORE</b>, in consideration
of the promises and of the mutual consents and obligations hereinafter set forth, and for other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
I. Restrictions on Shares; Lock-Up.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 1.01<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>The Parties agree that, from the Closing Date until the date that is 180 days from the date thereof (such period, the &#8220;<b>Lock-Up
Period</b>&#8221;), the Holders shall not:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Transfer (except as may be specifically
required by court order or by operation of law) any share of PubCo Common Stock, or securities convertible, exchangeable, or exercisable
into (a) shares of PubCo Common Stock, or such other securities beneficially owned or held by such Holders immediately following the Closing
and (b) securities of PubCo which may be issued upon exercise of an option to purchase shares of PubCo Common Stock or a warrant to purchase
shares of PubCo Common Stock (all such securities of PubCo, the &#8220;<b><span style="text-decoration:underline">Lock-Up Securities</span></b><span style="text-decoration:underline">&#8221;)</span>, where &#8220;Transfer&#8221;
means offer, sell, contract to sell, grant any option, right or warrant to purchase, lend, hypothecate, pledge or otherwise dispose of
(or enter into any transaction which is designed to), or might reasonably be expected to, result in the disposition, whether by actual
disposition or effective economic disposition due to cash settlement or otherwise, by the Holders or any Affiliate thereof or any person
in privity with the Holders or any Affiliate thereof, directly or indirectly;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">enter into any swap, short sale,
hedge or any purchase, sale or grant of any right (including, without limitation, any put or call option) with respect to any security
(other than a broad-based market basket or index) that includes, relates to or derives any significant part of its value from the Lock-Up
Securities or any other agreement that transfers, in whole or in part, any of the economic consequences of ownership of any Lock-Up Securities;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">grant any proxies or powers
of attorney with respect to any Lock-Up Securities, deposit any Lock-Up Securities into a voting trust, or enter into a voting agreement
or similar arrangement or commitment with respect to any Lock-Up Securities or make any public announcement that is in any manner inconsistent
with this <span style="text-decoration:underline">Article&#160;I</span>;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">make any demand for, or exercise
any right with respect to, the registration of any shares of PubCo Common Stock or any security convertible into or exercisable or exchangeable
for shares of PubCo Common Stock (other than such rights set forth in the Merger Agreement); or</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">make any offer or enter into
any agreement or binding arrangement or commitment providing for any of the foregoing actions in clauses (i) to (iv), or publicly disclose
the intention to take any of the foregoing actions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></p><div>

</div><!-- Field: Page; Sequence: 476 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 1.02<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>Notwithstanding the restrictions set forth in <span style="text-decoration:underline">Section&#160;1.01</span> of this Lock-Up Agreement:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">if the Party is a natural person,
the Party may transfer his or her Lock-Up Securities to any natural person related to the Party by blood or adoption who is an immediate
family member of the Party, or to a trust for the benefit of the Party or any member of the Party&#8217;s immediate family for estate
planning purposes, or to the Party&#8217;s estate, following the death of the Party, by will, intestacy, or other operation of law, or
as a bona fide gift to a charitable organization, or by operation of law pursuant to a qualified domestic order or in connection with
a divorce settlement or to any partnership, corporation or limited liability company which is controlled by the undersigned and/or by
any such member of the Party&#8217;s immediate family;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">if the Party is a corporation,
partnership or other business entity, the Party may transfer its Lock-Up Securities to another corporation, partnership or other business
entity that is an affiliate (as defined under Rule 12b-2 promulgated under the Securities and Exchange Act of 1934, as amended (the &#8220;<b><span style="text-decoration:underline">Exchange
Act</span></b>&#8221;) of the Party or as a distribution or dividend to equity holders (including, without limitation, general or limited
partners and members) of the Party (including upon the liquidation and dissolution of the undersigned pursuant to a plan of liquidation
approved by the undersigned&#8217;s equity holders), or as a bona fide gift to a charitable organization;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">if the Party is a trust, the
Party may transfer its Lock-Up Securities to any grantors or beneficiaries of the trust;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">nothing contained herein will
be deemed to restrict the ability of the Party to exercise an option to purchase shares of PubCo Common Stock, and any related transfer
of shares of PubCo Common Stock to PubCo for the purpose of paying the exercise price of such options as a result of the exercise of such
options; <span style="text-decoration:underline">provided</span>, that for the avoidance of doubt, the underlying shares of PubCo Common Stock shall continue to be subject to
the restrictions on transfer set forth in this Lock-Up Agreement until the applicable Lock-Up Period expires and after, if at all, all
Lock-Up Securities are disposed of pursuant to <span style="text-decoration:underline">Section&#160;1.01</span>. Additionally, the Party may (A) establish a trading plan pursuant
to Rule 10b5-1 promulgated under the Exchange Act for the transfer of Lock-Up Securities; <span style="text-decoration:underline">provided</span>, that such plan does not provide
for the transfer of Lock-Up Securities during the Lock-Up Period, or (B) transfer its Lock-Up Securities pursuant to a bona fide third
party tender offer, merger, consolidation or other similar transaction made to all holders of PubCo&#8217;s capital stock involving a
change of control of PubCo, provided that in the event that such tender offer, merger, consolidation or other such transaction is not
completed, the Lock-Up Securities shall remain subject to the restrictions contained in this Lock-Up Agreement; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><span style="text-decoration:underline">provided</span>, that with respect
to any transfer or distribution pursuant to <span style="text-decoration:underline">Section&#160;1.02</span>, (x) no filing by any party (donor, donee, transferor, transferee,
distributor or distributee, as the case may be) under the Exchange Act or other public announcement shall be required or shall be made
voluntarily in connection with such transfer or disposition during the respective Lock-Up Periods (other than (1) any exit filings or
public announcements that may be required under applicable federal and state securities laws or (2) in respect of a required filing under
the Exchange Act in connection with a transfer pursuant to <span style="text-decoration:underline">Section&#160;1.02(ii)</span> above or the exercise of an option to purchase
shares of Company Common Stock following such individual&#8217;s termination of employment that would otherwise expire during the Lock-Up
Period, provided that reasonable notice shall be provided to PubCo prior to any such filing), and (y) except with respect to <span style="text-decoration:underline">Section&#160;1.02(iv)(A)</span>
and <span style="text-decoration:underline">(B)</span> above, it shall be a condition to the transfer or distribution that the transferee or distributee executes an agreement,
in the form of this Lock-Up Agreement, stating that the transferee or distributee is receiving and holding such Lock-Up Securities subject
to the provisions of such agreement during the respective Lock-Up Periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
II. Miscellaneous.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 2.01<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>This Lock-Up Agreement shall terminate immediately and automatically upon the earlier of (i) all Lock-Up Securities having
been sold pursuant to <span style="text-decoration:underline">Section&#160;1.01</span> and (ii) if the Merger Agreement is validly terminated in accordance with its terms prior
to the Effective Time, upon the date of such termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 2.02<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>The Parties hereby represent and warrant that (i) if it is a corporation, partnership, limited liability company or other business
entity, it is duly organized and validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation,
(ii) he, she or it has full power and authority to enter into this Lock-Up Agreement, (iii) this Lock-Up Agreement has been duly and validly
executed and delivered by the Parties and constitutes the legal, valid and binding obligation of the Parties, enforceable against the
Parties in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors
and rules of law governing specific performance, injunctive relief and other equitable remedies, and (iv), upon request, he, she or it
will execute any additional documents necessary to ensure the validity or enforcement of this Lock-Up Agreement. All authority herein
conferred or agreed to be conferred and any obligations of the Parties shall be binding upon the successors, assigns, heirs or personal
representatives of the Parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 477 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 2.03<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>Any attempted transfer in violation of this Lock-Up Agreement will be of no effect and null and void, regardless of whether
the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this Lock-Up Agreement. Such
transfer will not be recorded on PubCo&#8217;s share register. To ensure compliance with the restrictions referred to herein, the Parties
agrees PubCo and its transfer agent and registrar are hereby authorized to decline to make any such transfer if it would constitute a
violation or breach of this Lock-Up Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 2.04<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>Any person having rights under any provision of this Lock-Up Agreement shall be entitled to enforce such rights specifically,
to recover damages caused by reason of any breach of any provision of this Lock-Up Agreement and to exercise all other rights existing
in their favor. The Parties agree and acknowledge that money damages would not be an adequate remedy for any breach of the provisions
of this Lock-Up Agreement and that any Party may in its sole discretion apply to any court of law or equity of competent jurisdiction
for, and obtain from any such court, specific performance and/or injunctive relief (without posting any bond or other security) in order
to enforce or prevent violation of the provisions of this Lock-Up Agreement and shall not be required to prove irreparable injury to such
Party or that such Party does not have an adequate remedy at law with respect to any breach of this Lock-Up Agreement (each of which elements
the Parties admit). The Parties further agree and acknowledge that each and every obligation applicable to it contained in this Lock-Up
Agreement shall be specifically enforceable against it and hereby waives and agrees not to assert any defenses against an action for specific
performance of their respective obligations hereunder. All rights and remedies existing under this Lock-Up Agreement are cumulative to,
and not exclusive of, any rights or remedies available under this Lock-Up Agreement or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 2.05<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>Except as provided in <span style="text-decoration:underline">Section&#160;1.02</span>, neither this Lock-Up Agreement nor any of the rights, interests or obligations
hereunder shall be assigned, in whole or in part, by operation of law or otherwise, by either Party without the prior written consent
of the other Party, <span style="text-decoration:underline">provided</span> that PubCo may assign its rights and interests to any of its Affiliates (as defined in the Merger
Agreement). Subject to the preceding sentence, this Lock-Up Agreement shall be binding upon, inure to the benefit of, and be enforceable
by, the Parties and their respective successors and permitted assigns. Any purported assignment not permitted under this <span style="text-decoration:underline">Section&#160;2.05</span>
shall be null and void.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 2.06<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>If any term or other provision of this Lock-Up Agreement is determined by a court of competent jurisdiction to be invalid,
illegal or incapable of being enforced by any rule of law or public policy, all other terms, provisions and conditions of this Lock-Up
Agreement shall nevertheless remain in full force and effect. Upon such determination that any term or other provision is invalid, illegal
or incapable of being enforced, the Parties shall negotiate in good faith to modify this Lock-Up Agreement so as to effect the original
intent of the Parties as closely as possible to the fullest extent permitted by applicable law in an acceptable manner to the end that
the transactions contemplated hereby are fulfilled to the extent possible.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 2.07<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>Each of the Parties agrees and acknowledges that this Lock-Up Agreement has been negotiated in good faith, at arm&#8217;s length,
and not by any means prohibited by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 2.08<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>This Lock-Up Agreement may be executed in counterparts (each of which shall be deemed to be an original but all of which taken
together shall constitute one and the same agreement).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 2.09<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>Each of the Parties specifically acknowledges that he, she or it (i) is a knowledgeable, informed, sophisticated Person capable
of understanding and evaluating the provisions set forth in this Lock-Up Agreement, (ii) has had the opportunity to review this Lock-Up
Agreement with counsel of his, her or its own choosing, (iii) has carefully read and fully understands all of the terms of this Lock-Up
Agreement, and (iv) is under no disability or impairment that affects its, his or her decision to sign this Lock-Up Agreement and he,
she or it knowingly and voluntarily intends to be legally bound by this Lock-Up Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 478 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 2.10<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received
hereunder (i) one Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight
courier service, (ii) upon delivery in the case of delivery by hand, or (iii) on the date delivered in the place of delivery if sent by
email or facsimile (with a written or electronic confirmation of delivery) prior to 5:00 p.m. Eastern time, otherwise on the next succeeding
Business Day, in each case to the intended recipient notice address as set forth in <span style="text-decoration:underline">Section 9.07</span> of the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 2.11<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>The Holders agree and consent to the entry of stop transfer instructions with PubCo&#8217;s transfer agent and registrar against
the transfer of shares of Company Common Stock or securities convertible into or exchangeable or exercisable for shares of Company Common
Stock held by the Holder except in compliance with the foregoing restrictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 2.12<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>This Lock-Up Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless
of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the
Parties arising out of or relating to this Lock-Up Agreement, each of the Parties: (i) irrevocably and unconditionally consents and submits
to the exclusive jurisdiction and venue of the federal courts located in the State of Delaware and the Court of Chancery of the State
of Delaware (collectively with any appellate courts thereof, the &#8220;<b>Courts</b>&#8221;); (ii) agrees that all claims in respect
of such action or proceeding shall be heard and determined exclusively in accordance with clause (i) of this <span style="text-decoration:underline">Section&#160;2.12</span>;
(iii) waives any objection to laying venue in any such action or proceeding in such Courts; (iv) waives any objection that such Courts
are an inconvenient forum or do not have jurisdiction over any Party; (v) agrees that service of process upon such Party in any such action
or proceeding shall be effective if notice is given in accordance with <span style="text-decoration:underline">Section&#160;2.10</span> of this Lock-Up Agreement; and (vi) irrevocably
and unconditionally waives the right to trial by jury. This Lock-Up Agreement, and any certificates, documents, instruments and writings
that are delivered pursuant hereto, constitutes the entire agreement and understanding of the Parties in respect of the subject matter
hereof and supersedes all prior understandings, agreements or representations by or among the Parties, written or oral, to the extent
they relate in any way to the subject matter hereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 2.13<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>Nothing herein shall grant to or create in any Person not a Party, or any such Person&#8217;s dependents, heirs, successors
or assigns any right to any benefits hereunder or any remedies hereunder, and no such Person shall be entitled to sue any Party with respect
thereto;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 2.14<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>Any amendment, supplement or waiver of this Lock-Up Agreement shall be effective only if in a written instrument executed by
each of the Parties. If any such amendment, supplement or waiver is to be entered into after the Effective Time, it shall have been approved
in advance by a majority of the board of directors of PubCo.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 2.15<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>This Lock-Up Agreement may be executed in counterparts, each of which shall be deemed an original, and all of which shall constitute
one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by PubCo the Company and the Holder
via facsimile or electronic transmission in .pdf format shall be sufficient to bind such Parties to the terms and conditions of this Lock-Up
Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Remainder of page intentionally left blank]</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 479 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>IN WITNESS WHEREOF</b>,
the Parties have caused this Lock-Up Agreement to be executed as of the date first above written.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2" style="font-weight: bold">AVALON GLOBOCARE CORP.</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%">By:</td>
    <td style="border-bottom: Black 1.5pt solid; width: 35%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>Name:&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>Title:</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>[Signature Page to Lock-Up
Agreement]</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 480 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>IN WITNESS WHEREOF</b>,
the Parties have caused this Lock-Up Agreement to be executed as of the date first above written.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2" style="font-weight: bold"><b>HOLDER</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%">By:</td>
    <td style="border-bottom: Black 1.5pt solid; width: 35%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>Name:&#160;</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>Title:</td>
    <td style="border-bottom: Black 1.5pt solid">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>[Signature Page to Lock-Up
Agreement]</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 481 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span style="text-decoration:underline">EXHIBIT C</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Form of Company Voting Agreement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>See attached</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17pt 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 482 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF VOTING AND SUPPORT AGREEMENT</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Company Voting and Support
Agreement (this &#8220;<b><span style="text-decoration:underline">Agreement</span></b>&#8221;), dated as of March 7, 2025, is entered into by and among Avalon GloboCare Corp.,
a Delaware corporation ( &#8220;<b><span style="text-decoration:underline">PubCo</span></b>&#8221;), YOOV Group Holding Limited, a British Virgin Islands company (the &#8220;<b>Company</b>&#8221;),
and the persons listed on the attached <span style="text-decoration:underline">Schedule A</span> who are signatories to this Agreement and holders of securities of the Company
(each, a &#8220;<b><span style="text-decoration:underline">Stockholder</span></b>&#8221;, and collectively, the &#8220;<b><span style="text-decoration:underline">Stockholders</span></b>&#8221;). Terms used herein and
not defined herein shall have the meaning ascribed to them in the Merger Agreement (as defined below).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RECITALS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, PubCo, the Company,
and Nexus MergerSub Limited, a British Virgin Islands company and wholly owned subsidiary of PubCo (&#8220;<b>Merger Sub</b>&#8221;),
have entered into an Agreement and Plan of Merger, dated as of March 7, 2025 (the &#8220;<b>Merger Agreement</b>&#8221;), providing that,
among other things, all outstanding Company Ordinary Shares will be exchanged for shares of PubCo Common Stock based on the terms and
conditions of the Merger Agreement;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, as of the date of
this Agreement, each Stockholder is the record and/or &#8220;beneficial owner&#8221; (within the meaning of Rule 13d-3 under the Exchange
Act) of the number of shares of Company Share Capital set forth on <span style="text-decoration:underline">Schedule A</span> opposite such Stockholder&#8217;s name (all of the
shares of Company Share Capital owned of record or beneficially by such Stockholder as of the date of this Agreement, the &#8220;<b><span style="text-decoration:underline">Owned
Shares</span></b>&#8221; and, together with any additional shares of Company Ordinary Shares or other voting securities of the Company of
which such Stockholder acquires record or beneficial ownership after the date of this Agreement, including by purchase, as a result of
a stock dividend, stock split, recapitalization, combination, consolidation, reclassification, exchange or change of such shares, or other
similar transaction, or upon exercise, vesting or conversion of any securities, such Stockholder&#8217;s &#8220;<b><span style="text-decoration:underline">Covered Shares</span></b>&#8221;);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, as a condition and
inducement to the willingness of the parties to enter into the Merger Agreement and consummate the transactions contemplated thereby,
including the Merger, the Stockholders are entering into this Agreement; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Stockholders
acknowledge that each of PubCo and the Company desire to enter into the Merger Agreement in reliance on the representations, warranties,
covenants and other agreements of the Stockholders set forth in this Agreement and would not enter into the Merger Agreement if the Stockholders
did not enter into this Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AGREEMENT</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing and the respective representations, warranties, covenants and agreements set forth below and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, do hereby
agree as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
I. Certain Definitions.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All capitalized terms that
are used but not defined herein have the respective meanings ascribed to them in the Merger Agreement. For all purposes of and under this
Agreement, the following terms have the following respective meanings:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 1.01<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>&#8220;<span style="text-decoration:underline">Entity</span>&#8221; means a corporation (including any non-profit corporation), partnership (including any general
partnership, limited partnership or limited liability partnership), joint venture, estate, trust, company (including any company limited
by shares, limited liability company or joint stock company), firm, society or other enterprise, association, organization or entity,
and each of its successors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 483 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 1.02<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>&#8220;<span style="text-decoration:underline">family member</span>&#8221; means of any natural person means (i) such individual&#8217;s spouse (former or current),
(ii) such individual&#8217;s parents and grandparents (in each case, natural or adoptive, of the whole or half-blood), (iii) such individual&#8217;s
children and grandchildren (in each case, natural or adoptive, of the whole or half-blood), (iv) such individual&#8217;s sons-in-law and
daughters-in-law (in each case, former or current), (v) any other ascendants and descendants (natural or adoptive, of the whole or half-blood)
of such individual&#8217;s parents or of the parents of such individual&#8217;s spouse (former or current) and (vi) any lineal descendants
(natural or adoptive, of the whole or half-blood) of such individual&#8217;s spouse.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 1.03<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>&#8220;<span style="text-decoration:underline">Permitted Liens</span>&#8221; means (i) Liens for Taxes that (A) are not yet due and payable or (B) are being contested
in good faith by appropriate proceedings, (ii) Liens for assessments and other governmental charges or landlords&#8217;, carriers&#8217;,
warehousemen&#8217;s, mechanics&#8217;, repairmen&#8217;s, workers&#8217; and other similar common law or statutory Liens arising or incurred
in the ordinary course of business consistent with past practice, in each case that (A) relate to obligations that are not delinquent
or (B) the applicable Stockholder or any of such Stockholder&#8217;s Affiliates is contesting in good faith by appropriate proceedings,
and (iii) Liens that are or may be imposed pursuant to this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 1.04<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>&#8220;<span style="text-decoration:underline">Termination Date</span>&#8221; means the earliest to occur of (i) the closing of the Merger, (ii) the occurrence of
a PubCo Adverse Recommendation Change with respect to an Intervening Event and (iii)&#160;the termination of the Merger Agreement in accordance
with its terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 1.05<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>A Person will be deemed to have effected a &#8220;<span style="text-decoration:underline">Transfer</span>&#8221; of a security if such Person, whether voluntarily
or involuntarily, directly or indirectly, (i) sells, pledges, encumbers, hypothecates, leases, assigns, gifts, grants an option with respect
to, transfers, exchanges, tenders or disposes (by merger, by testamentary disposition, by operation of law or otherwise) of such security
or any interest in such security, (ii) creates or permits to exist any Liens, (iii) deposits such security into a voting trust or enters
into a voting agreement or arrangement or grants any proxy, power of attorney or other authorization with respect thereto that is inconsistent
with this Agreement or (iv) enters into an agreement, option, commitment or other arrangement to take any of the actions referred to in
the foregoing clauses (i) through (iii).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
II. Transfer Restrictions.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From the date of this Agreement
until the Termination Date, Stockholder shall not Transfer (or cause or permit the Transfer of) any of such Stockholder&#8217;s Covered
Shares. Notwithstanding anything to the contrary in this Agreement, this <span style="text-decoration:underline">Article II</span> shall not prohibit a Transfer of Covered Shares
by a Stockholder (i) if Stockholder is an Entity, to one or more partners or members of Stockholder or an Affiliated corporation, trust
or other Entity under common control with Stockholder, or if Stockholder is a trust, a transfer to a beneficiary, (ii) if Stockholder
is a natural person, a family member of such Stockholder, (iii) to any other Stockholder a party to this Agreement, (iv) as the Company
may otherwise agree in writing in its sole discretion, (vi) to any natural person or Entity if and to the extent required by any non-consensual
legal order, by divorce decree or by will, intestacy or other similar law or for estate planning purposes; <span style="text-decoration:underline">provided</span> that in the
case of (i), (ii) and (iii), such a Transfer shall be permitted only if, as a precondition to such Transfer, the transferee agrees in
writing (in form and substance reasonably satisfactory to the Company) to be bound by all of the obligations of such Stockholder under
this Agreement with respect to such Covered Shares being Transferred. If any voluntary or involuntary Transfer of any Covered Shares occurs,
the transferee (which term, as used herein, shall include any and all transferees and subsequent transferees of the initial transferee)
shall take and hold such Covered Shares subject to all of the restrictions, Liabilities and rights under this Agreement, which shall continue
in full force and effect, notwithstanding that such transferee is not a Stockholder and has not executed a counterpart hereof or joinder
hereto. Any Transfer or attempted Transfer of any Covered Shares in violation of this <span style="text-decoration:underline">Article II</span> shall be null and void and of
no effect whatsoever.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 484 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
III. Agreement to Vote.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 3.01<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>From the date of this Agreement until the Termination Date, in connection with the Company obtaining the Company Shareholder
Approval, whether by written consent or at a meeting of Company Shareholders and any other meeting of the Company Shareholders (and at
every adjournment or postponement thereof), to vote on any matter contemplated by this Agreement, however called, each Stockholder unconditionally
and irrevocably agrees to vote, or cause to be voted, all such Stockholder&#8217;s Covered Shares held at that time:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">in favor of the Merger Agreement
and the Transactions;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">against any action or agreement
that would reasonably be expected to result in the conditions of the Transactions contemplated by the Merger Agreement not being fulfilled
or a breach of a covenant, representation or warranty or any other material obligation or agreement of the Company contained in the Merger
Agreement;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">against any action, proposal,
transaction or agreement that would reasonably be expected to prevent or materially delay the consummation of the Transactions and the
Merger, or the fulfillment of the Company&#8217;s or PubCo&#8217;s respective conditions to close the Merger and Transactions; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">against any Takeover Proposal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 3.02<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>From the date of this Agreement until the Termination Date, each Stockholder shall appear, or shall cause the applicable entity
that is the record holder of any of such Stockholder&#8217;s Covered Shares, as applicable (in person, by proxy or by any other means
permitted by the Company Organizational Documents) at each meeting of the Company Shareholders, or adjournment or postponement thereof,
to vote on any matter contemplated by this Agreement and shall cause all such Stockholder&#8217;s Covered Shares to be counted as present
thereat for purposes of calculating a quorum and shall vote all such Stockholder&#8217;s Covered Shares in accordance with this <span style="text-decoration:underline">Article
III</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 3.03<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>Nothing in this Agreement, including this <span style="text-decoration:underline">Article III</span>, limits or restricts any Stockholder, or any Affiliate or designee
of any Stockholder who serves as a member of the Company Board in acting or voting in his or her capacity as a director of the Company
and exercising his or her fiduciary duties and responsibilities, it being understood that this Agreement applies to each Stockholder solely
in such Stockholder&#8217;s capacity as a Company Shareholder and does not apply to such Stockholder&#8217;s or any such Affiliate&#8217;s
or designee&#8217;s actions, judgments or decisions as a director of the Company, and such actions (or failures to act) shall not be deemed
to constitute a breach of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
IV. No Inconsistent Agreements.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Stockholder hereby represents,
covenants and agrees that, except as contemplated by this Agreement, such Stockholder (a) has not entered into, and shall not enter into
at any time prior to the Termination Date, any voting agreement or voting trust with respect to any of such Stockholder&#8217;s Covered
Shares and (b) has not granted, and shall not grant at any time prior to the Termination Date of this Agreement, a proxy or power of attorney
with respect to any of such Stockholder&#8217;s Covered Shares, in either case, that is inconsistent with such Stockholder&#8217;s obligations
pursuant to this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
V. Representations and Warranties of each Stockholder.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Stockholder hereby represents
and warrants to PubCo, Merger Sub and the Company, solely as to itself and not as to any other Stockholder or other Person, as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.01<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">Power; Organization; Binding Agreement</span>. If such Stockholder is an Entity: (i) Stockholder is duly organized, validly
existing and in good standing under the laws of the jurisdiction in which it is incorporated, organized or constituted, (ii) Stockholder
has all necessary power and authority to execute and deliver this Agreement, to perform Stockholder&#8217;s obligations hereunder and
to consummate the transactions contemplated hereby, and (iii) the execution and delivery of this Agreement, performance of Stockholder&#8217;s
obligations hereunder and the consummation of the transactions contemplated hereby by Stockholder have been duly authorized by all necessary
action on the part of Stockholder and no other proceedings on the part of Stockholder are necessary to authorize this Agreement, or to
consummate the transactions contemplated hereby. If such Stockholder is an individual, Stockholder has the capacity to execute and deliver
this Agreement, to perform such Stockholder&#8217;s obligations hereunder and to consummate the transactions contemplated hereby. This
Agreement has been duly executed and delivered by such Stockholder, and, assuming due authorization, execution and delivery by PubCo and
the Company, this Agreement is enforceable against such Stockholder in accordance with its terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 485 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.02<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">No Conflicts</span>. None of the execution and delivery by such Stockholder of this Agreement, the performance by such Stockholder
of such Stockholder&#8217;s obligations hereunder or the consummation by such Stockholder of the transactions contemplated hereby will
(i) require any consent or approval under, or result in a violation or breach of, any agreement to which such Stockholder is a party or
by which such Stockholder may be bound, including any voting agreement or voting trust, (ii) result in the creation of any Lien on any
of the assets or properties of such Stockholder, (iii) violate any applicable Law or Judgment or (iv) with respect to a Stockholder that
is not a natural person, violate the organizational documents of such Stockholder, in each case, except for such consents, approvals,
breaches, Liens or violations that would not, individually or in the aggregate, prevent or materially delay such Stockholder from performing
such Stockholder&#8217;s obligations under this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.03<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">Ownership of Covered Shares</span>. Such Stockholder is the beneficial owner of such Stockholder&#8217;s Covered Shares. All
such Stockholder&#8217;s Covered Shares are owned free and clear of any Liens other than Permitted Liens, and no Person has a right to
acquire any of such Covered Shares, in each case other than pursuant to this Agreement, the Merger Agreement, under applicable federal
or state securities laws or pursuant to any written policies of the Company only with respect to restrictions upon the trading of securities
under applicable securities laws. As of the date of this Agreement, except as set forth on <span style="text-decoration:underline">Schedule A</span>, other than such Stockholder&#8217;s
Owned Shares, such Stockholder does not own beneficially or of record any (i) shares of capital stock or voting securities of the Company,
(ii) securities of the Company convertible into or exchangeable for shares of capital stock or voting securities of the Company or (iii)
options or other rights to acquire from the Company any capital stock, voting securities or securities convertible into or exchangeable
for capital stock or voting securities of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.04<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">Voting Power</span>. Such Stockholder has the requisite voting power, power of disposition, power to issue instructions with
respect to the matters set forth herein and power to agree to all of the matters set forth in this Agreement necessary to take all actions
required under this Agreement, in each case with respect to all of the securities subject to this Agreement owned by such Stockholder,
with no limitations, qualifications or restrictions on such rights, subject to applicable federal securities laws and those arising under
the terms of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.05<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">Reliance by the Company, PubCo and Merger Sub</span>. Such Stockholder understands and acknowledges that each of the Company,
PubCo and Merger Sub is entering into the Merger Agreement in reliance upon such Stockholder&#8217;s execution and delivery of this Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.06<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">Consents and Approvals.</span> The execution and delivery of this Agreement by such Stockholder does not, and the performance by
such Stockholder of such Stockholder&#8217;s obligations under this Agreement and the consummation of the transactions contemplated hereby
will not, require such Stockholder to obtain any consent, approval, authorization or permit of, or to make any filing with or notification
to, any Governmental Authority, except in each case for filings with the SEC or where the failure to obtain such consents, approvals,
authorizations or permits, or to make such filings and notifications, would not, either individually or in the aggregate, prevent or materially
delay the performance by such Stockholder of any of such Stockholder&#8217;s obligations hereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.07<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">Litigation</span>. As of the date of this Agreement, there is no Legal Action pending or, to the knowledge of such Stockholder,
threatened against such Stockholder that would reasonably be expected to prevent or delay the performance by such Stockholder of his,
her or its obligations under this Agreement in any material respect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 5.08<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">Brokers</span>. No investment banker, broker, finder or other intermediary is entitled to a fee or commission from PubCo or
the Company in respect of this Agreement based upon any contract made by or on behalf of Stockholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
VI. Additional Covered Shares.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the avoidance of doubt,
prior to the Termination Date, in the event that a Stockholder acquires record or beneficial ownership of, or the power to vote or direct
the voting of, any additional shares of Company Share Capital or other voting interests with respect to the Company, such shares of Company
Share Capital, or other voting interests will, without further action of the parties, be deemed Covered Shares held by such Stockholder
and subject to the provisions of this Agreement, the number of shares of Company Share Capital held by such Stockholder will be deemed
amended accordingly, and such shares of Company Share Capital or voting interests will automatically become subject to the terms of this
Agreement as Covered Shares. Notwithstanding the foregoing, nothing in this Agreement shall require a Stockholder to (i) convert, exercise
or exchange any options, warrants or convertible securities in order to obtain underlying shares of Company Share Capital or (ii) vote,
or execute any consent with respect to, any shares of Company Share Capital underlying such options, warrants or convertible securities
that have not yet been issued as of the applicable record date for such vote or consent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 486 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
VII. irrevocable proxy</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the final sentence of this <span style="text-decoration:underline">Article
VII</span>, by execution of this Agreement, such Stockholder does hereby appoint the Company and any of its designees with full power of
substitution and resubstitution, as Stockholder&#8217;s true and lawful attorney and irrevocable proxy, to the fullest extent of Stockholder&#8217;s
rights with respect to the Covered Shares, to vote and exercise all voting and related rights, including the right to sign such Stockholder&#8217;s
name (solely in its capacity as a stockholder) to any stockholder consent, if Stockholder is unable to perform or otherwise does not perform
his, her or its obligations under this Agreement, with respect to such Covered Shares solely with respect to the matters set forth in
<span style="text-decoration:underline">Section 3.01</span>. Such Stockholder intends this proxy to be irrevocable and coupled with an interest hereunder until the Termination
Date, hereby revokes any proxy previously granted by Stockholder with respect to the Covered Shares and represents that none of such previously-granted
proxies are irrevocable. The irrevocable proxy and power of attorney granted herein shall survive the death or incapacity of Stockholder
and the obligations of Stockholder shall be binding on Stockholder&#8217;s heirs, personal representatives, successors, transferees and
assigns. Stockholder hereby agrees not to grant any subsequent powers of attorney or proxies with respect to any Covered Shares with respect
to the matters set forth in <span style="text-decoration:underline">Section 3.01</span> until after the Termination Date. Such Stockholder hereby affirms that the proxy set forth
in this <span style="text-decoration:underline">Article VII</span> is given in connection with and granted in consideration of and as an inducement to the Company, PubCo and
Merger Sub to enter into the Merger Agreement and that such proxy is given to secure the obligations of Stockholder under <span style="text-decoration:underline">Section 3.01</span>.
Notwithstanding anything contained herein to the contrary, this irrevocable proxy shall automatically terminate upon the Termination Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
VIII. Stockholder Litigation.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Stockholder agrees not
to commence or participate in, and to take all actions necessary to opt out of any class in any class action with respect to, any claim,
derivative or otherwise, that may be brought against the Company or any of its successors and assigns relating to the negotiation, execution
or delivery of this Agreement, the Merger Agreement or the consummation of the transactions contemplated hereby and thereby; <span style="text-decoration:underline">provided</span>
that this <span style="text-decoration:underline">Article VIII </span>shall not be deemed a waiver of any rights of any Stockholder or such Stockholder&#8217;s Affiliates for
any breach of this Agreement or the Merger Agreement by the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
IX. Stop Transfer Instructions.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At all times commencing with
the execution and delivery of this Agreement and continuing until the Termination Date, in furtherance of this Agreement, each Stockholder
hereby authorizes the Company or its counsel to instruct the Company&#8217;s transfer agent to put in place a stop transfer order with
respect to all of the securities of the Company held of record by such Stockholder (and that this Agreement places limits on the voting
and transfer of such securities) except with respect to Transfers of any Covered Shares in accordance with <span style="text-decoration:underline">Article II</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
X. Termination.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement and all rights
and obligations of the parties hereunder will terminate and have no further force or effect as of the Termination Date; <span style="text-decoration:underline">provided</span>
that this <span style="text-decoration:underline">Article X</span> and <span style="text-decoration:underline">Article XI</span> shall survive the termination of this Agreement. Notwithstanding the foregoing, nothing
set forth in this <span style="text-decoration:underline">Article X</span> or elsewhere in this Agreement relieves any party hereto from liability, or otherwise limits the liability
of any party hereto, for any breach of this Agreement prior to such termination hereof or such party&#8217;s fraud.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
XI. Miscellaneous.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.01<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">Severability</span>. If any term, provision, covenant or restriction of this Agreement or the application of any such provision
to any person or circumstance shall be held invalid, illegal, void or unenforceable in any respect by a court of competent jurisdiction
or other Governmental Authority, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in
full force and effect and shall in no way be affected, impaired or invalidated. Upon such a holding, the parties hereto agree to negotiate
in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner,
in order that the transactions contemplated by this Agreement be consummated as originally contemplated to the fullest extent possible.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 487 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.02<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">Assignment</span>. Except in connection with a Transfer of any Covered Shares in accordance with <span style="text-decoration:underline">Article II</span>, neither
this Agreement nor any of the rights, interests or obligations hereunder shall be assigned, in whole or in part, by operation of Law or
otherwise by any of the parties without the prior written consent of the other parties and any purported assignment in violation hereof
shall be null and void <i>ab initio</i>. Subject to the immediately preceding sentence, this Agreement shall be binding upon, inure to
the benefit of and be enforceable by, the parties hereto and their respective successors and assigns.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.03<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">Amendment and Modification; Waiver</span>. This Agreement may be amended or waived by any party only if such amendment or waiver
is in writing and is signed, in the case of an amendment, by each party to this Agreement or, in the case of a waiver, by each party against
whom the waiver is to be effective. Any failure of any of the parties to comply with any obligation, covenant, agreement or condition
in this Agreement may be waived by any of the parties entitled to the benefit thereof only by a written instrument signed by each such
party granting such waiver. No failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a
waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any
other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies
provided by applicable Law or in equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.04<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">Specific Performance</span>. The parties agree that irreparable damage for which monetary damages, even if available, would
not be an adequate remedy, would occur and that the parties would not have any adequate remedy at law in the event that any of the provisions
of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that,
in addition to any other remedy to which the parties are entitled at law or in equity, (i) the parties shall be entitled to an injunction
or injunctions, specific performance or other equitable relief, to prevent breaches or threatened or anticipated breaches of this Agreement
and to enforce specifically the terms and provisions of this Agreement in the courts described in <span style="text-decoration:underline">Section 11.08</span>, without proof
of damages or otherwise, and (ii)&#160;the right of specific performance is an integral part of the transactions contemplated hereby and
without that right, none of the parties would have entered into this Agreement. Each of the parties agrees that it waives the defense
of adequacy of a remedy at law and will not oppose the granting of an injunction or injunctions, specific performance or other equitable
relief on the basis that (A) the other parties have an adequate remedy at law or (B) an award of an injunction, specific Performance or
other equitable relief is not an appropriate remedy for any reason at law or equity. The parties acknowledge and agree that any party
seeking an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this
Agreement in accordance with this <span style="text-decoration:underline">Section 11.04</span> shall not be required to provide any bond or other security in connection with
any such order or injunction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.05<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">Notices</span>. All notices or other communications required or permitted under, or otherwise given in connection with, this
Agreement shall be in writing and shall be deemed to have been duly given (i) when delivered, if delivered in person, (ii) on the next
Business Day if transmitted by national overnight courier (with confirmation of delivery) or (iii) on the date transmitted if sent by
email (<span style="text-decoration:underline">provided</span> that no &#8220;bounce back&#8221; or similar message of non-delivery is received with respect thereto), as follows
(or at such other address for a party as shall be specified by notice given in accordance with this <span style="text-decoration:underline">Section 11.05</span>):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If to the Stockholders, to
the address for notice set forth on <span style="text-decoration:underline">Schedule A</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><i>If to PubCo, to:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Avalon GloboCare Corp.<br/>
4400 Route 9 South, Suite 3100<br/>
Freehold, New Jersey 07728</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in"/><td style="width: 0.5in; text-align: left">Attn:</td><td style="text-align: justify">Luisa Ingargiola (email: [***])</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 488 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><i>With a copy which shall not constitute
notice to:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Lowenstein Sandler LLP<br/>
1251 Avenue of the Americas<br/>
New York, New York 10020</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in"/><td style="width: 0.5in; text-align: left">Attn:</td><td style="text-align: justify">Steven Skolnick, Esq. (email: [***])</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><i>If to the Company, to:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">YOOV Group Holding Limited</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">1 Raffles Place</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">#31-62 One Raffles
Place Tower 2</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Singapore 048616</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 1in"/><td style="width: 0.5in; text-align: left">Attn:</td><td style="text-align: justify">Phil Wong (email: [***])</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><i>With a copy which shall not constitute
notice to:</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Lucosky Brookman LLP<br/>
101 Wood Avenue South, 5th Floor<br/>
Iselin, New Jersey 08830</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 1in"/><td style="width: 0.5in">Attn:</td><td>Joseph M. Lucosky, Esq. (email: [***])<br/>
Scott Linsky, Esq. (email: [***])</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Ian Liao, Esq. (email:
[***])</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything in
this Agreement to the contrary, any notice given in accordance with the foregoing clauses (i) or (ii) of this <span style="text-decoration:underline">Section 11.05</span> shall
only be effective if a duplicative copy of such notice is also given by email in the method described in this <span style="text-decoration:underline">Section 11.05</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.06<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">No Third Party Beneficiaries</span>. This Agreement is not intended to confer upon any person other than the parties hereto
(and their respective successors and permitted assigns) any rights (legal, equitable or otherwise) or remedies, whether as third-party
beneficiaries or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.07<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">Governing Law</span>. This Agreement and all Legal Actions arising out of or relating to this Agreement shall be governed by,
and construed in accordance with, the Laws of the State of Delaware, regardless of the laws that might otherwise govern under any applicable
conflict of laws principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.08<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">Jurisdiction</span>. In any action or proceeding between any of the parties arising out of or relating to this Agreement, each
of the parties: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the federal courts
of the United States of America located in the State of Delaware and the Court of Chancery of the State of Delaware (collectively with
any appellate courts thereof, the &#8220;<b>Courts</b>&#8221;); (ii) agrees that all claims in respect of such action or proceeding shall
be heard and determined exclusively in accordance with clause (i) of this <span style="text-decoration:underline">Section 11.08</span>; (iii) waives any objection to laying venue
in any such action or proceeding in such Courts; (iv) waives any objection that such Courts are an inconvenient forum or do not have jurisdiction
over any Party; (v) agrees that service of process upon such party in any such action or proceeding shall be effective if notice is given
in accordance with <span style="text-decoration:underline">Section 11.05</span> of this Agreement; and (vi) irrevocably and unconditionally waives the right to trial by jury.
This Agreement, and any certificates, documents, instruments and writings that are delivered pursuant hereto, constitutes the entire agreement
and understanding of the Parties in respect of the subject matter hereof and supersedes all prior understandings, agreements or representations
by or among the Parties, written or oral, to the extent they relate in any way to the subject matter hereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.09<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b>&#8239;<span style="text-decoration:underline">WAIVER OF JURY TRIAL</span>. EACH PARTY HERETO ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS
AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE IT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE
FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY
ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH PARTY HERETO CERTIFIES AND ACKNOWLEDGES THAT
(A) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT,
IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B) IT UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF SUCH WAIVER,
(C) IT MAKES SUCH WAIVER VOLUNTARILY AND (D) IT HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVER
AND CERTIFICATIONS IN THIS <span style="text-decoration:underline">SECTION 11.09</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 489 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.10<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">Rules of Construction</span>. Each of the parties hereto acknowledges that such party has been represented by counsel of such
party&#8217;s choice throughout all negotiations that have preceded the execution of this Agreement, and that such party has executed
the same with the advice of such counsel. Each party and such party&#8217;s counsel cooperated and participated in the drafting and preparation
of this Agreement and the documents referred to in this Agreement, and any and all drafts relating thereto exchanged among the parties
shall be deemed the work product of all of the parties and may not be construed against any party by reason of such party&#8217;s drafting
or preparation. Accordingly, any rule of law or any legal decision that would require interpretation of any ambiguities in this Agreement
against any party that drafted or prepared it is of no application and is hereby expressly waived by each of the parties hereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.11<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">Entire Agreement</span>. This Agreement, taken together with the Schedules attached hereto, and the Merger Agreement to the
extent referenced herein, constitutes the entire agreement among the parties hereto with respect to the subject matter hereof, and supersedes
all prior agreements and understandings, both written and oral, among the parties hereto with respect thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.12<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">Interpretation</span>. The rules of interpretation set forth in Section 9.02 of the Merger Agreement shall apply to this Agreement,
<i>mutatis mutandis</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.13<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">Expenses</span>. Except as otherwise expressly provided in this Agreement and the Merger Agreement, all fees and expenses incurred
in connection with this Agreement and the transactions contemplated hereby shall be paid by the party hereto incurring such fees or expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Section 11.14<span style="font-family: Times New Roman, Times, Serif">&#160;
</span></b><span style="text-decoration:underline">No Recourse</span>. This Agreement may only be enforced against, and any claims or causes of action that may be based upon,
arise out of or relate to this Agreement, or the negotiation, execution or performance of this Agreement, may only be made against, the
Persons that are expressly identified as parties hereto and no former, current or future equity holders, controlling persons, directors,
officers, employees, agents or Affiliates of any party hereto or any former, current or future stockholder, controlling person, director,
officer, employee, general or limited partner, member, manager, agent or Affiliate of any of the foregoing shall have any liability for
any obligations or liabilities of the parties to this Agreement or for any claim (whether in tort, contract or otherwise) based on, in
respect of, or by reason of, the transactions contemplated hereby or in respect of any representations made or alleged to be made in connection
herewith.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
XII. Counterparts.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement may be signed
in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon
the same instrument. This Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by all
of the other parties hereto, it being understood and agreed that all parties hereto need not sign the same counterpart. Until and unless
each party has received a counterpart hereof signed by each other party hereto, this Agreement shall have no effect and no party shall
have any right or obligation hereunder (whether by virtue of any other oral or written agreement or other communication). Signatures to
this Agreement (which need not be on the same counterpart) transmitted by electronic mail in PDF form, or by any other electronic means
designed to preserve the original graphic and pictorial appearance of a document (including DocuSign), will be deemed to have the same
effect as physical delivery of the paper document bearing the original signatures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 490 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
XIII. Stockholder Obligation Several and Not Joint.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The obligations of each Stockholder
hereunder shall be several and not joint, and no Stockholder shall be liable for any breach of the terms of this Agreement by any other
Stockholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
XIV. No Ownership Interest.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Stockholder, solely as
to itself and not as to any other Stockholder or other Person, has agreed to enter into this Agreement and act in the manner specified
in this Agreement for consideration. Except as expressly set forth in this Agreement, all rights and all ownership and economic benefits
of and relating to each Stockholder&#8217;s Covered Shares will remain vested in and belong to such Stockholder, and nothing herein will,
or will be construed to, grant PubCo, Merger Sub or the Company any power, sole or shared, to direct or control the voting or disposition
of any of such Covered Shares. Nothing in this Agreement will be interpreted as creating or forming a &#8220;group&#8221; with any other
Person, including other holders listed on <span style="text-decoration:underline">Schedule A</span>, for purposes of Rule 13d-5(b)(1) of the Exchange Act or any other similar
provision of applicable Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article
XV. Disclosure.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Stockholder hereby (a)
authorizes PubCo and the Company to publish and disclose in any announcement or disclosure required by the SEC or other applicable Law
and in the Proxy Statement such Stockholder&#8217;s identity and ownership of the Covered Shares and the nature of such Stockholder&#8217;s
obligations under this Agreement and (b) agrees to promptly give to PubCo and Company any information it may reasonably require for the
preparation of any such announcement or disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[S<i>ignature pages follow</i>]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 491 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have executed this Agreement as of the date first written above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="3"><b>PUBCO:</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="3"><b>AVALON GLOBOCARE CORP.</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>By:</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 5%">Name:&#160;</td>
    <td style="width: 31%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Title:&#160;</td>
    <td>&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<i>Signature Page to Company
Voting Agreement</i>]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 492 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have executed this Agreement as of the date first written above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="3"><b>COMPANY</b>:</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="3"><b>YOOV GROUP HOLDING LIMITED</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>By:</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 5%">Name:&#160;</td>
    <td style="width: 31%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Title:&#160;</td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<i>Signature Page to Company
Voting Agreement</i>]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 493 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have executed this Agreement as of the date first written above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="3"><b>STOCKHOLDER</b>:</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>By:</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 5%">Name:&#160;</td>
    <td style="width: 31%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Title:&#160;</td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<i>Signature Page to Company
Voting Agreement</i>]</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 494 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_145"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="text-decoration:underline">ANNEX B: OPINION OF ROTH</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><img alt="" src="image_005.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">March 7<sup>th</sup>, 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Board of Directors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Avalon Globocare Corp.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">4400 Route 9 South, Suite 3100</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Freehold, NJ 07728</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Members of the Board of Directors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Roth Capital Partners, LLC (&#8220;Roth,
&#8220;us&#8221; or &#8220;we&#8221;) understands that Avalon Globocare Corp., a Delaware corporation (the &#8220;Company&#8221; or &#8220;PubCo&#8221;),
intends to enter into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), pursuant to which the Company will enter into
a business combination with Yoov Group Holding Limited Inc., a British Virgin Islands corporation (&#8220;Yoov&#8221;) (the &#8220;Transaction&#8221;).
Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">As more specifically set forth in the
Merger Agreement, and subject to the terms, conditions and adjustments set forth therein, Yoov will merge with and into Nexus MergerSub
Limited, a business company incorporated in the British Virgin Islands and a wholly owned subsidiary of PubCo (&#8220;Merger Sub&#8221;),
with Yoov surviving the merger as a wholly owned subsidiary of PubCo. Except for any Dissenting Shares or Excluded Company Shares, by
virtue of the Merger, each ordinary share, par value of $0.10 per share, of Yoov of any series or class (&#8220;Yoov Ordinary Share&#8221;)
will be exchanged for a number of shares of Common Stock, par value $0.0001 per share, of PubCo (&#8220;PubCo Common Stock&#8221;) equal
to the following Exchange Ratio (the &#8220;Merger Consideration&#8221;):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(i)</td><td style="text-align: justify">if the closing price of the PubCo Common Stock on NASDAQ on the second trading day immediately preceding
the Effective Time is less than or equal to $5.00, then the Exchange Ratio for each Yoov Ordinary Share will be equal to the ratio (rounded
to four decimal places) of 60,000,000 divided by the number of Company Outstanding Shares; or</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(ii)</td><td style="text-align: justify">if the closing price of the PubCo Common Stock on NASDAQ on the second trading day immediately preceding
the Effective Time is greater than $5.00, then the Exchange Ratio for each Yoov Ordinary Share will be equal to the ratio (rounded to
four decimal places) of 54,000,000 divided by the number of Company Outstanding Shares.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Prior to the Effective Time it is expected
that Yoov will issue additional YOOV Ordinary Shares in respect of the conversion of certain Company Preferred Shares in accordance with
Yoov&#8217;s memorandum and articles of association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">You have asked us to render an opinion,
as of the date hereof, as to the fairness, from a financial point of view, of the Merger Consideration payable by the Company pursuant
to the Merger Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9pt; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 4pt 0pt 0pt; text-align: center"><span style="font-size: 8pt">ROTH
CAPITAL PARTNERS, LLC</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.9pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">888
<span style="font-variant: small-caps">San Clemente Drive</span>, <span style="font-variant: small-caps">Newport Beach</span>, CA 92660
| 800. 678. 9 14 7 | WWW. ROTH.COM | Member SIP C/F INRA</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 495; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Board of Directors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Avalon Globocare Corp.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">March 7<sup>th</sup>, 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Page 2</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">For purposes of the opinion set
forth herein, we have, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">i.</td><td style="text-align: justify">reviewed a draft of the Merger Agreement, dated March 3<sup>rd</sup>, 2025 (the &#8220;Draft Merger Agreement&#8221;);</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">ii.</td><td style="text-align: justify">reviewed and analyzed certain information, including historic financial results and forecasts, relating
to the business, earnings, cash flow, assets, liabilities and prospects of Yoov and the Company that were furnished to us by or through
the management team of the Company;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">iii.</td><td style="text-align: justify">conducted discussions with members of the senior management of the Company concerning the information
described in clause (ii);</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">iv.</td><td style="text-align: justify">reviewed and analyzed certain publicly available information relating to the Company, including reported
prices and trading activity for the PubCo Common Stock, the Company&#8217;s recent annual report to stockholders, its annual report on
Form 10-K for the year ended December 31, 2023, the unaudited financial statements as of December 31, 2024 (on non-public-review basis),
and the most recent quarterly report on Form 10-Q for the three-month period ended September 30, 2024, as well as the Company&#8217;s
financial outlook for 2025, provided by the management of the Company;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">v.</td><td style="text-align: justify">reviewed and analyzed the financial information and data, to the extent publicly available, of certain
acquisitions that we deemed relevant;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">vi.</td><td style="text-align: justify">compared certain publicly available financial and other information for certain public companies that
we deemed relevant;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">vii.</td><td style="text-align: justify">participated in certain discussions with management of the Company, its legal advisors and the management
of Yoov;</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">viii.</td><td style="text-align: justify">[reviewed and analyzed the pro forma ownership structure of the combined entity resulting from the Transaction
furnished to us by or through the management team of the Company; and]</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">ix.</td><td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0">performed
such other analyses and considered such other factors as we deemed appropriate for the purpose of reviewing the proposed Transaction
and arriving at our opinion.&#160;</p></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We have assumed and relied upon,
without independent verification, the accuracy and completeness of the information that was publicly available or supplied or otherwise
made available to us by or through the management of the Company, and we have further relied upon the assurances of the management teams
of the Company and Yoov that such information does not contain an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements contained therein not misleading in any material respect. With respect
to any financial projections of the Company and of Yoov, we have been advised by the management of the Company and the management of
Yoov, and we have assumed, with your consent, that they have been reasonably prepared on bases reflecting the best currently available
estimates and judgments of the management of the Company and Yoov of the future financial performance of the Company and Yoov. We express
no opinion as to any such financial forecasts, estimates or forward-looking information or assumptions on which they are based or on
the assumed probabilities associated with future events contemplated thereby. In addition, we have assumed that the final executed Merger
Agreement will not differ in any material respect from the Draft Merger Agreement reviewed by us, and that the Transaction will be consummated
in accordance with the terms set forth in the Merger Agreement without any waiver, amendment or delay of any terms or conditions. We
have also assumed that, in connection with the receipt of all the necessary governmental, regulatory or other approvals and consents
required for the proposed Transaction, no delays, limitations, conditions or restrictions will be imposed that would have an adverse
effect on the Company or the contemplated benefits expected to be derived in the proposed Transaction. We are not legal, tax, accounting
or regulatory advisors. We have relied upon, without independent verification, the assessment of the Company and its legal, tax, accounting
and regulatory advisors with respect to legal, tax, accounting and regulatory matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">In arriving at our opinion, we have not
performed any appraisals or valuations of any specific assets or liabilities (fixed, contingent or other) of the Company or Yoov, and
have not been furnished or provided with any such appraisals or valuations. Without limiting the generality of the foregoing, we have
undertaken no independent analysis of any pending or threatened litigation, regulatory action, possible unasserted claims or other contingent
liabilities, to which Yoov, the Company or any of their respective affiliates is a party or may be subject, and at your direction and
with your consent, our opinion makes no assumption concerning, and therefore does not consider, the possible assertion of claims, outcomes
or damages arising out of any such matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9pt; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 4pt 0pt 0pt; text-align: center"><span style="font-size: 8pt">ROTH
CAPITAL PARTNERS, LLC</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.9pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">888
<span style="font-variant: small-caps">San Clemente Drive</span>, <span style="font-variant: small-caps">Newport Beach</span>, CA 92660
| 800. 678. 9 14 7 | WWW. ROTH.COM | Member SIP C/F INRA</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 496 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Board of Directors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Avalon Globocare Corp.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">March 7<sup>th</sup>, 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Page 3</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Our opinion addresses only the fairness,
from a financial point of view, as of the date hereof, to the Company of the Merger Consideration payable by the Company pursuant to the
Merger Agreement. Our opinion does not in any manner address any other aspect or implication of the Merger Agreement or any agreement,
arrangement or understanding entered into in connection with the Merger Agreement or otherwise, including, without limitation, the fairness
of the amount or nature of any compensation to any officers, directors or employees of any party to the Merger Agreement, or any class
of such persons, relative to the Merger Consideration. This opinion does not address the fairness of the Transaction to the holders of
any class of securities, creditors or other constituencies of the Company. Our opinion also does not address the relative merits of the
Merger Agreement as compared to any alternative business strategies that might exist for the Company, the underlying business decision
of the Company to proceed with the Merger Agreement, or the effects of any other transaction in which the Company might engage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The issuance of this opinion was approved
by an authorized internal fairness committee of Roth in accordance with our customary practice. Our opinion is necessarily based on the
economic, monetary, market, financial and other conditions as they exist and can be evaluated, and the information made available to us,
as of the date hereof. We express no opinion as to the underlying valuation, future performance or long-term viability of the Company
or Yoov. Further, we express no opinion as to the actual value of the shares of the Company or the prices at which shares of the Company,
in each case, including those shares of the Company to be issued in the Transaction, will trade at any time before or after the announcement
of the Merger Agreement or during the time between its announcement and closing. It should be understood that, although subsequent developments
or events may affect various assumptions used by us in preparing our opinion, we do not have any obligation to update, revise or reaffirm
our opinion based on such developments, events or otherwise and we expressly disclaim any responsibility to do so. Our opinion does not
address any legal, tax or accounting matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Roth has been engaged by the Board of
Directors to act as its financial advisor in connection with the Transaction. We have also been engaged to provide the Board of Directors
with this opinion. We will receive an opinion fee in the amount of $100,000 for the provision of this opinion, and we will receive an
additional transaction fee of $50,000 upon the successful consummation of the Transaction. In addition, the Company has agreed to reimburse
our expenses and to indemnify us for certain liabilities arising out of our engagement. We note that, in connection with performing and
rendering our services to the Board of Directors, we were not authorized by the Board of Directors to, and did not, solicit any expressions
of interest from any other parties with respect to any transaction involving the Company or Yoov, or review other alternative acquisitions
or transactions that the Company could pursue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Roth is a full-service securities firm
engaged in securities trading and brokerage activities, as well as providing investment banking and other financial services. In the ordinary
course of business, we and our affiliates may acquire, hold or sell, for our and our affiliates&#8217; own accounts and for the accounts
of customers, equity, debt and other securities and financial instruments (including bank loans and other obligations) of the Company
and the other parties to the Transaction, and, accordingly, may at any time hold a long or a short position in such securities. Except
as described above or as set forth below, we have not had a material relationship with, nor have we otherwise received any fees from the
Company, Yoov or any other parties to the Transaction during the two years preceding the date hereof. During the past two years prior
to the date hereof, Roth was engaged by the Company to provide certain services under the following two engagements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(i)</td><td style="text-align: justify">General financial advisory engagement under which Roth provided capital markets assistance, including
marketing a potential investment in the Company to prospective debt financing sources. In June 2023, the Company&#8217;s efforts to identify
debt financing sources were unsuccessful. Roth received $20,000 in compensation for these services. Additionally, under Roth&#8217;s engagement
letter relating to these advisory services, there was an additional amount of compensation due in the amount of $80,000 which was waived
by Roth in connection with the termination of the engagement. No fees associated with previous engagements are being paid in connection
with this Transaction, and no debt financing sources solicited under this prior engagement are participating in this Transaction.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 59.95pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(ii)</td><td style="text-align: justify">Between July 2023 and August 2024, Roth also executed an at-the-market equity offering for the Company
and received $104,797.30 in compensation for the services related thereto.</td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9pt; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 4pt 0pt 0pt; text-align: center"><span style="font-size: 8pt">ROTH
CAPITAL PARTNERS, LLC</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.9pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">888
<span style="font-variant: small-caps">San Clemente Drive</span>, <span style="font-variant: small-caps">Newport Beach</span>, CA 92660
| 800. 678. 9 14 7 | WWW. ROTH.COM | Member SIP C/F INRA</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 497 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Board of Directors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Avalon Globocare Corp.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">March 7<sup>th</sup>, 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Page 4</p><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Consistent with applicable legal and
regulatory requirements, Roth has adopted policies and procedures to establish and maintain the independence of our research departments
and personnel. As a result, our research analysts may hold views, make statements or investment recommendations and/or publish research
reports with respect to the Company or the Transaction that differ from the views of our investment banking personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">This opinion has been prepared for the
information of the Board of Directors for its use in connection with its consideration of the Transaction, and is not intended to be and
does not constitute a recommendation to any stockholder of the Company as to how such stockholder should vote on any matter relating to
the Transaction or any other matter. Except with respect to the inclusion of this opinion in the proxy statement/prospectus relating to
the Transaction in accordance with our engagement letter with the Company, this opinion shall not be disclosed, referred to or published
(in whole or in part), nor shall any public reference to us be made, without our prior written approval. The Board of Directors may furnish
copies of this letter to the Board of Directors&#8217; legal counsel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">On the basis of and subject to the foregoing,
we are of the opinion, as of the date hereof, that the Merger Consideration payable by the Company pursuant to the Merger Agreement is
fair from a financial point of view to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Very truly yours,</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 40%"><img alt="" src="image_006.jpg"/></td>
    <td style="width: 60%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>on behalf of</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><b>ROTH Capital Partners, LLC</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><b>&#160;</b></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>3/7/2025</td>
    <td>&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.9pt; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 4pt 0pt 0pt; text-align: center"><span style="font-size: 8pt">ROTH
CAPITAL PARTNERS, LLC</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.9pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">888
<span style="font-variant: small-caps">San Clemente Drive</span>, <span style="font-variant: small-caps">Newport Beach</span>, CA 92660
| 800. 678. 9 14 7 | WWW. ROTH.COM | Member SIP C/F INRA</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></p><div>

</div><!-- Field: Page; Sequence: 498 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></p><div>

</div><div><a id="a_146"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="text-decoration:underline">ANNEX C: REVERSE SPLIT
CHARTER AMENDMENT</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM OF CERTIFICATE OF AMENDMENT<br/>
OF THE<br/>
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION<br/>
OF<br/>
AVALON GLOBOCARE CORP.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Avalon GloboCare Corp., a
corporation duly organized and validly existing under and by virtue of the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>DOES HEREBY CERTIFY AS
FOLLOWS:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>FIRST:&#160;</b>That a
resolution was duly adopted on [________], 2025, by the Board of Directors of the Corporation pursuant to Section 242 of the General Corporation
Law of the State of Delaware setting forth an amendment to the Amended and Restated Certificate of Incorporation of the Corporation (as
amended to date, the &#8220;Certificate of Incorporation&#8221;) and declaring said amendment to be advisable. The stockholders of the
Corporation duly approved said proposed amendment at the special meeting of stockholders held on [_________], 2025, in accordance with
Section 242 of the General Corporation Law of the State of Delaware. The proposed amendment set forth as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Article IV of the Amended
and Restated Certificate of Incorporation of the Corporation be and hereby is amended by adding the following paragraph D to Article IV:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8220;D. <span style="text-decoration:underline">REVERSE STOCK SPLIT</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon effectiveness (&#8220;Effective
Time&#8221;) of this amendment to the Certificate of Incorporation, a one-for-[__]<sup>1</sup>&#160;reverse stock split (the &#8220;Reverse
Split&#8221;) of the Corporation&#8217;s Common Stock shall become effective, pursuant to which each [__] shares of Common Stock outstanding
and held of record by each stockholder of the Corporation and each share of Common Stock held in treasury by the Corporation immediately
prior to the Effective Time (&#8220;Old Common Stock&#8221;) shall automatically, and without any action by the holder thereof, be reclassified
and combined into one (1) validly issued, fully paid and non-assessable share of Common Stock (&#8220;New Common Stock&#8221;), subject
to the treatment of fractional interests as described below and with no corresponding reduction in the number of authorized shares of
our Common Stock. The Reverse Split shall also apply to any outstanding securities or rights convertible into, or exchangeable or exercisable
for, Old Common Stock and all references to such Old Common Stock in agreements, arrangements, documents and plans relating thereto or
any option or right to purchase or acquire shares of Old Common Stock shall be deemed to be references to the New Common Stock or options
or rights to purchase or acquire shares of New Common stock, as the case may be, after giving effect to the Reverse Split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No fractional shares of Common
Stock will be issued in connection with the Reverse Split. If, upon aggregating all of the Common Stock held by a holder of Common Stock
immediately following the Reverse Split a holder of Common Stock would otherwise be entitled to a fractional share of Common Stock, the
Corporation shall issue to such holder such fractions of a share of Common Stock as are necessary to round the number of shares of Common
Stock held by such holder up to the nearest whole share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each holder of record of a
certificate or certificates for one or more shares of the Old Common Stock shall be entitled to receive as soon as practicable, upon surrender
of such certificate, a certificate or certificates representing the largest whole number of shares of New Common Stock to which such holder
shall be entitled pursuant to the provisions of the immediately preceding paragraphs. Each stock certificate that, immediately prior to
the Effective Time, represented shares of Old Common Stock that were issued and outstanding immediately prior to the Effective Time shall,
from and after the Effective Time, automatically.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>SECOND:&#160;</b>That said
amendment will have an Effective Time of 12:01 a.m., Eastern Time, on [__] [__], 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><sup>1</sup></td><td style="text-align: justify">Shall be a whole number equal to or greater than two (2) and
equal to or lesser than twenty (20), which number is referred to as the &#8220;Approved Split Ratio&#8221; (it being understood that
any Approved Split Ratio within such range shall, together with the remaining provisions of this Certificate of Amendment not appearing
in brackets, constitute a separate amendment being approved and adopted by the Board of Directors of the Corporation and the stockholders
of the Corporation in accordance with Section 242 of the General Corporation Law of the State of Delaware). The Board of Directors of
the Corporation shall select the Approved Split Ratio prior to the filing of the Certificate of Amendment and any amendment not setting
forth the Approved Split Ratio selected by the Board of Directors and included in the Certificate of Amendment filed with the Secretary
of State shall be automatically abandoned upon the filing of such Certificate of Amendment.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 499; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_147"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="text-decoration:underline">ANNEX D: EQUITY PLAN
INCREASE</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>AMENDMENT
TO THE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>AVALON
GLOBOCARE CORP.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>AMENDED
AND RESTATED 2020 STOCK INCENTIVE PLAN</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>Dated:
february 11, 2025</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>WHEREAS</b>, the Board of
Directors (the &#8220;<span style="text-decoration:underline">Board</span>&#8221;) of Avalon GloboCare Corp., a Delaware corporation (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;) heretofore
established the Avalon GloboCare Corp. Amended and Restated 2020 Stock Incentive Plan (the &#8220;<span style="text-decoration:underline">Plan</span>&#8221;);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true"><b>WHEREAS</b>,
                                            after giving effect to (i) the 1-for-15 reverse stock split effectuated on October 28, 2024
                                            and (ii) the January 1, 2024 and January 1, 2025 &#8220;evergreen&#8221; increase in the
                                            number of shares of common stock of the Company (&#8220;<span style="text-decoration:underline">Common Stock</span>&#8221;), the
                                            maximum number of shares of Common Stock currently available for grants of &#8220;<span style="text-decoration:underline">Awards</span>&#8221;(as
                                            defined under the Plan) (without reduction for shares of Common Stock that have previously
                                            been issued pursuant to the Plan or that are the subject of outstanding Awards under the
                                            Plan) is 155,091;</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">

</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>WHEREAS</b>, after taking
into account shares of Common Stock that have previously been issued pursuant to the Plan or that are the subject of outstanding Awards
under the Plan, there are currently 142,424 shares of Common Stock remaining available for additional Awards under the Plan;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>WHEREAS</b>, in order to
ensure that a sufficient number of shares of Common Stock continue to be available under the Plan in order to properly incentivize those
eligible to participate in the Plan, including future eligible participants, the Board believes it to be in the best interests of the
Company and its shareholders to increase the maximum number of shares of Common Stock available for grants of Awards under the Plan by
2,500,000 additional shares of Common Stock (the &#8220;<span style="text-decoration:underline">Additional Reserved Shares</span>&#8221;);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>WHEREAS</b>, the Board further
believes it to be in the best interests of the Company and its shareholders that all such Additional Reserved Shares be available for
grants under the Plan as &#8220;incentive stock options&#8221; within the meaning of Section 422 of the Internal Revenue Code of 1986,
as amended (the &#8220;<span style="text-decoration:underline">Code</span>&#8221;);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>WHEREAS</b>, the Board further
believes it to be in the best interests of the Company and its shareholders that all shares of Common Stock that were added to the Plan&#8217;s
reserve effective as of January 1, 2024 and January 1, 2025 by virtue of the Plan&#8217;s &#8220;evergreen&#8221; provision also be available
for grants under the Plan as &#8220;incentive stock options&#8221; within the meaning of Section 422 of the Code; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>WHEREAS</b>, Section&#160;17.2
of the Plan authorizes the Board to amend the Plan, subject to stockholder approval to the extent that such approval is required by applicable
law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>NOW, THEREFORE</b>, subject
to approval of the Company&#8217;s stockholders, effective the date hereof,&#160;Section&#160;4.1(a) of the Plan is hereby amended in
its entirety, to read as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;(a) <span style="text-decoration:underline">Plan
Share Limitation</span>.&#160;&#160;&#160;Subject to adjustment pursuant to Section 4.2 and any other applicable provisions hereof, the
maximum aggregate number of shares of Common Stock which may be issued under all Awards granted to Participants under the Plan shall
be 2,655,091 shares, all of which may, but need not, be issued in respect of Incentive Stock Options. The foregoing number of shares
of Common Stock is in addition to the number of shares of Common Stock available for issuance under the Plan pursuant to the provisions
of Section 3.2(b) (&#8220;<b>Evergreen Shares</b>&#8221;). All Evergreen Shares added to the Plan due to the increase effective as of
January 1, 2024 and January 1, 2025 may, but need not, be issued in respect of Incentive Stock Options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 500; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">D-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="a_148"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="text-decoration:underline">ANNEX E: INCREASE CHARTER
AMENDMENT</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTIFICATE OF AMENDMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TO</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OF</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AVALON GLOBOCARE CORP.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Avalon GloboCare Corp. (the
&#8220;<b><i>Corporation</i></b>&#8221;), a corporation organized and existing under and by virtue of the General Corporation Law of the
State of Delaware, as amended (the &#8220;<b><i>DGCL</i></b>&#8221;), does hereby certify as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">1.</td><td style="text-align: justify">The name of the Corporation is Avalon GloboCare Corp. The Certificate of Incorporation of the Corporation
was originally filed with the Secretary of State of the State of Delaware on July 28, 2014 under the original name of the Corporation,
Global Technologies Corp., and was amended by the Certificate of Amendment filed with the Secretary of State of the State of Delaware
on September 29, 2016. An Amended and Restated Certificate of Incorporation was filed with the Secretary of State of the State of Delaware
on April 25, 2018. A Certificate of Amendment to the Amended and Restated Certificate of Incorporation was filed with the Secretary of
State of the State of Delaware on December 22, 2022. A Certificate of Amendment to the Amended and Restated Certificate of Incorporation
was filed with the Secretary of State of the State of Delaware on October 23, 2024 (the &#8220;<b><i>Certificate of Incorporation</i></b>&#8221;).</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">2.</td><td style="text-align: justify">The Board of Directors of the Corporation (the &#8220;<b><i>Board</i></b>&#8221;), acting in accordance
with the provisions of Sections 141 and 242 of the DGCL, adopted resolutions amending Article IV of the Certificate of Incorporation thereof
by deleting the following sentence in the first paragraph of Article IV.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The total number of shares of capital
stock which the Corporation shall have authority to issue is One Hundred Ten Million (110,000,000), of which (i) One Hundred Million (100,000,000)
shares shall be a class designated as common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), and (ii) Ten Million
(10,000,000) shares shall be a class designated as undesignated preferred stock, par value $0.0001 per share (the &#8220;Undesignated
Preferred Stock&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The sentence above in the first paragraph
of Article IV will be replaced by the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The total number of shares of capital
stock which the Corporation shall have authority to issue is Two Hundred Ten Million (210,000,000), of which (i) Two Hundred Million (200,000,000)
shares shall be a class designated as common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), and (ii) Ten Million
(10,000,000) shares shall be a class designated as undesignated preferred stock, par value $0.0001 per share (the &#8220;Undesignated
Preferred Stock&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">3.</td><td style="text-align: justify">The foregoing amendment to the Certificate of Incorporation was duly approved by the Board on [__], 2025.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">4.</td><td style="text-align: justify">Thereafter, pursuant to a resolution of the Board, this Certificate of Amendment was submitted to the
stockholders of the Corporation for their approval, and was duly adopted in accordance with the provisions of Section 242 of the DGCL
on [__].</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">5.</td><td style="text-align: justify">This amendment to the Certificate of Incorporation shall be effective on and as of the effective time
of [__], Eastern Time, on [__].</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In Witness Whereof, the undersigned
has caused this Certificate of Amendment to be signed by its duly authorized officer on the [__] day of [__].</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><b>Avalon GloboCare Corp.</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 5%">By:</td>
    <td style="width: 35%">&#160;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Name:</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Title:</td>
    <td>&#160;</td></tr>
  </table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 501; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">E-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_149"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">PART II</p><div>

</div><div><a id="a_150"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">INFORMATION NOT REQUIRED IN PROSPECTUS</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><div><a id="a_151"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Item&#8201;20. Indemnification of Directors
and Officers</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section 145 of the DGCL provides,
in general, that a corporation incorporated under the laws of the State of Delaware, as Avalon is, may indemnify any person who was or
is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than a derivative
action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent
of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another enterprise,
against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by
such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably
believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had
no reasonable cause to believe such person&#8217;s conduct was unlawful. In the case of a derivative action, a Delaware corporation may
indemnify any such person against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection
with the defense or settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed
to be in or not opposed to the best interests of the corporation, except that no indemnification will be made in respect of any claim,
issue or matter as to which such person will have been adjudged to be liable to the corporation unless and only to the extent that the
Court of Chancery of the State of Delaware or any other court in which such action was brought determines such person is fairly and reasonably
entitled to indemnity for such expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As permitted by the DGCL,
the Avalon Bylaws provide that Avalon will indemnify Avalon&#8217;s directors and officers, and may indemnify other employees and agents
under certain circumstances. Any indemnified person is also entitled, subject to certain limitations, to direct payment or reimbursement
of costs, charges and expenses incurred by such person in an action or proceeding to which such director, officer, employee or agent is
or are made a party by reason of his or her being or having been a director, officer, employee or agent of Avalon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, Avalon has entered
into separate indemnification agreements with Avalon&#8217;s current directors and officers. These agreements, subject to limitations
contained therein, obligate Avalon to indemnify the directors and officers to the fullest extent permitted by applicable law, for certain
expenses, including attorneys&#8217; fees, judgments, penalties, fines and settlement amounts actually and reasonably incurred by them
in any threatened, pending or completed action, suit, claim, investigation, inquiry, administrative hearing, arbitration or other proceeding
arising out of their services as a director or executive officer. Subject to certain limitations, the indemnification agreements provide
for the advancement of expenses incurred by the indemnitee, and the repayment to Avalon of the amounts advanced to the extent that it
is ultimately determined that the indemnitee is not entitled to be indemnified by Avalon. The indemnification agreements also create certain
rights in favor of Avalon, including the right to assume the defense of claims and to consent to settlements. The indemnification agreements
do not exclude any other rights to indemnification or advancement of expenses to which the indemnitee may be entitled under applicable
law, the Avalon Charter or Avalon Bylaws, any agreement, or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Avalon maintains a directors&#8217;
and officers&#8217; insurance policy pursuant to which Avalon&#8217;s directors and officers are insured against liability for actions
taken in their capacities as directors and officers. It is anticipated that the Combined Company will continue to maintain such policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling Avalon pursuant to the
foregoing provisions, Avalon been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed
in the Securities Act and is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than
the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of Avalon in the successful defense
of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being
registered, Avalon will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court
of appropriate jurisdiction the question whether such indemnification by Avalon is against public policy as expressed hereby in the Securities
Act and Avalon will be governed by the final adjudication of such issue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">See also the undertakings
set out in response to Item&#8201;22 of this Registration Statement.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 502; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><div><a id="a_152"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Item&#8201;21. Exhibits and Financial Statement
Schedules</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exhibit Index</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-size: 10pt"><b>Exhibit<br/>
    Number</b></span></td>
    <td style="width: 1%"><b>&#160;</b></td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify; width: 90%"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">1.1 </span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390019026166/f8k121319ex1-1_avalong.htm"><span style="font-size: 10pt">Open Market Sale Agreement<sup>SM</sup>, dated as of December 13, 2019, by and between Avalon GloboCare Corp. and Jefferies LLC. (incorporated by reference to Exhibit 1.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 13, 2019)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">2.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390022069925/ea167589ex2-1_avalonglob.htm"><span style="font-size: 10pt">Membership Interest Purchase Agreement, dated November 7, 2022, by and among the Registrant, Laboratory Services MSO, LLC, SCBC Holdings LLC, Avalon Laboratory Services, Inc., The Zoe Family Trust, Bryan Cox and Sarah Cox (incorporated by reference to Exhibit 2.1 of the Registrant&#8217;s Current Report on Form 8-K filed on November 8, 2022). </span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">2.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390023010503/ea173222ex2-1_avalonglobo.htm"><span style="font-size: 10pt">Amended and Restated Membership Interest Purchase Agreement, dated February 9, 2023 by and among the Registrant, Laboratory Services MSO, LLC, SCBC Holdings LLC, Avalon Laboratory Services, Inc., the Zoe Family Trust, Bryan Cox and Sarah Cox (incorporated by reference to Exhibit 2.1 of the Registrant&#8217;s Current Report on Form 8-K filed on February 13, 2023).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">2.3</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390025021943/ea023369601ex2-1_avalon.htm"><span style="font-size: 10pt">Agreement and Plan of Merger, dated March 7, 2025, by and among Avalon GloboCare Corp., Nexus MergerSub Limited and YOOV Group Holding Limited (incorporated by reference to Exhibit 2.1 to the registrant&#8217;s Current Report on Form 8-K filed on March 10, 2025).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">3.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577418002931/s109781_ex3-1.htm"><span style="font-size: 10pt">Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K/A filed with the Securities and Exchange Commission on April 26, 2018)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">3.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390023000680/ea171160ex3-1_avalon.htm"><span style="font-size: 10pt">Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of Avalon GloboCare Corp. (incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed on January 4, 2023).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">3.3</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577418002931/s109781_ex3-2.htm"><span style="font-size: 10pt">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K/A filed with the Securities and Exchange Commission on April 26, 2018)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">3.4</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390022069925/ea167589ex3-1_avalonglob.htm"><span style="font-size: 10pt">Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed on November 8, 2022)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">3.5</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390023010503/ea173222ex3-2_avalonglobo.htm"><span style="font-size: 10pt">Certificate of Designation of Preferences, Rights and Limitations of the Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.2 of the Registrant&#8217;s Current Report on Form 8-K filed on February 13, 2023)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">3.6</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390024091819/ea021907101ex3-1_avalon.htm"><span style="font-size: 10pt">Certificate of amendment dated October 23, 2024 (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s Current Report on Form 8-K filed with the SEC on October 29, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">3.7</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390024110582/ea022523001ex10-3_avalon.htm"><span style="font-size: 10pt">Certificate of Designations of Preferences and Rights of Series C Convertible Preferred Stock of the Company, as filed on December 13, 2024, with the Department of State, Division of Corporations, of the State of Delaware (incorporated by reference to Exhibit 10.3 to the registrant&#8217;s Current Report on Form 8-K filed with the SEC on December 19, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">3.8</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390025002723/ea022736401ex10-1_avalon.htm"><span style="font-size: 10pt">Certificate of Designations of Preferences and Rights of Series D Convertible Preferred Stock of the Company, as filed on January 6, 2025, with the Department of State, Division of Corporations, of the State of Delaware (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s Current Report on Form 8-K filed with the SEC on January 10, 2025).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">3.9</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390025021943/ea023369601ex3-1_avalon.htm"><span style="font-size: 10pt">Certificate of Elimination relating to the Series A Preferred Stock, filed with the Secretary of State of Delaware on March 7, 2025 (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s Current Report on Form 8-K filed with the SEC on March 10, 2025). </span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">3.10</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390025021943/ea023369601ex3-2_avalon.htm"><span style="font-size: 10pt">Certificate of Elimination relating to the Series B Preferred Stock, filed with the Secretary of State of Delaware on March 7, 2025 (incorporated by reference to Exhibit 3.2 to the registrant&#8217;s Current Report on Form 8-K filed with the SEC on March 10, 2025).</span></a></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 503 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 9%"><span style="font-size: 10pt">3.11</span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390025021943/ea023369601ex3-3_avalon.htm"><span style="font-size: 10pt">Amendment No. 1 to the Avalon Bylaws, as adopted and approved by the Avalon Board on March 7, 2025 (incorporated by reference to Exhibit 3.3 to the registrant&#8217;s Current Report on Form 8-K filed with the SEC on March 10, 2025).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577416009001/s105001_ex4-1.htm"><span style="font-size: 10pt">Form of Subscription Agreement by and between Avalon GloboCare Corp. and the December 2016 Accredited Investors (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 21, 2016)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.2 &#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417000729/s105400_ex4-1.htm"><span style="font-size: 10pt">Stock Option issued to Luisa Ingargiola dated February 21, 2017 (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 21, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.3</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417000921/s105501_ex4-1.htm"><span style="font-size: 10pt">Form of Subscription Agreement by and between Avalon GloboCare Corp. and the March 2017 Accredited Investor (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 7, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.4</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417000921/s105501_ex4-2.htm"><span style="font-size: 10pt">Share Subscription Agreement between Avalon GloboCare Corp., Avalon (Shanghai) Healthcare Technology Co., Ltd., Beijing DOING Biomedical Technology Co., Ltd. and Daron Liang (incorporated by reference to Exhibit 4.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 7, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417000921/s105501_ex4-3.htm"><span style="font-size: 10pt">Warranty Agreement by and between Lu Wenzhao and Beijing DOING Biomedical Technology Co., Ltd., dated February 27, 2017 (incorporated by reference to Exhibit 4.3 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 7, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.6</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417005933/s107865_ex4-1.htm"><span style="font-size: 10pt">Form of Subscription Agreement between Avalon GloboCare Corp. and the October 2017 Accredited Investors (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 26, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.7</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577418006942/s111554_ex4-8.htm"><span style="font-size: 10pt">Form of Warrant to Boustead Securities, LLC in connection with the private placements (incorporated by reference to Exhibit 4.8 of the Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on July 27, 2018)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.8</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390019007230/f8k042519ex4-1_avalon.htm"><span style="font-size: 10pt">Form of Warrant (April 2019) (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 26, 2019)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.9</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390025026308/ea023331001ex4-9_avalon.htm"><span style="font-size: 10pt">Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.9 to the registrant&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2025).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.10</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390022045471/ea163922ex4-1_avalonglob.htm"><span style="font-size: 10pt">Form of Subscription Agreement by and between Avalon GloboCare Corp. and Wenzhao &#8220;Daniel&#8221; Lu dated August 5, 2022 (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 8, 2022).</span></a><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">4.11</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390022045471/ea163922ex4-2_avalonglob.htm"><span style="font-size: 10pt">Form of Subscription Agreement by and between Avalon GloboCare Corp. and Emma Li Xu Qingbo dated August 5, 2022 (incorporated by reference to Exhibit 4.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 8, 2022).</span></a><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">5.1***</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Opinion of Lowenstein Sandler LLP.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">8.1***</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Opinion of Lucosky Brookman LLP counsel of YOOV Group Holding Limited
    regarding certain U.S. income tax aspects of the Merger.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">8.2***</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Opinion of Lowenstein Sandler LLP counsel of Avalon GloboCare Corp. regarding certain U.S. income tax aspects of the Merger.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577416007680/s104353_ex10-1.htm"><span style="font-size: 10pt">Share Exchange Agreement dated as of October 19, 2016 by and among Avalon Healthcare System, Inc., the shareholders of Avalon Healthcare System, Inc. and Avalon GloboCare Corp. (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 19, 2016)</span></a><span style="font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 504 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 9%"><span style="font-size: 10pt">10.2&#8224;</span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577416008673/s104827_ex10-1.htm"><span style="font-size: 10pt">Executive Employment Agreement, effective December 1, 2016, by and between Avalon GloboCare Corp. and David Jin (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 2, 2016)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.3</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577416009065/s105026_ex10-1.htm"><span style="font-size: 10pt">Agreement of Sale by and between Freehold Craig Road Partnership and Avalon GloboCare Corp., dated December 22, 2016 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 23, 2016)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.4&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417000115/s105112_ex10-1.htm"><span style="font-size: 10pt">Executive Employment Agreement by and between Avalon (Shanghai) Healthcare Technology Ltd. and Meng Li, dated January 11, 2017 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 11, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.5&#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417000729/s105400_ex10-1.htm"><span style="font-size: 10pt">Executive Retention Agreement by and between Avalon GloboCare Corp. and Luisa Ingargiola, dated February 21, 2017 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 21, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.6&#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417000729/s105400_ex10-2.htm"><span style="font-size: 10pt">Indemnification Agreement by and between Avalon GloboCare Corp. and Luisa Ingargiola, dated February 21, 2017 (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 21, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.7&#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417001927/s105965_ex10-1.htm"><span style="font-size: 10pt">Director Agreement by and between Avalon GloboCare Corp. and Steven P. Sukel dated April 28, 2017 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 28, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.8&#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417001927/s105965_ex10-2.htm"><span style="font-size: 10pt">Director Agreement by and between Avalon GloboCare Corp. and Yancen Lu dated April 28, 2017 (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 28, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.9</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417003531/s106743_ex10-8.htm"><span style="font-size: 10pt">Consultation Service Contract between Daopei Investment Management (Shanghai) Co., Ltd. and Avalon HealthCare System Inc. dated April 1, 2016 (English translation) (incorporated by reference to Exhibit 10.8 of Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 7, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.10</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417003531/s106743_ex10-9.htm"><span style="font-size: 10pt">Consultation Service Contract between Hebei Yanda Ludaopei Hospital Co., Ltd and Avalon HealthCare System Inc. dated April 1, 2016 (English translation) (incorporated by reference to Exhibit 10.9 of Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 7, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.11</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417003531/s106743_ex10-10.htm"><span style="font-size: 10pt">Consultation Service Contract between Nanshan Memorial Stem Cell Biotechnology Co., Ltd. and Avalon HealthCare System Inc. dated April 1, 2016 (English translation) (incorporated by reference to Exhibit 10.10 of Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 7, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.12</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417004366/s107144_ex10-12.htm"><span style="font-size: 10pt">Loan Agreement between Lotus Capital Overseas Limited and Avalon (Shanghai) Healthcare Technology Co., Ltd. dated April 19, 2017 (English translation) (incorporated by reference to Exhibit 10.12 of the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.13</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000161577417005933/s107865_ex10-1.htm"><span style="font-size: 10pt">Securities Purchase Agreement between Avalon GloboCare Corp. and Genexosome Technologies Inc. dated October 25, 2017 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 26, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 505 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><span style="font-size: 10pt">10.14</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417005933/s107865_ex10-2.htm"><span style="font-size: 10pt">Asset Purchase Agreement between Genexosome Technologies Inc. and Yu Zhou dated October 25, 2017 (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 26, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.15</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417005933/s107865_ex10-3.htm"><span style="font-size: 10pt">Stock Purchase Agreement between Genexosome Technologies Inc., Beijing Jieteng (Genexosome) Biotech Co. Ltd. and Yu Zhou dated October 25, 2017 (incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 26, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.16&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417005933/s107865_ex10-4.htm"><span style="font-size: 10pt">Executive Retention Agreement between Genexosome Technologies Inc. and Yu Zhou dated October 25, 2017 (incorporated by reference to Exhibit 10.4 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 26, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.17</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417005933/s107865_ex10-5.htm"><span style="font-size: 10pt">Invention Assignment, Confidentiality, Non-Compete and Non-Solicit Agreement between Genexosome Technologies Inc. and Yu Zhou dated October 25, 2017 (incorporated by reference to Exhibit 10.5 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 26, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.18&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417006312/s108045_ex10-1.htm"><span style="font-size: 10pt">Director Agreement by and between Avalon GloboCare Corp. and Wilbert J. Tauzin II dated November 1, 2017 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 7, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.19</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577417006312/s108045_ex10-2.htm"><span style="font-size: 10pt">Agreement between Avalon GloboCare Corp. and Tauzin Consultants, LLC dated November 1, 2017 (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 7, 2017)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.20&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577418002405/s109567_ex10-1.htm"><span style="font-size: 10pt">Letter Agreement by and between Avalon GloboCare Corp. and David Jin dated April 3, 2018 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 4, 2018) </span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.21&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577418002405/s109567_ex10-2.htm"><span style="font-size: 10pt">Letter Agreement by and between Avalon GloboCare Corp. and Meng Li dated April 3, 2018 (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 4, 2018) </span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.22</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577418002732/s109701_ex10-22.htm"><span style="font-size: 10pt">Advisory Service Contract between Ludaopei Hematology Research Institute Co., Ltd. and Avalon (Shanghai) Healthcare Technology Co., Ltd. dated April 1, 2018 (English translation) (incorporated by reference to that Form S-1 Registration Statement filed with the Securities and Exchange Commission on April 19, 2018)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.23</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577418002711/s109704_ex4-1.htm"><span style="font-size: 10pt">Form of Subscription Agreement by and between Avalon GloboCare Corp. and the April 2018 Accredited Investors (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 18, 2018). </span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.24</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577418002931/s109781_ex4-2.htm"><span style="font-size: 10pt">Supplementary Agreement Related to Share Subscription by and between Avalon GloboCare Corp., Avalon (Shanghai) Healthcare Technology Co., Ltd., Beijing DOING Biomedical Technology Co., Ltd. and Daron Liang dated April 23, 2018 (English translation) (incorporated by reference to Exhibit 4.2 of the Current Report on Form 8-K/A filed with the Securities and Exchange Commission on April 26, 2018)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.25</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577418003636/s110081_ex10-18.htm"><span style="font-size: 10pt">Loan Extension Agreement between Lotus Capital Overseas Limited and Avalon (Shanghai) Healthcare Technology Co., Ltd. dated May 3, 2018 (English translation) (incorporated by reference to Exhibit 10.18 of the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 11, 2018)</span></a><span style="font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 506 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 9%"><span style="font-size: 10pt">10.26&#8224;</span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577418004916/s110675_ex10-1.htm"><span style="font-size: 10pt">Director Agreement by and between Avalon GloboCare Corp. and Tevi Troy dated June 4, 2018 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 6, 2018)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.27</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577418004916/s110675_ex99-1.htm"><span style="font-size: 10pt">Joint Venture Agreement by and between Avalon (Shanghai) Healthcare Technology Co., Ltd. and Jiangsu Unicorn Biological Technology Co., Ltd. dated May 29, 2018 (English translation) (incorporated by reference to Exhibit 99.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 6, 2018)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.28&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577418006328/s111307_ex10-1.htm"><span style="font-size: 10pt">Director Agreement by and between Avalon GloboCare Corp. and William Stilley, III dated July 5, 2018 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 10, 2018)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.29&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577418007235/s111738_ex10-1.htm"><span style="font-size: 10pt">Director Agreement by and between Avalon GloboCare Corp. and Steven A. Sanders dated July 30, 2018 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 31, 2018)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.30</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577418007670/s111877_ex10-30.htm"><span style="font-size: 10pt">Loan Extension Agreement between Lotus Capital Overseas Limited and Avalon (Shanghai) Healthcare Technology Co., Ltd. dated August 3, 2018 (English translation) (incorporated by reference to Exhibit 10.30 of the Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on August 7, 2018)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.31</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577418007670/s111877_ex10-31.htm"><span style="font-size: 10pt">Strategic Partnership Agreement between Avalon GloboCare Corp. and Weill Cornell Medical College of Cornell University dated August 6, 2018 (incorporated by reference to Exhibit 10.31 of the Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on August 7, 2018)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.32</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000161577418011426/s113520_ex10-1.htm"><span style="font-size: 10pt">Equity Joint Venture Agreement by and between Avactis Biosciences, Inc., a wholly-owned subsidiary of Avalon GloboCare Corp., and Arbele Limited for the establishment of AVAR (China) BioTherapeutics Ltd. dated October 23, 2018 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 29, 2018)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.33</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000161577419000241/s115219_ex10-1.htm"><span style="font-size: 10pt">Letter Agreement by and between Avalon GloboCare Corp. and David Jin dated January 3, 2019 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 4, 2019)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.34</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000161577419000241/s115219_ex10-2.htm"><span style="font-size: 10pt">Letter Agreement by and between Avalon GloboCare Corp. and Luisa Ingargiola dated January 3, 2019 (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 4, 2019)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.35</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000161577419000241/s115219_ex10-3.htm"><span style="font-size: 10pt">Letter Agreement by and between Avalon (Shanghai) Healthcare Technology Co. Ltd. and Meng Li dated January 3, 2019 (incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 4, 2019)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.36</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390019004695/f8k031819ex10-1_avalonglobo.htm"><span style="font-size: 10pt">Promissory Note issued to Daniel Lu dated Mach 18, 2019 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 22, 2019)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.37&#8224;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390019005932/f8k040519ex10-1_avalonare.htm"><span style="font-size: 10pt">Director Agreement by and between Avalon GloboCare Corp. and Meng Li dated April 5, 2019 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 8, 2019)</span></a><span style="font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 507 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 9%"><span style="font-size: 10pt">10.38&#8224;</span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390019005932/f8k040519ex10-2_avalonare.htm"><span style="font-size: 10pt">Director Agreement by and between Avalon GloboCare Corp. and Yue &#8220;Charles&#8221; Li dated April 5, 2019 (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 8, 2019)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.39</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390019007230/f8k042519ex10-1_avalon.htm"><span style="font-size: 10pt">Form of Securities Purchase Agreement dated April 25, 2019 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 26, 2019)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.40</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390019017131/f8k082919ex10-1_avalonglob.htm"><span style="font-size: 10pt">Revolving Line of Credit Agreement dated as of August 29, 2019 between Avalon GloboCare Corp. and Wenzhao &#8220;Daniel&#8221; Lu dated August 29, 2019 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 3, 2019)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.41</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390019020662/f8k101819ex10-1_avalong.htm"><span style="font-size: 10pt">Form of Warrant Redemption and Cancellation Agreement (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 21, 2019)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.42</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390020004616/f8k022020ex10-1_avalonglobo.htm"><span style="font-size: 10pt">Letter Agreement by and between Avalon GloboCare Corp. and David Jin dated February 20, 2020 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 24, 2020)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.43</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390020004616/f8k022020ex10-2_avalonglobo.htm"><span style="font-size: 10pt">Letter Agreement by and between Avalon GloboCare Corp. and Meng Li dated February 20, 2020 (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 24, 2020)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.44</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390020004616/f8k022020ex10-3_avalonglobo.htm"><span style="font-size: 10pt">Letter Agreement by and between Avalon GloboCare Corp. and Luisa Ingargiola dated February 20, 2020 (incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 24, 2020)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.45</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390021066892/ea152873ex10-2_avalonglobo.htm"><span style="font-size: 10pt">Debt Settlement Agreement and Release between Avalon GloboCare Corp. and Wenzhao &#8220;Daniel&#8221; Lu (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 22, 2021)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.46</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390021036807/ea144185ex10-1_avalonglobo.htm"><span style="font-size: 10pt">Corporate Research Agreement between Avalon GloboCare Corp. and the University of Pittsburgh of the Commonwealth System of Higher Education dated July 8, 2021 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 14, 2021)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.47</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390022016231/f10k2021ex10-47_avalon.htm"><span style="font-size: 10pt">Form of Securities Purchase Agreement dated March 28, 2022 (incorporated by reference to Exhibit 10.47 of the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2022)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.48</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390022016231/f10k2021ex10-48_avalon.htm"><span style="font-size: 10pt">Form of Convertible Note - March 2022 (incorporated by reference to Exhibit 10.48 of the Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2022)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.49</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390022016231/f10k2021ex10-49_avalon.htm"><span style="font-size: 10pt">Loan Extension and Modification Agreement between Avalon GloboCare Corp. and Wenzhao Lu dated March 28, 2022 (incorporated by reference to Exhibit 10.49 of the Form 10-K filed with the Securities and Exchange Commission on March 30, 2022)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.50</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390024033023/ea020260401ex10-50_avalon.htm"><span style="font-size: 10pt">Consulting Agreement, dated February 9, 2023, by and between Laboratory Services MSO, LLC and Sarah Cox (incorporated by reference to Exhibit 10.50 to the registrant&#8217;s Annual Report on Form 10-K filed on April 15, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.51</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390022022542/ea159040ex10-3_avalonglobo.htm"><span style="font-size: 10pt">Form of Warrant - March 2022 (incorporated by reference to Exhibit 10.3 of the Form 8-K filed with the Securities and Exchange Commission on April 29, 2022)</span></a><span style="font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 508 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 9%"><span style="font-size: 10pt">10.52</span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390022025619/f10q0322ex10-53_avalonglobo.htm"><span style="font-size: 10pt">Amendment No. 1 to the Equity Joint Venture Agreement entered between Avalon GloboCare Corp., Avactis Biosciences Inc., Arbele Limited and Arbele Biotherapeutics Limited dated April 6, 2022 (incorporated by reference to Exhibit 10.53 of the Form 10-Q filed with the Securities and Exchange Commission on May 11, 2022)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.53</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390022031771/ea161324ex10-4_avalon.htm"><span style="font-size: 10pt">Letter Agreement between Avalon GloboCare Corp. and Fsunshine Trading PTE. Ltd. dated June 8, 2022 (incorporated by reference to Exhibit 10.4 of the Form 8-K filed with the Securities and Exchange Commission on June 8, 2022)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.54</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390022041793/ea163183ex10-2_avalon.htm"><span style="font-size: 10pt">Debt Settlement Agreement and Release between Avalon GloboCare Corp. and Wenzhao &#8220;Daniel&#8221; Lu dated July 25, 2022 (incorporated by reference to Exhibit 10.2 of the Form 8-K filed with the Securities and Exchange Commission on July 27, 2022)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.55</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390022041793/ea163183ex10-3_avalon.htm"><span style="font-size: 10pt">Conversion Agreement between Avalon GloboCare Corp. and Fsunshine Trading PTE. Ltd. Dated July 25, 2022 (incorporated by reference to Exhibit 10.3 of the Form 8-K filed with the Securities and Exchange Commission on July 27, 2022)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.56</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390022054814/ea165480ex10-1_avalonglob.htm"><span style="font-size: 10pt">Form of Balloon Promissory Note issued to S&amp;P Principal LLC (incorporated by reference to Exhibit 10.1 of the Form 8-K filed with the Securities and Exchange Commission on September 8, 2022)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.57</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390022054814/ea165480ex10-2_avalonglob.htm"><span style="font-size: 10pt">Form of Mortgage and Security Agreement (incorporated by reference to Exhibit 10.2 of the Form 8-K filed with the Securities and Exchange Commission on September 8, 2022)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.58</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390022054814/ea165480ex10-3_avalonglob.htm"><span style="font-size: 10pt">Form of Guaranty (incorporated by reference to Exhibit 10.3 of the Form 8-K filed with the Securities and Exchange Commission on September 8, 2022)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.59</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390022069925/ea167589ex10-1_avalonglob.htm"><span style="font-size: 10pt">Form of Securities Purchase Agreement for the purchase of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 10.1 of the Form 8-K filed with the Securities and Exchange Commission on November 8, 2022)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.60</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390023002142/ea171486ex10-1_avalon.htm"><span style="font-size: 10pt">Director Agreement by and Between Avalon GloboCare Corp. and Lourdes Felix dated January 9, 2023 (incorporated by reference to Exhibit 10.1 of the Registrants Current Report on Form 8-K filed with the SEC on January 11, 2023)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.61</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390023010503/ea173222ex10-1_avalonglobo.htm"><span style="font-size: 10pt">Second Amended and Restated Limited Company Agreement, dated February 9, 2023, by and among Laboratory Services MSO, LLC, SCBC Holdings LLC, the Zoe Family Trust, Bryan Cox, Sarah Cox and the members named therein (incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Current Report on Form 8-K filed on February 13, 2023) </span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.62</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390023043586/ea179379ex10-1_avalon.htm"><span style="font-size: 10pt">Securities Purchase Agreement, dated May 23, 2023, between Avalon GloboCare Corp. and Mast Hill Fund, L.P (incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on May 26, 2023) </span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.63</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390023043586/ea179379ex10-2_avalon.htm"><span style="font-size: 10pt">Security Agreement, dated May 23, 2023, by and among Avalon GloboCare Corp., Avalon Healthcare System Inc., Avalon Laboratory Services, Inc., Avalon RT 9 Properties, LLC, Avactis Biosciences, Inc., Laboratory Services MSO, LLC, Genexosome Technologies Inc., International Exosome Association LLC and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.2 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on May 26, 2023). </span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.64</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390023043586/ea179379ex10-3_avalon.htm"><span style="font-size: 10pt">Senior Secured Promissory Note, dated May 23, 2023, between Avalon Globocare Corp. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.3 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on May 26, 2023)</span></a><span style="font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 509 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 9%"><span style="font-size: 10pt">10.65</span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390023043586/ea179379ex10-4_avalon.htm"><span style="font-size: 10pt">First Warrant, dated May 23, 2023, by and between Avalon GloboCare Corp. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.4 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on May 26, 2023)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.66</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390023043586/ea179379ex10-5_avalon.htm"><span style="font-size: 10pt">Second Warrant, dated May 23, 2023, by and between Avalon GloboCare Corp. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.5 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on May 26, 2023)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.67</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390023043586/ea179379ex10-6_avalon.htm"><span style="font-size: 10pt">Form of Balloon Mortgage Note (incorporated by reference to Exhibit 10.6 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on May 26, 2023). </span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.68</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390023043586/ea179379ex10-7_avalon.htm"><span style="font-size: 10pt">Form of Second Mortgage and Security Agreement (incorporated by reference to Exhibit 10.7 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on May 26, 2023). </span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.69</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390023043586/ea179379ex10-8_avalon.htm"><span style="font-size: 10pt">Form of Guaranty (incorporated by reference to Exhibit 10.8 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on May 26, 2023). </span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.70</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390023043586/ea179379ex10-9_avalon.htm"><span style="font-size: 10pt">Form of Hazardous Material Guaranty and Indemnification Agreement (incorporated by reference to Exhibit 10.9 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on May 26, 2023). </span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.71</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390023049645/ea180444ex1-1_avalon.htm"><span style="font-size: 10pt">Sales Agreement, dated June 16, 2023, by and between Avalon GloboCare Corp. and Roth Capital Partners, LLC. (incorporated by reference to Exhibit 1.1 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on June 16, 2023)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.72</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390023055582/ea181514ex10-1_avalon.htm"><span style="font-size: 10pt">Securities Purchase Agreement, dated July 6, 2023, by and between Avalon Globocare Corp. and Firstfire Global Opportunities, LLC. (incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on July 10, 2023). </span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.73</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390023055582/ea181514ex10-2_avalon.htm"><span style="font-size: 10pt">Security Agreement, dated July 6, 2023, by and among Avalon GloboCare Corp., Avalon Healthcare System Inc., Avalon Laboratory Services, Inc., Avalon RT 9 Properties, LLC, Avactis Biosciences, Inc., Laboratory Services MSO, LLC, Genexosome Technologies Inc., International Exosome Association LLC and Firstfire Global Opportunities, LLC. (incorporated by reference to Exhibit 10.2 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on July 10, 2023). </span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.74</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390023055582/ea181514ex10-3_avalon.htm"><span style="font-size: 10pt">Senior Secured Promissory Note, dated July 6, 2023, by and between Avalon GloboCare Corp. and Firstfire Global Opportunities, LLC. (incorporated by reference to Exhibit 10.3 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on July 10, 2023). </span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.75</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390023055582/ea181514ex10-4_avalon.htm"><span style="font-size: 10pt">First Warrant dated July 6, 2023, by and between Avalon GloboCare Corp. and Firstfire Global Opportunities, LLC. (incorporated by reference to Exhibit 10.4 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on July 10, 2023). </span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.76</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390023055582/ea181514ex10-5_avalon.htm"><span style="font-size: 10pt">Second Warrant, dated July 6, 2023, by and between Avalon Globocare Corp. and Firstfire Global Opportunities, LLC. (incorporated by reference to Exhibit 10.5 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on July 10, 2023). </span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.77</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000101376223003840/ea186677ex10-1_avalonglob.htm"><span style="font-size: 10pt">Securities Purchase Agreement, dated October 9, 2023, between Avalon Globocare Corp. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on October 13, 2023). </span></a></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 510 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 9%"><span style="font-size: 10pt">10.78</span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000101376223003840/ea186677ex10-2_avalonglob.htm"><span style="font-size: 10pt">Security Agreement, dated October 9, 2023, among Avalon Globocare Corp., Avalon Healthcare System Inc., Avalon Laboratory Services, Inc., Avalon RT 9 Properties, LLC, Avactis Biosciences, Inc., Laboratory Services MSO, LLC, Genexosome Technologies Inc., International Exosome Association LLC and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.2 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on October 13, 2023)</span></a><span style="font-size: 10pt">.&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.79</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000101376223003840/ea186677ex10-3_avalonglob.htm"><span style="font-size: 10pt">Senior Secured Promissory Note, dated October 9, 2023, between Avalon Globocare Corp. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.3 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on October 13, 2023)</span></a><span style="font-size: 10pt">.&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.80</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000101376223003840/ea186677ex10-4_avalonglob.htm"><span style="font-size: 10pt">First Warrant, dated October 9, 2023, between Avalon Globocare Corp. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.4 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on October 13, 2023)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.81</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000101376223003840/ea186677ex10-5_avalonglob.htm"><span style="font-size: 10pt">Second Warrant, dated October 9, 2023, between Avalon Globocare Corp. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.5 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on October 13, 2023)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.82</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000101376223003840/ea186677ex10-6_avalonglob.htm"><span style="font-size: 10pt">Securities Purchase Agreement, dated October 9, 2023, between Avalon Globocare Corp. and Firstfire Global Opportunities Fund, LLC (incorporated by reference to Exhibit 10.6 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on October 13, 2023)</span></a><span style="font-size: 10pt">.&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.83</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000101376223003840/ea186677ex10-7_avalonglob.htm"><span style="font-size: 10pt">Security Agreement, dated October 9, 2023, among Avalon Globocare Corp., Avalon Healthcare System Inc., Avalon Laboratory Services, Inc., Avalon RT 9 Properties, LLC, Avactis Biosciences, Inc., Laboratory Services MSO, LLC, Genexosome Technologies Inc., International Exosome Association LLC and Firstfire Global Opportunities Fund, LLC (incorporated by reference to Exhibit 10.7 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on October 13, 2023)</span></a><span style="font-size: 10pt">.&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.84</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000101376223003840/ea186677ex10-8_avalonglob.htm"><span style="font-size: 10pt">Senior Secured Promissory Note, dated October 9, 2023, between Avalon Globocare Corp. and Firstfire Global Opportunities Fund, LLC (incorporated by reference to Exhibit 10.8 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on October 13, 2023)</span></a><span style="font-size: 10pt">.&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.85</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000101376223003840/ea186677ex10-9_avalonglob.htm"><span style="font-size: 10pt">First Warrant, dated October 9, 2023, between Avalon Globocare Corp. and Firstfire Global Opportunities Fund, LLC (incorporated by reference to Exhibit 10.9 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on October 13, 2023)</span></a><span style="font-size: 10pt">.&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.86</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000101376223003840/ea186677ex10-10_avalonglob.htm"><span style="font-size: 10pt">Second Warrant, dated October 9, 2023, between Avalon Globocare Corp. and Firstfire Global Opportunities Fund, LLC (incorporated by reference to Exhibit 10.10 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on October 13, 2023)</span></a><span style="font-size: 10pt">.&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.87</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000101376223003840/ea186677ex10-11_avalonglob.htm"><span style="font-size: 10pt">Mortgage and Security Agreement, dated October 9, 2023, between Avalon Globocare Corp., Mast Hill Fund, L.P and Firstfire Global Opportunities Fund, LLC (incorporated by reference to Exhibit 10.11 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on October 13, 2023)</span></a><span style="font-size: 10pt">.&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.88</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390023089631/ea188870ex10-1_avalonglobo.htm"><span style="font-size: 10pt">Membership Interest Purchase Agreement, dated November 17, 2023, between Avalon Globocare Corp. and Wenzhao Lu (incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on November 22, 2023)</span></a><span style="font-size: 10pt">.&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.89</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390024026600/ea020219401ex10-1_avalonglob.htm"><span style="font-size: 10pt">Mortgage and Security Agreement, dated March 27, 2024, between Avalon Globocare Corp. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on March 27, 2024)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.90</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390024026600/ea020219401ex10-2_avalonglob.htm"><span style="font-size: 10pt">Mortgage and Security Agreement, dated March 27, 2024, between Avalon Globocare Corp. and Firstfire Global Opportunities Fund, LLC (incorporated by reference to Exhibit 10.2 of the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on March 27, 2024)</span></a><span style="font-size: 10pt">.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 511 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 9%"><span style="font-size: 10pt">10.91</span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390024048093/ea020600301ex10-4_avalon.htm"><span style="font-size: 10pt">Senior Secured Convertible Promissory Note, dated March 7, 2024, between Avalon GloboCare Corp. and Mast Hill Fund, LP (incorporated by reference to Exhibit 10.4 of the Registrant&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 31, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.92</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390024048093/ea020600301ex10-5_avalon.htm"><span style="font-size: 10pt">Security Agreement, dated March 7, 2024, between Avalon GloboCare Corp. and Mast Hill Fund, LP.* (incorporated by reference to Exhibit 10.5 of the Registrant&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 31, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.93</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390024048093/ea020600301ex10-6_avalon.htm"><span style="font-size: 10pt">Warrant, dated March 7, 2024, between Avalon GloboCare Corp. and Mast Hill Fund, LP.* (incorporated by reference to Exhibit 10.6 of the Registrant&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 31, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.94</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390024050090/ea020740701ex10-1_avalon.htm"><span style="font-size: 10pt">Securities Purchase Agreement, dated June 5, 2024, between Avalon Globocare Corp. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on June 5, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.95</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390024050090/ea020740701ex10-2_avalon.htm"><span style="font-size: 10pt">Security Agreement, dated June 5, 2024, among Avalon Globocare Corp., Avalon Healthcare System Inc., Avalon Laboratory Services, Inc., Avalon RT 9 Properties, LLC, Avactis Biosciences, Inc., Genexosome Technologies Inc., International Exosome Association LLC and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on June 5, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.96</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390024050090/ea020740701ex10-3_avalon.htm"><span style="font-size: 10pt">Senior Secured Promissory Note, dated June 5, 2024, between Avalon Globocare Corp. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on June 5, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.97</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390024050090/ea020740701ex10-4_avalon.htm"><span style="font-size: 10pt">First Warrant, dated June 5, 2024, between Avalon Globocare Corp. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on June 5, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.98</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390024050090/ea020740701ex10-5_avalon.htm"><span style="font-size: 10pt">Second Warrant, dated June 5, 2024, between Avalon Globocare Corp. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on June 5, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.99</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390024050090/ea020740701ex10-6_avalon.htm"><span style="font-size: 10pt">Mortgage and Security Agreement, dated June 5, 2024, between Avalon Globocare Corp. and Mast Hill Fund, L.P. (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on June 5, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.100</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390024110582/ea022523001ex10-1_avalon.htm"><span style="font-size: 10pt">Consent, Acknowledgement, and Waiver Agreement, between the Company and Holder, dated as of December 15, 2024 (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s Current Report on Form 8-K filed with the SEC on December 19, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.101</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390024110582/ea022523001ex10-2_avalon.htm"><span style="font-size: 10pt">Common Stock Purchase Warrant, between the Company and Holder, dated as of December 15, 2024 (incorporated by reference to Exhibit 10.2 to the registrant&#8217;s Current Report on Form 8-K filed with the SEC on December 19, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.102</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390024112412/ea022590001ex10-1_avalon.htm"><span style="font-size: 10pt">Securities Purchase Agreement, between the Company and Holder, dated as of December 19, 2024 (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s Current Report on Form 8-K filed with the SEC on December 26, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.103</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390025017652/ea023227001ex10-1_avalon.htm"><span style="font-size: 10pt">Redemption and Abandonment Agreement, dated February 26, 2025, by and among Avalon GloboCare Corp., Avalon Laboratory Services, Inc., Laboratory Services MSO, LLC, SCBC Holdings LLC, the Zoe Family Trust, Bryan Cox and Sarah Cox (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s Current Report on Form 8-K filed with the SEC on February 27, 2025).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.104</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390025021943/ea023369601ex10-1_avalon.htm"><span style="font-size: 10pt">Form of Avalon Voting and Support Agreement (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s Current Report on Form 8-K filed with the SEC on March 10, 2025).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.105</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390025021943/ea023369601ex10-2_avalon.htm"><span style="font-size: 10pt">Form of YOOV Voting and Support Agreement (incorporated by reference to Exhibit 10.2 to the registrant&#8217;s Current Report on Form 8-K filed with the SEC on March 10, 2025).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">10.106</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390025021943/ea023369601ex10-3_avalon.htm"><span style="font-size: 10pt">Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.3 to the registrant&#8217;s Current Report on Form 8-K filed with the SEC on March 10, 2025).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true"><span style="font-size: 10pt">10.107+</span>&#8224;</span></td>
    <td style="text-align: justify"/>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390025035157/ea023879801ex10-107_avalon.htm"><span style="font-size: 10pt">Amended and Restated 2020 Stock Incentive Plan.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true"><span style="font-size: 10pt">10.108+</span>&#8224;</span></td>
    <td style="text-align: justify"/>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390025035157/ea023879801ex10-108_avalon.htm"><span style="font-size: 10pt">Employment Contract, dated
    March 10, 2023, between YOOV Internet Technology (HK) Limited and Lai Kam Fu (Kenny).</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true"><span style="font-size: 10pt">10.109+</span>&#8224;</span></td>
    <td style="text-align: justify"/>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390025035157/ea023879801ex10-109_avalon.htm"><span style="font-size: 10pt">Employment Contract, dated June 1, 2017, between YOOV Internet Technology Limited and Wong Ho Chi Mark.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true"><span style="font-size: 10pt">10.110+</span>&#8224;</span></td>
    <td style="text-align: justify"/>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390025035157/ea023879801ex10-110_avalon.htm"><span style="font-size: 10pt">Employment Contract, dated
    July 29, 2019, between YOOV Internet Technology Limited and Wong Ling Yan Philip.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">10.111*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ea024503201ex10-111_avalon.htm"><span style="-keep: true">Ingargiola Combined Company Executive Retention Agreement.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">10.112*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ea024503201ex10-112_avalon.htm"><span style="-keep: true">Wong Combined Company Executive Retention Agreement.</span></a></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 512 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">10.113*</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ea024503201ex10-113_avalon.htm"><span style="-keep: true">Mark Wong Combined Company Executive Retention Agreement.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 9%"><span style="font-size: 10pt">19.1</span></td>
    <td style="text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390025026308/ea023331001ex19-1_avalon.htm"><span style="font-size: 10pt">Insider Trading Policy (incorporated by reference to Exhibit 19.1 to the registrant&#8217;s Annual Report on Form 10-K filed with the SEC on March 31, 2025).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">21.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000161577418006733/s111400_ex21-1.htm"><span style="font-size: 10pt">List of Subsidiaries (incorporated by reference to Exhibit 21.1 of the Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on July 20, 2018)</span></a><span style="font-size: 10pt">.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">23.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea024503201ex23-1_avalon.htm">Consent of M&amp;K CPA&#8217;s, PLLC, independent registered public accounting firm of Avalon GloboCare Corp. for the fiscal year ended December 31, 2024.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">23.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea024503201ex23-2_avalon.htm">Consent of Marcum LLP, independent registered public accounting firm of Avalon GloboCare Corp. for the fiscal year ended December 31, 2023.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">23.3*</span></td>
    <td>&#160;</td>
    <td><a href="ea024503201ex23-3_avalon.htm">Consent of ARK Pro CPA &amp; Co, independent registered public accounting firm of YOOV, Inc.</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">23.4***</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Consent of Lowenstein Sandler, LLP (included in Exhibit 5.1).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">24.1+</span></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390025035157/ea0238798-s4_avalon.htm#a_154"><span style="font-size: 10pt">Power of Attorney (included on signature page of the Registration Statement).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">97.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1630212/000121390024033023/ea020260401ex97-1_avalon.htm"><span style="font-size: 10pt">Avalon GloboCare Corp. Compensation Recovery Policy (incorporated by reference to Exhibit 97.1 to the registrant&#8217;s Annual Report on Form 10-K filed with the SEC on April 15, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">99.1***</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Form of Proxy Card of Avalon GloboCare Corp. </span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">99.2+</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390025035157/ea023879801ex99-2_avalon.htm"><span style="-keep: true">Consent of Wong Ling Yan Philip to serve as a director of Avalon GloboCare Corp., to be renamed YOOV, Inc.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">99.3+</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390025035157/ea023879801ex99-3_avalon.htm"><span style="-keep: true">Consent of Devere Andrew Bryan to serve as a director of Avalon GloboCare Corp., to be renamed YOOV, Inc.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">99.4+</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390025035157/ea023879801ex99-4_avalon.htm"><span style="-keep: true">Consent of Lam Heung Yeung Herman to serve as a director of Avalon GloboCare Corp., to be renamed YOOV, Inc.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-size: 10pt">99.5+</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390025035157/ea023879801ex99-6_avalon.htm"><span style="-keep: true">Consent of Kirtsty Vanora Godfrey-Billy to serve as a director of Avalon GloboCare Corp., to be renamed YOOV, Inc.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.INS*</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.SCH*</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.CAL*</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.DEF*</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.LAB*</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">101.PRE*</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">104*</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">107+</span></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1630212/000121390025035157/ea023879801ex-fee_avalon.htm"><span style="font-size: 10pt">Filing Fee Table.</span></a></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">Filed herewith.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Furnished herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">***</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">To be filed by amendment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">&#8224;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Management contract or compensatory plan or arrangement.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">+</span></td>
    <td style="text-align: justify"><span style="-keep: true">Previously filed.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 513 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_153"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Item&#8201;22. Undertakings</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The undersigned registrant hereby undertakes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">A.</span></td><td style="text-align: justify"><span style="font-size: 10pt">To file, during any period in
which offers or sales are being made, a post-effective amendment to this registration statement:</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.35in; text-align: left"><span style="font-size: 10pt">(i)</span></td><td style="text-align: justify"><span style="font-size: 10pt">To include any prospectus required
by Section 10(a)(3) of the Securities Act;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.35in; text-align: left"><span style="font-size: 10pt">(ii)</span></td><td style="text-align: justify"><span style="font-size: 10pt">To reflect in the prospectus any
facts or events arising after the effective date of the o reflect in the prospectus any facts or events arising after the effective date
of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent
a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease
in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any
deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the
Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum
aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement;
and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.35in; text-align: left"><span style="font-size: 10pt">(iii)</span></td><td style="text-align: justify"><span style="font-size: 10pt">To include any material information
with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information
in the registration statement;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">B.</span></td><td style="text-align: justify"><span style="font-size: 10pt">That, for the purpose of determining
any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating
to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">C.</span></td><td style="text-align: justify"><span style="font-size: 10pt">To remove from registration by
means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">D.</span></td><td style="text-align: justify"><span style="font-size: 10pt">That, for the purpose of determining
liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration
statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance
on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness;
<i>provided, however</i>, that no statement made in a registration statement or prospectus that is part of the registration statement
or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of
the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement
that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately
prior to such date of first use.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">E.</span></td><td style="text-align: justify"><span style="font-size: 10pt">That, for the purpose of determining
liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned
registrant hereby undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement,
regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser
by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered
to offer or sell such securities to such purchaser:</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.35in; text-align: left"><span style="font-size: 10pt">(i)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Any preliminary prospectus or
prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.35in; text-align: left"><span style="font-size: 10pt">(ii)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Any free writing prospectus relating
to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.35in; text-align: left"><span style="font-size: 10pt">(iii)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The portion of any other free
writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided
by or on behalf of the undersigned registrant; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.35in; text-align: left"><span style="font-size: 10pt">(iv)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Any other communication that is
an offer in the offering made by the undersigned registrant to the purchaser.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 514 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">F.</span></td><td style="text-align: justify"><span style="font-size: 10pt">The undersigned registrant hereby
undertakes as follows: that prior to any public reoffering of the securities registered hereunder through use of a prospectus which is
a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule 145(c), the
issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with respect
to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable
form.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">G.</span></td><td style="text-align: justify"><span style="font-size: 10pt">The registrant undertakes that
every prospectus (i) that is filed pursuant to paragraph (F) immediately preceding, or (ii) that purports to meet the requirements of
Section 10(a)(3) of the Act and is used in connection with an offering of securities subject to Rule 415, will be filed as a part of
an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining
any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">H.</span></td><td style="text-align: justify"><span style="font-size: 10pt">Insofar as indemnification for
liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant
pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification
is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person
of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person
in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled
by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Act and will be governed by the final adjudication of such issue.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">I.</span></td><td style="text-align: justify"><span style="font-size: 10pt">The undersigned registrant hereby
undertakes to respond to requests for information that is incorporated by reference into the prospectus pursuant to Items 4, 10(b), 11,
or 13 of this form, within one business day of receipt of such request, and to send the incorporated documents by first class mail or
other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration
statement through the date of responding to the request.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">J.</span></td><td style="text-align: justify"><span style="font-size: 10pt">The undersigned registrant hereby
undertakes to supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired
involved therein, that was not the subject of and included in the registration statement when it became effective.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 515 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_154"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">SIGNATURES</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">Pursuant
to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement on Form S-4
to be signed on its behalf by the undersigned, thereunto duly authorized, in Freehold, NJ on June 9, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><span style="-keep: true">&#160;</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top"><td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AVALON GLOBOCARE CORP.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 37%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ David K. Jin, M.D., Ph.D.</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David K. Jin, M.D., Ph.D.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and
on the dates indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center; width: 30%"><span style="font-size: 10pt"><b>Signature</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center; width: 46%"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center; width: 20%"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
  <tr>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><i>/s/ David
    K. Jin </i></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">President, Chief Executive Officer and Chairman</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><p style="margin: 0pt 0"><span style="-keep: true">June 9, 2025</span></p></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">David K. Jin</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(<i>Principal Executive Officer</i>)</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><i>/s/ Luisa
    Ingargiola</i></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Chief Financial Officer</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">June 9, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Luisa Ingargiola</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(<i>Principal Financial and Accounting Officer</i>)</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><i>*</i></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Chairman of the Board of Directors</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">June 9, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Wenzhao Lu</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="-keep: true">*</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">June 9, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Steven A. Sanders</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">June 9, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Lourdes Felix</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><i>*</i></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">June 9, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Wilbert J. Tauzin II</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><i>*</i></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">June 9, 2025</span></td></tr>
  <tr>
    <td style="text-align: center"><span style="font-size: 10pt">William B. Stilley III</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><i>*</i></span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: top; text-align: center"><span style="-keep: true">June 9, 2025</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Tevi Troy</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>
</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-15</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>


</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentType">S-4/A</ix:nonNumeric>
<ix:nonFraction contextRef="c1" id="hidden-fact-1" name="avco:EquityMethodInvestmentPayableCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-2" name="us-gaap:NotesPayableToBankCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-4" name="us-gaap:LongTermNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-5" name="us-gaap:LongTermLoansPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-6" name="us-gaap:LiabilitiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-7" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-8" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-9" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-10" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-11" name="us-gaap:PreferredStockLiquidationPreferenceValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-12" name="us-gaap:PreferredStockLiquidationPreferenceValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-13" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c10" id="hidden-fact-14" name="us-gaap:PreferredStockLiquidationPreferenceValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-15" name="us-gaap:MinorityInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-16" name="us-gaap:MinorityInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-17" name="us-gaap:ReceivablesNetCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-18" name="us-gaap:LongTermInvestmentsAndReceivablesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-19" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-20" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-21" name="us-gaap:LiabilitiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-22" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-23" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-24" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-25" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-26" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-27" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-28" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-29" name="us-gaap:MinorityInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-30" name="us-gaap:MinorityInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-31" name="avco:DebtModificationCharge" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-32" name="us-gaap:AssetImpairmentCharges" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-33" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-34" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-35" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-36" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-37" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-38" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-39" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-40" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-41" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-42" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-43" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-44" name="avco:DeemedContributionOnExchangeOfEquityInstruments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-45" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-46" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-47" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-48" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-49" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-50" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-51" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-52" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-53" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-54" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-55" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-56" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-57" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-58" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-59" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-60" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-61" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-62" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-63" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-64" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-65" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-66" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-67" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-68" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-69" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-70" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-71" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-72" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-73" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-74" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-75" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-76" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-77" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-78" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-79" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-80" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-81" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-82" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-83" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-84" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-85" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-86" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-87" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-88" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-89" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-90" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-91" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-92" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-93" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-94" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-95" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-96" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-97" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-98" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-99" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-100" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-101" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-102" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-103" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-104" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-105" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-106" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-107" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-108" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-109" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-110" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-111" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-112" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-113" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-114" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-115" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-116" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-117" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-118" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-119" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-120" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-121" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-122" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-123" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-124" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-125" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-126" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-127" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-128" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-129" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-130" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-131" name="avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-132" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-133" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-134" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-135" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-136" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-137" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-138" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-139" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-140" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-141" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-142" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-143" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-144" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-145" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-146" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-147" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-148" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-149" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-150" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-151" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-152" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-153" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-154" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-155" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-156" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-157" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-158" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-159" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-160" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-161" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-162" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-163" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-164" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-165" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-166" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-167" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-168" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-169" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-170" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-171" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-172" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-173" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-174" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-175" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-176" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-177" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-178" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-179" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-180" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-181" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-182" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-183" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-184" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-185" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-186" name="avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-187" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-188" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-189" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-190" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-191" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-192" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-193" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-194" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-195" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-196" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-197" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-198" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-199" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-200" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-201" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-202" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-203" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-204" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-205" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-206" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-207" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-208" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-209" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-210" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-211" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-212" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-213" name="avco:StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-214" name="avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-215" name="avco:StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-216" name="avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-217" name="avco:StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-218" name="avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c78" id="hidden-fact-219" name="avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c79" id="hidden-fact-220" name="avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-221" name="avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-222" name="avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-223" name="avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-224" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-225" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-226" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c77" id="hidden-fact-227" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-228" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c78" id="hidden-fact-229" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c79" id="hidden-fact-230" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-231" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-232" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-233" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-234" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-235" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c77" id="hidden-fact-236" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-237" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-238" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c78" id="hidden-fact-239" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c79" id="hidden-fact-240" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-241" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-242" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-243" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-244" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c77" id="hidden-fact-245" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-246" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-247" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c79" id="hidden-fact-248" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-249" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-250" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c81" id="hidden-fact-251" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-252" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-253" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c90" id="hidden-fact-254" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-255" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c92" id="hidden-fact-256" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c93" id="hidden-fact-257" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c96" id="hidden-fact-258" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c97" id="hidden-fact-259" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-260" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-261" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c92" id="hidden-fact-262" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c93" id="hidden-fact-263" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-264" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c96" id="hidden-fact-265" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c97" id="hidden-fact-266" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-267" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-268" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c92" id="hidden-fact-269" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c93" id="hidden-fact-270" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-271" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c95" id="hidden-fact-272" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c96" id="hidden-fact-273" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c97" id="hidden-fact-274" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-275" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c92" id="hidden-fact-276" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c93" id="hidden-fact-277" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c94" id="hidden-fact-278" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c95" id="hidden-fact-279" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c97" id="hidden-fact-280" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-281" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-282" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c109" id="hidden-fact-283" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-284" name="avco:DistributionOfEarningsFromEquityMethodInvestment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-285" name="us-gaap:AssetImpairmentCharges" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-286" name="avco:ImpairmentOfLaboratoryEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-287" name="us-gaap:GainsLossesOnRestructuringOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-288" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-289" name="us-gaap:IncreaseDecreaseInSecurityDeposits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-290" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-291" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-292" name="us-gaap:ProceedsFromRelatedPartyDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-293" name="us-gaap:RepaymentsOfRelatedPartyDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-294" name="us-gaap:ProceedsFromNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-295" name="us-gaap:RepaymentsOfNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-296" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-297" name="avco:ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-298" name="avco:WarrantsIssuedWithConvertibleNotePayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-299" name="avco:AccruedPurchasePriceRelatedToEquityMethodInvestment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-300" name="avco:DeferredFinancingCostsInAccruedLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-301" name="us-gaap:DebtConversionConvertedInstrumentAmount1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-302" name="us-gaap:SupplementalDeferredPurchasePrice" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-303" name="avco:SettlementsOfDerivativeLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-304" name="avco:ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-305" name="avco:IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-306" name="us-gaap:StockIssued1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-307" name="avco:DistributionOfEarningsFromEquityMethodInvestment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-308" name="us-gaap:IncreaseDecreaseInOtherReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-309" name="us-gaap:IncreaseDecreaseInSecurityDeposits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-310" name="avco:AccruedLiabilitiesAndOtherPayablesRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-311" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-312" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-313" name="avco:ProceedsFromIssuanceOfConvertibleDebtAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-314" name="avco:PaymentsOfConvertibleDebtIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-315" name="us-gaap:RepaymentsOfConvertibleDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-316" name="us-gaap:ConversionOfStockAmountIssued1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-317" name="avco:CommonStockIssuedForAccruedLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-318" name="avco:ReceivableRelatedToSaleOfEquityMethodInvestment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-319" name="avco:RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-320" name="avco:SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-321" name="avco:SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-322" name="avco:WarrantsIssuedAsConvertibleNotePayableFindersFee" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-323" name="avco:WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-324" name="avco:CommonStockIssuedAsConvertibleNotePayableCommitmentFee" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-325" name="us-gaap:DebtConversionConvertedInstrumentAmount1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-326" name="avco:SettlementsOfDerivativeLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-327" name="avco:IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-328" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c147" id="hidden-fact-329" name="us-gaap:DerivativeLiabilitiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c162" id="hidden-fact-330" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-331" name="us-gaap:DeferredOfferingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-332" name="us-gaap:SecurityDeposit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-333" name="us-gaap:InventoryFinishedGoods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c165" id="hidden-fact-334" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c191" id="hidden-fact-335" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-336" name="us-gaap:NotesPayableCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-337" name="us-gaap:LongTermNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c371" decimals="0" id="hidden-fact-338" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" unitRef="usd">480000</ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-339" name="us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-340" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-341" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-342" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-343" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-344" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-345" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-346" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-347" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-348" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-349" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-350" name="us-gaap:DeferredTaxAssetInterestCarryforward" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-351" name="us-gaap:DeferredTaxLiabilitiesRegulatoryAssets" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-352" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-353" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c494" id="hidden-fact-354" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c494" id="hidden-fact-355" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c524" id="hidden-fact-356" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c525" id="hidden-fact-357" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c524" id="hidden-fact-358" name="us-gaap:OperatingExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c525" id="hidden-fact-359" name="us-gaap:OperatingExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c524" id="hidden-fact-360" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c525" id="hidden-fact-361" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c523" id="hidden-fact-362" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c525" id="hidden-fact-363" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c524" id="hidden-fact-364" name="us-gaap:OperatingCostsAndExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c524" id="hidden-fact-365" name="us-gaap:InterestExpenseNonoperating" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c524" id="hidden-fact-366" name="us-gaap:OtherIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c527" id="hidden-fact-367" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c528" id="hidden-fact-368" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c527" id="hidden-fact-369" name="us-gaap:OperatingExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c528" id="hidden-fact-370" name="us-gaap:OperatingExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c527" id="hidden-fact-371" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c528" id="hidden-fact-372" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c526" id="hidden-fact-373" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c528" id="hidden-fact-374" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c527" id="hidden-fact-375" name="us-gaap:OperatingCostsAndExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c527" id="hidden-fact-376" name="us-gaap:InterestExpenseNonoperating" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c527" id="hidden-fact-377" name="us-gaap:OtherIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-378" name="avco:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-379" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c593" id="hidden-fact-380" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c595" id="hidden-fact-381" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c598" id="hidden-fact-382" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c600" id="hidden-fact-383" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-384" name="us-gaap:PrepaidExpenseOtherNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c613" id="hidden-fact-385" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-386" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-387" name="avco:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c760" id="hidden-fact-388" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c761" id="hidden-fact-389" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c760" id="hidden-fact-390" name="us-gaap:OperatingExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c761" id="hidden-fact-391" name="us-gaap:OperatingExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c760" id="hidden-fact-392" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c761" id="hidden-fact-393" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c759" id="hidden-fact-394" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c761" id="hidden-fact-395" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c760" id="hidden-fact-396" name="us-gaap:OperatingCostsAndExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c760" id="hidden-fact-397" name="us-gaap:InterestExpenseNonoperating" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c760" id="hidden-fact-398" name="us-gaap:OtherIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c763" id="hidden-fact-399" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c764" id="hidden-fact-400" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c763" id="hidden-fact-401" name="us-gaap:OperatingExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c764" id="hidden-fact-402" name="us-gaap:OperatingExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c763" id="hidden-fact-403" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c764" id="hidden-fact-404" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c762" id="hidden-fact-405" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c764" id="hidden-fact-406" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c763" id="hidden-fact-407" name="us-gaap:OperatingCostsAndExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c763" id="hidden-fact-408" name="us-gaap:InterestExpenseNonoperating" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c763" id="hidden-fact-409" name="us-gaap:OtherIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-410" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-411" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-91439">0001630212</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-91440">true</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="avco-20250331.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_1_fact ix_2_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_3_fact ix_4_fact" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_5_fact hidden-fact-330" toRefs="ix_3_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_6_fact ix_7_fact" toRefs="ix_4_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-380 ix_8_fact" toRefs="ix_5_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-381 ix_9_fact" toRefs="ix_6_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_10_fact hidden-fact-382" toRefs="ix_7_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_11_fact hidden-fact-383" toRefs="ix_8_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_12_fact ix_13_fact" toRefs="ix_9_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-10-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonHealthcareSystemIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2015-05-18</xbrli:startDate>
    <xbrli:endDate>2015-05-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonRT9PropertiesLLCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisAndArbeleBiotherapeuticsLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-06</xbrli:startDate>
    <xbrli:endDate>2022-04-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisBiosciencesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-06</xbrli:startDate>
    <xbrli:endDate>2022-04-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisBiosciencesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-08</xbrli:startDate>
    <xbrli:endDate>2020-05-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonLabMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-09</xbrli:startDate>
    <xbrli:endDate>2023-02-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonLabMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-26</xbrli:startDate>
    <xbrli:endDate>2025-02-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-26</xbrli:startDate>
    <xbrli:endDate>2025-02-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonHealthcareSystemIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonRT9PropertiesLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonShanghaiHealthcareTechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:GenExosomeTechnologiesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisBiosciencesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisNanjingBiosciencesLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonLaboratoryServicesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:QADistributionLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avco:LaboratoryEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:EpiconBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:LaboratoryServicesMSOLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:LaboratoryServicesMSOLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RegulatoryAssetAxis">avco:DeferredOfferingCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">avco:AssetAndLiabilityAccountsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">avco:AssetAndLiabilityAccountsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">avco:AssetAndLiabilityAccountsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:DrYuZhouMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avco:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avco:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avco:LaboratoryEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avco:LaboratoryEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:EpiconBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonShangaiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:JiangsuUnicornBiologicalTechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:InvestmentInEpiconBiotechCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LaboratoryServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesBStatedValueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:SeriesBStatedValueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-09</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avco:LaboratoryServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avco:LaboratoryServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-09</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LaboratoryServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LaboratoryServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-09</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">avco:InvestmentInLaboratoryServicesMSOLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">avco:InvestmentInLaboratoryServicesMSOLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">avco:InvestmentInLaboratoryServicesMSOLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">avco:InvestmentInLaboratoryServicesMSOLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-09</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-23</xbrli:startDate>
    <xbrli:endDate>2023-05-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-23</xbrli:startDate>
    <xbrli:endDate>2023-05-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillFundLPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">us-gaap:OtherTradingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FirstWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillFundLPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:SecondWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillFundLPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-23</xbrli:startDate>
    <xbrli:endDate>2023-05-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-23</xbrli:startDate>
    <xbrli:endDate>2023-05-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-23</xbrli:startDate>
    <xbrli:endDate>2023-05-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-06</xbrli:startDate>
    <xbrli:endDate>2023-07-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-06</xbrli:startDate>
    <xbrli:endDate>2023-07-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-06</xbrli:startDate>
    <xbrli:endDate>2023-07-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FirstWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-06</xbrli:startDate>
    <xbrli:endDate>2023-07-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FirstWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:SecondWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-06</xbrli:startDate>
    <xbrli:endDate>2023-07-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:SecondWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-06</xbrli:startDate>
    <xbrli:endDate>2023-07-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-06</xbrli:startDate>
    <xbrli:endDate>2023-07-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-09</xbrli:startDate>
    <xbrli:endDate>2023-10-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">us-gaap:OtherTradingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-09</xbrli:startDate>
    <xbrli:endDate>2023-10-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FirstWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:SecondWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-09</xbrli:startDate>
    <xbrli:endDate>2023-10-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-09</xbrli:startDate>
    <xbrli:endDate>2023-10-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-09</xbrli:startDate>
    <xbrli:endDate>2023-10-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-07</xbrli:startDate>
    <xbrli:endDate>2024-03-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FirstWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-07</xbrli:startDate>
    <xbrli:endDate>2024-03-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:SecondWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-07</xbrli:startDate>
    <xbrli:endDate>2024-03-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-07</xbrli:startDate>
    <xbrli:endDate>2024-03-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-07</xbrli:startDate>
    <xbrli:endDate>2024-03-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-05</xbrli:startDate>
    <xbrli:endDate>2024-06-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FirstWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-05</xbrli:startDate>
    <xbrli:endDate>2024-06-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FirstWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:SecondWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-05</xbrli:startDate>
    <xbrli:endDate>2024-06-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:SecondWarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c279">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c280">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c281">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c282">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c283">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c284">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c285">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c286">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c287">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c288">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c289">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c290">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:WaiverFeeMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c291">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:PreFundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c292">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-15</xbrli:startDate>
    <xbrli:endDate>2024-12-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c293">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:WaiverFeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c294">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:DecemberFiveTwoThousandTwentyFourMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c295">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:JanuaryFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c296">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:FebruaryFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c297">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:MarchFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c298">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:AprilFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c299">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:MayFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c300">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:JuneFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c301">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c302">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c303">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c304">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c305">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c306">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c307">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c308">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c309">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c310">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c311">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c312">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c313">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c314">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c315">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c316">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c317">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c318">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c319">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c320">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c321">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c322">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c323">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c324">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c325">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c326">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c327">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c328">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c329">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c330">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c331">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c332">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c333">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c334">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c335">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillAndFirstfireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c336">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c337">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c338">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c339">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c340">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c341">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c342">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c343">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c344">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c345">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillAndFirstfireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c346">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillAndFirstfireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c347">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillAndFirstfireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c348">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillAndFirstfireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c349">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillAndFirstfireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c350">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillThirdPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c351">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:March72024FiveYearAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c352">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:March72024FiveYearAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c353">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March72024FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c354">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March72024FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c355">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March72024FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c356">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March72024FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c357">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March72024FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c358">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c359">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c360">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c361">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c362">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c363">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c364">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c365">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c366">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c367">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c368">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:PromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c369">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c370">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:PromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-01</xbrli:startDate>
    <xbrli:endDate>2022-11-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c371">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:PromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c372">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-01</xbrli:startDate>
    <xbrli:endDate>2023-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c373">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra/k4DNHXVKIYwN/zLXIt0iwZq6nYg/w27/nmgU3Bs4kyGGa1okQf8wpc8xue3C4gYCyO+De2FMpGD6T1rBTmQ8hA/UC+V/TeVcwU7ABGe/tb9Nse+XBO1hN0S6XbJQbcJwedpHBgl7i050GjffC4p7Iw/J3z5vZfcXGGwK1wcBZ+q2HcISatlXTlFgsMKO5QeDDlx75B8z8hjuvV5IPRmtFIaAZaCRuKG6FjDX4pVgOrB2QZGKSC/RsAjxVROlJNI=] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:PromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c374">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c375">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c376">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:BeijingGenexosomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c377">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:DrYuZhouMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c378">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:DrYuZhouMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c379">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:BeijingGenexosomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c380">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c381">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c382">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:WenzhaoLuMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c383">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:WenzhaoLuMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c384">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:LineOfCreditAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-08-29</xbrli:startDate>
    <xbrli:endDate>2019-08-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c385">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c386">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c387">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avco:MrLuMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c388">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-17</xbrli:startDate>
    <xbrli:endDate>2023-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c389">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avco:AvalonRT9Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c390">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:AvalonRT9Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-17</xbrli:startDate>
    <xbrli:endDate>2023-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c391">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c392">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:ConvertibleDebtNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c393">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c394">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c395">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c396">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c397">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c398">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesBHolderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c399">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c400">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c401">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:ConversionShareMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c402">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c403">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-02-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c404">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c405">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c406">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c407">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:JefferiesLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c408">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avco:JefferiesLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c409">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c410">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c411">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c412">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:CommonSharesIssuedForServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c413">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-01</xbrli:startDate>
    <xbrli:endDate>2024-11-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c414">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c415">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-01</xbrli:startDate>
    <xbrli:endDate>2024-10-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c416">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c417">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c418">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c419">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c420">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c421">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c422">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c423">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c424">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c425">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c426">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:May2023CovertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c427">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:May2023CovertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c428">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:May2023CovertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c429">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:BlackScholesValuationModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c430">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:BlackScholesValuationModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-23</xbrli:startDate>
    <xbrli:endDate>2023-05-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c431">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c432">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:May2023CovertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c433">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:May2023CovertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-23</xbrli:startDate>
    <xbrli:endDate>2023-05-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c434">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c435">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:FiveYearAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-06</xbrli:startDate>
    <xbrli:endDate>2023-07-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c436">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c437">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-06</xbrli:startDate>
    <xbrli:endDate>2023-07-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c438">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c439">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c440">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FirstfireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c441">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c442">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-06</xbrli:startDate>
    <xbrli:endDate>2023-07-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c443">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:OctoberTwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c444">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:OctoberTwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c445">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:OctoberTwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-09</xbrli:startDate>
    <xbrli:endDate>2023-10-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c446">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:OctoberTwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c447">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:BlackScholesValuationModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c448">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:BlackScholesValuationModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-09</xbrli:startDate>
    <xbrli:endDate>2023-10-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c449">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:MastMillAndFirstFireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c450">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:MarchTwoThousandTwentyFourWarrantIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c451">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:MastMillAndFirstFireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-07</xbrli:startDate>
    <xbrli:endDate>2024-03-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c452">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:MarchTwoThousandTwentyFourWarrantIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c453">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:MarchTwoThousandTwentyFourWarrantIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-07</xbrli:startDate>
    <xbrli:endDate>2024-03-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c454">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:MarchTwentyThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c455">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:MarchTwentyThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c456">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:MarchTwentyThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-07</xbrli:startDate>
    <xbrli:endDate>2024-03-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c457">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:TwoThousandTwentyFourJuneWarrantIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c458">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:TwoThousandTwentyFourJuneWarrantIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c459">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:TwoThousandTwentyFourJuneWarrantIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-05</xbrli:startDate>
    <xbrli:endDate>2024-06-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c460">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:TwoThousandTwentyFourJuneWarrantIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c461">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:TwoThousandTwentyFourJuneWarrantIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-05</xbrli:startDate>
    <xbrli:endDate>2024-06-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c462">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:TwoThousandTwentyFourJuneWarrantIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c463">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-05</xbrli:startDate>
    <xbrli:endDate>2024-06-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c464">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c465">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:MastHillMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:JuneTwentyThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c466">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:MastHillMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:TwoThousandTwentyFourJuneWarrantIssuedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c467">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FiveYearAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c468">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FiveYearAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-05</xbrli:startDate>
    <xbrli:endDate>2024-06-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c469">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-05</xbrli:startDate>
    <xbrli:endDate>2024-06-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c470">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:WarrantsExercisedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-05</xbrli:startDate>
    <xbrli:endDate>2024-06-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c471">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c472">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c473">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c474">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c475">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c476">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c477">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c478">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c479">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c480">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c481">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c482">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c483">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c484">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c485">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c486">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c487">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c488">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c489">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c490">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c491">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c492">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c493">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c494">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c495">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c496">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c497">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c498">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c499">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c500">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c501">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c502">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c503">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c504">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c505">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c506">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c507">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:DrYuZhouMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avco:FormerDirectorAndFormerCochiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c508">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">avco:PRCSubsidiariesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c509">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:OneCustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c510">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:OneCustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c511">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:OneCustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c512">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:TwoCustomersMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c513">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:OneCustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c514">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:TwoCustomersMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c515">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">us-gaap:PublicUtilitiesInventorySuppliesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c516">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">us-gaap:PublicUtilitiesInventorySuppliesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c517">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c518">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c519">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c520">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c521">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c522">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c523">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:RealPropertyOperationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c524">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c525">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:CorporateOtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c526">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:RealPropertyOperationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c527">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c528">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:CorporateOtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c529">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:RealPropertyOperatingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c530">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:RealPropertyOperatingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c531">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:CorporateOtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c532">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:CorporateOtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c533">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-10-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c534">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-10-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c535">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:DrZhouMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-10-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c536">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-10-25</xbrli:startDate>
    <xbrli:endDate>2017-10-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c537">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:DrZhouMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-10-25</xbrli:startDate>
    <xbrli:endDate>2017-10-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c538">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:DrZhouMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c539">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c540">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c541">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisBiotherapeuticsLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c542">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:ArbeleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c543">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisNanjingBiosciencesLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c544">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:ArbeleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c545">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c546">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c547">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c548">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c549">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c550">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c551">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c552">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-26</xbrli:startDate>
    <xbrli:endDate>2025-02-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c553">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-26</xbrli:startDate>
    <xbrli:endDate>2025-02-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c554">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c555">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c556">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MergerAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c557">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MergerAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c558">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MergerAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c559">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:CertificatesOfEliminationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c560">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:CertificatesOfEliminationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c561">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-10</xbrli:startDate>
    <xbrli:endDate>2025-03-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c562">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c563">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-31</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c564">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-31</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c565">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonHealthcareSystemIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2015-05-18</xbrli:startDate>
    <xbrli:endDate>2015-05-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c566">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonRT9PropertiesLLCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c567">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisBiosciencesIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-06</xbrli:startDate>
    <xbrli:endDate>2022-04-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c568">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisBiosciencesIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-08</xbrli:startDate>
    <xbrli:endDate>2020-05-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c569">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonLabMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-26</xbrli:startDate>
    <xbrli:endDate>2025-02-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c570">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonHealthcareSystemIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c571">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonRT9PropertiesLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c572">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonShanghaiHealthcareTechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c573">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:GenExosomeTechnologiesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c574">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisBiosciencesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c575">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisNanjingBiosciencesLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c576">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonLaboratoryServicesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c577">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:QADistributionLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c578">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c579">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c580">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c581">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c582">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:PreFundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c583">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c584">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c585">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c586">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c587">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c588">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c589">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avco:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c590">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avco:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c591">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c592">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c593">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c594">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c595">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c596">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c597">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c598">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c599">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c600">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c601">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c602">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c603">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LaboratoryServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c604">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c605">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c606">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesBStatedValueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c607">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avco:LaboratoryServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c608">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonShangaiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c609">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:JiangsuUnicornBiologicalTechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c610">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-02-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c611">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-26</xbrli:startDate>
    <xbrli:endDate>2025-02-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c612">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c613">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c614">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">avco:InvestmentInLaboratoryServicesMSOLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-02-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c615">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">avco:InvestmentInLaboratoryServicesMSOLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c616">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-05</xbrli:startDate>
    <xbrli:endDate>2024-06-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c617">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-05</xbrli:startDate>
    <xbrli:endDate>2024-06-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c618">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillFundLPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c619">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">us-gaap:OtherTradingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c620">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-30</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c621">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c622">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FirstWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c623">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:SecondWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c624">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c625">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c626">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c627">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c628">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c629">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c630">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-23</xbrli:startDate>
    <xbrli:endDate>2023-05-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c631">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:DecemberFiveTwoThousandTwentyFourMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c632">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:JanuaryFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c633">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:FebruaryFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c634">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:MarchFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c635">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:AprilFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c636">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:MayFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c637">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:JuneFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c638">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c639">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-05-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c640">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c641">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c642">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c643">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c644">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c645">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c646">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c647">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:findersFeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c648">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-07-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c649">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c650">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-31</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c651">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c652">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c653">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c654">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c655">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c656">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillAndFirstfireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c657">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c658">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c659">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c660">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c661">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c662">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c663">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c664">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c665">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c666">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c667">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c668">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c669">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c670">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c671">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c672">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillAndFirstfireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c673">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillAndFirstfireMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c674">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c675">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c676">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c677">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c678">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c679">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c680">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c681">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c682">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c683">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:PromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c684">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c685">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c686">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:BeijingGenexosomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-12-31</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c687">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:DrYuZhouMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c688">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:BeijingGenexosomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c689">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:LabServiceMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c690">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:AbandonmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c691">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:LabServiceMSOMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c692">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:LabServiceMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c693">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:LabServiceMSOMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c694">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avco:MrLuMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:AvalonRT9Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c695">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avco:MrLuMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:AvalonRT9Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-17</xbrli:startDate>
    <xbrli:endDate>2023-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c696">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avco:MrLuMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avco:MembershipInterestPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-11-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c697">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avco:MrLuMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-17</xbrli:startDate>
    <xbrli:endDate>2023-11-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c698">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avco:MrLuMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c699">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avco:MrLuMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c700">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-09</xbrli:startDate>
    <xbrli:endDate>2025-01-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c701">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c702">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c703">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c704">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c705">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:ConvertibleDebtNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c706">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c707">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c708">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesBHolderMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c709">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:AvalonLabMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c710">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c711">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c712">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:ConversionShareMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c713">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c714">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c715">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:ConversionShareMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c716">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MrLuMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c717">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:AvalonLabMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c718">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c719">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:CommonSharesIssuedForServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c720">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c721">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c722">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c723">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:WarrantsExercisedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c724">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c725">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:OptionsOutstandingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c726">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:OptionsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c727">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:OptionsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c728">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:OptionsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c729">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:OptionsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c730">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:OptionsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c731">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:OptionsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c732">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:OptionsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c733">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:OptionsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c734">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c735">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c736">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c737">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c738">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c739">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c740">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c741">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c742">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c743">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c744">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c745">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c746">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c747">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c748">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c749">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c750">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">avco:PRCSubsidiariesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c751">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:TwoCustomersMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c752">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c753">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c754">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c755">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c756">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c757">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c758">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c759">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:RealPropertyOperationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c760">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c761">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:CorporateOtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c762">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:RealPropertyOperationsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c763">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c764">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:CorporateOtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c765">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:RealPropertyOperatingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c766">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:CorporateOtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c767">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-10-25</xbrli:startDate>
    <xbrli:endDate>2017-10-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c768">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:DrZhouMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-10-25</xbrli:startDate>
    <xbrli:endDate>2017-10-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c769">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:DrZhouMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c770">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c771">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c772">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c773">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:ArbeleMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c774">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001630212</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-30</xbrli:startDate>
    <xbrli:endDate>2025-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="segments">
  <xbrli:measure>avco:segments</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="cny">
  <xbrli:measure>iso4217:CNY</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.111
<SEQUENCE>2
<FILENAME>ea024503201ex10-111_avalon.htm
<DESCRIPTION>INGARGIOLA COMBINED COMPANY EXECUTIVE RETENTION AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 10.111</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMENDED AND RESTATED EXECUTIVE RETENTION AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Amended and Restated
Executive Retention Agreement (the <B><I>&ldquo;Agreement&rdquo;) </I></B>is made and entered into by and between AVALON GLOBOCARE CORP.,
a Delaware corporation (the <B><I>&ldquo;Company&rdquo;) </I></B>and LUISA INGARGIOLA (the <B><I>&ldquo;Executive&rdquo;) </I></B>as of
_______________, 2025 to be effective upon the &ldquo;Merger&rdquo; (defined below) (the &ldquo;<B><I>Effective Date</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Recitals:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Executive is
a key employee of the Company who possesses valuable proprietary knowledge of the Company, its business and operations and the markets
in which the Company competes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Executive and
the Company have entered into that certain Executive Retention Agreement dated as of February 21, 2017 (the &ldquo;<B><I>Prior Agreement</I></B>&rdquo;)
pursuant to which the Executive is entitled to payment of certain payments and benefits in the event of a Termination Upon Change of Control
or certain other terminations pursuant to the terms of such Prior Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company, Nexus
MergerSub Limited, a business company incorporated in the British Virgin Islands and a wholly owned subsidiary of the Company (&ldquo;<B><I>Merger
Sub</I></B>&rdquo;) and YOOV Group Holding Limited, a business company incorporated in the British Virgin Islands (&ldquo;<B><I>YOOV</I></B>&rdquo;),
entered into an Agreement and Plan of Merger, dated March 7, 2025, pursuant to which Merger Sub will merge with and into YOOV, with YOOV
surviving the merger and becoming a wholly owned direct subsidiary of Avalon (the &ldquo;<B><I>Merger</I></B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company and the
Executive desire to enter into this Agreement to encourage the Executive to continue to devote the Executive&rsquo;s full attention, except
to the extent that Executive serves as a member of the Board of Directors for other companies, and dedication to the success of the Company
following the Merger, and to provide specified compensation and benefits to the Executive in the event of a Termination Upon Change of
Control or certain other terminations pursuant to the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, THE PARTIES
HEREBY AGREE AS FOLLOWS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><U>PURPOSE AND TERM; Effectiveness; DUTIES</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1&nbsp;The
purpose of this Agreement is to provide specified compensation and benefits to the Executive in the event of (i) a Termination Upon Change
of Control or (ii) an Involuntary Termination. Subject to the terms of any applicable written employment agreement between Company and
the Executive (as to which Executive acknowledges no other such agreement exists as of the date hereof), either the Executive or Company
may terminate the Executive&rsquo;s employment at any time for any reason, with or without notice. The term of this Agreement shall be
the period from the date set forth above until Executive&rsquo;s employment is terminated for any reason or this Agreement is terminated
by mutual agreement of the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2&nbsp;The
effectiveness of this Agreement is contingent on the closing of the Merger. If the closing of the Merger does not occur, this Agreement
shall be void and of no further force or effect, and the Prior Agreement shall remain in effect in accordance with its terms. Upon closing
of the Merger, this Agreement shall supersede the Prior Agreement and the Prior Agreement shall cease to be of any force or effect. For
avoidance of doubt, in the event the closing of the Merger occurs and the Executive continues in employment with the Company as of the
date of such closing, the Executive shall not be entitled to any termination payments or benefits under the Prior Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.3&nbsp;The
Executive shall be employed as the Company&rsquo;s principal financial officer with the title of Chief Financial Officer. The Executive&rsquo;s
job responsibilities will comprise managing and overseeing all financial operations and matters of the Company, including the subsidiaries,
including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Timely and accurate annual and quarterly financial reporting in accordance with Securities &amp; Exchange
Commission (&ldquo;SEC&rdquo;) rules and regulations, applicable law and United States Generally Accepted Accounting Principles.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Managing all capital markets activities as reasonably requested by the Company CEO including: attending
investor conferences, roadshows and meetings; managing investor relations and public relations; communicating with investment analysts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Establishing and maintaining adequate financial controls, sufficient as a minimum to enable the Executive&rsquo;s
appropriate certification of the Company&rsquo;s annual and quarterly reports in accordance with SEC rules.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Managing the treasury functions for the Company, as well as all borrowings, debt facilities and equity
fundraising, subject to the approval of the Board of Directors of the Company (the <B><I>&ldquo;Board&rdquo;).</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(e)</TD><TD STYLE="text-align: justify">Undertaking financial planning for the Company, including preparing annual and other budgets and projections
and managing in compliance with such budgets as may be approved by the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(f)</TD><TD STYLE="text-align: justify">Monthly management reporting and analysis for the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(g)</TD><TD STYLE="text-align: justify">All such functions as are customarily applicable to the Executive&rsquo;s position, as well as those that
are reasonably assigned to the Executive by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.4&nbsp;The
Executive will be permitted to work from Florida.. The Executive is entitled to four (4) weeks of vacation which will accrue on a pro-rata
basis during the year, in addition to all public holidays when the office is closed. The Executive will be eligible to participate in
all employee benefit plans established by the Company for its employees from time to time and if no health insurance is available, will
be reimbursed for private health insurance. In accordance with Company policies from time to time, the Company will reimburse the Executive
for all reasonable and proper travel and business expenses incurred by the Executive in the performance of her duties. For all air travel
in excess of 5 hours, Executive will be reimbursed for First Class or Business Class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><U>COMPENSATION AND TERMINATION GENERALLY</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1&nbsp;<U>Compensation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.1&nbsp;<U>Annual
Salar</U>y. The Executive&rsquo;s base salary shall be $350,000 per annum, subject to periodic review and modification by the Board or
the Compensation Committee of the Board (references herein to the Compensation Committee shall include reference to the Board if no such
Committee exists at any time) at such time or times as it shall determine. The Company&rsquo;s Compensation Committee shall also from
time to time, in its discretion, determine the type and amount of other forms of compensation for the Executive&rsquo;s service with the
Company (including, without limitation, stock options or other forms of equity awards).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.2&nbsp;<U>Sign-On
Bonus</U>. On or within ten (10) days following the closing of the Merger, the Company shall pay the Executive a lump sum payment in the
amount of three hundred and fifty thousand dollars ($350,000.00).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.3&nbsp;<U>Performance
Bonuses</U>. Executive will be eligible for annual bonuses, as determined by the Board or the Compensation Committee of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.4&nbsp;<U>Options</U>.
Within thirty (30) days following the Effective Date, the Executive will be granted an option to purchase 600,000 shares of the Company&rsquo;s
common stock, vesting over three (3) years, one third on the first anniversary of the Effective Date and the balance in equal quarterly
installments. The exercise price of such option shall be equal to the closing price of the Company&rsquo;s common stock on the date of
grant. The Executive may be eligible for additional equity incentive grants, subject to Executive&rsquo;s continued employment and satisfactory
job performance, which may be made from time to time, by the Board or the Compensation Committee of the Board, on the same terms as other
executive employees of the Company. Terms and conditions of all the equity incentive grants, will be in accordance with the terms of the
Company&rsquo;s Equity Incentive Plan in effect at the time of each such grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2&nbsp;<U>Termination
of Employment Generall</U>y. In the event the Executive&rsquo;s employment with the Company terminates, for any reason whatsoever including
death or disability the Executive shall be entitled to the benefits described in this Section 2.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.1&nbsp;<U>Accrued
Salar</U>y <U>and Vacation</U>. All salary and accrued vacation earned through the Termination Date shall be paid to Executive on such
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.2&nbsp;<U>Accrued
Bonus Payment</U>. The Executive shall receive a lump sum payment of any actual bonus amount to the extent that all the conditions for
payment of such bonus have been satisfied and any such bonus was earned and is unpaid on the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.3&nbsp;<U>Expense
Reimbursement</U>. Within ten (10) days following submission to the Company of proper expense reports by the Executive, the Company shall
reimburse the Executive for all expenses incurred by the Executive, consistent with the Company&rsquo;s expense reimbursement policy in
effect prior to the incurring of each such expense, in connection with the business of the Company prior to the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.4&nbsp;<U>Equi</U>ty
<U>Compensation</U>. The period during which the Executive may exercise any rights under any outstanding stock options and stock appreciation
rights, and the extent to which any outstanding shares of restricted stock, restricted stock units and any other equity award shall vest,
shall be determined under the terms of the Equity Incentive Plan under which they were granted and the applicable option or award agreements
governing such grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">3.</TD><TD STYLE="text-align: justify"><U>TERMINATION UPON CHANGE OF CONTROL</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;<U>Severance
Payment</U>. In the event of the Executive&rsquo;s Termination Upon Change of Control, the Executive shall be entitled to receive an amount
equal to the amount set forth in Section 4.1 which shall be paid within ten (10) days following the Termination Date; provided, however,
that if Section 409A of the Code would otherwise apply to such cash severance payment, it instead shall be paid at such time as permitted
by Section 409A of the Code. In addition to the foregoing severance payment, in the event of the Executive&rsquo;s Termination Upon Change
of Control, the Executive shall be entitled to receive, within ten (10) days following the Termination Upon Change of Control, a lump
sum payment equal to one hundred percent (100%) of (a) any actual bonus amount earned with respect to a previous year to the extent that
all the conditions for payment of such bonus have been satisfied (excluding any requirement to be in employment with the Company as of
a given date which is after the Termination Date) and any such bonus was earned but is unpaid on the Termination Date; and (b) the target
bonus then in effect for the Executive for the year in which such termination occurs, such payment to be prorated to reflect the number
of days the Executive remained in the employ of the Company; provided, however, that if Section 409A of the Code would otherwise apply
to such cash payment, it instead shall be paid at such time as permitted by Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2&nbsp;<U>Equity
Compensation Acceleration</U>. Upon the Executive&rsquo;s Termination Upon Change of Control, the vesting and exercisability of all then
outstanding stock options and shares of restricted stock (or any other equity award, including, without limitation, stock appreciation
rights and restricted stock units) granted to the Executive under any Equity Incentive Plan shall be accelerated as to 100% of the shares
subject to any such equity awards granted to the Executive. In addition, the applicable exercise period of the Executive&rsquo;s stock
options granted under the Equity Incentive Plan(s) shall be extended so as to expire on the last day of the term applicable to such stock
option, as measured from the date of Termination Upon Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3&nbsp;<U>COBRA</U>.
If the Executive timely elects coverage under the Consolidated Budget Reconciliation Act of 1985, as amended <B><I>(&ldquo;COBRA&rdquo;), </I></B>the
Company shall continue to provide to the Executive, at the Company&rsquo;s expense, the Company&rsquo;s health-related employee
insurance coverage for the employee only as in effect immediately prior to the Executive&rsquo;s Termination Upon Change of Control
for a period of twelve (12) months following such Termination Upon Change of Control. The date of the &ldquo;qualifying event&rdquo;
for the Executive and any dependents shall be the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4&nbsp;<U>Indemnification</U>.
In the event of the Executive&rsquo;s Termination Upon Change of Control, (a) the Company shall continue to indemnify the Executive against
all claims related to actions arising prior to the termination of the Executive&rsquo;s employment to the fullest extent permitted by
law, and (b) if the Executive was covered by the Company&rsquo;s directors&rsquo; and officers&rsquo; insurance policy, or an equivalent
thereto, (the <B><I>&ldquo;D&amp;O Insurance Policy&rdquo;) </I></B>immediately prior to the Change of Control, the Company or its Successor
shall continue to provide coverage under a D&amp;O Insurance Policy for not less than twenty-four (24) months following the Executive&rsquo;s
Termination Upon Change of Control on substantially the same terms of the D&amp;O Insurance Policy in effect immediately prior to the
Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><U>INVOLUNTARY TERMINATION</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1&nbsp;<U>Severance
Payment</U>. In the event of the Executive&rsquo;s Involuntary Termination, the Executive shall be entitled to receive an amount equal
to twelve (12) months of the Executive&rsquo;s Base Salary, which shall be paid according to the following schedule: (i) a lump sum payment
equal to one-fourth of such amount shall be payable within ten (10) days following the Termination Date, and (ii) one-fourth of such amount
shall be payable within ten (10) days of each of the three-month, six-month and nine-month anniversaries of the Termination Date (and
in each case no interest shall accrue on such amount); provided, however, that if Section 409A of the Code would otherwise apply to such
cash severance payment, it instead shall be paid at such time as permitted by Section 409A of the Code. In addition to the foregoing severance
payment, in the event of the Executive&rsquo;s Involuntary Termination, the Executive shall be entitled to receive, within ten (10) days
following the Executive&rsquo;s Involuntary Termination, a lump sum payment equal to one hundred percent (100%) of (a) any actual bonus
amount earned with respect to a previous year to the extent that all the conditions for payment of such bonus have been satisfied (excluding
any requirement to be in employment with the Company as of a given date which is after the Termination Date) and any such bonus was earned
but is unpaid on the Termination Date; and (b) the target bonus then in effect for the Executive for the year in which such termination
occurs, such payment to be prorated to reflect the number of days the Executive remained in the employ of the Company; provided, however,
that if Section 409A of the Code would otherwise apply to such cash payment, it instead shall be paid at such time as permitted by Section
409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2&nbsp;<U>Equity
Compensation Acceleration</U>. Upon the Executive&rsquo;s Involuntary Termination, the vesting and exercisability of all then outstanding
stock options and shares of restricted stock (or any other equity award, including, without limitation, stock appreciation rights and
restricted stock units) granted to the Executive under any Equity Incentive Plan shall be accelerated as to 100% of the shares subject
to any such equity awards granted to the Executive. In addition, the applicable exercise period of the Executive&rsquo;s stock options
granted under the Equity Incentive Plan(s) shall be extended so as to expire on the last day of the term applicable to such stock option,
as measured from the date of Involuntary Termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3&nbsp;<U>COBRA</U>.
In the event of the Executive&rsquo;s Involuntary Termination, if the Executive timely elects coverage under COBRA, the Company shall
continue to provide to the Executive, at the Company&rsquo;s expense, the Company&rsquo;s health-related employee insurance coverage for
the employee only as in effect immediately prior to the Executive&rsquo;s Involuntary Termination for a period of twelve (12) months following
such Involuntary Termination. The date of the &ldquo;qualifying event&rdquo; for the Executive and any dependents shall be the Termination
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4&nbsp;<U>Indemnification</U>.
In the event of the Executive&rsquo;s Involuntary Termination, (a) the Company shall continue to indemnify the Executive against all claims
related to actions arising prior to the Termination Date to the fullest extent permitted by law, and (b) if the Executive was covered
by the D&amp;O Insurance Policy immediately prior to the Termination Date, the Company shall continue to provide coverage under a D&amp;O
Insurance Policy for not less than twenty-four (24) months following the Executive&rsquo;s Involuntary Termination on substantially the
same terms of the D&amp;O Insurance Policy in effect immediately prior to the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">5.</TD><TD STYLE="text-align: justify"><U>FEDERAL EXCISE TAX UNDER SECTION 280G</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1&nbsp;<U>Excise
Tax</U>. If (a) any amounts payable to the Executive under this Agreement or otherwise are characterized as excess parachute payments
pursuant to Section 4999 of the Internal Revenue Code of 1986, as amended (the <B><I>&ldquo;Code&rdquo;), </I></B>and (b) the Executive
thereby would be subject to any United States federal excise tax due to that characterization, then if Executive would thereby be in a
better after-tax position, the Company may elect, in the Company&rsquo;s sole discretion, to reduce the amounts payable under this Agreement
or otherwise, or to have any portion of applicable options or restricted stock not vest or become exercisable, in order to avoid any &ldquo;excess
parachute payment&rdquo; under Section 280G(b)(1) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2&nbsp;<U>Calculation
b</U>y <U>Independent Public Accountants</U>. Unless the Company and the Executive otherwise agree in writing, any calculation of the
amount of any excess parachute payments payable by the Executive shall be made in writing by the Company&rsquo;s independent public accountants
(the <B><I>&ldquo;Accountants&rdquo;) </I></B>whose conclusion shall be final and binding on the parties. For purposes of making such
calculations, the Accountants may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999
of the Code. The Company and the Executive shall furnish to the Accountants such information and documents as the Accountants may reasonably
request in order to make the required calculations. The Company shall bear all fees and expenses the Accountants may charge in connection
with these services, but the engagement of the Accountants for this purpose shall be pursuant to an agreement between the Executive and
the Accountants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">6.</TD><TD STYLE="text-align: justify"><U>DEFINITIONS</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1&nbsp;<U>Capitalized
Terms Defined</U>. Capitalized terms used in this Agreement shall have the meanings set forth in this Section 4, unless the context clearly
requires a different meaning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2&nbsp;&ldquo;<U>Base
Salary</U>&rdquo; means the greater of (a) if applicable, the monthly salary of the Executive in effect immediately prior to the Change
of Control, or (b) the monthly salary of the Executive in effect immediately prior to the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3&nbsp;&ldquo;<U>Cause</U>&rdquo;
means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Executive willfully failed to follow the lawful written directions of the Board or the CEO; provided
that no termination for such Cause shall occur unless the Executive: (i) has been provided with notice, specifying such willful failure
in reasonable detail, of the Company&rsquo;s intention to terminate the Executive for Cause; and (ii) has failed to cure or correct such
willful failure within thirty (30) days of receiving such notice;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Executive engaged in gross misconduct, or gross incompetence which is materially detrimental to the
Company; provided that no termination for such Cause shall occur unless the Executive: (i) has been provided with notice, specifying such
gross misconduct or gross incompetence in reasonable detail, of the Company&rsquo;s intention to terminate the Executive for Cause; and
(ii) has failed to cure or correct such gross misconduct within thirty (30) days of receiving such notice;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the Executive willfully failed to comply in any material respect with the Employee Invention Assignment
&amp; Confidentiality Agreement, the Company&rsquo;s share dealing code, the Employee&rsquo;s non-competition agreement or any other reasonable
policies of the Company where non-compliance would be materially detrimental to the Company; provided that no termination for such Cause
shall occur unless the Executive: (i) has been provided with notice of the Company&rsquo;s intention to terminate the Executive for such
Cause, and (ii) has failed to cure or correct such willful failure within thirty (30) days of receiving such notice, provided that such
notice and cure period requirements shall not apply in the event that such non-compliance is of a nature that it is unable to be remedied;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(d)</TD><TD STYLE="text-align: justify">is convicted of a felony or crime involving moral turpitude (excluding drunk driving unless combined with
other aggravating circumstances or offenses) or commission of a fraud which the Company reasonably believes would reflect adversely on
the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.4&nbsp;&ldquo;<U>Change
of Control</U>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">any &ldquo;person&rdquo; (as such tennis used in Sections 13(d) and 14(d) of the Securities Exchange Act
of 1934, as amended (the <B><I>&ldquo;Exchange Act&rdquo;)</I></B><I>) </I>becomes the &ldquo;beneficial owner&rdquo; (as defined in Rule
l 3d-3 promulgated under the Exchange Act), directly or indirectly, of securities of the Company representing fifty (50%) percent or more
of (i) the outstanding shares of common stock of the Company, or (ii) the combined voting power of the Company&rsquo;s outstanding securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Company is party to a merger or consolidation, or series of related transactions, which results in
the voting securities of the Company outstanding immediately prior thereto failing to continue to represent (either by remaining outstanding
or by being converted into voting securities of the surviving entity), directly or indirectly, at least fifty (50%) percent of the combined
voting power of the voting securities of the Company or such surviving entity outstanding immediately after such merger or consolidation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the sale or disposition of all or substantially all of the Company&rsquo;s assets, or consummation of
any transaction, or series of related transactions, having similar effect (other than to a subsidiary of the Company).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything contained
herein to the contrary, the Merger shall not constitute a Change of Control for purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.5&nbsp;&ldquo;<U>Company</U>&rdquo;
shall mean Avalon GloboCare Corp. and any Successor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.6&nbsp;&ldquo;<U>Involuntary
Termination</U>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">any termination without Cause of the employment of the Executive by the Company; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">any resignation by Executive for Good Reason where such resignation occurs within one hundred twenty (120)
days following the occurrence of such Good Reason.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
the term &ldquo;Involuntary Termination&rdquo; shall not include any termination of the employment of the Executive: (1) by the Company
for Cause; (2) by the Company as a result of the Permanent Disability of the Executive; (3) as a result of the death of the Executive;
(4) that occurs within the period of time to qualify as a &ldquo;Termination Upon Change of Control&rdquo;; or (5) as a result of the
voluntary termination of employment by the Executive for any reason other than Good Reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.7&nbsp;&ldquo;<U>Good
Reason</U>&rdquo; means the occurrence of any of the following conditions, without the Executive&rsquo;s written consent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Any act, set of facts or omissions with respect to the Executive that would, as a matter of applicable
law, constitute a constructive termination of the Executive.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The assignment to the Executive of a title, position, responsibilities or duties that is not a &ldquo;Substantive
Functional Equivalent&rdquo; to the title, position, responsibilities or duties which the Executive had immediately prior to such assignment
(including, as relevant, immediately prior to the public announcement of the Change of Control).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(c)</TD><TD STYLE="text-align: justify">A reduction in the Executive&rsquo;s Base Salary or, if applicable, target bonus opportunity (subject
to applicable performance requirements with respect to the actual amount of bonus compensation earned similar to the applicable performance
requirements currently in effect), and in the event of a Change of Control, as compared to Executive&rsquo;s Base Salary and target bonus
opportunity in effect immediately prior to the public announcement of the Change of Control; provided, however, that this clause (c) shall
not apply in the event of a reduction in the Executive&rsquo;s Base Salary or, if applicable, target bonus opportunity as part of a Company-wide
or executive team-wide cost-cutting measure or Company-wide or executive team-wide cutback as a result of overall Company performance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The failure of the Company (i) to continue to provide the Executive an opportunity to participate in any
benefit or compensation plans provided to employees who hold positions with the Company comparable to the Executive&rsquo;s position,
(ii) to provide the Executive all other fringe benefits (or the equivalent) in effect for the benefit of any employee group which includes
any employee who hold a position with the Company comparable to the Executive&rsquo;s position, where in the event of a Change of Control,
such comparison shall be made relative to the time immediately prior to the public announcement of such Change of Control); or (iii) continue
to provide director&rsquo;s and officers&rsquo; insurance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(e)</TD><TD STYLE="text-align: justify">A material breach of this Agreement by the Company, including, in the event of a Change of Control, failure
of the Company to obtain the consent of a Successor to perform all of the obligations of the Company under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(f)</TD><TD STYLE="text-align: justify">The Company&rsquo;s failure to provide full and transparent access to all material financial. operational
and transactional activities of its executives, board of directors, subsidiaries or joint ventures as it relates to the Company, which
such failure continues for a period of a minimum of 60 days following Executive&rsquo;s written request to receive information or documentation
pertaining to the aforementioned items <B><I>(&ldquo;Internal Control Event&rdquo;).</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Executive must first give
the Company an opportunity to cure any of the foregoing within thirty (30) days following delivery to the Company of a written explanation
specifying the specific basis for Executive&rsquo;s belief that Executive is entitled to terminate employment for Good Reason, and Executive
terminates employment with the Company not later than (30) days following the Company&rsquo;s failure to cure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.8&nbsp;&ldquo;<U>Permanent
Disability</U>&rdquo; means that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Executive has been incapacitated by bodily injury, illness or disease so as to be prevented thereby
from engaging in the performance of the Executive&rsquo;s duties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">such total incapacity shall have continued for a period of six consecutive months; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(c)</TD><TD STYLE="text-align: justify">such incapacity will, in the opinion of a qualified physician, be permanent and continuous during the
remainder of the Executive&rsquo;s life.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.9&nbsp;&ldquo;<U>Substantive
Functional Equivalent</U>&rdquo; means that the Executive&rsquo;s position must:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">be in a substantive area of the Executive&rsquo;s competence (e.g., finance or executive management) and
not materially different from the position occupied immediately prior;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">allow the Executive to serve in a role and perform duties functionally equivalent to those performed immediately
prior; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">not otherwise constitute a material, adverse change in authority, title, status, responsibilities or duties
from those of the Executive immediately prior, causing the Executive to be of materially lesser rank or responsibility, including requiring
the Executive to report to a person other than the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.10&nbsp;&ldquo;<U>Successor</U>&rdquo;
means any successor in interest to, or assignee of, substantially all of the business and assets of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.11&nbsp;&ldquo;<U>Termination
Date</U>&rdquo; means the date of the termination of the Executive&rsquo;s employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.12&nbsp;&ldquo;<U>Termination
Upon Change of Control</U>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">any termination of the employment of the Executive by the Company without Cause during the period commencing
on or after the date that the Company first publicly announces a definitive agreement that results in a Change of Control (even though
still subject to approval by the Company&rsquo;s stockholders and other conditions and contingencies, but provided that the Change of
Control actually occurs) and ending on the date which is twelve (12) months following the Change of Control; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">any resignation by Executive for Good Reason where (i) such Good Reason occurs during the period commencing
on or after the date that the Company first publicly announces a definitive agreement that results in a Change of Control (even though
still subject to approval by the Company&rsquo;s stockholders and other conditions and contingencies, but provided that the Change of
Control actually occurs) and ending on the date which is twelve (12) months following the Change of Control, and (ii) such resignation
occurs at or after such Change of Control and in any event within six (6) months following the occurrence of such Good Reason.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
the term &ldquo;Termination Upon Change of Control&rdquo; shall not include any termination of the employment of the Executive: (1) by
the Company for Cause; (2) by the Company as a result of the Permanent Disability of the Executive; (3) as a result of the death of the
Executive; or (4) as a result of the voluntary termination of employment by the Executive for any reason other than Good Reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">7.</TD><TD STYLE="text-align: justify"><U>EXCLUSIVE REMEDY</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.1&nbsp;<U>No
Other Benefits Payable</U>. The Executive shall be entitled to no other termination, severance or change of control compensation, benefits,
or other payments from the Company as a result of any termination with respect to which the payments and benefits described in Section
2 have been provided to the Executive, except as expressly set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.2&nbsp;<U>No
Limitation of Regular Benefit Plans</U>. Except as may be provided elsewhere in this Agreement, this Agreement is not intended to and
shall not affect, limit or terminate any plans, programs or arrangements of the Company that are regularly made available to a significant
number of employees or officers of the Company, including, without limitation, the Company&rsquo;s stock option plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.3&nbsp;<U>Release
of Claims</U>. The payment of the benefits described in Sections 3 and 4 of this Agreement is conditioned upon the delivery by the Executive
to the Company of a signed and effective general release of claims as provided by the Company; provided, however, that the Executive shall
not be required to release any rights the Executive may have to be indemnified by the Company or as otherwise provided under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.4&nbsp;<U>Non-accumulation
of Benefits</U>. The Executive may not cumulate cash severance payments, stock option vesting and exercisability and restricted stock
vesting under this Agreement, any other written agreement with the Company and/or another plan or policy of the Company. If the Executive
has any other binding written agreement with the Company which provides that, upon a Change of Control or Termination Upon a Change of
Control or Involuntary Termination, the Executive shall receive termination, severance or similar benefits, then no benefits shall be
received by Executive under this Agreement unless, prior to payment or receipt of benefits under this Agreement, the Executive waives
Executive&rsquo;s rights to all such other benefits, in which case this Agreement shall supersede any such written agreement with respect
to such other benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">8.</TD><TD STYLE="text-align: justify"><U>NON-COMPETE; PROPRIETARY AND CONFIDENTIAL INFORMATION</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the term of this Agreement and following
any termination of employment, Executive agrees to continue to abide by the terms and conditions of each of the non-competition agreement
(during the term of such Agreement) and the Employee Invention Assignment &amp; Confidentiality Agreement between the Executive and the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">9.</TD><TD STYLE="text-align: justify"><U>ARBITRATION</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1&nbsp;<U>Disputes
Sub</U>j<U>ect to Arbitration</U>. Any claim, dispute or controversy arising out of this Agreement (other than claims relating to misuse
or misappropriation of the intellectual property of the Company), the interpretation, validity or enforceability of this Agreement or
the alleged breach thereof shall be submitted by the parties to binding arbitration by a sole arbitrator under the rules of the American
Arbitration Association; provided, however, that (a) the arbitrator shall have no authority to make any ruling or judgment that would
confer any rights with respect to the trade secrets, confidential and proprietary information or other intellectual property of the Company
upon the Executive or any third party; and (b) this arbitration provision shall not preclude the Company from seeking legal and equitable
relief from any court having jurisdiction with respect to any disputes or claims relating to or arising out of the misuse or misappropriation
of the Company&rsquo;s intellectual property. Judgment may be entered on the award of the arbitrator in any court having jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.2&nbsp;<U>Costs
of Arbitration</U>. All costs of arbitration, including reasonable attorney&rsquo;s fees of the Executive, will be borne by the Company,
except that if the Executive initiates arbitration and the arbitrator finds the Executive&rsquo;s claims to be frivolous the Executive
shall be responsible for her own costs and attorneys fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.3&nbsp;<U>Site
of Arbitration</U>. The site of the arbitration proceeding shall be in New York City, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">10.</TD><TD STYLE="text-align: justify"><U>NOTICES</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this Agreement, notices and all
other communications provided for in the Agreement shall be in writing and shall be deemed to have been duly given when delivered or five
(5) business days after being mailed, return receipt requested, as follows: (a) if to the Company, attention: Chief Executive Officer,
at the Company&rsquo;s offices at 4400 Route 9 South, Suite 3100, Freehold, New Jersey 07728 and, (b) if to the Executive, at the address
indicated below or such other address specified by the Executive in writing to the Company. Either party may provide the other with notices
of change of address, which shall be effective upon receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">11.</TD><TD STYLE="text-align: justify"><U>MISCELLANEOUS PROVISIONS</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.1&nbsp;<U>Heirs
and Representatives of the Executive; Successors and Ass</U>ig<U>ns of the Compan</U>y. This Agreement shall be binding upon and shall
inure to the benefit of and be enforceable by the Executive&rsquo;s personal and legal representatives, executors, administrators, successors,
heirs, distributees, devises and legatees. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the
successors and assigns of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.2&nbsp;<U>Amendment
and Waiver</U>. No provision of this Agreement shall be modified, amended, waived or discharged unless the modification, amendment, waiver
or discharge is agreed to in writing, specifying such modification, amendment, waiver or discharge, and signed by the Executive and by
an authorized officer of the Company (other than the Executive). No waiver by either party of any breach of, or of compliance with, any
condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the
same condition or provision at another time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.3&nbsp;<U>Withholding
Taxes</U>. All payments made under this Agreement shall be subject to deduction of all federal, state, local and other taxes required
to be withheld by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.4&nbsp;<U>Severabilit</U>y.
The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of
any other provision hereof, which shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.5&nbsp;<U>Choice
of Law</U>. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of
New Jersey, without regard to where the Executive has her residence or principal office or where she performs her duties hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.6&nbsp;<U>No
Du</U>ty <U>to Mitigate</U>. The Executive is not required to seek alternative employment following termination, and payments called for
under this Agreement will not be reduced by earnings from any other source.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.7&nbsp;<U>Section
409A of the Code</U>. To the extent (a) any payments or benefits to which Employee becomes entitled under this Agreement, or under any
agreement or plan referenced herein, in connection with Employee&rsquo;s termination of employment with the Company constitute deferred
compensation subject to Section 409A of the Code and (b) Employee is deemed at the time of such termination of employment to be a &ldquo;specified
employee&rdquo; under Section 409A of the Code, then such payments shall not be made or commence until the earliest of (i) the expiration
of the six (6)-month period measured from the date of Employee&rsquo;s &ldquo;separation from service&rdquo; (as such term is at the time
defined in Treasury Regulations under Section 409A of the Code) from the Company; or (ii) the date of Employee&rsquo;s death following
such separation from service; provided, however, that such deferral shall only be effected to the extent required to avoid adverse tax
treatment to Employee, including (without limitation) the additional twenty percent (20%) tax for which Employee would otherwise be liable
under Section 409A(a)(l)(B) of the Code in the absence of such deferral. Upon the expiration of the applicable deferral period, any payments
which would have otherwise been made during that period (whether in a single sum or in installments) in the absence of this paragraph
shall be paid to Employee or Employee&rsquo;s beneficiary in one lump sum (without interest). Any termination of Employee&rsquo;s employment
is intended to constitute a &ldquo;separation from service&rdquo; as such term is defined in Treasury Regulation Section 1.409A-1. It
is intended that each installment of the payments provided hereunder constitute separate &ldquo;payments&rdquo; for purposes of Treasury
Regulation Section l.409A-2(b)(2)(i). It is further intended that payments hereunder satisfy, to the greatest extent possible, the exemption
from the application of Code Section 409A (and any state law of similar effect) provided under Treasury Regulation Section l.409A-l(b)(4)
(as a &ldquo;short-term deferral&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.8&nbsp;<U>Entire
Agreement</U>. This Agreement represents the entire agreement and understanding between the parties as to the subject matter herein (whether
oral or written and whether express or implied).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[SIGNATURE PAGE FOLLOWS]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Options: NewSection; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-variant: small-caps">In
Witness Whereof</FONT>, each of the parties has executed this Agreement, in the case of the Company, by its duly authorized officer, as
of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Executive</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: Black 1.5pt solid"><B>Luisa Ingargiola</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Avalon GloboCare Corp.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>Title</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.112
<SEQUENCE>3
<FILENAME>ea024503201ex10-112_avalon.htm
<DESCRIPTION>WONG COMBINED COMPANY EXECUTIVE RETENTION AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 10.112</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMENDED AND RESTATED EXECUTIVE RETENTION AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Amended and Restated
Executive Retention Agreement (the <B><I>&ldquo;Agreement&rdquo;) </I></B>is made and entered into by and between YOOV, a Singapore corporation
(the <B><I>&ldquo;Company&rdquo;) </I></B>and Phil Wong (the <B><I>&ldquo;Executive&rdquo;) </I></B>as of _______________, 2025 to be
effective upon the &ldquo;Merger&rdquo; (defined below) (the &ldquo;<B><I>Effective Date</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Recitals:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Executive is
a key employee of the Company who possesses valuable proprietary knowledge of the Company, its business and operations and the markets
in which the Company competes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Executive and
the Company have entered into that certain Executive Retention Agreement dated as of ______________ (the &ldquo;<B><I>Prior Agreement,</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company, Nexus
MergerSub Limited, a business company incorporated in the British Virgin Islands and a wholly owned subsidiary of the Company (&ldquo;<B><I>Merger
Sub</I></B>&rdquo;) and YOOV Group Holding Limited, a business company incorporated in the British Virgin Islands (&ldquo;<B><I>YOOV</I></B>&rdquo;),
entered into an Agreement and Plan of Merger, dated March 7, 2025, pursuant to which Merger Sub will merge with and into YOOV, with YOOV
surviving the merger and becoming a wholly owned direct subsidiary of Avalon (the &ldquo;<B><I>Merger</I></B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company and the
Executive desire to enter into this Agreement to encourage the Executive to continue to devote the Executive&rsquo;s full attention, except
to the extent that Executive serves as a member of the Board of Directors for other companies, and dedication to the success of the Company
following the Merger, and to provide specified compensation and benefits to the Executive in the event of a Termination Upon Change of
Control or certain other terminations pursuant to the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, THE PARTIES
HEREBY AGREE AS FOLLOWS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><U>PURPOSE AND TERM; Effectiveness; DUTIES</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1&nbsp;The
purpose of this Agreement is to provide specified compensation and benefits to the Executive in the event of (i) a Termination Upon Change
of Control or (ii) an Involuntary Termination. Subject to the terms of any applicable written employment agreement between Company and
the Executive (as to which Executive acknowledges no other such agreement exists as of the date hereof), either the Executive or Company
may terminate the Executive&rsquo;s employment at any time for any reason, with or without notice. The term of this Agreement shall be
the period from the date set forth above until Executive&rsquo;s employment is terminated for any reason or this Agreement is terminated
by mutual agreement of the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2&nbsp;The
effectiveness of this Agreement is contingent on the closing of the Merger. If the closing of the Merger does not occur, this Agreement
shall be void and of no further force or effect, and the Prior Agreement shall remain in effect in accordance with its terms. Upon closing
of the Merger, this Agreement shall supersede the Prior Agreement and the Prior Agreement shall cease to be of any force or effect. For
avoidance of doubt, in the event the closing of the Merger occurs and the Executive continues in employment with the Company as of the
date of such closing, the Executive shall not be entitled to any termination payments or benefits under the Prior Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.3&nbsp;The Executive shall
be employed as the Company&rsquo;s Chief Executive Officer. The Executive&rsquo;s job responsibilities will comprise managing and overseeing
all Company operations and executing on the strategy set by the Company&rsquo;s Board of Directors including but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">1.3.1. Strategic Leadership</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">1.3.2. Product &amp; Technology
Oversight</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">1.3.3. Go-to-Market &amp; Customer
Success</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">1.3.4. Operations &amp; Scaling</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">1.3.5. Team Leadership &amp; Culture</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">1.3.6. Financial Stewardship</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">1.3.7. External Relations &amp;
Thought Leadership</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">1.3.8. Corporate Governance &amp;
Risk Management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.4&nbsp;The
Executive will be permitted to work from Asia. As part of the Executive&rsquo;s duties, the Executive will be required to travel to the
Company&rsquo;s offices. The Executive is entitled to four (4) weeks of vacation which will accrue on a pro-rata basis during the year,
in addition to all public holidays when the office is closed. The Executive will be eligible to participate in all employee benefit plans
established by the Company for its employees from time to time. In accordance with Company policies from time to time, the Company will
reimburse the Executive for all reasonable and proper travel and business expenses incurred by the Executive in the performance of his
duties. Any air travel of over 5 hours in length will be reimbursed as First Class or Business Class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">2.</TD><TD STYLE="text-align: justify"><U>COMPENSATION AND TERMINATION GENERALLY</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1&nbsp;<U>Compensation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.1&nbsp;<U>Annual
Salar</U>y. The Executive&rsquo;s base salary shall be $360,000 per annum, subject to periodic review and modification by the Board or
the Compensation Committee of the Board (references herein to the Compensation Committee shall include reference to the Board if no such
Committee exists at any time) at such time or times as it shall determine. The Company&rsquo;s Compensation Committee shall also from
time to time, in its discretion, determine the type and amount of other forms of compensation for the Executive&rsquo;s service with the
Company (including, without limitation, stock options or other forms of equity awards).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.2&nbsp;<U>Sign-On
Bonus</U>. Following the closing of the Merger, the Company shall pay the Executive a lump sum payment in the amount of ($360,000.00).
This will be paid upon determination by the Chief Financial Officer that there is sufficient cash available for this payment but in no
event will it be more than 12 months from the date of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.3&nbsp;<U>Performance
Bonuses</U>. Executive will be eligible for annual bonuses, as determined by the Board or the Compensation Committee of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.4&nbsp;<U>Options</U>.
Within thirty (30) days following the Effective Date, the Executive will be granted an option to purchase 1,000,000 shares of the Company&rsquo;s
common stock, vesting over three (3) years, one third on the first anniversary of the Effective Date and the balance in equal quarterly
installments. The exercise price of such option shall be equal to the closing price of the Company&rsquo;s common stock on the date of
grant. The Executive may be eligible for additional equity incentive grants, subject to Executive&rsquo;s continued employment and satisfactory
job performance, which may be made from time to time, by the Board or the Compensation Committee of the Board, on the same terms as other
executive employees of the Company. Terms and conditions of all the equity incentive grants, will be in accordance with the terms of the
Company&rsquo;s Equity Incentive Plan in effect at the time of each such grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2&nbsp;<U>Termination
of Employment Generall</U>y. In the event the Executive&rsquo;s employment with the Company terminates, for any reason whatsoever including
death or disability the Executive shall be entitled to the benefits described in this Section 2.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.1&nbsp;<U>Accrued
Salar</U>y <U>and Vacation</U>. All salary and accrued vacation earned through the Termination Date shall be paid to Executive on such
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.2&nbsp;<U>Accrued
Bonus Payment</U>. The Executive shall receive a lump sum payment of any actual bonus amount to the extent that all the conditions for
payment of such bonus have been satisfied and any such bonus was earned and is unpaid on the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.3&nbsp;<U>Expense
Reimbursement</U>. Within ten (10) days following submission to the Company of proper expense reports by the Executive, the Company shall
reimburse the Executive for all expenses incurred by the Executive, consistent with the Company&rsquo;s expense reimbursement policy in
effect prior to the incurring of each such expense, in connection with the business of the Company prior to the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.4&nbsp;<U>Equi</U>ty
<U>Compensation</U>. The period during which the Executive may exercise any rights under any outstanding stock options and stock appreciation
rights, and the extent to which any outstanding shares of restricted stock, restricted stock units and any other equity award shall vest,
shall be determined under the terms of the Equity Incentive Plan under which they were granted and the applicable option or award agreements
governing such grants, but in no event will they be less than 5 years post termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">3.</TD><TD STYLE="text-align: justify"><U>TERMINATION UPON CHANGE OF CONTROL</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;<U>Severance
Payment</U>. In the event of the Executive&rsquo;s Termination Upon Change of Control, the Executive shall be entitled to receive an amount
equal to the amount set forth in Section 4.1 which shall be paid according to the following schedule: (i) a lump sum payment equal to
one-half of such amount shall be payable within ten (10) days following the Termination Date, and (ii) one-third of the balance of such
amount shall be payable within ten (10) days of each of the three-month, six-month and nine-month anniversaries of the Termination Date
(and in each case no interest shall accrue on such amount); provided, however, that if Section 409A of the Code would otherwise apply
to such cash severance payment, it instead shall be paid at such time as permitted by Section 409A of the Code. In addition to the foregoing
severance payment, in the event of the Executive&rsquo;s Termination Upon Change of Control, the Executive shall be entitled to receive,
within ten (10) days following the Termination Upon Change of Control, a lump sum payment equal to one hundred percent (100%) of (a) any
actual bonus amount earned with respect to a previous year to the extent that all the conditions for payment of such bonus have been satisfied
(excluding any requirement to be in employment with the Company as of a given date which is after the Termination Date) and any such bonus
was earned but is unpaid on the Termination Date; and (b) the target bonus then in effect for the Executive for the year in which such
termination occurs, such payment to be prorated to reflect the number of days the Executive remained in the employ of the Company; provided,
however, that if Section 409A of the Code would otherwise apply to such cash payment, it instead shall be paid at such time as permitted
by Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2&nbsp;<U>Equity
Compensation Acceleration</U>. Upon the Executive&rsquo;s Termination Upon Change of Control, the vesting and exercisability of all then
outstanding stock options and shares of restricted stock (or any other equity award, including, without limitation, stock appreciation
rights and restricted stock units) granted to the Executive under any Equity Incentive Plan shall be accelerated as to 100% of the shares
subject to any such equity awards granted to the Executive. In addition, the applicable exercise period of the Executive&rsquo;s stock
options granted under the Equity Incentive Plan(s) shall be extended so as to expire on the last day of the term applicable to such stock
option, as measured from the date of Termination Upon Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3&nbsp;<U>COBRA</U>.
If the Executive timely elects coverage under the Consolidated Budget Reconciliation Act of 1985, as amended <B><I>(&ldquo;COBRA&rdquo;),
</I></B>the Company shall continue to provide to the Executive, at the Company&rsquo;s expense, the Company&rsquo;s health-related employee
insurance coverage for the employee only as in effect immediately prior to the Executive&rsquo;s Termination Upon Change of Control for
a period of twelve (12) months following such Termination Upon Change of Control. The date of the &ldquo;qualifying event&rdquo; for the
Executive and any dependents shall be the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4&nbsp;<U>Indemnification</U>.
In the event of the Executive&rsquo;s Termination Upon Change of Control, (a) the Company shall continue to indemnify the Executive against
all claims related to actions arising prior to the termination of the Executive&rsquo;s employment to the fullest extent permitted by
law, and (b) if the Executive was covered by the Company&rsquo;s directors&rsquo; and officers&rsquo; insurance policy, or an equivalent
thereto, (the <B><I>&ldquo;D&amp;O Insurance Policy&rdquo;) </I></B>immediately prior to the Change of Control, the Company or its Successor
shall continue to provide coverage under a D&amp;O Insurance Policy for not less than twenty-four (24) months following the Executive&rsquo;s
Termination Upon Change of Control on substantially the same terms of the D&amp;O Insurance Policy in effect immediately prior to the
Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">4.</TD><TD STYLE="text-align: justify"><U>INVOLUNTARY TERMINATION</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1&nbsp;<U>Severance
Payment</U>. In the event of the Executive&rsquo;s Involuntary Termination, the Executive shall be entitled to receive an amount equal
to twenty four (24) months of the Executive&rsquo;s Base Salary, which shall be paid within ten (10) days following the Termination Date.
In addition to the foregoing severance payment, in the event of the Executive&rsquo;s Involuntary Termination, the Executive shall be
entitled to receive, within ten (10) days following the Executive&rsquo;s Involuntary Termination, a lump sum payment equal to one hundred
percent (100%) of (a) any actual bonus amount earned with respect to a previous year to the extent that all the conditions for payment
of such bonus have been satisfied (excluding any requirement to be in employment with the Company as of a given date which is after the
Termination Date) and any such bonus was earned but is unpaid on the Termination Date; and (b) the target bonus then in effect for the
Executive for the year in which such termination occurs, such payment to be prorated to reflect the number of days the Executive remained
in the employ of the Company; provided, however, that if Section 409A of the Code would otherwise apply to such cash payment, it instead
shall be paid at such time as permitted by Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2&nbsp;<U>Equity
Compensation Acceleration</U>. Upon the Executive&rsquo;s Involuntary Termination, the vesting and exercisability of all then outstanding
stock options and shares of restricted stock (or any other equity award, including, without limitation, stock appreciation rights and
restricted stock units) granted to the Executive under any Equity Incentive Plan shall be accelerated as to 100% of the shares subject
to any such equity awards granted to the Executive. In addition, the applicable exercise period of the Executive&rsquo;s stock options
granted under the Equity Incentive Plan(s) shall be extended so as to expire on the last day of the term applicable to such stock option,
as measured from the date of Involuntary Termination and Executive shall have 5 years to exercise any such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3&nbsp;<U>COBRA</U>.
In the event of the Executive&rsquo;s Involuntary Termination, if the Executive timely elects coverage under COBRA, the Company shall
continue to provide to the Executive, at the Company&rsquo;s expense, the Company&rsquo;s health-related employee insurance coverage for
the employee only as in effect immediately prior to the Executive&rsquo;s Involuntary Termination for a period of twelve (12) months following
such Involuntary Termination. The date of the &ldquo;qualifying event&rdquo; for the Executive and any dependents shall be the Termination
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4&nbsp;<U>Indemnification</U>.
In the event of the Executive&rsquo;s Involuntary Termination, (a) the Company shall continue to indemnify the Executive against all claims
related to actions arising prior to the Termination Date to the fullest extent permitted by law, and (b) if the Executive was covered
by the D&amp;O Insurance Policy immediately prior to the Termination Date, the Company shall continue to provide coverage under a D&amp;O
Insurance Policy for not less than twenty-four (24) months following the Executive&rsquo;s Involuntary Termination on substantially the
same terms of the D&amp;O Insurance Policy in effect immediately prior to the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">5.</TD><TD STYLE="text-align: justify"><U>FEDERAL EXCISE TAX UNDER SECTION 280G</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1&nbsp;<U>Excise
Tax</U>. If (a) any amounts payable to the Executive under this Agreement or otherwise are characterized as excess parachute payments
pursuant to Section 4999 of the Internal Revenue Code of 1986, as amended (the <B><I>&ldquo;Code&rdquo;), </I></B>and (b) the Executive
thereby would be subject to any United States federal excise tax due to that characterization, then if Executive would thereby be in a
better after-tax position, the Company may elect, in the Company&rsquo;s sole discretion, to reduce the amounts payable under this Agreement
or otherwise, or to have any portion of applicable options or restricted stock not vest or become exercisable, in order to avoid any &ldquo;excess
parachute payment&rdquo; under Section 280G(b)(1) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2&nbsp;<U>Calculation
b</U>y <U>Independent Public Accountants</U>. Unless the Company and the Executive otherwise agree in writing, any calculation of the
amount of any excess parachute payments payable by the Executive shall be made in writing by the Company&rsquo;s independent public accountants
(the <B><I>&ldquo;Accountants&rdquo;) </I></B>whose conclusion shall be final and binding on the parties. For purposes of making such
calculations, the Accountants may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999
of the Code. The Company and the Executive shall furnish to the Accountants such information and documents as the Accountants may reasonably
request in order to make the required calculations. The Company shall bear all fees and expenses the Accountants may charge in connection
with these services, but the engagement of the Accountants for this purpose shall be pursuant to an agreement between the Executive and
the Accountants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">6.</TD><TD STYLE="text-align: justify"><U>DEFINITIONS</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1&nbsp;<U>Capitalized
Terms Defined</U>. Capitalized terms used in this Agreement shall have the meanings set forth in this Section 4, unless the context clearly
requires a different meaning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2&nbsp;&ldquo;<U>Base
Salary</U>&rdquo; means the greater of (a) if applicable, the monthly salary of the Executive in effect immediately prior to the Change
of Control, or (b) the monthly salary of the Executive in effect immediately prior to the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3&nbsp;&ldquo;<U>Cause</U>&rdquo;
means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Executive willfully failed to follow the lawful written directions of the Board; provided that no
termination for such Cause shall occur unless the Executive: (i) has been provided with notice, specifying such willful failure in reasonable
detail, of the Company&rsquo;s intention to terminate the Executive for Cause; and (ii) has failed to cure or correct such willful failure
within thirty (30) days of receiving such notice;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Executive engaged in gross misconduct, or gross incompetence which is materially detrimental to the
Company; provided that no termination for such Cause shall occur unless the Executive: (i) has been provided with notice, specifying such
gross misconduct or gross incompetence in reasonable detail, of the Company&rsquo;s intention to terminate the Executive for Cause; and
(ii) has failed to cure or correct such gross misconduct within thirty (30) days of receiving such notice;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the Executive willfully failed to comply in any material respect with the Employee Invention Assignment
&amp; Confidentiality Agreement, the Company&rsquo;s share dealing code, the Employee&rsquo;s non-competition agreement or any other reasonable
policies of the Company where non-compliance would be materially detrimental to the Company; provided that no termination for such Cause
shall occur unless the Executive: (i) has been provided with notice of the Company&rsquo;s intention to terminate the Executive for such
Cause, and (ii) has failed to cure or correct such willful failure within thirty (30) days of receiving such notice, provided that such
notice and cure period requirements shall not apply in the event that such non-compliance is of a nature that it is unable to be remedied;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">is convicted of a felony or crime involving moral turpitude (excluding drunk driving unless combined with
other aggravating circumstances or offenses) or commission of a fraud which the Company reasonably believes would reflect adversely on
the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.4&nbsp;&ldquo;<U>Change
of Control</U>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">any &ldquo;person&rdquo; (as such tennis used in Sections 13(d) and 14(d) of the Securities Exchange Act
of 1934, as amended (the <B><I>&ldquo;Exchange Act&rdquo;)</I></B><I>) </I>becomes the &ldquo;beneficial owner&rdquo; (as defined in Rule
l 3d-3 promulgated under the Exchange Act), directly or indirectly, of securities of the Company representing fifty (50%) percent or more
of (i) the outstanding shares of common stock of the Company, or (ii) the combined voting power of the Company&rsquo;s outstanding securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Company is party to a merger or consolidation, or series of related transactions, which results in
the voting securities of the Company outstanding immediately prior thereto failing to continue to represent (either by remaining outstanding
or by being converted into voting securities of the surviving entity), directly or indirectly, at least fifty (50%) percent of the combined
voting power of the voting securities of the Company or such surviving entity outstanding immediately after such merger or consolidation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the sale or disposition of all or substantially all of the Company&rsquo;s assets, or consummation of
any transaction, or series of related transactions, having similar effect (other than to a subsidiary of the Company).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything contained
herein to the contrary, the Merger shall not constitute a Change of Control for purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.5&nbsp;&ldquo;<U>Company</U>&rdquo;
shall mean Avalon GloboCare Corp. and YOOV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.6&nbsp;&ldquo;<U>Involuntary
Termination</U>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">any termination without Cause of the employment of the Executive by the Company; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">any resignation by Executive for Good Reason where such resignation occurs within one hundred twenty (120)
days following the occurrence of such Good Reason.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
the term &ldquo;Involuntary Termination&rdquo; shall not include any termination of the employment of the Executive: (1) by the Company
for Cause; (2) by the Company as a result of the Permanent Disability of the Executive; (3) as a result of the death of the Executive;
(4) that occurs within the period of time to qualify as a &ldquo;Termination Upon Change of Control&rdquo;; or (5) as a result of the
voluntary termination of employment by the Executive for any reason other than Good Reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.7&nbsp;&ldquo;<U>Good
Reason</U>&rdquo; means the occurrence of any of the following conditions, without the Executive&rsquo;s written consent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Any act, set of facts or omissions with respect to the Executive that would, as a matter of applicable
law, constitute a constructive termination of the Executive.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The assignment to the Executive of a title, position, responsibilities or duties that is not a &ldquo;Substantive
Functional Equivalent&rdquo; to the title, position, responsibilities or duties which the Executive had immediately prior to such assignment
(including, as relevant, immediately prior to the public announcement of the Change of Control).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(c)</TD><TD STYLE="text-align: justify">A reduction in the Executive&rsquo;s Base Salary or, if applicable, target bonus opportunity (subject
to applicable performance requirements with respect to the actual amount of bonus compensation earned similar to the applicable performance
requirements currently in effect), and in the event of a Change of Control, as compared to Executive&rsquo;s Base Salary and target bonus
opportunity in effect immediately prior to the public announcement of the Change of Control; provided, however, that this clause (c) shall
not apply in the event of a reduction in the Executive&rsquo;s Base Salary or, if applicable, target bonus opportunity as part of a Company-wide
or executive team-wide cost-cutting measure or Company-wide or executive team-wide cutback as a result of overall Company performance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The failure of the Company (i) to continue to provide the Executive an opportunity to participate in any
benefit or compensation plans provided to employees who hold positions with the Company comparable to the Executive&rsquo;s position,
(ii) to provide the Executive all other fringe benefits (or the equivalent) in effect for the benefit of any employee group which includes
any employee who hold a position with the Company comparable to the Executive&rsquo;s position, where in the event of a Change of Control,
such comparison shall be made relative to the time immediately prior to the public announcement of such Change of Control); or (iii) continue
to provide director&rsquo;s and officers&rsquo; insurance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(e)</TD><TD STYLE="text-align: justify">A material breach of this Agreement by the Company, including, in the event of a Change of Control, failure
of the Company to obtain the consent of a Successor to perform all of the obligations of the Company under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">The Company&rsquo;s failure to provide full and transparent access to all material financial. operational
and transactional activities of its executives, board of directors, subsidiaries or joint ventures as it relates to the Company, which
such failure continues for a period of a minimum of 60 days following Executive&rsquo;s written request to receive information or documentation
pertaining to the aforementioned items <B><I>(&ldquo;Internal Control Event&rdquo;).</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Executive must first give
the Company an opportunity to cure any of the foregoing within thirty (30) days following delivery to the Company of a written explanation
specifying the specific basis for Executive&rsquo;s belief that Executive is entitled to terminate employment for Good Reason, and Executive
terminates employment with the Company not later than (30) days following the Company&rsquo;s failure to cure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.8&nbsp;&ldquo;<U>Permanent
Disability</U>&rdquo; means that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Executive has been incapacitated by bodily injury, illness or disease so as to be prevented thereby
from engaging in the performance of the Executive&rsquo;s duties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">such total incapacity shall have continued for a period of six consecutive months; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(c)</TD><TD STYLE="text-align: justify">such incapacity will, in the opinion of a qualified physician, be permanent and continuous during the
remainder of the Executive&rsquo;s life.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.9&nbsp;&ldquo;<U>Substantive
Functional Equivalent</U>&rdquo; means that the Executive&rsquo;s position must:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">be in a substantive area of the Executive&rsquo;s competence (e.g., finance or executive management) and
not materially different from the position occupied immediately prior;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">allow the Executive to serve in a role and perform duties functionally equivalent to those performed immediately
prior; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(c)</TD><TD STYLE="text-align: justify">not otherwise constitute a material, adverse change in authority, title, status, responsibilities or duties
from those of the Executive immediately prior, causing the Executive to be of materially lesser rank or responsibility, including requiring
the Executive to report to a person other than the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.10&nbsp;&ldquo;<U>Successor</U>&rdquo;
means any successor in interest to, or assignee of, substantially all of the business and assets of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.11&nbsp;&ldquo;<U>Termination
Date</U>&rdquo; means the date of the termination of the Executive&rsquo;s employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.12&nbsp;&ldquo;<U>Termination
Upon Change of Control</U>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">any termination of the employment of the Executive by the Company without Cause during the period commencing
on or after the date that the Company first publicly announces a definitive agreement that results in a Change of Control (even though
still subject to approval by the Company&rsquo;s stockholders and other conditions and contingencies, but provided that the Change of
Control actually occurs) and ending on the date which is twelve (12) months following the Change of Control; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">any resignation by Executive for Good Reason where (i) such Good Reason occurs during the period commencing
on or after the date that the Company first publicly announces a definitive agreement that results in a Change of Control (even though
still subject to approval by the Company&rsquo;s stockholders and other conditions and contingencies, but provided that the Change of
Control actually occurs) and ending on the date which is twelve (12) months following the Change of Control, and (ii) such resignation
occurs at or after such Change of Control and in any event within six (6) months following the occurrence of such Good Reason.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
the term &ldquo;Termination Upon Change of Control&rdquo; shall not include any termination of the employment of the Executive: (1) by
the Company for Cause; (2) by the Company as a result of the Permanent Disability of the Executive; (3) as a result of the death of the
Executive; or (4) as a result of the voluntary termination of employment by the Executive for any reason other than Good Reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">7.</TD><TD STYLE="text-align: justify"><U>EXCLUSIVE REMEDY</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.1&nbsp;<U>No
Other Benefits Payable</U>. The Executive shall be entitled to no other termination, severance or change of control compensation, benefits,
or other payments from the Company as a result of any termination with respect to which the payments and benefits described in Section
2 have been provided to the Executive, except as expressly set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.2&nbsp;<U>No
Limitation of Regular Benefit Plans</U>. Except as may be provided elsewhere in this Agreement, this Agreement is not intended to and
shall not affect, limit or terminate any plans, programs or arrangements of the Company that are regularly made available to a significant
number of employees or officers of the Company, including, without limitation, the Company&rsquo;s stock option plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.3&nbsp;<U>Release
of Claims</U>. The payment of the benefits described in Sections 3 and 4 of this Agreement is conditioned upon the delivery by the Executive
to the Company of a signed and effective general release of claims as provided by the Company; provided, however, that the Executive shall
not be required to release any rights the Executive may have to be indemnified by the Company or as otherwise provided under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.4&nbsp;<U>Non-accumulation
of Benefits</U>. The Executive may not cumulate cash severance payments, stock option vesting and exercisability and restricted stock
vesting under this Agreement, any other written agreement with the Company and/or another plan or policy of the Company. If the Executive
has any other binding written agreement with the Company which provides that, upon a Change of Control or Termination Upon a Change of
Control or Involuntary Termination, the Executive shall receive termination, severance or similar benefits, then no benefits shall be
received by Executive under this Agreement unless, prior to payment or receipt of benefits under this Agreement, the Executive waives
Executive&rsquo;s rights to all such other benefits, in which case this Agreement shall supersede any such written agreement with respect
to such other benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify"><U>NON-COMPETE; PROPRIETARY AND CONFIDENTIAL INFORMATION</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the term of this Agreement and following
any termination of employment, Executive agrees to continue to abide by the terms and conditions of each of the non-competition agreement
(during the term of such Agreement) and the Employee Invention Assignment &amp; Confidentiality Agreement between the Executive and the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">9.</TD><TD STYLE="text-align: justify"><U>ARBITRATION</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1&nbsp;<U>Disputes
Sub</U>j<U>ect to Arbitration</U>. Any claim, dispute or controversy arising out of this Agreement (other than claims relating to misuse
or misappropriation of the intellectual property of the Company), the interpretation, validity or enforceability of this Agreement or
the alleged breach thereof shall be submitted by the parties to binding arbitration by a sole arbitrator under the rules of the American
Arbitration Association; provided, however, that (a) the arbitrator shall have no authority to make any ruling or judgment that would
confer any rights with respect to the trade secrets, confidential and proprietary information or other intellectual property of the Company
upon the Executive or any third party; and (b) this arbitration provision shall not preclude the Company from seeking legal and equitable
relief from any court having jurisdiction with respect to any disputes or claims relating to or arising out of the misuse or misappropriation
of the Company&rsquo;s intellectual property. Judgment may be entered on the award of the arbitrator in any court having jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.2&nbsp;<U>Costs
of Arbitration</U>. All costs of arbitration, including reasonable attorney&rsquo;s fees of the Executive, will be borne by the Company,
except that if the Executive initiates arbitration and the arbitrator finds the Executive&rsquo;s claims to be frivolous the Executive
shall be responsible for her own costs and attorneys fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.3&nbsp;<U>Site
of Arbitration</U>. The site of the arbitration proceeding shall be in New York City, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">10.</TD><TD STYLE="text-align: justify"><U>NOTICES</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this Agreement, notices and all
other communications provided for in the Agreement shall be in writing and shall be deemed to have been duly given when delivered or five
(5) business days after being mailed, return receipt requested, as follows: (a) if to the Company, attention: and, (b) if to the Executive,
at the address indicated below or such other address specified by the Executive in writing to the Company. Either party may provide the
other with notices of change of address, which shall be effective upon receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: justify"><U>MISCELLANEOUS PROVISIONS</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.1&nbsp;<U>Heirs
and Representatives of the Executive; Successors and Ass</U>ig<U>ns of the Compan</U>y. This Agreement shall be binding upon and shall
inure to the benefit of and be enforceable by the Executive&rsquo;s personal and legal representatives, executors, administrators, successors,
heirs, distributees, devises and legatees. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the
successors and assigns of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.2&nbsp;<U>Amendment
and Waiver</U>. No provision of this Agreement shall be modified, amended, waived or discharged unless the modification, amendment, waiver
or discharge is agreed to in writing, specifying such modification, amendment, waiver or discharge, and signed by the Executive and by
an authorized officer of the Company (other than the Executive). No waiver by either party of any breach of, or of compliance with, any
condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the
same condition or provision at another time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.3&nbsp;<U>Withholding
Taxes</U>. All payments made under this Agreement shall be subject to deduction of all federal, state, local and other taxes required
to be withheld by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.4&nbsp;<U>Severabilit</U>y.
The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of
any other provision hereof, which shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.5&nbsp;<U>Choice
of Law</U>. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of
New Jersey, without regard to where the Executive has his residence or principal office or where she performs his duties hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.6&nbsp;<U>No
Du</U>ty <U>to Mitigate</U>. The Executive is not required to seek alternative employment following termination, and payments called for
under this Agreement will not be reduced by earnings from any other source.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.7&nbsp;<U>Section
409A of the Code</U>. To the extent (a) any payments or benefits to which Employee becomes entitled under this Agreement, or under any
agreement or plan referenced herein, in connection with Employee&rsquo;s termination of employment with the Company constitute deferred
compensation subject to Section 409A of the Code and (b) Employee is deemed at the time of such termination of employment to be a &ldquo;specified
employee&rdquo; under Section 409A of the Code, then such payments shall not be made or commence until the earliest of (i) the expiration
of the six (6)-month period measured from the date of Employee&rsquo;s &ldquo;separation from service&rdquo; (as such term is at the time
defined in Treasury Regulations under Section 409A of the Code) from the Company; or (ii) the date of Employee&rsquo;s death following
such separation from service; provided, however, that such deferral shall only be effected to the extent required to avoid adverse tax
treatment to Employee, including (without limitation) the additional twenty percent (20%) tax for which Employee would otherwise be liable
under Section 409A(a)(l)(B) of the Code in the absence of such deferral. Upon the expiration of the applicable deferral period, any payments
which would have otherwise been made during that period (whether in a single sum or in installments) in the absence of this paragraph
shall be paid to Employee or Employee&rsquo;s beneficiary in one lump sum (without interest). Any termination of Employee&rsquo;s employment
is intended to constitute a &ldquo;separation from service&rdquo; as such term is defined in Treasury Regulation Section 1.409A-1. It
is intended that each installment of the payments provided hereunder constitute separate &ldquo;payments&rdquo; for purposes of Treasury
Regulation Section l.409A-2(b)(2)(i). It is further intended that payments hereunder satisfy, to the greatest extent possible, the exemption
from the application of Code Section 409A (and any state law of similar effect) provided under Treasury Regulation Section l.409A-l(b)(4)
(as a &ldquo;short-term deferral&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.8&nbsp;<U>Entire
Agreement</U>. This Agreement represents the entire agreement and understanding between the parties as to the subject matter herein (whether
oral or written and whether express or implied).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>[SIGNATURE PAGE FOLLOWS]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-variant: small-caps"></FONT></P>

<!-- Field: Page; Sequence: 12; Options: NewSection; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-variant: small-caps">In
Witness Whereof</FONT>, each of the parties has executed this Agreement, in the case of the Company, by its duly authorized officer, as
of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Executive</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: Black 1.5pt solid"><B>Phil Wong</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Avalon GloboCare Corp.</B></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.113
<SEQUENCE>4
<FILENAME>ea024503201ex10-113_avalon.htm
<DESCRIPTION>MARK WONG COMBINED COMPANY EXECUTIVE RETENTION AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 10.113</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">AMENDED AND RESTATED EXECUTIVE RETENTION AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Amended and Restated
Executive Retention Agreement (the <B><I>&ldquo;Agreement&rdquo;) </I></B>is made and entered into by and between YOOV, a Singapore corporation
(the <B><I>&ldquo;Company&rdquo;) </I></B>and Mark Wong (the <B><I>&ldquo;Executive&rdquo;) </I></B>as of _______________, 2025 to be
effective upon the &ldquo;Merger&rdquo; (defined below) (the &ldquo;<B><I>Effective Date</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Recitals:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Executive is
a key employee of the Company who possesses valuable proprietary knowledge of the Company, its business and operations and the markets
in which the Company competes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Executive and
the Company have entered into that certain Executive Retention Agreement dated as of ______________ (the &ldquo;<B><I>Prior Agreement,</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company, Nexus
MergerSub Limited, a business company incorporated in the British Virgin Islands and a wholly owned subsidiary of the Company (&ldquo;<B><I>Merger
Sub</I></B>&rdquo;) and YOOV Group Holding Limited, a business company incorporated in the British Virgin Islands (&ldquo;<B><I>YOOV</I></B>&rdquo;),
entered into an Agreement and Plan of Merger, dated March 7, 2025, pursuant to which Merger Sub will merge with and into YOOV, with YOOV
surviving the merger and becoming a wholly owned direct subsidiary of Avalon (the &ldquo;<B><I>Merger</I></B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company and the
Executive desire to enter into this Agreement to encourage the Executive to continue to devote the Executive&rsquo;s full attention, except
to the extent that Executive serves as a member of the Board of Directors for other companies, and dedication to the success of the Company
following the Merger, and to provide specified compensation and benefits to the Executive in the event of a Termination Upon Change of
Control or certain other terminations pursuant to the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, THE PARTIES
HEREBY AGREE AS FOLLOWS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">1.</TD><TD STYLE="text-align: justify"><U>PURPOSE AND TERM; Effectiveness; DUTIES</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1&nbsp;The
purpose of this Agreement is to provide specified compensation and benefits to the Executive in the event of (i) a Termination Upon Change
of Control or (ii) an Involuntary Termination. Subject to the terms of any applicable written employment agreement between Company and
the Executive (as to which Executive acknowledges no other such agreement exists as of the date hereof), either the Executive or Company
may terminate the Executive&rsquo;s employment at any time for any reason, with or without notice. The term of this Agreement shall be
the period from the date set forth above until Executive&rsquo;s employment is terminated for any reason or this Agreement is terminated
by mutual agreement of the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2&nbsp;The
effectiveness of this Agreement is contingent on the closing of the Merger. If the closing of the Merger does not occur, this Agreement
shall be void and of no further force or effect, and the Prior Agreement shall remain in effect in accordance with its terms. Upon closing
of the Merger, this Agreement shall supersede the Prior Agreement and the Prior Agreement shall cease to be of any force or effect. For
avoidance of doubt, in the event the closing of the Merger occurs and the Executive continues in employment with the Company as of the
date of such closing, the Executive shall not be entitled to any termination payments or benefits under the Prior Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.3&nbsp;The
Executive shall be employed as the Company&rsquo;s Chief Technology Officer. The Executive&rsquo;s job responsibilities will comprise
managing and overseeing all Company operations and executing on the strategy set by the Company&rsquo;s Board of Directors including but
not limited to:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; text-align: justify"><B>1.3.1. Technology Strategy and Vision</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; text-align: justify"><B>1.3.2. Product Development and Innovation</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; text-align: justify"><B>1.3.3. Leadership and Team Management</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; text-align: justify"><B>1.3.4. Infrastructure and Architecture</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; text-align: justify"><B>1.3.5. Security and Compliance</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; text-align: justify"><B>1.3.6. Collaboration with Stakeholders</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; text-align: justify"><B>1.3.7. Budget and Resource Allocation</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; text-align: justify"><B>1.3.8. AI/ML Research and Development</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; text-align: justify"><B>1.3.9. Performance Monitoring and Optimization</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.4&nbsp;The
Executive will be permitted to work from Asia. As part of the Executive&rsquo;s duties, the Executive will be required to travel to the
Company&rsquo;s offices. The Executive is entitled to four (4) weeks of vacation which will accrue on a pro-rata basis during the year,
in addition to all public holidays when the office is closed. The Executive will be eligible to participate in alls employee benefit plans
established by the Company for its employees from time to time. In accordance with Company policies from time to time, the Company will
reimburse the Executive for all reasonable and proper travel and business expenses incurred by the Executive in the performance of his
duties. Any air travel of over 5 hours in length will be reimbursed as First Class or Business Class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">2.</TD><TD STYLE="text-align: justify"><U>COMPENSATION AND TERMINATION GENERALLY</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1&nbsp;<U>Compensation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.1&nbsp;<U>Annual
Salar</U>y. The Executive&rsquo;s base salary shall be $150,000 per annum, subject to periodic review and modification by the Board or
the Compensation Committee of the Board (references herein to the Compensation Committee shall include reference to the Board if no such
Committee exists at any time) at such time or times as it shall determine. The Company&rsquo;s Compensation Committee shall also from
time to time, in its discretion, determine the type and amount of other forms of compensation for the Executive&rsquo;s service with the
Company (including, without limitation, stock options or other forms of equity awards).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.2&nbsp;<U>Sign-On
Bonus</U>. Following the closing of the Merger, the Company shall pay the Executive a lump sum payment in the amount of ($150,000.00).
This will be paid upon determination by the Chief Financial Officer that there is sufficient cash available for this payment but in no
event will it be more than 12 months from the date of the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.3&nbsp;<U>Performance
Bonuses</U>. Executive will be eligible for annual bonuses, as determined by the Board or the Compensation Committee of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.4&nbsp;<U>Options</U>.
Within thirty (30) days following the Effective Date, the Executive will be granted an option to purchase 1,000,000 shares of the Company&rsquo;s
common stock, vesting over three (3) years, one third on the first anniversary of the Effective Date and the balance in equal quarterly
installments. The exercise price of such option shall be equal to the closing price of the Company&rsquo;s common stock on the date of
grant. The Executive may be eligible for additional equity incentive grants, subject to Executive&rsquo;s continued employment and satisfactory
job performance, which may be made from time to time, by the Board or the Compensation Committee of the Board, on the same terms as other
executive employees of the Company. Terms and conditions of all the equity incentive grants, will be in accordance with the terms of the
Company&rsquo;s Equity Incentive Plan in effect at the time of each such grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2&nbsp;<U>Termination
of Employment Generall</U>y. In the event the Executive&rsquo;s employment with the Company terminates, for any reason whatsoever including
death or disability the Executive shall be entitled to the benefits described in this Section 2.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.1&nbsp;<U>Accrued
Salar</U>y <U>and Vacation</U>. All salary and accrued vacation earned through the Termination Date shall be paid to Executive on such
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.2&nbsp;<U>Accrued
Bonus Payment</U>. The Executive shall receive a lump sum payment of any actual bonus amount to the extent that all the conditions for
payment of such bonus have been satisfied and any such bonus was earned and is unpaid on the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.3&nbsp;<U>Expense
Reimbursement</U>. Within ten (10) days following submission to the Company of proper expense reports by the Executive, the Company shall
reimburse the Executive for all expenses incurred by the Executive, consistent with the Company&rsquo;s expense reimbursement policy in
effect prior to the incurring of each such expense, in connection with the business of the Company prior to the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.4&nbsp;<U>Equi</U>ty
<U>Compensation</U>. The period during which the Executive may exercise any rights under any outstanding stock options and stock appreciation
rights, and the extent to which any outstanding shares of restricted stock, restricted stock units and any other equity award shall vest,
shall be determined under the terms of the Equity Incentive Plan under which they were granted and the applicable option or award agreements
governing such grants, but in no event will they be less than 5 years post termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><U>TERMINATION UPON CHANGE OF CONTROL</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;<U>Severance
Payment</U>. In the event of the Executive&rsquo;s Termination Upon Change of Control, the Executive shall be entitled to receive an amount
equal to the amount set forth in Section 4.1 which shall be paid according to the following schedule: (i) a lump sum payment equal to
one-half of such amount shall be payable within ten (10) days following the Termination Date, and (ii) one-third of the balance of such
amount shall be payable within ten (10) days of each of the three-month, six-month and nine-month anniversaries of the Termination Date
(and in each case no interest shall accrue on such amount); provided, however, that if Section 409A of the Code would otherwise apply
to such cash severance payment, it instead shall be paid at such time as permitted by Section 409A of the Code. In addition to the foregoing
severance payment, in the event of the Executive&rsquo;s Termination Upon Change of Control, the Executive shall be entitled to receive,
within ten (10) days following the Termination Upon Change of Control, a lump sum payment equal to one hundred percent (100%) of (a) any
actual bonus amount earned with respect to a previous year to the extent that all the conditions for payment of such bonus have been satisfied
(excluding any requirement to be in employment with the Company as of a given date which is after the Termination Date) and any such bonus
was earned but is unpaid on the Termination Date; and (b) the target bonus then in effect for the Executive for the year in which such
termination occurs, such payment to be prorated to reflect the number of days the Executive remained in the employ of the Company; provided,
however, that if Section 409A of the Code would otherwise apply to such cash payment, it instead shall be paid at such time as permitted
by Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2&nbsp;<U>Equity
Compensation Acceleration</U>. Upon the Executive&rsquo;s Termination Upon Change of Control, the vesting and exercisability of all then
outstanding stock options and shares of restricted stock (or any other equity award, including, without limitation, stock appreciation
rights and restricted stock units) granted to the Executive under any Equity Incentive Plan shall be accelerated as to 100% of the shares
subject to any such equity awards granted to the Executive. In addition, the applicable exercise period of the Executive&rsquo;s stock
options granted under the Equity Incentive Plan(s) shall be extended so as to expire on the last day of the term applicable to such stock
option, as measured from the date of Termination Upon Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3&nbsp;<U>COBRA</U>.
If the Executive timely elects coverage under the Consolidated Budget Reconciliation Act of 1985, as amended <B><I>(&ldquo;COBRA&rdquo;),
</I></B>the Company shall continue to provide to the Executive, at the Company&rsquo;s expense, the Company&rsquo;s health-related employee
insurance coverage for the employee only as in effect immediately prior to the Executive&rsquo;s Termination Upon Change of Control for
a period of twelve (12) months following such Termination Upon Change of Control. The date of the &ldquo;qualifying event&rdquo; for the
Executive and any dependents shall be the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4&nbsp;<U>Indemnification</U>.
In the event of the Executive&rsquo;s Termination Upon Change of Control, (a) the Company shall continue to indemnify the Executive against
all claims related to actions arising prior to the termination of the Executive&rsquo;s employment to the fullest extent permitted by
law, and (b) if the Executive was covered by the Company&rsquo;s directors&rsquo; and officers&rsquo; insurance policy, or an equivalent
thereto, (the <B><I>&ldquo;D&amp;O Insurance Policy&rdquo;) </I></B>immediately prior to the Change of Control, the Company or its Successor
shall continue to provide coverage under a D&amp;O Insurance Policy for not less than twenty-four (24) months following the Executive&rsquo;s
Termination Upon Change of Control on substantially the same terms of the D&amp;O Insurance Policy in effect immediately prior to the
Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><U>INVOLUNTARY TERMINATION</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1&nbsp;<U>Severance
Payment</U>. In the event of the Executive&rsquo;s Involuntary Termination, the Executive shall be entitled to receive an amount equal
to twenty-four (24) months of the Executive&rsquo;s Base Salary, which shall be paid within ten (10) days following the Termination Date.
In addition to the foregoing severance payment, in the event of the Executive&rsquo;s Involuntary Termination, the Executive shall be
entitled to receive, within ten (10) days following the Executive&rsquo;s Involuntary Termination, a lump sum payment equal to one hundred
percent (100%) of (a) any actual bonus amount earned with respect to a previous year to the extent that all the conditions for payment
of such bonus have been satisfied (excluding any requirement to be in employment with the Company as of a given date which is after the
Termination Date) and any such bonus was earned but is unpaid on the Termination Date; and (b) the target bonus then in effect for the
Executive for the year in which such termination occurs, such payment to be prorated to reflect the number of days the Executive remained
in the employ of the Company; provided, however, that if Section 409A of the Code would otherwise apply to such cash payment, it instead
shall be paid at such time as permitted by Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2&nbsp;<U>Equity
Compensation Acceleration</U>. Upon the Executive&rsquo;s Involuntary Termination, the vesting and exercisability of all then outstanding
stock options and shares of restricted stock (or any other equity award, including, without limitation, stock appreciation rights and
restricted stock units) granted to the Executive under any Equity Incentive Plan shall be accelerated as to 100% of the shares subject
to any such equity awards granted to the Executive. In addition, the applicable exercise period of the Executive&rsquo;s stock options
granted under the Equity Incentive Plan(s) shall be extended so as to expire on the last day of the term applicable to such stock option,
as measured from the date of Involuntary Termination and Executive shall have 5 years to exercise any such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3&nbsp;<U>COBRA</U>.
In the event of the Executive&rsquo;s Involuntary Termination, if the Executive timely elects coverage under COBRA, the Company shall
continue to provide to the Executive, at the Company&rsquo;s expense, the Company&rsquo;s health-related employee insurance coverage for
the employee only as in effect immediately prior to the Executive&rsquo;s Involuntary Termination for a period of twelve (12) months following
such Involuntary Termination. The date of the &ldquo;qualifying event&rdquo; for the Executive and any dependents shall be the Termination
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4&nbsp;<U>Indemnification</U>.
In the event of the Executive&rsquo;s Involuntary Termination, (a) the Company shall continue to indemnify the Executive against all claims
related to actions arising prior to the Termination Date to the fullest extent permitted by law, and (b) if the Executive was covered
by the D&amp;O Insurance Policy immediately prior to the Termination Date, the Company shall continue to provide coverage under a D&amp;O
Insurance Policy for not less than twenty-four (24) months following the Executive&rsquo;s Involuntary Termination on substantially the
same terms of the D&amp;O Insurance Policy in effect immediately prior to the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">5.</TD><TD STYLE="text-align: justify"><U>FEDERAL EXCISE TAX UNDER SECTION 280G</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1&nbsp;<U>Excise
Tax</U>. If (a) any amounts payable to the Executive under this Agreement or otherwise are characterized as excess parachute payments
pursuant to Section 4999 of the Internal Revenue Code of 1986, as amended (the <B><I>&ldquo;Code&rdquo;), </I></B>and (b) the Executive
thereby would be subject to any United States federal excise tax due to that characterization, then if Executive would thereby be in a
better after-tax position, the Company may elect, in the Company&rsquo;s sole discretion, to reduce the amounts payable under this Agreement
or otherwise, or to have any portion of applicable options or restricted stock not vest or become exercisable, in order to avoid any &ldquo;excess
parachute payment&rdquo; under Section 280G(b)(1) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2&nbsp;<U>Calculation
b</U>y <U>Independent Public Accountants</U>. Unless the Company and the Executive otherwise agree in writing, any calculation of the
amount of any excess parachute payments payable by the Executive shall be made in writing by the Company&rsquo;s independent public accountants
(the <B><I>&ldquo;Accountants&rdquo;) </I></B>whose conclusion shall be final and binding on the parties. For purposes of making such
calculations, the Accountants may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999
of the Code. The Company and the Executive shall furnish to the Accountants such information and documents as the Accountants may reasonably
request in order to make the required calculations. The Company shall bear all fees and expenses the Accountants may charge in connection
with these services, but the engagement of the Accountants for this purpose shall be pursuant to an agreement between the Executive and
the Accountants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">6.</TD><TD STYLE="text-align: justify"><U>DEFINITIONS</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1&nbsp;<U>Capitalized
Terms Defined</U>. Capitalized terms used in this Agreement shall have the meanings set forth in this Section 4, unless the context clearly
requires a different meaning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2&nbsp;&ldquo;<U>Base
Salary</U>&rdquo; means the greater of (a) if applicable, the monthly salary of the Executive in effect immediately prior to the Change
of Control, or (b) the monthly salary of the Executive in effect immediately prior to the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3&nbsp;&ldquo;<U>Cause</U>&rdquo;
means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Executive willfully failed to follow the lawful written directions of the Board; provided that no
termination for such Cause shall occur unless the Executive: (i) has been provided with notice, specifying such willful failure in reasonable
detail, of the Company&rsquo;s intention to terminate the Executive for Cause; and (ii) has failed to cure or correct such willful failure
within thirty (30) days of receiving such notice;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Executive engaged in gross misconduct, or gross incompetence which is materially detrimental to the
Company; provided that no termination for such Cause shall occur unless the Executive: (i) has been provided with notice, specifying such
gross misconduct or gross incompetence in reasonable detail, of the Company&rsquo;s intention to terminate the Executive for Cause; and
(ii) has failed to cure or correct such gross misconduct within thirty (30) days of receiving such notice;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the Executive willfully failed to comply in any material respect with the Employee Invention Assignment
&amp; Confidentiality Agreement, the Company&rsquo;s share dealing code, the Employee&rsquo;s non-competition agreement or any other reasonable
policies of the Company where non-compliance would be materially detrimental to the Company; provided that no termination for such Cause
shall occur unless the Executive: (i) has been provided with notice of the Company&rsquo;s intention to terminate the Executive for such
Cause, and (ii) has failed to cure or correct such willful failure within thirty (30) days of receiving such notice, provided that such
notice and cure period requirements shall not apply in the event that such non-compliance is of a nature that it is unable to be remedied;
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">is convicted of a felony or crime involving moral turpitude (excluding drunk driving unless combined with
other aggravating circumstances or offenses) or commission of a fraud which the Company reasonably believes would reflect adversely on
the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.4&nbsp;&ldquo;<U>Change
of Control</U>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">any &ldquo;person&rdquo; (as such tennis used in Sections 13(d) and 14(d) of the Securities Exchange Act
of 1934, as amended (the <B><I>&ldquo;Exchange Act&rdquo;)</I></B><I>) </I>becomes the &ldquo;beneficial owner&rdquo; (as defined in Rule
l 3d-3 promulgated under the Exchange Act), directly or indirectly, of securities of the Company representing fifty (50%) percent or more
of (i) the outstanding shares of common stock of the Company, or (ii) the combined voting power of the Company&rsquo;s outstanding securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Company is party to a merger or consolidation, or series of related transactions, which results in
the voting securities of the Company outstanding immediately prior thereto failing to continue to represent (either by remaining outstanding
or by being converted into voting securities of the surviving entity), directly or indirectly, at least fifty (50%) percent of the combined
voting power of the voting securities of the Company or such surviving entity outstanding immediately after such merger or consolidation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the sale or disposition of all or substantially all of the Company&rsquo;s assets, or consummation of
any transaction, or series of related transactions, having similar effect (other than to a subsidiary of the Company).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything contained
herein to the contrary, the Merger shall not constitute a Change of Control for purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.5&nbsp;&ldquo;<U>Company</U>&rdquo;
shall mean Avalon GloboCare Corp. and YOOV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.6&nbsp;&ldquo;<U>Involuntary
Termination</U>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">any termination without Cause of the employment of the Executive by the Company; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">any resignation by Executive for Good Reason where such resignation occurs within one hundred twenty (120)
days following the occurrence of such Good Reason.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
the term &ldquo;Involuntary Termination&rdquo; shall not include any termination of the employment of the Executive: (1) by the Company
for Cause; (2) by the Company as a result of the Permanent Disability of the Executive; (3) as a result of the death of the Executive;
(4) that occurs within the period of time to qualify as a &ldquo;Termination Upon Change of Control&rdquo;; or (5) as a result of the
voluntary termination of employment by the Executive for any reason other than Good Reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.7&nbsp;&ldquo;<U>Good
Reason</U>&rdquo; means the occurrence of any of the following conditions, without the Executive&rsquo;s written consent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Any act, set of facts or omissions with respect to the Executive that would, as a matter of applicable
law, constitute a constructive termination of the Executive.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The assignment to the Executive of a title, position, responsibilities or duties that is not a &ldquo;Substantive
Functional Equivalent&rdquo; to the title, position, responsibilities or duties which the Executive had immediately prior to such assignment
(including, as relevant, immediately prior to the public announcement of the Change of Control).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(c)</TD><TD STYLE="text-align: justify">A reduction in the Executive&rsquo;s Base Salary or, if applicable, target bonus opportunity (subject
to applicable performance requirements with respect to the actual amount of bonus compensation earned similar to the applicable performance
requirements currently in effect), and in the event of a Change of Control, as compared to Executive&rsquo;s Base Salary and target bonus
opportunity in effect immediately prior to the public announcement of the Change of Control; provided, however, that this clause (c) shall
not apply in the event of a reduction in the Executive&rsquo;s Base Salary or, if applicable, target bonus opportunity as part of a Company-wide
or executive team-wide cost-cutting measure or Company-wide or executive team-wide cutback as a result of overall Company performance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The failure of the Company (i) to continue to provide the Executive an opportunity to participate in any
benefit or compensation plans provided to employees who hold positions with the Company comparable to the Executive&rsquo;s position,
(ii) to provide the Executive all other fringe benefits (or the equivalent) in effect for the benefit of any employee group which includes
any employee who hold a position with the Company comparable to the Executive&rsquo;s position, where in the event of a Change of Control,
such comparison shall be made relative to the time immediately prior to the public announcement of such Change of Control); or (iii) continue
to provide director&rsquo;s and officers&rsquo; insurance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">A material breach of this Agreement by the Company, including, in the event of a Change of Control, failure
of the Company to obtain the consent of a Successor to perform all of the obligations of the Company under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(f)</TD><TD STYLE="text-align: justify">The Company&rsquo;s failure to provide full and transparent access to all material financial. operational
and transactional activities of its executives, board of directors, subsidiaries or joint ventures as it relates to the Company, which
such failure continues for a period of a minimum of 60 days following Executive&rsquo;s written request to receive information or documentation
pertaining to the aforementioned items <B><I>(&ldquo;Internal Control Event&rdquo;).</I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Executive must first give
the Company an opportunity to cure any of the foregoing within thirty (30) days following delivery to the Company of a written explanation
specifying the specific basis for Executive&rsquo;s belief that Executive is entitled to terminate employment for Good Reason, and Executive
terminates employment with the Company not later than (30) days following the Company&rsquo;s failure to cure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.8&nbsp;&ldquo;<U>Permanent
Disability</U>&rdquo; means that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the Executive has been incapacitated by bodily injury, illness or disease so as to be prevented thereby
from engaging in the performance of the Executive&rsquo;s duties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">such total incapacity shall have continued for a period of six consecutive months; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(c)</TD><TD STYLE="text-align: justify">such incapacity will, in the opinion of a qualified physician, be permanent and continuous during the
remainder of the Executive&rsquo;s life.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.9&nbsp;&ldquo;<U>Substantive
Functional Equivalent</U>&rdquo; means that the Executive&rsquo;s position must:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">be in a substantive area of the Executive&rsquo;s competence (e.g., finance or executive management) and
not materially different from the position occupied immediately prior;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">allow the Executive to serve in a role and perform duties functionally equivalent to those performed immediately
prior; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(c)</TD><TD STYLE="text-align: justify">not otherwise constitute a material, adverse change in authority, title, status, responsibilities or duties
from those of the Executive immediately prior, causing the Executive to be of materially lesser rank or responsibility, including requiring
the Executive to report to a person other than the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.10&nbsp;&ldquo;<U>Successor</U>&rdquo;
means any successor in interest to, or assignee of, substantially all of the business and assets of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.11&nbsp;&ldquo;<U>Termination
Date</U>&rdquo; means the date of the termination of the Executive&rsquo;s employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.12&nbsp;&ldquo;<U>Termination
Upon Change of Control</U>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">any termination of the employment of the Executive by the Company without Cause during the period commencing
on or after the date that the Company first publicly announces a definitive agreement that results in a Change of Control (even though
still subject to approval by the Company&rsquo;s stockholders and other conditions and contingencies, but provided that the Change of
Control actually occurs) and ending on the date which is twelve (12) months following the Change of Control; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: -45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 1in"></TD><TD STYLE="text-align: justify; width: 0.5in">(b)</TD><TD STYLE="text-align: justify">any resignation by Executive for Good Reason where (i) such Good Reason occurs during the period commencing
on or after the date that the Company first publicly announces a definitive agreement that results in a Change of Control (even though
still subject to approval by the Company&rsquo;s stockholders and other conditions and contingencies, but provided that the Change of
Control actually occurs) and ending on the date which is twelve (12) months following the Change of Control, and (ii) such resignation
occurs at or after such Change of Control and in any event within six (6) months following the occurrence of such Good Reason.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
the term &ldquo;Termination Upon Change of Control&rdquo; shall not include any termination of the employment of the Executive: (1) by
the Company for Cause; (2) by the Company as a result of the Permanent Disability of the Executive; (3) as a result of the death of the
Executive; or (4) as a result of the voluntary termination of employment by the Executive for any reason other than Good Reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">7.</TD><TD STYLE="text-align: justify"><U>EXCLUSIVE REMEDY</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.1&nbsp;<U>No
Other Benefits Payable</U>. The Executive shall be entitled to no other termination, severance or change of control compensation, benefits,
or other payments from the Company as a result of any termination with respect to which the payments and benefits described in Section
2 have been provided to the Executive, except as expressly set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.2&nbsp;<U>No
Limitation of Regular Benefit Plans</U>. Except as may be provided elsewhere in this Agreement, this Agreement is not intended to and
shall not affect, limit or terminate any plans, programs or arrangements of the Company that are regularly made available to a significant
number of employees or officers of the Company, including, without limitation, the Company&rsquo;s stock option plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.3&nbsp;<U>Release
of Claims</U>. The payment of the benefits described in Sections 3 and 4 of this Agreement is conditioned upon the delivery by the Executive
to the Company of a signed and effective general release of claims as provided by the Company; provided, however, that the Executive shall
not be required to release any rights the Executive may have to be indemnified by the Company or as otherwise provided under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.4&nbsp;<U>Non-accumulation
of Benefits</U>. The Executive may not cumulate cash severance payments, stock option vesting and exercisability and restricted stock
vesting under this Agreement, any other written agreement with the Company and/or another plan or policy of the Company. If the Executive
has any other binding written agreement with the Company which provides that, upon a Change of Control or Termination Upon a Change of
Control or Involuntary Termination, the Executive shall receive termination, severance or similar benefits, then no benefits shall be
received by Executive under this Agreement unless, prior to payment or receipt of benefits under this Agreement, the Executive waives
Executive&rsquo;s rights to all such other benefits, in which case this Agreement shall supersede any such written agreement with respect
to such other benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">8.</TD><TD STYLE="text-align: justify"><U>NON-COMPETE; PROPRIETARY AND CONFIDENTIAL INFORMATION</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the term of this Agreement and following
any termination of employment, Executive agrees to continue to abide by the terms and conditions of each of the non-competition agreement
(during the term of such Agreement) and the Employee Invention Assignment &amp; Confidentiality Agreement between the Executive and the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">9.</TD><TD STYLE="text-align: justify"><U>ARBITRATION</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1&nbsp;<U>Disputes
Sub</U>j<U>ect to Arbitration</U>. Any claim, dispute or controversy arising out of this Agreement (other than claims relating to misuse
or misappropriation of the intellectual property of the Company), the interpretation, validity or enforceability of this Agreement or
the alleged breach thereof shall be submitted by the parties to binding arbitration by a sole arbitrator under the rules of the American
Arbitration Association; provided, however, that (a) the arbitrator shall have no authority to make any ruling or judgment that would
confer any rights with respect to the trade secrets, confidential and proprietary information or other intellectual property of the Company
upon the Executive or any third party; and (b) this arbitration provision shall not preclude the Company from seeking legal and equitable
relief from any court having jurisdiction with respect to any disputes or claims relating to or arising out of the misuse or misappropriation
of the Company&rsquo;s intellectual property. Judgment may be entered on the award of the arbitrator in any court having jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.2&nbsp;<U>Costs
of Arbitration</U>. All costs of arbitration, including reasonable attorney&rsquo;s fees of the Executive, will be borne by the Company,
except that if the Executive initiates arbitration and the arbitrator finds the Executive&rsquo;s claims to be frivolous the Executive
shall be responsible for her own costs and attorneys fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.3&nbsp;<U>Site
of Arbitration</U>. The site of the arbitration proceeding shall be in New York City, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in">10.</TD><TD STYLE="text-align: justify"><U>NOTICES</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of this Agreement, notices and all
other communications provided for in the Agreement shall be in writing and shall be deemed to have been duly given when delivered or five
(5) business days after being mailed, return receipt requested, as follows: (a) if to the Company, attention: and, (b) if to the Executive,
at the address indicated below or such other address specified by the Executive in writing to the Company. Either party may provide the
other with notices of change of address, which shall be effective upon receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: justify; text-indent: -0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: justify"><U>MISCELLANEOUS PROVISIONS</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.1&nbsp;<U>Heirs
and Representatives of the Executive; Successors and Ass</U>ig<U>ns of the Compan</U>y. This Agreement shall be binding upon and shall
inure to the benefit of and be enforceable by the Executive&rsquo;s personal and legal representatives, executors, administrators, successors,
heirs, distributees, devises and legatees. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the
successors and assigns of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.2&nbsp;<U>Amendment
and Waiver</U>. No provision of this Agreement shall be modified, amended, waived or discharged unless the modification, amendment, waiver
or discharge is agreed to in writing, specifying such modification, amendment, waiver or discharge, and signed by the Executive and by
an authorized officer of the Company (other than the Executive). No waiver by either party of any breach of, or of compliance with, any
condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the
same condition or provision at another time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.3&nbsp;<U>Withholding
Taxes</U>. All payments made under this Agreement shall be subject to deduction of all federal, state, local and other taxes required
to be withheld by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.4&nbsp;<U>Severabilit</U>y.
The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of
any other provision hereof, which shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.5&nbsp;<U>Choice
of Law</U>. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of
New Jersey, without regard to where the Executive has his residence or principal office or where she performs his duties hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.6&nbsp;<U>No
Du</U>ty <U>to Mitigate</U>. The Executive is not required to seek alternative employment following termination, and payments called for
under this Agreement will not be reduced by earnings from any other source.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.7&nbsp;<U>Section
409A of the Code</U>. To the extent (a) any payments or benefits to which Employee becomes entitled under this Agreement, or under any
agreement or plan referenced herein, in connection with Employee&rsquo;s termination of employment with the Company constitute deferred
compensation subject to Section 409A of the Code and (b) Employee is deemed at the time of such termination of employment to be a &ldquo;specified
employee&rdquo; under Section 409A of the Code, then such payments shall not be made or commence until the earliest of (i) the expiration
of the six (6)-month period measured from the date of Employee&rsquo;s &ldquo;separation from service&rdquo; (as such term is at the time
defined in Treasury Regulations under Section 409A of the Code) from the Company; or (ii) the date of Employee&rsquo;s death following
such separation from service; provided, however, that such deferral shall only be effected to the extent required to avoid adverse tax
treatment to Employee, including (without limitation) the additional twenty percent (20%) tax for which Employee would otherwise be liable
under Section 409A(a)(l)(B) of the Code in the absence of such deferral. Upon the expiration of the applicable deferral period, any payments
which would have otherwise been made during that period (whether in a single sum or in installments) in the absence of this paragraph
shall be paid to Employee or Employee&rsquo;s beneficiary in one lump sum (without interest). Any termination of Employee&rsquo;s employment
is intended to constitute a &ldquo;separation from service&rdquo; as such term is defined in Treasury Regulation Section 1.409A-1. It
is intended that each installment of the payments provided hereunder constitute separate &ldquo;payments&rdquo; for purposes of Treasury
Regulation Section l.409A-2(b)(2)(i). It is further intended that payments hereunder satisfy, to the greatest extent possible, the exemption
from the application of Code Section 409A (and any state law of similar effect) provided under Treasury Regulation Section l.409A-l(b)(4)
(as a &ldquo;short-term deferral&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.8&nbsp;<U>Entire
Agreement</U>. This Agreement represents the entire agreement and understanding between the parties as to the subject matter herein (whether
oral or written and whether express or implied).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[SIGNATURE PAGE FOLLOWS]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 12; Options: NewSection; Value: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-variant: small-caps">In
Witness Whereof</FONT>, each of the parties has executed this Agreement, in the case of the Company, by its duly authorized officer, as
of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Executive</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: Black 1.5pt solid"><B>Mark Wong</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Avalon GloboCare Corp.</B></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ea024503201ex23-1_avalon.htm
<DESCRIPTION>CONSENT OF M&K CPA'S, PLLC, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF AVALON GLOBOCARE CORP. FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="ex23-1_001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the incorporation by reference in
the Registration Statement on Forms S-4/A of our report dated March 31, 2025, with respect to the consolidated financial statements of
Avalon GloboCare Corp. included in this Annual Report on Form 10-K for the year ended December 31, 2024, and the reference to our firm
under the caption &ldquo;Experts&rdquo; in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>/s/ M&amp;K CPAS, PLLC</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Woodlands, TX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 9, 2025</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>6
<FILENAME>ea024503201ex23-2_avalon.htm
<DESCRIPTION>CONSENT OF MARCUM LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF AVALON GLOBOCARE CORP. FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.2&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Independent Registered Public Accounting
Firm&rsquo;s Consent</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the use in this Registration Statement
on Form S-4 of our report dated April 15, 2024 relating to the financial statements of Avalon GloboCare Corp. appearing in this Registration
Statement. We also consent to the reference to us under the heading &ldquo;Experts&rdquo; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 9, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>7
<FILENAME>ea024503201ex23-3_avalon.htm
<DESCRIPTION>CONSENT OF ARK PRO CPA & CO, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF YOOV, INC.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.3</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_008.jpg" ALT=""><B>&nbsp;</B></P>


<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We consent to the use in this Registration Statement
on Form S-4/A of our report dated April 24, 2025 relating to the financial statements of YOOV Group Holding Limited appearing in this
Registration Statement. We also consent to the reference to us under the heading &ldquo;Experts&rdquo; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ ARK Pro CPA &amp; Co</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ARK PRO CPA &amp; Co </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Hong Kong, China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">June 9, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PCAOB Firm ID: 3299&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !3 0P# 2(  A$! Q$!_\0
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M/DE3R&'K_P#7K.N/!NK0W0B2)9D)XD5AC\<]*Z;4]9A\&:!:0R@W%QLV(@.
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M=.B\X3 >9&& 8,!C//4<"O3J3%94JLJ4N:)Z&)PT,1#DF<%X"\*7NCW,U_J
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !< /X# 2(  A$! Q$!_\0
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M?@C@^)>J+$H4,(W..[%%)/YUZQ\"H8X_ 4DJJ \EY)O;UP% KSKXLZ#J]_\
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M2EHH **** "BBB@!,4M%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %] G # 2(  A$! Q$!_\0
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M76"7M=/\1G7_ (67H!'2.>Z\?:9YF<KF)&(RJD?F]_P:3G5?CM^T[_P4M_;
M\00O_:?B*S^%'A..XFD$LRW/C?6O&7BS7+8OSO"+X-\/L2I.,1A\$IG^V/XA
M_#?X>_%SP=K/P\^*O@;PC\2? 7B..UB\0>"O'?AS2/%GA36XK*^MM3LX]6\/
MZ[:7VE:@EIJ-E9W]LMU:RB"\M;>YB"S0QNO(?!W]G;X!?L\Z?K6D_ 3X)_"C
MX*Z7XDO;;4O$.G?"GX?>%/A_8ZYJ%G UK:7VKVOA72M*AU&[M;9WM[>XNTFE
MAA=XXV5&8'GR;QIPV5^ _$/A#/)<;6S7-LTQ57 \01QF$C@L#DV99KP]G&9Y
M=/!S@\;.IB<7D,7STJBHVJQ<H^Y+FJIELIYI1S!5(JG3A%3I<LN:=2%.K3A/
MF^&T8U=GKH^Z/8Z***_ 3U0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /QA_8B^$/[6G[2G[%_[(O[1?CK_ (*I?MOZ3XV^/O[,/P#^
M-7C'2O"?PN_X)AV/A73?%/Q3^%7A3QSX@T_PS8ZQ_P $Z->U>S\/V>K:[=V^
MC6NJ:YK.HV^G1VT-]JNHW*2W<WT__P ,;_M%?])8OV__ /PW/_!++_Z6G1_P
M2=_Y19?\$U/^S OV.?\ UG?X=5]_T ? '_#&_P"T5_TEB_;_ /\ PW/_  2R
M_P#I:='_  QO^T5_TEB_;_\ _#<_\$LO_I:=??\ 10!^+VMZ)\6="USQEH-W
M_P %*?\ @J<UU\/E\5W?B^Y7X/?\$C[6PTG0_!$=EJ/BKQ%%<ZG^P!8?VSIN
MD^&/$'@3QB;30$U77[_P]\1/"HTO1;[6X?%&C>&H;BP^)%EX=N?%.H_\%/?^
M"GUAH\6D:)XFM)Y?A-_P2/N'U3PCXM\/^/\ 7/ WBBSCT_\ X)^WIMK+QQ=?
M#G6/"_A[2=7.E^+%\5:GX<TO6O#NCQ:Q%=Q_KGK7PV^'?B243^(O /@O7IQK
MT/BH3:UX6T/5)1XHM]*L]!M_$@DOK&=QKT&AZ?8:-#K&?[0BTJQL].2X6SMH
M84\%^)7BW]FGX+W+>%_%/PZ\/V]GXIUWPIXTURT\-?"[3?$%M<^,Y_&T=]\/
MM:U?P]H.EW>N:]XUO?&&@ZMXH\(7FEZ#KNNPZIX(UC6K>6TU73]-:\B,E3C3
M5>HFW*C3E*T8*;=3!*K*/PPI3G268>Q4W*C2JU<'[:56E"N5:<O:.E2C*-*G
M7Q$G.57W*5&AC*S]K[/EYJ-*5.A*O.#I5IX2CC'35'$0IU7\03^&O'>FZMJV
MF^(O^"LG_!1CPW;:;=>)K2#5+[X:_P#!)C5/[7?P1?ZMI/C>]L_#'A3_ ()W
M^(O']AX>\'ZIH.LZ?KWC#Q'X/T+P=!/8![;7[JVU#29]0U;OP?XEL$TPW?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BOF#]IW]IV#]FN#X+V=G\%_C!\?O&WQ^^,$_P4^&WPV^"D_P &K'Q5
MJ7BJQ^#7Q@^/&K:AJ&K?'CXP? [X=Z3X?TGX=_ [QU?75U?>.H]1N-1CTK2]
M+TK4;G40(?'_ /ALC]HK_I$[^W__ .'&_P""67_TRR@#[_HKX _X;(_:*_Z1
M._M__P#AQO\ @EE_],LH_P"&R/VBO^D3O[?_ /X<;_@EE_\ 3+* /O\ HKX
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MYJVA7=QHUUJFAZ-J-QITEM-?:5IUR\MI#]/_ /#9'[17_2)W]O\ _P##C?\
M!++_ .F64?\ #9'[17_2)W]O_P#\.-_P2R_^F64?\-D?M%?](G?V_P#_ ,.-
M_P $LO\ Z990 ?\ #9'[17_2)W]O_P#\.-_P2R_^F65Y_P",O^"C7Q/^'_B+
MX3^$_%W_  2Z_;_TCQ!\<?B!J/PM^%UA_P )G_P3*O\ _A*/'>D_"SXE_&K4
M-"^U:9_P4<O;+1/L_P ,_@_\1?$O]I^(KG2-'E_X1W^QH-0D\0:MH6E:GZ!_
MPV1^T5_TB=_;_P#_  XW_!++_P"F65\P?'[XO?M:?%3XK?L1^.?#W_!*W]M^
MSTG]FO\ :?\ %?QK\=6^L_%'_@F';ZCJWA77?V,/VNOV=;33_"<-C_P47U&V
MOO$$?C;X^^#M4N;76+O0M.3PMIOB6]BU6;5K/2]#UD ^G_\ ALC]HK_I$[^W
M_P#^'&_X)9?_ $RRN+UC]H/XG>(==M_$WB#_ ((W?MO:]KMF_AV:PU'6_&7_
M  2GU:73KKPE>:[?^&=0TU-0_P""D]Q#IVJZ%=^)_$$VF:M8Q6^I6K:M>+'=
M!) H[3_ALC]HK_I$[^W_ /\ AQO^"67_ -,LH_X;(_:*_P"D3O[?_P#X<;_@
MEE_],LI.,9*THJ2=TU)*2:<91::DI)IQG.+333C.<6G&<E(Z-=':Z[\LHSC?
MTG&,EVE&,EJDUYAI?Q:\1:)>:?J&B_\ !$#]K#2+_2;E;W2K[2[C_@D/I]YI
MEXDD4R7>GW-I_P %%HIK*Y6:""59[9XY5DABD#AHT(RK?X@ZE;WVIZB/^"'G
M[6\][J]WI-Y=SW^K?\$E=3,<F@^%]$\%Z)!IT>H_\%'[J+1]/TCPMX<T;1M-
MTK2$L=,L[6S+6]G'/<W<L_LG_#9'[17_ $B=_;__ /#C?\$LO_IEE'_#9'[1
M7_2)W]O_ /\ #C?\$LO_ *995RG.4E.4YRFN:TY3G*:YY1E-QE*<I1<Y0A*<
MHRC*3C%RD[:PZ=-J:=.#52SJ)P@U4:]I;VB<&IV]K5MSJ=O:U;6]I4Y_*C\4
M];:XFNS_ ,$.OVJC=7-E9Z;<7)D_X)"&XN-.T[P]'X1T^PFF/_!17S);*Q\)
MQ1>&+.UD9H+7P]''HL$:::BVPMZ?\8O%.D/JLFE?\$1OVM=,DU[0[[PQKDFG
MWG_!(JR?6?#>J1VD6I^'M5>V_P""C$3:CH>HQ:?81WVDWAFL+N.RM$N+>1;:
M$)Z5_P -D?M%?](G?V__ /PXW_!++_Z991_PV1^T5_TB=_;_ /\ PXW_  2R
M_P#IEE2]7=ZNS5WJ[2]IS*[N[2]M6YE>TO;5N9/VM7VM22FU*:4Y1Y>64TIR
MCR\BCRRFI./*J<%&S7*H04>50@H>=WWQJ\8ZIHL'AO4_^")O[7>H^';6^LM4
MMM!OM1_X)&W>BV^IZ;X;C\&Z=J,&EW'_  49DL8;ZP\(11>%;*[C@6XM?#<4
M>AP21Z6BVH?_ ,+Q\?K>>'-0M_\ @C)^VS877A+Q-XH\8^'WTKQC_P $J-(2
MQ\3^-[[4=6\8ZR\&E_\ !2FTM[V\\4Z_JEWXI\0-J$5U'J_B];+Q??)/XGTS
M3=6M/0?^&R/VBO\ I$[^W_\ ^'&_X)9?_3+*/^&R/VBO^D3O[?\ _P"'&_X)
M9?\ TRRG=WYKOF;IMRN[MTG>DV[W;I/6DVVZ;UI^S:35-MQY6VX\LH<K;<>2
M?-SPY6W'DGSSYX<O++GGS1ESSYS_ (;(_:*_Z1._M_\ _AQO^"67_P!,LH_X
M;(_:*_Z1._M__P#AQO\ @EE_],LH_P"&R/VBO^D3O[?_ /X<;_@EE_\ 3+*\
M_P#A/_P4:^)_QQ^%GPU^-7PM_P""77[?_BCX9?%_P!X.^*'PZ\2_\)G_ ,$R
MM$_X2'P+X_\ #NG>*_"6N?V-XB_X*.:1X@TG^UM U;3[_P#LS7-*TS6+#[1]
MEU/3[*]BGMHT(] _X;(_:*_Z1._M_P#_ (<;_@EE_P#3+*/^&R/VBO\ I$[^
MW_\ ^'&_X)9?_3+*/^&R/VBO^D3O[?\ _P"'&_X)9?\ TRRC_ALC]HK_ *1.
M_M__ /AQO^"67_TRR@ _X;(_:*_Z1._M_P#_ (<;_@EE_P#3+*/V:= ^+WC?
M]J?]HO\ :L^(OP)^('[-_A_XC?L__LH?L]^%OAC\8O$OP3\0?%.ZUG]GOXB_
MMB_$?Q7X[N5_9X^+GQX^&5G\/_$%E^U%X1\/^$&G^)B^.[GQ%X-^( \0^!?#
M?A^W\&>(/&Q_PV1^T5_TB=_;_P#_  XW_!++_P"F64?\-D?M%?\ 2)W]O_\
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ME-7BE1PV#GBJ7+.2ERR6#>&Q=*=G*6'IT*L:EJ</:/#_ .'EG[.O_1.?V_\
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M#X _X)J?\F[_ !)_[/\ _P#@J]_Z](_;%K[_ *^ /^":G_)N_P 2?^S_ /\
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M\G&?\%8/^S^?AM_ZZW_X)MU]_P!? '[''_)QG_!6#_L_GX;?^NM_^";=??\
M4EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5^(/[$O_  4)_8%^!WPP^,?PM^-?[</[
M('P?^)OA?]O_ /X*G_\ "3?#KXI?M+?!?X?^._#O]M_\%-?VN/$6C?V[X1\6
M>-=(\0:1_:_A_5]*UW3/[0T^W^WZ/J>GZG:^;97MM/+^WU% 'P!_P]B_X)9?
M])+/V /_ !,C]G7_ .>-1_P]B_X)9?\ 22S]@#_Q,C]G7_YXU??]% 'P!_P]
MB_X)9?\ 22S]@#_Q,C]G7_YXU'_#V+_@EE_TDL_8 _\ $R/V=?\ YXU??]%
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M0U6^FDGF,<)O+V<65C#::99"WTVQLK2WZ3_A[%_P2R_Z26?L ?\ B9'[.O\
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M](T_V /_ !#?]G7_ .=S1_PZ=_X)9?\ 2-/]@#_Q#?\ 9U_^=S7W_7YP?\%
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M\/K.Z^'UA?:_X[O/%NF1K::8EA^AW_#IW_@EE_TC3_8 _P#$-_V=?_G<T?\
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MG?\ @EE_TC3_ & /_$-_V=?_ )W-'_#IW_@EE_TC3_8 _P#$-_V=?_G<T?\
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M?\)'_P (O_PG_ASQ!_PC_P#PD']@:#_;?]D_9/[5_L32/M_G_P!FV?D@'O\
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M ,4R^*=0?Z'_ .'3O_!++_I&G^P!_P"(;_LZ_P#SN:/^'3O_  2R_P"D:?[
M'_B&_P"SK_\ .YHI?NDUI43]M_$C=KVT''1J7,G2ERU*33:C.&L>2I4BR7OS
ME-MJ_LN6,7RQA[)OI%)3]HI3C4]I'WKPES.5&B'_  Z=_P""67_2-/\ 8 _\
M0W_9U_\ G<T?\.G?^"67_2-/]@#_ ,0W_9U_^=S1_P .G?\ @EE_TC3_ & /
M_$-_V=?_ )W-'_#IW_@EE_TC3_8 _P#$-_V=?_G<T '_  Z=_P""67_2-/\
M8 _\0W_9U_\ G<T?\.G?^"67_2-/]@#_ ,0W_9U_^=S7Q_\ MM_\$]?V!?@=
M\+?A!\4?@K^P]^Q_\'_B;X7_ &^?^"6Q\,_$7X7?LT?!?X?^._#IUK_@IA^R
M5X>U@Z%XN\)^"M)\0:1_:V@:MJNAZG_9^H6_V_1]3U#3+KS;*]N8)/V_H ^
M/^'3O_!++_I&G^P!_P"(;_LZ_P#SN:/^'3O_  2R_P"D:?[ '_B&_P"SK_\
M.YK[_HH ^ /^'3O_  2R_P"D:?[ '_B&_P"SK_\ .YH_X=._\$LO^D:?[ '_
M (AO^SK_ /.YKY@^$?[$7[%_[2G[6O\ P50\<_M&?LB?LP?'[QMI/[;7PL\)
MZ5XP^-?P"^%/Q4\4Z9X6L?\ @F1_P3OUBR\-:?X@\=>$]>U:S\/V>K:[K>J6
MNC6UW'IUOJ.L:K>Q6R7.H7<LWT__ ,.G?^"67_2-/]@#_P 0W_9U_P#G<T '
M_#IW_@EE_P!(T_V /_$-_P!G7_YW-'_#IW_@EE_TC3_8 _\ $-_V=?\ YW-'
M_#IW_@EE_P!(T_V /_$-_P!G7_YW-'_#IW_@EE_TC3_8 _\ $-_V=?\ YW-
M!_PZ=_X)9?\ 2-/]@#_Q#?\ 9U_^=S7P7_P3^N/VU8O^";7[ R?!^PUR?18O
MV./V-G\&2:@_P'71I]%N/V6/V:[=X=1&JWD'B5? MAJ!^+5[<%HX/B0_BI/"
MR6LMYX+\ZT;[T_X=._\ !++_ *1I_L ?^(;_ +.O_P [FC_AT[_P2R_Z1I_L
M ?\ B&_[.O\ \[FIE'F<7=KE=[)Z25T[25UH[=+.UTG9M%QGRII1@_WF'J7E
M%2:^KU?:J&J:]G6:5.O':I23INRE)OI/A9)^V+I_B+PQ<>/[:]\0^#]4U>[M
MM9T_Q'/\'](\5^&-"AUKQQINBZEKES\/TET35-5G\.P^%_$GBFV\+&>TNM;O
M?#^E>'8]!L+3QFLOVW7P!_PZ=_X)9?\ 2-/]@#_Q#?\ 9U_^=S1_PZ=_X)9?
M](T_V /_ !#?]G7_ .=S6LI\R2Y8*TIRYHJTFIQPZY9.]I1C*A*<'RQDGB*T
M=8>S4<H04(PBG)\E*E3;G.4W)T8*FJDG)NU2I",'5:;52K&5:7[VM5O]_P!%
M? '_  Z=_P""67_2-/\ 8 _\0W_9U_\ G<U\O_&#]B']B[]FO]K#_@ECXZ_9
MT_9#_9?^ 7C?5?VX/B5X3U/QC\%?@#\*/A7XJU'PM?\ _!,W_@H?J]]X:O\
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M/F<'&5ZBJ+EG%<T5%4YQES0MS3A)-PC4?TW7P!_P2>_Y19_\$UO^S!/V._\
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M=0ZQKR7&GE4CEM9FU6YFDAD1[A+6<R6D'Z@5\ ?\%+?^3<_A[_V?S_P2D_\
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MZ;4_VU_"W@W0%UGXE>!/$WA>X?69M&_LK2]3\/:U=1'0]!^&%WXXU*0ZQ?\
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MXF<:5>'P!^QO_P G%?\ !6+_ +/_ /AQ_P"NLO\ @FG7W_7P!^QO_P G%?\
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M_P!%%%24?F;_ ,%!_!T/CWXS?\$H/#=Q?RZ=;R_\%&]8UBXEBA2Y%U;^%_\
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M*I&U1RG/X _X)._\HLO^":G_ &8%^QS_ .L[_#JOO^O@#_@D[_RBR_X)J?\
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M^!+W0/&7ANU\4_VE/HVGXMS^UI\?)&\&Z=8_L>>/8-6\7Q>;?7E]/X\G\/\
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MOAW\<?'5C=6M]X%DU&WU&32M4TO5=.N=.!F /I^BO@#_ (8W_:*_Z2Q?M_\
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M#-%\#>']0\37VCZ5H.D7GB"\TG0K2XUFZTO0]&TZXU&2YFL=*TZV>*TA]@H
M*^ /VR?^3B?^"3W_ &?_ /$7_P!=:?\ !2JOO^OF#]IW]F*#]I2W^"]W:?&C
MXP? +QM\ OC!/\:_AM\2?@I!\&[[Q5IOBJ^^#?Q@^!&K6%_I/QX^#_QQ^'>K
M>']6^'GQP\<V-U:WW@634;?49-*U32]5TZYTX&8 ^GZ*^ /^&-_VBO\ I+%^
MW_\ ^&Y_X)9?_2TZ/^&-_P!HK_I+%^W_ /\ AN?^"67_ -+3H ^_Z*^ /^&-
M_P!HK_I+%^W_ /\ AN?^"67_ -+3H_X8W_:*_P"DL7[?_P#X;G_@EE_]+3H
M^_Z*_ ;X=P?M;ZY\?_VOO@[X@_X*&_\ !1[Q!I?P,_:$@^%WPZUSX;_"_P#X
M)$2W.H^%;/\ 84_9;_:FUS_A,=*\1?L16_BK5O%+>./C=KGA#3-6\*>"K+PD
MEMKWPL\.ZB\.M7&MZ_>>N> M%^)/CGQ-IG@^;_@J)_P4T\$>(=6DCMK;3_'7
MPM_X)&:6\>I*VKVVHZ+<RZ9_P3]UJ&'7-%UG2D\-:EI!D-__ ,))J$6CV$%]
M=:5XH'A^H0E4<8PBYRDVHJ*YFVI58-)*[;4J-1-6;7*FTHSI2JJ34+J32LH2
M=^D:BIN#;2:7.JM/DNTYWER<WLZWL/V=HKX _P"&-_VBO^DL7[?_ /X;G_@E
ME_\ 2TZ/^&-_VBO^DL7[?_\ X;G_ ()9?_2TZD9]_P!? '_!)[_E%G_P36_[
M,$_8[_\ 6>?AW1_PQO\ M%?])8OV_P#_ ,-S_P $LO\ Z6G7T_\ L]?!3PK^
MS7\ O@?^SIX%U#Q!JW@GX!?"'X:_!;P?JOBVZTV^\5:GX6^%O@S1? _A_4/$
MM[H^DZ#I%YX@O-)T*TN-9NM*T/1M.N-1DN9;'2M.MGBM(0#V"BBB@ KX ^'7
M_*4W]L7_ +, _P"";'_K17_!5ROO^OB#XM?L8:WX^^/OB+]HOX:_M@?M/_LQ
M^-_&?P@^%?P4\;:7\%-&_9'\1^%O%GA7X,>-/C9XZ\ 7^H6/[27[*G[06K:9
MX@TS5_V@/B+;W5UX8UO0-.U/3KK2H;_2I[G2X;M@#[?HKX _X8W_ &BO^DL7
M[?\ _P"&Y_X)9?\ TM.C_AC?]HK_ *2Q?M__ /AN?^"67_TM.@#[_K.U?1])
M\0:9?:+KVEZ=K>C:G;26>I:3J]E;:EIFH6DPVRVM]87D4UK=VTJ_+)!<121.
M.&4BOA'_ (8W_:*_Z2Q?M_\ _AN?^"67_P!+3H_X8W_:*_Z2Q?M__P#AN?\
M@EE_]+3H_1IKUC*,HOUC*$)1>\90A)-2A"46FT[IM-;--IK=:---:-K1K1M;
M-I_>&F:5I>B6-OI>C:;8:1IEHKK:Z=IEG;V%C;+)(\TBV]I:1Q6\*O-))*XC
MC4-)([MEF8G.U_PEX4\5K8+XH\,^'O$BZ5=/>Z8NOZ+INL+IUY);RVLEW8#4
M;:Y%G=/:S36SW%OY<K6\TL+.8Y'4_$'_  QO^T5_TEB_;_\ _#<_\$LO_I:=
M'_#&_P"T5_TEB_;_ /\ PW/_  2R_P#I:=)I.UTGRN+C=)\K@E&#5T[.*246
MK.*247%))2DDG%)*,HSA**2490J*:J0E%)1E&HJE15(RBXU%4J*<9JI44_O+
M3-,TW1=.T_1]'T^RTG2-)LK73=+TO3+2"PT[3=.L8([6RL-/L;6.*VL[*SMH
MHK>UM;>*."W@CCAAC2-%47:^ /\ AC?]HK_I+%^W_P#^&Y_X)9?_ $M.C_AC
M?]HK_I+%^W__ .&Y_P""67_TM.J;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;#
M_@I;_P FY_#W_L_G_@E)_P"O2/V.J^_Z_.#Q!_P3^\?>/IO!-E\7?^"C/[<'
MQ>\$>#?B]\#_ (TR_#;Q9X4_X)Y^'/"WBSQ3^SY\8_ OQV^'FG^)=6^%/[!'
MPX^(<7A^+XA_#GPM>ZS:^%?'/AC4=3TZUN=+.JP6UY<!OT?I %%%% 'P!^QQ
M_P G&?\ !6#_ +/Y^&W_ *ZW_P"";=??]? 'B#]A?Q8?B]\=/BW\)?V[/VO_
M -G<_M#^/O#7Q0^(7P]^%OAW]A[Q-X$/CKPS\%?A-\ X-=T.;X_?L7_&WQ_I
MG]I> /@KX$CU/3'\>7>C_P!L6FH:EINGZ;_:4\%'_#&_[17_ $EB_;__ /#<
M_P#!++_Z6G0!]_T5\ ?\,;_M%?\ 26+]O_\ \-S_ ,$LO_I:='_#&_[17_26
M+]O_ /\ #<_\$LO_ *6G0!]S:]X<\/>*=/.D^)]!T;Q'I9N;6\.FZ]I=CJ^G
MF[L9DN;*Z-GJ$%Q;_:;.XC2XM9_+\VWF1)8F210PTK6UMK*VM[*RMX+2SM((
MK:TM+6&.WMK6V@C6*"WMX(E2*&"&)%CBBC18XXU5$55  ^!_^&-_VBO^DL7[
M?_\ X;G_ ()9?_2TZ/\ AC?]HK_I+%^W_P#^&Y_X)9?_ $M.A:)I:*4E*26B
ME)1Y%*25E*2@E%2DI244HJ2BE%#UY6]7%2C%O5QC.2E*,6[N,92C&4HQ<8RE
M&,I*4HJ2^T/&GP]\ _$C2FT+XB>!_"'CW1'CO87T;QIX:T7Q3I3Q:E8W&EZC
M$VGZY97UHT=_IEW=Z=>H82MU8W5Q:3B2WFDC;K^G2O@#_AC?]HK_ *2Q?M__
M /AN?^"67_TM.C_AC?\ :*_Z2Q?M_P#_ (;G_@EE_P#2TZ%HG%:1<W4<5I%U
M'%0=1Q5HNHX1C!S<7-PC&#FXQ44-)R4FDY*"IJ32<E34Y5%34FG)4U4E*HJ:
MDH*I*4U!3E*<OO\ KX _;*_Y.&_X)1?]G_\ Q _]=>?\%)*/^&-_VBO^DL7[
M?_\ X;G_ ()9?_2TZ- _87\6GXN? OXL_%O]NW]L#]H<?L\?$#Q%\4OA]\/?
MBCX=_8=\,^!#X[\1_!?XL_ 677-=F^ 7[%WP3^(&I#3/ /QJ\=IIFF1^/+/1
M_P"V+O3]2U+3]2_LV""@#[_HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M% !7YP?$CXD?MH>/?VT/BG^SG^SG\5?V8/A!X)^$/[,'[,/QKU75?C7^R_\
M%;]H7Q3XL\4_M!_%;]L/P+>Z?I][X%_;&_9ETGPOX?\ #&D_LSZ)<VMK<Z)X
MHU'5-1\3ZK--JME;65I:-^C]? 'PZ_Y2F_MB_P#9@'_!-C_UHK_@JY0 ?\*Y
M_P""IO\ T>1^P!_XK3_:*_\ IL5'_"N?^"IO_1Y'[ '_ (K3_:*_^FQ5]_T4
M ? '_"N?^"IO_1Y'[ '_ (K3_:*_^FQ4?\*Y_P""IO\ T>1^P!_XK3_:*_\
MIL5??]% 'P!_PKG_ (*F_P#1Y'[ '_BM/]HK_P"FQ4?\*Y_X*F_]'D?L ?\
MBM/]HK_Z;%7W_10!\ ?\*Y_X*F_]'D?L ?\ BM/]HK_Z;%1_PKG_ (*F_P#1
MY'[ '_BM/]HK_P"FQ5]_T4 ?E!\:_&W_  4D_9KT+X<_$OQS^T/^P_\ %+P3
MJG[3G['/P7\8>"/"?["?QY^%GBG4_"W[2_[6OP4_9O\ $%_X:\?ZQ_P4?^+&
MD^&O$'AO2?BO=^)]&N]4^'/BW3KC4=&MK"]TI[:[EFA_5^O@#_@I;_R;G\/?
M^S^?^"4G_KTC]CJOO^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "OSF_;K\1:-X2^-O\ P2R\
M2>(+T:?HVC?MZ?$F]O[LPW-TZ0Q_\$M/^"E("6]G90W-]?WEQ(R6]EI]A;7-
M_?W<L%G8VUQ=SPPO^C-?FW^WMX4TKQI\<?\ @DWHFL_:A91?\%&];\0H;.<6
M\XU'P=_P3=_X*)>+]&/F%)/W(UC0K$W,>W,]L)H0R&3>J=[:*[NM&[77-#F5
M[-)N'M%%M-1DX2<91C*,VK=5>RFTD[7DJ=5PBW9M*5548R:3<82J2BG*,3ZH
M\6?%+]G+QEHFI>$?%_Q2^'<5E>Z=!K-]I6H?$.P\'^(+&PTW7(4TWQ+;.NMZ
M'XH\/G3O$=C:7&A^*+"73I[/5[:QOM(U**[2TGKQ*'PS^P3X%T_7HXOB#\+_
M  IIB/*VOF3]HB_TBUT[4M+U[P!XBO=9N))OB- FC^*(/$/A_P"'6I:MXGC>
MS\22WJ:*=2U.3^U=M[[2O[+OP0BOO#.JVOA35-/U;P;@>&=7TKQY\1-(U?2!
M_P (?X5\ LL&J:9XKM+^19?"7@KPYI-PMQ<3+<BTO+Z<2:EK.MWFH\S<?L9_
M *6.QMK?PYXBT^QM[W2;G4K&U^('CN2/Q'8:!X&\8?#O1?#NNW=_XAO=3E\-
M:?X:\;:G:KH^GW^G6]ZEAH-EJ9OM(T:TTU:@DD^:5G65&GB53A)*I"#<)2<I
M3YI0C3J8JI1I2C*5.I7C3YN95,6%1KFG[-2E&'UAX9U)4TTI.HZ4*L5&2C*<
M7&&(J46X-RG*,'3YH2Y70_AS^QAX=TR[;P_XQ\,:597>KV.DIJNG_M#>+(;O
M3-?^']EXO\82:?X=\01_$G^TO#&MZ;HWQ)\9ZYXKMO#FH:5J&K>'O%FIS^+5
MU#1;W!U?#UQ^QC#X:\2>'/#GC;X40^%O%_A+_A6VL6EE\4;:+3=6\(:/:^)?
M$)T;2+D^)U1;'3;/X@^([V34O#EQ%+:VVIM$]^D6DV<6G[&H?LV?LR_\*ZU#
M2=2T6VB^&]IHFJ6VJ7MQ\2_&]OIEIX=M?^$&75X;[Q.?&4=S;:-867PF\&Z/
M=)-JL=GI_AWP[<>&V$'A_4-=TW4,W3/V//V5-1.C:EH7@>VG?P?)<Z!H&I:#
M\0_'JR^&;GP[XPU76+O2M*O]*\8I)H][H/C.751<6UK-;W6E:A#+I<BP1V,=
MG!,Y5N6<Z<XSJ*-.:33A&5=8/ZQ2E*<7)TXQQE/">Q2BT\'4>-BO:X:A'$Q-
M2;C4:C*I>:E&=T^=U\5SM5?>7O4Y.HXNC[95XXRG4DHU>:CSGBO2?V&/&&C2
M:YXV\4_"Q]$^(7A[5_&CS^)/BK-X>M?$7A3XG7_@RYU'Q"MGJ/BS2]WA[Q3?
MZ!X+6TO$MXM-D/V.UTUHHM8N8;[;TG0OV//AM=W?AK3/$W@KP=_PJC0/"^FZ
MUI$GQ4U?2]$\(Z,?&GBOQ?X2L?%-O>>+(]"BNO\ A,;3Q=JFE6_B(2ZJ#::C
M%$HTNU$,9KO[+?[(_AM[[QKXJ\.Z-H\>D^$]+^&5_P"(/$_Q,\8VVG:-X3/@
MBU^&6E>%9+K6?&:Z=I%O<^%=1LK""%?LMU?:Q?VWB4O/XKNX]9D[>X_9H^!7
MB-=<U5O#U]J$7CC4CXHU*]M/B!X]>TU"XU%?B%<2S:9]E\5_8K#1-53XM_$*
M6\T71DM/#NK0^+=0%[IUW";58&XJ"_<N<Z,:]5U7&E&FYNDU+"14?;>QABJN
M'G6JS56K*&'J5H1A&>&]KB9JHI34N>,)SG&HZ7M'M*NHUL:FY1DZD'7HY9AZ
MLJ;A*M&BL;64)_5,)#SFU\(?L2^+=:EMM+\5?#/6_$&E:^LLUKH?QIN)]6TW
MQ'X \.^$Y)HI;;2?''VJSU+POX:\!>%K_4[1XXY;&PTC^U=2A47>HW5WR6G>
M%O\ @GY\/M+\*:1H'B;X:Z#IGA#5[?XF>'-+\*_%[6Y%LYY+CPAX^M_$%[8^
M'O&4\VI^&;R;X8>$/$2VVN17OA/4$\.VLIM+B&YN4N^[\&_L;_LP:!/&FG>'
MKCQ'XLTKP /AYJ_B76?B%XNUGQE>^%[SPWJWP[N1K5U%XCB%K=:GH]OKFB_;
M;&RTO[++:75MHRZ<=(MX;';U']B_]FO5M1\:ZMJ'PZFN=1^(L]]/XTNSXX^(
MD<NO"_UO3_$,MI<^5XMC6#2[?4]*L&TS1[-;;2M&LK==(TBSL=(>6Q<@I4XT
MN2I&+A&24J4)JE*-+%QK4%0YI0J1H5*E.MB6Y1E/#XF%.4(5*L:TZ=R4:M1N
MJG[.G7J*BYJ%>LL-7A*%6>JA2HXEJ35:$92I8BG-P52FW)R]D\,?%CX6>-=5
M.A>#?B7X \6ZV-,N=;.C^&/&7AW7M5&C66JG0[S5SI^E:E=W8TRTUM6T>YOS
M#]D@U4'3Y94NP8:^/_\ @D]_RBS_ .":W_9@G['?_K//P[KZE\#_  -^%_PX
MUFX\1>$/#D^GZ[=R>)Y;O5KWQ'XIU^^NYO&<WA*Y\43W5QXAUO57N9]8NO _
MAF\N9IB\JWEE<W<#Q7.KZU+J'RU_P2>_Y19_\$UO^S!/V.__ %GGX=U4N1<O
M(Y/1\SE%1][GG;E2<G;V?L[W=^?VB5X.#40]HXWJ*"E:.D')I?NZ/.FW:]JW
MUCE:23I?5VTJGMSWCX_^ OB7X_@\':=\/;TZ-!8:GJ>H^)-<L?C1\1/A+X@@
MM8[%$T_1M&M_!GA/Q9H?B"/Q!=.]IJ^H^,K"^B\*:9#/>>&-%N_$VHV&N>&?
M+_AA\%_VB_ _B/PKJNI?%"/7- M[U+;Q/X8\4?$7XB?$ C0;.]\86&F3V.N:
M[IFDW&M^)4\,7V@7&J7=W8Z!I>L^+]1U74K[3I-/\&^"K$_:]%33_=3<X)7=
M2-62G%3C*47*RE&5UR<DY4W&/)>#U;J*-6%S2FTVDK4G2]URC=-QDJC<9INK
M&4*;4[V:IQA*G*ESTZQ7P!\.O^4IO[8O_9@'_!-C_P!:*_X*N5]_U\ ?#K_E
M*;^V+_V8!_P38_\ 6BO^"KE 'W_1110!P>I?%#X=Z&?$AU_QEX?\.0^$=7T_
M0?$-[XEU&#PYING:OJFA67B;3[ ZIK;6&G74USH>HVFH)]BNKE%1Y8G9+BVN
M889(?B5X!NQH;Z=XMT/68O$>O67AC1[C0;Z+7[6YUW4O"DGCG3]/DN]%-_;6
M3WW@]$\1VDU_+;6UQI5WIUU%,Z:IIINN#^(7[-GP;^*D?B6#QYX8U+7;/QAJ
MFD:UXETP>-_'NE:1JNK:#HL/A[2+^;1]%\3Z=I<=S9:3;6L$<EO:0EYK2SOI
MO,O[2VNHIO#_ .SI\(_"VCVN@Z!H.MZ;IMCXRTWQ]8K'X_\ B'+>V/BC2/!=
MA\.],NK'5;CQ7-JMGIUGX*TRR\/P^'K:]B\."SB9SI)N9YYY9@Y-3]I%*2G3
MY.2:DITW*FJO,W&+A-1=:5.RG&2C3@[3G.<'.UZOL[M>SQ'L>=)/VOU9O"JH
MHMWI_6THXB6DO83<J4;PM.UK7[0GP5T'P]XN\67OQ'\.77AOP%#I4WC'6M!N
M)O%-AX>76M372-/BU&;PS!JXCNFO9(A=62A[S3K2:#4=1@M-.FBNWVK;XR?"
M:ZU>V\/)\2?!$/B.\U.YT>S\-WOB;2-.\1WFIVNIRZ/)9VF@:A=VVKW,LNHP
MM;V9@LI$OP\$]BUQ;W-O++R'@_\ 9D^"'@+2O$FB^%?!;Z?IWC#Q#HGBOQ+%
M<>*/&.KS:QXA\.ZKI^N:5JMU>ZSX@U"]^TQ:MI5C?70BN(XM3GCD.J1WBW5T
ML^=X%_9/^ 7PU\6Z1XY\&>!9M)\4Z#H\OA_1M4F\7^.M8_L[1)0@;2K6QUSQ
M-J6FQV*%"\%O]C,=M-+<SVXBFN[EYG3OS1]JK1EA\-*;IM.5/%?5I/&4XJ5E
M5P_UODAAJK=.K]7YJM6E[7]VU.UVZ:;5ZZC&;C%N/UAK#5)R2DHMX11E7I0C
M*V)G*%.JZ,(U)_15%%%,#X _X*6_\FY_#W_L_G_@E)_Z](_8ZK[_ *^ /^"E
MO_)N?P]_[/Y_X)2?^O2/V.J^_P"@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O@#]LG_DXG_@
MD]_V?_\ $7_UUI_P4JK[_K\X/^"@.OS^ O'O_!.?XNW?@CXP>-/!/P@_;?\
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MKXE?#;]I_5O!'Q2_8@_87\)>"?&/P4_8U_:X_:9\+:EXJ^%GQY_X*-:QX_\
M#6H>(/V;?@E\6-)\->(/#>D?%?X=:I=:-XGN]&U&XT[Q;I5[86UW;/-+" ?J
M]17P!_P\L_9U_P"B<_M__P#BIW_@J;_]!O1_P\L_9U_Z)S^W_P#^*G?^"IO_
M -!O0!]_T5\ ?\/+/V=?^B<_M_\ _BIW_@J;_P#0;T?\/+/V=?\ HG/[?_\
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MK/BKQ3HVG6^G:-<@7+W+V]O-^S] !1110 4444 %%%% !1110 4444 %%%%
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M_0Q_\D;Y^ '_ %=@/^,6?^JR5\__ /#V+_@EE_TDL_8 _P#$R/V=?_GC4?\
M#V+_ ()9?])+/V /_$R/V=?_ )XU04?0'_#2WPZ_Z%S]H#CX_P#_  S5_P F
MG?M3_P#)1?\ H8_^2-\_ #_J[ ?\8L_]5DH_X:6^'7_0N?M <?'_ /X9J_Y-
M._:G_P"2B_\ 0Q_\D;Y^ '_5V _XQ9_ZK)7K_A/Q9X5\?>%?#7CKP+XF\/\
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M%YX@O-)T+7-4M=&M[R34;C3M&U6]AMGMM.NY80#G_P#AI;X=?]"Y^T!Q\?\
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M&/@WS\ /7]K 9_9:'?XQT?\ #2WPZ&?^*<_: X^/X_9J_P"33OVIS_Q<4_\
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MJGUE4Y.$5[*$W*5.-:,9Q494YNLJMEAX4ZEY/EFZ7N,OQO\ @\FG2ZI'\3O
MU];1>';[Q:L>D>)=*UK4+OPYIN@MXIO=6TW2=(N;W5=5MH?#J_VT/[-LKN6;
M3FCN8(Y(Y8RU8_'GX-IK@\+S?$;PO;>*7UBTT*V\*WFH+9>*=0U*]2PD@32?
M#=VL.MZO:>5J5M+/J>EV%WIEK$E]+=7D,>F:DUI\WZ!X'_X)_1ZEIWB70-4^
M"XOM+\/>,_ VD:K#\383;MX6\4IXF\4>+]#TV2;Q6;'5-$>V^(?B2\/V47EG
MH>GZF;'3)=.LM(LK73MRSMOV)])TGP9XDN/'GP_L[-(O#'Q;\*Z_XR^,^JIJ
MVIVGE:CIGA3QU>ZKXR\:'7/$6G7%OXXFTS3-5\03ZC8WMMJNC6"/-#:Z%#:W
M3E"56$9.ZFI+V=-IU7.5?DH>SYE[[]FI0J4I4E5E7;C2A%0:2E*4*?-*5-)N
MK[.I-^SA.-/!TJDYS4GRKV6)6(=54:DH+"NE5=:+A5C/W&X_: ^!ENVH0CXO
M_#>]OM,TW7M6NM'TCQEH&MZ^;#PQH]WX@\02VGA[1[Z^US4)=)T6PO=3O+73
M]/NKN.SMI9O(*J:O^(?C7\(?!\<LWC/XF>"/!,$5W:V'VCQMXDTKP?;SWE[8
MZ%J-M;V=QXEN=+AOY'M?$WA\L+*2X$5QJUE93&.]E%N/G\^#/V+?"S^+/"=[
MXA\':8W@^RT]O&-KK_Q>\1-'X1LM?\$^.?A+H^G:MJFN>,Y(O#:7'@F;QSX;
MT?0I+VQ:TM+6ZO\ 3["WNM*LK^TZ.UB_9'\822^'+3Q_\//%E_I>LLEW8Q_&
MF3Q#KMMKO@1?!_BRZMM2F_X36\UEK_PS:_#[PEK.JV=],\ECI6BB74X5TR[U
M$7>,JK=!RH.A4JQH.;<JRCAW55.M-KG@JE2G07L:CE6ESKV5*O6BI4Z-1QZ7
M"/ME2BJW\9TG%T[UO?J82%&U)*[JS]I77U=?O/:RPM!2=2I.,?2K+]H3X&WT
MNNP1_%GP#;2^&]=F\-ZRFJ^)=,T7[+K,&G6>KO:(=8N+%;Q&TK4+'4H+NQ-S
M97-C=07=M<RP2+(>W\%>.?"/Q&\/Q>*_ VOV'B?PW/JGB+1K;6M+D:;3[K4/
M"?B/5?">OQ6EPR(EW#8^(-$U33UO+<RV5[]E-U87%U936]S+\,>)?AI_P3BG
M^P2>(-3^%FJ/8VMWXETU(?BWKFMW.GZ?KWA73%N]?M;?3/&=[<6.EZSX3\*:
M3(^JI'#8ZA8Z3:W"W$S[9)/J;X0^(/@38647PX^$/Q!\'>(C;#Q7XS&A:7\3
MH_B'XC>#7O&^K7_BOQ'=W6H^)/$7B:[L)?'6LZI:W5_>7<UCI^J7']B0/:);
MV]A#U/V+GBHTI5)JG7JPPZ<(QG["G6JVGBH1E-TJ_P!6@IUJ=-2H4JT:L(UI
MPISE#DC4;Y9.=!PFH.$H5&U*4J="$XPDY.%2*Q<ZE*G.,Y3G3E04X0KR<)_-
MG_!)W_E%E_P34_[,"_8Y_P#6=_AU7W_7P!_P2=_Y19?\$U/^S OV.?\ UG?X
M=5]_UF;!7P!^V3_R<3_P2>_[/_\ B+_ZZT_X*55]_P!?G-^W7XBT;PE\;?\
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M@[_@F[_P42\7Z,?,*2?N1K&A6)N8]N9[830AD,F]?TDKX _;)_Y.)_X)/?\
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M]D"QN_&'B?QSHWA_3KKXOZY>:7XIUSQ-\4/%FGMXKU^[\2VGBV31K2]U'QI
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MC;ZC)I6J:7JNG7.G S>/_P##&_[17_26+]O_ /\ #<_\$LO_ *6G7W_10!\
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MG S?3]% 'P!_PQO^T5_TEB_;_P#_  W/_!++_P"EIT?\,;_M%?\ 26+]O_\
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M!_PQO^T5_P!)8OV__P#PW/\ P2R_^EIT?\,;_M%?])8OV_\ _P -S_P2R_\
MI:=??]% 'P!_PQO^T5_TEB_;_P#_  W/_!++_P"EIT?\,;_M%?\ 26+]O_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'!T\.^1.JJM>M5]E"G&D>5W'A_\ X*4VFK1:!=?MT_\ !.2VUV<Z<(-%N/\
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M\$ZI^TY^QS\%_&'@CPG^PG\>?A9XIU/PM^TO^UK\%/V;_$%_X:\?ZQ_P4?\
MBQI/AKQ!X;TGXKW?B?1KO5/ASXMTZXU'1K:PO=*>VNY9H?U?KX _X*6_\FY_
M#W_L_G_@E)_Z](_8ZK[_ *0@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /@#]LC_DXK_@D[_P!G_P#Q'_\ 767_  4LK[_K\P?^"C'A&_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[BVU:>]?3(.+_P"':?[.O_11OV__ /Q;%_P5-_\ HR*/^':?[.O_ $4;]O\
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MD\0ZA\3?#UA,$U'2;;P^++Q,^L7<-[X?N]-;N];_ &[/AKX<\,:/XRUGX?\
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M7A'3/$G,7_[<+#0/!.H>'_#WP8UWQ!XLTKQS?S^'+C]I30_#4=E#X+\?:_\
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FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %] G # 2(  A$! Q$!_\0
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M !FJ%Y<:5IS>3-:Q@2,LC!( V7W?*2 ,EL@D<$_*:/4##,-PDCI+XSU^,*6
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M$;3GTP!Z"I(=1TF;RU2PR'D$8_<K@-]WGZ;@#_O?7!Y V8[L83B?QSKT+'&
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M?]"9KG_?ZR_^2*ADU:[EF$LO@;67D&W#-)8G!7)!'^D<$9//O4W_  D.J?\
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M\7W>IZ=;7]GX1UR2UNHEFA?S+,;D8 J<&XR,@CK0!8_X2'5/^A,US_O]9?\
MR11_PD.J?]"9KG_?ZR_^2*/^$AU3_H3-<_[_ %E_\D4?\)#JG_0F:Y_W^LO_
M )(H /\ A(=4_P"A,US_ +_67_R11HT5[<^(=1UFZTZ?3XY[2VM4@N7C:0F)
MYF+?NW==I\Y0/FSE6R ,$G_"0ZI_T)FN?]_K+_Y(H_X2'5/^A,US_O\ 67_R
M10!T%%<__P )#JG_ $)FN?\ ?ZR_^2*/^$AU3_H3-<_[_67_ ,D4 =!17/\
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M8KMY8CJ#G^%NW:CK81#_ ,)EI?\ SZZY_P""*]_^,T?\)EI?_/KKG_@BO?\
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MJZ"N?\/?\ASQ9_V%8_\ TBMJZ"@ HHHH **** "BBB@ HHHH **** "BBB@
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M[@N[6354V302"1&Q9VP.&'!P01^%=1110 4444 %%%% !1110 4444 %%%%
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M'/9W6ILEQ;RJ&CF46MPX#J>& 9$8 ]U!Z@4 2?\ "">#_P#H5-#_ /!=#_\
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M=#_\31_P@G@__H5-#_\ !=#_ /$T?\()X/\ ^A4T/_P70_\ Q-'_  @G@_\
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M4T/_ ,%T/_Q-'_"">#_^A4T/_P %T/\ \31_P@G@_P#Z%30__!=#_P#$T?\
M"">#_P#H5-#_ /!=#_\ $T '_"">#_\ H5-#_P#!=#_\31_P@G@__H5-#_\
M!=#_ /$UC^)?"?AO3-/L[RP\/Z5:74>JZ?LF@LHXW7-Y"#A@,C()'XUW% '/
M_P#"">#_ /H5-#_\%T/_ ,31_P ()X/_ .A4T/\ \%T/_P 37044 <__ ,()
MX/\ ^A4T/_P70_\ Q-'_  @G@_\ Z%30_P#P70__ !-9=AX:T'6?$GBJXU31
M--OIUU*-%DNK5)6"_8[8X!8$XR2<>YK4_P"$$\'_ /0J:'_X+H?_ (F@ _X0
M3P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\
MXFC_ (03P?\ ]"IH?_@NA_\ B: #_A!/!_\ T*FA_P#@NA_^)K!\*'7AX$T#
M["KE/[.M?+SY6,>3%USSM^_[YQVK>_X03P?_ -"IH?\ X+H?_B:/^$$\'_\
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M*71]0UB[N0M]9K#&5+D^4R[<8PO)ZG(/?&&!]MVBA#.?\/?\ASQ9_P!A6/\
M](K6N@KG_#W_ "'/%G_85C_](K6N@H *Y_Q#_P ASPG_ -A63_TBNJZ"N?\
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MBNJ V)Y_#5E.Z.SRAT;<K#;QRQ(Y'0[L8]%7TJ&3PI9ON*RR!FP,LB$ !LD
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M?]@JU_\ 12UT%<_X$_Y)[X:_[!5K_P"BEH Z"BBB@ KDVNY;?XC:LL41D/\
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MJG_0YZY_WYLO_D>@#H**Y_\ X1[5/^ASUS_OS9?_ "/1_P (]JG_ $.>N?\
M?FR_^1Z .@J-((8Y7E2*-9'^\X4 M]36'_PCVJ?]#GKG_?FR_P#D>C_A'M4_
MZ'/7/^_-E_\ (] '05#':6T,ADBMXD<YRRH >3D\^YK%_P"$>U3_ *'/7/\
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M%&LW4$5Q#<>1)':*KM%(LB@E(%;&Y!T(KI* "BBB@#G_  ]_R'/%G_85C_\
M2*VKH*Y^7PQ-_:=_>V7B+5;#[;*LTT,"6S)O$:1Y'F0LP^6->]'_  CVJ?\
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M#_H.Z'_X)IO_ )*KH** .?\ L?C#_H.Z'_X)IO\ Y*H^Q^,/^@[H?_@FF_\
MDJN@HH Y/4KGQ5HT-M=W&IZ-<P->VMO)%'I<L3%99TB)#&X8 @/GH>E=97/^
M,O\ D!V__85T[_TMAKH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YSQ/-'!JWA665MJ+JDA
M)QG_ )<KJNCKFO%,"7.K^$HY,[?[8+\'NMI<L/U H U9[[2[B)H)[RW"D;BI
MF", #P>H(Y'!JD(?#EJD@%S;1+_'_I9 !!4Y^]P<A>>O2KO]B:>'B<0LKQ?<
M997!7Y0O4'T4#_\ 6:B/AW32% BD5002!*WS *R@'GIACQ]/2@"**ST&&,^5
M/&JE@NX7;9#+N; .[@X=B<=CS3XCH0@DBBN+412Q^2P$_!49.!S_ +1Z>M/?
M1M)^PLCQ@6P4AB9FP%^7/.>GR*/H,=,TQ/#^COL>.W!\KY49)F^3#$X!!XP<
MT:@1SQ^'KB+S+B:VV3H9,O/M#*Y7)Y/0X7_)I\<6AV;&))88OLR*&7SR @W%
ME!YQUW'FB71-%A+7$T2)MC$)>29@%7;L"\GC@_UZU.=&TZ;S'\IF$S;R1*V#
MG=TYZ?.W XYH KK;Z!/*0DUN\BOR$N>0R@>C=0%'Y5"D'AJTCB2.6W18F\Y%
MCN#Q]UL\'D?(IYXXJ>W\/:1$?EB,DJQ>4SM*Q<K@KSSZ9%2/X<TJ1YW:U):<
MDR'S7^;)!]>F0.* +D-_9W,GEP7<$K[=VV.0,<9QG [9XK'\"?\ )/?#7_8*
MM?\ T4M:MMIEI9RF6"(K(=V6+LQ.[&>I[[1_DFLKP)_R3WPU_P!@JU_]%+0!
M?U6UN[L0K;-L"L2[BY>)NG &T$'/OT[<\BK9:=JEM/$[W>^,'#QR3/)Q\V,$
MCDXQZ<D^@K;HH *Y^S_Y*'K/_8*L/_1MW705S]G_ ,E#UG_L%6'_ *-NZ .@
MHHHH @>]M8O,\R>.,1,%<N=H!(R!D^QH%Y;-LVS(XD<(I0[@25W <>W-07>C
MV-\)1<PLZRL&=?-8 D# . <=*(M(LH(A''&ZJ)!*/WKY#!=HYSG[HQCI0 Z3
M5K"*":9KJ,Q0X\QD.X+DX&<4\:C9-*(OM4(D+;0A<!B<XZ=:AM]%T^UCECA@
MVK*X=\NQW,""#R?44VUT+3;.Y2X@MRLJ+M5C(QP/3DT :-%%% '/^,O^0';_
M /85T[_TMAKH*Y_QE_R [?\ ["NG?^EL-=!0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_II]S_:KE+'Q5HEM/%))XVT)TW'S(WU=) %RV "3DX!'7J>3T%;?_"=^#_\
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M/^/"?[_K]S_5_P#33[G^U6A5/4M6TW1K=;C5-0M+&!G"+)=3+$I;!. 6(&<
MG'L: (_[9M?^>5]_Q]_9/^/"?[_K]S_5_P#33[G^U1_;-K_SROO^/O[)_P >
M$_W_ %^Y_J_^FGW/]JL__A._!_\ T->A_P#@QA_^*H_X3OP?_P!#7H?_ (,8
M?_BJ -#^V;7_ )Y7W_'W]D_X\)_O^OW/]7_TT^Y_M4?VS:_\\K[_ (^_LG_'
MA/\ ?]?N?ZO_ *:?<_VJS_\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\
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MK/\ ^$[\'_\ 0UZ'_P"#&'_XJMR">&ZMXKBWECF@E0/')&P974C(((X(([T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=S)Y<%W!*^W=MCD#'&<9P.V>*Q_ G_)/?#7_ &"K7_T4M '04444 %<_9_\
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M_AVVEL;.VDEDS:JPC>/ .2,%N<\XR/Q/MBI-X/M&EADAG=&20NVY%(<'!VG
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M&3R< #K5BBB@ K+UK11K*V3+?W=C/97'VB&>U$98-Y;QD$2(RD%9&[>E:E%
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MO"J;BYG*D<$@$;<<[6 YZ@=,U9T[5?MTTL#PF&:,9*$Y[D=<>WYY],T 4/\
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M#_H.Z'_X)IO_ )*KH** .?\ L?C#_H.Z'_X)IO\ Y*H^Q^,/^@[H?_@FF_\
MDJN@HH Y_P"Q^,/^@[H?_@FF_P#DJC['XP_Z#NA_^":;_P"2JZ"B@#G_ +'X
MP_Z#NA_^":;_ .2J/L?C#_H.Z'_X)IO_ )*KH** .?\ L?C#_H.Z'_X)IO\
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M=,MG'% $USX?M+R-XYWE>-FD;:=I"E\YQQ[\5%-X8L9H!"7G11N V,%(!*G
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M85')XMTZ.::(K.3$^S.T .=P7"Y(SR?R!K=HH RM.UV#4[V:TB@GCDA!\SS
MN 0<8X)]ZU:C6"%9FF6*,2MU<*-QZ=_P'Y"I* "N?\"?\D]\-?\ 8*M?_12U
MT%<_X$_Y)[X:_P"P5:_^BEH Z"BBB@ KG[/_ )*'K/\ V"K#_P!&W==!7)M9
MR77Q&U8I*$"Z+:*#C.UVDNP&Q[#=^= (ZRBL&+0+R!=JZO.RX7 <R':0 &Q\
M_0X/';/&.M%SH5_,T:QZO/&JH 7#ONRH4*<!L')#DYZ[AUQF@#:N(5N;:6!R
M0LB%"1UP1BL^YT&TO8PER7FPP;+A3R-OMC^ ?K5.7P_?R1[5URYC^<L2-YX[
M*,OT!)]R"!VIR^'[L3JS:O,\ D5_)(; 56!"CYO08YSG-#07$D\(Z?(<F:Z!
MW%CAP,D@#GCG@#K6M86,>G6:VT18HK,V6 !RS%CT '4^E9<^AW\]S<3?VW<)
MYC;HT0,%BP>.-W/&0?7.>U*-%OH83Y&IMYBI(5#;PI=MY!/S'(&Y>N?N#&*+
ML+:FY17/Q>'[^*1F_MVY9>=J,7(4]1R7R0#CJ>@Q3%\-7@"[M;N'<%LN=VXY
M&!R'XQDG\O2@0_QE_P @.W_["NG?^EL-=!7)^)[.2WTSSI+J283:KII",3A/
M].B/ ).."HXQ]W/>NLH&%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!S_B'_ )#GA/\ ["LG_I%=5T%9^K:+9:W%!'>K/_H\OG0O!<R0.C[6
M3(>-E;[KL.O>L_\ X0W2_P#GZUS_ ,'M[_\ 'J .@K&M]"EBLI[>74)9A.%#
MELXX8EL L<9!V\>F:@_X0W2_^?K7/_![>_\ QZC_ (0W2_\ GZUS_P 'M[_\
M>H 5_#UWB01ZO.BMO(5"R_,W.<ANS<].Y'2E30[NXT5+.^O2TWG":60$L),<
MA><';D#CT'OPW_A#=+_Y^M<_\'M[_P#'J/\ A#=+_P"?K7/_  >WO_QZ@!;S
M0]0D$[VVK2QN>84!=40[LC.&Z8RN ,'@XR*O:58W%FC?:91)(45-P8MNQDEC
MGN2Q_#%4/^$-TO\ Y^M<_P#![>__ !ZC_A#=+_Y^M<_\'M[_ /'J .@HKG_^
M$-TO_GZUS_P>WO\ \>H_X0W2_P#GZUS_ ,'M[_\ 'J #P)_R3SPU_P!@JU_]
M%+7057L+&WTS3K:PLX_+M;6)884W$[44 *,GDX '6K% !7/^(?\ D-^$_P#L
M*O\ ^D5U705GZMHMEK<4$=ZL_P#H\OG1/!<R0.C[63(>-E;[KL.O>@#0HKG_
M /A#=+_Y^M<_\'M[_P#'J/\ A#=+_P"?K7/_  >WO_QZ@#H**Y__ (0W2_\
MGZUS_P 'M[_\>H_X0W2_^?K7/_![>_\ QZ@#H**Y_P#X0W2_^?K7/_![>_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% $<<$,+.T44:,_+%5 +<D\_B2?Q-2
M444 %%%% "%58@E02IR,CH:6BB@ HHHH **** "BBB@ HHHH **** "BBB@
MILD<<J;)$5UR#AAD9!R/UIU% #418T5$4*B@!548 'H*=110 4444 -CC2)
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ^ 1(# 2(  A$! Q$!_\0
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M+NV\D8SN&>E>+5]>>#;B:T^!-C<V[F.:+2W=''56 8@T <*/V:5'_,SG_P
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4H **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !  ,H# 2(  A$! Q$!_\0
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M4[#3?&&MQS7,<8E$,@&<EF*D' ')/ IQ3::%)[,=XL'_ !/_  L>_P!N;_T
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?'1W$]C4C7;&JCL *?24M($%%%% PHHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>fin_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fin_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X G # 2(  A$! Q$!_\0
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M_$%VMPNG$G]Z=@.[..G3WQFOHCP[*DWAVPFCO7OEDA5_M#N'9R1GD@#UQTH
MU:*^:=1\0ZN-4\4VJ7^MVT40D@&+DW"1C[SAOGP'Z*&4X W'%>L_"W4-1O\
M1KEM4N;V:Y$@(6<H\<<9&46.1!A_EP2>N3T% '>T5X_XXUR6P\?O:I>W<:J+
M1C$NHS1[_,?8=B*-HP!DY(S5GX;ZS?:KK4+:B-9NKYK/SGN)KJ,6R1.[!"L2
MXZE,9()XH ]7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ>:]US52[!IKJ=L*H[>@'H!7J'AS0(M"L=G#W,G,TGJ?0>PKRRTN;G2=22=
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MR>F:Z/PCX7'ABVOE::&6:]NC<2?9[<01K\JJ%5 3@ *._7-=%7(>-9[N6_\
M#VC6]_<6,.IWCQW$]LVV78D3/M5OX<D 9'.* +-UX3DGE\1W$6J20W6LI'$L
MHB!^S(B[0%!/)Y8Y]3[4[0_"4.@ZV]U:R@6@TZWL(H"O*B(L<D]\[JO>'[.:
MPTYK2;5Y-5,4KJL\N#(JYX1R.K#IG@FL#1O&]WJ>O6MO+I<<6FW\US!97"S[
MI&: D-O3'R@[6Q@GISUH [6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)DW-(=ORA<\+\X^8\=>U5W\>VD-J\L]J\<D2S^8@E4C=$4!56SAL^8,8]#0
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BZA#<)NFFD,R$'#1L<@#T(-=$.E%%5"$8:1(J595'>1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex23-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !; = # 2(  A$! Q$!_\0
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MTK?P0Q*\KG 1&) K^?JX_P""M'Q^DD+0^#?A-:Q]H_[+\4S8YX!DD\5*QX]
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MI=U+8ZA93HZJ5EMKJ"6)@0,[=PR""?T!_P""<G[74?P*^,$/@OQ=J8M_A?\
M%:\L=&U>6YE M/#7BUV%IX=\3EG(2WM;B21=#UR7<J"SN;.^G)72U%<W_P %
M2X_V?M9^)FE?'/X"?%GX9>-AX_/]F_$GPQX.\6:'J^I:?XIT^U!L/%XT[3KB
M246&O:; ++5[D(5BUBPM[F=VEU=V7\JFU]&5E)0A@01E1D$8(R#D9'<<^E?6
MT:66^)7 RI9IE^)P5'/LM=+&X+%8>OA\9E>94URU)4Z>,P^'JQJX#,*2Q."K
M2IJ-:C[&7/*&(Q"7YY4P7$'@7XLO%\.9S@LSQ7"&>+$95FF!QF&QF6Y_DE9N
M=.GB*V6XO%X>IALXR:O/ YIA8UI3PV)>*C[.%7!X.3_T"@0>G^<]#]/>BORK
M_P""5O[8D?[17P@D^&WC#51<_%KX.V5AI>I274RM>^*_!! M/#?BOYF\RYNK
M41C0?$$VUF&H6UG?W$A?68Q7ZJ5_GKQ+P_F'"N>9ED&9PY<7EV(E2<XJ2IXF
MA+W\+C*#DKRP^+P\J6(I/5I3G3D_:4:B7^T/!'%^4\>\*Y)Q;DE1SP&<X*GB
M%2G*+KX+%1M2QV78I0;4,7EV-AB,'B(V2E*E3K07LL31;_)3_@KW\1_''@KX
M)>!O#OANXOM-\,?$#QC>:+XWU.QDE@,]GI^DMJ6E^&KJYB9&CLM>N$N;BY@W
M*+Z+1VM)-\$LT4G\XHUT*  Y4   +D!0.  %. !T ' '3BO[9_B=\+_ GQD\
M$ZU\//B1X<L?%'A+7X%BU#3+T2(5DB<2VM]8W4#Q7>GZE8SJEQ8ZC93P7EI.
MBR0RJ<Y_!KXZ?\$7O&^G7=_J_P"SK\2-)\0Z2S23VO@GXFF72=<M5+$I967C
M'2;*ZTW5=JD".35=&TA\#%Q>S/F5OZ3\$?$[@S(N'H<,9Y4I9%CX8[%XG^TJ
M]*?U#,UBZD)4YXG%T*=66&Q6&IQ6$2Q=-X=X>G2=&O1_?4W_  G]*WZ/OB;Q
MIQM5X^X6A7XKRFKE&69?_86&Q--9MD/]G4*M.O3P&7XFO0IXW 8ZM.68R>7U
MHXR.-K5XXG"XG_9J\?F7]A'1?V4?'7Q"UK3OVH?%D>BI%;Z8? NBZYK=QX6\
M&^([Z:6Y75(]>\2VUU9/!=6B+9C3M*N=1TVTOTGNI&GN9($MA_0MX=_9)_9!
MN-+M[GPY\%/A%J^E3Q#[-J%MHFDZ]#<QE1ATU.4WS7.5(/F_:9&8$'<>#7\J
MWQ"_8F_;(^&DETGB?]GCQ_>V=J&,VJ^#M/M_'VD-&O6477@Z?69%B(YS<V]N
MX'#QJP('SSI7Q&^)7PEU?R=%\0>/_A;KD,F3:V.K>)_ FHK*IYWV*2Z5,[ \
M,LD#>C ]*^_XMX'J^(6,EF_"OBEC,)"5"C&&5Y=FBQV3TO94U'VE&GD6<X+&
MX=UFE5K/$4,3)U'*2G&+C2I_DWAGXC4/!?+(<.<?_1]RC-*L,5B9U.(,XX?>
M6<3XE5Z[G[#%5^+.&<VRS&QPJ;P^%6"Q6 @J$:=.5&<U/$5O[(M8_83_ &1=
M<1TN_@1X)MBX8>;HT.H^'IE+ @LDV@W^G2*PSD$-P>U:7P+_ &//@=^SIXF\
M3^+/ACH>K6&K>*-.M=)N&UC7;[7X]+TRVN'NY;+17U-I[NR@O[DP3:@LEU<&
M=K*S"M&D.UOY@?A]_P %2/VROA[)"(_B])XVL(G5GTOXC:-I'BJ*X12,QR:L
M(-.\2*& P7CUM7Y)+$U^JW[.'_!:SX>>--6TSPI^T1X1@^%>H:C-%9P>/_#E
M]<:Q\/UNIY(XH3KUC>J->\*VC,Q#Z@9]?TZVR'O[NQMEDN$_&^)_#+QGRC*\
M=AUGF8<4Y)6HM8W"9=GF9XR=;#TI0K6J91FD_K=6,94H5)4\)5Q$W[-)TJR7
M(_Z?X$\:/HR<09_E./EP9DO '%6%Q*GE699QPCD.60PV,KTZF%4J/$?#]&.7
MX>I.&)J485LPH82G'VTFL1AI2]K']RJ*@MKFVO;:WO+.X@N[2[@BN;6ZMI8Y
M[:YMIXUE@N+>>)GBF@FB=9(I8V:.2-E=&92"9Z_G9IIM----IIIIIIM---)I
MIIIII----)II?V>FI)2BU*+2:E%IIII----IIIIIIM----IILKSWXN>)X_!7
MPI^)OC&640Q^$_A_XR\2/*6"B,:)X=U'4M^XD %?LV0<CG%>A5\Y?M>_#SX@
M?%S]E_X[_"SX62Z-#X_^(OPS\4>"?#<WB&_GTO18KKQ-I\FCW$FH:A:V6HW%
MK MA=W;>9#97#[PBA!NW+W953P]7-,LI8NK3H82IF67T\57K2Y:5#"SQV#CB
M:U65I<M.GAW7G-\LK1BW9[/S<[J8JCDN<5<#1JXG'4\HS6>"P]"/-6KXV.6Y
M@\'1I1YH\U2KB_JM.FN:-YR7O1W7^?!'X[EN4%U/+F>Z+74^'P/.N2;B4C/.
M#)(W7GUYK]9/^"*4I\7?M]>"Y?\ 6KX5^'7Q/\2OD[Q'OT6W\,)(0!@8D\2*
MJD]'92"& KF5_P"" '_!0=55?[5_9X& !Q\1O% Z#';X?5^I_P#P21_X);_M
M)?L8_M ^.OBO\=[SX87.D:I\*[SP;X;3P+XIU;7[]=9U+Q-H.IWDEY!J/AG0
MX[>S.G:2ZB:.XED:=HT\G:6=?[R\1?$O@/%<"<6X/*>*LDQV8XS(\;@L'@\)
MBY5,17J8OZOAE3I4_JE--QHU*TFN>-H0EKI9_P"7?A)X$^)&6^)W F9YYP=Q
M!E^5Y9Q-EN9X_'8W!*GAJ%+ 2Q6,]I5J?7:ME+$4L/%/V<[SJ1TUNOVM_:2^
M!/A?]I3X)_$#X,^*PL5CXRT.>UT_5!$LEQX>\16I6\\.>)++(W+=:)K$%G>A
M8V0W$,4UG(_DW$@/^?[\2+#Q=\(_B#XT^%WCVQETCQGX \2:IX5\2:>[$+%J
M6DW+P//;,P'G:??Q"+4--NES'=Z?=6US&6CE4G_1TK\'_P#@IW_P1]\0_MH?
M%[PS\;?@IX[\"?#3Q?=>'/\ A&_BC!XSL->FL?%7]C&%/"7B"RD\/V]Y(NM6
M>GR76AZF;F*.*YTRST3RY#+9R*_X#X#^)> X/S#,,CXCQD<)P[FL)8RCBJRJ
MSHY;FV'IJ/-*-*E7J0HYEA5]7JN%*26*P^$JR2YI37]2_2A\$L;XD9;E'$O"
MN >+XMR.:RZOA*#HTZ^;Y%BZLJBIJ56KAZ<\1E&-;Q6']I6BW@\7CJ$)>["#
M_EYO?VB?'6H?"KP]\%+O7I9/AOX7\;:]\0M&T'A5@\4^)--LM*U"[DG#;IH$
MMK-Y+*S91#:7>I:O=1@RZC.:^_O^"4_[*MW^V'^T!!J?B?3Y9_@G\')M+\4_
M$2:='-CXCU=YGG\*?#Y90 DO]MW5I)J6NQ!@4\.:==P,T<FIVA?UIO\ @W-_
M:NP=O[0OP!+8^4'3?B* 3V!(T8D#U(!..E?TI?L.?LD^%?V+/V=O!OP5\/SV
MNKZW9QR:[\0_%\%JUK)XT\?ZND3Z_KK1R,TT5BC10:3H5K*Q>RT'3=-M9-T\
M<TDGZYXD>,_".7\*9AA. \VP6-SS.J^(H*KEU+$4?[.6/BYYGG%6=7!8-/&5
M::]EAZD93K2QE98F3C]4IR/P7PC^C-QKF7'63YEXG91C\)PWPYA\'B/J^:XC
M#XG^U5E34,ER"E3IX['..6T*K5;%491IT(X##RP<(R^O58GURB1Q1I'&J1Q1
MHJ1HBJD:(H"HB*H"JBJ JJH      K^ ?]N[4!X0_;2_:E\/*?+2R^-OC>Y1
M P4;-9U#^W5;&U?]8-3\S.T9WYY)R?[^CS^G\^?_ *]?RH?MZ_\ !&3]L']H
M/]KOXU?&KX3:C\&8? ?Q$US1]<TB+Q3XTU_1]=2XC\+Z)INK"^T^S\'ZM;PD
MZI8W1A,=]*)8#'*1&SM$GX_]'KBC(^&N),_J<09K@\IP>.R*E3IXC'UG1HU,
M5A\THUXTE-4JUZKI5:TTG%7C&;YNC_H+Z6/ /$/'?!_"U#AG)\?G6895Q-6Q
M%3#9;0C6KTL'B\DKX6I5E#VU"U&-:C0A)J5E*4%RM6M^#&B_$:31M<T+68KA
MH9-'UW1M6242#,;:;J=I>AQ_N&'=^'K7^D'HFJ0ZWHND:U;X^SZOI=AJD!!R
M/)U"TBNXL'G(V3+@\YK^**?_ (-_O^"A$L$T7]J_L\_O8I(_^2C^)^-Z%<\_
M#W'&<_6O[*O@YH/B7PK\(_A=X8\9?83XN\-_#OP7H'B@Z7=2WVFMXAT;PYIN
MG:P]A>36]I-=6;ZA;7#6UQ+:V\DL)1WAC9B@^@^D5Q)PIQ-0X3K\.Y[E><5\
M%6SBABZ>7XEUIT*&)I8"O1G53P]!QA.O0J0B[R]^ZLKW?RWT1^!.-.!,1QUA
MN*>'LWR3#9K0X?Q."GF6%]A"OB<#6S3#UX4I+$UU*<</BJ<Y+EC[EGS.UE_+
M'_P42_X**?&7XJ_M#^.OV<?!?C"]^%OPM\&_$*7X3R66F:I<^'KGQ3K-IK$/
MA_5_$/CO7K22#4ET :HT\EOH<$]MIMMH]M'=:A;WM\[O'^W'P5_X)5?LF?#+
MP&WAWQ?X&L_B]XKUG2S:^*O''C-[J6]N[J[B0WLOABRM+J"V\(0+.I?3[C1Q
M'KD,81KG6KNXW3'YV_X* ?\ !&/X>_M:^+]9^,GPI\<'X,?&37XUE\4QWFDM
MKOP[\>ZA##%;0ZIK>E6MQ9:KH&ORVT20W^NZ+/=PZ@L44U_H5W?F:^F^?OA)
M\-?^"]_[*6E:?X \,7'[//[3?P_\/11:=X?@\<^-FN;VQTFUCCM[.QL?$.MM
M\.?%ZV-O;Q1Q6=GK6H:TMA"BVUJZ0(D=9X[.\CSW@?AG*O#KC'*> L9EM"F^
M(L@S+&UN&,7FV8PH81/&RXAHX:=/,'#%T<57@L1CX4JT,52E*%&>%6$C63\&
M<1<.^)O&O$'B]P%FWBK@LYQ59<(\3Y?E^&XRP/#V45,5F$O[+I\)XO%1>51J
M8'$X'#3EA,LG6P\L!7A&I7IXV6/GH?&K_@F+^TC^S-XGN/C1^P!\3?$]\=.W
MW<WPYNM<AT_QO%91EKB32]-O[SRO"WQ'T?$9 \.>+K:UOY59(H9]9O75CV'[
M-'_!:[P\GB#_ (5!^V[X.O\ X)_$;2+M-&U+QL-#U;3?#T>H*4A">.?"%]$_
MB'P)=RN&>6_A35?#TGF?:"^CV*@CNKCXI_\ !>?Q+"VG:?\ LP_L:?#F>7*#
MQ#JWQ&U+Q!';!A@2I8Z;XYU9F:,G>!)97"DC!C8<'P_7/^"0/[67[7OCK2OB
M1_P4&_:U\.ZC<Z59/8Z;X2^!7@C2[1],TV>59Y=(LO$VJZ#X>LK* 2*KM-=>
M%O$ET[J=M\"[24H9AD6<9;4P?C%G7!.9O"X64,MXDX9SC^TN.Z4X1M1HS60Y
M// 9M0;W6;5J%DFY7<I35U>&N)N%\YIYC]'C)/$'(H8W&PJYSP5Q?DD<M\+L
M13J5+XG$4EQ)GL<TR#%*/PO(:-?F=E!*,(4G\E_\% ?VMM3_ ."A7[1O@/\
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M:1=*\16(35=+D?:'N;&2YL+C^U']LS]B7X+_ +;OPRG\ ?%+3&L=;TZ.ZN?
M/Q'T:"W7QA\/]<FB"K?Z1=2KMO=,N72%-<\-WS-I6MVL:QSK;WL%AJ%E_+)K
M'_!OS^WM9ZOJEIHWBG]G[6](MK^[@TO69_&OBK1Y]5TZ.=ULM0GTAO!%^VES
MW=N(YI]/-]>BTE9X%N[E469_Z4X4\9N N-^',1E_',\HR?&RH1PN;9=FO-_9
M.9PG&WUK+JDZ&(:A*<?:2PTYTL9E]=0G0Q-2G'#XF'\<\:?1H\2?#CB_"9QX
M93SW.\#2Q4L=D.;9,U'/LFJ4Y<RP>:4Z=?"QE.%.?L5BJ=.M@,UPSJ4\5@Z<
MYXK!S_J-_8Q_;I^"'[;G@0^)OAGJPTSQ=HUO;#Q[\+]:NK8>,/!-[.-F;F",
MHNK^'[F8,ND>)].C;3=13$<HL=2CN]-M/LZOXV_A'_P1@_X*I? ;XA>'_BI\
M(OB+\#O WCSPS<>=IFN:3\2_$V9('*_:]*U6QF^'DECK6A:E&OV?5-$U2"YT
M[4+<E)X"P1T_J\^ 6I_'?4_AGH;?M(^%? GA3XMV:FQ\21?#/Q+?^)O!.LRV
MZ1A-?T.;5M)T?5=*AU/+22Z#?PWDNES+)!'JFI0>5<O_ "]XD<*\)9)CGCN"
M>+,HS_),75?+EU+'^WS;*:DN:7L:BGA:#QV!^S1QD)+$4THTL;1<^3%5?[?\
M).,N.^(,KCEWB-P5G/#?$>!HQ]IFM3+?JV1YY3@HQ>(I<F+Q*RW,7I+$X"47
MA:LG.ME]>-/GP=#VBBF221Q(\LKI''&I9Y)&5$15&2SNQ"JH'))( ')->?R?
M$C1[V[FTOPC;W7C75(',4ZZ$$;2+&3./^)GXBG*:1:@8.Z*&>[O>#Y=E(<"O
MS)1<KV3=MWT7JW9+YM?,_8FTMWOLNK]%N_DC\NO^"M'[!OBG]J#P1H7Q7^#=
MG'J'QI^%FFZA9GPP9(K:;XB^"+B4W]UX?L+F9H[>/Q-HUZ)=2\-QW+PV^H?:
M]3TJ29+B\L7C_CRU77=5T#5=2T'7]/U30M>T6]GT[6=#UJSN-*UC2-0MI&CN
M+'5-+OH8;RPNX)%*2VUS#'(A'*X()_T<]/LM;N"MSK][;HY^9-(TCS4T^WY.
M%N+Z8)>ZG(HVY<QV%JQ!S8'AC\I_M/\ _!/W]E+]KV)[GXS?"_3KSQ:MJMG9
M_$?PQ/-X4^(=A%&H6!!XFTCR9M4M[91BWT_Q##K.EQ MML>37]$>%7CD^#<!
M1X;XDP6(S/(L/.?]GXW NG+,<KIU:DJM3#.A7E3IX_ JK4J5:4(U:&*PSJ5:
M=&=:C.-*G_(7CI]%VAXCYOB>,N$<RPV2\3XRG36;9?F"JQRC.ZV'HPH4L8L1
MAX5:V69E*A2HT*]5T,3@L8J-"K7IT,33G6K?QV_L9_\ !0CXF_L7>/[SQ/X,
MCM/%'@_Q,MG:_$#X<:S>RVND^*+6R:3['J%G?PQSR:'XHTI+BY72]9CMKN(Q
M3S66HV-[92".+^GCX)?\%J/V%?BSIUF/$WQ"N_@CXGECB6\\._%+2[O3[*&Z
M90)4L_&&DPZGX4N[1'R([FYU/39Y(]LDEC;EC&OYL_%S_@W#E:>ZO/@-^T]-
M;6[O(UIX=^+W@N/4&@C))BCD\7^#+S37EQG8TC>#F? #G>Q(KX<\5_\ ! K_
M (*#:!/*F@S_  *\=6Z,PBN-%^(VKZ/),H/#&V\4^$='$18?PM<MM'!<GFOT
MOB6I]'_Q.JQS/%\3TLCSJ=*G3GCU*ODN.JPIQ4*4,?A<QR^OE^,E1C:G"K*K
M&M&G%4UBJE*%-4_R?@;+?I2^"E"629;PM+B3AN%>K6IY36A0XARW#U*LW4KU
M,KQN59GA<URZ&)J7JU*$*,\-.M*59X&C6J595OZ\-"_:Q_9;\36T5WX?_:/^
M!6KP3*&C:Q^+'@29R#D#="NN^<A.#A9(U8^E6M2_:D_9ET:-Y=6_:)^!FFQQ
MYWM??%GP%;8P,D8FU]&+8(^4 MR,#FOXLIO^"'G_  4M#LO_  I;P+< $_O4
M^,'PY*/[CS]6BD_[ZC4^U:>F?\$*_P#@I#>R*EQ\,/AAH@) ,VI?%OPG(B@]
MW&C+J\F!W"1N?0'I7P<_"+PCC)S_ .(SX!4;W4>;AZ=51WLW#%M-VTNJ-^O+
MT/UF'CAX\2@J?_$ <4\3:W-S<5TZ#E:U[5,#&2BY:V]OHM.;[1_8]\-OVQ/V
M7/C'X]E^&'PI^.WPW^(GCN#1K[Q!)X>\'>(K77YQH^F7%G:W]ZMWIQGTYUM9
MK^T66&.\:X"RF01&*.5T^DZ_EF_8+_X(T_MN?LU?M)?";X_>(OB9\"_#5AX&
MUYW\2>&]$UCQGXGUCQ#X1UBQN='\4:!&Z^%=#TF&>^TF\G%I/+?RPVU_'9W#
M1S1PO$W]3-?D/'^1<)Y!F^&PO!W$\>*<MJ8"G4KXS]W[3#X^-:K3KX>;HX7#
M8>5.=-4:]!TO:VA*I"I4<HJ_[IX7\1\<\39%BL;Q_P (?ZFYQ2S.K2PV @ZS
MH8G+)4*-7#8F"Q.+Q>*C5A4>(P^(5?V/-.-*I3I1C*27^?)^V1XO^S?M>?M2
MV_F@>1^T+\7X<%Q_RS\=:V@ZGC@#CC'3%?-X\:_,@,PP9(@?G'(,B@C@]"."
M.XSGBOVG_:2_X(>_MS_%7]HGX\_%#PGJ?P)3PM\1_C%\1O'/AM-7\>^(K/54
MT+Q3XKU36=*74K2#P+=PVU\MC=PB[MXKJYCAG\R-)Y542-XM_P . /\ @H."
MI_M7]GCY7C8_\7&\3GA75CC/P^ZX!Q7]SY+XG>'%#)LFH5N,N'J=>AD^4T:U
M.>.DITZU'*<LHU:<U]1=ITZM*I3DKNTH25W:[_S&XC\!/%;%\1\0XK#\"\35
M</B^(<^Q6'K0R].G5H8K/<YQ-"K"7U]7A4H8BC4@^57A4B[*]E_47X1_8,_8
MPU7PGX6U.]_9D^#<]YJ'AO0KRZG;P5I2M-<7.EVDLTKA8@"\DCL[L?F=V+,2
MQ)/HNB?L5?LA^')%FT?]FCX(6LJ8*R2?#7PI>.",8;=?:9<DL,#YCEL\YS7O
MOA+3+K1?"OAK1[WRC>:3X?T;3+LP.9(3=6&G6UK<&&1E1GB\V)_+=D0LFUBJ
MDE1T%?Y_XKBCB.K4Q$'Q)G]2C*M6Y8O/<Y=-TW6K<EH_VJERN#CRJUN6RLEH
MO]4\#P-P9AZ.%J1X,X2I8F&'PZG4CPMPW&LJL:%!5&YK(7)3]I&;D[M\W,[M
MW;Y[P]X1\*>$;7[%X4\,>'O#%E@#[)X>T73=%M<+]T?9]-MK:+"]ALP.U=#1
M44[2I!,\,0GF2*1HH#((A-*J$QQ&5@RQ"1P$,A5@F[<00,5X,YU*LW.K4G5J
M3=Y5*M2=2<F]+SJ59U)R?>4IR?=GU=.E1P]*-*A2I4*-.-H4:%*G1IPBM>6G
M1H4Z5.*[1A2BKZ*-V?BM_P %GOVXX?V=/@Y;_ OP/K(M?B[\<],OK6\FLYS'
M?^$/A:'>P\1:X71@]I?>)I#-X7T*3ARAUZ^A:.;2HF/\@:^,PBJB/M50%55=
M0JJHP% QP   !V%?MU^U!_P2'_X*=_M5?'?XA_'7QWK'[/46J^-M9DDTO1E^
M)OBJ>S\*>%+'-IX7\):<S?#\C['H6DI#;O* IOK]K[4YA]HO9F/@T?\ P;__
M /!0626*.37/V>K:*26..6Y'Q!\43FVB=U62X$ \ (9C"A:00AT,I7RPR[LC
M^[/"_.O"[@+A/!Y7/C3AF>:XI1S#/<3#'.3K9C6I1YJ$)K -SP^74>7 X9)N
M,O9XBO%7Q*;_ ,R/&_@SQF\5^/,=GBX$XMIY'@5+*>&,'4R_DCALHH5IM8FI
M3>8\L,7FV(Y\RQDFE*/M<)AY/EP5EF?L0_\ !.SXX?MS>"O%GQ#\&^+?"GP]
M\&^&O$47A6RUCQI8:Y?)XJUJ.S6]UF'0XM'CP;?0([C3X;^ZGD$<EY?K:VZO
M):7GD_;7_#@_]HO_ *."^#?_ (3?C7_"OZ,?V;?@-X/_ &9/@=\-_@;X&A5=
M"^'WANSTEKXQ+%<Z[K#!KKQ!XDU *3NU'Q#K=Q?ZO>$LP26[,,9$,4:K[C7X
MGQ!](?C:MG>:3X=Q6 P61_7*T,JP]?)L#B<0L%2E[*C5KUL1+VLJV)C3>*J1
ME94GB(T(JU%M_P!"<*?0_P#"_#<-Y+2XLP&:YGQ*L!0GG>,PW$>:8+"SS&M'
MVV(HX7#86/L*>'PDJJP=*4;NO'"2Q$VY8A*/\K,O_!!/]I"*&62#X^_!N:9(
MI&B@.@>-8!-*JDQPM/Y<HA61PJ&4QR",'>8WV[3^$'C&;Q-\/O%WBCP'XSTR
M\\/^+O!FOZKX8\2Z)?$)=:7K6C7DMC?VDHQAPD\+-#,F8KFW>*XA9H948_Z0
MM?SS_P#!5O\ X)"_$7]JWXO>'?CM^S+>?#_0O&.O:5_87Q?T;QIJVH>'=.UN
M?1888?"_C#3KO2]$UPSZT=.#Z!K<$]M;"XL]/T2ZCEDFBNP_V7A?X^X[&YY7
MR[Q#S'+J678O"RE@<U6"P^74<!C</S5'2Q<L+&JIX?&T7*G"K.FW0Q5*DK^S
MQ$N7\^\9_HE9'@N'<-FOA/E6;RS; XQ1S/)IYIC,XK9IE^)4:2K8&..G1E3Q
M675U"K4I4ZJ6)P=>LVO:X6'/_/+^S/\ M:>*_P!F#XV>"/C/X2>6ZN/#&H"+
M7]!^T>5;^+/!^H%(/$WAB[."@74; &2QF=6%EK%MINH(/,M5K^_'X4?%#P9\
M:OAOX*^*_P /=6BUOP7X^\/Z?XC\/ZC$5#26=_%O:WN8U9_LVH:?<+/I^IV3
ML9;'4;6ZLY@LL#J/XU/^' /_  4'_P"@K^SS_P"'&\4?_.^K]T_^"27[*O[;
M7[&7A_QS\'/V@[OX7Z]\';^Y;Q;\/+CP;XTUC7=:\'^*[R=$\1Z*-/U/PMHL
M9\-^(XV365\F\)TS6[6^E2UE&N7$L&?CQB/#WB[*\+Q!P_Q5P_B>(\G4</5P
MF'QE\1FV4U:FM&">#I*KBLNKU'B<,I33GAJN,H1E[E.+[_HNY1XJ>'>;X_A7
MB?@_B;#<(9_*6,HXO%8%K#9'GM&DH_6)2^O5?8X/-L-26$QCC3<88S#Y?BI1
MO*M,_2_]H/\ :!^&'[,/PLU_XQ_%_6YM#\%>'9M+M+N>SLYM3U.\OM9U&VTO
M3M/TG2K;_2M2OKBYN5<6ULK2+:PW-TP$-O*Z_-O@3_@J1^P#\1$M_P"Q?VG_
M (;Z5<W"(PL/&UWJ'P_O8G?I#+'XVL-"02J?E81RR+NX5VX->6_\%/\ ]@+X
MH_M\>#_A[X3\%?'72?A?HG@35]3\27?A'7/!U]KNB^,/$=S:+I^D:KJFL:;X
M@L+RP_X1^QEU.WT^V32-13S-7O+EF$BPHO\ /AXO_P"#?O\ ;UT*24>'?$7P
M \>6PSY;:=XW\3>'[F5>P:T\1>"[:WC;_9_M"1 3C>0 :_/>!N#_  FSSAVE
M4XIX^J9!Q+5Q6*E+#0E"AA\+A(RC3PM*I',,KJ8;$5JBC4Q-2K1Q].$8UJ5"
MW-3J27Z[XD<<^.G#O%=6EP3X:87B7A"C@\'".*K0K5\7C,?*$ZV-KTIY7G%+
M%83#4W.GA*5&OEM6<I4*N(NHU:<7_7KIO[2'[/&LQ+-H_P >O@QJL+#<LNG?
M%'P/>QE>N0]MKDJX_&O(?CA\=OV#[GPO?V_QZ^*G[-&M^'%MY8KG3/&GBCP!
MXFE:*1'#I8Z-)=:EJDUP?F,0TVT>[67:8,3;#7\@=S_P0W_X*412&-?@S\/[
MQ03^_@^+WP\$;<]0+S4;6;GKS"#UZ9(K3T?_ ((7?\%([R94G^&7PQ\/JQ -
MQJ?Q;\)M$@)(W,-!76)\ 88A(6.,  G('UN'\*?"G"8BGBH>-F%I1I3C4A/"
M5\DPV-CRM-.EB*&.=2C/32=.GS1>JBVK/XC&>,WC?C\'6P-3Z/-2O/$4Y4IT
M\PH\18S+JG,G%JMA,3EGLJ]+5WIU:G)-:2DDW)>$_M3>//@!=?'_ .),_P"R
M]%JMG\"I=6MCX'@U<7\,@1=.M%UN72X=89M8MO#DVO#49?#=OJ^-2AT=K1+F
M.(A8D^?CXR4C;O>3>1&(U82/*TI$:0I&JL\LDK,(XXD5GD=@B*S, ?V:^&__
M  ;K_M1:W<6LOQ4^.GP;^'^FR.#=P>$K'Q=\1-<ACRNX1Q7UEX'T@RX+!&_M
M*:-64;E=37[3_LA_\$</V3_V4]:TCQY=VFM_&WXJ:++'=Z7XT^)HT^?3/#^H
MQG<FH^%/!.GV\7A_2;Z%@LEGJ6HKKNM:?*BS6.JV\HWU^QYKXW^&_"N54<)@
M,ZQO%V.P.#HX6A#"*OBJ^,J8:A"C"MF.=8O#8/"*I6E3C4Q6)C3Q%24I5)TZ
M$YN%_P":LH^BWXK\:Y[B<PS3(\MX%R[,\QQ&.Q4L2L/@L+EU+&8FIB*F&RCA
M[!8O'XSV.'C5E2P6"E5PM&G3A2IU,1""GR_4G[ 'A3XA^"/V,OV=?"_Q4AO[
M3QSI?PXTM=6T[56<ZGI%K=3W5[H6BZBLI,L-]HWA^YTK2[JUDQ)936CV;JK0
M$#[!HHK^#\UQ]3-<TS+-:M*E1JYGF&.S&I1H1Y:%&ICL7B,7.E1B]52IRQ#A
M"^KC&\O>E(_U#R'*:609'DN14*U?$T,ERG+,HHXC%24\3B*668#"8"G7Q$U=
M2K5882-2HTW%2GRQ?+" 45R^I^$M-U$O+#<ZQHUVYR;S0M7OM,DW<\M;PS&P
MF)/)%S9S D<@C(/"7_A/XL:;E_"_Q*M]3B4DII_C+0+"=B /E0ZMH\%G<'/0
ML]H3W+'MQJ,7]M1?:2DE_P"!)27WI'IMM?9;_P +3_!V?XGL=%?-E[X[^/7A
MKG6?AKI'B&W3<6O/#-W=R;U7JY@CEO[J/C)PUBG':LF']J32[:86WB#P3K^D
M3CB2-;BVED5LX/[B^32Y@/0%<]![U:H5'\"C/_!.,OPNG^!+JP7Q7C_BC)?H
MU^)]4T5X'8_M)?#&[($]UK6FD@9^VZ-<,H_X'8->J<'T)KL+/XR_"^_*B#QK
MHR,W1;N66P/T/VZ&VQ4NC56].:_[=;_),:G![3C]Z_6QZ916!:>+/"U_C[%X
MDT&[W $"VU?3YB0>1\L=PQ'T(S6Y'+'*NZ*1)%_O1NKK^:DC]:AIK=->J:_-
M(NZ[H?1112 **** "BBB@ HHHH ***H7.K:79 F\U+3[0#.3<WEO !CKDRR)
MC'?-%K[:^FOY 7Z*X>^^)?P^T[/VSQGX;C*]535[.=Q[;+>65R>V N<\8S7(
M7W[0'PJLLA?$3W[#^'3M+U2YR?19#:1PDGL?,P<YSC)%JG4EM3F_2,O\D2YP
M6\HKYK_-GL]%?,>H?M2>#H,C3-!\1ZBPZ--'8Z=$?3YI+N>4 G_IAGN0*X#4
M_P!JGQ!.[1:)X4TFT9R5B_M"^O-3GY'!$%I#IX=AV 9E)]1UT6%KO_EVU_B:
M7ZM_@0ZU-?:OZ)O]$OQ/MNJ]U=VEE"UQ>W-O:0(,O/=31V\*#KEI)61%&.>6
M%?#]OXD_:2\>!1IEOJNF6<YRMQ:Z7:>&[0(>ZZAJ2B[=0#D-!/(Q'*Y-=#I_
M[-WBKQ!,M[\0?&TTK,0[VMK/>:W=Y)RR&^U5TMX&Z\PVEPF<8.!5.A&'\2M3
MC_=A>I+[E9"]K*7P4YOSE:*^]GL_B'X[_#+P]YB/XABU:YC)#6NA1-J;;AV-
MS$5T].>/WEXI_ &N)M_BM\3O'9\OX<_#\Z=I\F57Q)XME>.T5<_ZV&%/(BE9
M5P=EO-J//!0Y&/0O"WP7^'?A,QS66@PZA?1<KJ.MG^U+H,,8:-9U^R6[ \JU
MM:PL">#TQZF         !@ #@  <  < #I4.5&/P0<W_ #579?*G&R_\"E\B
MK5)?%)17:"U_\"?Z1/#;+X07^N2)>_%/Q?JGC24,)/[ MI)-(\)POSE3IUF8
M&OE'&&G$*,!B2!Q7LVGZ;I^DVD.GZ796FGV-NH2"TLK>*VMHE':.&%4C7U)"
MY)Y))YJ[16<IRG:[T6T5:,5Z15E^#?F4HJ.RU[O5OU;N_P"M@HHHJ2@HHHH
M**** "BBB@ HHHH **** "BBB@#E?$/CCPCX3E@@\1^(--T>>ZB:>WAO)Q'-
M-"CB-Y8X@&=T5R%+!2 W%<H?CA\)U)!\<Z-D$@_-<D9'7D6Y''<YP.:^;_VK
MO^1D\,GN/#E\0?0_VB.17U;X3\/Z"WA;PXS:)I!:70='>5CIED6D=]/MV=Y"
M8,NS,2S,V2Q))))-=#ITX4J=27/)U+Z1<4E:_>+;T1DISE.<%RKDMJTW>Z79
MHCTOXH?#O6I%BTWQGX=N)7.$B;4K>WE<YP%6.Y>%V8G@*JDD]!7=JRLH92&5
M@&5E(*LI&001P01R".".17SO\;?"7POMO".K:AJFG:)H^MQ6<K:)<:?!:V.I
MW6I!2;6W2WMA$U_%-*%CN$GBECCA9Y2T102)S'[+>H>)+K3/$-M>2W5QX9LW
MLDTB2Y:22*WOV$YO[/3Y)/\ EV2,6\DL,9:&"9_E$;2.&3I1=*56#DE%I.,T
MM;V^&4=);[6N'.U-0DDW)-IQOI;NG>WWGT!X@\?^#/"EW%8>(O$6FZ1>36XN
MHK>\E9)'MR[QB90$;*%XW7.>JGBNK@FBN88;B!UE@GBCFAE4Y62*5 \;J>ZN
MC!@?0BOA#]J3'_"<Z/U_Y%5/7_H(:A^OTYZ>U?;GA[_D :'_ -@?3/\ TB@H
MJ4E"E2J)MNHFVG:RMVZ_>.,W*<XM*T&K/J[]S8J"ZNK>RM;F]NY4@M;2":ZN
M9Y#B.&WMXVEFE<\X2.-&=C@X52:GKFO&?_(G^+/^Q:UW_P!-=U6*5VEW:7WM
M+]2WHF^R;^Y-_H5_#WCOP?XLN)[7PWX@T[6+BV@6ZGALI6D>*W:01+*X*+A#
M(P4'.<D<5UM?"_[*?_(U^)?^Q;M?_2^VK[HK2O35*HX1;:2B[NU]4^UD12FY
MP4FDF[Z*]NG<*1F55+,0JJ"S,Q 55 R22>  .23P!R:HZIJ5KH^FW^K7S^79
MZ;9W-]=. "5M[6%YI2H) +;$.U<C+8&1FOA[3]6\9_M#^,)](FU:Y\/^$;2-
MK^ZTVPD*1VNF+*(;=)D4J-2U6\=]GF7?F6L!$\L5N(XEB<ITG44I-J$(*\YM
M-V\DEJWY:>;U'.:C9).4I.RBM/FV]D?6NK?$_P"'FANT>I^,O#]O*G#PKJ,%
MS,ASC#0VK3R*0>"&0$>E<]_POCX1[MO_  FVG9]?LNJ;><?Q_8-G<?Q=.>E:
M/AWX/_#CPS#''8>%M,N9D4!K[5H$U6]E8=9&EO5E6-CUQ;QP1C^"-:[3_A']
M!V>7_8FD>7C&S^S;+9C&,;?)QC''3I1^Y6B567G>$;_*TK?-A^\?6"\K2E^-
MU?[C%\._$'P5XLG:U\.>)=*U:Z2)IVM;6XS=+"C*KRFWD5)A&K.BL^S:"R@G
M)%=C6-I_ASP_I-U/?:5H>DZ;>742P7-S8:?:6<\\*.9%CEDMXHV= YW;6)!8
M G)48V:SERW]WF2_O--_>DD4KV]ZU_*]O+?4****0PK/U#2-*U>+R-5TS3]2
MAP1Y5_9V]Y'@]<)<1R*.O85H447MMIZ:?D!X_J_P'^%VK[V/AJ/39G))FT:Z
MN].()[B"&;[)^=L17FVJ_LK^'YBS:-XIUFPZE(M0M;+5(P>P+1+ITNWL3N+=
M\DU]4T5K&O6CM4EZ-\R_\F3_ #,W2IO>$?DK?E8^$M1_99\80[FT[7/#>I 9
MV+<)?:=,PYXP(+V($\=9@/<=3R=Q\"OBYI.6MM'EF53]_1M?M=QQCE8S>6<W
MT_=@CL.U?HS16JQE9;J$O6/^3_0GV%/IS1]'_P #]3\U#H?QPT;D67Q+M%C)
MPUK<ZW<1@#'0V=U<)CTQQWYZFLWC7XQZ=@3:YX_M=G&+V+5FQC/7[7;L#[[L
M\CZ5^FE%5];3^*A2?RM^<63["VU2:_K_ !(_,Q?C'\5;7&_QCJZ[>,7-G8-T
M]?/L"2?7)/TZU97X\_%*/C_A+V/ &9-+T1NG?+Z>>3W/4U^DLEO!+_K8(9,]
M?,C1_P#T)35-]'TB3_6:7IS]_GL;9N?7YHC3^M4NN&A_Y+_\@@]C/_G[+\?R
MYC\ZO^%__%(+M_X2V+_>.DZ$6ZYZ_8<?FO2F/\>?BDXQ_P )>PR"/W>EZ&I_
M\=T[K[U^BG]A:)_T!M*_\%UI_P#&:>FC:.G*:3IJ'.<I8VJ\],\1#G'%'UFC
M_P! T/\ R3_Y$/8U/^?S_'_Y(_-Q_C)\4[HG;XRU8Y[6MM8)UR>/(L0P/IS@
M>E0_\)G\7-3&Q/$'CV\#G&VS;6%#9[*+*.->1G&.#V&17Z:1VMM%_JK>"+'3
MRX8TQ_WRHJ>CZU!;8>FO_ ?_ )6'L9=:LOQ_^2/S"'A?XN:Y\SZ-\0=1#=7O
M%UO8V<YRU[,D8'UP/Q-:EG\"/BGJ)#?\(H]N#@F35-2TN ]N65[V2;(_ZYD_
M0\5^E-%+Z[-?#3IQ^3_^U0_J\>LI/[OUN? ^G_LP^/KD WNH>&=*'!(-S>7L
MHZ9 2"R6(D?]=P#CJ*[S3?V5+<;6UGQG<R]-\.E:3!;#IR%N+RYNSR>_V<?0
M=*^O**B6+KO[2C_ABE^+NQJA27V;^K?Y*QX5I7[.?PRTXJ]UI^HZVZ@9.K:G
M<-&6'4FWL?L,!!/\+1L,<'(Z^IZ-X0\+>'E5=#\/:/I908$EEI]M#.?=KA8_
M/<^[R,?>NBHK&52I/XIREZR=ONT7X&BA&/PQBO1+_A_Q"BBBH*"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /AO]JTX\2^&#Z>';X^O340
M>G>O7?#WP0\.WN@:)>-XE^($!O='TVZEMK;Q=>0VBO<V4,SI#"(CY42LY6.-
M6 1 JC@5@?'[0=*U?7-!EU"V:=X]&O(D(N;N !#=ARI6WGB5OFYRP+#H#CBO
MH[P[&D/A_0H8QMCBT?3(XU)9BJ)90*H+,69L* ,L2QZDDY-=4JKC0HJ#<6N:
M[TL]WU3[]D81@G4JN233:MOT23ZH\OT_X _#.SN!=W6DWVNW(((EU_5]0U/)
M!R-\<DZ0RC/\,L3H>ZU[!:6=II]M#9V-K;V=I;H([>UM88[>WAC!)"10Q*D<
M:Y).U% R2>I-6**YY3G/XI2E;:[;2]%LON-E&,=HI7WLE^>_XGP9^U+_ ,CS
MH_('_%+)U_["%_7VWX>XT#0\_P#0'TS_ -(H:^:?CKX>TC5O%>FW%_:M/,FA
M11*XNKN#$8OKQ@NVWGB0_,Q.XJ6YQG  KR0:%9* JW&MJJ@*JKXD\1*JJ!@*
MJC50%4         "NMQ56C0C=Q<(N_NWO>Z_F78P3<9U&DGS/O;:WDS]":YK
MQG_R)_BS_L6M=_\ 37=5\.?V'9_\_6N?^%-XC_\ EK7UKX:M8?\ A445FQFE
M@;PKJT#^?<W-Q.\<D%\KA[J>:2Z=BK$>8\QD QAA@8QE25/EES<WOQ5N6W5/
M^9]C12<N9.*7NO:5^C79=SYJ_93_ .1K\3?]BW:_^E]O7W17YU6GA71;0;[2
M*^M'= CO::SK5L[HIR$=X-0C9D! (5B5W#=C/-7?[#L_^?K7/_"F\1__ "UK
M>M3C5FY\SC=)6Y;[*W\R,J;E"*CRIVZ\UNW]UGW9XET6/Q'X>UO09)/*35]+
MO=/,P&3$;J"2))<#KY3LKX[[<=Z^%/AMK]Y\$/'U_I?C;3[FQM=1MAIM_.L3
MRK&L%P9;+6+(H"+_ $YF,BRM;AY$AF#;#+ \)]&^$NEV]MX[TR6.?5'9;74L
M+=:WK-["=UI(I+6]Y?SP.0/NEXV*'YD*MS7U/KGAS0?$MH;'7](L-7M3DK%?
M6T<_EL< O [#S+>3@?O('C<8X:LU)4>>E*\Z=1)RM[LD^CC=O96WTNOOJSJ6
MFO=G!M+[2=N^B[_=?Y2Z1KFC:]:I>Z+JEAJEK(JNLUC=0W*@, 0'\MV:-QD;
MHY KJ?E90016K7PQ\5/ 7A7PA<S3>&=/N-&E#,1)9:OK*,#N/0MJ#X' P!@#
M'2O"K+Q)XDGN8[27Q+XC:W9]IB&OZNJE=P&/DO%/3C@U4<*JD>>%1J-KVE#6
MW_;LF@=9Q=I15UI=2T_%7/U;R,XR,XSC/..F<=<9!&:6OF[X'Z!IEG<7.LPK
M>MJ5S8FVN+FYU;5KWS8/-BE"/#>7T\!*R*&1_*WIE@C*&8'Z1KFJ14).*=[=
36K:]=+O\S6,N97M;RO?\;(__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !# ML# 2(  A$! Q$!_\0
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M)8E#!U7/7GJHZUW/A]]/D\/V#Z5;FWT]H5:WB,93:AZ?*>16#=ZU_:'E_;?
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MHH **** "BBB@ HHHH **** "BBB@ HHHH *X;2;%[G4KYO['L[J(7[AIY6
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M&RF7&XLQ;I6G6.%P<:=.U1)LWQN83K5>:E)J/W&'_P (AH/_ $#H_P#OIO\
M&O+=2LVT_4KFT;K%(5'N.WZ5[=6)J/A32]4O6N[F.0RL "5<@'%1B\"JL5[-
M)-&F S)T9OVS;3^94\#:A]MT!8&.9+5O+/\ N]1_GVKIJY^#P;I=MN\AKN+=
MUV7#+G\JE_X1>R_Y^;__ ,"G_P :Z:*K0IJ,E=KS_P" <F(="I5E.#:3\O\
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MVTFN_<SEA8J+<9:JW;R\_P#@'5M<P)*L3S1K(WW4+ $_04+<P/,T*S1M*O5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** $I:** "BBB@!*:D4<>?+C1,]
M=HQFBBD ZBBBF M075I!?6Y@N8Q)$Q!*GV.1112:35F--K5$WI1110(6DHHI
0@+1110 E+110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>avco-20250331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Jun 09 23:27:56 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2025" targetNamespace="http://www.avalonglobocare.com/20250331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:avco="http://www.avalonglobocare.com/20250331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="avco-20250331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="avco-20250331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="avco-20250331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="avco-20250331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet" id="avco_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals" id="avco_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement" id="avco_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ConsolidatedIncomeStatementAlt0" id="avco_r_ConsolidatedIncomeStatementAlt0">
        <link:definition>003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Alternate 0</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable" id="avco_r_CondensedConsolidatedStatementsofChangesinDeficitEquityTable">
        <link:definition>004 - Statement - Condensed Consolidated Statements of Changes in (Deficit) Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable_Parentheticals" id="avco_r_CondensedConsolidatedStatementsofChangesinDeficitEquityTable_Parentheticals">
        <link:definition>005 - Statement - Condensed Consolidated Statements of Changes in (Deficit) Equity (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ConsolidatedCashFlow" id="avco_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/OrganizationandNatureofOperations" id="avco_r_OrganizationandNatureofOperations">
        <link:definition>007 - Disclosure - Organization and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernCondition" id="avco_r_BasisofPresentationandGoingConcernCondition">
        <link:definition>008 - Disclosure - Basis of Presentation and Going Concern Condition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPolicies" id="avco_r_SummaryofSignificantAccountingPolicies">
        <link:definition>009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/PrepaidExpenseandOtherCurrentAssets" id="avco_r_PrepaidExpenseandOtherCurrentAssets">
        <link:definition>010 - Disclosure - Prepaid Expense and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/PropertyandEquipment" id="avco_r_PropertyandEquipment">
        <link:definition>011 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/EquipmentHeldForSale" id="avco_r_EquipmentHeldForSale">
        <link:definition>012 - Disclosure - Equipment Held For Sale</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/InvestmentinRealEstate" id="avco_r_InvestmentinRealEstate">
        <link:definition>013 - Disclosure - Investment in Real Estate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/EquityMethodInvestments" id="avco_r_EquityMethodInvestments">
        <link:definition>014 - Disclosure - Equity Method Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayables" id="avco_r_AccruedLiabilitiesandOtherPayables">
        <link:definition>015 - Disclosure - Accrued Liabilities and Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ConvertibleNotePayable" id="avco_r_ConvertibleNotePayable">
        <link:definition>016 - Disclosure - Convertible Note Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/DerivativeLiability" id="avco_r_DerivativeLiability">
        <link:definition>017 - Disclosure - Derivative Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/NotePayableNet" id="avco_r_NotePayableNet">
        <link:definition>018 - Disclosure - Note Payable, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/RelatedPartyTransactions" id="avco_r_RelatedPartyTransactions">
        <link:definition>019 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/IncomeTaxes" id="avco_r_IncomeTaxes">
        <link:definition>020 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/Equity" id="avco_r_Equity">
        <link:definition>021 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssets" id="avco_r_StatutoryReserveandRestrictedNetAssets">
        <link:definition>022 - Disclosure - Statutory Reserve and Restricted Net Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/NoncontrollingInterest" id="avco_r_NoncontrollingInterest">
        <link:definition>023 - Disclosure - Noncontrolling Interest</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompany" id="avco_r_CondensedFinancialInformationoftheParentCompany">
        <link:definition>024 - Disclosure - Condensed Financial Information of the Parent Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/Concentrations" id="avco_r_Concentrations">
        <link:definition>025 - Disclosure - Concentrations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/SegmentInformation" id="avco_r_SegmentInformation">
        <link:definition>026 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/CommitmentsandContingencies" id="avco_r_CommitmentsandContingencies">
        <link:definition>027 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/SubsequentEvents" id="avco_r_SubsequentEvents">
        <link:definition>028 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy" id="avco_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsTables" id="avco_r_OrganizationandNatureofOperationsTables">
        <link:definition>996001 - Disclosure - Organization and Nature of Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables" id="avco_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996002 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/PrepaidExpenseandOtherCurrentAssetsTables" id="avco_r_PrepaidExpenseandOtherCurrentAssetsTables">
        <link:definition>996003 - Disclosure - Prepaid Expense and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/PropertyandEquipmentTables" id="avco_r_PropertyandEquipmentTables">
        <link:definition>996004 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/InvestmentinRealEstateTables" id="avco_r_InvestmentinRealEstateTables">
        <link:definition>996005 - Disclosure - Investment in Real Estate (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/EquityMethodInvestmentsTables" id="avco_r_EquityMethodInvestmentsTables">
        <link:definition>996006 - Disclosure - Equity Method Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayablesTables" id="avco_r_AccruedLiabilitiesandOtherPayablesTables">
        <link:definition>996007 - Disclosure - Accrued Liabilities and Other Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ConvertibleNotePayableTables" id="avco_r_ConvertibleNotePayableTables">
        <link:definition>996008 - Disclosure - Convertible Note Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/NotePayableNetTables" id="avco_r_NotePayableNetTables">
        <link:definition>996009 - Disclosure - Note Payable, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/RelatedPartyTransactionsTables" id="avco_r_RelatedPartyTransactionsTables">
        <link:definition>996010 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/IncomeTaxesTables" id="avco_r_IncomeTaxesTables">
        <link:definition>996011 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/EquityTables" id="avco_r_EquityTables">
        <link:definition>996012 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ConcentrationsTables" id="avco_r_ConcentrationsTables">
        <link:definition>996013 - Disclosure - Concentrations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/SegmentInformationTables" id="avco_r_SegmentInformationTables">
        <link:definition>996014 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables" id="avco_r_CommitmentsandContingenciesTables">
        <link:definition>996015 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails" id="avco_r_OrganizationandNatureofOperationsDetails">
        <link:definition>996016 - Disclosure - Organization and Nature of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable" id="avco_r_ScheduleofConsolidatedFinancialStatementsTable">
        <link:definition>996017 - Disclosure - Organization and Nature of Operations - Schedule of Consolidated Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails" id="avco_r_BasisofPresentationandGoingConcernConditionDetails">
        <link:definition>996018 - Disclosure - Basis of Presentation and Going Concern Condition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails" id="avco_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996019 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable" id="avco_r_ScheduleofDerivativeLiabilityMeasuredatFairValueTable">
        <link:definition>996020 - Disclosure - Summary of Significant Accounting Policies - Schedule of Derivative Liability Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable" id="avco_r_ScheduleofCashBalancesbyGeographicAreaTable">
        <link:definition>996021 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash Balances by Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable" id="avco_r_ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable">
        <link:definition>996022 - Disclosure - Summary of Significant Accounting Policies - Schedule of Securities that were Excluded from the Diluted Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable" id="avco_r_ScheduleofPrepaidExpenseandOtherCurrentAssetsTable">
        <link:definition>996023 - Disclosure - Prepaid Expense and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/PropertyandEquipmentDetails" id="avco_r_PropertyandEquipmentDetails">
        <link:definition>996024 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable" id="avco_r_ScheduleofPropertyandEquipmentTable">
        <link:definition>996025 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/EquipmentHeldForSaleDetails" id="avco_r_EquipmentHeldForSaleDetails">
        <link:definition>996026 - Disclosure - Equipment Held For Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/InvestmentinRealEstateDetails" id="avco_r_InvestmentinRealEstateDetails">
        <link:definition>996027 - Disclosure - Investment in Real Estate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofInvestmentinRealEstateTable" id="avco_r_ScheduleofInvestmentinRealEstateTable">
        <link:definition>996028 - Disclosure - Investment in Real Estate - Schedule of Investment in Real Estate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails" id="avco_r_EquityMethodInvestmentsDetails">
        <link:definition>996029 - Disclosure - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable" id="avco_r_ScheduleofEquityMethodInvestmentTable">
        <link:definition>996030 - Disclosure - Equity Method Investments - Schedule of Equity Method Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable" id="avco_r_ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable">
        <link:definition>996031 - Disclosure - Equity Method Investments - Schedule of Summarized Financial Information, as Provided to the Company by the Investee (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable" id="avco_r_ScheduleofFinancialInformationTable">
        <link:definition>996032 - Disclosure - Equity Method Investments - Schedule of Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable" id="avco_r_ScheduleofAccruedLiabilitiesandOtherPayablesTable">
        <link:definition>996033 - Disclosure - Accrued Liabilities and Other Payables - Schedule of Accrued Liabilities and Other Payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails" id="avco_r_ConvertibleNotePayableDetails">
        <link:definition>996034 - Disclosure - Convertible Note Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable" id="avco_r_ScheduleofAmortizationPaymentsinCashTable">
        <link:definition>996035 - Disclosure - Convertible Note Payable - Schedule of Amortization Payments in Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable" id="avco_r_ScheduleofConvertibleNotePayableTable">
        <link:definition>996036 - Disclosure - Convertible Note Payable - Schedule of Convertible Note Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/DerivativeLiabilityDetails" id="avco_r_DerivativeLiabilityDetails">
        <link:definition>996037 - Disclosure - Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/NotePayableNetDetails" id="avco_r_NotePayableNetDetails">
        <link:definition>996038 - Disclosure - Note Payable, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofNotePayableTable" id="avco_r_ScheduleofNotePayableTable">
        <link:definition>996039 - Disclosure - Note Payable, Net - Schedule of Note Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails" id="avco_r_RelatedPartyTransactionsDetails">
        <link:definition>996040 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofLineofCreditTable" id="avco_r_ScheduleofLineofCreditTable">
        <link:definition>996041 - Disclosure - Related Party Transactions - Schedule of Line of Credit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/IncomeTaxesDetails" id="avco_r_IncomeTaxesDetails">
        <link:definition>996042 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofCompanysLossBeforeIncomeTaxesTable" id="avco_r_ScheduleofCompanysLossBeforeIncomeTaxesTable">
        <link:definition>996043 - Disclosure - Income Taxes - Schedule of Company&#8217;s Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable" id="avco_r_ScheduleofComponentsofIncomeTaxesExpenseBenefitTable">
        <link:definition>996044 - Disclosure - Income Taxes - Schedule of Components of Income Taxes Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable" id="avco_r_ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable">
        <link:definition>996045 - Disclosure - Income Taxes - Schedule of U.S. Statutory Rate and the Company&#8217;s Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable" id="avco_r_ScheduleofDeferredTaxesTable">
        <link:definition>996046 - Disclosure - Income Taxes - Schedule of Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/EquityDetails" id="avco_r_EquityDetails">
        <link:definition>996047 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable" id="avco_r_ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable">
        <link:definition>996048 - Disclosure - Equity - Schedule of Common Stock Issuable Upon Exercise of Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable" id="avco_r_ScheduleofStockOptionActivityTable">
        <link:definition>996049 - Disclosure - Equity - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra/k4DNHXVKIYwN/zLXIt0iwZq6nYg/w27/nmgU3Bs4kyGGa1okQf8wpc8xue3C4gYCyO+De2FMpGD6T1rBTmQ8hA/UC+V/TeVcwU7ABGe/tb9Nse+XBO1hN0S6XbJQbcJwedpHBgl7i050GjffC4p7Iw/J3z5vZfcXGGwK1wcBZ+q2HcISatlXTlFgsMKO5QeDDlx75B8z8hjuvV5IPRmtFIaAZaCRuKG6FjDX4pVgOtJawmWPlxtgY4Pis/QDXNE=] CSR-->
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable" id="avco_r_ScheduleofNonvestedStockOptionsGrantedTable">
        <link:definition>996050 - Disclosure - Equity - Schedule of Nonvested Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable" id="avco_r_ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable">
        <link:definition>996051 - Disclosure - Equity - Schedule of Common Stock Issuable Upon Exercise of Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssetsDetails" id="avco_r_StatutoryReserveandRestrictedNetAssetsDetails">
        <link:definition>996052 - Disclosure - Statutory Reserve and Restricted Net Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/NoncontrollingInterestDetails" id="avco_r_NoncontrollingInterestDetails">
        <link:definition>996053 - Disclosure - Noncontrolling Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompanyDetails" id="avco_r_CondensedFinancialInformationoftheParentCompanyDetails">
        <link:definition>996054 - Disclosure - Condensed Financial Information of the Parent Company (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ConcentrationsDetails" id="avco_r_ConcentrationsDetails">
        <link:definition>996055 - Disclosure - Concentrations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable" id="avco_r_ScheduleofCustomerAccountedforCompanysRevenuesTable">
        <link:definition>996056 - Disclosure - Concentrations - Schedule of Customer Accounted for Company's Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/SegmentInformationDetails" id="avco_r_SegmentInformationDetails">
        <link:definition>996057 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable" id="avco_r_ScheduleofReportableBusinessSegmentsTable">
        <link:definition>996058 - Disclosure - Segment Information - Schedule of Reportable Business Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable" id="avco_r_ScheduleofIdentifiableLongLivedTangibleAssetsTable">
        <link:definition>996059 - Disclosure - Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable" id="avco_r_ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable">
        <link:definition>996060 - Disclosure - Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Geographic Areas) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails" id="avco_r_CommitmentsandContingenciesDetails">
        <link:definition>996061 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofLeaseTable" id="avco_r_ScheduleofLeaseTable">
        <link:definition>996062 - Disclosure - Commitments and Contingencies - Schedule of Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable" id="avco_r_ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable">
        <link:definition>996063 - Disclosure - Commitments and Contingencies - Schedule of Maturity of Lease Liabilities Under Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/SubsequentEventsDetails" id="avco_r_SubsequentEventsDetails">
        <link:definition>996064 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0" id="avco_r_ScheduleofConsolidatedFinancialStatementsTable0">
        <link:definition>996065 - Disclosure - Organization and Nature of Operations - Schedule of Consolidated Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable0" id="avco_r_ScheduleofDerivativeLiabilityMeasuredatFairValueTable0">
        <link:definition>996066 - Disclosure - Summary of Significant Accounting Policies - Schedule of Derivative Liability Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable0" id="avco_r_ScheduleofCashBalancesbyGeographicAreaTable0">
        <link:definition>996067 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash Balances by Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0" id="avco_r_ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0">
        <link:definition>996068 - Disclosure - Summary of Significant Accounting Policies - Schedule of Securities that were Excluded from the Diluted Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0" id="avco_r_ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0">
        <link:definition>996069 - Disclosure - Prepaid Expense and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable0" id="avco_r_ScheduleofEquityMethodInvestmentTable0">
        <link:definition>996070 - Disclosure - Equity Method Investments - Schedule of Equity Method Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable0" id="avco_r_ScheduleofFinancialInformationTable0">
        <link:definition>996071 - Disclosure - Equity Method Investments - Schedule of Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0" id="avco_r_ScheduleofAmortizationPaymentsinCashTable0">
        <link:definition>996072 - Disclosure - Convertible Note Payable - Schedule of Amortization Payments in Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0" id="avco_r_ScheduleofConvertibleNotePayableTable0">
        <link:definition>996073 - Disclosure - Convertible Note Payable - Schedule of Convertible Note Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofNotePayableTable0" id="avco_r_ScheduleofNotePayableTable0">
        <link:definition>996074 - Disclosure - Note Payable, Net - Schedule of Note Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0" id="avco_r_ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0">
        <link:definition>996075 - Disclosure - Equity - Schedule of Common Stock Issuable Upon Exercise of Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0" id="avco_r_ScheduleofStockOptionActivityTable0">
        <link:definition>996076 - Disclosure - Equity - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0" id="avco_r_ScheduleofNonvestedStockOptionsGrantedTable0">
        <link:definition>996077 - Disclosure - Equity - Schedule of Nonvested Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1" id="avco_r_ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1">
        <link:definition>996078 - Disclosure - Equity - Schedule of Common Stock Issuable Upon Exercise of Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable0" id="avco_r_ScheduleofCustomerAccountedforCompanysRevenuesTable0">
        <link:definition>996079 - Disclosure - Concentrations - Schedule of Customer Accounted for Company's Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0" id="avco_r_ScheduleofReportableBusinessSegmentsTable0">
        <link:definition>996080 - Disclosure - Segment Information - Schedule of Reportable Business Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable0" id="avco_r_ScheduleofIdentifiableLongLivedTangibleAssetsTable0">
        <link:definition>996081 - Disclosure - Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable0" id="avco_r_ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable0">
        <link:definition>996082 - Disclosure - Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Geographic Areas) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofLeaseTable0" id="avco_r_ScheduleofLeaseTable0">
        <link:definition>996083 - Disclosure - Commitments and Contingencies - Schedule of Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0" id="avco_r_ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0">
        <link:definition>996084 - Disclosure - Commitments and Contingencies - Schedule of Maturity of Lease Liabilities Under Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0Alt0" id="avco_r_ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0Alt0">
        <link:definition>996084 - Disclosure - Commitments and Contingencies - Schedule of Maturity of Lease Liabilities Under Operating Lease (Details) Alternate 0</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xs:element name="ScheduleOfConsolidatedFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfConsolidatedFinancialStatementsAbstract"/>
  <xs:element name="ScheduleOfDerivativeLiabilityMeasuredAtFairValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfDerivativeLiabilityMeasuredAtFairValueAbstract"/>
  <xs:element name="ScheduleOfCashBalancesByGeographicAreaAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfCashBalancesByGeographicAreaAbstract"/>
  <xs:element name="ScheduleOfSecuritiesThatWereExcludedFromTheDilutedPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfSecuritiesThatWereExcludedFromTheDilutedPerShareAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfInvestmentInRealEstateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfInvestmentInRealEstateAbstract"/>
  <xs:element name="ScheduleOfEquityMethodInvestmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfEquityMethodInvestmentAbstract"/>
  <xs:element name="ScheduleOfSummarizedFinancialInformationAsProvidedToTheCompanyByTheInvesteeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfSummarizedFinancialInformationAsProvidedToTheCompanyByTheInvesteeAbstract"/>
  <xs:element name="ScheduleOfFinancialInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfFinancialInformationAbstract"/>
  <xs:element name="ScheduleOfAmortizationPaymentsInCashAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfAmortizationPaymentsInCashAbstract"/>
  <xs:element name="ScheduleOfConvertibleNotePayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfConvertibleNotePayableAbstract"/>
  <xs:element name="ScheduleOfCommonStockIssuableUponExerciseOfWarrantsOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfCommonStockIssuableUponExerciseOfWarrantsOutstandingAbstract"/>
  <xs:element name="ScheduleOfStockOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfStockOptionActivityAbstract"/>
  <xs:element name="ScheduleOfNonvestedStockOptionsGrantedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfNonvestedStockOptionsGrantedAbstract"/>
  <xs:element name="ScheduleOfCommonStockIssuableUponExerciseOfOptionsOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfCommonStockIssuableUponExerciseOfOptionsOutstandingAbstract"/>
  <xs:element name="ScheduleOfCustomerAccountedForCompanysRevenuesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfCustomerAccountedForCompanysRevenuesAbstract"/>
  <xs:element name="ScheduleOfReportableBusinessSegmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfReportableBusinessSegmentsAbstract"/>
  <xs:element name="ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfIdentifiableLongLivedTangibleAssetsGeographicAreasAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfIdentifiableLongLivedTangibleAssetsGeographicAreasAbstract"/>
  <xs:element name="AssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AssetsAbstract0"/>
  <xs:element name="LessCommonStockHeldInTreasuryAtCostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_LessCommonStockHeldInTreasuryAtCostAbstract"/>
  <xs:element name="OtherOperatingExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_OtherOperatingExpensesAbstract"/>
  <xs:element name="OtherExpenseIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_OtherExpenseIncomeAbstract"/>
  <xs:element name="NetLossPerCommonShareAttributableToAvalonGlobocareCorpCommonShareholdersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_NetLossPerCommonShareAttributableToAvalonGlobocareCorpCommonShareholdersAbstract"/>
  <xs:element name="WeightedAverageCommonSharesOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_WeightedAverageCommonSharesOutstandingAbstract"/>
  <xs:element name="ComprehensiveLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ComprehensiveLossAbstract"/>
  <xs:element name="OtherComprehensiveIncomeLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_OtherComprehensiveIncomeLossAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_UnlabeledAbstract0"/>
  <xs:element name="CashPaidForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CashPaidForAbstract"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_UnlabeledAbstract2"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_UnlabeledAbstract5"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_UnlabeledAbstract6"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_UnlabeledAbstract7"/>
  <xs:element name="CashPaidForAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CashPaidForAbstract0"/>
  <xs:element name="PaymentForEquityMethodInvestmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_PaymentForEquityMethodInvestmentAbstract"/>
  <xs:element name="AccruedResearchAndDevelopmentsFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_AccruedResearchAndDevelopmentsFees"/>
  <xs:element name="AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty"/>
  <xs:element name="EquityMethodInvestmentPayableCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityMethodInvestmentPayableCurrent"/>
  <xs:element name="DebtModificationCharge" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_DebtModificationCharge"/>
  <xs:element name="DeemedContributionOnExchangeOfEquityInstruments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_DeemedContributionOnExchangeOfEquityInstruments"/>
  <xs:element name="StockIssuedDuringPeriodValueSharesIssuedForAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments"/>
  <xs:element name="StockIssuedDuringPeriodValueSaleOfCommonStockNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet"/>
  <xs:element name="StockIssuedDuringPeriodSharesSaleOfCommonStockNet" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet"/>
  <xs:element name="StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock"/>
  <xs:element name="StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock"/>
  <xs:element name="SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment"/>
  <xs:element name="SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments"/>
  <xs:element name="DistributionOfEarningsFromEquityMethodInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_DistributionOfEarningsFromEquityMethodInvestment"/>
  <xs:element name="BeneficialConversionFeatureRelatedToConvertibleNotePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable"/>
  <xs:element name="ImpairmentOfLaboratoryEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_ImpairmentOfLaboratoryEquipment"/>
  <xs:element name="IncreaseDecreaseInDeferredLeasingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_IncreaseDecreaseInDeferredLeasingCosts"/>
  <xs:element name="AccruedLiabilitiesAndOtherPayablesRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_AccruedLiabilitiesAndOtherPayablesRelatedParties"/>
  <xs:element name="ProceedsFromIssuanceOfConvertibleDebtAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants"/>
  <xs:element name="PaymentsOfConvertibleDebtIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_PaymentsOfConvertibleDebtIssuanceCosts"/>
  <xs:element name="CommonStockIssuedForAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_CommonStockIssuedForAccruedLiabilities"/>
  <xs:element name="ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment"/>
  <xs:element name="WarrantsIssuedWithConvertibleNotePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_WarrantsIssuedWithConvertibleNotePayable"/>
  <xs:element name="AccruedPurchasePriceRelatedToEquityMethodInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_AccruedPurchasePriceRelatedToEquityMethodInvestment"/>
  <xs:element name="WarrantsIssuedAsConvertibleNotePayableFindersFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_WarrantsIssuedAsConvertibleNotePayableFindersFee"/>
  <xs:element name="WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount"/>
  <xs:element name="ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock"/>
  <xs:element name="DeferredFinancingCostsInAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_DeferredFinancingCostsInAccruedLiabilities"/>
  <xs:element name="SettlementsOfDerivativeLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_SettlementsOfDerivativeLiability"/>
  <xs:element name="ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty"/>
  <xs:element name="IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant"/>
  <xs:element name="ReceivableRelatedToSaleOfEquityMethodInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_ReceivableRelatedToSaleOfEquityMethodInvestment"/>
  <xs:element name="RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment"/>
  <xs:element name="SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment"/>
  <xs:element name="SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock"/>
  <xs:element name="WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount"/>
  <xs:element name="CommonStockIssuedAsConvertibleNotePayableCommitmentFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee"/>
  <xs:element name="StatutoryReserveAndRestrictedNetAssetsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_StatutoryReserveAndRestrictedNetAssetsTextBlock"/>
  <xs:element name="DeferredOfferingCostsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_DeferredOfferingCostsPolicyTextBlock"/>
  <xs:element name="InvestmentInRealEstateAndDepreciationPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock"/>
  <xs:element name="DeferredRentalIncomePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_DeferredRentalIncomePolicyTextBlock"/>
  <xs:element name="RealPropertyRentalRevenuePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_RealPropertyRentalRevenuePolicyTextBlock"/>
  <xs:element name="DebtModificationsAndExtinguishmentsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_DebtModificationsAndExtinguishmentsPolicyTextBlock"/>
  <xs:element name="NoncontrollingInterestPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_NoncontrollingInterestPolicyTextBlock"/>
  <xs:element name="ReverseStockSplitPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ReverseStockSplitPolicyTextBlock"/>
  <xs:element name="EquityTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_EquityTablesTable"/>
  <xs:element name="EquityTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityTablesLineItems"/>
  <xs:element name="EquityMethodInvestmentPlaceAndDateOfIncorporation" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityMethodInvestmentPlaceAndDateOfIncorporation"/>
  <xs:element name="InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise"/>
  <xs:element name="CashPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="avco_CashPercentage"/>
  <xs:element name="PrepaidProfessionalFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_PrepaidProfessionalFees"/>
  <xs:element name="EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets"/>
  <xs:element name="EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets"/>
  <xs:element name="LabServicesMSOsNetIncomeAttributableToTheCompany" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_LabServicesMSOsNetIncomeAttributableToTheCompany"/>
  <xs:element name="AccruedTenantsImprovementReimbursement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_AccruedTenantsImprovementReimbursement"/>
  <xs:element name="AccruedBusinessExpenseReimbursement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_AccruedBusinessExpenseReimbursement"/>
  <xs:element name="AccruedRealPropertyCleaningServiceFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_AccruedRealPropertyCleaningServiceFee"/>
  <xs:element name="ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable"/>
  <xs:element name="ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems"/>
  <xs:element name="DrawDownFromLineOfCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_DrawDownFromLineOfCredit"/>
  <xs:element name="ReclassificationOfLineOfCreditToAdvanceFromRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty"/>
  <xs:element name="DeferredTaxAssetsPartnershipInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_DeferredTaxAssetsPartnershipInvestment"/>
  <xs:element name="EquityScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_EquityScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingDetailsTable"/>
  <xs:element name="EquityScheduleofStockOptionActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_EquityScheduleofStockOptionActivityDetailsTable"/>
  <xs:element name="EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues"/>
  <xs:element name="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities"/>
  <xs:element name="OrganizationandNatureofOperationsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_OrganizationandNatureofOperationsDetailsTable"/>
  <xs:element name="BasisofPresentationandGoingConcernConditionDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_BasisofPresentationandGoingConcernConditionDetailsTable"/>
  <xs:element name="BasisofPresentationandGoingConcernConditionDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_BasisofPresentationandGoingConcernConditionDetailsLineItems"/>
  <xs:element name="WorkingCapitalDeficit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_WorkingCapitalDeficit"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="EquityInterestPercent" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityInterestPercent"/>
  <xs:element name="PaymentOfEquityInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_PaymentOfEquityInvestment"/>
  <xs:element name="RegularPaymentsOnEquityInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_RegularPaymentsOnEquityInvestments"/>
  <xs:element name="OtherOperatingExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_OtherOperatingExpense"/>
  <xs:element name="EquityMethodInvestmentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_EquityMethodInvestmentsDetailsTable"/>
  <xs:element name="AggregateOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="avco_AggregateOfCommonStock"/>
  <xs:element name="ConvertibleNotePayableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_ConvertibleNotePayableDetailsTable"/>
  <xs:element name="DebtInstrumentConvertibleFloorPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_DebtInstrumentConvertibleFloorPrice"/>
  <xs:element name="PercentageOfPromissoryNotes" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_PercentageOfPromissoryNotes"/>
  <xs:element name="TradingPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="avco_TradingPrice"/>
  <xs:element name="PurchasePriceOfConvertibleNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_PurchasePriceOfConvertibleNote"/>
  <xs:element name="PaymentForCommission" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_PaymentForCommission"/>
  <xs:element name="DerivativeLiabilityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_DerivativeLiabilityDetailsTable"/>
  <xs:element name="WarrantsOfCashlessExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="avco_WarrantsOfCashlessExercised"/>
  <xs:element name="NotePayableNetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_NotePayableNetDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="AccruedAndUnpaidServicesCharge" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_AccruedAndUnpaidServicesCharge"/>
  <xs:element name="PurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_PurchasePrice"/>
  <xs:element name="BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage"/>
  <xs:element name="ExchangeShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ExchangeShare"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_IncomeTaxesDetailsTable"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_EquityDetailsTable"/>
  <xs:element name="PercentageOfCommonStockIssuedAndOutstanding" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_PercentageOfCommonStockIssuedAndOutstanding"/>
  <xs:element name="ConversionPricePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ConversionPricePercentage"/>
  <xs:element name="CommonStockOfAveragePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CommonStockOfAveragePrice"/>
  <xs:element name="OfferingCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_OfferingCost"/>
  <xs:element name="FairMarketValuesOfGrantDates" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_FairMarketValuesOfGrantDates"/>
  <xs:element name="RedemptionNetOfPayablesDueToLabServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_RedemptionNetOfPayablesDueToLabServices"/>
  <xs:element name="FairMarketValues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_FairMarketValues"/>
  <xs:element name="StatutoryReservePercent" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_StatutoryReservePercent"/>
  <xs:element name="RegisteredCapitalPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_RegisteredCapitalPercentage"/>
  <xs:element name="StatutoryReserve" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_StatutoryReserve"/>
  <xs:element name="NoncontrollingInterestDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_NoncontrollingInterestDetailsTable"/>
  <xs:element name="CondensedFinancialInformationoftheParentCompanyDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_CondensedFinancialInformationoftheParentCompanyDetailsTable"/>
  <xs:element name="RestrictedNetAssetsOfSubsidiaryExceedNetAssets" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets"/>
  <xs:element name="RestrictedNetAssetsPRCSubsidiaryDidNotExceed" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed"/>
  <xs:element name="ConcentrationsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_ConcentrationsDetailsTable"/>
  <xs:element name="SegmentInformationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_SegmentInformationDetailsTable"/>
  <xs:element name="SegmentInformationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_SegmentInformationDetailsLineItems"/>
  <xs:element name="PurchasedServicesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="avco_PurchasedServicesPercentage"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="PercentageOfPretaxProfit" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_PercentageOfPretaxProfit"/>
  <xs:element name="PreTaxProfit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_PreTaxProfit"/>
  <xs:element name="WorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_WorkingCapital"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_SubsequentEventsDetailsTable"/>
  <xs:element name="ExchangeRatioPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ExchangeRatioPerShare"/>
  <xs:element name="AbandonmentAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AbandonmentAgreementMember"/>
  <xs:element name="AprilFiveTwoThousandTwentyFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AprilFiveTwoThousandTwentyFiveMember"/>
  <xs:element name="ArbeleMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ArbeleMember"/>
  <xs:element name="AssetAndLiabilityAccountsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AssetAndLiabilityAccountsMember"/>
  <xs:element name="AvactisAndArbeleBiotherapeuticsLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AvactisAndArbeleBiotherapeuticsLimitedMember"/>
  <xs:element name="AvactisBiosciencesIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AvactisBiosciencesIncMember"/>
  <xs:element name="AvactisBiotherapeuticsLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AvactisBiotherapeuticsLimitedMember"/>
  <xs:element name="AvactisNanjingBiosciencesLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AvactisNanjingBiosciencesLtdMember"/>
  <xs:element name="AvalonHealthcareSystemIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AvalonHealthcareSystemIncMember"/>
  <xs:element name="AvalonLabMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AvalonLabMember"/>
  <xs:element name="AvalonLaboratoryServicesIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AvalonLaboratoryServicesIncMember"/>
  <xs:element name="AvalonRT9Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AvalonRT9Member"/>
  <xs:element name="AvalonRT9PropertiesLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AvalonRT9PropertiesLLCMember"/>
  <xs:element name="AvalonShangaiMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AvalonShangaiMember"/>
  <xs:element name="AvalonShanghaiHealthcareTechnologyCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember"/>
  <xs:element name="BeijingGenexosomeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_BeijingGenexosomeMember"/>
  <xs:element name="BlackScholesValuationModelMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_BlackScholesValuationModelMember"/>
  <xs:element name="CertificatesOfEliminationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CertificatesOfEliminationMember"/>
  <xs:element name="CommonSharesIssuedForServicesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CommonSharesIssuedForServicesMember"/>
  <xs:element name="ConversionShareMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ConversionShareMember"/>
  <xs:element name="ConvertibleDebtNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ConvertibleDebtNoteMember"/>
  <xs:element name="CorporateOtherMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CorporateOtherMember"/>
  <xs:element name="CustomerAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CustomerAMember"/>
  <xs:element name="CustomerBMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CustomerBMember"/>
  <xs:element name="CustomerCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CustomerCMember"/>
  <xs:element name="DecemberFiveTwoThousandTwentyFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_DecemberFiveTwoThousandTwentyFourMember"/>
  <xs:element name="DeferredOfferingCostsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_DeferredOfferingCostsMember"/>
  <xs:element name="DrYuZhouMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_DrYuZhouMember"/>
  <xs:element name="DrZhouMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_DrZhouMember"/>
  <xs:element name="EpiconBiotechCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_EpiconBiotechCoLtdMember"/>
  <xs:element name="ExercisePriceRangeFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ExercisePriceRangeFiveMember"/>
  <xs:element name="ExercisePriceRangeFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ExercisePriceRangeFourMember"/>
  <xs:element name="ExercisePriceRangeOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ExercisePriceRangeOneMember"/>
  <xs:element name="ExercisePriceRangeThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ExercisePriceRangeThreeMember"/>
  <xs:element name="ExercisePriceRangeTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ExercisePriceRangeTwoMember"/>
  <xs:element name="FebruaryFiveTwoThousandTwentyFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_FebruaryFiveTwoThousandTwentyFiveMember"/>
  <xs:element name="FirstFireMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_FirstFireMember"/>
  <xs:element name="FirstWarrantMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_FirstWarrantMember"/>
  <xs:element name="FirstfireMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_FirstfireMember"/>
  <xs:element name="FiveYearAnniversaryMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_FiveYearAnniversaryMember"/>
  <xs:element name="FormerDirectorAndFormerCochiefExecutiveOfficerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_FormerDirectorAndFormerCochiefExecutiveOfficerMember"/>
  <xs:element name="GenExosomeTechnologiesIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_GenExosomeTechnologiesIncMember"/>
  <xs:element name="InvestmentInEpiconBiotechCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_InvestmentInEpiconBiotechCoLtdMember"/>
  <xs:element name="InvestmentInLaboratoryServicesMSOLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_InvestmentInLaboratoryServicesMSOLLCMember"/>
  <xs:element name="JanuaryFiveTwoThousandTwentyFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_JanuaryFiveTwoThousandTwentyFiveMember"/>
  <xs:element name="JefferiesLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_JefferiesLLCMember"/>
  <xs:element name="JiangsuUnicornBiologicalTechnologyCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_JiangsuUnicornBiologicalTechnologyCoLtdMember"/>
  <xs:element name="July2023ConvertibleNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_July2023ConvertibleNoteMember"/>
  <xs:element name="July62023FiveYearAnniversaryMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_July62023FiveYearAnniversaryMember"/>
  <xs:element name="June2024ConvertibleNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_June2024ConvertibleNoteMember"/>
  <xs:element name="June52024FiveyearAnniversaryMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_June52024FiveyearAnniversaryMember"/>
  <xs:element name="JuneFiveTwoThousandTwentyFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_JuneFiveTwoThousandTwentyFiveMember"/>
  <xs:element name="JuneTwentyThousandTwentyFourConvertibleNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_JuneTwentyThousandTwentyFourConvertibleNoteMember"/>
  <xs:element name="LabServiceMSOMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_LabServiceMSOMember"/>
  <xs:element name="LabServicesMSOMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_LabServicesMSOMember"/>
  <xs:element name="LabServicesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_LabServicesMember"/>
  <xs:element name="LaboratoryEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_LaboratoryEquipmentMember"/>
  <xs:element name="LaboratoryServicesMSOLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_LaboratoryServicesMSOLLCMember"/>
  <xs:element name="LaboratoryServicesMSOMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_LaboratoryServicesMSOMember"/>
  <xs:element name="LineOfCreditAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_LineOfCreditAgreementMember"/>
  <xs:element name="March2024ConvertibleNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_March2024ConvertibleNoteMember"/>
  <xs:element name="March72024FiveYearAnniversaryMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_March72024FiveYearAnniversaryMember"/>
  <xs:element name="MarchFiveTwoThousandTwentyFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_MarchFiveTwoThousandTwentyFiveMember"/>
  <xs:element name="MarchTwentyThousandTwentyFourConvertibleNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_MarchTwentyThousandTwentyFourConvertibleNoteMember"/>
  <xs:element name="MarchTwoThousandTwentyFourWarrantIssuedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_MarchTwoThousandTwentyFourWarrantIssuedMember"/>
  <xs:element name="MastHillAndFirstfireMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_MastHillAndFirstfireMember"/>
  <xs:element name="MastHillFundLPMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_MastHillFundLPMember"/>
  <xs:element name="MastHillMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_MastHillMember"/>
  <xs:element name="MastHillThirdPartyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_MastHillThirdPartyMember"/>
  <xs:element name="MastMillAndFirstFireMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_MastMillAndFirstFireMember"/>
  <xs:element name="May2023ConvertibleNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_May2023ConvertibleNoteMember"/>
  <xs:element name="May2023CovertibleNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_May2023CovertibleNoteMember"/>
  <xs:element name="May232023FiveYearAnniversaryMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_May232023FiveYearAnniversaryMember"/>
  <xs:element name="MayFiveTwoThousandTwentyFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_MayFiveTwoThousandTwentyFiveMember"/>
  <xs:element name="MembershipInterestPurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_MembershipInterestPurchaseAgreementMember"/>
  <xs:element name="MergerAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_MergerAgreementMember"/>
  <xs:element name="MrLuMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_MrLuMember"/>
  <xs:element name="NonvestedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_NonvestedMember"/>
  <xs:element name="October2023ConvertibleNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_October2023ConvertibleNoteMember"/>
  <xs:element name="October92023FiveYearAnniversaryMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_October92023FiveYearAnniversaryMember"/>
  <xs:element name="OctoberTwoThousandTwentyThreeConvertibleNotesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_OctoberTwoThousandTwentyThreeConvertibleNotesMember"/>
  <xs:element name="OneCustomerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_OneCustomerMember"/>
  <xs:element name="OptionsOutstandingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_OptionsOutstandingMember"/>
  <xs:element name="OptionsToPurchaseCommonStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_OptionsToPurchaseCommonStockMember"/>
  <xs:element name="PRCSubsidiariesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_PRCSubsidiariesMember"/>
  <xs:element name="PreFundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_PreFundedWarrantsMember"/>
  <xs:element name="PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_PromissoryNoteMember"/>
  <xs:element name="QADistributionLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_QADistributionLLCMember"/>
  <xs:element name="RealPropertyOperatingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_RealPropertyOperatingMember"/>
  <xs:element name="RealPropertyOperationsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_RealPropertyOperationsMember"/>
  <xs:element name="RothCapitalPartnersLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_RothCapitalPartnersLLCMember"/>
  <xs:element name="SecondWarrantMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_SecondWarrantMember"/>
  <xs:element name="SeriesAConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_SeriesAConvertiblePreferredStockMember"/>
  <xs:element name="SeriesBConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_SeriesBConvertiblePreferredStockMember"/>
  <xs:element name="SeriesBHolderMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_SeriesBHolderMember"/>
  <xs:element name="SeriesBStatedValueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_SeriesBStatedValueMember"/>
  <xs:element name="StatutoryReserveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_StatutoryReserveMember"/>
  <xs:element name="TwoCustomersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_TwoCustomersMember"/>
  <xs:element name="TwoThousandTwentyFourJuneWarrantIssuedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_TwoThousandTwentyFourJuneWarrantIssuedMember"/>
  <xs:element name="WaiverFeeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_WaiverFeeMember"/>
  <xs:element name="WarrantsExercisedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_WarrantsExercisedMember"/>
  <xs:element name="WarrantsOutstandingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_WarrantsOutstandingMember"/>
  <xs:element name="WenzhaoLuMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_WenzhaoLuMember"/>
  <xs:element name="findersFeeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_findersFeeMember"/>
  <xs:element name="BasisOfPresentationAndGoingConcernConditionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_BasisOfPresentationAndGoingConcernConditionAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>18
<FILENAME>avco-20250331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Jun 09 23:27:56 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConsolidatedBalanceSheet" roleURI="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConsolidatedIncomeStatement" roleURI="http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConsolidatedCashFlow" roleURI="http://www.avalonglobocare.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofPrepaidExpenseandOtherCurrentAssetsTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofAccruedLiabilitiesandOtherPayablesTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofConvertibleNotePayableTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofNotePayableTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofNotePayableTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofCompanysLossBeforeIncomeTaxesTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofCompanysLossBeforeIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofComponentsofIncomeTaxesExpenseBenefitTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofDeferredTaxesTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofConvertibleNotePayableTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofNotePayableTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofNotePayableTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0Alt0" roleURI="http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0Alt0"/>
  <calculationLink xlink:role="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Cash" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesNetCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_RealEstateInvestments" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_EquityMethodInvestments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestmentsAndReceivablesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_LongTermInvestmentsAndReceivablesNet" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedResearchAndDevelopmentsFees" xlink:href="avco-20250331.xsd#avco_AccruedResearchAndDevelopmentsFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="avco_AccruedResearchAndDevelopmentsFees" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationReserveCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LitigationReserveCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" xlink:href="avco-20250331.xsd#avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentPayableCurrent" xlink:href="avco-20250331.xsd#avco_EquityMethodInvestmentPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="avco_EquityMethodInvestmentPayableCurrent" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableToBankCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableToBankCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableToBankCurrent" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="12" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermNotesPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermLoansPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermLoansPayable" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockCommonValue" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketingAndAdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketingAndAdvertisingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_MarketingAndAdvertisingExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_ProfessionalFees" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_LaborAndRelatedExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingCostsAndExpenses" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="avco_DebtModificationCharge" xlink:href="avco-20250331.xsd#avco_DebtModificationCharge"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="avco_DebtModificationCharge" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseOther" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseDebt" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_AssetImpairmentCharges" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_DeemedContributionOnExchangeOfEquityInstruments" xlink:href="avco-20250331.xsd#avco_DeemedContributionOnExchangeOfEquityInstruments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="avco_DeemedContributionOnExchangeOfEquityInstruments" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.avalonglobocare.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AssetImpairmentCharges" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_ImpairmentOfLaboratoryEquipment" xlink:href="avco-20250331.xsd#avco_ImpairmentOfLaboratoryEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="avco_ImpairmentOfLaboratoryEquipment" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_IncreaseDecreaseInDeferredLeasingCosts" xlink:href="avco-20250331.xsd#avco_IncreaseDecreaseInDeferredLeasingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="avco_IncreaseDecreaseInDeferredLeasingCosts" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StraightLineRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StraightLineRent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_StraightLineRent" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="avco_DistributionOfEarningsFromEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_DistributionOfEarningsFromEquityMethodInvestment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="avco_DistributionOfEarningsFromEquityMethodInvestment" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable" xlink:href="avco-20250331.xsd#avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnRestructuringOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnRestructuringOfDebt" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="17" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="18" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="19" weight="-1"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedLiabilitiesAndOtherPayablesRelatedParties" xlink:href="avco-20250331.xsd#avco_AccruedLiabilitiesAndOtherPayablesRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="avco_AccruedLiabilitiesAndOtherPayablesRelatedParties" order="20" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsToMinorityShareholders" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromOtherEquity" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra/k4DNHXVKIYwN/zLXIt0iwZq6nYg/w27/nmgU3Bs4kyGGa1okQf8wpc8xue3C4gYCyO+De2FMpGD6T1rBTmQ8hA/UC+V/TeVcwU7ABGe/tb9Nse+XBO1hN0S6XbJQbcJwedpHBgl7i050GjffC4p7Iw/J3z5vZfcXGGwK1wcBZ+q2HcISatlXTlFgsMKO5QeDDlx75B8z8hjuvV5IPRmtFIaAZaCRuKG6FjDX4pVgOiaSKB9my7JWwAbFzyy7l3E=] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants" xlink:href="avco-20250331.xsd#avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="avco_PaymentsOfConvertibleDebtIssuanceCosts" xlink:href="avco-20250331.xsd#avco_PaymentsOfConvertibleDebtIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="avco_PaymentsOfConvertibleDebtIssuanceCosts" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="avco_PrepaidProfessionalFees" xlink:href="avco-20250331.xsd#avco_PrepaidProfessionalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="avco_PrepaidProfessionalFees" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidReinsurancePremiums" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidReinsurancePremiums"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidReinsurancePremiums" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DeferredOfferingCosts" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsLeasingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsLeasingNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DeferredCostsLeasingNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_SecurityDeposit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromCorrespondentBrokers" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DueFromCorrespondentBrokers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DueFromCorrespondentBrokers" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InventoryFinishedGoods" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValueAddedTaxReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_ValueAddedTaxReceivable" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="9" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AssetsCurrent" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AssetsNoncurrent" order="4" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedTenantsImprovementReimbursement" xlink:href="avco-20250331.xsd#avco_AccruedTenantsImprovementReimbursement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="avco_AccruedTenantsImprovementReimbursement" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Deposits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_Deposits" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedBusinessExpenseReimbursement" xlink:href="avco-20250331.xsd#avco_AccruedBusinessExpenseReimbursement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="avco_AccruedBusinessExpenseReimbursement" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedUtilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedUtilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedUtilitiesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_DeferredIncome" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedRealPropertyCleaningServiceFee" xlink:href="avco-20250331.xsd#avco_AccruedRealPropertyCleaningServiceFee"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="avco_AccruedRealPropertyCleaningServiceFee" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="9" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofNotePayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNotesPayableCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNotesPayableCurrent" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNotesPayableCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofCompanysLossBeforeIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_DeferredTaxAssetsPartnershipInvestment" xlink:href="avco-20250331.xsd#avco_DeferredTaxAssetsPartnershipInvestment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="avco_DeferredTaxAssetsPartnershipInvestment" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesRegulatoryAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="avco_PrepaidProfessionalFees" xlink:href="avco-20250331.xsd#avco_PrepaidProfessionalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="avco_PrepaidProfessionalFees" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidReinsurancePremiums" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidReinsurancePremiums"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidReinsurancePremiums" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseOtherNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsLeasingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsLeasingNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DeferredCostsLeasingNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_SecurityDeposit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromCorrespondentBrokers" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DueFromCorrespondentBrokers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DueFromCorrespondentBrokers" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InventoryFinishedGoods" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValueAddedTaxReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_ValueAddedTaxReceivable" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="9" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofNotePayableTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0Alt0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>19
<FILENAME>avco-20250331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Jun 09 23:27:56 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConsolidatedBalanceSheet" roleURI="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConsolidatedIncomeStatement" roleURI="http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_CondensedConsolidatedStatementsofChangesinDeficitEquityTable" roleURI="http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_CondensedConsolidatedStatementsofChangesinDeficitEquityTable_Parentheticals" roleURI="http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConsolidatedCashFlow" roleURI="http://www.avalonglobocare.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_OrganizationandNatureofOperations" roleURI="http://www.avalonglobocare.com/role/OrganizationandNatureofOperations"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_BasisofPresentationandGoingConcernCondition" roleURI="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernCondition"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_PrepaidExpenseandOtherCurrentAssets" roleURI="http://www.avalonglobocare.com/role/PrepaidExpenseandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_PropertyandEquipment" roleURI="http://www.avalonglobocare.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_EquipmentHeldForSale" roleURI="http://www.avalonglobocare.com/role/EquipmentHeldForSale"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_InvestmentinRealEstate" roleURI="http://www.avalonglobocare.com/role/InvestmentinRealEstate"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_EquityMethodInvestments" roleURI="http://www.avalonglobocare.com/role/EquityMethodInvestments"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_AccruedLiabilitiesandOtherPayables" roleURI="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConvertibleNotePayable" roleURI="http://www.avalonglobocare.com/role/ConvertibleNotePayable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_DerivativeLiability" roleURI="http://www.avalonglobocare.com/role/DerivativeLiability"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_NotePayableNet" roleURI="http://www.avalonglobocare.com/role/NotePayableNet"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_RelatedPartyTransactions" roleURI="http://www.avalonglobocare.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_IncomeTaxes" roleURI="http://www.avalonglobocare.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_Equity" roleURI="http://www.avalonglobocare.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_StatutoryReserveandRestrictedNetAssets" roleURI="http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssets"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_NoncontrollingInterest" roleURI="http://www.avalonglobocare.com/role/NoncontrollingInterest"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_CondensedFinancialInformationoftheParentCompany" roleURI="http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompany"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_Concentrations" roleURI="http://www.avalonglobocare.com/role/Concentrations"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_SegmentInformation" roleURI="http://www.avalonglobocare.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_CommitmentsandContingencies" roleURI="http://www.avalonglobocare.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_SubsequentEvents" roleURI="http://www.avalonglobocare.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_AccountingPoliciesByPolicy" roleURI="http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_OrganizationandNatureofOperationsTables" roleURI="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_PrepaidExpenseandOtherCurrentAssetsTables" roleURI="http://www.avalonglobocare.com/role/PrepaidExpenseandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_PropertyandEquipmentTables" roleURI="http://www.avalonglobocare.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_InvestmentinRealEstateTables" roleURI="http://www.avalonglobocare.com/role/InvestmentinRealEstateTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_EquityMethodInvestmentsTables" roleURI="http://www.avalonglobocare.com/role/EquityMethodInvestmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_AccruedLiabilitiesandOtherPayablesTables" roleURI="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConvertibleNotePayableTables" roleURI="http://www.avalonglobocare.com/role/ConvertibleNotePayableTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_NotePayableNetTables" roleURI="http://www.avalonglobocare.com/role/NotePayableNetTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_RelatedPartyTransactionsTables" roleURI="http://www.avalonglobocare.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_IncomeTaxesTables" roleURI="http://www.avalonglobocare.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_EquityTables" roleURI="http://www.avalonglobocare.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConcentrationsTables" roleURI="http://www.avalonglobocare.com/role/ConcentrationsTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_SegmentInformationTables" roleURI="http://www.avalonglobocare.com/role/SegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_CommitmentsandContingenciesTables" roleURI="http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofConsolidatedFinancialStatementsTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofDerivativeLiabilityMeasuredatFairValueTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofCashBalancesbyGeographicAreaTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofPrepaidExpenseandOtherCurrentAssetsTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofInvestmentinRealEstateTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofInvestmentinRealEstateTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofEquityMethodInvestmentTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofFinancialInformationTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofAccruedLiabilitiesandOtherPayablesTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofAmortizationPaymentsinCashTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofConvertibleNotePayableTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofNotePayableTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofNotePayableTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofLineofCreditTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofLineofCreditTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofCompanysLossBeforeIncomeTaxesTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofCompanysLossBeforeIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofComponentsofIncomeTaxesExpenseBenefitTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofDeferredTaxesTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofStockOptionActivityTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofNonvestedStockOptionsGrantedTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofCustomerAccountedforCompanysRevenuesTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofReportableBusinessSegmentsTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofIdentifiableLongLivedTangibleAssetsTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofLeaseTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofLeaseTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofConsolidatedFinancialStatementsTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofDerivativeLiabilityMeasuredatFairValueTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofCashBalancesbyGeographicAreaTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofEquityMethodInvestmentTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofFinancialInformationTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofAmortizationPaymentsinCashTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofConvertibleNotePayableTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofNotePayableTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofNotePayableTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofStockOptionActivityTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofNonvestedStockOptionsGrantedTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1" roleURI="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofCustomerAccountedforCompanysRevenuesTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofReportableBusinessSegmentsTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofIdentifiableLongLivedTangibleAssetsTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofLeaseTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofLeaseTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_OrganizationandNatureofOperationsDetails" roleURI="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_BasisofPresentationandGoingConcernConditionDetails" roleURI="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_PropertyandEquipmentDetails" roleURI="http://www.avalonglobocare.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_EquipmentHeldForSaleDetails" roleURI="http://www.avalonglobocare.com/role/EquipmentHeldForSaleDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_InvestmentinRealEstateDetails" roleURI="http://www.avalonglobocare.com/role/InvestmentinRealEstateDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_EquityMethodInvestmentsDetails" roleURI="http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConvertibleNotePayableDetails" roleURI="http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_DerivativeLiabilityDetails" roleURI="http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_NotePayableNetDetails" roleURI="http://www.avalonglobocare.com/role/NotePayableNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_RelatedPartyTransactionsDetails" roleURI="http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_IncomeTaxesDetails" roleURI="http://www.avalonglobocare.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_EquityDetails" roleURI="http://www.avalonglobocare.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_StatutoryReserveandRestrictedNetAssetsDetails" roleURI="http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_NoncontrollingInterestDetails" roleURI="http://www.avalonglobocare.com/role/NoncontrollingInterestDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_CondensedFinancialInformationoftheParentCompanyDetails" roleURI="http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompanyDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConcentrationsDetails" roleURI="http://www.avalonglobocare.com/role/ConcentrationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_SegmentInformationDetails" roleURI="http://www.avalonglobocare.com/role/SegmentInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_CommitmentsandContingenciesDetails" roleURI="http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_SubsequentEventsDetails" roleURI="http://www.avalonglobocare.com/role/SubsequentEventsDetails"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RealEstateInvestments" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedResearchAndDevelopmentsFees" xlink:href="avco-20250331.xsd#avco_AccruedResearchAndDevelopmentsFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="avco_AccruedResearchAndDevelopmentsFees" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationReserveCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LitigationReserveCurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" xlink:href="avco-20250331.xsd#avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentPayableCurrent" xlink:href="avco-20250331.xsd#avco_EquityMethodInvestmentPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="avco_EquityMethodInvestmentPayableCurrent" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableToBankCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableToBankCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableToBankCurrent" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermNotesPayable" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermLoansPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermLoansPayable" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockValue" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonValue" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterest" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" order="41" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestmentsAndReceivablesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermInvestmentsAndReceivablesNet" order="42" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketingAndAdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketingAndAdvertisingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_MarketingAndAdvertisingExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfessionalFees" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingCostsAndExpenses" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpenseOther" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DebtModificationCharge" xlink:href="avco-20250331.xsd#avco_DebtModificationCharge"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="avco_DebtModificationCharge" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DeemedContributionOnExchangeOfEquityInstruments" xlink:href="avco-20250331.xsd#avco_DeemedContributionOnExchangeOfEquityInstruments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="avco_DeemedContributionOnExchangeOfEquityInstruments" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="33" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_StatutoryReserveMember" xlink:href="avco-20250331.xsd#avco_StatutoryReserveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="avco_StatutoryReserveMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments" xlink:href="avco-20250331.xsd#avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet" xlink:href="avco-20250331.xsd#avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet" xlink:href="avco-20250331.xsd#avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" xlink:href="avco-20250331.xsd#avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" xlink:href="avco-20250331.xsd#avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments" xlink:href="avco-20250331.xsd#avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StraightLineRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StraightLineRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StraightLineRent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DistributionOfEarningsFromEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_DistributionOfEarningsFromEquityMethodInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_DistributionOfEarningsFromEquityMethodInvestment" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable" xlink:href="avco-20250331.xsd#avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ImpairmentOfLaboratoryEquipment" xlink:href="avco-20250331.xsd#avco_ImpairmentOfLaboratoryEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_ImpairmentOfLaboratoryEquipment" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnRestructuringOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_GainsLossesOnRestructuringOfDebt" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_IncreaseDecreaseInDeferredLeasingCosts" xlink:href="avco-20250331.xsd#avco_IncreaseDecreaseInDeferredLeasingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_IncreaseDecreaseInDeferredLeasingCosts" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedLiabilitiesAndOtherPayablesRelatedParties" xlink:href="avco-20250331.xsd#avco_AccruedLiabilitiesAndOtherPayablesRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_AccruedLiabilitiesAndOtherPayablesRelatedParties" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromPaymentsToMinorityShareholders" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromOtherEquity" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CommonStockIssuedForAccruedLiabilities" xlink:href="avco-20250331.xsd#avco_CommonStockIssuedForAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_CommonStockIssuedForAccruedLiabilities" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment" order="41" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_WarrantsIssuedWithConvertibleNotePayable" xlink:href="avco-20250331.xsd#avco_WarrantsIssuedWithConvertibleNotePayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_WarrantsIssuedWithConvertibleNotePayable" order="42" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedPurchasePriceRelatedToEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_AccruedPurchasePriceRelatedToEquityMethodInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_AccruedPurchasePriceRelatedToEquityMethodInvestment" order="43" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_WarrantsIssuedAsConvertibleNotePayableFindersFee" xlink:href="avco-20250331.xsd#avco_WarrantsIssuedAsConvertibleNotePayableFindersFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_WarrantsIssuedAsConvertibleNotePayableFindersFee" order="44" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount" xlink:href="avco-20250331.xsd#avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount" order="45" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock" xlink:href="avco-20250331.xsd#avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock" order="46" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DeferredFinancingCostsInAccruedLiabilities" xlink:href="avco-20250331.xsd#avco_DeferredFinancingCostsInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_DeferredFinancingCostsInAccruedLiabilities" order="47" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="48" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalDeferredPurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalDeferredPurchasePrice" order="49" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SettlementsOfDerivativeLiability" xlink:href="avco-20250331.xsd#avco_SettlementsOfDerivativeLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_SettlementsOfDerivativeLiability" order="50" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty" xlink:href="avco-20250331.xsd#avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty" order="51" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant" xlink:href="avco-20250331.xsd#avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant" order="52" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StockIssued1" order="53" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" order="54" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants" xlink:href="avco-20250331.xsd#avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants" order="55" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PaymentsOfConvertibleDebtIssuanceCosts" xlink:href="avco-20250331.xsd#avco_PaymentsOfConvertibleDebtIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_PaymentsOfConvertibleDebtIssuanceCosts" order="56" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="57" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ReceivableRelatedToSaleOfEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_ReceivableRelatedToSaleOfEquityMethodInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_ReceivableRelatedToSaleOfEquityMethodInvestment" order="58" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment" order="59" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment" order="60" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" xlink:href="avco-20250331.xsd#avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" order="61" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount" xlink:href="avco-20250331.xsd#avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount" order="62" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee" xlink:href="avco-20250331.xsd#avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee" order="63" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="64" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/OrganizationandNatureofOperations" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernCondition" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="avco_BasisOfPresentationAndGoingConcernConditionAbstract" xlink:href="avco-20250331.xsd#avco_BasisOfPresentationAndGoingConcernConditionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_BasisOfPresentationAndGoingConcernConditionAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/PrepaidExpenseandOtherCurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/PropertyandEquipment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/EquipmentHeldForSale" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract" xlink:to="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/InvestmentinRealEstate" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RealEstateInvestmentsAbstract" xlink:to="us-gaap_RealEstateDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/EquityMethodInvestments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ConvertibleNotePayable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/DerivativeLiability" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/NotePayableNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestrictedAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="avco_StatutoryReserveAndRestrictedNetAssetsTextBlock" xlink:href="avco-20250331.xsd#avco_StatutoryReserveAndRestrictedNetAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherRestrictedAssetsAbstract" xlink:to="avco_StatutoryReserveAndRestrictedNetAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/NoncontrollingInterest" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompany" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/Concentrations" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/SegmentInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DeferredOfferingCostsPolicyTextBlock" xlink:href="avco-20250331.xsd#avco_DeferredOfferingCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avco_DeferredOfferingCostsPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock" xlink:href="avco-20250331.xsd#avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DeferredRentalIncomePolicyTextBlock" xlink:href="avco-20250331.xsd#avco_DeferredRentalIncomePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avco_DeferredRentalIncomePolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RealPropertyRentalRevenuePolicyTextBlock" xlink:href="avco-20250331.xsd#avco_RealPropertyRentalRevenuePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avco_RealPropertyRentalRevenuePolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LessorLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LessorLeasesPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstatePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstatePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RealEstatePolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DebtModificationsAndExtinguishmentsPolicyTextBlock" xlink:href="avco-20250331.xsd#avco_DebtModificationsAndExtinguishmentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avco_DebtModificationsAndExtinguishmentsPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_NoncontrollingInterestPolicyTextBlock" xlink:href="avco-20250331.xsd#avco_NoncontrollingInterestPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avco_NoncontrollingInterestPolicyTextBlock" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiscalPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiscalPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FiscalPeriod" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ReverseStockSplitPolicyTextBlock" xlink:href="avco-20250331.xsd#avco_ReverseStockSplitPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avco_ReverseStockSplitPolicyTextBlock" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="29" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/PrepaidExpenseandOtherCurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/InvestmentinRealEstateTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RealEstateInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/EquityMethodInvestmentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ConvertibleNotePayableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/NotePayableNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="avco_EquityTablesLineItems" xlink:href="avco-20250331.xsd#avco_EquityTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_EquityTablesTable" xlink:href="avco-20250331.xsd#avco_EquityTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avco_EquityTablesLineItems" xlink:to="avco_EquityTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityTablesTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_OptionsOutstandingMember" xlink:href="avco-20250331.xsd#avco_OptionsOutstandingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avco_OptionsOutstandingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_WarrantsOutstandingMember" xlink:href="avco-20250331.xsd#avco_WarrantsOutstandingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avco_WarrantsOutstandingMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityTablesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityTablesLineItems" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ConcentrationsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/SegmentInformationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_OwnershipAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonHealthcareSystemIncMember" xlink:href="avco-20250331.xsd#avco_AvalonHealthcareSystemIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvalonHealthcareSystemIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonRT9PropertiesLLCMember" xlink:href="avco-20250331.xsd#avco_AvalonRT9PropertiesLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvalonRT9PropertiesLLCMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember" xlink:href="avco-20250331.xsd#avco_AvalonShanghaiHealthcareTechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_GenExosomeTechnologiesIncMember" xlink:href="avco-20250331.xsd#avco_GenExosomeTechnologiesIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_GenExosomeTechnologiesIncMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvactisBiosciencesIncMember" xlink:href="avco-20250331.xsd#avco_AvactisBiosciencesIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvactisBiosciencesIncMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvactisNanjingBiosciencesLtdMember" xlink:href="avco-20250331.xsd#avco_AvactisNanjingBiosciencesLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvactisNanjingBiosciencesLtdMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonLaboratoryServicesIncMember" xlink:href="avco-20250331.xsd#avco_AvalonLaboratoryServicesIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvalonLaboratoryServicesIncMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_QADistributionLLCMember" xlink:href="avco-20250331.xsd#avco_QADistributionLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_QADistributionLLCMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentPlaceAndDateOfIncorporation" xlink:href="avco-20250331.xsd#avco_EquityMethodInvestmentPlaceAndDateOfIncorporation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="avco_EquityMethodInvestmentPlaceAndDateOfIncorporation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise" xlink:href="avco-20250331.xsd#avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="srt_StatementGeographicalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CashPercentage" xlink:href="avco-20250331.xsd#avco_CashPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="avco_CashPercentage" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_OptionsToPurchaseCommonStockMember" xlink:href="avco-20250331.xsd#avco_OptionsToPurchaseCommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="avco_OptionsToPurchaseCommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="avco_PrepaidProfessionalFees" xlink:href="avco-20250331.xsd#avco_PrepaidProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="avco_PrepaidProfessionalFees" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidReinsurancePremiums" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidReinsurancePremiums"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidReinsurancePremiums" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsLeasingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsLeasingNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsLeasingNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_SecurityDeposit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromCorrespondentBrokers" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DueFromCorrespondentBrokers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DueFromCorrespondentBrokers" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValueAddedTaxReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ValueAddedTaxReceivable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LaboratoryEquipmentMember" xlink:href="avco-20250331.xsd#avco_LaboratoryEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="avco_LaboratoryEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofInvestmentinRealEstateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRealEstatePropertiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RealEstateLineItems" xlink:to="us-gaap_ScheduleOfRealEstatePropertiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollateralAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRealEstatePropertiesTable" xlink:to="us-gaap_CollateralAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollateralDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollateralDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialRealEstateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialRealEstateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollateralDomain" xlink:to="us-gaap_CommercialRealEstateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollateralDomain" xlink:to="us-gaap_LandImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RealEstateLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestmentPropertyAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestmentPropertyAtCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RealEstateLineItems" xlink:to="us-gaap_RealEstateInvestmentPropertyAtCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RealEstateLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestmentPropertyNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestmentPropertyNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RealEstateLineItems" xlink:to="us-gaap_RealEstateInvestmentPropertyNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="avco_LabServicesMSOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets" xlink:href="avco-20250331.xsd#avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets" xlink:href="avco-20250331.xsd#avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LabServicesMSOsNetIncomeAttributableToTheCompany" xlink:href="avco-20250331.xsd#avco_LabServicesMSOsNetIncomeAttributableToTheCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="avco_LabServicesMSOsNetIncomeAttributableToTheCompany" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_InvestmentInLaboratoryServicesMSOLLCMember" xlink:href="avco-20250331.xsd#avco_InvestmentInLaboratoryServicesMSOLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="avco_InvestmentInLaboratoryServicesMSOLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquity" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedIncomeStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_InvestmentInLaboratoryServicesMSOLLCMember" xlink:href="avco-20250331.xsd#avco_InvestmentInLaboratoryServicesMSOLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="avco_InvestmentInLaboratoryServicesMSOLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_GrossProfit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_ProfitLoss" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedTenantsImprovementReimbursement" xlink:href="avco-20250331.xsd#avco_AccruedTenantsImprovementReimbursement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="avco_AccruedTenantsImprovementReimbursement" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Deposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_Deposits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedBusinessExpenseReimbursement" xlink:href="avco-20250331.xsd#avco_AccruedBusinessExpenseReimbursement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="avco_AccruedBusinessExpenseReimbursement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedUtilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedUtilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedUtilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedRealPropertyCleaningServiceFee" xlink:href="avco-20250331.xsd#avco_AccruedRealPropertyCleaningServiceFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="avco_AccruedRealPropertyCleaningServiceFee" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_AwardDateAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MastHillMember" xlink:href="avco-20250331.xsd#avco_MastHillMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="avco_MastHillMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DecemberFiveTwoThousandTwentyFourMember" xlink:href="avco-20250331.xsd#avco_DecemberFiveTwoThousandTwentyFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="avco_DecemberFiveTwoThousandTwentyFourMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_JanuaryFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_JanuaryFiveTwoThousandTwentyFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="avco_JanuaryFiveTwoThousandTwentyFiveMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_FebruaryFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_FebruaryFiveTwoThousandTwentyFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="avco_FebruaryFiveTwoThousandTwentyFiveMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MarchFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_MarchFiveTwoThousandTwentyFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="avco_MarchFiveTwoThousandTwentyFiveMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AprilFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_AprilFiveTwoThousandTwentyFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="avco_AprilFiveTwoThousandTwentyFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MayFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_MayFiveTwoThousandTwentyFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="avco_MayFiveTwoThousandTwentyFiveMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_JuneFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_JuneFiveTwoThousandTwentyFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="avco_JuneFiveTwoThousandTwentyFiveMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems" xlink:href="avco-20250331.xsd#avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable" xlink:href="avco-20250331.xsd#avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems" xlink:to="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofNotePayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_OtherNotesPayableCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofLineofCreditTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DrawDownFromLineOfCredit" xlink:href="avco-20250331.xsd#avco_DrawDownFromLineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="avco_DrawDownFromLineOfCredit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty" xlink:href="avco-20250331.xsd#avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofCompanysLossBeforeIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DeferredTaxAssetsPartnershipInvestment" xlink:href="avco-20250331.xsd#avco_DeferredTaxAssetsPartnershipInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="avco_DeferredTaxAssetsPartnershipInvestment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesRegulatoryAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_EquityScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingDetailsTable" xlink:href="avco-20250331.xsd#avco_EquityScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="avco_EquityScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingDetailsTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeOneMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeTwoMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeThreeMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeFourMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_EquityScheduleofStockOptionActivityDetailsTable" xlink:href="avco-20250331.xsd#avco_EquityScheduleofStockOptionActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avco_EquityScheduleofStockOptionActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityScheduleofStockOptionActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" xlink:href="avco-20250331.xsd#avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" xlink:to="srt_RestatementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" xlink:to="us-gaap_VestingAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_NonvestedMember" xlink:href="avco-20250331.xsd#avco_NonvestedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="avco_NonvestedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues" xlink:href="avco-20250331.xsd#avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_WarrantsOutstandingMember" xlink:href="avco-20250331.xsd#avco_WarrantsOutstandingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avco_WarrantsOutstandingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeOneMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeTwoMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeFourMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeFourMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeFiveMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeFiveMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CustomerAMember" xlink:href="avco-20250331.xsd#avco_CustomerAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="avco_CustomerAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CustomerBMember" xlink:href="avco-20250331.xsd#avco_CustomerBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="avco_CustomerBMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CustomerCMember" xlink:href="avco-20250331.xsd#avco_CustomerCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="avco_CustomerCMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RealPropertyOperationsMember" xlink:href="avco-20250331.xsd#avco_RealPropertyOperationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="avco_RealPropertyOperationsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="avco_LabServicesMSOMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CorporateOtherMember" xlink:href="avco-20250331.xsd#avco_CorporateOtherMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="avco_CorporateOtherMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InterestExpenseNonoperating" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherIncome" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RealPropertyOperatingMember" xlink:href="avco-20250331.xsd#avco_RealPropertyOperatingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="avco_RealPropertyOperatingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CorporateOtherMember" xlink:href="avco-20250331.xsd#avco_CorporateOtherMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="avco_CorporateOtherMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_NoncurrentAssets" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="srt_StatementGeographicalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_NoncurrentAssets" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofLeaseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities" xlink:href="avco-20250331.xsd#avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_OwnershipAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonHealthcareSystemIncMember" xlink:href="avco-20250331.xsd#avco_AvalonHealthcareSystemIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvalonHealthcareSystemIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonRT9PropertiesLLCMember" xlink:href="avco-20250331.xsd#avco_AvalonRT9PropertiesLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvalonRT9PropertiesLLCMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember" xlink:href="avco-20250331.xsd#avco_AvalonShanghaiHealthcareTechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_GenExosomeTechnologiesIncMember" xlink:href="avco-20250331.xsd#avco_GenExosomeTechnologiesIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_GenExosomeTechnologiesIncMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvactisBiosciencesIncMember" xlink:href="avco-20250331.xsd#avco_AvactisBiosciencesIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvactisBiosciencesIncMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvactisNanjingBiosciencesLtdMember" xlink:href="avco-20250331.xsd#avco_AvactisNanjingBiosciencesLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvactisNanjingBiosciencesLtdMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonLaboratoryServicesIncMember" xlink:href="avco-20250331.xsd#avco_AvalonLaboratoryServicesIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvalonLaboratoryServicesIncMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_QADistributionLLCMember" xlink:href="avco-20250331.xsd#avco_QADistributionLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_QADistributionLLCMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentPlaceAndDateOfIncorporation" xlink:href="avco-20250331.xsd#avco_EquityMethodInvestmentPlaceAndDateOfIncorporation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="avco_EquityMethodInvestmentPlaceAndDateOfIncorporation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="srt_StatementGeographicalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CashPercentage" xlink:href="avco-20250331.xsd#avco_CashPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="avco_CashPercentage" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_OptionsToPurchaseCommonStockMember" xlink:href="avco-20250331.xsd#avco_OptionsToPurchaseCommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="avco_OptionsToPurchaseCommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="avco_PrepaidProfessionalFees" xlink:href="avco-20250331.xsd#avco_PrepaidProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="avco_PrepaidProfessionalFees" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidReinsurancePremiums" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidReinsurancePremiums"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidReinsurancePremiums" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseOtherNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsLeasingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsLeasingNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsLeasingNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_SecurityDeposit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromCorrespondentBrokers" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DueFromCorrespondentBrokers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DueFromCorrespondentBrokers" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValueAddedTaxReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ValueAddedTaxReceivable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="avco_LabServicesMSOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LabServicesMSOsNetIncomeAttributableToTheCompany" xlink:href="avco-20250331.xsd#avco_LabServicesMSOsNetIncomeAttributableToTheCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="avco_LabServicesMSOsNetIncomeAttributableToTheCompany" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedIncomeStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_InvestmentInLaboratoryServicesMSOLLCMember" xlink:href="avco-20250331.xsd#avco_InvestmentInLaboratoryServicesMSOLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="avco_InvestmentInLaboratoryServicesMSOLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_GrossProfit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_ProfitLoss" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_AwardDateAxis" order="10" xbrldt:closed="true"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra/k4DNHXVKIYwN/zLXIt0iwZq6nYg/w27/nmgU3Bs4kyGGa1okQf8wpc8xue3C4gYCyO+De2FMpGD6T1rBTmQ8hA/UC+V/TeVcwU7ABGe/tb9Nse+XBO1hN0S6XbJQbcJwedpHBgl7i050GjffC4p7Iw/J3z5vZfcXGGwK1wcBZ+q2HcISatlXTlFgsMKO5QeDDlx75B8z8hjuvV5IPRmtFIaAZaCRuKG6FjDX4pVgOn4dIx+68+8sWetJxT3/aKc=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MastHillMember" xlink:href="avco-20250331.xsd#avco_MastHillMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="avco_MastHillMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DecemberFiveTwoThousandTwentyFourMember" xlink:href="avco-20250331.xsd#avco_DecemberFiveTwoThousandTwentyFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="avco_DecemberFiveTwoThousandTwentyFourMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_JanuaryFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_JanuaryFiveTwoThousandTwentyFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="avco_JanuaryFiveTwoThousandTwentyFiveMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_FebruaryFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_FebruaryFiveTwoThousandTwentyFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="avco_FebruaryFiveTwoThousandTwentyFiveMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MarchFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_MarchFiveTwoThousandTwentyFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="avco_MarchFiveTwoThousandTwentyFiveMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AprilFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_AprilFiveTwoThousandTwentyFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="avco_AprilFiveTwoThousandTwentyFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MayFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_MayFiveTwoThousandTwentyFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="avco_MayFiveTwoThousandTwentyFiveMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_JuneFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_JuneFiveTwoThousandTwentyFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="avco_JuneFiveTwoThousandTwentyFiveMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable" xlink:href="avco-20250331.xsd#avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofNotePayableTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_OptionsOutstandingMember" xlink:href="avco-20250331.xsd#avco_OptionsOutstandingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avco_OptionsOutstandingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeOneMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeTwoMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeThreeMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeFourMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_EquityScheduleofStockOptionActivityDetailsTable" xlink:href="avco-20250331.xsd#avco_EquityScheduleofStockOptionActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avco_EquityScheduleofStockOptionActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityScheduleofStockOptionActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" xlink:href="avco-20250331.xsd#avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" xlink:to="us-gaap_VestingAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_NonvestedMember" xlink:href="avco-20250331.xsd#avco_NonvestedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="avco_NonvestedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues" xlink:href="avco-20250331.xsd#avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_WarrantsOutstandingMember" xlink:href="avco-20250331.xsd#avco_WarrantsOutstandingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avco_WarrantsOutstandingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeOneMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeTwoMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeFourMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeFourMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeFiveMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeFiveMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CustomerAMember" xlink:href="avco-20250331.xsd#avco_CustomerAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="avco_CustomerAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CustomerBMember" xlink:href="avco-20250331.xsd#avco_CustomerBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="avco_CustomerBMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CustomerCMember" xlink:href="avco-20250331.xsd#avco_CustomerCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="avco_CustomerCMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RealPropertyOperationsMember" xlink:href="avco-20250331.xsd#avco_RealPropertyOperationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="avco_RealPropertyOperationsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="avco_LabServicesMSOMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CorporateOtherMember" xlink:href="avco-20250331.xsd#avco_CorporateOtherMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="avco_CorporateOtherMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InterestExpenseNonoperating" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherIncome" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ProfitLoss" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RealPropertyOperatingMember" xlink:href="avco-20250331.xsd#avco_RealPropertyOperatingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="avco_RealPropertyOperatingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CorporateOtherMember" xlink:href="avco-20250331.xsd#avco_CorporateOtherMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="avco_CorporateOtherMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_NoncurrentAssets" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="srt_StatementGeographicalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_NoncurrentAssets" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofLeaseTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_OrganizationandNatureofOperationsDetailsTable" xlink:href="avco-20250331.xsd#avco_OrganizationandNatureofOperationsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="avco_OrganizationandNatureofOperationsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_OrganizationandNatureofOperationsDetailsTable" xlink:to="srt_OwnershipAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_OrganizationandNatureofOperationsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_OrganizationandNatureofOperationsDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonHealthcareSystemIncMember" xlink:href="avco-20250331.xsd#avco_AvalonHealthcareSystemIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvalonHealthcareSystemIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonRT9PropertiesLLCMember" xlink:href="avco-20250331.xsd#avco_AvalonRT9PropertiesLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvalonRT9PropertiesLLCMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvactisAndArbeleBiotherapeuticsLimitedMember" xlink:href="avco-20250331.xsd#avco_AvactisAndArbeleBiotherapeuticsLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvactisAndArbeleBiotherapeuticsLimitedMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvactisBiosciencesIncMember" xlink:href="avco-20250331.xsd#avco_AvactisBiosciencesIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvactisBiosciencesIncMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonLabMember" xlink:href="avco-20250331.xsd#avco_AvalonLabMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvalonLabMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_LabServicesMSOMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="avco_BasisofPresentationandGoingConcernConditionDetailsLineItems" xlink:href="avco-20250331.xsd#avco_BasisofPresentationandGoingConcernConditionDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_BasisofPresentationandGoingConcernConditionDetailsTable" xlink:href="avco-20250331.xsd#avco_BasisofPresentationandGoingConcernConditionDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avco_BasisofPresentationandGoingConcernConditionDetailsLineItems" xlink:to="avco_BasisofPresentationandGoingConcernConditionDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_BasisofPresentationandGoingConcernConditionDetailsTable" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentOperatingActivitiesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="us-gaap_SegmentOperatingActivitiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentOperatingActivitiesDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="us-gaap_SegmentOperatingActivitiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentContinuingOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentOperatingActivitiesDomain" xlink:to="us-gaap_SegmentContinuingOperationsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_WorkingCapitalDeficit" xlink:href="avco-20250331.xsd#avco_WorkingCapitalDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_BasisofPresentationandGoingConcernConditionDetailsLineItems" xlink:to="avco_WorkingCapitalDeficit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_BasisofPresentationandGoingConcernConditionDetailsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_BasisofPresentationandGoingConcernConditionDetailsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_BasisofPresentationandGoingConcernConditionDetailsLineItems" xlink:to="us-gaap_ProfitLoss" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="avco-20250331.xsd#avco_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="avco-20250331.xsd#avco_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="avco_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegulatoryAssetAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegulatoryAssetAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RegulatoryAssetAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegulatoryAssetDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegulatoryAssetDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RegulatoryAssetAxis" xlink:to="us-gaap_RegulatoryAssetDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegulatoryAssetDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegulatoryAssetDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RegulatoryAssetAxis" xlink:to="us-gaap_RegulatoryAssetDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_EquityMethodInvestmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PreFundedWarrantsMember" xlink:href="avco-20250331.xsd#avco_PreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="avco_PreFundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LaboratoryEquipmentMember" xlink:href="avco-20250331.xsd#avco_LaboratoryEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="avco_LaboratoryEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="avco_LabServicesMSOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AssetAndLiabilityAccountsMember" xlink:href="avco-20250331.xsd#avco_AssetAndLiabilityAccountsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="avco_AssetAndLiabilityAccountsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesAConvertiblePreferredStockMember" xlink:href="avco-20250331.xsd#avco_SeriesAConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avco_SeriesAConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DeferredOfferingCostsMember" xlink:href="avco-20250331.xsd#avco_DeferredOfferingCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RegulatoryAssetDomain" xlink:to="avco_DeferredOfferingCostsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LaboratoryServicesMSOLLCMember" xlink:href="avco-20250331.xsd#avco_LaboratoryServicesMSOLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_LaboratoryServicesMSOLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_EpiconBiotechCoLtdMember" xlink:href="avco-20250331.xsd#avco_EpiconBiotechCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="avco_EpiconBiotechCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DrYuZhouMember" xlink:href="avco-20250331.xsd#avco_DrYuZhouMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="avco_DrYuZhouMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalReserveBankStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalReserveBankStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_FederalReserveBankStock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OtherAssetImpairmentCharges" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredIncome" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredAdvertisingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredAdvertisingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredAdvertisingCosts" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_EquityInterestPercent" xlink:href="avco-20250331.xsd#avco_EquityInterestPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="avco_EquityInterestPercent" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentDividendsOrDistributions" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PaymentOfEquityInvestment" xlink:href="avco-20250331.xsd#avco_PaymentOfEquityInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="avco_PaymentOfEquityInvestment" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RegularPaymentsOnEquityInvestments" xlink:href="avco-20250331.xsd#avco_RegularPaymentsOnEquityInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="avco_RegularPaymentsOnEquityInvestments" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableInvestmentSale" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableInvestmentSale"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ReceivableInvestmentSale" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AssetsCurrent" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DilutiveSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DilutiveSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DilutiveSecurities" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_CostsAndExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_OtherOperatingExpense" xlink:href="avco-20250331.xsd#avco_OtherOperatingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="avco_OtherOperatingExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/EquipmentHeldForSaleDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="avco_ImpairmentOfLaboratoryEquipment" xlink:href="avco-20250331.xsd#avco_ImpairmentOfLaboratoryEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract" xlink:to="avco_ImpairmentOfLaboratoryEquipment" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/InvestmentinRealEstateDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RealEstateInvestmentsAbstract" xlink:to="us-gaap_OtherDepreciationAndAmortization" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentsDetailsTable" xlink:href="avco-20250331.xsd#avco_EquityMethodInvestmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="avco_EquityMethodInvestmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityMethodInvestmentsDetailsTable" xlink:to="srt_OwnershipAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityMethodInvestmentsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityMethodInvestmentsDetailsTable" xlink:to="srt_RangeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityMethodInvestmentsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityMethodInvestmentsDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityMethodInvestmentsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonShangaiMember" xlink:href="avco-20250331.xsd#avco_AvalonShangaiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvalonShangaiMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_JiangsuUnicornBiologicalTechnologyCoLtdMember" xlink:href="avco-20250331.xsd#avco_JiangsuUnicornBiologicalTechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_JiangsuUnicornBiologicalTechnologyCoLtdMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesBStatedValueMember" xlink:href="avco-20250331.xsd#avco_SeriesBStatedValueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avco_SeriesBStatedValueMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesAConvertiblePreferredStockMember" xlink:href="avco-20250331.xsd#avco_SeriesAConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="avco_SeriesAConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesBConvertiblePreferredStockMember" xlink:href="avco-20250331.xsd#avco_SeriesBConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="avco_SeriesBConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="avco_SeriesBStatedValueMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LaboratoryServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LaboratoryServicesMSOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="avco_LaboratoryServicesMSOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_EpiconBiotechCoLtdMember" xlink:href="avco-20250331.xsd#avco_EpiconBiotechCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="avco_EpiconBiotechCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_InvestmentInEpiconBiotechCoLtdMember" xlink:href="avco-20250331.xsd#avco_InvestmentInEpiconBiotechCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="avco_InvestmentInEpiconBiotechCoLtdMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="avco_LaboratoryServicesMSOMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LabServicesMember" xlink:href="avco-20250331.xsd#avco_LabServicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="avco_LabServicesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PreferredStockValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentPayableCurrent" xlink:href="avco-20250331.xsd#avco_EquityMethodInvestmentPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="avco_EquityMethodInvestmentPayableCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AggregateOfCommonStock" xlink:href="avco-20250331.xsd#avco_AggregateOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="avco_AggregateOfCommonStock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_InvestmentOwnedAtCost" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LabServicesMSOsNetIncomeAttributableToTheCompany" xlink:href="avco-20250331.xsd#avco_LabServicesMSOsNetIncomeAttributableToTheCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="avco_LabServicesMSOsNetIncomeAttributableToTheCompany" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_GoodwillFairValueDisclosure" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_ConvertibleNotePayableDetailsTable" xlink:href="avco-20250331.xsd#avco_ConvertibleNotePayableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="avco_ConvertibleNotePayableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradingActivityByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_TradingActivityByTypeAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradingActivityByTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TradingActivityByTypeAxis" xlink:to="us-gaap_TradingActivityByTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradingActivityByTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TradingActivityByTypeAxis" xlink:to="us-gaap_TradingActivityByTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_FirstWarrantMember" xlink:href="avco-20250331.xsd#avco_FirstWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="avco_FirstWarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SecondWarrantMember" xlink:href="avco-20250331.xsd#avco_SecondWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="avco_SecondWarrantMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PreFundedWarrantsMember" xlink:href="avco-20250331.xsd#avco_PreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="avco_PreFundedWarrantsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MastHillFundLPMember" xlink:href="avco-20250331.xsd#avco_MastHillFundLPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_MastHillFundLPMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_FirstFireMember" xlink:href="avco-20250331.xsd#avco_FirstFireMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_FirstFireMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MastHillMember" xlink:href="avco-20250331.xsd#avco_MastHillMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_MastHillMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SeniorNotesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherTradingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherTradingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TradingActivityByTypeDomain" xlink:to="us-gaap_OtherTradingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_May2023ConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_May2023ConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="avco_May2023ConvertibleNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_July2023ConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_July2023ConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="avco_July2023ConvertibleNoteMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_October2023ConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_October2023ConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="avco_October2023ConvertibleNoteMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_March2024ConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_March2024ConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="avco_March2024ConvertibleNoteMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_June2024ConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_June2024ConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="avco_June2024ConvertibleNoteMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_WaiverFeeMember" xlink:href="avco-20250331.xsd#avco_WaiverFeeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="avco_WaiverFeeMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DebtInstrumentConvertibleFloorPrice" xlink:href="avco-20250331.xsd#avco_DebtInstrumentConvertibleFloorPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="avco_DebtInstrumentConvertibleFloorPrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PercentageOfPromissoryNotes" xlink:href="avco-20250331.xsd#avco_PercentageOfPromissoryNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="avco_PercentageOfPromissoryNotes" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_TradingPrice" xlink:href="avco-20250331.xsd#avco_TradingPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="avco_TradingPrice" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PurchasePriceOfConvertibleNote" xlink:href="avco-20250331.xsd#avco_PurchasePriceOfConvertibleNote"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="avco_PurchasePriceOfConvertibleNote" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonUnitOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CommonUnitOutstanding" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPriceIncrease" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NontradeReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NontradeReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NontradeReceivables" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PaymentForCommission" xlink:href="avco-20250331.xsd#avco_PaymentForCommission"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="avco_PaymentForCommission" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndDebtExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestAndDebtExpense" order="30" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/DerivativeLiabilityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_DerivativeLiabilityDetailsTable" xlink:href="avco-20250331.xsd#avco_DerivativeLiabilityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="avco_DerivativeLiabilityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_DerivativeLiabilityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_DerivativeLiabilityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_DerivativeLiabilityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_DerivativeLiabilityDetailsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_DerivativeLiabilityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_DerivativeLiabilityDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MastHillMember" xlink:href="avco-20250331.xsd#avco_MastHillMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="avco_MastHillMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_May232023FiveYearAnniversaryMember" xlink:href="avco-20250331.xsd#avco_May232023FiveYearAnniversaryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avco_May232023FiveYearAnniversaryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_July62023FiveYearAnniversaryMember" xlink:href="avco-20250331.xsd#avco_July62023FiveYearAnniversaryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avco_July62023FiveYearAnniversaryMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_October92023FiveYearAnniversaryMember" xlink:href="avco-20250331.xsd#avco_October92023FiveYearAnniversaryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avco_October92023FiveYearAnniversaryMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_March72024FiveYearAnniversaryMember" xlink:href="avco-20250331.xsd#avco_March72024FiveYearAnniversaryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avco_March72024FiveYearAnniversaryMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_June52024FiveyearAnniversaryMember" xlink:href="avco-20250331.xsd#avco_June52024FiveyearAnniversaryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avco_June52024FiveyearAnniversaryMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_FirstFireMember" xlink:href="avco-20250331.xsd#avco_FirstFireMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_FirstFireMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MastHillAndFirstfireMember" xlink:href="avco-20250331.xsd#avco_MastHillAndFirstfireMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_MastHillAndFirstfireMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MastHillThirdPartyMember" xlink:href="avco-20250331.xsd#avco_MastHillThirdPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_MastHillThirdPartyMember" order="2" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_MastHillMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_findersFeeMember" xlink:href="avco-20250331.xsd#avco_findersFeeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_findersFeeMember" order="4" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="avco_May232023FiveYearAnniversaryMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="avco_October92023FiveYearAnniversaryMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="avco_June52024FiveyearAnniversaryMember" order="2" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="avco_July62023FiveYearAnniversaryMember" order="3" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="avco_March72024FiveYearAnniversaryMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_June2024ConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_June2024ConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="avco_June2024ConvertibleNoteMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_WarrantsOfCashlessExercised" xlink:href="avco-20250331.xsd#avco_WarrantsOfCashlessExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="avco_WarrantsOfCashlessExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/NotePayableNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_NotePayableNetDetailsTable" xlink:href="avco-20250331.xsd#avco_NotePayableNetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="avco_NotePayableNetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_NotePayableNetDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PromissoryNoteMember" xlink:href="avco-20250331.xsd#avco_PromissoryNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="avco_PromissoryNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SecuredDebt" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseShortTermBorrowings" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_RelatedPartyTransactionsDetailsTable" xlink:href="avco-20250331.xsd#avco_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avco_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_RelatedPartyTransactionsDetailsTable" xlink:to="srt_OwnershipAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_CreditFacilityAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_RelatedPartyTransactionsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_BeijingGenexosomeMember" xlink:href="avco-20250331.xsd#avco_BeijingGenexosomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_BeijingGenexosomeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="avco_LabServicesMSOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MembershipInterestPurchaseAgreementMember" xlink:href="avco-20250331.xsd#avco_MembershipInterestPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="avco_MembershipInterestPurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LabServiceMSOMember" xlink:href="avco-20250331.xsd#avco_LabServiceMSOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="avco_LabServiceMSOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DrYuZhouMember" xlink:href="avco-20250331.xsd#avco_DrYuZhouMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_DrYuZhouMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_WenzhaoLuMember" xlink:href="avco-20250331.xsd#avco_WenzhaoLuMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_WenzhaoLuMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonRT9Member" xlink:href="avco-20250331.xsd#avco_AvalonRT9Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_AvalonRT9Member" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MrLuMember" xlink:href="avco-20250331.xsd#avco_MrLuMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="avco_MrLuMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="avco_AvalonRT9Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AbandonmentAgreementMember" xlink:href="avco-20250331.xsd#avco_AbandonmentAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="avco_AbandonmentAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LineOfCreditAgreementMember" xlink:href="avco-20250331.xsd#avco_LineOfCreditAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="avco_LineOfCreditAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RentalIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RentalIncomeNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RentalIncomeNonoperating" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherGeneralExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedAndUnpaidServicesCharge" xlink:href="avco-20250331.xsd#avco_AccruedAndUnpaidServicesCharge"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avco_AccruedAndUnpaidServicesCharge" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_Cash" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentPayableCurrent" xlink:href="avco-20250331.xsd#avco_EquityMethodInvestmentPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avco_EquityMethodInvestmentPayableCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseOther" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PurchasePrice" xlink:href="avco-20250331.xsd#avco_PurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avco_PurchasePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage" xlink:href="avco-20250331.xsd#avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" xlink:href="avco-20250331.xsd#avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PreferredStockValue" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentDividendsOrDistributions" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLoansHeldForInvestment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLoansHeldForInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsToAcquireLoansHeldForInvestment" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RegularPaymentsOnEquityInvestments" xlink:href="avco-20250331.xsd#avco_RegularPaymentsOnEquityInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avco_RegularPaymentsOnEquityInvestments" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableInvestmentSale" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableInvestmentSale"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ReceivableInvestmentSale" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherNotesPayable" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExchangeShare" xlink:href="avco-20250331.xsd#avco_ExchangeShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="avco_ExchangeShare" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="30" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_IncomeTaxesDetailsTable" xlink:href="avco-20250331.xsd#avco_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="avco_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_IncomeTaxesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_EquityDetailsTable" xlink:href="avco-20250331.xsd#avco_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="avco_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsTable" xlink:to="srt_OwnershipAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsTable" xlink:to="dei_LegalEntityAxis" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_May2023CovertibleNoteMember" xlink:href="avco-20250331.xsd#avco_May2023CovertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="avco_May2023CovertibleNoteMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_BlackScholesValuationModelMember" xlink:href="avco-20250331.xsd#avco_BlackScholesValuationModelMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="avco_BlackScholesValuationModelMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_July2023ConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_July2023ConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="avco_July2023ConvertibleNoteMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_OctoberTwoThousandTwentyThreeConvertibleNotesMember" xlink:href="avco-20250331.xsd#avco_OctoberTwoThousandTwentyThreeConvertibleNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="avco_OctoberTwoThousandTwentyThreeConvertibleNotesMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MarchTwoThousandTwentyFourWarrantIssuedMember" xlink:href="avco-20250331.xsd#avco_MarchTwoThousandTwentyFourWarrantIssuedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="avco_MarchTwoThousandTwentyFourWarrantIssuedMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MarchTwentyThousandTwentyFourConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_MarchTwentyThousandTwentyFourConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="avco_MarchTwentyThousandTwentyFourConvertibleNoteMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_TwoThousandTwentyFourJuneWarrantIssuedMember" xlink:href="avco-20250331.xsd#avco_TwoThousandTwentyFourJuneWarrantIssuedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="avco_TwoThousandTwentyFourJuneWarrantIssuedMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_JuneTwentyThousandTwentyFourConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_JuneTwentyThousandTwentyFourConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="avco_JuneTwentyThousandTwentyFourConvertibleNoteMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CommonSharesIssuedForServicesMember" xlink:href="avco-20250331.xsd#avco_CommonSharesIssuedForServicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="avco_CommonSharesIssuedForServicesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PreFundedWarrantsMember" xlink:href="avco-20250331.xsd#avco_PreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="avco_PreFundedWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_FirstfireMember" xlink:href="avco-20250331.xsd#avco_FirstfireMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="avco_FirstfireMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MastHillMember" xlink:href="avco-20250331.xsd#avco_MastHillMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="avco_MastHillMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_FiveYearAnniversaryMember" xlink:href="avco-20250331.xsd#avco_FiveYearAnniversaryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="avco_FiveYearAnniversaryMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_WarrantsExercisedMember" xlink:href="avco-20250331.xsd#avco_WarrantsExercisedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="avco_WarrantsExercisedMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MrLuMember" xlink:href="avco-20250331.xsd#avco_MrLuMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="avco_MrLuMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="avco_LabServicesMSOMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="avco_WarrantsExercisedMember" order="2" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="avco_PreFundedWarrantsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesAConvertiblePreferredStockMember" xlink:href="avco-20250331.xsd#avco_SeriesAConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avco_SeriesAConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesBConvertiblePreferredStockMember" xlink:href="avco-20250331.xsd#avco_SeriesBConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avco_SeriesBConvertiblePreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesBHolderMember" xlink:href="avco-20250331.xsd#avco_SeriesBHolderMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="avco_SeriesBHolderMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ConversionShareMember" xlink:href="avco-20250331.xsd#avco_ConversionShareMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_ConversionShareMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_LiabilityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_JefferiesLLCMember" xlink:href="avco-20250331.xsd#avco_JefferiesLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="avco_JefferiesLLCMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avco_FiveYearAnniversaryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RothCapitalPartnersLLCMember" xlink:href="avco-20250331.xsd#avco_RothCapitalPartnersLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="avco_RothCapitalPartnersLLCMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="avco_JefferiesLLCMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="avco_MastHillMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MastMillAndFirstFireMember" xlink:href="avco-20250331.xsd#avco_MastMillAndFirstFireMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="avco_MastMillAndFirstFireMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ConvertibleDebtNoteMember" xlink:href="avco-20250331.xsd#avco_ConvertibleDebtNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="avco_ConvertibleDebtNoteMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="avco_LabServicesMSOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonLabMember" xlink:href="avco-20250331.xsd#avco_AvalonLabMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="avco_AvalonLabMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PercentageOfCommonStockIssuedAndOutstanding" xlink:href="avco-20250331.xsd#avco_PercentageOfCommonStockIssuedAndOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="avco_PercentageOfCommonStockIssuedAndOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ConversionPricePercentage" xlink:href="avco-20250331.xsd#avco_ConversionPricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="avco_ConversionPricePercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CommonStockOfAveragePrice" xlink:href="avco-20250331.xsd#avco_CommonStockOfAveragePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="avco_CommonStockOfAveragePrice" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromOtherEquity" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_OfferingCost" xlink:href="avco-20250331.xsd#avco_OfferingCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="avco_OfferingCost" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_FairMarketValuesOfGrantDates" xlink:href="avco-20250331.xsd#avco_FairMarketValuesOfGrantDates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="avco_FairMarketValuesOfGrantDates" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProfessionalFees" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" order="41" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="42" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="43" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="44" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="45" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="46" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="47" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="48" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="49" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockRedemptionAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockRedemptionAmount" order="50" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RedemptionNetOfPayablesDueToLabServices" xlink:href="avco-20250331.xsd#avco_RedemptionNetOfPayablesDueToLabServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="avco_RedemptionNetOfPayablesDueToLabServices" order="51" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockRedemptionPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockRedemptionPremium" order="52" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="53" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_FairMarketValues" xlink:href="avco-20250331.xsd#avco_FairMarketValues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="avco_FairMarketValues" order="54" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="55" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PrepaidExpenseCurrent" order="56" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestrictedAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="avco_StatutoryReservePercent" xlink:href="avco-20250331.xsd#avco_StatutoryReservePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherRestrictedAssetsAbstract" xlink:to="avco_StatutoryReservePercent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RegisteredCapitalPercentage" xlink:href="avco-20250331.xsd#avco_RegisteredCapitalPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherRestrictedAssetsAbstract" xlink:to="avco_RegisteredCapitalPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_StatutoryReserve" xlink:href="avco-20250331.xsd#avco_StatutoryReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherRestrictedAssetsAbstract" xlink:to="avco_StatutoryReserve" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestrictedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherRestrictedAssetsAbstract" xlink:to="us-gaap_OtherRestrictedAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherRestrictedAssetsAbstract" xlink:to="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/NoncontrollingInterestDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_NoncontrollingInterestDetailsTable" xlink:href="avco-20250331.xsd#avco_NoncontrollingInterestDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="avco_NoncontrollingInterestDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_NoncontrollingInterestDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_NoncontrollingInterestDetailsTable" xlink:to="srt_OwnershipAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DrYuZhouMember" xlink:href="avco-20250331.xsd#avco_DrYuZhouMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_DrYuZhouMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_FormerDirectorAndFormerCochiefExecutiveOfficerMember" xlink:href="avco-20250331.xsd#avco_FormerDirectorAndFormerCochiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="avco_FormerDirectorAndFormerCochiefExecutiveOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompanyDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_CondensedFinancialInformationoftheParentCompanyDetailsTable" xlink:href="avco-20250331.xsd#avco_CondensedFinancialInformationoftheParentCompanyDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="avco_CondensedFinancialInformationoftheParentCompanyDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_CondensedFinancialInformationoftheParentCompanyDetailsTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PRCSubsidiariesMember" xlink:href="avco-20250331.xsd#avco_PRCSubsidiariesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="avco_PRCSubsidiariesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets" xlink:href="avco-20250331.xsd#avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed" xlink:href="avco-20250331.xsd#avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/ConcentrationsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_ConcentrationsDetailsTable" xlink:href="avco-20250331.xsd#avco_ConcentrationsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="avco_ConcentrationsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_ConcentrationsDetailsTable" xlink:to="srt_MajorCustomersAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_ConcentrationsDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_OneCustomerMember" xlink:href="avco-20250331.xsd#avco_OneCustomerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="avco_OneCustomerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_TwoCustomersMember" xlink:href="avco-20250331.xsd#avco_TwoCustomersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="avco_TwoCustomersMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventorySuppliesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventorySuppliesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="us-gaap_PublicUtilitiesInventorySuppliesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/SegmentInformationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="avco_SegmentInformationDetailsLineItems" xlink:href="avco-20250331.xsd#avco_SegmentInformationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_SegmentInformationDetailsTable" xlink:href="avco-20250331.xsd#avco_SegmentInformationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avco_SegmentInformationDetailsLineItems" xlink:to="avco_SegmentInformationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SegmentInformationDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="avco_LabServicesMSOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SegmentInformationDetailsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SegmentInformationDetailsLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PurchasedServicesPercentage" xlink:href="avco-20250331.xsd#avco_PurchasedServicesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SegmentInformationDetailsLineItems" xlink:to="avco_PurchasedServicesPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SegmentInformationDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_CommitmentsandContingenciesDetailsTable" xlink:href="avco-20250331.xsd#avco_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="avco_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_CommitmentsandContingenciesDetailsTable" xlink:to="srt_OwnershipAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_LitigationStatusAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationStatusDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvactisBiotherapeuticsLimitedMember" xlink:href="avco-20250331.xsd#avco_AvactisBiotherapeuticsLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvactisBiotherapeuticsLimitedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ArbeleMember" xlink:href="avco-20250331.xsd#avco_ArbeleMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_ArbeleMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvactisNanjingBiosciencesLtdMember" xlink:href="avco-20250331.xsd#avco_AvactisNanjingBiosciencesLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_AvactisNanjingBiosciencesLtdMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DrZhouMember" xlink:href="avco-20250331.xsd#avco_DrZhouMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="avco_DrZhouMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SettledLitigationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_SettledLitigationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LoansPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LitigationReserve" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PercentageOfPretaxProfit" xlink:href="avco-20250331.xsd#avco_PercentageOfPretaxProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="avco_PercentageOfPretaxProfit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PreTaxProfit" xlink:href="avco-20250331.xsd#avco_PreTaxProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="avco_PreTaxProfit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForRent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowsBetweenTransfereeAndTransferorServicingFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowsBetweenTransfereeAndTransferorServicingFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_CashFlowsBetweenTransfereeAndTransferorServicingFees" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashContributionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashContributionExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_NoncashContributionExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_WorkingCapital" xlink:href="avco-20250331.xsd#avco_WorkingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="avco_WorkingCapital" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.avalonglobocare.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_SubsequentEventsDetailsTable" xlink:href="avco-20250331.xsd#avco_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="avco_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SubsequentEventsDetailsTable" xlink:to="srt_OwnershipAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsegmentsAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsegmentsAxis" xlink:to="us-gaap_SubsegmentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsegmentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsegmentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsegmentsAxis" xlink:to="us-gaap_SubsegmentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SubsequentEventsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="avco_LabServicesMSOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesBConvertiblePreferredStockMember" xlink:href="avco-20250331.xsd#avco_SeriesBConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="avco_SeriesBConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MergerAgreementMember" xlink:href="avco-20250331.xsd#avco_MergerAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="avco_MergerAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CertificatesOfEliminationMember" xlink:href="avco-20250331.xsd#avco_CertificatesOfEliminationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="avco_CertificatesOfEliminationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="avco_LabServicesMSOMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsegmentsDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedemptionPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RedemptionPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RedemptionPremium" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExchangeRatioPerShare" xlink:href="avco-20250331.xsd#avco_ExchangeRatioPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="avco_ExchangeRatioPerShare" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesOutstanding" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_FairMarketValuesOfGrantDates" xlink:href="avco-20250331.xsd#avco_FairMarketValuesOfGrantDates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="avco_FairMarketValuesOfGrantDates" order="16" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>avco-20250331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Jun 09 23:27:56 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total Non-current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Noncurrent assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl1" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total Non-current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Noncurrent liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Avalon GloboCare Corp. stockholders&#8217; (deficit) equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total (Deficit) Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US">Total Other Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl0" xml:lang="en-US">Other operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TreasuryStockCommonShares_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockCommonShares_lbl1" xml:lang="en-US">Treasury stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">CASH - beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">CASH - end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Nature of Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_BasisOfPresentationAndGoingConcernConditionAbstract" xlink:href="avco-20250331.xsd#avco_BasisOfPresentationAndGoingConcernConditionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_BasisOfPresentationAndGoingConcernConditionAbstract_lbl" xml:lang="en-US">Basis of Presentation and Going Concern Condition [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BasisOfPresentationAndGoingConcernConditionAbstract" xlink:to="avco_BasisOfPresentationAndGoingConcernConditionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Balance of derivative liability beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl0" xml:lang="en-US">Balance of derivative liability ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl1" xml:lang="en-US">Derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl2" xml:lang="en-US">Derivative liability (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAbstract_lbl" xml:lang="en-US">Prepaid Expense and Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Schedule of Prepaid Expense and Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid expense and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract_lbl" xml:lang="en-US">Equipment Held For Sale [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealEstateInvestmentsAbstract_lbl" xml:lang="en-US">Investment in Real Estate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateInvestmentsAbstract" xlink:to="us-gaap_RealEstateInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollateralAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollateralAxis_lbl" xml:lang="en-US">Collateral Held [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xml:lang="en-US">Equity Method Investments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US">Equity investment carrying amount beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl0" xml:lang="en-US">Equity investment carrying amount ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl1" xml:lang="en-US">Equity method investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl2" xml:lang="en-US">Equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl3" xml:lang="en-US">Equity Method Investment, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl3"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl1" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ProfitLoss_lbl2" xml:lang="en-US">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl3" xml:lang="en-US">Net (loss) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl3"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Accrued Liabilities and Other Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Accrued Liabilities and Other Payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Convertible Note Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xml:lang="en-US">Debt Conversion Description [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Convertible note payable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl0" xml:lang="en-US">Convertible note payable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesAbstract_lbl" xml:lang="en-US">Derivative Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="us-gaap_DerivativeLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Note Payable, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableAbstract_lbl" xml:lang="en-US">Note Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNotesPayableCurrent_lbl" xml:lang="en-US">Note payable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayableCurrent" xlink:to="us-gaap_OtherNotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAbstract_lbl" xml:lang="en-US">Schedule of Line of Credit [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_LineOfCreditFacilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl" xml:lang="en-US">Outstanding principal under the Line of Credit, Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl0" xml:lang="en-US">Outstanding principal under the Line of Credit, Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_lbl" xml:lang="en-US">Schedule of Company&#8217;s Loss Before Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">LOSS BEFORE INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Schedule of Components of Income Taxes Expense (Benefit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current income taxes expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred income taxes (benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total income taxes expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US">Schedule of U.S. Statutory Rate and the Company&#8217;s Effective Tax Rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Total provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Deferred Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Total deferred tax assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl0" xml:lang="en-US">EQUITY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Options, Balance Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Options Outstanding, Number Outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US">Warrants Outstanding, Number Outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl3" xml:lang="en-US">Number of Options, Balance outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl3"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Balance Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Weighted Average Exercise Price, Balance outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of Options, Nonvested Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0" xml:lang="en-US">Number of Options, Nonvested Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Nonvested Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Nonvested Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestrictedAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherRestrictedAssetsAbstract_lbl" xml:lang="en-US">Statutory Reserve and Restricted Net Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestrictedAssetsAbstract" xlink:to="us-gaap_OtherRestrictedAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestAbstract_lbl" xml:lang="en-US">Noncontrolling Interest [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_NoncontrollingInterestAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_lbl" xml:lang="en-US">Condensed Financial Information of the Parent Company [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Concentrations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Schedule of Lease [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Schedule of Maturity of Lease Liabilities Under Operating Lease [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Note payable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl0" xml:lang="en-US">Current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US">Rent receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RealEstateInvestments_lbl" xml:lang="en-US">Investment in real estate, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateInvestments" xlink:to="us-gaap_RealEstateInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">LIABILITIES AND (DEFICIT) EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedResearchAndDevelopmentsFees" xlink:href="avco-20250331.xsd#avco_AccruedResearchAndDevelopmentsFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AccruedResearchAndDevelopmentsFees_lbl" xml:lang="en-US">Accrued research and development fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedResearchAndDevelopmentsFees" xlink:to="avco_AccruedResearchAndDevelopmentsFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xml:lang="en-US">Accrued payroll liability and compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationReserveCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationReserveCurrent_lbl" xml:lang="en-US">Accrued litigation settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationReserveCurrent" xlink:to="us-gaap_LitigationReserveCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities and other payables - related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease obligation, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Total present value of operating lease liabilities (current liability)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" xlink:href="avco-20250331.xsd#avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty_lbl" xml:lang="en-US">Advance from pending sale of noncontrolling interest - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" xlink:to="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty_lbl0" xml:lang="en-US">Advance from pending sale of noncontrolling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" xlink:to="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentPayableCurrent" xlink:href="avco-20250331.xsd#avco_EquityMethodInvestmentPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_EquityMethodInvestmentPayableCurrent_lbl" xml:lang="en-US">Equity method investment payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentPayableCurrent" xlink:to="avco_EquityMethodInvestmentPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableToBankCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableToBankCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableToBankCurrent_lbl" xml:lang="en-US">Note payable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableToBankCurrent" xlink:to="us-gaap_NotesPayableToBankCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease obligation, noncurrent portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Long-term portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Note payable, net - noncurrent portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermNotesPayable_lbl0" xml:lang="en-US">Noncurrent portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermLoansPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US">Loan payable - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred stock, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_PreferredStockValue_lbl1" xml:lang="en-US">Preferred stock, stated value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl2" xml:lang="en-US">Preferred stock, stated value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred stock, shares authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Issuance shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl1" xml:lang="en-US">Preferred stock, shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred stock, shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US">Preferred Stock,Liquidation preference (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 100,000,000 shares authorized; 1,445,979 shares issued and 1,442,512 shares outstanding at December 31, 2024; 736,769 shares issued and 733,302 shares outstanding at December 31, 2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common stock, shares authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Share issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_lbl" xml:lang="en-US">Statutory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:to="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_lbl0" xml:lang="en-US">Statutory totaled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:to="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Noncontrolling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AssetsAbstract0" xlink:href="avco-20250331.xsd#avco_AssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AssetsAbstract0_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AssetsAbstract0" xlink:to="avco_AssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US">Receivable from sale of equity method investment, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestmentsAndReceivablesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet_lbl" xml:lang="en-US">Receivable from sale of equity method investment, noncurrent portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:to="us-gaap_LongTermInvestmentsAndReceivablesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">(DEFICIT) EQUITY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_LessCommonStockHeldInTreasuryAtCostAbstract" xlink:href="avco-20250331.xsd#avco_LessCommonStockHeldInTreasuryAtCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_LessCommonStockHeldInTreasuryAtCostAbstract_lbl" xml:lang="en-US">Less: common stock held in treasury, at cost;</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LessCommonStockHeldInTreasuryAtCostAbstract" xlink:to="avco_LessCommonStockHeldInTreasuryAtCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">REAL PROPERTY RENTAL REVENUE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Net revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_Revenues_lbl1" xml:lang="en-US">Real property rental revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">REAL PROPERTY OPERATING EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Real property operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xml:lang="en-US">REAL PROPERTY OPERATING INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl0" xml:lang="en-US">Real property operating income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl" xml:lang="en-US">INCOME FROM EQUITY METHOD INVESTMENT - LAB SERVICES MSO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl0" xml:lang="en-US">Loss from equity method investment - Lab Services MSO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OTHER OPERATING EXPENSES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketingAndAdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketingAndAdvertisingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketingAndAdvertisingExpense_lbl" xml:lang="en-US">Advertising and marketing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingAndAdvertisingExpense" xlink:to="us-gaap_MarketingAndAdvertisingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Compensation and related benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Other general and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">(Loss) income from operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US">Income from operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER (EXPENSE) INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DebtModificationCharge" xlink:href="avco-20250331.xsd#avco_DebtModificationCharge"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_DebtModificationCharge_lbl" xml:lang="en-US">Debt modification charge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DebtModificationCharge" xlink:to="avco_DebtModificationCharge_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on debts extinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0" xml:lang="en-US">Gain on debts extinguishment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">LOSS BEFORE INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS AFTER NONCONTROLLING INTEREST</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss Per Common Share Attributable Common Shareholders Basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net Loss Per Common Share Attributable Common Shareholders Diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Common Shares Outstanding Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Common Shares Outstanding Diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">COMPREHENSIVE LOSS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xml:lang="en-US">OTHER COMPREHENSIVE LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">COMPREHENSIVE LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_OtherOperatingExpensesAbstract" xlink:href="avco-20250331.xsd#avco_OtherOperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_OtherOperatingExpensesAbstract_lbl" xml:lang="en-US">OTHER OPERATING EXPENSES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OtherOperatingExpensesAbstract" xlink:to="avco_OtherOperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_OtherExpenseIncomeAbstract" xlink:href="avco-20250331.xsd#avco_OtherExpenseIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_OtherExpenseIncomeAbstract_lbl" xml:lang="en-US">OTHER (EXPENSE) INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OtherExpenseIncomeAbstract" xlink:to="avco_OtherExpenseIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DeemedContributionOnExchangeOfEquityInstruments" xlink:href="avco-20250331.xsd#avco_DeemedContributionOnExchangeOfEquityInstruments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_DeemedContributionOnExchangeOfEquityInstruments_lbl" xml:lang="en-US">DEEMED CONTRIBUTION ON EXCHANGE OF EQUITY INSTRUMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeemedContributionOnExchangeOfEquityInstruments" xlink:to="avco_DeemedContributionOnExchangeOfEquityInstruments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_NetLossPerCommonShareAttributableToAvalonGlobocareCorpCommonShareholdersAbstract" xlink:href="avco-20250331.xsd#avco_NetLossPerCommonShareAttributableToAvalonGlobocareCorpCommonShareholdersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_NetLossPerCommonShareAttributableToAvalonGlobocareCorpCommonShareholdersAbstract_lbl" xml:lang="en-US">NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_NetLossPerCommonShareAttributableToAvalonGlobocareCorpCommonShareholdersAbstract" xlink:to="avco_NetLossPerCommonShareAttributableToAvalonGlobocareCorpCommonShareholdersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_WeightedAverageCommonSharesOutstandingAbstract" xlink:href="avco-20250331.xsd#avco_WeightedAverageCommonSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_WeightedAverageCommonSharesOutstandingAbstract_lbl" xml:lang="en-US">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WeightedAverageCommonSharesOutstandingAbstract" xlink:to="avco_WeightedAverageCommonSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ComprehensiveLossAbstract" xlink:href="avco-20250331.xsd#avco_ComprehensiveLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ComprehensiveLossAbstract_lbl" xml:lang="en-US">COMPREHENSIVE LOSS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ComprehensiveLossAbstract" xlink:to="avco_ComprehensiveLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_OtherComprehensiveIncomeLossAbstract" xlink:href="avco-20250331.xsd#avco_OtherComprehensiveIncomeLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_OtherComprehensiveIncomeLossAbstract_lbl" xml:lang="en-US">OTHER COMPREHENSIVE INCOME (LOSS)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OtherComprehensiveIncomeLossAbstract" xlink:to="avco_OtherComprehensiveIncomeLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments" xlink:href="avco-20250331.xsd#avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments_lbl" xml:lang="en-US">Shares issued for adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments" xlink:to="avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Shares issued for adjustments (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl0" xml:lang="en-US">Reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of Series B Convertible Preferred Stock for equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of Series B Convertible Preferred Stock for equity method investment (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock as convertible note payable commitment fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Common stock value issued as convertible note payable commitment fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock as convertible note payable commitment fee (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Issuance of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Common shares issued as convertible note payable commitment fee (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xml:lang="en-US">Shares of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl3" xml:lang="en-US">Share issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl3"/>
    <loc xlink:type="locator" xlink:label="avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet" xlink:href="avco-20250331.xsd#avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet_lbl" xml:lang="en-US">Sale of common stock, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet" xlink:to="avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet" xlink:href="avco-20250331.xsd#avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet_lbl" xml:lang="en-US">Sale of common stock, net (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet" xlink:to="avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock upon cashless exercise of stock warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock upon cashless exercise of stock warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Number of Warrants, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Common stock upon cashless exercise (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" xml:lang="en-US">Reclassification of derivative liability to equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl0" xml:lang="en-US">Reclassification of additional paid-in capital upon conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Sale of Series C Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Sale of Series C Convertible Preferred Stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Issuance of pre-funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" xlink:href="avco-20250331.xsd#avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock_lbl" xml:lang="en-US">Series D Convertible Preferred Stock issued in exchange of Series A Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" xlink:to="avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" xlink:href="avco-20250331.xsd#avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock_lbl" xml:lang="en-US">Series D Convertible Preferred Stock issued in exchange of Series A Convertible Preferred Stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" xlink:to="avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment_lbl" xml:lang="en-US">Series B Convertible Preferred Stock extinguished related to sale of equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment" xlink:to="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments" xlink:href="avco-20250331.xsd#avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments_lbl" xml:lang="en-US">Series B Convertible Preferred Stock extinguished related to sale of equity method investment (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments" xlink:to="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of operating lease right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation and service expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment of equity method investment - Epicon</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl0" xml:lang="en-US">Impairment of equity method investment - Epicon</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl1" xml:lang="en-US">Impairment of equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl2" xml:lang="en-US">Impairment loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair market value of derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl0" xml:lang="en-US">Change in fair value of derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl1" xml:lang="en-US">Gain from change in the fair value of derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl2" xml:lang="en-US">Loss from change in the fair value of derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl3" xml:lang="en-US">Fair value of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl4" xml:lang="en-US">Fair value of warrant (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl5" xml:lang="en-US">Fair value adjustment of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl5"/>
    <loc xlink:type="locator" xlink:label="avco_ImpairmentOfLaboratoryEquipment" xlink:href="avco-20250331.xsd#avco_ImpairmentOfLaboratoryEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ImpairmentOfLaboratoryEquipment_lbl" xml:lang="en-US">Impairment of laboratory equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ImpairmentOfLaboratoryEquipment" xlink:to="avco_ImpairmentOfLaboratoryEquipment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_ImpairmentOfLaboratoryEquipment_lbl0" xml:lang="en-US">Impairment charge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ImpairmentOfLaboratoryEquipment" xlink:to="avco_ImpairmentOfLaboratoryEquipment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xml:lang="en-US">Security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_IncreaseDecreaseInDeferredLeasingCosts" xlink:href="avco-20250331.xsd#avco_IncreaseDecreaseInDeferredLeasingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_IncreaseDecreaseInDeferredLeasingCosts_lbl" xml:lang="en-US">Deferred leasing costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_IncreaseDecreaseInDeferredLeasingCosts" xlink:to="avco_IncreaseDecreaseInDeferredLeasingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">NET CASH USED IN OPERATING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Negative cash flow from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">NET CASH PROVIDED BY INVESTING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from loan payable - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from issuance of convertible debts and warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from issuance of balloon promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl0" xml:lang="en-US">Borrowed amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromPaymentsToMinorityShareholders_lbl" xml:lang="en-US">Advance from pending sale of noncontrolling interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:to="us-gaap_ProceedsFromPaymentsToMinorityShareholders_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US">Proceeds from equity offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl0" xml:lang="en-US">Net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from issuance of convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">NET CASH PROVIDED BY FINANCING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_UnlabeledAbstract" xlink:href="avco-20250331.xsd#avco_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnlabeledAbstract" xlink:to="avco_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE ON CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_UnlabeledAbstract0" xlink:href="avco-20250331.xsd#avco_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnlabeledAbstract0" xlink:to="avco_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET (DECREASE) INCREASE IN CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CashPaidForAbstract" xlink:href="avco-20250331.xsd#avco_CashPaidForAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CashPaidForAbstract_lbl" xml:lang="en-US">Cash paid for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CashPaidForAbstract" xlink:to="avco_CashPaidForAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_UnlabeledAbstract1" xlink:href="avco-20250331.xsd#avco_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnlabeledAbstract1" xlink:to="avco_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">NON-CASH INVESTING AND FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CommonStockIssuedForAccruedLiabilities" xlink:href="avco-20250331.xsd#avco_CommonStockIssuedForAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CommonStockIssuedForAccruedLiabilities_lbl" xml:lang="en-US">Common stock issued for accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommonStockIssuedForAccruedLiabilities" xlink:to="avco_CommonStockIssuedForAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment_lbl" xml:lang="en-US">Reclassification of advances for equity interest purchase to equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment" xlink:to="avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_WarrantsIssuedWithConvertibleNotePayable" xlink:href="avco-20250331.xsd#avco_WarrantsIssuedWithConvertibleNotePayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_WarrantsIssuedWithConvertibleNotePayable_lbl" xml:lang="en-US">Series B Convertible Preferred Stock issued related to equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WarrantsIssuedWithConvertibleNotePayable" xlink:to="avco_WarrantsIssuedWithConvertibleNotePayable_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedPurchasePriceRelatedToEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_AccruedPurchasePriceRelatedToEquityMethodInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AccruedPurchasePriceRelatedToEquityMethodInvestment_lbl" xml:lang="en-US">Accrued purchase price related to equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedPurchasePriceRelatedToEquityMethodInvestment" xlink:to="avco_AccruedPurchasePriceRelatedToEquityMethodInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_WarrantsIssuedAsConvertibleNotePayableFindersFee" xlink:href="avco-20250331.xsd#avco_WarrantsIssuedAsConvertibleNotePayableFindersFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_WarrantsIssuedAsConvertibleNotePayableFindersFee_lbl" xml:lang="en-US">Warrants issued as convertible note payable finder&#8217;s fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WarrantsIssuedAsConvertibleNotePayableFindersFee" xlink:to="avco_WarrantsIssuedAsConvertibleNotePayableFindersFee_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount" xlink:href="avco-20250331.xsd#avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount_lbl" xml:lang="en-US">Warrants issued with convertible notes payable recorded as debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount" xlink:to="avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock" xlink:href="avco-20250331.xsd#avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock_lbl" xml:lang="en-US">Common stock issued as convertible notes payable commitment fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock" xlink:to="avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DeferredFinancingCostsInAccruedLiabilities" xlink:href="avco-20250331.xsd#avco_DeferredFinancingCostsInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_DeferredFinancingCostsInAccruedLiabilities_lbl" xml:lang="en-US">Deferred financing costs in accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeferredFinancingCostsInAccruedLiabilities" xlink:to="avco_DeferredFinancingCostsInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Equity method investment payable paid by a related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalDeferredPurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalDeferredPurchasePrice_lbl" xml:lang="en-US">Reclassification of deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalDeferredPurchasePrice" xlink:to="us-gaap_SupplementalDeferredPurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SettlementsOfDerivativeLiability" xlink:href="avco-20250331.xsd#avco_SettlementsOfDerivativeLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_SettlementsOfDerivativeLiability_lbl" xml:lang="en-US">Settlement of derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SettlementsOfDerivativeLiability" xlink:to="avco_SettlementsOfDerivativeLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty" xlink:href="avco-20250331.xsd#avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty_lbl" xml:lang="en-US">Reclassification of related party loan payable and accrued expenses to advance from related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty" xlink:to="avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant" xlink:href="avco-20250331.xsd#avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant_lbl" xml:lang="en-US">Issuance of common stock upon cashless exercise of stock warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant" xlink:to="avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Shares issued for adjustments for 1:15 reverse split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl" xml:lang="en-US">Proceeds from sale of equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl0" xml:lang="en-US">Carrying value equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_UnlabeledAbstract2" xlink:href="avco-20250331.xsd#avco_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnlabeledAbstract2" xlink:to="avco_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_UnlabeledAbstract3" xlink:href="avco-20250331.xsd#avco_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnlabeledAbstract3" xlink:to="avco_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_UnlabeledAbstract4" xlink:href="avco-20250331.xsd#avco_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnlabeledAbstract4" xlink:to="avco_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_UnlabeledAbstract5" xlink:href="avco-20250331.xsd#avco_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnlabeledAbstract5" xlink:to="avco_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_UnlabeledAbstract6" xlink:href="avco-20250331.xsd#avco_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnlabeledAbstract6" xlink:to="avco_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_UnlabeledAbstract7" xlink:href="avco-20250331.xsd#avco_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnlabeledAbstract7" xlink:to="avco_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CashPaidForAbstract0" xlink:href="avco-20250331.xsd#avco_CashPaidForAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CashPaidForAbstract0_lbl" xml:lang="en-US">Cash paid for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CashPaidForAbstract0" xlink:to="avco_CashPaidForAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US">Common stock issued for future services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ReceivableRelatedToSaleOfEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_ReceivableRelatedToSaleOfEquityMethodInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ReceivableRelatedToSaleOfEquityMethodInvestment_lbl" xml:lang="en-US">Receivable related to sale of equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ReceivableRelatedToSaleOfEquityMethodInvestment" xlink:to="avco_ReceivableRelatedToSaleOfEquityMethodInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment_lbl" xml:lang="en-US">Related party payable extinguished upon sale of equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment" xlink:to="avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment_lbl" xml:lang="en-US">Series B Convertible Preferred Stock extinguished related to sale of equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment" xlink:to="avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" xlink:href="avco-20250331.xsd#avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock_lbl" xml:lang="en-US">Series D Convertible Preferred Stock issued in exchange of Series A Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" xlink:to="avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount" xlink:href="avco-20250331.xsd#avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount_lbl" xml:lang="en-US">Warrants issued with convertible note payable recorded as debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount" xlink:to="avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee" xlink:href="avco-20250331.xsd#avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee_lbl" xml:lang="en-US">Common stock issued as convertible note payable commitment fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee" xlink:to="avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Initial ROU asset and lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xml:lang="en-US">Less: common stock held in treasury, at cost; 3,467 shares at December 31, 2024 and 2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Interest expense - amortization of debt discount and debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US">Interest expense - other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseOther_lbl0" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_lbl" xml:lang="en-US">Unrealized foreign currency translation gain (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">LESS: COMPREHENSIVE LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StraightLineRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StraightLineRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StraightLineRent_lbl" xml:lang="en-US">Change in straight-line rent receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StraightLineRent" xlink:to="us-gaap_StraightLineRent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Income from equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DistributionOfEarningsFromEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_DistributionOfEarningsFromEquityMethodInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avco_DistributionOfEarningsFromEquityMethodInvestment_lbl" xml:lang="en-US">Distribution of earnings from equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DistributionOfEarningsFromEquityMethodInvestment" xlink:to="avco_DistributionOfEarningsFromEquityMethodInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable" xlink:href="avco-20250331.xsd#avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable" xlink:to="avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnRestructuringOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnRestructuringOfDebt_lbl" xml:lang="en-US">Debt modification charge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="us-gaap_GainsLossesOnRestructuringOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Rent receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expense and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedLiabilitiesAndOtherPayablesRelatedParties" xlink:href="avco-20250331.xsd#avco_AccruedLiabilitiesAndOtherPayablesRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avco_AccruedLiabilitiesAndOtherPayablesRelatedParties_lbl" xml:lang="en-US">Accrued liabilities and other payables - related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedLiabilitiesAndOtherPayablesRelatedParties" xlink:to="avco_AccruedLiabilitiesAndOtherPayablesRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xml:lang="en-US">Payment for equity interest purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayments of loan payable - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payments of convertible debts issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Repayments of convertible debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payments of balloon promissory note issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xml:lang="en-US">Disbursements for equity offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants" xlink:href="avco-20250331.xsd#avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants_lbl" xml:lang="en-US">Proceeds from issuance of convertible debt and warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants" xlink:to="avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PaymentsOfConvertibleDebtIssuanceCosts" xlink:href="avco-20250331.xsd#avco_PaymentsOfConvertibleDebtIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avco_PaymentsOfConvertibleDebtIssuanceCosts_lbl" xml:lang="en-US">Payments of convertible debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PaymentsOfConvertibleDebtIssuanceCosts" xlink:to="avco_PaymentsOfConvertibleDebtIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl1" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl2" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl0" xml:lang="en-US">Series B</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl1" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl2" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl0" xml:lang="en-US">Series C</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl1" xml:lang="en-US">Series C Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl2" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xml:lang="en-US">Series D Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl0" xml:lang="en-US">Series D</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl1" xml:lang="en-US">Series D Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl2" xml:lang="en-US">Series D Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockMember_lbl0" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US">Treasury Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_StatutoryReserveMember" xlink:href="avco-20250331.xsd#avco_StatutoryReserveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_StatutoryReserveMember_lbl" xml:lang="en-US">Statutory Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReserveMember" xlink:to="avco_StatutoryReserveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Loss (Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">ORGANIZATION AND NATURE OF OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl" xml:lang="en-US">Schedule of Consolidated Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentPlaceAndDateOfIncorporation" xlink:href="avco-20250331.xsd#avco_EquityMethodInvestmentPlaceAndDateOfIncorporation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_EquityMethodInvestmentPlaceAndDateOfIncorporation_lbl" xml:lang="en-US">Place and Date of Incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentPlaceAndDateOfIncorporation" xlink:to="avco_EquityMethodInvestmentPlaceAndDateOfIncorporation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl" xml:lang="en-US">Percentage of Ownership</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl0" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl" xml:lang="en-US">Principal Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">BASIS OF PRESENTATION AND GOING CONCERN CONDITION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Derivative Liability Measured at Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise" xlink:href="avco-20250331.xsd#avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise_lbl" xml:lang="en-US">Initial fair value of derivative liability attributable to warrants issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise" xlink:to="avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash Balances by Geographic Area</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Total cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CashPercentage" xlink:href="avco-20250331.xsd#avco_CashPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CashPercentage_lbl" xml:lang="en-US">Percentage of Total cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CashPercentage" xlink:to="avco_CashPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Securities that were Excluded from the Diluted Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potentially dilutive securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSE AND OTHER CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Prepaid Expense and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PrepaidProfessionalFees" xlink:href="avco-20250331.xsd#avco_PrepaidProfessionalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PrepaidProfessionalFees_lbl" xml:lang="en-US">Prepaid professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrepaidProfessionalFees" xlink:to="avco_PrepaidProfessionalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidReinsurancePremiums" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidReinsurancePremiums"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidReinsurancePremiums_lbl" xml:lang="en-US">Prepaid directors and officers&#8217; liability insurance premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidReinsurancePremiums" xlink:to="us-gaap_PrepaidReinsurancePremiums_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidReinsurancePremiums_lbl0" xml:lang="en-US">Prepaid directors&#8217; and officers&#8217; liability insurance premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidReinsurancePremiums" xlink:to="us-gaap_PrepaidReinsurancePremiums_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsLeasingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsLeasingNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsLeasingNet_lbl" xml:lang="en-US">Deferred leasing costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsLeasingNet" xlink:to="us-gaap_DeferredCostsLeasingNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromCorrespondentBrokers" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DueFromCorrespondentBrokers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromCorrespondentBrokers_lbl" xml:lang="en-US">Due from broker</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromCorrespondentBrokers" xlink:to="us-gaap_DueFromCorrespondentBrokers_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValueAddedTaxReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValueAddedTaxReceivable_lbl" xml:lang="en-US">Recoverable VAT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValueAddedTaxReceivable" xlink:to="us-gaap_ValueAddedTaxReceivable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ValueAddedTaxReceivable_lbl0" xml:lang="en-US">Recoverable value-added tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValueAddedTaxReceivable" xlink:to="us-gaap_ValueAddedTaxReceivable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_lbl" xml:lang="en-US">EQUIPMENT HELD FOR SALE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:to="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RealEstateDisclosureTextBlock_lbl" xml:lang="en-US">INVESTMENT IN REAL ESTATE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateDisclosureTextBlock" xlink:to="us-gaap_RealEstateDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Investment in Real Estate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" xlink:to="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestmentPropertyAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestmentPropertyAtCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RealEstateInvestmentPropertyAtCost_lbl" xml:lang="en-US">Investment in real estate, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateInvestmentPropertyAtCost" xlink:to="us-gaap_RealEstateInvestmentPropertyAtCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestmentPropertyNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestmentPropertyNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RealEstateInvestmentPropertyNet_lbl" xml:lang="en-US">Investment in real estate, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateInvestmentPropertyNet" xlink:to="us-gaap_RealEstateInvestmentPropertyNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xml:lang="en-US">EQUITY METHOD INVESTMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl" xml:lang="en-US">Schedule of Equity Method Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PaymentForEquityMethodInvestmentAbstract" xlink:href="avco-20250331.xsd#avco_PaymentForEquityMethodInvestmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PaymentForEquityMethodInvestmentAbstract_lbl" xml:lang="en-US">Payment for equity method investment:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PaymentForEquityMethodInvestmentAbstract" xlink:to="avco_PaymentForEquityMethodInvestmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_lbl" xml:lang="en-US">The Company&#8217;s interest in the fair value of Lab Services MSO&#8217;s net assets at February 9, 2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:to="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets" xlink:href="avco-20250331.xsd#avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets_lbl" xml:lang="en-US">The Company&#8217;s interest in the net excess of Lab Services MSO&#8217;s fair value over net assets which was attributable to identifiable intangible assets at February 9, 2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets" xlink:to="avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets" xlink:href="avco-20250331.xsd#avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets_lbl" xml:lang="en-US">The Company&#8217;s interest in the net excess of Lab Services MSO&#8217;s fair value over net assets which was attributable to goodwill at February 9, 2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets" xlink:to="avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl" xml:lang="en-US">Total payment for equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl0" xml:lang="en-US">Purchased interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_LabServicesMSOsNetIncomeAttributableToTheCompany" xlink:href="avco-20250331.xsd#avco_LabServicesMSOsNetIncomeAttributableToTheCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_LabServicesMSOsNetIncomeAttributableToTheCompany_lbl" xml:lang="en-US">Lab Services MSO&#8217;s net income attributable to the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LabServicesMSOsNetIncomeAttributableToTheCompany" xlink:to="avco_LabServicesMSOsNetIncomeAttributableToTheCompany_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_LabServicesMSOsNetIncomeAttributableToTheCompany_lbl0" xml:lang="en-US">Lab services MSO&#8217;s net income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LabServicesMSOsNetIncomeAttributableToTheCompany" xlink:to="avco_LabServicesMSOsNetIncomeAttributableToTheCompany_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US">Schedule of Summarized Financial Information, as Provided to the Company by the Investee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" xml:lang="en-US">Schedule of Financial Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCRUED LIABILITIES AND OTHER PAYABLES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Liabilities and Other Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedTenantsImprovementReimbursement" xlink:href="avco-20250331.xsd#avco_AccruedTenantsImprovementReimbursement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AccruedTenantsImprovementReimbursement_lbl" xml:lang="en-US">Accrued tenants&#8217; improvement reimbursement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedTenantsImprovementReimbursement" xlink:to="avco_AccruedTenantsImprovementReimbursement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Deposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Tenants&#8217; security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedBusinessExpenseReimbursement" xlink:href="avco-20250331.xsd#avco_AccruedBusinessExpenseReimbursement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AccruedBusinessExpenseReimbursement_lbl" xml:lang="en-US">Accrued business expense reimbursement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedBusinessExpenseReimbursement" xlink:to="avco_AccruedBusinessExpenseReimbursement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedUtilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedUtilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedUtilitiesCurrent_lbl" xml:lang="en-US">Accrued utilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedUtilitiesCurrent" xlink:to="us-gaap_AccruedUtilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncome_lbl" xml:lang="en-US">Deferred rental income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncome" xlink:to="us-gaap_DeferredIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedRealPropertyCleaningServiceFee" xlink:href="avco-20250331.xsd#avco_AccruedRealPropertyCleaningServiceFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AccruedRealPropertyCleaningServiceFee_lbl" xml:lang="en-US">Accrued real property cleaning service fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedRealPropertyCleaningServiceFee" xlink:to="avco_AccruedRealPropertyCleaningServiceFee_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">CONVERTIBLE NOTE PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of Amortization Payments in Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Amortization payments description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Convertible Note Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Original issue discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US">DERIVATIVE LIABILITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">NOTE PAYABLE, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Note Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl" xml:lang="en-US">Schedule of Line of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DrawDownFromLineOfCredit" xlink:href="avco-20250331.xsd#avco_DrawDownFromLineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_DrawDownFromLineOfCredit_lbl" xml:lang="en-US">Draw down from Line of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DrawDownFromLineOfCredit" xlink:to="avco_DrawDownFromLineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty" xlink:href="avco-20250331.xsd#avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty_lbl" xml:lang="en-US">Reclassification of Line of Credit to advance from related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty" xlink:to="avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of Company&#8217;s Loss Before Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">United States loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">China loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Taxes Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Current:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">U.S. federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">U.S. state and local</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">China</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Deferred:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">U.S. federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">U.S. state and local</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">China</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of U.S. Statutory Rate and the Company&#8217;s Effective Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. federal rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US">U.S. state rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl" xml:lang="en-US">Permanent difference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Non-US rate differential</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">True ups</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">U.S. valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" xml:lang="en-US">Disallowed business interest deduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Accrued directors&#8217; compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Accrued settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DeferredTaxAssetsPartnershipInvestment" xlink:href="avco-20250331.xsd#avco_DeferredTaxAssetsPartnershipInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_DeferredTaxAssetsPartnershipInvestment_lbl" xml:lang="en-US">Partnership Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeferredTaxAssetsPartnershipInvestment" xlink:to="avco_DeferredTaxAssetsPartnershipInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xml:lang="en-US">Capital loss limitation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US">Deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule of Common Stock Issuable Upon Exercise of Warrants Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Options Outstanding,Range of Exercise Price lower limit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl0" xml:lang="en-US">Warrants Outstanding, Exercise Price, lower limit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Options Outstanding, Range of Exercise Price Upper limit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl0" xml:lang="en-US">Warrants Outstanding, Exercise Price, upper limit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options Outstanding, Weighted Average Remaining Contractual Life (Years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Warrants Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options Exercisable, Number Exercisable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Number of Options, Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US">Warrants Exercisable, Number Exercisable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Options Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl0" xml:lang="en-US">Warrants Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Options expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Nonvested Stock Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues" xlink:href="avco-20250331.xsd#avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues" xlink:to="avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Number of Options, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Common Stock Issuable Upon Exercise of Options Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Warrants Outstanding, Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_StatutoryReserveAndRestrictedNetAssetsTextBlock" xlink:href="avco-20250331.xsd#avco_StatutoryReserveAndRestrictedNetAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_StatutoryReserveAndRestrictedNetAssetsTextBlock_lbl" xml:lang="en-US">STATUTORY RESERVE AND RESTRICTED NET ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReserveAndRestrictedNetAssetsTextBlock" xlink:to="avco_StatutoryReserveAndRestrictedNetAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xml:lang="en-US">Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl" xml:lang="en-US">CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">CONCENTRATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US">Schedule of Customer Accounted for Company&apos;s Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Customer concentration percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl0" xml:lang="en-US">Concentration risk percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Reportable Business Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other (expense) income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherIncome_lbl0" xml:lang="en-US">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of Identifiable Long-Lived Tangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncurrentAssets_lbl" xml:lang="en-US">Total Identifiable long-lived tangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncurrentAssets" xlink:to="us-gaap_NoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_lbl" xml:lang="en-US">Schedule of Identifiable Long-Lived Tangible Assets (Geographic Areas)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowInvestingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowInvestingActivitiesLesseeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowInvestingActivitiesLesseeAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowInvestingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowInvestingActivitiesLesseeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows paid for operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligation:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities" xlink:href="avco-20250331.xsd#avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities_lbl" xml:lang="en-US">Operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities" xlink:to="avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturity of Lease Liabilities Under Operating Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">2026 and thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0" xml:lang="en-US">2028 and thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseOtherNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent_lbl" xml:lang="en-US">Prepaid NASDAQ listing fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total present value of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Intangible assets amortization amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Impairment of goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl0" xml:lang="en-US">Recognized impairment loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_lbl" xml:lang="en-US">Distribution of earnings from equity investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_lbl0" xml:lang="en-US">Sale of equity investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_lbl1" xml:lang="en-US">Distribution of earnings from investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xml:lang="en-US">Less: unamortized debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl" xml:lang="en-US">Less: unamortized debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Less: unamortized debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Repayment of Line of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets_lbl" xml:lang="en-US">Fixed assets and intangible assets book/tax basis difference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesRegulatoryAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets_lbl" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of Options, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price,	Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Warrants, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of Options, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Amount of lease payments representing interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonHealthcareSystemIncMember" xlink:href="avco-20250331.xsd#avco_AvalonHealthcareSystemIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AvalonHealthcareSystemIncMember_lbl" xml:lang="en-US">Avalon Healthcare System, Inc. (&#8220;AHS&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonHealthcareSystemIncMember" xlink:to="avco_AvalonHealthcareSystemIncMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_AvalonHealthcareSystemIncMember_lbl0" xml:lang="en-US">Avalon Healthcare System, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonHealthcareSystemIncMember" xlink:to="avco_AvalonHealthcareSystemIncMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonRT9PropertiesLLCMember" xlink:href="avco-20250331.xsd#avco_AvalonRT9PropertiesLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AvalonRT9PropertiesLLCMember_lbl" xml:lang="en-US">Avalon RT 9 Properties LLC (&#8220;Avalon RT 9&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonRT9PropertiesLLCMember" xlink:to="avco_AvalonRT9PropertiesLLCMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_AvalonRT9PropertiesLLCMember_lbl0" xml:lang="en-US">Avalon RT 9 Properties, LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonRT9PropertiesLLCMember" xlink:to="avco_AvalonRT9PropertiesLLCMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember" xlink:href="avco-20250331.xsd#avco_AvalonShanghaiHealthcareTechnologyCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember_lbl" xml:lang="en-US">Avalon (Shanghai) Healthcare Technology Co., Ltd. (&#8220;Avalon Shanghai&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember" xlink:to="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_GenExosomeTechnologiesIncMember" xlink:href="avco-20250331.xsd#avco_GenExosomeTechnologiesIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_GenExosomeTechnologiesIncMember_lbl" xml:lang="en-US">Genexosome Technologies Inc. (&#8220;Genexosome&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_GenExosomeTechnologiesIncMember" xlink:to="avco_GenExosomeTechnologiesIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AvactisBiosciencesIncMember" xlink:href="avco-20250331.xsd#avco_AvactisBiosciencesIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AvactisBiosciencesIncMember_lbl" xml:lang="en-US">Avactis Biosciences Inc. (&#8220;Avactis&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvactisBiosciencesIncMember" xlink:to="avco_AvactisBiosciencesIncMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_AvactisBiosciencesIncMember_lbl0" xml:lang="en-US">Avactis Biosciences Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvactisBiosciencesIncMember" xlink:to="avco_AvactisBiosciencesIncMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_AvactisNanjingBiosciencesLtdMember" xlink:href="avco-20250331.xsd#avco_AvactisNanjingBiosciencesLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AvactisNanjingBiosciencesLtdMember_lbl" xml:lang="en-US">Avactis Nanjing Biosciences Ltd. (&#8220;Avactis Nanjing&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvactisNanjingBiosciencesLtdMember" xlink:to="avco_AvactisNanjingBiosciencesLtdMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_AvactisNanjingBiosciencesLtdMember_lbl0" xml:lang="en-US">Avactis Nanjing Biosciences Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvactisNanjingBiosciencesLtdMember" xlink:to="avco_AvactisNanjingBiosciencesLtdMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonLaboratoryServicesIncMember" xlink:href="avco-20250331.xsd#avco_AvalonLaboratoryServicesIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AvalonLaboratoryServicesIncMember_lbl" xml:lang="en-US">Avalon Laboratory Services, Inc. (&#8220;Avalon Lab&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonLaboratoryServicesIncMember" xlink:to="avco_AvalonLaboratoryServicesIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_QADistributionLLCMember" xlink:href="avco-20250331.xsd#avco_QADistributionLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_QADistributionLLCMember_lbl" xml:lang="en-US">Q&amp;A Distribution LLC (&#8220;Q&amp;A Distribution&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_QADistributionLLCMember" xlink:to="avco_QADistributionLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Significant Unobservable Inputs (Level 3) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">United States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_CN_lbl" xml:lang="en-US">China [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="country_CN_lbl0" xml:lang="en-US">RMB [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="country_CN_lbl1" xml:lang="en-US">CHINA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl1"/>
    <loc xlink:type="locator" xlink:label="avco_OptionsToPurchaseCommonStockMember" xlink:href="avco-20250331.xsd#avco_OptionsToPurchaseCommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_OptionsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Options to purchase common stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OptionsToPurchaseCommonStockMember" xlink:to="avco_OptionsToPurchaseCommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants to purchase common stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Stock Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl0" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_LaboratoryEquipmentMember" xlink:href="avco-20250331.xsd#avco_LaboratoryEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LaboratoryEquipmentMember" xlink:to="avco_LaboratoryEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment and Furniture [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialRealEstateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialRealEstateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommercialRealEstateMember_lbl" xml:lang="en-US">Commercial real property building [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialRealEstateMember" xlink:to="us-gaap_CommercialRealEstateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandImprovementsMember_lbl" xml:lang="en-US">Improvement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandImprovementsMember" xlink:to="us-gaap_LandImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_LabServicesMSOMember_lbl" xml:lang="en-US">Lab Services MSO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LabServicesMSOMember" xlink:to="avco_LabServicesMSOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_InvestmentInLaboratoryServicesMSOLLCMember" xlink:href="avco-20250331.xsd#avco_InvestmentInLaboratoryServicesMSOLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_InvestmentInLaboratoryServicesMSOLLCMember_lbl" xml:lang="en-US">Investment in Laboratory Services MSO, LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_InvestmentInLaboratoryServicesMSOLLCMember" xlink:to="avco_InvestmentInLaboratoryServicesMSOLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DecemberFiveTwoThousandTwentyFourMember" xlink:href="avco-20250331.xsd#avco_DecemberFiveTwoThousandTwentyFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_DecemberFiveTwoThousandTwentyFourMember_lbl" xml:lang="en-US">December 5, 2024 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DecemberFiveTwoThousandTwentyFourMember" xlink:to="avco_DecemberFiveTwoThousandTwentyFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_JanuaryFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_JanuaryFiveTwoThousandTwentyFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_JanuaryFiveTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">January 5, 2025 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_JanuaryFiveTwoThousandTwentyFiveMember" xlink:to="avco_JanuaryFiveTwoThousandTwentyFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_FebruaryFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_FebruaryFiveTwoThousandTwentyFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_FebruaryFiveTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">February 5, 2025 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FebruaryFiveTwoThousandTwentyFiveMember" xlink:to="avco_FebruaryFiveTwoThousandTwentyFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_MarchFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_MarchFiveTwoThousandTwentyFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_MarchFiveTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">March 5, 2025	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MarchFiveTwoThousandTwentyFiveMember" xlink:to="avco_MarchFiveTwoThousandTwentyFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AprilFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_AprilFiveTwoThousandTwentyFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AprilFiveTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">April 5, 2025 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AprilFiveTwoThousandTwentyFiveMember" xlink:to="avco_AprilFiveTwoThousandTwentyFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_MayFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_MayFiveTwoThousandTwentyFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_MayFiveTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">May 5, 2025 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MayFiveTwoThousandTwentyFiveMember" xlink:to="avco_MayFiveTwoThousandTwentyFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_JuneFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_JuneFiveTwoThousandTwentyFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_JuneFiveTwoThousandTwentyFiveMember_lbl" xml:lang="en-US">June 5, 2025 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_JuneFiveTwoThousandTwentyFiveMember" xlink:to="avco_JuneFiveTwoThousandTwentyFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_MastHillMember" xlink:href="avco-20250331.xsd#avco_MastHillMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_MastHillMember_lbl" xml:lang="en-US">Mast Hill [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MastHillMember" xlink:to="avco_MastHillMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeOneMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ExercisePriceRangeOneMember_lbl" xml:lang="en-US">2.93 &#8211; 31.20 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeOneMember" xlink:to="avco_ExercisePriceRangeOneMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_ExercisePriceRangeOneMember_lbl0" xml:lang="en-US">7.50 &#8211; 37.50 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeOneMember" xlink:to="avco_ExercisePriceRangeOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="avco_ExercisePriceRangeOneMember_lbl1" xml:lang="en-US">2.93 - 31.20 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeOneMember" xlink:to="avco_ExercisePriceRangeOneMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeTwoMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ExercisePriceRangeTwoMember_lbl" xml:lang="en-US">48.75 &#8211; 123.00 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeTwoMember" xlink:to="avco_ExercisePriceRangeTwoMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_ExercisePriceRangeTwoMember_lbl0" xml:lang="en-US">67.50 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeTwoMember" xlink:to="avco_ExercisePriceRangeTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="avco_ExercisePriceRangeTwoMember_lbl1" xml:lang="en-US">48.75 - 123.00 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeTwoMember" xlink:to="avco_ExercisePriceRangeTwoMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeThreeMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ExercisePriceRangeThreeMember_lbl" xml:lang="en-US">154.50 &#8211; 289.50 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeThreeMember" xlink:to="avco_ExercisePriceRangeThreeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_ExercisePriceRangeThreeMember_lbl0" xml:lang="en-US">154.50 - 264.00 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeThreeMember" xlink:to="avco_ExercisePriceRangeThreeMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeFourMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ExercisePriceRangeFourMember_lbl" xml:lang="en-US">2.93 &#8211; 289.50 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeFourMember" xlink:to="avco_ExercisePriceRangeFourMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_ExercisePriceRangeFourMember_lbl0" xml:lang="en-US">187.50 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeFourMember" xlink:to="avco_ExercisePriceRangeFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="avco_ExercisePriceRangeFourMember_lbl1" xml:lang="en-US">2.93 - 264.00 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeFourMember" xlink:to="avco_ExercisePriceRangeFourMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockOptionMember_lbl1" xml:lang="en-US">Stock Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl2" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl2"/>
    <loc xlink:type="locator" xlink:label="avco_NonvestedMember" xlink:href="avco-20250331.xsd#avco_NonvestedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_NonvestedMember_lbl" xml:lang="en-US">Nonvested [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_NonvestedMember" xlink:to="avco_NonvestedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">Previously Reported [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeFiveMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ExercisePriceRangeFiveMember_lbl" xml:lang="en-US">7.50 &#8211; 187.50 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeFiveMember" xlink:to="avco_ExercisePriceRangeFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_WarrantsOutstandingMember" xlink:href="avco-20250331.xsd#avco_WarrantsOutstandingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_WarrantsOutstandingMember_lbl" xml:lang="en-US">Warrants Outstanding [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WarrantsOutstandingMember" xlink:to="avco_WarrantsOutstandingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CustomerAMember" xlink:href="avco-20250331.xsd#avco_CustomerAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CustomerAMember_lbl" xml:lang="en-US">Customer A [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CustomerAMember" xlink:to="avco_CustomerAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CustomerBMember" xlink:href="avco-20250331.xsd#avco_CustomerBMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CustomerBMember_lbl" xml:lang="en-US">Customer B [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CustomerBMember" xlink:to="avco_CustomerBMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CustomerCMember" xlink:href="avco-20250331.xsd#avco_CustomerCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CustomerCMember_lbl" xml:lang="en-US">Customer C [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CustomerCMember" xlink:to="avco_CustomerCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RealPropertyOperationsMember" xlink:href="avco-20250331.xsd#avco_RealPropertyOperationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_RealPropertyOperationsMember_lbl" xml:lang="en-US">Real Property Operations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RealPropertyOperationsMember" xlink:to="avco_RealPropertyOperationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CorporateOtherMember" xlink:href="avco-20250331.xsd#avco_CorporateOtherMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CorporateOtherMember_lbl" xml:lang="en-US">Corporate / Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CorporateOtherMember" xlink:to="avco_CorporateOtherMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_CorporateOtherMember_lbl0" xml:lang="en-US">Corporate/Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CorporateOtherMember" xlink:to="avco_CorporateOtherMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_RealPropertyOperatingMember" xlink:href="avco-20250331.xsd#avco_RealPropertyOperatingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_RealPropertyOperatingMember_lbl" xml:lang="en-US">Real property operations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RealPropertyOperatingMember" xlink:to="avco_RealPropertyOperatingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_OptionsOutstandingMember" xlink:href="avco-20250331.xsd#avco_OptionsOutstandingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_OptionsOutstandingMember_lbl" xml:lang="en-US">Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OptionsOutstandingMember" xlink:to="avco_OptionsOutstandingMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_OptionsOutstandingMember_lbl0" xml:lang="en-US">Options Outstanding [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OptionsOutstandingMember" xlink:to="avco_OptionsOutstandingMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Combination [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis_lbl" xml:lang="en-US">Operating Activities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegulatoryAssetAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegulatoryAssetAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RegulatoryAssetAxis_lbl" xml:lang="en-US">Regulatory Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegulatoryAssetAxis" xlink:to="us-gaap_RegulatoryAssetAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradingActivityByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradingActivityByTypeAxis_lbl" xml:lang="en-US">Trading Activity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingActivityByTypeAxis" xlink:to="us-gaap_TradingActivityByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US">Liability Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xml:lang="en-US">Supplier [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationStatusAxis_lbl" xml:lang="en-US">Litigation Status [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsegmentsAxis_lbl" xml:lang="en-US">Subsegments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsegmentsAxis" xlink:to="us-gaap_SubsegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_WorkingCapitalDeficit" xlink:href="avco-20250331.xsd#avco_WorkingCapitalDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_WorkingCapitalDeficit_lbl" xml:lang="en-US">Working capital deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WorkingCapitalDeficit" xlink:to="avco_WorkingCapitalDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US">Asset acquisition percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Exceed federally-insured limits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalReserveBankStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalReserveBankStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalReserveBankStock_lbl" xml:lang="en-US">Federally insured limits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalReserveBankStock" xlink:to="us-gaap_FederalReserveBankStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetImpairmentCharges_lbl" xml:lang="en-US">Impairment charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetImpairmentCharges" xlink:to="us-gaap_OtherAssetImpairmentCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredAdvertisingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredAdvertisingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredAdvertisingCosts_lbl" xml:lang="en-US">Advertising and marketing costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredAdvertisingCosts" xlink:to="us-gaap_DeferredAdvertisingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xml:lang="en-US">Foreign currency exchange rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Fair value warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" xml:lang="en-US">Warrants share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Preferred stock, convertible conversion price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl0" xml:lang="en-US">Conversion price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl1" xml:lang="en-US">Preferred stock, convertible per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl" xml:lang="en-US">Common stock, conversion price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl0" xml:lang="en-US">Conversion price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity interest percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xml:lang="en-US">Equity interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl2" xml:lang="en-US">Equity interest, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl3" xml:lang="en-US">Percentage of equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl3"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" xml:lang="en-US">Percentage of purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityInterestPercent" xlink:href="avco-20250331.xsd#avco_EquityInterestPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_EquityInterestPercent_lbl" xml:lang="en-US">Equity interest percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityInterestPercent" xlink:to="avco_EquityInterestPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentDividendsOrDistributions_lbl" xml:lang="en-US">Redemption aggregate cash amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="us-gaap_EquityMethodInvestmentDividendsOrDistributions_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PaymentOfEquityInvestment" xlink:href="avco-20250331.xsd#avco_PaymentOfEquityInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PaymentOfEquityInvestment_lbl" xml:lang="en-US">Payment of equity investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PaymentOfEquityInvestment" xlink:to="avco_PaymentOfEquityInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RegularPaymentsOnEquityInvestments" xlink:href="avco-20250331.xsd#avco_RegularPaymentsOnEquityInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_RegularPaymentsOnEquityInvestments_lbl" xml:lang="en-US">Regular payments on equity investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RegularPaymentsOnEquityInvestments" xlink:to="avco_RegularPaymentsOnEquityInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xml:lang="en-US">Carrying value of the extinguished</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl0" xml:lang="en-US">Lender&apos;s costs related to financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableInvestmentSale" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableInvestmentSale"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivableInvestmentSale_lbl" xml:lang="en-US">Receivable from sale of equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableInvestmentSale" xlink:to="us-gaap_ReceivableInvestmentSale_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DilutiveSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DilutiveSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DilutiveSecurities_lbl" xml:lang="en-US">Dilutive securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecurities" xlink:to="us-gaap_DilutiveSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_OtherOperatingExpense" xlink:href="avco-20250331.xsd#avco_OtherOperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_OtherOperatingExpense_lbl" xml:lang="en-US">Other operating expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OtherOperatingExpense" xlink:to="avco_OtherOperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherDepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDepreciationAndAmortization" xlink:to="us-gaap_OtherDepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Total ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl1" xml:lang="en-US">Percentage of own excess</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl2" xml:lang="en-US">Equity interests ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl3" xml:lang="en-US">Equity interest ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl3"/>
    <loc xlink:type="locator" xlink:label="avco_AggregateOfCommonStock" xlink:href="avco-20250331.xsd#avco_AggregateOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AggregateOfCommonStock_lbl" xml:lang="en-US">Aggregate of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AggregateOfCommonStock" xlink:to="avco_AggregateOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentOwnedAtCost_lbl" xml:lang="en-US">Cost of investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtCost" xlink:to="us-gaap_InvestmentOwnedAtCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Estimated useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Identified intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillFairValueDisclosure_lbl" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillFairValueDisclosure" xlink:to="us-gaap_GoodwillFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xml:lang="en-US">Percentage of secured promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xml:lang="en-US">Aggregate principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Purchase of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Warrants to purchase shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Common stock per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DebtInstrumentConvertibleFloorPrice" xlink:href="avco-20250331.xsd#avco_DebtInstrumentConvertibleFloorPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_DebtInstrumentConvertibleFloorPrice_lbl" xml:lang="en-US">Floor price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DebtInstrumentConvertibleFloorPrice" xlink:to="avco_DebtInstrumentConvertibleFloorPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Purchase price payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0" xml:lang="en-US">Principal payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Warrants exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Warrant exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrant measurement input</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PercentageOfPromissoryNotes" xlink:href="avco-20250331.xsd#avco_PercentageOfPromissoryNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PercentageOfPromissoryNotes_lbl" xml:lang="en-US">Percentage promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PercentageOfPromissoryNotes" xlink:to="avco_PercentageOfPromissoryNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Shares issued (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl" xml:lang="en-US">Conversion price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl0" xml:lang="en-US">Convertible per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xml:lang="en-US">Purchase warrant (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_TradingPrice" xlink:href="avco-20250331.xsd#avco_TradingPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_TradingPrice_lbl" xml:lang="en-US">Trading price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_TradingPrice" xlink:to="avco_TradingPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PurchasePriceOfConvertibleNote" xlink:href="avco-20250331.xsd#avco_PurchasePriceOfConvertibleNote"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PurchasePriceOfConvertibleNote_lbl" xml:lang="en-US">Purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PurchasePriceOfConvertibleNote" xlink:to="avco_PurchasePriceOfConvertibleNote_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonUnitOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonUnitOutstanding_lbl" xml:lang="en-US">Common stock shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonUnitOutstanding" xlink:to="us-gaap_CommonUnitOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPriceIncrease_lbl" xml:lang="en-US">Conversion price increase (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPriceIncrease" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_lbl" xml:lang="en-US">Conversion price decrease (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NontradeReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NontradeReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NontradeReceivables_lbl" xml:lang="en-US">Proceeds from convertible debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NontradeReceivables" xlink:to="us-gaap_NontradeReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Payments for previously issued notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PaymentForCommission" xlink:href="avco-20250331.xsd#avco_PaymentForCommission"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PaymentForCommission_lbl" xml:lang="en-US">Finder&#8217;s fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PaymentForCommission" xlink:to="avco_PaymentForCommission_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Fee amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndDebtExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US">Interest expense related to convertible note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl" xml:lang="en-US">Fair value warrant amount (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_WarrantsOfCashlessExercised" xlink:href="avco-20250331.xsd#avco_WarrantsOfCashlessExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_WarrantsOfCashlessExercised_lbl" xml:lang="en-US">Warrants of cashless exercised (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WarrantsOfCashlessExercised" xlink:to="avco_WarrantsOfCashlessExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Derivative liability (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl" xml:lang="en-US">Interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl" xml:lang="en-US">Interest payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuredDebt_lbl" xml:lang="en-US">Secured amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebt" xlink:to="us-gaap_SecuredDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Annual rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl0" xml:lang="en-US">Convertible debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseShortTermBorrowings_lbl" xml:lang="en-US">Interest expense related to note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseShortTermBorrowings" xlink:to="us-gaap_InterestExpenseShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RentalIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RentalIncomeNonoperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RentalIncomeNonoperating_lbl" xml:lang="en-US">Rental revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RentalIncomeNonoperating" xlink:to="us-gaap_RentalIncomeNonoperating_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Rent receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralExpense_lbl" xml:lang="en-US">Consulting expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralExpense" xlink:to="us-gaap_OtherGeneralExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedAndUnpaidServicesCharge" xlink:href="avco-20250331.xsd#avco_AccruedAndUnpaidServicesCharge"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AccruedAndUnpaidServicesCharge_lbl" xml:lang="en-US">Accrued and unpaid services charge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedAndUnpaidServicesCharge" xlink:to="avco_AccruedAndUnpaidServicesCharge_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Unpaid acquisition consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl0" xml:lang="en-US">Consideration amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Line of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Promissory note maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xml:lang="en-US">Bears interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_lbl" xml:lang="en-US">Accrued and unpaid interest for line of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:to="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl" xml:lang="en-US">Acquire percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PurchasePrice" xlink:href="avco-20250331.xsd#avco_PurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PurchasePrice_lbl" xml:lang="en-US">Purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PurchasePrice" xlink:to="avco_PurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage" xlink:href="avco-20250331.xsd#avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage_lbl" xml:lang="en-US">Additional acquire percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage" xlink:to="avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US">Acquired cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLoansHeldForInvestment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLoansHeldForInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireLoansHeldForInvestment_lbl" xml:lang="en-US">Payment of equity investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLoansHeldForInvestment" xlink:to="us-gaap_PaymentsToAcquireLoansHeldForInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNotesPayable_lbl" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ExchangeShare" xlink:href="avco-20250331.xsd#avco_ExchangeShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ExchangeShare_lbl" xml:lang="en-US">Exchange share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExchangeShare" xlink:to="avco_ExchangeShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xml:lang="en-US">Effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US">Foreign subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Federal and state net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US">U.S. federal net operating loss carryovers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">Federal net operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">federal net operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries_lbl" xml:lang="en-US">Foreign entity tax disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries" xlink:to="us-gaap_DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PercentageOfCommonStockIssuedAndOutstanding" xlink:href="avco-20250331.xsd#avco_PercentageOfCommonStockIssuedAndOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PercentageOfCommonStockIssuedAndOutstanding_lbl" xml:lang="en-US">Percentage of common stock issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PercentageOfCommonStockIssuedAndOutstanding" xlink:to="avco_PercentageOfCommonStockIssuedAndOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ConversionPricePercentage" xlink:href="avco-20250331.xsd#avco_ConversionPricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ConversionPricePercentage_lbl" xml:lang="en-US">Conversion percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ConversionPricePercentage" xlink:to="avco_ConversionPricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xml:lang="en-US">Conversion price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Consideration issuable shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US">Issued shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0" xml:lang="en-US">Issued shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Aggregate shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Aggregate shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Preferred stock and received proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xml:lang="en-US">Aggregate offering price amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CommonStockOfAveragePrice" xlink:href="avco-20250331.xsd#avco_CommonStockOfAveragePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CommonStockOfAveragePrice_lbl" xml:lang="en-US">Common stock of average price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommonStockOfAveragePrice" xlink:to="avco_CommonStockOfAveragePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_OfferingCost" xlink:href="avco-20250331.xsd#avco_OfferingCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_OfferingCost_lbl" xml:lang="en-US">Other offering cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OfferingCost" xlink:to="avco_OfferingCost_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_FairMarketValuesOfGrantDates" xlink:href="avco-20250331.xsd#avco_FairMarketValuesOfGrantDates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_FairMarketValuesOfGrantDates_lbl" xml:lang="en-US">Fair market values of grant dates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FairMarketValuesOfGrantDates" xlink:to="avco_FairMarketValuesOfGrantDates_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_FairMarketValuesOfGrantDates_lbl0" xml:lang="en-US">Fair market values (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FairMarketValuesOfGrantDates" xlink:to="avco_FairMarketValuesOfGrantDates_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Reduction in accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate intrinsic value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Stock options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Compensation and related benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xml:lang="en-US">Warrant issued, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US">Black-Scholes option-pricing volatility rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk free interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Cancelled warrants shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockRedemptionAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockRedemptionAmount_lbl" xml:lang="en-US">Payment of closing the redemption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionAmount" xlink:to="us-gaap_PreferredStockRedemptionAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RedemptionNetOfPayablesDueToLabServices" xlink:href="avco-20250331.xsd#avco_RedemptionNetOfPayablesDueToLabServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_RedemptionNetOfPayablesDueToLabServices_lbl" xml:lang="en-US">Redemption, net of payables due to lab services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RedemptionNetOfPayablesDueToLabServices" xlink:to="avco_RedemptionNetOfPayablesDueToLabServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockRedemptionPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockRedemptionPremium_lbl" xml:lang="en-US">Total redemption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionPremium" xlink:to="us-gaap_PreferredStockRedemptionPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_FairMarketValues" xlink:href="avco-20250331.xsd#avco_FairMarketValues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_FairMarketValues_lbl" xml:lang="en-US">Fair market values</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FairMarketValues" xlink:to="avco_FairMarketValues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_StatutoryReservePercent" xlink:href="avco-20250331.xsd#avco_StatutoryReservePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_StatutoryReservePercent_lbl" xml:lang="en-US">Statutory reserve percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReservePercent" xlink:to="avco_StatutoryReservePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RegisteredCapitalPercentage" xlink:href="avco-20250331.xsd#avco_RegisteredCapitalPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_RegisteredCapitalPercentage_lbl" xml:lang="en-US">Reserve registered capital percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RegisteredCapitalPercentage" xlink:to="avco_RegisteredCapitalPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_StatutoryReserve" xlink:href="avco-20250331.xsd#avco_StatutoryReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_StatutoryReserve_lbl" xml:lang="en-US">Statutory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReserve" xlink:to="avco_StatutoryReserve_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestrictedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherRestrictedAssets_lbl" xml:lang="en-US">Restricted net assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestrictedAssets" xlink:to="us-gaap_OtherRestrictedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets" xlink:href="avco-20250331.xsd#avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets_lbl" xml:lang="en-US">Consolidated subsidiary exceed net assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets" xlink:to="avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed" xlink:href="avco-20250331.xsd#avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed_lbl" xml:lang="en-US">Consolidated subsidiary did not exceed net assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed" xlink:to="avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Reportable segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PurchasedServicesPercentage" xlink:href="avco-20250331.xsd#avco_PurchasedServicesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PurchasedServicesPercentage_lbl" xml:lang="en-US">Purchased services percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PurchasedServicesPercentage" xlink:to="avco_PurchasedServicesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US">Loans payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationReserve_lbl" xml:lang="en-US">Litigation amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationReserve" xlink:to="us-gaap_LitigationReserve_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PercentageOfPretaxProfit" xlink:href="avco-20250331.xsd#avco_PercentageOfPretaxProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PercentageOfPretaxProfit_lbl" xml:lang="en-US">Percentage of pre-tax profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PercentageOfPretaxProfit" xlink:to="avco_PercentageOfPretaxProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PreTaxProfit" xlink:href="avco-20250331.xsd#avco_PreTaxProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PreTaxProfit_lbl" xml:lang="en-US">Pre-tax profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PreTaxProfit" xlink:to="avco_PreTaxProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Payment for rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowsBetweenTransfereeAndTransferorServicingFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowsBetweenTransfereeAndTransferorServicingFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowsBetweenTransfereeAndTransferorServicingFees_lbl" xml:lang="en-US">Cash services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowsBetweenTransfereeAndTransferorServicingFees" xlink:to="us-gaap_CashFlowsBetweenTransfereeAndTransferorServicingFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashContributionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashContributionExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashContributionExpense_lbl" xml:lang="en-US">Contribution amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashContributionExpense" xlink:to="us-gaap_NoncashContributionExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_WorkingCapital" xlink:href="avco-20250331.xsd#avco_WorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_WorkingCapital_lbl" xml:lang="en-US">Working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WorkingCapital" xlink:to="avco_WorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Percentage of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl" xml:lang="en-US">Percentage of owned</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedemptionPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RedemptionPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RedemptionPremium_lbl" xml:lang="en-US">Redemption amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedemptionPremium" xlink:to="us-gaap_RedemptionPremium_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ExchangeRatioPerShare" xlink:href="avco-20250331.xsd#avco_ExchangeRatioPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ExchangeRatioPerShare_lbl" xml:lang="en-US">Exchange ratio per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExchangeRatioPerShare" xlink:to="avco_ExchangeRatioPerShare_lbl"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra/k4DNHXVKIYwN/zLXIt0iwZq6nYg/w27/nmgU3Bs4kyGGa1okQf8wpc8xue3C4gYCyO+De2FMpGD6T1rBTmQ8hA/UC+V/TeVcwU7ABGe/tb9Nse+XBO1hN0S6XbJQbcJwedpHBgl7i050GjffC4p7Iw/J3z5vZfcXGGwK1wcBZ+q2HcISatlXTlFgsMKO5QeDDlx75B8z8hjuvV5IPRmtFIaAZaCRuKG6FjDX4pVgOvKP8sYq0oOXOi3OZPucTYQ=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl" xml:lang="en-US">Termination fee (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:to="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Instruments and Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Credit Risk and Uncertainties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Rent Receivable and Reserve for Credit Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DeferredOfferingCostsPolicyTextBlock" xlink:href="avco-20250331.xsd#avco_DeferredOfferingCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_DeferredOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeferredOfferingCostsPolicyTextBlock" xlink:to="avco_DeferredOfferingCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Leasing Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock" xlink:href="avco-20250331.xsd#avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock_lbl" xml:lang="en-US">Investment In Real Estate and Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock" xlink:to="avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US">Investment in Unconsolidated Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DeferredRentalIncomePolicyTextBlock" xlink:href="avco-20250331.xsd#avco_DeferredRentalIncomePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_DeferredRentalIncomePolicyTextBlock_lbl" xml:lang="en-US">Deferred Rental Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeferredRentalIncomePolicyTextBlock" xlink:to="avco_DeferredRentalIncomePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RealPropertyRentalRevenuePolicyTextBlock" xlink:href="avco-20250331.xsd#avco_RealPropertyRentalRevenuePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_RealPropertyRentalRevenuePolicyTextBlock_lbl" xml:lang="en-US">Real Property Rental Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RealPropertyRentalRevenuePolicyTextBlock" xlink:to="avco_RealPropertyRentalRevenuePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LessorLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_lbl" xml:lang="en-US">Office Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorLeasesPolicyTextBlock" xlink:to="us-gaap_LessorLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstatePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstatePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RealEstatePolicyTextBlock_lbl" xml:lang="en-US">Real Property Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstatePolicyTextBlock" xlink:to="us-gaap_RealEstatePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising and Marketing Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Receivable from Sale of Equity Method Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DebtModificationsAndExtinguishmentsPolicyTextBlock" xlink:href="avco-20250331.xsd#avco_DebtModificationsAndExtinguishmentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_DebtModificationsAndExtinguishmentsPolicyTextBlock_lbl" xml:lang="en-US">Debt Modifications and Extinguishments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DebtModificationsAndExtinguishmentsPolicyTextBlock" xlink:to="avco_DebtModificationsAndExtinguishmentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Per Share Data</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_NoncontrollingInterestPolicyTextBlock" xlink:href="avco-20250331.xsd#avco_NoncontrollingInterestPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_NoncontrollingInterestPolicyTextBlock_lbl" xml:lang="en-US">Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_NoncontrollingInterestPolicyTextBlock" xlink:to="avco_NoncontrollingInterestPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiscalPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiscalPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiscalPeriod_lbl" xml:lang="en-US">Fiscal Year End</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiscalPeriod" xlink:to="us-gaap_FiscalPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ReverseStockSplitPolicyTextBlock" xlink:href="avco-20250331.xsd#avco_ReverseStockSplitPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US">Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ReverseStockSplitPolicyTextBlock" xlink:to="avco_ReverseStockSplitPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Standards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl" xml:lang="en-US">Business Combination [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0" xml:lang="en-US">Business Combination, Series of Individually Immaterial Business Combinations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_AvactisAndArbeleBiotherapeuticsLimitedMember" xlink:href="avco-20250331.xsd#avco_AvactisAndArbeleBiotherapeuticsLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AvactisAndArbeleBiotherapeuticsLimitedMember_lbl" xml:lang="en-US">Avactis and Arbele Biotherapeutics Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvactisAndArbeleBiotherapeuticsLimitedMember" xlink:to="avco_AvactisAndArbeleBiotherapeuticsLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonLabMember" xlink:href="avco-20250331.xsd#avco_AvalonLabMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AvalonLabMember_lbl" xml:lang="en-US">Avalon Lab [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonLabMember" xlink:to="avco_AvalonLabMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentContinuingOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentContinuingOperationsMember_lbl" xml:lang="en-US">Continuing Operations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentContinuingOperationsMember" xlink:to="us-gaap_SegmentContinuingOperationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EpiconBiotechCoLtdMember" xlink:href="avco-20250331.xsd#avco_EpiconBiotechCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_EpiconBiotechCoLtdMember_lbl" xml:lang="en-US">Epicon Biotech Co., Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EpiconBiotechCoLtdMember" xlink:to="avco_EpiconBiotechCoLtdMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_EpiconBiotechCoLtdMember_lbl0" xml:lang="en-US">Epicon Biotech Co. Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EpiconBiotechCoLtdMember" xlink:to="avco_EpiconBiotechCoLtdMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_LaboratoryServicesMSOLLCMember" xlink:href="avco-20250331.xsd#avco_LaboratoryServicesMSOLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_LaboratoryServicesMSOLLCMember_lbl" xml:lang="en-US">Laboratory Services MSO, LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LaboratoryServicesMSOLLCMember" xlink:to="avco_LaboratoryServicesMSOLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DeferredOfferingCostsMember" xlink:href="avco-20250331.xsd#avco_DeferredOfferingCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_DeferredOfferingCostsMember_lbl" xml:lang="en-US">Deferred Offering Costs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeferredOfferingCostsMember" xlink:to="avco_DeferredOfferingCostsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentsMember_lbl" xml:lang="en-US">Equity Method Investment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsMember" xlink:to="us-gaap_EquityMethodInvestmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AssetAndLiabilityAccountsMember" xlink:href="avco-20250331.xsd#avco_AssetAndLiabilityAccountsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AssetAndLiabilityAccountsMember_lbl" xml:lang="en-US">Asset and liability Accounts [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AssetAndLiabilityAccountsMember" xlink:to="avco_AssetAndLiabilityAccountsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PreFundedWarrantsMember" xlink:href="avco-20250331.xsd#avco_PreFundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PreFundedWarrantsMember" xlink:to="avco_PreFundedWarrantsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_PreFundedWarrantsMember_lbl0" xml:lang="en-US">Pre Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PreFundedWarrantsMember" xlink:to="avco_PreFundedWarrantsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesAConvertiblePreferredStockMember" xlink:href="avco-20250331.xsd#avco_SeriesAConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesAConvertiblePreferredStockMember" xlink:to="avco_SeriesAConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DrYuZhouMember" xlink:href="avco-20250331.xsd#avco_DrYuZhouMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_DrYuZhouMember_lbl" xml:lang="en-US">Dr. Yu Zhou [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DrYuZhouMember" xlink:to="avco_DrYuZhouMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_DrYuZhouMember_lbl0" xml:lang="en-US">Dr Yu Zhou [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DrYuZhouMember" xlink:to="avco_DrYuZhouMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonShangaiMember" xlink:href="avco-20250331.xsd#avco_AvalonShangaiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AvalonShangaiMember_lbl" xml:lang="en-US">Avalon Shangai [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonShangaiMember" xlink:to="avco_AvalonShangaiMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_JiangsuUnicornBiologicalTechnologyCoLtdMember" xlink:href="avco-20250331.xsd#avco_JiangsuUnicornBiologicalTechnologyCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_JiangsuUnicornBiologicalTechnologyCoLtdMember_lbl" xml:lang="en-US">Jiangsu Unicorn Biological Technology Co., Ltd.[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_JiangsuUnicornBiologicalTechnologyCoLtdMember" xlink:to="avco_JiangsuUnicornBiologicalTechnologyCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_InvestmentInEpiconBiotechCoLtdMember" xlink:href="avco-20250331.xsd#avco_InvestmentInEpiconBiotechCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_InvestmentInEpiconBiotechCoLtdMember_lbl" xml:lang="en-US">Investment in Epicon Biotech Co., Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_InvestmentInEpiconBiotechCoLtdMember" xlink:to="avco_InvestmentInEpiconBiotechCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_LaboratoryServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LaboratoryServicesMSOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_LaboratoryServicesMSOMember_lbl" xml:lang="en-US">Lab Services MSO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LaboratoryServicesMSOMember" xlink:to="avco_LaboratoryServicesMSOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesBConvertiblePreferredStockMember" xlink:href="avco-20250331.xsd#avco_SeriesBConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesBConvertiblePreferredStockMember" xlink:to="avco_SeriesBConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesBStatedValueMember" xlink:href="avco-20250331.xsd#avco_SeriesBStatedValueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_SeriesBStatedValueMember_lbl" xml:lang="en-US">Series B Stated Value [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesBStatedValueMember" xlink:to="avco_SeriesBStatedValueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_LabServicesMember" xlink:href="avco-20250331.xsd#avco_LabServicesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_LabServicesMember_lbl" xml:lang="en-US">Lab Services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LabServicesMember" xlink:to="avco_LabServicesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_May2023ConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_May2023ConvertibleNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_May2023ConvertibleNoteMember_lbl" xml:lang="en-US">May 2023 Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_May2023ConvertibleNoteMember" xlink:to="avco_May2023ConvertibleNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeniorNotesMember_lbl" xml:lang="en-US">Senior Secured Promissory Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorNotesMember" xlink:to="us-gaap_SeniorNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_MastHillFundLPMember" xlink:href="avco-20250331.xsd#avco_MastHillFundLPMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_MastHillFundLPMember_lbl" xml:lang="en-US">Mast Hill Fund, L.P. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MastHillFundLPMember" xlink:to="avco_MastHillFundLPMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherTradingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherTradingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherTradingMember_lbl" xml:lang="en-US">Other Trading [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherTradingMember" xlink:to="us-gaap_OtherTradingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_FirstWarrantMember" xlink:href="avco-20250331.xsd#avco_FirstWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_FirstWarrantMember_lbl" xml:lang="en-US">First Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FirstWarrantMember" xlink:to="avco_FirstWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SecondWarrantMember" xlink:href="avco-20250331.xsd#avco_SecondWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_SecondWarrantMember_lbl" xml:lang="en-US">Second Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SecondWarrantMember" xlink:to="avco_SecondWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_July2023ConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_July2023ConvertibleNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_July2023ConvertibleNoteMember_lbl" xml:lang="en-US">July 2023 Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_July2023ConvertibleNoteMember" xlink:to="avco_July2023ConvertibleNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_FirstFireMember" xlink:href="avco-20250331.xsd#avco_FirstFireMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_FirstFireMember_lbl" xml:lang="en-US">FirstFire [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FirstFireMember" xlink:to="avco_FirstFireMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US">Measurement Input, Discount Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_October2023ConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_October2023ConvertibleNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_October2023ConvertibleNoteMember_lbl" xml:lang="en-US">October 2023 Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_October2023ConvertibleNoteMember" xlink:to="avco_October2023ConvertibleNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_March2024ConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_March2024ConvertibleNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_March2024ConvertibleNoteMember_lbl" xml:lang="en-US">March 2024 Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_March2024ConvertibleNoteMember" xlink:to="avco_March2024ConvertibleNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_June2024ConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_June2024ConvertibleNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_June2024ConvertibleNoteMember_lbl" xml:lang="en-US">June 2024 Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_June2024ConvertibleNoteMember" xlink:to="avco_June2024ConvertibleNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_WaiverFeeMember" xlink:href="avco-20250331.xsd#avco_WaiverFeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_WaiverFeeMember_lbl" xml:lang="en-US">Waiver Fee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WaiverFeeMember" xlink:to="avco_WaiverFeeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_May232023FiveYearAnniversaryMember" xlink:href="avco-20250331.xsd#avco_May232023FiveYearAnniversaryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_May232023FiveYearAnniversaryMember_lbl" xml:lang="en-US">May 23, 2023 - Five-Year Anniversary [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_May232023FiveYearAnniversaryMember" xlink:to="avco_May232023FiveYearAnniversaryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_July62023FiveYearAnniversaryMember" xlink:href="avco-20250331.xsd#avco_July62023FiveYearAnniversaryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_July62023FiveYearAnniversaryMember_lbl" xml:lang="en-US">July 6, 2023 - Five-Year Anniversary [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_July62023FiveYearAnniversaryMember" xlink:to="avco_July62023FiveYearAnniversaryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_October92023FiveYearAnniversaryMember" xlink:href="avco-20250331.xsd#avco_October92023FiveYearAnniversaryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_October92023FiveYearAnniversaryMember_lbl" xml:lang="en-US">October 9, 2023 - Five-Year Anniversary [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_October92023FiveYearAnniversaryMember" xlink:to="avco_October92023FiveYearAnniversaryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_June52024FiveyearAnniversaryMember" xlink:href="avco-20250331.xsd#avco_June52024FiveyearAnniversaryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_June52024FiveyearAnniversaryMember_lbl" xml:lang="en-US">June 5, 2024 - five-year anniversary [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_June52024FiveyearAnniversaryMember" xlink:to="avco_June52024FiveyearAnniversaryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_MastHillAndFirstfireMember" xlink:href="avco-20250331.xsd#avco_MastHillAndFirstfireMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_MastHillAndFirstfireMember_lbl" xml:lang="en-US">Mast Hill and Firstfire [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MastHillAndFirstfireMember" xlink:to="avco_MastHillAndFirstfireMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_MastHillThirdPartyMember" xlink:href="avco-20250331.xsd#avco_MastHillThirdPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_MastHillThirdPartyMember_lbl" xml:lang="en-US">Mast Hill Third Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MastHillThirdPartyMember" xlink:to="avco_MastHillThirdPartyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_March72024FiveYearAnniversaryMember" xlink:href="avco-20250331.xsd#avco_March72024FiveYearAnniversaryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_March72024FiveYearAnniversaryMember_lbl" xml:lang="en-US">March 7, 2024 - Five-Year Anniversary [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_March72024FiveYearAnniversaryMember" xlink:to="avco_March72024FiveYearAnniversaryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_findersFeeMember" xlink:href="avco-20250331.xsd#avco_findersFeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_findersFeeMember_lbl" xml:lang="en-US">finder&#8217;s fee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_findersFeeMember" xlink:to="avco_findersFeeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PromissoryNoteMember" xlink:href="avco-20250331.xsd#avco_PromissoryNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PromissoryNoteMember_lbl" xml:lang="en-US">Promissory Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PromissoryNoteMember" xlink:to="avco_PromissoryNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_BeijingGenexosomeMember" xlink:href="avco-20250331.xsd#avco_BeijingGenexosomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_BeijingGenexosomeMember_lbl" xml:lang="en-US">Beijing Genexosome [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BeijingGenexosomeMember" xlink:to="avco_BeijingGenexosomeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_BeijingGenexosomeMember_lbl0" xml:lang="en-US">Beijing GenExosome [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BeijingGenexosomeMember" xlink:to="avco_BeijingGenexosomeMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_WenzhaoLuMember" xlink:href="avco-20250331.xsd#avco_WenzhaoLuMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_WenzhaoLuMember_lbl" xml:lang="en-US">Wenzhao Lu [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WenzhaoLuMember" xlink:to="avco_WenzhaoLuMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_LineOfCreditAgreementMember" xlink:href="avco-20250331.xsd#avco_LineOfCreditAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_LineOfCreditAgreementMember_lbl" xml:lang="en-US">Line of Credit Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LineOfCreditAgreementMember" xlink:to="avco_LineOfCreditAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LetterOfCreditMember_lbl" xml:lang="en-US">Letter of Credit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_MrLuMember" xlink:href="avco-20250331.xsd#avco_MrLuMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_MrLuMember_lbl" xml:lang="en-US">Mr. Lu [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MrLuMember" xlink:to="avco_MrLuMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonRT9Member" xlink:href="avco-20250331.xsd#avco_AvalonRT9Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AvalonRT9Member_lbl" xml:lang="en-US">Avalon RT 9 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonRT9Member" xlink:to="avco_AvalonRT9Member_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_LabServiceMSOMember" xlink:href="avco-20250331.xsd#avco_LabServiceMSOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_LabServiceMSOMember_lbl" xml:lang="en-US">Lab Service MSO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LabServiceMSOMember" xlink:to="avco_LabServiceMSOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AbandonmentAgreementMember" xlink:href="avco-20250331.xsd#avco_AbandonmentAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AbandonmentAgreementMember_lbl" xml:lang="en-US">Abandonment Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AbandonmentAgreementMember" xlink:to="avco_AbandonmentAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_MembershipInterestPurchaseAgreementMember" xlink:href="avco-20250331.xsd#avco_MembershipInterestPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_MembershipInterestPurchaseAgreementMember_lbl" xml:lang="en-US">Membership Interest Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MembershipInterestPurchaseAgreementMember" xlink:to="avco_MembershipInterestPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ConvertibleDebtNoteMember" xlink:href="avco-20250331.xsd#avco_ConvertibleDebtNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ConvertibleDebtNoteMember_lbl" xml:lang="en-US">Convertible Debt Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ConvertibleDebtNoteMember" xlink:to="avco_ConvertibleDebtNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SeriesBHolderMember" xlink:href="avco-20250331.xsd#avco_SeriesBHolderMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_SeriesBHolderMember_lbl" xml:lang="en-US">Series B Holder [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesBHolderMember" xlink:to="avco_SeriesBHolderMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ConversionShareMember" xlink:href="avco-20250331.xsd#avco_ConversionShareMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ConversionShareMember_lbl" xml:lang="en-US">Conversion Share [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ConversionShareMember" xlink:to="avco_ConversionShareMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US">Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebtMember_lbl0" xml:lang="en-US">Convertible Debt [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_RothCapitalPartnersLLCMember" xlink:href="avco-20250331.xsd#avco_RothCapitalPartnersLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_RothCapitalPartnersLLCMember_lbl" xml:lang="en-US">Roth Capital Partners, LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RothCapitalPartnersLLCMember" xlink:to="avco_RothCapitalPartnersLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_JefferiesLLCMember" xlink:href="avco-20250331.xsd#avco_JefferiesLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_JefferiesLLCMember_lbl" xml:lang="en-US">Jefferies LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_JefferiesLLCMember" xlink:to="avco_JefferiesLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CommonSharesIssuedForServicesMember" xlink:href="avco-20250331.xsd#avco_CommonSharesIssuedForServicesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CommonSharesIssuedForServicesMember_lbl" xml:lang="en-US">Common Shares Issued for Services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommonSharesIssuedForServicesMember" xlink:to="avco_CommonSharesIssuedForServicesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_May2023CovertibleNoteMember" xlink:href="avco-20250331.xsd#avco_May2023CovertibleNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_May2023CovertibleNoteMember_lbl" xml:lang="en-US">May 2023 Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_May2023CovertibleNoteMember" xlink:to="avco_May2023CovertibleNoteMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_May2023CovertibleNoteMember_lbl0" xml:lang="en-US">May 2023 Covertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_May2023CovertibleNoteMember" xlink:to="avco_May2023CovertibleNoteMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_BlackScholesValuationModelMember" xlink:href="avco-20250331.xsd#avco_BlackScholesValuationModelMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_BlackScholesValuationModelMember_lbl" xml:lang="en-US">Black-Scholes Valuation Model [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BlackScholesValuationModelMember" xlink:to="avco_BlackScholesValuationModelMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_FiveYearAnniversaryMember" xlink:href="avco-20250331.xsd#avco_FiveYearAnniversaryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_FiveYearAnniversaryMember_lbl" xml:lang="en-US">Five Year Anniversary [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FiveYearAnniversaryMember" xlink:to="avco_FiveYearAnniversaryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilityMember_lbl" xml:lang="en-US">Liability [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityMember" xlink:to="us-gaap_LiabilityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_FirstfireMember" xlink:href="avco-20250331.xsd#avco_FirstfireMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_FirstfireMember_lbl" xml:lang="en-US">Firstfire [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FirstfireMember" xlink:to="avco_FirstfireMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_OctoberTwoThousandTwentyThreeConvertibleNotesMember" xlink:href="avco-20250331.xsd#avco_OctoberTwoThousandTwentyThreeConvertibleNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_OctoberTwoThousandTwentyThreeConvertibleNotesMember_lbl" xml:lang="en-US">October 2023 Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OctoberTwoThousandTwentyThreeConvertibleNotesMember" xlink:to="avco_OctoberTwoThousandTwentyThreeConvertibleNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_MastMillAndFirstFireMember" xlink:href="avco-20250331.xsd#avco_MastMillAndFirstFireMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_MastMillAndFirstFireMember_lbl" xml:lang="en-US">Mast Mill and FirstFire [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MastMillAndFirstFireMember" xlink:to="avco_MastMillAndFirstFireMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_MarchTwoThousandTwentyFourWarrantIssuedMember" xlink:href="avco-20250331.xsd#avco_MarchTwoThousandTwentyFourWarrantIssuedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_MarchTwoThousandTwentyFourWarrantIssuedMember_lbl" xml:lang="en-US">Warrants Issued in March 2024 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MarchTwoThousandTwentyFourWarrantIssuedMember" xlink:to="avco_MarchTwoThousandTwentyFourWarrantIssuedMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_MarchTwoThousandTwentyFourWarrantIssuedMember_lbl0" xml:lang="en-US">March Two Thousand Twenty Four Warrant Issued [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MarchTwoThousandTwentyFourWarrantIssuedMember" xlink:to="avco_MarchTwoThousandTwentyFourWarrantIssuedMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_MarchTwentyThousandTwentyFourConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_MarchTwentyThousandTwentyFourConvertibleNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_MarchTwentyThousandTwentyFourConvertibleNoteMember_lbl" xml:lang="en-US">March 2024 Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MarchTwentyThousandTwentyFourConvertibleNoteMember" xlink:to="avco_MarchTwentyThousandTwentyFourConvertibleNoteMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_MarchTwentyThousandTwentyFourConvertibleNoteMember_lbl0" xml:lang="en-US">March Twenty Thousand Twenty Four Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MarchTwentyThousandTwentyFourConvertibleNoteMember" xlink:to="avco_MarchTwentyThousandTwentyFourConvertibleNoteMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_TwoThousandTwentyFourJuneWarrantIssuedMember" xlink:href="avco-20250331.xsd#avco_TwoThousandTwentyFourJuneWarrantIssuedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_TwoThousandTwentyFourJuneWarrantIssuedMember_lbl" xml:lang="en-US">Warrants Issued in June 2024 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_TwoThousandTwentyFourJuneWarrantIssuedMember" xlink:to="avco_TwoThousandTwentyFourJuneWarrantIssuedMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_TwoThousandTwentyFourJuneWarrantIssuedMember_lbl0" xml:lang="en-US">Two Thousand Twenty Four June Warrant Issued [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_TwoThousandTwentyFourJuneWarrantIssuedMember" xlink:to="avco_TwoThousandTwentyFourJuneWarrantIssuedMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_JuneTwentyThousandTwentyFourConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_JuneTwentyThousandTwentyFourConvertibleNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_JuneTwentyThousandTwentyFourConvertibleNoteMember_lbl" xml:lang="en-US">June 2024 Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_JuneTwentyThousandTwentyFourConvertibleNoteMember" xlink:to="avco_JuneTwentyThousandTwentyFourConvertibleNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_WarrantsExercisedMember" xlink:href="avco-20250331.xsd#avco_WarrantsExercisedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_WarrantsExercisedMember_lbl" xml:lang="en-US">Warrants Exercised [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WarrantsExercisedMember" xlink:to="avco_WarrantsExercisedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_FormerDirectorAndFormerCochiefExecutiveOfficerMember" xlink:href="avco-20250331.xsd#avco_FormerDirectorAndFormerCochiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_FormerDirectorAndFormerCochiefExecutiveOfficerMember_lbl" xml:lang="en-US">Former Director And Former Co-chief executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FormerDirectorAndFormerCochiefExecutiveOfficerMember" xlink:to="avco_FormerDirectorAndFormerCochiefExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PRCSubsidiariesMember" xlink:href="avco-20250331.xsd#avco_PRCSubsidiariesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PRCSubsidiariesMember_lbl" xml:lang="en-US">PRC Subsidiaries [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PRCSubsidiariesMember" xlink:to="avco_PRCSubsidiariesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_OneCustomerMember" xlink:href="avco-20250331.xsd#avco_OneCustomerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_OneCustomerMember_lbl" xml:lang="en-US">One Customer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OneCustomerMember" xlink:to="avco_OneCustomerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Rent Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_TwoCustomersMember" xlink:href="avco-20250331.xsd#avco_TwoCustomersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_TwoCustomersMember_lbl" xml:lang="en-US">Two customers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_TwoCustomersMember" xlink:to="avco_TwoCustomersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventorySuppliesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventorySuppliesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PublicUtilitiesInventorySuppliesMember_lbl" xml:lang="en-US">Supplies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventorySuppliesMember" xlink:to="us-gaap_PublicUtilitiesInventorySuppliesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SettledLitigationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SettledLitigationMember_lbl" xml:lang="en-US">Settled Litigation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettledLitigationMember" xlink:to="us-gaap_SettledLitigationMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SettledLitigationMember_lbl0" xml:lang="en-US">Litigation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettledLitigationMember" xlink:to="us-gaap_SettledLitigationMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_DrZhouMember" xlink:href="avco-20250331.xsd#avco_DrZhouMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_DrZhouMember_lbl" xml:lang="en-US">Dr. Zhou [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DrZhouMember" xlink:to="avco_DrZhouMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AvactisBiotherapeuticsLimitedMember" xlink:href="avco-20250331.xsd#avco_AvactisBiotherapeuticsLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AvactisBiotherapeuticsLimitedMember_lbl" xml:lang="en-US">Avactis Biotherapeutics Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvactisBiotherapeuticsLimitedMember" xlink:to="avco_AvactisBiotherapeuticsLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ArbeleMember" xlink:href="avco-20250331.xsd#avco_ArbeleMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ArbeleMember_lbl" xml:lang="en-US">Arbele Biotherapeutics [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ArbeleMember" xlink:to="avco_ArbeleMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_MergerAgreementMember" xlink:href="avco-20250331.xsd#avco_MergerAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_MergerAgreementMember_lbl" xml:lang="en-US">Merger Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MergerAgreementMember" xlink:to="avco_MergerAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CertificatesOfEliminationMember" xlink:href="avco-20250331.xsd#avco_CertificatesOfEliminationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CertificatesOfEliminationMember_lbl" xml:lang="en-US">Certificates of Elimination [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CertificatesOfEliminationMember" xlink:to="avco_CertificatesOfEliminationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityTablesTable" xlink:href="avco-20250331.xsd#avco_EquityTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityTablesTable_lbl" xml:lang="en-US">Equity (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityTablesTable" xlink:to="avco_EquityTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityTablesLineItems" xlink:href="avco-20250331.xsd#avco_EquityTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityTablesLineItems_lbl" xml:lang="en-US">Equity (Tables) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityTablesLineItems" xlink:to="avco_EquityTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_lbl" xml:lang="en-US">Subsidiary of LLC or LP [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl" xml:lang="en-US">Schedule of Consolidated Financial Statements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US">Schedule of Derivative Liability Measured at Fair Value [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xml:lang="en-US">Cash and Cash Equivalent [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xml:lang="en-US">Schedule of Cash Balances by Geographic Area [Line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Schedule of Summarizes the Securities that were Excluded from the Diluted Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollateralDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollateralDomain_lbl" xml:lang="en-US">Collateral Held [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralDomain" xlink:to="us-gaap_CollateralDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRealEstatePropertiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTable_lbl" xml:lang="en-US">Real Estate Property, Ownership [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRealEstatePropertiesTable" xlink:to="us-gaap_ScheduleOfRealEstatePropertiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealEstateLineItems_lbl" xml:lang="en-US">Schedule of Investment in Real Estate [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateLineItems" xlink:to="us-gaap_RealEstateLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US">Investment, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xml:lang="en-US">Equity Method Investment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xml:lang="en-US">Schedule of Equity Method Investment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xml:lang="en-US">Consolidated Entities [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementTable_lbl" xml:lang="en-US">Condensed Balance Sheet Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl" xml:lang="en-US">Schedule of Summarized Financial Information, as Provided to the Company by the Investee [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedIncomeStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedIncomeStatementTable_lbl" xml:lang="en-US">Condensed Income Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems_lbl" xml:lang="en-US">Schedule of Financial Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US">Award Date [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionNameDomain_lbl" xml:lang="en-US">Debt Conversion, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="us-gaap_DebtConversionNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Schedule of Amortization Payments in Cash [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable" xlink:href="avco-20250331.xsd#avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable_lbl" xml:lang="en-US">Convertible Note Payable - Schedule of Convertible Note Payable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable" xlink:to="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems" xlink:href="avco-20250331.xsd#avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems_lbl" xml:lang="en-US">Schedule of Convertible Note Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems" xlink:to="avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Exercise Price Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingDetailsTable" xlink:href="avco-20250331.xsd#avco_EquityScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingDetailsTable_lbl" xml:lang="en-US">Equity - Schedule of Common Stock Issuable Upon Exercise of Warrants Outstanding (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingDetailsTable" xlink:to="avco_EquityScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Schedule of Common Stock Issuable Upon Exercise of Options Outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityScheduleofStockOptionActivityDetailsTable" xlink:href="avco-20250331.xsd#avco_EquityScheduleofStockOptionActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityScheduleofStockOptionActivityDetailsTable_lbl" xml:lang="en-US">Equity - Schedule of Stock Option Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityScheduleofStockOptionActivityDetailsTable" xlink:to="avco_EquityScheduleofStockOptionActivityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Schedule of Stock Option Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US">Revision of Prior Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" xlink:href="avco-20250331.xsd#avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable_lbl" xml:lang="en-US">Equity - Schedule of Nonvested Stock Options Granted (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" xlink:to="avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Schedule of Common Stock Issuable Upon Exercise of Options Outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Schedule of Customer Revenues [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Schedule of Reportable Business Segments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US">Schedule of Identifiable Long-Lived Tangible Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl0" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl0" xml:lang="en-US">Schedule of Identifiable Long-Lived Tangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US">Schedule of Convertible Note Payable [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" xml:lang="en-US">Schedule of Nonvested Stock Options Granted [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Combination [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_OrganizationandNatureofOperationsDetailsTable" xlink:href="avco-20250331.xsd#avco_OrganizationandNatureofOperationsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OrganizationandNatureofOperationsDetailsTable_lbl" xml:lang="en-US">Organization and Nature of Operations (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OrganizationandNatureofOperationsDetailsTable" xlink:to="avco_OrganizationandNatureofOperationsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl0" xml:lang="en-US">Organization and Nature of Operations [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentOperatingActivitiesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentOperatingActivitiesDomain_lbl" xml:lang="en-US">Operating Activities [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentOperatingActivitiesDomain" xlink:to="us-gaap_SegmentOperatingActivitiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_BasisofPresentationandGoingConcernConditionDetailsTable" xlink:href="avco-20250331.xsd#avco_BasisofPresentationandGoingConcernConditionDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_BasisofPresentationandGoingConcernConditionDetailsTable_lbl" xml:lang="en-US">Basis of Presentation and Going Concern Condition (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BasisofPresentationandGoingConcernConditionDetailsTable" xlink:to="avco_BasisofPresentationandGoingConcernConditionDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_BasisofPresentationandGoingConcernConditionDetailsLineItems" xlink:href="avco-20250331.xsd#avco_BasisofPresentationandGoingConcernConditionDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_BasisofPresentationandGoingConcernConditionDetailsLineItems_lbl" xml:lang="en-US">Basis of Presentation and Going Concern Condition [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BasisofPresentationandGoingConcernConditionDetailsLineItems" xlink:to="avco_BasisofPresentationandGoingConcernConditionDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegulatoryAssetDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegulatoryAssetDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RegulatoryAssetDomain_lbl" xml:lang="en-US">Regulatory Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegulatoryAssetDomain" xlink:to="us-gaap_RegulatoryAssetDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="avco-20250331.xsd#avco_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="avco_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="avco-20250331.xsd#avco_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentsDetailsTable" xlink:href="avco-20250331.xsd#avco_EquityMethodInvestmentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityMethodInvestmentsDetailsTable_lbl" xml:lang="en-US">Equity Method Investments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentsDetailsTable" xlink:to="avco_EquityMethodInvestmentsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl0" xml:lang="en-US">Equity Method Investments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US">Long-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradingActivityByTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradingActivityByTypeDomain_lbl" xml:lang="en-US">Trading Activity, by Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingActivityByTypeDomain" xlink:to="us-gaap_TradingActivityByTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ConvertibleNotePayableDetailsTable" xlink:href="avco-20250331.xsd#avco_ConvertibleNotePayableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ConvertibleNotePayableDetailsTable_lbl" xml:lang="en-US">Convertible Note Payable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ConvertibleNotePayableDetailsTable" xlink:to="avco_ConvertibleNotePayableDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl0" xml:lang="en-US">Convertible Note Payable [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_DerivativeLiabilityDetailsTable" xlink:href="avco-20250331.xsd#avco_DerivativeLiabilityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DerivativeLiabilityDetailsTable_lbl" xml:lang="en-US">Derivative Liability (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DerivativeLiabilityDetailsTable" xlink:to="avco_DerivativeLiabilityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesFairValueLineItems_lbl" xml:lang="en-US">Derivative Liability [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativesFairValueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_NotePayableNetDetailsTable" xlink:href="avco-20250331.xsd#avco_NotePayableNetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_NotePayableNetDetailsTable_lbl" xml:lang="en-US">Note Payable, Net (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_NotePayableNetDetailsTable" xlink:to="avco_NotePayableNetDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl1" xml:lang="en-US">Note Payable, Net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US">Credit Facility [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RelatedPartyTransactionsDetailsTable" xlink:href="avco-20250331.xsd#avco_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RelatedPartyTransactionsDetailsTable" xlink:to="avco_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_IncomeTaxesDetailsTable" xlink:href="avco-20250331.xsd#avco_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_IncomeTaxesDetailsTable" xlink:to="avco_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityDetailsTable" xlink:href="avco-20250331.xsd#avco_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityDetailsTable" xlink:to="avco_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_NoncontrollingInterestDetailsTable" xlink:href="avco-20250331.xsd#avco_NoncontrollingInterestDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_NoncontrollingInterestDetailsTable_lbl" xml:lang="en-US">Noncontrolling Interest (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_NoncontrollingInterestDetailsTable" xlink:to="avco_NoncontrollingInterestDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestLineItems_lbl" xml:lang="en-US">Noncontrolling Interest [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterestLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CondensedFinancialInformationoftheParentCompanyDetailsTable" xlink:href="avco-20250331.xsd#avco_CondensedFinancialInformationoftheParentCompanyDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CondensedFinancialInformationoftheParentCompanyDetailsTable_lbl" xml:lang="en-US">Condensed Financial Information of the Parent Company (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CondensedFinancialInformationoftheParentCompanyDetailsTable" xlink:to="avco_CondensedFinancialInformationoftheParentCompanyDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_lbl" xml:lang="en-US">Condensed Financial Information of the Parent Company [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" xml:lang="en-US">Supplier [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ConcentrationsDetailsTable" xlink:href="avco-20250331.xsd#avco_ConcentrationsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ConcentrationsDetailsTable_lbl" xml:lang="en-US">Concentrations (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ConcentrationsDetailsTable" xlink:to="avco_ConcentrationsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl0" xml:lang="en-US">Concentrations [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_SegmentInformationDetailsTable" xlink:href="avco-20250331.xsd#avco_SegmentInformationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SegmentInformationDetailsTable_lbl" xml:lang="en-US">Segment Information (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SegmentInformationDetailsTable" xlink:to="avco_SegmentInformationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SegmentInformationDetailsLineItems" xlink:href="avco-20250331.xsd#avco_SegmentInformationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SegmentInformationDetailsLineItems_lbl" xml:lang="en-US">Segment Information (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SegmentInformationDetailsLineItems" xlink:to="avco_SegmentInformationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationStatusDomain_lbl" xml:lang="en-US">Litigation Status [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_LitigationStatusDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CommitmentsandContingenciesDetailsTable" xlink:href="avco-20250331.xsd#avco_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommitmentsandContingenciesDetailsTable" xlink:to="avco_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsegmentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsegmentsDomain_lbl" xml:lang="en-US">Subsegments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsegmentsDomain" xlink:to="us-gaap_SubsegmentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SubsequentEventsDetailsTable" xlink:href="avco-20250331.xsd#avco_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SubsequentEventsDetailsTable" xlink:to="avco_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_AccruedAndUnpaidServicesCharge_lbl0" xml:lang="en-US">Represents the amount of accrued and unpaid services charge.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedAndUnpaidServicesCharge" xlink:to="avco_AccruedAndUnpaidServicesCharge_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_AccruedBusinessExpenseReimbursement_lbl0" xml:lang="en-US">Accrued business expense reimbursement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedBusinessExpenseReimbursement" xlink:to="avco_AccruedBusinessExpenseReimbursement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_AccruedLiabilitiesAndOtherPayablesRelatedParties_lbl0" xml:lang="en-US">The amount of accrued liabilities and other payables - related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedLiabilitiesAndOtherPayablesRelatedParties" xlink:to="avco_AccruedLiabilitiesAndOtherPayablesRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_AccruedPurchasePriceRelatedToEquityMethodInvestment_lbl0" xml:lang="en-US">Amount of accrued purchase price related to equity method investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedPurchasePriceRelatedToEquityMethodInvestment" xlink:to="avco_AccruedPurchasePriceRelatedToEquityMethodInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_AccruedRealPropertyCleaningServiceFee_lbl0" xml:lang="en-US">Accrued real property cleaning service fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedRealPropertyCleaningServiceFee" xlink:to="avco_AccruedRealPropertyCleaningServiceFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_AccruedResearchAndDevelopmentsFees_lbl0" xml:lang="en-US">Amount of accrued research and development fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedResearchAndDevelopmentsFees" xlink:to="avco_AccruedResearchAndDevelopmentsFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_AccruedTenantsImprovementReimbursement_lbl0" xml:lang="en-US">Accrued tenants&#8217; improvement reimbursement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedTenantsImprovementReimbursement" xlink:to="avco_AccruedTenantsImprovementReimbursement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty_lbl1" xml:lang="en-US">Advance from pending sale of noncontrolling interest - related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" xlink:to="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_AggregateOfCommonStock_lbl0" xml:lang="en-US">The shares of aggregate of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AggregateOfCommonStock" xlink:to="avco_AggregateOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable_lbl0" xml:lang="en-US">The amount of beneficial conversion feature related to convertible note payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable" xlink:to="avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage_lbl0" xml:lang="en-US">Percentage of equity in the acquiree held by additional acquiree.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage" xlink:to="avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_CashPercentage_lbl0" xml:lang="en-US">Percentage of cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CashPercentage" xlink:to="avco_CashPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee_lbl0" xml:lang="en-US">Common stock issued as convertible note payable commitment fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee" xlink:to="avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_CommonStockIssuedForAccruedLiabilities_lbl0" xml:lang="en-US">The amount of common stock issued for accrued liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommonStockIssuedForAccruedLiabilities" xlink:to="avco_CommonStockIssuedForAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_CommonStockOfAveragePrice_lbl0" xml:lang="en-US">Per share in average price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommonStockOfAveragePrice" xlink:to="avco_CommonStockOfAveragePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock_lbl0" xml:lang="en-US">Conversion of convertible note payable and accrued interest into common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock" xlink:to="avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_ConversionPricePercentage_lbl0" xml:lang="en-US">It represent conversion price percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ConversionPricePercentage" xlink:to="avco_ConversionPricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_DebtInstrumentConvertibleFloorPrice_lbl0" xml:lang="en-US">Debt Instrument Convertible floor price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DebtInstrumentConvertibleFloorPrice" xlink:to="avco_DebtInstrumentConvertibleFloorPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_DebtModificationCharge_lbl0" xml:lang="en-US">Debt modification charge.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DebtModificationCharge" xlink:to="avco_DebtModificationCharge_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_DebtModificationsAndExtinguishmentsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for debt modifications and extinguishments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DebtModificationsAndExtinguishmentsPolicyTextBlock" xlink:to="avco_DebtModificationsAndExtinguishmentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_DeemedContributionOnExchangeOfEquityInstruments_lbl0" xml:lang="en-US">The amount of deemed contribution on exchange of equity instruments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeemedContributionOnExchangeOfEquityInstruments" xlink:to="avco_DeemedContributionOnExchangeOfEquityInstruments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_DeferredFinancingCostsInAccruedLiabilities_lbl0" xml:lang="en-US">Deferred financing costs in accrued liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeferredFinancingCostsInAccruedLiabilities" xlink:to="avco_DeferredFinancingCostsInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_DeferredOfferingCostsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for deferred offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeferredOfferingCostsPolicyTextBlock" xlink:to="avco_DeferredOfferingCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_DeferredRentalIncomePolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for deferred rental income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeferredRentalIncomePolicyTextBlock" xlink:to="avco_DeferredRentalIncomePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_DeferredTaxAssetsPartnershipInvestment_lbl0" xml:lang="en-US">The amount of partnership investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeferredTaxAssetsPartnershipInvestment" xlink:to="avco_DeferredTaxAssetsPartnershipInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_DistributionOfEarningsFromEquityMethodInvestment_lbl0" xml:lang="en-US">Distribution of earnings from equity method investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DistributionOfEarningsFromEquityMethodInvestment" xlink:to="avco_DistributionOfEarningsFromEquityMethodInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_DrawDownFromLineOfCredit_lbl0" xml:lang="en-US">Draw Down From Line Of Credit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DrawDownFromLineOfCredit" xlink:to="avco_DrawDownFromLineOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_EquityInterestPercent_lbl0" xml:lang="en-US">The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityInterestPercent" xlink:to="avco_EquityInterestPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets_lbl0" xml:lang="en-US">Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in good wi.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets" xlink:to="avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_EquityMethodInvestmentPayableCurrent_lbl0" xml:lang="en-US">The amount of equity method investment payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentPayableCurrent" xlink:to="avco_EquityMethodInvestmentPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_EquityMethodInvestmentPlaceAndDateOfIncorporation_lbl0" xml:lang="en-US">The equity method investment place and date of incorporation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentPlaceAndDateOfIncorporation" xlink:to="avco_EquityMethodInvestmentPlaceAndDateOfIncorporation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets_lbl0" xml:lang="en-US">The Company&#8217;s interest in the net excess of Lab Services MSO&#8217;s fair value over carrying value w...</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets" xlink:to="avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_ExchangeRatioPerShare_lbl0" xml:lang="en-US">Exchange ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExchangeRatioPerShare" xlink:to="avco_ExchangeRatioPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_ExchangeShare_lbl0" xml:lang="en-US">Exchange share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExchangeShare" xlink:to="avco_ExchangeShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_FairMarketValues_lbl0" xml:lang="en-US">Amount of fair market value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FairMarketValues" xlink:to="avco_FairMarketValues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_FairMarketValuesOfGrantDates_lbl1" xml:lang="en-US">Represents the value of fair market values of grant dates.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FairMarketValuesOfGrantDates" xlink:to="avco_FairMarketValuesOfGrantDates_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_ImpairmentOfLaboratoryEquipment_lbl1" xml:lang="en-US">The amount of impairment of laboratory equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ImpairmentOfLaboratoryEquipment" xlink:to="avco_ImpairmentOfLaboratoryEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_IncreaseDecreaseInDeferredLeasingCosts_lbl0" xml:lang="en-US">Deferred leasing costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_IncreaseDecreaseInDeferredLeasingCosts" xlink:to="avco_IncreaseDecreaseInDeferredLeasingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise_lbl0" xml:lang="en-US">Initial fair value of derivative liability attributable to warrants issuance with fund raise.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise" xlink:to="avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for investment in real estate and depreciation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock" xlink:to="avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant_lbl0" xml:lang="en-US">Issuance of common stock upon cashless exercise of stock warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant" xlink:to="avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_LabServicesMSOsNetIncomeAttributableToTheCompany_lbl1" xml:lang="en-US">Lab Services MSO&#8217;s net income attributable to the Company.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LabServicesMSOsNetIncomeAttributableToTheCompany" xlink:to="avco_LabServicesMSOsNetIncomeAttributableToTheCompany_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_NoncontrollingInterestPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for noncontrolling interest policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_NoncontrollingInterestPolicyTextBlock" xlink:to="avco_NoncontrollingInterestPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_OfferingCost_lbl0" xml:lang="en-US">Offering Cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OfferingCost" xlink:to="avco_OfferingCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_OtherOperatingExpense_lbl0" xml:lang="en-US">Other operating expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OtherOperatingExpense" xlink:to="avco_OtherOperatingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_PaymentForCommission_lbl0" xml:lang="en-US">Represents the amount of payment for commission.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PaymentForCommission" xlink:to="avco_PaymentForCommission_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_PaymentOfEquityInvestment_lbl0" xml:lang="en-US">The amount of payment of equity investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PaymentOfEquityInvestment" xlink:to="avco_PaymentOfEquityInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_PaymentsOfConvertibleDebtIssuanceCosts_lbl0" xml:lang="en-US">Payments of convertible debt issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PaymentsOfConvertibleDebtIssuanceCosts" xlink:to="avco_PaymentsOfConvertibleDebtIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_PercentageOfCommonStockIssuedAndOutstanding_lbl0" xml:lang="en-US">The percentage of common stock issued and outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PercentageOfCommonStockIssuedAndOutstanding" xlink:to="avco_PercentageOfCommonStockIssuedAndOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_PercentageOfPretaxProfit_lbl0" xml:lang="en-US">Percentage of pre-tax profit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PercentageOfPretaxProfit" xlink:to="avco_PercentageOfPretaxProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_PercentageOfPromissoryNotes_lbl0" xml:lang="en-US">Percentage promissory notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PercentageOfPromissoryNotes" xlink:to="avco_PercentageOfPromissoryNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_PreTaxProfit_lbl0" xml:lang="en-US">The amount of pre-tax profit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PreTaxProfit" xlink:to="avco_PreTaxProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_PrepaidProfessionalFees_lbl0" xml:lang="en-US">The amount of prepaid professional fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrepaidProfessionalFees" xlink:to="avco_PrepaidProfessionalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants_lbl0" xml:lang="en-US">Proceeds from issuance of convertible debt and warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants" xlink:to="avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_PurchasePrice_lbl0" xml:lang="en-US">Represent the amount of purchase price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PurchasePrice" xlink:to="avco_PurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_PurchasePriceOfConvertibleNote_lbl0" xml:lang="en-US">Purchase price of convertible note.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PurchasePriceOfConvertibleNote" xlink:to="avco_PurchasePriceOfConvertibleNote_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_PurchasedServicesPercentage_lbl0" xml:lang="en-US">Purchased services percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PurchasedServicesPercentage" xlink:to="avco_PurchasedServicesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_RealPropertyRentalRevenuePolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for real property rental revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RealPropertyRentalRevenuePolicyTextBlock" xlink:to="avco_RealPropertyRentalRevenuePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_ReceivableRelatedToSaleOfEquityMethodInvestment_lbl0" xml:lang="en-US">Receivable related to sale of equity method investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ReceivableRelatedToSaleOfEquityMethodInvestment" xlink:to="avco_ReceivableRelatedToSaleOfEquityMethodInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment_lbl0" xml:lang="en-US">Reclassification of advances for equity interest purchase to equity method investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment" xlink:to="avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty_lbl0" xml:lang="en-US">Reclassification of Line of Credit to advance from related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty" xlink:to="avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty_lbl0" xml:lang="en-US">Amount of reclassification of related party loan payable and accrued expenses to advance from related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty" xlink:to="avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_RedemptionNetOfPayablesDueToLabServices_lbl0" xml:lang="en-US">Amount of redemption, net of payables due to lab services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RedemptionNetOfPayablesDueToLabServices" xlink:to="avco_RedemptionNetOfPayablesDueToLabServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_RegisteredCapitalPercentage_lbl0" xml:lang="en-US">Percentage of registered capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RegisteredCapitalPercentage" xlink:to="avco_RegisteredCapitalPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_RegularPaymentsOnEquityInvestments_lbl0" xml:lang="en-US">Regular payments on equity investments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RegularPaymentsOnEquityInvestments" xlink:to="avco_RegularPaymentsOnEquityInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment_lbl0" xml:lang="en-US">Related party payable extinguished upon sale of equity method investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment" xlink:to="avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets_lbl0" xml:lang="en-US">Represents percentage of net assets of subsidiary exceed.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets" xlink:to="avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed_lbl0" xml:lang="en-US">Represents restricted net assets of the company&apos;s subsidiary did not exceed consolidated net assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed" xlink:to="avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_ReverseStockSplitPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for reverse stock split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ReverseStockSplitPolicyTextBlock" xlink:to="avco_ReverseStockSplitPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities_lbl0" xml:lang="en-US">Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities" xlink:to="avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment_lbl0" xml:lang="en-US">Convertible Preferred Stock extinguished related to sale of equity method investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment" xlink:to="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments_lbl0" xml:lang="en-US">The number of series B convertible preferred stock extinguished related to sale of equity method investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments" xlink:to="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment_lbl0" xml:lang="en-US">Convertible Preferred Stock extinguished related to sale of equity method investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment" xlink:to="avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock_lbl0" xml:lang="en-US">Series D Convertible Preferred Stock issued in exchange of Series A Convertible Preferred Stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" xlink:to="avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_SettlementsOfDerivativeLiability_lbl0" xml:lang="en-US">Settlement of derivative liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SettlementsOfDerivativeLiability" xlink:to="avco_SettlementsOfDerivativeLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues_lbl0" xml:lang="en-US">Weighted average exercise price, vested.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues" xlink:to="avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_StatutoryReserve_lbl0" xml:lang="en-US">Statutory reserve.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReserve" xlink:to="avco_StatutoryReserve_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_StatutoryReserveAndRestrictedNetAssetsTextBlock_lbl0" xml:lang="en-US">Statutory reserve and restricted net assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReserveAndRestrictedNetAssetsTextBlock" xlink:to="avco_StatutoryReserveAndRestrictedNetAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_StatutoryReservePercent_lbl0" xml:lang="en-US">Percentage of statutory reserve.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReservePercent" xlink:to="avco_StatutoryReservePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock_lbl0" xml:lang="en-US">Number of shares series D convertible preferred stock issued in exchange of series A convertible preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" xlink:to="avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet_lbl0" xml:lang="en-US">The shares of sale of common stock, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet" xlink:to="avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet_lbl0" xml:lang="en-US">The amount of stock issued during period value sale of common stock net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet" xlink:to="avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock_lbl0" xml:lang="en-US">Value of series D convertible preferred stock issued in exchange of series A convertible preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" xlink:to="avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments_lbl0" xml:lang="en-US">The amount of shares issued for adjustments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments" xlink:to="avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_TradingPrice_lbl0" xml:lang="en-US">Trading price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_TradingPrice" xlink:to="avco_TradingPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_WarrantsIssuedAsConvertibleNotePayableFindersFee_lbl0" xml:lang="en-US">Amount of Warrants issued as convertible note payable finder&#8217;s fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WarrantsIssuedAsConvertibleNotePayableFindersFee" xlink:to="avco_WarrantsIssuedAsConvertibleNotePayableFindersFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_WarrantsIssuedWithConvertibleNotePayable_lbl0" xml:lang="en-US">Warrants issued with convertible note payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WarrantsIssuedWithConvertibleNotePayable" xlink:to="avco_WarrantsIssuedWithConvertibleNotePayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount_lbl0" xml:lang="en-US">Amount of warrants issued with convertible note payable recorded as debt discount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount" xlink:to="avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount_lbl0" xml:lang="en-US">Warrants issued with convertible note payable recorded as debt discount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount" xlink:to="avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_WarrantsOfCashlessExercised_lbl0" xml:lang="en-US">The number of shares in warrants in cash less exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WarrantsOfCashlessExercised" xlink:to="avco_WarrantsOfCashlessExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_WorkingCapital_lbl0" xml:lang="en-US">Amount of member capital in limited liability company (LLC).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WorkingCapital" xlink:to="avco_WorkingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_WorkingCapitalDeficit_lbl0" xml:lang="en-US">Working capital deficit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WorkingCapitalDeficit" xlink:to="avco_WorkingCapitalDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_RealPropertyOperatingMember_lbl0" xml:lang="en-US">Information by business segments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RealPropertyOperatingMember" xlink:to="avco_RealPropertyOperatingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Other Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ConvertibleDebtNoteMember_lbl0" xml:lang="en-US">Convertible Debt Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ConvertibleDebtNoteMember" xlink:to="avco_ConvertibleDebtNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CashPaidForAbstract0_lbl0" xml:lang="en-US">Cash Paid For Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CashPaidForAbstract0" xlink:to="avco_CashPaidForAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant_lbl1" xml:lang="en-US">Issuance Of Common Stock Upon Cashless Exercise Of Stock Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant" xlink:to="avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SeriesAConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series AConvertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesAConvertiblePreferredStockMember" xlink:to="avco_SeriesAConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl0" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl0" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_MastHillThirdPartyMember_lbl0" xml:lang="en-US">Mast Hill Third Party Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MastHillThirdPartyMember" xlink:to="avco_MastHillThirdPartyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AccruedRealPropertyCleaningServiceFee_lbl1" xml:lang="en-US">Accrued Real Property Cleaning Service Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedRealPropertyCleaningServiceFee" xlink:to="avco_AccruedRealPropertyCleaningServiceFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OfferingCost_lbl1" xml:lang="en-US">Offering Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OfferingCost" xlink:to="avco_OfferingCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AccruedLiabilitiesAndOtherPayablesRelatedParties_lbl1" xml:lang="en-US">Accrued Liabilities And Other Payables Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedLiabilitiesAndOtherPayablesRelatedParties" xlink:to="avco_AccruedLiabilitiesAndOtherPayablesRelatedParties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl0" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AvalonLabMember_lbl0" xml:lang="en-US">Avalon Lab Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonLabMember" xlink:to="avco_AvalonLabMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfSummarizedFinancialInformationAsProvidedToTheCompanyByTheInvesteeAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfSummarizedFinancialInformationAsProvidedToTheCompanyByTheInvesteeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfSummarizedFinancialInformationAsProvidedToTheCompanyByTheInvesteeAbstract_lbl" xml:lang="en-US">Schedule Of Summarized Financial Information As Provided To The Company By The Investee Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfSummarizedFinancialInformationAsProvidedToTheCompanyByTheInvesteeAbstract" xlink:to="avco_ScheduleOfSummarizedFinancialInformationAsProvidedToTheCompanyByTheInvesteeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DebtInstrumentConvertibleFloorPrice_lbl1" xml:lang="en-US">Debt Instrument Convertible Floor Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DebtInstrumentConvertibleFloorPrice" xlink:to="avco_DebtInstrumentConvertibleFloorPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl2" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableInvestmentSale_lbl0" xml:lang="en-US">Receivable, Investment, Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableInvestmentSale" xlink:to="us-gaap_ReceivableInvestmentSale_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ExercisePriceRangeFiveMember_lbl0" xml:lang="en-US">Exercise Price Range Five Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeFiveMember" xlink:to="avco_ExercisePriceRangeFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_FirstFireMember_lbl0" xml:lang="en-US">First Fire Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FirstFireMember" xlink:to="avco_FirstFireMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_lbl0" xml:lang="en-US">Equity Method Investment, Underlying Equity in Net Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:to="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl3" xml:lang="en-US">Asset Impairment Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealEstatePolicyTextBlock_lbl0" xml:lang="en-US">Real Estate, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstatePolicyTextBlock" xlink:to="us-gaap_RealEstatePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_FiveYearAnniversaryMember_lbl0" xml:lang="en-US">Five Year Anniversary Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FiveYearAnniversaryMember" xlink:to="avco_FiveYearAnniversaryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DrawDownFromLineOfCredit_lbl1" xml:lang="en-US">Draw Down From Line Of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DrawDownFromLineOfCredit" xlink:to="avco_DrawDownFromLineOfCredit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl0" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl0" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl1" xml:lang="en-US">Common Stock, Convertible, Conversion Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AggregateOfCommonStock_lbl1" xml:lang="en-US">Aggregate Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AggregateOfCommonStock" xlink:to="avco_AggregateOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl0" xml:lang="en-US">Treasury Stock, Common [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_LaboratoryServicesMSOLLCMember_lbl0" xml:lang="en-US">Laboratory Services MSOLLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LaboratoryServicesMSOLLCMember" xlink:to="avco_LaboratoryServicesMSOLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_MastHillFundLPMember_lbl0" xml:lang="en-US">Mast Hill Fund LPMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MastHillFundLPMember" xlink:to="avco_MastHillFundLPMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty_lbl1" xml:lang="en-US">Reclassification Of Line Of Credit To Advance From Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty" xlink:to="avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SeriesBConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series BConvertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesBConvertiblePreferredStockMember" xlink:to="avco_SeriesBConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl1" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OneCustomerMember_lbl0" xml:lang="en-US">One Customer Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OneCustomerMember" xlink:to="avco_OneCustomerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl1" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedAtCost_lbl0" xml:lang="en-US">Investment Owned, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtCost" xlink:to="us-gaap_InvestmentOwnedAtCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EpiconBiotechCoLtdMember_lbl1" xml:lang="en-US">Epicon Biotech Co Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EpiconBiotechCoLtdMember" xlink:to="avco_EpiconBiotechCoLtdMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl1" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DebtModificationsAndExtinguishmentsPolicyTextBlock_lbl1" xml:lang="en-US">Debt Modifications And Extinguishments Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DebtModificationsAndExtinguishmentsPolicyTextBlock" xlink:to="avco_DebtModificationsAndExtinguishmentsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl1" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationReserve_lbl0" xml:lang="en-US">Estimated Litigation Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationReserve" xlink:to="us-gaap_LitigationReserve_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_LaboratoryServicesMSOMember_lbl0" xml:lang="en-US">Laboratory Services MSOMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LaboratoryServicesMSOMember" xlink:to="avco_LaboratoryServicesMSOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_WarrantsOutstandingMember_lbl0" xml:lang="en-US">Warrants Outstanding Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WarrantsOutstandingMember" xlink:to="avco_WarrantsOutstandingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_NoncontrollingInterestPolicyTextBlock_lbl1" xml:lang="en-US">Noncontrolling Interest Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_NoncontrollingInterestPolicyTextBlock" xlink:to="avco_NoncontrollingInterestPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense Other, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfAmortizationPaymentsInCashAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfAmortizationPaymentsInCashAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfAmortizationPaymentsInCashAbstract_lbl" xml:lang="en-US">Schedule Of Amortization Payments In Cash Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfAmortizationPaymentsInCashAbstract" xlink:to="avco_ScheduleOfAmortizationPaymentsInCashAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl0" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl0" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OptionsToPurchaseCommonStockMember_lbl0" xml:lang="en-US">Options To Purchase Common Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OptionsToPurchaseCommonStockMember" xlink:to="avco_OptionsToPurchaseCommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherRestrictedAssets_lbl0" xml:lang="en-US">Other Restricted Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherRestrictedAssets" xlink:to="us-gaap_OtherRestrictedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AssetAndLiabilityAccountsMember_lbl0" xml:lang="en-US">Asset And Liability Accounts Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AssetAndLiabilityAccountsMember" xlink:to="avco_AssetAndLiabilityAccountsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl0" xml:lang="en-US">Cash Acquired from Acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DeferredRentalIncomePolicyTextBlock_lbl1" xml:lang="en-US">Deferred Rental Income Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeferredRentalIncomePolicyTextBlock" xlink:to="avco_DeferredRentalIncomePolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember_lbl0" xml:lang="en-US">Avalon Shanghai Healthcare Technology Co Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember" xlink:to="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl0" xml:lang="en-US">Debt Instrument, Unamortized Discount, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments_lbl1" xml:lang="en-US">Series BConvertible Preferred Stock Extinguished Related To Sale Of Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments" xlink:to="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl0" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl1" xml:lang="en-US">Convertible Debt [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock_lbl1" xml:lang="en-US">Series DConvertible Preferred Stock Issued In Exchange Of Series AConvertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" xlink:to="avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_WorkingCapitalDeficit_lbl1" xml:lang="en-US">Working Capital Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WorkingCapitalDeficit" xlink:to="avco_WorkingCapitalDeficit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_InvestmentInLaboratoryServicesMSOLLCMember_lbl0" xml:lang="en-US">Investment In Laboratory Services MSOLLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_InvestmentInLaboratoryServicesMSOLLCMember" xlink:to="avco_InvestmentInLaboratoryServicesMSOLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RothCapitalPartnersLLCMember_lbl0" xml:lang="en-US">Roth Capital Partners LLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RothCapitalPartnersLLCMember" xlink:to="avco_RothCapitalPartnersLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_FormerDirectorAndFormerCochiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Former Director And Former Cochief Executive Officer Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FormerDirectorAndFormerCochiefExecutiveOfficerMember" xlink:to="avco_FormerDirectorAndFormerCochiefExecutiveOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayable_lbl0" xml:lang="en-US">Loans Payable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_WeightedAverageCommonSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Common Shares Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WeightedAverageCommonSharesOutstandingAbstract" xlink:to="avco_WeightedAverageCommonSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise_lbl1" xml:lang="en-US">Initial Fair Value Of Derivative Liability Attributable To Warrants Issuance With Fund Raise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise" xlink:to="avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DeferredTaxAssetsPartnershipInvestment_lbl1" xml:lang="en-US">Deferred Tax Assets Partnership Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeferredTaxAssetsPartnershipInvestment" xlink:to="avco_DeferredTaxAssetsPartnershipInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PercentageOfPretaxProfit_lbl1" xml:lang="en-US">Percentage Of Pretax Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PercentageOfPretaxProfit" xlink:to="avco_PercentageOfPretaxProfit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl0" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebt_lbl0" xml:lang="en-US">Secured Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebt" xlink:to="us-gaap_SecuredDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_StatutoryReserveAndRestrictedNetAssetsTextBlock_lbl1" xml:lang="en-US">Statutory Reserve And Restricted Net Assets Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReserveAndRestrictedNetAssetsTextBlock" xlink:to="avco_StatutoryReserveAndRestrictedNetAssetsTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl1" xml:lang="en-US">Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RentalIncomeNonoperating_lbl0" xml:lang="en-US">Rental Income, Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RentalIncomeNonoperating" xlink:to="us-gaap_RentalIncomeNonoperating_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_findersFeeMember_lbl0" xml:lang="en-US">finders Fee Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_findersFeeMember" xlink:to="avco_findersFeeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PaymentForCommission_lbl1" xml:lang="en-US">Payment For Commission</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PaymentForCommission" xlink:to="avco_PaymentForCommission_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl0" xml:lang="en-US">Measurement Input, Discount Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl0" xml:lang="en-US">Costs and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_June52024FiveyearAnniversaryMember_lbl0" xml:lang="en-US">June52024 Fiveyear Anniversary Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_June52024FiveyearAnniversaryMember" xlink:to="avco_June52024FiveyearAnniversaryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment_lbl1" xml:lang="en-US">Related Party Payable Extinguished Upon Sale Of Equity Method Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment" xlink:to="avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl0" xml:lang="en-US">Previously Reported [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl0" xml:lang="en-US">Warrant or Right, Reason for Issuance, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ConversionPricePercentage_lbl1" xml:lang="en-US">Conversion Price Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ConversionPricePercentage" xlink:to="avco_ConversionPricePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PromissoryNoteMember_lbl0" xml:lang="en-US">Promissory Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PromissoryNoteMember" xlink:to="avco_PromissoryNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock_lbl1" xml:lang="en-US">Conversion Of Convertible Note Payable And Accrued Interest Into Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock" xlink:to="avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentContinuingOperationsMember_lbl0" xml:lang="en-US">Continuing Operations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentContinuingOperationsMember" xlink:to="us-gaap_SegmentContinuingOperationsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionPremium_lbl0" xml:lang="en-US">Preferred Stock Redemption Premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionPremium" xlink:to="us-gaap_PreferredStockRedemptionPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SettlementsOfDerivativeLiability_lbl1" xml:lang="en-US">Settlements Of Derivative Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SettlementsOfDerivativeLiability" xlink:to="avco_SettlementsOfDerivativeLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl1" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OctoberTwoThousandTwentyThreeConvertibleNotesMember_lbl0" xml:lang="en-US">October Two Thousand Twenty Three Convertible Notes Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OctoberTwoThousandTwentyThreeConvertibleNotesMember" xlink:to="avco_OctoberTwoThousandTwentyThreeConvertibleNotesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty_lbl2" xml:lang="en-US">Advance From Pending Sale Of Noncontrolling Interest Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" xlink:to="avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AccruedTenantsImprovementReimbursement_lbl1" xml:lang="en-US">Accrued Tenants Improvement Reimbursement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedTenantsImprovementReimbursement" xlink:to="avco_AccruedTenantsImprovementReimbursement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_July2023ConvertibleNoteMember_lbl0" xml:lang="en-US">July2023 Convertible Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_July2023ConvertibleNoteMember" xlink:to="avco_July2023ConvertibleNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalReserveBankStock_lbl0" xml:lang="en-US">Federal Reserve Bank Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalReserveBankStock" xlink:to="us-gaap_FederalReserveBankStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets_lbl1" xml:lang="en-US">Equity Method Investment Difference Between Carrying Amount Identifiable Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets" xlink:to="avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl0" xml:lang="en-US">Debt Conversion, Converted Instrument, Warrants or Options Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NontradeReceivables_lbl0" xml:lang="en-US">Nontrade Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NontradeReceivables" xlink:to="us-gaap_NontradeReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DebtModificationCharge_lbl1" xml:lang="en-US">Debt Modification Charge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DebtModificationCharge" xlink:to="avco_DebtModificationCharge_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl0" xml:lang="en-US">Lease, Cost [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment_lbl1" xml:lang="en-US">Series BConvertible Preferred Stock Extinguished Related To Sale Of Equity Method Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment" xlink:to="avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage_lbl1" xml:lang="en-US">Business Combination Step Acquisitions Additional Acquiree Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage" xlink:to="avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherDepreciationAndAmortization_lbl0" xml:lang="en-US">Other Depreciation and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDepreciationAndAmortization" xlink:to="us-gaap_OtherDepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl1" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl0" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership, Business Purpose</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ExercisePriceRangeTwoMember_lbl2" xml:lang="en-US">Exercise Price Range Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeTwoMember" xlink:to="avco_ExercisePriceRangeTwoMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl0" xml:lang="en-US">Repayments of Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_MarchFiveTwoThousandTwentyFiveMember_lbl0" xml:lang="en-US">March Five Two Thousand Twenty Five Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MarchFiveTwoThousandTwentyFiveMember" xlink:to="avco_MarchFiveTwoThousandTwentyFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayableCurrent_lbl0" xml:lang="en-US">Other Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayableCurrent" xlink:to="us-gaap_OtherNotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealEstateInvestmentPropertyAtCost_lbl0" xml:lang="en-US">Real Estate Investment Property, at Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateInvestmentPropertyAtCost" xlink:to="us-gaap_RealEstateInvestmentPropertyAtCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl0" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AprilFiveTwoThousandTwentyFiveMember_lbl0" xml:lang="en-US">April Five Two Thousand Twenty Five Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AprilFiveTwoThousandTwentyFiveMember" xlink:to="avco_AprilFiveTwoThousandTwentyFiveMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock_lbl1" xml:lang="en-US">Investment In Real Estate And Depreciation Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock" xlink:to="avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PercentageOfCommonStockIssuedAndOutstanding_lbl1" xml:lang="en-US">Percentage Of Common Stock Issued And Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PercentageOfCommonStockIssuedAndOutstanding" xlink:to="avco_PercentageOfCommonStockIssuedAndOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_TwoCustomersMember_lbl0" xml:lang="en-US">Two Customers Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_TwoCustomersMember" xlink:to="avco_TwoCustomersMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfInvestmentInRealEstateAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfInvestmentInRealEstateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfInvestmentInRealEstateAbstract_lbl" xml:lang="en-US">Schedule Of Investment In Real Estate Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfInvestmentInRealEstateAbstract" xlink:to="avco_ScheduleOfInvestmentInRealEstateAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl1" xml:lang="en-US">Notes Payable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl1" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DecemberFiveTwoThousandTwentyFourMember_lbl0" xml:lang="en-US">December Five Two Thousand Twenty Four Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DecemberFiveTwoThousandTwentyFourMember" xlink:to="avco_DecemberFiveTwoThousandTwentyFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_October92023FiveYearAnniversaryMember_lbl0" xml:lang="en-US">October92023 Five Year Anniversary Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_October92023FiveYearAnniversaryMember" xlink:to="avco_October92023FiveYearAnniversaryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl0" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl0" xml:lang="en-US">Debt Instrument, Fee Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_WaiverFeeMember_lbl0" xml:lang="en-US">Waiver Fee Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WaiverFeeMember" xlink:to="avco_WaiverFeeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfNonvestedStockOptionsGrantedAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfNonvestedStockOptionsGrantedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfNonvestedStockOptionsGrantedAbstract_lbl" xml:lang="en-US">Schedule Of Nonvested Stock Options Granted Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfNonvestedStockOptionsGrantedAbstract" xlink:to="avco_ScheduleOfNonvestedStockOptionsGrantedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CommonStockOfAveragePrice_lbl1" xml:lang="en-US">Common Stock Of Average Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommonStockOfAveragePrice" xlink:to="avco_CommonStockOfAveragePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl0" xml:lang="en-US">Stock Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_lbl1" xml:lang="en-US">Statutory Accounting Practices, Statutory Capital and Surplus, Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:to="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_FairMarketValuesOfGrantDates_lbl2" xml:lang="en-US">Fair Market Values Of Grant Dates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FairMarketValuesOfGrantDates" xlink:to="avco_FairMarketValuesOfGrantDates_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PurchasePriceOfConvertibleNote_lbl1" xml:lang="en-US">Purchase Price Of Convertible Note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PurchasePriceOfConvertibleNote" xlink:to="avco_PurchasePriceOfConvertibleNote_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl0" xml:lang="en-US">Conversion of Stock, Amount Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl0" xml:lang="en-US">Payments for Repurchase of Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfCommonStockIssuableUponExerciseOfWarrantsOutstandingAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfCommonStockIssuableUponExerciseOfWarrantsOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfCommonStockIssuableUponExerciseOfWarrantsOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Common Stock Issuable Upon Exercise Of Warrants Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfCommonStockIssuableUponExerciseOfWarrantsOutstandingAbstract" xlink:to="avco_ScheduleOfCommonStockIssuableUponExerciseOfWarrantsOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfReportableBusinessSegmentsAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfReportableBusinessSegmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfReportableBusinessSegmentsAbstract_lbl" xml:lang="en-US">Schedule Of Reportable Business Segments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfReportableBusinessSegmentsAbstract" xlink:to="avco_ScheduleOfReportableBusinessSegmentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CorporateOtherMember_lbl1" xml:lang="en-US">Corporate Other Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CorporateOtherMember" xlink:to="avco_CorporateOtherMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl1" xml:lang="en-US">Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl0" xml:lang="en-US">Debt Issuance Costs, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl0" xml:lang="en-US">Liabilities Subject to Compromise, Early Contract Termination Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:to="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonUnitOutstanding_lbl0" xml:lang="en-US">Common Unit, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonUnitOutstanding" xlink:to="us-gaap_CommonUnitOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SettledLitigationMember_lbl1" xml:lang="en-US">Settled Litigation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettledLitigationMember" xlink:to="us-gaap_SettledLitigationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl1" xml:lang="en-US">Equity Method Investment, Amount Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_July62023FiveYearAnniversaryMember_lbl0" xml:lang="en-US">July62023 Five Year Anniversary Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_July62023FiveYearAnniversaryMember" xlink:to="avco_July62023FiveYearAnniversaryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl0" xml:lang="en-US">Debt Instrument, Issued, Principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RealPropertyRentalRevenuePolicyTextBlock_lbl1" xml:lang="en-US">Real Property Rental Revenue Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RealPropertyRentalRevenuePolicyTextBlock" xlink:to="avco_RealPropertyRentalRevenuePolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl1" xml:lang="en-US">Reclassifications of Temporary to Permanent Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Repayments of Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_lbl0" xml:lang="en-US">Interest Expense, Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl0" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl2" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SeriesBStatedValueMember_lbl0" xml:lang="en-US">Series BStated Value Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesBStatedValueMember" xlink:to="avco_SeriesBStatedValueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityMember_lbl0" xml:lang="en-US">Liability [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityMember" xlink:to="us-gaap_LiabilityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PreTaxProfit_lbl1" xml:lang="en-US">Pre Tax Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PreTaxProfit" xlink:to="avco_PreTaxProfit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_NetLossPerCommonShareAttributableToAvalonGlobocareCorpCommonShareholdersAbstract_lbl0" xml:lang="en-US">Net Loss Per Common Share Attributable To Avalon Globocare Corp Common Shareholders Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_NetLossPerCommonShareAttributableToAvalonGlobocareCorpCommonShareholdersAbstract" xlink:to="avco_NetLossPerCommonShareAttributableToAvalonGlobocareCorpCommonShareholdersAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Shareholders&apos; Equity and Share-Based Payments [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayable_lbl0" xml:lang="en-US">Other Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl0" xml:lang="en-US">Increase (Decrease) in Security Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ExchangeRatioPerShare_lbl1" xml:lang="en-US">Exchange Ratio Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExchangeRatioPerShare" xlink:to="avco_ExchangeRatioPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0" xml:lang="en-US">Employee Benefits and Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromPaymentsToMinorityShareholders_lbl0" xml:lang="en-US">Proceeds from (Payments to) Noncontrolling Interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:to="us-gaap_ProceedsFromPaymentsToMinorityShareholders_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_WarrantsIssuedWithConvertibleNotePayable_lbl1" xml:lang="en-US">Warrants Issued With Convertible Note Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WarrantsIssuedWithConvertibleNotePayable" xlink:to="avco_WarrantsIssuedWithConvertibleNotePayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl0" xml:lang="en-US">Taxes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityMethodInvestmentPlaceAndDateOfIncorporation_lbl1" xml:lang="en-US">Equity Method Investment Place And Date Of Incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentPlaceAndDateOfIncorporation" xlink:to="avco_EquityMethodInvestmentPlaceAndDateOfIncorporation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet_lbl1" xml:lang="en-US">Stock Issued During Period Shares Sale Of Common Stock Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet" xlink:to="avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl0" xml:lang="en-US">Repayments of Lines of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PurchasePrice_lbl1" xml:lang="en-US">Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PurchasePrice" xlink:to="avco_PurchasePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OtherOperatingExpensesAbstract_lbl0" xml:lang="en-US">Other Operating Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OtherOperatingExpensesAbstract" xlink:to="avco_OtherOperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0" xml:lang="en-US">Payments of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_JuneTwentyThousandTwentyFourConvertibleNoteMember_lbl0" xml:lang="en-US">June Twenty Thousand Twenty Four Convertible Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_JuneTwentyThousandTwentyFourConvertibleNoteMember" xlink:to="avco_JuneTwentyThousandTwentyFourConvertibleNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl0" xml:lang="en-US">Proceeds from Issuance of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl2" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfConvertibleNotePayableAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfConvertibleNotePayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfConvertibleNotePayableAbstract_lbl" xml:lang="en-US">Schedule Of Convertible Note Payable Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfConvertibleNotePayableAbstract" xlink:to="avco_ScheduleOfConvertibleNotePayableAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OtherOperatingExpense_lbl1" xml:lang="en-US">Other Operating Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OtherOperatingExpense" xlink:to="avco_OtherOperatingExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount_lbl1" xml:lang="en-US">Warrants Issued With Convertible Note Payable Recorded As Debt Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount" xlink:to="avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_StatutoryReserve_lbl1" xml:lang="en-US">Statutory Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReserve" xlink:to="avco_StatutoryReserve_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl0" xml:lang="en-US">Labor and Related Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl0" xml:lang="en-US">Advertising Cost [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_lbl0" xml:lang="en-US">Deferred Tax Asset, Interest Carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl0" xml:lang="en-US">Interest Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl0" xml:lang="en-US">Business Combination, Voting Equity Interest Acquired, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl2" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl0" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_WarrantsOfCashlessExercised_lbl1" xml:lang="en-US">Warrants Of Cashless Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WarrantsOfCashlessExercised" xlink:to="avco_WarrantsOfCashlessExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_MembershipInterestPurchaseAgreementMember_lbl0" xml:lang="en-US">Membership Interest Purchase Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MembershipInterestPurchaseAgreementMember" xlink:to="avco_MembershipInterestPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl0" xml:lang="en-US">Debt Instrument, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashContributionExpense_lbl0" xml:lang="en-US">Noncash Contribution Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashContributionExpense" xlink:to="us-gaap_NoncashContributionExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_FirstfireMember_lbl0" xml:lang="en-US">Firstfire Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FirstfireMember" xlink:to="avco_FirstfireMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl1" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DrZhouMember_lbl0" xml:lang="en-US">Dr Zhou Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DrZhouMember" xlink:to="avco_DrZhouMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PreFundedWarrantsMember_lbl1" xml:lang="en-US">Pre Funded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PreFundedWarrantsMember" xlink:to="avco_PreFundedWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl0" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl1" xml:lang="en-US">Operating Costs and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DeferredOfferingCostsPolicyTextBlock_lbl1" xml:lang="en-US">Deferred Offering Costs Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeferredOfferingCostsPolicyTextBlock" xlink:to="avco_DeferredOfferingCostsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PercentageOfPromissoryNotes_lbl1" xml:lang="en-US">Percentage Of Promissory Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PercentageOfPromissoryNotes" xlink:to="avco_PercentageOfPromissoryNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl2" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfEquityMethodInvestmentAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfEquityMethodInvestmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfEquityMethodInvestmentAbstract_lbl" xml:lang="en-US">Schedule Of Equity Method Investment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfEquityMethodInvestmentAbstract" xlink:to="avco_ScheduleOfEquityMethodInvestmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_FebruaryFiveTwoThousandTwentyFiveMember_lbl0" xml:lang="en-US">February Five Two Thousand Twenty Five Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FebruaryFiveTwoThousandTwentyFiveMember" xlink:to="avco_FebruaryFiveTwoThousandTwentyFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestments_lbl4" xml:lang="en-US">Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl1" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredAdvertisingCosts_lbl0" xml:lang="en-US">Deferred Advertising Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredAdvertisingCosts" xlink:to="us-gaap_DeferredAdvertisingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPriceIncrease_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPriceIncrease" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Real Estate Properties [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" xlink:to="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl2" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AccruedResearchAndDevelopmentsFees_lbl1" xml:lang="en-US">Accrued Research And Developments Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedResearchAndDevelopmentsFees" xlink:to="avco_AccruedResearchAndDevelopmentsFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl2" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries_lbl0" xml:lang="en-US">Deferred Tax Liability Not Recognized, Events that Would Cause Temporary Difference to be Taxable, Undistributed Earnings of Foreign Subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries" xlink:to="us-gaap_DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_lbl0" xml:lang="en-US">Debt Conversion, Converted Instrument, Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl0" xml:lang="en-US">Equity Method Investments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DeferredFinancingCostsInAccruedLiabilities_lbl1" xml:lang="en-US">Deferred Financing Costs In Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeferredFinancingCostsInAccruedLiabilities" xlink:to="avco_DeferredFinancingCostsInAccruedLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValueAddedTaxReceivable_lbl1" xml:lang="en-US">Value Added Tax Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValueAddedTaxReceivable" xlink:to="us-gaap_ValueAddedTaxReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl1" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_InvestmentInEpiconBiotechCoLtdMember_lbl0" xml:lang="en-US">Investment In Epicon Biotech Co Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_InvestmentInEpiconBiotechCoLtdMember" xlink:to="avco_InvestmentInEpiconBiotechCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_March2024ConvertibleNoteMember_lbl0" xml:lang="en-US">March2024 Convertible Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_March2024ConvertibleNoteMember" xlink:to="avco_March2024ConvertibleNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl1" xml:lang="en-US">Convertible Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl1" xml:lang="en-US">Stockholders&apos; Equity, Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandImprovementsMember_lbl0" xml:lang="en-US">Land Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandImprovementsMember" xlink:to="us-gaap_LandImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl1" xml:lang="en-US">Equity Method Investment, Realized Gain (Loss) on Disposal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl0" xml:lang="en-US">Payments to Acquire Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SecondWarrantMember_lbl0" xml:lang="en-US">Second Warrant Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SecondWarrantMember" xlink:to="avco_SecondWarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl1" xml:lang="en-US">Preferred Stock, Convertible, Shares Issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ReverseStockSplitPolicyTextBlock_lbl1" xml:lang="en-US">Reverse Stock Split Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ReverseStockSplitPolicyTextBlock" xlink:to="avco_ReverseStockSplitPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl0" xml:lang="en-US">Unamortized Debt Issuance Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CommonStockIssuedForAccruedLiabilities_lbl1" xml:lang="en-US">Common Stock Issued For Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommonStockIssuedForAccruedLiabilities" xlink:to="avco_CommonStockIssuedForAccruedLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock_lbl1" xml:lang="en-US">Stock Issued During Period Share Series DConvertible Preferred Stock Issued In Exchange Of Series AConvertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" xlink:to="avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityMethodInvestmentPayableCurrent_lbl1" xml:lang="en-US">Equity Method Investment Payable Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentPayableCurrent" xlink:to="avco_EquityMethodInvestmentPayableCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_MayFiveTwoThousandTwentyFiveMember_lbl0" xml:lang="en-US">May Five Two Thousand Twenty Five Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MayFiveTwoThousandTwentyFiveMember" xlink:to="avco_MayFiveTwoThousandTwentyFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl0" xml:lang="en-US">Equity Method Investment, Aggregate Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RealPropertyOperatingMember_lbl1" xml:lang="en-US">Real Property Operating Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RealPropertyOperatingMember" xlink:to="avco_RealPropertyOperatingMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_MastMillAndFirstFireMember_lbl0" xml:lang="en-US">Mast Mill And First Fire Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MastMillAndFirstFireMember" xlink:to="avco_MastMillAndFirstFireMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_WenzhaoLuMember_lbl0" xml:lang="en-US">Wenzhao Lu Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WenzhaoLuMember" xlink:to="avco_WenzhaoLuMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="avco_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl0" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseShortTermBorrowings_lbl0" xml:lang="en-US">Interest Expense, Short-Term Borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseShortTermBorrowings" xlink:to="us-gaap_InterestExpenseShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OtherExpenseIncomeAbstract_lbl0" xml:lang="en-US">Other Expense Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OtherExpenseIncomeAbstract" xlink:to="avco_OtherExpenseIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_BeijingGenexosomeMember_lbl1" xml:lang="en-US">Beijing Genexosome Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BeijingGenexosomeMember" xlink:to="avco_BeijingGenexosomeMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_MarchTwoThousandTwentyFourWarrantIssuedMember_lbl1" xml:lang="en-US">March Two Thousand Twenty Four Warrant Issued Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MarchTwoThousandTwentyFourWarrantIssuedMember" xlink:to="avco_MarchTwoThousandTwentyFourWarrantIssuedMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_October2023ConvertibleNoteMember_lbl0" xml:lang="en-US">October2023 Convertible Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_October2023ConvertibleNoteMember" xlink:to="avco_October2023ConvertibleNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl1" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AvalonLaboratoryServicesIncMember_lbl0" xml:lang="en-US">Avalon Laboratory Services Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonLaboratoryServicesIncMember" xlink:to="avco_AvalonLaboratoryServicesIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilitiesInventorySuppliesMember_lbl0" xml:lang="en-US">Supplies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventorySuppliesMember" xlink:to="us-gaap_PublicUtilitiesInventorySuppliesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_TradingPrice_lbl1" xml:lang="en-US">Trading Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_TradingPrice" xlink:to="avco_TradingPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowsBetweenTransfereeAndTransferorServicingFees_lbl0" xml:lang="en-US">Cash Flows Between Transferor and Transferee, Servicing Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowsBetweenTransfereeAndTransferorServicingFees" xlink:to="us-gaap_CashFlowsBetweenTransfereeAndTransferorServicingFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_WorkingCapital_lbl1" xml:lang="en-US">Working Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WorkingCapital" xlink:to="avco_WorkingCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DeemedContributionOnExchangeOfEquityInstruments_lbl1" xml:lang="en-US">Deemed Contribution On Exchange Of Equity Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeemedContributionOnExchangeOfEquityInstruments" xlink:to="avco_DeemedContributionOnExchangeOfEquityInstruments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl0" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ExercisePriceRangeOneMember_lbl2" xml:lang="en-US">Exercise Price Range One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeOneMember" xlink:to="avco_ExercisePriceRangeOneMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillFairValueDisclosure_lbl0" xml:lang="en-US">Goodwill, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillFairValueDisclosure" xlink:to="us-gaap_GoodwillFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl0" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CommonSharesIssuedForServicesMember_lbl0" xml:lang="en-US">Common Shares Issued For Services Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommonSharesIssuedForServicesMember" xlink:to="avco_CommonSharesIssuedForServicesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AvalonHealthcareSystemIncMember_lbl1" xml:lang="en-US">Avalon Healthcare System Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonHealthcareSystemIncMember" xlink:to="avco_AvalonHealthcareSystemIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl0" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl1" xml:lang="en-US">Other Operating Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DeferredOfferingCostsMember_lbl0" xml:lang="en-US">Deferred Offering Costs Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeferredOfferingCostsMember" xlink:to="avco_DeferredOfferingCostsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityInterestPercent_lbl1" xml:lang="en-US">Equity Interest Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityInterestPercent" xlink:to="avco_EquityInterestPercent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_May2023ConvertibleNoteMember_lbl0" xml:lang="en-US">May2023 Convertible Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_May2023ConvertibleNoteMember" xlink:to="avco_May2023ConvertibleNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_MastHillMember_lbl0" xml:lang="en-US">Mast Hill Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MastHillMember" xlink:to="avco_MastHillMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl0" xml:lang="en-US">Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfCustomerAccountedForCompanysRevenuesAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfCustomerAccountedForCompanysRevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfCustomerAccountedForCompanysRevenuesAbstract_lbl" xml:lang="en-US">Schedule Of Customer Accounted For Companys Revenues Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfCustomerAccountedForCompanysRevenuesAbstract" xlink:to="avco_ScheduleOfCustomerAccountedForCompanysRevenuesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonValue_lbl0" xml:lang="en-US">Treasury Stock, Common, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PaymentOfEquityInvestment_lbl1" xml:lang="en-US">Payment Of Equity Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PaymentOfEquityInvestment" xlink:to="avco_PaymentOfEquityInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Values</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues" xlink:to="avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl0" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DrYuZhouMember_lbl1" xml:lang="en-US">Dr Yu Zhou Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DrYuZhouMember" xlink:to="avco_DrYuZhouMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl1" xml:lang="en-US">Goodwill, Impairment Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfConsolidatedFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfConsolidatedFinancialStatementsAbstract_lbl" xml:lang="en-US">Schedule Of Consolidated Financial Statements Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:to="avco_ScheduleOfConsolidatedFinancialStatementsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CashPercentage_lbl1" xml:lang="en-US">Cash Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CashPercentage" xlink:to="avco_CashPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherTradingMember_lbl0" xml:lang="en-US">Other Trading [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherTradingMember" xlink:to="us-gaap_OtherTradingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncurrentAssets_lbl0" xml:lang="en-US">Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncurrentAssets" xlink:to="us-gaap_NoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedemptionPremium_lbl0" xml:lang="en-US">Redemption Premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedemptionPremium" xlink:to="us-gaap_RedemptionPremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Accounts and Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl0" xml:lang="en-US">Class of Warrant or Right, Unissued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_TwoThousandTwentyFourJuneWarrantIssuedMember_lbl1" xml:lang="en-US">Two Thousand Twenty Four June Warrant Issued Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_TwoThousandTwentyFourJuneWarrantIssuedMember" xlink:to="avco_TwoThousandTwentyFourJuneWarrantIssuedMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnlabeledAbstract3" xlink:to="avco_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnlabeledAbstract2" xlink:to="avco_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnlabeledAbstract5" xlink:to="avco_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnlabeledAbstract4" xlink:to="avco_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnlabeledAbstract1" xlink:to="avco_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnlabeledAbstract0" xlink:to="avco_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PRCSubsidiariesMember_lbl0" xml:lang="en-US">PRCSubsidiaries Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PRCSubsidiariesMember" xlink:to="avco_PRCSubsidiariesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet_lbl0" xml:lang="en-US">Long-Term Investments and Receivables, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:to="us-gaap_LongTermInvestmentsAndReceivablesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl0" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnlabeledAbstract7" xlink:to="avco_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee_lbl1" xml:lang="en-US">Common Stock Issued As Convertible Note Payable Commitment Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee" xlink:to="avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnlabeledAbstract6" xlink:to="avco_UnlabeledAbstract6_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ComprehensiveLossAbstract_lbl0" xml:lang="en-US">Comprehensive Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ComprehensiveLossAbstract" xlink:to="avco_ComprehensiveLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireLoansHeldForInvestment_lbl0" xml:lang="en-US">Payment for Acquisition, Loan, Held-for-Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLoansHeldForInvestment" xlink:to="us-gaap_PaymentsToAcquireLoansHeldForInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_WarrantsExercisedMember_lbl0" xml:lang="en-US">Warrants Exercised Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WarrantsExercisedMember" xlink:to="avco_WarrantsExercisedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl0" xml:lang="en-US">Property, Plant and Equipment, Other, Accumulated Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AvactisBiotherapeuticsLimitedMember_lbl0" xml:lang="en-US">Avactis Biotherapeutics Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvactisBiotherapeuticsLimitedMember" xlink:to="avco_AvactisBiotherapeuticsLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DistributionOfEarningsFromEquityMethodInvestment_lbl1" xml:lang="en-US">Distribution Of Earnings From Equity Method Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DistributionOfEarningsFromEquityMethodInvestment" xlink:to="avco_DistributionOfEarningsFromEquityMethodInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsMember_lbl0" xml:lang="en-US">Equity Method Investments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsMember" xlink:to="us-gaap_EquityMethodInvestmentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_lbl0" xml:lang="en-US">Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RedemptionNetOfPayablesDueToLabServices_lbl1" xml:lang="en-US">Redemption Net Of Payables Due To Lab Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RedemptionNetOfPayablesDueToLabServices" xlink:to="avco_RedemptionNetOfPayablesDueToLabServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl0" xml:lang="en-US">Accrued Payroll Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetImpairmentCharges_lbl0" xml:lang="en-US">Other Asset Impairment Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetImpairmentCharges" xlink:to="us-gaap_OtherAssetImpairmentCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet_lbl1" xml:lang="en-US">Stock Issued During Period Value Sale Of Common Stock Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet" xlink:to="avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl2" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation_lbl0" xml:lang="en-US">Property, Plant, and Equipment, Owned, Accumulated Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl0" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SeriesBHolderMember_lbl0" xml:lang="en-US">Series BHolder Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesBHolderMember" xlink:to="avco_SeriesBHolderMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty_lbl1" xml:lang="en-US">Reclassification Of Related Party Loan Payable And Accrued Expenses To Advance From Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty" xlink:to="avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_LabServicesMSOMember_lbl0" xml:lang="en-US">Lab Services MSOMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LabServicesMSOMember" xlink:to="avco_LabServicesMSOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl1" xml:lang="en-US">Asset Acquisition, Consideration Transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CertificatesOfEliminationMember_lbl0" xml:lang="en-US">Certificates Of Elimination Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CertificatesOfEliminationMember" xlink:to="avco_CertificatesOfEliminationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentDividendsOrDistributions_lbl0" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="us-gaap_EquityMethodInvestmentDividendsOrDistributions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnlabeledAbstract" xlink:to="avco_UnlabeledAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfIdentifiableLongLivedTangibleAssetsGeographicAreasAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfIdentifiableLongLivedTangibleAssetsGeographicAreasAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfIdentifiableLongLivedTangibleAssetsGeographicAreasAbstract_lbl" xml:lang="en-US">Schedule Of Identifiable Long Lived Tangible Assets Geographic Areas Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfIdentifiableLongLivedTangibleAssetsGeographicAreasAbstract" xlink:to="avco_ScheduleOfIdentifiableLongLivedTangibleAssetsGeographicAreasAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0" xml:lang="en-US">Debt Instrument, Increase, Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl0" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_lbl0" xml:lang="en-US">OCI, Foreign Currency Transaction and Translation Gain (Loss), Arising During Period, Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_NonvestedMember_lbl0" xml:lang="en-US">Nonvested Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_NonvestedMember" xlink:to="avco_NonvestedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount_lbl1" xml:lang="en-US">Warrants Issued With Convertible Note Payables Recorded As Debt Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount" xlink:to="avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount_lbl1"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfFinancialInformationAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfFinancialInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfFinancialInformationAbstract_lbl" xml:lang="en-US">Schedule Of Financial Information Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfFinancialInformationAbstract" xlink:to="avco_ScheduleOfFinancialInformationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DilutiveSecurities_lbl0" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecurities" xlink:to="us-gaap_DilutiveSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RealPropertyOperationsMember_lbl0" xml:lang="en-US">Real Property Operations Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RealPropertyOperationsMember" xlink:to="avco_RealPropertyOperationsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl0" xml:lang="en-US">Security Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_IncreaseDecreaseInDeferredLeasingCosts_lbl1" xml:lang="en-US">Increase Decrease In Deferred Leasing Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_IncreaseDecreaseInDeferredLeasingCosts" xlink:to="avco_IncreaseDecreaseInDeferredLeasingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncome_lbl0" xml:lang="en-US">Deferred Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncome" xlink:to="us-gaap_DeferredIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_MastHillAndFirstfireMember_lbl0" xml:lang="en-US">Mast Hill And Firstfire Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MastHillAndFirstfireMember" xlink:to="avco_MastHillAndFirstfireMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AccruedPurchasePriceRelatedToEquityMethodInvestment_lbl1" xml:lang="en-US">Accrued Purchase Price Related To Equity Method Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedPurchasePriceRelatedToEquityMethodInvestment" xlink:to="avco_AccruedPurchasePriceRelatedToEquityMethodInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl0" xml:lang="en-US">Schedule of Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfSecuritiesThatWereExcludedFromTheDilutedPerShareAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfSecuritiesThatWereExcludedFromTheDilutedPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfSecuritiesThatWereExcludedFromTheDilutedPerShareAbstract_lbl" xml:lang="en-US">Schedule Of Securities That Were Excluded From The Diluted Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfSecuritiesThatWereExcludedFromTheDilutedPerShareAbstract" xlink:to="avco_ScheduleOfSecuritiesThatWereExcludedFromTheDilutedPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl0" xml:lang="en-US">Line of Credit Facility, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl0" xml:lang="en-US">Convertible Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_JiangsuUnicornBiologicalTechnologyCoLtdMember_lbl0" xml:lang="en-US">Jiangsu Unicorn Biological Technology Co Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_JiangsuUnicornBiologicalTechnologyCoLtdMember" xlink:to="avco_JiangsuUnicornBiologicalTechnologyCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_lbl0" xml:lang="en-US">Line of Credit Facility, Increase, Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:to="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl0" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl1" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AvactisNanjingBiosciencesLtdMember_lbl1" xml:lang="en-US">Avactis Nanjing Biosciences Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvactisNanjingBiosciencesLtdMember" xlink:to="avco_AvactisNanjingBiosciencesLtdMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_lbl2" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_JuneFiveTwoThousandTwentyFiveMember_lbl0" xml:lang="en-US">June Five Two Thousand Twenty Five Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_JuneFiveTwoThousandTwentyFiveMember" xlink:to="avco_JuneFiveTwoThousandTwentyFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_StatutoryReservePercent_lbl1" xml:lang="en-US">Statutory Reserve Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReservePercent" xlink:to="avco_StatutoryReservePercent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OtherComprehensiveIncomeLossAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OtherComprehensiveIncomeLossAbstract" xlink:to="avco_OtherComprehensiveIncomeLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RegisteredCapitalPercentage_lbl1" xml:lang="en-US">Registered Capital Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RegisteredCapitalPercentage" xlink:to="avco_RegisteredCapitalPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_LabServiceMSOMember_lbl0" xml:lang="en-US">Lab Service MSOMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LabServiceMSOMember" xlink:to="avco_LabServiceMSOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl0" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_May2023CovertibleNoteMember_lbl1" xml:lang="en-US">May2023 Covertible Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_May2023CovertibleNoteMember" xlink:to="avco_May2023CovertibleNoteMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialRealEstateMember_lbl0" xml:lang="en-US">Commercial Real Estate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialRealEstateMember" xlink:to="us-gaap_CommercialRealEstateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl0" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PurchasedServicesPercentage_lbl1" xml:lang="en-US">Purchased Services Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PurchasedServicesPercentage" xlink:to="avco_PurchasedServicesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0" xml:lang="en-US">Condensed Balance Sheet [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_QADistributionLLCMember_lbl0" xml:lang="en-US">QADistribution LLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_QADistributionLLCMember" xlink:to="avco_QADistributionLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl0" xml:lang="en-US">Number of Reportable Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl0" xml:lang="en-US">Loans Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">Other Current Assets [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_May232023FiveYearAnniversaryMember_lbl0" xml:lang="en-US">May232023 Five Year Anniversary Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_May232023FiveYearAnniversaryMember" xlink:to="avco_May232023FiveYearAnniversaryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PrepaidProfessionalFees_lbl1" xml:lang="en-US">Prepaid Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrepaidProfessionalFees" xlink:to="avco_PrepaidProfessionalFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeniorNotesMember_lbl0" xml:lang="en-US">Senior Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorNotesMember" xlink:to="us-gaap_SeniorNotesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_LaboratoryEquipmentMember_lbl0" xml:lang="en-US">Laboratory Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LaboratoryEquipmentMember" xlink:to="avco_LaboratoryEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable_lbl1" xml:lang="en-US">Beneficial Conversion Feature Related To Convertible Note Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable" xlink:to="avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ArbeleMember_lbl0" xml:lang="en-US">Arbele Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ArbeleMember" xlink:to="avco_ArbeleMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiscalPeriod_lbl0" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiscalPeriod" xlink:to="us-gaap_FiscalPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl0" xml:lang="en-US">Noncontrolling Interest [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedUtilitiesCurrent_lbl0" xml:lang="en-US">Accrued Utilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedUtilitiesCurrent" xlink:to="us-gaap_AccruedUtilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessor, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorLeasesPolicyTextBlock" xlink:to="us-gaap_LessorLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ReceivableRelatedToSaleOfEquityMethodInvestment_lbl1" xml:lang="en-US">Receivable Related To Sale Of Equity Method Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ReceivableRelatedToSaleOfEquityMethodInvestment" xlink:to="avco_ReceivableRelatedToSaleOfEquityMethodInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfCashBalancesByGeographicAreaAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfCashBalancesByGeographicAreaAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfCashBalancesByGeographicAreaAbstract_lbl" xml:lang="en-US">Schedule Of Cash Balances By Geographic Area Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfCashBalancesByGeographicAreaAbstract" xlink:to="avco_ScheduleOfCashBalancesByGeographicAreaAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AbandonmentAgreementMember_lbl0" xml:lang="en-US">Abandonment Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AbandonmentAgreementMember" xlink:to="avco_AbandonmentAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl1" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl1"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfStockOptionActivityAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfStockOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfStockOptionActivityAbstract_lbl" xml:lang="en-US">Schedule Of Stock Option Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfStockOptionActivityAbstract" xlink:to="avco_ScheduleOfStockOptionActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl0" xml:lang="en-US">Measurement Input, Share Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_MergerAgreementMember_lbl0" xml:lang="en-US">Merger Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MergerAgreementMember" xlink:to="avco_MergerAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl1" xml:lang="en-US">Proceeds from Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AvactisBiosciencesIncMember_lbl1" xml:lang="en-US">Avactis Biosciences Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvactisBiosciencesIncMember" xlink:to="avco_AvactisBiosciencesIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl0" xml:lang="en-US">Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_JanuaryFiveTwoThousandTwentyFiveMember_lbl0" xml:lang="en-US">January Five Two Thousand Twenty Five Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_JanuaryFiveTwoThousandTwentyFiveMember" xlink:to="avco_JanuaryFiveTwoThousandTwentyFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDebtExpense_lbl0" xml:lang="en-US">Interest and Debt Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_lbl0" xml:lang="en-US">Disclosure of Long-Lived Assets Held-for-Sale [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:to="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl1" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_WarrantsIssuedAsConvertibleNotePayableFindersFee_lbl1" xml:lang="en-US">Warrants Issued As Convertible Note Payable Finders Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WarrantsIssuedAsConvertibleNotePayableFindersFee" xlink:to="avco_WarrantsIssuedAsConvertibleNotePayableFindersFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets_lbl1" xml:lang="en-US">Equity Methodof Fair Value Over Carrying Valueodentifiableintangibleassets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets" xlink:to="avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock_lbl1" xml:lang="en-US">Stock Issued During Period Value Series DConvertible Preferred Stock Issued In Exchange Of Series AConvertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" xlink:to="avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ExercisePriceRangeFourMember_lbl2" xml:lang="en-US">Exercise Price Range Four Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeFourMember" xlink:to="avco_ExercisePriceRangeFourMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl3" xml:lang="en-US">Derivative Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AccruedAndUnpaidServicesCharge_lbl1" xml:lang="en-US">Accrued And Unpaid Services Charge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedAndUnpaidServicesCharge" xlink:to="avco_AccruedAndUnpaidServicesCharge_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CustomerCMember_lbl0" xml:lang="en-US">Customer CMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CustomerCMember" xlink:to="avco_CustomerCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl0" xml:lang="en-US">Repayments of Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CN_lbl2" xml:lang="en-US">CHINA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl0" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionAmount_lbl0" xml:lang="en-US">Preferred Stock, Redemption Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionAmount" xlink:to="us-gaap_PreferredStockRedemptionAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl0" xml:lang="en-US">Proceeds from Lines of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Other Finite-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_LessCommonStockHeldInTreasuryAtCostAbstract_lbl0" xml:lang="en-US">Less Common Stock Held In Treasury At Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LessCommonStockHeldInTreasuryAtCostAbstract" xlink:to="avco_LessCommonStockHeldInTreasuryAtCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl0" xml:lang="en-US">Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_LineOfCreditAgreementMember_lbl0" xml:lang="en-US">Line Of Credit Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LineOfCreditAgreementMember" xlink:to="avco_LineOfCreditAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RegularPaymentsOnEquityInvestments_lbl1" xml:lang="en-US">Regular Payments On Equity Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RegularPaymentsOnEquityInvestments" xlink:to="avco_RegularPaymentsOnEquityInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealEstateDisclosureTextBlock_lbl0" xml:lang="en-US">Real Estate Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateDisclosureTextBlock" xlink:to="us-gaap_RealEstateDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl1" xml:lang="en-US">Common Stock, Convertible, Conversion Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease_lbl1"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Identifiable Long Lived Tangible Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract" xlink:to="avco_ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment_lbl1" xml:lang="en-US">Series BConvertible Preferred Stocks Extinguished Related To Sale Of Equity Method Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment" xlink:to="avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl2" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ExchangeShare_lbl1" xml:lang="en-US">Exchange Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExchangeShare" xlink:to="avco_ExchangeShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_March72024FiveYearAnniversaryMember_lbl0" xml:lang="en-US">March72024 Five Year Anniversary Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_March72024FiveYearAnniversaryMember" xlink:to="avco_March72024FiveYearAnniversaryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Other General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl0" xml:lang="en-US">Other Nonoperating Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl1" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OptionsOutstandingMember_lbl1" xml:lang="en-US">Options Outstanding Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OptionsOutstandingMember" xlink:to="avco_OptionsOutstandingMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl4" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl0" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsLeasingNet_lbl0" xml:lang="en-US">Deferred Costs, Leasing, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsLeasingNet" xlink:to="us-gaap_DeferredCostsLeasingNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AvalonRT9PropertiesLLCMember_lbl1" xml:lang="en-US">Avalon RT9 Properties LLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonRT9PropertiesLLCMember" xlink:to="avco_AvalonRT9PropertiesLLCMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl0" xml:lang="en-US">Business Combination, Achieved in Stages, Preacquisition Equity Interest in Acquiree, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_JefferiesLLCMember_lbl0" xml:lang="en-US">Jefferies LLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_JefferiesLLCMember" xlink:to="avco_JefferiesLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants_lbl1" xml:lang="en-US">Proceeds From Issuance Of Convertible Debt And Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants" xlink:to="avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl0" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ConversionShareMember_lbl0" xml:lang="en-US">Conversion Share Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ConversionShareMember" xlink:to="avco_ConversionShareMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_BlackScholesValuationModelMember_lbl0" xml:lang="en-US">Black Scholes Valuation Model Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BlackScholesValuationModelMember" xlink:to="avco_BlackScholesValuationModelMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl0" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl0" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl0" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment_lbl1" xml:lang="en-US">Reclassification Of Advances For Equity Interest Purchase To Equity Method Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment" xlink:to="avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl2" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_FairMarketValues_lbl1" xml:lang="en-US">Fair Market Values</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FairMarketValues" xlink:to="avco_FairMarketValues_lbl1"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfCommonStockIssuableUponExerciseOfOptionsOutstandingAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfCommonStockIssuableUponExerciseOfOptionsOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfCommonStockIssuableUponExerciseOfOptionsOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Common Stock Issuable Upon Exercise Of Options Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfCommonStockIssuableUponExerciseOfOptionsOutstandingAbstract" xlink:to="avco_ScheduleOfCommonStockIssuableUponExerciseOfOptionsOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ExercisePriceRangeThreeMember_lbl1" xml:lang="en-US">Exercise Price Range Three Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeThreeMember" xlink:to="avco_ExercisePriceRangeThreeMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CashPaidForAbstract_lbl0" xml:lang="en-US">Cash Paid For Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CashPaidForAbstract" xlink:to="avco_CashPaidForAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments_lbl1" xml:lang="en-US">Stock Issued During Period Value Shares Issued For Adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments" xlink:to="avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalDeferredPurchasePrice_lbl0" xml:lang="en-US">Supplemental Deferred Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalDeferredPurchasePrice" xlink:to="us-gaap_SupplementalDeferredPurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_lbl1" xml:lang="en-US">Interest Expense, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnRestructuringOfDebt_lbl0" xml:lang="en-US">Gains (Losses) on Restructuring of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="us-gaap_GainsLossesOnRestructuringOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_MarchTwentyThousandTwentyFourConvertibleNoteMember_lbl1" xml:lang="en-US">March Twenty Thousand Twenty Four Convertible Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MarchTwentyThousandTwentyFourConvertibleNoteMember" xlink:to="avco_MarchTwentyThousandTwentyFourConvertibleNoteMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralExpense_lbl0" xml:lang="en-US">Other General Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralExpense" xlink:to="us-gaap_OtherGeneralExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl0" xml:lang="en-US">Condensed Financial Information of Parent Company Only Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Regulatory Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl2" xml:lang="en-US">Treasury Stock, Common, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AssetsAbstract0_lbl0" xml:lang="en-US">Assets Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AssetsAbstract0" xlink:to="avco_AssetsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl1" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_MrLuMember_lbl0" xml:lang="en-US">Mr Lu Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MrLuMember" xlink:to="avco_MrLuMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl0" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_LabServicesMember_lbl0" xml:lang="en-US">Lab Services Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LabServicesMember" xlink:to="avco_LabServicesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StraightLineRent_lbl0" xml:lang="en-US">Straight Line Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StraightLineRent" xlink:to="us-gaap_StraightLineRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PaymentForEquityMethodInvestmentAbstract_lbl0" xml:lang="en-US">Payment For Equity Method Investment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PaymentForEquityMethodInvestmentAbstract" xlink:to="avco_PaymentForEquityMethodInvestmentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromCorrespondentBrokers_lbl0" xml:lang="en-US">Due from Correspondent Brokers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromCorrespondentBrokers" xlink:to="us-gaap_DueFromCorrespondentBrokers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingAndAdvertisingExpense_lbl0" xml:lang="en-US">Marketing and Advertising Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingAndAdvertisingExpense" xlink:to="us-gaap_MarketingAndAdvertisingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AvalonShangaiMember_lbl0" xml:lang="en-US">Avalon Shangai Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonShangaiMember" xlink:to="avco_AvalonShangaiMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_FirstWarrantMember_lbl0" xml:lang="en-US">First Warrant Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FirstWarrantMember" xlink:to="avco_FirstWarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed_lbl1" xml:lang="en-US">Restricted Net Assets PRCSubsidiary Did Not Exceed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed" xlink:to="avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl1" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableToBankCurrent_lbl0" xml:lang="en-US">Notes Payable to Bank, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableToBankCurrent" xlink:to="us-gaap_NotesPayableToBankCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AvactisAndArbeleBiotherapeuticsLimitedMember_lbl0" xml:lang="en-US">Avactis And Arbele Biotherapeutics Limited Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvactisAndArbeleBiotherapeuticsLimitedMember" xlink:to="avco_AvactisAndArbeleBiotherapeuticsLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationReserveCurrent_lbl0" xml:lang="en-US">Estimated Litigation Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationReserveCurrent" xlink:to="us-gaap_LitigationReserveCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl1" xml:lang="en-US">Business Combination, Series of Individually Immaterial Business Combinations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealEstateInvestmentPropertyNet_lbl0" xml:lang="en-US">Real Estate Investment Property, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateInvestmentPropertyNet" xlink:to="us-gaap_RealEstateInvestmentPropertyNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl0" xml:lang="en-US">Cash, FDIC Insured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidReinsurancePremiums_lbl1" xml:lang="en-US">Prepaid Reinsurance Premiums</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidReinsurancePremiums" xlink:to="us-gaap_PrepaidReinsurancePremiums_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CustomerBMember_lbl0" xml:lang="en-US">Customer BMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CustomerBMember" xlink:to="avco_CustomerBMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl1" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealEstateInvestments_lbl0" xml:lang="en-US">Real Estate Investments, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateInvestments" xlink:to="us-gaap_RealEstateInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_GenExosomeTechnologiesIncMember_lbl0" xml:lang="en-US">Gen Exosome Technologies Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_GenExosomeTechnologiesIncMember" xlink:to="avco_GenExosomeTechnologiesIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ImpairmentOfLaboratoryEquipment_lbl2" xml:lang="en-US">Impairment Of Laboratory Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ImpairmentOfLaboratoryEquipment" xlink:to="avco_ImpairmentOfLaboratoryEquipment_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl0" xml:lang="en-US">Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AccruedBusinessExpenseReimbursement_lbl1" xml:lang="en-US">Accrued Business Expense Reimbursement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedBusinessExpenseReimbursement" xlink:to="avco_AccruedBusinessExpenseReimbursement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LetterOfCreditMember_lbl0" xml:lang="en-US">Letter of Credit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl0" xml:lang="en-US">Long-Term Debt [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl0" xml:lang="en-US">Condensed Income Statement [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_June2024ConvertibleNoteMember_lbl0" xml:lang="en-US">June2024 Convertible Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_June2024ConvertibleNoteMember" xlink:to="avco_June2024ConvertibleNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl0" xml:lang="en-US">Derivative Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets_lbl1" xml:lang="en-US">Restricted Net Assets Of Subsidiary Exceed Net Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets" xlink:to="avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl0" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowInvestingActivitiesLesseeAbstract_lbl0" xml:lang="en-US">Cash Flow, Investing Activities, Lessee [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowInvestingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowInvestingActivitiesLesseeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AvalonRT9Member_lbl0" xml:lang="en-US">Avalon RT9 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonRT9Member" xlink:to="avco_AvalonRT9Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl0" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CustomerAMember_lbl0" xml:lang="en-US">Customer AMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CustomerAMember" xlink:to="avco_CustomerAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_StatutoryReserveMember_lbl0" xml:lang="en-US">Statutory Reserve Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReserveMember" xlink:to="avco_StatutoryReserveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities_lbl1" xml:lang="en-US">Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities" xlink:to="avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl0" xml:lang="en-US">Investment Owned, Net Assets, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl0" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PaymentsOfConvertibleDebtIssuanceCosts_lbl1" xml:lang="en-US">Payments Of Convertible Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PaymentsOfConvertibleDebtIssuanceCosts" xlink:to="avco_PaymentsOfConvertibleDebtIssuanceCosts_lbl1"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfDerivativeLiabilityMeasuredAtFairValueAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfDerivativeLiabilityMeasuredAtFairValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfDerivativeLiabilityMeasuredAtFairValueAbstract_lbl" xml:lang="en-US">Schedule Of Derivative Liability Measured At Fair Value Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfDerivativeLiabilityMeasuredAtFairValueAbstract" xlink:to="avco_ScheduleOfDerivativeLiabilityMeasuredAtFairValueAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_LabServicesMSOsNetIncomeAttributableToTheCompany_lbl2" xml:lang="en-US">Lab Services MSOs Net Income Attributable To The Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LabServicesMSOsNetIncomeAttributableToTheCompany" xlink:to="avco_LabServicesMSOsNetIncomeAttributableToTheCompany_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl0" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl0" xml:lang="en-US">Convertible Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl1" xml:lang="en-US">Proceeds from Other Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>21
<FILENAME>avco-20250331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Jun 09 23:27:56 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConsolidatedBalanceSheet" roleURI="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConsolidatedIncomeStatement" roleURI="http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_CondensedConsolidatedStatementsofChangesinDeficitEquityTable" roleURI="http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_CondensedConsolidatedStatementsofChangesinDeficitEquityTable_Parentheticals" roleURI="http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConsolidatedCashFlow" roleURI="http://www.avalonglobocare.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_OrganizationandNatureofOperations" roleURI="http://www.avalonglobocare.com/role/OrganizationandNatureofOperations"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_BasisofPresentationandGoingConcernCondition" roleURI="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernCondition"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_PrepaidExpenseandOtherCurrentAssets" roleURI="http://www.avalonglobocare.com/role/PrepaidExpenseandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_PropertyandEquipment" roleURI="http://www.avalonglobocare.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_EquipmentHeldForSale" roleURI="http://www.avalonglobocare.com/role/EquipmentHeldForSale"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_InvestmentinRealEstate" roleURI="http://www.avalonglobocare.com/role/InvestmentinRealEstate"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_EquityMethodInvestments" roleURI="http://www.avalonglobocare.com/role/EquityMethodInvestments"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_AccruedLiabilitiesandOtherPayables" roleURI="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConvertibleNotePayable" roleURI="http://www.avalonglobocare.com/role/ConvertibleNotePayable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_DerivativeLiability" roleURI="http://www.avalonglobocare.com/role/DerivativeLiability"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_NotePayableNet" roleURI="http://www.avalonglobocare.com/role/NotePayableNet"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_RelatedPartyTransactions" roleURI="http://www.avalonglobocare.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_IncomeTaxes" roleURI="http://www.avalonglobocare.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_Equity" roleURI="http://www.avalonglobocare.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_StatutoryReserveandRestrictedNetAssets" roleURI="http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssets"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_NoncontrollingInterest" roleURI="http://www.avalonglobocare.com/role/NoncontrollingInterest"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_CondensedFinancialInformationoftheParentCompany" roleURI="http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompany"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_Concentrations" roleURI="http://www.avalonglobocare.com/role/Concentrations"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_SegmentInformation" roleURI="http://www.avalonglobocare.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_CommitmentsandContingencies" roleURI="http://www.avalonglobocare.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_SubsequentEvents" roleURI="http://www.avalonglobocare.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_AccountingPoliciesByPolicy" roleURI="http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_OrganizationandNatureofOperationsTables" roleURI="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_PrepaidExpenseandOtherCurrentAssetsTables" roleURI="http://www.avalonglobocare.com/role/PrepaidExpenseandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_PropertyandEquipmentTables" roleURI="http://www.avalonglobocare.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_InvestmentinRealEstateTables" roleURI="http://www.avalonglobocare.com/role/InvestmentinRealEstateTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_EquityMethodInvestmentsTables" roleURI="http://www.avalonglobocare.com/role/EquityMethodInvestmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_AccruedLiabilitiesandOtherPayablesTables" roleURI="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConvertibleNotePayableTables" roleURI="http://www.avalonglobocare.com/role/ConvertibleNotePayableTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_NotePayableNetTables" roleURI="http://www.avalonglobocare.com/role/NotePayableNetTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_RelatedPartyTransactionsTables" roleURI="http://www.avalonglobocare.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_IncomeTaxesTables" roleURI="http://www.avalonglobocare.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_EquityTables" roleURI="http://www.avalonglobocare.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConcentrationsTables" roleURI="http://www.avalonglobocare.com/role/ConcentrationsTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_SegmentInformationTables" roleURI="http://www.avalonglobocare.com/role/SegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_CommitmentsandContingenciesTables" roleURI="http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofConsolidatedFinancialStatementsTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofDerivativeLiabilityMeasuredatFairValueTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofCashBalancesbyGeographicAreaTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofPrepaidExpenseandOtherCurrentAssetsTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofInvestmentinRealEstateTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofInvestmentinRealEstateTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofEquityMethodInvestmentTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofFinancialInformationTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofAccruedLiabilitiesandOtherPayablesTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofAmortizationPaymentsinCashTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofConvertibleNotePayableTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofNotePayableTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofNotePayableTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofLineofCreditTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofLineofCreditTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofCompanysLossBeforeIncomeTaxesTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofCompanysLossBeforeIncomeTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofComponentsofIncomeTaxesExpenseBenefitTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofDeferredTaxesTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofStockOptionActivityTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofNonvestedStockOptionsGrantedTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofCustomerAccountedforCompanysRevenuesTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofReportableBusinessSegmentsTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofIdentifiableLongLivedTangibleAssetsTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofLeaseTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofLeaseTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofConsolidatedFinancialStatementsTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofDerivativeLiabilityMeasuredatFairValueTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofCashBalancesbyGeographicAreaTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofEquityMethodInvestmentTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofFinancialInformationTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofAmortizationPaymentsinCashTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofConvertibleNotePayableTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofNotePayableTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofNotePayableTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofStockOptionActivityTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofNonvestedStockOptionsGrantedTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1" roleURI="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofCustomerAccountedforCompanysRevenuesTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofReportableBusinessSegmentsTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofIdentifiableLongLivedTangibleAssetsTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofLeaseTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofLeaseTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0" roleURI="http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_OrganizationandNatureofOperationsDetails" roleURI="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_BasisofPresentationandGoingConcernConditionDetails" roleURI="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_PropertyandEquipmentDetails" roleURI="http://www.avalonglobocare.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_EquipmentHeldForSaleDetails" roleURI="http://www.avalonglobocare.com/role/EquipmentHeldForSaleDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_InvestmentinRealEstateDetails" roleURI="http://www.avalonglobocare.com/role/InvestmentinRealEstateDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_EquityMethodInvestmentsDetails" roleURI="http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConvertibleNotePayableDetails" roleURI="http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_DerivativeLiabilityDetails" roleURI="http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_NotePayableNetDetails" roleURI="http://www.avalonglobocare.com/role/NotePayableNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_RelatedPartyTransactionsDetails" roleURI="http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_IncomeTaxesDetails" roleURI="http://www.avalonglobocare.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_EquityDetails" roleURI="http://www.avalonglobocare.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_StatutoryReserveandRestrictedNetAssetsDetails" roleURI="http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_NoncontrollingInterestDetails" roleURI="http://www.avalonglobocare.com/role/NoncontrollingInterestDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_CondensedFinancialInformationoftheParentCompanyDetails" roleURI="http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompanyDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_ConcentrationsDetails" roleURI="http://www.avalonglobocare.com/role/ConcentrationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_SegmentInformationDetails" roleURI="http://www.avalonglobocare.com/role/SegmentInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_CommitmentsandContingenciesDetails" roleURI="http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#avco_r_SubsequentEventsDetails" roleURI="http://www.avalonglobocare.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20250331.xsd#DocumentAndEntityInformation" roleURI="http://www.avalonglobocare.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesDPreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestmentsAndReceivablesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestmentsAndReceivablesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_LongTermInvestmentsAndReceivablesNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RealEstateInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_EquityMethodInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedResearchAndDevelopmentsFees" xlink:href="avco-20250331.xsd#avco_AccruedResearchAndDevelopmentsFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="AccruedResearchAndDevelopmentsFees" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationReserveCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LitigationReserveCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" xlink:href="avco-20250331.xsd#avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentPayableCurrent" xlink:href="avco-20250331.xsd#avco_EquityMethodInvestmentPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="EquityMethodInvestmentPayableCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableToBankCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableToBankCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableToBankCurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermNotesPayable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermLoansPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermLoansPayable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LessCommonStockHeldInTreasuryAtCostAbstract" xlink:href="avco-20250331.xsd#avco_LessCommonStockHeldInTreasuryAtCostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="LessCommonStockHeldInTreasuryAtCostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityAbstract" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_MinorityInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesDPreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketingAndAdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketingAndAdvertisingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_MarketingAndAdvertisingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProfessionalFees" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseOther" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtModificationCharge" xlink:href="avco-20250331.xsd#avco_DebtModificationCharge"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="DebtModificationCharge" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="DeemedContributionOnExchangeOfEquityInstruments" xlink:href="avco-20250331.xsd#avco_DeemedContributionOnExchangeOfEquityInstruments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="DeemedContributionOnExchangeOfEquityInstruments" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ProfitLoss_0" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockCommonMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutoryReserveMember" xlink:href="avco-20250331.xsd#avco_StatutoryReserveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="StatutoryReserveMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_NoncontrollingInterestMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="8.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesDPreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueSharesIssuedForAdjustments" xlink:href="avco-20250331.xsd#avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueSharesIssuedForAdjustments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueSaleOfCommonStockNet" xlink:href="avco-20250331.xsd#avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueSaleOfCommonStockNet" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesSaleOfCommonStockNet" xlink:href="avco-20250331.xsd#avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesSaleOfCommonStockNet" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" xlink:href="avco-20250331.xsd#avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" xlink:href="avco-20250331.xsd#avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments" xlink:href="avco-20250331.xsd#avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares_0" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StraightLineRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StraightLineRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StraightLineRent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DistributionOfEarningsFromEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_DistributionOfEarningsFromEquityMethodInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DistributionOfEarningsFromEquityMethodInvestment" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BeneficialConversionFeatureRelatedToConvertibleNotePayable" xlink:href="avco-20250331.xsd#avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="BeneficialConversionFeatureRelatedToConvertibleNotePayable" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImpairmentOfLaboratoryEquipment" xlink:href="avco-20250331.xsd#avco_ImpairmentOfLaboratoryEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ImpairmentOfLaboratoryEquipment" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnRestructuringOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnRestructuringOfDebt" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInDeferredLeasingCosts" xlink:href="avco-20250331.xsd#avco_IncreaseDecreaseInDeferredLeasingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInDeferredLeasingCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedLiabilitiesAndOtherPayablesRelatedParties" xlink:href="avco-20250331.xsd#avco_AccruedLiabilitiesAndOtherPayablesRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="AccruedLiabilitiesAndOtherPayablesRelatedParties" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuanceOfConvertibleDebtAndWarrants" xlink:href="avco-20250331.xsd#avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfConvertibleDebtAndWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentsOfConvertibleDebtIssuanceCosts" xlink:href="avco-20250331.xsd#avco_PaymentsOfConvertibleDebtIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsOfConvertibleDebtIssuanceCosts" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsToMinorityShareholders" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromOtherEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedForAccruedLiabilities" xlink:href="avco-20250331.xsd#avco_CommonStockIssuedForAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="CommonStockIssuedForAccruedLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceivableRelatedToSaleOfEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_ReceivableRelatedToSaleOfEquityMethodInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ReceivableRelatedToSaleOfEquityMethodInvestment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" xlink:href="avco-20250331.xsd#avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsIssuedWithConvertibleNotePayable" xlink:href="avco-20250331.xsd#avco_WarrantsIssuedWithConvertibleNotePayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="WarrantsIssuedWithConvertibleNotePayable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedPurchasePriceRelatedToEquityMethodInvestment" xlink:href="avco-20250331.xsd#avco_AccruedPurchasePriceRelatedToEquityMethodInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="AccruedPurchasePriceRelatedToEquityMethodInvestment" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsIssuedAsConvertibleNotePayableFindersFee" xlink:href="avco-20250331.xsd#avco_WarrantsIssuedAsConvertibleNotePayableFindersFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="WarrantsIssuedAsConvertibleNotePayableFindersFee" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount" xlink:href="avco-20250331.xsd#avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedAsConvertibleNotePayableCommitmentFee" xlink:href="avco-20250331.xsd#avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="CommonStockIssuedAsConvertibleNotePayableCommitmentFee" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount" xlink:href="avco-20250331.xsd#avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock" xlink:href="avco-20250331.xsd#avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredFinancingCostsInAccruedLiabilities" xlink:href="avco-20250331.xsd#avco_DeferredFinancingCostsInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="DeferredFinancingCostsInAccruedLiabilities" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalDeferredPurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_SupplementalDeferredPurchasePrice" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SettlementsOfDerivativeLiability" xlink:href="avco-20250331.xsd#avco_SettlementsOfDerivativeLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="SettlementsOfDerivativeLiability" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty" xlink:href="avco-20250331.xsd#avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant" xlink:href="avco-20250331.xsd#avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/OrganizationandNatureofOperations" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernCondition" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="BasisOfPresentationAndGoingConcernConditionAbstract" xlink:href="avco-20250331.xsd#avco_BasisOfPresentationAndGoingConcernConditionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisOfPresentationAndGoingConcernConditionAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/PrepaidExpenseandOtherCurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/PropertyandEquipment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/EquipmentHeldForSale" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract" xlink:to="us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/InvestmentinRealEstate" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RealEstateInvestmentsAbstract" xlink:to="us-gaap_RealEstateDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/EquityMethodInvestments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ConvertibleNotePayable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/DerivativeLiability" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/NotePayableNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/Equity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestrictedAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="StatutoryReserveAndRestrictedNetAssetsTextBlock" xlink:href="avco-20250331.xsd#avco_StatutoryReserveAndRestrictedNetAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherRestrictedAssetsAbstract" xlink:to="StatutoryReserveAndRestrictedNetAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/NoncontrollingInterest" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompany" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/Concentrations" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/SegmentInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredOfferingCostsPolicyTextBlock" xlink:href="avco-20250331.xsd#avco_DeferredOfferingCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DeferredOfferingCostsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentInRealEstateAndDepreciationPolicyTextBlock" xlink:href="avco-20250331.xsd#avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="InvestmentInRealEstateAndDepreciationPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredRentalIncomePolicyTextBlock" xlink:href="avco-20250331.xsd#avco_DeferredRentalIncomePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DeferredRentalIncomePolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RealPropertyRentalRevenuePolicyTextBlock" xlink:href="avco-20250331.xsd#avco_RealPropertyRentalRevenuePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RealPropertyRentalRevenuePolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LessorLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LessorLeasesPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstatePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstatePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RealEstatePolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtModificationsAndExtinguishmentsPolicyTextBlock" xlink:href="avco-20250331.xsd#avco_DebtModificationsAndExtinguishmentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DebtModificationsAndExtinguishmentsPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoncontrollingInterestPolicyTextBlock" xlink:href="avco-20250331.xsd#avco_NoncontrollingInterestPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NoncontrollingInterestPolicyTextBlock" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiscalPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiscalPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FiscalPeriod" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReverseStockSplitPolicyTextBlock" xlink:href="avco-20250331.xsd#avco_ReverseStockSplitPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ReverseStockSplitPolicyTextBlock" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/PrepaidExpenseandOtherCurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseCurrentAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/InvestmentinRealEstateTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RealEstateInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/EquityMethodInvestmentsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ConvertibleNotePayableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/NotePayableNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/EquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityTablesTable" xlink:href="avco-20250331.xsd#avco_EquityTablesTable"/>
    <loc xlink:type="locator" xlink:label="EquityTablesLineItems" xlink:href="avco-20250331.xsd#avco_EquityTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="EquityTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityTablesTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OptionsOutstandingMember" xlink:href="avco-20250331.xsd#avco_OptionsOutstandingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="OptionsOutstandingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOutstandingMember" xlink:href="avco-20250331.xsd#avco_WarrantsOutstandingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="WarrantsOutstandingMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityTablesTable" xlink:to="EquityTablesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityTablesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityTablesLineItems" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ConcentrationsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/SegmentInformationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfConsolidatedFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_OwnershipAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AvalonHealthcareSystemIncMember" xlink:href="avco-20250331.xsd#avco_AvalonHealthcareSystemIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvalonHealthcareSystemIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvalonRT9PropertiesLLCMember" xlink:href="avco-20250331.xsd#avco_AvalonRT9PropertiesLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvalonRT9PropertiesLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvalonShanghaiHealthcareTechnologyCoLtdMember" xlink:href="avco-20250331.xsd#avco_AvalonShanghaiHealthcareTechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvalonShanghaiHealthcareTechnologyCoLtdMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenExosomeTechnologiesIncMember" xlink:href="avco-20250331.xsd#avco_GenExosomeTechnologiesIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="GenExosomeTechnologiesIncMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvactisBiosciencesIncMember" xlink:href="avco-20250331.xsd#avco_AvactisBiosciencesIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvactisBiosciencesIncMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvactisNanjingBiosciencesLtdMember" xlink:href="avco-20250331.xsd#avco_AvactisNanjingBiosciencesLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvactisNanjingBiosciencesLtdMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvalonLaboratoryServicesIncMember" xlink:href="avco-20250331.xsd#avco_AvalonLaboratoryServicesIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvalonLaboratoryServicesIncMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="QADistributionLLCMember" xlink:href="avco-20250331.xsd#avco_QADistributionLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="QADistributionLLCMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentPlaceAndDateOfIncorporation" xlink:href="avco-20250331.xsd#avco_EquityMethodInvestmentPlaceAndDateOfIncorporation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="EquityMethodInvestmentPlaceAndDateOfIncorporation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDerivativeLiabilityMeasuredAtFairValueAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfDerivativeLiabilityMeasuredAtFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDerivativeLiabilityMeasuredAtFairValueAbstract" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise" xlink:href="avco-20250331.xsd#avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashBalancesByGeographicAreaAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfCashBalancesByGeographicAreaAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashBalancesByGeographicAreaAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_CN" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashPercentage" xlink:href="avco-20250331.xsd#avco_CashPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="CashPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfSecuritiesThatWereExcludedFromTheDilutedPerShareAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfSecuritiesThatWereExcludedFromTheDilutedPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSecuritiesThatWereExcludedFromTheDilutedPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OptionsToPurchaseCommonStockMember" xlink:href="avco-20250331.xsd#avco_OptionsToPurchaseCommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="OptionsToPurchaseCommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaidProfessionalFees" xlink:href="avco-20250331.xsd#avco_PrepaidProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="PrepaidProfessionalFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidReinsurancePremiums" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidReinsurancePremiums"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidReinsurancePremiums" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsLeasingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsLeasingNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsLeasingNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_SecurityDeposit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromCorrespondentBrokers" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DueFromCorrespondentBrokers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DueFromCorrespondentBrokers" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValueAddedTaxReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ValueAddedTaxReceivable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LaboratoryEquipmentMember" xlink:href="avco-20250331.xsd#avco_LaboratoryEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LaboratoryEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofInvestmentinRealEstateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfInvestmentInRealEstateAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfInvestmentInRealEstateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRealEstatePropertiesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInvestmentInRealEstateAbstract" xlink:to="us-gaap_ScheduleOfRealEstatePropertiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollateralAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRealEstatePropertiesTable" xlink:to="us-gaap_CollateralAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollateralDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommercialRealEstateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialRealEstateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CommercialRealEstateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_LandImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRealEstatePropertiesTable" xlink:to="us-gaap_RealEstateLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RealEstateLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestmentPropertyAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestmentPropertyAtCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RealEstateLineItems" xlink:to="us-gaap_RealEstateInvestmentPropertyAtCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RealEstateLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestmentPropertyNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestmentPropertyNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RealEstateLineItems" xlink:to="us-gaap_RealEstateInvestmentPropertyNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEquityMethodInvestmentAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfEquityMethodInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentAbstract" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="LabServicesMSOMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets" xlink:href="avco-20250331.xsd#avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets" xlink:href="avco-20250331.xsd#avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LabServicesMSOsNetIncomeAttributableToTheCompany" xlink:href="avco-20250331.xsd#avco_LabServicesMSOsNetIncomeAttributableToTheCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="LabServicesMSOsNetIncomeAttributableToTheCompany" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestments_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfSummarizedFinancialInformationAsProvidedToTheCompanyByTheInvesteeAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfSummarizedFinancialInformationAsProvidedToTheCompanyByTheInvesteeAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSummarizedFinancialInformationAsProvidedToTheCompanyByTheInvesteeAbstract" xlink:to="srt_CondensedBalanceSheetStatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="InvestmentInLaboratoryServicesMSOLLCMember" xlink:href="avco-20250331.xsd#avco_InvestmentInLaboratoryServicesMSOLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="InvestmentInLaboratoryServicesMSOLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialInformationAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfFinancialInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedIncomeStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialInformationAbstract" xlink:to="srt_CondensedIncomeStatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="InvestmentInLaboratoryServicesMSOLLCMember" xlink:href="avco-20250331.xsd#avco_InvestmentInLaboratoryServicesMSOLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="InvestmentInLaboratoryServicesMSOLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_GrossProfit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_ProfitLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="AccruedTenantsImprovementReimbursement" xlink:href="avco-20250331.xsd#avco_AccruedTenantsImprovementReimbursement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedTenantsImprovementReimbursement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Deposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_Deposits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedBusinessExpenseReimbursement" xlink:href="avco-20250331.xsd#avco_AccruedBusinessExpenseReimbursement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedBusinessExpenseReimbursement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedUtilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedUtilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedUtilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncome" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedRealPropertyCleaningServiceFee" xlink:href="avco-20250331.xsd#avco_AccruedRealPropertyCleaningServiceFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedRealPropertyCleaningServiceFee" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAmortizationPaymentsInCashAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfAmortizationPaymentsInCashAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmortizationPaymentsInCashAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_AwardDateAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DecemberFiveTwoThousandTwentyFourMember" xlink:href="avco-20250331.xsd#avco_DecemberFiveTwoThousandTwentyFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="DecemberFiveTwoThousandTwentyFourMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JanuaryFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_JanuaryFiveTwoThousandTwentyFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="JanuaryFiveTwoThousandTwentyFiveMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FebruaryFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_FebruaryFiveTwoThousandTwentyFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="FebruaryFiveTwoThousandTwentyFiveMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarchFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_MarchFiveTwoThousandTwentyFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="MarchFiveTwoThousandTwentyFiveMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AprilFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_AprilFiveTwoThousandTwentyFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="AprilFiveTwoThousandTwentyFiveMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MayFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_MayFiveTwoThousandTwentyFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="MayFiveTwoThousandTwentyFiveMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JuneFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_JuneFiveTwoThousandTwentyFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="JuneFiveTwoThousandTwentyFiveMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MastHillMember" xlink:href="avco-20250331.xsd#avco_MastHillMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="MastHillMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfConvertibleNotePayableAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfConvertibleNotePayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable" xlink:href="avco-20250331.xsd#avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems" xlink:href="avco-20250331.xsd#avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertibleNotePayableAbstract" xlink:to="ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable" xlink:to="ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofNotePayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_OtherNotesPayableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofLineofCreditTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="DrawDownFromLineOfCredit" xlink:href="avco-20250331.xsd#avco_DrawDownFromLineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="DrawDownFromLineOfCredit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassificationOfLineOfCreditToAdvanceFromRelatedParty" xlink:href="avco-20250331.xsd#avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAbstract" xlink:to="ReclassificationOfLineOfCreditToAdvanceFromRelatedParty" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofCompanysLossBeforeIncomeTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsPartnershipInvestment" xlink:href="avco-20250331.xsd#avco_DeferredTaxAssetsPartnershipInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="DeferredTaxAssetsPartnershipInvestment" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesRegulatoryAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesRegulatoryAssets" xlink:to="us-gaap_DeferredTaxLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCommonStockIssuableUponExerciseOfWarrantsOutstandingAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfCommonStockIssuableUponExerciseOfWarrantsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingDetailsTable" xlink:href="avco-20250331.xsd#avco_EquityScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCommonStockIssuableUponExerciseOfWarrantsOutstandingAbstract" xlink:to="EquityScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingDetailsTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeOneMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeTwoMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeThreeMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeThreeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeFourMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeFourMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingDetailsTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivityAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityScheduleofStockOptionActivityDetailsTable" xlink:href="avco-20250331.xsd#avco_EquityScheduleofStockOptionActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="EquityScheduleofStockOptionActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfNonvestedStockOptionsGrantedAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfNonvestedStockOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" xlink:href="avco-20250331.xsd#avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNonvestedStockOptionsGrantedAbstract" xlink:to="EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" xlink:to="srt_RestatementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" xlink:to="us-gaap_VestingAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NonvestedMember" xlink:href="avco-20250331.xsd#avco_NonvestedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="NonvestedMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues" xlink:href="avco-20250331.xsd#avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCommonStockIssuableUponExerciseOfOptionsOutstandingAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfCommonStockIssuableUponExerciseOfOptionsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCommonStockIssuableUponExerciseOfOptionsOutstandingAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="WarrantsOutstandingMember" xlink:href="avco-20250331.xsd#avco_WarrantsOutstandingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="WarrantsOutstandingMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeOneMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeTwoMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeFourMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeFourMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeFiveMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeFiveMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCustomerAccountedForCompanysRevenuesAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfCustomerAccountedForCompanysRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCustomerAccountedForCompanysRevenuesAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CustomerAMember" xlink:href="avco-20250331.xsd#avco_CustomerAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerBMember" xlink:href="avco-20250331.xsd#avco_CustomerBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerCMember" xlink:href="avco-20250331.xsd#avco_CustomerCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfReportableBusinessSegmentsAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfReportableBusinessSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReportableBusinessSegmentsAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RealPropertyOperationsMember" xlink:href="avco-20250331.xsd#avco_RealPropertyOperationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="RealPropertyOperationsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="LabServicesMSOMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateOtherMember" xlink:href="avco-20250331.xsd#avco_CorporateOtherMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="CorporateOtherMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InterestExpenseNonoperating" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherIncome" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RealPropertyOperatingMember" xlink:href="avco-20250331.xsd#avco_RealPropertyOperatingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="RealPropertyOperatingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateOtherMember" xlink:href="avco-20250331.xsd#avco_CorporateOtherMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="CorporateOtherMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_NoncurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIdentifiableLongLivedTangibleAssetsGeographicAreasAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfIdentifiableLongLivedTangibleAssetsGeographicAreasAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIdentifiableLongLivedTangibleAssetsGeographicAreasAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_CN" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_NoncurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofLeaseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowInvestingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowInvestingActivitiesLesseeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_CashFlowInvestingActivitiesLesseeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowInvestingActivitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities" xlink:href="avco-20250331.xsd#avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfConsolidatedFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConsolidatedFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="srt_OwnershipAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AvalonHealthcareSystemIncMember" xlink:href="avco-20250331.xsd#avco_AvalonHealthcareSystemIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvalonHealthcareSystemIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvalonRT9PropertiesLLCMember" xlink:href="avco-20250331.xsd#avco_AvalonRT9PropertiesLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvalonRT9PropertiesLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvalonShanghaiHealthcareTechnologyCoLtdMember" xlink:href="avco-20250331.xsd#avco_AvalonShanghaiHealthcareTechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvalonShanghaiHealthcareTechnologyCoLtdMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenExosomeTechnologiesIncMember" xlink:href="avco-20250331.xsd#avco_GenExosomeTechnologiesIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="GenExosomeTechnologiesIncMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvactisBiosciencesIncMember" xlink:href="avco-20250331.xsd#avco_AvactisBiosciencesIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvactisBiosciencesIncMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvactisNanjingBiosciencesLtdMember" xlink:href="avco-20250331.xsd#avco_AvactisNanjingBiosciencesLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvactisNanjingBiosciencesLtdMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvalonLaboratoryServicesIncMember" xlink:href="avco-20250331.xsd#avco_AvalonLaboratoryServicesIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvalonLaboratoryServicesIncMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="QADistributionLLCMember" xlink:href="avco-20250331.xsd#avco_QADistributionLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="QADistributionLLCMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentPlaceAndDateOfIncorporation" xlink:href="avco-20250331.xsd#avco_EquityMethodInvestmentPlaceAndDateOfIncorporation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="EquityMethodInvestmentPlaceAndDateOfIncorporation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDerivativeLiabilityMeasuredAtFairValueAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfDerivativeLiabilityMeasuredAtFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDerivativeLiabilityMeasuredAtFairValueAbstract" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashBalancesByGeographicAreaAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfCashBalancesByGeographicAreaAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashBalancesByGeographicAreaAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_CN" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashPercentage" xlink:href="avco-20250331.xsd#avco_CashPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="CashPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfSecuritiesThatWereExcludedFromTheDilutedPerShareAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfSecuritiesThatWereExcludedFromTheDilutedPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSecuritiesThatWereExcludedFromTheDilutedPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OptionsToPurchaseCommonStockMember" xlink:href="avco-20250331.xsd#avco_OptionsToPurchaseCommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="OptionsToPurchaseCommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_SeriesDPreferredStockMember" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra/k4DNHXVKIYwN/zLXIt0iwZq6nYg/w27/nmgU3Bs4kyGGa1okQf8wpc8xue3C4gYCyO+De2FMpGD6T1rBTmQ8hA/UC+V/TeVcwU7ABGe/tb9Nse+XBO1hN0S6XbJQbcJwedpHBgl7i050GjffC4p7Iw/J3z5vZfcXGGwK1wcBZ+q2HcISatlXTlFgsMKO5QeDDlx75B8z8hjuvV5IPRmtFIaAZaCRuKG6FjDX4pVgOp5oPqEWkDsPjlHHH8ItpUw=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaidProfessionalFees" xlink:href="avco-20250331.xsd#avco_PrepaidProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="PrepaidProfessionalFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidReinsurancePremiums" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidReinsurancePremiums"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidReinsurancePremiums" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseOtherNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsLeasingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsLeasingNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsLeasingNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_SecurityDeposit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromCorrespondentBrokers" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DueFromCorrespondentBrokers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DueFromCorrespondentBrokers" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValueAddedTaxReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ValueAddedTaxReceivable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEquityMethodInvestmentAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfEquityMethodInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentAbstract" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="LabServicesMSOMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="LabServicesMSOsNetIncomeAttributableToTheCompany" xlink:href="avco-20250331.xsd#avco_LabServicesMSOsNetIncomeAttributableToTheCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="LabServicesMSOsNetIncomeAttributableToTheCompany" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestments_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialInformationAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfFinancialInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedIncomeStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialInformationAbstract" xlink:to="srt_CondensedIncomeStatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="InvestmentInLaboratoryServicesMSOLLCMember" xlink:href="avco-20250331.xsd#avco_InvestmentInLaboratoryServicesMSOLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="InvestmentInLaboratoryServicesMSOLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_GrossProfit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_ProfitLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAmortizationPaymentsInCashAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfAmortizationPaymentsInCashAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmortizationPaymentsInCashAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_AwardDateAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DecemberFiveTwoThousandTwentyFourMember" xlink:href="avco-20250331.xsd#avco_DecemberFiveTwoThousandTwentyFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="DecemberFiveTwoThousandTwentyFourMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JanuaryFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_JanuaryFiveTwoThousandTwentyFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="JanuaryFiveTwoThousandTwentyFiveMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FebruaryFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_FebruaryFiveTwoThousandTwentyFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="FebruaryFiveTwoThousandTwentyFiveMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarchFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_MarchFiveTwoThousandTwentyFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="MarchFiveTwoThousandTwentyFiveMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AprilFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_AprilFiveTwoThousandTwentyFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="AprilFiveTwoThousandTwentyFiveMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MayFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_MayFiveTwoThousandTwentyFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="MayFiveTwoThousandTwentyFiveMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JuneFiveTwoThousandTwentyFiveMember" xlink:href="avco-20250331.xsd#avco_JuneFiveTwoThousandTwentyFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="JuneFiveTwoThousandTwentyFiveMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="MastHillMember" xlink:href="avco-20250331.xsd#avco_MastHillMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="MastHillMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfConvertibleNotePayableAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfConvertibleNotePayableAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable" xlink:href="avco-20250331.xsd#avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertibleNotePayableAbstract" xlink:to="ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable" xlink:to="us-gaap_LineOfCreditFacilityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofNotePayableTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCommonStockIssuableUponExerciseOfOptionsOutstandingAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfCommonStockIssuableUponExerciseOfOptionsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCommonStockIssuableUponExerciseOfOptionsOutstandingAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OptionsOutstandingMember" xlink:href="avco-20250331.xsd#avco_OptionsOutstandingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="OptionsOutstandingMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeOneMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeTwoMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeThreeMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeThreeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeFourMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeFourMember" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivityAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityScheduleofStockOptionActivityDetailsTable" xlink:href="avco-20250331.xsd#avco_EquityScheduleofStockOptionActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="EquityScheduleofStockOptionActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofStockOptionActivityDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfNonvestedStockOptionsGrantedAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfNonvestedStockOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" xlink:href="avco-20250331.xsd#avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNonvestedStockOptionsGrantedAbstract" xlink:to="EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" xlink:to="us-gaap_VestingAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NonvestedMember" xlink:href="avco-20250331.xsd#avco_NonvestedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="NonvestedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityScheduleofNonvestedStockOptionsGrantedDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues" xlink:href="avco-20250331.xsd#avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCommonStockIssuableUponExerciseOfOptionsOutstandingAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfCommonStockIssuableUponExerciseOfOptionsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCommonStockIssuableUponExerciseOfOptionsOutstandingAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="WarrantsOutstandingMember" xlink:href="avco-20250331.xsd#avco_WarrantsOutstandingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="WarrantsOutstandingMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeOneMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeTwoMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeFourMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeFourMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeFiveMember" xlink:href="avco-20250331.xsd#avco_ExercisePriceRangeFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeFiveMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCustomerAccountedForCompanysRevenuesAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfCustomerAccountedForCompanysRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCustomerAccountedForCompanysRevenuesAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CustomerAMember" xlink:href="avco-20250331.xsd#avco_CustomerAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerBMember" xlink:href="avco-20250331.xsd#avco_CustomerBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerCMember" xlink:href="avco-20250331.xsd#avco_CustomerCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfReportableBusinessSegmentsAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfReportableBusinessSegmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfReportableBusinessSegmentsAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RealPropertyOperationsMember" xlink:href="avco-20250331.xsd#avco_RealPropertyOperationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="RealPropertyOperationsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="LabServicesMSOMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateOtherMember" xlink:href="avco-20250331.xsd#avco_CorporateOtherMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="CorporateOtherMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InterestExpenseNonoperating" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherIncome" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ProfitLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RealPropertyOperatingMember" xlink:href="avco-20250331.xsd#avco_RealPropertyOperatingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="RealPropertyOperatingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateOtherMember" xlink:href="avco-20250331.xsd#avco_CorporateOtherMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="CorporateOtherMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_NoncurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIdentifiableLongLivedTangibleAssetsGeographicAreasAbstract" xlink:href="avco-20250331.xsd#avco_ScheduleOfIdentifiableLongLivedTangibleAssetsGeographicAreasAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIdentifiableLongLivedTangibleAssetsGeographicAreasAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_CN" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_NoncurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofLeaseTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowInvestingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowInvestingActivitiesLesseeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_CashFlowInvestingActivitiesLesseeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowInvestingActivitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_OperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_OperatingLeaseLiability_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandNatureofOperationsDetailsTable" xlink:href="avco-20250331.xsd#avco_OrganizationandNatureofOperationsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationandNatureofOperationsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofOperationsDetailsTable" xlink:to="srt_OwnershipAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AvalonHealthcareSystemIncMember" xlink:href="avco-20250331.xsd#avco_AvalonHealthcareSystemIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvalonHealthcareSystemIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AvalonRT9PropertiesLLCMember" xlink:href="avco-20250331.xsd#avco_AvalonRT9PropertiesLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvalonRT9PropertiesLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AvactisAndArbeleBiotherapeuticsLimitedMember" xlink:href="avco-20250331.xsd#avco_AvactisAndArbeleBiotherapeuticsLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvactisAndArbeleBiotherapeuticsLimitedMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvactisBiosciencesIncMember" xlink:href="avco-20250331.xsd#avco_AvactisBiosciencesIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvactisBiosciencesIncMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AvalonLabMember" xlink:href="avco-20250331.xsd#avco_AvalonLabMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvalonLabMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="LabServicesMSOMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofOperationsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofOperationsDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofOperationsDetailsTable" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems" xlink:to="us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="BasisOfPresentationAndGoingConcernConditionAbstract" xlink:href="avco-20250331.xsd#avco_BasisOfPresentationAndGoingConcernConditionAbstract"/>
    <loc xlink:type="locator" xlink:label="BasisofPresentationandGoingConcernConditionDetailsTable" xlink:href="avco-20250331.xsd#avco_BasisofPresentationandGoingConcernConditionDetailsTable"/>
    <loc xlink:type="locator" xlink:label="BasisofPresentationandGoingConcernConditionDetailsLineItems" xlink:href="avco-20250331.xsd#avco_BasisofPresentationandGoingConcernConditionDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisOfPresentationAndGoingConcernConditionAbstract" xlink:to="BasisofPresentationandGoingConcernConditionDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisofPresentationandGoingConcernConditionDetailsTable" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentOperatingActivitiesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="us-gaap_SegmentOperatingActivitiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentContinuingOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="us-gaap_SegmentContinuingOperationsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisofPresentationandGoingConcernConditionDetailsTable" xlink:to="BasisofPresentationandGoingConcernConditionDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="WorkingCapitalDeficit" xlink:href="avco-20250331.xsd#avco_WorkingCapitalDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisofPresentationandGoingConcernConditionDetailsLineItems" xlink:to="WorkingCapitalDeficit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisofPresentationandGoingConcernConditionDetailsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisofPresentationandGoingConcernConditionDetailsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisofPresentationandGoingConcernConditionDetailsLineItems" xlink:to="us-gaap_ProfitLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="avco-20250331.xsd#avco_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="avco-20250331.xsd#avco_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAConvertiblePreferredStockMember" xlink:href="avco-20250331.xsd#avco_SeriesAConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesAConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesDPreferredStockMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegulatoryAssetAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegulatoryAssetAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RegulatoryAssetAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RegulatoryAssetDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RegulatoryAssetDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegulatoryAssetAxis" xlink:to="us-gaap_RegulatoryAssetDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DeferredOfferingCostsMember" xlink:href="avco-20250331.xsd#avco_DeferredOfferingCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RegulatoryAssetAxis" xlink:to="DeferredOfferingCostsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_CN" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LaboratoryEquipmentMember" xlink:href="avco-20250331.xsd#avco_LaboratoryEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LaboratoryEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LaboratoryServicesMSOLLCMember" xlink:href="avco-20250331.xsd#avco_LaboratoryServicesMSOLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="LaboratoryServicesMSOLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LabServicesMSOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_EquityMethodInvestmentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AssetAndLiabilityAccountsMember" xlink:href="avco-20250331.xsd#avco_AssetAndLiabilityAccountsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="AssetAndLiabilityAccountsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EpiconBiotechCoLtdMember" xlink:href="avco-20250331.xsd#avco_EpiconBiotechCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EpiconBiotechCoLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DrYuZhouMember" xlink:href="avco-20250331.xsd#avco_DrYuZhouMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="DrYuZhouMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrantsMember" xlink:href="avco-20250331.xsd#avco_PreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PreFundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsLineItems" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFDICInsuredAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalReserveBankStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalReserveBankStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_FederalReserveBankStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_OtherAssetImpairmentCharges" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredIncome" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredAdvertisingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredAdvertisingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredAdvertisingCosts" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityInterestPercent" xlink:href="avco-20250331.xsd#avco_EquityInterestPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="EquityInterestPercent" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentDividendsOrDistributions" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfEquityInvestment" xlink:href="avco-20250331.xsd#avco_PaymentOfEquityInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="PaymentOfEquityInvestment" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegularPaymentsOnEquityInvestments" xlink:href="avco-20250331.xsd#avco_RegularPaymentsOnEquityInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="RegularPaymentsOnEquityInvestments" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableInvestmentSale" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableInvestmentSale"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ReceivableInvestmentSale" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AssetsCurrent" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DilutiveSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DilutiveSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DilutiveSecurities" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_CostsAndExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherOperatingExpense" xlink:href="avco-20250331.xsd#avco_OtherOperatingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="OtherOperatingExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/EquipmentHeldForSaleDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ImpairmentOfLaboratoryEquipment" xlink:href="avco-20250331.xsd#avco_ImpairmentOfLaboratoryEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract" xlink:to="ImpairmentOfLaboratoryEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/InvestmentinRealEstateDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealEstateInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RealEstateInvestmentsAbstract" xlink:to="us-gaap_OtherDepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentsDetailsTable" xlink:href="avco-20250331.xsd#avco_EquityMethodInvestmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="EquityMethodInvestmentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentsDetailsTable" xlink:to="srt_OwnershipAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AvalonShangaiMember" xlink:href="avco-20250331.xsd#avco_AvalonShangaiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvalonShangaiMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JiangsuUnicornBiologicalTechnologyCoLtdMember" xlink:href="avco-20250331.xsd#avco_JiangsuUnicornBiologicalTechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="JiangsuUnicornBiologicalTechnologyCoLtdMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesBStatedValueMember" xlink:href="avco-20250331.xsd#avco_SeriesBStatedValueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBStatedValueMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentsDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAConvertiblePreferredStockMember" xlink:href="avco-20250331.xsd#avco_SeriesAConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="SeriesAConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBConvertiblePreferredStockMember" xlink:href="avco-20250331.xsd#avco_SeriesBConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="SeriesBConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBStatedValueMember_0" xlink:href="avco-20250331.xsd#avco_SeriesBStatedValueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="SeriesBStatedValueMember_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentsDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LaboratoryServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LaboratoryServicesMSOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="LaboratoryServicesMSOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EpiconBiotechCoLtdMember" xlink:href="avco-20250331.xsd#avco_EpiconBiotechCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EpiconBiotechCoLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentInEpiconBiotechCoLtdMember" xlink:href="avco-20250331.xsd#avco_InvestmentInEpiconBiotechCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="InvestmentInEpiconBiotechCoLtdMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LaboratoryServicesMSOMember_0" xlink:href="avco-20250331.xsd#avco_LaboratoryServicesMSOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="LaboratoryServicesMSOMember_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LabServicesMember" xlink:href="avco-20250331.xsd#avco_LabServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="LabServicesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentsDetailsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentSoldCarryingAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PreferredStockValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentPayableCurrent" xlink:href="avco-20250331.xsd#avco_EquityMethodInvestmentPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="EquityMethodInvestmentPayableCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateOfCommonStock" xlink:href="avco-20250331.xsd#avco_AggregateOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="AggregateOfCommonStock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_InvestmentOwnedAtCost" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LabServicesMSOsNetIncomeAttributableToTheCompany" xlink:href="avco-20250331.xsd#avco_LabServicesMSOsNetIncomeAttributableToTheCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="LabServicesMSOsNetIncomeAttributableToTheCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_GoodwillFairValueDisclosure" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotePayableDetailsTable" xlink:href="avco-20250331.xsd#avco_ConvertibleNotePayableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="ConvertibleNotePayableDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MastHillFundLPMember" xlink:href="avco-20250331.xsd#avco_MastHillFundLPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MastHillFundLPMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstFireMember" xlink:href="avco-20250331.xsd#avco_FirstFireMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="FirstFireMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MastHillMember" xlink:href="avco-20250331.xsd#avco_MastHillMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MastHillMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputSharePriceMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_SeniorNotesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradingActivityByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_TradingActivityByTypeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradingActivityByTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TradingActivityByTypeAxis" xlink:to="us-gaap_TradingActivityByTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherTradingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherTradingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TradingActivityByTypeAxis" xlink:to="us-gaap_OtherTradingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="May2023ConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_May2023ConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="May2023ConvertibleNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="July2023ConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_July2023ConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="July2023ConvertibleNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="October2023ConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_October2023ConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="October2023ConvertibleNoteMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="March2024ConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_March2024ConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="March2024ConvertibleNoteMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="June2024ConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_June2024ConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="June2024ConvertibleNoteMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WaiverFeeMember" xlink:href="avco-20250331.xsd#avco_WaiverFeeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="WaiverFeeMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="FirstWarrantMember" xlink:href="avco-20250331.xsd#avco_FirstWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="FirstWarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecondWarrantMember" xlink:href="avco-20250331.xsd#avco_SecondWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="SecondWarrantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrantsMember" xlink:href="avco-20250331.xsd#avco_PreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PreFundedWarrantsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotePayableDetailsTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentConvertibleFloorPrice" xlink:href="avco-20250331.xsd#avco_DebtInstrumentConvertibleFloorPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="DebtInstrumentConvertibleFloorPrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfPromissoryNotes" xlink:href="avco-20250331.xsd#avco_PercentageOfPromissoryNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="PercentageOfPromissoryNotes" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TradingPrice" xlink:href="avco-20250331.xsd#avco_TradingPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="TradingPrice" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePriceOfConvertibleNote" xlink:href="avco-20250331.xsd#avco_PurchasePriceOfConvertibleNote"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="PurchasePriceOfConvertibleNote" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonUnitOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CommonUnitOutstanding" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPriceIncrease" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NontradeReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NontradeReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NontradeReceivables" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentForCommission" xlink:href="avco-20250331.xsd#avco_PaymentForCommission"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="PaymentForCommission" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndDebtExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestAndDebtExpense" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/DerivativeLiabilityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="DerivativeLiabilityDetailsTable" xlink:href="avco-20250331.xsd#avco_DerivativeLiabilityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeLiabilitiesAbstract" xlink:to="DerivativeLiabilityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeLiabilityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MastHillMember" xlink:href="avco-20250331.xsd#avco_MastHillMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="MastHillMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeLiabilityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="May232023FiveYearAnniversaryMember" xlink:href="avco-20250331.xsd#avco_May232023FiveYearAnniversaryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="May232023FiveYearAnniversaryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="July62023FiveYearAnniversaryMember" xlink:href="avco-20250331.xsd#avco_July62023FiveYearAnniversaryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="July62023FiveYearAnniversaryMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="October92023FiveYearAnniversaryMember" xlink:href="avco-20250331.xsd#avco_October92023FiveYearAnniversaryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="October92023FiveYearAnniversaryMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="March72024FiveYearAnniversaryMember" xlink:href="avco-20250331.xsd#avco_March72024FiveYearAnniversaryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="March72024FiveYearAnniversaryMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="June52024FiveyearAnniversaryMember" xlink:href="avco-20250331.xsd#avco_June52024FiveyearAnniversaryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="June52024FiveyearAnniversaryMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeLiabilityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FirstFireMember" xlink:href="avco-20250331.xsd#avco_FirstFireMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="FirstFireMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MastHillAndFirstfireMember" xlink:href="avco-20250331.xsd#avco_MastHillAndFirstfireMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MastHillAndFirstfireMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MastHillThirdPartyMember" xlink:href="avco-20250331.xsd#avco_MastHillThirdPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MastHillThirdPartyMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MastHillMember_0" xlink:href="avco-20250331.xsd#avco_MastHillMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MastHillMember_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="findersFeeMember" xlink:href="avco-20250331.xsd#avco_findersFeeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="findersFeeMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeLiabilityDetailsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputSharePriceMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeLiabilityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeLiabilityDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="May232023FiveYearAnniversaryMember_0" xlink:href="avco-20250331.xsd#avco_May232023FiveYearAnniversaryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="May232023FiveYearAnniversaryMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="October92023FiveYearAnniversaryMember_0" xlink:href="avco-20250331.xsd#avco_October92023FiveYearAnniversaryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="October92023FiveYearAnniversaryMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="June52024FiveyearAnniversaryMember_0" xlink:href="avco-20250331.xsd#avco_June52024FiveyearAnniversaryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="June52024FiveyearAnniversaryMember_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="July62023FiveYearAnniversaryMember_0" xlink:href="avco-20250331.xsd#avco_July62023FiveYearAnniversaryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="July62023FiveYearAnniversaryMember_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="March72024FiveYearAnniversaryMember_0" xlink:href="avco-20250331.xsd#avco_March72024FiveYearAnniversaryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="March72024FiveYearAnniversaryMember_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="June2024ConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_June2024ConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="June2024ConvertibleNoteMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DerivativeLiabilityDetailsTable" xlink:to="us-gaap_DerivativesFairValueLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOfCashlessExercised" xlink:href="avco-20250331.xsd#avco_WarrantsOfCashlessExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="WarrantsOfCashlessExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/NotePayableNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="NotePayableNetDetailsTable" xlink:href="avco-20250331.xsd#avco_NotePayableNetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="NotePayableNetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayableNetDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PromissoryNoteMember" xlink:href="avco-20250331.xsd#avco_PromissoryNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PromissoryNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayableNetDetailsTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SecuredDebt" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseShortTermBorrowings" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="avco-20250331.xsd#avco_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="srt_OwnershipAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BeijingGenexosomeMember" xlink:href="avco-20250331.xsd#avco_BeijingGenexosomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="BeijingGenexosomeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesDPreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DrYuZhouMember" xlink:href="avco-20250331.xsd#avco_DrYuZhouMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="DrYuZhouMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WenzhaoLuMember" xlink:href="avco-20250331.xsd#avco_WenzhaoLuMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="WenzhaoLuMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvalonRT9Member" xlink:href="avco-20250331.xsd#avco_AvalonRT9Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AvalonRT9Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MrLuMember" xlink:href="avco-20250331.xsd#avco_MrLuMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="MrLuMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvalonRT9Member_0" xlink:href="avco-20250331.xsd#avco_AvalonRT9Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="AvalonRT9Member_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LabServiceMSOMember" xlink:href="avco-20250331.xsd#avco_LabServiceMSOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LabServiceMSOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_CreditFacilityAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_LetterOfCreditMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MembershipInterestPurchaseAgreementMember" xlink:href="avco-20250331.xsd#avco_MembershipInterestPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="MembershipInterestPurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AbandonmentAgreementMember" xlink:href="avco-20250331.xsd#avco_AbandonmentAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="AbandonmentAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="LabServicesMSOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LineOfCreditAgreementMember" xlink:href="avco-20250331.xsd#avco_LineOfCreditAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="LineOfCreditAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RentalIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RentalIncomeNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RentalIncomeNonoperating" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherGeneralExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedAndUnpaidServicesCharge" xlink:href="avco-20250331.xsd#avco_AccruedAndUnpaidServicesCharge"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="AccruedAndUnpaidServicesCharge" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_Cash" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentPayableCurrent" xlink:href="avco-20250331.xsd#avco_EquityMethodInvestmentPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="EquityMethodInvestmentPayableCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpenseOther" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityIncreaseAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LineOfCreditFacilityIncreaseAccruedInterest" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePrice" xlink:href="avco-20250331.xsd#avco_PurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="PurchasePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage" xlink:href="avco-20250331.xsd#avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" xlink:href="avco-20250331.xsd#avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="19.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PreferredStockValue" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_EquityMethodInvestmentDividendsOrDistributions" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLoansHeldForInvestment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLoansHeldForInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsToAcquireLoansHeldForInvestment" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegularPaymentsOnEquityInvestments" xlink:href="avco-20250331.xsd#avco_RegularPaymentsOnEquityInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="RegularPaymentsOnEquityInvestments" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableInvestmentSale" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivableInvestmentSale"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ReceivableInvestmentSale" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OtherNotesPayable" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeShare" xlink:href="avco-20250331.xsd#avco_ExchangeShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ExchangeShare" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="avco-20250331.xsd#avco_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_CN"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_CN" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/EquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="avco-20250331.xsd#avco_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesAConvertiblePreferredStockMember" xlink:href="avco-20250331.xsd#avco_SeriesAConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesAConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesDPreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBConvertiblePreferredStockMember" xlink:href="avco-20250331.xsd#avco_SeriesBConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBConvertiblePreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBHolderMember" xlink:href="avco-20250331.xsd#avco_SeriesBHolderMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBHolderMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MrLuMember" xlink:href="avco-20250331.xsd#avco_MrLuMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="MrLuMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LabServicesMSOMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExercisedMember" xlink:href="avco-20250331.xsd#avco_WarrantsExercisedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="WarrantsExercisedMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrantsMember" xlink:href="avco-20250331.xsd#avco_PreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="PreFundedWarrantsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleDebtMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="May2023CovertibleNoteMember" xlink:href="avco-20250331.xsd#avco_May2023CovertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="May2023CovertibleNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BlackScholesValuationModelMember" xlink:href="avco-20250331.xsd#avco_BlackScholesValuationModelMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="BlackScholesValuationModelMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="July2023ConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_July2023ConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="July2023ConvertibleNoteMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OctoberTwoThousandTwentyThreeConvertibleNotesMember" xlink:href="avco-20250331.xsd#avco_OctoberTwoThousandTwentyThreeConvertibleNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="OctoberTwoThousandTwentyThreeConvertibleNotesMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarchTwoThousandTwentyFourWarrantIssuedMember" xlink:href="avco-20250331.xsd#avco_MarchTwoThousandTwentyFourWarrantIssuedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="MarchTwoThousandTwentyFourWarrantIssuedMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="MarchTwentyThousandTwentyFourConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_MarchTwentyThousandTwentyFourConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="MarchTwentyThousandTwentyFourConvertibleNoteMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourJuneWarrantIssuedMember" xlink:href="avco-20250331.xsd#avco_TwoThousandTwentyFourJuneWarrantIssuedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="TwoThousandTwentyFourJuneWarrantIssuedMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="JuneTwentyThousandTwentyFourConvertibleNoteMember" xlink:href="avco-20250331.xsd#avco_JuneTwentyThousandTwentyFourConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="JuneTwentyThousandTwentyFourConvertibleNoteMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ConvertibleDebtNoteMember" xlink:href="avco-20250331.xsd#avco_ConvertibleDebtNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleDebtNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_OwnershipAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ConversionShareMember" xlink:href="avco-20250331.xsd#avco_ConversionShareMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ConversionShareMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FiveYearAnniversaryMember" xlink:href="avco-20250331.xsd#avco_FiveYearAnniversaryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="FiveYearAnniversaryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonSharesIssuedForServicesMember" xlink:href="avco-20250331.xsd#avco_CommonSharesIssuedForServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="CommonSharesIssuedForServicesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LabServicesMSOMember_0" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="LabServicesMSOMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvalonLabMember" xlink:href="avco-20250331.xsd#avco_AvalonLabMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="AvalonLabMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JefferiesLLCMember" xlink:href="avco-20250331.xsd#avco_JefferiesLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="JefferiesLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_LiabilityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="dei_LegalEntityAxis" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RothCapitalPartnersLLCMember" xlink:href="avco-20250331.xsd#avco_RothCapitalPartnersLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="RothCapitalPartnersLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JefferiesLLCMember_0" xlink:href="avco-20250331.xsd#avco_JefferiesLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="JefferiesLLCMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MastHillMember" xlink:href="avco-20250331.xsd#avco_MastHillMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="MastHillMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MastMillAndFirstFireMember" xlink:href="avco-20250331.xsd#avco_MastMillAndFirstFireMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="MastMillAndFirstFireMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrantsMember_0" xlink:href="avco-20250331.xsd#avco_PreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PreFundedWarrantsMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstfireMember" xlink:href="avco-20250331.xsd#avco_FirstfireMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="FirstfireMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MastHillMember_0" xlink:href="avco-20250331.xsd#avco_MastHillMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="MastHillMember_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FiveYearAnniversaryMember_0" xlink:href="avco-20250331.xsd#avco_FiveYearAnniversaryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="FiveYearAnniversaryMember_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExercisedMember_0" xlink:href="avco-20250331.xsd#avco_WarrantsExercisedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="WarrantsExercisedMember_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockValue" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfCommonStockIssuedAndOutstanding" xlink:href="avco-20250331.xsd#avco_PercentageOfCommonStockIssuedAndOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="PercentageOfCommonStockIssuedAndOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionPricePercentage" xlink:href="avco-20250331.xsd#avco_ConversionPricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ConversionPricePercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="18.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockOfAveragePrice" xlink:href="avco-20250331.xsd#avco_CommonStockOfAveragePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="CommonStockOfAveragePrice" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromOtherEquity" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OfferingCost" xlink:href="avco-20250331.xsd#avco_OfferingCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="OfferingCost" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairMarketValuesOfGrantDates" xlink:href="avco-20250331.xsd#avco_FairMarketValuesOfGrantDates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="FairMarketValuesOfGrantDates" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="30.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProfessionalFees" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" order="41.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="42.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="43.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="44.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="45.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="46.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="47.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="48.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="49.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockRedemptionAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockRedemptionAmount" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RedemptionNetOfPayablesDueToLabServices" xlink:href="avco-20250331.xsd#avco_RedemptionNetOfPayablesDueToLabServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="RedemptionNetOfPayablesDueToLabServices" order="51.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockRedemptionPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockRedemptionPremium" order="52.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="53.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="FairMarketValues" xlink:href="avco-20250331.xsd#avco_FairMarketValues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="FairMarketValues" order="54.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="55.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PrepaidExpenseCurrent" order="56.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestrictedAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="StatutoryReservePercent" xlink:href="avco-20250331.xsd#avco_StatutoryReservePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherRestrictedAssetsAbstract" xlink:to="StatutoryReservePercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegisteredCapitalPercentage" xlink:href="avco-20250331.xsd#avco_RegisteredCapitalPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherRestrictedAssetsAbstract" xlink:to="RegisteredCapitalPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutoryReserve" xlink:href="avco-20250331.xsd#avco_StatutoryReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherRestrictedAssetsAbstract" xlink:to="StatutoryReserve" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherRestrictedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestrictedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherRestrictedAssetsAbstract" xlink:to="us-gaap_OtherRestrictedAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherRestrictedAssetsAbstract" xlink:to="us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/NoncontrollingInterestDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="NoncontrollingInterestDetailsTable" xlink:href="avco-20250331.xsd#avco_NoncontrollingInterestDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="NoncontrollingInterestDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncontrollingInterestDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FormerDirectorAndFormerCochiefExecutiveOfficerMember" xlink:href="avco-20250331.xsd#avco_FormerDirectorAndFormerCochiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="FormerDirectorAndFormerCochiefExecutiveOfficerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncontrollingInterestDetailsTable" xlink:to="srt_OwnershipAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="DrYuZhouMember" xlink:href="avco-20250331.xsd#avco_DrYuZhouMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="DrYuZhouMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncontrollingInterestDetailsTable" xlink:to="us-gaap_MinorityInterestLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompanyDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CondensedFinancialInformationoftheParentCompanyDetailsTable" xlink:href="avco-20250331.xsd#avco_CondensedFinancialInformationoftheParentCompanyDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="CondensedFinancialInformationoftheParentCompanyDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CondensedFinancialInformationoftheParentCompanyDetailsTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PRCSubsidiariesMember" xlink:href="avco-20250331.xsd#avco_PRCSubsidiariesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="PRCSubsidiariesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CondensedFinancialInformationoftheParentCompanyDetailsTable" xlink:to="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RestrictedNetAssetsOfSubsidiaryExceedNetAssets" xlink:href="avco-20250331.xsd#avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="RestrictedNetAssetsOfSubsidiaryExceedNetAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedNetAssetsPRCSubsidiaryDidNotExceed" xlink:href="avco-20250331.xsd#avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="RestrictedNetAssetsPRCSubsidiaryDidNotExceed" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/ConcentrationsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ConcentrationsDetailsTable" xlink:href="avco-20250331.xsd#avco_ConcentrationsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="ConcentrationsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="srt_MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OneCustomerMember" xlink:href="avco-20250331.xsd#avco_OneCustomerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="OneCustomerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoCustomersMember" xlink:href="avco-20250331.xsd#avco_TwoCustomersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="TwoCustomersMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventorySuppliesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PublicUtilitiesInventorySuppliesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_PublicUtilitiesInventorySuppliesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/SegmentInformationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="SegmentInformationDetailsTable" xlink:href="avco-20250331.xsd#avco_SegmentInformationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SegmentInformationDetailsLineItems" xlink:href="avco-20250331.xsd#avco_SegmentInformationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="SegmentInformationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentInformationDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="LabServicesMSOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentInformationDetailsTable" xlink:to="SegmentInformationDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentInformationDetailsLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentInformationDetailsLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasedServicesPercentage" xlink:href="avco-20250331.xsd#avco_PurchasedServicesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentInformationDetailsLineItems" xlink:to="PurchasedServicesPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentInformationDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="avco-20250331.xsd#avco_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="srt_OwnershipAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AvactisBiotherapeuticsLimitedMember" xlink:href="avco-20250331.xsd#avco_AvactisBiotherapeuticsLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvactisBiotherapeuticsLimitedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ArbeleMember" xlink:href="avco-20250331.xsd#avco_ArbeleMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ArbeleMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvactisNanjingBiosciencesLtdMember" xlink:href="avco-20250331.xsd#avco_AvactisNanjingBiosciencesLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="AvactisNanjingBiosciencesLtdMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_LitigationStatusAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationStatusDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SettledLitigationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_SettledLitigationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DrZhouMember" xlink:href="avco-20250331.xsd#avco_DrZhouMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DrZhouMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LoansPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LitigationReserve" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfPretaxProfit" xlink:href="avco-20250331.xsd#avco_PercentageOfPretaxProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="PercentageOfPretaxProfit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreTaxProfit" xlink:href="avco-20250331.xsd#avco_PreTaxProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="PreTaxProfit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForRent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowsBetweenTransfereeAndTransferorServicingFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowsBetweenTransfereeAndTransferorServicingFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_CashFlowsBetweenTransfereeAndTransferorServicingFees" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashContributionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashContributionExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_NoncashContributionExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingCapital" xlink:href="avco-20250331.xsd#avco_WorkingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="WorkingCapital" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="avco-20250331.xsd#avco_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_OwnershipAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LabServicesMSOMember" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="LabServicesMSOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesDPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_PreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MergerAgreementMember" xlink:href="avco-20250331.xsd#avco_MergerAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="MergerAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CertificatesOfEliminationMember" xlink:href="avco-20250331.xsd#avco_CertificatesOfEliminationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="CertificatesOfEliminationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsegmentsAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsegmentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsegmentsAxis" xlink:to="us-gaap_SubsegmentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsegmentsAxis" xlink:to="us-gaap_SubsequentEventMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesBConvertiblePreferredStockMember" xlink:href="avco-20250331.xsd#avco_SeriesBConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="SeriesBConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LabServicesMSOMember_0" xlink:href="avco-20250331.xsd#avco_LabServicesMSOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="LabServicesMSOMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventLineItems" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedemptionPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RedemptionPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RedemptionPremium" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceDecrease" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRatioPerShare" xlink:href="avco-20250331.xsd#avco_ExchangeRatioPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ExchangeRatioPerShare" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesOutstanding" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="FairMarketValuesOfGrantDates" xlink:href="avco-20250331.xsd#avco_FairMarketValuesOfGrantDates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="FairMarketValuesOfGrantDates" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.avalonglobocare.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="avco-20250331.xsd#avco_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>144
<FILENAME>0001213900-25-052779-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-052779-xbrl.zip
M4$L#!!0    ( &V@R5IZKXA_P2,   _9 0 1    879C;RTR,#(U,#,S,2YX
M<V3M7>MSVSB2_[Y_!<]7=3=3LX[\=I)+9DOR*\[X-9:<269K:PLB(0D3BM0
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M.J)K<P$G#OUY :TJM.Z.Q,B53V\?D/G0M-<5"-T.T94G>[:$IZX)[=DUADN
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M^?M]F!,NAQ N.+1)I/=RPB7$ZUU==M"6ZEU!#H8A^B.)#XG2J/<M:PWI-VG
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ME9)5D);_T43#NV<Z&<;W7G_M]==>?^WU%U]_O>TRD#LZ&OO._P-02P,$%
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MV\;!E\&8NB<A,U"H)46-*G;M]7P;XT$X#!BCI;W_Z+T:;Y3F-RD[@'K'2LV
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M =NQ1W% =I->C268?V?/_LX##&W@M(8>@]KERZ06/6J6ED%''M" )F5+GI%
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M/Z8SRERV-<PR3PMFZI&R-_4C3H^"4XOJ(ZO"7Y)9'I+IG.6I!;/ 2[;3^4U
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M[Y"[)/#)/=-HKO8Z ,-N7JA@50,$;CH>2^2PRGV+6I3 B2#]C7EMGRB=)*/
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M)0BA,6YF0#&#^V..>-M/YB)@97M(Y),SDKT0$M5\EI7AKAN,7N\8Y6D%C?4
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MOZB8.\M3JCG3M&J49KU)I.,XC9X%V2!R,:&=Z17UIPSUE4I$9>2[1R@\'1/
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M4/:\,<^VQQ)#Z5\)SR&B!:C7 1-K?[>[^R% BW>S!]VY2*TXX3D<0!M/- 4
MM!C%Z.+4[4)@%:'S*,Y21%Z'\JZE8UV(FOU2+>KK'U.<1MQFJ2*+3O)]EY=H
M1%V_-]%DL@-OG"H@^?@2=X)K__U/#ZZ&[/K:78\4GF[[JSF"TQ;#3A!KB@\V
M)E) \2K.DTYX-09PZQ9V@UA3?BBE]V#OX_$+2:J;^0J\%@PJJV]&?7-](OV@
MC5*: I3EI_5Z+ OTD-73 NV.-DHG C[+$^8.6A2NP;/M_B-W9<>C"0N$*GEO
M>HQN\^.3$FE5=N'/W?.0ZX78"56TQN,%(\]J7I_5O/Y,@L4R([/)AB3>@MP3
M!@G]/4N)98]MN1>RMH]?8:S1GF?@--BKYX7<]^+0:<7N0M=6LF,>^8/)M*0Z
M, VLR_4;NB"AZF;M5: N+^)X$0_28#CF[V0P6*&*5H6;?R982J7!>#45V:;Z
MLA?+H:>IO!4'HH4!T==BT:A-WD^D5F-N$U8R)LBV.&U#K15)OV%71@Q!A%AQ
M .@<0:4:$\WI8A@?98.^,!9**4B 4">[I5],Y)%^$"%,J3WVX *,-%=W4S$?
M2$LC\@=%':6B%;GG+YJQX^#66_49]].1Q1ZB+211/]R=8&1N6L&"5/T(@]F>
M0G8 5I'3J!TG"TDKX,9J(>VU).]5N?L:.!I_>,\N,*JWM02.I:H3?V,#8!4F
MBP)>>^PA.L/@H3N0)UJ=L],CUX#6CM$5 /]!JZ]0<RM>1^3FU^5ZX)K-]>K4
M<NE+-*2+!?NAR!VYCNY($L0SC+HE&!R>%J(FDCCE)^UM#"ZO0]*4@)P/VH#'
M6:*0N/<8=&KR5K8.JKKL]2P&IBYY')[4I2:2CI[=5=N&P^N8=*8I^R?%V7T%
M*%_P3_$C8XP?<:\U1;$BTA[>KE?;D+3E&PZY&]#JU-*.P#W*N[+_$TD9QU%1
M!-RG/S[&[%=#]V!JLSVXH"77ZU4?<(U>ZL-<L2/2O!TG<S(58->&3OMY)XO^
M*D[F),CRA S5!\#C\&0O:"*I4\?(B1> P^V0M"LT^R<O0/<5H"[9;!\,PZJ1
MD=E%GE!-7O)21F8W8CIV8=C@"M*<@0$FW75>3Q8P:)5U=J/?BDK4Q2>N(S\A
M]%,7I/SO&-5=Q]F<M!_X^M"H=]U/0L=M7#2%(K/F'BV>QEC=8(2^NG" NC9P
M;T 3.V1 =,[PT!X<Z>+H,M%#7[ 0&1\FZR!-LE_N*6M>5HROF^Y!O]98U_1?
M^S7-&Q%->]NE>)BN<X8K5U!:-5X[P*&?I*$/B-.L"LERXPC9(!D"0,QZ>0Q6
M@G:2>& C:\T"G3:'+G-V49L<(:&L.3+2X=&?GN&*2^/>V@D4E&2P]MC.RS=S
MUA]'WF@JATL'/'7J6.8.,YY,)(ZH>#[A7-8N"DB0U"IVE PE'W$PGH]33NLI
MIQ5]%9UR6D\YK8-.C#SEM(X6.NR<UL)FV=DH!M7)#[_C]#&+>X?:N0*/I@=\
M"K)K_(-/(B\)XKN$;((X3\/M/5G'B4"F5GX-)0D'P6Q29UGMXE#+!DL;%3OP
M6>U7?A:\[^Q63AGT-IV7#YD8A@D"EX,^VNP?[##PQ*O6#L'MP2-B<7N\H%ON
MR@L2UM$<Y:6Y'\;?9(AB3Y@/ML#%*8-[4,OQC61P=TGD[4=E]LC]F]2;?:*O
M4Y7=R:G_T_ -3BZ+;S.5!AQ(=3ZW^?T=AE/EICE8A@+'0&_,O)D%US.&N)74
M;:12[HTR;'AH^2M<WM[HS1H..V4&]JG&#Q;GG^#:1*CQ(\[#/N7WG?+[</+[
M)*G43MV/;=9'[(XTG\@;5::.5H4R?[J?9!<Z\54<[5+56/35TSJ.ZH,@GA_7
MT53DP-ALS_/02]/IO'K@G2;W3'Q'T %M(06Q#B]LE52K"^[1<BW-0T5KG+,M
MISWW<99+=T6"RRS6A528-J.WA%J['QFNOG-G/JT TWXWW:F]RBD4]12*>@I%
M_51#46%5*\+!A,'AIWF\H6"-5>G$GM=C3GL\([MQZ#QW#5$= *U$,;KJHW8@
M"[&G@[;[4G1XRHYW(6HF&%H\@%<WX*;'QB"47?SM85=HZIABH)(<=%!VF1YY
MM#:F$3' 2O;]X3EK04[E?4D3F>S LZ4%)!]?XDYP[;__Z<'5D!V.'CPF>17G
M22>\&@,,\3T/&[*F_)1QKQ!X!9MNZK QP">)5T-^/;;KL9S63?Q"DO*G8!5D
M;<B'9?P>LNI2>UN\>Z"BUG/O1TNVG];KL2RV0U8_X<5VA-I@LWZ&WA1B2&UM
MH1851,M::=U=%X%'XGK\]X1)EO[^/(ZRQ/.SW L?2;+Z:F 11S8S<.IKL%R/
M?8.LD;1S:NL$S;7;:T3_FM*T99,XE>?4T&[8#>V<KJV#4UB:C@-W"EM:H0V^
MJYG(ML:7O1S'/4W%89H9U*G<%^CJOHN]:L1=Y/$D3?-5N^_$H YD-:-C- Z1
M(%,W2NPKC#Q/LWA%DHGOQSDKYSF/$S9=+]JF]V1#HIRD&''C<>039ABS*=P'
MZ6]'2$#%C(L)6=HV1R-B!'D+B*"YD,31V4J@FEM&)!N B&H0J,ZV2.'5,DKN
MFA;H+5DI@$V)@7<I$/-'OX02U26CA.>?U8K-TEBL\JW6D!F:+U]"%3SL28F5
MTP@F.+@02I:S@H4?O5_I45X=[RE00Q;.H'A6':!^$PE$'=YJ*G86IC2=MVB!
M=5\1C^U(=\G762UXB4A 2Q9*:8%T95$ X*P]2P<,=.,9@>RO,Q+YRY67_-:/
M$=8F-W)+[$!V6BTG86"K"?=CDQV2&YYAQEW%<O0.1=B?B79 &M].X^(W-&.M
M,X2(G69J#7W$ DI%>A4UAT\;ZGMA"S&5V$"MC2)V;^<^,PAW//R.$[>HEJFZ
M"U$\FB:>),\L)'DV/DF>:<=06TORW$*2Y^.3Y#E*9//N$< +2>T(OR4X+4'X
M- :D=@7V7^NQA"\GE)+T1_S=4>.;_L);@#_:2DDYCBGIYIEOR4PKM[*'UZBR
MI0:[$IWE*9U.FCZ4#P,8;U#5T"7-(%I<1_,X67G5-'#Z<^N0M-54^X1S,96S
M;?5'Y,I$VASTWJ3; '1!S2%]Z79_]K)K/U8ULCG<0QC5&Z2TL*).;(HPF.Z)
M=NLQJ42UWL6ZJ"B< @>ML=V7)M!9M2U0VK+!JL33I *?V7^$@<N<_$X(@)>P
M*8S\>^*%=TE,MWNVG=+_+S9L:G"QD0[@.+>0M[EWUQOYS.'OWS?>\P-)-H%/
MTH\/4P,)<[_HMN: 5+#\B0)[\LH;:IS0TX9NJFFV)"8)S-PO#EBD_(EJ9.;8
M:.0Z*@U8%>^&'812,+9/]U+!J9-3J:!H<?G*0B'!Q7\\OM/*"I8H<*2$4M:M
MV&<[8M<1O4J3BN0M@4Z*51 ;@EXR!THA0*RLPLO?\R#;?B39,IY=%S6H2_:]
MD(6T?Z#3O8G3=!I=!.DZ3KT0&$IC\N-4AN925N?D=5*:YW%*S>AHAJT\C^B,
M<W.*Q:;1>,H*J>LH(PE=)[4.B*.X9@(8*QFE,1YY4LDIT\*L#[]296.<=-7(
M#GL3=CG3:KFHLY@L=PH]'DL:-_ -4=MCC_/L.9"/.M&GGY>5ZQF=3# /F(OS
MAG[V)MB0V:,7+0+ZBTF:$M432Y>KVA65["4=*HF\<!^E&,UVC)0,8+VZ6+/1
M^27&D#+NHXP5,_UG''5=-/Q7&SLD'.4MG5YP@/<2Z&/.Z2'G])!S>LCI_I!C
M5-Y8]OT!7)OT'W',2A.?'AWL'AV@([+IM=;/DX1E^!>G"_3%YW!X=[=/2//K
M6&JZ:WX8-Z(/)%XDWGH9^).$>*<+TNF"=+H@.;T@L0CQG76SWYU>")3>+![;
M?>H@W$U((46=<#9CT,IET"0&EA4M'MMA5K1RE>Z $$L&^"8DI0:2'JU PEEZ
M='<PP"]%1;6E9/O+TX-$[BGQ_[R(-^^K#Y>BK_ZQEWQC* =EWK1V-Y-O<\:@
MX6OUP.>W8**D0XU!E&S&*/$EI^O.F[ONW- +#(&_P13#II/GM"AR#+Q.#@;O
M'(91C%=5ZD.+P6@3<>F;XF/#C;0XD Q*UZRBXN)T_I26M^OI<T8G0&;7T>6K
MORS;U"1MAF[HY3P(J<@.(V9$3L).%-PI(3%0$()#Z[70IBDJ@%XJ'I*LH',S
MC<F[#2@PW8TZ\M0)4X2']B)("PODGEK551IIG]#RR(\:6JX\-;H$]&4Z?/2R
M/ FR;65$-)1+48.Y/3=X$T.HVNKSZB(G2 :($6E;\^2&4*U.^*2V#4*W5(Z/
M+R3<D(]QE"VA#1AK-MR=FS8KH[DK[26/]$BMR]!D3F\J_R%>PCK%.5H';1[<
M*N"^%L*!W-$L*UU^'$'O]EFX+[!US"MP<.F)6ED#9$;->_K1R8K]JT^DA3R\
MX4TNEKNN(09DUVS/2Q=2+Y;,CMBH-[1*D.JDD9YZ+<11&H?!C)KYLZL@\B(_
M\,+=VT3Y3K=[ACFN<6/WU)X_I\$L\)+M=%[T7B2SO8#*/@_3I/K#G9=D$4G2
M9; ^\G-"/;9W9<>Z*,J^$H@="\@%<[HPA;=YQ65T@):5H,1.)X@ 8A*,WU6G
M+Q4/0($([?$&4&(==O_4[ZT'8@-O,-&B 19P<#BBPS #[KH[DBY:M?4#"B!!
M!%SI.@L=,!$P1BGUX@%@4M@6/Q OS);,N'C8IE2)7D>^07BO:HS^O3B2S;E[
M^E#.'+;:18/F_>/W5>0V-41O;DR*J4H'<'.'TI>U:-Z("_N!/6(MO6 /\R/Q
MEU$<Q@MZHMQD,V/9ZX[HK,RM'A;:@@$M?5LP\(%$EZ]Q&J_V).EZ,%,YJC&&
MJ7*4,X>M%5'#[6=!>A;$J1^0R#>5M.S[+B(0-)>X>,X:=1YLA7SK1;\&T:)!
MUUC#J(9Q%#NF*7&I '0:^=KJ^1OOF27LQ,FV+L!F8\+(1AGZX2J5@$[)!F/)
M_VMR$:19$CSGA0/+R(X1?7>X4A;.5J/?JKEL^66&[D+/)Y-H=L%2T^:L%D29
MI]:X6DNE;CZJ W6#X0>RE2E6PK#=U'9+M"Z,,PP/ZC%;3K-F,=R'8'AAM4.S
MY+#.XK[+Z:)/P7W0,$RY310>SG(Z DOK#;F'QZ<+D@0;JC$W^P>RC\1+\X3,
MO&S7L5SY!F6W\G?CWY)LST@1S7K$S32Z)RR,GIFH7AJD3U'\G%)KB7%V':WS
MC/XYCGSZ'=16#;VP;*]+$-G#>.E"9[?O/A)]KNBF6L+'O?/S6:?E?+;=_?A#
M0!**PW)[0S9$.\/79E'*B2)>=[2?W_K:[MREIL $K2W\CFHULR)*XI@5E*)*
M9K01K1^MFDMFVX<+LIZ,H1.#K-@ K]YD#+;#XDX]0:WWEMD)ZD(7I07+7Z/T
MU9-1<GG[M=)K7"1Y(D1K+'Q\@PA(BA.M*"7E-@K5E>$GESY*GT7*7>BE:3 /
M_++[S'3^2%;,\99L'^,[DJR\B%(O77; *\",ME/O@ZL580@/4F6TW>PGLU_S
MTEL[G?_L)8D'GV,MI^70#>[\-L@7_E!\3^=>NCSS0H^]-3YOVU75D#Q.C.0D
MFK'_L U >62'+):S2$6M<YTT/@'<F&09S?ZKGFD"R@\HEHKO5,.L-S>&T8(^
ME2KK)X;X5*KL5*KL5*JL*=]3J;+QE"KC'R23[)Q:P5MJ8Q?F<2_FWB%-ERXF
M"VM)4Y#PG6<9Q:KLB;<X@$I4J[S]%8<W/P-!<R>K6T*@AUO: [N6%FZE;.EE
M+R0AEZ]^F--[&)MRMB0709BS: >2/"Q9+#K.S6T29<&,4:(WZ#U+-2NL3A\+
MO\BSXG8\G5]Z":N*E-9<85WQP-BR#TC;&<\=><&]-H(PAVB$"6^8T N/?Q6%
MP0XBQ]7%[CS;\@= >-W'Y!3I"=#B'@VI"IH+%A5GM(@!/M%;;T50@@24Y!S=
MZGO<K.HUTY0^5OB BC)XQ( >\DZ[0 T,?/B @L*>GJZ+IZ_'^"Y/_*67$CJI
M51P]9+'_FT&JB\8P#B\9NFIM=\O0D0K*DW'U]H02SM$>VVT4@ DB MD@O<<^
MD(3MTCLJ<Y(D9";<"0 ][\247/H^;+"12@VG#%Q)\JPWH/B4Q@F40&JPF=EM
MDN>] <6G-$Z@!%+3JLAF"=1%;T#Q*8T3*('4U.G@5C[[.-JP B/T[GD;9T6=
M/W8/18%*3FLD1IVFX* SR(&N$B@53&%X&AS^,.Y&(, TK^L]O$U0[;3V@MGE
MZYI>?8D7S8JFK^?-;CNJYPB;A=\F.ZG(EO1JXCB5YTTHVU;EJ&C<)?&<I,RA
MX(571+/5BNB[;J]E%GCM[LQ"::!<E"MJ]R2(TCQAD9'T-ZL@!W^WDA!R5[C?
M$B<=X>$DK;09+KC==_M"W?J'M!R>6#"HB62(ULOFHC)LS^.4Y<IX*3WJ;@E\
MR@J?RB@5HE)T.D71[:YPA;&RO2#K. W :Z<<C.XT;:0C-$>24MZIK?9.3DIK
MD?*3KN.(]4P_2^+?2 )]3LDHN;Q2=]U!,@%J%%NS 8W538I8D;$K*JJ4FM ?
MXG@&C9> R(BA$HE-XU9M@U*5MT-O)X_>ZSWQ2;!!B,L141GUL204'729MYI@
MP5Z;::0V'6)"H[769<*K /L.TUKG,MS_=7W4UH:61"LPOY=9(#WXBO@E!-71
MJMUB,OE4T3(.#0@#!)P*:. &DDJ)N@@0-0>;'P(JEV;OH9U%+H>"N>/?$L*>
M*J!R%KN0'U):H\Y&V65P=9(Y2J\4$4FP!$@% 9=9D  [H$96)4:$;$DY29"4
M21WLW.5-]@8?>'YE\?IPXSW7)<$_/DP-(A>Y7W36UT)/@>S>7/BS1GEP$6AF
M8.M%1,7M=;N;X2*4'+ :XZR(])9DK-HWW:=96=:=':2/\>.25#5X+?:(QJ!C
MA,M2?&@]C">K.,F"/ZH0@^LH\Z(%"UPI+XW0T2!R8FZK4W?:?2HQHCV;E0OG
M)DY3YL 6L$X7V'1^$6R"&;U(I].DV7X!WN/<F2%W/K1NBP ""^6373_>F5WC
MV^MH'B>K?0E:H- =9H6<%^\L='*EW/8M=L^],C'"R"NC,(L-B)GZ,V7#:_M>
M+-GOMZRV'6JUP:Z0D8,"3\U6SY=19I3CJ@:,/[2KI%3M5=J 2R <+:<&"!A@
M'@W)X/W<B 7^#-4*E(&!Z*<0DP/Q42C0<.2<Z(X%CM-A;SQ<<UJ3T0N$6;\P
M@^%<-254JX+=5<I$.%AYS?=D0Z+\,"07H+AN-:R[3FYVA_VQ7+ D_R&AQC:+
M!08/0FN.[*8#:C?9MR2#$VT[I18'O1A$B_V]!SK.@D/!41FU;FAP187F$RAA
M1\"C,; SWW4W()JB&<A5N^DZNO.VQ5R"B%4@4P9#V,59/].C,J5S9)2,KMA&
M<=9\*IT"Q)M#8@0U\"A@J1MA^(("GW;<-T<BW:_15F[D%R\I^GYBE(AJC3V$
M/D^2I=AR"K>%HG%M_A]__Y^??_[N?__\\:>__I___6]_G;_^)_KF^]D?WVX6
M_]E&3Q?YRX=OD^^__>=7OSX];M/PVXW_QQ?AC]G[[('\^,>W7__V^J5_DWWQ
MWZNKKQ[^^7[S>G;^GR\VLX?$>__;7RYN?_CW3_^\_L_+[?L_;OY]G7T1O/SW
M][]&_UF\?_GJV_?1:O'T]5GZE]^V'SYX7\:__6O^W<O:_^XU)U^?_V7QG_/M
M]$\7Y*NKC^L/%W]]_#(Y>US]Z[OEY/W3^9]^>O](?O)?GKZ=G'T@[[/G[V]3
M\J=_GTV_7-Y^\?#7?S__^*]G_\<7,EO_<+8(OPV^^.:+#[_.Y^=_67][_?+^
MQZ__^&;SW[G_[P\?7O[YY8M_]M\__?[5#_[U@Y>%_WX,KQ;IQW].O_D7N;@(
M7[_]YNR[/[Y;_IIO?OKF^NY^E5U=>Y/_>N?W^3\__/7JUXM__V7]TV(:_65V
M_?JGOW[WI^_2GTGVX^OCU^^]?_K_^#_OSA_N/__<5FGND,0I4'4PNNL^5=S-
MS%W8Z!6CVH3@"T0=2]YE+2A#N>-U?V(*KLQB9UR?;9^BX/><7)#43X+"RD)0
M\WHTW8>1:2I_31'6^,&66VX31ZNL)R33@Q=/HK^,5J\8,[-8,$B8P/6<%"BG
M]>_ L=)3BH;G4>%J_.BEV0]!&!KX6@^^XC K6*41=@[5PUEBA ]=$+\8_2K8
MD,>7^'$9YZD7S1Y?J$+=7L5Y8B!BW;%<UA#A6X\[D6N+ ]K,*JC_Z$6YQ]+I
M>,3I+PVPT!S*<5% !1JZ\@"N#%C0OB+/"108NF,->&-HBT/'E6JA[Q-_"8&$
MUD#N@IY4*.C)0<>;:B;_R3H)0@CY:PTT7/GKR0&TL$"%.X@>TAAFP"I(1P@:
M!0(LCN4\(B!GLL8X3@-OE>>QCB!T:NH!O#HT[B6H;P]-.D[!L7Z-:$E*)U6D
MCP:G[;J,55E&G)1C)JKI_#PALR"[\ORBMRS68YN<EE7!=KZH5**\()D7A+R$
M8U&'J.YD^HI]-0)VWT@*0(YN7O0>EG&2/9)DQ?;U(_T"@LN73\-5A"SPPF]E
ME?.%B=9AY8@>BOM71,591*W6VI7B8O*@!8D,N,=7AHU#=V]79#2]NZ=RU[8)
M4'+%85[E&GX'M>U,>@3C5*X6DG&(CK;MH9852O;V4^25P6QD5E!.TYR5?:WJ
M$0$#I"#F]-ID#)1*<GC/_/OET>0A2(N6P#AEN+3)C@M#?6GBM*H1*&0<#!7$
MQH6<2G):'6MZ<&"8>"UL5E!S\D@5\[DD["\ZG[ Q( ,+R ; .52J*O"3J'74
M%<6K,0I^=^/&[5NU'<86,@?-6N1QCW,*B8Z>@<,E.V3D1D$O7O)=$\IBG5 >
MG]9Q=/E*$C](Z0>JMI73/$LS+YH%T0+E,"K[FWHIJVN_8F9PD2%3_#:=Y!F]
MJ+(%_D1I) 6S)5MWH1>E-:]W2>"3>R]:H/6;1V+2<L/MRY=TX.ML>\P9;@E1
M%&9[3]S!7:_\&J4X,+MK6\^>@I'>&MIC#R&+J)_=>I0_8/3\ *>X)ZRM[J),
MU3S;[C]3I3P6K.WYBV9L=FB!ZR@LN@UZY^Z=MD<= Q;@\&!,9A'>6)!6D=,G
M&B<+";QR"L"IS%.M*(_@\!Q^FL<;"M;J!"WWMYL>S\AN' X@,@!-'0"M1#&Z
M..XZ!%9[.FB[+T6G@1!C78AX"7;'CB6#.&?AEYU&4^#=A'8AAF*I8:3N':^*
M:602CB[[OLNN=(CG\0XIJ>S XV4$)!]?XDYP[;__Z<'5D!V.!N20I/!TVU_-
M$0:G"]$1:XH/-NQ"0-$P?5DZ@.,&!TX0X^0[P^04XOCIXQ>25![[%7PG9$Q6
MWXSZEK^5H**-$D4)RO+3>CV6!7K(ZFF!=D>[1Y]JXUHCNM4<7U5N<X3H>GC^
M''8D<;P0.Z&*5N&V8.19S>NSFM>?2;!89F0VV9#$6Y![PB"AOS^/HR)^)_="
ME@_Q%<8:[7D&;OLK];N0^UX<ZA!AI(=0Q:ZL9,>>3 XFTY+JP#2P+M=OZ(*$
MJINU5X&RBHCK13Q(@^&8OY/!8(6J3B450(/!4BH-QJNIR#;5E[U8#CU-Y:TX
M$"T,B+X6BT8IFWX"P1MSF_A9L FRK2+0N]>SX0A"UX?!C6WX=ND)+=I%2J5O
M7%[%=$PTCXMAT+0-^GN7LJD@3^'.^&55+%?W*7CY%+Q\"EX^!2]_JL'+>RV)
M4H;F>/SAO;G 14M)I(K5O^1GCW&?H8#7'GN(GC!XZ [D"1Z$<WKA&N#:,;H"
MX+]F8=2$ ^-U1#Y^7:X'KME<KTXM?WXOR2OZ[']@2CR]CNY($L2SHE7MP!8G
MC\/30M1$$J>\E;V-P>5U2)H2D/-!&_ X2Q02]QXC3O4WV56<S$F0Y0G9S6)@
MZI+'X4E=:B+IZ,U=M6TXO(Y)9YJR?U*<W5> \OG^%#PRQN 1UUI3'"@"W^_E
M%&]WNHOCQM9].ZR[^$\D91Q',U9KVJ<_/L;L5T/W8&JS/;B()=?K51_P:L%^
MU_?S:.<)C$CS=IS,R52 71O5DO\>WJZHZZF2V46>4#Y*>[H,*FR\2.XB",&O
M^.8,##!?I//ZLH!!JTN3FSOZ-%N2I/C$=>0GA'[J@I3_'>.5O>-L3C=X\/6A
M5_RLE\X'T:90[<T]6CAVJ8I7-G \!28#!B;+H.@<H:P]>-]M'WL(5-87+$3$
MLLV68*84/3,1PI6;(SOM_]AUM3?5=TM<:+T>*RHHH<;ML9U7;^2L/XZ\T7LX
MMNB !^8>R]QA/*V)Q!%[,W["F1)=%) @9:+G:B"GC D$57C*F#AE3)PR)DX9
M$V\E8Z(X^W9GG4$!Q</O.'5:<FWQW87O:'J8VO19?5=]%GB-=GR6#T%5 7\4
M=P8"EX/>D/9N0 P\\<H70G![X)HL;-X++R-77I#\Y(4YBO^Z'\;?Y+-=3Y@/
M-NGKE-4PJ.7X1K(:N@2W]Z,R>^3^3>K-/M'7*5-XRG$XY3B,*,<!PNQHLSYB
MT]-\(J?K$N2JP,N Z#"AGX9_F>>R^#9#=\&!U"L8:.:)@^%4N6$.EJ' Q=<;
M,V]FP?6,H3JSX5U?@6)TJJLXVH5YLI?1IW4<U7%M\?RX@D+Q?+JKTLJ)'[/1
MV>>AEZ;3>56P9IK<,RD>806D?17$.E0?[Z6'*]09A,LLEG(0AISI+:'6^8(,
MEZNXLT\C_*/?37<JK7D*%#D%BIP"13[50!%8U8IP,&%P^&D>;RA8ZZ7&#*$=
M^W#6I;09.[YVDYR2B.H N1V[SE$[D(78TT';?2DZ/&7'NQ UP_\MG)'5#9C7
MXE[#>RC^]K#SFSO&;JHDAQ+ *>UPKX&5[/O#>Z@".94EK; ;L@//95)WN+>"
M:__]3P^NANQP]."IV7P/S>;%\5T0> 6;;NJP,< GB5=#?CV6:K6<UE&[^.$:
MOX>LNM3>%N\>J*CU7/??DNVCUN_#76R'K'["B^T(M<%&MP^](."06II +2J(
M=B62>'4W09=6[=4'%:QF,P.GO@;+]=@WR!K!Z:>2OM!<N[U&]*\I3<OUBD/6
M3\7,AUW,W.G:,NEH?VIH_TDVM(<ZE?L"71UGWJM&W 4@3](T7[6KM@[J0%8S
M.D;C$ DRC5#RG@+)\S2+5R29^'Z<LV);\SAAT_6B;7I/-B3*2:JL/&H5.1Y'
M/F&F,9O$?9#^=H0%5-2XF)"E=7,T(D:8MX (FA-)')^M!*JY:42R 8BI!H'J
M;(L48"VCA ::=C2:?,E* 6Q*#*VZYS%_]$LH<5TR2G@>6JWH+(W%*M]J#9FA
M>?,E5,$#GY18.8UA@H,+H:1HFF2_?/1^I8=Y=<"GNCJ/?K.!#?W7'A?!H'AV
M':!^$PD$MEHHH\("E:;S%BU]3::0OGAL1[I+OLYJP4M$ EJ<2TI+3SUU \")
M0NJ(@6Y$(Y#]=48B?[GRDM_Z,<+:Y$9NB1W(KD8-_/'KF'1-N!^;[)#<\ PS
M[BJ6HW<HPOY,M /2^'8:%[^A&6N=(42L!%]KZ",64,K]JJ@Y?-Q0WPM;B*G$
M!FIM%-%[.P>:0<#CX7><.$:U3-5=D.+1-/$D>68AR;/Q2?),.XK:6I+G%I(\
M'Y\DSU%BFW?/ %Y(:E?X+<EPZJUS:0Q([0KLO]9S"5].*,67C_B[H\8W_86W
M '^VE9)R'%72S3/?DIE6=F4/[U'W9!TG&;L2G>4IG4Z:/I0/ SBO4-7@)=4@
M6EQ'\SA9>=5$</K;Z9"TU57[I',QE;-M]4?DZD3:'/3>Y,X =$'=(7WI=G_X
MLFL0XF7E&_7!+L*HX""EA15Y8E.(P71/M)N#2"6*V#VWI(-3Y* UMOOR!#JK
MM@5*6S98U7B:5."S^X\P<)F7WPD!\#(VA9E_3[SP+HGI=L^V4_K_Q89-#:XV
MT@$<YQ?R-O?N@B.?.?P-_,9[?B#))O!)^O%A:B!A[A?=UAV0"I8_46!?7GE'
MC1-ZVM!-5?2H-KF/\[XX8)'R)ZJ1G6.CD>O(-&!5O!MV$$K!V#[=2P6G5DZE
M@J+%Y2L+AP07__'X3JLK6*+ D1)*:;=BG^V(74?T,DTJDK<$.C%606P(>LD<
M*(4 L3(+R]:W'TFVC&?710W^DGTO9&'M'^AT;^(TG4870;J.4R\$AM*8_#B5
MH;F4U7EYG93F>9Q2,SJ:82O/(SKCW)QBL:F;K-@A=1UE)*'KI-8!<1373 !C
M):,TQB-/*CF47B&%[BY5-L9)5XWLL ]7ES.MEHM&QPR[G4+OI/,@NX'O_-<8
M>)1:JRD8G6X1_;RI7,_H7()YP%R;-_2S-\&&S!Z]:!'07TS2E*@?5[I<TJZH
M:"_I6$GDA?L(Q6BV8Z5D >N]Q9J-SF\PAI1QGV.LF.D_VZCKHN&_U]@AX2AG
MZ?1V [R70)]Q3D\XIR><TQ-.]R<<H^+&LN\/X,*D_WQC5ICX]-Q@]]P '8U-
M+[1^GB0LO[\X78#5Q]'P[NZ=D.;7L=1TU_PP[D0?2+Q(O/4R\"<)\4Y7I-,5
MZ71%<GQ%8O'A._MFOS^]$"BY63RV^\1!N+N00HHZH6S&H)7+H$D,+"=:/+;#
MG&CE*MT!(98,\%U(2@TD.5J!A+/DZ.Y@@%^+BFI+R?:7IP>)W%/B_WD1;]Y7
M'RY%7_UC+_G&4 [*O&GM;B;?YHQ!0]?J@<]OP41)AQJ#*-F,46)+3A>>-W?A
MN:%7&()QARD&3B?/:5'F&'BE' S>.0BC&*^JU8<6@=$FXM(_Q<>&&V=Q(!GH
MOEF[_<;*+D[G3VEYR9X^9W0.9'8=7;[ZR[)73=+FZ8;>T8,PR+;0E]X.G#@L
MIZJ&M).(<4(56]1$E=)+#462%70*IS%YMQ%OIIM61YXZL8SPT%X$:6&JW%/S
MN\HV[1-:'OE10\N5IT8[@;YLC(]>EB=4C5361JU6 I(6Q9K;<\.P1?AJC=*O
M#[:+G"!9*D:D;>V8&T(U.A$H[P:A6RK(QQ<2;LC'.,J6T):.-1ON['R;E='<
ME_:21WK1UF7H/\1+'E]B1RN@IN[2".X+^IVDL8KIZ3(RF=-[+..&]1%T!'R;
M![>G;E\+X$#N:#:7+C^.H'<;-M 7V%CY(E+ZU(RJ3$ RH[<Y^M')BOVK3Z2%
M/+SA32Z6NTXR"J I"^T$D3DXQHNERKLA;5,$B=9YZ0[N![2:V*C5KTJ0.-UY
M!%3W#OU^$&S0>Y,;L"E/G?085+?%-%EX4?!'D=3C1;-;YKL@\7Q?9^."9%X0
M[E]Z#CT45I%/^7,:S (OV4[G12M<,MNO\;+MSC2I_G#G)5E$DG09K(^>G:!B
MG[JR8[KABMA-7<ESHKT$T:MF(^(I2''),2#<=_&OAC+L'*=E&F@R?:FF !29
MU1[/8<<)^Q5<!YD<B 8VY:1% "S$ZG!$AX%5W(5U)%JT[A('%$#"IKC2=18L
M92)@S-813&62WW.JE"XWK##?%J5MEX@*(@;(*D8I/W7'&T#(<'+>A'00[SYZ
MZ6_R1:O QZ0S!"@^\!EQ,H1<)L<!X*.G]&SPJ3/V)O[O>9"6LH%7>2(JXU=Y
M0OEI-<H!@XS]F! <U:>FYSP%6+&*58 =2 ^GE)V2,+A&U /.H6J$A$W7+C3W
M'4P*=\X/Q NS)?/G/&Q3>C^^CGR#7%?5&/U'*4AN;;L;OW+FL#NE0?/^\?LJ
MC3D@Z<V-25<1Z0!N?)SZLA;-&_K&4Y/TLX"%G$\2^EMR%L0LL]E;DSP+_+3R
M#9F)7G] 1]D.&C@8" 7\P;W) R6=^@&)?)(::QOA]UV$Q1C(G3]GC8!#2T5S
MXST;ZY;]=YQU+-+3)HW)*1^-/\7*W3J2E-;MAJTP>'#]PVG[Q*7AL.J@RG\C
MN1^;U#6QJ^"3T%-X.K^.9L$FF.5>&&ZO5RLOH[_W0HY%RNT0 %#JQY(-=ZAJ
M7U';18%LQ8US8;-\0-LIE+I$Z3 >4(_9<EK%"/!Q$AXO386"%B=PYJ5!&L_O
M*#=4S=7.J0]Q49N8FD9)1/\S*\:'C!@HSCMSVD>@2$__+N-;72C-">H' =B.
MW6,X !2H.X/(6IZN:UON(H0F]**Q*6*+JM1WS"J7"JK.ZEU"[ UNE4N5F%'K
M77*(8Y; %)-S%*Y@N>@YM1DEDD0RMQ1TL4IH*C <1F%->!A1_.4'Q*GRH*1S
M2EW>1 T*2@F]070446HG#H R&0+G^15'PL]Q\AM3_]XZR+SP@DK*#S(M8XC_
MS?XOH> 6CT D.&KPEF1E,P6$7@?ML=UL"4AT!#+#B92@1,Z]='F7Q)N WJW.
MMD\IJW#!V=/PJ.D2=G&E1P)46];*)YA3NQ%DM#@M2*2E(5 K0^2KE9=LX_E#
ML(@"JJD]:B+Y11X=G=U='%+=34#S+ J)&I$U<YA8#FWE*S&BI>\FL1BV;P])
M-P!WIH*- %W[1<Y#+TVG\X<L]G_#](0<T7&=4F&_VKF.CV,Y:I2UM4&N20C%
MN\$AX#S$3[E<FYCP)(3U2GA,"]Q3(<!C"(X).S3PXIGOR2(/V=^W124Z!'W&
MH^#6BPNCQ[B24R=N ("$HL/X-/!3 20J3+(V)4"@Y)5):8'K+R$63G58%S@P
MLM ^Q4X# /I+L[6 +$3SU%K@U%K@U%H QFU6M!Z["]D6CF:L(_JZ: RW14JF
MU:'X-NZ96K*M406N$":DC99OJT/1=>:MP6K7 M(H'Q<)1G#;3Q-(AW8@'HR8
MM0KN"35*RT#&[6/B12E+GXBC]&S;_ O*_5>;\*CM2AM!UV!+:_-U11OINGQ$
MP+G+SWR)BW!#OD,?$D*X0'/1<7IYAL7&@:KL3S>^>678UG[26I>  *(KPF-:
M/>PZ<X6HL\LX8L.)7Y(2156,?+2&J"6M $,-V+SR@N0G+\S)6>GE+)YL$!2D
MF,[;N*1+Y%AC!UQ'=D>Q; #WD7AIGI#9-+HGK/ IY;V(]GF*XN>4)!O&^'6T
MSC/ZYSCR@S HPG^:[**H530VG5NIRJW#71_@:&$];V-Q#'X4H*XPAV?((-87
MWH/]51!YE+(77D<I'0@I'4M$Q7D!,J!C1R3$&C-ES6MCW K[9%YV+"T+)+ 4
MA3F'DY0YQ%+^GU#.&E#6G$8,*#9'<PG XJ';1=;IL@$_0J 7CMMSP\W:T;RF
MG&I5.CHJE 4KOP/?\Z>"E4>;\U2P\E2P$M.?4Z;#[2)%;MB'<=2EC-*;<'E+
M15D#^#WTM5M %45?RFFY=7EK+&0-L' 5I90HN))4H^5414("AENCH*;) C?*
M"E%QQ.Q8S!PH+JVWD#V@D&:=I O[\GY "T4Y\FDX]0IHK=PF. (YH41#<&F!
M*T$A*L/(BNH$#%IN@;\DLSPDTWE)]B/)EO'L.MJ0--LSW?PM(;?>2CMJ5Q5.
MW87\J"W)[L*OU2>41X5Q)*((ELF@(. RG0%@)]3 JL2(D/8@)PF2^Z"#G;L$
MB-[@0TN4J%)B?_:2A*J2:7(?+)88[UYB.F\CWD(BQUIG2A*_P)##S,+G4G)<
M7E"Y?)48(:E'#9I8V?EBG)S:I%!0H:E"O@['J1,HI^6@(TE?45S'EPZAP-&>
M?NDU9Q5'114(%'"/QW=9X5SJFVCMN6.Q("5_D3E)Z*+"0X!+PDF9,V,4^-)!
M:;M$25WEK-!8I6:YJDY024OT7;?E335LHEV%+.'LP?5.84LFVU_.;R7+/"7^
MGQ?QYGWUX7*55__8+_#&4([:5BE+#C !-V<,JD/J@9\>P$1)AQJ#*-F,0<V>
MNJE0G!0U1799HV8-E 3?=JIK#9+$F]V51(( UP=OI6N57NX+1]+B/E;@4>/W
M)"5T*DNZ#"[(AH1Q >WEZYI>60B*[:%#T2E<6B_Z[6P@#1EBU>(_=;[Z!#M?
ME:T#BV)8T;YW4N65,S%356.XPP<C;'W?=5$E.@2XRK4S.8_I33[)@N>0J"]Z
MHC*]>D,-XJ[!*7ZZ+\*K*1*4:W9)_*R'V[:,DDO/AQPA+3DA!9"7-,][PX9/
M:2S8".2DT?+8'IM);]CP*8T%&X&<@/LDMVE>](8-G])8L!'(2=F!V>+POZ@(
M3>?TOT7WAM3(3I-]WZ6XI06"=^>\=/88O9'VWHK&5?KFYMS*=\,=8C .!:6_
MAB\!#*E?K@,_CLZ"."/^\CR^R68&\A9^V9'S42_J:B=O\=QQW&,7R7_R_R[C
MW$2'M+\R#KD>SA,MRIQS>;\CB<_:[BS(=/Y3S*)=ZL[#:>4JF &?JI9,.( 2
MJ!=+5^DC1:44A]GU:NT%2=$[8>DE"_!V80(BSEJ#P:$I$E^?82G 8(FHN/&Q
M .,E%*'Z"FD57^*ERZN+Z_/KJ(B=F:P8R\!X\6GT[\X$1DH@.IUF;G9%7P@=
MV O9"T>R(6=>]%MQ50(&2T3E36PNH0C5]TP;Q+AW+6"\^#1&O[D$HJMPDA;+
MM()JFBU)THNI(:/T!NP-J2 K^,35_+KLLO*M&&E[58./W[H_E%8%B:S6%7@L
M0Y]1#&\ ,H4L*P1E)6BZ;*O)K'@03)'/KR,RX\=-+,$*,ED!#"L+,4X(9?H\
MIU0C?WOYZB^]:$'NO8P43_AA$3SS);3%J$EU_(!JRU>CARE@BLXTS]+,BV9T
M-M W-Q6Y-V"PJ$6J[N<(D%O0"+PH?V192G=)X$.?EMIDG3RK (.K+V.=EG>=
M4WC$#%!S+"$>N&ED1OLM(&XH;8W>7Y:P\QUYTY>(\K$,UGN7>B_>41[=T3L)
M#$2L;C)D=\O9D"@G]X3-F#%/DGF<K+S()]/G,%AX[<<3\'N/&?4W<%@;"URC
MO8I='2RJ7Y9Q2 =/RU7(.$M24OSA81T&T$YT'8IO07]K25:C+815T$1!KW[:
MK):17L0$]YNC5; R:>A41[<SAV.?D%EZ12?RX(D+E2 T0]6D.UHX+42L+FP,
M9Q-=L/P-$LW2:7(1I%D2/.=%OD8OAI&0^.C1-A6VNBRK>=:VMRTLLGFM2VHN
MM)2J^-MC/NA4@E%7?33'H0P-32JJZ30Z))MJ :(QS'B=?-J"4M>5LSK^:I+S
M"_*<7;XRMO,@71;O9PA^=S6]-_'BKR%6C9I7EI=#GP15U9EZ^;!3%_P6*" S
MWJVHEF"-F=1M8QUMF)8>?N@K7'OL-[&]#L15PP*5K]$F<QM'/B(PC>%';_L=
M"ZR&1NP(L7HD#D)J/F[( ZNX1>4$'BW#(? F-@Y/<#5$,J\&G?7?W^\G36G\
MMA/'W]N_KZBV9O[R\O)G;^.%<;0(XV<*;4+^[,>K]\7LZUHD7J,,2367SUJB
M):\98=6(/NMPU^=7/9D\TRN)YT-O<#6]#HY^X>!E*)3OYZN\R!&Z(.N$^&75
MN;XF*.7!;5*Z]B(X<&'8"!NK9$MA0C(VRF <\$JTA\.[JP%AA=:Q>&#[819*
MN4!^2IGSF!+FAI@)[K/\;XY$QK*Y:Z2;PT?U7;[Z8<XB)NJ4H.NH<#BF*5L&
MX+<>>TX<EBRUVD6=I*Z;CH!F5>RF^ ,)9U=QPBYP?5L5A37<I!^D3 QY0GHW
M.#18L2R1N8^WGLXY)>*T-*)JC"'J1GUP=VI3*2J=*C=H.V;O[ BB>^*%ERFK
M?Z;>,[8ZO:;0\'(B;0LY+=O'^.(0;-I[='E,5G&2!7]@V-I*<FZ+0&B@>92O
M(16>INV,>H!PWBA5^\$JK$/1)./X3@\5W:%/V+(>A%2(K581&H$.\G'P7N>\
M,.0O>W/@#L(<%)(YW@-QE-'%=AD6=2G_\5E:UL>%,KA9=89='!M0+ZGV>*Y;
MF1@LR+KMS(% U$'VUA(':^=T.*+#_DW<Y70D6I0V=QP*( V7N-)UUF')1, 8
M[>KV$715M=QF_2W,_IQ'=$:F6S0$AY0"(JZ0!IO TR30SR;1Z<0I6I^<[)R6
MA-"<N4>TL-H>'>+A0&,!H:&GR$P/BWN65@=D]NS'0G)>H-D[#2EH9"=9R5B_
M'J6.E'NH=:PT<XZ63DN:2"7W#L8',6X.)>K(JM&1)UJ;LU.[<1B#1MI?7)+[
M9A_C?>HO?NHO?NHOKCXU[I)XEOO9-*E*PP(9/=QAT9! LX#XTE'G<EKCL.]P
M05(P)Y!X;(?N(-G".Q _3R@(!I20&H@YI0#!F7W5"0=PPPNJ4W@'H#J1'Y^*
MZR9MC?1F8_SUJD)W0%A!P*%2A%CZ-; J,2)H4#E)$#6J@YTS7=H??."*MVR%
M53R!/["B4EY@TCF,\SU')>4%3VC[;E^\*>*4Y?\QH$32_"D*_#AA[0#">,'Z
MECX2?QFQ?VQ-^R*8C>@D254' T/!P*_SJHU5<3.;%1W<C1NN<;[L,*Q3N[\:
M;\ZP_>W8 OA(9[_*5V#.W?9XSM8UQV-=:^N#&4._$!4DO%=8H;;&&Z10VS-&
MZ>O^J75BE'I'X9LQVD-R!@>)<JCQ0**6BOXN&?9$Q0<57(5$<7>LKLW!'+9C
MT_(FRGN#G1J#:<IYX(W!]C?/ZZB3W+4&ZC\WPP("/9'H1I0,>:8Z.QNJY$A-
M<$?)2'T>?,N5TC27[^%TD3JY?HI=K;H%UBLEA]0KCEX#XZ11M)!3"O9L>^<A
ME! QH3QF1(TDC-21_%/K" B#G*(G#U!DH7SG?]K5KS%UJJSH-49\UR']ASB<
MG7M)LF69Z!A-!+7).KUB8T#+$ZU&7W2(IA3%]1\82!X%AZ[[;HAQQ:73I*X[
M-@]4@9/T.DUS\-;'$D)CU9HRV8%VI9/$@=QY6Q8!PBTN:)1N>S#0V# Q$!%2
M=[I3ZYV>-II&QQU9WSH++\ADL4C(PLLH^XU6,'IA%/ROCL_DEPI"H_><U9YJ
MVZ*S2890]8E/8VSZ3R$QC>9Q-OA<,=&0FV##2D1E7K1@F[*X%#ZE9)Z'-\$<
M6M]ID1PK>GKR1$H<;E9HF<X/Z(.[0N3$1GQ8J<2H3KNT >]#',]>@C#<.V-N
MXA0:- &1\1UF*JGI='#K]);R,$UO25;V2YYD9<<,9J0^QH]+PE[3O6AK_-2B
M->@8'<66XL/ISU929>N$M;P13(-R-YWWU(,&@*&QGI<06"!U<SM4_)2+75G-
M6NV +P0-DN.%6D>>&DW<NIRN5_24*!QR^WJ02$<LC]+XSUFN_#2;OZ'5 FSX
M$V[CC%3N(JS2F*QES'5$-5!>F!M(M?]$5&P](%(9Z5?ZTQ@&RVTO+/.G &1G
M?^B(H.^2?MH%=]Y\>2[]!6I8G0NV:,*I.->I.->I.!<?C7M2--FX\Y)L^YAX
M4>KYA8E^MFW^!4&K&1!VG MNI^5,!*OA6^P,+HKBXQ!PKOC,5[0(-M1*/L>$
MP-6@ !V':A :FUZJKW[B)<LZ&GGRBF5P*4CMT*M3U;)3U;)3U3+-6'OB,9]0
MF<JSSK-'^AT$'2<D,T;U)I:9SBL6'$XHZDU"R*F.4RU4%4"H.DY,$%S1R?%Q
MJNU@(,+4=C=QM,A(LF(>2"1-QR4Q3E\=7UHX;[R'M%!TFX"(HU)E.HM2!@=2
M"3(Y.7!])L/$J3;K!@M:,6UZ<R[[1&;!AIJ*9ULD/2:F,TYE)I&;.AX!#"@4
MM2:CY%BW*5>K$B)D+2>A":[JE#@YU7=04*%IOO:S,8+*XQ! A 53V?%$I1&H
M Q%?859CUAJ=@VJE[C2<>%6* 4$L(*LB"*[4I+ X56C=D$%38]4#[\]>DGA1
M-DWN@\420YN)Z8S3@)/(31W/!@849@@)EY)C TZY6I40(2LZ"4VLT!(Q3D[U
M'114>)IOG\"H7W_5!)ZC\5W&[\JK"4MDHKU1AE=ZLLNL(/SN146 (C$998$I
MR;D$1_U")/._'TNN%\ *BC_%H9<%81'CW@-J?)KCA4X@0Q05?DC[/DA_NTH(
MJ0N)W7M9/UOO_[;W;<V1XT;6_V7>=^;S>B^?(\8/NHY[0ZU2J#7N\+XXJ")4
MQ>D2*8.D+O/K%R")*K*(.S,)HJ=>[!Y)1 +G (E$(I&I$1PODSHTC0F^(.B\
M>G\AZXJDXNW6;'1J!,=+IPY-E*1>J@X\$.J0\1Z QI[ @$FA8-CK@V>1L N"
M-_Y6BV<(FVWY201&RYL,/(M<7CZ\=:<G%(J&;8=]0V[A">DS<@0+1O[SZXR6
ME09^Q6LXR6=1(*L<LTV@C$_MB'61I^[PRKX+7\_'"ESID$%MKD;,'277-7_/
MVDERR?&M^C:>&:P<O47*;X]I_#DIJ[_Q-]!,YLV= ]+2#X,FR%$_YMF#*Q\M
MFO)E_^-2[^OXFZ6C.1HC<!;L 64>4S.\=G68DO;U$KS>ZI \*RB_29)JT^GO
M<T;MASR2Z@,E!Z]PQKC %JD3@E;5EM N(@2% 8F L)N>16Q7GPD90!B*^7/R
MP;#[\]']JI-VT300%G)3E$E/Z>A @%T!;2'.>C<1=GT+ 76\->@&## VS]6Z
M*ECCTY W-A)2U5NC;X8"_B3SF0UDRR3^QQ1MHVTBJ(GHH&[T.-@<;3Q43DZF
M8:]O(0Z5H\4 V%7;B/R:9$S4-7$!^OB;.&;U:*18U1"&/>IQ^<!0+;?%+CV4
M0NF"*9K[S@>:;3;@AN;4WBS)1+K1I8>;##M6@J!AQ]K:#DQROLY>$NCLC7I9
MB]&!#D2.\ +W#^\/EWQ*M.(N:R9OP^9+5J1M28Y;\M;\"CY3AI70:%:A+8@V
M)7O!8B=O:SXVMNC)FO6IRDAYD>QV)#W_$%[;[@]G"5AVZ$TTM$^&'=JF-.X*
M1U4__C37MCN2&RZ7+L3F.H;1;*4Z&ZE*Z=>[HJ"2@C@*P]6FG049LU)&[ %!
MBA X>H.2YW6RVV_/=\G'\ZB$%/0K-KG("->1"CQCW2\ XJZ3-4&IAZ@4$Z/U
MV4?)HN07H,UR]<Y.*UG9!C#O?[G?,:'W*[\^Q&V?F"&VJ03FMQ3;4F3769[D
M:\++*_%<]. K42XE&M:4,&&5"I-.DU5=E562\YNN.19=7]QR7/7NJVL FT7I
M,,_B8:(8P%GZ6]W5+-NO9&"Z]++BV-X,>)DS]TX(*AWHVT_YFI*DA"Y]H145
MC>+3 X:7;%1,A+,\;?? WB(^#DK&(<Y.=!QKS0U-<Z+%Z4;_KWG2%I;C+SC:
MF')4ZU\F+YI%: &=.7&<UUUH_Z+BCG4_*\N"?C1A3U9^#MWW"S<IS./'26W5
M+[S=J%O6A^9GT/Y^I9RE.YXLD$(JG-5[>JWV/%X2%'O"378L'#HB:E%<RW=O
M.LCL.L*+UHHQ'$[DJY<FKWX[ZS!\]7[]6+@R!0!:4 _F FD4?!<X:N^Y'WRP
M<-0E(Q0HJAT6[C9"3=?;9.^\.@H9LC,3]$TL79E9P2#NF>'+/C4J]%<&"J)_
M2"HCBHL.!3R"#NC*0+;WDTA>!V?QD1Z";( 5%,-[)VS[@F0*.HO_[D@>683_
M#E\5XK;(*[9WDGNR)MDKSYP'[<:528C#H23%1E !F[R>';O7A*1-2>S>A."=
M!:9#)VGAEIX56((?L#CCUNYI8P6N"\IWVJSLYZ74&WVR#^,P]:1#%O""YP#N
MQ)6K)][!J_>*&3!U5FY;%5F"WRZ9Y46SGUA )VB#CZ8X"N @LT2YD'Z02Q0<
M*6$2S&A/_%[,G+4.](0#TDX-X4F_H^0YJY^!.3++BX8M"^@$;]J@""_>1.ZV
MLSQMU_,+R<&M:X602"P %40BK-GD?OCYI\/HF*!O>[)^'OZ\$ST8XMO;VX_)
M:[(K\LVN>&1,4O+CNGC^J1GF):',4JRR5W*3)8]--L4N*_4/ PC)>T5X&I,?
MO'VY0DZY#S$8(0:F>W6R/".,53 -DG<;HHOU;2#Y;9+=3C5]+2CIA10;$!@_
MCV*G$39MKG;-+?9??RC)IHO]!;PC4%38G:^ ]Q(J=EO.3HMRW</D\EJM!$D7
M>K'NL:RP)30LIJT%6_9YYL&Y0BW>+6=KB96\O0BS+??H9T2_)33EN5D05."P
M[>"%@CS4WA$Z..&,3;3#><+:X7GC6?>3%A<V#S;-7EB>?QS^ICL,-ST[="]/
M[W9)CE99"*6+856J=.*/ E/ :4&J\8'167"=C3:+@JKZ(!,)K0*)8B=B7>S_
M9CY[62;XNS&?I:CBA6.K\Q$B<#AKT1]WTUDSH57$H=9''PM"-9GGVX(]K&1O
M;C +HYM*MR,6K]\KO:ATGAHP\],$,(90U)Q&$%8PE96J,TU1$SNH"DXM$%S1
MZ?D)JO%@*,+4<Z?BFQZZSJ+R)G1%E%/M39O)>JJ]>:J]:7WE^ <LGNZAZW25
MTV$?T9W*II_*II_*IGM;V*=2KZ=2KT;63J5>3Z5>E\GDJ=3KJ=0K!IVG4J_+
M+O5Z*AD:JF3H=U-L31DJ:*J[!EYKZL^\XLPU.U[_@R3T+,]YS8@RH5+;3E-Q
MRM!,0-@Q@Y<&!:M,2&(PR&LV_==T!BV:^=X9M$$2L0367Z:3:-=22/ML%B(M
M 46JIO7?O)S15'5J;B?H^]69-*H%FFB%N?Y3"/Z8H%.-S7S_.M6,)$:-KS]R
M<6,4>YM1W<A[<L-4\WFXG#X.-8]EPX:.:A@(?-AFM.V9!\JCCQ=RUC& /!ZS
M;8GI)8_*?H=RGBQLT*S-TJV$X>BC12_ \1 MMHEEO)J>ZY"XW&&Z&>"F"X_E
MCM/!NM%%RB]_F-8'8YT=OO1ANIPW++20XWGCWT^%@"T* 4-7]CI5/_%(GF /
M'E9]V5/YJ) 46Q>1@G\*?JIUNK3)X%'Q%/[5X*DDD@^?=H618",>3N5VX'GT
M*KH#FSM5JAI^S;,FI_X<6G<O*R;B#*@9;5[G@\9>)3]=).5V1\I2[.5')"F.
M&;KOHS!=S2@8"]%.2Q4GGC#P?;*FE"!DZ=2(BLS@T,.&5IQ6*G8.FH+ZO""X
ML2H?BYG[D;L,[I(/_B[HEE1(:1^U*3)17I;<#%(]^KB8I,#8)WK4?#Y_CD>[
MW-FZ$4].['AZO&?Y>,\\[VS?[<&^:SF]VSN]VSN]V[/;.X;U*!UN):0?QG%3
M*Q\SEC_[*#-]LIXE@_]!S&(NB PFIPHE&UZ\B+EA5B9_3\)%'TJTGI.$9OGF
M[^Q_^4[6?_T%S)B[_#BH], 5[4YAV&W6FZQ(LW47\"CZ@+H253*7<VWNL"Z5
M %I'0DPRJ_.\3G9W;!JMLQ?VC[83N(:V7.12XE<<J%.!!QO"M@] YC=&)$6H
MK]5O.0H:!E"80TQ\T.X7[&K*BG>G,F#HE6+BV)?4*%D$H$#H+U%4\FR]9NVF
MLVP_*IE1;C]* (V.?1CZ#B;+9<V-F78[1.9/(32TN]^;0A6(-BY_KPH#@UI3
MUUF>L!TPWV#4O-.*BH8P/6 6EP!>-(F)T=6:^K)EG>"GB/."TN*-R8<FRT)@
M'/N:#7(=:\9B:FB7-ZI4RRC7. IA6/<Y1G%^S[,,D-E?\%@U-/=5CRU'>Z^=
M'1S3RWHY4E72ZI^KMYS0<IN]V%[\L(]Z$XO]UV%2C=L+G8_691YRMB2(6%3H
M\L;<_F['%O6PN665$VJ$+4J^;(D$NRL:'W2#7,>X HR9[?I+Q986UT==N-B7
MJEA_0[@^5LN)3;M8(&<NDS4I0+V1A)GINB\@>/T2XPR5!#T.$$)^)]*3A971
M^IB/@%?($]FP4V6 )O>I;M-T37<JWA1,^9V*-QG8":@*8RK>=%Z7[%Q;EF?K
M?]59F2&5?%9)"1XHZ*OYE+"9*SA!L<3_20E. *%97G %:)BX)K*.T,,I_&P4
M#*X,[8@+J!LA:4,M_VQ1IQK73OP.#4/[ND\(A=;G86T1@=:0-=:Q=*.QL/O,
M;"W18O0B#%4K7E"29CP(MJDA@5'\;BP@6B-1!A9./:BA)!P/H$S$+ M'5^5.
M.1W5/*![_R32X/U_"C8"ZC!_+O!\?SQ=[.JIEUT606/)92!Q@:NP%' );G1!
M;'X!4+VTOV=Y>EODR>$G_8ZCE+QPE1[HUM5J+@^BI%Q1Q=*$CAT!5Y)>! >U
M [$XAM>P_#;ZRWI+TGK'>GS%CN4\CVZU+=)/^2MIT_J,?TH(?_P&%(LR27QD
M!^OI< OZP:)8>9=4(L$B7PP" @;"0$Q^P:P)1N"'SV:1('$U-MP%"[.9CS[P
MU]%<Y$-6\;Y_RE->-*Y.=D Z5=YN="=P#42""FV8^'0^OF;5MNDU[^8V>WDH
MKO+*Z6SNRI1!8AB/I'&N*MDR 0@>6NC8 Q 5Z4-B,)6)P2/FU?8?,O.-[]%?
MEP-'_3;CE /GE /GE ,'+P?..<E^R_+-+R0G[T59/+NDP5%]&^:UG^9AQ/X=
MC7*T6 ZJ+X1FI#R_8S 22DG:Q*.B^!IUDD(^>%8'C@\3!6AP0M)(K<RSV;B1
M2XJ%&P5.P(5#AS(O9^-&+BD6;A0X(26FN2%5Q3/CMQ=M**1(101-L*:[_QXD
M@)*"@U'!\"9Y9.R_9FM2?OZR<MBVI1\& 7>"7V._I<MA0"D9V;3-NR1>G=_5
M=+WE.3DVE#3W(BZU#:U;"Y?IQ_/V]%!YRAXQW!7BNT"&ZR,0"U8QAY+U@+<<
M9#U#V0<D L*F$M%7>-3A GW":,B^I/^H_W=;U Z3^^B3A<QKQ60^'A_L#7-;
M-('DOV^3XL8%P^-O@EHF%C".Q@AL&39"SIKT)_</?W$ \OB;I0,Y&J-U>4@7
M.X,Z3<;>GP>%S_H%T<$\H*,9N<#JL.[C4LT2J$-R*^0QR=,B;SR)'N:GYO/Y
M[4W[0(\#QIKAPSXG:*TJ-@7$H<X';MWWRTE'J,%;"P#2P]Z\2G:?\G7Q3-C)
MHW@AE)T)P4N7*L4LQ#(RY8<RPX46?+E>\RSEY3U9D^RUJX0!S(Y<1K@3L0\S
M"IQ [W*$K%6U)91?;]!DU^7$ V9$)B&RI2(%R::&I_LFW29K/<O37_.7)$N%
MI^IBF]"-70([0Q.+L9BM\MB9\,!)R,VKX0&O@J;)R*9]"P-TH?>]EBM+4O5L
MY(LB+[.TV82*O.EB>T,!O4'8BHUFH;@#BI;"^W.6%Y19Y<)[N[]>[Y6V^&"#
M@J]$X")Y.1Y!6VJ=< 7.[]WH87E$<I<37EJ_4[$[6344A[GF (Q%NNXI!G4G
MCNV2C:72;9IX-3OMY<;!I >>QLS>4TM3\(Z6X@ -S)]:3G2;G@8RVS3>$R,3
M/R=5S77S)7S1*XV@N!:6#C'@=,?[N(J>_TE$8<Q4E,))=&1G C=8;9++@E1
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M4)QS6+CKY-<\%6%&[/.$YFR4Y>JILVK8\,HLS1(*_S Y[%B^FPTMQ#RPRUJ
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M)Y#L,O5Z\=1.DN->^.]('LW&Q)@37!UM4(^;FGY()\W_U#GQ75U.#2Y[O_(
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MV322U]ON. 6P.(2=JL8.MNRI2A;8R4O3^#S'!,4QS#0Y=418'\Y@U@S@2<W
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MZ]75Y'HZGJZ^;0G.C7:P);MS]:J<-3)F79@<0K8W'C8K'<[,&MZ<>C2[A<9
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ML*K'!D[5"<UXX5&R_U*7PXU*(1*7:D9 A()U1OH\S+U#*(%(]>91[*0FO68
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MZ2C\G]%J.OL )G^_F\R6DZ5C*YPI*FI&Q,98M6=7><3^2>DYI^FPY@(\EOV
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MR!=V]7PV&#=]6T94._IDC$[K?C5YH9VH7^$_?ENX[_*C=>'4<UWPI]^\Z\M
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MTV]70;C/M"=-95%Q$C%)YT4_XHJ.AU@XL4/J/-#5ITLYLO=7&#P^H5Y&S\B
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M?^/:J530[]"?CF7H:V!9PE]!4>;'%;!&#8(\![533:X1+37_AIYI5ET!92K
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M>E13 )]2L90!6)2LDPM34>Y8N,R;<\M:#PR9,DEC929'56<ND-%P**IIU%-
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M1%UQ@51:)ZX;,DB("Q3$-$(6^A%-KF0:$=T$Q0C(5G7^VN0!3"?+>Z\:< *
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MHR4A0_BK)H!;Y,-J"W!6>9N?S$H5E6'##I?)^C'!^]*+_:1^TM0%O\WW]?U
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ME3'(B66G'-=<Z!U9_EA@ZKK)#L>I#RJKK;U[[FR@TPCDOAN.$A@?^!9UX;E
M&LU),Z:62.]!^2&+6 8:CB%(@V\#/XOM1[1?^$@( 52J&S6NQRS'GJ!@H]R8
M(,/:^NACQ?JX<(>[-O;C/81^&)FD5?,]1[TK0-&'P"PA[L64(5VE10W&(\X;
MYJ-N(Q4VF.Q%?S?Q.2/?)T!+(BDPTBYW=EUI0IPX6D;R)XV:  'Z""D!$IEJ
MV 3Z>L+Q,A_OTW%D1 ,@HV9#ESA<:[)V[Z6V)FL E+K/G9M7+;=]U:E 6+>O
MZA%MJ7W)>"#E?<ELNR3^6_!TQ(D$6FZW<KT=Y-$TBF]GAUS3$NOUJ3A'1(\;
M'/YS$YQAU7G(ZWC%)84KCI:/TR>5.^%<:I@_%A'8!<R#?7H3/#^E^+UEY578
M$&,OB?>'E(C@[<MI@*##4XD]P>HOIO:5<*<D/,/,GM#J);QW+%""8Q1:$^[Q
M;,2-[OVL1]4Q6HM=G!^R1-38?E(U^G0/_U4R!5"8A)2R.&B4=[-DMTTPS4G"
MOZ&&)$)__ECFF7Q@UMN'MP2/:"!]\DI+ZO$+BD@=*Q8NX<[3.-5,=YO)SF"]
M_9(%V=;<$.//7I!5+U,GLCD+\OL\JXC&B+M. 5.GS8EV\.[K%0 AM7SG&XSC
MDG6"V' &D9@P)O#EK> 6+T(R;$=X31JR7!-X.)D$89U87E0[^;=#**!1]SDC
M D1S0/!+DA_+]+4QW/=]<*%*\^MX>5* 7TD"%YM!3:3KO  UDY!F4&Q8W?^N
M/S%0Z[L>$+)4H(0V+?J//WSS]7=_(C*!@Y6JT]+]M,W=$+U)$GRN,5[M9X_K
MZ'8)K_JTL,AD!.-%=-'4\$FNI/01=-9%^-K3K!=6$P9R5^!]<MQ/+#'Z_4+(
MCA8J65$);AXDYL?"R* 0<F7,5U["S,C@+&M-I4U:=/^I$O;VF**\F&@3_UJ,
M&!!9$;&FT&I=UYYOLL?KPZ#)0"8;Z)?ABXLIN'E23DQ&"5>#J"C1X$/&U+VI
M#:/*O;R_JI3@R"Z[*"GJ1IN-*X[=?:&+LEKQ4YMITJ."JPNF==5M+Z)R1UYQ
M91,??B)8$F59-=^SWTT!BCJVNJ3%>^LY;>1_'%I:3/G3*M4Z HR*H"[(*Q\:
M^=TFT5.2SM*04;B'_Q1Y 132R.AF+$KKP:^\R3"T(T;)M;ZN+4/:W1%SFV?/
MC[C8PQW(U1C'49%DSS^0_V4]0]E=>1^=^GM'BY/]_MXO-VL0=>J4L%I] ,%S
MYCTOE&[4F2Q-A&R9Y'&RJ4T5S4:SFA1D>X8)CM+"I17'Y14)T7!5;H!0D<!1
MK7]@94-G,'#S*_N^0+F])?)1CUA(/4H!%WHQY"?H3!69T#B)5YM-<:05S^<_
M7F1[ACY>)'#)K%!L5-NM94G'BX:KBK*F"A),8A/G+\K+(URA[$2;6> DFX:W
MF,M DPD=K4*$"C(ZN%)OPU:5Q"D(,)&!G54R($O36@:SVM9/M@IO5N\#9&-1
MEU6O"&]8%_-3;E,7T"!$/2,=4+H\%257?@5,&5,[MCE&:C/WPXYL!:^V\[PH
M\H]DEZD_>X,-O3_D]3 Y.$(6Z/S0,UGD"-%09<2+_1YL BG1G?(]?I]G;7?Y
MB45.NDV +NAB2*0MSF$X$:H7G!T#VX1TO.KW*U>@.4)>B'8-3\ZRBUJ;OG26
M> _?KW A% HI(3+2# SI&5,RJ'>E2?%SO\IHL_+O<4:$+9W'6R_:P?L9(@!"
M'A=='E/X\)K[*; VJN#0H.N\ $-7)VG]*%]E\8?L$"7Q RY>D@TN+W91\6R6
MIZ99PG=XH1H<C>$ERF)TI--06<]#&SHQ7*=3(PYU'4_UZ#L:76@'N=7F7\>D
M3"J6'5LF,;V^\NRQB+*2U?B;^M(QW39 00A3V"12QSB$HFX!"!'J5@C[$K-D
M=^\*LZ%+@'(/-O!)7M#=^$5$G_KBUHA"#HU><\?>?>2$HI=9?6#-%WQAOF\H
M358+F>;62KN1] ;+897F?1VZ=:DUVT6ZL!F%W/5C/DOC-LDP!!H1B4_F3,_I
M[Q/@]I("(Q$W&$/CR>B@P&*EY9@L"6>(*7<!C?!"O8LJZ&7U>CE]O(]BH[!M
M5GA0Y!F!? %%M*^GH/C$WQ3>X23BH-S)-,!]1#P9$<E&(J^C#0VV\^34M-K:
M?Q29!702^8.@JK)UJ)]Z.4,$D#DPNQ<[9DN3$49%\5X^HCML=@[A$+6 S]SD
MT$HI)+^F2[IM'01!+[/*L! W@3T_EG"]EQ?Y_BG)Z /FH<('[G%S17[J/IB;
MC/ZIP+@+PYQ8DB<!*82(3P&X5/;I0%%0;P#AGE)H>*F?C(".);SY*E9&EMS^
M#)\R-]S>KJ"8WU-13EYQ"3&G5P9=1B]"Y2J.Z0]1JCO*)%P?NX=W.1D)L.Q,
M:J<P@ZSX> H@:!/)0"N:4Y#/]<D,V5OUDC$\QKE-)[YV53OY#PI60*.^(F.:
MO;>,= ,#YO4R.S4X.[JAF@HQCWF]^&T>9>6?<1I?Y\5-]D(NTAEZWIKNZOV)
M; B8NMP.O#,PU47(&Z29$M3[9,GEGK'/@B+C FY.;- 7QZ*87O+D^X1P>,J
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M1/HN:U /$YXVA$6H:&>'O3;,6"HO<B*D@E.>:+?2>URMM_6E5%X>\6-.N/*
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M-DZ*/I% >[,8U,HB*S?].UYKKYC-O:=;PVL-70TP,AL:S*+"DS;S&M=G>"^
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M"CA<7_ &90DU[W"URV-&)HSM/"H:FX%F V_A!FHX)$+4"8[,8>+9FF#&KL;
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M7!>FT98^Y=< '@.!9?.IJ>K\6)*)98FZ@U/B-PEW=AIQ7'"DZLDT3?ELIHA
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MVFPD"82WNH@<.=="WR#V. JC'2PIY!I56AO_8$EJXYLM+EFQD4>+F!P*R>G
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M(#XG2-=IGA?*<_2D]1?B)J,MS#X]5/WW@]'B-N"/,3V"<.I='M/.WC!&'3E
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M7B$/67X*=FPXM#-H2G? Y!@%'AHN"'#VK2$347C4"?^):B 3?N]TYT ?$GJ
M5P#*0E5J  %333!*514K!T2FM;D/W.Q!I<H0%!>A)"*^'/4 AWV1;S".:8@]
M;\3K:1KD7FIL^=+3IUZ')2<D/9/HB48&-[G ]!F$9W;("YCI0KT 7.9K$&N?
MG*<OSE[=YJ"*%X_&D!E#) -3>E!$1/KU]$MC"\JR!+S"E1BIN2 A@/_W90U4
MVP?!H/I;,Z7K 2&LBA*,'P)<I,R0XNW[XN<K:;-4RWO\@K/CE"FI_3+D=5YJ
MP;8)]QF98C[@H1W)O']:]WB#DQ?P]K1U0%GA7KMDQVX9OJIJ4PK9)-G1/T.M
M$!?PU8%P_K_731H1-;6I+++>UG6:R^N\.$D4J\\:VT81IUO0#[O>A'[/K9&U
M<:PUEZ51YX@0<C$5R40R,RT[0AP7)QC<<JFDCSE7!ORTQK>I\,""\%^V)$A)
MQ)=9EQ1/#R\F1H0P$ D+@BZ _3Q0MWF4#>KLU5Z[TEHVNF#T0B E/3% *=E9
M6/FP=G26IF*TA/-F/$D-I&PJOH6PKM[C&.\/\-?WN%IOFQY,ET=R6G)Q+2:"
MU2QT1F-^F'>0];"*C_2&(ONV+XBP8F*$LX#S%K0*P\SGI(0[+[Z(#@E1CVTK
M>Q?M FC#5@AY*TB1$7!&@[A_9?'YF$9%Z[#,3KW+TB^JGMFXUDM:O^W4MQ[6
MOJM'3L0@(WJ$^6JZ@[C^IKN*@3B&T$VW9QQ_JS87*N969E&Q%@\[_XP>11F!
M%$Q :?^&S'L,E7@V!')R[K.Z">LM=(!-XB0J7J\^@>&[_9-!&%/?Q0^W)4O(
MI?'0[;HT]1G'@3]U&]0%#+>G7(!H- &8=_<7'9R72?P^KQBT!NPMVN5.> O.
MA$V=\QX=\O)/)<_N.(G!OEVS'<S>99XF<=1?)ZR;R(92)M*@(7.8ZP *:&,:
MB_)P2),I Z0+MG8=SE/"ZH$_;S6N A::$,>[MI4\[XA"_J%D56W63U5$'O[D
MYF@RQJ_S+O05<ORP0=75[FF3U/F"-&T)MGJ3;]\<R;_I%XGR>COX<UMI%[C=
MQ0BG='J;4!>6YV.(-12(\:0/<."3IQK9_ISSR-T5=0HH%6U>*QEER^=KUK=;
M(+I'7Q5TL_3[EIW)Z3:0IYDX\VN0,65,4';</T%:PA8L+-!*_+SG-S^TLE=.
M)'N?O>@-S[*Y..;[.M3A47XNQ]OBA,R><M9"YLJ<,$)V*<6#A7'?</7XV8R5
M=(9,R-@\=(E4TE:'QB?]9@?UU)5J:E!E;'HJ2@1N>D;Y%[BJ2G&=_R$HN" 7
MGV:>K+Y%V!-'C96 G29D\,X<*,GU!.%5D..,LY*.7$&HYS,%]ORU&U);@5<?
MHR)>4W]*^0,4$8Y_Q/":P''==*XM;-16VI"J0,W,MM]>6V* AA&>(5JE. YK
M//%%I*',>.5."*/- _G3$6HLW6/P,$K=7>TX,-+!P, 2<0+VD'-"O$*\9DX
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M&,[$)F_'%^WCG)&=:> 79_B\3O.\:#-@1)H&-25V<WO5GNCL4P^=;P$PP&W
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MV2)E;GBV N)::_]C,?J5 9ZBL\F8/%Y.J;*H *)D?]QKTA#9(/0/-BS(,W4
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MLR&25VW8N2-OVVF7B.%QS]KS@IEJ0Q![Q,5>RO$)NB[#WHANCKC=F140]D<
M0.@7\WR4%8G8W'P,6$>*FG3T-<Y/ZDFQ_D&2TO+!2TN=X"0QW.N(T-V^+OU-
M^'ZD34K5#6W\Z]BXQ&!!?Q&]%E 9]!GI=:5ML^UN6)/H)74.,6>JH"6((:D\
MUZ-MP6N[O].3K+&QT6+K5I7<VW78'=-:ZY2%VX/6;3?!7'@K.-#.=\5^H<-K
M>'&=GUY<K+90^0/%BKI5ZDLKAU]Q#\L3'W2O9N*,2LJZT4H8A"S]ME%0JIS^
MNE?01A FT*]3&5+]#<LFJ<836' \?RL2^SH+9YO*B]&N]JOQ8BCH8^'%T%+9
MBXH,P;TK(LHQB/,E+C=%0L59ZEILQB)N<!A-6 8ZSP,U>EZ36-@I\9C?D25W
MY SA,@\T62UL)F3V-7-[2>"AZS3I,1NHB*;$\*T[),\9#:T@)_N&!I9!R7VP
M4Y*/4Z\2=K-1-QTU\Q=40\@,3^$E:4$AWQ7H6!#N551 C]22@'?<'VD&Z"4F
M$,O;:34S43,5?<%-1O7L\/5L=/B)^&5*%8]V]ZOM%L.-A]ML'XC>O,= @R1-
MV&.Q2/("*KJU8["\$FZS'M^/&Y9$_37/$%V5E;GKAD(5R--PV1"5<1VI(F+Z
M. J'Z#MX3S0AH@6#;JRL>LSBQKK1@YK&8;Y-(0[2:#(QLEY;K<.^Y*721C74
M9WFI"2NCR1\09ME.;"ZZ<@'IMAJL!DJ($17\7F(-!'77=@+<L+.[16'#ECGU
M>M1F4*^(N"4-*AV&"1)T(X?HRQM%6<_.BGR#<5R>EK  IY_<5\'FH.V@Y >"
M>6%[8,CQ$?LI=/A[_R8;E4G6_DYS;*XO;J3M>H;AN&&^,S,4)5^6#7U\M]@%
M9T-=E1$DBOY<)BH3!W/!-&4MZ1?%S0K+*04Z(MYHL??89IW%F=S3%EQ,+(Q3
M/>J@&S:WT=U5J1W^,SNTV W4#V.*>"TW6?=@QC$NHI2F^(.&E&^B=-"066L3
M;MI4L\6:0@B@@] %S\2-JY<32^5"#.%7Z$Q4;Y_GZB5*\^P!DI=W4?)G'*75
M;A.!(K3997F:/[^>Y-(*+SJZ"&I60=TRJ%M'GE3L_;U@@_/P]6!/L5!U8UFF
M#"L)48>$Q]=Y<7VLB*H+W46A8II9WXPFC:@NF-&L1I/_V7JH67 I_33,T!=^
MMVXT]!K#^E1U47\?LH@%7."X28S6],RCT9)\7"2W1)M3/NRD%RI>T@15$2/M
MR.0_7G*$UYG<'@GSF98W&>L.[",&@=N6%GZG&W_.\00".LX1)"!EE\<D;%T)
MQBZ?&)13^K![S*&Y\7HK;KU6RC1WDT*6_&ZMY>(QI_V@(5).UNBN#*CN3T_!
M81#=3$SRW=M8UKS\'D/T.F;%J@[IR,[O]6JU2+'U C\>++$7'C8N!/2I9%[B
M0UXJ6-?\/;#BP( 0*P8\ G[MBMRG3:LZ**O&\"<H5=H6489>B()8DY;BZM/O
MQ0[52^FARKZUKHS7>LMFK*0S-#??I>KFJX^T&ZZ&&KGOZIDKQ<S@-]^4%)3<
M?-,SR5OV;5[\3,[J^L7(15F(Y*0>W+ZKZ^'AZK0+H1_P2(&C1T6V4VYNLENG
MWA)<V4GR&=Z:=IKPS11S1 ><LJ51R 1<\D/SN]HH6EM:RL9=&Z7ET&UKE:P+
M/[=_J'<Y:^Q89><@)SN=B5SE8=T_4Y%,K M-R0Y_'3;R:E>?0^ FSHA2K/WL
M84Y[Y#:SD*"CC/<N&0ID!I^V'G./'6?S8H^+RZ3 &W*^$/E@O[C(-[L$;Z\^
MX<T1 M+66W)3Z*KXLZFH68P&'-6_J]=#[8*H7G$![@07$@QXZDY'CP=W76RC
ME[_"-U)3E!@Y.TE!$K6;"W"NJC 2G95Z"OA]2][FV3,D5]_F4=:$.$EK[<"8
M)B),F,\<HK"1  $1X>6(>K7:]XO2GI2#YK->-75(!X5]A\6VSVIC5[(A6DI\
MW)S$H(0OZZO'7L1(-PKZ_:K8*=LV_]1DZ=#!74/495AHA"@(^2''U:>%YB1%
MLO; GK8@TD6>#/)>&R?VH#?3,-4^A.I@A_7P->Y -*_/=/(NB-*V,,AZ>TE.
MM)<(%)DN]IJ+CWS,FW)>C6/]QZ3:01>_^RB1=[FM]^&KN:RWJ-N+CUKGHS$?
M<]060&LV1+ CZW5(]PPJ'E,34& DF(-#/CT1U,ZWR].8/(*8_TO:XH#^]4P2
MD+L$IU$/#:E?2("LUT+>)\:"Y@6Z2PZ=R4D;T=E99A"W .?E74!,IQK%P;=D
M0QE_[_,ZPRT"<_E=@:OHTUV1;^5VZ6X\G*%L!F)30KZQ96@,N*#&UW,,^CO:
M?QDS(^SA6#4%(BX3* @ 9V:E22'@5D!T":XV6;,*RWE<1D*!.<:B\\V67EXO
M&DQ>RY \*T_&J8?T$V\"W2<=M,*+Y!09K\[8*JJ.X(RHK<HKPM@V,Q*J4#(C
MM"X[H%VF,>)3>R&7(@KE.>L[9AEM("P1'SI(70CG,^['M71@'2/7EI:J_WV=
M%UN<D'^?O'.^!P7TDIP%K=[J(_*Q*_;5U.5HX1,47*(P(@"2>Y8$CY,,PASA
M 1185'S>'._S"C<F2R[>6%P(F@SM3+1+"+\60"]BJ!1)G^=/6Z1NH(MSV=Y0
MK\2ZTI_HX1)E_5SJQ1;]LZ*&\&L=0UBO]GD^IXZ<$7EC;):7@.$R"^D9WTX)
MRCP9'B+NJ''V^?WA9SBG[_$!K/C9LT7!@GHJ:N?J*Q,$T:JU"(JU;4.Z^#,+
M;),,C$C76//^K,<A,G#@:?>M/I_"/-"/Q4CY=1TUSN!+S/Y[D]'<>),J%/)8
M-;84^J)9]$M(O6$E<4PK?03OJ.Q,%M$7-9K*OF)":]65J*?@G$G*LD[ %YK>
MZH?'->T8WXP.ZH 0@3\TN4EQ])WWFK"$%\+W"UI:]!EG4)Y.D%PO2WBM5Z!?
M46\-L]9<83XN<]1%WY(MX7PR]=0@R+?]M3:<]EHE#^VE"["6#M$SL9+*B.)1
M\X.V]V5= 3DKY5<9'=<6L(:1X;^=/N3B+T2$G6=?PN#E!=8,9C5)T_RC*I-?
M& _=3D?M_+!=<;3HB5AC3!5_JO5?CAG^W3=OO_GM=?*"7W%4K+(L@92]J'A5
MGUGM3-1,1=S<!42ZZE$;* >FU/!? )T]F&_SLER]1$G*HANXR@^UG_T\*I.-
MC&/@8JBK$GT!*WV)VK4@M( OH5$O=X;H@J&//4O\A18_%Q+ZRP[@"LC5SP$^
M<_K#@8"H2)J6Z>C]"GO-FZN7R@Y+:Y/8 X8WC*3,X N?A-)>CN>RJ/[W88.S
MJ$CRNP*_)/FQ3%^9609K2AQUXU$S(6R@IPDR/*_,D??=]X_=X&TYXGY9+*U.
MP]5^'E046TA+1@EJ*GU&20W?E133J"S7VSKP;UW0F.U[\@C),_+FASA \K$_
MYN_S#.\/:?Z*Y?I_O0;*"Q;P#@EXL XM(]5$%)Z).TR$>!S88RY\/[@2T&=4
M1M=6DB:U='%4ZLH$)>UC!C-0-R6HS4J*R.#FTJ#LMZ"&-@>SYRC/XOI$F"()
MMA<9 8_S9NW Y3M<26+T4+0DL,<0VSM"AJ0L\^(5G.HZM:09BV#P$GIWB\ ?
MVHRE.'I[(71?_WK+59  > ;^@Z9U-?DO_[XQ.!K)&X OZ$&9U#P;5IRKINWY
M#5OT'H[A'&X34$AQYHZDNG^_-C.-PUW=MBO3]$WH9G0=SDI1I&Y 9[8<*X4K
M6T<*WQV 2DP0WQ')N<0O.,UI)EM]JC,?ACS^@TVEUQXWN;L<#=P^0>)#M"B+
M0T4,*>6M!=UEOJ&U.1_)RE)5IAZ#8%"0X_ 44IZV8BP\EQ2+RAW\/YA87J(4
M?'E=9#"M!<^'"I^,E-YB9-@9ZTO<C3[C(ZS9B*@?=CV8(#H%0Q?X'D,OX1-O
M/ ,\O^K[E;+N<8Q9SW;R^WURW"OL8+U:9MU$5,\,VW)$B92(<T9T\%NKKJI2
MZMTMA>F8\LIS[3Q9^FO0=X$.KX&J:$8(KU[NGK[:A!F9%W#LA7<O10]48B5V
MAVO)X"N\:KVI<K+IX\?\<9<?2W(3/7XD\O+ZN"LP/H534\:!+87(6JA9#+'5
M$%UN\(X;MC[S_4DYH#_XRIQ)Z%?#Z4+06:\AEF+0F')LP_E9[&33IZ2.YU?%
M[P>.X-?A+'RJ65+,7\N1^ 7,_-"6Z [3"A7,/P@%B8BJ2":3*<_-XY]W+P*@
MWPA86Z^(8$E4K]FZ8/O+=H:6GBLWW#?L3HW!ISR6L/YB9&H#SR/.:"F)_:'(
M7S"+D4_V3\>BQ"HG?&,SJZ<C;C[J+1"0JT8(#CEH01>?$4WIZS=OO_GVY#;0
M!3.Q24/SYQ+BF!0("4*8M.A[?KO5#:7J-.#S*/NY-8P*ZRJRX6V>-$P8%)0.
M<L-)$!%=9TJ</>=X[ ]14L"7N"XND_*0EU&ZWD*%NEOR/JF;^QH&G7=K@5.\
M60UT%%CO#5VP==^9A:"'2.]PH(B(R>Z4]::]B*.8+I/MEMRJA%#GN/J(<781
M%<4K%-_:0VCV34S&)-L$U"YR_Q(!@%.DZP(MKU<T#!U#W5ZHW@PUNR&V'>+W
M0]V&@J[9OH_>R<DW.*YG8I#OJ*BGJG.5U3</>,2:7E9-&:YU46? L^KX7RL;
M?G4KGJ%VS5X;L+8>&CF,FC(';.70]:\=Z2&.!1A%7+^U XC>'L7X'F]P\@+2
M*0WX:(8B;FSH^UT OH@A4BQ]V9%H;Y(\)@? AKHG+G91(8]\HM\2/QRQ\2'/
M53$&@\-1A:CO2C&#;FHF55S:ZBQ=J1!6RIAZG9@C,WB9E0%F0ON,@@9>"UN-
M+,7"51H]*;YRC_=1DD&[$/I];ZICE$(-YV^D+HP)R_5P8 G*\[2@(0XV!,"%
MO><",$,JFR%DPFNQD'YWT-8N%E68[[JFU*AXW:FS+$)^::]A77CE28^G3%,R
MI9#GPO>0]@^)F;J2T'5]=1@J:3 >I.S]*?@BZDMP]'XYN+0];>MMD3?4D7G4
MRY.CX(<\):N!)Q<$:L82;EQ=: X:P:W0042_X=!"XH_XYOK)?*SWWP]PPB:K
MFG: LS3"#=:5;'+J"4(_9N&/9Y?UR);1W[,ZZW6WZ$74P&0@=8V_K0M??F8'
MJ1LG)CU-QPB#SR/U_%@F&2Y+@MY3DE'L'BI\6&W(]U@F%(=5'-,?HI3^ML &
M66;-LHA;%\'"B%\9=4NC9NVEY*.-),S@;)R$T'Z;)D'\R24^%'B3--E5?*<?
M:4@6C=+A)[+J9MS4L \K'6*B@\",&)^MCB\JV1Y M1<7R5^>87!"*L^NP\M9
MZ]4C<H2PB_6V[2-6IR3)_2)T HWZ:YNN-7,"ZR527(1.$C7B7D]TD*8"[XA
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M/:^*/97WN%,D57[$EE%Q7S?"9M-(AM:1CEI%\+0T<PV&HW-Q9;&'4"906RC
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MAIRE&%I/C;N5Y,E8F2H,-%_E,(D.E\ AP 3GN[:KGV02+6QP&5F!JZNH7EL
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MC [XM$7"_- J\)'1)Y0=?MK/*AY+F"*FF82-OE3B.SLJ;+1PXD9 ,R%N-*_
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M/@URY 9A$@20%^ @D@+L8AS,I(F'CQ/4$ UR316*/-^U7?TD%+1(ZQ3]&$-
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M^=U:?U%^YDZ< 6VYDOO_!^^&.F%*OO7V!>O?KT[?[)ORS22+[N8W7L=,:*W
M3%TIW'^5I2ZT-+UESGC%-V67%L2R,5D'HO"33N\'_5439M]HTM\&XU%Y,5<G
M2P;]:HX5-&&>PB^%^"@A8Y*W$.T2*N1NU4FMXWH3ZH(AQZGJ#=Y^J^*2UF!3
M>9G5U(_QAJU=FCQH,354K_F]SO/B'7OM9L/FO:3$U&!F:)F?9=<PIU?O#,S^
MZ?P[ZO2A(LR%RC$)A&,NR [CN6,;R\LBX6$G[^JP72+S#_?,CUQJCM_(V..#
M5(T06V8-J[?6Y>8 ';&IFR<=%[TIH%.<@0VOMJ\3$(=[TJRGS2SB<*DH\CW
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MM! H(8!S[S8 @6^>DTV!V>T,O$G[,\>O:XP[\O9U+[S:22?40R5S;1.1@/7
MN95&1_G!5B)1"+2V__NBJ<0=WHIC3MJ^L2Q+\SP<^AKLX1]F3.Y*0A\OJ)<T
MR#=5GK>^5/H2M/U2L]AJF 0@J]C/*>C#4F'),6X2^71NAVD"(@V*['U B0>:
MNW\6*?CEL]A/"6=<DE2H,_=W'*"1SNM&4'Z6 ;CNK*G_X(W?&RVN'(EH.AK$
M]*B\JQ)@!]5F8]Q3;AI54@CE4]"@0WK7VGA#C'Z4;EG2CW/[E>2I8 ]RA2U*
MBASHD-<4MN<GB D69=B\T&"F^MG\.-_(U%UOHX^]N:%[MQ'0:'$+;GC9[:"
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M=D2R\I)G%*/S%S](%VBQC*,UM2MF.$C9Q8+BNQ7%W6R7>M#L[%S62]#>K#0
M2%U>@2[P) SV(UK1R@9:G OM+;2M"1BSV</C^QIF>VA;T\8>\M@ _H,?X?0(
M%8LMIB<XB:AX%U'.QQW].4<.F:H,&/!61)2'D=ENQ2M:V8"D-ZF]'=GUX6)D
M!]#KB/J9>7B. LN,'QRR:]9P2QWKPIM6+3ZSB94H7-.&$@%#G(<M,*Y7.&04
MHE8E-E35S95LT+90>N0J(F2*J-I QRZV@9AT+FWAZ#*H49@G$5;@%8;4%(5H
M:<H9!1 V6/9P=WBMI08(58J'RXN<+Y?(9UX.1>G6V.31 &7EJIFA):*6[P)
M*CE+V7+4U^LHO$LB__,E(2F#]$#%YOP%Q3XF] ]^\>+8HT(T3Q.66<]*$(SE
M4A.B%=./X3'?L*MNPL1$,U=:8D$+6N0ZR@W 104H^<B(QR3'[ [J6MF1.!:H
M]">-(H 6C*"4)%1+Q\6K)%K0RZC48K=HB\+4^*Z3A@"_NUNTH58E6WR:4FL2
M$5)$4PWWU+4N_$XN%\RY7F*V_!7%[HI>+O10A$_,U(2(JD@#L!.4Z(9>C]W9
MWRT7GI7-7]'E#:V1RA)64/S$LC#HK5) JCB>#^$"Q45R!J6C^58T0%G9LDS
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MNM?6I"P1F+%<J6(ZE2QTD\Q[C)>-X\J'X;3G>8?4MG&N?O)<9>L>8S7#09J
M%T"+H+BV@$SXMZ>4RRZ/OR#\M*)83+8H]I[0=<I:H\V7C0)?2^I4&;QKABMH
M6G72EH)@W)#"IB384,QJL!W'*'2/C(YL0.MX0,$HU)?MQ@FJT-V:V!9E0TQO
MQZ6RG%%'Y9@C2[>&#,3Q!#*EZ%?R&.!]V2ST_.L'J\%G9PQ3D&)^%)H1QB0Q
M-3$]AVUSQ^R=15FH8_&/I:E8GDCS[D60S+Z(8GI]A&=IS+K8[>YC+R1!1NJR
M"GL29]6>LS1F@Y)0C*,%_'@_</1<5Q&IG2T9@=+G%&CZ._25/X !:-#8.55=
M!I('SB6G?8C;+NA!R9C"=+W7)E9*8M1[]8#$!OJ3$M?UZU;X#U[O;+6/W((E
M]RRJ#>7V%B*)EF?9DR>]@(NAWOG39WW20K/1G.$TON8L0_OC^%I@:A^QTT0^
M/@#7:E])U.R/Y#/C6XXU4T=1R,ZLS;E\7%A.#4.%X2]\0D&PT+R#O97I15P0
M0^G/VB:VXB;U1T.+ )Y[#3LF6V%<<_V!-"B791J'0*Z;-$T6BVSBJA?<>'AQ
M&9YY&YQX@17^M<,:AKZ4964'W<"FN@!UN[;"3S&<L6G3%HJY'>ARBQ*/VH>+
M,CW$"A\%0$:F7$6D NM"J<A"MH&4?KR[I;2+MXC'.D'>L."K(V&(:.-.!ZI,
M?#]=IUF'/5%TP\Z=)PUW$,.OI*\_>7(ZGL'"CS-:X74KJ,$X][(L;B<<U'06
M_5[=^QU8F>'.AS&J,RH@4Z5.49/^G4-VH>,K#3A#L2^[HRM-$@%,V-4,C;4-
MDX=E7 ND@1@Q\O.A!033#[5L4?P8&7L&K0/E+7"3#VETW!003#\, \E-P5!Y
M"]SD0QH=-P4$TU>QD-P4#):WP$T^I-%Q4T P_0@,##>K&[!B:W( #,9;D.$>
MCT"5J,MXC+7*6Z^^T 4FKDWSW74 *7- 2 U%#J[:1B!",4#?/-QDN9P4VS@Q
MO88L5]\,K;Y&DL.0-3)\9IV&E%KD7_>04@V[S_S09>CDLXNK.=E9#]?J8..+
M*#ZT=)5K(Z*Y]# >5+F\U"66V\<X =8YPFR4* 613T#>!!B\P[$J]%'H8E6*
M C[F 4I )K=G4<CPS>83Y#\GF)H(=\BG?YE@<#5NALL@(MDZLB%+:[#71GA5
M,1!)D45F](I$7EI</5*VR?HU>LY^TZ?^., <,?./J0?U9&E#)?3,Y&.@@PDW
MZ1_R)J-U&CH;9ORT6+5>@)CVV2> -@:%ZQC_O$6'S4MU&FFT;S5/&VH5-6A>
MMJPZ/A^NC40Z[5?[NF:SW\TW61?O\Q<4^YB -RI3AS]@_AL0U:3!JWDJ8+O@
MNA.#-@1&$9G3(2Q<@UAPC; /0=VA>(O]7@WP)NPQ2X"(G"9]86T[Z8ZX+P(^
MVGB-D)IP'65U2RM\]FZ]GYA'YLM[M-Y$L1?O[B.*_-H+]]F6P,Q7@SV*HZ](
M3K!NEG8#N0]A;X%\ >Q1,%^1G([[U4D'"WODO@CXR/5^"_-=Q>$J#XKWD:",
MLQBTF>\*6 #4X8_ "=0@:BD'YF$ZL!A=GH58>2*H)R3F7[NL3+PH,L2%WS"/
M\,&C-.@+I6_VE$)H'EV$B15G6G-8<F@+I3'*H37VE)E+$)%1-3G,JR*$J!WF
MV:+%+<H*/N^C/+J;F_*?4+**Z&ZW*-?_<J(&#G6X=I(%"I?2TNM0"/!]2":_
MP8,=\INV#2J7XN*F&XF,:5B.K&$-]]9LK&;&D&K(^!;1W1&<H"* E.OC6^1'
M3V&VH@,K'0+K8;_6]L[#4E2-(\+0/=+%#9D/M.FO4[8*1D/6=J"4+V6G]TXO
MY2[>P A>.79RIN]^[3+0:US/ S[7 JZD:N"B $?_4I T@L9Y=<=Y:#R]MU$[
M!"\8_)JJP1]Y+F5*EFF$>ILL RVI N=;:U'5P'G72J62AQIA6M&Q&V;?[E]O
M,G*N4()]+S@0ZM3&6_IJ;53L6+\UFQ"'8B"I]]"6H"94?U_;AW!_]LX\LKH(
MHF=[IZF$0.P?HB8H V?A&B5L/6HJ;S$EQ73W0%C0>$Z5IL="/!,_P=NL.L72
MQC00&,[9$G+]:$ZY,HF=#M-\ PZDOMAW.)@ C;@,HYO,=:%;R\RL^XB%M4(?
M!VS\265Z2N3VT%M'UZ6U"R-;]CGJNN?[#%&H/O8LA,UK2[N-//9U,JNR4Z>L
MT[ODCB+)1@4SS^^V\2X+8!8=+>_RX+M@=9.^&L<:='+9?@-7U)U'MPRY^9+N
M;4((2B9K%FW[(^/*^0M[GH$>O*0,WG5@RX74J/,(;)*$?L"S\:AG(^;9!/+V
MK@\1M<':WNB(0.4ECA)(*I7#6"+D8+X] 9'DA4:7'/$,8!69F6&2/^9D"=_E
M) XQKE(90,J+OJ6+19WB&HUQ1,*AY3"SF^YRO?%PG/47I2KO";RX3@#D[2D,
M$;7!^MVHB, 4A=FKBQ<<RD(ND)>D,=JGLE42WZZC!-UXN^:,4(&>,%C^+6D,
M$RYHM-"!U!T75(RS4H #O>;+HJP$6H6TPW):DN-"D720'K#ECHI@'#3;?$G7
MB&+V-SMV\VVDS8NN-=Y*8*.3EF"->+3._D</AX1M$I%Y>$NMF3CUDZPT8[Z<
MH4?H^%8GN+=G2W1S0*>_C]CQ,!>30[)\+M:VY80+[RW9%@I<T.D!)) 5S:@&
MRWI",Y3_M[+%(I_=T@N< N"!9&Y+OK:K4!3P!0R(^2P!G1X(A+?,TK40S^H"
MZ-2B5#\-'9QOD%/C+0S2<VBB6'1_W<W0)B+P;1XD +XJCC?)Z>J5NXG;K 1.
M_\GV%Q')VD/)I5S?\'J\E*43U ,4S+&]B1%U4Q8EJL4SV23,Q]!FX2[[1UD*
MB5=UO.7(KO%.95?)Y]CY?I12Z[>(8E&DZ2=Q2J%A[Q$'-CJNFV#RJN1&@0&N
MYK0W<2G%NL"7%&'1&R]NBHK@YE!>=)QWB#KM %^?H/V^+"6CW ITQS]YN"[C
MC>#'7T1;)^]/ZGFBSE+N'?O^9G*@0E^#H0P11<-0&P@PS9_+'19AM"'P.HHP
M6DD,EO.F583A[<I&%_[O*8X119U*;K*[";PPH?>;X'G)O$A#'K!;[:!_:FHU
M' IT!HP>P<A$/VEPTF"'6=1C*A!=^6V.G@[H-GV$%EF2E4)_*X@B+DFX RS"
M494%>1K#)4C;MB&<V0ZOXKY0H;-!PG3-J@24APL<>J'OT*9L0^!UV)2M)'::
M0U]59Y6(R,Y"0D(K*-=1)OVS(;H<FM1T6G5WBS:%%3-?6F9T*ZC7P>AV:D+6
MVQF?:M;TEVX-64DR:@$T0%//X#0?4]&U;7>S%S^&3XD=YP$9S-7C01JD]:;*
MY39* KX;*K&9+WJ5Y'>&ZR1<\%/,!4\_RHN.6U>KTQ"N.DV)UWL!/,*MY52+
M."RWU,CY*DDON <]4WOK"$^+YM8QI->@H%LIJ?%<!QM_K2@95I!$N'5AH'96
M#8S3G QX,ZM.0KBYZ*8GV")KA6!> 6O%)-0HRP*NQZB*W2' _PF'$<L6S1H>
M%$T/+9[E#L"O07VKT!FJD,M4'K)$(2OS-450QFV2==(0<+ZZB;=\$<54):6Q
MO_((]04NV7 '+[A)'P/LSY<4*=;6VH[[+ 7Z%:A\-5([KK7J=!';AI59"IYU
MS"4;NWBH4AQN#+O=)S-G3V6O0BQ4Z&PRF[V>F:<C$>=4=_G)?%G.T+NE2F@>
M,N39_]A]M_4"I@"S.F3L%ZVF)^&B_D'E+X%%QP:&KLT3U7=8*UQR50=0;LH(
M_7RD53-]MAAY4B543CQ@J>P9^9'E#?3-6HW8*)P*'9*R-%:+;T/$3.HB\F$K
M%-TX,7W7-MH#^&0=@"OU;4A/95H/R, E3>FY2S>;(-NT%Y2;O@R74;S.*6]I
M3(<D5*>^OZHX2),2JOV67D5=/J.-#0.E#@8P7X]7=VUQJ EWO3KNB$Y@B6IZ
M/G?1"VB?/ALN]GY@UB#(5G:J--PQ7?L*U'3;1NW0\[$84#59L]KL?&;]5]!7
M=SLPUU4KJB>@=E-WT!'N<*OQN1C?QS#*<;F(XJYV!X(T%\FE7 <MM-@H2R97
M36P.O9.DAKQ+\5-U3<<13QVV*I,-,,%4C;V'9.;BL?[0)0\M'C94-LW9;09C
ME.?:F+!@92**$G%'W2]$IL(G&E+=!IQ.L !VA&K#!O$!P]CJ<C03;B6_[2[#
M,EQ)K9?L&Q/)Y]A6.0(%.UHY@B6^00S9[(;R X\0O,2^E\^6F"RV[!F9I1R4
M@]P+A[9(/[B/S(P3,'AC]"M Z>VDNTZ9X)\+^2\X61G,<I!>;(R\EJ<46&JN
M1D.T4LQN8NP?S&F#(ZZSKM/R-AW>:A$/;GJ"_H&=$+X0TBVSK-$+I'-P)18=
MI9NA3CJXJ)\=K4Q8-WB*(]T,*_F889+U; 15UB(8KT $- @+EJQK%!X4R2[[
M0YRI)]F3K[FTVV1<D-BA) UULG#[,\MZ./]MQW]<(F!*5+AT6^7G@<.S!1_E
M0W?>TM^@_XTJ,B^I#,SAC% N0,AKDGEK)!QE=^_]/K,2W\M0\_U(8;D1LEJ%
M6"5'G>6T,NUSD,U",ID(LB%.[(+*7R^AWW^EP8[1BU>G;2D&QK$\T[2L4G9K
M7JK%A"P^O%&:_0KD+-EM'H93?0)(DARUK-M*C+>4JEM19W-A0+]CD1&J[&["
ME"P#J(4W#;=77S*O(B]LV _%# [6+C6/%!^W0].,NP, 'I]/9X?^I3B9!_:4
M!B!5"O[V9B5[^6:9; $BY/P%Q3YF]:+9KPIG1DI<=-<>XP6O3<>2[8Y2_&[Q
MTRJ9+Q\(RN;RS!\3#X?59\>+*.YGZ(4))N/3(2#T+Q.2>D\</&2^[N-:T.Y
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M23&RWA6]E6[CB%=T3!8%"5 (8%#-]5.$P^1G^@]*.EN'1A6Z]K.H )#]0Z4
MV.W%I2D(M8Z@"D0>2:RCF=!9QCO*"@_QI:7913U;M<PT\0);1Z\-DO8Q*\);
MI)$O4R&@_3.GBX7C/!4)WE=/FS:M1V$AMI</@UF(%3#,NJ8;K,W'*8-/X8+E
M#%B-.YI@HFM=,D#W%!#+8K9U&/DP7);V O"\>@X%1 2,3UH]:"TYPC!76A.
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M:_;V.*S@3X'3F(]SZQL8$,L RZ+Z>KBA]]?&P]F(RY @+US,DQ6*BQ3)?(A
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MOT"/,12C9-<:YH&2I@3T1&$Y1GVB6UQ!<$EJ(:<.@XA#<B0 +#Y0B\!N8AQ
M,$AJH4$R2(X$< %RU1,$HN4DEAFF@I/9OYO ]T]IB$ L!8EU7#\#"ZT$&1I
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M)LLQ/GGTDY@XX;D^[$IF0U,SFV*)$]B'MCVA*(1Y 8$:(*PR9V?)PFP%91#
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M>'ZIA;QE60P,'POWRU\CV\DG7%"NS54#IO/>AOCD=-V3ZP@W^D/Y61&ZK@8
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M$5VDA!PFUM]@D2@D48 73-0N<.B%/O:"_?-D_OCVH<4;T)XJT@Y7=Z"(Y*H
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MHN$"QA^9(/^,-GF6FD,O^BZH9:4%O'"TH>)_'@EB;[(0[X])'2#9MU%,?^G
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MY\C(PJG(9I^<7)*#P#(](T?=Q/)UYQ0&/%0B6)Q3H]0_9=BG(T\H(Y*+,PE
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MKAT==-MD,TO5;=/C#Y-H>>)(0NV3[F_F<UN(!,?NQ1""::\N(9T:WCT9W=S
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M>SI2O8C)WA<Q&3>#L7+(G>.G["K[L$X4MT5!5W%]Y_2(B( $Y_4BEQ.AUE.
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M1I<"%PB6C+R%.7E%Y H3M*&_I'J_^<%E3@>)MM??T:8J\3OMZ);N$^0>L3Q
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M0Z*ZL3(PKNN6PIR7K<WJ9O1@81I2/]7__(G)_Y(4B/WM?P%02P,$%     @
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M+^UNMWU^5CD[[\!WRH:S;^BT/H$)"Q;D'P(LQ+/C/\3G)CSF DR\W\!(A=O
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MU([ ACE)MW(#A&VJDYK<()P.LXXDU_) '$ONP**J9MI>2@.UVXI;.JXR&'!
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M$*5* A4<J^5PUL2OB8]L%K'L*0=L5+!7\V$U6BZAPOQ+-9@\<N-SXM _L'J
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M>87ATU^$]?(^6(_G=QXHVT-W(CZ:?MI+)ODS\U(WCG0(ZRE2<[T,_)J!-)W
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MF5+9*T@M ECSJ [U5GHQ^E@9_*C^^NC5QLE23,@TL':**4N]V55]SE'@"8[
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M1N;-HN>$+N4;A?&8JI;1OP&CX;IGE7 8B$$\&2F4,,YXZ#NC/@(>P*OB4/M
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M"\PW<MTRV6@0UC7*#61I@8;SD@S&+'?-P8;E^8W,?#2.&2F=J0Q%QI&;JB4
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M&Z/3#A,(1QH)+J2&^$L5\-B.IFS>%O&A'+$*7@AR++ Z:,QV@QFYX_$U813
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MLN]GB">*$AN[@J@M"M# B+-P:U-Y$N1E0>U%W!_SJ&K6\#,DG+A/QARNC8G
MD[2EE;MW!G2,V-$HI),A!8-BVU&2,/]<)VKVO4I)5:()@>-![KBJ]J+[LAK"
MZ#"K*/A92#3"R1&Q5SKJK0:W(8V'(_7D#/$!M$#1<E_7SU"U5*-V*+",EA*1
ME?X9/I:$5BM)^TE8Q'&#C\9Z@7V<8<=T,XPW/%!W</K8L$@7=ZEP'VF'5!N)
M%9,GG;O)#*V6\(2R-KTSB88SKO-:CH-(8^GH9WFNW-.MZ\4;&.>^/T5-E16.
M"ZI]N(@JU+FP0C!.1IW89**W^Z?:6IZI+%5GJK)U?LS 8$CJ>,%?<Q/I#^C*
MOLWCDEPA_Q+<DW"?5QU.J;[+:# _#5YJPEA_YVY7'W2W*WN%6X<H4SPL[C:%
MQC>65]U%$#@1D(*\+S+9-_6R*,'L3'1QM3?DX^3?L&]R*M#>8Z1#H^0]?DH<
M+BUF&9M7D_?!?BJ>H+9NBF_85%M5P48+U"I*E$:*X4$>@GRETK=KKJL1")U"
MYA_3%W5Q<""-%8LB!B%8O F-=\RDEA/0CM2 &7N/UY&T9>98B42RNMB.2I=]
MF(C6Q-GC+52<1#7.TVK)@&>>1=6R\AR=?>#,^-*TB5C\*SD/66#>:M*;V2JM
M:PG1HK"0*2?8Q"X.XJMPLO?(I_9[XBUW>[OP#+Q;L)_SG:EY?2'/>Y=0_0O-
M@CZ.2B>5X-%VN'W^ K?/'W)O<+$"LY%I V"@:]^$%)X(*_MG.@> !E6=>D"%
MU$"^JEZ@56 "RQYP9^*A[Y2#;4/LW?>\]TBD?7G^ H'NF>4]4_9?I9C_Z2]_
M&[,#_O?_^N[%R^]^V$NTD=2%LI&2_CM1Z 5$Y<8&@":4Y" 3W( $D3R(9.V'
M@WC<9_&0LY ->B'*<Q&W)#>1SLC ?W^ P_(@$O=9)#C3-D29@HZ%MEES)'2T
MI"D!6KF@;S!,>EZBA9630A&$8K\*ZGO&NDR+4I^<UD F_G<2R^FP!'9ET!A7
M>Z#MO,7N+O5(5-V31P=4G8^JN]>PNIW"<]_R9+TZVU=3-]W[MY+L4U$V*TU@
M25&!@8J6K\+7NV\)U2\0% QK.<X>B P"*Q!_IX[J98JXKL=_>?K04/'R8;1&
M+>=GYJAK!5/H:LB.TX>6&HJVXJO:>5LY3IMN2&)+KR8:9V]!H/:C&=;$KO!>
M"*5O<BD&H)"3Z_\5:-E;O/YLP\?HQ+2LA;FJ,: 9Z:VBMX?#F8N#,^R_0Q4^
M'Z1N :3\$P>#HUF%W5LH:$9$P*TP-0\VUX.9*4LYT0F6"=#+1N3U1 P-YVTG
M@Z'?$)V>5?3OHL1(<K?INQ<%Z*R \&BRB;QM;7M!H12$HFP+B1&"FSA2V_\.
MQWUB@7\CJ1'^QU3O[<").@+Y0_='S(3<HOF-XB4&Y,VL'4IS;UH+7NEQ6:;5
MITJ7J+^UA>T@^(3&(Q'60 L+_)M'9[:/M<T&L W/"6)%VT2*T? R[2!0 Q_<
MP40;K[V.#E6]3L$X^JCBG/AJG0DU).R%V>90M':M3 TB*RY'@[2L&L6],,1=
M^1$$,GP3$1["X$<XUT-<^'!,@5.I808LOB@J32Z?U5Q$)R+BMJZ<#%X.E]EN
M&.VVY>:$,$>A/K:D/Q@C'W;>6]?4B:+&*YGKF;NQISECFXB9GY\\06M6'G+0
MPY?KMMRHXBT$[@:N?)QJ#B7.>\9%1>3:\AT'1\C"NKR2GWV.I:];T9G"6]KH
M44G$P+@TO,.1)#J7WK1]_:ID\4S67%:PK0/YAO2]6D<EN0140:(=",Q?\\7;
MV5X&7-N#SKB_H8Z"0)Y+E:U!4BKT*E8;@[FM[AE9UJV+R(\.QU]!"GMG51SA
MM4RW&[==3ERL41T%FE@@!H=P@5&#^6YBJ=*C$#42!QXWWLFUMGQE!_>(5=+H
M2@:)JU#EDEM6I<U+I/6*:V,LU7<D:7V=47F9F[]GQ:QXA6+PJBC7TYL=T[-'
MC^".Z/U]%Y[ _R[AEDT*?SZ%?7FS0WL#GB7NC$GXVS_"1R]?/OGV9L=SJC*U
M7A8Y:($'+Y\^><@B]?+;1T?/GMWT7!W7$L'[WN;NKH*RHK.-]LFQ/3[DV+P<
MV]D]3+$YPQ/+X?OPN5VUWN6"'[<6;(95TZ/%DO\[?8R/ZUM.^BPE3YU- ;>6
M(/AK%*;)?_TI^C^/'CW%[''4$:/K&M7)[^_>'7_\5_C^37CZ\^O@P\?W_\^_
MPI/3X]/7[U[_=OH7^/ODP^M7I[^?R,"_=#L/C=":M;:?4OJW]D/]\8LA=;E)
M-JJ+I9#*:H5@A&6Z6&9<VE-110YQ:YJ:VT :56TWB+AT3E6F9H=JR+&/S+Q#
M5JJK)!SDL4"33Q&>3X L:M)'47O'F H<7@6)M>K^1+;>HC<!X5E51*=*+X3:
MO53;WLL$^!Q#+J#4"I.C[MV)ZY^4M\#0X2NP4]_ $H?O$-[XUDZ,J6CH$XQ+
MEX&.#-H=^^Q*=ZRW.S_X<%'=<Z?OW3'%F,9?-HHG_:,8T%S/^^?A,@8R,!UL
MS%ZN)GHRH(G:SQ=E,X,395$6L $QLE# (7.^!-.U-4E?,C;^?X,:<NRXAELE
M"4XYQ4[!Q+E6HDXX@HV^4#JZ'":*N.1TVI7(-'7D25@B.?P("J5*J8=?M,@+
M&&HLS;"XJ#%I8AL7D_0WUI]AF6:&:A4I<)B*K=Z$J/GF<& 7IM@,M!+ETN%B
MJL+%O$ZTWDR=_L2V-QBEF6OM5/ZBZN(XQ4HQ%8%RS39_$(W$61IS^@FY+RKG
M]0+'"7;>IJF42;EZMZI5O,QASA>;5NM=W5#QG))2>H)1P6:A(GW*RA[T+L4)
M:ZPEBY+_-+#KL8P6WMWQ1T!P_H&50!M+1 >R=C4J\$+RU&F]=7F;]/DE;081
M^664M"#O*%^TNO,B;BAD^^31DV<D'O"/I]_?SM>Y-)US(4%(__9158IZ?E.G
M3-X]NCO[C8RJ,X$<@=UF4G[92CZ[7,%,*Q9 KHV<H6H5.K!SYCBVRC(TRE(3
M.W%S<6RP@4 V2@I(B;YN%8[5)SES;[I1MW=156'I8@7&946]/ CV$\!V.#6Z
M+7P@IMJ[MZ>:(8'K"<L9V,7ACVG!.EDUH"TK<SE_K7\Q%9UH6F9B*^XUG!-%
M29S-CCS%Q5%B10K/!FIA3"\$8P@SABQ]*(NYJN#WX<FR6301O-/_BX4SF#']
M !.(+4<R>*DSC$$NHKHHI^'OANVKR5/PA,/_/OT7/"^1ON.$:T"\.QX--1J@
MD[!*/X?G"'<_PC[C6*J*DXK6>;RIL3B"<#AJ327Z3JO')HYA=)P$YYL*H2N7
M[5/3<ZSMG:4""9O/TQS!1V+R"1$"5=++@RKGT OLH;=-<#0%4E=X8.F+.*4#
M7C)3[,DLRFC5+UE4&U#A65_YYUT@HQ(ITW<4^;#GZ\!(G'1\ZY1/N0KZ7&'C
MA,I^FR*XK3"6P"GGY=%L"<XC)LFEF8%WX1KD,(>]+:\!B_QJF>81OYSIB^P.
MV1G1J^./1Z>T;OBOWW[I&B(WI(5O^@CXP*8=0<K8ODG_('?MQLZ 2YZ3JU'T
M7'V\:'+)\;8F3\QKH_T8HHAETO!UUK(_JPUHDM5-">#=.5Q1)VA5H#[# 5BA
M5DV07S"=-:BXE^E:T[CH;+EV'BC,\]]I^)-Q".PU3E< 598IW DTUO?A;X1"
M.H:5!0]JPID.\R=%25XWJ/S G/X]UXN.'\-?.,9?X(Y)L>*VP.@<=,6$60$7
M&^-K.,3>-:;K.-P#7LQ,U4*,4\S@&*JUDU1-C=K6;E"EI"6FN&WF&'#GXUS-
MJE3P>W2"9.$*7,6HC[3!_DJ\KB6U#U@).0Q8&]A-GG@":V(01)Y%0A.N5+TL
M$DUK%E7,U@C#+JK4HBQBU.9I33UZHDQ^3^0=XCW*A)Z@RU7=S$;IMTQYY^S_
MW]NYOWZ-9DCC@Z1"Q_%_FK3BWM$WZ#/=A3,@1"]4K68$B0^(@3^S$UF"3FG6
M9H.[UAT:I+@-V"K#?IJ4,*>V'#C]M$?,K5+-F\)=7V)B^SDC>\S7*>99H!$P
M)#3'WBOPH5I3I?@;-2L;#(BC/VST#3^0;*MGC[Z!/8I(?-*CQ+\%-B[^%@0$
MYQ7W?A6^.WD_"7_]]97Q$-K?&E\A.%XA#:HNL4=_9M*YEZXSQ%W_.8W95R%4
M Z@Q0F*BI8U34LFO)MRY"F;?AIF(8<N$>O 7PE,LEP9164K#5'PG?:MI^!.K
M).F/4W!10(G6>E0M)QHK2J$TRL%0]@!MX;2"!24KFFW.SGOITV5=4)J5 D>)
M6E%?>'3-F',)W1H#A2[<97JAN_8X6-+.0[PQ1>%'\P1V[6;PWX*I8AQR@G/&
M5./= N]N.$"B><%QHSPHIN39)@M,G^00.1]34PB85,PJ@(V4YKETD75%T+Y7
MSFRYJH1)F:-SZ^PBLTXWJ ANMRXZI7->N\F&M@WGDE;(P2*#^L@*C@6#.GFV
M%<41=H$4S,I7XWX43(-A:*X8W!!J7,/TQF>LM6A.AOJR< T7&]6X0N,G/X3O
M:3>C-:K.3R3Y]K4A(X[+:);&753$XP,F8@ 3<1-[S"867UQ[8A%K+"Y7V[RX
M/T?$<,8'IXWSAYJW4*<-X4#1Y)ZF-=^/X!HCV=G_I#C6\&T%#F<BUD]>F.8'
M(<8#(T-\BB<&D=C^;%-C?,\3>& $SU 3JI$)^'>22&-'D(PB]W9\J!%)'IJ[
M60J.^<]H9/Y2( SB791%FPH_Q%^>1NEY!$_&NX/K6J;:G3W#6F"W3!2?6"(Y
M9J,J1H0X3X6G.8_@.A_L?,7$B&CF497;YQ1G(-N$+U].O_N&!O#MT^F3;\CH
M+&JR_^@)QC+<8-$!5@,E-EN58R0:S.9Z607\U4\J)JL<SF6R")^!B45L+BE,
M!@:PT0J6&@1\#\NT.@FQC*[8*-VTPQ0W.6]'73JBBI?$O*>N3ST&VR(+GC[2
MMBA-I=PU"9\_"3$RSH16YEFM"3,ERBA?WSW[1H^3Y^2\*#_!?,3*A1+/F]PR
MY[YZ_1X''[COQ78SU3]GD7"&FI=SXVY<8"'9Y(F?H'"N@YFJ8Q$4[#))R6X<
MI+FIQ% "_-"\')$)I^!XE'[A!W=SR-)5RN%GF3?3B=+-RAR#N#X,?^5KY<)7
M4G$NGYHR,LSM-"71[!H3W/Q2!+/D3,&B1,)6[2/"AW;)IU>2XKT%"G-DB(%F
ME+0?[%XL1N<LU5FJNZK"MA+*V+>4\4@7:%\<1=51="3S#^OW-HI.'N)1W(@@
M5@S.2O\0MR<U/ZZ=2OL&S G&185T"U $B'>W(@>:"-?/*F*X#E:T$(+1.%J#
M592EC"\RO6'BK&@2D_<R706IS%Z)NG*51YK/RXA)$1L2'>V08CX&)F=5)"H+
MC(\><=.*B+)BU#644WU5?:2(2INZ'44;>HY]$P*RD:,-[T"^*O/>246OI1&@
M @+\Q25[?/<H^H1B:\I5)9-'C"@%J$@J :%^+0E.-45 C*19I MEY.P:XNK8
MM=(RPXP!'!:'WV$A#85K85M4:AK^N-&*II:%)4L %$Z0%T>4C27EGA7G[AAL
M2I;/DH[4$T$!7Z\DS_S9W$G(=2,JPXW+ M5]2@2[6%N+-@%I8CB+$$V-:$;G
MQIB$P8K,] ^),8-OM8(_'-V(1P1H?RG;FP@+Q)(:X$@P0L.F;.(>=2SO8:,%
M".P9PWU-O6"PR(H9SV"45S(3.<^"Y:?0OQ?.7<DW$Y=$4O(YI+"2)\M4+OST
MN$/+W%O )>:8Y@5VQL*E46@VI<CW/@DJ6$76&QM^.Y"Q\WK90C[1TAA[S#WE
MB!@@1:KW5/B(4WTF.0$Z>Y0/G6>!?YZ%[?/LDO?_*#3>9>W_';5L75\9LW&K
M!0AI_5]_^E-8E?%__0F,RH5"F/GTW^L%UJ/=_6GYHB$<6]!U@O6@91"MT!*O
MV$O9 >,NL5L'FJ-B[_X^/9G*?5!K?$8 "(='G5;*THX79#+\J*B]><SZ0^+?
MOY_\I,G\X="3#_]L>-9+TJ_^DT@OYXB9Z+G?S[^T?VP-3K[#?=@<7X#B;9V!
MVEN(,D'3Q$2E"],X#=])I;WW X]MA UFOII1["[%$FFI)8-1, ##$5 ,&"&\
MR#S.Y5.*:LH-5VMLTQU9TJ D,LR(WN5XGN'?C%4AIP-4-.G3)?8C6!>2CZ-F
M;,+F:9YL&Q\JW0^''IKF 1MD^O'^39%LZ)*E:.027H44/1TW!(R=1W"28R!.
MSU[ 1Q[EZM"&A<WM-AET7/9WY$B*4_Y40TV?V?:8CBL?]KOR]E>.&\Y-%<"&
M*N"\:#;P9)XJ6E8D'0'37087P^L5JW#=@(> ![_0ZI.N>:/ +( S]Z/DLWZD
M_HQSVT6I4K40K4A\Y^?IXT>D-].*JJ;1N<;BCT"DMG-';.8]X;PD*)$G+Y].
M^']?VO_%]\-_?_L$.;9PETT<2%PV!+NZPE#A0,SRY;7'+(4,Z:29W1]M/N;!
MOZG/<"3S+, DF$!&$"';>F80?<;Z]+BM$0R$;@1>4&0JV]A\*^\&O)@U8!.9
M4@)^VC2T<T\W\J*=R-1CK.G !D2WQ4"]Q"WO[>?>4_ (<6.D445$1UY=F=C;
M9!CHYY,?082!0>=NM0Y5*38F\$ YXWB QVI?D V#73?SV@:%;,&:UE>2/.1(
M8A]=US0\QH8+ 4/><JJPZUY/G3>8@9!*QX@L#%3*%>-V;I=P#Z1E=00;5:JS
MGE^:FKV)J;WB"KZKSMN.M%;&Y6V?'E*TDJ)]<DC17G**]B;-[$O(#7][?<6W
MISU'V&VIO?WNILS-5U)++AC_>^8 CK1]WZX(\TQ96^I.$$C5SFN3R\!G3IC6
M$;[(CUSZ9PH...WED.&(+1]IQ:C#WC'U&N5*?N2DTH ]NL%[!,NAX2C-WF 4
M,7KJF23^?"N*@@"$L"-O7D>74RQC+5>7G3:Y!9&AL?'!VE_ 8.<"^O,?/G!L
MYU:#2&P_634EPU-_2BN=U.:%>^@VX7-7&:/=,Q4C7EY'&8@QC9 #7?+K 9IG
M.#K9>*?7T[&>C[B/[TD@1PKG]PSB//YVRN?\(+KEM(=:/!B874)8DSC0=:;M
M%ZXHUJ&A*HALYU-V>\0G%,V:LD\V3S]CI/BTLTH.SVM 8%WB,\2Z"+PJK5:V
M]^;,-F5DAY0K5*KOD9:-O*^LJ*2E2FP:@/62@^>ZUZ;TZJP4.HWA@R=_K9KU
MW_+DKW_!_WT8U&5$6P*CE*FG%N'M3:6IKQ<)^/GY89AQ8BHB G4CIW]^/GWT
M:-(CKCC%_)(O'DT>/:+_CUD\:C8C(2S>F<Y6Y3V&;8K"!YN'X8(ZP<HVW>-)
MSY^UGQ1N?](T^-&)QG4G?,=DS\,_/YT^>XP?_:/)X4TU@ 9OAI%>T.3K$CWV
MF-N@.]/O]LD)N!/F3LH^)^IH)'[@S7!,U'.'^Q!PFTR$V*^$<%L"QOY4!EHP
M?:S3XR>/I]].0V^N[+W\6TP<K@<N^^'4)BC2QI.%K8I0']&=S3H-?U_;RN2>
ML 2M(Y?;]G8%E.R0&5=QGK?>]LGTY3?XS=/IHV]T5#3FL4ESB'DON[19G*Z&
MV?W0[U["T_ K^,?3;T+OL<'6QPYI(=@R>HVPV]/&"D_$-;VMGS#'.P*M,(*!
MW9.]"A%7J?H3JF%+WAN+UNS,D:MUG(H\JV!) ID_6XL:0[MX5]I1F$2/K^+/
M"U![#]VM5OD]J>0YHW82O8HHAY\XJ7*)Y!X7#%;<!,7'R&.[*YE6PR3X4RSR
MQ.H34(]43 ]F=D;IK-QTUA1)<BVZP:XM1D)AN6DY&2Y'9885QWSAATU6HQAQ
M:C;.HJHBG!2#(N 3OJ=4;^(G1;F LUO_S<^JJ+_S Y^C0=I NRV@=3^7LC@3
M4Q_^SA6B<L <#9C[RX2P)>73NW7@4FPW0U_^^1D<AB%8#NFJ686S-)$S2U=8
M9BE74_E=D]SMIL5Y#3/31'FM-6[99#RUN'9RT&EDQSO:B ]Q=F,:G<R(24H2
M5I-75A=$:T98:3//D\>G,^[PTI;V,L(I2'!)#"]!Y#5.\3:R;Z;<'O/XQ@;1
ML]M2!,I6,<PO0R$(UP=69Y1F>F,-D;T1Q5XWMG+D/P'KR37GVXUJ0XSUW=FD
MP[AW=K5K>WD"DVB23DP$? 75<,1Y9[<)/!71WWC"QH3+'C^ZNG#90-SN%7A)
MJ>X)[ZK%&SDUGSQ#^.CMQJ6^:AO>@76,8SV;(&?-FGH3]Y0&\UD8&8"7G#$?
MA YS,G20.E>X)ZB!607\&$NKV>K.$JX:-'O!SHAPLY GKV]"YY"JTC(2H*Q)
M?*HVE*?5N4C\RTX2-7C3E#@><4@&\ZCM>1N:-;+;DV*]+7/K.;N>TW33>_RZ
MD[+],A9H"3+&_S8QT[83HW&1\8E2Z6>*6V<1UXM;741R0M4NU!I/*)- W&*L
M0Y*EZ>LZ/]#_[FM:LQMXI(.$)H]\AFR_""6GJ(G7?$&$:6+Z/I$_P@@]L:)C
M>Y!T$%>=;;IJ4"# \D(0%L&\0/V<1R!:"=/(S%EW! [A\"1<[\?1.V2V]1QU
M S&4RS?I;KDH#)@CCZ\]>_=;D1^=. V'[D^:9\R#7_=W5R.^OH#.;HY?3G2@
MG<GHN(T<H[NYR".7!!W\9P,F,3N@+.IIZ7+V>:4/%*"(FGH)FOT/Y?^&7?.T
M#-Q?2" *'%EP5:G9G0" RLJKS70**I*SM*(+HQI^D*L-_I.+3<$5KR9.A1:8
M8ODGNA6V:>2$H_XYS(9"4+S;(I:.*$0RXW2P@0*'FGUY*KMUWQ<+%WGH&=E!
M"(3GORZ+3_7"4G=?>P[QNXYK._2__]=W+UY^]\->_82D:=E$PD$U!6;8,%82
M4?U$!:R6)9(E)"^PXR'YD<6<).Y33B&C#(EQ0#X110V2#-.2I;7<&.-G%;5.
MW!CKFX05B5XXTV"[%+,<QYK#OBIR"OW-_/AX1NSV!0@XW/,T^J0*F'!KF3V(
M,*PQ9_E667'^\(>>GD+7KCF?O)B^?-YQX Y"?#$AUI$*-6';"/TB"1FNB@0N
MT0)WQI3F$M$E_ 3:<2!S<T+#8I4NUL%1^!B^RT@ZJW258F(V,F89Q1OE5*!B
M/(?4J2.#MTO@K@Y(N06YN3]2\MD!*2E(R:<'I.1E(24')+,5B3]HWXMI7]H(
M&MFT@1M01QNT'Y&[%$[[E5H5)2C49H6?VE8W:%<$5JF"22X(>2RTBRSQI%6\
M>"].R9I?]>IGIB<0PNS>L%KD!NJ"=IQNP)9PD&"(UO$.C=![D79_V*CG=D0K
M$X7_W<#OT;4//L"\4%"OTFR"UV2T[&X(?#!/OL0\(18&*<C1#:'VL6L9%G;+
M#8J#B%R"B#B:A2-YJ+M8'U2>#S,0*'RHT4=DTY*A(!\8JY>:M:)M;/7UA!(4
M*5)0Z8@!%;@CX7^*E4I4-TRBZ]*;PK6Y6A3H+M+?I5I$)6MSCDCF6!$GQP&_
M!/TS1XZ+9H8A,;<_&F;^,9"*3^VOVA-WDOQ0XU#B#!4<FRD8ZX$OA-F=KJJ5
MF(;K<J8YANPWH>[.YNS$'O>R=QMBO.EJMN)>!LO!9KGX?F,QS#8VU%&$2>%$
M\'BS3&]H>:^W[K:HT4;1)AE9]/O^7TUL^:  "F8Y(V_#9DAX)@U]@LF/F+Y;
M?2A! 62-&H<'*)1L7-*3G=703TK/L,)9(3F5Z"S04$==#35J)$89NDI-,^5V
MHJE,1[=Q=/(V33MJ(+BF$X/9"@5A/F2S(@Q$%R-G&T9P(Y:S3#GN+:7#F KR
M;C%J2#:OM<^1QF'">IF6B4PC7,GJGC=L!%HH1U[S1(V;F3+%3L=[F.2A-LF=
M] %EU"@=)^8<=;&CE,*H4=@\(&?R"&]UF6F\;HKHII-UUW$N.EFY)]>>E2-"
MQS-%R>'79X/EA=>.-+RAO.#7>++@OV=(A,(M""3/1V8LIQC-J3-J&,SDEX?'
M"<-0/BIJ]) G;$._8IQE-]O1T9EYZ AI2$(Z:B!]CQ #'IO;;@S6OF<23 T3
M@?X719& .4_'5$0\$F/&0=.?L68S1(,$_8;C ,ZO!:ASS))6BG!B@IR!QV5-
MJ<V]J@C/R0U'D#GU8(J7HP:A79?.NUHNJC1I8N(J21IBXJ#PERNY672^]7P9
M.R"=WK[D\V74,#IG44?FK@P,/%)%]6G':Z_^?CS0,_X*3ZJ39JVHP%G;/K>$
M7O6&B.M_+LX1WS<9)>7[GTG24[Z-)7'/)N=H&:\'!QR<'F0,.AM[G26C!C%L
MF \;VYJ@VCFL?V0U6AIHZJA!"/V8RR8VV77D]!PCG64R8)Q1H]'(&Z:LWW(L
MT0'2=44<' 3,I]ZN=O;&#6:GMZ5+_KKGY'9I&34,EJQ)]]#U8X##)L3@L3IN
M.A#\Q<88/32&4W!?%V_WL3IJ)%_HXG7$XLJ.U8NTM;E>;^_9M9^AI[9 )AC
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M.Q@!IOQSMDHJ3UHY*:]9%=>EXJ0;G9A/?H!'PWQA I.VGYD'^3JF<BKX95F
M,*O OO0$Y W,T 3DE 1284 M9GRB&,*Z-DI[$-@#AEAW?5RD58'<@%!]CM">
M(NI#?B_'8$:]' QI7G\CNB."R?(B"G-B/\<!]L<6K"U(W73%VH/WC3]))",
MP[G&+O7)&<480&ND& M_:TN^O#<@7/ 258 ^^&E@9H(139PK+AJ3>F(RVMW3
MD1G:ZW3%9.7TVP#YR&O&?1"O>Y&12F#>>=0'6A-ABE;K"LZ DQIE9T7C2HT
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MO2J&//-"N0\VEV*C+KA+#&]6K%3I-A$QGTT"C$-+#P_T6MFN*TWT)*U;O97
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M/+0=(3.W0@U+(!17>*'JG;3+L#1]9>!2I(KA7KGU6++^IAYK1S$:EQ**[^F
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M7*10$.IMYV8K6E/TDHNF1)_9L^#9\EMJGEQ![VCV[%)7AC+&V2$$)A*F3E"
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MKS/0**'M#661Y^8W-P,F6;$%DO];H'['B6[7:LLIPTDM>RJ;>1%!JJ*5Z?I
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M82*QD'0BRJ9T0>5D2=ED%;L)<=&U=T^EYW.B<$K1%"E>)W$D_ I V/PS*5%
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M.H2I+_(*5D;I3X3 OS?2Z]SO]J43(':B4X"C<OGS9;@X##%G$"[H0JO80,:
M=BP6^+X+Z*L7)^Q[:&>=.G%0J-N1D4B(<:*2 =.7]/L*)EEB*W:8=9OC:F:_
M(W-P%A=^$1L"XZ[ZY49J7%=69#IB)4X5DT"-A467L[3MC56^TF3\K6/O>6-]
M;43AO=A;[](CRRO'&/V7!^4N"<K',@EI3PJ_*IV3 Y .)";23K!Y:7[BAF0
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M;G0SK;UT$".NA3XKB=P8X4G_3Z:/WC!CXH?E@0ZJ1"0V/E.+DU1*"%W90/R
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M*/*HS!LUDERS$:BYUEF5]AJ,)7POL=-I+RPG*DER@3)?#/>D8##'9.IF\L5
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MBVV0N"*XPIEY*:"\Z:VZAJ"'94*$%EALHXM?^] XZE D^#TW8(I-]_MM*DQ
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M/S9[\<8 ;J1>E5W(W.A]L,D#D+*_1C$,>*^\(X:K4"J.O=@>C3\3$6D,(:J
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MTJSA[-0:RL)EH=N_[ ;[X?N<6._\)6Z+#/@:^I[WAZ8]B*<OF:B<4DT)[U'
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M24?8/)V@Z-/KUP6\0_Z"/TXEZ&-#MY:!BSOQ8-+?LN*8*NZ76&9Q^@PKR!P
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M3(&X' + D^*)8)RU>!([G$A*O%$Q@S;?%F] 9_%.;:BS#?EKPW/_43C XP4
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MD$Y0JO?1RJ^#,D[A-B$(<5/M-^K\KT!T#.0<HOS^!1OZCHA04^XL[T0L7FI
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MI0=(/S@P 7OZ:5*:R#;7=NU5<FTD2@]<*=&DNC^JQ=-%J 36"GE\SPHVO#\
MY\\/8"LF28X'21NG4AXTH$2L-5FE#UEKXHSU?9E.4NKDKU>?U<,A69*DQ 3N
M"!E$LKS!BQEHQ^>O'^&BPOCBA[FL\LC#\3@0S!G(!LYG6[E].1)#H>U #$2T
M/:^T]\-HI(L@X\7:)M:6?DM&%CAT<E,<1'2WK;?)?H:U.]PT)M]HB7=')2D0
M4RS[/6GP:C@D3>5!U-;,)^:?*;SBQ68O-COUD$!.B*$0NT$UEDY0/&=F)'>"
M.O>EF%D1NU]L[6)K$\':;=U0K$^=EAG7_?FS^ %)7)Y-8YV^DVA3+5[S8GL7
MVYOX.<[B.M,!=%/=H([4' __]J;M'J[NN@<'FI;RAO(JH1\L'4F!K"P?V()(
MM_H%4T7FB28=U;ZP45S,=L%L#WU-K.^GPDCS.:U4M5PI>=_F\XQ*6\6L=EG=
M#)/J9BYF/U[G['H?N"^4.ZO> "(":Q%=6C0M!H''"68U/XZQN@U4 :NEEKXG
MOW-HXB0)'7(G0%5A=T*WS7S]DY\WKCM&W-)1:D46I:*H^KY[" ]"NRVS_B*]
M4B31F 0Q]4-N"321\+EOLV3K@KQB^78TSY[;-\8.N1PNV,U=U8<EE:;,N#]Z
MS#N\'55N>F&P!::ODZM:]8X6GPM;]#=GUDCISO&,8H'0+[X7'DV&VDRELXJ*
MHICP&6%+>K_,LD1-FYF*]\,"7U-!2R!A?A"TEES+H"4B%;R8[?XD'R(/#PWV
M)<*C7^*]5_V>!>+B-Q?$A2(N?GU!7#Q7DS8:'TR<;#R/TTF@J@*5/*$YC*$2
MY=%D%)SB:CDN*K2IDJ?MZW0>]MH7?"]-O_=%!'*.Z^><C%HP0?>%#A5:RG4#
M%)Q&2Z;3<0#USW:M@AR>.9JE-WALJ-;6X=;&-ND0N4_/O96Q,D$V*KI.8AQY
M(#TDKVJD7TR[F_(L%>N@ 2HU#IDL6GJ5C)%4F+G:SDU$XXG%J_$FZ<U2(#.&
M<Q5=(%JZ1OBY1.^RTR#3$]C8P4ZV*5US?Z#JW+3")N9WNPY_(E6->N?LO7PS
M/#G&HOB%UN7D%O\SIH A-,$1"'T@!4\?G8[+/E:TU5(8H*N :$C>(WC@B;[,
M(692U>,$!K!T"_^^-N_%W])?7B(44Z.H^\UQ?Z\T2/;Q+%@!DW2]KYL*0]#4
M-.[;ZLRJ\GI06UB*\!B2('*I7D?EAI%GT RI2I"7 Z&#"_ME;47YS%K1U[YW
MI1^,IP>4+/!Z)3A6@A<]K7'(MF-[BO8V&;WRQ'"HYBY/U%K_?:SO(8-12I;3
M[V.@FO>0KJ+U,#0RE;B?OJ4(C3+<5? 46C&9L&31H%A3/2!HUFP(]+J]SCN"
M6CPS@(F)&<Y]%B\OF\6AH_Z)?SQ]D3Q(">G-W&O) NPV/L"U'+)T26\*0,%1
M9&:241QIB!+D6;LS31[8C'Q#!7G/O:S\KJ"@<W+IOJPTA,"_9>^T=*AE/\CF
MX29NQ,-YV\%>HDN'PD)GT_0R^.>A6NKWE8U_\ASK^9!O!HE-,Q&>-Z=_"J9#
MNV(=6B8&F[$:U#MW?JS?*JU(SDH)09K3RHU =2T_>-H[R3E@4%D&4Z83,1Y)
MR,BY[U.(PEP&LE8*]]AZ \E60_ _OPL,B.>-\@--6AZ;9DM?!+9-GE=K6L%;
M5?8L9T,6RZ&QVY:=B6P2K;_XVZV6;@>2\+?WMJNSWM9?O*:P9F^%8P:*ICP$
M5G []ZKN=T->AU=969AR$4QVZ4#TVZ;9QRF?86TST>#9ZM,RTEQW'VE'6ST\
MK<D\J/9OY51[M_6P(8@>!X3[>D" F'[+='SST/)C]UR,Y(-\SZSQ6\BC<LTD
M;JW,7@R^%?&5H$'E2D;_^3XWQG/8G,DXOHF'D:>T/_GHXX_YB_TE5G>GJV_V
MZ6@)KX#@(_%$MKU7FZSFY7Z.__XAA:/TC3#?1:=(Q3MZ^I/*,3$4G/L><*TH
MX721_WW]S770K$ NB/HMTU2XNBN?]FS^]'P/U9G\1I(9JB-!PF%K7"@XQN42
MEHGHP0267]84H/'<M2M3SI:"_O)_M]!#_&9$[(GA))@AZ[9\"41A6O5?,\!-
M,)6[NA\ [Z 43-"5.ORGF'H N/D'M>6EOY&#3_?*]L9T0(X-3V.A\X ?!:![
M4N.NB-Q?B35OTGMQEV)%O A<'D'<1VE&)5*,=F?0,45\N-77&6KP+>U]PF>O
MOH+>)NSH?W_S];=?>:D;5C)W^C;=0;?OFND1)4A(?SM> >N%8#REWJB*XRW2
M2U &GN+S.CY(33K]&Z0)-Y'/XKC%6*'FKV5M08L(R0^;8U66!YM@JS1VP0I!
M8F\=\K4Y?[9$0O72%8MO)7=Y/J06F)*8/<;Z:0FX)7?WLB(-\C.P)B""Y<B.
MQ,+]$%BZ;^314QF^M$9PI@XF:V>M(!GK:YI,0&OCNHO[7<AI[="V4.$^L]72
MY++YL=D\Z]G+UJ73H9_SON)J[*Z\K\@.,5E2VV!/T?B*%2A"X7R6'30M(7RA
MC8^4ZZ0])B9!&E<T"!Y[41'ROH1R>*T0:;5%*Q:AHEH3L7X,.B+?)V^F:E?F
MGXMN: FF7GU>9\'<V5M0N$Z!.X_(I"]XQ,CMY,@(S!2D"=!H=D3/A#(*_;JW
M&A%+JON)=<CWXJ4991"<=FV?3DYB1LGO2<T[?4EY&&$+<@\;D_\!#UCR)O2.
MM<$ -PWQK%!_3:.ZM4ZL+BT$_#\"1I9:+F6>BEF)L&0._%K#=#-,QF?IPG,J
M#V;X3E%\WS%AT-*W/5/ELL%]/P6-08,=TE-EZ"GLZ@-U>^_:%?KMI2ND7:'?
M7+I";VUC90?C?32')L1CYZJ%83X(UM,$47>4Z+_KF^V+'OWZO&XP.VF^5OHE
M\)[DB8,KH"Z7.!'F8F!7Z[E+JYPS]'2%N_JFECX(M/EHVBH+-BS6>X,KW%#X
MG^^6;D/\1POIE#0*&LKW@<D?(*Y&T[0,&I4@HOBM>>5ZI95KNG&@#9X6UCW
MMH,]JA$^/HG(215TPF5,($4VNYC\ITBN,2\[;KG\>*_3H0?W-*;S/CR<V1#<
M=B@#+?1E#J#ZL3ZI0SS.ON/9E669=5"&I%<E*V%\BC#)6$US7Z'#<^9>K90
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MGT$(5! >WD4,B'&"23!-GU]"2UQ-DUAWD.DX0BF$@*Z.=K'6B[5.SEZQ3A,
MRSJ?/K\NV) LVV 39\X::TG@CS+87Y1#F^KAT_1S%Q.\F."$OGG:7H)5<J.Q
M?;K!^#S-Z5F MGY_ 6TI:.MW%]#6LS3I1U3W:)2,13"I+]WR<1*LNU9.MGH*
M[4BS&3Q3,!UO4R;M>=<T90F.>RF3Y)$GN5[]N7N((*PNSK10313J]8+7*Z_'
M=P3*2DG<_"A#\0;E5!"&'O:'ICL!;$2=IW2/"@-$RF,.J4?I]80!$%@:8'#J
M,_B)W'])SK0>;$"P!;Y)E>Q!Q9GR'>GE"C&5M&,R>95#-7?]=""4J1K"^?83
M:IK='A"C@8=/Z9[2O=7E*);"TX7/L"S5Z0S56"87 RE8$[>W<:V][74A8/&!
MME<F4^%@SS?M*ZD*._*>D&M[G4E^S(F"ESMS+WE*_#MV%H5^"2]XF"\X8F?:
M3'&RN]V&S8.GY>R61D1HP<8!4[#XHS!8 3IV97^L2WFT/.X_*W,4;2F,,2R^
M$.Y?6(A1][-4@H#LVUU3\\2 ER1(UI1?.#AW9J_+<M50HG7T56[6\AR+Z&,6
M/DV!9?R-&_853R0YW5Q[1'A#F4N>T/(I=<W23D#NCEOC@;U\CHHY,&* /AXT
MAA_.?*;KU5\R]Y6\7F9AQ30VH6T\._00?:M]ML,GNYL_\?1+$PO2Q[__-!2/
M+@^JHXI768%A<:3UB<EI1:S-C&PG$X>97\$8POAMP"&MIPTCTTX%2:E,(=HH
M#DXP0A;@X'T,H[86R9$A2]SFSQ>$9 P_RB+>U-P_/P58#W,UY27+U8FD!P&?
M&IJJ6 ;]QJ%8B@5JM,?'6ZG;R#K@E8WT._;6;#JV"99I-,-/)E-Q1B_D?8E4
MO(]#Q2F1_Q34HD">&J7HWT<?NGJ4/C3\_?2A+W!RDZ".&>R)%$=&4(*A$8<W
M*2*6KX.XE2&'61I>/J8+^('=!%$NX&!I'W9M&YM,&^//6\R82")PO?JVHR+S
M8<K>/^/Z=0PTUO_-2#I?[89 3DZ>P#?F<R3^IS6?A2ZUF\-599R]W?%47L6+
M9JI0>'@ U=,"RO5XJ(#&7&65SN50E@K)/32ARHAX\*\X#2IY4V'H(1&@8\HF
M>IIAU$U'4"76KF,>:_?HQ3:M\+P\=, =*,#%]/$G5TLA2S(M%J?JPG%0CYPN
M71'O1![XI#^EW\5<JP#O/*_,]$BR*IH0I>27Y=G77?JHAI.B$^G8V_.':6/#
M)K1=4JU8K?/^;,'M%/Y, +KWPD-!/M(O?,!*]W[%9 RVJ1[H'/72JT;[#KXB
M.DO=K70(! PS4]KLB1R9C>K<=6U'K"4W$J9HD#G!%YKL!>#<"LQ!KHSH57",
M1(@@X+5%4NT)^35'?&5!0E5%/%2Q4*U8^$K7JZ]RV?6G(>X.V2$I<W=6MUC@
M\)XD_$5-(4O75!S[2 /"Q?7IW@V:7\W)!K9AHP0(9*FO,V<K\+#*LL5NM :!
M5O(4>Z#+%1;?'4>FUB6,H2!.N3;T5D=W>-K4L4$11KKZRT][BH=_5A+P9UYH
M_]=+H5T+[;^_%-J?JTG[<F#=;BB$G">*&5(02B$?[\",JLF33\U4T1\GY\F#
M;H6BXAQL'<9NG26$UW-P_ O,([B"LKGKJ, !UFTNS*>0(N@(57E"HCC'A^$4
MQ4F'JG#%Y[!AK;QZZ=WJ[3&/IM)9=P?:O9@+(M7P)@<U]!?]L1']'@F,\MB$
MFY?X%?.%0&%5./0T;,IUK<I3-9XT5C5**KID>83S <5G.#/;!#^7;R(U,5=?
M(,DQ*;]0( VYFKQF9TG1YL28'$I6S-(E+Q$#KP\BLFW<<(^DTN*=7R1:CCQ6
M8M127<9)%NMOQ&VR11__Y)C<E@>D%)0O)<^9UV4L!.=VDZ>D0.A ^*2U^_(/
MS 2^.[)9+CZ6I+FWRLZE-N)^1JJ0@Y>TEW<WM:>9T&Y^M@6:4@RD?W,\$-'!
MZC6>E8S8AG^&,7A*-N+-X1%(4V/ G'OZ>4@FY,E+-SM/5S$N)*&UV2@A*>DU
M+$##;JBP=FRWO'TQU6D#13I"IE-/2@70QH>&.7SH^<B!;ZM^F^[X3;>/KEX[
MO9&OCANG/&A5TS' K*F9EXZB>-"BT5A_9 /(DA'^$%BO"E;"B9 $N>>5"DED
MY0M93TK=>$3?G31>O1CO&#9]C2ICULUB#D-,L17%!:F*3TU7EA(LKC0A-H7I
M?:!Q[#EB8Z^C5QP3R.I=EI7+]'D,6*0Y_/":T"FD*U#%' Z,_<[RL !]'7=3
MV^T%T4'0:2QWMIE/.0JE4S+A2GH;>,J6TJEF6DO.7L1S;?$\,4^\<POZ3)D^
M+)PX,M&?^1:=ELCYHO:6&29!XV6LDB:BQF7TY5*>E"?"Y$RI9%WX&?R1DK_<
M$Q_*T?0^_EVD#4PI2A#%RF.?K^7=O7/;D\_^#N=E^6ZX[VI^7U8%.<U.&26D
MI!)4.B_I]9B2-&ZG/SM]3QNS=5RJ:0NE+=5SZ'-028^*_I,H4_@C!\_R*E(6
MREC</%2G070G(&(AUV/?61^X*IFM\VBTK05=G;&LC"D-&X0D16CDBBT:3# /
M<&(9ZD\_?Z2&[[<XL8D"YC;Z1C\K;NHI40[[EH6K7!F9_%3QPN'8UE3BT)X?
M=[F$DTBI!%U8A2HNQV]ME&GHN$_;9^Q!)>D$(9=>>G7FI5$FE+GF:1SAYISS
MK%S!L)(3FU]I?6W^2RZR/<?B0::ZY8HU"&_O'1%L3;WCB5)-02.2W.D&9YX4
MB6FOI-#Y04EX85A2R[ZG,7;HW5'U><,TI^ECHX!%8>B!7-3^H.['3LK8?M^=
M>+.^Y/,Q16[@T5]25%F<<)< 2WDY.)E"@6Y#]>J1J%GNR@"?UW=M8\J+&L7G
MINE)*<G(]DM"=Y!YG@YT>C12H#_>-/5P%[?R))&.UP@.@':\&X2H<2=B!]PI
MEF>BWYP\C.LZ-124$4UH#-(JJ&[3[][5?.12SNBZ$>O5PU.5;N0UX-"N&[.]
MA9&O[);=Z4*,.O,)Q,YK7;L+90%NS?Z*D3..6_A S*6&15E=/#0>V&38U$AD
M>)W^<;WX-L9 ZEZI'/D=G,3K.8%N)L\G>3E$NW1*Y-0T%#_>N?S>DX+O."*<
MJ-B6)"@JY[0M3R2C!O5# E(5=X=LH(.3OVLUL>@%9JZN]:'C9$D,WL%Y<)?/
M4.;-4(S47*Z.(J1T(>[8Y"P$IPR+T_F%W.5G.*\O('6SG!Y[;3SKG.<ZFP\,
M="S-)<$*#K6F^['U98D=B2;>1"KYMX- 4=:SV.>NVDX:.57?UP2HDJ,+$AM=
M9DRS]PRL4BAM&08GR3]-",LJHR>CGT1Z/>%XX3FG'FA<CMRYY695B!=UIOC<
M?.)"@N,!&-)%*C$VLRQEM9DI:G(";+H3T 2H6E7Y53<^DK ]]DK9Q[M-F?#H
M2V(@CLY1.3=;O1Y9M@#'A0XF>*7/D))99831Q!Y?%)'/"TWZO?-.("-'J=)7
MM2BI[8Y$[%E YE1^FHW;4K,/U!#?M8GUATL32YM8_WII8CU+DW[,MY9AL$G]
M/JA88U2QF12:$EE^O*T'42CA2 CD4,DA0\[9LD".@='C8,B"[]ESI5+$)HLX
MQ6K.G_?)HW5[*@U\X7[S%0V)_(DYW75.1(=3IB,7%@L(J?DV>U_5P!4=77D0
M+:AP(R&#68;@1>!]I^TL4@EW8LD2@R2X JVC6M6'H#*9@2**ZW:E.OD$_$#I
M=C4X;64LO.!R,[Y')JHC'2@X\9:IM<ZIWDW[D!^N[T>W]X_)$6WNN!Q"443Z
MFO40+6SSD!W0?M+JF2!2/Q_^<6E*_BDJI53#V!\WCHTZHY%)#HR1652L(OWI
MZ"\*R%I_U&)$(:?#15-4\C0F[>/AJ&JQ/H,A1KP)XGBI#LN<@',H\DL?83F.
M-4CH_-=6BPB,(WS4#+CB=9,B?YL0)W=JJA1"*CNDF+>2KA,$W85%70J9!EJ"
MJYB92LALBW!:3<V9;(J+Y;\<VC/YUJWB.Y6V-I=7<U^;7,B62QH(PN]BU8P3
M:. K6PL0#*9C1390&\>'KG^S7MUUT,8>8G]?;Z+"[7JN,_"CZ%JQ A)VA2;:
ME8DY<5+5T\S)48FDZZ'<+SF>QI<Y=*,XV$:1Q=>K/Z>H*_:Z@48T>=+9HG5*
M* Z#2#$%98=T!QHT'Q4&)N=E.LINX]6PJ9IH:#!*0ZIC"ECXI\<QW6=8A[RP
MPJ3/E)V4 4HRP\NZX=MS[;N<DM333X\HZ#_[D<Q]>F15&1^J7;P]TAS-0(U_
M -2\H<B-40;IJ![,5/VN)IM[Z)K]K+2TA,Z+6Q:9E:"\28H,,$\&I?;5H=XV
MIZM((TLHY6AA?G-*<<25+%$8:3%YS9"S%P8LY1K]4S$0)5%+<J^P,.4/*>V3
MSS9()>E#VM?!*W,F>$2[A+$_R"[]EN!T$[40VD0%%X2VH70TPU0A7<T'4T#D
M[_,>9*[<6[AO1_X+++MT^!PH&UA8J@\,S+2C+1+M<.=-Z!R0.^OY*<L )JT-
M$:MLF-J4+/-(N>>F.O!6@<@?*8;G-]E,ZY:&?/)(:QE-UD.NK!0:<N X//6
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M'7!Q&JI=0W:/CO1U+.NJSQ;8&/-=,0,0+POXK'B3S(JUA$SR8=?W,JU<WA1
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M$1'M2PSU6*O99=UZ8:B(I%"Y"*C19;UFG;6;RS-#B(*(@G(+:GI+"VJ(@(B
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MRRL&-UK&ZCOC;(5!6RDS88D["M+9):D(^-W DL$V:PP/C.RY1&97\ C9[\(
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M_S][;]K<MI7]#;['IT!EDBEIAF*TVTZZ4Z5XZ7;'2=R6NU,]4_/BD@0IM$&
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M/T"SH(\ ^1\.3CC=2\9MB7#W9+<1V1W?(=E)F\R7C=:8FZD[+MT17UJK[BQ
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MVZKI?7>" J;7SZ9\31KX8* ICVQS)2!&#@[[05J:A_ZP$R22Y;WY_8->#2^
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M/JI/8.#-ID/V:-M3=J^P:3>LEM4T80J?#<,_T,\!HR),$WYZK?P9\!G.(]
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MS!X\V;\?*CW/P'Z,V>_<Z_YNLJ"3CK902P$2*TKR5O"F22=FW*_NVGB-<9&
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MX/ZO<-O(_,;_'7@WGJ)L?*3\7R$X] ]15DR5QLAZ: %%C&:\&O^OBGDQ9%N
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MT-.&2QL'^YW,%7UCE)9$>:"PW=-X(IN)5))DA(>C;&]M57@Z.*6-@/B=+-%
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M,1-U1<9@O<"^=CW]U/;V(#<5#+&P-9$\OXK'E<*R&0,C@"=B%%%)EEZP\\;
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M^G!_]59[C'4=?S1HCLU?[/XSW]4JHL?%_3,-C,1M/=$=WW!90P#,2L4$;GO
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MG2^G)IR7' /OQG!N*I7#5*V)?%G[6:-ZMCK>C)ZPGR1A^PI ([5RDD7L\%^
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M-,^3N MA=1"EL"&N4@<VX4.DVYA9:]SPC6;/-9,\W-J"W G/A#OX%V$L>IQ
MQT-6?M\"]K*4)CNAJ!:(<SJ)!%%F ;<)&)NW7L-$=1AGY6>"'51WYP2.PUYO
MF:VS@1O.DZ1ZO>>R:YSI+L@DA\_WCL.&K>:+@<!^V%<%K9.!C+E&H&G=P6*I
M)VCB"$_B%%OX0F2AE@)*'*P0)K#")(XJ+8=;1["0[)ON*;6N!ETCX7@A;V/
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M+IKH6.&""OS@%E7,V>FV94VO]S52*3I6^.!Z[GT2[#F"GK<(& 2+$L\>]EI
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MEI;[)8#2?S#B9SOH)OY90YNT,58?.1IM+<*.YE;KR$K#URDW#6X]%V_\#3!
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M_*FDEE:!&27+30M;Q-<EML18HREVB^%57>5Q24WF$):6UBP8-WBZ!G%=OL2
ML8Q-1-"C!(93:Y Z<+K&!(QDB8CKNCFIV^4 1_M?!>0X%;A]1C)T\7=-.Q=J
M%601=F#JN&?F%N,ZRBBU,V7JI&T.9)N]=N6TXV_@Y*CGF+ 'C68\Z":F]91#
MY]%.$T$W3;Q!S,8J7U G>EEUZQQY;M0N3Y;2-D\-/3V/5,H(3V6&2%#<]@Z!
MC(H+)4BZLHB7V7P._W..8.,:DQC.MD']SFV2'UKG*5# 59(0@VE=4V#6Q!1=
M1-P84>-;V_9#EI":]'8;I!50!X)2?8H(4)=F&:=R):G[FW</L#MH6:KQ!:M\
MZ[K2PY9YE;_$<2?1../#^H';'\"6?O/369I&G\.?I?*7)DU]/.#9!3Y.4+38
MM!AAJ<>1QIK%3KG 1I<;S(8/IO7,_*ZH4^G$5^^5B3#7O'F!Q\9W9"YCA9H]
MS$7ZBNS>H"O]NDER(_:2Q$S Q$K0NU.OD91<*--<UV,9BSS&3F3".-0"F3VU
M&N&NOC$![V$/Y^@SHJ'C:J1W5;*TDH%;H]%F=%P#^N<+Q<OEIM3"U.U&=JQT
M/4I_RS[I2Q5.8D'WGDQPUG7%Q^FYT6BPC#,DO1DW.6N5?:&T#P5U(/+DIK3E
M8E3E2T2WS^.R\(^7)(W;/ 3/S,,?SX%O*=V,'"'3"0DWRTV_4]UMUS)1OO63
M+&+RL-U? P;\GJ-68KAX&V:V3,3IM^#P1]8V+K(KY@7N0X*U3NTE6AJER:(#
MCS:9:PF7).[&;&8^1VUI-5D4FK=9L&G# $;8KTQS!_F^RX4#EY/U/4G6REUS
MG8@5-QF9QU-8F)C.4B!/9W+<<(_3V:.$]+YE5]"3@/YD.J#NI9-<34N?^UDF
MZH1!UGA^;@SKNOD(/5W<(UT@'"RV D"GH6Y*X#7/LOVF->"[8UOJ]I;4#%OW
M AN83@:!\'TMUT&'43GVF(8_82N"<$K=.+%',[Z&+>6PM64L3;>T>E'H'J7T
MKV[7-A+&TPK&+$0%)IZ)35:0U>59-2,5WFL:C4T8C#B]!\KOJ?>6J1>;O5<$
M+(RM+2KJ]">=8>?D!#(2%/3<F'0U<_I6C\)N*1%18\.Z,#W5 [$L$4 YFK"*
MFH"FV5/-XZ.:U3R/6QFCG\HH]"Y%N+U9M)9O.2-8JEF.] BVW%AW(<\5_8;&
MPZ5NU^LH^ZZ;8U"WB9#<L%MRFG(C=AR>>ALZ'=@&I&_[CZ"C$YL6'^SO_1+H
M#^H0C^<E92_HT4!ZP.E 4GN+0;I/]7>/PYV,FU'QWNV)<VRDBKC8U<T_@?5B
MAR%9$)@+L$]@[;5,^)]FAX!Q1]$>[ ZVWR8<<)G^.78#XSGL.V[>*[@D^+^U
M3;1K 9L[R;)/M"/LZ'3[Z5 ;I!8.T5_RK^62EQ==C<')4E>E&F@3%09%(FBR
M VR^J[E%H,;_J^(B=MP"I'=(!UI@%M&ENA>MNB>@6]<MQ!FT0C!84FIOODHM
M%;S7;;<_HI:@IY:O@UJ 5&#:\4)WQ]2GWM1+6^0+"_ DFB$AZ1[>NBVK]T*
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MA^(XBZ>!2Q!*N;%/VAY'A:0=@@N7L5]?(=A17H8F=(X$0'A(9BE#3"R.%F5
M3%LJ^D,URBY9$W43#RBN58M+8>!3N1D6"2\.2W7PXK)9><%A4#>5C3CYA*8^
M1=.%(J):V6X&.UJWQ--SK[)PYW"7"KF+6JHU^3(IYC,=AJ^ZWXDS8[K@*P&_
MXF1NZ8ODV>+BR#/\T?(_$P&T10'X22N\>XRA)U*%]+<HI;ABBZ_74H,0C)-M
M8&*\8RE F%,! B65Q1KRSG"<@'\EC@QW'KU#S)X,PXY3GVY-Y(Y8G4P.D<V
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MN&59CE\S.K6A"]. <YS6]^OF'D<]W[="6:("_QLIZU9FO[%ONJ,JB/[\0TC
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ME5DKVY^\9W7:LZDZS5:G/9VJTVZ1J%]9%4M]HV4L6\[%384<$Z;TTTB6/@E
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M,PF?,\];A!48/,\6L\VTNP'K\2)+C>52@,EA;?'-UG?7-"6\T@;#VAKU<##
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M<BTE9A)HLWJO#WH[BGQ)R.LR% >OU;DM7L.N>-A\BR0%;QTKTS&O4U5&$G#
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M<OR%ANPO@K*+,-!-GAI*NV0F4H>U5"Z 6DSD@QZ 7,8PWAS& ;Z)")<7L'J
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MQEA-5$:3O$U41I,H351&76XATI*_&>/K5#Z_.BZCH>?M2V9$]QBE,MKMC;X
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MCZQ'8K;<-9Z7CY]2;'1TSQF-T!GA31SIXX/L^X@[NH2G?JA"H8,'LB4OB_K
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M>);(,;RNM;01!H@N3&$UFA^XUU'B.?Z<5F#GJO\0G\?:=1*4\L8T&FH1XNY
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M%,1MD/0;?\5>QKG_?+QYDS4M,>[V&W[%%O:WUU@0/=./F>P&D^GC2X)9'4?
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MX(XZ0M0_MZ%!8:0G;OJF3:13 4_ D0JJ9OU9H5::#"=9M=7\'"W$)% [)NZ
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M)X9@+KLN #6OXR5&Y2YQ#92WD'BYXE<)R83&ZX4QP!L%FJ3H.H6KLI+:$<D
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M8G&;8T5 02EP % '#(^=XT!/T)Q EVQ.DWE6?VWP2^ O2I[1DW<8TCZBF2Y
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MW]AR]9FQO_%0!D5TG::D6S)@70;""P()*9=.!MRRYKA3 X!.@D_PI?WP)>U
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M1F;73)@4GD;(4X7D5U[P1NZ#KQM"F/@2VQ/ _?ICMZ!\5^L:;>MQ(.=T-"]
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ML?<QE1<VO(F6+<?6:6GGUU*!Q:1$<, 0H/1 ZT\S(&^G;<XG>FTH=?I_MW=
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M/$WUH^?%C*GDA66)7&B'#@HZGV7%HD1(F_[F#-TMJW;Y[ID#66'B?7Q!=>B
M&Z%[X;1!L34]*_Y/>\W4(*,B7?@.-SHM^A?;[AA<W<Z>'!FT8\'\0TL8VRXB
M<Q1U532<O0DNJU#E=]'XOUOY516 GI&+9#J1+)6L,-J'O]NPN_8A9QGN#!R@
M?AI?^;LYKB')  T8]5__G=*&U&M\N07M1L!21X F\A*C3.<8 L"V0R5*E$QZ
M993)1#\@3S".(I8P?"#;S_O;SW^A?^<<#3#;DF9C?>2M"NEYMH;T&$C/TS6D
MY[L7?[3XK+\!>A3#GXK#GZ1\49$"1%4;,1#H0DL +0OH2;J87%(#68@0HJ45
MZ[>."2$TUN9828<1!O(60^V80WLTK47UJ429X&0,VHO0(C<8J\BU+3"BT)TX
MCOVS<\SZ<=\4OX<AO+JXB"7AR_#,F6<:4A@[AIQ=F0TG=Q(G,<%&?C8BZ@D2
M0>RH>B--H34<]3M6/>YYR@]$(Q1CI-8@Z>"00?B0W#$Z=4MQQV[ ^/:;RYF&
M)NY#%!GJ2,O*?5K8=(",(=A')8!'*+))LVT?!),9"A/9B"F1;$H,6[]86\RX
MD&#I88,[!E0H*SXFY@VISR0'TSPO(FA50K:O*9J@UX,_<3E+4Y.5++T!P+.<
M]ZX/*PP3X 3%VGP80?X@'XOSH<)"%O+Y06!1RA+,>B-)O1,$:.H9'M5H\?^E
M78]2;W2TV:1'KL*]X3Z/#!SL%.YK&XM;(DY[:EY,X&BV8QR;)1G?9*/4YE5:
M=Y5R=Q5\,+\$A5P?9=1$:#+QHQ\-L.8N%\G'P(@@*X#NF8)N5S!.&'L)K:GU
M?*.*Q,0(^W" 1KO)QHM*."=N7.OZI]/VO6Z)]*RW#X"8@.<ZY$4HC!4(+']5
M1P)]N+(]?A4;F?6[\<G+&&^BW'>CBJ1=)UNN1%X]66>^.)94I18CK!;S_XS/
M0FW*[HCT.>1#G#3]W+U%3;0$3?2)@I@9O>4QQF8?9W&+2X)VO%?E5FJ<JO6#
M]ZS0UH&I4F;;^/T,.YVQO"7N-5;_]\P(>O:R4\C^15O('H*=V>A+EADUA&5#
MS:/_(<'5M>)HREUKX\?%XSE1$!-9FJ4<M.9PFP01.JD5O]AP_]GSC61S8W=S
MXVC3#8X R$(Y((L.9WED(N?N&0P@RLM<&Y1H,EZ"IA#D0+?AMI <FSZ%QOHV
MH:PYX3Q]BP%C8:"+J5='*VK!+=BJM?EK5,>),44< ]H=A<FQ)I>7H'\,&3VL
MMOYN[2AEI-#:5*#B;QD3$7P8*XA+D$+,S.JW%0>!AT/K0%P0X88#\+C#Y;90
M$5QX(PMX\N W3/G <E>D8>KIKYM05&?@+]0-286^3<X2*HLU^=^EZ/NPS"R;
M9^YWK9IF^I-&8ZL6LL;N!V$?6D%B7-N]<"HGV81<X[04 [6P=0K.@L.Y6ADG
M:X3V8;HR("Y?:Q\J7WJKVJP6F Y^==5Z;A?39(0)>Y0[6Y@P1@@M!@OF7KU"
M!L=8T("HV=Z^$2%S2W7/M>E5]>DEY.V]]DM^X(?BD@:K#3(U3!&8 9PW2(TO
MPI/KU_C:!8Y -EK)[_./"8PG-)X5P>Q/J\)J&C#XC^;<LJ?D)0Z+8DV<B=1*
M )Z94E@&&DIE$ Y1 M630Q7=#/3Z4N[ H3T3AOIA:JO \Y*B:OB?I3'6+A(M
MW)P$)$"GR*;W_3><\70N5^9R_$.@R-=B#-UYOH5HFTD)"2")<$(-VI(1E9%3
M?]Q0KNUY7F.( @*",RMDGFRU=57=TS*4-*G7F$F&N6/]CL.H;V*H*PC%"#KK
MS8H^:_)=FM1.P(K"T(U-!H?B&O4B='\3->R@[>A5,OJPF&*$3>8"1#693LD$
M\TH0,*?^16POOFF13T!PR7&U)0U\XI6ABA $OB):;(I9M6A<C!:6YP(RS!A"
MIOG4^W]8_T+.#S/T:_Q X5HO=NX'KO4'E 6>\5S@!NTA&"^9K \QT& )ST;%
M&?80Z:;&C66*1#>YN,BPO\8-]LDFPB ]F'\5,PPQL5F!_>/@[Z53=I.4\TK[
M*[>86L(QYP1G46_3=(XP:B\@DPQ+<)Y,1R4NBLR+? M?1ZUJ\KN8^Q]"061>
M2 J%(TK%8DZ6?S-(3+[^&UL]WX+TH6DH+MW7UH<TG?X&4)?TIY<])ZB"M<:'
M$,-%9^,_T[O06CMP)(-2EY8_="QH,1OAA4-3>J]%B%K$.KU@]&__$_VO:5-?
M[]+>9.1C%["J*?\'-7[O088&$S(Q96OPL$%I7Z& '# 0R0T@2PCBT+#GFJ2.
M:<]DQ1^Y[ VI'-> DV6BE%N *Y'7MIF%@]*39'S?&.063]O?,  UR?(46LC.
M>1V<GI0N.<T0C_OL0SHQ0&T<0 L@NU1ME%"AUK,60TK^ )O=BUPJ?@"F5%[<
M2=*20@^E@TC_2F5R]RPA3AGBX,U1Q*6(KTY[9X?1Z>OHL']V=# X/8.RP=Y)
M_^WI^_/COR+]V^G;MT<GA^=J\*8WB/J#<[]Z\8_3P9$$+E^?GDFL$M_P[MW9
MJ7X+/+VGG_2'OOZ([HZPLC'JZ8<=#2)]W^!-U#_!NT+7Z>>\.SWO'6]'7VLE
M:H9%)VC/KVMHCX'V/%M#>U;?X17K?O>K6?<5.:A;_++%U,GI=K2_!3OQZ+_>
M]P=_1>^.>R=Z<QZ<'?7TMI3K[LT_NE>3'Q>,LUCW6AO]4!P;KX0+F4^(#26_
M5,02XSD<=*A3'"K-QX2M)5.PO=MF+-6B$N((];-U_)Q*=N2S&GUJ#VHO?LI-
MM3DTJ\^G43$U[I?]F@T'V6O:>O;DSU*0@E;4?$X8)X R092DNYW4TP;+Q^B0
M;:5 +9VQT! (51L&N&6OT^%L 0"=W5UJOXB?3TX!WB@P*KY;V;NI&@*I9,=.
M!;2WU!=<- @&^#8)ZVD>G6J' Y9M[SF^\XFQ[MS2O#!JC68ZC+:'U!XU.-57
M<>.#IWJ- /R%\4[R<3 R:6JH+;K,VJHGA=9EY,,.4VP1ZU4)FZ18H;B2F(KY
M L,5Z \%!9V7QA*PLL%.9HJZSR#20U$?TUF&A4 .=0RN<ON.S-#8EIQ6HOV
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M:)F6FS(K,/?CE.BE[(@@7Z88CBMA&Y<PO(#D/BL<UDF291UAK@V8!67UP;Q
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M@<$Y5>2JAU%67J*:8AATP+B^O]X7O2E6O'R,>M:7-J<RTF1D4K'V\<ZA'KY
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M:QS92F !_B6>V'8,&J$6$8,$Z1& 7D6Z7>'GNF@&7H -+BE .YK#&O@H<KX
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MH=7',TE.-,VK2RP5E)%6;@&PMG[>WWZR>[_L$FU[0'9G93@/"Q_P8HT/,/B
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MD#"P=X"!LOLHFH*9W82RWL/=1D]7DDV#M/+I<+M3NQ>FBDVHIJKF1_?!A-M
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MO[Q5IAJLLN@+666$!%EFFJG6PV8UTXS>:*S=D(W6N!E4%QLM]*+')=<]H9/
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ME198#EN1*KJ(I(OFW-H#KLJ ><7TZR;YBF/>7ZJ$OF60046<O?F29#1?D-
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MVW['KT#E=6Y+59"B>7"Z4R7+=J(;#RK+Z=S[OKP"B4,2;1!@8Y#,_/JWIS,
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MSTHU]O>V=M;*=;SJ/ZMAE7 PYF+C=S(E-,?&]M[)#)S'2;_47!'H[#$8$IH
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M!-<^>KKXPV\__X 1_W+TSQ^VM[9^A/-<YOKEEYC0!S-#3P6>_<,OWC_*2'^
MOF@.WD^_S/W5+[>T(G'5C@\.CW\VIDH9N6^9IY'@2)S^=G+V$941G!M=R(O.
M2D.\R./I57&">J1N#!-\+!S)/H@9K"("<MI4/26B/0Z=\F'$6%="I?_B:/61
MP88Y4\ _RI7)CNA,FL1(V.!UHMNU5D]VU[3Q&O@22<4P![:Z$$Y"G% ^I59!
MS$OU4YGC'RAB]]&%N'P3XL9UCE=W#.[^&'Q\^S\G^@@X]R (-:K4,"UU;I9"
MH1N8P[VD8('^0)_;OV>25Y(,M @*@J,K;<NHU0UO$$7K<H6YK,LPP1H&'V[>
MA.JM:L @R1 [W$=<0\%='R4E#"C*64PR1FC6==])F XKM/3 .*4\F8_3]4SI
M=NT"TTZC";$[4ZPW\9!"R"@DJ T)OFVH=1X.-;BBJ$<PI<)%3QBST1%R+-?M
M*8S@7X&#"!-#]@7_!/^A2P)LM>[9Z1?^54&=\F"@XZUI=VKM[1B+S.&37YS[
M?5T>1P/%*6L(6SAG^;0[]]VY9POX_/T?%Z_P],/A7\J ;<V9<I:\9EBYJ$BZ
M-M#MH2&CR]R&<C!P-#:Q&38J FT.EZ0ZRL,AU:U$X.<TL[1T$/-P$KOWHF=Z
M/^%F):@)W;5:ME5O27R$BSXY1Z#3[5Q_0A>PZ;ASXBN)<@ME=/.&+OKR&L4G
M=:7@WUPI[,PJA0LW&W;QX6U-'YBU]CJET"F%6:7PYZ?/OVN+X+<*GNU_UJ6Z
M_@<#6>*O_?;YPSI)_9]:8[B^,R?%Y)2HR-3N>&%,:5A3;HN: ![EEA!JJWH2
M3O,L2<!&*#&AS1=QHA#DV<5.H7,M6"V8F(7-XE/M>-I.41VUP//M;8P5G:&A
M^*XJR2U%F\2^QA=P-XLBUZ,NK<F$OI2!"(W4QC!SOB)'&Y?':6>-0BPPJ<\X
ML":)&9(+=E5_MS:(J)$.)*T^['HYQ;T?Z]4+^>B7G]G< ;I37R@*?TY1>-=6
MZJ)AO_Q)#8=R5G5ZVTGO><VXEZW DE8TJ1^'2Q^N>'-?FM/G9D":'>]<X$-'
MC&I.7#0)2E;AYMFQ>0+D9:J29#0VFX7%B<F4%,$P)7/$%# %1K6<@L/^Z_F7
MP'^/3CK\*8["!RYT6GO__L-ZX'\4/\+\6F)A.(ZUC^_/X2-(4EKAP?L7T\X2
MW_"$"UWA)5CT"K_\S(,A65S[=/IY/7#@,6V+J91948IM4<#+J6<P]D6M H;B
M5SH7+$FCT;27QY$M_!);3J>0=#%OO;;22>R")]3_R@$UJA\&&Z;>'%(0L$C#
MZ9%N5IV@(AIQ*M:KM9(\1M;W$4%PX?QC>'3C#?N99P9VH'AHPNA55$?8PTRQ
M,Q\!'IBXH=YK+Q@35)S$U4^+3@O2(,>7!,X&IC3Z]EQ8:%I6W(H$;J$V=ZSM
M6*>+MA;\8Z?!TP<(J8R%,UA7,E'U46#Q.4T1H[[2J<_&QSKDR"V<YNKZ*G>/
M7Z[P#!G># $2\2F:F T\"UWQ,L[/)T=[O&7]0_O7G1^RXO]>S*_)0=A=M[K(
MZ7P;5,D@3L9.G;YRY==6C[HM<FY_H+YS=.T"%?<[Y;QY!I<4O(BB@YZU:^EW
M"GPF>).24R=5450>*/:Y[D&;TX;8*(IRJC_U(14K&4>GN*I6%TR]I&*CN4!_
M(,F?_RL<3WY^XU\(R  MZH>0Z.^X!73@/5HF>?5+LLPEI(OIO&8QG49OP'M)
M LV]:</L$BPT)^PTY5O"04^1Y',J/872%A.F4S,$B4N[;_? ]HO&X<0I'&;3
MT]Y6 BZ+Q<=NJPR;^=(II.W,9AV@TXIJZGNI78#JJB6(X+33>.["X/"SE,H"
MJ<40IHT*RO$=!$6D6<%8+_%J ,BCY9L58B84JE_IXF,=N&LH1S&L"<_GY,\+
M?^UD'/X%7_U3]0R$T+IS5X]BA*V_!#/< K69 NT-<( BQ:^U2-4,H%UKRWS>
M#9$W+K3:[PJM3*'57E=HM:I"3::?:>M[:YW>SB*=L4B-MG;LTC0K/>KS%[NN
MX"Q/6D=O-]W]#D8X8G3JD"F[0[();KKU3^X[EN0L=3)C,K0)D:$!(3PGI=T,
M<[AMT?5P+%R<E"8O*@+2VO1/#.$P=LF9ZF*GE%D7ZT<Q#L&%9"@TWH4G-4TZ
M\FQ[GII)Y1?A[;VKB-S%@1G7YFEWN@S<#:,^,$![K>&BCFI9[[>02(<FS$$7
MD);:6JE4P*$$6R\2"APW$!*XH6/"%P19KQCQH18(CCRG4Y&D^MLDH5Y /X55
M:4:&ZVU7B@(BIIU1DBNQV[_B8GV.)')<-Y_I['I.FU8-C[4."?+0CN$CGK S
MO4B:G8O[U35RQPO F+))H\9*=/IE@</[Q:7NMO4BGKBO<6$O*NJT<3@^N"4V
M<#Q@*D5.L9B$&^&C;*)S=R8<6U,1.I<36K8SVUC>5P'XNF#/@L\ZF:E@9O6C
M_49S^\+E[98$_YKCI_Z%Y^&S>/.!2X'TF9]?&%P6)P&NP64_GY\84%I9%L1E
MI\;0"(.Y?]O>VMS:]D&9)H1;2AB0.ZPXR;G^-P>YL2&+-#!^B=,TB.T.'TPK
M& NOIT]P!/K=IR>_?C9T<;",N\>;QS]ZU+,+[]C%1^YL(17*H )/G3Q><%IQ
M\H*>0O5L3O!.&22?%HP*BQ&%GVV/T#UO-W<^K.<DS!%8*@D$\4? [:6_RQX7
M-G.5<M)DNG>\)ID?X*^P-RZYGWXTAD#D@5B[1(<01C?6-R0^CT4(Q8/$XF#S
M\,C*Q;Z5B[F'TS+QZ2B*:9&CU$P-A=^$A-CJ=>JHR"2'FSHI1_T0FT5?O[LX
M"SRNYL3,YC/MEYZ;^(J+^K;;&"%B:+1#FCG]P>V'[F8@=O7D&57P4MP-.Y/#
M'#8G5[/0'R)P!%WVE4W$-IB]N>1]+L*BTYJI,1N<#(6MK_?F0Q;R' U(0!T,
MX(98A2]-!!7> 91S-4 TN);9%?W#LYXJEBQJ$QWNBZR/HO=7;<-KG!5-'+\:
M@I^^LBX^O"W,E44 >F %M-__'OGH*&.82+V,N6T>=Q;&GF,%Q*;_J\!.2Z95
M^H% 3!EG^7"+R+O0^;"#J56O@K3 H'O*J61CG!ZS(* $]4+56KC$VF%OA"Z
M*!Z._6(4#Q"5C^HQ9ZA(7?0I4*8O2_9^9:O*L3U:.&?Y/N,,0C(5 $/FJC77
MBC8,!QI)QL![8&],6@U"#/5+(P)>,Z(O8.,*M.<V_=8N0*&#\!S:2F)KXWL5
MKD&\#T=97F(94D#:%@6OH(!.(,"(+MT*:^VH+7@%8_C0_QW&K:8^)>3(&T,8
M/GV9B_P?L CCT<KZ_6HB8CO"(DELR5/(#+@K'^)6!P-)W\^J!+%K#019%%@J
M#:W:B5IPDF$D*A9<&U>CBY7^3"7UQHF+@RYQ81(7^UWBXK&%>E&B7^<M[C%!
M\;2B&1A0O#LH$X/#9;0[^D.V5YD;/M%B&<QPQB#N=)A26Q=Y94M (*^AY;3.
M%Q&6SO41UQ=?2P6X0@[A80D9H_TZ?*;_'4YP/IIJ=I9IEJIEBAG<3[<A!J\3
M@1DSQ3HU@!;'*'3HJJJ>@;$7S]$V$<WMH6G M\[T:[\4[!+./KI!VA<?JOQB
M?=$:5,_)6<.$Q*J-9.J"4P?<HF*(J!35D$P9EA@;3*3/TEA_V!-+UCV^24=<
M1N >$SV2X]S6D;H]UU %%YZ.K/94Y['>8\,9X6@UBMVXYM0ISR%/"0W0P,Z-
MHXH$JX =3!02HG*N@MT3!.!7-21E9Q@R,2I/(D43&OQ9HPCT.MESW7IT;;K3
M60*7Q=DC_W_3_QV,7F0)GA2L''D>B$HER:@.D>$Y=I]Q*\9;ZXAK\D_Q?:A9
MI_<+P7G4H!CCO%Z8W6O@2=O$!(<H-3&=@Y5+ )0X@\0E?6,\7^N?&7+N43S1
MJ))C<(V:1 R429U*2T6MC370P0+/]&$T@NPFP%7/G?I7(&NDHJ0=U(SN[(M+
M/X:Q+4(^ U&B @L,9RAFPW9T$O?0\D'VFDT>>OQ"J0#3)T3U.GG;3(_]Q/3&
M!$(]VA]AQ$X30@1.J:^-N#5RR4Q\RDY]+^= L&F=V02KY0KW)] LCQCVTXP2
M3M5=AJN-?CF7.=-2$#N(P-HBUBBCH%$,6PA%'-A8C^X'C!=:\D>MO,(J8A>=
MWEJA31?BDI(-8LH.V6;JNFH[O89(,]16AMBYIC/[7$/DDDIC3>&@@3LW9QUS
ML,8 *?0,!#KJ<1VO?0 <!5CUF%A4Y C; V@QO2DL16H1U,R(:9#21CDRJ"[8
MRPU5!\BWZJZ3\D[*+QR2!+X.06Z_.%1(G\]/K-3[*/8)UNB@<L5?Z>0X7DR2
M W,Y4A$2-/($$E1CQ[N9!N?BKD'&M-Q$SCW2/#1@#JC4>K).P4)+:DCZ5V:.
M&3:W2/:S-D*\@6A\-4*>.F+Y#)65Y<GR_XC/0ZR9X)9*;6U[,\R;;?07(\HX
MR\V*Z\VC)<<=K\<<T5.Q&<U=O%K-(I(RT^H@+'IR:=-N#I6Z=P$#3\(<#1TG
MAGZ23HG#]>^%I(;!>,"1FMO2U'(VV0!,[2=G!1B3'NLM,19MEH;#]VBY6"0^
M8V!A(S&5PV&5OVYOT+=YS-S39:&2 =J-5D.:!P4.(E #R:]H9#0Q2N."SS,&
M;$+PRP.Q.*T<-9I>.Q7ZTE7HQVSC%/.(!E!#]UFQD= G-EZ-H9_J (+U4.*_
M:%-:8FX:1-\H.DKC-RCWTL@T@3<#?48-% 9=CG+S\#$4Y!'3)#0TF1X<,2YP
MSPWS3CD.F>,RN3IY"F.K&%( ,Q^N3JI7GI(68V(WK89% =?Q*JUELX![9-,[
M 55#X-AQ870P^%OPO<C0H:'*FRU_TJ%22^]E@-*%CTNZDQJ%LZ82U>V*$I(A
MD\B<SS#$+);,,L3Y<LI1S@Y4,UUU6N:E:YD+AN;1\"B9!#A/0;J0\0=$\5V,
MIA#J'-02:*7A3Z7HL48=8FA)!C$W(6+7A!%DST7W9P73-V^1&(/T4<SH',N^
M88FVP!IR"L@%^M86(SF5G38@:E\(3KU*J$:]7D=E@Z^M5:8F]"H566XW1G\Z
M>^S#<4;D[[3(<6.1[6@\7C&C)-#WDX(I8W?4]7,3A(T)F^@!EV%.D6AK6Q1?
MXR2I$[O:2DTFN;)U5EX3*DWP%*.JSZJ5:E!];,W&&JRBV>/BMM.X=(^@D_L4
M^-'43@:YR"D@&,"<(@)2F!.+J;?;4+LE;EG"P6&7$X":!D!YB\(UD;1.ZW5:
M3Q?V;USHY*$.Q10,=O8O 3"%\S-R&8RX4D:;7B;U*'RK0;/8".O!X@8G5L21
MV@JS2JZS8?(E30^N0=WI(H;;DT,GWR(RS! ;>=<3&UG24(>M"(^AI2MZ+/2P
MQ^@ N5FISV%7ZF-*?0ZZ4I\5E^V>K13 K(M.$Q?/OK.K<?GN[&F>H?8@D.=R
M![7S/;!YX= SJ_E,#JRE%V#K"MZ4Q (=8#<GYFYA*DU 5)* 9 ]B9:?#1AIQ
M+A-S_:E&UPS\4_R#3&,G3FN:(VLES\C.0.S@#);C:<9PSN)K#[-IL)LD*1?E
MD*]-O-'"+ 0V=)@4A ?D%(77D81G3?'&<AHP86OI]L(<+.1< Y?(\*A0H9_'
M#,0W#"=-AG.+D1]BD2X( IK>',F8"<EJZG.YSS6874%@A/S$#>TFZ=4R>.*,
MS$+=N!2SA"M;"<D4D7JX%K,IWWAAI!-B&Z*].<<DO<8*G3.WVYBF]4<E:E ^
M@K%J>'I9!9FTX2?=_\Q&:XT\W6M&[2S9+T(02=5.HU1!'QBWSL&0!]JDMV!5
M"XNP=(0WS58=>3>>JF/@CL"6P>)Z44ZHLZPI6ZO>F,_KA@'U,)JB6JQH)J;'
MR"TXZG\EGQ:[X3$#@A52DRQ.F1Y&TQ0T*I#8Z-=%7&HH4( $(%'4$EN6 /SZ
MX!P%YKP%]-\&;(FB@(6/?\"CZ@#B-?^CO?QQ.=ARMN:]^W:$]\C4?6)N<*>
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MN4[5I 7,[<YH=T:7/*/G7#(VF]UHJ2NKH[1ZK3"X3H$M!H0F(O!<Z0*_KU&
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M?XXBN;:WSJD66V%:$)X#O"W#^+"BD$VB53Y_]MGPZ%S7.KUHWT"X<#]0M C
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MG-9>.P_6 -7<B29ZI.&2;*A(:CE,5RVE#BEERDE-ZUL8W+][\%9O;[L^M@L
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M\7P373<K%CKNBH5,L=!15RSTE"R EP+9:VV"7[793"8SON:#8]:^SC,LW;0
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M=$64,="4G'YD;>>::J-5"().N@)"':5KT( 8F."Y=(].N)XM65V=#?_*J"R
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M5%5:/E^YBVO"@H(G>\]/J".DVMM.>XY)!IXSX1"0T8O\*@@U%A?]A+F,,%2
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M57AHO)%SG1:L5E68I[:QU3A%IZ-8#?RWWU2_(J..<\8Y&WQ7&9B+14E\?Q3
M=)]GOL+)-="T:YJ""!0SQ5'QV=[,!]?]JU$&EWHNT1?,G!5MSPMU!29H<UV#
M20.CY.T:7BSBTZ&BB&9G48B?MQX(J)\4Y>=$THV=FZWOU=3(4U@S#!Q$*IHW
MBH>R&AY*$&]Q2D&E7$BSY*DK(%]0)%'-X*@FJ[$N3[@>MK56LGU'V@LVEGX
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MXJ?1>H_AA_AW67!RCEMW!?R@L:+$T,!'0AVXX>(^WALQR2A3DF#6"=[;PRY
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M$Z>7XE<X'G0H L01R9TC'E 6 92A>Q8Y['%R?F;S 9B)Q^T#G4NM.!2>+XC
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M8BS:."OWDPNH+TE;^SD*8\Q?#"<>9^_<ZE_P.+4&I]90@%8D,!D*?H^+^4U
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M.*EN3G)0B2#M@_2I<#*)18*G P.7=T<;:!<!ZJ$3R)E,6("0>V+]9>JQ]A*
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M&L>):O2B\)U8.EGB0SDM]NZ?J++.575X>:A5RQ;E;U=5D97+:;>^6T4"L"=
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ME\5LKC:-#<.76O:&^O)ZEES5/6.@/H&!$RSU%?V4CTY<< 3_A@&-G34:17#
M.Z!OEI:+BX-GN#<O'D?63XF/PN2C*+QD3$'@1.TUA0N&IJ8(\0W;)N<-YY=
MSOL)0A,8TRTUL0*LUFZ J1"OW/9SO^+.%C1,D=[UVI.>$O6]"0SN,'F/3!WN
M(='9V/&9?"%J3KP(#OT!FFHIFDDM*9E24A=AHC\FT-80A3 ?">8+/\V=2=G
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M$:B>KDV $D.$U%!*3(&"YYJA)H7F"DAA>55!:V==U;3&OMUA'_-T4;!",-M
MGQM('UC8&%C4V]=74A$ P210EK=(W**Q KUKMZF'+G"0\VODJY%OO0&=A+1F
M,Q=WS*\8I:!DF1]0$*JQJ<:FM08<I=@A ULQL$4?&\5+2Y019\',N5Z#YDXG
M3J)T3#K9A)HX+,KJ3N,T,?"0\O!;Q_-3ZBZ!E>^Q"P8VE@)MSF C4ERHMSXF
M6QOIM70&V%)-2<NF%(V53<C2E%S0!%V/+:615!W9XI=IN$>R()V"MU>M8<.
MW7X=L)L%[/;J@-WS0?_3"P$Y#5+\#*(].+Q5+0.6I!9./>%GSG^ _&,,[;W#
MQ7#A"6(Y$QF7%=VB&Y#8/34<EIZR.(TH%Y=LEG!5XX9Q0W%6;%[$]KIJ(A8$
M/+DMBM<-Q^,4N/R8P$0N%?B_\NXLP]H3V:QWWEAVXR5+$04=QM[,@V6:0($"
M8HD-XQ?EE)M'8N9197,Q3K6F,S%-F 4ED,.&>HJ1>TI9H\BA!-(+=^7)3 ?%
M':BE!<)!HT!TL+:EQR 1;Y27[OAQ *= 'JY(8GI'3@"9F,6!L=*;B9US[H3F
MVP2Y-R4#.^=V421CBCU,83WY8PWSO;R"!<\H]XNC. /J]SI:D,N;O+ XS0BV
M(8W8FNG\)4EQA*,_HRN57:^?V&)R6(_@*>"KXN<?[C ,6]P?-W[SE*XL<L-I
M7AX;?H;'*=;$R)-*F4OY"V5RDSPB3D?_48P!2V:3:1@$<K( 6*:/O1Q]\EU9
MFK&NF.DATT?ACK_E[F4<6Y$OR<B7%&M-Y8'5BN@VI +VSMQS>04B"XA.,2>5
MV5-X3X$*I-AYF$;J4(5G!(=4'[%1/+\?LR\%VQ^ZX9S$@@AC"MA;)=R&\25[
M(\IND](ZQ^0ZA;F98PJ,\V,W#/)LU/'3V%+/.AAA@9$0D9[^@\ $207]-R[K
MHR3RQ(F2AO!=C 6,O'%"3C(59N13*T;9I$Y76TWE&F8!YIZ9/?O@OJGFU%ZD
MPCA(!Z8@#4L?F'QT).G UL@)J%(:C*R[)$XW]>;H F0-G*RW^NYP9BTJ:.R#
ME,#A69-<RP>9SL,>1 GU8$LCCN:AOFK:$C/EG[<4N(9V()8""^.9-CCM>V$5
M3TP=TR([I-QYK$P(W/,/GM$0^-XC7+AUI"/.(3.#<4YQ)_L@LZJ]SEO05>%W
M&0R+=P"S:=* [9=7 "G\!8 ?8-6-FB3G)'DE!(TE"&;7\I>WUU?\!48/@V(T
MEDI-5C3*EL43M9PFU5TS?]EC,O'YS74>NBP5+*D,8Q]XS.-S#2<%"B5K2J,T
M%J=*"M/:^,I6F0XO&^><>-&,1\2AD!J,!%!GC9N 7C27X90COO@?KZ\^_"2[
M4X)V217ZI0IC+("&Q,74+-BF;64;(9*>Q;KQ-K)FGA3M)PDT-L3DHH,4L"IU
MPLSAI#TJOC&_D#P%([51S+J$/RYIHX*#7O,@E\J0RI=$'%;%+^L8RLF!?'0&
MG[E$*P>>8G1DZO^)L$[J#8R"*L0^QQ=,<PKHIN1(Q2>&^8G>+9)^%8G*TLU*
MK#40:V/=/$&VCK]A!392A7UD"MP-5K+:U5UC^3E,)V0I@'K"*I^[F3A?!2&^
M9NHVG329AHQ\6/"C..,/Q)$N6J^ ;@#"_0K_ ),R/R.GQDY^Q3ZSH 7D_!,;
MP#YE(=F$-2K_N$19B#PBML7&.ZI]]JMY_?'JL_F1FG3)KU0%-#@#)V;S&=<O
M,=4[*[JB,X9+"Y5&.TD:J@S?GJ=1G,K865E+)1L'O1_D?6<9*M)(<"SKQ%">
M"@F*XXQIY\O)8X ISUM0#C$WR U<)W(Q9L[#-_)MZ2;#TFHM;7'()HA%J*LL
M5UM8)!H>>.B&>1-DTK.EPY$D3PKRRP?/86M4LZH"^$M7#^]%=@>8_J",JQT(
M39,AA5N@8F$%\=O#13J6MDVRM]9\Z6T$=T*F<2.Y^0UPM9;[M%0TI7*SYI5[
M-0V$7A;(B]&F.7[E6@^2ZCLG\D+0*B?"16NY95*':H(Y7C=?I]^LW4BOIY0$
MW[Z^PJI.8S\EV664)G1KI&G8P%A-*AY #C/6:=]1&W89Z,\?0!_/2^3"(]?O
M/EM2%0.P>K&ZL9F)X;7  %@R4L'7C#(TWB\I@#C/SK] H[3A<$>Z#V2[QA=N
MF!# 3#($7*FU:JA/A1!F.5R!,8;!*VO5>OZ!YX:MV:6L_?K#/T@)-+1*%?3:
M50)KP%H7RJRN95^KETHG<IL9Z- *@@'%WQR422PN]V7IT="!'H;[O0 J*(53
MXS9R.!6'(F8I^IA4\$SEU6@UO'XYR>ZB0W<1XPZ*!_.9*WU]9JEWP?H!]2QW
M?(PJ]AT/)D)^8\E\+>_.&7-5D5B]5!Y6G@@<&6CVR!$^8L*&5+^)-B@-A[]2
M2LXO-Q^OKB0$I8N#(<DKH*;J6 8#  FBNX5(DC.E6CK9U'<_J'WWF>^^7_ON
MSQ[]T:HBF:)YA03P5V_\%6LH&RAPIIR*2!8"S+(C(5$&-D_1SVM1>!8'!W)"
M84+F0C09? W">RH00\0)K0WHQ%JP/Q8S7K"W-/T747Y,618<9306P#Z(KB^,
M2,S20!IM,0<.?D5#=\CUD/@3$$*,L..OQ_)OY-></L[&B*\>IN:1QLO1M1$G
M>"1I%'"G:^"$(%/3BGPA_Z![BHHN1J*1NXP$8,GQY"N"7Z QZ072& $P'A9U
M@2^E31AF\V8CT#<X*9"L[J&OEH*LU6(+?B8\6+GD$$JKK:&.2_-/9!DAY,9'
M4=K4X9:K"A0J/(=-HTD*4U;1@AQ*R099X(+.%==/>9P\8 $Q3(D81N6@J!3-
MYSQJ(3-G)))[?!BWX,Q%BC535&9O'D:/PA,I &@I#UR9SROB<>2-*,-403R2
M^=(R-SM:&)QXP^_CV1"P], !1\M<BFD/&",MOHW%G'4E-MAGT=.Q,\%51"-,
M$%()N0 ;:C.(\0=H!LLC[ CGX3$VP(4!^426AR^,B8MR(^<^, , 57@O;\H<
MXV])3.+2",$=]ODH'BC]@L+,B-)CQ2V#?B3H,)#3YYAN* #RG<NP7-XU#*0(
MI$6.QM.$:'@-]H*(3$+* B,-4>[E[*>%C,_,-TFXGF\1Y+;,PV#,!);2X51>
M/!^9$CM3.<2.F2=[Z7ISQ5'QRJL."A8H6*&=.5^%;-#,6O$<@T"$X2&TX/;P
M/4M683=JRZ#<.BX+<?0.4C:Y> VU,]>8P!N3Q\P Z1&7H\4E_A>M&*!HLRT#
M?S7&*9<4H(-%WRN!@*'C814"9ZQ\6Y3?C08#\@=>9?XO)'&4+!Q0NKDR*3RV
M,S*$2W'0D';DJ^LKNK F.]!$E(^&FH54X,MT/J_L%0CADDF$0TPYX1LY@"_<
MVRQ.*)9+0#11_C)>/EI?[KR0BHYX9!5F0JI&1#3U$G*QRN?PBA5-&FHGX]#E
MU#P"/<C!:OTDFVMJ')+G6*//L<'^+2+Q>)VUN=06*IEE!ELTP -DJ'RZ(S4"
M&)^TBM3'8^(U2'XS#^.\<+$:^2V^95RS'J'$_+?75[6P7I!6"NH6:IUCH,2^
M"519)FL)N". HZP'Y8=.ZOSUE26-?9@9CX>@IZ#RJRIW'KZBZ\VU$LB50SH=
M'C=@WI\";8$J-1778 !A,Q-G1MQ!U0QA+\M*::E:N,I%*!G/(V42<I-+1]5(
MF%FPCZ4AG5&-=,Y"EAN@<51^,6S**B!AA7"A ['2N$$CYDL&"DQYS6E<O>J9
MX]+EH IM:MW(D"(2=DB+I;7.,/&: AO#!R^5M-6H+>0&!*":AG[WX6!E66T\
M#V1$5$4(.QT MKJJR/:$C/MDMXCTHB8JLDK.1R8.?;*W),\QQ;;,J1<#E\+8
M#R#8QASXU,P9D_PC[3%\Y!K \V1I(GTD8RG!0FCT73GYB0NS$.!+TX++)$SD
MU5/0X %W"V27*#8RFP='9&@R!7%,]9RLT#%"!J>@FIE2,AF8)VB8'U1@YD.+
MG^1H8!1NL$P$3T>2S&N^%^;B<E@5R9%;?^03:J,4JA"HC!$+U8U+WQE1%C99
MO])8!L6B,A*$P65!*@=TK1V0L :R*\E $%>/NI&(8(!$B09[7S'UI>(ICQ&T
MHDXH(V\EG7   ["X*9,*_DT@;8O'4R )E/(BZ/JC6J:5*0+2/!,.&]6JZ 0I
M*0'5;LI")&6H$E_QF4<_(EDHW_SP/B#R3VO,I2PJ-!/ZN!2Z.2Y*B3R&=JE'
M@'(3+S-%ZL14<1, 4N1>HA2\0#J-!1!TM7G$>5&D&)L9]'.G+0LIAJ//BKIV
M@/HI@GL5\!%2@ @$?:K\  C"Z@'7FX&_TSF%'  9^VJI4PA59QB+(L0EC4;!
M%;D/4W^&I/Q-3B4POVA,)5@XSDL[H)SHH_*."8?CK%PGE^/ADLY<TR-G9WCI
MR\".+:,DXC7,WSRI&52*<+D8*67D2AF;R)B*I,OG9>MQ=B$81^@F&0>2H\V'
MY6BC6HZNR1T% \;L$9;57\B8;I'=/EG,F8&SLU_1. KA7/889*>?*ZGL+J:S
M5[81QDOV"63%R)D-92P^,_V@=,MTE$W[N4061F1&4DD@L702\S0P.^"J+]N&
M$H]$JE+2(4,I"C#^J.(:Y;)K:"!0;55DT1QDV:%/#F '+P5%99&? B-:[T65
M34%Z*=33*,(\TV2(U>E"9;  A!U#^HK,@J](1R(@PE2(KEK.S=Q[$I$]U1WF
M/C>#%((P,^]19A& &8R".RHO;?8EKZ6'Y.\-C C\DJO>7 /'((%6OI=[I[Z\
MN?[%DA4\XSQFF"*4]<!4I8?I9B&#PV?S@#P)'RL'#NT8BX\"YXZEFIZ['^$2
M<)6VB4>V)";5>L5 N P58@HOFVQ(,<-(12I4'U$6SI$;J#4+%HJV$N(8,8+^
M0[JEB!=8G(8TF+Q:'8M M\HN1CQ8N,PJ/"EF&6PD9XLS"3_*0@E/EG=9Q4US
M/<')[-/H+!=3QY^P0:XP]:*AP,+%DE@R-"A5!>.^86T1+[A*#Z?\0(5C+%M2
MLM17(9\G35L)-;D"O@$\B5+?$NUF5[+T.F?B/BU3.?J)"F/ III?!LP@:KO.
MS+EE"NX%_Y$-&>@ZJ3L')"Y*9%U!+J'(>T)*S:5GU>1*7YD(94[@J'6U;AF[
M1%%(I+2I&?15+1FZ9AFS8@60*8!^0^1")'K"H53CA!0>Q)*54<Z0)2"Y'J70
MD4F,',HJ3:%@-<'0=8M3]"; 2L@*"S+V)8KR;&K4?-69(]XIL525E4X5S>0K
MI+5Q@-68*8(6;26PB.9>^F'0OYRCM!Z!WZL\L]UJ-G1P#VL'=^;@'M0.[A._
M$ML5D-/$6Z!&0*PB0QE"+26:@9YYFQ4L)D:(X%SVSI9-IJ9N,\U,(L!I15QX
M0JFH2K2!T5V#.TJ0(<JU)+>X([::)G.@>Z2#*GV!<\V0+8J";5;II4NFQKR>
M=1:..:-]D!DLJS*8A$:"K!T(,R\1N%2TR (UU19469 *%TSNU25 *B&"O:M+
M*@XS$DV"S50;5IA!,-6U(!J_W6G^9+Z.TEOS8X2)WOA?>HF=U=GS],@G,4(V
M*9]0TF6\#)RB![I0+I@.A5@5ELQDUJ1E/T0\P?]C[TV;VS:RMN'O^!6H/,I=
M<A7$<%^23*H4V9YQ;F]C.9-WWB]/@20H8@("'"R2E5__G*6[T5BY2*(H"5,U
MCBT!Z.V<TV>]CL(03ET5EX3K;8<J:+AM-A]JXQKPRD(ZPPFB6RI^DNK@,I]1
MR'X!.YIZ9?4%J</3J&@.FP-/)Z'/Z)CP9;5QXAG0.GY73J["IAN?I2,K/YRY
M C9D<W+.H,6)+W4E3845X5XN:',5MCD?Y'E$ORZ-%1/TM'H5#5))\65TQ*I,
M[7'3?.'',RKB%(1*=12*E4+.WL ?4J3<05>8XMUTW)1L;2$Q,CM#WR']_OS#
M9V9PZF1 /V^9GY7:2RBI9,2CDD4)!S9:1U2P24/(*<C2P=1SGA8'LN\"I*=W
MV[AX?BE&SJ4K^_/R-D(YY\/M?\M$=IE@S::?+2;+_E!+8CV_.-_&QI4HX$3^
MDK8RM(C83<2:EO"M(O*\2P"Q,EPDA+82_=Q^CO1TZ0UUD?QLUR-KJ2ZAB'*6
MEZXW#YVT0(,%DZ%EH@KA><H8]6+>:6;+*\DNMN^ST0U\<?'A,F-M:*WV%%?)
MS9:I3:*-B+ C*0')D%'"N6I,3M]8RR/C>S!&LX3Z_ 71VHW!0N5#TV1.H'?0
MBV2/717\6UCLT$:+1B9Q*%O8XMYNF\;D'P>%[9 +Q@ "MS*4^.VB'9SL9!*I
M'FOYL:C"Q%U1?V$0>@M[Y:(WDNN']3P;-7A:(JRJHT7IKK*N*\U* 8BLV96I
M[(.3D0=GU!S<0]B0&TU'0S<=BQQ+5N2""^H?P9H\6H$I*U/P$^\E/('HII&"
M8QQ)38KJWL?3>50(/B1F F5!10#^JZ$[!+X!8G@>HGDQ1_4\9E17D=.(E6/D
M-K\(?% =(Z$3,:MFD>=%26T:]\&<-ZV @+E4IK:(?J662NVPC"Q*<19P$;E9
M0LRF,!8B+>SMZ_.,B,!EH@]-6Z1%*+2ZBYK!]3&A5^ G,2=CEALLV0C";!+J
MK;1^!$@2 2"H],;L3M@"KE!S8:NNZ@H9TF2 *?(G<\L9;O0)MQX6QCJ<0RN$
M@ ;&48"Z4,7BH7PMOU:+$'8YS4,M65^@V!+Y11Y!?-&.Z5*1$(P+5NO$)*CB
M'.2G-$>?:8"$!,\7!UTY>M>U0^)&'5PWQ6#S%8&BG6&_X?!'O"!C1\K@#W#Y
M7-FB?X$L,DI[NAY<!M=-]SB:?=7,\9-O,.Q6=V2)7G9Q58]?VRS=>E-MO7F*
M[XK$L0\V*(W_0+Z6;\F2978 I+]_"],RWK<^M\S3_+OJ%6I81^V51)16]H\@
M_1FU$A)S4T_F>;!2+_7*1>!YP<U9LI; K2CFTZ9&<Y$_/S>FP&$WA]-L*L_E
M\<W!FLF]4T133S ;=CU+!BK=E!,0159)A)7G7*O9Z7T/-."[E*J"I# W.!\I
MPNL>]&!TFP0QI^:<C-IMJ]UNHY>(L*7QFA.]K:@N(8H#S-31VH[DQX-IP^,C
M^@HU3Q3!QO1UZ8?"A!%J++UP1"+1#:6_QU&A#B;]\-@:#:H_C+:1:"/I"><*
MI><O65\P3WKM%JQ0>$#Y3?J=',C8:@KMT6C_*70FK4&;K7S8!MKZ=!!^(5@8
M)\/A@/90%P[4YOZM(@HE02+)\+(%C4XN6*9"QFZ:61;9*Z[F49B?<U>5]8MH
M'V:9(!&3ZT G!R09C3)!3'R:Q0'6O\#T>IRX"[H%_2,W^5[]Y!OY<9=+ARSK
M.]P\;]TPBA?H1BJ_>=3OC;][P12(]M,:3?>$44_I.B*D7G4=J1?N>AWAPY74
M\Z3P&W:-FG;:3=1414TG3=3TL:%&-EH9%]I%\1$N"B-E6;H8ZN71\1@AQWX1
M_);XCCG8:'MH$&I*Q=!T UW\7Z:/?I:/%N_HG/9I2"VI7N,T"QJGB&_85U>8
M3$JIIZ#!NFN,1:PPKD>J4M<:]X46E (-RR"+F#=2F9J>4=!;4S5-VR05DMA1
MJ^T.K?%.:NVV6FVG/[2&PTJE4C^G/(>EEV)&"91+-63T*$JFD3MW;6KSFB&2
M>!E@N8RP^=(,R%HZN2TA#HN3]V3JGWA.QB#T@&I:^K#(ZC!ED\UI#4!*ZU@J
M#U9!>\# \)(:-:(!FW#E:UH>;.1)(-4V(DW=(*H25>\8@N!\.1-[['((1V?
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MV"S79R0/=@R<=YO N0J<=YK ^0MD&(Q'2:DF-&:J1A"@B*PP@S!CT0G"*XE
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M%55#V;Z,!IR_,S\F<$OC)^';,@ 0!8OX!C5]J9Z?7KLV2*T$I@_7C09-_LH
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M- '<QVY**54OQKU71J79N (?. 2Q&>G#$CZ3:L>B,U<H,[)/XO%W=^;+!KU
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M-JS9L"9EA%0>5<'3K_%%)H:M(VM3"8N=S%U9(>,Y5UB5S'E)XF?4A-K37I#
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M[\V.1+?,Z."],BOU#\TXW;Y XCC[8>9FMU>/P0O,30IO?ZPH=]@9>+T(E?L
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M2CV(#'V/84:DFN(1^+"5"&V!YR':&Y2L=DP-C<PLRO]>R/XEZ/SRZ]OV>,P
MZF=)5#IS"#B29\5'0>1&1X1G;Z2@!RLG7@:XP]<.8QHQ4NIH4':\HL<]?YB@
M%9VYLUHS_J<ZM0C$#(*I^.9;9QHFF(35':;M*15(M.%XD7/#& J^#L=1!N\O
MF2^#0*):?8@#C'*4ZY;PIGDR[&F\22(#!"&L,7&C)?867 OPC1P\1'&G)+*$
M&P+Y_A<6BLB[\ *N].#8?1LOCT>%5_C5F=E)Y#!>HL"B9+Q,9L9(8(RF;8TE
MI N"6R#("\%<D E,QROA"^#()"9GS=-9 %$=<!->,K3\P'*(3R"JA<=(-"G0
MSR[C"'B5& 0,8JCP]>3B41#&)\I%@S^+X,B<UB<FM>W0V0TY+/I'!0Y;-9[5
MT0(^'!S9:S>$RU&#<*D0+H<-PN7S80/]XJB!\/OE D2J\99$JKP@_NW8H?F&
M]*1B\O9%KM-GS<,]DOI?2?OZP-K7FSJ88$ZM.N0E?SP'N:.XW^IT2S/Z*8G?
M_<MA3*8_&2()%#0="UR[9B5-W#J(ZNU4$(4XP5Z#/_0@&?[3??(G=\G2WBU&
MDB:N__)O(HLB^]]IIOOE8C_,'G7OOD<[9Q(?\TIZASG9.V7;C8:ER26([D^2
M+>$F?QKL)<+W7XM,C<KL'+F679-O3G9+JSGM6Y/AQ$+ \5U29UX=P<R'U@#.
M9]09[S/S Z3TE-  .Q_*::!NWXJ?UAZN>$YN$UPBZ"ZI>S1WI@\UDV[7Z@PF
M6T_DL %I[;3687#MSMD9GL+K'NS$1M2^:3@<;=ZI[#<?:#Y]:]S%/K$[SN<Q
MD^;>J)8>V?8K@2_ &[:Z46JV<Y^,DO(-WRMAI&/U^X7CV#HCI'PB3VX33GO6
M9%20:UOOPJ-(F<JT%Q0^*A)P*CWGKV2@:\NH\JZ'51\T+ES(^X2#N]9@U+8F
M[8+<WSKFNQVY'N\.G':L47M@#3H;:;5R"W*TFHUJ'YG-^X1<%L!TAO(^U"KJ
M&<]$I6.".C JA5JVT4H#VEHL@'L2*/>_H1I%%N-=(^">7MHVFW#R93<K6,8J
MT] $/^JRBJF0$U0'<)C&GS!.;2/PD@!G;]3/#J\#,J2;5=%=+5U^=FX;XX-&
M27RP+-[?&98&.^$=CN2L[+DC(^_7<'1!*/LLUYZFB&(:F2;E:K7<BR#% "^;
M6;=7WS\]9)1]%=\M^42OHP6N#?@"$X[GB8B\@/"OH(PH0QI5!S%WUC )MW(9
MH[$X?2U>;J3MY=1FD+@["Q9G&"@D:JC;E"@.9G^>36T.A*VP$81HSP,K$8D3
ME>W@S9,!&!/X'8.8AJ/;%7'>,JH9]T?;YW?D$P4X\+=PZ1GLC.!?82Z"(3E@
M!A-!GS7-ZKT]13''>2 ?+C_QKR.W8K=![5?0[91;LEH#Y\K _E40S*F_0/48
MQN8QNL.VPH/7.28_56SGV!G]A-#O-T[:"9'FYK.^$JRXTP0>&RA-[IHAXOTY
MA4.!V#W7=R1P"QTYDN&, ?*%.!))0&*#+4S!2/M6H@IOASYU5J@]97Q2^(-S
MN3S#3K=(P"KA(YO>D:9]J$20TA2C3H<_F3T>SP;]P*;N#CC-M?QY;D(=^;8:
M;!7,@9YF/#.0KN%5&<T/QQ-\KW6\_NY'RW0[T!7?XRM>>9[NZXKO#$%%'#WX
M)9OV1]KF^NK4*1W1?6@=AM(ZRL8?C]/QN8FH3]RBY_N4<AAR2N'JK;WEC)-N
ME9#8[Y;KC'>_Y4HT+U!NQD)6[WG/68,)9_J)^PV;D\BTQ=*KQ=CA^CK.^R.[
MKLK[XLQ\LW9GI:3?'[!&"9N%O=KY.;4:.#:1F*;1!G?OE:SRGP#4 E0VJ8,,
MIK+YL &)+[4*[N25MJ#!3O"4_: WFR'U,Z=S[7ME#?K],AV9VG$E,;;)FHMN
M3"JSDCY)1Z6G6!KW*Y[*,W0W)0D:FY,$.^UA2<IGFN<LAU+IJ]SK6<N:/;X,
MP,<TJ/]P#!13LS@-V==>II3PFYZL:N[6Z<K46$T2J;2!'X]7M:D-Y6\_MTQD
MOR8#8)]0?ARL*Z.4W?[ZVS:A.7XNHUL1XD_D_N7P"O$KD^%H4ENBLAD9,O?5
MFA/AF^#:\0)6J+EE&@C,$)M4:5>U#YO.?1CCZ"=\;'-)2$-D#9'1B< [<JC:
M:65J/1+0GV=\:W ;.'_^0\")YUC'$JP"_CG>+<XW<>V)AY!8IZ%-S=>PQ2=J
M@4C9F$N,'>7EXZSD4 M%2HV@%\4/6T^.P(_B+KN+Y5@6P6>C4,39M_(44UO7
MF9;;>,*Q\;J7#6F#MLS724@Y=AM'N4'%S9T7)Y=W$)G]]O>I+@3KS.OR<E!C
MDX5,@Y++53A@:4Q5' 2#J::X2.[5?A+:$W1W,"WI?QY]WM^1IZ&/FS1TE88^
M:M+0GQH;/+RTWY0!Q!)?)>KL*?-58DWF?:-"L.XF]E4%)SI:8#DSQYEKS;25
M"P'==3FCG_08X\8.03LI=2KUK/:8'22G/KN_@M"%4\..L?!=I]9W/DKC&YQL
MA?<3KK]0U2GG:+";HZSPDKQ\KZAH-E,HBTO,%\O:E>6RZ'F@;N'NW!60\_F1
MK(Z,-Q7W4[:?QLHWZ=?(OS[J3#(;EE_Z:N52T;#F[E#?*U^^<=+IC=7RY[DY
M59WO.G3@JR&5NJ$S#8M%>]:@W<Z[2T,G&S_%:7H![+/PPJ25FH:J,3[IR^^P
M=TZ\5J2O,I+JL;MW6RKO9:E<KMZ@U6>KG^&:"LF[0 .?C ?:)(NG6<<9]$H-
M8W0I$P@^;FS!&'!^@UU9H8(68/^Z(XT6]%49A55-;<\+ BI51ZK#:!4-4OSJ
MI#>LH=K\^QLF:9P,^Q5SW):/AIVZ^6S'149>($VT2>U5;0_BHU9X],?#:NXR
M*MF$>9,YJF6^5)7W#G=]IH!YG_N]"[0Q&775[;P-6D'NBD<.&N4_851_HI^1
M?UL,J O!#/5NIEJC_LKKM@OR>--\-JH>%<+5V$:X#B;=;76.DWTE:TD(;M2K
MD@]WE0L=J]NIN7<W2(;Q<"B2 1K!L%DPY(H30X?\;B$2JQT%&)>[-3WW3SP7
M8%N.DK%>B*<5NH11HP72$]"&7+BOYG1CP>F(" ?H*_"^%^ @3KAZ:?&,\DDT
M/NC,5W-!SSP64NA0_)UU;R FOI\<CKL)?)AI$KF^$T7EX/+'[ !NR.ZQR X%
M5,(>6$EJ>+EHGN T?T$/MZ'%(,C-#-:([Y/XI"0U(;:& '<E0-2RB*(<4KAE
M"(UT9O^VB6?=L]7SSC>0R#DO2N9\S6+,N(KEOX,T#!3;,,,%BP&9WP,WT)47
M3$%:Q"%%=0(X,#210-OVYN;2OJ:R.KR=6&W2,Z-0IKB1F<#]%6+&T_%HJUL#
M8CZQ$\<\'?@D:JUTRI;)R8>!!B[GV4+4VV#\,/P;3!9/T+ZV78\%))I-E&H^
M12TE2A:(T(BO T%@#F.TN$U3@3(Z"TS7"0W".02*H"M$90AQ#I&@## G@^1J
M:9;;Y1H)4;*D+>H_V$W4,C^1?X=R!SF/+K6#=9 Z>PKJ>6H)PHQ@9AC4O')\
M'$ F.E(JG)9]=^/(Z8--0%3N!\*GA !YE*Z-R2@>Z/D^U]#PEW&..9VN9?SA
M\#<HC P?@7M8)?_A7_3AQ3;Y$67.V;S-::HN;P>0Q8U(,6;1:<(0=%Z^P[Z'
MT'9A%&VN2A10"W/6 $J&5WI ((^CH**BWD!O^%<!>>JR;VIS)>C/D()C3&&+
M!%,B#?4&@<8YZ&HC0F%!(I."D=2<&:90:E-7_IJ6^5:Y;D V^9$]XSFL8,]
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MB,+Z].MZ>J&(JJ85=>*;(D! ,W=A&IF9IT$5X?Y8 6F+I$,+S1;8L!7-$,M
M,*V2\8@(KP)."*F&_Y./2['I5[DH.G%=P7@AXJ%.IEXRELA%YO _JR*-2R+Q
M2S10/VN&XV7JV_\LJ5J9D,<A@I^"7?+)-Y17#OV@+)%U!LHP.$6!),MIX942
M.9WQKM0=5BH 6;0S!@JZ,YVY\AI8YK^#$,@@\<UW*7[-/X J4#:\=U?XM 5"
MXE<<)UJ:_W)QJ\QWD4?UY2)$G)G5._%M-0'EF4!_!;MO,J($9TSA$!'&DMX<
MX<=XI^9*_=?(V\SA2T)K\.<BPPS3G!&R<"GOD=KML0R6U'E[J(QMS#S;H.#G
MU_/.G9/_Q]Z;-S=N76_"_^-3H#SVO%(5I&CO;B=QE5JM7N+NED:2[3B_FIH"
M25""#0(,0$A-?_KW;'?#PD6MA5(CE3@6"0(7=SGK<Y[#5%M5/:6??XJQ'#,S
MW&@N+C"UQCGS[YF64<=X.![-C>10V5)2G!,Z;O 7-Y@H?EQO>!WB5*E,H@[>
MV#J+RK2\)>> F 2$CPOGPQ1[?;.>WG(RXCB$I:=)7WS."\=^(MGAF"P5+6UO
MP2/33>^<5MK8<1,OM)OMZ;UG[<J=S;WMP!=H5S:V.SVJ' H%+:<<=@V'$]'7
M6"Y'":&U>)T!H')2\-_I*?Q[+F&X#A-/OJM:,[7QUP*>>2DX'OSC<U@,PO_*
MO$GLWY&=UJ,/Y=&V9>NMQ3+@+)5RP3!-8QR"U%Q47X;/J#ULG YSJE@DS5]E
M/O&RA+A!$'F33:JY8R4LIPTS8_)%3:^)VXBSU9Q'<X ?%Y:P\/GA:)!ZE(@.
M.<^/;\-O"R,O"T0+F$H>!!-D<-\(C@M!7D1FVU,U4S(KN8ZI>/P]OPPET*S]
MXH4-;Q/@PW#(:A6*!:I4K=</4*0E)2D_R]8F]1QR,])Q$O;)12$L@[?\FSE#
M0U1%/PF)X6W.2*OR5H,GY/?>[-\W07KT.E^);T2K&]0S"3-?"K7@>$RT='!4
M/&[@"Y\2LHG2I3QG>([DRVSH&$-:*?4H>XMD=+#+^YC5"-##^$,4&6W&\3B)
M^P2ZD"-.Q_X>=,Z*._M8=S13J]."1B,!GI%V7M;.,6[7S"W@5?=FZ.!@C&7@
MQX4CP\B04;Q$VSM;?C_$  3(VD$X+9J$[!R;SMHLI%\(3<K@/3I?,-6P.B"_
ME2EE[,<5L%I6>K]U\-\._ML"_[4.N_?(\%_S"^]1X;\VY-*[*_CO5V%P/1G@
M(V-P/87!-3NIP^!V&-QO"H/[3=D9U#[S'_%/;^&LP.?^$<_#U#]6%N,9FA1G
M<?&GS]&:WL,1(R]3J[425MC,\BQ_B?_TA:P:\RU611VL#]CB(?[+SM;.C@03
M4?B @1_IN$_H%R/RQ@8C4&QPV%E"9J@VHLVE!O(;JANB K>C"#.;(7$M\3P"
MDZ5&05HQHU$(&;6H3C0P0!.0A&$3(R!))C8>!6 L>2-,]&SYG9X=+34(1P!=
ME450Z3$X3$ :EK)4O6AR$T4\R+-/KW6!-=7;#+ 8.)<W6GXF4*J:J2 Y&?@2
M =*L%9%T0DQ!7X)&7*2_]M(#T9C3JY" E&6:1TC,')&J)GG25_*$+#7FRVUK
MAK'+S"U+#>/[[9?!@;2TP=F ?8[QDU[4#U7-N^&KEX-BULQ,3'W#+C6,EE;S
MMYD<[GA1Y=!::DYD(N]B272_(#.Y2XUET86HE;ZLDG.->N[^5,R#&P)*YW](
MA[SZ]Z?85SQJTJZO,7X7Z6:RL9HI4_%NM30Q_KLJA$<6,930MA<^7$0$:[&J
M%(8W5Y-J8?/@Y6/+S75M(RP"J]S=ZF"5&E;YJH-5+B%@Z!]@*@_^^5WX_[:W
M=Q'1&_[4_-@> FT6?_;,U6W:%M_]='1\=G'XX;-_^.OAQY//_MGQQ\.+#R>?
MS]]_.#WW#C^_X4^.W_BGAV<7O_L79X>?SP^/Z)+'[;;V^/+[NY^LD*_;2PN1
M?I<2)U+!R13.#4::HGYI>3VYM$LRF:N;2$>+P4K!*'04(O;%1!1] D:JGD]%
M/(K1:K=#C@%\BD?P7V%:8MYB._!4P9$NA+I!7H!0*&FQN%#5__-' 5&!X<4/
MQ1G7=2%Y5"8D1?40I]=9<DU;%2N\,%<CFX,_8'Q&5!0&H/']-G-SXI4$@-C^
M067>5#7:)*."56['546%3K3CKJV1)"PF_N2&@"KC)**T2%S A+.=L@)47]UV
M?43"PJE*8UB"LRY: ^EY0P'JW(Y54[Z"!/?^#SHC(J%H"EY3A@6?H[$'0D\%
M0CRFJ$HXPO9Q"L4#]^/<$]C<!4E@=*_5R9$@" \6/P5-PO^NXR(*1OW(E&.K
MH5C;_9^C.]*S%*S265GE^Q>JBW4ZB2<)?*[!J81!I^\.>UDY\0^OPP3^V)!_
M45 *[U@_UQ[IIF#$'KJ#WS]Z,Z/4CQ4R;_=[>S^=P=R'B7=F1T3/A#[_-%1=
M>O J^(?N5+[A7L.O]H"1FZ:RO&=\/BVH(7>A+7Q4/WC8O'A26-WPD,\X,?4@
M2=8/&4E.H_H7G,N($GAO-D\W=56_ 9476->OFAHSCI5XK1F28?@W&H%A7M_0
M?/B&Y@/^>*/$ .<H$1ANL$]VJP9NL6MP]#"$(1YN#I9(EU2!*WX*567_-A?\
ML,TTCI%>#.3&.(\3?W>+KCAXJ'S>:NR7Q4[_VRSW>IDDCA8+1P4-:Y:3!-$Y
M%;9KA?Y^?RO8DR THA=[F H1: 9M2F>W>I4["20U[ O&19!@NJ$VO"#\G^Y\
M7$&AX(_RZ I4 FX@C&MO^H>31=_-,^\FP"+)7L, X<G?\SN!(;Y'J+E*VH'/
M3\L;NW><]Y)>+TP(NE%<14['O^>XG9?06ZHWG7=J8<;F*Z5O-73RMLJY$OB_
MQ0F<@XEW$99_Q6F@[>4LKSB,S$F"4(J"N\80* PWJ;22+E2?P!H_8>$&:J1K
MS# B/A*T_=4O%?(O\&Q/%8:37::4M;(>9]!#0__[@]W@8(\/\?<O#X+]G9=+
M1M@;SRX#Z6N'UQD[4ZC<O8RB"TDN5SL_5F65ZF&-GY8IT;_H"96B326J:640
M:R=+;)J99ZDKLK?W.=>G9%AU'CRK3_<MYJ,FSAX.WO(89GBS0W H\_>QTN><
M YRGTN?<<ZULN.@!QSXK6S;/RUD%@3>+$QMI[UXX)JQ'+/@(&7L=Q7_@IGT7
MI=&7K,A&@I57%$M3Q8G__=Z^-,AI.+%MUH6<4KO[JH*K,1R6*9FD*PRF#U6[
M-;39\TW_]]+_SU4&]C<ZR)&)Q]!SY+-^MM&_BJ-AW2FGJ[#3:W:3<I#%O&;@
M6&F>+?;4<4\JVY41L3+"PG2$(\,POI4T>&!_??5)P&<-LD&I?PQ[GMVVETG!
MJ*!$PVYQ67K159@,*XI^$SQ!W_#%5UL <T>_T#D$^P<'N@&F@%Y'T>0J0S6A
M*Y75'FY[K@H'S8*3J6,V[X2I'34@<*I7>P='UQWL[@2OM@_8>GBQ$[S8.UC"
ME%_T6'C=L7C08]&R43RS493[MKL;O-C>(;Q3W9321!N6#66UDJ1(V9R(B-\8
M$?'LB$AUOS4;GO<F@;\U]W(I,J_=[0YUHE GVUL=ZF15-W7OI]<5N=00"'FH
MP3P"IP,]M4(&_:"/7P6'YR15Y+8[1&6#A#:VAU-A&:M,UV$C=4W;116B;U4.
MH,PY82FS2<03OI,GI74+<(C3/OX$+L]2NK4AV]#,$N[$F>;3A?OW1!=.PUB,
M+IQ>AI_&]52*K,VN!:@1C^BFRJZA_Y'N,\C#FU0*=B?UJ>JA/:[-(*$[3E-D
M&\FEVGO_!R[H0\@4)MEA-^#7U"D\MKQ70J]R0$XW:%<5XZHZD=[04VMR1859
MS&0![X%#I8I)9=+(CE+%FM12.ILH\A.D+<LC50AC;Z-JP@E?WB'SP+*WP(/[
M8&:-252H6@]+<?%KRP8TE??NS F8*T.?)Z? (3S,H5Y1U!2\Y#'BO_#48*H;
M'C6*RQ$5!49IF$RFFU[#/C8G5@S%PBJ<QPP*1QP'T3 LDPE5XA'3">Y9^MKZ
ME@O?0 CQ1%'AWR#J)U0%BK5'Y:28A-0-V^,=V/;F9"2S]T5-Z67]-8XCF7Y;
MF;@/:6LHNBFJ*QVH.?*=#R(#T*I,,P;CRQ$,BX+CN@I*-[C%65]Q(.$,B)4#
MQ5I\J+=!9K&IV13MS"][:SM;>\'.+G*M[Z_7 5R-VT#>U-BP:.>#>C9'R*+.
M;#U&("L,F)0V!P.4S,-;GC,#1V8/-XF&</'WU9O:EY#H_>ZGC84>[&X,OKLU
M% VLNLU"_";5-\VPN)<O?V@YD"TS]$9K$M)$[L177U;MQ!]:;S<?N+?]PWP7
M<-[\U6[Z:NF;RGJ^Y+#ULB]ZGPM\JY-VFR-5-:KTH5KNV#0OS.)S_>!'I7'Z
MSB(KD-M\"NYI6M;VMA:<E_5'VERMI_TL(B(O*N92UF7= @H'UQ14(P'C&)Q?
M+\7O3I+<2GRL[37OZ86%QATLZ>*[O+Z..[=5QS6';-X,[-QN*?=@^@=9"893
MT^S5-/92]UA4I>\L(_$=K/0W8-+/R,?- )ZT83BT>ZWB U:VP755M=_IYK#V
M=H*]O7T[GU%-*3AYW3P:)LP6$!;UAV]4GGGG\)8NE77'J2P[I#$KB85^9$6H
M(;S S83-VCE-^2COV2$"'CYT_XF6MKB*Q_X'M5A-I.[?/-_.K'&=I$NQ47S.
MKH7U_45@G:-&UO?07VR%**:]U"BJK.,M#?B6CH$OQV;CY*)M3EE&/F"]H40%
M"6 O0"D3Q563MKNEBQ ));W<*"QS;&2F6TDODH)2 G1VX;]"L"J&5[$@[ ;Y
MD76#BVJD>SF6$AOII5;%]/7;;22-/S18+L,8C[*0*C/YCLRVO.RZ3&ZBY%IS
M/EC!/7BX)IGGM[4&H8.X3 M->(*)H0.?9$L-0T]#;;T-L[[A57IA]L"\%5UV
M,JS55Y-:6R'I ME,[G\R=I=(2&B7&H?@FQL;&Q#?5L.;-K6'X"!Y&EUFDYA0
M&,L,@O(MMH2R.::4,,DUTY15]4NQ?\:+74F>Q%P_B HXU\NM"^:7OF#AD23'
M>([=;(JF987SL[WU$OXG>*N]E_M@<^Q5@31HEV;#I8:Q)+B;#!\=8,<TD^VN
M(Q<I@=K#9#EQCD3A6:HJIO 6>@LL;597K*"EQG'AR@-,%5@,8;CQI!V4SAH@
M3:;;%7IG?P68F.Z7<.DQ;+U36."^LI5/,9,\*)'IFYJV.D67%Q:[Q(/:?JO@
M8=,.9GG/27W*!0] @R&ALS_&69RR#,,*Y*9"=*M./<U&X/?(+$>)E!Q3=EE=
MA41Q:80,UZ#$"!O=6+6.XHS"?WY#J[# *E_7E M-]>M23=]8QBYT;5-LW#""
ML8.,&F?*I=8<Q%0N'1.%FL<2;>8]40",QDDV96X)I$0E.400\-P*?W&N.M04
M)^-,1 A_P8\B)<*WEAS]_@\>7'")O<K@CK69M)5AH($*<(=1/!&91.I,F=LV
M\PH9P&6A<^.,P,#4.8I+B5WC2K#AB[^J4!\?ENCJ'E%_N$F$^?C [IS6C_-^
M.4)+I8\[EQ1FQ::NW&'3/R2MQG 1ZC%4N._@-;Q#Z&H P_;B&RZ0*A5(H4L!
MF $=)][5(TR'W,IVX&D%-$)<$#<#Z6EB<V'WA]FKO&(@"]XX2;4Y:KP!SDL>
M(<=NX#D5#KS#I2L( \[I#S)F\3=HE''';P$K8'EH!MHX:!WJ(B-"HG$F*Z:Q
MT&\T&00V']!GUEJ[0((>Q$S<@_V'.S?A?EO$MGES%0DGD?,[ZG:2BIV89D3?
M @^YAJ.,_=U(I/"7S%"*CHSAWF>SNDQ#D&9)S,' JSA7BVZ"U$4X(H").J\-
MFQG$JYP2 L?3V9P4#&CB6CMY+@.0</+HA11+/K4K 1N%!HY+@53/A3 B,:I>
M&9KNHYR-JOU5NWEA9<X>CG%YL2+-A0#".QU 6 .$MSN <#/%YJRZPX'+3K?W
MN.QTGPX_'[X[_G3\^<(_?'MQ?.9?O#_V/QV?O3L^FWLZEQR=>T3U:9Q5+UV9
MJ_T[G*L9HVD/.A[#VFK3\T29GMX;PWD#DO'G:.H?L_45V4Q</>KKI9SDMTYP
MYU.47T9Y5[^^4.CWM-(&BR?/,^V&;/"AU?+NF%A=<>EPB&IE^-=!XRK-:("E
MV?R&\1>,*6 CB>LH]=9>K"N7(& FD[7]=>H0<Y6-](_,;3 (<YER"&#J_WYR
M\JMT(W-<>-7<Y+>,VG_"/WZ'R3F] AT^#OPWV(D$S-9TD,,RO,ZGL S>QW#D
MOX]*O)3^^3[*:7D^@IY'Z.C;*(F_\(9%*W'J_QJF8*WX[[+!,(^F&Z]AJ-)W
MSG2KJK^^.W[VX0(%4/8J80@[YI-B,RL8N'^XZ9^':.$@PQBBBM5DH>.@6AB9
M!^O(X"JPWC[Y=&.3&&(K$9X?7DKP,@I'K8*L'FQ2W$&->Q7\QU.P!^.!ZKMW
M1(7+QU6QB@XWG@;8L&5<A. V7.+;9TD8R$^D%Q 8\^8G*HB -Z;GO\_P:FHT
M2<_FGUY$_:LT2[++J?U;?-QF\["]ZB :GR"$1,:U92><6PR:MH6Z=4-U+@.G
MD15SDW:[_ X&>5&'2H-35U"/H8CX[%AUJ_ 'Q_:Q7Z4N<$#O*KMDWT\M8)Q;
MP6988;P+_;32\0+%&4DS^Z"@-Q7A]3J8Y;40Z;6=/-UV61@\K=ZO?)!_7)5<
M^A/@ZV1+N0%SC,@SNA4\(LUN\G!<\]YZ#=[;3'I-,"/1FW+LO0:T6 M4<.'#
M.!^ 5AMYLY<P]VT.+V_W,GI-=WYX^/?2#]_?K3Z]Z1U/13BL%>O5=VW -M8Q
MC/_KZ.CX^.W;^A9KI(Z=/9PF);6VO3YKAMHV_-?,>L/(;[.!]O968.#S!MEB
MIP0U<Z8!G['T7KEIQKO>8MA5PV4%9OHV6V3_Q0H,?+$M4K-+;R4ICNY24E@V
MZ@I,XVW6?W=G!0:^V/K7G8N6#7 7CVQP_9^P'GBU @.?.^-BES_JJ6X.[CS=
ME=]_!BM_)^MJ!^>>\'(^!6V]$@=Y1NSU"2__[@H,? 5.LPEWK^T\U;4\Z([R
M@H.@;$9JI3.>[J*_>/+J>!5*%"VPP5F91!LVX,"%+\Q)W*L8V3Z&J:P?VU-B
M@4KH9@V($C5.&EP=#U$;8\/$.<.M#]:AV[OCX.\R,^5$B"MAX-D]FUJ6V*OS
M)B!4X&\-? JJ'6:]E)84>GO]NWX8)8$YKQI%?%IH7S=OZFYZU?3N+#:]DB)<
M>()7(X6UJG5XQV'_:JEBA3I%-65-)1W6Q.6U)#)CZ=(:[%I6R&B8HXU:'V _
M,\1%EOU^5!0,HQZ4R901Y5)T^]\2YF\8,\[:_NU2HR"(=Y@G<40910)4" H[
MCT:,F[VXHG:2!*96V'*"7&*^\BH>%X@I%A2M3!KC:)<L-K+RCDU ^[8%V?0/
MD39L6&G750=P+%>?ETUT U";>;<.8JE97P)"F36H)8M]5*4!8K7'# 3_5&PZ
MR(1JDI<74Y?2Q;F58@Z+6^[9QG4A[$ X'B<@<4&&!>:M8< :^!3J]7/!4,^I
M]D<U.;=)21< 8A[, A<BNV/<OT.,82V/5-Q3M_?[;(%!#VB&^2R9+?/<;-F]
M#?;!&X(LK4^;X4=HE>_M!51^0YJ2JAB;:E>X?&HVL(IAAMS >&=K^V"3"HCI
MR5@JE!2JJ<_&,./: X6.\O2%5P15BK#0IT".F8(13U0NGT83.PLR ,F<9..1
M6O1>3E2:V366XV\)=PH\ 83\H-C 6HIT +.'I)9?L$U87$2;_GNL9;B$]P3U
MZO5!SA+&2N O7#+%!)16%X)>F/[)J,7KN-"%.;^!Q9)=QZ'_&KYF'!<8SZ!+
M8#$S^I"*5&!B=@(S,52W0)(;*1I!GC./*^7Z(C-BF *JJ,>Q(!(LC\:@::*2
MBDZ0@[/,(S7N:% *I51!6F#3I_8.^&"\#_S_OC4 +GO?M7[%OGR![7G>XQ4_
ML_H?*)-E6&*528$R"QXW0N,J12MCZO]R_F9'$?5:B\^&4.A_"@NXL57"X;\N
M8;=@2<OA8!2G,;PJ#\'4B%_A]Y'W2PI;+2^DLL0=%I6AY=%E7' I<U'"1I["
M>Z\X>NQ)0-ST(EI5X&2@:7I=MDNJQ7>I94N R8V%AHB?;"2'IOO78&A&PISI
MW]>(+0+/&"&$6^-]2@7YNHD8,QRL  IRU;L4['9%2+H(::<K0EK53=VKH8]:
ML=O?7,5[?69P)^R_"#S7QJMXKFW0=S;FWD:]G!B$=PAZO/UBL^*AL@$)PR,Z
MRY1IX/*83@R5=Z("D:=X#0![766+5B=YP"-LT3A.(CB9Q2#\+\EUG*W?L_Q/
M<,HSD"C'7_I7V$6<ZTK3.((AG5_IV@ZT4?!UR2-^8W<WHV=YYEE889-C^]BR
MA]Z8OIU5M.L?8W F#S]%?7@_>$=_C0?VX_G)QY/UP'^3AY=9.H2''J=1#M:I
M^MY_\_;CAW5Z[J]L+7X*<Z1/4Q=XOWXZ/%O71MK6"UUUCC9T4)WIJIG>O&ZB
MK5/-)*,+=^L51V"_?0HOT^A=6(!2US0!Y@T^?7YW" ,\54SS.,C:N*Y \/C7
M\&I96?AYEO"\ORX'EV"U.]-OFD3[AVF83+F(5R]"'E^#S>U9BUIYTF4>#DK5
MC'K[U<M7;"Z^SHH)C-JR%*5>_C48YJ#LC>$YB-",F&5_4H@'2[Q1T4A#/;B<
MYSDB.W[[U2M8G(+*F(27!D-*GUX?XHW?1V$"#V\S:UUS]CPKX=JW,,1X$-9>
M%\Q;$PV<9)X&^(>MJ]^+^B&VF4#G!T. 6$]-S(E_IME-$@VHG2<\8,!T,<K-
MN437B=X0V6XNRR2$)6.& E@_*C()K+*") H'PLI /0-Y&&(J?OK?X6C\]T.[
M+OLA>W0^N7CWIR6Y>2HE0XV%'(V6.5YI_;CZHZ4&,=-$M^.#MS#-EXOG"AT3
M1?Q+Y!2)!NRV@Z.<8'_[RFO/'+DUE'@Y.D#B4A!>F$D\P8HU1>[VZ^''D\_^
M\;^/CWZY^/#KL7]T\NGT^//YX<6'D\^;XL[X;XF/C-AB!M$DC/$&F+0HJ37N
MTK1O4L.CNR9;+4"K0H;:AZ:1131BZGT<,K]EN0F7\^L"'W0^4IP54>3,)C'5
M6//Y^O#HYW=G)[]\?K/4:$[>6I7H_H:F82P:HOEN^;62K1)DD9G9\/\1__0N
M2^"8+S6.TS 'K51.F-U,+9#:!QQ<?D:1<Y&ZC]/1J[G)<+V,LQUFO:*,J2L8
M+FHHCKV,O-V=:H@9H[[_WXRR615$WMDV(;ZC;.-M)6Y,,48JD=7!8P[_[IOP
MKW%%/(D84Q,M//A@:Z*H 0LT&C&K5T*]SAVRK+"?9P5;VX>GAT<4:<3L%YH_
M' 4&^R[NE6B01NDE,H3E5 X:A:-"V?**<NJPB,.-T["/?I+'=^K"E'=1;RX1
M[FV)<'.(W3-;XX8,YM^B'K$:),@O3HX/AC?APX],Q50/E1\$E3W&-WH+^HJ)
M%?7M JN'W0W<TDI/> [%$>\W#(65O,/@2<IQZB<QFMEF' ?X[2G3;%6'XAZI
M>EK%2M>8(^;5CQAU1+9^WO2S:IJG.I9A!D8*TW(+MY-/;D]T.>67SI)K]C:P
MIOB+-\$[(XH'F8>3! X.L=#YYV%X#C9 .,$6Y#0U2#<[BO\"UU4Y:]@>;P@F
M8B$#N*%Y2.HET*TO(0X2I@>OA&B \D$X OL\BV@(D.BR1&MPF(?P+;Q=F4N?
M<R-(-M QC<RZUJ23I$%>G_?Q.1]2?$7V+<]%!''6J&>&C-Q\VFL\[U]E&>$.
M3O-L&)%-"!-XK#,W^'-C7KTQ&S @O@V3-CG-DJFL@.6+>FLF=$(F'RR84!!+
M*3C.[TUF9"L:+R6Z%N=]#O:P?Z]?S#^V!"(<M\^A\/N"H3O*BM!Z. PQC&_"
M>Q2'3U[(N=M)W#YO,;=OJ82,><B]9V6^\3X.K>8IV,H.X5,[WN3;GJ>/7*<6
MHF0#H?ISF"<(!F$-9*#<CP[,:![]ZN-&B *>YIAL\ *<<X0J>$K)<Q!0A5I!
M-Z+4, 41U+)4+AW8^DB,("0T </+TJ>#<!)N#/(847=PCQNXKQ@2% M&Q1'E
M$MO'+J*@YL^C%"/3[_CJ3T0P1-;=?PX)=P'.![,'D26_,2S3OJ@AMM&1JQ*]
MAI=;AF(+1X!*BQR"C0(,%82/7E([7HII&AT7IS&2K\.("P:R\'QI==\>?N:D
M EE!CJ(T8);0+]/XOR7%<4 0AQJ[JLTGP<FPB)6)ZGL"3!%9B^'XU7 S'CQ5
MV+BI#TL0%+'_>QFE@=H];(+IC,3#RMJG+!U@,M$1V3&(*Q0.>'RM)"!L=N4O
MVULWS:Z-Y=H@)^RS!3(#[)H81OP74^(K&<*(>_$RAI.;D**G^AZ;WGM%C,=>
M?--%?G_:3]A\M3P9='3TL3W\T#3"3?\].1 JPV)<"8/(O8I'F+@AH>83+D!E
M^(P/Z!Q?_XRR)V\<T>+_.[Q&(/<"<D59XR*5Z8WP?4ZOID7<+ZCITZ<0P5MP
M[_X]]D9Z1#.B]509"_;8T*AI$_:>./(?\XR;X[P4:9_.S33EECS=JUWR# V(
M?F1"P]!$#X3!8A1V2Z2,GNN>C1N?.R-A-]LCNY](>^LX'SR\O^P6/V[=7UXU
M)5G)D-G51+.Q%VV\>I4L6E,6UELP21:C<A7T"_4PPE=)2QA$$2;2N^K[7>ZO
M&M@GB/M'@89A2GV:@!%\H+O0]J;-007&?Z]1GG9(WU"6=AVQ.W8*RVZ0T#(/
M=*L:S$$1O^I$'VA,&"V9V:C+>EF*:EE2Q<AYSZ.8SGC(;0<G-3Z@,J.-">Q(
M+RE'L'W+D6\U.C;SJ]*J7%F%2A>3A&  K6UOK<.*3*L]MY0,HZ8%TO2JMN%&
MX93F _9[C'>'F? 0B3&9(BP)IPEVQR6X(B@WK25&Q ?V#HI3[.!HRUG<[# /
M!38I0&#''UG/MZ98-362!X\PF,FQ1Z0UQDT+_Q_ C'MW/^.;_F\R;5<QMB98
MVX69&]1GSN@';&^DRCMN+1[KZ"IJ==:3B:5B/-/OS#3@.I!N&G Y=KJ:5TSH
M=G=!]!,UJ;BF$C2TV=9VU]EZ#G#/29,&8>'D9AMPO"E2:C6FN^.YT#@2U3(*
MA0PBCU1#IP0W7@$.<$+*NHO<+0>NWNO U1I<O=N!JY_FKE_6WL*TDZ6"D,.X
MV/1<=&,XD8:@:(NP[F'USJV()U1ZS+J''%K1L9A2)]65^)3,V_2K!/[<& >>
M.0OO-D<_-*HLZE:%UU"ZD=.^$8<G"*7)6%:5#R/+13HS29.;##OV14E$L$NT
MM[1.2!FQR7H^O '56 @ALTP)CH]M5U\,0.JL0[T"?38%J?L3/ QUA?4S,IW(
M9\,/J>Q<3#G&-'FW5AW?N"I8]E!\D#J]:SD2[I)Y]DHCX'J!A:_9,1B3,H:T
M@BB3G\ =PEBSXT'AWK!KVSOKJD$LPX:]'N'PV)_ 78OT'/C=6KA.1Q*L2+R'
MO;V1;0!W#9U3X3"GW8Z=PJX)X8!FCCJ@TNB)^N^AW<6 1=T(%2U>R^"F'E[\
M-&I41KW$V:"-A39AK;?.)Q^C]A.YF'#P:,R0O=107T\?X<]H;&Y_.FOVO:S?
M+W,RMK&9F R,>Q. #,A#79P_3.B]D0.^5.![,F8KS^4&&*:!)DO*=BH$VUT@
M(UR)#8K&</]4JP&73&GJM- E(U1L6@D[DA&+/T D9!X3C((O6R.!,E7= BVI
MM*XL9*\.)M5&M!%R7+"0Z3U$<5A^KN6ZZ$YMKOQ3MGC]2<ID-00%GFXCRZZN
MJ!SK1]HJ=V="#YHV)?9S+3(9=/1EC(VJQ1Y/0C#'835UES<4IF8 !$"!=_#L
MVY/H'45A4>92YLM\)"C^58/'9J&]J 3XMN)AM\ F=)&PVT?"5 UP6PRLD0Q@
MH1C8G(7TOB+Z=7#KZ%?=2/S*V(8[@6Z0RU\XR-46E+NC()??&.3:K@2YO*\-
M<JFI: AO^0N%M^+"A+>\^PAOW2J@V!8#^IKPEEJ_A:6=W:M,3_2"(:UMW>O>
MV .W#&IY=Q;46GH&C)CPNG#6 SOV^::GN5[NW:6_E>)X&&?>G(74(W3Q8SCS
M[@0MEE?JCL!7N?%?[\-;;$F+>^_I9(K(_=Q?V]ES7/BX>-8NO)JLAW/>U1.?
MC=M>,Q'NP6&O\@=9GK)RU3W+59?+'\A)=VX?>$_:27]X/[3UH;>M'[BW83YI
M/;.DIVZ5JK6XZ\U570OYZ^TK.R^1LI#3OGU[R$K=UKD#I[TRETM[[MZ#P%,>
MSG,W\W%+]]USW/=[0:<L,>'>O:)3=-/4!:1AL[_B3OF#./+>_:!3EIF+IGA&
M!TYY!&_>+-:#N/2WURV/D*1_++_>NZUMU9V(QW?NG0/U=1Z^*EU_; _?0\5_
M?QZ^33#P@&Z^>>QS\O4;3(G[<?AK1>KS$O3V;[K\_"W9E>[#<5X.XKK?05PU
MQ'6O@[@NL57I'Z9IQHL';9KQ.4LW%-&"87U[@JTBZ $-K9N_@<X7#6_-U,=[
MKP*/B^<C(0?;:20'(P6/)$+@#9>IQ)9@8&!\8\4RQUP^7$A/A8)# EBR&Z67
MF'&!G\/@_XQ(V<-ML:V#1.LTPZKG4""@UJ.!DJM"_+E_1E.K;AAOJ6B08VJ
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M)[!V/"DG"BY,/0]!@J<(0 -KD72 >B)(.;EO3,3Z:H0P, J4;]++>2B$.')
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MJ&1V9Q0(KTI8HB) 7CV, -&>A8%G]:-.B+P.)1(96QU1Y;@2-0"=1JV;0'Z
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M1AP",HBA2@&<:2SP9DPO(2=2GHOC,N6)8<$($L&6#,M$>88P<'P;IZUBC,T
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M-!0)2]%Y*U/8=R .-OWWJC,\+;E8-E*L3-/(##)QM4%'Y:V03D?O4P4@% .
ME@ICJWI!>=<01;9:/1(%8HUIV1:ID#'6$@_PYWH9DIB[ F6U^=49+FY9*KWK
M"S4U.,*)]*U!!4!CX=AR43E[<'-I0<L!=@3!44=5V,IE3EG_S&XY')HFML))
M4Q-O5M-@TQ]8VESJ#>Q.+,Z^OI,ZH'+DU/%JVF:+/I9'7COJ 4\,F(9P'A"O
M"@>2P&<(&"QS#)KFJ")-OV/<^$P[KDX[3@@N5$SX'FX:C-E)^=H*7\H!%#W7
MFSK?Q:EL&/E8"1^:&]7W&,&QFIR!?F?U4@ZQ>TI((,NK9Z-#/C3C3TS?(P=
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MO&O+*]RFYPR95=6^9EB2;>@$6!GBIK!N(;.ABK*C@8%N3@S;0&#Q4%8N9)I
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M!BI=8_'E*DG);-3@O^H\LS43H\\N?HIS77*N]:K9+M?-ULIUC#L[URVJ/R_
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M+"VHVMHJBG,_QI1:T."<7L]QT(RSW9"#G39WVF$AZY.R'@YGW>J_(FZXBY,
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M MD9C&W7#D+DTGN^MS-MT.CZ4FMU-.X2ECHJHYCYM8<CW1&+WO" D]<*>70
M=H#C33#&M-:)/K<*W2A7P"C8%DT\]V[*9KE9,]NU_=#5ZJ)B*I5E!W:"2%'S
MU-U/@$S3X;H)-@M5[2VE*6UZ^JNIZR?EIEEJU\U&>X;"GY)E]/HE8[2&[2C!
MZ)Y1#;: T5Q)^;5MHI6S9+./:(6O[TSASC7H>5+G5J+F2ZJX>R/J[]C0]\9*
M,GONC#0^0B%1-ENELMELSXB(O3F"#@)-)^4ZV%F-\D98.@J)63@=\B'5,KQ(
M5$^, LQD+@\+%]+AN9 ^4OJC=C#0.>[:L*^VJF9]5ME^!A=#I54W*\T9V7J@
M/J-+]YX'-.R&>'+7R&O-1&:?XP2K]4-V#PD)*IHOK,Q[S^Q *;>K9K6Z M.L
M+H>?>T>5IMEHKA @WO_5O#>G$!(B :&O\Y?LOVB#SEV;"=\6[J!-39BFV:K,
M\%?A"\JS0^6 0<^3FK:!+TB4B$BM@(763TSMN;<#VW-?@,.C;#;*F/NWF<?C
MY?B%JJ6666ZUC\8OE.0$(OI#BI!6&R6SU9@YC$.-D);;9K5^F*D4*]'_%0^E
M>)4R=P<"8^W"YC5.</VZY3(@MV366S-![^>5JOE"TDD-#,'Z;&+ @<O4+SP(
MWJ)%EZ;YF;YQ;KI)%8&1:%2U4T=.O68VVBNX<O;BVSVIE)MFM7&(&>/JM*U^
MW^<82A3U!P,^GM!/U)4:/YL>G+1CE%8:-;/:WJK3Z"G05-MFH[%"WF+.O??B
MK'$P%C8[MN]M^,J P;I<5%&.O8$]! CIZ#$##=X ZT5V,$(W\0'H(J='Y&9L
MFZ5JW6RWUA1S^1$NFVI7,S<-EN03()\ V@G[#"_"S.4O]AC89"#[$06I9FI/
M4SYV7O/1KH+-NH6"C]QN\*1MUEK8WF:S/>9%.UH)V.OE?;)W>CV]Z$#W[N.D
M'ST?",!E_0CT'[?_R$+?<@-'W)+]D>7>B5@<JDFN[4A91E"$UL_#<$A42H"\
M(\G8;C;-<FV/T;D=*6N)0-M394M!78=+7<^BD@G:2U/=BW. 54MFM;*9P_RE
M.,"JF&S:7MX7)L\JW@;4GR]76-5LY<D5UL!J]@-TA6V'$A:;JIDFZHZ. NO6
ML,QUA;2[_9!&&2MN9^W!PY ,11KZL>@[K]Y]H?8GV&LP-8\QAXC,%3"YXD<!
MWBE[;P5V7U1+VTX$(G;'B-NJ@_DITK36/#O([@4Y)O!< ?/LW)8A./]-/^&8
M68 %&P3+3JU1 )_9+@/@^C@[$#4>1PI9 J*0KP=V:^9!U,H)QSDYT8V@R6ZM
MOZM.QBMV+3ZNAOOYZPK]#*"LUZ:_42K:].LV_;6B3?].F"$Q"&.JCW^UZ..O
M^OB??^Y<?;KHLLNKS E+8@#3FQ,Y9:EHYK^M*[!HW+_BT+DL76J7_?ROE4>F
MF\HRG-[\6D5PV]_X#MK3)^>NZS&0+W'S*P>\CQ\M(OJ ]YB<:9&**<C/5&1!
M_)B,+\A;A(%*8X>/;TXD66VGLO0@$+A@C/)+00'1D"25_1''"YR<<44:SYIY
MI_L$\,A&>Q3 %<#M&[C=>FCGR#AI252;OV0*_4R!^>K=>\NA1DU6@$:8GH3%
M*J7*3+U:8D+*>BE*B[ZX>C*2?$MC^5L6NV*W"LT!(:/ A<:%V6HUS7IEIF[L
M9:+CI-$V:^69U+!UH9G1"0\-#T 6('3+I9G4HY=)%N42SOI:-"?K!2&C8K9K
M9;-6W:H$W4'L?L4X[5Q] (OL]M#E+R_I,7F!XZ12+N'\@)43=?*#D37U\-5T
M[RT4%L[!Z'I7V>Z.>[U. /E%\S/WMMC87%I9(IY;$QO]J[;[-^^'B699>6'
M HY\PI%3CIW9QP8K[@C%Y6K-+,U:90>*Z#F[.08M\3RKQ-D:_!V)/M%YX\0"
MCKW T6R8S75+7G/+O=F;R8^LK*V?\9I73&=62N]53.Y>B_RPRV9*1R [\@+'
MR1K=E I3?.4>/W-PF@MCO$#SCJMIUY:=JTPGH&PPU8O0Q5H @A/S-;$O(1]3
MZN9T.T(LO9YN6SB-K34R<N0W\M;,;A==U L$Y!@!)W,Z3ZZ,A]7RN?*,@FW3
MP--2]5;>R;:;LVS2\GT]XMDL%ES04T%/SSN796,;;]63VR3':J8R_^60R9SL
MK*=0R4OGO.P<KP*C3Y!E#;/>;IG5THQ-M=7;\>4@M&E6JS-"KZ#0IU%HLV2V
MFS,A^()"-Q6BU>96E9>"1,TZ3HF9[3Z8SU%]3_7UQXWJ\^:Y/'(XRF:Y7<?<
M[IS <RR>Y;EXS4\X=+-!/[G%][:F:N4[*%JDD11P9*@+Y;996ZL-?$[9>,Y&
M<A'T/&FMDC^2>PQG3PPX-/VQB'<6X;X" 6O%.[/G_A7QSB(^M<*EL1;Q%/'.
M@IZ>BY[R&N^L;!KO7*4<+W.Q]<DD7R-P5HQV5O;A5CX2A!;XW"8^3^IFH]$P
M6Z69259/P>DF<:3C0&>Y8I8K6Z7/EXM+(,UZRVS/#EDKT+D!.IN@$RR/%A>2
M<PWRK+=J0*)+@\8;D.=^)P-(" ZDF_TQ#PW([I"^F][CNSK2[-76G$%0+F80
MZ!D$]6(&P1-)>FK$0*T8,:!'#'2ZG]G'+]?_[A;3 W9X3183!5:)'^YR=,!'
M23R/'$B*<0!\(/M>:T_5>E"O[*4[A"[66T/S2LZ^?,._/*[\/'20 48LO=G'
MF^NO[/K;Q4WG%B^:SOGMY9^7MY<7W;?;P_**."S:.N]L\)Z4\JW*+UG&(V:@
M3GQO:(=R_O3T3G77RH7&=Z*WY:HV=:*QYCJ);9NOM.\MS&MXMW"A8E+UL@?W
MF%^V"3!Y8GV24O3-MPP[$Z*E. M]1Z=1RB2@ON?V;= ]W6G9@+_&#_M6,,+?
M8(>: >L]OCF1\UI?,V_"?3&NU>J']KT=VCQXF\-CRA4PN>)V =[)#0<8 LMY
M_88..J!LLB'K^WQ@B\:_?->M?T_J[899F0TS[3\'LMFLF)59+?5P),$LI!_X
M!#C=CIM)66,/H/O'VD/CTJI9;M7-=F.%D]T+SV( KFF6RAO.XLT1VW82AXCL
M&HMCAUL!%QL^]8:G(+"9!3R\Z]3Y6JEB-IIY&;E<*[?AF-<DN[SSL4SC#:V?
MS+&MGNW0I;MK%JZ703N?F7_P3.=:AG.MKE((D'/VO73ON5#%Q+1[VT4F]5!,
M[[I"L+7F[;8[85Q=LS@KW_QYCKIR0.5+V,>1\NI9?V2Y=YR2WFP7?DE)<#17
M$+3F7;,N)4BLW3IY9R4\=;A]:RN DQ?+>#6CZER>,'!PPB3""S<@;2LAJ0OS
MZ* 9O-/OPX)PK*!.<_L>HS:[YID&7+VPG568>.?586VS76J:C<KJ75"?G8-G
M(?L(8M?SD47C0]RU&"Y7 6VEO-RZU5+;;+;6O!7RS9C??#ZQ;.R2/.%NP(7<
ME<.@Z3X.]V(!G33:L,ORC!OX&7BU;%9;)3#'5O>HY)!7M;R=6(][$+;E<MVL
M-?+"IB?M\NJ3G_+-GMIP]?D]=Z.=R]N*V:Q4S49[32MQ=[X(LUEMF+7J'KT1
MN^-(/^(+!>W^'!-M..16/2_F3;-4-QOE-=TD^>;;+^1(W-^!GE0Q"M!:IP?!
MKB"IE9MF<[9=Z2'=GI?4;8J<A?NY/]MP=GD1N6OV+<DY'WI@K@3<O[?[',]R
M#WUP0']<)1JW'\E:77-^4 Z9L3,6FNP@XFSH>V-0A1RJ-L!"A!4EZS,7@]?,
M=ANS7+:J(#_SGBIFHUHSZ]453+:\BHN5"H>NUD_EF,9(SKK\8.LYT/%G1<,V
M5W[>+9[4&F6P9#8;%IA'O:3(+CMF&3.=;GQY]>=%=RK=.(=XSA4PN6)7Z5N-
M_/X([4"*8(:6>T?]Q?;B3VV9[1HZ3M;I^[>[Z$>I"EIQ;77K-$\<O/A<02L
M#2!\%*,&_Q/9DQ?4:O.DUJR8[>8*GIL\WJE93#J=9O!2#K)=K9CETGZ<-OL(
M:GE]S@>!L!?CO)*-C_BY;2T0G[7M1D'SUAXMYY?[>J:BM [A_YBI=E#&(2@.
MS7+=+,TVA]E2%YAGWEZY!$H1*$8KC8HZ./%7F(E')U22MN'US5?V\?*J<W5>
MV(:'ZA!8IJW =>I[#_"^78<,&V:K6C/+JT3J]A.K,*NM&@CF/28V;X&+7[V[
MX3*N1)G*>SL^;)-5!<NZO7JJRRYA*95:9K5]-!9^BB7[U@1SF(7%8/<BJANB
MW[B>>TJ?>HZ#:AXVR?)!Y=OUX>?%;BQ7JV:[MJ8$>?9[=]EYC_D__UBN[7)R
MZ(2/!V!/E<UVNV;6MQMX?OZH:;-NEEM[#&'G)L*H6ND=DNE8-2NM]E;&+.5V
MBTVSU@*2G"W5W.LDJ2*Z6!@3:\B7B^&0]ZEE)_\I:NJ8;X6ZOF[7NF&K:9:K
M.2C"J;0!YZ4]IJL\/YL^\P7^&[:22DG(P/Z'BXY\M%"ETFK!4OC8NR-27':X
M[SP)GSF:C) PMBMT&@R+TC]0E;ZW'+23=\SHU6;9+#7RTDWAI&J6RS6S.=LB
M/+]1TM4<DW2\(>OQ.]MU45,53:'9A/NV-WB:)G<0DVK:;<RR>+XTNH- 4@W(
MOVHV9V<WY&SXZ@XYA&.ESXYY(U\]_,MFM8D#97+&&_E"TK;$Q[-?%X4I^5),
MR6XTF3@TU\%RV, .^HX71#[E3I&2-W2\!U#]AIX_INY:1=>.0[(O!7B7,H;!
ML"_ KFUR;._0SDNU5*6$6:I'U5@I5<FX\^/,2UCJT+++B@OT15Z@07_$!Y%#
MUR=%DND*S0C\%-?H(7&P "\Q7GXX$U%>-$=^5Y=;]E3=Y[IJJVVSL6[J49ZX
M?1;2#QSX>@!:,<9PP>*/*.5\[ WL(8"H.PC#]V"5R Y&+ZA0)'/>%0Y66G5$
M#[9(*%7K9KM5%^.Q#EPZ?)T6"**EFHC]HZ-H8,,GH><S()L>'UG.4+F0SL6
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M@5(_89\]!RF*?;''8-T-SM@)DOY__U>K4BG]*I5I^JG\ZVO3"$?PI;L1L\.
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M';U9N;/U%I39M4'H)!!,%_*J_P-< XOV)7HQTX-3GD?R+K&GZ4+TRQ-GE+Y
M1$^*E!6Z%CAC'HZ\@399$TWEIM0"DOG)9K5IJ0ZWV- .E<BGX--:<*1[<<PB
M )86LU?4G1=XP_ !6,$DTY8RH:AW2XA_G_+!'8<OP*G*8?0VW.'KP ,W[(#C
MSD6VI .$00WXM.<M BDMV MNLDBF.,61U,\W>!N*SG3)#GZ QK7@>/#\']CO
M0:0\WF-W$C(,3'9^\U7<[E9H)5<0OQ>,["(.8IB#P*9<1-$@8ATP!H@)=$<
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M2TTVJGG4/;>T=TOZ4W ,AZK3$[\4"QTM]V?S0)+R9?89>FRPW":F5ZZ-/0I
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MG:D^8,GG\#7#"..-N)"0WTD!&HC8D<Q94+]-(E0FS='QVX&1IAIZ_X@[>+T
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MFR+0"0&'KFAW/[U/F0RDNHP!GO%.P.O43K0CTF[JE" RI"!B6A"9L20BMVV
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M,P?-1$Q"+X,&<:<Q,4 )\$$'361H_*E'@6J-4FY&CWT:F#'C66P,]NBI8_\
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M=%HIO:;W?>!$YC2&"G_^S <H,4[/M4L/Q,!%.AWB^@$^^D^$=[<&@+7*]?6
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MLK!Z;OKPR0D]K9C0^R"%S LY++$I_C!_/$>.,#1#@2*E298+JR%=6$S)J;K
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MK!/''4P"5*322A9Q7/18R"?B]#UXVX(1EDBU$T<_0X<(JCGPJU!S!.<.6T#
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MFK:P8\.-B$-8(V7(X513.<$4(14>D^$^AY8W@"<1&C$>-%)W"T?]5V#AS-6
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MO:@L&[$O;5/V=?O0_Z1D%OJL@=1:24C= J0:.@$8WGO Z3467YV. V9VQS
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M+.*JHA^GI)RC#-(JZ,:1%+@C5PX&?M>TL<NS]+JLVSHJ@W\-+(@= +2)!2?
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MR2<IS,H>>=*J1YXL'7G2O_^H?/AT^]_W%6*3]5B3BHPU*<6)MM&HDA7*2$@
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M^$Y/&09NJ)5'=KJT/A(F1Z+C9@2I1Y,,:-+4P<:)80,?C2T/*QN!B&@EX&C
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M'WMOWYTVLNP+_Z]/H>NSYUSG/FV/)-XSL[T6<4CB,X[Q-L[,F?O/73(TMLZ
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M,.$ZQD4[PT@_F/-,[>,N1T$_NZN*>(8I76$) D6KR[0*"?]F_B5K5B<TNC"
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M*90MO4K0J=WONU-S%(?6GI@OA*N]6TC$. '* &@9 #V,^%\9 "T#H&4 M R
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M&QL]/HW\V_(KEZ#%K,L*"5_/UFN<\?UO!NU'8T:KR2J5E7"C)8)2>E J33/
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MA"78"XP0PSBO5BF70H\[AVVJ_S4=O9"]H8M[]@26-W?I*B6^1'+AG)\QF8Q
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M/"M?;!V')>"C'4*O"/27ML#2E7T1)>IA6(\?@L(@T 9%H+CI4N+6@6^V>]_
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M^LTVIV#G\\%"VW=AJ@07PUZ7TM^)J64).[FTEFRWL^9.#9U56J\5+"Z^9^$
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M1-Y3N#3A2<#]@JW6!+(GWB>%FT"IQ%438>"K:.^3K<_M)UP=1=#@*6I3/D8
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M2GX!LKW$>5*J365)&,#\B]O"__W^Y"#$*^[G>UB[PU#FQ-8C15CRM:";P*3
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MW IJ]7\)P_6T2[!TA]J%& B\C0=UJ6OU:KU)@4'PE\8!SD$@[448U-S7R<*
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M\<!X8#PP'A@/!5@&Q@/C@?' >& \,!X8#XP'QL/"?I2#S'"'<_+H: /'=<7
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M5&*,GO+1^>S@G+E>NG-FIO1A27XO22YPB"/C@?' >& \,!X8#XP'Q@/C@?'
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MG_EO6);?2Y8+' _(>& \,!X8#XP'Q@/C@?' >& \,!X8#XP'Q@/C@?' >"C
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M5C3BED^,RBF[&FS1'M)%8N0\24'E%8Z-9ZX-,[>IR;C/G6.AL=4W+,N!J9[
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M!M7X!VMU1-O,-]OXLU7L94>Q8>'ZR*59M9(K)R"E.[3B5\?Q40?C_5E[?)O
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M^*S)HY')T\=I'&"DZFB*9X?T33&"]?+)-$S[5D5]2X?U,&U$*K2!]9W,.:S
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MA/'>"J)86J&57RLT62N41RLTDEHA$H5 >*3MK**F9^[]9/F(,!+->;43I^>
MPU<2S<1%:* VM(F!*V%.Z #]E6Z'P!ZN$,^A.0@N,$AGQ'?W-TV>W*MKPCZR
M T2[?3)3]0,+<#N_ .\PLN7Q>?8*)36D,=PG*K%](KCF_,\46@4_"OVC6(9R
M=&9 )UH:.(C:HS,Q!^@>ZIIR&]//$G3E2L8#SU6Y+Q7/50ENQ@'],A$J0P;!
M@MM:@#?,E6F]!1>LT CTRGL&L9(783;=&F63X/U<E.X:OIW\\&WO.^CDESZ>
M$IT1B"NSUI/R0^AR/RX)H#JC3 I4<29>@9OR6#5YYD3+?0[[F*%N5=,B0%P1
M_U1EU:=4,'2VUF8[;L.?,O P0V-A(CV993(M)-3M'QGRW?R0[^P=\N;I1;B<
MH=(F.AXU:Q<IJTV)AJ!@S3E44=7% '!I$%-+D>]H_4;X47=(3D..(S7GPUO[
M/I 0RG_]%C.-R&*"7SN@VF$LE!"+/]_@:'[7/4I>L;?D1BR-]+[ ="QEX-&F
M5U')6&\R]")EW1;H@GAVT&S0B387=/)YG@2M;!$_>T'4JJNM'/JCEU_U=+?G
M[2G?#1;!,B:>^*P%?\ODXU4T;8F;)SW&(W6KOHPD,LDJNIQ.<HZD$$,A$@V$
MWX.Q(+HIUB;0IBNB*=*OP^,A7W$,:<J1DY?@GZ03V%A*B9=]&.0]99GA-'&:
M)^8-9N7T2Y#3LT#1&!0Y]4_#)O(]J4$:P9!2YSEEF-(-_]NRF7#-IV=TU6-1
M'L>>&!R;WX^?S>%0P"/RO\>84G/<P-O18W71O*39N>*[&\VCXJ^=':J2C6[W
MA[33AVN\Y,+TH837E3[9OF2K##)+PN@V$QSXB,_J-^--IP(]\I M("*G.$)*
M(:0T-&]V7@(1_B%=/F:?6E'%>/Z5WLPKP9(N#8-K=G,F7:MI#17F[2C2_Z'J
M/XM-Z*/SAYK.:S6;?\!D7L%\W>-T9<O7!M>F7FOHM<Y\@-S"Z5XUD;N1[$72
ML%#9_(K.#)W0)J.15^-V=N1K*.5<BG@9%M=K24'TT_8Q.F=@GH7);;>C (C9
M,(?TO]VNWN@T5V(N=>;3)N_'K2O#C#O)K#6:<R]9;2%DTSZ]_"L[KV[ MSZ7
MN=79%A8LMWI3[_3:*]>U2 ID-SN:.WBFS>R?4UM(+R5E)]L+1EK54NU08!<U
M.SV]V>[N$54+#*7Y#X++-9_'&Z5<3PQS>(S98"HCG&@;HNC^'>-BQ;:0!QB!
M\I@=MW<[>A1C9.!WWQZ=.X%5IT"/2.[^3 L/O3FMZXW6ZDUB)[L!&R+O8(AL
M@KC-#1&L70U&B-YHMXILB"SJ0ETN?CXSI;EJ@/5\T&H"')#EQ!)IDS/G,:_5
M1K;=+0?IU=8LH%8=3-MZ1V\UUT=4?1&BTO:PY=SSA3[FW#PXO9K_;'$[(>C[
MN,D#*"VZS)/3O=[U72(S<$'[JV_P,*8J^RV>KH%=2.]YT_Z?%/SAQ/L1ITM!
M&TD-*)'.O*)3 _AF<!N(*=H3BLZDL@X4AX:D.Q1@+5EW9#1V/"%5\N1 %U]=
MT_>%#8KHU4[V$Y92T ;^1F.1J:=B>)A7B+7:!HD#.V/(6.,2,2HF5PD!<:*A
MZ,0IFS"C?DH<80B@,)E891B/%5D69KI;47&Z"&")^"',/A"8_N3%XO@IM"-,
M2*FD9B5\<> _83K"U=G#ES ?(0H]:;2KR?SA.%G 4,)4A4.%IN6B?E<6V 8G
MVC?IER C5>#%8"/DQ\:G!WR:-Y+L.)E0V+=A1&<0LAC)3HGO R&&,EVCDMKG
MM/Y*FJW,CTNZ6TM>6T0)VTFR+B1B AMD6$DN/%CJ[A.UO()RL;[!61IM ]?A
M1\_IFQEM5RQX7*OIU49C+4Y%+>)4E+%/KX87:$S"J(R)5;4D9&;X$-82ZTY)
MRS(@[J@XJV*58L0:,(\Q/C5)&S:>N (TJ4?FJN.MX&?8"^E42G)6$7.Q.YR+
M'>5BUS@7>]_@_K@IV?M0%\M38O.F;%<6IFQK>TC9WG_^>Z[$X\I,XK&V(/$X
M.9/%P>MV,]X;.3/>Z[L(4*IMDA&]=Q8Z6#=YE%Z9=V'!B+L$3P$FZ8OI8/4#
ML'5/=.VK/XP%3TI#&KE<5W 2S;CK$2-8&%L?\)M5 EHWUR?28$J7(L,R<OSQ
MP""@NO8=764N8]>%"!OTA*M8VR..YA@)/+[SIV/"2)$G#+G#)K)LI*(PQ>H5
MDIJ:KMP\26DZ'I,9$".2CDX2PER2,!1?4\%.*F?E1(NL]!AI;X:YKX1SG\4J
M;Y YOLKCV.".=Q./ VF46DV]W>G->1P!G[.D)29_0'D+,9<JBU>B>0 948E@
M06_BI(RF6-DN.&Q)*R30*!S!V[LP.]0V2&ZO[9!(;BN*+):>D#C+29!VZ53U
MG![-3.&Y4/=5<ND^+:'[-E<MZ;.Q=/SKA4IG432-#6[GTHNT9]0TK:/3>JNG
MMU(T398J&(T-KH VZG?[Z+2GUWIMO=VMS_4\6<0"ZS+C\4M4_B=^"(.[G;PQ
M7KC3',]7+U[O0*:RX8%,T>Z5<NO 1F'Y;<X>SBO=>NNX5@V3#=,HC=0IL2XY
M*CV91$O$[X[VXEA@7\O<P,&S@X2HJ,GD[(17+%%6X8(,J^3=SJ?X/0_IMQ]C
M1[/QGQ,K;U]H0E5(DK="46KE<?_M./J7O":2EJ.GF:XK7IR!3+Z?VA:6ES T
M&]:#6J,"9,1C.QA,7=2CH[FH"MD':"OX/BK)1 >PY;!0PA/,A1J[-#>E3C7\
MV N*/;_2CW$<PPR"TK6ID@*2[1H@V%CV@\Z>_%AZ,]&$)(Z?AR:5_I4=Q*4Q
M)A/K;<% \-=8BP&V#;PTP"326)9J42Z@LJ=/8;VA,WN(_T&]"V/%<>1E)<O4
M6IR1K%G=3E[RLH,![ TABOX2ZU>!:=N7+>#2F@>#9S&<6N)VE+X4BQ+(<"5Z
M*WW\-<$2N/=K8VQG!O'9HMIG:(_I:6GKE7B5&@^)19Z$\^0:$S =T#@UM%>J
MHA/2>KTSG]=:E\]K+D0CW_IMD:YK'\ECJZ]@SO&\S'W[O$%H8)@XUMXP<6SM
MH+*4-+!BC:"18P2[C3)54&O54]-NOMETE/;@RTH@6\^/F@O8VR0UJE7/[Y>E
MJX$S_US%%9#1G\U+ZV!<<;?9U%OU>2\M=])3P=/2DG.?K3(D!?U33<B0BSTC
MY7JK"YYP[V1U'LC26?BAZ(!N%@/08#O5NU6]UNM\&#@WWQ7.[2K N7NRH;;X
MX=TBP]4F=?X,;GWI4PA6 &&#,\KMB6 ;RQ[7]$YWM01F3B38V$@JW_+M7([!
M.ZB>;#'K=&Z'.K3EV> D?8O2U3@Z;>GUZGRD(PM7]M7;N7 U00>>K$[27%>X
M]IW$IQ*A'AV?RA][SX>:.54(46^1<]9JZXWJ_.7?5E*HWGGAUI#VK:W>SD6]
M#:)>K9ZLY@S)O$(K=]*22E4A/,0V'GET6WJSNL45.WR9>E\?L[LKF<J6,YJX
M@MK/?4&>\_Z=7=X?G5XY+I8_G#B>#$:<*R&;#*>@NYH1WL(DLZ$&JN"BA]?S
MVC/@SGK3+!/&-DQP#!-O"-6NG;J**=%_=H70QC"J9UF.0GB>S#X,RC(.):^E
M8XLWE1)5,61(+=W^]P59+!1%HF8R>?W\; PI8F_FH;3PNNBN:D&1Q$+>,&/9
M>MN7<2[WIO?7N2N&((+PM^SWRHO;2-QA=G<9%=P_E5_5\+.T$M]L%;V! 1KO
M?9N\WLU?ED4([VNSK5@!JH K&:J,<0UDY(A&@1Y1OB3)%<:I"- B9B#D?<.6
M2Y@D&S?]*;V+SRB&$"H2+HM1^)I/@\. &ID]J8T$UG&U+ JAP13L"H56>QFR
M%C>S2JXNKL^OY2?/B,0\FQ6"Y]2MJEY-L4*26DD&6B)S+-+Y2MR[B/L^J=,
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M+NR4VJTK"VG+2+Q5KQ9?TA0X"1M9!0UW\$Q9(>#^.A18IX K@;*&V*UL*R&
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M3_1+/F9RC:OF>"E2.!Z,YOD0'I\?[81-J(#UHHX*43 81N@FQ%M) H'1V(O
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M9?*Q"CNF#L6ER ^B<G*,@VUP[!IQ./HY"$=RP6#CT 00,A5LG"<'KX,GI[/
MF4!<I4V#?/4=-DH^(36#G F_[WK(>F70VEL9=%P&;;V501],JIM,;C^RVNB!
M*(BW@NEA+*?$8TI3<0"RF)^5J5U&7E68WMQCTEK[7#TFS(5]KJ_>=]8@&*=N
M4UX7,ZVTTY&%[]\IEI+?\4&>D]%[;I:A%<LL)K+MP'[<,A\-7 ,?WI5, (>I
MI=B>DA)V+&QX#?:B[;M+S)["^A_!*%P]V93#35KN]@..&0YBV8B>[/Q<.ZO
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M>?#RK@>OL_@ZL#%8.ZGX>E1$PT_\QI/L]7K)]$ 4>Z' ?/C5Y<N9?)7VZMU
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M$%+H-8P<RK=;?P8&G2-?//H."WKA(L)6>/X<Z??KVXMX$0\,*0]<=U@?CT0
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M*J9!K]PL/F$M*= UN/%33!;3*2:+&4PFDV8325L4G>UKBU8>J$71C-%DR?M
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MW,AIDPPNWZN?N$)80*@WQ41R?'(^42S54*QQ"9R!U-M.PM5&:<NXX$UL ZI
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M CC>N.R$,-P_^4Z @!6WCH]U3O:C<[,@%(M;4"S./=P=CXX?J>I3-:&KUP1
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MSRSZY=IH2KIEY+QN&:GY:**J<Y?3,%/T%4F@9Z;"$]AOV\Q04 &X)<T])DF
M3DT]ID-&@?7QJ&>/J3.(J18>TWA<VV.2TN4H(CL]-,B@/E8/[3%U#?G4O0T[
MUAI[3%(3&U9K XO3OPT[U@_O,4D-I<UH$6K:E[09(AY3=V@5:9(,3]K,SCPF
MJ;[')/?@,4FU/2;QN:Y&BV#CON3;ZM.5JC:ZJH$(NG"EI":N5#$BP9LKU8DK
M)08\\.9*]<W*?#P!>1=/H#2#W"FD@':8X:WZ>')R/C4439_V BG0^750'U)
M'T]/S@VSLOFTH&N\'TB!\@J'XS]?Y1@!\@Y&@+2/<:Q5B $[<!+2P1$#Y"1B
M@-08,:!-?5GKWF]='9V<@W=???P:NP]:"UBRSGJ_=77<AT\J31N !F2LQ^:X
M 4:+A'H'LJ,VE!WAU+#1OO6Y"]G1>HUGQ- !N[\I0 ^04N@!\A[0 XPA#335
M52SB&)\9V1;F!N@!QI!FF>HJ-3J>6=W-:C6,0>W/1/0 *\NYWQ2)H0?(C= #
MC"%-,]55JUOT *-%OJ.'W4T.B1ZP'_NX#A9 \> S:7]8 '()%L#;N+/2<6>]
M8P$<8<N_<?"\HTI-'!/%TK. W'L8;I9V27,1 *2&D8,W$( L"( V>@,!B$$
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MC8;\_@P5S$8M*WK\S$0Z^3N*UIC*HF_^2?F9:,D/MU9B%@EJ%SQCE2,)D X
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M\\3FL]C$*J3I'IVEZ VDRU3Q?3L+IZK%:)(.7X$BLVGXBCP2($I%)[K#'@I
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M?VL31L.U9:'VGM[]:.'NMP?[Z-C@@(&1KHW'&^K;W>>#SG!L^OOCV(RQ""*
M>BSKV#3M9+=Q<0W>F4<S1K2O3MI<O'T[_8^@P-=V9\94+/,^%/@^B/E>>#)C
M''ZGET$=6X<EI".3 <6QZ]D5\79BW@-<T!]:/ )E^_W2Q$2R35,UQ J5V4I#
MVFAN'_P_[RCU#M-%JDT7V5$[RB:'CL@^S7I6VL"MOK>I([%^R;V<.]+;)<[J
MVM[RN%LV=OP>)H[T=N<193N^53RB7NF8UB[FC13D#:X\;_D.<%D+>&X#X=.M
MX"^/^V!Q][3AL+AV>N-II3T^\9JUC%<%^;F*IAD<G?5&M>*R;@& _28?!V:W
MPQ!&@_VT&(; "5VM76+&U2IEG#LB^WLP D9'9\-^J]\@0/;8U;Z;<Q[NZ\5+
M+;ACK:\7![J;*6'#]W<!CMLT';NE)V>P;T_*<FZZ"\/&Z!.;JL?_^V3#IU\
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M))]1=VY/+P5-[AW\U?J7]OCH;-36VNUZD2+>NYP6'T-]XMMI9_2WK">]X4+
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M.!%NNYDAOWUZHV$S!OK@Z1R'8YMW&U"X#P]P4G@JG=01*!2X$<)&J4$E",R
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MH^-,7TW+4O*_Y.- B9?"?67#8J)["S85W*&I"%%I]Z&OF (T1B[H<E/8\B6
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M<G!+^*2Y\%0;U:*E/BP]^*CGA;*Z+?4^>(=BXD<7JM"+UIMJJ',#T\ +1Z/
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M3265K;?CJE8^.E"Y7+DZMB7$"QN"%M2,3EA*''%0X&9Q8#$_/J$P&HVQ47#
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MO)H*[@[,:;D,7]M2,@0WY-S"5\*.4@""9W$#G[_%H%2D;W\A0C#1(:0YJ(1
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MD.'4*0VJ$%D1^!ZI0O%FC:X8KOM0\*-1-B4T<FJVY,.M:.R0 #"*A?3\%\D
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MK+U%6R'B&NL:D:U/%*6'#I2GJ$HE,5P3$:,T#D"ZHM8C^\)W'% =3?CDX@$
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MB$3FK37/2]@3PHE-L>4MKMFHV8)E8;Q6U8/.WE&1U47*V-"BJCVWWJ]&RE(
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M,.'$3/BP>_1 _?#,X$?+G&H.Y@$'$WQM6!8L85>F;SW?5*1R79%D60Z;[YN
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M) B2V(X(V75N_^;@G[HN1ZWZ2\Q]TJ,.ZSFWA6*>:[/^F ,-XM[[1EO^MH,
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M:L@B23>K4AE:A3<N6H6G%5H/J 5^+KDE[94A7X\6G5++ IW-G.1E->ZB<('
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MG-C #@5FZKL%\)Y'_/%@WL_;V[73?3.4H3V?.L%+W8($O\2"PM489PN!KN3
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M,A?N\8M\2#^96U[0D_^(15-95LT-:;-$$R^@9N\B"-H^%BQ4$=[#[V%A -@
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M,KGIFQQ6_X%RU-:D!F7"%ZB-(G18N+I'G<5"V';S.YVY=)WTC2=/]EF5ZO<
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M: S<"Q%S<HE2$F,XA'\23<I3FHST#C*G!Y>GB*!^,>]QB,_$F/7U[CK AE_
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M= IFN"'.?=1E]<4X,R.ZK$9X4IM+LX>>=+A$N(3EQ&*(QM<@H]C#P.EQ%J5
MVJ.^3+4),-%A!6#O?@N<F'&&-:&A) O60 J'3?C!*B+SQB?SS74F5>8#_L @
MRSJ*SP=^>1J=TQF(*];A,/2SK#VA_%A,;FTPH%>8O$(@36M"+1"4_/*H>MC
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M##;3TU%9)>A'S[2+.1K2HES %R:7GYFR#]QKK%E96NRQ!]6<AJB4HRI-^%?
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MR! ,09D06I?E%HWJH :#MM%/88XQZ,R+2</R3)D$GB(JJ+!*S*U!_+;QW+!
MII-Q@^/$YE9D1L@%46J_:L0,"2Q(>"^?7 _)2FWBJ2PWDSX2^Z1/1%(<46<3
M*/- BO=-C]5'%0Q;WZ)>4RJN8*_5&^ZB02WTJV2PD3>%HU=*Z$H3UZ4OB<>C
ME]32?4'Z&E0[GE7Z9HUVN;T-8,&M]1$7=<J5?W^D<2ZGP2Z]4ZY,GURD"0&+
MH^@A\'#'??',1:*%Z3X)U2,&V1O'\023I2_WYT(GZ=@QQCGLL'2B<"P9W4MB
M )V*>(:[FOJ%P!2+3I[J1NH5M?T_EY<?/W[Z5+B916,,4$6$M5QAL=:Z\D>Y
ME2>#;CL_N'4%NMVSB>HXHJ>'\5.<6(#_Z(QZ1K_5TA?S%3(,3+R5I21A)+IR
MYCK%ZGHJ;&OCO9/(G_TDZ-$^;5VGYM:-UK1U6<M4?^<V>2"#IML]W]5NO5W%
M2LV"7>T.QT:W.RC8U<QUVN&!Y*;</=^X7KV-PV1.P<;UACVC/1@6;%SZ(NWG
M8;Q8>/9\WS>T7VM#VQC+6,N&IB_23H_AWFO/0;T]:Q>;,_W!&)WXPD/X5NY#
M)92[M[LYK+F;A18..OT(W.>AH_YDVDC H;NK)5))$2GVO3F717GYSGN)7<Z"
M6]P_+W[3! ZPO8[%83E*M\7K'_-KLF(Y<,E)-@69")]2.A#8(,I]9<TL?/4G
M"M=92/F*J(GEPH%@IW4ZO51D6OV8H2%EZ+I\+7)GO.8<VW5X%DKF7 >MX=%Y
M'PS,%**K,,>#F;-H,%J;6=:)2(79"+.YL)<@5'^)7!9A9]Y;"JD<5>*%W-:2
MC%*RWR$+=8EL5AS+<;][2$HA.;8/2(X92([] Y+C <GQO2(Y9BFA#7=PO4EX
MQWUH_XHNG+WG*Y8*3%G4O[CE*7PPD21RM7#3.>U-QYR_^G;0O@,^!9Q3FVKX
ML1>"DW(7=Y?ZJ-V/5[V@N4$?(=)9+"S WP<&CR@MB):R@%EC8L+7PSI=[+'(
M,(OT)\MBH$PJ  _X>4WXMV<_,Z_BW(9;;VXO7PW94100.IH.T?$^NS:^,*@$
M\:WE<D[M(*(50O9\1.ATSV#$#MP\^#DM,D^JJ;@7;\7Q8+4_V:PEZ_WQ@_?D
M>5&GA4/4C50VE*0OQI_DMTV,UEU?5L?V'676&VJ!+-2M,&S4&+*-"KIQB0I#
M/5EA&'+$<C5;LFQ-+RI;TTHDUQ]-A)X%R0-W 59(I/;A-7]9G@L&Q01) N$-
ML@VPHOP-N@UZ 0*X^HLIZC&<4K@=I?Q)C%P-.^GE)9F2IY6M;8W.K9KDB6E$
M9.VS@_UG?B8F?[J M=O5*J"#$E;D38@2Q*8I3B15399:AF+@[T@/K;TL&LE[
M"H5%JZVF1ONMIMK=BE)4,-L& 20YDPMGRE-1KIRO<#Y6'EV[GYW%*CVJ%&_U
M1DR8\^3,Q#$01DA,S+GP&-&QJ48WK)@D+__T;O+H(FJW2_'54Q0";!M]<J?6
M/(S>A65*L'^K)_JL_ZLHX"TM.(/&6F:=2]E'MLFS;A):SM"?762SEG9/P:R&
M>S6K 5@H_;,4@,]?#-VS_3]/9TBLZPGPZ8*IC?9J:L.C\]Y9-QE/_06;%+ '
M39\*/C']%6,J,$&M8((-XJD;F. HC9SF%V$=(3\-G-^Y/:.=Z^NOENF];UK[
MSPYFZ,"LH^@Y*2MTWWK#UFD'_M<_[1AA73B6EVO$1B!H TV14@CR3/P$H=-D
MOT$8T_:P^QX\W+"4%SR<%U>WY@*.Y)[\3^%]4LTOVA]) T-+>Z^[6D9=2MQU
M89 $/X-_//G6_!D>!5XHF+DT$9D_8(-F@1X9.Y"1NOCXV+7HS"83P2Z/'2X9
M%A2_@#-I4^[+CKXB;8GBDXV.3UO"&'P6]8,LI\CRJ'7:)EEN1SMQM'A,(M%-
M[S[;/H$IB/@&&7M@:DZGE$T+MG=FF4O$=* ^ B6N(#J-> \3G_:MA8FW"+A3
M@H =K0/:[* ]EU @TBQQ.SE9(4ARS$*TU%X->O:Q;XGPV?#D3/_-?;'@]P:L
M^Y[$,.0":\I6R"7+]U#?L_#'6IHP&T6Q,W>)EWI$IN!.WVC*=PTMWXA&<3[J
MCHSQN*@9Q,IJ;3>"'CGN312V?01*)R7H&,1:$NE43)QJ]1*G[TX<KYVP7KF=
MV@:)^Q LNA;!XR%E'(1:09<1. ZX6H[[ E[]@P#HX9W$'D<5M@?,#KS+J4V;
M=S*,)].GIQ1[3E-9/JAAB89!6N7)G%JE@'2B4R-("5..K50+66>\-IR,3Y;%
MM?ZE#EJG!3Y</Z/K*GHNXK<;'QXM&K&/-J;&;<#4YM_5 E]4L#P-0"C6%;KN
MM'.6*H)KEJ1$51=%MHO?>-8I N[!&DI/2/:,LYD8?D#V,;.!:#\]65.;+(=(
M1,94JGMPLSA"L\QYDHQ<30. *?P>PV35B&N-&^!#K"\(VNF $WC62JD:"I"8
MLM>70SV12"C)],)U1(L:/ 14)?Y#T-&Z @%P(OC3T#B*\*K)$CG_T;*XM <^
M_TH;@*&$H)0N8'93C'U?I,NRM]W0IRXUMX.V=:>O&H*]!#A@P8&3AQ9.FF<%
MIP_QR=R7X(HD/!PT_=@61G1%5'VN;)*FW-L/[)6F@"NN1GKCOT8I1"D_9_I%
MB%DFOL!Y\5<924O;"A)#LO;B/, O%AYA:WH*G_"PYB-[/!J?N97/2AW$:+)"
MZX&2?'.B*Y%"8:#[:4\$\MH<8WV@]);,J4X'+,JKEWJZ><W02IV8*X'0Q6/2
MGLQ7O%2$S8$; R;U$CUI#_:/1,:>"A("@Z4#3B1X$<C:QX:+<F;YQ%,+=\((
M(FF;B@!5='D#57.F?U"=[42JU_<MWS>XVY:^PM<N90H2KJZI/[E3.# 34SJF
M9'+"D UI[1N%RJ,!6$JC&[#+IN9PG 1OEJ:F)G9>N=)Q.^2RAC*;EL5FV JN
MOIONFU58OU\YUJR>R<O9:X^V7L?P/>;X(D@!6GE\:$@]A/1U6-=-$  )?G,6
M=E_$[OU]:RU>)S%FB<&O@Q@SK<Z\TX!_<<-TB^MF5PR$+B2SW-S$MK=,J7W,
MZUZ[R.FL1SFY5\Q%*L-D%?#_.&1K$>W<VB@"U\P(N$:JAVX#?..8Z0 B7,5V
M('S)?G]@#(=)_+UB0L#U,T3^_+O=;:T-D++J;O=WNML;8""J,J(OX _\"HL3
M!D13^HEBB]!(&-=V."K)WO'F5(T:#$<Y%"OWD5V#<B(X.#KO=HW^J#313)55
MC)-H_W3;UTAWK&/[AD?GXZ[12X&T7OOV;=9ZB8^K!O-YAD*1^9LMF+)15RG3
M*EWC/5WM5;M45H5YO$ML*BU[<R*_2J=O# :E!3\#=:F).CN(T'85YGI%: PW
M7V]L](>EF6S7+D);L,"2>K13))V7&8$N V/<)9>F\"4UCT /I'+JKF TZ_$H
M*KUDAUZELB>8'_9O>$NJ"'P7J8.,[GAH]#NCNB+?J2[RE0))![E9K\I<A]RT
MB?*]W04O-8DPL%6Y22.E5'$]]B"&OM4!?!+)V.4C5I _P1L??=VBK&<T'8'9
M)<%F$2E4D8FU6'U@$M9#*9'*SH,\B20>?"@_-]>@-N5"&3XCV\K+_\:SGNS5
M4SF9[H!,CT"B^RE-*;@&^>-OMW8_@R[,H ?Z?)36+>%9_B*@V-.X;"D]_9V
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M8BJ+Y*CA%RVQWB<B@@ 7#'\GLOR9 V/HHSFB/'L)\]<0X8$)=4_!UX]YKOA
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M6/>_ /2-89KO5[E<=/'V=]7B2/!KJI_N<!R@20'VEIE'P 7\!$? ?&+Z,P4
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M66&0T959O!2XF&"8]P(E*.)QA[$N@VX3+&4*T[T&Q9[4W<#=B>Z%H?L+<*E
M2= P)H_P6E)HGH<+17"(LM)'51,!QC@%'R*_$7!@OI(KJ7("A]NNK"ES! <9
M1U#&KTH$$H_#.*P,AF5\4D4LCZQL( S\;TPO_TGH5YX 7UFZ)+'RUF>3P)S-
MX'JG?P6U#VF/T2./X5Q^=?G4%/D\X>+@L#8XPZ*+%.\YJ25\<1@OSWYX7$8J
M@HE) -^F9*1XV)1#?'%7\ZG*YQ?)8M%LE1"J&AF+U!&YDPGA:D["@H>,2<&5
MRR=2XTIAKN%]5<YGO8)3F=*-!.5S#5]>5ZTP5"OK:E9PE8($D1G!AYEOE, 4
MI5V/!:)M-'10 _,CO&?[.?8MBMC^)USZA&*5@1<=Q8F;@S>/W2]ZA(HFJ [W
M0F9Y,T1N*-P8C')KHG HD?C,6!N4KO#6R7,QE*JG=#&*CTU+$QH]%)K<&IYU
M24U*LN9,1YYQ4=/N2^L]=E($3$8\9IV:D0AB\E2M!3\3D6>*GG--+OQF_AHL
M4L;^8Q&^-0V0I@((CJR/!T>=N+4)!TLOZA$=YK";GX+)@#?1B^M-?<M)MHC*
M>5_/E)XQOH?:91O&^L.C<[ F,KK%$AD,V\F5^43#A-@,6&]9\IFV8["VHG@C
M<VT=.G<FW".XQ-J3Z2!;$8@2=7J(;Y,IA!F%H,V,"\097&5)5I_K2#:!G/>=
M8<97,>T3WL8#O,4A#3-Y=&D* =-TKB_!U=<!+!Y-*W,M@Z1;^B5U+X>QE+T:
MB;%D+N=2CL%7+J;L0,B[KD_]N\NUFF@*B'J U"(\+/[7Z.9W7/V9OT3V XP#
M*WM@F BE%Z3W@Y)\88-=@?2^H' )OFS8L_ J_&*^8-O+$O5V8 )&TH/45C/'
M@V1R>*A$3Q(=<356E3RZ8$Z&1C\I0K#S4$?1.7/#.EFU?P 6_%]4,R\-5Q+E
M=.LUNPU K"'=N;X%-B/1%Z ?"*ZF>:*;\Z4(?PE$M"GEWN>\G OWA;HFPFI^
M'RU8WA$^.8G*R\0]6_[F@R'=GR@P\Y';7L$2"!/2.?T/DY/P*^3^!>@#BCV3
M;(>(YO#)'L7>"+S+'<6XS*R8);M=7EWBP]'BDYD,,<5[+<!_G9XP6)T,-+[&
M(>J4)YM!?EL+!/B]ZQEY]\(&\E7.NN:;&Y1*F/- ?-")]NP%K"G1C3ET4A*?
M"V\*479#RKZ:64]P96++U)H-4PM,!*DQ8JU^-OED\<N+/:10#<8*+=/\I*A>
M0CU+07F,>%IT_V/(P;*7 E%?PE@K5:51DXP>/[.)3EW.*%J(*>N<^9/R,]$2
MEC13AC0,/$+"!9 : $G@H#'O2J$>QPB(T)'8;.IQC0]./;Z6U,L@/8&( )1
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M.H<"ND,!W:& [E! =RB@VT?DSE[3TKGNFT/N+/+W]A2YD]&TU@!@J67-9LL
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M',PFQ#*L<>7,DQ;UNC,J%66O\S(#GBJO'TW'9!W:9^@J4T>1$8UWD(&O86J
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M6"^U?D *U^[J!ZX.]0,I]0,Q[(9*Y2K;KA(8#8J0AM8]OAIE J-A5F*O1)G
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M6[]H,=;FA-=;C.'1^3 C4(.FSSSLCH0I#F))Q'@.4H4@5[7OMB#(M3P(\N!
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M(1*4)H>/5<QNI/ZPOFSIS3[)TQ4L\V56&PC;,>]CXMBSV1MWO;V_&1]4OOZ
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MVDU_4\1)HO^"ZZ=HR)#B)CU%$@=%&Y!&-Y$P&R$&"!X#7#V@_:4^!EEE2FJ
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M(# "'Q@!*Z6Y\X;=A"7-%+](+(9UN(O5T:($]_+5X$,$MNY//..-L_OA$)Y
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MO;>N#'=LN_C]+-('_$XP$4K-UG;P\SX,@V2^JHWBJN[C5=V[BUK=^47=X]@
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M+>8@WMD(7"#_.+\*)6A1$=;#7)R7P'H,JU[DL;YCC-%NU,3@4SC1V07$7J7
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M3PGU^%*==QPP.B9[$']TI!NF;V\$X1P9LJ3 B.^;I\ENK%73F2E&@:'(#XB
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M&S5O,@HY)W#UT?)Q0]#(OEVE$O[X7CDT6(X5D&W(^'9Z,O4,(0">@_6R.$4
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M/(NLN2%"RSD ;N25L"XD8O!0A.FVE <=X.\$\#LE0M4DH!V,! NC$2TS?63
MOD!B]-0@!OE7A 4/ "%@)9@,@_/ Q\NN246)-[$<V>,:&'DQ2I7\S S.$!&N
MA90:(ZY;(7?JJ7OI5TE>4B$V"3@D7>CL")UK[' 1R&#5VD6Y4MN1"ML+*#A_
M$;X7(NZ2MM6[%/DS*LQHQ]W"G#-)?2U)ZL\3BK-27Q;D!?&OQ"O+.BIR0P47
M5.4Z$,E<7V%H,_>4DD,K!:R6W$0L=J51>V%,#=&JQS.8M4F;+*T2' M!65%J
M%[,NJF!!1;F"V0!))YV.?2!?BP2-2$D_[T7CLRGM*ZLDB%@]0S;.^%^(;9Y;
ME.(1UHE$+XZD=F8M)TQE"U5_P@,51,W[ZF$B*RT==Y6N[DTUG,_I_/_LO4EW
MXT:V+CJ/7X'!&8AK07I2=G8>CV0[7=?WN.R\F5FGWEIOO0%(@A(J08"%1DJ=
M7W]C=Q$[T) @4[*4%@?E2I$@$(AFM]_^=KMI%BCCZC*_20OX]ZI*6CME6,+#
ME)B0]=7IMQC(!A(KH3.VUL+\7XZ(]E5TE1;H00LW#(T$P:U,<0[MTPG%;?]>
M6)LMLS=U( B"0<:"N)#;H<BF'H&5M8&RC=U\LV?O!0R&YE]/EIJ_E\4I 5:
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M4]7=%RU8>\;M:4!2;_GB>;=>5>R-AND0V0%=IKF=5&FZ-5B"CN[N>IUH9L6
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M*F+!&H'34S0HT=WH!>/='307)3T84*7?)+Z[E@-NP#;[Y] 9#/?'E F,]IG
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M2W>7+:0,DPRW(00%SJ++";WL]HQJ0CNY@;"FD6Z+*P\@',X_^^'?41+<HR5
M11 G1MTF.50/"K@QSQQUO.I@;'\'4$TTF395">%NHZY$'B8 0W[.4T*&W<*C
M[%RLP4D9F'E/V0$+AP1]=FZM=;':8X[V)E*2<9CW/(XNE$)((QQJ#7<7O,,*
M ZBY,-%:*^$S3,P"D]*'D,2*/9E59A?2(M:1=;>R0 &$U5:: ]>]8B2OB!)T
M2MT0::Y=D:L)K7&.0E +P=>3A>"/5?FYTY[:#-!:'$:<_^+U=$X+:[_,<2Q0
MTE>@+9$L;ZP?4='.<5W: <*=(F(37.<FI]IFN"O]'JDE[&:E:GJZEXZ,![!M
MZ.I J:;U.B.4UPC]6M"/!JC@B(H\,+/,VI[APV7+<1,'FWAZQ_7?2_,'KNJ'
M= -UYLP:1^+LG[A"3=:WG+VH7+@*=!:!H$)%B@65;J ?^\^X=<\PKLH//B?_
M&Q;YL*-T::7RPIH&O_ZW.TB5((851E B"J38Z/'V0O7T3F9**A#-0 7B6"'F
M:#O;@9B]]U8$H*57YB:EQG;6_K]#Z[XPGKHEG%[,-]+DZI"$?[,X'$/XX,Y#
M0XX8KOO$(PN%EE:IPN)]U=*@CE0+H^,QH/(J%YE)%M9<9+(3S%>D +*KZ\".
M&IJ16DT)[C?NO"?BBW_OS"Y%:P.-S%.\I56P%3X,BZ6AK_UNV3,'V/I7GGX*
ML$^6-??YR,L/GW[]Z;=W=KW.H@_OWG]X]_'=[Y\N/_WZQ^\?H\O??X[^>?GA
MP^7OGWY]]]'\\4OT_A\__O1'9*_X%3YYBG/S0!%ME,/> (!DGY9<& + MN7U
MIB0\:9U*:R/V1;QNSZFK8""=X!*24.] ?3,H6 L;X+%VKI33ORY^2EC5($IZ
M2 4:C:%GB/1J]+.&T<.H$Y@07Q/RT'G+( H@M1RLPX3#&YYD^LT63^0TEA5W
MMX-S"09T$RTJX BJTI6=-C"LD\T&6)UF' R%, 2\>R<F 3?'"6-1+&4C;/)P
M%D+C=$ &IS<2?$:A0V]2:Y/</CVI&(6"R5S?S8!?6;]J]/'=3R!Z2T"<!"!7
M=%.IL!Q!E!LLT8<'.* O1VCL+9S-]@Z0VE599 OJ-/NW!%X'EN2R2/*[.B,=
M_"%MK%J"-MK$SHME,HJ^T,]1+1RD+H8#C[Q.$Z24D(WTP7I;T2\)I9X[X5ZU
MF!^<6/^EK&XAH?!;66(-TT<KL,DN5#%AOL'_ >V;D5Y"@)C]()>_?U8C3>8
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MY4F"TSZ4)(A55C9_+!;;EZ^?0"?OX6,Z'4"E*V;,9<#)$)S42X_#86SGCF!
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M4J3UZ1]?\O0.9-$Q*K C*D"F-ZATHD.5PK956Q6951..+P/F6\/>$5.#T<P
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M MW1LY6<IWC+D;/?0%GMDF6SW*;?76N@%%)1;1M)+M+O[;;7B5QW.ABPG'+
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MTD'H1,S%,QD' LS2XWX7K-X%'K)(EU!TW@M>4.SB-?@V]"?$+UZ/Q"_.[+(
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M&'6DL><X)E4"<75L]@*GC8T#3N3+($/HY" #I#HA\#7V4\/&IHVBII8?Q72
MLN(&TJO!2?#5@=9++._2%*M*Y<CJU;&SF8;N=V^RN^2$&9J/X1XVX1[>FNC@
M+>12LD[T[%/;=9W48;2<\R0&'6/0<C'LQ%3:IRBFW8IY=KT4X&2)N,?(>@OD
MORAI098OTCI6)@-4<%K!NBSS\HKE(WW@HQ]F@,"6H_2AX>:F6PU 9OZ1XE>/
M'DX,$9F?-$67M:!.QZO!#N3=&N\E0YY2<[?QG;C-@%$]C"70"D(5I)V\&JI)
MT\E;;RJ%H"12OWB*K2 PA/TN06HNJFR^92B/M)&^NWALE N-P$$6/U%[WB'1
M$RH"^/TFQ9LP3 H+(-097675FDI*R89I<.0>9X_2CQ:"46"=5K![YJ$1E$(\
M3(D>TJ:=V]OT1M8QS:6>X 7LOXL7L^'G0!OX&;,YL4_PJY\(L?J[F6!?'\';
M;YTF!><2@TW^_X[X #^(ULMF85:6N*P0!,?FU<D5F-E5V5Y=1R<YOH:\VL7Y
MI;Q5#ZDP'M\<P4RH[L%V=HW80)=^EO\ 0P(ACV1 >43Q\Y;:RT!J>SA50;7_
M: <AF=65LZ=%#0_9<]@@PTWZILPS9T<ZU8RRN*UK1GG$C+VB%44:!BAY 1>,
M2<6(E4%Y2B/@GG@,V1,K[UX;#H+[J5S'6?C.VIM*T,#9UY8WJR5OG7-,,*AS
M*6&&J(-Q"SV[T#ZIJ3H<WI4:9^R<*)R,CGEG.OBC(7_EL83W$\!)ND'LF>/_
M_ICC=SG^E^?''/]?X 1XTF:@UB<A6E+ LQ_R5=C'H$97-&RI:DXI X:! Q]_
MTV+)Z?@W3.B@M;S93\LK1=U!7S7)Y[1@_D-A/L02R' 0K\Y?C)M/SQYR,-B'
M^.)\,MCC'X7SK,QOS,P3TN1- 5.F]]6O^.)\(ON4ZSABNM!A#XU7[[,W#W(G
MP:';@9):IRB&:P=JO/7P "B*/?;DXYND@G]1TV^-GE5._5&)!BVM,)!T!;D1
MWPU6YV+#J,-!.5\V^_A&'^%&YF?<P>04K<JRX20_EUQW2/$'7/O'G-G'7]KY
MP-):P[S%NGOOC ],?/0S48_A]UWSVJ[7O+4_!]KP$RD8H< 21H=^<Y1AF'S'
MRF_7?MEU&##8'NXFJTIN1NY_-WO>R[;8MFR4>"M8!#NC(>B<3EQ_OO\GTN];
M.Q9BO_"W[Q&*3DU Y_RL9WZY;>9UP'*TF?<\X]JN"6WYPIZ8 %HB1 MZ^X)G
MIX,#AT7:E%.82!5&]H8QPYC1LU[)=& E,3X\TC2<K81)#</GJ::*&#)4=H)0
MCH;PH"%\,=D&O20\%>0_?THKK*W]"?V=T!9^YRQ=WVG&2[] ***EHV,]G6+Z
M^^!/O;C@T9GM]G*LM/. 7MY1]P]>('SOE'1@CHD>MN+(])*&&(R$YI[M@FK#
M1Y!_\03;P YD+HV-Q8G$^_O&RR*YS"5EGKDPFQ.]B\%?0_9VP2(9:6-OB!9&
M.I+&XI^"?>'[@F)FEGS895M17C,3J%!,8L%H-GUELGQ%Y^S'/>A/HNHA..$O
M)D_F;YE$P?6)-N_NS7=],953U959#QU%3K=L.8^&SZ/R=*V*R2%T3.&75,K!
MMV;_[9/2!(H4O2.VEXMLNLGVX#I&,!$[L2";O,*<X%)/4YCF0(7)(F'>F<D_
M*NI,I+NU3)@<LSW'_:=-CODK6!-/0LA,+ZVZ>#E96/3M^V,5U;WWH[AX>4@S
MBJ#MA&-@EXY/WA\3R$N/XV5 3M\/*N8$AF0?=QBS7V_+=?C]'KWFZ_N'3KI\
M3=T7$)CSM#N9*O$F#<M&Y]E^O\;FQ!UB[#?G%U;/G%R<#P&1%&,:8DC@)OCK
M<'N9(3JNKK>O&A%1RPP%U0I02YUA(19D-HPT>?0%>9K[0S8(QE(\ _WEC%);
M)1"S*1?1-?4@C 7RM#LHI+1#^)H4A7WD#,&8*859J=-"$<96$2@!_?@VUX!A
MLB8$=C;_<4;X6AKB_8W)4#LQ</W\&'ALG7$\^K(^L5WV_8$PB+='&(2'05P<
M81!_K5,ALG=$^"I]Z"-"/UH'=Y4UV!!P%C8;Y5PD!\BM8-HD=Z0L&9IUJ-C#
MKKE?%BER;3+#EKYWHN]\U[OO0 M>O%GT'R]>G\?GYX^_$$]S7]R(T9;GQAOL
MV'-1M7NA3B@1H/PV$M8#VN"J!NSQJJV3/.8_R]6*X(72:F;#G-M(Z5TA'!6J
MW+@/.:$G?==Q%Z*@U;Y$I__1)^M)KIU>NG4_"09VE=1=N_7$TPLE*=*7VQH\
M5JU S4R-.&+X-Q)S0_WB-9AA)YW2FK#'#MCP[IF]-D% @)(#B %.\WL*V]SM
MDBB)G'LLZOFRX."Y'&2(%F.9M]AAFKK5;U9C[7[NE$7Q+WM3^,4U\=/[G<@E
M.@!9+^^2')J?R3RLH&F7GXE5F@8;VX^2\^X-T;#[BFL58>+'W\?3^G,2UC_M
M$RU?Y E46MK-(@$ H :;^FL[_8[W7VL2[U.A?^1*O)#:\M2./[>F[4TJKZZ:
MO)8=0:_KWL8*WA;VD)1KN^J^H^' (]"P7J^AE1Q&"%T5(;;..K6C/ZVOTWP5
M?2Q7S6TBQ?$>'BYC)%[=8@F0\/^!_ P#J?,[HYKQ6I?T*+>&Y5:F!)?J4=;M
M).@J!.4(J&T5MB<[3O3(1.N0C._>3+0[5E(*/C;690'8=/2ZS)<:(<OFENH\
M(73772('%S(AL8Q1DU?GK\(HCNE$<?Y$Y-A?8UV'%U:K7_C)W(HK#"" FK7^
M:55"Q<FZ+-([P?,MI0.,,\A<WWA.L]R1!4!5KV0#2+6OH')B[E6YC(WK=DD<
MYU ;*-SY=Y3"F7GHJQ@0O:WIDS9!5DE5M*RAC 3C1F3GP]?_<8&Z\&CLCQG[
M7P9WC1B) =5"I=D8OLZWBVE5G8GJ^Y?6YNOB=]I[!2(,Z",/;@8ZB/XI0$L!
MK")\,N;(0P257K1)G<MQ;]AG#'=G18M6\JKA>L+1#A&KT//1H<>@ I\W/5S/
MN5#_^KN1((^^"9_DF1@^$MM"SV*(8P\.8'Z!;L!\A-;)9W:LEM"V@'L $[>W
M5ZNU]J*PV&W!Q9ONAH:H3]0MNAVEPK[8/$:N)2'6DBJ-AENP04/L!P(G_A5V
M1#;D5W==&EBMOR&/,^.F+XG'IKE[WK6UKD>5P?X:W;9[=RY=/))I[38D%CIY
M3Y0_BS ,3IQPY13.%^- =53DA4V6I7=<=!*TA=,9J)EV1R\I)/FA3_H?,T\1
M<RVXQA 8RE"-=WH-5%#W:#Z;;O?"223E[[;-)J;$;^RZ$7T. Z.5I-,6/K8@
M]%+"&_O.8KM%V ^F^>V0D4 .]6GO"3L0OITZH''0$M/!=%XO!"IJ@*EZ; ?2
MPP N("<(*5Q*AG'[US7%#A28[U:':(.8N=H]5K$'%'>F[LA"Q<RHLS-_'0"O
MW/N!Z=9"44XW'3WIN;T'C^ R!AZL32:'T:=7OA=T/FHRB@X"L655KA$@(C-=
MZ7W(1IT8JW*(QN\N5$8W$]X?WIJ@)?AVI@^?]8<.Q,V5M0F+;F<$'@.RVA/)
M!@(7N+S*9[[K-/VL><M\MR-AY>L@=^71SQX'=5!W\!?GQPRPSP"_.&: O_E#
ML#\>\]7DC(%.#A^AF -<!.=G;Y&*X"O0F*]\0^5=@$S 8-9A?4@_B5^?@;D*
M,;Y-64MT(^S.=QA2DA]BX"$A2-+:1#U:0%:'9(6!!N5G2G[(VFPTYHV]G>9R
MZK,V20G!RY.7B!!\]^'7CY=D11GFJMFD19U0,0HZWR[$*7]3+ML:M]9))D@!
M_>MTGM34"T[?(K4V)Q0>Q)S.6DO%"Z<N@8D'$A*GY>J4B6MB,R^+EMQ]B$QA
M=T4)N.K;HR$2TB$&<Q%[_Q-)_JZJ!-LC(8?.76^>%8T7S8MA*P]\BIVW4^G9
MFX0[//-@\%4<MVTG%9SFJU/\-@UAE#/@(@2>>#L?2W26XXBXQ C,CQF#3><Q
MUJ)U>#K( -GERE-*Q<DE>;9*_7!B/W-)#>RW.$9^.2@MJCY;G\&E#,.U=0TD
M[>EI"[^^[FE$4E36S:GZ$M.Y#7<I\)?J9F;!8^"?_-9NV$9^-D,WDHQ1P"&6
M@%!%VUCBL[(A,%ZH24R\+=H#Q_1-WB!1#!@!LF=]^EQZ5]&3U]#5NYLF4G.-
M[^*)Z 3G6_9S1V,4F>CE<S+>^-7EY+XG2_74ZW;!-D!E4/FJ:HR3<1+J;I\)
MB<C!5N@!SV2^]7? O5MSCT6= T-.7C<DB<YU_;+.\W:/T\A4]5ROQPHXB9Y[
M5-X?T;7S;?T:MRC&;N-=1;>S/30S&-WBQ 'W#S0@:J-EN6A=_]MNRT>FT("O
M5KSV;2%.(TMJYNQUN&(?U "( 0<.\(NRIO9L1>-^ _<P2R]AQ=_O7C_<TO+U
MZ_/S0,P#_='B.ET"@]$L)FDU<BMIW."(Z8QFV3ZQ/\P"QA&U*!1.::@_A)V>
M?]O[V;7GN(+G.+I03$L_E="IN3L6*0U()*EEUZ@ &XO:N7IZ7E==Z%HV?8"2
MUA;H3:N;#-0+X!:"D*3= C6)R5:*WC0^P2M*8;KC>,--QA34+N,#B)6JM-*B
M2+LM]88".N\3%-#!E%%0^AB2WL+D\3N%_8P0.6\1[NJ[7J(/+:KH<@4-*;%!
MBFM8X/02K/32;CLD0*U#'55SH8/IZ W^:>QNI^\1W@+J%F+!LBGS> /;&7=B
MG7U!B%P]26N:IG2W@[?VU#%TXOKZRUOP@^:J-D#=<;UX 3=R?[X\UT?7?F4^
M98V5L[_^=\><)ZT'-C8_JZ)GC-#'6H?@.^\1X(E[=8ZB0GL*,Q?XE)M;(2XO
M4Y'D/MGN>;RX./>/T6]V\1**YM7+S2@]2'@9GF<B1AZ8IO,W+^$:^_^OC)\(
M;1KVAAO=6M,[P>BLL[K'I^?5^0S,/C<39]'O/4IS.!!^AQ-%*O@_/L9+M3+A
M/NDMX/.6.TM-13BFY0YN\-KMWLH;Q1TH[U'Z'YG?DEMR9=P6]#)F6XNI@98@
ML$70 HE<(QNX^UGTSX[&4MD^'2UP!^(P37\BS90')C8DWH]6R4U9X9P%YH#Q
MY@!W=_>SDM5UZ]EFQVR"GG+& =$[<"\.%F$9DD5JLT$>953U(N72TB_V7#=L
MD21?R'0))^3UP(1X?NJAQ)4SM#"1@6P=. 0A\3 =5O!R-? R&"'!T65EH4KO
MMY .])I9[+CK\Y88Z9"ELK/'1,=IWU3EOVC^O1[OJ6_"20\='FYG9-_E.DWR
MYCHV$KSI!%PHR9G8&[O(!T"L>]$#W]_# 7I]1CBJ^2CQ8ZMZ)*!AQF9@GMZ5
MBIK!A6/<PP(/8"4/#/#J"[":(7&P!E@W<ZG^],>/'T+%_O;[\Q]-<.AX902@
MC!Y.=&5-^0W/'IDJ# >C,5@I26)Z45+UO"/M6[60(=\D&3Z?VIR/3Z>9.)W2
MT,,%::R,_GUPZ3-M+F(Q+G4J]Y(0)/P,(9G0\8JFPORC0$</&]\*/P=NH6!C
M4(@P'!UV?+%/I7BK_B7 )IJ$:H;X5QA8@U_D''7"?*P;C2Q,,)K'8P5_T.:2
M^XQASU3HQ3$5ZE.A+X^IT&]^_Y^L5&MIY@#GA,LRS:V)*)&U,!W&7-V8WEFO
MG?9HNBR?MYDUF"'G<L).5)(C%VO%MOU<5 ^C!E%B&S3 9FC$$KA%2OP%7.J8
M)Z>&L>>I?1AXJ,N6])*UY\ L(YM.(8<[N3&#U[-\'M<VL4L";(_X[Y6*(-.8
MQXD*WBD,CX6Q,X*VN\=1#45QR?+U<]E0NZPT3ZM@[1J[J;"V(>'\'?;YX%K(
M[M1 T80;$$X)HGJX]BXHL!@*T]WC;.[.1W P-MQ-')B,'4%:0D5L8!-(\-+-
M=#PT!Y&>@Z8T?_HN&5MWP^MNWWF!%8P46L=M;N<?8&&N(@G(-#+80XCT!%<E
MB.-\?_ZW3B@*?K:X3F# *;>F1,BHI*NI_A+:<RZNVR8UO)NFD-OHIR*33!@I
MHDC/34\N>,#;35;F;DMW<89&@.!AKZ@X^GM:7:58):\+*E5"PWWLZF(Q3Q%'
MZW()'GGI#>ETY!0^;]_M:F>T)^Y$7OI-N7K=-O>)#_EHR5OI,F5@3Z&UOZ$"
M?KL7 8?0Y.R= ZE,5=;U:;N),7-YZNQKCATMB<_3DS'LKYJRPF7D^.Q_2K[H
MM%*3?('+UAO$3W=B/V_?OJ5XJ'LK.BG/>[==\V[["/O&]/9-PXRMJK,5$UR"
M@)G(<!G[G8;=*!$\H/MBQ:K'4^Z(0HUP/Z(*@,:?@A 94MR##:3P:52T*+IG
M?H?N7@;E?\+515\N'I5^\8GLAVR']%DD *[Q(GR)X@?RV& 02>X9X4.B(ET=
M@[2/" XUB!SK>;/16B..**W%+&BA@-OX^!/($U>/Y]*8$^6'KO*SSB,&$SEJ
M#<;=#44<L<;?Q5A+KX#9 '\L@?%T@(F'P$)?*V1G]%MBW?KH0\HMBY[]A/JN
M4P+UM.?06&WKT5'[V;J8$N9SQ$5[5AT*9*RF.*644S.O-C:TJAQ_\:)$OA6@
M&I[;]^&J5U7OX^D4<ES.1/N\VSL?E_P3'%*L;^5>F&*?B%N[2@J[K8Q.$B.L
M"S^'0=GQ8P]:R%RR3X$)!&XO+.SGZ"5*R4YO-CO!\3%Z*44-*N'OC.C,_9.+
M]*J$)HRBKNRG5AE!D5G,?I%,;30VM22I:)9\B8U+S9@"ZD"K[+/UE#;9XG/:
M$# 1\*@;" _)GWEYNRQO"W]+F<XEWYP+?JSD0_BOM0P[)M:6+3?"1OW<&_#.
MM0H=+O_>R0'=M_*_RK W+O&[2I= ,1-3BB&.\G(!&"O"C:70D!Y3N[Y1*6X3
M#57&B]6?JFNXM\3G+7$JH _)/D*>&[ZW(Y?X3X&X1==9A48E=*\K71MS.QX?
M10O3+SX;=++UL=8NH7-H'8(Z03ED],M03IO-T&75VF%Q)(?:B:8:J,M?2=]@
MJ-6L,AG5#QP\ G^_KK']CL12F@0 $'2-_2"%O*4>A3VT5H*U!>Z.'\AO]\#E
M'QCJ12>V$K5)']O/;^UK<38>BO7AJ5]H5G_Y[>.E_=/^A=]@DLC*!?C(_HX=
M,=BC=(L=,TEA+PYR":4>D*%#0O]SFFYDUE1+6[EUXY59/</G0\ANO<ZN**[V
M@X&/X&4"?'400\*?P?1UH$+PQE_LY_-D\1GT1D$5I NKX:S9NKA.%Y_I$KZ]
MZ(5,IO$+3B^DL#<).:FF3E9I<T>3B@DXOLQ>MTJLKJ*O.*-)B'(<GIUJZW78
MG>NSTFJOPB5? "F]2K**WJW!4?P_15FH/[E+])<O7(2@U(27Y)Z70O6:_IU?
MH&MC'5O;BHDUB.+;F1L/\$I]Z'3',?'K\<_+#[_[=O9$'P+K!3NZ7F7I\@BZ
M]@"GK4&(7L5PT'9#8@4[*P4X:A&$-;V5VHU,&-_.0P4TM'N(X6)KS\E11&3
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M4R@_TNV=>J!>D@:& _(O\N+OXO7YB],W9K+LBSE+(]C &45G20Y#LP/L^+B
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M+EQD"N;)FO_GY\RDY2N:8 8(Z!.$N A]!)/_K[,/[Z E+_9JI;X%+B#@<>A
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M'^/JRG>3HMLRG=-!*DUZ,RR3@,11F3@.SA%" I#QK/4E6@1FH\WG23P!*UU
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MK;\Y$5@2$8&9VR0"VQ31#)A4OSD%6-)' 6:^.078X"=90>VC 'LV1 !V>B
M&Z!JVOXH$C:EI(]^Q]P>2Q,@8SQ+$WNI ^0^YB;YF9(@<1"P75!]Y-3Z*$TQ
M=B'F-_:,3)Z>/ 6KUAL]R<='_Y#'?WS]\F$+7+U+9%8(G_HE[DX(G_:H)0U*
M>P^$3[=+^+3U^C#74VP*F0/7T\T/8 O*)T.5HQBK#?(6-T;\1 ?'9LHGT_O'
ML,#UULF>D/KXSLF>'!WBMZ5[2@(:CQV8GEP.R-PWIJ?O9Z_NB!M[?,"->=S8
MTP-N[/N4?$<"I145O.]16_P[IY=JBBA @#S9)8@'"MNJJC<5>,AXP8_@"FD0
MB"*+NEL"@WO#"[)^-1QK"!!KF;6E7$V].K_HXYF!O$0Q$_J85$$LAKEF;H9C
MQGB.F5$/G627^:F'6F9+PJ<T62WJ2O^-Z@F1 L P?L*'I*13]X>@F+'5]V<D
MT--5 S9&!2)=>L/D D)?<C"K<C^?M59 =JOYZ\]M:@]L@(2U5(-I5=\"^K7!
M4"BPY(E7J-[<;:-!<OW^AN.(@)FMFJIH"=NQ -,2S0/U4 B#2EI^4B^X$H=&
MFO2--%49QUL8MLE:'R_L6QLH<5(^+^<.I8*9.8H"HAJW,&JT;H4P>)+GRX[D
M&*Y$A7O6K7[JC>')19'/DIG=,16&6R6RXU\;C,0J#WL,-1VJ5E?_!#8GV-PP
M&BD,Y(O<M_FW86Y1KX#=O94WL_%+(9^X$D AV;"MU)#1"*&PXFIHD@TAJRZE
MDU2G-Z42H2 7*[N0\B\^B"I"@_EMMK2Q[HH4#698)KE=]ZDP;H61<1-$I6,<
M5QS=.+[[C-QZ/7]?,!*.4>=/<-ZLY1B\I9-&D'IF0.-]T_/&:7%SG?,F/##W
M.FE4P>@W.&G6#9@TGE'-:?8^:?IT\G=PWJC40M])$YZ?W_2,2>2,,=TS1N^E
M^W[2/-RPBB/ZBD)U)H@2ITF5%X0/15FL0@.GAW:=0-QHP3-6"%4EU"@MM21-
M<SI'<F8<*215<H0M,!VDQ IJLUH0FX9]9T'OU^4N?5'5<)BH2WQ,+>T4Y_C2
M]#CES?A0Q0*;<:1.E9V$X3J,?F*P$T*$5@YIDGB&@NES=2E;#LCPSBUKK%OQ
M.C6,.L9*W26A7*I)0?;LWJ^;*K]Z-+$F0 7]K8M+N_O.<U'S5&H/>W/9$!F;
M\; YOA8^0 <P._4D8RN0;LX(#HOZQ0%K-]:M'87 >GB&H6?0_*ZP/,L=T6.H
M6E(DPWP2X*L58(_RIE@;@/-B]U>5-[U1=/O^I:_383 ^?[^A&#Z1?\@,M %A
MS%9C^,)$PH&(2;!X8$;;2+Q'#UNO"=<8<>T(]B]46)CHN)*4_U1)D&R_03DB
MD[2S2V.SA" ]\A+KDY5E[^Y6RZ@8E*)(7,!?U<-,I[>ZJ(>I>]Q^]61/?!\C
M;1M/ "F*5"2M+G#Q[_>[M :=7H"),?Y=#=81(JW]T(<JP_L$?I]NO;[OZN0C
M@C$)GWV(\':TQZ[,S^]JHV<4SL&?LPGP6SCU#>6F=9N5JH&<HP7J$KKO2]C^
MU!6@9512L 3_/L@N?[0ZHP!,AZ$$<F#:I9$[$5'T:&-J(,@5N.C*E?<^7D<1
M&ZHOG%#!X(83W <#8F5+O0UB)O2,?(%_YR' W1.D"\HQ>IQ9#K9WNB-B]#O7
M2K0W"MX;+0F\Q^8*%TS-!)S6)Z22E=48:A5Y7UC+"H@,)0<>U1WD%2!4,S [
M9[*!<BX**<CCO.*79"7S]A$:=:FL<S+9-Y4AE'DV=?QG@-I",(/LT]MK0O9B
MJ G9'31$VVDL.^;@GQQR\#X'_^R0@[_7^V$'_2<*T+,K&"Y*<"0+Q-(8LBQ(
MF,#YNI$OEVJN!0AWL7<=%1QH<%.RJ)=TO]-?YH'HKUW62Q8L#_ES2NQ=0_T>
MENA5S?.YM;&JZ0JK!8+2#\5 C.P735%-BD69A^1JBJ68J-C"DI+.DIHC:^5Q
MF=O6F9,2 [GH-RI"..\TL0G(A7*2X ")D\1DC##/B&&2H;U!NZ'Q57 \.O$*
MJENR3ES"?W:3VP.:(Q_7 -X]M3:Y8.]P'1&M*<^TGU0TD]4<5FN"21IZJ;FQ
MEXX.^TGVTZ7HO[ V=#N@.QM=#\[>VGY^97I5IP2*K, .9O8 "9S@69(S]3!'
M)Q6GSPVYDKEB0@?E4%2KJ*L&9(FL,[" 9ND<^>34DA2L"%LZ_@PE3@UI5:3W
MIFRD<.%3.1C\$RJN%ZNQ]3."X%(8.Q:EQK6>2'#)7@2\P3@_@E'SE#^;4NIQ
MP/B72+SV-(H*0KB^!$W)>)^ 9STB#G'(@YBSF,NI3 N,?9S8=_R6U0K?V^1)
MC"R&U@?SQ#2L.V/M*73B [5Q#\6]SU%%B[0F$I7QCIYG1(S F6ZFB[#V&(<<
MP"RQ.R\!B\-U#^SN8<H-)_\;606@AHDT2XILTJ)T^E6,B4UMI6_Z8 KNDOAE
MR9%$O.)HE2BQ^(Y1ZO T!M7(L&D%X2U5;87T<T)-"-9A7Y) 9QJ.-)QP.*]D
M5HKRD#)-,&N\&.K(P5*-"\ANJF,(1<H[-OXOH\$I2!RW7Y08,"H#LF??.9\V
M7#.Q/GIX]%6W<O'4VJ[$QW<!\;782#^0-PB=2,W1U<BQ_@7G%H@GU=0AY07V
M/56K VEC_ [*/_][%.2.U8,@I4A5I$U>S,=8X$T[W@_#-0*<Y43JPK3/<'(!
M1;C=%#^-B&,24Z#K3F\E-FT0] ;.!KNX2'03;<9V%-(KFQO8*-Z,Z#_$&9[R
M<D1^.4XCKR4GO@W.&=9W)SS5.,!=_7#'.0F$!5!9JYML.=ITJ<'_B"VS8C2"
M<?,3?^A=]5@$-8DHB]K.,O:V\ U3 @L,^I$X( <6T9W7]11889879IRU6*=/
MY>U3X.B'VX6MID1V!A#5%HA&73)14<H@4PW>S86OL8.*QQ)(#%K"JBK:&6AE
M\3DGH@"-?H"8&O4MQC<6T]4$2<>FJR7#E<*=YG(</3/"A'Y1+QC85))?(1R,
MNX!1"U4OH(U:O.#P$.EPW6,7-\$2^TK8Z?U2^Y[@K[*KUI_*?"K*EL(A^Q/2
MA%@33Z9!)"T>3X:KA!EO_YCN,:PDZ)RRY0YU1K^5HYW1=KP>I+*7V-AVX,PE
M*M8T9MT@P@T$K*4=^$71:F[6?H;(?II4$VD&1?/FG(4M^_N," \XZQ,Z"E(Q
MS*=KO@PNSM#*#*S*T:L1<M$"91_9%;S=(#*6UZM6$!.1K R.9$L1X,?E;2QU
M?0@G+25'ZU%/!K825;3G%?(L%/01\D)4(>%Q&KUBQ"?)ZQ$\:,^*5FV[J+<)
M$H6]:D0/02N3O&,/;($+\:A=_.*>W=P]=]VQHZ4Z=K>C"7FHL(S]6MB^0_7E
M*OFW@B:26#A\]I&TLP0C]%(TC?W%XZ>$-![AT<J&G]X==CS('HO+K#JMSPK9
M'\RWB^^A'N# <_)71&#VJ"&$WBZ6H@OED4AWJ?(0/NC!'>D3C#@WSJGW#8-
MM9IN6;I3&_V/Q&=.ZH5[X,:XN,):NY?+\"70TQK)*;?2=941R$P_&L.)T\$Q
MNOH;?6C)8'GS48J\^ZDJS/YMS[+(RC77.<N.K8L<Z3F@\.R(J++32.V0#0G7
MQRSU70SYU&Z'LEX0SKW/,._&!7 ST91;50N)V"5Y"*[I.J;OH!NX^#\<FIJ:
M==?!)^7+>A23.MJMW=8U4LJ%8<,%, ZQN;AI@Y-WA5LO-2JG:*5U0@T/)SF-
MH)Y=9^)[6]Y"ORGNX:5DQ_1+?B+3Z]E,U30EFJE/IC6\@N?Q81\RNS;@?E>;
MEXZK^$..15'5U$WYMDG#X^1L(VX,/_ 6,%#XWZ<(9/ANELEA 2YRT^\G"[I.
M;49KFTF;T1#]MV>JLB=E ]L8R,GH7],&G%&F5_7X!&[7!2<$A> 3%8+W3^#H
MB3Q(W4]'&?7/Q8_O"IX&^_5= ^K1:,M'X^^M38,-XKLF^6UE"^^%^.T^DAV1
M64\/R"R/S'I^0&;=X[VP#R[+ZF*ME$CIDFN<;U)9;&;KQIS<7.BCU%,Z$+.U
M>+Y>^=_?FB9X=OS#L^]L*8;60AC78<[AS',VZT@E781U7TC(75N&IG.\<(C(
MU;KVMHBQ0X0STV"^0ZC\9]A/-P Q18_/H(M[RQ$EPAG#Z 6OU=K=#?3P]6<4
MB!*1&$)$#P]:56+1ZJ8T1DU$WS0$_7,_>I+1-O#C/JRLSW#Z=/KHAZ,9II?F
MJ_(\\UVEL,A?OO7,FO*.ZEZ']EP%7S#<D?4JA0"2,7 0SG>A^<YZ]GT&50S/
M&BB$PTS7DEW=Q#77U:Z&Z4=,),#C79+C6]91QRWV/D]/_K-=+?ZVO+#&C_W_
M(+2M6+DGS"4MW&LB%8F2"D.KW"-# ZZ.%.II/GR:..E!:E<D*A7='XPV&2GV
M.>[;9\[81HKT&#D#(PQ#W <+Y1XHI<L;L-5OA$10%>E ZX\4(G_6HT<J\&F-
M_-R-5T80>#+.0I?RB01A82HCL-VCMD,[K8$XF?40)PBN.$"@YR&&'84!JQ;#
MBD)%0M&K*++%=4C9KKA8;GC>NQW8-PZ1L1S0T^\.0[*[CD#\G+5;4M9>!L&!
M'Q8]B1@%+M$>&.$M1B#XX-L"53U]?GSZ72F(RP$JA,$<SQK>V&WJ[Q)"/0VG
MV+4Z,G"@LB&T7L!ZD%/0J[VYS+%)RFN,+A:]*<:>82B"!L[K&\SK2[]2Z>_E
MCTK,6VV?W9_6UEG4[6@Y*X_#ZPQ(\9QPMMYPMKX_ 0_] >!C?>$UYSCXC)9\
M Q"K.++KVXIMG=X#C.&.>$>!&QZ=\>;X&!,N7&27@)VP1J+N>1@&FGM%\!US
MZ @L80:QR1"7 +$@ZFU'Z2T!.A(TFM.U#L]%/^.A.&V5W[!AN_0:NZ"5P90=
M<T9$F;^<%B(@((?DC<Y7#7ZJLB@PU#_ETM.\G*7$VY_/'8G_IG$35*!%97*%
M4.JB,JINUFY<N\E(O71&=%N"]3U+^$\LX43HA 0X2IL,+NJOU-Q,_*OY:DGM
M/5AL<FF1QLT0(<VOTAS650K@  .L8\QT[<&& <;*DY.$FZZ?P$PV!F+U"M5<
M0%$RA*#@EM4SEEZ; 1D'N# "Z2!VC-TUEAME^""&73%\J;P4O9RNG2LL7JH[
MW>TAI9NETGO.1F7\&9I#M%U9Y#!P'W,>E1+/WU?3<W&[XP "]EY1Z8$.$N*H
M:V<05++7QABEGII%6QF<L-[5=AJ6]:HV95U!A=\XQP9E7::@;2V89(T%,WPZ
MJ6/)#+0L=<GD5">),; &J73-P#?PH2%G5685T)=!&6, Z]IK1 ZY8ZK##_BJ
M&NL:YK$90!(@''7Z*V\UOO$]:Y%7K$6<L6MZ[8!P6;KYO(V[4]F 0PC@X1T\
MZ"F,>CV%+?=P9XP;]K2AF> C3@'QM#<BNN^:V_FV?.U[(ZJ[#&3'I.6S0]+2
M)RU?')*6]W<G[%$$^4UC3DDQZ];7)?]9_,U7U?WG_RK^INKMS'"5'1(6@IN<
M?+HHK&YDYR/LAMIU*HA6VAFU60/@5:[8TW49^]'6282=_'@- !<42[4N\*;1
MX' 0.;I9N*4[!=T8&=>^')V.!L-DO0<?67:*Q!?#'G63JC!']_V*^,C>_'&%
M_;95'111P3_><2S]X;JM8BII3SROGIEM(HZ[G:>XB-56H4Q7 ;=]()6#AZF*
MSU-]'P7I[T-(\9Y4+M](5'&Q*:K8K?WHD?9;BRL"ICJW8Z21[.E0]@WXJ!O(
MTUSC.I 7@N:3-:#YKA90Q2%]B'2MO6-8NCS,P=('( ([1DW7#W@P:FJN'37U
MC#B=DC/R85T+/"DPT*4.KL-&AX=.S[%/J$(WQXVU"01*MQ_:0LG?JL0"T<4"
M'.4)_#O_BG!^S5.?+9=6L2(8W7A?WH'0!88=$_&S!2%?'XF4G'Z=Y?A1F.ZC
MD%/G0K-OR$FQ \"'T@ZCJ=QTW'0CJ"8.>]Y@!-77'4M;^/415!,NA:LUX5P%
M"2^%K09.> PX)1QP"EC(N^MT#SR[^W;,_'2=F.J@8KIVY-]X*_G&8ZP;#=O=
MXJI#AFD0;R7TE"JQ=))*R*_N3 [(M>D])K>(A(9U)ZY8)Z[5&=9R8<334#1S
M4 )4Q'.3E-2S'D/D$+[<D 0)PY<;YCC=$M*P1<P2=UB)'!^QJ/C2/(0!DZ5$
MG((39-Q@I"H18=")X.P !H(J'90BQ<C.3J+9QTG$R":3TJ\[0KC<^6KCN,Q-
M.8R;HZ^;$RKFP4=@=^^.L#6R+6_ 9C2_NE*E5Z[:U%6.;=WMN;?'\\96W+XF
M&BUA(SA!S^ =,#)Q[9'.9F!X"?&'XM],I6J6APE/:37F>@"N3*Z<P,KQV(M)
M23Q"&X;"/^6/'F\!UB96/!ALT;8K.CNW )T;CX)?<()-U03S'+G/63I^H>2H
MJBN\ (-R?> 4U^#'.UN!"@FPEZ;?\W)M=+1[&?8_";GG@X7@,,SVF>74;%*J
M3FTI;=6JSCH=*DMBD4D&661@?F,E9/K#5H, >]D(_*V.TJUO"70#S3YYC\#Y
M1M<82/PB60>;=8$P7R4!GSR!_F^>%>YZ6/:'7>:;[ZR(VY9L=2MO[RL2C5>>
MV\4IXS7M%KJM%9>;^]@0'P0A? HK(5-PHL'9*4NCN67@T0%;&$JU%%],P[3$
M0&X@Y/7J<8"T\CDJ9IB#,)M2#J-=FP+T,8JA_A(_L<.C5,_6-.!,)7"$8R3*
M#?LKZ)@( YOFU .#W1.*>?5RX-B/G^0-!G""[KMABS"* X'^4$PW(<4J<8)<
M8,YEF >BT(S0,KHJH+W6[-%?LC8@:#8Z*:4\[-/'C^;VL1?)@APD+50+<(==
M? ZGDU27=!R$5= W."IVG#=N-H=<;^ZC-96%6 ?KA1Y)I$EJH_H%'L1(YG-Q
M<=5:[8Z!P+RTCVOJRBZ:'7B6-'4]_]$%L5/#5&O:6(YT/ 0D&+WS)8-3!Y1\
M2"HO91*>E05\%<T1Y$)-UZ0#UMFT!ZVJ=T0K/#^@%3Q:X2\'M,+W*?G[]"%[
MMK6*V5ADC076A_9D':M1VI.=M<91=P&1B.(3\BGI=1:):K@MV4V<>&B\ZW,B
M'U^_W%@4;S2:E"+:ZC()X"#SJ>_/&M"E4LP'/%Z?ZQ6[%2E3V15,&3ORI6#B
MO$QJ]D%:C!L1M2S<3L;4[X+6D!E&R\#TBAFI$L=(Y:9)^7C^W#7\Z7:#K)H"
MPU)G$T\A$-1HJ]1>X"ZV8?=%%P?!]KJ^?789T/;I7.0$NHQC\#LG@C/",K@&
MT:FV*?6\9]19.R1393.6PAST[H$VRVL%IF_RO6/B>PNH-U,3,$Y[4\-?%E,W
M#+*M09(#R=MK)':)ZW+E;=XK]F.6OL$(2:W=:<K$(\LNW%J\5FIJ.7>@$OWU
M MI@KZIBR3&&R\+J#?K8.44YN+5"8WV==IM/ZY5P^C0*5%FUS/T0<BHJGAJ[
M]ZT8//"VV..@?>S$>H%5)IW4T35J)5Q3>6+:D*>4Z@* <V1*E<9VKH%$E3>.
M\RZVH1Q!](?I6TCVD%%'9?W=W]THEM2).D75B6A!=S90CU8"W,PS;+L^2$2!
MK%%T+SIUTOY:9]O:E=5@-,JEN&ZBJ^'B566=W5SQ=B C@U.N4*" J IP?2 L
MMY26TL$E1K=5'O/CW'<2<3FX@AQT1EO:Y226%[F>)3<Y.O.#8>N@LQ!Y6'0"
MV;]> <S+0/PAI41RT4($P6X@K1!"GZ^"O>U=34H0<\D4XHP$4DE3WVE%X,>,
M%T:R90+9DJD(.7(=)[<665RR@H03IAZ8+*SVFD5U\4(6<#8#1>'L"O_WX"PP
MJF_V3DIYB&0'V[V@1$MJW7\\4ZUTOO[8Z..3 4K[[NF]IXGW@=GE Z[!1I2Z
M8%__-C>;MGGR;;:YV;S-DV^PS<WF;9[<TC974M/M.[)^L_>*^ZZ;W;<O>,V(
MP,;TBNZ0F;?KUI94Q4X[NU>OK8US)[VA;;2EF@E1FZ_I,YQ7E)4*68_T%WE7
M@QOE$/Y['R]!IJWC#J G!6A MMK.5R7'U54:T:A<'MY42U\1' S=;]_P+FNG
MV1\/V[";!(:=EY,"D9';B0:$@-EJE@BP<PSJ+30V4O*@#]6"T)ML2@C>B'>=
M:+/8_U8DP@%M,"8]^O"T?D3^;6G@B<!CR0L)/4>C/"ZO6.%#L;WIIL\;<98$
M 38;YV)B]6CCD3'\J1+5,(-1#<JU@J<2Q"E23@X 3Q,1NC53.OJD35S/0?=+
MGB^IQ:=0=GM,&\G)P.#I.-IXD*H/ZE\_^7+F96<[Q)Z)5+H""1S8XF87*3N.
M/5!FDC_#)@:02- *<[7@1VXM2E14\M-HV+F=U MNHT(1E<#3C,-%:X5DG"^_
M0/&.5_8]L-S4\"> ^6:UZ#1U&A2EBN^R)^H,NHY7*DT"5Q\G/V%\.>P/N'X2
MY"1C041J:_RGV>(8C*-O6X0(DAU#!-L,8T,X(#F$ Q1>ZI.CLQR8S)VX1HG:
MOW/51<;&WGIPAN+[O@E$AJ,6C*/$6\1158G&%ZS'8N48Y"B-QO.$;D*(BU<[
M#+6VNH_I[;*2'(D>)CN/5(%I_9!3DEK&_UN]S!^V).>!_=-O-ZOSWX=9PWH)
MN%',ICV,:W^^4DK ;)$28%_XD\<:M((3)<[#*4I+R=W5[4/(WDUU1\O:^C08
M'_,]I>#QL'6X_,1(ZH%1@:_LQX=G:5:V]<XV8ST&:4\'/)6^&3<]%2HT##B6
M*!+NPM[T>#)BL,Q%S#9RJ5N??2B)P9WQA.,2W///5\)&2) RCHGP7FM-8 7V
M.T:[K5O4LTG\^Y%'N5'Z"%$D=K1_2-<BXO#- 3J#YG&897(73D3!"APBGH 9
M$*/8[_G=_K:=%A/MN_ZSPK8IJ-[0HZ,P ,&Z952&%9*]I[_!G^;.^-6E"^A/
MH.$!0C.=-DAD.Q-+M>Y4G\0FK"#6.5-C7+!FGW%@!2#;KKPAV'^\M(JRTSBF
M)QN7G+&0I"9<4O\)#UK?[H@:>7% C7C4R \'U,CW*?D.-3+6%N;SW7 AIL]%
M5U@0:'+DCO7KD3 /N^<ABH(K4B_SBK7VIKA@Z.)9B\ ^%#O=7P2*G:R"Z0I.
M?PS90SM,;Z&@K0PO!54.$[(ACA%Z!#X#\^KO+]_Z; '>_KXYSZKBWQE'GUZY
M(N'!AG-@T%P]PE*VHZ?/1L#=U<9L'RX5P Z.R^7[?!V$G4.,PTB*"@H)8^(9
M!+8.F7?]7YW\DBWMR]O01%L2P:&SQN;VGZLF5X%=0^6"Y'E_!;O -Q=?BV8(
MWLT3CE0/X>UAXW0T&\,ZI+A<9AO*%\E=T$@ F6&]GN6B)M'(IK_7 "9>+QT$
MY'8?!3.N"B@D#W%$-H_\U0-3Q] I69FKV"8HAYK4:5YF5V2N.4X":])Q_[]B
M28 => ;3J?B97Z%5SDXCF;)HW/2Y;^ABHI<'>1^@CK%&7]VLYIYSA,-"TB90
M(G_9N"4"O)F[YT?NT(?HF?J+%AD?E#68_CJ"=X'X?)U M>GC$Q1]_W2. 7%-
MT;(IQ@%RQ&?*F&]]3I7?J@"FK_6:MII3X_)1G7C!+N1K&VB:1Y";\A9_7_T*
MM6M$WWR%5,T;OXT\ ON+-B>@-D?.IQS#\A'@OL87NF:@!X_ DHV$[D=V.;.
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MP#6"_T>-FHPVC\0HZ'316;5!M6D_VPEL.T>IV"*HQ3.H#-X+.R8%P WGP/"
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MZX52!R/?\T4^U5]/1[[_1K/_]^N*&I\$U(-7I0 EL+=%'#W E)(C^R?%A,+
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MR1IKTKW QD#/@T8R>\@&!E%9 GRG'TG62#E#4YQ?D"4G@A!7VZC([:X6\8L
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MW4DL5>]JHOXE+)-Q_)A0SD4<E^DV))=]_)U2<1=").!;\2-')&7TP23!V!8
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MB?5)Y(1FU;"8E569%!_G+.>(O_,_JUU4^4$;E^D-C<OI"097%Q,2P.;TZ'0
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M1B8PX23I&<H[5+,BTU,9^=OP6U><(ZPPODQM-_&/BQ@>(X3B82<?U@2O[&W
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MZ+$XP_GGA#]<BDL"M Z(*1]X<SIR<SHJKWB,+X19?E)>9>1Q\KF&*@@( ..
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M5)K3676):"\_ AD=D1R@\K$X2B>M<I#"79'&6FB=>=/DQ'T]K8@IP ,Z=]D
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MHT4/4PJZ]FNW[:=K3F65DHT8J26B$50[VB4VT9)R",SHLJ?"ZD!0F!OUL5$
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M0>&U65+8&%0]*<&T1EO$9,EBOK.J@N;#%"&RB 4_1*+)3+T?K,U-]8,MY._
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MYXIV=C-X6S[%K&OO-LL[6-X2H4)8SII+=LYQW9*CZ3:%57ERE'3S!]WA*H:
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MUP5''TW45<CBE S1*QX/).6?1M<QS- $OX(",RC[L'?BS,!5 34O)UR?G]S
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M__*D'\)NH&%T$(VDHSY8L3$9 STB=&PZR1"]D$"=P361S578Z[YN]> 0LJI
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M2TS7WV&(P^2&JWY".,JGR#NM(UJ*DSTL+((OH(B\T1&OG=GM/0'\=M*9Q <
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M)D4GTA[9(YKO0K%C@O$0*HZZ8^^PF.JQ@5.\Y)FPQ 1*S-2 2>$;#D_ SM0
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M=N*6V_DU#4%;\3\0(&)R-^V PO*:2$O >/JC&*>76L*QOTX:^EDR'(*2N0?
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M)5,ELEMA%LNX5QJK)><B,2V3+ LVO[U?I0MND(8L/TQK7*?.N+QRC?$5ZNF
M,3M@Y[8>JO) C$]@C4$V4]=:&_ @7U,/&>M'[H^71=$W=GPFSVVY$I=67MQ7
M/3U'/1]$+NCNIDZ.438;C2U&[T5N"F?7DD''2(R4,=R6A" \'>WGZ*TS795'
MXWHTSP''=9S AF+AJC9X\?$SL\!89C0>:!@W+14:$6>DX.=R>=M)9=Q!7I3U
M_IH[..K/I>X/Y#!'7L&/P/WZY@H_4XP'U.IB^ \LLE1JP16C-H"9\=Z#ASZ(
MLLP_".E@2WN%(4SE]#"V[V)2B#8@W!%C+ 4BI8.7PZ)X'7Y2-5>K&NQ2/8X:
M9NW;XS&:JP@]S/_T_)5[%B>H;@\?,];U];>(@(T8*V#:Z)/:6TILQR!.(=+"
M9EG("#"PO[W616(QP0%$="1U*Y$X%+1JDPAY2$.HBN%94, 52W$BR?JJ@[CE
M/8FEDWDE,3,RLC!;MB5SLOK3TQP==E7HP"I@H\XUB@;:RR6KL1A4W!_3LO,_
MU^KPD,*#ZVS08YERH?4:)6\PLOL<0WG422#B\,9UV ,A^=A+6LD^@1$DZ7#M
MUU;ZRSMO<W-]'6Z&V 9[_CG\&TS^^1CA5S=JZ^M\S0<P_BB1 3WY=Q#,Z-9?
MW]FI[S[FJ"?-"[N66+0RQ /EX/+OK]9?W?>I4Q.(;\&\=497>+_UO^KD9H9M
M<8-+O.+[6Y"D4:H>3I@-X!PJV8=[3^@7]GX===2OU#/@G7]Y5_R<5,6]32_J
M8G)S-!J T(XZ]H]*GW8TCK/0/QQ<XALFO=!?H2WLC?\_?_O;W_Z]2O> V1VE
M(/\TNX^C V4J\!1F8.)SY\R1[U8Y<ITC1]M0)<F73-"G[W=?.='<3H::E$6?
M( WYGR?NQ0^](1XE-Q&\,"8'SN'PTL.&P*-3WNQJ]:V:WP!/=ZRC28T^W*T=
M9GP!/NR/)/W&NR'^%^X/]?5J+WP)>^'YB.+VY]^2'IR381&;V7_7?K(-<1:_
MV&G#_H&-P02A_./DY(O_,4W&0_\WKL3TC["T'8_Q3SR4FG\6=KL]N-TIMBT]
M@9LTR]'M_VS47F_7_9-!I(;GT?#\"TK0UI]\FLYAC<(A.!/^^N;N=FW[R0=0
MV>A%V>C3J[CG?TU YY[#+L^_PI7[]L3NV[B=9-]N_?=IDGR#GUG.VWH-!"?I
M* =. AI;,'4?>DF2\E6'6=1#A ([FK&[N_'#>W"E!H%MQM]?H<VXRSK,;PAR
M:O_N]R2+AE?^IS5?%K'< :-E.F_#X&';'4R\C.[Z3.9@0AP7I3$.$W>\GAKO
M#QAKG6,($\%PXD&^%+F AH/IR;OS$%;3)(*#C#-X#<PX*3S7>9'XRI(5;'<]
M+NFSJA.I%LCOC*6'ZCIB6ZU:R&7P6/G0RQ)Y":SYHVR2%'#TH]%5TG$+.!X\
MX!\SQG__[.UST-<<)UC"FW;\4TJUO5< WFELI71S1;Y2-L&0=Y%BH,<> 8V!
MKQKQ1IK9L%@5[JW,4A9NTL-2(+YJ5T&N2 >?*>VPL\>K=I5D@.E=SC$23%_:
M><UE&2W[G9W?5P+J"NASL)EP(R6=<\.;21*I8 %LYI),D[H)CA/)@@V55-[[
M<$D/I 1SX G""99$EU8C<K?#$?&9=B5-*@PK!_"LFS"-D SI,DP[/<R3RD7$
M/L<@4%R.9NH=Z.F*3M7A=_;:PB&.=Z$[#--XT(Z'O5E($'XN27T.KI+?K49@
MTP/-]C#4M5[#-&E'W(?3BD8W6(524K<_C^@R=([GWN$-N1<&I8_QN,8#W5"@
M&E<->5DV;C%&0B+5[JKPW.YPYN8C.PBMR!6YQE,-X_, 8U*L#23V$JOV>S"<
MD7(@2M1%,Y#MJU;K_2M4M_1VHH;Y*^VDU^/M0_HK/%$=1! 8Z?I3J>=GI94R
M%Q <>E*&2RV%+JMOV2NS*RW1.A"L6Y8C@^$FEK+U97^,VLY#(M]%!XKQ(J*.
MF5]&Y,W[C.PELI/X .=05<R^E3(BJ1;E]I,_Y4)8\5Y(T/^TLIYTOD]^,T5Z
MQC/W5FCF2V^MP2[Y6I^7&&%<D4M@$*/M!=]X3*#!G<24F+M]]==B#LE-@0=>
MNZN31>EUS+A2-,PLLQ@6=?/)])<R%=JVYVS<8_*,O0<T/)8Z[87:SK=<M'P]
M@_I:I;\:!WI$#%;@O\/\W:YY%SE3H5H/VWB(IJXNM'V=I$TM/]14J?I_V"I(
M+9W2@C2R2N(T?[?"3C'Q'AX5UKKC>CMEY89X4VJ-\<I3,7QYHB5#"L(0M@IC
MA0T6NIE@?C+23F[ =.Z>6>U4TC)C@'RQ"8'9F<)^(M VIXJO1;5#H3N8HH>I
MK>*(^QJB6T'F5H*%< IR4>F0JRW:W:+W%KA%H]W>V'L[JR)^;1Q^:9[Y)Q_\
MWS^?_>%?G!TVCDPS=&/_-_^T<7;QA_];\ZQY<>(W]O]Q?/+UJ'GPL7GN-XX/
M_,;'LR;\Y\5OC0OX^P]__^3XXNP$;GG^A__UMT/X_:?&'W[C[/"\Z7\^/H!'
M7?QV>.[1SSXUCR_\PW/_Z/ ?S2-X]HE_>/SEY.A+$^[RZ?3H<+]QT3R@IQP<
M?OAPN/_Y""\__]P\#^C3"QS4AY.SIG]X00-\_X=_>';6_'*RWW@/-\1K/A_#
MB X.+PY/CAM'\!F]+_P>'@8_]SY\/CIJGE_XS7]=X&!.FV>?#B_PJ7"KQBF-
MX?U1TS]J? WH]<X./_YV@8_#M_JM 4/%2>%IP]_0)!X>^V?-\]/F_@7.*_[L
M" ;PL8&#@%<Y@R]@)"=G<*'ZR\,9.CS^Z)]\IA_!EV?-(_@%?$1#A6DR<W:"
MLPB//FL<GS?V\;;G-/%-F#6:,YZ,L@7<;YY=''XX5*MG+R>NH8?=",<G\/!3
M> 5X%@SA2Q/>_:,\MW%Q<7)VW/Q#O=D)+H)Z1./<_+!Y$,"LXA_G_+)TY5>0
M@X"EY?PSC,W^^=>3ST<'\/"+P(,9Q!=L?J&G?K#F#R2_V?P'SDGS&)9^OTD7
MHA!\/,')8GD.J#L"EHE$[OP"WI5?&(<(,W5^"!\W28+\0Q$UFD5X%HU+;N.M
M[*_R:O\#)LCZQ@<Y_0RS<W8H<K9R0!?B_=\WF\>XM)_W\0DXT(LFKG5Q'=__
M 3/[Z027G>8!OC[^B,()P_KT^>(SR!0_SL-'R-*IH=(<P>UFWG*;)"EB<*JP
MTWW*R_:J\C*KO*Q6E9>]=/%W_)#:^G-0V(][D7"Q&=ABXX&4-/TI((T"2;UU
MPKD*,VYKT5XNMTDHC%PYK'HN+F'[*J'$[!7AD&/ @;*W!D1<'D2',@81B3JJ
M'WXR[T^.Z4 /4 CK.M0^D"$MC4Z1A!UUAA-&;1JVS(>T@BCBP=P[R!NV$X$)
MX-.VA?RN PZ=-.SJYJ A-U;S$;.\R0Y_HDY',+'=*)5NM@(@@SE<J7 D/<L&
M:)=55.2!'>OD(0OM%?J5$'@":_G@I-H9\['(PB&V(640$$+:[DS,4L'*&Q2&
MENYIU*PNSF2J&?+H>*PG:,UON!20<!OLV.!@I(*JIW@\C+U-/8>^P_/,'(N$
MV@/W'>EN)YJR?BN^'&N*Q'PW<N$EZ,8T4NDBHX'B,E-^@MJ2'-Q  1&17MWH
M.VI(IL[0!N2B5.TJC\$UF<^!,-GD4(*6B0FI@(!X'3"D=<G)'FU=5(M1AKPZ
M! V@PQ9*T0O0_'R>]^303]J/N[WB1KD[X%%4<&7)R]B82N,&02[6X9E8AQ7;
M* 16D',V@4>H0 9!)5,D8\8A5:)?)OK/@=AVZ%A,!RTD58Y$SJHZ>,QJ_'MK
MZW5EX JB+O@Y0T0H*J88O%_C=_TQWCSS\=\@8ADACE7BX8C'<Z!U-;\/$?7!
MI.L%S@\Q2G5>T6QX&BRHB"@UR0X&Y'%TA> ,[T4/Q"#^&-TAKP0Y<,*M[T31
MT/[/,(P[BAO%P?GFIVKT*1H6,2'SJ"J1=$7R.5".X+!\%F'2+8NF(<7I4B6&
ML=#.JI6FX(P;(J%QT12ZBU9F27$HA1GB!R!:H8>ITRB?.(W*TJ8"ZU7.ER30
M! 9%I'C$L5^A'R*PA1H^.@VG5 )CY4V,"L:X7MS%CM#%1:Q$I"5  *04/ S4
M, :#ZXY'B*W&^".^;L6F6K2DUT.-X+H;S.B &](>(3\A'&RZ<*S"*U'7DMLH
MHK2(2HE8%$8E>/C*KY\\'(LDM&PL9BAZ)&8@@0_#H.PQW*_'?0ST>$1L]OL1
MDMGC/ ]@N*D,VAES#FS/%-FQ&=%851KS7],T.;01J;[ (G2QD/N*L.0*'88$
MU%]1I47$EX> HEP@V![EZI%84!E4TS.)+I)%^UP6S&8L&7+*2I@Q8(V3XV+1
MQ.$BW#F?797 .G:;"'?0=K\("[H$) 6':YC4)L<+1*4B*9B'R$4,-T-,JH*#
MP1@5GN'US;P&^F1NMQ<PD)T"80_,.8]B2H;#)98L,CPH1'N5Z2@,D<#(R0>Q
MXW#[,%$IDP<O;%UJ .VD;Q<+$'J,A1\J][8LD49&">T75"EM [=)9;QEP,'J
MP!ICD(<IM^C(AYT%&G:J8PI6<EO+ +_$"!&11>M7M<:RYG]F8E<Z3F+)FF>_
M49C-_ Z\9GKTAE^EM.Y.D?%85 7P%_^0RVBT*1< -QOQV0(+U988AG =IZ.Q
MV2($YI,W&WTLMHUZ"5;1ZII_;HE.DJ\'7V&9U#,+8IF43^UJ'A4HPI*E-($G
M^:K4^O3@ ^VT:C\PX[8OCN VGO"B"[!6A 4PPANK:!,NTW (@^- 9XP[,%:&
M8%%4J$G80AW<]%<,L?@!?(9OO1HP3EP1/4F]H&<4;7AUFV%;1HXP#O?1(=&^
MRW-:\'C%)*3':M3S16P^RY.=VUNOLG-6=JY>9>=^$M\KQYM\8C8#YB+B/>P8
M3/+O<" 85<[9=.>LP#=>2L>9(U7(K)G&S>]/G.E [=[V\NB?X#FK%Y62K"G4
MRF(BSMX)/>NV+V*O6 )E^4+8["<W<*K.KN*A?RC$&952S$,Q'N!.R'13R#<6
MC[*HU]6RS_15QF'+,4CSAZ<2$D%'6OGJ"2, E^'_LD_?UC#*3&5E,!!+2 &Z
M3!J0Q9U(I6U-.-A$H(I\C;E@KP5;3]EF+3L4 (8G)'UP+85.(/.D(M=N4L@;
M$)U?SC'(D(<IW&77()329T/<(KV$[Y5GT%4VAKLT!4X?;Q1@TEKYK"8)CN<.
M0C=6L'H2X3X?MU044-'W4@ ,H2)XN7VF%B X4!@(Q[*$F0$C7?1;9NBE O8X
M&R99K H*)#0E]>_V:Q.SIO28YM=0C5_G=#A.V$88;WD.:A45,:@VADN$!%$X
MG89A@BRFDCKCX+,T2@01;#+-^D/@&IDVD_AL)$J+)2Y^;:/S>FNEM;I26U4V
MOBFU#]BEI?GM&028H44]C5A,!Q2'SJ R^#,9?+#W!W&&['APHJJ,_#Q&7D56
M5\)5SV(>)[-AM2:QK2 6<7";LBMN[N$YUQT!8*T)0U>%%SIZ30P LB2XSIO[
M9I=P99YZ)F0#.$V3[[?< ,7!D_$$&\L9!BF8,L9;4Y4[%EB]%I_ M<$JN:]G
M.XGL#);L6*#PNCF'4+_[PY'@+&MD4[K0MKGQ@%(MY,'''!_D:#AUOZCBH2Y;
M:\^J2W(802=/^2)-QQUP%D7A?P11O\<8_N?\U_B="K30X58A,6,J_]]+-D$S
M13]J5?3#BGYL5-&/%Q[\.SSVOQY>'#?/S_VOV+QR\L'AT_,DD,_$(5))6S#!
M.H-)8/'=.,U&)M[= MN_G&[45,0AT5!L] V'&4BG^J\<MMCLPR]'(0/AG (U
MQ$+_2D1XU-'O@OA?\AF.#'WBO[_:H%J,T\_O]T_>4/6$A@5:\%.L[Q_C]O 2
MC2^-HY-C_^/1R?N3_<89-JN=G:Z]L)=Z]_[VS83GU?."-F4K>-C <F!4VPAN
M5385[F6;,UVU!5?1KG#WI1NUOS[*%)=]=H%\5V5C*AV BYBU%*[(<_AJX*KI
MQ"-M\N@ZB\/L?>& @U4,_4+]MWKEOUG^VV;EOU7^6^6_+9?_AFWYC>,_T-=Y
M\X*<G?QK,'#TV<GG4_^WDZ,#;!L_.OQT>-$\^)F]N(?\\\?Q !?[SV7V)Y?!
M,:J\R<?R)C<J;]+R)K<J;[+R)BMO<KF\R?.+D_U_H /6/'MI'N42.%Z5RU6Y
M7Y7[]0(G[='+X#<KU\]R_;8KU^\Q?!+Z1^C'G;^_"O]3V]Q"*0W?E8_O0455
M=U9.S5JHUS@^;O[+?__&/SD]/$8@O),/_MG)Q6^ZI_MQ-?QI[0G3.?T:]R_]
ML#?Z^RMP2M+VWU_%?9"G_ZRO;ZW].;Q$1I@G>NE?6_J]6XMY:/YE)UL1*M]]
M@R,K,RN?PK1]Y>_\FHV'[T97( OP[\"OK]>WEFJ8"Y2:10WI?8)(WH@]KOKK
MEVIX-J%VVQ!J+],0[^#U7K!NOGIG<83__EC<X(]EX$!3"0)!'^&+XO=F\<]\
M+&/-_\R[G)K$[@S1JO;#83P*>X3#/2#,BJ.C?7]%BMSQDL"3/\:9*G=/4E4%
M?Q,I!'\+#$L@.,IU(_!#PR, .^A0-E%_Q>(($$^]^#PJ956/##QFQ,ER/1VP
M4;OUL:>]D*I6I0G!?E(>>4??VV"M8[LZ]1S;E<C4,F">Z85^:YR!!Y A;D2_
M%0]"@\SS1Y)<EU.(^H>#-LW(>P1]SZ[\+S&NGW^8]6@>G?F1$>/=]*3;KW)A
MP"O4]VN>K&_\OQBHHFXO[)TQ,$6=J$OD"-+2836',PM5." L^E#14#%P6E_5
M1^>G[Q%"6W=(\3,I3R/S^T@Q*JU!;:('R#7Y1%X)KA/S?OQI@=#1LA" "3,-
M2!-0!Y_%6'/FOB.%@T<R14+8QV>H#I0.:\!Q]'V<R>*<CUN>B!M*FBVF0ZX#
M5U)F,#LGB".-"Y0AP9?%(G=ZERSNQ"%WGW.E^8JK6S  H[%&(;)Q>AU?J\;T
M/E^+;5IW/D!W6*FFQH,X0_@5O)=4V,,73:3[0-@MI;+\5>"W;CT#5&"$6*%>
M(. F/HV:D (,_?I@R/CJOZROU=819T=]"Y_1RZB2^$A16K5[(<RQK;/^B;HS
M#41-B:>:CPQ&*;V6A<V1R3LA>FV_CPVWV"A@#PW&M;Z^7LN-S%T-_LN^@[8B
M<%P->YZ((Q>HXUSJSJ$SM$!E9G/?;GQ3MUOX#GEO&S UI'W/N/5,(9[[$.Z6
M4FH*E6HYJR:SK*[$JS-QZ0HN"W9G$%A4&K>U!A1E YO3CAOG!XU_:G@-;$+L
M(*8&[6"=$$Q''YG>P' 0RAT"%2.*+36=:9 6G#W$@24V+B*F0^@X%#BT?W_9
M L&E',O ;59CD4--(*TL42#=M:=O1K0L+*JPV2)3'LIT-QFGA(_;AZN&R$R=
M46_<]GH .H/_]T%8"*!/>H.,YBG3<3(>:?X4-B/HE,S,.NK(3%%B?GH!?AD2
M?(GMH(I=\9$%%X%O)@GNUN9#!'?M\:7VD:W]*4'QRK3EEXG J!&9LLV0YW .
M,:X2N EC1#U7C$X^U6BYJU/&B$3,6:GJD$4F)^R=5G-\JD'*S0URC%6><MJI
M5[ ?@>L(BS+NLT?%7:2,!IAE29NA$7\:5_J/9"RX@=DW!)6DXUP:"2&CGPSC
M04PXDVYB78,U:P*];ABGZ-H&?C=-8&Y].-K $B (TQ"!,O#GUW%T$^0P>1TO
M!KRJ6[*ZHE-JE=5Q4+E)/^W)Y]&8Y/<F)<>F9J:P[?VUG< H-5^3]CEK#WWE
M)F1X Z1?%Y)2O-V^SN!4#;^U0S@TNF*"I3#(YYR\!SQQDR5C<AZS"'W+D[2+
MDX1Y$&^_<7IXT3@B-J;CYMDY!9P>+3LR95[N!]+K+#V]U>[NKE>\V768QB$.
M.8/=N_>Z'0ZS5^_.X:+]'IF+R#](8=?2: XSW@%&!4?UD?\>G0O]X_V&OU??
MWE[W_I^_N[Z^YF_O[*[Y>WYMT]_Q_Y__]>O7-<I!K>V??(*_.<3IGQ^>^ON_
M?/ /C\\:CS;_,YFP9:@8F#/[O?76/QE2L.8-#D;!/_^(*?'W]TN)_T@)\6<1
MR$79)_7B>0U?$C5;B(6I/6*J<,+3'C'S-^&)CYQ$GO!44H6Z><*/J0HOW'>>
M^, /.9 HPH#E Q5F%3S.*JBDPDU$!S'%6,/@. 2:M?BT9Q74G183B]=FBHBE
M$9YG"1N:J+DFD<T$=&3N^&Q"-LB$I!W;A#C1_0.ZUZ34Z-LJ[KF8-9Y[D8FC
M(^S=8C)71:$L&"<;<.XJSA!_NFW%0-(H&_<$8A#=JG:8(=:[@A!4@0V5(,1\
M6#I@8BNX],KO]I(;#+> W8"/;/X&9O9+*&:6Z9Q8 ;R+J.D0^+T[AAMG5YQ.
M'F<^$RL((:(GP(NP[S E6!3V#8X6W:J2P$5)X(PBB''S,494"=]KG&64IJ9<
M;M\MF,FB 49GK?5SEPYCJ2"Z Y7WM<07$=:ER@!I,GK(/^-C<J!:[@4M]_4B
M# X!\+41E?4ZC'LT;S:4G(U(:JV[;9O2"&,84<>C#([ X4E2!NM7KH4V9D)B
M)[#OJX/JF+RA<I_!F&P=A4D0R=2 ZF7(XY#E+@&Y R>I#ROZ^A_ZH;=@^OR(
M$C$'<%^*EVS4:*?<X,>/!R&\#&J$,;"9@@G,I DL_]M-?P5>8I ,7O,DON:9
M1I*:.%L-/&4Q^TDV4B_TWW$(<Y42))\,V%<#_J<>,-C.*'H-4P0:.03Q2SHR
M_/-H.)(QK/,8*&)^ Y).D?/B3'KFA9+QJ)<DW^@IZ"0$ALM,HN,3];S2V<7H
M[(-4EI(B>C5M+27TS' 4!DI-(V;<+"IW8*6\O+#]WW&<Q19)\8UFJ@#%CZ[#
MP:A:^06M_,Q[<Y^)>*<8:",$!$\JS%E&' C$VOFYE(<1'1>LLU>M\^.M\XP+
MG2?75@M6=,DF&67>_Y@Q&KF_LR0U8+3F5YYX\-4*+VR%9USB_YELQV'G)1#R
MT$(79B9[@1#F0@4L/8XZOH 1\Y$/_2K*B.,E5I6P-_4<EM_?R\YA.,Q_5U*R
M&._\^VPR,L=\"ITF>-J$U2Q@URA5F;C=BKF "FWU)=V0PN?L*"J['PY!!,%C
M)U #<3LEM(ABP9*KCG5X:8+,B[:X<;%+RD6_X#M@?9,$(]?L],R,XO20L./6
MVM[6TQ56S->R,V%47R-5)9.-^V(A8"^.-0\KVGYD8<6^Q6%$S8O^-0Y#F-7X
MX!*VV^,T;-_*\O>'O0@\/RS.%-VV_0)V\9!KK.A3($_#&('3D<G XMSTF)E5
M7S>#:<GO4C@TB45CK(ADTGI5?@^8!F)5TP//V:K,RT4>\*X4F**W(G&WW[63
M1-P<@403(2'*PRD/Z2S,P8X9W/I8!HC.5%?QC?9C.6NB<N0N\#3T//. TD4=
M5<F//Q_ 22_+L (-KNB'WX3MS9PF9436KW"<_3CK17QJ%OQ[_5RI7UOSOUH,
M\Y[0I5A546GR9]36#$3YR1(W0.<%8/0(88*.PPPGP!+' J[P^([V"HM "Z/D
M+5H%-$L4MJ:E@IO<6@.P4.H9E9ZI-)#I%<, 723N4W:H%<%)6BAT;>GUX/.X
M3QR\.)0_QYU+GNJB+$V2(L6 RZ2\UJ3F.8R+OX5UT>S$WB#1&1E#:<-$V_J>
M5KC6#)Q926["M/,:3^DL!T:>L8D 9W8HZSLP74RW1(\LU+BI+RR<RK" 5+2L
MV*Y4),(7M#Z*$_E:2Z;FR!TQE<.:?SC0199!?IGUDM+K]0R,#J<;O!PK"PIZ
M)^YVF>JW3,B-:U.>MO"U3P42.\X"D4L9A+4_.30VXSX^AXE2W5I.T[-3Z/<I
M/EO99&H9"Y&E$9-K8)PU7T+4"V]5^XC0<:56+Q"*BE!Q]K+$F<3 91,V@R/&
MT"$;JQX3YA@3<XE4% -\/)*XIM'E&!8O26\=-HPTN8;':0\!E]J8,;WYE^SQ
M ?*0T3M1B@#L(@FCV]Y$'.'@N\9B>C3]3I_OQ[M.,NYU%)\T&AWP>37[I>P!
M2J]D0(XP*J8D70PLYA><'6)3E14K>PE23]00%#XZ+8$A"K\') ECZC/RZ!WT
MW*G#%/U2F&?-SNS/N#-G8,"R239'G]R*8V%/H# 8%@BE)?#VY3_W<S\'N0<Y
M7"@MZ$+\GV<J=T5;5NZS&M,&<N)I7YN9:$"'PCA#)4JX22O4VRS9=VD;E'1:
MGA!]I1M_QQT1)1H>;+/EKN:% [[0>ZJGAL,[I3G?81F "MUJLBHF<)DP4O8=
M4&I)C=6&*O3Q>+C,4\#K^?"H%7@$C@PZ*H[4\^$CUO. GPO#%H:P0W1%.S[.
MPJ5HABW88F) 8;,87<OQ *</4PE,"Y_9G,)JYCQK8@/3S,MSEIM(PVP?ITIS
ML+<@[';A#K3KQMBAR#S)E.=B5FWNZ.2]!:2$G!BF+I-HJU?BW%BR1&X?NI_6
MGFVERM2F!?LK3K?CJ]+Y36#JU,3PM*A^!9H:?-P(";0SM%V=L$]L-&$:4R\-
MKK--Z_,(1J J:J^*VJNB]JJH_2<I:E\"$S:U@GV[*E;7Q>H_%(GYCR#E53WW
MX]9S;SSF$Y;&_CWO>?7$\N[#3@=C?1BT&_1NW695[ZYFU0E]KVY]U4-:6N56
M!;2:-=]^!WWFT'$XXL:65[-HA4/IG4XQH-.3$,>DRF1UZ@IUJ;('QVWLI%??
M&EPI/*C09A )S,V$^%?9,W1ZPBI$,X$9$ZD*G,51*82PC\$2BM5KRE8N9NS#
M"3:39(FPD<-9L4W%9AUEMPCR N8BN8TB<_2E,^2$;N) S0OAR'B*(79(Q-*Z
M:)?I72<M^YI_@<CDA?53*V:_J%H>.QPJMU:DU4G7TP,B5)JH/4[E5-V&)8G5
MF^H#."C""'?2.,JG%US)HLAFZ?#T:_9!/75TOB"H1-:MRF!D&<(>",J ?ZTQ
MC[(1PAQ=JJH6OX]J[4??XVRDPYHZ"\5E?HCL>8N2IV^"D R9\(T[]<U$O=N.
M5(AEXKI2O14%,K4P2*N%-?OQH 1U3,8[N 0C_N,'Z!8RJ@M,:69HYU0^QM()
M3&URN#OJ>*U;BC0K#NH.T\$/*(TG6@)"UD<@?[H3X>>5Y <HQ@./AQ=+,46%
M"]J.7)&',:B0/!S/5"J&0<,0I23IQ^W [R>#: 0W"?!UOT4@/66%7#9P6,;I
M'99H"M_#*R'4" ?V" ),TG)VKJ@L93L!<,'.7?F%W%5.9W0X,5!Y(R<[EOK@
M<EV^QK0'['4<I;O-F0I/XIMK_@?.!%.8<>H 8,*QP%>C=E$V56-HE20.5!WR
M2%2N]&)$&V1,%V1<M^N906"R24_@I ,!C^B<@Y,OH>0'5C]'^'SZ"0*9\&&"
M=H$N@\Y$#M>V-V4_[8!=EG"MW&MT@^%@*7XV?-TD((RFL^8?PHGMBI(NK4AM
MNDFB4DU@3J\H=8]X;'1 &H$AO(YZR9 2I[A,DA/$F&C(>1H\[B?CS$E$CC.5
MBL/YX PNAR#=R'HGH>U ,D"P5IH)G>1SB#(94'(OBSBEA%':M._9856M6+1]
MV@,.U'!MYT#EI46\0#.)SSR,^S0$C CC#BN".L)="XZYY7Z29WM&)O5"2VJ2
M+S]-MF4AHR*3>P6:3ND-W@=U)8(Z+WKZO$B^0)O< Y1]RWARBFR2 YG/!9K\
MJ_-<WO QJ>(\WYQ7/;FCV7'H=J3RE*3EY*:2G&X4*1.A',ZN_Y>:8#U9:=?K
M.-,NM;FWKJK(W=^S (]L#Z/+V]A?MOC^NK(&5 5WINZX9S+AE@?O3(Z3Z;?M
M'BX2^?0=1O.)^ZTQ)G!1.3$C.U 5:"-.$/4'L,!H$^Q29*?'S,U4T'UH'?BD
M\I727M'DQ+AL/)+P]!A?2-F=+$JO:0N0':2XE&22J'F-?%3C).2$S[>%CU>D
M$W?P1P$%Q-HQ&WFQ,&@1T923JX&U*GP8U!ZA$ \54KFT3SC>XG72TV":A=0@
MF4=J-9$CFN4<VS7]:,6MVV:F3L*T;^$.02?'R@.=PVA1VA!4JO=:9,TZ/_FT
M;2FK@BB\YBO=%P6"U$J3;W"VNXQ4EQ2=O:QN'K9&7 AT'3%Z+&R!@V_J#E+>
M:3J61.Y)D7&9%?JI!^N<<F&GZ0>]X?T1%<9*B-)VWZ;:D( .BU09"",*2)?I
MZL*OI-D(:YG5;J@;4U69(GV(RL'.-!VIL09E!/YP)VJ-K#>R)HQN8O6\8(TT
MEW:M&(\-YP1\SU"P=ODFQL'(\DEVW9GE:J58"\>?@RL#.1+ DWKDN]\ZKAW-
M44BN+SD#Z':E(TS>QNKD1]Z*>2D%>(L>N6F2)"XQ+O.R*I%:$;7I6J4)\!\=
MNRB1#]7PEEA"CH8%BW92OOPFLIPAV4*XHJ&+H0M5:N7I0S*7PJ4E)JLX.8YC
M>I-0EUUF8!>+)XT#<_TP!.-H_RA.4M6Q[(3%2-OP7)?S#MQ3.FW::IO1UI^\
M7BEJ4""X^$RST3P:#L*]"I)_BKKX6?%M/W)E2M'+N[763Y:8CWDD*KHLIBU(
M^'S4IC-+C&''MGW6\_A;LJ>@L=@SQV9&F]MX4")NNI"$[):,$.Z1@554YO?W
M\2"R&DSS_:U1%_6;U"K&4AIX9Z_\;NRFC ?&CUOC5]7Z_)<ZNWSD)ED13#&^
M>)C5&T-#.X]HRWCZ\&YF8'IRO5Z$AYE\"S >J]1*J/L&7,S" 9B!#<EI/%]G
M:)UQF6^\R^_!RXGWHAI+"N6HZ$R9?X\!!X70+X;>]B6/$[9V^=+7(?I0>)RU
M[ %7TD:$1QO&'?>)EO^?WR.X3K)T^<1-Q.I!L4>Q&#Q;D/&YIB-,BL#SCYH=
M[/5!MFNO,EX3C=>,UNN]Q&A^'_=NR0J0D#3&EW"!M&V31-,I5-=,H^J,7H/\
MOF:[)/X1YB#X<),+:DNIJ#(#M?7-8&=O9VUCHBDP>R,IM2KR'B4O'T:X*OFJ
M2KZJDJ^JY.LQBV&F5F#M5!58N@)KXT>JP%JN';"JI7K<6JK-*4]X^I5?2,22
MRDBRD6I@PQ0YUO&@OR[@$11!UXT9TAHF>36=I D[R1!=QB$=: Q.7#OJC%..
M$,&I&6Z+5%/X73^,N?66\].J;803]QA A%]%M-(=S!HR.Q;YM%P8,XC@J-O
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M' JWYJ836X]#G.^\/AP<-&-;W3T<*/<F0RAQ7YFMY&8+XO8^OMGN-UF%PIO
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M.%#2..SX+3XYJIDZ.__X1P:%[G-\+VS]>4(V41,F>0-) RQZ"N(R&M%J!=0
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M2XLG4@$!=D XJRX@K &4X&YCB%@/#4NB+TRN5\KB5/(3$DR);<97V[89(_=
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M?E7,X>DL\-!6!!QW$-!C!N1#?Z:>7B?KYT8=%N&>_YZB<.+:CB:T%$#"=HO
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MP:M?KY'=R7CZ*E,\W1PPE[1E&"=CWF]QUB+FXJ,"R-"I(P^W 6SS5<1/4K*
M[1M0DI"-^*PP:1+,#.P][S:SR_NEL9,BB#/6. 30>+*]-">A[19'MR6O1[-U
M :-U65825+:M K36OW];\I$C"F1?DDYOGR6YP[YU$,O1V@LAI\1JMZ0Z6T<
MAU_XLN=6GY?M\[;IAG]EQ2JP[M/ VBG2UJR*"1%F(XWU;$KT8NYI$CNOG'<1
M/?M'-^@V)"6,$3R9Z)C>1"GG$_)('T;B;?SV9"&;+!-SP2S[JB?S6#F7=/LI
M &($URZV#3S3+5X:BS_\7!?'(INLA_9Y,CG]RP![.A/BPGZ@KL:Q=*!^/W3V
MY]C6B143(^94H'(^R6XW7HX+9UA8P8'L*[?#C2^Q0 /^R*#=/JQ_LTY>O5:N
M4?;/D\5U_P.LCPZ3[G@7Z=C1739,^#3N)I7_H61QU[\A^^^)[I 0#LF"9/\\
ME3C+^WE5>-\5D?:^>DXBEQM[5OE%E\6QWOJT=[\Q>MNXU5EC 20;D?WSE'^5
M]_.DR&Z5CST$'WOI!"[MB#]'%GZ&9".R?Y[RK_)^GA3^%3![4(6;!>-1?\/6
M/?FDQN>WC3L]^!O;C8L+>1>JO,]3WK,FGZ>\)SSO65&2FLM[6EB?-HY)T>^3
MOZ,Y<9]<_RF%357C"<L3M1[KI;R3\D[B$KX[](@;=ZXSAQ3$9?^\?W'/**SW
MOO/Z= L]DE[HN06>M&!DN+@XTKK5BK#UX#2=HW:4/%\;"Y9U\,#KE7<GK3UQ
MC)I]&N>(5:PI)EWZ_&]*2/!XVGRV_57Z\+6)O9FES]\W;,=&-$H^OY\@G:SG
MAT;C%?L7-DUDQ_\BK_H:3,GW&&Q(!WG:&S3^[]=&\S4[T1R^^(A>=7U$?F3K
M4_H5"+\_C89XT*/DKS_<'G7>C4@P3G[>A\47G+OAJ(/5;]#2WZ#%WZ _&L[[
ML[\"[,^_L$M<+NQ'Y/GT"Z_U.756)W3RD^V_;@0V#C\P\,S7C6</O[>Q1;P6
M\WFQ2+$$B:?F"]5*"]6*A0J\HP==G[W_ZOC(B\2X<XYU^T=N87:)PUFC]KHX
M5S/DLDE]E_12[<MX<.!7)YR.5?P:<83JK MUZ=@/=\B=)M>J^.5IIR7I;I+D
MTM%M<9)PUJ27DF0Y\.PERLDC2W]=%G;A.+,G;V2;)PYK%42V063++%%FBQI4
M)PUG;8;KTES'UW[<^H[QXSN];SZ'EC*OBM84(\@.27H<2;3MDEQBXIE-=BCS
M>C'3*K=X.^0;<.1+N>0*Y=,XD5)+.>F"5)E'EI1O%K98V>-]REM_P;;CDNAU
M03,M$O'%.R,MY:<%R\!;AY1_OJ'3VQYIK/*^(C]O?I%=D)1KCL/G,@&C+GI5
MO*+EX@F6\M+\[#![O,@33ELI5RT@"<LA5LIO%Y-R9%=7*^6ABPSQ>98FY9$+
M%2C'"NUPR\)"!$>4E!<N)?'0.-E[*^6,2UJ5#D>6E%,N298^1Y:47RY)%AY<
M4J[XQ0$S1Q6<\L"BH_:0(\0J7W&*[OTO]%[J:.CPR41W'X1HA9,3MU,>=^1Y
MR+^8SN@A%.+E0FD$.%N>,"EO^Y'.=KYTB$C>E7WV3'UM@+T)%>QJ3!=.@'_A
M"9;RNA>VX4S1G?Y\%DX5/T8V&F,1XO  E/*\Y8G#6YV4]R7)72@15=W(#V^*
M#GDOFD\L)X7G-_U\"Y?RS5)(REM3'MDQ<]&$:!<_HE!F(OS5F"A=E-PY%CCE
MY*43N\4I=CNIL%":0;5XM&@J(2]/'-[JI*EL":R&NW"I "*MI)VU'(#>9T.K
M"28@^0@:[HR)3FJ+JW%8LU[8'I$A=[6:1_&I.".?-?/6-A6/Y!.;4\1T4L'I
MEN1>)/$)?,_7V53ZA" >^]W+F2V>(*G8PXH%.A$6N5X,1CHKG(AT'5Y7+&09
M=XC.*;XZJ?A3QAIR!.FF(HJ4:]CFF$\W%7WD%)VWB]=:\:I,[@MZ=8MY&M"[
MP*Z1BQV35;TA+L)?GCONR*1C%G,ZUQV"\N#1EE'0+D?0CHR"<C:?NET9!>5P
M,MV>C()R2I!N7T9!.45'=R"AH!U./M4=RB@HKP>A*:&@O'JSITDH*"\R]5(U
MU#9922'P2(?UDS)@'/[=QR2R+N<?E^'Z>ZEB2BZ1.4&@E^+IY!*9$PYZJ1I+
M+I$Y@:&7JJ_D$IGG)]*UE4PB\X)%CU^%22,R+VRDJR^91.;YY3Z_3ML@\E?T
MQ'Y3_'8(KTCH\PNQ\F7C!(=^IG@F4#:.?^IG"EP"9>,XHGZF""5.-I['Z6<*
M10)EXW6B9HHY G7*\R$9"B7=0M3;3:>.S5Y7?!L4UY-DJ)!*D)#G3S*41B5(
MR/$J@PPU40D2<GS+($,Q)%Y"GH<99.#G2I"0XV<&&8BY$K3,\3:#3!%D4>_>
M(O<1&X4WQO.\S2!3'!$N(<?;##)%$^$2\KQ-IH)%N(0\;Y.I/A$M(=?;9"I'
MA$O(.T.2J?H0KF6.MQFF:I $<7;GC$P3TP_2K6L=FQ?VB3[#OFXQKNU8]^B6
M]I0V++#&-O9L5S/Z5^^&7N_E81]%SQ(^Y@TRG >;?:* 4U\<5S5,M[^!?3R.
MGQNF*B&XC\>A^X:I4 CW\3@Q8)B*HW ?CQ- AJD@#/;Q>-%GF(K@<!^/%[I2
MX1_LXW'C7BIWN*)W)G,:B6AC&8G)"#_8X7DK8W[GZK9GL4=;+LJ=_EP*:Z@U
MTZ>,*A$]1[S2FJET0T[9>:=?FZE<0D[9.9M06C,]'D!*V7FG>INI+$!.V3DA
M4&NF0KR4LO,"@-9,Q6\I9>=Y=ZW).:3EC+%/)2VC_TMK<DYF"1. ZVDY\PN$
M"< =%L"96R!, )[/XXTK$"8 S_AY\PA$"<#+4#7>O %A O!<"&_(@# !>&:8
MGB102+]P+E'XG&3Y;;<[A.]R%<FG*^43GC?)(3V]0-3>XB[I>*$J/<*@*NEX
MJ$V/-*A*.IZ+3T\VJ$HZ[CB:TGHH=DG'BT[IT0<52=?CA:[T'(2JUH[G45H9
MFM&+V$7,XU=:&?K0RY"1ZUU*[JS(Y6-*[JW(Y6E*[J[(XV_:)?=7Y/$Z[9([
M+/+XGO1$AZUB)JC7LV?D&MA#9L'[BESWDY[U4+F8/ ^4GOQ0N9@\)Y2>"%&Y
MF#P_E)X44;F87%>4J?FB##'YWBA3W5*&F+Q)%EIZ)D358G+]9GH&A-A>C#Q.
M,ST8HEH9>1XS/2VB6AEY[C(])Z):&7EFTRFYSR^/HTP/B*A41JZ73$^#J'8=
MN;Z'-\C3TCUO,13,NQK?H>G,<75W?N<0@:>ZC6P_9-;*\3VI:%.MC%S?DPHU
MU<K(VWA)3X:H5D:>?TR/@*A61IY_[*;B3+4R\OQC-Q5G*I61ZQ^[J3A3[3KR
M_&,W]R'9;T2X<G*S;NY3L6)DY/J>W,=@Q<C(VQ?NYC[W*D9&KG_,?=!5C(P\
M_]C+5,^(EY'G'WN9ZAGA,G+]8_[)#6+6D3N+/E>?]V^ZZ^JV'SY)&9Q?>CQ#
MY6+RLLCT2(;*Q>0Y\_08ALK%Y/G*].B%RL7DNLM<_<Q"Q>1ZS%3DJ5I,KM-,
MCU6H6DRNWTQ/6)"XB3V/QTV/:0#\@#Q?G9[U /@!>5X^/3 "\ /RXD-ZZ@3@
M!^1%EO3H"L /R(M)?4@GG7)%,TAGG7+%P6H&$^:):%G&<)0H*B\V99G'4:*H
M/"><93!'B:+RW&F6"1TEBLISC,M1'3*)RG5Q@VK&Y^;I)QA4,T WCU]-3_&0
M\H@4W]&F@IZ<LG,]KR2G=_,D_.F9('+*SN/NT]-"Y)2=%P+3HT#DE)WG$M-S
M/J24G1MYTD,\I)2=Z]_3$SK$G5_C.NGT# V! O \;7K*A4 !N.ZRQ(.T?)]7
MXD%:GO&WTO,>! K 27-;Z:$-X@3@N9!6>O*". 'Z7 'X_832'7_L<R\EEJ[%
MO<_QM:WTJ(3*Q>3=1)N>BE"YF%REESQ?,)?&2YXPF$O=)<\8S*/K]*2%2CN\
MN+I.#V.H5D:>KM/S&B1<Q[W8,<:+$ QBY)V>+$?OKUX.';[M(G$/8?B.T<9W
M"!B5P'_(#+R:R(<LJ+3@@VTO0@Z0(KD/F8'*@Z!(WG7PVEYGF $IDON0&0Y!
M0U DK\[2,FR207A&7BG7RK"[!N 9>;5:*\.NG R/N$.+'$JBU<JPFR?#(^YX
MQ@%7C1FV 0$\(S=Q3P\Y@=MWP$WD6C7J_>$F.*T:]?[T.;LFK5:->G^XF4VK
M1KT_W+2FE:NC6-('Y.4T[5R]R)(^("_<MVO4Q<R-]>F1-G ?D!OHT\-PI-P#
MY<;P](0<.67GA>?TV!PY9>=%WO0L'3EEYP75]( =.67G;#BWTE-WY)2=%^O3
MHWCDE)T7QM/S>>24G1>ATW-[Y)2=%YO2\WP$;J[S DQZ6(]  7A1(CV)1Z
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MCN?ORKS@&2,X[BM6W+F.W>^Z%:#C4'/LC.MJ8LV/R:HQ,=8].$8,K.[E2ZS
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M<UU#<F$ EA'*8(U95"A(@^*F%0W T4,E[)87EV$M4JOZY54@*2K!6^<*.'L
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M)68 -UO6%S-E.0RP]&BIRJ?'4]7(@P@R8!G0&D.F+'<!EK(L4_>4P59'\$+
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M$/]Y[YCS#^1G$W]J??C_4$L#!!0    ( &V@R5I>\W^".S4  $52 0 >
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M'OD_KGN7'P\":URBS#T(CC\A=;S]Y=,[?N0OUY?X'UR_%3HXN]N[_/)K%!+
M7,#6DG5V@JKS0W/##;6YF"."^FQ5:>2(&PJO!OTGGB51$9/=Y]VZC?K(GZ@Q
M5-DB"<'I- (J0[OQ!M0I$#K:W&1=R$[2N&,\X<GFCIO$ALB<*N091@-KA&9P
M/C7C)E7>/5Y^55F>:8,''XL:5P 7RF2X"<)1,;<OO0^F;@751,RM+%@D<?UY
MY33Y'.B$Q"1^2*7(4!"3:@;?X;])D<.0X1C*[>!:+UT#!61C <*\+WE%X,2K
M) R&:3)Q4\EDCF]"3;"?H#L(Q'YT^R"1KLR4PLHP<8 -9&@O;[?Z\V!2Y(6(
MO%76:SL5P%EDMF)R<'=[SSO.TN=XS8>:5;D1+1R?ST&49*@,Z75D?6@[.!DN
M_C4($R)[>,9@4*2=RGM _=>T$\P2Q=Y6N!^.R;!(B>9AWP=$ZSSBCG7.5.Q@
M382IG*!V!/_GZ_$O,0 !&8IXH&T18D'(!+:9K>B!$U_Q];Q&*L\*H.],AK)Q
M$+</;@"T*[5G5/.?RO2V@_<)&(T"%X,&#)>%2=&'>9=XY.+UIF5V+BS'+HQF
M3CX+[YC1DI3L L.$VBTZNL;QH-]7=?SPU'"'^[+D0R$.X[%PZT"!V5I14 "1
MIDU+MF*GT[[S_VQM!>^5C,(WP0586 ?PX/\48'!)>'^PM:7C:6^/3WXW@_,5
MJ]V]!LWJ)7[7AR,@4_O=801R*=C=?@'CS))(A3"$;YANW8V]K*('\WW["\RB
M84)]X/%?MOH2S@;,>DJKX#_T9<-#<>+^%+Q]\+>U]$IOJ7_!M>;E716*V]U^
M[LF#ZGG&L\QN=W+#>OS!BNIIJN*!FH*$'<(1AS_AKV0X!&4A=4R%V 'Y/L=*
M#F&YS97G?"7K%34]H-WZ,^D#,\^ /V>JKR*%$IN]2JA7IBI#]WPL1N0@0JDQ
M0[8LZ6-4&E+9KS]!GT-:-?61O0ZB(C2FOG4NH=, _?_FQSYK1$'$OCK@<P]L
M*^[NOD+R7L(@W']1INU[&'F?3XZO?_O7,[3NGGWKH!_2DFN<K3%!F3W>:=K9
M&S1];XC-I0Q"G%O$WC"!LA-%GHACTASAN_\4H"W*%*YP))7**:BR2 X-VL45
MD'+*Y/I/,9F"<?EUH.T6(+:)RC(*TVHGY57OR+J%TR*23*2I'!41$VW'-U$B
M<4._?XJ)^*XP*IT%'T"8I@(=I-T!.M'@%_@C*4A]0[F*QS0BA?>[6+-KNGU0
MNNTO1[<?+?=#GBBF&#HV$4L@2N"F3(3 O=EF @I"\PFTB0Q)! PD7^L[ZIT[
M'OB&/;,A:<4JGL$=Z'I,XB%8I$#IL*9I(L)LG-QHKBHE$EMVX)BRO2V5D<=_
MIT4?J-E]>8#\?%+$Y)&%VUA#IWNU1BVB.=C&:^)]$L0[6(YX>UD.Y*BRL1'?
M:+6A7YL^AT"DR(8=QQVPNP>6(RM0<5!$&A0&@'LFQ83#$L0D&[T?8%--&1B
M#T8GNAJ:($!9%;#Z3:,08-:?-3+^WA&S\#6I/@E2#>_)9TF=159:I* ,%/&
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MUP9ID7GUF*JMCDGIP<,VD0*Y:%;.%BW5<-KO@"IB!29:ZC#68! !XS%L3&&
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M$55B1*_7,:(5XY?WJ&FYI/*,@M'U32GA=8V\[)AJ2X&NJH+,L0!.EX*VW3%
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M'M^OG$"@$Y"1E8/H F.$NU6_-CRGZ@ZL,S>S]&KXOP_K I7"YN*!$GU8AH:
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MB#\CH[%<JF+(5CP0LD/FDVF&MK+Q@I '@(&FJ3<8#70T#'.RQ@T8^XB0K7+
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M:HG8GB 601%HBU,RJ-*%[\H%F%\$D $*7#8+#D[RXJR8H!(UCDG+;YK #[A
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MB I'^VW-B#;LZ5&P)[4J''-)3&COLMW(2[48RN;K4G'OE2"+RXBM\#_LYS'
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MZ+Q!O 0]T,E<J#/MN_QD#"8Y=?W"6@AY,"X<WE0QMMV"@QZIQ#>M--48A/%
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MPJK_$=\AF'&'$%+QM4*RM%O&]2:# &,&J 7KD N+*$S6M#U231-Y\RU3<JA
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MI-Y=3;H\#QRG.H$>"#*79(5+E#BY]_ F7!XOHJ<)%:0J,(?G+!%[WCQ/TES
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MD14TD!E6%P, J2$SQ&<(I=G"]\[CU#%XC!2@K+.0.KEHR**J\Z4QG*!;%(P
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M R)-);92T 23SV8FE*K;H9Y6Q=U?BCM,!>,O:J9"D1C7\0;K^IQQ@@P(YZ>
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MEMTJ:ZEUL&U.!'&[Z-X4<5]T'6Z'UU>,D<"NUQH_E':].3EJG0#_N^B!WYD
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MYLA)ZZLG?4TXT0(<!9M(*EN(1XG74)%?#QE-)!W_KQG5&F7M*: -;9ML^;(
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M;^IAC2@>'YX??R8&]N?PW>GK_P]02P,$%     @ ;:#)6A*^])PE @  4P<
M !P   !E83 R-#4P,S(P,65X,C,M,5]A=F%L;VXN:'1MO57!CJ) $+V;^ \5
M#IY4U)D][(@DB.BP@TH ,SNG30N-]@2ZV:;9T;_?0G3VM(=-5CC0J:YZ]5Y5
M=Z>,YVCMF=V.\>Q8"URA_HS(C3S'-/1F1:]^=1OS[>(-PNC-<V9:*KAZ@O&H
M4!"QG):PH1\0B)SP?K/1AY!*EFH(1*C_K[@IY$0>&'^".G0T!45/:D R=L M
MR0Y'I9G&W'1.1[9G"B8/P[&ASU&V?P_"F')%Y86QQ_=E,6V'RW#7*P@#>Z;1
MT^1A,/XQ&HV'[\5! \N+9IK6JIA6"]^9]G83.IL(MDMP-PO'=_"'9N"LW#!R
M F<!_F[NN7:W8]GV=K>)W,T*EFZP-O2=V8+*6SON0O)>E8JE9\U\I1 +7B(G
M* 'J2('Q6,A"2**8X+ _@Z0IE93'M:O;J4,">F"END:$BBB:UPG06 J9EQ .
M'G4+1 JBD@C'9 H2C$I@361\A(=Q'R:CR9<^?#!UQ(BRH/&G@%J/R%@#2!DG
M/&8D@_+&4V)F/)1?)$/"52;VPB:2@HVJA[7ZK$H0R#@F8R58G%>(#AH55XG8
MOL$+I$)>",^42*"\1BUH3/,]E3>)CWT@/+E$_6D#ZJP+2YG,NYT*<4V:F!27
MAO2RY&<EILZIH%*5/7FQ&CU_:]WPWL?<SF4R7%,O=5CW2%Y,7\#VK; /ON?9
MAN[>Z[FT7&*$9_@J1)+AM4!D]/V_$6KFMXI3^-H\C<^T>CT4FRE9#]/?4$L#
M!!0    ( &V@R5KNN(IKVP$  &\&   <    96$P,C0U,#,R,#%E>#(S+3)?
M879A;&]N+FAT;<U52V\:,1"^(_$?1GO@!"RAR:'!70D2:%(1@L)&%4>S.[NX
M]=KNV$[HOZ\-251%[:%24N&#'_/X9KX92\.N\IMYUFZQJ^GX,IP0%\NO\_DT
M8^GA#-KT2<TFMY=K6.7K^?134FGESN%D8!SDHD$+"WR$.]UPU3T(NK!"$E42
M'(/K\E_]1M!PJH4ZAV@Z&('#G>MQ*>H@(E%O79*Q23;=;<5&.!A^Z \[:F/-
MB*63D/SR/<(6J!S2/N[_C,7NLVM5HL&P*0=W6 L;=%C"TF^D*&!<%-HK)U3=
M;LT$-1VR/[P>6;C0R@87EMYG;YIJ\L+_7;A_\]:)ZF>2?44H#A3 :7!;!&\1
MA I789\*0=P)K6#EN,,F6+9;X373U,"J=PJZ NT)"(TF!V6P*6%L2$@X.>O"
M<# \#3K)8^V>0U1"<54(+L$^8]J(,W[@,D!_EGJC+SAAJ"Z9/G!CD%/T_U->
M[=9+8GT(=+BT^C4GPBIT4Q48!=Z"#WVFO6:+O(S('5G&ADYW!LG9#NU?,9[U
MQ?8O=>@?;[>3++4IW' J? -L=KO(?P?L/81R\@AL&RYEK^#&)IF4AJ71](A_
M<9)%N[6F[UU8K-\0]HM7"!_W__7LF.F_ DSCP#A,D#AH?@%02P,$%     @
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M[\]*-98CJ2CXC13<J6G\168+IB[+DQK:X.S55;[107NL*(;AJ67\-V<W=*S
MAAE1[=";CF#0'PXO0/7Z!7%Z4M0OCY]02P,$%     @ ;:#)6F"AZ6>+(
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M#7L$XY)N^'1$>I]\PB;KI/#;87_W!\$L>I/[HGM6^6Z,138@MTJ76#6'W92
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M)% _5?/+IFUY5T)_1L]GK43>%*7X%,8W^"KHK8"3=[7G[$UOKOY)6\J$&D[
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M2;G0G=G_-CZ^YZGIH-=38P]:\X?D%8CVDR Z9]U-H(AKW)P7_T.#\,U7^$?
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M*O<.+>MTZ9.2WM35'>3.3"ZZ-E$F>6%4D?-0HV.#>C*V]B=AY XB2E9)HC>
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M_G:V)YV1J+G#ED72KKF*0BL)/*9CV2A:5&>T?;);48R%^UTZ$+5J_J-7H/H
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MT-^B(">G8**EHZ)G8^9@9V-F9>7D%>7GY!;F8645D!44%I>0DI+BX+^O (7
M1"6E('\_ 8))22G(*1AOW6*$<+%R0?YMW;0#:,  ?2 %",@-(* !@FB -]T
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M#T3.$,5,J0A7G8.M$_J$!)_Q0W\$/)O>66[XXFSRX?N;#\[$_+S!P<%;@_3
M-"DM+E<I8:0Z'U?6O*&H^N\27T^)6?HS[T!U?0=5.\B;CW/?)*$;&AAF 8(X
M1]_D?J:7O=-OVYF@E 9HSF#2R\U)YB _"(E?UA.)J!3497A9RE,@G/X?$RN]
MQN0UC+@1CI1%FV]G?R<A_JL9Y$HU;==P-/GCQ]S5X2:<88QC2;*G],-IM)*J
M;[4NW(M]6!=.#_@W#;R9_@]02P,$%     @ ;:#)6A/:,,4:"   CPD   T
M  !I;6%G95\P,#(N:G!GM95Y--3]'L=_/S-FAB$-4Y9&8QDA\FB0)X6DP83&
M$A/9(GF,D&I"D:SC(8HLB9*M+-FWGAI-,D:EFTAHR.Y)]MV0YG?5N<NYYSSW
MG.?><^_[<UY_?3[G<\[K?+[G?*$>:!#8>M2$; * ( BX;18 ]0+&  J!0"($
M44@D4D@()2R"%15!HT6DQ27$L+(R^)VR,CB<'$%#64Y!71&'4]%55=?<JZVM
MC5?>K_\S\:"&EC;Q^Q(0)20D@A:1$A65(LKCY(G_<:#G  8%. %\&*@ "&!
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M:D[=HL:+-/%C75PQP'7.#/M6&?NHY2RYY=_H>J9]QMM38\HAHXH\8QG*&(:
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M=50!<N-^ .XU)V$!Z_\/(/3QKU!+ P04    " !MH,E:B&GEB]LP 0!M70$
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M3.GTV4MD=_2K@11/3K#=AY%4OD7UY_?3[G)QL%2J[E.<^0DOL$<H*0J,G9*
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M5&!_<B7A@5EFRQJY+!4\/+.$.?VU)K)DTJ>/4$EH58\X>2!'.F[%<>?L8]3
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M)S>R"?46/L6!+/@283H5/",\A+,&O;G2,G\'@0@^6L_1]$%YH3P]ML"<I\R
M/EA7BN-!.:F+M5QV@E T*-:.*Q;;;,\Y[>@"$!]26Z!\OW-#^E54R=2Z.@_V
MJL@ \HY"^U&NR88H_0H41>G*-Y=_?8N$2.MMY!-F\_YVY7(VJ","SS,M4.!;
MW]BH\&'?WZZ<F"]:1>DF9$5UU&4:R6)[ O './^B!>B>\"95C%AP@?J LNLP
M39V%&@#IEX O2<78]] ]H-H(3'Q>;H$@:^$Q!5/!2GL#'G>_LA%$Y$@(+I+#
MJV!Y@W*G(]M?XZ$;%.(5'CP.9P)EM!C?X%77<I![9[-5X.W'1OR9S1[<EB"
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MG8%P)<'\M7I'490:%YW.4]V7TM .GE>N^_5*W,K+R]=<G+<N8WPGVX+#?,O
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M@G6EY+C](EU2@%%NKTGPW0W>54Q$!4]#)6<GC\08F'\>ZLPT+O>3&N[,&EU
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MR,,#^#F&J!T?/_I>Z)2XU8%(RZBP'W +OA9TM=RDJ-)1'%$*E>H[U59_9%^
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M?W:S4/@39M)S\YFM#@;NSLM^B?@-*FFK#-:Z MLB6=%"**E5.XD)$8U+VUU
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MVEQ\S-2<PF!.DFY>+A(=KKD9>97S-">/ ?S^()?'.;<($V;_(3JD]Z37FES
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M0$]333@Z<*,PH F@1X3$>O-)8X^U<SO9!64'SK7>U8V_,S]V_B):@ML<MC[
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M991@%MR#Y6=1@Z2(V'8"^=U-/&K)HK-HK^U!MAE< 0GCUFH$/7\Z()2>LST
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MQR[$6?6OC%_=.&[C^@L5:&+84-CYY.EP.=RH+,#@-*?2K::L+O-PDQMWOO5
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M*WS)6'#:N/[%TBFS52JO.>'0NU7$/;Z<E%<#+XL"/,',+W0V$=0H%*PJBA=
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M=^3'U$/,_#U9T_0VBZCP++Q2O?&T[-3STE]-'O .]9N-ZW'PG>F&,.^N0$V
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MP5-!VRS?]_=M/&D4PMB<OG]FR16B_YDEUQ@N3,0CM\0R6YM(D1$1&Z? !&_
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M!HAK3XO(X'M!!G:U2"A^64B4L32.=<(DA0-8$%E"^+IX.]W<H@:M.:W8)9-
MV8Y1J0:>+CJ0Q>*!J/CBW4,8::;@?/<8 Y+S:%ZQ^,?VX0A=N_3KBW9O5D+,
MV(Z9'Y$JN@[-Z+I#:Y+?O%93Z* IW'7V3Z\5$8R/B$BWZ_Q_O;8%,(Q"\$K9
M$B\,E3'? YW07DK"U/Y820MNZ&:/)RJ%2);F_PSLJ_& ST-5(3+\,""J!HUU
M ^[PJ'VG3-Q:)K=G.;;0KPV3[ U=:?41T]=!&[$IP#:ATI2XTG!90^S4%@@(
M%1? %.B;09DB_ HB;M@I+HO')V'V6[G,8=HC&<J<R#'^H;7T[R\&VA2F\'<
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M[38LJ2'"',-D>9YW=$VX1 V/F-^-Y=K! .V+NU"! =(#JX*9[K3<-<^8>-*
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MS91T'<?.GV_^9AAH0\.-:/7MV0)%?"AC:UM5UY9-N#JYNGSXVO&5S?N]C'C
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MN@= $!&GL#OU5HINBU)M?)/&Q(H:B+^=]9LQ?AMZD05/- ]A#NX%HNW^L:?
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MR0Q?K$#3>G_%Z95J.+@@K7/U"#U[\V'NJ5<*S\R>&/7^_<]$)*]LKY>__0
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M03D^5TSA4EY>DZ@$.$.HDKKE<WFF?PHW:W=RRLR+ZF.L%Z]C]UZ:78_U)_L
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M6ZY#G-$VL .T(%/7(J[%ZG(0X3._9\6 DB/&ZC?<K@U+T55GT+^)LI0S2!+
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M>!$TT')C/F=$9CU6>2+(Z-,C7:%>^)SQBETKJ<\]/[K5GWN^J>7)9A%G?.W
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MX8KV1;(I#(\HHYG4=IVQ!LJ?RMF@'+=7!'C)V3HG0"]E:QX>&O$8R3W9LIR
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MKP7B1W T/P@N\#O)E8\@WAU\Y4YEN?T0HAKY3-E6,V!UV08C=,ULOL'3*&=
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M>O,7@?<KZZ.TQCS;Q'><Z]>.S'@R5Y[@@RGVF--PP=!;36@P8&@B'08L=-)
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MGYC:%&=_[D"#LU34@PK]>PYB].F9TW[N5\A,D!9GC3^AJ#^G^9]1]S_!.::
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M(Q@4O)4%^&2 _%R@<_97+X>!UK4Y7:K69N#>U$>/>+$7J9Y62* A[+&P-:R
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M^G;((N.;Y  SV<5GE,_,D5T>D(;3)-(C!,  //M+\LT7DV9IQJB;?82=%49
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M?J9Z<0#9_W8S> H^&=T#5^G0IE(6>!6SKT9:WY$Z[*%$U7G$@TX?@+[.?P>
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M(_#3S87%$ONQ%[7!T8BHSBG47Q+&H91A-AP,#?Y*'XUF]U7G#(&'!M4*QOK
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MZ(_G".*LMM9S1D(B+SB<$OCU7&W!KF<S#5,>7KO=J4?P= QNLOLGI+W:PER
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M     &%V8V\M,C R-3 S,S$N>'-D4$L! A0#%     @ ;:#)6GV4!'.V&0
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M,3 M,3$R7V%V86QO;BYH=&U02P$"% ,4    " !MH,E:N&R-E=\S   X20$
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M &9I;E\P,#$N:G!G4$L! A0#%     @ ;:#)6FI[%)\'$0  \!$   T
M         ( !PV0/ &EM86=E7S P,2YJ<&=02P$"% ,4    " !MH,E:$]HP
MQ1H(  "/"0  #0              @ 'U=0\ :6UA9V5?,# R+FIP9U!+ 0(4
M Q0    ( &V@R5J(:>6+VS ! &U= 0 -              "  3I^#P!I;6%G
M95\P,#,N:G!G4$L! A0#%     @ ;:#)6G[F10W55   \'0   T
M     ( !0*\0 &EM86=E7S P-"YJ<&=02P$"% ,4    " !MH,E:4H^:!8X.
M  !?#P  #0              @ % !!$ :6UA9V5?,# U+FIP9U!+ 0(4 Q0
M   ( &V@R5K(=FB<L0D  %$*   -              "  ?D2$0!I;6%G95\P
<,#8N:G!G4$L%!@     3 !, [P0  -4<$0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>ea0245032-s4a1_avalon_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avco="http://www.avalonglobocare.com/20250331"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="avco-20250331.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonHealthcareSystemIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-18</startDate>
            <endDate>2015-05-18</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonRT9PropertiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisAndArbeleBiotherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-06</startDate>
            <endDate>2022-04-06</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-06</startDate>
            <endDate>2022-04-06</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-08</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonLabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-09</startDate>
            <endDate>2023-02-09</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-26</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-26</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonHealthcareSystemIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonRT9PropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonShanghaiHealthcareTechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:GenExosomeTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisNanjingBiosciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonLaboratoryServicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:QADistributionLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avco:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:EpiconBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:LaboratoryServicesMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:LaboratoryServicesMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RegulatoryAssetAxis">avco:DeferredOfferingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">avco:AssetAndLiabilityAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">avco:AssetAndLiabilityAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">avco:AssetAndLiabilityAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:DrYuZhouMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <instant>2023-02-09</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avco:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avco:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avco:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avco:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:CommercialRealEstateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:EpiconBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonShangaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:JiangsuUnicornBiologicalTechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:InvestmentInEpiconBiotechCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LaboratoryServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesBStatedValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:SeriesBStatedValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-09</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <startDate>2023-02-09</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avco:LaboratoryServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avco:LaboratoryServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-09</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LaboratoryServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LaboratoryServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-09</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">avco:InvestmentInLaboratoryServicesMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">avco:InvestmentInLaboratoryServicesMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">avco:InvestmentInLaboratoryServicesMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">avco:InvestmentInLaboratoryServicesMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-09</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-23</startDate>
            <endDate>2023-05-23</endDate>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-23</startDate>
            <endDate>2023-05-23</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillFundLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-23</instant>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-23</instant>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">us-gaap:OtherTradingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-23</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FirstWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillFundLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-23</instant>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:SecondWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillFundLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-23</instant>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <startDate>2023-05-23</startDate>
            <endDate>2023-05-23</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-23</startDate>
            <endDate>2023-05-23</endDate>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-23</startDate>
            <endDate>2023-05-23</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-23</instant>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-23</instant>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-23</instant>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-23</instant>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-23</instant>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-06</startDate>
            <endDate>2023-07-06</endDate>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-06</startDate>
            <endDate>2023-07-06</endDate>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <startDate>2023-07-06</startDate>
            <endDate>2023-07-06</endDate>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FirstWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-06</startDate>
            <endDate>2023-07-06</endDate>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FirstWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:SecondWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-06</startDate>
            <endDate>2023-07-06</endDate>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:SecondWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-06</startDate>
            <endDate>2023-07-06</endDate>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-06</startDate>
            <endDate>2023-07-06</endDate>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-09</startDate>
            <endDate>2023-10-09</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">us-gaap:OtherTradingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-09</startDate>
            <endDate>2023-10-09</endDate>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FirstWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:SecondWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-09</startDate>
            <endDate>2023-10-09</endDate>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-09</startDate>
            <endDate>2023-10-09</endDate>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-09</startDate>
            <endDate>2023-10-09</endDate>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-07</startDate>
            <endDate>2024-03-07</endDate>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FirstWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-07</startDate>
            <endDate>2024-03-07</endDate>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:SecondWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-07</startDate>
            <endDate>2024-03-07</endDate>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-07</startDate>
            <endDate>2024-03-07</endDate>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-07</startDate>
            <endDate>2024-03-07</endDate>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March2024ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-05</startDate>
            <endDate>2024-06-05</endDate>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FirstWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-05</startDate>
            <endDate>2024-06-05</endDate>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FirstWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:SecondWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-05</startDate>
            <endDate>2024-06-05</endDate>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:SecondWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:WaiverFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-15</instant>
        </period>
    </context>
    <context id="c291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-15</instant>
        </period>
    </context>
    <context id="c292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-15</startDate>
            <endDate>2024-12-15</endDate>
        </period>
    </context>
    <context id="c293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:WaiverFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-15</instant>
        </period>
    </context>
    <context id="c294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:DecemberFiveTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:JanuaryFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:FebruaryFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:MarchFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:AprilFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:MayFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:JuneFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-23</instant>
        </period>
    </context>
    <context id="c304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-23</instant>
        </period>
    </context>
    <context id="c305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <instant>2023-05-23</instant>
        </period>
    </context>
    <context id="c306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-18</instant>
        </period>
    </context>
    <context id="c328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillAndFirstfireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <instant>2024-11-18</instant>
        </period>
    </context>
    <context id="c343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillAndFirstfireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillAndFirstfireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillAndFirstfireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillAndFirstfireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillAndFirstfireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="c351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:March72024FiveYearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="c352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:March72024FiveYearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March72024FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March72024FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March72024FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March72024FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:March72024FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-01</instant>
        </period>
    </context>
    <context id="c369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <instant>2022-09-01</instant>
        </period>
    </context>
    <context id="c370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="c371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:BeijingGenexosomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:DrYuZhouMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:DrYuZhouMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:BeijingGenexosomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:WenzhaoLuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:WenzhaoLuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:LineOfCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-29</startDate>
            <endDate>2019-08-29</endDate>
        </period>
    </context>
    <context id="c385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avco:MrLuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-17</instant>
        </period>
    </context>
    <context id="c388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <startDate>2023-11-17</startDate>
            <endDate>2023-11-17</endDate>
        </period>
    </context>
    <context id="c389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avco:AvalonRT9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-17</instant>
        </period>
    </context>
    <context id="c390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:AvalonRT9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-17</startDate>
            <endDate>2023-11-17</endDate>
        </period>
    </context>
    <context id="c391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:ConvertibleDebtNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-09</instant>
        </period>
    </context>
    <context id="c394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-09</instant>
        </period>
    </context>
    <context id="c395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesBHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-13</instant>
        </period>
    </context>
    <context id="c400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:ConversionShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-09</instant>
        </period>
    </context>
    <context id="c403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-09</instant>
        </period>
    </context>
    <context id="c404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:JefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avco:JefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:CommonSharesIssuedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-18</endDate>
        </period>
    </context>
    <context id="c414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-18</instant>
        </period>
    </context>
    <context id="c415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-28</endDate>
        </period>
    </context>
    <context id="c416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-15</instant>
        </period>
    </context>
    <context id="c417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-15</instant>
        </period>
    </context>
    <context id="c418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:May2023CovertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:May2023CovertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-23</instant>
        </period>
    </context>
    <context id="c428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:May2023CovertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-23</instant>
        </period>
    </context>
    <context id="c429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:BlackScholesValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-23</instant>
        </period>
    </context>
    <context id="c430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:BlackScholesValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-23</startDate>
            <endDate>2023-05-23</endDate>
        </period>
    </context>
    <context id="c431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-23</instant>
        </period>
    </context>
    <context id="c432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:May2023CovertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-23</instant>
        </period>
    </context>
    <context id="c433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:May2023CovertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-23</startDate>
            <endDate>2023-05-23</endDate>
        </period>
    </context>
    <context id="c434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:FiveYearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-06</startDate>
            <endDate>2023-07-06</endDate>
        </period>
    </context>
    <context id="c436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:LiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-06</startDate>
            <endDate>2023-07-06</endDate>
        </period>
    </context>
    <context id="c438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FirstfireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:July2023ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-06</startDate>
            <endDate>2023-07-06</endDate>
        </period>
    </context>
    <context id="c443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:OctoberTwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:OctoberTwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:OctoberTwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-09</startDate>
            <endDate>2023-10-09</endDate>
        </period>
    </context>
    <context id="c446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:OctoberTwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:BlackScholesValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:BlackScholesValuationModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-09</startDate>
            <endDate>2023-10-09</endDate>
        </period>
    </context>
    <context id="c449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:MastMillAndFirstFireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:MarchTwoThousandTwentyFourWarrantIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:MastMillAndFirstFireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-07</startDate>
            <endDate>2024-03-07</endDate>
        </period>
    </context>
    <context id="c452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:MarchTwoThousandTwentyFourWarrantIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="c453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:MarchTwoThousandTwentyFourWarrantIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-07</startDate>
            <endDate>2024-03-07</endDate>
        </period>
    </context>
    <context id="c454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:MarchTwentyThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="c455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:MarchTwentyThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="c456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:MarchTwentyThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-07</startDate>
            <endDate>2024-03-07</endDate>
        </period>
    </context>
    <context id="c457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:TwoThousandTwentyFourJuneWarrantIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:TwoThousandTwentyFourJuneWarrantIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:TwoThousandTwentyFourJuneWarrantIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-05</startDate>
            <endDate>2024-06-05</endDate>
        </period>
    </context>
    <context id="c460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:TwoThousandTwentyFourJuneWarrantIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:TwoThousandTwentyFourJuneWarrantIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-05</startDate>
            <endDate>2024-06-05</endDate>
        </period>
    </context>
    <context id="c462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:TwoThousandTwentyFourJuneWarrantIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <startDate>2024-06-05</startDate>
            <endDate>2024-06-05</endDate>
        </period>
    </context>
    <context id="c464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:MastHillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:JuneTwentyThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:MastHillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:TwoThousandTwentyFourJuneWarrantIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FiveYearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FiveYearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-05</startDate>
            <endDate>2024-06-05</endDate>
        </period>
    </context>
    <context id="c469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-05</startDate>
            <endDate>2024-06-05</endDate>
        </period>
    </context>
    <context id="c470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:WarrantsExercisedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-05</startDate>
            <endDate>2024-06-05</endDate>
        </period>
    </context>
    <context id="c471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:DrYuZhouMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avco:FormerDirectorAndFormerCochiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">avco:PRCSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:TwoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:TwoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">us-gaap:PublicUtilitiesInventorySuppliesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">us-gaap:PublicUtilitiesInventorySuppliesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:RealPropertyOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:CorporateOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:RealPropertyOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:CorporateOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:RealPropertyOperatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:RealPropertyOperatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:CorporateOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:CorporateOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-25</instant>
        </period>
    </context>
    <context id="c534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <instant>2017-10-25</instant>
        </period>
    </context>
    <context id="c535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:DrZhouMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-25</instant>
        </period>
    </context>
    <context id="c536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-25</startDate>
            <endDate>2017-10-25</endDate>
        </period>
    </context>
    <context id="c537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:DrZhouMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-25</startDate>
            <endDate>2017-10-25</endDate>
        </period>
    </context>
    <context id="c538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:DrZhouMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisBiotherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-06</instant>
        </period>
    </context>
    <context id="c542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:ArbeleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-06</instant>
        </period>
    </context>
    <context id="c543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisNanjingBiosciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-06</instant>
        </period>
    </context>
    <context id="c544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:ArbeleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-06</instant>
        </period>
    </context>
    <context id="c546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-06</instant>
        </period>
    </context>
    <context id="c547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-09</instant>
        </period>
    </context>
    <context id="c549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-09</instant>
        </period>
    </context>
    <context id="c550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="c551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="c552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-26</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="c553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-26</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="c554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:CertificatesOfEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:CertificatesOfEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-10</startDate>
            <endDate>2025-03-10</endDate>
        </period>
    </context>
    <context id="c562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-10</instant>
        </period>
    </context>
    <context id="c563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonHealthcareSystemIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-18</startDate>
            <endDate>2015-05-18</endDate>
        </period>
    </context>
    <context id="c566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonRT9PropertiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-06</startDate>
            <endDate>2022-04-06</endDate>
        </period>
    </context>
    <context id="c568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-08</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="c569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonLabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-26</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="c570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonHealthcareSystemIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonRT9PropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonShanghaiHealthcareTechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:GenExosomeTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvactisNanjingBiosciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonLaboratoryServicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:QADistributionLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="c585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avco:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avco:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LaboratoryServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesBStatedValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avco:LaboratoryServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:AvalonShangaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="c609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:JiangsuUnicornBiologicalTechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="c610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="c611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <startDate>2025-02-26</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="c612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">avco:InvestmentInLaboratoryServicesMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-02-26</endDate>
        </period>
    </context>
    <context id="c615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">avco:InvestmentInLaboratoryServicesMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May2023ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-05</startDate>
            <endDate>2024-06-05</endDate>
        </period>
    </context>
    <context id="c617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-05</startDate>
            <endDate>2024-06-05</endDate>
        </period>
    </context>
    <context id="c618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillFundLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">us-gaap:OtherTradingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:FirstWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">avco:SecondWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June2024ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-23</startDate>
            <endDate>2023-05-23</endDate>
        </period>
    </context>
    <context id="c631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:DecemberFiveTwoThousandTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:JanuaryFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:FebruaryFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:MarchFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:AprilFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:MayFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">avco:JuneFiveTwoThousandTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-23</instant>
        </period>
    </context>
    <context id="c640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:findersFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-06</instant>
        </period>
    </context>
    <context id="c649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:July62023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillAndFirstfireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-09</instant>
        </period>
    </context>
    <context id="c658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-26</instant>
        </period>
    </context>
    <context id="c659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:FirstFireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:October92023FiveYearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MastHillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillAndFirstfireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:MastHillAndFirstfireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:May232023FiveYearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-05</instant>
        </period>
    </context>
    <context id="c677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:June52024FiveyearAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:BeijingGenexosomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-31</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:DrYuZhouMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:BeijingGenexosomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:LabServiceMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:AbandonmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:LabServiceMSOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:LabServiceMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:LabServiceMSOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avco:MrLuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:AvalonRT9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-17</instant>
        </period>
    </context>
    <context id="c695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avco:MrLuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:AvalonRT9Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-17</startDate>
            <endDate>2023-11-17</endDate>
        </period>
    </context>
    <context id="c696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avco:MrLuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avco:MembershipInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-17</instant>
        </period>
    </context>
    <context id="c697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avco:MrLuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-17</startDate>
            <endDate>2023-11-17</endDate>
        </period>
    </context>
    <context id="c698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avco:MrLuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avco:MrLuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
        </entity>
        <period>
            <startDate>2025-01-09</startDate>
            <endDate>2025-01-09</endDate>
        </period>
    </context>
    <context id="c701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-09</instant>
        </period>
    </context>
    <context id="c702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-09</instant>
        </period>
    </context>
    <context id="c703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avco:ConvertibleDebtNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avco:SeriesBHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:AvalonLabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="c710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="c711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:ConversionShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-06</instant>
        </period>
    </context>
    <context id="c714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:ConversionShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:MrLuMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-09</instant>
        </period>
    </context>
    <context id="c717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:AvalonLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:CommonSharesIssuedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:WarrantsExercisedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:OptionsOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:OptionsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:OptionsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:OptionsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:OptionsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:OptionsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:OptionsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:OptionsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:OptionsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c740">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avco:NonvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c746">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c748">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WarrantsOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">avco:PRCSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:TwoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c753">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c754">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c757">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avco:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c758">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="c759">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:RealPropertyOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c760">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c761">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:CorporateOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c762">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:RealPropertyOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:LabServicesMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c764">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:CorporateOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:RealPropertyOperatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:CorporateOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c767">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-25</startDate>
            <endDate>2017-10-25</endDate>
        </period>
    </context>
    <context id="c768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:DrZhouMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-25</startDate>
            <endDate>2017-10-25</endDate>
        </period>
    </context>
    <context id="c769">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">avco:DrZhouMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c770">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c773">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">avco:ArbeleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c774">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="segments">
        <measure>avco:segments</measure>
    </unit>
    <unit id="cny">
        <measure>iso4217:CNY</measure>
    </unit>
    <dei:AmendmentDescription contextRef="c0" id="ixv-88773">Amendment No. 1</dei:AmendmentDescription>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-88774">AVALON GLOBOCARE CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-96">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-262">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-269">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-277">false</dei:EntityEmergingGrowthCompany>
    <us-gaap:Cash contextRef="c1" decimals="0" id="ixv-88775" unitRef="usd">2856309</us-gaap:Cash>
    <us-gaap:Cash contextRef="c2" decimals="0" id="ixv-88776" unitRef="usd">285400</us-gaap:Cash>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c1" decimals="0" id="ixv-88777" unitRef="usd">80829</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c2" decimals="0" id="ixv-88778" unitRef="usd">197473</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c1" decimals="0" id="ixv-88779" unitRef="usd">299360</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" id="ixv-88780" unitRef="usd">367994</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="0" id="ixv-88781" unitRef="usd">3236498</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="0" id="ixv-88782" unitRef="usd">850867</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="0" id="ixv-88783" unitRef="usd">4709</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="0" id="ixv-88784" unitRef="usd">128250</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="0" id="ixv-88785" unitRef="usd">12912</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" id="ixv-88786" unitRef="usd">38083</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RealEstateInvestments contextRef="c1" decimals="0" id="ixv-88787" unitRef="usd">7022721</us-gaap:RealEstateInvestments>
    <us-gaap:RealEstateInvestments contextRef="c2" decimals="0" id="ixv-88788" unitRef="usd">7191404</us-gaap:RealEstateInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c1" decimals="0" id="ixv-88789" unitRef="usd">10636544</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c2" decimals="0" id="ixv-88790" unitRef="usd">12095020</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherAssetsNoncurrent contextRef="c1" decimals="0" id="ixv-88791" unitRef="usd">71794</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c2" decimals="0" id="ixv-88792" unitRef="usd">278912</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c1" decimals="0" id="ixv-88793" unitRef="usd">17748680</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c2" decimals="0" id="ixv-88794" unitRef="usd">19731669</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c1" decimals="0" id="ixv-88795" unitRef="usd">20985178</us-gaap:Assets>
    <us-gaap:Assets contextRef="c2" decimals="0" id="ixv-88796" unitRef="usd">20582536</us-gaap:Assets>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c1" decimals="0" id="ixv-88797" unitRef="usd">611462</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c2" decimals="0" id="ixv-88798" unitRef="usd">1804100</us-gaap:AccruedProfessionalFeesCurrent>
    <avco:AccruedResearchAndDevelopmentsFees contextRef="c1" decimals="0" id="ixv-88799" unitRef="usd">153772</avco:AccruedResearchAndDevelopmentsFees>
    <avco:AccruedResearchAndDevelopmentsFees contextRef="c2" decimals="0" id="ixv-88800" unitRef="usd">208772</avco:AccruedResearchAndDevelopmentsFees>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="c1" decimals="0" id="ixv-88801" unitRef="usd">501258</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="c2" decimals="0" id="ixv-88802" unitRef="usd">588722</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:LitigationReserveCurrent contextRef="c1" decimals="0" id="ixv-88803" unitRef="usd">373450</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent contextRef="c2" decimals="0" id="ixv-88804" unitRef="usd">450000</us-gaap:LitigationReserveCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-88805" unitRef="usd">434117</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-88806" unitRef="usd">272915</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c3" decimals="0" id="ixv-88807" unitRef="usd">732916</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c4" decimals="0" id="ixv-88808" unitRef="usd">206458</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c1" decimals="0" id="ixv-88809" unitRef="usd">10709</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="0" id="ixv-88810" unitRef="usd">129396</us-gaap:OperatingLeaseLiabilityCurrent>
    <avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty contextRef="c3" decimals="0" id="ixv-88811" unitRef="usd">3108106</avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty>
    <avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty contextRef="c4" decimals="0" id="ixv-88812" unitRef="usd">485714</avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty>
    <avco:EquityMethodInvestmentPayableCurrent contextRef="c2" decimals="0" id="ixv-88813" unitRef="usd">666667</avco:EquityMethodInvestmentPayableCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-88814" unitRef="usd">127545</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-88815" unitRef="usd">24796</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:NotesPayableToBankCurrent contextRef="c1" decimals="0" id="ixv-88816" unitRef="usd">5715447</us-gaap:NotesPayableToBankCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c1" decimals="0" id="ixv-88817" unitRef="usd">2113773</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c2" decimals="0" id="ixv-88818" unitRef="usd">1925146</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-88819" unitRef="usd">13882555</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="0" id="ixv-88820" unitRef="usd">6762686</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="0" id="ixv-88821" unitRef="usd">4855</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermNotesPayable contextRef="c2" decimals="0" id="ixv-88822" unitRef="usd">5596219</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermLoansPayable contextRef="c4" decimals="0" id="ixv-88823" unitRef="usd">850000</us-gaap:LongTermLoansPayable>
    <us-gaap:LiabilitiesNoncurrent contextRef="c2" decimals="0" id="ixv-88824" unitRef="usd">6451074</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c1" decimals="0" id="ixv-88825" unitRef="usd">13882555</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c2" decimals="0" id="ixv-88826" unitRef="usd">13213760</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="4"
      id="ixv-88827"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="4"
      id="ixv-88828"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-88829"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-88830"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c5"
      decimals="INF"
      id="ixv-88831"
      unitRef="shares">9000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c6"
      decimals="INF"
      id="ixv-88832"
      unitRef="shares">9000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="ixv-88833"
      unitRef="shares">9000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c6"
      decimals="INF"
      id="ixv-88834"
      unitRef="shares">9000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="c5" decimals="-6" id="ixv-88835" unitRef="usd">9000000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockValue contextRef="c5" decimals="0" id="ixv-88836" unitRef="usd">9000000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c6" decimals="0" id="ixv-88837" unitRef="usd">9000000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c7"
      decimals="INF"
      id="ixv-88838"
      unitRef="shares">11000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c8"
      decimals="INF"
      id="ixv-88839"
      unitRef="shares">11000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c7"
      decimals="INF"
      id="ixv-88840"
      unitRef="shares">11000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c8"
      decimals="INF"
      id="ixv-88841"
      unitRef="shares">11000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="c7" decimals="-6" id="ixv-88842" unitRef="usd">11000000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockValue contextRef="c7" decimals="0" id="ixv-88843" unitRef="usd">11000000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c8" decimals="0" id="ixv-88844" unitRef="usd">11000000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c9"
      decimals="INF"
      id="ixv-88845"
      unitRef="shares">3500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c10"
      decimals="INF"
      id="ixv-88846"
      unitRef="shares">3500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c9"
      decimals="INF"
      id="ixv-88847"
      unitRef="shares">3500</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c10"
      decimals="INF"
      id="ixv-88848"
      unitRef="shares">3500</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="c9" decimals="-5" id="ixv-88849" unitRef="usd">3500000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockValue contextRef="c9" decimals="0" id="ixv-88850" unitRef="usd">3500000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="4"
      id="ixv-88851"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="4"
      id="ixv-88852"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-88853"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-88854"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c1"
      decimals="INF"
      id="ixv-88855"
      unitRef="shares">1445979</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-88856"
      unitRef="shares">1442512</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-88857"
      unitRef="shares">736769</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-88858"
      unitRef="shares">733302</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c1" decimals="0" id="ixv-88859" unitRef="usd">145</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" id="ixv-88860" unitRef="usd">74</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c1" decimals="0" id="ixv-88861" unitRef="usd">72023525</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="0" id="ixv-88862" unitRef="usd">67886082</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c1"
      decimals="INF"
      id="ixv-88863"
      unitRef="shares">3467</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c2"
      decimals="INF"
      id="ixv-88864"
      unitRef="shares">3467</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c1" decimals="0" id="ixv-88865" unitRef="usd">522500</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c2" decimals="0" id="ixv-88866" unitRef="usd">522500</us-gaap:TreasuryStockCommonValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="0" id="ixv-88867" unitRef="usd">-87673125</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="0" id="ixv-88868" unitRef="usd">-79769731</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance contextRef="c1" decimals="0" id="ixv-88869" unitRef="usd">6578</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance contextRef="c2" decimals="0" id="ixv-88870" unitRef="usd">6578</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c1" decimals="0" id="ixv-88871" unitRef="usd">-232000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="0" id="ixv-88872" unitRef="usd">-231727</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="0" id="ixv-88873" unitRef="usd">7102623</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" id="ixv-88874" unitRef="usd">7368776</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c1" decimals="0" id="ixv-88875" unitRef="usd">7102623</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" id="ixv-88876" unitRef="usd">7368776</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="0" id="ixv-88877" unitRef="usd">20985178</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="0" id="ixv-88878" unitRef="usd">20582536</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c18" decimals="0" id="ixv-88879" unitRef="usd">1333403</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c19" decimals="0" id="ixv-88880" unitRef="usd">1255681</us-gaap:Revenues>
    <us-gaap:OperatingExpenses contextRef="c18" decimals="0" id="ixv-88881" unitRef="usd">1065574</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c19" decimals="0" id="ixv-88882" unitRef="usd">1017493</us-gaap:OperatingExpenses>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c18" decimals="0" id="ixv-88883" unitRef="usd">267829</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c19" decimals="0" id="ixv-88884" unitRef="usd">238188</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c18" decimals="0" id="ixv-88885" unitRef="usd">-846588</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c19" decimals="0" id="ixv-88886" unitRef="usd">-8571647</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:MarketingAndAdvertisingExpense contextRef="c18" decimals="0" id="ixv-88887" unitRef="usd">237671</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense contextRef="c19" decimals="0" id="ixv-88888" unitRef="usd">1666721</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:ProfessionalFees contextRef="c18" decimals="0" id="ixv-88889" unitRef="usd">1822105</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c19" decimals="0" id="ixv-88890" unitRef="usd">3076477</us-gaap:ProfessionalFees>
    <us-gaap:LaborAndRelatedExpense contextRef="c18" decimals="0" id="ixv-88891" unitRef="usd">1431328</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c19" decimals="0" id="ixv-88892" unitRef="usd">1768449</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c18" decimals="0" id="ixv-88893" unitRef="usd">857869</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c19" decimals="0" id="ixv-88894" unitRef="usd">908577</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OperatingCostsAndExpenses contextRef="c18" decimals="0" id="ixv-88895" unitRef="usd">4348973</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c19" decimals="0" id="ixv-88896" unitRef="usd">7420224</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c18" decimals="0" id="ixv-88897" unitRef="usd">-4927732</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c19" decimals="0" id="ixv-88898" unitRef="usd">-15753683</us-gaap:OperatingIncomeLoss>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c18" decimals="0" id="ixv-88899" unitRef="usd">1411042</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c19" decimals="0" id="ixv-88900" unitRef="usd">544010</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestExpenseOther contextRef="c18" decimals="0" id="ixv-88901" unitRef="usd">983486</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c19" decimals="0" id="ixv-88902" unitRef="usd">773780</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseDebt contextRef="c18" decimals="0" id="ixv-88903" unitRef="usd">42445</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c19" decimals="0" id="ixv-88904" unitRef="usd">33712</us-gaap:InterestExpenseDebt>
    <avco:DebtModificationCharge contextRef="c18" decimals="0" id="ixv-88905" unitRef="usd">-838794</avco:DebtModificationCharge>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c18" decimals="0" id="ixv-88906" unitRef="usd">-374365</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c19" decimals="0" id="ixv-88907" unitRef="usd">-188374</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AssetImpairmentCharges contextRef="c19" decimals="0" id="ixv-88908" unitRef="usd">454679</us-gaap:AssetImpairmentCharges>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c19" decimals="0" id="ixv-88909" unitRef="usd">682979</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingExpense contextRef="c18" decimals="0" id="ixv-88910" unitRef="usd">74260</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="c19" decimals="0" id="ixv-88911" unitRef="usd">18499</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c18" decimals="0" id="ixv-88912" unitRef="usd">-2975662</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c19" decimals="0" id="ixv-88913" unitRef="usd">-953327</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c18" decimals="0" id="ixv-88914" unitRef="usd">-7903394</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c19" decimals="0" id="ixv-88915" unitRef="usd">-16707010</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c18" decimals="0" id="ixv-88916" unitRef="usd">-7903394</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c19" decimals="0" id="ixv-88917" unitRef="usd">-16707010</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss contextRef="c18" decimals="0" id="ixv-88918" unitRef="usd">-7903394</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c19" decimals="0" id="ixv-88919" unitRef="usd">-16707010</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c18"
      decimals="2"
      id="ixv-88920"
      unitRef="usdPershares">-8.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c18"
      decimals="2"
      id="ixv-88921"
      unitRef="usdPershares">-8.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c19"
      decimals="2"
      id="ixv-88922"
      unitRef="usdPershares">-23.8</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c19"
      decimals="2"
      id="ixv-88923"
      unitRef="usdPershares">-23.8</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c18"
      decimals="INF"
      id="ixv-88924"
      unitRef="shares">936614</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c18"
      decimals="INF"
      id="ixv-88925"
      unitRef="shares">936614</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c19"
      decimals="INF"
      id="ixv-88926"
      unitRef="shares">701932</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c19"
      decimals="INF"
      id="ixv-88927"
      unitRef="shares">701932</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss contextRef="c18" decimals="0" id="ixv-88928" unitRef="usd">-7903394</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c19" decimals="0" id="ixv-88929" unitRef="usd">-16707010</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="c18" decimals="0" id="ixv-88930" unitRef="usd">273</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="c19" decimals="0" id="ixv-88931" unitRef="usd">18590</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c18" decimals="0" id="ixv-88932" unitRef="usd">-7903667</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c19" decimals="0" id="ixv-88933" unitRef="usd">-16725600</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c18" decimals="0" id="ixv-88934" unitRef="usd">-7903667</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c19" decimals="0" id="ixv-88935" unitRef="usd">-16725600</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c22"
      decimals="INF"
      id="ixv-88936"
      unitRef="shares">9000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c22" decimals="0" id="ixv-88937" unitRef="usd">9000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c25"
      decimals="INF"
      id="ixv-88938"
      unitRef="shares">667572</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c25" decimals="0" id="ixv-88939" unitRef="usd">67</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c26" decimals="0" id="ixv-88940" unitRef="usd">65950661</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c27"
      decimals="INF"
      id="ixv-88941"
      unitRef="shares">-3467</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c27" decimals="0" id="ixv-88942" unitRef="usd">-522500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c28" decimals="0" id="ixv-88943" unitRef="usd">-63062721</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c29" decimals="0" id="ixv-88944" unitRef="usd">6578</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c30" decimals="0" id="ixv-88945" unitRef="usd">-213137</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c32" decimals="0" id="ixv-88946" unitRef="usd">11158948</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c19" id="ixv-88947">1:10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c36"
      decimals="INF"
      id="ixv-88948"
      unitRef="shares">3333</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c34"
      decimals="INF"
      id="ixv-88949"
      unitRef="shares">11000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c34" decimals="0" id="ixv-88950" unitRef="usd">11000000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c19" decimals="0" id="ixv-88951" unitRef="usd">11000000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c36"
      decimals="INF"
      id="ixv-88952"
      unitRef="shares">11333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c36" decimals="0" id="ixv-88953" unitRef="usd">1</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c37" decimals="0" id="ixv-88954" unitRef="usd">236399</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c19" decimals="0" id="ixv-88955" unitRef="usd">236400</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <avco:StockIssuedDuringPeriodSharesSaleOfCommonStockNet
      contextRef="c36"
      decimals="INF"
      id="ixv-88956"
      unitRef="shares">30442</avco:StockIssuedDuringPeriodSharesSaleOfCommonStockNet>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet contextRef="c36" decimals="0" id="ixv-88957" unitRef="usd">3</avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet contextRef="c37" decimals="0" id="ixv-88958" unitRef="usd">414393</avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet contextRef="c19" decimals="0" id="ixv-88959" unitRef="usd">414396</avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c36"
      decimals="INF"
      id="ixv-88960"
      unitRef="shares">24089</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c36" decimals="0" id="ixv-88961" unitRef="usd">3</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c37" decimals="0" id="ixv-88962" unitRef="usd">999652</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c19" decimals="0" id="ixv-88963" unitRef="usd">999655</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c37" decimals="0" id="ixv-88964" unitRef="usd">284977</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c19" decimals="0" id="ixv-88965" unitRef="usd">284977</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c40" decimals="0" id="ixv-88966" unitRef="usd">-18590</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c19" decimals="0" id="ixv-88967" unitRef="usd">-18590</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:ProfitLoss contextRef="c38" decimals="0" id="ixv-88968" unitRef="usd">-16707010</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c19" decimals="0" id="ixv-88969" unitRef="usd">-16707010</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c42"
      decimals="INF"
      id="ixv-88970"
      unitRef="shares">9000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c42" decimals="0" id="ixv-88971" unitRef="usd">9000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c43"
      decimals="INF"
      id="ixv-88972"
      unitRef="shares">11000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c43" decimals="0" id="ixv-88973" unitRef="usd">11000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c45"
      decimals="INF"
      id="ixv-88974"
      unitRef="shares">736769</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c45" decimals="0" id="ixv-88975" unitRef="usd">74</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c46" decimals="0" id="ixv-88976" unitRef="usd">67886082</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c47"
      decimals="INF"
      id="ixv-88977"
      unitRef="shares">-3467</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c47" decimals="0" id="ixv-88978" unitRef="usd">-522500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c48" decimals="0" id="ixv-88979" unitRef="usd">-79769731</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c49" decimals="0" id="ixv-88980" unitRef="usd">6578</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c50" decimals="0" id="ixv-88981" unitRef="usd">-231727</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" id="ixv-88982" unitRef="usd">7368776</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c55"
      decimals="INF"
      id="ixv-88983"
      unitRef="shares">33800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c55" decimals="0" id="ixv-88984" unitRef="usd">3</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c56" decimals="0" id="ixv-88985" unitRef="usd">320543</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c18" decimals="0" id="ixv-88986" unitRef="usd">320546</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <avco:StockIssuedDuringPeriodSharesSaleOfCommonStockNet
      contextRef="c55"
      decimals="INF"
      id="ixv-88987"
      unitRef="shares">281843</avco:StockIssuedDuringPeriodSharesSaleOfCommonStockNet>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet contextRef="c55" decimals="0" id="ixv-88988" unitRef="usd">28</avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet contextRef="c56" decimals="0" id="ixv-88989" unitRef="usd">2544283</avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet contextRef="c18" decimals="0" id="ixv-88990" unitRef="usd">2544311</avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c55"
      decimals="INF"
      id="ixv-88991"
      unitRef="shares">42381</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c55" decimals="0" id="ixv-88992" unitRef="usd">4</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c56" decimals="0" id="ixv-88993" unitRef="usd">-4</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c55"
      decimals="INF"
      id="ixv-88994"
      unitRef="shares">145153</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c55" decimals="0" id="ixv-88995" unitRef="usd">15</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c56" decimals="0" id="ixv-88996" unitRef="usd">530335</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c18" decimals="0" id="ixv-88997" unitRef="usd">530350</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="c56" decimals="0" id="ixv-88998" unitRef="usd">2354</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="c18" decimals="0" id="ixv-88999" unitRef="usd">2354</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c54"
      decimals="INF"
      id="ixv-89000"
      unitRef="shares">3500</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c54" decimals="0" id="ixv-89001" unitRef="usd">3500000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c18" decimals="0" id="ixv-89002" unitRef="usd">3500000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c56" decimals="0" id="ixv-89003" unitRef="usd">688794</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c18" decimals="0" id="ixv-89004" unitRef="usd">688794</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c56" decimals="0" id="ixv-89005" unitRef="usd">51159</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c18" decimals="0" id="ixv-89006" unitRef="usd">51159</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c55"
      decimals="INF"
      id="ixv-89007"
      unitRef="shares">206033</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments contextRef="c55" decimals="0" id="ixv-89008" unitRef="usd">21</avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments contextRef="c56" decimals="0" id="ixv-89009" unitRef="usd">-21</avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c59" decimals="0" id="ixv-89010" unitRef="usd">-273</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c18" decimals="0" id="ixv-89011" unitRef="usd">-273</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:ProfitLoss contextRef="c57" decimals="0" id="ixv-89012" unitRef="usd">-7903394</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c18" decimals="0" id="ixv-89013" unitRef="usd">-7903394</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c61"
      decimals="INF"
      id="ixv-89014"
      unitRef="shares">9000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c61" decimals="0" id="ixv-89015" unitRef="usd">9000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c62"
      decimals="INF"
      id="ixv-89016"
      unitRef="shares">11000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c62" decimals="0" id="ixv-89017" unitRef="usd">11000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c63"
      decimals="INF"
      id="ixv-89018"
      unitRef="shares">3500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c63" decimals="0" id="ixv-89019" unitRef="usd">3500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c64"
      decimals="INF"
      id="ixv-89020"
      unitRef="shares">1445979</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c64" decimals="0" id="ixv-89021" unitRef="usd">145</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c65" decimals="0" id="ixv-89022" unitRef="usd">72023525</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c66"
      decimals="INF"
      id="ixv-89023"
      unitRef="shares">-3467</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c66" decimals="0" id="ixv-89024" unitRef="usd">-522500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c67" decimals="0" id="ixv-89025" unitRef="usd">-87673125</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c68" decimals="0" id="ixv-89026" unitRef="usd">6578</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c69" decimals="0" id="ixv-89027" unitRef="usd">-232000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c1" decimals="0" id="ixv-89028" unitRef="usd">7102623</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c18" decimals="0" id="ixv-89029" unitRef="usd">-7903394</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c19" decimals="0" id="ixv-89030" unitRef="usd">-16707010</us-gaap:ProfitLoss>
    <us-gaap:Depreciation contextRef="c18" decimals="0" id="ixv-89031" unitRef="usd">177917</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c19" decimals="0" id="ixv-89032" unitRef="usd">211720</us-gaap:Depreciation>
    <us-gaap:StraightLineRent contextRef="c18" decimals="0" id="ixv-89033" unitRef="usd">-46607</us-gaap:StraightLineRent>
    <us-gaap:StraightLineRent contextRef="c19" decimals="0" id="ixv-89034" unitRef="usd">-10496</us-gaap:StraightLineRent>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c18" decimals="0" id="ixv-89035" unitRef="usd">122553</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c19" decimals="0" id="ixv-89036" unitRef="usd">118226</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation contextRef="c18" decimals="0" id="ixv-89037" unitRef="usd">521509</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c19" decimals="0" id="ixv-89038" unitRef="usd">1179761</us-gaap:ShareBasedCompensation>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c18" decimals="0" id="ixv-89039" unitRef="usd">-846588</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c19" decimals="0" id="ixv-89040" unitRef="usd">-8589822</us-gaap:IncomeLossFromEquityMethodInvestments>
    <avco:DistributionOfEarningsFromEquityMethodInvestment contextRef="c18" decimals="0" id="ixv-89041" unitRef="usd">-611888</avco:DistributionOfEarningsFromEquityMethodInvestment>
    <us-gaap:AssetImpairmentCharges contextRef="c19" decimals="0" id="ixv-89042" unitRef="usd">454679</us-gaap:AssetImpairmentCharges>
    <avco:BeneficialConversionFeatureRelatedToConvertibleNotePayable contextRef="c18" decimals="0" id="ixv-89043" unitRef="usd">-1411042</avco:BeneficialConversionFeatureRelatedToConvertibleNotePayable>
    <avco:BeneficialConversionFeatureRelatedToConvertibleNotePayable contextRef="c19" decimals="0" id="ixv-89044" unitRef="usd">-544010</avco:BeneficialConversionFeatureRelatedToConvertibleNotePayable>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c18" decimals="0" id="ixv-89045" unitRef="usd">-374365</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c19" decimals="0" id="ixv-89046" unitRef="usd">-188374</us-gaap:FairValueAdjustmentOfWarrants>
    <avco:ImpairmentOfLaboratoryEquipment contextRef="c18" decimals="0" id="ixv-89047" unitRef="usd">111033</avco:ImpairmentOfLaboratoryEquipment>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="c18" decimals="0" id="ixv-89048" unitRef="usd">-688794</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c19" decimals="0" id="ixv-89049" unitRef="usd">682979</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c18" decimals="0" id="ixv-89050" unitRef="usd">-130739</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c19" decimals="0" id="ixv-89051" unitRef="usd">46220</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInSecurityDeposits contextRef="c19" decimals="0" id="ixv-89052" unitRef="usd">396</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <avco:IncreaseDecreaseInDeferredLeasingCosts contextRef="c18" decimals="0" id="ixv-89053" unitRef="usd">33402</avco:IncreaseDecreaseInDeferredLeasingCosts>
    <avco:IncreaseDecreaseInDeferredLeasingCosts contextRef="c19" decimals="0" id="ixv-89054" unitRef="usd">33402</avco:IncreaseDecreaseInDeferredLeasingCosts>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c18" decimals="0" id="ixv-89055" unitRef="usd">91496</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c19" decimals="0" id="ixv-89056" unitRef="usd">-411</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c18" decimals="0" id="ixv-89057" unitRef="usd">-1165418</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c19" decimals="0" id="ixv-89058" unitRef="usd">-16601</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <avco:AccruedLiabilitiesAndOtherPayablesRelatedParties contextRef="c18" decimals="0" id="ixv-89059" unitRef="usd">14051</avco:AccruedLiabilitiesAndOtherPayablesRelatedParties>
    <avco:AccruedLiabilitiesAndOtherPayablesRelatedParties contextRef="c19" decimals="0" id="ixv-89060" unitRef="usd">-106458</avco:AccruedLiabilitiesAndOtherPayablesRelatedParties>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c18" decimals="0" id="ixv-89061" unitRef="usd">-122553</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c19" decimals="0" id="ixv-89062" unitRef="usd">-112915</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c18" decimals="0" id="ixv-89063" unitRef="usd">-4969205</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c19" decimals="0" id="ixv-89064" unitRef="usd">-6504718</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c19" decimals="0" id="ixv-89065" unitRef="usd">22159</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c18" decimals="0" id="ixv-89066" unitRef="usd">100000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c18" decimals="0" id="ixv-89067" unitRef="usd">-100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c19" decimals="0" id="ixv-89068" unitRef="usd">-22159</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c19" decimals="0" id="ixv-89069" unitRef="usd">850000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c18" decimals="0" id="ixv-89070" unitRef="usd">400000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c18" decimals="0" id="ixv-89071" unitRef="usd">3367750</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c19" decimals="0" id="ixv-89072" unitRef="usd">2565000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c18" decimals="0" id="ixv-89073" unitRef="usd">282700</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c19" decimals="0" id="ixv-89074" unitRef="usd">327200</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c18" decimals="0" id="ixv-89075" unitRef="usd">3388222</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c19" decimals="0" id="ixv-89076" unitRef="usd">300000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromNotesPayable contextRef="c19" decimals="0" id="ixv-89077" unitRef="usd">1000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c19" decimals="0" id="ixv-89078" unitRef="usd">64436</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders contextRef="c18" decimals="0" id="ixv-89079" unitRef="usd">2122392</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders contextRef="c19" decimals="0" id="ixv-89080" unitRef="usd">485714</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromOtherEquity contextRef="c18" decimals="0" id="ixv-89081" unitRef="usd">2857852</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity contextRef="c19" decimals="0" id="ixv-89082" unitRef="usd">635391</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering contextRef="c18" decimals="0" id="ixv-89083" unitRef="usd">138405</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering contextRef="c19" decimals="0" id="ixv-89084" unitRef="usd">19132</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="c18" decimals="0" id="ixv-89085" unitRef="usd">3500000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c18" decimals="0" id="ixv-89086" unitRef="usd">7638667</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c19" decimals="0" id="ixv-89087" unitRef="usd">4825337</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c18" decimals="0" id="ixv-89088" unitRef="usd">1447</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c19" decimals="0" id="ixv-89089" unitRef="usd">-3970</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c18" decimals="0" id="ixv-89090" unitRef="usd">2570909</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c19" decimals="0" id="ixv-89091" unitRef="usd">-1705510</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" id="ixv-89092" unitRef="usd">285400</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c32" decimals="0" id="ixv-89093" unitRef="usd">1990910</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="0" id="ixv-89094" unitRef="usd">2856309</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" id="ixv-89095" unitRef="usd">285400</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c18" decimals="0" id="ixv-89096" unitRef="usd">1088512</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c19" decimals="0" id="ixv-89097" unitRef="usd">718753</us-gaap:InterestPaidNet>
    <avco:CommonStockIssuedForAccruedLiabilities contextRef="c18" decimals="0" id="ixv-89098" unitRef="usd">60000</avco:CommonStockIssuedForAccruedLiabilities>
    <avco:CommonStockIssuedForAccruedLiabilities contextRef="c19" decimals="0" id="ixv-89099" unitRef="usd">164871</avco:CommonStockIssuedForAccruedLiabilities>
    <avco:ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment contextRef="c19" decimals="0" id="ixv-89100" unitRef="usd">9000000</avco:ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment>
    <avco:WarrantsIssuedWithConvertibleNotePayable contextRef="c19" decimals="0" id="ixv-89101" unitRef="usd">11000000</avco:WarrantsIssuedWithConvertibleNotePayable>
    <avco:AccruedPurchasePriceRelatedToEquityMethodInvestment contextRef="c19" decimals="0" id="ixv-89102" unitRef="usd">666667</avco:AccruedPurchasePriceRelatedToEquityMethodInvestment>
    <avco:WarrantsIssuedAsConvertibleNotePayableFindersFee contextRef="c18" decimals="0" id="ixv-89103" unitRef="usd">40900</avco:WarrantsIssuedAsConvertibleNotePayableFindersFee>
    <avco:WarrantsIssuedAsConvertibleNotePayableFindersFee contextRef="c19" decimals="0" id="ixv-89104" unitRef="usd">16977</avco:WarrantsIssuedAsConvertibleNotePayableFindersFee>
    <avco:WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount contextRef="c18" decimals="0" id="ixv-89105" unitRef="usd">438568</avco:WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount>
    <avco:WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount contextRef="c19" decimals="0" id="ixv-89106" unitRef="usd">196193</avco:WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount>
    <avco:ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock contextRef="c18" decimals="0" id="ixv-89107" unitRef="usd">320546</avco:ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock>
    <avco:ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock contextRef="c19" decimals="0" id="ixv-89108" unitRef="usd">236400</avco:ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock>
    <avco:DeferredFinancingCostsInAccruedLiabilities contextRef="c19" decimals="0" id="ixv-89109" unitRef="usd">202892</avco:DeferredFinancingCostsInAccruedLiabilities>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c18" decimals="0" id="ixv-89110" unitRef="usd">566667</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:SupplementalDeferredPurchasePrice contextRef="c18" decimals="0" id="ixv-89111" unitRef="usd">175136</us-gaap:SupplementalDeferredPurchasePrice>
    <avco:SettlementsOfDerivativeLiability contextRef="c18" decimals="0" id="ixv-89112" unitRef="usd">2354</avco:SettlementsOfDerivativeLiability>
    <avco:ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty contextRef="c18" decimals="0" id="ixv-89113" unitRef="usd">500000</avco:ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty>
    <avco:IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant contextRef="c18" decimals="0" id="ixv-89114" unitRef="usd">4</avco:IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant>
    <us-gaap:StockIssued1 contextRef="c18" decimals="0" id="ixv-89115" unitRef="usd">21</us-gaap:StockIssued1>
    <us-gaap:NatureOfOperations contextRef="c18" id="ixv-58929">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 1 - &lt;span style="text-decoration:underline"&gt;ORGANIZATION AND NATURE
OF OPERATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Avalon GloboCare Corp. (the &#x201c;Company&#x201d;
or &#x201c;ALBT&#x201d;) was incorporated under the laws of the State of Delaware on July 28, 2014.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company is a commercial-stage company dedicated
to developing and delivering precision diagnostic consumer products. The Company is currently marketing the KetoAir breathalyzer device
and plans to develop additional diagnostic uses of the breathalyzer technology. The Company also provided laboratory services in 2024
and 2023, offering a broad portfolio of diagnostic tests, including drug testing, toxicology, and a broad array of test services, from
general bloodwork to anatomic pathology, and urine toxicology.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 18, 2015, Avalon Healthcare System, Inc.
(&#x201c;AHS&#x201d;) was incorporated under the laws of the State of Delaware. AHS owns 100% of the capital stock of Avalon (Shanghai)
Healthcare Technology Co., Ltd. (&#x201c;Avalon Shanghai&#x201d;), which is a wholly foreign-owned enterprise organized under the laws of
the People&#x2019;s Republic of China (&#x201c;PRC&#x201d;). Avalon Shanghai was incorporated on April 29, 2016, and was engaged in medical
related consulting services for customers. Due to the winding down of the medical related consulting services in 2022, the Company decided
to cease all operations of Avalon Shanghai and no longer has any material revenues or expenses in Avalon Shanghai. As a result, Avalon
Shanghai is no longer an operating entity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 7, 2017, the Company formed Avalon
RT 9 Properties, LLC (&#x201c;Avalon RT 9&#x201d;), a New Jersey limited liability company. On May 5, 2017, Avalon RT 9 purchased a real
property located in Township of Freehold, County of Monmouth, State of New Jersey, having a street address of 4400 Route 9 South, Freehold,
NJ 07728. This property was purchased to serve as the Company&#x2019;s world-wide headquarters for all corporate administration and operations.
In addition, the property generates rental income. Avalon RT 9 owns this office building. Avalon RT 9&#x2019;s business consists of the
ownership and operation of the income-producing real estate property in New Jersey. As of December 31, 2024, the occupancy rate of the
building is 98.5%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 18, 2018, the Company formed a wholly
owned subsidiary, Avactis Biosciences Inc. (&#x201c;Avactis&#x201d;), a Nevada corporation, which is a patent holding company. Commencing
on April 6, 2022, the Company owns 60% of Avactis and Arbele Biotherapeutics Limited (&#x201c;Arbele Biotherapeutics&#x201d;) owns 40% of
Avactis. Avactis owns 100% of the capital stock of Avactis Nanjing Biosciences Ltd., a company incorporated in the PRC on May 8, 2020
(&#x201c;Avactis Nanjing&#x201d;), which only owns a patent and is not considered an operating entity. Currently, Avactis and Avactis Nanjing
are dormant and are in process of being dissolved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 14, 2022, the Company formed a wholly
owned subsidiary, Avalon Laboratory Services, Inc. (&#x201c;Avalon Lab&#x201d;), a Delaware company. On February 9, 2023, Avalon Lab purchased
40% of the issued and outstanding equity interests of Laboratory Services MSO, LLC, a private limited company formed under the laws of
the State of Delaware on September 6, 2019 (&#x201c;Lab Services MSO&#x201d;), and its subsidiaries. Lab Services MSO, through its subsidiaries,
is engaged in providing laboratory testing services. During 2025, to preserve cash, the Company entered into discussions with Lab Services
MSO for the potential redemption of our investment and on February 26, 2025, Lab Services MSO redeemed the 40% equity interest in Lab
Services MSO held by Avalon Lab. See Note 22 - Subsequent Events - Redemption Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;On May 1,
2024, the Company formed a wholly owned subsidiary, Q&amp;amp;A Distribution LLC (&#x201c;Q&amp;amp;A Distribution&#x201d;), a Texas company. Q&amp;amp;A
Distribution is engaged in distribution of KetoAir device.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Details of the Company&#x2019;s subsidiaries which
are included in these consolidated financial statements as of December 31, 2024 are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; width: 30%; text-align: left"&gt;Name of Subsidiary&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 17%; text-align: center"&gt;Place and date of&lt;br/&gt; Incorporation&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 2%; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 15%; text-align: center"&gt;Percentage of&lt;br/&gt; Ownership&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"&gt;Principal Activities&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Avalon Healthcare System, Inc. (&#x201c;AHS&#x201d;)&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;Delaware &lt;br/&gt;
May 18, 2015&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;100% held by ALBT&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;Holding company for payroll and other expenses&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Avalon RT 9 Properties LLC (&#x201c;Avalon RT 9&#x201d;) &#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;New Jersey&lt;br/&gt; February 7, 2017 &#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;100% held by ALBT &#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;Owns and operates an income-producing real property and holds and manages the corporate headquarters&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Avalon (Shanghai) Healthcare Technology Co., Ltd. (&#x201c;Avalon Shanghai&#x201d;)&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;PRC &lt;br/&gt;
April 29, 2016 &#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;100% held by AHS &#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;Is not considered an operating entity &#160; &#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Genexosome Technologies Inc. (&#x201c;Genexosome&#x201d;)&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;Nevada&lt;br/&gt; July 31, 2017&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;60% held by ALBT&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;No current activities to report, dormant &#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Avactis Biosciences Inc. (&#x201c;Avactis&#x201d;)&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;Nevada&lt;br/&gt; July 18, 2018&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;60% held by ALBT&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;Dormant, is in process of being dissolved&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Avactis Nanjing Biosciences Ltd. (&#x201c;Avactis Nanjing&#x201d;)&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;PRC &lt;br/&gt;
May 8, 2020&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;100% held by Avactis&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;Dormant, is in process of being dissolved&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Avalon Laboratory Services, Inc. (&#x201c;Avalon Lab&#x201d;)&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;Delaware&lt;br/&gt; October 14, 2022&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;100% held by ALBT&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;Laboratory holding company with a 40% membership interest in Lab Services MSO (1)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left; vertical-align: top"&gt;Q&amp;amp;A Distribution LLC (&#x201c;Q&amp;amp;A Distribution&#x201d;)&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: top"&gt;Texas &lt;br/&gt;
May 1, 2024&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: top"&gt;100% held by ALBT&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; vertical-align: top; text-align: center"&gt;Distributes KetoAir device&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;(1)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On February 26, 2025, the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement,
whereby Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by the Company.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c111"
      decimals="2"
      id="ixv-89116"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c112"
      decimals="3"
      id="ixv-89117"
      unitRef="pure">0.985</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c113"
      decimals="2"
      id="ixv-89118"
      unitRef="pure">0.60</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c114"
      decimals="2"
      id="ixv-89119"
      unitRef="pure">0.40</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c115"
      decimals="2"
      id="ixv-89120"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c116"
      decimals="2"
      id="ixv-89121"
      unitRef="pure">0.40</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c117"
      decimals="2"
      id="ixv-89122"
      unitRef="pure">0.40</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock contextRef="c18" id="ixv-58978">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Details of the Company&#x2019;s subsidiaries which
are included in these consolidated financial statements as of December 31, 2024 are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; width: 30%; text-align: left"&gt;Name of Subsidiary&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 17%; text-align: center"&gt;Place and date of&lt;br/&gt; Incorporation&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 2%; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 15%; text-align: center"&gt;Percentage of&lt;br/&gt; Ownership&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; width: 2%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"&gt;Principal Activities&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Avalon Healthcare System, Inc. (&#x201c;AHS&#x201d;)&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;Delaware &lt;br/&gt;
May 18, 2015&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;100% held by ALBT&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;Holding company for payroll and other expenses&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Avalon RT 9 Properties LLC (&#x201c;Avalon RT 9&#x201d;) &#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;New Jersey&lt;br/&gt; February 7, 2017 &#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;100% held by ALBT &#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;Owns and operates an income-producing real property and holds and manages the corporate headquarters&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Avalon (Shanghai) Healthcare Technology Co., Ltd. (&#x201c;Avalon Shanghai&#x201d;)&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;PRC &lt;br/&gt;
April 29, 2016 &#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;100% held by AHS &#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;Is not considered an operating entity &#160; &#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Genexosome Technologies Inc. (&#x201c;Genexosome&#x201d;)&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;Nevada&lt;br/&gt; July 31, 2017&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;60% held by ALBT&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;No current activities to report, dormant &#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Avactis Biosciences Inc. (&#x201c;Avactis&#x201d;)&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;Nevada&lt;br/&gt; July 18, 2018&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;60% held by ALBT&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;Dormant, is in process of being dissolved&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Avactis Nanjing Biosciences Ltd. (&#x201c;Avactis Nanjing&#x201d;)&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;PRC &lt;br/&gt;
May 8, 2020&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;100% held by Avactis&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;Dormant, is in process of being dissolved&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;Avalon Laboratory Services, Inc. (&#x201c;Avalon Lab&#x201d;)&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;Delaware&lt;br/&gt; October 14, 2022&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;100% held by ALBT&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;Laboratory holding company with a 40% membership interest in Lab Services MSO (1)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: rgb(204,238,255)"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: White"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left; vertical-align: top"&gt;Q&amp;amp;A Distribution LLC (&#x201c;Q&amp;amp;A Distribution&#x201d;)&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: top"&gt;Texas &lt;br/&gt;
May 1, 2024&lt;/td&gt; &lt;td style="text-align: center; vertical-align: top"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; text-align: center; vertical-align: top"&gt;100% held by ALBT&lt;/td&gt; &lt;td style="vertical-align: top; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1pt; vertical-align: top; text-align: center"&gt;Distributes KetoAir device&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;(1)&lt;/td&gt;&lt;td style="text-align: justify"&gt;On February 26, 2025, the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement,
whereby Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by the Company.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock>
    <avco:EquityMethodInvestmentPlaceAndDateOfIncorporation contextRef="c119" id="ixv-58997">Delaware
May 18, 2015</avco:EquityMethodInvestmentPlaceAndDateOfIncorporation>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c119"
      decimals="2"
      id="ixv-89123"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c119" id="ixv-89124">Holding company for payroll and other expenses</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <avco:EquityMethodInvestmentPlaceAndDateOfIncorporation contextRef="c120" id="ixv-59015">New Jersey February 7, 2017</avco:EquityMethodInvestmentPlaceAndDateOfIncorporation>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c120"
      decimals="2"
      id="ixv-89125"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c120" id="ixv-89126">Owns and operates an income-producing real property and holds and manages the corporate headquarters</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <avco:EquityMethodInvestmentPlaceAndDateOfIncorporation contextRef="c121" id="ixv-59033">PRC
April 29, 2016</avco:EquityMethodInvestmentPlaceAndDateOfIncorporation>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c121"
      decimals="2"
      id="ixv-89127"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c121" id="ixv-89128">Is not considered an operating entity</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <avco:EquityMethodInvestmentPlaceAndDateOfIncorporation contextRef="c122" id="ixv-59051">Nevada July 31, 2017</avco:EquityMethodInvestmentPlaceAndDateOfIncorporation>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c122"
      decimals="2"
      id="ixv-89129"
      unitRef="pure">0.60</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c122" id="ixv-89130">No current activities to report, dormant</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <avco:EquityMethodInvestmentPlaceAndDateOfIncorporation contextRef="c123" id="ixv-59069">Nevada July 18, 2018</avco:EquityMethodInvestmentPlaceAndDateOfIncorporation>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c123"
      decimals="2"
      id="ixv-89131"
      unitRef="pure">0.60</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c123" id="ixv-89132">Dormant, is in process of being dissolved</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <avco:EquityMethodInvestmentPlaceAndDateOfIncorporation contextRef="c124" id="ixv-59079">PRC
May 8, 2020</avco:EquityMethodInvestmentPlaceAndDateOfIncorporation>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c124"
      decimals="2"
      id="ixv-89133"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c124" id="ixv-89134">Dormant, is in process of being dissolved</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <avco:EquityMethodInvestmentPlaceAndDateOfIncorporation contextRef="c125" id="ixv-59097">Delaware October 14, 2022</avco:EquityMethodInvestmentPlaceAndDateOfIncorporation>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c125"
      decimals="2"
      id="ixv-89135"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c125" id="ix_0_fact">Laboratory holding company with a 40% membership interest in Lab Services MSO (1)</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <avco:EquityMethodInvestmentPlaceAndDateOfIncorporation contextRef="c126" id="ixv-59115">Texas
May 1, 2024</avco:EquityMethodInvestmentPlaceAndDateOfIncorporation>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c126"
      decimals="2"
      id="ixv-89137"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c126" id="ixv-89138">Distributes KetoAir device</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c118"
      decimals="2"
      id="ixv-89140"
      unitRef="pure">0.40</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c18" id="ixv-59129">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;NOTE
2 - &lt;span style="text-decoration:underline"&gt;BASIS OF PRESENTATION AND GOING CONCERN CONDITION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Basis of Presentation &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S.
GAAP&#x201d;) and with the rules and regulations of the U.S. Securities and Exchange Commission for financial information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s consolidated financial statements
include the accounts of the Company and its subsidiaries. All significant intercompany accounts and transactions have been eliminated
in consolidation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Going Concern&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company is a commercial-stage company dedicated
to developing and delivering precision diagnostic consumer products. The Company is currently marketing the KetoAir breathalyzer device
and plans to develop additional diagnostic uses of the breathalyzer technology. In addition, the Company owns commercial real estate
that houses its headquarters in Freehold, New Jersey. These consolidated financial statements have been prepared assuming that the Company
will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities
in the normal course of business.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As reflected in the accompanying consolidated
financial statements, the Company had a working capital deficit of approximately $10,646,000 at December 31, 2024 and had incurred recurring
net losses and generated negative cash flow from operating activities of approximately $7,903,000 and $4,969,000 for the year ended December
31, 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has a limited operating history and
its continued growth is dependent upon the continuation of generating rental revenue from its income-producing real estate property in
New Jersey and obtaining additional financing to fund future obligations and pay liabilities arising from normal business operations.
In addition, the current cash balance cannot be projected to cover the operating expenses for the next twelve months from the release
date of this report. These matters raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. The ability
of the Company to continue as a going concern is dependent on the Company&#x2019;s ability to raise additional capital, implement its business
plan, and generate significant revenue. There are no assurances that the Company will be successful in its efforts to generate significant
revenue, maintain sufficient cash balance or report profitable operations or to continue as a going concern. The Company plans on raising
capital through the sale of equity to implement its business plan. However, there is no assurance these plans will be realized and that
any additional financings will be available to the Company on satisfactory terms and conditions, if any.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification
of liabilities that may result should the Company be unable to continue as a going concern.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <avco:WorkingCapitalDeficit contextRef="c1" decimals="0" id="ixv-89141" unitRef="usd">10646000</avco:WorkingCapitalDeficit>
    <us-gaap:NetIncomeLoss contextRef="c18" decimals="-3" id="ixv-89142" unitRef="usd">-7903000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c18" decimals="-3" id="ixv-89143" unitRef="usd">-4969000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c18" id="ixv-59185">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 3 - &lt;span style="text-decoration:underline"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The preparation
of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting period. Changes in these estimates and assumptions may have a material
impact on the consolidated financial statements and accompanying notes. Making estimates requires management to exercise significant judgment.
It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the
date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or
more future confirming events. Accordingly, the actual results could differ significantly from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Significant estimates during the years ended December
31, 2024 and 2023 include the useful life of investment in real estate and intangible assets, the assumptions used in assessing impairment
of long-term assets, the valuation of deferred tax assets and the associated valuation allowances, the valuation of stock-based compensation,
the assumptions used to determine fair value of warrants and embedded conversion features of convertible note payable, and the fair value
of the consideration given and assets acquired in the purchase of 40% of Lab Services MSO.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Fair Value of Financial Instruments and
Fair Value Measurements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
Company adopted the guidance of Accounting Standards Codification (&#x201c;ASC&#x201d;) 820 for fair value measurements which clarifies
the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs
used in measuring fair value as follows&lt;/span&gt;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Level &lt;span style="background-color: white"&gt;1-Inputs are
unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Level &lt;span style="background-color: white"&gt;2-Inputs are
unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities
in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable
market data.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Level &lt;span style="background-color: white"&gt;3-Inputs are
unobservable inputs which reflect the reporting entity&#x2019;s own assumptions on what assumptions the market participants would use
in pricing the asset or liability based on the best available information.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of the Company&#x2019;s assets and
liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying
amounts represented in the accompanying consolidated financial statements, primarily due to their short-term nature&lt;span style="background-color: white"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Assets
and liabilities measured at fair value on a recurring basis.&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;Certain assets and liabilities are measured at
fair value on a recurring basis. These assets and liabilities are measured at fair value on an ongoing basis. These assets and liabilities
include derivative liability&lt;span style="background-color: white"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;i&gt;Derivative
liability.&lt;/i&gt;&#160;Derivative liability is carried at fair value and measured on an ongoing basis.&#160;The table below reflects the
activity of derivative liability measured at fair value for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Significant Unobservable Inputs &lt;br/&gt;
(Level 3)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance of derivative liability as of January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-329"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Initial fair value of derivative liability attributable to warrants issuance with May, July, and October 2023 fund raises&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;213,170&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain from change in the fair value of derivative liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(188,374&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance of derivative liability as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,796&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Initial fair value of derivative liability attributable to warrants issuance with March and June 2024 fund raises&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;479,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Reclassification of additional paid-in capital upon conversion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,354&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain from change in the fair value of derivative liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(374,365&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance of derivative liability as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;127,545&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Assets
and liabilities measured at fair value on a nonrecurring basis.&lt;/i&gt;&lt;/b&gt;&#160;Certain assets and liabilities are measured at fair value
on a nonrecurring basis. These assets and liabilities are not measured at fair value on an ongoing basis, but are subject to fair value
adjustments in certain circumstances. These assets and liabilities can include equipment held for sale and equity method investment that
are written down to fair value when they are impaired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;i&gt;Laboratory
equipment. &lt;/i&gt;The Company conducted an impairment assessment on its laboratory equipment based on the guidelines established in Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) ASC Topic 360 to determine the estimated fair market value of its laboratory equipment
as of December 31, 2024. Upon completion of its 2024 impairment analysis, the Company determined that the carrying value exceeded the
fair market value of laboratory equipment. The fair market value of laboratory equipment is a level 3 valuation. The Company recorded
an impairment charge of $111,033 for the year ended December 31, 2024, which was included in other general and administrative expenses
on the accompanying consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;i&gt;Equity
method investment in Epicon Biotech Co., Ltd.&lt;/i&gt;&#160;The factors used to determine fair value are subject to management&#x2019;s judgment
and expertise and include, but are not limited to, the investee&#x2019;s series of operating losses and the joint venture partner unable
to obtain funds to commence operations. These assumptions represent Level 3 inputs. Impairment of equity method investment in Epicon Biotech
Co., Ltd. for the year ended December 31, 2023 was $454,679. There is no comparative impairment for the year ended December 31, 2024 since
the investment was fully impaired at December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;i&gt;Equity
method investment in &lt;/i&gt;&lt;/span&gt;&lt;i&gt;Laboratory Services MSO, LLC &lt;/i&gt;&lt;span style="background-color: white"&gt;The factors used to determine
fair value are subject to management&#x2019;s judgment and expertise. These assumptions represent Level 3 inputs. Impairment of equity
method investment in Laboratory Services MSO, LLC for the years ended December 31, 2024 and 2023 was $259,579 and $9,196,682, respectively,
which have been included in loss from equity method investment - Lab Services MSO on the accompanying consolidated statements of
operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;ASC
825-10 &#x201c;Financial Instruments&#x201d;, allows entities to voluntarily choose to measure certain financial assets and liabilities
at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless
a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should
be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding
instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At December 31, 2024 and 2023, the Company&#x2019;s
cash balances by geographic area were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Country:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,844,522&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;99.6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;280,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;98.2&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;China&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,787&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1.8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total cash&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,856,309&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;285,400&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For purposes of the consolidated statements of
cash flows, the Company considers all highly liquid instruments with a maturity of three months or less when purchased and money market
accounts to be cash equivalents. The Company had no cash equivalents at December 31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Credit Risk and Uncertainties&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
maintains a portion of its cash on deposits with bank and financial institution within the U.S. that at times may exceed federally-insured
limits of $250,000. The Company manages this credit risk by concentrating its cash balances in high quality financial institutions and
by periodically evaluating the credit quality of the primary financial institutions holding such deposits. The Company has not experienced
any losses in such bank accounts and believes it is not exposed to any risks on its cash in bank accounts. At December 31, 2024, the Company&#x2019;s
cash balances in United States bank accounts had approximately $2,413,000 in excess of the federally-insured limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company&#x2019;s
concentrations of credit risk with respect to its rent receivable is limited due to short-term payment terms. The Company also performs
ongoing credit evaluations of its tenants to help further reduce credit risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Rent Receivable and Reserve for Credit
Losses&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Rent receivable
is presented net of reserve for credit losses. Rent receivable balance consists of base rents, tenant reimbursements and receivables arising
from straight-lining of rents represent amounts accrued and unpaid from tenants in accordance with the terms of the respective leases,
subject to the Company&#x2019;s revenue recognition policy. A reverse for the uncollectible portion of rent receivable is determined based
upon an analysis of the tenant&#x2019;s payment history, the financial condition of the tenant, business conditions in the industry in
which the tenant operates and economic conditions in Freehold, New Jersey in which the property is located.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Management
believes that the rent receivable is fully collectable. Therefore, no material reverse for credit losses is deemed to be required on its
rent receivable at December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Deferred Offering Costs&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred offering costs consist of legal, accounting
and other costs that are directly related to the Company&#x2019;s open market sale equity financing and will be charged to stockholders&#x2019;
equity upon completion of the equity offering. As of December 31, 2024 and 2023, deferred offering costs amounted to $0&#160;and $175,136,
respectively, which were included in prepaid expense and other current assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Deferred Leasing Costs&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Costs incurred
to obtain tenant leases are amortized using the straight-line method over the term of the related lease agreement. Such costs include
lease incentives and leasing commissions. If the lease is terminated early, the remaining unamortized deferred leasing cost is written
off.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment are carried at cost less
accumulated depreciation, and are depreciated on a straight-line basis over the estimated useful lives of the assets. The cost of repairs
and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of,
the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the period
of disposition. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances
reflect the fact that their recorded value may not be recoverable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Investment In Real
Estate and Depreciation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Investment in real estate is carried at cost less
accumulated depreciation, and consists of building and improvement. The Company depreciates real estate building and improvement on a
straight-line basis over estimated useful life. Expenditures for ordinary repair and maintenance costs are charged to expense as incurred.
Expenditure for improvements, renovations, and replacements of real estate asset is capitalized and depreciated over its estimated useful
life if the expenditure qualifies as betterment.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Impairment of Long-lived Assets&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC Topic 360, the Company
reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may
not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future
cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset&#x2019;s
estimated fair value and its book value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;For the
year ended December 31, 2024, the Company incurred impairment charges in operations of $111,033 on its laboratory equipment. The valuation
of the laboratory equipment, and the amount of the impairment charge, were based on impairment assessment conducted on the equipment at
December 31, 2024.&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Investment in Unconsolidated
Companies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company uses the equity method of accounting
for its investment in, and earning or loss of, investees that it does not control but over which it does exert significant influence.
The Company applies the equity method by initially recording these investments at cost, as equity method investments, subsequently adjusted
for equity in earnings and cash distributions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers whether the fair value of
its equity method investment has declined below its carrying value whenever adverse events or changes in circumstances indicate that recorded
value may not be recoverable. If the Company considers any decline to be other than temporary (based on various factors, including historical
financial results and the overall health of the investee), then a write-down would be recorded to estimated fair value. Impairment of
equity method investment amounted to $259,579 and $9,651,361 for the years ended December 31, 2024 and 2023, respectively. See Note 8
for discussion of equity method investments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company classifies distributions received
from equity method investments using the cumulative earnings approach. Distributions received are considered returns on the investment
and classified as cash inflows from operating activities. If, however, the investor&#x2019;s cumulative distributions received, less distributions
received in prior periods determined to be returns of investment, exceeds cumulative equity in earnings recognized, the excess is considered
a return of investment and is classified as cash inflows from investing activities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Deferred Rental Income&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred rental income represents rental income
collected but not earned as of the reporting date. The Company defers the revenue related to lease payments received from tenants in advance
of their due dates. As of December 31, 2024 and 2023, deferred rental income totaled $38,346 and $11,429, respectively, which were included
in accrued liabilities and other payables on the accompanying consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;Real Property Rental Revenue&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
has determined that ASC 606 does not apply to rental contracts, which are within the scope of other revenue recognition accounting standards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Rental income from operating leases is recognized
on a straight-line basis under the guidance of ASC 842. Lease payments under tenant leases are recognized on a straight-line basis over
the term of the related leases. The cumulative difference between lease revenue recognized under the straight-line method and contractual
lease payments are included in rent receivable on the consolidated balance sheets&lt;span style="background-color: white"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Office Lease&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;When a lease contains &#x201c;rent holidays&#x201d;,
the Company records rental expense on a straight-line basis over the term of the lease. The Company begins recording rent expense on the
lease possession date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Real Property Operating Expenses&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Real property operating expenses consist of property
management fees, property insurance, real estate taxes, depreciation, repairs and maintenance fees, utilities and other expenses related
to the Company&#x2019;s rental properties.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Expenditures for research and product development
costs are expensed as incurred. The Company incurred research and development expense of $0&#160;and $109,618&#160;in the years ended
December 31, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Advertising and Marketing Costs&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;All costs related to advertising and marketing
are expensed as incurred. For the years ended December 31, 2024 and 2023, advertising and marketing costs amounted to $237,671 and $1,666,721,
respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock-based Compensation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
accounts for its stock-based compensation awards in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 718, Compensation-Stock
Compensation (&#x201c;ASC 718&#x201d;). ASC 718 requires all stock-based payments to employees and non-employees including grants of stock
options, to be recognized as expense in the statements of operations based on their grant date fair values. The Company estimates the
grant date fair value of each option award using the Black-Scholes option-pricing model.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
periodically issues common stock and common stock options to consultants for various services. Costs of these transactions are measured
at the fair value of the service received or the fair value of the equity instruments issued, whichever is more reliably measurable. The
value of the common stock is measured at the earlier of (i) the date at which a firm commitment for performance by the counterparty to
earn the equity instruments is reached or (ii) the date at which the counterparty&#x2019;s performance is complete.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;Debt
Modifications and Extinguishments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;When the
Company modifies or extinguishes debt, it first evaluates whether the modification qualifies as a troubled debt restructuring (TDR) under
ASC Topic 470-60, which requires debt modifications to be evaluated to determine if (1) the borrower is experiencing financial difficulty,
and (2) the lender grants the borrower a concession. If a TDR is determined not to have occurred, the Company evaluates the modification
in accordance with ASC Topic 470-50-40, which requires modification to debt instruments to be evaluated to assess whether debt modification
or debt extinguishment accounting is applicable. This evaluation includes analyzing whether there are significant and consequential changes
to the economic substance of the note. If the change is deemed insignificant then the change is considered a debt modification, whereas
if the change is substantial the change is reflected as a debt extinguishment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;If debt
extinguishment guidance applies, the previous debt principal amount is removed, the previously capitalized debt issuance costs are expensed,
the value of instruments exchanged are recorded, including cash, new debt, warrants and common stock, and a gain or loss on extinguishment
of debt is recorded. If debt modification guidance applies, no gain or loss is recorded and the effective interest rate of the debt is
updated based on the carrying value of the debt and the revised future cash flows. Any previously capitalized debt issuance costs in a
debt modification are amortized as interest expense over the term of the new debt instrument.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
is governed by the income tax laws of China and the United States. The Company accounts for income taxes using the asset/liability method
prescribed by ASC 740, &#x201c;Income Taxes.&#x201d; Under this method, deferred tax assets and liabilities are determined based on the
difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the
period in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if, based
on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized.
The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
follows the accounting guidance for uncertainty in income taxes using the provisions of ASC 740 &#x201c;Income Taxes&#x201d;. Using that
guidance, the benefit for tax positions taken can only be recognized in the financial statements when it is more likely than not the position
will be sustained upon examination by the tax authorities. As of December 31, 2024 and 2023, the Company had no significant uncertain
tax positions which would require either recognition of a liability or disclosure in the financial statements. For United States entities,
tax year that remains subject to examination is the years ended December 31, 2024, 2023, 2022 and 2021. For China entities, income tax
returns for the tax years ended December 31, 2020 through December 31, 2024 remain open for statutory examination by PRC tax authorities.
The Company recognizes interest and penalties related to significant uncertain income tax positions in income tax expense. However, no
such interest and penalties were recorded as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Foreign Currency Translation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The reporting
currency of the Company is the U.S. dollar. The functional currency of the parent company, AHS, Avalon RT 9, Avalon Lab, and Q&amp;amp;A Distribution
is the U.S. dollar and the functional currency of Avalon Shanghai is the Chinese Renminbi (&#x201c;RMB&#x201d;). For Avalon Shanghai whose
functional currency is the RMB, result of operations and cash flows are translated at average exchange rates during the period, assets
and liabilities are translated at the unified exchange rate at the end of the period, and equity is translated at historical exchange
rates. As a result, amounts relating to assets and liabilities reported on the statements of cash flows may not necessarily agree with
the changes in the corresponding balances on the balance sheets. Translation adjustments resulting from the process of translating the
local currency financial statements into U.S. dollars are included in determining comprehensive income/loss. Transactions denominated
in foreign currencies are translated into the functional currency at the exchange rates prevailing on the transaction dates. Assets and
liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the balance
sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency
other than the functional currency are included in the results of operations as incurred. All of the Company&#x2019;s revenue transactions
are transacted in the functional currency of the operating subsidiaries. The Company does not enter into any material transaction in foreign
currencies. Transaction gains or losses have not had, and are not expected to have, a material effect on the results of operations of
the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Asset and
liability accounts at December 31, 2024 and 2023 were translated at 7.2980 RMB and 7.0786 RMB to $1.00, respectively, which were the exchange
rates on the balance sheet dates. Equity accounts were stated at their historical rates. The average translation rates applied to the
statements of operations for the years ended December 31, 2024 and 2023 were 7.1889 RMB and 7.0752 RMB to $1.00, respectively. Cash flows
from the Company&#x2019;s operations are calculated based upon the local currencies using the average translation rate.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Comprehensive Loss&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Comprehensive loss is comprised of net loss and
all changes to the statements of equity, except those due to investments by stockholders, changes in paid-in capital and distributions
to stockholders. For the Company, comprehensive loss for the years ended December 31, 2024 and 2023 consisted of net loss and unrealized
loss from foreign currency translation adjustment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;Commitments
and Contingencies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In the normal
course of business, the Company is subject to contingencies, such as legal proceedings and claims arising out of its business, that cover
a wide range of matters. Liabilities for such contingencies are recorded when it is probable that a liability has been incurred and the
amount of the assessment can be reasonably estimated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Per Share Data&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ASC Topic 260 &#x201c;Earnings per Share,&#x201d;
requires presentation of both basic and diluted earnings per share (&#x201c;EPS&#x201d;) with a reconciliation of the numerator and denominator
of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic net loss per share is computed by dividing
net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents
and potentially dilutive securities outstanding during each period. For the years ended December 31, 2024 and 2023, potentially dilutive
common shares consist of the common shares issuable upon the conversion of convertible preferred stock and convertible notes (using the
if-converted method) and exercise of common stock options and warrants (using the treasury stock method). Common stock equivalents are
not included in the calculation of diluted net loss per share if their effect would be anti-dilutive. In a period in which the Company
has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares outstanding as they would have
had an anti-dilutive impact.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The calculation of basic and diluted net loss
per common share attributable to the Company common shareholders includes 150,000 of the pre-funded warrants that remain outstanding as
of December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the securities
that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Years Ended&lt;br/&gt;
 December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;52,479&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;56,880&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;182,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43,035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Series A convertible preferred stock &lt;sup&gt;(*)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Series B convertible preferred stock &lt;sup&gt;(**)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194,004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194,004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Series C convertible preferred stock &lt;sup&gt;(***)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,452,282&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-330"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Convertible notes &lt;sup&gt;(****)&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;227,269&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;60,740&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Potentially dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,169,030&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;414,659&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Assumed the Series A convertible preferred stock was converted
into shares of common stock of the Company at a conversion price of $150.00 per share&lt;span style="background-color: white"&gt;.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="background-color: white"&gt;(**)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="background-color: white"&gt;Assumed the Series
B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="background-color: white"&gt;(***)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="background-color: white"&gt;Assumed the Series
C convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $2.41 per share.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="background-color: white"&gt;(****)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="background-color: white"&gt;Assumed the convertible
notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the year ended December
31, 2024. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and
$22.50 per share for the year ended December 31, 2023.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Noncontrolling Interest&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2024, Dr. Yu Zhou, former director
and former Co-Chief Executive Officer of Genexosome, who owns 40% of the equity interests of Genexosome, which is not under the Company&#x2019;s
control. Since the fourth quarter of 2019, the non-controlling interest has remained inactive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Reclassification&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Certain prior period
amounts have been reclassified to conform to the current period presentation. These reclassifications have no effect on the previously
reported financial position, results of operations and cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Segment Reporting&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The segment
reporting structure uses the Company&#x2019;s management reporting structure as its foundation to reflect how the Company manages the businesses
internally and is mainly organized by services. The Company is organized into two services-oriented strategic business units: real property
rental services and laboratory testing services - which are led by our strategic business unit managers. Operating segments are
defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating
decision maker (&#x201c;CODM&#x201d;) in deciding how to make operating decisions, allocate resources and assess performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 9, 2023, the Company purchased 40%
of Lab Services MSO. Commencing from the purchase date, February 9, 2023, the Company is active in the management of Lab Services MSO.
During the years ended December 31, 2024 and 2023, the Company operated in two reportable business segments: (1) the real property operating
segment, and (2) laboratory testing services segment (which commenced with the purchase date, February 9, 2023) since Lab Services MSO&#x2019;s
operating results are regularly reviewed by the Company&#x2019;s chief operating decision maker to determine the resources to be allocated
to the segment and assess its performance. The Company regularly reviews the operating results and performance of Lab Services MSO, for
which the Company accounts for under the equity method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s President and Chief Executive
Officer is its CODM. The Company reports operational data to its CODM at the segment level, which he uses to evaluate performance and
allocate resources based on real property operating income and loss from equity method investment - Lab Services MSO.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Fiscal Year End&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
Company has adopted a fiscal year end of December 31st.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Reverse Stock Split&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
effectuated a 1-for-15 reverse stock split of its outstanding shares of common stock on October 28, 2024. The reverse split did not change
the par value of common stock. All references in these consolidated financial statements to shares, share prices, exercise prices, and
other per share information in all periods have been adjusted, on a retroactive basis, to reflect the reverse stock split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Recent Accounting
Standards&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In August
2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic
470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40), to simplify accounting for certain
financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion
features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts
in an entity&#x2019;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments
that are indexed to and settled in an entity&#x2019;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including
the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after
December 15, 2022, including interim periods within those fiscal years, with early adoption permitted. The adoption of ASU 2020-06 did
not have a material effect on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In November
2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280). The amendments in this update improve reportable segment disclosure
requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 became effective for the Company&#x2019;s
annual period beginning on January 1, 2024 and interim periods beginning after January 1, 2025. The Company adopted this guidance in the
fourth quarter of 2024. Refer to Note 20 - Segment Information. The Company&#x2019;s results of operations, cash flows, and financial condition
were not impacted by the adoption of this ASU.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In December
2023, the FASB ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This guidance is intended to enhance the
transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income
tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign
jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to
apply the standard retrospectively. Early adoption is permitted. The adoption of ASU 2023-09 did not have a material effect on the Company&#x2019;s
consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Other accounting
standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material
impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated
to have an impact on or are unrelated to its consolidated financial condition, results of operations, cash flows or disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c18" id="ixv-59190">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The preparation
of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting period. Changes in these estimates and assumptions may have a material
impact on the consolidated financial statements and accompanying notes. Making estimates requires management to exercise significant judgment.
It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the
date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or
more future confirming events. Accordingly, the actual results could differ significantly from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Significant estimates during the years ended December
31, 2024 and 2023 include the useful life of investment in real estate and intangible assets, the assumptions used in assessing impairment
of long-term assets, the valuation of deferred tax assets and the associated valuation allowances, the valuation of stock-based compensation,
the assumptions used to determine fair value of warrants and embedded conversion features of convertible note payable, and the fair value
of the consideration given and assets acquired in the purchase of 40% of Lab Services MSO.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c127"
      decimals="2"
      id="ixv-89144"
      unitRef="pure">0.40</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c18" id="ixv-59229">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Fair Value of Financial Instruments and
Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
Company adopted the guidance of Accounting Standards Codification (&#x201c;ASC&#x201d;) 820 for fair value measurements which clarifies
the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs
used in measuring fair value as follows&lt;/span&gt;:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Level &lt;span style="background-color: white"&gt;1-Inputs are
unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Level &lt;span style="background-color: white"&gt;2-Inputs are
unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities
in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable
market data.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Level &lt;span style="background-color: white"&gt;3-Inputs are
unobservable inputs which reflect the reporting entity&#x2019;s own assumptions on what assumptions the market participants would use
in pricing the asset or liability based on the best available information.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of the Company&#x2019;s assets and
liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying
amounts represented in the accompanying consolidated financial statements, primarily due to their short-term nature&lt;span style="background-color: white"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Assets
and liabilities measured at fair value on a recurring basis.&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;Certain assets and liabilities are measured at
fair value on a recurring basis. These assets and liabilities are measured at fair value on an ongoing basis. These assets and liabilities
include derivative liability&lt;span style="background-color: white"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;i&gt;Derivative
liability.&lt;/i&gt;&#160;Derivative liability is carried at fair value and measured on an ongoing basis.&#160;The table below reflects the
activity of derivative liability measured at fair value for the years ended December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Significant Unobservable Inputs &lt;br/&gt;
(Level 3)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance of derivative liability as of January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-329"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Initial fair value of derivative liability attributable to warrants issuance with May, July, and October 2023 fund raises&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;213,170&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain from change in the fair value of derivative liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(188,374&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance of derivative liability as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,796&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Initial fair value of derivative liability attributable to warrants issuance with March and June 2024 fund raises&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;479,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Reclassification of additional paid-in capital upon conversion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,354&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain from change in the fair value of derivative liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(374,365&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance of derivative liability as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;127,545&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Assets
and liabilities measured at fair value on a nonrecurring basis.&lt;/i&gt;&lt;/b&gt;&#160;Certain assets and liabilities are measured at fair value
on a nonrecurring basis. These assets and liabilities are not measured at fair value on an ongoing basis, but are subject to fair value
adjustments in certain circumstances. These assets and liabilities can include equipment held for sale and equity method investment that
are written down to fair value when they are impaired.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;i&gt;Laboratory
equipment. &lt;/i&gt;The Company conducted an impairment assessment on its laboratory equipment based on the guidelines established in Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) ASC Topic 360 to determine the estimated fair market value of its laboratory equipment
as of December 31, 2024. Upon completion of its 2024 impairment analysis, the Company determined that the carrying value exceeded the
fair market value of laboratory equipment. The fair market value of laboratory equipment is a level 3 valuation. The Company recorded
an impairment charge of $111,033 for the year ended December 31, 2024, which was included in other general and administrative expenses
on the accompanying consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;i&gt;Equity
method investment in Epicon Biotech Co., Ltd.&lt;/i&gt;&#160;The factors used to determine fair value are subject to management&#x2019;s judgment
and expertise and include, but are not limited to, the investee&#x2019;s series of operating losses and the joint venture partner unable
to obtain funds to commence operations. These assumptions represent Level 3 inputs. Impairment of equity method investment in Epicon Biotech
Co., Ltd. for the year ended December 31, 2023 was $454,679. There is no comparative impairment for the year ended December 31, 2024 since
the investment was fully impaired at December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;i&gt;Equity
method investment in &lt;/i&gt;&lt;/span&gt;&lt;i&gt;Laboratory Services MSO, LLC &lt;/i&gt;&lt;span style="background-color: white"&gt;The factors used to determine
fair value are subject to management&#x2019;s judgment and expertise. These assumptions represent Level 3 inputs. Impairment of equity
method investment in Laboratory Services MSO, LLC for the years ended December 31, 2024 and 2023 was $259,579 and $9,196,682, respectively,
which have been included in loss from equity method investment - Lab Services MSO on the accompanying consolidated statements of
operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;ASC
825-10 &#x201c;Financial Instruments&#x201d;, allows entities to voluntarily choose to measure certain financial assets and liabilities
at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless
a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should
be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding
instruments.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="c18" id="ixv-89145">The table below reflects the
activity of derivative liability measured at fair value for the years ended December 31, 2024 and 2023:&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Significant Unobservable Inputs &lt;br/&gt;
(Level 3)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance of derivative liability as of January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-329"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Initial fair value of derivative liability attributable to warrants issuance with May, July, and October 2023 fund raises&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;213,170&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain from change in the fair value of derivative liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(188,374&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance of derivative liability as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,796&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Initial fair value of derivative liability attributable to warrants issuance with March and June 2024 fund raises&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;479,468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Reclassification of additional paid-in capital upon conversion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,354&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Gain from change in the fair value of derivative liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(374,365&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance of derivative liability as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;127,545&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <avco:InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise contextRef="c148" decimals="0" id="ixv-89146" unitRef="usd">213170</avco:InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c148" decimals="0" id="ixv-89147" unitRef="usd">188374</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c149" decimals="0" id="ixv-89148" unitRef="usd">24796</us-gaap:DerivativeLiabilitiesCurrent>
    <avco:InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise contextRef="c150" decimals="0" id="ixv-89149" unitRef="usd">479468</avco:InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="c150" decimals="0" id="ixv-89150" unitRef="usd">2354</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c150" decimals="0" id="ixv-89151" unitRef="usd">374365</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c151" decimals="0" id="ixv-89152" unitRef="usd">127545</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:AssetImpairmentCharges contextRef="c128" decimals="0" id="ixv-89153" unitRef="usd">111033</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c129" decimals="0" id="ixv-89154" unitRef="usd">454679</us-gaap:AssetImpairmentCharges>
    <us-gaap:EquityMethodInvestments contextRef="c130" decimals="0" id="ixv-89155" unitRef="usd">259579</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c131" decimals="0" id="ixv-89156" unitRef="usd">9196682</us-gaap:EquityMethodInvestments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c18" id="ixv-59405">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At December 31, 2024 and 2023, the Company&#x2019;s
cash balances by geographic area were as follows:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Country:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,844,522&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;99.6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;280,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;98.2&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;China&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,787&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1.8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total cash&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,856,309&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;285,400&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For purposes of the consolidated statements of
cash flows, the Company considers all highly liquid instruments with a maturity of three months or less when purchased and money market
accounts to be cash equivalents. The Company had no cash equivalents at December 31, 2024 and 2023.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c18" id="ixv-59409">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At December 31, 2024 and 2023, the Company&#x2019;s
cash balances by geographic area were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Country:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,844,522&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;99.6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;280,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;98.2&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;China&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,787&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1.8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total cash&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,856,309&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;285,400&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c152" decimals="0" id="ixv-89157" unitRef="usd">2844522</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <avco:CashPercentage
      contextRef="c152"
      decimals="3"
      id="ixv-89158"
      unitRef="pure">0.996</avco:CashPercentage>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c142" decimals="0" id="ixv-89159" unitRef="usd">280197</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <avco:CashPercentage
      contextRef="c142"
      decimals="3"
      id="ixv-89160"
      unitRef="pure">0.982</avco:CashPercentage>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c140" decimals="0" id="ixv-89161" unitRef="usd">11787</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <avco:CashPercentage
      contextRef="c140"
      decimals="3"
      id="ixv-89162"
      unitRef="pure">0.004</avco:CashPercentage>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c141" decimals="0" id="ixv-89163" unitRef="usd">5203</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <avco:CashPercentage
      contextRef="c141"
      decimals="3"
      id="ixv-89164"
      unitRef="pure">0.018</avco:CashPercentage>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="0" id="ixv-89165" unitRef="usd">2856309</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <avco:CashPercentage contextRef="c1" decimals="3" id="ixv-89166" unitRef="pure">1</avco:CashPercentage>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" id="ixv-89167" unitRef="usd">285400</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <avco:CashPercentage contextRef="c2" decimals="3" id="ixv-89168" unitRef="pure">1</avco:CashPercentage>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c18" id="ixv-59481">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Credit Risk and Uncertainties&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
maintains a portion of its cash on deposits with bank and financial institution within the U.S. that at times may exceed federally-insured
limits of $250,000. The Company manages this credit risk by concentrating its cash balances in high quality financial institutions and
by periodically evaluating the credit quality of the primary financial institutions holding such deposits. The Company has not experienced
any losses in such bank accounts and believes it is not exposed to any risks on its cash in bank accounts. At December 31, 2024, the Company&#x2019;s
cash balances in United States bank accounts had approximately $2,413,000 in excess of the federally-insured limits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company&#x2019;s
concentrations of credit risk with respect to its rent receivable is limited due to short-term payment terms. The Company also performs
ongoing credit evaluations of its tenants to help further reduce credit risk.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount contextRef="c1" decimals="0" id="ixv-89169" unitRef="usd">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:FederalReserveBankStock contextRef="c1" decimals="0" id="ixv-89170" unitRef="usd">2413000</us-gaap:FederalReserveBankStock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c18" id="ixv-59493">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Rent Receivable and Reserve for Credit
Losses&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Rent receivable
is presented net of reserve for credit losses. Rent receivable balance consists of base rents, tenant reimbursements and receivables arising
from straight-lining of rents represent amounts accrued and unpaid from tenants in accordance with the terms of the respective leases,
subject to the Company&#x2019;s revenue recognition policy. A reverse for the uncollectible portion of rent receivable is determined based
upon an analysis of the tenant&#x2019;s payment history, the financial condition of the tenant, business conditions in the industry in
which the tenant operates and economic conditions in Freehold, New Jersey in which the property is located.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Management
believes that the rent receivable is fully collectable. Therefore, no material reverse for credit losses is deemed to be required on its
rent receivable at December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <avco:DeferredOfferingCostsPolicyTextBlock contextRef="c18" id="ixv-59533">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Deferred Offering Costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred offering costs consist of legal, accounting
and other costs that are directly related to the Company&#x2019;s open market sale equity financing and will be charged to stockholders&#x2019;
equity upon completion of the equity offering. As of December 31, 2024 and 2023, deferred offering costs amounted to $0&#160;and $175,136,
respectively, which were included in prepaid expense and other current assets.&lt;/p&gt;</avco:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts contextRef="c132" decimals="0" id="ixv-89171" unitRef="usd">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts contextRef="c2" decimals="0" id="ixv-89172" unitRef="usd">175136</us-gaap:DeferredOfferingCosts>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c18" id="ixv-59542">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Deferred Leasing Costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Costs incurred
to obtain tenant leases are amortized using the straight-line method over the term of the related lease agreement. Such costs include
lease incentives and leasing commissions. If the lease is terminated early, the remaining unamortized deferred leasing cost is written
off.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c18" id="ixv-59550">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment are carried at cost less
accumulated depreciation, and are depreciated on a straight-line basis over the estimated useful lives of the assets. The cost of repairs
and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of,
the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the period
of disposition. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances
reflect the fact that their recorded value may not be recoverable.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <avco:InvestmentInRealEstateAndDepreciationPolicyTextBlock contextRef="c18" id="ixv-59558">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Investment In Real
Estate and Depreciation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Investment in real estate is carried at cost less
accumulated depreciation, and consists of building and improvement. The Company depreciates real estate building and improvement on a
straight-line basis over estimated useful life. Expenditures for ordinary repair and maintenance costs are charged to expense as incurred.
Expenditure for improvements, renovations, and replacements of real estate asset is capitalized and depreciated over its estimated useful
life if the expenditure qualifies as betterment.&#160;&lt;/p&gt;</avco:InvestmentInRealEstateAndDepreciationPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c18" id="ixv-59565">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Impairment of Long-lived Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC Topic 360, the Company
reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may
not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future
cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset&#x2019;s
estimated fair value and its book value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;For the
year ended December 31, 2024, the Company incurred impairment charges in operations of $111,033 on its laboratory equipment. The valuation
of the laboratory equipment, and the amount of the impairment charge, were based on impairment assessment conducted on the equipment at
December 31, 2024.&#160;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges contextRef="c128" decimals="0" id="ixv-89173" unitRef="usd">111033</us-gaap:AssetImpairmentCharges>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c18" id="ixv-59576">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Investment in Unconsolidated
Companies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company uses the equity method of accounting
for its investment in, and earning or loss of, investees that it does not control but over which it does exert significant influence.
The Company applies the equity method by initially recording these investments at cost, as equity method investments, subsequently adjusted
for equity in earnings and cash distributions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers whether the fair value of
its equity method investment has declined below its carrying value whenever adverse events or changes in circumstances indicate that recorded
value may not be recoverable. If the Company considers any decline to be other than temporary (based on various factors, including historical
financial results and the overall health of the investee), then a write-down would be recorded to estimated fair value. Impairment of
equity method investment amounted to $259,579 and $9,651,361 for the years ended December 31, 2024 and 2023, respectively. See Note 8
for discussion of equity method investments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company classifies distributions received
from equity method investments using the cumulative earnings approach. Distributions received are considered returns on the investment
and classified as cash inflows from operating activities. If, however, the investor&#x2019;s cumulative distributions received, less distributions
received in prior periods determined to be returns of investment, exceeds cumulative equity in earnings recognized, the excess is considered
a return of investment and is classified as cash inflows from investing activities.&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:OtherAssetImpairmentCharges contextRef="c133" decimals="0" id="ixv-89174" unitRef="usd">259579</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OtherAssetImpairmentCharges contextRef="c134" decimals="0" id="ixv-89175" unitRef="usd">9651361</us-gaap:OtherAssetImpairmentCharges>
    <avco:DeferredRentalIncomePolicyTextBlock contextRef="c18" id="ixv-59616">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Deferred Rental Income&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Deferred rental income represents rental income
collected but not earned as of the reporting date. The Company defers the revenue related to lease payments received from tenants in advance
of their due dates. As of December 31, 2024 and 2023, deferred rental income totaled $38,346 and $11,429, respectively, which were included
in accrued liabilities and other payables on the accompanying consolidated balance sheets.&lt;/p&gt;</avco:DeferredRentalIncomePolicyTextBlock>
    <us-gaap:DeferredIncome contextRef="c1" decimals="0" id="ixv-89176" unitRef="usd">38346</us-gaap:DeferredIncome>
    <us-gaap:DeferredIncome contextRef="c2" decimals="0" id="ixv-89177" unitRef="usd">11429</us-gaap:DeferredIncome>
    <avco:RealPropertyRentalRevenuePolicyTextBlock contextRef="c18" id="ixv-59624">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;Real Property Rental Revenue&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
has determined that ASC 606 does not apply to rental contracts, which are within the scope of other revenue recognition accounting standards.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Rental income from operating leases is recognized
on a straight-line basis under the guidance of ASC 842. Lease payments under tenant leases are recognized on a straight-line basis over
the term of the related leases. The cumulative difference between lease revenue recognized under the straight-line method and contractual
lease payments are included in rent receivable on the consolidated balance sheets&lt;span style="background-color: white"&gt;.&lt;/span&gt;&lt;/p&gt;</avco:RealPropertyRentalRevenuePolicyTextBlock>
    <us-gaap:LessorLeasesPolicyTextBlock contextRef="c18" id="ixv-59637">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Office Lease&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;When a lease contains &#x201c;rent holidays&#x201d;,
the Company records rental expense on a straight-line basis over the term of the lease. The Company begins recording rent expense on the
lease possession date.&lt;/p&gt;</us-gaap:LessorLeasesPolicyTextBlock>
    <us-gaap:RealEstatePolicyTextBlock contextRef="c18" id="ixv-59644">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Real Property Operating Expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Real property operating expenses consist of property
management fees, property insurance, real estate taxes, depreciation, repairs and maintenance fees, utilities and other expenses related
to the Company&#x2019;s rental properties.&lt;/p&gt;</us-gaap:RealEstatePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c18" id="ixv-59652">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Expenditures for research and product development
costs are expensed as incurred. The Company incurred research and development expense of $0&#160;and $109,618&#160;in the years ended
December 31, 2024 and 2023, respectively.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c135" decimals="0" id="ixv-89178" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c136" decimals="0" id="ixv-89179" unitRef="usd">109618</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c18" id="ixv-59661">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Advertising and Marketing Costs&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;All costs related to advertising and marketing
are expensed as incurred. For the years ended December 31, 2024 and 2023, advertising and marketing costs amounted to $237,671 and $1,666,721,
respectively.&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:DeferredAdvertisingCosts contextRef="c1" decimals="0" id="ixv-89180" unitRef="usd">237671</us-gaap:DeferredAdvertisingCosts>
    <us-gaap:DeferredAdvertisingCosts contextRef="c2" decimals="0" id="ixv-89181" unitRef="usd">1666721</us-gaap:DeferredAdvertisingCosts>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c18" id="ixv-59668">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock-based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
accounts for its stock-based compensation awards in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 718, Compensation-Stock
Compensation (&#x201c;ASC 718&#x201d;). ASC 718 requires all stock-based payments to employees and non-employees including grants of stock
options, to be recognized as expense in the statements of operations based on their grant date fair values. The Company estimates the
grant date fair value of each option award using the Black-Scholes option-pricing model.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
periodically issues common stock and common stock options to consultants for various services. Costs of these transactions are measured
at the fair value of the service received or the fair value of the equity instruments issued, whichever is more reliably measurable. The
value of the common stock is measured at the earlier of (i) the date at which a firm commitment for performance by the counterparty to
earn the equity instruments is reached or (ii) the date at which the counterparty&#x2019;s performance is complete.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <avco:DebtModificationsAndExtinguishmentsPolicyTextBlock contextRef="c18" id="ixv-59709">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;Debt
Modifications and Extinguishments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;When the
Company modifies or extinguishes debt, it first evaluates whether the modification qualifies as a troubled debt restructuring (TDR) under
ASC Topic 470-60, which requires debt modifications to be evaluated to determine if (1) the borrower is experiencing financial difficulty,
and (2) the lender grants the borrower a concession. If a TDR is determined not to have occurred, the Company evaluates the modification
in accordance with ASC Topic 470-50-40, which requires modification to debt instruments to be evaluated to assess whether debt modification
or debt extinguishment accounting is applicable. This evaluation includes analyzing whether there are significant and consequential changes
to the economic substance of the note. If the change is deemed insignificant then the change is considered a debt modification, whereas
if the change is substantial the change is reflected as a debt extinguishment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;If debt
extinguishment guidance applies, the previous debt principal amount is removed, the previously capitalized debt issuance costs are expensed,
the value of instruments exchanged are recorded, including cash, new debt, warrants and common stock, and a gain or loss on extinguishment
of debt is recorded. If debt modification guidance applies, no gain or loss is recorded and the effective interest rate of the debt is
updated based on the carrying value of the debt and the revised future cash flows. Any previously capitalized debt issuance costs in a
debt modification are amortized as interest expense over the term of the new debt instrument.&lt;/span&gt;&lt;/p&gt;</avco:DebtModificationsAndExtinguishmentsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c18" id="ixv-59724">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
is governed by the income tax laws of China and the United States. The Company accounts for income taxes using the asset/liability method
prescribed by ASC 740, &#x201c;Income Taxes.&#x201d; Under this method, deferred tax assets and liabilities are determined based on the
difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the
period in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if, based
on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized.
The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
follows the accounting guidance for uncertainty in income taxes using the provisions of ASC 740 &#x201c;Income Taxes&#x201d;. Using that
guidance, the benefit for tax positions taken can only be recognized in the financial statements when it is more likely than not the position
will be sustained upon examination by the tax authorities. As of December 31, 2024 and 2023, the Company had no significant uncertain
tax positions which would require either recognition of a liability or disclosure in the financial statements. For United States entities,
tax year that remains subject to examination is the years ended December 31, 2024, 2023, 2022 and 2021. For China entities, income tax
returns for the tax years ended December 31, 2020 through December 31, 2024 remain open for statutory examination by PRC tax authorities.
The Company recognizes interest and penalties related to significant uncertain income tax positions in income tax expense. However, no
such interest and penalties were recorded as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c18" id="ixv-59736">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Foreign Currency Translation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The reporting
currency of the Company is the U.S. dollar. The functional currency of the parent company, AHS, Avalon RT 9, Avalon Lab, and Q&amp;amp;A Distribution
is the U.S. dollar and the functional currency of Avalon Shanghai is the Chinese Renminbi (&#x201c;RMB&#x201d;). For Avalon Shanghai whose
functional currency is the RMB, result of operations and cash flows are translated at average exchange rates during the period, assets
and liabilities are translated at the unified exchange rate at the end of the period, and equity is translated at historical exchange
rates. As a result, amounts relating to assets and liabilities reported on the statements of cash flows may not necessarily agree with
the changes in the corresponding balances on the balance sheets. Translation adjustments resulting from the process of translating the
local currency financial statements into U.S. dollars are included in determining comprehensive income/loss. Transactions denominated
in foreign currencies are translated into the functional currency at the exchange rates prevailing on the transaction dates. Assets and
liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the balance
sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency
other than the functional currency are included in the results of operations as incurred. All of the Company&#x2019;s revenue transactions
are transacted in the functional currency of the operating subsidiaries. The Company does not enter into any material transaction in foreign
currencies. Transaction gains or losses have not had, and are not expected to have, a material effect on the results of operations of
the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Asset and
liability accounts at December 31, 2024 and 2023 were translated at 7.2980 RMB and 7.0786 RMB to $1.00, respectively, which were the exchange
rates on the balance sheet dates. Equity accounts were stated at their historical rates. The average translation rates applied to the
statements of operations for the years ended December 31, 2024 and 2023 were 7.1889 RMB and 7.0752 RMB to $1.00, respectively. Cash flows
from the Company&#x2019;s operations are calculated based upon the local currencies using the average translation rate.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c137"
      decimals="4"
      id="ixv-89182"
      unitRef="pure">7.298</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c138"
      decimals="4"
      id="ixv-89183"
      unitRef="pure">7.0786</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c139"
      decimals="2"
      id="ixv-89184"
      unitRef="pure">1</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c140"
      decimals="4"
      id="ixv-89185"
      unitRef="pure">7.1889</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c141"
      decimals="4"
      id="ixv-89186"
      unitRef="pure">7.0752</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="c142"
      decimals="2"
      id="ixv-89187"
      unitRef="pure">1</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c18" id="ixv-59781">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Comprehensive Loss&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Comprehensive loss is comprised of net loss and
all changes to the statements of equity, except those due to investments by stockholders, changes in paid-in capital and distributions
to stockholders. For the Company, comprehensive loss for the years ended December 31, 2024 and 2023 consisted of net loss and unrealized
loss from foreign currency translation adjustment.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c18" id="ixv-59789">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;Commitments
and Contingencies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In the normal
course of business, the Company is subject to contingencies, such as legal proceedings and claims arising out of its business, that cover
a wide range of matters. Liabilities for such contingencies are recorded when it is probable that a liability has been incurred and the
amount of the assessment can be reasonably estimated.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c18" id="ixv-59799">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Per Share Data&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ASC Topic 260 &#x201c;Earnings per Share,&#x201d;
requires presentation of both basic and diluted earnings per share (&#x201c;EPS&#x201d;) with a reconciliation of the numerator and denominator
of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic net loss per share is computed by dividing
net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents
and potentially dilutive securities outstanding during each period. For the years ended December 31, 2024 and 2023, potentially dilutive
common shares consist of the common shares issuable upon the conversion of convertible preferred stock and convertible notes (using the
if-converted method) and exercise of common stock options and warrants (using the treasury stock method). Common stock equivalents are
not included in the calculation of diluted net loss per share if their effect would be anti-dilutive. In a period in which the Company
has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares outstanding as they would have
had an anti-dilutive impact.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The calculation of basic and diluted net loss
per common share attributable to the Company common shareholders includes 150,000 of the pre-funded warrants that remain outstanding as
of December 31, 2024.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the securities
that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Years Ended&lt;br/&gt;
 December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;52,479&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;56,880&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;182,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43,035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Series A convertible preferred stock &lt;sup&gt;(*)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Series B convertible preferred stock &lt;sup&gt;(**)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194,004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194,004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Series C convertible preferred stock &lt;sup&gt;(***)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,452,282&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-330"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Convertible notes &lt;sup&gt;(****)&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;227,269&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;60,740&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Potentially dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,169,030&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;414,659&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Assumed the Series A convertible preferred stock was converted
into shares of common stock of the Company at a conversion price of $150.00 per share&lt;span style="background-color: white"&gt;.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="background-color: white"&gt;(**)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="background-color: white"&gt;Assumed the Series
B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="background-color: white"&gt;(***)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="background-color: white"&gt;Assumed the Series
C convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $2.41 per share.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="background-color: white"&gt;(****)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="background-color: white"&gt;Assumed the convertible
notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the year ended December
31, 2024. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and
$22.50 per share for the year ended December 31, 2023.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c143"
      decimals="0"
      id="ixv-89188"
      unitRef="shares">150000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c18" id="ixv-59812">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the securities
that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Years Ended&lt;br/&gt;
 December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Options to purchase common stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;52,479&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;56,880&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Warrants to purchase common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;182,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43,035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Series A convertible preferred stock &lt;sup&gt;(*)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Series B convertible preferred stock &lt;sup&gt;(**)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194,004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194,004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Series C convertible preferred stock &lt;sup&gt;(***)&lt;/sup&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,452,282&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-330"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Convertible notes &lt;sup&gt;(****)&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;227,269&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;60,740&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Potentially dilutive securities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,169,030&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;414,659&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Assumed the Series A convertible preferred stock was converted
into shares of common stock of the Company at a conversion price of $150.00 per share&lt;span style="background-color: white"&gt;.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="background-color: white"&gt;(**)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="background-color: white"&gt;Assumed the Series
B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="background-color: white"&gt;(***)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="background-color: white"&gt;Assumed the Series
C convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $2.41 per share.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="background-color: white"&gt;(****)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="background-color: white"&gt;Assumed the convertible
notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the year ended December
31, 2024. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and
$22.50 per share for the year ended December 31, 2023.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c153"
      decimals="INF"
      id="ixv-89189"
      unitRef="shares">52479</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c154"
      decimals="INF"
      id="ixv-89190"
      unitRef="shares">56880</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c155"
      decimals="INF"
      id="ixv-89191"
      unitRef="shares">182996</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c156"
      decimals="INF"
      id="ixv-89192"
      unitRef="shares">43035</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c157"
      decimals="INF"
      id="ix_1_fact"
      unitRef="shares">60000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c158"
      decimals="INF"
      id="ix_2_fact"
      unitRef="shares">60000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c159"
      decimals="INF"
      id="ix_3_fact"
      unitRef="shares">194004</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c160"
      decimals="INF"
      id="ix_4_fact"
      unitRef="shares">194004</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c161"
      decimals="INF"
      id="ix_5_fact"
      unitRef="shares">1452282</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c163"
      decimals="INF"
      id="ix_6_fact"
      unitRef="shares">227269</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c164"
      decimals="INF"
      id="ix_7_fact"
      unitRef="shares">60740</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c18"
      decimals="INF"
      id="ixv-89200"
      unitRef="shares">2169030</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c19"
      decimals="INF"
      id="ixv-89201"
      unitRef="shares">414659</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c144"
      decimals="2"
      id="ixv-89202"
      unitRef="usdPershares">150</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c7"
      decimals="2"
      id="ixv-89203"
      unitRef="usdPershares">56.7</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c9"
      decimals="2"
      id="ixv-89204"
      unitRef="usdPershares">2.41</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="c18"
      decimals="2"
      id="ixv-89205"
      unitRef="usdPershares">11.25</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="c36"
      decimals="2"
      id="ixv-89206"
      unitRef="usdPershares">67.5</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="c19"
      decimals="2"
      id="ixv-89207"
      unitRef="usdPershares">22.5</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <avco:NoncontrollingInterestPolicyTextBlock contextRef="c18" id="ixv-59974">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Noncontrolling Interest&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2024, Dr. Yu Zhou, former director
and former Co-Chief Executive Officer of Genexosome, who owns 40% of the equity interests of Genexosome, which is not under the Company&#x2019;s
control. Since the fourth quarter of 2019, the non-controlling interest has remained inactive.&lt;/p&gt;</avco:NoncontrollingInterestPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c145"
      decimals="2"
      id="ixv-89208"
      unitRef="pure">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c18" id="ixv-59982">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Reclassification&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Certain prior period
amounts have been reclassified to conform to the current period presentation. These reclassifications have no effect on the previously
reported financial position, results of operations and cash flows.&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c18" id="ixv-59991">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Segment Reporting&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The segment
reporting structure uses the Company&#x2019;s management reporting structure as its foundation to reflect how the Company manages the businesses
internally and is mainly organized by services. The Company is organized into two services-oriented strategic business units: real property
rental services and laboratory testing services - which are led by our strategic business unit managers. Operating segments are
defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating
decision maker (&#x201c;CODM&#x201d;) in deciding how to make operating decisions, allocate resources and assess performance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 9, 2023, the Company purchased 40%
of Lab Services MSO. Commencing from the purchase date, February 9, 2023, the Company is active in the management of Lab Services MSO.
During the years ended December 31, 2024 and 2023, the Company operated in two reportable business segments: (1) the real property operating
segment, and (2) laboratory testing services segment (which commenced with the purchase date, February 9, 2023) since Lab Services MSO&#x2019;s
operating results are regularly reviewed by the Company&#x2019;s chief operating decision maker to determine the resources to be allocated
to the segment and assess its performance. The Company regularly reviews the operating results and performance of Lab Services MSO, for
which the Company accounts for under the equity method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s President and Chief Executive
Officer is its CODM. The Company reports operational data to its CODM at the segment level, which he uses to evaluate performance and
allocate resources based on real property operating income and loss from equity method investment - Lab Services MSO.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c146"
      decimals="2"
      id="ixv-89209"
      unitRef="pure">0.40</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:FiscalPeriod contextRef="c18" id="ixv-60006">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;Fiscal Year End&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
Company has adopted a fiscal year end of December 31st.&lt;/span&gt;&lt;/p&gt;</us-gaap:FiscalPeriod>
    <avco:ReverseStockSplitPolicyTextBlock contextRef="c18" id="ixv-60015">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Reverse Stock Split&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
effectuated a 1-for-15 reverse stock split of its outstanding shares of common stock on October 28, 2024. The reverse split did not change
the par value of common stock. All references in these consolidated financial statements to shares, share prices, exercise prices, and
other per share information in all periods have been adjusted, on a retroactive basis, to reflect the reverse stock split.&lt;/span&gt;&lt;/p&gt;</avco:ReverseStockSplitPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c18" id="ixv-89210">1-for-15</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c18" id="ixv-60023">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Recent Accounting
Standards&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In August
2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic
470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40), to simplify accounting for certain
financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion
features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts
in an entity&#x2019;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments
that are indexed to and settled in an entity&#x2019;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including
the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after
December 15, 2022, including interim periods within those fiscal years, with early adoption permitted. The adoption of ASU 2020-06 did
not have a material effect on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In November
2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280). The amendments in this update improve reportable segment disclosure
requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 became effective for the Company&#x2019;s
annual period beginning on January 1, 2024 and interim periods beginning after January 1, 2025. The Company adopted this guidance in the
fourth quarter of 2024. Refer to Note 20 - Segment Information. The Company&#x2019;s results of operations, cash flows, and financial condition
were not impacted by the adoption of this ASU.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In December
2023, the FASB ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This guidance is intended to enhance the
transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income
tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign
jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to
apply the standard retrospectively. Early adoption is permitted. The adoption of ASU 2023-09 did not have a material effect on the Company&#x2019;s
consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Other accounting
standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material
impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated
to have an impact on or are unrelated to its consolidated financial condition, results of operations, cash flows or disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c18" id="ixv-60079">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;NOTE 4 -&#160;&lt;span style="text-decoration:underline"&gt;PREPAID EXPENSE
AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;At December 31, 2024 and 2023, prepaid expense
and other current assets consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, &lt;br/&gt;
2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, &lt;br/&gt;
2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid professional fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33,665&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid directors and officers&#x2019; liability insurance premium&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred offering costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-331"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;175,136&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred leasing costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,587&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,402&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Security deposit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,654&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-332"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Due from broker&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,885&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finished goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;92,230&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-333"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Recoverable VAT&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,218&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;72,353&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;55,797&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;299,360&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;367,994&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c18" id="ixv-60084">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;At December 31, 2024 and 2023, prepaid expense
and other current assets consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, &lt;br/&gt;
2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, &lt;br/&gt;
2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Prepaid professional fees&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33,665&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid directors and officers&#x2019; liability insurance premium&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,192&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred offering costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-331"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;175,136&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred leasing costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,587&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,402&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Security deposit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,654&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-332"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Due from broker&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,885&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finished goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;92,230&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-333"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Recoverable VAT&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,218&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;72,353&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;55,797&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;299,360&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;367,994&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <avco:PrepaidProfessionalFees contextRef="c1" decimals="0" id="ixv-89211" unitRef="usd">33665</avco:PrepaidProfessionalFees>
    <avco:PrepaidProfessionalFees contextRef="c2" decimals="0" id="ixv-89212" unitRef="usd">33062</avco:PrepaidProfessionalFees>
    <us-gaap:PrepaidReinsurancePremiums contextRef="c1" decimals="0" id="ixv-89213" unitRef="usd">9741</us-gaap:PrepaidReinsurancePremiums>
    <us-gaap:PrepaidReinsurancePremiums contextRef="c2" decimals="0" id="ixv-89214" unitRef="usd">27192</us-gaap:PrepaidReinsurancePremiums>
    <us-gaap:DeferredOfferingCosts contextRef="c2" decimals="0" id="ixv-89215" unitRef="usd">175136</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredCostsLeasingNet contextRef="c1" decimals="0" id="ixv-89216" unitRef="usd">31587</us-gaap:DeferredCostsLeasingNet>
    <us-gaap:DeferredCostsLeasingNet contextRef="c2" decimals="0" id="ixv-89217" unitRef="usd">33402</us-gaap:DeferredCostsLeasingNet>
    <us-gaap:SecurityDeposit contextRef="c1" decimals="0" id="ixv-89218" unitRef="usd">17654</us-gaap:SecurityDeposit>
    <us-gaap:DueFromCorrespondentBrokers contextRef="c1" decimals="0" id="ixv-89219" unitRef="usd">32885</us-gaap:DueFromCorrespondentBrokers>
    <us-gaap:DueFromCorrespondentBrokers contextRef="c2" decimals="0" id="ixv-89220" unitRef="usd">37187</us-gaap:DueFromCorrespondentBrokers>
    <us-gaap:InventoryFinishedGoods contextRef="c1" decimals="0" id="ixv-89221" unitRef="usd">92230</us-gaap:InventoryFinishedGoods>
    <us-gaap:ValueAddedTaxReceivable contextRef="c1" decimals="0" id="ixv-89222" unitRef="usd">9245</us-gaap:ValueAddedTaxReceivable>
    <us-gaap:ValueAddedTaxReceivable contextRef="c2" decimals="0" id="ixv-89223" unitRef="usd">6218</us-gaap:ValueAddedTaxReceivable>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c1" decimals="0" id="ixv-89224" unitRef="usd">72353</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c2" decimals="0" id="ixv-89225" unitRef="usd">55797</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c1" decimals="0" id="ixv-89226" unitRef="usd">299360</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" id="ixv-89227" unitRef="usd">367994</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c18" id="ixv-60204">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;NOTE 5 -&#160;&lt;span style="text-decoration:underline"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;At December 31, 2024
and 2023, property and equipment consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;5 Years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-334"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;100,548&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Office equipment and furniture&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;3 - 10 Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;54,499&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;54,797&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;155,345&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(41,587&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(117,262&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,912&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;38,083&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;For the years ended December
31, 2024 and 2023, depreciation expense of property and equipment amounted to $9,234 and $43,037, respectively, of which, $8,623 and $7,221
was included in real property operating expenses, $611 and $417 was included in other operating expenses, and $0 and $35,399 was included
in research and development expense, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c18" id="ixv-60209">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;At December 31, 2024
and 2023, property and equipment consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;5 Years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-334"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;100,548&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Office equipment and furniture&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;3 - 10 Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;54,499&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;54,797&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;155,345&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(41,587&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(117,262&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;12,912&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;38,083&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c165" id="ixv-89228">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c166" decimals="0" id="ixv-89229" unitRef="usd">100548</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c167" id="ixv-89230">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c168" id="ixv-89231">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c169" decimals="0" id="ixv-89232" unitRef="usd">54499</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c170" decimals="0" id="ixv-89233" unitRef="usd">54797</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c1" decimals="0" id="ixv-89234" unitRef="usd">54499</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="0" id="ixv-89235" unitRef="usd">155345</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c1" decimals="0" id="ixv-89236" unitRef="usd">41587</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="0" id="ixv-89237" unitRef="usd">117262</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="0" id="ixv-89238" unitRef="usd">12912</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" id="ixv-89239" unitRef="usd">38083</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation contextRef="c1" decimals="0" id="ixv-89240" unitRef="usd">9234</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation contextRef="c2" decimals="0" id="ixv-89241" unitRef="usd">43037</us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <us-gaap:CostsAndExpenses contextRef="c18" decimals="0" id="ixv-89242" unitRef="usd">8623</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c19" decimals="0" id="ixv-89243" unitRef="usd">7221</us-gaap:CostsAndExpenses>
    <avco:OtherOperatingExpense contextRef="c18" decimals="0" id="ixv-89244" unitRef="usd">611</avco:OtherOperatingExpense>
    <avco:OtherOperatingExpense contextRef="c19" decimals="0" id="ixv-89245" unitRef="usd">417</avco:OtherOperatingExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c18" decimals="0" id="ixv-89246" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c19" decimals="0" id="ixv-89247" unitRef="usd">35399</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock contextRef="c18" id="ixv-60308">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;NOTE
6 - &lt;span style="text-decoration:underline"&gt;EQUIPMENT HELD FOR SALE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company measures
long-lived assets to be disposed of by sale at the lower of carrying amount or fair value, less associated costs to sell these assets.
The assets held for sale is no longer subject to depreciation as they are not used in operations. As of December 31, 2024, the Company
committed to a plan to sell certain laboratory equipment that was used to research and development as equipment held for sale, which was
included in &#x201c;Other non-current assets&#x201d; on the accompanying consolidated balance sheets. The Company evaluated equipment for
impairment at December 31, 2024. The Company compared the estimated fair value of the equipment to its carrying value with impairment
indicators and recorded an impairment charge for the excess of carrying value over fair value. For the year ended December 31, 2024, the
Company incurred an impairment charge in operations of $111,033 on laboratory equipment. Although the Company is actively seeking and
negotiating with potential buyers, the Company can give no assurances that the sale process will be successful and, if it were successful,
there are no assurances as to the amount or timing of any potential proceeds.&lt;/p&gt;</us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock>
    <avco:ImpairmentOfLaboratoryEquipment contextRef="c18" decimals="0" id="ixv-89248" unitRef="usd">111033</avco:ImpairmentOfLaboratoryEquipment>
    <us-gaap:RealEstateDisclosureTextBlock contextRef="c18" id="ixv-60318">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;NOTE
7 - &lt;span style="text-decoration:underline"&gt;INVESTMENT IN REAL ESTATE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;At December 31, 2024
and 2023, investment in real estate consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 60%; text-align: left"&gt;Commercial real property building&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 15%; text-align: center"&gt;39 Years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,708,571&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,708,571&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Improvement&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;12 Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;529,372&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;529,372&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,237,943&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,237,943&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,215,222&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,046,539&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,022,721&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,191,404&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;For both the years ended
December 31, 2024 and 2023, depreciation expense of this commercial real property amounted to $168,683, which was included in real property
operating expenses.&lt;/p&gt;</us-gaap:RealEstateDisclosureTextBlock>
    <us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock contextRef="c18" id="ixv-60325">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;At December 31, 2024
and 2023, investment in real estate consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Useful Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 60%; text-align: left"&gt;Commercial real property building&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 15%; text-align: center"&gt;39 Years&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,708,571&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,708,571&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Improvement&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;12 Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;529,372&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;529,372&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,237,943&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,237,943&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,215,222&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,046,539&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,022,721&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,191,404&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c171" id="ixv-89249">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RealEstateInvestmentPropertyAtCost contextRef="c171" decimals="0" id="ixv-89250" unitRef="usd">7708571</us-gaap:RealEstateInvestmentPropertyAtCost>
    <us-gaap:RealEstateInvestmentPropertyAtCost contextRef="c172" decimals="0" id="ixv-89251" unitRef="usd">7708571</us-gaap:RealEstateInvestmentPropertyAtCost>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c173" id="ixv-89252">P12Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RealEstateInvestmentPropertyAtCost contextRef="c173" decimals="0" id="ixv-89253" unitRef="usd">529372</us-gaap:RealEstateInvestmentPropertyAtCost>
    <us-gaap:RealEstateInvestmentPropertyAtCost contextRef="c174" decimals="0" id="ixv-89254" unitRef="usd">529372</us-gaap:RealEstateInvestmentPropertyAtCost>
    <us-gaap:RealEstateInvestmentPropertyAtCost contextRef="c1" decimals="0" id="ixv-89255" unitRef="usd">8237943</us-gaap:RealEstateInvestmentPropertyAtCost>
    <us-gaap:RealEstateInvestmentPropertyAtCost contextRef="c2" decimals="0" id="ixv-89256" unitRef="usd">8237943</us-gaap:RealEstateInvestmentPropertyAtCost>
    <us-gaap:PropertyPlantAndEquipmentOwnedAccumulatedDepreciation contextRef="c1" decimals="0" id="ixv-89257" unitRef="usd">1215222</us-gaap:PropertyPlantAndEquipmentOwnedAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentOwnedAccumulatedDepreciation contextRef="c2" decimals="0" id="ixv-89258" unitRef="usd">1046539</us-gaap:PropertyPlantAndEquipmentOwnedAccumulatedDepreciation>
    <us-gaap:RealEstateInvestmentPropertyNet contextRef="c1" decimals="0" id="ixv-89259" unitRef="usd">7022721</us-gaap:RealEstateInvestmentPropertyNet>
    <us-gaap:RealEstateInvestmentPropertyNet contextRef="c2" decimals="0" id="ixv-89260" unitRef="usd">7191404</us-gaap:RealEstateInvestmentPropertyNet>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c18" decimals="0" id="ixv-89261" unitRef="usd">168683</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c19" decimals="0" id="ixv-89262" unitRef="usd">168683</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="c18" id="ixv-60406">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 8 -&#160;&lt;span style="text-decoration:underline"&gt;EQUITY
METHOD INVESTMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Investment in&#160;Epicon
Biotech Co., Ltd.&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;As of December 31, 2023,
the equity method investment in Epicon Biotech Co., Ltd. (&#x201c;Epicon&#x201d;) amounted to $0. The investment represents the Company&#x2019;s
subsidiary, Avalon Shanghai&#x2019;s interest in Epicon. Epicon was incorporated on August 14, 2018 in PRC. Avalon Shanghai and an unrelated
company, Jiangsu Unicorn Biological Technology Co., Ltd. (&#x201c;Unicorn&#x201d;), have an ownership interest in Epicon of 40% and 60%,
respectively. Epicon is focused on cell preparation, third party testing, biological sample repository for commercial and scientific research
purposes and clinical transformation of scientific achievements. The Company is not involved in the management of Epicon. Therefore, it
is a passive investment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In June 2023, the Company
assessed its equity method investment in Epicon for any impairment and concluded that there were indicators of impairment as of June 30,
2023. The impairment is due to the Company&#x2019;s conclusion that it will be unable to recover the carrying amount of the investment
due to the investee&#x2019;s series of operating losses and the inability of Avalon Shanghai&#x2019;s joint venture partner (Unicorn) to
obtain adequate funding to commence operations. The Company calculated that the estimated undiscounted cash flows were less than the carrying
amount related to the equity method investment. The Company has recognized an impairment loss of $454,679 related to the equity method
investment for the year ended December 31, 2023, which reduced the investment value to zero.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Under the equity method,
if there is a commitment for the Company to fund the losses of its equity method investees, the Company would continue to record its share
of losses resulting in a negative equity method investment, which would be presented as a liability on the consolidated balance sheets.
Commitments may be explicit and may include formal guarantees, legal obligations, or arrangements by contract. Implicit commitments may
arise from reputational expectations, intercompany relationships, statements by the Company of its intention to provide support, a history
of providing financial support or other facts and circumstances. When the Company has no commitment to fund the losses of its equity method
investees, the carrying value of its equity method investments will not be reduced below zero. The Company has no commitment to fund additional
losses of its equity method investments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Investment in Laboratory
Services MSO, LLC&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On February 9, 2023 (the
&#x201c;Closing Date&#x201d;), the Company entered into and closed an Amended and Restated Membership Interest Purchase Agreement (the &#x201c;Amended
MIPA&#x201d;), by and among Avalon Lab, SCBC Holdings LLC (the &#x201c;Seller&#x201d;), the Zoe Family Trust, Bryan Cox and Sarah Cox as
individuals (each an &#x201c;Owner&#x201d; and collectively, the &#x201c;Owners&#x201d;), and Lab Services MSO.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Pursuant to the terms
and conditions set forth in the Amended MIPA, Avalon Lab acquired from the Seller,&#160;40% of the issued and outstanding equity interests
of Lab Services MSO (the &#x201c;Purchased Interests&#x201d;). The consideration paid by Avalon Lab to Seller for the Purchased Interests
consisted of $20,666,667, which was comprised of (i) $9,000,000&#160;in cash, (ii) $11,000,000&#160;pursuant to the issuance of&#160;11,000&#160;shares
of the Company&#x2019;s Series B Convertible Preferred Stock (the &#x201c;Series B Preferred Stock&#x201d;), stated value $1,000&#160;(the
&#x201c;Series B Stated Value&#x201d;), which approximated the fair value, and (iii) a $666,667&#160;cash payment on February 9, 2024. The
Series B Preferred Stock is convertible into shares of the Company&#x2019;s common stock at a conversion price per share equal to $56.70,
which approximated the market price at the date of closing, or an aggregate of&#160;194,004&#160;shares of the Company&#x2019;s common
stock, which are subject to a lock-up period and restrictions on sale.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Lab Services MSO, through
its subsidiaries, is engaged in providing laboratory testing services. Avalon Lab and an unrelated company, have an ownership interest
in Lab Services MSO of&#160;40% and&#160;60%, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In accordance with ASC
810, the Company determined that Lab Services MSO does not qualify as a variable interest entity, nor does it have a controlling financial
interest over the legal entity. However, the Company determined that it does have significant influence as a result of its board representation.
Therefore, the Company treats the equity investment in the consolidated financial statements under the equity method. Under the equity
method, the investment is initially recorded at cost, adjusted for any excess of the Company&#x2019;s share of the purchased-date fair
values of the investee&#x2019;s identifiable net assets over the cost of the investment (if any). At February 9, 2023 (date of investment),
the excess of the Company&#x2019;s share of the fair values of the investee&#x2019;s identifiable net assets over the cost of the investment
was approximately $19,460,000&#160;which was attributable to intangible assets and goodwill. Thereafter, the investment is adjusted for
the post purchase change in the Company&#x2019;s share of the investee&#x2019;s net assets and any impairment loss relating to the investment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Intangible assets consist
of the valuation of identifiable intangible assets acquired, representing trade names and customers relationships, which are being amortized
on a straight-line method over the estimated useful life of&#160;15&#160;years. The straight-line method of amortization represents the
Company&#x2019;s best estimate of the distribution of the economic value of the identifiable intangible assets. For the year ended December
31, 2024 and for the period from February 9, 2023 (date of investment) through December 31, 2023, amortization expense of these intangible
assets amounted to $666,932&#160;and $611,356, respectively, which was included in loss from equity method investment - Lab Services
MSO in the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Goodwill represents the
excess of the purchase price paid over the fair value of net assets acquired in the business acquisition of Lab Services MSO incurred
on February 9, 2023. Goodwill is not amortized but is tested for impairment at least once annually, or more frequently if events or changes
in circumstances indicate that the asset might be impaired.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In September 2024 and
December 2023, the Company assessed its equity method investment in Laboratory Services MSO, LLC for any impairment and concluded that
there were indicators of impairment as of September 30, 2024 and December 31, 2023, respectively. The Company calculated that the estimated
undiscounted cash flows of goodwill were less than the carrying amount of goodwill related to the equity method investment. The Company
has recognized impairment loss of $259,579 and $9,196,682&#160;related to the equity method investment for the year ended December 31,
2024 and for the period from February 9, 2023 (date of investment) through December 31, 2023, respectively, which was included in loss
from equity method investment - Lab Services MSO in the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;For the year ended December
31, 2024 and for the period from February 9, 2023 (date of investment) through December 31, 2023, the Company&#x2019;s share of Lab Services
MSO&#x2019;s net income was $79,923&#160;and $1,236,391, respectively, which was included in loss from equity method investment -
Lab Services MSO in the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company classifies
distributions received from its investment on Lab Services MSO using the cumulative earnings approach. Distributions received are considered
returns on the investment and classified as cash inflows from operating activities. For the year ended December 31, 2024 and for the
period from February 9, 2023 (date of investment) through December 31, 2023, distribution of earnings from the Company&#x2019;s investment
on Lab Services MSO amounted to $611,888 and $0, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In the years ended December
31, 2024 and 2023, activity recorded for the Company&#x2019;s equity method investment in Lab Services MSO is summarized in the following
table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Equity investment carrying amount at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-335"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Payment for equity method investment:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;The Company&#x2019;s interest in the fair value of Lab Services MSO&#x2019;s net assets at February 9, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,206,406&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;The Company&#x2019;s interest in the net excess of Lab Services MSO&#x2019;s fair value over net assets which was attributable to identifiable intangible assets at February 9, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,004,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;The Company&#x2019;s interest in the net excess of Lab Services MSO&#x2019;s fair value over net assets which was attributable to goodwill at February 9, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,456,261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Total payment for equity method investment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,666,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Lab Services MSO&#x2019;s net income attributable to the Company&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,236,391&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Intangible assets amortization amount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(611,356&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Impairment of goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,196,682&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Equity investment carrying amount at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,095,020&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Lab Services MSO&#x2019;s net income attributable to the Company&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Intangible assets amortization amount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(666,932&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Distribution of earnings from equity investment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(611,888&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Impairment of goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(259,579&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Equity investment carrying amount at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,636,544&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2024, the Company&#x2019;s carrying
value of the identified intangible assets and goodwill which are included in the equity investment carrying amount was $8,725,712&#160;and
$0, respectively. As of December 31, 2023, the Company&#x2019;s carrying value of the identified intangible assets and goodwill which are
included in the equity investment carrying amount was $9,392,644&#160;and $259,579, respectively.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The tables below present the summarized financial
information, as provided to the Company by the investee, for the unconsolidated company:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Current assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,917,880&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,930,254&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Noncurrent assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,509,185&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,228,044&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;611,391&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;828,713&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Noncurrent liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,346,725&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,104,183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,468,949&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,225,402&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the year Ended December 31, 2024&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the Period from&lt;br/&gt;
February 9,&lt;br/&gt;
 2023 (Date of Investment) through December 31, 2023&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,558,711&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12,699,683&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,534,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,744,277&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;(Loss) income from operation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(265,754&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,393,830&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;199,808&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,090,977&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During 2025, to preserve cash, the Company entered
into discussions with Lab Services MSO for the potential redemption of our investment and on February 26, 2025, the Company and Lab Services
MSO entered into a Redemption and Abandonment Agreement (the &#x201c;Redemption Agreement&#x201d;), whereby Lab Services MSO redeemed the
40% equity interest in Lab Services MSO held by the Company. See Note 22 - Subsequent Events - Redemption Agreement.&lt;/p&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestments contextRef="c175" decimals="0" id="ixv-89263" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c176"
      decimals="2"
      id="ixv-89264"
      unitRef="pure">0.40</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c177"
      decimals="2"
      id="ixv-89265"
      unitRef="pure">0.60</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:AssetImpairmentCharges contextRef="c178" decimals="0" id="ixv-89266" unitRef="usd">-454679</us-gaap:AssetImpairmentCharges>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c179"
      decimals="2"
      id="ixv-89267"
      unitRef="pure">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c18" decimals="0" id="ixv-89268" unitRef="usd">20666667</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:PreferredStockValue contextRef="c180" decimals="0" id="ixv-89269" unitRef="usd">9000000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c181" decimals="0" id="ixv-89270" unitRef="usd">11000000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c181"
      decimals="0"
      id="ixv-89271"
      unitRef="shares">11000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c182" decimals="0" id="ixv-89272" unitRef="usd">1000</us-gaap:PreferredStockValue>
    <avco:EquityMethodInvestmentPayableCurrent contextRef="c183" decimals="0" id="ixv-89273" unitRef="usd">666667</avco:EquityMethodInvestmentPayableCurrent>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c181"
      decimals="2"
      id="ixv-89274"
      unitRef="usdPershares">56.7</us-gaap:PreferredStockConvertibleConversionPrice>
    <avco:AggregateOfCommonStock
      contextRef="c181"
      decimals="0"
      id="ixv-89275"
      unitRef="shares">194004</avco:AggregateOfCommonStock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c184"
      decimals="2"
      id="ixv-89276"
      unitRef="pure">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c185"
      decimals="2"
      id="ixv-89277"
      unitRef="pure">0.60</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentOwnedAtCost contextRef="c146" decimals="0" id="ixv-89278" unitRef="usd">19460000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c1" id="ixv-89279">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c18" decimals="0" id="ixv-89280" unitRef="usd">666932</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c186" decimals="0" id="ixv-89281" unitRef="usd">611356</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:GoodwillImpairmentLoss contextRef="c18" decimals="0" id="ixv-89282" unitRef="usd">259579</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c186" decimals="0" id="ixv-89283" unitRef="usd">9196682</us-gaap:GoodwillImpairmentLoss>
    <avco:LabServicesMSOsNetIncomeAttributableToTheCompany contextRef="c187" decimals="0" id="ixv-89284" unitRef="usd">79923</avco:LabServicesMSOsNetIncomeAttributableToTheCompany>
    <avco:LabServicesMSOsNetIncomeAttributableToTheCompany contextRef="c188" decimals="0" id="ixv-89285" unitRef="usd">1236391</avco:LabServicesMSOsNetIncomeAttributableToTheCompany>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions contextRef="c189" decimals="0" id="ixv-89286" unitRef="usd">611888</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions contextRef="c190" decimals="0" id="ixv-89287" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentsTextBlock contextRef="c18" id="ixv-60507">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In the years ended December
31, 2024 and 2023, activity recorded for the Company&#x2019;s equity method investment in Lab Services MSO is summarized in the following
table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Equity investment carrying amount at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-335"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Payment for equity method investment:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;The Company&#x2019;s interest in the fair value of Lab Services MSO&#x2019;s net assets at February 9, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,206,406&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;The Company&#x2019;s interest in the net excess of Lab Services MSO&#x2019;s fair value over net assets which was attributable to identifiable intangible assets at February 9, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,004,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;The Company&#x2019;s interest in the net excess of Lab Services MSO&#x2019;s fair value over net assets which was attributable to goodwill at February 9, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,456,261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Total payment for equity method investment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,666,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Lab Services MSO&#x2019;s net income attributable to the Company&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,236,391&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Intangible assets amortization amount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(611,356&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Impairment of goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,196,682&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Equity investment carrying amount at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,095,020&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Lab Services MSO&#x2019;s net income attributable to the Company&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Intangible assets amortization amount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(666,932&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Distribution of earnings from equity investment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(611,888&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Impairment of goodwill&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(259,579&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Equity investment carrying amount at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,636,544&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets contextRef="c192" decimals="0" id="ixv-89288" unitRef="usd">1206406</us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets>
    <avco:EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets contextRef="c193" decimals="0" id="ixv-89289" unitRef="usd">10004000</avco:EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets>
    <avco:EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets contextRef="c193" decimals="0" id="ixv-89290" unitRef="usd">9456261</avco:EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c193" decimals="0" id="ixv-89291" unitRef="usd">20666667</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <avco:LabServicesMSOsNetIncomeAttributableToTheCompany contextRef="c193" decimals="0" id="ixv-89292" unitRef="usd">1236391</avco:LabServicesMSOsNetIncomeAttributableToTheCompany>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c193" decimals="0" id="ixv-89293" unitRef="usd">611356</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:GoodwillImpairmentLoss contextRef="c193" decimals="0" id="ixv-89294" unitRef="usd">9196682</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:EquityMethodInvestments contextRef="c192" decimals="0" id="ixv-89295" unitRef="usd">12095020</us-gaap:EquityMethodInvestments>
    <avco:LabServicesMSOsNetIncomeAttributableToTheCompany contextRef="c194" decimals="0" id="ixv-89296" unitRef="usd">79923</avco:LabServicesMSOsNetIncomeAttributableToTheCompany>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c194" decimals="0" id="ixv-89297" unitRef="usd">666932</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions contextRef="c194" decimals="0" id="ixv-89298" unitRef="usd">611888</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:GoodwillImpairmentLoss contextRef="c194" decimals="0" id="ixv-89299" unitRef="usd">259579</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:EquityMethodInvestments contextRef="c195" decimals="0" id="ixv-89300" unitRef="usd">10636544</us-gaap:EquityMethodInvestments>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c1" decimals="0" id="ixv-89301" unitRef="usd">8725712</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:GoodwillFairValueDisclosure contextRef="c1" decimals="0" id="ixv-89302" unitRef="usd">0</us-gaap:GoodwillFairValueDisclosure>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c2" decimals="0" id="ixv-89303" unitRef="usd">9392644</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:GoodwillFairValueDisclosure contextRef="c2" decimals="0" id="ixv-89304" unitRef="usd">259579</us-gaap:GoodwillFairValueDisclosure>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="c18" id="ixv-60605">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The tables below present the summarized financial
information, as provided to the Company by the investee, for the unconsolidated company:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Current assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,917,880&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,930,254&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Noncurrent assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,509,185&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,228,044&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;611,391&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;828,713&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Noncurrent liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,346,725&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,104,183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,468,949&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,225,402&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:AssetsCurrent contextRef="c196" decimals="0" id="ixv-89305" unitRef="usd">2917880</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c197" decimals="0" id="ixv-89306" unitRef="usd">4930254</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent contextRef="c196" decimals="0" id="ixv-89307" unitRef="usd">4509185</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c197" decimals="0" id="ixv-89308" unitRef="usd">5228044</us-gaap:AssetsNoncurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c196" decimals="0" id="ixv-89309" unitRef="usd">611391</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c197" decimals="0" id="ixv-89310" unitRef="usd">828713</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c196" decimals="0" id="ixv-89311" unitRef="usd">4346725</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c197" decimals="0" id="ixv-89312" unitRef="usd">4104183</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:StockholdersEquity contextRef="c196" decimals="0" id="ixv-89313" unitRef="usd">-2468949</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c197" decimals="0" id="ixv-89314" unitRef="usd">-5225402</us-gaap:StockholdersEquity>
    <srt:ScheduleOfCondensedIncomeStatementTableTextBlock contextRef="c18" id="ixv-60670">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the year Ended December 31, 2024&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the Period from&lt;br/&gt;
February 9,&lt;br/&gt;
 2023 (Date of Investment) through December 31, 2023&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,558,711&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12,699,683&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,534,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,744,277&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;(Loss) income from operation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(265,754&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,393,830&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net loss income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;199,808&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,090,977&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedIncomeStatementTableTextBlock>
    <us-gaap:Revenues contextRef="c198" decimals="0" id="ixv-89315" unitRef="usd">13558711</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c199" decimals="0" id="ixv-89316" unitRef="usd">12699683</us-gaap:Revenues>
    <us-gaap:GrossProfit contextRef="c198" decimals="0" id="ixv-89317" unitRef="usd">3534503</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c199" decimals="0" id="ixv-89318" unitRef="usd">4744277</us-gaap:GrossProfit>
    <us-gaap:OperatingIncomeLoss contextRef="c198" decimals="0" id="ixv-89319" unitRef="usd">-265754</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c199" decimals="0" id="ixv-89320" unitRef="usd">2393830</us-gaap:OperatingIncomeLoss>
    <us-gaap:ProfitLoss contextRef="c198" decimals="0" id="ixv-89321" unitRef="usd">199808</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c199" decimals="0" id="ixv-89322" unitRef="usd">3090977</us-gaap:ProfitLoss>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c18" id="ixv-60747">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 9 -&#160;&lt;span style="text-decoration:underline"&gt;ACCRUED LIABILITIES
AND OTHER PAYABLES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;At December 31, 2024
and 2023, accrued liabilities and other payables consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, &lt;br/&gt;
2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued tenants&#x2019; improvement reimbursement&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;43,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;43,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tenants&#x2019; security deposit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81,233&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81,233&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued business expense reimbursement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,781&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,061&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued utilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,075&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,166&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred rental income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,346&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued real property cleaning service fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,570&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55,027&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Taxes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;177,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,794&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,258&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,135&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;434,117&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;272,915&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c18" id="ixv-60753">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;At December 31, 2024
and 2023, accrued liabilities and other payables consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, &lt;br/&gt;
2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued tenants&#x2019; improvement reimbursement&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;43,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;43,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tenants&#x2019; security deposit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81,233&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81,233&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued business expense reimbursement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,781&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,061&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued utilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,075&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,166&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred rental income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,346&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued real property cleaning service fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,570&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55,027&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Taxes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;177,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,794&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;23,258&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,135&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;434,117&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;272,915&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <avco:AccruedTenantsImprovementReimbursement contextRef="c1" decimals="0" id="ixv-89323" unitRef="usd">43500</avco:AccruedTenantsImprovementReimbursement>
    <avco:AccruedTenantsImprovementReimbursement contextRef="c2" decimals="0" id="ixv-89324" unitRef="usd">43500</avco:AccruedTenantsImprovementReimbursement>
    <us-gaap:Deposits contextRef="c1" decimals="0" id="ixv-89325" unitRef="usd">81233</us-gaap:Deposits>
    <us-gaap:Deposits contextRef="c2" decimals="0" id="ixv-89326" unitRef="usd">81233</us-gaap:Deposits>
    <avco:AccruedBusinessExpenseReimbursement contextRef="c1" decimals="0" id="ixv-89327" unitRef="usd">34781</avco:AccruedBusinessExpenseReimbursement>
    <avco:AccruedBusinessExpenseReimbursement contextRef="c2" decimals="0" id="ixv-89328" unitRef="usd">25061</avco:AccruedBusinessExpenseReimbursement>
    <us-gaap:AccruedUtilitiesCurrent contextRef="c1" decimals="0" id="ixv-89329" unitRef="usd">26075</us-gaap:AccruedUtilitiesCurrent>
    <us-gaap:AccruedUtilitiesCurrent contextRef="c2" decimals="0" id="ixv-89330" unitRef="usd">15166</us-gaap:AccruedUtilitiesCurrent>
    <us-gaap:DeferredIncome contextRef="c1" decimals="0" id="ixv-89331" unitRef="usd">38346</us-gaap:DeferredIncome>
    <us-gaap:DeferredIncome contextRef="c2" decimals="0" id="ixv-89332" unitRef="usd">11429</us-gaap:DeferredIncome>
    <avco:AccruedRealPropertyCleaningServiceFee contextRef="c1" decimals="0" id="ixv-89333" unitRef="usd">9200</avco:AccruedRealPropertyCleaningServiceFee>
    <avco:AccruedRealPropertyCleaningServiceFee contextRef="c2" decimals="0" id="ixv-89334" unitRef="usd">7570</avco:AccruedRealPropertyCleaningServiceFee>
    <us-gaap:InterestPayableCurrent contextRef="c2" decimals="0" id="ixv-89335" unitRef="usd">55027</us-gaap:InterestPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c1" decimals="0" id="ixv-89336" unitRef="usd">177724</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c2" decimals="0" id="ixv-89337" unitRef="usd">11794</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c1" decimals="0" id="ixv-89338" unitRef="usd">23258</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c2" decimals="0" id="ixv-89339" unitRef="usd">22135</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c1" decimals="0" id="ixv-89340" unitRef="usd">434117</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c2" decimals="0" id="ixv-89341" unitRef="usd">272915</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:LongTermDebtTextBlock contextRef="c18" id="ixv-60871">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;NOTE 10 - &lt;span style="text-decoration:underline"&gt;CONVERTIBLE NOTE PAYABLE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;May 2023 Convertible
Note&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On May 23, 2023, the
Company entered into securities purchase agreements with Mast Hill Fund, L.P. (&#x201c;Mast Hill&#x201d;) for the issuance of&#160;13.0%
senior secured promissory notes in the aggregate principal amount of $1,500,000&#160;(collectively, the &#x201c;May 2023 Convertible Note&#x201d;)
convertible into shares of the Company&#x2019;s common stock, as well as the issuance of&#160;5,000&#160;shares of common stock as a commitment
fee and warrants for the purchase of&#160;15,366&#160;shares of common stock of the Company. The Company and its subsidiaries also entered
into a security agreement, creating a security interest in certain property of the Company and its subsidiaries to secure the prompt payment,
performance and discharge in full of all of the Company&#x2019;s obligations under the May 2023 Convertible Note. Principal amount and
interest under the May 2023 Convertible Note were convertible into shares of common stock of the Company at a conversion price of $67.50&#160;per
share unless the Company failed to make an amortization payment when due, in which case the conversion price would be the lower of $67.50&#160;or
the trading price of the shares, subject to a floor of $22.50.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Mast Hill acquired the
May 2023 Convertible Note with principal amount of $1,500,000&#160;and paid the purchase price of $1,425,000&#160;after an original issue
discount of $75,000. On May 23, 2023, the Company issued (i) a warrant to purchase&#160;8,333&#160;shares of common stock with an exercise
price of $67.50&#160;exercisable until the five-year anniversary of May 23, 2023 (&#x201c;First Warrant&#x201d;), (ii) a warrant to purchase&#160;7,033&#160;shares
of common stock with an exercise price of $48.00&#160;exercisable until the five-year anniversary of May 23, 2023 (&#x201c;Second Warrant&#x201d;).The
Second Warrant was never fair valued and was cancelled and extinguished against payment of the May 2023 Convertible Note, and (iii)&#160;5,000&#160;shares
of common stock as a commitment fee for the purchase of the May 2023 Convertible Note, which were earned in full as of May 23, 2023. On
May 23, 2023, the Company delivered such duly executed May 2023 Convertible Note, warrants and common stock to Mast Hill against delivery
of such purchase price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company was obligated
to make amortization payments in cash to Mast Hill toward the repayment of the May 2023 Convertible Note, as described in the May 2023
Convertible Note. As of December 31, 2024, the May 2023 Convertible Note was repaid in full.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In connection with the
issuance of the May 2023 Convertible Note, the Company incurred debt issuance costs of $175,162&#160;(including the issuance of&#160;667&#160;warrants
as a finder&#x2019;s fee) which was capitalized and was amortized into interest expense over the term of the May 2023 Convertible Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Based upon the Company&#x2019;s
analysis of the criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a
finder&#x2019;s fee met the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances.
Accordingly, the fair value of the&#160;9,000&#160;warrants with an exercise price of $67.50&#160;exercisable until the five-year anniversary
of May 23, 2023 was classified as derivative liability on May 23, 2023. The fair values of the&#160;9,000&#160;warrants with an exercise
price of $67.50&#160;exercisable until the five-year anniversary of May 23, 2023 issued on May 23, 2023 were computed using the Black-Scholes
option-pricing model with the following assumptions: stock price of $29.40, volatility of&#160;88.80%, risk-free rate of&#160;3.76%, annual
dividend yield of&#160;0% and expected life of&#160;5&#160;years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 470-20-25-2, proceeds from
the sale of a debt instrument with stock purchase warrants are allocated to the two elements based on the&#160;relative fair values&#160;of
the debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds allocated to
the warrants are accounted for as derivative liability. The remainder of the proceeds are allocated to the debt instrument portion of
the transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company recorded
a total debt discount of $349,654&#160;related to the original issue discount, common shares issued and warrants issued to Mast Hill,
which was amortized over the term of the May 2023 Convertible Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;July&#160;2023 Convertible
Note&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On July 6, 2023, the
Company entered into securities purchase agreements with FirstFire Global Opportunities Fund, LLC (&#x201c;FirstFire&#x201d;) for the issuance
of 13.0% senior secured promissory notes in the aggregate principal amount of $500,000 (collectively, the &#x201c;July 2023 Convertible
Note&#x201d;) convertible into shares of the Company&#x2019;s common stock, as well as the issuance of 1,667 shares of common stock as a
commitment fee and warrants for the purchase of 5,122 shares of common stock of the Company. The Company and its subsidiaries also entered
into a security agreement, creating a security interest in certain property of the Company and its subsidiaries to secure the prompt payment,
performance and discharge in full of all of the Company&#x2019;s obligations under the July 2023 Convertible Note. Principal amount and
interest under the July 2023 Convertible Note were convertible into shares of common stock of the Company at a conversion price of $67.50
per share unless the Company failed to make an amortization payment when due, in which case the conversion price would be the lower of
$67.50 or the trading price of the shares, subject to a floor of $22.50.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;FirstFire acquired the
July 2023 Convertible Note with principal amount of $500,000 and paid the purchase price of $475,000 after an original issue discount
of $25,000. On July 6, 2023, the Company issued (i) a warrant to purchase 2,778 shares of common stock with an exercise price of $67.50
exercisable until the five-year anniversary of July 6, 2023 (&#x201c;First Warrant&#x201d;), (ii) a warrant to purchase 2,344 shares of
common stock with an exercise price of $48.00 exercisable until the five-year anniversary of July 6, 2023 (&#x201c;Second Warrant&#x201d;).
The Second Warrant was never fair valued and was cancelled and extinguished against payment of the July 2023 Convertible Note, and (iii)
1,667 shares of common stock as a commitment fee for the purchase of the July 2023 Convertible Note, which were earned in full as of July
6, 2023. On July 6, 2023, the Company delivered such duly executed July 2023 Convertible Note, warrants and common stock to FirstFire
against delivery of such purchase price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company was obligated
to make amortization payments in cash to FirstFire toward the repayment of the July 2023 Convertible Note, as described in the July 2023
Convertible Note. As of December 31, 2024, the July 2023 Convertible Note was repaid in full.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In connection with the
issuance of the July 2023 Convertible Note, the Company incurred debt issuance costs of $74,204&#160;(including the issuance of&#160;222&#160;warrants
as a finder&#x2019;s fee), which was capitalized and was amortized into interest expense over the term of the July 2023 Convertible Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Based upon the Company&#x2019;s
analysis of the criteria contained in ASC 815, the Company determined that all the warrants issued to Firstfire and a third party as a
finder&#x2019;s fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances.
Accordingly, the fair value of the&#160;3,000&#160;warrants with an exercise price of $67.50&#160;exercisable until the five-year anniversary
of July 6, 2023 was classified as a derivative liability on July 6, 2023. The fair values of the&#160;3,000&#160;warrants with an exercise
price of $67.50&#160;exercisable until the five-year anniversary of July 6, 2023 issued on July 6, 2023 were computed using the Black-Scholes
option-pricing model with the following assumptions: stock price of $21.30, volatility of&#160;88.52%, risk-free rate of&#160;4.37%, annual
dividend yield of&#160;0% and expected life of&#160;5&#160;years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In accordance with
ASC 470-20-25-2, proceeds from the sale of a debt instrument with stock purchase warrants are allocated to the two elements based on
the relative fair values of the debt instrument without the warrants and of the warrants themselves at time of issuance. The portion
of the proceeds allocated to the warrants are accounted for as derivative liability. The remainder of the proceeds are allocated to the
debt instrument portion of the transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recorded a total debt discount of
$89,191&#160;related to the original issue discount, common shares issued and warrants issued to Firstfire, which was amortized over the
term of the July 2023 Convertible Note.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;October&#160;2023
Convertible Note&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On October 9, 2023, the
Company entered into securities purchase agreements with Mast Hill and FirstFire for the issuance of 13.0% senior secured promissory notes
in the aggregate principal amount of $700,000 (collectively, the &#x201c;October 2023 Convertible Note&#x201d;) convertible into shares
of the Company&#x2019;s common stock, as well as the issuance of 4,666 shares of common stock as a commitment fee and warrants for the
purchase of 12,834 shares of common stock of the Company. The Company and its subsidiaries also entered into that certain security agreements,
creating a security interest in certain property of the Company and its subsidiaries to secure the prompt payment, performance and discharge
in full of all of the Company&#x2019;s obligations under the October 2023 Convertible Note. Principal amount and interest under the October
2023 Convertible Note were convertible into shares of common stock of the Company at a conversion price of $22.50 per share unless the
Company failed to make an amortization payment when due, in which case the conversion price would be the lower of $22.50 or the market
price (as defined in the October 2023 Convertible Note) of the shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Mast Hill acquired the
October 2023 Convertible Note with principal amount of $350,000&#160;and paid the purchase price of $332,500&#160;after an original issue
discount of $17,500. On October 9, 2023, the Company issued (i) a warrant to purchase&#160;3,500&#160;shares of common stock with an exercise
price of $37.50&#160;exercisable until the five-year anniversary of October 9, 2023 (&#x201c;First Warrant&#x201d;), (ii) a warrant to purchase&#160;2,917&#160;shares
of common stock with an exercise price of $27.00&#160;exercisable until the five-year anniversary of October 9, 2023 (&#x201c;Second Warrant&#x201d;).
The Second Warrant was never fair valued and was cancelled and extinguished against payment of the October 2023 Convertible Note, and
(iii)&#160;2,333&#160;shares of common stock as a commitment fee for the purchase of the October 2023 Convertible Note, which were earned
in full as of October 9, 2023. On October 9, 2023, the Company delivered such duly executed October 2023 Convertible Note, warrants and
common stock to Mast Hill against delivery of such purchase price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company was obligated to make amortization
payments in cash to Mast Hill toward the repayment of the October 2023 Convertible Note, as described in the October 2023 Convertible
Note. As of December 31, 2024, the October 2023 Convertible Note was repaid in full.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;FirstFire&#160;acquired
the October 2023 Convertible Note with principal amount of $350,000&#160;and paid the purchase price of $332,500&#160;after an original
issue discount of $17,500. On October 9, 2023, the Company issued (i) a warrant to purchase&#160;3,500&#160;shares of common stock with
an exercise price of $37.50&#160;exercisable until the five-year anniversary of October 9, 2023 (&#x201c;First Warrant&#x201d;), (ii) a
warrant to purchase&#160;2,917&#160;shares of common stock with an exercise price of $27.00&#160;exercisable until the five-year anniversary
of October 9, 2023 (&#x201c;Second Warrant&#x201d;). The Second Warrant was never fair valued and was cancelled and extinguished against
payment of the October 2023 Convertible Note, and (iii)&#160;2,333&#160;shares of common stock as a commitment fee for the purchase of
the October 2023 Convertible Note, which were earned in full as of October 9, 2023. On October 9, 2023, the Company delivered such duly
executed October 2023 Convertible Note, warrants and common stock to FirstFire against delivery of such purchase price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company was obligated to make amortization
payments in cash to FirstFire toward the repayment of the October 2023 Convertible Note, as described in the October 2023 Convertible
Note. As of December 31, 2024, the October 2023 Convertible Note was repaid in full.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the issuance of the October
2023 Convertible Note, the Company incurred debt issuance costs of $95,349&#160;(including the issuance of&#160;560&#160;warrants as a
finder&#x2019;s fee), which was capitalized and was amortized into interest expense over the term of the October 2023 Convertible Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Based upon the Company&#x2019;s analysis of the
criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and Firstfire and a third party as a finder&#x2019;s
fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances. Accordingly,
the fair value of the&#160;7,560&#160;warrants with an exercise price of $37.50&#160;exercisable until the five-year anniversary of October
9, 2023 was classified as a derivative liability on October 9, 2023. The fair values of the&#160;7,560&#160;warrants with an exercise
price of $37.50&#160;exercisable until the five-year anniversary of October 9, 2023 issued on October 9, 2023 were computed using the
Black-Scholes option-pricing model with the following assumptions: stock price of $11.55, volatility of&#160;89.70%, risk-free rate of&#160;4.75%,
annual dividend yield of&#160;0% and expected life of&#160;5&#160;years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In accordance with ASC 470-20-25-2, proceeds
from the sale of a debt instrument with stock purchase warrants are allocated to the two elements based on the relative fair values of
the debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds allocated to
the warrants are accounted for as derivative liability. The remainder of the proceeds are allocated to the debt instrument portion of
the transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recorded a total debt discount of
$128,748&#160;related to the original issue discount, common shares issued and warrants issued to Mast Hill and Firstfire, which was amortized
over the term of the October 2023 Convertible Note.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;March 2024 Convertible
Note&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On March 7, 2024, the
Company entered into securities purchase agreements with Mast Hill for the issuance of&#160;13.0% senior secured promissory notes in the
aggregate principal amount of $700,000&#160;(collectively, the &#x201c;March 2024 Convertible Note&#x201d;) convertible into shares of the
Company&#x2019;s common stock, as well as the issuance of&#160;7,000&#160;shares of common stock as a commitment fee and warrants for the
purchase of&#160;16,827&#160;shares of common stock of the Company. The Company and its subsidiaries also entered into a security agreement,
creating a security interest in certain property of the Company and its subsidiaries to secure the prompt payment, performance and discharge
in full of all of the Company&#x2019;s obligations under the March 2024 Convertible Note. Principal amount and interest under the March
2024 Convertible Note were convertible into shares of common stock of the Company at a conversion price of $15.00&#160;per share unless
the Company failed to make an amortization payment when due, in which case the conversion price would be the lower of $15.00&#160;or the
market price (as defined in the March 2024 Convertible Note) of the shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Mast Hill acquired the
March 2024 Convertible Note with principal amount of $700,000&#160;and paid the purchase price of $665,000&#160;after an original issue
discount of $35,000. On March 7, 2024, the Company issued (i) a warrant to purchase&#160;8,750&#160;shares of common stock with an exercise
price of $30.00&#160;exercisable until the five-year anniversary of March 7, 2024 (&#x201c;First Warrant&#x201d;), (ii) a warrant to purchase&#160;8,077&#160;shares
of common stock with an exercise price of $19.50&#160;exercisable until the five-year anniversary of March 7, 2024 (&#x201c;Second Warrant&#x201d;).
The Second Warrant was never fair valued and was cancelled and extinguished against payment of the March 2024 Convertible Note, and (iii)&#160;7,000&#160;shares
of common stock as a commitment fee for the purchase of the March 2024 Convertible Note, which were earned in full as of March 7, 2024.
On March 7, 2024, the Company delivered such duly executed March 2024 Convertible Note, warrants and common stock to Mast Hill against
delivery of such purchase price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company was obligated to make amortization
payments in cash to Mast Hill toward the repayment of the March 2024 Convertible Note, as described in the March 2024 Convertible Note.
As of December 31, 2024, the March 2024 Convertible Note was repaid in full.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the issuance of the March 2024
Convertible Note, the Company incurred debt issuance costs of $74,379&#160;(including the issuance of&#160;700&#160;warrants as a finder&#x2019;s
fee) which was capitalized and was amortized into interest expense over the term of the March 2024 Convertible Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Based upon the Company&#x2019;s analysis of the
criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a finder&#x2019;s
fee met the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances. Accordingly,
the fair value of the&#160;9,450&#160;warrants with an exercise price of $30.00&#160;exercisable until the five-year anniversary of March
7, 2024 was classified as derivative liability on March 7, 2024. The fair values of the&#160;9,450&#160;warrants with an exercise price
of $30.00&#160;exercisable until the five-year anniversary of March 7, 2024 issued on March 7, 2024 were computed using the Black-Scholes
option-pricing model with the following assumptions: stock price of $6.00, volatility of&#160;85.24%, risk-free rate of&#160;4.07%, annual
dividend yield of&#160;0% and expected life of&#160;5&#160;years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 470-20-25-2, proceeds from
the sale of a debt instrument with stock purchase warrants are allocated to the two elements based on the relative fair values of the
debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds allocated to the
warrants are accounted for as derivative liability. The remainder of the proceeds are allocated to the debt instrument portion of the
transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recorded a total debt discount of
$97,374&#160;related to the original issue discount, common shares issued and warrants issued to Mast Hill, which was amortized over the
term of the March 2024 Convertible Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;June 2024 Convertible
Note&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On June 5, 2024, the
Company entered into securities purchase agreements with Mast Hill for the issuance of&#160;13.0% senior secured promissory notes in the
aggregate principal amount of $2,845,000&#160;(collectively, the &#x201c;June 2024 Convertible Note&#x201d;) convertible into shares of
the Company&#x2019;s common stock, as well as the issuance of&#160;26,800&#160;shares of common stock as a commitment fee and warrants
for the purchase of&#160;146,667&#160;shares of common stock of the Company. The Company and its subsidiaries have also entered into a
security agreement, creating a security interest in certain property of the Company and its subsidiaries to secure the prompt payment,
performance and discharge in full of all of the Company&#x2019;s obligations under the June 2024 Convertible Note. Principal amount and
interest under the June 2024 Convertible Note are convertible into shares of common stock of the Company at a conversion price of $11.25&#160;per
share unless the Company fails to make an amortization payment when due, in which case the conversion price shall be the lesser of $11.25&#160;or
the market price (as defined in the June 2024 Convertible Note).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Mast Hill acquired the
June 2024 Convertible Note with principal amount of $2,845,000&#160;and paid the purchase price of $2,702,750&#160;after an original issue
discount of $142,250. On June 5, 2024, the Company issued (i) a warrant to purchase&#160;66,667&#160;shares of common stock with an exercise
price of $9.75&#160;exercisable until the five-year anniversary of June 5, 2024 (&#x201c;First Warrant&#x201d;), (ii) a warrant to purchase&#160;80,000&#160;shares
of common stock with an exercise price of $7.50&#160;exercisable until the five-year anniversary of June 5, 2024 (&#x201c;Second Warrant&#x201d;).
The Second Warrant will not be fair valued and shall be cancelled and extinguished against payment of the June 2024 Convertible Note,
and (iii)&#160;26,800&#160;shares of common stock as a commitment fee for the purchase of the June 2024 Convertible Note, which were earned
in full as of June 5, 2024. On June 5, 2024, the Company delivered such duly executed June 2024 Convertible Note, warrants and common
stock to Mast Hill against delivery of such purchase price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company received
net cash amount of $881,210&#160;from the June 2024 Convertible Note financing after using the proceeds to pay off all previously issued
convertible notes to Mast Hill of $1,206,867&#160;and FirstFire of $454,673, respectively, and to pay finder&#x2019;s fee of $120,000&#160;and
lender&#x2019;s costs of $40,000&#160;related to this financing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company is obligated
to make amortization payments in cash to Mast Hill toward the repayment of the June 2024 Convertible Note, as provided in the following
table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 30%"&gt;Payment Date:&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; white-space: nowrap; width: 2%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 68%"&gt;Payment Amount:&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="white-space: nowrap"&gt;December 5, 2024&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;$284,500 plus accrued interest through December 5, 2024&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="white-space: nowrap"&gt;January 5, 2025&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;$284,500 plus accrued interest through January 5, 2025&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="white-space: nowrap"&gt;February 5, 2025&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;$379,336 plus accrued interest through February 5, 2025&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="white-space: nowrap"&gt;March 5, 2025&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;$474,167 plus accrued interest through March 5, 2025&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="white-space: nowrap"&gt;April 5, 2025&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;$474,167 plus accrued interest through April 5, 2025&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="white-space: nowrap"&gt;May 5, 2025&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;$569,000 plus accrued interest through May 5, 2025&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="white-space: nowrap"&gt;June 5, 2025&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;The entire remaining outstanding balance of the June 2024 Convertible Note&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In connection with the
issuance of the June 2024 Convertible Note, the Company incurred debt issuance costs of $224,221&#160;(including the issuance of&#160;5,333&#160;warrants
as a finder&#x2019;s fee) which is capitalized and will be amortized into interest expense over the term of the June 2024 Convertible Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Based upon the Company&#x2019;s
analysis of the criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a
finder&#x2019;s fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances.
Management determined the probability of failing to make an amortization payment when due to be remote and as such the fair value of the&#160;80,000&#160;warrants
with an exercise price of $7.50&#160;exercisable until the five-year anniversary of June 5, 2024, which warrant shall be cancelled and
extinguished against payment of the June 2024 Convertible Note, has been estimated to be zero. Accordingly, the fair value of the&#160;72,000&#160;warrants
with an exercise price of $9.75&#160;exercisable until the five-year anniversary of June 5, 2024 was classified as derivative liability
on June 5, 2024. The fair values of the&#160;72,000&#160;warrants with an exercise price of $9.75&#160;exercisable until the five-year
anniversary of June&#160;5, 2024 issued on June 5, 2024 were computed using the Black-Scholes option-pricing model with the following
assumptions: stock price of $10.39, volatility of&#160;85.72%, risk-free rate of&#160;4.31%, annual dividend yield of&#160;0% and expected
life of 5 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In accordance with ASC
470-20-25-2, proceeds from the sale of a debt instrument with stock purchase warrants are allocated to the two elements based on the relative
fair values of the debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds
allocated to the warrants are accounted for as derivative liability. The remainder of the proceeds are allocated to the debt instrument
portion of the transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In accordance with ASC
480-10-25-14, the Company determined that the conversion provisions contain an embedded derivative feature and the Company valued the
derivative feature separately, recording debt discount and derivative liability in accordance with the provisions of the convertible debt
(see Note 11). However, management determined the probability of failing to make an amortization payment when due to be remote and as
such the fair value of the embedded conversion feature has been estimated to be zero.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company recorded
a total debt discount of $838,990&#160;related to the original issue discount, common shares issued and warrants issued to Mast Hill,
which will be amortized over the term of the June 2024 Convertible Note.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On December 15, 2024,
the Company and Mast Hill entered into that certain consent, acknowledgement, and waiver agreement (&#x201c;Agreement&#x201d;), pursuant
to which Mast Hill waived all amortization payments required to be made under the June 2024 Convertible Note, the Company paid a waiver
fee of $150,000 to Mast Hill, and the Company issued to Mast Hill a common stock purchase warrant for the purchase of up to 150,000 shares
of the Company&#x2019;s common stock (&#x201c;Pre-Funded Warrants&#x201d;). The Pre-Funded Warrants are immediately exercisable at issuance
and until the Pre-Funded Warrants are exercised in full and have an exercise price of $0.01 per share. The Pre-Funded Warrants were classified
as a component of permanent equity on the accompanying consolidated balance sheets as they are freestanding financial instrument that
is immediately exercisable, does not embody an obligation for the Company to repurchase its own shares and permit the holder to receive
a fixed number of shares of common stock upon exercise. All of the shares underlying the Pre-Funded Warrants have been included in the
weighted-average number of shares of common stock used to calculate net loss per share, basic and diluted, attributable to the Company&#x2019;s
common stockholders because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original
issuance date of the Pre-Funded Warrants. Based on the Company&#x2019;s assess, this arrangement was accounted for as a modification of
debt and, as such, $838,794 related to the waiver fee and Pre-Fund Warrants issued to Mast Hill were expensed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
convertible note payable as of December 31, 2024 and 2023 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Principal amount&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,556,777&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,400,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: unamortized debt issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(93,425&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(183,840&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: unamortized debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(349,579&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(291,014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Convertible note payable, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,113,773&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,925,146&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;For the years ended December
31, 2024 and 2023, amortization of debt discount and debt issuance costs related to convertible note payable amounted to $1,291,814&#160;and
$437,453, respectively, which have been included in interest expense - amortization of debt discount and debt issuance costs on
the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;For the years ended December
31, 2024 and 2023, interest expense related to convertible note payable amounted to $325,486&#160;and $167,058, respectively, which have
been included in interest expense - other on the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c200"
      decimals="3"
      id="ixv-89342"
      unitRef="pure">0.13</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c200" decimals="0" id="ixv-89343" unitRef="usd">1500000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c201"
      decimals="0"
      id="ixv-89344"
      unitRef="shares">5000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c202"
      decimals="0"
      id="ixv-89345"
      unitRef="shares">15366</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c203"
      decimals="2"
      id="ixv-89346"
      unitRef="usdPershares">67.5</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c204"
      decimals="2"
      id="ixv-89347"
      unitRef="usdPershares">67.5</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <avco:DebtInstrumentConvertibleFloorPrice
      contextRef="c201"
      decimals="2"
      id="ixv-89348"
      unitRef="usdPershares">22.5</avco:DebtInstrumentConvertibleFloorPrice>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c201" decimals="0" id="ixv-89349" unitRef="usd">1500000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c203" decimals="0" id="ixv-89350" unitRef="usd">1425000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c203" decimals="0" id="ixv-89351" unitRef="usd">75000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c205"
      decimals="0"
      id="ixv-89352"
      unitRef="shares">8333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c205"
      decimals="2"
      id="ixv-89353"
      unitRef="usdPershares">67.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c206"
      decimals="0"
      id="ixv-89354"
      unitRef="shares">7033</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c206"
      decimals="2"
      id="ixv-89355"
      unitRef="usdPershares">48</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c207"
      decimals="0"
      id="ixv-89356"
      unitRef="shares">5000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DeferredFinanceCostsNet contextRef="c208" decimals="0" id="ixv-89357" unitRef="usd">175162</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c209"
      decimals="0"
      id="ixv-89358"
      unitRef="shares">667</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c210" decimals="0" id="ixv-89359" unitRef="usd">9000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c210"
      decimals="2"
      id="ixv-89360"
      unitRef="usdPershares">67.5</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c211" decimals="0" id="ixv-89361" unitRef="usd">9000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c211"
      decimals="2"
      id="ixv-89362"
      unitRef="usdPershares">67.5</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c212"
      decimals="2"
      id="ixv-89363"
      unitRef="pure">29.4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c213"
      decimals="2"
      id="ixv-89364"
      unitRef="pure">88.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c214"
      decimals="2"
      id="ixv-89365"
      unitRef="pure">3.76</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c215"
      decimals="0"
      id="ixv-89366"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c216"
      decimals="0"
      id="ixv-89367"
      unitRef="pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c208" decimals="0" id="ixv-89368" unitRef="usd">349654</us-gaap:DebtInstrumentUnamortizedDiscount>
    <avco:PercentageOfPromissoryNotes
      contextRef="c217"
      decimals="3"
      id="ixv-89369"
      unitRef="pure">0.13</avco:PercentageOfPromissoryNotes>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c217" decimals="0" id="ixv-89370" unitRef="usd">500000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c218"
      decimals="0"
      id="ixv-89371"
      unitRef="shares">1667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c219"
      decimals="0"
      id="ixv-89372"
      unitRef="shares">5122</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c219"
      decimals="2"
      id="ixv-89373"
      unitRef="usdPershares">67.5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="c217"
      decimals="2"
      id="ixv-89374"
      unitRef="usdPershares">67.5</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="c220"
      decimals="2"
      id="ixv-89375"
      unitRef="usdPershares">22.5</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c221" decimals="0" id="ixv-89376" unitRef="usd">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c222" decimals="0" id="ixv-89377" unitRef="usd">475000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c222" decimals="0" id="ixv-89378" unitRef="usd">25000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="c223"
      decimals="0"
      id="ixv-89379"
      unitRef="shares">2778</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c224"
      decimals="2"
      id="ixv-89380"
      unitRef="usdPershares">67.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="c225"
      decimals="0"
      id="ixv-89381"
      unitRef="shares">2344</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c226"
      decimals="2"
      id="ixv-89382"
      unitRef="usdPershares">48</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c227"
      decimals="0"
      id="ixv-89383"
      unitRef="shares">1667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DeferredFinanceCostsNet contextRef="c219" decimals="0" id="ixv-89384" unitRef="usd">74204</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c228"
      decimals="0"
      id="ixv-89385"
      unitRef="shares">222</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c229" decimals="0" id="ixv-89386" unitRef="usd">3000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c229"
      decimals="2"
      id="ixv-89387"
      unitRef="usdPershares">67.5</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c227" decimals="0" id="ixv-89388" unitRef="usd">3000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c227"
      decimals="2"
      id="ixv-89389"
      unitRef="usdPershares">67.5</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c230"
      decimals="2"
      id="ixv-89390"
      unitRef="pure">21.3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c231"
      decimals="2"
      id="ixv-89391"
      unitRef="pure">88.52</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c232"
      decimals="2"
      id="ixv-89392"
      unitRef="pure">4.37</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c233"
      decimals="0"
      id="ixv-89393"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c234"
      decimals="0"
      id="ixv-89394"
      unitRef="pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c235" decimals="0" id="ixv-89395" unitRef="usd">89191</us-gaap:DebtInstrumentUnamortizedDiscount>
    <avco:PercentageOfPromissoryNotes
      contextRef="c236"
      decimals="3"
      id="ixv-89396"
      unitRef="pure">0.13</avco:PercentageOfPromissoryNotes>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c236" decimals="0" id="ixv-89397" unitRef="usd">700000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c236"
      decimals="0"
      id="ixv-89398"
      unitRef="shares">4666</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c237"
      decimals="0"
      id="ixv-89399"
      unitRef="shares">12834</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c238"
      decimals="2"
      id="ixv-89400"
      unitRef="usdPershares">22.5</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <avco:TradingPrice
      contextRef="c239"
      decimals="2"
      id="ixv-89401"
      unitRef="usdPershares">22.5</avco:TradingPrice>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c240" decimals="0" id="ixv-89402" unitRef="usd">350000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c241" decimals="0" id="ixv-89403" unitRef="usd">332500</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c242" decimals="0" id="ixv-89404" unitRef="usd">17500</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c243"
      decimals="0"
      id="ixv-89405"
      unitRef="shares">3500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c243"
      decimals="2"
      id="ixv-89406"
      unitRef="usdPershares">37.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c244"
      decimals="0"
      id="ixv-89407"
      unitRef="shares">2917</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c244"
      decimals="2"
      id="ixv-89408"
      unitRef="usdPershares">27</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c245"
      decimals="0"
      id="ixv-89409"
      unitRef="shares">2333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c246" decimals="0" id="ixv-89410" unitRef="usd">350000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c247" decimals="0" id="ixv-89411" unitRef="usd">332500</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c248" decimals="0" id="ixv-89412" unitRef="usd">17500</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c249"
      decimals="0"
      id="ixv-89413"
      unitRef="shares">3500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c237"
      decimals="2"
      id="ixv-89414"
      unitRef="usdPershares">37.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c250"
      decimals="0"
      id="ixv-89415"
      unitRef="shares">2917</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c250"
      decimals="2"
      id="ixv-89416"
      unitRef="usdPershares">27</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c251"
      decimals="0"
      id="ixv-89417"
      unitRef="shares">2333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DeferredFinanceCostsNet contextRef="c238" decimals="0" id="ixv-89418" unitRef="usd">95349</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c251"
      decimals="0"
      id="ixv-89419"
      unitRef="shares">560</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c236" decimals="0" id="ixv-89420" unitRef="usd">7560</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c236"
      decimals="2"
      id="ixv-89421"
      unitRef="usdPershares">37.5</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c252" decimals="0" id="ixv-89422" unitRef="usd">7560</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c252"
      decimals="2"
      id="ixv-89423"
      unitRef="usdPershares">37.5</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c253"
      decimals="2"
      id="ixv-89424"
      unitRef="pure">11.55</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c254"
      decimals="2"
      id="ixv-89425"
      unitRef="pure">89.7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c255"
      decimals="2"
      id="ixv-89426"
      unitRef="pure">4.75</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c256"
      decimals="0"
      id="ixv-89427"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c257"
      decimals="0"
      id="ixv-89428"
      unitRef="pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c258" decimals="0" id="ixv-89429" unitRef="usd">128748</us-gaap:DebtInstrumentUnamortizedDiscount>
    <avco:PercentageOfPromissoryNotes
      contextRef="c259"
      decimals="3"
      id="ixv-89430"
      unitRef="pure">0.13</avco:PercentageOfPromissoryNotes>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c259" decimals="0" id="ixv-89431" unitRef="usd">700000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c259"
      decimals="0"
      id="ixv-89432"
      unitRef="shares">7000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c260"
      decimals="0"
      id="ixv-89433"
      unitRef="shares">16827</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c261"
      decimals="2"
      id="ixv-89434"
      unitRef="usdPershares">15</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <avco:TradingPrice
      contextRef="c261"
      decimals="2"
      id="ixv-89435"
      unitRef="usdPershares">15</avco:TradingPrice>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c259" decimals="0" id="ixv-89436" unitRef="usd">700000</us-gaap:DebtInstrumentIssuedPrincipal>
    <avco:PurchasePriceOfConvertibleNote contextRef="c259" decimals="0" id="ixv-89437" unitRef="usd">665000</avco:PurchasePriceOfConvertibleNote>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c261" decimals="0" id="ixv-89438" unitRef="usd">35000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="c262"
      decimals="0"
      id="ixv-89439"
      unitRef="shares">8750</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c262"
      decimals="2"
      id="ixv-89440"
      unitRef="usdPershares">30</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="c259"
      decimals="0"
      id="ixv-89441"
      unitRef="shares">8077</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c263"
      decimals="2"
      id="ixv-89442"
      unitRef="usdPershares">19.5</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:CommonUnitOutstanding
      contextRef="c264"
      decimals="0"
      id="ixv-89443"
      unitRef="shares">7000</us-gaap:CommonUnitOutstanding>
    <us-gaap:DeferredFinanceCostsNet contextRef="c261" decimals="0" id="ixv-89444" unitRef="usd">74379</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c261"
      decimals="0"
      id="ixv-89445"
      unitRef="shares">700</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c265" decimals="0" id="ixv-89446" unitRef="usd">9450</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c265"
      decimals="2"
      id="ixv-89447"
      unitRef="usdPershares">30</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c266" decimals="0" id="ixv-89448" unitRef="usd">9450</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c266"
      decimals="2"
      id="ixv-89449"
      unitRef="usdPershares">30</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c267"
      decimals="2"
      id="ixv-89450"
      unitRef="pure">6</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c268"
      decimals="2"
      id="ixv-89451"
      unitRef="pure">85.24</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c269"
      decimals="2"
      id="ixv-89452"
      unitRef="pure">4.07</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c270"
      decimals="0"
      id="ixv-89453"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c271"
      decimals="0"
      id="ixv-89454"
      unitRef="pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c272" decimals="0" id="ixv-89455" unitRef="usd">97374</us-gaap:DebtInstrumentUnamortizedDiscount>
    <avco:PercentageOfPromissoryNotes
      contextRef="c273"
      decimals="3"
      id="ixv-89456"
      unitRef="pure">0.13</avco:PercentageOfPromissoryNotes>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c273" decimals="0" id="ixv-89457" unitRef="usd">2845000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c273"
      decimals="0"
      id="ixv-89458"
      unitRef="shares">26800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c274"
      decimals="0"
      id="ixv-89459"
      unitRef="shares">146667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentConvertibleConversionPriceIncrease
      contextRef="c273"
      decimals="2"
      id="ixv-89460"
      unitRef="usdPershares">11.25</us-gaap:DebtInstrumentConvertibleConversionPriceIncrease>
    <us-gaap:DebtInstrumentConvertibleConversionPriceDecrease
      contextRef="c273"
      decimals="2"
      id="ixv-89461"
      unitRef="usdPershares">11.25</us-gaap:DebtInstrumentConvertibleConversionPriceDecrease>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c273" decimals="0" id="ixv-89462" unitRef="usd">2845000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c274" decimals="0" id="ixv-89463" unitRef="usd">2702750</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c274" decimals="0" id="ixv-89464" unitRef="usd">142250</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="c275"
      decimals="0"
      id="ixv-89465"
      unitRef="shares">66667</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c276"
      decimals="2"
      id="ixv-89466"
      unitRef="usdPershares">9.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="c277"
      decimals="0"
      id="ixv-89467"
      unitRef="shares">80000</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c278"
      decimals="2"
      id="ixv-89468"
      unitRef="usdPershares">7.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c277"
      decimals="0"
      id="ixv-89469"
      unitRef="shares">26800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:NontradeReceivables contextRef="c279" decimals="0" id="ixv-89470" unitRef="usd">881210</us-gaap:NontradeReceivables>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c280" decimals="0" id="ixv-89471" unitRef="usd">1206867</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c281" decimals="0" id="ixv-89472" unitRef="usd">454673</us-gaap:ProceedsFromConvertibleDebt>
    <avco:PaymentForCommission contextRef="c282" decimals="0" id="ixv-89473" unitRef="usd">120000</avco:PaymentForCommission>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c282" decimals="0" id="ixv-89474" unitRef="usd">40000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c18" id="ixv-61099">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company is obligated
to make amortization payments in cash to Mast Hill toward the repayment of the June 2024 Convertible Note, as provided in the following
table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 30%"&gt;Payment Date:&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; white-space: nowrap; width: 2%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 68%"&gt;Payment Amount:&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="white-space: nowrap"&gt;December 5, 2024&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;$284,500 plus accrued interest through December 5, 2024&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="white-space: nowrap"&gt;January 5, 2025&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;$284,500 plus accrued interest through January 5, 2025&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="white-space: nowrap"&gt;February 5, 2025&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;$379,336 plus accrued interest through February 5, 2025&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="white-space: nowrap"&gt;March 5, 2025&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;$474,167 plus accrued interest through March 5, 2025&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="white-space: nowrap"&gt;April 5, 2025&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;$474,167 plus accrued interest through April 5, 2025&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="white-space: nowrap"&gt;May 5, 2025&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;$569,000 plus accrued interest through May 5, 2025&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="white-space: nowrap"&gt;June 5, 2025&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;The entire remaining outstanding balance of the June 2024 Convertible Note&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentDescription contextRef="c294" id="ixv-89475">$284,500 plus accrued interest through December 5, 2024</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentDescription contextRef="c295" id="ixv-89476">$284,500 plus accrued interest through January 5, 2025</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentDescription contextRef="c296" id="ixv-89477">$379,336 plus accrued interest through February 5, 2025</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentDescription contextRef="c297" id="ixv-89478">$474,167 plus accrued interest through March 5, 2025</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentDescription contextRef="c298" id="ixv-89479">$474,167 plus accrued interest through April 5, 2025</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentDescription contextRef="c299" id="ixv-89480">$569,000 plus accrued interest through May 5, 2025</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentDescription contextRef="c300" id="ixv-89481">The entire remaining outstanding balance of the June 2024 Convertible Note</us-gaap:DebtInstrumentDescription>
    <us-gaap:DeferredFinanceCostsNet contextRef="c279" decimals="0" id="ixv-89482" unitRef="usd">224221</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c283"
      decimals="0"
      id="ixv-89483"
      unitRef="shares">5333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c284"
      decimals="0"
      id="ixv-89484"
      unitRef="shares">80000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c274"
      decimals="2"
      id="ixv-89485"
      unitRef="usdPershares">7.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c284"
      decimals="0"
      id="ixv-89486"
      unitRef="shares">72000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c284"
      decimals="2"
      id="ixv-89487"
      unitRef="usdPershares">9.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c284"
      decimals="0"
      id="ixv-89488"
      unitRef="shares">72000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c284"
      decimals="2"
      id="ixv-89489"
      unitRef="usdPershares">9.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c285"
      decimals="0"
      id="ixv-89490"
      unitRef="pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c286"
      decimals="2"
      id="ixv-89491"
      unitRef="pure">10.39</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c287"
      decimals="2"
      id="ixv-89492"
      unitRef="pure">85.72</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c288"
      decimals="2"
      id="ixv-89493"
      unitRef="pure">4.31</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c289"
      decimals="0"
      id="ixv-89494"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c279" decimals="0" id="ixv-89495" unitRef="usd">838990</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c290" decimals="0" id="ixv-89496" unitRef="usd">150000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c291"
      decimals="0"
      id="ixv-89497"
      unitRef="shares">150000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c292"
      decimals="2"
      id="ixv-89498"
      unitRef="usdPershares">0.01</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c293" decimals="0" id="ixv-89499" unitRef="usd">838794</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="c18" id="ixv-61182">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
convertible note payable as of December 31, 2024 and 2023 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Principal amount&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,556,777&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,400,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: unamortized debt issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(93,425&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(183,840&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: unamortized debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(349,579&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(291,014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Convertible note payable, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,113,773&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,925,146&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c301" decimals="0" id="ixv-89500" unitRef="usd">2556777</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c302" decimals="0" id="ixv-89501" unitRef="usd">2400000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c301" decimals="0" id="ixv-89502" unitRef="usd">93425</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c302" decimals="0" id="ixv-89503" unitRef="usd">183840</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent contextRef="c301" decimals="0" id="ixv-89504" unitRef="usd">349579</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent contextRef="c302" decimals="0" id="ixv-89505" unitRef="usd">291014</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c301" decimals="0" id="ixv-89506" unitRef="usd">2113773</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c302" decimals="0" id="ixv-89507" unitRef="usd">1925146</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c18" decimals="0" id="ixv-89508" unitRef="usd">1291814</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c19" decimals="0" id="ixv-89509" unitRef="usd">437453</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestAndDebtExpense contextRef="c18" decimals="0" id="ixv-89510" unitRef="usd">325486</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c19" decimals="0" id="ixv-89511" unitRef="usd">167058</us-gaap:InterestAndDebtExpense>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="c18" id="ixv-61242">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;NOTE 11 -&#160;&lt;span style="text-decoration:underline"&gt;DERIVATIVE LIABILITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;As stated
in Note 10, June 2024 Convertible Note, the Company determined that the convertible note payable contains an embedded derivative feature
in the form of a conversion provision which is adjustable based on future prices of the Company&#x2019;s common stock. In accordance with
ASC 815-10-25, each derivative feature is initially recorded at its fair value using the Black-Scholes option valuation method and then
re-value at each reporting date, with changes in the fair value reported in the statements of operations. However, on June 5, 2024 and
December 31, 2024, management determined the probability of failing to make an amortization payment and repayment, respectively, when
due to be remote and as such the fair value of the embedded conversion feature has been estimated to be zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 23, 2023, the Company issued 9,000 warrants
with an exercise price of $67.50 exercisable until the five-year anniversary of May 23, 2023 to Mast Hill and a third party as a finder&#x2019;s
fee. Upon evaluation, the warrants meet the definition of a derivative liability under FASB ASC 815, as the Company cannot avoid a net
cash settlement under certain circumstances. Accordingly, the fair value of the 9,000 warrants was classified as a derivative liability
on May 23, 2023. On December 31, 2023, the estimated fair value of the 9,000 warrants was $14,805. The estimated fair value of the warrants
was computed as of December 31, 2023 using Black-Scholes option-pricing model, with the following assumptions: stock price of $7.24, volatility
of 83.96%, risk-free rate of 3.84%, annual dividend yield of 0% and expected life of 4.4 years. On December 31, 2024, the estimated fair
value of the 9,000 warrants was $3,714. The estimated fair value of the warrants was computed as of December 31, 2024 using Black-Scholes
option-pricing model, with the following assumptions: stock price of $3.26, volatility of 97.00%, risk-free rate of 4.27%, annual dividend
yield of 0% and expected life of 3.4 years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 6, 2023, the Company issued&#160;3,000&#160;warrants
with an exercise price of $67.50&#160;exercisable until the five-year anniversary of July 6, 2023 to FirstFire and a third party as a
finder&#x2019;s fee. Upon evaluation, the warrants meet the definition of a derivative liability under ASC 815, as the Company cannot avoid
a net cash settlement under certain circumstances. Accordingly, the fair value of the&#160;3,000&#160;warrants was classified as a derivative
liability on July 6, 2023. On December 31, 2023, the estimated fair value of the&#160;3,000&#160;warrants was $5,098.&#160;The estimated
fair value of the warrants was computed as of December 31, 2023 using Black-Scholes&#160;option-pricing model, with the following assumptions:
stock price of $7.24, volatility of&#160;83.66%, risk-free rate of&#160;3.84%, annual dividend yield of&#160;0% and expected life of&#160;4.5&#160;years.
On November 18, 2024, 2,778 warrants held by FirstFire were cashless exercised. On December 31, 2024, the estimated fair value of the&#160;rest
of 222&#160;warrants was $94. The estimated fair value of the warrants was computed as of December 31, 2024 using Black-Scholes option-pricing
model, with the following assumptions: stock price of $3.26, volatility of&#160;95.85%, risk-free rate of&#160;4.27%, annual dividend
yield of&#160;0% and expected life of&#160;3.5&#160;years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 9, 2023, the Company issued&#160;7,560&#160;warrants
with an exercise price of $37.50&#160;exercisable until the five-year anniversary of October 9, 2023 to Mast Hill and FirstFire and a
third party as a finder&#x2019;s fee. Upon evaluation, the warrants meet the definition of a derivative liability under ASC 815, as the
Company cannot avoid a net cash settlement under certain circumstances. Accordingly, the fair value of the&#160;7,560&#160;warrants was
classified as a derivative liability on October 9, 2023. On December 31, 2023, the estimated fair value of the&#160;7,560&#160;warrants
was $20,920.&#160;The estimated fair value of the warrants was computed as of December 31, 2023 using Black-Scholes&#160;option-pricing
model, with the following assumptions: stock price of $7.24, volatility of&#160;86.33%, risk-free rate of&#160;3.84%, annual dividend
yield of&#160;0% and expected life of&#160;4.8&#160;years. On November 18, 2024, 3,500 warrants held by FirstFire were cashless exercised.
On December 31, 2024, the estimated fair value of the&#160;rest of 4,060&#160;warrants was $2,880. The estimated fair value of the warrants
was computed as of December 31, 2024 using Black-Scholes option-pricing model, with the following assumptions: stock price of $3.26, volatility
of&#160;93.90%, risk-free rate of&#160;4.27%, annual dividend yield of&#160;0% and expected life of&#160;3.8&#160;years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On March 7, 2024, the
Company issued&#160;9,450&#160;warrants with an exercise price of $30.00&#160;exercisable until the five-year anniversary of March 7,
2024 to Mast Hill and a third party as a finder&#x2019;s fee. Upon evaluation, the warrants meet the definition of a derivative liability
under FASB ASC 815, as the Company cannot avoid a net cash settlement under certain circumstances. Accordingly, the fair value of the&#160;9,450&#160;warrants
was classified as a derivative liability on March 7, 2024. On December 31, 2024, the estimated fair value of the&#160;9,450&#160;warrants
was $8,191. The estimated fair value of the warrants was computed as of December 31, 2024 using Black-Scholes option-pricing model, with
the following assumptions: stock price of $3.26, volatility of&#160;90.43%, risk-free rate of&#160;4.38%, annual dividend yield of&#160;0%
and expected life of&#160;4.2&#160;years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On June 5, 2024, the
Company issued&#160;152,000&#160;warrants to Mast Hill and a third party as a finder&#x2019;s fee (see Note 10). Upon evaluation, the warrants
meet the definition of a derivative liability under ASC 815, as the Company cannot avoid a net cash settlement under certain circumstances.
Management determined the probability of failing to make an amortization payment when due to be remote and as such the fair value of the&#160;80,000&#160;warrants
with an exercise price of $7.50&#160;exercisable until the five-year anniversary of June 5, 2024, which warrant shall be cancelled and
extinguished against payment of the June 2024 Convertible Note, has been estimated to be zero. Accordingly, the fair value of the&#160;72,000&#160;warrants
with an exercise price of $9.75&#160;exercisable until the five-year anniversary of June 5, 2024 was classified as a derivative liability
on June 5, 2024. On December 31, 2024, the estimated fair value of the&#160;72,000&#160;warrants with an exercise price of $9.75&#160;exercisable
until the five-year anniversary of June 5, 2024 as derivative liability was $112,666. The estimated fair value of the warrants was computed
as of December 31, 2024 using Black-Scholes option-pricing model, with the following assumptions: stock price of $3.26, volatility of&#160;88.64%,
risk-free rate of&#160;4.38%, annual dividend yield of&#160;0% and expected life of&#160;4.4&#160;years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Increases or decreases
in fair value of the derivative liability are included as a component of total other (expenses) income in the accompanying consolidated
statements of operations and comprehensive loss. The changes to the derivative liability resulted in a decrease of $374,365&#160;and $188,374&#160;in
the derivative liability and the corresponding increase in other income as a gain for the years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c303"
      decimals="0"
      id="ixv-89512"
      unitRef="shares">9000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c304"
      decimals="2"
      id="ixv-89513"
      unitRef="usdPershares">67.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c305"
      decimals="0"
      id="ixv-89514"
      unitRef="shares">9000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c306"
      decimals="0"
      id="ixv-89515"
      unitRef="shares">9000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c307" decimals="0" id="ixv-89516" unitRef="usd">14805</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c308"
      decimals="2"
      id="ixv-89517"
      unitRef="pure">7.24</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c309"
      decimals="2"
      id="ixv-89518"
      unitRef="pure">83.96</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c310"
      decimals="2"
      id="ixv-89519"
      unitRef="pure">3.84</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c311"
      decimals="0"
      id="ixv-89520"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c312"
      decimals="1"
      id="ixv-89521"
      unitRef="pure">4.4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c313"
      decimals="0"
      id="ixv-89522"
      unitRef="shares">9000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="c313"
      decimals="0"
      id="ixv-89523"
      unitRef="shares">3714</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c314"
      decimals="2"
      id="ixv-89524"
      unitRef="pure">3.26</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c315"
      decimals="2"
      id="ixv-89525"
      unitRef="pure">97</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c316"
      decimals="2"
      id="ixv-89526"
      unitRef="pure">4.27</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c317"
      decimals="0"
      id="ixv-89527"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c318"
      decimals="1"
      id="ixv-89528"
      unitRef="pure">3.4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c222"
      decimals="0"
      id="ixv-89529"
      unitRef="shares">3000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c319"
      decimals="2"
      id="ixv-89530"
      unitRef="usdPershares">67.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c320"
      decimals="0"
      id="ixv-89531"
      unitRef="shares">3000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c321"
      decimals="0"
      id="ixv-89532"
      unitRef="shares">3000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="c321"
      decimals="0"
      id="ixv-89533"
      unitRef="shares">5098</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c322"
      decimals="2"
      id="ixv-89534"
      unitRef="pure">7.24</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c323"
      decimals="2"
      id="ixv-89535"
      unitRef="pure">83.66</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c324"
      decimals="2"
      id="ixv-89536"
      unitRef="pure">3.84</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c325"
      decimals="0"
      id="ixv-89537"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c326"
      decimals="1"
      id="ixv-89538"
      unitRef="pure">4.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <avco:WarrantsOfCashlessExercised
      contextRef="c327"
      decimals="0"
      id="ixv-89539"
      unitRef="shares">2778</avco:WarrantsOfCashlessExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c328"
      decimals="0"
      id="ixv-89540"
      unitRef="shares">222</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c329" decimals="0" id="ixv-89541" unitRef="usd">94</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c330"
      decimals="2"
      id="ixv-89542"
      unitRef="pure">3.26</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c331"
      decimals="2"
      id="ixv-89543"
      unitRef="pure">95.85</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c332"
      decimals="2"
      id="ixv-89544"
      unitRef="pure">4.27</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c333"
      decimals="0"
      id="ixv-89545"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c334"
      decimals="1"
      id="ixv-89546"
      unitRef="pure">3.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c335"
      decimals="0"
      id="ixv-89547"
      unitRef="shares">7560</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c237"
      decimals="2"
      id="ixv-89548"
      unitRef="usdPershares">37.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c336"
      decimals="0"
      id="ixv-89549"
      unitRef="shares">7560</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c337"
      decimals="0"
      id="ixv-89550"
      unitRef="shares">7560</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="c337"
      decimals="0"
      id="ixv-89551"
      unitRef="shares">20920</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c322"
      decimals="2"
      id="ixv-89552"
      unitRef="pure">7.24</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c338"
      decimals="2"
      id="ixv-89553"
      unitRef="pure">86.33</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c339"
      decimals="2"
      id="ixv-89554"
      unitRef="pure">3.84</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c340"
      decimals="0"
      id="ixv-89555"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c341"
      decimals="1"
      id="ixv-89556"
      unitRef="pure">4.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <avco:WarrantsOfCashlessExercised
      contextRef="c342"
      decimals="0"
      id="ixv-89557"
      unitRef="shares">3500</avco:WarrantsOfCashlessExercised>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="c343"
      decimals="0"
      id="ixv-89558"
      unitRef="shares">4060</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c344" decimals="0" id="ixv-89559" unitRef="usd">2880</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c345"
      decimals="2"
      id="ixv-89560"
      unitRef="pure">3.26</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c346"
      decimals="2"
      id="ixv-89561"
      unitRef="pure">93.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c347"
      decimals="2"
      id="ixv-89562"
      unitRef="pure">4.27</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c348"
      decimals="0"
      id="ixv-89563"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c349"
      decimals="1"
      id="ixv-89564"
      unitRef="pure">3.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c350"
      decimals="0"
      id="ixv-89565"
      unitRef="shares">9450</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c264"
      decimals="2"
      id="ixv-89566"
      unitRef="usdPershares">30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c351"
      decimals="0"
      id="ixv-89567"
      unitRef="shares">9450</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c352"
      decimals="0"
      id="ixv-89568"
      unitRef="shares">9450</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="c352"
      decimals="0"
      id="ixv-89569"
      unitRef="shares">8191</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c353"
      decimals="2"
      id="ixv-89570"
      unitRef="pure">3.26</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c354"
      decimals="2"
      id="ixv-89571"
      unitRef="pure">90.43</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c355"
      decimals="2"
      id="ixv-89572"
      unitRef="pure">4.38</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c356"
      decimals="0"
      id="ixv-89573"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c357"
      decimals="1"
      id="ixv-89574"
      unitRef="pure">4.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c358"
      decimals="0"
      id="ixv-89575"
      unitRef="shares">152000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c359"
      decimals="0"
      id="ixv-89576"
      unitRef="shares">80000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c274"
      decimals="2"
      id="ixv-89577"
      unitRef="usdPershares">7.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c360"
      decimals="0"
      id="ixv-89578"
      unitRef="shares">72000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c360"
      decimals="2"
      id="ixv-89579"
      unitRef="usdPershares">9.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c361"
      decimals="0"
      id="ixv-89580"
      unitRef="shares">72000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c362"
      decimals="2"
      id="ixv-89581"
      unitRef="usdPershares">9.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c360" decimals="0" id="ixv-89582" unitRef="usd">112666</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c363"
      decimals="2"
      id="ixv-89583"
      unitRef="pure">3.26</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c364"
      decimals="2"
      id="ixv-89584"
      unitRef="pure">88.64</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c365"
      decimals="2"
      id="ixv-89585"
      unitRef="pure">4.38</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c366"
      decimals="0"
      id="ixv-89586"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c367"
      decimals="1"
      id="ixv-89587"
      unitRef="pure">4.4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c18" decimals="0" id="ixv-89588" unitRef="usd">-374365</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c19" decimals="0" id="ixv-89589" unitRef="usd">-188374</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtDisclosureTextBlock contextRef="c18" id="ixv-61293">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;NOTE 12 -&#160;&lt;span style="text-decoration:underline"&gt;NOTE PAYABLE, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;On
September 1, 2022, the Company issued a balloon promissory note in the form of a mortgage on its headquarters to a third party company
in the principal amount of $4,800,000, which carries interest of 11.0% per annum. Interest is due in monthly payments of $44,000 beginning
November 1, 2022 and payable monthly thereafter until September 1, 2025 when the principal outstanding and all remaining interest is due.
The principal of $4,800,000 can be extended for an additional 36 months, provided that the Company has not defaulted. The Company may
not prepay the principal of $&lt;span style="-sec-ix-hidden: hidden-fact-338"&gt;4,800,00&lt;/span&gt; for a period of 12 months. The principal of $4,800,000 is secured by a first mortgage on the Company&#x2019;s
real property located in Township of Freehold, County of Monmouth, State of New Jersey, having a street address of 4400 Route 9 South,
Freehold, NJ 07728.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In May 2023, the Company
borrowed $1,000,000 from the same lender. The principal of $1,000,000 accrues interest at an annual rate of 13.0% and is payable in monthly
installments of interest-only in the amount of $10,833, commencing in June 2023 and continuing through October 2025 (at which point any
unpaid balance of principal, interest and other charges are due and payable). The loan is secured by a second-lien mortgage on certain
real property and improvements located at 4400 Route 9, Freehold, Monmouth County, New Jersey.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
note payable as of December 31, 2024 and 2023 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Principal amount&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,800,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,800,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: unamortized debt issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(84,553&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(203,781&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Note payable, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,715,447&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,596,219&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Current portion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,715,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-336"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Noncurrent portion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-337"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,596,219&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;For the years ended December
31, 2024 and 2023, amortization of debt issuance costs related to note payable amounted to $119,228 and $106,557, respectively, which
have been included in interest expense - amortization of debt discount and debt issuance costs on the accompanying consolidated
statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;For the years ended December
31, 2024 and 2023, interest expense related to note payable amounted to $658,000 and $606,722, respectively, which have been included
in interest expense - other on the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c368" decimals="0" id="ixv-89590" unitRef="usd">4800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="c369"
      decimals="3"
      id="ixv-89591"
      unitRef="pure">0.11</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c370" decimals="0" id="ixv-89592" unitRef="usd">44000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c371" decimals="0" id="ixv-89593" unitRef="usd">4800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:SecuredDebt contextRef="c1" decimals="0" id="ixv-89594" unitRef="usd">4800000</us-gaap:SecuredDebt>
    <us-gaap:ProceedsFromNotesPayable contextRef="c372" decimals="0" id="ixv-89595" unitRef="usd">1000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c373" decimals="0" id="ixv-89596" unitRef="usd">1000000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c373"
      decimals="3"
      id="ixv-89597"
      unitRef="pure">0.13</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c373" decimals="0" id="ixv-89598" unitRef="usd">10833</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c18" id="ixv-61337">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="background-color: white"&gt;The
note payable as of December 31, 2024 and 2023 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Principal amount&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,800,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,800,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: unamortized debt issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(84,553&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(203,781&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Note payable, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,715,447&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,596,219&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Current portion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,715,447&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-336"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Noncurrent portion&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-337"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5,596,219&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c1" decimals="0" id="ixv-89599" unitRef="usd">5800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c2" decimals="0" id="ixv-89600" unitRef="usd">5800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c1" decimals="0" id="ixv-89601" unitRef="usd">84553</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c2" decimals="0" id="ixv-89602" unitRef="usd">203781</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:OtherNotesPayableCurrent contextRef="c1" decimals="0" id="ixv-89603" unitRef="usd">5715447</us-gaap:OtherNotesPayableCurrent>
    <us-gaap:OtherNotesPayableCurrent contextRef="c2" decimals="0" id="ixv-89604" unitRef="usd">5596219</us-gaap:OtherNotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c1" decimals="0" id="ixv-89605" unitRef="usd">5715447</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable contextRef="c2" decimals="0" id="ixv-89606" unitRef="usd">5596219</us-gaap:LongTermNotesPayable>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c18" decimals="0" id="ixv-89607" unitRef="usd">119228</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c19" decimals="0" id="ixv-89608" unitRef="usd">106557</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseShortTermBorrowings contextRef="c18" decimals="0" id="ixv-89609" unitRef="usd">658000</us-gaap:InterestExpenseShortTermBorrowings>
    <us-gaap:InterestExpenseShortTermBorrowings contextRef="c19" decimals="0" id="ixv-89610" unitRef="usd">606722</us-gaap:InterestExpenseShortTermBorrowings>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c18" id="ixv-61409">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;NOTE 13 -&#160;&lt;span style="text-decoration:underline"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;Rental
Revenue from Related Party and Rent Receivable - Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company leases space of its commercial real
property located in New Jersey to D.P. Capital Investments LLC, which is controlled by Wenzhao Lu, the Company&#x2019;s chairman of the
Board of Directors. The term of the related party lease agreement is five years commencing on May 1, 2021 and will expire on April 30,
2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;For both
the years ended December 31, 2024 and 2023, the related party rental revenue amounted to $50,400 and has been included in real property
rental revenue on the accompanying consolidated statements of operations and comprehensive loss. At December 31, 2024 and 2023, the related
party rent receivable totaled $0 and $124,500, respectively, which has been included in rent receivable on the accompanying consolidated
balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;Services
Provided by Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From time to time, Wilbert Tauzin, a director
of the Company, and his son provide consulting services to the Company. As compensation for professional services provided, the Company
recognized consulting expenses of $63,644 and $86,528 for the years ended December 31, 2024 and 2023, respectively, which have been included
in professional fees on the accompanying consolidated statements of operations and comprehensive loss. As of both December 31, 2024 and
2023, the accrued and unpaid services charge related to this director&#x2019;s son amounted to $15,000, which have been included in accrued
professional fees on the accompanying consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Accrued Liabilities and Other Payables -
Related Parties&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In 2017, the Company acquired Beijing Genexosome
for a cash payment of $450,000. As of both December 31, 2024 and 2023, the unpaid acquisition consideration of $100,000, was payable to
Dr. Yu Zhou, former director and former co-chief executive officer and 40% owner of Genexosome, and has been included in accrued liabilities
and other payables - related parties on the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From time to time, Lab Services MSO paid shared
expense on behalf of the Company. In addition, Lab Services MSO made a payment of $566,667 for equity method investment payable on behalf
of the Company in the year ended December 31, 2024. As of December 31, 2024 and 2023, the balance due to Lab Services MSO amounted to
$632,916 and $72,746, respectively, which has been included in accrued liabilities and other payables - related parties on the accompanying
consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2024 and 2023, $0 and $33,712
of accrued and unpaid interest related to borrowings from Wenzhao Lu, the Company&#x2019;s chairman of the Board of Directors, respectively,
have been included in accrued liabilities and other payables - related parties on the accompanying consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Borrowings from Related Party&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Line of Credit &lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 29, 2019, the Company entered into a
Line of Credit Agreement (the &#x201c;Line of Credit Agreement&#x201d;) providing the Company with a $20 million line of credit (the &#x201c;Line
of Credit&#x201d;) from Mr. Lu, the Company&#x2019;s chairman of the Board of Directors. The Line of Credit allowed the Company to request
loans thereunder and to use the proceeds of such loans for working capital and operating expense purposes until the facility matured on
December 31, 2024. The loans are unsecured and are not convertible into equity of the Company. Loans drawn under the Line of Credit bear
interest at an annual rate of 5% and each individual loan is payable three years from the date of issuance. The Company has a right to
draw down on the line of credit and not at the discretion of Mr. Lu, the related party lender. The Company may, at its option, prepay
any borrowings under the Line of Credit, in whole or in part at any time prior to maturity, without premium or penalty. The Line of Credit
Agreement includes customary events of default. If any such event of default occurs, Mr. Lu may declare all outstanding loans under the
Line of Credit to be due and payable immediately.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the years ended December 31, 2024 and 2023,
activity recorded for the Line of Credit is summarized in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Outstanding principal under the Line of Credit at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-339"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Draw down from Line of Credit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;850,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding principal under the Line of Credit at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;850,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Repayment of Line of Credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(400,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Reclassification of Line of Credit to advance from related party&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(450,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Outstanding principal under the Line of Credit at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the years ended December 31, 2024 and 2023,
the interest expense related to related party borrowing amounted to $42,445 and $33,712, respectively, and has been reflected as interest
expense - related party on the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2024 and 2023, the related
accrued and unpaid interest for Line of Credit was $0 and $33,712, respectively, and has been included in accrued liabilities and other
payables - related parties on the accompanying consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Membership Interest
Purchase Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On November 17, 2023,
the Company entered into a Membership Interest Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with Mr. Lu, the Company&#x2019;s
chairman of the Board of Directors, pursuant to which (i) Mr. Lu will acquire from the Company 30% of the total outstanding membership
interests of Avalon RT 9, a wholly owned subsidiary of the Company, for a cash purchase price of $3,000,000 (the &#x201c;Acquisition&#x201d;),
and (ii) for a period of twelve months following the closing of the Acquisition, Mr. Lu shall have the option to purchase from the Company
up to an additional 70% of the outstanding membership interests of Avalon RT 9 for a purchase price of up to $7,000,000 (the &#x201c;Option&#x201d;),
subject to the terms and conditions of a membership interest purchase agreement to be negotiated and entered into between the Purchaser
and the Company at such time that the Purchaser desires to exercise the Option. The Company received $3,108,106 and $485,714 from Wenzhao
Lu as of December 31, 2024 and 2023, respectively, which was recorded as advance from pending sale of noncontrolling interest -
related party on the accompanying consolidated balance sheets. The Acquisition is expected to be closed in the fourth quarter of 2025.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RentalIncomeNonoperating contextRef="c374" decimals="0" id="ixv-89611" unitRef="usd">50400</us-gaap:RentalIncomeNonoperating>
    <us-gaap:RentalIncomeNonoperating contextRef="c375" decimals="0" id="ixv-89612" unitRef="usd">50400</us-gaap:RentalIncomeNonoperating>
    <us-gaap:AccountsReceivableNet contextRef="c3" decimals="0" id="ixv-89613" unitRef="usd">0</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c4" decimals="0" id="ixv-89614" unitRef="usd">124500</us-gaap:AccountsReceivableNet>
    <us-gaap:OtherGeneralExpense contextRef="c18" decimals="0" id="ixv-89615" unitRef="usd">63644</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense contextRef="c19" decimals="0" id="ixv-89616" unitRef="usd">86528</us-gaap:OtherGeneralExpense>
    <avco:AccruedAndUnpaidServicesCharge contextRef="c1" decimals="0" id="ixv-89617" unitRef="usd">15000</avco:AccruedAndUnpaidServicesCharge>
    <avco:AccruedAndUnpaidServicesCharge contextRef="c2" decimals="0" id="ixv-89618" unitRef="usd">15000</avco:AccruedAndUnpaidServicesCharge>
    <us-gaap:Cash contextRef="c376" decimals="0" id="ixv-89619" unitRef="usd">450000</us-gaap:Cash>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c377" decimals="0" id="ixv-89620" unitRef="usd">100000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c378" decimals="0" id="ixv-89621" unitRef="usd">100000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c379"
      decimals="2"
      id="ixv-89622"
      unitRef="pure">0.40</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <avco:EquityMethodInvestmentPayableCurrent contextRef="c380" decimals="0" id="ixv-89623" unitRef="usd">566667</avco:EquityMethodInvestmentPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="c380" decimals="0" id="ixv-89624" unitRef="usd">632916</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="c381" decimals="0" id="ixv-89625" unitRef="usd">72746</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="c382" decimals="0" id="ixv-89626" unitRef="usd">0</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="c383" decimals="0" id="ixv-89627" unitRef="usd">33712</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="c384"
      decimals="-6"
      id="ixv-89628"
      unitRef="usd">20000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c384" id="ixv-89629">2024-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="c384"
      decimals="2"
      id="ixv-89630"
      unitRef="pure">0.05</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock contextRef="c18" id="ixv-61483">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In the years ended December 31, 2024 and 2023,
activity recorded for the Line of Credit is summarized in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Outstanding principal under the Line of Credit at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-339"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Draw down from Line of Credit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;850,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding principal under the Line of Credit at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;850,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Repayment of Line of Credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(400,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Reclassification of Line of Credit to advance from related party&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(450,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Outstanding principal under the Line of Credit at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <avco:DrawDownFromLineOfCredit contextRef="c18" decimals="0" id="ixv-89631" unitRef="usd">850000</avco:DrawDownFromLineOfCredit>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding contextRef="c1" decimals="0" id="ixv-89632" unitRef="usd">850000</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c18" decimals="0" id="ixv-89633" unitRef="usd">400000</us-gaap:RepaymentsOfLinesOfCredit>
    <avco:ReclassificationOfLineOfCreditToAdvanceFromRelatedParty contextRef="c18" decimals="0" id="ixv-89634" unitRef="usd">-450000</avco:ReclassificationOfLineOfCreditToAdvanceFromRelatedParty>
    <us-gaap:InterestExpenseOther contextRef="c374" decimals="0" id="ixv-89635" unitRef="usd">42445</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c375" decimals="0" id="ixv-89636" unitRef="usd">33712</us-gaap:InterestExpenseOther>
    <us-gaap:LineOfCreditFacilityIncreaseAccruedInterest contextRef="c385" decimals="0" id="ixv-89637" unitRef="usd">0</us-gaap:LineOfCreditFacilityIncreaseAccruedInterest>
    <us-gaap:LineOfCreditFacilityIncreaseAccruedInterest contextRef="c386" decimals="0" id="ixv-89638" unitRef="usd">33712</us-gaap:LineOfCreditFacilityIncreaseAccruedInterest>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="c387"
      decimals="2"
      id="ixv-89639"
      unitRef="pure">0.30</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <avco:PurchasePrice contextRef="c388" decimals="0" id="ixv-89640" unitRef="usd">3000000</avco:PurchasePrice>
    <avco:BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage
      contextRef="c389"
      decimals="2"
      id="ixv-89641"
      unitRef="pure">0.70</avco:BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage>
    <avco:PurchasePrice contextRef="c390" decimals="0" id="ixv-89642" unitRef="usd">7000000</avco:PurchasePrice>
    <avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty contextRef="c382" decimals="0" id="ixv-89643" unitRef="usd">3108106</avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty>
    <avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty contextRef="c383" decimals="0" id="ixv-89644" unitRef="usd">485714</avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c18" id="ixv-61556">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 14 -&#160;&lt;span style="text-decoration:underline"&gt;INCOME
TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
is governed by the Income Tax Law of the PRC and the U.S. Internal Revenue Code of 1986, as amended. Under the Income Tax Laws of PRC,
Chinese companies are generally subject to an income tax at an effective rate of 25% on income reported in the statutory financial statements
after appropriate tax adjustments. The Company has a cumulative deficit from its foreign subsidiary of $3,399,273 as of December 31, 2024,
which is included in the consolidated accumulated deficit.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company&#x2019;s
loss before income taxes includes the following components:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;United States loss before income taxes&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,639,148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,928,780&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;China loss before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;264,246&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;778,230&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0.125in; text-align: left"&gt;Total loss before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,903,394&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,707,010&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Components of income taxes expense (benefit) consisted
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;U.S. federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-340"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-341"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;U.S. state and local&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-342"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-343"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;China&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-344"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-345"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;Total current income taxes expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-346"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-347"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; width: 76%; text-align: left"&gt;U.S. federal&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,874&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(3,256,007&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;U.S. state and local&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,650&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,102,392&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;China&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;93,437&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(183,443&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;Total deferred income taxes (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;86,913&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,541,842&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(86,913&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,541,842&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Total income taxes expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-348"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-349"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The table below summarizes the differences between
the U.S. statutory rate and the Company&#x2019;s effective tax rate for the years ended December 31, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;U.S. federal rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;U.S. state rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.7&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent difference&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-US rate differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;True ups&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(27.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;U.S. valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1.1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(27.2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the years ended December 31, 2024 and 2023,
the Company did not incur any income taxes expense since it did not generate any taxable income in those periods. The Company&#x2019;s
foreign entity did not pay any income taxes during the years ended December 31, 2024 and 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s components of deferred taxes
as of December 31, 2024 and 2023 were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31,&lt;br/&gt;
 2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, &lt;br/&gt;
2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 76%; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,598,257&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,501,507&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Disallowed business interest deduction&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-350"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,476&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Research and development expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;106,783&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;130,823&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Accrued directors&#x2019; compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104,977&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165,490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Accrued settlement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,904&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;126,496&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Partnership Investment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,167,965&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,422,744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,687&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,935&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Capital loss limitation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;149,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;149,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Net operating loss carryforward&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,648,077&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,493,570&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;Total deferred tax assets, gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,918,044&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,020,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,784,638&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,871,551&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Total deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;133,406&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;148,884&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Fixed assets and intangible assets book/tax basis difference&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(133,406&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(129,636&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-351"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19,248&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(133,406&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(148,884&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-352"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-353"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;As of December
31, 2024 and 2023, the Company&#x2019;s both federal and state net operating loss carryforwards amounted to $60,926,204 and $52,929,248,
respectively. As of December 31, 2024, the Company has $58,438,649 of U.S. federal net operating loss carryovers that have no expiration
date, and $2,487,555 of the federal net operating loss and state net operating loss carry-forwards begin to expire in 2034.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2024, the Company had net operating
loss carryforwards in China of $2,086,886&#160;that begin to expire in 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Additionally,
as of December 31, 2024, $61,847 of the future utilization of the net operating loss carryforward to offset future taxable income is subject
to special tax rules which may limit their usage under IRS Section 382 (Change of Ownership) and possibly the Separate Return Limitation
Year (&#x201c;SRLY&#x201d;) rules.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A full valuation allowance has been provided against
the Company&#x2019;s deferred tax assets at December 31, 2024 as the Company believes it is more likely than not that sufficient taxable
income will not be generated to realize these temporary differences.&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
has been notified and assessed an IRS Section 6038 penalty of $10,000 for failure to file a foreign entity tax disclosure. The Company
has appealed the penalty and awaits the Internal Revenue Service&#x2019;s review of the appeal. There is no assurance such appeal will
be successful.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
has not been audited by any jurisdiction since its inception. The Company is open for audit by the U.S. Internal Revenue Service and U.S.
state tax jurisdictions from 2021 to 2024, and open for audit by the Chinese Ministry of Finance from 2020 to 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;There were
no material uncertain tax positions as of December 31, 2024 and 2023. The Company recognizes interest and penalties related to unrecognized
tax benefits as income tax expense, if any. The Company does not have any significant uncertain tax positions or events leading to uncertainty
in a tax position.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther contextRef="c18" decimals="2" id="ixv-89645" unitRef="pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="c1" decimals="0" id="ixv-89646" unitRef="usd">3399273</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c18" id="ixv-61564">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company&#x2019;s
loss before income taxes includes the following components:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;United States loss before income taxes&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,639,148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,928,780&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;China loss before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;264,246&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;778,230&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0.125in; text-align: left"&gt;Total loss before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,903,394&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;16,707,010&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c18" decimals="0" id="ixv-89647" unitRef="usd">7639148</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c19" decimals="0" id="ixv-89648" unitRef="usd">15928780</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c18" decimals="0" id="ixv-89649" unitRef="usd">264246</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c19" decimals="0" id="ixv-89650" unitRef="usd">778230</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c18" decimals="0" id="ixv-89651" unitRef="usd">7903394</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c19" decimals="0" id="ixv-89652" unitRef="usd">16707010</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c18" id="ixv-61613">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Components of income taxes expense (benefit) consisted
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;U.S. federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-340"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-341"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;U.S. state and local&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-342"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-343"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;China&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-344"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-345"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;Total current income taxes expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-346"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-347"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; width: 76%; text-align: left"&gt;U.S. federal&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(4,874&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(3,256,007&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;U.S. state and local&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,650&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,102,392&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in"&gt;China&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;93,437&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(183,443&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;Total deferred income taxes (benefit)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;86,913&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,541,842&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(86,913&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,541,842&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Total income taxes expense&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-348"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-349"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c18" decimals="0" id="ixv-89653" unitRef="usd">-4874</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c19" decimals="0" id="ixv-89654" unitRef="usd">-3256007</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c18" decimals="0" id="ixv-89655" unitRef="usd">-1650</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c19" decimals="0" id="ixv-89656" unitRef="usd">-1102392</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c18" decimals="0" id="ixv-89657" unitRef="usd">93437</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c19" decimals="0" id="ixv-89658" unitRef="usd">-183443</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c18" decimals="0" id="ixv-89659" unitRef="usd">86913</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c19" decimals="0" id="ixv-89660" unitRef="usd">-4541842</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c18" decimals="0" id="ixv-89661" unitRef="usd">86913</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c19" decimals="0" id="ixv-89662" unitRef="usd">-4541842</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c18" id="ixv-61760">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The table below summarizes the differences between
the U.S. statutory rate and the Company&#x2019;s effective tax rate for the years ended December 31, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;U.S. federal rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;U.S. state rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.7&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Permanent difference&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Non-US rate differential&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;True ups&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(27.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.6&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;U.S. valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1.1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(27.2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total provision for income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.0&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c18" decimals="3" id="ixv-89663" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c19" decimals="3" id="ixv-89664" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c18" decimals="3" id="ixv-89665" unitRef="pure">0.064</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c19" decimals="3" id="ixv-89666" unitRef="pure">0.067</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness contextRef="c18" decimals="3" id="ixv-89667" unitRef="pure">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness contextRef="c19" decimals="3" id="ixv-89668" unitRef="pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c18" decimals="3" id="ixv-89669" unitRef="pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c19" decimals="3" id="ixv-89670" unitRef="pure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes contextRef="c18" decimals="3" id="ixv-89671" unitRef="pure">-0.273</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes contextRef="c19" decimals="3" id="ixv-89672" unitRef="pure">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c18" decimals="3" id="ixv-89673" unitRef="pure">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c19" decimals="3" id="ixv-89674" unitRef="pure">-0.272</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c18" decimals="3" id="ixv-89675" unitRef="pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c19" decimals="3" id="ixv-89676" unitRef="pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c18" id="ixv-61879">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s components of deferred taxes
as of December 31, 2024 and 2023 were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31,&lt;br/&gt;
 2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, &lt;br/&gt;
2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 76%; text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,598,257&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,501,507&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Disallowed business interest deduction&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-350"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,476&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Research and development expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;106,783&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;130,823&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Accrued directors&#x2019; compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104,977&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165,490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Accrued settlement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,904&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;126,496&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Partnership Investment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,167,965&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,422,744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,687&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,935&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Capital loss limitation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;149,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;149,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Net operating loss carryforward&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,648,077&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15,493,570&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left"&gt;Total deferred tax assets, gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,918,044&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,020,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,784,638&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,871,551&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Total deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;133,406&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;148,884&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left"&gt;Fixed assets and intangible assets book/tax basis difference&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(133,406&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(129,636&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-351"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19,248&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Total deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(133,406&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(148,884&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-352"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-353"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c1" decimals="0" id="ixv-89677" unitRef="usd">1598257</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c2" decimals="0" id="ixv-89678" unitRef="usd">3501507</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetInterestCarryforward contextRef="c2" decimals="0" id="ixv-89679" unitRef="usd">9476</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c1" decimals="0" id="ixv-89680" unitRef="usd">106783</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c2" decimals="0" id="ixv-89681" unitRef="usd">130823</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c1" decimals="0" id="ixv-89682" unitRef="usd">104977</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c2" decimals="0" id="ixv-89683" unitRef="usd">165490</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c1" decimals="0" id="ixv-89684" unitRef="usd">140904</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c2" decimals="0" id="ixv-89685" unitRef="usd">126496</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <avco:DeferredTaxAssetsPartnershipInvestment contextRef="c1" decimals="0" id="ixv-89686" unitRef="usd">2167965</avco:DeferredTaxAssetsPartnershipInvestment>
    <avco:DeferredTaxAssetsPartnershipInvestment contextRef="c2" decimals="0" id="ixv-89687" unitRef="usd">2422744</avco:DeferredTaxAssetsPartnershipInvestment>
    <us-gaap:DeferredTaxAssetsOther contextRef="c1" decimals="0" id="ixv-89688" unitRef="usd">1687</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c2" decimals="0" id="ixv-89689" unitRef="usd">20935</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c1" decimals="0" id="ixv-89690" unitRef="usd">149394</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c2" decimals="0" id="ixv-89691" unitRef="usd">149394</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c1" decimals="0" id="ixv-89692" unitRef="usd">17648077</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c2" decimals="0" id="ixv-89693" unitRef="usd">15493570</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross contextRef="c1" decimals="0" id="ixv-89694" unitRef="usd">21918044</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c2" decimals="0" id="ixv-89695" unitRef="usd">22020435</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c1" decimals="0" id="ixv-89696" unitRef="usd">21784638</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c2" decimals="0" id="ixv-89697" unitRef="usd">21871551</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c1" decimals="0" id="ixv-89698" unitRef="usd">133406</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c2" decimals="0" id="ixv-89699" unitRef="usd">148884</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesOtherFiniteLivedAssets contextRef="c1" decimals="0" id="ixv-89700" unitRef="usd">133406</us-gaap:DeferredTaxLiabilitiesOtherFiniteLivedAssets>
    <us-gaap:DeferredTaxLiabilitiesOtherFiniteLivedAssets contextRef="c2" decimals="0" id="ixv-89701" unitRef="usd">129636</us-gaap:DeferredTaxLiabilitiesOtherFiniteLivedAssets>
    <us-gaap:DeferredTaxLiabilitiesRegulatoryAssets contextRef="c2" decimals="0" id="ixv-89702" unitRef="usd">19248</us-gaap:DeferredTaxLiabilitiesRegulatoryAssets>
    <us-gaap:DeferredTaxLiabilities contextRef="c1" decimals="0" id="ixv-89703" unitRef="usd">133406</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c2" decimals="0" id="ixv-89704" unitRef="usd">148884</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards contextRef="c1" decimals="0" id="ixv-89705" unitRef="usd">60926204</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c2" decimals="0" id="ixv-89706" unitRef="usd">52929248</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="c1" decimals="0" id="ixv-89707" unitRef="usd">58438649</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c1" decimals="0" id="ixv-89708" unitRef="usd">2487555</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="c140" decimals="0" id="ixv-89709" unitRef="usd">2086886</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c1" decimals="0" id="ixv-89710" unitRef="usd">61847</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries contextRef="c18" id="ixv-89711">$10,000</us-gaap:DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="c18" id="ixv-62118">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 15 -&#160;&lt;span style="text-decoration:underline"&gt;EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company is authorized
to issue an aggregate of&#160;100,000,000&#160;shares of common stock and&#160;10,000,000&#160;shares of &#x201c;blank check&#x201d; preferred
stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Series A Convertible
Preferred Stock&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company designated
up to 15,000 shares of its previously undesignated preferred stock as Series A Preferred Stock. Each share of Series A Preferred Stock
has a par value of $0.0001 per share and a stated value equal to $1,000.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The shares of Series
A Preferred Stock have identical terms and include the terms as set forth below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Dividends.&lt;/i&gt;&#160;The Series A Holders are
entitled to receive, and the Company shall pay, dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-common-stock
basis, disregarding for such purpose any conversion limitations set forth in the Series A Certificate of Designations) to and in the same
form as dividends actually paid on shares of the Company&#x2019;s common stock when, as and if such dividends are paid on shares of the
common stock. No other dividends shall be paid on shares of Series A Preferred Stock. The Company will not pay any dividends on its common
stock unless the Company simultaneously complies with the terms set forth in the Series A Certificate of Designation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Liquidation.&lt;/i&gt;&#160;Upon any dissolution,
liquidation or winding-up of the Company, whether voluntary or involuntary (a &#x201c;Liquidation&#x201d;), the Series A Holders will be
entitled to receive out of the assets available for distribution to the stockholders, (i) after and subject to the payment in full of
all amounts required to be distributed to the holders of another class or series of stock of the Company ranking on liquidation prior
and in preference to the Series A Preferred Stock, (ii) ratably with any class or series of stock ranking on liquidation on parity with
the Series A Preferred Stock and (iii) in preference and priority to the holders of the shares of the Company&#x2019;s common stock, an
amount equal to 100% of the Series A Stated Value, and no more, in proportion to the full and preferential amount that all shares of the
Series A Preferred Stock are entitled to receive. The Company shall mail written notice of any Liquidation not less than twenty (20) days
prior to the payment date stated therein, to each Series A Holder.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Conversion.&lt;/i&gt;&#160;Each share of Series A
Preferred Stock shall be convertible, at any time and from time to time from and after the later of (i) the date of the stockholder approval
as described above, in accordance with the Nasdaq Stock Market Listing Rules, and (ii) the&#160;nine&#160;(9) month anniversary of the
Closing (the &#x201c;Initial Conversion Date&#x201d;), at the option of the Series A Holder, into that number of shares of common stock
(subject to the limitations set forth in Series A Certificate of Designations, determined by dividing the Stated Value of such share of
Series A Preferred Stock by the Conversion Price (as defined below)). The Series A Holders may effect conversions by providing the Company
with the form of conversion notice attached as Annex A to the Series A Certificate of Designation. The Series A Holders may convert such
shares into shares of the Company&#x2019;s common stock at a conversion price per share equal to the greater of (i) one hundred fifty dollars
($150.0) and (ii) ninety percent (90%) of the closing price of the Company&#x2019;s common stock on Nasdaq on the day prior to receipt
of a conversion notice (collectively, the &#x201c;Conversion Price&#x201d;), subject to adjustment for stock splits and similar matters.
In addition, following the Initial Conversion Date, each Series A Holder agrees that it shall not be entitled to in any calendar month,
sell a number of Series A Conversion Shares into the open market in an amount exceeding more than ten percent (10%) of the number of Series
A Conversion Shares issuable upon conversion of the Series A Preferred Stock then held by such Series A Holder.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Conversion Price Adjustment:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Stock Dividends and Stock Splits.&lt;/i&gt;&#160;If
the Company, at any time while the Series A Preferred Stock is outstanding: (i) pays a stock dividend or otherwise makes a distribution
or distributions payable in shares of common stock on shares of common stock or any other common stock equivalents (which, for avoidance
of doubt, shall not include any shares of common stock issued by the Company upon conversion of, or payment of a dividend on, the Series
A Preferred Stock), (ii) subdivides outstanding shares of common stock into a larger number of shares, (iii) combines (including by way
of a reverse stock split) outstanding shares of common stock into a smaller number of shares, or (iv) issues, in the event of a reclassification
of shares of the common stock, any shares of capital stock of the Company, then the conversion price of the Series A Preferred Stock shall
be multiplied by a fraction of which the numerator shall be the number of shares of common stock (excluding any treasury shares of the
Company) outstanding immediately before such event, and of which the denominator shall be the number of shares of common stock outstanding
immediately after such event. Any of the foregoing adjustments shall become effective immediately after the record date for the determination
of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the
case of a subdivision, combination or re-classification.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Fundamental Transaction.&lt;/i&gt;&#160;If, at any
time while the Series A Preferred Stock is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another individual or corporation, partnership, trust, incorporated or unincorporated
association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other
entity of any kind (a &#x201c;Person&#x201d;), (ii) the Company (and all of its subsidiaries, taken as a whole), directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company
or another Person) is completed pursuant to which holders of the Company&#x2019;s common stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of fifty percent (50%) or more of the outstanding
common stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the common stock or any compulsory share exchange pursuant to which the common stock is effectively converted into
or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates
a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than fifty percent (50%) of the outstanding
shares of common stock (not including any shares of common stock held by the other Person or other Persons making or party to, or associated
or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a
&#x201c;Fundamental Transaction&#x201d;), then, the Series A Holder shall have the right to receive, for each conversion share that would
have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation
set forth in the Series A Certificate of Designation on the conversion of the Series A Preferred Stock), the number of shares of common
stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and/or any additional consideration
(the &#x201c;Alternate Consideration&#x201d;) receivable as a result of such Fundamental Transaction by a holder of the number of shares
of common stock for which the Series A Preferred Stock is convertible immediately prior to such Fundamental Transaction (without regard
to the limitations set forth in the Series A Certificate of Designation on the conversion of the Series A Preferred Stock). For purposes
of any such conversion, the determination of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of common stock in such Fundamental Transaction, and the
Company shall apportion the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of
any different components of the Alternate Consideration. If holders of common stock are given any choice as to the securities, cash or
property to be received in a Fundamental Transaction, then the Series A Holder shall be given the same choice as to the Alternate Consideration
it receives upon such Fundamental Transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Voting Rights.&lt;/i&gt;&#160;The Series A Holders
will have no voting rights, except as otherwise required by the Delaware General Corporation Law. Notwithstanding the foregoing, as long
as any shares of Series A Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority
of the then outstanding shares of Series A Preferred Stock, voting as a separate class, (a) alter or change adversely the powers, preferences
or rights given to the Series A Preferred Stock in the Series A Certificate of Designation, (b) increase the number of authorized shares
of Series A Preferred Stock, (c) authorize or issue an additional class or series of capital stock that ranks senior to the Series A Preferred
Stock with respect to the distribution of assets on liquidation or (d) enter into any agreement with respect to any of the foregoing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Fractional Shares.&lt;/i&gt;&#160;No
fractional shares or scrip representing fractional shares shall be issued upon the conversion of the Series A Preferred Stock. As to any
fraction of a share of Company common stock which a Series A Holder would otherwise be entitled to upon such conversion, the Company will,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Conversion Price or round up to the next whole share. Notwithstanding the foregoing, nothing shall prevent any Series A Holder from converting
fractional shares of Series A Preferred Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;As of December 31, 2024
and 2023, 9,000 shares of Series A Preferred Stock were issued and outstanding. On January 9, 2025, the 9,000 shares of Series A Preferred
Stock were exchanged for 5,000 shares of Series D Preferred Stock of the Company (see Note 22 - Subsequent Events - Series D Convertible
Preferred Stock).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Series B Convertible
Preferred Stock&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company designated
up to 15,000 shares of its previously undesignated preferred stock as Series B Preferred Stock. Each share of Series B Preferred Stock
has a par value of $0.0001 per share and a stated value equal to $1,000.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The shares of Series
B Preferred Stock have identical terms and include the terms as set forth below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Dividends.&lt;/i&gt;&#160;The Series B Holders shall
be entitled to receive, and the Company shall pay, dividends on shares of Series B Preferred Stock equal (on an as-if-converted-to-common-stock
basis, disregarding for such purpose any conversion limitations set forth in the Series B Certificate of Designations) to and in the same
form as dividends actually paid on shares of the Company&#x2019;s common stock when, as and if such dividends are paid on shares of the
common stock. No other dividends shall be paid on shares of Series B Preferred Stock. The Company will not pay any dividends on its common
stock unless the Company simultaneously complies with the terms set forth in the Series B Certificate of Designation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Rank.&lt;/i&gt;&#160;The Series B Preferred Stock
will rank subordinate to the shares of the Company&#x2019;s Series A Preferred Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Liquidation.&#160;&lt;/i&gt;Upon any Liquidation,
the Series B Holders will be entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to
the payment in full of all amounts required to be distributed to the holders of another class or series of stock of the Company ranking
on liquidation prior and in preference to the Series B Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any
class or series of stock ranking on liquidation on parity with the Series B Preferred Stock and (iii) in preference and priority to the
holders of the shares of common stock, an amount equal to one hundred percent (100%) of the Series B Stated Value and no more, in proportion
to the full and preferential amount that all shares of the Series B Preferred Stock are entitled to receive. The Company shall mail written
notice of any such Liquidation not less than twenty (20) days prior to the payment date stated therein, to each Series B Holder.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Conversion.&lt;/i&gt;&#160;Each share of Series B
Preferred Stock shall be convertible, at any time and from time to time from and after the later of (i) the date of the stockholder approval
and (ii) the one year anniversary of the Closing Date (the &#x201c;Lock Up Period&#x201d;), at the option of the Series B Holder thereof,
into that number of shares of common stock (subject to the limitations set forth in Series B Certificate of Designation determined by
dividing the Series B Stated Value of such share of Series B Preferred Stock by the conversion price of the Series B Preferred Stock).
Series B Holders may effect conversions by providing the Company with the form of conversion notice attached as Annex A to the Series
B Certificate of Designation. The Series B Preferred Stock will be convertible into shares of the Company&#x2019;s common stock at a conversion
price per share equal to $56.70, subject to the adjustments set forth in the Series B Certificate of Designation. Notwithstanding the
foregoing or the transactions contemplated by the Amended MIPA, until the consummation of the Lock Up Period, the Series B Holders shall
not, directly or indirectly, sell, transfer or otherwise dispose of any Series B Preferred Stock issued upon conversion of the Series
B Conversion Shares or pursuant to the Equity Earnout Payment (the &#x201c;Restricted Securities&#x201d;) without Company&#x2019;s prior
written consent; provided, however, the Series B Holders may sell, transfer or otherwise dispose of Restricted Securities to an Affiliate,
as defined in the Amended MIPA, of a Series B Holder without Company&#x2019;s prior written consent; provided, further, that such Series
B Holder provide prompt written notice to Company of such transfer, including the name and contact information of the Affiliate transferee,
and such Affiliate transferee agrees in writing to be bound by the terms of the transaction documents contemplated by the Amended MIPA
to which the Series B Holder is a party (which agreement shall also be provided to Company with such notice). After the expiration of
the Lock Up Period, the Series B Holder agrees that it and any of its Affiliate transferees shall not be entitled to in any calendar month,
sell a number of shares of Company common stock into the open market in an amount exceeding more than ten percent (10%) of the total number
of shares of Company common stock issuable upon conversion of the Company common stock then held by the Seller and its Affiliates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Conversion Price Adjustment:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Stock Dividends and Stock Splits.&lt;/i&gt;&#160;If
the Company, at any time while the Series B Preferred Stock is outstanding: (i) pays a stock dividend or otherwise makes a distribution
or distributions payable in shares of common stock on shares of common stock or any other common stock equivalents (which, for avoidance
of doubt, shall not include any shares of common stock issued by the Company upon conversion of, or payment of a dividend on, the Series
B Preferred Stock), (ii) subdivides outstanding shares of common stock into a larger number of shares, (iii) combines (including by way
of a reverse stock split) outstanding shares of common stock into a smaller number of shares, or (iv) issues, in the event of a reclassification
of shares of the common stock, any shares of capital stock of the Company, then the conversion price of the Series B Preferred Stock shall
be multiplied by a fraction of which the numerator shall be the number of shares of common stock (excluding any treasury shares of the
Company) outstanding immediately before such event, and of which the denominator shall be the number of shares of common stock outstanding
immediately after such event. Any of the foregoing adjustments shall become effective immediately after the record date for the determination
of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the
case of a subdivision, combination or re-classification.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Fundamental Transaction.&lt;/i&gt;&#160;If, at any
time while the Series B Preferred Stock is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another Person, (ii) the Company (and all of its subsidiaries, taken as a whole),
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of the Company&#x2019;s common stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of fifty percent
(50%) or more of the outstanding common stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any
reclassification, reorganization or recapitalization of the common stock or any compulsory share exchange pursuant to which the common
stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in
one or more related transactions consummates a Fundamental Transaction, then, at the closing of such Fundamental Transaction, without
any action on the part of the Series B Holder, the Series B Holder shall have the right to receive, for each conversion share that would
have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation
in the Series B Certificate of Designation on the conversion of the Series B Preferred Stock), the number of shares of common stock of
the successor or acquiring corporation or of the Company, if it is the surviving corporation, and/or any Alternate Consideration receivable
as a result of such Fundamental Transaction by a holder of the number of shares of common stock for which the Series B Preferred Stock
is convertible immediately prior to such Fundamental Transaction (without regard to the limitations set forth in the Series B Certificate
of Designation on the conversion of the Series B Preferred Stock). For purposes of any such conversion, the determination of the conversion
price of the Series B Preferred Stock shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of
Alternate Consideration issuable in respect of one share of common stock in such Fundamental Transaction, and the Company shall apportion
the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of common stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Series B Holder shall be given the same choice as to the Alternate Consideration it receives upon
such Fundamental Transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Voting Rights&lt;/i&gt;. The Series B Holders will
have no voting rights, except as otherwise required by the Delaware General Corporation Law. Notwithstanding the foregoing, in addition,
as long as any shares of Series B Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders
of a majority of the then outstanding shares of the Series B Preferred Stock, voting as a separate class, (a) alter or change adversely
the powers, preferences or rights given to the Series B Preferred Stock in the Series B Certificate of Designation, (b) increase the number
of authorized shares of Series B Preferred Stock, (c) except with respect to the Series A Preferred Stock, authorize or issue an additional
class or series of capital stock that ranks senior to the Series B Preferred Stock with respect to the distribution of assets on liquidation
or (d) enter into any agreement with respect to any of the foregoing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Fractional Shares.&lt;/i&gt;
No fractional shares or scrip representing fractional shares shall be issued upon the conversion of the Series B Preferred Stock. As to
any fraction of a share which a Series B Holder would otherwise be entitled to upon such conversion, the Company shall at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price
or round up to the next whole share. Notwithstanding the foregoing, nothing shall prevent any Series B Holder from converting fractional
shares of Series B Preferred Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;As of December 31, 2024
and 2023, 11,000 shares of Series B Preferred Stock were issued and outstanding. On February 26, 2025, all shares of the Company&#x2019;s
Series B Convertible Preferred Stock were permanently surrendered and relinquished to the Company for no additional consideration (see
Note 22 - Subsequent Events - Redemption Agreement).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Series C Convertible
Preferred Stock&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On December 13, 2024,
the Company filed a certificate of designations of preferences, rights, and limitations of Series C Convertible Preferred Stock (the &#x201c;Series
C Certificate of Designations&#x201d;) with the Department of State, Division of Corporations, of the State of Delaware, which provides
for the designation of 10,000 shares of Series C Preferred Stock of the Company, par value $0.0001 per share. Each share of Series C Preferred
Stock has a stated value of $1,000.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Series C Preferred
Stock shall rank (i) senior to the Company&#x2019;s common stock (the &#x201c;Common Stock&#x201d;) and any other class or series of capital
stock of the Company created hereafter, the terms of which specifically provide that such class or series shall rank junior to the Series
C Preferred Stock, (ii) pari passu with any class or series of capital stock of the Company created hereafter specifically ranking, by
its terms, on par with the Series C Preferred Stock, (iii) pari passu with Series B Convertible Preferred Stock of the Company (the &#x201c;Series
B Preferred Stock&#x201d;) with respect to its rights, preferences and restrictions, and (iv) subordinate to the Series A Convertible Preferred
Stock of the Company (the &#x201c;Series A Preferred Stock&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Holders of the Series
C Preferred Stock shall be entitled to receive, and the Company shall pay, dividends on shares of Series C Preferred Stock equal (on an
as-if-converted-to-Common-Stock basis, disregarding for such purpose any conversion limitations hereunder) to and in the same form as
dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Holders of the Series
C Preferred Stock have no voting power except as otherwise required by the Delaware General Corporation Law.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Upon any liquidation,
dissolution or winding-up of the Company, whether voluntary or involuntary (a &#x201c;Liquidation&#x201d;), the holders of the Series C
Preferred Stock shall be entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to the
payment in full of all amounts required to be distributed to the holders of another class or series of stock of the Company ranking on
liquidation prior and in preference to the Series C Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any class
or series of stock ranking on liquidation on parity with the Series C Preferred Stock and (iii) in preference and priority to the holders
of the shares of Common Stock, an amount equal to 100% of the Stated Value of the Series C Preferred Stock, in proportion to the full
and preferential amount that all shares of the Series C Preferred Stock are entitled to receive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Each share of Series
C Preferred Stock shall be convertible into Common Stock (the &#x201c;Conversion Shares&#x201d;) at a conversion per share equal to $2.41,
at the option of the holder, at any time after the later of (i) the date of the shareholder approval of the issuance of the Conversion
Shares pursuant to the rules of the Nasdaq Stock Market and (ii) the one year anniversary of the date of the first issuance of any shares
of the Series C Preferred Stock. In addition, the holder shall not have the right to convert any portion of the Series C Preferred Stock
if, after giving effect to the conversion, such holder (together with its affiliates) would beneficially own in excess of 19.99% of the
number of shares of the Common Stock outstanding immediately after giving effect to the issuance of the respective Conversion Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;As of December 31, 2024,
3,500 shares of Series C Preferred Stock were issued and outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Series B Convertible
Preferred Stock Issued for Equity Method Investment&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 9, 2023, the Company issued 11,000 shares of its Series
B Convertible Preferred Stock as a part of consideration for the purchase of 40% of equity interest of Lab Services MSO. The Series B
Preferred Stock is convertible into shares of the Company&#x2019;s common stock at a conversion price per share equal to $56.70, which
approximated the market price at the date of closing, or an aggregate of 194,004 shares of the Company&#x2019;s common stock and are subject
to a lock-up period and restrictions on sale.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Series C Convertible
Preferred Stock Sold for Cash&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;During the year ended December 31, 2024, the Company sold an aggregate
of 3,500 shares of Series C Convertible Preferred stock and received proceeds of $3,500,000. Each share of Series C Convertible Preferred
Stock is convertible into common stock of the Company (the &#x201c;Conversion Shares&#x201d;) at a conversion per share equal to $2.41,
which approximated the market price at the date of transaction, at the option of the holder, at any time after the later of (i) the date
of the shareholder approval of the issuance of the Conversion Shares pursuant to the rules of the Nasdaq Stock Market (the &#x201c;Shareholder
Approval&#x201d;) and (ii) the one year anniversary of the date of the first issuance of any shares of the Series C Convertible Preferred
Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company evaluated
the features of the Series C Convertible Preferred Stock under ASC 480, and classified them as permanent equity because the Series C Convertible
Preferred Stock is not mandatorily or contingently redeemable at the stockholder&#x2019;s option and the liquidation preference that exists
does not fall within the guidance of SEC Accounting Series Release No. 268 -&#160;&lt;i&gt;Presentation in Financial Statements of &#x201c;Redeemable
Preferred Stocks&#x201d;&lt;/i&gt;&#160;(&#x201c;ASR 268&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Common Shares Issued
as Convertible Note Payable Commitment Fee&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;During the year ended
December 31, 2023, the Company issued a total of 11,333 shares of its common stock as commitment fee for the purchases of May 2023 Convertible
Note, July 2023 Convertible Note, and October 2023 Convertible Note. These shares were valued at $236,400, the fair market values on the
grant dates using the reported closing share prices on the dates of grant, and the Company recorded it as debt discount.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;During the year ended
December 31, 2024, the Company issued a total of&#160;33,800&#160;shares of its common stock as commitment fee for the purchase of March
2024 Convertible Note and June 2024 Convertible Note. These shares were valued at $320,546, the fair market value on the grant dates using
the reported closing share prices on the dates of grant, and the Company recorded it as debt discount.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Common Shares Sold
for Cash&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June 2023, the Company entered into a sales
agreement (the &#x201c;Sales Agreement&#x201d;) with Roth Capital Partners, LLC (&#x201c;Roth&#x201d;) under which the Company may offer and
sell from time to time shares of its common stock having an aggregate offering price of up to $3.5&#160;million. During the year ended
December 31, 2023, Roth sold an aggregate of&#160;30,442&#160;shares of common stock at an average price of $20.85&#160;per share to investors
and the Company recorded net proceeds of $414,396, net of commission and other offering costs of $220,995.&#160;During the year ended
December 31, 2024, Roth sold an aggregate of&#160;281,843&#160;shares of common stock at an average price of $10.14&#160;per share to
investors and the Company recorded net proceeds of $2,544,311, net of commission and other offering costs of $313,541.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Common Shares Issued for Services&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;During the
year ended December 31, 2023, the Company issued a total of 24,089 shares of its common stock for services rendered. These shares were
valued at $999,655, the fair market values on the grant dates using the reported closing share prices on the dates of grant, and the Company
recorded stock-based compensation expense of $834,784 for the year ended December 31, 2023 and reduced accrued liabilities of $164,871.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2024, the Company
issued a total of 145,153 shares of its common stock for services rendered. These shares were valued at $530,350, the fair market values
on the grant dates using the reported closing share prices on the dates of grant, and the Company recorded stock-based compensation expense
of $470,350 for the year ended December 31, 2024 and reduced accrued liabilities of $60,000.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Common Shares Issued
for Warrant Exercise&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On November 18, 2024,
the Company issued 42,381 shares of its common stock upon cashless exercise of warrants to purchase 6,278 shares of common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Common Shares Issued
for Adjustment for 1:15 Reverse Split&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company issued 206,033
shares of its common stock, resulting from the rounding up of the fractional shares at the one-for-fifteen reverse stock split effected
on October 28, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Pre-Funded Warrants
Issued for Debt Modification&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On December 15, 2024,
the Company issued to Mast Hill a common stock purchase warrant for the purchase of up to 150,000 shares of the Company&#x2019;s common
stock. The Pre-Funded Warrants are immediately exercisable at issuance and until the Pre-Funded Warrants are exercised in full and have
an exercise price of $0.01 per share. The Pre-Funded Warrants were classified as a component of permanent equity as they are freestanding
financial instrument that is immediately exercisable, does not embody an obligation for the Company to repurchase its own shares and permit
the holder to receive a fixed number of shares of common stock upon exercise.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The following table summarizes
the shares of the Company&#x2019;s common stock issuable upon exercise of options outstanding at December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Range&lt;br/&gt; of Exercise &lt;br/&gt; Price&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number &lt;br/&gt;
Outstanding at&lt;br/&gt; December 31, &lt;br/&gt;
2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted Average&lt;/p&gt; &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number Exercisable at&lt;br/&gt; December 31, &lt;br/&gt;
2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Exercise &lt;br/&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;2.93 - 31.20&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;20,198&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;3.54&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;14.76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;14,591&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;16.38&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48.75 - 123.00&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;154.50 - 289.50&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,764&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3.44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;218.21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,764&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;218.21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.93 - 289.50&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;52,479&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.93&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;85.45&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46,872&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;94.41&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Stock option activity
for the years ended December 31, 2024 and 2023 was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Outstanding at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;53,357&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;195.45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,929&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(267.90&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,880&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;149.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,666&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(275.14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;52,479&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;85.45&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Options exercisable at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,872&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;94.41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options expected to vest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10.56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The aggregate intrinsic value of stock options
outstanding and stock options exercisable at December 31, 2024 was approximately $1,900&#160;an $900, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The fair values of options granted during
the year ended December 31, 2024 were estimated at the date of grant using the Black-Scholes option-pricing model with the following
assumptions: volatility of&#160;83.10% -&#160;96.36%, risk-free rate of&#160;3.47% -&#160;4.79%, annual dividend yield of&#160;0%, and
expected life of&#160;3.00 - 5.00&#160;years. The aggregate fair value of the options granted during the year ended December 31, 2024
was $28,694.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The fair values of options granted during
the year ended December 31, 2023 were estimated at the date of grant using the Black-Scholes option-pricing model with the following
assumptions: volatility of&#160;79.76% -&#160;96.37%, risk-free rate of&#160;3.58% -&#160;4.76%, annual dividend yield of&#160;0%, and
expected life of&#160;3.00&#160;-&#160;5.00&#160;years. The aggregate fair value of the options granted during the year ended December
31, 2023 was $319,380.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the years ended December 31, 2024 and 2023,
stock-based compensation expense associated with stock options granted amounted to $51,159&#160;and $284,977, of which, $19,878&#160;and
$172,943&#160;was recorded as compensation and related benefits, $31,281&#160;and $106,565&#160;was recorded as professional fees, and
$0&#160;and $5,469&#160;was recorded as research and development expenses, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of the status of the Company&#x2019;s
nonvested stock options granted as of December 31, 2024 and changes during the years ended December 31, 2024 and 2023 is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Nonvested at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,334&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;64.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,475&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(47.14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Nonvested at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,311&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,969&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10.90&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Nonvested at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,607&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10.56&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Warrants (Except Pre-Funded Warrants)&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the shares of the
Company&#x2019;s common stock issuable upon exercise of warrants outstanding at December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Warrants Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Warrants Exercisable&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Range of&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number&lt;br/&gt; Outstanding at &lt;br/&gt;
December 31, &lt;br/&gt;
2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number&lt;br/&gt; Exercisable at&lt;br/&gt; December 31&lt;br/&gt;
, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;Weighted Average Exercise&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13.5%; text-align: right"&gt;7.50 - 37.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;165,510&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4.40&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13.5%; text-align: right"&gt;10.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13.5%; text-align: right"&gt;85,510&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13.5%; text-align: right"&gt;13.31&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;187.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2.30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;187.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;187.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.50 - 187.50&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;182,996&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.25&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;102,996&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;32.13&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Stock warrant activity
for the years ended December 31, 2024 and 2023 was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number of Warrants&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Outstanding at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,264&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;187.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Issued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;34,771&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48.90&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43,035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;169,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled (*)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(23,288&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(32.85&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,278&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(50.77&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;182,996&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants exercisable at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;32.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants expected to vest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;*&lt;/td&gt;&lt;td style="text-align: justify"&gt;Second Warrant, which was issued on May 23, 2023, July 6,
2023, October 9, 2023, and March 7, 2024, was cancelled in June 2024. Second Warrant, which was issued on June 5, 2024, is still outstanding
as of December 31, 2024.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The aggregate intrinsic value of both stock warrants
outstanding and stock warrants exercisable at December 31, 2024 was $0.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Warrants Issued in
May 2023&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In connection with the
issuance of May 2023 Convertible Note (See Note 10), the Company issued (i) a warrant to purchase 8,333 shares of common stock with an
exercise price of $67.50 exercisable until the five-year anniversary of May 23, 2023, and (ii) a warrant to purchase 7,033 shares of common
stock with an exercise price of $48.00 exercisable until the five-year anniversary of May 23, 2023, which warrant was never fair valued
and was cancelled and extinguished against payment of the May 2023 Convertible Note, to Mast Hill; and issued a warrant to purchase 667
shares of common stock with an exercise price of $67.50 exercisable until the five-year anniversary of May 23, 2023 to a third party as
a finder&#x2019;s fee.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Based upon the Company&#x2019;s
analysis of the criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a
finder&#x2019;s fee meet the definition of derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances.
Accordingly, the fair value of the 9,000 warrants with an exercise price of $67.50 exercisable until the five-year anniversary of May
23, 2023 was classified as derivative liability on May 23, 2023. The fair values of the 9,000 warrants with an exercise price of $67.50
exercisable until the five-year anniversary of May 23, 2023 issued on May 23, 2023 were computed using the Black-Scholes option-pricing
model with the following assumptions: stock price of $29.40, volatility of 88.80%, risk-free rate of 3.76%, annual dividend yield of 0%
and expected life of 5 years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The warrants with an
exercise price of $67.50 exercisable until the five-year anniversary of May 23, 2023 issued to Mast Hill to purchase 8,333 shares of the
Company&#x2019;s common stock were treated as a discount on the convertible note payable and were valued at $127,654 and were amortized
over the term of the May 2023 Convertible Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The warrants with an
exercise price of $67.50 exercisable until the five-year anniversary of May 23, 2023 issued to a third party as a finder&#x2019;s fee to
purchase 667 shares of the Company&#x2019;s common stock were treated as convertible debt issuance costs and were valued at $11,162 and
were amortized over the term of the May 2023 Convertible Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Warrants Issued in
July 2023&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In connection with the
issuance of July 2023 Convertible Note (See Note 10), the Company issued (i) a warrant to purchase 2,778 shares of common stock with an
exercise price of $67.50 exercisable until the five-year anniversary of July 6, 2023, and (ii) a warrant to purchase 2,344 shares of common
stock with an exercise price of $48.00 exercisable until the five-year anniversary of July 6, 2023, which warrant was never fair valued
and was cancelled and extinguished against payment of the July 2023 Convertible Note, to Firstfire; and issued a warrant to purchase 222
shares of common stock with an exercise price of $67.50 exercisable until the five-year anniversary of July 6, 2023 to a third party as
a finder&#x2019;s fee.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Based upon the Company&#x2019;s
analysis of the criteria contained in ASC 815, the Company determined that all the warrants issued to Firstfire and a third party as a
finder&#x2019;s fee meet the definition of derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances.
Accordingly, the fair value of the 3,000 warrants with an exercise price of $67.50 exercisable until the five-year anniversary of July
6, 2023 was classified as derivative liability on July 6, 2023. The fair values of the 3,000 warrants with an exercise price of $67.50
exercisable until the five-year anniversary of July 6, 2023 issued on July 6, 2023 were computed using the Black-Scholes option-pricing
model with the following assumptions: stock price of $21.30, volatility of 88.52%, risk-free rate of 4.37%, annual dividend yield of 0%
and expected life of 5 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The warrants with an
exercise price of $67.50 exercisable until the five-year anniversary of July 6, 2023 issued to Firstfire to purchase 2,778 shares of the
Company&#x2019;s common stock were treated as a discount on the convertible note payable and were valued at $28,691 and were amortized
over the term of the July 2023 Convertible Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The warrants with an exercise price of $67.50
exercisable until the five-year anniversary of July 6, 2023 issued to a third party as a finder&#x2019;s fee to purchase 222 shares of
the Company&#x2019;s common stock were treated as convertible debt issuance costs and were valued at $2,435 and were amortized over the
term of the July 2023 Convertible Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Warrants Issued in
October 2023&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In connection with the
issuance of October 2023 Convertible Note (See Note 10), the Company issued (i) a warrant to purchase 7,000 shares of common stock with
an exercise price of $37.50 exercisable until the five-year anniversary of October 9, 2023, (ii) a warrant to purchase 5,834 shares of
common stock with an exercise price of $27.00 exercisable until the five-year anniversary of October 9, 2023, which warrant was never
fair valued and was cancelled and extinguished against payment of the October 2023 Convertible Note, to Mast Hill and Firstfire; and issued
a warrant to purchase 560 shares of common stock with an exercise price of $37.50 exercisable until the five-year anniversary of October
9, 2023 to a third party as a finder&#x2019;s fee.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Based upon the Company&#x2019;s analysis of the
criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and Firstfire and a third party as a finder&#x2019;s
fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances. Accordingly,
the fair value of the 7,560 warrants with an exercise price of $37.50 exercisable until the five-year anniversary of October 9, 2023 was
classified as a derivative liability on October 9, 2023. The fair values of the 7,560 warrants with an exercise price of $37.50 exercisable
until the five-year anniversary of October 9, 2023 issued on October 9, 2023 were computed using the Black-Scholes option-pricing model
with the following assumptions: stock price of $11.55, volatility of 89.70%, risk-free rate of 4.75%, annual dividend yield of 0% and
expected life of 5 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The warrants with an
exercise price of $37.50 exercisable until the five-year anniversary of October 9, 2023 issued to Mast Hill and Firstfire to purchase
7,000 shares of the Company&#x2019;s common stock were treated as a discount on the convertible note payable and were valued at $39,848
and were amortized over the term of the October 2023 Convertible Note.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The warrants with an exercise price of $37.50
exercisable until the five-year anniversary of October 9, 2023 issued to a third party as a finder&#x2019;s fee to purchase 560 shares
of the Company&#x2019;s common stock were treated as convertible debt issuance costs and were valued at $3,380 and were amortized over
the term of the October 2023 Convertible Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Warrants Issued in
March 2024&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In connection with the
issuance of March 2024 Convertible Note (See Note 10), the Company issued&#160;(i) a warrant to purchase 8,750 shares of common stock
with an exercise price of $30.00 exercisable until the five-year anniversary of March 7, 2024 (&#x201c;First Warrant&#x201d;), (ii) a warrant
to purchase 8,077 shares of common stock with an exercise price of $19.50 (&#x201c;Second Warrant&#x201d;), which warrant was never fair
valued and was cancelled and extinguished against payment of the March 2024 Convertible Note, to Mast Hill; and issued a warrant to purchase
700 shares of common stock with an exercise price of $30.00 exercisable until the five-year anniversary of March 7, 2024 to a third party
as a finder&#x2019;s fee.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Based upon the Company&#x2019;s
analysis of the criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a
finder&#x2019;s fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances.
The fair value of the&#160;9,450&#160;warrants with an exercise price of $30.00&#160;exercisable until the five-year anniversary of March
7, 2024 was classified as a derivative liability on March 7, 2024. The fair values of the&#160;9,450&#160;warrants with an exercise price
of $30.00&#160;exercisable until the five-year anniversary of March 7, 2024 issued on March 7, 2024 were computed using the Black-Scholes
option-pricing model with the following assumptions: stock price of $6.00, volatility of&#160;85.24%, risk-free rate of&#160;4.07%, annual
dividend yield of&#160;0% and expected life of&#160;5&#160;years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The warrants with an
exercise price of $30.00&#160;exercisable until the five-year anniversary of March 7, 2024 issued to Mast Hill to purchase&#160;8,750&#160;shares
of the Company&#x2019;s common stock were treated as a discount on the convertible note payable and were valued at $20,374&#160;and were
amortized over the term of the March 2024 Convertible Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The warrants with an
exercise price of $30.00&#160;exercisable until the five-year anniversary of March 7, 2024 issued to a third party as a finder&#x2019;s
fee to purchase&#160;700&#160;shares of the Company&#x2019;s common stock were treated as convertible debt issuance costs and were valued
at $1,679&#160;and were amortized over the term of the March 2024 Convertible Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Warrants Issued in
June 2024&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the issuance of June 2024 Convertible
Note (See Note 10), the Company issued&#160;(i) a warrant to purchase 66,667 shares of common stock with an exercise price of $9.75 exercisable
until the five-year anniversary of June 5, 2024 (&#x201c;First Warrant&#x201d;), (ii) a warrant to purchase 80,000 shares of common stock
with an exercise price of $7.50 exercisable until the five-year anniversary of June 5, 2024 (&#x201c;Second Warrant&#x201d;), which warrant
shall be cancelled and extinguished against payment of the June 2024 Convertible Note, to Mast Hill; and issued a warrant to purchase
5,333 shares of common stock with an exercise price of $9.75 exercisable until the five-year anniversary of June 5, 2024 to a third party
as a finder&#x2019;s fee.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Based upon the Company&#x2019;s analysis of the
criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a finder&#x2019;s
fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances. Management
determined the probability of failing to make an amortization payment when due to be remote and as such the fair value of the&#160;80,000&#160;warrants
with an exercise price of $7.50&#160;exercisable until the five-year anniversary of June 5, 2024, which warrant shall be cancelled and
extinguished against payment of the June 2024 Convertible Note, has been estimated to be zero. Accordingly, the fair value of the&#160;72,000&#160;warrants
with an exercise price of $9.75&#160;exercisable until the five-year anniversary of June 5, 2024 was classified as a derivative liability
on June 5, 2024. The fair values of the&#160;72,000&#160;warrants with an exercise price of $9.75&#160;exercisable until the five-year
anniversary of June 5, 2024 issued on June 5, 2024 were computed using the Black-Scholes option-pricing model with the following assumptions:
stock price of $10.39, volatility of&#160;85.72%, risk-free rate of&#160;4.31%, annual dividend yield of&#160;0% and expected life of&#160;5&#160;years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The warrants with an exercise price of $9.75&#160;exercisable
until the five-year anniversary of June 5, 2024 issued to Mast Hill to purchase&#160;66,667&#160;shares of the Company&#x2019;s common
stock were treated as a discount on the convertible note payable and were valued at $418,194&#160;and will be amortized over the term
of the June 2024 Convertible Note.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The warrants with an exercise price of $9.75&#160;exercisable
until the five-year anniversary of June 5, 2024 issued to a third party as a finder&#x2019;s fee to purchase&#160;5,333&#160;shares of
the Company&#x2019;s common stock were treated as convertible debt issuance costs and were valued at $39,221&#160;and will be amortized
over the term of the June 2024 Convertible Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Warrants Cancelled
in June 2024&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;As of June 5, 2024, the
Company paid in full of its outstanding May 2023 Convertible Note, July 2023 Convertible Note, October 2023 Convertible Note, and March
2024 Convertible Note and cancelled&#160;23,288&#160;warrants since these convertible notes were fully extinguished.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;i&gt;Warrants Exercised
in November 2024&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On November 18, 2024,
6,278 warrants were cashless exercised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;A summary of the status
of the Company&#x2019;s nonvested stock warrants issued as of December 31, 2024 and changes during the years ended December 31, 2024 and
2023 was presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number of Warrants&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Nonvested at January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-354"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-355"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%"&gt;Issued&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;34,771&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;48.90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19,560&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;55.95&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Nonvested at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;169,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(23,288&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(32.85&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(81,450&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12.10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Nonvested at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;80,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="0"
      id="ixv-89712"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c1"
      decimals="0"
      id="ixv-89713"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c61"
      decimals="0"
      id="ixv-89714"
      unitRef="shares">15000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c61"
      decimals="4"
      id="ixv-89715"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockValue contextRef="c144" decimals="0" id="ixv-89716" unitRef="usd">1000</us-gaap:PreferredStockValue>
    <avco:PercentageOfCommonStockIssuedAndOutstanding
      contextRef="c391"
      decimals="2"
      id="ixv-89717"
      unitRef="pure">1</avco:PercentageOfCommonStockIssuedAndOutstanding>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c5"
      decimals="1"
      id="ixv-89718"
      unitRef="usdPershares">150</us-gaap:PreferredStockConvertibleConversionPrice>
    <avco:ConversionPricePercentage
      contextRef="c391"
      decimals="2"
      id="ixv-89719"
      unitRef="pure">-0.90</avco:ConversionPricePercentage>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="c392"
      decimals="2"
      id="ixv-89720"
      unitRef="pure">0.10</us-gaap:DebtConversionConvertedInstrumentRate>
    <avco:PercentageOfCommonStockIssuedAndOutstanding contextRef="c18" decimals="2" id="ixv-89721" unitRef="pure">-0.50</avco:PercentageOfCommonStockIssuedAndOutstanding>
    <avco:PercentageOfCommonStockIssuedAndOutstanding contextRef="c55" decimals="2" id="ixv-89722" unitRef="pure">-0.50</avco:PercentageOfCommonStockIssuedAndOutstanding>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c55"
      decimals="0"
      id="ixv-89723"
      unitRef="shares">1</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c5"
      decimals="0"
      id="ixv-89724"
      unitRef="shares">9000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="ixv-89725"
      unitRef="shares">9000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c6"
      decimals="0"
      id="ixv-89726"
      unitRef="shares">9000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c6"
      decimals="0"
      id="ixv-89727"
      unitRef="shares">9000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c393"
      decimals="0"
      id="ixv-89728"
      unitRef="shares">9000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c394"
      decimals="0"
      id="ixv-89729"
      unitRef="shares">5000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c395"
      decimals="0"
      id="ixv-89730"
      unitRef="shares">15000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c396"
      decimals="4"
      id="ixv-89731"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockValue contextRef="c396" decimals="0" id="ixv-89732" unitRef="usd">1000</us-gaap:PreferredStockValue>
    <avco:PercentageOfCommonStockIssuedAndOutstanding
      contextRef="c397"
      decimals="2"
      id="ixv-89733"
      unitRef="pure">-1</avco:PercentageOfCommonStockIssuedAndOutstanding>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="c397"
      decimals="2"
      id="ixv-89734"
      unitRef="usdPershares">56.7</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <avco:PercentageOfCommonStockIssuedAndOutstanding
      contextRef="c398"
      decimals="2"
      id="ixv-89735"
      unitRef="pure">-0.50</avco:PercentageOfCommonStockIssuedAndOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c7"
      decimals="0"
      id="ixv-89736"
      unitRef="shares">11000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c7"
      decimals="0"
      id="ixv-89737"
      unitRef="shares">11000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c8"
      decimals="0"
      id="ixv-89738"
      unitRef="shares">11000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c8"
      decimals="0"
      id="ixv-89739"
      unitRef="shares">11000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c399"
      decimals="0"
      id="ixv-89740"
      unitRef="shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c399"
      decimals="4"
      id="ixv-89741"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockValue contextRef="c399" decimals="0" id="ixv-89742" unitRef="usd">1000</us-gaap:PreferredStockValue>
    <avco:PercentageOfCommonStockIssuedAndOutstanding
      contextRef="c400"
      decimals="2"
      id="ixv-89743"
      unitRef="pure">1</avco:PercentageOfCommonStockIssuedAndOutstanding>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c9"
      decimals="2"
      id="ixv-89744"
      unitRef="usdPershares">2.41</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c401"
      decimals="4"
      id="ixv-89745"
      unitRef="pure">0.1999</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c9"
      decimals="0"
      id="ixv-89746"
      unitRef="shares">3500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c9"
      decimals="0"
      id="ixv-89747"
      unitRef="shares">3500</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c402"
      decimals="0"
      id="ixv-89748"
      unitRef="shares">11000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c403"
      decimals="2"
      id="ixv-89749"
      unitRef="pure">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c402"
      decimals="2"
      id="ixv-89750"
      unitRef="usdPershares">56.7</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c402"
      decimals="0"
      id="ixv-89751"
      unitRef="shares">194004</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c54"
      decimals="0"
      id="ixv-89752"
      unitRef="shares">3500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="c54" decimals="0" id="ixv-89753" unitRef="usd">3500000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c63"
      decimals="2"
      id="ixv-89754"
      unitRef="usdPershares">2.41</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c404"
      decimals="0"
      id="ixv-89755"
      unitRef="shares">11333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c404" decimals="0" id="ixv-89756" unitRef="usd">236400</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c405"
      decimals="0"
      id="ixv-89757"
      unitRef="shares">33800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c405" decimals="0" id="ixv-89758" unitRef="usd">320546</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="c406"
      decimals="-5"
      id="ixv-89759"
      unitRef="usd">3500000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c407"
      decimals="0"
      id="ixv-89760"
      unitRef="shares">30442</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <avco:CommonStockOfAveragePrice
      contextRef="c407"
      decimals="2"
      id="ixv-89761"
      unitRef="usdPershares">20.85</avco:CommonStockOfAveragePrice>
    <us-gaap:ProceedsFromOtherEquity contextRef="c407" decimals="0" id="ixv-89762" unitRef="usd">414396</us-gaap:ProceedsFromOtherEquity>
    <avco:OfferingCost contextRef="c408" decimals="0" id="ixv-89763" unitRef="usd">220995</avco:OfferingCost>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c409"
      decimals="0"
      id="ixv-89764"
      unitRef="shares">281843</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <avco:CommonStockOfAveragePrice
      contextRef="c410"
      decimals="2"
      id="ixv-89765"
      unitRef="usdPershares">10.14</avco:CommonStockOfAveragePrice>
    <us-gaap:ProceedsFromOtherEquity contextRef="c410" decimals="0" id="ixv-89766" unitRef="usd">2544311</us-gaap:ProceedsFromOtherEquity>
    <avco:OfferingCost contextRef="c411" decimals="0" id="ixv-89767" unitRef="usd">313541</avco:OfferingCost>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c36"
      decimals="0"
      id="ixv-89768"
      unitRef="shares">24089</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <avco:FairMarketValuesOfGrantDates contextRef="c19" decimals="0" id="ixv-89769" unitRef="usd">999655</avco:FairMarketValuesOfGrantDates>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c19" decimals="0" id="ixv-89770" unitRef="usd">834784</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c19" decimals="0" id="ixv-89771" unitRef="usd">164871</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c412"
      decimals="0"
      id="ixv-89772"
      unitRef="shares">145153</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <avco:FairMarketValuesOfGrantDates contextRef="c412" decimals="0" id="ixv-89773" unitRef="usd">530350</avco:FairMarketValuesOfGrantDates>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c18" decimals="0" id="ixv-89774" unitRef="usd">470350</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c55" decimals="0" id="ixv-89775" unitRef="usd">60000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c413"
      decimals="0"
      id="ixv-89776"
      unitRef="shares">42381</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c414"
      decimals="0"
      id="ixv-89777"
      unitRef="shares">6278</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c415"
      decimals="0"
      id="ixv-89778"
      unitRef="shares">206033</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c416"
      decimals="0"
      id="ixv-89779"
      unitRef="shares">150000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c417"
      decimals="2"
      id="ixv-89780"
      unitRef="usdPershares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="c18" id="ixv-62463">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The following table summarizes
the shares of the Company&#x2019;s common stock issuable upon exercise of options outstanding at December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Range&lt;br/&gt; of Exercise &lt;br/&gt; Price&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number &lt;br/&gt;
Outstanding at&lt;br/&gt; December 31, &lt;br/&gt;
2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted Average&lt;/p&gt; &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number Exercisable at&lt;br/&gt; December 31, &lt;br/&gt;
2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Exercise &lt;br/&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 17%; text-align: right"&gt;2.93 - 31.20&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;20,198&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;3.54&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;14.76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;14,591&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;16.38&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48.75 - 123.00&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,517&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;154.50 - 289.50&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,764&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3.44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;218.21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11,764&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;218.21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.93 - 289.50&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;52,479&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.93&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;85.45&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;46,872&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;94.41&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c471"
      decimals="2"
      id="ixv-89781"
      unitRef="usdPershares">2.93</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c471"
      decimals="2"
      id="ixv-89782"
      unitRef="usdPershares">31.2</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c472"
      decimals="INF"
      id="ixv-89783"
      unitRef="shares">20198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c471" id="ixv-89784">P3Y6M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c472"
      decimals="2"
      id="ixv-89785"
      unitRef="usdPershares">14.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c472"
      decimals="INF"
      id="ixv-89786"
      unitRef="shares">14591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c472"
      decimals="2"
      id="ixv-89787"
      unitRef="usdPershares">16.38</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c473"
      decimals="2"
      id="ixv-89788"
      unitRef="usdPershares">48.75</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c473"
      decimals="2"
      id="ixv-89789"
      unitRef="usdPershares">123</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c474"
      decimals="INF"
      id="ixv-89790"
      unitRef="shares">20517</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c473" id="ixv-89791">P2Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c474"
      decimals="2"
      id="ixv-89792"
      unitRef="usdPershares">78.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c474"
      decimals="INF"
      id="ixv-89793"
      unitRef="shares">20517</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c474"
      decimals="2"
      id="ixv-89794"
      unitRef="usdPershares">78.91</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c475"
      decimals="2"
      id="ixv-89795"
      unitRef="usdPershares">154.5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c475"
      decimals="2"
      id="ixv-89796"
      unitRef="usdPershares">289.5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c476"
      decimals="INF"
      id="ixv-89797"
      unitRef="shares">11764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c475" id="ixv-89798">P3Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c476"
      decimals="2"
      id="ixv-89799"
      unitRef="usdPershares">218.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c476"
      decimals="INF"
      id="ixv-89800"
      unitRef="shares">11764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c476"
      decimals="2"
      id="ixv-89801"
      unitRef="usdPershares">218.21</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c477"
      decimals="2"
      id="ixv-89802"
      unitRef="usdPershares">2.93</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c477"
      decimals="2"
      id="ixv-89803"
      unitRef="usdPershares">289.5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c478"
      decimals="INF"
      id="ixv-89804"
      unitRef="shares">52479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c477" id="ixv-89805">P2Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c478"
      decimals="2"
      id="ixv-89806"
      unitRef="usdPershares">85.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c478"
      decimals="INF"
      id="ixv-89807"
      unitRef="shares">46872</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c478"
      decimals="2"
      id="ixv-89808"
      unitRef="usdPershares">94.41</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="c18" id="ixv-62634">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Stock option activity
for the years ended December 31, 2024 and 2023 was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Outstanding at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;53,357&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;195.45&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,929&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(267.90&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,880&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;149.03&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,666&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(275.14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;52,479&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;85.45&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Options exercisable at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,872&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;94.41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options expected to vest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;10.56&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Stock warrant activity
for the years ended December 31, 2024 and 2023 was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number of Warrants&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Outstanding at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,264&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;187.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Issued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;34,771&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48.90&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43,035&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;75.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;169,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled (*)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(23,288&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(32.85&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,278&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(50.77&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;182,996&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants exercisable at December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102,996&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;32.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants expected to vest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c479"
      decimals="INF"
      id="ixv-89809"
      unitRef="shares">53357</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c479"
      decimals="2"
      id="ixv-89810"
      unitRef="usdPershares">195.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c480"
      decimals="INF"
      id="ixv-89811"
      unitRef="shares">12452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c480"
      decimals="2"
      id="ixv-89812"
      unitRef="usdPershares">35.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c480"
      decimals="INF"
      id="ixv-89813"
      unitRef="shares">8929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c480"
      decimals="2"
      id="ixv-89814"
      unitRef="usdPershares">267.9</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c481"
      decimals="INF"
      id="ixv-89815"
      unitRef="shares">56880</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c481"
      decimals="2"
      id="ixv-89816"
      unitRef="usdPershares">149.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c482"
      decimals="INF"
      id="ixv-89817"
      unitRef="shares">10265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c482"
      decimals="2"
      id="ixv-89818"
      unitRef="usdPershares">4.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c482"
      decimals="INF"
      id="ixv-89819"
      unitRef="shares">14666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c482"
      decimals="2"
      id="ixv-89820"
      unitRef="usdPershares">275.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c483"
      decimals="INF"
      id="ixv-89821"
      unitRef="shares">52479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c483"
      decimals="2"
      id="ixv-89822"
      unitRef="usdPershares">85.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c483"
      decimals="INF"
      id="ixv-89823"
      unitRef="shares">46872</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c483"
      decimals="2"
      id="ixv-89824"
      unitRef="usdPershares">94.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c483"
      decimals="INF"
      id="ixv-89825"
      unitRef="shares">5607</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c483"
      decimals="2"
      id="ixv-89826"
      unitRef="usdPershares">10.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c418" decimals="0" id="ixv-89827" unitRef="usd">1900</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c418" decimals="0" id="ixv-89828" unitRef="usd">900</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c419"
      decimals="4"
      id="ixv-89829"
      unitRef="pure">0.831</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c420"
      decimals="4"
      id="ixv-89830"
      unitRef="pure">0.9636</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c419"
      decimals="4"
      id="ixv-89831"
      unitRef="pure">0.0347</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c420"
      decimals="4"
      id="ixv-89832"
      unitRef="pure">0.0479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c18" decimals="2" id="ixv-89833" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c419" id="ixv-89834">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c420" id="ixv-89835">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c1" decimals="0" id="ixv-89836" unitRef="usd">28694</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c421"
      decimals="4"
      id="ixv-89837"
      unitRef="pure">0.7976</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c422"
      decimals="4"
      id="ixv-89838"
      unitRef="pure">0.9637</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c421"
      decimals="4"
      id="ixv-89839"
      unitRef="pure">0.0358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c422"
      decimals="4"
      id="ixv-89840"
      unitRef="pure">0.0476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c19" decimals="2" id="ixv-89841" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c421" id="ixv-89842">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c422" id="ixv-89843">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c2" decimals="0" id="ixv-89844" unitRef="usd">319380</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c423" decimals="0" id="ixv-89845" unitRef="usd">51159</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c424" decimals="0" id="ixv-89846" unitRef="usd">284977</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c18" decimals="0" id="ixv-89847" unitRef="usd">19878</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c19" decimals="0" id="ixv-89848" unitRef="usd">172943</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ProfessionalFees contextRef="c423" decimals="0" id="ixv-89849" unitRef="usd">31281</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c424" decimals="0" id="ixv-89850" unitRef="usd">106565</us-gaap:ProfessionalFees>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c423" decimals="0" id="ixv-89851" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c424" decimals="0" id="ixv-89852" unitRef="usd">5469</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="c18" id="ixv-62747">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of the status of the Company&#x2019;s
nonvested stock options granted as of December 31, 2024 and changes during the years ended December 31, 2024 and 2023 is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Nonvested at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,334&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;64.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(8,475&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(47.14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Nonvested at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,311&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,265&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,969&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10.90&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Nonvested at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,607&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10.56&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;A summary of the status
of the Company&#x2019;s nonvested stock warrants issued as of December 31, 2024 and changes during the years ended December 31, 2024 and
2023 was presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number of Warrants&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Nonvested at January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-354"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-355"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%"&gt;Issued&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;34,771&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;48.90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19,560&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;55.95&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Nonvested at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,211&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;39.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;169,527&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(23,288&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(32.85&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(81,450&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(12.10&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Nonvested at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;80,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c489"
      decimals="INF"
      id="ixv-89853"
      unitRef="shares">1334</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c489"
      decimals="2"
      id="ixv-89854"
      unitRef="usdPershares">64.35</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c490"
      decimals="INF"
      id="ixv-89855"
      unitRef="shares">12452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c490"
      decimals="2"
      id="ixv-89856"
      unitRef="usdPershares">35.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c490"
      decimals="INF"
      id="ixv-89857"
      unitRef="shares">8475</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <avco:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues
      contextRef="c490"
      decimals="2"
      id="ixv-89858"
      unitRef="usdPershares">-47.14</avco:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c491"
      decimals="INF"
      id="ixv-89859"
      unitRef="shares">5311</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c491"
      decimals="2"
      id="ixv-89860"
      unitRef="usdPershares">23.55</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c492"
      decimals="INF"
      id="ixv-89861"
      unitRef="shares">10265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c492"
      decimals="2"
      id="ixv-89862"
      unitRef="usdPershares">4.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c492"
      decimals="INF"
      id="ixv-89863"
      unitRef="shares">9969</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <avco:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues
      contextRef="c492"
      decimals="2"
      id="ixv-89864"
      unitRef="usdPershares">-10.9</avco:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c493"
      decimals="INF"
      id="ixv-89865"
      unitRef="shares">5607</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c493"
      decimals="2"
      id="ixv-89866"
      unitRef="usdPershares">10.56</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c18" id="ixv-62868">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the shares of the
Company&#x2019;s common stock issuable upon exercise of warrants outstanding at December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Warrants Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Warrants Exercisable&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Range of&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number&lt;br/&gt; Outstanding at &lt;br/&gt;
December 31, &lt;br/&gt;
2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Number&lt;br/&gt; Exercisable at&lt;br/&gt; December 31&lt;br/&gt;
, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;Weighted Average Exercise&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13.5%; text-align: right"&gt;7.50 - 37.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;165,510&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;4.40&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13.5%; text-align: right"&gt;10.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13.5%; text-align: right"&gt;85,510&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13.5%; text-align: right"&gt;13.31&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;187.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2.30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;187.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;187.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7.50 - 187.50&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;182,996&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4.25&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21.37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;102,996&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;32.13&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;*&lt;/td&gt;&lt;td style="text-align: justify"&gt;Second Warrant, which was issued on May 23, 2023, July 6,
2023, October 9, 2023, and March 7, 2024, was cancelled in June 2024. Second Warrant, which was issued on June 5, 2024, is still outstanding
as of December 31, 2024.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c499"
      decimals="2"
      id="ixv-89867"
      unitRef="usdPershares">7.5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c499"
      decimals="INF"
      id="ixv-89868"
      unitRef="usdPershares">37.5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c500"
      decimals="0"
      id="ixv-89869"
      unitRef="shares">165510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c499" id="ixv-89870">P4Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c500"
      decimals="2"
      id="ixv-89871"
      unitRef="usdPershares">10.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c500"
      decimals="0"
      id="ixv-89872"
      unitRef="shares">85510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c500"
      decimals="2"
      id="ixv-89873"
      unitRef="usdPershares">13.31</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c501"
      decimals="2"
      id="ixv-89874"
      unitRef="usdPershares">67.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c501"
      decimals="0"
      id="ixv-89875"
      unitRef="shares">9222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c502" id="ixv-89876">P3Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c501"
      decimals="2"
      id="ixv-89877"
      unitRef="usdPershares">67.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c501"
      decimals="0"
      id="ixv-89878"
      unitRef="shares">9222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c501"
      decimals="2"
      id="ixv-89879"
      unitRef="usdPershares">67.5</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c503"
      decimals="2"
      id="ixv-89880"
      unitRef="usdPershares">187.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c503"
      decimals="0"
      id="ixv-89881"
      unitRef="shares">8264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c504" id="ixv-89882">P2Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c503"
      decimals="2"
      id="ixv-89883"
      unitRef="usdPershares">187.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c503"
      decimals="0"
      id="ixv-89884"
      unitRef="shares">8264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c503"
      decimals="2"
      id="ixv-89885"
      unitRef="usdPershares">187.5</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c505"
      decimals="2"
      id="ixv-89886"
      unitRef="usdPershares">7.5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c505"
      decimals="INF"
      id="ixv-89887"
      unitRef="usdPershares">187.5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c506"
      decimals="0"
      id="ixv-89888"
      unitRef="shares">182996</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c505" id="ixv-89889">P4Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c506"
      decimals="2"
      id="ixv-89890"
      unitRef="usdPershares">21.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c506"
      decimals="0"
      id="ixv-89891"
      unitRef="shares">102996</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c506"
      decimals="2"
      id="ixv-89892"
      unitRef="usdPershares">32.13</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c484"
      decimals="INF"
      id="ixv-89893"
      unitRef="shares">8264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c484"
      decimals="2"
      id="ixv-89894"
      unitRef="usdPershares">187.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c485"
      decimals="INF"
      id="ixv-89895"
      unitRef="shares">34771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c485"
      decimals="2"
      id="ixv-89896"
      unitRef="usdPershares">48.9</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c486"
      decimals="INF"
      id="ixv-89897"
      unitRef="shares">43035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c486"
      decimals="2"
      id="ixv-89898"
      unitRef="usdPershares">75.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c487"
      decimals="INF"
      id="ixv-89899"
      unitRef="shares">169527</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c487"
      decimals="2"
      id="ixv-89900"
      unitRef="usdPershares">10.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c487"
      decimals="INF"
      id="ixv-89901"
      unitRef="shares">23288</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c487"
      decimals="2"
      id="ixv-89902"
      unitRef="usdPershares">32.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c487"
      decimals="INF"
      id="ixv-89903"
      unitRef="shares">6278</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice
      contextRef="c487"
      decimals="2"
      id="ixv-89904"
      unitRef="usdPershares">50.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c488"
      decimals="INF"
      id="ixv-89905"
      unitRef="shares">182996</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c488"
      decimals="2"
      id="ixv-89906"
      unitRef="usdPershares">21.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c488"
      decimals="INF"
      id="ixv-89907"
      unitRef="shares">102996</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c488"
      decimals="2"
      id="ixv-89908"
      unitRef="usdPershares">32.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c488"
      decimals="INF"
      id="ixv-89909"
      unitRef="shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c488"
      decimals="2"
      id="ixv-89910"
      unitRef="usdPershares">7.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c425" decimals="0" id="ixv-89911" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="c426" id="ixv-89912">(i) a warrant to purchase 8,333 shares of common stock with an
exercise price of $67.50 exercisable until the five-year anniversary of May 23, 2023, and (ii) a warrant to purchase 7,033 shares of common
stock with an exercise price of $48.00 exercisable until the five-year anniversary of May 23, 2023, which warrant was never fair valued
and was cancelled and extinguished against payment of the May 2023 Convertible Note, to Mast Hill; and issued a warrant to purchase 667
shares of common stock with an exercise price of $67.50 exercisable until the five-year anniversary of May 23, 2023 to a third party as
a finder&#x2019;s fee.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c427"
      decimals="0"
      id="ixv-89913"
      unitRef="shares">9000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c427"
      decimals="2"
      id="ixv-89914"
      unitRef="usdPershares">67.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c428"
      decimals="0"
      id="ixv-89915"
      unitRef="shares">9000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c428"
      decimals="2"
      id="ixv-89916"
      unitRef="usdPershares">67.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharePrice
      contextRef="c429"
      decimals="2"
      id="ixv-89917"
      unitRef="usdPershares">29.4</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c430"
      decimals="4"
      id="ixv-89918"
      unitRef="pure">0.888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c430"
      decimals="4"
      id="ixv-89919"
      unitRef="pure">0.0376</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c430"
      decimals="2"
      id="ixv-89920"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c430" id="ixv-89921">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c431"
      decimals="2"
      id="ixv-89922"
      unitRef="usdPershares">67.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c431"
      decimals="0"
      id="ixv-89923"
      unitRef="shares">8333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ConvertibleNotesPayable contextRef="c305" decimals="0" id="ixv-89924" unitRef="usd">127654</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c432"
      decimals="2"
      id="ixv-89925"
      unitRef="usdPershares">67.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c432"
      decimals="0"
      id="ixv-89926"
      unitRef="shares">667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c433" decimals="0" id="ixv-89927" unitRef="usd">11162</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="c434" id="ixv-89928">(i) a warrant to purchase 2,778 shares of common stock with an
exercise price of $67.50 exercisable until the five-year anniversary of July 6, 2023, and (ii) a warrant to purchase 2,344 shares of common
stock with an exercise price of $48.00 exercisable until the five-year anniversary of July 6, 2023, which warrant was never fair valued
and was cancelled and extinguished against payment of the July 2023 Convertible Note, to Firstfire; and issued a warrant to purchase 222
shares of common stock with an exercise price of $67.50 exercisable until the five-year anniversary of July 6, 2023 to a third party as
a finder&#x2019;s fee.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c435" decimals="0" id="ixv-89929" unitRef="usd">3000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c436"
      decimals="2"
      id="ixv-89930"
      unitRef="usdPershares">67.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c437" decimals="0" id="ixv-89931" unitRef="usd">3000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c438"
      decimals="2"
      id="ixv-89932"
      unitRef="usdPershares">67.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharePrice
      contextRef="c439"
      decimals="2"
      id="ixv-89933"
      unitRef="usdPershares">21.3</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c220"
      decimals="4"
      id="ixv-89934"
      unitRef="pure">0.8852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c220"
      decimals="4"
      id="ixv-89935"
      unitRef="pure">0.0437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c220"
      decimals="2"
      id="ixv-89936"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c220" id="ixv-89937">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c440"
      decimals="2"
      id="ixv-89938"
      unitRef="usdPershares">67.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c440"
      decimals="0"
      id="ixv-89939"
      unitRef="shares">2778</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ConvertibleNotesPayable contextRef="c441" decimals="0" id="ixv-89940" unitRef="usd">28691</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c319"
      decimals="2"
      id="ixv-89941"
      unitRef="usdPershares">67.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c319"
      decimals="0"
      id="ixv-89942"
      unitRef="shares">222</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c442" decimals="0" id="ixv-89943" unitRef="usd">2435</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="c443" id="ixv-89944">(i) a warrant to purchase 7,000 shares of common stock with
an exercise price of $37.50 exercisable until the five-year anniversary of October 9, 2023, (ii) a warrant to purchase 5,834 shares of
common stock with an exercise price of $27.00 exercisable until the five-year anniversary of October 9, 2023, which warrant was never
fair valued and was cancelled and extinguished against payment of the October 2023 Convertible Note, to Mast Hill and Firstfire; and issued
a warrant to purchase 560 shares of common stock with an exercise price of $37.50 exercisable until the five-year anniversary of October
9, 2023 to a third party as a finder&#x2019;s fee.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c252" decimals="0" id="ixv-89945" unitRef="usd">7560</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c444"
      decimals="2"
      id="ixv-89946"
      unitRef="usdPershares">37.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c445" decimals="0" id="ixv-89947" unitRef="usd">7560</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c446"
      decimals="2"
      id="ixv-89948"
      unitRef="usdPershares">37.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharePrice
      contextRef="c447"
      decimals="2"
      id="ixv-89949"
      unitRef="usdPershares">11.55</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c448"
      decimals="4"
      id="ixv-89950"
      unitRef="pure">0.897</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c448"
      decimals="4"
      id="ixv-89951"
      unitRef="pure">0.0475</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c448"
      decimals="2"
      id="ixv-89952"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c448" id="ixv-89953">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c449"
      decimals="2"
      id="ixv-89954"
      unitRef="usdPershares">37.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c449"
      decimals="0"
      id="ixv-89955"
      unitRef="shares">7000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ConvertibleNotesPayable contextRef="c250" decimals="0" id="ixv-89956" unitRef="usd">39848</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c444"
      decimals="2"
      id="ixv-89957"
      unitRef="usdPershares">37.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c444"
      decimals="0"
      id="ixv-89958"
      unitRef="shares">560</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c445" decimals="0" id="ixv-89959" unitRef="usd">3380</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="c450" id="ixv-89960">(i) a warrant to purchase 8,750 shares of common stock
with an exercise price of $30.00 exercisable until the five-year anniversary of March 7, 2024 (&#x201c;First Warrant&#x201d;), (ii) a warrant
to purchase 8,077 shares of common stock with an exercise price of $19.50 (&#x201c;Second Warrant&#x201d;), which warrant was never fair
valued and was cancelled and extinguished against payment of the March 2024 Convertible Note, to Mast Hill; and issued a warrant to purchase
700 shares of common stock with an exercise price of $30.00 exercisable until the five-year anniversary of March 7, 2024 to a third party
as a finder&#x2019;s fee.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c451" decimals="0" id="ixv-89961" unitRef="usd">9450</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c452"
      decimals="2"
      id="ixv-89962"
      unitRef="usdPershares">30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c453" decimals="0" id="ixv-89963" unitRef="usd">9450</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c452"
      decimals="2"
      id="ixv-89964"
      unitRef="usdPershares">30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharePrice
      contextRef="c452"
      decimals="2"
      id="ixv-89965"
      unitRef="usdPershares">6</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c453"
      decimals="4"
      id="ixv-89966"
      unitRef="pure">0.8524</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c453"
      decimals="4"
      id="ixv-89967"
      unitRef="pure">0.0407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c453"
      decimals="2"
      id="ixv-89968"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c453" id="ixv-89969">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c454"
      decimals="2"
      id="ixv-89970"
      unitRef="usdPershares">30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c454"
      decimals="0"
      id="ixv-89971"
      unitRef="shares">8750</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ConvertibleNotesPayable contextRef="c454" decimals="0" id="ixv-89972" unitRef="usd">20374</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c455"
      decimals="2"
      id="ixv-89973"
      unitRef="usdPershares">30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c455"
      decimals="0"
      id="ixv-89974"
      unitRef="shares">700</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c456" decimals="0" id="ixv-89975" unitRef="usd">1679</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="c457" id="ixv-89976">(i) a warrant to purchase 66,667 shares of common stock with an exercise price of $9.75 exercisable
until the five-year anniversary of June 5, 2024 (&#x201c;First Warrant&#x201d;), (ii) a warrant to purchase 80,000 shares of common stock
with an exercise price of $7.50 exercisable until the five-year anniversary of June 5, 2024 (&#x201c;Second Warrant&#x201d;), which warrant
shall be cancelled and extinguished against payment of the June 2024 Convertible Note, to Mast Hill; and issued a warrant to purchase
5,333 shares of common stock with an exercise price of $9.75 exercisable until the five-year anniversary of June 5, 2024 to a third party
as a finder&#x2019;s fee.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c458"
      decimals="0"
      id="ixv-89977"
      unitRef="shares">80000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c458"
      decimals="2"
      id="ixv-89978"
      unitRef="usdPershares">7.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c459" decimals="0" id="ixv-89979" unitRef="usd">72000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c460"
      decimals="2"
      id="ixv-89980"
      unitRef="usdPershares">9.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c461" decimals="0" id="ixv-89981" unitRef="usd">72000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c462"
      decimals="2"
      id="ixv-89982"
      unitRef="usdPershares">9.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c463" id="ixv-89983">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharePrice
      contextRef="c464"
      decimals="2"
      id="ixv-89984"
      unitRef="usdPershares">10.39</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c463"
      decimals="4"
      id="ixv-89985"
      unitRef="pure">0.8572</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c463"
      decimals="4"
      id="ixv-89986"
      unitRef="pure">0.0431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c463"
      decimals="2"
      id="ixv-89987"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c465"
      decimals="2"
      id="ixv-89988"
      unitRef="usdPershares">9.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c466"
      decimals="0"
      id="ixv-89989"
      unitRef="shares">66667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ConvertibleNotesPayable contextRef="c466" decimals="0" id="ixv-89990" unitRef="usd">418194</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c467"
      decimals="2"
      id="ixv-89991"
      unitRef="usdPershares">9.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c467"
      decimals="0"
      id="ixv-89992"
      unitRef="shares">5333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c468" decimals="0" id="ixv-89993" unitRef="usd">39221</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c469"
      decimals="0"
      id="ixv-89994"
      unitRef="shares">23288</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c470"
      decimals="0"
      id="ixv-89995"
      unitRef="shares">6278</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c495"
      decimals="INF"
      id="ixv-89996"
      unitRef="shares">34771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c495"
      decimals="2"
      id="ixv-89997"
      unitRef="usdPershares">48.9</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c495"
      decimals="INF"
      id="ixv-89998"
      unitRef="shares">19560</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <avco:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues
      contextRef="c495"
      decimals="2"
      id="ixv-89999"
      unitRef="usdPershares">55.95</avco:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c496"
      decimals="INF"
      id="ixv-90000"
      unitRef="shares">15211</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c496"
      decimals="2"
      id="ixv-90001"
      unitRef="usdPershares">39.9</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c497"
      decimals="INF"
      id="ixv-90002"
      unitRef="shares">169527</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c497"
      decimals="2"
      id="ixv-90003"
      unitRef="usdPershares">10.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c497"
      decimals="INF"
      id="ixv-90004"
      unitRef="shares">23288</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="c497"
      decimals="2"
      id="ixv-90005"
      unitRef="usdPershares">32.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c497"
      decimals="INF"
      id="ixv-90006"
      unitRef="shares">81450</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <avco:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues
      contextRef="c497"
      decimals="2"
      id="ixv-90007"
      unitRef="usdPershares">-12.1</avco:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c498"
      decimals="INF"
      id="ixv-90008"
      unitRef="shares">80000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c498"
      decimals="2"
      id="ixv-90009"
      unitRef="usdPershares">7.5</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <avco:StatutoryReserveAndRestrictedNetAssetsTextBlock contextRef="c18" id="ixv-63411">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 16 - &lt;span style="text-decoration:underline"&gt;STATUTORY
RESERVE AND RESTRICTED NET ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company&#x2019;s PRC
subsidiary, Avalon Shanghai, is restricted in its ability to transfer a portion of its net asset to the Company. The payment of dividends
by entities organized in China is subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment
of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company is required
to make appropriations to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus reserve, based
on after-tax net income determined in accordance with generally accepted accounting principles of the PRC (&#x201c;PRC GAAP&#x201d;). Appropriations
to the statutory surplus reserve are required to be at least&#160;10% of the after-tax net income determined in accordance with PRC GAAP
until the reserve is equal to&#160;50% of the entity&#x2019;s registered capital. Appropriations to the discretionary surplus reserve are
made at the discretion of the Board of Directors. The statutory reserve may be applied against prior year losses, if any, and may be used
for general business expansion and production or increase in registered capital, but are not distributable as cash dividends. The Company
did not make any appropriation to statutory reserve for Avalon Shanghai during the years ended December 31, 2024 and 2023 as it incurred
net loss in the periods. As of both December 31, 2024 and 2023, the restricted amount as determined pursuant to PRC statutory laws totaled
$6,578.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Relevant PRC laws and
regulations restrict the Company&#x2019;s PRC subsidiary, Avalon Shanghai, from transferring a portion of its net assets, equivalent to
its statutory reserve and its share capital, to the Company&#x2019;s shareholders in the form of loans, advances or cash dividends. Only
PRC entity&#x2019;s accumulated profit may be distributed as dividend to the Company&#x2019;s shareholders without the consent of a third
party. As of December 31, 2024 and 2023, total restricted net assets amounted to $1,206,578 and $1,106,578, respectively.&lt;/p&gt;</avco:StatutoryReserveAndRestrictedNetAssetsTextBlock>
    <avco:StatutoryReservePercent contextRef="c18" decimals="2" id="ixv-90010" unitRef="pure">0.10</avco:StatutoryReservePercent>
    <avco:RegisteredCapitalPercentage contextRef="c18" decimals="2" id="ixv-90011" unitRef="pure">0.50</avco:RegisteredCapitalPercentage>
    <avco:StatutoryReserve contextRef="c1" decimals="0" id="ixv-90012" unitRef="usd">6578</avco:StatutoryReserve>
    <avco:StatutoryReserve contextRef="c2" decimals="0" id="ixv-90013" unitRef="usd">6578</avco:StatutoryReserve>
    <us-gaap:OtherRestrictedAssets contextRef="c1" decimals="0" id="ixv-90014" unitRef="usd">1206578</us-gaap:OtherRestrictedAssets>
    <us-gaap:OtherRestrictedAssets contextRef="c2" decimals="0" id="ixv-90015" unitRef="usd">1106578</us-gaap:OtherRestrictedAssets>
    <us-gaap:MinorityInterestDisclosureTextBlock contextRef="c18" id="ixv-63444">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 17 - &lt;span style="text-decoration:underline"&gt;NONCONTROLLING
INTEREST&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;As of December
31, 2024, Dr. Yu Zhou, former director and former co-chief executive officer of Genexosome, who owns 40% of the equity interests of Genexosome,
which is not under the Company&#x2019;s control. During the years ended December 31, 2024 and 2023, the Company did not allocate any net
loss and foreign currency translation adjustment to the noncontrolling interest holder due to its inability to satisfy these deficits.&lt;/span&gt;&lt;/p&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c507"
      decimals="2"
      id="ixv-90016"
      unitRef="pure">0.40</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock contextRef="c18" id="ixv-63454">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 18 - &lt;span style="background-color: white"&gt;&lt;span style="text-decoration:underline"&gt;CONDENSED
FINANCIAL INFORMATION OF THE PARENT COMPANY&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Pursuant to the requirements
of Rule 12-04(a), 5-04(c) and 4-08(e)(3) of Regulation S-X, the condensed financial information of the parent company shall be filed when
the restricted net assets of consolidated subsidiary exceed 25% of consolidated net assets as of the end of the most recently completed
fiscal year. For purposes of this test, restricted net assets of consolidated subsidiary shall mean that amount of the Company&#x2019;s
proportionate share of net assets of consolidated subsidiary (after intercompany eliminations) which as of the end of the most recent
fiscal year may not be transferred to the parent company by subsidiary in the form of loans, advances or cash dividends without the consent
of a third party.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company performed
a test on the restricted net assets of consolidated subsidiary in accordance with such requirement and concluded that it was not applicable
to the Company as the restricted net assets of the Company&#x2019;s PRC subsidiary did not exceed 25% of the consolidated net assets of
the Company, therefore, the condensed financial statements for the parent company have not been required.&lt;/p&gt;</us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock>
    <avco:RestrictedNetAssetsOfSubsidiaryExceedNetAssets contextRef="c1" decimals="2" id="ixv-90017" unitRef="pure">0.25</avco:RestrictedNetAssetsOfSubsidiaryExceedNetAssets>
    <avco:RestrictedNetAssetsPRCSubsidiaryDidNotExceed
      contextRef="c508"
      decimals="2"
      id="ixv-90018"
      unitRef="pure">0.25</avco:RestrictedNetAssetsPRCSubsidiaryDidNotExceed>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c18" id="ixv-63466">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 19 -&#160;&lt;span style="text-decoration:underline"&gt;CONCENTRATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Customers&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The following
table sets forth information as to each customer that accounted for 10% or more of the Company&#x2019;s revenues for the years ended December
31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;Customer&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;A&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;B&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;C&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;One customer, which is
a third party, whose outstanding receivable accounted for 10% or more of the Company&#x2019;s total outstanding rent receivable at December
31, 2024, accounted for 76.9% of the Company&#x2019;s total outstanding rent receivable at December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Two customers, of which
one is a related party and the other is a third party, whose outstanding receivables accounted for 10% or more of the Company&#x2019;s
total outstanding rent receivable at December 31, 2023, accounted for 80.6% of the Company&#x2019;s total outstanding rent receivable at
December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Suppliers&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;No supplier
accounted for 10% or more of the Company&#x2019;s purchase during the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c18" id="ixv-63475">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The following
table sets forth information as to each customer that accounted for 10% or more of the Company&#x2019;s revenues for the years ended December
31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;Customer&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;A&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;29&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;B&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;C&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c509"
      decimals="2"
      id="ixv-90019"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c510"
      decimals="2"
      id="ixv-90020"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c517"
      decimals="2"
      id="ixv-90021"
      unitRef="pure">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c518"
      decimals="2"
      id="ixv-90022"
      unitRef="pure">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c519"
      decimals="2"
      id="ixv-90023"
      unitRef="pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c520"
      decimals="2"
      id="ixv-90024"
      unitRef="pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c521"
      decimals="2"
      id="ixv-90025"
      unitRef="pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c522"
      decimals="2"
      id="ixv-90026"
      unitRef="pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c511"
      decimals="2"
      id="ixv-90027"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c512"
      decimals="3"
      id="ixv-90028"
      unitRef="pure">0.769</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c513"
      decimals="2"
      id="ixv-90029"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c514"
      decimals="3"
      id="ixv-90030"
      unitRef="pure">0.806</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c515"
      decimals="2"
      id="ixv-90031"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c516"
      decimals="2"
      id="ixv-90032"
      unitRef="pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c18" id="ixv-63536">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;NOTE
20 -&#160;&lt;span style="text-decoration:underline"&gt;SEGMENT INFORMATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The segment reporting structure uses the Company&#x2019;s
management reporting structure as its foundation to reflect how the Company manages the businesses internally. The management reporting
structure is composed of two strategic business units, mainly organized by services, led by the Company&#x2019;s President and Chief Executive
Officer, who is its Chief Operating Decision Maker. Using the accounting guidance on segment reporting, the Company determined that its
two operating segments are aligned with its two reportable segments corresponding to its strategic business units.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 9, 2023, the Company purchased 40%
of Lab Services MSO. Commencing from the purchase date, February 9, 2023, the Company was active in the management of Lab Services MSO.
During the years ended December 31, 2024 and 2023, the Company operated in two reportable business segments: (1) the real property operating
segment, and (2) laboratory testing services segment (which commenced with the purchase date, February 9, 2023) since Lab Services MSO&#x2019;s
operating results are regularly reviewed by the Company&#x2019;s chief operating decision maker to make decisions about resources to be
allocated to the segment and assess its performance. The Company regularly reviews the operating results and performance of Lab Services
MSO, which is the Company&#x2019;s equity method investee. See Note 22-Subsequent Events-Redemption Agreement.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accounting policies for the segments are the
same as those described in Note 3. Our reportable segments are aligned principally around the differences in services. Real property operating
income is calculated by subtracting real property operating expenses from real property rental revenue; loss from equity method investment
- Lab Services MSO is calculated by subtracting amortization of intangible assets acquired from acquisition and impairment of goodwill
acquired from acquisition and distribution of earnings from equity investment from the Company&#x2019;s share of Lab Services MSO&#x2019;s
net income. The assets and certain expenses related to corporate activities are not allocated to the segments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Information with respect to these reportable business
segments for the years ended December 31, 2024 and 2023 was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Year Ended December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Real Property Operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Lab Services MSO&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Corporate / Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Real property rental revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,333,403&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-356"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-357"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,333,403&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Real property operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,065,574&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-358"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-359"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,065,574&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Real property operating income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;267,829&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-360"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-361"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;267,829&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss from equity method investment - Lab Services MSO&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-362"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(846,588&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-363"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(846,588&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(354,311&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-364"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,994,662&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,348,973&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other (expense) income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&#160;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(777,228&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-365"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,659,745&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,436,973&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&#160;Other expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(80&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-366"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(538,609&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(538,689&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(863,790&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(846,588&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,193,016&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,903,394&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Year Ended December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Real Property Operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Lab Services MSO&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Corporate / Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Real property rental revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,255,681&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-367"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-368"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,255,681&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Real property operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,017,493&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-369"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-370"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,017,493&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Real property operating income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;238,188&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-371"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-372"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;238,188&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss from equity method investment - Lab Services MSO&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-373"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,571,647&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-374"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,571,647&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(347,356&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-375"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,072,868&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,420,224&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other (expense) income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&#160;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(918,885&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-376"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(432,617&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,351,502&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&#160;Other income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-377"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;398,160&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;398,175&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,028,038&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,571,647&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,107,325&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(16,707,010&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Identifiable long-lived tangible assets at December 31, 2024 and 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Real property operations&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,034,335&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,211,641&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Corporate/Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,298&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,846&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&#160;&#160;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,035,633&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,229,487&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Identifiable long-lived tangible assets at December 31, 2024 and 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,034,335&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,227,533&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;China&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,298&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,954&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&#160;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,035,633&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,229,487&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c18"
      decimals="0"
      id="ixv-90033"
      unitRef="segments">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c18"
      decimals="0"
      id="ixv-90034"
      unitRef="segments">2</us-gaap:NumberOfReportableSegments>
    <avco:PurchasedServicesPercentage contextRef="c1" decimals="2" id="ixv-90035" unitRef="pure">0.40</avco:PurchasedServicesPercentage>
    <us-gaap:NumberOfReportableSegments
      contextRef="c18"
      decimals="0"
      id="ixv-90036"
      unitRef="segments">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c18"
      decimals="0"
      id="ixv-90037"
      unitRef="segments">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c18" id="ixv-63577">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Information with respect to these reportable business
segments for the years ended December 31, 2024 and 2023 was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Year Ended December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Real Property Operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Lab Services MSO&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Corporate / Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Real property rental revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,333,403&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-356"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-357"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,333,403&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Real property operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,065,574&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-358"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-359"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,065,574&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Real property operating income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;267,829&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-360"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-361"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;267,829&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss from equity method investment - Lab Services MSO&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-362"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(846,588&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-363"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(846,588&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(354,311&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-364"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,994,662&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,348,973&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other (expense) income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&#160;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(777,228&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-365"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,659,745&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,436,973&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&#160;Other expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(80&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-366"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(538,609&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(538,689&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(863,790&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(846,588&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,193,016&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,903,394&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Year Ended December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Real Property Operations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Lab Services MSO&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Corporate / Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Real property rental revenue&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,255,681&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-367"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-368"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,255,681&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Real property operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,017,493&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-369"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-370"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,017,493&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Real property operating income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;238,188&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-371"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-372"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;238,188&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss from equity method investment - Lab Services MSO&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-373"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,571,647&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-374"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,571,647&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other operating expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(347,356&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-375"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,072,868&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,420,224&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other (expense) income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&#160;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(918,885&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-376"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(432,617&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,351,502&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&#160;Other income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-377"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;398,160&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;398,175&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,028,038&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,571,647&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,107,325&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(16,707,010&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues contextRef="c523" decimals="0" id="ixv-90038" unitRef="usd">1333403</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c18" decimals="0" id="ixv-90039" unitRef="usd">1333403</us-gaap:Revenues>
    <us-gaap:OperatingExpenses contextRef="c523" decimals="0" id="ixv-90040" unitRef="usd">1065574</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c18" decimals="0" id="ixv-90041" unitRef="usd">1065574</us-gaap:OperatingExpenses>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c523" decimals="0" id="ixv-90042" unitRef="usd">267829</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c18" decimals="0" id="ixv-90043" unitRef="usd">267829</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c524" decimals="0" id="ixv-90044" unitRef="usd">-846588</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c18" decimals="0" id="ixv-90045" unitRef="usd">-846588</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:OperatingCostsAndExpenses contextRef="c523" decimals="0" id="ixv-90046" unitRef="usd">354311</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c525" decimals="0" id="ixv-90047" unitRef="usd">3994662</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c18" decimals="0" id="ixv-90048" unitRef="usd">4348973</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:InterestExpenseNonoperating contextRef="c523" decimals="0" id="ixv-90049" unitRef="usd">777228</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c525" decimals="0" id="ixv-90050" unitRef="usd">1659745</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c18" decimals="0" id="ixv-90051" unitRef="usd">2436973</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherIncome contextRef="c523" decimals="0" id="ixv-90052" unitRef="usd">-80</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c525" decimals="0" id="ixv-90053" unitRef="usd">-538609</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c18" decimals="0" id="ixv-90054" unitRef="usd">-538689</us-gaap:OtherIncome>
    <us-gaap:NetIncomeLoss contextRef="c523" decimals="0" id="ixv-90055" unitRef="usd">-863790</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c524" decimals="0" id="ixv-90056" unitRef="usd">-846588</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c525" decimals="0" id="ixv-90057" unitRef="usd">-6193016</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c18" decimals="0" id="ixv-90058" unitRef="usd">-7903394</us-gaap:NetIncomeLoss>
    <us-gaap:Revenues contextRef="c526" decimals="0" id="ixv-90059" unitRef="usd">1255681</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c19" decimals="0" id="ixv-90060" unitRef="usd">1255681</us-gaap:Revenues>
    <us-gaap:OperatingExpenses contextRef="c526" decimals="0" id="ixv-90061" unitRef="usd">1017493</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c19" decimals="0" id="ixv-90062" unitRef="usd">1017493</us-gaap:OperatingExpenses>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c526" decimals="0" id="ixv-90063" unitRef="usd">238188</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c19" decimals="0" id="ixv-90064" unitRef="usd">238188</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c527" decimals="0" id="ixv-90065" unitRef="usd">-8571647</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c19" decimals="0" id="ixv-90066" unitRef="usd">-8571647</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:OperatingCostsAndExpenses contextRef="c526" decimals="0" id="ixv-90067" unitRef="usd">347356</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c528" decimals="0" id="ixv-90068" unitRef="usd">7072868</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c19" decimals="0" id="ixv-90069" unitRef="usd">7420224</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:InterestExpenseNonoperating contextRef="c526" decimals="0" id="ixv-90070" unitRef="usd">918885</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c528" decimals="0" id="ixv-90071" unitRef="usd">432617</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c19" decimals="0" id="ixv-90072" unitRef="usd">1351502</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherIncome contextRef="c526" decimals="0" id="ixv-90073" unitRef="usd">15</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c528" decimals="0" id="ixv-90074" unitRef="usd">398160</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c19" decimals="0" id="ixv-90075" unitRef="usd">398175</us-gaap:OtherIncome>
    <us-gaap:NetIncomeLoss contextRef="c526" decimals="0" id="ixv-90076" unitRef="usd">-1028038</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c527" decimals="0" id="ixv-90077" unitRef="usd">-8571647</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c528" decimals="0" id="ixv-90078" unitRef="usd">-7107325</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c19" decimals="0" id="ixv-90079" unitRef="usd">-16707010</us-gaap:NetIncomeLoss>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock contextRef="c18" id="ixv-64003">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Identifiable long-lived tangible assets at December 31, 2024 and 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Real property operations&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,034,335&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,211,641&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Corporate/Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,298&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17,846&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&#160;&#160;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,035,633&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,229,487&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:NoncurrentAssets contextRef="c529" decimals="0" id="ixv-90080" unitRef="usd">7034335</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c530" decimals="0" id="ixv-90081" unitRef="usd">7211641</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c531" decimals="0" id="ixv-90082" unitRef="usd">1298</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c532" decimals="0" id="ixv-90083" unitRef="usd">17846</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c1" decimals="0" id="ixv-90084" unitRef="usd">7035633</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c2" decimals="0" id="ixv-90085" unitRef="usd">7229487</us-gaap:NoncurrentAssets>
    <us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock contextRef="c18" id="ixv-64044">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;Identifiable long-lived tangible assets at December 31, 2024 and 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,034,335&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,227,533&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;China&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,298&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,954&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&#160;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,035,633&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,229,487&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock>
    <us-gaap:NoncurrentAssets contextRef="c152" decimals="0" id="ixv-90086" unitRef="usd">7034335</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c142" decimals="0" id="ixv-90087" unitRef="usd">7227533</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c140" decimals="0" id="ixv-90088" unitRef="usd">1298</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c141" decimals="0" id="ixv-90089" unitRef="usd">1954</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c1" decimals="0" id="ixv-90090" unitRef="usd">7035633</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c2" decimals="0" id="ixv-90091" unitRef="usd">7229487</us-gaap:NoncurrentAssets>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c18" id="ixv-64088">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 21 -&#160;&lt;span style="text-decoration:underline"&gt;COMMITMENTS
AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Litigation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From time to time, the Company is subject to ordinary routine litigation incidental to its normal business operations. The Company
is not currently a party to, and its property is not subject to, any material legal proceedings, except as set forth below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October
25, 2017, Genexosome entered into and closed a Stock Purchase Agreement with Beijing Genexosome and Yu Zhou, MD, PhD, the sole shareholder
of Beijing Genexosome, pursuant to which Genexosome acquired all of the issued and outstanding securities of Beijing Genexosome in consideration
of a cash payment in the amount of $450,000, of which $100,000 is still owed. Further, on October 25, 2017, Genexosome entered into and
closed an Asset Purchase Agreement with Dr. Zhou, pursuant to which the Company acquired all assets, including all intellectual property
and exosome separation systems, held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies.
In consideration of the assets, Genexosome paid Dr. Zhou $876,087 in cash, transferred 3,333 shares of common stock of the Company to
Dr. Zhou and issued Dr. Zhou 400 shares of common stock of Genexosome. Further, the Company had not been able to realize the financial
projections provided by Dr. Zhou at the time of the acquisition and has decided to impair the intangible asset associated with this acquisition
to zero. Dr. Zhou was terminated as Co-CEO of Genexosome on August 14, 2019. Further, on October 28, 2019, Research Institute at Nationwide
Children&#x2019;s Hospital (&#x201c;Research Institute&#x201d;) filed a Complaint in the United States District Court for the Southern District
of Ohio Eastern Division against Dr. Zhou, Li Chen, the Company and Genexosome with various claims against the Company and Genexosome.
The criminal proceedings against Dr. Zhou and Li Chen have been concluded. The Company, Genexosome and the Research Institute entered
into a Settlement Agreement dated June 7, 2022 (the &#x201c;Settlement Date&#x201d;) whereby the Company agreed to pay the Research Institute
$450,000 on each of the sixty-day, one year and two-year anniversaries of the Settlement Date. In addition, the Company agreed to pay
the Research Institute 30% of the Company&#x2019;s initial pre-tax profit of $3,333,333, 20% of the Company&#x2019;s second pre-tax profit
of $3,333,333 and 10% of the Company&#x2019;s third pre-tax profit of $3,333,333. The parties provided a mutual release as well. As of
December 31, 2024, the accrued litigation settlement amounted to $373,450.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;Operating
Leases Commitment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The Company
is a party to leases for office space. These lease agreements expired through February 2025. Rent expense under all operating leases amounted
to approximately $127,000 and $129,000 for the years ended December 31, 2024 and 2023, respectively.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Supplemental
cash flow information related to leases for the years ended December 31, 2024 and 2023 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&#160;&#160;Operating cash flows paid for operating lease&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;125,076&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;125,929&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&#160;Operating lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-378"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;235,893&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the lease term
and discount rate for the Company&#x2019;s operating lease as of December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Operating Lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;Weighted average remaining lease term (in years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.08&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table summarizes the maturity of lease liabilities under
operating lease as of December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;For the Year Ending December 31:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Operating Lease&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,753&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2026 and thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-379"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,753&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Amount of lease payments representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total present value of operating lease liabilities (current liability)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,709&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Joint Venture - Avactis Biosciences Inc.&lt;/b&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On July 18, 2018, the
Company formed a wholly owned subsidiary, Avactis Biosciences Inc. (&#x201c;Avactis&#x201d;), a Nevada corporation, which focuses on accelerating
commercial activities related to cellular therapies as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others. When
formed, Avactis was designed to integrate and optimize the Company&#x2019;s global scientific and clinical resources to further advance
the use of cellular therapies to treat certain cancers, however the Company is no longer pursuing any commercial activities with respect
to cellular immunotherapy and CAR-T, in particular. As of April 6, 2022, the Company owns 60% of Avactis and Arbele Biotherapeutics Limited
(&#x201c;Arbele Biotherapeutics&#x201d;) owns 40% of Avactis. Avactis owns 100% of the capital stock of Avactis Nanjing Biosciences Ltd.,
a company incorporated in the PRC on May 8, 2020 (&#x201c;Avactis Nanjing&#x201d;), which only owns a patent and is not considered an operating
entity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company is required
to contribute $10 million (or equivalent in RMB) in cash and/or services, which shall be contributed in tranches based on milestones to
be determined jointly by Avactis and the Company in writing subject to the Company&#x2019;s cash reserves. Within 30 days, Arbele Biotherapeutics
shall make contribution of $6.66 million in the form of entering into a License Agreement with Avactis granting Avactis an exclusive right
and license in China to its technology and intellectual property pertaining to CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy technology
and any additional technology developed in the future with terms and conditions to be mutually agreed upon the Company and Avactis and
services. As of the date hereof, the License Agreement has not been finalized by the parties.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;In addition, the Company
is responsible for contributing registered capital of RMB 5,000,000 (approximately $0.7 million) for working capital purposes as required
by local regulation, which is not required to be contributed immediately and will be contributed subject to the Company&#x2019;s discretion.
As of the date hereof, Avactis&#x2019; activities have been limited to that of a patent holding company and there is no other activity
or planned contributions in 2025 or into the foreseeable future.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:Cash contextRef="c533" decimals="0" id="ixv-90092" unitRef="usd">450000</us-gaap:Cash>
    <us-gaap:LoansPayable contextRef="c534" decimals="0" id="ixv-90093" unitRef="usd">100000</us-gaap:LoansPayable>
    <us-gaap:Cash contextRef="c535" decimals="0" id="ixv-90094" unitRef="usd">876087</us-gaap:Cash>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c536"
      decimals="0"
      id="ixv-90095"
      unitRef="shares">3333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c537"
      decimals="0"
      id="ixv-90096"
      unitRef="shares">400</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:LitigationReserve contextRef="c1" decimals="0" id="ixv-90097" unitRef="usd">450000</us-gaap:LitigationReserve>
    <avco:PercentageOfPretaxProfit contextRef="c18" decimals="2" id="ixv-90098" unitRef="pure">0.30</avco:PercentageOfPretaxProfit>
    <avco:PreTaxProfit contextRef="c18" decimals="0" id="ixv-90099" unitRef="usd">3333333</avco:PreTaxProfit>
    <avco:PercentageOfPretaxProfit
      contextRef="c538"
      decimals="2"
      id="ixv-90100"
      unitRef="pure">0.20</avco:PercentageOfPretaxProfit>
    <avco:PreTaxProfit contextRef="c18" decimals="0" id="ixv-90101" unitRef="usd">3333333</avco:PreTaxProfit>
    <avco:PercentageOfPretaxProfit
      contextRef="c539"
      decimals="2"
      id="ixv-90102"
      unitRef="pure">0.10</avco:PercentageOfPretaxProfit>
    <avco:PreTaxProfit contextRef="c539" decimals="0" id="ixv-90103" unitRef="usd">3333333</avco:PreTaxProfit>
    <us-gaap:LitigationReserve contextRef="c540" decimals="0" id="ixv-90104" unitRef="usd">373450</us-gaap:LitigationReserve>
    <us-gaap:PaymentsForRent contextRef="c18" decimals="0" id="ixv-90105" unitRef="usd">127000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="c19" decimals="0" id="ixv-90106" unitRef="usd">129000</us-gaap:PaymentsForRent>
    <us-gaap:LeaseCostTableTextBlock contextRef="c18" id="ixv-64138">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Supplemental
cash flow information related to leases for the years ended December 31, 2024 and 2023 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&#160;&#160;Operating cash flows paid for operating lease&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;125,076&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;125,929&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&#160;Operating lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-378"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;235,893&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table summarizes the lease term
and discount rate for the Company&#x2019;s operating lease as of December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Operating Lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;Weighted average remaining lease term (in years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.08&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c18" decimals="0" id="ixv-90107" unitRef="usd">125076</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c19" decimals="0" id="ixv-90108" unitRef="usd">125929</us-gaap:OperatingLeasePayments>
    <avco:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities contextRef="c19" decimals="0" id="ixv-90109" unitRef="usd">235893</avco:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2" id="ixv-90110">P0Y29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="3" id="ixv-90111" unitRef="pure">0.11</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c18" id="ixv-64217">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The following table summarizes the maturity of lease liabilities under
operating lease as of December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;For the Year Ending December 31:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Operating Lease&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10,753&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2026 and thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-379"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,753&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Amount of lease payments representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total present value of operating lease liabilities (current liability)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,709&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c1" decimals="0" id="ixv-90112" unitRef="usd">10753</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c1" decimals="0" id="ixv-90113" unitRef="usd">10753</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c1" decimals="0" id="ixv-90114" unitRef="usd">44</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c1" decimals="0" id="ixv-90115" unitRef="usd">10709</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c541"
      decimals="2"
      id="ixv-90116"
      unitRef="pure">0.60</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c542"
      decimals="2"
      id="ixv-90117"
      unitRef="pure">0.40</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c543"
      decimals="2"
      id="ixv-90118"
      unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:CashFlowsBetweenTransfereeAndTransferorServicingFees contextRef="c18" decimals="-6" id="ixv-90119" unitRef="usd">10000000</us-gaap:CashFlowsBetweenTransfereeAndTransferorServicingFees>
    <us-gaap:NoncashContributionExpense
      contextRef="c544"
      decimals="-4"
      id="ixv-90120"
      unitRef="usd">6660000</us-gaap:NoncashContributionExpense>
    <avco:WorkingCapital contextRef="c18" decimals="0" id="ixv-90121" unitRef="cny">5000000</avco:WorkingCapital>
    <avco:WorkingCapital contextRef="c18" decimals="-5" id="ixv-90122" unitRef="usd">700000</avco:WorkingCapital>
    <us-gaap:SubsequentEventsTextBlock contextRef="c18" id="ixv-64300">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;NOTE 22 - &lt;span style="text-decoration:underline"&gt;SUBSEQUENT
EVENTS&lt;/span&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Company evaluated
subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued.
Based upon this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment
or disclosure in the financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Series D Convertible
Preferred Stock&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On January 6, 2025, the
Company filed a certificate of designations of preferences, rights, and limitations of Series D Convertible Preferred Stock (the &#x201c;Series
D Certificate of Designations&#x201d;) with the Department of State, Division of Corporations, of the State of Delaware, which provides
for the designation of 5,000 shares of Series D Preferred Stock of the Company, par value $0.0001 per share, upon the terms and conditions
as set forth in the Series D Certificate of Designations. Each share of Series D Preferred Stock has a stated value of $1,000 (the &#x201c;Stated
Value&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The Series D Preferred
Stock shall rank (i) senior to the Company&#x2019;s common stock (the &#x201c;Common Stock&#x201d;) and any other class or series of capital
stock of the Company created hereafter, the terms of which specifically provide that such class or series shall rank junior to the Series
D Preferred Stock, (ii) pari passu with any class or series of capital stock of the Company created hereafter specifically ranking, by
its terms, on par with the Series D Preferred Stock, (iii) pari passu with the Series B Convertible Preferred Stock of the Company (the
&#x201c;Series B Preferred Stock&#x201d;) with respect to its rights, preferences and restrictions, and (iv) pari passu with the Series
C Convertible Preferred Stock of the Company (the &#x201c;Series C Preferred Stock&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Holders of the Series
D Preferred Stock have no voting power except as otherwise required by the Delaware General Corporation Law.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Upon any liquidation,
dissolution or winding-up of the Company, whether voluntary or involuntary (a &#x201c;Liquidation&#x201d;), the holders of the Series D
Preferred Stock shall be entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to the
payment in full of all amounts required to be distributed to the holders of another class or series of stock of the Company ranking on
liquidation prior and in preference to the Series D Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any class
or series of stock ranking on liquidation on parity with the Series D Preferred Stock and (iii) in preference and priority to the holders
of the shares of Common Stock, an amount equal to 100% of the Stated Value of the Series D Preferred Stock, in proportion to the full
and preferential amount that all shares of the Series D Preferred Stock are entitled to receive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Each share of Series
D Preferred Stock shall be convertible into Common Stock (the &#x201c;Conversion Shares&#x201d;) at a conversion per share equal to $2.41,
at the option of the holder, at any time after the Company has obtained shareholder approval for the issuance of the Conversion Shares
pursuant to the rules of the Nasdaq Stock Market. In addition, the holder shall not have the right to convert any portion of the Series
D Preferred Stock if, after giving effect to the conversion, such holder (together with its affiliates) would beneficially own in excess
of 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of the respective Conversion
Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On January 9, 2025, the
Company entered into an exchange agreement with Wenzhao Lu, the Company&#x2019;s chairman of the Board of Directors, pursuant to which
Mr. Lu exchanged 9,000 shares of Series A Preferred Stock of the Company for 5,000 shares of Series D Preferred Stock of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Redemption Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;During 2025, to preserve
cash, the Company entered into discussions with Lab Services MSO for the potential redemption of our investment and on February 26, 2025,
the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement (the &#x201c;Redemption Agreement&#x201d;), whereby
Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by the Company for cash and the surrender of its Series B Convertible
Preferred Stock having a carrying value of $11,000,000. The aggregate cash amount to the Company for the redemption was $1,745,000, to
be paid as follows: one payment of $95,000 at the closing of the redemption and, beginning in March 2025, monthly payments of $75,000
until December 2026. In addition, pursuant to the terms of the Redemption Agreement, all shares of the Company&#x2019;s Series B Convertible
Preferred Stock previously issued to SCBC Holdings LLC as partial consideration for the equity interests of Laboratory Services MSO, were
permanently surrendered and relinquished to the Company for no additional consideration. Accordingly, beginning in February 2025, the
Company no longer offers laboratory services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;b&gt;Agreement and Plan
of Merger&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;On March 7, 2025, the
Company, Nexus MergerSub Limited, a business company incorporated in the British Virgin Islands and a wholly owned subsidiary of the Company
(&#x201c;Merger Sub&#x201d;), and YOOV Group Holding Limited, a business company incorporated in the British Virgin Islands (&#x201c;YOOV&#x201d;),
entered into an Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;) pursuant to which Merger Sub will merge with and into
YOOV, with YOOV surviving the merger and becoming a direct, wholly owned subsidiary of the Company (the &#x201c;Merger&#x201d;). The Merger
is expected to be completed in the third quarter of 2025, subject to customary closing conditions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Subject to the terms and conditions of the Merger
Agreement, immediately prior to the effective time of the Merger (the &#x201c;Effective Time&#x201d;), each then-outstanding share of YOOV
preferred shares, par value $0.10 per share, will either automatically be converted into shares of YOOV ordinary shares, par value $0.10
per share (the &#x201c;YOOV Ordinary Shares&#x201d;) or canceled and cease to exist in accordance with their terms. At the Effective Time,
each then-outstanding YOOV Ordinary Share (other than any shares held in treasury and Dissenting Shares (as defined in the Merger Agreement))
will be automatically converted into a number of shares of the Company&#x2019;s common stock, par value $0.0001 per share (the &#x201c;Avalon
Common Stock&#x201d;), equal to the Exchange Ratio. The &#x201c;Exchange Ratio&#x201d; will be the ratio (rounded to four decimal places),
determined as follows: if the closing price of the Avalon Common Stock on The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) on the second
trading day immediately preceding the Effective Time is (x) less than or equal to $5.00, the Exchange Ratio shall be 60,000,000 divided
by YOOV Outstanding Shares (as defined in the Merger Agreement); or (y) greater than $5.00, the Exchange Ratio shall be 54,000,000 divided
by YOOV Outstanding Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the terms of the Merger Agreement,
(i) each then-outstanding share of Avalon Common Stock will remain issued and outstanding after the Effective Time and (ii) each then-outstanding
option to purchase Avalon Common Stock, whether or not vested, will remain issued and outstanding after the Effective Time. The then-outstanding
shares of Series C Convertible Preferred Stock of the Company and Series D Convertible Preferred Stock of the Company will remain outstanding
in accordance with their terms. Additionally, at the Effective Time, the name of the Company will be changed to &#x201c;YOOV, Inc.&#x201d;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the Merger, the Company will
seek approval of its stockholders to, among other things, (i) approve the issuance of the shares of Avalon Common Stock to be issued to
YOOV shareholders in connection with the Merger pursuant to the rules of Nasdaq and (ii) amend the Company&#x2019;s certificate of incorporation
to effect a reverse stock split of the Avalon Common Stock to the extent the Company and YOOV mutually agree implementing such reverse
stock split is necessary to meet Nasdaq&#x2019;s listing requirements (collectively, the &#x201c;Avalon Stockholder Matters&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Each of the Company and YOOV have made customary
representations, warranties and covenants in the Merger Agreement, including, among other things, covenants relating to (i) obtaining
the requisite approval of its respective stockholders, (ii) non-solicitation or facilitation of any Takeover Proposal or Superior Proposal
(as each is defined in the Merger Agreement), (iii) the conduct of its respective business during the period between the signing of the
Merger Agreement and the closing of the Merger, and (iv) the Company filing with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;)
and causing to become effective a registration statement on Form S-4 (the &#x201c;Registration Statement&#x201d;) to register the shares
of Avalon Common Stock to be issued in connection with the Merger.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Consummation of the Merger is subject to certain
closing conditions, including, among other things, (i) approval of the Avalon Stockholder Matters by the requisite the Company stockholders,
(ii) adoption and approval of the Merger Agreement, and the transactions contemplated thereby, by the requisite YOOV shareholders, (iii)
the effectiveness of the Registration Statement and (iv) the listing of the Avalon Common Stock issuable in connection with the Merger
on Nasdaq. Each party&#x2019;s obligation to consummate the Merger is also subject to other specified customary conditions, including regarding
the accuracy of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance
in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the
Effective Time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Merger Agreement contains certain termination
rights for both the Company and YOOV, including the right to terminate the Merger Agreement at any time before the Effective Time, whether
before or after the Avalon Stockholder Matters have been approved, by mutual written consent of the parties. In addition, the Merger Agreement
may be terminated at any time by either party if the Merger is not consummated on or before March 7, 2026 (the &#x201c;End Date&#x201d;),
provided that the End Date may be extended by either party for up to 60 days in the event that the SEC has not declared effective the
Registration Statement by the date which is 60 days prior to the End Date. Upon termination of the Merger Agreement under specified circumstances,
the Company may be required to pay YOOV a termination fee of $1.0 million; however, YOOV is not required to pay the Company a termination
fee.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At the Effective Time, the board of directors
of the Company (the &#x201c;Avalon Board&#x201d;) is expected to consist of seven (7) members, five (5) of whom will be designated by YOOV
and two (2) of whom will be designated by the Company, as provided in the Merger Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Voting and Support Agreements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Concurrently with the execution of the Merger
Agreement, (i) the officers, directors and certain shareholders of YOOV (solely in their respective capacities as YOOV shareholders) have
entered into voting and support agreements with the Company and YOOV, pursuant to which such YOOV shareholders agree, among other things
to, (a) not transfer their capital stock of YOOV, subject to certain limited exceptions and (b) vote all of their shares of capital stock
of YOOV in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and against, among other
things, any Takeover Proposals (the &#x201c;YOOV Voting Agreement&#x201d;) and (ii) the officers, directors and certain stockholders of
the Company (solely in their respective capacities as Avalon Stockholders) have entered into voting and support agreements with the Company
and YOOV, pursuant to which such the Company stockholders agree, among other things to, (a) not transfer their capital stock of the Company,
subject to certain limited exceptions and (b) vote all of their shares of capital stock of the Company in favor of, among other things,
the Avalon Stockholder Matters and against, among other things, any Takeover Proposals (the &#x201c;Avalon Voting Agreement&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Lock-Up Agreements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Concurrently with the execution of the Merger
Agreement, certain directors, officers and stockholders of each of the Company and YOOV have entered into lock-up agreements (the &#x201c;Lock-Up
Agreement&#x201d;), pursuant to which, subject to specified exceptions, they have agreed not to transfer their shares of Avalon Common
Stock, during the 180-day period following the Effective Time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Certificates of Elimination&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company previously designated (i) 15,000 shares
of preferred stock as Series A Convertible Preferred Stock (the &#x201c;Series A Preferred Stock&#x201d;), of which no shares remain outstanding
as a result of the exchange agreement entered with Wenzhao Lu on January 9, 2025 and (ii) 15,000 shares of Series B Preferred Stock, of
which no shares remain outstanding as a result of the surrender of the Series B Preferred Stock in connection with the redemption and
abandonment agreement with the Company, Avalon Laboratory Services, Inc., Laboratory Services MSO, LLC and the other parties signatory
thereto on February 26, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 7, 2025, the Company filed a Certificate
of Elimination relating to each of the Series A Preferred Stock and the Series B Preferred Stock (the &#x201c;Eliminations of Designation&#x201d;)
with the Secretary of State of the State of Delaware, thereby terminating the designations of the Series A Preferred Stock and the Series
B Preferred Stock. The Eliminations of Designation were effective upon filing and eliminated from the Company&#x2019;s Amended and Restated
Certificate of Incorporation (as amended and/or restated from time to time, the &#x201c;Avalon Charter&#x201d;) all matters set forth in
the previously-filed Certificates of Designations with respect to the previously designated Series A Preferred Stock and Series B Preferred
Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Bylaws Amendment&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 7, 2025, the Avalon Board approved and
adopted an amendment (the&#160;&#x201c;Amendment&#x201d;) to the Company&#x2019;s Amended and Restated Bylaws (the&#160;&#x201c;Avalon Bylaws&#x201d;).&#160;The
Amendment reduces the quorum at any meeting of stockholders, except as otherwise required by law or by the Avalon Charter or the Avalon
Bylaws, to one-third of the voting power of the shares of capital stock outstanding and entitled to vote at the meeting, present in person,
present by remote communication, if applicable, or represented by proxy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Common Shares Issued for Warrant Exercise&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In March 2025, the Company issued 186,877 shares
of its common stock upon cashless exercise of warrants to purchase 11,833 shares of common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Common Shares Issued for Services&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In March 2025, the Company issued a total of 22,278
shares of its common stock for services rendered and to be rendered. These shares were valued at $113,847, the fair market values on the
grant dates using the reported closing share prices on the dates of grant.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c545"
      decimals="0"
      id="ixv-90123"
      unitRef="shares">5000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c546"
      decimals="4"
      id="ixv-90124"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockValue contextRef="c546" decimals="0" id="ixv-90125" unitRef="usd">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="c547"
      decimals="2"
      id="ixv-90126"
      unitRef="pure">1</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c17"
      decimals="2"
      id="ixv-90127"
      unitRef="usdPershares">2.41</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:InvestmentOwnedPercentOfNetAssets contextRef="c17" decimals="4" id="ixv-90128" unitRef="pure">0.0499</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c548"
      decimals="0"
      id="ixv-90129"
      unitRef="shares">9000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c549"
      decimals="0"
      id="ixv-90130"
      unitRef="shares">5000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c550"
      decimals="2"
      id="ixv-90131"
      unitRef="pure">0.40</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:PreferredStockValue contextRef="c551" decimals="0" id="ixv-90132" unitRef="usd">11000000</us-gaap:PreferredStockValue>
    <us-gaap:RedemptionPremium contextRef="c552" decimals="0" id="ixv-90133" unitRef="usd">1745000</us-gaap:RedemptionPremium>
    <us-gaap:RedemptionPremium contextRef="c553" decimals="0" id="ixv-90134" unitRef="usd">95000</us-gaap:RedemptionPremium>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c554"
      decimals="2"
      id="ixv-90135"
      unitRef="usdPershares">0.1</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c555"
      decimals="2"
      id="ixv-90136"
      unitRef="usdPershares">0.1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockConvertibleConversionPriceDecrease
      contextRef="c18"
      decimals="4"
      id="ixv-90137"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockConvertibleConversionPriceDecrease>
    <avco:ExchangeRatioPerShare
      contextRef="c18"
      decimals="2"
      id="ixv-90138"
      unitRef="usdPershares">5</avco:ExchangeRatioPerShare>
    <us-gaap:SharesOutstanding
      contextRef="c556"
      decimals="0"
      id="ixv-90139"
      unitRef="shares">60000000</us-gaap:SharesOutstanding>
    <avco:ExchangeRatioPerShare
      contextRef="c557"
      decimals="2"
      id="ixv-90140"
      unitRef="usdPershares">5</avco:ExchangeRatioPerShare>
    <us-gaap:SharesOutstanding
      contextRef="c558"
      decimals="0"
      id="ixv-90141"
      unitRef="shares">54000000</us-gaap:SharesOutstanding>
    <us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees contextRef="c1" decimals="-5" id="ixv-90142" unitRef="usd">1000000</us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c559"
      decimals="0"
      id="ixv-90143"
      unitRef="shares">15000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c560"
      decimals="0"
      id="ixv-90144"
      unitRef="shares">15000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c561"
      decimals="0"
      id="ixv-90145"
      unitRef="shares">186877</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c562"
      decimals="0"
      id="ixv-90146"
      unitRef="shares">11833</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c563"
      decimals="0"
      id="ixv-90147"
      unitRef="shares">22278</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avco:FairMarketValuesOfGrantDates contextRef="c564" decimals="0" id="ixv-90148" unitRef="usd">113847</avco:FairMarketValuesOfGrantDates>
    <us-gaap:Cash contextRef="c11" decimals="0" id="ixv-90149" unitRef="usd">1369586</us-gaap:Cash>
    <us-gaap:Cash contextRef="c1" decimals="0" id="ixv-90150" unitRef="usd">2856309</us-gaap:Cash>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c11" decimals="0" id="ixv-90151" unitRef="usd">81854</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c1" decimals="0" id="ixv-90152" unitRef="usd">80829</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c11" decimals="0" id="ixv-90153" unitRef="usd">975000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c11" decimals="0" id="ixv-90154" unitRef="usd">367818</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c1" decimals="0" id="ixv-90155" unitRef="usd">299360</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c11" decimals="0" id="ixv-90156" unitRef="usd">2794258</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="0" id="ixv-90157" unitRef="usd">3236498</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c11" decimals="0" id="ixv-90158" unitRef="usd">113253</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="0" id="ixv-90159" unitRef="usd">4709</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LongTermInvestmentsAndReceivablesNet contextRef="c11" decimals="0" id="ixv-90160" unitRef="usd">675000</us-gaap:LongTermInvestmentsAndReceivablesNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c11" decimals="0" id="ixv-90161" unitRef="usd">10660</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="0" id="ixv-90162" unitRef="usd">12912</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RealEstateInvestments contextRef="c11" decimals="0" id="ixv-90163" unitRef="usd">6980551</us-gaap:RealEstateInvestments>
    <us-gaap:RealEstateInvestments contextRef="c1" decimals="0" id="ixv-90164" unitRef="usd">7022721</us-gaap:RealEstateInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c1" decimals="0" id="ixv-90165" unitRef="usd">10636544</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherAssetsNoncurrent contextRef="c11" decimals="0" id="ixv-90166" unitRef="usd">36067</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c1" decimals="0" id="ixv-90167" unitRef="usd">71794</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c11" decimals="0" id="ixv-90168" unitRef="usd">7815531</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c1" decimals="0" id="ixv-90169" unitRef="usd">17748680</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c11" decimals="0" id="ixv-90170" unitRef="usd">10609789</us-gaap:Assets>
    <us-gaap:Assets contextRef="c1" decimals="0" id="ixv-90171" unitRef="usd">20985178</us-gaap:Assets>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c11" decimals="0" id="ixv-90172" unitRef="usd">984869</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c1" decimals="0" id="ixv-90173" unitRef="usd">611462</us-gaap:AccruedProfessionalFeesCurrent>
    <avco:AccruedResearchAndDevelopmentsFees contextRef="c11" decimals="0" id="ixv-90174" unitRef="usd">153772</avco:AccruedResearchAndDevelopmentsFees>
    <avco:AccruedResearchAndDevelopmentsFees contextRef="c1" decimals="0" id="ixv-90175" unitRef="usd">153772</avco:AccruedResearchAndDevelopmentsFees>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="c11" decimals="0" id="ixv-90176" unitRef="usd">550931</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="c1" decimals="0" id="ixv-90177" unitRef="usd">501258</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:LitigationReserveCurrent contextRef="c11" decimals="0" id="ixv-90178" unitRef="usd">373450</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent contextRef="c1" decimals="0" id="ixv-90179" unitRef="usd">373450</us-gaap:LitigationReserveCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c11" decimals="0" id="ixv-90180" unitRef="usd">524872</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-90181" unitRef="usd">434117</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c12" decimals="0" id="ixv-90182" unitRef="usd">100000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c3" decimals="0" id="ixv-90183" unitRef="usd">732916</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c11" decimals="0" id="ixv-90184" unitRef="usd">67547</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c1" decimals="0" id="ixv-90185" unitRef="usd">10709</us-gaap:OperatingLeaseLiabilityCurrent>
    <avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty contextRef="c12" decimals="0" id="ixv-90186" unitRef="usd">3328078</avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty>
    <avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty contextRef="c3" decimals="0" id="ixv-90187" unitRef="usd">3108106</avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c11" decimals="0" id="ixv-90188" unitRef="usd">223052</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-90189" unitRef="usd">127545</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:NotesPayableToBankCurrent contextRef="c11" decimals="0" id="ixv-90190" unitRef="usd">5745254</us-gaap:NotesPayableToBankCurrent>
    <us-gaap:NotesPayableToBankCurrent contextRef="c1" decimals="0" id="ixv-90191" unitRef="usd">5715447</us-gaap:NotesPayableToBankCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c11" decimals="0" id="ixv-90192" unitRef="usd">2397528</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c1" decimals="0" id="ixv-90193" unitRef="usd">2113773</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c11" decimals="0" id="ixv-90194" unitRef="usd">14449353</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="0" id="ixv-90195" unitRef="usd">13882555</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c11" decimals="0" id="ixv-90196" unitRef="usd">51706</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c11" decimals="0" id="ixv-90197" unitRef="usd">51706</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c11" decimals="0" id="ixv-90198" unitRef="usd">14501059</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c1" decimals="0" id="ixv-90199" unitRef="usd">13882555</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c11"
      decimals="4"
      id="ixv-90200"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="4"
      id="ixv-90201"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c11"
      decimals="INF"
      id="ixv-90202"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-90203"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c13"
      decimals="INF"
      id="ixv-90204"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c13"
      decimals="INF"
      id="ixv-90205"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c5"
      decimals="INF"
      id="ixv-90206"
      unitRef="shares">9000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="ixv-90207"
      unitRef="shares">9000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c5" decimals="0" id="ixv-90208" unitRef="usd">9000000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c14"
      decimals="INF"
      id="ixv-90209"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c14"
      decimals="INF"
      id="ixv-90210"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c7"
      decimals="INF"
      id="ixv-90211"
      unitRef="shares">11000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c7"
      decimals="INF"
      id="ixv-90212"
      unitRef="shares">11000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c7" decimals="0" id="ixv-90213" unitRef="usd">11000000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c15"
      decimals="INF"
      id="ixv-90214"
      unitRef="shares">3500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c9"
      decimals="INF"
      id="ixv-90215"
      unitRef="shares">3500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c15"
      decimals="INF"
      id="ixv-90216"
      unitRef="shares">3500</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c9"
      decimals="INF"
      id="ixv-90217"
      unitRef="shares">3500</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="c15" decimals="-5" id="ixv-90218" unitRef="usd">3500000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockValue contextRef="c15" decimals="0" id="ixv-90219" unitRef="usd">3500000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c9" decimals="0" id="ixv-90220" unitRef="usd">3500000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c16"
      decimals="INF"
      id="ixv-90221"
      unitRef="shares">5000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c16"
      decimals="INF"
      id="ixv-90222"
      unitRef="shares">5000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c17"
      decimals="INF"
      id="ixv-90223"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c17"
      decimals="INF"
      id="ixv-90224"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="c16" decimals="-6" id="ixv-90225" unitRef="usd">5000000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockValue contextRef="c16" decimals="0" id="ixv-90226" unitRef="usd">8837527</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c11"
      decimals="4"
      id="ixv-90227"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="4"
      id="ixv-90228"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c11"
      decimals="INF"
      id="ixv-90229"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-90230"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c11"
      decimals="INF"
      id="ixv-90231"
      unitRef="shares">1655134</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c11"
      decimals="INF"
      id="ixv-90232"
      unitRef="shares">1651667</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c1"
      decimals="INF"
      id="ixv-90233"
      unitRef="shares">1445979</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-90234"
      unitRef="shares">1442512</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c11" decimals="0" id="ixv-90235" unitRef="usd">166</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c1" decimals="0" id="ixv-90236" unitRef="usd">145</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c11" decimals="0" id="ixv-90237" unitRef="usd">74673916</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c1" decimals="0" id="ixv-90238" unitRef="usd">72023525</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c11"
      decimals="INF"
      id="ixv-90239"
      unitRef="shares">3467</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c1"
      decimals="INF"
      id="ixv-90240"
      unitRef="shares">3467</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c11" decimals="0" id="ixv-90241" unitRef="usd">522500</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c1" decimals="0" id="ixv-90242" unitRef="usd">522500</us-gaap:TreasuryStockCommonValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c11" decimals="0" id="ixv-90243" unitRef="usd">-90155236</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="0" id="ixv-90244" unitRef="usd">-87673125</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance contextRef="c11" decimals="0" id="ixv-90245" unitRef="usd">6578</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance contextRef="c1" decimals="0" id="ixv-90246" unitRef="usd">6578</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c11" decimals="0" id="ixv-90247" unitRef="usd">-231721</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c1" decimals="0" id="ixv-90248" unitRef="usd">-232000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="0" id="ixv-90249" unitRef="usd">-3891270</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="0" id="ixv-90250" unitRef="usd">7102623</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c11" decimals="0" id="ixv-90251" unitRef="usd">-3891270</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c1" decimals="0" id="ixv-90252" unitRef="usd">7102623</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c11" decimals="0" id="ixv-90253" unitRef="usd">10609789</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="0" id="ixv-90254" unitRef="usd">20985178</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c20" decimals="0" id="ixv-90255" unitRef="usd">349800</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c21" decimals="0" id="ixv-90256" unitRef="usd">314588</us-gaap:Revenues>
    <us-gaap:OperatingExpenses contextRef="c20" decimals="0" id="ixv-90257" unitRef="usd">280390</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c21" decimals="0" id="ixv-90258" unitRef="usd">263126</us-gaap:OperatingExpenses>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c20" decimals="0" id="ixv-90259" unitRef="usd">69410</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c21" decimals="0" id="ixv-90260" unitRef="usd">51462</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c20" decimals="0" id="ixv-90261" unitRef="usd">392677</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c21" decimals="0" id="ixv-90262" unitRef="usd">107469</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:MarketingAndAdvertisingExpense contextRef="c20" decimals="0" id="ixv-90263" unitRef="usd">71150</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense contextRef="c21" decimals="0" id="ixv-90264" unitRef="usd">45000</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:ProfessionalFees contextRef="c20" decimals="0" id="ixv-90265" unitRef="usd">1691579</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c21" decimals="0" id="ixv-90266" unitRef="usd">442335</us-gaap:ProfessionalFees>
    <us-gaap:LaborAndRelatedExpense contextRef="c20" decimals="0" id="ixv-90267" unitRef="usd">340420</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c21" decimals="0" id="ixv-90268" unitRef="usd">353571</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c20" decimals="0" id="ixv-90269" unitRef="usd">165713</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c21" decimals="0" id="ixv-90270" unitRef="usd">161087</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OperatingCostsAndExpenses contextRef="c20" decimals="0" id="ixv-90271" unitRef="usd">2268862</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c21" decimals="0" id="ixv-90272" unitRef="usd">1001993</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c20" decimals="0" id="ixv-90273" unitRef="usd">-1806775</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c21" decimals="0" id="ixv-90274" unitRef="usd">-843062</us-gaap:OperatingIncomeLoss>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c20" decimals="0" id="ixv-90275" unitRef="usd">313562</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c21" decimals="0" id="ixv-90276" unitRef="usd">272196</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestExpenseOther contextRef="c20" decimals="0" id="ixv-90277" unitRef="usd">246456</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c21" decimals="0" id="ixv-90278" unitRef="usd">236215</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseDebt contextRef="c21" decimals="0" id="ixv-90279" unitRef="usd">10596</us-gaap:InterestExpenseDebt>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c20" decimals="0" id="ixv-90280" unitRef="usd">114360</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c21" decimals="0" id="ixv-90281" unitRef="usd">-31212</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingExpense contextRef="c20" decimals="0" id="ixv-90282" unitRef="usd">958</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="c21" decimals="0" id="ixv-90283" unitRef="usd">36656</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c20" decimals="0" id="ixv-90284" unitRef="usd">-675336</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c21" decimals="0" id="ixv-90285" unitRef="usd">-524451</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c20" decimals="0" id="ixv-90286" unitRef="usd">-2482111</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c21" decimals="0" id="ixv-90287" unitRef="usd">-1367513</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c20" decimals="0" id="ixv-90288" unitRef="usd">-2482111</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c21" decimals="0" id="ixv-90289" unitRef="usd">-1367513</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss contextRef="c20" decimals="0" id="ixv-90290" unitRef="usd">-2482111</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c21" decimals="0" id="ixv-90291" unitRef="usd">-1367513</us-gaap:NetIncomeLoss>
    <avco:DeemedContributionOnExchangeOfEquityInstruments contextRef="c20" decimals="0" id="ixv-90292" unitRef="usd">162473</avco:DeemedContributionOnExchangeOfEquityInstruments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c20" decimals="0" id="ixv-90293" unitRef="usd">-2319638</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c21" decimals="0" id="ixv-90294" unitRef="usd">-1367513</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20"
      decimals="2"
      id="ixv-90295"
      unitRef="usdPershares">-1.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20"
      decimals="2"
      id="ixv-90296"
      unitRef="usdPershares">-1.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c21"
      decimals="2"
      id="ixv-90297"
      unitRef="usdPershares">-1.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c21"
      decimals="2"
      id="ixv-90298"
      unitRef="usdPershares">-1.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20"
      decimals="INF"
      id="ixv-90299"
      unitRef="shares">1624629</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20"
      decimals="INF"
      id="ixv-90300"
      unitRef="shares">1624629</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c21"
      decimals="INF"
      id="ixv-90301"
      unitRef="shares">735225</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c21"
      decimals="INF"
      id="ixv-90302"
      unitRef="shares">735225</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss contextRef="c20" decimals="0" id="ixv-90303" unitRef="usd">-2482111</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c21" decimals="0" id="ixv-90304" unitRef="usd">-1367513</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="c20" decimals="0" id="ixv-90305" unitRef="usd">-279</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax contextRef="c21" decimals="0" id="ixv-90306" unitRef="usd">2920</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c20" decimals="0" id="ixv-90307" unitRef="usd">-2481832</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c21" decimals="0" id="ixv-90308" unitRef="usd">-1370433</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c20" decimals="0" id="ixv-90309" unitRef="usd">-2481832</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c21" decimals="0" id="ixv-90310" unitRef="usd">-1370433</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c61"
      decimals="INF"
      id="ixv-90311"
      unitRef="shares">9000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c61" decimals="0" id="ixv-90312" unitRef="usd">9000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c62"
      decimals="INF"
      id="ixv-90313"
      unitRef="shares">11000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c62" decimals="0" id="ixv-90314" unitRef="usd">11000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c63"
      decimals="INF"
      id="ixv-90315"
      unitRef="shares">3500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c63" decimals="0" id="ixv-90316" unitRef="usd">3500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c64"
      decimals="INF"
      id="ixv-90317"
      unitRef="shares">1445979</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c64" decimals="0" id="ixv-90318" unitRef="usd">145</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c65" decimals="0" id="ixv-90319" unitRef="usd">72023525</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c66"
      decimals="INF"
      id="ixv-90320"
      unitRef="shares">-3467</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c66" decimals="0" id="ixv-90321" unitRef="usd">-522500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c67" decimals="0" id="ixv-90322" unitRef="usd">-87673125</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c68" decimals="0" id="ixv-90323" unitRef="usd">6578</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c1" decimals="0" id="ixv-90324" unitRef="usd">7102623</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c69" decimals="0" id="ixv-90325" unitRef="usd">-232000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c74"
      decimals="INF"
      id="ixv-90326"
      unitRef="shares">186877</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c74" decimals="0" id="ixv-90327" unitRef="usd">19</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c75" decimals="0" id="ixv-90328" unitRef="usd">-19</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c74"
      decimals="INF"
      id="ixv-90329"
      unitRef="shares">22278</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c74" decimals="0" id="ixv-90330" unitRef="usd">2</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c75" decimals="0" id="ixv-90331" unitRef="usd">111230</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c76" decimals="0" id="ixv-90332" unitRef="usd">111232</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="c75" decimals="0" id="ixv-90333" unitRef="usd">18853</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="c76" decimals="0" id="ixv-90334" unitRef="usd">18853</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <avco:StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock
      contextRef="c71"
      decimals="INF"
      id="ixv-90335"
      unitRef="shares">-9000</avco:StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock>
    <avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock contextRef="c71" decimals="0" id="ixv-90336" unitRef="usd">-9000000</avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock>
    <avco:StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock
      contextRef="c77"
      decimals="INF"
      id="ixv-90337"
      unitRef="shares">5000</avco:StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock>
    <avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock contextRef="c77" decimals="0" id="ixv-90338" unitRef="usd">8837527</avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock>
    <avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock contextRef="c75" decimals="0" id="ixv-90339" unitRef="usd">162473</avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock>
    <avco:SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments
      contextRef="c72"
      decimals="INF"
      id="ixv-90340"
      unitRef="shares">-11000</avco:SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments>
    <avco:SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment contextRef="c72" decimals="0" id="ixv-90341" unitRef="usd">-11000000</avco:SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment>
    <avco:SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment contextRef="c75" decimals="0" id="ixv-90342" unitRef="usd">2348695</avco:SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment>
    <avco:SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment contextRef="c0" decimals="0" id="ixv-90343" unitRef="usd">-8651305</avco:SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c75" decimals="0" id="ixv-90344" unitRef="usd">9159</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c0" decimals="0" id="ixv-90345" unitRef="usd">9159</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c0" decimals="0" id="ixv-90346" unitRef="usd">279</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c80" decimals="0" id="ixv-90347" unitRef="usd">279</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:ProfitLoss contextRef="c78" decimals="0" id="ixv-90348" unitRef="usd">-2482111</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-90349" unitRef="usd">-2482111</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c83"
      decimals="INF"
      id="ixv-90350"
      unitRef="shares">3500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c83" decimals="0" id="ixv-90351" unitRef="usd">3500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c84"
      decimals="INF"
      id="ixv-90352"
      unitRef="shares">5000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c84" decimals="0" id="ixv-90353" unitRef="usd">8837527</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c85"
      decimals="INF"
      id="ixv-90354"
      unitRef="shares">1655134</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c85" decimals="0" id="ixv-90355" unitRef="usd">166</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c86" decimals="0" id="ixv-90356" unitRef="usd">74673916</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c87"
      decimals="INF"
      id="ixv-90357"
      unitRef="shares">-3467</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c87" decimals="0" id="ixv-90358" unitRef="usd">-522500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c88" decimals="0" id="ixv-90359" unitRef="usd">-90155236</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c89" decimals="0" id="ixv-90360" unitRef="usd">6578</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c11" decimals="0" id="ixv-90361" unitRef="usd">-3891270</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c91" decimals="0" id="ixv-90362" unitRef="usd">-231721</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c42"
      decimals="INF"
      id="ixv-90363"
      unitRef="shares">9000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c42" decimals="0" id="ixv-90364" unitRef="usd">9000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c43"
      decimals="INF"
      id="ixv-90365"
      unitRef="shares">11000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c43" decimals="0" id="ixv-90366" unitRef="usd">11000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c45"
      decimals="INF"
      id="ixv-90367"
      unitRef="shares">736769</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c45" decimals="0" id="ixv-90368" unitRef="usd">74</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c46" decimals="0" id="ixv-90369" unitRef="usd">67886082</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c47"
      decimals="INF"
      id="ixv-90370"
      unitRef="shares">-3467</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c47" decimals="0" id="ixv-90371" unitRef="usd">-522500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c48" decimals="0" id="ixv-90372" unitRef="usd">-79769731</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c49" decimals="0" id="ixv-90373" unitRef="usd">6578</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c50" decimals="0" id="ixv-90374" unitRef="usd">-231727</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" id="ixv-90375" unitRef="usd">7368776</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c94"
      decimals="INF"
      id="ixv-90376"
      unitRef="shares">7000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c94" decimals="0" id="ixv-90377" unitRef="usd">1</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c95" decimals="0" id="ixv-90378" unitRef="usd">41999</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c100" decimals="0" id="ixv-90379" unitRef="usd">42000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c95" decimals="0" id="ixv-90380" unitRef="usd">13533</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c100" decimals="0" id="ixv-90381" unitRef="usd">13533</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c98" decimals="0" id="ixv-90382" unitRef="usd">-2920</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="c100" decimals="0" id="ixv-90383" unitRef="usd">-2920</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:ProfitLoss contextRef="c96" decimals="0" id="ixv-90384" unitRef="usd">-1367513</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c100" decimals="0" id="ixv-90385" unitRef="usd">-1367513</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c101"
      decimals="INF"
      id="ixv-90386"
      unitRef="shares">9000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c101" decimals="0" id="ixv-90387" unitRef="usd">9000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c102"
      decimals="INF"
      id="ixv-90388"
      unitRef="shares">11000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c102" decimals="0" id="ixv-90389" unitRef="usd">11000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c103"
      decimals="INF"
      id="ixv-90390"
      unitRef="shares">743769</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c103" decimals="0" id="ixv-90391" unitRef="usd">75</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c104" decimals="0" id="ixv-90392" unitRef="usd">67941614</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c105"
      decimals="INF"
      id="ixv-90393"
      unitRef="shares">-3467</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c105" decimals="0" id="ixv-90394" unitRef="usd">-522500</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c106" decimals="0" id="ixv-90395" unitRef="usd">-81137244</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c107" decimals="0" id="ixv-90396" unitRef="usd">6578</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c108" decimals="0" id="ixv-90397" unitRef="usd">-234647</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c110" decimals="0" id="ixv-90398" unitRef="usd">6053876</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-90399" unitRef="usd">-2482111</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c100" decimals="0" id="ixv-90400" unitRef="usd">-1367513</us-gaap:ProfitLoss>
    <us-gaap:Depreciation contextRef="c0" decimals="0" id="ixv-90401" unitRef="usd">44428</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c100" decimals="0" id="ixv-90402" unitRef="usd">44481</us-gaap:Depreciation>
    <us-gaap:StraightLineRent contextRef="c0" decimals="0" id="ixv-90403" unitRef="usd">-29288</us-gaap:StraightLineRent>
    <us-gaap:StraightLineRent contextRef="c100" decimals="0" id="ixv-90404" unitRef="usd">-20548</us-gaap:StraightLineRent>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="0" id="ixv-90405" unitRef="usd">18956</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c100" decimals="0" id="ixv-90406" unitRef="usd">29448</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" id="ixv-90407" unitRef="usd">26371</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c100" decimals="0" id="ixv-90408" unitRef="usd">45746</us-gaap:ShareBasedCompensation>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c0" decimals="0" id="ixv-90409" unitRef="usd">392677</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c100" decimals="0" id="ixv-90410" unitRef="usd">107469</us-gaap:IncomeLossFromEquityMethodInvestments>
    <avco:DistributionOfEarningsFromEquityMethodInvestment contextRef="c100" decimals="0" id="ixv-90411" unitRef="usd">-160788</avco:DistributionOfEarningsFromEquityMethodInvestment>
    <avco:BeneficialConversionFeatureRelatedToConvertibleNotePayable contextRef="c0" decimals="0" id="ixv-90412" unitRef="usd">-313562</avco:BeneficialConversionFeatureRelatedToConvertibleNotePayable>
    <avco:BeneficialConversionFeatureRelatedToConvertibleNotePayable contextRef="c100" decimals="0" id="ixv-90413" unitRef="usd">-272196</avco:BeneficialConversionFeatureRelatedToConvertibleNotePayable>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c0" decimals="0" id="ixv-90414" unitRef="usd">114360</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c100" decimals="0" id="ixv-90415" unitRef="usd">-31212</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c100" decimals="0" id="ixv-90416" unitRef="usd">-113024</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInSecurityDeposits contextRef="c0" decimals="0" id="ixv-90417" unitRef="usd">5473</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <avco:IncreaseDecreaseInDeferredLeasingCosts contextRef="c0" decimals="0" id="ixv-90418" unitRef="usd">8021</avco:IncreaseDecreaseInDeferredLeasingCosts>
    <avco:IncreaseDecreaseInDeferredLeasingCosts contextRef="c100" decimals="0" id="ixv-90419" unitRef="usd">8350</avco:IncreaseDecreaseInDeferredLeasingCosts>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="0" id="ixv-90420" unitRef="usd">24698</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c100" decimals="0" id="ixv-90421" unitRef="usd">3739</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="0" id="ixv-90422" unitRef="usd">556057</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c100" decimals="0" id="ixv-90423" unitRef="usd">-14758</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <avco:AccruedLiabilitiesAndOtherPayablesRelatedParties contextRef="c100" decimals="0" id="ixv-90424" unitRef="usd">62151</avco:AccruedLiabilitiesAndOtherPayablesRelatedParties>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="0" id="ixv-90425" unitRef="usd">-18956</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c100" decimals="0" id="ixv-90426" unitRef="usd">-23448</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-90427" unitRef="usd">-1801926</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c100" decimals="0" id="ixv-90428" unitRef="usd">-915709</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c0" decimals="0" id="ixv-90429" unitRef="usd">95000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" id="ixv-90430" unitRef="usd">95000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <avco:ProceedsFromIssuanceOfConvertibleDebtAndWarrants contextRef="c100" decimals="0" id="ixv-90431" unitRef="usd">-665000</avco:ProceedsFromIssuanceOfConvertibleDebtAndWarrants>
    <avco:PaymentsOfConvertibleDebtIssuanceCosts contextRef="c100" decimals="0" id="ixv-90432" unitRef="usd">72700</avco:PaymentsOfConvertibleDebtIssuanceCosts>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c100" decimals="0" id="ixv-90433" unitRef="usd">866000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders contextRef="c0" decimals="0" id="ixv-90434" unitRef="usd">219972</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders contextRef="c100" decimals="0" id="ixv-90435" unitRef="usd">1210472</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" id="ixv-90436" unitRef="usd">219972</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c100" decimals="0" id="ixv-90437" unitRef="usd">936772</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c0" decimals="0" id="ixv-90438" unitRef="usd">231</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c100" decimals="0" id="ixv-90439" unitRef="usd">-995</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="0" id="ixv-90440" unitRef="usd">-1486723</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c100" decimals="0" id="ixv-90441" unitRef="usd">20068</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="0" id="ixv-90442" unitRef="usd">2856309</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" id="ixv-90443" unitRef="usd">285400</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c11" decimals="0" id="ixv-90444" unitRef="usd">1369586</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c110" decimals="0" id="ixv-90445" unitRef="usd">305468</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="0" id="ixv-90446" unitRef="usd">164500</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c100" decimals="0" id="ixv-90447" unitRef="usd">238782</us-gaap:InterestPaidNet>
    <us-gaap:ConversionOfStockAmountIssued1 contextRef="c0" decimals="0" id="ixv-90448" unitRef="usd">51635</us-gaap:ConversionOfStockAmountIssued1>
    <avco:CommonStockIssuedForAccruedLiabilities contextRef="c0" decimals="0" id="ixv-90449" unitRef="usd">42385</avco:CommonStockIssuedForAccruedLiabilities>
    <avco:ReceivableRelatedToSaleOfEquityMethodInvestment contextRef="c0" decimals="0" id="ixv-90450" unitRef="usd">1745000</avco:ReceivableRelatedToSaleOfEquityMethodInvestment>
    <avco:RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment contextRef="c0" decimals="0" id="ixv-90451" unitRef="usd">632916</avco:RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment>
    <avco:SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment contextRef="c0" decimals="0" id="ixv-90452" unitRef="usd">11000000</avco:SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment>
    <avco:SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock contextRef="c0" decimals="0" id="ixv-90453" unitRef="usd">9000000</avco:SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock>
    <avco:WarrantsIssuedAsConvertibleNotePayableFindersFee contextRef="c100" decimals="0" id="ixv-90454" unitRef="usd">1679</avco:WarrantsIssuedAsConvertibleNotePayableFindersFee>
    <avco:WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount contextRef="c100" decimals="0" id="ixv-90455" unitRef="usd">20374</avco:WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount>
    <avco:CommonStockIssuedAsConvertibleNotePayableCommitmentFee contextRef="c100" decimals="0" id="ixv-90456" unitRef="usd">42000</avco:CommonStockIssuedAsConvertibleNotePayableCommitmentFee>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c100" decimals="0" id="ixv-90457" unitRef="usd">666667</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <avco:SettlementsOfDerivativeLiability contextRef="c0" decimals="0" id="ixv-90458" unitRef="usd">18853</avco:SettlementsOfDerivativeLiability>
    <avco:IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant contextRef="c0" decimals="0" id="ixv-90459" unitRef="usd">19</avco:IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="0" id="ixv-90460" unitRef="usd">127486</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations contextRef="c0" id="ixv-72279">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;NOTE 1 - &lt;span style="text-decoration:underline"&gt;ORGANIZATION AND NATURE OF OPERATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Avalon GloboCare Corp. (the &#x201c;Company&#x201d;
or &#x201c;ALBT&#x201d;) was incorporated under the laws of the State of Delaware on July 28, 2014.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;The Company is a
commercial-stage company dedicated to developing and delivering precision diagnostic consumer products and the advancement of intellectual
property in cellular therapy. The Company is currently marketing the KetoAir&#x2122; breathalyzer device and plans to develop additional
diagnostic uses of the breathalyzer technology. The KetoAir&lt;/span&gt;&lt;span style="-sec-ix-redline:true;font-size: 12.5pt"&gt;&lt;sup&gt;TM&lt;/sup&gt;&lt;/span&gt; &lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;is
registered with the U.S. Food and Drug Administration as a Class I medical device.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On May 18, 2015, Avalon Healthcare System, Inc.
(&#x201c;AHS&#x201d;) was incorporated under the laws of the State of Delaware. AHS owns 100% of the capital stock of Avalon (Shanghai)
Healthcare Technology Co., Ltd. (&#x201c;Avalon Shanghai&#x201d;), which is a wholly foreign-owned enterprise organized under the laws
of the People&#x2019;s Republic of China (&#x201c;PRC&#x201d;). Avalon Shanghai was incorporated on April 29, 2016, and was engaged in medical
related consulting services for customers. Due to the winding down of the medical related consulting services in 2022, the Company decided
to cease all operations of Avalon Shanghai and no longer has any material revenues or expenses in Avalon Shanghai. As a result, Avalon
Shanghai is no longer an operating entity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On February 7, 2017, the Company formed Avalon
RT 9 Properties, LLC (&#x201c;Avalon RT 9&#x201d;), a New Jersey limited liability company. On May 5, 2017, Avalon RT 9 purchased a real
property located in Township of Freehold, County of Monmouth, State of New Jersey, having a street address of 4400 Route 9 South, Freehold,
NJ 07728. This property was purchased to serve as the Company&#x2019;s world-wide headquarters for all corporate administration and operations.
In addition, the property generates rental income. Avalon RT 9 owns this office building. Avalon RT 9&#x2019;s business consists of the
ownership and operation of the income-producing real estate property in New Jersey. As of March 31, 2025, the occupancy rate of the building
is 96.2%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On July 18, 2018, the Company formed a wholly
owned subsidiary, Avactis Biosciences Inc. (&#x201c;Avactis&#x201d;), a Nevada corporation, which is a patent holding company. Commencing
on April 6, 2022, the Company owns 60% of Avactis and Arbele Biotherapeutics Limited (&#x201c;Arbele Biotherapeutics&#x201d;) owns 40%
of Avactis. Avactis owns 100% of the capital stock of Avactis Nanjing Biosciences Ltd., a company incorporated in the PRC on May 8, 2020
(&#x201c;Avactis Nanjing&#x201d;), which only owns a patent and is not considered an operating entity. Currently, Avactis and Avactis Nanjing
are dormant and are in process of being dissolved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On October 14, 2022, the Company formed a wholly
owned subsidiary, Avalon Laboratory Services, Inc. (&#x201c;Avalon Lab&#x201d;), a Delaware company. On February 9, 2023, Avalon Lab purchased
40% of the issued and outstanding equity interests of Laboratory Services MSO, LLC, a private limited company formed under the laws of
the State of Delaware on September 6, 2019 (&#x201c;Lab Services MSO&#x201d;), and its subsidiaries. Lab Services MSO, through its subsidiaries,
is engaged in providing laboratory testing services. During the first quarter of 2025, to preserve cash, the Company entered into discussions
with Lab Services MSO for the potential redemption of our investment and on February 26, 2025, Lab Services MSO redeemed the 40% equity
interest in Lab Services MSO held by Avalon Lab.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On May 1, 2024, the Company formed a wholly owned
subsidiary, Q&amp;amp;A Distribution LLC (&#x201c;Q&amp;amp;A Distribution&#x201d;), a Texas company. Q&amp;amp;A Distribution is engaged in distribution
of KetoAir device.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Details of the Company&#x2019;s subsidiaries which
are included in these condensed consolidated financial statements as of March 31, 2025 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr&gt; &lt;td style="border-bottom: black 1.5pt solid; vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 29%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Name of Subsidiary&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-bottom: 1.5pt; padding-left: 5.65pt; text-align: center; width: 2%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 15%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Place and Date of Incorporation&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-bottom: 1.5pt; padding-left: 5.65pt; text-align: center; width: 2%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 15%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Percentage of Ownership&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-bottom: 1.5pt; padding-left: 5.65pt; text-align: center; width: 2%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 35%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Principal Activities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: #CCEEFF"&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Avalon Healthcare System, Inc. (&#x201c;AHS&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Delaware May 18, 2015&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;100% held by ALBT&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Holding company for payroll and other expenses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: #CCEEFF"&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Avalon RT 9 Properties LLC (&#x201c;Avalon RT 9&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;New Jersey February 7, 2017&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;100% held by ALBT&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Owns and operates an income-producing real property and holds and manages the corporate headquarters&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: #CCEEFF"&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Avalon (Shanghai) Healthcare Technology Co., Ltd. (&#x201c;Avalon Shanghai&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;PRC April 29, 2016&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;100% held by AHS&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Not considered an operating entity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: #CCEEFF"&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Genexosome Technologies Inc. (&#x201c;Genexosome&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Nevada July 31, 2017&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;60% held by ALBT&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;No current activities to report; dormant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: #CCEEFF"&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Avactis Biosciences Inc. (&#x201c;Avactis&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Nevada July 18, 2018&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;60% held by ALBT&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Dormant; in process of being dissolved&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: #CCEEFF"&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Avactis Nanjing Biosciences Ltd. (&#x201c;Avactis Nanjing&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;PRC May 8, 2020&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;100% held by Avactis&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Dormant; in process of being dissolved&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: #CCEEFF"&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Avalon Laboratory Services, Inc. (&#x201c;Avalon Lab&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Delaware October 14, 2022&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;100% held by ALBT&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;No current activities to report; dormant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: #CCEEFF"&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Q&amp;amp;A Distribution LLC (&#x201c;Q&amp;amp;A Distribution&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Texas May 1, 2024&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;100% held by ALBT&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Distributes KetoAir device&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c565"
      decimals="2"
      id="ixv-90461"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c566"
      decimals="3"
      id="ixv-90462"
      unitRef="pure">0.962</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c113"
      decimals="2"
      id="ixv-90463"
      unitRef="pure">0.60</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c567"
      decimals="2"
      id="ixv-90464"
      unitRef="pure">0.40</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c568"
      decimals="2"
      id="ixv-90465"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c116"
      decimals="2"
      id="ixv-90466"
      unitRef="pure">0.40</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c569"
      decimals="2"
      id="ixv-90467"
      unitRef="pure">0.40</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock contextRef="c0" id="ixv-72344">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Details of the Company&#x2019;s subsidiaries which
are included in these condensed consolidated financial statements as of March 31, 2025 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr&gt; &lt;td style="border-bottom: black 1.5pt solid; vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 29%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Name of Subsidiary&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-bottom: 1.5pt; padding-left: 5.65pt; text-align: center; width: 2%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 15%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Place and Date of Incorporation&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-bottom: 1.5pt; padding-left: 5.65pt; text-align: center; width: 2%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 15%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Percentage of Ownership&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-bottom: 1.5pt; padding-left: 5.65pt; text-align: center; width: 2%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 35%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Principal Activities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: #CCEEFF"&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Avalon Healthcare System, Inc. (&#x201c;AHS&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Delaware May 18, 2015&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;100% held by ALBT&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Holding company for payroll and other expenses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: #CCEEFF"&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Avalon RT 9 Properties LLC (&#x201c;Avalon RT 9&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;New Jersey February 7, 2017&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;100% held by ALBT&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Owns and operates an income-producing real property and holds and manages the corporate headquarters&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: #CCEEFF"&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Avalon (Shanghai) Healthcare Technology Co., Ltd. (&#x201c;Avalon Shanghai&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;PRC April 29, 2016&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;100% held by AHS&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Not considered an operating entity&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: #CCEEFF"&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Genexosome Technologies Inc. (&#x201c;Genexosome&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Nevada July 31, 2017&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;60% held by ALBT&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;No current activities to report; dormant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: #CCEEFF"&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Avactis Biosciences Inc. (&#x201c;Avactis&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Nevada July 18, 2018&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;60% held by ALBT&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Dormant; in process of being dissolved&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: #CCEEFF"&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Avactis Nanjing Biosciences Ltd. (&#x201c;Avactis Nanjing&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;PRC May 8, 2020&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;100% held by Avactis&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Dormant; in process of being dissolved&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: #CCEEFF"&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Avalon Laboratory Services, Inc. (&#x201c;Avalon Lab&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Delaware October 14, 2022&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;100% held by ALBT&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;No current activities to report; dormant&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: #CCEEFF"&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Q&amp;amp;A Distribution LLC (&#x201c;Q&amp;amp;A Distribution&#x201d;)&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Texas May 1, 2024&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;100% held by ALBT&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Distributes KetoAir device&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock>
    <avco:EquityMethodInvestmentPlaceAndDateOfIncorporation contextRef="c570" id="ixv-72372">Delaware May 18, 2015</avco:EquityMethodInvestmentPlaceAndDateOfIncorporation>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c570"
      decimals="2"
      id="ixv-90468"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c570" id="ixv-72381">Holding company for payroll and other expenses</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <avco:EquityMethodInvestmentPlaceAndDateOfIncorporation contextRef="c571" id="ixv-72404">New Jersey February 7, 2017</avco:EquityMethodInvestmentPlaceAndDateOfIncorporation>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c571"
      decimals="2"
      id="ixv-90469"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c571" id="ixv-72413">Owns and operates an income-producing real property and holds and manages the corporate headquarters</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <avco:EquityMethodInvestmentPlaceAndDateOfIncorporation contextRef="c572" id="ixv-72436">PRC April 29, 2016</avco:EquityMethodInvestmentPlaceAndDateOfIncorporation>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c572"
      decimals="2"
      id="ixv-90470"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c572" id="ixv-72445">Not considered an operating entity</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <avco:EquityMethodInvestmentPlaceAndDateOfIncorporation contextRef="c573" id="ixv-72468">Nevada July 31, 2017</avco:EquityMethodInvestmentPlaceAndDateOfIncorporation>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c573"
      decimals="2"
      id="ixv-90471"
      unitRef="pure">0.60</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c573" id="ixv-72477">No current activities to report; dormant</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <avco:EquityMethodInvestmentPlaceAndDateOfIncorporation contextRef="c574" id="ixv-72500">Nevada July 18, 2018</avco:EquityMethodInvestmentPlaceAndDateOfIncorporation>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c574"
      decimals="2"
      id="ixv-90472"
      unitRef="pure">0.60</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c574" id="ixv-72509">Dormant; in process of being dissolved</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <avco:EquityMethodInvestmentPlaceAndDateOfIncorporation contextRef="c575" id="ixv-72532">PRC May 8, 2020</avco:EquityMethodInvestmentPlaceAndDateOfIncorporation>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c575"
      decimals="2"
      id="ixv-90473"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c575" id="ixv-72541">Dormant; in process of being dissolved</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <avco:EquityMethodInvestmentPlaceAndDateOfIncorporation contextRef="c576" id="ixv-72564">Delaware October 14, 2022</avco:EquityMethodInvestmentPlaceAndDateOfIncorporation>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c576"
      decimals="2"
      id="ixv-90474"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c576" id="ixv-72573">No current activities to report; dormant</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <avco:EquityMethodInvestmentPlaceAndDateOfIncorporation contextRef="c577" id="ixv-72596">Texas May 1, 2024</avco:EquityMethodInvestmentPlaceAndDateOfIncorporation>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest
      contextRef="c577"
      decimals="2"
      id="ixv-90475"
      unitRef="pure">1</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest>
    <us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose contextRef="c577" id="ixv-72605">Distributes KetoAir device</us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c0" id="ixv-72611">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;NOTE 2 - &lt;span style="text-decoration:underline"&gt;BASIS OF PRESENTATION AND GOING CONCERN CONDITION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;These interim condensed consolidated financial
statements of the Company and its subsidiaries are unaudited. In the opinion of management, all adjustments (consisting of normal recurring
accruals) and disclosures necessary for a fair presentation of these interim condensed consolidated financial statements have been included.
The results reported in the condensed consolidated financial statements for any interim periods are not necessarily indicative of the
results that may be reported for the entire year. The accompanying condensed consolidated financial statements have been prepared in
accordance with the rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) and do not include all information
and footnotes necessary for a complete presentation of financial statements in conformity with accounting principles generally accepted
in the United States (&#x201c;U.S. GAAP&#x201d;). The Company&#x2019;s condensed consolidated financial statements include the accounts
of the Company and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Certain information and footnote disclosures normally
included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These
condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements
and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC
on March 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Going Concern&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company is a commercial-stage company dedicated
to developing and delivering precision diagnostic consumer products. The Company is currently marketing the KetoAir breathalyzer device
and plans to develop additional diagnostic uses of the breathalyzer technology. In addition, the Company owns commercial real estate
that houses its headquarters in Freehold, New Jersey. These condensed consolidated financial statements have been prepared assuming that
the Company will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction
of liabilities in the normal course of business.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As reflected in the accompanying condensed consolidated
financial statements, the Company had a working capital deficit of approximately $11,655,000 at March 31, 2025 and had incurred recurring
net losses and generated negative cash flow from operating activities of approximately $2,482,000 and $1,802,000 for the three months
ended March 31, 2025, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has a limited operating history and
its continued growth is dependent upon the continuation of generating rental revenue from its income-producing real estate property in
New Jersey, generating revenue for selling of KetoAir, and obtaining additional financing to fund future obligations and pay liabilities
arising from normal business operations. In addition, the current cash balance cannot be projected to cover the operating expenses for
the next twelve months from the release date of this report. These matters raise substantial doubt about the Company&#x2019;s ability
to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company&#x2019;s ability
to raise additional capital, implement its business plan, and generate significant revenue. There are no assurances that the Company
will be successful in its efforts to generate significant revenue, maintain sufficient cash balance or report profitable operations or
to continue as a going concern. The Company plans on raising capital through the sale of equity to implement its business plan. However,
there is no assurance these plans will be realized and that any additional financings will be available to the Company on satisfactory
terms and conditions, if any.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The accompanying condensed consolidated financial
statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and
classification of liabilities that may result should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <avco:WorkingCapitalDeficit contextRef="c11" decimals="0" id="ixv-90476" unitRef="usd">11655000</avco:WorkingCapitalDeficit>
    <us-gaap:ProfitLoss
      contextRef="c578"
      decimals="-3"
      id="ixv-90477"
      unitRef="usd">-2482000</us-gaap:ProfitLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-90478" unitRef="usd">-1802000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-72682">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;NOTE 3 - &lt;span style="text-decoration:underline"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The preparation of condensed consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Changes in these estimates and assumptions may have a material impact on the condensed
consolidated financial statements and accompanying notes. Making estimates requires management to exercise significant judgment. It is
at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date
of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more
future confirming events. Accordingly, the actual results could differ significantly from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Significant estimates during the three months
ended March 31, 2025 and 2024 include the useful life of investment in real estate and intangible assets, the assumptions used in assessing
impairment of long-term assets, the valuation of deferred tax assets and the associated valuation allowances, the valuation of stock-based
compensation, the valuation of Series D convertible preferred stock (&#x201c;Series D Preferred Stock&#x201d;), and the assumptions used
to determine fair value of warrants and embedded conversion features of convertible note payable.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Fair Value of Financial Instruments and Fair Value Measurements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company adopted the guidance of the Financial
Accounting Standards Board&#x2019;s (the &#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820 for fair value
measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value
hierarchy to classify the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Level 1-Inputs are unadjusted quoted prices in active markets for
    identical assets or liabilities available at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Level 2-Inputs are unadjusted quoted prices for similar assets and
    liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs
    other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Level 3-Inputs are unobservable inputs which reflect the reporting
    entity&#x2019;s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the
    best available information.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The fair value of the Company&#x2019;s assets and
liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying
amounts represented in the accompanying condensed consolidated financial statements, primarily due to their short-term nature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;b&gt;&lt;i&gt;Assets and liabilities measured at fair
value on a recurring basis. &lt;/i&gt;&lt;/b&gt;Certain assets and liabilities are measured at fair value on a recurring basis. These assets and
liabilities are measured at fair value on an ongoing basis. These assets and liabilities include derivative liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Derivative liability. &lt;/i&gt;Derivative liability
is carried at fair value and measured on an ongoing basis. The table below reflects the activity of derivative liability measured at
fair value for the three months ended March 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Significant &lt;br/&gt;
    Unobservable Inputs&lt;br/&gt; (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Balance of derivative liability as of January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;127,545&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Reclassification of additional paid-in capital upon conversion&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(18,853&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss from change in the fair value of derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;114,360&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Balance of derivative liability as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;223,052&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ASC 825-10 &#x201c;Financial Instruments&#x201d;,
allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair
value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value
option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent
reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;At March 31, 2025 and December 31, 2024, the Company&#x2019;s
cash balances by geographic area were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Country:&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March 31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December 31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,351,923&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;98.7&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,844,522&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;99.6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;17,663&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;11,787&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total cash&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,369,586&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;100.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,856,309&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;100.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For purposes of the condensed consolidated statements
of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less when purchased and money market
accounts to be cash equivalents. The Company had no cash equivalents at March 31, 2025 and December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Credit Risk and Uncertainties&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company maintains a portion of its cash on
deposits with bank and financial institution within the U.S. that at times may exceed federally-insured limits of $250,000. The Company
manages this credit risk by concentrating its cash balances in high quality financial institutions and by periodically evaluating the
credit quality of the primary financial institutions holding such deposits. The Company has not experienced any losses in such bank accounts
and believes it is not exposed to any risks on its cash in bank accounts. At March 31, 2025, the Company&#x2019;s cash balances in United
States bank accounts had approximately $840,000 in excess of the federally-insured limits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company&#x2019;s concentrations of credit risk
with respect to its rent receivable is limited due to short-term payment terms. The Company also performs ongoing credit evaluations
of its tenants to help further reduce credit risk.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Investment in Unconsolidated Company&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company uses the equity method of accounting
for its investment in, and earning or loss of, investees that it does not control but over which it does exert significant influence.
The Company applies the equity method by initially recording these investments at cost, as equity method investments, subsequently adjusted
for equity in earnings and cash distributions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company considers whether the fair value of
its equity method investment has declined below its carrying value whenever adverse events or changes in circumstances indicate that
recorded value may not be recoverable. If the Company considers any decline to be other than temporary (based on various factors, including
historical financial results and the overall health of the investee), then a write-down would be recorded to estimated fair value. See
Note 5 for discussion of equity method investment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company classifies distributions received
from equity method investments using the cumulative earnings approach. Distributions received are considered returns on the investment
and classified as cash inflows from operating activities. If, however, the investor&#x2019;s cumulative distributions received, less distributions
received in prior periods determined to be returns of investment, exceeds cumulative equity in earnings recognized, the excess is considered
a return of investment and is classified as cash inflows from investing activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Receivable from Sale of Equity Method Investment&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the first quarter of 2025, to preserve
cash, the Company entered into discussions with Lab Services MSO for the potential redemption of our investment and on February 26, 2025,
the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement (the &#x201c;Redemption Agreement&#x201d;), whereby
Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by the Company for cash and the surrender of its Series B
convertible preferred stock (&#x201c;Series B Preferred Stock&#x201d;) having a carrying value of $11,000,000. The aggregate cash amount
to the Company for the redemption was $1,745,000, to be paid as follows: one payment of $95,000 at the closing of the redemption and,
beginning in March 2025, monthly payments of $75,000 until December 2026. In addition, pursuant to the terms of the Redemption Agreement,
all shares of the Company&#x2019;s Series B Preferred Stock previously issued to SCBC Holdings LLC as partial consideration for the equity
interests of Laboratory Services MSO, were permanently surrendered and relinquished to the Company for no additional consideration. The
difference of $2,348,695 between the carrying value of the extinguished Series B Preferred Stock, the aggregate cash amount to the Company
for the redemption, net of the payables due to Lab Services MSO of $632,916, totaling $13,377,916, and the carrying value of the equity
method investment of $11,029,221 was accounted for as an increase to additional paid-in capital (See Note 10 - Series B Convertible Preferred
Stock Extinguished Related to Sale of Equity Method Investment). Accordingly, beginning in February 2025, the Company no longer offers
laboratory services. As of March 31, 2025, the receivable from sale of equity method investment amounted to $1,650,000, of which $975,000
was included in current assets and $675,000 was included in non-current assets. Management believes that the receivable is fully collectable.
Therefore, no material allowance for doubtful accounts was deemed to be required on the receivable at March 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Per Share Data&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ASC Topic 260 &#x201c;Earnings per Share,&#x201d;
requires presentation of both basic and diluted earnings per share (&#x201c;EPS&#x201d;) with a reconciliation of the numerator and denominator
of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Basic net loss per share is computed by dividing
net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents
and potentially dilutive securities outstanding during each period. The Company had $162,473 in deemed contribution during the three
months ended March 31, 2025, which increases the numerator in the net loss per share calculation. For the three months ended March 31,
2025 and 2024, potentially dilutive common shares consisted of the common shares issuable upon the conversion of convertible preferred
stock and convertible notes (using the if-converted method) and exercise of common stock options and warrants (using the treasury stock
method). Common stock equivalents are not included in the calculation of diluted net loss per share if their effect would be anti-dilutive.
In a period in which the Company has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares
outstanding as they would have had an anti-dilutive impact.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The calculation of basic and diluted net loss
per common share attributable to the Company common shareholders includes 150,000 of the pre-funded warrants that remained outstanding
as of March 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table summarizes the securities
that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,451,425&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;47,287&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;171,163&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;60,562&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Series A convertible preferred stock &lt;/span&gt;&lt;span style="-sec-ix-redline:true;font-size: 12.5pt"&gt;&lt;sup&gt;(*)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-380"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Series B convertible preferred stock &lt;/span&gt;&lt;span style="-sec-ix-redline:true;font-size: 12.5pt"&gt;&lt;sup&gt;(**)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-381"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;194,004&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Series C convertible preferred stock &lt;/span&gt;&lt;span style="-sec-ix-redline:true;font-size: 12.5pt"&gt;&lt;sup&gt;(***)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,452,282&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-382"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Series D convertible preferred stock (****)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,074,689&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-383"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Convertible notes and related accrued interest
    &lt;/span&gt;&lt;span style="-sec-ix-redline:true;font-size: 12.5pt"&gt;&lt;sup&gt;(*****)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;234,554&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;90,133&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,384,113&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;451,986&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.6in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;(*)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Assumed the Series A convertible preferred stock (&#x201c;Series A Preferred Stock&#x201d;) was converted into shares of common stock of the Company at a conversion price of $150.00 per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.6in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;(**)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Assumed the Series B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.6in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;(***)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Assumed the Series C convertible preferred stock (&#x201c;Series C Preferred Stock&#x201d;) was converted into shares of common stock of the Company at a conversion price of $2.41 per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.6in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;(****)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Assumed the Series D convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $2.41 per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.6in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;(*****)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the three months ended March 31, 2025. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and $22.50 and $15.00 per share for the three months ended March 31, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Real Property Rental Revenue&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has determined that ASC 606 does not
apply to rental contracts, which are within the scope of other revenue recognition accounting standards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Rental income from operating leases is recognized
on a straight-line basis under the guidance of ASC 842. Lease payments under tenant leases are recognized on a straight-line basis over
the term of the related leases. The cumulative difference between lease revenue recognized under the straight-line method and contractual
lease payments are included in rent receivable on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In the normal course of business, the Company
is subject to contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters. Liabilities
for such contingencies are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably
estimated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Segment Reporting&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The segment reporting structure uses the Company&#x2019;s
management reporting structure as its foundation to reflect how the Company manages the businesses internally and was mainly organized
by services. During the three months ended March 31, 2025 and 2024, the Company is organized into two services-oriented strategic business
units: real property rental services and laboratory testing services (which ended on the redemption date, February 26, 2025) - which
are led by our strategic business unit managers. Operating segments are defined as components of an enterprise for which separate financial
information is available and evaluated regularly by the chief operating decision maker (&#x201c;CODM&#x201d;) in deciding how to make operating
decisions, allocate resources and assess performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On February 9, 2023, the Company purchased 40%
of Lab Services MSO. During the first quarter of 2025, to preserve cash, the Company entered into discussions with Lab Services MSO for
the potential redemption of Avalon Lab&#x2019;s investment and on February 26, 2025, Lab Services MSO redeemed the 40% equity interest
in Lab Services MSO held by Avalon Lab. Commencing from the purchase date, February 9, 2023, through the redemption date, February 26,
2025, the Company was active in the management of Lab Services MSO. During the three months ended March 31, 2025 and 2024, the Company
operated in two reportable business segments: (1) the real property operating segment, and (2) laboratory testing services segment (which
ended on the redemption date, February 26, 2025) since Lab Services MSO&#x2019;s operating results are regularly reviewed by the Company&#x2019;s
chief operating decision maker to determine the resources to be allocated to the segment and assess its performance. Prior to February
26, 2025, the Company regularly reviewed the operating results and performance of Lab Services MSO, for which the Company accounted for
under the equity method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company&#x2019;s President and Chief Executive
Officer is its CODM. The Company reports operational data to its CODM at the segment level, which he uses to evaluate performance and
allocate resources based on real property operating income and income from equity method investment - Lab Services MSO.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Reverse Stock Split&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company effectuated a 1-for-15 reverse stock
split of its outstanding shares of common stock on October 28, 2024. The reverse split did not change the par value of common stock.
All references in these condensed consolidated financial statements to shares, share prices, exercise prices, and other per share information
in all periods have been adjusted, on a retroactive basis, to reflect the reverse stock split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Recent Accounting Standards&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In August 2020, the FASB issued Accounting Standards
Update (&#x201c;ASU&#x201d;) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts
in Entity&#x2019;s Own Equity (Subtopic 815-40), to simplify accounting for certain financial instruments. ASU 2020-06 eliminated the
then-current models that required separation of beneficial conversion and cash conversion features from convertible instruments and simplified
the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#x2019;s own equity. ASU 2020-06
also introduced additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#x2019;s
own equity. ASU 2020-06 amended the diluted earnings per share guidance, including the requirement to use the if-converted method for
all convertible instruments. ASU 2020-06 was effective for fiscal years beginning after December 15, 2023, including interim periods
within those fiscal years, with early adoption permitted. The adoption of ASU 2020-06 did not have a material effect on the Company&#x2019;s
condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In November 2023, the FASB issued ASU 2023-07,
Segment Reporting (Topic 280). The amendments in this update improve reportable segment disclosure requirements, primarily through enhanced
disclosures about significant segment expenses. ASU 2023-07 became effective for the Company&#x2019;s annual period beginning on January
1, 2024 and interim periods beginning after January 1, 2025. The Company adopted this guidance in the fourth quarter of 2024. The Company&#x2019;s
results of operations, cash flows, and financial condition were not impacted by the adoption of this ASU.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In December 2023, the FASB issued ASU 2023-09,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This guidance was intended to enhance the transparency and decision-usefulness
of income tax disclosures. The amendments in ASU 2023-09 addressed investor requests for enhanced income tax information primarily through
changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09
was effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively.
Early adoption was permitted. The adoption of ASU 2023-09 did not have a material effect on the Company&#x2019;s condensed consolidated
financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other accounting standards that have been issued
or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the condensed consolidated
financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on
or are unrelated to its condensed consolidated financial condition, results of operations, cash flows or disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-72688">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The preparation of condensed consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Changes in these estimates and assumptions may have a material impact on the condensed
consolidated financial statements and accompanying notes. Making estimates requires management to exercise significant judgment. It is
at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date
of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more
future confirming events. Accordingly, the actual results could differ significantly from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Significant estimates during the three months
ended March 31, 2025 and 2024 include the useful life of investment in real estate and intangible assets, the assumptions used in assessing
impairment of long-term assets, the valuation of deferred tax assets and the associated valuation allowances, the valuation of stock-based
compensation, the valuation of Series D convertible preferred stock (&#x201c;Series D Preferred Stock&#x201d;), and the assumptions used
to determine fair value of warrants and embedded conversion features of convertible note payable.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-72732">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Fair Value of Financial Instruments and Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company adopted the guidance of the Financial
Accounting Standards Board&#x2019;s (the &#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820 for fair value
measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value
hierarchy to classify the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Level 1-Inputs are unadjusted quoted prices in active markets for
    identical assets or liabilities available at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Level 2-Inputs are unadjusted quoted prices for similar assets and
    liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs
    other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; width: 0.25in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Level 3-Inputs are unobservable inputs which reflect the reporting
    entity&#x2019;s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the
    best available information.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The fair value of the Company&#x2019;s assets and
liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying
amounts represented in the accompanying condensed consolidated financial statements, primarily due to their short-term nature.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;b&gt;&lt;i&gt;Assets and liabilities measured at fair
value on a recurring basis. &lt;/i&gt;&lt;/b&gt;Certain assets and liabilities are measured at fair value on a recurring basis. These assets and
liabilities are measured at fair value on an ongoing basis. These assets and liabilities include derivative liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Derivative liability. &lt;/i&gt;Derivative liability
is carried at fair value and measured on an ongoing basis. The table below reflects the activity of derivative liability measured at
fair value for the three months ended March 31, 2025:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Significant &lt;br/&gt;
    Unobservable Inputs&lt;br/&gt; (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Balance of derivative liability as of January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;127,545&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Reclassification of additional paid-in capital upon conversion&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(18,853&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss from change in the fair value of derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;114,360&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Balance of derivative liability as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;223,052&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ASC 825-10 &#x201c;Financial Instruments&#x201d;,
allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair
value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value
option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent
reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="c0" id="ixv-90479">The table below reflects the activity of derivative liability measured at
fair value for the three months ended March 31, 2025:&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Significant &lt;br/&gt;
    Unobservable Inputs&lt;br/&gt; (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Balance of derivative liability as of January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;127,545&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Reclassification of additional paid-in capital upon conversion&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(18,853&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Loss from change in the fair value of derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;114,360&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Balance of derivative liability as of March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;223,052&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c151" decimals="0" id="ixv-90480" unitRef="usd">127545</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="c585" decimals="0" id="ixv-90481" unitRef="usd">18853</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c585" decimals="0" id="ixv-90482" unitRef="usd">-114360</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c586" decimals="0" id="ixv-90483" unitRef="usd">223052</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-72858">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;At March 31, 2025 and December 31, 2024, the Company&#x2019;s
cash balances by geographic area were as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Country:&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March 31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December 31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,351,923&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;98.7&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,844,522&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;99.6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;17,663&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;11,787&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total cash&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,369,586&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;100.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,856,309&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;100.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For purposes of the condensed consolidated statements
of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less when purchased and money market
accounts to be cash equivalents. The Company had no cash equivalents at March 31, 2025 and December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c0" id="ixv-72863">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;At March 31, 2025 and December 31, 2024, the Company&#x2019;s
cash balances by geographic area were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Country:&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March 31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December 31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,351,923&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;98.7&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,844,522&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;99.6&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;17,663&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;11,787&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total cash&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,369,586&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;100.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,856,309&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;100.0&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c587" decimals="0" id="ixv-90484" unitRef="usd">1351923</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <avco:CashPercentage
      contextRef="c587"
      decimals="3"
      id="ixv-90485"
      unitRef="pure">0.987</avco:CashPercentage>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c152" decimals="0" id="ixv-90486" unitRef="usd">2844522</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <avco:CashPercentage
      contextRef="c152"
      decimals="3"
      id="ixv-90487"
      unitRef="pure">0.996</avco:CashPercentage>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c588" decimals="0" id="ixv-90488" unitRef="usd">17663</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <avco:CashPercentage
      contextRef="c588"
      decimals="3"
      id="ixv-90489"
      unitRef="pure">0.013</avco:CashPercentage>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c140" decimals="0" id="ixv-90490" unitRef="usd">11787</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <avco:CashPercentage
      contextRef="c140"
      decimals="3"
      id="ixv-90491"
      unitRef="pure">0.004</avco:CashPercentage>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c11" decimals="0" id="ixv-90492" unitRef="usd">1369586</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <avco:CashPercentage contextRef="c11" decimals="3" id="ixv-90493" unitRef="pure">1</avco:CashPercentage>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="0" id="ixv-90494" unitRef="usd">2856309</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <avco:CashPercentage contextRef="c1" decimals="3" id="ixv-90495" unitRef="pure">1</avco:CashPercentage>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-73029">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Credit Risk and Uncertainties&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company maintains a portion of its cash on
deposits with bank and financial institution within the U.S. that at times may exceed federally-insured limits of $250,000. The Company
manages this credit risk by concentrating its cash balances in high quality financial institutions and by periodically evaluating the
credit quality of the primary financial institutions holding such deposits. The Company has not experienced any losses in such bank accounts
and believes it is not exposed to any risks on its cash in bank accounts. At March 31, 2025, the Company&#x2019;s cash balances in United
States bank accounts had approximately $840,000 in excess of the federally-insured limits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company&#x2019;s concentrations of credit risk
with respect to its rent receivable is limited due to short-term payment terms. The Company also performs ongoing credit evaluations
of its tenants to help further reduce credit risk.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount contextRef="c11" decimals="0" id="ixv-90496" unitRef="usd">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:FederalReserveBankStock contextRef="c11" decimals="0" id="ixv-90497" unitRef="usd">840000</us-gaap:FederalReserveBankStock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c0" id="ixv-73044">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Investment in Unconsolidated Company&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company uses the equity method of accounting
for its investment in, and earning or loss of, investees that it does not control but over which it does exert significant influence.
The Company applies the equity method by initially recording these investments at cost, as equity method investments, subsequently adjusted
for equity in earnings and cash distributions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company considers whether the fair value of
its equity method investment has declined below its carrying value whenever adverse events or changes in circumstances indicate that
recorded value may not be recoverable. If the Company considers any decline to be other than temporary (based on various factors, including
historical financial results and the overall health of the investee), then a write-down would be recorded to estimated fair value. See
Note 5 for discussion of equity method investment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company classifies distributions received
from equity method investments using the cumulative earnings approach. Distributions received are considered returns on the investment
and classified as cash inflows from operating activities. If, however, the investor&#x2019;s cumulative distributions received, less distributions
received in prior periods determined to be returns of investment, exceeds cumulative equity in earnings recognized, the excess is considered
a return of investment and is classified as cash inflows from investing activities.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-73064">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Receivable from Sale of Equity Method Investment&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the first quarter of 2025, to preserve
cash, the Company entered into discussions with Lab Services MSO for the potential redemption of our investment and on February 26, 2025,
the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement (the &#x201c;Redemption Agreement&#x201d;), whereby
Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by the Company for cash and the surrender of its Series B
convertible preferred stock (&#x201c;Series B Preferred Stock&#x201d;) having a carrying value of $11,000,000. The aggregate cash amount
to the Company for the redemption was $1,745,000, to be paid as follows: one payment of $95,000 at the closing of the redemption and,
beginning in March 2025, monthly payments of $75,000 until December 2026. In addition, pursuant to the terms of the Redemption Agreement,
all shares of the Company&#x2019;s Series B Preferred Stock previously issued to SCBC Holdings LLC as partial consideration for the equity
interests of Laboratory Services MSO, were permanently surrendered and relinquished to the Company for no additional consideration. The
difference of $2,348,695 between the carrying value of the extinguished Series B Preferred Stock, the aggregate cash amount to the Company
for the redemption, net of the payables due to Lab Services MSO of $632,916, totaling $13,377,916, and the carrying value of the equity
method investment of $11,029,221 was accounted for as an increase to additional paid-in capital (See Note 10 - Series B Convertible Preferred
Stock Extinguished Related to Sale of Equity Method Investment). Accordingly, beginning in February 2025, the Company no longer offers
laboratory services. As of March 31, 2025, the receivable from sale of equity method investment amounted to $1,650,000, of which $975,000
was included in current assets and $675,000 was included in non-current assets. Management believes that the receivable is fully collectable.
Therefore, no material allowance for doubtful accounts was deemed to be required on the receivable at March 31, 2025.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <avco:EquityInterestPercent
      contextRef="c579"
      decimals="2"
      id="ixv-90498"
      unitRef="pure">0.40</avco:EquityInterestPercent>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c580" decimals="0" id="ixv-90499" unitRef="usd">11000000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions contextRef="c0" decimals="0" id="ixv-90500" unitRef="usd">1745000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <avco:PaymentOfEquityInvestment contextRef="c0" decimals="0" id="ixv-90501" unitRef="usd">95000</avco:PaymentOfEquityInvestment>
    <avco:RegularPaymentsOnEquityInvestments contextRef="c0" decimals="0" id="ixv-90502" unitRef="usd">75000</avco:RegularPaymentsOnEquityInvestments>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c581" decimals="0" id="ixv-90503" unitRef="usd">2348695</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c580" decimals="0" id="ixv-90504" unitRef="usd">632916</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c582" decimals="0" id="ixv-90505" unitRef="usd">13377916</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions contextRef="c580" decimals="0" id="ixv-90506" unitRef="usd">11029221</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:ReceivableInvestmentSale contextRef="c11" decimals="0" id="ixv-90507" unitRef="usd">1650000</us-gaap:ReceivableInvestmentSale>
    <us-gaap:AssetsCurrent contextRef="c579" decimals="0" id="ixv-90508" unitRef="usd">975000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent contextRef="c579" decimals="0" id="ixv-90509" unitRef="usd">675000</us-gaap:AssetsNoncurrent>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-73074">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Per Share Data&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ASC Topic 260 &#x201c;Earnings per Share,&#x201d;
requires presentation of both basic and diluted earnings per share (&#x201c;EPS&#x201d;) with a reconciliation of the numerator and denominator
of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Basic net loss per share is computed by dividing
net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents
and potentially dilutive securities outstanding during each period. The Company had $162,473 in deemed contribution during the three
months ended March 31, 2025, which increases the numerator in the net loss per share calculation. For the three months ended March 31,
2025 and 2024, potentially dilutive common shares consisted of the common shares issuable upon the conversion of convertible preferred
stock and convertible notes (using the if-converted method) and exercise of common stock options and warrants (using the treasury stock
method). Common stock equivalents are not included in the calculation of diluted net loss per share if their effect would be anti-dilutive.
In a period in which the Company has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares
outstanding as they would have had an anti-dilutive impact.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The calculation of basic and diluted net loss
per common share attributable to the Company common shareholders includes 150,000 of the pre-funded warrants that remained outstanding
as of March 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table summarizes the securities
that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,451,425&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;47,287&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;171,163&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;60,562&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Series A convertible preferred stock &lt;/span&gt;&lt;span style="-sec-ix-redline:true;font-size: 12.5pt"&gt;&lt;sup&gt;(*)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-380"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Series B convertible preferred stock &lt;/span&gt;&lt;span style="-sec-ix-redline:true;font-size: 12.5pt"&gt;&lt;sup&gt;(**)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-381"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;194,004&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Series C convertible preferred stock &lt;/span&gt;&lt;span style="-sec-ix-redline:true;font-size: 12.5pt"&gt;&lt;sup&gt;(***)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,452,282&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-382"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Series D convertible preferred stock (****)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,074,689&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-383"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Convertible notes and related accrued interest
    &lt;/span&gt;&lt;span style="-sec-ix-redline:true;font-size: 12.5pt"&gt;&lt;sup&gt;(*****)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;234,554&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;90,133&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,384,113&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;451,986&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.6in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;(*)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Assumed the Series A convertible preferred stock (&#x201c;Series A Preferred Stock&#x201d;) was converted into shares of common stock of the Company at a conversion price of $150.00 per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.6in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;(**)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Assumed the Series B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.6in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;(***)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Assumed the Series C convertible preferred stock (&#x201c;Series C Preferred Stock&#x201d;) was converted into shares of common stock of the Company at a conversion price of $2.41 per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.6in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;(****)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Assumed the Series D convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $2.41 per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.6in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;(*****)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the three months ended March 31, 2025. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and $22.50 and $15.00 per share for the three months ended March 31, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:DilutiveSecurities contextRef="c0" decimals="0" id="ixv-90510" unitRef="usd">162473</us-gaap:DilutiveSecurities>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c583"
      decimals="0"
      id="ixv-90511"
      unitRef="shares">150000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-73129">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table summarizes the securities
that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,451,425&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;47,287&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;171,163&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;60,562&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Series A convertible preferred stock &lt;/span&gt;&lt;span style="-sec-ix-redline:true;font-size: 12.5pt"&gt;&lt;sup&gt;(*)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-380"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Series B convertible preferred stock &lt;/span&gt;&lt;span style="-sec-ix-redline:true;font-size: 12.5pt"&gt;&lt;sup&gt;(**)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-381"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;194,004&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Series C convertible preferred stock &lt;/span&gt;&lt;span style="-sec-ix-redline:true;font-size: 12.5pt"&gt;&lt;sup&gt;(***)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,452,282&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-382"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Series D convertible preferred stock (****)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,074,689&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-383"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Convertible notes and related accrued interest
    &lt;/span&gt;&lt;span style="-sec-ix-redline:true;font-size: 12.5pt"&gt;&lt;sup&gt;(*****)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;234,554&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;90,133&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,384,113&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;451,986&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.6in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;(*)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Assumed the Series A convertible preferred stock (&#x201c;Series A Preferred Stock&#x201d;) was converted into shares of common stock of the Company at a conversion price of $150.00 per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.6in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;(**)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Assumed the Series B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.6in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;(***)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Assumed the Series C convertible preferred stock (&#x201c;Series C Preferred Stock&#x201d;) was converted into shares of common stock of the Company at a conversion price of $2.41 per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.6in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;(****)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Assumed the Series D convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $2.41 per share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.6in"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;(*****)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the three months ended March 31, 2025. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and $22.50 and $15.00 per share for the three months ended March 31, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c589"
      decimals="INF"
      id="ixv-90512"
      unitRef="shares">1451425</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c590"
      decimals="INF"
      id="ixv-90513"
      unitRef="shares">47287</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c591"
      decimals="INF"
      id="ixv-90514"
      unitRef="shares">171163</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c592"
      decimals="INF"
      id="ixv-90515"
      unitRef="shares">60562</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c594"
      decimals="INF"
      id="ix_8_fact"
      unitRef="shares">60000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c596"
      decimals="INF"
      id="ix_9_fact"
      unitRef="shares">194004</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c597"
      decimals="INF"
      id="ix_10_fact"
      unitRef="shares">1452282</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c599"
      decimals="INF"
      id="ix_11_fact"
      unitRef="shares">2074689</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c601"
      decimals="INF"
      id="ix_12_fact"
      unitRef="shares">234554</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c602"
      decimals="INF"
      id="ix_13_fact"
      unitRef="shares">90133</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="INF"
      id="ixv-90522"
      unitRef="shares">5384113</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c100"
      decimals="INF"
      id="ixv-90523"
      unitRef="shares">451986</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c13"
      decimals="2"
      id="ixv-90524"
      unitRef="usdPershares">150</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c14"
      decimals="2"
      id="ixv-90525"
      unitRef="usdPershares">56.7</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c15"
      decimals="2"
      id="ixv-90526"
      unitRef="usdPershares">2.41</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c16"
      decimals="2"
      id="ixv-90527"
      unitRef="usdPershares">2.41</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="c0"
      decimals="2"
      id="ixv-90528"
      unitRef="usdPershares">11.25</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c81"
      decimals="2"
      id="ixv-90529"
      unitRef="usdPershares">67.5</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c82"
      decimals="2"
      id="ixv-90530"
      unitRef="usdPershares">22.5</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c83"
      decimals="2"
      id="ixv-90531"
      unitRef="usdPershares">15</us-gaap:PreferredStockConvertibleConversionPrice>
    <avco:RealPropertyRentalRevenuePolicyTextBlock contextRef="c0" id="ixv-73377">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Real Property Rental Revenue&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has determined that ASC 606 does not
apply to rental contracts, which are within the scope of other revenue recognition accounting standards.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Rental income from operating leases is recognized
on a straight-line basis under the guidance of ASC 842. Lease payments under tenant leases are recognized on a straight-line basis over
the term of the related leases. The cumulative difference between lease revenue recognized under the straight-line method and contractual
lease payments are included in rent receivable on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;</avco:RealPropertyRentalRevenuePolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c0" id="ixv-73421">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In the normal course of business, the Company
is subject to contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters. Liabilities
for such contingencies are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably
estimated.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-73431">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Segment Reporting&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The segment reporting structure uses the Company&#x2019;s
management reporting structure as its foundation to reflect how the Company manages the businesses internally and was mainly organized
by services. During the three months ended March 31, 2025 and 2024, the Company is organized into two services-oriented strategic business
units: real property rental services and laboratory testing services (which ended on the redemption date, February 26, 2025) - which
are led by our strategic business unit managers. Operating segments are defined as components of an enterprise for which separate financial
information is available and evaluated regularly by the chief operating decision maker (&#x201c;CODM&#x201d;) in deciding how to make operating
decisions, allocate resources and assess performance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On February 9, 2023, the Company purchased 40%
of Lab Services MSO. During the first quarter of 2025, to preserve cash, the Company entered into discussions with Lab Services MSO for
the potential redemption of Avalon Lab&#x2019;s investment and on February 26, 2025, Lab Services MSO redeemed the 40% equity interest
in Lab Services MSO held by Avalon Lab. Commencing from the purchase date, February 9, 2023, through the redemption date, February 26,
2025, the Company was active in the management of Lab Services MSO. During the three months ended March 31, 2025 and 2024, the Company
operated in two reportable business segments: (1) the real property operating segment, and (2) laboratory testing services segment (which
ended on the redemption date, February 26, 2025) since Lab Services MSO&#x2019;s operating results are regularly reviewed by the Company&#x2019;s
chief operating decision maker to determine the resources to be allocated to the segment and assess its performance. Prior to February
26, 2025, the Company regularly reviewed the operating results and performance of Lab Services MSO, for which the Company accounted for
under the equity method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company&#x2019;s President and Chief Executive
Officer is its CODM. The Company reports operational data to its CODM at the segment level, which he uses to evaluate performance and
allocate resources based on real property operating income and income from equity method investment - Lab Services MSO.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c146"
      decimals="2"
      id="ixv-90532"
      unitRef="pure">0.40</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c584"
      decimals="2"
      id="ixv-90533"
      unitRef="pure">0.40</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <avco:ReverseStockSplitPolicyTextBlock contextRef="c0" id="ixv-73451">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Reverse Stock Split&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company effectuated a 1-for-15 reverse stock
split of its outstanding shares of common stock on October 28, 2024. The reverse split did not change the par value of common stock.
All references in these condensed consolidated financial statements to shares, share prices, exercise prices, and other per share information
in all periods have been adjusted, on a retroactive basis, to reflect the reverse stock split.&lt;/span&gt;&lt;/p&gt;</avco:ReverseStockSplitPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c0" id="ixv-90534">1-for-15</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-73461">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Recent Accounting Standards&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In August 2020, the FASB issued Accounting Standards
Update (&#x201c;ASU&#x201d;) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts
in Entity&#x2019;s Own Equity (Subtopic 815-40), to simplify accounting for certain financial instruments. ASU 2020-06 eliminated the
then-current models that required separation of beneficial conversion and cash conversion features from convertible instruments and simplified
the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#x2019;s own equity. ASU 2020-06
also introduced additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#x2019;s
own equity. ASU 2020-06 amended the diluted earnings per share guidance, including the requirement to use the if-converted method for
all convertible instruments. ASU 2020-06 was effective for fiscal years beginning after December 15, 2023, including interim periods
within those fiscal years, with early adoption permitted. The adoption of ASU 2020-06 did not have a material effect on the Company&#x2019;s
condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In November 2023, the FASB issued ASU 2023-07,
Segment Reporting (Topic 280). The amendments in this update improve reportable segment disclosure requirements, primarily through enhanced
disclosures about significant segment expenses. ASU 2023-07 became effective for the Company&#x2019;s annual period beginning on January
1, 2024 and interim periods beginning after January 1, 2025. The Company adopted this guidance in the fourth quarter of 2024. The Company&#x2019;s
results of operations, cash flows, and financial condition were not impacted by the adoption of this ASU.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In December 2023, the FASB issued ASU 2023-09,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This guidance was intended to enhance the transparency and decision-usefulness
of income tax disclosures. The amendments in ASU 2023-09 addressed investor requests for enhanced income tax information primarily through
changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09
was effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively.
Early adoption was permitted. The adoption of ASU 2023-09 did not have a material effect on the Company&#x2019;s condensed consolidated
financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other accounting standards that have been issued
or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the condensed consolidated
financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on
or are unrelated to its condensed consolidated financial condition, results of operations, cash flows or disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c0" id="ixv-73523">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;NOTE 4 - &lt;span style="text-decoration:underline"&gt;PREPAID EXPENSE AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;At March 31, 2025 and December 31, 2024, prepaid expense and other
current assets consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March 31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December 31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Prepaid professional fees&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;90,431&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;33,665&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Prepaid directors&#x2019; and officers&#x2019; liability insurance premium&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;12,834&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;9,741&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Prepaid NASDAQ listing fee&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;39,750&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-384"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Deferred leasing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;28,980&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;31,587&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Security deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;12,256&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;17,654&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due from broker&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;33,160&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;32,885&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;90,116&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;92,230&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Recoverable value-added tax&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;10,094&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;9,245&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Others&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;50,197&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;72,353&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;367,818&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;299,360&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c0" id="ixv-73529">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;At March 31, 2025 and December 31, 2024, prepaid expense and other
current assets consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March 31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December 31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Prepaid professional fees&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;90,431&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;33,665&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Prepaid directors&#x2019; and officers&#x2019; liability insurance premium&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;12,834&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;9,741&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Prepaid NASDAQ listing fee&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;39,750&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-384"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Deferred leasing costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;28,980&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;31,587&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Security deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;12,256&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;17,654&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Due from broker&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;33,160&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;32,885&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;90,116&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;92,230&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Recoverable value-added tax&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;10,094&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;9,245&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Others&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;50,197&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;72,353&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;367,818&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;299,360&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <avco:PrepaidProfessionalFees contextRef="c11" decimals="0" id="ixv-90535" unitRef="usd">90431</avco:PrepaidProfessionalFees>
    <avco:PrepaidProfessionalFees contextRef="c1" decimals="0" id="ixv-90536" unitRef="usd">33665</avco:PrepaidProfessionalFees>
    <us-gaap:PrepaidReinsurancePremiums contextRef="c11" decimals="0" id="ixv-90537" unitRef="usd">12834</us-gaap:PrepaidReinsurancePremiums>
    <us-gaap:PrepaidReinsurancePremiums contextRef="c1" decimals="0" id="ixv-90538" unitRef="usd">9741</us-gaap:PrepaidReinsurancePremiums>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="c11" decimals="0" id="ixv-90539" unitRef="usd">39750</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:DeferredCostsLeasingNet contextRef="c11" decimals="0" id="ixv-90540" unitRef="usd">28980</us-gaap:DeferredCostsLeasingNet>
    <us-gaap:DeferredCostsLeasingNet contextRef="c1" decimals="0" id="ixv-90541" unitRef="usd">31587</us-gaap:DeferredCostsLeasingNet>
    <us-gaap:SecurityDeposit contextRef="c11" decimals="0" id="ixv-90542" unitRef="usd">12256</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit contextRef="c1" decimals="0" id="ixv-90543" unitRef="usd">17654</us-gaap:SecurityDeposit>
    <us-gaap:DueFromCorrespondentBrokers contextRef="c11" decimals="0" id="ixv-90544" unitRef="usd">33160</us-gaap:DueFromCorrespondentBrokers>
    <us-gaap:DueFromCorrespondentBrokers contextRef="c1" decimals="0" id="ixv-90545" unitRef="usd">32885</us-gaap:DueFromCorrespondentBrokers>
    <us-gaap:InventoryFinishedGoods contextRef="c11" decimals="0" id="ixv-90546" unitRef="usd">90116</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c1" decimals="0" id="ixv-90547" unitRef="usd">92230</us-gaap:InventoryFinishedGoods>
    <us-gaap:ValueAddedTaxReceivable contextRef="c11" decimals="0" id="ixv-90548" unitRef="usd">10094</us-gaap:ValueAddedTaxReceivable>
    <us-gaap:ValueAddedTaxReceivable contextRef="c1" decimals="0" id="ixv-90549" unitRef="usd">9245</us-gaap:ValueAddedTaxReceivable>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c11" decimals="0" id="ixv-90550" unitRef="usd">50197</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c1" decimals="0" id="ixv-90551" unitRef="usd">72353</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c11" decimals="0" id="ixv-90552" unitRef="usd">367818</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c1" decimals="0" id="ixv-90553" unitRef="usd">299360</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="c0" id="ixv-73747">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;NOTE 5 - &lt;span style="text-decoration:underline"&gt;EQUITY METHOD INVESTMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On February 9, 2023, the Company entered into
and closed an Amended and Restated Membership Interest Purchase Agreement (the &#x201c;Amended MIPA&#x201d;), by and among Avalon Lab,
SCBC Holdings LLC (the &#x201c;Seller&#x201d;), the Zoe Family Trust, Bryan Cox and Sarah Cox as individuals (each an &#x201c;Owner&#x201d;
and collectively, the &#x201c;Owners&#x201d;), and Lab Services MSO. &lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Pursuant to the terms and conditions set forth
in the Amended MIPA, Avalon Lab acquired from the Seller, 40% of the issued and outstanding equity interests of Lab Services MSO (the
&#x201c;Purchased Interests&#x201d;). The consideration paid by Avalon Lab to Seller for the Purchased Interests consisted of $20,666,667,
which was comprised of (i) $9,000,000 in cash, (ii) $11,000,000 pursuant to the issuance of 11,000 shares of the Company&#x2019;s Series
B Preferred Stock, stated value $1,000 (the &#x201c;Series B Stated Value&#x201d;), which approximated the fair value, and (iii) a $666,667
cash payment on February 9, 2024. The Series B Preferred Stock was convertible into shares of the Company&#x2019;s common stock at a conversion
price per share equal to $56.70, which approximated the market price at the date of closing, or an aggregate of 194,004 shares of the
Company&#x2019;s common stock, which were subject to a lock-up period and restrictions on sale.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the first quarter of 2025, to preserve
cash, the Company entered into discussions with Lab Services MSO for the potential redemption of the Company&#x2019;s investment and on
February 26, 2025, the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement, whereby Lab Services MSO redeemed
the 40% equity interest in Lab Services MSO held by the Company (See Note 3 - Receivable from Sale of Equity Method Investment).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Lab Services MSO, through its subsidiaries, was
engaged in providing laboratory testing services. During the period from February 9, 2023 (date of investment) through February 26, 2025
(date of sale), Avalon Lab and an unrelated company, had an ownership interest in Lab Services MSO of 40% and 60%, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In accordance with ASC 810, the Company determined
that Lab Services MSO did not qualify as a variable interest entity, nor did it have a controlling financial interest over the legal
entity. However, the Company determined that it does have significant influence as a result of its board representation. Therefore, the
Company treats the equity investment in the condensed consolidated financial statements under the equity method. Under the equity method,
the investment is initially recorded at cost, adjusted for any excess of the Company&#x2019;s share of the purchased-date fair values
of the investee&#x2019;s identifiable net assets over the cost of the investment (if any). At February 9, 2023 (date of investment), the
excess of the Company&#x2019;s share of the fair values of the investee&#x2019;s identifiable net assets over the cost of the investment
was approximately $19,460,000 which was attributable to intangible assets and goodwill. Thereafter, the investment was adjusted for the
post purchase change in the Company&#x2019;s share of the investee&#x2019;s net assets and any impairment loss relating to the investment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Intangible assets consisted of the valuation of
identifiable intangible assets acquired, representing trade names and customers relationships, which were being amortized on a straight-line
method over the estimated useful life of 15 years. The straight-line method of amortization represents the Company&#x2019;s best estimate
of the distribution of the economic value of the identifiable intangible assets. For the period from January 1, 2025 through February
26, 2025 (date of sale) and for the three months ended March 31, 2024, amortization expense of these intangible assets amounted to $111,156
and $166,733, respectively, which was included in income from equity method investment - Lab Services MSO in the accompanying condensed
consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Goodwill represents the excess of the purchase
price paid over the fair value of net assets acquired in the business acquisition of Lab Services MSO incurred on February 9, 2023. Goodwill
is not amortized but is tested for impairment at least once annually, or more frequently if events or changes in circumstances indicate
that the asset might be impaired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the period from January 1, 2025 through February
26, 2025 (date of sale) and for the three months ended March 31, 2024, the Company&#x2019;s share of Lab Services MSO&#x2019;s net income
was $503,833 and $274,202, respectively, which was included in income from equity method investment - Lab Services MSO in the accompanying
condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company classifies distributions received
from its investment on Lab Services MSO using the cumulative earnings approach. Distributions received are considered returns on the
investment and classified as cash inflows from operating activities. For the period from January 1, 2025 through February 26, 2025 (date
of sale) and for the three months ended March 31, 2024, distribution of earnings from the Company&#x2019;s investment on Lab Services
MSO amounted to $0 and $160,788, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In the three months ended March 31, 2025, activity
recorded for the Company&#x2019;s equity method investment in Lab Services MSO is summarized in the following table:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Equity investment carrying amount at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;10,636,544&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Lab Services MSO&#x2019;s net income attributable to the Company&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;503,833&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Intangible assets amortization amount&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(111,156&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Sale of equity investment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(11,029,221&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Equity investment carrying amount at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-385"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of December 31, 2024, the Company&#x2019;s carrying
value of the identified intangible assets and goodwill which are included in the equity investment carrying amount was $8,725,712 and
$0, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The tables below present the summarized financial
information, as provided to the Company by the investee, for the unconsolidated company:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the Period&lt;br/&gt; from January
    1,&lt;br/&gt; 2025 through&lt;br/&gt; February 26,&lt;br/&gt; 2025 &lt;br/&gt; (Date of Sale)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the Three&lt;br/&gt; Months Ended &lt;br/&gt;
    March 31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4,241,732&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,376,372&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,155,760&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,003,789&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Income from operation&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,513,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;275,026&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,259,582&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;685,504&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c603"
      decimals="2"
      id="ixv-90554"
      unitRef="pure">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c0" decimals="0" id="ixv-90555" unitRef="usd">20666667</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:PreferredStockValue contextRef="c604" decimals="0" id="ixv-90556" unitRef="usd">9000000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c605" decimals="0" id="ixv-90557" unitRef="usd">11000000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c605"
      decimals="0"
      id="ixv-90558"
      unitRef="shares">11000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c606" decimals="0" id="ixv-90559" unitRef="usd">1000</us-gaap:PreferredStockValue>
    <avco:EquityMethodInvestmentPayableCurrent contextRef="c183" decimals="0" id="ixv-90560" unitRef="usd">666667</avco:EquityMethodInvestmentPayableCurrent>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c605"
      decimals="2"
      id="ixv-90561"
      unitRef="usdPershares">56.7</us-gaap:PreferredStockConvertibleConversionPrice>
    <avco:AggregateOfCommonStock
      contextRef="c605"
      decimals="0"
      id="ixv-90562"
      unitRef="shares">194004</avco:AggregateOfCommonStock>
    <avco:LabServicesMSOsNetIncomeAttributableToTheCompany contextRef="c607" decimals="0" id="ixv-90563" unitRef="usd">40</avco:LabServicesMSOsNetIncomeAttributableToTheCompany>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c608"
      decimals="2"
      id="ixv-90564"
      unitRef="pure">0.40</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c609"
      decimals="2"
      id="ixv-90565"
      unitRef="pure">0.60</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:InvestmentOwnedAtCost contextRef="c146" decimals="0" id="ixv-90566" unitRef="usd">19460000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c11" id="ixv-90567">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c610" decimals="0" id="ixv-90568" unitRef="usd">111156</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c100" decimals="0" id="ixv-90569" unitRef="usd">166733</us-gaap:AmortizationOfIntangibleAssets>
    <avco:LabServicesMSOsNetIncomeAttributableToTheCompany contextRef="c610" decimals="0" id="ixv-90570" unitRef="usd">503833</avco:LabServicesMSOsNetIncomeAttributableToTheCompany>
    <avco:LabServicesMSOsNetIncomeAttributableToTheCompany contextRef="c100" decimals="0" id="ixv-90571" unitRef="usd">274202</avco:LabServicesMSOsNetIncomeAttributableToTheCompany>
    <us-gaap:GoodwillImpairmentLoss contextRef="c611" decimals="0" id="ixv-90572" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c100" decimals="0" id="ixv-90573" unitRef="usd">160788</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:EquityMethodInvestmentsTextBlock contextRef="c0" id="ixv-73819">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In the three months ended March 31, 2025, activity
recorded for the Company&#x2019;s equity method investment in Lab Services MSO is summarized in the following table:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Equity investment carrying amount at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;10,636,544&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Lab Services MSO&#x2019;s net income attributable to the Company&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;503,833&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Intangible assets amortization amount&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(111,156&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Sale of equity investment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(11,029,221&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Equity investment carrying amount at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-385"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestments contextRef="c195" decimals="0" id="ixv-90574" unitRef="usd">10636544</us-gaap:EquityMethodInvestments>
    <avco:LabServicesMSOsNetIncomeAttributableToTheCompany contextRef="c612" decimals="0" id="ixv-90575" unitRef="usd">503833</avco:LabServicesMSOsNetIncomeAttributableToTheCompany>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c612" decimals="0" id="ixv-90576" unitRef="usd">111156</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions contextRef="c612" decimals="0" id="ixv-90577" unitRef="usd">11029221</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c1" decimals="0" id="ixv-90578" unitRef="usd">8725712</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:GoodwillFairValueDisclosure contextRef="c1" decimals="0" id="ixv-90579" unitRef="usd">0</us-gaap:GoodwillFairValueDisclosure>
    <srt:ScheduleOfCondensedIncomeStatementTableTextBlock contextRef="c0" id="ixv-73915">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The tables below present the summarized financial
information, as provided to the Company by the investee, for the unconsolidated company:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the Period&lt;br/&gt; from January
    1,&lt;br/&gt; 2025 through&lt;br/&gt; February 26,&lt;br/&gt; 2025 &lt;br/&gt; (Date of Sale)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the Three&lt;br/&gt; Months Ended &lt;br/&gt;
    March 31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4,241,732&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,376,372&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,155,760&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,003,789&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Income from operation&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,513,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;275,026&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,259,582&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;685,504&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedIncomeStatementTableTextBlock>
    <us-gaap:Revenues contextRef="c614" decimals="0" id="ixv-90580" unitRef="usd">4241732</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c615" decimals="0" id="ixv-90581" unitRef="usd">3376372</us-gaap:Revenues>
    <us-gaap:GrossProfit contextRef="c614" decimals="0" id="ixv-90582" unitRef="usd">2155760</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c615" decimals="0" id="ixv-90583" unitRef="usd">1003789</us-gaap:GrossProfit>
    <us-gaap:OperatingIncomeLoss contextRef="c614" decimals="0" id="ixv-90584" unitRef="usd">1513000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c615" decimals="0" id="ixv-90585" unitRef="usd">275026</us-gaap:OperatingIncomeLoss>
    <us-gaap:ProfitLoss contextRef="c614" decimals="0" id="ixv-90586" unitRef="usd">1259582</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c615" decimals="0" id="ixv-90587" unitRef="usd">685504</us-gaap:ProfitLoss>
    <us-gaap:LongTermDebtTextBlock contextRef="c0" id="ixv-74025">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;NOTE 6 - &lt;span style="text-decoration:underline"&gt;CONVERTIBLE NOTE PAYABLE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;June 2024 Convertible Note&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 5, 2024, the Company entered into securities
purchase agreements with Mast Hill Fund L.P. (&#x201c;Mast Hill&#x201d;) for the issuance of 13.0% senior secured promissory notes in the
aggregate principal amount of $2,845,000 (collectively, the &#x201c;June 2024 Convertible Note&#x201d;) convertible into shares of the
Company&#x2019;s common stock, as well as the issuance of 26,800 shares of common stock as a commitment fee and warrants for the purchase
of 146,667 shares of common stock of the Company. The Company and its subsidiaries have also entered into a security agreement, creating
a security interest in certain property of the Company and its subsidiaries to secure the prompt payment, performance and discharge in
full of all of the Company&#x2019;s obligations under the June 2024 Convertible Note. Principal amount and interest under the June 2024
Convertible Note are convertible into shares of common stock of the Company at a conversion price of $11.25 per share unless the Company
fails to make an amortization payment when due, in which case the conversion price shall be the lesser of $11.25 or the market price
(as defined in the June 2024 Convertible Note).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Mast Hill acquired the June 2024 Convertible Note
with principal amount of $2,845,000 and paid the purchase price of $2,702,750 after an original issue discount of $142,250. On June 5,
2024, the Company issued (i) a warrant to purchase 66,667 shares of common stock with an exercise price of $9.75 exercisable until June
5, 2029 (&#x201c;First Warrant&#x201d;), (ii) a warrant to purchase 80,000 shares of common stock with an exercise price of $7.50 exercisable
until June 5, 2029 (&#x201c;Second Warrant&#x201d;), and (iii) 26,800 shares of common stock as a commitment fee for the purchase of the
June 2024 Convertible Note, which were earned in full as of June 5, 2024. The Second Warrant is not fair valued and shall be cancelled
and extinguished against payment of the June 2024 Convertible Note. On June 5, 2024, the Company delivered such duly executed June 2024
Convertible Note, warrants and common stock to Mast Hill against delivery of the purchase price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company received net cash amount of $881,210
from the June 2024 Convertible Note financing after using the proceeds to pay off all previously issued convertible notes of $1,661,540,
and to pay finder&#x2019;s fee of $120,000 and lender&#x2019;s costs of $40,000 related to this financing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company is obligated to make amortization
payments in cash to Mast Hill toward the repayment of the June 2024 Convertible Note, as provided in the following table:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: black 1.5pt solid; width: 49%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;Payment Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 1.5pt; width: 2%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: black 1.5pt solid; width: 49%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;Payment Amount&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;December 5, 2024&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$284,500 plus accrued interest through December 5, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;January 5, 2025&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$284,500 plus accrued interest through January 5, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;February 5, 2025&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$379,336 plus accrued interest through February 5, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;March 5, 2025&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$474,167 plus accrued interest through March 5, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;April 5, 2025&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$474,167 plus accrued interest through April 5, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;May 5, 2025&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$569,000 plus accrued interest through May 5, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;June 5, 2025&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;The entire remaining outstanding balance of the June 2024 Convertible Note&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In connection with the issuance of the June 2024
Convertible Note, the Company incurred debt issuance costs of $224,221 (including the issuance of 5,333 warrants as a finder&#x2019;s
fee) which is capitalized and will be amortized into interest expense over the term of the June 2024 Convertible Note.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Based upon the Company&#x2019;s analysis of the
criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a finder&#x2019;s
fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances. Management
determined the probability of failing to make an amortization payment when due to be remote and as such the fair value of the 80,000
warrants with an exercise price of $7.50 exercisable until June 5, 2029, which warrant shall be cancelled and extinguished against payment
of the June 2024 Convertible Note, has been estimated to be zero. Accordingly, the fair value of the 72,000 warrants with an exercise
price of $9.75 exercisable until June 5, 2029 was classified as derivative liability on June 5, 2024. The fair values of the 72,000 warrants
with an exercise price of $9.75 exercisable until June 5, 2029 issued on June 5, 2024 were computed using the Black-Scholes option-pricing
model with the following assumptions: stock price of $10.39, volatility of 85.72%, risk-free rate of 4.31%, annual dividend yield of
0% and expected life of 5 years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In accordance with ASC 470-20-25-2, proceeds from
the sale of a debt instrument with stock purchase warrants are allocated to the two elements based on the relative fair values of the
debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds allocated to the
warrants are accounted for as derivative liability. The remainder of the proceeds are allocated to the debt instrument portion of the
transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In accordance with ASC 480-10-25-14, the Company
determined that the conversion provisions contain an embedded derivative feature and the Company valued the derivative feature separately,
recording debt discount and derivative liability in accordance with the provisions of the convertible debt (see Note 7). However, management
determined the probability of failing to make an amortization payment when due to be remote and as such the fair value of the embedded
conversion feature has been estimated to be zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company recorded a total debt discount of
$838,990 related to the original issue discount, common shares issued and warrants issued to Mast Hill, which will be amortized over
the term of the June 2024 Convertible Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On December 15, 2024, the Company and Mast Hill
entered into that certain consent, acknowledgement, and waiver agreement, pursuant to which Mast Hill waived all amortization payments
required to be made under the June 2024 Convertible Note, the Company paid a waiver fee of $150,000 to Mast Hill, and the Company issued
to Mast Hill a common stock purchase warrant for the purchase of up to 150,000 shares of the Company&#x2019;s common stock (&#x201c;Pre-Funded
Warrants&#x201d;). The Pre-Funded Warrants are immediately exercisable at issuance and until the Pre-Funded Warrants are exercised in
full and have an exercise price of $0.01 per share. The Pre-Funded Warrants were classified as a component of permanent equity on the
accompanying consolidated balance sheets as they are freestanding financial instruments that are immediately exercisable, do not embody
an obligation for the Company to repurchase its own shares and permit the holder to receive a fixed number of shares of common stock
upon exercise. All of the shares underlying the Pre-Funded Warrants have been included in the weighted-average number of shares of common
stock used to calculate net loss per share, basic and diluted, attributable to the Company&#x2019;s common stockholders because the shares
may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the Pre-Funded
Warrants. Based on the Company&#x2019;s assess, this arrangement was accounted for as a modification of debt and, as such, $838,794 related
to the waiver fee and Pre-Fund Warrants issued to Mast Hill were expensed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The convertible note payable as of March 31, 2025
and December 31, 2024 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March 31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December 31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,556,777&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,556,777&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less: unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(33,584&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(93,425&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less: unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(125,665&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(349,579&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Convertible note payable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,397,528&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,113,773&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the three months ended March 31, 2025 and
2024, amortization of debt discount and debt issuance costs related to convertible note payable amounted to $283,755 and $242,389, respectively,
which have been included in interest expense - amortization of debt discount and debt issuance costs on the accompanying condensed consolidated
statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the three months ended March 31, 2025 and
2024, interest expense related to convertible note payable amounted to $81,956 and $71,715, respectively, which have been included in
interest expense - other on the accompanying condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="c616"
      decimals="3"
      id="ixv-90588"
      unitRef="pure">0.13</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c617" decimals="0" id="ixv-90589" unitRef="usd">2845000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c273"
      decimals="0"
      id="ixv-90590"
      unitRef="shares">26800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c618"
      decimals="0"
      id="ixv-90591"
      unitRef="shares">146667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c274"
      decimals="2"
      id="ixv-90592"
      unitRef="usdPershares">11.25</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c619"
      decimals="2"
      id="ixv-90593"
      unitRef="usdPershares">11.25</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c620" decimals="0" id="ixv-90594" unitRef="usd">2845000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c621" decimals="0" id="ixv-90595" unitRef="usd">2702750</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c621" decimals="0" id="ixv-90596" unitRef="usd">142250</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c622"
      decimals="0"
      id="ixv-90597"
      unitRef="shares">66667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c622"
      decimals="2"
      id="ixv-90598"
      unitRef="usdPershares">9.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c623"
      decimals="0"
      id="ixv-90599"
      unitRef="shares">80000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c623"
      decimals="2"
      id="ixv-90600"
      unitRef="usdPershares">7.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c624"
      decimals="0"
      id="ixv-90601"
      unitRef="usdPershares">26800</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:NontradeReceivables contextRef="c625" decimals="0" id="ixv-90602" unitRef="usd">881210</us-gaap:NontradeReceivables>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c626" decimals="0" id="ixv-90603" unitRef="usd">1661540</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c627" decimals="0" id="ixv-90604" unitRef="usd">120000</us-gaap:ProceedsFromConvertibleDebt>
    <avco:PaymentForCommission contextRef="c628" decimals="0" id="ixv-90605" unitRef="usd">40000</avco:PaymentForCommission>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c0" id="ixv-74047">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company is obligated to make amortization
payments in cash to Mast Hill toward the repayment of the June 2024 Convertible Note, as provided in the following table:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: black 1.5pt solid; width: 49%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;Payment Date&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; padding-bottom: 1.5pt; width: 2%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: black 1.5pt solid; width: 49%"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;Payment Amount&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;December 5, 2024&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$284,500 plus accrued interest through December 5, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;January 5, 2025&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$284,500 plus accrued interest through January 5, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;February 5, 2025&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$379,336 plus accrued interest through February 5, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;March 5, 2025&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$474,167 plus accrued interest through March 5, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;April 5, 2025&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$474,167 plus accrued interest through April 5, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;May 5, 2025&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$569,000 plus accrued interest through May 5, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;June 5, 2025&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;The entire remaining outstanding balance of the June 2024 Convertible Note&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentDescription contextRef="c631" id="ixv-74070">$284,500 plus accrued interest through December 5, 2024</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentDescription contextRef="c632" id="ixv-74078">$284,500 plus accrued interest through January 5, 2025</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentDescription contextRef="c633" id="ixv-74086">$379,336 plus accrued interest through February 5, 2025</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentDescription contextRef="c634" id="ixv-74094">$474,167 plus accrued interest through March 5, 2025</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentDescription contextRef="c635" id="ixv-74102">$474,167 plus accrued interest through April 5, 2025</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentDescription contextRef="c636" id="ixv-74110">$569,000 plus accrued interest through May 5, 2025</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentDescription contextRef="c637" id="ixv-74118">The entire remaining outstanding balance of the June 2024 Convertible Note</us-gaap:DebtInstrumentDescription>
    <us-gaap:DeferredFinanceCostsNet contextRef="c625" decimals="0" id="ixv-90606" unitRef="usd">224221</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c629"
      decimals="0"
      id="ixv-90607"
      unitRef="shares">5333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c284"
      decimals="0"
      id="ixv-90608"
      unitRef="shares">80000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c274"
      decimals="2"
      id="ixv-90609"
      unitRef="usdPershares">7.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c630" decimals="0" id="ixv-90610" unitRef="usd">72000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c630"
      decimals="2"
      id="ixv-90611"
      unitRef="usdPershares">9.75</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c284"
      decimals="0"
      id="ixv-90612"
      unitRef="shares">72000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c284"
      decimals="2"
      id="ixv-90613"
      unitRef="usdPershares">9.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c285"
      decimals="0"
      id="ixv-90614"
      unitRef="pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c286"
      decimals="2"
      id="ixv-90615"
      unitRef="pure">10.39</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c287"
      decimals="2"
      id="ixv-90616"
      unitRef="pure">85.72</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c288"
      decimals="2"
      id="ixv-90617"
      unitRef="pure">4.31</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c289"
      decimals="0"
      id="ixv-90618"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c625" decimals="0" id="ixv-90619" unitRef="usd">838990</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c290" decimals="0" id="ixv-90620" unitRef="usd">150000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c291"
      decimals="0"
      id="ixv-90621"
      unitRef="shares">150000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="c292"
      decimals="2"
      id="ixv-90622"
      unitRef="usdPershares">0.01</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:DebtInstrumentFeeAmount contextRef="c293" decimals="0" id="ixv-90623" unitRef="usd">838794</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="c0" id="ixv-74181">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The convertible note payable as of March 31, 2025
and December 31, 2024 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March 31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December 31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,556,777&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,556,777&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less: unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(33,584&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(93,425&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less: unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(125,665&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(349,579&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Convertible note payable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,397,528&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,113,773&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c638" decimals="0" id="ixv-90624" unitRef="usd">2556777</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c301" decimals="0" id="ixv-90625" unitRef="usd">2556777</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c638" decimals="0" id="ixv-90626" unitRef="usd">33584</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c301" decimals="0" id="ixv-90627" unitRef="usd">93425</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent contextRef="c638" decimals="0" id="ixv-90628" unitRef="usd">125665</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent contextRef="c301" decimals="0" id="ixv-90629" unitRef="usd">349579</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c638" decimals="0" id="ixv-90630" unitRef="usd">2397528</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c301" decimals="0" id="ixv-90631" unitRef="usd">2113773</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c0" decimals="0" id="ixv-90632" unitRef="usd">283755</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="c100" decimals="0" id="ixv-90633" unitRef="usd">242389</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestAndDebtExpense contextRef="c0" decimals="0" id="ixv-90634" unitRef="usd">81956</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c100" decimals="0" id="ixv-90635" unitRef="usd">71715</us-gaap:InterestAndDebtExpense>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="c0" id="ixv-74311">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;NOTE 7 - &lt;span style="text-decoration:underline"&gt;DERIVATIVE LIABILITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As stated in Note 6, June 2024 Convertible Note,
the Company determined that the convertible note payable contains an embedded derivative feature in the form of a conversion provision
which is adjustable based on future prices of the Company&#x2019;s common stock. In accordance with ASC 815-10-25, each derivative feature
is initially recorded at its fair value using the Black-Scholes option valuation method and then re-value at each reporting date, with
changes in the fair value reported in the statements of operations. However, on June 5, 2024 and March 31, 2025, management determined
the probability of failing to make an amortization payment and repayment, respectively, when due to be remote and as such the fair value
of the embedded conversion feature has been estimated to be zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On May 23, 2023, the Company issued 9,000 warrants
with an exercise price of $67.50 exercisable until May 23, 2028 to Mast Hill and a third party as a finder&#x2019;s fee. Upon evaluation,
the warrants meet the definition of a derivative liability under ASC 815, as the Company cannot avoid a net cash settlement under certain
circumstances. Accordingly, the fair value of the 9,000 warrants was classified as a derivative liability on May 23, 2023. In March 2025,
8,333 warrants held by Mast Hill were cashless exercised. On March 31, 2025, the estimated fair value of the rest of 667 warrants was
$701. The estimated fair value of the warrants was computed as of March 31, 2025 using Black-Scholes option-pricing model, with the following
assumptions: stock price of $4.80, volatility of 108.28%, risk-free rate of 3.89%, annual dividend yield of 0% and expected life of 3.1
years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On July 6, 2023, the Company issued 222 warrants
with an exercise price of $67.50 exercisable until July 6, 2028 to a third party as a finder&#x2019;s fee. Upon evaluation, the warrants
meet the definition of a derivative liability under ASC 815, as the Company cannot avoid a net cash settlement under certain circumstances.
Accordingly, the fair value of the 222 warrants was classified as a derivative liability on July 6, 2023. On March 31, 2025, the estimated
fair value of the 222 warrants was $237. The estimated fair value of the warrants was computed as of March 31, 2025 using Black-Scholes
option-pricing model, with the following assumptions: stock price of $4.80, volatility of 106.65%, risk-free rate of 3.89%, annual dividend
yield of 0% and expected life of 3.3 years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On October 9, 2023, the Company issued 4,060 warrants
with an exercise price of $37.50 exercisable until October 9, 2028 to Mast Hill and a third party as a finder&#x2019;s fee. Upon evaluation,
the warrants meet the definition of a derivative liability under ASC 815, as the Company cannot avoid a net cash settlement under certain
circumstances. Accordingly, the fair value of the 4,060 warrants was classified as a derivative liability on October 9, 2023. On March
26, 2025, 3,500 warrants held by Mast Hill were cashless exercised. On March 31, 2025, the estimated fair value of the rest of 560 warrants
was $866. The estimated fair value of the warrants was computed as of March 31, 2025 using Black-Scholes option-pricing model, with the
following assumptions: stock price of $4.80, volatility of 103.38%, risk-free rate of 3.89%, annual dividend yield of 0% and expected
life of 3.5 years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On March 7, 2024, the Company issued 9,450 warrants
with an exercise price of $30.00 exercisable until March 7, 2029 to Mast Hill and a third party as a finder&#x2019;s fee. Upon evaluation,
the warrants meet the definition of a derivative liability under FASB ASC 815, as the Company cannot avoid a net cash settlement under
certain circumstances. Accordingly, the fair value of the 9,450 warrants was classified as a derivative liability on March 7, 2024. On
March 31, 2025, the estimated fair value of the 9,450 warrants was $17,134. The estimated fair value of the warrants was computed as
of March 31, 2025 using Black-Scholes option-pricing model, with the following assumptions: stock price of $4.80, volatility of 99.62%,
risk-free rate of 3.89%, annual dividend yield of 0% and expected life of 3.9 years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 5, 2024, the Company issued 152,000 warrants
to Mast Hill and a third party as a finder&#x2019;s fee (see Note 6). Upon evaluation, the warrants meet the definition of a derivative
liability under ASC 815, as the Company cannot avoid a net cash settlement under certain circumstances. Management determined the probability
of failing to make an amortization payment when due to be remote and as such the fair value of the 80,000 warrants with an exercise price
of $7.50 exercisable until June 5, 2029, which warrant shall be cancelled and extinguished against payment of the June 2024 Convertible
Note, has been estimated to be zero. Accordingly, the fair value of the 72,000 warrants with an exercise price of $9.75 exercisable until
June 5, 2029 was classified as a derivative liability on June 5, 2024. On March 31, 2025, the estimated fair value of the 72,000 warrants
with an exercise price of $9.75 exercisable until the five-year anniversary of June 5, 2024 as derivative liability was $204,114. The
estimated fair value of the warrants was computed as of March 31, 2025 using Black-Scholes option-pricing model, with the following assumptions:
stock price of $4.80, volatility of 97.66%, risk-free rate of 3.96%, annual dividend yield of 0% and expected life of 4.2 years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Increases or decreases in fair value of the derivative
liability are included as a component of total other (expenses) income in the accompanying condensed consolidated statements of operations
and comprehensive loss. The changes to the derivative liability resulted in an increase of $114,360 in the derivative liability and the
corresponding increase in other expense as a loss for the three months ended March 31, 2025. The changes to the derivative liability
resulted in a decrease of $31,212 in the derivative liability and the corresponding increase in other income as a gain for the three
months ended March 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c303"
      decimals="0"
      id="ixv-90636"
      unitRef="shares">9000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c304"
      decimals="2"
      id="ixv-90637"
      unitRef="usdPershares">67.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c639"
      decimals="0"
      id="ixv-90638"
      unitRef="shares">9000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c639"
      decimals="0"
      id="ixv-90639"
      unitRef="shares">8333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c640"
      decimals="0"
      id="ixv-90640"
      unitRef="shares">667</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c641" decimals="0" id="ixv-90641" unitRef="usd">701</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c642"
      decimals="2"
      id="ixv-90642"
      unitRef="pure">4.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c642"
      decimals="2"
      id="ixv-90643"
      unitRef="pure">4.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c643"
      decimals="2"
      id="ixv-90644"
      unitRef="pure">108.28</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c644"
      decimals="2"
      id="ixv-90645"
      unitRef="pure">3.89</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c645"
      decimals="0"
      id="ixv-90646"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c646"
      decimals="1"
      id="ixv-90647"
      unitRef="pure">3.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c647"
      decimals="0"
      id="ixv-90648"
      unitRef="shares">222</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c319"
      decimals="2"
      id="ixv-90649"
      unitRef="usdPershares">67.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c648"
      decimals="0"
      id="ixv-90650"
      unitRef="shares">222</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c649"
      decimals="0"
      id="ixv-90651"
      unitRef="shares">222</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c650" decimals="0" id="ixv-90652" unitRef="usd">237</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c651"
      decimals="2"
      id="ixv-90653"
      unitRef="pure">4.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c652"
      decimals="2"
      id="ixv-90654"
      unitRef="pure">106.65</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c653"
      decimals="2"
      id="ixv-90655"
      unitRef="pure">3.89</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c654"
      decimals="0"
      id="ixv-90656"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c655"
      decimals="1"
      id="ixv-90657"
      unitRef="pure">3.3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c656"
      decimals="0"
      id="ixv-90658"
      unitRef="shares">4060</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c237"
      decimals="2"
      id="ixv-90659"
      unitRef="usdPershares">37.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c657"
      decimals="0"
      id="ixv-90660"
      unitRef="shares">4060</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c658"
      decimals="0"
      id="ixv-90661"
      unitRef="shares">3500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c659"
      decimals="0"
      id="ixv-90662"
      unitRef="shares">560</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c660" decimals="0" id="ixv-90663" unitRef="usd">866</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c661"
      decimals="2"
      id="ixv-90664"
      unitRef="pure">4.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c662"
      decimals="2"
      id="ixv-90665"
      unitRef="pure">103.38</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c663"
      decimals="2"
      id="ixv-90666"
      unitRef="pure">3.89</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c664"
      decimals="0"
      id="ixv-90667"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c665"
      decimals="1"
      id="ixv-90668"
      unitRef="pure">3.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c350"
      decimals="0"
      id="ixv-90669"
      unitRef="shares">9450</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c264"
      decimals="2"
      id="ixv-90670"
      unitRef="usdPershares">30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c351"
      decimals="0"
      id="ixv-90671"
      unitRef="shares">9450</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c649"
      decimals="0"
      id="ixv-90672"
      unitRef="shares">9450</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c666" decimals="0" id="ixv-90673" unitRef="usd">17134</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c667"
      decimals="2"
      id="ixv-90674"
      unitRef="pure">4.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c668"
      decimals="2"
      id="ixv-90675"
      unitRef="pure">99.62</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c669"
      decimals="2"
      id="ixv-90676"
      unitRef="pure">3.89</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c670"
      decimals="0"
      id="ixv-90677"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c671"
      decimals="1"
      id="ixv-90678"
      unitRef="pure">3.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c358"
      decimals="0"
      id="ixv-90679"
      unitRef="shares">152000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c359"
      decimals="0"
      id="ixv-90680"
      unitRef="shares">80000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c274"
      decimals="2"
      id="ixv-90681"
      unitRef="usdPershares">7.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c672"
      decimals="0"
      id="ixv-90682"
      unitRef="pure">72000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c673"
      decimals="2"
      id="ixv-90683"
      unitRef="pure">9.75</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c674"
      decimals="0"
      id="ixv-90684"
      unitRef="shares">72000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c675"
      decimals="2"
      id="ixv-90685"
      unitRef="usdPershares">9.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c676" decimals="0" id="ixv-90686" unitRef="usd">204114</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c677"
      decimals="2"
      id="ixv-90687"
      unitRef="pure">4.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c678"
      decimals="2"
      id="ixv-90688"
      unitRef="pure">97.66</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c679"
      decimals="2"
      id="ixv-90689"
      unitRef="pure">3.96</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c680"
      decimals="0"
      id="ixv-90690"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c681"
      decimals="1"
      id="ixv-90691"
      unitRef="pure">4.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DerivativeLiabilities contextRef="c649" decimals="0" id="ixv-90692" unitRef="usd">114360</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c682" decimals="0" id="ixv-90693" unitRef="usd">31212</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0" id="ixv-74366">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;NOTE 8 - &lt;span style="text-decoration:underline"&gt;NOTE PAYABLE, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On September 1, 2022, the Company issued a balloon
promissory note in the form of a mortgage on its headquarters to a third party company in the principal amount of $4,800,000, which carries
interest of 11.0% per annum. Interest is due in monthly payments of $44,000 beginning November 1, 2022 and payable monthly thereafter
until September 1, 2025 when the principal outstanding and all remaining interest is due. The principal of $4,800,000 can be extended
for an additional 36 months, provided that the Company has not defaulted. The Company may not prepay the principal of $4,800,000 for
a period of 12 months. The principal of $4,800,000 is secured by a first mortgage on the Company&#x2019;s real property located at 4400
Route 9 South, Freehold, Monmouth County, New Jersey..&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In May 2023, the Company borrowed $1,000,000 from
the same lender. The principal of $1,000,000 accrues interest at an annual rate of 13.0% and is payable in monthly installments of interest-only
in the amount of $10,833, commencing in June 2023 and continuing through October 2025 (at which point any unpaid balance of principal,
interest and other charges are due and payable). The loan is secured by a second-lien mortgage on certain real property and improvements
located at 4400 Route 9 South, Freehold, Monmouth County, New Jersey.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The note payable as of March 31, 2025 and December
31, 2024 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;March 31,&lt;br/&gt; 2025&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;December
    31, &lt;br/&gt; 2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,800,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,800,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less: unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(54,746&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(84,553&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Note payable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,745,254&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,715,447&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the three months ended March 31, 2025 and
2024, amortization of debt issuance costs related to note payable amounted to $29,807 and $29,807, respectively, which have been included
in interest expense - amortization of debt discount and debt issuance costs on the accompanying condensed consolidated statements of
operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the three months ended March 31, 2025 and
2024, interest expense related to note payable amounted to $164,500 and $164,500, respectively, which have been included in interest
expense - other on the accompanying condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c368" decimals="0" id="ixv-90694" unitRef="usd">4800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="c369"
      decimals="3"
      id="ixv-90695"
      unitRef="pure">0.11</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c370" decimals="0" id="ixv-90696" unitRef="usd">44000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c683" decimals="0" id="ixv-90697" unitRef="usd">4800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment contextRef="c683" decimals="0" id="ixv-90698" unitRef="usd">4800000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:SecuredDebt contextRef="c11" decimals="0" id="ixv-90699" unitRef="usd">4800000</us-gaap:SecuredDebt>
    <us-gaap:ProceedsFromNotesPayable contextRef="c372" decimals="0" id="ixv-90700" unitRef="usd">1000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c373" decimals="0" id="ixv-90701" unitRef="usd">1000000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c373"
      decimals="3"
      id="ixv-90702"
      unitRef="pure">0.13</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c373" decimals="0" id="ixv-90703" unitRef="usd">10833</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c0" id="ixv-74380">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The note payable as of March 31, 2025 and December
31, 2024 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;March 31,&lt;br/&gt; 2025&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;December
    31, &lt;br/&gt; 2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,800,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,800,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Less: unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(54,746&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(84,553&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Note payable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,745,254&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,715,447&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c11" decimals="0" id="ixv-90704" unitRef="usd">5800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c1" decimals="0" id="ixv-90705" unitRef="usd">5800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c11" decimals="0" id="ixv-90706" unitRef="usd">54746</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c1" decimals="0" id="ixv-90707" unitRef="usd">84553</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:NotesPayableCurrent contextRef="c11" decimals="0" id="ixv-90708" unitRef="usd">5745254</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c1" decimals="0" id="ixv-90709" unitRef="usd">5715447</us-gaap:NotesPayableCurrent>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c0" decimals="0" id="ixv-90710" unitRef="usd">29807</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c100" decimals="0" id="ixv-90711" unitRef="usd">29807</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseShortTermBorrowings contextRef="c0" decimals="0" id="ixv-90712" unitRef="usd">164500</us-gaap:InterestExpenseShortTermBorrowings>
    <us-gaap:InterestExpenseShortTermBorrowings contextRef="c100" decimals="0" id="ixv-90713" unitRef="usd">164500</us-gaap:InterestExpenseShortTermBorrowings>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-74472">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;NOTE 9 - &lt;span style="text-decoration:underline"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Rental Revenue from Related Party and Rent
Receivable - Related Party&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company leases space of its commercial real
property located in New Jersey to D.P. Capital Investments LLC, which is controlled by Wenzhao Lu, the Company&#x2019;s chairman of the
Board of Directors. The term of the related party lease agreement is five years commencing on May 1, 2021 and will expire on April 30,
2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For both the three months ended March 31, 2025
and 2024, the related party rental revenue amounted to $12,600 and has been included in real property rental revenue on the accompanying
condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Services Provided by Related Party&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;From time to time, Wilbert Tauzin, a director
of the Company, and his son provide consulting services to the Company. As compensation for professional services provided, the Company
recognized consulting expenses of $15,597 and $16,731 for the three months ended March 31, 2025 and 2024, respectively, which have been
included in professional fees on the accompanying condensed consolidated statements of operations and comprehensive loss. As of March
31, 2025 and December 31, 2024, the accrued and unpaid services charge related to this director&#x2019;s son amounted to $2,615 and $15,000,
respectively, which have been included in accrued professional fees on the accompanying condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Accrued Liabilities and Other Payables - Related
Parties&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In 2017, the Company acquired Beijing Jieteng
(Genexosome) Biotech Co., Ltd. (&#x201c;Beijing GenExosome&#x201d;) for a cash payment of $450,000. As of both March 31, 2025 and December
31, 2024, the unpaid acquisition consideration of $100,000, was payable to Dr. Yu Zhou, former director and former co-chief executive
officer and 40% owner of Genexosome, and has been included in accrued liabilities and other payables - related parties on the accompanying
condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;From time to time, Lab Services MSO paid shared
expense on behalf of the Company. In addition, Lab Services MSO made a payment of $566,667 for equity method investment payable on behalf
of the Company in 2024. During the first quarter of 2025, to preserve cash, the Company entered into discussions with Lab Services MSO
for the potential redemption of our investment and on February 26, 2025, the Company and Lab Services MSO entered into a Redemption and
Abandonment Agreement, whereby Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by the Company for cash and
the surrender of its Series B Preferred Stock having a carrying value of $11,000,000. The aggregate cash amount to the Company for the
redemption was $1,745,000, to be paid as follows: one payment of $95,000 at the closing of the redemption and, beginning in March 2025,
monthly payments of $75,000 until December 2026. In addition, pursuant to the terms of the Redemption Agreement, all shares of the Company&#x2019;s
Series B Preferred Stock previously issued to SCBC Holdings LLC as partial consideration for the equity interests of Laboratory Services
MSO, were permanently surrendered and relinquished to the Company for no additional consideration. The difference of $2,348,695 between
the carrying value of the extinguished Series B Preferred Stock, the aggregate cash amount to the Company for the redemption, net of
payables due to Lab Services MSO of $632,916, totaling $13,377,916, and the carrying value of the equity method investment of $11,029,221
was accounted for as an increase to additional paid-in capital (See Note 10 - Series B Convertible Preferred Stock Extinguished Related
to Sale of Equity Method Investment). As of March 31, 2025 and December 31, 2024, the balance due to Lab Services MSO amounted to $0
and $632,916, respectively, which has been included in accrued liabilities and other payables - related parties on the accompanying condensed
consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Membership Interest Purchase Agreement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 17, 2023, the Company entered into
a Membership Interest Purchase Agreement with Mr. Lu, the Company&#x2019;s chairman of the Board of Directors, pursuant to which (i) Mr.
Lu will acquire from the Company 30% of the total outstanding membership interests of Avalon RT 9, a wholly owned subsidiary of the Company,
for a cash purchase price of $3,000,000 (the &#x201c;Acquisition&#x201d;), and (ii) for a period of twelve months following the closing
of the Acquisition, Mr. Lu shall have the option to purchase from the Company up to an additional 70% of the outstanding membership interests
of Avalon RT 9 for a purchase price of up to $7,000,000 (the &#x201c;Option&#x201d;), subject to the terms and conditions of a membership
interest purchase agreement to be negotiated and entered into between Mr. Lu and the Company at such time that Mr. Lu desires to exercise
the Option. The Company received $3,328,078 and $3,108,106 from Mr. Lu as of March 31, 2025 and December 31, 2024, respectively, which
was recorded as advance from pending sale of noncontrolling interest - related party on the accompanying condensed consolidated balance
sheets. The Acquisition is expected to close in the fourth quarter of 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Series D Convertible Preferred Stock Issued
in Exchange of Series A Convertible Preferred Stock&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On January 9, 2025, the Company entered into an
exchange agreement with Wenzhao Lu, the Company&#x2019;s chairman of the Board of Directors, pursuant to which Mr. Lu exchanged 9,000
shares of Series A Preferred Stock of the Company, having a carrying value of $9,000,000, for 5,000 shares of Series D Preferred Stock
of the Company. The Company determined that the exchange of the Series A Preferred Stock for the Series D Preferred Stock resulted in
the extinguishment of the Series A Preferred Stock. As a result, the difference between the carrying amount of the Series A Preferred
Stock and the fair value of the Series D Preferred Stock of $162,473 was recognized as a deemed contribution in the three months ended
March 31, 2025 that increased additional paid-in capital and income available to common shareholders in calculating earnings per share
(See Note 10 - Series D Convertible Preferred Stock Issued in Exchange of Series A Convertible Preferred Stock).&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RentalIncomeNonoperating contextRef="c684" decimals="0" id="ixv-90714" unitRef="usd">12600</us-gaap:RentalIncomeNonoperating>
    <us-gaap:RentalIncomeNonoperating contextRef="c685" decimals="0" id="ixv-90715" unitRef="usd">12600</us-gaap:RentalIncomeNonoperating>
    <us-gaap:OtherGeneralExpense contextRef="c0" decimals="0" id="ixv-90716" unitRef="usd">15597</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense contextRef="c100" decimals="0" id="ixv-90717" unitRef="usd">16731</us-gaap:OtherGeneralExpense>
    <avco:AccruedAndUnpaidServicesCharge contextRef="c11" decimals="0" id="ixv-90718" unitRef="usd">2615</avco:AccruedAndUnpaidServicesCharge>
    <avco:AccruedAndUnpaidServicesCharge contextRef="c1" decimals="0" id="ixv-90719" unitRef="usd">15000</avco:AccruedAndUnpaidServicesCharge>
    <us-gaap:CashAcquiredFromAcquisition contextRef="c686" decimals="0" id="ixv-90720" unitRef="usd">450000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c687" decimals="0" id="ixv-90721" unitRef="usd">100000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c377" decimals="0" id="ixv-90722" unitRef="usd">100000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c688"
      decimals="2"
      id="ixv-90723"
      unitRef="pure">0.40</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <avco:EquityMethodInvestmentPayableCurrent contextRef="c689" decimals="0" id="ixv-90724" unitRef="usd">566667</avco:EquityMethodInvestmentPayableCurrent>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c690"
      decimals="2"
      id="ixv-90725"
      unitRef="pure">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PreferredStockValue contextRef="c691" decimals="0" id="ixv-90726" unitRef="usd">11000000</us-gaap:PreferredStockValue>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions contextRef="c0" decimals="0" id="ixv-90727" unitRef="usd">1745000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:PaymentsToAcquireLoansHeldForInvestment contextRef="c0" decimals="0" id="ixv-90728" unitRef="usd">95000</us-gaap:PaymentsToAcquireLoansHeldForInvestment>
    <avco:RegularPaymentsOnEquityInvestments contextRef="c0" decimals="0" id="ixv-90729" unitRef="usd">75000</avco:RegularPaymentsOnEquityInvestments>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c581" decimals="0" id="ixv-90730" unitRef="usd">2348695</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="c692" decimals="0" id="ixv-90731" unitRef="usd">632916</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c692" decimals="0" id="ixv-90732" unitRef="usd">13377916</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ReceivableInvestmentSale contextRef="c689" decimals="0" id="ixv-90733" unitRef="usd">11029221</us-gaap:ReceivableInvestmentSale>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c689" decimals="0" id="ixv-90734" unitRef="usd">0</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherNotesPayable contextRef="c693" decimals="0" id="ixv-90735" unitRef="usd">632916</us-gaap:OtherNotesPayable>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="c694"
      decimals="2"
      id="ixv-90736"
      unitRef="pure">0.30</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <avco:PurchasePrice contextRef="c695" decimals="0" id="ixv-90737" unitRef="usd">3000000</avco:PurchasePrice>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="c696"
      decimals="2"
      id="ixv-90738"
      unitRef="pure">0.70</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <avco:PurchasePrice contextRef="c697" decimals="0" id="ixv-90739" unitRef="usd">7000000</avco:PurchasePrice>
    <avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty contextRef="c698" decimals="0" id="ixv-90740" unitRef="usd">3328078</avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty>
    <avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty contextRef="c699" decimals="0" id="ixv-90741" unitRef="usd">3108106</avco:AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty>
    <avco:ExchangeShare
      contextRef="c700"
      decimals="0"
      id="ixv-90742"
      unitRef="shares">9000</avco:ExchangeShare>
    <us-gaap:PreferredStockValue contextRef="c701" decimals="0" id="ixv-90743" unitRef="usd">9000000</us-gaap:PreferredStockValue>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c702"
      decimals="0"
      id="ixv-90744"
      unitRef="usdPershares">5000</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c16"
      decimals="0"
      id="ixv-90745"
      unitRef="usdPershares">162473</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="c0" id="ixv-74576">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;NOTE 10 - &lt;span style="text-decoration:underline"&gt;EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company is authorized to issue an aggregate
of 100,000,000 shares of common stock and 10,000,000 shares of &#x201c;blank check&#x201d; preferred stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Series A Convertible Preferred Stock&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company designated up to 15,000 shares of
its previously undesignated preferred stock as Series A Preferred Stock. Each share of Series A Preferred Stock has a par value of $0.0001
per share and a stated value equal to $1,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The shares of Series A Preferred Stock have identical
terms and include the terms as set forth below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Dividends.&lt;/i&gt; Holders of Series A Preferred
Stock (each, a &#x201c;Series A Holder&#x201d; and collectively, the &#x201c;Series A Holders&#x201d;) are entitled to receive, and the Company
shall pay, dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-common-stock basis, disregarding for such
purpose any conversion limitations set forth in the Series A Certificate of Designations) to and in the same form as dividends actually
paid on shares of the Company&#x2019;s common stock when, as and if such dividends are paid on shares of the common stock. No other dividends
shall be paid on shares of Series A Preferred Stock. The Company will not pay any dividends on its common stock unless the Company simultaneously
complies with the terms set forth in the Series A Certificate of Designations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Liquidation.&lt;/i&gt; Upon any dissolution, liquidation
or winding-up of the Company, whether voluntary or involuntary (a &#x201c;Liquidation&#x201d;), the Series A Holders will be entitled to
receive out of the assets available for distribution to the stockholders, (i) after and subject to the payment in full of all amounts
required to be distributed to the holders of another class or series of stock of the Company ranking on liquidation prior and in preference
to the Series A Preferred Stock, (ii) ratably with any class or series of stock ranking on liquidation on parity with the Series A Preferred
Stock and (iii) in preference and priority to the holders of the shares of the Company&#x2019;s common stock, an amount equal to 100%
of the Series A Stated Value, and no more, in proportion to the full and preferential amount that all shares of the Series A Preferred
Stock are entitled to receive. The Company shall mail written notice of any Liquidation not less than twenty (20) days prior to the payment
date stated therein, to each Series A Holder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Conversion.&lt;/i&gt; Each share of Series A Preferred
Stock shall be convertible, at any time and from time to time from and after the later of (i) the date of the stockholder approval as
described above, in accordance with the Nasdaq Stock Market Listing Rules, and (ii) the nine (9) month anniversary of the Closing (the
&#x201c;Initial Conversion Date&#x201d;), at the option of the Series A Holder, into that number of shares of common stock (subject to
the limitations set forth in Series A Certificate of Designations, determined by dividing the Stated Value of such share of Series A
Preferred Stock by the conversion price (as defined below)). The Series A Holders may effect conversions by providing the Company with
the form of conversion notice attached as Annex A to the Series A Certificate of Designations. The Series A Holders may convert such
shares into shares of the Company&#x2019;s common stock at a conversion price per share equal to the greater of (i) one hundred fifty
dollars ($150.0) and (ii) ninety percent (90%) of the closing price of the Company&#x2019;s common stock on Nasdaq on the day prior to
receipt of a conversion notice, subject to adjustment for stock splits and similar matters. In addition, following the Initial Conversion
Date, each Series A Holder agrees that it shall not be entitled to in any calendar month, sell a number of Series A conversion shares
into the open market in an amount exceeding more than ten percent (10%) of the number of Series A conversion shares issuable upon conversion
of the Series A Preferred Stock then held by such Series A Holder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;Conversion Price Adjustment:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Stock Dividends and Stock Splits.&lt;/i&gt; If the
Company, at any time while the Series A Preferred Stock is outstanding: (i) pays a stock dividend or otherwise makes a distribution or
distributions payable in shares of common stock on shares of common stock or any other common stock equivalents (which, for avoidance
of doubt, shall not include any shares of common stock issued by the Company upon conversion of, or payment of a dividend on, the Series
A Preferred Stock), (ii) subdivides outstanding shares of common stock into a larger number of shares, (iii) combines (including by way
of a reverse stock split) outstanding shares of common stock into a smaller number of shares, or (iv) issues, in the event of a reclassification
of shares of the common stock, any shares of capital stock of the Company, then the conversion price of the Series A Preferred Stock
shall be multiplied by a fraction of which the numerator shall be the number of shares of common stock (excluding any treasury shares
of the Company) outstanding immediately before such event, and of which the denominator shall be the number of shares of common stock
outstanding immediately after such event. Any of the foregoing adjustments shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Fundamental Transaction.&lt;/i&gt; If, at any time
while the Series A Preferred Stock is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another individual or corporation, partnership, trust, incorporated or unincorporated
association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other
entity of any kind (a &#x201c;Person&#x201d;), (ii) the Company (and all of its subsidiaries, taken as a whole), directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in
one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the
Company or another Person) is completed pursuant to which holders of the Company&#x2019;s common stock are permitted to sell, tender or
exchange their shares for other securities, cash or property and has been accepted by the holders of fifty percent (50%) or more of the
outstanding common stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the common stock or any compulsory share exchange pursuant to which the common stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than fifty percent (50%)
of the outstanding shares of common stock (not including any shares of common stock held by the other Person or other Persons making
or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business
combination) (each a &#x201c;Fundamental Transaction&#x201d;), then, the Series A Holder shall have the right to receive, for each conversion
share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without
regard to any limitation set forth in the Series A Certificate of Designations on the conversion of the Series A Preferred Stock), the
number of shares of common stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and/or
any additional consideration (the &#x201c;Alternate Consideration&#x201d;) receivable as a result of such Fundamental Transaction by a
holder of the number of shares of common stock for which the Series A Preferred Stock is convertible immediately prior to such Fundamental
Transaction (without regard to the limitations set forth in the Series A Certificate of Designations on the conversion of the Series
A Preferred Stock). For purposes of any such conversion, the determination of the conversion price shall be appropriately adjusted to
apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of common stock
in such Fundamental Transaction, and the Company shall apportion the conversion price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of common stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Series A Holder shall be given
the same choice as to the Alternate Consideration it receives upon such Fundamental Transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Voting Rights.&lt;/i&gt; The Series A Holders will
have no voting rights, except as otherwise required by the Delaware General Corporation Law. Notwithstanding the foregoing, as long as
any shares of Series A Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority
of the then outstanding shares of Series A Preferred Stock, voting as a separate class, (a) alter or change adversely the powers, preferences
or rights given to the Series A Preferred Stock in the Series A Certificate of Designations, (b) increase the number of authorized shares
of Series A Preferred Stock, (c) authorize or issue an additional class or series of capital stock that ranks senior to the Series A
Preferred Stock with respect to the distribution of assets on liquidation or (d) enter into any agreement with respect to any of the
foregoing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Fractional Shares.&lt;/i&gt; No fractional shares
or scrip representing fractional shares shall be issued upon the conversion of the Series A Preferred Stock. As to any fraction of a
share of Company common stock which a Series A Holder would otherwise be entitled to upon such conversion, the Company will, at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the conversion price
or round up to the next whole share. Notwithstanding the foregoing, nothing shall prevent any Series A Holder from converting fractional
shares of Series A Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of December 31, 2024, 9,000 shares of Series
A Preferred Stock were issued and outstanding. On January 9, 2025, the Company entered into an exchange agreement with Wenzhao Lu, the
Company&#x2019;s chairman of the Board of Directors, pursuant to which Mr. Lu exchanged 9,000 shares of Series A Preferred Stock of the
Company for 5,000 shares of Series D Preferred Stock of the Company (See Note 10 - Series D Convertible Preferred Stock Issued in Exchange
of Series A Convertible Preferred Stock). As of March 31, 2025, there were no shares of Series A Preferred Stock remain outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Series B Convertible Preferred Stock&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company designated up to 15,000 shares of
its previously undesignated preferred stock as Series B Preferred Stock. Each share of Series B Preferred Stock has a par value of $0.0001
per share and a stated value equal to $1,000.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The shares of Series B Preferred Stock have identical
terms and include the terms as set forth below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Dividends.&lt;/i&gt; The holders of Series B Preferred
Stock (each, a &#x201c;Series B Holder&#x201d; and collectively, the &#x201c;Series B Holders&#x201d;) shall be entitled to receive, and
the Company shall pay, dividends on shares of Series B Preferred Stock equal (on an as-if-converted-to-common-stock basis, disregarding
for such purpose any conversion limitations set forth in the Series B Certificate of Designations) to and in the same form as dividends
actually paid on shares of the Company&#x2019;s common stock when, as and if such dividends are paid on shares of the common stock. No
other dividends shall be paid on shares of Series B Preferred Stock. The Company will not pay any dividends on its common stock unless
the Company simultaneously complies with the terms set forth in the Series B Certificate of Designations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Rank.&lt;/i&gt; The Series B Preferred Stock will
rank subordinate to the shares of the Company&#x2019;s Series A Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Liquidation. &lt;/i&gt;Upon any Liquidation, the
Series B Holders will be entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to the
payment in full of all amounts required to be distributed to the holders of another class or series of stock of the Company ranking on
liquidation prior and in preference to the Series B Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any class
or series of stock ranking on liquidation on parity with the Series B Preferred Stock and (iii) in preference and priority to the holders
of the shares of common stock, an amount equal to one hundred percent (100%) of the Series B Stated Value and no more, in proportion
to the full and preferential amount that all shares of the Series B Preferred Stock are entitled to receive. The Company shall mail written
notice of any such Liquidation not less than twenty (20) days prior to the payment date stated therein, to each Series B Holder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Conversion.&lt;/i&gt; Each share of Series B Preferred
Stock shall be convertible, at any time and from time to time from and after the later of (i) the date of the stockholder approval and
(ii) February 9, 2024 (the &#x201c;Lock Up Period&#x201d;), at the option of the Series B Holder thereof, into that number of shares of
common stock (subject to the limitations set forth in Series B Certificate of Designations determined by dividing the Series B Stated
Value of such share of Series B Preferred Stock by the conversion price of the Series B Preferred Stock). Series B Holders may effectuate
conversions by providing the Company with the form of conversion notice attached as Annex A to the Series B Certificate of Designations.
The Series B Preferred Stock will be convertible into shares of the Company&#x2019;s common stock at a conversion price per share equal
to $56.70, subject to the adjustments set forth in the Series B Certificate of Designations. Notwithstanding the foregoing or the transactions
contemplated by the Amended MIPA, until the consummation of the Lock Up Period, the Series B Holders shall not, directly or indirectly,
sell, transfer or otherwise dispose of any Series B Preferred Stock issued upon conversion of the Series B conversion shares or pursuant
to the Equity Earnout Payment (the &#x201c;Restricted Securities&#x201d;) without Company&#x2019;s prior written consent; provided, however,
the Series B Holders may sell, transfer or otherwise dispose of Restricted Securities to an Affiliate, as defined in the Amended MIPA,
of a Series B Holder without Company&#x2019;s prior written consent; provided, further, that such Series B Holder provide prompt written
notice to Company of such transfer, including the name and contact information of the Affiliate transferee, and such Affiliate transferee
agrees in writing to be bound by the terms of the transaction documents contemplated by the Amended MIPA to which the Series B Holder
is a party (which agreement shall also be provided to Company with such notice). After the expiration of the Lock Up Period, the Series
B Holder agrees that it and any of its Affiliate transferees shall not be entitled to in any calendar month, sell a number of shares
of Company common stock into the open market in an amount exceeding more than ten percent (10%) of the total number of shares of Company
common stock issuable upon conversion of the Company common stock then held by the Seller and its Affiliates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;Conversion Price Adjustment:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Stock Dividends and Stock Splits.&lt;/i&gt; If the
Company, at any time while the Series B Preferred Stock is outstanding: (i) pays a stock dividend or otherwise makes a distribution or
distributions payable in shares of common stock on shares of common stock or any other common stock equivalents (which, for avoidance
of doubt, shall not include any shares of common stock issued by the Company upon conversion of, or payment of a dividend on, the Series
B Preferred Stock), (ii) subdivides outstanding shares of common stock into a larger number of shares, (iii) combines (including by way
of a reverse stock split) outstanding shares of common stock into a smaller number of shares, or (iv) issues, in the event of a reclassification
of shares of the common stock, any shares of capital stock of the Company, then the conversion price of the Series B Preferred Stock
shall be multiplied by a fraction of which the numerator shall be the number of shares of common stock (excluding any treasury shares
of the Company) outstanding immediately before such event, and of which the denominator shall be the number of shares of common stock
outstanding immediately after such event. Any of the foregoing adjustments shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Fundamental Transaction.&lt;/i&gt; If, at any time
while the Series B Preferred Stock is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another Person, (ii) the Company (and all of its subsidiaries, taken as a whole),
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of the Company&#x2019;s common stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of fifty percent
(50%) or more of the outstanding common stock, (iv) the Company, directly or indirectly, in one or more related transactions effects
any reclassification, reorganization or recapitalization of the common stock or any compulsory share exchange pursuant to which the common
stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a Fundamental Transaction, then, at the closing of such Fundamental Transaction, without
any action on the part of the Series B Holder, the Series B Holder shall have the right to receive, for each conversion share that would
have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation
in the Series B Certificate of Designations on the conversion of the Series B Preferred Stock), the number of shares of common stock
of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and/or any Alternate Consideration receivable
as a result of such Fundamental Transaction by a holder of the number of shares of common stock for which the Series B Preferred Stock
is convertible immediately prior to such Fundamental Transaction (without regard to the limitations set forth in the Series B Certificate
of Designations on the conversion of the Series B Preferred Stock). For purposes of any such conversion, the determination of the conversion
price of the Series B Preferred Stock shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of
Alternate Consideration issuable in respect of one share of common stock in such Fundamental Transaction, and the Company shall apportion
the conversion price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of common stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Series B Holder shall be given the same choice as to the Alternate Consideration it receives upon
such Fundamental Transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Voting Rights&lt;/i&gt;. The Series B Holders will
have no voting rights, except as otherwise required by the Delaware General Corporation Law. Notwithstanding the foregoing, in addition,
as long as any shares of Series B Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders
of a majority of the then outstanding shares of the Series B Preferred Stock, voting as a separate class, (a) alter or change adversely
the powers, preferences or rights given to the Series B Preferred Stock in the Series B Certificate of Designations, (b) increase the
number of authorized shares of Series B Preferred Stock, (c) except with respect to the Series A Preferred Stock, authorize or issue
an additional class or series of capital stock that ranks senior to the Series B Preferred Stock with respect to the distribution of
assets on liquidation or (d) enter into any agreement with respect to any of the foregoing.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Fractional Shares.&lt;/i&gt; No fractional shares
or scrip representing fractional shares shall be issued upon the conversion of the Series B Preferred Stock. As to any fraction of a
share which a Series B Holder would otherwise be entitled to upon such conversion, the Company shall at its election, either pay a cash
adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the conversion price or round up to the
next whole share. Notwithstanding the foregoing, nothing shall prevent any Series B Holder from converting fractional shares of Series
B Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of December 31, 2024, 11,000 shares of Series
B Preferred Stock were issued and outstanding. During the first quarter of 2025, to preserve cash, the Company entered into discussions
with Lab Services MSO for the potential redemption of our investment and on February 26, 2025, the Company and Lab Services MSO entered
into a Redemption and Abandonment Agreement, whereby Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by the
Company for cash and the surrender of its Series B Preferred Stock having a carrying value of $11,000,000. Pursuant to the terms of the
Redemption Agreement, all shares of the Company&#x2019;s Series B Preferred Stock previously issued to SCBC Holdings LLC as partial consideration
for the equity interests of Laboratory Services MSO, were permanently surrendered and relinquished to the Company for no additional consideration
(See Note 10 - Series B Convertible Preferred Stock Extinguished Related to Sale of Equity Method Investment). As of March 31, 2025,
there were no shares of Series B Preferred Stock remain outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Series C Convertible Preferred Stock&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On December 13, 2024, the Company filed a certificate
of designations of preferences, rights, and limitations of Series C Preferred Stock (the &#x201c;Series C Certificate of Designations&#x201d;)
with the Department of State, Division of Corporations, of the State of Delaware, which provides for the designation of 10,000 shares
of Series C Preferred Stock of the Company, par value $0.0001 per share. Each share of Series C Preferred Stock has a stated value of
$1,000.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Series C Preferred Stock shall rank (i) senior
to the Company&#x2019;s common stock and any other class or series of capital stock of the Company created hereafter, the terms of which
specifically provide that such class or series shall rank junior to the Series C Preferred Stock, (ii) pari passu with any class or series
of capital stock of the Company created hereafter specifically ranking, by its terms, on par with the Series C Preferred Stock, (iii)
pari passu with Series B Preferred Stock of the Company with respect to its rights, preferences and restrictions, and (iv) subordinate
to the Series A Preferred Stock of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Holders of the Series C Preferred Stock shall
be entitled to receive, and the Company shall pay, dividends on shares of Series C Preferred Stock equal (on an as-if-converted-to-common-stock
basis, disregarding for such purpose any conversion limitations hereunder) to and in the same form as dividends actually paid on shares
of the common stock when, as and if such dividends are paid on shares of the common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Holders of the Series C Preferred Stock have no
voting power except as otherwise required by the Delaware General Corporation Law.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Upon any liquidation, dissolution or winding-up
of the Company, whether voluntary or involuntary (a &#x201c;Liquidation&#x201d;), the holders of the Series C Preferred Stock shall be
entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to the payment in full of all
amounts required to be distributed to the holders of another class or series of stock of the Company ranking on liquidation prior and
in preference to the Series C Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any class or series of stock
ranking on liquidation on parity with the Series C Preferred Stock and (iii) in preference and priority to the holders of the shares
of common stock, an amount equal to 100% of the Stated Value of the Series C Preferred Stock, in proportion to the full and preferential
amount that all shares of the Series C Preferred Stock are entitled to receive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Each share of Series C Preferred Stock shall be
convertible into common stock (the &#x201c;Series C Conversion Shares&#x201d;) at a conversion per share equal to $2.41, at the option
of the holder, at any time after the later of (i) the date of the shareholder approval of the issuance of the Series C Conversion Shares
pursuant to the rules of the Nasdaq Stock Market and (ii) the one year anniversary of the date of the first issuance of any shares of
the Series C Preferred Stock. In addition, the holder shall not have the right to convert any portion of the Series C Preferred Stock
if, after giving effect to the conversion, such holder (together with its affiliates) would beneficially own in excess of 19.99% of the
number of shares of the common stock outstanding immediately after giving effect to the issuance of the respective Series C Conversion
Shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of both March 31, 2025 and December 31, 2024,
3,500 shares of Series C Preferred Stock were issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Series D Convertible Preferred Stock&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On January 6, 2025, the Company filed a certificate
of designations of preferences, rights, and limitations of Series D Preferred Stock (the &#x201c;Series D Certificate of Designations&#x201d;)
with the Department of State, Division of Corporations, of the State of Delaware, which provides for the designation of 5,000 shares
of Series D Preferred Stock of the Company, par value $0.0001 per share, upon the terms and conditions as set forth in the Series D Certificate
of Designations. Each share of Series D Preferred Stock has a stated value of $1,000.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Series D Preferred Stock shall rank (i) senior
to the Company&#x2019;s common stock and any other class or series of capital stock of the Company created hereafter, the terms of which
specifically provide that such class or series shall rank junior to the Series D Preferred Stock, (ii) pari passu with any class or series
of capital stock of the Company created hereafter specifically ranking, by its terms, on par with the Series D Preferred Stock, (iii)
pari passu with the Series B Preferred Stock of the Company with respect to its rights, preferences and restrictions, and (iv) pari passu
with the Series C Preferred Stock of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Holders of the Series D Preferred Stock have no
voting power except as otherwise required by the Delaware General Corporation Law.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Upon any liquidation, dissolution or winding-up
of the Company, whether voluntary or involuntary (a &#x201c;Liquidation&#x201d;), the holders of the Series D Preferred Stock shall be
entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to the payment in full of all
amounts required to be distributed to the holders of another class or series of stock of the Company ranking on liquidation prior and
in preference to the Series D Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any class or series of stock
ranking on liquidation on parity with the Series D Preferred Stock and (iii) in preference and priority to the holders of the shares
of common stock, an amount equal to 100% of the Stated Value of the Series D Preferred Stock, in proportion to the full and preferential
amount that all shares of the Series D Preferred Stock are entitled to receive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Each share of Series D Preferred Stock shall be
convertible into common stock (the &#x201c;Series D Conversion Shares&#x201d;) at a conversion per share equal to $2.41, at the option
of the holder, at any time after the Company has obtained shareholder approval for the issuance of the Series D Conversion Shares pursuant
to the rules of the Nasdaq Stock Market. In addition, the holder shall not have the right to convert any portion of the Series D Preferred
Stock if, after giving effect to the conversion, such holder (together with its affiliates) would beneficially own in excess of 4.99%
of the number of shares of the common stock outstanding immediately after giving effect to the issuance of the respective Series D Conversion
Shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of March 31, 2025, 5,000 shares of Series D
Preferred Stock were issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Series D Convertible Preferred Stock Issued
in Exchange of Series A Convertible Preferred Stock&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On January 9, 2025, the Company entered into an
exchange agreement with Wenzhao Lu, the Company&#x2019;s chairman of the Board of Directors, pursuant to which Mr. Lu exchanged 9,000
shares of Series A Preferred Stock of the Company, having a carrying value of $9,000,000, for 5,000 shares of Series D Preferred Stock
of the Company. The Company determined that the exchange of the Series A Preferred Stock for the Series D Preferred Stock resulted in
the extinguishment of the Series A Preferred Stock. As a result, the difference between the carrying amount of the Series A Preferred
Stock and the fair value of the Series D Preferred Stock of $162,473 was recognized as a deemed contribution in the three months ended
March 31, 2025 that increased additional paid-in capital and income available to common shareholders in calculating earnings per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Each share of Series D Preferred Stock is convertible
into common stock of the Company (the &#x201c;Series D Conversion Shares&#x201d;) at a conversion per share equal to $2.41, which approximated
the market price at the date of transaction, at the option of the holder, at any time after the Company has obtained shareholder approval
for the issuance of the Series D Conversion Shares pursuant to the rules of the Nasdaq Stock Market.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company evaluated the features of the Series
D Preferred Stock under ASC 480, and classified them as permanent equity because the Series D Preferred Stock is not mandatorily or contingently
redeemable at the stockholder&#x2019;s option and the liquidation preference that exists does not fall within the guidance of SEC Accounting
Series Release No. 268 - &lt;i&gt;Presentation in Financial Statements of &#x201c;Redeemable Preferred Stocks&#x201d;&lt;/i&gt; (&#x201c;ASR 268&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Series B Convertible Preferred Stock Extinguished
Related to Sale of Equity Method Investment&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the first quarter of 2025, to preserve
cash, the Company entered into discussions with Lab Services MSO for the potential redemption of our investment and on February 26, 2025,
the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement, whereby Lab Services MSO redeemed the 40% equity
interest in Lab Services MSO held by the Company for cash and the surrender of its Series B Preferred Stock having a carrying value of
$11,000,000. The aggregate cash amount to the Company for the redemption was $1,745,000, to be paid as follows: one payment of $95,000
at the closing of the redemption and, beginning in March 2025, monthly payments of $75,000 until December 2026. In addition, pursuant
to the terms of the Redemption Agreement, all shares of the Company&#x2019;s Series B Preferred Stock previously issued to SCBC Holdings
LLC as partial consideration for the equity interests of Laboratory Services MSO, were permanently surrendered and relinquished to the
Company for no additional consideration. The difference of $2,348,695 between the carrying value of the extinguished Series B preferred
stock, the aggregate cash amount to the Company for the redemption, net of payables due to Lab Services MSO of $632,916, totaling $13,377,916,
and the carrying value of the equity method investment of $11,029,221 was accounted for as an increase to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Common Shares Issued for Services&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the three months ended March 31, 2025,
the Company issued a total of 22,278 shares of its common stock for services rendered and to be rendered. These shares were valued at
$111,232, the fair market values on the grant dates using the reported closing share prices on the dates of grant, and the Company recorded
stock-based compensation expense of $17,212 for the three months ended March 31, 2025 and reduced accrued liabilities of $42,385 and
recorded prepaid expense of $51,635 as of March 31, 2025 which will be amortized over the rest of corresponding service periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Common Shares Issued for Warrant Exercise&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In March 2025, pursuant to the terms of related
warrant agreements, the Company issued 186,877 shares of its common stock upon cashless exercise of warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Options&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table summarizes the shares of the
Company&#x2019;s common stock issuable upon exercise of options outstanding at March 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Range of&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number &lt;br/&gt; Outstanding&lt;br/&gt; at March 31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual Life &lt;br/&gt; (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted &lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number &lt;br/&gt; Exercisable at &lt;br/&gt; March 31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted &lt;br/&gt; Average&lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 1%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 24%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2.93 - 31.20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;21,010&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3.48&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;12.19&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;17,078&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;14.28&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;span style="font-size: 10pt"&gt;48.75 - 123.00&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;20,517&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1.79&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;78.91&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;20,517&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;78.91&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td colspan="2" style="text-align: right; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;span style="font-size: 10pt"&gt;154.50 - 264.00&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;9,898&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3.82&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;214.71&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;9,898&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;214.71&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-top: Black 1.5pt solid; text-align: right; padding-bottom: 2.5pt; border-bottom: Black 4pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid; text-align: right; padding-bottom: 2.5pt; border-bottom: Black 4pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2.93 - 264.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;51,425&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2.87&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;77.79&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;47,493&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;83.97&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock option activity for the three months ended
March 31, 2025 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of &lt;br/&gt; Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise
    &lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;52,479&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;85.45&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,665&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3.26&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Expired / cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(3,719&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(132.47&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;51,425&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;77.79&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Options exercisable at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;47,493&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;83.97&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Options expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,932&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3.13&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The aggregate intrinsic value of stock options
outstanding and stock options exercisable at March 31, 2025 was approximately $17,000 an $10,000, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The fair values of options granted during the
three months ended March 31, 2025 were estimated at the date of grant using the Black-Scholes option-pricing model with the following
assumptions: volatility of 105.10%, risk-free rate of 4.29%, annual dividend yield of 0%, and expected life of 3.00 years. The aggregate
fair value of the options granted during the three months ended March 31, 2025 was $6,115.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The fair values of options granted during the
three months ended March 31, 2024 were estimated at the date of grant using the Black-Scholes option-pricing model with the following
assumptions: volatility of 91.17%, risk-free rate of 3.93%, annual dividend yield of 0%, and expected life of 5.00 years. The aggregate
fair value of the options granted during the three months ended March 31, 2024 was $12,137.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the three months ended March 31, 2025 and
2024, stock-based compensation expense associated with stock options granted amounted to $9,159 and $13,533, of which, $4,858 and $5,103
was recorded as compensation and related benefits, $4,301 and $8,430 was recorded as professional fees, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;A summary of the status of the Company&#x2019;s
nonvested stock options granted as of March 31, 2025 and changes during the three months ended March 31, 2025 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of &lt;br/&gt; Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise
    &lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Nonvested at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,943&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;11.54&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,665&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3.26&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,853&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(27.40&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,823&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(5.03&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Nonvested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,932&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3.13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Warrants (Except Pre-Funded Warrants)&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table summarizes the shares of the
Company&#x2019;s common stock issuable upon exercise of warrants outstanding at March 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="12" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Warrants Outstanding&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Warrants Exercisable&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Range of&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Number &lt;br/&gt; Outstanding&lt;br/&gt; at March 31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual Life &lt;br/&gt; (Years)&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Weighted &lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Number &lt;br/&gt; Exercisable at &lt;br/&gt; March 31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Weighted &lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;7.50 - 37.50&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;162,010&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;4.17&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;9.92&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;82,010&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;12.27&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;67.50&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;889&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;3.18&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;67.50&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;889&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;67.50&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;187.50&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;8,264&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;2.06&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;187.50&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;8,264&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;187.50&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;7.50 - 187.50&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;171,163&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;4.06&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;18.79&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;91,163&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;28.70&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock warrant activity for the three months ended
March 31, 2025 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of &lt;br/&gt; Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted &lt;br/&gt;
    Average &lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;182,996&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;21.37&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(11,833&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(58.63&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;171,163&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;18.79&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Warrants exercisable at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;91,163&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;28.70&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Warrants expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7.50&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The aggregate intrinsic value of both stock warrants
outstanding and stock warrants exercisable at March 31, 2025 was $0.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;Warrants Exercised in March 2025&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In March 2025, pursuant to the terms of related
warrant agreements, the Company issued 186,877 shares of its common stock upon cashless exercise of warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;A summary of the status of the Company&#x2019;s
nonvested stock warrants issued as of March 31, 2025 and changes during the three months ended March 31, 2025 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of &lt;br/&gt; Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise&lt;br/&gt;
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Nonvested at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-386"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-387"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Nonvested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Pre-Funded Warrants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of March 31, 2025, there were 150,000 pre-funded
warrants outstanding with an exercise price of $0.01 per share. There was no activity related to these warrants during the three months
ended March 31, 2025.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c11"
      decimals="0"
      id="ixv-90746"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c11"
      decimals="0"
      id="ixv-90747"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c81"
      decimals="0"
      id="ixv-90748"
      unitRef="shares">15000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c81"
      decimals="4"
      id="ixv-90749"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockValue contextRef="c703" decimals="0" id="ixv-90750" unitRef="usd">1000</us-gaap:PreferredStockValue>
    <avco:PercentageOfCommonStockIssuedAndOutstanding
      contextRef="c704"
      decimals="2"
      id="ixv-90751"
      unitRef="pure">1</avco:PercentageOfCommonStockIssuedAndOutstanding>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c13"
      decimals="1"
      id="ixv-90752"
      unitRef="usdPershares">150</us-gaap:PreferredStockConvertibleConversionPrice>
    <avco:ConversionPricePercentage
      contextRef="c704"
      decimals="2"
      id="ixv-90753"
      unitRef="pure">-0.90</avco:ConversionPricePercentage>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="c705"
      decimals="2"
      id="ixv-90754"
      unitRef="pure">0.10</us-gaap:DebtConversionConvertedInstrumentRate>
    <avco:PercentageOfCommonStockIssuedAndOutstanding contextRef="c0" decimals="2" id="ixv-90755" unitRef="pure">-0.50</avco:PercentageOfCommonStockIssuedAndOutstanding>
    <avco:PercentageOfCommonStockIssuedAndOutstanding contextRef="c74" decimals="2" id="ixv-90756" unitRef="pure">-0.50</avco:PercentageOfCommonStockIssuedAndOutstanding>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c74"
      decimals="0"
      id="ixv-90757"
      unitRef="shares">1</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c5"
      decimals="0"
      id="ixv-90758"
      unitRef="shares">9000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="ixv-90759"
      unitRef="shares">9000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c701"
      decimals="0"
      id="ixv-90760"
      unitRef="shares">9000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c702"
      decimals="0"
      id="ixv-90761"
      unitRef="shares">5000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c706"
      decimals="0"
      id="ixv-90762"
      unitRef="shares">15000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c707"
      decimals="4"
      id="ixv-90763"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockValue contextRef="c707" decimals="0" id="ixv-90764" unitRef="usd">1000</us-gaap:PreferredStockValue>
    <avco:PercentageOfCommonStockIssuedAndOutstanding
      contextRef="c581"
      decimals="2"
      id="ixv-90765"
      unitRef="pure">1</avco:PercentageOfCommonStockIssuedAndOutstanding>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="c581"
      decimals="2"
      id="ixv-90766"
      unitRef="usdPershares">56.7</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <avco:PercentageOfCommonStockIssuedAndOutstanding
      contextRef="c708"
      decimals="2"
      id="ixv-90767"
      unitRef="pure">0.50</avco:PercentageOfCommonStockIssuedAndOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c7"
      decimals="0"
      id="ixv-90768"
      unitRef="shares">11000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c7"
      decimals="0"
      id="ixv-90769"
      unitRef="shares">11000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c709"
      decimals="2"
      id="ixv-90770"
      unitRef="pure">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments contextRef="c710" decimals="0" id="ixv-90771" unitRef="usd">11000000</us-gaap:EquityMethodInvestments>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c399"
      decimals="0"
      id="ixv-90772"
      unitRef="shares">10000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c399"
      decimals="4"
      id="ixv-90773"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockValue contextRef="c399" decimals="0" id="ixv-90774" unitRef="usd">1000</us-gaap:PreferredStockValue>
    <avco:PercentageOfCommonStockIssuedAndOutstanding
      contextRef="c711"
      decimals="2"
      id="ixv-90775"
      unitRef="pure">1</avco:PercentageOfCommonStockIssuedAndOutstanding>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c15"
      decimals="2"
      id="ixv-90776"
      unitRef="usdPershares">2.41</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c712"
      decimals="4"
      id="ixv-90777"
      unitRef="pure">0.1999</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c83"
      decimals="0"
      id="ixv-90778"
      unitRef="shares">3500</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c63"
      decimals="0"
      id="ixv-90779"
      unitRef="shares">3500</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c713"
      decimals="0"
      id="ixv-90780"
      unitRef="shares">5000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c713"
      decimals="4"
      id="ixv-90781"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockValue contextRef="c713" decimals="0" id="ixv-90782" unitRef="usd">1000</us-gaap:PreferredStockValue>
    <avco:PercentageOfCommonStockIssuedAndOutstanding
      contextRef="c714"
      decimals="2"
      id="ixv-90783"
      unitRef="pure">1</avco:PercentageOfCommonStockIssuedAndOutstanding>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c84"
      decimals="2"
      id="ixv-90784"
      unitRef="usdPershares">2.41</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c715"
      decimals="4"
      id="ixv-90785"
      unitRef="pure">0.0499</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c712"
      decimals="0"
      id="ixv-90786"
      unitRef="shares">5000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c712"
      decimals="0"
      id="ixv-90787"
      unitRef="shares">5000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c716"
      decimals="0"
      id="ixv-90788"
      unitRef="shares">9000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:EquityMethodInvestments contextRef="c702" decimals="0" id="ixv-90789" unitRef="usd">9000000</us-gaap:EquityMethodInvestments>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c702"
      decimals="0"
      id="ixv-90790"
      unitRef="shares">5000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c16"
      decimals="0"
      id="ixv-90791"
      unitRef="shares">162473</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c16"
      decimals="2"
      id="ixv-90792"
      unitRef="usdPershares">2.41</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c717"
      decimals="2"
      id="ixv-90793"
      unitRef="pure">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments contextRef="c718" decimals="0" id="ixv-90794" unitRef="usd">11000000</us-gaap:EquityMethodInvestments>
    <us-gaap:PreferredStockRedemptionAmount contextRef="c11" decimals="0" id="ixv-90795" unitRef="usd">1745000</us-gaap:PreferredStockRedemptionAmount>
    <us-gaap:PreferredStockRedemptionAmount contextRef="c707" decimals="0" id="ixv-90796" unitRef="usd">95000</us-gaap:PreferredStockRedemptionAmount>
    <us-gaap:PreferredStockRedemptionAmount contextRef="c706" decimals="0" id="ixv-90797" unitRef="usd">75000</us-gaap:PreferredStockRedemptionAmount>
    <us-gaap:PreferredStockValue contextRef="c82" decimals="0" id="ixv-90798" unitRef="usd">2348695</us-gaap:PreferredStockValue>
    <avco:RedemptionNetOfPayablesDueToLabServices contextRef="c11" decimals="0" id="ixv-90799" unitRef="usd">632916</avco:RedemptionNetOfPayablesDueToLabServices>
    <us-gaap:PreferredStockRedemptionPremium contextRef="c0" decimals="0" id="ixv-90800" unitRef="usd">13377916</us-gaap:PreferredStockRedemptionPremium>
    <us-gaap:EquityMethodInvestments contextRef="c707" decimals="0" id="ixv-90801" unitRef="usd">11029221</us-gaap:EquityMethodInvestments>
    <us-gaap:CommonStockSharesIssued
      contextRef="c719"
      decimals="0"
      id="ixv-90802"
      unitRef="shares">22278</us-gaap:CommonStockSharesIssued>
    <avco:FairMarketValues contextRef="c74" decimals="0" id="ixv-90803" unitRef="usd">111232</avco:FairMarketValues>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="0" id="ixv-90804" unitRef="usd">17212</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c11" decimals="0" id="ixv-90805" unitRef="usd">42385</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c11" decimals="0" id="ixv-90806" unitRef="usd">51635</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:CommonStockSharesIssued
      contextRef="c85"
      decimals="0"
      id="ixv-90807"
      unitRef="shares">186877</us-gaap:CommonStockSharesIssued>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c725" id="ixv-75010">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table summarizes the shares of the
Company&#x2019;s common stock issuable upon exercise of options outstanding at March 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Range of&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number &lt;br/&gt; Outstanding&lt;br/&gt; at March 31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual Life &lt;br/&gt; (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted &lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Number &lt;br/&gt; Exercisable at &lt;br/&gt; March 31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted &lt;br/&gt; Average&lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 1%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 24%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2.93 - 31.20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;21,010&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3.48&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;12.19&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;17,078&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;14.28&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;span style="font-size: 10pt"&gt;48.75 - 123.00&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;20,517&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1.79&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;78.91&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;20,517&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;78.91&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td colspan="2" style="text-align: right; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;span style="font-size: 10pt"&gt;154.50 - 264.00&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;9,898&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3.82&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;214.71&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;9,898&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;214.71&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-top: Black 1.5pt solid; text-align: right; padding-bottom: 2.5pt; border-bottom: Black 4pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid; text-align: right; padding-bottom: 2.5pt; border-bottom: Black 4pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2.93 - 264.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;51,425&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2.87&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;77.79&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;47,493&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;83.97&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c726"
      decimals="2"
      id="ixv-90808"
      unitRef="usdPershares">2.93</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c726"
      decimals="2"
      id="ixv-90809"
      unitRef="usdPershares">31.2</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c727"
      decimals="INF"
      id="ixv-90810"
      unitRef="shares">21010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c726" id="ixv-75108">P3Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c727"
      decimals="2"
      id="ixv-90811"
      unitRef="usdPershares">12.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c727"
      decimals="INF"
      id="ixv-90812"
      unitRef="shares">17078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c727"
      decimals="2"
      id="ixv-90813"
      unitRef="usdPershares">14.28</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c728"
      decimals="2"
      id="ixv-90814"
      unitRef="usdPershares">48.75</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c728"
      decimals="2"
      id="ixv-90815"
      unitRef="usdPershares">123</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c729"
      decimals="INF"
      id="ixv-90816"
      unitRef="shares">20517</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c728" id="ixv-75153">P1Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c729"
      decimals="2"
      id="ixv-90817"
      unitRef="usdPershares">78.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c729"
      decimals="INF"
      id="ixv-90818"
      unitRef="shares">20517</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c729"
      decimals="2"
      id="ixv-90819"
      unitRef="usdPershares">78.91</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c730"
      decimals="2"
      id="ixv-90820"
      unitRef="usdPershares">154.5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c730"
      decimals="2"
      id="ixv-90821"
      unitRef="usdPershares">264</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c731"
      decimals="INF"
      id="ixv-90822"
      unitRef="shares">9898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c730" id="ixv-75198">P3Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c731"
      decimals="2"
      id="ixv-90823"
      unitRef="usdPershares">214.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c731"
      decimals="INF"
      id="ixv-90824"
      unitRef="shares">9898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c731"
      decimals="2"
      id="ixv-90825"
      unitRef="usdPershares">214.71</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c732"
      decimals="2"
      id="ixv-90826"
      unitRef="usdPershares">2.93</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c732"
      decimals="2"
      id="ixv-90827"
      unitRef="usdPershares">264</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c733"
      decimals="INF"
      id="ixv-90828"
      unitRef="shares">51425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c732" id="ixv-75244">P2Y10M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c733"
      decimals="2"
      id="ixv-90829"
      unitRef="usdPershares">77.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c733"
      decimals="INF"
      id="ixv-90830"
      unitRef="shares">47493</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c733"
      decimals="2"
      id="ixv-90831"
      unitRef="usdPershares">83.97</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="c0" id="ixv-75274">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock option activity for the three months ended
March 31, 2025 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of &lt;br/&gt; Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise
    &lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;52,479&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;85.45&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,665&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3.26&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Expired / cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(3,719&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(132.47&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;51,425&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;77.79&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Options exercisable at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;47,493&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;83.97&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Options expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,932&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3.13&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock warrant activity for the three months ended
March 31, 2025 was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of &lt;br/&gt; Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted &lt;br/&gt;
    Average &lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;182,996&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;21.37&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(11,833&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(58.63&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;171,163&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;18.79&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Warrants exercisable at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;91,163&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;28.70&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Warrants expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7.50&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c483"
      decimals="INF"
      id="ixv-90832"
      unitRef="shares">52479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c483"
      decimals="2"
      id="ixv-90833"
      unitRef="usdPershares">85.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c734"
      decimals="INF"
      id="ixv-90834"
      unitRef="shares">2665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c734"
      decimals="2"
      id="ixv-90835"
      unitRef="usdPershares">3.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c734"
      decimals="INF"
      id="ixv-90836"
      unitRef="shares">3719</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c734"
      decimals="2"
      id="ixv-90837"
      unitRef="usdPershares">132.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c735"
      decimals="INF"
      id="ixv-90838"
      unitRef="shares">51425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c735"
      decimals="2"
      id="ixv-90839"
      unitRef="usdPershares">77.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c735"
      decimals="INF"
      id="ixv-90840"
      unitRef="shares">47493</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c735"
      decimals="2"
      id="ixv-90841"
      unitRef="usdPershares">83.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c735"
      decimals="INF"
      id="ixv-90842"
      unitRef="shares">3932</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c735"
      decimals="2"
      id="ixv-90843"
      unitRef="usdPershares">3.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c720" decimals="0" id="ixv-90844" unitRef="usd">17000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c720" decimals="0" id="ixv-90845" unitRef="usd">10000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c0" decimals="4" id="ixv-90846" unitRef="pure">1.051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c0" decimals="4" id="ixv-90847" unitRef="pure">0.0429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c0" decimals="2" id="ixv-90848" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0" id="ixv-90849">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c11" decimals="0" id="ixv-90850" unitRef="usd">6115</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c100"
      decimals="4"
      id="ixv-90851"
      unitRef="pure">0.9117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c100"
      decimals="4"
      id="ixv-90852"
      unitRef="pure">0.0393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c100"
      decimals="2"
      id="ixv-90853"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c100" id="ixv-90854">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c110" decimals="0" id="ixv-90855" unitRef="usd">12137</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c721" decimals="0" id="ixv-90856" unitRef="usd">9159</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c722" decimals="0" id="ixv-90857" unitRef="usd">13533</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c0" decimals="0" id="ixv-90858" unitRef="usd">4858</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c100" decimals="0" id="ixv-90859" unitRef="usd">5103</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ProfessionalFees contextRef="c721" decimals="0" id="ixv-90860" unitRef="usd">4301</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c722" decimals="0" id="ixv-90861" unitRef="usd">8430</us-gaap:ProfessionalFees>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="c0" id="ixv-75466">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;A summary of the status of the Company&#x2019;s
nonvested stock options granted as of March 31, 2025 and changes during the three months ended March 31, 2025 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of &lt;br/&gt; Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise
    &lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Nonvested at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5,943&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;11.54&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,665&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3.26&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,853&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(27.40&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,823&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(5.03&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Nonvested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,932&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3.13&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;A summary of the status of the Company&#x2019;s
nonvested stock warrants issued as of March 31, 2025 and changes during the three months ended March 31, 2025 is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of &lt;br/&gt; Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise&lt;br/&gt;
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Nonvested at January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7.50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-386"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-387"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Nonvested at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7.50&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c738"
      decimals="INF"
      id="ixv-90862"
      unitRef="shares">5943</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c738"
      decimals="2"
      id="ixv-90863"
      unitRef="usdPershares">11.54</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c739"
      decimals="INF"
      id="ixv-90864"
      unitRef="shares">2665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c739"
      decimals="2"
      id="ixv-90865"
      unitRef="usdPershares">3.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c739"
      decimals="INF"
      id="ixv-90866"
      unitRef="shares">1853</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="c739"
      decimals="2"
      id="ixv-90867"
      unitRef="usdPershares">27.4</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c739"
      decimals="INF"
      id="ixv-90868"
      unitRef="shares">2823</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <avco:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues
      contextRef="c739"
      decimals="2"
      id="ixv-90869"
      unitRef="usdPershares">-5.03</avco:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c740"
      decimals="INF"
      id="ixv-90870"
      unitRef="shares">3932</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c740"
      decimals="2"
      id="ixv-90871"
      unitRef="usdPershares">3.13</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c741" id="ixv-75592">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table summarizes the shares of the
Company&#x2019;s common stock issuable upon exercise of warrants outstanding at March 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="12" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Warrants Outstanding&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Warrants Exercisable&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Range of&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Number &lt;br/&gt; Outstanding&lt;br/&gt; at March 31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Remaining &lt;br/&gt; Contractual Life &lt;br/&gt; (Years)&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Weighted &lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Number &lt;br/&gt; Exercisable at &lt;br/&gt; March 31,&lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;Weighted &lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;7.50 - 37.50&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;162,010&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;4.17&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;9.92&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;82,010&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;12.27&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;67.50&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;889&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;3.18&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;67.50&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;889&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;67.50&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;187.50&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;8,264&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;2.06&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;187.50&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;8,264&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;187.50&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;7.50 - 187.50&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;171,163&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;4.06&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;18.79&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;91,163&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;28.70&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c742"
      decimals="2"
      id="ixv-90872"
      unitRef="usdPershares">7.5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c742"
      decimals="2"
      id="ixv-90873"
      unitRef="usdPershares">37.5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c743"
      decimals="INF"
      id="ixv-90874"
      unitRef="shares">162010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c742" id="ixv-75680">P4Y2M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c743"
      decimals="2"
      id="ixv-90875"
      unitRef="usdPershares">9.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c743"
      decimals="INF"
      id="ixv-90876"
      unitRef="shares">82010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c743"
      decimals="2"
      id="ixv-90877"
      unitRef="usdPershares">12.27</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c744"
      decimals="2"
      id="ixv-90878"
      unitRef="usdPershares">67.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c744"
      decimals="INF"
      id="ixv-90879"
      unitRef="shares">889</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c745" id="ixv-75726">P3Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c744"
      decimals="2"
      id="ixv-90880"
      unitRef="usdPershares">67.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c744"
      decimals="INF"
      id="ixv-90881"
      unitRef="shares">889</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c744"
      decimals="2"
      id="ixv-90882"
      unitRef="usdPershares">67.5</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c746"
      decimals="2"
      id="ixv-90883"
      unitRef="usdPershares">187.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c746"
      decimals="INF"
      id="ixv-90884"
      unitRef="shares">8264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c747" id="ixv-75772">P2Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c746"
      decimals="2"
      id="ixv-90885"
      unitRef="usdPershares">187.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c746"
      decimals="INF"
      id="ixv-90886"
      unitRef="shares">8264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c746"
      decimals="2"
      id="ixv-90887"
      unitRef="usdPershares">187.5</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c748"
      decimals="2"
      id="ixv-90888"
      unitRef="usdPershares">7.5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c748"
      decimals="2"
      id="ixv-90889"
      unitRef="usdPershares">187.5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c749"
      decimals="INF"
      id="ixv-90890"
      unitRef="shares">171163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c748" id="ixv-75818">P4Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c749"
      decimals="2"
      id="ixv-90891"
      unitRef="usdPershares">18.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c749"
      decimals="INF"
      id="ixv-90892"
      unitRef="shares">91163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c749"
      decimals="2"
      id="ixv-90893"
      unitRef="usdPershares">28.7</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c488"
      decimals="INF"
      id="ixv-90894"
      unitRef="shares">182996</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c488"
      decimals="2"
      id="ixv-90895"
      unitRef="usdPershares">21.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c736"
      decimals="INF"
      id="ixv-90896"
      unitRef="shares">11833</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice
      contextRef="c736"
      decimals="2"
      id="ixv-90897"
      unitRef="usdPershares">58.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c737"
      decimals="INF"
      id="ixv-90898"
      unitRef="shares">171163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c737"
      decimals="2"
      id="ixv-90899"
      unitRef="usdPershares">18.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c737"
      decimals="INF"
      id="ixv-90900"
      unitRef="shares">91163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c737"
      decimals="2"
      id="ixv-90901"
      unitRef="usdPershares">28.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c737"
      decimals="INF"
      id="ixv-90902"
      unitRef="shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c737"
      decimals="2"
      id="ixv-90903"
      unitRef="usdPershares">7.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c723" decimals="0" id="ixv-90904" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c85"
      decimals="0"
      id="ixv-90905"
      unitRef="shares">186877</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c1"
      decimals="INF"
      id="ixv-90906"
      unitRef="shares">80000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c1"
      decimals="2"
      id="ixv-90907"
      unitRef="usdPershares">7.5</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c11"
      decimals="INF"
      id="ixv-90908"
      unitRef="shares">80000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c11"
      decimals="2"
      id="ixv-90909"
      unitRef="usdPershares">7.5</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c724"
      decimals="0"
      id="ixv-90910"
      unitRef="shares">150000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c724"
      decimals="2"
      id="ixv-90911"
      unitRef="usdPershares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <avco:StatutoryReserveAndRestrictedNetAssetsTextBlock contextRef="c0" id="ixv-76113">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;NOTE 11 - &lt;span style="text-decoration:underline"&gt;STATUTORY RESERVE AND RESTRICTED
NET ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company&#x2019;s PRC subsidiary, Avalon Shanghai,
is restricted in its ability to transfer a portion of its net asset to the Company. The payment of dividends by entities organized in
China is subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment of dividends only out of
accumulated profits as determined in accordance with accounting standards and regulations in China.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company is required to make appropriations
to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus reserve, based on after-tax net income
determined in accordance with generally accepted accounting principles of the PRC (&#x201c;PRC GAAP&#x201d;). Appropriations to the statutory
surplus reserve are required to be at least 10% of the after-tax net income determined in accordance with PRC GAAP until the reserve
is equal to 50% of the entity&#x2019;s registered capital. Appropriations to the discretionary surplus reserve are made at the discretion
of the Board of Directors. The statutory reserve may be applied against prior year losses, if any, and may be used for general business
expansion and production or increase in registered capital, but are not distributable as cash dividends. The Company did not make any
appropriation to statutory reserve for Avalon Shanghai during the three months ended March 31, 2025 as it incurred net loss in the period.
As of both March 31, 2025 and December 31, 2024, the restricted amount as determined pursuant to PRC statutory laws totaled $6,578.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Relevant PRC laws and regulations restrict the
Company&#x2019;s PRC subsidiary, Avalon Shanghai, from transferring a portion of its net assets, equivalent to its statutory reserve and
its share capital, to the Company&#x2019;s shareholders in the form of loans, advances or cash dividends. Only PRC entity&#x2019;s accumulated
profit may be distributed as dividend to the Company&#x2019;s shareholders without the consent of a third party. As of both March 31,
2025 and December 31, 2024, total restricted net assets amounted to $1,206,578.&lt;/span&gt;&lt;/p&gt;</avco:StatutoryReserveAndRestrictedNetAssetsTextBlock>
    <avco:StatutoryReservePercent contextRef="c0" decimals="2" id="ixv-90912" unitRef="pure">0.10</avco:StatutoryReservePercent>
    <avco:RegisteredCapitalPercentage contextRef="c0" decimals="2" id="ixv-90913" unitRef="pure">0.50</avco:RegisteredCapitalPercentage>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance contextRef="c11" decimals="0" id="ixv-90914" unitRef="usd">6578</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance contextRef="c1" decimals="0" id="ixv-90915" unitRef="usd">6578</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance>
    <us-gaap:OtherRestrictedAssets contextRef="c11" decimals="0" id="ixv-90916" unitRef="usd">1206578</us-gaap:OtherRestrictedAssets>
    <us-gaap:OtherRestrictedAssets contextRef="c1" decimals="0" id="ixv-90917" unitRef="usd">1206578</us-gaap:OtherRestrictedAssets>
    <us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock contextRef="c0" id="ixv-76133">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;NOTE 12 - &lt;span style="text-decoration:underline"&gt;CONDENSED FINANCIAL INFORMATION
OF THE PARENT COMPANY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Pursuant to the requirements of Rule 12-04(a),
5-04(c) and 4-08(e)(3) of Regulation S-X, the condensed financial information of the parent company shall be filed when the restricted
net assets of consolidated subsidiary exceed 25% of consolidated net assets as of the end of the most recently completed fiscal year.
For purposes of this test, restricted net assets of consolidated subsidiary shall mean that amount of the Company&#x2019;s proportionate
share of net assets of consolidated subsidiary (after intercompany eliminations) which as of the end of the most recent fiscal year may
not be transferred to the parent company by subsidiary in the form of loans, advances or cash dividends without the consent of a third
party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company performed a test on the restricted
net assets of consolidated subsidiary in accordance with such requirement and concluded that it was not applicable to the Company as
the restricted net assets of the Company&#x2019;s PRC subsidiary did not exceed 25% of the consolidated net assets of the Company, therefore,
the condensed financial statements for the parent company have not been required.&lt;/span&gt;&lt;/p&gt;</us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock>
    <avco:RestrictedNetAssetsOfSubsidiaryExceedNetAssets contextRef="c11" decimals="2" id="ixv-90918" unitRef="pure">0.25</avco:RestrictedNetAssetsOfSubsidiaryExceedNetAssets>
    <avco:RestrictedNetAssetsPRCSubsidiaryDidNotExceed
      contextRef="c750"
      decimals="2"
      id="ixv-90919"
      unitRef="pure">0.25</avco:RestrictedNetAssetsPRCSubsidiaryDidNotExceed>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c0" id="ixv-76169">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;NOTE 13 - &lt;span style="text-decoration:underline"&gt;CONCENTRATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Customers&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table sets forth information as
to each customer that accounted for 10% or more of the Company&#x2019;s revenue for the three months ended March 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Customer&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;A&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;B&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;C&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;One customer, which is a third party, whose outstanding
receivable accounted for 10% or more of the Company&#x2019;s total outstanding rent receivable at March 31, 2025, accounted for 79.8%
of the Company&#x2019;s total outstanding rent receivable at March 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;One customer, which is a third party, whose outstanding
receivable accounted for 10% or more of the Company&#x2019;s total outstanding rent receivable at December 31, 2024, accounted for 76.9%
of the Company&#x2019;s total outstanding rent receivable at December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Suppliers&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;No supplier accounted for 10% or more of the Company&#x2019;s
purchase during the three months ended March 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c0" id="ixv-76179">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table sets forth information as
to each customer that accounted for 10% or more of the Company&#x2019;s revenue for the three months ended March 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Customer&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;A&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;28&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;B&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;C&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c752"
      decimals="2"
      id="ixv-90920"
      unitRef="pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c753"
      decimals="2"
      id="ixv-90921"
      unitRef="pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c754"
      decimals="2"
      id="ixv-90922"
      unitRef="pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c755"
      decimals="2"
      id="ixv-90923"
      unitRef="pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c756"
      decimals="2"
      id="ixv-90924"
      unitRef="pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c757"
      decimals="2"
      id="ixv-90925"
      unitRef="pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c751"
      decimals="3"
      id="ixv-90926"
      unitRef="pure">0.798</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c512"
      decimals="3"
      id="ixv-90927"
      unitRef="pure">0.769</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0" id="ixv-76286">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;NOTE 14 - &lt;span style="text-decoration:underline"&gt;SEGMENT INFORMATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The segment reporting structure uses the Company&#x2019;s
management reporting structure as its foundation to reflect how the Company manages the businesses internally. During the three months
ended March 31, 2025 and 2024, the management reporting structure was composed of two strategic business units, mainly organized by services,
led by the Company&#x2019;s President and Chief Executive Officer, who is its Chief Operating Decision Maker. Using the accounting guidance
on segment reporting, the Company determined that its two operating segments were aligned with its two reportable segments corresponding
to its strategic business units.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On February 9, 2023, the Company purchased 40%
of Lab Services MSO. During the first quarter of 2025, to preserve cash, the Company entered into discussions with Lab Services MSO for
the potential redemption of our investment and on February 26, 2025, the Company and Lab Services MSO entered into a Redemption and Abandonment
Agreement, whereby Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by the Company. During the three months
ended March 31, 2025 and 2024, the Company operated in two reportable business segments: (1) the real property operating segment, and
(2) laboratory testing services segment (which ended on February 26, 2025) since Lab Services MSO&#x2019;s operating results were regularly
reviewed by the Company&#x2019;s chief operating decision maker to make decisions about resources to be allocated to the segment and assess
its performance. The Company regularly reviewed the operating results and performance of Lab Services MSO, which was the Company&#x2019;s
equity method investee.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The accounting policies for the segments are the
same as those described in Note 3. Our reportable segments are aligned principally around the differences in services. Real property
operating income is calculated by subtracting real property operating expenses from real property rental revenue; income from equity
method investment - Lab Services MSO is calculated by subtracting amortization of intangible assets acquired from acquisition and distribution
of earnings from equity investment from the Company&#x2019;s share of Lab Services MSO&#x2019;s net income. The assets and certain expenses
related to corporate activities are not allocated to the segments. Information with respect to these reportable business segments for
the three months ended March 31, 2025 and 2024 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Real Property Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Lab Services&lt;br/&gt;
 MSO&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Corporate /&lt;br/&gt;
 Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Real property rental revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;349,800&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-388"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-389"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;349,800&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Real property operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(280,390&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-390"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-391"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(280,390&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Real property operating income&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;69,410&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-392"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-393"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;69,410&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Income from equity method investment - Lab Services MSO&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-394"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;392,677&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-395"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;392,677&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(90,762&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-396"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,178,100&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,268,862&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other (expense) income:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(194,307&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-397"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(365,711&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(560,018&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;228&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-398"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(115,546&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(115,318&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(215,431&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;392,677&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,659,357&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,482,111&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Real Property Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Lab Services&lt;br/&gt;
 MSO&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Corporate /&lt;br/&gt;
 Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Real property rental revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;314,588&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-399"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-400"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;314,588&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Real property operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(263,126&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-401"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-402"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(263,126&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Real property operating income&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;51,462&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-403"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-404"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;51,462&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Income from equity method investment - Lab Services MSO&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-405"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;107,469&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-406"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;107,469&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(114,287&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-407"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(887,706&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,001,993&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other (expense) income:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(194,307&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-408"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(324,700&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(519,007&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-409"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(5,448&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(5,444&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(257,128&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;107,469&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,217,854&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,367,513&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Identifiable long-lived tangible assets at March 31, 2025 and December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March 31, &lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December 31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Real property operations&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,990,058&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,034,335&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Corporate/Other&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,153&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,298&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 9.25pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,991,211&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,035,633&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Identifiable long-lived tangible assets at March 31, 2025 and December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March 31, &lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December 31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,990,058&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,034,335&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,153&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,298&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 9.25pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,991,211&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,035,633&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c0"
      decimals="0"
      id="ixv-90928"
      unitRef="segments">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c0"
      decimals="0"
      id="ixv-90929"
      unitRef="segments">2</us-gaap:NumberOfReportableSegments>
    <avco:PurchasedServicesPercentage
      contextRef="c146"
      decimals="2"
      id="ixv-90930"
      unitRef="pure">0.40</avco:PurchasedServicesPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c758"
      decimals="2"
      id="ixv-90931"
      unitRef="pure">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:NumberOfReportableSegments
      contextRef="c0"
      decimals="0"
      id="ixv-90932"
      unitRef="segments">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c100"
      decimals="0"
      id="ixv-90933"
      unitRef="segments">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c0" id="ixv-90934">Information with respect to these reportable business segments for
the three months ended March 31, 2025 and 2024 was as follows:&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Real Property Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Lab Services&lt;br/&gt;
 MSO&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Corporate /&lt;br/&gt;
 Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Real property rental revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;349,800&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-388"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-389"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;349,800&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Real property operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(280,390&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-390"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-391"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(280,390&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Real property operating income&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;69,410&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-392"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-393"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;69,410&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Income from equity method investment - Lab Services MSO&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-394"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;392,677&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-395"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;392,677&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(90,762&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-396"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,178,100&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,268,862&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other (expense) income:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(194,307&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-397"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(365,711&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(560,018&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;228&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-398"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(115,546&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(115,318&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(215,431&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;392,677&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,659,357&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(2,482,111&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Real Property Operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Lab Services&lt;br/&gt;
 MSO&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Corporate /&lt;br/&gt;
 Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Real property rental revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;314,588&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-399"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-400"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;314,588&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Real property operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(263,126&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-401"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-402"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(263,126&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Real property operating income&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;51,462&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-403"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-404"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;51,462&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Income from equity method investment - Lab Services MSO&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-405"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;107,469&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-406"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;107,469&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(114,287&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-407"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(887,706&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,001,993&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other (expense) income:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(194,307&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-408"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(324,700&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(519,007&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-409"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(5,448&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(5,444&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(257,128&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;107,469&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,217,854&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(1,367,513&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues contextRef="c759" decimals="0" id="ixv-90935" unitRef="usd">349800</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="0" id="ixv-90936" unitRef="usd">349800</us-gaap:Revenues>
    <us-gaap:OperatingExpenses contextRef="c759" decimals="0" id="ixv-90937" unitRef="usd">280390</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" id="ixv-90938" unitRef="usd">280390</us-gaap:OperatingExpenses>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c759" decimals="0" id="ixv-90939" unitRef="usd">69410</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c0" decimals="0" id="ixv-90940" unitRef="usd">69410</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c760" decimals="0" id="ixv-90941" unitRef="usd">392677</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c0" decimals="0" id="ixv-90942" unitRef="usd">392677</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:OperatingCostsAndExpenses contextRef="c759" decimals="0" id="ixv-90943" unitRef="usd">90762</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c761" decimals="0" id="ixv-90944" unitRef="usd">2178100</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c0" decimals="0" id="ixv-90945" unitRef="usd">2268862</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:InterestExpenseNonoperating contextRef="c759" decimals="0" id="ixv-90946" unitRef="usd">194307</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c761" decimals="0" id="ixv-90947" unitRef="usd">365711</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c0" decimals="0" id="ixv-90948" unitRef="usd">560018</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherIncome contextRef="c759" decimals="0" id="ixv-90949" unitRef="usd">228</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c761" decimals="0" id="ixv-90950" unitRef="usd">-115546</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c0" decimals="0" id="ixv-90951" unitRef="usd">-115318</us-gaap:OtherIncome>
    <us-gaap:ProfitLoss contextRef="c759" decimals="0" id="ixv-90952" unitRef="usd">-215431</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c760" decimals="0" id="ixv-90953" unitRef="usd">392677</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c761" decimals="0" id="ixv-90954" unitRef="usd">-2659357</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" id="ixv-90955" unitRef="usd">-2482111</us-gaap:ProfitLoss>
    <us-gaap:Revenues contextRef="c762" decimals="0" id="ixv-90956" unitRef="usd">314588</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c100" decimals="0" id="ixv-90957" unitRef="usd">314588</us-gaap:Revenues>
    <us-gaap:OperatingExpenses contextRef="c762" decimals="0" id="ixv-90958" unitRef="usd">263126</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c100" decimals="0" id="ixv-90959" unitRef="usd">263126</us-gaap:OperatingExpenses>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c762" decimals="0" id="ixv-90960" unitRef="usd">51462</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c100" decimals="0" id="ixv-90961" unitRef="usd">51462</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c763" decimals="0" id="ixv-90962" unitRef="usd">107469</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c100" decimals="0" id="ixv-90963" unitRef="usd">107469</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:OperatingCostsAndExpenses contextRef="c762" decimals="0" id="ixv-90964" unitRef="usd">114287</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c764" decimals="0" id="ixv-90965" unitRef="usd">887706</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c100" decimals="0" id="ixv-90966" unitRef="usd">1001993</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:InterestExpenseNonoperating contextRef="c762" decimals="0" id="ixv-90967" unitRef="usd">194307</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c764" decimals="0" id="ixv-90968" unitRef="usd">324700</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c100" decimals="0" id="ixv-90969" unitRef="usd">519007</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherIncome contextRef="c762" decimals="0" id="ixv-90970" unitRef="usd">4</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c764" decimals="0" id="ixv-90971" unitRef="usd">-5448</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c100" decimals="0" id="ixv-90972" unitRef="usd">-5444</us-gaap:OtherIncome>
    <us-gaap:ProfitLoss contextRef="c762" decimals="0" id="ixv-90973" unitRef="usd">-257128</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c763" decimals="0" id="ixv-90974" unitRef="usd">107469</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c764" decimals="0" id="ixv-90975" unitRef="usd">-1217854</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c100" decimals="0" id="ixv-90976" unitRef="usd">-1367513</us-gaap:ProfitLoss>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock contextRef="c0" id="ixv-77075">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Identifiable long-lived tangible assets at March 31, 2025 and December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March 31, &lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December 31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Real property operations&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,990,058&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,034,335&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Corporate/Other&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,153&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,298&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 9.25pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,991,211&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,035,633&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:NoncurrentAssets contextRef="c765" decimals="0" id="ixv-90977" unitRef="usd">6990058</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c529" decimals="0" id="ixv-90978" unitRef="usd">7034335</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c766" decimals="0" id="ixv-90979" unitRef="usd">1153</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c531" decimals="0" id="ixv-90980" unitRef="usd">1298</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c11" decimals="0" id="ixv-90981" unitRef="usd">6991211</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c1" decimals="0" id="ixv-90982" unitRef="usd">7035633</us-gaap:NoncurrentAssets>
    <us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock contextRef="c0" id="ixv-77153">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Identifiable long-lived tangible assets at March 31, 2025 and December
    31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;March 31, &lt;br/&gt; 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December 31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,990,058&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,034,335&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,153&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,298&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 9.25pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6,991,211&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,035,633&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock>
    <us-gaap:NoncurrentAssets contextRef="c587" decimals="0" id="ixv-90983" unitRef="usd">6990058</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c152" decimals="0" id="ixv-90984" unitRef="usd">7034335</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c588" decimals="0" id="ixv-90985" unitRef="usd">1153</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c140" decimals="0" id="ixv-90986" unitRef="usd">1298</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c11" decimals="0" id="ixv-90987" unitRef="usd">6991211</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c1" decimals="0" id="ixv-90988" unitRef="usd">7035633</us-gaap:NoncurrentAssets>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-77252">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;NOTE 15 - &lt;span style="text-decoration:underline"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Litigation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;From time to time, the Company is subject to ordinary
routine litigation incidental to its normal business operations. The Company is not currently a party to, and its property is not subject
to, any material legal proceedings, except as set forth below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On October 25, 2017, Genexosome entered into and
closed a Stock Purchase Agreement with Beijing Genexosome and Yu Zhou, MD, PhD, the sole shareholder of Beijing Genexosome, pursuant
to which Genexosome acquired all of the issued and outstanding securities of Beijing Genexosome in consideration of a cash payment in
the amount of $450,000, of which $100,000 is still owed. Further, on October 25, 2017, Genexosome entered into and closed an Asset Purchase
Agreement with Dr. Zhou, pursuant to which the Company acquired all assets, including all intellectual property and exosome separation
systems, held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies. In consideration
of the assets, Genexosome paid Dr. Zhou $876,087 in cash, transferred 3,333 shares of common stock of the Company to Dr. Zhou and issued
Dr. Zhou 400 shares of common stock of Genexosome. Dr. Zhou was terminated as Co-CEO of Genexosome on August 14, 2019. Further, on October
28, 2019, Research Institute at Nationwide Children&#x2019;s Hospital (&#x201c;Research Institute&#x201d;) filed a Complaint in the United
States District Court for the Southern District of Ohio Eastern Division against Dr. Zhou, Li Chen, the Company and Genexosome with various
claims against the Company and Genexosome. The Company, Genexosome and the Research Institute entered into a Settlement Agreement dated
June 7, 2022 (the &#x201c;Settlement Date&#x201d;) whereby the Company agreed to pay the Research Institute $450,000 on each of the sixty-day,
one year and two-year anniversaries of the Settlement Date. In addition, the Company agreed to pay the Research Institute 30% of the
Company&#x2019;s initial pre-tax profit of $3,333,333, 20% of the Company&#x2019;s second pre-tax profit of $3,333,333 and 10% of the Company&#x2019;s
third pre-tax profit of $3,333,333. The parties provided a mutual release as well. As of both March 31, 2025 and December 31, 2024, the
accrued litigation settlement amounted to $373,450.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Operating Leases Commitment&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company is a party to leases for office space.
These lease agreements expire through December 2025. Rent expense under all operating leases amounted to approximately $32,000 for both
the three months ended March 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Supplemental cash flow information related to
leases for the three months ended March 31, 2025 and 2024 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: left; padding-left: 9.25pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating cash flows paid for operating lease&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;27,535&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;26,533&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Right-of-use assets obtained in exchange for lease obligation:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;127,486&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-410"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table summarizes the lease term
and discount rate for the Company&#x2019;s operating lease as of March 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating &lt;br/&gt; Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;13.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table summarizes the maturity of lease liabilities under
operating lease as of March 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the Twelve-month Period Ending March 31:&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating &lt;br/&gt; Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;78,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;54,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-411"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;132,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(12,747&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;119,253&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;67,547&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;51,706&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;119,253&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Joint Venture - Avactis Biosciences Inc.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On July 18, 2018, the Company formed a wholly
owned subsidiary, Avactis Biosciences Inc. (&#x201c;Avactis&#x201d;), a Nevada corporation, which focuses on accelerating commercial activities
related to cellular therapies as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others. When formed, Avactis was designed
to integrate and optimize the Company&#x2019;s global scientific and clinical resources to further advance the use of cellular therapies
to treat certain cancers; however the Company is no longer pursuing any commercial activities with respect to cellular immunotherapy
and CAR-T, in particular. Commencing on April 6, 2022, the Company owns 60% of Avactis and Arbele Biotherapeutics Limited (&#x201c;Arbele
Biotherapeutics&#x201d;) owns 40% of Avactis. Avactis owns 100% of the capital stock of Avactis Nanjing Biosciences Ltd., a company incorporated
in the PRC on May 8, 2020 (&#x201c;Avactis Nanjing&#x201d;), which only owns a patent and is not considered an operating entity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company is required to contribute $10 million
(or equivalent in RMB) in cash and/or services, which shall be contributed in tranches based on milestones to be determined jointly by
Avactis and the Company in writing subject to the Company&#x2019;s cash reserves. Within 30 days, Arbele Biotherapeutics shall make contribution
of $6.66 million in the form of entering into a License Agreement with Avactis granting Avactis an exclusive right and license in China
to its technology and intellectual property pertaining to CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy technology and any additional
technology developed in the future with terms and conditions to be mutually agreed upon the Company and Avactis and services. As of the
date hereof, the License Agreement has not been finalized by the parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In addition, the Company is responsible for contributing
registered capital of RMB 5,000,000 (approximately $0.7 million) for working capital purposes as required by local regulation, which
is not required to be contributed immediately and will be contributed subject to the Company&#x2019;s discretion. As of the date hereof,
Avactis&#x2019; activities have been limited to that of a patent holding company and there is no other activity or planned contributions
in the rest of 2025 or into the foreseeable future.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c767" decimals="0" id="ixv-90989" unitRef="usd">450000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:LoansPayable contextRef="c534" decimals="0" id="ixv-90990" unitRef="usd">100000</us-gaap:LoansPayable>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c768" decimals="0" id="ixv-90991" unitRef="usd">876087</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c536"
      decimals="0"
      id="ixv-90992"
      unitRef="shares">3333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c537"
      decimals="0"
      id="ixv-90993"
      unitRef="shares">400</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:LitigationReserve contextRef="c11" decimals="0" id="ixv-90994" unitRef="usd">450000</us-gaap:LitigationReserve>
    <avco:PercentageOfPretaxProfit contextRef="c0" decimals="2" id="ixv-90995" unitRef="pure">0.30</avco:PercentageOfPretaxProfit>
    <avco:PreTaxProfit contextRef="c0" decimals="0" id="ixv-90996" unitRef="usd">3333333</avco:PreTaxProfit>
    <avco:PercentageOfPretaxProfit
      contextRef="c769"
      decimals="2"
      id="ixv-90997"
      unitRef="pure">0.20</avco:PercentageOfPretaxProfit>
    <avco:PreTaxProfit contextRef="c0" decimals="0" id="ixv-90998" unitRef="usd">3333333</avco:PreTaxProfit>
    <avco:PercentageOfPretaxProfit
      contextRef="c770"
      decimals="2"
      id="ixv-90999"
      unitRef="pure">0.10</avco:PercentageOfPretaxProfit>
    <avco:PreTaxProfit contextRef="c770" decimals="0" id="ixv-91000" unitRef="usd">3333333</avco:PreTaxProfit>
    <us-gaap:LitigationReserve contextRef="c771" decimals="0" id="ixv-91001" unitRef="usd">373450</us-gaap:LitigationReserve>
    <us-gaap:LitigationReserve contextRef="c772" decimals="0" id="ixv-91002" unitRef="usd">373450</us-gaap:LitigationReserve>
    <us-gaap:PaymentsForRent contextRef="c0" decimals="0" id="ixv-91003" unitRef="usd">32000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="c100" decimals="0" id="ixv-91004" unitRef="usd">32000</us-gaap:PaymentsForRent>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0" id="ixv-77278">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Supplemental cash flow information related to
leases for the three months ended March 31, 2025 and 2024 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-size: 10pt; text-align: left; padding-left: 9.25pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating cash flows paid for operating lease&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;27,535&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;26,533&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Right-of-use assets obtained in exchange for lease obligation:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;127,486&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-410"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table summarizes the lease term
and discount rate for the Company&#x2019;s operating lease as of March 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating &lt;br/&gt; Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;13.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="0" id="ixv-91005" unitRef="usd">27535</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c100" decimals="0" id="ixv-91006" unitRef="usd">26533</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="0" id="ixv-91007" unitRef="usd">127486</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c1" id="ixv-77406">P1Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c1" decimals="3" id="ixv-91008" unitRef="pure">0.13</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-77458">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table summarizes the maturity of lease liabilities under
operating lease as of March 31, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the Twelve-month Period Ending March 31:&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Operating &lt;br/&gt; Lease&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;78,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;54,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-411"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;132,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(12,747&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;119,253&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;67,547&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;51,706&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;119,253&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c11" decimals="0" id="ixv-91009" unitRef="usd">78000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c11" decimals="0" id="ixv-91010" unitRef="usd">54000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c11" decimals="0" id="ixv-91011" unitRef="usd">132000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c11" decimals="0" id="ixv-91012" unitRef="usd">12747</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c11" decimals="0" id="ixv-91013" unitRef="usd">119253</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c11" decimals="0" id="ixv-91014" unitRef="usd">67547</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c11" decimals="0" id="ixv-91015" unitRef="usd">51706</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c11" decimals="0" id="ixv-91016" unitRef="usd">119253</us-gaap:OperatingLeaseLiability>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c541"
      decimals="2"
      id="ixv-91017"
      unitRef="pure">0.60</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c542"
      decimals="2"
      id="ixv-91018"
      unitRef="pure">0.40</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c543"
      decimals="2"
      id="ixv-91019"
      unitRef="pure">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:CashFlowsBetweenTransfereeAndTransferorServicingFees contextRef="c0" decimals="-6" id="ixv-91020" unitRef="usd">10000000</us-gaap:CashFlowsBetweenTransfereeAndTransferorServicingFees>
    <us-gaap:NoncashContributionExpense
      contextRef="c773"
      decimals="-4"
      id="ixv-91021"
      unitRef="usd">6660000</us-gaap:NoncashContributionExpense>
    <avco:WorkingCapital contextRef="c0" decimals="0" id="ixv-91022" unitRef="cny">5000000</avco:WorkingCapital>
    <avco:WorkingCapital contextRef="c0" decimals="-5" id="ixv-91023" unitRef="usd">700000</avco:WorkingCapital>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-77605">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;NOTE 16 - &lt;span style="text-decoration:underline"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company evaluated subsequent events and transactions
that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than
as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Common Shares Issued for Warrant Exercise&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In April 2025, the Company issued 242,304 shares
of its common stock upon the exercise of warrants on a cashless basis.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c774"
      decimals="0"
      id="ixv-91024"
      unitRef="shares">242304</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <dei:DocumentType contextRef="c0" id="hidden-fact-0">S-4/A</dei:DocumentType>
    <avco:EquityMethodInvestmentPayableCurrent
      contextRef="c1"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableToBankCurrent
      contextRef="c2"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c1"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermNotesPayable
      contextRef="c1"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermLoansPayable
      contextRef="c3"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="c1"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c1"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c1"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="c6"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="c8"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c10"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="c10"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MinorityInterest
      contextRef="c1"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MinorityInterest
      contextRef="c2"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ReceivablesNetCurrent
      contextRef="c1"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermInvestmentsAndReceivablesNet
      contextRef="c1"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c11"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c1"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="c1"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c11"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c1"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c11"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c1"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c13"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c14"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c17"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MinorityInterest
      contextRef="c11"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MinorityInterest
      contextRef="c1"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:DebtModificationCharge
      contextRef="c19"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetImpairmentCharges
      contextRef="c18"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c18"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c18"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c19"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c18"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c19"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="c18"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="c19"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c21"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c20"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c21"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:DeemedContributionOnExchangeOfEquityInstruments
      contextRef="c21"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="c20"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="c21"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c23"
      id="hidden-fact-47"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c23"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c24"
      id="hidden-fact-49"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c24"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c31"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments
      contextRef="c33"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments
      contextRef="c34"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments
      contextRef="c35"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments
      contextRef="c36"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments
      contextRef="c37"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments
      contextRef="c38"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments
      contextRef="c39"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments
      contextRef="c40"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments
      contextRef="c41"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments
      contextRef="c19"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c33"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c35"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c36"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c37"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c38"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c39"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c40"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c41"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c33"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c34"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c35"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c38"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c39"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c40"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c41"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet
      contextRef="c33"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet
      contextRef="c34"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet
      contextRef="c35"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet
      contextRef="c38"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet
      contextRef="c39"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet
      contextRef="c40"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet
      contextRef="c41"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c33"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c34"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c35"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c38"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c39"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c40"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c41"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c33"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c34"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c35"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c36"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c38"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c39"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c40"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c41"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c33"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c34"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c35"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c36"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c37"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c38"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c39"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c41"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c33"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c34"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c35"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c36"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c37"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c39"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c40"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c41"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c44"
      id="hidden-fact-115"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c44"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c51"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c52"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c53"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c54"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c57"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c58"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c59"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c60"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet
      contextRef="c52"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet
      contextRef="c53"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet
      contextRef="c54"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet
      contextRef="c57"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet
      contextRef="c58"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet
      contextRef="c59"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSaleOfCommonStockNet
      contextRef="c60"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c52"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c53"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c54"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c57"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c58"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c59"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c60"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c18"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c52"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c53"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c54"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c57"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c58"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c59"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c60"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="c52"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="c53"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="c54"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="c55"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="c57"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="c58"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="c59"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="c60"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c52"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c53"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c55"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c56"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c57"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c58"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c59"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c60"
      id="hidden-fact-162"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c52"
      id="hidden-fact-163"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c53"
      id="hidden-fact-164"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c54"
      id="hidden-fact-165"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c55"
      id="hidden-fact-166"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c57"
      id="hidden-fact-167"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c58"
      id="hidden-fact-168"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c59"
      id="hidden-fact-169"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c60"
      id="hidden-fact-170"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c52"
      id="hidden-fact-171"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c53"
      id="hidden-fact-172"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c54"
      id="hidden-fact-173"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c55"
      id="hidden-fact-174"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c57"
      id="hidden-fact-175"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c58"
      id="hidden-fact-176"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c59"
      id="hidden-fact-177"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c60"
      id="hidden-fact-178"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments
      contextRef="c52"
      id="hidden-fact-179"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments
      contextRef="c53"
      id="hidden-fact-180"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments
      contextRef="c54"
      id="hidden-fact-181"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments
      contextRef="c57"
      id="hidden-fact-182"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments
      contextRef="c58"
      id="hidden-fact-183"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments
      contextRef="c59"
      id="hidden-fact-184"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments
      contextRef="c60"
      id="hidden-fact-185"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSharesIssuedForAdjustments
      contextRef="c18"
      id="hidden-fact-186"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c52"
      id="hidden-fact-187"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c53"
      id="hidden-fact-188"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c54"
      id="hidden-fact-189"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c55"
      id="hidden-fact-190"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c56"
      id="hidden-fact-191"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c57"
      id="hidden-fact-192"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c58"
      id="hidden-fact-193"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c60"
      id="hidden-fact-194"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c52"
      id="hidden-fact-195"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c53"
      id="hidden-fact-196"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c54"
      id="hidden-fact-197"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c55"
      id="hidden-fact-198"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c56"
      id="hidden-fact-199"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c58"
      id="hidden-fact-200"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c59"
      id="hidden-fact-201"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c60"
      id="hidden-fact-202"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c70"
      id="hidden-fact-203"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c71"
      id="hidden-fact-204"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c72"
      id="hidden-fact-205"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c73"
      id="hidden-fact-206"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c71"
      id="hidden-fact-207"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c72"
      id="hidden-fact-208"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c73"
      id="hidden-fact-209"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="c71"
      id="hidden-fact-210"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="c72"
      id="hidden-fact-211"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="c73"
      id="hidden-fact-212"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock
      contextRef="c72"
      id="hidden-fact-213"
      unitRef="shares"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock
      contextRef="c72"
      id="hidden-fact-214"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock
      contextRef="c73"
      id="hidden-fact-215"
      unitRef="shares"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock
      contextRef="c73"
      id="hidden-fact-216"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock
      contextRef="c74"
      id="hidden-fact-217"
      unitRef="shares"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock
      contextRef="c74"
      id="hidden-fact-218"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock
      contextRef="c78"
      id="hidden-fact-219"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock
      contextRef="c79"
      id="hidden-fact-220"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock
      contextRef="c0"
      id="hidden-fact-221"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock
      contextRef="c76"
      id="hidden-fact-222"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock
      contextRef="c80"
      id="hidden-fact-223"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c71"
      id="hidden-fact-224"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c72"
      id="hidden-fact-225"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c73"
      id="hidden-fact-226"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c77"
      id="hidden-fact-227"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c74"
      id="hidden-fact-228"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c78"
      id="hidden-fact-229"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c79"
      id="hidden-fact-230"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c76"
      id="hidden-fact-231"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c80"
      id="hidden-fact-232"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c71"
      id="hidden-fact-233"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c72"
      id="hidden-fact-234"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c73"
      id="hidden-fact-235"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c77"
      id="hidden-fact-236"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c74"
      id="hidden-fact-237"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c75"
      id="hidden-fact-238"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c78"
      id="hidden-fact-239"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c79"
      id="hidden-fact-240"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c76"
      id="hidden-fact-241"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c71"
      id="hidden-fact-242"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c72"
      id="hidden-fact-243"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c73"
      id="hidden-fact-244"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c77"
      id="hidden-fact-245"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c74"
      id="hidden-fact-246"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c75"
      id="hidden-fact-247"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c79"
      id="hidden-fact-248"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c76"
      id="hidden-fact-249"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c81"
      id="hidden-fact-250"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c81"
      id="hidden-fact-251"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c82"
      id="hidden-fact-252"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c82"
      id="hidden-fact-253"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c90"
      id="hidden-fact-254"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c51"
      id="hidden-fact-255"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c92"
      id="hidden-fact-256"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c93"
      id="hidden-fact-257"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c96"
      id="hidden-fact-258"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c97"
      id="hidden-fact-259"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c98"
      id="hidden-fact-260"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c99"
      id="hidden-fact-261"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c92"
      id="hidden-fact-262"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c93"
      id="hidden-fact-263"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c94"
      id="hidden-fact-264"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c96"
      id="hidden-fact-265"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c97"
      id="hidden-fact-266"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c98"
      id="hidden-fact-267"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c99"
      id="hidden-fact-268"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c92"
      id="hidden-fact-269"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c93"
      id="hidden-fact-270"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c94"
      id="hidden-fact-271"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c95"
      id="hidden-fact-272"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c96"
      id="hidden-fact-273"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c97"
      id="hidden-fact-274"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="c99"
      id="hidden-fact-275"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c92"
      id="hidden-fact-276"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c93"
      id="hidden-fact-277"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c94"
      id="hidden-fact-278"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c95"
      id="hidden-fact-279"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c97"
      id="hidden-fact-280"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c98"
      id="hidden-fact-281"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c99"
      id="hidden-fact-282"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c109"
      id="hidden-fact-283"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:DistributionOfEarningsFromEquityMethodInvestment
      contextRef="c19"
      id="hidden-fact-284"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetImpairmentCharges
      contextRef="c18"
      id="hidden-fact-285"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:ImpairmentOfLaboratoryEquipment
      contextRef="c19"
      id="hidden-fact-286"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="c19"
      id="hidden-fact-287"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c18"
      id="hidden-fact-288"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="c18"
      id="hidden-fact-289"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c18"
      id="hidden-fact-290"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="c19"
      id="hidden-fact-291"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="c18"
      id="hidden-fact-292"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="c19"
      id="hidden-fact-293"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c18"
      id="hidden-fact-294"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c18"
      id="hidden-fact-295"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="c19"
      id="hidden-fact-296"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment
      contextRef="c18"
      id="hidden-fact-297"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:WarrantsIssuedWithConvertibleNotePayable
      contextRef="c18"
      id="hidden-fact-298"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:AccruedPurchasePriceRelatedToEquityMethodInvestment
      contextRef="c18"
      id="hidden-fact-299"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:DeferredFinancingCostsInAccruedLiabilities
      contextRef="c18"
      id="hidden-fact-300"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="c19"
      id="hidden-fact-301"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SupplementalDeferredPurchasePrice
      contextRef="c19"
      id="hidden-fact-302"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:SettlementsOfDerivativeLiability
      contextRef="c19"
      id="hidden-fact-303"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty
      contextRef="c19"
      id="hidden-fact-304"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant
      contextRef="c19"
      id="hidden-fact-305"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="c19"
      id="hidden-fact-306"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:DistributionOfEarningsFromEquityMethodInvestment
      contextRef="c0"
      id="hidden-fact-307"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="c0"
      id="hidden-fact-308"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="c100"
      id="hidden-fact-309"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:AccruedLiabilitiesAndOtherPayablesRelatedParties
      contextRef="c0"
      id="hidden-fact-310"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="c100"
      id="hidden-fact-311"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c100"
      id="hidden-fact-312"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:ProceedsFromIssuanceOfConvertibleDebtAndWarrants
      contextRef="c0"
      id="hidden-fact-313"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:PaymentsOfConvertibleDebtIssuanceCosts
      contextRef="c0"
      id="hidden-fact-314"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="c0"
      id="hidden-fact-315"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="c100"
      id="hidden-fact-316"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:CommonStockIssuedForAccruedLiabilities
      contextRef="c100"
      id="hidden-fact-317"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:ReceivableRelatedToSaleOfEquityMethodInvestment
      contextRef="c100"
      id="hidden-fact-318"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment
      contextRef="c100"
      id="hidden-fact-319"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment
      contextRef="c100"
      id="hidden-fact-320"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock
      contextRef="c100"
      id="hidden-fact-321"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:WarrantsIssuedAsConvertibleNotePayableFindersFee
      contextRef="c0"
      id="hidden-fact-322"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount
      contextRef="c0"
      id="hidden-fact-323"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:CommonStockIssuedAsConvertibleNotePayableCommitmentFee
      contextRef="c0"
      id="hidden-fact-324"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="c0"
      id="hidden-fact-325"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:SettlementsOfDerivativeLiability
      contextRef="c100"
      id="hidden-fact-326"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant
      contextRef="c100"
      id="hidden-fact-327"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c100"
      id="hidden-fact-328"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c147"
      id="hidden-fact-329"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c162"
      id="hidden-fact-330"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:DeferredOfferingCosts
      contextRef="c1"
      id="hidden-fact-331"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SecurityDeposit
      contextRef="c2"
      id="hidden-fact-332"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryFinishedGoods
      contextRef="c2"
      id="hidden-fact-333"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c165"
      id="hidden-fact-334"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c191"
      id="hidden-fact-335"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="c2"
      id="hidden-fact-336"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermNotesPayable
      contextRef="c1"
      id="hidden-fact-337"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="c371"
      decimals="0"
      id="hidden-fact-338"
      unitRef="usd">480000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding
      contextRef="c2"
      id="hidden-fact-339"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c18"
      id="hidden-fact-340"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c19"
      id="hidden-fact-341"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c18"
      id="hidden-fact-342"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c19"
      id="hidden-fact-343"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="c18"
      id="hidden-fact-344"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="c19"
      id="hidden-fact-345"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c18"
      id="hidden-fact-346"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c19"
      id="hidden-fact-347"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c18"
      id="hidden-fact-348"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c19"
      id="hidden-fact-349"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="c1"
      id="hidden-fact-350"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxLiabilitiesRegulatoryAssets
      contextRef="c1"
      id="hidden-fact-351"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c1"
      id="hidden-fact-352"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c2"
      id="hidden-fact-353"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c494"
      id="hidden-fact-354"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c494"
      id="hidden-fact-355"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c524"
      id="hidden-fact-356"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c525"
      id="hidden-fact-357"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingExpenses
      contextRef="c524"
      id="hidden-fact-358"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingExpenses
      contextRef="c525"
      id="hidden-fact-359"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="c524"
      id="hidden-fact-360"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="c525"
      id="hidden-fact-361"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="c523"
      id="hidden-fact-362"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="c525"
      id="hidden-fact-363"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="c524"
      id="hidden-fact-364"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c524"
      id="hidden-fact-365"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="c524"
      id="hidden-fact-366"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c527"
      id="hidden-fact-367"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c528"
      id="hidden-fact-368"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingExpenses
      contextRef="c527"
      id="hidden-fact-369"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingExpenses
      contextRef="c528"
      id="hidden-fact-370"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="c527"
      id="hidden-fact-371"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="c528"
      id="hidden-fact-372"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="c526"
      id="hidden-fact-373"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="c528"
      id="hidden-fact-374"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="c527"
      id="hidden-fact-375"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c527"
      id="hidden-fact-376"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="c527"
      id="hidden-fact-377"
      unitRef="usd"
      xsi:nil="true"/>
    <avco:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities
      contextRef="c18"
      id="hidden-fact-378"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="c1"
      id="hidden-fact-379"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c593"
      id="hidden-fact-380"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c595"
      id="hidden-fact-381"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c598"
      id="hidden-fact-382"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c600"
      id="hidden-fact-383"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseOtherNoncurrent
      contextRef="c1"
      id="hidden-fact-384"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c613"
      id="hidden-fact-385"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c0"
      id="hidden-fact-386"
      unitRef="shares"
      xsi:nil="true"/>
    <avco:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues
      contextRef="c0"
      id="hidden-fact-387"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c760"
      id="hidden-fact-388"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c761"
      id="hidden-fact-389"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingExpenses
      contextRef="c760"
      id="hidden-fact-390"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingExpenses
      contextRef="c761"
      id="hidden-fact-391"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="c760"
      id="hidden-fact-392"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="c761"
      id="hidden-fact-393"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="c759"
      id="hidden-fact-394"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="c761"
      id="hidden-fact-395"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="c760"
      id="hidden-fact-396"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c760"
      id="hidden-fact-397"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="c760"
      id="hidden-fact-398"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c763"
      id="hidden-fact-399"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c764"
      id="hidden-fact-400"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingExpenses
      contextRef="c763"
      id="hidden-fact-401"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingExpenses
      contextRef="c764"
      id="hidden-fact-402"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="c763"
      id="hidden-fact-403"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="c764"
      id="hidden-fact-404"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="c762"
      id="hidden-fact-405"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="c764"
      id="hidden-fact-406"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="c763"
      id="hidden-fact-407"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c763"
      id="hidden-fact-408"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="c763"
      id="hidden-fact-409"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c100"
      id="hidden-fact-410"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="c11"
      id="hidden-fact-411"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-91439">0001630212</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-91440">true</dei:AmendmentFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On February 26, 2025, the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement,
whereby Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by the Company.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Assumed the Series A convertible preferred stock was converted
into shares of common stock of the Company at a conversion price of $150.00 per share<xhtml:span style="background-color: white">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color: white">Assumed the Series
B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-330"
          xlink:label="hidden-fact-330"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color: white">Assumed the Series
C convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $2.41 per share.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-330"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color: white">Assumed the convertible
notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the year ended December
31, 2024. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and
$22.50 per share for the year ended December 31, 2023.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-380"
          xlink:label="hidden-fact-380"
          xlink:type="locator"/>
        <link:footnote id="ix_5_footnote" xlink:label="ix_5_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Assumed the Series A convertible preferred stock (&#x201c;Series A Preferred Stock&#x201d;) was converted into shares of common stock of the Company at a conversion price of $150.00 per share.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-380"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-381"
          xlink:label="hidden-fact-381"
          xlink:type="locator"/>
        <link:footnote id="ix_6_footnote" xlink:label="ix_6_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Assumed the Series B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-381"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-382"
          xlink:label="hidden-fact-382"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_7_footnote" xlink:label="ix_7_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Assumed the Series C convertible preferred stock (&#x201c;Series C Preferred Stock&#x201d;) was converted into shares of common stock of the Company at a conversion price of $2.41 per share.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-382"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_7_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-383"
          xlink:label="hidden-fact-383"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_8_footnote" xlink:label="ix_8_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Assumed the Series D convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $2.41 per share.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-383"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_8_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_9_footnote" xlink:label="ix_9_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-size: 10pt">Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the three months ended March 31, 2025. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and $22.50 and $15.00 per share for the three months ended March 31, 2024.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_9_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001630212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Amendment No. 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-4/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AVALON GLOBOCARE CORP.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 1,369,586<span></span>
</td>
<td class="nump">$ 2,856,309<span></span>
</td>
<td class="nump">$ 285,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Rent receivable</a></td>
<td class="nump">81,854<span></span>
</td>
<td class="nump">80,829<span></span>
</td>
<td class="nump">197,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivable from sale of equity method investment, current portion</a></td>
<td class="nump">975,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current assets</a></td>
<td class="nump">367,818<span></span>
</td>
<td class="nump">299,360<span></span>
</td>
<td class="nump">367,994<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">2,794,258<span></span>
</td>
<td class="nump">3,236,498<span></span>
</td>
<td class="nump">850,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">113,253<span></span>
</td>
<td class="nump">4,709<span></span>
</td>
<td class="nump">128,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAndReceivablesNet', window );">Receivable from sale of equity method investment, noncurrent portion</a></td>
<td class="nump">675,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,660<span></span>
</td>
<td class="nump">12,912<span></span>
</td>
<td class="nump">38,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstateInvestments', window );">Investment in real estate, net</a></td>
<td class="nump">6,980,551<span></span>
</td>
<td class="nump">7,022,721<span></span>
</td>
<td class="nump">7,191,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,636,544<span></span>
</td>
<td class="nump">12,095,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">36,067<span></span>
</td>
<td class="nump">71,794<span></span>
</td>
<td class="nump">278,912<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Non-current Assets</a></td>
<td class="nump">7,815,531<span></span>
</td>
<td class="nump">17,748,680<span></span>
</td>
<td class="nump">19,731,669<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">10,609,789<span></span>
</td>
<td class="nump">20,985,178<span></span>
</td>
<td class="nump">20,582,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">984,869<span></span>
</td>
<td class="nump">611,462<span></span>
</td>
<td class="nump">1,804,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_AccruedResearchAndDevelopmentsFees', window );">Accrued research and development fees</a></td>
<td class="nump">153,772<span></span>
</td>
<td class="nump">153,772<span></span>
</td>
<td class="nump">208,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Accrued payroll liability and compensation</a></td>
<td class="nump">550,931<span></span>
</td>
<td class="nump">501,258<span></span>
</td>
<td class="nump">588,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Accrued litigation settlement</a></td>
<td class="nump">373,450<span></span>
</td>
<td class="nump">373,450<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued liabilities and other payables</a></td>
<td class="nump">524,872<span></span>
</td>
<td class="nump">434,117<span></span>
</td>
<td class="nump">272,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligation, current portion</a></td>
<td class="nump">67,547<span></span>
</td>
<td class="nump">10,709<span></span>
</td>
<td class="nump">129,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPayableCurrent', window );">Equity method investment payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">666,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td>
<td class="nump">223,052<span></span>
</td>
<td class="nump">127,545<span></span>
</td>
<td class="nump">24,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableToBankCurrent', window );">Note payable, net</a></td>
<td class="nump">5,745,254<span></span>
</td>
<td class="nump">5,715,447<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible note payable, net</a></td>
<td class="nump">2,397,528<span></span>
</td>
<td class="nump">2,113,773<span></span>
</td>
<td class="nump">1,925,146<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">14,449,353<span></span>
</td>
<td class="nump">13,882,555<span></span>
</td>
<td class="nump">6,762,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligation, noncurrent portion</a></td>
<td class="nump">51,706<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable, net - noncurrent portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,596,219<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Non-current Liabilities</a></td>
<td class="nump">51,706<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,451,074<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">14,501,059<span></span>
</td>
<td class="nump">13,882,555<span></span>
</td>
<td class="nump">13,213,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 100,000,000 shares authorized; 1,445,979 shares issued and 1,442,512 shares outstanding at December 31, 2024; 736,769 shares issued and 733,302 shares outstanding at December 31, 2023</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">74,673,916<span></span>
</td>
<td class="nump">72,023,525<span></span>
</td>
<td class="nump">67,886,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Less: common stock held in treasury, at cost; 3,467 shares at December 31, 2024 and 2023</a></td>
<td class="num">(522,500)<span></span>
</td>
<td class="num">(522,500)<span></span>
</td>
<td class="num">(522,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(90,155,236)<span></span>
</td>
<td class="num">(87,673,125)<span></span>
</td>
<td class="num">(79,769,731)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance', window );">Statutory reserve</a></td>
<td class="nump">6,578<span></span>
</td>
<td class="nump">6,578<span></span>
</td>
<td class="nump">6,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(231,721)<span></span>
</td>
<td class="num">(232,000)<span></span>
</td>
<td class="num">(231,727)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Avalon GloboCare Corp. stockholders&#8217; (deficit) equity</a></td>
<td class="num">(3,891,270)<span></span>
</td>
<td class="nump">7,102,623<span></span>
</td>
<td class="nump">7,368,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total (Deficit) Equity</a></td>
<td class="num">(3,891,270)<span></span>
</td>
<td class="nump">7,102,623<span></span>
</td>
<td class="nump">7,368,776<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Equity</a></td>
<td class="nump">10,609,789<span></span>
</td>
<td class="nump">20,985,178<span></span>
</td>
<td class="nump">20,582,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">8,837,527<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Accrued liabilities and other payables - related parties</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">732,916<span></span>
</td>
<td class="nump">206,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty', window );">Advance from pending sale of noncontrolling interest - related party</a></td>
<td class="nump">$ 3,328,078<span></span>
</td>
<td class="nump">3,108,106<span></span>
</td>
<td class="nump">485,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Loan payable - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 850,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_AccruedResearchAndDevelopmentsFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued research and development fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_AccruedResearchAndDevelopmentsFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance from pending sale of noncontrolling interest - related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityMethodInvestmentPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity method investment payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityMethodInvestmentPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestmentsAndReceivablesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle) and amount due to the Entity from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such investments and receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestmentsAndReceivablesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableToBankCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableToBankCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstateInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of real estate investments, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; (7) other real estate investments; (8) real estate joint ventures; and (9) unconsolidated real estate and other joint ventures not separately presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstateInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of statutory capital and surplus (stockholders' equity) as of the balance sheet date using prescribed or permitted statutory accounting practices (rather than GAAP, if different) of the state or country.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478420/944-505-55-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478420/944-505-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477908/944-505-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parentheticals) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">1,655,134<span></span>
</td>
<td class="nump">1,445,979<span></span>
</td>
<td class="nump">736,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">1,651,667<span></span>
</td>
<td class="nump">1,442,512<span></span>
</td>
<td class="nump">733,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock</a></td>
<td class="nump">3,467<span></span>
</td>
<td class="nump">3,467<span></span>
</td>
<td class="nump">3,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred Stock,Liquidation preference (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred Stock,Liquidation preference (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred Stock,Liquidation preference (in Dollars)</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred Stock,Liquidation preference (in Dollars)</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REAL PROPERTY RENTAL REVENUE</a></td>
<td class="nump">$ 349,800<span></span>
</td>
<td class="nump">$ 314,588<span></span>
</td>
<td class="nump">$ 1,333,403<span></span>
</td>
<td class="nump">$ 1,255,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">REAL PROPERTY OPERATING EXPENSES</a></td>
<td class="nump">280,390<span></span>
</td>
<td class="nump">263,126<span></span>
</td>
<td class="nump">1,065,574<span></span>
</td>
<td class="nump">1,017,493<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">REAL PROPERTY OPERATING INCOME</a></td>
<td class="nump">69,410<span></span>
</td>
<td class="nump">51,462<span></span>
</td>
<td class="nump">267,829<span></span>
</td>
<td class="nump">238,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">INCOME FROM EQUITY METHOD INVESTMENT - LAB SERVICES MSO</a></td>
<td class="nump">392,677<span></span>
</td>
<td class="nump">107,469<span></span>
</td>
<td class="num">(846,588)<span></span>
</td>
<td class="num">(8,571,647)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OTHER OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketingAndAdvertisingExpense', window );">Advertising and marketing expenses</a></td>
<td class="nump">71,150<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="nump">237,671<span></span>
</td>
<td class="nump">1,666,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">1,691,579<span></span>
</td>
<td class="nump">442,335<span></span>
</td>
<td class="nump">1,822,105<span></span>
</td>
<td class="nump">3,076,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Compensation and related benefits</a></td>
<td class="nump">340,420<span></span>
</td>
<td class="nump">353,571<span></span>
</td>
<td class="nump">1,431,328<span></span>
</td>
<td class="nump">1,768,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other general and administrative expenses</a></td>
<td class="nump">165,713<span></span>
</td>
<td class="nump">161,087<span></span>
</td>
<td class="nump">857,869<span></span>
</td>
<td class="nump">908,577<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total Other Operating Expenses</a></td>
<td class="nump">2,268,862<span></span>
</td>
<td class="nump">1,001,993<span></span>
</td>
<td class="nump">4,348,973<span></span>
</td>
<td class="nump">7,420,224<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(1,806,775)<span></span>
</td>
<td class="num">(843,062)<span></span>
</td>
<td class="num">(4,927,732)<span></span>
</td>
<td class="num">(15,753,683)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER (EXPENSE) INCOME</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Interest expense - amortization of debt discount and debt issuance costs</a></td>
<td class="num">(313,562)<span></span>
</td>
<td class="num">(272,196)<span></span>
</td>
<td class="num">(1,411,042)<span></span>
</td>
<td class="num">(544,010)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense - other</a></td>
<td class="num">(246,456)<span></span>
</td>
<td class="num">(236,215)<span></span>
</td>
<td class="num">(983,486)<span></span>
</td>
<td class="num">(773,780)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,596)<span></span>
</td>
<td class="num">(42,445)<span></span>
</td>
<td class="num">(33,712)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_DebtModificationCharge', window );">Debt modification charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(838,794)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative liability</a></td>
<td class="num">(114,360)<span></span>
</td>
<td class="nump">31,212<span></span>
</td>
<td class="nump">374,365<span></span>
</td>
<td class="nump">188,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of equity method investment - Epicon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(454,679)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debts extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">682,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="num">(958)<span></span>
</td>
<td class="num">(36,656)<span></span>
</td>
<td class="num">(74,260)<span></span>
</td>
<td class="num">(18,499)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Expense, net</a></td>
<td class="num">(675,336)<span></span>
</td>
<td class="num">(524,451)<span></span>
</td>
<td class="num">(2,975,662)<span></span>
</td>
<td class="num">(953,327)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(2,482,111)<span></span>
</td>
<td class="num">(1,367,513)<span></span>
</td>
<td class="num">(7,903,394)<span></span>
</td>
<td class="num">(16,707,010)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">INCOME TAXES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET LOSS</a></td>
<td class="num">(2,482,111)<span></span>
</td>
<td class="num">(1,367,513)<span></span>
</td>
<td class="num">(7,903,394)<span></span>
</td>
<td class="num">(16,707,010)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS AFTER NONCONTROLLING INTEREST</a></td>
<td class="num">(2,482,111)<span></span>
</td>
<td class="num">(1,367,513)<span></span>
</td>
<td class="num">$ (7,903,394)<span></span>
</td>
<td class="num">$ (16,707,010)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_DeemedContributionOnExchangeOfEquityInstruments', window );">DEEMED CONTRIBUTION ON EXCHANGE OF EQUITY INSTRUMENTS</a></td>
<td class="nump">162,473<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS</a></td>
<td class="num">$ (2,319,638)<span></span>
</td>
<td class="num">$ (1,367,513)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss Per Common Share Attributable Common Shareholders Basic (in Dollars per share)</a></td>
<td class="num">$ (1.43)<span></span>
</td>
<td class="num">$ (1.86)<span></span>
</td>
<td class="num">$ (8.44)<span></span>
</td>
<td class="num">$ (23.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss Per Common Share Attributable Common Shareholders Diluted (in Dollars per share)</a></td>
<td class="num">$ (1.43)<span></span>
</td>
<td class="num">$ (1.86)<span></span>
</td>
<td class="num">$ (8.44)<span></span>
</td>
<td class="num">$ (23.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Common Shares Outstanding Basic (in Shares)</a></td>
<td class="nump">1,624,629<span></span>
</td>
<td class="nump">735,225<span></span>
</td>
<td class="nump">936,614<span></span>
</td>
<td class="nump">701,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Common Shares Outstanding Diluted (in Shares)</a></td>
<td class="nump">1,624,629<span></span>
</td>
<td class="nump">735,225<span></span>
</td>
<td class="nump">936,614<span></span>
</td>
<td class="nump">701,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>COMPREHENSIVE LOSS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET LOSS</a></td>
<td class="num">$ (2,482,111)<span></span>
</td>
<td class="num">$ (1,367,513)<span></span>
</td>
<td class="num">$ (7,903,394)<span></span>
</td>
<td class="num">$ (16,707,010)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>OTHER COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax', window );">Unrealized foreign currency translation gain (loss)</a></td>
<td class="nump">279<span></span>
</td>
<td class="num">(2,920)<span></span>
</td>
<td class="num">(273)<span></span>
</td>
<td class="num">(18,590)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">COMPREHENSIVE LOSS</a></td>
<td class="num">(2,481,832)<span></span>
</td>
<td class="num">(1,370,433)<span></span>
</td>
<td class="num">(7,903,667)<span></span>
</td>
<td class="num">(16,725,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">LESS: COMPREHENSIVE LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS</a></td>
<td class="num">$ (2,481,832)<span></span>
</td>
<td class="num">$ (1,370,433)<span></span>
</td>
<td class="num">$ (7,903,667)<span></span>
</td>
<td class="num">$ (16,725,600)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_DebtModificationCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt modification charge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_DebtModificationCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_DeemedContributionOnExchangeOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deemed contribution on exchange of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_DeemedContributionOnExchangeOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingAndAdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total expense recognized in the period for promotion, public relations, and brand or product advertising.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingAndAdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in (Deficit) Equity - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series A</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Series B</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Series C</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Series D</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Statutory Reserve</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss (Deficit)</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 65,950,661<span></span>
</td>
<td class="num">$ (522,500)<span></span>
</td>
<td class="num">$ (63,062,721)<span></span>
</td>
<td class="nump">$ 6,578<span></span>
</td>
<td class="num">$ (213,137)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 11,158,948<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments', window );">Shares issued for adjustments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Shares issued for adjustments (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of Series B Convertible Preferred Stock for equity method investment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of Series B Convertible Preferred Stock for equity method investment (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock as convertible note payable commitment fee</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">236,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">236,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock as convertible note payable commitment fee (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet', window );">Sale of common stock, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">414,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">414,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet', window );">Sale of common stock, net (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">999,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">999,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">284,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">284,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(18,590)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(18,590)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,707,010)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(16,707,010)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">67,886,082<span></span>
</td>
<td class="num">$ (522,500)<span></span>
</td>
<td class="num">(79,769,731)<span></span>
</td>
<td class="nump">6,578<span></span>
</td>
<td class="num">(231,727)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7,368,776<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">736,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock as convertible note payable commitment fee</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">41,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock as convertible note payable commitment fee (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,920)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,920)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,367,513)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,367,513)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">67,941,614<span></span>
</td>
<td class="num">$ (522,500)<span></span>
</td>
<td class="num">(81,137,244)<span></span>
</td>
<td class="nump">6,578<span></span>
</td>
<td class="num">(234,647)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,053,876<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">67,886,082<span></span>
</td>
<td class="num">$ (522,500)<span></span>
</td>
<td class="num">(79,769,731)<span></span>
</td>
<td class="nump">6,578<span></span>
</td>
<td class="num">(231,727)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7,368,776<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">736,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments', window );">Shares issued for adjustments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Shares issued for adjustments (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock as convertible note payable commitment fee</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">320,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">320,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock as convertible note payable commitment fee (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet', window );">Sale of common stock, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">2,544,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,544,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet', window );">Sale of common stock, net (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon cashless exercise of stock warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon cashless exercise of stock warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">530,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">530,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Reclassification of derivative liability to equity</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Sale of Series C Convertible Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Sale of Series C Convertible Preferred Stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">688,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">688,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">51,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">51,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(273)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,903,394)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,903,394)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">72,023,525<span></span>
</td>
<td class="num">$ (522,500)<span></span>
</td>
<td class="num">(87,673,125)<span></span>
</td>
<td class="nump">6,578<span></span>
</td>
<td class="num">(232,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7,102,623<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,445,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon cashless exercise of stock warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon cashless exercise of stock warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">111,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Reclassification of derivative liability to equity</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock', window );">Series D Convertible Preferred Stock issued in exchange of Series A Convertible Preferred Stock</a></td>
<td class="num">$ (9,000,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,837,527<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">162,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock', window );">Series D Convertible Preferred Stock issued in exchange of Series A Convertible Preferred Stock (in Shares)</a></td>
<td class="num">(9,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment', window );">Series B Convertible Preferred Stock extinguished related to sale of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,348,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,651,305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments', window );">Series B Convertible Preferred Stock extinguished related to sale of equity method investment (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">279<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,482,111)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,482,111)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 8,837,527<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">$ 74,673,916<span></span>
</td>
<td class="num">$ (522,500)<span></span>
</td>
<td class="num">$ (90,155,236)<span></span>
</td>
<td class="nump">$ 6,578<span></span>
</td>
<td class="num">$ (231,721)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (3,891,270)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">1,655,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock extinguished related to sale of equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of series B convertible preferred stock extinguished related to sale of equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares series D convertible preferred stock issued in exchange of series A convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The shares of sale of common stock, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of stock issued during period value sale of common stock net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of series D convertible preferred stock issued in exchange of series A convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of shares issued for adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-21<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in (Deficit) Equity (Parentheticals)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse split</a></td>
<td class="text">1-for-15<span></span>
</td>
<td class="text">1-for-15<span></span>
</td>
<td class="text">1:10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (2,482,111)<span></span>
</td>
<td class="num">$ (1,367,513)<span></span>
</td>
<td class="num">$ (7,903,394)<span></span>
</td>
<td class="num">$ (16,707,010)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">44,428<span></span>
</td>
<td class="nump">44,481<span></span>
</td>
<td class="nump">177,917<span></span>
</td>
<td class="nump">211,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StraightLineRent', window );">Change in straight-line rent receivable</a></td>
<td class="nump">29,288<span></span>
</td>
<td class="nump">20,548<span></span>
</td>
<td class="nump">46,607<span></span>
</td>
<td class="nump">10,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use asset</a></td>
<td class="nump">18,956<span></span>
</td>
<td class="nump">29,448<span></span>
</td>
<td class="nump">122,553<span></span>
</td>
<td class="nump">118,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation and service expense</a></td>
<td class="nump">26,371<span></span>
</td>
<td class="nump">45,746<span></span>
</td>
<td class="nump">521,509<span></span>
</td>
<td class="nump">1,179,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income from equity method investment</a></td>
<td class="num">(392,677)<span></span>
</td>
<td class="num">(107,469)<span></span>
</td>
<td class="nump">846,588<span></span>
</td>
<td class="nump">8,589,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_DistributionOfEarningsFromEquityMethodInvestment', window );">Distribution of earnings from equity method investment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">160,788<span></span>
</td>
<td class="nump">611,888<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of equity method investment - Epicon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">454,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">313,562<span></span>
</td>
<td class="nump">272,196<span></span>
</td>
<td class="nump">1,411,042<span></span>
</td>
<td class="nump">544,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair market value of derivative liability</a></td>
<td class="nump">114,360<span></span>
</td>
<td class="num">(31,212)<span></span>
</td>
<td class="num">(374,365)<span></span>
</td>
<td class="num">(188,374)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ImpairmentOfLaboratoryEquipment', window );">Impairment of laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,033<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Debt modification charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688,794<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debts extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(682,979)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Rent receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">113,024<span></span>
</td>
<td class="nump">130,739<span></span>
</td>
<td class="num">(46,220)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Security deposit</a></td>
<td class="nump">5,473<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_IncreaseDecreaseInDeferredLeasingCosts', window );">Deferred leasing costs</a></td>
<td class="nump">8,021<span></span>
</td>
<td class="nump">8,350<span></span>
</td>
<td class="nump">33,402<span></span>
</td>
<td class="nump">33,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expense and other assets</a></td>
<td class="num">(24,698)<span></span>
</td>
<td class="num">(3,739)<span></span>
</td>
<td class="num">(91,496)<span></span>
</td>
<td class="nump">411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued liabilities and other payables</a></td>
<td class="nump">556,057<span></span>
</td>
<td class="num">(14,758)<span></span>
</td>
<td class="num">(1,165,418)<span></span>
</td>
<td class="num">(16,601)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_AccruedLiabilitiesAndOtherPayablesRelatedParties', window );">Accrued liabilities and other payables - related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(62,151)<span></span>
</td>
<td class="num">(14,051)<span></span>
</td>
<td class="nump">106,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease obligation</a></td>
<td class="num">(18,956)<span></span>
</td>
<td class="num">(23,448)<span></span>
</td>
<td class="num">(122,553)<span></span>
</td>
<td class="num">(112,915)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH USED IN OPERATING ACTIVITIES</a></td>
<td class="num">(1,801,926)<span></span>
</td>
<td class="num">(915,709)<span></span>
</td>
<td class="num">(4,969,205)<span></span>
</td>
<td class="num">(6,504,718)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(22,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payment for equity interest purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">95,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH PROVIDED BY INVESTING ACTIVITIES</a></td>
<td class="nump">95,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="num">(22,159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from loan payable - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">850,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments of loan payable - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(400,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of convertible debts and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,367,750<span></span>
</td>
<td class="nump">2,565,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of convertible debts issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(282,700)<span></span>
</td>
<td class="num">(327,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants', window );">Proceeds from issuance of convertible debt and warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PaymentsOfConvertibleDebtIssuanceCosts', window );">Payments of convertible debt issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(72,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of convertible debt</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(866,000)<span></span>
</td>
<td class="num">(3,388,222)<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of balloon promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments of balloon promissory note issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(64,436)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders', window );">Advance from pending sale of noncontrolling interest in subsidiary</a></td>
<td class="nump">219,972<span></span>
</td>
<td class="nump">1,210,472<span></span>
</td>
<td class="nump">2,122,392<span></span>
</td>
<td class="nump">485,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Proceeds from equity offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,857,852<span></span>
</td>
<td class="nump">635,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering', window );">Disbursements for equity offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(138,405)<span></span>
</td>
<td class="num">(19,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH PROVIDED BY FINANCING ACTIVITIES</a></td>
<td class="nump">219,972<span></span>
</td>
<td class="nump">936,772<span></span>
</td>
<td class="nump">7,638,667<span></span>
</td>
<td class="nump">4,825,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">EFFECT OF EXCHANGE RATE ON CASH</a></td>
<td class="nump">231<span></span>
</td>
<td class="num">(995)<span></span>
</td>
<td class="nump">1,447<span></span>
</td>
<td class="num">(3,970)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET (DECREASE) INCREASE IN CASH</a></td>
<td class="num">(1,486,723)<span></span>
</td>
<td class="nump">20,068<span></span>
</td>
<td class="nump">2,570,909<span></span>
</td>
<td class="num">(1,705,510)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH - beginning of period</a></td>
<td class="nump">2,856,309<span></span>
</td>
<td class="nump">285,400<span></span>
</td>
<td class="nump">285,400<span></span>
</td>
<td class="nump">1,990,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH - end of period</a></td>
<td class="nump">1,369,586<span></span>
</td>
<td class="nump">305,468<span></span>
</td>
<td class="nump">2,856,309<span></span>
</td>
<td class="nump">285,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">164,500<span></span>
</td>
<td class="nump">238,782<span></span>
</td>
<td class="nump">1,088,512<span></span>
</td>
<td class="nump">718,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Common stock issued for future services</a></td>
<td class="nump">51,635<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CommonStockIssuedForAccruedLiabilities', window );">Common stock issued for accrued liabilities</a></td>
<td class="nump">42,385<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">164,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ReceivableRelatedToSaleOfEquityMethodInvestment', window );">Receivable related to sale of equity method investment</a></td>
<td class="nump">1,745,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment', window );">Related party payable extinguished upon sale of equity method investment</a></td>
<td class="nump">632,916<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment', window );">Series B Convertible Preferred Stock extinguished related to sale of equity method investment</a></td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock', window );">Series D Convertible Preferred Stock issued in exchange of Series A Convertible Preferred Stock</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment', window );">Reclassification of advances for equity interest purchase to equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_WarrantsIssuedWithConvertibleNotePayable', window );">Series B Convertible Preferred Stock issued related to equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_AccruedPurchasePriceRelatedToEquityMethodInvestment', window );">Accrued purchase price related to equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">666,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_WarrantsIssuedAsConvertibleNotePayableFindersFee', window );">Warrants issued as convertible note payable finder&#8217;s fee</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,679<span></span>
</td>
<td class="nump">40,900<span></span>
</td>
<td class="nump">16,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount', window );">Warrants issued with convertible note payable recorded as debt discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">20,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee', window );">Common stock issued as convertible note payable commitment fee</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount', window );">Warrants issued with convertible notes payable recorded as debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">438,568<span></span>
</td>
<td class="nump">196,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock', window );">Common stock issued as convertible notes payable commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,546<span></span>
</td>
<td class="nump">236,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_DeferredFinancingCostsInAccruedLiabilities', window );">Deferred financing costs in accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">202,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Equity method investment payable paid by a related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">666,667<span></span>
</td>
<td class="nump">566,667<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalDeferredPurchasePrice', window );">Reclassification of deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,136<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SettlementsOfDerivativeLiability', window );">Settlement of derivative liability</a></td>
<td class="nump">18,853<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,354<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty', window );">Reclassification of related party loan payable and accrued expenses to advance from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant', window );">Issuance of common stock upon cashless exercise of stock warrants</a></td>
<td class="nump">19<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Initial ROU asset and lease liability</a></td>
<td class="nump">$ 127,486<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Shares issued for adjustments for 1:15 reverse split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_AccruedLiabilitiesAndOtherPayablesRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued liabilities and other payables - related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_AccruedLiabilitiesAndOtherPayablesRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_AccruedPurchasePriceRelatedToEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued purchase price related to equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_AccruedPurchasePriceRelatedToEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of beneficial conversion feature related to convertible note payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued as convertible note payable commitment fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_CommonStockIssuedForAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of common stock issued for accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_CommonStockIssuedForAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible note payable and accrued interest into common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_DeferredFinancingCostsInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred financing costs in accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_DeferredFinancingCostsInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_DistributionOfEarningsFromEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Distribution of earnings from equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_DistributionOfEarningsFromEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ImpairmentOfLaboratoryEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment of laboratory equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ImpairmentOfLaboratoryEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_IncreaseDecreaseInDeferredLeasingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred leasing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_IncreaseDecreaseInDeferredLeasingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon cashless exercise of stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PaymentsOfConvertibleDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of convertible debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PaymentsOfConvertibleDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of convertible debt and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ReceivableRelatedToSaleOfEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable related to sale of equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ReceivableRelatedToSaleOfEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of advances for equity interest purchase to equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reclassification of related party loan payable and accrued expenses to advance from related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party payable extinguished upon sale of equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock extinguished related to sale of equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Series D Convertible Preferred Stock issued in exchange of Series A Convertible Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_SettlementsOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement of derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_SettlementsOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_WarrantsIssuedAsConvertibleNotePayableFindersFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Warrants issued as convertible note payable finder&#8217;s fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_WarrantsIssuedAsConvertibleNotePayableFindersFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_WarrantsIssuedWithConvertibleNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants issued with convertible note payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_WarrantsIssuedWithConvertibleNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of warrants issued with convertible note payable recorded as debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants issued with convertible note payable recorded as debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 60<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481408/470-60-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (m)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StraightLineRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between actual rental income due and rental income recognized on a straight-line basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StraightLineRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalDeferredPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalDeferredPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Nature of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">ORGANIZATION AND NATURE OF OPERATIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">NOTE 1 - <span style="text-decoration:underline">ORGANIZATION AND NATURE OF OPERATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Avalon GloboCare Corp. (the &#8220;Company&#8221;
or &#8220;ALBT&#8221;) was incorporated under the laws of the State of Delaware on July 28, 2014.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">The Company is a
commercial-stage company dedicated to developing and delivering precision diagnostic consumer products and the advancement of intellectual
property in cellular therapy. The Company is currently marketing the KetoAir&#8482; breathalyzer device and plans to develop additional
diagnostic uses of the breathalyzer technology. The KetoAir</span><span style="-sec-ix-redline:true;font-size: 12.5pt"><sup>TM</sup></span> <span style="-sec-ix-redline:true;font-size: 10pt">is
registered with the U.S. Food and Drug Administration as a Class I medical device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On May 18, 2015, Avalon Healthcare System, Inc.
(&#8220;AHS&#8221;) was incorporated under the laws of the State of Delaware. AHS owns 100% of the capital stock of Avalon (Shanghai)
Healthcare Technology Co., Ltd. (&#8220;Avalon Shanghai&#8221;), which is a wholly foreign-owned enterprise organized under the laws
of the People&#8217;s Republic of China (&#8220;PRC&#8221;). Avalon Shanghai was incorporated on April 29, 2016, and was engaged in medical
related consulting services for customers. Due to the winding down of the medical related consulting services in 2022, the Company decided
to cease all operations of Avalon Shanghai and no longer has any material revenues or expenses in Avalon Shanghai. As a result, Avalon
Shanghai is no longer an operating entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On February 7, 2017, the Company formed Avalon
RT 9 Properties, LLC (&#8220;Avalon RT 9&#8221;), a New Jersey limited liability company. On May 5, 2017, Avalon RT 9 purchased a real
property located in Township of Freehold, County of Monmouth, State of New Jersey, having a street address of 4400 Route 9 South, Freehold,
NJ 07728. This property was purchased to serve as the Company&#8217;s world-wide headquarters for all corporate administration and operations.
In addition, the property generates rental income. Avalon RT 9 owns this office building. Avalon RT 9&#8217;s business consists of the
ownership and operation of the income-producing real estate property in New Jersey. As of March 31, 2025, the occupancy rate of the building
is 96.2%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 18, 2018, the Company formed a wholly
owned subsidiary, Avactis Biosciences Inc. (&#8220;Avactis&#8221;), a Nevada corporation, which is a patent holding company. Commencing
on April 6, 2022, the Company owns 60% of Avactis and Arbele Biotherapeutics Limited (&#8220;Arbele Biotherapeutics&#8221;) owns 40%
of Avactis. Avactis owns 100% of the capital stock of Avactis Nanjing Biosciences Ltd., a company incorporated in the PRC on May 8, 2020
(&#8220;Avactis Nanjing&#8221;), which only owns a patent and is not considered an operating entity. Currently, Avactis and Avactis Nanjing
are dormant and are in process of being dissolved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On October 14, 2022, the Company formed a wholly
owned subsidiary, Avalon Laboratory Services, Inc. (&#8220;Avalon Lab&#8221;), a Delaware company. On February 9, 2023, Avalon Lab purchased
40% of the issued and outstanding equity interests of Laboratory Services MSO, LLC, a private limited company formed under the laws of
the State of Delaware on September 6, 2019 (&#8220;Lab Services MSO&#8221;), and its subsidiaries. Lab Services MSO, through its subsidiaries,
is engaged in providing laboratory testing services. During the first quarter of 2025, to preserve cash, the Company entered into discussions
with Lab Services MSO for the potential redemption of our investment and on February 26, 2025, Lab Services MSO redeemed the 40% equity
interest in Lab Services MSO held by Avalon Lab.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On May 1, 2024, the Company formed a wholly owned
subsidiary, Q&amp;A Distribution LLC (&#8220;Q&amp;A Distribution&#8221;), a Texas company. Q&amp;A Distribution is engaged in distribution
of KetoAir device.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Details of the Company&#8217;s subsidiaries which
are included in these condensed consolidated financial statements as of March 31, 2025 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 29%"><span style="-sec-ix-redline:true;font-size: 10pt">Name of Subsidiary</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-bottom: 1.5pt; padding-left: 5.65pt; text-align: center; width: 2%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 15%"><span style="-sec-ix-redline:true;font-size: 10pt">Place and Date of Incorporation</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-bottom: 1.5pt; padding-left: 5.65pt; text-align: center; width: 2%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 15%"><span style="-sec-ix-redline:true;font-size: 10pt">Percentage of Ownership</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-bottom: 1.5pt; padding-left: 5.65pt; text-align: center; width: 2%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 35%"><span style="-sec-ix-redline:true;font-size: 10pt">Principal Activities</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Avalon Healthcare System, Inc. (&#8220;AHS&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Delaware May 18, 2015</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">100% held by ALBT</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Holding company for payroll and other expenses</span></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Avalon RT 9 Properties LLC (&#8220;Avalon RT 9&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">New Jersey February 7, 2017</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">100% held by ALBT</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Owns and operates an income-producing real property and holds and manages the corporate headquarters</span></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Avalon (Shanghai) Healthcare Technology Co., Ltd. (&#8220;Avalon Shanghai&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">PRC April 29, 2016</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">100% held by AHS</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Not considered an operating entity</span></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Genexosome Technologies Inc. (&#8220;Genexosome&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Nevada July 31, 2017</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">60% held by ALBT</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">No current activities to report; dormant</span></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Avactis Biosciences Inc. (&#8220;Avactis&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Nevada July 18, 2018</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">60% held by ALBT</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Dormant; in process of being dissolved</span></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Avactis Nanjing Biosciences Ltd. (&#8220;Avactis Nanjing&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">PRC May 8, 2020</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">100% held by Avactis</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Dormant; in process of being dissolved</span></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Avalon Laboratory Services, Inc. (&#8220;Avalon Lab&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Delaware October 14, 2022</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">100% held by ALBT</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">No current activities to report; dormant</span></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Q&amp;A Distribution LLC (&#8220;Q&amp;A Distribution&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Texas May 1, 2024</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">100% held by ALBT</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Distributes KetoAir device</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 - <span style="text-decoration:underline">ORGANIZATION AND NATURE
OF OPERATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Avalon GloboCare Corp. (the &#8220;Company&#8221;
or &#8220;ALBT&#8221;) was incorporated under the laws of the State of Delaware on July 28, 2014.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company is a commercial-stage company dedicated
to developing and delivering precision diagnostic consumer products. The Company is currently marketing the KetoAir breathalyzer device
and plans to develop additional diagnostic uses of the breathalyzer technology. The Company also provided laboratory services in 2024
and 2023, offering a broad portfolio of diagnostic tests, including drug testing, toxicology, and a broad array of test services, from
general bloodwork to anatomic pathology, and urine toxicology.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 18, 2015, Avalon Healthcare System, Inc.
(&#8220;AHS&#8221;) was incorporated under the laws of the State of Delaware. AHS owns 100% of the capital stock of Avalon (Shanghai)
Healthcare Technology Co., Ltd. (&#8220;Avalon Shanghai&#8221;), which is a wholly foreign-owned enterprise organized under the laws of
the People&#8217;s Republic of China (&#8220;PRC&#8221;). Avalon Shanghai was incorporated on April 29, 2016, and was engaged in medical
related consulting services for customers. Due to the winding down of the medical related consulting services in 2022, the Company decided
to cease all operations of Avalon Shanghai and no longer has any material revenues or expenses in Avalon Shanghai. As a result, Avalon
Shanghai is no longer an operating entity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 7, 2017, the Company formed Avalon
RT 9 Properties, LLC (&#8220;Avalon RT 9&#8221;), a New Jersey limited liability company. On May 5, 2017, Avalon RT 9 purchased a real
property located in Township of Freehold, County of Monmouth, State of New Jersey, having a street address of 4400 Route 9 South, Freehold,
NJ 07728. This property was purchased to serve as the Company&#8217;s world-wide headquarters for all corporate administration and operations.
In addition, the property generates rental income. Avalon RT 9 owns this office building. Avalon RT 9&#8217;s business consists of the
ownership and operation of the income-producing real estate property in New Jersey. As of December 31, 2024, the occupancy rate of the
building is 98.5%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 18, 2018, the Company formed a wholly
owned subsidiary, Avactis Biosciences Inc. (&#8220;Avactis&#8221;), a Nevada corporation, which is a patent holding company. Commencing
on April 6, 2022, the Company owns 60% of Avactis and Arbele Biotherapeutics Limited (&#8220;Arbele Biotherapeutics&#8221;) owns 40% of
Avactis. Avactis owns 100% of the capital stock of Avactis Nanjing Biosciences Ltd., a company incorporated in the PRC on May 8, 2020
(&#8220;Avactis Nanjing&#8221;), which only owns a patent and is not considered an operating entity. Currently, Avactis and Avactis Nanjing
are dormant and are in process of being dissolved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 14, 2022, the Company formed a wholly
owned subsidiary, Avalon Laboratory Services, Inc. (&#8220;Avalon Lab&#8221;), a Delaware company. On February 9, 2023, Avalon Lab purchased
40% of the issued and outstanding equity interests of Laboratory Services MSO, LLC, a private limited company formed under the laws of
the State of Delaware on September 6, 2019 (&#8220;Lab Services MSO&#8221;), and its subsidiaries. Lab Services MSO, through its subsidiaries,
is engaged in providing laboratory testing services. During 2025, to preserve cash, the Company entered into discussions with Lab Services
MSO for the potential redemption of our investment and on February 26, 2025, Lab Services MSO redeemed the 40% equity interest in Lab
Services MSO held by Avalon Lab. See Note 22 - Subsequent Events - Redemption Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">On May 1,
2024, the Company formed a wholly owned subsidiary, Q&amp;A Distribution LLC (&#8220;Q&amp;A Distribution&#8221;), a Texas company. Q&amp;A
Distribution is engaged in distribution of KetoAir device.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Details of the Company&#8217;s subsidiaries which
are included in these consolidated financial statements as of December 31, 2024 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; width: 30%; text-align: left">Name of Subsidiary</td> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 17%; text-align: center">Place and date of<br/> Incorporation</td> <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 2%; text-align: center">&#160;</td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 15%; text-align: center">Percentage of<br/> Ownership</td> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center">Principal Activities</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Avalon Healthcare System, Inc. (&#8220;AHS&#8221;)</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">Delaware <br/>
May 18, 2015</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">100% held by ALBT</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">Holding company for payroll and other expenses</td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Avalon RT 9 Properties LLC (&#8220;Avalon RT 9&#8221;) &#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">New Jersey<br/> February 7, 2017 &#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">100% held by ALBT &#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">Owns and operates an income-producing real property and holds and manages the corporate headquarters</td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Avalon (Shanghai) Healthcare Technology Co., Ltd. (&#8220;Avalon Shanghai&#8221;)</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">PRC <br/>
April 29, 2016 &#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">100% held by AHS &#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">Is not considered an operating entity &#160; &#160;</td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Genexosome Technologies Inc. (&#8220;Genexosome&#8221;)</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">Nevada<br/> July 31, 2017</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">60% held by ALBT</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">No current activities to report, dormant &#160;</td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Avactis Biosciences Inc. (&#8220;Avactis&#8221;)</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">Nevada<br/> July 18, 2018</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">60% held by ALBT</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">Dormant, is in process of being dissolved</td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Avactis Nanjing Biosciences Ltd. (&#8220;Avactis Nanjing&#8221;)</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">PRC <br/>
May 8, 2020</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">100% held by Avactis</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">Dormant, is in process of being dissolved</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Avalon Laboratory Services, Inc. (&#8220;Avalon Lab&#8221;)</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">Delaware<br/> October 14, 2022</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">100% held by ALBT</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">Laboratory holding company with a 40% membership interest in Lab Services MSO (1)</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left; vertical-align: top">Q&amp;A Distribution LLC (&#8220;Q&amp;A Distribution&#8221;)</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: top">Texas <br/>
May 1, 2024</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: top">100% held by ALBT</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="padding-bottom: 1pt; vertical-align: top; text-align: center">Distributes KetoAir device</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in">(1)</td><td style="text-align: justify">On February 26, 2025, the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement,
whereby Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by the Company.</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Going Concern Condition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_BasisOfPresentationAndGoingConcernConditionAbstract', window );"><strong>Basis of Presentation and Going Concern Condition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">BASIS OF PRESENTATION AND GOING CONCERN CONDITION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">NOTE 2 - <span style="text-decoration:underline">BASIS OF PRESENTATION AND GOING CONCERN CONDITION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">Basis of Presentation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">These interim condensed consolidated financial
statements of the Company and its subsidiaries are unaudited. In the opinion of management, all adjustments (consisting of normal recurring
accruals) and disclosures necessary for a fair presentation of these interim condensed consolidated financial statements have been included.
The results reported in the condensed consolidated financial statements for any interim periods are not necessarily indicative of the
results that may be reported for the entire year. The accompanying condensed consolidated financial statements have been prepared in
accordance with the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) and do not include all information
and footnotes necessary for a complete presentation of financial statements in conformity with accounting principles generally accepted
in the United States (&#8220;U.S. GAAP&#8221;). The Company&#8217;s condensed consolidated financial statements include the accounts
of the Company and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Certain information and footnote disclosures normally
included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These
condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements
and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC
on March 31, 2025.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company is a commercial-stage company dedicated
to developing and delivering precision diagnostic consumer products. The Company is currently marketing the KetoAir breathalyzer device
and plans to develop additional diagnostic uses of the breathalyzer technology. In addition, the Company owns commercial real estate
that houses its headquarters in Freehold, New Jersey. These condensed consolidated financial statements have been prepared assuming that
the Company will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction
of liabilities in the normal course of business.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As reflected in the accompanying condensed consolidated
financial statements, the Company had a working capital deficit of approximately $11,655,000 at March 31, 2025 and had incurred recurring
net losses and generated negative cash flow from operating activities of approximately $2,482,000 and $1,802,000 for the three months
ended March 31, 2025, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has a limited operating history and
its continued growth is dependent upon the continuation of generating rental revenue from its income-producing real estate property in
New Jersey, generating revenue for selling of KetoAir, and obtaining additional financing to fund future obligations and pay liabilities
arising from normal business operations. In addition, the current cash balance cannot be projected to cover the operating expenses for
the next twelve months from the release date of this report. These matters raise substantial doubt about the Company&#8217;s ability
to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company&#8217;s ability
to raise additional capital, implement its business plan, and generate significant revenue. There are no assurances that the Company
will be successful in its efforts to generate significant revenue, maintain sufficient cash balance or report profitable operations or
to continue as a going concern. The Company plans on raising capital through the sale of equity to implement its business plan. However,
there is no assurance these plans will be realized and that any additional financings will be available to the Company on satisfactory
terms and conditions, if any.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The accompanying condensed consolidated financial
statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and
classification of liabilities that may result should the Company be unable to continue as a going concern.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="background-color: white"><b>NOTE
2 - <span style="text-decoration:underline">BASIS OF PRESENTATION AND GOING CONCERN CONDITION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Basis of Presentation </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S.
GAAP&#8221;) and with the rules and regulations of the U.S. Securities and Exchange Commission for financial information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s consolidated financial statements
include the accounts of the Company and its subsidiaries. All significant intercompany accounts and transactions have been eliminated
in consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company is a commercial-stage company dedicated
to developing and delivering precision diagnostic consumer products. The Company is currently marketing the KetoAir breathalyzer device
and plans to develop additional diagnostic uses of the breathalyzer technology. In addition, the Company owns commercial real estate
that houses its headquarters in Freehold, New Jersey. These consolidated financial statements have been prepared assuming that the Company
will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities
in the normal course of business.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As reflected in the accompanying consolidated
financial statements, the Company had a working capital deficit of approximately $10,646,000 at December 31, 2024 and had incurred recurring
net losses and generated negative cash flow from operating activities of approximately $7,903,000 and $4,969,000 for the year ended December
31, 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has a limited operating history and
its continued growth is dependent upon the continuation of generating rental revenue from its income-producing real estate property in
New Jersey and obtaining additional financing to fund future obligations and pay liabilities arising from normal business operations.
In addition, the current cash balance cannot be projected to cover the operating expenses for the next twelve months from the release
date of this report. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The ability
of the Company to continue as a going concern is dependent on the Company&#8217;s ability to raise additional capital, implement its business
plan, and generate significant revenue. There are no assurances that the Company will be successful in its efforts to generate significant
revenue, maintain sufficient cash balance or report profitable operations or to continue as a going concern. The Company plans on raising
capital through the sale of equity to implement its business plan. However, there is no assurance these plans will be realized and that
any additional financings will be available to the Company on satisfactory terms and conditions, if any.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification
of liabilities that may result should the Company be unable to continue as a going concern.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_BasisOfPresentationAndGoingConcernConditionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_BasisOfPresentationAndGoingConcernConditionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">NOTE 3 - <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The preparation of condensed consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Changes in these estimates and assumptions may have a material impact on the condensed
consolidated financial statements and accompanying notes. Making estimates requires management to exercise significant judgment. It is
at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date
of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more
future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Significant estimates during the three months
ended March 31, 2025 and 2024 include the useful life of investment in real estate and intangible assets, the assumptions used in assessing
impairment of long-term assets, the valuation of deferred tax assets and the associated valuation allowances, the valuation of stock-based
compensation, the valuation of Series D convertible preferred stock (&#8220;Series D Preferred Stock&#8221;), and the assumptions used
to determine fair value of warrants and embedded conversion features of convertible note payable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">Fair Value of Financial Instruments and Fair Value Measurements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i style="-sec-ix-redline:true;-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company adopted the guidance of the Financial
Accounting Standards Board&#8217;s (the &#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820 for fair value
measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value
hierarchy to classify the inputs used in measuring fair value as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="-sec-ix-redline:true;font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Level 1-Inputs are unadjusted quoted prices in active markets for
    identical assets or liabilities available at the measurement date.</span></td></tr>
</table>

<p style="margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="-sec-ix-redline:true;font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Level 2-Inputs are unadjusted quoted prices for similar assets and
    liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs
    other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.</span></td></tr>
</table>

<p style="margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="-sec-ix-redline:true;font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Level 3-Inputs are unobservable inputs which reflect the reporting
    entity&#8217;s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the
    best available information.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The fair value of the Company&#8217;s assets and
liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying
amounts represented in the accompanying condensed consolidated financial statements, primarily due to their short-term nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><b><i>Assets and liabilities measured at fair
value on a recurring basis. </i></b>Certain assets and liabilities are measured at fair value on a recurring basis. These assets and
liabilities are measured at fair value on an ongoing basis. These assets and liabilities include derivative liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><i>Derivative liability. </i>Derivative liability
is carried at fair value and measured on an ongoing basis. The table below reflects the activity of derivative liability measured at
fair value for the three months ended March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Significant <br/>
    Unobservable Inputs<br/> (Level 3)</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Balance of derivative liability as of January 1, 2025</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">127,545</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Reclassification of additional paid-in capital upon conversion</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(18,853</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Loss from change in the fair value of derivative liability</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">114,360</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Balance of derivative liability as of March 31, 2025</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">223,052</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">ASC 825-10 &#8220;Financial Instruments&#8221;,
allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair
value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value
option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent
reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Cash and Cash Equivalents</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">At March 31, 2025 and December 31, 2024, the Company&#8217;s
cash balances by geographic area were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Country:</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">March 31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">December 31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">United States</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,351,923</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">98.7</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,844,522</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">99.6</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">China</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">17,663</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.3</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">11,787</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.4</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Total cash</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,369,586</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">100.0</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,856,309</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">100.0</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For purposes of the condensed consolidated statements
of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less when purchased and money market
accounts to be cash equivalents. The Company had no cash equivalents at March 31, 2025 and December 31, 2024.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Credit Risk and Uncertainties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company maintains a portion of its cash on
deposits with bank and financial institution within the U.S. that at times may exceed federally-insured limits of $250,000. The Company
manages this credit risk by concentrating its cash balances in high quality financial institutions and by periodically evaluating the
credit quality of the primary financial institutions holding such deposits. The Company has not experienced any losses in such bank accounts
and believes it is not exposed to any risks on its cash in bank accounts. At March 31, 2025, the Company&#8217;s cash balances in United
States bank accounts had approximately $840,000 in excess of the federally-insured limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company&#8217;s concentrations of credit risk
with respect to its rent receivable is limited due to short-term payment terms. The Company also performs ongoing credit evaluations
of its tenants to help further reduce credit risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Investment in Unconsolidated Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company uses the equity method of accounting
for its investment in, and earning or loss of, investees that it does not control but over which it does exert significant influence.
The Company applies the equity method by initially recording these investments at cost, as equity method investments, subsequently adjusted
for equity in earnings and cash distributions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company considers whether the fair value of
its equity method investment has declined below its carrying value whenever adverse events or changes in circumstances indicate that
recorded value may not be recoverable. If the Company considers any decline to be other than temporary (based on various factors, including
historical financial results and the overall health of the investee), then a write-down would be recorded to estimated fair value. See
Note 5 for discussion of equity method investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company classifies distributions received
from equity method investments using the cumulative earnings approach. Distributions received are considered returns on the investment
and classified as cash inflows from operating activities. If, however, the investor&#8217;s cumulative distributions received, less distributions
received in prior periods determined to be returns of investment, exceeds cumulative equity in earnings recognized, the excess is considered
a return of investment and is classified as cash inflows from investing activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Receivable from Sale of Equity Method Investment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the first quarter of 2025, to preserve
cash, the Company entered into discussions with Lab Services MSO for the potential redemption of our investment and on February 26, 2025,
the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement (the &#8220;Redemption Agreement&#8221;), whereby
Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by the Company for cash and the surrender of its Series B
convertible preferred stock (&#8220;Series B Preferred Stock&#8221;) having a carrying value of $11,000,000. The aggregate cash amount
to the Company for the redemption was $1,745,000, to be paid as follows: one payment of $95,000 at the closing of the redemption and,
beginning in March 2025, monthly payments of $75,000 until December 2026. In addition, pursuant to the terms of the Redemption Agreement,
all shares of the Company&#8217;s Series B Preferred Stock previously issued to SCBC Holdings LLC as partial consideration for the equity
interests of Laboratory Services MSO, were permanently surrendered and relinquished to the Company for no additional consideration. The
difference of $2,348,695 between the carrying value of the extinguished Series B Preferred Stock, the aggregate cash amount to the Company
for the redemption, net of the payables due to Lab Services MSO of $632,916, totaling $13,377,916, and the carrying value of the equity
method investment of $11,029,221 was accounted for as an increase to additional paid-in capital (See Note 10 - Series B Convertible Preferred
Stock Extinguished Related to Sale of Equity Method Investment). Accordingly, beginning in February 2025, the Company no longer offers
laboratory services. As of March 31, 2025, the receivable from sale of equity method investment amounted to $1,650,000, of which $975,000
was included in current assets and $675,000 was included in non-current assets. Management believes that the receivable is fully collectable.
Therefore, no material allowance for doubtful accounts was deemed to be required on the receivable at March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Per Share Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">ASC Topic 260 &#8220;Earnings per Share,&#8221;
requires presentation of both basic and diluted earnings per share (&#8220;EPS&#8221;) with a reconciliation of the numerator and denominator
of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Basic net loss per share is computed by dividing
net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents
and potentially dilutive securities outstanding during each period. The Company had $162,473 in deemed contribution during the three
months ended March 31, 2025, which increases the numerator in the net loss per share calculation. For the three months ended March 31,
2025 and 2024, potentially dilutive common shares consisted of the common shares issuable upon the conversion of convertible preferred
stock and convertible notes (using the if-converted method) and exercise of common stock options and warrants (using the treasury stock
method). Common stock equivalents are not included in the calculation of diluted net loss per share if their effect would be anti-dilutive.
In a period in which the Company has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares
outstanding as they would have had an anti-dilutive impact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The calculation of basic and diluted net loss
per common share attributable to the Company common shareholders includes 150,000 of the pre-funded warrants that remained outstanding
as of March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes the securities
that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended March 31,</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Options to purchase common stock</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,451,425</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">47,287</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Warrants to purchase common stock</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">171,163</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">60,562</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 10pt">Series A convertible preferred stock </span><span style="-sec-ix-redline:true;font-size: 12.5pt"><sup>(*)</sup></span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-380"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">60,000</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 10pt">Series B convertible preferred stock </span><span style="-sec-ix-redline:true;font-size: 12.5pt"><sup>(**)</sup></span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-381"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">194,004</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 10pt">Series C convertible preferred stock </span><span style="-sec-ix-redline:true;font-size: 12.5pt"><sup>(***)</sup></span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,452,282</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-382"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Series D convertible preferred stock (****)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,074,689</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-383"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 10pt">Convertible notes and related accrued interest
    </span><span style="-sec-ix-redline:true;font-size: 12.5pt"><sup>(*****)</sup></span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">234,554</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">90,133</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Potentially dilutive securities</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,384,113</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">451,986</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="-sec-ix-redline:true;font-size: 10pt">(*)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the Series A convertible preferred stock (&#8220;Series A Preferred Stock&#8221;) was converted into shares of common stock of the Company at a conversion price of $150.00 per share.</span></td></tr> </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="-sec-ix-redline:true;font-size: 10pt">(**)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the Series B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.</span></td></tr> </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="-sec-ix-redline:true;font-size: 10pt">(***)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the Series C convertible preferred stock (&#8220;Series C Preferred Stock&#8221;) was converted into shares of common stock of the Company at a conversion price of $2.41 per share.</span></td></tr> </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="-sec-ix-redline:true;font-size: 10pt">(****)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the Series D convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $2.41 per share.</span></td></tr> </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="-sec-ix-redline:true;font-size: 10pt">(*****)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the three months ended March 31, 2025. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and $22.50 and $15.00 per share for the three months ended March 31, 2024.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Real Property Rental Revenue</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has determined that ASC 606 does not
apply to rental contracts, which are within the scope of other revenue recognition accounting standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Rental income from operating leases is recognized
on a straight-line basis under the guidance of ASC 842. Lease payments under tenant leases are recognized on a straight-line basis over
the term of the related leases. The cumulative difference between lease revenue recognized under the straight-line method and contractual
lease payments are included in rent receivable on the condensed consolidated balance sheets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In the normal course of business, the Company
is subject to contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters. Liabilities
for such contingencies are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably
estimated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Segment Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The segment reporting structure uses the Company&#8217;s
management reporting structure as its foundation to reflect how the Company manages the businesses internally and was mainly organized
by services. During the three months ended March 31, 2025 and 2024, the Company is organized into two services-oriented strategic business
units: real property rental services and laboratory testing services (which ended on the redemption date, February 26, 2025) - which
are led by our strategic business unit managers. Operating segments are defined as components of an enterprise for which separate financial
information is available and evaluated regularly by the chief operating decision maker (&#8220;CODM&#8221;) in deciding how to make operating
decisions, allocate resources and assess performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On February 9, 2023, the Company purchased 40%
of Lab Services MSO. During the first quarter of 2025, to preserve cash, the Company entered into discussions with Lab Services MSO for
the potential redemption of Avalon Lab&#8217;s investment and on February 26, 2025, Lab Services MSO redeemed the 40% equity interest
in Lab Services MSO held by Avalon Lab. Commencing from the purchase date, February 9, 2023, through the redemption date, February 26,
2025, the Company was active in the management of Lab Services MSO. During the three months ended March 31, 2025 and 2024, the Company
operated in two reportable business segments: (1) the real property operating segment, and (2) laboratory testing services segment (which
ended on the redemption date, February 26, 2025) since Lab Services MSO&#8217;s operating results are regularly reviewed by the Company&#8217;s
chief operating decision maker to determine the resources to be allocated to the segment and assess its performance. Prior to February
26, 2025, the Company regularly reviewed the operating results and performance of Lab Services MSO, for which the Company accounted for
under the equity method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company&#8217;s President and Chief Executive
Officer is its CODM. The Company reports operational data to its CODM at the segment level, which he uses to evaluate performance and
allocate resources based on real property operating income and income from equity method investment - Lab Services MSO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Reverse Stock Split</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company effectuated a 1-for-15 reverse stock
split of its outstanding shares of common stock on October 28, 2024. The reverse split did not change the par value of common stock.
All references in these condensed consolidated financial statements to shares, share prices, exercise prices, and other per share information
in all periods have been adjusted, on a retroactive basis, to reflect the reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Recent Accounting Standards</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In August 2020, the FASB issued Accounting Standards
Update (&#8220;ASU&#8221;) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts
in Entity&#8217;s Own Equity (Subtopic 815-40), to simplify accounting for certain financial instruments. ASU 2020-06 eliminated the
then-current models that required separation of beneficial conversion and cash conversion features from convertible instruments and simplified
the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#8217;s own equity. ASU 2020-06
also introduced additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#8217;s
own equity. ASU 2020-06 amended the diluted earnings per share guidance, including the requirement to use the if-converted method for
all convertible instruments. ASU 2020-06 was effective for fiscal years beginning after December 15, 2023, including interim periods
within those fiscal years, with early adoption permitted. The adoption of ASU 2020-06 did not have a material effect on the Company&#8217;s
condensed consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In November 2023, the FASB issued ASU 2023-07,
Segment Reporting (Topic 280). The amendments in this update improve reportable segment disclosure requirements, primarily through enhanced
disclosures about significant segment expenses. ASU 2023-07 became effective for the Company&#8217;s annual period beginning on January
1, 2024 and interim periods beginning after January 1, 2025. The Company adopted this guidance in the fourth quarter of 2024. The Company&#8217;s
results of operations, cash flows, and financial condition were not impacted by the adoption of this ASU.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In December 2023, the FASB issued ASU 2023-09,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This guidance was intended to enhance the transparency and decision-usefulness
of income tax disclosures. The amendments in ASU 2023-09 addressed investor requests for enhanced income tax information primarily through
changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09
was effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively.
Early adoption was permitted. The adoption of ASU 2023-09 did not have a material effect on the Company&#8217;s condensed consolidated
financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Other accounting standards that have been issued
or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the condensed consolidated
financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on
or are unrelated to its condensed consolidated financial condition, results of operations, cash flows or disclosures.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3 - <span style="text-decoration:underline">SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The preparation
of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting period. Changes in these estimates and assumptions may have a material
impact on the consolidated financial statements and accompanying notes. Making estimates requires management to exercise significant judgment.
It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the
date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or
more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant estimates during the years ended December
31, 2024 and 2023 include the useful life of investment in real estate and intangible assets, the assumptions used in assessing impairment
of long-term assets, the valuation of deferred tax assets and the associated valuation allowances, the valuation of stock-based compensation,
the assumptions used to determine fair value of warrants and embedded conversion features of convertible note payable, and the fair value
of the consideration given and assets acquired in the purchase of 40% of Lab Services MSO.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Fair Value of Financial Instruments and
Fair Value Measurements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company adopted the guidance of Accounting Standards Codification (&#8220;ASC&#8221;) 820 for fair value measurements which clarifies
the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs
used in measuring fair value as follows</span>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Level <span style="background-color: white">1-Inputs are
unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Level <span style="background-color: white">2-Inputs are
unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities
in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable
market data.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Level <span style="background-color: white">3-Inputs are
unobservable inputs which reflect the reporting entity&#8217;s own assumptions on what assumptions the market participants would use
in pricing the asset or liability based on the best available information.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the Company&#8217;s assets and
liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying
amounts represented in the accompanying consolidated financial statements, primarily due to their short-term nature<span style="background-color: white">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Assets
and liabilities measured at fair value on a recurring basis.</i></b><i>&#160;</i></span>Certain assets and liabilities are measured at
fair value on a recurring basis. These assets and liabilities are measured at fair value on an ongoing basis. These assets and liabilities
include derivative liability<span style="background-color: white">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><i>Derivative
liability.</i>&#160;Derivative liability is carried at fair value and measured on an ongoing basis.&#160;The table below reflects the
activity of derivative liability measured at fair value for the years ended December 31, 2024 and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Significant Unobservable Inputs <br/>
(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance of derivative liability as of January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-329">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: left">Initial fair value of derivative liability attributable to warrants issuance with May, July, and October 2023 fund raises</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">213,170</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain from change in the fair value of derivative liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(188,374</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Balance of derivative liability as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,796</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Initial fair value of derivative liability attributable to warrants issuance with March and June 2024 fund raises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">479,468</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reclassification of additional paid-in capital upon conversion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,354</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain from change in the fair value of derivative liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(374,365</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance of derivative liability as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">127,545</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Assets
and liabilities measured at fair value on a nonrecurring basis.</i></b>&#160;Certain assets and liabilities are measured at fair value
on a nonrecurring basis. These assets and liabilities are not measured at fair value on an ongoing basis, but are subject to fair value
adjustments in certain circumstances. These assets and liabilities can include equipment held for sale and equity method investment that
are written down to fair value when they are impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><i>Laboratory
equipment. </i>The Company conducted an impairment assessment on its laboratory equipment based on the guidelines established in Financial
Accounting Standards Board (&#8220;FASB&#8221;) ASC Topic 360 to determine the estimated fair market value of its laboratory equipment
as of December 31, 2024. Upon completion of its 2024 impairment analysis, the Company determined that the carrying value exceeded the
fair market value of laboratory equipment. The fair market value of laboratory equipment is a level 3 valuation. The Company recorded
an impairment charge of $111,033 for the year ended December 31, 2024, which was included in other general and administrative expenses
on the accompanying consolidated statements of operations and comprehensive loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><i>Equity
method investment in Epicon Biotech Co., Ltd.</i>&#160;The factors used to determine fair value are subject to management&#8217;s judgment
and expertise and include, but are not limited to, the investee&#8217;s series of operating losses and the joint venture partner unable
to obtain funds to commence operations. These assumptions represent Level 3 inputs. Impairment of equity method investment in Epicon Biotech
Co., Ltd. for the year ended December 31, 2023 was $454,679. There is no comparative impairment for the year ended December 31, 2024 since
the investment was fully impaired at December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><i>Equity
method investment in </i></span><i>Laboratory Services MSO, LLC </i><span style="background-color: white">The factors used to determine
fair value are subject to management&#8217;s judgment and expertise. These assumptions represent Level 3 inputs. Impairment of equity
method investment in Laboratory Services MSO, LLC for the years ended December 31, 2024 and 2023 was $259,579 and $9,196,682, respectively,
which have been included in loss from equity method investment - Lab Services MSO on the accompanying consolidated statements of
operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">ASC
825-10 &#8220;Financial Instruments&#8221;, allows entities to voluntarily choose to measure certain financial assets and liabilities
at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless
a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should
be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding
instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Cash and Cash Equivalents</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2024 and 2023, the Company&#8217;s
cash balances by geographic area were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Country:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,844,522</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">99.6</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">280,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">98.2</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">China</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,787</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,203</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,856,309</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">285,400</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the consolidated statements of
cash flows, the Company considers all highly liquid instruments with a maturity of three months or less when purchased and money market
accounts to be cash equivalents. The Company had no cash equivalents at December 31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Credit Risk and Uncertainties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
maintains a portion of its cash on deposits with bank and financial institution within the U.S. that at times may exceed federally-insured
limits of $250,000. The Company manages this credit risk by concentrating its cash balances in high quality financial institutions and
by periodically evaluating the credit quality of the primary financial institutions holding such deposits. The Company has not experienced
any losses in such bank accounts and believes it is not exposed to any risks on its cash in bank accounts. At December 31, 2024, the Company&#8217;s
cash balances in United States bank accounts had approximately $2,413,000 in excess of the federally-insured limits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company&#8217;s
concentrations of credit risk with respect to its rent receivable is limited due to short-term payment terms. The Company also performs
ongoing credit evaluations of its tenants to help further reduce credit risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Rent Receivable and Reserve for Credit
Losses</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Rent receivable
is presented net of reserve for credit losses. Rent receivable balance consists of base rents, tenant reimbursements and receivables arising
from straight-lining of rents represent amounts accrued and unpaid from tenants in accordance with the terms of the respective leases,
subject to the Company&#8217;s revenue recognition policy. A reverse for the uncollectible portion of rent receivable is determined based
upon an analysis of the tenant&#8217;s payment history, the financial condition of the tenant, business conditions in the industry in
which the tenant operates and economic conditions in Freehold, New Jersey in which the property is located.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Management
believes that the rent receivable is fully collectable. Therefore, no material reverse for credit losses is deemed to be required on its
rent receivable at December 31, 2024 and 2023.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Deferred Offering Costs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred offering costs consist of legal, accounting
and other costs that are directly related to the Company&#8217;s open market sale equity financing and will be charged to stockholders&#8217;
equity upon completion of the equity offering. As of December 31, 2024 and 2023, deferred offering costs amounted to $0&#160;and $175,136,
respectively, which were included in prepaid expense and other current assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Deferred Leasing Costs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Costs incurred
to obtain tenant leases are amortized using the straight-line method over the term of the related lease agreement. Such costs include
lease incentives and leasing commissions. If the lease is terminated early, the remaining unamortized deferred leasing cost is written
off.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Property and Equipment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are carried at cost less
accumulated depreciation, and are depreciated on a straight-line basis over the estimated useful lives of the assets. The cost of repairs
and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of,
the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the period
of disposition. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances
reflect the fact that their recorded value may not be recoverable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Investment In Real
Estate and Depreciation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investment in real estate is carried at cost less
accumulated depreciation, and consists of building and improvement. The Company depreciates real estate building and improvement on a
straight-line basis over estimated useful life. Expenditures for ordinary repair and maintenance costs are charged to expense as incurred.
Expenditure for improvements, renovations, and replacements of real estate asset is capitalized and depreciated over its estimated useful
life if the expenditure qualifies as betterment.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Impairment of Long-lived Assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC Topic 360, the Company
reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may
not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future
cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset&#8217;s
estimated fair value and its book value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">For the
year ended December 31, 2024, the Company incurred impairment charges in operations of $111,033 on its laboratory equipment. The valuation
of the laboratory equipment, and the amount of the impairment charge, were based on impairment assessment conducted on the equipment at
December 31, 2024.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Investment in Unconsolidated
Companies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the equity method of accounting
for its investment in, and earning or loss of, investees that it does not control but over which it does exert significant influence.
The Company applies the equity method by initially recording these investments at cost, as equity method investments, subsequently adjusted
for equity in earnings and cash distributions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers whether the fair value of
its equity method investment has declined below its carrying value whenever adverse events or changes in circumstances indicate that recorded
value may not be recoverable. If the Company considers any decline to be other than temporary (based on various factors, including historical
financial results and the overall health of the investee), then a write-down would be recorded to estimated fair value. Impairment of
equity method investment amounted to $259,579 and $9,651,361 for the years ended December 31, 2024 and 2023, respectively. See Note 8
for discussion of equity method investments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies distributions received
from equity method investments using the cumulative earnings approach. Distributions received are considered returns on the investment
and classified as cash inflows from operating activities. If, however, the investor&#8217;s cumulative distributions received, less distributions
received in prior periods determined to be returns of investment, exceeds cumulative equity in earnings recognized, the excess is considered
a return of investment and is classified as cash inflows from investing activities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Deferred Rental Income</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred rental income represents rental income
collected but not earned as of the reporting date. The Company defers the revenue related to lease payments received from tenants in advance
of their due dates. As of December 31, 2024 and 2023, deferred rental income totaled $38,346 and $11,429, respectively, which were included
in accrued liabilities and other payables on the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>Real Property Rental Revenue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
has determined that ASC 606 does not apply to rental contracts, which are within the scope of other revenue recognition accounting standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rental income from operating leases is recognized
on a straight-line basis under the guidance of ASC 842. Lease payments under tenant leases are recognized on a straight-line basis over
the term of the related leases. The cumulative difference between lease revenue recognized under the straight-line method and contractual
lease payments are included in rent receivable on the consolidated balance sheets<span style="background-color: white">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Office Lease</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When a lease contains &#8220;rent holidays&#8221;,
the Company records rental expense on a straight-line basis over the term of the lease. The Company begins recording rent expense on the
lease possession date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Real Property Operating Expenses</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Real property operating expenses consist of property
management fees, property insurance, real estate taxes, depreciation, repairs and maintenance fees, utilities and other expenses related
to the Company&#8217;s rental properties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expenditures for research and product development
costs are expensed as incurred. The Company incurred research and development expense of $0&#160;and $109,618&#160;in the years ended
December 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Advertising and Marketing Costs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All costs related to advertising and marketing
are expensed as incurred. For the years ended December 31, 2024 and 2023, advertising and marketing costs amounted to $237,671 and $1,666,721,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
accounts for its stock-based compensation awards in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718, Compensation-Stock
Compensation (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees and non-employees including grants of stock
options, to be recognized as expense in the statements of operations based on their grant date fair values. The Company estimates the
grant date fair value of each option award using the Black-Scholes option-pricing model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
periodically issues common stock and common stock options to consultants for various services. Costs of these transactions are measured
at the fair value of the service received or the fair value of the equity instruments issued, whichever is more reliably measurable. The
value of the common stock is measured at the earlier of (i) the date at which a firm commitment for performance by the counterparty to
earn the equity instruments is reached or (ii) the date at which the counterparty&#8217;s performance is complete.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Debt
Modifications and Extinguishments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">When the
Company modifies or extinguishes debt, it first evaluates whether the modification qualifies as a troubled debt restructuring (TDR) under
ASC Topic 470-60, which requires debt modifications to be evaluated to determine if (1) the borrower is experiencing financial difficulty,
and (2) the lender grants the borrower a concession. If a TDR is determined not to have occurred, the Company evaluates the modification
in accordance with ASC Topic 470-50-40, which requires modification to debt instruments to be evaluated to assess whether debt modification
or debt extinguishment accounting is applicable. This evaluation includes analyzing whether there are significant and consequential changes
to the economic substance of the note. If the change is deemed insignificant then the change is considered a debt modification, whereas
if the change is substantial the change is reflected as a debt extinguishment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">If debt
extinguishment guidance applies, the previous debt principal amount is removed, the previously capitalized debt issuance costs are expensed,
the value of instruments exchanged are recorded, including cash, new debt, warrants and common stock, and a gain or loss on extinguishment
of debt is recorded. If debt modification guidance applies, no gain or loss is recorded and the effective interest rate of the debt is
updated based on the carrying value of the debt and the revised future cash flows. Any previously capitalized debt issuance costs in a
debt modification are amortized as interest expense over the term of the new debt instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
is governed by the income tax laws of China and the United States. The Company accounts for income taxes using the asset/liability method
prescribed by ASC 740, &#8220;Income Taxes.&#8221; Under this method, deferred tax assets and liabilities are determined based on the
difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the
period in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if, based
on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized.
The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
follows the accounting guidance for uncertainty in income taxes using the provisions of ASC 740 &#8220;Income Taxes&#8221;. Using that
guidance, the benefit for tax positions taken can only be recognized in the financial statements when it is more likely than not the position
will be sustained upon examination by the tax authorities. As of December 31, 2024 and 2023, the Company had no significant uncertain
tax positions which would require either recognition of a liability or disclosure in the financial statements. For United States entities,
tax year that remains subject to examination is the years ended December 31, 2024, 2023, 2022 and 2021. For China entities, income tax
returns for the tax years ended December 31, 2020 through December 31, 2024 remain open for statutory examination by PRC tax authorities.
The Company recognizes interest and penalties related to significant uncertain income tax positions in income tax expense. However, no
such interest and penalties were recorded as of December 31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Foreign Currency Translation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The reporting
currency of the Company is the U.S. dollar. The functional currency of the parent company, AHS, Avalon RT 9, Avalon Lab, and Q&amp;A Distribution
is the U.S. dollar and the functional currency of Avalon Shanghai is the Chinese Renminbi (&#8220;RMB&#8221;). For Avalon Shanghai whose
functional currency is the RMB, result of operations and cash flows are translated at average exchange rates during the period, assets
and liabilities are translated at the unified exchange rate at the end of the period, and equity is translated at historical exchange
rates. As a result, amounts relating to assets and liabilities reported on the statements of cash flows may not necessarily agree with
the changes in the corresponding balances on the balance sheets. Translation adjustments resulting from the process of translating the
local currency financial statements into U.S. dollars are included in determining comprehensive income/loss. Transactions denominated
in foreign currencies are translated into the functional currency at the exchange rates prevailing on the transaction dates. Assets and
liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the balance
sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency
other than the functional currency are included in the results of operations as incurred. All of the Company&#8217;s revenue transactions
are transacted in the functional currency of the operating subsidiaries. The Company does not enter into any material transaction in foreign
currencies. Transaction gains or losses have not had, and are not expected to have, a material effect on the results of operations of
the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Asset and
liability accounts at December 31, 2024 and 2023 were translated at 7.2980 RMB and 7.0786 RMB to $1.00, respectively, which were the exchange
rates on the balance sheet dates. Equity accounts were stated at their historical rates. The average translation rates applied to the
statements of operations for the years ended December 31, 2024 and 2023 were 7.1889 RMB and 7.0752 RMB to $1.00, respectively. Cash flows
from the Company&#8217;s operations are calculated based upon the local currencies using the average translation rate.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Comprehensive Loss</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comprehensive loss is comprised of net loss and
all changes to the statements of equity, except those due to investments by stockholders, changes in paid-in capital and distributions
to stockholders. For the Company, comprehensive loss for the years ended December 31, 2024 and 2023 consisted of net loss and unrealized
loss from foreign currency translation adjustment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Commitments
and Contingencies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In the normal
course of business, the Company is subject to contingencies, such as legal proceedings and claims arising out of its business, that cover
a wide range of matters. Liabilities for such contingencies are recorded when it is probable that a liability has been incurred and the
amount of the assessment can be reasonably estimated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Per Share Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC Topic 260 &#8220;Earnings per Share,&#8221;
requires presentation of both basic and diluted earnings per share (&#8220;EPS&#8221;) with a reconciliation of the numerator and denominator
of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per share is computed by dividing
net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents
and potentially dilutive securities outstanding during each period. For the years ended December 31, 2024 and 2023, potentially dilutive
common shares consist of the common shares issuable upon the conversion of convertible preferred stock and convertible notes (using the
if-converted method) and exercise of common stock options and warrants (using the treasury stock method). Common stock equivalents are
not included in the calculation of diluted net loss per share if their effect would be anti-dilutive. In a period in which the Company
has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares outstanding as they would have
had an anti-dilutive impact.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The calculation of basic and diluted net loss
per common share attributable to the Company common shareholders includes 150,000 of the pre-funded warrants that remain outstanding as
of December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the securities
that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended<br/>
 December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Options to purchase common stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">52,479</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">56,880</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrants to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">182,996</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,035</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series A convertible preferred stock <sup>(*)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series B convertible preferred stock <sup>(**)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194,004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194,004</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series C convertible preferred stock <sup>(***)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,452,282</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-330">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Convertible notes <sup>(****)</sup></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">227,269</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">60,740</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,169,030</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">414,659</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left">(*)</td><td style="text-align: justify">Assumed the Series A convertible preferred stock was converted
into shares of common stock of the Company at a conversion price of $150.00 per share<span style="background-color: white">.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="background-color: white">(**)</span></td><td style="text-align: justify"><span style="background-color: white">Assumed the Series
B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="background-color: white">(***)</span></td><td style="text-align: justify"><span style="background-color: white">Assumed the Series
C convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $2.41 per share.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="background-color: white">(****)</span></td><td style="text-align: justify"><span style="background-color: white">Assumed the convertible
notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the year ended December
31, 2024. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and
$22.50 per share for the year ended December 31, 2023.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Noncontrolling Interest</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024, Dr. Yu Zhou, former director
and former Co-Chief Executive Officer of Genexosome, who owns 40% of the equity interests of Genexosome, which is not under the Company&#8217;s
control. Since the fourth quarter of 2019, the non-controlling interest has remained inactive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Reclassification</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Certain prior period
amounts have been reclassified to conform to the current period presentation. These reclassifications have no effect on the previously
reported financial position, results of operations and cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Segment Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The segment
reporting structure uses the Company&#8217;s management reporting structure as its foundation to reflect how the Company manages the businesses
internally and is mainly organized by services. The Company is organized into two services-oriented strategic business units: real property
rental services and laboratory testing services - which are led by our strategic business unit managers. Operating segments are
defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating
decision maker (&#8220;CODM&#8221;) in deciding how to make operating decisions, allocate resources and assess performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 9, 2023, the Company purchased 40%
of Lab Services MSO. Commencing from the purchase date, February 9, 2023, the Company is active in the management of Lab Services MSO.
During the years ended December 31, 2024 and 2023, the Company operated in two reportable business segments: (1) the real property operating
segment, and (2) laboratory testing services segment (which commenced with the purchase date, February 9, 2023) since Lab Services MSO&#8217;s
operating results are regularly reviewed by the Company&#8217;s chief operating decision maker to determine the resources to be allocated
to the segment and assess its performance. The Company regularly reviews the operating results and performance of Lab Services MSO, for
which the Company accounts for under the equity method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s President and Chief Executive
Officer is its CODM. The Company reports operational data to its CODM at the segment level, which he uses to evaluate performance and
allocate resources based on real property operating income and loss from equity method investment - Lab Services MSO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Fiscal Year End</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company has adopted a fiscal year end of December 31st.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Reverse Stock Split</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
effectuated a 1-for-15 reverse stock split of its outstanding shares of common stock on October 28, 2024. The reverse split did not change
the par value of common stock. All references in these consolidated financial statements to shares, share prices, exercise prices, and
other per share information in all periods have been adjusted, on a retroactive basis, to reflect the reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Recent Accounting
Standards</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In August
2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic
470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40), to simplify accounting for certain
financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion
features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts
in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments
that are indexed to and settled in an entity&#8217;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including
the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after
December 15, 2022, including interim periods within those fiscal years, with early adoption permitted. The adoption of ASU 2020-06 did
not have a material effect on the Company&#8217;s consolidated financial statements and related disclosures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In November
2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280). The amendments in this update improve reportable segment disclosure
requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 became effective for the Company&#8217;s
annual period beginning on January 1, 2024 and interim periods beginning after January 1, 2025. The Company adopted this guidance in the
fourth quarter of 2024. Refer to Note 20 - Segment Information. The Company&#8217;s results of operations, cash flows, and financial condition
were not impacted by the adoption of this ASU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In December
2023, the FASB ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This guidance is intended to enhance the
transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income
tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign
jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to
apply the standard retrospectively. Early adoption is permitted. The adoption of ASU 2023-09 did not have a material effect on the Company&#8217;s
consolidated financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Other accounting
standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material
impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated
to have an impact on or are unrelated to its consolidated financial condition, results of operations, cash flows or disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expense and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAbstract', window );"><strong>Prepaid Expense and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSE AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">NOTE 4 - <span style="text-decoration:underline">PREPAID EXPENSE AND OTHER CURRENT ASSETS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">At March 31, 2025 and December 31, 2024, prepaid expense and other
current assets consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">March 31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">December 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Prepaid professional fees</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">90,431</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">33,665</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Prepaid directors&#8217; and officers&#8217; liability insurance premium</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">12,834</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">9,741</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Prepaid NASDAQ listing fee</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">39,750</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-384"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Deferred leasing costs</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">28,980</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">31,587</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Security deposit</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">12,256</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">17,654</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Due from broker</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">33,160</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">32,885</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Finished goods</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">90,116</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">92,230</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Recoverable value-added tax</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">10,094</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">9,245</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Others</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">50,197</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">72,353</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">367,818</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">299,360</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 4 -&#160;<span style="text-decoration:underline">PREPAID EXPENSE
AND OTHER CURRENT ASSETS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">At December 31, 2024 and 2023, prepaid expense
and other current assets consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>
2024</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>
2023</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid professional fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">33,665</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">33,062</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid directors and officers&#8217; liability insurance premium</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,741</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,192</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-331">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,136</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred leasing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,587</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,402</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Security deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,654</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-332">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Due from broker</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,885</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,187</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finished goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,230</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-333">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Recoverable VAT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,218</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72,353</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">55,797</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">299,360</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">367,994</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 5 -&#160;<span style="text-decoration:underline">PROPERTY AND EQUIPMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">At December 31, 2024
and 2023, property and equipment consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Useful Life</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center">5 Years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-334">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">100,548</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Office equipment and furniture</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">3 - 10 Years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,499</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,797</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,499</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,345</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(41,587</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(117,262</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,912</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">38,083</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For the years ended December
31, 2024 and 2023, depreciation expense of property and equipment amounted to $9,234 and $43,037, respectively, of which, $8,623 and $7,221
was included in real property operating expenses, $611 and $417 was included in other operating expenses, and $0 and $35,399 was included
in research and development expense, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment Held For Sale<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract', window );"><strong>Equipment Held For Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock', window );">EQUIPMENT HELD FOR SALE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>NOTE
6 - <span style="text-decoration:underline">EQUIPMENT HELD FOR SALE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company measures
long-lived assets to be disposed of by sale at the lower of carrying amount or fair value, less associated costs to sell these assets.
The assets held for sale is no longer subject to depreciation as they are not used in operations. As of December 31, 2024, the Company
committed to a plan to sell certain laboratory equipment that was used to research and development as equipment held for sale, which was
included in &#8220;Other non-current assets&#8221; on the accompanying consolidated balance sheets. The Company evaluated equipment for
impairment at December 31, 2024. The Company compared the estimated fair value of the equipment to its carrying value with impairment
indicators and recorded an impairment charge for the excess of carrying value over fair value. For the year ended December 31, 2024, the
Company incurred an impairment charge in operations of $111,033 on laboratory equipment. Although the Company is actively seeking and
negotiating with potential buyers, the Company can give no assurances that the sale process will be successful and, if it were successful,
there are no assurances as to the amount or timing of any potential proceeds.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Real Estate<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstateInvestmentsAbstract', window );"><strong>Investment in Real Estate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstateDisclosureTextBlock', window );">INVESTMENT IN REAL ESTATE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>NOTE
7 - <span style="text-decoration:underline">INVESTMENT IN REAL ESTATE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">At December 31, 2024
and 2023, investment in real estate consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Useful Life</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Commercial real property building</td><td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: center">39 Years</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,708,571</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,708,571</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Improvement</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">12 Years</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">529,372</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">529,372</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8,237,943</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8,237,943</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,215,222</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,046,539</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,022,721</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,191,404</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For both the years ended
December 31, 2024 and 2023, depreciation expense of this commercial real property amounted to $168,683, which was included in real property
operating expenses.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstateDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for certain real estate investment financial statements, real estate investment trust operating support agreements, real estate owned, retail land sales, time share transactions, as well as other real estate related disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 974<br> -SubTopic 720<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477728/974-720-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 976<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/976/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 978<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/978/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 970<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/970/tableOfContent<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 972<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/972/tableOfContent<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 974<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/974/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstateDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstateInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstateInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">EQUITY METHOD INVESTMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">NOTE 5 - <span style="text-decoration:underline">EQUITY METHOD INVESTMENT</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On February 9, 2023, the Company entered into
and closed an Amended and Restated Membership Interest Purchase Agreement (the &#8220;Amended MIPA&#8221;), by and among Avalon Lab,
SCBC Holdings LLC (the &#8220;Seller&#8221;), the Zoe Family Trust, Bryan Cox and Sarah Cox as individuals (each an &#8220;Owner&#8221;
and collectively, the &#8220;Owners&#8221;), and Lab Services MSO. <b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Pursuant to the terms and conditions set forth
in the Amended MIPA, Avalon Lab acquired from the Seller, 40% of the issued and outstanding equity interests of Lab Services MSO (the
&#8220;Purchased Interests&#8221;). The consideration paid by Avalon Lab to Seller for the Purchased Interests consisted of $20,666,667,
which was comprised of (i) $9,000,000 in cash, (ii) $11,000,000 pursuant to the issuance of 11,000 shares of the Company&#8217;s Series
B Preferred Stock, stated value $1,000 (the &#8220;Series B Stated Value&#8221;), which approximated the fair value, and (iii) a $666,667
cash payment on February 9, 2024. The Series B Preferred Stock was convertible into shares of the Company&#8217;s common stock at a conversion
price per share equal to $56.70, which approximated the market price at the date of closing, or an aggregate of 194,004 shares of the
Company&#8217;s common stock, which were subject to a lock-up period and restrictions on sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the first quarter of 2025, to preserve
cash, the Company entered into discussions with Lab Services MSO for the potential redemption of the Company&#8217;s investment and on
February 26, 2025, the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement, whereby Lab Services MSO redeemed
the 40% equity interest in Lab Services MSO held by the Company (See Note 3 - Receivable from Sale of Equity Method Investment).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Lab Services MSO, through its subsidiaries, was
engaged in providing laboratory testing services. During the period from February 9, 2023 (date of investment) through February 26, 2025
(date of sale), Avalon Lab and an unrelated company, had an ownership interest in Lab Services MSO of 40% and 60%, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In accordance with ASC 810, the Company determined
that Lab Services MSO did not qualify as a variable interest entity, nor did it have a controlling financial interest over the legal
entity. However, the Company determined that it does have significant influence as a result of its board representation. Therefore, the
Company treats the equity investment in the condensed consolidated financial statements under the equity method. Under the equity method,
the investment is initially recorded at cost, adjusted for any excess of the Company&#8217;s share of the purchased-date fair values
of the investee&#8217;s identifiable net assets over the cost of the investment (if any). At February 9, 2023 (date of investment), the
excess of the Company&#8217;s share of the fair values of the investee&#8217;s identifiable net assets over the cost of the investment
was approximately $19,460,000 which was attributable to intangible assets and goodwill. Thereafter, the investment was adjusted for the
post purchase change in the Company&#8217;s share of the investee&#8217;s net assets and any impairment loss relating to the investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Intangible assets consisted of the valuation of
identifiable intangible assets acquired, representing trade names and customers relationships, which were being amortized on a straight-line
method over the estimated useful life of 15 years. The straight-line method of amortization represents the Company&#8217;s best estimate
of the distribution of the economic value of the identifiable intangible assets. For the period from January 1, 2025 through February
26, 2025 (date of sale) and for the three months ended March 31, 2024, amortization expense of these intangible assets amounted to $111,156
and $166,733, respectively, which was included in income from equity method investment - Lab Services MSO in the accompanying condensed
consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Goodwill represents the excess of the purchase
price paid over the fair value of net assets acquired in the business acquisition of Lab Services MSO incurred on February 9, 2023. Goodwill
is not amortized but is tested for impairment at least once annually, or more frequently if events or changes in circumstances indicate
that the asset might be impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For the period from January 1, 2025 through February
26, 2025 (date of sale) and for the three months ended March 31, 2024, the Company&#8217;s share of Lab Services MSO&#8217;s net income
was $503,833 and $274,202, respectively, which was included in income from equity method investment - Lab Services MSO in the accompanying
condensed consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company classifies distributions received
from its investment on Lab Services MSO using the cumulative earnings approach. Distributions received are considered returns on the
investment and classified as cash inflows from operating activities. For the period from January 1, 2025 through February 26, 2025 (date
of sale) and for the three months ended March 31, 2024, distribution of earnings from the Company&#8217;s investment on Lab Services
MSO amounted to $0 and $160,788, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In the three months ended March 31, 2025, activity
recorded for the Company&#8217;s equity method investment in Lab Services MSO is summarized in the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Equity investment carrying amount at January 1, 2025</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">10,636,544</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Lab Services MSO&#8217;s net income attributable to the Company</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">503,833</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Intangible assets amortization amount</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(111,156</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Sale of equity investment</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(11,029,221</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Equity investment carrying amount at March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-385"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of December 31, 2024, the Company&#8217;s carrying
value of the identified intangible assets and goodwill which are included in the equity investment carrying amount was $8,725,712 and
$0, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The tables below present the summarized financial
information, as provided to the Company by the investee, for the unconsolidated company:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">For the Period<br/> from January
    1,<br/> 2025 through<br/> February 26,<br/> 2025 <br/> (Date of Sale)</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">For the Three<br/> Months Ended <br/>
    March 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net revenue</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4,241,732</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,376,372</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Gross profit</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,155,760</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,003,789</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Income from operation</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,513,000</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">275,026</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net income</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,259,582</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">685,504</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 8 -&#160;<span style="text-decoration:underline">EQUITY
METHOD INVESTMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Investment in&#160;Epicon
Biotech Co., Ltd.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As of December 31, 2023,
the equity method investment in Epicon Biotech Co., Ltd. (&#8220;Epicon&#8221;) amounted to $0. The investment represents the Company&#8217;s
subsidiary, Avalon Shanghai&#8217;s interest in Epicon. Epicon was incorporated on August 14, 2018 in PRC. Avalon Shanghai and an unrelated
company, Jiangsu Unicorn Biological Technology Co., Ltd. (&#8220;Unicorn&#8221;), have an ownership interest in Epicon of 40% and 60%,
respectively. Epicon is focused on cell preparation, third party testing, biological sample repository for commercial and scientific research
purposes and clinical transformation of scientific achievements. The Company is not involved in the management of Epicon. Therefore, it
is a passive investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In June 2023, the Company
assessed its equity method investment in Epicon for any impairment and concluded that there were indicators of impairment as of June 30,
2023. The impairment is due to the Company&#8217;s conclusion that it will be unable to recover the carrying amount of the investment
due to the investee&#8217;s series of operating losses and the inability of Avalon Shanghai&#8217;s joint venture partner (Unicorn) to
obtain adequate funding to commence operations. The Company calculated that the estimated undiscounted cash flows were less than the carrying
amount related to the equity method investment. The Company has recognized an impairment loss of $454,679 related to the equity method
investment for the year ended December 31, 2023, which reduced the investment value to zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Under the equity method,
if there is a commitment for the Company to fund the losses of its equity method investees, the Company would continue to record its share
of losses resulting in a negative equity method investment, which would be presented as a liability on the consolidated balance sheets.
Commitments may be explicit and may include formal guarantees, legal obligations, or arrangements by contract. Implicit commitments may
arise from reputational expectations, intercompany relationships, statements by the Company of its intention to provide support, a history
of providing financial support or other facts and circumstances. When the Company has no commitment to fund the losses of its equity method
investees, the carrying value of its equity method investments will not be reduced below zero. The Company has no commitment to fund additional
losses of its equity method investments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Investment in Laboratory
Services MSO, LLC</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On February 9, 2023 (the
&#8220;Closing Date&#8221;), the Company entered into and closed an Amended and Restated Membership Interest Purchase Agreement (the &#8220;Amended
MIPA&#8221;), by and among Avalon Lab, SCBC Holdings LLC (the &#8220;Seller&#8221;), the Zoe Family Trust, Bryan Cox and Sarah Cox as
individuals (each an &#8220;Owner&#8221; and collectively, the &#8220;Owners&#8221;), and Lab Services MSO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the terms
and conditions set forth in the Amended MIPA, Avalon Lab acquired from the Seller,&#160;40% of the issued and outstanding equity interests
of Lab Services MSO (the &#8220;Purchased Interests&#8221;). The consideration paid by Avalon Lab to Seller for the Purchased Interests
consisted of $20,666,667, which was comprised of (i) $9,000,000&#160;in cash, (ii) $11,000,000&#160;pursuant to the issuance of&#160;11,000&#160;shares
of the Company&#8217;s Series B Convertible Preferred Stock (the &#8220;Series B Preferred Stock&#8221;), stated value $1,000&#160;(the
&#8220;Series B Stated Value&#8221;), which approximated the fair value, and (iii) a $666,667&#160;cash payment on February 9, 2024. The
Series B Preferred Stock is convertible into shares of the Company&#8217;s common stock at a conversion price per share equal to $56.70,
which approximated the market price at the date of closing, or an aggregate of&#160;194,004&#160;shares of the Company&#8217;s common
stock, which are subject to a lock-up period and restrictions on sale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Lab Services MSO, through
its subsidiaries, is engaged in providing laboratory testing services. Avalon Lab and an unrelated company, have an ownership interest
in Lab Services MSO of&#160;40% and&#160;60%, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In accordance with ASC
810, the Company determined that Lab Services MSO does not qualify as a variable interest entity, nor does it have a controlling financial
interest over the legal entity. However, the Company determined that it does have significant influence as a result of its board representation.
Therefore, the Company treats the equity investment in the consolidated financial statements under the equity method. Under the equity
method, the investment is initially recorded at cost, adjusted for any excess of the Company&#8217;s share of the purchased-date fair
values of the investee&#8217;s identifiable net assets over the cost of the investment (if any). At February 9, 2023 (date of investment),
the excess of the Company&#8217;s share of the fair values of the investee&#8217;s identifiable net assets over the cost of the investment
was approximately $19,460,000&#160;which was attributable to intangible assets and goodwill. Thereafter, the investment is adjusted for
the post purchase change in the Company&#8217;s share of the investee&#8217;s net assets and any impairment loss relating to the investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Intangible assets consist
of the valuation of identifiable intangible assets acquired, representing trade names and customers relationships, which are being amortized
on a straight-line method over the estimated useful life of&#160;15&#160;years. The straight-line method of amortization represents the
Company&#8217;s best estimate of the distribution of the economic value of the identifiable intangible assets. For the year ended December
31, 2024 and for the period from February 9, 2023 (date of investment) through December 31, 2023, amortization expense of these intangible
assets amounted to $666,932&#160;and $611,356, respectively, which was included in loss from equity method investment - Lab Services
MSO in the accompanying consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Goodwill represents the
excess of the purchase price paid over the fair value of net assets acquired in the business acquisition of Lab Services MSO incurred
on February 9, 2023. Goodwill is not amortized but is tested for impairment at least once annually, or more frequently if events or changes
in circumstances indicate that the asset might be impaired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In September 2024 and
December 2023, the Company assessed its equity method investment in Laboratory Services MSO, LLC for any impairment and concluded that
there were indicators of impairment as of September 30, 2024 and December 31, 2023, respectively. The Company calculated that the estimated
undiscounted cash flows of goodwill were less than the carrying amount of goodwill related to the equity method investment. The Company
has recognized impairment loss of $259,579 and $9,196,682&#160;related to the equity method investment for the year ended December 31,
2024 and for the period from February 9, 2023 (date of investment) through December 31, 2023, respectively, which was included in loss
from equity method investment - Lab Services MSO in the accompanying consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For the year ended December
31, 2024 and for the period from February 9, 2023 (date of investment) through December 31, 2023, the Company&#8217;s share of Lab Services
MSO&#8217;s net income was $79,923&#160;and $1,236,391, respectively, which was included in loss from equity method investment -
Lab Services MSO in the accompanying consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company classifies
distributions received from its investment on Lab Services MSO using the cumulative earnings approach. Distributions received are considered
returns on the investment and classified as cash inflows from operating activities. For the year ended December 31, 2024 and for the
period from February 9, 2023 (date of investment) through December 31, 2023, distribution of earnings from the Company&#8217;s investment
on Lab Services MSO amounted to $611,888 and $0, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In the years ended December
31, 2024 and 2023, activity recorded for the Company&#8217;s equity method investment in Lab Services MSO is summarized in the following
table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Equity investment carrying amount at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-335">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Payment for equity method investment:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">The Company&#8217;s interest in the fair value of Lab Services MSO&#8217;s net assets at February 9, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,206,406</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">The Company&#8217;s interest in the net excess of Lab Services MSO&#8217;s fair value over net assets which was attributable to identifiable intangible assets at February 9, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,004,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">The Company&#8217;s interest in the net excess of Lab Services MSO&#8217;s fair value over net assets which was attributable to goodwill at February 9, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,456,261</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Total payment for equity method investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,666,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Lab Services MSO&#8217;s net income attributable to the Company</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,236,391</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Intangible assets amortization amount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(611,356</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Impairment of goodwill</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,196,682</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Equity investment carrying amount at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,095,020</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Lab Services MSO&#8217;s net income attributable to the Company</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,923</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Intangible assets amortization amount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(666,932</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Distribution of earnings from equity investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(611,888</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Impairment of goodwill</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(259,579</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Equity investment carrying amount at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,636,544</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024, the Company&#8217;s carrying
value of the identified intangible assets and goodwill which are included in the equity investment carrying amount was $8,725,712&#160;and
$0, respectively. As of December 31, 2023, the Company&#8217;s carrying value of the identified intangible assets and goodwill which are
included in the equity investment carrying amount was $9,392,644&#160;and $259,579, respectively.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tables below present the summarized financial
information, as provided to the Company by the investee, for the unconsolidated company:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,917,880</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,930,254</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Noncurrent assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,509,185</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,228,044</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">611,391</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">828,713</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Noncurrent liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,346,725</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,104,183</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,468,949</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,225,402</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">For the year Ended December 31, 2024</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">For the Period from<br/>
February 9,<br/>
 2023 (Date of Investment) through December 31, 2023</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,558,711</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,699,683</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,534,503</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,744,277</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">(Loss) income from operation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(265,754</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,393,830</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199,808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,090,977</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2025, to preserve cash, the Company entered
into discussions with Lab Services MSO for the potential redemption of our investment and on February 26, 2025, the Company and Lab Services
MSO entered into a Redemption and Abandonment Agreement (the &#8220;Redemption Agreement&#8221;), whereby Lab Services MSO redeemed the
40% equity interest in Lab Services MSO held by the Company. See Note 22 - Subsequent Events - Redemption Agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478156/740-323-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 323<br> -Publisher FASB<br> -URI https://asc.fasb.org/323/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities and Other Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Liabilities and Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED LIABILITIES AND OTHER PAYABLES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9 -&#160;<span style="text-decoration:underline">ACCRUED LIABILITIES
AND OTHER PAYABLES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">At December 31, 2024
and 2023, accrued liabilities and other payables consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>
2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,<br/>
 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued tenants&#8217; improvement reimbursement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">43,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">43,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tenants&#8217; security deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,233</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,233</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued business expense reimbursement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,781</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,061</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued utilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,075</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,166</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred rental income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,346</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,429</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued real property cleaning service fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,570</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,027</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">177,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,794</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,258</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,135</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">434,117</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">272,915</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Note Payable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Note Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">CONVERTIBLE NOTE PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">NOTE 6 - <span style="text-decoration:underline">CONVERTIBLE NOTE PAYABLE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">June 2024 Convertible Note</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 5, 2024, the Company entered into securities
purchase agreements with Mast Hill Fund L.P. (&#8220;Mast Hill&#8221;) for the issuance of 13.0% senior secured promissory notes in the
aggregate principal amount of $2,845,000 (collectively, the &#8220;June 2024 Convertible Note&#8221;) convertible into shares of the
Company&#8217;s common stock, as well as the issuance of 26,800 shares of common stock as a commitment fee and warrants for the purchase
of 146,667 shares of common stock of the Company. The Company and its subsidiaries have also entered into a security agreement, creating
a security interest in certain property of the Company and its subsidiaries to secure the prompt payment, performance and discharge in
full of all of the Company&#8217;s obligations under the June 2024 Convertible Note. Principal amount and interest under the June 2024
Convertible Note are convertible into shares of common stock of the Company at a conversion price of $11.25 per share unless the Company
fails to make an amortization payment when due, in which case the conversion price shall be the lesser of $11.25 or the market price
(as defined in the June 2024 Convertible Note).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Mast Hill acquired the June 2024 Convertible Note
with principal amount of $2,845,000 and paid the purchase price of $2,702,750 after an original issue discount of $142,250. On June 5,
2024, the Company issued (i) a warrant to purchase 66,667 shares of common stock with an exercise price of $9.75 exercisable until June
5, 2029 (&#8220;First Warrant&#8221;), (ii) a warrant to purchase 80,000 shares of common stock with an exercise price of $7.50 exercisable
until June 5, 2029 (&#8220;Second Warrant&#8221;), and (iii) 26,800 shares of common stock as a commitment fee for the purchase of the
June 2024 Convertible Note, which were earned in full as of June 5, 2024. The Second Warrant is not fair valued and shall be cancelled
and extinguished against payment of the June 2024 Convertible Note. On June 5, 2024, the Company delivered such duly executed June 2024
Convertible Note, warrants and common stock to Mast Hill against delivery of the purchase price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company received net cash amount of $881,210
from the June 2024 Convertible Note financing after using the proceeds to pay off all previously issued convertible notes of $1,661,540,
and to pay finder&#8217;s fee of $120,000 and lender&#8217;s costs of $40,000 related to this financing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company is obligated to make amortization
payments in cash to Mast Hill toward the repayment of the June 2024 Convertible Note, as provided in the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: black 1.5pt solid; width: 49%"><span style="-sec-ix-redline:true;font-size: 10pt"><b>Payment Date</b></span></td> <td style="white-space: nowrap; padding-bottom: 1.5pt; width: 2%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="white-space: nowrap; border-bottom: black 1.5pt solid; width: 49%"><span style="-sec-ix-redline:true;font-size: 10pt"><b>Payment Amount</b></span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">December 5, 2024</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">$284,500 plus accrued interest through December 5, 2024</span></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">January 5, 2025</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">$284,500 plus accrued interest through January 5, 2025</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">February 5, 2025</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">$379,336 plus accrued interest through February 5, 2025</span></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">March 5, 2025</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">$474,167 plus accrued interest through March 5, 2025</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">April 5, 2025</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">$474,167 plus accrued interest through April 5, 2025</span></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">May 5, 2025</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">$569,000 plus accrued interest through May 5, 2025</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">June 5, 2025</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">The entire remaining outstanding balance of the June 2024 Convertible Note</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In connection with the issuance of the June 2024
Convertible Note, the Company incurred debt issuance costs of $224,221 (including the issuance of 5,333 warrants as a finder&#8217;s
fee) which is capitalized and will be amortized into interest expense over the term of the June 2024 Convertible Note.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Based upon the Company&#8217;s analysis of the
criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a finder&#8217;s
fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances. Management
determined the probability of failing to make an amortization payment when due to be remote and as such the fair value of the 80,000
warrants with an exercise price of $7.50 exercisable until June 5, 2029, which warrant shall be cancelled and extinguished against payment
of the June 2024 Convertible Note, has been estimated to be zero. Accordingly, the fair value of the 72,000 warrants with an exercise
price of $9.75 exercisable until June 5, 2029 was classified as derivative liability on June 5, 2024. The fair values of the 72,000 warrants
with an exercise price of $9.75 exercisable until June 5, 2029 issued on June 5, 2024 were computed using the Black-Scholes option-pricing
model with the following assumptions: stock price of $10.39, volatility of 85.72%, risk-free rate of 4.31%, annual dividend yield of
0% and expected life of 5 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In accordance with ASC 470-20-25-2, proceeds from
the sale of a debt instrument with stock purchase warrants are allocated to the two elements based on the relative fair values of the
debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds allocated to the
warrants are accounted for as derivative liability. The remainder of the proceeds are allocated to the debt instrument portion of the
transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In accordance with ASC 480-10-25-14, the Company
determined that the conversion provisions contain an embedded derivative feature and the Company valued the derivative feature separately,
recording debt discount and derivative liability in accordance with the provisions of the convertible debt (see Note 7). However, management
determined the probability of failing to make an amortization payment when due to be remote and as such the fair value of the embedded
conversion feature has been estimated to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company recorded a total debt discount of
$838,990 related to the original issue discount, common shares issued and warrants issued to Mast Hill, which will be amortized over
the term of the June 2024 Convertible Note.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On December 15, 2024, the Company and Mast Hill
entered into that certain consent, acknowledgement, and waiver agreement, pursuant to which Mast Hill waived all amortization payments
required to be made under the June 2024 Convertible Note, the Company paid a waiver fee of $150,000 to Mast Hill, and the Company issued
to Mast Hill a common stock purchase warrant for the purchase of up to 150,000 shares of the Company&#8217;s common stock (&#8220;Pre-Funded
Warrants&#8221;). The Pre-Funded Warrants are immediately exercisable at issuance and until the Pre-Funded Warrants are exercised in
full and have an exercise price of $0.01 per share. The Pre-Funded Warrants were classified as a component of permanent equity on the
accompanying consolidated balance sheets as they are freestanding financial instruments that are immediately exercisable, do not embody
an obligation for the Company to repurchase its own shares and permit the holder to receive a fixed number of shares of common stock
upon exercise. All of the shares underlying the Pre-Funded Warrants have been included in the weighted-average number of shares of common
stock used to calculate net loss per share, basic and diluted, attributable to the Company&#8217;s common stockholders because the shares
may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the Pre-Funded
Warrants. Based on the Company&#8217;s assess, this arrangement was accounted for as a modification of debt and, as such, $838,794 related
to the waiver fee and Pre-Fund Warrants issued to Mast Hill were expensed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The convertible note payable as of March 31, 2025
and December 31, 2024 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">March 31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">December 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Principal amount</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,556,777</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,556,777</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Less: unamortized debt issuance costs</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(33,584</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(93,425</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Less: unamortized debt discount</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(125,665</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(349,579</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Convertible note payable, net</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,397,528</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,113,773</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For the three months ended March 31, 2025 and
2024, amortization of debt discount and debt issuance costs related to convertible note payable amounted to $283,755 and $242,389, respectively,
which have been included in interest expense - amortization of debt discount and debt issuance costs on the accompanying condensed consolidated
statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For the three months ended March 31, 2025 and
2024, interest expense related to convertible note payable amounted to $81,956 and $71,715, respectively, which have been included in
interest expense - other on the accompanying condensed consolidated statements of operations and comprehensive loss.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 10 - <span style="text-decoration:underline">CONVERTIBLE NOTE PAYABLE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>May 2023 Convertible
Note</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On May 23, 2023, the
Company entered into securities purchase agreements with Mast Hill Fund, L.P. (&#8220;Mast Hill&#8221;) for the issuance of&#160;13.0%
senior secured promissory notes in the aggregate principal amount of $1,500,000&#160;(collectively, the &#8220;May 2023 Convertible Note&#8221;)
convertible into shares of the Company&#8217;s common stock, as well as the issuance of&#160;5,000&#160;shares of common stock as a commitment
fee and warrants for the purchase of&#160;15,366&#160;shares of common stock of the Company. The Company and its subsidiaries also entered
into a security agreement, creating a security interest in certain property of the Company and its subsidiaries to secure the prompt payment,
performance and discharge in full of all of the Company&#8217;s obligations under the May 2023 Convertible Note. Principal amount and
interest under the May 2023 Convertible Note were convertible into shares of common stock of the Company at a conversion price of $67.50&#160;per
share unless the Company failed to make an amortization payment when due, in which case the conversion price would be the lower of $67.50&#160;or
the trading price of the shares, subject to a floor of $22.50.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Mast Hill acquired the
May 2023 Convertible Note with principal amount of $1,500,000&#160;and paid the purchase price of $1,425,000&#160;after an original issue
discount of $75,000. On May 23, 2023, the Company issued (i) a warrant to purchase&#160;8,333&#160;shares of common stock with an exercise
price of $67.50&#160;exercisable until the five-year anniversary of May 23, 2023 (&#8220;First Warrant&#8221;), (ii) a warrant to purchase&#160;7,033&#160;shares
of common stock with an exercise price of $48.00&#160;exercisable until the five-year anniversary of May 23, 2023 (&#8220;Second Warrant&#8221;).The
Second Warrant was never fair valued and was cancelled and extinguished against payment of the May 2023 Convertible Note, and (iii)&#160;5,000&#160;shares
of common stock as a commitment fee for the purchase of the May 2023 Convertible Note, which were earned in full as of May 23, 2023. On
May 23, 2023, the Company delivered such duly executed May 2023 Convertible Note, warrants and common stock to Mast Hill against delivery
of such purchase price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company was obligated
to make amortization payments in cash to Mast Hill toward the repayment of the May 2023 Convertible Note, as described in the May 2023
Convertible Note. As of December 31, 2024, the May 2023 Convertible Note was repaid in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
issuance of the May 2023 Convertible Note, the Company incurred debt issuance costs of $175,162&#160;(including the issuance of&#160;667&#160;warrants
as a finder&#8217;s fee) which was capitalized and was amortized into interest expense over the term of the May 2023 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Based upon the Company&#8217;s
analysis of the criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a
finder&#8217;s fee met the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances.
Accordingly, the fair value of the&#160;9,000&#160;warrants with an exercise price of $67.50&#160;exercisable until the five-year anniversary
of May 23, 2023 was classified as derivative liability on May 23, 2023. The fair values of the&#160;9,000&#160;warrants with an exercise
price of $67.50&#160;exercisable until the five-year anniversary of May 23, 2023 issued on May 23, 2023 were computed using the Black-Scholes
option-pricing model with the following assumptions: stock price of $29.40, volatility of&#160;88.80%, risk-free rate of&#160;3.76%, annual
dividend yield of&#160;0% and expected life of&#160;5&#160;years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 470-20-25-2, proceeds from
the sale of a debt instrument with stock purchase warrants are allocated to the two elements based on the&#160;relative fair values&#160;of
the debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds allocated to
the warrants are accounted for as derivative liability. The remainder of the proceeds are allocated to the debt instrument portion of
the transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company recorded
a total debt discount of $349,654&#160;related to the original issue discount, common shares issued and warrants issued to Mast Hill,
which was amortized over the term of the May 2023 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>July&#160;2023 Convertible
Note</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On July 6, 2023, the
Company entered into securities purchase agreements with FirstFire Global Opportunities Fund, LLC (&#8220;FirstFire&#8221;) for the issuance
of 13.0% senior secured promissory notes in the aggregate principal amount of $500,000 (collectively, the &#8220;July 2023 Convertible
Note&#8221;) convertible into shares of the Company&#8217;s common stock, as well as the issuance of 1,667 shares of common stock as a
commitment fee and warrants for the purchase of 5,122 shares of common stock of the Company. The Company and its subsidiaries also entered
into a security agreement, creating a security interest in certain property of the Company and its subsidiaries to secure the prompt payment,
performance and discharge in full of all of the Company&#8217;s obligations under the July 2023 Convertible Note. Principal amount and
interest under the July 2023 Convertible Note were convertible into shares of common stock of the Company at a conversion price of $67.50
per share unless the Company failed to make an amortization payment when due, in which case the conversion price would be the lower of
$67.50 or the trading price of the shares, subject to a floor of $22.50.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">FirstFire acquired the
July 2023 Convertible Note with principal amount of $500,000 and paid the purchase price of $475,000 after an original issue discount
of $25,000. On July 6, 2023, the Company issued (i) a warrant to purchase 2,778 shares of common stock with an exercise price of $67.50
exercisable until the five-year anniversary of July 6, 2023 (&#8220;First Warrant&#8221;), (ii) a warrant to purchase 2,344 shares of
common stock with an exercise price of $48.00 exercisable until the five-year anniversary of July 6, 2023 (&#8220;Second Warrant&#8221;).
The Second Warrant was never fair valued and was cancelled and extinguished against payment of the July 2023 Convertible Note, and (iii)
1,667 shares of common stock as a commitment fee for the purchase of the July 2023 Convertible Note, which were earned in full as of July
6, 2023. On July 6, 2023, the Company delivered such duly executed July 2023 Convertible Note, warrants and common stock to FirstFire
against delivery of such purchase price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company was obligated
to make amortization payments in cash to FirstFire toward the repayment of the July 2023 Convertible Note, as described in the July 2023
Convertible Note. As of December 31, 2024, the July 2023 Convertible Note was repaid in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
issuance of the July 2023 Convertible Note, the Company incurred debt issuance costs of $74,204&#160;(including the issuance of&#160;222&#160;warrants
as a finder&#8217;s fee), which was capitalized and was amortized into interest expense over the term of the July 2023 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Based upon the Company&#8217;s
analysis of the criteria contained in ASC 815, the Company determined that all the warrants issued to Firstfire and a third party as a
finder&#8217;s fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances.
Accordingly, the fair value of the&#160;3,000&#160;warrants with an exercise price of $67.50&#160;exercisable until the five-year anniversary
of July 6, 2023 was classified as a derivative liability on July 6, 2023. The fair values of the&#160;3,000&#160;warrants with an exercise
price of $67.50&#160;exercisable until the five-year anniversary of July 6, 2023 issued on July 6, 2023 were computed using the Black-Scholes
option-pricing model with the following assumptions: stock price of $21.30, volatility of&#160;88.52%, risk-free rate of&#160;4.37%, annual
dividend yield of&#160;0% and expected life of&#160;5&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">In accordance with
ASC 470-20-25-2, proceeds from the sale of a debt instrument with stock purchase warrants are allocated to the two elements based on
the relative fair values of the debt instrument without the warrants and of the warrants themselves at time of issuance. The portion
of the proceeds allocated to the warrants are accounted for as derivative liability. The remainder of the proceeds are allocated to the
debt instrument portion of the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded a total debt discount of
$89,191&#160;related to the original issue discount, common shares issued and warrants issued to Firstfire, which was amortized over the
term of the July 2023 Convertible Note.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>October&#160;2023
Convertible Note</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On October 9, 2023, the
Company entered into securities purchase agreements with Mast Hill and FirstFire for the issuance of 13.0% senior secured promissory notes
in the aggregate principal amount of $700,000 (collectively, the &#8220;October 2023 Convertible Note&#8221;) convertible into shares
of the Company&#8217;s common stock, as well as the issuance of 4,666 shares of common stock as a commitment fee and warrants for the
purchase of 12,834 shares of common stock of the Company. The Company and its subsidiaries also entered into that certain security agreements,
creating a security interest in certain property of the Company and its subsidiaries to secure the prompt payment, performance and discharge
in full of all of the Company&#8217;s obligations under the October 2023 Convertible Note. Principal amount and interest under the October
2023 Convertible Note were convertible into shares of common stock of the Company at a conversion price of $22.50 per share unless the
Company failed to make an amortization payment when due, in which case the conversion price would be the lower of $22.50 or the market
price (as defined in the October 2023 Convertible Note) of the shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Mast Hill acquired the
October 2023 Convertible Note with principal amount of $350,000&#160;and paid the purchase price of $332,500&#160;after an original issue
discount of $17,500. On October 9, 2023, the Company issued (i) a warrant to purchase&#160;3,500&#160;shares of common stock with an exercise
price of $37.50&#160;exercisable until the five-year anniversary of October 9, 2023 (&#8220;First Warrant&#8221;), (ii) a warrant to purchase&#160;2,917&#160;shares
of common stock with an exercise price of $27.00&#160;exercisable until the five-year anniversary of October 9, 2023 (&#8220;Second Warrant&#8221;).
The Second Warrant was never fair valued and was cancelled and extinguished against payment of the October 2023 Convertible Note, and
(iii)&#160;2,333&#160;shares of common stock as a commitment fee for the purchase of the October 2023 Convertible Note, which were earned
in full as of October 9, 2023. On October 9, 2023, the Company delivered such duly executed October 2023 Convertible Note, warrants and
common stock to Mast Hill against delivery of such purchase price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company was obligated to make amortization
payments in cash to Mast Hill toward the repayment of the October 2023 Convertible Note, as described in the October 2023 Convertible
Note. As of December 31, 2024, the October 2023 Convertible Note was repaid in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">FirstFire&#160;acquired
the October 2023 Convertible Note with principal amount of $350,000&#160;and paid the purchase price of $332,500&#160;after an original
issue discount of $17,500. On October 9, 2023, the Company issued (i) a warrant to purchase&#160;3,500&#160;shares of common stock with
an exercise price of $37.50&#160;exercisable until the five-year anniversary of October 9, 2023 (&#8220;First Warrant&#8221;), (ii) a
warrant to purchase&#160;2,917&#160;shares of common stock with an exercise price of $27.00&#160;exercisable until the five-year anniversary
of October 9, 2023 (&#8220;Second Warrant&#8221;). The Second Warrant was never fair valued and was cancelled and extinguished against
payment of the October 2023 Convertible Note, and (iii)&#160;2,333&#160;shares of common stock as a commitment fee for the purchase of
the October 2023 Convertible Note, which were earned in full as of October 9, 2023. On October 9, 2023, the Company delivered such duly
executed October 2023 Convertible Note, warrants and common stock to FirstFire against delivery of such purchase price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company was obligated to make amortization
payments in cash to FirstFire toward the repayment of the October 2023 Convertible Note, as described in the October 2023 Convertible
Note. As of December 31, 2024, the October 2023 Convertible Note was repaid in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the issuance of the October
2023 Convertible Note, the Company incurred debt issuance costs of $95,349&#160;(including the issuance of&#160;560&#160;warrants as a
finder&#8217;s fee), which was capitalized and was amortized into interest expense over the term of the October 2023 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon the Company&#8217;s analysis of the
criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and Firstfire and a third party as a finder&#8217;s
fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances. Accordingly,
the fair value of the&#160;7,560&#160;warrants with an exercise price of $37.50&#160;exercisable until the five-year anniversary of October
9, 2023 was classified as a derivative liability on October 9, 2023. The fair values of the&#160;7,560&#160;warrants with an exercise
price of $37.50&#160;exercisable until the five-year anniversary of October 9, 2023 issued on October 9, 2023 were computed using the
Black-Scholes option-pricing model with the following assumptions: stock price of $11.55, volatility of&#160;89.70%, risk-free rate of&#160;4.75%,
annual dividend yield of&#160;0% and expected life of&#160;5&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In accordance with ASC 470-20-25-2, proceeds
from the sale of a debt instrument with stock purchase warrants are allocated to the two elements based on the relative fair values of
the debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds allocated to
the warrants are accounted for as derivative liability. The remainder of the proceeds are allocated to the debt instrument portion of
the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded a total debt discount of
$128,748&#160;related to the original issue discount, common shares issued and warrants issued to Mast Hill and Firstfire, which was amortized
over the term of the October 2023 Convertible Note.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>March 2024 Convertible
Note</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On March 7, 2024, the
Company entered into securities purchase agreements with Mast Hill for the issuance of&#160;13.0% senior secured promissory notes in the
aggregate principal amount of $700,000&#160;(collectively, the &#8220;March 2024 Convertible Note&#8221;) convertible into shares of the
Company&#8217;s common stock, as well as the issuance of&#160;7,000&#160;shares of common stock as a commitment fee and warrants for the
purchase of&#160;16,827&#160;shares of common stock of the Company. The Company and its subsidiaries also entered into a security agreement,
creating a security interest in certain property of the Company and its subsidiaries to secure the prompt payment, performance and discharge
in full of all of the Company&#8217;s obligations under the March 2024 Convertible Note. Principal amount and interest under the March
2024 Convertible Note were convertible into shares of common stock of the Company at a conversion price of $15.00&#160;per share unless
the Company failed to make an amortization payment when due, in which case the conversion price would be the lower of $15.00&#160;or the
market price (as defined in the March 2024 Convertible Note) of the shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Mast Hill acquired the
March 2024 Convertible Note with principal amount of $700,000&#160;and paid the purchase price of $665,000&#160;after an original issue
discount of $35,000. On March 7, 2024, the Company issued (i) a warrant to purchase&#160;8,750&#160;shares of common stock with an exercise
price of $30.00&#160;exercisable until the five-year anniversary of March 7, 2024 (&#8220;First Warrant&#8221;), (ii) a warrant to purchase&#160;8,077&#160;shares
of common stock with an exercise price of $19.50&#160;exercisable until the five-year anniversary of March 7, 2024 (&#8220;Second Warrant&#8221;).
The Second Warrant was never fair valued and was cancelled and extinguished against payment of the March 2024 Convertible Note, and (iii)&#160;7,000&#160;shares
of common stock as a commitment fee for the purchase of the March 2024 Convertible Note, which were earned in full as of March 7, 2024.
On March 7, 2024, the Company delivered such duly executed March 2024 Convertible Note, warrants and common stock to Mast Hill against
delivery of such purchase price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company was obligated to make amortization
payments in cash to Mast Hill toward the repayment of the March 2024 Convertible Note, as described in the March 2024 Convertible Note.
As of December 31, 2024, the March 2024 Convertible Note was repaid in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the issuance of the March 2024
Convertible Note, the Company incurred debt issuance costs of $74,379&#160;(including the issuance of&#160;700&#160;warrants as a finder&#8217;s
fee) which was capitalized and was amortized into interest expense over the term of the March 2024 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon the Company&#8217;s analysis of the
criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a finder&#8217;s
fee met the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances. Accordingly,
the fair value of the&#160;9,450&#160;warrants with an exercise price of $30.00&#160;exercisable until the five-year anniversary of March
7, 2024 was classified as derivative liability on March 7, 2024. The fair values of the&#160;9,450&#160;warrants with an exercise price
of $30.00&#160;exercisable until the five-year anniversary of March 7, 2024 issued on March 7, 2024 were computed using the Black-Scholes
option-pricing model with the following assumptions: stock price of $6.00, volatility of&#160;85.24%, risk-free rate of&#160;4.07%, annual
dividend yield of&#160;0% and expected life of&#160;5&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 470-20-25-2, proceeds from
the sale of a debt instrument with stock purchase warrants are allocated to the two elements based on the relative fair values of the
debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds allocated to the
warrants are accounted for as derivative liability. The remainder of the proceeds are allocated to the debt instrument portion of the
transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded a total debt discount of
$97,374&#160;related to the original issue discount, common shares issued and warrants issued to Mast Hill, which was amortized over the
term of the March 2024 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>June 2024 Convertible
Note</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On June 5, 2024, the
Company entered into securities purchase agreements with Mast Hill for the issuance of&#160;13.0% senior secured promissory notes in the
aggregate principal amount of $2,845,000&#160;(collectively, the &#8220;June 2024 Convertible Note&#8221;) convertible into shares of
the Company&#8217;s common stock, as well as the issuance of&#160;26,800&#160;shares of common stock as a commitment fee and warrants
for the purchase of&#160;146,667&#160;shares of common stock of the Company. The Company and its subsidiaries have also entered into a
security agreement, creating a security interest in certain property of the Company and its subsidiaries to secure the prompt payment,
performance and discharge in full of all of the Company&#8217;s obligations under the June 2024 Convertible Note. Principal amount and
interest under the June 2024 Convertible Note are convertible into shares of common stock of the Company at a conversion price of $11.25&#160;per
share unless the Company fails to make an amortization payment when due, in which case the conversion price shall be the lesser of $11.25&#160;or
the market price (as defined in the June 2024 Convertible Note).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Mast Hill acquired the
June 2024 Convertible Note with principal amount of $2,845,000&#160;and paid the purchase price of $2,702,750&#160;after an original issue
discount of $142,250. On June 5, 2024, the Company issued (i) a warrant to purchase&#160;66,667&#160;shares of common stock with an exercise
price of $9.75&#160;exercisable until the five-year anniversary of June 5, 2024 (&#8220;First Warrant&#8221;), (ii) a warrant to purchase&#160;80,000&#160;shares
of common stock with an exercise price of $7.50&#160;exercisable until the five-year anniversary of June 5, 2024 (&#8220;Second Warrant&#8221;).
The Second Warrant will not be fair valued and shall be cancelled and extinguished against payment of the June 2024 Convertible Note,
and (iii)&#160;26,800&#160;shares of common stock as a commitment fee for the purchase of the June 2024 Convertible Note, which were earned
in full as of June 5, 2024. On June 5, 2024, the Company delivered such duly executed June 2024 Convertible Note, warrants and common
stock to Mast Hill against delivery of such purchase price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company received
net cash amount of $881,210&#160;from the June 2024 Convertible Note financing after using the proceeds to pay off all previously issued
convertible notes to Mast Hill of $1,206,867&#160;and FirstFire of $454,673, respectively, and to pay finder&#8217;s fee of $120,000&#160;and
lender&#8217;s costs of $40,000&#160;related to this financing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company is obligated
to make amortization payments in cash to Mast Hill toward the repayment of the June 2024 Convertible Note, as provided in the following
table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 30%">Payment Date:</td> <td style="padding-bottom: 1.5pt; white-space: nowrap; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 68%">Payment Amount:</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap">December 5, 2024</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap">$284,500 plus accrued interest through December 5, 2024</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap">January 5, 2025</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap">$284,500 plus accrued interest through January 5, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap">February 5, 2025</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap">$379,336 plus accrued interest through February 5, 2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap">March 5, 2025</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap">$474,167 plus accrued interest through March 5, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap">April 5, 2025</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap">$474,167 plus accrued interest through April 5, 2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap">May 5, 2025</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap">$569,000 plus accrued interest through May 5, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap">June 5, 2025</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap">The entire remaining outstanding balance of the June 2024 Convertible Note</td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
issuance of the June 2024 Convertible Note, the Company incurred debt issuance costs of $224,221&#160;(including the issuance of&#160;5,333&#160;warrants
as a finder&#8217;s fee) which is capitalized and will be amortized into interest expense over the term of the June 2024 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Based upon the Company&#8217;s
analysis of the criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a
finder&#8217;s fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances.
Management determined the probability of failing to make an amortization payment when due to be remote and as such the fair value of the&#160;80,000&#160;warrants
with an exercise price of $7.50&#160;exercisable until the five-year anniversary of June 5, 2024, which warrant shall be cancelled and
extinguished against payment of the June 2024 Convertible Note, has been estimated to be zero. Accordingly, the fair value of the&#160;72,000&#160;warrants
with an exercise price of $9.75&#160;exercisable until the five-year anniversary of June 5, 2024 was classified as derivative liability
on June 5, 2024. The fair values of the&#160;72,000&#160;warrants with an exercise price of $9.75&#160;exercisable until the five-year
anniversary of June&#160;5, 2024 issued on June 5, 2024 were computed using the Black-Scholes option-pricing model with the following
assumptions: stock price of $10.39, volatility of&#160;85.72%, risk-free rate of&#160;4.31%, annual dividend yield of&#160;0% and expected
life of 5 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In accordance with ASC
470-20-25-2, proceeds from the sale of a debt instrument with stock purchase warrants are allocated to the two elements based on the relative
fair values of the debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds
allocated to the warrants are accounted for as derivative liability. The remainder of the proceeds are allocated to the debt instrument
portion of the transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In accordance with ASC
480-10-25-14, the Company determined that the conversion provisions contain an embedded derivative feature and the Company valued the
derivative feature separately, recording debt discount and derivative liability in accordance with the provisions of the convertible debt
(see Note 11). However, management determined the probability of failing to make an amortization payment when due to be remote and as
such the fair value of the embedded conversion feature has been estimated to be zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company recorded
a total debt discount of $838,990&#160;related to the original issue discount, common shares issued and warrants issued to Mast Hill,
which will be amortized over the term of the June 2024 Convertible Note.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On December 15, 2024,
the Company and Mast Hill entered into that certain consent, acknowledgement, and waiver agreement (&#8220;Agreement&#8221;), pursuant
to which Mast Hill waived all amortization payments required to be made under the June 2024 Convertible Note, the Company paid a waiver
fee of $150,000 to Mast Hill, and the Company issued to Mast Hill a common stock purchase warrant for the purchase of up to 150,000 shares
of the Company&#8217;s common stock (&#8220;Pre-Funded Warrants&#8221;). The Pre-Funded Warrants are immediately exercisable at issuance
and until the Pre-Funded Warrants are exercised in full and have an exercise price of $0.01 per share. The Pre-Funded Warrants were classified
as a component of permanent equity on the accompanying consolidated balance sheets as they are freestanding financial instrument that
is immediately exercisable, does not embody an obligation for the Company to repurchase its own shares and permit the holder to receive
a fixed number of shares of common stock upon exercise. All of the shares underlying the Pre-Funded Warrants have been included in the
weighted-average number of shares of common stock used to calculate net loss per share, basic and diluted, attributable to the Company&#8217;s
common stockholders because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original
issuance date of the Pre-Funded Warrants. Based on the Company&#8217;s assess, this arrangement was accounted for as a modification of
debt and, as such, $838,794 related to the waiver fee and Pre-Fund Warrants issued to Mast Hill were expensed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">The
convertible note payable as of December 31, 2024 and 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Principal amount</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,556,777</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,400,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: unamortized debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(93,425</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(183,840</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: unamortized debt discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(349,579</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(291,014</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Convertible note payable, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,113,773</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,925,146</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For the years ended December
31, 2024 and 2023, amortization of debt discount and debt issuance costs related to convertible note payable amounted to $1,291,814&#160;and
$437,453, respectively, which have been included in interest expense - amortization of debt discount and debt issuance costs on
the accompanying consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For the years ended December
31, 2024 and 2023, interest expense related to convertible note payable amounted to $325,486&#160;and $167,058, respectively, which have
been included in interest expense - other on the accompanying consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Derivative Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">DERIVATIVE LIABILITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">NOTE 7 - <span style="text-decoration:underline">DERIVATIVE LIABILITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As stated in Note 6, June 2024 Convertible Note,
the Company determined that the convertible note payable contains an embedded derivative feature in the form of a conversion provision
which is adjustable based on future prices of the Company&#8217;s common stock. In accordance with ASC 815-10-25, each derivative feature
is initially recorded at its fair value using the Black-Scholes option valuation method and then re-value at each reporting date, with
changes in the fair value reported in the statements of operations. However, on June 5, 2024 and March 31, 2025, management determined
the probability of failing to make an amortization payment and repayment, respectively, when due to be remote and as such the fair value
of the embedded conversion feature has been estimated to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On May 23, 2023, the Company issued 9,000 warrants
with an exercise price of $67.50 exercisable until May 23, 2028 to Mast Hill and a third party as a finder&#8217;s fee. Upon evaluation,
the warrants meet the definition of a derivative liability under ASC 815, as the Company cannot avoid a net cash settlement under certain
circumstances. Accordingly, the fair value of the 9,000 warrants was classified as a derivative liability on May 23, 2023. In March 2025,
8,333 warrants held by Mast Hill were cashless exercised. On March 31, 2025, the estimated fair value of the rest of 667 warrants was
$701. The estimated fair value of the warrants was computed as of March 31, 2025 using Black-Scholes option-pricing model, with the following
assumptions: stock price of $4.80, volatility of 108.28%, risk-free rate of 3.89%, annual dividend yield of 0% and expected life of 3.1
years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 6, 2023, the Company issued 222 warrants
with an exercise price of $67.50 exercisable until July 6, 2028 to a third party as a finder&#8217;s fee. Upon evaluation, the warrants
meet the definition of a derivative liability under ASC 815, as the Company cannot avoid a net cash settlement under certain circumstances.
Accordingly, the fair value of the 222 warrants was classified as a derivative liability on July 6, 2023. On March 31, 2025, the estimated
fair value of the 222 warrants was $237. The estimated fair value of the warrants was computed as of March 31, 2025 using Black-Scholes
option-pricing model, with the following assumptions: stock price of $4.80, volatility of 106.65%, risk-free rate of 3.89%, annual dividend
yield of 0% and expected life of 3.3 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On October 9, 2023, the Company issued 4,060 warrants
with an exercise price of $37.50 exercisable until October 9, 2028 to Mast Hill and a third party as a finder&#8217;s fee. Upon evaluation,
the warrants meet the definition of a derivative liability under ASC 815, as the Company cannot avoid a net cash settlement under certain
circumstances. Accordingly, the fair value of the 4,060 warrants was classified as a derivative liability on October 9, 2023. On March
26, 2025, 3,500 warrants held by Mast Hill were cashless exercised. On March 31, 2025, the estimated fair value of the rest of 560 warrants
was $866. The estimated fair value of the warrants was computed as of March 31, 2025 using Black-Scholes option-pricing model, with the
following assumptions: stock price of $4.80, volatility of 103.38%, risk-free rate of 3.89%, annual dividend yield of 0% and expected
life of 3.5 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On March 7, 2024, the Company issued 9,450 warrants
with an exercise price of $30.00 exercisable until March 7, 2029 to Mast Hill and a third party as a finder&#8217;s fee. Upon evaluation,
the warrants meet the definition of a derivative liability under FASB ASC 815, as the Company cannot avoid a net cash settlement under
certain circumstances. Accordingly, the fair value of the 9,450 warrants was classified as a derivative liability on March 7, 2024. On
March 31, 2025, the estimated fair value of the 9,450 warrants was $17,134. The estimated fair value of the warrants was computed as
of March 31, 2025 using Black-Scholes option-pricing model, with the following assumptions: stock price of $4.80, volatility of 99.62%,
risk-free rate of 3.89%, annual dividend yield of 0% and expected life of 3.9 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 5, 2024, the Company issued 152,000 warrants
to Mast Hill and a third party as a finder&#8217;s fee (see Note 6). Upon evaluation, the warrants meet the definition of a derivative
liability under ASC 815, as the Company cannot avoid a net cash settlement under certain circumstances. Management determined the probability
of failing to make an amortization payment when due to be remote and as such the fair value of the 80,000 warrants with an exercise price
of $7.50 exercisable until June 5, 2029, which warrant shall be cancelled and extinguished against payment of the June 2024 Convertible
Note, has been estimated to be zero. Accordingly, the fair value of the 72,000 warrants with an exercise price of $9.75 exercisable until
June 5, 2029 was classified as a derivative liability on June 5, 2024. On March 31, 2025, the estimated fair value of the 72,000 warrants
with an exercise price of $9.75 exercisable until the five-year anniversary of June 5, 2024 as derivative liability was $204,114. The
estimated fair value of the warrants was computed as of March 31, 2025 using Black-Scholes option-pricing model, with the following assumptions:
stock price of $4.80, volatility of 97.66%, risk-free rate of 3.96%, annual dividend yield of 0% and expected life of 4.2 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Increases or decreases in fair value of the derivative
liability are included as a component of total other (expenses) income in the accompanying condensed consolidated statements of operations
and comprehensive loss. The changes to the derivative liability resulted in an increase of $114,360 in the derivative liability and the
corresponding increase in other expense as a loss for the three months ended March 31, 2025. The changes to the derivative liability
resulted in a decrease of $31,212 in the derivative liability and the corresponding increase in other income as a gain for the three
months ended March 31, 2024.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 11 -&#160;<span style="text-decoration:underline">DERIVATIVE LIABILITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As stated
in Note 10, June 2024 Convertible Note, the Company determined that the convertible note payable contains an embedded derivative feature
in the form of a conversion provision which is adjustable based on future prices of the Company&#8217;s common stock. In accordance with
ASC 815-10-25, each derivative feature is initially recorded at its fair value using the Black-Scholes option valuation method and then
re-value at each reporting date, with changes in the fair value reported in the statements of operations. However, on June 5, 2024 and
December 31, 2024, management determined the probability of failing to make an amortization payment and repayment, respectively, when
due to be remote and as such the fair value of the embedded conversion feature has been estimated to be zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 23, 2023, the Company issued 9,000 warrants
with an exercise price of $67.50 exercisable until the five-year anniversary of May 23, 2023 to Mast Hill and a third party as a finder&#8217;s
fee. Upon evaluation, the warrants meet the definition of a derivative liability under FASB ASC 815, as the Company cannot avoid a net
cash settlement under certain circumstances. Accordingly, the fair value of the 9,000 warrants was classified as a derivative liability
on May 23, 2023. On December 31, 2023, the estimated fair value of the 9,000 warrants was $14,805. The estimated fair value of the warrants
was computed as of December 31, 2023 using Black-Scholes option-pricing model, with the following assumptions: stock price of $7.24, volatility
of 83.96%, risk-free rate of 3.84%, annual dividend yield of 0% and expected life of 4.4 years. On December 31, 2024, the estimated fair
value of the 9,000 warrants was $3,714. The estimated fair value of the warrants was computed as of December 31, 2024 using Black-Scholes
option-pricing model, with the following assumptions: stock price of $3.26, volatility of 97.00%, risk-free rate of 4.27%, annual dividend
yield of 0% and expected life of 3.4 years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2023, the Company issued&#160;3,000&#160;warrants
with an exercise price of $67.50&#160;exercisable until the five-year anniversary of July 6, 2023 to FirstFire and a third party as a
finder&#8217;s fee. Upon evaluation, the warrants meet the definition of a derivative liability under ASC 815, as the Company cannot avoid
a net cash settlement under certain circumstances. Accordingly, the fair value of the&#160;3,000&#160;warrants was classified as a derivative
liability on July 6, 2023. On December 31, 2023, the estimated fair value of the&#160;3,000&#160;warrants was $5,098.&#160;The estimated
fair value of the warrants was computed as of December 31, 2023 using Black-Scholes&#160;option-pricing model, with the following assumptions:
stock price of $7.24, volatility of&#160;83.66%, risk-free rate of&#160;3.84%, annual dividend yield of&#160;0% and expected life of&#160;4.5&#160;years.
On November 18, 2024, 2,778 warrants held by FirstFire were cashless exercised. On December 31, 2024, the estimated fair value of the&#160;rest
of 222&#160;warrants was $94. The estimated fair value of the warrants was computed as of December 31, 2024 using Black-Scholes option-pricing
model, with the following assumptions: stock price of $3.26, volatility of&#160;95.85%, risk-free rate of&#160;4.27%, annual dividend
yield of&#160;0% and expected life of&#160;3.5&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 9, 2023, the Company issued&#160;7,560&#160;warrants
with an exercise price of $37.50&#160;exercisable until the five-year anniversary of October 9, 2023 to Mast Hill and FirstFire and a
third party as a finder&#8217;s fee. Upon evaluation, the warrants meet the definition of a derivative liability under ASC 815, as the
Company cannot avoid a net cash settlement under certain circumstances. Accordingly, the fair value of the&#160;7,560&#160;warrants was
classified as a derivative liability on October 9, 2023. On December 31, 2023, the estimated fair value of the&#160;7,560&#160;warrants
was $20,920.&#160;The estimated fair value of the warrants was computed as of December 31, 2023 using Black-Scholes&#160;option-pricing
model, with the following assumptions: stock price of $7.24, volatility of&#160;86.33%, risk-free rate of&#160;3.84%, annual dividend
yield of&#160;0% and expected life of&#160;4.8&#160;years. On November 18, 2024, 3,500 warrants held by FirstFire were cashless exercised.
On December 31, 2024, the estimated fair value of the&#160;rest of 4,060&#160;warrants was $2,880. The estimated fair value of the warrants
was computed as of December 31, 2024 using Black-Scholes option-pricing model, with the following assumptions: stock price of $3.26, volatility
of&#160;93.90%, risk-free rate of&#160;4.27%, annual dividend yield of&#160;0% and expected life of&#160;3.8&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On March 7, 2024, the
Company issued&#160;9,450&#160;warrants with an exercise price of $30.00&#160;exercisable until the five-year anniversary of March 7,
2024 to Mast Hill and a third party as a finder&#8217;s fee. Upon evaluation, the warrants meet the definition of a derivative liability
under FASB ASC 815, as the Company cannot avoid a net cash settlement under certain circumstances. Accordingly, the fair value of the&#160;9,450&#160;warrants
was classified as a derivative liability on March 7, 2024. On December 31, 2024, the estimated fair value of the&#160;9,450&#160;warrants
was $8,191. The estimated fair value of the warrants was computed as of December 31, 2024 using Black-Scholes option-pricing model, with
the following assumptions: stock price of $3.26, volatility of&#160;90.43%, risk-free rate of&#160;4.38%, annual dividend yield of&#160;0%
and expected life of&#160;4.2&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On June 5, 2024, the
Company issued&#160;152,000&#160;warrants to Mast Hill and a third party as a finder&#8217;s fee (see Note 10). Upon evaluation, the warrants
meet the definition of a derivative liability under ASC 815, as the Company cannot avoid a net cash settlement under certain circumstances.
Management determined the probability of failing to make an amortization payment when due to be remote and as such the fair value of the&#160;80,000&#160;warrants
with an exercise price of $7.50&#160;exercisable until the five-year anniversary of June 5, 2024, which warrant shall be cancelled and
extinguished against payment of the June 2024 Convertible Note, has been estimated to be zero. Accordingly, the fair value of the&#160;72,000&#160;warrants
with an exercise price of $9.75&#160;exercisable until the five-year anniversary of June 5, 2024 was classified as a derivative liability
on June 5, 2024. On December 31, 2024, the estimated fair value of the&#160;72,000&#160;warrants with an exercise price of $9.75&#160;exercisable
until the five-year anniversary of June 5, 2024 as derivative liability was $112,666. The estimated fair value of the warrants was computed
as of December 31, 2024 using Black-Scholes option-pricing model, with the following assumptions: stock price of $3.26, volatility of&#160;88.64%,
risk-free rate of&#160;4.38%, annual dividend yield of&#160;0% and expected life of&#160;4.4&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Increases or decreases
in fair value of the derivative liability are included as a component of total other (expenses) income in the accompanying consolidated
statements of operations and comprehensive loss. The changes to the derivative liability resulted in a decrease of $374,365&#160;and $188,374&#160;in
the derivative liability and the corresponding increase in other income as a gain for the years ended December 31, 2024 and 2023, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 182<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-182<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 185<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-185<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 184<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-184<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 181<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-181<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 15<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480960/815-15-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 183<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-183<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4I<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4F<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Payable, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Note Payable, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTE PAYABLE, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">NOTE 8 - <span style="text-decoration:underline">NOTE PAYABLE, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On September 1, 2022, the Company issued a balloon
promissory note in the form of a mortgage on its headquarters to a third party company in the principal amount of $4,800,000, which carries
interest of 11.0% per annum. Interest is due in monthly payments of $44,000 beginning November 1, 2022 and payable monthly thereafter
until September 1, 2025 when the principal outstanding and all remaining interest is due. The principal of $4,800,000 can be extended
for an additional 36 months, provided that the Company has not defaulted. The Company may not prepay the principal of $4,800,000 for
a period of 12 months. The principal of $4,800,000 is secured by a first mortgage on the Company&#8217;s real property located at 4400
Route 9 South, Freehold, Monmouth County, New Jersey..</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In May 2023, the Company borrowed $1,000,000 from
the same lender. The principal of $1,000,000 accrues interest at an annual rate of 13.0% and is payable in monthly installments of interest-only
in the amount of $10,833, commencing in June 2023 and continuing through October 2025 (at which point any unpaid balance of principal,
interest and other charges are due and payable). The loan is secured by a second-lien mortgage on certain real property and improvements
located at 4400 Route 9 South, Freehold, Monmouth County, New Jersey.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The note payable as of March 31, 2025 and December
31, 2024 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><b style="-sec-ix-redline:true;-keep: true">March 31,<br/> 2025</b></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><b style="-sec-ix-redline:true;-keep: true">December
    31, <br/> 2024</b></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Principal amount</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,800,000</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,800,000</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Less: unamortized debt issuance costs</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(54,746</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(84,553</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Note payable, net</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,745,254</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,715,447</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For the three months ended March 31, 2025 and
2024, amortization of debt issuance costs related to note payable amounted to $29,807 and $29,807, respectively, which have been included
in interest expense - amortization of debt discount and debt issuance costs on the accompanying condensed consolidated statements of
operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For the three months ended March 31, 2025 and
2024, interest expense related to note payable amounted to $164,500 and $164,500, respectively, which have been included in interest
expense - other on the accompanying condensed consolidated statements of operations and comprehensive loss.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 12 -&#160;<span style="text-decoration:underline">NOTE PAYABLE, NET</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">On
September 1, 2022, the Company issued a balloon promissory note in the form of a mortgage on its headquarters to a third party company
in the principal amount of $4,800,000, which carries interest of 11.0% per annum. Interest is due in monthly payments of $44,000 beginning
November 1, 2022 and payable monthly thereafter until September 1, 2025 when the principal outstanding and all remaining interest is due.
The principal of $4,800,000 can be extended for an additional 36 months, provided that the Company has not defaulted. The Company may
not prepay the principal of $<span style="-sec-ix-hidden: hidden-fact-338">4,800,00</span> for a period of 12 months. The principal of $4,800,000 is secured by a first mortgage on the Company&#8217;s
real property located in Township of Freehold, County of Monmouth, State of New Jersey, having a street address of 4400 Route 9 South,
Freehold, NJ 07728.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In May 2023, the Company
borrowed $1,000,000 from the same lender. The principal of $1,000,000 accrues interest at an annual rate of 13.0% and is payable in monthly
installments of interest-only in the amount of $10,833, commencing in June 2023 and continuing through October 2025 (at which point any
unpaid balance of principal, interest and other charges are due and payable). The loan is secured by a second-lien mortgage on certain
real property and improvements located at 4400 Route 9, Freehold, Monmouth County, New Jersey.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">The
note payable as of December 31, 2024 and 2023 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Principal amount</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,800,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,800,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: unamortized debt issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(84,553</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(203,781</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Note payable, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,715,447</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,596,219</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current portion</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,715,447</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-336">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Noncurrent portion</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-337">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,596,219</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For the years ended December
31, 2024 and 2023, amortization of debt issuance costs related to note payable amounted to $119,228 and $106,557, respectively, which
have been included in interest expense - amortization of debt discount and debt issuance costs on the accompanying consolidated
statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">For the years ended December
31, 2024 and 2023, interest expense related to note payable amounted to $658,000 and $606,722, respectively, which have been included
in interest expense - other on the accompanying consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">NOTE 9 - <span style="text-decoration:underline">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Rental Revenue from Related Party and Rent
Receivable - Related Party</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company leases space of its commercial real
property located in New Jersey to D.P. Capital Investments LLC, which is controlled by Wenzhao Lu, the Company&#8217;s chairman of the
Board of Directors. The term of the related party lease agreement is five years commencing on May 1, 2021 and will expire on April 30,
2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For both the three months ended March 31, 2025
and 2024, the related party rental revenue amounted to $12,600 and has been included in real property rental revenue on the accompanying
condensed consolidated statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Services Provided by Related Party</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">From time to time, Wilbert Tauzin, a director
of the Company, and his son provide consulting services to the Company. As compensation for professional services provided, the Company
recognized consulting expenses of $15,597 and $16,731 for the three months ended March 31, 2025 and 2024, respectively, which have been
included in professional fees on the accompanying condensed consolidated statements of operations and comprehensive loss. As of March
31, 2025 and December 31, 2024, the accrued and unpaid services charge related to this director&#8217;s son amounted to $2,615 and $15,000,
respectively, which have been included in accrued professional fees on the accompanying condensed consolidated balance sheets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Accrued Liabilities and Other Payables - Related
Parties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In 2017, the Company acquired Beijing Jieteng
(Genexosome) Biotech Co., Ltd. (&#8220;Beijing GenExosome&#8221;) for a cash payment of $450,000. As of both March 31, 2025 and December
31, 2024, the unpaid acquisition consideration of $100,000, was payable to Dr. Yu Zhou, former director and former co-chief executive
officer and 40% owner of Genexosome, and has been included in accrued liabilities and other payables - related parties on the accompanying
condensed consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">From time to time, Lab Services MSO paid shared
expense on behalf of the Company. In addition, Lab Services MSO made a payment of $566,667 for equity method investment payable on behalf
of the Company in 2024. During the first quarter of 2025, to preserve cash, the Company entered into discussions with Lab Services MSO
for the potential redemption of our investment and on February 26, 2025, the Company and Lab Services MSO entered into a Redemption and
Abandonment Agreement, whereby Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by the Company for cash and
the surrender of its Series B Preferred Stock having a carrying value of $11,000,000. The aggregate cash amount to the Company for the
redemption was $1,745,000, to be paid as follows: one payment of $95,000 at the closing of the redemption and, beginning in March 2025,
monthly payments of $75,000 until December 2026. In addition, pursuant to the terms of the Redemption Agreement, all shares of the Company&#8217;s
Series B Preferred Stock previously issued to SCBC Holdings LLC as partial consideration for the equity interests of Laboratory Services
MSO, were permanently surrendered and relinquished to the Company for no additional consideration. The difference of $2,348,695 between
the carrying value of the extinguished Series B Preferred Stock, the aggregate cash amount to the Company for the redemption, net of
payables due to Lab Services MSO of $632,916, totaling $13,377,916, and the carrying value of the equity method investment of $11,029,221
was accounted for as an increase to additional paid-in capital (See Note 10 - Series B Convertible Preferred Stock Extinguished Related
to Sale of Equity Method Investment). As of March 31, 2025 and December 31, 2024, the balance due to Lab Services MSO amounted to $0
and $632,916, respectively, which has been included in accrued liabilities and other payables - related parties on the accompanying condensed
consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Membership Interest Purchase Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 17, 2023, the Company entered into
a Membership Interest Purchase Agreement with Mr. Lu, the Company&#8217;s chairman of the Board of Directors, pursuant to which (i) Mr.
Lu will acquire from the Company 30% of the total outstanding membership interests of Avalon RT 9, a wholly owned subsidiary of the Company,
for a cash purchase price of $3,000,000 (the &#8220;Acquisition&#8221;), and (ii) for a period of twelve months following the closing
of the Acquisition, Mr. Lu shall have the option to purchase from the Company up to an additional 70% of the outstanding membership interests
of Avalon RT 9 for a purchase price of up to $7,000,000 (the &#8220;Option&#8221;), subject to the terms and conditions of a membership
interest purchase agreement to be negotiated and entered into between Mr. Lu and the Company at such time that Mr. Lu desires to exercise
the Option. The Company received $3,328,078 and $3,108,106 from Mr. Lu as of March 31, 2025 and December 31, 2024, respectively, which
was recorded as advance from pending sale of noncontrolling interest - related party on the accompanying condensed consolidated balance
sheets. The Acquisition is expected to close in the fourth quarter of 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Series D Convertible Preferred Stock Issued
in Exchange of Series A Convertible Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 9, 2025, the Company entered into an
exchange agreement with Wenzhao Lu, the Company&#8217;s chairman of the Board of Directors, pursuant to which Mr. Lu exchanged 9,000
shares of Series A Preferred Stock of the Company, having a carrying value of $9,000,000, for 5,000 shares of Series D Preferred Stock
of the Company. The Company determined that the exchange of the Series A Preferred Stock for the Series D Preferred Stock resulted in
the extinguishment of the Series A Preferred Stock. As a result, the difference between the carrying amount of the Series A Preferred
Stock and the fair value of the Series D Preferred Stock of $162,473 was recognized as a deemed contribution in the three months ended
March 31, 2025 that increased additional paid-in capital and income available to common shareholders in calculating earnings per share
(See Note 10 - Series D Convertible Preferred Stock Issued in Exchange of Series A Convertible Preferred Stock).</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>NOTE 13 -&#160;<span style="text-decoration:underline">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Rental
Revenue from Related Party and Rent Receivable - Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company leases space of its commercial real
property located in New Jersey to D.P. Capital Investments LLC, which is controlled by Wenzhao Lu, the Company&#8217;s chairman of the
Board of Directors. The term of the related party lease agreement is five years commencing on May 1, 2021 and will expire on April 30,
2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">For both
the years ended December 31, 2024 and 2023, the related party rental revenue amounted to $50,400 and has been included in real property
rental revenue on the accompanying consolidated statements of operations and comprehensive loss. At December 31, 2024 and 2023, the related
party rent receivable totaled $0 and $124,500, respectively, which has been included in rent receivable on the accompanying consolidated
balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Services
Provided by Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, Wilbert Tauzin, a director
of the Company, and his son provide consulting services to the Company. As compensation for professional services provided, the Company
recognized consulting expenses of $63,644 and $86,528 for the years ended December 31, 2024 and 2023, respectively, which have been included
in professional fees on the accompanying consolidated statements of operations and comprehensive loss. As of both December 31, 2024 and
2023, the accrued and unpaid services charge related to this director&#8217;s son amounted to $15,000, which have been included in accrued
professional fees on the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Accrued Liabilities and Other Payables -
Related Parties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b>&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2017, the Company acquired Beijing Genexosome
for a cash payment of $450,000. As of both December 31, 2024 and 2023, the unpaid acquisition consideration of $100,000, was payable to
Dr. Yu Zhou, former director and former co-chief executive officer and 40% owner of Genexosome, and has been included in accrued liabilities
and other payables - related parties on the accompanying consolidated balance sheets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, Lab Services MSO paid shared
expense on behalf of the Company. In addition, Lab Services MSO made a payment of $566,667 for equity method investment payable on behalf
of the Company in the year ended December 31, 2024. As of December 31, 2024 and 2023, the balance due to Lab Services MSO amounted to
$632,916 and $72,746, respectively, which has been included in accrued liabilities and other payables - related parties on the accompanying
consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024 and 2023, $0 and $33,712
of accrued and unpaid interest related to borrowings from Wenzhao Lu, the Company&#8217;s chairman of the Board of Directors, respectively,
have been included in accrued liabilities and other payables - related parties on the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Borrowings from Related Party</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Line of Credit </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 29, 2019, the Company entered into a
Line of Credit Agreement (the &#8220;Line of Credit Agreement&#8221;) providing the Company with a $20 million line of credit (the &#8220;Line
of Credit&#8221;) from Mr. Lu, the Company&#8217;s chairman of the Board of Directors. The Line of Credit allowed the Company to request
loans thereunder and to use the proceeds of such loans for working capital and operating expense purposes until the facility matured on
December 31, 2024. The loans are unsecured and are not convertible into equity of the Company. Loans drawn under the Line of Credit bear
interest at an annual rate of 5% and each individual loan is payable three years from the date of issuance. The Company has a right to
draw down on the line of credit and not at the discretion of Mr. Lu, the related party lender. The Company may, at its option, prepay
any borrowings under the Line of Credit, in whole or in part at any time prior to maturity, without premium or penalty. The Line of Credit
Agreement includes customary events of default. If any such event of default occurs, Mr. Lu may declare all outstanding loans under the
Line of Credit to be due and payable immediately.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the years ended December 31, 2024 and 2023,
activity recorded for the Line of Credit is summarized in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Outstanding principal under the Line of Credit at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-339">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Draw down from Line of Credit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">850,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding principal under the Line of Credit at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">850,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Repayment of Line of Credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(400,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Reclassification of Line of Credit to advance from related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(450,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Outstanding principal under the Line of Credit at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2024 and 2023,
the interest expense related to related party borrowing amounted to $42,445 and $33,712, respectively, and has been reflected as interest
expense - related party on the accompanying consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024 and 2023, the related
accrued and unpaid interest for Line of Credit was $0 and $33,712, respectively, and has been included in accrued liabilities and other
payables - related parties on the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Membership Interest
Purchase Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On November 17, 2023,
the Company entered into a Membership Interest Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Mr. Lu, the Company&#8217;s
chairman of the Board of Directors, pursuant to which (i) Mr. Lu will acquire from the Company 30% of the total outstanding membership
interests of Avalon RT 9, a wholly owned subsidiary of the Company, for a cash purchase price of $3,000,000 (the &#8220;Acquisition&#8221;),
and (ii) for a period of twelve months following the closing of the Acquisition, Mr. Lu shall have the option to purchase from the Company
up to an additional 70% of the outstanding membership interests of Avalon RT 9 for a purchase price of up to $7,000,000 (the &#8220;Option&#8221;),
subject to the terms and conditions of a membership interest purchase agreement to be negotiated and entered into between the Purchaser
and the Company at such time that the Purchaser desires to exercise the Option. The Company received $3,108,106 and $485,714 from Wenzhao
Lu as of December 31, 2024 and 2023, respectively, which was recorded as advance from pending sale of noncontrolling interest -
related party on the accompanying consolidated balance sheets. The Acquisition is expected to be closed in the fourth quarter of 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 14 -&#160;<span style="text-decoration:underline">INCOME
TAXES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
is governed by the Income Tax Law of the PRC and the U.S. Internal Revenue Code of 1986, as amended. Under the Income Tax Laws of PRC,
Chinese companies are generally subject to an income tax at an effective rate of 25% on income reported in the statutory financial statements
after appropriate tax adjustments. The Company has a cumulative deficit from its foreign subsidiary of $3,399,273 as of December 31, 2024,
which is included in the consolidated accumulated deficit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company&#8217;s
loss before income taxes includes the following components:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">United States loss before income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,639,148</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,928,780</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">China loss before income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">264,246</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">778,230</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0.125in; text-align: left">Total loss before income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,903,394</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,707,010</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Components of income taxes expense (benefit) consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">U.S. federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-340">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-341">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">U.S. state and local</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-342">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-343">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">China</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-344">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-345">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left">Total current income taxes expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-346">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-347">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">U.S. federal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,874</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,256,007</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">U.S. state and local</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,650</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,102,392</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">China</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,437</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(183,443</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Total deferred income taxes (benefit)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">86,913</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,541,842</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(86,913</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,541,842</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Total income taxes expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-348">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-349">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below summarizes the differences between
the U.S. statutory rate and the Company&#8217;s effective tax rate for the years ended December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">U.S. federal rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">U.S. state rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent difference</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.1</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-US rate differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">True ups</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">U.S. valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27.2</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2024 and 2023,
the Company did not incur any income taxes expense since it did not generate any taxable income in those periods. The Company&#8217;s
foreign entity did not pay any income taxes during the years ended December 31, 2024 and 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s components of deferred taxes
as of December 31, 2024 and 2023 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,<br/>
 2024</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>
2023</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Stock-based compensation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,598,257</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,501,507</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Disallowed business interest deduction</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-350">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,476</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Research and development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106,783</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130,823</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Accrued directors&#8217; compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,977</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165,490</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Accrued settlement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,904</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">126,496</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Partnership Investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,167,965</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,422,744</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,687</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,935</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Capital loss limitation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,394</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net operating loss carryforward</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,648,077</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,493,570</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left">Total deferred tax assets, gross</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,918,044</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,020,435</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,784,638</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,871,551</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total deferred tax assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">133,406</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">148,884</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Fixed assets and intangible assets book/tax basis difference</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(133,406</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(129,636</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-351">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,248</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(133,406</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(148,884</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-352">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-353">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As of December
31, 2024 and 2023, the Company&#8217;s both federal and state net operating loss carryforwards amounted to $60,926,204 and $52,929,248,
respectively. As of December 31, 2024, the Company has $58,438,649 of U.S. federal net operating loss carryovers that have no expiration
date, and $2,487,555 of the federal net operating loss and state net operating loss carry-forwards begin to expire in 2034.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024, the Company had net operating
loss carryforwards in China of $2,086,886&#160;that begin to expire in 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Additionally,
as of December 31, 2024, $61,847 of the future utilization of the net operating loss carryforward to offset future taxable income is subject
to special tax rules which may limit their usage under IRS Section 382 (Change of Ownership) and possibly the Separate Return Limitation
Year (&#8220;SRLY&#8221;) rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A full valuation allowance has been provided against
the Company&#8217;s deferred tax assets at December 31, 2024 as the Company believes it is more likely than not that sufficient taxable
income will not be generated to realize these temporary differences.<span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
has been notified and assessed an IRS Section 6038 penalty of $10,000 for failure to file a foreign entity tax disclosure. The Company
has appealed the penalty and awaits the Internal Revenue Service&#8217;s review of the appeal. There is no assurance such appeal will
be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
has not been audited by any jurisdiction since its inception. The Company is open for audit by the U.S. Internal Revenue Service and U.S.
state tax jurisdictions from 2021 to 2024, and open for audit by the Chinese Ministry of Finance from 2020 to 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">There were
no material uncertain tax positions as of December 31, 2024 and 2023. The Company recognizes interest and penalties related to unrecognized
tax benefits as income tax expense, if any. The Company does not have any significant uncertain tax positions or events leading to uncertainty
in a tax position.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">NOTE 10 - <span style="text-decoration:underline">EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company is authorized to issue an aggregate
of 100,000,000 shares of common stock and 10,000,000 shares of &#8220;blank check&#8221; preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Series A Convertible Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company designated up to 15,000 shares of
its previously undesignated preferred stock as Series A Preferred Stock. Each share of Series A Preferred Stock has a par value of $0.0001
per share and a stated value equal to $1,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The shares of Series A Preferred Stock have identical
terms and include the terms as set forth below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><i>Dividends.</i> Holders of Series A Preferred
Stock (each, a &#8220;Series A Holder&#8221; and collectively, the &#8220;Series A Holders&#8221;) are entitled to receive, and the Company
shall pay, dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-common-stock basis, disregarding for such
purpose any conversion limitations set forth in the Series A Certificate of Designations) to and in the same form as dividends actually
paid on shares of the Company&#8217;s common stock when, as and if such dividends are paid on shares of the common stock. No other dividends
shall be paid on shares of Series A Preferred Stock. The Company will not pay any dividends on its common stock unless the Company simultaneously
complies with the terms set forth in the Series A Certificate of Designations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><i>Liquidation.</i> Upon any dissolution, liquidation
or winding-up of the Company, whether voluntary or involuntary (a &#8220;Liquidation&#8221;), the Series A Holders will be entitled to
receive out of the assets available for distribution to the stockholders, (i) after and subject to the payment in full of all amounts
required to be distributed to the holders of another class or series of stock of the Company ranking on liquidation prior and in preference
to the Series A Preferred Stock, (ii) ratably with any class or series of stock ranking on liquidation on parity with the Series A Preferred
Stock and (iii) in preference and priority to the holders of the shares of the Company&#8217;s common stock, an amount equal to 100%
of the Series A Stated Value, and no more, in proportion to the full and preferential amount that all shares of the Series A Preferred
Stock are entitled to receive. The Company shall mail written notice of any Liquidation not less than twenty (20) days prior to the payment
date stated therein, to each Series A Holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><i>Conversion.</i> Each share of Series A Preferred
Stock shall be convertible, at any time and from time to time from and after the later of (i) the date of the stockholder approval as
described above, in accordance with the Nasdaq Stock Market Listing Rules, and (ii) the nine (9) month anniversary of the Closing (the
&#8220;Initial Conversion Date&#8221;), at the option of the Series A Holder, into that number of shares of common stock (subject to
the limitations set forth in Series A Certificate of Designations, determined by dividing the Stated Value of such share of Series A
Preferred Stock by the conversion price (as defined below)). The Series A Holders may effect conversions by providing the Company with
the form of conversion notice attached as Annex A to the Series A Certificate of Designations. The Series A Holders may convert such
shares into shares of the Company&#8217;s common stock at a conversion price per share equal to the greater of (i) one hundred fifty
dollars ($150.0) and (ii) ninety percent (90%) of the closing price of the Company&#8217;s common stock on Nasdaq on the day prior to
receipt of a conversion notice, subject to adjustment for stock splits and similar matters. In addition, following the Initial Conversion
Date, each Series A Holder agrees that it shall not be entitled to in any calendar month, sell a number of Series A conversion shares
into the open market in an amount exceeding more than ten percent (10%) of the number of Series A conversion shares issuable upon conversion
of the Series A Preferred Stock then held by such Series A Holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">Conversion Price Adjustment:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><i>Stock Dividends and Stock Splits.</i> If the
Company, at any time while the Series A Preferred Stock is outstanding: (i) pays a stock dividend or otherwise makes a distribution or
distributions payable in shares of common stock on shares of common stock or any other common stock equivalents (which, for avoidance
of doubt, shall not include any shares of common stock issued by the Company upon conversion of, or payment of a dividend on, the Series
A Preferred Stock), (ii) subdivides outstanding shares of common stock into a larger number of shares, (iii) combines (including by way
of a reverse stock split) outstanding shares of common stock into a smaller number of shares, or (iv) issues, in the event of a reclassification
of shares of the common stock, any shares of capital stock of the Company, then the conversion price of the Series A Preferred Stock
shall be multiplied by a fraction of which the numerator shall be the number of shares of common stock (excluding any treasury shares
of the Company) outstanding immediately before such event, and of which the denominator shall be the number of shares of common stock
outstanding immediately after such event. Any of the foregoing adjustments shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><i>Fundamental Transaction.</i> If, at any time
while the Series A Preferred Stock is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another individual or corporation, partnership, trust, incorporated or unincorporated
association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other
entity of any kind (a &#8220;Person&#8221;), (ii) the Company (and all of its subsidiaries, taken as a whole), directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in
one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the
Company or another Person) is completed pursuant to which holders of the Company&#8217;s common stock are permitted to sell, tender or
exchange their shares for other securities, cash or property and has been accepted by the holders of fifty percent (50%) or more of the
outstanding common stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the common stock or any compulsory share exchange pursuant to which the common stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than fifty percent (50%)
of the outstanding shares of common stock (not including any shares of common stock held by the other Person or other Persons making
or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business
combination) (each a &#8220;Fundamental Transaction&#8221;), then, the Series A Holder shall have the right to receive, for each conversion
share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without
regard to any limitation set forth in the Series A Certificate of Designations on the conversion of the Series A Preferred Stock), the
number of shares of common stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and/or
any additional consideration (the &#8220;Alternate Consideration&#8221;) receivable as a result of such Fundamental Transaction by a
holder of the number of shares of common stock for which the Series A Preferred Stock is convertible immediately prior to such Fundamental
Transaction (without regard to the limitations set forth in the Series A Certificate of Designations on the conversion of the Series
A Preferred Stock). For purposes of any such conversion, the determination of the conversion price shall be appropriately adjusted to
apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of common stock
in such Fundamental Transaction, and the Company shall apportion the conversion price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of common stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Series A Holder shall be given
the same choice as to the Alternate Consideration it receives upon such Fundamental Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><i>Voting Rights.</i> The Series A Holders will
have no voting rights, except as otherwise required by the Delaware General Corporation Law. Notwithstanding the foregoing, as long as
any shares of Series A Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority
of the then outstanding shares of Series A Preferred Stock, voting as a separate class, (a) alter or change adversely the powers, preferences
or rights given to the Series A Preferred Stock in the Series A Certificate of Designations, (b) increase the number of authorized shares
of Series A Preferred Stock, (c) authorize or issue an additional class or series of capital stock that ranks senior to the Series A
Preferred Stock with respect to the distribution of assets on liquidation or (d) enter into any agreement with respect to any of the
foregoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><i>Fractional Shares.</i> No fractional shares
or scrip representing fractional shares shall be issued upon the conversion of the Series A Preferred Stock. As to any fraction of a
share of Company common stock which a Series A Holder would otherwise be entitled to upon such conversion, the Company will, at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the conversion price
or round up to the next whole share. Notwithstanding the foregoing, nothing shall prevent any Series A Holder from converting fractional
shares of Series A Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of December 31, 2024, 9,000 shares of Series
A Preferred Stock were issued and outstanding. On January 9, 2025, the Company entered into an exchange agreement with Wenzhao Lu, the
Company&#8217;s chairman of the Board of Directors, pursuant to which Mr. Lu exchanged 9,000 shares of Series A Preferred Stock of the
Company for 5,000 shares of Series D Preferred Stock of the Company (See Note 10 - Series D Convertible Preferred Stock Issued in Exchange
of Series A Convertible Preferred Stock). As of March 31, 2025, there were no shares of Series A Preferred Stock remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Series B Convertible Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company designated up to 15,000 shares of
its previously undesignated preferred stock as Series B Preferred Stock. Each share of Series B Preferred Stock has a par value of $0.0001
per share and a stated value equal to $1,000.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The shares of Series B Preferred Stock have identical
terms and include the terms as set forth below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><i>Dividends.</i> The holders of Series B Preferred
Stock (each, a &#8220;Series B Holder&#8221; and collectively, the &#8220;Series B Holders&#8221;) shall be entitled to receive, and
the Company shall pay, dividends on shares of Series B Preferred Stock equal (on an as-if-converted-to-common-stock basis, disregarding
for such purpose any conversion limitations set forth in the Series B Certificate of Designations) to and in the same form as dividends
actually paid on shares of the Company&#8217;s common stock when, as and if such dividends are paid on shares of the common stock. No
other dividends shall be paid on shares of Series B Preferred Stock. The Company will not pay any dividends on its common stock unless
the Company simultaneously complies with the terms set forth in the Series B Certificate of Designations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><i>Rank.</i> The Series B Preferred Stock will
rank subordinate to the shares of the Company&#8217;s Series A Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><i>Liquidation. </i>Upon any Liquidation, the
Series B Holders will be entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to the
payment in full of all amounts required to be distributed to the holders of another class or series of stock of the Company ranking on
liquidation prior and in preference to the Series B Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any class
or series of stock ranking on liquidation on parity with the Series B Preferred Stock and (iii) in preference and priority to the holders
of the shares of common stock, an amount equal to one hundred percent (100%) of the Series B Stated Value and no more, in proportion
to the full and preferential amount that all shares of the Series B Preferred Stock are entitled to receive. The Company shall mail written
notice of any such Liquidation not less than twenty (20) days prior to the payment date stated therein, to each Series B Holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><i>Conversion.</i> Each share of Series B Preferred
Stock shall be convertible, at any time and from time to time from and after the later of (i) the date of the stockholder approval and
(ii) February 9, 2024 (the &#8220;Lock Up Period&#8221;), at the option of the Series B Holder thereof, into that number of shares of
common stock (subject to the limitations set forth in Series B Certificate of Designations determined by dividing the Series B Stated
Value of such share of Series B Preferred Stock by the conversion price of the Series B Preferred Stock). Series B Holders may effectuate
conversions by providing the Company with the form of conversion notice attached as Annex A to the Series B Certificate of Designations.
The Series B Preferred Stock will be convertible into shares of the Company&#8217;s common stock at a conversion price per share equal
to $56.70, subject to the adjustments set forth in the Series B Certificate of Designations. Notwithstanding the foregoing or the transactions
contemplated by the Amended MIPA, until the consummation of the Lock Up Period, the Series B Holders shall not, directly or indirectly,
sell, transfer or otherwise dispose of any Series B Preferred Stock issued upon conversion of the Series B conversion shares or pursuant
to the Equity Earnout Payment (the &#8220;Restricted Securities&#8221;) without Company&#8217;s prior written consent; provided, however,
the Series B Holders may sell, transfer or otherwise dispose of Restricted Securities to an Affiliate, as defined in the Amended MIPA,
of a Series B Holder without Company&#8217;s prior written consent; provided, further, that such Series B Holder provide prompt written
notice to Company of such transfer, including the name and contact information of the Affiliate transferee, and such Affiliate transferee
agrees in writing to be bound by the terms of the transaction documents contemplated by the Amended MIPA to which the Series B Holder
is a party (which agreement shall also be provided to Company with such notice). After the expiration of the Lock Up Period, the Series
B Holder agrees that it and any of its Affiliate transferees shall not be entitled to in any calendar month, sell a number of shares
of Company common stock into the open market in an amount exceeding more than ten percent (10%) of the total number of shares of Company
common stock issuable upon conversion of the Company common stock then held by the Seller and its Affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">Conversion Price Adjustment:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><i>Stock Dividends and Stock Splits.</i> If the
Company, at any time while the Series B Preferred Stock is outstanding: (i) pays a stock dividend or otherwise makes a distribution or
distributions payable in shares of common stock on shares of common stock or any other common stock equivalents (which, for avoidance
of doubt, shall not include any shares of common stock issued by the Company upon conversion of, or payment of a dividend on, the Series
B Preferred Stock), (ii) subdivides outstanding shares of common stock into a larger number of shares, (iii) combines (including by way
of a reverse stock split) outstanding shares of common stock into a smaller number of shares, or (iv) issues, in the event of a reclassification
of shares of the common stock, any shares of capital stock of the Company, then the conversion price of the Series B Preferred Stock
shall be multiplied by a fraction of which the numerator shall be the number of shares of common stock (excluding any treasury shares
of the Company) outstanding immediately before such event, and of which the denominator shall be the number of shares of common stock
outstanding immediately after such event. Any of the foregoing adjustments shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><i>Fundamental Transaction.</i> If, at any time
while the Series B Preferred Stock is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another Person, (ii) the Company (and all of its subsidiaries, taken as a whole),
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of the Company&#8217;s common stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of fifty percent
(50%) or more of the outstanding common stock, (iv) the Company, directly or indirectly, in one or more related transactions effects
any reclassification, reorganization or recapitalization of the common stock or any compulsory share exchange pursuant to which the common
stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a Fundamental Transaction, then, at the closing of such Fundamental Transaction, without
any action on the part of the Series B Holder, the Series B Holder shall have the right to receive, for each conversion share that would
have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation
in the Series B Certificate of Designations on the conversion of the Series B Preferred Stock), the number of shares of common stock
of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and/or any Alternate Consideration receivable
as a result of such Fundamental Transaction by a holder of the number of shares of common stock for which the Series B Preferred Stock
is convertible immediately prior to such Fundamental Transaction (without regard to the limitations set forth in the Series B Certificate
of Designations on the conversion of the Series B Preferred Stock). For purposes of any such conversion, the determination of the conversion
price of the Series B Preferred Stock shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of
Alternate Consideration issuable in respect of one share of common stock in such Fundamental Transaction, and the Company shall apportion
the conversion price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of common stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Series B Holder shall be given the same choice as to the Alternate Consideration it receives upon
such Fundamental Transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><i>Voting Rights</i>. The Series B Holders will
have no voting rights, except as otherwise required by the Delaware General Corporation Law. Notwithstanding the foregoing, in addition,
as long as any shares of Series B Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders
of a majority of the then outstanding shares of the Series B Preferred Stock, voting as a separate class, (a) alter or change adversely
the powers, preferences or rights given to the Series B Preferred Stock in the Series B Certificate of Designations, (b) increase the
number of authorized shares of Series B Preferred Stock, (c) except with respect to the Series A Preferred Stock, authorize or issue
an additional class or series of capital stock that ranks senior to the Series B Preferred Stock with respect to the distribution of
assets on liquidation or (d) enter into any agreement with respect to any of the foregoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><i>Fractional Shares.</i> No fractional shares
or scrip representing fractional shares shall be issued upon the conversion of the Series B Preferred Stock. As to any fraction of a
share which a Series B Holder would otherwise be entitled to upon such conversion, the Company shall at its election, either pay a cash
adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the conversion price or round up to the
next whole share. Notwithstanding the foregoing, nothing shall prevent any Series B Holder from converting fractional shares of Series
B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of December 31, 2024, 11,000 shares of Series
B Preferred Stock were issued and outstanding. During the first quarter of 2025, to preserve cash, the Company entered into discussions
with Lab Services MSO for the potential redemption of our investment and on February 26, 2025, the Company and Lab Services MSO entered
into a Redemption and Abandonment Agreement, whereby Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by the
Company for cash and the surrender of its Series B Preferred Stock having a carrying value of $11,000,000. Pursuant to the terms of the
Redemption Agreement, all shares of the Company&#8217;s Series B Preferred Stock previously issued to SCBC Holdings LLC as partial consideration
for the equity interests of Laboratory Services MSO, were permanently surrendered and relinquished to the Company for no additional consideration
(See Note 10 - Series B Convertible Preferred Stock Extinguished Related to Sale of Equity Method Investment). As of March 31, 2025,
there were no shares of Series B Preferred Stock remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Series C Convertible Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On December 13, 2024, the Company filed a certificate
of designations of preferences, rights, and limitations of Series C Preferred Stock (the &#8220;Series C Certificate of Designations&#8221;)
with the Department of State, Division of Corporations, of the State of Delaware, which provides for the designation of 10,000 shares
of Series C Preferred Stock of the Company, par value $0.0001 per share. Each share of Series C Preferred Stock has a stated value of
$1,000.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Series C Preferred Stock shall rank (i) senior
to the Company&#8217;s common stock and any other class or series of capital stock of the Company created hereafter, the terms of which
specifically provide that such class or series shall rank junior to the Series C Preferred Stock, (ii) pari passu with any class or series
of capital stock of the Company created hereafter specifically ranking, by its terms, on par with the Series C Preferred Stock, (iii)
pari passu with Series B Preferred Stock of the Company with respect to its rights, preferences and restrictions, and (iv) subordinate
to the Series A Preferred Stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Holders of the Series C Preferred Stock shall
be entitled to receive, and the Company shall pay, dividends on shares of Series C Preferred Stock equal (on an as-if-converted-to-common-stock
basis, disregarding for such purpose any conversion limitations hereunder) to and in the same form as dividends actually paid on shares
of the common stock when, as and if such dividends are paid on shares of the common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Holders of the Series C Preferred Stock have no
voting power except as otherwise required by the Delaware General Corporation Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Upon any liquidation, dissolution or winding-up
of the Company, whether voluntary or involuntary (a &#8220;Liquidation&#8221;), the holders of the Series C Preferred Stock shall be
entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to the payment in full of all
amounts required to be distributed to the holders of another class or series of stock of the Company ranking on liquidation prior and
in preference to the Series C Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any class or series of stock
ranking on liquidation on parity with the Series C Preferred Stock and (iii) in preference and priority to the holders of the shares
of common stock, an amount equal to 100% of the Stated Value of the Series C Preferred Stock, in proportion to the full and preferential
amount that all shares of the Series C Preferred Stock are entitled to receive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Each share of Series C Preferred Stock shall be
convertible into common stock (the &#8220;Series C Conversion Shares&#8221;) at a conversion per share equal to $2.41, at the option
of the holder, at any time after the later of (i) the date of the shareholder approval of the issuance of the Series C Conversion Shares
pursuant to the rules of the Nasdaq Stock Market and (ii) the one year anniversary of the date of the first issuance of any shares of
the Series C Preferred Stock. In addition, the holder shall not have the right to convert any portion of the Series C Preferred Stock
if, after giving effect to the conversion, such holder (together with its affiliates) would beneficially own in excess of 19.99% of the
number of shares of the common stock outstanding immediately after giving effect to the issuance of the respective Series C Conversion
Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of both March 31, 2025 and December 31, 2024,
3,500 shares of Series C Preferred Stock were issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Series D Convertible Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 6, 2025, the Company filed a certificate
of designations of preferences, rights, and limitations of Series D Preferred Stock (the &#8220;Series D Certificate of Designations&#8221;)
with the Department of State, Division of Corporations, of the State of Delaware, which provides for the designation of 5,000 shares
of Series D Preferred Stock of the Company, par value $0.0001 per share, upon the terms and conditions as set forth in the Series D Certificate
of Designations. Each share of Series D Preferred Stock has a stated value of $1,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Series D Preferred Stock shall rank (i) senior
to the Company&#8217;s common stock and any other class or series of capital stock of the Company created hereafter, the terms of which
specifically provide that such class or series shall rank junior to the Series D Preferred Stock, (ii) pari passu with any class or series
of capital stock of the Company created hereafter specifically ranking, by its terms, on par with the Series D Preferred Stock, (iii)
pari passu with the Series B Preferred Stock of the Company with respect to its rights, preferences and restrictions, and (iv) pari passu
with the Series C Preferred Stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Holders of the Series D Preferred Stock have no
voting power except as otherwise required by the Delaware General Corporation Law.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Upon any liquidation, dissolution or winding-up
of the Company, whether voluntary or involuntary (a &#8220;Liquidation&#8221;), the holders of the Series D Preferred Stock shall be
entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to the payment in full of all
amounts required to be distributed to the holders of another class or series of stock of the Company ranking on liquidation prior and
in preference to the Series D Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any class or series of stock
ranking on liquidation on parity with the Series D Preferred Stock and (iii) in preference and priority to the holders of the shares
of common stock, an amount equal to 100% of the Stated Value of the Series D Preferred Stock, in proportion to the full and preferential
amount that all shares of the Series D Preferred Stock are entitled to receive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Each share of Series D Preferred Stock shall be
convertible into common stock (the &#8220;Series D Conversion Shares&#8221;) at a conversion per share equal to $2.41, at the option
of the holder, at any time after the Company has obtained shareholder approval for the issuance of the Series D Conversion Shares pursuant
to the rules of the Nasdaq Stock Market. In addition, the holder shall not have the right to convert any portion of the Series D Preferred
Stock if, after giving effect to the conversion, such holder (together with its affiliates) would beneficially own in excess of 4.99%
of the number of shares of the common stock outstanding immediately after giving effect to the issuance of the respective Series D Conversion
Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of March 31, 2025, 5,000 shares of Series D
Preferred Stock were issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Series D Convertible Preferred Stock Issued
in Exchange of Series A Convertible Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 9, 2025, the Company entered into an
exchange agreement with Wenzhao Lu, the Company&#8217;s chairman of the Board of Directors, pursuant to which Mr. Lu exchanged 9,000
shares of Series A Preferred Stock of the Company, having a carrying value of $9,000,000, for 5,000 shares of Series D Preferred Stock
of the Company. The Company determined that the exchange of the Series A Preferred Stock for the Series D Preferred Stock resulted in
the extinguishment of the Series A Preferred Stock. As a result, the difference between the carrying amount of the Series A Preferred
Stock and the fair value of the Series D Preferred Stock of $162,473 was recognized as a deemed contribution in the three months ended
March 31, 2025 that increased additional paid-in capital and income available to common shareholders in calculating earnings per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Each share of Series D Preferred Stock is convertible
into common stock of the Company (the &#8220;Series D Conversion Shares&#8221;) at a conversion per share equal to $2.41, which approximated
the market price at the date of transaction, at the option of the holder, at any time after the Company has obtained shareholder approval
for the issuance of the Series D Conversion Shares pursuant to the rules of the Nasdaq Stock Market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company evaluated the features of the Series
D Preferred Stock under ASC 480, and classified them as permanent equity because the Series D Preferred Stock is not mandatorily or contingently
redeemable at the stockholder&#8217;s option and the liquidation preference that exists does not fall within the guidance of SEC Accounting
Series Release No. 268 - <i>Presentation in Financial Statements of &#8220;Redeemable Preferred Stocks&#8221;</i> (&#8220;ASR 268&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Series B Convertible Preferred Stock Extinguished
Related to Sale of Equity Method Investment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the first quarter of 2025, to preserve
cash, the Company entered into discussions with Lab Services MSO for the potential redemption of our investment and on February 26, 2025,
the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement, whereby Lab Services MSO redeemed the 40% equity
interest in Lab Services MSO held by the Company for cash and the surrender of its Series B Preferred Stock having a carrying value of
$11,000,000. The aggregate cash amount to the Company for the redemption was $1,745,000, to be paid as follows: one payment of $95,000
at the closing of the redemption and, beginning in March 2025, monthly payments of $75,000 until December 2026. In addition, pursuant
to the terms of the Redemption Agreement, all shares of the Company&#8217;s Series B Preferred Stock previously issued to SCBC Holdings
LLC as partial consideration for the equity interests of Laboratory Services MSO, were permanently surrendered and relinquished to the
Company for no additional consideration. The difference of $2,348,695 between the carrying value of the extinguished Series B preferred
stock, the aggregate cash amount to the Company for the redemption, net of payables due to Lab Services MSO of $632,916, totaling $13,377,916,
and the carrying value of the equity method investment of $11,029,221 was accounted for as an increase to additional paid-in capital.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Common Shares Issued for Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the three months ended March 31, 2025,
the Company issued a total of 22,278 shares of its common stock for services rendered and to be rendered. These shares were valued at
$111,232, the fair market values on the grant dates using the reported closing share prices on the dates of grant, and the Company recorded
stock-based compensation expense of $17,212 for the three months ended March 31, 2025 and reduced accrued liabilities of $42,385 and
recorded prepaid expense of $51,635 as of March 31, 2025 which will be amortized over the rest of corresponding service periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Common Shares Issued for Warrant Exercise</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In March 2025, pursuant to the terms of related
warrant agreements, the Company issued 186,877 shares of its common stock upon cashless exercise of warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes the shares of the
Company&#8217;s common stock issuable upon exercise of options outstanding at March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: White"> <td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Options Outstanding</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Options Exercisable</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Range of<br/> Exercise<br/> Price</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Number <br/> Outstanding<br/> at March 31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted <br/> Average <br/> Remaining <br/> Contractual Life <br/> (Years)</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted <br/> Average<br/> Exercise<br/> Price</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Number <br/> Exercisable at <br/> March 31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted <br/> Average<br/> Exercise <br/> Price</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">$</span></td> <td style="width: 24%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.93 - 31.20</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">21,010</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.48</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">12.19</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">17,078</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">14.28</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif">&#160;<span style="font-size: 10pt">48.75 - 123.00&#160;</span></span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,517</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.79</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">78.91</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,517</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">78.91</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="2" style="text-align: right; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif">&#160;<span style="font-size: 10pt">154.50 - 264.00&#160;</span></span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">9,898</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.82</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">214.71</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">9,898</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">214.71</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-top: Black 1.5pt solid; text-align: right; padding-bottom: 2.5pt; border-bottom: Black 4pt double"><span style="-sec-ix-redline:true;-keep: true">$</span></td> <td style="border-top: Black 1.5pt solid; text-align: right; padding-bottom: 2.5pt; border-bottom: Black 4pt double"><span style="-sec-ix-redline:true;-keep: true">2.93 - 264.00</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">51,425</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.87</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">77.79</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">47,493</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">83.97</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> </table>


<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Stock option activity for the three months ended
March 31, 2025 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Number of <br/> Options</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Weighted <br/> Average <br/> Exercise
    <br/> Price</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding at January 1, 2025</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">52,479</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">85.45</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,665</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.26</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Expired / cancelled</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(3,719</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(132.47</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding at March 31, 2025</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">51,425</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">77.79</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Options exercisable at March 31, 2025</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">47,493</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">83.97</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Options expected to vest</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,932</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.13</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The aggregate intrinsic value of stock options
outstanding and stock options exercisable at March 31, 2025 was approximately $17,000 an $10,000, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The fair values of options granted during the
three months ended March 31, 2025 were estimated at the date of grant using the Black-Scholes option-pricing model with the following
assumptions: volatility of 105.10%, risk-free rate of 4.29%, annual dividend yield of 0%, and expected life of 3.00 years. The aggregate
fair value of the options granted during the three months ended March 31, 2025 was $6,115.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The fair values of options granted during the
three months ended March 31, 2024 were estimated at the date of grant using the Black-Scholes option-pricing model with the following
assumptions: volatility of 91.17%, risk-free rate of 3.93%, annual dividend yield of 0%, and expected life of 5.00 years. The aggregate
fair value of the options granted during the three months ended March 31, 2024 was $12,137.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For the three months ended March 31, 2025 and
2024, stock-based compensation expense associated with stock options granted amounted to $9,159 and $13,533, of which, $4,858 and $5,103
was recorded as compensation and related benefits, $4,301 and $8,430 was recorded as professional fees, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">A summary of the status of the Company&#8217;s
nonvested stock options granted as of March 31, 2025 and changes during the three months ended March 31, 2025 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Number of <br/> Options</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Weighted <br/> Average <br/> Exercise
    <br/> Price</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Nonvested at January 1, 2025</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,943</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">11.54</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,665</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.26</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Cancelled</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,853</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(27.40</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Vested</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,823</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(5.03</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Nonvested at March 31, 2025</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,932</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.13</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Warrants (Except Pre-Funded Warrants)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes the shares of the
Company&#8217;s common stock issuable upon exercise of warrants outstanding at March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="12" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Warrants Outstanding</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Warrants Exercisable</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Range of<br/> Exercise<br/> Price</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Number <br/> Outstanding<br/> at March 31,<br/> 2025</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Weighted <br/> Average <br/> Remaining <br/> Contractual Life <br/> (Years)</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Weighted <br/> Average<br/> Exercise<br/> Price</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Number <br/> Exercisable at <br/> March 31,<br/> 2025</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Weighted <br/> Average<br/> Exercise<br/> Price</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="-sec-ix-redline:true;font-size: 10pt">$</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">7.50 - 37.50</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">162,010</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">4.17</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-size: 10pt">$</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">9.92</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">82,010</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-size: 10pt">$</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">12.27</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">67.50</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">889</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">3.18</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">67.50</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">889</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">67.50</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">187.50</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">8,264</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">2.06</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">187.50</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">8,264</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">187.50</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">7.50 - 187.50</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">171,163</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">4.06</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">18.79</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">91,163</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">28.70</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Stock warrant activity for the three months ended
March 31, 2025 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Number of <br/> Warrants</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Weighted <br/>
    Average <br/> Exercise <br/> Price</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding at January 1, 2025</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">182,996</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">21.37</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(11,833</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(58.63</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding at March 31, 2025</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">171,163</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">18.79</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Warrants exercisable at March 31, 2025</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">91,163</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">28.70</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Warrants expected to vest</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">80,000</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The aggregate intrinsic value of both stock warrants
outstanding and stock warrants exercisable at March 31, 2025 was $0.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">Warrants Exercised in March 2025</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In March 2025, pursuant to the terms of related
warrant agreements, the Company issued 186,877 shares of its common stock upon cashless exercise of warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">A summary of the status of the Company&#8217;s
nonvested stock warrants issued as of March 31, 2025 and changes during the three months ended March 31, 2025 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Number of <br/> Warrants</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Weighted <br/> Average <br/> Exercise<br/>
    Price</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Nonvested at January 1, 2025</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="white-space: nowrap; width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">80,000</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Vested</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-386"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-387"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Nonvested at March 31, 2025</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">80,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Pre-Funded Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of March 31, 2025, there were 150,000 pre-funded
warrants outstanding with an exercise price of $0.01 per share. There was no activity related to these warrants during the three months
ended March 31, 2025.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 15 -&#160;<span style="text-decoration:underline">EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company is authorized
to issue an aggregate of&#160;100,000,000&#160;shares of common stock and&#160;10,000,000&#160;shares of &#8220;blank check&#8221; preferred
stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Series A Convertible
Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company designated
up to 15,000 shares of its previously undesignated preferred stock as Series A Preferred Stock. Each share of Series A Preferred Stock
has a par value of $0.0001 per share and a stated value equal to $1,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The shares of Series
A Preferred Stock have identical terms and include the terms as set forth below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dividends.</i>&#160;The Series A Holders are
entitled to receive, and the Company shall pay, dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-common-stock
basis, disregarding for such purpose any conversion limitations set forth in the Series A Certificate of Designations) to and in the same
form as dividends actually paid on shares of the Company&#8217;s common stock when, as and if such dividends are paid on shares of the
common stock. No other dividends shall be paid on shares of Series A Preferred Stock. The Company will not pay any dividends on its common
stock unless the Company simultaneously complies with the terms set forth in the Series A Certificate of Designation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Liquidation.</i>&#160;Upon any dissolution,
liquidation or winding-up of the Company, whether voluntary or involuntary (a &#8220;Liquidation&#8221;), the Series A Holders will be
entitled to receive out of the assets available for distribution to the stockholders, (i) after and subject to the payment in full of
all amounts required to be distributed to the holders of another class or series of stock of the Company ranking on liquidation prior
and in preference to the Series A Preferred Stock, (ii) ratably with any class or series of stock ranking on liquidation on parity with
the Series A Preferred Stock and (iii) in preference and priority to the holders of the shares of the Company&#8217;s common stock, an
amount equal to 100% of the Series A Stated Value, and no more, in proportion to the full and preferential amount that all shares of the
Series A Preferred Stock are entitled to receive. The Company shall mail written notice of any Liquidation not less than twenty (20) days
prior to the payment date stated therein, to each Series A Holder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Conversion.</i>&#160;Each share of Series A
Preferred Stock shall be convertible, at any time and from time to time from and after the later of (i) the date of the stockholder approval
as described above, in accordance with the Nasdaq Stock Market Listing Rules, and (ii) the&#160;nine&#160;(9) month anniversary of the
Closing (the &#8220;Initial Conversion Date&#8221;), at the option of the Series A Holder, into that number of shares of common stock
(subject to the limitations set forth in Series A Certificate of Designations, determined by dividing the Stated Value of such share of
Series A Preferred Stock by the Conversion Price (as defined below)). The Series A Holders may effect conversions by providing the Company
with the form of conversion notice attached as Annex A to the Series A Certificate of Designation. The Series A Holders may convert such
shares into shares of the Company&#8217;s common stock at a conversion price per share equal to the greater of (i) one hundred fifty dollars
($150.0) and (ii) ninety percent (90%) of the closing price of the Company&#8217;s common stock on Nasdaq on the day prior to receipt
of a conversion notice (collectively, the &#8220;Conversion Price&#8221;), subject to adjustment for stock splits and similar matters.
In addition, following the Initial Conversion Date, each Series A Holder agrees that it shall not be entitled to in any calendar month,
sell a number of Series A Conversion Shares into the open market in an amount exceeding more than ten percent (10%) of the number of Series
A Conversion Shares issuable upon conversion of the Series A Preferred Stock then held by such Series A Holder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Conversion Price Adjustment:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stock Dividends and Stock Splits.</i>&#160;If
the Company, at any time while the Series A Preferred Stock is outstanding: (i) pays a stock dividend or otherwise makes a distribution
or distributions payable in shares of common stock on shares of common stock or any other common stock equivalents (which, for avoidance
of doubt, shall not include any shares of common stock issued by the Company upon conversion of, or payment of a dividend on, the Series
A Preferred Stock), (ii) subdivides outstanding shares of common stock into a larger number of shares, (iii) combines (including by way
of a reverse stock split) outstanding shares of common stock into a smaller number of shares, or (iv) issues, in the event of a reclassification
of shares of the common stock, any shares of capital stock of the Company, then the conversion price of the Series A Preferred Stock shall
be multiplied by a fraction of which the numerator shall be the number of shares of common stock (excluding any treasury shares of the
Company) outstanding immediately before such event, and of which the denominator shall be the number of shares of common stock outstanding
immediately after such event. Any of the foregoing adjustments shall become effective immediately after the record date for the determination
of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the
case of a subdivision, combination or re-classification.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fundamental Transaction.</i>&#160;If, at any
time while the Series A Preferred Stock is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another individual or corporation, partnership, trust, incorporated or unincorporated
association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other
entity of any kind (a &#8220;Person&#8221;), (ii) the Company (and all of its subsidiaries, taken as a whole), directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company
or another Person) is completed pursuant to which holders of the Company&#8217;s common stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of fifty percent (50%) or more of the outstanding
common stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the common stock or any compulsory share exchange pursuant to which the common stock is effectively converted into
or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates
a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than fifty percent (50%) of the outstanding
shares of common stock (not including any shares of common stock held by the other Person or other Persons making or party to, or associated
or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a
&#8220;Fundamental Transaction&#8221;), then, the Series A Holder shall have the right to receive, for each conversion share that would
have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation
set forth in the Series A Certificate of Designation on the conversion of the Series A Preferred Stock), the number of shares of common
stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and/or any additional consideration
(the &#8220;Alternate Consideration&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares
of common stock for which the Series A Preferred Stock is convertible immediately prior to such Fundamental Transaction (without regard
to the limitations set forth in the Series A Certificate of Designation on the conversion of the Series A Preferred Stock). For purposes
of any such conversion, the determination of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of common stock in such Fundamental Transaction, and the
Company shall apportion the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of
any different components of the Alternate Consideration. If holders of common stock are given any choice as to the securities, cash or
property to be received in a Fundamental Transaction, then the Series A Holder shall be given the same choice as to the Alternate Consideration
it receives upon such Fundamental Transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Voting Rights.</i>&#160;The Series A Holders
will have no voting rights, except as otherwise required by the Delaware General Corporation Law. Notwithstanding the foregoing, as long
as any shares of Series A Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders of a majority
of the then outstanding shares of Series A Preferred Stock, voting as a separate class, (a) alter or change adversely the powers, preferences
or rights given to the Series A Preferred Stock in the Series A Certificate of Designation, (b) increase the number of authorized shares
of Series A Preferred Stock, (c) authorize or issue an additional class or series of capital stock that ranks senior to the Series A Preferred
Stock with respect to the distribution of assets on liquidation or (d) enter into any agreement with respect to any of the foregoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Fractional Shares.</i>&#160;No
fractional shares or scrip representing fractional shares shall be issued upon the conversion of the Series A Preferred Stock. As to any
fraction of a share of Company common stock which a Series A Holder would otherwise be entitled to upon such conversion, the Company will,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Conversion Price or round up to the next whole share. Notwithstanding the foregoing, nothing shall prevent any Series A Holder from converting
fractional shares of Series A Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As of December 31, 2024
and 2023, 9,000 shares of Series A Preferred Stock were issued and outstanding. On January 9, 2025, the 9,000 shares of Series A Preferred
Stock were exchanged for 5,000 shares of Series D Preferred Stock of the Company (see Note 22 - Subsequent Events - Series D Convertible
Preferred Stock).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Series B Convertible
Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company designated
up to 15,000 shares of its previously undesignated preferred stock as Series B Preferred Stock. Each share of Series B Preferred Stock
has a par value of $0.0001 per share and a stated value equal to $1,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The shares of Series
B Preferred Stock have identical terms and include the terms as set forth below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dividends.</i>&#160;The Series B Holders shall
be entitled to receive, and the Company shall pay, dividends on shares of Series B Preferred Stock equal (on an as-if-converted-to-common-stock
basis, disregarding for such purpose any conversion limitations set forth in the Series B Certificate of Designations) to and in the same
form as dividends actually paid on shares of the Company&#8217;s common stock when, as and if such dividends are paid on shares of the
common stock. No other dividends shall be paid on shares of Series B Preferred Stock. The Company will not pay any dividends on its common
stock unless the Company simultaneously complies with the terms set forth in the Series B Certificate of Designation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Rank.</i>&#160;The Series B Preferred Stock
will rank subordinate to the shares of the Company&#8217;s Series A Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Liquidation.&#160;</i>Upon any Liquidation,
the Series B Holders will be entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to
the payment in full of all amounts required to be distributed to the holders of another class or series of stock of the Company ranking
on liquidation prior and in preference to the Series B Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any
class or series of stock ranking on liquidation on parity with the Series B Preferred Stock and (iii) in preference and priority to the
holders of the shares of common stock, an amount equal to one hundred percent (100%) of the Series B Stated Value and no more, in proportion
to the full and preferential amount that all shares of the Series B Preferred Stock are entitled to receive. The Company shall mail written
notice of any such Liquidation not less than twenty (20) days prior to the payment date stated therein, to each Series B Holder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Conversion.</i>&#160;Each share of Series B
Preferred Stock shall be convertible, at any time and from time to time from and after the later of (i) the date of the stockholder approval
and (ii) the one year anniversary of the Closing Date (the &#8220;Lock Up Period&#8221;), at the option of the Series B Holder thereof,
into that number of shares of common stock (subject to the limitations set forth in Series B Certificate of Designation determined by
dividing the Series B Stated Value of such share of Series B Preferred Stock by the conversion price of the Series B Preferred Stock).
Series B Holders may effect conversions by providing the Company with the form of conversion notice attached as Annex A to the Series
B Certificate of Designation. The Series B Preferred Stock will be convertible into shares of the Company&#8217;s common stock at a conversion
price per share equal to $56.70, subject to the adjustments set forth in the Series B Certificate of Designation. Notwithstanding the
foregoing or the transactions contemplated by the Amended MIPA, until the consummation of the Lock Up Period, the Series B Holders shall
not, directly or indirectly, sell, transfer or otherwise dispose of any Series B Preferred Stock issued upon conversion of the Series
B Conversion Shares or pursuant to the Equity Earnout Payment (the &#8220;Restricted Securities&#8221;) without Company&#8217;s prior
written consent; provided, however, the Series B Holders may sell, transfer or otherwise dispose of Restricted Securities to an Affiliate,
as defined in the Amended MIPA, of a Series B Holder without Company&#8217;s prior written consent; provided, further, that such Series
B Holder provide prompt written notice to Company of such transfer, including the name and contact information of the Affiliate transferee,
and such Affiliate transferee agrees in writing to be bound by the terms of the transaction documents contemplated by the Amended MIPA
to which the Series B Holder is a party (which agreement shall also be provided to Company with such notice). After the expiration of
the Lock Up Period, the Series B Holder agrees that it and any of its Affiliate transferees shall not be entitled to in any calendar month,
sell a number of shares of Company common stock into the open market in an amount exceeding more than ten percent (10%) of the total number
of shares of Company common stock issuable upon conversion of the Company common stock then held by the Seller and its Affiliates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Conversion Price Adjustment:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stock Dividends and Stock Splits.</i>&#160;If
the Company, at any time while the Series B Preferred Stock is outstanding: (i) pays a stock dividend or otherwise makes a distribution
or distributions payable in shares of common stock on shares of common stock or any other common stock equivalents (which, for avoidance
of doubt, shall not include any shares of common stock issued by the Company upon conversion of, or payment of a dividend on, the Series
B Preferred Stock), (ii) subdivides outstanding shares of common stock into a larger number of shares, (iii) combines (including by way
of a reverse stock split) outstanding shares of common stock into a smaller number of shares, or (iv) issues, in the event of a reclassification
of shares of the common stock, any shares of capital stock of the Company, then the conversion price of the Series B Preferred Stock shall
be multiplied by a fraction of which the numerator shall be the number of shares of common stock (excluding any treasury shares of the
Company) outstanding immediately before such event, and of which the denominator shall be the number of shares of common stock outstanding
immediately after such event. Any of the foregoing adjustments shall become effective immediately after the record date for the determination
of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the
case of a subdivision, combination or re-classification.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fundamental Transaction.</i>&#160;If, at any
time while the Series B Preferred Stock is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another Person, (ii) the Company (and all of its subsidiaries, taken as a whole),
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of the Company&#8217;s common stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of fifty percent
(50%) or more of the outstanding common stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any
reclassification, reorganization or recapitalization of the common stock or any compulsory share exchange pursuant to which the common
stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in
one or more related transactions consummates a Fundamental Transaction, then, at the closing of such Fundamental Transaction, without
any action on the part of the Series B Holder, the Series B Holder shall have the right to receive, for each conversion share that would
have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation
in the Series B Certificate of Designation on the conversion of the Series B Preferred Stock), the number of shares of common stock of
the successor or acquiring corporation or of the Company, if it is the surviving corporation, and/or any Alternate Consideration receivable
as a result of such Fundamental Transaction by a holder of the number of shares of common stock for which the Series B Preferred Stock
is convertible immediately prior to such Fundamental Transaction (without regard to the limitations set forth in the Series B Certificate
of Designation on the conversion of the Series B Preferred Stock). For purposes of any such conversion, the determination of the conversion
price of the Series B Preferred Stock shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of
Alternate Consideration issuable in respect of one share of common stock in such Fundamental Transaction, and the Company shall apportion
the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of common stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Series B Holder shall be given the same choice as to the Alternate Consideration it receives upon
such Fundamental Transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Voting Rights</i>. The Series B Holders will
have no voting rights, except as otherwise required by the Delaware General Corporation Law. Notwithstanding the foregoing, in addition,
as long as any shares of Series B Preferred Stock are outstanding, the Company shall not, without the affirmative vote of the holders
of a majority of the then outstanding shares of the Series B Preferred Stock, voting as a separate class, (a) alter or change adversely
the powers, preferences or rights given to the Series B Preferred Stock in the Series B Certificate of Designation, (b) increase the number
of authorized shares of Series B Preferred Stock, (c) except with respect to the Series A Preferred Stock, authorize or issue an additional
class or series of capital stock that ranks senior to the Series B Preferred Stock with respect to the distribution of assets on liquidation
or (d) enter into any agreement with respect to any of the foregoing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Fractional Shares.</i>
No fractional shares or scrip representing fractional shares shall be issued upon the conversion of the Series B Preferred Stock. As to
any fraction of a share which a Series B Holder would otherwise be entitled to upon such conversion, the Company shall at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price
or round up to the next whole share. Notwithstanding the foregoing, nothing shall prevent any Series B Holder from converting fractional
shares of Series B Preferred Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As of December 31, 2024
and 2023, 11,000 shares of Series B Preferred Stock were issued and outstanding. On February 26, 2025, all shares of the Company&#8217;s
Series B Convertible Preferred Stock were permanently surrendered and relinquished to the Company for no additional consideration (see
Note 22 - Subsequent Events - Redemption Agreement).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Series C Convertible
Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On December 13, 2024,
the Company filed a certificate of designations of preferences, rights, and limitations of Series C Convertible Preferred Stock (the &#8220;Series
C Certificate of Designations&#8221;) with the Department of State, Division of Corporations, of the State of Delaware, which provides
for the designation of 10,000 shares of Series C Preferred Stock of the Company, par value $0.0001 per share. Each share of Series C Preferred
Stock has a stated value of $1,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Series C Preferred
Stock shall rank (i) senior to the Company&#8217;s common stock (the &#8220;Common Stock&#8221;) and any other class or series of capital
stock of the Company created hereafter, the terms of which specifically provide that such class or series shall rank junior to the Series
C Preferred Stock, (ii) pari passu with any class or series of capital stock of the Company created hereafter specifically ranking, by
its terms, on par with the Series C Preferred Stock, (iii) pari passu with Series B Convertible Preferred Stock of the Company (the &#8220;Series
B Preferred Stock&#8221;) with respect to its rights, preferences and restrictions, and (iv) subordinate to the Series A Convertible Preferred
Stock of the Company (the &#8220;Series A Preferred Stock&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Holders of the Series
C Preferred Stock shall be entitled to receive, and the Company shall pay, dividends on shares of Series C Preferred Stock equal (on an
as-if-converted-to-Common-Stock basis, disregarding for such purpose any conversion limitations hereunder) to and in the same form as
dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Holders of the Series
C Preferred Stock have no voting power except as otherwise required by the Delaware General Corporation Law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Upon any liquidation,
dissolution or winding-up of the Company, whether voluntary or involuntary (a &#8220;Liquidation&#8221;), the holders of the Series C
Preferred Stock shall be entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to the
payment in full of all amounts required to be distributed to the holders of another class or series of stock of the Company ranking on
liquidation prior and in preference to the Series C Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any class
or series of stock ranking on liquidation on parity with the Series C Preferred Stock and (iii) in preference and priority to the holders
of the shares of Common Stock, an amount equal to 100% of the Stated Value of the Series C Preferred Stock, in proportion to the full
and preferential amount that all shares of the Series C Preferred Stock are entitled to receive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Each share of Series
C Preferred Stock shall be convertible into Common Stock (the &#8220;Conversion Shares&#8221;) at a conversion per share equal to $2.41,
at the option of the holder, at any time after the later of (i) the date of the shareholder approval of the issuance of the Conversion
Shares pursuant to the rules of the Nasdaq Stock Market and (ii) the one year anniversary of the date of the first issuance of any shares
of the Series C Preferred Stock. In addition, the holder shall not have the right to convert any portion of the Series C Preferred Stock
if, after giving effect to the conversion, such holder (together with its affiliates) would beneficially own in excess of 19.99% of the
number of shares of the Common Stock outstanding immediately after giving effect to the issuance of the respective Conversion Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As of December 31, 2024,
3,500 shares of Series C Preferred Stock were issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Series B Convertible
Preferred Stock Issued for Equity Method Investment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 9, 2023, the Company issued 11,000 shares of its Series
B Convertible Preferred Stock as a part of consideration for the purchase of 40% of equity interest of Lab Services MSO. The Series B
Preferred Stock is convertible into shares of the Company&#8217;s common stock at a conversion price per share equal to $56.70, which
approximated the market price at the date of closing, or an aggregate of 194,004 shares of the Company&#8217;s common stock and are subject
to a lock-up period and restrictions on sale.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Series C Convertible
Preferred Stock Sold for Cash</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During the year ended December 31, 2024, the Company sold an aggregate
of 3,500 shares of Series C Convertible Preferred stock and received proceeds of $3,500,000. Each share of Series C Convertible Preferred
Stock is convertible into common stock of the Company (the &#8220;Conversion Shares&#8221;) at a conversion per share equal to $2.41,
which approximated the market price at the date of transaction, at the option of the holder, at any time after the later of (i) the date
of the shareholder approval of the issuance of the Conversion Shares pursuant to the rules of the Nasdaq Stock Market (the &#8220;Shareholder
Approval&#8221;) and (ii) the one year anniversary of the date of the first issuance of any shares of the Series C Convertible Preferred
Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company evaluated
the features of the Series C Convertible Preferred Stock under ASC 480, and classified them as permanent equity because the Series C Convertible
Preferred Stock is not mandatorily or contingently redeemable at the stockholder&#8217;s option and the liquidation preference that exists
does not fall within the guidance of SEC Accounting Series Release No. 268 -&#160;<i>Presentation in Financial Statements of &#8220;Redeemable
Preferred Stocks&#8221;</i>&#160;(&#8220;ASR 268&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Common Shares Issued
as Convertible Note Payable Commitment Fee</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During the year ended
December 31, 2023, the Company issued a total of 11,333 shares of its common stock as commitment fee for the purchases of May 2023 Convertible
Note, July 2023 Convertible Note, and October 2023 Convertible Note. These shares were valued at $236,400, the fair market values on the
grant dates using the reported closing share prices on the dates of grant, and the Company recorded it as debt discount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During the year ended
December 31, 2024, the Company issued a total of&#160;33,800&#160;shares of its common stock as commitment fee for the purchase of March
2024 Convertible Note and June 2024 Convertible Note. These shares were valued at $320,546, the fair market value on the grant dates using
the reported closing share prices on the dates of grant, and the Company recorded it as debt discount.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Common Shares Sold
for Cash</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2023, the Company entered into a sales
agreement (the &#8220;Sales Agreement&#8221;) with Roth Capital Partners, LLC (&#8220;Roth&#8221;) under which the Company may offer and
sell from time to time shares of its common stock having an aggregate offering price of up to $3.5&#160;million. During the year ended
December 31, 2023, Roth sold an aggregate of&#160;30,442&#160;shares of common stock at an average price of $20.85&#160;per share to investors
and the Company recorded net proceeds of $414,396, net of commission and other offering costs of $220,995.&#160;During the year ended
December 31, 2024, Roth sold an aggregate of&#160;281,843&#160;shares of common stock at an average price of $10.14&#160;per share to
investors and the Company recorded net proceeds of $2,544,311, net of commission and other offering costs of $313,541.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Shares Issued for Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">During the
year ended December 31, 2023, the Company issued a total of 24,089 shares of its common stock for services rendered. These shares were
valued at $999,655, the fair market values on the grant dates using the reported closing share prices on the dates of grant, and the Company
recorded stock-based compensation expense of $834,784 for the year ended December 31, 2023 and reduced accrued liabilities of $164,871.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2024, the Company
issued a total of 145,153 shares of its common stock for services rendered. These shares were valued at $530,350, the fair market values
on the grant dates using the reported closing share prices on the dates of grant, and the Company recorded stock-based compensation expense
of $470,350 for the year ended December 31, 2024 and reduced accrued liabilities of $60,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Common Shares Issued
for Warrant Exercise</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On November 18, 2024,
the Company issued 42,381 shares of its common stock upon cashless exercise of warrants to purchase 6,278 shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Common Shares Issued
for Adjustment for 1:15 Reverse Split</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company issued 206,033
shares of its common stock, resulting from the rounding up of the fractional shares at the one-for-fifteen reverse stock split effected
on October 28, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Pre-Funded Warrants
Issued for Debt Modification</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On December 15, 2024,
the Company issued to Mast Hill a common stock purchase warrant for the purchase of up to 150,000 shares of the Company&#8217;s common
stock. The Pre-Funded Warrants are immediately exercisable at issuance and until the Pre-Funded Warrants are exercised in full and have
an exercise price of $0.01 per share. The Pre-Funded Warrants were classified as a component of permanent equity as they are freestanding
financial instrument that is immediately exercisable, does not embody an obligation for the Company to repurchase its own shares and permit
the holder to receive a fixed number of shares of common stock upon exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table summarizes
the shares of the Company&#8217;s common stock issuable upon exercise of options outstanding at December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Options Outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Options Exercisable</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Range<br/> of Exercise <br/> Price</td> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number <br/>
Outstanding at<br/> December 31, <br/>
2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted Average</p> <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number Exercisable at<br/> December 31, <br/>
2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise <br/>Price</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">2.93 - 31.20</td> <td style="width: 1%">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">20,198</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">3.54</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">14.76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">14,591</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">16.38</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: right">48.75 - 123.00</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,517</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2.04</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">78.91</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,517</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">78.91</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">154.50 - 289.50</td> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,764</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.44</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">218.21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,764</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">218.21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.93 - 289.50</td> <td>&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">52,479</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2.93</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">85.45</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">46,872</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">94.41</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Stock option activity
for the years ended December 31, 2024 and 2023 was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Options</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">53,357</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">195.45</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,452</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,929</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(267.90</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149.03</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,265</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.13</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,666</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(275.14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">52,479</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">85.45</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Options exercisable at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,872</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">94.41</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options expected to vest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10.56</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value of stock options
outstanding and stock options exercisable at December 31, 2024 was approximately $1,900&#160;an $900, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The fair values of options granted during
the year ended December 31, 2024 were estimated at the date of grant using the Black-Scholes option-pricing model with the following
assumptions: volatility of&#160;83.10% -&#160;96.36%, risk-free rate of&#160;3.47% -&#160;4.79%, annual dividend yield of&#160;0%, and
expected life of&#160;3.00 - 5.00&#160;years. The aggregate fair value of the options granted during the year ended December 31, 2024
was $28,694.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The fair values of options granted during
the year ended December 31, 2023 were estimated at the date of grant using the Black-Scholes option-pricing model with the following
assumptions: volatility of&#160;79.76% -&#160;96.37%, risk-free rate of&#160;3.58% -&#160;4.76%, annual dividend yield of&#160;0%, and
expected life of&#160;3.00&#160;-&#160;5.00&#160;years. The aggregate fair value of the options granted during the year ended December
31, 2023 was $319,380.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2024 and 2023,
stock-based compensation expense associated with stock options granted amounted to $51,159&#160;and $284,977, of which, $19,878&#160;and
$172,943&#160;was recorded as compensation and related benefits, $31,281&#160;and $106,565&#160;was recorded as professional fees, and
$0&#160;and $5,469&#160;was recorded as research and development expenses, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the status of the Company&#8217;s
nonvested stock options granted as of December 31, 2024 and changes during the years ended December 31, 2024 and 2023 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Options</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Nonvested at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,334</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">64.35</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,452</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,475</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47.14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Nonvested at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,311</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23.55</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,265</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.13</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,969</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10.90</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Nonvested at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,607</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10.56</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants (Except Pre-Funded Warrants)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the shares of the
Company&#8217;s common stock issuable upon exercise of warrants outstanding at December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants Exercisable</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Range of<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">Number<br/> Outstanding at <br/>
December 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average<br/> Remaining<br/> Contractual<br/> Life (Years)</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">Weighted<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">Number<br/> Exercisable at<br/> December 31<br/>
, 2024</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Weighted Average Exercise</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Price</p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 13.5%; text-align: right">7.50 - 37.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">&#160;&#160;&#160;&#160;&#160;165,510</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4.40</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 13.5%; text-align: right">10.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13.5%; text-align: right">85,510</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 13.5%; text-align: right">13.31</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: right">67.50</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,222</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.40</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">67.50</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,222</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">67.50</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">187.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.30</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">187.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">187.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7.50 - 187.50</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">182,996</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4.25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">102,996</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">32.13</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Stock warrant activity
for the years ended December 31, 2024 and 2023 was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Warrants</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,264</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">187.50</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Issued</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34,771</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48.90</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,035</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75.53</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,527</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.28</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23,288</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(32.85</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,278</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(50.77</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">182,996</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants exercisable at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102,996</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">32.13</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants expected to vest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.50</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Second Warrant, which was issued on May 23, 2023, July 6,
2023, October 9, 2023, and March 7, 2024, was cancelled in June 2024. Second Warrant, which was issued on June 5, 2024, is still outstanding
as of December 31, 2024.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value of both stock warrants
outstanding and stock warrants exercisable at December 31, 2024 was $0.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Warrants Issued in
May 2023</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
issuance of May 2023 Convertible Note (See Note 10), the Company issued (i) a warrant to purchase 8,333 shares of common stock with an
exercise price of $67.50 exercisable until the five-year anniversary of May 23, 2023, and (ii) a warrant to purchase 7,033 shares of common
stock with an exercise price of $48.00 exercisable until the five-year anniversary of May 23, 2023, which warrant was never fair valued
and was cancelled and extinguished against payment of the May 2023 Convertible Note, to Mast Hill; and issued a warrant to purchase 667
shares of common stock with an exercise price of $67.50 exercisable until the five-year anniversary of May 23, 2023 to a third party as
a finder&#8217;s fee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Based upon the Company&#8217;s
analysis of the criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a
finder&#8217;s fee meet the definition of derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances.
Accordingly, the fair value of the 9,000 warrants with an exercise price of $67.50 exercisable until the five-year anniversary of May
23, 2023 was classified as derivative liability on May 23, 2023. The fair values of the 9,000 warrants with an exercise price of $67.50
exercisable until the five-year anniversary of May 23, 2023 issued on May 23, 2023 were computed using the Black-Scholes option-pricing
model with the following assumptions: stock price of $29.40, volatility of 88.80%, risk-free rate of 3.76%, annual dividend yield of 0%
and expected life of 5 years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The warrants with an
exercise price of $67.50 exercisable until the five-year anniversary of May 23, 2023 issued to Mast Hill to purchase 8,333 shares of the
Company&#8217;s common stock were treated as a discount on the convertible note payable and were valued at $127,654 and were amortized
over the term of the May 2023 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The warrants with an
exercise price of $67.50 exercisable until the five-year anniversary of May 23, 2023 issued to a third party as a finder&#8217;s fee to
purchase 667 shares of the Company&#8217;s common stock were treated as convertible debt issuance costs and were valued at $11,162 and
were amortized over the term of the May 2023 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Warrants Issued in
July 2023</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
issuance of July 2023 Convertible Note (See Note 10), the Company issued (i) a warrant to purchase 2,778 shares of common stock with an
exercise price of $67.50 exercisable until the five-year anniversary of July 6, 2023, and (ii) a warrant to purchase 2,344 shares of common
stock with an exercise price of $48.00 exercisable until the five-year anniversary of July 6, 2023, which warrant was never fair valued
and was cancelled and extinguished against payment of the July 2023 Convertible Note, to Firstfire; and issued a warrant to purchase 222
shares of common stock with an exercise price of $67.50 exercisable until the five-year anniversary of July 6, 2023 to a third party as
a finder&#8217;s fee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Based upon the Company&#8217;s
analysis of the criteria contained in ASC 815, the Company determined that all the warrants issued to Firstfire and a third party as a
finder&#8217;s fee meet the definition of derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances.
Accordingly, the fair value of the 3,000 warrants with an exercise price of $67.50 exercisable until the five-year anniversary of July
6, 2023 was classified as derivative liability on July 6, 2023. The fair values of the 3,000 warrants with an exercise price of $67.50
exercisable until the five-year anniversary of July 6, 2023 issued on July 6, 2023 were computed using the Black-Scholes option-pricing
model with the following assumptions: stock price of $21.30, volatility of 88.52%, risk-free rate of 4.37%, annual dividend yield of 0%
and expected life of 5 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The warrants with an
exercise price of $67.50 exercisable until the five-year anniversary of July 6, 2023 issued to Firstfire to purchase 2,778 shares of the
Company&#8217;s common stock were treated as a discount on the convertible note payable and were valued at $28,691 and were amortized
over the term of the July 2023 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants with an exercise price of $67.50
exercisable until the five-year anniversary of July 6, 2023 issued to a third party as a finder&#8217;s fee to purchase 222 shares of
the Company&#8217;s common stock were treated as convertible debt issuance costs and were valued at $2,435 and were amortized over the
term of the July 2023 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Warrants Issued in
October 2023</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
issuance of October 2023 Convertible Note (See Note 10), the Company issued (i) a warrant to purchase 7,000 shares of common stock with
an exercise price of $37.50 exercisable until the five-year anniversary of October 9, 2023, (ii) a warrant to purchase 5,834 shares of
common stock with an exercise price of $27.00 exercisable until the five-year anniversary of October 9, 2023, which warrant was never
fair valued and was cancelled and extinguished against payment of the October 2023 Convertible Note, to Mast Hill and Firstfire; and issued
a warrant to purchase 560 shares of common stock with an exercise price of $37.50 exercisable until the five-year anniversary of October
9, 2023 to a third party as a finder&#8217;s fee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon the Company&#8217;s analysis of the
criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and Firstfire and a third party as a finder&#8217;s
fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances. Accordingly,
the fair value of the 7,560 warrants with an exercise price of $37.50 exercisable until the five-year anniversary of October 9, 2023 was
classified as a derivative liability on October 9, 2023. The fair values of the 7,560 warrants with an exercise price of $37.50 exercisable
until the five-year anniversary of October 9, 2023 issued on October 9, 2023 were computed using the Black-Scholes option-pricing model
with the following assumptions: stock price of $11.55, volatility of 89.70%, risk-free rate of 4.75%, annual dividend yield of 0% and
expected life of 5 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The warrants with an
exercise price of $37.50 exercisable until the five-year anniversary of October 9, 2023 issued to Mast Hill and Firstfire to purchase
7,000 shares of the Company&#8217;s common stock were treated as a discount on the convertible note payable and were valued at $39,848
and were amortized over the term of the October 2023 Convertible Note.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants with an exercise price of $37.50
exercisable until the five-year anniversary of October 9, 2023 issued to a third party as a finder&#8217;s fee to purchase 560 shares
of the Company&#8217;s common stock were treated as convertible debt issuance costs and were valued at $3,380 and were amortized over
the term of the October 2023 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Warrants Issued in
March 2024</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
issuance of March 2024 Convertible Note (See Note 10), the Company issued&#160;(i) a warrant to purchase 8,750 shares of common stock
with an exercise price of $30.00 exercisable until the five-year anniversary of March 7, 2024 (&#8220;First Warrant&#8221;), (ii) a warrant
to purchase 8,077 shares of common stock with an exercise price of $19.50 (&#8220;Second Warrant&#8221;), which warrant was never fair
valued and was cancelled and extinguished against payment of the March 2024 Convertible Note, to Mast Hill; and issued a warrant to purchase
700 shares of common stock with an exercise price of $30.00 exercisable until the five-year anniversary of March 7, 2024 to a third party
as a finder&#8217;s fee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Based upon the Company&#8217;s
analysis of the criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a
finder&#8217;s fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances.
The fair value of the&#160;9,450&#160;warrants with an exercise price of $30.00&#160;exercisable until the five-year anniversary of March
7, 2024 was classified as a derivative liability on March 7, 2024. The fair values of the&#160;9,450&#160;warrants with an exercise price
of $30.00&#160;exercisable until the five-year anniversary of March 7, 2024 issued on March 7, 2024 were computed using the Black-Scholes
option-pricing model with the following assumptions: stock price of $6.00, volatility of&#160;85.24%, risk-free rate of&#160;4.07%, annual
dividend yield of&#160;0% and expected life of&#160;5&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The warrants with an
exercise price of $30.00&#160;exercisable until the five-year anniversary of March 7, 2024 issued to Mast Hill to purchase&#160;8,750&#160;shares
of the Company&#8217;s common stock were treated as a discount on the convertible note payable and were valued at $20,374&#160;and were
amortized over the term of the March 2024 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The warrants with an
exercise price of $30.00&#160;exercisable until the five-year anniversary of March 7, 2024 issued to a third party as a finder&#8217;s
fee to purchase&#160;700&#160;shares of the Company&#8217;s common stock were treated as convertible debt issuance costs and were valued
at $1,679&#160;and were amortized over the term of the March 2024 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Warrants Issued in
June 2024</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the issuance of June 2024 Convertible
Note (See Note 10), the Company issued&#160;(i) a warrant to purchase 66,667 shares of common stock with an exercise price of $9.75 exercisable
until the five-year anniversary of June 5, 2024 (&#8220;First Warrant&#8221;), (ii) a warrant to purchase 80,000 shares of common stock
with an exercise price of $7.50 exercisable until the five-year anniversary of June 5, 2024 (&#8220;Second Warrant&#8221;), which warrant
shall be cancelled and extinguished against payment of the June 2024 Convertible Note, to Mast Hill; and issued a warrant to purchase
5,333 shares of common stock with an exercise price of $9.75 exercisable until the five-year anniversary of June 5, 2024 to a third party
as a finder&#8217;s fee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon the Company&#8217;s analysis of the
criteria contained in ASC 815, the Company determined that all the warrants issued to Mast Hill and a third party as a finder&#8217;s
fee meet the definition of a derivative liability, as the Company cannot avoid a net cash settlement under certain circumstances. Management
determined the probability of failing to make an amortization payment when due to be remote and as such the fair value of the&#160;80,000&#160;warrants
with an exercise price of $7.50&#160;exercisable until the five-year anniversary of June 5, 2024, which warrant shall be cancelled and
extinguished against payment of the June 2024 Convertible Note, has been estimated to be zero. Accordingly, the fair value of the&#160;72,000&#160;warrants
with an exercise price of $9.75&#160;exercisable until the five-year anniversary of June 5, 2024 was classified as a derivative liability
on June 5, 2024. The fair values of the&#160;72,000&#160;warrants with an exercise price of $9.75&#160;exercisable until the five-year
anniversary of June 5, 2024 issued on June 5, 2024 were computed using the Black-Scholes option-pricing model with the following assumptions:
stock price of $10.39, volatility of&#160;85.72%, risk-free rate of&#160;4.31%, annual dividend yield of&#160;0% and expected life of&#160;5&#160;years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants with an exercise price of $9.75&#160;exercisable
until the five-year anniversary of June 5, 2024 issued to Mast Hill to purchase&#160;66,667&#160;shares of the Company&#8217;s common
stock were treated as a discount on the convertible note payable and were valued at $418,194&#160;and will be amortized over the term
of the June 2024 Convertible Note.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants with an exercise price of $9.75&#160;exercisable
until the five-year anniversary of June 5, 2024 issued to a third party as a finder&#8217;s fee to purchase&#160;5,333&#160;shares of
the Company&#8217;s common stock were treated as convertible debt issuance costs and were valued at $39,221&#160;and will be amortized
over the term of the June 2024 Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Warrants Cancelled
in June 2024</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As of June 5, 2024, the
Company paid in full of its outstanding May 2023 Convertible Note, July 2023 Convertible Note, October 2023 Convertible Note, and March
2024 Convertible Note and cancelled&#160;23,288&#160;warrants since these convertible notes were fully extinguished.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i>Warrants Exercised
in November 2024</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On November 18, 2024,
6,278 warrants were cashless exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">A summary of the status
of the Company&#8217;s nonvested stock warrants issued as of December 31, 2024 and changes during the years ended December 31, 2024 and
2023 was presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Warrants</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Nonvested at January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-354">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-355">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%">Issued</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">34,771</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">48.90</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,560</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">55.95</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Nonvested at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,211</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39.90</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,527</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.28</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23,288</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(32.85</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(81,450</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12.10</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Nonvested at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">80,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7.50</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statutory Reserve and Restricted Net Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherRestrictedAssetsAbstract', window );"><strong>Statutory Reserve and Restricted Net Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_StatutoryReserveAndRestrictedNetAssetsTextBlock', window );">STATUTORY RESERVE AND RESTRICTED NET ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">NOTE 11 - <span style="text-decoration:underline">STATUTORY RESERVE AND RESTRICTED
NET ASSETS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company&#8217;s PRC subsidiary, Avalon Shanghai,
is restricted in its ability to transfer a portion of its net asset to the Company. The payment of dividends by entities organized in
China is subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment of dividends only out of
accumulated profits as determined in accordance with accounting standards and regulations in China.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company is required to make appropriations
to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus reserve, based on after-tax net income
determined in accordance with generally accepted accounting principles of the PRC (&#8220;PRC GAAP&#8221;). Appropriations to the statutory
surplus reserve are required to be at least 10% of the after-tax net income determined in accordance with PRC GAAP until the reserve
is equal to 50% of the entity&#8217;s registered capital. Appropriations to the discretionary surplus reserve are made at the discretion
of the Board of Directors. The statutory reserve may be applied against prior year losses, if any, and may be used for general business
expansion and production or increase in registered capital, but are not distributable as cash dividends. The Company did not make any
appropriation to statutory reserve for Avalon Shanghai during the three months ended March 31, 2025 as it incurred net loss in the period.
As of both March 31, 2025 and December 31, 2024, the restricted amount as determined pursuant to PRC statutory laws totaled $6,578.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Relevant PRC laws and regulations restrict the
Company&#8217;s PRC subsidiary, Avalon Shanghai, from transferring a portion of its net assets, equivalent to its statutory reserve and
its share capital, to the Company&#8217;s shareholders in the form of loans, advances or cash dividends. Only PRC entity&#8217;s accumulated
profit may be distributed as dividend to the Company&#8217;s shareholders without the consent of a third party. As of both March 31,
2025 and December 31, 2024, total restricted net assets amounted to $1,206,578.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 16 - <span style="text-decoration:underline">STATUTORY
RESERVE AND RESTRICTED NET ASSETS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company&#8217;s PRC
subsidiary, Avalon Shanghai, is restricted in its ability to transfer a portion of its net asset to the Company. The payment of dividends
by entities organized in China is subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment
of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company is required
to make appropriations to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus reserve, based
on after-tax net income determined in accordance with generally accepted accounting principles of the PRC (&#8220;PRC GAAP&#8221;). Appropriations
to the statutory surplus reserve are required to be at least&#160;10% of the after-tax net income determined in accordance with PRC GAAP
until the reserve is equal to&#160;50% of the entity&#8217;s registered capital. Appropriations to the discretionary surplus reserve are
made at the discretion of the Board of Directors. The statutory reserve may be applied against prior year losses, if any, and may be used
for general business expansion and production or increase in registered capital, but are not distributable as cash dividends. The Company
did not make any appropriation to statutory reserve for Avalon Shanghai during the years ended December 31, 2024 and 2023 as it incurred
net loss in the periods. As of both December 31, 2024 and 2023, the restricted amount as determined pursuant to PRC statutory laws totaled
$6,578.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Relevant PRC laws and
regulations restrict the Company&#8217;s PRC subsidiary, Avalon Shanghai, from transferring a portion of its net assets, equivalent to
its statutory reserve and its share capital, to the Company&#8217;s shareholders in the form of loans, advances or cash dividends. Only
PRC entity&#8217;s accumulated profit may be distributed as dividend to the Company&#8217;s shareholders without the consent of a third
party. As of December 31, 2024 and 2023, total restricted net assets amounted to $1,206,578 and $1,106,578, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_StatutoryReserveAndRestrictedNetAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Statutory reserve and restricted net assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_StatutoryReserveAndRestrictedNetAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestrictedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestrictedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Noncontrolling Interest<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">Noncontrolling Interest</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 17 - <span style="text-decoration:underline">NONCONTROLLING
INTEREST</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As of December
31, 2024, Dr. Yu Zhou, former director and former co-chief executive officer of Genexosome, who owns 40% of the equity interests of Genexosome,
which is not under the Company&#8217;s control. During the years ended December 31, 2024 and 2023, the Company did not allocate any net
loss and foreign currency translation adjustment to the noncontrolling interest holder due to its inability to satisfy these deficits.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Financial Information of the Parent Company<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information of the Parent Company [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock', window );">CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">NOTE 12 - <span style="text-decoration:underline">CONDENSED FINANCIAL INFORMATION
OF THE PARENT COMPANY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Pursuant to the requirements of Rule 12-04(a),
5-04(c) and 4-08(e)(3) of Regulation S-X, the condensed financial information of the parent company shall be filed when the restricted
net assets of consolidated subsidiary exceed 25% of consolidated net assets as of the end of the most recently completed fiscal year.
For purposes of this test, restricted net assets of consolidated subsidiary shall mean that amount of the Company&#8217;s proportionate
share of net assets of consolidated subsidiary (after intercompany eliminations) which as of the end of the most recent fiscal year may
not be transferred to the parent company by subsidiary in the form of loans, advances or cash dividends without the consent of a third
party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company performed a test on the restricted
net assets of consolidated subsidiary in accordance with such requirement and concluded that it was not applicable to the Company as
the restricted net assets of the Company&#8217;s PRC subsidiary did not exceed 25% of the consolidated net assets of the Company, therefore,
the condensed financial statements for the parent company have not been required.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 18 - <span style="background-color: white"><span style="text-decoration:underline">CONDENSED
FINANCIAL INFORMATION OF THE PARENT COMPANY</span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the requirements
of Rule 12-04(a), 5-04(c) and 4-08(e)(3) of Regulation S-X, the condensed financial information of the parent company shall be filed when
the restricted net assets of consolidated subsidiary exceed 25% of consolidated net assets as of the end of the most recently completed
fiscal year. For purposes of this test, restricted net assets of consolidated subsidiary shall mean that amount of the Company&#8217;s
proportionate share of net assets of consolidated subsidiary (after intercompany eliminations) which as of the end of the most recent
fiscal year may not be transferred to the parent company by subsidiary in the form of loans, advances or cash dividends without the consent
of a third party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company performed
a test on the restricted net assets of consolidated subsidiary in accordance with such requirement and concluded that it was not applicable
to the Company as the restricted net assets of the Company&#8217;s PRC subsidiary did not exceed 25% of the consolidated net assets of
the Company, therefore, the condensed financial statements for the parent company have not been required.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Concentrations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">CONCENTRATIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">NOTE 13 - <span style="text-decoration:underline">CONCENTRATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">Customers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table sets forth information as
to each customer that accounted for 10% or more of the Company&#8217;s revenue for the three months ended March 31, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended March 31,</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Customer</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">A</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">28</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">28</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">B</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">17</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">18</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">C</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">11</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">12</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">One customer, which is a third party, whose outstanding
receivable accounted for 10% or more of the Company&#8217;s total outstanding rent receivable at March 31, 2025, accounted for 79.8%
of the Company&#8217;s total outstanding rent receivable at March 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">One customer, which is a third party, whose outstanding
receivable accounted for 10% or more of the Company&#8217;s total outstanding rent receivable at December 31, 2024, accounted for 76.9%
of the Company&#8217;s total outstanding rent receivable at December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">Suppliers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">No supplier accounted for 10% or more of the Company&#8217;s
purchase during the three months ended March 31, 2025 and 2024.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 19 -&#160;<span style="text-decoration:underline">CONCENTRATIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Customers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The following
table sets forth information as to each customer that accounted for 10% or more of the Company&#8217;s revenues for the years ended December
31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">Customer</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">29</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">30</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">One customer, which is
a third party, whose outstanding receivable accounted for 10% or more of the Company&#8217;s total outstanding rent receivable at December
31, 2024, accounted for 76.9% of the Company&#8217;s total outstanding rent receivable at December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Two customers, of which
one is a related party and the other is a third party, whose outstanding receivables accounted for 10% or more of the Company&#8217;s
total outstanding rent receivable at December 31, 2023, accounted for 80.6% of the Company&#8217;s total outstanding rent receivable at
December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Suppliers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">No supplier
accounted for 10% or more of the Company&#8217;s purchase during the years ended December 31, 2024 and 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-3A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">NOTE 14 - <span style="text-decoration:underline">SEGMENT INFORMATION</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The segment reporting structure uses the Company&#8217;s
management reporting structure as its foundation to reflect how the Company manages the businesses internally. During the three months
ended March 31, 2025 and 2024, the management reporting structure was composed of two strategic business units, mainly organized by services,
led by the Company&#8217;s President and Chief Executive Officer, who is its Chief Operating Decision Maker. Using the accounting guidance
on segment reporting, the Company determined that its two operating segments were aligned with its two reportable segments corresponding
to its strategic business units.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On February 9, 2023, the Company purchased 40%
of Lab Services MSO. During the first quarter of 2025, to preserve cash, the Company entered into discussions with Lab Services MSO for
the potential redemption of our investment and on February 26, 2025, the Company and Lab Services MSO entered into a Redemption and Abandonment
Agreement, whereby Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by the Company. During the three months
ended March 31, 2025 and 2024, the Company operated in two reportable business segments: (1) the real property operating segment, and
(2) laboratory testing services segment (which ended on February 26, 2025) since Lab Services MSO&#8217;s operating results were regularly
reviewed by the Company&#8217;s chief operating decision maker to make decisions about resources to be allocated to the segment and assess
its performance. The Company regularly reviewed the operating results and performance of Lab Services MSO, which was the Company&#8217;s
equity method investee.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The accounting policies for the segments are the
same as those described in Note 3. Our reportable segments are aligned principally around the differences in services. Real property
operating income is calculated by subtracting real property operating expenses from real property rental revenue; income from equity
method investment - Lab Services MSO is calculated by subtracting amortization of intangible assets acquired from acquisition and distribution
of earnings from equity investment from the Company&#8217;s share of Lab Services MSO&#8217;s net income. The assets and certain expenses
related to corporate activities are not allocated to the segments. Information with respect to these reportable business segments for
the three months ended March 31, 2025 and 2024 was as follows:</span></p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="14" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended March 31, 2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Real Property Operations</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Lab Services<br/>
 MSO</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Corporate /<br/>
 Other</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Real property rental revenue</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">349,800</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-388"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-389"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">349,800</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Real property operating expenses</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(280,390</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-390"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-391"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(280,390</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Real property operating income</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">69,410</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-392"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-393"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">69,410</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Income from equity method investment - Lab Services MSO</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-394"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">392,677</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-395"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">392,677</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Other operating expenses</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(90,762</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-396"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,178,100</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,268,862</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Other (expense) income:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-sec-ix-redline:true;-keep: true">Interest expense</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(194,307</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-397"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(365,711</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(560,018</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-sec-ix-redline:true;-keep: true">Other income (expense)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">228</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-398"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(115,546</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(115,318</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net (loss) income</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(215,431</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">392,677</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,659,357</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,482,111</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="14" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended March 31, 2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Real Property Operations</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Lab Services<br/>
 MSO</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Corporate /<br/>
 Other</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Real property rental revenue</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">314,588</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-399"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-400"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">314,588</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Real property operating expenses</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(263,126</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-401"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-402"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(263,126</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Real property operating income</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">51,462</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-403"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-404"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">51,462</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Income from equity method investment - Lab Services MSO</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-405"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">107,469</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-406"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">107,469</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Other operating expenses</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(114,287</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-407"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(887,706</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,001,993</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Other (expense) income:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-sec-ix-redline:true;-keep: true">Interest expense</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(194,307</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-408"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(324,700</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(519,007</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-sec-ix-redline:true;-keep: true">Other income (expense)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-409"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(5,448</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(5,444</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net (loss) income</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(257,128</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">107,469</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,217,854</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,367,513</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Identifiable long-lived tangible assets at March 31, 2025 and December
    31, 2024</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">March 31, <br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">December 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Real property operations</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,990,058</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,034,335</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Corporate/Other</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,153</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,298</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 9.25pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,991,211</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,035,633</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Identifiable long-lived tangible assets at March 31, 2025 and December
    31, 2024</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">March 31, <br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">December 31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">United States</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,990,058</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,034,335</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">China</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,153</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,298</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 9.25pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,991,211</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,035,633</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>NOTE
20 -&#160;<span style="text-decoration:underline">SEGMENT INFORMATION</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The segment reporting structure uses the Company&#8217;s
management reporting structure as its foundation to reflect how the Company manages the businesses internally. The management reporting
structure is composed of two strategic business units, mainly organized by services, led by the Company&#8217;s President and Chief Executive
Officer, who is its Chief Operating Decision Maker. Using the accounting guidance on segment reporting, the Company determined that its
two operating segments are aligned with its two reportable segments corresponding to its strategic business units.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 9, 2023, the Company purchased 40%
of Lab Services MSO. Commencing from the purchase date, February 9, 2023, the Company was active in the management of Lab Services MSO.
During the years ended December 31, 2024 and 2023, the Company operated in two reportable business segments: (1) the real property operating
segment, and (2) laboratory testing services segment (which commenced with the purchase date, February 9, 2023) since Lab Services MSO&#8217;s
operating results are regularly reviewed by the Company&#8217;s chief operating decision maker to make decisions about resources to be
allocated to the segment and assess its performance. The Company regularly reviews the operating results and performance of Lab Services
MSO, which is the Company&#8217;s equity method investee. See Note 22-Subsequent Events-Redemption Agreement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accounting policies for the segments are the
same as those described in Note 3. Our reportable segments are aligned principally around the differences in services. Real property operating
income is calculated by subtracting real property operating expenses from real property rental revenue; loss from equity method investment
- Lab Services MSO is calculated by subtracting amortization of intangible assets acquired from acquisition and impairment of goodwill
acquired from acquisition and distribution of earnings from equity investment from the Company&#8217;s share of Lab Services MSO&#8217;s
net income. The assets and certain expenses related to corporate activities are not allocated to the segments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information with respect to these reportable business
segments for the years ended December 31, 2024 and 2023 was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ended December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Real Property Operations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Lab Services MSO</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Corporate / Other</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Real property rental revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,333,403</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-356">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-357">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,333,403</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Real property operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,065,574</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-358">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-359">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,065,574</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Real property operating income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">267,829</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-360">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-361">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">267,829</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from equity method investment - Lab Services MSO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-362">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(846,588</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-363">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(846,588</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(354,311</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-364">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,994,662</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,348,973</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other (expense) income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;&#160;Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(777,228</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-365">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,659,745</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,436,973</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;&#160;Other expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(80</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-366">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(538,609</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(538,689</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(863,790</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(846,588</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,193,016</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(7,903,394</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ended December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Real Property Operations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Lab Services MSO</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Corporate / Other</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Real property rental revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,255,681</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-367">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-368">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,255,681</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Real property operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,017,493</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-369">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-370">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,017,493</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Real property operating income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">238,188</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-371">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-372">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">238,188</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from equity method investment - Lab Services MSO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-373">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,571,647</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-374">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,571,647</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(347,356</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-375">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,072,868</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,420,224</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other (expense) income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;&#160;Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(918,885</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-376">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(432,617</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,351,502</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;&#160;Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-377">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">398,160</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">398,175</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,028,038</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(8,571,647</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(7,107,325</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(16,707,010</td><td style="text-align: left">)</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Identifiable long-lived tangible assets at December 31, 2024 and 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Real property operations</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,034,335</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,211,641</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Corporate/Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,298</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,846</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;&#160;&#160;Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,035,633</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,229,487</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Identifiable long-lived tangible assets at December 31, 2024 and 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,034,335</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,227,533</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">China</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,298</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,954</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;&#160;Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,035,633</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,229,487</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">NOTE 15 - <span style="text-decoration:underline">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Litigation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">From time to time, the Company is subject to ordinary
routine litigation incidental to its normal business operations. The Company is not currently a party to, and its property is not subject
to, any material legal proceedings, except as set forth below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On October 25, 2017, Genexosome entered into and
closed a Stock Purchase Agreement with Beijing Genexosome and Yu Zhou, MD, PhD, the sole shareholder of Beijing Genexosome, pursuant
to which Genexosome acquired all of the issued and outstanding securities of Beijing Genexosome in consideration of a cash payment in
the amount of $450,000, of which $100,000 is still owed. Further, on October 25, 2017, Genexosome entered into and closed an Asset Purchase
Agreement with Dr. Zhou, pursuant to which the Company acquired all assets, including all intellectual property and exosome separation
systems, held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies. In consideration
of the assets, Genexosome paid Dr. Zhou $876,087 in cash, transferred 3,333 shares of common stock of the Company to Dr. Zhou and issued
Dr. Zhou 400 shares of common stock of Genexosome. Dr. Zhou was terminated as Co-CEO of Genexosome on August 14, 2019. Further, on October
28, 2019, Research Institute at Nationwide Children&#8217;s Hospital (&#8220;Research Institute&#8221;) filed a Complaint in the United
States District Court for the Southern District of Ohio Eastern Division against Dr. Zhou, Li Chen, the Company and Genexosome with various
claims against the Company and Genexosome. The Company, Genexosome and the Research Institute entered into a Settlement Agreement dated
June 7, 2022 (the &#8220;Settlement Date&#8221;) whereby the Company agreed to pay the Research Institute $450,000 on each of the sixty-day,
one year and two-year anniversaries of the Settlement Date. In addition, the Company agreed to pay the Research Institute 30% of the
Company&#8217;s initial pre-tax profit of $3,333,333, 20% of the Company&#8217;s second pre-tax profit of $3,333,333 and 10% of the Company&#8217;s
third pre-tax profit of $3,333,333. The parties provided a mutual release as well. As of both March 31, 2025 and December 31, 2024, the
accrued litigation settlement amounted to $373,450.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Operating Leases Commitment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company is a party to leases for office space.
These lease agreements expire through December 2025. Rent expense under all operating leases amounted to approximately $32,000 for both
the three months ended March 31, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Supplemental cash flow information related to
leases for the three months ended March 31, 2025 and 2024 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended March 31,</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-sec-ix-redline:true;-keep: true">Operating cash flows paid for operating lease</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">27,535</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">26,533</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Right-of-use assets obtained in exchange for lease obligation:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-sec-ix-redline:true;-keep: true">Operating lease</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">127,486</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-410"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes the lease term
and discount rate for the Company&#8217;s operating lease as of March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>



<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Operating <br/> Lease</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Weighted average remaining lease term (in years)</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.75</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Weighted average discount rate</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">13.0</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes the maturity of lease liabilities under
operating lease as of March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">For the Twelve-month Period Ending March 31:</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Operating <br/> Lease</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">2026</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">78,000</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">2027</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">54,000</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">2028 and thereafter</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-411"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total lease payments</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">132,000</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Amount of lease payments representing interest</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(12,747</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total present value of operating lease liabilities</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">119,253</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Current portion</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">67,547</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Long-term portion</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">51,706</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">119,253</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Joint Venture - Avactis Biosciences Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 18, 2018, the Company formed a wholly
owned subsidiary, Avactis Biosciences Inc. (&#8220;Avactis&#8221;), a Nevada corporation, which focuses on accelerating commercial activities
related to cellular therapies as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others. When formed, Avactis was designed
to integrate and optimize the Company&#8217;s global scientific and clinical resources to further advance the use of cellular therapies
to treat certain cancers; however the Company is no longer pursuing any commercial activities with respect to cellular immunotherapy
and CAR-T, in particular. Commencing on April 6, 2022, the Company owns 60% of Avactis and Arbele Biotherapeutics Limited (&#8220;Arbele
Biotherapeutics&#8221;) owns 40% of Avactis. Avactis owns 100% of the capital stock of Avactis Nanjing Biosciences Ltd., a company incorporated
in the PRC on May 8, 2020 (&#8220;Avactis Nanjing&#8221;), which only owns a patent and is not considered an operating entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company is required to contribute $10 million
(or equivalent in RMB) in cash and/or services, which shall be contributed in tranches based on milestones to be determined jointly by
Avactis and the Company in writing subject to the Company&#8217;s cash reserves. Within 30 days, Arbele Biotherapeutics shall make contribution
of $6.66 million in the form of entering into a License Agreement with Avactis granting Avactis an exclusive right and license in China
to its technology and intellectual property pertaining to CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy technology and any additional
technology developed in the future with terms and conditions to be mutually agreed upon the Company and Avactis and services. As of the
date hereof, the License Agreement has not been finalized by the parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In addition, the Company is responsible for contributing
registered capital of RMB 5,000,000 (approximately $0.7 million) for working capital purposes as required by local regulation, which
is not required to be contributed immediately and will be contributed subject to the Company&#8217;s discretion. As of the date hereof,
Avactis&#8217; activities have been limited to that of a patent holding company and there is no other activity or planned contributions
in the rest of 2025 or into the foreseeable future.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 21 -&#160;<span style="text-decoration:underline">COMMITMENTS
AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Litigation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company is subject to ordinary routine litigation incidental to its normal business operations. The Company
is not currently a party to, and its property is not subject to, any material legal proceedings, except as set forth below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October
25, 2017, Genexosome entered into and closed a Stock Purchase Agreement with Beijing Genexosome and Yu Zhou, MD, PhD, the sole shareholder
of Beijing Genexosome, pursuant to which Genexosome acquired all of the issued and outstanding securities of Beijing Genexosome in consideration
of a cash payment in the amount of $450,000, of which $100,000 is still owed. Further, on October 25, 2017, Genexosome entered into and
closed an Asset Purchase Agreement with Dr. Zhou, pursuant to which the Company acquired all assets, including all intellectual property
and exosome separation systems, held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies.
In consideration of the assets, Genexosome paid Dr. Zhou $876,087 in cash, transferred 3,333 shares of common stock of the Company to
Dr. Zhou and issued Dr. Zhou 400 shares of common stock of Genexosome. Further, the Company had not been able to realize the financial
projections provided by Dr. Zhou at the time of the acquisition and has decided to impair the intangible asset associated with this acquisition
to zero. Dr. Zhou was terminated as Co-CEO of Genexosome on August 14, 2019. Further, on October 28, 2019, Research Institute at Nationwide
Children&#8217;s Hospital (&#8220;Research Institute&#8221;) filed a Complaint in the United States District Court for the Southern District
of Ohio Eastern Division against Dr. Zhou, Li Chen, the Company and Genexosome with various claims against the Company and Genexosome.
The criminal proceedings against Dr. Zhou and Li Chen have been concluded. The Company, Genexosome and the Research Institute entered
into a Settlement Agreement dated June 7, 2022 (the &#8220;Settlement Date&#8221;) whereby the Company agreed to pay the Research Institute
$450,000 on each of the sixty-day, one year and two-year anniversaries of the Settlement Date. In addition, the Company agreed to pay
the Research Institute 30% of the Company&#8217;s initial pre-tax profit of $3,333,333, 20% of the Company&#8217;s second pre-tax profit
of $3,333,333 and 10% of the Company&#8217;s third pre-tax profit of $3,333,333. The parties provided a mutual release as well. As of
December 31, 2024, the accrued litigation settlement amounted to $373,450.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Operating
Leases Commitment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
is a party to leases for office space. These lease agreements expired through February 2025. Rent expense under all operating leases amounted
to approximately $127,000 and $129,000 for the years ended December 31, 2024 and 2023, respectively.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Supplemental
cash flow information related to leases for the years ended December 31, 2024 and 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">&#160;&#160;Operating cash flows paid for operating lease</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">125,076</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">125,929</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;&#160;Operating lease</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-378">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">235,893</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the lease term
and discount rate for the Company&#8217;s operating lease as of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Operating Lease</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Weighted average remaining lease term (in years)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.08</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted average discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">11.0</td><td style="text-align: left">%</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the maturity of lease liabilities under
operating lease as of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">For the Year Ending December 31:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Operating Lease</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,753</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2026 and thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-379">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,753</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Amount of lease payments representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(44</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total present value of operating lease liabilities (current liability)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,709</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Joint Venture - Avactis Biosciences Inc.</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On July 18, 2018, the
Company formed a wholly owned subsidiary, Avactis Biosciences Inc. (&#8220;Avactis&#8221;), a Nevada corporation, which focuses on accelerating
commercial activities related to cellular therapies as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others. When
formed, Avactis was designed to integrate and optimize the Company&#8217;s global scientific and clinical resources to further advance
the use of cellular therapies to treat certain cancers, however the Company is no longer pursuing any commercial activities with respect
to cellular immunotherapy and CAR-T, in particular. As of April 6, 2022, the Company owns 60% of Avactis and Arbele Biotherapeutics Limited
(&#8220;Arbele Biotherapeutics&#8221;) owns 40% of Avactis. Avactis owns 100% of the capital stock of Avactis Nanjing Biosciences Ltd.,
a company incorporated in the PRC on May 8, 2020 (&#8220;Avactis Nanjing&#8221;), which only owns a patent and is not considered an operating
entity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company is required
to contribute $10 million (or equivalent in RMB) in cash and/or services, which shall be contributed in tranches based on milestones to
be determined jointly by Avactis and the Company in writing subject to the Company&#8217;s cash reserves. Within 30 days, Arbele Biotherapeutics
shall make contribution of $6.66 million in the form of entering into a License Agreement with Avactis granting Avactis an exclusive right
and license in China to its technology and intellectual property pertaining to CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy technology
and any additional technology developed in the future with terms and conditions to be mutually agreed upon the Company and Avactis and
services. As of the date hereof, the License Agreement has not been finalized by the parties.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In addition, the Company
is responsible for contributing registered capital of RMB 5,000,000 (approximately $0.7 million) for working capital purposes as required
by local regulation, which is not required to be contributed immediately and will be contributed subject to the Company&#8217;s discretion.
As of the date hereof, Avactis&#8217; activities have been limited to that of a patent holding company and there is no other activity
or planned contributions in 2025 or into the foreseeable future.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">NOTE 16 - <span style="text-decoration:underline">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company evaluated subsequent events and transactions
that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than
as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Common Shares Issued for Warrant Exercise</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In April 2025, the Company issued 242,304 shares
of its common stock upon the exercise of warrants on a cashless basis.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>NOTE 22 - <span style="text-decoration:underline">SUBSEQUENT
EVENTS</span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company evaluated
subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued.
Based upon this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment
or disclosure in the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Series D Convertible
Preferred Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On January 6, 2025, the
Company filed a certificate of designations of preferences, rights, and limitations of Series D Convertible Preferred Stock (the &#8220;Series
D Certificate of Designations&#8221;) with the Department of State, Division of Corporations, of the State of Delaware, which provides
for the designation of 5,000 shares of Series D Preferred Stock of the Company, par value $0.0001 per share, upon the terms and conditions
as set forth in the Series D Certificate of Designations. Each share of Series D Preferred Stock has a stated value of $1,000 (the &#8220;Stated
Value&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Series D Preferred
Stock shall rank (i) senior to the Company&#8217;s common stock (the &#8220;Common Stock&#8221;) and any other class or series of capital
stock of the Company created hereafter, the terms of which specifically provide that such class or series shall rank junior to the Series
D Preferred Stock, (ii) pari passu with any class or series of capital stock of the Company created hereafter specifically ranking, by
its terms, on par with the Series D Preferred Stock, (iii) pari passu with the Series B Convertible Preferred Stock of the Company (the
&#8220;Series B Preferred Stock&#8221;) with respect to its rights, preferences and restrictions, and (iv) pari passu with the Series
C Convertible Preferred Stock of the Company (the &#8220;Series C Preferred Stock&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Holders of the Series
D Preferred Stock have no voting power except as otherwise required by the Delaware General Corporation Law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Upon any liquidation,
dissolution or winding-up of the Company, whether voluntary or involuntary (a &#8220;Liquidation&#8221;), the holders of the Series D
Preferred Stock shall be entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to the
payment in full of all amounts required to be distributed to the holders of another class or series of stock of the Company ranking on
liquidation prior and in preference to the Series D Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any class
or series of stock ranking on liquidation on parity with the Series D Preferred Stock and (iii) in preference and priority to the holders
of the shares of Common Stock, an amount equal to 100% of the Stated Value of the Series D Preferred Stock, in proportion to the full
and preferential amount that all shares of the Series D Preferred Stock are entitled to receive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Each share of Series
D Preferred Stock shall be convertible into Common Stock (the &#8220;Conversion Shares&#8221;) at a conversion per share equal to $2.41,
at the option of the holder, at any time after the Company has obtained shareholder approval for the issuance of the Conversion Shares
pursuant to the rules of the Nasdaq Stock Market. In addition, the holder shall not have the right to convert any portion of the Series
D Preferred Stock if, after giving effect to the conversion, such holder (together with its affiliates) would beneficially own in excess
of 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of the respective Conversion
Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On January 9, 2025, the
Company entered into an exchange agreement with Wenzhao Lu, the Company&#8217;s chairman of the Board of Directors, pursuant to which
Mr. Lu exchanged 9,000 shares of Series A Preferred Stock of the Company for 5,000 shares of Series D Preferred Stock of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Redemption Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">During 2025, to preserve
cash, the Company entered into discussions with Lab Services MSO for the potential redemption of our investment and on February 26, 2025,
the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement (the &#8220;Redemption Agreement&#8221;), whereby
Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by the Company for cash and the surrender of its Series B Convertible
Preferred Stock having a carrying value of $11,000,000. The aggregate cash amount to the Company for the redemption was $1,745,000, to
be paid as follows: one payment of $95,000 at the closing of the redemption and, beginning in March 2025, monthly payments of $75,000
until December 2026. In addition, pursuant to the terms of the Redemption Agreement, all shares of the Company&#8217;s Series B Convertible
Preferred Stock previously issued to SCBC Holdings LLC as partial consideration for the equity interests of Laboratory Services MSO, were
permanently surrendered and relinquished to the Company for no additional consideration. Accordingly, beginning in February 2025, the
Company no longer offers laboratory services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Agreement and Plan
of Merger</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On March 7, 2025, the
Company, Nexus MergerSub Limited, a business company incorporated in the British Virgin Islands and a wholly owned subsidiary of the Company
(&#8220;Merger Sub&#8221;), and YOOV Group Holding Limited, a business company incorporated in the British Virgin Islands (&#8220;YOOV&#8221;),
entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) pursuant to which Merger Sub will merge with and into
YOOV, with YOOV surviving the merger and becoming a direct, wholly owned subsidiary of the Company (the &#8220;Merger&#8221;). The Merger
is expected to be completed in the third quarter of 2025, subject to customary closing conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms and conditions of the Merger
Agreement, immediately prior to the effective time of the Merger (the &#8220;Effective Time&#8221;), each then-outstanding share of YOOV
preferred shares, par value $0.10 per share, will either automatically be converted into shares of YOOV ordinary shares, par value $0.10
per share (the &#8220;YOOV Ordinary Shares&#8221;) or canceled and cease to exist in accordance with their terms. At the Effective Time,
each then-outstanding YOOV Ordinary Share (other than any shares held in treasury and Dissenting Shares (as defined in the Merger Agreement))
will be automatically converted into a number of shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Avalon
Common Stock&#8221;), equal to the Exchange Ratio. The &#8220;Exchange Ratio&#8221; will be the ratio (rounded to four decimal places),
determined as follows: if the closing price of the Avalon Common Stock on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) on the second
trading day immediately preceding the Effective Time is (x) less than or equal to $5.00, the Exchange Ratio shall be 60,000,000 divided
by YOOV Outstanding Shares (as defined in the Merger Agreement); or (y) greater than $5.00, the Exchange Ratio shall be 54,000,000 divided
by YOOV Outstanding Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Merger Agreement,
(i) each then-outstanding share of Avalon Common Stock will remain issued and outstanding after the Effective Time and (ii) each then-outstanding
option to purchase Avalon Common Stock, whether or not vested, will remain issued and outstanding after the Effective Time. The then-outstanding
shares of Series C Convertible Preferred Stock of the Company and Series D Convertible Preferred Stock of the Company will remain outstanding
in accordance with their terms. Additionally, at the Effective Time, the name of the Company will be changed to &#8220;YOOV, Inc.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Merger, the Company will
seek approval of its stockholders to, among other things, (i) approve the issuance of the shares of Avalon Common Stock to be issued to
YOOV shareholders in connection with the Merger pursuant to the rules of Nasdaq and (ii) amend the Company&#8217;s certificate of incorporation
to effect a reverse stock split of the Avalon Common Stock to the extent the Company and YOOV mutually agree implementing such reverse
stock split is necessary to meet Nasdaq&#8217;s listing requirements (collectively, the &#8220;Avalon Stockholder Matters&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the Company and YOOV have made customary
representations, warranties and covenants in the Merger Agreement, including, among other things, covenants relating to (i) obtaining
the requisite approval of its respective stockholders, (ii) non-solicitation or facilitation of any Takeover Proposal or Superior Proposal
(as each is defined in the Merger Agreement), (iii) the conduct of its respective business during the period between the signing of the
Merger Agreement and the closing of the Merger, and (iv) the Company filing with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;)
and causing to become effective a registration statement on Form S-4 (the &#8220;Registration Statement&#8221;) to register the shares
of Avalon Common Stock to be issued in connection with the Merger.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consummation of the Merger is subject to certain
closing conditions, including, among other things, (i) approval of the Avalon Stockholder Matters by the requisite the Company stockholders,
(ii) adoption and approval of the Merger Agreement, and the transactions contemplated thereby, by the requisite YOOV shareholders, (iii)
the effectiveness of the Registration Statement and (iv) the listing of the Avalon Common Stock issuable in connection with the Merger
on Nasdaq. Each party&#8217;s obligation to consummate the Merger is also subject to other specified customary conditions, including regarding
the accuracy of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance
in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the
Effective Time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Merger Agreement contains certain termination
rights for both the Company and YOOV, including the right to terminate the Merger Agreement at any time before the Effective Time, whether
before or after the Avalon Stockholder Matters have been approved, by mutual written consent of the parties. In addition, the Merger Agreement
may be terminated at any time by either party if the Merger is not consummated on or before March 7, 2026 (the &#8220;End Date&#8221;),
provided that the End Date may be extended by either party for up to 60 days in the event that the SEC has not declared effective the
Registration Statement by the date which is 60 days prior to the End Date. Upon termination of the Merger Agreement under specified circumstances,
the Company may be required to pay YOOV a termination fee of $1.0 million; however, YOOV is not required to pay the Company a termination
fee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Effective Time, the board of directors
of the Company (the &#8220;Avalon Board&#8221;) is expected to consist of seven (7) members, five (5) of whom will be designated by YOOV
and two (2) of whom will be designated by the Company, as provided in the Merger Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Voting and Support Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrently with the execution of the Merger
Agreement, (i) the officers, directors and certain shareholders of YOOV (solely in their respective capacities as YOOV shareholders) have
entered into voting and support agreements with the Company and YOOV, pursuant to which such YOOV shareholders agree, among other things
to, (a) not transfer their capital stock of YOOV, subject to certain limited exceptions and (b) vote all of their shares of capital stock
of YOOV in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and against, among other
things, any Takeover Proposals (the &#8220;YOOV Voting Agreement&#8221;) and (ii) the officers, directors and certain stockholders of
the Company (solely in their respective capacities as Avalon Stockholders) have entered into voting and support agreements with the Company
and YOOV, pursuant to which such the Company stockholders agree, among other things to, (a) not transfer their capital stock of the Company,
subject to certain limited exceptions and (b) vote all of their shares of capital stock of the Company in favor of, among other things,
the Avalon Stockholder Matters and against, among other things, any Takeover Proposals (the &#8220;Avalon Voting Agreement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Lock-Up Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrently with the execution of the Merger
Agreement, certain directors, officers and stockholders of each of the Company and YOOV have entered into lock-up agreements (the &#8220;Lock-Up
Agreement&#8221;), pursuant to which, subject to specified exceptions, they have agreed not to transfer their shares of Avalon Common
Stock, during the 180-day period following the Effective Time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Certificates of Elimination</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company previously designated (i) 15,000 shares
of preferred stock as Series A Convertible Preferred Stock (the &#8220;Series A Preferred Stock&#8221;), of which no shares remain outstanding
as a result of the exchange agreement entered with Wenzhao Lu on January 9, 2025 and (ii) 15,000 shares of Series B Preferred Stock, of
which no shares remain outstanding as a result of the surrender of the Series B Preferred Stock in connection with the redemption and
abandonment agreement with the Company, Avalon Laboratory Services, Inc., Laboratory Services MSO, LLC and the other parties signatory
thereto on February 26, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2025, the Company filed a Certificate
of Elimination relating to each of the Series A Preferred Stock and the Series B Preferred Stock (the &#8220;Eliminations of Designation&#8221;)
with the Secretary of State of the State of Delaware, thereby terminating the designations of the Series A Preferred Stock and the Series
B Preferred Stock. The Eliminations of Designation were effective upon filing and eliminated from the Company&#8217;s Amended and Restated
Certificate of Incorporation (as amended and/or restated from time to time, the &#8220;Avalon Charter&#8221;) all matters set forth in
the previously-filed Certificates of Designations with respect to the previously designated Series A Preferred Stock and Series B Preferred
Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Bylaws Amendment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 7, 2025, the Avalon Board approved and
adopted an amendment (the&#160;&#8220;Amendment&#8221;) to the Company&#8217;s Amended and Restated Bylaws (the&#160;&#8220;Avalon Bylaws&#8221;).&#160;The
Amendment reduces the quorum at any meeting of stockholders, except as otherwise required by law or by the Avalon Charter or the Avalon
Bylaws, to one-third of the voting power of the shares of capital stock outstanding and entitled to vote at the meeting, present in person,
present by remote communication, if applicable, or represented by proxy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Shares Issued for Warrant Exercise</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2025, the Company issued 186,877 shares
of its common stock upon cashless exercise of warrants to purchase 11,833 shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Shares Issued for Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2025, the Company issued a total of 22,278
shares of its common stock for services rendered and to be rendered. These shares were valued at $113,847, the fair market values on the
grant dates using the reported closing share prices on the dates of grant.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The preparation of condensed consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Changes in these estimates and assumptions may have a material impact on the condensed
consolidated financial statements and accompanying notes. Making estimates requires management to exercise significant judgment. It is
at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date
of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more
future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Significant estimates during the three months
ended March 31, 2025 and 2024 include the useful life of investment in real estate and intangible assets, the assumptions used in assessing
impairment of long-term assets, the valuation of deferred tax assets and the associated valuation allowances, the valuation of stock-based
compensation, the valuation of Series D convertible preferred stock (&#8220;Series D Preferred Stock&#8221;), and the assumptions used
to determine fair value of warrants and embedded conversion features of convertible note payable.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The preparation
of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting period. Changes in these estimates and assumptions may have a material
impact on the consolidated financial statements and accompanying notes. Making estimates requires management to exercise significant judgment.
It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the
date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or
more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant estimates during the years ended December
31, 2024 and 2023 include the useful life of investment in real estate and intangible assets, the assumptions used in assessing impairment
of long-term assets, the valuation of deferred tax assets and the associated valuation allowances, the valuation of stock-based compensation,
the assumptions used to determine fair value of warrants and embedded conversion features of convertible note payable, and the fair value
of the consideration given and assets acquired in the purchase of 40% of Lab Services MSO.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments and Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b style="-sec-ix-redline:true;-keep: true">Fair Value of Financial Instruments and Fair Value Measurements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company adopted the guidance of the Financial
Accounting Standards Board&#8217;s (the &#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820 for fair value
measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value
hierarchy to classify the inputs used in measuring fair value as follows:</span></p><table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="-sec-ix-redline:true;font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Level 1-Inputs are unadjusted quoted prices in active markets for
    identical assets or liabilities available at the measurement date.</span></td></tr>
</table><table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="-sec-ix-redline:true;font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Level 2-Inputs are unadjusted quoted prices for similar assets and
    liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs
    other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.</span></td></tr>
</table><table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: justify; width: 0.25in"><span style="-sec-ix-redline:true;font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Level 3-Inputs are unobservable inputs which reflect the reporting
    entity&#8217;s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the
    best available information.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The fair value of the Company&#8217;s assets and
liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying
amounts represented in the accompanying condensed consolidated financial statements, primarily due to their short-term nature.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><b><i>Assets and liabilities measured at fair
value on a recurring basis. </i></b>Certain assets and liabilities are measured at fair value on a recurring basis. These assets and
liabilities are measured at fair value on an ongoing basis. These assets and liabilities include derivative liability.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><i>Derivative liability. </i>Derivative liability
is carried at fair value and measured on an ongoing basis. The table below reflects the activity of derivative liability measured at
fair value for the three months ended March 31, 2025:</span></p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Significant <br/>
    Unobservable Inputs<br/> (Level 3)</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Balance of derivative liability as of January 1, 2025</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">127,545</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Reclassification of additional paid-in capital upon conversion</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(18,853</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Loss from change in the fair value of derivative liability</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">114,360</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Balance of derivative liability as of March 31, 2025</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">223,052</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">ASC 825-10 &#8220;Financial Instruments&#8221;,
allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair
value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value
option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent
reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Fair Value of Financial Instruments and
Fair Value Measurements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company adopted the guidance of Accounting Standards Codification (&#8220;ASC&#8221;) 820 for fair value measurements which clarifies
the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs
used in measuring fair value as follows</span>:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Level <span style="background-color: white">1-Inputs are
unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.</span></td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Level <span style="background-color: white">2-Inputs are
unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities
in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable
market data.</span></td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font: normal 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">Level <span style="background-color: white">3-Inputs are
unobservable inputs which reflect the reporting entity&#8217;s own assumptions on what assumptions the market participants would use
in pricing the asset or liability based on the best available information.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the Company&#8217;s assets and
liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying
amounts represented in the accompanying consolidated financial statements, primarily due to their short-term nature<span style="background-color: white">.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Assets
and liabilities measured at fair value on a recurring basis.</i></b><i>&#160;</i></span>Certain assets and liabilities are measured at
fair value on a recurring basis. These assets and liabilities are measured at fair value on an ongoing basis. These assets and liabilities
include derivative liability<span style="background-color: white">.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><i>Derivative
liability.</i>&#160;Derivative liability is carried at fair value and measured on an ongoing basis.&#160;The table below reflects the
activity of derivative liability measured at fair value for the years ended December 31, 2024 and 2023:</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Significant Unobservable Inputs <br/>
(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance of derivative liability as of January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-329">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: left">Initial fair value of derivative liability attributable to warrants issuance with May, July, and October 2023 fund raises</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">213,170</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain from change in the fair value of derivative liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(188,374</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Balance of derivative liability as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,796</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Initial fair value of derivative liability attributable to warrants issuance with March and June 2024 fund raises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">479,468</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reclassification of additional paid-in capital upon conversion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,354</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain from change in the fair value of derivative liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(374,365</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance of derivative liability as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">127,545</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Assets
and liabilities measured at fair value on a nonrecurring basis.</i></b>&#160;Certain assets and liabilities are measured at fair value
on a nonrecurring basis. These assets and liabilities are not measured at fair value on an ongoing basis, but are subject to fair value
adjustments in certain circumstances. These assets and liabilities can include equipment held for sale and equity method investment that
are written down to fair value when they are impaired.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><i>Laboratory
equipment. </i>The Company conducted an impairment assessment on its laboratory equipment based on the guidelines established in Financial
Accounting Standards Board (&#8220;FASB&#8221;) ASC Topic 360 to determine the estimated fair market value of its laboratory equipment
as of December 31, 2024. Upon completion of its 2024 impairment analysis, the Company determined that the carrying value exceeded the
fair market value of laboratory equipment. The fair market value of laboratory equipment is a level 3 valuation. The Company recorded
an impairment charge of $111,033 for the year ended December 31, 2024, which was included in other general and administrative expenses
on the accompanying consolidated statements of operations and comprehensive loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><i>Equity
method investment in Epicon Biotech Co., Ltd.</i>&#160;The factors used to determine fair value are subject to management&#8217;s judgment
and expertise and include, but are not limited to, the investee&#8217;s series of operating losses and the joint venture partner unable
to obtain funds to commence operations. These assumptions represent Level 3 inputs. Impairment of equity method investment in Epicon Biotech
Co., Ltd. for the year ended December 31, 2023 was $454,679. There is no comparative impairment for the year ended December 31, 2024 since
the investment was fully impaired at December 31, 2023.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><i>Equity
method investment in </i></span><i>Laboratory Services MSO, LLC </i><span style="background-color: white">The factors used to determine
fair value are subject to management&#8217;s judgment and expertise. These assumptions represent Level 3 inputs. Impairment of equity
method investment in Laboratory Services MSO, LLC for the years ended December 31, 2024 and 2023 was $259,579 and $9,196,682, respectively,
which have been included in loss from equity method investment - Lab Services MSO on the accompanying consolidated statements of
operations and comprehensive loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">ASC
825-10 &#8220;Financial Instruments&#8221;, allows entities to voluntarily choose to measure certain financial assets and liabilities
at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless
a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should
be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding
instruments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Cash and Cash Equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">At March 31, 2025 and December 31, 2024, the Company&#8217;s
cash balances by geographic area were as follows:</span></p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Country:</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">March 31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">December 31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">United States</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,351,923</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">98.7</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,844,522</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">99.6</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">China</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">17,663</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.3</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">11,787</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.4</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Total cash</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,369,586</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">100.0</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,856,309</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">100.0</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For purposes of the condensed consolidated statements
of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less when purchased and money market
accounts to be cash equivalents. The Company had no cash equivalents at March 31, 2025 and December 31, 2024.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Cash and Cash Equivalents</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2024 and 2023, the Company&#8217;s
cash balances by geographic area were as follows:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Country:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,844,522</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">99.6</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">280,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">98.2</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">China</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,787</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,203</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,856,309</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">285,400</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the consolidated statements of
cash flows, the Company considers all highly liquid instruments with a maturity of three months or less when purchased and money market
accounts to be cash equivalents. The Company had no cash equivalents at December 31, 2024 and 2023.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Credit Risk and Uncertainties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Credit Risk and Uncertainties</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company maintains a portion of its cash on
deposits with bank and financial institution within the U.S. that at times may exceed federally-insured limits of $250,000. The Company
manages this credit risk by concentrating its cash balances in high quality financial institutions and by periodically evaluating the
credit quality of the primary financial institutions holding such deposits. The Company has not experienced any losses in such bank accounts
and believes it is not exposed to any risks on its cash in bank accounts. At March 31, 2025, the Company&#8217;s cash balances in United
States bank accounts had approximately $840,000 in excess of the federally-insured limits.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company&#8217;s concentrations of credit risk
with respect to its rent receivable is limited due to short-term payment terms. The Company also performs ongoing credit evaluations
of its tenants to help further reduce credit risk.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Credit Risk and Uncertainties</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
maintains a portion of its cash on deposits with bank and financial institution within the U.S. that at times may exceed federally-insured
limits of $250,000. The Company manages this credit risk by concentrating its cash balances in high quality financial institutions and
by periodically evaluating the credit quality of the primary financial institutions holding such deposits. The Company has not experienced
any losses in such bank accounts and believes it is not exposed to any risks on its cash in bank accounts. At December 31, 2024, the Company&#8217;s
cash balances in United States bank accounts had approximately $2,413,000 in excess of the federally-insured limits.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company&#8217;s
concentrations of credit risk with respect to its rent receivable is limited due to short-term payment terms. The Company also performs
ongoing credit evaluations of its tenants to help further reduce credit risk.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Rent Receivable and Reserve for Credit Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Rent Receivable and Reserve for Credit
Losses</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Rent receivable
is presented net of reserve for credit losses. Rent receivable balance consists of base rents, tenant reimbursements and receivables arising
from straight-lining of rents represent amounts accrued and unpaid from tenants in accordance with the terms of the respective leases,
subject to the Company&#8217;s revenue recognition policy. A reverse for the uncollectible portion of rent receivable is determined based
upon an analysis of the tenant&#8217;s payment history, the financial condition of the tenant, business conditions in the industry in
which the tenant operates and economic conditions in Freehold, New Jersey in which the property is located.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Management
believes that the rent receivable is fully collectable. Therefore, no material reverse for credit losses is deemed to be required on its
rent receivable at December 31, 2024 and 2023.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_DeferredOfferingCostsPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Deferred Offering Costs</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred offering costs consist of legal, accounting
and other costs that are directly related to the Company&#8217;s open market sale equity financing and will be charged to stockholders&#8217;
equity upon completion of the equity offering. As of December 31, 2024 and 2023, deferred offering costs amounted to $0&#160;and $175,136,
respectively, which were included in prepaid expense and other current assets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Deferred Leasing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Deferred Leasing Costs</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Costs incurred
to obtain tenant leases are amortized using the straight-line method over the term of the related lease agreement. Such costs include
lease incentives and leasing commissions. If the lease is terminated early, the remaining unamortized deferred leasing cost is written
off.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Property and Equipment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are carried at cost less
accumulated depreciation, and are depreciated on a straight-line basis over the estimated useful lives of the assets. The cost of repairs
and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of,
the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the period
of disposition. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances
reflect the fact that their recorded value may not be recoverable.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock', window );">Investment In Real Estate and Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Investment In Real
Estate and Depreciation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investment in real estate is carried at cost less
accumulated depreciation, and consists of building and improvement. The Company depreciates real estate building and improvement on a
straight-line basis over estimated useful life. Expenditures for ordinary repair and maintenance costs are charged to expense as incurred.
Expenditure for improvements, renovations, and replacements of real estate asset is capitalized and depreciated over its estimated useful
life if the expenditure qualifies as betterment.&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Impairment of Long-lived Assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC Topic 360, the Company
reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may
not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future
cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset&#8217;s
estimated fair value and its book value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">For the
year ended December 31, 2024, the Company incurred impairment charges in operations of $111,033 on its laboratory equipment. The valuation
of the laboratory equipment, and the amount of the impairment charge, were based on impairment assessment conducted on the equipment at
December 31, 2024.&#160;&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment in Unconsolidated Company</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Investment in Unconsolidated Company</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company uses the equity method of accounting
for its investment in, and earning or loss of, investees that it does not control but over which it does exert significant influence.
The Company applies the equity method by initially recording these investments at cost, as equity method investments, subsequently adjusted
for equity in earnings and cash distributions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company considers whether the fair value of
its equity method investment has declined below its carrying value whenever adverse events or changes in circumstances indicate that
recorded value may not be recoverable. If the Company considers any decline to be other than temporary (based on various factors, including
historical financial results and the overall health of the investee), then a write-down would be recorded to estimated fair value. See
Note 5 for discussion of equity method investment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company classifies distributions received
from equity method investments using the cumulative earnings approach. Distributions received are considered returns on the investment
and classified as cash inflows from operating activities. If, however, the investor&#8217;s cumulative distributions received, less distributions
received in prior periods determined to be returns of investment, exceeds cumulative equity in earnings recognized, the excess is considered
a return of investment and is classified as cash inflows from investing activities.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Investment in Unconsolidated
Companies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the equity method of accounting
for its investment in, and earning or loss of, investees that it does not control but over which it does exert significant influence.
The Company applies the equity method by initially recording these investments at cost, as equity method investments, subsequently adjusted
for equity in earnings and cash distributions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers whether the fair value of
its equity method investment has declined below its carrying value whenever adverse events or changes in circumstances indicate that recorded
value may not be recoverable. If the Company considers any decline to be other than temporary (based on various factors, including historical
financial results and the overall health of the investee), then a write-down would be recorded to estimated fair value. Impairment of
equity method investment amounted to $259,579 and $9,651,361 for the years ended December 31, 2024 and 2023, respectively. See Note 8
for discussion of equity method investments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company classifies distributions received
from equity method investments using the cumulative earnings approach. Distributions received are considered returns on the investment
and classified as cash inflows from operating activities. If, however, the investor&#8217;s cumulative distributions received, less distributions
received in prior periods determined to be returns of investment, exceeds cumulative equity in earnings recognized, the excess is considered
a return of investment and is classified as cash inflows from investing activities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_DeferredRentalIncomePolicyTextBlock', window );">Deferred Rental Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Deferred Rental Income</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred rental income represents rental income
collected but not earned as of the reporting date. The Company defers the revenue related to lease payments received from tenants in advance
of their due dates. As of December 31, 2024 and 2023, deferred rental income totaled $38,346 and $11,429, respectively, which were included
in accrued liabilities and other payables on the accompanying consolidated balance sheets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RealPropertyRentalRevenuePolicyTextBlock', window );">Real Property Rental Revenue</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Real Property Rental Revenue</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has determined that ASC 606 does not
apply to rental contracts, which are within the scope of other revenue recognition accounting standards.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Rental income from operating leases is recognized
on a straight-line basis under the guidance of ASC 842. Lease payments under tenant leases are recognized on a straight-line basis over
the term of the related leases. The cumulative difference between lease revenue recognized under the straight-line method and contractual
lease payments are included in rent receivable on the condensed consolidated balance sheets.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>Real Property Rental Revenue</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
has determined that ASC 606 does not apply to rental contracts, which are within the scope of other revenue recognition accounting standards.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rental income from operating leases is recognized
on a straight-line basis under the guidance of ASC 842. Lease payments under tenant leases are recognized on a straight-line basis over
the term of the related leases. The cumulative difference between lease revenue recognized under the straight-line method and contractual
lease payments are included in rent receivable on the consolidated balance sheets<span style="background-color: white">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorLeasesPolicyTextBlock', window );">Office Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Office Lease</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When a lease contains &#8220;rent holidays&#8221;,
the Company records rental expense on a straight-line basis over the term of the lease. The Company begins recording rent expense on the
lease possession date.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstatePolicyTextBlock', window );">Real Property Operating Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Real Property Operating Expenses</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Real property operating expenses consist of property
management fees, property insurance, real estate taxes, depreciation, repairs and maintenance fees, utilities and other expenses related
to the Company&#8217;s rental properties.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expenditures for research and product development
costs are expensed as incurred. The Company incurred research and development expense of $0&#160;and $109,618&#160;in the years ended
December 31, 2024 and 2023, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Marketing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Advertising and Marketing Costs</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All costs related to advertising and marketing
are expensed as incurred. For the years ended December 31, 2024 and 2023, advertising and marketing costs amounted to $237,671 and $1,666,721,
respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Receivable from Sale of Equity Method Investment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Receivable from Sale of Equity Method Investment</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the first quarter of 2025, to preserve
cash, the Company entered into discussions with Lab Services MSO for the potential redemption of our investment and on February 26, 2025,
the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement (the &#8220;Redemption Agreement&#8221;), whereby
Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by the Company for cash and the surrender of its Series B
convertible preferred stock (&#8220;Series B Preferred Stock&#8221;) having a carrying value of $11,000,000. The aggregate cash amount
to the Company for the redemption was $1,745,000, to be paid as follows: one payment of $95,000 at the closing of the redemption and,
beginning in March 2025, monthly payments of $75,000 until December 2026. In addition, pursuant to the terms of the Redemption Agreement,
all shares of the Company&#8217;s Series B Preferred Stock previously issued to SCBC Holdings LLC as partial consideration for the equity
interests of Laboratory Services MSO, were permanently surrendered and relinquished to the Company for no additional consideration. The
difference of $2,348,695 between the carrying value of the extinguished Series B Preferred Stock, the aggregate cash amount to the Company
for the redemption, net of the payables due to Lab Services MSO of $632,916, totaling $13,377,916, and the carrying value of the equity
method investment of $11,029,221 was accounted for as an increase to additional paid-in capital (See Note 10 - Series B Convertible Preferred
Stock Extinguished Related to Sale of Equity Method Investment). Accordingly, beginning in February 2025, the Company no longer offers
laboratory services. As of March 31, 2025, the receivable from sale of equity method investment amounted to $1,650,000, of which $975,000
was included in current assets and $675,000 was included in non-current assets. Management believes that the receivable is fully collectable.
Therefore, no material allowance for doubtful accounts was deemed to be required on the receivable at March 31, 2025.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
accounts for its stock-based compensation awards in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718, Compensation-Stock
Compensation (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based payments to employees and non-employees including grants of stock
options, to be recognized as expense in the statements of operations based on their grant date fair values. The Company estimates the
grant date fair value of each option award using the Black-Scholes option-pricing model.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
periodically issues common stock and common stock options to consultants for various services. Costs of these transactions are measured
at the fair value of the service received or the fair value of the equity instruments issued, whichever is more reliably measurable. The
value of the common stock is measured at the earlier of (i) the date at which a firm commitment for performance by the counterparty to
earn the equity instruments is reached or (ii) the date at which the counterparty&#8217;s performance is complete.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_DebtModificationsAndExtinguishmentsPolicyTextBlock', window );">Debt Modifications and Extinguishments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Debt
Modifications and Extinguishments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">When the
Company modifies or extinguishes debt, it first evaluates whether the modification qualifies as a troubled debt restructuring (TDR) under
ASC Topic 470-60, which requires debt modifications to be evaluated to determine if (1) the borrower is experiencing financial difficulty,
and (2) the lender grants the borrower a concession. If a TDR is determined not to have occurred, the Company evaluates the modification
in accordance with ASC Topic 470-50-40, which requires modification to debt instruments to be evaluated to assess whether debt modification
or debt extinguishment accounting is applicable. This evaluation includes analyzing whether there are significant and consequential changes
to the economic substance of the note. If the change is deemed insignificant then the change is considered a debt modification, whereas
if the change is substantial the change is reflected as a debt extinguishment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">If debt
extinguishment guidance applies, the previous debt principal amount is removed, the previously capitalized debt issuance costs are expensed,
the value of instruments exchanged are recorded, including cash, new debt, warrants and common stock, and a gain or loss on extinguishment
of debt is recorded. If debt modification guidance applies, no gain or loss is recorded and the effective interest rate of the debt is
updated based on the carrying value of the debt and the revised future cash flows. Any previously capitalized debt issuance costs in a
debt modification are amortized as interest expense over the term of the new debt instrument.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
is governed by the income tax laws of China and the United States. The Company accounts for income taxes using the asset/liability method
prescribed by ASC 740, &#8220;Income Taxes.&#8221; Under this method, deferred tax assets and liabilities are determined based on the
difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the
period in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if, based
on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized.
The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
follows the accounting guidance for uncertainty in income taxes using the provisions of ASC 740 &#8220;Income Taxes&#8221;. Using that
guidance, the benefit for tax positions taken can only be recognized in the financial statements when it is more likely than not the position
will be sustained upon examination by the tax authorities. As of December 31, 2024 and 2023, the Company had no significant uncertain
tax positions which would require either recognition of a liability or disclosure in the financial statements. For United States entities,
tax year that remains subject to examination is the years ended December 31, 2024, 2023, 2022 and 2021. For China entities, income tax
returns for the tax years ended December 31, 2020 through December 31, 2024 remain open for statutory examination by PRC tax authorities.
The Company recognizes interest and penalties related to significant uncertain income tax positions in income tax expense. However, no
such interest and penalties were recorded as of December 31, 2024 and 2023.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Foreign Currency Translation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The reporting
currency of the Company is the U.S. dollar. The functional currency of the parent company, AHS, Avalon RT 9, Avalon Lab, and Q&amp;A Distribution
is the U.S. dollar and the functional currency of Avalon Shanghai is the Chinese Renminbi (&#8220;RMB&#8221;). For Avalon Shanghai whose
functional currency is the RMB, result of operations and cash flows are translated at average exchange rates during the period, assets
and liabilities are translated at the unified exchange rate at the end of the period, and equity is translated at historical exchange
rates. As a result, amounts relating to assets and liabilities reported on the statements of cash flows may not necessarily agree with
the changes in the corresponding balances on the balance sheets. Translation adjustments resulting from the process of translating the
local currency financial statements into U.S. dollars are included in determining comprehensive income/loss. Transactions denominated
in foreign currencies are translated into the functional currency at the exchange rates prevailing on the transaction dates. Assets and
liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the balance
sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency
other than the functional currency are included in the results of operations as incurred. All of the Company&#8217;s revenue transactions
are transacted in the functional currency of the operating subsidiaries. The Company does not enter into any material transaction in foreign
currencies. Transaction gains or losses have not had, and are not expected to have, a material effect on the results of operations of
the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Asset and
liability accounts at December 31, 2024 and 2023 were translated at 7.2980 RMB and 7.0786 RMB to $1.00, respectively, which were the exchange
rates on the balance sheet dates. Equity accounts were stated at their historical rates. The average translation rates applied to the
statements of operations for the years ended December 31, 2024 and 2023 were 7.1889 RMB and 7.0752 RMB to $1.00, respectively. Cash flows
from the Company&#8217;s operations are calculated based upon the local currencies using the average translation rate.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Comprehensive Loss</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comprehensive loss is comprised of net loss and
all changes to the statements of equity, except those due to investments by stockholders, changes in paid-in capital and distributions
to stockholders. For the Company, comprehensive loss for the years ended December 31, 2024 and 2023 consisted of net loss and unrealized
loss from foreign currency translation adjustment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Commitments and Contingencies</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In the normal course of business, the Company
is subject to contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters. Liabilities
for such contingencies are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably
estimated.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>Commitments
and Contingencies</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In the normal
course of business, the Company is subject to contingencies, such as legal proceedings and claims arising out of its business, that cover
a wide range of matters. Liabilities for such contingencies are recorded when it is probable that a liability has been incurred and the
amount of the assessment can be reasonably estimated.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Per Share Data</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Per Share Data</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">ASC Topic 260 &#8220;Earnings per Share,&#8221;
requires presentation of both basic and diluted earnings per share (&#8220;EPS&#8221;) with a reconciliation of the numerator and denominator
of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Basic net loss per share is computed by dividing
net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents
and potentially dilutive securities outstanding during each period. The Company had $162,473 in deemed contribution during the three
months ended March 31, 2025, which increases the numerator in the net loss per share calculation. For the three months ended March 31,
2025 and 2024, potentially dilutive common shares consisted of the common shares issuable upon the conversion of convertible preferred
stock and convertible notes (using the if-converted method) and exercise of common stock options and warrants (using the treasury stock
method). Common stock equivalents are not included in the calculation of diluted net loss per share if their effect would be anti-dilutive.
In a period in which the Company has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares
outstanding as they would have had an anti-dilutive impact.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The calculation of basic and diluted net loss
per common share attributable to the Company common shareholders includes 150,000 of the pre-funded warrants that remained outstanding
as of March 31, 2025.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes the securities
that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:</span></p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended March 31,</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Options to purchase common stock</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,451,425</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">47,287</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Warrants to purchase common stock</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">171,163</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">60,562</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 10pt">Series A convertible preferred stock </span><span style="-sec-ix-redline:true;font-size: 12.5pt"><sup>(*)</sup></span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-380"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">60,000</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 10pt">Series B convertible preferred stock </span><span style="-sec-ix-redline:true;font-size: 12.5pt"><sup>(**)</sup></span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-381"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">194,004</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 10pt">Series C convertible preferred stock </span><span style="-sec-ix-redline:true;font-size: 12.5pt"><sup>(***)</sup></span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,452,282</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-382"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Series D convertible preferred stock (****)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,074,689</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-383"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 10pt">Convertible notes and related accrued interest
    </span><span style="-sec-ix-redline:true;font-size: 12.5pt"><sup>(*****)</sup></span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">234,554</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">90,133</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Potentially dilutive securities</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,384,113</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">451,986</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="-sec-ix-redline:true;font-size: 10pt">(*)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the Series A convertible preferred stock (&#8220;Series A Preferred Stock&#8221;) was converted into shares of common stock of the Company at a conversion price of $150.00 per share.</span></td></tr> </table><table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="-sec-ix-redline:true;font-size: 10pt">(**)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the Series B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.</span></td></tr> </table><table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="-sec-ix-redline:true;font-size: 10pt">(***)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the Series C convertible preferred stock (&#8220;Series C Preferred Stock&#8221;) was converted into shares of common stock of the Company at a conversion price of $2.41 per share.</span></td></tr> </table><table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="-sec-ix-redline:true;font-size: 10pt">(****)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the Series D convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $2.41 per share.</span></td></tr> </table><table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="-sec-ix-redline:true;font-size: 10pt">(*****)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the three months ended March 31, 2025. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and $22.50 and $15.00 per share for the three months ended March 31, 2024.</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Per Share Data</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC Topic 260 &#8220;Earnings per Share,&#8221;
requires presentation of both basic and diluted earnings per share (&#8220;EPS&#8221;) with a reconciliation of the numerator and denominator
of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per share is computed by dividing
net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents
and potentially dilutive securities outstanding during each period. For the years ended December 31, 2024 and 2023, potentially dilutive
common shares consist of the common shares issuable upon the conversion of convertible preferred stock and convertible notes (using the
if-converted method) and exercise of common stock options and warrants (using the treasury stock method). Common stock equivalents are
not included in the calculation of diluted net loss per share if their effect would be anti-dilutive. In a period in which the Company
has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares outstanding as they would have
had an anti-dilutive impact.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The calculation of basic and diluted net loss
per common share attributable to the Company common shareholders includes 150,000 of the pre-funded warrants that remain outstanding as
of December 31, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the securities
that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended<br/>
 December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Options to purchase common stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">52,479</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">56,880</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrants to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">182,996</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,035</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series A convertible preferred stock <sup>(*)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series B convertible preferred stock <sup>(**)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194,004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194,004</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series C convertible preferred stock <sup>(***)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,452,282</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-330">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Convertible notes <sup>(****)</sup></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">227,269</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">60,740</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,169,030</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">414,659</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left">(*)</td><td style="text-align: justify">Assumed the Series A convertible preferred stock was converted
into shares of common stock of the Company at a conversion price of $150.00 per share<span style="background-color: white">.</span></td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="background-color: white">(**)</span></td><td style="text-align: justify"><span style="background-color: white">Assumed the Series
B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.</span></td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="background-color: white">(***)</span></td><td style="text-align: justify"><span style="background-color: white">Assumed the Series
C convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $2.41 per share.</span></td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="background-color: white">(****)</span></td><td style="text-align: justify"><span style="background-color: white">Assumed the convertible
notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the year ended December
31, 2024. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and
$22.50 per share for the year ended December 31, 2023.</span></td>
</tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_NoncontrollingInterestPolicyTextBlock', window );">Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Noncontrolling Interest</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024, Dr. Yu Zhou, former director
and former Co-Chief Executive Officer of Genexosome, who owns 40% of the equity interests of Genexosome, which is not under the Company&#8217;s
control. Since the fourth quarter of 2019, the non-controlling interest has remained inactive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Reclassification</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Certain prior period
amounts have been reclassified to conform to the current period presentation. These reclassifications have no effect on the previously
reported financial position, results of operations and cash flows.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Segment Reporting</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The segment reporting structure uses the Company&#8217;s
management reporting structure as its foundation to reflect how the Company manages the businesses internally and was mainly organized
by services. During the three months ended March 31, 2025 and 2024, the Company is organized into two services-oriented strategic business
units: real property rental services and laboratory testing services (which ended on the redemption date, February 26, 2025) - which
are led by our strategic business unit managers. Operating segments are defined as components of an enterprise for which separate financial
information is available and evaluated regularly by the chief operating decision maker (&#8220;CODM&#8221;) in deciding how to make operating
decisions, allocate resources and assess performance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On February 9, 2023, the Company purchased 40%
of Lab Services MSO. During the first quarter of 2025, to preserve cash, the Company entered into discussions with Lab Services MSO for
the potential redemption of Avalon Lab&#8217;s investment and on February 26, 2025, Lab Services MSO redeemed the 40% equity interest
in Lab Services MSO held by Avalon Lab. Commencing from the purchase date, February 9, 2023, through the redemption date, February 26,
2025, the Company was active in the management of Lab Services MSO. During the three months ended March 31, 2025 and 2024, the Company
operated in two reportable business segments: (1) the real property operating segment, and (2) laboratory testing services segment (which
ended on the redemption date, February 26, 2025) since Lab Services MSO&#8217;s operating results are regularly reviewed by the Company&#8217;s
chief operating decision maker to determine the resources to be allocated to the segment and assess its performance. Prior to February
26, 2025, the Company regularly reviewed the operating results and performance of Lab Services MSO, for which the Company accounted for
under the equity method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company&#8217;s President and Chief Executive
Officer is its CODM. The Company reports operational data to its CODM at the segment level, which he uses to evaluate performance and
allocate resources based on real property operating income and income from equity method investment - Lab Services MSO.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Segment Reporting</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The segment
reporting structure uses the Company&#8217;s management reporting structure as its foundation to reflect how the Company manages the businesses
internally and is mainly organized by services. The Company is organized into two services-oriented strategic business units: real property
rental services and laboratory testing services - which are led by our strategic business unit managers. Operating segments are
defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating
decision maker (&#8220;CODM&#8221;) in deciding how to make operating decisions, allocate resources and assess performance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 9, 2023, the Company purchased 40%
of Lab Services MSO. Commencing from the purchase date, February 9, 2023, the Company is active in the management of Lab Services MSO.
During the years ended December 31, 2024 and 2023, the Company operated in two reportable business segments: (1) the real property operating
segment, and (2) laboratory testing services segment (which commenced with the purchase date, February 9, 2023) since Lab Services MSO&#8217;s
operating results are regularly reviewed by the Company&#8217;s chief operating decision maker to determine the resources to be allocated
to the segment and assess its performance. The Company regularly reviews the operating results and performance of Lab Services MSO, for
which the Company accounts for under the equity method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s President and Chief Executive
Officer is its CODM. The Company reports operational data to its CODM at the segment level, which he uses to evaluate performance and
allocate resources based on real property operating income and loss from equity method investment - Lab Services MSO.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Year End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Fiscal Year End</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">The
Company has adopted a fiscal year end of December 31st.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Reverse Stock Split</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company effectuated a 1-for-15 reverse stock
split of its outstanding shares of common stock on October 28, 2024. The reverse split did not change the par value of common stock.
All references in these condensed consolidated financial statements to shares, share prices, exercise prices, and other per share information
in all periods have been adjusted, on a retroactive basis, to reflect the reverse stock split.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Reverse Stock Split</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company
effectuated a 1-for-15 reverse stock split of its outstanding shares of common stock on October 28, 2024. The reverse split did not change
the par value of common stock. All references in these consolidated financial statements to shares, share prices, exercise prices, and
other per share information in all periods have been adjusted, on a retroactive basis, to reflect the reverse stock split.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">Recent Accounting Standards</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In August 2020, the FASB issued Accounting Standards
Update (&#8220;ASU&#8221;) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts
in Entity&#8217;s Own Equity (Subtopic 815-40), to simplify accounting for certain financial instruments. ASU 2020-06 eliminated the
then-current models that required separation of beneficial conversion and cash conversion features from convertible instruments and simplified
the derivative scope exception guidance pertaining to equity classification of contracts in an entity&#8217;s own equity. ASU 2020-06
also introduced additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity&#8217;s
own equity. ASU 2020-06 amended the diluted earnings per share guidance, including the requirement to use the if-converted method for
all convertible instruments. ASU 2020-06 was effective for fiscal years beginning after December 15, 2023, including interim periods
within those fiscal years, with early adoption permitted. The adoption of ASU 2020-06 did not have a material effect on the Company&#8217;s
condensed consolidated financial statements and related disclosures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In November 2023, the FASB issued ASU 2023-07,
Segment Reporting (Topic 280). The amendments in this update improve reportable segment disclosure requirements, primarily through enhanced
disclosures about significant segment expenses. ASU 2023-07 became effective for the Company&#8217;s annual period beginning on January
1, 2024 and interim periods beginning after January 1, 2025. The Company adopted this guidance in the fourth quarter of 2024. The Company&#8217;s
results of operations, cash flows, and financial condition were not impacted by the adoption of this ASU.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In December 2023, the FASB issued ASU 2023-09,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This guidance was intended to enhance the transparency and decision-usefulness
of income tax disclosures. The amendments in ASU 2023-09 addressed investor requests for enhanced income tax information primarily through
changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09
was effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively.
Early adoption was permitted. The adoption of ASU 2023-09 did not have a material effect on the Company&#8217;s condensed consolidated
financial statements and related disclosures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Other accounting standards that have been issued
or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the condensed consolidated
financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on
or are unrelated to its condensed consolidated financial condition, results of operations, cash flows or disclosures.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Recent Accounting
Standards</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In August
2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic
470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40), to simplify accounting for certain
financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion
features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts
in an entity&#8217;s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments
that are indexed to and settled in an entity&#8217;s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including
the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for fiscal years beginning after
December 15, 2022, including interim periods within those fiscal years, with early adoption permitted. The adoption of ASU 2020-06 did
not have a material effect on the Company&#8217;s consolidated financial statements and related disclosures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In November
2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280). The amendments in this update improve reportable segment disclosure
requirements, primarily through enhanced disclosures about significant segment expenses. ASU 2023-07 became effective for the Company&#8217;s
annual period beginning on January 1, 2024 and interim periods beginning after January 1, 2025. The Company adopted this guidance in the
fourth quarter of 2024. Refer to Note 20 - Segment Information. The Company&#8217;s results of operations, cash flows, and financial condition
were not impacted by the adoption of this ASU.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">In December
2023, the FASB ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This guidance is intended to enhance the
transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income
tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign
jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to
apply the standard retrospectively. Early adoption is permitted. The adoption of ASU 2023-09 did not have a material effect on the Company&#8217;s
consolidated financial statements and related disclosures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Other accounting
standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material
impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated
to have an impact on or are unrelated to its consolidated financial condition, results of operations, cash flows or disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_DebtModificationsAndExtinguishmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for debt modifications and extinguishments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_DebtModificationsAndExtinguishmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_DeferredRentalIncomePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferred rental income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_DeferredRentalIncomePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in real estate and depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_NoncontrollingInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for noncontrolling interest policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_NoncontrollingInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_RealPropertyRentalRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for real property rental revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_RealPropertyRentalRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements entered into by lessor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -SubTopic 30<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-3A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-3A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -SubTopic 30<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstatePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for entities that primarily develop and then sell real property at retail or otherwise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 970<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482170/970-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstatePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Nature of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock', window );">Schedule of Consolidated Financial Statements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Details of the Company&#8217;s subsidiaries which
are included in these condensed consolidated financial statements as of March 31, 2025 are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 29%"><span style="-sec-ix-redline:true;font-size: 10pt">Name of Subsidiary</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-bottom: 1.5pt; padding-left: 5.65pt; text-align: center; width: 2%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 15%"><span style="-sec-ix-redline:true;font-size: 10pt">Place and Date of Incorporation</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-bottom: 1.5pt; padding-left: 5.65pt; text-align: center; width: 2%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 15%"><span style="-sec-ix-redline:true;font-size: 10pt">Percentage of Ownership</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-bottom: 1.5pt; padding-left: 5.65pt; text-align: center; width: 2%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center; width: 35%"><span style="-sec-ix-redline:true;font-size: 10pt">Principal Activities</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Avalon Healthcare System, Inc. (&#8220;AHS&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Delaware May 18, 2015</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">100% held by ALBT</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Holding company for payroll and other expenses</span></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Avalon RT 9 Properties LLC (&#8220;Avalon RT 9&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">New Jersey February 7, 2017</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">100% held by ALBT</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Owns and operates an income-producing real property and holds and manages the corporate headquarters</span></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Avalon (Shanghai) Healthcare Technology Co., Ltd. (&#8220;Avalon Shanghai&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">PRC April 29, 2016</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">100% held by AHS</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Not considered an operating entity</span></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Genexosome Technologies Inc. (&#8220;Genexosome&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Nevada July 31, 2017</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">60% held by ALBT</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">No current activities to report; dormant</span></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Avactis Biosciences Inc. (&#8220;Avactis&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Nevada July 18, 2018</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">60% held by ALBT</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Dormant; in process of being dissolved</span></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Avactis Nanjing Biosciences Ltd. (&#8220;Avactis Nanjing&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">PRC May 8, 2020</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">100% held by Avactis</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Dormant; in process of being dissolved</span></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Avalon Laboratory Services, Inc. (&#8220;Avalon Lab&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Delaware October 14, 2022</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">100% held by ALBT</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">No current activities to report; dormant</span></td></tr> <tr> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Q&amp;A Distribution LLC (&#8220;Q&amp;A Distribution&#8221;)</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Texas May 1, 2024</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">100% held by ALBT</span></td> <td style="vertical-align: bottom; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="vertical-align: top; padding-right: 5.65pt; padding-left: 5.65pt; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Distributes KetoAir device</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Details of the Company&#8217;s subsidiaries which
are included in these consolidated financial statements as of December 31, 2024 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; width: 30%; text-align: left">Name of Subsidiary</td> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 17%; text-align: center">Place and date of<br/> Incorporation</td> <td style="padding-bottom: 1.5pt; vertical-align: bottom; width: 2%; text-align: center">&#160;</td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 15%; text-align: center">Percentage of<br/> Ownership</td> <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center">Principal Activities</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Avalon Healthcare System, Inc. (&#8220;AHS&#8221;)</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">Delaware <br/>
May 18, 2015</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">100% held by ALBT</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">Holding company for payroll and other expenses</td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Avalon RT 9 Properties LLC (&#8220;Avalon RT 9&#8221;) &#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">New Jersey<br/> February 7, 2017 &#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">100% held by ALBT &#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">Owns and operates an income-producing real property and holds and manages the corporate headquarters</td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Avalon (Shanghai) Healthcare Technology Co., Ltd. (&#8220;Avalon Shanghai&#8221;)</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">PRC <br/>
April 29, 2016 &#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">100% held by AHS &#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">Is not considered an operating entity &#160; &#160;</td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Genexosome Technologies Inc. (&#8220;Genexosome&#8221;)</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">Nevada<br/> July 31, 2017</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">60% held by ALBT</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">No current activities to report, dormant &#160;</td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Avactis Biosciences Inc. (&#8220;Avactis&#8221;)</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">Nevada<br/> July 18, 2018</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">60% held by ALBT</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">Dormant, is in process of being dissolved</td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Avactis Nanjing Biosciences Ltd. (&#8220;Avactis Nanjing&#8221;)</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">PRC <br/>
May 8, 2020</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">100% held by Avactis</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">Dormant, is in process of being dissolved</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Avalon Laboratory Services, Inc. (&#8220;Avalon Lab&#8221;)</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">Delaware<br/> October 14, 2022</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">100% held by ALBT</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">Laboratory holding company with a 40% membership interest in Lab Services MSO (1)</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td></tr> <tr style="background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left; vertical-align: top">Q&amp;A Distribution LLC (&#8220;Q&amp;A Distribution&#8221;)</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: top">Texas <br/>
May 1, 2024</td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="padding-bottom: 1pt; text-align: center; vertical-align: top">100% held by ALBT</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="padding-bottom: 1pt; vertical-align: top; text-align: center">Distributes KetoAir device</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="vertical-align: top">
<td style="width: 0.25in">(1)</td><td style="text-align: justify">On February 26, 2025, the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement,
whereby Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by the Company.</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Schedule of Derivative Liability Measured at Fair Value</a></td>
<td class="text">The table below reflects the activity of derivative liability measured at
fair value for the three months ended March 31, 2025:<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Significant <br/>
    Unobservable Inputs<br/> (Level 3)</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Balance of derivative liability as of January 1, 2025</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">127,545</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Reclassification of additional paid-in capital upon conversion</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(18,853</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Loss from change in the fair value of derivative liability</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">114,360</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Balance of derivative liability as of March 31, 2025</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">223,052</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text">The table below reflects the
activity of derivative liability measured at fair value for the years ended December 31, 2024 and 2023:<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Significant Unobservable Inputs <br/>
(Level 3)</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance of derivative liability as of January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-329">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 88%; text-align: left">Initial fair value of derivative liability attributable to warrants issuance with May, July, and October 2023 fund raises</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">213,170</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain from change in the fair value of derivative liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(188,374</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Balance of derivative liability as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,796</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Initial fair value of derivative liability attributable to warrants issuance with March and June 2024 fund raises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">479,468</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reclassification of additional paid-in capital upon conversion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,354</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Gain from change in the fair value of derivative liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(374,365</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance of derivative liability as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">127,545</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash Balances by Geographic Area</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">At March 31, 2025 and December 31, 2024, the Company&#8217;s
cash balances by geographic area were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Country:</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">March 31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">December 31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">United States</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,351,923</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">98.7</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,844,522</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">99.6</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">China</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">17,663</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.3</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">11,787</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.4</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Total cash</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,369,586</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">100.0</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,856,309</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">100.0</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2024 and 2023, the Company&#8217;s
cash balances by geographic area were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Country:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,844,522</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">99.6</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">280,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">98.2</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">China</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,787</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.4</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,203</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total cash</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,856,309</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">285,400</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Securities that were Excluded from the Diluted Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes the securities
that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended March 31,</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Options to purchase common stock</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,451,425</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">47,287</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Warrants to purchase common stock</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">171,163</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">60,562</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 10pt">Series A convertible preferred stock </span><span style="-sec-ix-redline:true;font-size: 12.5pt"><sup>(*)</sup></span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-380"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">60,000</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 10pt">Series B convertible preferred stock </span><span style="-sec-ix-redline:true;font-size: 12.5pt"><sup>(**)</sup></span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-381"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">194,004</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;font-size: 10pt">Series C convertible preferred stock </span><span style="-sec-ix-redline:true;font-size: 12.5pt"><sup>(***)</sup></span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,452,282</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-382"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Series D convertible preferred stock (****)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,074,689</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-383"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-size: 10pt">Convertible notes and related accrued interest
    </span><span style="-sec-ix-redline:true;font-size: 12.5pt"><sup>(*****)</sup></span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">234,554</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">90,133</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Potentially dilutive securities</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,384,113</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">451,986</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="-sec-ix-redline:true;font-size: 10pt">(*)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the Series A convertible preferred stock (&#8220;Series A Preferred Stock&#8221;) was converted into shares of common stock of the Company at a conversion price of $150.00 per share.</span></td></tr> </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="-sec-ix-redline:true;font-size: 10pt">(**)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the Series B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.</span></td></tr> </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="-sec-ix-redline:true;font-size: 10pt">(***)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the Series C convertible preferred stock (&#8220;Series C Preferred Stock&#8221;) was converted into shares of common stock of the Company at a conversion price of $2.41 per share.</span></td></tr> </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="-sec-ix-redline:true;font-size: 10pt">(****)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the Series D convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $2.41 per share.</span></td></tr> </table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.6in"><span style="-sec-ix-redline:true;font-size: 10pt">(*****)</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the three months ended March 31, 2025. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and $22.50 and $15.00 per share for the three months ended March 31, 2024.</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the securities
that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended<br/>
 December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Options to purchase common stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">52,479</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">56,880</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warrants to purchase common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">182,996</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,035</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series A convertible preferred stock <sup>(*)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Series B convertible preferred stock <sup>(**)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194,004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194,004</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Series C convertible preferred stock <sup>(***)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,452,282</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-330">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Convertible notes <sup>(****)</sup></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">227,269</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">60,740</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Potentially dilutive securities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,169,030</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">414,659</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left">(*)</td><td style="text-align: justify">Assumed the Series A convertible preferred stock was converted
into shares of common stock of the Company at a conversion price of $150.00 per share<span style="background-color: white">.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="background-color: white">(**)</span></td><td style="text-align: justify"><span style="background-color: white">Assumed the Series
B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="background-color: white">(***)</span></td><td style="text-align: justify"><span style="background-color: white">Assumed the Series
C convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $2.41 per share.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="background-color: white">(****)</span></td><td style="text-align: justify"><span style="background-color: white">Assumed the convertible
notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the year ended December
31, 2024. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and
$22.50 per share for the year ended December 31, 2023.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expense and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAbstract', window );"><strong>Prepaid Expense and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expense and Other Current Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">At March 31, 2025 and December 31, 2024, prepaid expense and other
current assets consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">March 31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">December 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Prepaid professional fees</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">90,431</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">33,665</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Prepaid directors&#8217; and officers&#8217; liability insurance premium</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">12,834</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">9,741</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Prepaid NASDAQ listing fee</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">39,750</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-384"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Deferred leasing costs</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">28,980</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">31,587</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Security deposit</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">12,256</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">17,654</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Due from broker</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">33,160</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">32,885</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Finished goods</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">90,116</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">92,230</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Recoverable value-added tax</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">10,094</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">9,245</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Others</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">50,197</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">72,353</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">367,818</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">299,360</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">At December 31, 2024 and 2023, prepaid expense
and other current assets consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>
2024</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>
2023</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Prepaid professional fees</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">33,665</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">33,062</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid directors and officers&#8217; liability insurance premium</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,741</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,192</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-331">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">175,136</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred leasing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,587</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,402</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Security deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,654</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-332">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Due from broker</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,885</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,187</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finished goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,230</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-333">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Recoverable VAT</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,218</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72,353</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">55,797</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">299,360</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">367,994</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">At December 31, 2024
and 2023, property and equipment consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Useful Life</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: center">5 Years</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-334">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">100,548</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Office equipment and furniture</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">3 - 10 Years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,499</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,797</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,499</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">155,345</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(41,587</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(117,262</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">12,912</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">38,083</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Real Estate (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstateInvestmentsAbstract', window );"><strong>Investment in Real Estate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock', window );">Schedule of Investment in Real Estate</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">At December 31, 2024
and 2023, investment in real estate consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Useful Life</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Commercial real property building</td><td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: center">39 Years</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,708,571</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,708,571</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Improvement</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="text-align: center; padding-bottom: 1.5pt">12 Years</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">529,372</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">529,372</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8,237,943</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8,237,943</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,215,222</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,046,539</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,022,721</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,191,404</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstateInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstateInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of real estate properties and units in those properties that are included in the discussion of the nature of an entity's operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of Equity Method Investment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In the three months ended March 31, 2025, activity
recorded for the Company&#8217;s equity method investment in Lab Services MSO is summarized in the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Equity investment carrying amount at January 1, 2025</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">10,636,544</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Lab Services MSO&#8217;s net income attributable to the Company</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">503,833</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Intangible assets amortization amount</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(111,156</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Sale of equity investment</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(11,029,221</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Equity investment carrying amount at March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-385"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In the years ended December
31, 2024 and 2023, activity recorded for the Company&#8217;s equity method investment in Lab Services MSO is summarized in the following
table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Equity investment carrying amount at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-335">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Payment for equity method investment:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">The Company&#8217;s interest in the fair value of Lab Services MSO&#8217;s net assets at February 9, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,206,406</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">The Company&#8217;s interest in the net excess of Lab Services MSO&#8217;s fair value over net assets which was attributable to identifiable intangible assets at February 9, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,004,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">The Company&#8217;s interest in the net excess of Lab Services MSO&#8217;s fair value over net assets which was attributable to goodwill at February 9, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,456,261</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Total payment for equity method investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,666,667</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Lab Services MSO&#8217;s net income attributable to the Company</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,236,391</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Intangible assets amortization amount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(611,356</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Impairment of goodwill</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,196,682</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Equity investment carrying amount at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,095,020</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Lab Services MSO&#8217;s net income attributable to the Company</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">79,923</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Intangible assets amortization amount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(666,932</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Distribution of earnings from equity investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(611,888</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Impairment of goodwill</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(259,579</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Equity investment carrying amount at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,636,544</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of Summarized Financial Information, as Provided to the Company by the Investee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The tables below present the summarized financial
information, as provided to the Company by the investee, for the unconsolidated company:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,917,880</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,930,254</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Noncurrent assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,509,185</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,228,044</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">611,391</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">828,713</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Noncurrent liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,346,725</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,104,183</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,468,949</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,225,402</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock', window );">Schedule of Financial Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The tables below present the summarized financial
information, as provided to the Company by the investee, for the unconsolidated company:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">For the Period<br/> from January
    1,<br/> 2025 through<br/> February 26,<br/> 2025 <br/> (Date of Sale)</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">For the Three<br/> Months Ended <br/>
    March 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net revenue</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4,241,732</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,376,372</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Gross profit</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,155,760</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,003,789</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Income from operation</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,513,000</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">275,026</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net income</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,259,582</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">685,504</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">For the year Ended December 31, 2024</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">For the Period from<br/>
February 9,<br/>
 2023 (Date of Investment) through December 31, 2023</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,558,711</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,699,683</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,534,503</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,744,277</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">(Loss) income from operation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(265,754</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,393,830</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199,808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,090,977</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedIncomeStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities and Other Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Liabilities and Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities and Other Payables</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">At December 31, 2024
and 2023, accrued liabilities and other payables consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>
2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,<br/>
 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued tenants&#8217; improvement reimbursement</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">43,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">43,500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tenants&#8217; security deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,233</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,233</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued business expense reimbursement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,781</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,061</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued utilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,075</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,166</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred rental income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,346</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,429</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued real property cleaning service fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,570</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,027</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">177,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,794</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,258</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,135</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">434,117</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">272,915</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Note Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Note Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Amortization Payments in Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company is obligated to make amortization
payments in cash to Mast Hill toward the repayment of the June 2024 Convertible Note, as provided in the following table:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: black 1.5pt solid; width: 49%"><span style="-sec-ix-redline:true;font-size: 10pt"><b>Payment Date</b></span></td> <td style="white-space: nowrap; padding-bottom: 1.5pt; width: 2%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="white-space: nowrap; border-bottom: black 1.5pt solid; width: 49%"><span style="-sec-ix-redline:true;font-size: 10pt"><b>Payment Amount</b></span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">December 5, 2024</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">$284,500 plus accrued interest through December 5, 2024</span></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">January 5, 2025</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">$284,500 plus accrued interest through January 5, 2025</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">February 5, 2025</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">$379,336 plus accrued interest through February 5, 2025</span></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">March 5, 2025</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">$474,167 plus accrued interest through March 5, 2025</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">April 5, 2025</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">$474,167 plus accrued interest through April 5, 2025</span></td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">May 5, 2025</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">$569,000 plus accrued interest through May 5, 2025</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">June 5, 2025</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="white-space: nowrap"><span style="-sec-ix-redline:true;font-size: 10pt">The entire remaining outstanding balance of the June 2024 Convertible Note</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company is obligated
to make amortization payments in cash to Mast Hill toward the repayment of the June 2024 Convertible Note, as provided in the following
table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 30%">Payment Date:</td> <td style="padding-bottom: 1.5pt; white-space: nowrap; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 68%">Payment Amount:</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap">December 5, 2024</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap">$284,500 plus accrued interest through December 5, 2024</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap">January 5, 2025</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap">$284,500 plus accrued interest through January 5, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap">February 5, 2025</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap">$379,336 plus accrued interest through February 5, 2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap">March 5, 2025</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap">$474,167 plus accrued interest through March 5, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap">April 5, 2025</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap">$474,167 plus accrued interest through April 5, 2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="white-space: nowrap">May 5, 2025</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap">$569,000 plus accrued interest through May 5, 2025</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap">June 5, 2025</td> <td style="white-space: nowrap">&#160;</td> <td style="white-space: nowrap">The entire remaining outstanding balance of the June 2024 Convertible Note</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Convertible Note Payable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The convertible note payable as of March 31, 2025
and December 31, 2024 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 12pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">March 31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">December 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Principal amount</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,556,777</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,556,777</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Less: unamortized debt issuance costs</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(33,584</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(93,425</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Less: unamortized debt discount</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(125,665</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(349,579</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Convertible note payable, net</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,397,528</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,113,773</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">The
convertible note payable as of December 31, 2024 and 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Principal amount</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,556,777</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,400,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: unamortized debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(93,425</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(183,840</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: unamortized debt discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(349,579</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(291,014</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Convertible note payable, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,113,773</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,925,146</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Payable, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Note Payable, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Note Payable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The note payable as of March 31, 2025 and December
31, 2024 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><b style="-sec-ix-redline:true;-keep: true">March 31,<br/> 2025</b></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><b style="-sec-ix-redline:true;-keep: true">December
    31, <br/> 2024</b></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Principal amount</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,800,000</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,800,000</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Less: unamortized debt issuance costs</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(54,746</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(84,553</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Note payable, net</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,745,254</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,715,447</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">The
note payable as of December 31, 2024 and 2023 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Principal amount</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,800,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,800,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: unamortized debt issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(84,553</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(203,781</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Note payable, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,715,447</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,596,219</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current portion</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,715,447</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-336">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Noncurrent portion</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-337">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,596,219</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Line of Credit</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the years ended December 31, 2024 and 2023,
activity recorded for the Line of Credit is summarized in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Outstanding principal under the Line of Credit at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-339">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Draw down from Line of Credit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">850,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding principal under the Line of Credit at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">850,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Repayment of Line of Credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(400,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Reclassification of Line of Credit to advance from related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(450,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Outstanding principal under the Line of Credit at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Company&#8217;s Loss Before Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The Company&#8217;s
loss before income taxes includes the following components:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">United States loss before income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,639,148</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,928,780</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">China loss before income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">264,246</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">778,230</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0.125in; text-align: left">Total loss before income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,903,394</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">16,707,010</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Taxes Expense (Benefit)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Components of income taxes expense (benefit) consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">U.S. federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-340">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-341">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">U.S. state and local</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-342">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-343">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">China</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-344">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-345">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left">Total current income taxes expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-346">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-347">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">U.S. federal</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,874</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(3,256,007</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">U.S. state and local</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,650</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,102,392</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in">China</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,437</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(183,443</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-align: left">Total deferred income taxes (benefit)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">86,913</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,541,842</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(86,913</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,541,842</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Total income taxes expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-348">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-349">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of U.S. Statutory Rate and the Company&#8217;s Effective Tax Rate</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below summarizes the differences between
the U.S. statutory rate and the Company&#8217;s effective tax rate for the years ended December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">U.S. federal rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">U.S. state rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent difference</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.1</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Non-US rate differential</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">True ups</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.6</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">U.S. valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.1</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27.2</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total provision for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s components of deferred taxes
as of December 31, 2024 and 2023 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,<br/>
 2024</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, <br/>
2023</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left">Stock-based compensation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,598,257</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,501,507</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Disallowed business interest deduction</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-350">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,476</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Research and development expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106,783</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130,823</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Accrued directors&#8217; compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,977</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165,490</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Accrued settlement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,904</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">126,496</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Partnership Investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,167,965</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,422,744</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,687</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,935</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Capital loss limitation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149,394</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net operating loss carryforward</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,648,077</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,493,570</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left">Total deferred tax assets, gross</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,918,044</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,020,435</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,784,638</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,871,551</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total deferred tax assets, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">133,406</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">148,884</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left">Fixed assets and intangible assets book/tax basis difference</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(133,406</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(129,636</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-351">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,248</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(133,406</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(148,884</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-352">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-353">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityTablesLineItems', window );"><strong>Equity (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Schedule of Common Stock Issuable Upon Exercise of Warrants Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table summarizes
the shares of the Company&#8217;s common stock issuable upon exercise of options outstanding at December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Options Outstanding</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Options Exercisable</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Range<br/> of Exercise <br/> Price</td> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number <br/>
Outstanding at<br/> December 31, <br/>
2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted Average</p> <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number Exercisable at<br/> December 31, <br/>
2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise <br/>Price</td><td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 17%; text-align: right">2.93 - 31.20</td> <td style="width: 1%">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">20,198</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">3.54</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">14.76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">14,591</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">16.38</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: right">48.75 - 123.00</td> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,517</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2.04</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">78.91</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,517</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">78.91</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">154.50 - 289.50</td> <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,764</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.44</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">218.21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,764</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">218.21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.93 - 289.50</td> <td>&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">52,479</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2.93</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">85.45</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">46,872</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">94.41</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Stock option activity for the three months ended
March 31, 2025 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Number of <br/> Options</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Weighted <br/> Average <br/> Exercise
    <br/> Price</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding at January 1, 2025</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">52,479</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">85.45</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,665</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.26</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Expired / cancelled</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(3,719</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(132.47</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding at March 31, 2025</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">51,425</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">77.79</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Options exercisable at March 31, 2025</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">47,493</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">83.97</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Options expected to vest</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,932</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.13</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Stock warrant activity for the three months ended
March 31, 2025 was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Number of <br/> Warrants</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Weighted <br/>
    Average <br/> Exercise <br/> Price</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding at January 1, 2025</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">182,996</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">21.37</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(11,833</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(58.63</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding at March 31, 2025</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">171,163</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">18.79</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Warrants exercisable at March 31, 2025</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">91,163</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">28.70</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Warrants expected to vest</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">80,000</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Stock option activity
for the years ended December 31, 2024 and 2023 was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Options</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">53,357</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">195.45</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,452</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,929</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(267.90</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">149.03</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,265</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.13</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,666</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(275.14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">52,479</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">85.45</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Options exercisable at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,872</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">94.41</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options expected to vest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,607</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10.56</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Stock warrant activity
for the years ended December 31, 2024 and 2023 was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Warrants</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,264</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">187.50</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Issued</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34,771</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48.90</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,035</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75.53</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,527</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.28</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23,288</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(32.85</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,278</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(50.77</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">182,996</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants exercisable at December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102,996</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">32.13</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants expected to vest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.50</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Nonvested Stock Options Granted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">A summary of the status of the Company&#8217;s
nonvested stock options granted as of March 31, 2025 and changes during the three months ended March 31, 2025 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Number of <br/> Options</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Weighted <br/> Average <br/> Exercise
    <br/> Price</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Nonvested at January 1, 2025</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,943</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">11.54</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,665</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.26</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Cancelled</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,853</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(27.40</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Vested</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,823</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(5.03</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Nonvested at March 31, 2025</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,932</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.13</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">A summary of the status of the Company&#8217;s
nonvested stock warrants issued as of March 31, 2025 and changes during the three months ended March 31, 2025 is presented below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Number of <br/> Warrants</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Weighted <br/> Average <br/> Exercise<br/>
    Price</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Nonvested at January 1, 2025</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="white-space: nowrap; width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">80,000</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Vested</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-386"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-387"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Nonvested at March 31, 2025</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">80,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the status of the Company&#8217;s
nonvested stock options granted as of December 31, 2024 and changes during the years ended December 31, 2024 and 2023 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Options</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Nonvested at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,334</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">64.35</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,452</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35.25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,475</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47.14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Nonvested at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,311</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23.55</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,265</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.13</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,969</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10.90</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Nonvested at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,607</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10.56</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">A summary of the status
of the Company&#8217;s nonvested stock warrants issued as of December 31, 2024 and changes during the years ended December 31, 2024 and
2023 was presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of Warrants</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Nonvested at January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-354">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-355">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%">Issued</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">34,771</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">48.90</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,560</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">55.95</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Nonvested at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,211</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39.90</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,527</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.28</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23,288</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(32.85</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(81,450</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12.10</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Nonvested at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">80,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7.50</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Common Stock Issuable Upon Exercise of Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the shares of the
Company&#8217;s common stock issuable upon exercise of warrants outstanding at December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants Exercisable</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Range of<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">Number<br/> Outstanding at <br/>
December 31, <br/>
2024</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average<br/> Remaining<br/> Contractual<br/> Life (Years)</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">Weighted<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">Number<br/> Exercisable at<br/> December 31<br/>
, 2024</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Weighted Average Exercise</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Price</p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 13.5%; text-align: right">7.50 - 37.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">&#160;&#160;&#160;&#160;&#160;165,510</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">4.40</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 13.5%; text-align: right">10.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13.5%; text-align: right">85,510</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 13.5%; text-align: right">13.31</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">&#160;</td><td style="text-align: right">67.50</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,222</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.40</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">67.50</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,222</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">67.50</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">187.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.30</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">187.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">187.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7.50 - 187.50</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">182,996</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4.25</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">21.37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">102,996</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">32.13</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Second Warrant, which was issued on May 23, 2023, July 6,
2023, October 9, 2023, and March 7, 2024, was cancelled in June 2024. Second Warrant, which was issued on June 5, 2024, is still outstanding
as of December 31, 2024.</td>
</tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_OptionsOutstandingMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityTablesLineItems', window );"><strong>Equity (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Common Stock Issuable Upon Exercise of Options Outstanding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes the shares of the
Company&#8217;s common stock issuable upon exercise of options outstanding at March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: White"> <td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Options Outstanding</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Options Exercisable</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Range of<br/> Exercise<br/> Price</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Number <br/> Outstanding<br/> at March 31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted <br/> Average <br/> Remaining <br/> Contractual Life <br/> (Years)</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted <br/> Average<br/> Exercise<br/> Price</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Number <br/> Exercisable at <br/> March 31,<br/> 2025</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted <br/> Average<br/> Exercise <br/> Price</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">$</span></td> <td style="width: 24%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.93 - 31.20</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">21,010</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.48</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">12.19</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">17,078</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">14.28</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif">&#160;<span style="font-size: 10pt">48.75 - 123.00&#160;</span></span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,517</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.79</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">78.91</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,517</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">78.91</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td colspan="2" style="text-align: right; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif">&#160;<span style="font-size: 10pt">154.50 - 264.00&#160;</span></span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">9,898</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.82</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">214.71</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">9,898</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">214.71</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-top: Black 1.5pt solid; text-align: right; padding-bottom: 2.5pt; border-bottom: Black 4pt double"><span style="-sec-ix-redline:true;-keep: true">$</span></td> <td style="border-top: Black 1.5pt solid; text-align: right; padding-bottom: 2.5pt; border-bottom: Black 4pt double"><span style="-sec-ix-redline:true;-keep: true">2.93 - 264.00</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">51,425</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.87</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">77.79</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">47,493</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">83.97</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_WarrantsOutstandingMember', window );">Warrants Outstanding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityTablesLineItems', window );"><strong>Equity (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Common Stock Issuable Upon Exercise of Options Outstanding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes the shares of the
Company&#8217;s common stock issuable upon exercise of warrants outstanding at March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="12" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Warrants Outstanding</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Warrants Exercisable</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Range of<br/> Exercise<br/> Price</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Number <br/> Outstanding<br/> at March 31,<br/> 2025</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Weighted <br/> Average <br/> Remaining <br/> Contractual Life <br/> (Years)</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Weighted <br/> Average<br/> Exercise<br/> Price</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Number <br/> Exercisable at <br/> March 31,<br/> 2025</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-size: 10pt">Weighted <br/> Average<br/> Exercise<br/> Price</span></td> <td style="padding-bottom: 1.5pt; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="-sec-ix-redline:true;font-size: 10pt">$</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">7.50 - 37.50</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">162,010</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">4.17</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-size: 10pt">$</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">9.92</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">82,010</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;font-size: 10pt">$</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">12.27</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">67.50</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">889</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">3.18</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">67.50</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">889</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">67.50</span></td> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">187.50</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">8,264</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">2.06</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">187.50</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">8,264</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">187.50</span></td> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">7.50 - 187.50</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">171,163</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">4.06</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">18.79</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">91,163</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: black 4.5pt double"><span style="-sec-ix-redline:true;font-size: 10pt">$</span></td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">28.70</span></td> <td style="padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> </table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avco_OptionsOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avco_OptionsOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avco_WarrantsOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avco_WarrantsOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Concentrations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Customer Accounted for Company's Revenues</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table sets forth information as
to each customer that accounted for 10% or more of the Company&#8217;s revenue for the three months ended March 31, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended March 31,</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Customer</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">A</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">28</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">28</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">B</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">17</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">18</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">C</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">11</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">12</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">The following
table sets forth information as to each customer that accounted for 10% or more of the Company&#8217;s revenues for the years ended December
31, 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">Customer</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">A</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">29</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">30</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Reportable Business Segments</a></td>
<td class="text">Information with respect to these reportable business segments for
the three months ended March 31, 2025 and 2024 was as follows:<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="14" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended March 31, 2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Real Property Operations</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Lab Services<br/>
 MSO</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Corporate /<br/>
 Other</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Real property rental revenue</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">349,800</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-388"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-389"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">349,800</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Real property operating expenses</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(280,390</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-390"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-391"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(280,390</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Real property operating income</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">69,410</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-392"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-393"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">69,410</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Income from equity method investment - Lab Services MSO</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-394"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">392,677</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-395"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">392,677</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Other operating expenses</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(90,762</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-396"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,178,100</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,268,862</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Other (expense) income:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-sec-ix-redline:true;-keep: true">Interest expense</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(194,307</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-397"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(365,711</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(560,018</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-sec-ix-redline:true;-keep: true">Other income (expense)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">228</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-398"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(115,546</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(115,318</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net (loss) income</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(215,431</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">392,677</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,659,357</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,482,111</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="14" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended March 31, 2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Real Property Operations</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Lab Services<br/>
 MSO</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Corporate /<br/>
 Other</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Real property rental revenue</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">314,588</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-399"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-400"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">314,588</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Real property operating expenses</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(263,126</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-401"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-402"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(263,126</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Real property operating income</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">51,462</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-403"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-404"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">51,462</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Income from equity method investment - Lab Services MSO</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-405"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">107,469</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-406"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">107,469</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Other operating expenses</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(114,287</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-407"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(887,706</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,001,993</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Other (expense) income:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-sec-ix-redline:true;-keep: true">Interest expense</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(194,307</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-408"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(324,700</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(519,007</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-sec-ix-redline:true;-keep: true">Other income (expense)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-409"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(5,448</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(5,444</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net (loss) income</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(257,128</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">107,469</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,217,854</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,367,513</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information with respect to these reportable business
segments for the years ended December 31, 2024 and 2023 was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ended December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Real Property Operations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Lab Services MSO</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Corporate / Other</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Real property rental revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,333,403</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-356">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-357">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,333,403</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Real property operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,065,574</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-358">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-359">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,065,574</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Real property operating income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">267,829</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-360">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-361">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">267,829</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from equity method investment - Lab Services MSO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-362">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(846,588</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-363">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(846,588</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(354,311</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-364">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,994,662</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,348,973</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other (expense) income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;&#160;Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(777,228</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-365">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,659,745</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,436,973</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;&#160;Other expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(80</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-366">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(538,609</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(538,689</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(863,790</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(846,588</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,193,016</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(7,903,394</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ended December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Real Property Operations</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Lab Services MSO</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Corporate / Other</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Total</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Real property rental revenue</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,255,681</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-367">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-368">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,255,681</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Real property operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,017,493</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-369">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-370">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,017,493</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Real property operating income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">238,188</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-371">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-372">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">238,188</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from equity method investment - Lab Services MSO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-373">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,571,647</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-374">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,571,647</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(347,356</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-375">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,072,868</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,420,224</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other (expense) income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;&#160;Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(918,885</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-376">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(432,617</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,351,502</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;&#160;Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-377">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">398,160</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">398,175</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,028,038</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(8,571,647</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(7,107,325</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(16,707,010</td><td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of Identifiable Long-Lived Tangible Assets</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Identifiable long-lived tangible assets at March 31, 2025 and December
    31, 2024</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">March 31, <br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">December 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Real property operations</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,990,058</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,034,335</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Corporate/Other</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,153</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,298</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 9.25pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,991,211</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,035,633</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Identifiable long-lived tangible assets at December 31, 2024 and 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Real property operations</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,034,335</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,211,641</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Corporate/Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,298</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,846</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;&#160;&#160;Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,035,633</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,229,487</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock', window );">Schedule of Identifiable Long-Lived Tangible Assets (Geographic Areas)</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Identifiable long-lived tangible assets at March 31, 2025 and December
    31, 2024</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">March 31, <br/> 2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">December 31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">United States</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,990,058</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,034,335</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">China</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,153</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,298</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 9.25pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6,991,211</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,035,633</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">Identifiable long-lived tangible assets at December 31, 2024 and 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,034,335</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,227,533</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">China</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,298</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,954</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;&#160;Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,035,633</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,229,487</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>192
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Supplemental cash flow information related to
leases for the three months ended March 31, 2025 and 2024 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended March 31,</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-sec-ix-redline:true;-keep: true">Operating cash flows paid for operating lease</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">27,535</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">26,533</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Right-of-use assets obtained in exchange for lease obligation:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9.25pt"><span style="-sec-ix-redline:true;-keep: true">Operating lease</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">127,486</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-410"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes the lease term
and discount rate for the Company&#8217;s operating lease as of March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>



<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Operating <br/> Lease</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Weighted average remaining lease term (in years)</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.75</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">Weighted average discount rate</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">13.0</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Supplemental
cash flow information related to leases for the years ended December 31, 2024 and 2023 is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2024</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">&#160;&#160;Operating cash flows paid for operating lease</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">125,076</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">125,929</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;&#160;Operating lease</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-378">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">235,893</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the lease term
and discount rate for the Company&#8217;s operating lease as of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Operating Lease</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Weighted average remaining lease term (in years)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.08</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted average discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">11.0</td><td style="text-align: left">%</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Lease Liabilities Under Operating Lease</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes the maturity of lease liabilities under
operating lease as of March 31, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">For the Twelve-month Period Ending March 31:</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true">Operating <br/> Lease</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">2026</span></td><td style="width: 1%; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">78,000</span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">2027</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">54,000</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">2028 and thereafter</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-411"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total lease payments</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">132,000</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Amount of lease payments representing interest</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(12,747</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Total present value of operating lease liabilities</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">119,253</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Current portion</span></td><td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">67,547</span></td><td style="font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Long-term portion</span></td><td style="font-size: 10pt; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">51,706</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="font-size: 10pt; padding-bottom: 2.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">119,253</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the maturity of lease liabilities under
operating lease as of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid">For the Year Ending December 31:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Operating Lease</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,753</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">2026 and thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-379">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,753</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Amount of lease payments representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(44</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total present value of operating lease liabilities (current liability)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,709</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>193
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Feb. 09, 2023</div></th>
<th class="th"><div>Apr. 06, 2022</div></th>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>May 18, 2015</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvalonHealthcareSystemIncMember', window );">Avalon Healthcare System, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvalonHealthcareSystemIncMember', window );">Avalon Healthcare System, Inc. [Member] | Business Combination, Series of Individually Immaterial Business Combinations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvalonRT9PropertiesLLCMember', window );">Avalon RT 9 Properties, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvalonRT9PropertiesLLCMember', window );">Avalon RT 9 Properties, LLC [Member] | Business Combination, Series of Individually Immaterial Business Combinations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.20%<span></span>
</td>
<td class="nump">98.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvactisAndArbeleBiotherapeuticsLimitedMember', window );">Avactis and Arbele Biotherapeutics Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvactisBiosciencesIncMember', window );">Avactis Biosciences Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvactisBiosciencesIncMember', window );">Avactis Biosciences Inc. [Member] | Business Combination, Series of Individually Immaterial Business Combinations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvalonLabMember', window );">Avalon Lab [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvalonLabMember', window );">Avalon Lab [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_LabServicesMSOMember', window );">Lab Services MSO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Organization and Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Ownership percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvalonHealthcareSystemIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvalonHealthcareSystemIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvalonRT9PropertiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvalonRT9PropertiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvactisAndArbeleBiotherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvactisAndArbeleBiotherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvactisBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvactisBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvalonLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvalonLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_LabServicesMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_LabServicesMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>194
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations - Schedule of Consolidated Financial Statements (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 06, 2022</div></th>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>May 18, 2015</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvalonHealthcareSystemIncMember', window );">Avalon Healthcare System, Inc. (&#8220;AHS&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPlaceAndDateOfIncorporation', window );">Place and Date of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Delaware May 18, 2015<span></span>
</td>
<td class="text">Delaware
May 18, 2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Holding company for payroll and other expenses<span></span>
</td>
<td class="text">Holding company for payroll and other expenses<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvalonRT9PropertiesLLCMember', window );">Avalon RT 9 Properties LLC (&#8220;Avalon RT 9&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPlaceAndDateOfIncorporation', window );">Place and Date of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">New Jersey February 7, 2017<span></span>
</td>
<td class="text">New Jersey February 7, 2017<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Owns and operates an income-producing real property and holds and manages the corporate headquarters<span></span>
</td>
<td class="text">Owns and operates an income-producing real property and holds and manages the corporate headquarters<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvalonShanghaiHealthcareTechnologyCoLtdMember', window );">Avalon (Shanghai) Healthcare Technology Co., Ltd. (&#8220;Avalon Shanghai&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPlaceAndDateOfIncorporation', window );">Place and Date of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">PRC April 29, 2016<span></span>
</td>
<td class="text">PRC
April 29, 2016<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Not considered an operating entity<span></span>
</td>
<td class="text">Is not considered an operating entity<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_GenExosomeTechnologiesIncMember', window );">Genexosome Technologies Inc. (&#8220;Genexosome&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPlaceAndDateOfIncorporation', window );">Place and Date of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nevada July 31, 2017<span></span>
</td>
<td class="text">Nevada July 31, 2017<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">No current activities to report; dormant<span></span>
</td>
<td class="text">No current activities to report, dormant<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvactisBiosciencesIncMember', window );">Avactis Biosciences Inc. (&#8220;Avactis&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPlaceAndDateOfIncorporation', window );">Place and Date of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nevada July 18, 2018<span></span>
</td>
<td class="text">Nevada July 18, 2018<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of Ownership</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dormant; in process of being dissolved<span></span>
</td>
<td class="text">Dormant, is in process of being dissolved<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvactisNanjingBiosciencesLtdMember', window );">Avactis Nanjing Biosciences Ltd. (&#8220;Avactis Nanjing&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPlaceAndDateOfIncorporation', window );">Place and Date of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">PRC May 8, 2020<span></span>
</td>
<td class="text">PRC
May 8, 2020<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dormant; in process of being dissolved<span></span>
</td>
<td class="text">Dormant, is in process of being dissolved<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvalonLaboratoryServicesIncMember', window );">Avalon Laboratory Services, Inc. (&#8220;Avalon Lab&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPlaceAndDateOfIncorporation', window );">Place and Date of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Delaware October 14, 2022<span></span>
</td>
<td class="text">Delaware October 14, 2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">No current activities to report; dormant<span></span>
</td>
<td class="text">Laboratory holding company with a 40% membership interest in Lab Services MSO (1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_QADistributionLLCMember', window );">Q&amp;A Distribution LLC (&#8220;Q&amp;A Distribution&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPlaceAndDateOfIncorporation', window );">Place and Date of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Texas May 1, 2024<span></span>
</td>
<td class="text">Texas
May 1, 2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Distributes KetoAir device<span></span>
</td>
<td class="text">Distributes KetoAir device<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">On February 26, 2025, the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement,
whereby Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by the Company.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityMethodInvestmentPlaceAndDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity method investment place and date of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityMethodInvestmentPlaceAndDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business purpose of the subsidiary of the limited liability company or limited partnership, for example, its day-to-day operating functions and whether it acts as a holding or operating company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvalonHealthcareSystemIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvalonHealthcareSystemIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvalonRT9PropertiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvalonRT9PropertiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvalonShanghaiHealthcareTechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvalonShanghaiHealthcareTechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_GenExosomeTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_GenExosomeTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvactisBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvactisBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvactisNanjingBiosciencesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvactisNanjingBiosciencesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvalonLaboratoryServicesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvalonLaboratoryServicesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_QADistributionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_QADistributionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>195
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Going Concern Condition (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_BasisofPresentationandGoingConcernConditionDetailsLineItems', window );"><strong>Basis of Presentation and Going Concern Condition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_WorkingCapitalDeficit', window );">Working capital deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,655,000<span></span>
</td>
<td class="nump">$ 10,646,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,646,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,482,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,367,513)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,903,394)<span></span>
</td>
<td class="num">$ (16,707,010)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Negative cash flow from operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,801,926)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (915,709)<span></span>
</td>
<td class="num">(4,969,205)<span></span>
</td>
<td class="num">(6,504,718)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="num">$ (2,482,111)<span></span>
</td>
<td class="num">(2,482,111)<span></span>
</td>
<td class="num">$ (1,367,513)<span></span>
</td>
<td class="num">$ (1,367,513)<span></span>
</td>
<td class="num">$ (7,903,394)<span></span>
</td>
<td class="num">$ (16,707,010)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_BasisofPresentationandGoingConcernConditionDetailsLineItems', window );"><strong>Basis of Presentation and Going Concern Condition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,482,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_BasisofPresentationandGoingConcernConditionDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_BasisofPresentationandGoingConcernConditionDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>196
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 26, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 09, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 09, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 454,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,636,544<span></span>
</td>
<td class="nump">12,095,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Exceed federally-insured limits</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalReserveBankStock', window );">Federally insured limits</a></td>
<td class="nump">$ 840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,413,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">175,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncome', window );">Deferred rental income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,346<span></span>
</td>
<td class="nump">11,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredAdvertisingCosts', window );">Advertising and marketing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237,671<span></span>
</td>
<td class="nump">$ 1,666,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Common stock, conversion price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Percentage of purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">1-for-15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-15<span></span>
</td>
<td class="text">1:10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Carrying value equity method investment</a></td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Redemption aggregate cash amount</a></td>
<td class="nump">1,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PaymentOfEquityInvestment', window );">Payment of equity investment</a></td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RegularPaymentsOnEquityInvestments', window );">Regular payments on equity investments</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivableInvestmentSale', window );">Receivable from sale of equity method investment</a></td>
<td class="nump">1,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">2,794,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,236,498<span></span>
</td>
<td class="nump">$ 850,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">7,815,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,748,680<span></span>
</td>
<td class="nump">19,731,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Dilutive securities</a></td>
<td class="nump">$ 162,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=avco_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in Shares) | shares</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_EpiconBiotechCoLtdMember', window );">Epicon Biotech Co., Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_DrYuZhouMember', window );">Dr. Yu Zhou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Common stock, conversion price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 109,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Business Combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Asset acquisition percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember', window );">Equity Method Investment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 259,579<span></span>
</td>
<td class="nump">9,651,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=avco_LabServicesMSOMember', window );">Lab Services MSO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityInterestPercent', window );">Equity interest percent</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Carrying value equity method investment</a></td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Redemption aggregate cash amount</a></td>
<td class="nump">11,029,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Carrying value of the extinguished</a></td>
<td class="nump">632,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=avco_LabServicesMSOMember', window );">Lab Services MSO [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Carrying value equity method investment</a></td>
<td class="nump">$ 13,377,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_LaboratoryServicesMSOLLCMember', window );">Laboratory Services MSO, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,579<span></span>
</td>
<td class="nump">$ 9,196,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=avco_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">RMB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.1889<span></span>
</td>
<td class="nump">7.0752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">RMB [Member] | Asset and liability Accounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.298<span></span>
</td>
<td class="nump">7.0786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member] | Asset and liability Accounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegulatoryAssetAxis=avco_DeferredOfferingCostsMember', window );">Deferred Offering Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=avco_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock, convertible conversion price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock, convertible conversion price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 56.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Common stock, conversion price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 56.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Carrying value of the extinguished</a></td>
<td class="nump">$ 2,348,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock, convertible conversion price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Lab Services MSO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock, convertible conversion price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock, convertible conversion price (in Dollars per share) | $ / shares</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock, convertible conversion price (in Dollars per share) | $ / shares</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock, convertible conversion price (in Dollars per share) | $ / shares</a></td>
<td class="nump">67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock, convertible conversion price (in Dollars per share) | $ / shares</a></td>
<td class="nump">2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Convertible Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock, convertible conversion price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityInterestPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityInterestPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PaymentOfEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payment of equity investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PaymentOfEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_RegularPaymentsOnEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regular payments on equity investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_RegularPaymentsOnEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interest acquired in business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-38<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredAdvertisingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs of direct-response advertising whose primary purpose is to elicit sales to customers who could be shown to have responded specifically to the advertising and that results in probable future benefits and are reported as assets net of accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredAdvertisingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalReserveBankStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal Reserve Bank stock represents an equity interest in the Federal Reserve Bank. It does not have a readily determinable fair value because its ownership is restricted and it lacks a market (liquidity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 325<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477974/942-325-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalReserveBankStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479424/830-30-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableInvestmentSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable from sale of investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableInvestmentSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=avco_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=avco_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_EpiconBiotechCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_EpiconBiotechCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_DrYuZhouMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_DrYuZhouMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=avco_LabServicesMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=avco_LabServicesMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_LaboratoryServicesMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_LaboratoryServicesMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=avco_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=avco_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=avco_AssetAndLiabilityAccountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=avco_AssetAndLiabilityAccountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegulatoryAssetAxis=avco_DeferredOfferingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegulatoryAssetAxis=avco_DeferredOfferingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avco_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avco_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>197
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Derivative Liability Measured at Fair Value (Details) - Significant Unobservable Inputs (Level 3) [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Schedule of Derivative Liability Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Balance of derivative liability beginning balance</a></td>
<td class="nump">$ 127,545<span></span>
</td>
<td class="nump">$ 24,796<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise', window );">Initial fair value of derivative liability attributable to warrants issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">479,468<span></span>
</td>
<td class="nump">213,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Reclassification of additional paid-in capital upon conversion</a></td>
<td class="num">(18,853)<span></span>
</td>
<td class="num">(2,354)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain from change in the fair value of derivative liability</a></td>
<td class="nump">114,360<span></span>
</td>
<td class="num">(374,365)<span></span>
</td>
<td class="num">(188,374)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Balance of derivative liability ending balance</a></td>
<td class="nump">$ 223,052<span></span>
</td>
<td class="nump">$ 127,545<span></span>
</td>
<td class="nump">$ 24,796<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fair value of derivative liability attributable to warrants issuance with fund raise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>198
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Cash Balances by Geographic Area (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Schedule of Cash Balances by Geographic Area [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash</a></td>
<td class="nump">$ 1,369,586<span></span>
</td>
<td class="nump">$ 2,856,309<span></span>
</td>
<td class="nump">$ 285,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CashPercentage', window );">Percentage of Total cash</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Schedule of Cash Balances by Geographic Area [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash</a></td>
<td class="nump">$ 1,351,923<span></span>
</td>
<td class="nump">$ 2,844,522<span></span>
</td>
<td class="nump">$ 280,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CashPercentage', window );">Percentage of Total cash</a></td>
<td class="nump">98.70%<span></span>
</td>
<td class="nump">99.60%<span></span>
</td>
<td class="nump">98.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Schedule of Cash Balances by Geographic Area [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash</a></td>
<td class="nump">$ 17,663<span></span>
</td>
<td class="nump">$ 11,787<span></span>
</td>
<td class="nump">$ 5,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CashPercentage', window );">Percentage of Total cash</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_CashPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_CashPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>199
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Securities that were Excluded from the Diluted Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Summarizes the Securities that were Excluded from the Diluted Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">5,384,113<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">451,986<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,169,030<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">414,659<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avco_OptionsToPurchaseCommonStockMember', window );">Options to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Summarizes the Securities that were Excluded from the Diluted Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">1,451,425<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">47,287<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">52,479<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">56,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Summarizes the Securities that were Excluded from the Diluted Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">171,163<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">60,562<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">182,996<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">43,035<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Summarizes the Securities that were Excluded from the Diluted Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">60,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">60,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">60,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Summarizes the Securities that were Excluded from the Diluted Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">194,004<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">194,004<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">194,004<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Summarizes the Securities that were Excluded from the Diluted Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">1,452,282<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">1,452,282<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Summarizes the Securities that were Excluded from the Diluted Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">234,554<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">90,133<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">227,269<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="nump">60,740<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[8]</sup></td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the Series A convertible preferred stock (&#8220;Series A Preferred Stock&#8221;) was converted into shares of common stock of the Company at a conversion price of $150.00 per share.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Assumed the Series A convertible preferred stock was converted
into shares of common stock of the Company at a conversion price of $150.00 per share<span style="background-color: white">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the Series B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color: white">Assumed the Series
B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the Series C convertible preferred stock (&#8220;Series C Preferred Stock&#8221;) was converted into shares of common stock of the Company at a conversion price of $2.41 per share.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color: white">Assumed the Series
C convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $2.41 per share.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the three months ended March 31, 2025. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and $22.50 and $15.00 per share for the three months ended March 31, 2024.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color: white">Assumed the convertible
notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the year ended December
31, 2024. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and
$22.50 per share for the year ended December 31, 2023.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avco_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avco_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>200
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expense and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Schedule of Prepaid Expense and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PrepaidProfessionalFees', window );">Prepaid professional fees</a></td>
<td class="nump">$ 90,431<span></span>
</td>
<td class="nump">$ 33,665<span></span>
</td>
<td class="nump">$ 33,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidReinsurancePremiums', window );">Prepaid directors and officers&#8217; liability insurance premium</a></td>
<td class="nump">12,834<span></span>
</td>
<td class="nump">9,741<span></span>
</td>
<td class="nump">27,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">175,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsLeasingNet', window );">Deferred leasing costs</a></td>
<td class="nump">28,980<span></span>
</td>
<td class="nump">31,587<span></span>
</td>
<td class="nump">33,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">12,256<span></span>
</td>
<td class="nump">17,654<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromCorrespondentBrokers', window );">Due from broker</a></td>
<td class="nump">33,160<span></span>
</td>
<td class="nump">32,885<span></span>
</td>
<td class="nump">37,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">90,116<span></span>
</td>
<td class="nump">92,230<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivable', window );">Recoverable VAT</a></td>
<td class="nump">10,094<span></span>
</td>
<td class="nump">9,245<span></span>
</td>
<td class="nump">6,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Others</a></td>
<td class="nump">50,197<span></span>
</td>
<td class="nump">72,353<span></span>
</td>
<td class="nump">55,797<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 367,818<span></span>
</td>
<td class="nump">$ 299,360<span></span>
</td>
<td class="nump">$ 367,994<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PrepaidProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of prepaid professional fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PrepaidProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsLeasingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents costs incurred by the lessor that are (a) costs to originate a lease incurred in transactions with independent third parties that (i) result directly from and are essential to acquire that lease and (ii) would not have been incurred had that leasing transaction not occurred and (b) certain costs directly related to specified activities performed by the lessor for that lease. Those activities are: evaluating the prospective lessee's financial condition; evaluating and recording guarantees, collateral, and other security arrangements; negotiating lease terms; preparing and processing lease documents; and closing the transaction. This element is net of accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481178/840-20-25-16<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481123/840-20-35-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479341/842-30-25-10<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481178/840-20-25-17<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsLeasingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromCorrespondentBrokers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount receivable from correspondent broker-dealer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481833/940-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromCorrespondentBrokers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidReinsurancePremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The unexpired portion of premiums ceded on policies in force as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477351/944-825-50-1B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479510/944-340-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidReinsurancePremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>201
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 9,234<span></span>
</td>
<td class="nump">$ 43,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">8,623<span></span>
</td>
<td class="nump">7,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_OtherOperatingExpense', window );">Other operating expense</a></td>
<td class="nump">611<span></span>
</td>
<td class="nump">417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 35,399<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_OtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other operating expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_OtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>202
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,499<span></span>
</td>
<td class="nump">$ 155,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,587)<span></span>
</td>
<td class="num">(117,262)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">$ 10,660<span></span>
</td>
<td class="nump">$ 12,912<span></span>
</td>
<td class="nump">38,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=avco_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100,548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment and Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,499<span></span>
</td>
<td class="nump">$ 54,797<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment and Furniture [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment and Furniture [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=avco_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=avco_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>203
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment Held For Sale (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract', window );"><strong>Equipment Held For Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ImpairmentOfLaboratoryEquipment', window );">Impairment charge</a></td>
<td class="nump">$ 111,033<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ImpairmentOfLaboratoryEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment of laboratory equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ImpairmentOfLaboratoryEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>204
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Real Estate (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstateInvestmentsAbstract', window );"><strong>Investment in Real Estate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 168,683<span></span>
</td>
<td class="nump">$ 168,683<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstateInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstateInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>205
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investment in Real Estate - Schedule of Investment in Real Estate (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstateLineItems', window );"><strong>Schedule of Investment in Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstateInvestmentPropertyAtCost', window );">Investment in real estate, Gross</a></td>
<td class="nump">$ 8,237,943<span></span>
</td>
<td class="nump">$ 8,237,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,215,222)<span></span>
</td>
<td class="num">(1,046,539)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstateInvestmentPropertyNet', window );">Investment in real estate, net</a></td>
<td class="nump">$ 7,022,721<span></span>
</td>
<td class="nump">7,191,404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAxis=us-gaap_CommercialRealEstateMember', window );">Commercial real property building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstateLineItems', window );"><strong>Schedule of Investment in Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstateInvestmentPropertyAtCost', window );">Investment in real estate, Gross</a></td>
<td class="nump">$ 7,708,571<span></span>
</td>
<td class="nump">7,708,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAxis=us-gaap_LandImprovementsMember', window );">Improvement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstateLineItems', window );"><strong>Schedule of Investment in Real Estate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstateInvestmentPropertyAtCost', window );">Investment in real estate, Gross</a></td>
<td class="nump">$ 529,372<span></span>
</td>
<td class="nump">$ 529,372<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation from long-lived, depreciable flight asset owned. Excludes right-of-use asset from finance lease for flight asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstateInvestmentPropertyAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstateInvestmentPropertyAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstateInvestmentPropertyNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstateInvestmentPropertyNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 976<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477332/976-310-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=us-gaap_CommercialRealEstateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=us-gaap_CommercialRealEstateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=us-gaap_LandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=us-gaap_LandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>206
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 09, 2024</div></th>
<th class="th"><div>Feb. 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investment, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,095,020<span></span>
</td>
<td class="nump">$ 10,636,544<span></span>
</td>
<td class="nump">$ 12,095,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">454,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Purchased interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPayableCurrent', window );">Equity method investment payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,667<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Cost of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,460,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,733<span></span>
</td>
<td class="nump">611,356<span></span>
</td>
<td class="nump">$ 666,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Recognized impairment loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,788<span></span>
</td>
<td class="nump">9,196,682<span></span>
</td>
<td class="nump">259,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_LabServicesMSOsNetIncomeAttributableToTheCompany', window );">Lab services MSO&#8217;s net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 503,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Identified intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,392,644<span></span>
</td>
<td class="nump">8,725,712<span></span>
</td>
<td class="nump">9,392,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillFairValueDisclosure', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,579<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">259,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_EpiconBiotechCoLtdMember', window );">Epicon Biotech Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investment, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_InvestmentInEpiconBiotechCoLtdMember', window );">Investment in Epicon Biotech Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (454,679)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_LaboratoryServicesMSOMember', window );">Lab Services MSO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Distribution of earnings from investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 611,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avco_LaboratoryServicesMSOMember', window );">Lab Services MSO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_LabServicesMSOsNetIncomeAttributableToTheCompany', window );">Lab services MSO&#8217;s net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,236,391<span></span>
</td>
<td class="nump">79,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=avco_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=avco_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Issuance shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_AggregateOfCommonStock', window );">Aggregate of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=avco_SeriesBStatedValueMember', window );">Series B Stated Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPayableCurrent', window );">Equity method investment payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Lab Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Lab Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=avco_SeriesBStatedValueMember', window );">Series B Stated Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvalonShangaiMember', window );">Avalon Shangai [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Total ownership percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_JiangsuUnicornBiologicalTechnologyCoLtdMember', window );">Jiangsu Unicorn Biological Technology Co., Ltd.[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Total ownership percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_AggregateOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The shares of aggregate of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_AggregateOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityMethodInvestmentPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity method investment payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityMethodInvestmentPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_LabServicesMSOsNetIncomeAttributableToTheCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lab Services MSO&#8217;s net income attributable to the Company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_LabServicesMSOsNetIncomeAttributableToTheCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_EpiconBiotechCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_EpiconBiotechCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_InvestmentInEpiconBiotechCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_InvestmentInEpiconBiotechCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_LaboratoryServicesMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_LaboratoryServicesMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=avco_LaboratoryServicesMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=avco_LaboratoryServicesMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=avco_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=avco_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=avco_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=avco_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=avco_SeriesBStatedValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=avco_SeriesBStatedValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_LabServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_LabServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avco_SeriesBStatedValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avco_SeriesBStatedValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvalonShangaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvalonShangaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_JiangsuUnicornBiologicalTechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_JiangsuUnicornBiologicalTechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>207
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments - Schedule of Equity Method Investment (Details) - Lab Services MSO [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investment carrying amount beginning balance</a></td>
<td class="nump">$ 10,636,544<span></span>
</td>
<td class="nump">$ 12,095,020<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets', window );">The Company&#8217;s interest in the fair value of Lab Services MSO&#8217;s net assets at February 9, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,206,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets', window );">The Company&#8217;s interest in the net excess of Lab Services MSO&#8217;s fair value over net assets which was attributable to identifiable intangible assets at February 9, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,004,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets', window );">The Company&#8217;s interest in the net excess of Lab Services MSO&#8217;s fair value over net assets which was attributable to goodwill at February 9, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,456,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Total payment for equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,666,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_LabServicesMSOsNetIncomeAttributableToTheCompany', window );">Lab Services MSO&#8217;s net income attributable to the Company</a></td>
<td class="nump">503,833<span></span>
</td>
<td class="nump">79,923<span></span>
</td>
<td class="nump">1,236,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible assets amortization amount</a></td>
<td class="num">(111,156)<span></span>
</td>
<td class="num">(666,932)<span></span>
</td>
<td class="num">(611,356)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Distribution of earnings from equity investment</a></td>
<td class="num">(11,029,221)<span></span>
</td>
<td class="num">(611,888)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(259,579)<span></span>
</td>
<td class="num">(9,196,682)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investment carrying amount ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10,636,544<span></span>
</td>
<td class="nump">$ 12,095,020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in good wi.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Company&#8217;s interest in the net excess of Lab Services MSO&#8217;s fair value over carrying value w...</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_LabServicesMSOsNetIncomeAttributableToTheCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lab Services MSO&#8217;s net income attributable to the Company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_LabServicesMSOsNetIncomeAttributableToTheCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_LabServicesMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_LabServicesMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>208
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity Method Investments - Schedule of Summarized Financial Information, as Provided to the Company by the Investee (Details) - Investment in Laboratory Services MSO, LLC [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Schedule of Summarized Financial Information, as Provided to the Company by the Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">$ 2,917,880<span></span>
</td>
<td class="nump">$ 4,930,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Noncurrent assets</a></td>
<td class="nump">4,509,185<span></span>
</td>
<td class="nump">5,228,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">611,391<span></span>
</td>
<td class="nump">828,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="nump">4,346,725<span></span>
</td>
<td class="nump">4,104,183<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Equity</a></td>
<td class="nump">$ 2,468,949<span></span>
</td>
<td class="nump">$ 5,225,402<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedBalanceSheetStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=avco_InvestmentInLaboratoryServicesMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=avco_InvestmentInLaboratoryServicesMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>209
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments - Schedule of Financial Information (Details) - Investment in Laboratory Services MSO, LLC [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Schedule of Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue</a></td>
<td class="nump">$ 4,241,732<span></span>
</td>
<td class="nump">$ 3,376,372<span></span>
</td>
<td class="nump">$ 12,699,683<span></span>
</td>
<td class="nump">$ 13,558,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">2,155,760<span></span>
</td>
<td class="nump">1,003,789<span></span>
</td>
<td class="nump">4,744,277<span></span>
</td>
<td class="nump">3,534,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">(Loss) income from operation</a></td>
<td class="nump">1,513,000<span></span>
</td>
<td class="nump">275,026<span></span>
</td>
<td class="nump">2,393,830<span></span>
</td>
<td class="num">(265,754)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,259,582<span></span>
</td>
<td class="nump">$ 685,504<span></span>
</td>
<td class="nump">$ 3,090,977<span></span>
</td>
<td class="nump">$ 199,808<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedIncomeStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedIncomeStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=avco_InvestmentInLaboratoryServicesMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=avco_InvestmentInLaboratoryServicesMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>210
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities and Other Payables - Schedule of Accrued Liabilities and Other Payables (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Schedule of Accrued Liabilities and Other Payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_AccruedTenantsImprovementReimbursement', window );">Accrued tenants&#8217; improvement reimbursement</a></td>
<td class="nump">$ 43,500<span></span>
</td>
<td class="nump">$ 43,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Deposits', window );">Tenants&#8217; security deposit</a></td>
<td class="nump">81,233<span></span>
</td>
<td class="nump">81,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_AccruedBusinessExpenseReimbursement', window );">Accrued business expense reimbursement</a></td>
<td class="nump">34,781<span></span>
</td>
<td class="nump">25,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedUtilitiesCurrent', window );">Accrued utilities</a></td>
<td class="nump">26,075<span></span>
</td>
<td class="nump">15,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncome', window );">Deferred rental income</a></td>
<td class="nump">38,346<span></span>
</td>
<td class="nump">11,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_AccruedRealPropertyCleaningServiceFee', window );">Accrued real property cleaning service fee</a></td>
<td class="nump">9,200<span></span>
</td>
<td class="nump">7,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">177,724<span></span>
</td>
<td class="nump">11,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Others</a></td>
<td class="nump">23,258<span></span>
</td>
<td class="nump">22,135<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 434,117<span></span>
</td>
<td class="nump">$ 272,915<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_AccruedBusinessExpenseReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued business expense reimbursement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_AccruedBusinessExpenseReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_AccruedRealPropertyCleaningServiceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued real property cleaning service fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_AccruedRealPropertyCleaningServiceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_AccruedTenantsImprovementReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued tenants&#8217; improvement reimbursement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_AccruedTenantsImprovementReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedUtilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for utilities, such as electrical power, heating oil, natural gas, and water. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedUtilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>211
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Note Payable (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 15, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 05, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 07, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 09, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 06, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 23, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 28, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 18, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original issue discount</a></td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,360<span></span>
</td>
<td class="nump">114,360<span></span>
</td>
<td class="num">$ (31,212)<span></span>
</td>
<td class="num">$ (31,212)<span></span>
</td>
<td class="num">$ (374,365)<span></span>
</td>
<td class="num">(188,374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Conversion price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonUnitOutstanding', window );">Common stock shares outstanding (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,389<span></span>
</td>
<td class="nump">$ 1,291,814<span></span>
</td>
<td class="nump">437,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest expense related to convertible note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,715<span></span>
</td>
<td class="nump">325,486<span></span>
</td>
<td class="nump">$ 167,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares) | shares</a></td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,834<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.5<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares) | shares</a></td>
<td class="nump">9,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,450<span></span>
</td>
<td class="nump">$ 7,560<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,880<span></span>
</td>
<td class="nump">$ 14,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 37.5<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=avco_FirstWarrantMember', window );">First Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=avco_SecondWarrantMember', window );">Second Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=avco_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares) | shares</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_May2023ConvertibleNoteMember', window );">May 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Common stock per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_DebtInstrumentConvertibleFloorPrice', window );">Floor price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Purchase price payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_May2023ConvertibleNoteMember', window );">May 2023 Convertible Note [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_July2023ConvertibleNoteMember', window );">July 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfPromissoryNotes', window );">Percentage promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Conversion price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_July2023ConvertibleNoteMember', window );">July 2023 Convertible Note [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_July2023ConvertibleNoteMember', window );">July 2023 Convertible Note [Member] | First Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Purchase warrant (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_July2023ConvertibleNoteMember', window );">July 2023 Convertible Note [Member] | Second Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Purchase warrant (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_October2023ConvertibleNoteMember', window );">October 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Common stock per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfPromissoryNotes', window );">Percentage promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_October2023ConvertibleNoteMember', window );">October 2023 Convertible Note [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_October2023ConvertibleNoteMember', window );">October 2023 Convertible Note [Member] | First Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_October2023ConvertibleNoteMember', window );">October 2023 Convertible Note [Member] | Second Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_March2024ConvertibleNoteMember', window );">March 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Common stock per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfPromissoryNotes', window );">Percentage promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Purchase warrant (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_TradingPrice', window );">Trading price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PurchasePriceOfConvertibleNote', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_March2024ConvertibleNoteMember', window );">March 2024 Convertible Note [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_March2024ConvertibleNoteMember', window );">March 2024 Convertible Note [Member] | First Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Purchase warrant (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_March2024ConvertibleNoteMember', window );">March 2024 Convertible Note [Member] | Second Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_June2024ConvertibleNoteMember', window );">June 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,845,000<span></span>
</td>
<td class="nump">$ 2,845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Common stock per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Purchase price payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,702,750<span></span>
</td>
<td class="nump">$ 2,702,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 224,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224,221<span></span>
</td>
<td class="nump">224,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="nump">838,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,250<span></span>
</td>
<td class="nump">$ 142,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838,990<span></span>
</td>
<td class="nump">838,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfPromissoryNotes', window );">Percentage promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPriceIncrease', window );">Conversion price increase (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease', window );">Conversion price decrease (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NontradeReceivables', window );">Proceeds from convertible debt</a></td>
<td class="nump">$ 881,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881,210<span></span>
</td>
<td class="nump">$ 881,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PaymentForCommission', window );">Finder&#8217;s fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Lender's costs related to financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_June2024ConvertibleNoteMember', window );">June 2024 Convertible Note [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares) | shares</a></td>
<td class="nump">5,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,333<span></span>
</td>
<td class="nump">5,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_June2024ConvertibleNoteMember', window );">June 2024 Convertible Note [Member] | First Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Purchase warrant (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_June2024ConvertibleNoteMember', window );">June 2024 Convertible Note [Member] | Second Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Purchase warrant (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_WaiverFeeMember', window );">Waiver Fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 838,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingActivityByTypeAxis=us-gaap_OtherTradingMember', window );">Other Trading [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Common stock per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_TradingPrice', window );">Trading price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Secured Promissory Notes [Member] | May 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Percentage of secured promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Secured Promissory Notes [Member] | June 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | May 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | July 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | October 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | June 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | May 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | July 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | October 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | June 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | May 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | July 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | October 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | June 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | May 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | May 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | July 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | October 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | June 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate [Member] | July 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate [Member] | October 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate [Member] | June 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">33,800<span></span>
</td>
<td class="nump">11,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | First Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Second Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillFundLPMember', window );">Mast Hill Fund, L.P. [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillFundLPMember', window );">Mast Hill Fund, L.P. [Member] | First Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillFundLPMember', window );">Mast Hill Fund, L.P. [Member] | Second Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_FirstFireMember', window );">FirstFire [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Purchase price payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_FirstFireMember', window );">FirstFire [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Purchase price payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 332,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares) | shares</a></td>
<td class="nump">560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_FirstFireMember', window );">FirstFire [Member] | July 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_FirstFireMember', window );">FirstFire [Member] | October 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_FirstFireMember', window );">FirstFire [Member] | October 2023 Convertible Note [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_FirstFireMember', window );">FirstFire [Member] | June 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Payments for previously issued notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillMember', window );">Mast Hill [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillMember', window );">Mast Hill [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillMember', window );">Mast Hill [Member] | Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillMember', window );">Mast Hill [Member] | October 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillMember', window );">Mast Hill [Member] | October 2023 Convertible Note [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Purchase price payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 332,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillMember', window );">Mast Hill [Member] | March 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillMember', window );">Mast Hill [Member] | June 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Payments for previously issued notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,661,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,206,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillMember', window );">Mast Hill [Member] | Waiver Fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillMember', window );">Mast Hill [Member] | Measurement Input, Share Price [Member] | March 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillMember', window );">Mast Hill [Member] | Measurement Input, Price Volatility [Member] | March 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillMember', window );">Mast Hill [Member] | Measurement Input, Risk Free Interest Rate [Member] | March 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillMember', window );">Mast Hill [Member] | Measurement Input, Expected Term [Member] | March 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillMember', window );">Mast Hill [Member] | Measurement Input, Discount Rate [Member] | March 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | July 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_DebtInstrumentConvertibleFloorPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible floor price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_DebtInstrumentConvertibleFloorPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PaymentForCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of payment for commission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PaymentForCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PercentageOfPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PercentageOfPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PurchasePriceOfConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of convertible note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PurchasePriceOfConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_TradingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_TradingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common units of ownership outstanding of a limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of annual principal payment for debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of debt instrument. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in conversion price of debt instrument. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NontradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amounts due as of the balance sheet date of the sum of amounts receivable other than from customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NontradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=avco_FirstWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=avco_FirstWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=avco_SecondWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=avco_SecondWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=avco_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=avco_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avco_May2023ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avco_May2023ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avco_July2023ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avco_July2023ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avco_October2023ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avco_October2023ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avco_March2024ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avco_March2024ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avco_June2024ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avco_June2024ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avco_WaiverFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avco_WaiverFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingActivityByTypeAxis=us-gaap_OtherTradingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingActivityByTypeAxis=us-gaap_OtherTradingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillFundLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillFundLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_FirstFireMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_FirstFireMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>212
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Note Payable - Schedule of Amortization Payments in Cash (Details) - Mast Hill [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=avco_DecemberFiveTwoThousandTwentyFourMember', window );">December 5, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Amortization Payments in Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Amortization payments description</a></td>
<td class="text">$284,500 plus accrued interest through December 5, 2024<span></span>
</td>
<td class="text">$284,500 plus accrued interest through December 5, 2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=avco_JanuaryFiveTwoThousandTwentyFiveMember', window );">January 5, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Amortization Payments in Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Amortization payments description</a></td>
<td class="text">$284,500 plus accrued interest through January 5, 2025<span></span>
</td>
<td class="text">$284,500 plus accrued interest through January 5, 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=avco_FebruaryFiveTwoThousandTwentyFiveMember', window );">February 5, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Amortization Payments in Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Amortization payments description</a></td>
<td class="text">$379,336 plus accrued interest through February 5, 2025<span></span>
</td>
<td class="text">$379,336 plus accrued interest through February 5, 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=avco_MarchFiveTwoThousandTwentyFiveMember', window );">March 5, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Amortization Payments in Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Amortization payments description</a></td>
<td class="text">$474,167 plus accrued interest through March 5, 2025<span></span>
</td>
<td class="text">$474,167 plus accrued interest through March 5, 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=avco_AprilFiveTwoThousandTwentyFiveMember', window );">April 5, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Amortization Payments in Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Amortization payments description</a></td>
<td class="text">$474,167 plus accrued interest through April 5, 2025<span></span>
</td>
<td class="text">$474,167 plus accrued interest through April 5, 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=avco_MayFiveTwoThousandTwentyFiveMember', window );">May 5, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Amortization Payments in Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Amortization payments description</a></td>
<td class="text">$569,000 plus accrued interest through May 5, 2025<span></span>
</td>
<td class="text">$569,000 plus accrued interest through May 5, 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=avco_JuneFiveTwoThousandTwentyFiveMember', window );">June 5, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Amortization Payments in Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Amortization payments description</a></td>
<td class="text">The entire remaining outstanding balance of the June 2024 Convertible Note<span></span>
</td>
<td class="text">The entire remaining outstanding balance of the June 2024 Convertible Note<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=avco_DecemberFiveTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=avco_DecemberFiveTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=avco_MastHillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=avco_MastHillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=avco_JanuaryFiveTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=avco_JanuaryFiveTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=avco_FebruaryFiveTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=avco_FebruaryFiveTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=avco_MarchFiveTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=avco_MarchFiveTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=avco_AprilFiveTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=avco_AprilFiveTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=avco_MayFiveTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=avco_MayFiveTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=avco_JuneFiveTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=avco_JuneFiveTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>213
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Note Payable - Schedule of Convertible Note Payable (Details) - Convertible Notes Payable [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems', window );"><strong>Schedule of Convertible Note Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 2,556,777<span></span>
</td>
<td class="nump">$ 2,556,777<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Less: unamortized debt issuance costs</a></td>
<td class="num">(33,584)<span></span>
</td>
<td class="num">(93,425)<span></span>
</td>
<td class="num">(183,840)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Less: unamortized debt discount</a></td>
<td class="num">(125,665)<span></span>
</td>
<td class="num">(349,579)<span></span>
</td>
<td class="num">(291,014)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible note payable, net</a></td>
<td class="nump">$ 2,397,528<span></span>
</td>
<td class="nump">$ 2,113,773<span></span>
</td>
<td class="nump">$ 1,925,146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>214
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 07, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 09, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 06, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 23, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 26, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 18, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 05, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,360<span></span>
</td>
<td class="nump">$ 114,360<span></span>
</td>
<td class="num">$ (31,212)<span></span>
</td>
<td class="num">$ (31,212)<span></span>
</td>
<td class="num">$ (374,365)<span></span>
</td>
<td class="num">$ (188,374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_WarrantsOfCashlessExercised', window );">Warrants of cashless exercised (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability (in Dollars) | $</a></td>
<td class="nump">$ 223,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223,052<span></span>
</td>
<td class="nump">$ 127,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,545<span></span>
</td>
<td class="nump">$ 24,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_October92023FiveYearAnniversaryMember', window );">October 9, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_June2024ConvertibleNoteMember', window );">June 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares)</a></td>
<td class="nump">9,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.5<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,834<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant (in Dollars) | $</a></td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 9,450<span></span>
</td>
<td class="nump">$ 7,560<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,880<span></span>
</td>
<td class="nump">$ 14,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Fair value warrant amount (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (in Dollars) | $</a></td>
<td class="nump">$ 114,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | May 23, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares)</a></td>
<td class="nump">667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member] | June 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares)</a></td>
<td class="nump">5,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,333<span></span>
</td>
<td class="nump">5,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | May 23, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | October 9, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | June 5, 2024 - five-year anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">3.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | July 6, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">3.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | March 7, 2024 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member] | June 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | May 23, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">108.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | October 9, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">103.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | June 5, 2024 - five-year anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">97.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.66<span></span>
</td>
<td class="nump">88.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.64<span></span>
</td>
<td class="nump">83.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | July 6, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">106.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106.65<span></span>
</td>
<td class="nump">95.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | March 7, 2024 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | June 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | May 23, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | October 9, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | June 5, 2024 - five-year anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">3.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.96<span></span>
</td>
<td class="nump">4.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.38<span></span>
</td>
<td class="nump">3.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | July 6, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.89<span></span>
</td>
<td class="nump">4.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | March 7, 2024 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | June 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | May 23, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | October 9, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | June 5, 2024 - five-year anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | July 6, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | March 7, 2024 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | May 23, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | October 9, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | June 5, 2024 - five-year anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | July 6, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | March 7, 2024 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | June 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_FirstFireMember', window );">FirstFire [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_FirstFireMember', window );">FirstFire [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares)</a></td>
<td class="nump">560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_WarrantsOfCashlessExercised', window );">Warrants of cashless exercised (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillAndFirstfireMember', window );">Mast Hill and Firstfire [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillAndFirstfireMember', window );">Mast Hill and Firstfire [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillAndFirstfireMember', window );">Mast Hill and Firstfire [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="nump">3.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillAndFirstfireMember', window );">Mast Hill and Firstfire [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.75<span></span>
</td>
<td class="nump">93.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillAndFirstfireMember', window );">Mast Hill and Firstfire [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillAndFirstfireMember', window );">Mast Hill and Firstfire [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillAndFirstfireMember', window );">Mast Hill and Firstfire [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillThirdPartyMember', window );">Mast Hill Third Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillMember', window );">Mast Hill [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_findersFeeMember', window );">finder&#8217;s fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_May232023FiveYearAnniversaryMember', window );">May 23, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Fair value warrant amount (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_July62023FiveYearAnniversaryMember', window );">July 6, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Fair value warrant amount (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_July62023FiveYearAnniversaryMember', window );">July 6, 2023 - Five-Year Anniversary [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_October92023FiveYearAnniversaryMember', window );">October 9, 2023 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Fair value warrant amount (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_October92023FiveYearAnniversaryMember', window );">October 9, 2023 - Five-Year Anniversary [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_March72024FiveYearAnniversaryMember', window );">March 7, 2024 - Five-Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Fair value warrant amount (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_June52024FiveyearAnniversaryMember', window );">June 5, 2024 - five-year anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=avco_MastHillMember', window );">Mast Hill [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Fair value warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=avco_MastHillMember', window );">Mast Hill [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrant (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=avco_MastHillMember', window );">Mast Hill [Member] | Warrant [Member] | June 2024 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=avco_MastHillMember', window );">Mast Hill [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=avco_MastHillMember', window );">Mast Hill [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">99.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=avco_MastHillMember', window );">Mast Hill [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=avco_MastHillMember', window );">Mast Hill [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=avco_MastHillMember', window );">Mast Hill [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivative Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_WarrantsOfCashlessExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares in warrants in cash less exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_WarrantsOfCashlessExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-21<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 182<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-182<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avco_October92023FiveYearAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avco_October92023FiveYearAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avco_June2024ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avco_June2024ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avco_May232023FiveYearAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avco_May232023FiveYearAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avco_June52024FiveyearAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avco_June52024FiveyearAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avco_July62023FiveYearAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avco_July62023FiveYearAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avco_March72024FiveYearAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avco_March72024FiveYearAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_FirstFireMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_FirstFireMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillAndFirstfireMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillAndFirstfireMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillThirdPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillThirdPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_MastHillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_findersFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_findersFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avco_May232023FiveYearAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avco_May232023FiveYearAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avco_July62023FiveYearAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avco_July62023FiveYearAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avco_October92023FiveYearAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avco_October92023FiveYearAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avco_March72024FiveYearAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avco_March72024FiveYearAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avco_June52024FiveyearAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avco_June52024FiveyearAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=avco_MastHillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=avco_MastHillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>215
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Payable, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Borrowed amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,807<span></span>
</td>
<td class="nump">$ 29,807<span></span>
</td>
<td class="nump">119,228<span></span>
</td>
<td class="nump">106,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseShortTermBorrowings', window );">Interest expense related to note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,500<span></span>
</td>
<td class="nump">$ 164,500<span></span>
</td>
<td class="nump">658,000<span></span>
</td>
<td class="nump">$ 606,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_PromissoryNoteMember', window );">Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Interest payment</a></td>
<td class="nump">$ 44,000<span></span>
</td>
<td class="nump">$ 10,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Annual rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of annual principal payment for debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate interest expense incurred on short-term borrowings including commercial paper and Federal funds purchased and securities sold under agreements to repurchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph b<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avco_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avco_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>216
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note Payable, Net - Schedule of Note Payable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Note Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized debt issuance costs</a></td>
<td class="num">(54,746)<span></span>
</td>
<td class="num">(84,553)<span></span>
</td>
<td class="num">(203,781)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNotesPayableCurrent', window );">Note payable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,715,447<span></span>
</td>
<td class="nump">5,596,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion</a></td>
<td class="nump">$ 5,745,254<span></span>
</td>
<td class="nump">5,715,447<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Noncurrent portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,596,219<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>217
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 09, 2025</div></th>
<th class="th"><div>Nov. 17, 2023</div></th>
<th class="th"><div>Aug. 29, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralExpense', window );">Consulting expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,731<span></span>
</td>
<td class="nump">$ 63,644<span></span>
</td>
<td class="nump">$ 86,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_AccruedAndUnpaidServicesCharge', window );">Accrued and unpaid services charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,615<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,369,586<span></span>
</td>
<td class="nump">2,856,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,856,309<span></span>
</td>
<td class="nump">285,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPayableCurrent', window );">Equity method investment payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">983,486<span></span>
</td>
<td class="nump">773,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PurchasePrice', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Redemption aggregate cash amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLoansHeldForInvestment', window );">Payment of equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RegularPaymentsOnEquityInvestments', window );">Regular payments on equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Carrying value equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivableInvestmentSale', window );">Receivable from sale of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ExchangeShare', window );">Exchange share (in Shares)</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avco_LineOfCreditAgreementMember', window );">Line of Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Promissory note maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Bears interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=avco_LabServicesMSOMember', window );">Lab Services MSO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPayableCurrent', window );">Equity method investment payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accrued liabilities and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,916<span></span>
</td>
<td class="nump">72,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_AbandonmentAgreementMember', window );">Abandonment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=avco_LabServiceMSOMember', window );">Lab Service MSO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPayableCurrent', window );">Equity method investment payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 566,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Carrying value of the extinguished</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Carrying value equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,377,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivableInvestmentSale', window );">Receivable from sale of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,029,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=avco_MrLuMember', window );">Mr. Lu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Acquire percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PurchasePrice', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty', window );">Advance from pending sale of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,328,078<span></span>
</td>
<td class="nump">3,108,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,108,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=avco_MrLuMember', window );">Mr. Lu [Member] | Membership Interest Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Acquire percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=avco_AvalonRT9Member', window );">Avalon RT 9 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage', window );">Additional acquire percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RentalIncomeNonoperating', window );">Rental revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="nump">50,400<span></span>
</td>
<td class="nump">50,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Rent receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">124,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,445<span></span>
</td>
<td class="nump">33,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty', window );">Advance from pending sale of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,328,078<span></span>
</td>
<td class="nump">3,108,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,108,106<span></span>
</td>
<td class="nump">485,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest', window );">Accrued and unpaid interest for line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Lab Service MSO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_DrYuZhouMember', window );">Dr. Yu Zhou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Unpaid acquisition consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_WenzhaoLuMember', window );">Wenzhao Lu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accrued liabilities and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty', window );">Advance from pending sale of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,108,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,108,106<span></span>
</td>
<td class="nump">485,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_AvalonRT9Member', window );">Avalon RT 9 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PurchasePrice', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_AvalonRT9Member', window );">Avalon RT 9 [Member] | Mr. Lu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Acquire percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PurchasePrice', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Carrying value of the extinguished</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,348,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Lab Service MSO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,837,527<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued (in Dollars per share)</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_BeijingGenexosomeMember', window );">Beijing GenExosome [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Acquired cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_AccruedAndUnpaidServicesCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued and unpaid services charge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_AccruedAndUnpaidServicesCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance from pending sale of noncontrolling interest - related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity in the acquiree held by additional acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityMethodInvestmentPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity method investment payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityMethodInvestmentPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ExchangeShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ExchangeShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of purchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_RegularPaymentsOnEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regular payments on equity investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_RegularPaymentsOnEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(10)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-38<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-9<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the credit facility for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general expenses not normally included in Other Operating Costs and Expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLoansHeldForInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with purchasing loans held for investment purposes during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLoansHeldForInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableInvestmentSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable from sale of investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableInvestmentSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RentalIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income earned by providing the use of assets to an outside party in exchange for a payment or series of payments that is nonoperating in nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RentalIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avco_LineOfCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avco_LineOfCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=avco_LabServicesMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=avco_LabServicesMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_AbandonmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_AbandonmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=avco_LabServiceMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=avco_LabServiceMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=avco_MrLuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=avco_MrLuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avco_MembershipInterestPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avco_MembershipInterestPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=avco_AvalonRT9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=avco_AvalonRT9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_DrYuZhouMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_DrYuZhouMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_WenzhaoLuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_WenzhaoLuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_AvalonRT9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_AvalonRT9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_BeijingGenexosomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_BeijingGenexosomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>218
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Schedule of Line of Credit (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>Schedule of Line of Credit [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Outstanding principal under the Line of Credit, Balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_DrawDownFromLineOfCredit', window );">Draw down from Line of Credit</a></td>
<td class="nump">850,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Outstanding principal under the Line of Credit, Balance</a></td>
<td class="nump">850,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of Line of Credit</a></td>
<td class="num">(400,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty', window );">Reclassification of Line of Credit to advance from related party</a></td>
<td class="num">$ (450,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_DrawDownFromLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Draw Down From Line Of Credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_DrawDownFromLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of Line of Credit to advance from related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the amount outstanding under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>219
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Effective tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Foreign subsidiary</a></td>
<td class="nump">$ 3,399,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal and state net operating loss carryforwards</a></td>
<td class="nump">60,926,204<span></span>
</td>
<td class="nump">$ 52,929,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">U.S. federal net operating loss carryovers</a></td>
<td class="nump">58,438,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Federal net operating loss</a></td>
<td class="nump">2,487,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">federal net operating loss</a></td>
<td class="nump">$ 61,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries', window );">Foreign entity tax disclosure</a></td>
<td class="text">$10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Foreign subsidiary</a></td>
<td class="nump">$ 2,086,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of events that would cause the temporary difference for which a deferred tax liability has not been recognized, because of the exceptions to comprehensive recognition of deferred taxes related to undistributed earnings of foreign subsidiaries, to become taxable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>220
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Company&#8217;s Loss Before Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract', window );"><strong>Schedule of Company&#8217;s Loss Before Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States loss before income taxes</a></td>
<td class="nump">$ 7,639,148<span></span>
</td>
<td class="nump">$ 15,928,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">China loss before income taxes</a></td>
<td class="nump">264,246<span></span>
</td>
<td class="nump">778,230<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="nump">$ 7,903,394<span></span>
</td>
<td class="nump">$ 16,707,010<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>221
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Income Taxes Expense (Benefit) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">U.S. federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">U.S. state and local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income taxes expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S. federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,874)<span></span>
</td>
<td class="num">(3,256,007)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">U.S. state and local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,650)<span></span>
</td>
<td class="num">(1,102,392)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,437<span></span>
</td>
<td class="num">(183,443)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income taxes (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,913<span></span>
</td>
<td class="num">(4,541,842)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86,913)<span></span>
</td>
<td class="nump">4,541,842<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income taxes expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>222
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of U.S. Statutory Rate and the Company&#8217;s Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Schedule of U.S. Statutory Rate and the Company&#8217;s Effective Tax Rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">U.S. state rate</a></td>
<td class="nump">6.40%<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness', window );">Permanent difference</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Non-US rate differential</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">True ups</a></td>
<td class="num">(27.30%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">U.S. valuation allowance</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="num">(27.20%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total provision for income taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>223
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">$ 1,598,257<span></span>
</td>
<td class="nump">$ 3,501,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Disallowed business interest deduction</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development expense</a></td>
<td class="nump">106,783<span></span>
</td>
<td class="nump">130,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Accrued directors&#8217; compensation</a></td>
<td class="nump">104,977<span></span>
</td>
<td class="nump">165,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued settlement</a></td>
<td class="nump">140,904<span></span>
</td>
<td class="nump">126,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_DeferredTaxAssetsPartnershipInvestment', window );">Partnership Investment</a></td>
<td class="nump">2,167,965<span></span>
</td>
<td class="nump">2,422,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Lease liability</a></td>
<td class="nump">1,687<span></span>
</td>
<td class="nump">20,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital loss limitation</a></td>
<td class="nump">149,394<span></span>
</td>
<td class="nump">149,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">17,648,077<span></span>
</td>
<td class="nump">15,493,570<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets, gross</a></td>
<td class="nump">21,918,044<span></span>
</td>
<td class="nump">22,020,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(21,784,638)<span></span>
</td>
<td class="num">(21,871,551)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Total deferred tax assets, net</a></td>
<td class="nump">133,406<span></span>
</td>
<td class="nump">148,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets', window );">Fixed assets and intangible assets book/tax basis difference</a></td>
<td class="num">(133,406)<span></span>
</td>
<td class="num">(129,636)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesRegulatoryAssets', window );">Right-of-use assets</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(19,248)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(133,406)<span></span>
</td>
<td class="num">(148,884)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_DeferredTaxAssetsPartnershipInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of partnership investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_DeferredTaxAssetsPartnershipInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from long-lived assets other than property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesRegulatoryAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from regulatory assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesRegulatoryAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>224
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 05, 2024</div></th>
<th class="th"><div>Mar. 07, 2024</div></th>
<th class="th"><div>Oct. 09, 2023</div></th>
<th class="th"><div>Jul. 06, 2023</div></th>
<th class="th"><div>May 23, 2023</div></th>
<th class="th"><div>Nov. 18, 2024</div></th>
<th class="th"><div>Oct. 28, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Jan. 09, 2025</div></th>
<th class="th"><div>Jan. 06, 2025</div></th>
<th class="th"><div>Dec. 15, 2024</div></th>
<th class="th"><div>Dec. 13, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Feb. 09, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in Shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in Shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, stated value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfCommonStockIssuedAndOutstanding', window );">Percentage of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued as convertible note payable commitment fee (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock value issued as convertible note payable commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="nump">$ 320,546<span></span>
</td>
<td class="nump">$ 236,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,857,852<span></span>
</td>
<td class="nump">635,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_FairMarketValuesOfGrantDates', window );">Fair market values of grant dates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">999,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,350<span></span>
</td>
<td class="nump">834,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Reduction in accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value</a></td>
<td class="nump">6,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,115<span></span>
</td>
<td class="nump">28,694<span></span>
</td>
<td class="nump">$ 12,137<span></span>
</td>
<td class="nump">$ 28,694<span></span>
</td>
<td class="nump">$ 319,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.17%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.29%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.93%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Compensation and related benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,103<span></span>
</td>
<td class="nump">$ 19,878<span></span>
</td>
<td class="nump">$ 172,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,691,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">442,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,822,105<span></span>
</td>
<td class="nump">3,076,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Black-Scholes option-pricing volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.72%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Convertible debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,807<span></span>
</td>
<td class="nump">119,228<span></span>
</td>
<td class="nump">106,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,360<span></span>
</td>
<td class="nump">114,360<span></span>
</td>
<td class="num">(31,212)<span></span>
</td>
<td class="num">$ (31,212)<span></span>
</td>
<td class="num">(374,365)<span></span>
</td>
<td class="num">(188,374)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10,636,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,636,544<span></span>
</td>
<td class="nump">$ 12,095,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionAmount', window );">Payment of closing the redemption</a></td>
<td class="nump">1,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RedemptionNetOfPayablesDueToLabServices', window );">Redemption, net of payables due to lab services</a></td>
<td class="nump">$ 632,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPremium', window );">Total redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,377,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Share issued (in Shares)</a></td>
<td class="nump">1,655,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,655,134<span></span>
</td>
<td class="nump">1,445,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,445,979<span></span>
</td>
<td class="nump">736,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 42,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expense</a></td>
<td class="nump">$ 51,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,834<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.5<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="nump">$ 237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,450<span></span>
</td>
<td class="nump">$ 7,560<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,880<span></span>
</td>
<td class="nump">$ 14,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants share (in Shares)</a></td>
<td class="nump">9,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=avco_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants share (in Shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=avco_FirstfireMember', window );">Firstfire [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=avco_FiveYearAnniversaryMember', window );">Five Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Convertible debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avco_RothCapitalPartnersLLCMember', window );">Roth Capital Partners, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Aggregate offering price amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CommonStockOfAveragePrice', window );">Common stock of average price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,544,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_OfferingCost', window );">Other offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 313,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avco_JefferiesLLCMember', window );">Jefferies LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Aggregate shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CommonStockOfAveragePrice', window );">Common stock of average price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 414,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avco_MastHillMember', window );">Mast Hill [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avco_MastMillAndFirstFireMember', window );">Mast Mill and FirstFire [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=avco_JefferiesLLCMember', window );">Jefferies LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_OfferingCost', window );">Other offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_LabServicesMSOMember', window );">Lab Services MSO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10,636,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,636,544<span></span>
</td>
<td class="nump">$ 12,095,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_AvalonLabMember', window );">Avalon Lab [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfCommonStockIssuedAndOutstanding', window );">Percentage of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Consideration issuable shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued as convertible note payable commitment fee (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">33,800<span></span>
</td>
<td class="nump">11,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock value issued as convertible note payable commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,153<span></span>
</td>
<td class="nump">24,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Reduction in accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock upon cashless exercise (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Share issued (in Shares)</a></td>
<td class="nump">186,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_FairMarketValues', window );">Fair market values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Roth Capital Partners, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Aggregate shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=avco_CommonSharesIssuedForServicesMember', window );">Common Shares Issued for Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_FairMarketValuesOfGrantDates', window );">Fair market values of grant dates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 530,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Share issued (in Shares)</a></td>
<td class="nump">22,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_FiveYearAnniversaryMember', window );">Five Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_FiveYearAnniversaryMember', window );">Five Year Anniversary [Member] | Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,533<span></span>
</td>
<td class="nump">51,159<span></span>
</td>
<td class="nump">$ 284,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Stock options exercisable</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,430<span></span>
</td>
<td class="nump">31,281<span></span>
</td>
<td class="nump">106,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common shares issued as convertible note payable commitment fee (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,800<span></span>
</td>
<td class="nump">11,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock value issued as convertible note payable commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,546<span></span>
</td>
<td class="nump">$ 236,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled warrants shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member] | Warrants Exercised [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock upon cashless exercise (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=avco_May2023CovertibleNoteMember', window );">May 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Warrant issued, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) a warrant to purchase 8,333 shares of common stock with an
exercise price of $67.50 exercisable until the five-year anniversary of May 23, 2023, and (ii) a warrant to purchase 7,033 shares of common
stock with an exercise price of $48.00 exercisable until the five-year anniversary of May 23, 2023, which warrant was never fair valued
and was cancelled and extinguished against payment of the May 2023 Convertible Note, to Mast Hill; and issued a warrant to purchase 667
shares of common stock with an exercise price of $67.50 exercisable until the five-year anniversary of May 23, 2023 to a third party as
a finder&#8217;s fee.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Convertible debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=avco_May2023CovertibleNoteMember', window );">May 2023 Convertible Note [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=avco_May2023CovertibleNoteMember', window );">May 2023 Convertible Note [Member] | Five Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=avco_BlackScholesValuationModelMember', window );">Black-Scholes Valuation Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Black-Scholes option-pricing volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=avco_July2023ConvertibleNoteMember', window );">July 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Warrant issued, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) a warrant to purchase 2,778 shares of common stock with an
exercise price of $67.50 exercisable until the five-year anniversary of July 6, 2023, and (ii) a warrant to purchase 2,344 shares of common
stock with an exercise price of $48.00 exercisable until the five-year anniversary of July 6, 2023, which warrant was never fair valued
and was cancelled and extinguished against payment of the July 2023 Convertible Note, to Firstfire; and issued a warrant to purchase 222
shares of common stock with an exercise price of $67.50 exercisable until the five-year anniversary of July 6, 2023 to a third party as
a finder&#8217;s fee.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Convertible debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=avco_July2023ConvertibleNoteMember', window );">July 2023 Convertible Note [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=avco_OctoberTwoThousandTwentyThreeConvertibleNotesMember', window );">October 2023 Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Warrant issued, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) a warrant to purchase 7,000 shares of common stock with
an exercise price of $37.50 exercisable until the five-year anniversary of October 9, 2023, (ii) a warrant to purchase 5,834 shares of
common stock with an exercise price of $27.00 exercisable until the five-year anniversary of October 9, 2023, which warrant was never
fair valued and was cancelled and extinguished against payment of the October 2023 Convertible Note, to Mast Hill and Firstfire; and issued
a warrant to purchase 560 shares of common stock with an exercise price of $37.50 exercisable until the five-year anniversary of October
9, 2023 to a third party as a finder&#8217;s fee.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Convertible debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=avco_OctoberTwoThousandTwentyThreeConvertibleNotesMember', window );">October 2023 Convertible Note [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=avco_MarchTwoThousandTwentyFourWarrantIssuedMember', window );">March Two Thousand Twenty Four Warrant Issued [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Warrant issued, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) a warrant to purchase 8,750 shares of common stock
with an exercise price of $30.00 exercisable until the five-year anniversary of March 7, 2024 (&#8220;First Warrant&#8221;), (ii) a warrant
to purchase 8,077 shares of common stock with an exercise price of $19.50 (&#8220;Second Warrant&#8221;), which warrant was never fair
valued and was cancelled and extinguished against payment of the March 2024 Convertible Note, to Mast Hill; and issued a warrant to purchase
700 shares of common stock with an exercise price of $30.00 exercisable until the five-year anniversary of March 7, 2024 to a third party
as a finder&#8217;s fee.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Black-Scholes option-pricing volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.07%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=avco_MarchTwentyThousandTwentyFourConvertibleNoteMember', window );">March Twenty Thousand Twenty Four Convertible Note [Member] | Mast Hill [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=avco_MarchTwentyThousandTwentyFourConvertibleNoteMember', window );">March Twenty Thousand Twenty Four Convertible Note [Member] | Five Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Convertible debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=avco_TwoThousandTwentyFourJuneWarrantIssuedMember', window );">Two Thousand Twenty Four June Warrant Issued [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Warrant issued, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) a warrant to purchase 66,667 shares of common stock with an exercise price of $9.75 exercisable
until the five-year anniversary of June 5, 2024 (&#8220;First Warrant&#8221;), (ii) a warrant to purchase 80,000 shares of common stock
with an exercise price of $7.50 exercisable until the five-year anniversary of June 5, 2024 (&#8220;Second Warrant&#8221;), which warrant
shall be cancelled and extinguished against payment of the June 2024 Convertible Note, to Mast Hill; and issued a warrant to purchase
5,333 shares of common stock with an exercise price of $9.75 exercisable until the five-year anniversary of June 5, 2024 to a third party
as a finder&#8217;s fee.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=avco_TwoThousandTwentyFourJuneWarrantIssuedMember', window );">Two Thousand Twenty Four June Warrant Issued [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants share (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=avco_TwoThousandTwentyFourJuneWarrantIssuedMember', window );">Two Thousand Twenty Four June Warrant Issued [Member] | Mast Hill [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 418,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=avco_TwoThousandTwentyFourJuneWarrantIssuedMember', window );">Two Thousand Twenty Four June Warrant Issued [Member] | Five Year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=avco_JuneTwentyThousandTwentyFourConvertibleNoteMember', window );">June 2024 Convertible Note [Member] | Mast Hill [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=avco_WarrantsExercisedMember', window );">Warrants Exercised [Member] | Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=avco_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrants (in Shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.10%<span></span>
</td>
<td class="nump">79.76%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.47%<span></span>
</td>
<td class="nump">3.58%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.36%<span></span>
</td>
<td class="nump">96.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.79%<span></span>
</td>
<td class="nump">4.76%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, stated value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfCommonStockIssuedAndOutstanding', window );">Percentage of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ConversionPricePercentage', window );">Conversion percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in Shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in Shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Issued shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in Shares)</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock value issued as convertible note payable commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Issued shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Convertible Debt Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Mr. Lu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Issued shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=avco_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, stated value</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, stated value</a></td>
<td class="nump">$ 8,837,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,837,527<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfCommonStockIssuedAndOutstanding', window );">Percentage of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in Shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in Shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Issued shares (in Shares)</a></td>
<td class="nump">162,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member] | Avalon Lab [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest, percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Issued shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member] | Conversion Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of own excess</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=avco_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, stated value</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="nump">11,029,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,029,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionAmount', window );">Payment of closing the redemption</a></td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=avco_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in Shares)</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionAmount', window );">Payment of closing the redemption</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, stated value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfCommonStockIssuedAndOutstanding', window );">Percentage of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="nump">$ 56.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.7<span></span>
</td>
<td class="nump">$ 56.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in Shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in Shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Issued shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, stated value</a></td>
<td class="nump">$ 2,348,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,348,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock value issued as convertible note payable commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Lab Services MSO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=avco_SeriesBHolderMember', window );">Series B Holder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfCommonStockIssuedAndOutstanding', window );">Percentage of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, stated value</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfCommonStockIssuedAndOutstanding', window );">Percentage of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in Shares)</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in Shares)</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in Shares)</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Aggregate shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Preferred stock and received proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock value issued as convertible note payable commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Convertible Preferred Stock [Member] | Conversion Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in Shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in Shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of own excess</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_CommonStockOfAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share in average price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_CommonStockOfAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ConversionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represent conversion price percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ConversionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_FairMarketValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fair market value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_FairMarketValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_FairMarketValuesOfGrantDates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of fair market values of grant dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_FairMarketValuesOfGrantDates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_OfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering Cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_OfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PercentageOfCommonStockIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of common stock issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PercentageOfCommonStockIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_RedemptionNetOfPayablesDueToLabServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of redemption, net of payables due to lab services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_RedemptionNetOfPayablesDueToLabServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of reason for issuing warrant or right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of (1) fair value of the consideration transferred to the holders of the preferred stock over (2) the carrying amount of the preferred stock in the registrant's balance sheet, during the accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480408/260-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=avco_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=avco_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=avco_FirstfireMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=avco_FirstfireMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=avco_FiveYearAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=avco_FiveYearAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avco_RothCapitalPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avco_RothCapitalPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avco_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avco_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avco_MastHillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avco_MastHillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avco_MastMillAndFirstFireMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avco_MastMillAndFirstFireMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=avco_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=avco_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_LabServicesMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_LabServicesMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_AvalonLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_AvalonLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=avco_CommonSharesIssuedForServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=avco_CommonSharesIssuedForServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avco_FiveYearAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avco_FiveYearAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_LiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_LiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=avco_WarrantsExercisedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=avco_WarrantsExercisedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=avco_May2023CovertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=avco_May2023CovertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=avco_BlackScholesValuationModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=avco_BlackScholesValuationModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=avco_July2023ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=avco_July2023ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=avco_OctoberTwoThousandTwentyThreeConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=avco_OctoberTwoThousandTwentyThreeConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=avco_MarchTwoThousandTwentyFourWarrantIssuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=avco_MarchTwoThousandTwentyFourWarrantIssuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=avco_MarchTwentyThousandTwentyFourConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=avco_MarchTwentyThousandTwentyFourConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=avco_TwoThousandTwentyFourJuneWarrantIssuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=avco_TwoThousandTwentyFourJuneWarrantIssuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=avco_MastHillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=avco_MastHillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=avco_JuneTwentyThousandTwentyFourConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=avco_JuneTwentyThousandTwentyFourConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=avco_WarrantsExercisedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=avco_WarrantsExercisedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=avco_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=avco_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avco_ConvertibleDebtNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avco_ConvertibleDebtNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=avco_MrLuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=avco_MrLuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avco_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avco_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_ConversionShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_ConversionShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avco_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avco_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=avco_LabServicesMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=avco_LabServicesMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avco_SeriesBHolderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avco_SeriesBHolderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>225
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Common Stock Issuable Upon Exercise of Warrants Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeOneMember', window );">2.93 &#8211; 31.20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Schedule of Common Stock Issuable Upon Exercise of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options Outstanding,Range of Exercise Price lower limit</a></td>
<td class="nump">$ 2.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options Outstanding, Range of Exercise Price Upper limit</a></td>
<td class="nump">$ 31.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Number Outstanding (in Shares) | shares</a></td>
<td class="nump">20,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">3 years 6 months 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 14.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, Number Exercisable (in Shares) | shares</a></td>
<td class="nump">14,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable</a></td>
<td class="nump">$ 16.38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeTwoMember', window );">48.75 &#8211; 123.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Schedule of Common Stock Issuable Upon Exercise of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options Outstanding,Range of Exercise Price lower limit</a></td>
<td class="nump">48.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options Outstanding, Range of Exercise Price Upper limit</a></td>
<td class="nump">$ 123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Number Outstanding (in Shares) | shares</a></td>
<td class="nump">20,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">2 years 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 78.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, Number Exercisable (in Shares) | shares</a></td>
<td class="nump">20,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable</a></td>
<td class="nump">$ 78.91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeThreeMember', window );">154.50 &#8211; 289.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Schedule of Common Stock Issuable Upon Exercise of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options Outstanding,Range of Exercise Price lower limit</a></td>
<td class="nump">154.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options Outstanding, Range of Exercise Price Upper limit</a></td>
<td class="nump">$ 289.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Number Outstanding (in Shares) | shares</a></td>
<td class="nump">11,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">3 years 5 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 218.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, Number Exercisable (in Shares) | shares</a></td>
<td class="nump">11,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable</a></td>
<td class="nump">$ 218.21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeFourMember', window );">2.93 &#8211; 289.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Schedule of Common Stock Issuable Upon Exercise of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options Outstanding,Range of Exercise Price lower limit</a></td>
<td class="nump">2.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options Outstanding, Range of Exercise Price Upper limit</a></td>
<td class="nump">$ 289.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Number Outstanding (in Shares) | shares</a></td>
<td class="nump">52,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">2 years 11 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 85.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, Number Exercisable (in Shares) | shares</a></td>
<td class="nump">46,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable</a></td>
<td class="nump">$ 94.41<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>226
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Stock Option Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Beginning Balance</a></td>
<td class="nump">52,479<span></span>
</td>
<td class="nump">56,880<span></span>
</td>
<td class="nump">53,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 85.45<span></span>
</td>
<td class="nump">$ 149.03<span></span>
</td>
<td class="nump">$ 195.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">2,665<span></span>
</td>
<td class="nump">10,265<span></span>
</td>
<td class="nump">12,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 3.26<span></span>
</td>
<td class="nump">$ 4.13<span></span>
</td>
<td class="nump">$ 35.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Warrants, Cancelled</a></td>
<td class="num">(3,719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="num">$ (132.47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,666)<span></span>
</td>
<td class="num">(8,929)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (275.14)<span></span>
</td>
<td class="num">$ (267.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Balance Ending</a></td>
<td class="nump">51,425<span></span>
</td>
<td class="nump">52,479<span></span>
</td>
<td class="nump">56,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Balance Ending</a></td>
<td class="nump">$ 77.79<span></span>
</td>
<td class="nump">$ 85.45<span></span>
</td>
<td class="nump">$ 149.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Options exercisable</a></td>
<td class="nump">47,493<span></span>
</td>
<td class="nump">46,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable</a></td>
<td class="nump">$ 83.97<span></span>
</td>
<td class="nump">$ 94.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Options expected to vest</a></td>
<td class="nump">3,932<span></span>
</td>
<td class="nump">5,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options expected to vest</a></td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="nump">$ 10.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Stock Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Stock Option Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Beginning Balance</a></td>
<td class="nump">182,996<span></span>
</td>
<td class="nump">43,035<span></span>
</td>
<td class="nump">8,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 21.37<span></span>
</td>
<td class="nump">$ 75.53<span></span>
</td>
<td class="nump">$ 187.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,527<span></span>
</td>
<td class="nump">34,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.28<span></span>
</td>
<td class="nump">$ 48.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Warrants, Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (32.85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Warrants, Exercised</a></td>
<td class="num">(11,833)<span></span>
</td>
<td class="num">(6,278)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="num">$ (58.63)<span></span>
</td>
<td class="num">$ (50.77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Balance Ending</a></td>
<td class="nump">171,163<span></span>
</td>
<td class="nump">182,996<span></span>
</td>
<td class="nump">43,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Balance Ending</a></td>
<td class="nump">$ 18.79<span></span>
</td>
<td class="nump">$ 21.37<span></span>
</td>
<td class="nump">$ 75.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Options exercisable</a></td>
<td class="nump">91,163<span></span>
</td>
<td class="nump">102,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable</a></td>
<td class="nump">$ 28.7<span></span>
</td>
<td class="nump">$ 32.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Options expected to vest</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options expected to vest</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could acquire or could have acquired the underlying shares with respect to any other type of change in shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>227
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Nonvested Stock Options Granted (Details) - Nonvested [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=avco_NonvestedMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options, Nonvested Beginning</a></td>
<td class="nump">5,943<span></span>
</td>
<td class="nump">5,311<span></span>
</td>
<td class="nump">1,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Nonvested Beginning</a></td>
<td class="nump">$ 11.54<span></span>
</td>
<td class="nump">$ 23.55<span></span>
</td>
<td class="nump">$ 64.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Warrants, Cancelled</a></td>
<td class="num">(1,853)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="num">$ (27.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">2,665<span></span>
</td>
<td class="nump">10,265<span></span>
</td>
<td class="nump">12,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 3.26<span></span>
</td>
<td class="nump">$ 4.13<span></span>
</td>
<td class="nump">$ 35.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Options, Vested</a></td>
<td class="num">(2,823)<span></span>
</td>
<td class="num">(9,969)<span></span>
</td>
<td class="num">(8,475)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues', window );">Weighted Average Exercise Price, Vested</a></td>
<td class="num">$ (5.03)<span></span>
</td>
<td class="num">$ (10.9)<span></span>
</td>
<td class="num">$ (47.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options, Nonvested Ending</a></td>
<td class="nump">3,932<span></span>
</td>
<td class="nump">5,943<span></span>
</td>
<td class="nump">5,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Nonvested Ending</a></td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="nump">$ 11.54<span></span>
</td>
<td class="nump">$ 23.55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=avco_NonvestedMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options, Nonvested Beginning</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">15,211<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Nonvested Beginning</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 39.9<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of Options, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,527<span></span>
</td>
<td class="nump">34,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.28<span></span>
</td>
<td class="nump">$ 48.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Warrants, Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (32.85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Options, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81,450)<span></span>
</td>
<td class="num">(19,560)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues', window );">Weighted Average Exercise Price, Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12.1)<span></span>
</td>
<td class="nump">$ 55.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options, Nonvested Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">15,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Nonvested Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 39.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options, Nonvested Beginning</a></td>
<td class="nump">5,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Nonvested Beginning</a></td>
<td class="nump">$ 10.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options, Nonvested Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Nonvested Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=avco_NonvestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=avco_NonvestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>228
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Common Stock Issuable Upon Exercise of Options Outstanding (Details) - Warrants Outstanding [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_WarrantsOutstandingMember', window );">7.50 &#8211; 37.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Common Stock Issuable Upon Exercise of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Warrants Outstanding, Exercise Price, lower limit</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Warrants Outstanding, Number Outstanding (in Shares)</a></td>
<td class="nump">162,010<span></span>
</td>
<td class="nump">165,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">4 years 2 months 1 day<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Warrants Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 9.92<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Warrants Outstanding, Exercise Price, upper limit</a></td>
<td class="nump">$ 37.5<span></span>
</td>
<td class="nump">$ 37.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Warrants Exercisable, Number Exercisable (in Shares)</a></td>
<td class="nump">82,010<span></span>
</td>
<td class="nump">85,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Warrants Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 12.27<span></span>
</td>
<td class="nump">$ 13.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_WarrantsOutstandingMember', window );">67.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Common Stock Issuable Upon Exercise of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Warrants Outstanding, Number Outstanding (in Shares)</a></td>
<td class="nump">889<span></span>
</td>
<td class="nump">9,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">3 years 2 months 4 days<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Warrants Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Warrants Exercisable, Number Exercisable (in Shares)</a></td>
<td class="nump">889<span></span>
</td>
<td class="nump">9,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Warrants Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Warrants Outstanding, Exercise Price</a></td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_WarrantsOutstandingMember', window );">187.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Common Stock Issuable Upon Exercise of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Warrants Outstanding, Number Outstanding (in Shares)</a></td>
<td class="nump">8,264<span></span>
</td>
<td class="nump">8,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">2 years 21 days<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Warrants Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 187.5<span></span>
</td>
<td class="nump">$ 187.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Warrants Exercisable, Number Exercisable (in Shares)</a></td>
<td class="nump">8,264<span></span>
</td>
<td class="nump">8,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Warrants Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 187.5<span></span>
</td>
<td class="nump">$ 187.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Warrants Outstanding, Exercise Price</a></td>
<td class="nump">187.5<span></span>
</td>
<td class="nump">187.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_WarrantsOutstandingMember', window );">7.50 &#8211; 187.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Common Stock Issuable Upon Exercise of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Warrants Outstanding, Exercise Price, lower limit</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Warrants Outstanding, Number Outstanding (in Shares)</a></td>
<td class="nump">171,163<span></span>
</td>
<td class="nump">182,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">4 years 21 days<span></span>
</td>
<td class="text">4 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Warrants Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 18.79<span></span>
</td>
<td class="nump">$ 21.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Warrants Outstanding, Exercise Price, upper limit</a></td>
<td class="nump">$ 187.5<span></span>
</td>
<td class="nump">$ 187.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Warrants Exercisable, Number Exercisable (in Shares)</a></td>
<td class="nump">91,163<span></span>
</td>
<td class="nump">102,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Warrants Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 28.7<span></span>
</td>
<td class="nump">$ 32.13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avco_WarrantsOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avco_WarrantsOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>229
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statutory Reserve and Restricted Net Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherRestrictedAssetsAbstract', window );"><strong>Statutory Reserve and Restricted Net Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_StatutoryReservePercent', window );">Statutory reserve percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RegisteredCapitalPercentage', window );">Reserve registered capital percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_StatutoryReserve', window );">Statutory reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,578<span></span>
</td>
<td class="nump">$ 6,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherRestrictedAssets', window );">Restricted net assets</a></td>
<td class="nump">$ 1,206,578<span></span>
</td>
<td class="nump">1,206,578<span></span>
</td>
<td class="nump">1,106,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance', window );">Statutory totaled</a></td>
<td class="nump">$ 6,578<span></span>
</td>
<td class="nump">$ 6,578<span></span>
</td>
<td class="nump">$ 6,578<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_RegisteredCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of registered capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_RegisteredCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_StatutoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Statutory reserve.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_StatutoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_StatutoryReservePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of statutory reserve.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_StatutoryReservePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestrictedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total assets that cannot be used for operating purposes because of contract or regulatory requirements that are in effect for a period that extends beyond one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestrictedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestrictedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestrictedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of statutory capital and surplus (stockholders' equity) as of the balance sheet date using prescribed or permitted statutory accounting practices (rather than GAAP, if different) of the state or country.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478420/944-505-55-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478420/944-505-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477908/944-505-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>230
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Noncontrolling Interest (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=avco_FormerDirectorAndFormerCochiefExecutiveOfficerMember', window );">Former Director And Former Co-chief executive Officer [Member] | Dr Yu Zhou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Equity interests ownership percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=avco_FormerDirectorAndFormerCochiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=avco_FormerDirectorAndFormerCochiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_DrYuZhouMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_DrYuZhouMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>231
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Financial Information of the Parent Company (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Condensed Financial Information of the Parent Company [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets', window );">Consolidated subsidiary exceed net assets</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=avco_PRCSubsidiariesMember', window );">PRC Subsidiaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Condensed Financial Information of the Parent Company [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed', window );">Consolidated subsidiary did not exceed net assets</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of net assets of subsidiary exceed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents restricted net assets of the company's subsidiary did not exceed consolidated net assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=avco_PRCSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=avco_PRCSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>232
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations (Details) - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Supplies [Member] | Rent Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">One Customer [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">One Customer [Member] | Rent Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Two customers [Member] | Rent Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">79.80%<span></span>
</td>
<td class="nump">76.90%<span></span>
</td>
<td class="nump">80.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=us-gaap_PublicUtilitiesInventorySuppliesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=us-gaap_PublicUtilitiesInventorySuppliesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=avco_OneCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=avco_OneCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=avco_TwoCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=avco_TwoCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>233
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations - Schedule of Customer Accounted for Company's Revenues (Details) - Customer Concentration Risk [Member] - Revenue Benchmark [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Customer Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Customer concentration percentage</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Customer Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Customer concentration percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Customer Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Customer concentration percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=avco_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=avco_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=avco_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=avco_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=avco_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=avco_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>234
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details) - segments<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Feb. 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SegmentInformationDetailsLineItems', window );"><strong>Segment Information (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Reportable segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PurchasedServicesPercentage', window );">Purchased services percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_LabServicesMSOMember', window );">Lab Services MSO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SegmentInformationDetailsLineItems', window );"><strong>Segment Information (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PurchasedServicesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchased services percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PurchasedServicesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_SegmentInformationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_SegmentInformationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_LabServicesMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_LabServicesMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>235
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Reportable Business Segments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Reportable Business Segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Real property rental revenue</a></td>
<td class="nump">$ 349,800<span></span>
</td>
<td class="nump">$ 349,800<span></span>
</td>
<td class="nump">$ 314,588<span></span>
</td>
<td class="nump">$ 314,588<span></span>
</td>
<td class="nump">$ 1,333,403<span></span>
</td>
<td class="nump">$ 1,255,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Real property operating expenses</a></td>
<td class="num">(280,390)<span></span>
</td>
<td class="num">(280,390)<span></span>
</td>
<td class="num">(263,126)<span></span>
</td>
<td class="num">(263,126)<span></span>
</td>
<td class="num">(1,065,574)<span></span>
</td>
<td class="num">(1,017,493)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Real property operating income</a></td>
<td class="nump">69,410<span></span>
</td>
<td class="nump">69,410<span></span>
</td>
<td class="nump">51,462<span></span>
</td>
<td class="nump">51,462<span></span>
</td>
<td class="nump">267,829<span></span>
</td>
<td class="nump">238,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Loss from equity method investment - Lab Services MSO</a></td>
<td class="nump">392,677<span></span>
</td>
<td class="nump">392,677<span></span>
</td>
<td class="nump">107,469<span></span>
</td>
<td class="nump">107,469<span></span>
</td>
<td class="num">(846,588)<span></span>
</td>
<td class="num">(8,571,647)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Other operating expenses</a></td>
<td class="num">(2,268,862)<span></span>
</td>
<td class="num">(2,268,862)<span></span>
</td>
<td class="num">(1,001,993)<span></span>
</td>
<td class="num">(1,001,993)<span></span>
</td>
<td class="num">(4,348,973)<span></span>
</td>
<td class="num">(7,420,224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(560,018)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(519,007)<span></span>
</td>
<td class="num">(2,436,973)<span></span>
</td>
<td class="num">(1,351,502)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(115,318)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,444)<span></span>
</td>
<td class="num">(538,689)<span></span>
</td>
<td class="nump">398,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,482,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,367,513)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,903,394)<span></span>
</td>
<td class="num">(16,707,010)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=avco_RealPropertyOperationsMember', window );">Real Property Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Reportable Business Segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Real property rental revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,588<span></span>
</td>
<td class="nump">1,333,403<span></span>
</td>
<td class="nump">1,255,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Real property operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(280,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(263,126)<span></span>
</td>
<td class="num">(1,065,574)<span></span>
</td>
<td class="num">(1,017,493)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Real property operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,462<span></span>
</td>
<td class="nump">267,829<span></span>
</td>
<td class="nump">238,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Loss from equity method investment - Lab Services MSO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Other operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,762)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114,287)<span></span>
</td>
<td class="num">(354,311)<span></span>
</td>
<td class="num">(347,356)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(194,307)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(194,307)<span></span>
</td>
<td class="num">(777,228)<span></span>
</td>
<td class="num">(918,885)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(863,790)<span></span>
</td>
<td class="num">(1,028,038)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=avco_LabServicesMSOMember', window );">Lab Services MSO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Reportable Business Segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Real property rental revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Real property operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Real property operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Loss from equity method investment - Lab Services MSO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,469<span></span>
</td>
<td class="num">(846,588)<span></span>
</td>
<td class="num">(8,571,647)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Other operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(846,588)<span></span>
</td>
<td class="num">(8,571,647)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=avco_CorporateOtherMember', window );">Corporate / Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Reportable Business Segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Real property rental revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Real property operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Real property operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Loss from equity method investment - Lab Services MSO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Other operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,178,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(887,706)<span></span>
</td>
<td class="num">(3,994,662)<span></span>
</td>
<td class="num">(7,072,868)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(365,711)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(324,700)<span></span>
</td>
<td class="num">(1,659,745)<span></span>
</td>
<td class="num">(432,617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (115,546)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,448)<span></span>
</td>
<td class="num">(538,609)<span></span>
</td>
<td class="nump">398,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,193,016)<span></span>
</td>
<td class="num">$ (7,107,325)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=avco_RealPropertyOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=avco_RealPropertyOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=avco_LabServicesMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=avco_LabServicesMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=avco_CorporateOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=avco_CorporateOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>236
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total Identifiable long-lived tangible assets</a></td>
<td class="nump">$ 6,991,211<span></span>
</td>
<td class="nump">$ 7,035,633<span></span>
</td>
<td class="nump">$ 7,229,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=avco_RealPropertyOperatingMember', window );">Real property operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total Identifiable long-lived tangible assets</a></td>
<td class="nump">6,990,058<span></span>
</td>
<td class="nump">7,034,335<span></span>
</td>
<td class="nump">7,211,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=avco_CorporateOtherMember', window );">Corporate/Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total Identifiable long-lived tangible assets</a></td>
<td class="nump">$ 1,153<span></span>
</td>
<td class="nump">$ 1,298<span></span>
</td>
<td class="nump">$ 17,846<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=avco_RealPropertyOperatingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=avco_RealPropertyOperatingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=avco_CorporateOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=avco_CorporateOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>237
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Geographic Areas) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Schedule of Identifiable Long-Lived Tangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total Identifiable long-lived tangible assets</a></td>
<td class="nump">$ 6,991,211<span></span>
</td>
<td class="nump">$ 7,035,633<span></span>
</td>
<td class="nump">$ 7,229,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Schedule of Identifiable Long-Lived Tangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total Identifiable long-lived tangible assets</a></td>
<td class="nump">6,990,058<span></span>
</td>
<td class="nump">7,034,335<span></span>
</td>
<td class="nump">7,227,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Schedule of Identifiable Long-Lived Tangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total Identifiable long-lived tangible assets</a></td>
<td class="nump">$ 1,153<span></span>
</td>
<td class="nump">$ 1,298<span></span>
</td>
<td class="nump">$ 1,954<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>238
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 23, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 25, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 06, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,369,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,856,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock (in Shares) | shares</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Litigation amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfPretaxProfit', window );">Percentage of pre-tax profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PreTaxProfit', window );">Pre-tax profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payment for rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowsBetweenTransfereeAndTransferorServicingFees', window );">Cash services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">&#165; 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">&#165; 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=avco_DrZhouMember', window );">Dr. Zhou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">876,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfPretaxProfit', window );">Percentage of pre-tax profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">876,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Litigation amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 373,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 373,450<span></span>
</td>
<td class="nump">$ 373,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfPretaxProfit', window );">Percentage of pre-tax profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PreTaxProfit', window );">Pre-tax profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Dr. Zhou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvactisBiotherapeuticsLimitedMember', window );">Avactis Biotherapeutics Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_ArbeleMember', window );">Arbele Biotherapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashContributionExpense', window );">Contribution amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvactisNanjingBiosciencesLtdMember', window );">Avactis Nanjing Biosciences Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PercentageOfPretaxProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of pre-tax profit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PercentageOfPretaxProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PreTaxProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of pre-tax profit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PreTaxProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of member capital in limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowsBetweenTransfereeAndTransferorServicingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Flows between a transferee and a transferor attributable to servicing fees related to a securitization, asset-backed financing arrangement, or similar transfer in which the transferor has continuing involvement with the transferred financial assets underlying the transaction (including, but not limited to, servicing, recourse, and restrictions on transferor's interests in the transferred financial assets).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowsBetweenTransfereeAndTransferorServicingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashContributionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash charitable contributions made by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashContributionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=avco_DrZhouMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=avco_DrZhouMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvactisBiotherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvactisBiotherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_ArbeleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_ArbeleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvactisNanjingBiosciencesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvactisNanjingBiosciencesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>239
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Lease (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowInvestingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows paid for operating lease</a></td>
<td class="nump">$ 27,535<span></span>
</td>
<td class="nump">$ 26,533<span></span>
</td>
<td class="nump">$ 125,076<span></span>
</td>
<td class="nump">$ 125,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities', window );">Operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 235,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months<span></span>
</td>
<td class="text">29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowInvestingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowInvestingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>240
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Maturity of Lease Liabilities Under Operating Lease (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Maturity of Lease Liabilities Under Operating Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="nump">$ 10,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2026 and thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">132,000<span></span>
</td>
<td class="nump">10,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Amount of lease payments representing interest</a></td>
<td class="num">(12,747)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Total present value of operating lease liabilities (current liability)</a></td>
<td class="nump">$ 67,547<span></span>
</td>
<td class="nump">$ 10,709<span></span>
</td>
<td class="nump">$ 129,396<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>241
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 10, 2025</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Jul. 06, 2023</div></th>
<th class="th"><div>May 23, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 09, 2025</div></th>
<th class="th"><div>Jan. 06, 2025</div></th>
<th class="th"><div>Oct. 09, 2023</div></th>
<th class="th"><div>Feb. 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, stated value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceDecrease', window );">Convertible per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ExchangeRatioPerShare', window );">Exchange ratio per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees', window );">Termination fee (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_FairMarketValuesOfGrantDates', window );">Fair market values (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 999,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=avco_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, stated value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock, convertible per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedemptionPremium', window );">Redemption amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_FairMarketValuesOfGrantDates', window );">Fair market values (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Lab Services MSO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedemptionPremium', window );">Redemption amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, stated value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=avco_MergerAgreementMember', window );">Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ExchangeRatioPerShare', window );">Exchange ratio per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, stated value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,837,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Percentage of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock, convertible per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedPercentOfNetAssets', window );">Percentage of owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, stated value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, stated value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock, convertible per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Certificates of Elimination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,278<span></span>
</td>
<td class="nump">186,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued</a></td>
<td class="nump">242,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, stated value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred stock, convertible per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Certificates of Elimination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_LabServicesMSOMember', window );">Lab Services MSO [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Equity interest ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ExchangeRatioPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ExchangeRatioPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_FairMarketValuesOfGrantDates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of fair market values of grant dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_FairMarketValuesOfGrantDates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedPercentOfNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of investment owned to net assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedPercentOfNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of early contract termination fees included in liabilities subject to compromise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedemptionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedemptionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=avco_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=avco_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_LabServicesMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_LabServicesMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=avco_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=avco_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=avco_CertificatesOfEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=avco_CertificatesOfEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_LabServicesMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_LabServicesMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>242
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations - Schedule of Consolidated Financial Statements (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 06, 2022</div></th>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>May 18, 2015</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvalonHealthcareSystemIncMember', window );">Avalon Healthcare System, Inc. (&#8220;AHS&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPlaceAndDateOfIncorporation', window );">Place and Date of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Delaware May 18, 2015<span></span>
</td>
<td class="text">Delaware
May 18, 2015<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Holding company for payroll and other expenses<span></span>
</td>
<td class="text">Holding company for payroll and other expenses<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvalonRT9PropertiesLLCMember', window );">Avalon RT 9 Properties LLC (&#8220;Avalon RT 9&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPlaceAndDateOfIncorporation', window );">Place and Date of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">New Jersey February 7, 2017<span></span>
</td>
<td class="text">New Jersey February 7, 2017<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Owns and operates an income-producing real property and holds and manages the corporate headquarters<span></span>
</td>
<td class="text">Owns and operates an income-producing real property and holds and manages the corporate headquarters<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvalonShanghaiHealthcareTechnologyCoLtdMember', window );">Avalon (Shanghai) Healthcare Technology Co., Ltd. (&#8220;Avalon Shanghai&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPlaceAndDateOfIncorporation', window );">Place and Date of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">PRC April 29, 2016<span></span>
</td>
<td class="text">PRC
April 29, 2016<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Not considered an operating entity<span></span>
</td>
<td class="text">Is not considered an operating entity<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_GenExosomeTechnologiesIncMember', window );">Genexosome Technologies Inc. (&#8220;Genexosome&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPlaceAndDateOfIncorporation', window );">Place and Date of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nevada July 31, 2017<span></span>
</td>
<td class="text">Nevada July 31, 2017<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">No current activities to report; dormant<span></span>
</td>
<td class="text">No current activities to report, dormant<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvactisBiosciencesIncMember', window );">Avactis Biosciences Inc. (&#8220;Avactis&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPlaceAndDateOfIncorporation', window );">Place and Date of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nevada July 18, 2018<span></span>
</td>
<td class="text">Nevada July 18, 2018<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of Ownership</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dormant; in process of being dissolved<span></span>
</td>
<td class="text">Dormant, is in process of being dissolved<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvactisNanjingBiosciencesLtdMember', window );">Avactis Nanjing Biosciences Ltd. (&#8220;Avactis Nanjing&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPlaceAndDateOfIncorporation', window );">Place and Date of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">PRC May 8, 2020<span></span>
</td>
<td class="text">PRC
May 8, 2020<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dormant; in process of being dissolved<span></span>
</td>
<td class="text">Dormant, is in process of being dissolved<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_AvalonLaboratoryServicesIncMember', window );">Avalon Laboratory Services, Inc. (&#8220;Avalon Lab&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPlaceAndDateOfIncorporation', window );">Place and Date of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Delaware October 14, 2022<span></span>
</td>
<td class="text">Delaware October 14, 2022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">No current activities to report; dormant<span></span>
</td>
<td class="text">Laboratory holding company with a 40% membership interest in Lab Services MSO (1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=avco_QADistributionLLCMember', window );">Q&amp;A Distribution LLC (&#8220;Q&amp;A Distribution&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems', window );"><strong>Schedule of Consolidated Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentPlaceAndDateOfIncorporation', window );">Place and Date of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Texas May 1, 2024<span></span>
</td>
<td class="text">Texas
May 1, 2024<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest', window );">Percentage of Ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose', window );">Principal Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Distributes KetoAir device<span></span>
</td>
<td class="text">Distributes KetoAir device<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">On February 26, 2025, the Company and Lab Services MSO entered into a Redemption and Abandonment Agreement,
whereby Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by the Company.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityMethodInvestmentPlaceAndDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity method investment place and date of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityMethodInvestmentPlaceAndDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business purpose of the subsidiary of the limited liability company or limited partnership, for example, its day-to-day operating functions and whether it acts as a holding or operating company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvalonHealthcareSystemIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvalonHealthcareSystemIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvalonRT9PropertiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvalonRT9PropertiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvalonShanghaiHealthcareTechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvalonShanghaiHealthcareTechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_GenExosomeTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_GenExosomeTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvactisBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvactisBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvactisNanjingBiosciencesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvactisNanjingBiosciencesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_AvalonLaboratoryServicesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_AvalonLaboratoryServicesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=avco_QADistributionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=avco_QADistributionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>243
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Derivative Liability Measured at Fair Value (Details) - Significant Unobservable Inputs (Level 3) [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Schedule of Derivative Liability Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Balance of derivative liability beginning balance</a></td>
<td class="nump">$ 127,545<span></span>
</td>
<td class="nump">$ 24,796<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Reclassification of additional paid-in capital upon conversion</a></td>
<td class="num">(18,853)<span></span>
</td>
<td class="num">(2,354)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Loss from change in the fair value of derivative liability</a></td>
<td class="nump">114,360<span></span>
</td>
<td class="num">(374,365)<span></span>
</td>
<td class="num">(188,374)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Balance of derivative liability ending balance</a></td>
<td class="nump">$ 223,052<span></span>
</td>
<td class="nump">$ 127,545<span></span>
</td>
<td class="nump">$ 24,796<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>244
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Cash Balances by Geographic Area (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Schedule of Cash Balances by Geographic Area [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash</a></td>
<td class="nump">$ 1,369,586<span></span>
</td>
<td class="nump">$ 2,856,309<span></span>
</td>
<td class="nump">$ 285,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CashPercentage', window );">Percentage of Total cash</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Schedule of Cash Balances by Geographic Area [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash</a></td>
<td class="nump">$ 1,351,923<span></span>
</td>
<td class="nump">$ 2,844,522<span></span>
</td>
<td class="nump">$ 280,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CashPercentage', window );">Percentage of Total cash</a></td>
<td class="nump">98.70%<span></span>
</td>
<td class="nump">99.60%<span></span>
</td>
<td class="nump">98.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Schedule of Cash Balances by Geographic Area [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash</a></td>
<td class="nump">$ 17,663<span></span>
</td>
<td class="nump">$ 11,787<span></span>
</td>
<td class="nump">$ 5,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CashPercentage', window );">Percentage of Total cash</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_CashPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_CashPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>245
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Securities that were Excluded from the Diluted Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Summarizes the Securities that were Excluded from the Diluted Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,384,113<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">451,986<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,169,030<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">414,659<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avco_OptionsToPurchaseCommonStockMember', window );">Options to purchase common stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Summarizes the Securities that were Excluded from the Diluted Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,451,425<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">47,287<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">52,479<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">56,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Summarizes the Securities that were Excluded from the Diluted Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">171,163<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">60,562<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">182,996<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">43,035<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Summarizes the Securities that were Excluded from the Diluted Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">60,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">60,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">60,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Summarizes the Securities that were Excluded from the Diluted Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">194,004<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">194,004<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">194,004<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Summarizes the Securities that were Excluded from the Diluted Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,452,282<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">1,452,282<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesDPreferredStockMember', window );">Series D Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Summarizes the Securities that were Excluded from the Diluted Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">2,074,689<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Summarizes the Securities that were Excluded from the Diluted Per Share [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">234,554<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="nump">90,133<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="nump">227,269<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="nump">60,740<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[9]</sup></td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the Series A convertible preferred stock (&#8220;Series A Preferred Stock&#8221;) was converted into shares of common stock of the Company at a conversion price of $150.00 per share.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Assumed the Series A convertible preferred stock was converted
into shares of common stock of the Company at a conversion price of $150.00 per share<span style="background-color: white">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the Series B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color: white">Assumed the Series
B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the Series C convertible preferred stock (&#8220;Series C Preferred Stock&#8221;) was converted into shares of common stock of the Company at a conversion price of $2.41 per share.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color: white">Assumed the Series
C convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $2.41 per share.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the Series D convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $2.41 per share.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top"><span style="-sec-ix-redline:true;font-size: 10pt">Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the three months ended March 31, 2025. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and $22.50 and $15.00 per share for the three months ended March 31, 2024.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[9]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color: white">Assumed the convertible
notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the year ended December
31, 2024. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and
$22.50 per share for the year ended December 31, 2023.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avco_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avco_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesDPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesDPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>246
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expense and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Schedule of Prepaid Expense and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PrepaidProfessionalFees', window );">Prepaid professional fees</a></td>
<td class="nump">$ 90,431<span></span>
</td>
<td class="nump">$ 33,665<span></span>
</td>
<td class="nump">$ 33,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidReinsurancePremiums', window );">Prepaid directors&#8217; and officers&#8217; liability insurance premium</a></td>
<td class="nump">12,834<span></span>
</td>
<td class="nump">9,741<span></span>
</td>
<td class="nump">27,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseOtherNoncurrent', window );">Prepaid NASDAQ listing fee</a></td>
<td class="nump">39,750<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsLeasingNet', window );">Deferred leasing costs</a></td>
<td class="nump">28,980<span></span>
</td>
<td class="nump">31,587<span></span>
</td>
<td class="nump">33,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">12,256<span></span>
</td>
<td class="nump">17,654<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromCorrespondentBrokers', window );">Due from broker</a></td>
<td class="nump">33,160<span></span>
</td>
<td class="nump">32,885<span></span>
</td>
<td class="nump">37,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">90,116<span></span>
</td>
<td class="nump">92,230<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivable', window );">Recoverable value-added tax</a></td>
<td class="nump">10,094<span></span>
</td>
<td class="nump">9,245<span></span>
</td>
<td class="nump">6,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Others</a></td>
<td class="nump">50,197<span></span>
</td>
<td class="nump">72,353<span></span>
</td>
<td class="nump">55,797<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 367,818<span></span>
</td>
<td class="nump">$ 299,360<span></span>
</td>
<td class="nump">$ 367,994<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PrepaidProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of prepaid professional fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PrepaidProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsLeasingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents costs incurred by the lessor that are (a) costs to originate a lease incurred in transactions with independent third parties that (i) result directly from and are essential to acquire that lease and (ii) would not have been incurred had that leasing transaction not occurred and (b) certain costs directly related to specified activities performed by the lessor for that lease. Those activities are: evaluating the prospective lessee's financial condition; evaluating and recording guarantees, collateral, and other security arrangements; negotiating lease terms; preparing and processing lease documents; and closing the transaction. This element is net of accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481178/840-20-25-16<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481123/840-20-35-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479341/842-30-25-10<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481178/840-20-25-17<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsLeasingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromCorrespondentBrokers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount receivable from correspondent broker-dealer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481833/940-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromCorrespondentBrokers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseOtherNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseOtherNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidReinsurancePremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The unexpired portion of premiums ceded on policies in force as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477351/944-825-50-1B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479510/944-340-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidReinsurancePremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>247
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments - Schedule of Equity Method Investment (Details) - Lab Services MSO [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investment carrying amount beginning balance</a></td>
<td class="nump">$ 10,636,544<span></span>
</td>
<td class="nump">$ 12,095,020<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_LabServicesMSOsNetIncomeAttributableToTheCompany', window );">Lab Services MSO&#8217;s net income attributable to the Company</a></td>
<td class="nump">503,833<span></span>
</td>
<td class="nump">79,923<span></span>
</td>
<td class="nump">1,236,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible assets amortization amount</a></td>
<td class="num">(111,156)<span></span>
</td>
<td class="num">(666,932)<span></span>
</td>
<td class="num">(611,356)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Sale of equity investment</a></td>
<td class="num">(11,029,221)<span></span>
</td>
<td class="num">(611,888)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investment carrying amount ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10,636,544<span></span>
</td>
<td class="nump">$ 12,095,020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_LabServicesMSOsNetIncomeAttributableToTheCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lab Services MSO&#8217;s net income attributable to the Company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_LabServicesMSOsNetIncomeAttributableToTheCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_LabServicesMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avco_LabServicesMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>248
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments - Schedule of Financial Information (Details) - Investment in Laboratory Services MSO, LLC [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Schedule of Financial Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue</a></td>
<td class="nump">$ 4,241,732<span></span>
</td>
<td class="nump">$ 3,376,372<span></span>
</td>
<td class="nump">$ 12,699,683<span></span>
</td>
<td class="nump">$ 13,558,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">2,155,760<span></span>
</td>
<td class="nump">1,003,789<span></span>
</td>
<td class="nump">4,744,277<span></span>
</td>
<td class="nump">3,534,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operation</a></td>
<td class="nump">1,513,000<span></span>
</td>
<td class="nump">275,026<span></span>
</td>
<td class="nump">2,393,830<span></span>
</td>
<td class="num">(265,754)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,259,582<span></span>
</td>
<td class="nump">$ 685,504<span></span>
</td>
<td class="nump">$ 3,090,977<span></span>
</td>
<td class="nump">$ 199,808<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedIncomeStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedIncomeStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=avco_InvestmentInLaboratoryServicesMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=avco_InvestmentInLaboratoryServicesMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>249
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Note Payable - Schedule of Amortization Payments in Cash (Details) - Mast Hill [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=avco_DecemberFiveTwoThousandTwentyFourMember', window );">December 5, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Amortization Payments in Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Amortization payments description</a></td>
<td class="text">$284,500 plus accrued interest through December 5, 2024<span></span>
</td>
<td class="text">$284,500 plus accrued interest through December 5, 2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=avco_JanuaryFiveTwoThousandTwentyFiveMember', window );">January 5, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Amortization Payments in Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Amortization payments description</a></td>
<td class="text">$284,500 plus accrued interest through January 5, 2025<span></span>
</td>
<td class="text">$284,500 plus accrued interest through January 5, 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=avco_FebruaryFiveTwoThousandTwentyFiveMember', window );">February 5, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Amortization Payments in Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Amortization payments description</a></td>
<td class="text">$379,336 plus accrued interest through February 5, 2025<span></span>
</td>
<td class="text">$379,336 plus accrued interest through February 5, 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=avco_MarchFiveTwoThousandTwentyFiveMember', window );">March 5, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Amortization Payments in Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Amortization payments description</a></td>
<td class="text">$474,167 plus accrued interest through March 5, 2025<span></span>
</td>
<td class="text">$474,167 plus accrued interest through March 5, 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=avco_AprilFiveTwoThousandTwentyFiveMember', window );">April 5, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Amortization Payments in Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Amortization payments description</a></td>
<td class="text">$474,167 plus accrued interest through April 5, 2025<span></span>
</td>
<td class="text">$474,167 plus accrued interest through April 5, 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=avco_MayFiveTwoThousandTwentyFiveMember', window );">May 5, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Amortization Payments in Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Amortization payments description</a></td>
<td class="text">$569,000 plus accrued interest through May 5, 2025<span></span>
</td>
<td class="text">$569,000 plus accrued interest through May 5, 2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=avco_JuneFiveTwoThousandTwentyFiveMember', window );">June 5, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Amortization Payments in Cash [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Amortization payments description</a></td>
<td class="text">The entire remaining outstanding balance of the June 2024 Convertible Note<span></span>
</td>
<td class="text">The entire remaining outstanding balance of the June 2024 Convertible Note<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=avco_DecemberFiveTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=avco_DecemberFiveTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=avco_MastHillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=avco_MastHillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=avco_JanuaryFiveTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=avco_JanuaryFiveTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=avco_FebruaryFiveTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=avco_FebruaryFiveTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=avco_MarchFiveTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=avco_MarchFiveTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=avco_AprilFiveTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=avco_AprilFiveTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=avco_MayFiveTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=avco_MayFiveTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=avco_JuneFiveTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=avco_JuneFiveTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>250
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Note Payable - Schedule of Convertible Note Payable (Details) - Convertible Notes Payable [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Schedule of Convertible Note Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 2,556,777<span></span>
</td>
<td class="nump">$ 2,556,777<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Less: unamortized debt issuance costs</a></td>
<td class="num">(33,584)<span></span>
</td>
<td class="num">(93,425)<span></span>
</td>
<td class="num">(183,840)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Less: unamortized debt discount</a></td>
<td class="num">(125,665)<span></span>
</td>
<td class="num">(349,579)<span></span>
</td>
<td class="num">(291,014)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible note payable, net</a></td>
<td class="nump">$ 2,397,528<span></span>
</td>
<td class="nump">$ 2,113,773<span></span>
</td>
<td class="nump">$ 1,925,146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>251
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note Payable, Net - Schedule of Note Payable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Note Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized debt issuance costs</a></td>
<td class="num">(54,746)<span></span>
</td>
<td class="num">(84,553)<span></span>
</td>
<td class="num">(203,781)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable, net</a></td>
<td class="nump">$ 5,745,254<span></span>
</td>
<td class="nump">$ 5,715,447<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>252
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Common Stock Issuable Upon Exercise of Options Outstanding (Details) - Options Outstanding [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_OptionsOutstandingMember', window );">2.93 - 31.20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options Outstanding,Range of Exercise Price lower limit</a></td>
<td class="nump">$ 2.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options Outstanding, Range of Exercise Price Upper limit</a></td>
<td class="nump">$ 31.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Number Outstanding (in Shares) | shares</a></td>
<td class="nump">21,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">3 years 5 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 12.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, Number Exercisable (in Shares) | shares</a></td>
<td class="nump">17,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable</a></td>
<td class="nump">$ 14.28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_OptionsOutstandingMember', window );">48.75 - 123.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options Outstanding,Range of Exercise Price lower limit</a></td>
<td class="nump">48.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options Outstanding, Range of Exercise Price Upper limit</a></td>
<td class="nump">$ 123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Number Outstanding (in Shares) | shares</a></td>
<td class="nump">20,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">1 year 9 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 78.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, Number Exercisable (in Shares) | shares</a></td>
<td class="nump">20,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable</a></td>
<td class="nump">$ 78.91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_OptionsOutstandingMember', window );">154.50 - 264.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options Outstanding,Range of Exercise Price lower limit</a></td>
<td class="nump">154.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options Outstanding, Range of Exercise Price Upper limit</a></td>
<td class="nump">$ 264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Number Outstanding (in Shares) | shares</a></td>
<td class="nump">9,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">3 years 9 months 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 214.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, Number Exercisable (in Shares) | shares</a></td>
<td class="nump">9,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable</a></td>
<td class="nump">$ 214.71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_OptionsOutstandingMember', window );">2.93 - 264.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options Outstanding,Range of Exercise Price lower limit</a></td>
<td class="nump">2.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options Outstanding, Range of Exercise Price Upper limit</a></td>
<td class="nump">$ 264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding, Number Outstanding (in Shares) | shares</a></td>
<td class="nump">51,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">2 years 10 months 13 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 77.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, Number Exercisable (in Shares) | shares</a></td>
<td class="nump">47,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable</a></td>
<td class="nump">$ 83.97<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avco_OptionsOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avco_OptionsOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>253
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Stock Option Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Balance outstanding</a></td>
<td class="nump">51,425<span></span>
</td>
<td class="nump">52,479<span></span>
</td>
<td class="nump">56,880<span></span>
</td>
<td class="nump">53,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Balance outstanding</a></td>
<td class="nump">$ 77.79<span></span>
</td>
<td class="nump">$ 85.45<span></span>
</td>
<td class="nump">$ 149.03<span></span>
</td>
<td class="nump">$ 195.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">2,665<span></span>
</td>
<td class="nump">10,265<span></span>
</td>
<td class="nump">12,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 3.26<span></span>
</td>
<td class="nump">$ 4.13<span></span>
</td>
<td class="nump">$ 35.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Warrants, Cancelled</a></td>
<td class="num">(3,719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="num">$ (132.47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Options exercisable</a></td>
<td class="nump">47,493<span></span>
</td>
<td class="nump">46,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable</a></td>
<td class="nump">$ 83.97<span></span>
</td>
<td class="nump">$ 94.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Options expected to vest</a></td>
<td class="nump">3,932<span></span>
</td>
<td class="nump">5,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options expected to vest</a></td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="nump">$ 10.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Stock Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Stock Option Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Balance outstanding</a></td>
<td class="nump">171,163<span></span>
</td>
<td class="nump">182,996<span></span>
</td>
<td class="nump">43,035<span></span>
</td>
<td class="nump">8,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Balance outstanding</a></td>
<td class="nump">$ 18.79<span></span>
</td>
<td class="nump">$ 21.37<span></span>
</td>
<td class="nump">$ 75.53<span></span>
</td>
<td class="nump">$ 187.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Warrants, Exercised</a></td>
<td class="num">(11,833)<span></span>
</td>
<td class="num">(6,278)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="num">$ (58.63)<span></span>
</td>
<td class="num">$ (50.77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,527<span></span>
</td>
<td class="nump">34,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.28<span></span>
</td>
<td class="nump">$ 48.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Warrants, Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (32.85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Options exercisable</a></td>
<td class="nump">91,163<span></span>
</td>
<td class="nump">102,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable</a></td>
<td class="nump">$ 28.7<span></span>
</td>
<td class="nump">$ 32.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Options expected to vest</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options expected to vest</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could acquire or could have acquired the underlying shares with respect to any other type of change in shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>254
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Nonvested Stock Options Granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Nonvested Stock Options Granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options, Nonvested Beginning</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Nonvested Beginning</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Options, Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues', window );">Weighted Average Exercise Price, Vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options, Nonvested Ending</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Nonvested Ending</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Nonvested Stock Options Granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">2,665<span></span>
</td>
<td class="nump">10,265<span></span>
</td>
<td class="nump">12,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Warrants, Cancelled</a></td>
<td class="num">(3,719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=avco_NonvestedMember', window );">Nonvested [Member] | Stock Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Nonvested Stock Options Granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options, Nonvested Beginning</a></td>
<td class="nump">5,943<span></span>
</td>
<td class="nump">5,311<span></span>
</td>
<td class="nump">1,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Nonvested Beginning</a></td>
<td class="nump">$ 11.54<span></span>
</td>
<td class="nump">$ 23.55<span></span>
</td>
<td class="nump">$ 64.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">2,665<span></span>
</td>
<td class="nump">10,265<span></span>
</td>
<td class="nump">12,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 3.26<span></span>
</td>
<td class="nump">$ 4.13<span></span>
</td>
<td class="nump">$ 35.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Warrants, Cancelled</a></td>
<td class="num">(1,853)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="num">$ (27.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Options, Vested</a></td>
<td class="num">(2,823)<span></span>
</td>
<td class="num">(9,969)<span></span>
</td>
<td class="num">(8,475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues', window );">Weighted Average Exercise Price, Vested</a></td>
<td class="num">$ (5.03)<span></span>
</td>
<td class="num">$ (10.9)<span></span>
</td>
<td class="num">$ (47.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options, Nonvested Ending</a></td>
<td class="nump">3,932<span></span>
</td>
<td class="nump">5,943<span></span>
</td>
<td class="nump">5,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Nonvested Ending</a></td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="nump">$ 11.54<span></span>
</td>
<td class="nump">$ 23.55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=avco_NonvestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=avco_NonvestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>255
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Common Stock Issuable Upon Exercise of Options Outstanding (Details) - Warrants Outstanding [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_WarrantsOutstandingMember', window );">7.50 &#8211; 37.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Common Stock Issuable Upon Exercise of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Warrants Outstanding, Exercise Price, lower limit</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Warrants Outstanding, Number Outstanding (in Shares)</a></td>
<td class="nump">162,010<span></span>
</td>
<td class="nump">165,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">4 years 2 months 1 day<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Warrants Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 9.92<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Warrants Outstanding, Exercise Price, upper limit</a></td>
<td class="nump">$ 37.5<span></span>
</td>
<td class="nump">$ 37.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Warrants Exercisable, Number Exercisable (in Shares)</a></td>
<td class="nump">82,010<span></span>
</td>
<td class="nump">85,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Warrants Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 12.27<span></span>
</td>
<td class="nump">$ 13.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_WarrantsOutstandingMember', window );">67.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Common Stock Issuable Upon Exercise of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Warrants Outstanding, Number Outstanding (in Shares)</a></td>
<td class="nump">889<span></span>
</td>
<td class="nump">9,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">3 years 2 months 4 days<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Warrants Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Warrants Exercisable, Number Exercisable (in Shares)</a></td>
<td class="nump">889<span></span>
</td>
<td class="nump">9,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Warrants Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Warrants Outstanding, Exercise Price</a></td>
<td class="nump">$ 67.5<span></span>
</td>
<td class="nump">$ 67.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_WarrantsOutstandingMember', window );">187.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Common Stock Issuable Upon Exercise of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Warrants Outstanding, Number Outstanding (in Shares)</a></td>
<td class="nump">8,264<span></span>
</td>
<td class="nump">8,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">2 years 21 days<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Warrants Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 187.5<span></span>
</td>
<td class="nump">$ 187.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Warrants Exercisable, Number Exercisable (in Shares)</a></td>
<td class="nump">8,264<span></span>
</td>
<td class="nump">8,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Warrants Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 187.5<span></span>
</td>
<td class="nump">$ 187.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Warrants Outstanding, Exercise Price</a></td>
<td class="nump">187.5<span></span>
</td>
<td class="nump">187.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_WarrantsOutstandingMember', window );">7.50 &#8211; 187.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Common Stock Issuable Upon Exercise of Options Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Warrants Outstanding, Exercise Price, lower limit</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Warrants Outstanding, Number Outstanding (in Shares)</a></td>
<td class="nump">171,163<span></span>
</td>
<td class="nump">182,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">4 years 21 days<span></span>
</td>
<td class="text">4 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Warrants Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 18.79<span></span>
</td>
<td class="nump">$ 21.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Warrants Outstanding, Exercise Price, upper limit</a></td>
<td class="nump">$ 187.5<span></span>
</td>
<td class="nump">$ 187.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Warrants Exercisable, Number Exercisable (in Shares)</a></td>
<td class="nump">91,163<span></span>
</td>
<td class="nump">102,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Warrants Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 28.7<span></span>
</td>
<td class="nump">$ 32.13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avco_WarrantsOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avco_WarrantsOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>256
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations - Schedule of Customer Accounted for Company's Revenues (Details) - Customer Concentration Risk [Member] - Revenue Benchmark [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Customer Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Customer concentration percentage</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Customer Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Customer concentration percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Customer Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Customer concentration percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=avco_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=avco_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=avco_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=avco_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=avco_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=avco_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>257
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Reportable Business Segments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Reportable Business Segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Real property rental revenue</a></td>
<td class="nump">$ 349,800<span></span>
</td>
<td class="nump">$ 349,800<span></span>
</td>
<td class="nump">$ 314,588<span></span>
</td>
<td class="nump">$ 314,588<span></span>
</td>
<td class="nump">$ 1,333,403<span></span>
</td>
<td class="nump">$ 1,255,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Real property operating expenses</a></td>
<td class="num">(280,390)<span></span>
</td>
<td class="num">(280,390)<span></span>
</td>
<td class="num">(263,126)<span></span>
</td>
<td class="num">(263,126)<span></span>
</td>
<td class="num">(1,065,574)<span></span>
</td>
<td class="num">(1,017,493)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Real property operating income</a></td>
<td class="nump">69,410<span></span>
</td>
<td class="nump">69,410<span></span>
</td>
<td class="nump">51,462<span></span>
</td>
<td class="nump">51,462<span></span>
</td>
<td class="nump">267,829<span></span>
</td>
<td class="nump">238,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Loss from equity method investment - Lab Services MSO</a></td>
<td class="nump">392,677<span></span>
</td>
<td class="nump">392,677<span></span>
</td>
<td class="nump">107,469<span></span>
</td>
<td class="nump">107,469<span></span>
</td>
<td class="num">(846,588)<span></span>
</td>
<td class="num">(8,571,647)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Other operating expenses</a></td>
<td class="num">(2,268,862)<span></span>
</td>
<td class="num">(2,268,862)<span></span>
</td>
<td class="num">(1,001,993)<span></span>
</td>
<td class="num">(1,001,993)<span></span>
</td>
<td class="num">(4,348,973)<span></span>
</td>
<td class="num">(7,420,224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(560,018)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(519,007)<span></span>
</td>
<td class="num">(2,436,973)<span></span>
</td>
<td class="num">(1,351,502)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(115,318)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,444)<span></span>
</td>
<td class="num">(538,689)<span></span>
</td>
<td class="nump">398,175<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">$ (2,482,111)<span></span>
</td>
<td class="num">(2,482,111)<span></span>
</td>
<td class="num">$ (1,367,513)<span></span>
</td>
<td class="num">(1,367,513)<span></span>
</td>
<td class="num">(7,903,394)<span></span>
</td>
<td class="num">(16,707,010)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=avco_RealPropertyOperationsMember', window );">Real Property Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Reportable Business Segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Real property rental revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,588<span></span>
</td>
<td class="nump">1,333,403<span></span>
</td>
<td class="nump">1,255,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Real property operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(280,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(263,126)<span></span>
</td>
<td class="num">(1,065,574)<span></span>
</td>
<td class="num">(1,017,493)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Real property operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,462<span></span>
</td>
<td class="nump">267,829<span></span>
</td>
<td class="nump">238,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Loss from equity method investment - Lab Services MSO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Other operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,762)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114,287)<span></span>
</td>
<td class="num">(354,311)<span></span>
</td>
<td class="num">(347,356)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(194,307)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(194,307)<span></span>
</td>
<td class="num">(777,228)<span></span>
</td>
<td class="num">(918,885)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(215,431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(257,128)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=avco_LabServicesMSOMember', window );">Lab Services MSO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Reportable Business Segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Real property rental revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Real property operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Real property operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Loss from equity method investment - Lab Services MSO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,469<span></span>
</td>
<td class="num">(846,588)<span></span>
</td>
<td class="num">(8,571,647)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Other operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=avco_CorporateOtherMember', window );">Corporate / Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Reportable Business Segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Real property rental revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Real property operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Real property operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Loss from equity method investment - Lab Services MSO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Other operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,178,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(887,706)<span></span>
</td>
<td class="num">(3,994,662)<span></span>
</td>
<td class="num">(7,072,868)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(365,711)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(324,700)<span></span>
</td>
<td class="num">(1,659,745)<span></span>
</td>
<td class="num">(432,617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(115,546)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,448)<span></span>
</td>
<td class="num">$ (538,609)<span></span>
</td>
<td class="nump">$ 398,160<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,659,357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,217,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=avco_RealPropertyOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=avco_RealPropertyOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=avco_LabServicesMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=avco_LabServicesMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=avco_CorporateOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=avco_CorporateOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>258
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total Identifiable long-lived tangible assets</a></td>
<td class="nump">$ 6,991,211<span></span>
</td>
<td class="nump">$ 7,035,633<span></span>
</td>
<td class="nump">$ 7,229,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=avco_RealPropertyOperatingMember', window );">Real property operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total Identifiable long-lived tangible assets</a></td>
<td class="nump">6,990,058<span></span>
</td>
<td class="nump">7,034,335<span></span>
</td>
<td class="nump">7,211,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=avco_CorporateOtherMember', window );">Corporate/Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total Identifiable long-lived tangible assets</a></td>
<td class="nump">$ 1,153<span></span>
</td>
<td class="nump">$ 1,298<span></span>
</td>
<td class="nump">$ 17,846<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=avco_RealPropertyOperatingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=avco_RealPropertyOperatingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=avco_CorporateOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=avco_CorporateOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>259
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Geographic Areas) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Schedule of Identifiable Long-Lived Tangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total Identifiable long-lived tangible assets</a></td>
<td class="nump">$ 6,991,211<span></span>
</td>
<td class="nump">$ 7,035,633<span></span>
</td>
<td class="nump">$ 7,229,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Schedule of Identifiable Long-Lived Tangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total Identifiable long-lived tangible assets</a></td>
<td class="nump">6,990,058<span></span>
</td>
<td class="nump">7,034,335<span></span>
</td>
<td class="nump">7,227,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Schedule of Identifiable Long-Lived Tangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Total Identifiable long-lived tangible assets</a></td>
<td class="nump">$ 1,153<span></span>
</td>
<td class="nump">$ 1,298<span></span>
</td>
<td class="nump">$ 1,954<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>260
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Lease (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowInvestingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows paid for operating lease</a></td>
<td class="nump">$ 27,535<span></span>
</td>
<td class="nump">$ 26,533<span></span>
</td>
<td class="nump">$ 125,076<span></span>
</td>
<td class="nump">$ 125,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease</a></td>
<td class="nump">$ 127,486<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months<span></span>
</td>
<td class="text">29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowInvestingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowInvestingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>261
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Maturity of Lease Liabilities Under Operating Lease (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Maturity of Lease Liabilities Under Operating Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="nump">$ 10,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2028 and thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">132,000<span></span>
</td>
<td class="nump">10,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Amount of lease payments representing interest</a></td>
<td class="num">(12,747)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total present value of operating lease liabilities</a></td>
<td class="nump">119,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">67,547<span></span>
</td>
<td class="nump">10,709<span></span>
</td>
<td class="nump">$ 129,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion</a></td>
<td class="nump">51,706<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 119,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>262
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>775</ContextCount>
  <ElementCount>535</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>187</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Changes in (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable</Role>
      <ShortName>Condensed Consolidated Statements of Changes in (Deficit) Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Changes in (Deficit) Equity (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable_Parentheticals</Role>
      <ShortName>Condensed Consolidated Statements of Changes in (Deficit) Equity (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/OrganizationandNatureofOperations</Role>
      <ShortName>Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Basis of Presentation and Going Concern Condition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernCondition</Role>
      <ShortName>Basis of Presentation and Going Concern Condition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Prepaid Expense and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/PrepaidExpenseandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expense and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Equipment Held For Sale</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/EquipmentHeldForSale</Role>
      <ShortName>Equipment Held For Sale</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Investment in Real Estate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/InvestmentinRealEstate</Role>
      <ShortName>Investment in Real Estate</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Equity Method Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/EquityMethodInvestments</Role>
      <ShortName>Equity Method Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Accrued Liabilities and Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayables</Role>
      <ShortName>Accrued Liabilities and Other Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Convertible Note Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ConvertibleNotePayable</Role>
      <ShortName>Convertible Note Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Derivative Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/DerivativeLiability</Role>
      <ShortName>Derivative Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note Payable, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/NotePayableNet</Role>
      <ShortName>Note Payable, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Statutory Reserve and Restricted Net Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssets</Role>
      <ShortName>Statutory Reserve and Restricted Net Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Noncontrolling Interest</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/NoncontrollingInterest</Role>
      <ShortName>Noncontrolling Interest</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Condensed Financial Information of the Parent Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompany</Role>
      <ShortName>Condensed Financial Information of the Parent Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Concentrations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/Concentrations</Role>
      <ShortName>Concentrations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Organization and Nature of Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsTables</Role>
      <ShortName>Organization and Nature of Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/OrganizationandNatureofOperations</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Prepaid Expense and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/PrepaidExpenseandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expense and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/PrepaidExpenseandOtherCurrentAssets</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/PropertyandEquipment</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Investment in Real Estate (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/InvestmentinRealEstateTables</Role>
      <ShortName>Investment in Real Estate (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/InvestmentinRealEstate</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Equity Method Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/EquityMethodInvestmentsTables</Role>
      <ShortName>Equity Method Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/EquityMethodInvestments</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Accrued Liabilities and Other Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayablesTables</Role>
      <ShortName>Accrued Liabilities and Other Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Convertible Note Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ConvertibleNotePayableTables</Role>
      <ShortName>Convertible Note Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/ConvertibleNotePayable</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Note Payable, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/NotePayableNetTables</Role>
      <ShortName>Note Payable, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/NotePayableNet</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/RelatedPartyTransactions</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/IncomeTaxes</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/EquityMethodInvestments</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Concentrations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ConcentrationsTables</Role>
      <ShortName>Concentrations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/Concentrations</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/SegmentInformation</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/CommitmentsandContingencies</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Organization and Nature of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails</Role>
      <ShortName>Organization and Nature of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Organization and Nature of Operations - Schedule of Consolidated Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable</Role>
      <ShortName>Organization and Nature of Operations - Schedule of Consolidated Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Basis of Presentation and Going Concern Condition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails</Role>
      <ShortName>Basis of Presentation and Going Concern Condition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernCondition</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Summary of Significant Accounting Policies - Schedule of Derivative Liability Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Derivative Liability Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash Balances by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Cash Balances by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Summary of Significant Accounting Policies - Schedule of Securities that were Excluded from the Diluted Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Securities that were Excluded from the Diluted Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Prepaid Expense and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable</Role>
      <ShortName>Prepaid Expense and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Equipment Held For Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/EquipmentHeldForSaleDetails</Role>
      <ShortName>Equipment Held For Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/EquipmentHeldForSale</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Investment in Real Estate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/InvestmentinRealEstateDetails</Role>
      <ShortName>Investment in Real Estate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/InvestmentinRealEstateTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Investment in Real Estate - Schedule of Investment in Real Estate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofInvestmentinRealEstateTable</Role>
      <ShortName>Investment in Real Estate - Schedule of Investment in Real Estate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails</Role>
      <ShortName>Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/EquityMethodInvestmentsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Equity Method Investments - Schedule of Equity Method Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable</Role>
      <ShortName>Equity Method Investments - Schedule of Equity Method Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Equity Method Investments - Schedule of Summarized Financial Information, as Provided to the Company by the Investee (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable</Role>
      <ShortName>Equity Method Investments - Schedule of Summarized Financial Information, as Provided to the Company by the Investee (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Equity Method Investments - Schedule of Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable</Role>
      <ShortName>Equity Method Investments - Schedule of Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Accrued Liabilities and Other Payables - Schedule of Accrued Liabilities and Other Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable</Role>
      <ShortName>Accrued Liabilities and Other Payables - Schedule of Accrued Liabilities and Other Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Convertible Note Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails</Role>
      <ShortName>Convertible Note Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/ConvertibleNotePayableTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Convertible Note Payable - Schedule of Amortization Payments in Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable</Role>
      <ShortName>Convertible Note Payable - Schedule of Amortization Payments in Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Convertible Note Payable - Schedule of Convertible Note Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable</Role>
      <ShortName>Convertible Note Payable - Schedule of Convertible Note Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/DerivativeLiabilityDetails</Role>
      <ShortName>Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/DerivativeLiability</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Note Payable, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/NotePayableNetDetails</Role>
      <ShortName>Note Payable, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/NotePayableNetTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Note Payable, Net - Schedule of Note Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofNotePayableTable</Role>
      <ShortName>Note Payable, Net - Schedule of Note Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Related Party Transactions - Schedule of Line of Credit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofLineofCreditTable</Role>
      <ShortName>Related Party Transactions - Schedule of Line of Credit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/IncomeTaxesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Income Taxes - Schedule of Company???s Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofCompanysLossBeforeIncomeTaxesTable</Role>
      <ShortName>Income Taxes - Schedule of Company???s Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Income Taxes - Schedule of Components of Income Taxes Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable</Role>
      <ShortName>Income Taxes - Schedule of Components of Income Taxes Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Income Taxes - Schedule of U.S. Statutory Rate and the Company???s Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable</Role>
      <ShortName>Income Taxes - Schedule of U.S. Statutory Rate and the Company???s Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Income Taxes - Schedule of Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable</Role>
      <ShortName>Income Taxes - Schedule of Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/EquityMethodInvestmentsTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Equity - Schedule of Common Stock Issuable Upon Exercise of Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable</Role>
      <ShortName>Equity - Schedule of Common Stock Issuable Upon Exercise of Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Equity - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable</Role>
      <ShortName>Equity - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Equity - Schedule of Nonvested Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable</Role>
      <ShortName>Equity - Schedule of Nonvested Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996051 - Disclosure - Equity - Schedule of Common Stock Issuable Upon Exercise of Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable</Role>
      <ShortName>Equity - Schedule of Common Stock Issuable Upon Exercise of Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996052 - Disclosure - Statutory Reserve and Restricted Net Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssetsDetails</Role>
      <ShortName>Statutory Reserve and Restricted Net Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssets</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996053 - Disclosure - Noncontrolling Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/NoncontrollingInterestDetails</Role>
      <ShortName>Noncontrolling Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/NoncontrollingInterest</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996054 - Disclosure - Condensed Financial Information of the Parent Company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompanyDetails</Role>
      <ShortName>Condensed Financial Information of the Parent Company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompany</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Concentrations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ConcentrationsDetails</Role>
      <ShortName>Concentrations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/ConcentrationsTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996056 - Disclosure - Concentrations - Schedule of Customer Accounted for Company's Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable</Role>
      <ShortName>Concentrations - Schedule of Customer Accounted for Company's Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996057 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/SegmentInformationTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996058 - Disclosure - Segment Information - Schedule of Reportable Business Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable</Role>
      <ShortName>Segment Information - Schedule of Reportable Business Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996059 - Disclosure - Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable</Role>
      <ShortName>Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>996060 - Disclosure - Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Geographic Areas) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable</Role>
      <ShortName>Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Geographic Areas) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>996061 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>996062 - Disclosure - Commitments and Contingencies - Schedule of Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofLeaseTable</Role>
      <ShortName>Commitments and Contingencies - Schedule of Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>996063 - Disclosure - Commitments and Contingencies - Schedule of Maturity of Lease Liabilities Under Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable</Role>
      <ShortName>Commitments and Contingencies - Schedule of Maturity of Lease Liabilities Under Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>996064 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/SubsequentEvents</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>996065 - Disclosure - Organization and Nature of Operations - Schedule of Consolidated Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0</Role>
      <ShortName>Organization and Nature of Operations - Schedule of Consolidated Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>996066 - Disclosure - Summary of Significant Accounting Policies - Schedule of Derivative Liability Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable0</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Derivative Liability Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>996067 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash Balances by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable0</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Cash Balances by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>996068 - Disclosure - Summary of Significant Accounting Policies - Schedule of Securities that were Excluded from the Diluted Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Securities that were Excluded from the Diluted Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>996069 - Disclosure - Prepaid Expense and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0</Role>
      <ShortName>Prepaid Expense and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>996070 - Disclosure - Equity Method Investments - Schedule of Equity Method Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable0</Role>
      <ShortName>Equity Method Investments - Schedule of Equity Method Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>996071 - Disclosure - Equity Method Investments - Schedule of Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable0</Role>
      <ShortName>Equity Method Investments - Schedule of Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>996072 - Disclosure - Convertible Note Payable - Schedule of Amortization Payments in Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0</Role>
      <ShortName>Convertible Note Payable - Schedule of Amortization Payments in Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>996073 - Disclosure - Convertible Note Payable - Schedule of Convertible Note Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0</Role>
      <ShortName>Convertible Note Payable - Schedule of Convertible Note Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>996074 - Disclosure - Note Payable, Net - Schedule of Note Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofNotePayableTable0</Role>
      <ShortName>Note Payable, Net - Schedule of Note Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>996075 - Disclosure - Equity - Schedule of Common Stock Issuable Upon Exercise of Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0</Role>
      <ShortName>Equity - Schedule of Common Stock Issuable Upon Exercise of Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>996076 - Disclosure - Equity - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0</Role>
      <ShortName>Equity - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>996077 - Disclosure - Equity - Schedule of Nonvested Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0</Role>
      <ShortName>Equity - Schedule of Nonvested Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>996078 - Disclosure - Equity - Schedule of Common Stock Issuable Upon Exercise of Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1</Role>
      <ShortName>Equity - Schedule of Common Stock Issuable Upon Exercise of Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>996079 - Disclosure - Concentrations - Schedule of Customer Accounted for Company's Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable0</Role>
      <ShortName>Concentrations - Schedule of Customer Accounted for Company's Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>996080 - Disclosure - Segment Information - Schedule of Reportable Business Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0</Role>
      <ShortName>Segment Information - Schedule of Reportable Business Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>996081 - Disclosure - Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable0</Role>
      <ShortName>Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>996082 - Disclosure - Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Geographic Areas) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable0</Role>
      <ShortName>Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Geographic Areas) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>996083 - Disclosure - Commitments and Contingencies - Schedule of Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofLeaseTable0</Role>
      <ShortName>Commitments and Contingencies - Schedule of Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="ea0245032-s4a1_avalon.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>996084 - Disclosure - Commitments and Contingencies - Schedule of Maturity of Lease Liabilities Under Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0</Role>
      <ShortName>Commitments and Contingencies - Schedule of Maturity of Lease Liabilities Under Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>avco-20250331.xsd</File>
    <File>avco-20250331_cal.xml</File>
    <File>avco-20250331_def.xml</File>
    <File>avco-20250331_lab.xml</File>
    <File>avco-20250331_pre.xml</File>
    <File doctype="S-4/A" isDefinitelyFs="true" isUsgaap="true" original="ea0245032-s4a1_avalon.htm">ea0245032-s4a1_avalon.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>fin_001.jpg</File>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="2515">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="9">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>264
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0245032-s4a1_avalon.htm": {
   "nsprefix": "avco",
   "nsuri": "http://www.avalonglobocare.com/20250331",
   "dts": {
    "schema": {
     "local": [
      "avco-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "avco-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "avco-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "avco-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avco-20250331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0245032-s4a1_avalon.htm"
     ]
    }
   },
   "keyStandard": 443,
   "keyCustom": 92,
   "axisStandard": 46,
   "axisCustom": 0,
   "memberStandard": 45,
   "memberCustom": 104,
   "hidden": {
    "total": 414,
    "http://fasb.org/us-gaap/2025": 340,
    "http://www.avalonglobocare.com/20250331": 71,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 775,
   "entityCount": 1,
   "segmentCount": 187,
   "elementCount": 920,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 2515,
    "http://xbrl.sec.gov/dei/2025": 9,
    "http://fasb.org/srt/2025": 3
   },
   "report": {
    "R1": {
     "role": "http://www.avalonglobocare.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement",
     "longName": "003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c20",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20",
      "name": "us-gaap:MarketingAndAdvertisingExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
     "longName": "004 - Statement - Condensed Consolidated Statements of Changes in (Deficit) Equity",
     "shortName": "Condensed Consolidated Statements of Changes in (Deficit) Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c22",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c22",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable_Parentheticals",
     "longName": "005 - Statement - Condensed Consolidated Statements of Changes in (Deficit) Equity (Parentheticals)",
     "shortName": "Condensed Consolidated Statements of Changes in (Deficit) Equity (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.avalonglobocare.com/role/ConsolidatedCashFlow",
     "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.avalonglobocare.com/role/OrganizationandNatureofOperations",
     "longName": "007 - Disclosure - Organization and Nature of Operations",
     "shortName": "Organization and Nature of Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernCondition",
     "longName": "008 - Disclosure - Basis of Presentation and Going Concern Condition",
     "shortName": "Basis of Presentation and Going Concern Condition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "009 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.avalonglobocare.com/role/PrepaidExpenseandOtherCurrentAssets",
     "longName": "010 - Disclosure - Prepaid Expense and Other Current Assets",
     "shortName": "Prepaid Expense and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.avalonglobocare.com/role/PropertyandEquipment",
     "longName": "011 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.avalonglobocare.com/role/EquipmentHeldForSale",
     "longName": "012 - Disclosure - Equipment Held For Sale",
     "shortName": "Equipment Held For Sale",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.avalonglobocare.com/role/InvestmentinRealEstate",
     "longName": "013 - Disclosure - Investment in Real Estate",
     "shortName": "Investment in Real Estate",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:RealEstateDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:RealEstateDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.avalonglobocare.com/role/EquityMethodInvestments",
     "longName": "014 - Disclosure - Equity Method Investments",
     "shortName": "Equity Method Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayables",
     "longName": "015 - Disclosure - Accrued Liabilities and Other Payables",
     "shortName": "Accrued Liabilities and Other Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.avalonglobocare.com/role/ConvertibleNotePayable",
     "longName": "016 - Disclosure - Convertible Note Payable",
     "shortName": "Convertible Note Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.avalonglobocare.com/role/DerivativeLiability",
     "longName": "017 - Disclosure - Derivative Liability",
     "shortName": "Derivative Liability",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.avalonglobocare.com/role/NotePayableNet",
     "longName": "018 - Disclosure - Note Payable, Net",
     "shortName": "Note Payable, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.avalonglobocare.com/role/RelatedPartyTransactions",
     "longName": "019 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.avalonglobocare.com/role/IncomeTaxes",
     "longName": "020 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.avalonglobocare.com/role/Equity",
     "longName": "021 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssets",
     "longName": "022 - Disclosure - Statutory Reserve and Restricted Net Assets",
     "shortName": "Statutory Reserve and Restricted Net Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "avco:StatutoryReserveAndRestrictedNetAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "avco:StatutoryReserveAndRestrictedNetAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.avalonglobocare.com/role/NoncontrollingInterest",
     "longName": "023 - Disclosure - Noncontrolling Interest",
     "shortName": "Noncontrolling Interest",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompany",
     "longName": "024 - Disclosure - Condensed Financial Information of the Parent Company",
     "shortName": "Condensed Financial Information of the Parent Company",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.avalonglobocare.com/role/Concentrations",
     "longName": "025 - Disclosure - Concentrations",
     "shortName": "Concentrations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.avalonglobocare.com/role/SegmentInformation",
     "longName": "026 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.avalonglobocare.com/role/CommitmentsandContingencies",
     "longName": "027 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.avalonglobocare.com/role/SubsequentEvents",
     "longName": "028 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsTables",
     "longName": "996001 - Disclosure - Organization and Nature of Operations (Tables)",
     "shortName": "Organization and Nature of Operations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996002 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.avalonglobocare.com/role/PrepaidExpenseandOtherCurrentAssetsTables",
     "longName": "996003 - Disclosure - Prepaid Expense and Other Current Assets (Tables)",
     "shortName": "Prepaid Expense and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.avalonglobocare.com/role/PropertyandEquipmentTables",
     "longName": "996004 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.avalonglobocare.com/role/InvestmentinRealEstateTables",
     "longName": "996005 - Disclosure - Investment in Real Estate (Tables)",
     "shortName": "Investment in Real Estate (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RealEstateDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RealEstateDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.avalonglobocare.com/role/EquityMethodInvestmentsTables",
     "longName": "996006 - Disclosure - Equity Method Investments (Tables)",
     "shortName": "Equity Method Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayablesTables",
     "longName": "996007 - Disclosure - Accrued Liabilities and Other Payables (Tables)",
     "shortName": "Accrued Liabilities and Other Payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.avalonglobocare.com/role/ConvertibleNotePayableTables",
     "longName": "996008 - Disclosure - Convertible Note Payable (Tables)",
     "shortName": "Convertible Note Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.avalonglobocare.com/role/NotePayableNetTables",
     "longName": "996009 - Disclosure - Note Payable, Net (Tables)",
     "shortName": "Note Payable, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.avalonglobocare.com/role/RelatedPartyTransactionsTables",
     "longName": "996010 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.avalonglobocare.com/role/IncomeTaxesTables",
     "longName": "996011 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.avalonglobocare.com/role/EquityTables",
     "longName": "996012 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.avalonglobocare.com/role/ConcentrationsTables",
     "longName": "996013 - Disclosure - Concentrations (Tables)",
     "shortName": "Concentrations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.avalonglobocare.com/role/SegmentInformationTables",
     "longName": "996014 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables",
     "longName": "996015 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails",
     "longName": "996016 - Disclosure - Organization and Nature of Operations (Details)",
     "shortName": "Organization and Nature of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c111",
      "name": "us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c565",
      "name": "us-gaap:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable",
     "longName": "996017 - Disclosure - Organization and Nature of Operations - Schedule of Consolidated Financial Statements (Details)",
     "shortName": "Organization and Nature of Operations - Schedule of Consolidated Financial Statements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c570",
      "name": "avco:EquityMethodInvestmentPlaceAndDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R48": {
     "role": "http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails",
     "longName": "996018 - Disclosure - Basis of Presentation and Going Concern Condition (Details)",
     "shortName": "Basis of Presentation and Going Concern Condition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "avco:WorkingCapitalDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c11",
      "name": "avco:WorkingCapitalDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996019 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c19",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable",
     "longName": "996020 - Disclosure - Summary of Significant Accounting Policies - Schedule of Derivative Liability Measured at Fair Value (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Derivative Liability Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c151",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c150",
      "name": "avco:InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable",
     "longName": "996021 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash Balances by Geographic Area (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Cash Balances by Geographic Area (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R52": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable",
     "longName": "996022 - Disclosure - Summary of Significant Accounting Policies - Schedule of Securities that were Excluded from the Diluted Per Share (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Securities that were Excluded from the Diluted Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R53": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable",
     "longName": "996023 - Disclosure - Prepaid Expense and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)",
     "shortName": "Prepaid Expense and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "avco:PrepaidProfessionalFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://www.avalonglobocare.com/role/PropertyandEquipmentDetails",
     "longName": "996024 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:PropertyPlantAndEquipmentOtherAccumulatedDepreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable",
     "longName": "996025 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.avalonglobocare.com/role/EquipmentHeldForSaleDetails",
     "longName": "996026 - Disclosure - Equipment Held For Sale (Details)",
     "shortName": "Equipment Held For Sale (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "avco:ImpairmentOfLaboratoryEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R57": {
     "role": "http://www.avalonglobocare.com/role/InvestmentinRealEstateDetails",
     "longName": "996027 - Disclosure - Investment in Real Estate (Details)",
     "shortName": "Investment in Real Estate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RealEstateDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RealEstateDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofInvestmentinRealEstateTable",
     "longName": "996028 - Disclosure - Investment in Real Estate - Schedule of Investment in Real Estate (Details)",
     "shortName": "Investment in Real Estate - Schedule of Investment in Real Estate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:RealEstateInvestmentPropertyAtCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock",
       "us-gaap:RealEstateDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:RealEstateInvestmentPropertyAtCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock",
       "us-gaap:RealEstateDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
     "longName": "996029 - Disclosure - Equity Method Investments (Details)",
     "shortName": "Equity Method Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:EquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EquityMethodInvestmentSoldCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable",
     "longName": "996030 - Disclosure - Equity Method Investments - Schedule of Equity Method Investment (Details)",
     "shortName": "Equity Method Investments - Schedule of Equity Method Investment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c195",
      "name": "us-gaap:EquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c192",
      "name": "us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable",
     "longName": "996031 - Disclosure - Equity Method Investments - Schedule of Summarized Financial Information, as Provided to the Company by the Investee (Details)",
     "shortName": "Equity Method Investments - Schedule of Summarized Financial Information, as Provided to the Company by the Investee (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c196",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c196",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable",
     "longName": "996032 - Disclosure - Equity Method Investments - Schedule of Financial Information (Details)",
     "shortName": "Equity Method Investments - Schedule of Financial Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c614",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R63": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable",
     "longName": "996033 - Disclosure - Accrued Liabilities and Other Payables - Schedule of Accrued Liabilities and Other Payables (Details)",
     "shortName": "Accrued Liabilities and Other Payables - Schedule of Accrued Liabilities and Other Payables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "avco:AccruedTenantsImprovementReimbursement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "avco:AccruedTenantsImprovementReimbursement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
     "longName": "996034 - Disclosure - Convertible Note Payable (Details)",
     "shortName": "Convertible Note Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c207",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c264",
      "name": "us-gaap:CommonUnitOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable",
     "longName": "996035 - Disclosure - Convertible Note Payable - Schedule of Amortization Payments in Cash (Details)",
     "shortName": "Convertible Note Payable - Schedule of Amortization Payments in Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c631",
      "name": "us-gaap:DebtInstrumentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R66": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable",
     "longName": "996036 - Disclosure - Convertible Note Payable - Schedule of Convertible Note Payable (Details)",
     "shortName": "Convertible Note Payable - Schedule of Convertible Note Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c638",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R67": {
     "role": "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails",
     "longName": "996037 - Disclosure - Derivative Liability (Details)",
     "shortName": "Derivative Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c264",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c342",
      "name": "avco:WarrantsOfCashlessExercised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.avalonglobocare.com/role/NotePayableNetDetails",
     "longName": "996038 - Disclosure - Note Payable, Net (Details)",
     "shortName": "Note Payable, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c369",
      "name": "us-gaap:LongTermDebtPercentageBearingVariableInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofNotePayableTable",
     "longName": "996039 - Disclosure - Note Payable, Net - Schedule of Note Payable (Details)",
     "shortName": "Note Payable, Net - Schedule of Note Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:OtherNotesPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
     "longName": "996040 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherGeneralExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherGeneralExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofLineofCreditTable",
     "longName": "996041 - Disclosure - Related Party Transactions - Schedule of Line of Credit (Details)",
     "shortName": "Related Party Transactions - Schedule of Line of Credit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "avco:DrawDownFromLineOfCredit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "avco:DrawDownFromLineOfCredit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.avalonglobocare.com/role/IncomeTaxesDetails",
     "longName": "996042 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofCompanysLossBeforeIncomeTaxesTable",
     "longName": "996043 - Disclosure - Income Taxes - Schedule of Company\u2019s Loss Before Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Company\u2019s Loss Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable",
     "longName": "996044 - Disclosure - Income Taxes - Schedule of Components of Income Taxes Expense (Benefit) (Details)",
     "shortName": "Income Taxes - Schedule of Components of Income Taxes Expense (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable",
     "longName": "996045 - Disclosure - Income Taxes - Schedule of U.S. Statutory Rate and the Company\u2019s Effective Tax Rate (Details)",
     "shortName": "Income Taxes - Schedule of U.S. Statutory Rate and the Company\u2019s Effective Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable",
     "longName": "996046 - Disclosure - Income Taxes - Schedule of Deferred Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.avalonglobocare.com/role/EquityDetails",
     "longName": "996047 - Disclosure - Equity (Details)",
     "shortName": "Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "avco:PercentageOfCommonStockIssuedAndOutstanding",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable",
     "longName": "996048 - Disclosure - Equity - Schedule of Common Stock Issuable Upon Exercise of Warrants Outstanding (Details)",
     "shortName": "Equity - Schedule of Common Stock Issuable Upon Exercise of Warrants Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c471",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c471",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable",
     "longName": "996049 - Disclosure - Equity - Schedule of Stock Option Activity (Details)",
     "shortName": "Equity - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c483",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c482",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable",
     "longName": "996050 - Disclosure - Equity - Schedule of Nonvested Stock Options Granted (Details)",
     "shortName": "Equity - Schedule of Nonvested Stock Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c738",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c497",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable",
     "longName": "996051 - Disclosure - Equity - Schedule of Common Stock Issuable Upon Exercise of Options Outstanding (Details)",
     "shortName": "Equity - Schedule of Common Stock Issuable Upon Exercise of Options Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c742",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R82": {
     "role": "http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssetsDetails",
     "longName": "996052 - Disclosure - Statutory Reserve and Restricted Net Assets (Details)",
     "shortName": "Statutory Reserve and Restricted Net Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "avco:StatutoryReservePercent",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "avco:StatutoryReserveAndRestrictedNetAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "avco:StatutoryReservePercent",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "avco:StatutoryReserveAndRestrictedNetAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.avalonglobocare.com/role/NoncontrollingInterestDetails",
     "longName": "996053 - Disclosure - Noncontrolling Interest (Details)",
     "shortName": "Noncontrolling Interest (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c507",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c507",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompanyDetails",
     "longName": "996054 - Disclosure - Condensed Financial Information of the Parent Company (Details)",
     "shortName": "Condensed Financial Information of the Parent Company (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "avco:RestrictedNetAssetsOfSubsidiaryExceedNetAssets",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c11",
      "name": "avco:RestrictedNetAssetsOfSubsidiaryExceedNetAssets",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.avalonglobocare.com/role/ConcentrationsDetails",
     "longName": "996055 - Disclosure - Concentrations (Details)",
     "shortName": "Concentrations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c515",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c515",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable",
     "longName": "996056 - Disclosure - Concentrations - Schedule of Customer Accounted for Company's Revenues (Details)",
     "shortName": "Concentrations - Schedule of Customer Accounted for Company's Revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c752",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R87": {
     "role": "http://www.avalonglobocare.com/role/SegmentInformationDetails",
     "longName": "996057 - Disclosure - Segment Information (Details)",
     "shortName": "Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segments",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segments",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable",
     "longName": "996058 - Disclosure - Segment Information - Schedule of Reportable Business Segments (Details)",
     "shortName": "Segment Information - Schedule of Reportable Business Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c20",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c523",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable",
     "longName": "996059 - Disclosure - Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Details)",
     "shortName": "Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R90": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable",
     "longName": "996060 - Disclosure - Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Geographic Areas) (Details)",
     "shortName": "Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Geographic Areas) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R91": {
     "role": "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails",
     "longName": "996061 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c534",
      "name": "us-gaap:LoansPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofLeaseTable",
     "longName": "996062 - Disclosure - Commitments and Contingencies - Schedule of Lease (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c19",
      "name": "avco:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable",
     "longName": "996063 - Disclosure - Commitments and Contingencies - Schedule of Maturity of Lease Liabilities Under Operating Lease (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Maturity of Lease Liabilities Under Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R94": {
     "role": "http://www.avalonglobocare.com/role/SubsequentEventsDetails",
     "longName": "996064 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "avco:ExchangeRatioPerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0",
     "longName": "996065 - Disclosure - Organization and Nature of Operations - Schedule of Consolidated Financial Statements (Details)",
     "shortName": "Organization and Nature of Operations - Schedule of Consolidated Financial Statements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c570",
      "name": "avco:EquityMethodInvestmentPlaceAndDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R96": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable0",
     "longName": "996066 - Disclosure - Summary of Significant Accounting Policies - Schedule of Derivative Liability Measured at Fair Value (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Derivative Liability Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c151",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R97": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable0",
     "longName": "996067 - Disclosure - Summary of Significant Accounting Policies - Schedule of Cash Balances by Geographic Area (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Cash Balances by Geographic Area (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R98": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0",
     "longName": "996068 - Disclosure - Summary of Significant Accounting Policies - Schedule of Securities that were Excluded from the Diluted Per Share (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Securities that were Excluded from the Diluted Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c599",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0",
     "longName": "996069 - Disclosure - Prepaid Expense and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)",
     "shortName": "Prepaid Expense and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "avco:PrepaidProfessionalFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:PrepaidExpenseOtherNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable0",
     "longName": "996070 - Disclosure - Equity Method Investments - Schedule of Equity Method Investment (Details)",
     "shortName": "Equity Method Investments - Schedule of Equity Method Investment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c195",
      "name": "us-gaap:EquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R101": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable0",
     "longName": "996071 - Disclosure - Equity Method Investments - Schedule of Financial Information (Details)",
     "shortName": "Equity Method Investments - Schedule of Financial Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c614",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R102": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0",
     "longName": "996072 - Disclosure - Convertible Note Payable - Schedule of Amortization Payments in Cash (Details)",
     "shortName": "Convertible Note Payable - Schedule of Amortization Payments in Cash (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c631",
      "name": "us-gaap:DebtInstrumentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R103": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0",
     "longName": "996073 - Disclosure - Convertible Note Payable - Schedule of Convertible Note Payable (Details)",
     "shortName": "Convertible Note Payable - Schedule of Convertible Note Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c638",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R104": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofNotePayableTable0",
     "longName": "996074 - Disclosure - Note Payable, Net - Schedule of Note Payable (Details)",
     "shortName": "Note Payable, Net - Schedule of Note Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R105": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0",
     "longName": "996075 - Disclosure - Equity - Schedule of Common Stock Issuable Upon Exercise of Options Outstanding (Details)",
     "shortName": "Equity - Schedule of Common Stock Issuable Upon Exercise of Options Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c726",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c726",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true,
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0",
     "longName": "996076 - Disclosure - Equity - Schedule of Stock Option Activity (Details)",
     "shortName": "Equity - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c735",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R107": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0",
     "longName": "996077 - Disclosure - Equity - Schedule of Nonvested Stock Options Granted (Details)",
     "shortName": "Equity - Schedule of Nonvested Stock Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R108": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1",
     "longName": "996078 - Disclosure - Equity - Schedule of Common Stock Issuable Upon Exercise of Options Outstanding (Details)",
     "shortName": "Equity - Schedule of Common Stock Issuable Upon Exercise of Options Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "c742",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R109": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable0",
     "longName": "996079 - Disclosure - Concentrations - Schedule of Customer Accounted for Company's Revenues (Details)",
     "shortName": "Concentrations - Schedule of Customer Accounted for Company's Revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "c752",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R110": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0",
     "longName": "996080 - Disclosure - Segment Information - Schedule of Reportable Business Segments (Details)",
     "shortName": "Segment Information - Schedule of Reportable Business Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "c20",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c759",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    },
    "R111": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable0",
     "longName": "996081 - Disclosure - Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Details)",
     "shortName": "Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "111",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R112": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable0",
     "longName": "996082 - Disclosure - Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Geographic Areas) (Details)",
     "shortName": "Segment Information - Schedule of Identifiable Long-Lived Tangible Assets (Geographic Areas) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "112",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R113": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofLeaseTable0",
     "longName": "996083 - Disclosure - Commitments and Contingencies - Schedule of Lease (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "113",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R114": {
     "role": "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0",
     "longName": "996084 - Disclosure - Commitments and Contingencies - Schedule of Maturity of Lease Liabilities Under Operating Lease (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Maturity of Lease Liabilities Under Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "114",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c11",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0245032-s4a1_avalon.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "avco_AbandonmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AbandonmentAgreementMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Abandonment Agreement [Member]",
        "label": "Abandonment Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent receivable",
        "label": "Accounts and Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Accounts Payable and Accrued Liabilities",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCRUED LIABILITIES AND OTHER PAYABLES",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r73",
      "r78",
      "r1493"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities and other payables",
        "label": "Accounts Payable and Other Accrued Liabilities",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities and other payables",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent Receivable [Member]",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r1135",
      "r1408"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r1046",
      "r1134",
      "r1280",
      "r1570",
      "r1571"
     ]
    },
    "avco_AccruedAndUnpaidServicesCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AccruedAndUnpaidServicesCharge",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued and unpaid services charge",
        "documentation": "Represents the amount of accrued and unpaid services charge.",
        "label": "Accrued And Unpaid Services Charge"
       }
      }
     },
     "auth_ref": []
    },
    "avco_AccruedBusinessExpenseReimbursement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AccruedBusinessExpenseReimbursement",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued business expense reimbursement",
        "documentation": "Accrued business expense reimbursement.",
        "label": "Accrued Business Expense Reimbursement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities and Other Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_AccruedLiabilitiesAndOtherPayablesRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AccruedLiabilitiesAndOtherPayablesRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued liabilities and other payables - related parties",
        "documentation": "The amount of accrued liabilities and other payables - related parties.",
        "label": "Accrued Liabilities And Other Payables Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedPayrollTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll liability and compensation",
        "label": "Accrued Payroll Taxes, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "avco_AccruedPurchasePriceRelatedToEquityMethodInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AccruedPurchasePriceRelatedToEquityMethodInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued purchase price related to equity method investment",
        "documentation": "Amount of accrued purchase price related to equity method investment.",
        "label": "Accrued Purchase Price Related To Equity Method Investment"
       }
      }
     },
     "auth_ref": []
    },
    "avco_AccruedRealPropertyCleaningServiceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AccruedRealPropertyCleaningServiceFee",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued real property cleaning service fee",
        "documentation": "Accrued real property cleaning service fee.",
        "label": "Accrued Real Property Cleaning Service Fee"
       }
      }
     },
     "auth_ref": []
    },
    "avco_AccruedResearchAndDevelopmentsFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AccruedResearchAndDevelopmentsFees",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development fees",
        "documentation": "Amount of accrued research and development fees.",
        "label": "Accrued Research And Developments Fees"
       }
      }
     },
     "auth_ref": []
    },
    "avco_AccruedTenantsImprovementReimbursement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AccruedTenantsImprovementReimbursement",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued tenants\u2019 improvement reimbursement",
        "documentation": "Accrued tenants\u2019 improvement reimbursement.",
        "label": "Accrued Tenants Improvement Reimbursement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedUtilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedUtilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued utilities",
        "label": "Accrued Utilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for utilities, such as electrical power, heating oil, natural gas, and water. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r220",
      "r929"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r90",
      "r227",
      "r922",
      "r974",
      "r978",
      "r1521"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss (Deficit)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r15",
      "r22",
      "r741",
      "r744",
      "r819",
      "r969",
      "r970",
      "r1335",
      "r1336",
      "r1337",
      "r1398",
      "r1399",
      "r1400",
      "r1403"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r1247",
      "r1605"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1398",
      "r1399",
      "r1400",
      "r1403",
      "r1522",
      "r1611"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1457",
      "r1462"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of pre-funded warrants",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r46",
      "r120"
     ]
    },
    "avco_AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AdvanceFromPendingSaleOfNoncontrollingInterestRelatedParty",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advance from pending sale of noncontrolling interest - related party",
        "verboseLabel": "Advance from pending sale of noncontrolling interest",
        "documentation": "Advance from pending sale of noncontrolling interest - related party.",
        "label": "Advance From Pending Sale Of Noncontrolling Interest Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising and Marketing Costs",
        "label": "Advertising Cost [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "avco_AggregateOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AggregateOfCommonStock",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate of common stock (in Shares)",
        "documentation": "The shares of aggregate of common stock.",
        "label": "Aggregate Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r565",
      "r574"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.avalonglobocare.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Description",
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.avalonglobocare.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r100",
      "r487",
      "r1546"
     ]
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/NotePayableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "verboseLabel": "Convertible debt issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r487",
      "r1387",
      "r1546"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense - amortization of debt discount and debt issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r1199",
      "r1200",
      "r1387",
      "r1546"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable",
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Intangible assets amortization amount",
        "terseLabel": "Intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r250",
      "r428",
      "r434",
      "r1155",
      "r1163",
      "r1164",
      "r1166",
      "r1168"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable",
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable",
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable",
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Summarizes the Securities that were Excluded from the Diluted Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable",
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "avco_AprilFiveTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AprilFiveTwoThousandTwentyFiveMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable",
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 5, 2025 [Member]",
        "label": "April Five Two Thousand Twenty Five Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ArbeleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ArbeleMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arbele Biotherapeutics [Member]",
        "label": "Arbele Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid acquisition consideration",
        "verboseLabel": "Consideration amount",
        "label": "Asset Acquisition, Consideration Transferred",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r1223",
      "r1512",
      "r1513",
      "r1514"
     ]
    },
    "avco_AssetAndLiabilityAccountsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AssetAndLiabilityAccountsMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset and liability Accounts [Member]",
        "label": "Asset And Liability Accounts Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow",
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of equity method investment - Epicon",
        "negatedLabel": "Impairment of equity method investment - Epicon",
        "verboseLabel": "Impairment of equity method investment",
        "netLabel": "Impairment loss",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r41",
      "r1257",
      "r1258"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r152",
      "r222",
      "r259",
      "r264",
      "r265",
      "r305",
      "r322",
      "r347",
      "r351",
      "r398",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r674",
      "r679",
      "r784",
      "r905",
      "r906",
      "r916",
      "r1051",
      "r1183",
      "r1184",
      "r1201",
      "r1247",
      "r1271",
      "r1273",
      "r1287",
      "r1445",
      "r1446",
      "r1556"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "terseLabel": "Current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r229",
      "r259",
      "r264",
      "r265",
      "r398",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r674",
      "r679",
      "r784",
      "r1247",
      "r1445",
      "r1446",
      "r1556"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Non-current Assets",
        "terseLabel": "Noncurrent assets",
        "verboseLabel": "Non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r264",
      "r265",
      "r398",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r674",
      "r679",
      "r784",
      "r1445",
      "r1446",
      "r1556"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT ASSETS:",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_AvactisAndArbeleBiotherapeuticsLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AvactisAndArbeleBiotherapeuticsLimitedMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Avactis and Arbele Biotherapeutics Limited [Member]",
        "label": "Avactis And Arbele Biotherapeutics Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_AvactisBiosciencesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AvactisBiosciencesIncMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Avactis Biosciences Inc. (\u201cAvactis\u201d) [Member]",
        "verboseLabel": "Avactis Biosciences Inc. [Member]",
        "label": "Avactis Biosciences Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_AvactisBiotherapeuticsLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AvactisBiotherapeuticsLimitedMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Avactis Biotherapeutics Limited [Member]",
        "label": "Avactis Biotherapeutics Limited Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_AvactisNanjingBiosciencesLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AvactisNanjingBiosciencesLtdMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Avactis Nanjing Biosciences Ltd. (\u201cAvactis Nanjing\u201d) [Member]",
        "verboseLabel": "Avactis Nanjing Biosciences Ltd. [Member]",
        "label": "Avactis Nanjing Biosciences Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_AvalonHealthcareSystemIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AvalonHealthcareSystemIncMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Avalon Healthcare System, Inc. (\u201cAHS\u201d) [Member]",
        "verboseLabel": "Avalon Healthcare System, Inc. [Member]",
        "label": "Avalon Healthcare System Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_AvalonLabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AvalonLabMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Avalon Lab [Member]",
        "label": "Avalon Lab Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_AvalonLaboratoryServicesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AvalonLaboratoryServicesIncMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Avalon Laboratory Services, Inc. (\u201cAvalon Lab\u201d) [Member]",
        "label": "Avalon Laboratory Services Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_AvalonRT9Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AvalonRT9Member",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Avalon RT 9 [Member]",
        "label": "Avalon RT9 Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_AvalonRT9PropertiesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AvalonRT9PropertiesLLCMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Avalon RT 9 Properties LLC (\u201cAvalon RT 9\u201d) [Member]",
        "verboseLabel": "Avalon RT 9 Properties, LLC [Member]",
        "label": "Avalon RT9 Properties LLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "avco_AvalonShangaiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AvalonShangaiMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Avalon Shangai [Member]",
        "label": "Avalon Shangai Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_AvalonShanghaiHealthcareTechnologyCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "AvalonShanghaiHealthcareTechnologyCoLtdMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Avalon (Shanghai) Healthcare Technology Co., Ltd. (\u201cAvalon Shanghai\u201d) [Member]",
        "label": "Avalon Shanghai Healthcare Technology Co Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable",
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1463",
      "r1464",
      "r1465",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473",
      "r1474",
      "r1475",
      "r1476",
      "r1477",
      "r1478",
      "r1479",
      "r1480",
      "r1481",
      "r1482",
      "r1483",
      "r1485",
      "r1486",
      "r1487",
      "r1488",
      "r1489"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityTables",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1",
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable",
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r534",
      "r535",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561"
     ]
    },
    "avco_BasisOfPresentationAndGoingConcernConditionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "BasisOfPresentationAndGoingConcernConditionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Going Concern Condition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_BasisofPresentationandGoingConcernConditionDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "BasisofPresentationandGoingConcernConditionDetailsLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Going Concern Condition [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_BasisofPresentationandGoingConcernConditionDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "BasisofPresentationandGoingConcernConditionDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Going Concern Condition (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_BeijingGenexosomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "BeijingGenexosomeMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beijing Genexosome [Member]",
        "verboseLabel": "Beijing GenExosome [Member]",
        "label": "Beijing Genexosome Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_BeneficialConversionFeatureRelatedToConvertibleNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "BeneficialConversionFeatureRelatedToConvertibleNotePayable",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of debt issuance costs and debt discount",
        "documentation": "The amount of beneficial conversion feature related to convertible note payable.",
        "label": "Beneficial Conversion Feature Related To Convertible Note Payable"
       }
      }
     },
     "auth_ref": []
    },
    "avco_BlackScholesValuationModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "BlackScholesValuationModelMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Black-Scholes Valuation Model [Member]",
        "label": "Black Scholes Valuation Model Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r982",
      "r1212",
      "r1213",
      "r1508",
      "r1510",
      "r1511"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r982",
      "r1212",
      "r1213",
      "r1508",
      "r1510",
      "r1511"
     ]
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition percentage",
        "label": "Business Combination, Voting Equity Interest Acquired, Percentage",
        "documentation": "Percentage of voting equity interest acquired in business combination."
       }
      }
     },
     "auth_ref": [
      "r619",
      "r1217",
      "r1218"
     ]
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquire percentage",
        "label": "Business Combination, Achieved in Stages, Preacquisition Equity Interest in Acquiree, Percentage",
        "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination."
       }
      }
     },
     "auth_ref": [
      "r1216",
      "r1217",
      "r1218",
      "r1222",
      "r1508",
      "r1509"
     ]
    },
    "avco_BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "BusinessCombinationStepAcquisitionsAdditionalAcquireePercentage",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional acquire percentage",
        "documentation": "Percentage of equity in the acquiree held by additional acquiree.",
        "label": "Business Combination Step Acquisitions Additional Acquiree Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernCondition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BASIS OF PRESENTATION AND GOING CONCERN CONDITION",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1314",
      "r1388"
     ]
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "CN",
     "presentation": [
      "http://www.avalonglobocare.com/role/IncomeTaxesDetails",
      "http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable",
      "http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable0",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable0",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China [Member]",
        "verboseLabel": "RMB [Member]",
        "netLabel": "CHINA",
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "verboseLabel": "Cash payment",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r919",
      "r1014",
      "r1044",
      "r1247",
      "r1271",
      "r1273",
      "r1287",
      "r1316"
     ]
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired cash payment",
        "label": "Cash Acquired from Acquisition",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable",
      "http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r218",
      "r1156"
     ]
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable",
      "http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash Balances by Geographic Area [Line items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "CASH - beginning of period",
        "periodEndLabel": "CASH - end of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r106",
      "r256"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET (DECREASE) INCREASE IN CASH",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r106"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exceed federally-insured limits",
        "label": "Cash, FDIC Insured Amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowInvestingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowInvestingActivitiesLesseeAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofLeaseTable",
      "http://www.avalonglobocare.com/role/ScheduleofLeaseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Cash Flow, Investing Activities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowsBetweenTransfereeAndTransferorServicingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowsBetweenTransfereeAndTransferorServicingFees",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash services",
        "label": "Cash Flows Between Transferor and Transferee, Servicing Fees",
        "documentation": "Cash Flows between a transferee and a transferor attributable to servicing fees related to a securitization, asset-backed financing arrangement, or similar transfer in which the transferor has continuing involvement with the transferred financial assets underlying the transaction (including, but not limited to, servicing, recourse, and restrictions on transferor's interests in the transferred financial assets)."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "avco_CashPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "CashPercentage",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable",
      "http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of Total cash",
        "documentation": "Percentage of cash.",
        "label": "Cash Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "avco_CertificatesOfEliminationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "CertificatesOfEliminationMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of Elimination [Member]",
        "label": "Certificates Of Elimination Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r224",
      "r225",
      "r226",
      "r259",
      "r265",
      "r294",
      "r295",
      "r298",
      "r300",
      "r307",
      "r308",
      "r398",
      "r456",
      "r458",
      "r459",
      "r460",
      "r463",
      "r464",
      "r496",
      "r497",
      "r499",
      "r500",
      "r502",
      "r505",
      "r507",
      "r508",
      "r511",
      "r512",
      "r514",
      "r784",
      "r991",
      "r992",
      "r993",
      "r994",
      "r1002",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1015",
      "r1036",
      "r1059",
      "r1082",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1289",
      "r1391",
      "r1393",
      "r1404"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r307",
      "r499",
      "r507",
      "r508",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r738",
      "r991",
      "r992",
      "r993",
      "r994",
      "r1202",
      "r1289",
      "r1389",
      "r1391"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1458"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails",
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price (in Dollars per share)",
        "verboseLabel": "Warrants exercise price (in Dollars per share)",
        "netLabel": "Exercise price (in Dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r268",
      "r515"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Issuable Upon Exercise of Options Outstanding [Line Items]",
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of warrants (in Shares)",
        "verboseLabel": "Warrants to purchase shares",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding (in Shares)",
        "verboseLabel": "Fair value warrants (in Shares)",
        "netLabel": "Warrants share (in Shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightReasonForIssuingToNonemployees",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant issued, description",
        "label": "Warrant or Right, Reason for Issuance, Description",
        "documentation": "Description of reason for issuing warrant or right."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightUnissued",
     "presentation": [
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value warrant amount (in Shares)",
        "label": "Class of Warrant or Right, Unissued",
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollateralAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollateralAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofInvestmentinRealEstateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collateral Held [Axis]",
        "documentation": "Information by category of collateral or no collateral, from lender's perspective."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r261",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1259",
      "r1260"
     ]
    },
    "us-gaap_CollateralDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollateralDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofInvestmentinRealEstateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collateral Held [Domain]",
        "documentation": "Category of collateral or no collateral, from lender's perspective."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r261",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1259",
      "r1260"
     ]
    },
    "us-gaap_CommercialRealEstateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommercialRealEstateMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofInvestmentinRealEstateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial real property building [Member]",
        "label": "Commercial Real Estate [Member]",
        "documentation": "Property that is solely used for business purposes."
       }
      }
     },
     "auth_ref": [
      "r1189",
      "r1191",
      "r1459",
      "r1460"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r135",
      "r918",
      "r1035"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r448",
      "r449",
      "r1136",
      "r1434",
      "r1439"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r1137"
     ]
    },
    "avco_CommitmentsandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "CommitmentsandContingenciesDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_CommonSharesIssuedForServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "CommonSharesIssuedForServicesMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Shares Issued for Services [Member]",
        "label": "Common Shares Issued For Services Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate shares (in Shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_CommonStockConvertibleConversionPriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockConvertibleConversionPriceDecrease",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price per share (in Dollars per share)",
        "verboseLabel": "Convertible per share (in Dollars per share)",
        "label": "Common Stock, Convertible, Conversion Price, Decrease",
        "documentation": "Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_CommonStockConvertibleConversionPriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockConvertibleConversionPriceIncrease",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, conversion price (in Dollars per share)",
        "verboseLabel": "Conversion price per share (in Dollars per share)",
        "label": "Common Stock, Convertible, Conversion Price, Increase",
        "documentation": "Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "avco_CommonStockIssuedAsConvertibleNotePayableCommitmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "CommonStockIssuedAsConvertibleNotePayableCommitmentFee",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued as convertible note payable commitment fee",
        "documentation": "Common stock issued as convertible note payable commitment fee.",
        "label": "Common Stock Issued As Convertible Note Payable Commitment Fee"
       }
      }
     },
     "auth_ref": []
    },
    "avco_CommonStockIssuedForAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "CommonStockIssuedForAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for accrued liabilities",
        "documentation": "The amount of common stock issued for accrued liabilities.",
        "label": "Common Stock Issued For Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1277",
      "r1278",
      "r1279",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1398",
      "r1399",
      "r1403",
      "r1522",
      "r1603",
      "r1611"
     ]
    },
    "avco_CommonStockOfAveragePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "CommonStockOfAveragePrice",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock of average price (in Dollars per share)",
        "documentation": "Per share in average price.",
        "label": "Common Stock Of Average Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Common stock, shares authorized (in Shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r1036"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Share issued (in Shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r83",
      "r1036",
      "r1057",
      "r1611",
      "r1612"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value; 100,000,000 shares authorized; 1,445,979 shares issued and 1,442,512 shares outstanding at December 31, 2024; 736,769 shares issued and 733,302 shares outstanding at December 31, 2023",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r497",
      "r504",
      "r921",
      "r1247"
     ]
    },
    "us-gaap_CommonUnitOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonUnitOutstanding",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares outstanding (in Shares)",
        "label": "Common Unit, Outstanding",
        "documentation": "Number of common units of ownership outstanding of a limited liability company (LLC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Taxes Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r233",
      "r235",
      "r243",
      "r903",
      "r938",
      "r940"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMPREHENSIVE LOSS:",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "LESS: COMPREHENSIVE LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r60",
      "r63",
      "r233",
      "r235",
      "r242",
      "r902",
      "r938",
      "r939"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMPREHENSIVE LOSS",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r126",
      "r233",
      "r235",
      "r241",
      "r901",
      "r938"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConcentrationsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable",
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r359",
      "r983",
      "r984",
      "r1135",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConcentrationsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable",
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r359",
      "r983",
      "r984",
      "r1135",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Risk and Uncertainties",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r780"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/Concentrations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONCENTRATIONS",
        "label": "Concentration Risk Disclosure [Text Block]",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r314",
      "r776",
      "r778",
      "r779",
      "r781",
      "r782",
      "r1173",
      "r1406"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConcentrationsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable",
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Customer Revenues [Line Items]",
        "terseLabel": "Concentrations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313",
      "r1135",
      "r1171",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConcentrationsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable",
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer concentration percentage",
        "verboseLabel": "Concentration risk percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r359",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable",
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r313",
      "r1135",
      "r1171",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411"
     ]
    },
    "avco_ConcentrationsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ConcentrationsDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CondensedBalanceSheetStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CondensedBalanceSheetStatementTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Balance Sheet Statement [Table]",
        "documentation": "Disclosure of information about condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r260",
      "r271",
      "r909",
      "r1293"
     ]
    },
    "srt_CondensedBalanceSheetStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CondensedBalanceSheetStatementsCaptionsLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Summarized Financial Information, as Provided to the Company by the Investee [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r260",
      "r271",
      "r909",
      "r1293"
     ]
    },
    "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Information of the Parent Company [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompany"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY",
        "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]",
        "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r271",
      "r909",
      "r1293"
     ]
    },
    "avco_CondensedFinancialInformationoftheParentCompanyDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "CondensedFinancialInformationoftheParentCompanyDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Information of the Parent Company (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CondensedIncomeStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CondensedIncomeStatementTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable",
      "http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Income Statement [Table]",
        "documentation": "Disclosure of information about condensed income statement including, but not limited to, income statements of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r260",
      "r271",
      "r909",
      "r1293"
     ]
    },
    "srt_CondensedIncomeStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CondensedIncomeStatementsCaptionsLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable",
      "http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r260",
      "r271",
      "r909",
      "r1293"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompanyDetails",
      "http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable",
      "http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable0",
      "http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "documentation": "Information by consolidated entity or group of entities."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r195",
      "r260",
      "r271",
      "r674",
      "r675",
      "r678",
      "r679",
      "r680",
      "r828",
      "r909",
      "r1142",
      "r1310",
      "r1311",
      "r1312",
      "r1444",
      "r1447",
      "r1448"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "documentation": "Entity or group of entities consolidated into reporting entity."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r195",
      "r260",
      "r271",
      "r674",
      "r675",
      "r678",
      "r679",
      "r680",
      "r828",
      "r909",
      "r1142",
      "r1310",
      "r1311",
      "r1312",
      "r1444",
      "r1447",
      "r1448"
     ]
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Information of the Parent Company [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "avco_ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ConversionOfConvertibleNotePayableAndAccruedInterestIntoCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued as convertible notes payable commitment fee",
        "documentation": "Conversion of convertible note payable and accrued interest into common stock.",
        "label": "Conversion Of Convertible Note Payable And Accrued Interest Into Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockAmountIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for future services",
        "label": "Conversion of Stock, Amount Issued",
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration issuable shares (in Shares)",
        "label": "Conversion of Stock, Shares Issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "avco_ConversionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ConversionPricePercentage",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion percentage",
        "documentation": "It represent conversion price percentage.",
        "label": "Conversion Price Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ConversionShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ConversionShareMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion Share [Member]",
        "label": "Conversion Share Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Note [Member]",
        "verboseLabel": "Convertible Debt [Member]",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r466",
      "r467",
      "r477",
      "r478",
      "r479",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200"
     ]
    },
    "avco_ConvertibleDebtNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ConvertibleDebtNoteMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt Note [Member]",
        "label": "Convertible Debt Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Convertible Note Payable",
        "label": "Convertible Debt [Table Text Block]",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ConvertibleNotePayableDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ConvertibleNotePayableDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note Payable (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Convertible Note Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ConvertibleNotePayableScheduleofConvertibleNotePayableDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable",
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note Payable - Schedule of Convertible Note Payable (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes payable",
        "label": "Convertible Notes Payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r134",
      "r1569"
     ]
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 12.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable",
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Convertible note payable, net",
        "terseLabel": "Convertible note payable, net",
        "label": "Convertible Notes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable",
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0",
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable",
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes [Member]",
        "verboseLabel": "Convertible Notes Payable [Member]",
        "label": "Convertible Notes Payable [Member]",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r131"
     ]
    },
    "avco_CorporateOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "CorporateOtherMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable0",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate / Other [Member]",
        "verboseLabel": "Corporate/Other [Member]",
        "label": "Corporate Other Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r1443"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r1443"
     ]
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1301",
      "r1389",
      "r1395",
      "r1502"
     ]
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1301",
      "r1389",
      "r1395"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current income taxes expense",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r1389",
      "r1395"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. state and local",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1301",
      "r1389",
      "r1395",
      "r1502"
     ]
    },
    "avco_CustomerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "CustomerAMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable",
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer A [Member]",
        "label": "Customer AMember"
       }
      }
     },
     "auth_ref": []
    },
    "avco_CustomerBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "CustomerBMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable",
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer B [Member]",
        "label": "Customer BMember"
       }
      }
     },
     "auth_ref": []
    },
    "avco_CustomerCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "CustomerCMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable",
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer C [Member]",
        "label": "Customer CMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConcentrationsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable",
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk [Member]",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r1408"
     ]
    },
    "us-gaap_DebtConversionByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionByUniqueDescriptionAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable",
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion Description [Axis]",
        "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investment payable paid by a related party",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentRate",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price",
        "label": "Debt Conversion, Converted Instrument, Rate",
        "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase warrant (in Shares)",
        "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued",
        "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r33"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/NotePayableNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOTE PAYABLE, NET",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r259",
      "r262",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r454",
      "r455",
      "r465",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r481",
      "r488",
      "r489",
      "r491",
      "r738",
      "r802"
     ]
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/NotePayableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price payment",
        "verboseLabel": "Principal payment",
        "label": "Debt Instrument, Annual Principal Payment",
        "documentation": "Amount of annual principal payment for debt instrument."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/NotePayableNetDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r72",
      "r73",
      "r131",
      "r134",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1245",
      "r1389",
      "r1390",
      "r1392",
      "r1397",
      "r1435",
      "r1436",
      "r1437",
      "r1545",
      "r1547",
      "r1566"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock per share (in Dollars per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r468"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleConversionPriceDecrease",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price decrease (in Dollars per share)",
        "label": "Debt Instrument, Convertible, Conversion Price, Decrease",
        "documentation": "Per share decrease in conversion price of debt instrument. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r515"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleConversionPriceIncrease",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price increase (in Dollars per share)",
        "label": "Debt Instrument, Convertible, Conversion Price, Increase",
        "documentation": "Per share increase in conversion price of debt instrument. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r515"
     ]
    },
    "avco_DebtInstrumentConvertibleFloorPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "DebtInstrumentConvertibleFloorPrice",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Floor price (in Dollars per share)",
        "documentation": "Debt Instrument Convertible floor price.",
        "label": "Debt Instrument Convertible Floor Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of secured promissory notes",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentDescription",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable",
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization payments description",
        "label": "Debt Instrument, Description",
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r50",
      "r65",
      "r72",
      "r131",
      "r134",
      "r802"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable": {
       "parentTag": "us-gaap_ConvertibleNotesPayableCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofNotePayableTable": {
       "parentTag": "us-gaap_OtherNotesPayableCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0": {
       "parentTag": "us-gaap_ConvertibleNotesPayableCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofNotePayableTable0": {
       "parentTag": "us-gaap_NotesPayableCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/NotePayableNetDetails",
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable",
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0",
      "http://www.avalonglobocare.com/role/ScheduleofNotePayableTable",
      "http://www.avalonglobocare.com/role/ScheduleofNotePayableTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "verboseLabel": "Original issue discount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r802",
      "r803",
      "r1197",
      "r1198",
      "r1245"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fee amount",
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/NotePayableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Debt Instrument, Increase, Accrued Interest",
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r1389",
      "r1392"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://www.avalonglobocare.com/role/NotePayableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual rate",
        "label": "Debt Instrument, Interest Rate During Period",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r484",
      "r1545"
     ]
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentIssuedPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principal amount",
        "label": "Debt Instrument, Issued, Principal",
        "documentation": "Amount of principal of debt issued."
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/NotePayableNetDetails",
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable",
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Amortization Payments in Cash [Line Items]",
        "terseLabel": "Convertible Note Payable [Line Items]",
        "verboseLabel": "Note Payable, Net [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r490",
      "r738",
      "r909",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1245",
      "r1389",
      "r1390",
      "r1392",
      "r1397",
      "r1545",
      "r1547"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory note maturity date",
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r1196",
      "r1528",
      "r1529"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/NotePayableNetDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1245",
      "r1389",
      "r1390",
      "r1392",
      "r1397",
      "r1435",
      "r1436",
      "r1437",
      "r1545",
      "r1547",
      "r1566"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/NotePayableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest payment",
        "label": "Debt Instrument, Periodic Payment, Interest",
        "documentation": "Amount of the required periodic payments applied to interest."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable",
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r50",
      "r51",
      "r64",
      "r118",
      "r119",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r490",
      "r738",
      "r909",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1245",
      "r1389",
      "r1390",
      "r1392",
      "r1397",
      "r1545",
      "r1547"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r1450",
      "r1544",
      "r1545",
      "r1547"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscountCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable": {
       "parentTag": "us-gaap_ConvertibleNotesPayableCurrent",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0": {
       "parentTag": "us-gaap_ConvertibleNotesPayableCurrent",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable",
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: unamortized debt discount",
        "label": "Debt Instrument, Unamortized Discount, Current",
        "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1544",
      "r1545",
      "r1547"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofNotePayableTable": {
       "parentTag": "us-gaap_OtherNotesPayableCurrent",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofNotePayableTable0": {
       "parentTag": "us-gaap_NotesPayableCurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNotePayableTable",
      "http://www.avalonglobocare.com/role/ScheduleofNotePayableTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: unamortized debt issuance costs",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r492",
      "r801",
      "r802",
      "r803",
      "r1197",
      "r1198",
      "r1245"
     ]
    },
    "avco_DebtModificationCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "DebtModificationCharge",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt modification charge",
        "documentation": "Debt modification charge.",
        "label": "Debt Modification Charge"
       }
      }
     },
     "auth_ref": []
    },
    "avco_DebtModificationsAndExtinguishmentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "DebtModificationsAndExtinguishmentsPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Modifications and Extinguishments",
        "documentation": "Disclosure of accounting policy for debt modifications and extinguishments.",
        "label": "Debt Modifications And Extinguishments Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "avco_DecemberFiveTwoThousandTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "DecemberFiveTwoThousandTwentyFourMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable",
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 5, 2024 [Member]",
        "label": "December Five Two Thousand Twenty Four Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_DeemedContributionOnExchangeOfEquityInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "DeemedContributionOnExchangeOfEquityInstruments",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DEEMED CONTRIBUTION ON EXCHANGE OF EQUITY INSTRUMENTS",
        "documentation": "The amount of deemed contribution on exchange of equity instruments.",
        "label": "Deemed Contribution On Exchange Of Equity Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredAdvertisingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredAdvertisingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising and marketing costs",
        "label": "Deferred Advertising Costs",
        "documentation": "The costs of direct-response advertising whose primary purpose is to elicit sales to customers who could be shown to have responded specifically to the advertising and that results in probable future benefits and are reported as assets net of accumulated amortization."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r156",
      "r157"
     ]
    },
    "us-gaap_DeferredCostsLeasingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsLeasingNet",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable",
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred leasing costs",
        "label": "Deferred Costs, Leasing, Net",
        "documentation": "This element represents costs incurred by the lessor that are (a) costs to originate a lease incurred in transactions with independent third parties that (i) result directly from and are essential to acquire that lease and (ii) would not have been incurred had that leasing transaction not occurred and (b) certain costs directly related to specified activities performed by the lessor for that lease. Those activities are: evaluating the prospective lessee's financial condition; evaluating and recording guarantees, collateral, and other security arrangements; negotiating lease terms; preparing and processing lease documents; and closing the transaction. This element is net of accumulated amortization."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r1550"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1389",
      "r1395",
      "r1501",
      "r1502"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1450",
      "r1544",
      "r1545",
      "r1547"
     ]
    },
    "avco_DeferredFinancingCostsInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "DeferredFinancingCostsInAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred financing costs in accrued liabilities",
        "documentation": "Deferred financing costs in accrued liabilities.",
        "label": "Deferred Financing Costs In Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1389",
      "r1395",
      "r1501"
     ]
    },
    "us-gaap_DeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred rental income",
        "label": "Deferred Income",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r1294",
      "r1572",
      "r1600"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets, net",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r582"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred income taxes (benefit)",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r170",
      "r1389",
      "r1395"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred offering costs",
        "label": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1429"
     ]
    },
    "avco_DeferredOfferingCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "DeferredOfferingCostsMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Offering Costs [Member]",
        "label": "Deferred Offering Costs Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_DeferredOfferingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Offering Costs",
        "documentation": "Disclosure of accounting policy for deferred offering costs.",
        "label": "Deferred Offering Costs Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "avco_DeferredRentalIncomePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "DeferredRentalIncomePolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Rental Income",
        "documentation": "Disclosure of accounting policy for deferred rental income.",
        "label": "Deferred Rental Income Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. state and local",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1389",
      "r1395",
      "r1501",
      "r1502"
     ]
    },
    "us-gaap_DeferredTaxAssetInterestCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetInterestCarryforward",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disallowed business interest deduction",
        "label": "Deferred Tax Asset, Interest Carryforward",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward."
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital loss limitation",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets, gross",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1498"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign subsidiary",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. federal net operating loss carryovers",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal net operating loss",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "federal net operating loss",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "avco_DeferredTaxAssetsPartnershipInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "DeferredTaxAssetsPartnershipInvestment",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partnership Investment",
        "documentation": "The amount of partnership investment.",
        "label": "Deferred Tax Assets Partnership Investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued directors\u2019 compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued settlement",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1498"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOtherFiniteLivedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesOtherFiniteLivedAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fixed assets and intangible assets book/tax basis difference",
        "label": "Deferred Tax Liabilities, Other Finite-Lived Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from long-lived assets other than property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesRegulatoryAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesRegulatoryAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDeferredTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use assets",
        "label": "Deferred Tax Liabilities, Regulatory Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from regulatory assets."
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "us-gaap_DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilityNotRecognizedEventsThatWouldCauseTemporaryDifferenceToBeTaxableUndistributedEarningsOfForeignSubsidiaries",
     "presentation": [
      "http://www.avalonglobocare.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign entity tax disclosure",
        "label": "Deferred Tax Liability Not Recognized, Events that Would Cause Temporary Difference to be Taxable, Undistributed Earnings of Foreign Subsidiaries",
        "documentation": "Description of events that would cause the temporary difference for which a deferred tax liability has not been recognized, because of the exceptions to comprehensive recognition of deferred taxes related to undistributed earnings of foreign subsidiaries, to become taxable."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "us-gaap_Deposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Deposits",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tenants\u2019 security deposit",
        "label": "Deposits",
        "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r42",
      "r249",
      "r1163",
      "r1164",
      "r1166",
      "r1168"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r1024",
      "r1026",
      "r1041",
      "r1042",
      "r1043",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1106",
      "r1107",
      "r1110",
      "r1112",
      "r1158",
      "r1159",
      "r1162",
      "r1228",
      "r1229",
      "r1277",
      "r1279",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1517",
      "r1518",
      "r1519",
      "r1520",
      "r1530",
      "r1531",
      "r1532",
      "r1533",
      "r1534",
      "r1535",
      "r1537",
      "r1538"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r1024",
      "r1026",
      "r1041",
      "r1042",
      "r1043",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1106",
      "r1107",
      "r1110",
      "r1112",
      "r1158",
      "r1159",
      "r1162",
      "r1228",
      "r1229",
      "r1277",
      "r1279",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332",
      "r1333",
      "r1334",
      "r1517",
      "r1518",
      "r1519",
      "r1520",
      "r1530",
      "r1531",
      "r1532",
      "r1533",
      "r1534",
      "r1535",
      "r1537",
      "r1538"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/DerivativeLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DERIVATIVE LIABILITY",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r739",
      "r751",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability (in Dollars)",
        "label": "Derivative Liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r737",
      "r757",
      "r758",
      "r769",
      "r773",
      "r774",
      "r775",
      "r1016",
      "r1017",
      "r1018",
      "r1020",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1052",
      "r1054",
      "r1055",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1158",
      "r1160",
      "r1161",
      "r1162",
      "r1527",
      "r1528",
      "r1529",
      "r1604"
     ]
    },
    "us-gaap_DerivativeLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails",
      "http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable",
      "http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance of derivative liability beginning balance",
        "periodEndLabel": "Balance of derivative liability ending balance",
        "terseLabel": "Derivative liability",
        "verboseLabel": "Derivative liability (in Dollars)",
        "label": "Derivative Liability, Current",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "avco_DerivativeLiabilityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "DerivativeLiabilityDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativesFairValueLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r695",
      "r696",
      "r697",
      "r698",
      "r1229"
     ]
    },
    "us-gaap_DilutiveSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DilutiveSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive securities",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share",
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquipmentHeldForSale"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUIPMENT HELD FOR SALE",
        "label": "Disclosure of Long-Lived Assets Held-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "avco_DistributionOfEarningsFromEquityMethodInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "DistributionOfEarningsFromEquityMethodInvestment",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Distribution of earnings from equity method investment",
        "documentation": "Distribution of earnings from equity method investment.",
        "label": "Distribution Of Earnings From Equity Method Investment"
       }
      }
     },
     "auth_ref": []
    },
    "avco_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.avalonglobocare.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "avco_DrYuZhouMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "DrYuZhouMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/NoncontrollingInterestDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dr. Yu Zhou [Member]",
        "verboseLabel": "Dr Yu Zhou [Member]",
        "label": "Dr Yu Zhou Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_DrZhouMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "DrZhouMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dr. Zhou [Member]",
        "label": "Dr Zhou Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_DrawDownFromLineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "DrawDownFromLineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofLineofCreditTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Draw down from Line of Credit",
        "documentation": "Draw Down From Line Of Credit.",
        "label": "Draw Down From Line Of Credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DueFromCorrespondentBrokers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DueFromCorrespondentBrokers",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable",
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due from broker",
        "label": "Due from Correspondent Brokers",
        "documentation": "Amount receivable from correspondent broker-dealer."
       }
      }
     },
     "auth_ref": [
      "r1565"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Common Share Attributable Common Shareholders Basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r244",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r286",
      "r291",
      "r294",
      "r298",
      "r299",
      "r300",
      "r303",
      "r495",
      "r564",
      "r615",
      "r671",
      "r754",
      "r755",
      "r904",
      "r941",
      "r1170"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Common Share Attributable Common Shareholders Diluted (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r244",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r286",
      "r294",
      "r298",
      "r299",
      "r300",
      "r303",
      "r495",
      "r564",
      "r615",
      "r671",
      "r754",
      "r755",
      "r904",
      "r941",
      "r1170"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per Share Data",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r302"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EFFECT OF EXCHANGE RATE ON CASH",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total provision for income taxes",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r1215"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of U.S. Statutory Rate and the Company\u2019s Effective Tax Rate [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. federal rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r267",
      "r585",
      "r605",
      "r1215"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r1215",
      "r1389",
      "r1396",
      "r1495"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfBusiness",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent difference",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r1389",
      "r1396",
      "r1495",
      "r1496"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-US rate differential",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r588",
      "r1215",
      "r1389",
      "r1396",
      "r1495"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r586",
      "r1215"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "True ups",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense."
       }
      }
     },
     "auth_ref": [
      "r1389",
      "r1396",
      "r1495",
      "r1496"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofUSStatutoryRateandtheCompanysEffectiveTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. state rate",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1492",
      "r1495",
      "r1496"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "presentation": [
      "http://www.avalonglobocare.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits."
       }
      }
     },
     "auth_ref": [
      "r1215",
      "r1389",
      "r1396",
      "r1495",
      "r1497"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation and related benefits",
        "label": "Employee Benefits and Share-Based Compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1338"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.avalonglobocare.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1288"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.avalonglobocare.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1288"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.avalonglobocare.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1288"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.avalonglobocare.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.avalonglobocare.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1288"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.avalonglobocare.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1288"
     ]
    },
    "avco_EpiconBiotechCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "EpiconBiotechCoLtdMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Epicon Biotech Co., Ltd [Member]",
        "verboseLabel": "Epicon Biotech Co. Ltd [Member]",
        "label": "Epicon Biotech Co Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "EQUITY:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r209",
      "r211",
      "r212",
      "r237",
      "r238",
      "r239",
      "r272",
      "r273",
      "r274",
      "r276",
      "r284",
      "r287",
      "r289",
      "r306",
      "r400",
      "r403",
      "r436",
      "r494",
      "r517",
      "r564",
      "r603",
      "r604",
      "r612",
      "r613",
      "r614",
      "r616",
      "r670",
      "r671",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r753",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r798",
      "r804",
      "r806",
      "r819",
      "r936",
      "r969",
      "r970",
      "r971",
      "r1002",
      "r1082"
     ]
    },
    "avco_EquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "EquityDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_EquityInterestPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "EquityInterestPercent",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest percent",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Interest Percent"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/SegmentInformationDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r397",
      "r611",
      "r784",
      "r1290",
      "r1291",
      "r1292",
      "r1503",
      "r1504",
      "r1505",
      "r1506"
     ]
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentAggregateCost",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate offering price amount",
        "label": "Equity Method Investment, Aggregate Cost",
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "avco_EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountIdentifiableIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Company\u2019s interest in the net excess of Lab Services MSO\u2019s fair value over net assets which was attributable to goodwill at February 9, 2023",
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in good wi.",
        "label": "Equity Method Investment Difference Between Carrying Amount Identifiable Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption aggregate cash amount",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r12",
      "r93",
      "r931"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/SegmentInformationDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest percent",
        "verboseLabel": "Ownership percentage",
        "netLabel": "Equity interest rate",
        "label": "Equity interest, percentage",
        "totalLabel": "Percentage of equity",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r784"
     ]
    },
    "avco_EquityMethodInvestmentPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "EquityMethodInvestmentPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investment payable",
        "documentation": "The amount of equity method investment payable.",
        "label": "Equity Method Investment Payable Current"
       }
      }
     },
     "auth_ref": []
    },
    "avco_EquityMethodInvestmentPlaceAndDateOfIncorporation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "EquityMethodInvestmentPlaceAndDateOfIncorporation",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Place and Date of Incorporation",
        "documentation": "The equity method investment place and date of incorporation.",
        "label": "Equity Method Investment Place And Date Of Incorporation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME FROM EQUITY METHOD INVESTMENT - LAB SERVICES MSO",
        "verboseLabel": "Loss from equity method investment - Lab Services MSO",
        "label": "Equity Method Investment, Realized Gain (Loss) on Disposal",
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment."
       }
      }
     },
     "auth_ref": [
      "r1340",
      "r1342",
      "r1387"
     ]
    },
    "us-gaap_EquityMethodInvestmentSoldCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentSoldCarryingAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total payment for equity method investment",
        "verboseLabel": "Purchased interests",
        "label": "Equity Method Investment, Amount Sold",
        "documentation": "Amount of the entity's equity method investment which has been sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentUnderlyingEquityInNetAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Company\u2019s interest in the fair value of Lab Services MSO\u2019s net assets at February 9, 2023",
        "label": "Equity Method Investment, Underlying Equity in Net Assets",
        "documentation": "This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity."
       }
      }
     },
     "auth_ref": [
      "r1424"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable",
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable0",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Equity investment carrying amount beginning balance",
        "periodEndLabel": "Equity investment carrying amount ending balance",
        "terseLabel": "Equity method investments, net",
        "verboseLabel": "Equity method investment",
        "netLabel": "Equity Method Investment, Amount",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r332",
      "r351",
      "r392",
      "r1317",
      "r1424"
     ]
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_EquityMethodInvestmentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "EquityMethodInvestmentsDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY METHOD INVESTMENTS",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r396",
      "r399",
      "r1292"
     ]
    },
    "us-gaap_EquityMethodInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment [Member]",
        "label": "Equity Method Investments [Member]",
        "documentation": "Investment in the stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition."
       }
      }
     },
     "auth_ref": [
      "r1152",
      "r1244"
     ]
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investment",
        "label": "Equity Method Investments [Table Text Block]",
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "avco_EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "EquityMethodofFairValueOverCarryingValueodentifiableintangibleassets",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Company\u2019s interest in the net excess of Lab Services MSO\u2019s fair value over net assets which was attributable to identifiable intangible assets at February 9, 2023",
        "documentation": "The Company\u2019s interest in the net excess of Lab Services MSO\u2019s fair value over carrying value w...",
        "label": "Equity Methodof Fair Value Over Carrying Valueodentifiableintangibleassets"
       }
      }
     },
     "auth_ref": []
    },
    "avco_EquityScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "EquityScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity - Schedule of Common Stock Issuable Upon Exercise of Warrants Outstanding (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_EquityScheduleofNonvestedStockOptionsGrantedDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "EquityScheduleofNonvestedStockOptionsGrantedDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable",
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity - Schedule of Nonvested Stock Options Granted (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_EquityScheduleofStockOptionActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "EquityScheduleofStockOptionActivityDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity - Schedule of Stock Option Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_EquityTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "EquityTablesLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Tables) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_EquityTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "EquityTablesTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ExchangeRatioPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ExchangeRatioPerShare",
     "presentation": [
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange ratio per share (in Dollars per share)",
        "documentation": "Exchange ratio.",
        "label": "Exchange Ratio Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ExchangeShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ExchangeShare",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange share (in Shares)",
        "documentation": "Exchange share.",
        "label": "Exchange Share"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ExercisePriceRangeFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ExercisePriceRangeFiveMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "7.50 \u2013 187.50 [Member]",
        "label": "Exercise Price Range Five Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ExercisePriceRangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ExercisePriceRangeFourMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.93 \u2013 289.50 [Member]",
        "verboseLabel": "187.50 [Member]",
        "netLabel": "2.93 - 264.00 [Member]",
        "label": "Exercise Price Range Four Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ExercisePriceRangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ExercisePriceRangeOneMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.93 \u2013 31.20 [Member]",
        "verboseLabel": "7.50 \u2013 37.50 [Member]",
        "netLabel": "2.93 - 31.20 [Member]",
        "label": "Exercise Price Range One Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ExercisePriceRangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ExercisePriceRangeThreeMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "154.50 \u2013 289.50 [Member]",
        "verboseLabel": "154.50 - 264.00 [Member]",
        "label": "Exercise Price Range Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ExercisePriceRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ExercisePriceRangeTwoMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "48.75 \u2013 123.00 [Member]",
        "verboseLabel": "67.50 [Member]",
        "netLabel": "48.75 - 123.00 [Member]",
        "label": "Exercise Price Range Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_FairMarketValues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "FairMarketValues",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair market values",
        "documentation": "Amount of fair market value.",
        "label": "Fair Market Values"
       }
      }
     },
     "auth_ref": []
    },
    "avco_FairMarketValuesOfGrantDates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "FairMarketValuesOfGrantDates",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair market values of grant dates",
        "verboseLabel": "Fair market values (in Dollars)",
        "documentation": "Represents the value of fair market values of grant dates.",
        "label": "Fair Market Values Of Grant Dates"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 6.0
      },
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow",
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement",
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable",
      "http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair market value of derivative liability",
        "negatedLabel": "Change in fair value of derivative liability",
        "negatedTerseLabel": "Gain from change in the fair value of derivative liability",
        "negatedNetLabel": "Loss from change in the fair value of derivative liability",
        "verboseLabel": "Fair value of warrants",
        "netLabel": "Fair value of warrant (in Dollars)",
        "label": "Fair value adjustment of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r770",
      "r1152",
      "r1235",
      "r1244"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r770",
      "r1152",
      "r1235",
      "r1244"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable",
      "http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r526",
      "r527",
      "r756",
      "r758",
      "r759",
      "r760",
      "r761",
      "r768",
      "r769",
      "r771",
      "r773",
      "r835",
      "r836",
      "r837",
      "r1152",
      "r1197",
      "r1198",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1233",
      "r1237",
      "r1244"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r770"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable",
      "http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Unobservable Inputs (Level 3) [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r526",
      "r527",
      "r758",
      "r759",
      "r760",
      "r761",
      "r769",
      "r773",
      "r837",
      "r1152",
      "r1197",
      "r1198",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1233",
      "r1237",
      "r1244"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r770"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments and Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable",
      "http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Derivative Liability Measured at Fair Value [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r763",
      "r765",
      "r766",
      "r767",
      "r770"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable",
      "http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r770"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Derivative Liability Measured at Fair Value",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r767",
      "r770"
     ]
    },
    "avco_FebruaryFiveTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "FebruaryFiveTwoThousandTwentyFiveMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable",
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "February 5, 2025 [Member]",
        "label": "February Five Two Thousand Twenty Five Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FederalReserveBankStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FederalReserveBankStock",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federally insured limits",
        "label": "Federal Reserve Bank Stock",
        "documentation": "Federal Reserve Bank stock represents an equity interest in the Federal Reserve Bank. It does not have a readily determinable fair value because its ownership is restricted and it lacks a market (liquidity)."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r490",
      "r513",
      "r738",
      "r751",
      "r772",
      "r783",
      "r786",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r913",
      "r937",
      "r1194",
      "r1233",
      "r1235",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1248",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1524",
      "r1527",
      "r1528",
      "r1529",
      "r1536",
      "r1539",
      "r1540",
      "r1541"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "avco_FirstFireMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "FirstFireMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FirstFire [Member]",
        "label": "First Fire Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_FirstWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "FirstWarrantMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Warrant [Member]",
        "label": "First Warrant Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_FirstfireMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "FirstfireMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Firstfire [Member]",
        "label": "Firstfire Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiscalPeriod": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiscalPeriod",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fiscal Year End",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "avco_FiveYearAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "FiveYearAnniversaryMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Five Year Anniversary [Member]",
        "label": "Five Year Anniversary Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency exchange rate",
        "label": "Foreign Currency Exchange Rate, Translation",
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency."
       }
      }
     },
     "auth_ref": [
      "r799",
      "r800"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "avco_FormerDirectorAndFormerCochiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "FormerDirectorAndFormerCochiefExecutiveOfficerMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/NoncontrollingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Former Director And Former Co-chief executive Officer [Member]",
        "label": "Former Director And Former Cochief Executive Officer Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow",
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on debts extinguishment",
        "negatedLabel": "Gain on debts extinguishment",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r47",
      "r48"
     ]
    },
    "us-gaap_GainsLossesOnRestructuringOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnRestructuringOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt modification charge",
        "label": "Gains (Losses) on Restructuring of Debt",
        "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r247"
     ]
    },
    "avco_GenExosomeTechnologiesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "GenExosomeTechnologiesIncMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genexosome Technologies Inc. (\u201cGenexosome\u201d) [Member]",
        "label": "Gen Exosome Technologies Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill, Fair Value Disclosure",
        "documentation": "Fair value portion of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r1233",
      "r1234",
      "r1525",
      "r1526",
      "r1536",
      "r1542"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Impairment of goodwill",
        "terseLabel": "Recognized impairment loss",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r414",
      "r420",
      "r424",
      "r426",
      "r669",
      "r1195",
      "r1234"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrossProfit",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable",
      "http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r94",
      "r151",
      "r259",
      "r264",
      "r265",
      "r398",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r784",
      "r1177",
      "r1183",
      "r1405",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1445"
     ]
    },
    "avco_ImpairmentOfLaboratoryEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ImpairmentOfLaboratoryEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow",
      "http://www.avalonglobocare.com/role/EquipmentHeldForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of laboratory equipment",
        "verboseLabel": "Impairment charge",
        "documentation": "The amount of impairment of laboratory equipment.",
        "label": "Impairment Of Laboratory Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r113"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofCompanysLossBeforeIncomeTaxesTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCompanysLossBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r266",
      "r584"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS BEFORE INCOME TAXES",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r139",
      "r151",
      "r905",
      "r907",
      "r932",
      "r1165",
      "r1167",
      "r1169",
      "r1177",
      "r1183",
      "r1405",
      "r1414",
      "r1415",
      "r1416",
      "r1417"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofCompanysLossBeforeIncomeTaxesTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCompanysLossBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r266",
      "r584"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofCompanysLossBeforeIncomeTaxesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCompanysLossBeforeIncomeTaxesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS BEFORE INCOME TAXES",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r944",
      "r1177",
      "r1271",
      "r1273",
      "r1405",
      "r1414",
      "r1415",
      "r1416",
      "r1417"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income from equity method investment",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r93",
      "r138",
      "r305",
      "r329",
      "r351",
      "r392",
      "r931"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable",
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Distribution of earnings from equity investment",
        "negatedTerseLabel": "Sale of equity investment",
        "terseLabel": "Distribution of earnings from investment",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r444",
      "r445",
      "r693",
      "r699",
      "r716",
      "r723",
      "r763",
      "r767",
      "r770",
      "r785",
      "r786",
      "r787",
      "r966",
      "r968",
      "r1067",
      "r1151",
      "r1152",
      "r1217",
      "r1219",
      "r1229",
      "r1231",
      "r1236",
      "r1244",
      "r1507",
      "r1509",
      "r1573"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r445",
      "r693",
      "r699",
      "r716",
      "r723",
      "r763",
      "r767",
      "r770",
      "r785",
      "r786",
      "r787",
      "r966",
      "r968",
      "r1067",
      "r1151",
      "r1152",
      "r1217",
      "r1219",
      "r1229",
      "r1231",
      "r1236",
      "r1244",
      "r1507",
      "r1509",
      "r1573"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r267",
      "r578",
      "r585",
      "r590",
      "r591",
      "r592",
      "r593",
      "r599",
      "r606",
      "r608",
      "r609",
      "r610",
      "r912",
      "r981",
      "r996",
      "r1215"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement",
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total income taxes expense",
        "negatedLabel": "INCOME TAXES",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r171",
      "r259",
      "r288",
      "r289",
      "r305",
      "r330",
      "r351",
      "r583",
      "r585",
      "r607",
      "r945",
      "r1165",
      "r1167",
      "r1169",
      "r1215"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company\u2019s Loss Before Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r579",
      "r580",
      "r593",
      "r594",
      "r598",
      "r601",
      "r990"
     ]
    },
    "avco_IncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "IncomeTaxesDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in accrued liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "avco_IncreaseDecreaseInDeferredLeasingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "IncreaseDecreaseInDeferredLeasingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred leasing costs",
        "documentation": "Deferred leasing costs.",
        "label": "Increase Decrease In Deferred Leasing Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease obligation",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1297",
      "r1386"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities and other payables",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Rent receivable",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expense and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncreaseDecreaseInSecurityDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInSecurityDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposit",
        "label": "Increase (Decrease) in Security Deposits",
        "documentation": "The increase (decrease) during the reporting period in security deposits."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "avco_InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "InitialFairValueOfDerivativeLiabilityAttributableToWarrantsIssuanceWithFundRaise",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial fair value of derivative liability attributable to warrants issuance",
        "documentation": "Initial fair value of derivative liability attributable to warrants issuance with fund raise.",
        "label": "Initial Fair Value Of Derivative Liability Attributable To Warrants Issuance With Fund Raise"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Identified intangible assets",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r1430",
      "r1431"
     ]
    },
    "us-gaap_InterestAndDebtExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestAndDebtExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense related to convertible note payable",
        "label": "Interest and Debt Expense",
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r1341"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense - related party",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r485",
      "r493",
      "r1199",
      "r1200",
      "r1608"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r1165",
      "r1169",
      "r1343"
     ]
    },
    "us-gaap_InterestExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense - other",
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Other",
        "documentation": "Amount of interest expense classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseShortTermBorrowings",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/NotePayableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense related to note payable",
        "label": "Interest Expense, Short-Term Borrowings",
        "documentation": "The aggregate interest expense incurred on short-term borrowings including commercial paper and Federal funds purchased and securities sold under agreements to repurchase."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r173",
      "r174"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r254",
      "r255"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest payable",
        "label": "Interest Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable",
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1323"
     ]
    },
    "avco_InvestmentInEpiconBiotechCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "InvestmentInEpiconBiotechCoLtdMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in Epicon Biotech Co., Ltd. [Member]",
        "label": "Investment In Epicon Biotech Co Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_InvestmentInLaboratoryServicesMSOLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "InvestmentInLaboratoryServicesMSOLLCMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable",
      "http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable0",
      "http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in Laboratory Services MSO, LLC [Member]",
        "label": "Investment In Laboratory Services MSOLLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "avco_InvestmentInRealEstateAndDepreciationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "InvestmentInRealEstateAndDepreciationPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment In Real Estate and Depreciation",
        "documentation": "Disclosure of accounting policy for investment in real estate and depreciation.",
        "label": "Investment In Real Estate And Depreciation Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentOwnedAtCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentOwnedAtCost",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of investment",
        "label": "Investment Owned, Cost",
        "documentation": "Cost of the investment."
       }
      }
     },
     "auth_ref": [
      "r986",
      "r1022",
      "r1023",
      "r1092",
      "r1095",
      "r1103",
      "r1119",
      "r1279",
      "r1287",
      "r1604"
     ]
    },
    "us-gaap_InvestmentOwnedPercentOfNetAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentOwnedPercentOfNetAssets",
     "presentation": [
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of owned",
        "label": "Investment Owned, Net Assets, Percentage",
        "documentation": "Percentage of investment owned to net assets."
       }
      }
     },
     "auth_ref": [
      "r1019",
      "r1022",
      "r1023",
      "r1091",
      "r1102",
      "r1104",
      "r1105",
      "r1120",
      "r1279",
      "r1604"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in Unconsolidated Company",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r942",
      "r986",
      "r987",
      "r988",
      "r989",
      "r1093",
      "r1094"
     ]
    },
    "avco_IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "IssuanceOfCommonStockUponCashlessExerciseOfStockWarrant",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon cashless exercise of stock warrants",
        "documentation": "Issuance of common stock upon cashless exercise of stock warrants.",
        "label": "Issuance Of Common Stock Upon Cashless Exercise Of Stock Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "avco_JanuaryFiveTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "JanuaryFiveTwoThousandTwentyFiveMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable",
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 5, 2025 [Member]",
        "label": "January Five Two Thousand Twenty Five Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_JefferiesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "JefferiesLLCMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jefferies LLC [Member]",
        "label": "Jefferies LLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "avco_JiangsuUnicornBiologicalTechnologyCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "JiangsuUnicornBiologicalTechnologyCoLtdMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jiangsu Unicorn Biological Technology Co., Ltd.[Member]",
        "label": "Jiangsu Unicorn Biological Technology Co Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_July2023ConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "July2023ConvertibleNoteMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "July 2023 Convertible Note [Member]",
        "label": "July2023 Convertible Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_July62023FiveYearAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "July62023FiveYearAnniversaryMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "July 6, 2023 - Five-Year Anniversary [Member]",
        "label": "July62023 Five Year Anniversary Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_June2024ConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "June2024ConvertibleNoteMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 2024 Convertible Note [Member]",
        "label": "June2024 Convertible Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_June52024FiveyearAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "June52024FiveyearAnniversaryMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 5, 2024 - five-year anniversary [Member]",
        "label": "June52024 Fiveyear Anniversary Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_JuneFiveTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "JuneFiveTwoThousandTwentyFiveMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable",
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 5, 2025 [Member]",
        "label": "June Five Two Thousand Twenty Five Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_JuneTwentyThousandTwentyFourConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "JuneTwentyThousandTwentyFourConvertibleNoteMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 2024 Convertible Note [Member]",
        "label": "June Twenty Thousand Twenty Four Convertible Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_LabServiceMSOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "LabServiceMSOMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab Service MSO [Member]",
        "label": "Lab Service MSOMember"
       }
      }
     },
     "auth_ref": []
    },
    "avco_LabServicesMSOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "LabServicesMSOMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable",
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable0",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0",
      "http://www.avalonglobocare.com/role/SegmentInformationDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab Services MSO [Member]",
        "label": "Lab Services MSOMember"
       }
      }
     },
     "auth_ref": []
    },
    "avco_LabServicesMSOsNetIncomeAttributableToTheCompany": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "LabServicesMSOsNetIncomeAttributableToTheCompany",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable",
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab Services MSO\u2019s net income attributable to the Company",
        "verboseLabel": "Lab services MSO\u2019s net income",
        "documentation": "Lab Services MSO\u2019s net income attributable to the Company.",
        "label": "Lab Services MSOs Net Income Attributable To The Company"
       }
      }
     },
     "auth_ref": []
    },
    "avco_LabServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "LabServicesMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab Services [Member]",
        "label": "Lab Services Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation and related benefits",
        "label": "Labor and Related Expense",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r1167",
      "r1339"
     ]
    },
    "avco_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_LaboratoryServicesMSOLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "LaboratoryServicesMSOLLCMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory Services MSO, LLC [Member]",
        "label": "Laboratory Services MSOLLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "avco_LaboratoryServicesMSOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "LaboratoryServicesMSOMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab Services MSO [Member]",
        "label": "Laboratory Services MSOMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LandImprovementsMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofInvestmentinRealEstateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Improvement [Member]",
        "label": "Land Improvements [Member]",
        "documentation": "Additions or improvements to real estate held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofLeaseTable",
      "http://www.avalonglobocare.com/role/ScheduleofLeaseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligation:",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1548"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "avco_LessCommonStockHeldInTreasuryAtCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "LessCommonStockHeldInTreasuryAtCostAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: common stock held in treasury, at cost;",
        "label": "Less Common Stock Held In Treasury At Cost Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Leasing Costs",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturity of Lease Liabilities Under Operating Lease",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1549"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable",
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r1390",
      "r1397",
      "r1566"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable",
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026 and thereafter",
        "verboseLabel": "2028 and thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r1390",
      "r1397",
      "r1566"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable",
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "verboseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r1390",
      "r1397",
      "r1566"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r1390",
      "r1397",
      "r1566"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable",
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amount of lease payments representing interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_LessorLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LessorLeasesPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Lease",
        "label": "Lessor, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r817"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of Credit [Member]",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r72",
      "r73",
      "r74",
      "r77",
      "r78",
      "r79",
      "r80",
      "r259",
      "r264",
      "r265",
      "r398",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r675",
      "r679",
      "r680",
      "r784",
      "r1034",
      "r1176",
      "r1201",
      "r1287",
      "r1445",
      "r1556",
      "r1557"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r137",
      "r926",
      "r1247",
      "r1271",
      "r1273",
      "r1389",
      "r1394",
      "r1425",
      "r1543"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "terseLabel": "Current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r217",
      "r259",
      "r264",
      "r265",
      "r398",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r675",
      "r679",
      "r680",
      "r784",
      "r1247",
      "r1445",
      "r1556",
      "r1557"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Non-current Liabilities",
        "terseLabel": "Noncurrent liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r77",
      "r78",
      "r79",
      "r80",
      "r259",
      "r264",
      "r265",
      "r398",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r675",
      "r679",
      "r680",
      "r784",
      "r1445",
      "r1556",
      "r1557"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT LIABILITIES:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesSubjectToCompromiseEarlyContractTerminationFees",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination fee (in Dollars)",
        "label": "Liabilities Subject to Compromise, Early Contract Termination Fees",
        "documentation": "The amount of early contract termination fees included in liabilities subject to compromise."
       }
      }
     },
     "auth_ref": [
      "r1555"
     ]
    },
    "us-gaap_LiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilityMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability [Member]",
        "label": "Liability [Member]",
        "documentation": "Liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": []
    },
    "avco_LineOfCreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "LineOfCreditAgreementMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Agreement [Member]",
        "label": "Line Of Credit Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Line of Credit [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofLineofCreditTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding principal under the Line of Credit, Balance",
        "periodEndLabel": "Outstanding principal under the Line of Credit, Balance",
        "label": "Line of Credit Facility, Fair Value of Amount Outstanding",
        "documentation": "Fair value of the amount outstanding under the credit facility."
       }
      }
     },
     "auth_ref": [
      "r1540"
     ]
    },
    "us-gaap_LineOfCreditFacilityIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued and unpaid interest for line of credit",
        "label": "Line of Credit Facility, Increase, Accrued Interest",
        "documentation": "Increase for accrued, but unpaid interest on the credit facility for the period."
       }
      }
     },
     "auth_ref": [
      "r1389",
      "r1392"
     ]
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bears interest rate",
        "label": "Line of Credit Facility, Interest Rate During Period",
        "documentation": "The effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r76"
     ]
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Convertible Note Payable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r1389",
      "r1392",
      "r1443"
     ]
    },
    "us-gaap_LitigationReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LitigationReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation amount",
        "label": "Estimated Litigation Liability",
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r1440"
     ]
    },
    "us-gaap_LitigationReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LitigationReserveCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued litigation settlement",
        "label": "Estimated Litigation Liability, Current",
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r1440"
     ]
    },
    "us-gaap_LitigationStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LitigationStatusAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Status [Axis]",
        "documentation": "Information by status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r1435",
      "r1436",
      "r1437",
      "r1440"
     ]
    },
    "us-gaap_LitigationStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LitigationStatusDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Status [Domain]",
        "documentation": "Status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r1435",
      "r1436",
      "r1437",
      "r1440"
     ]
    },
    "us-gaap_LoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans payable",
        "label": "Loans Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r134",
      "r1569"
     ]
    },
    "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtPercentageBearingVariableInterestRate",
     "presentation": [
      "http://www.avalonglobocare.com/role/NotePayableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest percentage",
        "label": "Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate",
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONVERTIBLE NOTE PAYABLE",
        "label": "Long-Term Debt [Text Block]",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_LongTermInvestmentsAndReceivablesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermInvestmentsAndReceivablesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable from sale of equity method investment, noncurrent portion",
        "label": "Long-Term Investments and Receivables, Net",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle) and amount due to the Entity from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such investments and receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r1319"
     ]
    },
    "us-gaap_LongTermLoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermLoansPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan payable - related party",
        "label": "Loans Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ScheduleofNotePayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note payable, net - noncurrent portion",
        "verboseLabel": "Noncurrent portion",
        "label": "Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r1435",
      "r1436",
      "r1437"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r45",
      "r1435",
      "r1436",
      "r1437"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConcentrationsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable",
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r1203",
      "r1206",
      "r1262",
      "r1267",
      "r1572",
      "r1574",
      "r1575",
      "r1577",
      "r1578",
      "r1579",
      "r1580",
      "r1581",
      "r1582",
      "r1583",
      "r1584",
      "r1585",
      "r1586",
      "r1587",
      "r1588",
      "r1589",
      "r1590",
      "r1591",
      "r1592",
      "r1593",
      "r1594",
      "r1595",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1601",
      "r1602"
     ]
    },
    "avco_March2024ConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "March2024ConvertibleNoteMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2024 Convertible Note [Member]",
        "label": "March2024 Convertible Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_March72024FiveYearAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "March72024FiveYearAnniversaryMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 7, 2024 - Five-Year Anniversary [Member]",
        "label": "March72024 Five Year Anniversary Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_MarchFiveTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "MarchFiveTwoThousandTwentyFiveMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable",
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 5, 2025\t[Member]",
        "label": "March Five Two Thousand Twenty Five Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_MarchTwentyThousandTwentyFourConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "MarchTwentyThousandTwentyFourConvertibleNoteMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2024 Convertible Note [Member]",
        "verboseLabel": "March Twenty Thousand Twenty Four Convertible Note [Member]",
        "label": "March Twenty Thousand Twenty Four Convertible Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_MarchTwoThousandTwentyFourWarrantIssuedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "MarchTwoThousandTwentyFourWarrantIssuedMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Issued in March 2024 [Member]",
        "verboseLabel": "March Two Thousand Twenty Four Warrant Issued [Member]",
        "label": "March Two Thousand Twenty Four Warrant Issued Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketingAndAdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketingAndAdvertisingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising and marketing expenses",
        "label": "Marketing and Advertising Expense",
        "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r1167"
     ]
    },
    "avco_MastHillAndFirstfireMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "MastHillAndFirstfireMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mast Hill and Firstfire [Member]",
        "label": "Mast Hill And Firstfire Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_MastHillFundLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "MastHillFundLPMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mast Hill Fund, L.P. [Member]",
        "label": "Mast Hill Fund LPMember"
       }
      }
     },
     "auth_ref": []
    },
    "avco_MastHillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "MastHillMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable",
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mast Hill [Member]",
        "label": "Mast Hill Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_MastHillThirdPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "MastHillThirdPartyMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mast Hill Third Party [Member]",
        "label": "Mast Hill Third Party Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_MastMillAndFirstFireMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "MastMillAndFirstFireMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mast Mill and FirstFire [Member]",
        "label": "Mast Mill And First Fire Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r178",
      "r180",
      "r181",
      "r183",
      "r201",
      "r203",
      "r204",
      "r207",
      "r208",
      "r317",
      "r450",
      "r451",
      "r452",
      "r453",
      "r529",
      "r558",
      "r559",
      "r560",
      "r575",
      "r761",
      "r864",
      "r965",
      "r967",
      "r979",
      "r1025",
      "r1026",
      "r1089",
      "r1096",
      "r1100",
      "r1101",
      "r1114",
      "r1127",
      "r1128",
      "r1130",
      "r1131",
      "r1149",
      "r1150",
      "r1189",
      "r1202",
      "r1214",
      "r1217",
      "r1220",
      "r1221",
      "r1237",
      "r1238",
      "r1242",
      "r1243",
      "r1263",
      "r1449",
      "r1558",
      "r1559",
      "r1560",
      "r1561",
      "r1562",
      "r1563"
     ]
    },
    "avco_May2023ConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "May2023ConvertibleNoteMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "May 2023 Convertible Note [Member]",
        "label": "May2023 Convertible Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_May2023CovertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "May2023CovertibleNoteMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "May 2023 Convertible Note [Member]",
        "verboseLabel": "May 2023 Covertible Note [Member]",
        "label": "May2023 Covertible Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_May232023FiveYearAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "May232023FiveYearAnniversaryMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "May 23, 2023 - Five-Year Anniversary [Member]",
        "label": "May232023 Five Year Anniversary Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_MayFiveTwoThousandTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "MayFiveTwoThousandTwentyFiveMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable",
      "http://www.avalonglobocare.com/role/ScheduleofAmortizationPaymentsinCashTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "May 5, 2025 [Member]",
        "label": "May Five Two Thousand Twenty Five Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Discount Rate [Member]",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1217",
      "r1220",
      "r1221",
      "r1527",
      "r1528",
      "r1529"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Expected Dividend Rate [Member]",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r1527",
      "r1528",
      "r1529"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Expected Term [Member]",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r1527",
      "r1528",
      "r1529"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Price Volatility [Member]",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r1237",
      "r1527",
      "r1528",
      "r1529"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Risk Free Interest Rate [Member]",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r1527",
      "r1528",
      "r1529"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Share Price [Member]",
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1527",
      "r1528",
      "r1529"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r759",
      "r760",
      "r761",
      "r1217",
      "r1220",
      "r1221",
      "r1237"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r759",
      "r760",
      "r761",
      "r1217",
      "r1220",
      "r1221",
      "r1237"
     ]
    },
    "avco_MembershipInterestPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "MembershipInterestPurchaseAgreementMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Membership Interest Purchase Agreement [Member]",
        "label": "Membership Interest Purchase Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_MergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "MergerAgreementMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Agreement [Member]",
        "label": "Merger Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r178",
      "r180",
      "r181",
      "r183",
      "r201",
      "r203",
      "r204",
      "r207",
      "r208",
      "r317",
      "r450",
      "r451",
      "r452",
      "r453",
      "r529",
      "r558",
      "r559",
      "r560",
      "r575",
      "r761",
      "r864",
      "r965",
      "r967",
      "r979",
      "r1025",
      "r1026",
      "r1089",
      "r1096",
      "r1100",
      "r1101",
      "r1114",
      "r1127",
      "r1128",
      "r1130",
      "r1131",
      "r1149",
      "r1150",
      "r1189",
      "r1202",
      "r1214",
      "r1217",
      "r1220",
      "r1221",
      "r1237",
      "r1238",
      "r1242",
      "r1263",
      "r1449",
      "r1558",
      "r1559",
      "r1560",
      "r1561",
      "r1562",
      "r1563"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r136",
      "r259",
      "r264",
      "r265",
      "r398",
      "r456",
      "r458",
      "r459",
      "r460",
      "r463",
      "r464",
      "r925",
      "r1038",
      "r1543"
     ]
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterestDisclosureTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/NoncontrollingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_MinorityInterestLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterestLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/NoncontrollingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/NoncontrollingInterestDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total ownership percentage",
        "verboseLabel": "Ownership percentage",
        "netLabel": "Percentage of own excess",
        "label": "Equity interests ownership percentage",
        "totalLabel": "Equity interest ownership percentage",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "avco_MrLuMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "MrLuMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mr. Lu [Member]",
        "label": "Mr Lu Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r1203",
      "r1206",
      "r1262",
      "r1267",
      "r1572",
      "r1574",
      "r1575",
      "r1577",
      "r1578",
      "r1579",
      "r1580",
      "r1581",
      "r1582",
      "r1583",
      "r1584",
      "r1585",
      "r1586",
      "r1587",
      "r1588",
      "r1589",
      "r1590",
      "r1591",
      "r1592",
      "r1593",
      "r1594",
      "r1595",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1601",
      "r1602"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.avalonglobocare.com/role/OrganizationandNatureofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND NATURE OF OPERATIONS",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r311",
      "r1172",
      "r1174"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH PROVIDED BY INVESTING ACTIVITIES",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails",
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES",
        "terseLabel": "Negative cash flow from operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r108"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails",
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS AFTER NONCONTROLLING INTEREST",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r108",
      "r140",
      "r212",
      "r215",
      "r232",
      "r234",
      "r239",
      "r259",
      "r264",
      "r265",
      "r270",
      "r275",
      "r279",
      "r280",
      "r282",
      "r283",
      "r284",
      "r288",
      "r289",
      "r296",
      "r398",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r495",
      "r498",
      "r501",
      "r506",
      "r564",
      "r615",
      "r671",
      "r755",
      "r784",
      "r935",
      "r1058",
      "r1080",
      "r1081",
      "r1165",
      "r1167",
      "r1169",
      "r1285",
      "r1445"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r127",
      "r232",
      "r234",
      "r284",
      "r288",
      "r289",
      "r934",
      "r1337"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r245",
      "r279",
      "r280",
      "r282",
      "r283",
      "r291",
      "r292",
      "r297",
      "r300",
      "r498",
      "r501",
      "r506",
      "r671"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashContributionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashContributionExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contribution amount",
        "label": "Noncash Contribution Expense",
        "documentation": "Noncash charitable contributions made by the entity during the period."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CASH INVESTING AND FINANCING ACTIVITIES:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncontrollingInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_NoncontrollingInterestDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "NoncontrollingInterestDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/NoncontrollingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r517",
      "r1398",
      "r1399",
      "r1400",
      "r1403",
      "r1611"
     ]
    },
    "avco_NoncontrollingInterestPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "NoncontrollingInterestPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest",
        "documentation": "Disclosure of accounting policy for noncontrolling interest policy.",
        "label": "Noncontrolling Interest Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable0",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Identifiable long-lived tangible assets",
        "label": "Long-Lived Assets",
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Expense, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER (EXPENSE) INCOME",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NontradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NontradeReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from convertible debt",
        "label": "Nontrade Receivables",
        "documentation": "Carrying amounts due as of the balance sheet date of the sum of amounts receivable other than from customers."
       }
      }
     },
     "auth_ref": [
      "r1322"
     ]
    },
    "avco_NonvestedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "NonvestedMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable",
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonvested [Member]",
        "label": "Nonvested Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_NotePayableNetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "NotePayableNetDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/NotePayableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable, Net (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofNotePayableTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNotePayableTable",
      "http://www.avalonglobocare.com/role/ScheduleofNotePayableTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Note payable, net",
        "terseLabel": "Current portion",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73"
     ]
    },
    "us-gaap_NotesPayableToBankCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayableToBankCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note payable, net",
        "label": "Notes Payable to Bank, Current",
        "documentation": "Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r73"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.avalonglobocare.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r1184",
      "r1413"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.avalonglobocare.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r1178",
      "r1188",
      "r1413"
     ]
    },
    "avco_October2023ConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "October2023ConvertibleNoteMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "October 2023 Convertible Note [Member]",
        "label": "October2023 Convertible Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_October92023FiveYearAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "October92023FiveYearAnniversaryMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "October 9, 2023 - Five-Year Anniversary [Member]",
        "label": "October92023 Five Year Anniversary Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_OctoberTwoThousandTwentyThreeConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "OctoberTwoThousandTwentyThreeConvertibleNotesMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "October 2023 Convertible Note [Member]",
        "label": "October Two Thousand Twenty Three Convertible Notes Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_OfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "OfferingCost",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other offering cost",
        "documentation": "Offering Cost.",
        "label": "Offering Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Equipment and Furniture [Member]",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "avco_OneCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "OneCustomerMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One Customer [Member]",
        "label": "One Customer Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Operating Expenses",
        "negatedLabel": "Other operating expenses",
        "label": "Operating Costs and Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REAL PROPERTY OPERATING EXPENSES",
        "negatedLabel": "Real property operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r1169"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER OPERATING EXPENSES:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement",
      "http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable",
      "http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS FROM OPERATIONS",
        "terseLabel": "(Loss) income from operation",
        "verboseLabel": "Income from operation",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r1165",
      "r1169",
      "r1177",
      "r1405",
      "r1414",
      "r1415",
      "r1416",
      "r1417"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturity of Lease Liabilities Under Operating Lease [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0Alt0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total present value of operating lease liabilities",
        "terseLabel": "Total",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0Alt0": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable",
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease obligation, current portion",
        "verboseLabel": "Total present value of operating lease liabilities (current liability)",
        "netLabel": "Current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0Alt0": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ScheduleofMaturityofLeaseLiabilitiesUnderOperatingLeaseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease obligation, noncurrent portion",
        "verboseLabel": "Long-term portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofLeaseTable",
      "http://www.avalonglobocare.com/role/ScheduleofLeaseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows paid for operating lease",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r809",
      "r811"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets, net",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of operating lease right-of-use asset",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1387"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofLeaseTable",
      "http://www.avalonglobocare.com/role/ScheduleofLeaseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r1246"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofLeaseTable",
      "http://www.avalonglobocare.com/role/ScheduleofLeaseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r1246"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal and state net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "avco_OptionsOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "OptionsOutstandingMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityTables",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options [Member]",
        "verboseLabel": "Options Outstanding [Member]",
        "label": "Options Outstanding Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_OptionsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "OptionsToPurchaseCommonStockMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable",
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options to purchase common stock [Member]",
        "label": "Options To Purchase Common Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Nature of Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_OrganizationandNatureofOperationsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "OrganizationandNatureofOperationsDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Nature of Operations (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities and other payables - related parties",
        "label": "Other Accounts Payable and Accrued Liabilities",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges",
        "label": "Other Asset Impairment Charges",
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value."
       }
      }
     },
     "auth_ref": [
      "r1387",
      "r1433"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized foreign currency translation gain (loss)",
        "label": "OCI, Foreign Currency Transaction and Translation Gain (Loss), Arising During Period, Tax",
        "documentation": "Amount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r789",
      "r790",
      "r797"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r790",
      "r797"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER COMPREHENSIVE LOSS",
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/PrepaidExpenseandOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PREPAID EXPENSE AND OTHER CURRENT ASSETS",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherDepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/InvestmentinRealEstateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Other Depreciation and Amortization",
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r42",
      "r96"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other general and administrative expenses",
        "label": "Other General and Administrative Expense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r1610"
     ]
    },
    "us-gaap_OtherGeneralExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherGeneralExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting expenses",
        "label": "Other General Expense",
        "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r1183"
     ]
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense",
        "verboseLabel": "Other income (expense)",
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r943",
      "r1060",
      "r1116",
      "r1117",
      "r1118",
      "r1271",
      "r1273"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expense",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_OtherNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other payables",
        "label": "Other Notes Payable",
        "documentation": "Amount of long-term notes payable classified as other."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r134",
      "r1569"
     ]
    },
    "us-gaap_OtherNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofNotePayableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNotePayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Note payable, net",
        "label": "Other Notes Payable, Current",
        "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "avco_OtherOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "OtherOperatingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating expense",
        "documentation": "Other operating expense.",
        "label": "Other Operating Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "REAL PROPERTY OPERATING INCOME",
        "terseLabel": "Real property operating income",
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 9.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable",
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1324",
      "r1428"
     ]
    },
    "us-gaap_OtherRestrictedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherRestrictedAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted net assets",
        "label": "Other Restricted Assets",
        "documentation": "Total assets that cannot be used for operating purposes because of contract or regulatory requirements that are in effect for a period that extends beyond one year."
       }
      }
     },
     "auth_ref": [
      "r1132",
      "r1133",
      "r1318"
     ]
    },
    "us-gaap_OtherRestrictedAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherRestrictedAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statutory Reserve and Restricted Net Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherTradingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherTradingMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Trading [Member]",
        "label": "Other Trading [Member]",
        "documentation": "Trading in a derivative instrument whose primary underlying risk is classified as other."
       }
      }
     },
     "auth_ref": [
      "r1227",
      "r1231"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/NoncontrollingInterestDetails",
      "http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "avco_PRCSubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "PRCSubsidiariesMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PRC Subsidiaries [Member]",
        "label": "PRCSubsidiaries Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Payables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_PaymentForCommission": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "PaymentForCommission",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finder\u2019s fee",
        "documentation": "Represents the amount of payment for commission.",
        "label": "Payment For Commission"
       }
      }
     },
     "auth_ref": []
    },
    "avco_PaymentOfEquityInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "PaymentOfEquityInvestment",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of equity investment",
        "documentation": "The amount of payment of equity investment.",
        "label": "Payment Of Equity Investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for rent",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfInitialPublicOffering",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Disbursements for equity offering costs",
        "label": "Payments for Repurchase of Initial Public Offering",
        "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "avco_PaymentsOfConvertibleDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "PaymentsOfConvertibleDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of convertible debt issuance costs",
        "documentation": "Payments of convertible debt issuance costs.",
        "label": "Payments Of Convertible Debt Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying value of the extinguished",
        "verboseLabel": "Lender's costs related to financing",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of convertible debts issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment for equity interest purchase",
        "label": "Payments to Acquire Equity Method Investments",
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_PaymentsToAcquireLoansHeldForInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireLoansHeldForInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of equity investment",
        "label": "Payment for Acquisition, Loan, Held-for-Investment",
        "documentation": "The cash outflow associated with purchasing loans held for investment purposes during the period."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "avco_PercentageOfCommonStockIssuedAndOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "PercentageOfCommonStockIssuedAndOutstanding",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of common stock issued and outstanding",
        "documentation": "The percentage of common stock issued and outstanding.",
        "label": "Percentage Of Common Stock Issued And Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "avco_PercentageOfPretaxProfit": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "PercentageOfPretaxProfit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of pre-tax profit",
        "documentation": "Percentage of pre-tax profit.",
        "label": "Percentage Of Pretax Profit"
       }
      }
     },
     "auth_ref": []
    },
    "avco_PercentageOfPromissoryNotes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "PercentageOfPromissoryNotes",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage promissory notes",
        "documentation": "Percentage promissory notes.",
        "label": "Percentage Of Promissory Notes"
       }
      }
     },
     "auth_ref": []
    },
    "avco_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants [Member]",
        "verboseLabel": "Pre Funded Warrants [Member]",
        "label": "Pre Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_PreTaxProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "PreTaxProfit",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-tax profit",
        "documentation": "The amount of pre-tax profit.",
        "label": "Pre Tax Profit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, convertible conversion price (in Dollars per share)",
        "verboseLabel": "Conversion price per share (in Dollars per share)",
        "netLabel": "Preferred stock, convertible per share (in Dollars per share)",
        "label": "Preferred Stock, Convertible, Conversion Price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued shares (in Shares)",
        "verboseLabel": "Issued shares",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of preferred stock",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r508",
      "r1090",
      "r1097",
      "r1099",
      "r1115"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockLiquidationPreferenceValue",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock,Liquidation preference (in Dollars)",
        "label": "Preferred Stock, Liquidation Preference, Value",
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r263",
      "r511",
      "r516"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "verboseLabel": "Preferred Stock [Member]",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r1277",
      "r1278",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1603",
      "r1611"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r507"
     ]
    },
    "us-gaap_PreferredStockRedemptionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockRedemptionAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of closing the redemption",
        "label": "Preferred Stock, Redemption Amount",
        "documentation": "The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r81",
      "r750"
     ]
    },
    "us-gaap_PreferredStockRedemptionPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockRedemptionPremium",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total redemption",
        "label": "Preferred Stock Redemption Premium",
        "documentation": "The excess of (1) fair value of the consideration transferred to the holders of the preferred stock over (2) the carrying amount of the preferred stock in the registrant's balance sheet, during the accounting period."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred stock, shares authorized (in Shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r1036"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, shares issued",
        "verboseLabel": "Issuance shares (in Shares)",
        "netLabel": "Preferred stock, shares issued (in Shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r507"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, shares outstanding",
        "verboseLabel": "Preferred stock, shares outstanding (in Shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r1036",
      "r1057",
      "r1611",
      "r1612"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "verboseLabel": "Preferred stock, value",
        "netLabel": "Preferred stock, stated value",
        "label": "Preferred stock, stated value (in Dollars)",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r497",
      "r503",
      "r920",
      "r1247"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable",
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Prepaid expense and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1325"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Prepaid Expense and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expense",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r412",
      "r413",
      "r1157"
     ]
    },
    "us-gaap_PrepaidExpenseCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseOtherNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseOtherNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid NASDAQ listing fee",
        "label": "Prepaid Expense Other, Noncurrent",
        "documentation": "Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1318"
     ]
    },
    "avco_PrepaidProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "PrepaidProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable",
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid professional fees",
        "documentation": "The amount of prepaid professional fees.",
        "label": "Prepaid Professional Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidReinsurancePremiums": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidReinsurancePremiums",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable",
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid directors and officers\u2019 liability insurance premium",
        "verboseLabel": "Prepaid directors\u2019 and officers\u2019 liability insurance premium",
        "label": "Prepaid Reinsurance Premiums",
        "documentation": "The unexpired portion of premiums ceded on policies in force as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r963",
      "r984",
      "r1271",
      "r1272"
     ]
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r1315"
     ]
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for previously issued notes",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "avco_ProceedsFromIssuanceOfConvertibleDebtAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ProceedsFromIssuanceOfConvertibleDebtAndWarrants",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Proceeds from issuance of convertible debt and warrants",
        "documentation": "Proceeds from issuance of convertible debt and warrants.",
        "label": "Proceeds From Issuance Of Convertible Debt And Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of convertible preferred stock",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of convertible debts and warrants",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1385"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock and received proceeds",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit",
        "label": "Proceeds from Lines of Credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r1389",
      "r1392"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow",
      "http://www.avalonglobocare.com/role/NotePayableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of balloon promissory note",
        "verboseLabel": "Borrowed amount",
        "label": "Proceeds from Notes Payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow",
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from equity offering",
        "verboseLabel": "Net proceeds",
        "label": "Proceeds from Other Equity",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromPaymentsToMinorityShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromPaymentsToMinorityShareholders",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advance from pending sale of noncontrolling interest in subsidiary",
        "label": "Proceeds from (Payments to) Noncontrolling Interests",
        "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from loan payable - related party",
        "label": "Proceeds from Related Party Debt",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of equity method investment",
        "verboseLabel": "Carrying value equity method investment",
        "label": "Proceeds from Sale of Equity Method Investments",
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r205",
      "r355",
      "r865",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r964",
      "r1153",
      "r1164",
      "r1167",
      "r1169",
      "r1203",
      "r1204",
      "r1261",
      "r1263",
      "r1264",
      "r1268",
      "r1275",
      "r1296",
      "r1313",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354",
      "r1355",
      "r1356",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1441",
      "r1442",
      "r1572",
      "r1574",
      "r1575",
      "r1576",
      "r1577",
      "r1578",
      "r1579",
      "r1580",
      "r1581",
      "r1582",
      "r1583",
      "r1584",
      "r1585",
      "r1586",
      "r1587",
      "r1588",
      "r1589",
      "r1590",
      "r1591",
      "r1592",
      "r1593",
      "r1594",
      "r1595",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1601",
      "r1602"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r205",
      "r355",
      "r865",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r964",
      "r1153",
      "r1164",
      "r1167",
      "r1169",
      "r1203",
      "r1204",
      "r1261",
      "r1263",
      "r1264",
      "r1268",
      "r1275",
      "r1296",
      "r1313",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354",
      "r1355",
      "r1356",
      "r1357",
      "r1358",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1365",
      "r1366",
      "r1367",
      "r1368",
      "r1369",
      "r1370",
      "r1371",
      "r1372",
      "r1373",
      "r1374",
      "r1375",
      "r1376",
      "r1377",
      "r1378",
      "r1379",
      "r1380",
      "r1381",
      "r1382",
      "r1383",
      "r1384",
      "r1441",
      "r1442",
      "r1572",
      "r1574",
      "r1575",
      "r1576",
      "r1577",
      "r1578",
      "r1579",
      "r1580",
      "r1581",
      "r1582",
      "r1583",
      "r1584",
      "r1585",
      "r1586",
      "r1587",
      "r1588",
      "r1589",
      "r1590",
      "r1591",
      "r1592",
      "r1593",
      "r1594",
      "r1595",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1601",
      "r1602"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement",
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "label": "Professional Fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1183",
      "r1285",
      "r1609",
      "r1610"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails",
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow",
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement",
      "http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable",
      "http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable0",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income",
        "terseLabel": "Net loss for the year",
        "verboseLabel": "Net loss",
        "netLabel": "NET LOSS",
        "totalLabel": "Net (loss) income",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r215",
      "r232",
      "r234",
      "r252",
      "r259",
      "r264",
      "r265",
      "r270",
      "r275",
      "r284",
      "r288",
      "r289",
      "r398",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r495",
      "r564",
      "r615",
      "r671",
      "r673",
      "r676",
      "r677",
      "r755",
      "r784",
      "r905",
      "r907",
      "r933",
      "r1001",
      "r1058",
      "r1080",
      "r1081",
      "r1224",
      "r1225",
      "r1286",
      "r1337",
      "r1445"
     ]
    },
    "avco_PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "PromissoryNoteMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/NotePayableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory Note [Member]",
        "label": "Promissory Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAssetsHeldForSaleDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment Held For Sale [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r816"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r164",
      "r168",
      "r169"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, useful life",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r219",
      "r930"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r816",
      "r911",
      "r930",
      "r1247"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentOtherAccumulatedDepreciation",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Property, Plant and Equipment, Other, Accumulated Depreciation",
        "documentation": "Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentOwnedAccumulatedDepreciation",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofInvestmentinRealEstateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Property, Plant, and Equipment, Owned, Accumulated Depreciation",
        "documentation": "Amount of accumulated depreciation from long-lived, depreciable flight asset owned. Excludes right-of-use asset from finance lease for flight asset."
       }
      }
     },
     "auth_ref": [
      "r1432"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r164",
      "r168",
      "r928"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/PropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r816"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofInvestmentinRealEstateTable",
      "http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, gross",
        "verboseLabel": "Useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PublicUtilitiesInventorySuppliesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PublicUtilitiesInventorySuppliesMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplies [Member]",
        "label": "Supplies [Member]",
        "documentation": "Materials used as supplies by the entity."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "avco_PurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "PurchasePrice",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price",
        "documentation": "Represent the amount of purchase price.",
        "label": "Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "avco_PurchasePriceOfConvertibleNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "PurchasePriceOfConvertibleNote",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price",
        "documentation": "Purchase price of convertible note.",
        "label": "Purchase Price Of Convertible Note"
       }
      }
     },
     "auth_ref": []
    },
    "avco_PurchasedServicesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "PurchasedServicesPercentage",
     "presentation": [
      "http://www.avalonglobocare.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased services percentage",
        "documentation": "Purchased services percentage.",
        "label": "Purchased Services Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "avco_QADistributionLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "QADistributionLLCMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Q&amp;A Distribution LLC (\u201cQ&amp;A Distribution\u201d) [Member]",
        "label": "QADistribution LLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r178",
      "r180",
      "r181",
      "r183",
      "r201",
      "r203",
      "r204",
      "r207",
      "r208",
      "r317",
      "r450",
      "r451",
      "r452",
      "r453",
      "r518",
      "r529",
      "r558",
      "r559",
      "r560",
      "r563",
      "r575",
      "r761",
      "r838",
      "r848",
      "r864",
      "r965",
      "r967",
      "r979",
      "r1025",
      "r1026",
      "r1089",
      "r1096",
      "r1100",
      "r1101",
      "r1114",
      "r1127",
      "r1128",
      "r1130",
      "r1131",
      "r1149",
      "r1150",
      "r1189",
      "r1202",
      "r1214",
      "r1217",
      "r1220",
      "r1221",
      "r1237",
      "r1238",
      "r1242",
      "r1243",
      "r1263",
      "r1279",
      "r1438",
      "r1449",
      "r1528",
      "r1559",
      "r1560",
      "r1561",
      "r1562",
      "r1563"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r178",
      "r180",
      "r181",
      "r183",
      "r201",
      "r203",
      "r204",
      "r207",
      "r208",
      "r317",
      "r450",
      "r451",
      "r452",
      "r453",
      "r518",
      "r529",
      "r558",
      "r559",
      "r560",
      "r563",
      "r575",
      "r761",
      "r838",
      "r848",
      "r864",
      "r965",
      "r967",
      "r979",
      "r1025",
      "r1026",
      "r1089",
      "r1096",
      "r1100",
      "r1101",
      "r1114",
      "r1127",
      "r1128",
      "r1130",
      "r1131",
      "r1149",
      "r1150",
      "r1189",
      "r1202",
      "r1214",
      "r1217",
      "r1220",
      "r1221",
      "r1237",
      "r1238",
      "r1242",
      "r1243",
      "r1263",
      "r1279",
      "r1438",
      "r1449",
      "r1528",
      "r1559",
      "r1560",
      "r1561",
      "r1562",
      "r1563"
     ]
    },
    "us-gaap_RealEstateDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RealEstateDisclosureTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/InvestmentinRealEstate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVESTMENT IN REAL ESTATE",
        "label": "Real Estate Disclosure [Text Block]",
        "documentation": "The entire disclosure for certain real estate investment financial statements, real estate investment trust operating support agreements, real estate owned, retail land sales, time share transactions, as well as other real estate related disclosures."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r1148"
     ]
    },
    "us-gaap_RealEstateInvestmentPropertyAtCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RealEstateInvestmentPropertyAtCost",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofInvestmentinRealEstateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in real estate, Gross",
        "label": "Real Estate Investment Property, at Cost",
        "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments."
       }
      }
     },
     "auth_ref": [
      "r914",
      "r915"
     ]
    },
    "us-gaap_RealEstateInvestmentPropertyNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RealEstateInvestmentPropertyNet",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofInvestmentinRealEstateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in real estate, net",
        "label": "Real Estate Investment Property, Net",
        "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments."
       }
      }
     },
     "auth_ref": [
      "r1567",
      "r1568"
     ]
    },
    "us-gaap_RealEstateInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RealEstateInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in real estate, net",
        "label": "Real Estate Investments, Net",
        "documentation": "Amount of real estate investments, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; (7) other real estate investments; (8) real estate joint ventures; and (9) unconsolidated real estate and other joint ventures not separately presented."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r914",
      "r915",
      "r1274",
      "r1276",
      "r1606"
     ]
    },
    "us-gaap_RealEstateInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RealEstateInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in Real Estate [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RealEstateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RealEstateLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofInvestmentinRealEstateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Investment in Real Estate [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "us-gaap_RealEstatePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RealEstatePolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real Property Operating Expenses",
        "label": "Real Estate, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for entities that primarily develop and then sell real property at retail or otherwise."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "avco_RealPropertyOperatingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "RealPropertyOperatingMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real property operations [Member]",
        "documentation": "Information by business segments.",
        "label": "Real Property Operating Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_RealPropertyOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "RealPropertyOperationsMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real Property Operations [Member]",
        "label": "Real Property Operations Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_RealPropertyRentalRevenuePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "RealPropertyRentalRevenuePolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real Property Rental Revenue",
        "documentation": "Disclosure of accounting policy for real property rental revenue.",
        "label": "Real Property Rental Revenue Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivableInvestmentSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivableInvestmentSale",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable from sale of equity method investment",
        "label": "Receivable, Investment, Sale",
        "documentation": "Amount of receivable from sale of investment."
       }
      }
     },
     "auth_ref": [
      "r1045",
      "r1087",
      "r1287"
     ]
    },
    "avco_ReceivableRelatedToSaleOfEquityMethodInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ReceivableRelatedToSaleOfEquityMethodInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable related to sale of equity method investment",
        "documentation": "Receivable related to sale of equity method investment.",
        "label": "Receivable Related To Sale Of Equity Method Investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable from sale of equity method investment, current portion",
        "label": "Receivables, Net, Current",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r1247"
     ]
    },
    "avco_ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ReclassificationOfAdvancesForEquityInterestPurchaseToEquityMethodInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of advances for equity interest purchase to equity method investment",
        "documentation": "Reclassification of advances for equity interest purchase to equity method investment.",
        "label": "Reclassification Of Advances For Equity Interest Purchase To Equity Method Investment"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ReclassificationOfLineOfCreditToAdvanceFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ReclassificationOfLineOfCreditToAdvanceFromRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofLineofCreditTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of Line of Credit to advance from related party",
        "documentation": "Reclassification of Line of Credit to advance from related party.",
        "label": "Reclassification Of Line Of Credit To Advance From Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ReclassificationOfRelatedPartyLoanPayableAndAccruedExpensesToAdvanceFromRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of related party loan payable and accrued expenses to advance from related party",
        "documentation": "Amount of reclassification of related party loan payable and accrued expenses to advance from related party.",
        "label": "Reclassification Of Related Party Loan Payable And Accrued Expenses To Advance From Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReclassificationsOfTemporaryToPermanentEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable",
      "http://www.avalonglobocare.com/role/ScheduleofDerivativeLiabilityMeasuredatFairValueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of derivative liability to equity",
        "negatedLabel": "Reclassification of additional paid-in capital upon conversion",
        "label": "Reclassifications of Temporary to Permanent Equity",
        "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r1451",
      "r1453",
      "r1454",
      "r1455"
     ]
    },
    "avco_RedemptionNetOfPayablesDueToLabServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "RedemptionNetOfPayablesDueToLabServices",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption, net of payables due to lab services",
        "documentation": "Amount of redemption, net of payables due to lab services.",
        "label": "Redemption Net Of Payables Due To Lab Services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RedemptionPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RedemptionPremium",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption amount (in Dollars)",
        "label": "Redemption Premium",
        "documentation": "The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share."
       }
      }
     },
     "auth_ref": []
    },
    "avco_RegisteredCapitalPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "RegisteredCapitalPercentage",
     "presentation": [
      "http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve registered capital percentage",
        "documentation": "Percentage of registered capital.",
        "label": "Registered Capital Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "avco_RegularPaymentsOnEquityInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "RegularPaymentsOnEquityInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regular payments on equity investments",
        "documentation": "Regular payments on equity investments.",
        "label": "Regular Payments On Equity Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RegulatoryAssetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RegulatoryAssetAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory Asset [Axis]",
        "documentation": "Information by type of regulatory asset."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r147"
     ]
    },
    "us-gaap_RegulatoryAssetDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RegulatoryAssetDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory Asset [Domain]",
        "documentation": "Rate action of a regulator resulting in capitalization of costs incurred."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r269",
      "r270",
      "r360",
      "r525",
      "r528",
      "r823",
      "r824",
      "r917",
      "r927",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1056",
      "r1088",
      "r1607"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "verboseLabel": "Related Party [Member]",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r269",
      "r270",
      "r823",
      "r824",
      "r825",
      "r826",
      "r917",
      "r927",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1056",
      "r1088"
     ]
    },
    "avco_RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "RelatedPartyPayableExtinguishedUponSaleOfEquityMethodInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party payable extinguished upon sale of equity method investment",
        "documentation": "Related party payable extinguished upon sale of equity method investment.",
        "label": "Related Party Payable Extinguished Upon Sale Of Equity Method Investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r269",
      "r270",
      "r823",
      "r824",
      "r1554"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r269",
      "r270",
      "r1554"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r269",
      "r270",
      "r360",
      "r823",
      "r824",
      "r826",
      "r1063",
      "r1064",
      "r1067"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r269",
      "r270",
      "r360",
      "r525",
      "r528",
      "r823",
      "r824",
      "r917",
      "r927",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1056",
      "r1088",
      "r1554",
      "r1607"
     ]
    },
    "avco_RelatedPartyTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "RelatedPartyTransactionsDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r820",
      "r821",
      "r822",
      "r824",
      "r827",
      "r997",
      "r998",
      "r999",
      "r1065",
      "r1066",
      "r1067",
      "r1085",
      "r1086"
     ]
    },
    "us-gaap_RentalIncomeNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RentalIncomeNonoperating",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rental revenue",
        "label": "Rental Income, Nonoperating",
        "documentation": "Income earned by providing the use of assets to an outside party in exchange for a payment or series of payments that is nonoperating in nature."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of convertible debt",
        "label": "Repayments of Convertible Debt",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofLineofCreditTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of Line of Credit",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r1389",
      "r1392"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of balloon promissory note issuance costs",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of loan payable - related party",
        "label": "Repayments of Related Party Debt",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense",
        "verboseLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r1151",
      "r1165",
      "r1166",
      "r1183",
      "r1564"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r1494"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RestatementAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r210",
      "r211",
      "r212",
      "r213",
      "r248",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r281",
      "r282",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r303",
      "r401",
      "r402",
      "r494",
      "r495",
      "r564",
      "r613",
      "r614",
      "r615",
      "r616",
      "r670",
      "r671",
      "r752",
      "r753",
      "r754",
      "r755",
      "r805",
      "r818",
      "r819",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r985",
      "r1418"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RestatementDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r210",
      "r211",
      "r212",
      "r213",
      "r248",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r281",
      "r282",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r303",
      "r401",
      "r402",
      "r494",
      "r495",
      "r564",
      "r613",
      "r614",
      "r615",
      "r616",
      "r670",
      "r671",
      "r752",
      "r753",
      "r754",
      "r755",
      "r805",
      "r818",
      "r819",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r985",
      "r1418"
     ]
    },
    "avco_RestrictedNetAssetsOfSubsidiaryExceedNetAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "RestrictedNetAssetsOfSubsidiaryExceedNetAssets",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated subsidiary exceed net assets",
        "documentation": "Represents percentage of net assets of subsidiary exceed.",
        "label": "Restricted Net Assets Of Subsidiary Exceed Net Assets"
       }
      }
     },
     "auth_ref": []
    },
    "avco_RestrictedNetAssetsPRCSubsidiaryDidNotExceed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "RestrictedNetAssetsPRCSubsidiaryDidNotExceed",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedFinancialInformationoftheParentCompanyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated subsidiary did not exceed net assets",
        "documentation": "Represents restricted net assets of the company's subsidiary did not exceed consolidated net assets.",
        "label": "Restricted Net Assets PRCSubsidiary Did Not Exceed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r120",
      "r923",
      "r973",
      "r978",
      "r995",
      "r1037",
      "r1247"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r211",
      "r212",
      "r272",
      "r273",
      "r274",
      "r276",
      "r284",
      "r287",
      "r289",
      "r400",
      "r403",
      "r436",
      "r494",
      "r564",
      "r603",
      "r604",
      "r612",
      "r613",
      "r614",
      "r616",
      "r670",
      "r671",
      "r740",
      "r742",
      "r743",
      "r745",
      "r753",
      "r804",
      "r806",
      "r969",
      "r971",
      "r1002",
      "r1611"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent Receivable and Reserve for Credit Losses",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of purchase",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement",
      "http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable",
      "http://www.avalonglobocare.com/role/ScheduleofFinancialInformationTable0",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REAL PROPERTY RENTAL REVENUE",
        "verboseLabel": "Net revenue",
        "netLabel": "Real property rental revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r240",
      "r259",
      "r264",
      "r265",
      "r305",
      "r323",
      "r324",
      "r345",
      "r351",
      "r355",
      "r357",
      "r359",
      "r398",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r784",
      "r905",
      "r907",
      "r1183",
      "r1226",
      "r1271",
      "r1273",
      "r1445"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable0",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Schedule of Identifiable Long-Lived Tangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "avco_ReverseStockSplitPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ReverseStockSplitPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Stock Split",
        "documentation": "Disclosure of accounting policy for reverse stock split.",
        "label": "Reverse Stock Split Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "avco_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofLeaseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow",
      "http://www.avalonglobocare.com/role/ScheduleofLeaseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial ROU asset and lease liability",
        "verboseLabel": "Operating lease",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r812",
      "r1246"
     ]
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RisksAndUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_RothCapitalPartnersLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "RothCapitalPartnersLLCMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Roth Capital Partners, LLC [Member]",
        "label": "Roth Capital Partners LLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate shares issued (in Shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConcentrationsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable",
      "http://www.avalonglobocare.com/role/ScheduleofCustomerAccountedforCompanysRevenuesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark [Member]",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r1408",
      "r1409"
     ]
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Previously Reported [Member]",
        "label": "Previously Reported [Member]",
        "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r272",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r289",
      "r303",
      "r494",
      "r495",
      "r564",
      "r613",
      "r615",
      "r616",
      "r670",
      "r671",
      "r752",
      "r753",
      "r754",
      "r805",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r985",
      "r1298",
      "r1299",
      "r1300",
      "r1401",
      "r1402",
      "r1418",
      "r1426",
      "r1427",
      "r1523",
      "r1551",
      "r1552"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Liabilities and Other Payables",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "avco_ScheduleOfAmortizationPaymentsInCashAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ScheduleOfAmortizationPaymentsInCashAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Amortization Payments In Cash Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable",
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Securities that were Excluded from the Diluted Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable",
      "http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalent [Table]",
        "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash Balances by Geographic Area",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "avco_ScheduleOfCashBalancesByGeographicAreaAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ScheduleOfCashBalancesByGeographicAreaAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cash Balances By Geographic Area Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ScheduleOfCommonStockIssuableUponExerciseOfOptionsOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ScheduleOfCommonStockIssuableUponExerciseOfOptionsOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Common Stock Issuable Upon Exercise Of Options Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ScheduleOfCommonStockIssuableUponExerciseOfWarrantsOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ScheduleOfCommonStockIssuableUponExerciseOfWarrantsOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Common Stock Issuable Upon Exercise Of Warrants Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Taxes Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1500"
     ]
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Summarized Financial Information, as Provided to the Company by the Investee",
        "label": "Condensed Balance Sheet [Table Text Block]",
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r1309",
      "r1390",
      "r1397",
      "r1566"
     ]
    },
    "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Information",
        "label": "Condensed Income Statement [Table Text Block]",
        "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r1309",
      "r1390",
      "r1397",
      "r1566"
     ]
    },
    "avco_ScheduleOfConsolidatedFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ScheduleOfConsolidatedFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Consolidated Financial Statements Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ScheduleOfConvertibleNotePayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ScheduleOfConvertibleNotePayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Convertible Note Payable Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ScheduleOfCustomerAccountedForCompanysRevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ScheduleOfCustomerAccountedForCompanysRevenuesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Customer Accounted For Companys Revenues Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amortization Payments in Cash",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r50",
      "r51",
      "r64",
      "r118",
      "r119",
      "r1197",
      "r1199",
      "r1390",
      "r1397",
      "r1545",
      "r1566"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/NotePayableNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Note Payable",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Taxes",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1498"
     ]
    },
    "avco_ScheduleOfDerivativeLiabilityMeasuredAtFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ScheduleOfDerivativeLiabilityMeasuredAtFairValueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Derivative Liability Measured At Fair Value Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of U.S. Statutory Rate and the Company\u2019s Effective Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r1215",
      "r1495"
     ]
    },
    "us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Identifiable Long-Lived Tangible Assets (Geographic Areas)",
        "label": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]",
        "documentation": "Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "avco_ScheduleOfEquityMethodInvestmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ScheduleOfEquityMethodInvestmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Equity Method Investment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable",
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable0",
      "http://www.avalonglobocare.com/role/SegmentInformationDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r397",
      "r611",
      "r784",
      "r1290",
      "r1291",
      "r1292",
      "r1503",
      "r1504",
      "r1505",
      "r1506"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable",
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Equity Method Investment [Line Items]",
        "terseLabel": "Equity Method Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r265",
      "r394",
      "r395",
      "r397",
      "r398",
      "r784"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable",
      "http://www.avalonglobocare.com/role/ScheduleofEquityMethodInvestmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment [Table]",
        "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r259",
      "r265",
      "r394",
      "r395",
      "r397",
      "r398",
      "r784"
     ]
    },
    "avco_ScheduleOfFinancialInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ScheduleOfFinancialInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Information Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Identifiable Long Lived Tangible Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "avco_ScheduleOfIdentifiableLongLivedTangibleAssetsGeographicAreasAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ScheduleOfIdentifiableLongLivedTangibleAssetsGeographicAreasAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Identifiable Long Lived Tangible Assets Geographic Areas Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company\u2019s Loss Before Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1389",
      "r1395"
     ]
    },
    "avco_ScheduleOfInvestmentInRealEstateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ScheduleOfInvestmentInRealEstateAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Investment In Real Estate Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Line of Credit",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r76"
     ]
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Nonvested Stock Options Granted",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "avco_ScheduleOfNonvestedStockOptionsGrantedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ScheduleOfNonvestedStockOptionsGrantedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Nonvested Stock Options Granted Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/PrepaidExpenseandOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expense and Other Current Assets",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "avco_ScheduleOfPropertyAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r816"
     ]
    },
    "us-gaap_ScheduleOfRealEstatePropertiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRealEstatePropertiesTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofInvestmentinRealEstateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate Property, Ownership [Table]",
        "documentation": "Disclosure of information about real estate property by ownership of property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRealEstatePropertiesTableTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/InvestmentinRealEstateTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investment in Real Estate",
        "label": "Schedule of Real Estate Properties [Table Text Block]",
        "documentation": "Tabular disclosure of real estate properties and units in those properties that are included in the discussion of the nature of an entity's operations."
       }
      }
     },
     "auth_ref": []
    },
    "avco_ScheduleOfReportableBusinessSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ScheduleOfReportableBusinessSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Reportable Business Segments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Identifiable Long-Lived Tangible Assets",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r91"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable0",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Identifiable Long-Lived Tangible Assets [Abstract]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r91"
     ]
    },
    "avco_ScheduleOfSecuritiesThatWereExcludedFromTheDilutedPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ScheduleOfSecuritiesThatWereExcludedFromTheDilutedPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Securities That Were Excluded From The Diluted Per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reportable Business Segments",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r123"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Issuable Upon Exercise of Options Outstanding",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "avco_ScheduleOfStockOptionActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ScheduleOfStockOptionActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stock Option Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipDescriptionTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Consolidated Financial Statements",
        "label": "Schedule of Subsidiary of Limited Liability Company or Limited Partnership, Description [Table Text Block]",
        "documentation": "Tabular disclosure of the key aspects of a subsidiary (partnership, corporation, or other entity) of the limited liability company or limited partnership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary of LLC or LP [Table]",
        "documentation": "Disclosure of information about subsidiary of limited liability company (LLC) or limited partnership (LP)."
       }
      }
     },
     "auth_ref": []
    },
    "avco_ScheduleOfSummarizedFinancialInformationAsProvidedToTheCompanyByTheInvesteeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "ScheduleOfSummarizedFinancialInformationAsProvidedToTheCompanyByTheInvesteeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Summarized Financial Information As Provided To The Company By The Investee Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConcentrationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Customer Accounted for Company's Revenues",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r1407",
      "r1412"
     ]
    },
    "avco_SecondWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "SecondWarrantMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Warrant [Member]",
        "label": "Second Warrant Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecuredDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/NotePayableNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured amount",
        "label": "Secured Debt",
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r134",
      "r1569"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable",
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposit",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r1318"
     ]
    },
    "us-gaap_SegmentContinuingOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentContinuingOperationsMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Continuing Operations [Member]",
        "label": "Continuing Operations [Member]",
        "documentation": "Component of an entity expected to operate in the foreseeable future."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable0",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r305",
      "r319",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r353",
      "r359",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r435",
      "r446",
      "r447",
      "r663",
      "r666",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r1180",
      "r1183",
      "r1184",
      "r1195",
      "r1266",
      "r1572",
      "r1574",
      "r1575",
      "r1576",
      "r1577",
      "r1578",
      "r1579",
      "r1580",
      "r1581",
      "r1582",
      "r1583",
      "r1584",
      "r1585",
      "r1586",
      "r1587",
      "r1588",
      "r1589",
      "r1590",
      "r1591",
      "r1592",
      "r1593",
      "r1594",
      "r1595",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1601",
      "r1602"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/IncomeTaxesDetails",
      "http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable",
      "http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable0",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable0",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r179",
      "r182",
      "r184",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r313",
      "r357",
      "r358",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r905",
      "r906",
      "r907",
      "r908",
      "r1018",
      "r1021",
      "r1023",
      "r1091",
      "r1098",
      "r1104",
      "r1120",
      "r1127",
      "r1129",
      "r1130",
      "r1131",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1154",
      "r1171",
      "r1203",
      "r1205",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1265",
      "r1279",
      "r1572",
      "r1574",
      "r1575",
      "r1577",
      "r1578",
      "r1579",
      "r1580",
      "r1581",
      "r1582",
      "r1583",
      "r1584",
      "r1585",
      "r1586",
      "r1587",
      "r1588",
      "r1589",
      "r1590",
      "r1591",
      "r1592",
      "r1593",
      "r1594",
      "r1595",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1601",
      "r1602"
     ]
    },
    "avco_SegmentInformationDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "SegmentInformationDetailsLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_SegmentInformationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "SegmentInformationDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentOperatingActivitiesDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Activities [Domain]",
        "documentation": "Operations of an entity including continuing and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT INFORMATION",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r305",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r334",
      "r336",
      "r337",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r359",
      "r1178",
      "r1181",
      "r1182",
      "r1183",
      "r1185",
      "r1187",
      "r1188"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reportable Business Segments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r354",
      "r357",
      "r1179",
      "r1180",
      "r1186"
     ]
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Secured Promissory Notes [Member]",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "avco_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Stock [Member]",
        "label": "Series AConvertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable",
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Stock",
        "verboseLabel": "Series A",
        "netLabel": "Series A Preferred Stock [Member]",
        "label": "Series A Convertible Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1320",
      "r1321",
      "r1452",
      "r1457"
     ]
    },
    "avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Convertible Preferred Stock extinguished related to sale of equity method investment",
        "documentation": "Convertible Preferred Stock extinguished related to sale of equity method investment.",
        "label": "Series BConvertible Preferred Stock Extinguished Related To Sale Of Equity Method Investment"
       }
      }
     },
     "auth_ref": []
    },
    "avco_SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "SeriesBConvertiblePreferredStockExtinguishedRelatedToSaleOfEquityMethodInvestments",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Convertible Preferred Stock extinguished related to sale of equity method investment (in Shares)",
        "documentation": "The number of series B convertible preferred stock extinguished related to sale of equity method investment.",
        "label": "Series BConvertible Preferred Stock Extinguished Related To Sale Of Equity Method Investments"
       }
      }
     },
     "auth_ref": []
    },
    "avco_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Convertible Preferred Stock [Member]",
        "label": "Series BConvertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "SeriesBConvertiblePreferredStocksExtinguishedRelatedToSaleOfEquityMethodInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Convertible Preferred Stock extinguished related to sale of equity method investment",
        "documentation": "Convertible Preferred Stock extinguished related to sale of equity method investment.",
        "label": "Series BConvertible Preferred Stocks Extinguished Related To Sale Of Equity Method Investment"
       }
      }
     },
     "auth_ref": []
    },
    "avco_SeriesBHolderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "SeriesBHolderMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Holder [Member]",
        "label": "Series BHolder Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable",
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Convertible Preferred Stock",
        "verboseLabel": "Series B",
        "netLabel": "Series B Preferred Stock [Member]",
        "label": "Series B Convertible Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1320",
      "r1321",
      "r1452",
      "r1457"
     ]
    },
    "avco_SeriesBStatedValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "SeriesBStatedValueMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Stated Value [Member]",
        "label": "Series BStated Value Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable",
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C Convertible Preferred Stock",
        "verboseLabel": "Series C",
        "netLabel": "Series C Preferred Stock [Member]",
        "label": "Series C Convertible Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1320",
      "r1321",
      "r1452",
      "r1457"
     ]
    },
    "avco_SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "SeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D Convertible Preferred Stock issued in exchange of Series A Convertible Preferred Stock",
        "documentation": "Series D Convertible Preferred Stock issued in exchange of Series A Convertible Preferred Stock.",
        "label": "Series DConvertible Preferred Stock Issued In Exchange Of Series AConvertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesDPreferredStockMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D Convertible Preferred Stock",
        "verboseLabel": "Series D",
        "netLabel": "Series D Preferred Stock [Member]",
        "label": "Series D Convertible Preferred Stock [Member]",
        "documentation": "Series D preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1320",
      "r1321",
      "r1452",
      "r1457"
     ]
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Member]",
        "verboseLabel": "Business Combination, Series of Individually Immaterial Business Combinations [Member]",
        "label": "Business Combination, Series of Individually Immaterial Business Combinations [Member]",
        "documentation": "Series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r1508",
      "r1510",
      "r1511"
     ]
    },
    "us-gaap_SettledLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SettledLitigationMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settled Litigation [Member]",
        "verboseLabel": "Litigation [Member]",
        "label": "Settled Litigation [Member]",
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval."
       }
      }
     },
     "auth_ref": [
      "r1440"
     ]
    },
    "avco_SettlementsOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "SettlementsOfDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of derivative liability",
        "documentation": "Settlement of derivative liability.",
        "label": "Settlements Of Derivative Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation and service expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled warrants shares (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Outstanding, Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": [
      "r1484"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk free interest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Black-Scholes option-pricing volatility rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable",
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activity [Line Items]",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "verboseLabel": "Schedule of Nonvested Stock Options Granted [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r563"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Exercisable, Number Exercisable (in Shares)",
        "verboseLabel": "Number of Options, Options exercisable",
        "netLabel": "Warrants Exercisable, Number Exercisable (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price, Options exercisable",
        "netLabel": "Warrants Outstanding, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable",
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Warrants, Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable",
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable",
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options, Beginning Balance",
        "periodEndLabel": "Number of Options, Balance Ending",
        "terseLabel": "Options Outstanding, Number Outstanding (in Shares)",
        "verboseLabel": "Warrants Outstanding, Number Outstanding (in Shares)",
        "netLabel": "Number of Options, Balance outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance",
        "periodEndLabel": "Weighted Average Exercise Price, Balance Ending",
        "terseLabel": "Weighted Average Exercise Price, Balance outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Issuable Upon Exercise of Warrants Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]",
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Options expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Options expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Issued",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityTables",
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r534",
      "r535",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Weighted Average Exercise Price,\tExpired",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Weighted Average Exercise Price, Cancelled",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "verboseLabel": "Weighted Average Exercise Price, Issued",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Weighted Average Exercise Price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could acquire or could have acquired the underlying shares with respect to any other type of change in shares reserved for issuance."
       }
      }
     },
     "auth_ref": [
      "r1491"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable from Sale of Equity Method Investment",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r536",
      "r555",
      "r556",
      "r557",
      "r558",
      "r561",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Common Stock Issuable Upon Exercise of Options Outstanding [Line Items]",
        "terseLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding,Range of Exercise Price lower limit",
        "verboseLabel": "Warrants Outstanding, Exercise Price, lower limit",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding, Range of Exercise Price Upper limit",
        "verboseLabel": "Warrants Outstanding, Exercise Price, upper limit",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Axis]",
        "documentation": "Information by supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Domain]",
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in Dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1490"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable",
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options, Nonvested Beginning",
        "periodEndLabel": "Number of Options, Nonvested Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": [
      "r1491"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable",
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Weighted Average Exercise Price, Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": [
      "r1491"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable",
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Nonvested Beginning",
        "periodEndLabel": "Weighted Average Exercise Price, Nonvested Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": [
      "r1491"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Outstanding, Weighted Average Remaining Contractual Life (Years)",
        "verboseLabel": "Warrants Outstanding, Weighted Average Remaining Contractual Life (Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable",
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": [
      "r1491"
     ]
    },
    "avco_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValues",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable",
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Vested",
        "documentation": "Weighted average exercise price, vested.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Values"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable0",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Exercisable",
        "verboseLabel": "Warrants Exercisable, Weighted Average Exercise Price",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r1456",
      "r1461"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share (in Dollars per share)",
        "verboseLabel": "Shares issued (in Dollars per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "terseLabel": "Shares outstanding",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable",
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r1435",
      "r1436",
      "r1437"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r1435",
      "r1436",
      "r1437"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsTable0",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable",
      "http://www.avalonglobocare.com/role/ScheduleofReportableBusinessSegmentsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r152",
      "r214",
      "r305",
      "r319",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r353",
      "r359",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r435",
      "r438",
      "r446",
      "r447",
      "r663",
      "r666",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r1180",
      "r1183",
      "r1184",
      "r1195",
      "r1266",
      "r1572",
      "r1574",
      "r1575",
      "r1576",
      "r1577",
      "r1578",
      "r1579",
      "r1580",
      "r1581",
      "r1582",
      "r1583",
      "r1584",
      "r1585",
      "r1586",
      "r1587",
      "r1588",
      "r1589",
      "r1590",
      "r1591",
      "r1592",
      "r1593",
      "r1594",
      "r1595",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1601",
      "r1602"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r224",
      "r225",
      "r226",
      "r259",
      "r265",
      "r294",
      "r295",
      "r298",
      "r300",
      "r307",
      "r308",
      "r398",
      "r456",
      "r458",
      "r459",
      "r460",
      "r463",
      "r464",
      "r496",
      "r497",
      "r499",
      "r500",
      "r502",
      "r505",
      "r507",
      "r508",
      "r511",
      "r512",
      "r514",
      "r784",
      "r991",
      "r992",
      "r993",
      "r994",
      "r1002",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1015",
      "r1036",
      "r1059",
      "r1082",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1289",
      "r1391",
      "r1393",
      "r1404"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/EquityMethodInvestmentsDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r83",
      "r86",
      "r87",
      "r209",
      "r211",
      "r212",
      "r237",
      "r238",
      "r239",
      "r272",
      "r273",
      "r274",
      "r276",
      "r284",
      "r287",
      "r289",
      "r306",
      "r400",
      "r403",
      "r436",
      "r494",
      "r517",
      "r564",
      "r603",
      "r604",
      "r612",
      "r613",
      "r614",
      "r616",
      "r670",
      "r671",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r753",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r798",
      "r804",
      "r806",
      "r819",
      "r936",
      "r969",
      "r970",
      "r971",
      "r1002",
      "r1082"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/IncomeTaxesDetails",
      "http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable",
      "http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable0",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable0",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r179",
      "r182",
      "r184",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r313",
      "r357",
      "r358",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r905",
      "r906",
      "r907",
      "r908",
      "r1018",
      "r1021",
      "r1023",
      "r1091",
      "r1098",
      "r1104",
      "r1120",
      "r1127",
      "r1129",
      "r1130",
      "r1131",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1154",
      "r1171",
      "r1203",
      "r1205",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1265",
      "r1279",
      "r1572",
      "r1574",
      "r1575",
      "r1577",
      "r1578",
      "r1579",
      "r1580",
      "r1581",
      "r1582",
      "r1583",
      "r1584",
      "r1585",
      "r1586",
      "r1587",
      "r1588",
      "r1589",
      "r1590",
      "r1591",
      "r1592",
      "r1593",
      "r1594",
      "r1595",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1601",
      "r1602"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r306",
      "r496",
      "r497",
      "r499",
      "r502",
      "r806",
      "r865",
      "r986",
      "r1003",
      "r1015",
      "r1027",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1036",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1061",
      "r1062",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1082",
      "r1167",
      "r1169",
      "r1280",
      "r1607"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Activities [Axis]",
        "documentation": "Information by continuing and discontinuing operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r306",
      "r360",
      "r496",
      "r497",
      "r499",
      "r502",
      "r806",
      "r865",
      "r986",
      "r1003",
      "r1015",
      "r1027",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1036",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1061",
      "r1062",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1082",
      "r1167",
      "r1169",
      "r1280",
      "r1607"
     ]
    },
    "us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory reserve",
        "verboseLabel": "Statutory totaled",
        "label": "Statutory Accounting Practices, Statutory Capital and Surplus, Balance",
        "documentation": "The amount of statutory capital and surplus (stockholders' equity) as of the balance sheet date using prescribed or permitted statutory accounting practices (rather than GAAP, if different) of the state or country."
       }
      }
     },
     "auth_ref": [
      "r924",
      "r980",
      "r1269",
      "r1270"
     ]
    },
    "avco_StatutoryReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "StatutoryReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory reserve",
        "documentation": "Statutory reserve.",
        "label": "Statutory Reserve"
       }
      }
     },
     "auth_ref": []
    },
    "avco_StatutoryReserveAndRestrictedNetAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "StatutoryReserveAndRestrictedNetAssetsTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STATUTORY RESERVE AND RESTRICTED NET ASSETS",
        "documentation": "Statutory reserve and restricted net assets.",
        "label": "Statutory Reserve And Restricted Net Assets Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "avco_StatutoryReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "StatutoryReserveMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory Reserve",
        "label": "Statutory Reserve Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_StatutoryReservePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "StatutoryReservePercent",
     "presentation": [
      "http://www.avalonglobocare.com/role/StatutoryReserveandRestrictedNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory reserve percentage",
        "documentation": "Percentage of statutory reserve.",
        "label": "Statutory Reserve Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for adjustments for 1:15 reverse split",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "avco_StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "StockIssuedDuringPeriodShareSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D Convertible Preferred Stock issued in exchange of Series A Convertible Preferred Stock (in Shares)",
        "documentation": "Number of shares series D convertible preferred stock issued in exchange of series A convertible preferred stock.",
        "label": "Stock Issued During Period Share Series DConvertible Preferred Stock Issued In Exchange Of Series AConvertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series B Convertible Preferred Stock for equity method investment (in Shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r50",
      "r83",
      "r86",
      "r120",
      "r482"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Series C Convertible Preferred Stock (in Shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r50",
      "r82",
      "r83",
      "r120"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for services (in Shares)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails",
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock as convertible note payable commitment fee (in Shares)",
        "verboseLabel": "Issuance of common stock (in Shares)",
        "netLabel": "Common shares issued as convertible note payable commitment fee (in Shares)",
        "label": "Shares of common stock (in Shares)",
        "totalLabel": "Share issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r82",
      "r83",
      "r120",
      "r991",
      "r1082",
      "r1122"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for adjustments (in Shares)",
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "avco_StockIssuedDuringPeriodSharesSaleOfCommonStockNet": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesSaleOfCommonStockNet",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock, net (in Shares)",
        "documentation": "The shares of sale of common stock, net.",
        "label": "Stock Issued During Period Shares Sale Of Common Stock Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon cashless exercise of stock warrants (in Shares)",
        "negatedLabel": "Number of Warrants, Exercised",
        "verboseLabel": "Common stock upon cashless exercise (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r82",
      "r83",
      "r120",
      "r542"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series B Convertible Preferred Stock for equity method investment",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r83",
      "r86",
      "r87",
      "r120"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Series C Convertible Preferred Stock",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r83",
      "r86",
      "r87",
      "r120"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for services",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock as convertible note payable commitment fee",
        "verboseLabel": "Common stock value issued as convertible note payable commitment fee",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r82",
      "r83",
      "r120",
      "r1002",
      "r1082",
      "r1122",
      "r1286"
     ]
    },
    "avco_StockIssuedDuringPeriodValueSaleOfCommonStockNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "StockIssuedDuringPeriodValueSaleOfCommonStockNet",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock, net",
        "documentation": "The amount of stock issued during period value sale of common stock net.",
        "label": "Stock Issued During Period Value Sale Of Common Stock Net"
       }
      }
     },
     "auth_ref": []
    },
    "avco_StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "StockIssuedDuringPeriodValueSeriesDConvertiblePreferredStockIssuedInExchangeOfSeriesAConvertiblePreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D Convertible Preferred Stock issued in exchange of Series A Convertible Preferred Stock",
        "documentation": "Value of series D convertible preferred stock issued in exchange of series A convertible preferred stock.",
        "label": "Stock Issued During Period Value Series DConvertible Preferred Stock Issued In Exchange Of Series AConvertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "avco_StockIssuedDuringPeriodValueSharesIssuedForAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "StockIssuedDuringPeriodValueSharesIssuedForAdjustments",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued for adjustments",
        "documentation": "The amount of shares issued for adjustments.",
        "label": "Stock Issued During Period Value Shares Issued For Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon cashless exercise of stock warrants",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r83",
      "r86",
      "r87",
      "r120"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable",
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option [Member]",
        "verboseLabel": "Equity Option [Member]",
        "netLabel": "Stock Warrant [Member]",
        "label": "Stock Options [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r1279",
      "r1515"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet",
      "http://www.avalonglobocare.com/role/ScheduleofSummarizedFinancialInformationasProvidedtotheCompanybytheInvesteeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Avalon GloboCare Corp. stockholders\u2019 (deficit) equity",
        "negatedTotalLabel": "Equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r86",
      "r87",
      "r110",
      "r1038",
      "r1057",
      "r1083",
      "r1084",
      "r1247",
      "r1287",
      "r1389",
      "r1393",
      "r1394",
      "r1425",
      "r1543",
      "r1611"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(DEFICIT) EQUITY:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total (Deficit) Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r61",
      "r209",
      "r210",
      "r211",
      "r212",
      "r238",
      "r272",
      "r273",
      "r274",
      "r276",
      "r284",
      "r287",
      "r400",
      "r403",
      "r436",
      "r494",
      "r517",
      "r564",
      "r603",
      "r604",
      "r612",
      "r613",
      "r614",
      "r616",
      "r670",
      "r671",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r753",
      "r792",
      "r793",
      "r798",
      "r805",
      "r819",
      "r970",
      "r971",
      "r1000",
      "r1038",
      "r1057",
      "r1083",
      "r1084",
      "r1126",
      "r1271",
      "r1273",
      "r1286",
      "r1389",
      "r1393",
      "r1394",
      "r1425",
      "r1543",
      "r1611"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable_Parentheticals",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse split",
        "verboseLabel": "Reverse stock split",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_StraightLineRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StraightLineRent",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in straight-line rent receivable",
        "label": "Straight Line Rent",
        "documentation": "Difference between actual rental income due and rental income recognized on a straight-line basis."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_SubsegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsegmentsAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsegments [Axis]",
        "documentation": "Information by business subsegments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsegmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsegmentsDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsegments [Domain]",
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r799",
      "r830"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r799",
      "r830"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r799",
      "r830"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails",
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r799",
      "r830"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.avalonglobocare.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r831"
     ]
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipBusinessPurpose",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal Activities",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership, Business Purpose",
        "documentation": "Description of business purpose of the subsidiary of the limited liability company or limited partnership, for example, its day-to-day operating functions and whether it acts as a holding or operating company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Consolidated Financial Statements [Line Items]",
        "terseLabel": "Organization and Nature of Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest",
     "presentation": [
      "http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable",
      "http://www.avalonglobocare.com/role/ScheduleofConsolidatedFinancialStatementsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of Ownership",
        "verboseLabel": "Ownership percentage",
        "label": "Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest",
        "documentation": "The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership."
       }
      }
     },
     "auth_ref": []
    },
    "avco_SummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "avco_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalDeferredPurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalDeferredPurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of deferred offering costs",
        "label": "Supplemental Deferred Purchase Price",
        "documentation": "A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofAccruedLiabilitiesandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/NoncontrollingInterestDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r1419",
      "r1553"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradingActivityByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TradingActivityByTypeAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Activity [Axis]",
        "documentation": "Information by type of trading activity."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r1231",
      "r1516"
     ]
    },
    "us-gaap_TradingActivityByTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TradingActivityByTypeDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Activity, by Type [Domain]",
        "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit)."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r1231",
      "r1516"
     ]
    },
    "avco_TradingPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "TradingPrice",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading price (in Dollars per share)",
        "documentation": "Trading price.",
        "label": "Trading Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r490",
      "r513",
      "r738",
      "r751",
      "r772",
      "r783",
      "r786",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r913",
      "r937",
      "r1233",
      "r1235",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1248",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1524",
      "r1527",
      "r1528",
      "r1529",
      "r1536",
      "r1539",
      "r1540",
      "r1541"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.avalonglobocare.com/role/CondensedConsolidatedStatementsofChangesinDeficitEquityTable",
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "terseLabel": "Treasury stock",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: common stock held in treasury, at cost; 3,467 shares at December 31, 2024 and 2023",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r86"
     ]
    },
    "avco_TwoCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "TwoCustomersMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two customers [Member]",
        "label": "Two Customers Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_TwoThousandTwentyFourJuneWarrantIssuedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "TwoThousandTwentyFourJuneWarrantIssuedMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Issued in June 2024 [Member]",
        "verboseLabel": "Two Thousand Twenty Four June Warrant Issued [Member]",
        "label": "Two Thousand Twenty Four June Warrant Issued Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable",
      "http://www.avalonglobocare.com/role/ScheduleofCashBalancesbyGeographicAreaTable0",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable",
      "http://www.avalonglobocare.com/role/ScheduleofIdentifiableLongLivedTangibleAssetsGeographicAreasTable0",
      "http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States [Member]",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable": {
       "parentTag": "us-gaap_ConvertibleNotesPayableCurrent",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0": {
       "parentTag": "us-gaap_ConvertibleNotesPayableCurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable",
      "http://www.avalonglobocare.com/role/ScheduleofConvertibleNotePayableTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: unamortized debt issuance costs",
        "label": "Unamortized Debt Issuance Expense",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r310",
      "r315",
      "r316",
      "r317",
      "r905",
      "r907",
      "r1175"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofComponentsofIncomeTaxesExpenseBenefitTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_ValueAddedTaxReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValueAddedTaxReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 8.0
      },
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable",
      "http://www.avalonglobocare.com/role/ScheduleofPrepaidExpenseandOtherCurrentAssetsTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recoverable VAT",
        "verboseLabel": "Recoverable value-added tax",
        "label": "Value Added Tax Receivable",
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities."
       }
      }
     },
     "auth_ref": [
      "r1322"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable",
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1463",
      "r1464",
      "r1465",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473",
      "r1474",
      "r1475",
      "r1476",
      "r1477",
      "r1478",
      "r1479",
      "r1480",
      "r1481",
      "r1482",
      "r1483",
      "r1485",
      "r1486",
      "r1487",
      "r1488",
      "r1489"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1463",
      "r1464",
      "r1465",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473",
      "r1474",
      "r1475",
      "r1476",
      "r1477",
      "r1478",
      "r1479",
      "r1480",
      "r1481",
      "r1482",
      "r1483",
      "r1485",
      "r1486",
      "r1487",
      "r1488",
      "r1489"
     ]
    },
    "avco_WaiverFeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "WaiverFeeMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Waiver Fee [Member]",
        "label": "Waiver Fee Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantExercisePriceIncrease",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price (in Dollars per share)",
        "label": "Warrant, Exercise Price, Increase",
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails",
      "http://www.avalonglobocare.com/role/EquityDetails",
      "http://www.avalonglobocare.com/role/ScheduleofNonvestedStockOptionsGrantedTable",
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable",
      "http://www.avalonglobocare.com/role/ScheduleofSecuritiesthatwereExcludedfromtheDilutedPerShareTable0",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable",
      "http://www.avalonglobocare.com/role/ScheduleofStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase common stock [Member]",
        "verboseLabel": "Stock Warrant [Member]",
        "netLabel": "Warrant [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r1277",
      "r1278",
      "r1281",
      "r1282",
      "r1283",
      "r1284"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConvertibleNotePayableDetails",
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant measurement input",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1527",
      "r1528",
      "r1529"
     ]
    },
    "avco_WarrantsExercisedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "WarrantsExercisedMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Exercised [Member]",
        "label": "Warrants Exercised Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_WarrantsIssuedAsConvertibleNotePayableFindersFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "WarrantsIssuedAsConvertibleNotePayableFindersFee",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued as convertible note payable finder\u2019s fee",
        "documentation": "Amount of Warrants issued as convertible note payable finder\u2019s fee.",
        "label": "Warrants Issued As Convertible Note Payable Finders Fee"
       }
      }
     },
     "auth_ref": []
    },
    "avco_WarrantsIssuedWithConvertibleNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "WarrantsIssuedWithConvertibleNotePayable",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Convertible Preferred Stock issued related to equity method investment",
        "documentation": "Warrants issued with convertible note payable.",
        "label": "Warrants Issued With Convertible Note Payable"
       }
      }
     },
     "auth_ref": []
    },
    "avco_WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "WarrantsIssuedWithConvertibleNotePayableRecordedAsDebtDiscount",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued with convertible notes payable recorded as debt discount",
        "documentation": "Amount of warrants issued with convertible note payable recorded as debt discount.",
        "label": "Warrants Issued With Convertible Note Payable Recorded As Debt Discount"
       }
      }
     },
     "auth_ref": []
    },
    "avco_WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "WarrantsIssuedWithConvertibleNotePayablesRecordedAsDebtDiscount",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued with convertible note payable recorded as debt discount",
        "documentation": "Warrants issued with convertible note payable recorded as debt discount.",
        "label": "Warrants Issued With Convertible Note Payables Recorded As Debt Discount"
       }
      }
     },
     "auth_ref": []
    },
    "avco_WarrantsOfCashlessExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "WarrantsOfCashlessExercised",
     "presentation": [
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants of cashless exercised (in Shares)",
        "documentation": "The number of shares in warrants in cash less exercised.",
        "label": "Warrants Of Cashless Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "avco_WarrantsOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "WarrantsOutstandingMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/EquityTables",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable",
      "http://www.avalonglobocare.com/role/ScheduleofCommonStockIssuableUponExerciseofOptionsOutstandingTable1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Outstanding [Member]",
        "label": "Warrants Outstanding Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Common Shares Outstanding Diluted (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r300"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Common Shares Outstanding Basic (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r300"
     ]
    },
    "avco_WenzhaoLuMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "WenzhaoLuMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wenzhao Lu [Member]",
        "label": "Wenzhao Lu Member"
       }
      }
     },
     "auth_ref": []
    },
    "avco_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "WorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital",
        "documentation": "Amount of member capital in limited liability company (LLC).",
        "label": "Working Capital"
       }
      }
     },
     "auth_ref": []
    },
    "avco_WorkingCapitalDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "WorkingCapitalDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital deficit",
        "documentation": "Working capital deficit.",
        "label": "Working Capital Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "avco_findersFeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avalonglobocare.com/20250331",
     "localname": "findersFeeMember",
     "presentation": [
      "http://www.avalonglobocare.com/role/DerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "finder\u2019s fee [Member]",
        "label": "finders Fee Member"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "970",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482170/970-10-05-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "60",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481408/470-60-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-12"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "980",
   "SubTopic": "340",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478742/980-340-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "980",
   "SubTopic": "715",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478574/980-715-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "970",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/970/tableOfContent"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "972",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/972/tableOfContent"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "974",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/974/tableOfContent"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "976",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/976/tableOfContent"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "978",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/978/tableOfContent"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "980",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478742/980-340-50-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481178/840-20-25-16"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481178/840-20-25-17"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481123/840-20-35-2"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "SubTopic": "30",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-14"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "SubTopic": "30",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3A"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3A"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/323/tableOfContent"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-23"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480408/260-10-S99-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2A"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-15"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2AG",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AG"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4H"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4H"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4I"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "15",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480960/815-15-50-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-5"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-21"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "325",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477974/942-325-45-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479510/944-340-25-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(10)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "974",
   "SubTopic": "720",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477728/974-720-50-1"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-20"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-3A"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(d)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-9"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-38"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-48"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "183",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-183"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "185",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-185"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480095/942-10-S50-1"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480035/942-10-S99-6"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479255/942-310-S50-4"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.H.2.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478116/942-310-S99-2"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478420/944-505-55-1"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478420/944-505-55-2"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-12"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481174/470-10-25-2"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1394": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1395": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1396": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1397": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1398": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1399": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1400": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r1402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r1403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r1407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r1413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r1419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r1427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r1428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r1430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r1433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r1434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r1449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r1452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r1453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r1454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r1455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r1456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r1457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r1462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r1463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r1493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r1517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-13"
  },
  "r1543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479341/842-30-25-10"
  },
  "r1551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r1552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r1553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-2"
  },
  "r1556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481833/940-20-45-3"
  },
  "r1566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r1601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
